<SEC-DOCUMENT>0001370368-21-000006.txt : 20210126
<SEC-HEADER>0001370368-21-000006.hdr.sgml : 20210126
<ACCEPTANCE-DATETIME>20210126085634
ACCESSION NUMBER:		0001370368-21-000006
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		285
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210126
DATE AS OF CHANGE:		20210126

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVARTIS AG
		CENTRAL INDEX KEY:			0001114448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15024
		FILM NUMBER:		21551822

	BUSINESS ADDRESS:	
		STREET 1:		LICHTSTRASSE 35
		CITY:			BASEL
		STATE:			V8
		ZIP:			CH 4056
		BUSINESS PHONE:		01141613241111

	MAIL ADDRESS:	
		STREET 1:		LICHTSTRASSE 35
		CITY:			BASEL
		STATE:			V8
		ZIP:			CH 4056
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>a21012620f.htm
<DESCRIPTION>20-F
<TEXT>

<html>
<head>
<title>20-F</title>
</head>
<body bgcolor="#ffffff">




<br>
<img src="x_coverfront.jpg">
<br>
<br>



<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"></font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>



   <div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"><b>As filed with the Securities and Exchange Commission on January 26, 2021</b></font>
  </div>
</div>
<div style="width:100%;padding-bottom:20px;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%">
    <div style="border:none;border-bottom:solid .25em;padding:0in 0in 1.0pt 0in"></div>
    <div style="border:none;border-bottom:solid .05em;padding:0in 0in 1.0pt 0in"></div>
  </div>
</div>
<div style="width:100%;">
  <div style="padding-bottom:20px;TEXT-ALIGN: center; WIDTH: 99%;">
    <font style="font-family:arial,helvetica,sans-serif; font-size:16pt; font-weight: bold; color:#000000;">UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION</font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"><b>Washington D.C. 20549</b></font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%;padding-top:20px;padding-bottom:20px;">
    <HR noshade align="center" Width="120">
    <font style="font-family:arial,helvetica,sans-serif; font-size:16pt; font-weight: bold; color:#000000;">Form 20-F</font>
    <HR noshade align="center" Width="120">
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: left; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"> <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font> REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934</font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">OR</font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: left; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"> <font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font> ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2020</font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">OR</font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: left; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"> <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">OR</font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: left; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"> <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font> SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font>
  </div>
</div>
	  <div style="width:100%;">
  <div style="TEXT-ALIGN: left; WIDTH: 99%; padding-bottom:15px;">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Date of event requiring this shell company report............</font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%; padding-bottom:15px;">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">For the transition period from _____ to _____</font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"> <b>Commission file number 1-15024</b></font>
  </div>
</div>
<div style="width:100%;">
  <div style="padding-bottom:5px;TEXT-ALIGN: center; WIDTH: 99%;">
    <font style="font-family:arial,helvetica,sans-serif; font-size:16pt; font-weight: bold; color:#000000;">Novartis AG</font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%; padding-bottom:15px;">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">(Exact name of Registrant as specified in its charter)</font>
  </div>
</div>
<div style="width:100%;">
  <div style="padding-bottom:5px;TEXT-ALIGN: center; WIDTH: 99%;">
    <font style="font-family:arial,helvetica,sans-serif; font-size:16pt; font-weight: bold; color:#000000;">NOVARTIS Inc.</font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%; padding-bottom:15px;">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">(Translation of Registrant&#x2019;s name into English)</font>
  </div>
</div>
<div style="width:100%;">
  <div style="padding-bottom:5px;TEXT-ALIGN: center; WIDTH: 99%;">
    <font style="font-family:arial,helvetica,sans-serif; font-size:16pt; font-weight: bold; color:#000000;">Switzerland</font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%; padding-bottom:5px;">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">(Jurisdiction of incorporation or organization)</font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"><b>Lichtstrasse 35<br>4056 Basel, Switzerland</b></font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">(Address of principal executive offices)</font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Shannon Thyme Klinger<br>
    Chief Legal Officer<br>Novartis AG<br>CH 4056 Basel<br>Switzerland<br>Tel.: +41-61-324-1111<br>Fax: +41-61-324-7826</font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Securities registered&nbsp;or to be registered pursuant to Section 12(b) of the Act:</font>
  </div>
</div>

<div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%">
    <table width="100%" border="0">
      <tr>
        <td width="33%"><div align="center"><u><font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Title of each class</font></u></div></td>
       <td width="33%"><div align="center"><u><font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Trading Symbol(s)</font></u></div></td>
        <td width="33%"><div align="center"><u><font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Name of each exchange on which registered</font></u></div></td>
      </tr>
      <tr>
        <td><div align="center"><font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">American Depositary Shares<br>
        each representing 1 share        </font></div></td>
        <td><div align="center"><font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">NVS<br></font></div></td>
        <td><div align="center"><font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">New York Stock Exchange</font></div></td>
      </tr>
      <tr>
        <td><div align="center"><font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Ordinary shares, nominal value CHF 0.50 per share*</font></div></td>
        <td><div align="center"><font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">NOVN</font></div></td>
        <td><div align="center"><font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">New York Stock Exchange*</font></div></td>
      </tr>
    </table>

  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%"></div>
</div>

<div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Securities registered or to be registered pursuant to Section 12(g) of the Act:</font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"><b>None</b></font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:</font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"><b>None</b></font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: left; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Indicate the number of outstanding shares of each of the issuer&#x2019;s classes of capital or common stock as of the close of the period covered by the annual report:</font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"><b>2 256 822 048 ordinary shares</b></font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: left; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</font>
  </div>
</div>
<div style="width:100%;">
  <div style="padding-top:10px;padding-bottom:10px;TEXT-ALIGN: center; WIDTH: 99%;">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"><b>&nbsp;&nbsp;&nbsp;</b><b>Yes</b>&nbsp;&nbsp;&nbsp; <font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font>&nbsp;&nbsp;&nbsp;<b>No</b>&nbsp;&nbsp;&nbsp; <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: left; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.</font>
  </div>
</div>
<div style="width:100%;">
  <div style="padding-top:10px;padding-bottom:10px;TEXT-ALIGN: center; WIDTH: 99%;">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"><b>&nbsp;&nbsp;&nbsp;</b><b>Yes</b>&nbsp;&nbsp;&nbsp; <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font>&nbsp;&nbsp;&nbsp;<b>No</b>&nbsp;&nbsp;&nbsp; <font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: left; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Note&mdash;Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.</font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: left; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</font>
  </div>
</div>
<div style="width:100%;">
  <div style="padding-top:10px;padding-bottom:10px;TEXT-ALIGN: center; WIDTH: 99%;">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"><b>&nbsp;&nbsp;&nbsp;</b><b>Yes</b>&nbsp;&nbsp;&nbsp; <font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font>&nbsp;&nbsp;&nbsp;<b>No</b>&nbsp;&nbsp;&nbsp; <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: left; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#xA7;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</font>
  </div>
</div>
<div style="width:100%;">
  <div style="padding-top:10px;padding-bottom:10px;TEXT-ALIGN: center; WIDTH: 99%;">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"><b>&nbsp;&nbsp;&nbsp;</b><b>Yes</b>&nbsp;&nbsp;&nbsp; <font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font>&nbsp;&nbsp;&nbsp;<b>No</b>&nbsp;&nbsp;&nbsp; <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: left; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See&nbsp;definition of &#x201C;large accelerated filer,&#x201D; &#x201C;accelerated filer,&#x201D; and &#x201C;emerging growth company&#x201D; in Rule 12b-2 of the Exchange Act.</font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%">

    <table width="100%" border="0">
      <tr>
        <td><div align="center"><font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Large accelerated filer <font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></font></div></td>
        <td><div align="center"><font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"><font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Accelerated filer </font><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div></td>
        <td><div align="center"><font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"><font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Non-accelerated filer </font><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div></td>
        <td><div align="center"><font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"><font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Emerging growth company </font><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div></td>
      </tr>
    </table>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: left; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#x2020; provided pursuant to Section 13(a) of the Exchange Act. <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: left; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">&#x2020; The term &#x201C;new or revised financial accounting standard&#x201D; refers to any update issued by the Financial&nbsp;Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.</font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: left; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: left; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%">

    <table width="100%" border="0">
      <tr>
        <td><div align="center"><font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">U.S. GAAP <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div></td>
        <td><div align="center"><font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">International Financial Reporting Standards as issued by the International Accounting Standards Board <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></font></font></div></td>
        <td><div align="center"><font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Other <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div></td>
      </tr>
    </table>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: left; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">If &#x201C;Other&#x201D; has been checked in response to the previous question, indicate by check mark which financial&nbsp;statement item the registrant has elected to follow.</font>
  </div>
</div>
<div style="width:100%;">
  <div style="padding-top:10px;padding-bottom:10px;TEXT-ALIGN: center; WIDTH: 99%;">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"><b>&nbsp;&nbsp;&nbsp;</b><b>Item 17</b>&nbsp;&nbsp;&nbsp; <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font>&nbsp;&nbsp;&nbsp;<b>Item 18</b>&nbsp;&nbsp;&nbsp; <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: left; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</font>
  </div>
</div>
<div style="width:100%;">
  <div style="padding-top:10px;padding-bottom:10px;TEXT-ALIGN: center; WIDTH: 99%;">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"><b>&nbsp;&nbsp;&nbsp;</b><b>Yes</b>&nbsp;&nbsp;&nbsp; <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font>&nbsp;&nbsp;&nbsp;<b>No</b>&nbsp;&nbsp;&nbsp; <font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></font>
  </div>
</div>
<div style="width:100%;">
  <div style="TEXT-ALIGN: left; WIDTH: 99%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">* Not for trading but only in connection with the registration of American Depositary Shares representing such ordinary shares.</font>
  </div>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="width:100%;padding-top:30px;padding-bottom:20px;">
  <div style="TEXT-ALIGN: center; WIDTH: 99%">
    <div style="border:none;border-bottom:solid .05em;padding:0in 0in 1.0pt 0in"></div>
    <div style="border:none;border-bottom:solid .25em;padding:0in 0in 1.0pt 0in"></div>
  </div>
</div>





    <a name="anchorId00137514"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Table of contents</p>


    <br>
 <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00237515">Introduction and use of certain terms</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00237534">Forward-looking statements</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;text-transform:uppercase;font-weight:bold;"><a style="text-decoration: none;" href="#anchorId00337546">Part I</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00337548">Item 1.  Identity of Directors, Senior&#xA0;Management and Advisers</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00337554">Item 2.  Offer Statistics and Expected Timetable</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00337560">Item 3.  Key Information</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00337562">3.A Selected financial data</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00339257">3.B Capitalization and indebtedness</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00339261">3.C Reasons for the offer and use of proceeds</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00339267">3.D Risk factors </a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00339728">Item&#xA0;4.  Information on the Company</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00339730">4.A History and development of Novartis</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00339752">4.B Business overview</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 54px;"><a style="text-decoration: none;" href="#anchorId00339786">Innovative Medicines</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 54px;"><a style="text-decoration: none;" href="#anchorId00344881">Sandoz</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00345710">4.C Organizational structure</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00345720">4.D Property, plants and equipment</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00345891">Item&#xA0;4A.  Unresolved Staff Comments</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId0010037584">Item 5. Operating and Financial Review and&nbsp;Prospects</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId0010037587">5.A Operating results</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId0010050882">5.B Liquidity and capital resources</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId0010054465">5.C Research and development, patents and licenses</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId0010054484">5.D Trend information</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId0010054491">5.E Off-balance sheet arrangements</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId0010054501">5.F Tabular disclosure of contractual obligations</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00437515">Item 6.  Directors, Senior Management and Employees</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00437517">6.A Directors and senior management</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00937732">6.B Compensation</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001037534">6.C Board practices </a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00537529">6.D Employees</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00538483">6.E Share ownership</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00538489">Item&#xA0;7.  Major Shareholders and Related Party Transactions</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00538491">7.A Major shareholders</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00538965">7.B Related party transactions</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00538969">7.C Interests of experts and counsel</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00538975">Item&nbsp;8.  Financial Information</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00538978">8.A Consolidated statements and other financial information</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00539022">8.B Significant changes</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00539029">Item&nbsp;9.  The Offer and Listing</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00539032">9.A Offer and listing details</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00539044">9.B Plan of distribution</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00539048">9.C Markets</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00539054">9.D Selling shareholders</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00539058">9.E Dilution</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00539062">9.F Expenses of the issue</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00539068">Item&nbsp;10.  Additional Information</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00539071">10.A Share capital</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00539075">10.B Memorandum and articles of association</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00539340">10.C Material contracts</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00539358">10.D Exchange controls</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00539364">10.E Taxation</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00539631">10.F Dividends and paying agents</a></div>
    <br />
    <br />


<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">2</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00539637">10.G Statement by experts</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00539641">10.H Documents on display</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00539649">10.I Subsidiary information</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00539655">Item&#xA0;11.  Quantitative and Qualitative Disclosures About Market Risk</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00539666">Item&#xA0;12.  Description of Securities Other Than Equity Securities</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00539668">12.A Debt securities</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00539672">12.B Warrants and rights</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00539676">12.C Other securities</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId00539680">12.D American Depositary Shares</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;text-transform:uppercase;font-weight:bold;"><a style="text-decoration: none;" href="#anchorId00539863">PART II</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00539865">Item&#xA0;13.  Defaults, Dividend Arrearages and Delinquencies</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00539871">Item&#xA0;14.  Material Modifications to the Rights of Security Holders and Use of Proceeds</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00637515">Item&nbsp;15.  Controls and Procedures</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00737518">Item&nbsp;16A.  Audit Committee Financial Expert</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00737532">Item&nbsp;16B.  Code of Ethics</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00737541">Item&nbsp;16C.  Principal Accountant Fees and Services</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00737552">Item&nbsp;16D.  Exemptions from the Listing Standards for Audit Committees</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00737559">Item&#xA0;16E.  Purchases of Equity Securities by the Issuer and Affiliated Purchasers</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00738222">Item&nbsp;16F.  Change in Registrant&#x2019;s Certifying Accountant</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00738229">Item&nbsp;16G.  Corporate Governance</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00738263">Item&nbsp;16H.  Mine Safety Disclosure</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;text-transform:uppercase;font-weight:bold;"><a style="text-decoration: none;" href="#anchorId00738270">PART III</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00738272">Item&nbsp;17.  Financial Statements</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId00738281">Item&nbsp;18.  Financial Statements</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId001837517">Item&#xA0;19.  Exhibits</a></div>











<br>
<br>



<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">3</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>



    <a name="anchorId00237515"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Introduction and use of certain terms</p>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis AG and its consolidated affiliates publish consolidated financial statements expressed in US dollars. Our consolidated financial statements responsive to Item 18 of this Annual Report on Form&nbsp;20-F (Annual Report) are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). &#x201C;Item 5. Operating and Financial Review and Prospects,&#x201D; together with the sections on products in development and key development projects of our businesses (see &#x201C;Item 4. Information on the Company&mdash;Item 4.B. Business overview&#x201D;), constitute the Operating and Financial Review (&#x201C;Lagebericht&#x201D;), as defined by the Swiss Code of Obligations.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Unless the context requires otherwise, the words &#x201C;we,&#x201D; &#x201C;our,&#x201D; &#x201C;us,&#x201D; &#x201C;Novartis,&#x201D; &#x201C;Group,&#x201D; &#x201C;Company,&#x201D; and similar words or phrases in this Annual Report refer to Novartis AG and its consolidated affiliates. However, each Group company is legally separate from all other Group companies and manages its business independently through its respective board of directors or similar supervisory body or other top local management body, if applicable. Each executive identified in this Annual Report reports directly to other executives of the Group company that employs the executive, or to that Group company&#x2019;s board of directors.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In this Annual Report, references to &#x201C;US dollars,&#x201D; &#x201C;USD&#x201D; or &#x201C;$&#x201D; are to the lawful currency of the United States of America, references to &#x201C;CHF&#x201D; are to Swiss francs, and references to &#x201C;euro&#x201D; or &#x201C;EUR&#x201D; are to the lawful currency of 27 member states participating in the European Union; references to the &#x201C;United States&#x201D; or to &#x201C;US&#x201D; are to the United States of America, references to the &#x201C;European Union&#x201D; or to &#x201C;EU&#x201D; are to the European Union and its 27 member states, references to &#x201C;Latin America&#x201D; are to Central and South America, including the Caribbean, and references to &#x201C;Australasia&#x201D; are to Australia, New Zealand, Melanesia, Micronesia and Polynesia, unless the context otherwise requires; references to the &#x201C;EC&#x201D; are to the European Commission; references to &#x201C;associates&#x201D; are to employees of our affiliates; references to the &#x201C;SEC&#x201D; are to the US Securities and Exchange Commission; references to the &#x201C;FDA&#x201D; are to the US Food and Drug Administration; references to the &#x201C;EMA&#x201D; are to the European Medicines Agency, an agency of the EU, and references to the &#x201C;CHMP&#x201D; are to the Committee for Medicinal Products for Human Use of the EMA; references to &#x201C;ADR&#x201D; or &#x201C;ADRs&#x201D; are to Novartis American Depositary Receipts, and references to &#x201C;ADS&#x201D; or &#x201C;ADSs&#x201D; are to Novartis American Depositary Shares; references to the &#x201C;NYSE&#x201D; are to the New York Stock Exchange, and references to &#x201C;SIX&#x201D; are to the SIX Swiss Exchange; references to &#x201C;ECN&#x201D; are to the Executive Committee of Novartis; references to &#x201C;GSK&#x201D; are to GlaxoSmithKline plc, references to &#x201C;AAA&#x201D; are to Advanced Accelerator Applications S.A., references to &#x201C;Novartis Gene Therapies&#x201D; are to Novartis Gene Therapies, Inc. (formerly AveXis), and references to &#x201C;Endocyte&#x201D; are to Endocyte, Inc.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">All product names appearing in italics are trademarks owned by or licensed to Group companies. Product names identified by a &#x201C;<sup>&#xAE;</sup>&#x201D; or a &#x201C;&#x2122;&#x201D; are trademarks that are not owned by or licensed to Group companies and are the property of their respective owners.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">4</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00237534"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Forward-looking statements</p>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">This Annual Report contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended (the &#x201C;Exchange Act&#x201D;), and the United States Private Securities &#xAD;Litigation Reform Act of 1995, as amended. Other written materials filed with or furnished to the SEC by Novartis, as well as other written and oral statements made to the public, may also contain forward-looking statements. Forward-looking statements can be identified by words such as &#x201C;potential,&#x201D; &#x201C;expected,&#x201D; &#x201C;will,&#x201D; &#x201C;planned,&#x201D; &#x201C;pipeline,&#x201D; &#x201C;outlook,&#x201D; &#x201C;may,&#x201D; &#x201C;could,&#x201D; &#x201C;would,&#x201D; &#x201C;anticipate,&#x201D; &#x201C;seek,&#x201D; or similar terms, or by express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products; or regarding the potential outcome, or financial or other impact on Novartis, of the acquisition of The Medicines Company, and other transactions described; or regarding the potential impact of share buybacks; or regarding potential future sales or earnings of the Group or any of its divisions or potential shareholder returns; or regarding potential future credit ratings of the Group; or by discussions of strategy, plans, expectations or intentions. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the &#xAD;forward-looking statements. You should not place undue reliance on these statements.</div>
<div style="padding-top:15px;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In particular, our expectations could be affected by, among other things:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Uncertainties regarding the success of key products and commercial priorities;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Global trends toward healthcare cost-containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Uncertainties in the research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products that commenced in prior years and is expected to continue this year;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The potential that the strategic benefits, operational efficiencies or opportunities expected from our recent transactions or our organizational, structural and cultural transformations may not be realized or may take longer to realize than expected;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Our performance on environmental, social and governance measures;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Uncertainties in the development or adoption of potentially transformational technologies and business models;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Uncertainties regarding potential significant breaches of information security or disruptions of our information technology systems;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Our reliance on outsourcing key business functions to third parties;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Our ability to attract, integrate and retain key personnel and qualified individuals;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Uncertainties regarding actual or potential legal proceedings, including, among others, litigation and other legal disputes with respect to our recent transactions, product liability litigation, litigation and investigations regarding sales and marketing practices, intellectual property disputes and government investigations generally;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"> &#x2022; Regulatory actions or delays or government regulation generally, including potential regulatory actions or delays with respect to the development of the products described in this Annual Report;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Our ability to comply with data privacy laws and regulations, and uncertainties regarding potential significant breaches of data privacy;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"> &#x2022; Safety, quality, data integrity or manufacturing issues;</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">5</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; General political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The impact of pandemic diseases such as COVID-19 on enrollment in, initiation and completion of our clinical trials in the future, and research and development timelines;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Uncertainties involved in predicting shareholder returns;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Uncertainties regarding the effects of recent and anticipated future changes in tax laws and their application to us;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Uncertainties regarding future global exchange rates; and</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Uncertainties regarding future demand for our products.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Some of these factors are discussed in more detail in this Annual Report, including under &#x201C;Item 3. Key Information&#x2014;Item 3.D. Risk factors,&#x201D; &#x201C;Item 4. Information on the Company,&#x201D; and &#x201C;Item 5. Operating and Financial Review and Prospects.&#x201D; Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this Annual Report as anticipated, believed, estimated or expected. We provide the information in this Annual Report as of the date of its filing. We do not intend, and do not assume any obligation, to update any information or forward-looking statements set out in this Annual Report as a result of new information, future events or otherwise.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">6</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>


    <a name="anchorId00337546"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000;">Part I</p><a name="anchorId00337548"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item 1.  Identity of Directors, Senior&#xA0;Management and Advisers</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">7</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00337554"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item 2.  Offer Statistics and Expected Timetable</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">8</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00337560"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item 3.  Key Information</p><a name="anchorId00337562"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">3.A Selected financial data</p>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The selected financial information set out below has been extracted from our consolidated financial statements prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standard Board (IASB). Our consolidated financial statements for the years ended December 31, 2020, 2019 and 2018, are included in &#x201C;Item 18. Financial Statements&#x201D; in this Form&#xA0;20-F.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">All financial data should be read in conjunction with &#x201C;Item 5. Operating and Financial Review and Prospects.&#x201D; All financial data presented in this Form&#xA0;20-F are qualified in their entirety by reference to the consolidated financial statements and their notes.</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="9" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Year ended December 31,</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="9" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="9" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">(USD millions, except per share information)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2017</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">INCOME STATEMENT DATA<sup>1</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48&nbsp;659</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;445</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 44&nbsp;751</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 42&nbsp;338</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 41&nbsp;975</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&nbsp;152</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;086</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;403</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;702</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;248</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 673</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 659</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;438</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;108</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 703</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;869</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;850</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;932</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;750</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;675</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;78</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 45</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 186</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 42</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;385</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;878</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;940</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;095</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;102</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;891</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;807</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;793</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;295</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;603</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;095</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;071</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;147</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;800</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;499</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;796</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net (loss) / income from discontinued operations before gain  on distribution of Alcon Inc. to Novartis shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;101</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;186</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   204</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;98</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;691</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income/(loss) from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;590</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;186</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 204</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;98</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;071</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;737</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;614</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;703</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;698</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Attributable to:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shareholders of Novartis AG</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;072</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;732</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;611</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;703</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;712</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-controlling interests</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic earnings per share (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.55</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.52</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.86</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.00</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.08</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.08</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.04</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.55</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.44</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.28</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.82</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Diluted earnings per share (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.52</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.08</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.46</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.84</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.98</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.08</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.08</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.04</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.52</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.06</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.38</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.80</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash dividends<sup>2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;987</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;645</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;966</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;495</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;475</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash dividends per share in CHF<sup>3</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.00</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.95</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.85</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.80</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.75</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Personnel cost from continuing operations<sup>4, 5</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&nbsp;898</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13&nbsp;843</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13&nbsp;515</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;009</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;950</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Full-time equivalent associates of continuing operations at year-end<sup>5</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 105&nbsp;794</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 103&nbsp;914</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 104&nbsp;780</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102&nbsp;467</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 99&nbsp;747</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Continuing operations include the businesses of the Innovative Medicines and Sandoz Divisions and Corporate activities. Discontinued operations included the Alcon business, which was divested in 2019. To reflect these transactions, Novartis reported the Group&#x2019;s financial results for 2020 to 2016 as &#x201C;continuing operations&#x201D; and &#x201C;discontinued operations,&#x201D; as required by IFRS.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Cash dividends represent cash payments in the applicable year that generally relates to earnings of the previous year.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Cash dividends per share represent dividends proposed that relate to earnings of the current year. Dividends for 2016 through 2019 were approved at the respective AGMs, and dividends for 2020 will be proposed to the Annual General Meeting on March 2, 2021, for approval.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> Personnel cost include wages, salaries, allowances, commissions and bonuses to staff, overtime, awards, holiday pay, severance payments and social welfare expenses.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;5&nbsp;</sup> Own employees</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">9</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="9" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Year ended December 31,</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="9" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="9" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2017</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">BALANCE SHEET DATA</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash, cash equivalents, and marketable securities  and derivative financial instruments</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   11&nbsp;563</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   11&nbsp;446</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   15&nbsp;964</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   9&nbsp;485</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   7&nbsp;777</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;131</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;982</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;956</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;867</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;255</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&nbsp;979</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;235</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;836</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;856</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;899</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 102&nbsp;386</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 88&nbsp;866</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 110&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 104&nbsp;871</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 105&nbsp;193</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Assets of disposal group held for sale<sup>1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 841</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 807</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 132&nbsp;059</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 118&nbsp;370</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 145&nbsp;563</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 133&nbsp;079</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 130&nbsp;124</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade accounts payable</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;403</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;424</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;556</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;169</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;873</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27&nbsp;656</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22&nbsp;809</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&nbsp;234</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;336</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 42&nbsp;334</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34&nbsp;555</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37&nbsp;264</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35&nbsp;449</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33&nbsp;024</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities of disposal group held for sale<sup>1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 51</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 75&nbsp;393</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 62&nbsp;819</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 66&nbsp;871</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 58&nbsp;852</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;233</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity attributable to shareholders  of Novartis AG</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   56&nbsp;598</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   55&nbsp;474</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   78&nbsp;614</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   74&nbsp;168</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   74&nbsp;832</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-controlling interests</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 68</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 77</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 78</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 59</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 59</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 56&nbsp;666</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;551</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 78&nbsp;692</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 74&nbsp;227</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 74&nbsp;891</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liabilities and equity</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 132&nbsp;059</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 118&nbsp;370</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 145&nbsp;563</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 133&nbsp;079</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 130&nbsp;124</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 56&nbsp;666</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 55&nbsp;551</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 78&nbsp;692</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 74&nbsp;227</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 74&nbsp;891</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Outstanding share capital</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 860</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 856</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 875</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 869</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 896</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total outstanding shares (millions)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;257</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;265</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;311</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;317</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;374</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> In 2019 and 2018, the disposal group held for sale related to the assets and liabilities of the planned divestment of the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo Pharma USA Inc., as announced on September 6, 2018. In March 2020, Novartis took the decision to retain these businesses. (see &#x201C;Item 18. Financial Statements&#x2014;Note 2. Significant transactions").</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup> </div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup>     </div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Cash dividends per share</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash dividends are translated into US dollars at the Bloomberg Market System Rate on the payment date. Because we pay dividends in Swiss francs, exchange rate fluctuations will affect the US dollar amounts received by holders of ADRs.</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"><br>Year earned</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Month and <br> year paid</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total dividend <br> per share<br> (CHF)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total dividend <br> per share<br> (USD)</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2016</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> March 2017</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.75</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.72</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2017</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> March 2018</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.80</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.94</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2018</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> March 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.85</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.84</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> March 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.95</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2020<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> March 2021</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.00</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.40<sup style="white-space: nowrap"> 2</sup></div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Dividend to be proposed at the Annual General Meeting on March 2, 2021, and to be distributed from March 8, 2021.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Translated into US dollars at the December 31, 2020, rate of USD 1.135 to the Swiss franc. This translation is an example only, and should not be construed as a representation that the Swiss franc amount represents, or has been or could be converted into US dollars at that or any other rate.</div>
      </td>
    </tr>
  </table>
</div><a name="anchorId00339257"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">3.B Capitalization and indebtedness</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div><a name="anchorId00339261"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">3.C Reasons for the offer and use of proceeds</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">10</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00339267"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">3.D Risk factors </p>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our businesses face significant risks and uncertainties. You should carefully consider all of the information set forth in this Annual Report and in other documents we file with or furnish to the SEC, including the following risk factors, before deciding to invest in or to maintain an investment in any Novartis securities. Our business, as well as our reputation, financial condition, results of operations, and share price, could be materially adversely affected by any of these risks, as well as other risks and uncertainties not currently known to us or not currently considered material.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">&#xA0;</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Strategic risks</font>
</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Key products and commercial priorities</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Failure to deliver key commercial priorities and successfully launch new products</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our ability to maintain and grow our business and to replace revenue and income lost to generic, biosimilar and other competition depends heavily on the commercial success of our new or existing key products. The commercial success of these products could be impacted at any time by a number of factors, including pressure from new or existing competitive products, changes in the prescribing habits of healthcare professionals, unexpected side effects or safety signals, supply chain issues or other product shortages, pricing pressure, regulatory proceedings, changes in labeling, loss of intellectual property protection, and global pandemics. In addition, our revenue and margins could be significantly impacted by the timing and rate of commercial acceptance of new products. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We face competition from scientific advances and other company&#x2019;s new products. Healthcare professionals, patients and payers may choose competitor products instead of ours for various reasons, including if they perceive them to be better in terms of efficacy, safety, cost, convenience or other reasons. The commercial success of our key products and launches in the face of increasing competition and pressures on pricing requires significant attention and management focus. Such competitive products could significantly affect the revenue from our products and our results of operations. This impact could also be compounded to the extent such competition results in us making significant additional investments in research and development, marketing or sales.</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Pricing, reimbursement and access</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Pricing and reimbursement pressure, including access to healthcare</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our businesses experience significant pressures on the pricing of our products and on our ability to obtain and maintain satisfactory rates of reimbursement for our products by governments, insurers and other payers. These pressures have many sources, including growth of healthcare costs as a percentage of gross domestic product; funding restrictions and policy changes; management of the COVID-19 pandemic and its impact on healthcare spending; and public controversies, political debate, investigations and legal proceedings regarding pharmaceutical pricing. Pressures on pricing may negatively impact, in parallel, both our product pricing and our market access. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, we face numerous cost-containment measures imposed by governments and other payers, including government-imposed industrywide price reductions, mandatory pricing systems, reference pricing systems, payers limiting access to treatments based on cost-benefit analyses, imports of drugs from lower-cost countries to higher-cost countries, shifting of the payment burden to patients through higher co-payments and co-pay accumulator programs, limiting physicians&#x2019; ability to choose among competing medicines, mandatory substitution of generic drugs for the patented equivalent, pressure on physicians to reduce the prescribing of patented prescription medicines, increasing pressure on intellectual property protections, and growing requirements for increased transparency on pricing. For more information on price controls, see &#x201C;Item&#xA0;4. Information on the Company&#x2014;Item&#xA0;4.B Business overview&#x2014;Innovative Medicines&#x2014;Price controls.&#x201D; </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">These challenges are expected to continue to increase in 2021 and beyond as healthcare investment into the management of the COVID-19 pandemic continues; political pressures mount; and healthcare payers around the globe, including government-controlled health authorities, insurance companies and managed care organizations, step up initiatives to reduce the overall cost of healthcare, restrict access to higher-priced new medicines, increase the use of generics, and impose overall price cuts. These factors may materially affect our ability to achieve value-based prices and maintain an acceptable return on our investments in the research and development of our products, and may impact our ability to research and develop new products. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, our Sandoz Division has faced and may in the future face strong competition from other generic and biosimilar pharmaceutical companies, which aggressively compete for market share, including through significant price competition. Such competitive actions may increase the costs and risks associated with our efforts to introduce and market generic and biosimilar products, may delay the introduction or marketing of such products, and may further limit the prices at which we are able to sell these products. In particular, in the US in past years, industrywide price competition among generic pharmaceutical companies and consolidation of buyers caused significant declines in sales and profits of Sandoz.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">11</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Research and development</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Failure or delay in the research and development of new products or new indications for existing products</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We engage in extensive and costly research and development activities, both through our own internal resources and through collaborations with third parties, in an effort to identify and develop new products and new indications for existing products that address unmet and changing medical needs and are commercially successful. Our ability to grow our business; to replace sales lost due to branded competition, entry of generics, or other reasons; and to bring to market products that take advantage of new and potentially disruptive technologies, including cell, gene and radioligand therapies, depends in significant part upon the success of these efforts. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Research and development of new products of our Innovative Medicines Division, including the research and development of our cell and gene therapies, is a costly, lengthy and uncertain process. Because intellectual property protections are limited in scope and duration, the longer it takes to develop a product, the less time there may be for us to recoup our research and development costs before loss of exclusivity. Failure can occur at any point in the process, including in later stages after substantial investment. In spite of such substantial investment, there can be no guarantee that our research and development activities will produce commercially successful new products that will enable us to replace revenue and income lost to competition and to grow our business. See also &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Business overview&#x2014;Innovative Medicines&#x2014;Research and development&#x201D; with regards to the research and development efforts of our Innovative Medicines Division.   </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">New products must undergo intensive preclinical and clinical testing, and must be approved by means of highly complex, lengthy and expensive approval processes that can vary from country to country. Further, regulatory authorities continue to establish new and increasingly rigorous and time-consuming requirements for approval and reimbursement of new products and new indications. Similarly, the post-approval regulatory burden has also increased. These requirements make the maintenance of regulatory approvals for our products increasingly expensive, and further heighten the risk of recalls, product withdrawals, loss of market share, and loss of revenue and profitability. The clinical testing, regulatory processes and post-approval activities described above become more difficult during pandemics, such as the COVID-19 pandemic. This is primarily due to challenges related to recruiting, enrolling and treating patients in clinical trials. In addition, travel restrictions resulting from pandemics make it more difficult for regulatory authorities to inspect sites. For a further description of the research and development and approval processes for the products of our Innovative Medicines Division, see the sections headed &#x201C;Research and development&#x201D; and &#x201C;Regulation&#x201D; included in the description of our Innovative Medicines Division under &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Business overview&#x2014;Innovative Medicines.&#x201D;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our Sandoz Division has made, and expects to continue to make, significant investments in the development of biotechnology-based, &#x201C;biologic&#x201D; medicines intended for sale as bioequivalent or &#x201C;biosimilar&#x201D; versions of currently marketed biotechnology products. While the development of such products typically is significantly less costly and complex than the development of the equivalent originator medicines, it is nonetheless significantly more costly and complex than that for typical small-molecule generic products. See also &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Business overview&#x2014;Sandoz&#x2014;Development and registration&#x201D; with regards to the research and development efforts of our Sandoz Division. In addition, many countries do not yet have fully developed legislative or regulatory pathways to facilitate the development of biosimilars and permit their sale in a manner in which they are readily substitutable alternatives to the originator product. Further delays or difficulties in the development or marketing of biosimilars could put at risk the significant investments that Sandoz has made, and will continue to make, in its Biopharmaceuticals business. Failure to successfully develop and market biosimilars could have a material adverse effect on the success of the Sandoz Division and the Group as a whole. For more information about the approval processes that must be followed to market Sandoz Division products, see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Business overview&#x2014;Sandoz&#x2014;Regulation.&#x201D; </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Further, our research and development activities must be conducted in an ethical and compliant manner. Among other things, we are concerned with patient safety, data privacy, Current Good Clinical Practices (cGCP) requirements, data integrity, the fair treatment of patients, and animal welfare. Should we fail to properly manage such issues, we risk injury to third parties, damage to our reputation, negative financial consequences as a result of potential claims for damages, sanctions and fines, and the potential that investments in research and development activities could have no benefit to the Group. Research to find new targets for drug discovery and the therapeutic agents to treat unmet medical needs is made more difficult during pandemics, such as the COVID-19 pandemic.&#xA0;This is primarily due to safety-related restrictions on the ability of laboratory scientists to work in research laboratories, and impacts our ability to collaborate with academic and commercial research organizations facing similar challenges and restrictions.</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Intellectual property</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Expiry, assertion or loss of intellectual property protection </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Many products of our Innovative Medicines Division are protected by intellectual property rights, which may provide us with exclusive rights to market those products for a limited time and enable us to sustainably finance our research and development. However, the strength and duration of those rights can vary significantly from </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">12</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">product to product and country to country, and they may be successfully challenged by third parties or governmental authorities. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Loss of intellectual property protection and the introduction of generic or biosimilar competition for a patented branded medicine typically result in a significant and rapid reduction in net sales and operating income for the branded product, because generic or biosimilar manufacturers typically offer their versions at sharply lower prices. Such competition can occur after successful challenges to intellectual property rights or the regular expiration of the patent term or other intellectual property rights. Such competition can also result from the entry of generic or biosimilar versions of another medicine in the same therapeutic class as one of our drugs or in a competing therapeutic class, from a Declaration of Public Interest or the compulsory licensing of our drugs by governments, or from a general weakening of intellectual property and governing laws in certain countries around the world. In addition, generic or biosimilar manufacturers may sometimes conduct so-called &#x201C;launches at risk&#x201D; of products that are still under legal challenge for infringement, or whose patents are still under legal challenge for validity, before final resolution of legal proceedings.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We also rely in all aspects of our businesses on unpatented proprietary technology, know-how, trade secrets and other confidential information, which we seek to protect through various measures, including confidentiality agreements with licensees, employees, third-party collaborators, and consultants who may have access to such information. If these agreements are breached or our other protective measures should fail, then our contractual or other remedies may not be adequate to cover our losses.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We may also be subject to assertions of intellectual property rights against our innovative medicines by third parties. If successful, these actions may involve payment of damages, for example for patent infringement, and may also involve injunctive relief requiring removal of a product from the market (or removing a therapeutic indication from the product&#x2019;s approved labeling) for some period of time or throughout the life of the asserted intellectual property right. These damages or an injunction may have a material impact on our operating income and net sales.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In any given year, we may experience a potentially significant impact on our net sales from products that have already lost intellectual property protections, as well as products that may lose protection during the year. Because we may have substantially reduced marketing and research and development expenses related to products that are in their final years of exclusivity, the initial loss of protection for a product during a given year could also have an impact on our operating income for that year in an amount corresponding to a significant portion of the product&#x2019;s lost sales. The magnitude of the impact of generic or biosimilar competition on our income could depend on a number of factors, including, with respect to income in a given year, the time of year at which the generic or biosimilar competitor is launched; the ease or difficulty of manufacturing a competitor product and obtaining regulatory approval to market it; the number of generic or biosimilar competitor products approved, including whether, in the US, a single competitor is granted an exclusive marketing period; whether an authorized generic is launched; the geographies in which generic or biosimilar competitor products are approved, including the strength of the market for generic or biosimilar pharmaceutical products in such geographies, and the comparative profitability of branded pharmaceutical products in such geographies; and our ability to successfully develop and launch profitable new products to replace the income lost to generic or biosimilar competition. For more information on the patent and generic competition status of our Innovative Medicines Division products, see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Business overview&#x2014;Innovative Medicines&#x2014;Intellectual property.&#x201D;</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Alliances, acquisitions and divestments</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Failure to identify external business opportunities or realize the expected benefits from our strategic acquisitions or divestments</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As part of our strategy, from time to time we acquire and divest products or entire businesses, and enter into strategic alliances and collaborations. For example, in 2020 we completed the acquisitions of The Medicines Company and the Japanese operations and associated assets of Aspen Global Incorporated. This strategy depends in part on our ability to identity strategic external business opportunities and to move forward with such opportunities on acceptable terms.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Once a strategic transaction is agreed upon with a third party, we may not be able to complete the transaction in a timely manner or at all, nor can we be sure that pre-transaction due diligence will identify all possible issues that might arise during and after the transaction. Our efforts on such transactions can also divert management&#x2019;s attention from our existing businesses.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Further, after an acquisition, efforts to develop and market acquired products, to integrate the acquired business or to achieve expected synergies may fail or may not fully meet expectations, as a result of difficulties in retaining key personnel, customers and suppliers; failure to obtain marketing approval or reimbursement within expected time frames or at all; differences in corporate culture, standards, controls, processes and policies; or other factors. Acquisitions can also result in liabilities being incurred that were not known at the time of acquisition, or the creation of tax or accounting issues. Acquired businesses are not always in full compliance with legal, regulatory or Novartis standards, including, for example, Current Good Manufacturing Practices (cGMP) or cGCP standards, which can be costly and time-consuming to remedy. Also, our strategic alliances and collaborations with third parties may not achieve their intended goals and objectives within expected time frames, or at all.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Similarly, we cannot ensure that we will be able to successfully divest or spin off businesses or other assets that we have identified for this purpose, or that any completed divestment or spin-off will achieve the expected strategic benefits, operational efficiencies or opportuni-</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">13</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">ties, or that the divestment or spin-off will ultimately maximize shareholder value. </div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Environmental, social and governance matters</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Unsuccessful management of environmental, social and governance matters</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Increasingly, in addition to financial results, companies are being judged by performance on a variety of environmental, social and governance (ESG) matters, which can contribute to the long-term sustainability of companies&#x2019; performance. An inability to successfully perform on ESG matters can result in negative impacts to our reputation, recruitment, retention, operations, financial results, and the price of our shares.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A variety of organizations measure the performance of companies on ESG topics, and the results of these assessments are widely publicized. In addition, investment in funds that specialize in companies that perform well in such assessments are increasingly popular, and major institutional investors have publicly emphasized the importance of such ESG measures in making their investment decisions. Topics taken into account in such assessments include, among others, the unintentional costs or benefits of our actions on third parties not involved in such actions, which may impact society and the environment, such as with respect to climate change, the degradation of biodiversity, and inequality in society. In particular, the resulting costs of such actions may in the long-term impact our operations and ability to achieve our strategic goals, ultimately resulting in broader negative impacts on the value of Novartis. Therefore, the role of our Board of Directors and executive officers in supervising various sustainability issues is becoming increasingly important. In addition to the topics typically considered in such assessments in the healthcare industry, the public&#x2019;s ability to access our medicines is particularly important. If our advocacy and lobbying efforts are not aligned with our publicly stated ESG targets, our performance on ESG assessments may be negatively impacted.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We actively manage a broad range of such ESG matters, taking into consideration their expected impact on the sustainability of our business over time, and the potential impact of our business on society and the environment. However, in light of investors&#x2019; increasing focus on ESG matters and rapidly changing views on acceptable levels of action across a range of topics, there can be no certainty that we will manage such issues successfully, or that we will successfully meet society&#x2019;s or investors&#x2019; expectations as to our proper role. </div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Organizational, structural and cultural transformations</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Failure to successfully achieve our organizational, structural and cultural transformations</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">From time to time we reassess our business organization to ensure we have the optimal structure with which to execute our strategy. This resulted in our decision to centralize and optimize our manufacturing and business services organizations, which is currently being effected through a series of complex initiatives. For example, our Novartis Technical Operations organizational unit is currently undergoing a transformation to change its operating model by building two global operations centers that will allow our manufacturing sites to focus on their core activity, which is the manufacture of our medicines. This structural transformation is expected to be completed over the next 24 months, and a failure to complete this transformation in the expected time frame, or at all, could negatively impact our operations. We are also undertaking a cultural transformation to an &#x201C;inspired, curious and unbossed&#x201D; organization, which is a core organizational imperative. Inability to successfully implement this cultural change may result in cynicism and disengagement of our associates, as well as impede our ability to retain key talent in strategically important areas. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">These organizational changes are being implemented in parallel and have interdependencies that could negatively impact each other and their timing of implementation. The overall extent and pace of organizational change, and the additional workload and complexity for our employees in some areas, could trigger uncertainty, stress and fatigue among employees, potentially resulting in instability within the organization that may lead to failure in delivering the desired organizational changes. As a result, the expected benefits of these organizational changes may never be fully realized or may take longer to realize than expected.  </div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Digitalization and emerging business models</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Missed opportunities in digitalization and emerging business models  </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Rapid progress in medical and digital technologies and in the development of new business models is substantially transforming our industry and is creating new businesses and new opportunities for improving patient care and increasing revenue and profit, while sometimes quickly rendering established businesses uncompetitive or obsolete. Such transformations, both positive and negative, may impact our businesses. For example, numerous technology companies are seeking to enter the healthcare field, which generates opportunities for partnerships and alliances for us that may accelerate innovation and complement our current capabilities, although we also may be impacted by potential innovative technological advances among our existing competitors, through partnerships and alliances with technology companies or otherwise.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To take advantage of these opportunities, we are implementing a digital transformation strategy, with the goal of becoming an industry leader in leveraging advanced analytics and digital technologies. We expect to invest substantial resources into efforts to improve the way we use data in drug discovery and development; to improve the ways we engage with patients, doctors and other stakeholders; and to automate business processes. Our success in these efforts will depend on many </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">14</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">factors, including data quality, technology architecture, entering into successful partnerships and alliances with technology companies, a cultural change among our employees, attracting and retaining employees with appropriate skills and mindsets, and successfully innovating across a variety of technology fields. The COVID-19 pandemic has accelerated our digital transformation, including in the ways we engage and interact with our stakeholders, bring our products to market, and meet the needs of patients. These initiatives include the development and implementation of personalized engagement models enabled by digital technologies, the demand for which has increased in response to the COVID-19 pandemic. Our digital transformation efforts have started to gain significant traction, but we do not yet know whether they will be sustainable as they are scaled and made a part of our normal business operations. There is also no guarantee that these efforts will succeed, that we will successfully implement our digital transformation strategy, or that we will be able to do so within our budget or in the expected time frame.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">At the same time, other technology companies with specialized expertise or business models and substantial resources are entering the healthcare field, from research and development to pharmaceutical distribution and delivery of care. These new entrants could disrupt our relationships with patients, healthcare professionals, customers, distributors and suppliers, with unknown potential consequences for us. Such new competitors may impact our share of the healthcare value chain, or successfully develop products or technologies that could make our products or business models uncompetitive or obsolete. The risks described above may result in our business being supplanted in whole or in part by new competitors with disruptive new technologies or business models.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Operational risks</font>
</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Cybersecurity and IT systems</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cybersecurity breaches and catastrophic loss of IT systems</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We are heavily dependent on critical, complex and interdependent information technology (IT) systems, including internet-based systems to support our business processes. We also have outsourced significant parts of our IT&#xA0;infrastructure to&#xA0;third-party&#xA0;providers, and we currently use these providers to perform business-critical IT services for us. We are therefore vulnerable to cybersecurity attacks and incidents on such networks and systems, whether our own or those of the third-party providers we contract, and we have experienced and may in the future experience such cybersecurity threats and attacks. Cybersecurity threats and attacks take many forms, and the size, age and complexity of our IT systems make them potentially vulnerable to external and internal security threats; outages; malicious intrusions and attacks; cybercrimes, including state-sponsored cybercrimes; malware; misplaced or lost data; programming or human errors; or other similar events. In the context of the COVID-19 pandemic, the risk of such threats and attacks has increased, as virtual and remote working has become more widely used, and sensitive data is accessed by employees working in less secure, home-based environments. In addition, due to our reliance on third-party providers, we have experienced and may in the future experience interruptions, delays or outages in IT service availability due to a variety of factors outside of our control, including technical failures, natural disasters, fraud, or security attacks experienced by or caused by the third-party provider. Interruptions in the service provided by these third parties could affect our ability to perform critical tasks.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A significant information security or other event, such as a disruption or loss of availability of one or more of our IT systems, whether managed by us or a third-party service provider, has previously and could in the future negatively impact important business processes, such as the conduct of scientific research and clinical trials, the submission of data and information to health authorities, our manufacturing and supply chain processes, our shipments to customers, our compliance with legal obligations, and communication between employees and with third parties. IT issues have previously and could in the future also lead to the compromise of trade secrets or other intellectual property that could be sold and used by competitors to accelerate the development or manufacturing of competing products; to the compromise of personal financial and health information; and to the compromise of IT security data such as usernames, passwords and encryption keys, as well as security strategies and information about network infrastructure, which could allow unauthorized parties to gain access to additional systems or data. In addition, malfunctions in software or medical devices that make significant use of IT could lead to a risk of direct harm to patients.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Although we have experienced some of the events described above, to date they have not had a material impact on our operations. Nonetheless, the occurrence of any of the events described above in the future could disrupt our business operations and result in enforcement actions or liability, including potential government fines and penalties, claims for damages, and shareholder litigation or allegations that the public health, or the health of individuals, has been harmed.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Any significant events of this type could require us to expend significant resources beyond those we already invest to remediate any damage, to further modify or enhance our protective measures, and to enable the continuity of our business.</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Third-party management </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Failure to maintain adequate governance and oversight over third-party relationships, and failure of third parties to meet their contractual, regulatory or other obligations</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We outsource the performance of certain key business functions to third parties, and invest a significant amount of effort and resources into doing so, including to manage and oversee such third parties. Such outsourced </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">15</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">functions include research and development collaborations, manufacturing operations, warehousing and distribution activities, certain finance functions, sales and marketing activities, data management and others. Some of these third parties, particularly those in developing countries, do not have internal compliance systems comparable to those within our organization.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our reliance on outsourcing and third parties for the research and development, sales or manufacturing of our products poses certain risks, including misappropriation of our intellectual property, failure of the third party to comply with regulatory and quality assurance requirements, unexpected supply disruptions, breach of the research and development or manufacturing agreement by the third party, and the unexpected termination or nonrenewal of the agreement by the third party.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, governments and the public expect companies like Novartis to take responsibility for and report on compliance with various human rights, responsible sourcing and environmental practices, as well as other actions of their third-party contractors around the world. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Ultimately, if third parties fail to meet their obligations to us, we may lose our investment in the collaborations or fail to receive the expected benefits of our agreements with such third parties. In addition, should any of these third parties fail to comply with the law or our standards, or should they otherwise act inappropriately in the course of their performance of services for us, there is a risk that we could be held responsible for their acts, that our reputation may suffer, and that penalties may be imposed upon us.</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Manufacturing and product quality</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inability to ensure proper controls in product development and product manufacturing, and failure to comply with applicable regulations and standards</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The development and manufacture of our products is complex and heavily regulated by governmental health authorities around the world. Whether or not our products and the related raw materials are developed and manufactured at our own manufacturing sites or by third parties, we must ensure that all development and manufacturing processes comply with regulatory requirements as well as our own quality standards. Failure to comply with regulatory requirements has resulted in, and may in the future result in, warning letters, suspension of manufacturing, seizure of products, injunctions, product recalls, failure to secure product approvals, or debarment.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In recent years, global health authorities have substantially intensified their scrutiny of manufacturers&#x2019; compliance with regulatory requirements. Any significant failure by us or our third-party suppliers to comply with regulatory requirements, or with health authorities&#x2019; expectations, may create the need to suspend clinical trials, shut down production facilities or production lines, and recall commercial products. A failure to fully comply with regulatory requirements could also lead to a delay in the approval of new products, an inability to ship or import our products, and significant penalties and reputational harm. </div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Talent management</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description  </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inability to attract, integrate and retain key personnel and qualified individuals</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We rely on a diverse, capable workforce across our businesses and functions. Novartis invests in attracting, recruiting, developing and retaining highly skilled individuals to achieve our business objectives. The loss of key personnel &#x2013; including senior members of our scientific and management teams, high-quality researchers and development specialists, and skilled personnel in key markets &#x2013; could delay or prevent the achievement of our major business objectives.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our future growth will demand that we retain talented associates and leaders while also recruiting new talent who bring new skills and perspectives. The market for skilled labor has become increasingly competitive. We are experiencing challenges in attracting skilled talent in several areas, including in our Oncology business unit and for our chimeric antigen receptor T-cell (CAR-T) therapies, gene therapies and radioligand therapy products. The supply of new talent is especially limited in many of the geographies that are expected to be sources of growth for Novartis, including Emerging Growth Markets such as China, where there is a limited pool of executives and functional experts with the experience needed to work successfully in a global organization like Novartis. The geographic mobility of talent worldwide is decreasing, with ample career opportunities available closer to home to talented individuals in developed and developing countries. This decrease in mobility may be worsened by anti-immigrant sentiments in many countries, and laws discouraging immigration. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The constraints associated with lockdowns and social distancing during the COVID-19 pandemic complicated and initially slowed our talent acquisition activities. The necessity to adopt remote working across a portion of the workforce has accelerated our transition toward a new working model, in which a number of our associates have the flexibility to determine where, when and how they work. Our transition toward a more flexible working model accelerated our efforts to expand our sources to recruit talent from an increasingly global pool. We aspire to become less inhibited by job location requirements or candidate mobility preferences when searching for the highest caliber talent to fill openings. However, these efforts may not achieve the intended results in any particular time frame, or at all, or may have unanticipated negative consequences, including possible negative impacts on company culture and productivity. In addition, in many of the specialized fields from which we draw talent, such as clinical development, biosciences, chemistry, drug manufacturing and IT, and in many senior leadership positions, high demand will continue to limit the pool of external talent and increase the risk of turnover.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">16</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Legal and compliance</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Challenges in keeping up with legal and regulatory requirements, and evolving societal expectations</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We are obligated to comply with the laws of all of the countries in which we operate and sell products with respect to an extremely wide and growing range of activities. Such legal requirements are extensive and complex. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The laws and regulations relevant to the healthcare industry and applicable to us are broad in scope and are subject to change and evolving interpretations, which could require us to incur substantial costs associated with compliance or to alter one or more of our business practices. For example, we have been, are currently and may in the future be subject to various significant legal proceedings, such as private party litigation, government investigations and law enforcement actions worldwide. These types of matters may take various forms based upon evolving government enforcement and private party litigation priorities, and could include matters pertaining to pricing; bribery and corruption; trade regulation and embargo legislation; product liability; commercial disputes; employment and wrongful discharge; antitrust; securities; government benefit programs; reimbursement; rebates; healthcare fraud; sales and marketing practices; insider trading; occupational health and safety; environmental regulations; tax; cybersecurity; data privacy; regulatory interactions; and intellectual property. Such activities can involve criminal proceedings, and can retroactively challenge practices previously considered to be legal. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There is also a risk that governance for our medical and patient support activities, and our interactions with governments, public officials/institutions, healthcare professionals, healthcare organizations and patient organizations may be inadequate or fail, or that we may undertake activities based on improper or inadequate scientific justification.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our Sandoz Division may from time to time seek approval to market a generic version of a product before the expiration of patents claimed by the marketer of the patented product. We do this in cases where we believe the relevant patents are invalid or unenforceable, or would not be infringed by our generic product. As a result, affiliates of our Sandoz Division frequently face patent litigation, and in certain circumstances, we may make the business decision to market a generic product even though patent infringement actions are still pending. Should we elect to do so and conduct a so-called &#x201C;launch at risk,&#x201D; we could face substantial damages if the final court decision is adverse to us.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Legal proceedings and investigations are inherently unpredictable, and large judgments sometimes occur. As a consequence, we may in the future incur judgments that could involve large payments, including the potential repayment of amounts allegedly obtained improperly, and other penalties, including treble damages. In addition, such legal proceedings and investigations, even if meritless, may affect our reputation, may create a risk of potential exclusion from government reimbursement programs in the US and other countries, and may lead to civil litigation. As a result, having taken into account all relevant factors, we have in the past and may again in the future enter into major settlements of such claims without bringing them to final legal adjudication by courts or other such bodies, despite having potentially significant defenses against them, in order to limit the risks they pose to our business and reputation. Such settlements may require us to pay significant sums of money and to enter into corporate integrity or similar agreements, which are intended to regulate company behavior for extended periods. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For information on significant legal matters pending against us, see &#x201C;Item 18. Financial Statements&#x2014;Note 22. Provisions and other non-current liabilities&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 28. Commitments and contingencies.&#x201D;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">New requirements may also be imposed on us as a result of changing government and societal expectations regarding the healthcare industry, and acceptable corporate behavior generally. For example, we are faced with laws and regulations requiring changes in how we do business, including with respect to disclosures concerning our interactions with healthcare professionals, healthcare organizations and patient organizations. These laws and regulations include requirements that we disclose payments or other transfers of value made to healthcare professionals and organizations, as well as information relating to the costs and prices for our products, which represent evolving standards of acceptable corporate behavior. These requirements may incur significant costs, including substantial time and additional resources, that are necessary to bring our interactions with healthcare professionals and organizations into compliance with these evolving standards.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition to legal and regulatory requirements, as a company we aim to meet the evolving societal expectations of the public and our investors regarding ethical behavior and the increasing importance placed on ESG matters. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To help us in our efforts to comply with the many requirements that impact us, we have a significant global ethics and compliance program in place, and we devote substantial time and resources to efforts to ensure that our business is conducted in a lawful and publicly acceptable manner. Despite our efforts, an actual or alleged failure to comply with law or with heightened public expectations could lead to substantial liabilities that may not be covered by insurance, or to other significant losses.</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Data privacy</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Noncompliance with personal data protection laws and regulations</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We operate in an environment that relies on the collection, processing, analysis and interpretation of large sets of patients&#x2019; and other individuals&#x2019; personal information, including via social media and mobile technologies. Also, the operation of our business requires data to flow freely across borders of numerous countries in which there are </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">17</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">different, and potentially conflicting, frequently changing data privacy laws in effect. For example, the EU General Data Protection Regulation (GDPR), which took effect in May 2018; the California Consumer Privacy Act, which took effect in January 2020; and Brazil&#x2019;s General Personal Data Protection Law, which entered into force in September 2020, impose stringent requirements on how we and third parties with whom we contract collect, share, export or otherwise process personal information, and provide for significant penalties for noncompliance. Further examples of countries with data-specific requirements governing where data is stored and whether it can be transferred outside the country are Russia and China. Breaches of our systems or those of our third-party contractors, or other failures to protect the data we collect from misuse or breach by third parties, could expose such personal information to unauthorized persons. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Any event involving the substantial loss of personal information, use of personal information without a legal basis, or other privacy violations could give rise to significant liability, reputational harm, damaged relationships with business partners, and potentially substantial monetary penalties under laws enacted or being enacted around the world. Such events could also lead to restrictions on our ability to use personal information and/or transfer personal information across country borders. In addition, there is a trend of increasing divergence of data privacy legal frameworks, not only across these frameworks but also within individual legal frameworks themselves. This divergence may constrain the implementation of global business processes and may lead to different approaches on the use of health data for scientific research, which may have a negative impact on our business and operations.</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Supply chain</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inability to maintain continuity of product supply</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Many of our products are produced using technically complex manufacturing processes and require a supply of highly specialized raw materials. For some of our products and raw materials, we may rely on a single source of supply. In addition, we manufacture and sell a number of sterile products, biologic products, and products involving advanced therapy platforms, such as CAR-T therapies, gene therapies and radioligand therapy products, all of which are particularly complex and involve highly specialized manufacturing technologies. Because the production process for some of our products is complex, there is a risk of production failures, which may result in supply interruptions or product recalls due to defective product being distributed to the market.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, due to the inherent complexities of our production processes, we are required to plan our production activities well in advance. If we suffer from third-party raw material shortages, underestimate market demand for a product, or fail to accurately predict when a new product will be approved for sale, then we may not be able to produce sufficient product to meet demand. These issues could be made worse during a pandemic like the COVID-19 pandemic, and can lead to (i) a sudden increase in demand for selected medicinal products, resulting in the short-term unavailability of raw material; (ii) logistical and supply challenges that may lead to our inability to ship products from one place to another due to restrictions imposed as a result of a pandemic, which can impact transportation and warehousing costs; or (iii) our inability to properly operate a production site due to restrictions imposed as the result of a pandemic.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our or our third-party suppliers&#x2019; inability to manage such issues could lead to shutdowns, to product shortages, or to our being entirely unable to supply products to patients for an extended period of time. Further, because our products are intended to promote the health of patients, such shortages or shutdowns could endanger our reputation and have led to, and could continue to lead to, significant losses of sales revenue, potential litigation or allegations that the public health, or the health of individuals, has been harmed.</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Falsified medicines</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Impact on patient safety and reputational and financial harm to Novartis and our products</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We continue to be challenged by the vulnerability of distribution channels to falsified medicines, which include counterfeit, stolen, tampered and illegally diverted medicines under the definition of the World Health Organization. The COVID-19 pandemic has substantially increased the presence of falsified medicines in the markets affected and on the internet. Falsified medicines pose patient safety risks and can be seriously harmful or life-threatening. Reports of adverse events related to falsified medicines and increased levels of falsified medicines in the healthcare system affect patient confidence in our genuine medicines and in healthcare systems in general. These events could also cause us substantial reputational and financial harm, and potentially lead to litigation if the adverse event from the falsified medicine is mistakenly attributed to the genuine one. Stolen or illegally diverted medicines, which are then not properly stored and are later sold through unauthorized channels, could adversely impact patient safety, our reputation and our business. Further, there is a direct financial loss when, for example, falsified medicines replace sales of genuine medicines, or genuine medicines are recalled following discovery of falsified products.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Emerging risks</font>
</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Geo-political and socio-economic threats</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Negative impact of geo- and socio-political threats and economic instability</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Unpredictable political conditions currently exist in various parts of the world, including a backlash in certain areas against free trade; anti-immigrant sentiment; </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">18</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">anti-corporatist sentiment; social unrest; fears of terrorism; risk of direct conflicts between nations; a global pandemic; and economic downturn. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The imposition of tariffs, including those imposed by the US and China, and the possibility of additional tariffs or other trade restrictions relating to trade between the US and other countries, could have a material negative impact on our business. Given that the status of trade negotiations remains subject to change, we cannot be certain of the nature or extent of the potential impact on our business. For example, if tariffs on pharmaceutical products or active pharmaceutical ingredients (APIs) were increased, this could impact the profitability of our products and disrupt our supply chain. Increasing opposition to free trade may increase the risks we face in our efforts to improve and harmonize standards in regulation and intellectual property.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Furthermore, significant conflicts continue in certain parts of the world. Collectively, such unstable conditions could, among other things, disturb the international flow of goods and increase the costs and difficulties of international transactions, which could significantly impact time to market and our ability to supply our products to patients in an undisrupted fashion, and further erode reimbursement levels for innovative therapies. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, local economic conditions may adversely affect the ability of payers, as well as our distributors, customers, suppliers and service providers, to pay for our products, or otherwise to buy necessary inventory or raw materials, and to perform their obligations under agreements with us. Although we make efforts to monitor these third parties&#x2019; financial condition and their liquidity, our ability to do so is limited, and some of them may become unable to pay their bills in a timely manner, or may even become insolvent. These risks may be elevated with respect to our interactions with fiscally challenged government payers, or with third parties with substantial exposure to such payers.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our business may be impacted by economic and financial conditions directly affecting consumers. Given that in many countries, patients directly pay a large portion of their own healthcare costs, there is a risk that consumers may cut back on prescription drugs due to financial constraints. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">At the same time, significant changes and potential future volatility in the financial markets, in the consumer and business environment, in the competitive landscape, and in the global political and security landscape make it increasingly difficult for us to predict our revenues and earnings. As a result, any revenue or earnings guidance or outlook that we have given or might give may be overtaken by events, or may otherwise turn out to be inaccurate. Though we endeavor to give reasonable estimates of future revenues and earnings at the time we give such guidance, based on then-current knowledge and conditions, there is a risk that such guidance or outlook will turn out to be incorrect.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Financial market issues may also result in a lower return on our financial investments, and a lower value on some of our assets. Alternatively, inflation could accelerate, which could lead to higher interest rates, increasing our costs of raising capital. Uncertainties around future central bank and other economic policies in the US and EU, as well as high debt levels in certain other countries, could also impact world trade. Sudden increases in economic, currency or financial market volatility in different countries have also impacted, and may continue to unpredictably impact, our business or results of operations, including the conversion of our operating results into our reporting currency, the US dollar, as well as the value of our investments in our pension plans. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For a discussion of effect of price controls on our business, see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B&#x2014;Business overview&#x2014;Innovative Medicines&#x2014;Price controls.&#x201D; See also &#x201C;Item 5. Operating and Financial Review and Prospects&#x2014;Item 5.B Liquidity and capital resources&#x2014;Effects of currency fluctuations,&#x201D; &#x201C;Item 5. Operating and Financial Review and Prospects&#x2014;Item 5.B Liquidity and capital resources&#x2014;Condensed consolidated balance sheets,&#x201D; &#x201C;Item 18. Financial Statements&#x2014;Note 15. Trade receivables&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 29. Financial instruments&#x2014;additional disclosures.&#x201D;</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Social media and digital engagement </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inappropriate or illegal use of social media, interactive internet platforms or mobile applications</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our increasing use of social media, interactive internet platforms and other mobile applications (together, digital engagement platforms) carries risks related to potential violations of rules regulating the promotion of prescription medicines and the potential disclosure of confidential information, trade secrets, or loss of other intellectual property. As a result of the COVID-19 pandemic, the use and rate of adoption of digital engagement platforms is increasing and expanding into new uses that may have unforeseen impacts and consequences on our business.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There continue to be uncertainties as to the rules that apply to such communications and as to the interpretations that health authorities will apply in this context, and as a result, despite our efforts to comply with applicable rules, there is a risk that our use of digital engagement platforms may cause us to be found in violation of applicable regulations.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For example, patients may use digital engagement platforms to comment on the effectiveness of a product or to report an adverse event, which may result in a failure to follow applicable adverse event reporting obligations if such platforms are not properly monitored. In addition, our associates may use digital engagement platforms inappropriately, for example to discuss our products or confidential projects, which may lead to a disclosure of confidential information, trade secrets, or loss of other intellectual property, and may give rise to liability or incur other harm to our business. Further, large numbers of or highly visible negative posts or comments about us or our executives could damage our reputation.</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Global ERP implementation</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inability to implement and properly operate our new global enterprise resource planning (ERP) system</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">19</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We rely on various information and other business systems to leverage data in order to operate our complex global business. We are currently in the design and planning phase for the implementation of a new global ERP system that seeks to simplify, standardize and digitize processes in our commercial and finance functions as well as our Novartis Technical Operations unit to help ensure efficient and compliant business operations as well as the availability of high-quality data necessary to aid our decision-making. We expect the planning, design and build phase to continue through 2021, with the first implementations of our new ERP system expected to begin in the second half of 2022. We expect our new ERP system to be fully implemented by 2027, when our current system is no longer supported by the software provider. Implementing and operating a new ERP system involves certain risks, including a failure of the new system to operate as expected, a failure to properly integrate with other systems we use, potential loss of data or information, compliance issues, cost overruns and delays, and operational disruptions. Any disruptions or malfunctions of our new ERP system could cause critical information we use to be delayed, defective, corrupted, inadequate or inaccessible. In addition, if the design or implementation of our new ERP system is deficient, it could adversely affect our operations, and could negatively impact the effectiveness of our internal controls.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">General risks</font>
</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Indebtedness</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our indebtedness could adversely affect our operations</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As of December 31, 2020, we had USD 26.3 billion of non-current financial debt, and USD 9.8 billion of current financial debt. Our current and long-term debt requires us to dedicate a portion of our cash flow to service interest and principal payments and, if interest rates rise, this amount may increase. As a result, our existing debt may limit our ability to use our cash flow to fund capital expenditures, to engage in transactions, or to meet other capital needs, or otherwise may place us at a competitive disadvantage relative to competitors that have less debt. Our debt could also limit our flexibility to plan for and react to changes in our business or industry, and increase our vulnerability to general adverse economic and industry conditions, including changes in interest rates or a downturn in our business or the economy. We may also have difficulty refinancing our existing debt or incurring new debt on terms that we would consider to be commercially reasonable, if at all.</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Intangible assets and goodwill</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Intangible assets and goodwill resulting in significant impairment charges</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We carry a significant amount of goodwill and other intangible assets on our consolidated balance sheet, primarily due to acquisitions, including, in particular, substantial goodwill and other intangible assets obtained through acquisitions, including most recently through our acquisitions of The Medicines Company, <i>Xiidra</i>, Endocyte, Novartis Gene Therapies (formerly AveXis), AAA, and certain oncology products from GSK. As a result, we may incur significant impairment charges in the future if the fair value of the intangible assets and the groupings of cash-generating units containing goodwill would be less than their carrying value on the Group&#x2019;s consolidated balance sheet at any point in time.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We regularly review for impairment our long-lived intangible and tangible assets, including identifiable intangible assets, investments in associated companies, and goodwill. Any significant impairment charges could have a material adverse effect on our results of operations and financial condition. In 2020, for example, we recorded intangible asset impairment charges of USD 914 million. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For a detailed discussion of how we determine whether an impairment has occurred, what factors could result in an impairment, and the impact of impairment charges on our results of operations, see &#x201C;Item 5. Operating and Financial Review and Prospects&#x2014;Item 5.A Operating results&#x2014;Critical accounting policies and estimates&#x2014;Impairment of goodwill, intangible assets and property, plant and equipment,&#x201D; &#x201C;Item 18. Financial Statements&#x2014;Note 1. Significant accounting policies&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 11. Goodwill and intangible assets.&#x201D;</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Tax laws and developments</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Changes in tax laws or their application</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate. Changes in tax laws or in their application could lead to an increased risk of international tax disputes and an increase in our effective tax rate, which could adversely affect our financial results. The integrated nature of our worldwide operations can produce conflicting claims from revenue authorities in different countries as to the profits to be taxed in the individual countries, including potential disputes relating to the prices our subsidiaries charge one another for intercompany transactions, known as transfer pricing. The majority of the jurisdictions in which we operate have double tax treaties with other foreign jurisdictions, which provide a framework for mitigating the impact of double taxation on our revenues and capital gains. However, mechanisms developed to resolve such conflicting claims are largely untried and can be expected to be very lengthy. Accruals for tax contingencies are made based on past experience, interpretations of tax law, and judgments about potential actions by tax authorities; however, due to the complexity of tax contingencies, the ultimate resolution of any tax matter may result in payments materially different from the amounts accrued.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">20</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2019, the Organization for Economic Co-operation and Development (OECD) launched a new initiative on behalf of the G20 to minimize profit shifting by working toward a global tax framework that ensures that corporate income taxes are paid where consumption takes place and also introduces a global standard on minimum taxation combined with new tax dispute resolution processes. The respective principles are currently being evaluated. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The EU also adopted a new Directive on Administrative Cooperation (DAC6) in 2018, which seeks additional reporting since July 2020. Recently, the EU announced it will introduce new centralized taxation powers to address the financial impact of the COVID-19 pandemic. In addition, the European Commission continues to extend the application of its policies seeking to limit fiscal aid by member states to particular companies, and the related investigation of the member states&#x2019; practices regarding the issuance of rulings on tax matters relating to individual companies.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In Switzerland, the Basel-Stadt Cantonal Tax Reform was approved by voters in February 2019, with parts retroactive from January 1, 2019. In May 2019, Swiss voters approved the Swiss Federal Tax Reform. With the enactment of this tax reform, new elements were introduced into law as of January 1, 2020.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Although we have taken steps to be in compliance with evolving initiatives like that of the OECD, the EU and of Switzerland, and will continue to do so, significant uncertainties remain as to the outcome of our efforts.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For more information, see &#x201C;Item 18. Financial Statements&#x2014;Note 12. Deferred tax assets and liabilities.&#x201D;</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Foreign currency exchange rates</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Negative effect on financial results due to foreign currency exchange rate fluctuations</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Changes in exchange rates between the US dollar, our reporting currency, and other currencies can result in significant increases or decreases in our reported sales, costs and earnings as expressed in US dollars, and in the reported value of our assets, liabilities and cash flows.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition to ordinary market risk, there is a risk that countries could take affirmative steps that could significantly impact the value of their currencies. Such steps could include &#x201C;quantitative easing&#x201D; measures and potential withdrawals by countries from common currencies. In addition, countries facing local financial difficulties, including countries experiencing high inflation rates and highly indebted countries facing large capital outflows, may impose controls on the exchange of foreign currency. Currency exchange controls could limit our ability to distribute retained earnings from our local affiliates, or to pay intercompany payables due from those countries. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Despite measures undertaken to reduce or hedge against foreign currency exchange risks, because a significant portion of our earnings and expenditures are in currencies other than the US dollar, including expenditures in Swiss francs that are significantly higher than our revenue in Swiss francs, any such exchange rate volatility may negatively and materially impact our results of operations and financial condition, and may impact the reported value of our net sales, earnings, assets and liabilities. In addition, the timing and extent of such volatility can be difficult to predict. Further, depending on the movements of particular foreign exchange rates, we may be materially adversely affected at a time when the same currency movements are benefiting some of our competitors.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For more information on the effects of currency fluctuations on our consolidated financial statements and on how we manage currency risk, see &#x201C;Item 5. Operating and Financial Review and Prospects&#x2014;Item 5.B Liquidity and capital resources&#x2014;Effects of currency fluctuations&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 29. Financial instruments&#x2014;additional disclosures.&#x201D;</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Key customers</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Ongoing consolidation among our distributors and retailers, and the concentration of credit risk</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Increasingly, a significant portion of our global sales is made to a relatively small number of drug wholesalers, retail chains and other purchasing organizations. For example, our three most important customers globally accounted for approximately 17%, 11% and 6%, respectively, of net sales in 2020. The largest trade receivables outstanding were for these three customers, amounting to 14%, 12% and 6%, respectively, of the Group&#x2019;s trade receivables at December 31, 2020. The trend has been toward further consolidation among distributors and retailers. As a result, we may be affected by fluctuations in the buying patterns of such customers. Furthermore, these customers are gaining additional purchasing leverage, increasing the pricing pressures facing our businesses. These pressures can particularly impact our Sandoz Division, the generic products of which can often be obtained from numerous competitors. Moreover, we are exposed to a concentration of credit risk as a result of this concentration among our customers. If one or more of our major customers experienced financial difficulties, the effect on us would be substantial, and could include a substantial loss of sales and an inability to collect amounts owed to us.</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Environmental matters</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Impact of environmental liabilities</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The environmental laws of various jurisdictions impose actual and potential obligations on us to investigate and remediate contaminated sites, including in connection with activities in the past by businesses that are no longer part of Novartis. In some cases, these remediation efforts may take many years. While we have set aside substantial provisions for known worldwide environmental liabilities that are probable and estimable, there is no guarantee that additional costs will not be incurred beyond the amounts for which we have provided in the </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">21</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Group consolidated financial statements. If environmental contamination related to our facilities or products adversely impacts third parties or if we fail to properly manage the safety of our facilities, including the safety of our associates and contractors, and the environmental risks, we may face substantial costs and other expenses, and be required to further increase our provisions for environmental liabilities. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">See also &#x201C;Item 4. Information on the Company&#x2014;Item 4.D Property, plants and equipment&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 20. Provisions and other non-current liabilities.&#x201D;</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Climate change</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Climate change and increased risk of major natural disasters</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis is exposed to both physical risks and transition risks (which include financial, credit rating and market-driven risks) associated with climate change, which could be either acute/short-term or chronic/long-term.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Extreme weather events and changing weather patterns have become more common. As a result, we are potentially exposed to increased extreme weather and associated risks such as hurricanes, tornadoes, droughts or floods, or other events that result from the impact of climate change on the environment, such as loss of biodiversity, sea level rise or wildfires. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For example, some of our production facilities that depend on the availability of significant water supplies are located in areas where water is increasingly scarce. Other facilities are located in places that, because of increasingly violent weather events, sea level rise, or both, are increasingly at risk of substantial flooding. In regions where this risk is present, it impacts not only our own operations but also our distributed supply chain. Such events could result in increased costs, business interruptions, destruction of facilities, and loss of life. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Climate change may trigger the adoption of new regulatory requirements across the globe. Such legislation could include increased requirements to invest in technology to reduce energy use, water use and greenhouse gas emissions, beyond what we expect to invest in our existing plans. In addition, legislation could include carbon pricing, climate risk disclosure mandates, and changes in zoning or building codes to increase climate resilience. The combined impact of these transition risks could increase our direct operating costs and result in the same impact across our supply chain.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, our corporate headquarters, the headquarters of our Innovative Medicines and Sandoz Divisions, and certain of our major Innovative Medicines Division production and research facilities are located near earthquake fault lines in Basel, Switzerland. Other major facilities are located near major earthquake fault lines in various locations around the world. In the event of a major earthquake, we could experience business interruptions, destruction of facilities, and loss of life.</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Pension plans </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inaccuracies in the assumptions and estimates used to calculate our pension plan and other post-employment obligations</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We sponsor pension and other post-employment benefit plans in various forms that cover a significant portion of our current and former associates. For post-employment plans with defined benefit obligations, we are required to make significant assumptions and estimates about future events in calculating the expense and the present value of the liability related to these plans. These include assumptions about the discount rates we apply to estimate future defined benefit obligations and net periodic pension expense, as well as rates of future pension increases. In addition, our actuarial consultants provide our management with historical statistical information, such as withdrawal and mortality rates in connection with these estimates. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Assumptions and estimates we use may differ materially from the actual results we experience due to changing market and economic conditions, higher or lower withdrawal rates, and longer or shorter life spans of participants, among other factors. Depending on events, such differences could have a material effect on our total equity and may require us to make additional contributions to our pension funds.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For more information on obligations under retirement and other post-employment benefit plans and underlying actuarial assumptions, see &#x201C;Item 5. Operating and Financial Review and Prospects&#x2014;Item 5.A Operating results&#x2014;Critical accounting policies and estimates&#x2014; Retirement and other post-employment benefit plans&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 25. Post-employment benefits for associates.&#x201D;</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">22</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00339728"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;4.  Information on the Company</p><a name="anchorId00339730"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">4.A History and development of Novartis</p><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Novartis AG</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis AG was incorporated on February&#xA0;29, 1996, under the laws of Switzerland as a stock corporation (&#x201C;Aktiengesellschaft&#x201D;) with an indefinite duration. On December&#xA0;20, 1996, our predecessor companies, Ciba-Geigy AG and Sandoz AG, merged into this new entity, creating Novartis. We are domiciled in and governed by the laws of Switzerland. Our registered office is located at the following address:</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Novartis AG</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Lichtstrasse 35</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">CH-4056 Basel, Switzerland</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Telephone: +41-61-324-1111</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Web: www.novartis.com</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Novartis is a multinational group of companies specializing in the research, development, manufacturing and marketing of a broad range of innovative pharmaceuticals and cost-saving generic medicines. Novartis AG, our Swiss holding company, owns, directly or indirectly, all of our significant operating companies. For a list of our significant operating subsidiaries, see &#x201C;Item 18. Financial Statements&#x2014;Note 32. Principal Group subsidiaries and associated companies.&#x201D;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">For a description of important corporate developments since January 1, 2018, see &#x201C;Item 18. Financial Statements&#x2014;Note 2. Significant Transactions.&#x201D;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The SEC maintains an internet site at http://www.sec.gov that contains reports, information statements, and other information regarding issuers that file electronically with the SEC.</div><a name="anchorId00339752"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">4.B Business overview</p><a name=""></a><div style="padding-top:10px;  padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Overview</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our purpose is to reimagine medicine to improve and extend people&#x2019;s lives. We use innovative science and technology to address some of society&#x2019;s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company. Our vision is to be a trusted leader in changing the practice of medicine. Our strategy is to build a leading, focused medicines company powered by advanced therapy platforms and data science. As we implement our strategy, we have five priorities to shape our future and help us continue to create value for our company, our shareholders and society: unleash the power of our people, deliver transformative innovation, embrace operational excellence, go big on data and digital, and build trust with society.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2020, Novartis achieved net sales from continuing operations of USD 48.7&#xA0;billion, while net income from continuing operations amounted to USD 8.1&#xA0;billion, and total net income amounted to USD 8.1 billion. Headquartered in Basel, Switzerland, our Group companies employed approximately 106 000 full-time equivalent associates as of December&#xA0;31, 2020. Our products are sold in approximately 155 countries around the world.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group comprises two global operating divisions:</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">&#xA0;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">&#x2022; Innovative Medicines: innovative patent-protected prescription medicines</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:11px;margin-right:0mm;margin-top:0mm;">For a description of our Innovative Medicines Division, see &#x201C;&#x2014;Innovative Medicines&#x2014;Overview&#x201D; below.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">&#x2022; Sandoz: generic pharmaceuticals and biosimilars</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:11px;margin-right:0mm;margin-top:0mm;">For a description of our Sandoz Division, see &#x201C;&#x2014;Sandoz&#x201D; below.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our divisions are supported by the following organizational units: the Novartis Institutes for BioMedical Research (NIBR), Global Drug Development (GDD), Novartis Technical Operations (NTO) and Novartis Business Services (NBS). The financial results of these organizational units are included in the results of the divisions for which their work is performed. For more information about NIBR, see &#x201C;&#x2014;Innovative Medicines&#x2014;Research and development&#x2014;Research program&#x201D; below.  For more information about GDD, see &#x201C;&#x2014;Innovative Medicines&#x2014;Research and development&#x2014;Development program&#x201D; below. For more information about NTO, see &#x201C;&#x2014;Item 4.D Property, plants and equipment.&#x201D; For more information about NBS, see &#x201C;Item 18. Financial Statements&#x2014;Note 3. Segmentation of key figures 2020, 2019 and 2018.&#x201D;</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Corporate activities</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We separately report the results of Corporate activities. The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries. In addi-</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">23</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">tion, Corporate includes other items of income and expense that are not attributable to specific segments, such as certain revenues from intellectual property rights and certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations and sponsorships.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"> </div><a name="anchorId00339786"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Innovative Medicines</p><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Overview</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our Innovative Medicines Division is a world leader in offering patent-protected medicines to patients and physicians. The Innovative Medicines Division researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two global business units: Novartis Oncology and Novartis Pharmaceuticals.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Novartis Oncology business unit is responsible for the commercialization of products in the areas of cancer and hematologic disorders. The Novartis Pharmaceuticals business unit is organized into the following global business franchises responsible for the commercialization of various products in their respective therapeutic areas: Immunology, Hepatology and Dermatology; Ophthalmology; Neuroscience; Cardiovascular, Renal and Metabolism; Respiratory; and Established Medicines. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Innovative Medicines Division is the larger of our two divisions in terms of consolidated net sales. It reported consolidated net sales of USD 39.0&nbsp;billion in 2020, which represented 80% of the Group&#x2019;s net sales.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The product portfolio of the Innovative Medicines Division includes a significant number of key marketed products, many of which are among the leaders in their respective therapeutic areas.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Innovative Medicines Division products</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following summaries describe certain key marketed products in our Innovative Medicines Division, listed according to year-end net sales within each franchise. While we typically seek to sell our marketed products throughout the world, not all products and indications are available in every country. Therefore, the indications described in these summaries may vary by country. In addition, a product may be available under different brand names depending on country and indication. Some of the products described below have lost patent protection or are otherwise subject to generic competition. Others are subject to patent challenges by potential generic competitors. Please see &#x201C;&mdash;Intellectual property&#x201D; for general information on intellectual property and regulatory data protection, and for further information on the status of patents and exclusivity for Innovative Medicines Division products.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key marketed products</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Novartis Oncology business unit</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;">Oncology</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Tasigna </i>(nilotinib) is an oral tyrosine kinase inhibitor targeting the BCR-ABL protein. It is approved in the US, the EU and other countries to treat:</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic and/or accelerated phase who are resistant or intolerant to existing treatment. Ph+ CML is a cancer that starts in the blood-forming cells of bone marrow </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Newly diagnosed adults and children with Ph+ CML in the chronic phase </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Promacta/Revolade</i> (eltrombopag) is a once-daily oral thrombopoietin receptor agonist that works by stimulating bone marrow cells to produce platelets. It is approved in the US, the EU and other countries to treat:</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Immune thrombocytopenia (ITP) in patients who have had an insufficient response to or have failed previous therapies. ITP is a bleeding disorder caused by an unusually low number of platelets </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Thrombocytopenia in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Patients with severe aplastic anemia (SAA). SAA is a condition in which the body does not produce enough blood cells</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;"><i>Promacta/Revolade</i> is marketed under a research, development and license agreement between Novartis and RPI Finance Trust (dba Royalty Pharma), as assignee of Ligand Pharmaceuticals.</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Tafinlar&nbsp;</i>+<i>&nbsp;Mekinist</i> (dabrafenib + trametinib) is an oral combination therapy. <i>Tafinlar</i> and <i>Mekinist</i> are kinase inhibitors of the BRAF and MEK1/2 proteins, respectively, approved in combination in the US, the EU and other countries to treat patients who have certain types of cancer with a change in the BRAF gene (called a BRAF V600 mutation), including: </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with unresectable or metastatic melanoma with a BRAF V600 mutation. Melanoma is a form of skin cancer; unresectable melanoma cannot be removed with surgery, and metastatic melanoma has spread to other parts of the body. <i>Tafinlar</i> and <i>Mekinist</i> are also approved as single agents for this indication</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with stage III melanoma with a BRAF V600 mutation as an adjuvant treatment (following surgery)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation. NSCLC is the most common type of lung cancer </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">24</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with locally advanced or metastatic anaplastic thyroid cancer with a BRAF V600 mutation and no satisfactory treatment options. Anaplastic thyroid cancer is a rare and aggressive form of thyroid cancer</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Approved indications vary by country. Novartis has worldwide exclusive rights to develop, manufacture and commercialize trametinib granted by Japan Tobacco Inc.</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Sandostatin</i> SC (octreotide acetate for injection) and <i>Sandostatin LAR</i> (octreotide acetate for injectable suspension) are somatostatin analogs approved in the US, the EU and other countries to treat:</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with acromegaly that is inadequately controlled by surgery or radiotherapy. Acromegaly is a chronic disease caused by the oversecretion of growth hormone</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Patients with certain symptoms associated with carcinoid tumors and other types of functional gastrointestinal and pancreatic neuroendocrine tumors</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;"><i>Sandostatin LAR</i> is also approved in the EU and other countries to treat patients with advanced neuroendocrine tumors of the midgut or of unknown primary tumor origin. </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Jakavi</i> (ruxolitinib) is an oral inhibitor of the JAK1 and JAK2 tyrosine kinases. It is the first therapy approved in the EU and other countries to treat: </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with myelofibrosis (MF), including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. MF is a rare blood cancer characterized by abnormal blood cell production and scarring in the bone marrow, which can lead to an enlarged spleen</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with polycythemia vera (PV) who are resistant or intolerant to a medication called hydroxyurea. PV is a rare blood cancer in which the bone marrow produces too many red blood cells, resulting in serious problems like clots   </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Novartis licensed ruxolitinib from Incyte Corporation for development and commercialization in the indications of oncology, hematology and graft-versus-host disease outside the US. Incyte Corporation markets ruxolitinib as Jakafi<sup>&#xAE;</sup> in the US. </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"><i>&#x2022;</i><i> Gleevec/Glivec</i> (imatinib mesylate/imatinib) is an oral tyrosine kinase inhibitor approved in the US, the EU and other countries to treat patients with certain types of cancer, including:</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic, accelerated or blast crisis (acute) phase. Ph+ CML is a cancer that starts in the blood-forming cells of bone marrow</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults and children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Ph+ ALL is a rare subtype of the most common childhood cancer </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with KIT (CD117)-positive gastrointestinal stromal tumors (GISTs). GISTs are tumors found in the digestive system  </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have a rearrangement of two genes called FIP1L1 and PDGFR-alpha. HES and CEL are closely related diseases in which the body produces too many eosinophils (a type of white blood cell)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with myelodysplastic syndromes (MDS) and myeloproliferative disorders (MPD). MDS and MPD are a group of diseases of the blood and bone marrow</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with aggressive systemic mastocytosis (ASM) and dermatofibrosarcoma protuberans (DFSP) when surgery is not possible or the disease has spread. ASM is a form of mast cell disease, and DFSP is a rare skin cancer </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Approved indications vary by country.</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Afinitor/Votubia</i> (everolimus) is an oral inhibitor of the mTOR pathway. <i>Afinitor</i> is approved in the US, the EU and other countries to treat patients with certain types of cancer, including:</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Postmenopausal women with advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer, in combination with the medicine exemestane, when certain other medicines have not worked. HR+/HER2- breast cancer is the most common subtype of breast cancer </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with neuroendocrine tumors of the pancreas, and non-symptomatic neuroendocrine tumors of the stomach and intestine (gastrointestinal) or lung that have progressed and cannot be treated with surgery </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Everolimus is also approved as <i>Afinitor/Afinitor Disperz</i> in the US and other countries, and as <i>Votubia</i> (tablets and dispersible tablets) in the EU, to treat certain patients with a genetic condition called tuberous sclerosis complex (TSC), including:</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with TSC and angiomyolipoma (a kidney tumor) when the tumor does not require immediate surgery </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults and children with TSC and subependymal giant cell astrocytoma (a brain tumor) when the tumor cannot be removed completely by surgery</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Approved indications vary by country. Everolimus is available under the trade names <i>Zortress/Certican</i> for use in transplantation, and is exclusively licensed to Abbott Laboratories and sublicensed to Boston Scientific for use in drug-eluting stents.</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Kisqali</i> (ribociclib) is an oral cyclin-dependent kinase inhibitor approved in the US, the EU and other countries to treat: </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Pre-, peri- and postmenopausal women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer, in combination with an aromatase inhibitor as initial endo-</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">25</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">crine-based therapy. HR+/HER2- breast cancer is the most common subtype of breast cancer </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Postmenopausal women with HR+/HER2- locally advanced or metastatic breast cancer, in combination with fulvestrant, as first- or second-line therapy</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;"><i>Kisqali</i> was developed by the Novartis Institutes for BioMedical Research under a research collaboration with Astex Pharmaceuticals.</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Kymriah </i>(tisagenlecleucel) suspension for intravenous infusion is a CD19-directed genetically modified autologous chimeric antigen receptor T-cell (CAR-T) therapy. It is approved in the US, the EU and other countries to treat: </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Patients up to 25&nbsp;years old with B-cell acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. ALL is a cancer of the lymphocytes, a type of white blood cell involved in the body&#x2019;s immune system </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. DLBCL is the most common form of non-Hodgkin lymphoma and a cancer of the B-lymphocytes  </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Lutathera</i> (lutetium Lu 177 dotatate/lutetium (<sup>177</sup>Lu) oxodotreotide) is an intravenous targeted radioligand therapy approved in the US, the EU and other countries to treat:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). GEP-NETs are rare tumors found in the digestive tract, including the foregut, midgut and hindgut    </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Piqray</i> (alpelisib) is an oral kinase inhibitor approved in the US, the EU and other countries to treat:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Postmenopausal women, and men, with PIK3CA-mutated, hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer, in combination with fulvestrant, after disease progression following endocrine therapy as monotherapy (EU), or after disease progression on or following endocrine therapy (US). HR+/HER2- breast cancer is the most common subtype of breast cancer</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Adakveo</i> (crizanlizumab) is a humanized monoclonal antibody that binds to P-selectin, a cell adhesion protein that plays a central role in the multicellular interactions that can lead to vaso-occlusion in sickle cell disease (SCD). Delivered via intravenous infusion, <i>Adakveo</i> is approved in the US, the EU and other countries to:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Prevent or reduce the frequency of vaso-occlusive crises (VOCs), or pain crises, in patients aged 16 years and older with SCD. SCD is a group of inherited blood disorders in which the body makes abnormally shaped red blood cells that become sticky and can block blood vessels, leading to unpredictable, painful VOCs   </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Novartis Pharmaceuticals business unit</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;">Immunology, Hepatology and Dermatology<sup>1</sup></div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"><i>&#x2022;</i><i> Cosentyx</i> (secukinumab) is an injectable fully human monoclonal antibody that specifically inhibits interleukin-17A (IL-17A), a cytokine involved in several immunological diseases. It is approved in the US, the EU and other countries to treat:</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Patients with moderate-to-severe plaque psoriasis. Psoriasis is a debilitating systemic inflammatory disease that is characterized by the appearance of raised, red patches on the skin </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with active ankylosing spondylitis (AS). AS is a long-term inflammatory disease that is characterized by chronic back pain and is generally visible on X-rays</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with active non-radiographic axial spondyloarthritis (nr-axSpA). nr-axSpA is a long-term inflammatory disease that is characterized by chronic back pain and is not visible on X-rays</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with active psoriatic arthritis (PsA). PsA is a type of inflammatory arthritis that results in swollen and painful joints and tendons</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;">Ophthalmology</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"><i>&#x2022;</i><i> Lucentis</i> (ranibizumab) is a recombinant, humanized, high-affinity antibody fragment that binds to vascular endothelial growth factor A (VEGF-A), a protein that can cause the growth of blood vessels in the eye, potentially leading to vision loss. <i>Lucentis</i> is an anti-VEGF therapy that is injected into the eye. It is approved in the EU and other countries to treat patients with certain eye conditions, including:</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with neovascular (wet) age-related macular degeneration (AMD). Wet AMD develops when abnormal blood vessels grow under the macula and leak blood and other fluids in the back of the eye, which can scar the macula</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with proliferative diabetic retinopathy, non-proliferative diabetic retinopathy and/or diabetic macular edema. These conditions are complications of diabetes</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO). Retinal vein occlusion&nbsp;is a blockage of the branch or central retinal vein, which carry blood away from the retina</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"><sup>1</sup>  <i>Xolair</i> sales for all indications are reported in the Respiratory franchise.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">26</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Approved indications vary by country. <i>Lucentis</i> is licensed from Genentech, and Novartis holds the rights to commercialize the product outside the US. Genentech holds the rights to commercialize <i>Lucentis</i> in the US. For further information, see &#x201C;Item 18. Financial Statements&mdash;Note 27. Transactions with related parties&mdash;Roche Holding AG.&#x201D;</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Xiidra</i> (lifitegrast 0.5%), an LFA-1 antagonist, is a prescription eye drop designed to reduce inflammation by blocking the interaction of two key proteins. It is approved in the US and other countries to treat:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The signs and symptoms of dry eye disease in adults</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Beovu</i> (brolucizumab) is the first humanized single-chain antibody fragment approved for clinical use. <i>Beovu</i> acts as an anti-VEGF agent and is administered via injection. It is approved in the US, the EU and other countries to treat:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Patients with neovascular (wet) age-related macular degeneration (AMD). Wet AMD develops when abnormal blood vessels grow under the macula and leak blood and other fluids in the back of the eye, which can scar the macula </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;">Neuroscience</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"><i>&#x2022;</i><i> Gilenya </i>(fingolimod) is an oral sphingosine-1-phosphate (S1P) receptor modulator that crosses the blood-brain barrier to bind to the S1P receptors based in the central nervous system. It is approved:  </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; In the US to treat adults and children aged 10 years and older with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (SPMS). Multiple sclerosis is a disease in which the immune system attacks the protective covering of nerves (known as myelin) </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; In the EU to treat adults and children aged 10 years and older who have highly active RRMS despite treatment with at least one disease-modifying agent, or who have rapidly evolving severe RRMS </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;"><i>Gilenya</i> is licensed from Mitsubishi Tanabe Pharma Corporation.</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Zolgensma</i> (onasemnogene abeparvovec) is a one-time intravenous gene therapy designed to address the genetic root cause of spinal muscular atrophy (SMA) by replacing the function of the missing or nonworking SMN1 gene. <i>Zolgensma</i> delivers a new working copy of the SMN1 gene into a patient&#x2019;s cells. It is approved in the US, the EU and other countries to treat:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Babies and young children who have SMA and a biallelic mutation in the SMN1 gene. SMA is a rare, genetic neuromuscular disease resulting in the progressive and irreversible loss of motor neurons, which causes muscle weakness and atrophy</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"><i>&#x2022;</i><i> Mayzent</i> (siponimod) is an oral, selective sphingosine-1-phosphate (S1P) receptor modulator that selectively binds to S1P1 and S1P5 receptors and penetrates the central nervous system, where it may impact central nervous system inflammation and repair mechanisms. It is approved:</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; In the US and other countries to treat adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (SPMS). Multiple sclerosis is a disease in which the immune system attacks the protective covering of nerves (known as myelin) </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; In the EU and other countries to treat adults with active SPMS </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Approved indications vary across other countries.</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Kesimpta</i> (ofatumumab) is an anti-CD20 monoclonal antibody that enables the targeted depletion of B-cells, specifically in lymph nodes. <i>Kesimpta</i> is self-administered as a once-monthly injection via the <i>Sensoready</i> autoinjector pen. It is approved in the US to treat:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (SPMS). Multiple sclerosis is a disease in which the immune system attacks the protective covering of nerves (known as myelin) </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Ofatumumab was originally developed by Genmab and licensed to GlaxoSmithKline (GSK). Novartis obtained the rights to ofatumumab from GSK across all indications.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;">Cardiovascular, Renal and Metabolism </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"><i>&#x2022;</i><i> Entresto</i> (sacubitril/valsartan) is an oral, first-in-class angiotensin receptor/neprilysin inhibitor. <i>Entresto</i> enhances the protective effects of a hormone system called the natriuretic peptide system, and simultaneously suppresses the harmful effects of a hormone system called the renin-angiotensin-aldosterone system. It is approved in the US, the EU and other countries to treat:</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults who have symptomatic chronic heart failure with reduced ejection fraction (HFrEF). HFrEF is a disease in which the heart cannot pump enough blood </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Children aged 1 year and older who have symptomatic heart failure with systemic left ventricular dysfunction. This is a disease in which the heart cannot pump enough blood </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Approved indications vary by country.</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Leqvio</i> (inclisiran) is an injectable small-interfering RNA that reduces LDL cholesterol in patients with atherosclerotic cardiovascular disease. <i>Leqvio</i> is administered twice a year, following an initial dose and a dose at three months. It is approved in the EU to treat:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with primary hypercholesterolemia (high cholesterol) or mixed dyslipidemia, in combination with maximally tolerated statin therapy. Mixed dyslipidemia is a disorder characterized by elevated levels of LDL cholesterol and triglycerides, and decreased levels of HDL cholesterol </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">27</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Novartis obtained global rights to develop, manufacture and commercialize inclisiran under a license and collaboration agreement with Alnylam Pharmaceuticals, Inc.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;">Respiratory</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"><i>&#x2022;</i>  <i>Xolair</i> (omalizumab) is an injectable prescription medicine and the only approved antibody designed to target and block immunoglobulin E (IgE). It is approved in the US, the EU and other countries to treat:</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults and children aged 6 years and older with moderate-to-severe, or severe, persistent allergic asthma </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults and children aged 12 years and older with chronic spontaneous urticaria/chronic idiopathic urticaria (hives)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with nasal polyps or chronic rhinosinusitis with nasal polyps (CRSwNP). CRSwNP is a chronic inflammation of the nose and the sinuses with the presence of benign lesions (nasal polyps) on the lining of the nasal sinuses or nasal cavity </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Approved indications vary by country. <i>Xolair</i> is provided as lyophilized powder for reconstitution, and as liquid formulation in a pre-filled syringe. Novartis co-promotes <i>Xolair</i> with Genentech in the US and shares a portion of operating income, but Novartis does not record any US sales. Novartis records all sales of <i>Xolair</i> outside the US. For further information, see &#x201C;Item 18. Financial Statements&mdash;Note 27. Transactions with related parties&mdash;Roche Holding AG.&#x201D;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;">Established Medicines</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"><i>&#x2022;</i><i> Galvus</i> (vildagliptin) is an oral inhibitor of the DPP-4 enzyme approved in the EU and other countries to treat: </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with type 2 diabetes that is inadequately controlled by diet and exercise. It can be used as monotherapy; in dual combination with metformin, a sulfonylurea or a thiazolidinedione (antidiabetic medicines); in triple combination with metformin and a sulfonylurea; and as an add-on to insulin with or without metformin </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">An oral single-pill combination of vildagliptin and metformin, marketed as <i>Eucreas/GalvusMet</i>, is also approved in the EU and other countries to treat adults with type&nbsp;2 diabetes. </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"><i>&#x2022;</i><i> Diovan</i> (valsartan) is an oral angiotensin II receptor blocker (ARB) approved in the US, the EU and other countries to treat:</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults and children with high blood pressure </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with heart failure </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Adults with certain types of heart failure following a heart attack</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">An oral single-pill combination of valsartan and hydrochlorothiazide, marketed as <i>Diovan HCT/Co-Diovan</i>, is also approved in the US, the EU and other countries to treat high blood pressure.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Compounds in development</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides an overview of the key Innovative Medicines Division projects currently in the Confirmatory Development stage and may also describe certain projects in the Exploratory Development stage. Projects typically enter Confirmatory Development and become the responsibility of our Global Drug Development organization during Phase II testing. (For more information about our drug development program, see &#x201C;&mdash;Research and development&mdash;Development program.&#x201D;) Projects are listed in alphabetical order by compound code, or by product name where applicable. Projects include those seeking to develop potential uses of new molecular entities as well as potential additional indications or new formulations for already marketed products. The table below, entitled &#x201C;Projects removed from the development table since 2019,&#x201D; highlights changes to the table entitled &#x201C;Selected development projects&#x201D; from the previous year.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The year that each project entered the current phase of development refers to the year of the first patient&#x2019;s first visit in the first clinical trial of that phase. For projects in Phase II, the year refers to the first patient&#x2019;s first visit in the first Phase II trial, which can happen prior to the Confirmatory Development stage. We previously reported the current phase based on the year in which the decision to enter the phase was made, and as a result, there may be variations between the reported phases in this year&#x2019;s table versus last year&#x2019;s table. Certain previously disclosed projects, noted below, have not yet achieved &#x201C;first patient, first visit&#x201D; in any Phase I-III study for the reported indication and route of administration. We have included these projects in the table to maintain continuity with last year&#x2019;s disclosures, and have disclosed them using the reporting criteria from last year.  </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"> A reference to a project being in registration means that an application has been submitted to a health authority for marketing approval. Compounds and new indications in development are subject to required regulatory approvals and, in certain instances, contractual limitations. These compounds and indications are in various stages of development throughout the world. It may not be possible to obtain regulatory approval for any or all of the new compounds and new indications referred to in this Form&nbsp;20-F in any country or in every country. See &#x201C;&mdash;Regulation&#x201D; for further information on the approval process.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">28</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Selected development projects</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="top">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"><br><br><br>Compound/<br>product</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Common <br> name</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Mechanism <br> of action</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> <br> Potential indication</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Business<br> franchise</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Formulation/<br> route of<br> administration</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Year project<br> entered<br> current<br> development<br> phase</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Planned filing<br> dates/current<br> phase</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">ABL001</div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> asciminib</div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BCR-ABL inhibitor</div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia, 3<sup>rd</sup> line</div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021/III</div>
      </td>
      <td align="left" width="1%"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">ACZ885</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> canakinumab</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IL-1 beta inhibitor</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Non-small cell lung cancer, 2<sup>nd</sup> line</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021/III</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Non-small cell lung cancer, 1<sup>st</sup> line</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021/III</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Non-small cell lung cancer, adjuvant</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">AVXS-101<br> (OAV101)</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> onasemno-<br>  gene abepar-<br>  vovec</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Survival motor neuron <br>  (SMN) gene therapy<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy <br>  (IT formulation)<sup>1</sup><br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intrathecal injection<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TBC based on<br>  FDA feedback/<br>  I/II</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">AVXS-201<br> (OAV201)</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TBD<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Methyl-CpG binding <br>  protein 2 (MECP2) gene <br>  therapy</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Rett syndrome<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intrathecal injection<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/I<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Beovu</I></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> brolucizumab</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VEGF inhibitor</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Diabetic macular edema</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravitreal injection</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021/III</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Retinal vein occlusion</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravitreal injection</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Diabetic retinopathy<sup>2</sup></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravitreal injection</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">BYL719</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> alpelisib</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PI3K-alpha inhibitor</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PIK3CA-related overgrowth spectrum</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021/II</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Triple negative breast cancer</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Human epidermal growth factor <br>  receptor 2-positive (HER2+) <br>  advanced breast cancer<sup>3</sup></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/III<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ovarian cancer</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019<sup>4</sup></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Head and neck squamous cell carcinoma,<br>  2<sup>nd</sup> and 3<sup>rd</sup> line<sup>5</sup></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019<sup>6</sup><br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/III<br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CEE321</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TBD<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Pan-JAK inhibitor<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Atopic dermatitis<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, <br>  Hepatology and <br>  Dermatology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Topical<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019<sup>7</sup><br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/I<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CFZ533<sup>8</sup></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> iscalimab<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CD40 inhibitor<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Renal transplantation<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, <br>  Hepatology and <br>  Dermatology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/II<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Liver transplantation<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, <br>  Hepatology and <br>  Dermatology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/II<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Sj&#xF6;gren's syndrome<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, <br>  Hepatology and <br>  Dermatology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/II<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Coartem</I></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> artemether + <br>  lumefantrine</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PGH-1<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Malaria, uncomplicated (&lt;5 kg patients)<sup>9</sup><br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established<br>  Medicines</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/III<br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Cosentyx</I></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> secukinumab<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IL-17A inhibitor<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ankylosing spondylitis head-to-head study <br>  versus Sandoz biosimilar <I>Hyrimoz</I> <br>  (adalimumab)</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, <br>  Hepatology and <br>  Dermatology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022/III<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hidradenitis suppurativa<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, <br>  Hepatology and <br>  Dermatology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022/III<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Giant cell arteritis<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, <br>  Hepatology and <br>  Dermatology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/II<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Lichen planus<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, <br>  Hepatology and <br>  Dermatology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/II<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Lupus nephritis<sup>10</sup><br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, <br>  Hepatology and <br>  Dermatology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/III<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriatic arthritis (IV formulation)<sup>11</sup><br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, <br>  Hepatology and <br>  Dermatology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022/III<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ankylosing spondylitis (IV formulation)<sup>12</sup><br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, <br>  Hepatology and <br>  Dermatology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CSJ117</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TBD</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TSLP inhibitor</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Asthma<sup>13</sup></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Respiratory</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Inhalation</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/II</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">ECF843</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TBD</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> rh-Lubricin</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Dry eye</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Topical</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/II</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top">
      <td height="10px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Preclinical studies to address partial clinical hold are on track. The FDA has acknowledged the potential of AVXS-101 IT in this patient population and recommends a pivotal confirmatory study, to be initiated after partial clinical hold is lifted.</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Previously disclosed as proliferative diabetic retinopathy</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Previously disclosed as hormone receptor-negative (HR-)/human epidermal growth factor receptor 2-positive (HER2+) advanced breast cancer</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> Reflects the year in which the decision to enter the disclosed phase was made; &#x201C;first patient, first visit&#x201D; has not yet occurred</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;5&nbsp;</sup> Previously disclosed as head and neck squamous cell carcinoma</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;6&nbsp;</sup> Reflects the year in which the decision to enter the disclosed phase was made; &#x201C;first patient, first visit&#x201D; has not yet occurred</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;7&nbsp;</sup> Reflects the year in which the decision to enter the disclosed phase was made; &#x201C;first patient, first visit&#x201D; has not yet occurred</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;8&nbsp;</sup> The renal transplantation and liver transplantation indications were previously disclosed as solid organ transplantation. This has since split into two separate projects.</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;9&nbsp;</sup> Project added to selected development projects table in 2020 &#x2013; entered Confirmatory Development</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>10&nbsp;</sup> Project added to selected development projects table in 2020 &#x2013; entered Confirmatory Development</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>11&nbsp;</sup> Project added to selected development projects table in 2020 &#x2013; in Confirmatory Development</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>12&nbsp;</sup> Project added to selected development projects table in 2020 &#x2013; in Confirmatory Development</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>13&nbsp;</sup> Previously disclosed as severe asthma</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">29</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="top">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"><br><br><br>Compound/<br>product</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Common <br> name</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Mechanism <br> of action</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> <br> Potential indication</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Business<br> franchise</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Formulation/<br> route of<br> administration</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Year project<br> entered<br> current<br> development<br> phase</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Planned filing<br> dates/current<br> phase</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"><I>Entresto</I></div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> valsartan and <br>  sacubitril <br>  (as sodium <br>  salt complex)</div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Angiotensin receptor/ <br>  neprilysin inhibitor<br>  <br>  </div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure with preserved <br>  ejection fraction<br>  <br>  </div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, <br>  Renal <br>  and Metabolism<br>  </div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br>  <br>  <br>  </div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020<br>  <br>  <br>  </div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> US registration<br>  <br>  <br>  </div>
      </td>
      <td align="left" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Post-acute myocardial infarction<br>  <br>  </div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, <br>  Renal <br>  and Metabolism</div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br>  <br>  </div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2016<br>  <br>  </div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021/III<br>  <br>  </div>
      </td>
      <td align="left" width="1%"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Jakavi</I></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ruxolitinib</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JAK1/2 inhibitor</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Acute graft-versus-host disease</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021/III</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic graft-versus-host disease</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021/III</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">KAE609</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> cipargamin<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PfATP4 inhibitor<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Malaria, uncomplicated<sup>14</sup><br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established<br>  Medicines</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/II<br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Malaria, severe<sup>15</sup><br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established<br>  Medicines</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019<sup>16</sup><br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/II<br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">KAF156</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ganaplacide<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Imidazolopiperazines <br>  derivative</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Malaria, uncomplicated<sup>17</sup><br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established<br>  Medicines</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/II<br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Kisqali</I></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ribociclib<br>  <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CDK4 inhibitor<br>  <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hormone receptor-positive <br>  (HR+)/human epidermal growth <br>  factor receptor 2-negative (HER2-)<br>  early breast cancer (adjuvant)<sup>18</sup></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology<br>  <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br>  <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018<br>  <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III<br>  <br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">KJX839<sup>19</sup></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> inclisiran<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> siRNA <br>  (regulation of LDL-C)<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hyperlipidemia<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, <br>  Renal <br>  and Metabolism</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EU approved<br>  US<sup>20</sup><br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Secondary prevention of cardiovascular <br>  events in patients with elevated levels <br>  of LDL-C</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, <br>  Renal <br>  and Metabolism</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/III<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Kymriah</I></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> tisagen-<br>  lecleucel</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CD19 CAR-T<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsed/refractory follicular lymphoma<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021/II<br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsed/refractory diffuse large B-cell <br>  lymphoma in 1<sup>st</sup> relapse</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021/III<br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">LJC242</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> tropifexor, <br>  cenicriviroc <br>  (in fixed-dose<br>  combination)</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> FXR agonist and <br>  CCR2 inhibitor<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Nonalcoholic steatohepatitis<br>  <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, <br>  Hepatology and <br>  Dermatology<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br>  <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018<br>  <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/II<br>  <br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">LJN452</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> tropifexor, <br>  licogliflozin <br>  (in fixed-dose<br>  combination)</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> FXR agonist and<br>  SGLT1/2 inhibitor<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Nonalcoholic steatohepatitis<br>  <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, <br>  Hepatology and <br>  Dermatology<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br>  <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019<br>  <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/II<br>  <br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">LMI070</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> branaplam<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SMN2 RNA splicing <br>  modulator</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/II<br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">LNP023</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> iptacopan<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CFB inhibitor<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IgA nephropathy<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, <br>  Renal <br>  and Metabolism</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/II<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> C3 glomerulopathy<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, <br>  Renal <br>  and Metabolism</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/II<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Paroxysmal nocturnal hemoglobinuria<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, <br>  Renal <br>  and Metabolism</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/II<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Membranous nephropathy<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, <br>  Renal <br>  and Metabolism</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/II<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">LOU064</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> remibrutinib<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BTK inhibitor<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic spontaneous urticaria<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, <br>  Hepatology and <br>  Dermatology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/II<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Sj&#xF6;gren's syndrome<sup>21</sup><br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, <br>  Hepatology and <br>  Dermatology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/II<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Lutathera</I></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> lutetium <br>  Lu 177 <br>  dotatate/<br>  lutetium <br>  (<sup>177</sup>Lu)<br>  oxodotreotide</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Radioligand therapy <br>  targeting SSTR<br>  <br>  <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Gastroenteropancreatic <br>  neuroendocrine tumors, <br>  1<sup>st</sup> line in G2/3 tumors<sup>22</sup><br>  <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology<br>  <br>  <br>  <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion<br>  <br>  <br>  <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020<br>  <br>  <br>  <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III<br>  <br>  <br>  <br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top">
      <td height="10px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>14&nbsp;</sup> Previously disclosed as malaria</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>15&nbsp;</sup> Previously disclosed as severe malaria</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>16&nbsp;</sup> Reflects the year in which the decision to enter the disclosed phase was made; &#x201C;first patient, first visit&#x201D; has not yet occurred</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>17&nbsp;</sup> Previously disclosed as malaria</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>18&nbsp;</sup> Previously disclosed as HR+/HER2- breast cancer (adjuvant)</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>19&nbsp;</sup> Approved in the EU as <I>Leqvio</I> for primary hypercholesterolemia and mixed dyslipidemia</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>20&nbsp;</sup> Novartis received a complete response letter (CRL) from the FDA due to unresolved facility inspection-related conditions at a third-party manufacturing facility in Europe. The FDA has not raised any concerns related to the efficacy or safety of inclisiran. A response to the CRL is planned to be submitted in Q2-Q3 2021.</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>21&nbsp;</sup> Project added to selected development projects table in 2020 &#x2013; in Confirmatory Development</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>22&nbsp;</sup> Project added to selected development projects table in 2020 &#x2013; entered Confirmatory Development</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">30</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="top">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"><br><br><br>Compound/<br>product</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Common <br> name</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Mechanism <br> of action</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> <br> Potential indication</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Business<br> franchise</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Formulation/<br> route of<br> administration</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Year project<br> entered<br> current<br> development<br> phase</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Planned filing<br> dates/current<br> phase</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><sup>177</sup>Lu-<br> PSMA-617</div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TBD<br>  </div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Radioligand therapy <br>  targeting PSMA</div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Metastatic castration-resistant <br>  prostate cancer</div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology<br>  </div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion<br>  </div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018<br>  </div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021/III<br>  </div>
      </td>
      <td align="left" width="1%"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">LXE408</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TBD<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Protozoane inhibitor<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Visceral leishmaniasis<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established<br>  Medicines</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019<sup>23</sup><br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/II<br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">MBG453</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> sabatolimab</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TIM-3 antagonist</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelodysplastic syndrome</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021/III</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Unfit acute myeloid leukemia<sup>24</sup></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/II</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">OMB157<sup>25</sup></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ofatumumab<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti-CD20 monoclonal <br>  antibody</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> US approved<br>  EU registration</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">PDR001</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> spartalizumab</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PD-1 inhibitor</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Malignant melanoma (combo)<sup>26</sup></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/II</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">QBW251</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> icenticaftor</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CFTR potentiator</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic obstructive pulmonary disease</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Respiratory</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/II</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">QGE031</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ligelizumab<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IgE inhibitor<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic spontaneous urticaria<sup>27</sup><br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, <br>  Hepatology and <br>  Dermatology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022/III<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">SAF312</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TBD</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRPV1 antagonist</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic ocular surface pain</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Topical</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2016</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/II</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Tabrecta</I></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> capmatinib</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> c-MET inhibitor</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid tumors</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019<sup>28</sup></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/II</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">TQJ230</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> pelacarsen<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ASO targeting Lp(a)<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Secondary prevention of cardiovascular <br>  events in patients with elevated levels <br>  of lipoprotein(a)</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, <br>  Renal and <br>  Metabolism</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/III<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">UNR844</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TBD<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Reduction of <br>  disulfide bonds</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Presbyopia<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Topical<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/II<br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">VAY736</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ianalumab<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BAFF-R inhibitor<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Autoimmune hepatitis<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, <br>  Hepatology and <br>  Dermatology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/II<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Sj&#xF6;gren&#x2019;s syndrome<sup>29</sup><br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, <br>  Hepatology and <br>  Dermatology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/II<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">VPM087</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> gevokizumab</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IL-1 beta antagonist</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Colorectal cancer, 1<sup>st</sup> line</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2025/I</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Xolair</I></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> omalizumab</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IgE inhibitor</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Food allergy</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Respiratory</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022/III</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top">
      <td height="10px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>23&nbsp;</sup> Reflects the year in which the decision to enter the disclosed phase was made; &#x201C;first patient, first visit&#x201D; has not yet occurred</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>24&nbsp;</sup> Previously disclosed as acute myeloid leukemia</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>25&nbsp;</sup> Approved in the US as <I>Kesimpta</I> for relapsing multiple sclerosis</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>26&nbsp;</sup> Previously disclosed as metastatic melanoma (combo)</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>27&nbsp;</sup> Previously disclosed as chronic spontaneous urticaria/chronic idiopathic urticaria</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>28&nbsp;</sup> Reflects the year in which the decision to enter the disclosed phase was made; &#x201C;first patient, first visit&#x201D; has not yet occurred</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>29&nbsp;</sup> Previously disclosed as primary Sj&#xF6;gren&#x2019;s syndrome</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Projects removed from the development table since 2019</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="top">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">Compound/<br>product</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Potential indication</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Change</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Reason</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">AVXS-101</div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy (IV formulation)</div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Commercialized as <I>Zolgensma</I></div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="left" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">BYL719</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PIK3CA mutant hormone receptor-positive   (HR+)/human epidermal growth factor   receptor 2-negative (HER2-)   postmenopausal advanced breast cancer,   2<sup>nd</sup> line (+ fulvestrant)</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Commercialized as <I>Piqray</I>        </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">         </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Cosentyx</I></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Non-radiographic axial spondyloarthritis</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Commercialized</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriatic arthritis head-to-head study   versus Humira<sup>&#xAE;</sup> (adalimumab)</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Publication achieved  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">INC280</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Non-small cell lung cancer</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Commercialized as <I>Tabrecta</I></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Kymriah</I></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsed/refractory diffuse large B-cell   lymphoma (+ pembrolizumab)</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">LAM320</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Multidrug-resistant tuberculosis  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Planned US submission  discontinued</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">PDR001</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Metastatic BRAF V600+ melanoma  (w/ <I>Tafinlar</I> + <I>Mekinist</I>)</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">QMF149</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Asthma</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Commercialized as <I>Atectura Breezhaler</I></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">QVM149</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Asthma</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Commercialized as <I>Enerzair Breezhaler</I></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">RTH258</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neovascular (wet) age-related   macular degeneration</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Commercialized as <I>Beovu</I>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">SEG101</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Sickle cell disease</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Commercialized as <I>Adakveo</I></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">VPM087</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Renal cell carcinoma, 1<sup>st</sup> line</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Xolair</I></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Nasal polyps</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Commercialized</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">ZPL389</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Atopic dermatitis</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">31</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Principal markets</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Innovative Medicines Division sells products in approximately 140 countries worldwide. Net sales are primarily concentrated in the US and Europe. The following table sets forth the aggregate 2020 net sales of the Innovative Medicines Division by region:</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020 net sales  to third parties</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD millions</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United States</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&nbsp;342</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&nbsp;484</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 35</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia, Africa, Australasia</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;718</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;469</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 39&nbsp;013</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Of which in Established Markets<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29&nbsp;643</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Of which in Emerging Growth Markets<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;370</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Many of our Innovative Medicines Division products are used for chronic conditions that require patients to consume the product over long periods of time, ranging from months to years. However, certain of our marketed products and development projects, such as cell and gene therapies, are administered only once. Net sales of the vast majority of our products are not subject to material changes in seasonal demand.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Production</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our primary goal is to ensure the uninterrupted, timely and cost-effective supply of products that meet all product specifications and quality standards. The manufacturing of our products is highly regulated by governmental health authorities around the world, including the FDA and EMA. In addition to regulatory requirements, many of our products involve technically complex manufacturing processes or require highly specialized raw materials.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2020, we established five integrated manufacturing and supply platforms: large molecules, small molecules, Sandoz Technical Operations, cell and gene therapy, and local market manufacturing. We manufacture our products across these platforms at facilities worldwide, producing active pharmaceutical ingredients in our own facilities or purchasing them from third-party suppliers (see also &#x201C;&mdash;Item&nbsp;4.D Property, plants and equipment&#x201D;). In our manufacturing network, we maintain state-of-the-art processes, with quality as a priority, and require our suppliers to adhere to the same high standards we expect from our own people and processes. Those processes include chemical and biological syntheses; sterile processing, including CAR-T cell processing; and formulation and packaging. We are constantly working to improve our existing manufacturing processes, to develop new and innovative technologies, and to review and adapt our manufacturing network to meet our needs and those of our patients and customers.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We produce raw materials for manufacturing in-house or we purchase them from a number of third-party suppliers. Where possible, we maintain multiple supply sources so that the business is not dependent on a single or limited number of suppliers. However, our ability to do so may at times be limited by regulatory or other requirements. We monitor market developments that could have an adverse effect on the supply of essential materials. Our suppliers of raw materials are required to comply with applicable regulations and Novartis quality standards.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Because the manufacturing of our products is complex and highly regulated by governmental health authorities, supply is never guaranteed. If we or our third-party suppliers fail to comply with applicable regulations, then there could be a product recall or other disruption to our production activities. We have experienced supply interruptions for our products in the past, and there can be no assurance that supply will not be interrupted again in the future. However, we have implemented a global manufacturing strategy to maximize business continuity in case of such events. </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Marketing and sales</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Innovative Medicines Division serves customers with 24 432 field force representatives, as of December&nbsp;31, 2020, including supervisors and administrative personnel. These trained representatives present the therapeutic risks and benefits of our products to physicians, pharmacists, hospitals, insurance groups, managed care organizations and other healthcare professionals. In the US, Novartis advertises certain products via digital and traditional media channels, including the internet, television, newspapers and magazines. Novartis also pursues co-promotion/co-marketing opportunities as well as licensing and distribution agreements with other companies in various markets. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The marketplace for healthcare is evolving: Customer groups beyond prescribers have increasing influence on treatment decisions and guidelines, while patients con-</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">32</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">tinue to become more informed stakeholders in their healthcare decisions and look for solutions to meet their changing needs. Novartis is responding by adapting our business practices to engage appropriately with patients, customer groups and other stakeholders, including by delivering innovative solutions to drive education, access and improved patient care. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The COVID-19 pandemic has accelerated additional changes related to marketing and sales techniques in the healthcare industry. For example, many healthcare professionals have increased their use of virtual platforms when interacting with pharmaceutical companies, and prefer to receive information in a more convenient and personalized way. In response, Novartis has expedited the planned implementation of a new customer engagement model, which combines traditional face-to-face visits with digital methods of engaging healthcare professionals. We are similarly changing our approach to engaging healthcare systems, payers and other healthcare providers.  </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Although specific distribution patterns vary by country, Novartis generally sells its prescription drugs primarily to wholesale and retail drug distributors, hospitals, clinics, government agencies and managed healthcare providers. The growing number of so-called &#x201C;specialty&#x201D; drugs in our portfolio has resulted in increased engagement with specialty pharmacies. In the US, specialty pharmacies continue to grow as a distribution channel for specialty products. Most specialty drugs can only be dispensed through specialty pharmacies that are wholly owned by national pharmacy benefit managers.  </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the US, the US Centers for Medicare&nbsp;&amp; Medicaid Services (CMS) is the largest single payer for healthcare services as a result of continuing changes in healthcare economics and an aging population. In addition, both commercial and government-sponsored managed care organizations continue to be among the largest groups of payers for healthcare services in the US. In other countries, national health services are often the only significant payer for healthcare services. In an effort to control prescription drug costs, almost all managed care organizations and national health services use formularies that list specific drugs that may be reimbursed and/or the level of reimbursement for each drug. Managed care organizations and national health services also increasingly use cost-benefit analyses to determine whether or not newly approved drugs will be added to a formulary and/or the level of reimbursement for that drug, and to determine whether or not to continue to reimburse existing drugs. We have dedicated teams that actively seek to optimize patient access, including formulary positions, for our products.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The trend toward consolidation among distributors and retailers of Innovative Medicines Division products continues in the US and internationally, both within country and across countries. This has increased our customers&#x2019; purchasing leverage and resulted in increased pricing pressure on our products. Moreover, we are exposed to increased concentration of credit risk as a result of the consolidation among our customers. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Drug pricing is an increasingly prominent issue in many countries as healthcare spending continues to rise. This issue has received significant attention in the US (please see &#x201C;&mdash;Price controls&#x201D; for further information). At Novartis, we are increasing our efforts to enable patient access through innovative pricing and access initiatives in the US, Europe and other markets. These include contract structures such as pay-over-time and outcome-based agreements.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2019, Novartis Gene Therapies (formerly AveXis) formed an agreement with Accredo Health Group, Inc. in the US to offer a pay-over-time option of up to five years for <i>Zolgensma</i> to help ease possible short-term budget constraints for customers. Novartis Gene Therapies also offers payers outcome-based agreements for <i>Zolgensma</i> based on measures included in the clinical trial program, and has these agreements in place with both commercial and Medicaid contracts. In these agreements, if a patient has a significant negative outcome during a five-year period, Novartis Gene Therapies reimburses a percentage of the cost of the therapy relative to the time passed. Following conditional approval of <i>Zolgensma</i> in Europe in 2020, Novartis Gene Therapies established &#x201C;Day One&#x201D; early access agreements in multiple European countries. These agreements support early patient access by allowing a variety of customizable options, including retroactive rebates, deferred payments, installment options and outcome-based rebates.  </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Additionally, Novartis has established an outcome-based framework in the US for one of the approved indications of <i>Kymriah</i>, whereby the product invoice is linked to a successful outcome for each patient at an agreed milestone. Novartis also offers outcome-based agreements for approved indications of <i>Kymriah</i> and <i>Luxturna</i> in certain countries other than the US. These typically involve a full upfront payment of the product with a partial refund in case of failed outcomes, or installment payments based on successful patient outcomes at agreed milestones. </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Competition</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The global pharmaceutical market is highly competitive. We compete against other major international corporations that have substantial financial and other resources, as well as against smaller companies that operate regionally or nationally. Competition within the industry is intense and extends across a wide range of activities, including pricing, product characteristics, customer service, sales and marketing, and research and development.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Like other companies selling patented pharmaceuticals, Novartis faces challenges from companies selling competing patented products. Generic forms of our products may follow the expiry of intellectual property protection, and generic companies may also gain entry to the market through successfully challenging our intellectual property rights. We use legally permissible measures to defend those rights. See also &#x201C;&mdash;Intellectual property&#x201D; below. We also may face competition from over-the-counter (OTC) products that do not require a prescription from a physician. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There is ongoing consolidation in the pharmaceutical industry. At the same time, new entrants are looking to use their expertise to establish or expand their presence in healthcare, including technology companies </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">33</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">seeking to benefit from the increasing importance of data and data management in our industry.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Research and development</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The discovery and development of a new drug usually requires approximately 10 to 15&nbsp;years from the initial research to bringing a drug to market. This includes approximately six to eight years from Phase&nbsp;I clinical trials to market entry. At each of these steps, there is a substantial risk that a compound will not meet the requirements to progress further. In such an event, we may be required to abandon the development of a compound in which we have made a substantial investment.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We manage our research and development expenditures across our entire portfolio in accordance with our strategic priorities. We make decisions about whether or not to proceed with development projects on a project-by-project basis. These decisions are based on the project&#x2019;s potential to meet a significant unmet medical need or to improve patient outcomes, the strength of the science underlying the project, and the potential of the project (subject to the risks inherent in pharmaceutical development) to generate significant positive financial results for the Company. Once a management decision has been made to proceed with the development of a particular molecule, the level of research and development investment required will be driven by many factors. These include the medical indications for which it is being developed, the number of indications being pursued, whether the molecule is of a chemical or biological nature, the stage of development, and the level of evidence necessary to demonstrate clinical efficacy and safety.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Research program</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our research program is conducted by the Novartis Institutes for BioMedical Research (NIBR), which is the research and early development innovation engine of Novartis. NIBR is responsible for the discovery of new medicines for diseases with unmet medical need. We focus our work in areas where we believe we can have the most impact for patients. This requires the hiring and retention of highly talented employees, a focus on fundamental disease mechanisms that are relevant across different disease areas, continuous improvement in technologies for drug discovery and potential therapies, close alliances with clinical colleagues, and the establishment of strategic external alliances.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Approximately 5 600 full-time-equivalent scientists, physicians and business professionals work at NIBR sites in Basel, Switzerland; Cambridge, Massachusetts; East Hanover, New Jersey; San Diego, California; Emeryville, California; and Shanghai, China. They contribute to research into disease areas such as cardiovascular and metabolic diseases, neuroscience, oncology, muscle disorders, ophthalmology, autoimmune diseases and respiratory diseases. Research at the Friedrich Miescher Institute and the Genomics Institute of the Novartis Research Foundation focuses on basic genetic and genomic research, and the Novartis Institute for Tropical Diseases (NITD), in Emeryville, California, focuses on discovering new medicines to fight tropical diseases, including malaria and cryptosporidiosis.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">All drug candidates go through proof-of-concept trials to enable an early assessment of the safety and efficacy of the drug while collecting basic information on pharmacokinetics and tolerability, and adhering to the guidance for early clinical testing set forth by health authorities. Following proof of concept, our Global Drug Development unit conducts confirmatory trials on the drug candidates.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In July 2018, we announced the decision to exit antibacterial and antiviral research. While the science for these programs is compelling, we decided to prioritize our resources in other areas where we believe we are better positioned to develop innovative medicines that will have a positive impact for patients. Since then, we have executed three out-licensing deals with Gilead Sciences, Boston Pharmaceuticals and Amplyx Pharmaceuticals for assets from our infectious diseases portfolio. However, in response to the COVID-19 pandemic, we started a robust and collaborative drug discovery effort to develop an antiviral molecule to potentially treat all coronaviruses, including the virus that causes COVID-19. This longer-term effort with the University of California, Berkeley, and other pharmaceutical companies will target the self-replication machinery that coronaviruses share.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2020, we discontinued early discovery research at NIBR&#x2019;s Shanghai site and focused our research and development activities there on expanding the scale and scope of our early clinical development and later-stage clinical trial operations to help accelerate the development of new medicines.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Development program</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our Global Drug Development (GDD) organization oversees drug development activities for our Innovative Medicines Division. GDD works collaboratively with NIBR to execute our overall pipeline strategy. The GDD organization includes centralized global functions such as Regulatory Affairs and Global Development Operations, and global Development Units aligned with our business franchises. GDD was created to improve resource allocation, technology implementation and process standardization to further increase innovation. GDD includes approximately 11 000 full-time equivalent associates worldwide.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The traditional model of development consists of three phases:</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>Phase&nbsp;I:</b>  The first clinical trials of a new compound &ndash; generally performed in a small number of healthy human volunteers &ndash; to assess the drug&#x2019;s safety profile, including the safe dosage range. These trials also determine how a drug is absorbed, distributed, metabolized and excreted, and the duration of its action.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>Phase&nbsp;II:</b>  Clinical studies performed with patients who have the target disease, with the aim of continuing the Phase&nbsp;I safety assessment in a larger group, assessing the efficacy of the drug in the patient population, and determining the appropriate doses for further evaluation.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>Phase&nbsp;III:</b>  Large-scale clinical studies with several hundred to several thousand patients, which are conducted </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">34</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">to establish the safety and efficacy of the drug in specific indications for regulatory approval. Phase&nbsp;III trials may also be used to compare a new drug against a current standard of care to evaluate the overall benefit-risk relationship of the new medicine.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">In each of these phases, physicians monitor volunteer patients closely to assess the potential new drug&#x2019;s safety and efficacy.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Though we use this traditional model, we have tailored the development process to be simpler, more flexible and efficient. We divide the development process into two stages: Exploratory Development to establish proof of concept, followed by Confirmatory Development to confirm the concept in large numbers of patients. Exploratory Development consists of clinical proof-of-concept (PoC) studies, which are small clinical trials (typically involving in the range of between five and 15 patients) that combine elements of traditional Phase&nbsp;I/II testing. NIBR conducts these customized trials, which are designed to give early insights into issues such as safety, efficacy and toxicity for a drug in a given indication. Once a positive proof of concept has been established, the drug moves to the Confirmatory Development stage and becomes the responsibility of GDD. Confirmatory Development has elements of traditional Phase&nbsp;II/III testing and includes trials aimed at confirming the safety and efficacy of the drug in the given indication, leading up to submission of a dossier to health authorities for approval. This stage can also include trials that compare the drug to the current standard of care for the disease in order to evaluate the drug&#x2019;s overall benefit-risk profile. Further, with new treatment approaches such as gene therapy for rare diseases, elements of Exploratory and Confirmatory Development may be combined and suffice for registration under certain conditions such as high unmet medical need and clinical data showing highly favorable benefit-risk. In these cases, additional post-approval studies may be required by the regulatory authorities to continue to gather important data to further support approval.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The vast amount of data that must be collected and evaluated makes clinical testing the most time-consuming and expensive part of new drug development. The next stage in the drug development process is to seek registration for the new drug. For more information, see &#x201C;&mdash;Regulation.&#x201D;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our Innovation Management Board (IMB) manages our activities at each phase of clinical development. The IMB is responsible for all major aspects of our development portfolio and oversees our drug development budget as well as major project phase transitions and milestones following a positive proof-of-concept outcome, including transitions to Confirmatory Development and the decision to submit a regulatory application to the health authorities. The IMB is also responsible for the endorsement of overall development strategy, the endorsement of development project priorities, and decisions on project discontinuations. Our Chief Executive Officer chairs the IMB, and other representatives from Novartis senior management, with expertise spanning multiple fields, are among its core and extended membership.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Alliances and acquisitions</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our Innovative Medicines Division enters into business development agreements with other pharmaceutical and biotechnology companies and with academic and other institutions to develop new products and access new markets. We license products that complement our current product line and are appropriate to our business strategy. We focus on strategic alliances and acquisition activities for key disease areas and indications that we expect to be growth drivers in the future. We review products and compounds we are considering licensing, using the same criteria that we use for our own internally discovered drugs. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In January 2021, we announced a strategic collaboration agreement to in-license tislelizumab from an affiliate of BeiGene, Ltd. in major markets outside of China. Tislelizumab is an anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcyR on macrophages, which accelerates the potential for Novartis to enter the large and growing checkpoint inhibitor field. Closing of this transaction is subject to expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. For additional information, see &#x201C;Item 18. Financial Statements&mdash;Note 28. Commitments and contingencies&mdash;Research and development commitments.&#x201D; </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For additional information, see &#x201C;Item 18. Financial Statements&mdash;Note 2. Significant transactions.&#x201D;</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Regulation</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The international pharmaceutical industry is highly regulated. Regulatory authorities around the world administer numerous laws and regulations regarding the testing, approval, manufacturing, importing, labeling and marketing of drugs, and review the safety and efficacy of pharmaceutical products. Extensive controls exist on the non-clinical and clinical development of pharmaceutical products. These regulatory requirements, and the implementation of them by local health authorities around the globe, are a major factor in determining whether a substance can be developed into a marketable product, and the amount of time and expense associated with that development.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Health authorities, including those in the US and the EU, have high standards of technical evaluation. The introduction of new pharmaceutical products generally entails a lengthy approval process. Products must be authorized or registered prior to marketing, and such authorization or registration must subsequently be maintained. In recent years, the registration process has required increased testing and documentation for the approval of new drugs, with a corresponding increase in the expense of product introduction.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To register a pharmaceutical product, a registration dossier containing evidence establishing the safety, efficacy and quality of the product must be submitted to regulatory authorities. Generally, a therapeutic product must be registered in each country in which it will be sold. In every country, the submission of an application to a regulatory authority does not guarantee that approval to market the product will be granted. Although the criteria </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">35</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">for the registration of therapeutic drugs are similar in most countries, the formal structure of the necessary registration documents and the specific requirements, including risk tolerance, of the local health authorities can vary significantly from country to country. Even if a drug is registered and marketed in one country, the registration authority in another country may request additional information from the pharmaceutical company prior to registration or even reject the product. A drug may be approved for different indications in different countries.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The registration process generally takes between six months and several years, depending on the country, the quality of the data submitted, the efficiency of the registration authority&#x2019;s procedures, and the nature of the product. Many countries provide for accelerated processing of registration applications for innovative products of particular therapeutic interest. In recent years, the US and the EU have made efforts to harmonize registration requirements in order to achieve shorter development and registration times for medical products. However, the requirement in many countries to negotiate selling prices or reimbursement levels with government regulators and other payers can substantially extend the time until a product may finally be available to patients.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following provides a summary of the regulatory processes in the principal markets served by Innovative Medicines Division affiliates:</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">United States</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In the US, applications for drug registration are submitted to and reviewed by the FDA. The FDA regulates the testing, manufacturing, labeling and approval for marketing of pharmaceutical products intended for commercialization in the US. The FDA continues to monitor the safety of pharmaceutical products after they have been approved for sale in the US market. The pharmaceutical development and registration process is typically intensive, lengthy and rigorous. When a pharmaceutical company has gathered data that it believes sufficiently demonstrates a drug&#x2019;s safety, efficacy and quality, then the company may file&nbsp;a New Drug Application (NDA) or Biologics License Application (BLA), as applicable, for the drug. The NDA or BLA must contain all the scientific information that has been gathered about the drug. This typically includes information regarding the clinical experiences of patients tested in the drug&#x2019;s clinical trials. A Supplemental New Drug Application (sNDA) or BLA amendment must be filed for new indications for a previously approved drug.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Once an application is submitted, the FDA assigns reviewers from its staff, including experts in biopharmaceutics, chemistry, clinical microbiology, pharmacology/toxicology, and statistics. After a complete review, these content experts provide written evaluations of the NDA or BLA. These recommendations are consolidated and are used by senior FDA staff in its final evaluation of the NDA or BLA. Based on that final evaluation, the FDA then provides to the NDA or BLA&#x2019;s sponsor an approval, or a &#x201C;complete response&#x201D; letter if the NDA or BLA application is not approved. If not approved, the letter will state the specific deficiencies in the NDA or BLA that need to be addressed. The sponsor must then submit an adequate response to the deficiencies in order to restart the review procedure.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Once the FDA has approved an NDA, BLA, sNDA or BLA amendment, the company can make the new drug available for physicians and other healthcare providers to prescribe. The drug owner must submit periodic reports to the FDA, including any cases of adverse reactions. For some medications, the FDA requires additional post-approval studies (Phase&nbsp;IV) to evaluate long-term effects or to gather information on the use of the product under specified conditions.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Throughout the life cycle of a product, the FDA requires compliance with standards relating to good laboratory, clinical and manufacturing practices. The FDA also requires compliance with rules pertaining to the manner in which we may promote our products.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">European Union</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In the EU, there are three main procedures for application for authorization to market pharmaceutical products in more than one EU member state at the same time: the centralized procedure, the mutual recognition procedure and the decentralized procedure. It is also possible to obtain a national authorization for products intended for commercialization in a single EU member state only, or for additional indications for licensed products. The procedure used for first authorization must continue to be followed for subsequent changes, e.g., to add an indication for a licensed product.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Under the centralized procedure, applications are made to the EMA for an authorization that is valid for the European Union (all member states). The centralized procedure is mandatory for all biotechnology products; new chemical entities in cancer, neurodegenerative disorders, diabetes, AIDS, autoimmune diseases and other immune dysfunctions; advanced therapy medicines, such as gene therapy, somatic cell therapy and tissue-engineered medicines; and orphan medicines (medicines for rare diseases). It is optional for other new chemical entities, innovative medicinal products, and medicines for which authorization would be in the interest of public health. When a pharmaceutical company has gathered data that it believes sufficiently demonstrates a drug&#x2019;s safety, efficacy and quality, the company may submit an application to the EMA. The EMA then receives and validates the application, and the specialized committee for human medicines, the CHMP, appoints a rapporteur and co-rapporteur to review it. The entire review cycle must be completed within 210&nbsp;days, although there is a &#x201C;clock stop&#x201D; at Day 120 to allow the company to respond to questions set forth in the rapporteur and co-rapporteur&#x2019;s assessment report. When the company&#x2019;s complete response is received by the EMA, the clock restarts on Day 121. If there are further aspects of the dossier requiring clarification, the CHMP will issue further questions at Day 180, and may also request an oral explanation, in which case the sponsor must not only respond to the further questions but also appear before the committee to justify its responses. On Day 210, the CHMP will take a vote to recommend the approval or non-approval of the application, and their opinion is transferred to the EC. The final EC decision under this </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">36</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">centralized procedure is a decision that is applicable to all member states. This decision occurs 60&nbsp;days, on average, after a positive CHMP recommendation.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Under both the mutual recognition procedure (MRP) and the decentralized procedure (DCP), the assessment is led by one member state, called the reference member state (RMS) which then liaises with other member states, known as the concerned member states. In the MRP, the company first obtains a marketing authorization in the RMS, which is then recognized by the concerned member states in 90 days. In the DCP, the application is done simultaneously in the RMS and all concerned member states. During the DCP, the RMS drafts an assessment report within 120&nbsp;days. Within an additional 90&nbsp;days, the concerned member states review the application and can issue objections or requests for additional information. On Day 90, each concerned member state must be assured that the product is safe and effective, and that it will cause no risks to the public health. Once an agreement has been reached, each member state grants national marketing authorizations for the product.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">After receiving the marketing authorizations, the company must submit periodic safety reports to the relevant health authority (EMA for the centralized procedure, national health authorities for DCP or MRP). In addition, pharmacovigilance measures must be implemented and monitored, including the collection, evaluation and expedited reporting of adverse events, and updates to risk management plans. For some medications, post-approval studies (Phase&nbsp;IV) may be imposed to complement available data with additional data to evaluate long-term effects (called a Post-Approval Safety Study, or PASS) or to gather additional efficacy data (called a Post-Approval Efficacy Study, or PAES).</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">European marketing authorizations have an initial duration of five years. The holder of the marketing authorization must actively apply for its renewal after this first five-year period. As part of the renewal procedure, the competent authority will perform a full benefit-risk review of the product. Should the authority conclude that the benefit-risk balance is no longer positive, the marketing authorization can be suspended or revoked. Once renewed, the marketing authorization is valid for an unlimited period. If the holder does not apply for renewal, the marketing authorization automatically lapses. Any marketing authorization that is not followed within three years of its granting by the actual placing on the market of the corresponding medicinal product ceases to be valid.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Price controls</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In most of the markets where we operate, the prices of pharmaceutical products are subject to both direct and indirect price controls and to drug reimbursement programs with varying price control mechanisms. Due to increasing political pressure and governmental budget constraints, we expect these mechanisms to remain robust &ndash; and potentially even to be strengthened &ndash; and to have a continued negative influence on the prices we are able to charge for our products.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Direct governmental efforts to control prices</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><i>United States:</i>  In the US, former President Donald Trump and congressional leaders declared the reduction of drug prices a key priority in 2020. Former President Trump signed an executive order that included a most favored nation (MFN) policy limiting prices in Medicare parts B and D to no greater than those paid by developed countries outside the US, and his administration finalized the rule to begin implementing a seven-year demonstration project for the MFN in Medicare Part B on January 1, 2021. However, lawsuits were filed in several US states, and the district courts granted orders delaying implementation. The Biden administration will likely determine next steps. Former President Trump also signed an executive order allowing US states to develop plans for the importation of drugs from Canada and permit personal importation from countries outside the US. These state plans must be approved by the US Department of Health and Human Services (HHS) prior to implementation. However, a lawsuit was filed against HHS challenging the importation of certain prescription drugs from Canada without drug manufacturer authorization or oversight, and in parallel, the Canadian government blocked the distribution of certain medicines outside Canada to avoid shortages within the country. It is anticipated that focus on drug pricing will continue at the federal level in 2021. Further, by December 31, 2020, 18 US states had passed legislation intended to impact pricing or requiring price transparency reporting, with five of these states also allowing for price control review boards. The disclosure requirements vary by state. Many states require multiple types of reporting, including for new drug applications, new drug launches, prior notice of price increases, and quarterly or annual reporting. It is expected in 2021 that state legislatures will continue to focus on drug pricing and that similar bills will be passed in more states. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"><i>Europe:  </i>In Europe, our operations are subject to significant price and marketing regulations. Many governments are introducing healthcare reforms in a further attempt to curb increasing healthcare costs. In some member states, these include reforms to permit the reimbursed use of off-label medicines, despite the presence of licensed alternatives on the market. In the EU, governments influence the price of pharmaceutical products through their control of national healthcare systems that fund a large part of the cost of such products to patients. The downward pressure on healthcare costs in general in the EU, particularly with regard to prescription drugs, is intense. Increasingly strict analyses are applied when evaluating the entry of new products, and as a result, access to innovative medicines is limited based on strict cost-benefit assessments. In addition, prices for marketed products are referenced within member states and across international borders, further impacting individual EU member state pricing. Member states also collaborate to enhance pricing transparency and have started conducting joint health technology assessments, joint pricing negotiations and/or joint purchasing. As an additional control for healthcare budgets, some EU countries have passed legislation to impose further mandatory rebates for pharmaceutical products and/or finan-</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">37</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">cial claw-backs on the pharmaceutical industry. The calculation of these rebates and claw-backs may lack transparency in some cases and can be difficult to predict.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Regulations favoring generics and biosimilars</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In response to rising healthcare costs, most governments and private medical care providers have established reimbursement schemes that favor the substitution of generic pharmaceuticals for more expensive brand-name pharmaceuticals. All US states have generic substitution statutes. These statutes permit or require the dispensing pharmacist to substitute a less expensive generic drug instead of an original drug. Other countries, including many European countries, have similar laws. We expect that the pressure for generic substitution will continue to increase. In addition, the US, the EU and other jurisdictions are increasingly crafting laws and regulations encouraging the development of biosimilar versions of biologic drugs, which can also be expected to have an impact on pricing.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Cross-border sales</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Price controls in one country can have an impact in other countries as a result of cross-border sales. In the EU, products that we have sold to customers in countries with stringent price controls can be legally resold to customers in other EU countries at a lower price than the price at which the product is otherwise available in the importing country (known as parallel trade). In North America, products that we have sold to customers in Canada &ndash; which has relatively stringent price controls &ndash; are sometimes resold into the US, again at a lower price than the price at which the product is otherwise sold in the US. Such imports from Canada and other countries into the US are currently illegal. However, given the increased focus on pharmaceutical prices in the US, the former Trump administration, certain members of the US Congress, and several US states continued to explore regulatory and legislative ways to allow the safe importation of pharmaceutical products into the US from select countries, including Canada. Six US states have enacted drug importation laws, but the Secretary of HHS must certify that each state&#x2019;s importation plan is safe and cost-effective before it can be implemented. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We expect that pressures on pricing will continue worldwide and will likely increase. Because of these pressures, there can be no certainty that in every instance we will be able to charge prices for a product that, in a particular country or in the aggregate, would enable us to earn an adequate return on our investment in that product.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Intellectual property</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We attach great importance to intellectual property (IP) rights &ndash; including patents, trademarks, copyrights, know-how, trade secrets and regulatory data protection &ndash; as essential to our purpose of reimagining medicine to improve and extend people&#x2019;s lives, and to protect our investment in research and development, manufacturing and marketing. The IP system provides a means to attract the investments needed to conduct and sustainably finance innovative R&amp;D, and to manage the risks inherent in our work. For example, we seek IP protection under applicable laws for significant product developments in major markets. Among other things, patents may cover the products themselves, including the product&#x2019;s active ingredient or ingredients and its formulation. Patents may cover processes for manufacturing a product, including processes for manufacturing intermediate substances used in the manufacture of the product. Patents may also cover particular uses of a product, such as its use to treat a particular disease, or its dosage regimen. In addition, patents may cover tests for certain diseases or biomarkers &ndash; which can improve patient outcomes when administered with certain drugs &ndash; as well as assays, research tools and other techniques used to identify new drugs. The protection afforded, which may vary from country to country, depends upon the type of patent, its duration and its scope of coverage.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the US and other countries, the law recognizes that product development and review by the FDA and other health authorities can take an extended period, and permits an extension of patent term for a period related to the time taken for the conduct of clinical trials and for the health authority&#x2019;s review. However, the length of this extension and the patents to which it applies cannot be known in advance and can only be determined after the product is approved. In practice, it is not uncommon for patent term extensions (PTEs) to not fully account for the time it took to develop the product and receive marketing authorization. As a result, for example, it is rarely the case that a product&#x2019;s active ingredient(s) will have a full patent term at the time the product is approved by the FDA and other health authorities.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition to patent protection, various countries offer regulatory data protection (RDP) or marketing exclusivities for a prescribed period of time. RDP is a distinct type of IP right providing exclusivity that precludes a potential competitor from filing a regulatory application that relies on the sponsor&#x2019;s clinical trial data, or that precludes the regulatory authority from approving the application for a set period of time. The RDP period can vary depending upon the type of data included in the sponsor&#x2019;s application. When it is available, market exclusivity, unlike RDP, may preclude a competitor from obtaining marketing approval for a product even if a competitor&#x2019;s application relies on its own data. RDP and market exclusivity periods generally run from the date a product is approved, and so their expiration dates cannot be known with certainty until the product approval date is known and exclusivity has been granted by the relevant authorities.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">United States</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Patents</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In the US, a patent issued for an application filed today will receive a term of 20&nbsp;years from the earliest application filing date, subject to potential patent term adjustments for delays in patent issuance based upon certain delays in prosecution by the United States Patent and Trademark Office (USPTO). A US pharmaceutical patent that claims a product, method of treatment using a product, or method of manufacturing a product may also be eligible for a PTE. This type of extension may only extend the patent term for a maximum of five&nbsp;years, and may not </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">38</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">extend the patent term beyond 14&nbsp;years from regulatory approval. Only one patent may be extended for any product based on FDA review.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">RDP and market exclusivity</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Separate from patent exclusivities, the FDA may provide RDP or market exclusivity, which runs in parallel to any patent protection. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  A new small-molecule active pharmaceutical ingredient receives five&nbsp;years of RDP, during which time a competitor generally may not submit or obtain approval of an application to the FDA based on a sponsor&#x2019;s clinical data.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; For a small-molecule active pharmaceutical ingredient, the FDA may also request that a sponsor conduct pediatric studies and, in exchange, it will grant an additional six-month period of pediatric market exclusivity if the FDA accepts the data, the sponsor makes a timely application for approval for pediatric treatment, and the sponsor has either a patent-based or regulatory-based exclusivity period for the product that can be extended.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Orphan drug exclusivity provides seven&nbsp;years of market exclusivity for drugs designated by the FDA as orphan drugs, meaning drugs that treat rare diseases. During this period, a potential competitor generally may not market the same or similar drug for the same indication even if the competitor&#x2019;s application does not rely on data from the sponsor.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  A new biologic active pharmaceutical ingredient receives 12&nbsp;years of market exclusivity, during which time a competitor generally may not market the same or similar drug. </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">European community</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Patents</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Patent applications in Europe may be filed in the European Patent Office (EPO) or in a particular country or countries. The EPO system permits a single application to be granted for the EU plus other non-EU countries such as Switzerland and Turkey. When the EPO grants a patent, it is then validated in the countries that the patent owner designates. The term of a patent granted by the EPO or a European country office is generally 20&nbsp;years from the earliest application filing date. Pharmaceutical patents can be granted a further period of exclusivity under the Supplementary Protection Certificate (SPC) system. SPCs are designed, in part, to account for the time it took to receive marketing authorization of a product by the European health authorities. An SPC may be granted to provide, in combination with the patent, up to 15&nbsp;years of exclusivity from the date of the first European marketing authorization. However, an SPC cannot last longer than five&nbsp;years. The SPC duration may be extended by a further six&nbsp;months if the product is the subject of an agreed pediatric investigation plan. The post-grant phase of patents, including the SPC system, is currently administered on a country-by-country basis under national laws that, while differing, are intended to (but do not always) have the same effect.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">RDP and market exclusivity</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Separate from patent exclusivities, the EU provides a system of regulatory data protection for authorized human medicines that runs in parallel to any patent protection. The system for drugs being approved today is usually referred to as &#x201C;8+2+1&#x201D; because it provides an initial period of eight&nbsp;years of data protection, during which a competitor cannot rely on the relevant data; a further period of two&nbsp;years of market exclusivity, during which the data can be used to support applications for marketing authorization but a competitive product cannot be launched; and a possible one-year extension of the market exclusivity period if, during the initial eight-year data exclusivity period, the sponsor registered a new therapeutic indication with &#x201C;significant clinical benefit.&#x201D; This system applies both to national and centralized authorizations. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The EU also has an orphan drug exclusivity system for medicines. If a medicine is designated as an orphan drug, then it benefits from 10&nbsp;years of market exclusivity after it is authorized, during which time an application for the same or similar medicine for the same indication will not generally be accepted or granted. Under certain circumstances, this exclusivity can be extended with a two-year pediatric extension.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Third-party patents and challenges to intellectual property</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Third parties can challenge our IP, including patents, patent term extensions, RDP and marketing exclusivities (such as pediatric extensions and orphan drug exclusivity), through various proceedings. For example, patents in the US can be challenged in the USPTO through various proceedings, including Inter Partes Review (IPR) and Post-Grant Review (PGR) proceedings. They may also be challenged through patent infringement litigation under the Abbreviated New Drug Application (ANDA) provisions of the Hatch-Waxman Act or under the Biologics Price Competition and Innovation Act (BPCIA). In the EU, patents may be challenged through oppositions in the EPO, or national patents may be challenged in national courts or national patent offices. The outcomes of such challenges can be difficult to predict.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition to directly challenging our IP rights, in some circumstances a competitor may be able to market a generic version of one of our products by, for example, designing around our patents or marketing the generic product for non-patent-protected indications. Despite RDP, a competitor could opt to incur the costs of conducting its own clinical trials and preparing its own regulatory application, and avoid our RDP altogether. There is a risk that some countries may seek to impose limitations on or seek not to recognize the availability of IP rights for pharmaceutical products, or limit the extent to which such rights may be enforced. Also, even though we may own, co-own or in-license patents protecting our products, and conduct freedom-to-operate analyses, a third party may nevertheless assert that one of our products infringes a third-party patent for which we do not have a license.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As a result, there can be no assurance that our IP rights will protect our products or that we will be able to avoid adverse effects from the loss of IP protection or from third-party patents in the future.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">39</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Intellectual property protection for certain key marketed products and compounds in development</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We present below additional details regarding IP protection for certain Innovative Medicines Division products. For each, we identify issued, unexpired patents by general subject matter and, in parentheses, years of expiry in, if relevant, the US and the EU. The identified patents are owned, co-owned or exclusively in-licensed by Novartis and relate to at least one dosage strength of the product or to the method of treatment or its use as it is currently approved and marketed or, in the case of a compound in development, as it is currently submitted to the FDA and/or the EMA for approval. Identification of an EU patent refers to national patents in EU countries and/or to the national patents that have been derived from a patent granted by the EPO. Novartis may own, co-own, control or have rights to additional patents, for example, relating to compound forms, methods of treatment or use, formulations, devices, processes, synthesis, purification and detection.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We identify unexpired RDP periods and, in parentheses, years of expiry if the relevant marketing authorizations have been authorized or granted. We identify certain unexpired patent term extensions and marketing exclusivities and, in parentheses, years of expiry if they are granted; their subject matter scope may be limited and is not specified. Marketing exclusivities and patent term extensions include orphan drug exclusivity (ODE), pediatric exclusivity (PE), patent term extension (PTE) and supplementary protection certificate (SPC). We designate them as &#x201C;pending&#x201D; if they have been applied for but not granted and include years of expiry if estimable. Such pending applications may or may not ultimately be granted. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the case of the EU, identification of a patent, supplementary protection certificate, marketing exclusivity or regulatory data protection means grant, authorization and maintenance in at least one country. However, it could be pending, not granted, or found invalid in others. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For each product below, we indicate whether there is current generic or biosimilar competition for one or more product versions in one or more approved indications in either the US or the EU, if IP is otherwise disclosed. We identify certain enforcement actions, or ongoing challenges to the disclosed IP that have not been finally resolved, including IPRs or PGRs if instituted by the USPTO. Challenges identified as being in administrative entities, such as national patent offices, include judicial appeals from decisions of those entities. Resolution of challenges to the disclosed IP, which in the EU may involve IP in one or more EU countries, may include settlement agreements under which Novartis permits or does not permit future launch of generic versions of our products before expiration of that IP. We identify certain material terms of such settlement agreements where they could have a material adverse effect on our business. In other cases, such settlement agreements may contain confidentiality obligations restricting what may be disclosed.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For additional information regarding commercial arrangements with respect to these products, see &#x201C;&mdash;Key marketed products.&#x201D;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Novartis Oncology business unit</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;">Oncology</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Tasigna.</i> US: Patent on compound (2023), PE (2024); three patents on salt forms (2026, 2027, 2028), three PEs (2027, 2028, 2029); patent on polymorph compound form (2026), PE&nbsp;(2027); two patents on capsule form (2026, 2027), two PEs (2027, 2028); patent on method of treatment (2032), PE (2032). EU: Patent on compound (2023); patent on salt form (2026); patent on polymorph compound form (2026); patent on capsule form (2027); patent on method of treatment (2030). There is no generic competition in the US or the EU. In the US, generic manufacturers have filed ANDAs challenging certain patents other than the compound patent. In the EU, the method-of-treatment patent and the capsule form patent are being opposed in the EPO. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Promacta/Revolade.</i> US: Patent on compound (2021), PTE (2022), PE (2023); two patents on compound (2021, 2021), two PEs (2021, 2021); patent on thrombocytopenia use (2021), PE (2021); patent on method of enhancing platelet production (2021), PE (2021); patent on method of enhancing platelet production using salt (2023), PE (2023); patent on salt form and thrombocytopenia use (2025), PE (2026); five patents on tablet formulations of different dose strengths (2027) (5), five PEs&nbsp;(2028) (5); ODE on severe aplastic anemia patients with an insufficient response to immunosuppressive therapy (2021), PE (2022); ODE on severe aplastic anemia patients in combination with standard immunosuppressive therapy (2025). EU: Patent on compound (2021), SPC (2025), PE (2025); patent on salt form (2023); patent on formulation (2027); patent on severe aplastic anemia use (2028); patent on severe aplastic anemia dosing regimen (2030). There is no generic competition in the US or the EU. In the US, generic manufacturers have filed ANDAs challenging certain patents other than the compound patent. In the EU, the formulation patent is being opposed in the EPO.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Tafinlar </i>and<i> Mekinist.</i></div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:11px;margin-right:0mm;margin-top:0mm;"><i>Tafinlar</i>. US: Two patents on compound (2030, 2030); patent on method of treatment (2029). EU: Patent on compound (2029); RDP (2023). There is no generic competition in the US or the EU. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:11px;margin-right:0mm;margin-top:0mm;"><i>Mekinist</i>. US: Patent on compound (2025), PTE (2027); patent on method of treatment (2025); four patents on formulation (2032) (4). EU: Patent on compound (2025), SPC (2029); patent on formulation (2031); RDP (2025). There is no generic competition in the US or the EU. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:11px;margin-right:0mm;margin-top:0mm;">Use of <i>Mekinist</i> with <i>Tafinlar</i> or <i>Tafinlar</i> with <i>Mekinist</i>. US: Patent on combination (2030); two patents on method of use of combination (2025, 2030); ODE on melanoma with certain mutations (2021); ODE on non-small cell lung cancer (2024); ODE on adjuvant treatment of melanoma (2025); ODE on anaplastic thyroid cancer (2025). EU: Patent on combination (2030); </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">40</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:11px;margin-right:0mm;margin-top:0mm;">RDP (2025). There is no generic competition in the US or the EU. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Sandostatin </i>SC and<i> Sandostatin LAR.</i></div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:11px;margin-right:0mm;margin-top:0mm;"><i>Sandostatin</i> SC. There is no such patent protection in the US or the EU. There is generic competition in the US and the EU.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:11px;margin-right:0mm;margin-top:0mm;"><i>Sandostatin LAR</i>. There is no such patent protection in the US or the EU. There is generic competition in some EU markets but no generic competition in the US.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Jakavi.</i> EU: Patent on compound (2026), SPC (2027); patent on salt form (2028); patent on compound for polycythemia vera (PV) use (2026); patent on salt form for PV use (2028); RDP (2023). There is no generic competition in the EU. In the EU, the salt form patent and the patent on salt form for PV use are being opposed in the EPO.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"><i>&#x2022;</i><i> Gleevec/Glivec.</i> US: Patent on gastrointestinal stromal tumor (GIST) use (2021), PE (2022). EU: Patent on GIST use (2021); patent on tablet formulation (2023). There is generic competition in the US and the EU. National enforcement and validity actions are also ongoing on the GIST use patent in certain EU countries.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Afinitor/Votubia</i> and <i>Afinitor Disperz/Votubia</i> dispersible tablets. US: Patent on dispersible tablet formulation (2022), PE (2023); patent on tuberous sclerosis complex (TSC)/subependymal giant cell astrocytoma (SEGA) use (2022), PE (2022); patent on breast cancer use (2022), PE (2022); patent on renal cell carcinoma use (2025), PE (2026); patent on pancreatic neuroendocrine tumor use (2028); ODE for <i>Afinitor</i> on neuroendocrine tumors of gastrointestinal or lung origin (2023); ODE for <i>Afinitor Disperz</i> on tuberous sclerosis (2025). EU: Two patents on dispersible tablet formulation (2022, 2022); patent on breast cancer use (2022); patent on renal cell carcinoma use (2022); patent on neuroendocrine tumors of pancreatic origin use (2022); patent on neuroendocrine tumors of lung origin use (2022); patent on TSC/SEGA, TSC/renal angiomyolipoma and TSC/seizures use (2027); ODE (<i>Votubia</i>, tuberous sclerosis) (2023). There is generic competition in the EU, and in the US for the three lower-dosage strengths for <i>Afinitor</i>. In the US, Novartis has resolved patent litigation relating to <i>Afinitor</i>, which may result in further generic competition prior to the expiration in February 2022 of the breast cancer use patent. Also in the US, Novartis has resolved patent litigation relating to <i>Afinitor Disperz</i>, which may result in generic competition prior to the expiration in February 2022 of the TSC use patent.  In the EU, the breast cancer use patent, the TSC/SEGA, TSC/renal angiomyolipoma and TSC/seizures use patent, the renal cell carcinoma use patent, and the use patents on neuroendocrine tumors of pancreatic origin and of lung origin are being opposed in the EPO. National enforcement and validity actions are also ongoing on some of these patents in certain EU countries. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"> &#x2022;  <i>Kisqali</i>. US: Three patents on compound (2028, 2030, 2031), PTE pending (2031); three patents on methods of treatment (2029, 2029, 2031); patent on salt form (2031); RDP (2022). EU: Patent on compound (2027); patent on compound (2029), SPC (2032); patent on salt form (2031); patent on methods of use (2029); RDP (2027). There is no generic competition in the US or the EU.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Kymriah</i>. US: Seven patents on cells and/or pharmaceutical compositions comprising the cells (2031) (7); four patents on methods of use of cells and/or pharmaceutical compositions comprising the cells (2031) (4); RDP (2029), PE (2030); ODE for relapsed or refractory (r/r) pediatric acute lymphoblastic leukemia (2024), PE (2025); ODE for r/r diffuse large B-cell lymphoma (2025), PE (2025). EU: Patent on methods of use (2031), SPC (2033); RDP (2028); ODE (2028), PE (2030). There is no generic competition in the US or the EU.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Lutathera</i>. US: Patent on formulation (2038); patent on formulation process (2038); RDP (2023); ODE (2025). EU: RDP (2027); ODE (2027). There is no generic competition in the US or the EU.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Piqray</i>. US: Patent on compound (2029); patent on compound and use (2030), PTE pending (2033); RDP (2024). EU: Patent on compound and use (2029), SPC (2034); RDP (2030). There is no generic competition in the US or the EU.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Adakveo</i>. US: Patent on composition of matter (2028), PTE pending (2032); patent on methods of treatment (2027); RDP (2031), PE (2032); ODE (2026). EU: Patent on composition of matter (2027); patent on dissociation use (2031); RDP (2030); ODE (2030). There is no generic competition in the US or the EU. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Novartis Pharmaceuticals business unit</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;">Immunology, Hepatology and Dermatology</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"><i>&#x2022;</i><i> Cosentyx.</i> US: Patent on composition of matter (2026), PTE (2029); patent on psoriasis use (2032); patent on ankylosing spondylitis use (2033); RDP (2027). EU: Patent on composition of matter (2025), SPC (2030), PE (2030); patent on psoriasis use (2031); RDP (2026). There is no generic competition in the US or the EU.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;">Ophthalmology</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"><i>&#x2022;</i><i> Lucentis.</i> EU: Patent on composition of matter (2018), SPC (2022), PE (2022). There is no generic competition in the EU. In the EU, the pre-filled syringe patent is being opposed in the EPO. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Xiidra</i>. US: Patent on compound (2024); three patents on compound and use (2024, 2024, 2025); patent on formulation (2024); five patents on method of treatment (2024, 2024, 2026, 2029, 2029); two patents on polymorph compound form (2029, 2029); RDP (2021). PTE pending. There is no generic competition in the US. <i>Xiidra</i> is not marketed in the EU. In the US, the compound, compound and use, formulation, method of treatment, and polymorph compound form patents are being challenged in ANDA proceedings against a generic manufacturer. </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">41</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Beovu</i>.&nbsp;US:&nbsp;Patent on composition of matter (2029), PTE pending (2033); patent on method of treatment (2029); patent on nucleic acid molecule (2029); patent on antibodies (2023); patent on dosing regimen (2035); RDP (2031).&nbsp;EU:&nbsp;Two patents on composition of matter (2029, 2029), SPC (2034); patent on antibodies (2023); RDP (2030). There is no generic competition in the US or the EU. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;">Neuroscience</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"><i>&#x2022;</i><i> Gilenya.</i> US: Patent on dosage regimen (2027), PE (2027); patent on 0.25 mg formulation (2032), PE (2032); patent on method of treatment (2027); RDP for pediatric use and 0.25 mg (2021), PE (2021). EU: Patent on formulation (2024), SPC (2026); patent on 0.25 mg formulation (2032); RDP (2022). There is no generic competition in the US or the EU. In the US, the dosage regimen patent is being challenged in ANDA proceedings against a generic manufacturer and was upheld as being valid and infringed. The decision has been appealed. In parallel, an appeal against a USPTO decision upholding that patent in IPR proceedings is ongoing. Novartis is also enforcing the method of treatment patent against a generic manufacturer. Novartis has entered into settlement agreements with a number of manufacturers that had filed ANDAs to market a generic version of 0.5 mg <i>Gilenya</i>. Under the confidential terms of these settlements, these ANDA filers will be able to launch a generic version of 0.5 mg <i>Gilenya</i> on an agreed-upon date that is prior to the expiration of the dosage regimen patent. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"><i>&#x2022;</i><i> Zolgensma</i>. US: Three patents on vector (2024, 2024, 2026); two patents on methods of treatment (2028, 2028); ODE for spinal muscular atrophy (SMA) in patients less than 2 years old with biallelic mutations in the SMN1 gene (2026); RDP (2031). EU: Two patents on vector (2024, 2028); two patents on methods of use (2028, 2028); ODE for SMA in patients with a biallelic mutation in the SMN1 gene, or patients with a biallelic mutation in the SMN1 gene and up to three copies of the SMN2 gene (2030); RDP (2030).  There is no generic competition in the US or the EU.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"><i>&#x2022;</i><i> Mayzent</i>. US: Patent on compound (2024); patent on treatment initiation use (2030); RDP (2024). PTE pending. EU: Patent on compound (2024); patent on solid form (2029); patent on treatment initiation use (2029), SPC (2034); patent on formulation (2032); RDP (2030). There is no generic competition in the US or the EU.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"><i>&#x2022;</i><i> Kesimpta</i>. US: Patent on compound (2031); RDP (2021). EU: Three patents on compound (2023) (3); two patents on formulation (2028, 2028); patent on dosing regimen (2037). There is no generic competition in the US. <i>Kesimpta</i> is not currently marketed in the EU. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;">Cardiovascular, Renal and Metabolism</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"><i>&#x2022;</i><i> Entresto.</i> US: Four patents on combination (2023) (4), four PEs (2023 (3), 2024); two patents on complex (2026, 2027), two PEs (2027, 2027); RDP for new pediatric patient population (2022), PE (2023). PTE pending. EU: Patent on combination (2023), SPC (2028); two patents on complex (2026, 2026), two SPCs (2030, pending 2030); patent on method of use (2034); RDP (2025). There is no generic competition in the US or the EU. In the US, two combination patents and the two complex patents are being challenged in ANDA proceedings against generic manufacturers. In the EU, the two complex patents and the use patent are being opposed in the EPO. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Leqvio</i>. US: Patent on composition of matter (2034), anticipated PTE (2035); patent on dosing regimen (2036). EU: Patent on composition of matter (2033), anticipated SPC (2035); RDP (2030). There is no generic competition in the EU. <i>Leqvio</i> is not currently marketed in the US. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;">Respiratory</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Xolair.</i> US: Two patents on syringe formulation (2021, 2025). EU: Two patents on syringe formulation (2021, 2024). There is no generic competition in the US or the EU. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;">Established Medicines</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"><i>&#x2022;</i><i> Galvus</i> and <i>Eucreas</i>. EU: Patent on compound (2019), SPC (2022); patent on combination (2021), SPC (2022); patent on <i>Galvus</i> formulation (2025); patent on <i>Eucreas</i> formulation (2026). <i>Galvus/Eucreas</i> is not marketed in the US. There is generic competition for <i>Galvus</i> and <i>Eucreas</i> in some EU countries. The EU <i>Galvus</i> formulation patent is being opposed in the EPO.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Diovan</i> and <i>Co-Diovan/Diovan HCT. Diovan</i>: There is no such patent protection for <i>Diovan</i> in the US or the EU. There is generic competition in the US and the EU. <i>Co-Diovan/Diovan HCT</i>: There is no such patent protection for <i>Co-Diovan/Diovan HCT</i> in the US or the EU. There is generic competition in the US and the EU.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Compounds in development </font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We provide patent information for non-marketed compounds in development that have been submitted to the FDA and/or the EMA for registration but have not yet been approved by either agency. We currently do not have any non-marketed compounds in development that have been submitted for registration but have not yet been approved by either agency. </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">42</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"></div><a name="anchorId00344881"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Sandoz</p>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our Sandoz Division is a global leader in generic pharmaceuticals and biosimilars, and sells products in well over 100 countries. In 2020, the Sandoz Division achieved consolidated net sales of USD 9.6&nbsp;billion, representing 20% of the Group&#x2019;s total net sales. Sandoz develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Sandoz is organized globally into three franchises: Retail Generics, Anti-Infectives and Biopharmaceuticals. In Retail Generics, Sandoz develops, manufactures and markets active ingredients and finished dosage forms of small-molecule pharmaceuticals to third parties across a broad range of therapeutic areas, as well as finished dosage form anti-infectives sold to third parties. In Anti-Infectives, Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates &ndash; mainly antibiotics &ndash; for internal use by Retail Generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products, including biosimilars, and provides biotechnology manufacturing services to other companies. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Sandoz strategic ambition is to be the world&#x2019;s leading and most valued generics company (including biosimilars). Our divisional strategy focuses on three areas: developing a broad and consistent pipeline of off-patent launches across key geographies and across a broad range of therapeutic areas; positioning Sandoz to be &#x201C;first in&#x201D; by having a strong pipeline with a focus on being first to market and &#x201C;last out&#x201D; by way of competitive costs and stable supply; and instilling a true &#x201C;generic mindset,&#x201D; with a focus on priorities, simple and rapid decision-making, and focused resource allocation.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Sandoz is the global market leader in biosimilars, with a total of eight approved and marketed products, and a pipeline of over 15 molecules. In addition to internally developed projects, our biosimilar portfolio comprises publicly announced commercialization agreements with BioCon, Gan &amp; Lee, EirGenix and Polpharma Biologics. Availability of our biosimilars varies by country. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Sandoz is also the global market leader in generic antibiotics. Its Kundl, Austria, manufacturing site is the hub of the last vertically integrated antibiotics production chain in Europe, which offers certain competitive advantages including added supply chain resilience.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">On January 31, 2020, we closed the previously announced acquisition of the Japanese business of Aspen Global Incorporated, consisting of off-patent branded medicines with a focus on anesthetics and specialty brands.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We received a CRL from the FDA in 2018 for our submission for a generic form of fluticasone propionate and salmeterol inhalation powder, for oral inhalation (GSK&#x2019;s Advair<sup>&#xAE;</sup>). In January 2020, we decided to discontinue the generic Advair<sup>&#xAE;</sup> development program in the US, following a detailed review of the latest data read-outs.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">On March 2, 2020, we announced a resolution with the US Department of Justice (DOJ) Antitrust Division concerning the DOJ&#x2019;s antitrust investigation into the US generic drug industry. For more information, see &#x201C;Item 18. Financial Statements&mdash;Note 20. Provisions and other non-current liabilities.&#x201D; </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2018, Novartis announced an agreement to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, to Aurobindo Pharma USA Inc., for USD 0.8 billion in cash and potential earn-outs. On April 2, 2020, Novartis announced the mutual agreement with Aurobindo to terminate the sale agreement, as approval from the US Federal Trade Commission for the transaction was not obtained within anticipated timelines. Sandoz continues to operate its oral solids and dermatology businesses as well as its dermatology development center as part of the Sandoz US business.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">On July 27, 2020, Sandoz and the Austrian government announced a planned combined investment of more than EUR 150 million to enhance the long-term competitiveness and supply resilience of European production for key antibiotics. </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Key marketed products</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Sandoz global portfolio covers a wide range of therapeutic areas. The following are some of the Sandoz key marketed products in each of its franchises (availability varies by market):</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Retail Generics</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="top">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">Product</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Originator drug</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Description</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amoxicillin/clavulanic acid</div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Augmentin<sup>&#xAE;</sup></div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Antibiotic</div>
      </td>
      <td align="left" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Zoledronic acid</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Aclasta</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Osteoporosis treatment</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acetylcysteine</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Various</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Mucolytic agent</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tacrolimus</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Various</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunosuppressive agent</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">43</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Anti-Infectives</font>
</div>
<div style="padding-top:10px; padding-bottom:10px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="top">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">Active ingredients</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Description</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td width="48%" height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Oral and sterile penicillins</div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left" width="48%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti-infectives</div>
      </td>
      <td align="left" width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Oral and sterile cephalosporins</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti-infectives</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Clavulanic acid and mixtures with clavulanic acid</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#xDF;-lactam inhibitors</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Classical and semisynthetic macrolides</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti-infectives</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="top">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">Intermediates</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Description</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td width="48%" height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Various cephalosporin intermediates</div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left" width="48%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti-infectives</div>
      </td>
      <td align="left" width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Macrolide base intermediates</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti-infectives</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Various crude compounds produced by fermentation</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cyclosporine, ascomycin, rapamycin, mycophenolic acid, etc.</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Biopharmaceuticals</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="top">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">Product</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Originator drug</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Description</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Omnitrope</div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Genotropin<sup>&#xAE;</sup>  </div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Recombinant human growth hormone to treat growth   disorders and growth hormone deficiency</div>
      </td>
      <td align="left" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Binocrit</I> and Epoetin alfa <I>Hexal</I></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Eprex<sup>&#xAE;</sup>/Erypo<sup>&#xAE;</sup>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Recombinant protein (erythropoiesis-stimulating) agent  to treat anemia</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Zarzio, Zarxio</I> and <I>Filgrastim Hexal</I></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neupogen<sup>&#xAE;</sup>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Recombinant protein (granulocyte colony-stimulating   factor (GCSF), short-acting) used in oncology</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Glatopa</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Copaxone<sup>&#xAE;</sup></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Treatment for relapsing forms of multiple sclerosis (MS)</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Erelzi<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Enbrel<sup>&#xAE;</sup>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Fusion protein (TNF-&#x3B1; receptor) to treat multiple   immune-mediated inflammatory diseases</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Rixathon</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MabThera<sup>&#xAE;</sup>    </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chimeric monoclonal antibody (directed against   CD20 protein on B-cells) to treat blood cancers   and immunological diseases</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Hyrimoz</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Humira<sup>&#xAE;</sup>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Monoclonal antibody (TNF-&#x3B1; antibody) to treat multiple   immune-mediated inflammatory diseases</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zessly</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Remicade<sup>&#xAE;</sup>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Monoclonal antibody (TNF-&#x3B1; antibody) to treat multiple   immune-mediated  inflammatory diseases</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ziextenzo</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neulasta<sup>&#xAE;</sup>      </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PEGylated form of a recombinant human granulocyte colony-  stimulating factor (GCSF) (long-acting) to reduce duration   of chemotherapy-induced neutropenia and incidence of   chemotherapy-induced febrile neutropenia</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Approved in the US in 2016. Launch in the US pending final resolution of litigation with Amgen, which markets Enbrel<sup>&#xAE;</sup>. The US District Court of New Jersey ruled against Sandoz in August 2019, which was upheld on appeal; Sandoz is now considering its further appeal options.</div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Selected development projects &ndash; Biosimilars in Phase&nbsp;III development and registration</font>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table describes Sandoz biosimilar projects that are in Phase&nbsp;III clinical trials (including filing preparation) and registration:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="top">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">Project/<br>product</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Common <br> name</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Mechanism of action</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Potential indication/indications</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Therapeutic areas</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Route of<br> administration</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Current phase</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">GP2017</div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> adalimumab    </div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TNF-&#x3B1; antibody    </div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Arthritides (rheumatoid arthritis, ankylosing   spondylitis, psoriatic arthritis), plaque psoriasis   and others (same as originator)</div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous    </div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EU approved  US approved<sup>1</sup>  </div>
      </td>
      <td align="left" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">GP2411<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> denosumab    </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti-RANKL   monoclonal antibody  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Osteoporosis, treatment-induced bone loss,   metastases to bone, giant cell tumor   (indications vary in US and EU)</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Endocrinology,   Neurology  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous    </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Phase III    </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">EGI014A1<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> trastuzumab    </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti-HER2 recombinat   IgG1, humanized   monoclonal antibody</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast and gastric tumors    </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology    </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous    </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Phase III    </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">DST356A1<sup style="white-space: nowrap">&nbsp;4</sup></div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> natalizumab    </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti-&#x3B1;4 integrin   monoclonal antibody  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Monotherapy for relapsing-remitting forms of   multiple sclerosis (RRMS); in US, second-line   treatment for active Crohn&#x2019;s disease</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neurology,   Immunology (US only)  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous    </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Phase III    </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Launched as <I>Hyrimoz</I> in the EU in October 2018. Also in October 2018, we announced a global resolution of all intellectual property-related litigation with AbbVie concerning adalimumab. Under the terms of the agreement, AbbVie grants us a non-exclusive license to AbbVie&#x2019;s intellectual property relating to Humira<sup>&#xAE;</sup>, beginning on certain dates in certain countries in which AbbVie has intellectual property. We are not entitled to launch <I>Hyrimoz</I> in the US until the second half of 2023.</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Development in collaboration with Hexal AG.</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Development in collaboration with EirGenix, Inc.</div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> Development in collaboration with Polpharma Biologics.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">44</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Principal markets</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The two largest generics markets in the world &ndash; the US and Europe &ndash; are the principal markets for Sandoz. The following table sets forth the aggregate 2020 net sales of Sandoz by region:</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020 net sales  to third parties</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD millions</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;231</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 54</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United States</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;142</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia, Africa, Australasia</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;501</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 772</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;646</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Of which in Established Markets<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;089</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 73</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Of which in Emerging Growth Markets<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;557</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Many Sandoz products are used for chronic conditions that require patients to consume the product over long periods of time, from months to years. Sales of our anti-infective products and over-the-counter cough and cold products are subject to seasonal variation. Sales of the vast majority of our other products are not subject to material changes in seasonal demand.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Production</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For information on the production of our products, see &#x201C;&mdash;Item 4.B Business overview&mdash;Innovative Medicines&mdash;Production.&#x201D;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In September 2020, as part of a broader reorganization of Novartis Technical Operations (NTO), we established the Sandoz Technical Operations (STO) platform within NTO. STO will focus on producing generic medicines for Sandoz, as well as related external supply operations and supply chain. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Due to impurities found in the active ingredient batches sourced from third-party manufacturers, we recalled Sandoz valsartan, losartan and irbesartan products in the second half of 2018 and first quarter of 2019, and ranitidine film-coated tablets in the second half of 2019, from several markets, in line with our quality standards for all of our marketed products.  The discovery of nitrosamines in some types of drug products led several health regulators (e.g., EMA, FDA and others) to conduct a detailed analysis of these impurities in affected medicinal products. Novartis works with health authorities around the world to continuously review all chemical and biological human medicines for the possible presence of nitrosamines. The EMA, FDA and other health authorities have provided guidance to the pharmaceutical industry to prevent unacceptable levels of nitrosamines in medicines. The EMA review is due to conclude in March 2021 for chemical human medicines and in July 2021 for biological human medicines.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Marketing and sales</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sandoz sells a broad portfolio of products, including the products of our Retail Generics franchise and biosimilars, to wholesalers, pharmacies, hospitals and other healthcare outlets. Sandoz adapts its marketing and sales approach to local decision-making processes, depending on the structure of the market in each country.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In response to rising healthcare costs, many governments and private medical care providers, such as health maintenance organizations, have instituted reimbursement schemes that favor the substitution of bioequivalent generic versions of originator pharmaceutical products, such as those sold by our Retail Generics franchise. In the US, statutes have been enacted by all states that permit or require pharmacists to substitute a less expensive generic product for the brand-name version of a drug that has been prescribed to a patient. Generic use is growing in Europe, but penetration rates in many EU countries (as a percentage of volume) remain well below those in the US.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Recent trends have been toward continued consolidation among distributors and retailers of Sandoz products, both in the US and internationally, which has increased our customers&#x2019; purchasing leverage.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Legislative or regulatory changes can have a significant impact on our business in a country. For more information on such changes, see &#x201C;&#x201C;&mdash;Item 4.B Business overview&mdash;Innovative Medicines&mdash;Price controls.&#x201D;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our Anti-Infectives franchise supplies active pharmaceutical ingredients and intermediates &ndash; mainly antibiotics &ndash; for internal use by Retail Generics and for sale to the pharmaceutical industry worldwide.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our Biopharmaceuticals franchise operates in an emerging business environment, particularly in the US. Regulatory pathways for approving biosimilar products are either relatively new or still in development, and policies have not yet been fully defined or implemented regarding the automatic substitution and reimbursement of biosimilars in many markets, including the US. As a result, in many of these markets, our biosimilar products are marketed as branded competitors to the originator products.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">45</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Competition</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The market for generic products is characterized by increasing demand for high-quality pharmaceuticals that can be marketed at lower costs due to comparatively minimal initial research and development investments. Increasing pressure on healthcare expenditure and numerous patent and data exclusivity period expirations have encouraged more generic product launches, resulting in increased competition among the companies selling generic pharmaceutical products, leading to ongoing price pressure. In particular, Sandoz faces increased industrywide pressure on prices for generic products, particularly in the US, driven by factors including customer consolidation and growing competition from other manufacturers of generic medicines. These factors contributed to a decline in US sales that began in 2017 and continued through 2020. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, research-based pharmaceutical companies are participating directly in the generic conversion process by licensing their patented products to generic companies (so-called &#x201C;authorized generics&#x201D;). Consequently, generic companies that were not otherwise in a position to launch a specific product may participate in the market using the innovator&#x2019;s product authorization. Authorized generics serve as a business opportunity for Sandoz when the product of a research-based pharmaceutical company loses patent protection and Sandoz secures a license from the research-based pharmaceutical company to launch the authorized generic of that product.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Development and registration</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Development of Sandoz Biopharmaceuticals is jointly overseen by Sandoz and by Global Drug Development (GDD) and is mostly executed by GDD. Development and registration activities for Retail Generics products, and certain registration activities for Biopharmaceuticals products, continue to be overseen directly by Sandoz.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Before a generic pharmaceutical may be marketed, intensive technical and clinical development work must be performed to demonstrate, in bioavailability studies, the bioequivalence of the generic product to the reference product. Nevertheless, research and development costs associated with generic pharmaceuticals are much lower than those of the originator pharmaceuticals, as no preclinical studies or clinical trials on dose finding, safety and efficacy must be performed by the generic company. As a result, generic pharmaceutical products can be offered for sale at prices often much lower than those of products protected by patents and data exclusivity, which must recoup substantial research and development costs through higher prices over the life of the product&#x2019;s patent and data exclusivity period.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">While generic pharmaceuticals are follow-on versions of chemically synthesized molecules, biosimilar products contain a version of the active substance of an already approved biological reference medicine. Due to the inherent variability and complexity of biologic products, including batch-to-batch differences and variations following manufacturing changes, the development and the regulatory pathway of biosimilars differ significantly from that of generics.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The development of a biosimilar product is much more technically challenging than the development of a typical generic small-molecule pharmaceutical. While generic pharmaceuticals normally do not require clinical studies in patients, regulators worldwide do require such targeted studies for biosimilar products. Biosimilars are engineered to match the reference medicine in quality, safety and efficacy. This is achieved by systematically defining the target range of the reference medicine and then comparing the biosimilar to the reference medicine at various development stages to confirm biosimilarity and to establish that there are no clinically meaningful differences between the proposed biosimilar and the reference biologic. Because the purpose of a biosimilar clinical development program is to confirm biosimilarity and not to establish efficacy and safety de novo, the clinical studies required are less than those required for a reference biologic. Therefore, the cost of development for a biosimilar is usually less than that of a reference biologic.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Development and Registration staff employed by affiliates of the Sandoz Division are based worldwide, including at facilities in Holzkirchen, Germany; Hyderabad, India; Kundl, Austria; Ljubljana, Slovenia; and Rudolstadt, Germany. In November 2020, Sandoz completed (i) the previously announced closure of the Holzkirchen, Germany, development and registration site, with the exception of patch development and the project management group, and; (ii) the closure of the product development and registration site as well as the maintenance and development regulatory centers in Unterach, Austria. We are conducting a review of our global development and regulatory network to consolidate and streamline operations and optimize our network structure to enable Sandoz to compete sustainably in an increasingly challenging generics environment. As part of this review, in the fourth quarter of 2020, Sandoz announced the planned closure of its maintenance regulatory center in Barleben, Germany, which we expect will be completed in the fourth quarter of 2021. Sandoz also announced the planned closure of the Fougera development center located in Melville, New York as well as the product development center in Boucherville, Canada, which we expect will be completed in 2021. </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Regulation</font>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Generics</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Hatch-Waxman Act in the US (and similar legislation in the EU and in other countries) eliminated the requirement that manufacturers of generic pharmaceuticals repeat the extensive clinical trials required for reference products, so long as the generic version could be shown to be therapeutically equivalent to the reference product.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the US, the decision on whether a generic pharmaceutical is therapeutically equivalent to the original product is made by the FDA based on an Abbreviated New Drug Application (ANDA) filed by the generic product&#x2019;s manufacturer. The process typically takes nearly two years from the filing of the ANDA until FDA approval. </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">46</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">However, delays can occur if issues arise, for example, regarding the interpretation of bioequivalence study data, labeling requirements for the generic product, or qualifying the supply of active ingredients. In addition, the Hatch-Waxman Act requires a generic manufacturer to certify in certain situations that the generic product does not infringe on any current applicable patents on the product held by the holder of the marketing authorization for the reference product, or to certify that such patents are invalid. This certification often results in a patent infringement lawsuit being brought against the generic company. In the event of such a lawsuit, the Hatch-Waxman Act imposes an automatic 30-month delay in the approval of the ANDA to allow the parties to resolve the intellectual property issues. For generic applicants who are the first to file their ANDA containing a certification claiming non-infringement or patent invalidity, the Hatch-Waxman Act generally provides those applicants with 180&nbsp;days of marketing exclusivity to recoup the expense of challenging the patents on the reference product. However, generic applicants must launch their products within certain timeframes or risk losing the marketing exclusivity that they had gained by being a first-to-file applicant.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the EU, decisions on the granting of a marketing authorization are made either by the European Commission based on a positive recommendation by the EMA under the centralized procedure, or by a single member state under the national or decentralized procedure. See &#x201C;&mdash;Innovative Medicines&mdash;Regulation&mdash;European Union.&#x201D; Companies may submit Abridged Applications for approval of a generic medicinal product based upon its &#x201C;essential similarity&#x201D; to a medicinal product authorized and marketed in the EU following the expiration of the product&#x2019;s data exclusivity period. In such cases, the generic company is able to submit its Abridged Application based on the data submitted by the innovator company for the reference product, without the need to conduct extensive Phase&nbsp;III clinical trials of its own. For all products that received a marketing authorization in the EU after late 2005, the Abridged Application can be submitted throughout the EU. However, the data submitted by the innovator company in support of its application for a marketing authorization for the reference product will be protected for 10 years after the first grant of marketing authorization in all member states, and can be extended for an additional year if a further innovative indication has been authorized for that product, based on preclinical and clinical trials filed by the innovator company that show a significant clinical benefit in comparison to the existing therapies.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Biosimilars</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The regulatory pathways for approval of biosimilar medicines are still being developed and established in many countries of the world. A regulatory framework for the approval of biosimilars has been established in the EU, Japan, Canada and the US, while the World Health Organization (WHO) has issued guidance. Sandoz has successfully registered and launched the first biosimilar (or biosimilar-type) medicine in Europe, the US, Canada, Japan, Taiwan, Australia, and many countries in Latin America and Asia. Sandoz was the first company to secure approval for and launch a biosimilar under the US biosimilar pathway that was established as part of the Biologics Price Competition and Innovation Act (BPCIA).</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The approval of biosimilars in Europe follows a process similar to that followed for small molecules. However, biosimilars usually have to be approved through the centralized procedure because they are manufactured using recombinant DNA technology. As part of the approval process in the EU, biosimilars have to demonstrate comparability to the reference medicine in terms of safety, efficacy and quality through an extensive comparability exercise, based on strict guidelines set by the authorities. Regulators will only approve a biosimilar based on data that allows the regulators to conclude that there are no clinically meaningful differences between the reference medicine and the biosimilar.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the US, under the BPCIA, a biosimilar must be highly similar with no clinically meaningful differences compared to the reference medicine. Approval of a biosimilar in the US requires the submission of an ABLA to the FDA, including an assessment of immunogenicity, and pharmacokinetics or pharmacodynamics. The ABLA for a biosimilar can be submitted as soon as four years after the initial approval of the reference biologic, but can only be approved 12&nbsp;years after the initial approval of the reference biologic. </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Intellectual property</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We take all reasonable steps to ensure that our products do not infringe valid intellectual property rights held by others. Nevertheless, competing companies commonly assert patent and other intellectual property rights. As a result, we can become involved in significant litigation regarding our products. If we are unsuccessful in defending these suits, we could be subject to injunctions preventing us from selling our products and to potentially substantial damages.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Wherever possible, our products are protected by our own patents. Among other things, patents may cover the products themselves, including the product&#x2019;s formulation, or the processes for manufacturing a product. However, there can be no assurance that our intellectual property will protect our products or that we will be able to avoid adverse effects from the loss of intellectual property protection in the future.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">47</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00345710"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">4.C Organizational structure</p><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Organizational structure</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">See &#x201C;Item&#xA0;4. Information on the Company&#x2014;Item&#xA0;4.A History and development of Novartis&#x201D; and &#x201C;Item&#xA0;4. Information on the Company&#x2014;Item&#xA0;4.B Business overview&#x2014;Overview.&#x201D;</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant subsidiaries</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">See &#x201C;Item 18. Financial Statements&#x2014;Note 32. Principal Group subsidiaries and associated companies.&#x201D;</div><a name="anchorId00345720"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">4.D Property, plants and equipment</p>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our principal executive offices are located in Basel, Switzerland. Our divisions operate through a number of affiliates that have offices, research and development facilities, and production sites throughout the world.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We generally own our facilities or have entered into long-term lease arrangements for them. Some of our principal facilities are subject to mortgages and other security interests granted to secure certain debts. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis Technical Operations (NTO) manages the production, supply chains and quality of our Innovative Medicines and Sandoz Division products through a network of 54 manufacturing sites, as well as through external suppliers, and warehouse and distribution centers. In addition, our Innovative Medicines Division manages six AAA sites for radioligand therapies production and six sites for Novartis Gene Therapies (formerly AveXis) for research and development, production, warehousing and administrative offices. Endocyte manages two sites for research and its headquarters and administrative offices. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table sets forth our major headquarters and most significant production, research and development, and administrative facilities. See also &#x201C;&#x2014;Item 4.B Business overview&#x2014;Innovative Medicines&#x2014;Production&#x201D; and &#x201C;&#x2014;Item 4.B Business overview&#x2014;Sandoz&#x2014;Production&#x201D; for a discussion of our manufacturing processes.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Major facilities</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="top">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"><br>Location</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Size of site (in <br> square meters)</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Major activity</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel, Switzerland &#x2013; St.&#xA0;Johann</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 589&nbsp;000    </div>
      </td>
      <td align="right" width="1%"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Global Group headquarters; global Innovative Medicines Division headquarters; Global Sandoz   Division headquarters; research and development; production of drug substances and   drug intermediates</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Kundl and Schaftenau, Austria</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 480&nbsp;000  </div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Production of biotechnological products, drug products and finished products, anti-infectives,   active drug substances, product development</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, New Jersey</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 391&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Innovative Medicines Division US headquarters, research and development</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Barleben, Germany</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 340&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Production of broad range of generics finished dosage forms</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cambridge, Massachusetts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 201&nbsp;800</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Research and development</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shanghai, China</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 106&nbsp;500</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Research and development</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Stein, Switzerland</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64&nbsp;700  </div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Production of sterile vials, pre-filled syringes and ampoules; inhalation capsules,   tablets and transdermals; active pharmaceutical ingredients, and cell and gene therapies</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Holzkirchen, Germany</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64&nbsp;200  </div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Global Sandoz Division, production of oral films, transdermal delivery systems,   matrix patches, product development</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Huningue, France</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 35&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Production of drug substances for clinical and commercial supply</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Princeton, New Jersey</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&nbsp;300</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Sandoz Division US headquarters</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Libertyville, Illinois</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;800  </div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Production, warehouse and administrative offices for the Novartis Gene Therapies unit   within the Innovative Medicines Division</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As our product portfolio evolves, NTO is adapting our manufacturing capacity and capabilities to meet our changing needs, shifting from high-volume products toward lower-volume, customized and personalized medicines. As of December 31, 2020, we have closed, exited or sold 18 manufacturing sites since 2016 and have announced the closure, exit or sale of seven additional manufacturing sites. We have continued to expand our capacity in personalized medicines and complex biologic drugs, such as in Stein, Switzerland, as well as investing in new facilities to provide cell and gene therapies, such as in Les Ulis, France. We are leveraging innovation to increase the reliability and productivity of our manufacturing network, including using data and digital technologies. We continue to seek opportunities to manage our production facilities as efficiently as possible, optimize </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">48</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">external spend, and simplify and standardize across our manufacturing network to help us lower costs and help optimize the value of our products. At the same time, we are working to improve our environmental sustainability, for example by reducing energy and water consumption at our sites.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For a description of the impact of environmental matters, see &#x201C;Item&#xA0;3. Key Information&#x2014;Item&#xA0;3.D Risk factors&#x2014;Environmental, social and governance&#x2014;Unsuccessful management of environmental, social and governance matters,&#x201D; &#x201C;Item 3. Key Information&#x2014;Item 3.D Risk factors&#x2014;Environmental matters&#x2014;Impact of environmental liabilities,&#x201D; and &#x201C;Item 3. Key Information&#x2014;Item 3.D Risk factors&#x2014;Climate change&#x2014;Climate change and associated increased risk of major natural disasters.&#x201D; See also &#x201C;Item 18. Financial Statements&#x2014;Note&#xA0;20. Provisions and other non-current liabilities.&#x201D;</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">49</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00345891"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;4A.  Unresolved Staff Comments</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">50</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>



    <a name="anchorId0010037584"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item 5. Operating and Financial Review and&nbsp;Prospects</p><a name="anchorId0010037587"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">5.A Operating results</p>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">This operating and financial review should be read with the Group&#x2019;s consolidated financial statements in this Annual Report, which have been prepared in accordance with International Financial Reporting Standards (IFRS) as published by the International Accounting Standards Board (see &#x201C;Item 18. Financial Statements&#x201D;). &#x201C;Item 5. Operating and Financial Review and Prospects&#x201D; with the sections on compounds in development and selected development projects of our divisions (see &#x201C;Item 4. Information on the Company&mdash;Item 4.B Business overview&#x201D;) constitute the Operating and Financial Review (<i>Lagebericht</i>), as defined by the Swiss Code of Obligations.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The discussion and analysis of the financial condition and results of operations of certain items from fiscal year ended December 31, 2018 and year to year comparison between fiscal year ended December 31, 2019 and December 31, 2018 that are not included in this Form 20-F can be found in &#x201C;<a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1114448/000137036820000003/a20012920f.htm#anchorId0010031971">Item 5. Operating and Financial Review and Prospects</a>&#x201D; of our Form 20-F for the fiscal year ended December 31, 2019, which is incorporated by reference herein.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Overview</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our purpose is to reimagine medicine to improve and extend people&#x2019;s lives. We use innovative science and technology to address some of society&#x2019;s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our Company. Our vision is to become the most valued and trusted medicines company in the world.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The businesses of Novartis are divided operationally on a worldwide basis into two identified reporting segments:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Innovative Medicines: innovative patent-protected prescription medicines</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Sandoz: generic pharmaceuticals and biosimilars</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In addition, we separately report the results of Corporate activities. The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries. Corporate also includes other items of income and expense that are not attributable to specific segments, such as certain revenues from intellectual property rights and certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations and sponsorships.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our divisions are supported by the following organizational units: the Novartis Institutes for BioMedical Research, Global Drug Development, Novartis Technical Operations and Novartis Business Services. The financial results of these organizational units are included in the results of the divisions for which their work is performed. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Significant transactions are discussed in &#x201C;Item 18. Financial Statements&mdash;Note 2. Significant transactions&#x201D;, &#x201C;Item 18. Financial Statements&mdash;Note 3. Segmentation of key figures 2020, 2019 and 2018,&#x201D; and &#x201C;Item 18. Financial Statements&mdash;Note 30. Discontinued operations.&#x201D;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Following the February 28, 2019, shareholders&#x2019; approval of the spin-off of the Alcon business, the Group reported its consolidated financial statements as &#x201C;continuing operations&#x201D; and &#x201C;discontinued operations&#x201D; for the current and prior years to comply with IFRS. Continuing operations include the businesses of the Innovative Medicines and Sandoz Divisions, and the continuing Corporate activities. Discontinued operations include the Alcon eye care devices business and certain Corporate activities attributable to the Alcon business prior to the spin-off, the gain on distribution of Alcon Inc. to Novartis AG shareholders and certain other expenses related to the spin-off. See &#x201C;Item 18. Financial Statements&mdash;Note 1. Significant Accounting Policies&#x201D;, &#x201C;Item 18. Financial Statements&mdash;Note 2. Significant Transactions&#x201D; and &#x201C;Item 18. Financial Statements&mdash;Note 30. Discontinued operations.&#x201D;</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Our environment</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We live in an era of amazing medical innovation, driven by better understanding of the genetic and biological roots of disease, and surging use of data analytics and digital technology in science and healthcare. At the same time, the world&#x2019;s population continues to grow and people are living longer, fueling a rise in chronic diseases. Together, these factors are increasing demand for high-quality care worldwide and pressuring healthcare systems to restrain spending growth.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Our strategy</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our strategy is to build a leading, focused medicines company powered by advanced therapy platforms and data science. As we implement our strategy, we have five priorities to shape our future and help us continue to create value for our company, our shareholders and society: </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Unleash the power of people</i>. We believe that culture is fundamental to driving our performance and value for stakeholders. We are implementing this priority by building one consistent organizational culture that is inspired, curious and unbossed. Engagement of our associates is now at an all-time high. Externally, more than half of our candidates reference culture as one of the reasons to join Novartis. In the future, we expect to make real-time insights on company culture available </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">51</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">to our leaders to drive our performance and further foster our culture.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Deliver transformative innovation</i>. We prioritize first-in-class medicines in our pipeline to address the needs of patients with no or limited treatment options. Our commitment is to go beyond traditional modalities (for example, small molecules and biologics) and invest in advanced therapy platforms (for example, cell therapy, gene therapy, radioligand therapy and RNA-based therapeutics). Novartis has a leading pipeline based on scale, innovation and future value, including 118 assets in Phase I or II, 49 in Phase III or undergoing registration and more than 65 new molecular entities as of December 31, 2020. The pipeline is expected to fuel growth in the mid-to long-term, with around 90% potential first-in-class/first-in-indication medicines and about 80% of targets in areas of high unmet patient need. The company is strengthening its advanced therapy platforms along the value chain with 20 advanced platform therapies in clinical development alongside a large number of pre-clinical projects. We are also making significant progress on the manufacturing and commercialization of these advanced therapy platforms. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Embrace operational excellence</i>. We believe that operational excellence is becoming an increasingly important factor to the success of our business. We are focused on three key areas: (i) Launch excellence and the performance of our growth drivers. We are reinforcing our approach to product launches to become more consistent across markets. To ensure we deploy our resources effectively, we are investing in earlier pre-launch preparations, including talking with doctors, patients and insurers to better understand their needs. Using data science, we are expanding our ability to test and learn from new commercial models and employ real-time analysis of marketing data in order to target customers with personalized content, orchestrated across multiple marketing channels; (ii) Transformation of NTO to deliver consistent productivity gains together with high levels of quality and service. We are consolidating our manufacturing footprint to achieve better asset utilization and increased focus on making medicines. At the same time, we are investing in innovative technologies and advanced therapy platforms, while supporting launches and growth drivers through dedicated product management teams. NTO is digitizing its key processes and leveraging data to establish next-generation manufacturing capabilities. Our resilient supply network has helped us to respond to the COVID-19 pandemic, supporting an uninterrupted supply of our medicines; and (iii) NBS continuing on its journey to become an industry-leading enterprise transformation engine. We are strengthening our Global Service Centers, while building strong IT and digital foundations, realizing significant procurement efficiencies, and driving simplification of key enterprise processes.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Go big on data and digital. </i> We believe that the growth and implementation of digital technologies in our industry, including for research and development, production, marketing and sales, and as a component of our products is an important trend in our industry. Our digital ambition is to transform how we innovate, how we engage with customers and how we operate. We plan to achieve this by focusing on four areas: (i) Scale our digital foundational programs designed to jumpstart our digital transformation in key areas of our business; (ii) Make Novartis digital by working to build up our talent, infrastructure and ways of working to enable us to work more efficiently with data and to improve the quality of that data; (iii) Become the healthcare partner of choice in the tech ecosystem by transforming how we work with all of our partners - from nimble start-ups and innovative academic institutions to some of the biggest organizations in the industry. We have created the Novartis Biome as a bridge to help our partners become more like an extension of our own teams and to work with us as easily and productively as possible; and (iv) We are preparing for potential future disruptive healthcare scenarios such as AI-based digital disease management. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  <i>Build trust with society.</i> Building trust with society has become an important requirement for companies like Novartis. Stakeholders are increasingly expressing preference for companies with clear ESG plans, and some institutional investors increasingly believe there is a correlation between company valuations and ESG performance. We focus on four strategic pillars defined as material by strategic stakeholders: (i) Ethical standards: In 2020, we focused our activities on operational excellence including the launch of a new Code of Ethics and strengthening our third-party risk management framework; (ii) Pricing and Access: We continue to systematically integrate access strategies into the research, development and delivery of our medicines globally, including in low and middle-income countries. In 2020, we issued the first healthcare industry sustainability-linked bond which was also the first sustainability-linked bond incorporating social targets tied to targets for expanding access to our innovative medicines and addressing key global health challenges, two areas where we believe we can drive the greatest value for society; (iii) Global Health Challenges: We continue to expand our global health programs in malaria, leprosy, Chagas disease, and sickle-cell-disease, and in 2020 launched our new Sub-Saharan-Africa strategy with our Sub-Saharan-Africa unit deploying innovative approaches to increase patient reach across countries regardless of income level; and (iv) Corporate Citizenship: We aim at achieving gender balance in management and fulfill our UN pay equity and transparency pledge by 2023.  We also aim to achieve full carbon, plastic and water neutrality by 2030. Beyond our four strategic pillars, we continue our efforts to strengthen our governance and increase transparency. In 2020, we created an ESG Management Office within Corporate Strategy tasked with improving oversight, and facilitating embedding ESG measures into our business operations. Further, we have created an ESG Index to allow ESG analysts to more easily locate our ESG disclosures across our public disclosures and channels.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">52</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Results of operations</font>
</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Financial year 2020 compared to 2019</font>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key figures<sup>1</sup></font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions unless indicated otherwise)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Year ended<br> Dec 31, 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Year ended<br> Dec 31, 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Change<br> in USD<br> %</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br> constant<br> currencies<br> %<sup style="white-space: nowrap">    2</sup></div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48&nbsp;659</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;445</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48&nbsp;659</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;498</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;239</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;179</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15&nbsp;121</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14&nbsp;425</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 34&nbsp;777</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;252</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14&nbsp;197</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14&nbsp;369</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8&nbsp;980</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9&nbsp;402</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;742</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;031</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;17</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;190</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;426</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&nbsp;152</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;086</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 19</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">% of net sales to third parties</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20.9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 673</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 659</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;869</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;850</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;78</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 45</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;878</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;940</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 17</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;807</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;793</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;071</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;147</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net loss from discontinued operations  before gain on distribution of Alcon Inc.  to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2013;&#x2005;101</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc.  to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   4&nbsp;691</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;590</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;071</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;737</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;27</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Shareholders of Novartis AG</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 8&nbsp;072</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 11&nbsp;732</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;27</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Non-controlling interests</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic earnings per share from continuing operations (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.55</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3.12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 21</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basic earnings per share from discontinued operations (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.00</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total basic earnings per share (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.55</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;26</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from operating activities from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;650</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;547</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Free cash flow from continuing operations<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;691</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;937</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Continuing operations include the businesses of the Innovative Medicines and Sandoz Divisions and the continuing Corporate activities and discontinued operations include the Alcon eye care devices business and certain Corporate activities attributable to the Alcon business prior to the spin-off, the gain on distribution of Alcon Inc. to Novartis AG shareholders in 2019 and certain other expenses related to the distribution. See &#x201C;Item 18. Financial Statements&#x2014;Note 1. Significant accounting policies&#x201D;, &#x201C;Item 18. Financial Statements&#x2014;Note 2. Significant transactions&#x2014;Significant transactions in 2019,&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 30. Discontinued operations.&#x201D;</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> For an explanation of non-IFRS measures and reconciliation tables, see "Item 5.A Operating results&#x2014;Non-IFRS measures as defined by Novartis."</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">53</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Group overview</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The COVID-19 situation continues to evolve and is taking differing courses across the multitude of geographies that Novartis operates in. We continue to take strong actions to help address the pandemic consequences. Our primary concerns remain the health and safety of our associates and patients. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">During the year, there have been COVID-19 related lockdowns in several geographies negatively impacting certain therapeutic areas, most notably in: ophthalmology, dermatology and the Sandoz Retail Generics Business. However, our operations remain stable and cash collections continue to be according to our normal trade terms, with days sales outstanding at normal levels. Novartis remains well positioned to meet its ongoing financial obligations and has sufficient liquidity to support our normal business activities. At present, drug development operations are continuing with manageable disruptions, with our range of digital technologies allowing us to proactively manage our clinical trials portfolio and rapidly mitigate any disruptions (see the section on compounds in development and selected development projects of our divisions within &#x201C;Item 4. Information on the Company &ndash; Item 4.B Business overview&#x201D;). </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis launched a first-of-its-kind not-for-profit portfolio of 15 medicines from the Sandoz Division for symptomatic treatment of COVID-19. The portfolio addresses urgent unmet needs and is sold at no profit to governments in up to 79 eligible low and lower middle income countries. We continue to work closely with third parties to fight the COVID-19 pandemic. Novartis is also undertaking drug discovery efforts to develop the first oral medicines for COVID-19 and other coronaviruses. We are investigating two potential medicines, DFV890 and MAS825, in early stage development focused on the immune response. In October, we announced a collaboration with Molecular Partners to develop, manufacture and commercialize Molecular Partners&#x2019; anti-COVID-19 DARPin<sup>&#xAE;</sup> program, potential medicines for the prevention and treatment of COVID-19.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2020, Novartis delivered sales growth, margin expansion, and continued to progress its next wave of medicines.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net sales to third parties for Novartis continuing operations were USD&nbsp;48.7 billion, up 3% in reported terms and up 3% measured in constant currencies (cc) to remove the impact of exchange rate movements. Sales growth was driven by volume growth of 9 percentage points, mainly driven by<i> Entresto,</i>  <i>Zolgensma</i>, <i>Cosentyx, Ilaris</i> and the <i>Xiidra</i> acquisition for the Novartis Pharmaceuticals business unit and <i>Promacta</i>/<i>Revolade</i>, <i>Jakavi</i>, <i>Kisqali</i>, <i>Tafinlar + Mekinist</i> and <i>Piqray</i> for the Novartis Oncology business unit. The strong volume growth was partly offset by the negative impacts of pricing (3 percentage points) and generic competition (3 percentage points).</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">By division, Innovative Medicines delivered net sales of USD&nbsp;39.0 billion (+3%, +4% cc). Sandoz net sales were USD&nbsp;9.6 billion (-1%, 0% cc), impacted by ongoing disruptions to hospitals and HCP practices due to COVID- 19, which limited patient access to treatments for our retail business across regions.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In Emerging Growth Markets, which comprise all markets excluding the US, Canada, Western Europe, Japan, Australia and New Zealand, sales from continuing operations were USD&nbsp;11.9 billion (+1%, +6% cc) driven by China (USD&nbsp;2.6 billion) growing 16%, (+16% cc).</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Operating income from continuing operations was USD 10.2 billion (+12%, +19% cc), mainly driven by higher sales and productivity including lower spend. Operating income margin from continuing operations was 20.9% of net sales, increasing by 1.7 percentage point (+2.9 percentage points cc). </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net income from continuing operations was USD 8.1 billion (+13%, +20% cc) mainly driven by higher operating income. Earnings per share from continuing operations were USD 3.55 (+14%, +21% cc), growing faster than net income and benefiting from lower weighted average number of shares outstanding.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net cash flows from operating activities from continuing operations amounted to USD 13.6 billion, compared to USD 13.5 billion in 2019. This increase was mainly driven by higher net income adjusted for non-cash items and other adjustments including divestment gains, partly offset by higher payments out of provisions related to legal matters.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Free cash flow from continuing operations amounted to USD 11.7 billion (-10%) compared to USD 12.9 billion in 2019, as higher operating income adjusted for non-cash items was more than offset by payments related to legal matters and lower divestment proceeds.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We also present our core results<sup>1</sup>, which exclude the impact of amortization, impairments, disposals, acquisitions, restructurings and other significant items, to help investors understand our underlying performance.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Core operating income from continuing operations was USD 15.4 billion (+9%, +13% cc) driven by sales growth, lower spend and productivity. Core operating income margin was 31.7% of net sales, increasing by 2.0 percentage points (+2.8 percentage points cc).</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Core net income from continuing operations was USD 13.2 billion (+9%, +12% cc) mainly driven by growth in core operating income. Core earnings per share from continuing operations were USD 5.78 (+9%, +13% cc), growing faster than core net income benefiting from lower weighted average number of shares outstanding.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2020, there were no operational activities related to discontinued operations. In 2019, discontinued operations net sales were USD 1.8 billion, operating income amounted to USD 71 million and net income from discontinued operations was USD 4.6 billion, including the non-taxable non-cash net gain on distribution of Alcon Inc. to Novartis AG shareholders which amounted to USD 4.7 billion.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For the total Group, net income amounted to USD 8.1 billion compared to USD 11.7 billion in the prior year, including the non-taxable non-cash net gain on distribution of Alcon Inc. which amounted to USD 4.7 billion. Basic earnings per share were USD 3.55 compared to USD 5.12 in prior year. Cash flow from operating activities for the total Group amounted to USD 13.6 billion and free cash flow to USD 11.7 billion.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"><sup>1</sup> For an explanation of non-IFRS measures and reconciliation tables, see &#x201C;Item 5.A Operating results&mdash;Non-IFRS measures as defined by Novartis.&#x201D;</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">54</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Net sales by segment</font>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides an overview of net sales to third parties by segment:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Year ended<br> Dec 31, 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Year ended<br> Dec 31, 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Change<br> in USD<br> %</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br> constant<br>  currencies<br> %</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39&nbsp;013</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37&nbsp;714</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;646</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;731</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48&nbsp;659</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;445</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Innovative Medicines</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Innovative Medicines Division delivered net sales of USD 39.0 billion in 2020, up 3% in reported terms and 4% in constant currencies (cc). The Novartis Pharmaceuticals business unit delivered net sales of USD 24.3 billion in 2020, growing 4% (+5% cc), driven by <i>Entresto</i>, <i>Zolgensma</i>, <i>Cosentyx</i>, <i>Ilaris </i>and the<i> Xiidra </i>acquisition. Growth was partly offset by declines in <i>Gilenya, </i>and lower demand for <i>Lucentis</i> due to COVID-19. Other Ophthalmology products were also impacted by both COVID-19 and generic competition. The Novartis Oncology business unit delivered net sales of USD 14.7 billion, growing 2% (+3% cc), driven by <i>Promacta/Revolade</i>, <i>Jakavi</i>, <i>Kisqali</i>, <i>Tafinlar + Mekinist</i> and <i>Piqray</i>, partially offset by generic competition for <i>Afinitor</i> and <i>Exjade</i>. Volume contributed 10 percentage points to sales growth. Pricing had a negative impact of 3 percentage points. Generic competition had a negative impact of 3 percentage points.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Regionally, US sales (USD 14.3 billion, +4%) delivered strong performance <i>of Entresto, Zolgensma </i>and <i>Cosentyx</i>. Europe sales (USD 13.5 billion, +5%, +4% cc) grew driven by <i>Entresto, Zolgensma, Jakavi, Kisqali</i> and <i>Kymriah.</i> Japan sales were USD 2.4 billion (0%, -3% cc) as growth was negatively impacted by the <i>Galvus </i>co-promotion agreement. Emerging Growth Markets sales grew 3% (+7% cc), led by double-digit growth in China, including the launches of <i>Cosentyx </i>and <i>Entresto</i>.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table provides an overview of net sales to third parties by business franchise in the Innovative Medicines Division:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Year ended<br> Dec 31, 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Year ended<br> Dec 31, 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Change<br> in USD<br> %</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br> constant<br>  currencies<br> %</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Novartis Oncology business unit</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;711</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;370</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Novartis Pharmaceuticals business unit</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 24&nbsp;302</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;344</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Immunology, Hepatology and Dermatology</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;868</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;222</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ophthalmology</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;410</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;776</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Neuroscience</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;323</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;773</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cardiovascular, Renal and Metabolism</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;498</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;750</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 42</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Respiratory</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;900</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;825</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Established Medicines</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;303</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;998</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Innovative Medicines</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 39&nbsp;013</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37&nbsp;714</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">55</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides the top 20 Innovative Medicines Division product net sales in 2020 as well as the change compared to 2019:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> US</div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of world</div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"><br>Brands</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Business franchise</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Indication</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br> change<br> USD/cc<sup style="white-space: nowrap">   2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br> change<br> USD</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br> change<br> cc<sup style="white-space: nowrap">   2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br> change<br> USD</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % <br> change<br> cc<sup style="white-space: nowrap">   2</sup></div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td width="12%" height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Cosentyx</div>
      </td>
      <td align="right" width="1%"></td>
      <td width="12%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     Immunology,   Hepatology and  Dermatology</div>
      </td>
      <td align="right" width="1%"></td>
      <td width="12%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis, ankylosing   spondylitis, psoriatic  arthritis and   non-radiographic axial   spondyloarthritis</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">         2&nbsp;516</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">         13</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">         1&nbsp;479</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">         11</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">         12</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">         3&nbsp;995</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">         13</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">         13</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;562</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;441</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;003</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Entresto</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, Renal   and Metabolism</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Chronic heart failure</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   1&nbsp;277</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   38</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   1&nbsp;220</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   52</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   52</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   2&nbsp;497</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   45</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   44</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 859</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;099</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;958</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Lucentis</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Ophthalmology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related   macular degeneration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   1&nbsp;933</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   1&nbsp;933</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   &#x2013;&#x2005;7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   &#x2013;&#x2005;8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Promacta/Revolade</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune thrombocytopenia   (ITP), severe aplastic   anemia (SAA)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     833</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     905</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     26</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">     1&nbsp;738</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">     23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">     23</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <I>Tafinlar</I> + <I>Mekinist</I></div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic   and adjuvant melanoma;   advanced non-small cell   lung cancer (NSCLC)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       569</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       973</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">       1&nbsp;542</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">       15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">       16</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Sandostatin</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors  and acromegaly</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   837</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   602</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   1&nbsp;439</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   &#x2013;&#x2005;9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   &#x2013;&#x2005;8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Jakavi</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF),   polycythemia vera (PV)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   1&nbsp;339</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   1&nbsp;339</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   20</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Xolair<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     Respiratory</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe zllergic zsthma  (SAA), chronic spontaneous   urticaria (CSU) and nasal polyps</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     1&nbsp;251</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">     1&nbsp;251</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">     7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">     8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Galvus</I> Group</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;199</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;199</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Gleevec/Glivec</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid   leukemia and GIST</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   315</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   873</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   1&nbsp;188</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   &#x2013;&#x2005;6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   &#x2013;&#x2005;6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/TSC</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 644</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;36</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 439</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;083</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;29</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Diovan</I> Group</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 124</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 879</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;003</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Exforge</I> Group</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 964</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 980</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Zolgensma</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Neuroscience</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy   (SMA)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   459</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   50</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   461</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   920</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   155</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   151</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Ilaris</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology,   Hepatology and  Dermatology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,   TRAPS, HIDS/MKD, FMF, SJIA,   AOSD and gout)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     400</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     473</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     29</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">     873</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">     30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">     31</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Kisqali</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2- metastatic  breast cancer</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   318</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   27</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   369</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   60</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   65</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   687</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   43</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   45</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic iron overload</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 138</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;69</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 515</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 653</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;33</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;33</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Renal cell carcinoma</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 259</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 376</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 635</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;15</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;126</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&nbsp;790</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&nbsp;916</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;216</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;881</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;097</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division sales</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;342</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 24&nbsp;671</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 39&nbsp;013</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="22">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="22">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Net sales reflect <I>Xolair</I> sales for all indications.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="22">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Constant currencies (cc) is a non-IFRS measure. For an explanation of non-IFRS measures, see " &#x2014;Item 5.A Operating results&#x2014;Non-IFRS measures as defined by Novartis."</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="22">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For the table providing the top 20 Innovative Medicines Division product net sales in 2019, see &#x201C;Item 18. Financial statements&mdash;Note 3. Segmentation of key figures 2020, 2019 and 2018.&#x201D;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For information about the approved indications for certain products described, see &#x201C;Item 4. Information on the Company&mdash;Item 4.B Business overview&mdash;Innovative Medicines&mdash; Innovative Medicines Division products.&#x201D;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Novartis Oncology business unit</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><i>Tasigna</i> (USD 2.0 billion, +4%, +5% cc) sales grew due to a strong performance in key markets including the US and China, partly offset by a decline in Europe.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Promacta/Revolade </i>(USD 1.7 billion, +23%, +23% cc) grew across all regions, driven by increased use in chronic immune thrombocytopenia (ITP) and as first-line treatment for severe aplastic anemia (SAA) in the US.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Tafinlar </i>+<i> Mekinist </i>(USD 1.5 billion, +15%, +16% cc), the worldwide leader in BRAF/MEK-inhibition, continued to deliver strong growth driven by demand in adjuvant melanoma, as well as advanced NSCLC. <i>Tafinlar + </i></div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">56</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><i>Mekinist</i> is the first and only targeted therapy to achieve five-year relapse-free survival (RFS) and overall survival (OS) data in the adjuvant and metastatic melanoma settings, respectively.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Sandostatin </i>(USD 1.4 billion, -9%, -8% cc) sales declined due to ongoing competitive pressure in Europe, US and Japan. The brand was also impacted by generic competition in Europe.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Jakavi </i>(USD 1.3 billion, +20%, +20% cc) growth was driven by strong demand in the myelofibrosis and polycythemia vera indications. Data readouts from two Phase III studies (REACH2 and REACH3) showed  <i>Jakavi</i> significantly improved outcomes in patients with steroid-resistant/dependent graft-versus-host disease (GvHD) compared to best available therapy. Regulatory filings based on the GvHD data are planned for 2021.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Gleevec/Glivec </i>(USD 1.2 billion, -6%, -6% cc) declined due to increased generic competition.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Afinitor/Votubia </i>(USD 1.1 billion, -30%, -29% cc) declined due to generic competition in the US, Europe and Emerging Growth Markets.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Kisqali </i>(USD 687 million, +43%, +45% cc) continued strong growth across all geographies benefiting from the impact of positive overall survival (OS) data from two pivotal Phase III trials (MONALEESA-7 and MONALEESA-3). <i>Kisqali</i> stands apart as the only CDK4/6 inhibitor that significantly improves OS in two large Phase III trials, regardless of metastatic sites, endocrine treatment (ET) resistance, ET partner, treatment line or menopausal status, while maintaining quality of life.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Exjade/Jadenu </i>(USD 653 million, -33%, -33% cc) declined mainly due to pressure from generic competition in the US and other regions.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Votrient </i>(USD 635 million, -16%, -15% cc) declined due to increased competition in Europe and the US.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Kymriah </i>(USD 474 million, +71%, +68% cc) grew strongly in Europe, US and Japan. Coverage continued to expand, with more than 280 qualified treatment centers and 27 countries having coverage for at least one indication. FDA granted Regenerative Medicine Advanced Therapy designation and orphan drug status for <i>Kymriah</i> in follicular lymphoma. At the interim analysis, the Phase II ELARA trial in patients with relapsed or refractory follicular lymphoma met its primary endpoint of complete response rate. Regulatory approvals in Switzerland, France and Japan expanded manufacturing capabilities for <i>Kymriah</i> to meet increased demand.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Lutathera </i>(USD 445 million, +1%, +1% cc) sales were broadly in line with prior year, as the COVID-19 pandemic had an impact on the brand. There are 384 total centers now actively treating patients. Sales from all AAA brands (including <i>Lutathera</i> and radiopharmaceutical diagnostic products) were USD 681 million.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Piqray </i>(USD 320 million, +176%, +176% cc) grew significantly in the US as the launch roll out continued. <i>Piqray</i> in combination with fulvestrant received European Commission (EC) approval to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation. <i>Piqray</i> is the first and only therapy specifically developed for the approximately 40% of HR+/HER2- advanced breast cancer patients who have a PIK3CA mutation, which is associated with poor prognosis. <i>Piqray</i> is now approved in more than 50 countries, including the US and EU member states. <i>Piqray</i> launched in the US in June 2019.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Adakveo </i>(USD 105 million) US launch continued to progress well, with more than 600 accounts purchasing <i>Adakveo</i> to date. Payer coverage decisions expanded, both in Medicaid and commercial (with 94% coverage among commercial plans to date). Following approval in Europe in Q4, reimbursement discussions with individual countries are underway.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Tabrecta</i> (USD 35 million) US launch progressed well. Ninety leading lung cancer institutions have started patients on treatment. <i>Tabrecta</i> is the first and only therapy approved by the US FDA to specifically target metastatic NSCLC with a mutation that leads to MET exon 14 skipping (METex14), as detected by an FDA-approved test. <i>Tabrecta</i> also secured regulatory approval in Japan.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Novartis Pharmaceuticals business unit</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Immunology, Hepatology and Dermatology</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sales in the Immunology, Hepatology and Dermatology franchise reached USD&nbsp;4.9 billion (+15%, +16% cc), of which <i>Cosentyx</i> delivered USD&nbsp;4.0 billion.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Cosentyx</i> (USD 4.0 billion, +13%, +13% cc) saw continued growth across indications despite lower new patient starts across the market in dermatology and rheumatology in most geographies due to COVID-19. In the second quarter, <i>Cosentyx</i> received approval and launched in the EU and US for non-radiographic axial spondyloarthritis (nr-axSpA), its fourth major indication, and in August became the first treatment approved in Japan for this indication. In April, <i>Cosentyx </i>also became the first IL17A inhibitor approved in China for the treatment of AS. In July, <i>Cosentyx </i>received EU approval as a first-line systemic treatment for pediatric psoriasis. In November, <i>Cosentyx</i> received EC approval for a new 300 mg autoinjector and pre-filled syringe, which enable the 300 mg dose to be administered in a single injection. In China, <i>Cosentyx</i> has been listed in the National Reimbursement Drug List (NRDL) as the only interleukin inhibitor with planned execution March 1, 2021</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Ilaris</i> (USD 873 million, +30%, +31% cc) sales were driven by strong double-digit volume growth, particularly coming from the US, Europe and Japan. In June, <i>Ilaris</i> was granted a new indication in the US for active Still&#x2019;s disease including Adult-Onset Still&#x2019;s Disease (AOSD); this is in addition to its previously-granted indication for systemic juvenile idiopathic arthritis (SJIA). <i>Ilaris</i> is the first FDA-approved treatment for AOSD.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Ophthalmology</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sales in the Ophthalmology franchise were USD 4.4 billion (-8%, -8% cc) and were impacted by the COVID-19 pandemic.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Lucentis </i>(USD 1.9 billion, -7%, -8% cc) sales declined due to the negative impact of the COVID-19 pandemic, which has significantly disrupted ophthalmology practices and limited patient access to treatment of retinal diseases. Sales have been consistently recovering from the COVID-19 impact since May until the end of the third quarter, and showed less impact of the pandemic in the fourth quarter compared to the second quarter.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">57</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Xiidra</i> (USD 376 million, +96%, +95% cc) was impacted by COVID-19 pandemic as ophthalmology visits declined significantly. In the latter part of the second quarter, the US dry eye market began to rebound as eye care practices began opening. Novartis has informed the European Medicines Agency of its decision to withdraw the centralized application for Marketing Authorization of <i>Xiidra</i>. Novartis acquired <i>Xiidra</i> from Takeda and began recording sales as of July 1, 2019.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Beovu </i>(USD 190 million) launch roll-out continued, with approval now in 57 countries. Post marketing case reports termed as &#x201C;retinal vasculitis&#x201D; and/or &#x201C;retinal vascular occlusion&#x201D; that may result in severe vision loss, typically associated with intraocular inflammation, and the COVID-19 pandemic had an unfavorable impact on sales. Novartis has a comprehensive plan, in strong collaboration with leading external global experts to educate the retina community about the positive benefit / risk profile of <i>Beovu</i>. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Other Ophthalmology products declined due to the negative impact of the COVID-19 pandemic and generic impacts in the US, primarily for <i>Travatan</i> and <i>Ciprodex</i>.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Neuroscience</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sales in the Neuroscience franchise were USD 4.3 billion (+15%, +14% cc), mainly driven by the sales growth of <i>Zolgensma</i>, partly offset by sales decline of <i>Gilenya</i>. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Gilenya </i>(USD 3.0 billion, -7%, -7% cc) sales declined due to increased competition and the impact of the COVID-19 pandemic. <i>Gilenya</i> remains the top prescribed high efficacy therapy in 41 countries and the only one approved to treat pediatric RMS.&nbsp;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Zolgensma</i> (USD 920 million, +155%, +151% cc) delivered significant growth despite the negative impact of the COVID-19 pandemic in the US and ex-US, with geographic expansion in Europe and Japan contributing strongly. Reimbursement is now secured in six countries, with access pathways in nine EU countries through our Day One Access initiative representing approximately 25% of the EU population. As anticipated, there was a shift from prevalent patients to incident patients in all markets post launch, with increased newborn screening in the US contributing to growth. <i>Zolgensma</i> recent approvals include Brazil, Israel, Canada and Taiwan. <i>Zolgensma</i> is viewed as an essential one-time treatment and is the only therapy for spinal muscular atrophy (SMA) that addresses the genetic root cause of SMA by replacing the function of the missing SMN1 gene. Its clinical profile and one-time dosing are anticipated to remain differentiators for both physicians and patients when making a treatment choice. <i>Zolgensma</i> launched in the US in June 2019.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Mayzent</i> (USD 170 million) continued to grow steadily. Growth was driven by fulfilling an important unmet need in patients showing signs of progression despite being on other treatments. <i>Mayzent </i>is the first and only oral DMT studied and proven to delay disease progression in a broad SPMS patient population. In addition to the US and EU, <i>Mayzent</i> is now approved in the UK, Australia, Canada, Japan and Switzerland.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Aimovig</i> (USD 164 million, ex-US, ex-Japan, +59%, +57% cc) is the most prescribed anti-CGRP worldwide, with more than half a million patients prescribed worldwide in the post-trial setting. <i>Aimovig</i> is co-commercialized with Amgen in the US, where Amgen records sales. Novartis has exclusive rights and records sales in all ex-US territories excluding Japan. During the ongoing litigation between the companies the collaboration continues and will remain in force until a final court decision.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Kesimpta</i> (ofatumumab, formerly OMB157) (USD 15 million) was launched in the US following FDA approval in August. To initiate access, we are providing <i>Kesimpta</i> free of charge to US patients who are eligible for reimbursement until they are covered by their insurance.<i> Kesimpta</i> is a targeted B-cell therapy that can deliver sustained high efficacy, with a favorable safety profile and the flexibility of an at home self-administration for a broad population of RMS patients. We have seen a promising start with our flexible hybrid face-to-face / digital launch.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Cardiovascular, Renal and Metabolism</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sales in the Cardiovascular, Renal and Metabolism franchise were USD&nbsp;2.5 billion (+43%, +42% cc). </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Entresto</i> (USD 2.5 billion, +45%, +44% cc) sustained strong growth with increased patient share across markets, driven by demand as the essential first choice therapy for HF patients (reduced ejection fraction). <i>Entresto</i> was successfully launched in Japan in August. FDA Cardiovascular and Renal Drugs Advisory Committee voted 12 to 1 to support the use of <i>Entresto</i> in treatment of patients with heart failure with preserved ejection fraction (HFpEF). Expected FDA approval has the potential to make <i>Entresto</i> the first therapy indicated for both HFpEF and HFrEF in the US, and a final decision is expected in the first quarter of 2021.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Respiratory</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sales in the Respiratory franchise were USD&nbsp;1.9 billion (+4%, +5% cc), of which <i>Xolair</i> delivered USD&nbsp;1.3 billion.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Xolair </i>(USD 1.3 billion, +7%, +8% cc) continued growth in the severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU) indications. In the first half 2020,<i> Xolair </i>received approval from the US and the European Commission (EC) for a new indication to treat severe chronic rhinosinusitis with nasal polyps (CRSwNP). Novartis co-promotes <i>Xolair </i>with Genentech in the US and shares a portion of operating income, but we do not record any US sales.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Ultibro </i>Group (USD 623 million, -1%, -1% cc) sales were broadly in line with prior year, as strong <i>Ultibro Breezhaler</i> sales were offset by the decline in <i>Seebri Breezhaler</i> and <i>Onbrez Breezhaler</i>. <i>Ultibro</i> Group consists of inhaled COPD therapies <i>Ultibro Breezhaler</i>, <i>Seebri Breezhaler</i> and <i>Onbrez Breezhaler</i>.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Enerzair</i> Group consists of <i>Enerzair Breezhaler</i> and <i>Atectura Breezhaler</i>. <i>Enerzair Breezhaler</i> (indacaterol / glycopyrronium bromide / mometasone, formerly known as QVM149) is an inhaled LABA/LAMA/ICS combination for patients whose asthma is uncontrolled with LABA/ICS. <i>Atectura Breezhaler</i> (indacaterol / mometasone, formerly known as QMF149) is a LABA/ICS fixed-dose combination for patients whose asthma is uncontrolled with SABA and ICS. Both medicines were approved in the EU, Japan, Canada, Australia, Switzerland and South Korea in 2020, together with the digital companion (sensor and app) for <i>Enerzair Breezhaler</i> in the EU and Switzerland. They have been launched to date in seven markets, including Germany, Japan and the UK.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">58</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Established Medicines</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Established Medicines franchise had sales of USD 6.3 billion (-10%, -8% cc).</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Galvus </i>Group (USD 1.2 billion, -8%, -5% cc) declined primarily due to generic competition in Emerging Growth Markets and pricing impact from our co-promotion agreement in Japan that started in 2019.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Diovan </i>Group (USD 1.0 billion, -6%, -4% cc) declined mainly due to generic competition and the impact of VBP in China. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Exforge </i>Group (USD 980 million, -4%, -3% cc) declined in Europe due to generic competition, partly offset by growth in China.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Zortress/Certican </i>(USD 452 million, -7%, -7% cc) declined mainly due to generic competition in the US. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Neoral/Sandimmun(e)</i> (USD 393 million, -6%, -6% cc) declined mainly due to generic competition and mandatory price reductions.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"><i>Voltaren/Cataflam</i> (USD 360 million, -14%, -12% cc) declined mainly due to generic competition and external supply issues following the COVID-19 pandemic. </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Sandoz</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Net sales were USD 9.6 billion (-1%, 0% cc) with volume growth of 2 percentage points despite the COVID-19 impacts. There was a negative price effect of 2 percentage points, despite the benefit from off-contract sales and favorable revenue deduction adjustments.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Sales in Europe were USD 5.2 billion (+2%, +2% cc). Sales in the US were USD 2.1 billion (-14%), due to the continued volume decline in oral solids including partnership terminations. Sales in Asia / Africa / Australasia were USD 1.5 billion (+12%, +11% cc) including the contribution from the Aspen Japan acquisition. Sales in Canada and Latin America were USD 772 million (-2%, +8% cc).</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table provides an overview of net sales to third parties by business franchise in the Sandoz Division:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Year ended<br> Dec 31, 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Year ended<br> Dec 31, 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Change<br> in USD<br> %</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br> constant<br>  currencies<br> %</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Retail Generics<sup>1</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;244</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;590</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Biopharmaceuticals</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;928</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;607</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Anti-Infectives  (partner label/API)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   474</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   534</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Sandoz</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;646</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;731</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Of which USD 694 million (2019: USD 784 million) represents anti-infectives sold under the Sandoz name</div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Retail Generics </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In Retail Generics, Sandoz develops, manufactures and markets active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a broad range of therapeutic areas, as well as finished dosage form of anti-infectives sold to third parties. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Retail Generics sales were USD 7.2 billion (-5%, -4% cc) impacted by the declines in the US and COVID-19 related impact across regions.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Biopharmaceuticals</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- and other biotechnology-based products, including biosimilars, and provides biotechnology manufacturing services to other companies. The Biopharmaceuticals business also includes <i>Glatopa</i>, a generic version of Copaxone<sup>&#xAE;</sup>, which treats relapsing forms of multiple sclerosis and is marketed in the US. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Global sales of Biopharmaceuticals (biosimilars, biopharmaceutical contract manufacturing and <i>Glatopa</i>) grew to USD 1.9 billion (+20%, +19% cc), driven by continued double-digit growth in Europe from <i>Hyrimoz</i> (adalimumab),  <i>Erelzi</i> (etanercept) and <i>Zessly</i> (infliximab) and growth from <i>Omnitrope</i> (somatropin) across all regions. Launch roll-outs in other geographies also contributed to growth.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Anti-Infectives</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In Anti-Infectives, Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by Retail Generics and for sale to third-party customers. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Total Anti-Infectives franchise sales were USD 1.2 billion (-11%, -11% cc) including finished dosage forms sold under the Sandoz name (USD 694 million, -11%, -10% cc) and Anti-Infectives sold to third parties for sale under their own name (USD 474 million, -11%, -12% cc), which were impacted by a planned contract discontinuation. </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">59</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Operating income from continuing operations</font>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides an overview of operating income from continuing operations by segment:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Year ended<br> Dec 31, 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % of<br> net sales<br> to third<br> parties</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Year ended<br> Dec 31, 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> % of<br> net sales<br> to third<br> parties</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Change<br> in USD<br> %</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br> constant<br> currencies<br> %</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;172</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23.5</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;287</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24.6</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;043</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10.8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 551</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 89</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 106</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;63</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;752</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&nbsp;152</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20.9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;086</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 19.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 19</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Operating income was USD 10.2 billion (+12%, +19% cc) mainly driven by higher sales and productivity including lower spend.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Core operating income from continuing operations key figures</font><font style="font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000; font-weight:bold; vertical-align:super;">1</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions unless indicated otherwise)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Year ended<br> Dec 31, 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Year ended<br> Dec 31, 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Change<br> in USD<br> %</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br> constant<br> currencies<br> %</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core gross profit from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 38&nbsp;663</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37&nbsp;392</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14&nbsp;093</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14&nbsp;319</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8&nbsp;484</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8&nbsp;386</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 323</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 495</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;35</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;39</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;993</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;070</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core operating income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&nbsp;416</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;112</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">As % of net sales to third parties</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 29.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> For an explanation of non-IFRS measures and reconciliation tables, see "Item 5.A Operating results&#x2014;Non-IFRS measures as defined by Novartis."</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The adjustments made to operating income from continuing operations to arrive at core operating income from continuing operations amounted to USD&nbsp;5.3 billion (compared to USD&nbsp;5.0 billion in the prior year). For details please see &#x201C;Item 5.A Operating results&ndash;2020 and 2019 reconciliation from IFRS results to core results.&#x201D;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Core operating income was USD 15.4 billion (+9%, +13% cc) driven by sales growth, lower spend and productivity. Core operating income margin was 31.7% of net sales, increasing by 2.0 percentage points (+2.8 percentage points cc).</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides an overview of core operating income from continuing operations by segment:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Year ended<br> Dec 31, 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % of<br> net sales<br> to third<br> parties</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Year ended<br> Dec 31, 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> % of<br> net sales<br> to third<br> parties</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Change<br> in USD<br> %</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br> constant<br> currencies<br> %</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;645</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 35.0</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;650</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 33.5</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;334</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 24.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;094</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 21.5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;563</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;632</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core operating income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&nbsp;416</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 31.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;112</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 29.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Operating income was USD 9.2 billion (-1%, +4% cc). Growth at constant currencies was mainly driven by sales growth, partly offset by lower divestment gains and higher amortization. Operating income margin was 23.5% of net sales, decreasing 1.1 percentage points (+0.1 percentage points cc).</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Core adjustments were USD 4.5 billion, mainly due to USD 3.0 billion of amortization. Core adjustments increased compared to prior year (USD 3.4 billion) mainly due to lower divestment gains and higher amortization. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Core operating income was USD 13.6 billion (+8%, +11% cc) mainly driven by sales growth, lower COVID-19 related spending and improved gross margin productiv-</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">60</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">ity. Core operating income margin was 35.0% of net sales, increasing 1.5 percentage points (+2.2 percentage points cc). </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Core gross margin increased by 0.4 percentage points (cc) mainly driven by productivity. Core R&amp;D expenses as a percentage of net sales decreased by 0.9 percentage points (cc) mainly driven by the higher net sales, productivity, and COVID-19 related spending impacts. Core SG&amp;A expenses declined by 1.2 percentage points (cc) benefiting from COVID-19 related spending impacts. Core Other Income and Expense net decreased the margin by 0.3 percentage points (cc).</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Operating income was USD 1.0 billion, (+89%, +106% cc), an increase of USD 492 million versus prior year mainly due to lower impairments, continued gross margin improvements and lower spending. Operating income margin increased by 6.0 percentage points in constant currencies; currency had a negative impact of 0.9 percentage points, resulting in a net increase of 5.1 percentage points to 10.8% of net sales.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Core adjustments were USD 1.3 billion, mainly from USD 0.6 billion of amortization and impairments and USD 0.4 billion legal charges. Prior year core adjustments were USD 1.5 billion. The change in core adjustments compared to prior year was mainly due to higher prior year impairments.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Core operating income was USD 2.3 billion (+11%, +15% cc), driven by gross margin improvements, lower spending from cost discipline and COVID-19. Core operating income margin was 24.2% of net sales, increasing 2.7 percentage points (3.3 percentage points cc). Core gross margin increased by 1.9 percentage points (cc), driven by favorable product and geographic mix, ongoing productivity improvements and lower price effects. Core R&amp;D increased by 0.5 percentage points (cc) driven by biosimilar pipeline investments. Core SG&amp;A expenses declined by 1.6 percentage points (cc) benefiting from COVID-19 related spending impacts. Core Other Income and Expense decreased by 0.3 percentage points (cc).</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Corporate income and expense, net</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Corporate income and expense, which includes the cost of Group headquarter and coordination functions, amounted to an expense of USD 63 million in the full year, compared to an expense of USD 752 million in prior year, mainly driven by favorable contributions from the Novartis Venture Fund, income from a fair value adjustment on contingent receivables, royalty settlement gains related to intellectual property rights and lower restructuring costs.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Innovative Medicines Division research and development</font>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides an overview of the reported and core research and development expense of the Innovative Medicines Division:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions unless indicated otherwise)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Year ended<br> Dec 31, 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Year ended<br> Dec 31, 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Change<br> in USD<br> %</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br> constant<br> currencies<br> %</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and exploratory development</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;737</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;855</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Confirmatory development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5&nbsp;381</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;297</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Innovative Medicines Division research and development expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;8&nbsp;118</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;8&nbsp;152</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">As % of Innovative Medicines net sales to third parties</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20.8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core research and exploratory development<sup>1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;682</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;706</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core confirmatory development<sup>1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4&nbsp;954</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4&nbsp;879</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total core Innovative Medicines Division research and development expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;7&nbsp;636</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;7&nbsp;585</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">As % of Innovative Medicines net sales to third parties</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20.1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Core excludes impairments, amortization and certain other items. For an explanation of non-IFRS measures and reconciliation tables, see "Item 5.A Operating results&#x2014;Non-IFRS measures as defined by Novartis."&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Innovative Medicines Division research and exploratory development expense decreased by 4% (+6% cc) to USD 2.7 billion, and confirmatory development expense amounted to USD 5.4 billion, increasing by 2% (-1% cc) versus prior year. This was mainly due to lower impairment charges, lower spending due to COVID-19 and productivity.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Total core research and development expense in the Innovative Medicines Division as a percentage of sales decreased by 0.5 percentage points (0.9 percentage points cc) to 19.6% of net sales, mainly driven by the higher net sales, productivity, and COVID-19 related spending impacts.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">61</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Non-operating income and expense</font>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The term &#x201C;non-operating income and expense&#x201D; includes all income and expense items outside operating income. The following table provides an overview of non-operating income and expense from continuing operations:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions unless indicated otherwise)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Year ended<br> Dec 31, 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Year ended<br> Dec 31, 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Change<br> in USD<br> %</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br> constant<br> currencies<br> %</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&nbsp;152</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;086</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 19</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 673</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 659</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;869</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;850</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;78</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 45</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;878</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;940</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 17</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;807</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;793</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;071</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;147</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net loss from discontinued operations  before gain on distribution of Alcon Inc.  to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2013;&#x2005;101</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc.  to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   4&nbsp;691</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;590</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;071</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;737</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;27</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Shareholders of Novartis AG</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 8&nbsp;072</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 11&nbsp;732</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;27</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Non-controlling interests</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic earnings per share from continuing operations (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.55</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3.12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 21</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basic earnings per share from discontinued operations (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.00</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total basic earnings per share (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.55</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;26</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">        </div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful        </div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Income from associated companies</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Income from associated companies amounted to USD 673 million in 2020 compared to USD 659 million in the prior year. This comprises mainly the share of income from Roche amounting to USD 677 million, which was broadly in line with the prior year amount of USD 662 million.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest expense and other financial income and expense</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Interest expense increased to USD 869 million from USD 850 million in the prior year, mainly due to an increase in interest expense from discounting long term liabilities. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Other financial income and expense amounted to a loss of USD 78 million compared to an income of USD 45 million in prior year mainly due to lower interest income in 2020.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Taxes</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The tax rate for continuing operations was 18.3% compared to 20.1% in the prior year. The current year tax rate was impacted by the effect of non-deductible legal charges and uncertain tax positions. The prior year tax rate was impacted by a one-time, non-cash deferred tax expense resulting from legal entity reorganizations, a prior year item and an increase to an uncertain tax position, partially offset by the deferred tax credit from Swiss tax reform.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Excluding these impacts, the rate from continuing operations would have been 15.6% compared to 15.4% in the prior year. The increase from prior year was mainly the result of a change in profit mix.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net income from continuing operations</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Net income was USD 8.1 billion (+13%, +20% cc) mainly driven by higher operating income.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Earnings per share</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Basic earnings per share from continuing operations were USD 3.55 (+14%, +21% cc), growing faster than net income and benefiting from lower weighted average number of shares outstanding.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">62</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Core non-operating income and expense from continuing operations</font><font style="font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000; font-weight:bold; vertical-align:super;">1</font>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides an overview of core non-operating income and expense from continuing operations:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions unless indicated otherwise)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Year ended<br> Dec 31, 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Year ended<br> Dec 31, 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Change<br> in USD<br> %</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br> constant<br> currencies<br> %</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core operating income from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&nbsp;416</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;112</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core income from associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;097</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;086</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core interest expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;869</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;850</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core other financial income and expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;83</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 56</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core income before taxes from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&nbsp;561</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;404</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;403</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;300</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core net income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;158</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;104</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core basic earnings per share from continuing operations (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5.78</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.28</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> For an explanation of non-IFRS measures and reconciliation tables, see "Item 5.A Operating results&#x2014;Non-IFRS measures as defined by Novartis."</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Core income from associated companies</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Core income from associated companies was USD 1.1 billion in 2020, in line with the prior year, mainly driven by the core income contribution from Roche. </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Core interest expense and other financial income and expense</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Core interest expense increased to USD 869 million from USD 850 million in the prior year, mainly due to an increase in interest expense from discounting long term liabilities. Core other financial income and expense amounted to a loss of USD 83 million compared to an income of USD 56 million in prior year mainly due to lower interest income in 2020.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Core taxes</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The core tax rate from continuing operations (core taxes as a percentage of core income before tax from continuing operations) was 15.4% compared to 16.0% in the prior year mainly as a result of a change in profit mix.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Core net income </font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Core net income was USD 13.2 billion (+9%, +12% cc) mainly driven by growth in core operating income. </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Core earnings per share</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Core earnings per share were USD 5.78 (+9%, +13% cc), growing faster than core net income and benefiting from lower weighted average number of shares outstanding. </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Discontinued operations</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Discontinued operations include the business of Alcon and certain corporate costs directly attributable to Alcon up to the spin-off date. As the Alcon spin-off was completed on April 9, 2019, the prior year included three months of operating results of the divested business.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2020, there were no operational activities related to discontinued operations. In 2019, discontinued operations net sales were USD 1.8 billion, operating income amounted to USD 71 million and net income from discontinued operations was USD 4.6 billion, including the non-taxable non-cash net gain on distribution of Alcon Inc. to Novartis AG shareholders which amounted to USD 4.7 billion. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For further details, see &#x201C;Item 18. Financial Statements&mdash;Note 1. Significant accounting policies&mdash;Distribution of Alcon Inc. to Novartis AG shareholders,&#x201D; &#x201C;Item 18. Financial Statements&mdash;Note 2. Significant transactions&mdash;Significant transactions in 2019&mdash;Completion of the spin-off of the Alcon business through a dividend in kind distribution to Novartis AG shareholders,&#x201D; and &#x201C;Item 18. Financial Statements&mdash;Note 30. Discontinued operations.&#x201D;</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Total Group</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For the total Group, net income amounted to USD 8.1 billion compared to USD 11.7 billion in the prior year, including the non-taxable non-cash net gain on distribution of Alcon Inc. which amounted to USD 4.7 billion. Basic earnings per share were USD 3.55 compared to USD 5.12 in prior year. Cash flow from operating activities for the total Group amounted to USD 13.6 billion and free cash flow to USD 11.7 billion. </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">63</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Factors affecting comparability of year-on-year results of operations</font>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions in 2020 and 2019</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The comparability of the year-on-year results of our operations for the total Group can be significantly affected by acquisitions and divestments. As part of our long-term strategy to focus Novartis as a leading medicines company, we announced and/or completed several acquisitions and divestments during 2020 and 2019.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A detailed description of significant transactions in 2020 and 2019, can be found in &#x201C;Item 18. Financial Statements&mdash;Note 2. Significant transactions.&#x201D;</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Critical accounting policies and estimates</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our significant accounting policies which are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB) are set out in &#x201C;Item 18. Financial Statements&mdash;Note 1. Significant accounting policies.&#x201D;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Given the uncertainties inherent in our business activities, we must make certain estimates and assumptions that require difficult, subjective and complex judgments. Because of uncertainties inherent in such judgments, actual outcomes and results may differ from our assumptions and estimates, which could materially affect the Group&#x2019;s consolidated financial statements. Application of the following accounting policies requires certain assumptions and estimates that have the potential for the most significant impact on our consolidated financial statements.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Deductions from revenues</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As is typical in the pharmaceutical industry, our gross sales are subject to various deductions, which are primarily composed of rebates and discounts to retail customers, government agencies, wholesalers, health insurance companies and managed healthcare organizations. These deductions represent estimates of the related obligations, requiring the use of judgment when estimating the effect of these sales deductions on gross sales for a reporting period. These adjustments are deducted from gross sales to arrive at net sales.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following summarizes the nature of some of these deductions and how the deduction is estimated. After recording these, net sales represent our best estimate of the cash that we expect to ultimately collect. The US market has the most complex arrangements related to revenue deductions.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">United States-specific healthcare plans and program rebates</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The United States Medicaid Drug Rebate Program is administered by state governments, using state and federal funds to provide assistance to certain vulnerable and needy individuals and families. Calculating the rebates to be paid related to this program involves interpreting relevant regulations, which are subject to challenge or change in interpretative guidance by government authorities. Provisions for estimating Medicaid rebates are calculated using a combination of historical experience, product and population growth, product pricing, and the mix of contracts and specific terms in the individual state agreements.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The United States Federal Medicare Program, which funds healthcare benefits to individuals aged 65 and older, and to people with certain disabilities, provides prescription drug benefits under the Part D section of the program. This benefit is provided and administered through private prescription drug plans. Provisions for estimating Medicare Part D rebates are calculated based on the terms of individual plan agreements, product sales and population growth, product pricing, and the mix of contracts.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We offer rebates to key managed healthcare and private plans in an effort to ensure patient access to our products and to sustain and increase the market share of our products. These programs provide a rebate after the plans have demonstrated they have met all terms and conditions set forth in their contract with us. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">These rebates are estimated based on the terms of individual agreements, historical experience, product pricing and projected product growth rates, and are recorded as a deduction from revenue at the time the related revenues are recorded. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">These provisions are adjusted based on established processes and experiences from filing data with individual states and plans. There is often a time lag of several months between recording of the revenue deductions and the final accounting for them.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Non-United States-specific healthcare plans and program rebates</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In certain countries other than the US, we provide rebates to governments and other entities. These rebates are often mandated by laws or government regulations. These rebates are estimated based on government regulations, laws and terms of individual rebate arrangements, historical experience and other relevant factors, and are recorded as a deduction from revenue at the time the related revenue is recorded. These estimates are adjusted periodically to reflect actual experience. There is often a time lag of several months between the recording of revenue deductions and the final accounting for them.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative pay-for-performance arrangements</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In several countries, we enter into innovative pay-for-performance arrangements (i.e. outcome based arrange-</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">64</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">ments) with certain healthcare providers. Under these agreements, we may be required to make refunds to the healthcare providers or to provide additional medicines free of charge if anticipated treatment outcomes do not meet predefined targets. The impact of potential refunds or the delivery of additional medicines at no cost is estimated and recorded as a deduction from revenue at the time the related revenues are recorded. Estimates are based on historical experience and clinical data. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until such history is available.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There is often a time lag of several months between recording of the revenue deductions and the final accounting for them.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Non-healthcare plans and program rebates, returns and other deductions</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We offer rebates to purchasing organizations and other direct and indirect customers to sustain and increase market share and to ensure patient access to our products. Since rebates are contractually agreed upon, the related provisions are estimated based on the terms of the individual agreements, historical experience and projected product sales growth rates. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Chargebacks occur where our subsidiaries have arrangements with indirect customers to sell products at prices that are lower than the price charged to wholesalers. A chargeback represents the difference between the invoice price to the wholesaler and the indirect customer&#x2019;s contract price. We account for chargebacks by reducing revenue by the estimate of chargebacks attributable to a sales transaction. Provisions for estimated chargebacks are calculated using a combination of factors, such as historical experience, product growth rates, product pricing, level of inventory in the distribution channel, and the terms of individual agreements.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">When we sell a product providing a customer the right to return it, we record a provision for estimated sales returns based on our sales return policy and historical return rates. Other factors considered include actual product recalls, expected marketplace changes, the remaining shelf life of the product, and the expected entry of generic products. In 2020, sales returns amounted to approximately 1% of gross product sales. If sufficient experience is not available, sales are only recorded based on evidence of product consumption or when the right of return has expired.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We enter into distribution service agreements with major wholesalers, which provide a financial disincentive for the wholesalers to purchase product quantities in excess of current customer demand. Where possible, we adjust shipping patterns for our products to maintain wholesalers&#x2019; inventory levels consistent with underlying patient demand.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We offer cash discounts to customers to encourage prompt payment. Cash discounts are estimated and accrued at the time of invoicing and are deducted from revenue.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Following a decrease in the price of a product, we generally grant customers a &#x201C;shelf stock adjustment&#x201D; for their existing inventory for the relevant product. Provisions for shelf stock adjustments, which are primarily relevant within the Sandoz Division, are determined at the time of the price decline or at the point of sale, if the impact of a price decline on the products sold can be reasonably estimated based on the customer&#x2019;s inventory levels of the relevant product.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Other sales discounts, such as consumer coupons and copay discount cards, are offered in some markets. The estimated amounts of these discounts are recorded at the time of sale or when the coupons are issued, and are estimated utilizing historical experience and the specific terms for each program. If a discount for a probable future transaction is offered as part of a sales transaction, then an appropriate portion of revenue is deferred to cover this estimated obligation. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, we offer global patient assistance programs.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We adjust provisions for revenue deductions periodically to reflect actual experience. To evaluate the adequacy of provision balances, we use internal and external estimates of the inventory in transit, the level of inventory in the distribution and retail channels, actual claims data received, and the time lag for processing rebate claims. External data sources include reports from wholesalers and third-party market data purchased by Novartis.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For the table showing the worldwide extent of our revenue deductions provisions and related payment experiences for the Group see &#x201C;Item 18. Financial Statements&mdash;Note 22. Provisions and other current liabilities.&#x201D;</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Gross-to-net sales reconciliation</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The table below shows the gross-to-net sales reconciliation for our Innovative Medicines Division:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> In % of<br> gross sales<br> to third <br> parties</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> In % of<br> gross sales<br> to third <br> parties</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines gross sales subject to deductions</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 56&nbsp;067</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100.0</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 52&nbsp;956</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100.0</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US-specific healthcare plans and program rebates</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5&nbsp;412</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9.7</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4&nbsp;824</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9.1</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-US-specific healthcare plans and program rebates</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;746</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;438</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6.5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-healthcare plans and program-related rebates,  returns and other deductions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;7&nbsp;896</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;14.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;6&nbsp;980</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;13.2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Innovative Medicines gross-to-net sales adjustments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;17&nbsp;054</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;30.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;15&nbsp;242</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;28.8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines net sales</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 39&nbsp;013</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 69.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37&nbsp;714</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71.2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">65</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impairment of goodwill, intangible assets and property, plant and equipment</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We review long-lived intangible assets and property, plant and equipment for impairment whenever events or changes in circumstance indicate that the asset&#x2019;s balance sheet carrying amount may not be recoverable. Goodwill and other currently not amortized intangible assets are reviewed for impairment at least annually.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">An asset is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value in use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or cash generating units (CGUs), and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group&#x2019;s activities as indicated in &#x201C;Item 18. Financial Statements&mdash;Note 1. Significant accounting policies.&#x201D; Due to these factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The recoverable amount of the grouping of cash-generating units to which goodwill is allocated is based on fair value less costs of disposal. The valuations are derived from applying discounted future cash flows based on key assumptions, including the terminal growth rate and discount rate. For additional information on impairment charges recognized and reversed by divisions, see &#x201C;Item 18. Financial Statements&mdash;Note 1. Significant accounting policies&mdash;Impairment of goodwill and intangible assets&#x201D; and &#x201C;Item 18. Financial Statements&mdash;Note 11. Goodwill and intangible assets.&#x201D;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Goodwill and other intangible assets represent a significant part of our consolidated balance sheet, primarily due to acquisitions. Although no significant additional impairments are currently anticipated, impairment evaluation could lead to material impairment charges in the future. For more information, see &#x201C;Item 18. Financial Statements&mdash;Note 11. Goodwill and intangible assets.&#x201D;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For net impairment charges for property, plant and equipment from continuing operations see &#x201C;Item 18. Financial Statements&mdash;Note 9. Property, plant and equipment.&#x201D;</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Contingent consideration</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In an acquisition or divestment of a business, it is necessary to recognize contingent future amounts due to previous owners representing contractually defined potential amounts as a liability or asset. Usually for Novartis, these are linked to milestone or royalty payments related to certain assets and are recognized as a financial liability or financial asset at their fair value, which is then remeasured at each subsequent reporting date. These estimations typically depend on factors such as technical milestones or market performance, and are adjusted for the probability of their likelihood of payment and, if material, are appropriately discounted to reflect the impact of time.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the consolidated income statement in &#x201C;Cost of goods sold&#x201D; for currently marketed products and in &#x201C;Research and development&#x201D; for in-process research and development (IPR&amp;D). Changes in contingent consideration assets are recognized in &#x201C;Other income&#x201D; or &#x201C;Other expense,&#x201D; depending on their nature.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The effect of unwinding the discount over time is recognized for contingent liabilities in &#x201C;Interest expense&#x201D; and for contingent assets as interest income recognized in the consolidated income statement within &#x201C;Other financial income and expense.&#x201D;</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Retirement and other post-employment benefit plans</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We sponsor pension and other post-employment benefit plans in various forms that cover a significant portion of our current and former associates. For post-employment plans with defined benefit obligations, we are required to make significant assumptions and estimates about future events in calculating the expense and the present value of the liability related to these plans. These include assumptions about the interest rates we apply to estimate future defined benefit obligations and net periodic pension expense, as well as rates of future pension increases. In addition, our actuarial consultants provide our management with historical statistical information, such as withdrawal and mortality rates in connection with these estimates.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Assumptions and estimates used by the Group may differ materially from the actual results we experience due to changing market and economic conditions, higher or lower withdrawal rates, and longer or shorter life spans of participants, among other factors. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Depending on events, such differences could have a material effect on our total equity. For more information on obligations under retirement and other post-employment benefit plans and underlying actuarial assumptions, see &#x201C;Item 18. Financial Statements&mdash;Note 25. Post-employment benefits for associates.&#x201D;</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Provisions and contingencies</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">A number of Group companies are involved in various government investigations and legal proceedings (intellectual property, sales and marketing practices, product liability, commercial, employment and wrongful discharge, environmental claims, etc.) arising out of the normal conduct of their businesses. For more information, see &#x201C;Item 18. Financial Statements&mdash;Note 20. Provisions and other </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">66</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">non-current liabilities&#x201D; and &#x201C;Item 18. Financial Statements&mdash;Note 28. Commitments and contingencies.&#x201D;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We record provisions for legal proceedings when it is probable that a liability has been incurred and the amount can be reliably estimated. These provisions are adjusted periodically as assessments change or additional information becomes available. For significant product liability cases, the provision is actuarially determined based on factors such as past experience, amount and number of claims reported, and estimates of claims incurred but not yet reported.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Provisions are recorded for environmental remediation costs when expenditure on remedial work is probable and the cost can be reliably estimated. Remediation costs are provided for under &#x201C;Non-current liabilities&#x201D; in the Group&#x2019;s consolidated balance sheet.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Provisions relating to estimated future expenditure for liabilities do not usually reflect any insurance or other claims or recoveries, since these are only recognized as assets when the amount is reasonably estimable and collection is virtually certain.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Research and development</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Internal research and development (R&amp;D) costs are fully charged to the consolidated income statement in the period in which they are incurred. We consider that regulatory and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset usually until marketing approval from the regulatory authority is obtained in a relevant major market, such as for the United States, the European Union or Switzerland.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Costs for post-approval studies performed to support the continued registration of a marketed product are recognized as marketing expenses. Costs for activities that are required by regulatory authorities as a condition for obtaining marketing approval are capitalized and recognized as currently marketed products.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Healthcare contributions</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In some countries, our subsidiaries are required to make contributions to the country&#x2019;s healthcare costs as part of programs other than the ones mentioned above under deductions from revenues. The amounts to be paid depend on various criteria such as the subsidiary&#x2019;s market share or sales volume compared to certain targets. Considerable judgment is required in estimating these contributions, as not all data is available when the estimates need to be made.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The largest of these healthcare contributions relates to the US healthcare reform fee, which was introduced in 2011. This fee is an annual levy paid by US pharmaceutical companies, including various Novartis subsidiaries. The calculation of the annual expense for this levy requires use of management judgement and estimates. This is required as the US healthcare reform fee owed is based on the Group&#x2019;s percentage share of the total industry qualifying sales subject to the healthcare reform fee, which requires estimation as the total industry qualifying sales subject to the healthcare reform fee is not publicly available until the following year when the fee is due for payment. This pharmaceutical fee levy is recognized in &#x201C;Other expense.&#x201D;</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Taxes</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We prepare and file our tax returns based on an interpretation of tax laws and regulations, and we record estimates based on these judgments and interpretations. Our tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made, requiring payments of additional tax, interest or penalties. Since Novartis uses its intellectual property globally to deliver goods and services, the transfer prices within the Group as well as arrangements between subsidiaries to finance research and development and other activities may be challenged by the national tax authorities in any of the jurisdictions in which Novartis operates. Therefore, inherent uncertainties exist in our estimates of our tax positions, but we believe that our estimated amounts for current and deferred tax assets or liabilities, including any amounts related to any uncertain tax positions, are appropriate based on currently known facts and circumstances.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Internal control over financial reporting</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s management has assessed the effectiveness of internal control over financial reporting. The Group&#x2019;s independent statutory auditor also issued an opinion on the effectiveness of internal control over financial reporting. Both the Group&#x2019;s management and its external auditors concluded that the Group maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020. For more details, see &#x201C;Item 15. Controls and Procedures.&#x201D;</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Approach to risk management</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">See &#x201C;Item 6. Directors, Senior Management and Employees&mdash;Item 6.C Board practices&mdash;Corporate governance&mdash;Information and control systems&mdash;Risk management&#x201D; and &#x201C;Item 18. Financial Statements&mdash;Note 29. Financial instruments &ndash; additional disclosures.&#x201D;</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">67</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Non-IFRS measures as defined by Novartis</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis uses certain non-IFRS metrics when measuring performance, especially when measuring current-year results against prior periods, including core results, constant currencies, free cash flow and net debt.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Despite the use of these measures by management in setting goals and measuring the Group&#x2019;s performance, these are non-IFRS measures that have no standardized meaning prescribed by IFRS. As a result, such measures have limits in their usefulness to investors.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Because of their non-standardized definitions, the non-IFRS measures (unlike IFRS measures) may not be comparable to the calculation of similar measures of other companies. These non-IFRS measures are presented solely to permit investors to more fully understand how the Group&#x2019;s management assesses underlying performance. These non-IFRS measures are not, and should not be viewed as, a substitute for IFRS measures, and should be viewed in conjunction with IFRS financials.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As an internal measure of Group performance, these non-IFRS measures have limitations, and the Group&#x2019;s performance management process is not solely restricted to these metrics.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Core results</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s core results &ndash; including core operating income, core net income and core earnings per share &ndash; exclude fully the amortization and impairment charges of intangible assets, excluding software, net gains and losses on fund investments and equity securities valued at fair value through profit and loss, and certain acquisition- and divestment-related items. The following items that exceed a threshold of USD&nbsp;25 million are also excluded: integration- and divestment-related income and expenses; divestment gains and losses; restructuring charges/releases and related items; legal-related items; impairments of property, plant and equipment, and financial assets, and income and expense items that management deems exceptional and that are or are expected to accumulate within the year to be over a USD&nbsp;25 million threshold. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis believes that investor understanding of the Group&#x2019;s performance is enhanced by disclosing core measures of performance since, core measures exclude items that can vary significantly from year to year, they enable better comparison of business performance across years. For this same reason, Novartis uses these core measures in addition to IFRS and other measures as important factors in assessing the Group&#x2019;s performance.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The following are examples of how these core measures are utilized:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; In addition to monthly reports containing financial information prepared under International Financial Reporting Standards (IFRS), senior management receives a monthly analysis incorporating these core measures.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Annual budgets are prepared for both IFRS and core measures. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As an internal measure of Group performance, the core results measures have limitations, and the Group&#x2019;s performance management process is not solely restricted to these metrics. A limitation of the core results measures is that they provide a view of the Group&#x2019;s operations without including all events during a period, such as the effects of an acquisition, divestment, or amortization/impairments of purchased intangible assets and restructurings.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Constant currencies</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Changes in the relative values of non-US currencies to the US dollar can affect the Group&#x2019;s financial results and financial position. To provide additional information that may be useful to investors, including changes in sales volume, we present information about our net sales and various values relating to operating and net income that are adjusted for such foreign currency effects.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Constant currency calculations have the goal of eliminating two exchange rate effects so that an estimate can be made of underlying changes in the consolidated income statement excluding the impact of fluctuations in exchanges rates:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The impact of translating the income statements of consolidated entities from their non-USD functional currencies to USD</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The impact of exchange rate movements on the major transactions of consolidated entities performed in currencies other than their functional currency</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We calculate constant currency measures by translating the current year&#x2019;s foreign currency values for sales and other income statement items into USD, using the average exchange rates from the prior year and comparing them to the prior-year values in USD.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We use these constant currency measures in evaluating the Group&#x2019;s performance, since they may assist us in evaluating our ongoing performance from year to year. However, in performing our evaluation, we also consider equivalent measures of performance that are not affected by changes in the relative value of currencies.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Growth rate calculation</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For ease of understanding, Novartis uses a sign convention for its growth rates such that a reduction in operating expenses or losses compared to the prior year is shown as a positive growth.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">68</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Free cash flow</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis defines free cash flow as net cash flows from operating activities and cash flows from investing activities associated with purchases and sales of property, plant and equipment, of intangible assets, of financial assets and of other non-current assets. Excluded from free cash flow are cash flows from investing activities associated with acquisitions and divestments of businesses and of interests in associated companies, purchases and sales of marketable securities and commodities and net cash flows from financing activities.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Free cash flow is a non-IFRS measure and is not intended to be a substitute measure for net cash flows from operating activities as determined under IFRS. Free cash flow is presented as additional information because management believes it is a useful supplemental indicator of the Group&#x2019;s ability to operate without reliance on additional borrowing or use of existing cash. Free cash flow is a measure of the net cash generated that is available for investment in strategic opportunities, returning to shareholders and for debt repayment. Free cash flow is a non-IFRS measure, which means it should not be interpreted as a measure determined under IFRS. </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Net debt</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis calculates net debt as current financial debts and derivative financial instruments plus non-current financial debt less cash and cash equivalents and marketable securities, commodities, time deposits and derivative financial instruments.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net debt is a non-IFRS measure, which means it should not be interpreted as a measure determined under IFRS. Net debt is presented as additional information because management believes it is a useful supplemental indicator of the Group&#x2019;s ability to pay dividends, to meet financial commitments, and to invest in new strategic opportunities, including strengthening its balance sheet. </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Novartis Cash Value Added</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis Cash Value Added (NCVA) is a metric that is based on what the Company assesses to be its cash flow return less a capital charge on gross operating assets. NCVA is used as the primary internal financial measure for determining payouts under the old Long-Term Performance Plan (LTPP) introduced in 2014. The LTPP performance measures were changed effective January 1, 2019, and from the 2019 cycle onward no longer include NCVA as a performance measure. More information on NCVA is presented as part of the Compensation Report; see &#x201C;Item 6. Directors, Senior Management and Employees&mdash;Item 6.B Compensation.&#x201D;</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Additional information</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">EBITDA</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis defines earnings before interest, tax, depreciation and amortization (EBITDA) as operating income, excluding depreciation of property, plant and equipment, depreciation of right-of-use assets, amortization of intangible assets, and impairments of plant and equipment, right-of-use assets and of intangible assets.</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from  continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   10&nbsp;152</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   9&nbsp;086</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of property,  plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   1&nbsp;318</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1&nbsp;345</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of the   right-of-use-assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   330</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   305</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of intangible  assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   3&nbsp;462</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   2&nbsp;836</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairments of property,  plant and equipment, and  intangible assets<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     1&nbsp;354</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     1&nbsp;340</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">EBITDA from continuing  operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   16&nbsp;616</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   14&nbsp;912</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from  discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   71</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of property,  plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   42</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of the   right-of-use-assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of intangible  assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   174</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">EBITDA from discontinued  operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   296</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">EBITDA Total Group</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&nbsp;616</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&nbsp;208</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td></td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> There were no impairments of right-of-use assets in 2020 and 2019.</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Enterprise value</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Enterprise value represents the total amount that shareholders and debt holders have invested in Novartis, less the Group&#x2019;s liquidity.</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Dec 31, 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Market capitalization</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 214&nbsp;269</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 214&nbsp;815</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-controlling interests</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 68</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 77</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current financial debts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&nbsp;259</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20&nbsp;353</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current financial debts and  derivatives financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   9&nbsp;785</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   7&nbsp;031</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities,  commodities, time deposits  and derivative financial  instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       &#x2013;&#x2005;1&nbsp;905</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">       &#x2013;&#x2005;334</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9&nbsp;658</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11&nbsp;112</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Enterprise value</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 238&nbsp;818</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 230&nbsp;830</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">69</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Reconciliation from IFRS results to core results</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables provide an overview of the reconciliation from IFRS results to core results.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2020 and 2019 reconciliation from IFRS results to core results</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative Medicines</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions unless indicated otherwise)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">IFRS operating income from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;172</div>
      </td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;287</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;043</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 551</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;63</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;752</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&nbsp;152</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;086</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Amortization of intangible assets</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;999</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;447</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 366</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 314</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;365</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;761</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairments</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 759</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 632</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 141</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 503</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 900</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;135</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment related to the Group-wide  rationalization of manufacturing sites</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   321</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   83</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   112</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   69</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   433</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   152</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other property, plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 43</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total impairment charges</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;080</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 725</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 255</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 605</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;335</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;330</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquisition or divestment of businesses and related items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;73</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;108</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;78</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;116</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 107</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 87</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 89</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 115</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 218</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 202</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total acquisition or divestment of  businesses and related items, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   102</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   79</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   140</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   86</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Divestment gains</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;348</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;091</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;27</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;39</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;414</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;089</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial assets - fair value adjustments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;153</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;183</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;336</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;38</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Restructuring and related items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;36</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;58</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;28</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;94</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;71</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 484</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 509</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 252</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 390</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 35</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 113</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 771</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;012</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Legal-related items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;32</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 555</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 999</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 406</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 156</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;26</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 935</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;155</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additional income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;264</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;316</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;361</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;95</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;631</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;415</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additional expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 54</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 87</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 53</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 121</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 86</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 119</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 193</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 327</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 292</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 112</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 648</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 624</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;516</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 113</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 424</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 849</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total adjustments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;473</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;363</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;291</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;543</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;500</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 120</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;264</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;026</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core operating income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;645</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;650</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;334</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;094</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;563</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;632</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&nbsp;416</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;112</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">as % of net sales</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 35.0%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 33.5%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 24.2%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 21.5%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 31.7%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 29.7%</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 670</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 656</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 673</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 659</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core adjustments to income from associated companies, net of tax</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 424</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 427</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 424</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 427</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;869</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;850</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;78</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 45</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core adjustments to other financial income and expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes, adjusted for above items (core taxes)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;403</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;300</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core net income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;158</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;104</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core net income from discontinued operations<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 278</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;158</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;382</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core net income attributable to shareholders of Novartis AG</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;159</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;377</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core basic EPS from continuing operations (USD)<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5.78</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.28</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core basic EPS from discontinued operations (USD)<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core basic EPS (USD)<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5.78</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.40</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> For details on discontinued operations reconciliation from IFRS to core net income, please refer to page 76.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">70</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2020 and 2019 reconciliation from IFRS results to core results &ndash; Group</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>2020 (USD millions unless indicated otherwise)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> IFRS results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Amortization<br> of intangible<br> assets<sup style="white-space: nowrap">    1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> Impairments<sup style="white-space: nowrap">    2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Acquisition or <br> divestment of <br> businesses and<br> related items<sup style="white-space: nowrap">    3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Other <br> items<sup style="white-space: nowrap">    4</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> Core results</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 34&nbsp;777</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;301</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 377</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 70</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 138</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 38&nbsp;663</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&nbsp;152</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;365</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;335</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 140</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 424</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&nbsp;416</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;878</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;789</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;335</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 140</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 419</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&nbsp;561</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes from continuing operations<sup style="white-space: nowrap">&nbsp;5</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;807</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;403</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;071</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;158</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;071</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;158</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic EPS from continuing operations (USD)<sup style="white-space: nowrap">&nbsp;6</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.55</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5.78</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic EPS (USD)<sup style="white-space: nowrap">&nbsp;6</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.55</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5.78</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">            </div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;239</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;136</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;103</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15&nbsp;121</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;301</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 377</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 274</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11&nbsp;099</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">            </div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14&nbsp;197</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 88</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14&nbsp;093</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8&nbsp;980</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 523</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;94</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8&nbsp;484</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;742</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;78</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;335</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 323</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;190</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 441</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 129</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;627</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;993</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">            </div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core income before taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 673</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 424</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;097</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;78</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;83</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">      </div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to currently marketed products and other production-related intangible assets; research and development includes the amortization of acquired rights for technologies; income from associated companies includes USD 424 million for the Novartis share of the estimated Roche core items</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Impairments: cost of goods sold and research and development include impairment charges related to intangible assets; other income includes an impairment reversal related to property, plant and equipment; other expense includes impairment charges related to property, plant and equipment</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: cost of goods sold, selling, general and administration, research and development and other expense include net charges related to acquisitions; other income and other expense include transitional service-fee income and expenses related to the Alcon distribution</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> Other items: other revenues includes a settlement of royalties; cost of goods sold includes the cumulative amount of the depreciation up to December 31, 2019, recognized with the reclassification of property, plant and equipment out of assets of disposal group held for sale (see Item 18. Financial Statements&#x2013;Note 2. Significant transactions&#x2013;Significant transactions in 2020); cost of goods sold, other income and other expense include net restructuring and other charges related to the Group-wide rationalization of manufacturing sites; cost of goods sold, selling, general and administration, research and development, other income and other expense include other restructuring income and charges and related items; cost of goods sold and research and development also include adjustments to contingent considerations; selling, general and administration and other expense include expenses related to COVID-19 donations; selling, general and administration also includes adjustments to provisions; other income and other expense include fair value adjustments and divestment gains and losses on financial assets, and adjustments to environmental provisions; other income also includes net gains from the divestment of products, a fair value adjustment on a contingent receivable and adjustments to provisions; other expense includes adjustments to legal provisions, legal-related items and a termination fee; other financial income and expense includes a revaluation impact of a financial liability incurred through the Alcon distribution</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;5&nbsp;</sup> Taxes on the adjustments between IFRS and core results take into account, for each individual item included in the adjustment, the tax rate that will finally be applicable to the item based on the jurisdiction where the adjustment will finally have a tax impact. Generally, this results in amortization and impairment of intangible assets and acquisition-related restructuring and integration items having a full tax impact. There is usually a tax impact on other items, although this is not always the case for items arising from legal settlements in certain jurisdictions. Adjustments related to income from associated companies are recorded net of any related tax effect. Due to these factors and the differing effective tax rates in the various jurisdictions, the tax on the total adjustments for continuing operations of USD 5.7 billion to arrive at the core results before tax amounts to USD 596 million. The average tax rate on the adjustments is 10.5%.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;6&nbsp;</sup> Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">71</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>2019 (USD millions unless indicated otherwise)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> IFRS results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Amortization<br> of intangible<br> assets<sup style="white-space: nowrap">    1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> Impairments<sup style="white-space: nowrap">    2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Acquisition or <br> divestment of <br> businesses and<br> related items<sup style="white-space: nowrap">    3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Other <br> items<sup style="white-space: nowrap">    4</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> Core results</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;252</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;711</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 85</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 48</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 296</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37&nbsp;392</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;086</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;761</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;330</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 86</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 849</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;112</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;940</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;188</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;330</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 86</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 860</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;404</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes from continuing operations<sup style="white-space: nowrap">&nbsp;5</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;793</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;300</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;147</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;104</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income from discontinued operations<sup style="white-space: nowrap">&nbsp;6</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;590</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 278</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;737</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;382</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic EPS from continuing operations (USD)<sup style="white-space: nowrap">&nbsp;7</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3.12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.28</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basic EPS from discontinued operations (USD)<sup style="white-space: nowrap">&nbsp;7</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.00</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic EPS (USD)<sup style="white-space: nowrap">&nbsp;7</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.40</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;179</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;66</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;113</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14&nbsp;425</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;711</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 85</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 48</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 362</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11&nbsp;219</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14&nbsp;369</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 40</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14&nbsp;319</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9&nbsp;402</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 50</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;078</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;122</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8&nbsp;386</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;031</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;116</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;418</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 495</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;426</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 169</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 134</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;053</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;070</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core income before taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 659</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 427</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;086</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 45</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 56</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to currently marketed products and other production-related intangible assets; research and development includes the amortization of acquired rights for technologies; income from associated companies includes USD 427 million for the Novartis share of the estimated Roche core items</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Impairments: cost of goods sold, and research and development include impairment charges related to intangible assets; research and development also includes the reversal of an impairment charge; cost of goods sold, other income and other expense include net impairment charges related to property, plant and equipment</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: cost of goods sold, selling, general and administration, research and development, other income and other expense include net charges related to acquisitions; other income and other expense also include transitional service fee income and expenses related to the portfolio transformation and the Alcon distribution</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> Other items: other revenues includes income from an outlicensing agreement, and income related to an amendment of a collaboration agreement; cost of goods sold, other income and other expense include net restructuring and other charges related to the Group-wide rationalization of manufacturing sites; cost of goods sold, research and development, selling, general and administration, other income and other expense include other restructuring income and charges and related items; cost of goods sold, and research and development also include fair value adjustments of contingent consideration liabilities; cost of goods sold also includes inventory write-offs and other provisions; selling, general and administration includes receivable expected credit loss provisions and other provisions; other income and other expense include fair value adjustments and divestment gains and losses on financial assets and legal-related items as well as environmental provisions; other income also includes net gains from the divestment of products and property, plant and equipment, and provision releases; other expense includes a provision for onerous contracts and other provisions; other financial income and expense includes a revaluation impact of a financial liability incurred through the Alcon distribution</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;5&nbsp;</sup> Taxes on the adjustments between IFRS and core results take into account, for each individual item included in the adjustment, the tax rate that will finally be applicable to the item based on the jurisdiction where the adjustment will finally have a tax impact. Generally, this results in amortization and impairment of intangible assets and acquisition-related restructuring and integration items having a full tax impact. There is usually a tax impact on other items, although this is not always the case for items arising from legal settlements in certain jurisdictions. Adjustments related to income from associated companies are recorded net of any related tax effect. Due to these factors and the differing effective tax rates in the various jurisdictions, the tax on the total adjustments for continuing operations of USD 5.5 billion to arrive at the core results before tax amounts to USD 507 million. The average tax rate on the adjustments is 9.3%.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;6&nbsp;</sup> For details on discontinued operations reconciliation from IFRS to core net income please refer to page 76.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;7&nbsp;</sup> Earnings per share (EPS) is calculated on the amount of net income, attributable to shareholders of Novartis AG.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">72</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2020 and 2019 reconciliation from IFRS results to core results &ndash; Innovative Medicines</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>2020<br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> IFRS results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Amortization<br> of intangible<br> assets<sup style="white-space: nowrap">    1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> Impairments<sup style="white-space: nowrap">    2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Acquisition or <br> divestment of <br> businesses and<br> related items<sup style="white-space: nowrap">    3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Other <br> items<sup style="white-space: nowrap">    4</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> Core results</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&nbsp;896</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;935</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 250</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 146</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33&nbsp;275</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;172</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;999</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;080</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 102</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 292</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;645</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10&nbsp;927</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;935</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 48</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 146</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7&nbsp;548</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11&nbsp;657</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 58</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11&nbsp;583</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8&nbsp;118</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 509</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;94</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7&nbsp;636</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 922</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;687</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 229</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;871</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 322</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 869</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;640</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to currently marketed products and other production-related intangible assets; research and development includes the amortization of acquired rights for technologies</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Impairments: cost of goods sold and research and development include impairment charges related to intangible assets; other income and other expense include net impairment charges related to property, plant and equipment</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: cost of goods sold, selling, general and administration, research and development and other expense include net charges related to acquisitions; other income and other expense include transitional service-fee income and expenses related to the Alcon distribution</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> Other items: cost of goods sold, other income and other expense include net restructuring and other charges related to the Group-wide rationalization of manufacturing sites; cost of goods sold, selling, general and administration, research and development, other income and other expense include other restructuring income and charges and related items; cost of goods sold and research and development also include adjustments to contingent considerations; selling, general and administration includes expenses related to COVID-19 donations and adjustments to provisions; other income and other expense include fair value adjustments on financial assets; other income also includes net gains from the divestment of products and financial assets and adjustments to provisions; other expense includes legal-related items and a termination fee</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>2019 <br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> IFRS results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Amortization<br> of intangible<br> assets<sup style="white-space: nowrap">    1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> Impairments<sup style="white-space: nowrap">    2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Acquisition or <br> divestment of <br> businesses and<br> related items<sup style="white-space: nowrap">    3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Other <br> items<sup style="white-space: nowrap">    4</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> Core results</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 29&nbsp;539</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;397</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 48</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 116</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 32&nbsp;100</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;287</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;447</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 725</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 79</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 112</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;650</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;092</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;66</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;026</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10&nbsp;050</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;397</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 48</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 182</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;7&nbsp;423</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11&nbsp;617</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11&nbsp;582</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8&nbsp;152</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 50</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 632</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;125</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;7&nbsp;585</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;586</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;230</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 347</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;069</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 94</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;326</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;630</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to currently marketed products and other production-related intangible assets; research and development includes the amortization of acquired rights for technologies</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Impairments: research and development includes impairment charges and a reversal of impairment charges related to intangible assets; other income and other expense include net impairment charges related to property, plant and equipment</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: cost of goods sold, selling, general and administration, research and development, other income and other expense include net charges related to acquisitions; other income and other expense also include transitional service-fee income and expenses related to the portfolio transformation and the Alcon distribution</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> Other items: other revenues includes a net income from an outlicensing agreement and an income related to an amendment of a collaboration agreement; cost of goods sold, other income and other expense include restructuring and other charges related to the Group-wide rationalization of manufacturing sites; cost of goods sold, research and development, other income and other expense include other restructuring income and charges and related items; cost of goods sold, and research and development also include fair value adjustments of contingent consideration liabilities; selling, general and administration includes other provisions; other income and other expense include fair value adjustments and divestment gains and losses on financial assets; other income also includes net gains from the divestment of products and property, plant and equipment, and provision releases; other expense includes legal-related items</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">73</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2020 and 2019 reconciliation from IFRS to core results &ndash; Sandoz</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>2020<br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> IFRS results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Amortization <br> of intangible<br> assets<sup style="white-space: nowrap">    1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> Impairments<sup style="white-space: nowrap">    2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Acquisition or <br> divestment of <br> businesses and<br> related items<sup style="white-space: nowrap">    3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Other <br> items<sup style="white-space: nowrap">    4</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> Core results</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;636</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 366</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 127</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 128</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;279</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;043</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 366</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 255</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 648</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;334</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5&nbsp;252</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 366</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 127</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 128</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4&nbsp;609</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;076</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;046</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;862</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;848</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 176</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;62</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 109</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;831</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 119</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 552</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;160</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to currently marketed products and other production-related intangible assets</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Impairments: cost of goods sold and research and development include impairment charges related to intangible assets; other income includes an impairment reversal related to property, plant and equipment; other expense includes impairment charges related to property, plant and equipment</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: cost of goods sold includes net charges related to an acquisition</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> Other items: cost of goods sold includes the cumulative amount of the depreciation up to December 31, 2019, recognized with the reclassification of property, plant and equipment out of assets of disposal group held for sale (see Item 18. Financial Statements&#x2013;Note 2. Significant transactions&#x2013;Significant transactions in 2020); cost of goods sold and other expense include restructuring and other charges related to the Group-wide rationalization of manufacturing sites; cost of goods sold, selling, general and administration, other income and other expense include other restructuring income and charges and related items; selling, general and administration also includes expenses related to COVID-19 donations and adjustments to provisions; other income includes net gains from the divestment of a product and adjustments to provisions; other expense includes a legal provision and legal-related items</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>2019 <br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> IFRS results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Amortization <br> of intangible<br> assets<sup style="white-space: nowrap">    1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> Impairments<sup style="white-space: nowrap">    2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Acquisition or <br> divestment of <br> businesses and<br> related items</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Other <br> items<sup style="white-space: nowrap">    3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> Core results</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;601</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 314</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 85</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 180</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;180</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 551</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 314</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 605</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 624</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;094</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;334</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 314</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 85</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 180</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4&nbsp;755</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;218</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;203</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 446</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;801</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 167</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;39</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 127</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;749</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 75</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 465</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;209</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to currently marketed products and other production-related intangible assets</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Impairments: cost of goods sold, and research and development include impairment charges related to intangible assets; cost of goods sold, other income and other expense include net impairment charges related to property, plant and equipment</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Other items: cost of goods sold and other expense include net restructuring and other charges related to the Group-wide rationalization of manufacturing sites; cost of goods sold, selling, general and administration, other income and other expense include restructuring income and charges and related items; cost of goods sold also includes inventory write-offs and other provisions; selling, general and administration includes receivable expected credit loss provisions and other provisions; other income and other expense also include legal-related items; other expense also includes an environmental provision, a provision for onerous contracts and other provisions</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">74</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2020 and 2019 reconciliation from IFRS results to core results &ndash; Corporate</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>2020<br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> IFRS results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Amortization <br> of intangible<br> assets</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> Impairments</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Acquisition or <br> divestment of <br> businesses and<br> related items<sup style="white-space: nowrap">    1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Other <br> items<sup style="white-space: nowrap">    2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> Core results</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 245</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;136</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 109</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating loss</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;63</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;516</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;563</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 168</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;136</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating loss</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 644</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;73</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;586</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;488</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 89</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 206</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;193</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: other income and other expense include transitional service fee income and expenses related to the Alcon distribution</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Other items: other revenues includes a settlement of royalties; other income and other expense include fair value adjustments and divestment gains and losses on financial assets, adjustments to environmental provisions and restructuring income and charges and related items; other income also includes a fair value adjustment on a contingent receivable and adjustments to provisions; other expense includes adjustments to legal provisions and expenses related to COVID-19 donations</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>2019<br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> IFRS results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Amortization <br> of intangible<br> assets</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> Impairments</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Acquisition or <br> divestment of <br> businesses and<br> related items<sup style="white-space: nowrap">    1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Other <br> items<sup style="white-space: nowrap">    2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> Core results</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 112</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 112</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating loss</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;752</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 113</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;632</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating loss</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 278</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;108</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;149</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;608</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 115</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 262</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;231</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: other income and other expense include transitional service fee income and expenses related to the portfolio transformation and the Alcon distribution</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Other items: other income and other expense include fair value adjustments and divestment gains and losses on financial assets, restructuring income and charges and related items as well as environmental provisions</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">75</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2019 reconciliation of IFRS results to core results &ndash; Discontinued operations</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>2019 <br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> IFRS results</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Amortization <br> of intangible<br> assets<sup style="white-space: nowrap">    1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> Impairments</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Acquisition or <br> divestment of <br> businesses and<br> related items<sup style="white-space: nowrap">    2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Other <br> items<sup style="white-space: nowrap">    3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> Core results</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 949</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 165</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;123</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income of discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 167</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 112</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 350</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes of discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 58</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 337</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes<sup style="white-space: nowrap">&nbsp;4</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;159</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;59</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net (loss)/income from discontinued operations before gain on distribution of Alcon Inc. to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     &#x2013;&#x2005;101</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     278</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   4&nbsp;691</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;4&nbsp;691</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;590</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 278</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basic EPS (USD)<sup style="white-space: nowrap">&nbsp;5</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2.00</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0.12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;860</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 165</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;686</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;638</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;624</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;142</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;136</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;113</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 88</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;25</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to currently marketed products and other production-related intangible assets; research and development includes the amortization of acquired rights for technologies</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Acquisition or divestment of businesses and related items represents the non-taxable non-cash gain adjustment related to the distribution of Alcon Inc. (spin-off) to Novartis AG shareholders</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Other items: cost of goods sold, selling, general and administration, research and development and other expense include other restructuring charges and related items; research and development also includes amortization of option rights and the fair value adjustment of a contingent consideration liability; other income includes fair value adjustments on a financial asset; other expense also includes legal-related items</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> Taxes on the adjustments between IFRS and core results take into account, for each individual item included in the adjustment, the tax rate that will finally be applicable to the item based on the jurisdiction where the adjustment will finally have a tax impact. Generally, this results in amortization and impairment of intangible assets and acquisition-related restructuring and integration items having a full tax impact. There is usually a tax impact on other items, although this is not always the case for items arising from legal settlements in certain jurisdictions. Due to these factors and the differing effective tax rates in the various jurisdictions, the tax on the total adjustments, excluding the non-taxable non-cash gain on the distribution (spin-off) of Alcon Inc. to Novartis AG shareholders of USD 279 million to arrive at the core results before tax amounts to USD 100 million. The 2019 core tax rate, excluding the effect of the gain on the distribution of Alcon Inc. to Novartis AG shareholders, is 17.5%.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;5&nbsp;</sup> Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">76</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId0010050882"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">5.B Liquidity and capital resources</p>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables summarize the Group&#x2019;s cash flows and net debt.</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows from operating activities from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&nbsp;650</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13&nbsp;547</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows from operating activities from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 78</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows used in investing activities from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13&nbsp;055</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;067</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows used in investing activities from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;127</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;159</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows used in financing activities from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;158</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;16&nbsp;884</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows used in/from financing activities from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;50</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;257</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of exchange rate changes on cash and cash equivalents</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 286</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 69</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net change in cash and cash equivalents</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;454</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;2&nbsp;159</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in marketable securities, commodities, time deposits and derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;571</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;359</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current and non-current financial debts and derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8&nbsp;660</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;764</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Change in net debt</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;8&nbsp;543</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 246</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net debt at January 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15&nbsp;938</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;16&nbsp;184</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt at December 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;24&nbsp;481</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;15&nbsp;938</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Cash flow</font>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Financial year 2020 compared to 2019</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Net cash flows from operating activities from continuing operations amounted to USD 13.6 billion, compared to USD 13.5 billion in 2019. This increase was mainly driven by higher net income adjusted for non-cash items and other adjustments, including divestment gains, partly offset by higher payments out of provisions related to legal matters.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net cash outflows used in investing activities from continuing operations amounted to USD 13.1 billion, compared to USD 1.1 billion in 2019.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The current year cash outflows were mainly driven by USD 10.0 billion for acquisitions and divestments of businesses, net (including the acquisition of The Medicines Company for USD 9.5 billion, net of cash acquired USD 0.1 billion, and the acquisition of the Japanese business of Aspen Global Incorporated for USD 0.3 billion); USD 1.4 billion for net purchases of marketable securities and commodities; USD 1.3 billion for purchases of property, plant and equipment; and USD 1.3 billion for purchases of intangible assets. These cash outflows were partly offset by cash inflows of USD 0.7 billion from the sale of financial assets (including USD 0.3 billion proceeds from the sale of Alcon Inc. shares) and USD 0.4 billion from the sale of intangible assets. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2019, net cash flows used in investing activities from continuing operations were driven by USD 3.8 billion for acquisitions and divestments of businesses, net (including the acquisition of <i>Xiidra</i> from Takeda Pharmaceutical Company Limited for USD 3.5 billion and the acquisition of IFM Tre, Inc. for USD 0.3 billion); USD 1.4 billion for purchases of property, plant and equipment; USD 0.9 billion for purchases of intangible assets; and USD 0.4 billion for purchases of financial assets and other non-current assets. These cash outflows were partly offset by cash inflows of USD 2.3 billion from the net proceeds from the sale of marketable securities and commodities; USD 0.9 billion from the sale of property, plant and equipment (including the proceeds from the sale and leaseback of real estate); USD 1.2 billion from the sale of financial assets (including USD 1.0 billion proceeds from the sale of Alcon Inc. shares); and USD 1.0 billion from the sale of intangible assets.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net cash flows used in investing activities from discontinued operations amounted to USD 0.1 billion compared to USD 1.2 billion in 2019. The current year includes payments for transaction related expenditures. In 2019, the net outflows were mainly driven by USD 0.3 billion for the acquisition of PowerVision, Inc.; USD 0.6 billion due to derecognized cash and cash equivalents following the completion of the Alcon spin-off, on April 9, 2019; and transaction related expenditures.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net cash flows used in financing activities from continuing operations amounted to USD 2.2 billion, compared to USD 16.9 billion in 2019.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The current year cash outflows were driven by USD 7.0 billion for the dividend payment; USD 2.1 billion for net treasury share transactions; USD 2.0 billion for the repayment of two US dollar bonds at maturity; USD 0.3 billion net payments for lease liabilities; and USD 0.2 billion for other financing cash outflows, net. These cash outflows were partly offset by cash inflows of USD 7.1 billion from the increase in non-current financial debts, mainly consisting of USD 4.9 billion from the issuance of bonds denominated in US dollars (notional amount of USD 5.0 billion) and USD 2.1 billion from the issuance of a sustainability-linked bond denominated in euro (notional amount of EUR 1.85 billion); and USD 2.3 billion from the net increase in current financial debts.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2019, net cash flows used in financing activities from continuing operations were driven by USD 6.6 billion for the dividend payment; USD 5.3 billion for the net treasury share transactions (mainly related to the up-to USD 5 billion share buyback); USD 3.1 billion for net </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">77</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">non-current financial debts (mainly driven by the repayment at maturity of a US dollar bond of USD 3.0 billion); USD 1.6 billion for net repayments of current financial debts; and USD 0.3 billion for payments of lease liabilities, net.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net cash flows used in financing activities from discontinued operations amounted to USD 50 million, compared to a cash inflow of USD 3.3 billion in 2019. The current year cash outflows are for transaction costs. In 2019, cash inflows included mainly proceeds from the USD 3.5 billion Alcon borrowings, partly offset by USD 0.2 billion payments for transaction costs.</div><a name=""></a><div style="padding-top:10px;  padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Free cash flow</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Free cash flow is a non-IFRS measure, see &#x201C;Item 5.A Operating results&mdash;Non-IFRS measures as defined by Novartis&mdash;Free cash flow&#x201D; above for further information. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The following table is a summary of the free cash flow:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&nbsp;152</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;086</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Adjustments for non-cash items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation, amortization and impairments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;129</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;788</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;411</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;871</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 260</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;476</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income adjusted for non-cash items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 17&nbsp;952</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&nbsp;269</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends received from associated companies and others</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 490</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 463</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest and other financial receipts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 511</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 242</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest and other financial payments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;742</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;826</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes paid</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;833</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;876</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments out of provisions and other net cash movements in non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;437</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;924</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in inventory and trade receivables less trade payables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;730</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;809</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other net current assets and other operating cash flow items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 439</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;008</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from operating activities from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;650</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;547</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of property, plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;275</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;379</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of property, plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 88</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 857</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;310</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;878</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 380</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 973</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of financial assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;230</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;302</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of financial assets<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 447</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 176</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of other non-current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;61</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;60</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of other non-current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Free cash flow from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;691</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;937</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Free cash flow from discontinued operations<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;62</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total free cash flow</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;691</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;875</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> For the free cash flow, proceeds from the sale of financial assets excludes the cash inflows from the sale of a portion of the Alcon Inc. shares received by certain consolidated foundations through the Alcon spin-off, which amounted to USD 276 million (2019: USD 976 million). See "Item 18. Financial Statements&#x2013;Note 2. Significant transactions&#x2013;Significant transactions in 2019."</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> In 2019, the free cash flow from discontinued operations was a cash outflow of USD 62 million consisting of USD 78 million net cash inflows from operating activities from discontinued operations, USD 1.2 billion net cash flows used in investing activities from discontinued operations  adjusted by USD 362 million of net cash outflows for acquisition and divestments of businesses and by USD 657 million for cash outflows attributable to the spin-off of the Alcon business.</div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Financial year 2020 compared to 2019</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Free cash flow from continuing operations amounted to USD 11.7 billion (-10%) compared to USD 12.9 billion in 2019, as higher operating income adjusted for non-cash items was more than offset by payments related to legal matters and lower divestment proceeds.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">78</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-top:10px;  padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Condensed consolidated balance sheets</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Dec 31, 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Assets</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&nbsp;263</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;069</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;676</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;677</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29&nbsp;999</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26&nbsp;524</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets other than goodwill</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36&nbsp;809</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28&nbsp;787</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Investments in associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;632</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;644</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;214</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;909</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial assets and other non-current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;793</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;256</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 102&nbsp;386</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 88&nbsp;866</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;131</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;982</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;217</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;301</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current assets and income tax receivable</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;762</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;934</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, commodities, time deposits and derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;905</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 334</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;658</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;112</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Assets of disposal group held for sale</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 841</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&nbsp;673</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 29&nbsp;504</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 132&nbsp;059</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 118&nbsp;370</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Equity and liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 56&nbsp;666</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;551</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&nbsp;259</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20&nbsp;353</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;719</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;703</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;422</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;867</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;934</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;632</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 42&nbsp;334</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;555</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;403</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;424</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debts and derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;785</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;031</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 286</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 246</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other current liabilities and  current income tax liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   17&nbsp;585</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   15&nbsp;532</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities of disposal group held for sale</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33&nbsp;059</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 28&nbsp;264</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 75&nbsp;393</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 62&nbsp;819</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity and liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 132&nbsp;059</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 118&nbsp;370</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As of December 31, 2019, the assets and liabilities of the Sandoz US generic oral solids and dermatology businesses were reported as current assets and liabilities held for sale in the consolidated balance sheet. In March 2020, Novartis decided to retain the Sandoz US generic oral solids and dermatology businesses and, on April 2, 2020, announced the mutual agreement with Aurobindo to terminate the sale agreement. As such, these assets and liabilities are reclassified to their respective consolidated balance sheet lines as from March 31, 2020; the prior year consolidated balance sheet is not restated. For further details see &#x201C;Item 18. Financial Statements&mdash;Note 2. Significant transactions&mdash;Significant transactions in 2020&mdash;Sandoz &ndash; retention of US dermatology business and generic US oral solids portfolio, previously planned to be divested.&#x201D;</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Assets</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Total non-current assets of USD 102.4 billion at December 31, 2020, increased by USD 13.5 billion compared to December 31, 2019. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Intangible assets other than goodwill increased by USD 8.0 billion mainly due to the acquisitions of The Medicines Company and of the Japanese business of Aspen Global Incorporated, net additions, favorable currency translation adjustments and the reclassification of the intangible assets of the disposal group held for sale of USD 0.3 billion, partially offset by amortization and impairments. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Goodwill increased by USD 3.5 billion, and deferred tax assets by USD 0.3 billion, mainly due to the acquisition of The Medicines Company and favorable currency translation adjustments. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Investments in associated companies increased by USD 1.0 billion primarily due to favorable currency trans-</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">79</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">lation adjustments, as income from associated companies was largely offset by dividends received. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Financial and other non-current assets increased by USD 0.5 billion, mainly due to fair value adjustments on financial assets. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Property, plant and equipment increased by USD 0.2 billion, mainly due to net additions and the reclassification of property, plant and equipment of the disposal group held for sale of USD 0.1 billion and favorable currency translation adjustments, partly offset by depreciation and impairments. Right-of-use assets were broadly in line with December 31, 2019. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Total current assets of USD 29.7 billion at December 31, 2020, increased by USD 0.2 billion compared to December 31, 2019. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities, commodities, time deposits, and derivative financial instruments increased by USD 1.6 billion, mainly due to the investment of a portion of the September 16, 2020 issuance of the euro denominated sustainability-linked bond. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Inventories increased by USD 1.1 billion, which includes USD 0.2 billion from the reclassification of the inventory of the disposal group held for sale. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">These increases were partly offset by a decrease in cash and cash equivalents by USD 1.5 billion, and in other current assets by USD 0.2 billion. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Trade receivables and income tax receivables were broadly in line with December 31, 2019.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We consider our provisions for doubtful trade receivables to be adequate. We continue to monitor the level of trade receivables, particularly in Argentina, Brazil, Greece, Italy, Portugal, Russia, Saudi Arabia, Spain and Turkey. Should there be a substantial deterioration in our economic exposure with respect to those countries, we may change the terms of trade on which we operate. The gross trade receivables from these countries at December 31, 2020, amounted to USD&nbsp;1.5 billion (2019: USD&nbsp;1.6 billion), of which USD&nbsp;55 million is past due for more than one year (2019: USD&nbsp;61 million), and for which provisions of USD&nbsp;27 million have been recorded (2019: USD&nbsp;24 million). At December 31, 2020, amounts past due for more than one year were not significant in any of these countries on a standalone basis. The majority of the outstanding trade receivables from Portugal, Saudi Arabia, Spain and Greece are due directly from local governments or government-funded entities.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table provides an overview of the aging analysis of total trade receivables and the total amount of the provision for doubtful trade receivables as of December 31, 2020 and 2019:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not overdue</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;714</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;763</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for not more than one month</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 150</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 161</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one month  but less than three months</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   118</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   123</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than three months  but less than six months</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   102</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   103</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than six months  but less than one year</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   77</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   96</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one year</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 149</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 150</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;93</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;95</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;217</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;301</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There is also a risk that certain countries could devalue their currency. Currency exposures are described in more detail in &#x201C;&mdash;Effects of currency fluctuations.&#x201D;</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Liabilities</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Total non-current liabilities of USD 42.3 billion increased by USD 7.8 billion compared to December 31, 2019. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Non-current financial debts increased by USD 5.9 billion, mainly driven by the issuance of a euro denominated sustainability-linked bond for a notional amount of EUR 1.85 billion (USD 2.2 billion), and the issuance of US dollar denominated bonds for a total notional amount of USD 5.0 billion. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">This increase was partly offset by the reclassification from non-current to current financial debt for a total of USD 2.3 billion consisting of a EUR 1.25 billion (USD 1.5 billion) bond and a EUR 0.6 billion (USD 0.7 billion) bond due in March 2021 and November 2021, respectively. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Deferred tax liabilities increased by USD 1.6 billion mainly due to the acquisition of The Medicines Company. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Provisions and other non-current liabilities increased by USD 0.3 billion, and lease liabilities were broadly in line compared to December 31, 2019.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Total current liabilities of USD 33.1 billion increased by USD 4.8 billion compared to December 31, 2019. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Current financial debts and derivative financial instruments increased by USD 2.8 billion, due to the reclassification from non-current to current financial debt of USD 2.3 billion and higher short-term borrowings, partly offset by the repayment at maturity of two US dollar bonds totaling USD 2.0 billion. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Provisions and other current liabilities increased by USD 1.8 billion mainly due to a USD 1.8 billion treasury share repurchase obligation under a share buyback trading plan and current income tax liabilities increased by USD 0.3 billion. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Trade payables and lease liabilities were broadly in line compared to December 31, 2019.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In our key countries, Switzerland and the United States, assessments have been agreed by the tax authorities up to 2015 in Switzerland and 2014 in the United States, respectively, with the exception of one open United States position related to the 2007 tax filing. In addition, a subsidiary in France, acquired with the AAA acquisition, has an open position related to the tax years 2014 and 2015. Uncertainties also exist on the application of a German non-resident tax regulation for license or capital gains income derived from German registered intellectual property rights.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis believes that its total provisions are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities in this area, Novartis may incur additional costs beyond the amounts provided. Management believes that such additional amounts, if any, would not be material to the Group&#x2019;s financial condition but could be material to the results of operations or cash flows in a given period.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Equity</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s equity increased by USD 1.1 billion to USD 56.7 billion at December 31, 2020 compared to December 31, 2019. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">This increase was mainly due to the net income of USD 8.1 billion, the net effect of the exercise of options </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">80</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">and employee transactions of USD 0.8 billion, equity-based compensation of USD 0.7 billion, favorable currency translation differences of USD 3.2 billion and the net favorable fair value adjustments on financial instruments of USD 0.3 billion. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">This was partly offset by the cash-dividend payment of USD 7.0 billion, purchase of treasury shares of USD 3.1 billion and the increase of the treasury share repurchase obligation of USD 1.8 billion. </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Summary of equity movements attributable to Novartis AG shareholders</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Number of outstanding shares  (in millions)</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity attributable to   Novartis AG shareholders</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020<br> USD millions</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019<br> USD millions</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at beginning of year</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;265.0</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;311.2</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 55&nbsp;474</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 78&nbsp;614</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in accounting policy<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Restated equity at January 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 55&nbsp;474</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 78&nbsp;617</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be canceled</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;32.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;60.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;897</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;351</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;159</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;160</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 806</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 210</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repurchase of options</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;89</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 730</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 833</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees as a result of the Alcon spin-off</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes on treasury share transactions<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;189</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Increase)/decrease of treasury share repurchase  obligation under a share buyback trading plan</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;1&nbsp;769</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   284</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transaction costs, net of taxes<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;253</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6&nbsp;987</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6&nbsp;645</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend in kind to effect the spin-off of Alcon Inc.<sup style="white-space: nowrap">&nbsp;4</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;23&nbsp;434</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income of the year attributable to shareholders of Novartis AG</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;072</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;732</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other comprehensive income attributable to shareholders of Novartis AG</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;331</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;207</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements<sup style="white-space: nowrap">&nbsp;5</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at end of year</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;256.8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;265.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 56&nbsp;598</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;474</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> In 2019, the impact of change in accounting policy includes USD 3 million related to the implementation of IFRS 16 Leases (see &#x201C;Item 18. Financial Statements&#x2014;Note 1. Significant accounting policies").</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Included in 2019 is a USD 69 million impact related to the revaluation of deferred tax liability on treasury shares. This revaluation resulted from the Swiss federal tax reform enacted in May 2019 (see &#x201C;Item 18. Financial Statements&#x2014;Note 12. Deferred tax assets and liabilities").</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> In 2019 transaction costs, net of tax of USD 36 million, directly attributable to the distribution (spin-off) of Alcon to Novartis shareholders (see &#x201C;Item 18. Financial Statements&#x2014;Note 1. Significant accounting policies").</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> Included in 2019 is the fair value of the dividend in kind of Alcon Inc. shares to Novartis AG shareholders and ADR (American Depositary Receipt) holders approved at the 2019 Annual General Meeting held on February 28, 2019. Distribution was effected on April 8, 2019, whereby each Novartis AG shareholder and ADR holder received one Alcon Inc. share for every five Novartis AG shares/ADRs they held on April 8, 2019, close of business (see &#x201C;Item 18. Financial Statements&#x2014;Note 1. Significant accounting policies").</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;5&nbsp;</sup> Impact of hyperinflationary economies (see &#x201C;Item 18. Financial Statements&#x2014;Note 1. Significant accounting policies").</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2020, Novartis repurchased a total of 32.6 million shares for USD 2.9 billion on the SIX Swiss Exchange second trading line, including 8.0 million shares (USD 0.7 billion) bought back under the up-to USD 2.5 billion share buyback announced in November 2020, and 24.6 million shares (USD 2.2 billion) to mitigate dilution related to participation plans of associates. In addition, 1.7 million shares (USD 0.2 billion) were repurchased from associates. In the same period, 26.1 million shares (for an equity value of USD 1.5 billion) were delivered as a result of options exercised and share deliveries related to participation plans of associates. Consequently, the total number of shares outstanding decreased by 8.2 million versus December 31, 2019. These treasury share transactions resulted in a decrease in equity of USD 1.6 billion and a net cash outflow of USD 2.1 billion including the benefit from net option proceeds.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2019, Novartis repurchased a total of 60.3 million shares for USD&nbsp;5.4 billion on the SIX Swiss Exchange second trading line, including 46.5 million shares (USD&nbsp;4.2 billion) bought back under the up-to USD&nbsp;5 billion share buyback announced in June 2018, and 13.8 million shares (USD&nbsp;1.1 billion) to mitigate dilution related to participation plans of associates. In addition, 1.7 million shares (USD&nbsp;0.2 billion) were repurchased from associates. In the same period, 15.8 million shares (for an equity value of USD&nbsp;1.1 billion) were delivered as a result of options exercised and share deliveries related to participation plans of associates. Consequently, the total number of shares outstanding decreased by 46.2 million versus December 31, 2018. These treasury share transactions resulted in a decrease in equity of USD&nbsp;4.5 billion and a net cash outflow of USD&nbsp;5.3 billion. </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Treasury shares</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At December 31, 2020, our holding of treasury shares amounted to 210.2 million shares, or approximately 9% of the total number of issued shares. Approximately 103 </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">81</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">million treasury shares were held in entities that restrict their availability for use.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">At December 31, 2019, our holding of treasury shares amounted to 262.3 million shares, or approximately 10% of the total number of issued shares. Approximately 118 million treasury shares were held in entities that restrict their availability for use.</div><a name=""></a><div style="padding-top:10px;  padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Effects of currency fluctuations</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">We transact our business in many currencies other than the US dollar, our reporting currency.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The following table provides an overview of net sales and operating expenses for our continuing operations based on IFRS values for 2020 and 2019, for currencies most important to the Group:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>Currency</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Net sales<br> %</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Operating<br> expenses<br> %<sup style="white-space: nowrap">   1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Net sales<br> %</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Operating<br> expenses<br> %<sup style="white-space: nowrap">   1</sup></div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 36</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chinese yuan (CNY)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canadian dollar (CAD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">British pound (GBP)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Brazilian real (BRL)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Russian ruble (RUB)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Australian dollar (AUD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other currencies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Operating expenses include cost of goods sold; selling, general and administration; research and development; other income and other expense.</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We prepare our consolidated financial statements in US dollars. As a result, fluctuations in the exchange rates between the US dollar and other currencies can have a significant effect on both the Group&#x2019;s results of operations as well as the reported value of our assets, liabilities and cash flows. This in turn may significantly affect reported earnings (both positively and negatively) and the comparability of period-to-period results of operations.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For purposes of our consolidated balance sheets, we translate assets and liabilities denominated in other currencies into US dollars at the prevailing market exchange rates as of the relevant balance sheet date. For purposes of the Group&#x2019;s consolidated income and cash flow statements, revenue, expense and cash flow items in local currencies are translated into US dollars at average exchange rates prevailing during the relevant period. As a result, even if the amounts or values of these items remain unchanged in the respective local currency, changes in exchange rates have an impact on the amounts or values of these items in our consolidated financial statements.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Because our expenditure in Swiss francs is significantly higher than our revenue in Swiss francs, volatility in the value of the Swiss franc can have a significant impact on the reported value of our earnings, assets and liabilities, and the timing and extent of such volatility can be difficult to predict. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There is also a risk that certain countries could devalue their currency. If this occurs, it could impact the effective prices we would be able to charge for our products and also have an adverse impact on both our consolidated income statement and balance sheet. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Subsidiaries whose functional currencies have experienced a cumulative inflation rate of more than 100% over the past three years apply the rules of IAS 29 &#x201C;Financial Reporting in Hyperinflationary Economies.&#x201D; Gains and losses incurred upon adjusting the carrying amounts of non-monetary assets and liabilities for inflation are recognized in the income statement. The hyperinflationary economies in which Novartis operates are Argentina and Venezuela. Venezuela was hyperinflationary for all years presented, and Argentina became hyperinflationary effective July 1, 2018, requiring retroactive implementation of hyperinflation accounting as of January 1, 2018. The impacts from applying IAS 29 were not significant.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group manages its global currency exposure by engaging in hedging transactions where management deems appropriate, after taking into account the natural hedging afforded by our global business activity. For 2020, we entered into various contracts that change in value with movements in foreign exchange rates, to preserve the value of assets, commitments and expected transactions. We use forward contracts and foreign currency options to hedge. For more information on how these transactions affect our consolidated financial statements and on how foreign exchange rate exposure is managed, see &#x201C;Item 18. Financial Statements&mdash;Note 1. Significant accounting policies,&#x201D; &#x201C;Item 18. Financial Statements&mdash;Note 5. Interest expense and other financial income and expense,&#x201D; &#x201C;Item 18. Financial Statements&mdash;Note 15. Trade receivables,&#x201D; &#x201C;Item 18. Financial Statements&mdash;Note 28. Commitments and contingencies&#x201D; and &#x201C;Item 18. Financial Statements&mdash;Note 29. Financial instruments &ndash; additional disclosures.&#x201D;</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">82</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table sets forth the foreign exchange rates of the US dollar against key currencies used for foreign currency translation when preparing the Group&#x2019;s consolidated financial statements:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Average for year</div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Year-end</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">USD per unit</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in %</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in %</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Australian dollar (AUD)</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.690</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.695</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.771</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.701</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Brazilian real (BRL)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.196</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.254</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.193</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.249</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;22</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canadian dollar (CAD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.746</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.754</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.784</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.767</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.066</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.006</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.135</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.032</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chinese yuan (CNY)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.145</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.145</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.153</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.144</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.141</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.120</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.229</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.121</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">British pound (GBP)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.283</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.277</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.365</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.313</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY (100))</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.937</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.918</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.970</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.920</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Russian ruble (RUB (100))</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.389</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.546</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.337</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.613</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;17</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides a summary of the currency impact on key Group figures due to their conversion into US dollars, the Group&#x2019;s reporting currency, of the financial data from entities reporting in non-US dollars. Constant currency (cc) calculations apply the exchange rates of the prior year to the current-year financial data for entities reporting in non-US dollars.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Currency impact on key figures</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Change in<br> USD %<br> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br>  constant<br>  currencies %<br> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Percentage<br> point currency<br>  impact<br> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Change in<br> USD %<br> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change in<br>  constant<br>  currencies %<br> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Percentage<br> point currency<br>  impact<br> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Group - Continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net sales to third parties</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;44</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;41</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basic earnings per share (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;43</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;40</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core basic earnings per share (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net sales to third parties</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net sales to third parties</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 89</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 106</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;59</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;53</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Corporate</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Operating loss</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating loss</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For additional information on the effects of currency fluctuations, see &#x201C;Item 18. Financial Statements&mdash;Note 29. Financial instruments &ndash; additional disclosures.&#x201D;</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">83</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-top:10px;  padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Group liquidity, financial debts and net debt</font>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows Group liquidity, financial debts and net debt:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current financial debts</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;26&nbsp;259</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;20&nbsp;353</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current financial debts  and derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     &#x2013;&#x2005;9&nbsp;785</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2013;&#x2005;7&nbsp;031</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial debts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;36&nbsp;044</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;27&nbsp;384</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less liquidity</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;658</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;112</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities,  commodities, time deposits  and derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       1&nbsp;905</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">       334</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liquidity</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;563</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;446</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt at December 31<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;24&nbsp;481</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;15&nbsp;938</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> For further information about the net debt measure, which is a non-IFRS measure, see &#x201C;Item 5.A Operating results&#x2014;Non-IFRS measures as defined by Novartis&#x2014;Net debt&#x201D;.</div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Financial year 2020</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Group net debt at December 31, 2020, increased to USD&nbsp;24.5 billion, compared to USD&nbsp;15.9 billion at December 31, 2019.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Total financial debts increased by USD 8.7 billion to USD 36.0 billion at December 31, 2020. Non-current financial debts increased by USD 5.9 billion, mainly driven by the issuance of a euro denominated sustainability-linked bond for a notional amount of EUR 1.85 billion (USD 2.2 billion), and the issuance of US dollar denominated bonds for a total notional amount of USD 5.0 billion. This increase was partly offset by the reclassification from non-current to current financial debt for a total of USD 2.3 billion consisting of a EUR 1.25 billion (USD 1.5 billion) bond and a EUR 0.6 billion (USD 0.7 billion) bond due in March 2021 and November 2021, respectively.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Current financial debts and derivative financial instruments increased by USD 2.8 billion, due to the reclassification from non-current to current financial debt of USD 2.3 billion and higher short-term borrowings, partly offset by the repayment at maturity of two US dollar bonds totaling USD 2.0 billion.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis has two US commercial paper programs under which it can issue up to USD 9.0 billion in the aggregate of unsecured commercial paper notes. Novartis also has a Japanese commercial paper program under which it can issue up to JPY 150 billion (approximately USD 1.5 billion) of unsecured commercial paper notes. Commercial paper notes totaling USD 4.3 billion under these three programs were outstanding as per December 31, 2020 (2019: USD 2.3 billion).</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis also has a committed credit facility of USD&nbsp;6.0 billion, which was renewed in 2019. This credit facility is provided by a syndicate of banks and is intended to be used as a backstop for the US commercial paper programs. The renewed facility matures in September 2024 and was undrawn as per December 31, 2020, and December 31, 2019.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of year-end 2020, Moody&#x2019;s Investors Service rated the Company A1 for long-term maturities and P-1 for short-term maturities and S&amp;P Global Ratings rated the company AA- for long-term maturities and A-1+ for short-term maturities.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For the tables showing the maturity schedule of our current financial assets, current and non-current financial debts and net debt at December 31, 2020 and December 31, 2019 see &#x201C;Item 18. Financial Statements&ndash;Note 29. Financial instruments &ndash; Additional disclosures&mdash;Nature and extent of risks arising from financial instruments&mdash;Liquidity risk.&#x201D;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For a description of risks and restrictions on the ability of subsidiaries to transfer funds to the Company via cash dividends, loan or advances please see &#x201C;Item 5.B Liquidity and capital resources&mdash;Group liquidity, financial debts and net debt&ndash;Liquidity/short-term funding&#x201D; and &#x201C;Item 18. Financial Statements&mdash;Note 29. Financial instruments &ndash; Additional disclosures&mdash;Nature and extent of risks arising from financial instruments.&#x201D; </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Information regarding the Company&#x2019;s material commitments for capital expenditures as of the end of 2020 and 2019 and an indication of the general purpose of such commitments and the anticipated sources of funds needed to fulfill such commitments are provided in &#x201C;Item 5.F Tabular disclosure of contractual obligations.&#x201D;</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">84</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Liquidity and financial debt by currency</font>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides a breakdown of liquidity and financial debt by currency as of December 31:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Liquidity<br> in % 2020<sup style="white-space: nowrap">   1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Liquidity<br> in % 2019<sup style="white-space: nowrap">   1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Financial<br> debt in %<br> 2020<sup style="white-space: nowrap">   2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Financial<br> debt in %<br> 2019<sup style="white-space: nowrap">   2</sup></div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USD</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 72</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 55</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">EUR</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 29</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">JPY</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Liquidity includes cash and cash equivalents, marketable securities, commodities and time deposits.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Financial debt includes non-current and current financial debt.</div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Bonds </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In February 2020, a 3-year USD bond of USD 1.0 billion with a coupon of 1.80% was repaid at maturity.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In February 2020, four US dollar bonds totaling USD 5.0 billion were issued: a 5-year bond of USD 1.0 billion with a coupon of 1.75%, a 7-year bond of USD 1.25 billion with a coupon of 2.00%, a 10-year bond of USD 1.5 billion with a coupon of 2.20%, and a 30-year bond of USD 1.25 billion with a coupon of 2.75%.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In April 2020, a 10-year USD bond of USD 1.0 billion with a coupon of 4.40% was repaid at maturity.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In September 2020, an 8-year euro sustainability-linked bond of EUR 1.85 billion with a coupon of 0.00% was issued.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In February 2019, a 10-year USD bond of USD 3.0 billion with a coupon of 5.125% was repaid at maturity.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Liquidity/short-term funding</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s liquidity amounted to USD 11.6 billion at December 31, 2020, compared to USD 11.4 billion at December 31, 2019. Total non-current and current financial debts, including derivatives, amounted to USD 36.0 billion at December 31, 2020, compared to USD 27.4 billion at December 31, 2019. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The debt/equity ratio increased to 0.64:1 at December 31, 2020, compared to 0.49:1 at December 31, 2019. The net debt increased to USD 24.5 billion at December 31, 2020, compared to USD 15.9 billion at December 31, 2019.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We continuously track our liquidity position and asset/liability profile. This involves modeling cash flow maturity profiles based on both historical experiences and contractual expectations to project our liquidity requirements. We seek to preserve prudent liquidity and funding capabilities. We are confident that we have sufficient liquidity to support our normal business activities for the foreseeable future.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Certain countries have legal or economic restrictions on the ability of subsidiaries to transfer funds to the Group in the form of cash dividends, loans or advances, but these restrictions do not have an impact on the ability of the Group to meet its cash obligations. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We are not aware of any significant demands to change the level of liquidity needed to support our normal business activities. We make use of various borrowing facilities provided by several financial institutions. We also successfully issued various bonds in previous years (including 2018), and raised funds through our commercial paper programs.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The maturity schedule of our net debt can be found in &#x201C;Item 18. Financial Statements&ndash;Note 29. Financial instruments &ndash;Additional disclosures&mdash;Nature and extent of risks arising from financial instruments&mdash;Liquidity risk.&#x201D;</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">85</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId0010054465"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">5.C Research and development, patents and licenses</p>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our research and development spending from continuing operations totaled USD&nbsp;9.0 billion and USD&nbsp;9.4 billion (Core research and development USD&nbsp;8.5 billion and USD&nbsp;8.4 billion) for the years 2020 and 2019, respectively. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Each of our divisions has its own research and development and patent policies. Our divisions have numerous products in various stages of development. For further information on these policies and these products in development, see &#x201C;Item 4. Information on the Company&mdash;Item 4.B Business overview.&#x201D;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As described in the risk factors section and elsewhere in this Annual Report, our drug development efforts are subject to the risks and uncertainties inherent in any new drug development program. Due to the risks and uncertainties involved in progressing through preclinical development and clinical trials, and the time and cost involved in obtaining regulatory approvals, among other factors, we cannot reasonably estimate the timing, completion dates and costs, or range of costs, of our drug development programs, or of the development of any particular development compound (see &#x201C;Item 3. Key Information&mdash;Item 3.D Risk factors&#x201D;). In addition, for a description of the research and development process for the development of new drugs and our other products, and the regulatory process for their approval, see &#x201C;Item 4. Information on the Company&mdash;Item 4.B Business overview.&#x201D;</div><a name="anchorId0010054484"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">5.D Trend information</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Please see &#x201C;&mdash;Item 5.A Operating results&#x201D;, &#x201C;&mdash;Item 5.B Liquidity and capital resources&#x201D; and &#x201C;Item 4. Information on the Company&mdash;Item 4.B Business overview&#x201D; for trend information.</div><a name="anchorId0010054491"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">5.E Off-balance sheet arrangements</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We have no unconsolidated special purpose financing or partnership entities or other off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources, that is material to investors. See also &#x201C;Item 18. Financial Statements&mdash;Note 28. Commitments and contingencies,&#x201D; and matters described in &#x201C;&mdash; Item 5.F Tabular disclosure of contractual obligations.&#x201D;</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">86</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId0010054501"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">5.F Tabular disclosure of contractual obligations</p>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the Group&#x2019;s contractual obligations and other commercial commitments, as well as the effect these obligations and commitments are expected to have on the Group&#x2019;s liquidity and cash flow in future periods:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="9" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Payments due by period</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="9" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="9" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Total</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Less than<br> 1 year</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> 2&#x2013;3 years</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> 4&#x2013;5 years</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> After<br> 5 years</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current financial debt, including current portion</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28&nbsp;531</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;272</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;177</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;444</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&nbsp;638</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest on non-current financial debt, including current portion</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;647</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 550</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;014</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 832</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;251</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities, non-current and current portion</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;005</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 286</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 415</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 277</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;027</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest on lease liabilities, non-current and current portion</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;502</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 52</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 85</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 66</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;299</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Unfunded pensions and other post-employment benefit plans</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;760</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 93</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 190</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 191</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;286</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development potential milestone commitments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;232</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 449</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;016</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 764</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;003</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;046</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 62</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 327</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 312</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 345</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment purchase commitments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 256</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 223</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquisition of business commitments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 235</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 210</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development commitments on transactions  entered into but not closed in 2020<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   3&nbsp;296</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   549</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   408</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   930</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   1&nbsp;409</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total contractual cash obligations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 50&nbsp;510</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;746</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;668</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;816</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28&nbsp;280</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> For research and development commitments on transactions entered into but not closed in 2020, please refer to &#x201C;Item 18. Financial Statements &#x2013; Note 28 Commitments and contingencies &#x2013; research and development commitments&#x201D;.</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group intends to fund the research and development; property, plant and equipment; intangible asset purchase commitments with internally generated resources, and the acquisition of business commitment through available cash and short- and long-term borrowings. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For other contingencies, see &#x201C;Item 8. Financial Information&mdash;Item 8.A Consolidated statements and other financial information,&#x201D; &#x201C;Item 18. Financial Statements &mdash; Note 10. Right-of-use assets and lease liabilities,&#x201D; &#x201C;Item 18. Financial Statements&mdash;Note 20. Provisions and other non-current liabilities,&#x201D; and &#x201C;Item 18. Financial Statements&mdash;Note 28. Commitments and contingencies.&#x201D;</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">87</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>


    <a name="anchorId00437515"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item 6.  Directors, Senior Management and Employees</p><a name="anchorId00437517"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">6.A Directors and senior management</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The information set forth under &#x201C;Item 6. Directors, Senior Management and Employees&#x2014;Item 6.C Board practices&#x2014;Corporate governance&#x2014;Board of Directors&#x201D; and &#x201C;Item 6. Directors, Senior Management and Employees&#x2014;Item 6.C Board practices&#x2014;Corporate governance&#x2014;Executive Committee&#x201D; is incorporated by reference. </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">88</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>




<a name="anchorId00937732"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">6.B Compensation</p><a name=""></a><div style="padding-top:10px;  padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Dear shareholder, </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">I am pleased to share with you the 2020 Compensation Report of Novartis AG. It follows a similar structure to the previous year&#x2019;s report, which was supported by over 92% of shareholders.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">From the 2020 Annual General Meeting (AGM), we welcomed new member Bridgette Heller and permanent guest Simon Moroney to the Compensation Committee. I have been grateful for their contributions during the year. In addition, I would like to express my sincere gratitude to Srikant Datar, who will step down from the Compensation Committee at the 2021 AGM, for his valuable engagement throughout his tenure with the Committee.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Feedback from shareholders prior to our last AGM and, more recently, toward the end of 2020 suggested that shareholders were in agreement that our current compensation system is aligned with the Company&#x2019;s purpose, strategy and culture. No changes are therefore proposed for 2021. </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">COVID-19 pandemic</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2020, Novartis navigated the pandemic well. We increased our focus on associates&#x2019; health and well-being by implementing a number of support programs, including additional paid leave, childcare assistance during school closures, a one-time payment for home office setup, a new flexible working scheme within the country of employment, and a one-time payment to associates and external contractors required to work on site (i.e., in our laboratories or our manufacturing units). No government assistance (e.g., subsidies, furloughs) was sought by the Company, and no COVID-19-related associate redundancies were made. Through these actions, we were able to minimize the disruption to our business operations and consequently were in a position to commit to making no changes to our dividend policy for 2021.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To help tackle the issues caused by the pandemic directly, Novartis made a number of commitments, collaborating with healthcare peers and other organizations on anti-COVID-19 programs, including the rollout of treatments to the developing world. More information on Novartis response efforts can be found in our Novartis in Society ESG Report 2020.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2020 Company performance</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Financial performance in 2020 was solid despite the impact of the global pandemic. Net sales to third parties for Novartis continuing operations grew 3% in reported terms and 3% measured in constant currencies (cc), which removes the impact of exchange rate movements. Growth was mainly driven by <i>Cosentyx</i> (USD 4.0 billion in sales), <i>Entresto</i> (USD 2.5 billion), <i>Promacta/Revolade</i> (USD 1.7 billion), and <i>Zolgensma</i> (USD 0.9 billion). Other recently launched products, including <i>Kisqali</i>, <i>Piqray</i> and <i>Kymriah</i>, also contributed. However, this was below our ambitious net sales plan, as COVID-19 weighed on certain therapeutic areas, most notably dermatology and ophthalmology, and the Sandoz Retail Generics business. The safety updates on <i>Beovu</i> also impacted the business.  </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Operating income grew 19% versus the prior year (cc), and net income grew 20% versus the prior year (cc). Core operating income grew 13% versus the prior year (cc), exceeding the target, driven by improved productivity in marketing and sales as well as research and development, and Novartis Technical Operations (NTO) network transformation initiatives. Core operating income margin increased to 31.7% (+2.8 percentage points cc versus the prior year, and +1.5 percentage points cc versus target), with Innovative Medicines core margin reaching 35%. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Free cash flow amounted to USD 11.7 billion. The target, as a percentage of sales, was slightly overachieved due to continued strong cash collection despite higher legal fee payouts.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Financial performance determines 60% of the CEO&#x2019;s Annual Incentive balanced scorecard. Targets for the financial measures were set at the start of the year, and the Compensation Committee determined that it would not adjust or apply upwards discretion to reflect the negative impact of the pandemic or settlements of legacy legal cases. Overall, our aforementioned performance resulted in achievement meeting target for this element of the Annual Incentive.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Strategic objectives determine the remaining 40% of the CEO&#x2019;s Annual Incentive balanced scorecard. Progress against these objectives resulted in achievement meeting target for this element of the CEO&#x2019;s Annual Incentive. More details on our strategic objectives as well as our financial performance can be found in &#x201C;&mdash;2020 CEO balanced scorecard.&#x201D;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Two of the five strategic objectives in the CEO&#x2019;s Annual Incentive balanced scorecard relate to environmental, social and governance (ESG) matters: &#x201C;people and culture&#x201D; and &#x201C;building trust with society.&#x201D; We continue to integrate ESG, a priority for the Novartis Board of Directors and the Executive Committee, across our operations. Novartis focuses on four strategic ESG pillars: ethical standards, pricing and access, global health challenges and corporate citizenship. In addition to the COVID-19-related efforts previously mentioned, particular achievements in 2020 included:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Setting ambitious long-term environmental targets for our entire supply chain </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Increasing our patient reach in low- and middle-income countries with emerging market brands and flagship programs (i.e., Chagas disease, leprosy, malaria and sickle cell disease)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Continuing to make great progress on our diversity and inclusion strategy related to gender balance, LGBTI equity, disability equity, and race and ethnicity </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Issuing a sustainability-linked bond, the first of its kind in the healthcare industry</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Launching our new Code of Ethics</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">89</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Significant upgrades from ESG rating agencies such as MSCI and Sustainalytics in the latest reporting season were based on closing compliance-related allegations; strong governance, including extensive ethics policies; leading programs to expand access to healthcare for low-income populations; and a comprehensive employee engagement strategy relative to peers. </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2020 realized compensation</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Based on the overall balanced scorecard assessment meeting target, the Board of Directors decided on an Annual Incentive resulting in a payout for the CEO amounting to CHF 2 636 550, which is 100% of target, within the range of 0&ndash;200%.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The 2018-2020 Long-Term Incentive (LTI) plans comprise the Long-Term Performance Plan (LTPP) and the Long-Term Relative Performance Plan (LTRPP). The 2018-2020 LTPP delivered strong results. The Cash Value Added target &ndash; which has continued to increase for the last three cycles &ndash; was exceeded, and innovation was above target. For the 2018-2020 LTRPP, Novartis was above median, ranking 7 out of a total of 15 global healthcare peers (including Novartis) on three-year relative total shareholder return (TSR). Overall, when considering both plans, the Board of Directors awarded the CEO a total LTI payout of CHF 8 054 923, corresponding to a 126% payout against a maximum of 200%. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">No Annual Incentive or LTI targets were adjusted as a result of the pandemic. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Board determined that no adjustments were required to the incentive payouts, notwithstanding the Company&#x2019;s supportive treatment of associates and ability to adapt to new ways of working throughout the pandemic, without government assistance or making any COVID-19-related redundancies. In addition, Novartis is committing to a 2021 dividend to shareholders, in line with its policy.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">These incentive performance outcomes, combined with base salary and other benefits, pension, Alcon   Keep Whole awards and dividend equivalents, resulted in 2020 total realized compensation for the CEO of CHF&nbsp;12&nbsp;724&nbsp;166.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The higher total realized compensation for the CEO compared to 2019 can be attributed to the vesting of his first LTI granted after his promotion to CEO in 2018.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The 2020 total realized compensation for the Executive Committee members (comprising the CEO and the other 12 active Executive Committee members) was CHF&nbsp;58 819 813. This is lower than the prior year due to the reduction in members reported (two members stepped down and were replaced in 2019, whereas no members stepped down in 2020). For more detail on the 2020 realized pay for the CEO and ECN members, please see &#x201C;&mdash;2020 realized compensation for the CEO and other Executive Committee members.&#x201D;</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Board compensation </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2020, the Compensation Committee reviewed, with its independent advisor, the Board of Directors&#x2019; compensation system against the Swiss Market Index. Additional information on our Board benchmarking practices is  provided in &#x201C;&mdash;2020 Board compensation.&#x201D; </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">They found that the Chairman and retainer fees of the other Board members are well positioned and competitive among the benchmarked companies in relation to the Company&#x2019;s size, operational complexity and corporate headquarters location. The Compensation Committee therefore proposed no changes to the Board of Directors&#x2019; fees for the 2021-2022 AGM.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2021 AGM</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In line with our Articles of Incorporation, at the 2021 AGM, shareholders will be asked to approve, in a binding vote, the maximum aggregate amount of compensation for the Board of Directors from the 2021 AGM to the 2022 AGM, and the maximum aggregate amount of compensation for the Executive Committee for the financial year 2022. Shareholders will also be asked to endorse this Compensation Report in an advisory vote.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">This will be my last year as Chairman of the Compensation Committee of the Board of Directors, and I would like to thank you all for your support throughout my nine-year tenure. I will stand for election as a member of our Compensation Committee at the 2021 AGM to ensure a smooth transition to my successor. We will also ask shareholders to elect Simon Moroney to the Compensation Committee and, if support is received, the Board of Directors will then appoint him as the new Chairman of the Compensation Committee.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">On behalf of Novartis and the Compensation Committee, I would like to thank you for your continued engagement and feedback, which we consider extremely valuable in driving improvements in our compensation systems and practices. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Respectfully,</div>
<div style="padding-top:15px"><img src="comp_0001.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><b>Enrico Vanni, Ph.D.</b></div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Chairman of the Compensation Committee</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">90</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00937881"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Compensation&nbsp;at&nbsp;a&nbsp;glance</p><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Executive Committee compensation system </font>
</div>
<div style="padding-top:15px"><img src="comp_0003.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">2020 fixed pay and benefitsAnnual base salaryPension and other benefitsPerformance-related variable pay2020 Annual IncentiveLong-Term Incentive awards cycle 2018-2020LTPP1LTRPP2PurposeReflects responsibilities, experience and skill setsProvides retirement and risk insurances (tailored to local market practices/regulations)Rewards for performance against short-term financial and strategic objectives, and Values and BehaviorsRewards long-term shareholder value creation and innovation in line with our strategyForm of paymentCashCountry/individual-specific and aligned with other employees50% cash50% equity3 deferredfor three yearsEquity, vesting following a three-year performance periodPerformance measuresBalanced scorecard comprising:&#x2022;Financial measures (60%)&#x2022;Strategic objectives4 (40%)&#x2022;Novartis Cash Value Added (75%)&#x2022;Innovation milestones (25%)&#x2022;Relative TSR versus global sector peers (100%)51LTPP = Long-Term Performance Plan 2LTRPP = Long-Term Relative Performance Plan3Executive Committee members may elect to receive more of their Annual Incentive in equity instead of cash.4  Strategic objectives are aligned with the five strategic pillars: innovation, operational excellence, data and digital, people and culture, and building trust with society.5  For the 2018-2020 performance cycle, the peer group comprises 15 global healthcare companies, including Novartis, as listed in &#x201C;Approach to market benchmarking.&#x201D;  </div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Target incentive opportunity levels for the CEO are 150% and 325% of base salary for the Annual Incentive and LTI, respectively. Based on Novartis compensation guidelines, the other members of the Executive Committee have Annual Incentive and LTI target opportunity levels that range from 80% to 120%, and 160% to 270% of base salary, respectively. The payout range remains at 0% to 200% of target opportunity based on achievement against performance.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">&nbsp;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The 2018-2020 cycle will be the last vesting of the LTRPP plan, which was discontinued as of grants made in 2019. The LTPP metrics were subsequently transformed into four equally weighted measures: net sales compound annual growth rate, core operating income compound annual growth rate, innovation and relative TSR.  </div><a name=""></a><div style="border-top: 1px solid black; margin: 10px 0; line-height: 20px; padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Compensation governance at&nbsp;a&nbsp;glance</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">A summary of the compensation decision authorization levels within the parameters set by the AGM is shown below, along with an overview of the risk management principles.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;">Decision on</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;"> Decision-making authority</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Compensation of Chairman and other Board members</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Board of Directors</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Compensation of CEO</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Board of Directors</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Compensation of other Executive Committee members</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Compensation Committee</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:8pt; font-weight:bold; color:#0070f7; text-transform:uppercase;">Executive Committee compensation risk management principles<div style="border:none;border-bottom:solid 1px; padding: 0 0 0 0"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Rigorous performance management process</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Balanced mix of short-term and long-term variable compensation elements</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Performance evaluation under the Annual Incentive includes an individual balanced scorecard</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Performance-based LTI, with three-year cycles </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; All variable compensation is capped at 200% of target</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Contractual notice period of 12 months</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Post-contractual non-compete period limited to a maximum of 12 months from the end of employment. Resulting compensation is limited to the annual base salary plus the prior-year Annual Incentive as per contract, if applicable</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Good and bad leaver provisions apply to the variable compensation of leavers</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; No severance payments or change-of-control clauses</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Clawback and malus principles apply to all elements of variable compensation</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Share ownership requirements; no hedging or pledging of Novartis share ownership position</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">91</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">2020 CEO pay for performance &ndash; outcomes </font>
</div>
<div style="padding-top:15px"><img src="comp_0024.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">MeasureTarget1Achievement versus target2020 Annual Incentive (see &#x201C;2020 annual incentive&#x201D;)Financial measures  60% of total Annual Incentive, comprising:Group net sales (cc) (30%)USD 50 781 millionBelowGroup operating income (cc) (30%)USD 9 745 millionSignificantly above Group free cash flow as a % of sales (cc) (20%)24.3%Above Share of peers for Novartis Group (USD) (20%)8.3%MetOverall assessment of Group financial targets in constant currenciesMet1For performance evaluation purposes, target as well as actual financial KPIs included the results of the Sandoz US dermatology business and generic oral solids portfolio, which were expected to be divested to Aurobindo Pharma USA Inc. This deal was later terminated by mutual agreement with Aurobindo.Strategic objectives  40% of total Annual Incentive, comprising:Innovation (20%)MetOperational excellence (20%)MetData and digital (20%)MetPeople and culture (including Values and Behaviors) (20%)Met Building trust with society (including access to healthcare, reputation and other ESG topics) (20%)Significantly aboveOverall assessment of strategic objectivesMetOverall assessment of CEO balanced scorecardMetTOTAL Annual Incentive:100% of target (payout range 0% 200%) 2018-2020 Long-Term Incentives (see &#x201C; Long-Term Incentive plans, 2018-2020 cycle&#x201D;)Long-Term Performance Plan (LTPP)Novartis Cash Value Added (cc) (75%)USD 8.3 billionAboveKey innovation milestones (25%)AboveTOTAL LTPP1: 143% of target (payout range 0%  200%)Long-Term Relative Performance Plan (LTRPP)Relative TSR against a global healthcare peer group (USD)Above medianTOTAL LTRPP1: 100% of target (payout range 0%  200%)1Combined LTI payout is 126% of target. </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">2020 total realized compensation for the CEO</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The 2020 total realized compensation for the CEO was CHF 12 724 166. It includes payouts of the Annual Incentive, LTPP and LTRPP based on actual performance assessed for cycles concluding in 2020. More information on the overall assessment of the CEO by the Board of Directors can be found in &#x201C;&mdash;2020 CEO balanced scorecard.&#x201D;</div>
<div style="padding-top:15px"><img src="comp_0027.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">CHFAnnual basesalaryPension and otherbenefits2020 Annual IncentiveLTPP 2018-2020 cycle<sup>1</sup>LTRPP 2018-2020 cycle<sup>1</sup>Total realized compensationVasant Narasimhan(CEO)1743750288943263655056051002449823127241661The shown amounts represent the underlying share value of the total number of shares vested (including Alcon Keep Whole awards of CHF 784 497 as well as dividend equivalents of CHF 660 900) to the CEO for the LTPP and LTRPP performance cycle 2018-2020.</div>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">92</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">2020 Board compensation system </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The compensation system applicable to the Board of Directors is shown below and remains unchanged since the prior year. All fees to the Board members are delivered at least 50% in shares and the remainder in cash. </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; font-style:italic; color:#000000;"><br>CHF 000s</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> AGM 2020-2021<br> annual fee</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chairman of the Board</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;800</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Board membership</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 280</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vice Chairman</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chair of the Audit and Compliance Committee</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 130</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chair of the Compensation Committee</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 90</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chair of the following committees:<br> &#x2022; Governance, Nomination and Corporate Responsibilities Committee<br> &#x2022; Science &amp; Technology Committee<br> &#x2022; Risk Committee</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  <br>  70</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Membership of the Audit and Compliance Committee</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Membership of the following committees:<br> &#x2022; Compensation Committee<br> &#x2022; Governance, Nomination and Corporate Responsibilities Committee<br> &#x2022; Science &amp; Technology Committee<br> &#x2022; Risk Committee</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  <br>  <br>  40</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
  </table>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">2020 Board compensation </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Total actual compensation earned by Board members in the 2020 financial year is shown in the table below.</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>CHF 000s</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2020<br> total compensation<sup style="white-space: nowrap">  1</sup></div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chairman of the Board</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 805</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other 13 members of the Board</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4 925</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8 729</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="4">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="4">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Includes an amount of CHF 26 118 for mandatory employer contributions for all Board members paid by Novartis to governmental social security systems. This amount is out of total employer contributions of CHF 430 023 , and provides a right to the maximum future insured government pension benefit for the Board member.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">93</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div><a name="anchorId00938289"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Executive Committee compensation&nbsp;philosophy and principles</p><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Novartis compensation philosophy</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our compensation philosophy aims to ensure that we attract and retain outstanding Executive Committee members and that they are rewarded according to their success in implementing the Company strategy, and their contribution to Company performance and long-term value creation.  </div>
<div style="padding-top:15px"><img src="comp_0006.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Pay for performance&#x2022;Variable compensation is tied directly to the achievement of strategic Company targetsShareholderalignment&#x2022;Our incentives are significantly weighted toward long-term equity-based plans&#x2022;Measures under the Long-Term Incentive plans are calibrated to promote the creation of shareholder value&#x2022;Executive Committee members are expected to build and maintain substantial shareholdingsBalanced rewards&#x2022;Balanced set of measures to create sustainable value&#x2022;Mix of targets based on financial metrics, strategic objectives, and performance versus our competitorsBusiness ethics&#x2022;The Novartis Values and Behaviors are an integral part of our compensation system&#x2022;They underpin the assessment of overall performance for the Annual IncentiveCompetitive compensation&#x2022;Total compensation must be sufficient to attract and retain key global talent&#x2022;Overarching emphasis on pay for performance</div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Alignment with Company strategy</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our strategy is to build a leading, focused medicines company powered by advanced therapy platforms and data science. We foster a company culture that is inspired, curious and unbossed. We believe these elements drive continued innovation and will support the creation of value over the long term for our Company, society and shareholders.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To align the compensation system with this strategy and to ensure that Novartis is a high-performing organization, the Company operates both a short-term Annual Incentive and an LTI plan with a balanced set of measures and targets. The Board of Directors determines specific, measurable and time-bound performance measures for the Annual Incentive and LTI plan. The Compensation Committee has reviewed the existing compensation system and determined that it continues to support our strategy.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Approach to market benchmarking</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There remains significant competition for top executive talent with deep expertise, competencies and proven performance within the pharmaceutical and biotechnology industries. As such, external peer compensation data is one of a number of key reference points considered by the Board of Directors and the Compensation Committee when making decisions on executive pay, helping to ensure that the compensation system and compensation levels at Novartis remain competitive. Novartis makes the commitment to shareholders to confirm benchmarking practices, including the peer group, each year. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Compensation Committee believes in a rigorous approach to peer group construction and maintenance. The Compensation Committee also believes that using a consistent set of peers that is similar in size and scope enables shareholders to evaluate the compensation year on year and make pay-for-performance comparisons. As such, following a review of the benchmarking peer group, the Compensation Committee decided to maintain the same primary peer group of 14 global healthcare companies until the end of 2020 (with the exception of Celgene, which was acquired by Bristol-Myers Squibb), as presented below.</div>
<div style="padding-top:15px"><img src="comp_0005.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Global healthcare peer groupAbbVieBiogen GlaxoSmithKlineNovo NordiskRocheAmgenBristol-Myers SquibbGilead SciencesMerck &amp; Co.SanofiAstraZenecaEli Lilly &amp; Co.Johnson &amp; JohnsonPfizer</div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The companies in this peer group reflect our industry and are similar to Novartis in terms of both size and scope of operations. Novartis target compensation is generally positioned around the market median benchmark for comparable roles within this group.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Although Novartis is headquartered in Switzerland, more than a third of its sales come from the US market, and the US remains a significant talent pool for the recruitment of executives by the Company. It is therefore critical that Novartis is able to attract and retain key talent globally, especially from the US. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For consideration of European and local practices, the Compensation Committee also references a cross-industry peer group of Europe-headquartered multinational companies, selected on the basis of comparability in size, scale, global scope of operations, and economic influence to Novartis. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Six of these companies focus mainly on healthcare: AstraZeneca, GlaxoSmithKline, Merck KgaA, Novo Nordisk, Roche and Sanofi. Nine companies are selected from the STOXX<sup>&#xAE;</sup> All Europe 100 Index representing multiple sectors: Anheuser-Busch InBev, Bayer, BMW, Daimler, Danone, Heineken, L&#x2019;Or&#xE9;al, Nestl&#xE9; and Unilever.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Due to the varying impact of the global pandemic on different companies, we believe that this year has demonstrated the importance of using a more homogeneous industry peer group, where possible.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">94</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Executive Committee appointments compensation policy</font>
</div>
<div style="padding-top:15px"><img src="comp_0007.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Element of compensationPolicyLevelThe overall package should be market-competitive to enable the recruitment of global executive talent with deep expertise and competencies.Annual base salaryThe Compensation Committee may appoint individuals who are new to a role on an annual base salary that is below the market level, with a view to increase this toward a market level over a period of three to four years as an individual develops in the role.This prudent approach ensures pay levels are merit-based, with increases dependent on strong performance and proven ability in the role over a sustained period.IncentivesThe ongoing compensation package will normally include the key compensation elements and incentive opportunities in line with those offered to current Executive Committee members.In exceptional circumstances, higher Long-Term Incentive opportunities than those offered to current Executive Committee members may be provided at the Compensation Committee&#x2019;s discretion.Performance measures may include business-specific measures tailored to the specific role.Pension and other benefitsNewly appointed Executive Committee members are eligible for a local market pension and other benefits in line with the wider employee group.BuyoutsThe Compensation Committee seeks to balance the need to offer competitive compensation opportunities to acquire the talent required by the business with the principle of maintaining a strong focus on pay for performance.As such, when an individual forfeits variable compensation as a result of an appointment at Novartis, the Compensation Committee may offer replacement awards in such form as the Compensation Committee considers appropriate, taking into account relevant factors.Relevant factors include the replacement vehicle (i.e., cash, restricted share units, restricted shares or performance share units), whether the award is contingent on meeting performance conditions or not, the expected value of the forfeited award, the timing of forfeiture (i.e., Novartis mirrors the blocking or vesting period of the forfeited award) and the leaver conditions, in case the recruited individual leaves Novartis prior to the end of the blocking or vesting period.The Compensation Committee will seek to pay no more than is required to match the commercial value or fair value of payments and awards forfeited by the individual.International mobility If individuals are required to relocate or be assigned away from their home location to take up their position, relocation support may be provided in line with our global mobility policies (i.e., relocation support, tax equalization).</div>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">95</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Treatment of variable compensation for Executive Committee leavers</font>
</div>
<div style="padding-top:15px"><img src="comp_0008.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Element of compensationPolicyAnnual Incentive cash elementRetirement, termination by the Company (for reasons other than performance or conduct), change of control, disability, death i.e. &#x201C;good leavers&#x201D;Pro-rata Annual Incentive is paid to reflect the portion of the year the individual was employed.Any other reasonNo Annual Incentive.Annual Incentive  mandatory deferral into restricted shares/ RSUsIf a participant leaves employment due to voluntary resignation or misconduct, unvested restricted shares and restricted share units (RSUs) are forfeited. If a participant leaves involuntarily, restricted shares and RSUs are released on the original blocking end date. All awards are subject to non-compete terms until the end of the three-year blocking date, starting from the date of grant.Annual Incentive  voluntary restricted shares/RSUs/ADRs (US associates only)Awards are not subject to forfeiture during the deferral period.  Long-Term Incentives (LTPP/LTRPP)Voluntary resignation or termination by the Company for misconductAll of the award will be forfeited.Termination by the Company for reasons other than performance or conduct, and change in control due to divestment (including retirement)Awards vest on the regular vesting date, subject to performance, on a pro-rata basis for time spent with the Company during the performance cycle. There is no accelerated vesting.Death or long-term disability Accelerated vesting at target will be applied.Non-compete agreementAll awards are subject to non-compete terms against the healthcare peer group until the vesting date.   </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Malus and clawback</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Any incentive compensation paid to Executive Committee members is subject to malus and clawback rules. This means that the Board of Directors for the CEO, and the Compensation Committee for the other Executive Committee members, may decide &ndash; subject to applicable law &ndash; to retain any unpaid or unvested incentive compensation (malus), or to recover incentive compensation that has been paid or has vested in the past (clawback). This applies in cases where the payout has resulted from a violation of laws or conflicts with internal management standards, including Company and accounting policies. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">This principle applies to both the short-term Annual Incentive and LTI plans.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">96</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Executive C</font><font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">ommittee performance&nbsp;management process</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">To foster a high-performance culture, the Company applies a uniform performance management process worldwide, based on quantitative and qualitative criteria, including our Values and Behaviors. All Novartis associates, including the CEO and other Executive Committee members, are subject to a formal three-step process: objective setting, performance evaluation and compensation determination. This process is explained below.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Performance targets are generally set before the start of the relevant performance cycle. There is a rigorous framework in place for establishing targets to ensure they are suitably robust and challenging, and align with the strategic priorities of the Group. The key factors taken into account when setting targets include:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Novartis strategic priorities</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Internal and external market expectations</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Regulatory factors (e.g., new launches, patent expiries)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Investment in capital expenditure</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Values and Behaviors</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The targets are challenged at multiple stages before they are ultimately approved by the Board of Directors. In line with good governance practices, the Compensation Committee works to set targets that are ambitious and challenging but do not encourage undue risk-taking. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Following the end of the performance cycle, the Board of Directors and the Compensation Committee consider performance against the targets originally set. The CEO and Executive Committee members are not present while the Board of Directors and the Compensation Committee discuss their individual performance evaluations. Prior to determining the final outcome, related factors such as performance relative to peers, wider market conditions, general industry trends and good practice are used to inform the overall performance assessment. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
<div style="padding-top:15px"><img src="comp_0009.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Objective setting&#x2022;The CEO proposes his targets to the Chairman of the Board; they are then reviewed and approved by the Board of Directors, based on input from the Compensation Committee.&#x2022;For other Executive Committee members, targets for their division or unit are initially discussed with the CEO and subsequently approved by the Board of Directors and Compensation Committee.Performance evaluation&#x2022;The CEO&#x2019;s performance against the individual balanced scorecard is assessed by the Board of Directors.&#x2022;For Executive Committee members, the CEO discusses with the Chairman each member&#x2019;s performance (assessed against his or her individual balanced scorecard) before making recommendations to the Board of Directors.&#x2022;Periodic assessments, including at the mid-year stage, ensure progress is suitably tracked.Compensation determination &#x2022;A recommendation for the CEO&#x2019;s variable pay is made by the Compensation Committee to the Board of Directors for final determination.&#x2022;For the Long-Term Incentive financial measures payout schedules, a formulaic approach applies and the Compensation Committee can also exercise judgment to ensure there is appropriate alignment between payout levels and overall performance achieved. The same principle of discretion applies to the relative TSR and innovation performance measures.&#x2022;The CEO&#x2019;s recommendations for other Executive Committee members are considered and approved by the Compensation Committee, after which the Board of Directors is notified of the outcomes.</div>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">97</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00938396"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">2020 Executive Committee compensation </p><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Performance outcomes </font>
</div>
<div style="padding-top:15px"><img src="comp_0010.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Annual base salaryOverview&#x2022;The annual base salary is reviewed each year, taking into account the individual&#x2019;s role, performance and experience, business performance and the external environment, increases across the Group and market movements.2020 annual base salariesThe 2020 annual base salaries were as follows:&#x2022;CEO (effective March 1, 2020): CHF 1757700     &#x2022;OTHER EXECUTIVE COMMITTEE MEMBERS (effective March 1, 2020): All other members of the Executive Committee were awarded increases in line with the average of all Novartis employees, with the exception of four individuals as disclosed in Item 6.B of the 2019 Annual Report. These members were appointed to their roles with base salaries below external market median level and have demonstrated excellent performance during their tenure.Pension and other benefitsOverview&#x2022;Pension and other benefits do not constitute a significant proportion of total compensation and are provided to the Executive Committee on the same terms as all other associates based on local country practices and regulations. &#x2022;The CEO and all other Swiss-based members of the Executive Committee are members of the Novartis Swiss pension funds, which provide Company contributions on the base salary and Annual Incentive up to the legal cap on the insured salary of CHF 853 200. No supplementary pension plans or savings plans are provided. The CEO&#x2019;s employer pension contributions represent 10.04% of his base salary.&#x2022;Globally the Company operates both defined benefit and defined contribution pension plans (see also Note 25 to the Group&#x2019;s consolidated financial statements). &#x2022;Novartis may provide other benefits according to local market practice. These include Company car provision, tax and financial planning, and insurance benefits.&#x2022;Executive Committee members who are required to relocate internationally may also receive additional benefits (including tax equalization), in line with the Company&#x2019;s global mobility policies. </div>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">98</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2020 Annual Incentive</font>
</div>
<div style="padding-top:15px"><img src="comp_0012.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">PLAN OVERVIEWTarget Annual Incentive On-target opportunities&#x2022;CEO: 150% of annual base salary&#x2022;Other Executive Committee members: 80% to 120% of annual base salaryPerformance measures&#x2022;An Annual Incentive balanced scorecard containing:&#x2022;Financial performance measures related to Group, division or business unit, where relevant (60% weighting)&#x2022;Five key strategic objectives in the areas of innovation, operational excellence, data and digital, people and culture, and building trust with society (40% weighting)&#x2022;The 2020 balanced scorecard targets and achievements of the CEO are detailed on the next page.&#x2022;The 2020 balanced scorecards for other Executive Committee members include Group financial targets as well as financial or other quantitative targets that relate to their division or business unit, if applicable.&#x2022;Values and Behaviors are a key component of the Annual Incentive and are embedded in our culture. As such, members of the Executive Committee are expected to demonstrate these to the highest standards.Target setting&#x2022;Financial targets are set at the beginning of each financial year and align with the strategic plan proposed by management to the Board of Directors for approval.&#x2022;The strategic objectives are aligned with the most important priorities in any performance year.Payout ranges&#x2022;The payout schedule for the Annual Incentive incorporates performance against financial and strategic objectives. The payout range is 0% to 200% of on-target opportunity based on performance, as shown below:PERFORMANCEPAYOUT (% of on-target)Outstanding170%  200%Exceeds expectations130%  160%Meets expectations80%  120%Partially meets expectations40%  70%Below expectations0%Payout formulaPayout vehicle&#x2022;At the end of the performance period, 50% is paid in cash, and the remaining 50% is delivered in Novartis restricted shares or RSUs, deferred for three years (see &#x201C;Treatment of variable compensation for Executive Committee leavers&#x201D;).&#x2022;Executives may choose to receive all or part of the cash portion of their Annual Incentive in Novartis shares or American Depositary Receipts (ADRs; US only) that will not be subject to forfeiture conditions. In the US, awards may also be delivered in cash under the US-deferred compensation plan.&#x2022;Clawback and malus provisions apply to all Annual Incentive awards.Dividend rights, voting rights and settlement&#x2022;Novartis restricted shares carry voting rights and dividends during the vesting period. RSUs are of equivalent value but do not carry voting rights and dividends during the vesting period.&#x2022;Following the vesting period, settlement of RSUs is made in unrestricted Novartis shares or ADRs. Annual base salaryxTarget incentive (% of base salary)=Target Annual IncentiveAnnual base salaryxTarget incentive (% of base salary)xPayout factor (% of target: 0%200%)=Realized Annual Incentive</div>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">99</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:15px"><img src="comp_0014.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">2020 CEO BALANCED SCORECARD This section presents the balanced scorecard for the CEO. Balanced scorecard performance is measured in constant currencies to reflect operational performance that can be influenced. The Board of Directors uses a stringent process to set ambitious financial targets to incentivize superior performance. No adjustments were made to the targets as a result of the COVID-19 pandemic. In addition to the financial targets, the CEO also has ambitious strategic objectives across five key pillars, two of which are related to ESG matters. During the year, the Compensation Committee took the opportunity to benchmark its approach to incentive target setting. The committee asked its independent advisor to survey several organizations, representing global multinationals from various industries, to gain insight into their variable incentive target-setting processes. Through this review, it was concluded that Novartis practices are in line with the surveyed companies, and no changes to the target-setting process were made.Achievement versusCEO achievements  2020Target1targetFinancial measures  60% of total Annual Incentive, comprising: Group net sales (cc) (30%) 50781 millionBelowGroup operating income (cc) (30%)| 9745 million|Significantly aboveGroup free cash flow as a % of sales (cc) (20%)| 24.3%|AboveShare of peers for Novartis Group (USD) (20%) 8.3%MetOverall assessment of Group financial targets in constant currencies Met1For performance evaluation purposes, target as well as actual financial KPIs included the results of the Sandoz US dermatology business and generic oral solids portfolio, which were expected to be divested to Aurobindo Pharma USA Inc. This deal was later terminated by mutual agreement with Aurobindo.Strategic objectives  40% of total Annual Incentive, comprising:Innovation (20%)|MetNovartis continued to strengthen its product portfolio with 26 major approvals and 13 major submissions. Thirty-one new targets or technologies were discovered; 35 projects achieved first patient, first visit; and 13 positive proofs of concept/proofs of mechanism were achieved. However, due to pandemic and data-related delays, milestones for Lu-PSMA-617 and Entresto (for heart failure with preserved ejection fraction) were missed.Despite the pandemic, launches of Kesimpta, Cosentyx (for non-radiographic axial spondyloarthritis), Enerzair and Tabrectashowed strong early performance, with Tabrecta being the first-ever fully virtual launch. The launch of AVXS-101 intrathecal was delayed due to a partial hold on clinical trials based on findings in a small preclinical animal study.We continued to strengthen our advanced therapy platforms across the value chain, moving forward a breadth of clinical and preclinical programs, expanding our manufacturing capacity, and making our marketed therapies like Zolgensma, Kymriahand Lutathera widely available around the world.Operational excellence (20%)| MetSolid sales growth (3% increase compared to 2019), transformation of our NTO network, and improved productivity in marketing and sales as well as research and development drove double-digit cc growth in core operating income to USD 15.4 billion. Compared to the prior year, core operating income margin increased by 2.8 percentage points (cc) to 31.7%. Net income from continuing operations grew 13% (20% cc), mainly driven by higher operating income. Full-year free cash flow was USD 11.7 billion, as higher operating income was more than offset by increased legal payments and lower divestments.Data and digital (20%)|MetWe continued to advance and accelerate our digital lighthouse platforms in areas of biggest impact. The data42 analytics platform is now scaled. We have more than 5 000 users on our Nerve Live platform to manage clinical trials in real time. Through our remote clinical trial program, we ran over 35 000 remote monitoring interventions to mitigate the impact of the pandemic. In the commercial and medical space, we transitioned all sales representatives globally to a harmonized customer relationship management tool. We also continued to significantly invest in next-generation marketing and sales, with 1 400 marketers trained. SpotOn, our control center for manufacturing and supply chain flow, is now live at five sites with three technology platforms, and is supporting our NTO organization to connect and contextualize data to predict and simulate scenarios. </div>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">100</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:15px"><img src="comp_0026.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">2020 CEO BALANCED SCORECARD &#x2212; CONTINUEDPeople and culture (20%)|MetWe continued to build a culture that is inspired, curious and unbossed. The score for engagement in our quarterly employee survey reached an all-time high of 80 (out of 100) in the fourth quarter of 2020, compared to 74 a year earlier, bringing us further above the pharmaceutical industry benchmark of 73 and the global benchmark of 74. We made good progress toward our associate learning initiatives in 2020, with 45.7 learning hours per associate on average. Additionally, the Unbossed Leadership Experience leadership program reached over 5 000 leaders. We continued to make steady progress toward our Equal Pay International Coalition (EPIC) pledge to achieve gender balance in management by 2023. The percentage of women in management overall rose to 45% in 2020 (from 44% a year earlier) and to 33% for Novartis Top Leaders (up 2%, slightly below the 2020 aspiration). Novartis has a global median pay gap of -3.1% and a global mean pay gap of +3.6% (available data at the time of disclosure). While we acknowledge this percentage is influenced by worldwide workforce demographics, this is significantly ahead of the Bloomberg benchmarks of +19% median and +23% mean. We introduced an inclusion index and achieved a 74 score versus a global benchmark of 71 and a pharmaceutical industry benchmark of 70.Building trust with society (including access to healthcare, reputation and other ESG topics) (20%) |Significantly aboveThe Company&#x2019;s ESG strategy comprises four key pillars. Some particular highlights for 2020 include the settling of historic litigations matters, issuing a sustainability-linked bond, committing to achieve full carbon neutrality by 2030, and integrating ESG across all functions. These efforts contributed to improvements in our scores on a number of ESG indices from external agencies. Namely, we were sector leaders for Sustainalytics and FTSE4Good, and received an &#x201C;A&#x201D; rating from MSCI in the most recent reporting cycle. Additional information on these achievements is provided below and in the Novartis in Society ESG Report 2020.ETHICAL STANDARDS In June 2020, Novartis reached settlements for the investigations into historical conduct by the Company and its subsidiaries dating back to 2012. With these agreements, all legacy compliance-related allegations against Novartis are closed. Our new Code of Ethics was rolled out in September, providing our associates with a robust framework for decision-making to help navigate situations that are complex or unclear. Third-party risk assessments were conducted for 100% of new eligible suppliers and distributors.PRICING AND ACCESS Compared to 2019, we increased our reach with strategic innovative therapies to patients in low- and middle-income countries (LMICs) by 27%, a significant step toward reaching our 2025 goal (200% increase in patient reach). In 2020, we launched 22 emerging market brands, and 100% of new launches have an access strategy in place. Piqray in India, for instance, was one month ahead of the first European country launch thanks to early planning and more formalized processes. In response to the COVID-19 pandemic, Novartis partnered with the Africa Medical Supplies Platform (AMSP) to facilitate the supply of 15 Sandoz medicines to 55 African and 15 CARICOM-eligible countries. In 2020, Novartis issued a sustainability bond linked to our access targets for strategic innovative therapies and our flagship programs, becoming the first healthcare company to issue a corporate bond of this kind.GLOBAL HEALTH The four Novartis global health flagship programs in leprosy, malaria, Chagas disease and sickle cell disease focus on diseases where there is a market failure and where we have the ability to innovate. Progress in this area was delayed, as the pandemic limited accessibility to clinics. However, we were able to treat approximately 5 000 patients with sickle cell disease in sub-Saharan Africa and expand the rollout of the Africa sickle cell disease program to Kenya, Tanzania and Uganda.RESPONSIBLE CITIZENSHIP Novartis advanced its ambition to reduce its environmental impact, aiming to achieve full carbon, plastic and water neutrality by 2030. In 2020, we reduced our carbon emissions, waste disposal and water consumption compared to 2019 by an estimated 16%, 21% and 25%, respectively  well ahead of our 8% target in each of the three areas. We made measurable progress toward our public equity pledges, preparing to go live with pay transparency in 10 new countries from February 2021, and eliminating the use of historical salary data in 75% of cases when making internal and external hiring decisions. To address racial inequalities, our Novartis US Foundation has shifted focus and is dedicated to tackling this issue.Overall assessment of strategic objectives Met Overall assessment of CEO balanced scorecard MetANNUAL INCENTIVE PAYOUTPayoutBased on the overall assessment, the Board of Directors decided on an Annual Incentive resulting in a payout for the CEO amounting to CHF 2 636 550, which is 100% of target, within the rangeof 0200%.</div>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">101</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Long-Term Incentive plans, 2018-2020 cycle</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Long-Term Performance Plan (LTPP) is the first of two LTI plans operated over the 2018-2020 cycle and rewards creation of long-term value and innovation.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Long-Term Relative Performance Plan (LTRPP) is the second of two LTI plans operated over the 2018-2020 cycle and rewards competitive shareholder return relative to the global healthcare peer group.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The structure of the two plans is summarized below.</div>
<div style="padding-top:15px"><img src="comp_0016.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">OVERVIEW OF LONG-TERM INCENTIVE PLANSGrant formula At the start of the performance cycle, performance share units (PSUs) are granted under each of the Long-Term Incentive plans, as follows:On-target opportunity LTPP:&#x2022;CEO: 200% of annual base salary&#x2022;Other Executive Committee members: between 130% and 190% of annual base salaryLTRPP:&#x2022;CEO: 125% of annual base salary&#x2022;Other Executive Committee members: between 30% and 80% of annual base salaryPayout range&#x2022;From 0% to 200% of the on-target amount based on performanceAward vehiclePSUs granted at the beginning of the cycle vest at the end of the three-year performance cycle and are converted into Novartis shares.PSUs carry dividend equivalents that are paid in shares at the end of the cycle to the extent that performance conditions have been met.Payout formula:Policy information in &#x201C;&#x2014;Treatment of variable compensation for Executive Committee leavers&#x201D; provides details on the treatment of Long-Term Incentive awards for leavers.Step 1Annual base salaryxTarget incentive %=Grant valueStep 2Grant value/Share price=Target number of PSUsTarget number of PSUsxPerformance factor+Dividend equivalents=Realized PSUs</div>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">102</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">LTPP performance outcomes</font>
</div>
<div style="padding-top:15px"><img src="comp_0015.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">NOVARTIS CASH VALUE ADDED (NCVA) (75% OF LTPP)DescriptionNCVA incentivizes sales growth and margin improvement as well as asset efficiency. It is calculated as follows:1 WACC = weighted average cost of capital2 NCVA = (cash flow return on investment %  WACC) x gross operational assets in constant currenciesThe NCVA performance factor is based on a 1:3 payout curve, whereby a 1% deviation in realization versus target leads to a 3% change in payout (for example, a realization of 105% leads to a payout factor of 115%).Accordingly, if performance over the three-year vesting period falls below 67% of target, no payout is made for this portion of the LTPP. Conversely, if performance over the three-year vesting period is above 133% of target, payout for this portion of the LTPP is capped at 200% of target.Group performance outcome for the 2018-2020 cycleFor the last three cycles, the Board of Directors has set increasingly ambitious NCVA targets to promote improvements to operational efficiencies. During the 2018-2020 cycle, Novartis delivered an NCVA of USD 9.6 billion, 16% ahead of a target of USD 8.3 billion in constant currencies.When setting the target for the 2018-2020 cycle, which increased by USD 2.2 billion (i.e., 37% versus the 2017-2019 cycle), the Compensation Committee took into account the following: &#x2022;An expected increase in operational performance&#x2022;Key business transformation investments and restructuring costs, particularly in the manufacturing and business services organizationsThe 2018-2020 NCVA performance was mainly driven by the following:&#x2022;Out-performance of sales targets over the three-year cycle (predominantly in 2019) by Innovative Medicines (+USD 1.3 billion, mainly driven by Entresto, Promacta/Revolade, and Tafinlar + Mekinist)&#x2022;Significant increase in productivity, mainly in manufacturing (with core production cost of goods sold as a percentage of sales improving by 2% points in constant currencies), marketing and sales, and research and development. This allowed for targeted launch investments and increased core operating income margin in constant currenciesNo adjustments were made to the target to reflect the impact of the COVID-19 pandemic.Following the application of the agreed payout curve, the 116% achievement versus target generates a performance factor of 147% of target for this part of the LTPP.This will be the last year NCVA is considered in our LTI plans. For LTPP cycles starting from 2019, NCVA has been replaced with a combination of a three-year net sales compound annual growth rate (CAGR) and core operating income CAGR.INNOVATION (25% OF LTPP)DescriptionInnovation is a key value driver for shareholders and is critical to our future. At the beginning of the cycle, the Science &amp; Technology Committee (formerly the Research &amp; Development Committee) determines the most important target milestones, considering the following:&#x2022;The expected future potential revenue&#x2022;The potential qualitative impact of research and development on science and medicine&#x2022;The potential impact of research and development on the treatment or care of patientsFor the cycle 2018-2020, innovation performance is based on group-wide innovation using a combination of Novartis Institutes for BioMedical Research (NIBR) and Global Drug Development(GDD) targets.At the end of the cycle, the Compensation Committee determines the payout factor based on the performance assessment made by the Science &amp; Technology Committee. In the healthcare industry, achievement of 60% to 80% of pipeline targets set at the beginning of a three-year cycle is considered good performance. The payout range 0% to 150% of target is based on the achievement of the target milestones, and payout above 150% of target is only delivered for truly exceptional performance. Group performance outcome for the 2018-2020 cycleIn the 2018-2020 period, Novartis exceeded its innovation performance targets. We achieved a number of readouts and submissions in the Innovative Medicines Division, including approvals for Mayzent in the US and the EU to treat multiple sclerosis (MS); Kesimpta in the US to treat MS; Beovu in the US and the EU to treat neovascular (wet) age-related macular degeneration; Piqray in the US and the EU to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation; Atectura and Enerzair in the EU to treat asthma; and Adakveo in the US and the EU to treat sickle cell disease. Entresto for heart failure with preserved ejection fraction (US) and Cosentyx for non-radiographic axial spondyloarthritis (US and EU) were also approved. Although the readout for QAW039 (fevipiprant) in asthma was attained, the program failed to meet its goals in Phase III clinical trials and was therefore terminated. Overall, Novartis achieved nine approvals for new molecular entities over the cycle.Sandoz achieved US approval for long-acting oncology supportive care biosimilar Ziextenzo (pegfilgrastim-bmez), becoming the first and only company to offer US patients long- and short-acting filgrastim biosimilar treatment options. NIBR achieved its targets, discovering eight new first-in-class potential targets for liver diseases and initiating first-in-human studies of a CD19-targeted CAR-T therapy with an advanced manufacturing process.Following input from the Science &amp; Technology Committee, the Board of Directors approved an innovation performance factor for the CEO and Executive Committee members of 131% of target.LTPP PAYOUTPayoutOverall, the Board of Directors approved an LTPP payout for the CEO amounting to CHF 5 605 100, which is 143% of target, within the range of 0-200%. This includes dividend equivalents of CHF 459 895.Operating income+Amortization, impairments, and adjusting for gains/losses from non-operating assetsTaxesCapital charge (based on WACC1) on gross operational assets=NCVA2</div>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">103</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">LTRPP performance outcomes </font>
</div>
<div style="padding-top:15px"><img src="comp_0021.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">RELATIVE TOTAL SHAREHOLDER RETURN (TSR) (100% OF LTRPP)DescriptionPerformance is based on our TSR relative to a global healthcare peer group. Outperformance of this peer group is a key indicator that Novartis is delivering long-term value to its shareholders.The peer group and payout matrix for the 2018-2020 performance cycle are as follows:The payout matrix includes a significant reduction (including scope to reduce to nil) when Novartis does not outperform the majority of the companies in the group. At the end of the performance cycle, all companies are ranked in order of highest to lowest TSR in USD. As communicated in the 2019 Annual Report, for the 2018-2020 cycle, a one-day pricing approach was taken to determine the share value at the start of the performance cycle, and a three-month averaging method was then used at the end of the cycle.The Compensation Committee uses its discretion to determine the payout factor within the ranges shown above, and takes into consideration factors such as absolute TSR, overall economic conditions, currency fluctuations and other unforeseeable economic situations. Group performance outcomefor the 2018-2020 cycleNovartis TSR over the three-year period (2018-2020) was 29.4% using the methodology described above. When compared to the global healthcare peer group, Novartis TSR ranked No. 7 out of 15 companies. LTRPP PAYOUT FOR THE 2018-2020 CYCLEPayout Based on the ranking, the Board of Directors approved an LTRPP payout of 100% of target for the CEO, resulting in CHF 2 449 823, which includes dividend equivalents of CHF 201 005.Combined LTI (LTPP and LTRPP) outcomes for the 2018-2020 cyclePayout When considering both the LTPP and LTRPP, the total combined LTI payout was 126% of target for the CEO, resulting in CHF 8 054 923, compared to 157% last year. This amount includes CHF 660 900 of dividend equivalents accrued over the three-year cycle and CHF 784 497 in Alcon Keep Whole awards. Further detail can be found in the tables &#x201C;2018-2020 LTPP performance cycle&#x201D; and &#x201C;2018-2020 LTRPP performance cycle.&#x201D;2018-2020 peer group (14 companies, excluding Novartis)AbbVieBiogenGlaxoSmithKlineNovo NordiskRocheAmgenBristol-Myers SquibbGilead SciencesMerck &amp; Co.SanofiAstraZenecaEli Lilly &amp; Co.Johnson &amp; JohnsonPfizerNovartis position Payout rangein the peer group(% of target)Position 1  2Position 3  5Position 6  8Position 9  15170%  200% 130%  160%80%  120%0%</div>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">104</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Realized compensation</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">To aid shareholders&#x2019; understanding of the link between pay and performance, the Compensation Committee discloses the realized compensation for the CEO individually, and for the other members of the Executive Committee on an aggregated basis. Disclosing realized compensation means that the Annual Incentive and the LTI are disclosed at the end of their respective performance cycles, reflecting actual payouts based on performance.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The total actual payout may vary year on year depending on multiple factors, including the composition of the Executive Committee and the tenure of its members (as new members may not have a vested LTI), compensation increases, payout of variable compensation based on actual performance, share price fluctuations of the LTI, and dividend equivalents.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As communicated in the 2018 and 2019 Annual Reports, all Novartis shareholders received a dividend in kind in Alcon shares at the spin-off date, which created immediate and significant value to shareholders. However, unvested performance share units (PSUs), such as the LTPP and LTRPP, were not entitled to such dividend in kind. To ensure equal treatment relative to shareholders, PSU holders were instead awarded Alcon Keep Whole awards of similar value to the dividend in kind. These are only realized at the same time as the underlying PSUs, and are subject to the same performance conditions. The vesting of these Alcon Keep Whole awards will be considered in the realized compensation of the CEO and ECN members.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2020 realized compensation for the CEO and other Executive Committee members</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board reconsidered the executive incentive targets set prior to the pandemic and concluded that no changes should be made.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To determine the appropriateness of the 2020 CEO and executive compensation payouts under the Annual Incentive and LTI plans, the Board of Directors and the Compensation Committee reviewed management&#x2019;s performance and contribution, taking the following into consideration:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; No COVID-19-related government support or employee redundancies </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Supportive treatment of associates and responsible societal approach adopted throughout the pandemic</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Resilient operational and financial performance against targets</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Strong progress toward strengthening our global product portfolio</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Accomplishments across all strategic pillars, with careful attention to ESG targets</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; 29.4% shareholder return over cycle 2018-2020, when considering a three-month price averaging at the end of the cycle (40.4% when considering the spot rate on December 31, 2020)</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">On this basis, the Board of Directors determined that no discretionary judgments were required to the resulting payouts. More detail on the performance of the CEO can be found in &#x201C;&mdash;2020 CEO balanced scorecard.&#x201D;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The Board of Directors awarded the CEO a 2020 Annual Incentive of CHF 2 636 550, which is 100% of target, within the payout range of 0% to 200%.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The 2018-2020 LTI plans comprise the LTPP and the LTRPP. The 2018-2020 LTPP delivered strong results, with Cash Value Added and innovation above target (see &#x201C;&mdash;LTPP performance outcomes&#x201D;). For the 2018-2020 LTRPP, Novartis ranked above median at position 7 out of a total of 15 global healthcare peers (including Novartis), on three-year relative TSR. Overall, when considering both plans, the Board of Directors awarded the CEO a total LTI payout of CHF 8 054 923, corresponding to a 126% payout against a maximum of 200%.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">These incentive performance outcomes, combined with base salary and other benefits, pension, Alcon Keep Whole awards and dividend equivalents, resulted in 2020 total realized compensation for the CEO of <b>CHF&nbsp;12&nbsp;724&nbsp;166</b>.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">105</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table reports fixed and other compensation for the year, including the Annual Incentive for the 2020 performance year, the realized LTI for the 2018-2020 performance cycle, and any buyouts vesting in 2020. The portion of the Annual Incentive paid in shares for the year 2020 is disclosed using the underlying value of Novartis shares at the date of grant, while the realized values of any other equity awards (including dividend equivalents and Alcon Keep Whole awards) are calculated using the share price on the date of vesting.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2020 realized compensation for the CEO and other Executive Committee members</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   </div>
      </td>
      <td></td>
      <td colspan="1" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2020 annual base  salary</div>
      </td>
      <td></td>
      <td colspan="1" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2020  pension  benefits<sup>1</sup></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2020 Annual Incentive  </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-Term Incentives  </div>
      </td>
      <td></td>
      <td colspan="1" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other 2020   compensation</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   </div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   </div>
      </td>
      <td></td>
      <td colspan="1" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> LTPP 2018-2020   cycle</div>
      </td>
      <td></td>
      <td colspan="1" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> LTRPP 2018-2020   cycle</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   </div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Currency</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Cash (amount)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Amount</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Cash</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Equity<sup>2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Equity (value <br> at vesting date)<sup>3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Equity (value<br> at vesting date)<sup>3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Amount<sup>2,4,5</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total realized <br> compensation <br> (incl. share<br> price movement)<sup>6</sup></div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="20" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td colspan="20">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members</div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan (CEO)</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;743&nbsp;750</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 175&nbsp;102</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;318&nbsp;275</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;318&nbsp;275</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;605&nbsp;100</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;449&nbsp;823</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 113&nbsp;841</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&nbsp;724&nbsp;166</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="20" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aggregate realized  compensation of the other 12 Executive Committee  members<sup style="white-space: nowrap">&nbsp;7</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       9&nbsp;792&nbsp;833</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       2&nbsp;320&nbsp;106</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       4&nbsp;901&nbsp;015</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       5&nbsp;997&nbsp;169</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       14&nbsp;416&nbsp;662</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       3&nbsp;863&nbsp;980</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       4&nbsp;803&nbsp;881</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       46&nbsp;095&nbsp;647</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="20" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;536&nbsp;583</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;495&nbsp;208</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;219&nbsp;290</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;315&nbsp;444</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20&nbsp;021&nbsp;762</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;313&nbsp;803</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;917&nbsp;722</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 58&nbsp;819&nbsp;813</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="20" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="20">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="20">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">See 2019 realized compensation for the CEO and other Executive Committee members for 2019 comparative figures.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="20">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 1&nbsp;</sup> Includes mandatory employer contributions of CHF 8 336 for the CEO and CHF 59 591 for the other Executive Committee members paid by Novartis to governmental social security systems. This amount is out of total employer contributions of CHF 6 088 770 paid in 2020 for all Executive Committee members, and provides a right to the maximum future insured government pension benefit for the Executive Committee members.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="20">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 2&nbsp;</sup> The portion of the Annual Incentive delivered in equity is rounded up to the nearest share, based on the closing share price on the grant date (January 20, 2021) of CHF 86.01 per Novartis share and USD 96.92 per ADR.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="20">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 3&nbsp;</sup> The amounts represent the underlying share value of the 245'786 LTPP PSUs and 75'714 LTRPP PSUs vesting on January 18, 2021, to the CEO and other Executive Committee members for the performance cycle 2018-2020, inclusive of earned Alcon Keep Whole awards and dividend equivalents for the three-year cycle (for details see LTPP performance cycle and LTRPP performance cycle). The taxable value is determined using the closing share price on the day the Novartis Board of Directors approved the final LTPP and LTRPP performance factors (i.e., January 20, 2021) of CHF 86.01 per Novartis share and USD 96.92 per ADR. Bertrand Bodson, Shannon Thyme Klinger, Steffen Lang, Susanne Schaffert and Marie-France Tschudin were promoted to the Executive Committee during the course of the performance period 2018-2020, and as such, the information disclosed reflects their pro-rata LTPP and LTRPP 2018-2020 payouts attributable to the period in which they were a member of the Executive Committee. Klaus Moosmayer, John Tsai and Richard Saynor joined Novartis after the 2018 LTI awards being made and hence did not receive LTPP and LTRPP awards for the 2018-2020 performance period.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="20">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 4&nbsp;</sup> Includes any other perquisites, benefits in kind, international assignment benefits as per the global mobility policy (e.g., housing, international health insurance, children's school fees, tax equalization). The 2020 tax payments for Richard Saynor were CHF 1 181 889 and for Susanne Schaffert were CHF 431 180.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="20">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 5&nbsp;</sup> Includes 6 128 vested RSUs (CHF 471 666), of which 698 vested on March,13 2020, and 5 430 on July 28, 2020, as well as 4 022 vested PSUs (CHF 281 379) on March 13, 2020, to John Tsai in lieu of the LTI that he forfeited when leaving his previous employer. Also includes 2 421 vested RSUs (USD 229 487) on January 4, 2020, to James Bradner in lieu of the LTI that he forfeited when leaving his previous employer and 6 011 vested PSUs (CHF 550 788) on January 17, 2020, to Klaus Moosmayer in lieu of the LTI he forfeited when leaving his previous employer. Lastly, includes 2 348 vested RSUs (CHF 224 516) and 2 178 vested PSUs (CHF 208 260) on February 15, 2020, to Richard Saynor in lieu of the LTI that he forfeited when leaving his previous employer. The PSUs had the same performance measures as the LTPP for the 2017-2019 performance cycle (NCVA and long-term innovation).</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="20">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 6&nbsp;</sup> All amounts are before deduction of the social security contribution and income tax due by the Executive Committee member.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="20">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 7&nbsp;</sup> Amounts for Executive Committee members paid in USD were converted at a rate of USD 1.00 = CHF 0.939, which is the same average exchange rate used in the Group's 2020 consolidated financial statements (similar rule applies in case of payments made in other currencies during the year).</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The table and information below provide additional details on awards granted as part of the 2018-2020 LTPP and LTRPP performance cycle, including the number of shares awarded and delivered, following the application of the payout factor and the addition of dividend equivalent shares.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2018-2020 LTPP performance cycle </font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> PSUs at grant</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td></td>
      <td colspan="9" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Shares delivered at vesting</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="9" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="9" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> PSUs<br> (target number)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> PSUs<br> (target value<br> at grant date)<br> (CHF)<sup style="white-space: nowrap">     2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Payout factor <br> for LTPP <br> (% of target)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Performance shares <br> delivered at vesting<br> (number)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Performance shares <br> delivered at vesting<br> (value at vesting date)<br> (CHF)<sup style="white-space: nowrap">     3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Dividend <br> equivalent shares <br> delivered at vesting<br> (number)<sup style="white-space: nowrap">     4</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Dividend <br> equivalent shares <br> delivered at vesting<br> (value at vesting date)<br> (CHF)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total shares<br> delivered at vesting<br> (value at <br> vesting date)<br> (CHF)</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 41&nbsp;833</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;467&nbsp;956</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 143%</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 59&nbsp;821</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;145&nbsp;204</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;347</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 459&nbsp;895</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;605&nbsp;100</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other 12 Executive Committee  members</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   106&nbsp;674</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   8&nbsp;800&nbsp;729</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   143%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   152&nbsp;457</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   13&nbsp;285&nbsp;757</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   12&nbsp;984</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   1&nbsp;147&nbsp;618</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   14&nbsp;416&nbsp;662</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 148&nbsp;507</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12&nbsp;268&nbsp;684</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 212&nbsp;278</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&nbsp;430&nbsp;962</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&nbsp;331</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;607&nbsp;514</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20&nbsp;021&nbsp;762</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Bertrand Bodson, Shannon Thyme Klinger, Steffen Lang, Susanne Schaffert and Marie-France Tschudin joined the Executive Committee during the course of the performance period 2018-2020. As such, the information disclosed reflects their pro-rata LTPP 2018-2020 payout attributable to the period they were a member of the Executive Committee. Klaus Moosmayer, John Tsai and Richard Saynor joined Novartis post the 2018 LTPP awards being made and hence did not receive an LTPP award for the 2018-2020 performance period.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> The shown amounts represent the underlying share value of the target number of PSUs granted to each Executive Committee member for the performance period 2018-2020, based on the closing share price on the grant date (January 18, 2018) of CHF 82.9 per Novartis share and USD 86.41 per ADR (pre-Alcon spin-off share price).</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> The shown amounts, inclusive of earned Alcon Keep Whole awards and dividend equivalents, represent the underlying share value of the target number of PSUs vested for the performance period 2018-2020, based on the last closing share price on the day the Novartis Board of Directors approved the final LTPP and LTRPP performance payout factors (i.e., January 20, 2021) of CHF 86.01 per Novartis share and USD 96.92 per ADR.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> Dividend equivalent shares are calculated on the dividend each member of the Executive Committee would have received, based on the actual number of shares delivered at the end of the performance period 2018-2020. At vesting, the dividend equivalents are credited in shares or ADRs.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">106</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2018-2020 LTRPP performance cycle </font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> PSUs at grant</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td></td>
      <td colspan="9" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Shares delivered at vesting</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="9" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="9" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> PSUs<br> (target number)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> PSUs<br> (target value<br> at grant date)<br> (CHF)<sup style="white-space: nowrap">     2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Payout factor <br> for LTRPP <br> (% of target)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Performance shares <br> delivered at vesting<br> (number)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Performance shares <br> delivered at vesting<br> (value at vesting date)<br> (CHF)<sup style="white-space: nowrap">     3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Dividend <br> equivalent shares <br> delivered at vesting<br> (number)<sup style="white-space: nowrap">     4</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Dividend <br> equivalent shares <br> delivered at vesting<br> (value at vesting date)<br> (CHF)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total shares<br> delivered at vesting<br> (value at <br> vesting date)<br> (CHF)</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&nbsp;146</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;167&nbsp;503</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&nbsp;146</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;248&nbsp;817</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;337</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 201&nbsp;005</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;449&nbsp;823</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other 12 Executive Committee  members</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   40&nbsp;722</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   3&nbsp;355&nbsp;831</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   100%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   40&nbsp;722</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   3&nbsp;559&nbsp;493</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   3&nbsp;486</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   309&nbsp;988</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   3&nbsp;863&nbsp;980</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 66&nbsp;868</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;523&nbsp;335</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 66&nbsp;868</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;808&nbsp;310</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;823</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 510&nbsp;993</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;313&nbsp;803</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Shannon Thyme Klinger, Steffen Lang, Susanne Schaffert and Marie-France Tschudin joined the Executive Committee during the course of the performance period 2018-2020. As such, the information disclosed reflects their pro-rata LTRPP 2018-2020 payout attributable to the period they were a member of the Executive Committee. Klaus Moosmayer, John Tsai and Richard Saynor joined Novartis post the 2018 LTRPP awards being made and hence did not receive an LTRPP award for the 2018-2020 performance period.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> The shown amounts represent the underlying share value of the target number of PSUs granted to each Executive Committee member for the performance period 2018-2020, based on the closing share price on the grant date (January 18, 2018) of CHF 82.9 per Novartis share and USD 86.41 per ADR (pre-Alcon spin-off share price).</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> The shown amounts, inclusive of earned Alcon Keep Whole awards and dividend equivalents, represent the underlying share value of the target number of PSUs vested for the performance period 2018-2020, based on the last closing share price on the day the Novartis Board of Directors approved the final LTPP and LTRPP performance payout factors (i.e., January 20, 2021) of CHF 86.01 per Novartis share and USD 96.92 per ADR.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> Dividend equivalent shares are calculated on the dividend each member of the Executive Committee would have received, based on the actual number of shares delivered at the end of the performance period 2018-2020. At vesting, the dividend equivalents are credited in shares or ADRs.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">107</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The table and information below provide details on the 2019 realized compensation for the CEO and other Executive Committee members, for comparative purposes.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2019 realized compensation for the CEO and other Executive Committee members</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   </div>
      </td>
      <td></td>
      <td colspan="1" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2019 annual base  salary</div>
      </td>
      <td></td>
      <td colspan="1" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2019 pension  benefits<sup>1</sup></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2019 Annual Incentive  </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-Term Incentives  </div>
      </td>
      <td></td>
      <td colspan="1" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other 2019  compensation</div>
      </td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   </div>
      </td>
      <td></td>
      <td colspan="1" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> LTPP  2017-2019 cycle</div>
      </td>
      <td></td>
      <td colspan="1" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> LTRPP  2017-2019 cycle</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   </div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Currency</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Cash (amount)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Amount</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Cash</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Equity<sup>2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Equity (value <br> at vesting date)<sup>3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Equity (value<br> at vesting date)<sup>3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Amount<sup>2,4,5</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total realized <br> compensation <br> (incl. share<br> price movement)<sup>6</sup></div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="20" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td colspan="20">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members</div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan (CEO)</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;653&nbsp;333</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 165&nbsp;547</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;008&nbsp;800</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;008&nbsp;839</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;510&nbsp;963</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;107&nbsp;806</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 160&nbsp;452</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;615&nbsp;740</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="20" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aggregate realized  compensation of the other 14 Executive Committee  members, including the two members  who stepped down  during financial year 2019<sup style="white-space: nowrap">&nbsp;7, 8</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">           CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">           9&nbsp;370&nbsp;547</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">           2&nbsp;131&nbsp;905</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">           5&nbsp;809&nbsp;455</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">           7&nbsp;013&nbsp;842</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">           17&nbsp;932&nbsp;704</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">           6&nbsp;383&nbsp;700</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">           7&nbsp;233&nbsp;594</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">           55&nbsp;875&nbsp;748</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="20" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;023&nbsp;880</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;297&nbsp;452</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;818&nbsp;255</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;022&nbsp;682</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 21&nbsp;443&nbsp;667</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;491&nbsp;506</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;394&nbsp;046</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 66&nbsp;491&nbsp;488</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="20" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="20">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="20">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="20">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 1&nbsp;</sup> Includes mandatory employer contributions of CHF 4 373 for the CEO and CHF 63 461 for the other Executive Committee members paid by Novartis to governmental social security systems. This amount is out of total employer contributions of CHF 3 923 070 paid in 2019 for all Executive Committee members, and provides a right to the maximum future insured government pension benefit for the Executive Committee members.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="20">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 2&nbsp;</sup> The portion of the Annual Incentive delivered in equity is rounded up to the nearest share, based on the closing share price on the grant date (January 21, 2020) of CHF 92.89 per Novartis share and USD 95.19 per ADR.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="20">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 3&nbsp;</sup> The amounts represent the underlying share value of the 232 425 LTPP PSUs and 77 904 LTRPP PSUs vesting on January 17, 2020, to the CEO and other Executive Committee members for the performance cycle 2017-2019, inclusive of earned dividend equivalents for the three-year cycle (details in ''LTPP performance cycle and LTRPP performance cycle").The taxable value is determined using the closing share price on the day the Novartis Board of Directors approved the final LTPP and LTRPP performance factors (i.e., January 21, 2020) of CHF 92.89 per Novartis share and USD 95.19 per ADR. Shannon Thyme Klinger, Steffen Lang, Susanne Schaffert and Marie-France Tschudin were promoted to the Executive Committee during the course of the performance period 2017-2019, and as such, the information disclosed reflects their pro-rata LTPP and LTRPP 2017-2019 payouts attributable to the period they were a member of the Executive Committee. Bertrand Bodson, Klaus Moosmayer, John Tsai, Robert Weltevreden and Richard Saynor joined Novartis post the 2017 LTI awards were made and hence did not receive LTPP and LTRPP awards for the 2017-2019 performance period.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="20">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 4&nbsp;</sup> Includes any other perquisites, benefits in kind, international assignment benefits as per the global mobility policy (e.g., housing, international health insurance, children's school fees, tax equalization) as well as vested shares under LTPP and LTRPP after the ''step down'' date.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="20">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 5&nbsp;</sup> Includes 5 430 vested RSUs (CHF 502 003) on July 28, 2019, to John Tsai, in lieu of the LTI that he forfeited when leaving his previous employer and 1 323 vested RSUs (CHF 123 092) and 14 470 vested PSUs (CHF 1 346 289) on March 24, 2019, to Paul Hudson in lieu of the LTI that he forfeited when leaving his previous employer. The PSUs had the same performance measures as the LTPP for the 2016-2018 performance cycle (NCVA and long-term innovation).</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="20">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 6&nbsp;</sup> All amounts are before deduction of the social security contribution and income tax due by the Executive Committee member.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="20">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 7&nbsp;</sup> Comprises the compensation of Richard Francis, the former CEO of Sandoz including the vesting of his Long-Term Incentives for performance cycle 2017-2019, as per the plan rules. Unvested shares for Paul Hudson were forfeited upon his departure from the Company.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="20">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 8&nbsp;</sup> Amounts for Executive Committee members paid in USD were converted at a rate of USD 1.00 = CHF 0.9938, which is the same average exchange rate used in the Group's 2019 consolidated financial statements.</div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Realized compensation for the CEO and other Executive Committee members for 2020 compared to 2019</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">When comparing the 2020 CEO realized pay to 2019, there is an overall increase of 19.9%. The change is driven by a significant increase in realized LTI due to the following:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The vesting of the CEO&#x2019;s first LTI granted following his appointment to CEO. For the 2018-2020 cycle, Vasant Narasimhan received an increase in target LTI to reflect his promotion from Global Head of Drug Development to CEO. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The vesting of the CEO&#x2019;s Alcon Keep Whole awards. The total vesting value of these Alcon Keep Whole awards was CHF 784 497, which is included in the corresponding LTPP and LTRPP values in the prior tables.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The increase was partly offset by the lower variable incentive performance payout for the 2020 Annual Incentive (100% versus 160% in 2019) and the LTI cycle 2018-2020 (126% for the LTPP and LTRPP combined versus 157% for cycle 2017-2019).</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The 2020 total realized compensation for the Executive Committee members (comprising the CEO and the other 12 active Executive Committee members) was CHF 58 819 813. This is a decrease compared to the prior year and can be attributed to (i) lower Annual Incentive payouts on average and lower 2018-2020 LTI payouts as well as (ii) a reduction in members reported (two members stepped down and were replaced in 2019, whereas no members stepped down in 2020).</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Forecasts for 2021 realized compensation for the other Executive Committee members</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">A number of current members joined the Executive Committee, both from internal and external positions, during 2018. The LTPP 2019-2021 will therefore be their first annual LTI to be realized/fully reported since their appointment. It may therefore be reasonable to expect an increase in realized compensation for these members next year, depending on the performance of the plan against target and the evolution of the share price.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">108</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Compensation at grant value</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In accordance with the Swiss Ordinance against Excessive Compensation in Listed Companies, Novartis continues to disclose total compensation at grant value for the CEO and other Executive Committee members. The following tables disclose for the CEO and other Executive Committee members:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Fixed 2020 compensation (base salary and benefits)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The actual cash portion and the deferred portion granted in equity of the 2020 Annual Incentive</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  2020-2022 LTPP performance cycle awards, which are reported at target value at grant date under the assumption that the awards will vest at 100% achievement, excluding any share price movement and dividend equivalents that may be accrued over the performance cycle. The future payout will be determined only after the performance cycle concludes in three years (i.e., the end of 2022), with a payout range of 0% to 200% of the target value.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Other compensation for 2020, which includes other benefits, either paid in cash or granted in equity in the year</div>
<div style="border:solid #eeeeee 3px; background-color:#eeeeee;padding-bottom:0px;">
  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">To assess CEO actual pay for performance in 2020, including the Annual Incentive payout for the 2020 performance year and the LTI payouts for the 2018-2020 performance cycle, shareholders should refer to the 2020 realized compensation table in &#x201C;&mdash;2020 realized compensation for the CEO and other Executive Committee members.&#x201D;</div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2020 compensation at grant value for the CEO and other Executive Committee members</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Fixed compensation and  pension benefits</div>
      </td>
      <td></td>
      <td colspan="7" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Variable compensation  </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   </div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     </div>
      </td>
      <td></td>
      <td colspan="7" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Actual compensation paid or granted for 2020    </div>
      </td>
      <td></td>
      <td colspan="1" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-Term Incentive   2020-2022 cycle  grants at target</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     </div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">       </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2020 annual base  salary    </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2020 pension  benefits    </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2020 Annual Incentive   (performance achieved)    </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> LTPP 2020-2022 cycle      </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other 2020  compensation    </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total   compensation   paid, promised  or granted 2020</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Currency</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Cash<br> (amount)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Amount<sup style="white-space: nowrap">   1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Cash<br> (amount)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Equity<br> (value at<br> grant date)<sup style="white-space: nowrap">   2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> PSUs<br> (target value<br> at grant date)<sup style="white-space: nowrap">   3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Amount<sup style="white-space: nowrap">   4</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Amount<sup style="white-space: nowrap">   5</sup></div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members active on December 31, 2020</div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;743&nbsp;750</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 175&nbsp;102</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;318&nbsp;275</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;318&nbsp;275</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;712&nbsp;549</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 113&nbsp;841</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&nbsp;381&nbsp;793</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steven Baert</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 798&nbsp;617</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 167&nbsp;294</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 480&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 480&nbsp;022</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;679&nbsp;265</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 85&nbsp;587</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;690&nbsp;785</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bertrand Bodson</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 634&nbsp;834</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 177&nbsp;088</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 256&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 256&nbsp;052</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;152&nbsp;115</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 131&nbsp;745</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;607&nbsp;834</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">James Bradner<sup style="white-space: nowrap">&nbsp;6</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;203&nbsp;654</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 373&nbsp;063</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 768&nbsp;900</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 768&nbsp;963</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;911&nbsp;862</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 88&nbsp;472</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;114&nbsp;914</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Harry Kirsch</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;063&nbsp;433</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 171&nbsp;930</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 585&nbsp;750</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 585&nbsp;814</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;769&nbsp;330</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50&nbsp;294</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;226&nbsp;551</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shannon Thyme Klinger</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 862&nbsp;500</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 182&nbsp;852</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 525&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 525&nbsp;005</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;925&nbsp;517</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32&nbsp;773</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;053&nbsp;647</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steffen Lang</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 758&nbsp;333</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 171&nbsp;130</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 228&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 684&nbsp;038</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;367&nbsp;619</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&nbsp;918</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;222&nbsp;037</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Klaus Moosmayer</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 520&nbsp;833</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 184&nbsp;884</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 241&nbsp;500</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 241&nbsp;516</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 840&nbsp;004</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29&nbsp;496</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;058&nbsp;233</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Richard Saynor</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 778&nbsp;333</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 190&nbsp;372</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 390&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 390&nbsp;055</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;482&nbsp;060</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;737&nbsp;100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;967&nbsp;920</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Susanne Schaffert</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 871&nbsp;250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 173&nbsp;111</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 341&nbsp;445</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 796&nbsp;797</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;013&nbsp;669</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 581&nbsp;188</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;777&nbsp;460</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">John Tsai</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 868&nbsp;333</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 182&nbsp;517</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 478&nbsp;500</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 478&nbsp;560</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;175&nbsp;855</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 104&nbsp;669</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;288&nbsp;434</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marie-France Tschudin</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 871&nbsp;250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 182&nbsp;216</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 437&nbsp;750</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 437&nbsp;791</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;013&nbsp;669</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;942&nbsp;677</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Weltevreden</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 634&nbsp;834</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 186&nbsp;392</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 215&nbsp;040</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 399&nbsp;430</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;152&nbsp;115</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;925</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;590&nbsp;735</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;536&nbsp;583</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;495&nbsp;208</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;219&nbsp;290</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;315&nbsp;444</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 27&nbsp;018&nbsp;132</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;965&nbsp;615</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 57&nbsp;550&nbsp;273</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
      <td bgcolor="#eeeeee" colspan="3" align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&nbsp;Based on assumption of&nbsp;100% payout at target.&nbsp;Actual payout (0-200% of&nbsp;target) will be known at &nbsp;the end of the three-year&nbsp;cycle in January 2023</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">See next page for 2019 comparative figures.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 1&nbsp;</sup> Includes mandatory employer contributions of CHF 8 336 for the CEO and CHF 59 591 for the other Executive Committee members paid by Novartis to governmental social security systems. This amount is out of total employer contributions of CHF 6 088 770 paid in 2020 for all Executive Committee members, and provides a right to the maximum future insured government pension benefit for the Executive Committee members.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 2&nbsp;</sup> The portion of the Annual Incentive delivered in equity is rounded up to the nearest share, based on the closing share price on the grant date (January 20, 2021) of CHF 86.01 per Novartis share and USD 96.92 per ADR.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 3&nbsp;</sup> The amounts represent the underlying share value of the target number of PSUs granted to Executive Committee members for the performance cycle 2020-2022, based on the closing share price on the grant date (January 21, 2020) of CHF 92.89 per Novartis share and USD 95.19 per ADR for all members.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 4&nbsp;</sup> Includes any other perquisites, benefits in kind, and international assignment benefits as per the global mobility policy (e.g., housing, international health insurance, children's school fees, tax equalization)</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 5&nbsp;</sup> All amounts are before deduction of the social security contribution and income tax due by the Executive Committee member.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 6&nbsp;</sup> Amounts in USD for James Bradner were converted at a rate of CHF 1.00 = USD 1.0649, which is the average rate used in the Group&#x2019;s 2020 consolidated financial statements.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">109</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2019 compensation at grant value for the CEO and other Executive Committee members</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For comparative purposes, the table below provides the compensation at grant value for 2019. </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="margin-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:11pt; font-weight:bold; color:#000000;">Executive Committee member compensation at grant for financial year 2019</div>
      </td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Fixed compensation and  pension benefits</div>
      </td>
      <td></td>
      <td colspan="7" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Variable compensation  </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   </div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     </div>
      </td>
      <td></td>
      <td colspan="7" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Actual compensation paid or granted for 2019    </div>
      </td>
      <td></td>
      <td colspan="1" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-Term Incentive  2019-2021 cycle  grants at target</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     </div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">       </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2019 annual base  salary    </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2019 pension  benefits    </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2019 Annual Incentive   (performance achieved)    </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> LTPP   2019-2021 cycle    </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other 2019  compensation    </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total   compensation   paid, promised  or granted 2019</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Currency</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Cash<br> (amount)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Amount<sup style="white-space: nowrap">   1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Cash<br> (amount)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Equity<br> (value at<br> grant date)<sup style="white-space: nowrap">   2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> PSUs<br> (target value<br> at grant date)<sup style="white-space: nowrap">   3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Amount<sup style="white-space: nowrap">   4</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Amount<sup style="white-space: nowrap">   5</sup></div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members active on December 31, 2019</div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;653&nbsp;333</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 165&nbsp;547</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;008&nbsp;800</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;008&nbsp;839</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;440&nbsp;530</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 160&nbsp;452</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&nbsp;437&nbsp;501</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steven Baert</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 789&nbsp;750</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 161&nbsp;454</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 633&nbsp;360</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 633&nbsp;417</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;662&nbsp;585</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 124&nbsp;979</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;005&nbsp;545</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bertrand Bodson</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 607&nbsp;500</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 170&nbsp;178</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 341&nbsp;040</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 341&nbsp;092</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 974&nbsp;476</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 137&nbsp;826</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;572&nbsp;111</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">James Bradner<sup style="white-space: nowrap">&nbsp;6</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;126&nbsp;781</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 359&nbsp;961</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 951&nbsp;720</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 951&nbsp;805</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;832&nbsp;511</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 85&nbsp;498</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;308&nbsp;275</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Harry Kirsch</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;053&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 164&nbsp;467</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;045&nbsp;044</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;045&nbsp;105</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;744&nbsp;591</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27&nbsp;658</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;079&nbsp;865</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shannon Thyme Klinger</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 783&nbsp;333</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 188&nbsp;990</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 468&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 468&nbsp;073</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;600&nbsp;005</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 111&nbsp;375</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;619&nbsp;776</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steffen Lang</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 745&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 167&nbsp;815</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 408&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 612&nbsp;145</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;200&nbsp;026</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;810</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;142&nbsp;796</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Klaus Moosmayer</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 125&nbsp;483</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 260&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 260&nbsp;092</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 800&nbsp;047</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 171&nbsp;749</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;117&nbsp;371</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Richard Saynor (from July 15, 2019)<sup style="white-space: nowrap">&nbsp;7</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 356&nbsp;021</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 87&nbsp;118</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 179&nbsp;315</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 179&nbsp;371</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;950&nbsp;908</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;752&nbsp;732</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Susanne Schaffert<sup style="white-space: nowrap">&nbsp;7</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 850&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 167&nbsp;096</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 459&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;071&nbsp;115</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;870&nbsp;066</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 160&nbsp;252</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;577&nbsp;528</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">John Tsai</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 858&nbsp;333</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 181&nbsp;048</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 602&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 602&nbsp;020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;064&nbsp;063</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 377&nbsp;544</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;685&nbsp;007</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marie-France Tschudin (from June 7, 2019)<sup style="white-space: nowrap">&nbsp;7</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 481&nbsp;667</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 92&nbsp;090</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 290&nbsp;630</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 290&nbsp;653</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 968&nbsp;249</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;123&nbsp;289</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Weltevreden</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 607&nbsp;500</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 157&nbsp;423</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 158&nbsp;340</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 475&nbsp;132</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 974&nbsp;476</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;860</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;377&nbsp;731</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&nbsp;405&nbsp;223</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;186&nbsp;434</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;799&nbsp;341</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;932&nbsp;950</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;114&nbsp;040</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;322&nbsp;378</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 55&nbsp;760&nbsp;366</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members who stepped down during 2019</div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Richard Francis (until March 19, 2019)<sup style="white-space: nowrap">&nbsp;8, 9</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 179&nbsp;315</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36&nbsp;025</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18&nbsp;914</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37&nbsp;435</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 720&nbsp;460</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;808&nbsp;445</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;800&nbsp;594</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Paul Hudson (until June 7, 2019)<sup style="white-space: nowrap">&nbsp;9, 10</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 439&nbsp;342</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 74&nbsp;994</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 270&nbsp;451</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;885&nbsp;164</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;669&nbsp;950</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 618&nbsp;657</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 111&nbsp;018</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&nbsp;914</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 37&nbsp;435</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 990&nbsp;910</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;693&nbsp;609</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;470&nbsp;543</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;023&nbsp;880</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;297&nbsp;452</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;818&nbsp;255</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;970&nbsp;384</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 24&nbsp;104&nbsp;951</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&nbsp;015&nbsp;988</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 64&nbsp;230&nbsp;910</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
      <td bgcolor="#eeeeee" colspan="3" align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&nbsp;Based on assumption of&nbsp;100% payout at target.&nbsp;Actual payout (0-200% of&nbsp;target) will be known at &nbsp;the end of the three-year&nbsp;cycle in January 2022.</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 1&nbsp;</sup> Includes mandatory employer contributions of CHF 4'373 for the CEO and CHF 63'461 for the other Executive Committee members paid by Novartis to governmental social security systems. This amount is out of total employer contributions of CHF 3'923'070 paid in 2019 for all Executive Committee members, and provides a right to the maximum future insured government pension benefit for the Executive Committee member.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 2&nbsp;</sup> The portion of the Annual Incentive delivered in equity is rounded up to the nearest share, based on the closing share price on the grant date (January 21, 2020) of CHF 92.89 per Novartis share and USD 95.19 per ADR.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 3&nbsp;</sup> The amounts represent the underlying share value of the target number of PSUs granted to Executive Committee members for the performance cycle 2019-2021, based on the closing share price on the grant date (January 22, 2019) of CHF 88.14 per Novartis share and USD 88.32 per ADR for all members except for Richard Saynor, who was not part of the Company at the annual grant date and hence did not receive an LTPP award.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 4&nbsp;</sup> Includes any other perquisites, benefits in kind, and international assignment benefits as per the global mobility policy (e.g., housing, international health insurance, children's school fees, tax equalization).</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 5&nbsp;</sup> All amounts are before deduction of the social security contribution and income tax due by the Executive Committee member.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 6&nbsp;</sup> Amounts in USD for James Bradner were converted at a rate of CHF 1.00 = USD 1.006, which is the average rate used in the Group&#x2019;s 2019 consolidated financial statements.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 7&nbsp;</sup> For those members who joined the Executive Committee in 2019, the information under the columns &#x201C;Actual compensation paid or granted for 2019&#x201D; and &#x201C;Long-Term Incentive 2019-2021 cycle grants at target&#x201D; includes their pro-rata compensation from the date they joined the Executive Committee to December 31, 2019, or to the end of the performance cycle in the case of the &#x201C;Long-Term Incentive 2019-2021 cycle grants at target.&#x201D;</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 8&nbsp;</sup> Richard Francis stepped down as CEO, Sandoz on March 19, 2019, and left the Company on March 31, 2020, in line with his contractual notice period. Until the end of the notice period, he received further contractual compensation that includes the base salary, Annual Incentive and pension benefits. In accordance with the plan rules, the LTPP 2019-2021 cycle grant (21 217 PSUs), included in full in the above table, will vest on the normal vesting date pro-rata based on the number of months of Novartis employment during the performance cycle. The vesting of this grant is subject to performance conditions assessed at the end of the period.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 9&nbsp;</sup> For those members leaving the Executive Committee in 2019, the columns under &#x201C;Actual compensation paid or granted for 2019&#x201D; and &#x201C;Long-Term Incentive 2019-2021 cycle grants at target&#x201D; reflect the pro-rata compensation for their period as Executive Committee member. The column &#x201C;Other 2019 compensation&#x201D; includes inter alia their pro-rata compensation from the date they left the Executive Committee to December 31, 2019, or to the end of the performance cycle in the case of the &#x201C;Long-Term Incentive 2019-2021 cycle grants at target&#x201D;. See &#x201C;&#x2014;2019 Executive Committee member departures" for details.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup> 10&nbsp;</sup> Paul Hudson stepped down as CEO, Novartis Pharmaceuticals on June 7, 2019, and left the Company on August 31, 2019, in line with his reduced contractual notice period (for more details &#x201C;&#x2014;2019 Executive Committee member departures.&#x201D;) The Annual Incentive and LTPP 2019-2021 cycle grant (31 553 PSUs), included in the table above, were forfeited in full upon his departure.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">110</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Compensation at grant value for the CEO and other Executive Committee for 2020 compared to 2019</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Grant compensation delivered to the CEO decreased slightly by CHF 1.1 million from 2019 to 2020, largely due to the lower Annual Incentive payout, which was partly offset by a 5% increase in annual base salary from March 31, 2020, as reported in Item 6.B of the 2019 Annual Report. There was no change to his target Annual Incentive or his target Long-Term Incentive, as a percentage of annual base salary, in 2020.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Similarly, there is an overall decrease when comparing the 2020 Executive Committee total compensation at grant value of CHF 57. 6  million to the 2019 grant value of CHF 64.2 million. This reduction can be largely explained by the fact that two members stepped down in 2019, whereas no members stepped down in 2020.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">111</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Additional disclosures for the CEO and other Executive Committee members</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">This section provides additional disclosures, including information about the shareholdings of the CEO and the other Executive Committee members.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Malus and clawback</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Per our &#x201C;&mdash;Executive Committee compensation philosophy and principles,&#x201D; in 2020, there was no legal or factual basis on which to exercise malus or clawback for current or former Executive Committee members. </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Number of equity instruments granted to the CEO and other Executive Committee members for financial year 2020</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Variable compensation<sup>1</sup></div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td colspan="1" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2020 Annual Incentive  (performance achieved)</div>
      </td>
      <td></td>
      <td colspan="1" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> LTPP  2020-2022 cycle</div>
      </td>
      <td></td>
      <td colspan="1" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other  </div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity<br> (number)<sup style="white-space: nowrap">  2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> PSUs<br> (target number)<sup style="white-space: nowrap">  3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity/PSUs<br> (number)</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members active on December 31, 2020</div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&nbsp;327</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 61&nbsp;498</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steven Baert</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;581</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18&nbsp;078</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bertrand Bodson</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;977</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&nbsp;403</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">James Bradner</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;934</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30&nbsp;590</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Harry Kirsch</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;811</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29&nbsp;813</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shannon Thyme Klinger</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;104</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20&nbsp;729</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steffen Lang</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;953</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&nbsp;723</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Klaus Moosmayer</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;808</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;043</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Richard Saynor</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;535</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&nbsp;955</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Susanne Schaffert</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;264</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21&nbsp;678</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">John Tsai</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;564</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23&nbsp;424</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marie-France Tschudin</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;090</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21&nbsp;678</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Weltevreden</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;644</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&nbsp;403</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 84&nbsp;592</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 292&nbsp;015</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">See next page for 2019 comparative figures.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> The values of the awards are reported in the table "2020 compensation at grant value for the CEO and other Executive Committee members."</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Vested shares, restricted shares and/or RSUs granted under the Annual Incentive for performance period 2020.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Target number of PSUs granted under the LTPP as applicable for the performance cycle 2020-2022.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">112</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Number of equity instruments granted to the CEO and other Executive Committee members for financial year 2019 (comparative information)</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Variable compensation<sup>1</sup></div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td colspan="1" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2019 Annual Incentive  (performance achieved)</div>
      </td>
      <td></td>
      <td colspan="1" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> LTPP  2019-2021 cycle</div>
      </td>
      <td></td>
      <td colspan="1" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other  </div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity<br> (number)<sup style="white-space: nowrap">  2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> PSUs<br> (target number)<sup style="white-space: nowrap">  3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity/PSUs<br> (number)</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members active on December 31, 2019</div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21&nbsp;626</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 61&nbsp;726</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steven Baert</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;819</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18&nbsp;863</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bertrand Bodson</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;672</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&nbsp;056</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">James Bradner</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;999</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32&nbsp;071</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Harry Kirsch</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&nbsp;251</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31&nbsp;139</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shannon Thyme Klinger</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;039</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18&nbsp;153</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steffen Lang</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;590</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&nbsp;615</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Klaus Moosmayer</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;800</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;077</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Richard Saynor (from July 15, 2019)<sup style="white-space: nowrap">&nbsp;4</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;931</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&nbsp;452</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Susanne Schaffert</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&nbsp;531</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21&nbsp;217</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">John Tsai</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;481</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23&nbsp;418</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marie-France Tschudin (from June 7, 2019)<sup style="white-space: nowrap">&nbsp;4</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;129</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&nbsp;085</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Weltevreden</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;115</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&nbsp;056</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 95&nbsp;983</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 262&nbsp;476</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;452</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members who stepped down during 2019</div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Richard Francis (until March 19, 2019)<sup style="white-space: nowrap">&nbsp;5, 6</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 403</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;841</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Paul Hudson (until June 7, 2019)<sup style="white-space: nowrap">&nbsp;5, 7</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;525</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 403</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;366</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 96&nbsp;386</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 275&nbsp;842</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;452</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> The values of the awards are reported in the table "2019 compensation at grant value for the CEO and other Executive Committee members."</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Vested shares, restricted shares and/or RSUs granted under the Annual Incentive for performance period 2019.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Target number of PSUs granted under the LTPP as applicable for the performance cycle 2019-2021.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> For those members who joined the Executive Committee in 2019, the information under the column &#x201C;Variable compensation&#x201D; includes their pro-rata number of equity instruments from the date they joined the Executive Committee to December 31, 2019, or to the end of the performance cycle in the case of the "LTPP 2019-2021 cycle."</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;5&nbsp;</sup> For those members leaving the Executive Committee in 2019, the column under &#x201C;Variable compensation&#x201D; reflects the pro-rata number of equity instruments for their period as Executive Committee member. The column &#x201C;Other&#x201D; includes their pro-rata compensation from the date they left the Executive Committee to December 31, 2019, or to the end of the performance cycle in the case of the &#x201C;LTPP 2019-2021 cycle.&#x201D; See &#x201C;2019 Executive Committee member departures&#x201D; for details.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;6&nbsp;</sup> Richard Francis stepped down as CEO, Sandoz on March 19, 2019, and left the Company on March 31, 2020, in line with his contractual notice period. In accordance with the plan rules, the LTPP 2019-2021 cycle grant (21 217 PSUs), included in full in the above table, will vest on the normal vesting date pro-rata based on the number of months of Novartis employment during the performance cycle. The vesting of this grant is subject to performance conditions assessed at the end of the period.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;7&nbsp;</sup> Paul Hudson stepped down as CEO, Novartis Pharmaceuticals on June 7, 2019, and left the Company on August 31, 2019, in line with his reduced contractual notice period (for more details &#x201C;&#x2014;2019 Executive Committee member departures&#x201D;). The 2019 Annual Incentive and LTPP 2019-2021 cycle grant (31 553 PSUs), included in the table above, were forfeited in full upon his departure.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">113</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Share ownership requirements for the CEO and other Executive Committee members</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Executive Committee members are required to own at least a minimum multiple of their annual base salary in Novartis shares or RSUs within five years of hire or promotion, as set out in the table below. In addition, the CEO and CFO are required to hold the equity vesting under the LTPP plan (granted since 2020) for a minimum of two years after the vesting date. In the event of a substantial rise or drop in the share price, the Board of Directors may, at its discretion, amend that time period accordingly.</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;">Function</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;"> Ownership level</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CEO</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 x base compensation</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other Executive Committee members</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 x base compensation</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The determination of equity amounts against the share ownership requirements is defined to include vested and unvested Novartis shares or American Depositary Receipts (ADRs), and RSUs acquired under the Company&#x2019;s compensation plans. However, unvested matching shares granted under former matching programs, such as the Leveraged Share Savings Plan (LSSP), and any unvested PSUs are excluded. The determination also includes other shares and vested options of Novartis shares or ADRs that are owned directly or indirectly by &#x201C;persons closely linked&#x201D; to an Executive Committee member. The Compensation Committee reviews compliance with the share ownership guideline on an annual basis.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Shares, ADRs and other equity rights owned by Executive Committee members at December 31, 2020<sup>1</sup></font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows, in alphabetical order after the CEO, the total number of shares, ADRs and other equity rights owned by the CEO and the other Executive Committee members and &#x201C;persons closely linked&#x201D; to them as of December 31, 2020. As of December 31, 2020, no members of the Executive Committee, either individually or together with &#x201C;persons closely linked&#x201D; to them, owned 1% or more of the outstanding shares or ADRs of Novartis. As of December 31, 2020, all members who have served at least five years on the Executive Committee have met or exceeded their personal Novartis share ownership requirements.</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Vested shares <br> and ADRs<sup style="white-space: nowrap">   1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Unvested shares <br> and other equity rights<sup style="white-space: nowrap">   2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity ownership level <br> as a multiple of <br> annual base salary<sup style="white-space: nowrap">   3</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Unvested target PSUs <br> (e.g., LTPP/LTRPP)<sup style="white-space: nowrap">   4</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Matching shares <br> under the LSSP<sup style="white-space: nowrap">   5</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total at<br> December 31, <br> 2020</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 104&nbsp;277</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 90&nbsp;466</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9x</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 159&nbsp;962</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;342</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 358&nbsp;047</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steven Baert</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 69&nbsp;679</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&nbsp;773</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10x</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 51&nbsp;501</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 149&nbsp;953</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bertrand Bodson</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&nbsp;403</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;869</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2x</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24&nbsp;193</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44&nbsp;465</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">James Bradner</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 69&nbsp;551</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 41&nbsp;274</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8x</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 83&nbsp;724</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 194&nbsp;549</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Harry Kirsch</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 198&nbsp;331</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37&nbsp;457</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18x</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 82&nbsp;446</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 318&nbsp;234</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shannon Thyme Klinger</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29&nbsp;128</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23&nbsp;248</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5x</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37&nbsp;547</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;884</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 91&nbsp;807</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steffen Lang</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 81&nbsp;714</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&nbsp;413</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11x</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31&nbsp;543</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;726</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 143&nbsp;396</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Klaus Moosmayer</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;011</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;824</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1x</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&nbsp;153</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27&nbsp;988</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Richard Saynor</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&nbsp;746</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1x</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;578</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23&nbsp;324</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Susanne Schaffert</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 106&nbsp;981</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30&nbsp;548</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13x</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 45&nbsp;844</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 183&nbsp;373</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">John Tsai</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17&nbsp;783</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&nbsp;981</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4x</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32&nbsp;896</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 79&nbsp;660</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marie-France Tschudin</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&nbsp;300</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29&nbsp;212</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3x</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 46&nbsp;636</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 88&nbsp;148</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Weltevreden</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;734</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&nbsp;395</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1x</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30&nbsp;050</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 45&nbsp;179</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 708&nbsp;892</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 378&nbsp;206</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 652&nbsp;073</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;952</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;748&nbsp;123</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Includes holdings of "persons closely linked" to Executive Committee members (see definition &#x201C;Persons closely linked")</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Includes unvested shares and ADRs as well as other equity rights applicable for the determination of equity amounts for the share ownership requirements, as per the definition above. Also includes unvested Alcon Keep Whole shares received in connection to the Alcon spin-off.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> The multiple is calculated based on the full-year annual base salary and the closing share price as at the end of the 2020 financial year. The share price on the final trading day of 2020 was CHF 83.65 / USD 94.43 as at December 31, 2020.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> The target number of PSUs is disclosed pro-rata to December 31, 2020, unless the award qualified for full vesting under the relevant plan rules.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;5&nbsp;</sup> Matching shares under the Leveraged Share Savings Plan (LSSP) are disclosed pro-rata to December 31, 2020, unless the award qualified for full vesting under the plan rules. LSSP participation for Executive Committee members ceased in 2014, although some current members received later grants under this plan prior to becoming members of the Executive Committee. Outstanding awards will vest five years from the grant date, subject to the LSSP plan rules.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">114</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Fixed and variable compensation</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The CEO and other Executive Committee members&#x2019; annual base salary and variable compensation mix at grant value for financial year 2020:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Annual <br> base salary<sup style="white-space: nowrap">  1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Variable<br> compensation<sup style="white-space: nowrap">  2</sup></div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17.1%</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 82.9%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steven Baert</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22.7%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 77.3%</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bertrand Bodson</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26.1%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 73.9%</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">James Bradner</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21.0%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 79.0%</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Harry Kirsch</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21.0%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 79.0%</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shannon Thyme Klinger</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22.3%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 77.7%</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steffen Lang</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24.9%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 75.1%</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Klaus Moosmayer</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27.8%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 72.2%</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Richard Saynor</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16.3%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 83.7%</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Susanne Schaffert</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.9%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 81.1%</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">John Tsai</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21.1%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 78.9%</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marie-France Tschudin</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.2%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76.8%</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Weltevreden</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26.4%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 73.6%</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 21.0%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 79.0%</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Excludes pension and other benefits.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> See the table ''2020 compensation at grant value for the CEO and other Executive Committee members'' with regard to the disclosure principles of variable compensation.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other payments to Executive Committee members </font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2020, no other payments or waivers of claims other than those set out in the tables (including their footnotes) contained in this Compensation Report were made to Executive Committee members or to &#x201C;persons closely linked&#x201D; to them.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Payments to former Executive Committee members</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Under the former Executive Committee members&#x2019; contracts and in line with the Company&#x2019;s LTI plan rules, payments were made to 8 former members. Of this, CHF 11 559 192 relates to the vesting of the LTPP and LTRPP for the 2018-2020 performance cycle and the vesting of buyout awards. In addition, contractual amounts totaling 643 065 were made (comprising base salary, the Annual Incentive and other benefits), and 3 individuals received CHF 3 147 567 in tax equalization on incentive compensation granted during an international assignment.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">No other payments (or waivers of claims) were made to former Executive Committee members or to &#x201C;persons closely linked&#x201D; to them during 2020.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Loans to Executive Committee members</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our policy does not allow loans to be granted to current or former members of the Executive Committee or to &#x201C;persons closely linked&#x201D; to them. Therefore, no loans were granted in 2020, and none were outstanding as of December 31, 2020.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Persons closely linked</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">&#x201C;Persons closely linked&#x201D; are (i) their spouse, (ii) their children below age 18, (iii) any legal entities that they own or otherwise control, and (iv) any legal or natural person who is acting as their fiduciary.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Note 27 to the Group&#x2019;s audited consolidated financial statements</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The total expense for the year for compensation awarded to Executive Committee and Board members, using International Financial Reporting Standards (IFRS) measurement rules, is presented in Note 27 to the Group&#x2019;s audited consolidated financial statements.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Award and delivery of equity to Novartis associates </font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2020, 14.7 million unvested restricted shares (or ADRs), RSUs and target PSUs were granted, and 13.8 million Novartis vested shares (or ADRs) were delivered to Novartis associates under various equity-based participation plans. Current unvested equity instruments (restricted shares, RSUs and target PSUs) and outstanding equity options held by associates represent 1.38% of issued shares. Novartis delivers treasury shares to associates to fulfill these obligations, and aims to offset the dilutive impact from its equity-based participation plans.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">115</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Interim update regarding ongoing LTI performance cycles </font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">    Below we report how performance is tracking against target for our ongoing LTI performance cycles. </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2019-2021 LTPP </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">This will be the first cycle vesting under the new system of four equally weighted measures: net sales CAGR, core operating income CAGR, innovation and relative TSR. After the first two years of the three-year LTI performance cycle, net sales CAGR is tracking above target despite a slowdown in sales in 2020, due to a significant over-delivery in 2019. Core operating income is exceeding expectations and is currently above target. Innovation for the cycle is currently tracking at target, with a number of target filings already achieved. Forecasts at the end of December place the Novartis relative TSR at median among our global healthcare peer group.  </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;">Performance measures</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;"> Tracking</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net sales growth CAGR (25%)</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Above target</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating income CAGR (25%)</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Above target</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovation (25%)</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> At target</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Relative TSR (25%)</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> At median</div>
      </td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="4">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="4">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">CAGR = compound annual growth rate</div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2020-2022 LTPP </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">After the first year of the three-year performance cycle, net sales CAGR is tracking below target. This is largely due to the impact of the pandemic on our sales execution. Core operating income CAGR is tracking above target, mainly driven by gross margin improvements and lower-than-planned function costs. Innovation is tracking at target, against the selected development projects in Innovative Medicines published in Item 4.B of this report. Relative TSR is currently positioned 11 out of a peer group of 15 (including Novartis).</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;">Performance measures</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;"> Tracking</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net sales growth CAGR (25%)</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Below target</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating income CAGR (25%)</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Above target</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovation (25%)</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> At target</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Relative TSR (25%)</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Below median</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="4">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="4">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">CAGR = compound annual growth rate</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">116</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div><a name="anchorId00946569"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">2021 Executive Committee compensation</p><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Executive Committee member appointments and departures</font>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Appointment of Head of Customer &amp; Technology Solutions - Robert Weltevreden</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Robert Weltevreden joined the Executive Committee on June 1, 2018 as Head of Novartis Business Services (NBS). Effective February 1, 2021, the Digital function will be merged with NBS to form a new Customer and Technology Solutions unit, which Mr. Weltevreden has been appointed to lead. Effective March 1, 2021, Mr. Weltevreden will receive an annual base salary of CHF 680 000, a target Annual Incentive of 80%, and a target Long-Term Incentive of 190%. This represents an increase in annual base salary of 6.3% and a 10% increase in target LTI, as a percentage of his annual base salary. There is no change to his target Annual Incentive.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Departure of Chief Digital Officer - Bertrand Bodson</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Mr. Bodson will step down from the Executive Committee on February 1, 2021. Mr. Bodson will be treated as a good leaver for compensation purposes in line with the policy outlined in the &#x201C;&mdash;Treatment of variable compensation for Executive Committee leavers&#x201D;. During his contractual notice period, which ends on January 31, 2022, he will receive his annual base salary, benefits and Annual Incentive at target level in accordance with the Annual Incentive plan rules. He did not receive a Long-Term Performance Plan grant in January 2021 for the 2021-2023 performance cycle.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Mr. Bodson&#x2019;s unvested Long-Term Incentives for outstanding performance cycles will be pro-rated for time employed during the three-year performance periods. In line with the plan rules, there will be no accelerated vesting, as awards will remain subject to performance over the full cycle. Clawback and malus, and non-compete restrictions as defined by the plan rules will apply. No severance or non-compete payments will be made.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">2021 Executive Committee member compensation increases</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As outlined in &#x201C;&mdash;Executive Committee appointments compensation policy,&#x201D; some members were appointed with total target compensation below external market median level. Each year, we collaborate with our advisors to benchmark the compensation levels of the members of the Executive Committee. Taking the current climate of the pandemic into consideration, while bearing in mind the need to ensure our competitiveness in a global competitive talent market, the following members will receive an increase in total target compensation for 2021, in line with their demonstrated performance and ability in their respective roles. </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Steffen Lang, Head of Novartis Technical Operations</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Steffen Lang led the manufacturing and supply chain function to a very strong financial and operational performance in 2020. Highlights included the uninterrupted supply during the pandemic, the further improvement of our manufacturing network utilization and footprint, the upscaling of data and digital technologies in NTO and an outstanding improvement in our environmental impact. Effective March 1, 2021, Mr. Lang will receive an annual base salary increase of 3.3% and an increase in target Annual Incentive of 10%, as a percentage of annual base salary. He will also receive a target Long-Term Incentive (LTI) increase of 20%, as a percentage of annual base salary. </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Klaus Moosmayer, Chief Ethics, Risk and Compliance Officer</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Having joined Novartis in December 2018, Mr. Moosmayer is a globally recognized leader in compliance and risk management.  He plays a key role in Novartis trust with society priority.  Mr. Moosmayer is leading the roll-out of the Code of Ethics and advancing our Third Party Risk Management practice as well as coordinating our COVID-19 risk management, enabling the organization to function seamlessly. Effective March 1, 2021, Mr. Moosmayer will receive an annual base salary increase of 9.5% and a 20% increase in target LTI, as a percentage of annual base salary. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Another two ECN members will receive a 10% increase for their LTI target 2021-2023 (in addition to an annual base salary increase in line with local market increases), leading to an overall increase in target compensation not exceeding 3%. The LTI is subject to three-year performance conditions and provides for an overall payout between 0% and 200%.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">All other Executive Committee members, including the CEO, were awarded annual base salary increases in line with the annual compensation review applicable to all associates in Switzerland and, where applicable, the US.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">117</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-top:10px;  padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Implementation of a Global Employee Share Plan</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2020, the Board of Directors approved the implementation of a global Employee Share Purchase Plan (ESPP). Novartis aims to launch in country waves over the next five years, which will provide associates, including Executive Committee members, the option to invest up to 15% of their base salary (capped at USD 25 000) to purchase Novartis shares at a 15% discount. The shares purchased under this plan will be subjected to a minimum mandatory two-year holding period.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">118</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div><a name="anchorId00946611"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">2020 Board compensation</p><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Philosophy and benchmarking</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Aligned with market practice in Switzerland, the Board of Directors sets compensation for its members at a level that allows for the attraction of high-caliber individuals, including both Swiss and international members, who have global experience.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Board members do not receive variable compensation, in line with their focus on corporate strategy, supervision and governance. Each year at the AGM, shareholders are requested to approve, in a binding vote, the total compensation of the Board of Directors until the following AGM.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Board of Directors sets the level of compensation for its Chairman and the other members to be in line with relevant benchmark companies, which include other large Switzerland-based multinational companies: ABB, Credit Suisse, Lafarge Holcim, Nestl&#xE9;, Roche and UBS. This peer group was chosen for Board compensation due to the comparability of Swiss legal requirements, including broad personal and individual liabilities under Swiss law (and new criminal liability under Swiss rules regarding board and executive committee compensation related to the Ordinance against Excessive Compensation in Listed Companies), and under US law (due to the Company&#x2019;s secondary listing on the New York Stock Exchange). The Board of Directors reviews the compensation of its members, including the Chairman, each year based on a proposal by the Compensation Committee and on advice from its independent advisor, including relevant benchmarking information. The peer group used for the Board of Directors is different than that used for the Executive Committee to ensure independence of decision-making.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Chairman&#x2019;s contract and the Board of Directors compensation policy do not provide for any termination-related payments.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Chairman of&nbsp;the&nbsp;Board</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As Chairman, Joerg Reinhardt receives total annual compensation valued at CHF 3.8 million. The total compensation is comprised equally of cash and shares, as follows:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Cash compensation: CHF 1.9 million per year</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Share compensation: annual value equal to CHF 1.9 million of unrestricted Novartis shares</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For 2020, the Chairman voluntarily waived the increase in compensation to which he is contractually entitled, which is an amount not lower than the average annual compensation increase awarded to associates based in Switzerland (0.8% for 2020). </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Other Board&nbsp;members</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The annual fee rates for Board membership and additional functions are included in the table below. These were approved by the Board of Directors with effect from the 2020 AGM. Aggregate Board compensation is aligned with other large Swiss companies.</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br>CHF 000s</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2020-2021 AGM <br> annual fee</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chairman of the Board</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;800</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Board membership</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 280</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vice Chairman</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chair of the Audit and Compliance Committee</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 130</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chair of the Compensation Committee</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 90</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chair of the following committees:<br> &#x2022; Governance, Nomination and <br>  Corporate Responsibilities Committee<br> &#x2022; Science &amp; Technology Committee<br> &#x2022; Risk Committee</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  <br>  <br>  70</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Membership of the Audit <br> and Compliance Committee</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  70</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Membership of the following committees:<br> &#x2022; Compensation Committee<br> &#x2022; Governance, Nomination and <br>  Corporate Responsibilities Committee<br> &#x2022; Science &amp; Technology Committee<br> &#x2022; Risk Committee</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br>  <br>  <br>  <br>  <br>  40</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In addition, the following policies apply regarding Board compensation:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; 50% of compensation is delivered in cash, paid on a quarterly basis in arrears. Board members may choose to receive more of their compensation in shares instead of cash.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; At least 50% of compensation is delivered in shares in two installments: one six months after the AGM, and one 12 months after the AGM.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Board members bear the full cost of their employee social security contributions, if any, and do not receive share options or pension benefits. </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">2021 Board compensation</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2020, the Compensation Committee reviewed, with its independent advisor, the Board of Directors&#x2019; compensation system against the Swiss Market Index. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">They found that the Chairman and retainer fees of the other Board members are well positioned and competitive among the benchmarked companies in relation to the Company&#x2019;s size, operational complexity and corporate headquarters location. The Board of Directors compensation system and fee levels will therefore remain unchanged in 2021. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Lead Independent Director Role is currently combined with the Vice Chair role, and no additional compensation will be paid.  It is expected that the Lead Independent Director role will evolve going forward and compensation for this role will be kept under review.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">119</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Board member total compensation earned for the financial year 2020</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="middle">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">       Board   membership</div>
      </td>
      <td></td>
      <td align="middle">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     Audit and  Compliance  Committee</div>
      </td>
      <td></td>
      <td align="middle">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">       Compensation   Committee</div>
      </td>
      <td></td>
      <td align="middle">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Governance,   Nomination   and Corporate   Responsibilities   Committee</div>
      </td>
      <td></td>
      <td align="middle">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     Science &amp;   Technology  Committee</div>
      </td>
      <td></td>
      <td align="middle">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">       Risk  Committee</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">       Shares   (number)<sup style="white-space: nowrap">         1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     Cash   (CHF)  (A)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     Shares   (CHF)  (B)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     Other  (CHF)  (C)<sup style="white-space: nowrap">         2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     Total  (CHF)  (A)+(B)+(C)<sup style="white-space: nowrap">         3</sup></div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #ffffff 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td colspan="24">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Board members active on December 31, 2020</div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Joerg Reinhardt<sup style="white-space: nowrap">&nbsp;4</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chair</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chair</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22&nbsp;629</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;900&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;900&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;501</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;804&nbsp;501</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Enrico Vanni</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Vice Chair</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chair</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;156</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 265&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 265&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;614</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 533&nbsp;614</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nancy C. Andrews</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;143</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 180&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 180&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 360&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ton Buechner</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;508</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29&nbsp;167</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 354&nbsp;167</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;501</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 387&nbsp;835</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Patrice Bula</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;750</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 133&nbsp;333</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 186&nbsp;666</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;501</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 324&nbsp;500</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Srikant Datar</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chair</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;348</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 153&nbsp;333</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 306&nbsp;666</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 459&nbsp;999</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Elizabeth Doherty</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chair</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;424</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 131&nbsp;250</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 318&nbsp;750</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 450&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ann Fudge</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;249</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 183&nbsp;333</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 183&nbsp;333</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 366&nbsp;666</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bridgette Heller<sup style="white-space: nowrap">&nbsp;5</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;059</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 133&nbsp;333</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 133&nbsp;333</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 266&nbsp;666</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frans van Houten</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;810</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 320&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 320&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Simon Moroney<sup style="white-space: nowrap">&nbsp;5</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;059</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 133&nbsp;333</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 133&nbsp;333</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;501</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 271&nbsp;167</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Andreas von Planta</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chair</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;739</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 230&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 230&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;501</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 464&nbsp;501</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charles L. Sawyers</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;143</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 180&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 180&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 360&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">William T. Winters</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;<sup style="white-space: nowrap">&nbsp;5</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;287</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 360&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 360&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #ffffff 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 58&nbsp;304</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;652&nbsp;082</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;051&nbsp;248</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26&nbsp;118</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;729&nbsp;448</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="24" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="24">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="24">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">See next page for 2019 comparative figures.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="24">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 1&nbsp;</sup> The shown amounts represent the gross number of shares delivered to each Board member in 2020 for the respective Board member&#x2019;s service period. The number of shares reported in this column represent: (i) the second and final equity installment delivered in February 2020 for the services from the 2019 AGM to the 2020 AGM, and (ii) the first of two equity installments delivered in August 2020 for the services from the 2020 AGM to the 2021 AGM. The second and final equity installment for the services from the 2020 AGM to the 2021 AGM will take place in February 2021.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="24">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 2&nbsp;</sup> Includes an amount of CHF 26 118 for mandatory employer contributions for all Board members paid by Novartis to governmental social security systems. This amount is out of total employer contributions of CHF 430 023 , and provides a right to the maximum future insured government pension benefit for the Board member.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="24">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 3&nbsp;</sup> All amounts are before deduction of the social security contribution and income tax due by the Board member.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="24">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 4&nbsp;</sup> No additional committee fees for chairing the Science &amp; Technology Committee were delivered to Joerg Reinhardt.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="24">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 5&nbsp;</sup> From February 28, 2020.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="24">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="24">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="24">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup>           </div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">120</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Board member total compensation earned for the financial year 2019</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="middle">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">       Board   membership</div>
      </td>
      <td></td>
      <td align="middle">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     Audit and  Compliance  Committee</div>
      </td>
      <td></td>
      <td align="middle">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">       Compensation   Committee</div>
      </td>
      <td></td>
      <td align="middle">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Governance,   Nomination   and Corporate   Responsibilities   Committee</div>
      </td>
      <td></td>
      <td align="middle">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     Research &amp;  Development  Committee</div>
      </td>
      <td></td>
      <td align="middle">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">       Risk  Committee</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">       Shares   (number)<sup style="white-space: nowrap">         1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     Cash   (CHF)  (A)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     Shares   (CHF)  (B)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     Other  (CHF)  (C)<sup style="white-space: nowrap">         2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     Total  (CHF)  (A)+(B)+(C)<sup style="white-space: nowrap">         3</sup></div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #ffffff 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td colspan="24">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Board members active on December 31, 2019</div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Joerg Reinhardt<sup style="white-space: nowrap">&nbsp;4</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> Chair</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> Chair</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21&nbsp;498</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;900&nbsp;000</div>
      </td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;900&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;373</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;804&nbsp;373</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Enrico Vanni</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> Vice Chair</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> Chair</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;494</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 220&nbsp;833</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 309&nbsp;166</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;512</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 533&nbsp;511</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nancy Andrews</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;035</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 180&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 180&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 360&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ton Buechner</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;967</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 145&nbsp;833</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 204&nbsp;166</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;373</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 354&nbsp;372</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Patrice Bula<sup style="white-space: nowrap">&nbsp;5</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;813</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 266&nbsp;667</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;373</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 271&nbsp;040</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Srikant Datar</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> Chair</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;602</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 230&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 230&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 460&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Elizabeth Doherty</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> Chair</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;544</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 225&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 225&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 450&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ann Fudge</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;262</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 200&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 200&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 400&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frans van Houten</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;716</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26&nbsp;667</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 293&nbsp;334</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 320&nbsp;001</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Andreas von Planta</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> Chair</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;602</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 230&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 230&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;373</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 464&nbsp;373</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charles L. Sawyers</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;035</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 180&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 180&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 360&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">William T. Winters</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;<sup style="white-space: nowrap">&nbsp;5</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;620</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 353&nbsp;333</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 353&nbsp;333</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #ffffff 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
      <td style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="middle" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 51&nbsp;188</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;538&nbsp;333</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;571&nbsp;666</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 21&nbsp;002</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;131&nbsp;001</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 3px;"></td>
      <td style="border-bottom: solid #000000 3px;"></td>
      <td style="border-bottom: solid #000000 3px;"></td>
      <td style="border-bottom: solid #000000 3px;"></td>
      <td style="border-bottom: solid #000000 3px;"></td>
      <td style="border-bottom: solid #000000 3px;"></td>
      <td style="border-bottom: solid #000000 3px;"></td>
      <td style="border-bottom: solid #000000 3px;"></td>
      <td style="border-bottom: solid #000000 3px;"></td>
      <td style="border-bottom: solid #000000 3px;"></td>
      <td style="border-bottom: solid #000000 3px;"></td>
      <td style="border-bottom: solid #000000 3px;"></td>
      <td style="border-bottom: solid #000000 3px;"></td>
      <td style="border-bottom: solid #ffffff 3px;"></td>
      <td style="border-bottom: solid #000000 3px;"></td>
      <td style="border-bottom: solid #000000 3px;"></td>
      <td style="border-bottom: solid #000000 3px;"></td>
      <td style="border-bottom: solid #000000 3px;"></td>
      <td style="border-bottom: solid #000000 3px;"></td>
      <td style="border-bottom: solid #000000 3px;"></td>
      <td style="border-bottom: solid #000000 3px;"></td>
      <td style="border-bottom: solid #000000 3px;"></td>
      <td style="border-bottom: solid #000000 3px;"></td>
      <td style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="24">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="24">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 1&nbsp;</sup> The shown amounts represent the gross number of shares delivered to each Board member in 2019 for the respective Board member&#x2019;s service period. The number of shares reported in this column represent: (i) the second and final equity installment delivered in February 2019 for the services from the 2018 AGM to the 2019 AGM, and (ii) the first of two equity installments delivered in August 2019 for the services from the 2019 AGM to the 2020 AGM.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="24">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 2&nbsp;</sup> Includes an amount of CHF 21'002 for mandatory employer contributions for all Board members paid by Novartis to governmental social security systems. This amount is out of total employer contributions of CHF 413'985 , and provides a right to the maximum future insured government pension benefit for the Board member.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="24">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 3&nbsp;</sup> All amounts are before deduction of the social security contribution and income tax due by the Board member.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="24">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 4&nbsp;</sup> No additional committee fees for chairing the Research &amp; Development Committee were delivered to Joerg Reinhardt.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="24">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 5&nbsp;</sup> From February 28, 2019.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="24">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp; 6&nbsp;</sup> Until February 28, 2019.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">121</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Additional disclosures</font>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Share ownership requirements for Board members </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Chairman is required to own a minimum of 30000 Novartis shares, and other members of the Board of Directors are required to own at least 5000 Novartis shares within five years after joining the Board of Directors, to ensure their interests are aligned with those of shareholders. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Board members are prohibited from hedging or pledging their ownership positions in Novartis shares that are part of their guideline share ownership requirement, and are required to hold these shares for 12 months after retiring from the Board of Directors. As of December 31, 2020, all current and former members of the Board of Directors who were required to meet the minimum share ownership requirements did so. </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Shares, ADRs and share options owned by Board members</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The total number of vested Novartis shares and ADRs owned by members of the Board of Directors and &#x201C;persons closely linked&#x201D; to them as of December 31, 2020, is shown in the table below. As of December 31, 2020, no members of the Board, either individually or together with &#x201C;persons closely linked&#x201D; to them, owned 1% or more of the outstanding shares (or ADRs) of Novartis. As of the same date, no members of the Board of Directors held any share options to purchase Novartis shares.</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Number of shares <br> at December 31, 2020<sup style="white-space: nowrap">  1,2</sup></div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Joerg Reinhardt</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 586&nbsp;326</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Enrico Vanni</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&nbsp;847</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nancy C. Andrews</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;872</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ton Buechner</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&nbsp;338</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Patrice Bula</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;621</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Srikant Datar</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43&nbsp;845</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Elizabeth Doherty</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;744</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ann Fudge</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&nbsp;201</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bridgette Heller</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 794</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frans van Houten</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;621</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Simon Moroney</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 731</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Andreas von Planta</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 163&nbsp;834</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charles L. Sawyers</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&nbsp;593</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">William T. Winters</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21&nbsp;289</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 917&nbsp;656</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="4">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="4">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Includes holdings of "persons closely linked" to Board members (see definition &#x201C;Persons closely linked").</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="4">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Each share provides entitlement to one vote.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="4">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Loans to Board members</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our policy does not allow loans to be granted to current or former members of the Board of Directors or to &#x201C;persons closely linked&#x201D; to them. Therefore, no loans were granted in 2020, and none were outstanding as of December 31, 2020.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other payments to Board members</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2020, no payments (or waivers of claims) other than those set out in the Board member compensation table titled &#x201C;Board member total compensation earned for the financial year 2020&#x201D; (including its footnotes) were made to current members of the Board or to &#x201C;persons closely linked&#x201D; to them.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Payments to former Board members</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2020, no payments (or waivers of claims) were made to former Board members or to &#x201C;persons closely linked&#x201D; to them, except for the payments reported in Note 27 to the Group&#x2019;s audited consolidated financial statements.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">122</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00949154"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Compensation governance </p><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Legal framework</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Swiss Code of Obligations and the Corporate Governance Guidelines of the SIX Swiss Exchange require listed companies to disclose certain information about the compensation of Board of Directors and Executive Committee members, their equity participation in the Group, and loans made to them. This Annual Report fulfills that requirement. In addition, the Annual Report is in line with the principles of the Swiss Code of Best Practice for Corporate Governance of the Swiss Business Federation (economiesuisse).</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Risk management principles</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Compensation Committee, with support from its independent advisor, reviews market trends in compensation, and changes in corporate governance rules and best practices. Together with the Risk Committee, it also reviews the Novartis compensation systems to ensure that they do not encourage inappropriate or excessive risk-taking, and instead encourage behaviors that support sustainable value creation. A summary of the risk management principles is outlined below.</div>
<div style="padding-top:15px"><img src="comp_0023.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">RISK MANAGEMENT PRINCIPLES&#x2022;Rigorous performance management process, with approval of targets and evaluation of performance for the CEO by the Board of Directors&#x2022;Balanced mix of short-term and long-term variable compensation elements&#x2022;Values and Behaviors are a key component of the Annual Incentive and are embedded in our culture&#x2022;Clawback and malus principles apply to all elements of the variable compensation&#x2022;Performance-vesting Long-Term Incentives only, with three-year cycles &#x2022;All variable compensation is capped at 200% of target&#x2022;Contractual notice period of 12months&#x2022;Post-contractual non-compete period limited to a maximum of 12 months from the end of employment. Resulting compensation is limited to the annual base salary plus the prior-year Annual Incentive as per contract, if applicable&#x2022;Good and bad leaver provisions apply to variable compensation of leavers&#x2022;No severance payments or change-of-control clauses&#x2022;Share ownership requirements; no hedging or pledging of Novartis share ownership</div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Executive Committee employment contracts provide for a notice period of up to 12 months and contain no change-of-control clauses or severance provisions (for example, agreements concerning special notice periods, longer-term contracts, &#x201C;golden parachutes,&#x201D; waiver of lockup periods for equities and bonds, shorter vesting periods, and additional contributions to occupational pension schemes). For share ownership requirements, please refer to &#x201C;&mdash;Share ownership requirements for the CEO and other Executive Committee members.&#x201D;</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Compensation decision-making authorities</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Authority for decisions related to compensation is governed by the Articles of Incorporation, Board Regulations and the Compensation Committee Charter, which are all published on the Company website: www.novartis.com/investors/company-overview/corporate-governance. The Compensation Committee serves as the supervisory and governing body for compensation policies and plans within Novartis, and has overall responsibility for determining, reviewing and proposing compensation policies and plans for approval by the Board of Directors in line with the Compensation Committee Charter. A summary of discussions and conclusions of each committee meeting is delivered to the full Board of Directors. A summary of the compensation decision-making authorities is set out below.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Compensation authorization levels within the parameters set by the shareholders&#x2019; meeting</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;">Decision on</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;"> Decision-making authority</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Compensation of Chairman and  other Board members</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Board of Directors  </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Compensation of CEO</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Board of Directors</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Compensation of other Executive  Committee members</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Compensation Committee  </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #ffffff 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
      <td style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div><a name=""></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Committee member independence</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Compensation Committee is composed exclusively of members of the Board of Directors who meet the independence criteria set forth in the Board Regulations. From the 2020 AGM, the Compensation Committee had the following five members: Patrice Bula, Bridgette Heller (from the 2020 AGM), Srikant Datar, Enrico Vanni and William Winters. Simon Moroney also attended each Compensation Committee meeting after the 2020 AGM as a permanent guest. Mr. Vanni has served as a member since 2011 and as Chair since 2012.</div><a name=""></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Role of the Compensation Committee&#x2019;s independent advisor</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Compensation Committee retained Mercer Limited during the financial year 2020 as its independent external compensation advisor to support the committee in determining the design and implementation of compensation and benefits. The advisor was hired directly by the Compensation Committee in 2017, and the Compensation Committee has been fully satisfied with the performance and independence of the advisor since its engagement. In determining whether to renew the engagement with the advisor, the Compensation Committee evaluates, at least annually, the quality of the consulting service, the independence of the advisor, and the benefits of rotating advisors. Mercer Limited also provides services related to management development at the mid- and frontline leader level and in respect of corporate pensions. The individual Mercer Limited consultants who advise and support the committee are not responsible or rewarded for work beyond support to the Compensation Committee and the People &amp; Organization function on senior compensation. </div><a name=""></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Meetings held&nbsp;in 2020 and self-evaluation</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2020, the Compensation Committee held six formal meetings. In line with prior years, it collaborated with the Science &amp; Technology Committee to review and endorse for approval by the Board of Directors the innovation targets and achievements of the Annual Incentive and LTPP. The assessment of the Compensation Committee was included in the Board&#x2019;s overall 2020 self-evaluation.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">123</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>



    <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">(This page has been left blank intentionally.)</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">124</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>










    <a name="anchorId001037534"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">6.C Board practices </p>
<div style="font-family:arial,helvetica,sans-serif; font-size:28pt; color:#000000; font-weight:bold;">Corporate governance </div><a name=""></a><div style="padding-top:10px;  padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Framework </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis is committed to effective corporate governance, and our corporate governance framework is intended to support sustainable financial performance and long-term value creation for our shareholders, patients, employees and other stakeholders based on our Values and Behaviors.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Novartis corporate governance principles are further described in key governance documents, in particular in our Articles of Incorporation and the Regulations of the&nbsp;Board, the Board Committees and the Executive Committee (Board Regulations) (www.novartis.com/investors/company-overview/corporate-governance). The Governance, Nomination and Corporate Responsibilities Committee (GNCRC) regularly reviews both the corporate governance principles and the key governance documents against evolving best practice standards and new developments in line with our commitment to maintaining the highest standards. </div>
<div style="padding-top:15px"><img src="cogo_0002.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Our leadership structureGovernance bodies General Meeting of ShareholdersApproves operating and financial review, Novartis Group consolidated financial statements, and financial statements of Novartis AG; decides appropriation of available earnings and dividend; approves compensation of Board and Executive Committee; elects Board members, Chairman, Compensation Committee members, Independent Proxy and external auditor; adopts and modifies Articles of IncorporationExternal auditorProvides opinion on compliance of Novartis Group consolidated financial statements and the financial statements of Novartis&#xA0;AG with applicable standards and Swiss law, on compliance of the Compensation Report with applicable law, on effectiveness of internal controls over financial reporting, and on the corporate responsibility reporting of NovartisBoard of DirectorsAudit and Compliance CommitteeCompensation CommitteeGovernance, Nomi&#xAD;nation and Corporate Responsibilities CommitteeRISKCommitteeSCIENCE &amp;TECHNOLOGYCommitteeSets strategic direction of Novartis, appoints and oversees key executives, approves major transactions and&#xA0;investmentsExecutive CommitteeResponsible for operational management of Novartis</div>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">125</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-top:10px;  padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Group structure and shareholders</font>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Group structure</font>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Novartis AG and Group companies</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis AG, the Group&#x2019;s holding company, is a corporation organized under Swiss law with issued registered shares and registered office at Lichtstrasse 35, CH-4056 Basel, Switzerland. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The principal subsidiaries and associated companies of the Novartis Group are shown in &#x201C;Item 18. Financial Statements&mdash;Note 32. Principal Group subsidiaries and associated companies.&#x201D;</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Divisions</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has two focused, customer-facing divisions: Innovative Medicines, which includes the Novartis Pharmaceuticals and Novartis Oncology business units; and Sandoz, the generics and biosimilars division. The divisions are supported by the Novartis Institutes for BioMedical Research (NIBR), Global Drug Development (GDD), Novartis Technical Operations (NTO), Novartis Business Services (NBS) and corporate functions. A&nbsp; detailed review of the 2020 business results can be found in &#x201C;Item 18. Financial Statements&mdash;Note 3. Segmentation of key figures 2020, 2019 and 2018.&#x201D;</div>
<div style="padding-top:15px"><img src="cogo_0026.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Shareholdings</font>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Majority holdings in publicly traded Group companies</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Novartis Group owns 70.7% of Novartis India Ltd., with registered office in Mumbai, India, and listing on the Bombay Stock Exchange (ISIN INE234A01025, symbol: HCBA). The total market value of the 29.3% free float of Novartis India Ltd. was USD&nbsp;67.8 million on December 31, 2020, using the quoted market share price at year-end. Applying this share price to all the shares of the company, the market capitalization of the whole company was USD&nbsp;231.4 million, and that of the shares owned by Novartis was USD&nbsp;163.6 million.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Significant minority shareholding owned by the Group</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Novartis Group owns 33.3% of the bearer shares of Roche Holding AG, with registered office in Basel, Switzerland, and listing on the SIX Swiss Exchange (ISIN CH0012032113, symbol: RO). The market value of the Group&#x2019;s interest in Roche Holding AG, as of December&nbsp;31, 2020, was USD&nbsp;18.8 billion. The total market value of Roche Holding AG was USD&nbsp;302.8 billion. Novartis does not exercise control over Roche Holding AG, which is independently governed, managed and operated.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Shareholders</font>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Significant shareholders</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to the Share Register, as of December&nbsp;31, 2020, the following registered shareholders, including nominees and the American Depositary Share (ADS) depositary, held more than 2% of the total share capital, with the right to vote all their shares based on exemptions granted by the Board of Directors (&#x201C;Board&#x201D;) (see &#x201C;&mdash;Item 6.C Board practices&mdash;Shareholder participation&mdash;Voting rights, restrictions and representation&mdash;Registration restrictions&#x201D;):<sup>1</sup></div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % holding of<br> share capital<br> Dec 31, 2020</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Shareholders registered for their own account:</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Emasan AG, Basel</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.6</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">UBS Fund Management (Switzerland) AG, Basel</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credit Suisse Funds AG, Zurich</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % holding of<br> share capital<br> Dec 31, 2020</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Shareholders registered as nominees:</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chase Nominees Ltd., London</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9.6</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">The Bank of New York Mellon, New York</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.4</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Through The Bank of New York Mellon, Everett</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 1.7</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Through The Bank of New York Mellon, New York</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 1.2</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Through The Bank of New York Mellon, SA/NV, Brussels</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 0.5</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nortrust Nominees Ltd., London</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.2</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Shareholder acting as American Depositary Share (ADS) depositary:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">JPMorgan Chase Bank, N.A., New York</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"><sup>1</sup> Excluding 4.3% of the share capital held as treasury shares by Novartis AG or its fully owned subsidiaries</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">126</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">According to a disclosure notification filed with Novartis&nbsp;AG, Norges Bank (Central Bank of Norway), Oslo, held 2.3% of the share capital but was not registered in the Share Register as of December&nbsp;31, 2020. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">According to a disclosure notification filed with Novartis&nbsp;AG and the SIX Swiss Exchange, BlackRock,&nbsp;Inc., New&nbsp;York, held between 3% and 5%, but was registered with less than 2% of the share capital as of December&nbsp;31,&nbsp;2020.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Disclosure notifications pertaining to shareholdings filed with Novartis AG and the SIX Swiss Exchange are published on the latter&#x2019;s electronic publication platform: </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">www.six-exchange-regulation.com/en/home/publications/significant-shareholders.html.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Duty to make an offer</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to the Swiss Federal Act on Financial Infrastructures, anyone who &ndash; directly, indirectly or acting in concert with third parties &ndash; acquires equity securities exceeding 33 1/3% of the voting rights of a company (whether or not such rights are exercisable) is required to make an offer to acquire all listed equity securities of that company. A company may raise this threshold up to 49% of the voting rights (&#x201C;opting up&#x201D;) or may, under certain circumstances, waive the threshold (&#x201C;opting out&#x201D;). Novartis AG has not adopted any such measures.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Cross shareholdings</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis AG has no cross shareholdings in excess of 5% of capital, or voting rights with any other company.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Overview on shareholder structure</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables relate only to registered shareholders and cannot be assumed to represent the entire investor base because nominees and JPMorgan Chase Bank, N.A., as ADS depositary, are registered as shareholders for a large number of beneficial owners.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of December 31, 2020, Novartis AG had approximately 176&nbsp;000 registered shareholders. </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Number of registered shareholders/shares</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>As of December 31, 2020<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Number of<br> registered <br> shareholders</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> % of <br> share capital</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1&#x2013;100</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31&nbsp;457</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.07</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">101&#x2013;1&#xA0;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 104&nbsp;629</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.73</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1&#xA0;001&#x2013;10&#xA0;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36&nbsp;429</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.10</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10&#xA0;001&#x2013;100&#xA0;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;230</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.39</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">100&#xA0;001&#x2013;1&#xA0;000&#xA0;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 478</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.81</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1&#xA0;000&#xA0;001&#x2013;5&#xA0;000&#xA0;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.72</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5&#xA0;000&#xA0;001 or more<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 48.13</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total registered shareholders/shares</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 176&nbsp;319</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 67.95</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Unregistered shares</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32.05</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100.00</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> At the record date of the 2020 Annual General Meeting of Shareholders (AGM), unregistered shares amounted to 15%.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Including significant registered shareholders as listed above</div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Registered shareholders by type</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">As of December 31, 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Shareholders in %</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Shares in %</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Individual shareholders</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 96.61</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14.00</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Legal entities<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34.51</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nominees, fiduciaries  and ADS depositary</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   0.05</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   51.49</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100.00</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100.00</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Excluding 4.3% of the share capital held as treasury shares by Novartis AG or its fully owned subsidiaries</div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Registered shareholders by country<sup>1</sup></font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">As of December 31, 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Shareholders in %</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Shares in %</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Belgium</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.12</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.03</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">France</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.01</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.31</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Germany</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.68</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.80</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japan</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.59</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Luxembourg</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.06</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.69</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 87.45</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44.08</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United Kingdom</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.59</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.09</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United States</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.28</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24.36</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other countries</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.61</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.05</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100.00</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100.00</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Registered shares held by nominees are shown in the country where the company/affiliate entered in the Share Register as shareholder has its registered seat.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Excluding 4.3% of the share capital held as treasury shares by Novartis AG or its fully owned subsidiaries</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">127</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-top:10px;  padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Capital structure</font>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Share capital</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As of December 31, 2020, the share capital amounted to CHF&nbsp;1233530460 fully paid-in and divided into 2467060920 registered shares with a nominal value of CHF&nbsp;0.50 each. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Shares are listed on the SIX Swiss Exchange (ISIN CH0012005267, symbol: NOVN) and on the New York Stock Exchange (NYSE) in the form of American Depositary Receipts (ADRs) representing American Depositary Shares (ADSs) (ISIN US66987V1098, symbol: NVS).</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">No authorized and conditional capital exists as of December 31, 2020.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Shares, participation certificates, non-voting equity securities, profit-sharing certificates</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Shares are issued as uncertificated securities (in the sense of the Swiss Code of Obligations) and as book entry securities (in terms of the Swiss Act on Intermediated Securities). All shares have equal voting rights and carry equal entitlements to dividends. No participation certificates, non-voting equity securities (Genussscheine) or profit-sharing certificates have been issued.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Convertible securities and options</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis AG has not issued convertible or exchangeable bonds, warrants, options or other securities granting rights to shares, other than options (or similar instruments such as stock appreciation rights) granted under or in connection with equity-based participation plans of associates. Novartis AG does not grant any new stock options under these plans. </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Limitation on transferability </font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">No transferability restrictions are imposed on shares (for registration restrictions, see &#x201C;&mdash;Item 6.C Board practices&mdash;Shareholder participation&mdash;Voting rights, restrictions and representation&mdash;Registration restrictions&#x201D;). The registration of shareholders in the Share Register or in the ADR register kept by JPMorgan Chase Bank, N.A., does not affect the tradability of shares or ADRs. </div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Changes to share capital</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="top">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"><br>AGM</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Shareholder decision</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Shares canceled</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Average repurchase <br> share price (CHF)<sup style="white-space: nowrap">  1</sup></div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2018</div>
      </td>
      <td align="right" width="1%"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022; Capital reduction by CHF 33.11 million (from CHF&#xA0;1&#x2005;308&#x2005;422&#x2005;410 to CHF&#xA0;1&#x2005;275&#x2005;312&#x2005;410)</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 66&nbsp;220&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 78.34</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2019</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022; Capital reduction by CHF 11.63 million (from CHF 1&#x2005;275&#x2005;312&#x2005;410 to CHF 1&#x2005;263&#x2005;687&#x2005;410) <br> &#x2022; Authorization of the Board to repurchase shares up to a maximum of CHF 10 billion     until the 2022 AGM under an eighth share repurchase program</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23&nbsp;250&nbsp;000    </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 79.08    </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2020</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022; Capital reduction by CHF 30.16 million (from CHF&#xA0;1&#x2005;263&#x2005;687&#x2005;410 to CHF&#xA0;1&#x2005;233&#x2005;530&#x2005;460)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60&nbsp;313&nbsp;900</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 88.18</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="top">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"><br>AGM</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Proposal to the shareholders</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Shares to be canceled</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Average repurchase <br> share price (CHF)<sup style="white-space: nowrap">  1</sup></div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2021</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022; Capital reduction by CHF 16.3 million (from CHF&#xA0;1&#x2005;233&#x2005;530&#x2005;460 to CHF&#xA0;1 217 210 460) <br> &#x2022; Authorization of the Board to repurchase shares as deemed appropriate from time to time     up to a maximum of CHF 10 billion between the 2021 AGM and the 2024 AGM</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32&nbsp;640&nbsp;000    </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 80.57    </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top">
      <td height="10px" colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="top">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> All shares were repurchased on the SIX Swiss Exchange second trading line.</div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key Novartis share data</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Issued shares</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;467&nbsp;060&nbsp;920</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;527&nbsp;374&nbsp;820</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;550&nbsp;624&nbsp;820</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Treasury shares<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 210&nbsp;238&nbsp;872</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 262&nbsp;366&nbsp;332</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 239&nbsp;453&nbsp;391</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding shares at December 31</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;256&nbsp;822&nbsp;048</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;265&nbsp;008&nbsp;488</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;311&nbsp;171&nbsp;429</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Weighted average number of shares outstanding</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;277&nbsp;041&nbsp;940</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;290&nbsp;792&nbsp;782</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;319&nbsp;322&nbsp;369</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Approximately 103 million treasury shares (2019: 118 million; 2018: 122 million) are held in Novartis entities that restrict their availability for use.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">128</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Per-share information<sup>1</sup></font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basic earnings per share from continuing operations (USD)</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.55</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.12</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.52</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basic earnings per share from discontinued operations (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.00</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.08</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total basic earnings per share (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.55</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.44</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Diluted earnings per share from continuing operations (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.52</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.08</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.46</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Diluted earnings per share from discontinued operations (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.98</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.08</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total diluted earnings per share (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.52</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.06</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.38</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flow from operating activities of continuing operations (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.99</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.91</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.63</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Year-end equity for Novartis AG shareholders (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.07</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24.49</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34.01</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend (CHF)<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.00</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.95</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.85</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Calculated on the weighted average number of shares outstanding, except year-end equity</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> 2020: proposal to shareholders for approval at the AGM on March 2, 2021</div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key ratios &ndash; December 31</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Price/earnings ratio<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26.7</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18.5</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15.7</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Price/earnings ratio from  continuing operations<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   26.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   30.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   15.4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend yield (%)<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Based on the Novartis share price at December 31 of each year</div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key data on ADRs issued in the US</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020<sup style="white-space: nowrap"> 1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019<sup style="white-space: nowrap"> 1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Year-end ADR price (USD)</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 94.43</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 94.69</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 85.81</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">High<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.01</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 96.14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 93.91</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Low<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70.67</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 75.40</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 72.44</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Number of  ADRs outstanding<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   288&nbsp;755&nbsp;853</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   315&nbsp;073&nbsp;094</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   338&nbsp;641&nbsp;387</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> 2020 and 2019 exclude the business of Alcon, which was spun off in April 2019 into a separately traded standalone company. </div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Based on the daily closing prices </div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> The depositary, JPMorgan Chase Bank, N.A., holds one Novartis AG share for every ADR issued. </div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Share price (CHF)</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020<sup style="white-space: nowrap"> 1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019<sup style="white-space: nowrap"> 1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Year-end share price</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 83.65</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 91.90</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 84.04</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">High<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 95.82</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 96.04</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 91.84</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Low<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 69.96</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 77.03</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 72.42</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Year-end market capitalization  (USD billions)<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   214.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   214.8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   197.0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Year-end market capitalization  (CHF billions)<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   188.8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   208.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   194.2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> 2020 and 2019 exclude the business of Alcon, which was spun off in April 2019 into a separately traded standalone company.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Based on the daily closing prices</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Market capitalization is calculated based on the number of shares outstanding (excluding treasury shares). Market capitalization in USD is based on the market capitalization in CHF converted at the year-end CHF/USD exchange rate.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">129</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId001039173"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Shareholder participation </p><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Shareholder engagement</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Shareholder engagement is fundamental to our commitment to governance and transparency, and the feedback we receive during these engagements helps us create long-term and sustainable value.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We concentrate our outreach efforts on our largest 100 shareholders &ndash; portfolio managers; buy-side professionals; stewardship teams; and environmental, social and governance (ESG) analysts &ndash; who represent 60% of our ownership. While the Chairman, CEO and CFO together with Investor Relations are accountable for ensuring effective shareholder engagement, other senior managers from within and outside the Executive Committee also participate in the meetings. We conduct regular outreach to investors throughout the year. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:8pt; font-weight:bold; color:#0070f7; text-transform:uppercase;">Types of engagements (select examples):<div style="border:none;border-bottom:solid 2px;"></div>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; AGM and quarterly results teleconferences (TCs)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Bank conferences and management roadshows</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; &#x201C;Meet Novartis Management&#x201D; capital markets event </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Oncology pipeline update</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Governance and compensation roadshow, and governance TCs</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chairman&#x2019;s lunch in Zurich, and TCs for US and UK investors</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; ESG Investor Day and roadshows, including sustainability-linked bond roadshow</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:8pt; font-weight:bold; color:#0070f7; text-transform:uppercase;">Topics discussed with shareholders during 2020:<div style="border:none;border-bottom:solid 2px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;text-transform:uppercase;">INNOVATION:</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Progress and milestones</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Data of pipeline projects (e.g., <sup>177</sup>Lu-PSMA-617, ABL001, ACZ885, LNP023)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Launches (e.g.,  <i>Kesimpta, Tabrecta</i>)</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;text-transform:uppercase;">OPERATIONAL EXECUTION:</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Financial prudence and supply chain resilience during COVID-19</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Progress on financial, strategic and operational performance</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Long-term sustainability of financial performance</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Capital allocation strategy</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Policy and pricing environment</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Lifecycle management</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;text-transform:uppercase;">DATA AND DIGITAL:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; New initiatives and progress</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;text-transform:uppercase;">BUILDING TRUST WITH SOCIETY AND CULTURE (ESG):</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; COVID-19 response to address all stakeholder needs</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board accountability on ESG, and integration of ESG and compensation</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Strong governance, enhanced process and focus on material ESG factors, leading to improved rating agency scores </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; New ESG targets: full carbon neutrality, patient access targets for strategic innovative therapies, and global health flagship programs</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; New ESG index to improve primary ESG data</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Sustainability-linked bond demonstrating ESG innovation</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Key resolutions (settlements with US DOJ and SEC resolving all Foreign Corrupt Practices Act investigations including Greece, resolution with DOJ Antitrust Division concerning US generics industry investigation, settlement concerning speaker program litigation with Southern District of New York)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Progress on culture and metrics </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;text-transform:uppercase;">Compensation AND Governance: </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Diversity of the Board, the Executive Committee and the Company</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board refreshment, succession planning and evaluation</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Link of compensation system to key strategic priorities</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Risk oversight</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Independence of some Board members and the external auditor</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Overboarding</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We appreciate the value that shareholders attach to ESG matters. We will continue to integrate ESG into our strategy and to promote transparency through our comprehensive ESG engagement program. We have more than doubled the number of investor engagements on ESG matters in recent years, and in 2020, our CEO led our ESG Investor Day for the second time (marking our seventh dedicated ESG event for investors since 2014). We also held our second ESG roadshow in the Netherlands, and our first ESG roadshows in France, the US and Switzerland. We are the first company in the healthcare industry to issue an innovative sustainability-linked bond, and the first company to issue such a bond based on social targets.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Voting rights, restrictions and representation</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;text-transform:uppercase;">Registration</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Shareholders have the right to vote and to execute all other rights as granted under Swiss law and the Articles of Incorporation (see, in particular, articles 17 and 18 of the Articles of Incorporation: www.novartis.com/investors/company-overview/corporate-governance).</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Each share registered with the right to vote by the third business day before the General Meeting entitles the holder to one vote at General Meetings. To be registered with voting rights, a shareholder must declare that he or she acquired the shares in his or her own name and for his or her own account. According to article 5, paragraph 3 of the Articles of Incorporation (www.novartis.com/investors/company-overview/corporate-governance), the Board may register nominees with the right to vote. The Share Register is an internal, non-public register subject to statutory confidentiality and data privacy.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;text-transform:uppercase;">Registration restrictions</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Article 5, paragraph 2 of the Articles of Incorporation (www.novartis.com/investors/company-overview/corporate-governance) provides that no shareholder shall be registered with the right to vote for more than 2% of the share capital. Given that shareholder representation at General Meetings traditionally has been rather low in Switzerland, Novartis AG considers registration restrictions necessary to prevent a minority shareholder from dominating a General Meeting. The Board may, upon request, grant an exemption. Considerations include whether the shareholder supports our goal of creating sustainable value and has a long-term investment horizon. Exemptions are in force for the registered shareholders listed in &#x201C;&mdash;Item 6.C Board practices&mdash;Group structure and shareholders&mdash;Shareholders&mdash;Significant shareholders.&#x201D; These include Credit Suisse Funds AG, Zurich, which received an exemption in 2020 based on the fulfillment of the requirements. Exemptions also apply to the Novartis Foundation for Employee Participation, Basel, which as of December 31, 2020, was registered in the Share Register with less than 2% of the share capital, and to Norges Bank (Central Bank of Norway), Oslo, which as of December 31, 2020, was not registered but held 2.3% according to a disclosure notification filed with Novartis AG. The same restrictions indirectly apply to ADR holders. </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">130</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Article 5, paragraph 3 of the Articles of Incorporation provides that no nominee shall be registered with the right to vote for more than 0.5% of the registered share capital. The Board may, upon request, grant an exemption from this restriction if the nominee discloses the names, addresses and number of shares of the persons for whose account it holds 0.5% or more of the registered share capital. Exemptions are in force for the nominees listed in &#x201C;&mdash;Item 6.C Board practices&mdash;Group structure and shareholders&mdash;Shareholders&mdash;Significant shareholders,&#x201D; and for the nominee Citibank, London, which in 2015 requested an exemption, but as of December 31, 2020, was not registered in the Share Register. The same restrictions indirectly apply to ADR holders.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Shareholders, ADR holders, or nominees who are linked to each other or who act in concert to circumvent registration restrictions are treated as one person or nominee for the purposes of the restrictions on registration.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The registration restrictions may be changed by resolution of the General Meeting, with approval of at least two-thirds of the votes represented at the meeting.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;text-transform:uppercase;">Representation and Sherpany Platform</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Normally, shareholders can vote their shares by themselves or appoint another shareholder or the Independent Proxy to vote on their behalf. However, in accordance with Swiss legislation passed in response to the COVID-19 pandemic, the Board has decided that voting rights at our 2021 AGM can only be exercised through the Independent Proxy. It will not be possible to physically attend our 2021 AGM. All shareholders (who are not yet registered on the online platform) will receive an invitation with a form to appoint the Independent Proxy. On this form, shareholders can also instruct the Independent Proxy to vote on alternative or additional motions related to the agenda items either (i) following the recommendations of the Board for such alternative or additional motions, or (ii) against such alternative or additional motions. They can also abstain from voting.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Shareholders can use the online Sherpany platform to receive invitations to General Meetings exclusively by email and to exercise their voting rights. Not-yet-registered shareholders can sign up with the account opening document that will be sent to them with the invitation to the 2021 AGM or by ordering the document from the Share Registry. Shareholders can deactivate their online account at any time and again receive invitations in paper form.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;text-transform:uppercase;">ADR holders</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">ADR holders have the rights enumerated in the deposit agreement (such as the right to give voting instructions and to receive dividends). The ADS depositary of Novartis&nbsp;AG &ndash; JPMorgan Chase Bank, N.A., New York &ndash; holds the shares underlying the ADRs and is registered as a shareholder in the Share Register. An ADR is not a share, and an ADR holder is not a Novartis AG shareholder. Each ADR represents one share. ADR holders exercise their voting rights by instructing the depositary to exercise their voting rights. The ADS depositary exercises the voting rights for registered shares underlying ADRs for which no voting instructions have been given by providing a discretionary proxy to an uninstructed independent designee. Such designee has to be a shareholder.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">General Meeting</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;text-transform:uppercase;">Convening </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The AGM must be held within six months after the end of our financial year (December 31), and normally takes place in late February/early March. Extraordinary General Meetings may be requested by the Board, the external auditor, or shareholders representing at least 10% of the share capital.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;text-transform:uppercase;">Agenda</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Shareholders representing shares with an aggregate nominal value of at least CHF&nbsp;1 million may request that an item be included in a General Meeting agenda. Such requests must be made in writing at least 45 days before the meeting, specifying the requested item and proposal.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;text-transform:uppercase;">Powers</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following powers are vested exclusively in the General Meeting:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adoption and amendment of the Articles of Incorporation</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Election and removal of the Chairman, the Board and Compensation Committee members, the Independent Proxy and the external auditor</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Approval of the management report and of the consolidated financial statements</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Approval of the financial statements of Novartis AG, and decision on the appropriation of available earnings shown on the balance sheet, including dividends</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Approval of the maximum aggregate compensation of the Board (from an AGM until the next AGM) and of the Executive Committee (for the financial year following the AGM). If the maximum aggregate amount of compensation already approved by the AGM is not sufficient to cover the compensation of newly appointed or promoted Executive Committee members, Novartis may use up to 40% of the amount last approved for the newly appointed or promoted Executive Committee members.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discharge of Board and Executive Committee members</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Decision on other matters that are reserved by law or by the Articles of Incorporation (e.g., advisory vote on the Compensation Report) to the General Meeting </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;text-transform:uppercase;">Statutory Quorums</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The General Meeting passes resolutions and elections with the absolute majority of the votes represented at the meeting. However, under article 18 of the Articles of Incorporation (www.novartis.com/investors/company-overview/corporate-governance), the approval of two-thirds of the votes represented at the meeting is required for: </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Alteration of the purpose of Novartis AG</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Creation of shares with increased voting powers</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Implementation of restrictions on the transfer of registered shares, and the removal of such restrictions</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Authorized or conditional increase of the share capital</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Increase of the share capital out of equity, by contribution in kind, for the purpose of an acquisition of property or the grant of special rights</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Restriction or cancellation of subscription rights</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Change of the registered office of Novartis&nbsp;AG</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Dissolution of Novartis AG</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In addition, the law provides for a qualified majority for other resolutions, such as a merger or demerger.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">131</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-top:10px;  padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Board of Directors</font>
</div>
<div style="padding-top:15px"><img src="cogo_0005.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Composition (as per December 31, 2020)Chairman: J. ReinhardtVice Chairman: E. Vanni1N. AndrewsT. BuechnerP. BulaS. DatarE. Doherty A. FudgeB. HellerF. van HoutenS. MoroneyA. von PlantaC. SawyersW. WintersAudit and Compliance CommitteeE. Doherty (Chair)T. BuechnerS. DatarA. von PlantaE. VanniCompensation CommitteeE. Vanni (Chair)P. BulaS. DatarB. HellerW. WintersGovernance, Nomination and Corporate Respon-sibilities CommitteeA. von Planta (Chair)A. FudgeC. SawyersE. VanniW. WintersRisk CommitteeS. Datar (Chair)N. AndrewsT. BuechnerE. DohertyA. von PlantaSCIENCE &amp; TECHNOLOGY CommitteeJ. Reinhardt (Chair)N. AndrewsA. FudgeF. van HoutenS. MoroneyC. Sawyers1In addition to his role as Vice Chairman, Enrico Vanni was appointed Lead Independent Director as of January 1, 2021.</div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Election and term of office</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Board members (including the Chairman) and Compensation Committee members are elected individually by shareholders at the General Meeting for a one-year term of office. The term of office expires at the end of the next AGM.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There is currently no mandatory term limit for Board members. However, Board members who are 70 years old as of the General Meeting are no longer eligible for re-election to the Board (see article 20, paragraph 3 of the Articles of Incorporation: www.novartis.com/investors/company-overview/corporate-governance). The General Meeting may, under special circumstances, grant exceptions to this rule.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">At the 2021 AGM, the Board will propose to shareholders an amendment to the Articles of Incorporation that for future re-elections would replace the current age limit with a term limit. The proposal foresees that a member shall not serve on the Board for more than 12 years. The Board may recommend to shareholders exceptions under certain circumstances and if deemed to be in the best interests of the Company.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The proposed term limit supports our commitment to renew the Board on an ongoing basis. It also follows international best practice, which increasingly asks for an overall tenure of no more than 12 years. We believe age is still a relevant factor in Board composition, and the GNCRC will consider this and other factors &ndash; including gender and ethnicity &ndash; when evaluating candidates and exploring ways to improve Board diversity.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Succession planning</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Chairman, supported by the GNCRC, ensures effective succession plans for the Board, the CEO and the Executive Committee. These plans are discussed by the Board in private meetings without management. A search for a new Board member is launched &ndash; normally with the support of a professional executive search company &ndash; with individual selection criteria defined based on the evolving needs of the Company and a continuing focus on diversity. The set of competencies (further explained in &#x201C;&mdash;Item 6.C Board practices&mdash;Board of Directors&mdash;Board skills&#x201D;) is also an important criterion for the GNCRC when evaluating new candidates. Candidates are interviewed by the Chairman, members of the GNCRC, other Board members, and members of the Executive Committee. The GNCRC then makes a recommendation to the full Board, and the Board ultimately decides who should be proposed for election at the upcoming AGM. </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Independence</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">All Board members &ndash; including the Chairman &ndash; are non-executive and independent, pursuant to applicable corporate governance rules and Novartis independence criteria, which are outlined in Appendix II to the Board Regulations (www.novartis.com/investors/company-overview/corporate-governance). In particular, no Board member is or was a member of the management of Novartis AG or of any other Novartis Group company in the last three financial years up to December 31, 2020, or has a significant business relationship with Novartis AG or with any other Novartis Group company. We assess independence annually. Because all Board members are independent, no separate meetings of independent Board members were held in 2020. </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">132</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Diversity</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Diversity is a key factor to success and Board effectiveness. A diverse Board ensures that the appropriate balance of skills, expertise and experience is represented to discharge responsibilities to shareholders, and helps create long-term value. We are continuously looking for opportunities to improve our Board diversity, including gender and ethnic diversity. Last year, we disclosed our aspiration to find female candidates for two of the next three nominations. At the 2020 AGM, our Board welcomed its fourth female member, Bridgette Heller. Compared to last year, the female representation on our Board rose to 29% from 25%. The GNCRC is focused on achieving even greater diversity when identifying new Board member candidates and aims to further increase the number of women on the Board.</div>
<div style="padding-top:15px"><img src="cogo_0027.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Diversity profileNationality1pAmerican36%pSwiss28%pBritish11%pDutch11%pGerman11%pNew Zealander3%GenderpMale71%pFemale29%Agep55&#x2013;6029%p61&#x2013;6550%p&gt;6521%Tenurep&lt;3&#xA0;y21%p3&#x2013;6&#xA0;y29%p7&#x2013;9&#xA0;y29%p&gt;9&#xA0;y21%1Please note that four Board members have two nationalities. Each of these nationalities is counted as a half in the above chart.</div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Board skills</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Upon proposal by the GNCRC, the Board has determined a diverse set of competencies for its members that align with our status as a listed company as well as our business portfolio, geographic reach and culture. Based on this set of competencies, our Board members were asked to identify their most relevant skills highlighted by their educational background, professional experience and personal achievements. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The GNCRC assesses the set of competencies as well as the individual skills annually to ensure that an appropriate balance of skills, expertise, experience and diversity is represented on the Board.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To learn more about our Board members&#x2019; biographies and their individual skills, see &#x201C;&mdash;Item 6.C Board practices&mdash;Board of Directors&mdash;Members of the Board of Directors.&#x201D;</div>
<div style="padding-top:15px"><img src="cogo_0059.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Board skill distributionMedicine/healthcare/R&amp;D50%7/14Leadership/management 86%12/14Finance/accounting50%7/14Law/regulatory/risk management50%7/14Data/digital21%3/14Environmental, social 43%6/14and governance (ESG)</div>
</div>

    <br>
<br>



<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">133</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>



<a name="anchorId001137527"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Members of the Board of Directors</p>
<div style="padding-top:15px"><img src="cogo_0030.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Joerg Reinhardt, Ph.D.</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Chairman since 2013 | Nationality: German | Year of birth: 1956</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Joerg Reinhardt is a healthcare industry veteran whose career spans nearly 40 years. After receiving his doctorate in pharmaceutical sciences, Mr. Reinhardt joined Sandoz Pharma Ltd., a predecessor to Novartis, in 1982. He held a number of senior leadership positions at Novartis, including Chief Operating Officer and Head of the Vaccines and Diagnostics Division. Additionally, he led Bayer HealthCare AG as chairman of the board of management and the executive committee from 2010 to 2013.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chairman of the board of management and the executive committee, Bayer HealthCare AG,   Germany (2010&ndash;2013)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chief Operating Officer, Novartis AG, Switzerland (2008&ndash;2010)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Head of the Vaccines and Diagnostics Division, Novartis AG, Switzerland (2006&ndash;2008)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Various managerial positions at Sandoz Pharma Ltd. and Novartis AG, Switzerland (1982&ndash;2006)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Senate member, Helmholtz Association of German Research Centres, Germany </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chairman of the board of trustees, Institute of Molecular and Clinical Ophthalmology Basel (IOB), Switzerland</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chairman of the board of trustees, Novartis Foundation, Switzerland</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Swiss Re AG, Switzerland</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Member of the European Advisory Panel, Temasek Holdings Private Ltd., Singapore</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Lonza Group AG, Switzerland (2012&ndash;2013)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chairman, Genomics Institute of the Novartis Research Foundation, US (2000&ndash;2010) </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Doctorate in pharmaceutical sciences, Saarland University, Germany</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
  <font><img src="skill-x.jpg" border="0"></font>&nbsp;Medicine/healthcare/R&amp;D&nbsp;<font><img src="skill-g.jpg" border="0"></font>&nbsp;Leadership/management&nbsp;<font><img src="skill-l.jpg" border="0"></font>&nbsp;Law/regulatory/risk management&nbsp;</div>
<div style="padding-top:15px"><img src="cogo_0029.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Enrico Vanni, Ph.D.</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Vice Chairman since 2011 | Lead Independent Director since January 1, 2021 | Nationality: Swiss | Year of birth: 1951</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Enrico Vanni is an expert in business management, healthcare and technology who began his career as a research engineer at the International Business Machines Corp. (IBM) in the US. He later joined McKinsey &amp; Co. in Switzerland, where he managed the Geneva office and led the firm&#x2019;s European pharmaceutical practice. Since retiring in 2007, Mr. Vanni has continued to support leaders of pharmaceutical and biotechnology companies on core strategic challenges facing the healthcare industry.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Independent consultant supporting leaders of pharmaceutical and biotechnology companies (2008&ndash;2015)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Director, consulting in pharmaceutical, consumer and financial sectors, McKinsey &amp; Co.,   Switzerland (1994&ndash;2007)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Head of the Geneva office, McKinsey &amp; Co., Switzerland (1988&ndash;2004)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Advanced Oncotherapy PLC, UK</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Lombard Odier &amp; Cie SA, Switzerland</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Banque Priv&#xE9;e BCP (Suisse) SA, Switzerland</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Eclosion2 SA, Switzerland (2009&ndash;2017)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Alcon Inc., Switzerland (2010&ndash;2011)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Actavis PLC, Ireland (2010)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Master of Business Administration, INSEAD, France</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Doctorate in physical chemistry, University of Lausanne, Switzerland</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Engineering degree in chemistry, Federal Polytechnic School of Lausanne, Switzerland</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
  <font><img src="skill-x.jpg" border="0"></font>&nbsp;Medicine/healthcare/R&amp;D&nbsp;<font><img src="skill-m.jpg" border="0"></font>&nbsp;Finance/accounting&nbsp;</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">134</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:15px"><img src="cogo_0028.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Nancy C. Andrews, M.D., Ph.D.</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2015 | Nationality: American/Swiss | Year of birth: 1958</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Nancy C. Andrews has extensive experience as a physician, scientist, professor and senior administrator at leading academic institutions and hospitals. Her distinguished career spans more than 30 years, with leadership roles at both Harvard Medical School and the Duke University School of Medicine. Dr. Andrews currently chairs the board of the American Academy of Arts and Sciences, and is credited with conducting research that led to advances in understanding iron biology and iron diseases.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Dean emerita, Duke University School of Medicine, and vice chancellor emerita for academic affairs, Duke University, US (2017&ndash;present)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Dean, Duke University School of Medicine, and vice chancellor for academic affairs,   Duke University, US (2007&ndash;2017)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Professor of pediatrics, pharmacology and cancer biology, Duke University, US (2007&ndash;present)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Dean for basic sciences and graduate studies, Harvard Medical School, US (2003&ndash;2007)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Director, Harvard/MIT M.D.-Ph.D. Program, US (1999&ndash;2003)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Biomedical research investigator, Howard Hughes Medical Institute, US (1993&ndash;2006)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Charles River Laboratories Inc., US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Member of the executive committee of the Corporation, Massachusetts Institute of Technology, US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Council member, National Academy of Sciences, US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Former council member (2013&ndash;2019) and member, National Academy of Medicine, US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chair of the board, American Academy of Arts and Sciences, US </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Member of the Scientific Advisory Board, Dyne Therapeutics Inc., US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member and former chair, Burroughs Wellcome Fund, US (2011&ndash;2019)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the Scientific Management Review Board, National Institutes of Health, US (2014&ndash;2019)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Doctor of medicine, Harvard Medical School, US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Doctorate in biology, Massachusetts Institute of Technology, US</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master of Science and Bachelor of Science in molecular biophysics and biochemistry, Yale University, US</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
  <font><img src="skill-x.jpg" border="0"></font>&nbsp;Medicine/healthcare/R&amp;D&nbsp;<font><img src="skill-g.jpg" border="0"></font>&nbsp;Leadership/management  </div>
<div style="padding-top:15px"><img src="cogo_0032.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Ton Buechner</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2016 | Nationality: Dutch/Swiss | Year of birth: 1965</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Ton Buechner is an engineer by training who started his career in the oil and gas construction industry. He spent almost two decades at Sulzer AG, and held leadership roles including CEO and divisional president. Mr. Buechner most recently served as chairman and CEO of the executive board of AkzoNobel NV, a company widely recognized as a leader in sustainability, where he implemented significant ESG policies.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; CEO and chairman of the executive board, AkzoNobel NV, Netherlands (2012&ndash;2017)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  CEO, Sulzer AG, Switzerland (2007&ndash;2011)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  President, Sulzer Pumps, Switzerland (2003&ndash;2006)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; President, Sulzer Turbomachinery Services, Switzerland (2000&ndash;2002)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Various managerial positions at Sulzer AG, China and Switzerland (1994&ndash;2000)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chairman of the board of directors, Burckhardt Compression AG, Switzerland</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chairman of the board of directors, Swiss Prime Site AG, Switzerland</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Advisor, Ammega, Switzerland </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the presidential and shareholder committees, Voith GmbH &amp; Co. KGaA, Germany (2014&ndash;2020)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Member of the supervisory board, Voith GmbH &amp; Co. KGaA, Germany (2014&ndash;2018)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Master of Business Administration, IMD business school, Switzerland</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Master of Science in civil engineering, Delft University of Technology, Netherlands</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
  <font><img src="skill-g.jpg" border="0"></font>&nbsp;Leadership/management&nbsp;<font><img src="skill-m.jpg" border="0"></font>&nbsp;Finance/accounting&nbsp;<font><img src="skill-l.jpg" border="0"></font>&nbsp;Law/regulatory/risk management&nbsp;  <font><img src="skill-z.jpg" border="0"></font>&nbsp;Environmental, social and governance (ESG)</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">135</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:15px"><img src="cogo_0025.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Patrice Bula</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2019 | Nationality: Swiss | Year of birth: 1956</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Patrice Bula has 40 years of global management experience and is a leader in the consumer goods industry across established and emerging markets. He has served in various senior roles at Nestl&#xE9; SA, including as general manager of its businesses in China, Germany and South Africa. In his current position, he has successfully led the Nestl&#xE9; Group&#x2019;s brand strategies, digital marketing transformation and Nespresso business.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Executive vice president and head of strategic business units, marketing, sales and Nespresso, Nestl&#xE9;&nbsp;SA, Switzerland (2011&ndash;February 2021)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Market head of the Greater China region, Nestl&#xE9; SA, Switzerland (2007&ndash;2011)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Market head of Germany, Nestl&#xE9; SA, Switzerland (2003&ndash;2007)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Head of the confectionery and biscuits strategic business unit, Nestl&#xE9; SA, Switzerland (2000&ndash;2003)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Various managerial positions at Nestl&#xE9; SA, Switzerland (1980&ndash;2000)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Schindler AG, Switzerland</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Co-chairman, Cereal Partners Worldwide SA, Switzerland <i>(Nestl&#xE9; representative)</i></div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chairman, Froneri Lux Topco Sarl, Luxembourg (as of January 1, 2021)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Froneri Lux Topco Sarl, Luxembourg <i>(Nestl&#xE9; representative) </i>(2016&ndash;2020)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Bobst Group SA, Switzerland (2017&ndash;2019)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chairman, Blue Bottle Coffee Inc., US <i>(Nestl&#xE9; representative) </i>(2017&ndash;2019)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chairman, Nestl&#xE9; Nespresso SA, Switzerland <i>(Nestl&#xE9; representative) </i>(2011&ndash;2019)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Hsu Fu Chi Food Companies, China (<i>Nestl&#xE9; representative</i>) (2011&ndash;2019)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Program for Executive Development, IMD business school, Switzerland</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Master&#x2019;s degree in economic sciences, HEC Lausanne, Switzerland</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
  <font><img src="skill-g.jpg" border="0"></font>&nbsp;Leadership/management&nbsp;<font><img src="skill-m.jpg" border="0"></font>&nbsp;Finance/accounting&nbsp;<font><img src="skill-y.jpg" border="0"></font>&nbsp;Data/digital</div>
<div style="padding-top:15px"><img src="cogo_0031.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Srikant</font><font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"> Datar, Ph.D.</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2003 | Nationality: American | Year of birth: 1953 |  <br>Audit Committee Financial Expert</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Srikant Datar has extensive academic experience in accounting, governance, finance, innovative thinking, machine learning and other business areas. He has served as a professor at Harvard Business School, the Stanford Graduate School of Business, and Carnegie Mellon University, and has co-authored the leading cost accounting textbook, many research papers, and cases on companies. In 2020, he was selected by the National Association of Corporate Directors as public company director of the year for his outstanding contributions in the boardroom. He was appointed dean of Harvard Business School, effective January 1, 2021.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Dean, Harvard Business School, US (as of January 1, 2021)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Professor of business administration, Harvard Business School, US (1996&ndash;present)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Faculty chair, Harvard Innovation Labs, US (2015&ndash;2020)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Senior associate dean for university affairs, Harvard Business School, US (2015&ndash;2020)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Professor of accounting and management, Stanford Graduate School of Business, US (1989&ndash;1996)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Professor of industrial administration, Carnegie Mellon University (1986&ndash;1988)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member and chair of the governance and nominating committee, ICF International Inc., US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Stryker Corp., US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member and chair of the audit committee, T-Mobile US Inc., US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Former board member (2012&ndash;2014) and strategic advisor, HCL Technologies Ltd., India </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, KPIT Cummins Infosystems Ltd., India (2007&ndash;2012)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Doctorate in business (accounting), Stanford University, US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Master of Arts in economics, Stanford University, US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Master of Science in statistics, Stanford University, US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Postgraduate diploma in business management, Indian Institute of Management, India</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Bachelor of Science in mathematics and economics, Bombay University, India</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
  <font><img src="skill-g.jpg" border="0"></font>&nbsp;Leadership/management&nbsp;<font><img src="skill-m.jpg" border="0"></font>&nbsp;Finance/accounting </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">136</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:15px"><img src="cogo_0035.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Elizabeth (Liz) Doherty</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2016 | Nationality: British | Year of birth: 1957 |  <br>Audit Committee Financial Expert</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Elizabeth (Liz) Doherty is an expert in finance and accounting who has broad operational experience in international consumer and retail businesses. She began her career in internal audit at Unilever&nbsp;PLC and has held senior finance and accounting roles there and at other companies including Tesco PLC and Reckitt Benckiser Group PLC.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; CFO (interim), Cognita Schools Ltd., UK (2014&ndash;2015) </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  CFO and board member, Reckitt Benckiser Group PLC, UK (2011&ndash;2013)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; CFO (interim), City Inn, UK (2010)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  CFO, Brambles Ltd., Australia (2007&ndash;2009)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Group international finance director, Tesco PLC, UK (2001&ndash;2007)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Various managerial positions at Unilever PLC, UK (1981&ndash;2001)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Corbion NV, Netherlands</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Member of the supervisory board and chair of the audit committee, Royal Philips NV, Netherlands</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Advisor, Affinity Petcare SA and GB Foods SA, Spain</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Dunelm Group PLC, UK (2013&ndash;2019)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, HM Courts &amp; Tribunals Service, UK (2015&ndash;2019)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Ministry of Justice, UK (2015&ndash;2019)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Delhaize Group, Belgium (2013&ndash;2016)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Nokia Corp., Finland (2013&ndash;2016)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Brambles Ltd., Australia (2007&ndash;2009)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, SABMiller PLC, UK (2004&ndash;2010) </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Fellow, Chartered Institute of Management Accountants, UK</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Bachelor&#x2019;s degree in liberal studies in science (physics), University of Manchester, UK</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
  <font><img src="skill-g.jpg" border="0"></font>&nbsp;Leadership/management&nbsp;<font><img src="skill-m.jpg" border="0"></font>&nbsp;Finance/accounting&nbsp;<font><img src="skill-l.jpg" border="0"></font>&nbsp;Law/regulatory/risk management</div>
<div style="padding-top:15px"><img src="cogo_0034.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Ann Fudge</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2008 | Nationality: American | Year of birth: 1951</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Ann Fudge has a track record of success across global technology and consumer goods companies, and is widely considered one of the most influential women in American business. Before serving as chairman and CEO of Young &amp; Rubicam Brands, Ms. Fudge spent 15 years in leadership roles at Kraft Foods Inc. She is deeply committed to social initiatives, including the Executive Leadership Council, a nonprofit focused on helping African American leaders positively impact business and communities. With WGBH Public Media, she has brought greater focus to more diverse media programming and broadening the reach of community-based initiatives. More recently, she has consulted with companies and educational institutions as they develop social justice initiatives.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chairman and CEO, Young &amp; Rubicam Brands, US (2003&ndash;2007)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  President of the Beverages, Desserts and Post Division brands, Kraft Foods Inc., US (2000&ndash;2001)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Various managerial positions at Kraft Foods Inc., US (1986&ndash;2000)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Senior trustee, the Brookings Institution, US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Member, American Academy of Arts and Sciences, US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Northrop Grumman Corp., US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chair of the board of trustees, WGBH Public Media, US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chair of the United States Program Advisory Panel, Bill &amp; Melinda Gates Foundation, US (2007&ndash;2019)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the visiting committee, Harvard Business School, US (2014&ndash;2019)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member and former vice chair, Unilever PLC and NV, UK and Netherlands (2009&ndash;2018)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, General Electric Co., US (1999&ndash;2015)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Master of Business Administration, Harvard Business School, US </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Bachelor&#x2019;s degree in management, Simmons College, US</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
  <font><img src="skill-g.jpg" border="0"></font>&nbsp;Leadership/management&nbsp;<font><img src="skill-z.jpg" border="0"></font>&nbsp;Environmental, social and governance (ESG)</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">137</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:15px"><img src="cogo_0060.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Bridgette Heller</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since February 28, 2020 | Nationality: American | Year of birth: 1961</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Bridgette Heller has proven experience in the standalone divisions of companies such as Johnson &amp; Johnson, Merck &amp; Co. Inc. and Danone SA, and has served on the audit committees of ADT Corp. and Tech Data Corp. During her career, she has overseen the performance of CFOs and made decisions on strategic R&amp;D priorities. Ms.&nbsp;Heller is an advocate for diversity, equity and inclusion, and traveled globally to reinforce Danone&#x2019;s commitment to infant and maternal health, inclusive diversity, an equitable workforce for women, and sustainable communities. She is co-founder and CEO of the Shirley Proctor Puller Foundation, an education and youth empowerment nonprofit, and devotes much of her time to strengthening education and sustainability in an underserved community in the US.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Co-founder and CEO, Shirley Proctor Puller Foundation, US (2019&ndash;present)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  EVP and president of specialized nutrition, Danone SA, Netherlands (2017&ndash;2019)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  EVP of early life nutrition, Danone SA, Netherlands (2016&ndash;2019)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  EVP and president of consumer care, Merck &amp; Co. Inc., US (2010&ndash;2015)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Global president of the baby global business unit, Johnson &amp; Johnson, US (2007&ndash;2009)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; President of the US baby, kids and wound care business and of global innovation development, Johnson &amp; Johnson, US (2005&ndash;2007)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Managing partner, Heller Associates: Ideas for Growth Inc., US (2004&ndash;2005)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  CEO, Chung&#x2019;s Gourmet Foods, US (2003&ndash;2004)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Various managerial positions at Kraft Foods Inc., US (1985&ndash;2003)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Dexcom Inc., US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Newman&#x2019;s Own Inc., US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Member of the board of trustees, Northwestern University, US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Member of the advisory board, Kellogg School of Management at Northwestern University, US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Shirley Proctor Puller Foundation, US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Tech Data Corp., US (2016&ndash;2020)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, ADT Corp., US (2012&ndash;2016)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Girls Inc., US (2002&ndash;2014)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Master&#x2019;s degree in marketing and management policy, Kellogg School of Management at Northwestern University, US</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Bachelor&#x2019;s degree in economics and computer studies, Northwestern University, US</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
  <font><img src="skill-x.jpg" border="0"></font>&nbsp;Medicine/healthcare/R&amp;D<font><img src="skill-g.jpg" border="0"></font>&nbsp;Leadership/management&nbsp;<font><img src="skill-m.jpg" border="0"></font>&nbsp;Finance/accounting  <font><img src="skill-z.jpg" border="0"></font>&nbsp;Environmental, social and governance (ESG)</div>
<div style="padding-top:15px"><img src="cogo_0033.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Frans van Houten</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2017 | Nationality: Dutch | Year of birth: 1960</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Frans van Houten is passionate about purpose-driven innovation, entrepreneurship and business transformation to drive competitiveness and customer value. Under his leadership as CEO, Royal Philips NV has transformed into a focused health technology leader through targeted divestments, acquisitions and organic business development. Royal Philips NV has also adopted a comprehensive set of commitments across all the ESG dimensions, and is today carbon neutral in its operations and recycles 90% of its operational waste. Mr. van Houten was an initiator of The Compact for Responsive and Responsible Leadership, which aims to create a corporate governance framework with a focus on the long-term sustainability of corporations and the long-term goals of society.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; CEO and chairman of the executive committee and the board of management, Royal Philips NV, Netherlands (2011&ndash;present)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Interim management, ING Group NV, Netherlands (2009&ndash;2010)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; CEO and chairman of the management board, NXP Semiconductors NV (formerly Philips Semiconductors NV), Netherlands (2004&ndash;2009)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Various managerial positions at Royal Philips Electronics NV, Netherlands (1986&ndash;2004)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Member of the steering committee, European Round Table for Industry (ERT), Belgium</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Vice chairman and member of the supervisory board, Philips Lighting, Netherlands (2016&ndash;2017)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Master of Science in economics and business management, Erasmus University Rotterdam, Netherlands</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Bachelor of Science in economics, Erasmus University Rotterdam, Netherlands</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
  <font><img src="skill-x.jpg" border="0"></font>&nbsp;Medicine/healthcare/R&amp;D&nbsp;<font><img src="skill-g.jpg" border="0"></font>&nbsp;Leadership/management&nbsp;<font><img src="skill-l.jpg" border="0"></font>&nbsp;Law/regulatory/risk management  <font><img src="skill-y.jpg" border="0"></font>&nbsp;Data/digital&nbsp;<font><img src="skill-z.jpg" border="0"></font>&nbsp;Environmental, social and governance (ESG)</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">138</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:15px"><img src="cogo_0061.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Simon Moroney, D.Phil.</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since February 28, 2020 | Nationality: German/New Zealander | Year of birth: 1959</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">As co-founder and CEO of MorphoSys AG, Simon Moroney played a central role in establishing the company as a force in the field of therapeutic antibodies, with one of the broadest pipelines of drug candidates in the industry. Mr. Moroney holds both a doctorate and a Master of Science in chemistry.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Co-founder and CEO, MorphoSys AG, Germany (1992&ndash;2019)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Research associate, Department of Pharmacology, University of Cambridge, UK (1991&ndash;1992)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Assistant professor, Department of Chemistry, University of British Columbia, Canada (1989&ndash;1990)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Doctorate in chemistry, University of Oxford, UK</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Master of Science in chemistry, University of Waikato, New Zealand</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
  <font><img src="skill-x.jpg" border="0"></font>&nbsp;Medicine/healthcare/R&amp;D&nbsp;<font><img src="skill-g.jpg" border="0"></font>&nbsp;Leadership/management<font><img src="skill-l.jpg" border="0"></font>&nbsp;Law/regulatory/risk management</div>
<div style="padding-top:15px"><img src="cogo_0038.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Andreas von Planta, Ph.D.</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2006 | Nationality: Swiss | Year of birth: 1955</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Andreas von Planta is a leading expert in corporate governance, corporate law and stock exchange regulation. He advises boards of public companies on corporate governance matters and is a sought-after speaker and writer on these topics. He has co-authored the Switzerland chapter of the International Comparative Legal Guide to Corporate Governance for many years.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Senior counsel, Lenz &amp; Staehelin, Switzerland (2017&ndash;present)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Partner, Lenz &amp; Staehelin, Switzerland (1988&ndash;2017)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Helvetia Holding AG, Switzerland</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, A.P. Moller Finance SA, Switzerland</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Helvetia Schweizerische Lebensversicherungsgesellschaft AG, Switzerland</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Helvetia Schweizerische Versicherungsgesellschaft AG, Switzerland</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chairman, HSBC Private Bank (Suisse) SA, Switzerland</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chairman, HSBC Private Banking Holdings (Suisse) SA, Switzerland</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Socotab Frana SA, Switzerland </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chairman of the regulatory board, SIX Swiss Exchange AG, Switzerland</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Burberry (Suisse) SA, Switzerland</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chairman of the audit committee, International Road Transport Union, Switzerland</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Raymond Weil SA, Switzerland (2007&ndash;2018)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member and former chairman, Clinique G&#xE9;n&#xE9;rale-Beaulieu SA, Switzerland (2008&ndash;2016)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member and former chairman, Schweizerische National Versicherungs AG, Switzerland (1997&ndash;2015)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Holcim AG, Switzerland (2003&ndash;2014)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Master of Laws, Columbia Law School, US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Bar examination, Switzerland</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Doctorate in law, University of Basel, Switzerland</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Licentiatus iuris, University of Basel, Switzerland</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
  <font><img src="skill-l.jpg" border="0"></font>&nbsp;Law/regulatory/risk management&nbsp;<font><img src="skill-z.jpg" border="0"></font>&nbsp;Environmental, social and governance (ESG)</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">139</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:15px"><img src="cogo_0037.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Charles L. Sawyers, M.D.</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2013 | Nationality: American | Year of birth: 1959</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Charles L. Sawyers is a highly accomplished expert and leader in cancer research. As a physician and prominent scientist, he has a deep understanding of the benefits of drugs for patients and society at large, and the importance of access to medicines. Dr.&nbsp;Sawyers co-developed the Novartis cancer drug <i>Gleevec</i>/<i>Glivec</i> and has received numerous honors and awards, including the Lasker-DeBakey Clinical Medical Research Award.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair of the Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, US (2006&ndash;present)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Professor of medicine (2008&ndash;present), and professor of cell and developmental biology (2011&ndash;present), Weill Cornell Graduate School of Medical Sciences, US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Investigator, Howard Hughes Medical Institute, US (2002&ndash;2006 and 2008&ndash;present)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Associate chief, Division of Hematology-Oncology, University of California, Los Angeles, US (1996&ndash;2006)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Member, National Academy of Medicine, US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Member, National Academy of Sciences, US </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Investigator, Howard Hughes Medical Institute, US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Science advisor for the following US companies: Agios Pharmaceuticals Inc.; Arsenal Capital Partners; BeiGene Ltd.; Blueprint Medicines Corp.; Foghorn Therapeutics Inc.; Housey Pharmaceutical Research Laboratories; KSQ Therapeutics Inc.; Nextech Invest Ltd.; ORIC Pharmaceuticals Inc.; PMV Pharmaceuticals Inc.; The Column Group </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Member, National Cancer Advisory Board, US (2012&ndash;2020)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; President, American Association for Cancer Research, US (2013&ndash;2014)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Doctor of medicine, Johns Hopkins University School of Medicine, US</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Bachelor of Arts, Princeton University, US</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
  <font><img src="skill-x.jpg" border="0"></font>&nbsp;Medicine/healthcare/R&amp;D&nbsp;<font><img src="skill-g.jpg" border="0"></font>&nbsp;Leadership/management&nbsp;<font><img src="skill-z.jpg" border="0"></font>&nbsp;Environmental, social and governance (ESG)</div>
<div style="padding-top:15px"><img src="cogo_0036.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">William T. Winters</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2013 | Nationality: British/American | Year of birth: 1961</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">William T. Winters has extensive leadership experience in the financial sector. He began his career at JPMorgan Chase &amp; Co. in 1983 and has held management roles across several market areas and in corporate finance. Mr. Winters founded Renshaw Bay LLP, an alternative asset management firm, and now serves as CEO of Standard Chartered PLC, where he is leading a digital transformation of the global bank.</div><a name=""></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; CEO, Standard Chartered PLC, UK (2015&ndash;present)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chairman and CEO, Renshaw Bay LLP, UK (2011&ndash;2015)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Co-CEO of the Investment Bank, JPMorgan Chase &amp; Co., UK (2004&ndash;2010)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Various managerial positions at JPMorgan Chase &amp; Co., UK and US (1983&ndash;2004)</div><a name=""></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Standard Chartered Bank PLC, UK</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, International Rescue Committee, UK</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chair of the board of trustees, The Coronet Theatre, UK</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Commissioner, Independent Commission on Banking, UK (2010&ndash;2011) </div><a name=""></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Master of Business Administration, Wharton School of the University of Pennsylvania, US</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Bachelor&#x2019;s degree in international relations, Colgate University, US</div><a name=""></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
  <font><img src="skill-g.jpg" border="0"></font>&nbsp;Leadership/management&nbsp;<font><img src="skill-m.jpg" border="0"></font>&nbsp;Finance/accounting&nbsp;<font><img src="skill-l.jpg" border="0"></font>&nbsp;Law/regulatory/risk management&nbsp;<font><img src="skill-y.jpg" border="0"></font>&nbsp;Data/digital</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Corporate Secretary</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;font-weight:bold;padding-top:5px;padding-bottom:5px;">Charlotte Pamer-Wieser, Ph.D.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">140</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>



      <a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Self-assessment</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board and its committees conduct a self-assessment once a year, covering topics including Board composition, purpose, scope and responsibilities; Board processes and governance; Board meetings and pre-reading material; team effectiveness; and Chairman and peer evaluation. Every third year, this process is conducted by an independent external consultant. This last happened in 2017 and was repeated in 2020 with the consulting firm Egon Zehnder. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As part of the 2020 self-assessment, each Board member filled out a questionnaire prepared by Egon Zehnder, and then participated in an interview to share his or her perspectives on current strengths and potential areas for development, best practices exhibited by other boards, the contributions of each Board member, and the interaction between the Board and the Executive Committee. Additionally, representatives from Egon Zehnder met with each Executive Committee member to capture his or her perspectives on how the Board functions as a whole and interacts with the Executive Committee, and to solicit ideas on how the Board can be even more effective. Egon Zehnder representatives also observed parts of a Board meeting.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In a meeting with the Chairman, Egon Zehnder first shared the preliminary results of the in-depth assessment. Thereafter, Egon Zehnder led a qualitative review with the Board, sharing its key observations and recommendations, and held individual feedback sessions with each Board member. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The results of the 2020 in-depth assessment by Egon Zehnder determined that the Board and its committees are perceived as functioning well, and that the Board is evolving positively, both in how it operates and in its composition. Board meetings are considered to have a high level of transparency, and provide clarity around decisions. The feedback from management on the Board&#x2019;s evaluation showed that the Executive Committee welcomes the longer-term perspective of the Board and the level of strategic discussion, as well as the interactions with individual Board members. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The report did make a number of recommendations for the Board&#x2019;s consideration, including succession planning (the right degree of continuity, diversity, and breadth of skills), and where the Board should focus its attention, factoring in the current challenges posed by the pandemic.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Trainings</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our Board receives regular briefings and trainings on ethics, risks and compliance, and other relevant topics. In 2020, each Board member completed the following e-learning courses: </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Data Privacy</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Novartis Code of Ethics</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Fit to Commit, focusing on our ethical commitments around anti-bribery, antitrust and fair competition, insider trading and third-party risk management</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our Chief Legal Officer also provides regular updates to our Board members on developments related to insider trading laws and regulations. In addition, the Company offers to its Board members a broad set of external trainings. </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Role of the Board and its committees</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board is responsible for the overall direction and oversight of management, and holds the ultimate decision-making authority, with the exception of decisions reserved for shareholders.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Board has delegated certain of its duties and responsibilities to its five committees led by a Board-elected committee chair, as set out in the Board Regulations (www.novartis.com/investors/company-overview/corporate-governance). In some cases, these responsibilities are of an advisory or preparatory nature (A/P). In other cases, the committee has decision-making power that is subject to final Board approval (FBA), or the responsibilities have been fully delegated to the committee (FD). All committees have the authority to retain external consultants.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Any Board member may request a Board or committee meeting and the inclusion of an agenda item. Before meetings, Board members receive materials to help them prepare the discussions and decision-making. </div>


    <br>
<br>



<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">141</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>




<br>
<img src="x_cg001.gif">

<div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
              Board of DirectorsPrimary responsibilities&#x2022;Strategy: decides on the ultimate direction of the Group&#x2019;s business (including portfolio, markets, acquisitions and divestments)&#x2022;Structure and organization: determines major changes in the Group&#x2019;s structure and organization&#x2022;Culture: oversees the strategy and implementation of the corporate culture &#x2022;Ethics and compliance: oversees the Group&#x2019;s ethics and compliance framework, including the approval of fundamental corporate policies such as the Novartis Code of Ethics&#x2022;Risk management: oversees the Group&#x2019;s risk management system, the most significant risks and how these risks are managed&#x2022;Finance: determines the Group&#x2019;s accounting system, financial controls and financial planning; reviewsand approves the Annual Report (including the Compensation Report)&#x2022;People and organization: nominates or appoints, removes, and determines responsibilities of key executives, and succession planningKey activities in 2020Strategic priorities5&#x2022;Oversaw the overall Company strategy focused on the five strategic pillarsp i e d s&#x2022;Oversaw the COVID-19 response plan at Novartis and closely monitored, together withthe Executive Committee, the implementation of innovative solutions (e.g., the Choice with Responsibility working model)p e&#x2022;Reviewed the Company&#x2019;s ESG strategy and efforts, also as reflected in external ESG rankings s&#x2022;Reviewed and discussed the culture transformation and efforts to strengthen Novartisleadership, focusing on sustainability and talent management with &#x201C;big bet&#x201D; solutions(e.g., unbossed leadership experience)ps&#x2022;Followed up on the NTO and NBS transformation programs powered by data, digital and technologyi e d&#x2022;Discussed longer-term Board succession planning and required profiles, and approved the creation of a Lead Independent Director role1p&#x2022;Agreed to propose a term limit for Board members at the 2021 AGM2p&#x2022;Focused on accelerating our drive to scale up data and digital through innovation,engagement and operation, and on ensuring high-quality data and clear data governancei e d&#x2022;Discussed and reviewed the annual Board self-evaluation conducted by an external consultantpMeetingsNumber of meetings held10Number of members14Approximate average duration (hours)4:46Meeting attendance99%The Board met 10 times in 2020. This includes regular meetings in January, April, June, August, October and December, and additional special meetings to deal with ad hoc matters. Board committees typically meet the day before the meetings of the full Board. In response to the COVID-19 pandemic, the Board seamlessly moved to virtual meetings as of April 2020. J. Reinhardt (Chair)10E. Vanni(Vice Chairman, Lead Independent Director3)10N. Andrews10T. Buechner10P. Bula10S. Datar 10E. Doherty10A. Fudge10B. Heller48F. van Houten9S. Moroney48A. von Planta10C. Sawyers10W. Winters9Documents&#x2022;Articles of Incorporation of Novartis AG &#x2022;Board Regulations www.novartis.com/investors/company-overview/corporate-governance1See &#x201C;Item 6.C Board practicesBoard of DirectorsVice Chairman and Lead Independent Director&#x201D;2See &#x201C;Item 6.C Board practicesBoard of DirectorsElection and term of office&#x201D;3As of January 1, 20214Ms. Heller and Mr. Moroney were elected at the 2020 AGM and have attended all Board meetings since their election.5Strategic priorities: pUnleash the power of our peopleiDeliver transformative innovationeEmbrace operational excellencedGo big on data and digitalsBuild trust with society
</div>

<br>
<br>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">142</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>


<br>
<img src="x_cg002.gif">
<div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
              Audit and Compliance CommitteePrimary responsibilities&#x2022;Supervises the external auditor, and selects and nominates the external auditor for election by the shareholders (FD)**&#x2022;Oversees Internal Audit (FD)**&#x2022;Oversees accounting policies, financial controls, and compliance with accounting and internal control standards (FD)**&#x2022;Approves financial statements for the first three quarters of each calendar year and the corresponding financial results releases (FD)**, and reviews the annual financial statements and the corresponding financial results releases (FBA)***&#x2022;Oversees internal control and compliance processes and procedures (FD)**&#x2022;Oversees compliance with laws, regulations and internal policies falling into its subject matter expertise (FD)**Key activities in 2020Strategic priorities2&#x2022;Tendered the external audit mandate for the selection of an audit firm to be proposedto shareholders for election at the 2022 AGM1e&#x2022;Evaluated the performance and nomination of the external auditorPricewaterhouseCoopers AG (PwC) for re-election at the 2021 AGMe&#x2022;Reviewed the accounting and financial reporting, focusing in particular on those areas involving significant risk or judgmente&#x2022;Reviewed progress on the transformation of Group Financial Reporting &amp; Accounting (FRA),and assessed its operational stabilitye&#x2022;Received the risk assessment of high-risk countries and associated plans to mitigate the riskse s&#x2022;Received reports and updates from Internal Audit; Quality; Ethics, Risk &amp; Compliance (ERC);the SpeakUp Office; Health, Safety and Environment (HSE); Tax; and Legal, anddiscussed progress on identifying and remedying the root causes of issuesp sMeetingsNumber of meetings held8Number of members5Approximate average duration (hours)2:43Meeting attendance100%E. Doherty(Chair, Audit Committee Financial Expert)8T. Buechner8S. Datar(Audit Committee Financial Expert)8A. von Planta8E. Vanni8Documents&#x2022;Board Committees Charter, Appendix I to the Board Regulationswww.novartis.com/investors/company-overview/corporate-governance*A/P = advisory or preparatory task**FD = fully delegated task***FBA = task subject to final Board approval1See &#x201C;Item 6.C Board practicesAuditorsAuditor tender process&#x201D;2Strategic priorities: pUnleash the power of our peopleiDeliver transformative innovationeEmbrace operational excellencedGo big on data and digitalsBuild trust with society
</div>


<br>
<br>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">143</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>

<br>
<img src="x_cg003.gif">
<div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
              Compensation CommitteePrimary responsibilities&#x2022;Designs, reviews and recommends to the Board the compensation policies and programs (FBA)***&#x2022;Advises the Board on the compensation of Board members and of the CEO (A/P)*&#x2022;Decides on the compensation of Executive Committee members (FD)**&#x2022;Prepares the Compensation Report and the Say-on-Pay brochure, and submits them to the Board for approval (FBA)***Key activities in 2020 Strategic priorities3&#x2022;Made decisions relating to Executive Committee compensation during the yearp&#x2022;Determined the critical performance measures (including financial, strategic, operational,innovation and ESG) to be considered in the 2020 incentive plan targetsp i e s&#x2022;Reviewed the achievement of incentive plan targets for the Executive Committee membersp s&#x2022;Reviewed shareholder and proxy advisor feedback related to Novartis compensation practices and disclosuresp s&#x2022;Considered additional disclosures in the 2020 Compensation Reports&#x2022;Proposed appropriate peer companies for comparisons of board and executive committee compensation, and assessed the Company&#x2019;s level of compensation against the peer groupsMeetingsNumber of meetings held6Number of members5Approximate average duration (hours)2:11Meeting attendance100%E. Vanni(Chair)16P. Bula6S. Datar6B. Heller25W. Winters6Documents&#x2022;Board Committees Charter, Appendix I to the Board Regulationswww.novartis.com/investors/company-overview/corporate-governance*A/P = advisory or preparatory task**FD = fully delegated task***FBA = task subject to final Board approval1At the 2021 AGM, Mr. Vanni will stand for re-election as member of the Compensation Committee, but will step down as committee chair. The Board proposes to shareholders the election of Mr.Moroney as new member of the Compensation Committee. Subject to his election, the Board intends to designate Mr.Moroney as successor of Mr.Vanni in the role of the chair. Mr.Moroney attended each Compensation Committee meeting after the 2020 AGM as a permanent guest. 2Ms. Heller was elected at the 2020 AGM and has attended all Compensation Committee meetings since her election.3Strategic priorities: pUnleash the power of our peopleiDeliver transformative innovationeEmbrace operational excellencedGo big on data and digitalsBuild trust with society
</div>
<br>
<br>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">144</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>


<br>
<img src="x_cg004.gif">
    <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
              Governance, Nomination and Corporate Responsibilities CommitteePrimary responsibilities&#x2022;Oversees the Company&#x2019;s strategy, governance and progress on ESG, global health and corporate responsibility (FBA)***&#x2022;Recommends to the Board corporate governance best practices (FBA)***&#x2022;Reviews periodically the Articles of Incorporation and Board Regulations, with a view to fostering shareholder rights (FD)**&#x2022;Reviews regularly the composition and size of the Board and its committees (FBA)***&#x2022;Identifies new Board member candidates and recommends to the Board whether existing Board members should stand for re-election (FBA)***&#x2022;Prepares and reviews succession plans for the Chairman, the Vice Chairman, the Lead Independent Director, Boardmembers, committee members and chairs, and the CEO (FBA)***&#x2022;Reviews annually the independence of each Board member (FBA)***&#x2022;Reviews directorships and agreements of Board members for conflicts of interest, and deals with conflicts of interest (FBA)***Key activities in 2020Strategic priorities3&#x2022;Evaluated sustainability at Novartis, focusing on material ESG factors, strategy andcorresponding short- and mid-term ESG targets, and ways to leverage Novartis ESG efforts s&#x2022;Assessed ESG rating agency scores and identified potential gapss&#x2022;Reviewed access-to-medicine and global health targets announced in September, as well asthe issuance of an innovative sustainability-linked bonds&#x2022;Discussed the progress of the Global Health &amp; Corporate Responsibility function,including the COVID-19 response such as the creation of donation funds worth up toUSD 40 million to support communities impacted by the pandemics&#x2022;Received an update on the patient advocacy key achievements in 2020 and discussedthe priorities for 2021s&#x2022;Discussed the succession of Board and committee members (including committee chairs),taking into account upcoming retirements and the desire to increase diversityp&#x2022;Discussed and recommended to the Board the creation of a Lead Independent Director role1 and the introduction of a term limit for Board members2p&#x2022;Reviewed the skill matrix and independence of the Boardp&#x2022;Discussed the format of the 2021 AGMsMeetings Number of meetings held4Number of members5Approximate average duration (hours)1:53Meeting attendance100%A. von Planta(Chair)4A. Fudge4C. Sawyers4E. Vanni4W. Winters4Documents&#x2022; Board Committees Charter, Appendix I to the Board Regulationswww.novartis.com/investors/company-overview/corporate-governance*A/P = advisory or preparatory task**FD = fully delegated task***FBA = task subject to final Board approval1See &#x201C;Item 6.C Board practicesBoard of DirectorsVice Chairman and Lead Independent Director&#x201D;2See &#x201C;Item 6.C Board practicesBoard of DirectorsElection and term of office&#x201D;3Strategic priorities: pUnleash the power of our peopleiDeliver transformative innovationeEmbrace operational excellencedGo big on data and digitalsBuild trust with society
</div>
<br>
<br>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">145</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>

<br>
<img src="x_cg005.gif">
<div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
              Risk CommitteePrimary responsibilities&#x2022;Oversees the risk management system and processes (FBA)***&#x2022;Reviews, together with management, the prioritization and handling of risks, the risk portfolio, and actions implemented by management (FBA)***&#x2022;Performs deep dives into key risk areas and fosters a culture of smart risk-taking (FBA)***Key activities in 2020 Strategic priorities1&#x2022;Reviewed and discussed the Company&#x2019;s Third-Party Risk Management programe s&#x2022;Analyzed the Company&#x2019;s launch excellence, including risks and challengesi e&#x2022;Discussed the culture transformation and how to engage Novartis leaders in the processp s&#x2022;Received two updates on cybersecurity from the Chief Information Security Officerd&#x2022;Evaluated various risks and their coverage (e.g., developments in EU data privacy) e&#x2022;Analyzed pricing developmentse&#x2022;Reviewed the NTO transformation and the risk management frameworki e&#x2022;Reviewed the Enterprise Risk Management (ERM) resultseMeetingsNumber of meetings held4Number of members5Approximate average duration (hours)2:10Meeting attendance100%S. Datar(Chair)4N. Andrews4T. Buechner4E. Doherty4A. von Planta4Documents&#x2022;Board Committees Charter, Appendix I to the Board Regulationswww.novartis.com/investors/company-overview/corporate-governance*A/P = advisory or preparatory task**FD = fully delegated task***FBA = task subject to final Board approval1 Strategic priorities: pUnleash the power of our peopleiDeliver transformative innovationeEmbrace operational excellencedGo big on data and digitalsBuild trust with society
</div>
<br>
<br>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">146</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>

<br>
<img src="x_cg006.gif">
    <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
              Science &amp; Technology CommitteePrimary responsibilities&#x2022;Monitors emerging scientific, data-related, technological and research trends and issues, and brings recommendations to the Board (FBA)***&#x2022;Periodically informs the Board about critical developments for the success of the portfolio and for scientific, technologicaland research activities as well as benchmarking (A/P)*&#x2022;Assists the Board with setting the Company&#x2019;s strategy for science, data, technology and research (A/P)*&#x2022;Assists the Board with oversight and evaluation of the performance of the Company&#x2019;s scientific, technological, andresearch and development activities (FBA)***&#x2022;Reviews performance and proposed targets in the area of science, technology and research (FD)**&#x2022;Reviews such other matters in relation to science, data, technology and research as the committee may, in its own discretion, deem desirable in connection with its responsibilities (A/P)*Key activities in 2020 Strategic priorities2&#x2022;Expanded its scope to digital technology and implemented name change from Research &amp; Development Committee to Science &amp; Technology Committeed&#x2022;Reviewed the Company&#x2019;s digitization process and discussed the further development of the digital investmenti d&#x2022;Reviewed an external assessment of the portfolio and productivity of Novartis research and development i e&#x2022;Discussed the cardiovascular, renal and metabolism; ophthalmology; and hematology portfoliosiMeetingsNumber of meetings held3Number of members6Approximate average duration (hours)7:10Meeting attendance100%J. Reinhardt(Chair)3N. Andrews3A. Fudge3F. van Houten3S. Moroney13C. Sawyers3Documents&#x2022;Board Committees Charter, Appendix I to the Board Regulationswww.novartis.com/investors/company-overview/corporate-governance*A/P = advisory or preparatory task**FD = fully delegated task***FBA = task subject to final Board approval1Mr. Moroney was elected at the 2020 AGM and has attended all Science &amp; Technology Committee meetings since his election.2Strategic priorities: pUnleash the power of our peopleiDeliver transformative innovationeEmbrace operational excellencedGo big on data and digitalsBuild trust with society
</div>
<br>
<br>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">147</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>


    <a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Chairman</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Chairman leads the Board to represent the interests of all stakeholders, and ensures an appropriate balance of power between the Board and the Executive Committee. In this role, he:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Provides leadership to the Board</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Supports and mentors the CEO</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Ensures that the Board and its committees work effectively</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Sets the agenda, style and tone of Board discussions, promoting constructive dialogue and effective decision-making</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Ensures onboarding programs for new Board members, and continuing education and specialization for all Board members</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Ensures the Board&#x2019;s annual performance evaluation</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Promotes effective relationships and communication between Board and Executive Committee members</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Ensures effective communication with the Company&#x2019;s shareholders, other stakeholders and the public</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Vice Chairman and Lead&nbsp;Independent&nbsp;Director</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Until December 31, 2020, the Vice Chairman had the following responsibilities:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Leads the Board in case and as long as the Chairman is incapacitated</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chairs the sessions of the independent Board members, and leads the independent Board members if and as long as the Chairman is not independent</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Leads the yearly session of the Board members to evaluate the performance of the Chairman, during which the Chairman is not present</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">To support adequate control mechanisms, the Board amended, with effect as of January 1, 2021, the Board Regulations (www.novartis.com/investors/company-overview/corporate-governance) to introduce the additional role of the Lead Independent Director with the following duties: </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chairs the sessions of the independent Board members</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Leads the independent Board members in case of a crisis or matter requiring their separate consideration or decision</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Vice Chairman will continue to lead the Board in case and as long as the Chairman is incapacitated. In addition, the Vice Chairman leads the Board&#x2019;s annual assessment of the Chairman. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The roles of the Vice Chairman and the Lead Independent Director can be held by two Board members or by one Board member (combined role). </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Board appointed Enrico Vanni as Vice Chairman and Lead Independent Director (combined role) effective as of January 1, 2021. With his long-standing experience, Mr. Vanni will help shape the role of the Lead Independent Director during his remaining time on the Board.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Honorary Chairmen</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Alex Krauer and Daniel Vasella have been appointed Honorary Chairmen in recognition of their significant achievements on behalf of Novartis. They are not provided with Board documents and do not attend Board meetings.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Mandates outside the Novartis Group</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to article 34, paragraph 1 of the Articles of Incorporation (www.novartis.com/investors/company- overview/corporate-governance), the following limitations on mandates apply: </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Maximum number <br> of mandates</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mandates</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other listed companies<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="4">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="4">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Chairmanship of the board of directors in other listed companies counts as two mandates.</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to article 34, paragraph 3 of the Articles of Incorporation (www.novartis.com/investors/company- overview/corporate-governance), the following mandates are not subject to the above-mentioned limitations: </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Maximum number <br> of mandates</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mandates in companies that are controlled by Novartis AG</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> No limit</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mandates held at the request of Novartis AG  or companies controlled by it</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mandates in associations, charitable organizations,  foundations, trusts and employee welfare foundations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   10</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">&#x201C;Mandates&#x201D; means those in the supreme governing body of a legal entity that is required to be registered in the commercial register or a comparable foreign register. Mandates in different legal entities that are under joint control are deemed one mandate.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">148</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>


    <a name="anchorId002437533"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Executive Committee</p>
<div style="padding-top:15px"><img src="cogo_0021.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Composition (as per December 31, 2020)Vasant (Vas) NarasimhanChief Executive OfficerSteven BaertChief People &amp; Organization OfficerBertrand Bodson1Chief Digital OfficerJames (Jay) BradnerPresident of the Novartis Institutesfor BioMedical Research (NIBR)Harry KirschChief Financial OfficerShannon Thyme KlingerChief Legal OfficerSteffen LangGlobal Head of NovartisTechnical Operations (NTO)Klaus MoosmayerChief Ethics, Risk &amp; Compliance OfficerRichard SaynorChief Executive Officer of SandozSusanne SchaffertPresident of Novartis OncologyJohn TsaiHead of Global Drug Developmentand Chief Medical OfficerMarie-France TschudinPresident of Novartis PharmaceuticalsRobert Weltevreden1Head of Novartis Business Services (NBS)1Effective February 1, 2021, the Digital function will be merged with NBS to form a new Customer &amp; Technology Solutions (CTS) unit, which Mr. Weltevreden has been appointed to lead. Mr.Bodson will step down from the Executive Committee on February 1, 2021.</div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Role of the Executive Committee</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board has appointed the Executive Committee members and delegated to them the overall responsibility for and oversight of the operational management of Novartis, including:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Recruiting, appointing and promoting senior management</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Ensuring the efficient operation of the Group and the achievement of optimal results</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Promoting an active internal and external communications policy </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Developing policies and strategic plans for Board approval, and implementing those approved</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Submitting the following to the Board for approval: investments, divestments, transactions, contracts and litigations with a value exceeding USD 500 million, capital market and other important financing transactions, as well as all other matters of fundamental significance to the Novartis Group</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Preparing and submitting quarterly and annual reports to the Board and its committees</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Informing the Board of all matters of fundamental significance to the businesses</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Dealing with any other matters delegated by the Board</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There are no contracts between Novartis and third parties whereby Novartis would delegate any business management tasks to such third parties.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">CEO</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">With the support of the Executive Committee, the CEO is responsible for the operational management of Novartis. This includes effectively implementing the Company strategy, delivering financial results, and shaping a corporate culture of empowerment and responsibility to help drive innovation, performance and reputation.&nbsp;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition to other Board-assigned duties, the CEO leads the Executive Committee, building and maintaining an effective executive team. With the support of the Executive Committee, the CEO is responsible for:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Ensuring Novartis has the capabilities to achieve its long-term strategic objectives</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Developing robust management succession and development plans for presentation to the Board</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Promoting effective communication with shareholders and other stakeholders</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Ensuring Novartis conducts its business in a legal and ethical manner</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Developing an effective risk control framework for all business activities </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ensuring the flow of information to the Board is accurate, timely and clear</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">149</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Diversity</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The composition as of December 31, 2020, in terms of nationality, gender, age and length of tenure, is shown in the following charts: </div>
<div style="padding-top:15px"><img src="cogo_0039.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Diversity profileNationality1pAmerican31%pGerman23%pSwiss15%pBelgian15%pDutch8%pBritish8%GenderpMale77%pFemale23%Agep&lt;458%p45&#x2013;5038%p&gt;5054%Tenurep&lt;2&#xA0;y23%p2&#x2013;4&#xA0;y62%p&gt;4&#xA0;y15%1Please note that two Executive Committee members have two nationalities. Each of these nationalities is counted as a half in the above chart.</div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Mandates outside the Novartis Group</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to article 34, paragraph 2 of the Articles of Incorporation (www.novartis.com/investors/company-overview/corporate-governance), the following limitations on mandates apply:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Maximum number <br> of mandates</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mandates</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other listed companies<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="4">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="4">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Chairmanship of the board of directors in other listed companies is not allowed.</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to article 34, paragraph 3 of the Articles of Incorporation (www.novartis.com/investors/company-overview/corporate-governance), the following mandates are not subject to above-mentioned limitations: </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Maximum number <br> of mandates</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mandates in companies that are controlled by Novartis AG</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> No limit</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mandates held at the request of Novartis AG  or companies controlled by it</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mandates in associations, charitable organizations,  foundations, trusts and employee welfare foundations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   10</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">&#x201C;Mandates&#x201D; means those in the supreme governing body of a legal entity that is required to be registered in the commercial register or a comparable foreign register. Mandates in different legal entities that are under joint control are deemed one mandate.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">150</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>


    <a name="anchorId002537544"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Members of the Executive Committee </p>
<div style="padding-top:15px"><img src="cogo_0043.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Vasant (Vas) Narasimhan, M.D.</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Chief Executive Officer of Novartis since 2018 | Nationality: American | Year of birth: 1976</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Global Head of Drug Development and Chief Medical Officer, Novartis AG, Switzerland (2016&ndash;2018)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Global Head of Development, Novartis Pharmaceuticals, Switzerland (2014&ndash;2016)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Global Head of Biopharmaceuticals and Oncology Injectables, Sandoz International, Germany (2014)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Global Head of Development, Novartis Vaccines, US (2012&ndash;2014)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  North America Region Head, Novartis Vaccines, and US Country President, Novartis Vaccines and Diagnostics, US (2008&ndash;2012)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Joined Novartis in 2005 </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Member, National Academy of Medicine, US </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, African Parks Network, South Africa</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Committee member, Biopharmaceutical CEOs Roundtable (BCR), International Federation of Pharmaceutical Manufacturers &amp; Associations (IFPMA), Switzerland</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Member of the board of fellows, Harvard Medical School, US</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Pharmaceutical Research and Manufacturers of America (PhRMA), US</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Doctor of medicine, Harvard Medical School, US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Master&#x2019;s degree in public policy, John F. Kennedy School of Government, Harvard University, US</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Bachelor&#x2019;s degree in biological sciences, University of Chicago, US</div>
<div style="padding-top:15px"><img src="cogo_0042.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Steven Baert</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Chief People &amp; Organization Officer of Novartis since 2014 | Nationality: Belgian | Year of birth: 1974</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Global Head of Human Resources, Novartis Oncology, Switzerland (2012&ndash;2014)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Head of Human Resources for the US and Canada, Novartis Pharmaceuticals, US (2009&ndash;2012)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Head of Human Resources for Emerging Growth Markets, Novartis Pharmaceuticals,   Switzerland (2008&ndash;2009)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Head of Human Resources Global Functions, Novartis Pharmaceuticals, Switzerland (2006&ndash;2008)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, WeSeeHope charity, US</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Represented Novartis on the board of GlaxoSmithKline Consumer Healthcare Holdings Ltd. (2015&ndash;2018)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Master of Business Administration, Vlerick Business School, Belgium</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Master of Laws, Katholieke Universiteit Leuven, Belgium</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Bachelor of Laws, Katholieke Universiteit Brussels, Belgium </div>
<div style="padding-top:15px"><img src="cogo_0041.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Bertrand Bodson</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Chief Digital Officer of Novartis from 2018 through January 31, 2021 | Mr. Bodson will step down from the Executive Committee on February 1, 2021 | Nationality: Belgian | Year of birth: 1975</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chief digital and marketing officer, Sainsbury&#x2019;s Argos, UK (2013&ndash;2017)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Executive vice president of the global digital business, EMI Music, UK (2010&ndash;2013)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Co-founder and CEO, Bragster.com, UK (2006&ndash;2010)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Senior group product manager, Amazon Inc., US and UK (2003&ndash;2006)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Member of the supervisory board, Wolters Kluwer NV, Netherlands </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Electrocomponents PLC, UK (2015&ndash;2021) </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Master of Business Administration, Harvard Business School, US</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Master&#x2019;s degree in commercial engineering, Solvay Business School, Belgium/McGill University, Canada</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">151</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:15px"><img src="cogo_0040.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">James (Jay) Bradner, M.D.</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">President of the Novartis Institutes for BioMedical Research (NIBR) since 2016 | Nationality: American |  <br>Year of birth: 1972</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Associate professor, Department of Medicine, Harvard Medical School, US (2014&ndash;2016)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Assistant professor, Department of Medicine, Harvard Medical School, US (2010&ndash;2014)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Attending physician, Department of Medical Oncology, Dana-Farber Cancer Institute, US (2005&ndash;2015)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Co-founder of five biotechnology companies</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Co-author of more than 250 scientific publications and 50&nbsp;US patent applications</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Science advisor for the Abdul Latif Jameel Clinic for Machine Learning in Health, Massachusetts Institute of Technology, US, and for Brigham and Women&#x2019;s Hospital, US</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chairman, Genomics Institute of the Novartis Research Foundation, US</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Doctor of medicine, University of Chicago Pritzker School of Medicine, US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Bachelor&#x2019;s degree in biochemistry, Harvard University, US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Postdoctoral training in chemistry and chemical biology, Harvard University, US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Fellowship in medical oncology and hematology, Dana-Farber Cancer Institute, US</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Residency in medicine, Brigham and Women&#x2019;s Hospital, US</div>
<div style="padding-top:15px"><img src="cogo_0047.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Harry Kirsch</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Chief Financial Officer of Novartis since 2013 | Nationality: German/Swiss | Year of birth: 1965</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chief Financial Officer of the Pharmaceuticals Division (now known as the Innovative Medicines Division), Novartis Pharmaceuticals, Switzerland (2010-2013)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chief Financial Officer of Pharma Europe, Novartis Pharmaceuticals, Switzerland (2008&ndash;2010)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Head of Business Planning &amp; Analysis for the Pharmaceuticals Division, Novartis Pharmaceuticals, Switzerland (2005&ndash;2008) </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Joined Novartis in 2003 as Head Finance Global Primary Care, and over the years held positions of increasing responsibility within Finance </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Represented Novartis on the board of GlaxoSmithKline Consumer Healthcare Holdings Ltd. (2015&ndash;2018)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Diploma degree in industrial engineering and economics, University of Karlsruhe, Germany</div>
<div style="padding-top:15px"><img src="cogo_0046.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Shannon Thyme Klinger</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Chief Legal Officer of Novartis since 2018 | Nationality: American | Year of birth: 1971</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chief Ethics, Risk &amp; Compliance Officer, Novartis AG, Switzerland (April&ndash;May 2018)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chief Ethics and Compliance Officer and Global Head of Litigation, Novartis AG, Switzerland (2016&ndash;2018)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; General Counsel and Global Head of Legal, Sandoz International, Germany (2012&ndash;2016)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  General Counsel for North America, Sandoz Inc., US (2011&ndash;2012)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Partner, Mayer Brown LLP, US (2010&ndash;2011)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; General counsel and senior vice president, Solvay Pharmaceuticals Inc., US (2008&ndash;2010) </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, SwissHoldings, the Swiss federation of industrial and service groups, Switzerland</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, SIX Group, Switzerland (2016&ndash;2020)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Bar memberships: State of Georgia, District of Columbia, US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Juris doctor with honors, University of North Carolina at Chapel Hill, US</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Bachelor&#x2019;s degree in psychology, University of Notre Dame, US</div>
<div style="padding-top:15px"><img src="cogo_0045.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Steffen Lang, Ph.D.</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Global Head of Novartis Technical Operations (NTO) since 2017 | Nationality: German/Swiss | Year of birth: 1967</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Global Head of Biologics Technical Development and Manufacturing, Novartis Technical Operations, Switzerland (2015&ndash;2017)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Global Head of Technical Research and Development, Novartis Pharmaceuticals, Switzerland (2009&ndash;2015)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Joined Novartis in 1994 as Head of Laboratory in Research, and over the years held positions of increasing responsibility within Pharmaceuticals Development</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Bachem Holding AG, Switzerland </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Doctorate in pharmaceutical technology, Swiss Federal Institute of Technology, Switzerland </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Master&#x2019;s degree in pharmaceutical sciences, University of Heidelberg, Germany</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">152</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:15px"><img src="cogo_0044.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Klaus Moosmayer, Ph.D.</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Chief Ethics, Risk &amp; Compliance Officer of Novartis since 2018 | Nationality: German | Year of birth: 1968</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chief compliance officer, Siemens AG, Germany (2014&ndash;2018)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chief counsel compliance, Siemens AG, Germany (2009&ndash;2013)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Compliance operating officer, Siemens AG, Germany (2007&ndash;2009)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Vice chair, Business at OECD (BIAC) executive board, Paris </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Member of the advisory panel, Pharmaceutical Supply Chain Initiative, US</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Co-founder and board member, European Chief Compliance and Integrity Officers&#x2019; Forum</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chair of the Anti-Corruption Committee of the Business and Industry Advisory Committee (BIAC), Organization for Economic Co-operation and Development (OECD), Paris (2013&ndash;2020)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Co-chair, B20 Integrity &amp; Compliance Task Force under the G20 presidency of Saudi Arabia (2020)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Co-chair, B20 Integrity &amp; Compliance Task Force under the G20 presidency of Argentina (2018)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chair, B20 Integrity &amp; Compliance Task Force under the G20 presidency of Germany (2017)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; First and second state examination in law, Germany</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Doctor of jurisprudence, University of Freiburg, Germany</div>
<div style="padding-top:15px"><img src="cogo_0052.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Richard Saynor</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Chief Executive Officer of Sandoz since 2019 | Nationality: British | Year of birth: 1967</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Senior vice president of classic and established products, and commercial and digital platforms, GlaxoSmithKline (GSK) Pte. Ltd., UK (March&ndash;June 2019) </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Senior vice president and global head of classic and established products, GSK, UK (2014&ndash;2019)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Senior vice president and global head of established products, GSK, UK (2013&ndash;2014)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Senior vice president of classic brands and generics for Europe, Japan, and the emerging markets and Asia-Pacific (EMAP) region, GSK, Singapore (2010&ndash;2013)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Region Head of Asian Markets, Sandoz International, Singapore (2008&ndash;2010)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Region Head of Asia-Pacific, Latin America, Canada and Turkey, Sandoz International, Germany (2005&ndash;2008)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Member, Royal Pharmaceutical Society, UK </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, GSK India, India (2018&ndash;2019)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Bachelor of Pharmacy, University of Bradford, UK</div>
<div style="padding-top:15px"><img src="cogo_0051.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Susanne Schaffert, Ph.D.</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">President of Novartis Oncology since 2019 | Nationality: German | Year of birth: 1967</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chairperson and President, Advanced Accelerator Applications, Switzerland (2018&ndash;2019)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  General Manager of Europe, Novartis Oncology, Italy (2012&ndash;2018)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Global Head of Investor Relations, Novartis AG, Switzerland (2010&ndash;2012)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Global Franchise Head for Immunology and Infectious Diseases, Novartis AG, Switzerland (2009&ndash;2010)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  General Manager of Northern and Central Europe, Novartis Oncology, Italy (2007&ndash;2009)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  General Manager of Germany, Novartis Oncology, Germany (2004&ndash;2007)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Novartis AG, Germany</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board and executive committee member, European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Represented Novartis on the board of GlaxoSmithKline Consumer Healthcare Holdings Ltd. (2015&ndash;2018)</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Doctorate in organic chemistry, University of Erlangen, Germany</div>
<div style="padding-top:15px"><img src="cogo_0050.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">John Tsai, M.D.</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Head of Global Drug Development and Chief Medical Officer for Novartis since 2018 | Nationality: American |  <br>Year of birth: 1967</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chief medical officer and senior vice president of Global Medical, Amgen Inc., US (2017&ndash;2018)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Global head of clinical development for marketed products, Bristol-Meyers Squibb Co. (BMS), US (2016&ndash;2017)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Full development team leader in oncology, BMS, US (2015&ndash;2016) </div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Head of Worldwide Medical, BMS, US (2014&ndash;2015)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chief medical officer for Europe, BMS, France (2012&ndash;2014)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Vice president of US Medical, BMS, US (2010&ndash;2012) </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Vice president of Cardiovascular Medical, BMS, US (2006&ndash;2010) </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Doctor of medicine, University of Louisville School of Medicine, US</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Bachelor of Science in electrical engineering, Washington University in St. Louis, US </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">153</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:15px"><img src="cogo_0049.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Marie-France Tschudin</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">President of Novartis Pharmaceuticals since 2019 | Nationality: Swiss | Year of birth: 1971</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; President, Advanced Accelerator Applications, France (March&ndash;June 2019)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Europe Region Head, Novartis Pharmaceuticals, Switzerland (2017&ndash;2019)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Corporate vice president of hematology and oncology for Europe, the Middle East and Africa, Celgene International, Switzerland (2014&ndash;2016)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Regional vice president of northern Europe, Celgene International, Switzerland (2012&ndash;2014)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  General manager of Austria, Switzerland, the Czech Republic, Poland, Slovenia and Slovakia, Celgene International, Switzerland (2009&ndash;2011)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Country manager of Switzerland, Celgene International, Switzerland (2008&ndash;2009) </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, AXA, France</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Master of Business Administration, IMD business school, Switzerland</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Bachelor of Science, Georgetown University, US </div>
<div style="padding-top:15px"><img src="cogo_0048.jpg" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Robert Weltevreden</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Head of Novartis Business Services (NBS) from 2018 through January 31, 2021 | Head of Customer &amp;  <br>Technology Solutions (CTS) as of February 1, 2021 | Nationality: Dutch | Year of birth: 1969</div><a name=""></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Head of business services, Syngenta AG, Switzerland (2015&ndash;2017)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Head of business process management, Syngenta AG, Switzerland (2014)</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Head of finance services, Syngenta AG, Switzerland, (2009&ndash;2014)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chief financial officer of the Asia-Pacific region, Syngenta Crop Protection AG, Singapore (2007&ndash;2009) </div><a name=""></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</font>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Master&#x2019;s degree in international finance, economics and business administration, Erasmus University Rotterdam, Netherlands</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Master of Business Administration in financial management, Vlerick Business School, Belgium</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">154</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>


 <a name="anchorId002637533"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Information and control systems </p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board&#x2019;s information and control systems vis-&#xE0;-vis management include a steady flow of information from senior management; monthly financial reports; a comprehensive and integrated risk management framework; an integrated assurance framework; and the independent evaluation of our risk management and internal control framework by Novartis Business Assurance &amp; Advisory (NBAA).</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Information from senior management</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board ensures that it receives sufficient information from the Executive Committee through:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Monthly CEO reporting (including detailed written updates from each division and business unit head), frequent communications from the CEO on current developments, and a yearly presentation</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Executive Committee meeting minutes</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Regular meetings/teleconferences by the Board and/or Board committees with the CEO and/or other members of the Executive Committee (e.g., the CFO, the Chief Legal Officer, the Chief Ethics, Risk &amp; Compliance Officer), and occasional meetings/teleconferences with senior management (e.g., the Global Head of NBAA and Head of Internal Audit)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Information from Executive Committee members or other Novartis associates, and visits to Novartis sites</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">To get an outside view, the Board and/or Board committees occasionally invite external advisors (e.g., the independent advisor of the Compensation Committee, the external auditor) to attend a meeting and/or represent a specific topic.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Monthly financial reports</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis produces comprehensive, consolidated (unaudited) financial statements on a monthly basis for the Group and its operating divisions. These are typically available within 10 days after the end of the month, and include the following:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Consolidated income statement of the month and year to date, in accordance with International Financial Reporting Standards (IFRS), as well as adjustments to arrive at core results, as defined by Novartis (see &#x201C;Item 5. Operating and Financial Review and Prospects&mdash;Item 5.A Operating results&mdash;Non-IFRS measures as defined by Novartis&#x201D;). The IFRS and core figures are compared to the prior-year period and targets in both USD and on a constant currency basis.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Supplementary data on a monthly and year-to-date basis, such as free cash flow and earnings per share on a USD basis </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Management information related to the consolidated income statements and free cash flow is made available to Board members through the monthly CEO Report, including an analysis of key deviations from the prior year or target.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Prior to the release of each quarter&#x2019;s results, the Board receives the actual consolidated financial statement information and an outlook of the full-year results in accordance with IFRS and core results (as defined by Novartis), together with related commentary.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Annually, in the middle of the year, the Board approves the Company&#x2019;s strategic plan for the next three years. In the fourth quarter of the year, the Board approves the operating targets for the following year as well as the financial targets for the following three-year period, including a projected consolidated income statement in USD prepared in accordance with IFRS and non-IFRS measures as defined by Novartis (core results).</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Board does not have direct access to the Novartis financial and management reporting systems but can, at any time, request more detailed information.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">155</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Risk management</font>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Overview</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At Novartis, our continued success depends on our ability to manage risk. Our Board has ultimate oversight of the Enterprise Risk Management (ERM) system and regularly reviews the most significant risks and how these risks are managed. As further explained below, the Board is supported by its committees. Furthermore, our NBAA function provides an independent evaluation of risk management (see &#x201C;&mdash;Item 6.C Board practices&mdash;Information and control systems&mdash;Novartis Business Assurance &amp; Advisory&#x201D;). </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:8pt; font-weight:bold; color:#0070f7; text-transform:uppercase;">Board committees<div style="border:none;border-bottom:solid 2px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;text-transform:uppercase;">Risk committee</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Oversees the risk management system and processes</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Reviews, together with management, the prioritization and handling of risks, the risk portfolio, and actions implemented by management</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Performs deep dives into key risk areas and fosters a culture of smart risk-taking</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Receives updates at its four annual meetings from designated risk owners as well as the Chief Ethics, Risk &amp; Compliance Officer and/or the Head of Risk &amp; Resilience</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;text-transform:uppercase;">Audit and compliance committee</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Ensures that Internal Audit plans are aligned with key risks and that the function provides independent assurance and insights around these risks</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Works closely with the Risk Committee to minimize gaps in risk&nbsp;coverage</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews the integrated assurance report with the Chief Ethics, Risk&nbsp;&amp; Compliance Officer and the Global Head of NBAA   and Head&nbsp;of Internal Audit</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Receives biannually a presentation from the Chief Ethics,   Risk &amp; Compliance Officer</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Pays particular attention to financial risk</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Has closed sessions individually with the Chief Ethics,   Risk &amp; Compliance Officer and the Global Head of NBAA   and Head&nbsp;of Internal Audit</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;text-transform:uppercase;">Compensation committee</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Works closely with the Risk Committee to ensure that the compensation system does not lead to excessive risk-taking (see&nbsp;&#x201C;&mdash;Item 6.B Compensation&mdash;Compensation governance&mdash;Risk&nbsp;management principles&#x201D;)  </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:8pt; font-weight:bold; color:#0070f7; text-transform:uppercase;">Executive committee of NOVARTIS<div style="border:none;border-bottom:solid 2px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Regularly assesses risks and fosters a culture of risk awareness, in line with the Novartis Values and Behaviors and the Novartis Code&nbsp;of Ethics</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:8pt; font-weight:bold; color:#0070f7; text-transform:uppercase;">Ethics, risk &amp; compliance<div style="border:none;border-bottom:solid 2px;"></div>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Governs the Novartis Code of Ethics</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Provides an integrated ERM framework (further described in the following section)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Governs the global compliance program within Novartis</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:8pt; font-weight:bold; color:#0070f7; text-transform:uppercase;">SENIOR LEADERS OF DIVISIONS, ORGANIZATIONAL UNITS AND&nbsp;GROUP FUNCTIONS, AT ALL LEVELS<div style="border:none;border-bottom:solid 2px;"></div>
</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Provide appropriate risk management within their area of responsibility</div>
<div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Establish adequate risk prevention and mitigation strategies when risk exposure is identified, including tracking progress and providing resources for possible actions</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Assess emerging risks, trends and overall exposure as part of the ERM process</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Enterprise Risk Management framework</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Ethics, Risk &amp; Compliance (ERC) function provides an integrated ERM framework to obtain a holistic view of Company risks and drive a culture of smart risk-taking. Under the leadership of the Chief Ethics, Risk &amp; Compliance Officer, the Risk &amp; Resilience team is responsible for the overall ERM process. This process covers, but is not limited to covering, risks associated with: </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The research, development, manufacturing, marketing and sales of products</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Finance; taxes; intellectual property; compliance with law and regulations; security; product safety; human resources; and health, safety and environmental protection</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Business objectives and strategies, including mergers and acquisitions</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; External factors such as the social, political and economic environment</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The ERM process continued to evolve in 2020 based on the Company&#x2019;s changing needs. The Risk &amp; Resilience team conducted risk workshops and collaborated with all risk assurance functions to identify key risks across the Company. Each Novartis unit organized a focused risk workshop at the leadership team level. In parallel, risk workshops were held in the top 11 countries (by revenue) and in certain focus markets. Once key risks were identified, mitigation action plans were created to effectively address them. The findings from these workshops were consolidated into the Novartis Risk Compass, which enables senior management, the Executive Committee and the Board to focus discussions on key risks and more closely align our corporate strategy with our risk exposure and ways of working.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2020, we strengthened our ERM framework within the Novartis Risk &amp; Resilience organization by further developing certain components. In addition to the ERM, Business Continuity Management (BCM) and Novartis Emergency Management (NEM) functions, we now have a Risk &amp; Internal Control department to provide a holistic control framework, and a team to support Enterprise Policy Management (EPM).</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">156</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Novartis Business Assurance &amp;&nbsp;Advisory </font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">NBAA brings together the SpeakUp Office, Internal Audit and Global Security. NBAA supports Novartis in achieving its objectives and culture transformation; identifying and managing major risks; and complying with policies, laws and regulations. NBAA conducts fair, timely and thorough investigations, and proactively shares insights, best practices, ongoing findings and root causes with the business to foster continuous learning. </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">SpeakUp Office</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our SpeakUp Office provides a safe place for associates to report potential misconduct. They have the option to do so anonymously. </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Internal Audit</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our Internal Audit function executes the risk-based annual audit plan approved by the ACC at the Group and entity levels, and reports the results to the audited units, the Executive Committee and the ACC (in the form of formal quarterly presentations and audit report executive summaries). Potential material irregularities are escalated to the ACC and to the SpeakUp Office for triage and possible investigation, and action plans are developed together with the audited units. Internal Audit conducts desktop follow-up for high-risk findings prior to the due date for remediation actions. If the audit opinion is &#x201C;needs major improvement,&#x201D; a follow-up audit takes place the next year. Audit findings and action plans are stored and monitored in a single application to enable efficient follow-up.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2020, a larger portion of the audit plan was dedicated to advisories, enabling more proactive risk management and forward-looking collaboration with the business. Additionally, Internal Audit developed a new approach called &#x201C;internal reviews&#x201D; to cover smaller markets, units that have not been audited for more than five years, and follow-up visits on &#x201C;needs improvement&#x201D; audits. The following outlines the number of audits, internal reviews and advisories performed in 2020, and key topics that we repeatedly observed in our work.</div>
<div style="padding-top:15px"><img src="cogo_0062.gif" border="0"></div>
<div style="padding-bottom:16px;">
  <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">
  </div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We performed 81% of planned activities (equating to 62&nbsp;engagements) in 2020, most conducted remotely, despite the obstacles created by COVID-19. These engagements comprised 39 audits, 17 advisories and six internal reviews covering the entire value chain of Novartis and key risks. Internal Audit continues to invest in and refine its remote audit methodology.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">NBAA and ERC continue to work toward integrated assurance by improving collaboration with other Novartis risk and assurance providers. This includes the coordination of internal plans, alignment on messaging and reporting, and increased communication around potential issues and risks. </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">NBAA leadership</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our Global Head of NBAA and Head of Internal Audit reports administratively to the CEO, and functionally to the Chair of the ACC, and meets with the latter and the Chairman of the Board at least quarterly. She has full access to the ACC and the Chairman of the Board, and confirms the organizational independence of the Internal Audit function annually to the ACC.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">157</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId002637775"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Auditors</p><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Du</font><font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">ration of the mandate and&nbsp;terms&nbsp;of&nbsp;office</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On behalf of the Board, the ACC selects and nominates an independent auditor for election at the AGM. PwC assumed its existing auditing mandate for Novartis in 1996. Luc Schulthess, auditor in charge, began serving in his role in 2018, and Kris Muller, global relationship partner, began serving in her role in 2019. The ACC together with PwC ensure that these partners are rotated at least every five years. </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Auditing fees and additional fees</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The ACC monitors and preapproves the fees paid to the external auditor for all audit and non-audit services. It has developed and approved a policy with clear guidelines on the engagement of the independent auditor firm. This policy is designed to help ensure that the independence of the external auditor is maintained. It limits the scope of services that the external auditor may provide to the Group, stipulating certain permissible types of audit-related and non-audit services, including tax services and other services that have been preapproved by the ACC. The ACC preapproves all other services on a case-by-case basis. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The external auditor is required to report periodically to the ACC about the scope of the services it has provided to the Group and the fees for the services it has performed to date. PwC fees for professional services related to the 12-month periods ended December 31, 2020, and December 31, 2019, are as follows: </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020<br> USD million</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019<br> USD million</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Audit services</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20.5</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21.2</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Audit-related services</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tax services</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other services</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23.5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24.3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Audit services include work performed to issue opinions on consolidated financial statements and parent company financial statements of Novartis AG, to issue opinions related to the effectiveness of the Group&#x2019;s internal control over financial reporting, and to issue reports on local statutory financial statements. Also included are audit services that generally can only be provided by the statutory auditor, such as the audit of the Compensation Report, audits of the adoption of new accounting policies, audits of information systems and the related control environment, as well as reviews of quarterly financial results.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Audit-related services include other assurance services provided by the independent auditor but not restricted to those that can only be provided by the statutory auditor. They include services such as audits of pension and other employee benefit plans; audits in connection with non-recurring transactions; contract audits of third-party arrangements; corporate responsibility assurance; and other audit-related services.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Tax services represent tax compliance, assistance with historical tax matters, and other tax-related services.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Other services include procedures related to corporate integrity agreements, benchmarking studies, and license fees for use of accounting and other reporting guidance databases.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Information to the Board and the ACC</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The ACC, acting on behalf of the Board, is responsible for overseeing the activities of PwC. In 2020, this committee held eight meetings. PwC was invited to six of these meetings to attend the discussions on auditing matters and any other matters relevant to its audit.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The ACC recommended to the Board to approve the audited consolidated financial statements and the separate parent company financial statements of Novartis&nbsp;AG for the year ended December 31, 2020. The Board proposed the acceptance of these financial statements for approval by the shareholders at the next AGM.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The ACC regularly evaluates the performance of PwC and, based on this, once a year determines whether PwC should be proposed to the shareholders for re-election. To assess the performance of PwC, the ACC holds private meetings with the CFO and the Global Head of NBAA and Head of Internal Audit and, if necessary, obtains an independent external assessment. Criteria applied for the performance assessment of PwC include an evaluation of its technical and operational competence; its independence and objectivity; the sufficiency of the resources it has employed; its focus on areas of significant risk to Novartis; its willingness to probe and challenge; its ability to provide effective, practical recommendations; and the openness and effectiveness of its communications and coordination with the ACC, the Internal Audit function and management. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Once a year, the auditor in charge and the global relationship partner report to the Board on PwC&#x2019;s activities during the current year and on the audit plan for the coming year. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">On an annual basis, PwC provides the ACC with written disclosures required by the US Public Company Accounting Oversight Board, and the committee and PwC discuss PwC&#x2019;s independence from Novartis. </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">158</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Auditor tender process</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In April 2020, the ACC decided to invite several audit firms, including PwC, to participate in a tender process that would lead to the selection of an external audit firm to be proposed for election at the 2022 AGM.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Key criteria in identifying potential participant firms included their expertise, experience and footprint to audit a company with our global scale and complexity of operations. The ACC determined that PwC, KPMG, Deloitte, and Ernst &amp; Young met these criteria and invited them to participate in the tender process. The audit tender was conducted through a fair, transparent and balanced process according to defined selection criteria under a strong governance structure, ensuring that all audit firms had equal access to management and information. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the first phase of the tender process, the firms had an introductory meeting with the CFO and the Head of Group FRA, were granted access to a data room containing both financial and organizational information, and met with select members of Group management. In the second phase, the firms submitted written proposals and made presentations to select members of Group management, including the CEO, the CFO and the Chief Legal Officer, and met with the Chair of the ACC. In the third phase, the entire ACC evaluated management&#x2019;s assessment of the four firms against the selection criteria and shortlisted two firms to present to the entire ACC, the Chairman, the CEO, the CFO, the Chief Legal Officer and the Head of Group FRA. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Based on the assessment of the two shortlisted firms against the selection criteria, the ACC plans to propose to the shareholders at the 2022 AGM the election of KPMG AG as the external auditor commencing for the 2022 financial year. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For the 2021 financial year, the ACC will propose to the shareholders at the 2021 AGM the re-election of PwC. </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">159</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId002637928"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Information policy</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis is committed to open and transparent communication with shareholders, investors, financial analysts, customers, suppliers and other stakeholders. Novartis disseminates information about material developments in its businesses in a broad and timely manner that complies with the rules of the SIX Swiss Exchange and&nbsp;the NYSE.  </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Communications</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis publishes this Annual Report to provide information on the Group&#x2019;s results and operations. Novartis discloses financial results in accordance with IFRS on a quarterly basis, and issues press releases from time to time regarding business developments.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis publishes press releases related to financial results and material events to the US Securities and Exchange Commission (SEC) via Form 6-K. An archive containing annual reports, US SEC Form 20-F, quarterly results releases, and all related materials &ndash; including presentations and conference call webcasts &ndash; is available at www.novartis.com/investors.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis also publishes a Novartis in Society ESG Report, available at www.novartis.com/nisreport2020, which details progress on ESG topics and demonstrates the company&#x2019;s commitment in global health and corporate responsibility. The Novartis in Society ESG Report has been prepared in accordance with the Global Reporting Initiative (GRI) Standards: Core option, and fulfills the Company&#x2019;s reporting requirement as a signatory of the United Nations Global Compact. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The information on Board and Executive Committee compensation is outlined in the Compensation Report (see &#x201C;&mdash;Item 6.B Compensation&#x201D; in general, and for certain compensation information with respect to our Board that is responsive to Item 6.C.2 of Form 20-F, see &#x201C;&mdash;Item 6.B Compensation&mdash;2020 Board compensation&mdash;Philosophy and benchmarking&#x201D;). Please also refer to articles 29-35 of the Articles of Incorporation (www.novartis.com/investors/company-overview/corporate-governance). There are no change-of-control and &#x201C;golden parachute&#x201D; clauses benefiting Board members, Executive Committee members, or other members of senior management. Employment contracts with Executive Committee members are either for a fixed term not exceeding one year or for an indefinite period with a notice period not exceeding 12&nbsp;months, and do not contain commissions for the acquisition or transfer of enterprises or severance payments. No loans or credits are granted to Board and Executive Committee members.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Information contained in reports and releases issued by Novartis is only correct and accurate at the time of release. Novartis does not update past releases to reflect subsequent events, and advises against relying on them for current information. </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Investor Relations </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Investor Relations manages the Group&#x2019;s interactions with the international financial community. Several events are held each year to provide institutional investors and analysts with various opportunities to learn more about Novartis.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Investor Relations is based at the Group&#x2019;s headquarters in Basel. Part of the team is located in the US to coordinate interaction with US investors. More information is available at www.novartis.com/investors.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Website information</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="top">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">Topic</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Information</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Share capital</div>
      </td>
      <td width="1%"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Articles of Incorporation of Novartis AG <br>  www.novartis.com/investors/company-overview/corporate-governance<br>  Novartis key share data<br>  www.novartis.com/key-share-data</div>
      </td>
      <td width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Shareholder rights</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Articles of Incorporation of Novartis AG <br>  www.novartis.com/investors/company-overview/corporate-governance</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Annual General Meeting of Shareholders</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Annual General Meeting of Shareholders<br>  www.novartis.com/investors/shareholder-information/annual-general-meeting</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Board Regulations</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Board Regulations<br>  www.novartis.com/investors/company-overview/corporate-governance</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis code for senior financial officers</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Code of Ethical Conduct for CEO and Senior Financial Officers<br>  www.novartis.com/investors/company-overview/corporate-governance</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis in Society ESG Report</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis in Society ESG Report<br>  www.novartis.com/nisreport2020</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis financial data</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis financial data<br>  www.novartis.com/investors/financial-data</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Press releases</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Press releases<br>  www.novartis.com/news/news-archive?type=press_release<br>  Free email service<br>  www.novartis.com/news/stay-up-to-date</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Additional information <br> (including Novartis investors event calendar, registered office, <br> contact and email addresses, phone numbers, etc.)</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Investor Relations <br>  www.novartis.com/investors<br>  </div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">160</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>


    <a name="anchorId00537529"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">6.D Employees</p>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The table below sets forth the breakdown of the total year-end number of our full-time equivalent employees by main category of activity and geographic area for the past three years.</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">For the year ended<br>December 31, 2020<br>(full-time equivalents)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Marketing and<br> sales</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Production and<br> supply</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Research and<br>  development</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> NBS<sup style="white-space: nowrap">   1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> General and <br> administration</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USA</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;978</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;954</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;554</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 636</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 820</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&nbsp;942</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;405</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;286</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 504</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 928</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 401</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;524</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&nbsp;066</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18&nbsp;628</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&nbsp;043</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;506</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;852</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 52&nbsp;095</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17&nbsp;240</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;346</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;537</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;991</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;119</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 31&nbsp;233</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 42&nbsp;689</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26&nbsp;214</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20&nbsp;638</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;061</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;192</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 105&nbsp;794</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">For the year ended<br>December 31, 2019<br>(full-time equivalents)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Marketing and<br> sales</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Production and<br> supply</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Research and<br>  development</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> NBS<sup style="white-space: nowrap">   1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> General and <br> administration</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USA</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;360</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;830</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;412</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 614</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 763</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;979</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;396</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 838</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 480</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 864</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 397</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;975</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16&nbsp;395</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19&nbsp;386</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;988</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;352</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;666</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 52&nbsp;787</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;455</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;163</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;296</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;233</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;026</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 30&nbsp;173</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 42&nbsp;606</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&nbsp;217</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&nbsp;176</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&nbsp;063</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;852</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 103&nbsp;914</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">For the year ended<br>December 31, 2018<br>(full-time equivalents)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Marketing and<br> sales</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Production and<br> supply</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Research and<br>  development</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> NBS<sup style="white-space: nowrap">   1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> General and <br> administration</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USA</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;825</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;524</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;700</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;467</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 911</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;427</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;584</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 960</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 508</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 899</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 490</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;441</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19&nbsp;608</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21&nbsp;397</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;049</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;845</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;780</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 58&nbsp;679</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20&nbsp;099</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;636</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;977</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;613</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;289</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 35&nbsp;614</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 51&nbsp;116</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 36&nbsp;517</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 21&nbsp;234</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&nbsp;824</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;470</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 125&nbsp;161</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td bgcolor="#ffffff" height="16px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">      </div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof continuing operations<sup>2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 43&nbsp;954</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 25&nbsp;862</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 19&nbsp;803</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 10&nbsp;824</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 4&nbsp;337</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 104&nbsp;780</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof discontinued operations<sup>2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 7&nbsp;162</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 10&nbsp;655</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 1&nbsp;431</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &#x2013;&#x2005;</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 1&nbsp;133</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 20&nbsp;381</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> NBS relates to full-time equivalent employees from our Novartis Business Services organizational unit.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Continuing operations include the businesses of the Innovative Medicines and Sandoz Divisions and the continuing Corporate activities, and discontinued operations include the Alcon eye care devices business and certain corporate activities attributable to Alcon prior to the spin-off. See &#x201C;Item 18. Financial Statements&#x2014;Note 2. Significant transactions&#x2014;Significant transactions in 2019.&#x201D;</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As of December 31, 2019, the number of our full-time equivalent employees decreased by 21 247 compared to December 31, 2018, mainly due to the April 2019 completion of the Alcon spin-off. For more information on this transaction, please see &#x201C;Item 18. Financial Statements&#x2014;Note 2. Significant transactions in 2019.&#x201D;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A significant number of our associates are represented by unions or works councils. We have not experienced any material work stoppages in recent years, and we consider our employee relations to be good.</div><a name="anchorId00538483"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">6.E Share ownership</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The information set forth under &#x201C;Item 6. Directors, Senior Management and Employees&#x2014;Item 6.B Compensation&#x2014;2020 Executive Committee compensation&#x2014;Additional disclosures for the CEO and other Executive Committee members&#x2014;Shares, ADRs and other equity rights owned by Executive Committee members at December&#xA0;31, 2020&#x201D; and under &#x201C;Item 6. Directors, Senior Management and Employees&#x2014;Item 6.B Compensation&#x2014;2020 Board compensation&#x2014;Additional disclosures&#x2014;Shares, ADRs and share options owned by Board members&#x201D; is incorporated by reference. For more information on our equity-based participation plans, see the information set forth under &#x201C;Item 18. Financial Statements&#x2014;Note&#xA0;26. Equity-based participation plans for associates,&#x201D; which is incorporated by reference.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">161</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00538489"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;7.  Major Shareholders and Related Party Transactions</p><a name="anchorId00538491"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">7.A Major shareholders</p>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis shares are widely held. As of December&#xA0;31, 2020, Novartis had approximately 176&#xA0;000 shareholders listed in the Novartis Share Register, representing approximately 67.9% of issued shares. Based on the Novartis Share Register and excluding treasury shares, approximately 44.1% of the shares registered by name were held in Switzerland, and approximately 24.4% were held in the US. Approximately 14% of the shares registered in our share register were held by individual investors, while approximately 34.5% were held by legal entities (excluding 4.3% of our share capital held as treasury shares by Novartis AG or its fully owned subsidiaries), and 51.5% by nominees, fiduciaries and the ADS depositary.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Based on our share register, we believe that we are not directly or indirectly owned or controlled by another corporation or government, or by any other natural or legal persons. There are no arrangements that may result in a change of control.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The tables below set forth information with respect to our major shareholders according to our share register as of December 31, 2020, excluding 4.3% of our share capital held as treasury shares by Novartis AG or its fully owned subsidiaries. The following registered shareholders (including nominees and the ADS depositary) held more than 2% of the total share capital of Novartis with the right to vote all their Novartis shares based on an exemption granted by the Board of Directors:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   </div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % of respective share capital beneficially owned   as of:</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Ordinary shares<br> beneficially owned as of <br> Dec 31, 2020</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Dec 31, 2020</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> <br> <br> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Dec 31, 2019</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> <br> <br> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Dec 31, 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Shareholders registered for their own account:</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Emasan AG, Basel, Switzerland</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 89&nbsp;135&nbsp;960</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.6</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.5</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.5</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Foundation for Employee Participation, Basel, Switzerland<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &lt;2.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">UBS Fund Management (Switzerland) AG, Basel, Switzerland</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 56&nbsp;764&nbsp;402</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credit Suisse Funds AG, Zurich, Switzerland</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50&nbsp;187&nbsp;090</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &lt;2.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &lt;2.0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> The Novartis Foundation for Employee Participation (the "Employee Foundation") is a special purpose entity that was founded by, but is independent from, Novartis.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % of respective share capital held as of:</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Ordinary shares<br> held as of <br> Dec 31, 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Dec 31, 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Dec 31, 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Dec 31, 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Shareholders registered as nominees:</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="1%"></td>
      <td align="right" width="1%"></td>
      <td align="right" width="1%"></td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chase Nominees Ltd., London, England</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 237&nbsp;417&nbsp;808</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9.6</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10.4</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9.8</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">The Bank of New York Mellon, New York, NY</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 83&nbsp;805&nbsp;997</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.4</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.8</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.1</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Through The Bank of New York Mellon, Everett, MA</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 41&nbsp;574&nbsp;113</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 1.7</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 2.0</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 2.1</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Through The Bank of New York Mellon, New York, NY</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 28&nbsp;683&nbsp;674</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 1.2</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 1.2</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 1.3</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Through The Bank of New York Mellon, SA/NV, Brussels, Belgium</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 13&nbsp;548&nbsp;210</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 0.5</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 0.6</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 0.7</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nortrust Nominees Ltd., London, England</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 104&nbsp;327&nbsp;562</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.2</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.9</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.6</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Shareholder acting as American Depositary Share (ADS) depositary:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">JPMorgan Chase Bank, N.A., New York, NY</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 288&nbsp;785&nbsp;853</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12.5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13.3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to a disclosure notification filed with Novartis AG, Norges Bank (Central Bank of Norway), Oslo, Norway, held 2.3% of the share capital of Novartis AG, or 56&#xA0;513&#xA0;527 shares, as of December&#xA0;31, 2020, but was not registered in our share register as of December&#xA0;31, 2020. Provided that these shares are registered in the share register on the record date of the Annual General Meeting, Norges Bank will have full voting rights for all of these shares. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">According to a disclosure notification filed with Novartis AG and the SIX Swiss Exchange, BlackRock,&#xA0;Inc., New&#xA0;York, NY, held between 3% and 5%, but was registered with less than 2% of the share capital of Novartis AG in our share register as of December&#xA0;31, 2020.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">According to disclosure notifications filed with Novartis AG and the SIX Swiss Exchange, The Capital Group Companies, Inc., Los Angeles, California, held </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">162</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">between 3% and 5%, but was not registered in our share register as of December 31, 2019, and December 31, 2018.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of December&#xA0;31, 2020, no other shareholder was registered as owner of more than 2% of the registered share capital.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Articles of Incorporation provide that no shareholder shall be registered with the right to vote shares comprising more than 2% of the registered share capital. The Board of Directors may, upon request, grant an exemption from this restriction. Considerations include whether the shareholder supports the Novartis goal of creating sustainable value and has a long-term investment horizon. In 2020, the Board approved an exemption requested by Credit Suisse Funds AG, Zurich, based on the fulfilment of the requirements described above. Exemptions are in force for the registered major shareholders as described above. Novartis has not entered into any agreement with any shareholder regarding the voting or holding of Novartis shares.</div><a name="anchorId00538965"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">7.B Related party transactions</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The information set forth under &#x201C;Item 18. Financial Statements&#x2014;Note&#xA0;27. Transactions with related parties&#x201D; is incorporated by reference. </div><a name="anchorId00538969"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">7.C Interests of experts and counsel</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">163</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00538975"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&nbsp;8.  Financial Information</p><a name="anchorId00538978"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">8.A Consolidated statements and other financial information</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">See &#x201C;Item&nbsp;18. Financial Statements.&#x201D;</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Dividend policy</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Subject to the dividend policy described below, our Board of Directors expects to recommend the payment of a dividend in respect of each financial year. If approved by our shareholders at the relevant annual shareholders&#x2019; meeting, the dividends will be payable shortly following such approval. Any shareholder who purchases our shares before the ex-dividend date and holds the shares until that date shall be deemed to be entitled to receive the dividends approved at that meeting. Dividends are reflected in our financial statements in the year in which they are approved by our shareholders.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our dividend policy is to pay a growing annual dividend in Swiss francs. This policy is subject to our financial conditions and outlook at the time, the results of our operations, and other factors.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Board will propose a dividend of CHF 3.00 per share to the shareholders for approval at the Annual General Meeting to be held on March 2, 2021. Because we pay dividends in Swiss francs, exchange rate fluctuations will affect the US dollar amounts received by holders of ADRs. For a summary of dividends we paid in the past five years, see &#x201C;Item&nbsp;3. Key Information&mdash;Item&nbsp;3.A Selected financial data&mdash;Cash dividends per share.&#x201D; </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Disclosure pursuant to Section&nbsp;219 of the Iran Threat Reduction&nbsp;&amp; Syria Human Rights Act (ITRA)</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At Novartis, our purpose is to reimagine medicine to improve and extend people&#x2019;s lives, regardless of where they live. This includes the compliant sale of medicines and other healthcare products worldwide. To help us fulfill this mission, we have for many years maintained two representative offices located in Iran.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of October&nbsp;18, 2010, a non-US affiliate within our Innovative Medicines Division entered into a non-binding Memorandum of Understanding (MoU) with the Ministry of Health and Medical Education of the Islamic Republic of Iran. Pursuant to the MoU, the Iranian Ministry of Health acknowledges certain benefits that may apply to sales of certain Innovative Medicines Division medicines by third-party distributors in Iran. These include fast-track registration, market exclusivity, end-user subsidies, and exemptions from customs tariffs. Novartis receives no payments from the Iranian Ministry of Health under the MoU, and the MoU creates no obligations on the part of either Novartis or the Iranian Ministry of Health.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">From time to time, including in 2020, non-US affiliates in our Innovative Medicines and Sandoz Divisions made payments to government entities in Iran related to patents, trademarks, exit fees and other transactions ordinarily incident to travel by doctors and other medical professionals resident in Iran to attend conferences or other events outside Iran. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">From time to time, including in 2020, non-US affiliates in our Innovative Medicines and Sandoz Divisions enter into agreements with hospitals, research institutes, medical associations and universities in Iran to provide grants and sponsor congresses, seminars and symposia, and with doctors and other healthcare professionals for consulting services, including participation in advisory boards and investigator services for observational (non-interventional) studies. Some hospitals and research institutes are owned or controlled by the government of Iran, and some doctors and healthcare professionals are employed by hospitals that may be public or government-owned.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Because our Innovative Medicines and Sandoz Divisions have operations in Iran, including employees, they obtain services and have other dealings incidental to their activities in that country, including paying taxes and salaries either directly or indirectly through a service provider, and obtaining office rentals, insurance, electricity, water and telecommunications services, office and similar supplies, and customs-related services from Iranian companies that may be owned or controlled by the government of Iran. In addition, from time to time, representatives of our non-US affiliates participate in meetings with Iranian officials to discuss issues relevant to our business and the pharmaceutical industry.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Non-US affiliates in our Innovative Medicines and Sandoz Divisions maintain local accounts at banks that are, as of November 5, 2018, on the Specially Designated Nationals and Blocked Persons List (SDN List). These non-US affiliates make local transactions for employee payroll and local vendor payment purposes. These transactions are conducted for the purpose of facilitating the provision of medicine to Iran, in line with the humanitarian exceptions contained in Section 11 of Executive Order 13902 and other applicable sanctions by legal authorities. No transactions are made with an Iranian financial institution designated on the SDN List in connection with Iran&#x2019;s support for international terrorism or proliferation of weapons of mass destruction. </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">164</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">  </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"></div><a name="anchorId00539022"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">8.B Significant changes</p>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">None.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">165</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div><a name="anchorId00539029"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&nbsp;9.  The Offer and Listing</p><a name="anchorId00539032"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">9.A Offer and listing details</p>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our shares are listed in Switzerland on the SIX Swiss Exchange (SIX).</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">ADSs, each representing one share, have been available in the US through an ADR program since December 1996. This program was established pursuant to a deposit agreement that we entered into with JPMorgan Chase Bank, N.A., as depositary (&#x201C;Deposit Agreement&#x201D;). Our ADRs have been listed on the NYSE since May 2000 and are traded under the symbol NVS.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The depositary has informed us that as of January&nbsp;20, 2021, there were 289 million ADRs outstanding, each representing one Novartis share (approximately 12% of total Novartis shares issued). On January&nbsp;20, 2021, the closing price per share on the SIX was CHF 86.01 and USD 96.92 per ADR on the NYSE.</div><a name="anchorId00539044"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">9.B Plan of distribution</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div><a name="anchorId00539048"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">9.C Markets</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">See &#x201C;&mdash;Item&nbsp;9.A Offer and listing details.&#x201D;</div><a name="anchorId00539054"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">9.D Selling shareholders</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div><a name="anchorId00539058"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">9.E Dilution</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div><a name="anchorId00539062"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">9.F Expenses of the issue</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">166</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00539068"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&nbsp;10.  Additional Information</p><a name="anchorId00539071"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.A Share capital</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div><a name="anchorId00539075"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.B Memorandum and articles of association</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following is a non-exhaustive summary of certain provisions of our Articles of Incorporation (&#x201C;Articles&#x201D;), our Regulations of the Board, the Board Committees and the Executive Committee (&#x201C;Board Regulations&#x201D;) and of Swiss law, particularly the Swiss Code of Obligations (&#x201C;Swiss CO&#x201D;), and is qualified in its entirety by reference to the Articles and the Board Regulations, which are an exhibit to this Form&nbsp;20-F, and to Swiss law.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.1 Company purpose</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis AG is registered in the commercial register of the canton of Basel-Stadt, Switzerland, under number CHE-103.867.266. Our business purpose, as stated in Article&nbsp;2 of the Articles, is to hold interests in enterprises in the area of healthcare or nutrition. We may also hold interests in enterprises in the areas of biology, chemistry, physics, information technology or related areas. We may acquire, mortgage, liquidate or sell real estate and intellectual property rights in Switzerland or abroad. In pursuing our business purpose, we strive to create sustainable value.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.2 Directors</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to our Articles, the Board of Directors (&#x201C;Board&#x201D;) consists of a minimum of eight and a maximum of 16 members. The members of the Board (including the Chairman) are elected individually by the General Meeting of Shareholders (&#x201C;General Meeting&#x201D;) for a one year term of office lasting until completion of the next Annual General Meeting of Shareholders (&#x201C;AGM&#x201D;).</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(a)  A board resolution requires the affirmative majority of the votes cast. According to our Board Regulations, a member of our Board (&#x201C;Director&#x201D;) may not participate in decisions and resolutions on matters that affect, or reasonably might affect, the Director&#x2019;s interests or the interests of a person close to the Director. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(b) Compensation of the Directors is subject to the approval of the aggregate amounts of such compensation by a shareholders&#x2019; resolution under the Ordinance against Excessive Compensation in Public Companies of the Swiss Federal Council.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(c) The Articles prohibit the granting of loans or credits to Directors.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(d) Directors who have turned 70 years of age at the date of the General Meeting may no longer be elected as members of the Board. The General Meeting may, under special circumstances, grant exceptions to this rule. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(e) Our Directors are not required to be shareholders at the time of the election by the General Meeting. However, according to our share ownership guidelines, the Chairman is required to own a minimum of 30 000 Novartis AG shares, and other Directors are required to own at least 5 000 Novartis AG shares within five years after joining the Board, to ensure their interests are aligned with those of our shareholders.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.3 Shareholder rights</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Because Novartis AG has only one class of registered shares, the following information applies to all shareholders.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(a) Under the Swiss CO, we may only pay dividends out of balance sheet profits or out of distributable reserves. In any event, under the Swiss CO, while the Board may propose that a dividend be paid, we may only pay dividends upon shareholders&#x2019; approval at a General Meeting. Furthermore, the Swiss CO requires us to accrue general legal reserves under certain circumstances so long as these reserves amount to less than 20% of our registered share capital, and Swiss law and the Articles permit us to accrue additional reserves beyond the statutory reserves. Our auditors must confirm that the dividend proposal of our Board conforms with the Swiss CO and the Articles. Our Board expects to recommend the payment of a dividend in respect of each financial year. See &#x201C;Item&nbsp;3.&nbsp;Key Information&mdash;Item&nbsp;3.A. Selected financial data&mdash;Cash dividends per share&#x201D; and &#x201C;Item&nbsp;8.&nbsp;Financial Information&mdash;Item&nbsp;8.A. Consolidated statements and other financial information&mdash;Dividend policy.&#x201D;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">Dividends are usually due and payable shortly after the shareholders have passed a resolution approving the payment. Dividends that have not been claimed within five years after the due date revert to us and are allocated to our general reserves. For information about deduction of the withholding tax or other duties from dividend payments, see &#x201C;&mdash;Item&nbsp;10.E Taxation.&#x201D;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(b) Each share is entitled to one vote at a General Meeting. Voting rights may only be exercised for shares registered with the right to vote on the record date </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">167</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;">for the applicable General Meeting. In order to do so, the shareholder must file&nbsp;a share registration form with us, setting forth the shareholder&#x2019;s name, address and citizenship (or, in the case of a legal entity, its registered office). If the shareholder has not timely registered its shares, then the shareholder may not vote at, or participate in, a General Meeting.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">To vote its shares, the shareholder must also explicitly declare that it has acquired the shares in its own name and for its own account. If the shareholder refuses to make such a declaration, the shares may not be voted unless the Board recognizes such shareholder as a nominee.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">The Articles provide that no shareholder shall be registered with the right to vote shares comprising more than 2% of the registered share capital. The Board may, upon request, grant an exemption from this restriction. Considerations include whether the shareholder supports our goal of creating sustainable value and has a long-term investment horizon. Furthermore, the Articles provide that no nominee shall be registered with the right to vote shares comprising more than 0.5% of the registered share capital. The Board may, upon request, grant an exemption from this restriction if the nominee discloses the names, addresses and number of shares of the persons for whose account it holds 0.5% or more of the registered share capital. The same restrictions indirectly apply to ADR holders. We have in the past granted exemptions from the 2% rule for shareholders and the 0.5% rule for nominees.  </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">For purposes of the 2% rule for shareholders and the 0.5% rule for nominees, groups of companies and groups of shareholders acting in concert are considered to be one shareholder. These rules also apply to shares acquired or subscribed by the exercise of subscription, option or conversion rights.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">After hearing the registered shareholder or nominee, the Board may cancel, with retroactive effect as of the date of registration, the registration of the shareholders if the registration was effected based on false information.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">Registration restrictions in the Articles may only be removed upon a resolution carrying a two-thirds majority of the votes represented at a General Meeting.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">Except as noted below, shareholders&#x2019; resolutions require the approval of an absolute majority of the votes present at a General Meeting. As a result, abstentions have the effect of votes against such resolutions. Some examples of shareholders&#x2019; resolutions requiring a vote by such &#x201C;absolute majority of the votes&#x201D; are: </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022; Adoption and amendment of the Articles </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022; Election and removal of the Chairman, the Board and Compensation Committee members, the Independent Proxy and the external auditor</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022; Approval of the management report and of the consolidated financial statements</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022; Approval of the financial statements of Novartis AG, and decision on the appropriation of available earnings shown on the balance sheet, including dividends, if any</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022; Approval of the maximum aggregate compensation of the Board (from an AGM until the next AGM) and of the Executive Committee (for the financial year following the AGM)</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022; Discharge of Board and Executive Committee members from liability for matters disclosed to the General Meeting</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022; Decision on other matters that are reserved by law or by the Articles (e.g., advisory vote on the Compensation Report) to the General Meeting</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">According to the Articles and Swiss law, the following matters require the approval of a &#x201C;supermajority&#x201D; of at least two-thirds of the votes present at a General Meeting: </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022; Alteration of the purpose of Novartis AG</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022; Creation of shares with increased voting powers</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022; Implementation of restrictions on the transfer of registered shares, and the removal of such restrictions</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022; Authorized or conditional increase of the share capital</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022; Increase of the share capital out of equity, by contribution in kind, for the purpose of an acquisition of property or the grant of special rights</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022; Restriction or cancellation of subscription rights</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Change of the registered office of Novartis&nbsp;AG</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022; Dissolution of Novartis AG</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">In addition, the law provides for a qualified majority for other resolutions, such as a merger or demerger.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">Our shareholders are required to annually elect all Directors (including the Chairman), the Compensation Committee members, the external auditor and the Independent Proxy. The Articles do not provide for cumulative voting of shares.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">At a General Meeting, shareholders can be represented by a proxy, which must either be the shareholder&#x2019;s legal representative, another shareholder with the right to vote, or the Independent Proxy. Votes are taken either by a show of hands or by electronic voting, unless the General Meeting resolves to have a ballot or where a ballot is ordered by the chair of the meeting. However, in accordance with Swiss legislation passed in response to the COVID-19 pandemic, the Board has decided that voting rights at our 2021 AGM can only be exercised through the Independent Proxy. It will not be possible to physically attend our 2021 AGM. </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">168</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">ADSs, each representing one Novartis AG share and evidenced by ADRs, are issued by our depositary JPMorgan Chase Bank, N.A., New York, and not by us. The ADR is vested with rights defined and enumerated in the Deposit Agreement (such as the rights to vote, to receive a dividend and to receive a share of Novartis AG in exchange for a certain number of ADRs). The enumeration of rights, including any limitations on those rights in the Deposit Agreement, is final. There are no other rights given to the ADR holders. Only the ADS depositary, holding our shares underlying the ADRs, is registered as shareholder in our share register. An ADR is not a Novartis AG share and an ADR holder is not a Novartis AG shareholder.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">The Deposit Agreement between our depositary, the ADR holder and us has granted certain indirect rights to vote to the ADR holders. ADR holders may not attend a General Meeting in person. ADR holders exercise their voting rights by instructing JPMorgan Chase Bank, N.A., our depositary, to exercise the voting rights attached to the registered shares underlying the ADRs. Each ADR represents one Novartis AG share. JPMorgan Chase Bank, N.A., exercises the voting rights for registered shares underlying ADRs for which no voting instructions have been given by providing a discretionary proxy to an uninstructed independent designee. Such designee has to be a shareholder of Novartis AG. The same voting restrictions apply to ADR holders as to those holding Novartis AG shares (i.e., the right to vote up to 2% of the Novartis AG registered share capital &ndash; unless otherwise granted an exemption by the Board &ndash; and the disclosure requirement for nominees).</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(c) Shareholders have the right to allocate the profit shown on our balance sheet and to distribute dividends by vote taken at the General Meeting, subject to the legal requirements described in &#x201C;Item&nbsp;10.B.3(a) Shareholder rights.&#x201D;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(d) Under the Swiss CO, any surplus arising out of a liquidation of Novartis AG (i.e., after the settlement of all claims of all creditors) would be distributed to the shareholders in proportion to the paid-in nominal value of their shares.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(e) The Swiss CO limits a corporation&#x2019;s ability to hold or repurchase its own shares. We and our subsidiaries may only repurchase shares if we have sufficient freely disposable equity in the amount of the purchase price of the acquired shares. The aggregate nominal value of all Novartis AG shares held by us and our subsidiaries may not exceed 10% of our registered share capital. However, it is accepted that a Swiss corporation may repurchase its own shares beyond the statutory limit of 10% if the repurchased shares are clearly earmarked for cancellation. In addition, we are required to recognize a negative position, or if our subsidiaries acquire our shares, to create a special reserve on our balance sheet in the amount of the purchase price of the acquired shares. Repurchased shares held by us or our subsidiaries do not carry any rights to vote at a General Meeting, but are entitled to the economic benefits generally connected with the shares. The definition of subsidiaries, and therefore, treasury shares, for purposes of the above described reserves requirement and voting restrictions differs from the definition of subsidiaries for purposes of consolidation in our consolidated financial statements. The definition in the consolidated financial statements requires consolidation for financial reporting purposes of special purpose entities in instances where we have the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities. Therefore, our consolidated financial statements include special purpose entities, mainly foundations, which do not qualify as subsidiaries subject to the reserve requirements and voting restrictions of the Swiss CO because we do not hold a majority participation in these special purpose entities. Accordingly, no reserve requirements apply to shares held by such special purpose entities, and such entities are not restricted from independently voting their shares.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">Under the Swiss CO, we may not cancel treasury shares without the approval of a capital reduction by our shareholders.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(f) Not applicable.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(g) Since all of our issued and outstanding shares have been fully paid in, our shareholders are not obliged to make further contributions with respect to their shares. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(h)  See &#x201C;&mdash;Item&nbsp;10.B.3(b) Shareholder rights&#x201D; and &#x201C;&mdash;Item&nbsp;10.B.7 Change in control.&#x201D;</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.4 Changes to shareholder rights</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Under the Swiss CO, we may not issue new shares without the prior approval of a capital increase by our shareholders. If a capital increase is approved, then our shareholders would generally have certain pre-emptive rights to obtain newly issued shares in an amount proportional to the nominal value of the shares they already hold. These pre-emptive rights could be excluded in certain limited circumstances with the approval of a resolution adopted at a General Meeting by a supermajority of two-thirds of the votes. In addition, we may not create shares with increased voting powers or place restrictions on the transfer of registered shares without the approval of a resolution adopted at a General Meeting by a supermajority of votes. In addition, see &#x201C;&mdash;Item&nbsp;10.B.3(b) Shareholder rights&#x201D; with regard to the Board&#x2019;s ability to cancel the registration of shares under limited circumstances.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.5 Shareholder meetings</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Under the Swiss CO and the Articles, we must hold an AGM within six months after the end of our financial year. A General Meeting may be convened by the Board or, if necessary, by the external auditor. The Board is further required to convene an extraordinary General Meeting if so resolved by a General Meeting, or if so requested by shareholders representing at least 10% of the share capital, specifying the items for the agenda and their proposals. Shareholders representing shares with an aggregate nominal value of at least CHF&nbsp;1&nbsp;000&nbsp;000 may request that an item be included in a General Meeting agenda. A General Meeting is convened by publishing a notice in the Swiss Official Gazette of Commerce </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">169</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">(<i>Schweizerisches</i><i> Handelsamtsblatt</i>) at least 20&nbsp;days prior to such meeting. Shareholders may also be informed by mail. Neither the Swiss CO nor the Articles require a quorum for a General Meeting. In addition, see &#x201C;&mdash;Item&nbsp;10.B.3(b) Shareholder rights&#x201D; regarding conditions for exercising a shareholder&#x2019;s right to vote at a General Meeting.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.6 Limitations</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There are no limitations under the Swiss CO or our Articles on the right of non-Swiss residents or nationals to own or vote shares other than the restrictions applicable to all shareholders. But see &#x201C;&mdash;Item&nbsp;10.B.3(b) Shareholder rights&#x201D; regarding conditions for exercising an ADR holder&#x2019;s right to vote at a shareholder meeting.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.7 Change in control</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Articles and the Board Regulations contain no provision that would have an effect of delaying, deferring or preventing a change in control of Novartis AG and that would operate only with respect to a merger, acquisition or corporate restructuring involving us or any of our subsidiaries.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">According to the Swiss Merger Act, shareholders may pass a resolution to merge with another corporation at any time. Such a resolution would require the consent of at least two-thirds of all votes present at the necessary General Meeting.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Under the Swiss Financial Market Infrastructure Act, shareholders and groups of shareholders acting in concert who acquire more than 33 1/3% of our shares would be under an obligation to make an offer to acquire all remaining Novartis AG shares. Novartis AG has neither opted out from the mandatory takeover offer obligation nor opted to increase the threshold for mandatory takeover offers in its Articles.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.8 Disclosure of shareholdings</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Under the Swiss Financial Market Infrastructure Act, persons who directly, indirectly or in concert with other parties acquire or dispose of our shares or purchase or sale rights relating to our shares are required to notify us and the SIX of the level of their holdings whenever such holdings reach, exceed or fall below certain thresholds &ndash; 3%, 5%, 10%, 15%, 20%, 25%, 33 1/3%, 50% and 66 2/3% &ndash; of the voting rights represented by our share capital (whether exercisable or not). This also applies to anyone who has discretionary power to exercise voting rights associated with our shares. Following receipt of such notification, we are required to inform the public by publishing the information via the electronic publication platform operated by the SIX.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">An additional disclosure obligation exists under the Swiss CO that requires us to disclose, once a year in the notes to the financial statements published in our Annual Report, the identity of all of our shareholders (or related groups of shareholders) who have been granted exemption entitling them to vote more than 2% of our registered share capital, as described in &#x201C;&mdash;Item&nbsp;10.B.3(b) Shareholder rights.&#x201D;</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.9 Differences in the law</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">See the references to Swiss law throughout this &#x201C;&mdash;Item&nbsp;10.B Memorandum and articles of association.&#x201D;</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.10 Changes in capital</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The requirements of the Articles regarding changes in capital are not more stringent than the requirements of Swiss law.</div><a name="anchorId00539340"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.C Material contracts</p><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Alcon spin-off</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In connection with the spin-off of our Alcon business, we entered into a Separation and Distribution Agreement, a Tax Matters Agreement and several other agreements with Alcon to effect the separation of the Alcon business and provide a framework for our relationship with Alcon after the spin-off. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Separation and Distribution Agreement sets forth the parties&#x2019; agreements regarding the principal actions to be taken in connection with the separation of the Alcon business and the spin-off, including the conditions of the spin-off and the rights and obligations of the parties with respect to the distribution. The Separation and Distribution Agreement identifies the assets to be transferred, liabilities to be assumed and contracts to be assigned to each of Novartis and Alcon as part of the internal transactions effected prior to the distribution, and provides for when and how such transfers, assumptions and assignments should occur. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Tax Matters Agreement imposes certain restrictions and indemnity obligations on Alcon designed to preserve the tax-neutral nature of the spin-off for Swiss tax and US federal income tax purposes. The Tax Matters Agreement also provides that Alcon will generally indemnify Novartis for any taxes of Novartis and its subsidiaries to the extent such taxes are attributable to the Alcon business, and Novartis will generally indemnify Alcon for any of Alcon&#x2019;s or its subsidiaries&#x2019; taxes to the extent such taxes are attributable to the Novartis retained businesses. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In connection with the spin-off, we also entered into an employee matters agreement, a transition services agreement, forward and reverse manufacturing supply agreements, and certain intellectual property agreements, each of which is not material to Novartis.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">170</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Acquisition of The Medicines Company</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 23, 2019, we entered into an Agreement and Plan of Merger (the &#x201C;Merger Agreement&#x201D;) with US-based pharmaceutical company The Medicines Company. Pursuant to the Merger Agreement, on December 5, 2019, Novartis, through a subsidiary, commenced a tender offer to acquire all outstanding shares of The Medicines Company for USD 85 per share, or a total consideration of approximately USD 9.6 billion in cash on a fully diluted basis. The tender offer expired on January 3, 2020, and on January 6, 2020, the acquiring subsidiary merged with and into The Medicines Company, resulting in The Medicines Company becoming an indirect wholly owned subsidiary of Novartis. This merger broadens our cardiovascular portfolio by adding inclisiran, an investigational cholesterol-lowering therapy.</div><a name="anchorId00539358"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.D Exchange controls</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There are no Swiss governmental laws, decrees or regulations that affect &ndash; in a manner material to Novartis AG &ndash; the export or import of capital, including the availability of cash and cash equivalents for use by Novartis or any foreign exchange controls that affect the remittance of dividends, interest or other payments to non-residents or non-citizens of Switzerland who hold Novartis AG securities. </div><a name="anchorId00539364"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.E Taxation</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The taxation discussion set forth below is intended only as a descriptive summary and does not purport to be a complete analysis or listing of all potential tax effects relevant to the ownership or disposition of our shares or ADRs. The statements of US and Swiss tax laws set forth below are based on the laws and regulations in force as of the date of this 20-F &#x2013; including the current Convention Between the US and the Swiss Confederation for the Avoidance of Double Taxation with Respect to Taxes on Income, entered into force on December&#xA0;19, 1997 (&#x201C;the Treaty&#x201D;); the US Internal Revenue Code of 1986, as amended (&#x201C;the Code&#x201D;); Treasury regulations; rulings; judicial decisions; and administrative pronouncements &#x2013; and may be subject to any changes in US and Swiss law, and in any double taxation convention or treaty between the US and Switzerland occurring after that date, which changes may have retroactive effect.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Swiss taxation</font>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Swiss residents</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "><i>Withholding Tax on dividends and distributions.</i>  Dividends that we pay and similar cash or in-kind distributions that we may make to a holder of shares or ADRs (including distributions of liquidation proceeds in excess of the nominal value, stock dividends and, under certain circumstances, proceeds from repurchases of shares by us in excess of the nominal value) are generally subject to a Swiss federal withholding tax (&#x201C;the Withholding Tax&#x201D;) at a current rate of 35%. Under certain circumstances, distributions out of capital contribution reserves made by shareholders after December&#xA0;31, 1996, are exempt from the Withholding Tax. We are required to withhold Withholding Tax due from the gross distribution and to pay the Withholding Tax to the Swiss Federal Tax Administration. The Withholding Tax is refundable in full to Swiss tax residents who are the beneficial owners of the taxable distribution at the time it is resolved and duly report the gross distribution received on their personal tax return or in their financial statements for tax purposes, as the case may be.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"><i>Income tax on dividends.</i>  A Swiss tax resident who receives dividends and similar distributions (including stock dividends and liquidation surplus) on shares or ADRs is required to include such amounts in the shareholder&#x2019;s personal income tax return. However, distributions out of qualified capital contribution reserves are not subject to income tax. A corporate shareholder may claim substantial relief from taxation of dividends and similar distributions received if the shares held represent a fair market value of at least CHF&#xA0;1&#xA0;million.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"><i>Capital gains tax upon disposal of shares.</i>  Under current Swiss tax law, the gain realized on shares held by a Swiss resident who holds shares or ADRs as part of his private property is generally not subject to any federal, cantonal or municipal income taxation on gains realized on the sale or other disposal of shares or ADRs. However, gains realized upon a repurchase of shares by us may be characterized as taxable dividend income if certain conditions are met. Book gains realized on shares or ADRs held by a Swiss corporate entity or by a Swiss resident individual as part of the shareholder&#x2019;s business property are, in general, included in the taxable income of such person. However, the Federal Law on the Direct Federal Tax of December&#xA0;14, 1990, and several cantonal laws on direct cantonal taxes provide for exceptions for Swiss corporate entities holding more than 10% of our voting stock for more than one year.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Residents of other countries</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Recipients of dividends and similar distributions on our shares who are neither residents of Switzerland for tax purposes nor holding shares as part of a business conducted through a permanent establishment situated in Switzerland (&#x201C;Non-Resident Holders&#x201D;) are not subject to </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">171</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Swiss income taxes in respect of such distributions. Moreover, gains realized by such recipients upon the disposal of shares are not subject to Swiss income taxes.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Non-Resident Holders of shares are, however, subject to the Withholding Tax on dividends and similar distributions mentioned above and, under certain circumstances, to the Stamp Duty described below. Such Non-Resident Holders may be entitled to a partial refund of the Withholding Tax if the country in which they reside has entered into a bilateral treaty for the avoidance of double taxation with Switzerland. Non-Resident Holders should be aware that the procedures for claiming treaty refunds (and the time frame required for obtaining a refund) may differ from country to country. Non-Resident Holders should consult their own tax advisors regarding receipt, ownership, purchase, sale or other dispositions of shares or ADRs, and the procedures for claiming a refund of the Withholding Tax.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of January&#xA0;1, 2021, Switzerland has entered into bilateral treaties for the avoidance of double taxation with respect to income taxes with the following countries, whereby a part of the above-mentioned Withholding  Tax may be refunded (subject to the limitations set forth in such treaties):</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Albania</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Algeria</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Argentina</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Armenia</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Australia</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Austria</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Azerbaijan</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Bahrain</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Bangladesh</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Belarus</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Belgium</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Bulgaria</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Canada</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Chile</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">China</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Colombia</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Croatia</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cyprus</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Czech Republic</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Denmark</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Ecuador</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Egypt</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Estonia</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Finland</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">France</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Georgia</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Germany</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Ghana</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Greece</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Hong Kong</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Hungary</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Iceland</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">India</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Indonesia</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Iran</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Republic of Ireland</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Israel</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Italy</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Ivory Coast</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Jamaica</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Japan</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Kazakhstan</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Republic of Korea</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">(South Korea)</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Kosovo</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Kuwait</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Kyrgyzstan</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Latvia</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Liechtenstein</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Lithuania</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Luxembourg</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Macedonia</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Malaysia</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Malta</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Mexico</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Moldova</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Mongolia</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Montenegro</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Morocco</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Netherlands</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">New Zealand</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Norway</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Oman</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Pakistan</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Peru</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Philippines</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Poland</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Portugal</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Qatar</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Romania</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Russia</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Serbia</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Singapore</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Slovak Republic</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Slovenia</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">South Africa</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Spain</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sri Lanka</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sweden</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Taiwan</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Tajikistan</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Thailand</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Trinidad and Tobago</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Tunisia</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Turkey</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Turkmenistan</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Ukraine</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">United Arab Emirates</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">United Kingdom</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">United States of America</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Uruguay</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Uzbekistan</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Venezuela</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Vietnam </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Zambia</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The tax treaty with Bahrain is not applicable to the healthcare industry. Tax treaty negotiations are underway, or have been conducted, with Bahrain, Bosnia and Herzegovina, Brazil, Costa Rica, Ethiopia, Libya, North Korea, Saudi Arabia, Senegal, Syria and Zimbabwe. Tax treaty negotiations between Switzerland and some of the countries listed in the immediately preceding sentence have been ongoing for an extended period of time, and we are not certain when or if such negotiations will be completed, and when or if the corresponding treaties will come into effect.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">A Non-Resident Holder of shares or ADRs will not be liable for any Swiss taxes other than the Withholding Tax described above and, if the transfer occurs through or with a Swiss bank or other Swiss securities dealer, the Stamp Duty described below. If, however, the shares or ADRs of Non-Resident Holders can be attributed to a permanent establishment or a fixed place of business maintained by such person within Switzerland during the relevant tax year, the shares or ADRs may be subject to Swiss income taxes in respect of income and gains realized on the shares or ADRs, and such person may qualify for a full refund of the Withholding Tax based on Swiss tax law.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"><i>Residents of the US.</i>  A Non-Resident Holder who is a resident of the US for purposes of the Treaty is eligible for a reduced rate of tax on dividends equal to 15% of the dividend, provided that such holder (i)&#xA0;qualifies for benefits under the Treaty, (ii)&#xA0;is not a company (or, if it is a company, such company directly holds less than 10% of our voting stock), and (iii)&#xA0;does not conduct business through a permanent establishment or fixed base in Switzerland to which the shares or ADRs are attributable. Such an eligible holder must apply for a refund of the amount of the Withholding Tax in excess of the 15% Treaty rate. A Non-Resident Holder who is a resident of the US for purposes of the Treaty is eligible for a reduced rate of tax on dividends equal to 5% of the dividend, provided that such holder (i)&#xA0;is a company, (ii)&#xA0;qualifies for benefits under the Treaty, (iii)&#xA0;holds directly at least 10% of our voting stock, and (iv)&#xA0;does not conduct business through a permanent establishment or fixed place of business in Switzerland to which the shares or ADRs are attributable. Such an eligible holder must apply for a </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">172</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">refund of the amount of the Withholding Tax in excess of the 5% Treaty rate. Claims for refunds must be filed on Swiss Tax Form&#xA0;82 (82C for corporations; 82I for individuals; 82E for other entities), which may be obtained from any Swiss Consulate General in the US or from the Federal Tax Administration of Switzerland at the address below, together with an instruction form. Four copies of the form must be duly completed, signed before a notary public of the US, and sent to the Federal Tax Administration of Switzerland, Eigerstrasse 65, CH-3003 Bern, Switzerland. The form must be accompanied by suitable evidence of deduction of Swiss tax withheld at source, such as certificates of deduction, signed bank vouchers or credit slips. The form may be filed on or after July&#xA0;1 or January&#xA0;1 following the date the dividend was payable, but no later than December&#xA0;31 of the third year following the calendar year in which the dividend became payable. For US resident holders of ADRs, JPMorgan Chase Bank, N.A., as depositary, will comply with these Swiss procedures on behalf of the holders, and will remit the net amount to the holders.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"><i>Stamp Duty upon transfer of securities.</i>  The sale of shares, whether by Swiss residents or Non-Resident Holders, may be subject to federal securities transfer Stamp Duty of 0.15%, calculated on the sale proceeds, if the sale occurs through or with a Swiss bank or other Swiss securities dealer, as defined in the Swiss Federal Stamp Duty Act. The Stamp Duty has to be paid by the securities dealer and may be charged to the parties in a taxable transaction who are not securities dealers. Stamp Duty may also be due if a sale of shares occurs with or through a non-Swiss bank or securities dealer, provided (i)&#xA0;such bank or dealer is a member of the SIX, and (ii)&#xA0;the sale takes place on the SIX. In addition to this Stamp Duty, the sale of shares by or through a member of the SIX may be subject to a minor stock exchange levy.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">US federal income taxation</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following is a general discussion of the material US federal income tax consequences of the ownership and disposition of our shares or ADRs that may be relevant to you if you are a US Holder (as defined below). Because this discussion does not consider any specific circumstances of any particular holder of our shares or ADRs, persons who are subject to US taxation are strongly urged to consult their own tax advisors as to the overall US federal, state and local tax consequences, as well as to the overall Swiss and other foreign tax consequences, of the ownership and disposition of our shares or ADRs. In particular, additional or different rules may apply to US expatriates; banks and other financial institutions; regulated investment companies; traders in securities who elect to apply a mark-to-market method of accounting; dealers in securities or currencies; tax-exempt entities; insurance companies; broker-dealers; investors liable for alternative minimum tax; investors that hold shares or ADRs as part of a straddle, hedging or conversion transaction; holders whose functional currency is not the US dollar; partnerships or other pass-through entities; persons who acquired our shares pursuant to the exercise of employee stock options or otherwise as compensation; and persons who hold, directly, indirectly or by attribution, 10% or more of our outstanding shares. This discussion generally applies only to US Holders who hold the shares or ADRs as a capital asset (generally, for investment purposes), and whose functional currency is the US dollar. Investors are urged to consult their own tax advisors concerning whether they are eligible for benefits under the Treaty.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For purposes of this discussion, a US Holder is a beneficial owner of our shares or ADRs who is (i)&#xA0;an individual who is a citizen or resident of the US for US federal income tax purposes; (ii)&#xA0;a corporation (or other entity taxable as a corporation for US federal income tax purposes) created or organized in or under the laws of the US or a state thereof or the District of Columbia; (iii)&#xA0;an estate the income of which is subject to US federal income taxation regardless of its source; or (iv)&#xA0;a trust (i)&#xA0;subject to the primary supervision of a US court and the control of one or more US persons, or (ii)&#xA0;that has a valid election in place to be treated as a US person. If a partnership (or other entity treated as a partnership for US federal income tax purposes) holds shares or ADRs, the tax treatment of a partner generally will depend upon the status of the partner and the activities of the partnership. Partners in a partnership that holds shares or ADRs are urged to consult their own tax advisor regarding the specific tax consequences of the owning and disposing of such shares or ADRs by the partnership.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For US federal income tax purposes, a US Holder of ADRs generally will be treated as the beneficial owner of our shares represented by the ADRs. However, see the discussion below under &#x201C;&#x2014;Dividends&#x201D; regarding certain statements made by the US Treasury concerning depositary arrangements.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">This discussion assumes that each obligation in the Deposit Agreement and any related agreement will be performed in accordance with its terms.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"><i>Dividends.</i>  US Holders will be required to include in gross income, as an item of ordinary income, the full amount (without reduction for any Withholding Tax) of the dividend paid with respect to our shares or ADRs at the time that such dividend is received by the US Holder, in the case of shares, or by the depositary, in the case of ADRs. For this purpose, a &#x201C;dividend&#x201D; will include any distribution paid by us with respect to our shares or ADRs (other than certain pro rata distributions of our capital stock) paid out of our current or accumulated earnings and profits, as determined under US federal income tax principles. To the extent the amount of a distribution by us exceeds our current and accumulated earnings and profits, such excess will first be treated as a tax-free return of capital to the extent of a US Holder&#x2019;s tax basis in the shares or ADRs (with a corresponding reduction in such tax basis), and thereafter will be treated as capital gain, which will be long-term capital gain if the US Holder held our shares or ADRs for more than one year. Under the Code, dividend payments by us on the shares or ADRs are not eligible for the dividends received deduction generally allowed to corporate shareholders.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Dividend income in respect of our shares or ADRs will constitute income from sources outside the US for US foreign tax credit purposes. Subject to the limitations </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">173</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">and conditions provided in the Code, US Holders generally may claim as a credit against their US federal income tax liability, any Withholding Tax withheld from a dividend. The rules governing the foreign tax credit are complex. Each US Holder is urged to consult its own tax advisor concerning whether, and to what extent, a foreign tax credit will be available with respect to dividends received from us. Alternatively, a US Holder may claim the Withholding Tax as a deduction for the taxable year within which the Withholding Tax is paid or accrued, provided a deduction is claimed for all of the foreign income taxes the US Holder pays or accrues in the particular year. A deduction does not reduce US tax on a dollar-for-dollar basis like a tax credit. The deduction, however, is not subject to the limitations applicable to foreign tax credits, but may be subject to other limitations, and each US Holder is urged to consult its own tax advisor.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The US Treasury has expressed concern that parties to whom ADRs are released may be taking actions inconsistent with the claiming of foreign tax credits for US Holders of ADRs. Accordingly, the summary above of the creditability of the Withholding Tax could be affected by future actions that may be taken by the US Treasury.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In general, a US Holder will be required to determine the amount of any dividend paid in Swiss francs, including the amount of any Withholding Tax imposed thereon, by translating the Swiss francs into US dollars at the spot rate on the date the dividend is actually or constructively received by a US Holder, in the case of shares, or by the depositary, in the case of ADRs, regardless of whether the Swiss francs are in fact converted into US dollars. If a US Holder converts the Swiss francs so received into US dollars on the date of receipt, the US Holder generally should not recognize foreign currency gain or loss on such conversion. If a US Holder does not convert the Swiss francs so received into US dollars on the date of receipt, the US Holder will have a tax basis in the Swiss francs equal to the US dollar value on such date. Any foreign currency gain or loss that a US Holder recognizes on a subsequent conversion or other disposition of the Swiss francs generally will be treated as US source ordinary income or loss.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For a non-corporate US Holder, the US dollar amount of any dividends paid that constitute qualified dividend income generally will be taxable at a maximum rate of 15% (or 20% in the case of taxpayers with annual income that exceeds certain thresholds), provided that the US Holder meets certain holding period and other requirements. In addition, the dividends could be subject to a 3.8% net investment income tax. This tax is applied against the lesser of the US Holder&#x2019;s net investment income or the amount by which modified adjusted gross income exceeds a statutory threshold amount based on filing status. We currently believe that dividends paid with respect to our shares and ADRs will constitute qualified dividend income for US federal income tax purposes, provided that the US Holder meets certain holding period and other requirements. US Holders of shares or ADRs are urged to consult their own tax advisors regarding the availability to them of the reduced dividend rate in light of their own particular situation and the computations of their foreign tax credit limitation with respect to any qualified dividends paid to them, as applicable.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"><i>Sale or other taxable disposition.</i>  Upon a sale or other taxable disposition of shares or ADRs, US Holders generally will recognize capital gain or loss in an amount equal to the difference between the US dollar value of the amount realized on the disposition and the US Holder&#x2019;s tax basis (determined in US dollars) in the shares or ADRs. This capital gain or loss generally will be US source gain or loss and will be treated as long-term capital gain or loss if the holding period in the shares or ADRs exceeds one year. In the case of a non-corporate US Holder, any long-term capital gain generally will be subject to US federal income tax at preferential rates, with a maximum rate of 15% (or 20% in the case of taxpayers with annual income that exceeds certain thresholds). In addition, the gains could be subject to a 3.8% investment income tax. This tax is applied against the lesser of the US Holder&#x2019;s net investment income or the amount by which modified adjusted gross income exceeds a statutory threshold amount based on filing status. The deductibility of capital losses is subject to significant limitations under the Code. Deposits or withdrawals of our shares by US Holders in exchanges for ADRs will not result in the realization of gain or loss for US federal income tax purposes.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"><i>US information reporting and backup withholding.</i>  Dividend payments with respect to shares or ADRs and proceeds from the sale, exchange or other disposition of shares or ADRs received in the United States or through US-related financial intermediaries may be subject to information reporting to the US Internal Revenue Service (IRS) and possible US backup withholding. Certain exempt recipients (such as corporations) are not subject to these information reporting and backup withholding requirements. Backup withholding will not apply to a US Holder who furnishes a correct taxpayer identification number and makes any other required certification or who is otherwise exempt from backup withholding. Any US Holders required to establish their exempt status generally must provide a properly executed IRS Form&#xA0;W-9 (Request for Taxpayer Identification Number and Certification). Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against a US Holder&#x2019;s US federal income tax liability, and a US Holder may obtain a refund of any excess amounts withheld under the backup withholding rules by timely filing the appropriate claim for refund with the IRS and furnishing any required information.</div><a name="anchorId00539631"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.F Dividends and paying agents</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">174</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00539637"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.G Statement by experts</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div><a name="anchorId00539641"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.H Documents on display</p>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Any statement in this Form&#xA0;20-F about any of our contracts or other documents is not necessarily complete. If the contract or document is filed as an exhibit to the Form&#xA0;20-F, the contract or document is deemed to modify the description contained in this Form&#xA0;20-F. You must review the exhibits themselves for a complete description of the contract or document.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The SEC maintains an internet site at http://www.sec.gov that contains reports and other information regarding issuers that file electronically with the SEC. These SEC filings are also available to the public from commercial document retrieval services.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We are required to file or furnish reports and other information with the SEC under the Exchange Act and regulations under that act. As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the form and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short swing profit recovery provisions contained in Section&#xA0;16 of the Exchange Act.</div><a name="anchorId00539649"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.I Subsidiary information</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">175</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00539655"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;11.  Quantitative and Qualitative Disclosures About Market Risk</p>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The major financial risks facing the Group are managed centrally by Group Treasury. We have a written Treasury Directive and have implemented a strict segregation of front-office and back-office controls. The Group does regular reconciliations of its positions with its counterparties. In addition, the Treasury function is included in management&#x2019;s internal control assessment.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For information about the effects of currency fluctuations and how we manage currency risk, see &#x201C;Item&#xA0;5. Operating and Financial Review and Prospects&#x2014;Item&#xA0;5.B Liquidity and capital resources.&#x201D;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The information set forth under &#x201C;Item 18. Financial Statements&#x2014;Note&#xA0;29. Financial instruments&#x2014;additional disclosures&#x201D; is incorporated by reference.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">176</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00539666"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;12.  Description of Securities Other Than Equity Securities</p><a name="anchorId00539668"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">12.A Debt securities</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div><a name="anchorId00539672"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">12.B Warrants and rights</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div><a name="anchorId00539676"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">12.C Other securities</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div><a name="anchorId00539680"></a><p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">12.D American Depositary Shares</p><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Fees payable by ADR holders</font>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to our Deposit Agreement with the ADS depositary, JPMorgan Chase Bank, N.A. (JPMorgan), holders of our ADRs may have to pay to JPMorgan, either directly or indirectly, fees or charges up to the amounts set forth below:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="top">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">Category</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Depositary actions</div>
      </td>
      <td></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Associated fee</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depositing or substituting <br> underlying shares</div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Acceptance of shares surrendered, and issuance of ADRs in exchange, <br>  including surrenders and issuances in respect of:<br>  &#x2014; Share distributions<br>  &#x2014; Stock split<br>  &#x2014; Rights<br>  &#x2014; Merger<br>  &#x2014; Exchange of shares or any other transaction or event or other distribution <br>  affecting the ADSs or the deposited shares</div>
      </td>
      <td align="left" width="1%"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD 5.00 for each 100 ADSs <br>  (or portion thereof) <br>  evidenced by the new <br>  ADRs delivered<br>  <br>  <br>  <br>  </div>
      </td>
      <td align="left" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Withdrawing <br> underlying shares</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Acceptance of ADRs surrendered for withdrawal of deposited shares<br>  <br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD 5.00 for each 100 ADSs <br>  (or portion thereof) <br>  evidenced by the ADRs <br>  surrendered</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling or <br> exercising rights</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Distribution or sale of shares, the fee being in an amount equal to the fee <br>  for the execution and delivery of ADRs that would have been charged <br>  as a result of the deposit of such shares</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD 5.00 for each 100 ADSs <br>  (or portion thereof)<br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transferring, <br> splitting or <br> grouping receipts</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Transfers, combining or grouping of depositary receipts<br>  <br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD 1.50 per ADR<br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expenses of the <br> depositary</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Expenses incurred on behalf of holders in connection with:<br>  &#x2014; Compliance with foreign exchange control regulations or any law or <br>  regulation relating to foreign investment<br>  &#x2014; The depositary&#x2019;s or its custodian&#x2019;s compliance with applicable law, <br>  rule or regulation<br>  &#x2014; Stock transfer or other taxes and other governmental charges<br>  &#x2014; Cable, telex and facsimile transmission and delivery<br>  &#x2014; Expenses of the depositary in connection with the conversion of foreign <br>  currency into US dollars (which are paid out of such foreign currency)<br>  &#x2014; Any other charge payable by any of the depositary or its agents</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Expenses payable at the sole <br>  discretion of the depositary <br>  by billing holders or by <br>  deducting charges from one <br>  or more cash dividends or <br>  other cash distributions<br>  <br>  <br>  <br>  </div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="top" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Advance tax relief</div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Tax relief/reclamation process for qualified holders<br>  </div>
      </td>
      <td align="left"></td>
      <td align="left">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> A depositary service charge <br>  of USD 0.008 per ADS</div>
      </td>
      <td align="left"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">177</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Fees payable by the depositary to the issuer</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Pursuant to an agreement effective as of May&#xA0;11, 2017 (&#x201C;the Agreement&#x201D;), JPMorgan, as our ADS depositary, has agreed to make an annual contribution payment to Novartis at the end of each 12-month period beginning on the effective date of the Agreement and on each subsequent anniversary of the effective date of the Agreement (each such 12-month period is a &#x201C;Contract Year&#x201D;). This annual contribution payment will equal: (a)(1) USD 1.7&#xA0;million less (a)(2) the custody costs, fees and expenses (including, without limitation, any central securities depository fees, charges and expenses) incurred during the applicable Contract Year (the items in (a)(2) collectively are the &#x201C;Custody Costs&#x201D;) plus (b)&#xA0;70% of the gross issuance and cancellation fees collected by JPMorgan under the Deposit Agreement during such Contract Year minus (c)&#xA0;that portion (if any) of JPMorgan&#x2019;s legal fees, charges and out-of-pocket expenses in excess of USD 50&#x2005;000 for such Contract Year. To the extent that the Custody Costs for a Contract Year exceed USD 1.7&#xA0;million, these costs would be capped at USD 1.7&#xA0;million.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">JPMorgan has further agreed to waive the USD 0.05 per ADS issuance fees that would normally be owed by Novartis in connection with our deposits of shares as part of our employee stock ownership and employee participation plans. Novartis is responsible for reimbursing JPMorgan for all taxes and governmental charges required to have been withheld and/or paid, and not so withheld and/or paid, arising from such waived fees.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">178</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00539863"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000;">PART II</p><a name="anchorId00539865"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;13.  Defaults, Dividend Arrearages and Delinquencies</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">None.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">179</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00539871"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;14.  Material Modifications to the Rights of Security Holders and Use of Proceeds</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">None.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">180</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>


    <a name="anchorId00637515"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&nbsp;15.  Controls and Procedures</p>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(a)  Novartis AG&#x2019;s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rule&nbsp;13a-15(e)) as of the end of the period covered by this Annual Report, have concluded that, as of such date, our disclosure controls and procedures were effective.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(b) Report of Novartis Management on Internal Control Over Financial Reporting: The Board of Directors and management of the Group are responsible for establishing and maintaining adequate internal control over financial reporting. The Group&#x2019;s internal control over financial reporting was designed to provide reasonable assurance to the Group&#x2019;s management and Board of Directors regarding the reliability of financial reporting and the preparation and fair presentation of its published consolidated financial statements.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">Internal controls over financial reporting, no matter how well designed, have inherent limitations. Therefore, even those internal controls over financial reporting determined to be effective may not prevent or detect misstatements and can provide only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">Group management assessed the effectiveness of the Group&#x2019;s internal control over financial reporting as of December&nbsp;31, 2020. In making this assessment, it used the criteria established in <i>Internal Control&mdash;Integrated Framework (2013)</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on our assessment, management concluded that, as of December&nbsp;31, 2020, the Group&#x2019;s internal control over financial reporting is effective based on those criteria.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">PricewaterhouseCoopers AG, Switzerland, an independent registered public accounting firm, has issued an unqualified opinion on the effectiveness of the Group&#x2019;s internal control over financial reporting, which is included in this Annual Report under &#x201C;Item&nbsp;18. Financial Statements&mdash;Report of independent registered public accounting firm.&#x201D;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(c)  See the report of PwC, an independent registered public accounting firm, included under &#x201C;Item&nbsp;18. Financial Statements&mdash;Report of independent registered public accounting firm.&#x201D;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(d) There were no changes to our internal control over financial reporting that occurred during the period covered by this Annual Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">181</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>

    <a name="anchorId00737518"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&nbsp;16A.  Audit Committee Financial Expert</p>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our Audit and Compliance Committee has determined that Srikant Datar and Elizabeth Doherty each possess specific accounting and financial management expertise and that each is an Audit Committee Financial Expert as defined by the SEC. The Board of Directors has also determined that Srikant Datar and Elizabeth Doherty are each &#x201C;independent&#x201D; in accordance with the applicable requirements of Rule&nbsp;10A-3 of the Exchange Act, and that other members of the Audit and Compliance Committee have sufficient experience and ability in finance and compliance matters to enable them to adequately discharge their responsibilities.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">182</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00737532"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&nbsp;16B.  Code of Ethics</p>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In addition to our Code of Ethics and Professional Practices Policy, which are applicable to all of our associates, we have adopted Ethical Conduct Requirements that impose additional obligations on our principal executive officer, principal financial officer, principal accounting officer, and persons performing similar functions. This document is accessible on our internet website at:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">https://www.novartis.com/investors/company-overview/corporate-governance</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">183</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00737541"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&nbsp;16C.  Principal Accountant Fees and Services</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The information set forth under &#x201C;Item 6. Directors, Senior Management and Employees&mdash;Item 6.C Board practices&mdash;Corporate governance&mdash;Auditors&#x201D; is incorporated by reference.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">184</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00737552"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&nbsp;16D.  Exemptions from the Listing Standards for Audit Committees</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">185</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00737559"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;16E.  Purchases of Equity Securities by the Issuer and Affiliated Purchasers</p>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"><br>2020</div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> <br> <br> <br> <br> <br> Total number of <br> shares purchased<br> (a)<sup style="white-space: nowrap">           1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> <br> <br> <br> <br> Average price <br> paid per share <br> in USD<br> (b)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Total number <br> of shares<br> purchased <br> as part of <br> publicly <br> announced <br> plans or <br> programs<br> (c)<sup style="white-space: nowrap">           2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Maximum <br> approximate <br> value of <br> shares that <br> may yet be <br> purchased <br> under the <br> plans or <br> programs <br> (CHF millions)<br> (d)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Maximum <br> approximate <br> value of <br> shares that <br> may yet be <br> purchased <br> under the <br> plans or <br> programs <br> (USD millions)<br> (e)<sup style="white-space: nowrap">           3</sup></div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Jan. 1-31</div>
      </td>
      <td align="right" width="8%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;127&nbsp;034</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 95.09</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;752</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;897</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Feb. 1-28</div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 315&nbsp;761</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 95.18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;752</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;913</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mar. 1-31</div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&nbsp;093</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 89.61</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;752</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;937</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Apr. 1-30</div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 67&nbsp;831</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 83.63</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;752</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;881</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">May 1-31</div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;990</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 85.29</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;752</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;932</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Jun. 1-30</div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22&nbsp;601</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 86.85</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;752</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;989</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Jul. 1-31</div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&nbsp;275</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 87.91</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;752</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;245</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aug. 1-31</div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;806&nbsp;646</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 87.15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;800&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;610</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;102</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sep. 1-30</div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&nbsp;951&nbsp;800</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 88.85</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&nbsp;917&nbsp;162</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;559</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;862</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Oct. 1-31</div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;896&nbsp;929</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 87.06</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;882&nbsp;838</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;774</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;032</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nov. 1-30</div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;350&nbsp;036</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 89.71</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;340&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;665</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;953</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dec. 1-31</div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;715&nbsp;051</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 91.22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;700&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;122</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;409</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 34&nbsp;303&nbsp;047</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 88.99</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 32&nbsp;640&nbsp;000</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Column (a) shows shares repurchased on the SIX Swiss Exchange second trading line plus shares we purchased from employees who had obtained the shares through a Novartis Employee Ownership Plan. See "Item 18. Financial Statements - Note 26 Equity-based participation plans for associates."</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Column (c) shows shares repurchased on the SIX Swiss Exchange second trading line under the eighth CHF 10 billion share buyback authority approved at the 2019 AGM. See "Item 6. Directors, Senior Management and Employees - Item 6C. Board Practices - Our capital structure - Changes in capital."</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Column (e) shows the Swiss franc amount from column (d) converted into US dollars as of the month-end, using the Swiss franc/US dollar  exchange rate at the applicable month-end</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">186</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00738222"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&nbsp;16F.  Change in Registrant&#x2019;s Certifying Accountant</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">187</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00738229"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&nbsp;16G.  Corporate Governance</p>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis AG is subject to and compliant with the laws and regulations of Switzerland (in particular, Swiss company and securities laws, SIX Swiss Exchange rules and the Swiss Code of Best Practice for Corporate Governance) and the securities laws of the United States, including New York Stock Exchange (NYSE) rules, as applicable to foreign private issuers of securities. The following summarizes some significant ways in which our corporate governance practices differ from those followed by domestic listed US companies under the listing standards of the NYSE:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Novartis AG shareholders do not receive written reports directly from Board committees.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; External auditors are appointed by shareholders at the Annual General Meeting of Shareholders (AGM), as opposed to being appointed by the Audit and Compliance Committee.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; While shareholders cannot vote on all equity compensation plans, they are entitled to hold separate, yearly binding votes on Board and Executive Committee compensation.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Board has set up a separate Risk Committee that oversees the risk management system and processes, as opposed to delegating this responsibility to the Audit and Compliance Committee.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The full Board is responsible for overseeing the performance evaluation of the Board and Executive Committee.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The full Board is responsible for setting objectives relevant to the CEO&#x2019;s compensation and for evaluating his performance.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">188</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00738263"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&nbsp;16H.  Mine Safety Disclosure</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">189</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00738270"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000;">PART III</p><a name="anchorId00738272"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&nbsp;17.  Financial Statements</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">See response to &#x201C;Item&nbsp;18. Financial Statements.&#x201D;</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">190</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId00738281"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&nbsp;18.  Financial Statements</p>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following financial statements are filed as part of this Annual Report.</div>



  <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId001537716">Consolidated income statements</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId001538517">Consolidated statements of comprehensive income</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId001539001">Consolidated balance sheets</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId001539917">Consolidated statements of changes in equity</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId001542811">Consolidated statements of cash flows</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId001544012">Notes to the Novartis Group&nbsp;consolidated&nbsp;financial statements</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001544016">1. Significant accounting policies</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001544667">2. Significant transactions</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001545388">3. Segmentation of key figures 2020, 2019 and 2018</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001557602">4. Associated companies</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001558665">5. Interest expense and&nbsp;other&nbsp;financial&nbsp;income&nbsp;and&nbsp;expense</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001558939">6. Taxes</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001559602">7. Earnings per share</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001559964">8. Changes in consolidated statements of&nbsp;comprehensive income</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001561648">9. Property, plant and equipment</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001563331">10. Right-of-use assets and lease liabilities</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001564174">11. Goodwill and intangible assets</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001567048">12. Deferred tax assets and liabilities </a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001569569">13. Financial and other non-current assets</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001569790">14. Inventories</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001569957">15. Trade receivables</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001570628">16. Marketable securities, commodities, time&nbsp;deposits, derivative financial instruments, and&nbsp;cash and cash equivalents</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001570770">17. Other current assets</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001570864">18. Equity</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001572762">19. Non-current financial debt</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001574591">20. Provisions and other non-current liabilities</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001575559">21. Current financial debt and&nbsp;derivative&nbsp;financial&nbsp;instruments</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001575719">22. Provisions and other current liabilities</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001577662">23. Details to the consolidated statements of cash flows</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001579570">24. Acquisitions of businesses</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001579975">25. Post-employment benefits for associates</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001583055">26. Equity-based participation plans for associates</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001584465">27. Transactions with related parties</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001584910">28. Commitments and contingencies</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001585072">29. Financial instruments &ndash; additional disclosures</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001592389">30. Discontinued operations</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001593427">31. Events subsequent to the December 31, 2020, consolidated balance sheet date</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;"><a style="text-decoration: none;" href="#anchorId001593466">32. Principal Group subsidiaries and&#xA0;associated&#xA0;companies</a></div>
<div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;"><a style="text-decoration: none;" href="#anchorId001737515">Report of Independent Registered Public Accounting Firm</a></div>
    <br>
<br>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">191</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
     <a name="anchorId001837517"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;19.  Exhibits</p>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The SEC maintains an internet site at http://www.sec.gov that contains reports and other information regarding issuers that file electronically with the SEC. These SEC filings are also available to the public from commercial document retrieval services.</div>
<div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> </font>
</div>
<div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 1.1 <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1114448/000110465920127414/tm2036313d1_ex4-1.htm">Articles of Incorporation of Novartis AG, as amended February 28, 2020 (English translation) </a><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1114448/000110465920127414/tm2036313d1_ex4-1.htm">(incorporated by reference to Exhibit&#xA0;4.1 to Novartis AG&#x2019;s registration statement on Form&#xA0;S-8 (File No.&#xA0;333-250207) as filed with the SEC on November&#xA0;19, 2020).</a> </font>
</div>
<div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 1.2 <a style="-sec-extract:exhibit" href="a21012620f-ex1_2.htm">Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG, effective January 1, 2021. </a></font>
</div>
<div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 2.1 Amended and Restated Deposit Agreement, dated as of May&#xA0;11, 2000, among Novartis AG, JPMorgan Chase Bank (fka Morgan Guaranty Trust Company of New York), as depositary, and all holders from time to time of ADRs issued thereunder (incorporated by reference to Exhibit&#xA0;(a)(1) to Post-Effective Amendment No.&#xA0;1 to Novartis AG&#x2019;s registration statement on Form&#xA0;F-6 (File No.&#xA0;333-11758) as filed with the SEC on September&#xA0;8, 2000).</font>
</div>
<div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 2.2 Amendment No.&#xA0;1 to the Amended and Restated Deposit Agreement (incorporated by reference to Exhibit&#xA0;(a)(2) to Post-Effective Amendment No.&#xA0;1 to Novartis AG&#x2019;s registration statement on Form&#xA0;F-6 (File No.&#xA0;333-11758) as filed with the SEC on September&#xA0;8, 2000).</font>
</div>
<div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 2.3 Amendment No.&#xA0;2 to the Amended and Restated Deposit Agreement (incorporated by reference to Exhibit&#xA0;(a)(3) to Novartis AG&#x2019;s registration statement on Form&#xA0;F-6 (File No.&#xA0;333-13446) as filed with the SEC on May&#xA0;3, 2001). </font>
</div>
<div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 2.4 <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1114448/000094787102000101/f3_013102.txt">Restricted Issuance Agreement, dated as of January&#xA0;11, 2002, among Novartis AG, JPMorgan Chase Bank, as depositary, and all holders from time to time of ADRs representing ADSs issued thereunder (incorporated by reference to Exhibit&#xA0;4 to the Registration Statement on Form&#xA0;F-3 (File No.&#xA0;333-81862) as filed with the SEC on January&#xA0;31, 2002). </a></font>
</div>
<div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 2.5 <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1114448/000104746908000606/a2182117zex-2_4.htm">Letter Agreement, dated December&#xA0;14, 2007, between Novartis AG and JPMorgan Chase Bank, as depositary (incorporated by reference to Exhibit&#xA0;2.4 to the Form&#xA0;20-F for the year ended December&#xA0;31, 2007, as filed with the SEC on January&#xA0;28, 2008). </a></font>
</div>
<div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 2.6 <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1114448/000119380514001802/e612683_ex99-a7.htm">Form of American Depositary Receipt (incorporated by reference to Exhibit&#xA0;(a)(7) to the Registration Statement on Form&#xA0;F-6 (File No.&#xA0;333-198623) as filed with the SEC on September&#xA0;8, 2014).</a></font>
</div>
<div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 2.7 The total amount of long-term debt securities authorized under any instrument does not exceed 10% of the total assets of the Company and its subsidiaries on a consolidated basis. We hereby agree to furnish to the SEC, upon its request, a copy of any instrument defining the rights of holders of long-term debt of the Company or of its subsidiaries for which consolidated or unconsolidated financial statements are required to be filed.</font>
</div>
<div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 2.8 <a style="-sec-extract:exhibit" href="a21012620f-ex2_8.htm">Description of Securities registered under Section 12 of the Exchange Act.</a> </font>
</div>
<div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 8.1 <a style="-sec-extract:exhibit" href="#anchorNote31">For a list of all of our principal Group subsidiaries and associated companies, see &#x201C;Item 18. Financial Statements&#x2014;Note&#xA0;32. Principal Group subsidiaries and associated companies.&#x201D;</a></font>
</div>
<div style="margin-bottom:20px;margin-left:31px;text-indent:-31px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 12.1 <a style="-sec-extract:exhibit" href="a21012620f-ex12_1.htm">Certification of Vasant Narasimhan, Chief Executive Officer of Novartis AG, pursuant to Section&#xA0;302 of the Sarbanes-Oxley Act of 2002.</a></font>
</div>
<div style="margin-bottom:20px;margin-left:31px;text-indent:-31px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 12.2 <a style="-sec-extract:exhibit" href="a21012620f-ex12_2.htm">Certification of Harry Kirsch, Chief Financial Officer of Novartis AG, pursuant to Section&#xA0;302 of the Sarbanes-Oxley Act of 2002.</a></font>
</div>
<div style="margin-bottom:20px;margin-left:31px;text-indent:-31px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 13.1 <a style="-sec-extract:exhibit" href="a21012620f-ex13_1.htm">Certification of Vasant Narasimhan, Chief Executive Officer of Novartis AG, pursuant to Section&#xA0;18 U.S.C. Section&#xA0;1350, as adopted pursuant to Section&#xA0;906 of the Sarbanes-Oxley Act of 2002.</a></font>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">192</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="margin-bottom:20px;margin-left:31px;text-indent:-31px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 13.2 <a style="-sec-extract:exhibit" href="a21012620f-ex13_2.htm">Certification of Harry Kirsch, Chief Financial Officer of Novartis AG, pursuant to Section&#xA0;18 U.S.C. Section&#xA0;1350, as adopted pursuant to Section&#xA0;906 of the Sarbanes-Oxley Act of 2002.</a></font>
</div>
<div style="margin-bottom:20px;margin-left:31px;text-indent:-31px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 15.1 <a style="-sec-extract:exhibit" href="a21012620f-ex15_1.htm">Consent of PricewaterhouseCoopers AG.</a></font>
</div>
<div style="margin-bottom:20px;margin-left:50px;text-indent:-50px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 101.INS XBRL Instance Document </font>
</div>
<div style="margin-bottom:20px;margin-left:50px;text-indent:-50px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 101.SCH XBRL Taxonomy Extension Schema Document </font>
</div>
<div style="margin-bottom:20px;margin-left:50px;text-indent:-50px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document </font>
</div>
<div style="margin-bottom:20px;margin-left:50px;text-indent:-50px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 101.DEF XBRL Taxonomy Extension Definition Linkbase Document</font>
</div>
<div style="margin-bottom:20px;margin-left:50px;text-indent:-50px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 101.LAB XBRL Taxonomy Extension Label Linkbase Document </font>
</div>
<div style="margin-bottom:20px;margin-left:50px;text-indent:-50px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document</font>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">193</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>






    <a name="anchorId00837515"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">SIGNATURES</p>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The registrant hereby certifies that it meets all of the requirements for filing on Form&nbsp;20-F and that it has duly caused and authorized the undersigned to sign this Annual Report on its behalf.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
<div style="margin-left:380px;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Novartis AG</div>
<div style="margin-left:400px;padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"></div>
<div style="margin-left:400px;text-indent:-20px;padding-top:20px;text-decoration:underline;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">By: /s/ Harry Kirsch</div>
<div style="margin-left:400px;padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Name: Harry Kirsch</div>
<div style="margin-left:400px;padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Title: <i>Chief Financial Officer of Novartis</i></div>
<div style="margin-left:400px;padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"></div>
<div style="margin-left:400px;text-indent:-20px;padding-top:20px;text-decoration:underline;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">By: /s/ Shannon Thyme Klinger</div>
<div style="margin-left:400px;padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Name: Shannon Thyme Klinger</div>
<div style="margin-left:400px;padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Title: <i>Chief Legal Officer of Novartis</i></div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Date: January&nbsp;26, 2021</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">194</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">  </div>






<a name="anchorId001537712"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Novartis Group consolidated&nbsp;financial&nbsp;statements</p><a name="anchorId001537716"></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Consolidated income statements</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">(For the years ended December 31, 2020, 2019 and 2018) </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions unless indicated otherwise)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48&nbsp;659</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;445</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 44&nbsp;751</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to discontinued segment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 82</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48&nbsp;659</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;498</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 44&nbsp;833</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;239</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;179</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;266</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15&nbsp;121</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14&nbsp;425</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14&nbsp;510</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 34&nbsp;777</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;252</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31&nbsp;589</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14&nbsp;197</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14&nbsp;369</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;13&nbsp;717</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8&nbsp;980</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9&nbsp;402</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8&nbsp;489</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;742</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;031</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;629</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;190</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;426</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;609</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&nbsp;152</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;086</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;403</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 673</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 659</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;438</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;869</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;850</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;932</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;78</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 45</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 186</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;878</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;940</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;095</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;807</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;793</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;295</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;071</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;147</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;800</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net loss from discontinued operations before gain on  distribution of Alcon Inc. to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;101</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;186</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;691</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income/(loss) from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;590</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;186</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;071</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;737</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;614</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Shareholders of Novartis AG</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 8&nbsp;072</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 11&nbsp;732</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 12&nbsp;611</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Non-controlling interests</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basic earnings per share (USD) from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.55</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.52</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basic earnings per share (USD) from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.00</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.08</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total basic earnings per share (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.55</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.44</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Diluted earnings per share (USD) from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.52</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.08</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.46</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Diluted earnings per share (USD) from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.98</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.08</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total diluted earnings per share (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.52</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.06</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.38</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">The accompanying Notes form an integral part of the consolidated financial statements.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-1</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId001538517"></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Consolidated statements of comprehensive income</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">(For the years ended December 31, 2020, 2019 and 2018) </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;071</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;737</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;614</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Other comprehensive income to be eventually recycled into the consolidated income statement:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 20px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on debt securities, net of taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 20px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on deferred cash flow hedges, net of taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total fair value adjustments on financial instruments, net of taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of other comprehensive income  recognized by associated companies, net of taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;56</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;94</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;482</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;201</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 95</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;194</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 352</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 315</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of items to eventually recycle</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;937</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 304</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;60</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Other comprehensive income never to be recycled into the consolidated income statement:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Actuarial gains/(losses) from defined benefit plans, net of taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 143</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;467</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;359</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, net of taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;47</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of items never to be recycled</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 393</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;514</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;346</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total comprehensive income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;401</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;527</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;208</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Shareholders of Novartis AG</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 11&nbsp;403</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 11&nbsp;525</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 12&nbsp;210</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 20px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 11&nbsp;403</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 6&nbsp;948</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 12&nbsp;417</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 20px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 4&nbsp;577</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &#x2013;&#x2005;207</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Non-controlling interests</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">The accompanying Notes form an integral part of the consolidated financial statements.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-2</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId001539001"></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Consolidated balance sheets</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">(At December 31, 2020 and 2019) </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Assets</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current assets</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&nbsp;263</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;069</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;676</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;677</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29&nbsp;999</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26&nbsp;524</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets other than goodwill</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36&nbsp;809</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28&nbsp;787</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Investments in associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;632</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;644</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;214</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;909</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;901</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;518</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 892</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 738</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 102&nbsp;386</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 88&nbsp;866</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;131</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;982</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;217</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;301</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income tax receivables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 239</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 254</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, commodities, time deposits and derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;905</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 334</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;658</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;112</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;523</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;680</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current assets without disposal group</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&nbsp;673</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 28&nbsp;663</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Assets of disposal group held for sale</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 841</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&nbsp;673</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 29&nbsp;504</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 132&nbsp;059</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 118&nbsp;370</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Equity and liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Equity</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Share capital</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 913</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 936</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Treasury shares</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;53</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;80</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reserves</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 55&nbsp;738</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 54&nbsp;618</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Equity attributable to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 56&nbsp;598</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;474</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-controlling interests</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 68</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 77</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 56&nbsp;666</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;551</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&nbsp;259</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20&nbsp;353</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;719</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;703</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;422</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;867</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;934</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;632</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 42&nbsp;334</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;555</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;403</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;424</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debts and derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;785</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;031</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 286</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 246</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current income tax liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;458</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;194</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&nbsp;127</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13&nbsp;338</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current liabilities without disposal group</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33&nbsp;059</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 28&nbsp;233</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities of disposal group held for sale</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33&nbsp;059</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 28&nbsp;264</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 75&nbsp;393</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 62&nbsp;819</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity and liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 132&nbsp;059</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 118&nbsp;370</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">The accompanying Notes form an integral part of the consolidated financial statements.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-3</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId001539917"></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Consolidated statements of changes in equity</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">(For the years ended December 31, 2020, 2019 and 2018) </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Reserves</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> Note</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Share<br> capital</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Treasury<br> shares</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Retained<br> earnings</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Total value<br> adjustments</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity<br> attributable <br> to Novartis <br> shareholders</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Non-<br> controlling<br> interests</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Total<br> equity</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity at December 31, 2017, as  previously reported</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   969</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   &#x2013;&#x2005;100</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   77&nbsp;639</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   &#x2013;&#x2005;4&nbsp;340</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   74&nbsp;168</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   59</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   74&nbsp;227</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in accounting policies</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 237</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;177</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 60</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 60</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Restated equity at January 1, 2018</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 969</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;100</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 77&nbsp;876</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;517</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 74&nbsp;228</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 59</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 74&nbsp;287</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;611</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;611</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;614</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other comprehensive income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;482</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 81</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;401</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;406</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total comprehensive income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;129</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 81</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;210</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;208</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6&nbsp;966</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6&nbsp;966</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6&nbsp;966</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of treasury shares</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;960</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;973</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;973</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reduction of share capital</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 430</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 434</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 434</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share sales</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 261</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 263</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 263</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 752</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 756</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 756</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase of treasury share repurchase  obligation under a share buyback trading plan</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   18.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;284</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;284</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;284</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transaction costs, net of taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;79</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;79</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;79</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on financial assets sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in non-controlling interests</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 38</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 38</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 38</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total of other equity movements</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;7&nbsp;814</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;7&nbsp;824</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;7&nbsp;803</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity at December 31, 2018, as  previously reported</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   944</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   &#x2013;&#x2005;69</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   82&nbsp;191</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   &#x2013;&#x2005;4&nbsp;452</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   78&nbsp;614</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   78</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   78&nbsp;692</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in accounting policies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Restated equity at January 1, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 944</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;69</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 82&nbsp;194</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;452</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 78&nbsp;617</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 78</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 78&nbsp;695</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;732</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;732</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;737</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other comprehensive income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;94</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;113</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;207</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;210</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total comprehensive income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;638</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;113</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;525</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;527</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6&nbsp;645</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6&nbsp;645</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6&nbsp;645</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend in kind to effect the spin-off of Alcon Inc.</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;23&nbsp;434</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;23&nbsp;434</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;23&nbsp;434</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of treasury shares</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;480</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;511</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;511</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reduction of share capital</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 207</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 210</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 210</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 828</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 833</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 833</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees as a result of the Alcon spin-off</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   18.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   18</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes on treasury share transactions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;189</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;189</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;189</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Decrease of treasury share repurchase  obligation under a share buyback trading plan</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   18.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   284</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   284</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   284</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transaction costs, net of taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;253</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;253</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;253</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on financial assets sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 95</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;95</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in non-controlling interests</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments related to divestments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total of other equity movements</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;34&nbsp;557</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;92</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;34&nbsp;668</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;34&nbsp;671</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity at December 31, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 936</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;80</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 59&nbsp;275</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;657</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;474</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 77</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;551</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;072</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;072</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;071</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other comprehensive income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;56</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;387</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;331</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;330</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total comprehensive income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;016</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;387</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;403</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;401</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6&nbsp;987</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6&nbsp;987</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6&nbsp;987</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of treasury shares</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;038</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;056</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;056</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reduction of share capital</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 798</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 806</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 806</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repurchase of options</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;89</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;89</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;89</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 724</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 730</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 730</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees as a result of the Alcon spin-off</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   18.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   30</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes on treasury share transactions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase of treasury share repurchase  obligation under a share buyback trading plan</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   18.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;1&nbsp;769</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;1&nbsp;769</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;1&nbsp;769</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on financial assets sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 150</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;150</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments related to divestments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total of other equity movements</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 27</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;10&nbsp;134</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;149</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;10&nbsp;279</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;10&nbsp;286</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity at December 31, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 913</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;53</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 57&nbsp;157</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;419</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 56&nbsp;598</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 68</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 56&nbsp;666</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">The accompanying Notes form an integral part of the consolidated financial statements.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-4</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId001542811"></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Consolidated statements of cash flows</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">(For the years ended December 31, 2020, 2019 and 2018) </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;071</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;147</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;800</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Adjustments to reconcile net income from continuing operations to  net cash flows from operating activities from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of non-cash items and other adjustments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;881</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;122</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;486</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends received from associated companies and others</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 490</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 463</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 719</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest received</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 47</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 214</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 241</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest paid</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;703</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;793</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;816</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial receipts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 464</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 218</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial payments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;39</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;33</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;31</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes paid</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;833</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;876</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;506</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from operating activities from continuing operations before working capital and provision changes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   16&nbsp;378</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   14&nbsp;272</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   13&nbsp;111</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments out of provisions and other net cash movements in non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;437</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;924</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;638</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in net current assets and other operating cash flow items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;291</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 199</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 576</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from operating activities from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;650</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;547</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;049</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows from operating activities from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 78</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;223</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total net cash flows from operating activities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;650</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;625</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;272</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of property, plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;275</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;379</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;254</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of property, plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 88</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 857</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;310</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;878</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;394</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 380</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 973</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 823</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of financial assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;230</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;302</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;205</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of financial assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 723</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;152</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 165</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of other non-current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;61</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;60</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;39</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of other non-current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquisitions and divestments of interests in associated companies, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;854</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquisitions and divestments of businesses, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9&nbsp;957</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;760</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;13&nbsp;683</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of marketable securities and commodities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;900</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;228</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;440</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of marketable securities and commodities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 492</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;561</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 472</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows used in investing activities from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;13&nbsp;055</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;067</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;590</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows used in investing activities from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;127</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;159</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;001</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total net cash flows used in investing activities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;13&nbsp;182</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;2&nbsp;226</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;5&nbsp;591</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends paid to shareholders of Novartis AG</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6&nbsp;987</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6&nbsp;645</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6&nbsp;966</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquisitions of treasury shares</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;842</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;533</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;036</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from exercised options and other treasury share transactions, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 748</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 201</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 700</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;126</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 93</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;856</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of non-current financial debts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;003</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;195</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;366</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;261</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;582</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;687</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;312</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;273</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;19</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financing cash flows, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;147</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 56</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 67</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows used in financing activities from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2&nbsp;158</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;16&nbsp;884</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;077</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows used in/from financing activities from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;50</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;257</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;167</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total net cash flows used in financing activities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2&nbsp;208</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;13&nbsp;627</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;244</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net change in cash and cash equivalents before effect of exchange  rate changes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   &#x2013;&#x2005;1&nbsp;740</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   &#x2013;&#x2005;2&nbsp;228</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   4&nbsp;437</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of exchange rate changes on cash and cash equivalents</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 286</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 69</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;26</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total net change in cash and cash equivalents</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;454</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;2&nbsp;159</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;411</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents at January 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&nbsp;112</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13&nbsp;271</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;860</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash and cash equivalents at December 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;658</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;112</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;271</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">The accompanying Notes form an integral part of the consolidated financial statements.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-5</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId001544012"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Notes to the Novartis Group&nbsp;consolidated&nbsp;financial statements</p><a name="anchorId001544016"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">1. Significant accounting policies</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Novartis Group (Novartis or Group) is a multinational group of companies specializing in the research, development, manufacturing and marketing of a broad range of innovative pharmaceuticals and cost-saving generic medicines. The Group is headquartered in Basel, Switzerland.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consolidated financial statements of the Group are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). They are prepared in accordance with the historical cost convention, except for items that are required to be accounted for at fair value.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s financial year-end is December 31, which is also the annual closing date of the individual entities&#x2019; financial statements incorporated into the Group&#x2019;s consolidated financial statements.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The preparation of financial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the year, which affect the reported amounts of revenues, expenses, assets, liabilities and contingent amounts. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Estimates are based on historical experience and other assumptions that are considered reasonable under the given circumstances and are regularly monitored. Actual outcomes and results could differ from those estimates and assumptions. Revisions to estimates are recognized in the period in which the estimate is revised.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Listed below are accounting policies of significance to Novartis or, in cases where IFRS provides alternatives, the option adopted by Novartis.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Scope of consolidation </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated financial statements include all entities, including structured entities, over which Novartis AG, Basel, Switzerland, directly or indirectly has control (generally as a result of owning more than 50% of the entity&#x2019;s voting interest). Consolidated entities are also referred to as &#x201C;subsidiaries.&#x201D; </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In cases where Novartis does not fully own a subsidiary, it has elected to value any remaining outstanding non-controlling interest at the time of acquiring control of the subsidiary at its proportionate share of the fair value of the net identified assets.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The contribution of a business to an associate or joint venture is accounted for by applying the option under IFRS that permits the accounting for the retained interest of the business contributed at its net book value at the time of the contribution.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Investments in associated companies (generally defined as investments in entities in which Novartis holds between 20% and 50% of voting shares or over which it otherwise has significant influence) and joint ventures are accounted for using the equity method, except for selected venture fund investments for which the Group has elected to apply the method of fair value through the consolidated income statement.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Foreign currencies</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated financial statements of Novartis are presented in US dollars (USD). The functional currency of subsidiaries is generally the local currency of the respective entity. The functional currency used for the reporting of certain Swiss and foreign finance entities is USD instead of their respective local currencies. This reflects the fact that the cash flows and transactions of these entities are primarily denominated in these currencies.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For subsidiaries not operating in hyperinflationary economies, the subsidiary&#x2019;s results, financial position and cash flows that do not have USD as their functional currency are translated into USD using the following exchange rates:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Income, expense and cash flows using for each month the average exchange rate, with the US dollar values for each month being aggregated during the year</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Balance sheets using year-end exchange rates</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Resulting exchange rate differences are recognized in other comprehensive income</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For subsidiaries operating in hyperinflationary economies, the impact of the restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period is recorded in retained earnings in equity. The subsequent gains or losses resulting from the restatement of non-monetary assets are recorded in &#x201C;Other financial income and expense&#x201D; in the consolidated income statement. </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Non-current assets held for sale or held for distribution to owners</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Non-current assets are accounted for as assets held for sale or related to discontinued operations when their carrying amount is to be recovered principally through a sale transaction or distribution to owners and a sale or distribution to owners is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell with any resulting impairment recognized. Assets related to discontinued operations and assets of disposal group held for sale are not depreciated or amortized. The prior year consolidated balance sheet is not restated.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If in a subsequent period, the criteria for classification as held for sale are no longer met, the recoverable amount of assets and liabilities are reclassified out of </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-6</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">assets held for sale into the respective balance sheet lines, prior year consolidated balance sheet is not restated. The cumulative amount of depreciation and amortization not recorded since the date of their classification to assets held for sale, and any required adjustments to the recoverable amounts of assets are recognized in the consolidated income statement.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Distribution of Alcon Inc. to Novartis AG shareholders </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During the first quarter of 2019, at the Annual General Meeting (AGM) of Novartis AG shareholders, held on February 28, 2019, the Novartis AG shareholders approved a special distribution by way of a dividend in kind to effect the spin-off of Alcon Inc. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The February 28, 2019, shareholder approval for the spin-off required the Alcon Division and selected portions of corporate activities attributable to Alcon&#x2019;s business (the &#x201C;Alcon business&#x201D;) to be reported as discontinued operations. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The shareholder approval to spin off the Alcon business also required the recognition of a distribution liability at the fair value of the Alcon business. The Group elected to measure the distribution liability at the fair value of the Alcon business net assets taken as a whole. The distribution liability was recognized through a reduction in retained earnings. It was required to be adjusted at each balance sheet date for changes in its estimated fair value, up to the date of the distribution to shareholders through retained earnings. Any resulting impairment of the business assets to be distributed would have been recognized in the consolidated income statements in &#x201C;Other expense&#x201D; of discontinued operations, at the date of initial recognition of the distribution liability or at subsequent dates resulting from changes of the distribution liability valuation. At the April 8, 2019 distribution settlement date, the resulting gain, which was measured as the excess amount of the distribution liability over the then-carrying value of the net assets of the business distributed, was recognized on the line &#x201C;Gain on distribution of Alcon Inc. to Novartis AG shareholders&#x201D; in the income statement of discontinued operations.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The recognition of the distribution liability required the use of valuation techniques for purposes of impairment testing of the Alcon business&#x2019; assets to be distributed and for the measurement of the fair value of the distribution liability. These valuations required the use of management assumptions and estimates related to the Alcon business&#x2019; future cash flows, market multiples to estimate day one market value, and control premiums to apply in estimating the Alcon business fair value. These fair value measurements were classified as &#x201C;Level 3&#x201D; in the fair value hierarchy. The section &#x201C;&mdash;Impairment of goodwill and intangible assets&#x201D; in this Note 1 provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Transaction costs that were directly attributable to the distribution (spin-off) of Alcon to the Novartis shareholders, and that would otherwise have been avoided, were recorded as a deduction from equity.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For additional disclosures, refer to &#x201C;Note 2. Significant transactions&mdash;Significant transactions in 2019&mdash;Completion of the spin-off of the Alcon business through a dividend in kind distribution to Novartis AG shareholders,&#x201D; and &#x201C;Note 30. Discontinued operations.&#x201D;</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Acquisition of assets and businesses</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Assets separately acquired are recorded at cost, which includes the purchase price and any directly attributable costs for bringing the asset into the condition to operate as intended. Expected costs for obligations to dismantle and remove property, plant and equipment when they are no longer used are included in their cost.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Acquired businesses are accounted for using the acquisition method, unless the optional concentration test is applied. The optional concentration test allows for the election on a transaction-by-transaction basis to account for the acquired business as an asset separately acquired when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The acquisition method requires that the assets acquired and liabilities assumed be recorded at their respective fair values on the date the Group obtains control. The excess of the fair value of the total purchase consideration transferred and the fair value of the acquired assets and assumed liabilities is recognized as goodwill. The related valuations are based on information available at the acquisition date. Acquisition related costs are expensed as incurred.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The application of the acquisition method requires certain estimates and assumptions to be made, especially concerning the fair values of the acquired intangible assets, inventories, property, plant and equipment and the liabilities assumed at the acquisition date, and the useful lives of the intangible assets and property, plant and equipment. Estimates of fair value require the use of valuation techniques. These valuations require the use of management assumptions and estimates, including value of comparable assets in the market, amount and timing of future cash flows, outcomes and costs of research and development activities, probability of obtaining regulatory approval, long-term sales forecasts, actions of competitors, discount rates and terminal growth rates. The section &#x201C;&mdash;Impairment of goodwill and intangible assets&#x201D; in this Note 1 provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Property, plant and equipment</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Property, plant and equipment are depreciated on a straight-line basis in the consolidated income statement over their estimated useful lives. Freehold land is not depreciated. The related depreciation expense is included in the costs of the functions using the asset.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Property, plant and equipment are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-7</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the respective useful lives for property, plant and equipment:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Useful life</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buildings</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20 to 40 years</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and other equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7 to 20 years</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Furniture and vehicles</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 10 years</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Computer hardware</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 7 years</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Government grants obtained for construction activities, including any related equipment, are deducted from the gross acquisition cost to arrive at the balance sheet carrying value of the related assets.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Leases and right-of-use assets</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">From January 1, 2019, with the adoption of IFRS 16 Leases, the Group adopted the following accounting policies for leases and right-of-use assets:</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As lessee, the Group assesses whether a contract contains a lease at inception of a contract and upon the modification of a contract. The Group elected to allocate the consideration in the contract to the lease and non-lease components on the basis of the relative standalone price. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a lessee, except for leases with a term of 12 months or less (short-term leases) and low-value leases. For these short-term and low-value leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease to the end of the lease term. The lease term includes the period of any lease extension that in management&#x2019;s assessment is highly probable to be exercised by the Group. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the Novartis incremental borrowing rate for the asset subject to the lease in the respective markets.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever there is a change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The portion of the lease payments attributable to the repayment of lease liabilities is recognized in cash flows used in financing activities, and the portion attributable to the payment of interest is included in cash flows from operating activities.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are initially recognized on the balance sheet at cost, which comprises the amount of the initial measurement of the corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease incentive received and any initial direct costs incurred by Novartis, and expected costs for obligations to dismantle and remove right-of-use assets when they are no longer used.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease over the shorter of the useful life of the right-of-use asset or the end of the lease term. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In arrangements where the Group is the lessor, it determines at lease inception whether the lease is a finance lease or an operating lease. Leases that transfer substantially all of the risk and rewards incidental to ownership of the underlying asset to the counterparty (the lessee) are accounted for as finance leases. Leases that do not transfer substantially all of the risks and rewards of ownership are accounted for as operating leases. Lease payments received under operating leases are recognized on a straight-line basis over the lease term in the consolidated income statement in either &#x201C;net sales&#x201D; or &#x201C;other income,&#x201D; depending on the nature of and underlying asset to the lease arrangement.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Prior to January 1, 2019, the Group applied the following accounting policies for leases: </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Leases that transferred substantially all of the risks and rewards of ownership were recognized as finance leases, with the leased asset measured initially at an amount equal to the lower of their fair value and the present value of the minimum lease payments. Minimum lease payments were the payments over the lease term that the Group, as leasee, was required to make, excluding contingent rent. The underlying asset was accounted for in accordance with the accounting policy applicable to that asset. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Leases that did not transfer substantially all of the risks and rewards of ownership were accounted for as operating leases and were not recognized in the consolidated balance sheet. Payments made under operating leases were recognized in the consolidated income statement on a straight-line basis over the term of the lease. Lease incentives received were deferred and recognized as a component of lease expense over the term of the lease. The future undiscounted lease payments under operating leases were disclosed as commitments in the notes to the consolidated financial statements.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Lessor accounting policies were not substantially different from those applied upon the adoption of IFRS 16 Leases, as described above. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The section &#x201C;&mdash;Impact of adopting significant new IFRS standards in 2019&#x201D; in this Note 1 provides additional disclosures on the impact of adoption of IFRS 16 Leases. </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Goodwill and intangible assets</font>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Goodwill</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Goodwill arises in the acquisition of a business when applying the acquisition method and is the excess of the fair value of the consideration transferred to acquire a business over the underlying fair value of the net identified assets acquired. It is allocated to groups of cash-generating units (CGUs), which are usually represented by the reported segments. Goodwill is tested for impairment </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-8</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">annually at the level of these groups of CGUs, and any impairment charges are recorded under &#x201C;Other expense&#x201D; in the consolidated income statement.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Intangible assets available for use</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has the following classes of available for use intangible assets: currently marketed products; technologies; other intangible assets (including computer software).</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Currently marketed products represent the composite value of acquired intellectual property (IP), patents, distribution rights and product trade names.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Technologies represent identified and separable acquired know-how used in the research, development and production processes.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Significant investments in internally developed and acquired computer software are capitalized and included in the &#x201C;Other&#x201D; category, and amortized once available for use.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Intangible assets available for use with a definite useful life are amortized over their estimated useful lives on a straight-line basis and are evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the respective useful lives for intangible assets available for use and the location in the consolidated income statement in which the respective amortization and any potential impairment charge is recognized:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Useful life</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income statement location<br> for amortization and<br> impairment charges</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 20 years</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Technologies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10 to 20 years    </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"   or "Research   and development"</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other (including computer software)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 7 years  </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> In the respective   functional expense</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Intangible assets not yet available for use</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Acquired research and development intangible assets that are still under development and have accordingly not yet obtained marketing approval are recognized as in-process research and development (IPR&amp;D).</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">IPR&amp;D is not amortized, but is evaluated for potential impairment on an annual basis or when facts and circumstances warrant. Any impairment charge is recorded in the consolidated income statement under &#x201C;Research and development.&#x201D; Once a project included in IPR&amp;D has been successfully developed, it is transferred to the &#x201C;Currently marketed products&#x201D; category.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impairment of goodwill and intangible assets</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">An asset is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value-in-use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or CGUs, and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group&#x2019;s activities with regard to:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Amount and timing of projected future cash flows</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Long-term sales forecasts </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Actions of competitors (launch of competing products, marketing initiatives, etc.)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Sales erosion rates after the end of patent or other intellectual property rights protection, and timing of the entry of generic competition</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Outcome of research and development activities (compound efficacy, results of clinical trials, etc.)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Amount and timing of projected costs to develop IPR&amp;D into commercially viable products</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Profit margins</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Probability of obtaining regulatory approval</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Future tax rate</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Appropriate terminal growth rate</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Appropriate discount rate</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Generally, for intangible assets with a definite useful life, Novartis uses cash flow projections for the whole useful life of these assets. For goodwill, Novartis generally utilizes cash flow projections for a five-year period based on management forecasts, with a terminal value based on cash flow projections usually in line with inflation rates for later periods. Probability-weighted scenarios are typically used.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Discount rates used consider the Group&#x2019;s estimated weighted average cost of capital, adjusted for specific asset, country and currency risks associated with cash flow projections, to approximate the discount rate that market participants would use to value the asset.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Due to the above factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impairment of associated companies accounted for at equity</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis considers investments in associated companies for impairment evaluation whenever objective evidence indicates the net investment may be impaired, including when a quoted share price indicates a fair value less than the per-share balance sheet carrying value for the investment.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-9</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If the recoverable amount of the investment is estimated to be lower than the balance sheet carrying amount, an impairment charge is recognized for the difference in the consolidated income statement under &#x201C;Income from associated companies.&#x201D; </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Cash and cash equivalents</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash and cash equivalents include highly liquid investments with original maturities of three months or less, which are readily convertible to known amounts of cash. Bank overdrafts are usually presented within current financial debts on the consolidated balance sheet, except in cases where a right of offset has been agreed with a bank, which then allows for presentation on a net basis.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Marketable securities, commodities and non-current financial assets </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Commodities, which include gold bullion or coins, are valued at the lower of cost or fair value using current market prices. The changes in fair value below cost are immediately recorded in &#x201C;Other financial income and expense.&#x201D;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities are financial assets held for short-term purposes which are principally traded in liquid markets and are classified within current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#x201C;Other financial income and expense&#x201D; in the consolidated income statement. Non-current financial assets held for long-term strategic purposes are classified within non-current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#x201C;Other income&#x201D; and &#x201C;Other expense&#x201D; in the consolidated income statement.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities and non-current financial assets are initially recorded at fair value on their trade date, which is different from the settlement date when the transaction is ultimately effected. Quoted securities are remeasured at each reporting date to fair value based on current market prices. If the market for a financial asset is not active or no market is available, fair values are established using valuation techniques. The majority of non-quoted investments are valued initially at fair value through the established purchase price between a willing buyer and seller. Non-quoted investments are subsequently adjusted based on values derived from discounted cash flow analysis or other pricing models. These investment values are classified as &#x201C;Level 3&#x201D; in the fair value hierarchy.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group classifies and accounts for its marketable securities and non-current financial assets in the following categories:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Debt securities are valued at fair value through other comprehensive income with subsequent recycling into the consolidated income statement, as they meet both the &#x201C;solely payment of principal and interest&#x201D; and the business model criteria. Unrealized gains and losses, except exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are recognized in the consolidated income statement when the debt instrument is sold, at which time the gain is transferred to &#x201C;Other financial income and expense.&#x201D; Exchange gains and losses related to debt instruments are immediately recognized in the consolidated income statement to &#x201C;Other financial income and expense.&#x201D;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Fund investments and equity securities of the Novartis venture fund are valued at fair value through profit and loss (FVPL). Unrealized gains and losses, including exchange gains and losses, are recognized in the consolidated income statement to &#x201C;Other income&#x201D; for gains and &#x201C;Other expense&#x201D; for losses.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Equity securities held as strategic investments, typically held outside of the Novartis venture fund, are generally designated at the date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. Unrealized gains and losses, including exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are reclassified to retained earnings when the equity security is sold. If these equity securities are not designated at the date of acquisition as financial assets valued at fair value through other comprehensive income, they are valued at FVPL, as described above.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Other non-current financial assets, such as loans and long-term receivables from customers, advances and other deposits, are valued at amortized cost, which reflects the time value of money less any allowances for expected credit losses.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group assesses on a forward-looking basis the expected credit losses associated with its debt securities valued at fair value through other comprehensive income. Impairments on debt securities are recorded in &#x201C;Other financial income and expense.&#x201D;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For other financial assets valued at amortized cost, impairments, which are based on their expected credit losses, and exchange rate losses are included in &#x201C;Other expense&#x201D; in the consolidated income statement. Exchange rate gains and interest income, using the effective interest rate method, are included in &#x201C;Other income&#x201D; or &#x201C;Other financial income&#x201D; in the consolidated income statement, depending on the nature of the item.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Derivative financial instruments</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Derivative financial instruments are initially recognized in the balance sheet at fair value and are remeasured to their current fair value at the end of each subsequent reporting period. The valuation of a forward exchange rate contract is based on the discounted cash flow model, using interest curves and spot rates at the reporting date as observable inputs.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Options are valued based on a modified Black-Scholes model using volatility and exercise prices as major observable inputs.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group utilizes derivative financial instruments for the purpose of hedging to reduce the volatility in the Group&#x2019;s performance due to the exposure to various business related risks. To mitigate these risks, the Group </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-10</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">enters into certain derivative financial instruments. The risk reduction is obtained because the derivative&#x2019;s value or cash flows are expected, wholly or partly, to offset changes in the value or cash flows of the recognized assets or liabilities. The overall strategy is aiming to mitigate the currency and interest rate risk of positions that are contractually agreed, and to partially mitigate the exposure risk of selected anticipated transactions.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Certain derivative financial instruments meet the criteria for hedge accounting treatment. A prerequisite for obtaining this accounting-hedge relationship is extensive documentation on inception and proving on a regular basis that the economic hedge is effective for accounting purposes. Other derivative financial instruments do not meet the criteria to qualify for hedge accounting. Changes in the fair value of these derivative instruments are recognized immediately in &#x201C;Other financial income and expense&#x201D; in the consolidated income statement.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, the Group has designated certain long-term debt components as hedges of the translation risk arising on certain net investments in foreign operations. On consolidation, foreign currency differences arising on long-term debt designated as net investment hedges of a foreign operation are recognized in other comprehensive income and accumulated in currency translation effects, to the extent that the hedge is effective. The foreign currency differences arising from hedge ineffectiveness are recognized in the income statement in &#x201C;Other financial income and expense.&#x201D;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">When a hedged net investment is disposed of, the proportionate portion of the cumulative amount recognized in equity in relation to the hedged net investment is transferred to the consolidated income statement as an adjustment to the gain or loss on disposal.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Inventories</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inventory is valued at the lower of acquisition or production cost determined on a first-in, first-out basis and net realizable value. This value is used for the &#x201C;Cost of goods sold&#x201D; in the consolidated income statement. Unsaleable inventory is fully written off in the consolidated income statement under &#x201C;Cost of goods sold.&#x201D;</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Trade receivables</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Trade receivables are initially recognized at their invoiced amounts, including any related sales taxes less adjustments for estimated revenue deductions such as rebates, chargebacks and cash discounts.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The provisions for doubtful trade receivables are established using an expected credit loss model (ECL). The provisions are based on a forward-looking ECL, which includes possible default events on the trade receivables over the entire holding period of the trade receivable. These provisions represent the difference between the trade receivable&#x2019;s carrying amount in the consolidated balance sheet and the estimated collectible amount. Charges for doubtful trade receivables are recorded as marketing and selling costs recognized in the consolidated income statement within &#x201C;Selling, general and administration&#x201D; expenses.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Legal and environmental liabilities</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis and its subsidiaries are subject to contingencies arising in the ordinary course of business, such as patent litigation, environmental remediation liabilities and other product-related litigation, commercial litigation, and governmental investigations and proceedings. Provisions are recorded where a reliable estimate can be made of the probable outcome of legal or other disputes against the subsidiary.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Contingent consideration</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In an acquisition or a divestment of a business, it is necessary to recognize contingent future amounts due to previous owners, representing contractually defined potential amounts as a liability or an asset. Usually for Novartis, these are linked to milestone or royalty payments related to certain assets and are recognized as a financial liability or financial asset at fair value, which is then remeasured at each subsequent reporting date. These estimations typically depend on factors such as technical milestones or market performance, and are adjusted for the probability of their likelihood of payment, and are appropriately discounted to reflect the impact of time.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the consolidated income statement in &#x201C;Cost of goods sold&#x201D; for currently marketed products and in &#x201C;Research and development&#x201D; for IPR&amp;D. Changes in contingent consideration assets are recognized in &#x201C;Other income&#x201D; or &#x201C;Other expense,&#x201D; depending on their nature. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The effect of unwinding the discount over time is recognized for contingent liabilities in &#x201C;Interest expense&#x201D; and for contingent assets as interest income recognized in the consolidated income statement within &#x201C;Other financial income and expense.&#x201D;</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Defined ben</font><font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">efit pension plans and&nbsp;other&nbsp;post-employment benefits</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The liability in respect of defined benefit pension plans and other post-employment benefits is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions in which associates are employed, while the net interest on the net defined benefit liability or asset is recognized as &#x201C;Other expense&#x201D; or &#x201C;Other income.&#x201D;</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Treasury shares</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Treasury shares are initially recorded at fair value on their trade date, which is different from the settlement date, when the transaction is ultimately effected. Treasury shares are deducted from consolidated equity at their nominal value of CHF&nbsp;0.50 per share. Differences between the nominal amount and the transaction price on purchases or sales of treasury shares with third par-</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-11</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">ties, or the value of services received for the shares allocated to associates as part of share-based compensation arrangements, are recorded in &#x201C;Retained earnings&#x201D; in the consolidated statement of changes in equity.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Revenue recognition</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Revenue on the sale of Novartis Group products and services, which is recorded as &#x201C;Net sales&#x201D; in the consolidated income statement, is recognized when a contractual promise to a customer (performance obligation) has been fulfilled by transferring control over the promised goods and services to the customer, substantially all of which is at the point in time of shipment to or receipt of the products by the customer or when the services are performed. If contracts contain customer acceptance provisions, revenue is recognized upon the satisfaction of the acceptance criteria. If products are stockpiled at the request of the customer, revenue is only recognized once the products have been inspected and accepted by the customer, and there is no right of return or replenishment on product expiry. The amount of revenue recognized is based on the consideration Novartis expects to receive in exchange for its goods and services, when it is highly probable that a significant reversal will not occur. If a contract contains more than one performance obligation, the consideration is allocated based on the standalone selling price of each performance obligation. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consideration Novartis receives in exchange for its goods or services may be fixed or variable. Variable consideration is only recognized when it is highly probable that a significant reversal will not occur. The most common elements of variable consideration are listed below.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Rebates and discounts granted to government agencies, wholesalers, retail pharmacies, managed healthcare organizations and other customers, as well as chargebacks are provisioned and recorded as a revenue deduction at the time the related revenues are recorded or when the incentives are offered. They are calculated on the basis of historical experience, regulations, the specific terms in the individual agreements, product pricing and the mix of products, contracts, channels and payors.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Refunds granted to healthcare providers under innovative pay-for-performance agreements (i.e., outcome based arrangements) are provisioned and recorded as a revenue deduction at the time the related sales are recorded. They are calculated on the basis of historical experience and clinical data available for the product, as well as the specific terms in the individual agreements. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until the uncertainty is resolved or until such history is available.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Cash discounts are offered to customers to encourage prompt payment and are provisioned and recorded as revenue deductions at the time the related sales are recorded.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Shelf stock adjustments are generally granted to customers, primarily of the Sandoz Division, to cover the inventory held by them at the time a price decline becomes effective. Revenue deduction provisions for shelf stock adjustments are recorded when the price decline is anticipated, based on the impact of the price decline on the customer&#x2019;s estimated inventory levels. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Sales returns provisions are recognized and recorded as revenue deductions when there is historical experience of Novartis agreeing to customer returns and Novartis can reasonably estimate expected future returns. In doing so, the estimated rate of return is applied, determined on the basis of historical experience of customer returns and considering any other relevant factors. This is applied to the amounts invoiced, also considering the amount of returned products to be destroyed versus products that can be placed back in inventory for resale. Where shipments are made on a resale or return basis, without sufficient historical experience for estimating sales returns, revenue is only recorded when there is evidence of consumption or when the right of return has expired. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Net sales and provisions for revenue deductions are adjusted to actual amounts as rebates, refunds, discounts and returns are processed. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these sales deductions.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">&#x201C;Other revenue&#x201D; includes income from profit-sharing arrangements with our collaboration partners, and royalty and milestone income from the out-licensing of intellectual property when Novartis retains an interest in the intellectual property through a license. Royalty income earned through a license is recognized when the underlying sales have occurred. Milestone income is recognized at the point in time when it is highly probable that the relevant milestone event criteria are met, and the risk of reversal of revenue recognition is remote. Other revenue also includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales, and is recognized when control transfers to the third party and our performance obligations are satisfied.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Research and development</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Internal research and development (R&amp;D) costs are fully charged to &#x201C;Research and development&#x201D; in the consolidated income statement in the period in which they are incurred. The Group considers that regulatory and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained in a major market such as the United States, the European Union, Switzerland or Japan.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Payments made to third parties, such as contract research and development organizations in compensation for subcontracted R&amp;D, that are deemed not to transfer intellectual property to Novartis are expensed as internal R&amp;D expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-12</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">been achieved from a regulatory authority in a major market.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Payments made to third parties to in-license or acquire intellectual property rights, compounds and products, including initial upfront and subsequent milestone payments, are capitalized, as are payments for other assets, such as technologies to be used in R&amp;D activities. If additional payments are made to the originator company to continue to perform R&amp;D activities, an evaluation is made as to the nature of the payments. Such additional payments will be expensed if they are deemed to be compensation for subcontracted R&amp;D services not resulting in an additional transfer of intellectual property rights to Novartis. Such additional payments will be capitalized if they are deemed to be compensation for the transfer to Novartis of additional intellectual property developed at the risk of the originator company. Subsequent internal R&amp;D costs in relation to IPR&amp;D and other assets are expensed, since the technical feasibility of the internal R&amp;D activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Costs for post-approval studies performed to support the continued registration of a marketed product are recognized as marketing expenses. Costs for activities that are required by regulatory authorities as a condition for obtaining marketing approval are capitalized and recognized as currently marketed products.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Inventory produced ahead of regulatory approval is fully provisioned, and the charge is included in &#x201C;Other expense&#x201D; in the consolidated income statement, as its ultimate use cannot be assured. If this inventory can be subsequently sold, the provision is released to &#x201C;Other income&#x201D; in the consolidated income statement, either on approval by the appropriate regulatory authority or, exceptionally in Europe, on recommendation by the Committee for Medicinal Products for Human Use (CHMP), if approval is virtually certain.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Share-based compensation</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Vested Novartis shares and American Depositary Receipts (ADRs) that are granted as compensation are valued at their market value on the grant date and are immediately expensed in the consolidated income statement.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair values of unvested restricted shares (RSs), restricted share units (RSUs) and performance share units (PSUs) in Novartis shares and ADRs granted to associates as compensation are recognized as an expense over the related vesting period. The expense recorded in the consolidated income statement is included in the personnel expenses of the various functions in which the associates are employed.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Unvested restricted shares, restricted ADRs and RSUs are only conditional on the provision of services by the plan participant during the vesting period. They are valued at fair value on the grant date. As RSUs do not entitle the holder to dividends, the fair value is based on the Novartis share price at the grant date adjusted for the net present value of the dividends expected to be paid during the holding period. The fair value of these grants, after making adjustments for assumptions related to forfeiture during the vesting period, is expensed on a straight-line basis over the respective vesting period.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">PSUs are subject to the achievement of certain performance criteria during the vesting period and require plan participants to provide services during this period. The following paragraphs provide an overview of the accounting policies for the share-based compensation plans that grant PSUs. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs granted under plans that are subject to performance criteria based on Novartis internal performance metrics and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on assumptions concerning the expected performance against the internal performance metrics throughout the vesting period. The assumptions are based on the Group&#x2019;s targets for those performance metrics, and the expected forfeitures due to plan participants not meeting their service conditions. The assumptions are periodically adjusted over the vesting period. Any change in estimates for past services is recorded immediately as an expense or income in the consolidated income statement, and amounts for the remaining vesting period are expensed on a straight-line basis. As a result, at the end of the vesting period, the charge during the entire vesting period represents the amount that will finally vest. The number of equity instruments that finally vest is determined at the vesting date.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs granted under plans that are subject to performance criteria based on variables that can be observed in the market, which for Novartis plans is the Novartis total shareholder return (TSR) relative to a specific peer group of companies over the vesting period, and that are conditional on the provision of services by the plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on the total fair value of the grant over the vesting period. IFRS requires that these variables that can be observed in the market are taken into account in determining the fair value of the PSUs at the grant date. Novartis determined the fair value of these PSUs at the date of grant using a Monte Carlo simulation model. Adjustments to the number of equity instruments granted are only made if a plan participant does not fulfill the service conditions.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs granted under plans that are subject to both performance criteria based on Novartis internal performance metrics and Novartis TSR relative to a specific peer group of companies over the vesting period and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on a bifurcation into the components based on the performance criteria related to Novartis internal performance metrics and TSR, as described in the paragraphs above. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Measuring the fair values of PSUs granted that include TSR performance criteria requires use of estimates. The Monte Carlo simulation used to determine the fair value of the PSUs TSR performance criteria requires the probability of factors related to uncertain future events; the term of the award; the grant price of underlying shares or ADRs; expected volatilities; the </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-13</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">expected correlation matrix of the underlying equity instruments with those of the peer group of companies; and the risk-free interest rate as input parameters.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If a plan participant leaves Novartis for reasons other than retirement, disability or death, then unvested restricted shares, restricted ADRs, RSUs and PSUs are forfeited, unless determined otherwise by the provision of the plan rules or by the Compensation Committee of the Novartis Board of Directors, for example, in connection with a reorganization or divestment.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Government grants</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Grants from governments or similar organizations are recognized at their fair value when there is a reasonable assurance that the grant will be received and the Group will comply with all attached conditions.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Government grants received to compensate for cost are deferred and recognized in the consolidated income statement over the period necessary to match them against the related costs that they are intended to compensate.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The accounting policy for property, plant and equipment describes the treatment of any related grants.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Restructuring charges</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Restructuring provisions are recognized for the direct expenditures arising from the restructuring, where the plans are sufficiently detailed and where appropriate communication to those affected has been made.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Charges to increase restructuring provisions are included in &#x201C;Other expense&#x201D; in the consolidated income statements. Corresponding releases are recorded in &#x201C;Other income&#x201D; in the consolidated income statement. </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Healthcare contributions</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Healthcare contribution levies and fees under governmental programs that require the Group to contribute to a country&#x2019;s healthcare costs, other than programs described in Revenue recognition in this Note 1, are recognized in Other expense in the consolidated income statement. Provisions for healthcare contributions are adjusted to the actual amounts levied. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these healthcare contributions. </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Taxes</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Taxes on income are provided in the same periods as the revenues and expenses to which they relate and include interest and penalties incurred during the period. Deferred taxes are determined using the comprehensive liability method and are calculated on the temporary differences that arise between the tax base of an asset or liability and its carrying value in the balance sheet prepared for consolidation purposes, except for those temporary differences related to investments in subsidiaries and associated companies, where the timing of their reversal can be controlled and it is probable that the difference will not reverse in the foreseeable future. Since the retained earnings are reinvested, withholding or other taxes on eventual distribution of a subsidiary&#x2019;s retained earnings are only taken into account when a dividend has been planned.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimated amounts for current and deferred tax assets or liabilities, including any amounts related to any uncertain tax positions, are based on currently known facts and circumstances. Tax returns are based on an interpretation of tax laws and regulations, and reflect estimates based on these judgments and interpretations. The tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made requiring payments of additional tax, interest or penalties. Inherent uncertainties exist in the estimates of the tax positions.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impact of adopting significant new IFRS standard in 2020</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following new IFRS standard has been adopted by Novartis from January 1, 2020:</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">IFRS 3 Business Combination amendments</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The IASB issued amendments to IFRS 3 Business Combinations that revised the definition of a business, which assist entities with the evaluation of when an asset or group of assets acquired should be considered a business. This amended standard has been applied to transactions entered into on or after January 1, 2020. The amended standard allows an entity to apply an optional concentration test, on a transaction-by-transaction basis, to evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this optional concentration test is met, the set of activities and assets is determined not to be a business. The adoption of this amended standard on January 1, 2020 did not have a significant impact on our consolidated financial statements and is not expected to have a significant impact in future periods. However, this will depend on the facts and circumstances of future transactions and if the Group decides to apply the optional concentration test in the assessment of whether an acquired set of activities and assets is or is not a business.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">There are no other IFRS standards or interpretations not yet effective that would be expected to have a material impact on the Group.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impact of adopting significant new IFRS standard in 2019</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following new IFRS standard has been adopted by Novartis from January 1, 2019: </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">IFRS 16 Leases</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">IFRS 16 Leases substantially changed the financial statements, as the majority of leases for which the Group is </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-14</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">the lessee became on-balance sheet liabilities with corresponding right-of-use assets also recognized on the balance sheet. The lease liability reflects the net present value of the remaining lease payments, and the right-of-use asset corresponds to the lease liability, adjusted for payments made before the commencement date, lease incentives and other items related to the lease agreement. The standard replaces IAS 17 Leases and related interpretations. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Upon adoption of the new standard, a portion of the annual operating lease costs, which was previously fully recognized as functional expenses, as a component of operating income, is recorded as interest expense. In addition, the portion of the lease payments that represents the reduction of the lease liability is recognized in the cash flow statement as an outflow from financing activities, which was previously fully recognized as an outflow from operating activities. Given the leases involved, these effects are not significant to the consolidated income statement and consolidated statement of cash flow.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group implemented the new standard on January 1, 2019, and applied the modified retrospective method, with right-of-use assets measured at an amount equal to the lease liability, adjusted by the amount of the prepaid or accrued lease payments relating to those leases recognized in the balance sheet immediately before the date of initial application and did not restate prior years.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Results of our impact assessment:  </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The undiscounted operating lease commitments as of December 31, 2018, amounted to USD 3.6 billion. This includes approximately USD 0.1 billion of leases with a commencement date in 2019, as well as short-term leases and low-value leases that are recognized from January 1, 2019, upon adoption of IFRS 16, on a straight-line basis as expense in profit and loss. This also includes USD 0.2 billion lease commitments related to the Alcon Division, which is attributable to discontinued operation in 2019. For the remaining undiscounted lease commitments attributable to continuing operations of USD 3.3 billion, the Group recognized on January 1, 2019, lease liabilities of USD 1.74 billion and right-of-use assets of USD 1.55 billion (after the reclassification of USD 0.1 billion from property, plant and equipment, and net adjustments for the USD 0.3 billion recognition of sublease receivables, prepayments, and accrued lease payments recognized as at December 31, 2018). For the lease commitments attributable to discontinued operations, the Group recognized on January 1, 2019, lease liabilities and right-of-use assets of USD 0.2 billion. This does not include the discontinued operations right-of-use assets and lease liability on finance lease agreements of USD 75 million and USD 89 million, respectively. There was an insignificant increase to retained earnings upon adoption of IFRS 16 of USD 3 million that arose from subleases that were accounted for as operating lease agreements under IAS 17 and are accounted for as finance leases under IFRS 16.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As a lessor, the Group had no significant impact upon adoption. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">For additional significant accounting policies applicable to the discontinued operations business see Note 30.</div><a name="anchorId001544667"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">2. Significant transactions</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions in 2020</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group applied the acquisition method of accounting for businesses acquired, and did not elect to apply the optional concentration test to account for acquired business as an asset separately acquired.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &ndash; acquisition of The&nbsp;Medicines Company</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 23, 2019, Novartis entered into an agreement and plan of merger (the Merger Agreement) with The Medicines Company, a US-based pharmaceutical company headquartered in Parsippany, New Jersey USA. Pursuant to the Merger Agreement, on December 5, 2019, Novartis, through a subsidiary, commenced a tender offer to acquire all outstanding shares of The Medicines Company for USD 85 per share, or a total consideration of approximately USD 9.6 billion in cash on a fully diluted basis, including the equivalent share value related to The Medicines Company&#x2019;s convertible notes, in accordance with their terms. The tender offer expired on January 3, 2020, and on January 6, 2020, the acquiring subsidiary merged with and into The Medicines Company, resulting in The Medicines Company becoming an indirect wholly owned subsidiary of Novartis. Novartis financed the transaction through available cash, and short- and long-term borrowings. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Medicines Company is focused on the development of inclisiran, a potentially first-in-class, twice yearly therapy that allows administration during patients&#x2019; routine visits to their healthcare professionals and will potentially contribute to improved patient adherence and sustained lower LDL-C levels.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was USD 9.6 billion. The purchase price allocation resulted in net identifiable assets of approximately USD 7.1 billion, consisting of USD 8.5 billion intangible assets, USD 1.4 billion net deferred tax liabilities and goodwill of approximately USD 2.5 billion. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Results of operations since the date of acquisition were not material.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-15</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz &ndash; acquisition of the Japanese business of Aspen Global Incorporated </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 11, 2019, Sandoz entered into an agreement for the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. Under the agreement, Sandoz acquired the shares in Aspen Japan K.K. and associated assets held by AGI. The transaction closed on January 31, 2020.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Aspen&#x2019;s portfolio in Japan consists of off-patent medicines with a focus on anesthetics and specialty brands. The acquisition will enable Sandoz to expand its presence in the third-largest worldwide generics marketplace.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The purchase price consists of EUR 274 million (USD 303 million) upfront payment, less customary purchase price adjustment of EUR 27 million (USD 30 million), plus potential milestone payments of up to EUR 70 million (USD 77 million), which AGI is eligible to receive upon the achievement of specified milestones.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was EUR 294 million (USD 324 million). The amount consisted of a cash payment of EUR 247 million (USD 273 million) and the fair value of contingent consideration of EUR 47 million (USD 51 million), which AGI is eligible to receive upon the achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD 238 million, consisting of USD 196 million intangible assets, USD 26 million other net assets, USD 16 million net deferred tax assets. Goodwill amounted to USD 86 million. Results of operations since the date of acquisition were not material.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz &ndash; retention of US dermatology business and generic US oral solids portfolio, previously planned to be divested</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On September 6, 2018, Novartis announced that it entered into a stock and asset purchase agreement (SAPA) with Aurobindo Pharma USA Inc. (Aurobindo) for the sale of selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, for USD 0.8 billion in cash and potential earnouts. The closing was conditional on obtaining regulatory approval.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In March 2020, Novartis took the decision to retain the Sandoz US generic oral solids and dermatology businesses and on April 2, 2020 entered into a mutual agreement with Aurobindo to terminate the transaction. The decision was taken as approval from the US Federal Trade Commission for the transaction was not obtained within the agreed timelines.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The cumulative amount of the depreciation on property, plant and equipment (USD 38 million) and amortization on intangible assets (USD 102 million), not recorded in the consolidated income statement since the date of classification as held for sale was recognized in the consolidated income statement in the first quarter of 2020. In addition, an impairment of currently marketed products of USD 42 million was recognized in the first quarter of 2020 consolidated income statement.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As at March 31, 2020, the assets and liabilities of the Sandoz US generic oral solids and dermatology businesses were reclassified out of assets and liabilities of disposal group held for sale. The prior year balance sheet is not required to be restated.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the Group&#x2019;s consolidated balance sheet at December 31, 2019, the assets and liabilities classified as disposal group assets and liabilities held for sale consisted of the following:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31,<br> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Assets of disposal group classified as held for sale</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 169</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets other than goodwill</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 475</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 181</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 841</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31,<br> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Liabilities of disposal group classified as held for sale</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other non-current  liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There were no cumulative income or expenses included in the other comprehensive income relating to the disposal group.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions in 2019</font>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Completion of the spin-off of the Alcon business through a dividend in kind distribution to Novartis AG shareholders </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On June 29, 2018, Novartis announced its intention to seek shareholder approval for the spin-off of the Alcon business into a separately traded standalone company, following the complete structural separation of the Alcon business into a standalone company (the Alcon business or Alcon Inc.). </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Novartis AG shareholders approved the spin-off of the Alcon business at the 2019 Annual General Meeting held on February 28, 2019, subject to completion of certain conditions precedent to the distribution. Upon shareholder approval, the Alcon business was reported as discontinued operations, and the fair value of the Alcon business exceeded the carrying value of its net assets.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The conditions precedent to the spin-off were met and on April 8, 2019 the spin-off of the Alcon business was effected by way of a distribution of a dividend in kind of Alcon Inc. shares to Novartis AG shareholders and ADR (American Depositary Receipt) holders (the Distribution), which amounted to USD 23.4 billion and is recognized as a reduction to retained earnings. Through the </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-16</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Distribution, each Novartis AG shareholder received one Alcon Inc. share for every five Novartis AG shares/ADRs they held on April 8, 2019, close of business. As of April 9, 2019, the shares of Alcon Inc. are listed on the SIX Swiss Exchange (SIX) and on the New York Stock Exchange (NYSE) under the symbol &#x201C;ALC.&#x201D; </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The dividend in kind distribution liability to effect the spin-off of the Alcon business (the distribution liability) amounted to USD 26.4 billion at March 31, 2019, unchanged from its initial recognition on February 28, 2019, and was in excess of the carrying value of the Alcon business net assets as of February 28, 2019, and as of March 31, 2019. The net assets of the Alcon business amounted to USD 23.1 billion as at March 31, 2019.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">On March 6, 2019, Alcon entered into financing arrangements with a syndicate of banks under which it borrowed on April 2, 2019, a total amount of USD 3.2 billion. These borrowings consisted of approximately USD 2.8 billion and the equivalent of USD 0.4 billion in EUR in bridge and other term loans under such Alcon facilities agreement. In addition, approximately USD 0.3 billion of borrowings under a number of local bilateral facilities in different countries, with the largest share of borrowings in Japan, were raised. This resulted in a total gross debt of USD 3.5 billion. These outstanding borrowings of the Alcon legal entities were recorded in the balance sheet and financing cash flow from discontinued operations. Prior to the spin-off, through a series of intercompany transactions, Alcon legal entities paid approximately USD 3.1 billion in cash to Novartis and its affiliates.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">At the April 8, 2019 Distribution, the fair value of the distribution liability of the Alcon business amounted to USD 23.4 billion, a decrease of USD 3.0 billion from March 31, 2019. As mentioned above, prior to the spin-off, through a series of intercompany transactions, Alcon legal entities incurred additional net financial debt and paid approximately USD 3.1 billion in cash to Novartis and its affiliates. This additional net debt and transactions resulted in a decrease in Alcon&#x2019;s net assets to USD 20.0 billion at the date of the Distribution of the dividend in kind to Novartis AG shareholders on April 8, 2019. The distribution liability at April 8, 2019, remained in excess of the then-carrying value of the Alcon business net assets.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Certain consolidated foundations own Novartis AG dividend-bearing shares restricting their availability for use by the Group. These Novartis AG shares are accounted for as treasury shares. Through the Distribution, these foundations received Alcon Inc. shares representing an approximate 4.7% equity interest in Alcon Inc. Upon the loss of control of Alcon Inc. through the Distribution, the financial investment in Alcon Inc. was recognized at its fair value based on the opening traded share price of Alcon Inc. on April 9, 2019 (a Level 1 hierarchy valuation). At initial recognition, its fair value of USD 1.3 billion was reported on the Group&#x2019;s consolidated balance sheet as a financial asset. Management has designated this investment at fair value through other comprehensive income.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The total non-taxable, non-cash gain recognized at the distribution date of the spin-off of the Alcon business amounted to USD 4.7 billion consisting of:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> April 8,<br> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net assets derecognized<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;20&nbsp;025</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derecognition of distribution liability</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23&nbsp;434</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Difference between net assets and distribution liability</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;409</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Recognition of Alcon Inc. shares obtained  through consolidated foundations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1&nbsp;273</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation gains recycled into  the consolidated income statement</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   123</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transaction costs recognized in the  consolidated income statement</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;114</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gain on distribution of Alcon Inc. to  Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   4&nbsp;691</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="4">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="4">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> See Note 30 for additional information.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For additional disclosures on discontinued operations, refer to Note 30.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &ndash; acquisition of IFM Tre, Inc. </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On May 7, 2019, Novartis acquired IFM Tre, Inc., a privately held, US-based biopharmaceutical company focused on developing anti-inflammatory medicines targeting the NLRP3 inflammasome. The acquisition gives Novartis full rights to IFM Tre, Inc.&#x2019;s portfolio of NLRP3 antagonists. The NLRP3 antagonists portfolio consists of one clinical program and two preclinical programs: IFM-2427, a first-in-class, clinical-stage systemic antagonist for an array of chronic inflammatory disorders, including atherosclerosis and nonalcoholic steatohepatitis (NASH); a preclinical-stage gut-directed molecule for the treatment of inflammatory bowel disease; and a preclinical-stage central nervous system (CNS)-penetrant molecule.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The previously held interest of 9% was adjusted to its fair value of USD 33 million through the consolidated income statement at acquisition date. This remeasurement resulted in a gain of USD 14 million. The fair value of the total purchase consideration for acquiring the 91% stake Novartis did not already own amounted to USD 361 million. The amount consisted of an initial cash payment of USD 285 million, and the fair value of the contingent consideration of USD 76 million due to the IFM Tre, Inc. shareholders, which they are eligible to receive upon the achievement of specified development and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 355 million, mainly intangible assets, and goodwill of USD 39 million. The 2019 results of operations since the date of acquisition were not material.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &ndash; acquisition of <i>Xiidra</i></font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On May 8, 2019, Novartis entered into an agreement with Takeda Pharmaceutical Company Limited (Takeda) to acquire the assets associated with <i>Xiidra</i> (lifitegrast ophthalmic solution) 5% worldwide. <i>Xiidra</i> is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease. The transaction bolsters the Novartis front-of-the-eye portfolio and ophthalmic leadership. The transaction closed on July 1, 2019. The purchase price consists of a USD 3.4 billion upfront payment, customary purchase price adjustments of USD 0.1 billion, and the potential milestone payments of up to USD 1.9</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-17</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> billion, which Takeda is eligible to receive upon the achievement of specified commercialization milestones. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration is USD 3.7 billion. The amount consists of an initial cash payment of USD 3.5 billion, and the fair value of the contingent consideration of USD 0.2 billion, which Takeda is eligible to receive upon the achievement of specified commercialization milestones.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The purchase price allocation resulted in net identifiable assets of approximately USD 3.6 billion, consisting mainly of intangible assets of USD 3.6 billion, and goodwill amounted to approximately USD 0.1 billion. In 2019, from the date of acquisition, the business generated net sales of USD 0.2 billion. Management estimates that net sales for the entire year of 2019 would have amounted to USD 0.3 billion, had the business been acquired at the beginning of the 2019 reporting period. The 2019 results of operations since the date of acquisition were not material.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions in 2018</font>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &ndash; acquisition of Advanced Accelerator Applications S.A.</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On October 30, 2017, Novartis entered into a binding memorandum of understanding with Advanced Accelerator Applications S.A. (AAA), a company headquartered in Saint-Genis-Pouilly, France, under which Novartis agreed to commence a tender offer for 100% of the share capital of AAA subject to certain conditions. Novartis commenced the tender offer on December 7, 2017, to purchase all of the outstanding ordinary shares for a price of USD&nbsp;41 per share and USD&nbsp;82 per American Depositary Share (ADS), each representing two ordinary shares of AAA, which expired on January 19, 2018. The offer valued AAA&#x2019;s equity at USD&nbsp;3.9 billion, on a fully diluted basis. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of January 19, 2018, the expiration date of the tender offer, approximately 97% of the then-outstanding fully diluted ordinary shares, including ordinary shares represented by ADSs (hereinafter collectively referred to as &#x201C;the outstanding shares&#x201D;), were validly tendered. On January 22, 2018, Novartis accepted and paid USD 3.9 billion for the outstanding shares tendered in the offer. On January 22, 2018, Novartis commenced a subsequent offering period that expired on January 31, 2018. As of the expiration of the subsequent offering period, an additional 1.8% of the outstanding shares were validly tendered. Novartis accepted and paid approximately USD 60 million, resulting in an increase in Novartis ownership in AAA to 98.7%. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was USD 3.9 billion. The purchase price allocation resulted in net identifiable assets of approximately USD 1.9 billion, consisting of USD 2.5 billion intangible assets, USD 0.6 billion net deferred tax liabilities, and goodwill of approximately USD 2.0 billion. In 2018, from the date of the acquisition, the business generated net sales of USD 0.4 billion. Management estimated that net sales for the entire year of 2018 would have amounted to USD 0.4 billion had AAA been acquired at the beginning of 2018. The 2018 results from operations since the acquisition were not material.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of December 31, 2020, Novartis held 99.2% of the then-outstanding fully diluted ordinary shares, including ordinary shares represented by ADSs.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">AAA is a radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicines &ndash; including <i>Lutathera</i> (USAN: lutetium Lu 177 dotatate/INN: lutetium (<sup>177</sup>Lu) oxodotreotide), a first-in-class radioligand therapy product for neuroendocrine tumors &ndash; and a portfolio of diagnostic products. Radiopharmaceuticals, such as <i>Lutathera</i>, are unique medicinal formulations containing radioisotopes, which are used clinically for both diagnosis and therapy.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &ndash; acquisition of AveXis, Inc.</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On April 6, 2018, Novartis entered into an agreement and plan of merger with AveXis, Inc., a US-based clinical stage gene therapy company, under which Novartis commenced on April 17, 2018, a tender offer to purchase all outstanding common stock of AveXis, Inc. for USD 218 per share in cash. On May 15, 2018, Novartis completed the acquisition of the common stock of AveXis, Inc. and paid a total of USD 8.7 billion. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was USD 8.7 billion. The purchase price allocation resulted in net identifiable assets of approximately USD 7.2 billion, consisting of USD  8.5 billion intangible assets, USD 1.6 billion net deferred tax liabilities and other net assets of USD 0.3 billion, and goodwill of approximately USD 1.5 billion. The 2018 results of operations since the date of acquisition were not material. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">AveXis, Inc. is focused on developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. AveXis, Inc.&#x2019;s initial product candidate, AVXS-101, is a proprietary gene therapy currently in development for the treatment of spinal muscular atrophy (SMA) type 1 &ndash; the leading genetic cause of infant mortality &ndash; and SMA types 2 and 3. In addition, AveXis, Inc. has a pipeline of other novel treatments for rare neurological diseases, including Rett syndrome (RTT) and a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &ndash; acquisition of Endocyte, Inc.</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On October 18, 2018, Novartis entered into an agreement and plan of merger with Endocyte, Inc. (Endocyte), a US-based biopharmaceutical company focused on developing targeted therapeutics for cancer treatment. The transaction was completed on December 21, 2018. Under the terms of the agreement, Novartis acquired all outstanding shares of Endocyte common stock for USD 24 per share. The total consideration amounted to USD 2.1 billion.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was USD 2.1 billion. The purchase price allocation resulted in net identifiable assets of approximately USD 1.5 billion, consisting of USD 1.5 billion intangible assets, USD 0.3 billion net deferred tax liabilities and other net assets of USD 0.3 billion, and goodwill of approximately USD 0.6 billion. The purchase price allocation was preliminary at December 31, 2018, as the transaction closed on December 21, 2018, which was close to the Group&#x2019;s year-end and therefore did not provide sufficient time to complete the valuation of the intangible assets, deferred taxes, </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-18</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">assumed liabilities and goodwill. During 2019, there were no significant revisions to the purchase price allocation.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Endocyte uses drug conjugation technology to develop targeted therapies with companion imaging agents, including 177Lu-PSMA-617, a potential first-in-class investigational radioligand therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC).</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Corporate &ndash; divestment of 36.5% stake in GlaxoSmithKline Consumer Healthcare Holdings Ltd. </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On March 27, 2018, Novartis entered into an agreement with GlaxoSmithKline plc (GSK) to divest its 36.5% stake in GlaxoSmithKline Consumer Healthcare Holdings Ltd. to GSK for USD 13.0 billion in cash. As a result, Novartis discontinued the use of equity method accounting starting from April 1, 2018. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">On June 1, 2018, the transaction closed and Novartis realized a pre-tax gain of USD 5.8 billion, recorded in income from associated companies.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">For significant transactions in 2019 for discontinued operations, see Note 30. There were no significant transactions in 2020 for discontinued operations.</div><a name="anchorId001545388"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">3. Segmentation of key figures 2020, 2019 and 2018</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The businesses of Novartis are divided operationally on a worldwide basis into two identified reporting segments: Innovative Medicines and Sandoz. In addition, we separately report Corporate activities.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Reporting segments are presented in a manner consistent with the internal reporting to the chief operating decision-maker, which is the Executive Committee of Novartis. The reporting segments are managed separately because they each research, develop, manufacture, distribute and sell distinct products that require differing marketing strategies. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Executive Committee of Novartis is responsible for allocating resources and assessing the performance of the reporting segments.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The reporting segments are as follows:</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines. The Innovative Medicines Division is organized into two global business units: Novartis Oncology and Novartis Pharmaceuticals. Novartis Oncology consists of the global business franchise Oncology, and Novartis Pharmaceuticals consists of the global business franchises Immunology, Hepatology and Dermatology; Ophthalmology; Neuroscience; Cardiovascular, Renal and Metabolism; Respiratory; and Established Medicines.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Sandoz develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. Sandoz is organized globally into three franchises: Retail Generics, Anti-Infectives and Biopharmaceuticals. In Retail Generics, Sandoz develops, manufactures and markets active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a broad range of therapeutic areas, as well as finished dosage form of anti-infectives sold to third parties. In Anti-Infectives, Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by Retail Generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products, including biosimilars, and provides biotechnology manufacturing services to other companies. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Income and expenses relating to Corporate include the costs of the Group headquarters and those of corporate coordination functions in major countries. In addition, Corporate includes other items of income and expense that are not attributable to specific segments, such as certain revenues from intellectual property rights, certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations and sponsorships. Usually, no allocation of Corporate items is made to the segments. As a result, Corporate assets and liabilities principally consist of net liquidity (cash and cash equivalents, marketable securities less financial debts), investments in associated companies, and current and deferred taxes and non-segment-specific environmental remediation and post-employment benefit liabilities. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Our divisions are supported by the Novartis Institutes for BioMedical Research, Global Drug Development, Novartis Technical Operations and Novartis Business Services organizations.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Novartis Institutes for BioMedical Research (NIBR) conducts research activities for the Innovative Medicines Division and also collaborates with Sandoz. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Global Drug Development organization oversees all drug development activities for our Innovative Medicines Division and collaborates with our Sandoz Division on the development of its biosimilars portfolio.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Novartis Technical Operations organization manages our manufacturing operations across our Innovative Medicines and Sandoz Divisions.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Novartis Business Services (NBS) is our shared services organization that delivers business support services across the Group, such as information technology, real estate and facility services, procurement, product lifecycle services, human resources, and financial reporting and accounting operations.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-19</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Following the February 28, 2019, shareholders&#x2019; approval of the spin-off of the Alcon business (refer to Notes 1, 2 and 30 for further details), the Group reported its consolidated financial statements as &#x201C;continuing operations&#x201D; and &#x201C;discontinued operations.&#x201D; </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Continuing operations comprise the activities of the Innovative Medicines and Sandoz Divisions, and the continuing Corporate activities. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Discontinued operations include the operational results from the Alcon eye care devices business and certain corporate activities attributable to the Alcon business prior to the spin-off, the gain on distribution of Alcon Inc. to Novartis AG shareholders, and certain other expenses related to the Distribution (refer to Notes 1, 2 and 30 for further details). </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The accounting policies mentioned in Note 1 are used in the reporting of segment results. Inter-segmental sales are made at amounts that are considered to approximate arm&#x2019;s length transactions. The Executive Committee of Novartis evaluates segmental performance and allocates resources among the segments based on a number of measures, including net sales, operating income and net operating assets. Segment net operating assets consist primarily of property, plant and equipment; right-of-use assets; intangible assets; goodwill; inventories; and trade and other operating receivables less operating liabilities.</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Segmentation &ndash; consolidated income statements</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines  </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz  </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate  (including eliminations)</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group  </div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 39&nbsp;013</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37&nbsp;714</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;646</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;731</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48&nbsp;659</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;445</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to continuing and discontinued segments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 792</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 783</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 189</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 141</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;981</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;871</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 39&nbsp;805</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 38&nbsp;497</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;835</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;872</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;981</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;871</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48&nbsp;659</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;498</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;018</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;092</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 53</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 63</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 168</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;239</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;179</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10&nbsp;927</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10&nbsp;050</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5&nbsp;252</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;334</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;058</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 959</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15&nbsp;121</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14&nbsp;425</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&nbsp;896</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 29&nbsp;539</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;636</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;601</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 245</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 112</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 34&nbsp;777</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;252</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11&nbsp;657</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11&nbsp;617</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;076</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;218</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;464</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;534</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14&nbsp;197</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14&nbsp;369</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8&nbsp;118</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8&nbsp;152</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;862</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8&nbsp;980</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9&nbsp;402</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 922</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;586</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 176</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 167</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 644</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 278</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;742</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;031</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;871</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;069</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;831</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;749</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;488</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;608</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;190</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;426</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;172</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;287</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;043</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 551</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;63</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;752</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&nbsp;152</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;086</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 670</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 656</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 673</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 659</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;869</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;850</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;78</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 45</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;878</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;940</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;807</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;793</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;071</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;147</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net loss from discontinued operations before gain on  distribution of Alcon Inc. to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;101</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;691</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;590</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;071</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;737</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Shareholders of Novartis AG</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 8&nbsp;072</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 11&nbsp;732</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Non-controlling interests</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net income from continuing operations are:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 91</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 245</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of property, plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;912</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;952</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;282</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;283</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;124</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;110</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;318</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;345</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of right-of-use assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;273</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;247</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;41</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;41</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;330</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;305</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;080</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;509</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;370</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;315</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;462</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;836</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on property, plant and equipment, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;324</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;116</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;101</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;440</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;202</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on intangible assets, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;768</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;632</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;141</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;506</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;914</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;138</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges and fair value  changes on financial assets, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   153</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   182</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   335</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   38</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to restructuring provisions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;217</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;229</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;98</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;165</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;39</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;98</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;354</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;492</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation of Novartis equity plans</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;714</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;761</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;64</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;67</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;180</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;239</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;958</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;067</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-20</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines  </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz  </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate  (including eliminations)</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group  </div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37&nbsp;714</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;892</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;731</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;859</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;445</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 44&nbsp;751</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to continuing and discontinued segments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 783</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 741</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 141</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 177</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;871</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;836</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 82</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 38&nbsp;497</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 35&nbsp;633</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;872</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&nbsp;036</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;871</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;836</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;498</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 44&nbsp;833</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;092</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;188</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 63</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 62</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;179</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;266</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10&nbsp;050</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9&nbsp;870</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;334</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;530</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 959</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 890</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14&nbsp;425</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14&nbsp;510</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 29&nbsp;539</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&nbsp;951</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;601</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;568</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 112</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 70</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;252</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31&nbsp;589</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11&nbsp;617</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10&nbsp;907</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;218</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;305</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;534</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;505</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14&nbsp;369</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;13&nbsp;717</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8&nbsp;152</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;7&nbsp;675</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;814</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9&nbsp;402</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8&nbsp;489</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;586</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 977</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 167</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 505</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 278</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 147</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;031</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;629</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;069</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;475</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;749</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;622</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;608</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;512</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;426</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;609</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;287</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;871</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 551</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;332</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;752</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;800</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;086</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;403</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 656</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;432</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 659</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;438</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;850</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;932</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 45</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 186</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;940</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;095</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;793</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;295</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;147</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;800</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net loss from discontinued operations before gain on  distribution of Alcon Inc. to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;101</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;186</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;691</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income/(loss) from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;590</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;186</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;737</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;614</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Shareholders of Novartis AG</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 11&nbsp;732</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 12&nbsp;611</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Non-controlling interests</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net income from continuing operations are:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 245</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 292</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of property, plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;952</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;075</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;283</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;285</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;110</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;122</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;345</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;482</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of right-of-use assets<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;247</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;41</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;305</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;509</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;214</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;315</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;366</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;836</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;587</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on property, plant and equipment, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;239</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;101</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;60</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;202</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;301</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on intangible assets, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;632</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;592</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;506</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;249</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;138</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;841</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges and fair value  changes on financial assets, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   107</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;113</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   38</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to restructuring provisions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;229</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;395</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;165</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;98</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;94</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;492</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;521</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation of Novartis equity plans</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;761</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;645</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;67</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;53</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;239</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;220</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;067</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;918</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Depreciation of right-of-use assets recognized from January 1, 2019, the date of implementation of IFRS 16 Leases. Note 1 provides additional disclosures.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-21</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Segmentation &ndash; consolidated balance sheets</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines  </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz  </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate   (including eliminations)</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group  </div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total assets</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 83&nbsp;112</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71&nbsp;225</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&nbsp;825</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&nbsp;468</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 32&nbsp;122</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 30&nbsp;677</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 132&nbsp;059</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 118&nbsp;370</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liabilities</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;15&nbsp;472</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;15&nbsp;332</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;786</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;804</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;56&nbsp;135</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;43&nbsp;683</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;75&nbsp;393</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;62&nbsp;819</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 56&nbsp;666</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;551</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net debt<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24&nbsp;481</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&nbsp;938</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24&nbsp;481</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&nbsp;938</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net operating assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 67&nbsp;640</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;893</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;039</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;664</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 468</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;932</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 81&nbsp;147</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71&nbsp;489</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in assets and liabilities are:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total property, plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;863</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;632</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;849</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;888</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 551</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 549</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&nbsp;263</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;069</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to property, plant  and equipment<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   926</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1&nbsp;114</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   229</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   217</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   110</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   143</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   1&nbsp;265</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1&nbsp;474</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total right-of-use assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;489</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;487</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 133</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 136</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 54</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 54</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;676</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;677</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to right-of-use assets<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 264</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 454</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 67</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 49</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 346</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 537</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total goodwill and intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 56&nbsp;839</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 46&nbsp;336</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;817</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;892</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 152</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 83</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 66&nbsp;808</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 55&nbsp;311</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to goodwill and  intangible assets<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   1&nbsp;235</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   647</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   105</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   68</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   85</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   52</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   1&nbsp;425</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   767</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total investment in associated  companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   194</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   128</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   9&nbsp;430</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   8&nbsp;509</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   9&nbsp;632</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   8&nbsp;644</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to investment in associated  companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   44</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   55</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents, marketable securities, commodities, time deposits and derivative  financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     11&nbsp;563</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     11&nbsp;446</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     11&nbsp;563</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     11&nbsp;446</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debts and derivative  financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   36&nbsp;044</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   27&nbsp;384</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   36&nbsp;044</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   27&nbsp;384</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current income tax and deferred tax liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;880</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;061</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;880</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;061</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Note 29 provides additional disclosures related to net debt</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Excluding the impact of business acquisitions</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows countries that accounted for more than 5% of at least one of the respective Group totals, as well as regional information for net sales to third parties for the years ended December 31, 2020, 2019 and 2018, and for selected non-current assets for the years ended December 31, 2020 and 2019:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="11" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net sales<sup>1</sup></div>
      </td>
      <td></td>
      <td colspan="7" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total of selected non-current assets<sup>2</sup></div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="11" height="3"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="11" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="11" height="3"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Country</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 800</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 848</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 795</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34&nbsp;904</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33&nbsp;032</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 43</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United States</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&nbsp;484</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16&nbsp;280</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14&nbsp;618</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39&nbsp;889</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28&nbsp;893</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">France</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;442</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;442</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;505</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;115</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;933</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Germany</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;518</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;120</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;972</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;607</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;554</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japan</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;804</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;656</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;575</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 313</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 309</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">China</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;573</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;214</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;953</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 714</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 684</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19&nbsp;038</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&nbsp;885</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&nbsp;333</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 40</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;837</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;296</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48&nbsp;659</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;445</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 44&nbsp;751</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 90&nbsp;379</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 77&nbsp;701</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Region</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18&nbsp;715</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;933</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 38</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;259</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 47&nbsp;798</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 53</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 46&nbsp;103</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 59</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Americas</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19&nbsp;725</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 41</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19&nbsp;713</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 41</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&nbsp;032</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40&nbsp;391</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 45</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 29&nbsp;389</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 38</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&nbsp;219</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;799</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;460</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;190</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;209</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48&nbsp;659</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;445</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 44&nbsp;751</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 90&nbsp;379</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 77&nbsp;701</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td colspan="22">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="22">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Net sales to third party from continuing operations by location of customer</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="22">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Total of property, plant and equipment; right-of-use assets; goodwill; intangible assets and investment in associated companies</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-22</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s largest, second-largest and third-largest customers account for approximately 17%, 11% and 6% of net sales, respectively (2019: 18%, 13% and 8%, respectively; 2018: 18%, 14% and 8%, respectively). All segments had sales to these customers in 2020, 2019 and 2018.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The highest amounts of trade receivables outstanding were for these same three customers and amounted to approximately 14%, 12% and 6%, respectively, of the trade receivables at December 31, 2020 (2019: 14%, 12% and 7%, respectively).</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Segmentation &ndash; Net sales by region<sup>1</sup></font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> 2020<br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> 2019<br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br> (2019<br> to 2020)<br> USD %</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> 2018<br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br> (2018<br> to 2019)<br> USD %</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&nbsp;484</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;818</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;296</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&nbsp;342</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13&nbsp;789</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;864</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;718</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;458</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;097</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;469</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;649</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;635</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 39&nbsp;013</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37&nbsp;714</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;892</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29&nbsp;643</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28&nbsp;573</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26&nbsp;258</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;370</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;141</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;634</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;231</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;115</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;963</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;142</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;491</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;754</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;501</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;341</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;363</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 772</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 784</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 779</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;646</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;731</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;859</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;089</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;111</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;233</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;557</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;620</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;626</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18&nbsp;715</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;933</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;259</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&nbsp;484</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16&nbsp;280</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14&nbsp;618</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&nbsp;219</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;799</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;460</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;241</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;433</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;414</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48&nbsp;659</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;445</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 44&nbsp;751</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36&nbsp;732</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35&nbsp;684</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33&nbsp;491</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&nbsp;927</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;761</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;260</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Net sales to third parties from continuing operations by location of customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-23</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines Division net sales by business franchise</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> 2020<br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> 2019<br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br> (2019 to<br> 2020)<br> USD %</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> 2018<br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br> (2018 to<br> 2019)<br> USD %</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Oncology</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;958</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;880</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;874</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;738</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;416</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;174</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Tafinlar</I> + <I>Mekinist</I></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;542</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;338</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;155</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;439</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;585</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;587</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;339</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;114</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 977</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;188</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;263</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;561</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;19</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;083</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;539</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;556</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 687</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 480</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 235</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 104</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 653</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 975</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;33</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;099</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 635</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 755</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 828</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 474</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 278</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 71</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lutathera</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 445</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 441</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 167</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 164</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Piqray</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 320</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 116</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 176</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Adakveo</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 105</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tabrecta</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 35</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;070</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;189</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;139</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Novartis  Oncology business unit</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">     14&nbsp;711</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     14&nbsp;370</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">     2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     13&nbsp;428</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Immunology, Hepatology and Dermatology</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;995</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;551</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;837</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 873</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 671</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 554</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Immunology,  Hepatology and  Dermatology</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">     4&nbsp;868</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     4&nbsp;222</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">     15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     3&nbsp;392</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     24</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ophthalmology</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;933</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;086</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;046</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xiidra</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 376</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 192</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 96</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Beovu</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 190</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;911</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;463</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;995</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Ophthalmology</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;410</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;776</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;558</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Neuroscience</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;003</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;223</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;341</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 920</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 361</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 155</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Mayzent</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 170</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Aimovig</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 164</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 103</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 59</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 51</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 60</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 80</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;25</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Neuroscience</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;323</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;773</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;429</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> 2020<br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> 2019<br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br> (2019 to<br> 2020)<br> USD %</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> 2018<br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br> (2018 to<br> 2019)<br> USD %</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cardiovascular, Renal and Metabolism</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;497</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;726</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 45</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;028</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 68</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;96</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Cardiovascular,  Renal and Metabolism</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   2&nbsp;498</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   1&nbsp;750</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   43</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   1&nbsp;050</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   67</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Respiratory</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;251</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;173</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;039</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Ultibro</I> Group</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 623</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 630</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 703</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Respiratory</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;900</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;825</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;767</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Established Medicines</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Galvus</I> Group</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;199</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;297</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;284</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Diovan</I> Group</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;003</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;064</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;023</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Exforge</I> Group</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 980</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;025</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;002</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zortress/Certican</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 452</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 485</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 464</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Neoral/Sandimmun(e)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 393</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 419</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 463</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Voltaren/Cataflam</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 360</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 417</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 445</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;916</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;291</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;587</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Established  Medicines</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   6&nbsp;303</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   6&nbsp;998</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   &#x2013;&#x2005;10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   7&nbsp;268</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   &#x2013;&#x2005;4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Novartis  Pharmaceuticals business unit</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">     24&nbsp;302</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     23&nbsp;344</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">     4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     21&nbsp;464</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division  net sales</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   39&nbsp;013</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   37&nbsp;714</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   34&nbsp;892</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Net sales reflect <I>Xolair</I> sales for all indications.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-24</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Top 20 Innovative Medicines Division product net sales &ndash; 2020</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"><br>Brands</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Business franchise</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Key indication</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> US<br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of <br> world<br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Total<br> USD m</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td width="21%" height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Cosentyx</div>
      </td>
      <td align="right" width="1%"></td>
      <td width="21%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       Immunology, Hepatology  and Dermatology</div>
      </td>
      <td align="right" width="1%"></td>
      <td width="21%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis, ankylosing   spondylitis, psoriatic  arthritis and   non-radiographic axial   spondyloarthritis</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">         2&nbsp;516</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">         1&nbsp;479</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">         3&nbsp;995</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;562</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;441</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;003</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Entresto</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, Renal   and Metabolism</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Chronic heart failure</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   1&nbsp;277</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   1&nbsp;220</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   2&nbsp;497</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 859</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;099</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;958</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular degeneration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;933</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;933</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Promacta/Revolade</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune thrombocytopenia (ITP),   severe aplastic anemia (SAA)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   833</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   905</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   1&nbsp;738</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <I>Tafinlar</I> + <I>Mekinist</I></div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic and   adjuvant melanoma; advanced   non-small cell lung cancer (NSCLC)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     569</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     973</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">     1&nbsp;542</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors and acromegaly</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 837</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 602</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;439</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Jakavi</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF),   polycythemia vera (PV)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   1&nbsp;339</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   1&nbsp;339</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Xolair<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     Respiratory</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA)   and chronic spontaneous urticaria   (CSU) and nasal polyps</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     1&nbsp;251</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">     1&nbsp;251</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Galvus</I> Group</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;199</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;199</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia and GIST</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 315</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 873</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;188</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/TSC</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 644</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 439</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;083</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Diovan</I> Group</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 124</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 879</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;003</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Exforge</I> Group</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 964</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 980</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy (SMA)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 459</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 461</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 920</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Ilaris</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Immunology, Hepatology  and Dermatology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,   TRAPS, HIDS/MKD, FMF, SJIA,   AOSD and gout)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     400</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     473</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">     873</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2- metastatic breast cancer</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 318</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 369</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 687</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic iron overload</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 138</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 515</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 653</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Renal cell carcinoma</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 259</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 376</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 635</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;126</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&nbsp;790</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&nbsp;916</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;216</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;881</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;097</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division sales</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;342</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 24&nbsp;671</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 39&nbsp;013</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Net sales reflect <I>Xolair</I> sales for all indications.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-25</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Top 20 Innovative Medicines Division product net sales &ndash; 2019</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"><br>Brands</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Business franchise</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Key indication</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> US<br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rest of <br> world<br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> <br> Total<br> USD m</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td width="21%" height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Cosentyx</div>
      </td>
      <td align="right" width="1%"></td>
      <td width="21%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, Hepatology  and Dermatology</div>
      </td>
      <td align="right" width="1%"></td>
      <td width="21%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis, ankylosing   spondylitis and psoriatic arthritis</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   2&nbsp;220</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1&nbsp;331</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   3&nbsp;551</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;736</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;487</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;223</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular degeneration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;086</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;086</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 804</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;076</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;880</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Entresto</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, Renal   and Metabolism</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Chronic heart failure</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   925</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   801</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   1&nbsp;726</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors and acromegaly</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 881</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 704</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;585</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/TSC</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;003</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 536</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;539</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Promacta/Revolade</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune thrombocytopenia (ITP),   severe aplastic anemia (SAA)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   691</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   725</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   1&nbsp;416</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <I>Tafinlar</I> + <I>Mekinist</I></div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic and   adjuvant melanoma; advanced   non-small cell lung cancer (NSCLC)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     481</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     857</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     1&nbsp;338</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Galvus</I> Group</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;297</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;297</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia and GIST</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 334</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 929</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;263</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Xolair<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     Respiratory</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA)   and chronic spontaneous urticaria   (CSU)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     1&nbsp;173</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     1&nbsp;173</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Jakavi</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF),   polycythemia vera (PV)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1&nbsp;114</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   1&nbsp;114</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Diovan</I> Group</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 86</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 978</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;064</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Exforge</I> Group</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;012</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;025</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic iron overload</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 450</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 525</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 975</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Renal cell carcinoma</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 332</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 423</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 755</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Ilaris</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Immunology, Hepatology  and Dermatology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,   TRAPS, HIDS/MKD, FMF, SJIA,   AOSD and gout)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     304</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     367</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     671</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zortress/Certican</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Transplantation</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 169</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 316</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 485</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2- metastatic breast cancer</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 230</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 480</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&nbsp;679</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 17&nbsp;967</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 28&nbsp;646</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;110</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;958</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;068</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division sales</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;789</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;925</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37&nbsp;714</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Net sales reflect <I>Xolair</I> sales for all indications.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-26</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Top 20 Innovative Medicines Division product net sales &ndash; 2018</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"><br>Brands</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Business franchise</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> Key indication</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> US<br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rest of <br> world<br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> <br> Total<br> USD m</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td width="21%" height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
      </td>
      <td align="right" width="1%"></td>
      <td width="21%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
      </td>
      <td align="right" width="1%"></td>
      <td width="21%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;765</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;576</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;341</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Cosentyx</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, Hepatology  and Dermatology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis, ankylosing   spondylitis and psoriatic arthritis</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1&nbsp;674</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1&nbsp;163</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   2&nbsp;837</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular degeneration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;046</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;046</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 806</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;068</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;874</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors and acromegaly</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 817</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 770</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;587</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia and GIST</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 440</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;121</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;561</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/TSC</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 929</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 627</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;556</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Galvus</I> Group</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;284</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;284</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Promacta/Revolade</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune thrombocytopenia (ITP),   severe aplastic anemia (SAA)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   581</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   593</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   1&nbsp;174</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <I>Tafinlar</I> + <I>Mekinist</I></div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic and   adjuvant melanoma; advanced   non-small cell lung cancer (NSCLC)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     457</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     698</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     1&nbsp;155</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic iron overload</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 521</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 578</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;099</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Xolair<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     Respiratory</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA)   and chronic spontaneous urticaria   (CSU)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     1&nbsp;039</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     1&nbsp;039</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Entresto</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, Renal   and Metabolism</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Chronic heart failure</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   556</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   472</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   1&nbsp;028</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Diovan</I> Group</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 84</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 939</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;023</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><I>Exforge</I> Group</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 983</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;002</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Jakavi</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF),   polycythemia vera (PV)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   977</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   977</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Renal cell carcinoma</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 404</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 424</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 828</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Ilaris</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Immunology, Hepatology  and Dermatology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,   TRAPS, HIDS/MKD, FMF, SJIA,   AOSD and gout)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     262</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     292</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     554</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Travoprost Group</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Ophthalmology</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Reduction of elevated intraocular   pressure</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   194</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   323</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   517</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zortress/Certican</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Transplantation</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 145</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 319</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 464</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;654</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 17&nbsp;292</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&nbsp;946</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;210</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;736</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;946</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division sales</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;864</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;028</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;892</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Net sales reflect <I>Xolair</I> sales for all indications.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-27</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz Division net sales by business franchise</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> 2020<br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> 2019<br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br> (2019 to<br> 2020)<br> USD %</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> 2018<br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br> (2018 to<br> 2019)<br> USD %</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Retail Generics<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;244</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;590</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;880</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Biopharmaceuticals</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;928</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;607</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;436</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Anti-Infectives</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 474</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 534</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 543</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;646</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;731</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;859</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Of which USD 694 million (2019: USD 784 million; 2018: USD 826 million) represents anti-infectives sold under the Sandoz name</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The product portfolio of Sandoz is widely spread in 2020, 2019 and 2018.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Segmentation &ndash; other revenue</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines  </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz  </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate   (including eliminations)</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group  </div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Profit-sharing income</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 835</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 732</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 835</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 734</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Royalty income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 107</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 104</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 168</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 300</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 147</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Milestone income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 201</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 231</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 55</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 54</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 67</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other revenues</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;018</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;092</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 53</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 63</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 168</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;239</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;179</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Innovative Medicines  </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Sandoz  </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Corporate   (including eliminations)</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Group  </div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Profit-sharing income</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 732</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 874</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 734</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 877</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Royalty income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 104</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 162</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 147</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 188</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Milestone income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 201</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 128</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 45</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 231</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 173</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 55</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 67</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other revenues</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;092</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;188</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 63</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 62</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;179</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;266</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-28</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId001557602"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">4. Associated companies</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net income statement effect</div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other comprehensive income effect</div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total comprehensive income effect</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018<sup style="white-space: nowrap"> 1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="20" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Roche Holding AG, Switzerland</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 677</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 662</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 526</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;56</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;94</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 75</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 621</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 568</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 601</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="20" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">GlaxoSmithKline Consumer  Healthcare Holdings Ltd., UK</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   5&nbsp;910</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;557</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   5&nbsp;353</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="20" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="20" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies related to continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   673</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   659</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   6&nbsp;438</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   &#x2013;&#x2005;56</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   &#x2013;&#x2005;94</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   &#x2013;&#x2005;482</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   617</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   565</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   5&nbsp;956</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="20" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="20">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="20">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> In 2018, Novartis share of other comprehensive income recognized by associated companies, net of taxes of USD 511 million was recycled into the consolidated income statement as a result of the divestment of the investment in GSK Consumer Healthcare Holdings Ltd. No Novartis share of other comprehensive income recognized by associated companies, net of taxes was recycled into the consolidated income statement in 2020 and 2019. <b></b><b></b></div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has a significant investment in Roche Holding AG, Basel (Roche), as well as certain other smaller investments that are accounted for as associated companies. The investment in GlaxoSmithKline Consumer Healthcare Holdings Ltd., Brentford, Middlesex, UK, was divested on June 1, 2018, to GlaxoSmithKline plc, Great Britain.</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Balance sheet value</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> December 31,<br> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31,<br> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Roche Holding AG, Switzerland</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;407</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;445</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 225</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 199</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;632</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;644</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Roche Holding AG </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s holding in Roche voting shares was 33.3% at December 31, 2020, 2019 and 2018. This investment represents approximately 6.2% of Roche&#x2019;s total outstanding voting and non-voting equity instruments at December 31, 2020, 2019 and 2018.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Since full-year 2020 financial data for Roche is not available when Novartis produces its consolidated financial results, a survey of analyst estimates is used to estimate the Group&#x2019;s share of Roche&#x2019;s net income. Any differences between these estimates and actual results will be adjusted in the Group&#x2019;s 2021 consolidated financial statements when available.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following tables show summarized financial information for Roche, including current values of fair value adjustments made at the time of the acquisition of the shares, for the year ended December 31, 2019, and for the six months ended June 30, 2020 (since full-year 2020 data is not yet available):</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(CHF billions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Current assets</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-current <br> assets</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Current <br> liabilities</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-current <br> liabilities</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">December 31, 2019</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31.3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 56.4</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24.1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23.1</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">June 30, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 55.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22.5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(CHF billions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Revenue</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Net income</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other <br> comprehen-<br> sive income</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br> comprehen-<br> sive income</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">December 31, 2019</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 63.8</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12.3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.9</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11.4</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">June 30, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;0.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">A purchase price allocation was performed on the basis of publicly available information at the time of acquisition of the investment. The December 31, 2020, balance sheet value allocation is as follows:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> December 31,<br> 2020</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of Roche&#x2019;s estimated net assets</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;585</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of reappraised intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 117</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Implicit Novartis goodwill</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;233</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current value of share in net identifiable assets  and goodwill</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   5&nbsp;935</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated equity accounting  adjustments and translation  effects less dividends received</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     3&nbsp;472</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance sheet value</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;407</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The identified intangible assets principally relate to the value of currently marketed products and are amortized on a straight-line basis over their estimated average useful life of 20 years.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2020, dividends received from Roche in relation to the distribution of its 2019 net income amounted to USD&nbsp;487 million (2019: USD 460 million in relation to the distribution of its 2018 net income).</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consolidated income statement effects from applying Novartis accounting principles for this investment in 2020, 2019 and 2018 are as follows:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of Roche's  estimated current-year  consolidated net income</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     913</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     910</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     799</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prior-year adjustment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;64</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;129</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;125</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of fair value  adjustments relating to  intangible assets, net of taxes  of USD 26 million (2019: USD 24  million; 2018: USD 40 million)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">         &#x2013;&#x2005;172</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">         &#x2013;&#x2005;162</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">         &#x2013;&#x2005;148</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Partial release of deferred tax  liability recognized</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   43</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income effect</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 677</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 662</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 526</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The publicly quoted market value of the Novartis interest in Roche (SIX symbol: RO) at December&nbsp;31, 2020, was USD&nbsp;18.8 billion (2019: USD&nbsp;16.9 billion).</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-29</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">GlaxoSmithKline Consumer Healthcare Holdings&nbsp;Ltd.</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On March 27, 2018, Novartis entered into an agreement with GlaxoSmithKline plc, Great Britain (GSK), to divest its 36.5% stake in GSK Consumer Healthcare Holdings Ltd. (GSK Consumer Healthcare) to GSK for USD 13.0 billion in cash. As a result, Novartis discontinued the use of equity method accounting starting from April 1, 2018. The divestment transaction closed on June 1, 2018, and Novartis realized a pre-tax gain of USD 5.8 billion, recorded in income from associated companies. See Note 2. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">GSK Consumer Healthcare was formed in March 2015 via contribution of businesses from both Novartis and GSK. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Until June 1, 2018, Novartis had a 36.5% interest in GSK Consumer Healthcare and had four of 11 seats on the GSK Consumer Healthcare board of directors. Furthermore, Novartis had customary minority rights as well as exit rights at a predefined, market-based pricing mechanism.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consolidated income statement effects from applying Novartis accounting principles for this investment in 2018 are as follows:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of GSK Consumer Healthcare's estimated current-year consolidated net income</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">       119</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prior-year adjustment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of fair value adjustments relating to intangible assets and inventory, net of taxes of USD 1 million</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">       &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Pre-tax gain on divestment of  GSK Consumer Healthcare</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   5&nbsp;790</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income effect</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;910</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div><a name="anchorId001558665"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">5. Interest expense and&nbsp;other&nbsp;financial&nbsp;income&nbsp;and&nbsp;expense</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest expense</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;708</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;714</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;877</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense on lease liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;67</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;66</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense arising from  discounting long-term liabilities and capitalized borrowing costs</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     &#x2013;&#x2005;94</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2013;&#x2005;70</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2013;&#x2005;55</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total interest expense  from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   &#x2013;&#x2005;869</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   &#x2013;&#x2005;850</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   &#x2013;&#x2005;932</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other financial income and expense</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 91</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 245</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 292</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;52</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;52</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;39</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency result, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;135</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;160</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;68</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other financial income  and expense from  continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">     &#x2013;&#x2005;78</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     45</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     186</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-30</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId001558939"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">6. Taxes</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Income before taxes</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;786</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;097</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;887</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 92</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 843</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;208</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes  from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   9&nbsp;878</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   8&nbsp;940</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   14&nbsp;095</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Current and deferred income tax expense</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;932</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;186</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;615</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;168</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;961</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;988</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current income tax expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2&nbsp;100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;2&nbsp;147</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;603</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;137</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;93</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;120</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 430</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 447</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 428</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Deferred tax income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 293</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 354</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 308</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income tax expense  from continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   &#x2013;&#x2005;1&nbsp;807</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   &#x2013;&#x2005;1&nbsp;793</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   &#x2013;&#x2005;1&nbsp;295</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Analysis of tax rate</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has a substantial business presence in many countries and is therefore subject to different income and expense items that are non-taxable (permanent differences) or are taxed at different rates in those tax jurisdictions. This results in a difference between our applicable tax rate and effective tax rate.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The main elements contributing to the difference between the Group&#x2019;s overall applicable tax rate (which can change each year since it is calculated as the weighted average tax rate based on the pre-tax income of each subsidiary) and the effective tax rate are shown in the following table:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(As a percentage)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Applicable tax rate</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13.6</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11.7</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14.3</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of disallowed expenditures</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of utilization of tax losses  brought forward from prior periods</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;0.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;0.1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;0.1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of income taxed at reduced rates</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;0.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of income not subject to tax<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;0.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3.7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of tax credits and allowances</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2.3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of release of  contingent consideration liability</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;0.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;0.5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;0.2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of tax rate change  on current and deferred  tax assets and liabilities<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     0.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2013;&#x2005;1.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2013;&#x2005;0.1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of write-off of deferred tax assets<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of write-down and reversal of  write-down of investments in subsidiaries</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;0.8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;0.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   0.0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of prior-year items</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of other items<sup style="white-space: nowrap">&nbsp;4</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Effective tax rate for continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20.1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9.2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><b> </b></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Included in 2018 is the effect of income not subject to tax (-3.7%) arising from the portion of the non-taxable gain on the divestment of the Group's investment in GSK Consumer Healthcare Holdings Ltd. attributable to Switzerland.<b> </b></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> 2019 is mainly related to the revaluation of the deferred tax assets and liabilities resulting from the tax reforms enacted in Switzerland in 2019. Refer to Note 12 for additional disclosures.<b> </b></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> 2019 is primarily related to a non-cash, one-time deferred tax expense for the write-off of a deferred tax asset resulting from legal entity reorganizations.<b> </b></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> In 2020, other items (+1.9%) include changes in uncertain tax positions (+2.0%) and other items (-0.1%).<br> In 2019, other items (+3.0%) include changes in uncertain tax positions (+2.6%) and other items (+0.4%).</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The utilization of tax-loss carry-forwards lowered the tax charge by USD&nbsp;29 million in 2020, by USD&nbsp;11 million in 2019, and by USD&nbsp;19 million in 2018.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For the amount of taxes attributable to discontinued operations, see Note 30.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-31</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId001559602"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">7. Earnings per share</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income attributable to shareholders of Novartis AG (USD millions)</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;072</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;142</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;797</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;590</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;186</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;072</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;732</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;611</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Number of shares (in millions)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Weighted average number of shares outstanding used in basic earnings per share</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;277</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;291</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;319</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Weighted average number of shares in diluted earnings per share</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;296</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;319</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;344</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic earnings per share (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.55</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.52</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.00</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.08</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.55</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.44</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Diluted earnings per share (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Continuing operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.52</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.08</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.46</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.98</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.08</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.52</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.06</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.38</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Basic earnings per share (EPS) is calculated by dividing net income attributable to shareholders of Novartis AG by the weighted average number of shares outstanding in a reporting period. This calculation excludes the average number of issued shares purchased by the Group and held as treasury shares.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For diluted EPS, the weighted average number of shares outstanding is adjusted to assume the vesting of all restricted shares, restricted share units, and the conversion of all potentially dilutive shares arising from options on Novartis shares that have been issued.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">No options were excluded from the calculation of diluted EPS in 2020, 2019 or 2018, as all options were dilutive in all years.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-32</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId001559964"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">8. Changes in consolidated statements of&nbsp;comprehensive income</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated statements of comprehensive income include the Group&#x2019;s net income for the year as well as all other valuation adjustments recorded in the Group&#x2019;s consolidated balance sheet which under IFRS are not recorded in the consolidated income statement. These include fair value adjustments to financial instruments, actuarial gains or losses on defined benefit pension plans, and currency translation effects, net of tax.</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Note</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Fair value<br> adjustments <br> on financial<br> instruments</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Actuarial<br> gains/(losses)<br> from defined<br> benefit plans</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Cumulative<br> currency <br> translation<br> effects</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total value<br> adjustments<br> attributable to <br> Novartis AG <br> shareholders</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Non-<br> controlling<br> interest</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> Total value<br> adjustments</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2017, as previously reported</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   395</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   &#x2013;&#x2005;5&nbsp;064</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   329</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   &#x2013;&#x2005;4&nbsp;340</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   &#x2013;&#x2005;21</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   &#x2013;&#x2005;4&nbsp;361</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of adoption of IFRS 9 on retained  earnings and OCI</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;177</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;177</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;177</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Restated value adjustments at January 1, 2018</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 218</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;5&nbsp;064</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 329</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;517</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;538</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on deferred cash flow  hedges, net of taxes of USD -1 million</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, net of taxes of USD -5 million<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   13</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 95</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 95</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 95</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes  of USD 69 million</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;359</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;359</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;359</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.1</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 320</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 320</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 315</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2018</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;359</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 415</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 81</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 76</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities  sold, reclassified to retained earnings</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;16</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2018</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 227</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;5&nbsp;423</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 744</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;452</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;26</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;478</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on deferred cash flow hedges</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on debt securities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities,  net of taxes of USD 47 million<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;47</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;47</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;47</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes of USD -313 million<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;466</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;466</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;467</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.1</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 354</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 354</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 352</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;45</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;466</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 398</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;113</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;116</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities  sold, reclassified to retained earnings</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;95</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;95</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;95</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments related to divestments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;30</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 120</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;5&nbsp;919</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;142</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;4&nbsp;657</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;29</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;4&nbsp;686</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities,  net of taxes of USD -36 million<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   250</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;201</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;201</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;201</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes of USD -3 million</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   145</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   145</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   143</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.1</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;193</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;193</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;194</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 145</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;992</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;387</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;386</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities  sold, reclassified to retained earnings</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;150</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;150</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;150</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments related to divestments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 220</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;5&nbsp;773</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;134</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;419</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;29</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;448</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Includes fair value adjustments on equity securities designated as financial assets valued at fair value through other comprehensive income with no subsequent recycling into the<br>consolidated income statement</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Included in 2019 is a USD -358 million impact related to the revaluation of deferred tax assets on Swiss post-employment benefits that were previously recognized through other<br>comprehensive income. This revaluation resulted from the Swiss tax reforms enacted by the voters in 2019. Refer to Note 12 for additional disclosures.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-33</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">8.1) In 2020, no currency translation losses or gains were recycled through the income statement.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2019, cumulative currency translation gains of USD&nbsp;129 million were recycled through the income statement mainly as a result of the spin-off of the Alcon business through a dividend in kind distribution to Novartis AG shareholders. See Notes 2 and 30.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2018, cumulative currency translation losses of USD&nbsp;946 million were recycled through the income statement as a result of the divestment of the investment in GSK Consumer Healthcare Holdings Ltd. See Notes 2 and 4. </div><a name="anchorId001561648"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">9. Property, plant and equipment</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of property, plant and equipment during 2020:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Land</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Buildings</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Construction <br> in progress</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Machinery <br> and other <br> equipment</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cost</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2020</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 512</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;463</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;350</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;674</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26&nbsp;999</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of assets reclassified out of assets of  disposal group held for sale<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   117</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   36</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   168</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   332</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 433</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;038</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 595</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 115</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 847</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 296</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;265</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;465</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;57</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;656</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;201</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 695</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 110</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 956</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;797</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 555</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12&nbsp;377</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;248</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;038</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28&nbsp;218</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Accumulated depreciation</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;5&nbsp;124</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;60</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;9&nbsp;726</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;14&nbsp;930</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation on assets reclassified out of assets of  disposal group held for sale<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;58</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;101</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;163</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation on disposals and derecognitions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 433</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;543</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;004</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;491</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;827</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;318</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;194</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;228</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;447</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;373</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;731</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;108</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;5&nbsp;807</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;66</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;10&nbsp;063</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;15&nbsp;955</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 536</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;570</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;182</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;975</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12&nbsp;263</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for purchases of property, plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 256</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Capitalized borrowing costs</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Note 2 provides additional disclosures related to the reclassification out of assets of the disposal group held for sale.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Depreciation charge includes USD 38 million (USD 20 million for buildings and USD 18 million for machinery and other equipment), representing the cumulative amount of depreciation charge on the disposal group held for sale for property, plant and equipment from the date of classification to held for sale, September 2018, to March 31, 2020, the date of reclassification out of assets of disposal group held for sale. See Note 2 for further details.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-34</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of property, plant and equipment during 2019:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Land</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Buildings</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Construction <br> in progress</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Machinery <br> and other <br> equipment</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cost</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2019</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 696</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;135</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;042</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 17&nbsp;155</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;028</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of assets related to discontinued operations<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;61</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;615</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;655</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;678</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;009</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification to right-of-use assets<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;122</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;127</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of assets related to disposal group held for sale<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;23</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 57</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 332</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 630</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 112</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;001</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 355</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;474</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;75</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;551</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;774</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;409</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 512</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;463</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;350</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;674</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&nbsp;999</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Accumulated depreciation</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;43</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;6&nbsp;328</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;37</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;11&nbsp;924</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;18&nbsp;332</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation on assets related to discontinued operations<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 562</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;541</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;118</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification to right-of-use assets<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation on assets related to disposal group held for sale<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation on disposals and derecognitions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;170</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;674</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;846</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge<sup style="white-space: nowrap">&nbsp;4</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;447</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;898</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;345</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge<sup style="white-space: nowrap">&nbsp;5</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;51</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;110</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;205</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;33</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;43</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;5&nbsp;124</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;60</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;9&nbsp;726</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;14&nbsp;930</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 492</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;339</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;290</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;948</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;069</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for purchases of property, plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 220</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Capitalized borrowing costs</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Represents the cost of assets and accumulated depreciation at January 1, 2019, related to the Alcon business reported as discontinued operations. Notes 1, 2 and 30 provide information related to discontinued operations.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Reclassification to right-of-use assets at January 1, 2019, upon adoption of IFRS 16 Leases. Refer to Note 1 for additional disclosure.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Note 2 provides additional disclosures related to disposal group held for sale.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> No depreciation charge in the disposal group held for sale for the period from January 1, 2019, to December 31, 2019, was recorded.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;5&nbsp;</sup> Impairments in the disposal group held for sale for the period from January 1, 2019, to December 31, 2019, were USD 2 million.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-35</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId001563331"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">10. Right-of-use assets and lease liabilities</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of the right-of-use assets of continuing operations:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Right-of-use assets at January 1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;677</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;554</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 346</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 537</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;330</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;305</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease contract terminations<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;63</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;98</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of divestments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;17</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 46</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total right-of-use assets at December 31<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;676</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;677</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Lease contract terminations also includes modifications to existing leases that result in reductions to the right-of-use assets, and reductions due to sub-leasing.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> No impairment charge was recorded in 2020 (2019: nil).</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the right-of-use assets carrying value and depreciation charge of continuing operations at December 31, 2020 and 2019, by underlying class of asset: </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> December 31,<br> 2020<br> carrying value</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Depreciation <br> charge<br> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31,<br> 2019<br> carrying value</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Depreciation <br> charge<br> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Land</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 528</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 537</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buildings</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 963</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 207</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 990</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 194</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vehicles</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 155</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 129</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 87</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and equipment, and other assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     10</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total right-of-use assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   1&nbsp;676</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   330</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   1&nbsp;677</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   305</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
  </table>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the lease liabilities of continuing operations by maturity at December 31, 2020 and 2019:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Lease liabilities<br> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Lease liabilities<br> undiscounted<br> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Lease liabilities<br> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Lease liabilities<br> undiscounted<br> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less than one year</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 286</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 338</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 246</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 295</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between one and two years</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 229</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 274</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 202</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 246</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between two and three years</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 186</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 226</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 163</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 202</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between three and four years</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 148</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 183</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 138</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 173</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between four and five years</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 129</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 160</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 119</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 150</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After five years</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;027</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;326</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;081</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;419</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total lease liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;005</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;507</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;949</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;485</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion of lease liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;286</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;338</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;246</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;295</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current portion of lease liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;719</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;169</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;703</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;190</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At December 31, 2020 and December 31, 2019, there were no material future cash outflows, including extension options, excluded from the measurement of lease liabilities. The Group&#x2019;s most material lease with a lease term extension, representing a lease liability value of USD 0.6 billion (2019: USD 0.6 billion), has a determined lease term end date of 2071 (2019: 2071).</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2019, the Group completed sale and leaseback transactions for certain property, plant and equipment as part of its plans to consolidate sites. Transactions resulted in net cash inflows of USD 0.7 billion and the recognition of USD 96 million of lease liabilities, and USD 37 million of right-of-use assets. The right-of-use assets value reflects the proportion of the property, plant and equipment retained for a period of one to five years, with two five-year extension periods for certain right-of-use assets. The liabilities reflect the net present value of future lease payments. The net gain on the sale and leaseback transactions amounted to USD 478 million. There were no significant sale and leaseback transactions completed in 2020.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table provides additional disclosures related to right-of-use assets and lease liabilities of continuing operations for 2020 and 2019:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense on lease liabilities<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 67</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 66</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense on short-term leases</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense on low-value leases</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total cash outflows for leases</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 379</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 339</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cash outflows for short-term leases  and low-value leases<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">   11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">   15</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Payments of interest<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 56</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 51</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Payments of lease liabilities<sup style="white-space: nowrap">&nbsp;4</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 312</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 273</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> The weighted average interest rate is 3.4% (2019: 3.9%).</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Cash flows from short-term and low-value leases are included within total net cash flows from operating activities. The portfolio of short-term leases to which the Group is committed to at December 31, 2020 and 2019, is similar to the portfolio of short-term leases the Group entered into during 2020 and 2019.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Included within total net cash flows from operating activities.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> Reported as cash outflows used in financing activities net of lease incentives received of USD nil (2019: USD 33 million).</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The net investment held and income from subleasing right-of-use assets were not significant for 2020 and 2019. Income from leasing Novartis property, plant and equipment to third parties for both 2020 and 2019 was not significant. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 30 provides additional disclosures on discontinued operations.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-36</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId001564174"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">11. Goodwill and intangible assets</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of goodwill and intangible assets in 2020:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="1" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill</div>
      </td>
      <td></td>
      <td colspan="9" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible assets other than goodwill</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="9" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="9" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Total</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> In-process<br> research and<br> development</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Technologies</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently<br> marketed <br> products</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other<br> intangible<br> assets</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cost</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2020</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26&nbsp;825</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;429</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 884</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 43&nbsp;548</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;558</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 53&nbsp;419</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of assets reclassified out of assets of disposal group held for sale<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   276</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   1&nbsp;112</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   1&nbsp;400</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;580</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;600</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 196</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 218</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;014</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9&nbsp;272</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;274</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 339</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 674</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 412</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;425</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions<sup style="white-space: nowrap">&nbsp;4</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;421</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;101</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;39</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;572</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 916</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 208</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 58</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;568</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 205</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;039</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 30&nbsp;321</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;893</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;115</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 57&nbsp;333</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;384</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 67&nbsp;725</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Accumulated amortization</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;301</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2&nbsp;005</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;721</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;20&nbsp;969</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;937</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;24&nbsp;632</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization on assets reclassified out of assets of disposal group held for sale<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;107</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;816</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;925</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization charge<sup style="white-space: nowrap">&nbsp;5</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;72</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;215</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;175</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;462</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization on disposals  and derecognitions<sup style="white-space: nowrap">&nbsp;4</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   421</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   101</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   39</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   567</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge<sup style="white-space: nowrap">&nbsp;6</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;515</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;40</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;338</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;914</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;92</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;46</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;267</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;145</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;550</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;322</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2&nbsp;193</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;885</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;26&nbsp;566</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;272</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;30&nbsp;916</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&nbsp;999</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;700</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 230</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 30&nbsp;767</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;112</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 36&nbsp;809</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Note 2 provides additional disclosures related to the reclassification out of assets of disposal group held for sale as of March 31, 2020.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> No addition for the disposal group held for sale for the period from January 1, 2020, to March 31, 2020</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;5&nbsp;</sup> Amortization charge includes USD 102 million (USD 73 million for currently marketed products and USD 29 million for technologies), representing the cumulative amount of amortization charge for the disposal group held for sale for intangible assets from the date of reclassification to held for sale, September 6, 2018, to March 31, 2020, the date of reclassification out of assets of disposal group held for sale. See Note 2 for further details.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;6&nbsp;</sup> Impairment charge includes USD 42 million on currently marketed products that were previously classified within assets of disposal group held for sale. See Note 2 for further details.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-37</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of goodwill and intangible assets in 2019:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="1" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Goodwill</div>
      </td>
      <td></td>
      <td colspan="13" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Intangible assets other than goodwill</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="13" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="13" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="13" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Total</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> In-process<br> research and<br> development</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Alcon <br> brand name</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Technologies</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Currently<br> marketed <br> products</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Marketing <br> know-how</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other<br> intangible<br> assets</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cost</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2019</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 35&nbsp;700</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&nbsp;167</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;980</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;253</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 35&nbsp;412</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;960</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;253</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 69&nbsp;025</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of assets related to  discontinued operations<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;9&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;249</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;2&nbsp;980</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;5&nbsp;369</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;4&nbsp;440</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;5&nbsp;960</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;572</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;19&nbsp;570</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of assets related to disposal group held for sale, net<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 186</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 342</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;550</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;914</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9&nbsp;069</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;069</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions<sup style="white-space: nowrap">&nbsp;4</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 265</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 243</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 259</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 767</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions<sup style="white-space: nowrap">&nbsp;5</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;75</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;544</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;436</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;055</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;61</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 49</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 254</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 335</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&nbsp;825</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;429</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 884</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 43&nbsp;548</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;558</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 53&nbsp;419</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Accumulated amortization</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;406</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;120</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;758</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;21&nbsp;218</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;906</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;304</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;30&nbsp;306</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization on assets related to discontinued operations<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   101</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   4&nbsp;184</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   2&nbsp;592</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1&nbsp;906</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   128</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   8&nbsp;813</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization charge<sup style="white-space: nowrap">&nbsp;6</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;42</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;657</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;137</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;836</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization on disposals  and derecognitions<sup style="white-space: nowrap">&nbsp;5</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   70</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   494</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   419</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   983</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge<sup style="white-space: nowrap">&nbsp;6</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;984</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;105</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;54</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;175</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;126</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;148</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;301</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;2&nbsp;005</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;721</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;20&nbsp;969</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;937</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;24&nbsp;632</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&nbsp;524</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;424</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 163</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;579</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 621</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 28&nbsp;787</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Represents the cost of assets and accumulated amortization at January 1, 2019, related to the Alcon business reported as discontinued operations. Notes 1, 2 and 30 provide information related to discontinued operations.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Note 2 provides additional disclosures related to assets of disposal group held for sale.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> No addition in the disposal group held for sale for the period from January 1, 2019, to December 31, 2019</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;5&nbsp;</sup> Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;6&nbsp;</sup> No amortization or impairment charges related to the disposal group held for sale for the period from January 1, 2019, to December 31, 2019.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2020:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="1" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill</div>
      </td>
      <td></td>
      <td colspan="9" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible assets other than goodwill</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="9" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="9" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Total</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> In-process<br> research and<br> development</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Technologies</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently<br> marketed <br> products</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other<br> intangible<br> assets</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21&nbsp;718</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;548</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29&nbsp;645</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 925</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 35&nbsp;121</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;274</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 152</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 227</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;122</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 42</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;543</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 145</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 145</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&nbsp;999</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;700</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 230</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 30&nbsp;767</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;112</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 36&nbsp;809</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2019:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="1" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Goodwill</div>
      </td>
      <td></td>
      <td colspan="9" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Intangible assets other than goodwill</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="9" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="1" height="3"></td>
      <td height="1"></td>
      <td colspan="9" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Total</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> In-process<br> research and<br> development</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Technologies</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Currently<br> marketed <br> products</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other<br> intangible<br> assets</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&nbsp;750</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;339</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21&nbsp;720</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 520</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27&nbsp;586</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;767</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 85</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 156</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 859</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;125</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&nbsp;524</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;424</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 163</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;579</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 621</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 28&nbsp;787</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-38</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Innovative Medicines and Sandoz Divisions&#x2019; cash-generating units, to which goodwill is allocated, each comprise a group of smaller cash-generating units. The valuation method of the recoverable amount of the cash-generating units, to which goodwill is allocated, is based on the fair value less costs of disposal. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following assumptions are used in the calculations:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(As a percentage)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative <br> Medicines</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Sandoz</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Terminal growth rate</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.5</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.5</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Discount rate (post-tax)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The discount rates for all divisions consider the Group&#x2019;s weighted average cost of capital, adjusted to approximate the weighted average cost of capital of a comparable market participant.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value less costs of disposal, for all cash-generating units containing goodwill, is reviewed for the impact of reasonably possible changes in key assumptions. In particular, we considered an increase in the discount rate, a decrease in the terminal growth rate, and certain negative impacts on the forecasted cash flows. These reasonably possible changes in key assumptions did not indicate an impairment.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">&#x201C;Note 1. Significant accounting policies&mdash;Impairment of goodwill and intangible assets&#x201D; provides additional disclosures on how the Group performs goodwill and intangible asset impairment testing.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the intangible asset and goodwill impairment charges for continuing operations for 2020, 2019 and 2018: </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;768</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;669</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;592</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;141</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;506</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;249</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;914</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;175</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;841</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> 2020 includes an impairment of USD 485 million related to the write-down of IPR&amp;D related to cessation of clinical development program ZPL389 for atopic dermatitis and USD 181 million related to a partial write-down of the <I>Votrient</I> currently marketed product.<br>2019 includes an impairment of USD 416 million related to the write-down of IPR&amp;D related to cessation of clinical development program EMA401 and a USD 108 million write-down related to the cessation of clinical development program for MOR106 for atopic dermatitis.<br>2018 includes an impairment of USD 400 million related to a partial write-down of the <I>Votrient</I> currently marketed product.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> 2019 includes an impairment of USD 442 million related to the write-down of IPR&amp;D related to the discontinuation of the generic Advair<sup>&#xAE;</sup> development program.<br>2018 includes impairments of USD 220 million related to the write-down of the allocated goodwill (USD 183 million) and the currently marketed products (USD 37 million) related to the retained Sandoz US dermatology business and generic US oral solids portfolio. See Note 2.</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2020, there were no reversals of prior-year impairment charges (2019: USD 37 million; 2018: nil).</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Note 30 provides additional disclosures on discontinued operations.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-39</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId001567048"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">12. Deferred tax assets and liabilities </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Property, <br> plant and<br> equipment</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Intangible<br> assets</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pensions and<br> other benefit <br> obligations <br> of associates</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> Inventories</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Tax loss<br> carry-<br> forwards</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Other assets,<br> provisions<br> and accruals</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> Total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax assets at January 1, 2020</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 108</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;469</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;078</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;446</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 255</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;596</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;952</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax liabilities at January 1, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;390</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;610</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;291</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;287</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;325</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;5&nbsp;910</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at January 1, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;282</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2&nbsp;141</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 787</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;159</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 248</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;271</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;042</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;282</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2&nbsp;141</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 787</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;159</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 248</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;271</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;042</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 89</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 110</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 212</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;164</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 71</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 293</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to equity</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to other comprehensive income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;36</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;39</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;945</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 408</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;501</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;53</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 58</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;35</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;241</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;918</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 797</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;343</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 497</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;314</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 792</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax assets at December 31, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 189</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;351</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;137</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;502</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 507</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;658</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;344</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax liabilities at December 31, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;430</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5&nbsp;269</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;340</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;159</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;344</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7&nbsp;552</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;241</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;918</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 797</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;343</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 497</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;314</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 792</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After offsetting the following amount of deferred tax assets and liabilities within the same tax jurisdiction, the balance amounts to:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 130</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets at December 31, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;214</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities at December 31, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7&nbsp;422</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 792</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax assets at January 1, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 191</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;233</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;188</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;722</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 273</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;175</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;782</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax liabilities at January 1, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;622</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;5&nbsp;384</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;273</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;474</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;805</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;7&nbsp;558</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at January 1, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;431</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;151</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 915</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;248</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 273</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;370</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;224</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;431</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;151</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 915</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;248</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 273</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;370</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;224</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net deferred tax balance related to discontinued operations<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 82</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;403</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;123</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;248</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;39</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;217</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 858</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 74</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 605</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 308</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;818</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;113</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 298</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 354</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to equity</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 75</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;166</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;83</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to other comprehensive income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;313</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;289</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;45</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;26</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;47</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;282</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;2&nbsp;141</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 787</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;159</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 248</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;271</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;042</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax assets at December 31, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 108</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;469</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;078</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;446</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 255</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;596</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;952</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax liabilities at December 31, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;390</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;610</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;291</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;287</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;325</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;910</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;282</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;2&nbsp;141</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 787</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;159</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 248</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;271</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;042</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After offsetting the following amount of deferred tax assets and liabilities within the same tax jurisdiction, the balance amounts to:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 43</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets at December 31, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;909</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities at December 31, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;867</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;042</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup> <b> </b> <b> </b> <b> </b> <b> </b> <b> </b> <b> </b> <b> </b></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Notes 1, 2 and 30 provide information related to discontinued operations.<b> </b></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup><b></b></div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-40</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table presents deferred tax assets and deferred tax liabilities, which are expected to have an impact on current taxes payable after more than 12&nbsp;months:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD billions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected to have an impact on current tax  payable after more than 12 months</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Deferred tax assets</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.5</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.3</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Deferred tax liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Deferred tax liabilities have not been recognized for the withholding tax and other taxes that would be payable on the remittance of earnings of foreign subsidiaries, as the Group has the ability to control any future reversal and the unremitted earnings are retained in the foreign subsidiaries for reinvestment. The total unremitted earnings retained for reinvestment in the Group&#x2019;s foreign subsidiaries that would be subject to withholding tax or other taxes if remitted to the Group are estimated at approximately USD 27 billion in 2020 (2019: USD 26 billion).</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Temporary differences on which no deferred tax has been provided as they are permanent in nature related to:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD billions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Investments in subsidiaries</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill from acquisitions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;27</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;24</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The gross value of tax-loss carry-forwards that have or have not been capitalized as deferred tax assets, with their expiry dates, is as follows:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Not capitalized</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Capitalized</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020 total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One year</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Two years</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Three years</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Four years</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Five years</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 51</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">More than five years<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;400</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;291</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;691</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not subject to expiry</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 323</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 683</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;006</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;780</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;025</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;805</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Not capitalized more than five years includes USD 3.2 billion attributable to US state tax-loss carry-forwards, of which USD 1.6 billion relates to The Medicines Company, which was acquired in 2020 (see Note 2).   </div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Not capitalized</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Capitalized</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019 total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One year</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Two years</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Three years</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Four years</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 46</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 62</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Five years</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 127</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 164</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">More than five years</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 125</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;214</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;339</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not subject to expiry</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 310</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 345</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 648</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;338</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;986</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tax losses carried forward  that expired</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   14</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   9</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   8</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Deferred tax assets related to taxable losses of relevant Group entities are recognized to the extent it is considered probable that future taxable profits will be available against which such losses can be utilized in the foreseeable future.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The Basel-Stadt cantonal tax reform was approved by voters in February 2019, with parts of the reform retroactively enacted per January 1, 2019. The newly enacted tax rate resulted in a decrease of the blended cantonal and federal tax rate from 22% to 13%. This change impacted the Group&#x2019;s Basel-Stadt-domiciled operating subsidiaries. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Swiss federal tax reform was approved by voters in May 2019. The enactment of the Swiss federal tax reform required the abolishment of the holding company tax regimes as of January 1, 2020. As a result, the holding company tax rate increased from the current 8% to 13%, effective January 1, 2020. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The enactment of these Swiss tax reforms required a revaluation of the deferred tax assets and liabilities to the newly enacted tax rates at the date of enactment. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the impact on the revaluation of deferred assets and liabilities in 2019, as at the respective dates of the enactment of the Swiss tax reforms:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Income <br> statement<br> continuing<br> operations</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> Equity</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> <br> <br> <br> Total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax asset  and liability revaluation</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Items previously recognized  in consolidated income statement</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   234</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   234</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Items previously recognized  in other comprehensive income<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;358</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;358</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total revaluation of deferred  tax assets and liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   234</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;358</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;124</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Related to post-employment benefits</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-41</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId001569569"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">13. Financial and other non-current assets</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Financial assets</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity securities</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;577</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;524</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 366</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 233</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial investments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;979</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;790</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term receivables from finance subleases</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 83</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 66</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other long-term receivables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 125</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 104</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 625</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 399</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances and security deposits</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 89</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 159</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;901</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;518</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Note 29 provides additional disclosures related to contingent considerations.</div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other non-current assets</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred compensation plans</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 471</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 414</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid post-employment benefit plans</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 202</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 148</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 219</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 176</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other non-current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 892</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 738</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div><a name="anchorId001569790"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">14. Inventories</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Raw material, consumables</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 967</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 751</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Work in progress</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;324</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;024</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Finished products</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;840</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;207</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total inventories</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;131</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;982</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the amount of inventory recognized as an expense in &#x201C;Cost of goods sold&#x201D; in the consolidated income statements from continuing operations: </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD billions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8.5</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8.5</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8.3</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the recognized amount of inventory provision and reversals of inventory provision recorded in the consolidated income statements from continuing operations:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventory provisions</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;702</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;752</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;603</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversals of inventory provisions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 255</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 218</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 216</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The reversals mainly result from the release of products initially requiring additional quality control inspections and from the reassessment of inventory values manufactured prior to regulatory approval but for which approval was subsequently received.</div><a name="anchorId001569957"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">15. Trade receivables</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total gross trade receivables</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;310</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;396</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;93</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;95</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;217</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;301</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-42</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movement in the provision for doubtful trade receivables:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;95</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;126</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;190</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions related to discontinued operations<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 54</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables charged to the consolidated income statement<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;59</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;89</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;47</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Utilization of provisions for doubtful trade receivables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of provisions for doubtful trade receivables credited to the consolidated income statement<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 53</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;93</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;95</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;126</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">  </div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Notes 1, 2 and 30 provide information related to discontinued operations.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Provisions charged to the consolidated income statement from continuing operations were USD 30 million in 2018.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Reversal of provisions credited to the consolidated income statement from continuing operations were USD 44 million in 2018.</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the trade receivables that are not overdue as specified in the payment terms and conditions established with Novartis customers, as well as an analysis of overdue amounts and related provisions for doubtful trade receivables:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not overdue</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;714</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;763</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for not more than one month</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 150</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 161</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one month  but less than three months</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   118</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   123</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than three months  but less than six months</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   102</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   103</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than six months  but less than one year</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   77</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   96</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one year</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 149</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 150</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;93</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;95</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;217</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;301</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Trade receivable balances represent amounts due from our customers, which are mainly drug wholesalers, retailers, private health systems, government agencies, managed care providers, pharmacy benefit managers and government-supported healthcare systems. Novartis continues to monitor sovereign debt issues and economic conditions in the countries in which it operates, particularly in Argentina, Brazil, Greece, Italy, Portugal, Russia, Saudi Arabia, Spain and Turkey, and evaluates trade receivables in these countries for potential collection risks. The majority of the outstanding trade receivables from Portugal, Saudi Arabia, Spain and Greece are due directly from local governments or from government-funded entities. Deteriorating credit and economic conditions as well as other factors in these closely monitored countries have resulted in, and may continue to result in, an increase in the average length of time that it takes to collect these trade receivables, and may require the Group to re-evaluate the expected credit loss amount of these trade receivables in future periods.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the gross trade receivables balance from these closely monitored countries at December 31, 2020 and 2019; the amounts that are past due for more than one year; and the related provisions that have been recorded:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total balance of gross trade receivables from closely  monitored countries</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     1&nbsp;505</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     1&nbsp;588</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one year</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 55</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At December 31, 2020, amounts past due for more than one year are not significant in any of these countries on a standalone basis.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Total trade receivables include amounts denominated in the following major currencies:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;311</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;466</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;668</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;384</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 437</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 466</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Russian ruble (RUB)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 288</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 341</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chinese yuan (CNY)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 208</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 279</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">British pound (GBP)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 191</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 202</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Australian dollar (AUD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 153</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 125</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Brazilian real (BRL)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 148</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 165</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canadian dollar (CAD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 125</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 129</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 124</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 89</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other currencies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;564</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;655</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;217</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;301</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-43</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId001570628"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">16. Marketable securities, commodities, time&nbsp;deposits, derivative financial instruments, and&nbsp;cash and cash equivalents</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Marketable securities, commodities, time&nbsp;deposits and derivative financial instruments</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 111</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 110</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;609</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 159</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities, commodities, time deposits and derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;905</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 334</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Cash and cash equivalents</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current accounts</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;750</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;247</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity less than 90 days</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;908</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;865</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total cash and cash equivalents</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;658</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;112</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div><a name="anchorId001570770"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">17. Other current assets</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">VAT receivable</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 544</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 508</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Withholding tax recoverable</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 73</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 108</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid expenses</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 943</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 898</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Receivables from associated companies</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other receivables and current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 963</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;165</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;523</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;680</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div><a name="anchorId001570864"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">18. Equity</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movement in the share capital:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Jan 1, 2018</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Movement<br> in year</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Dec 31, 2018</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Movement<br> in year</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Dec 31, 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Movement<br> in year</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Dec 31, 2020</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Share capital</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 969</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;25</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 944</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 936</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;23</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 913</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Treasury shares</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;69</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;80</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;53</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding share capital</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 869</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 875</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 856</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 860</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-44</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movement in the shares:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>Number of outstanding shares <br>(in millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Note</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br> Novartis <br> shares</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br> treasury <br> shares<sup style="white-space: nowrap">   1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br> outstanding <br> shares</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br> Novartis <br> shares</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br> treasury <br> shares<sup style="white-space: nowrap">   1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br> outstanding <br> shares</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br> Novartis <br> shares</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br> treasury <br> shares<sup style="white-space: nowrap">   1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br> outstanding <br> shares</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at beginning of year</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;527.3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;262.3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;265.0</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;550.6</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;239.4</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;311.2</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;616.8</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;299.3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="4%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;317.5</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares canceled for capital  reduction<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;60.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   60.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;23.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   23.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;66.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   66.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be  canceled<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;32.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;32.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;60.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;60.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;23.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;23.3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases<sup style="white-space: nowrap">&nbsp;4</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1.2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options  and employee transactions<sup style="white-space: nowrap">&nbsp;5</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   18.9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   14.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   14.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   5.5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   5.5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   7.8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   7.8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation<sup style="white-space: nowrap">&nbsp;5</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7.4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   0.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   0.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   0.9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   0.9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share sales</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total movements</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;60.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 52.1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;8.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;23.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;22.9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;46.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;66.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 59.9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;6.3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at end of year</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;467.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;210.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;256.8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;527.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;262.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;265.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;550.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;239.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;311.2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="22" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="22">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="22">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Approximately 103.0 million treasury shares (2019: 117.6 million; 2018: 121.6 million) are held in Novartis entities that restrict their availability for use.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="22">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Novartis reduced its share capital by canceling shares that were repurchased on the SIX Swiss Exchange second trading line during previous years.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="22">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2016 Annual General Meeting (AGM) for transactions before February 28, 2019, and under a new CHF 10 billion share buyback authority approved at the 2019 AGM for transactions after such date</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="22">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="22">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;5&nbsp;</sup> Shares delivered as a result of options being exercised and physical share deliveries related to equity-based participation plans.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="22">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">18.1) The amount available for distribution as a dividend to shareholders is based on the available distributable retained earnings of Novartis AG determined in accordance with the legal provisions of the Swiss Code of Obligations.</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend per share (in CHF)</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.95</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.85</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.80</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total dividend payment  (in USD billion)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   7.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   6.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   7.0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">18.2) The following table summarizes the treasury shares movements:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> Note</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Number of <br> outstanding <br> shares<br> (in millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Equity impact<br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Number of <br> outstanding <br> shares<br> (in millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Equity impact<br> USD m</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Number of <br> outstanding <br> shares<br> (in millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Equity impact<br> USD m</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be canceled<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;32.6</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;897</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;60.3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;351</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;23.3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="6%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;859</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;159</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;160</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;114</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of treasury shares</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;34.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;056</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;62.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;511</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;24.5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;973</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 806</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 210</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7.8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 434</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation<sup style="white-space: nowrap">&nbsp;4</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 730</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 833</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 756</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share sales</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 263</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;8.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;490</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;46.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;450</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;6.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;520</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2016 AGM for transactions before February 28, 2019, and under a new CHF 10 billion share buyback authority approved at the 2019 AGM for transactions after such date</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Shares delivered as a result of options being exercised related to equity-based participation plans and the delivery of treasury shares. The average share price of the shares delivered was significantly below market price, reflecting the strike price of the options exercised.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> Equity-settled share-based compensation is expensed in the consolidated income statement in accordance with the vesting period of the share-based compensation plans. The value for the shares and options granted is credited to consolidated equity over the respective vesting period. In addition, tax benefits arising from tax-deductible amounts exceeding the expense recognized in the income statement are credited to equity.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-45</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.3) In November 2020, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD 2.5 billion share buyback. Novartis is able to cancel this arrangement at any time but could be subject to a 90-day waiting period. The commitment under this arrangement therefore reflects the obligated purchases by the bank under such trading plan over a rolling 90-day period, or if shorter, until the maturity date of such trading plan.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The commitment under this arrangement amounted to USD 1.8 billion as of December 31, 2020.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In August 2020, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares to mitigate dilution related to participation plans of associates. Novartis was able to cancel this arrangement at any time but would have been subjected to a 90-day waiting period. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">This trading plan commitment was fully executed and expired, and as a consequence, there is no contingent liability related to this plan recognized as of December 31, 2020.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2019, Novartis entered into a similar irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD&nbsp;5 billion share buyback and to repurchase Novartis shares to mitigate dilution related to participation plans of associates. The commitment under this arrangement therefore reflects the obligated purchases by the bank under such trading plan over a rolling 90-day period, or if shorter, until the maturity date of such trading plan.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The trading plan commitment was fully executed and expired, and as a consequence, there is no contingent liability related to this plan recognized as of December 31, 2019.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2018, Novartis entered into a similar irrevocable, non-discretionary arrangements with a bank to repurchase Novartis shares. The commitments under this arrangement reflected the expected purchases by the bank under such trading plan over a rolling 90-day period. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The commitment under this arrangement amounted to USD 284 million as of December 31, 2018. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.4) In October 2020, Novartis entered into an agreement with the market maker for its employee options to repurchase a portion of the outstanding written call options. A total of 3.7 million options were repurchased under this agreement. This agreement was terminated in November 2020.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.5) The impact of change in ownership of consolidated entities represents the excess of the amount paid to non-controlling interest over their carrying value and equity allocation to non-controlling interest due to change in ownership percentage. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.6) Changes in non-controlling interests represent the impact on the non-controlling interest of transactions with minority shareholders, such as change in ownership percentage, dividend payments and other equity transactions.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.7) Other movements includes, for subsidiaries in hyperinflationary economies, the impact of the restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period as well as the restatement of the equity balances of the current year. In 2020, the amount recorded in equity related to hyperinflation accounting was USD 18 million (2019: USD 22 million; 2018: USD 38 million). See Note 29 for additional disclosures.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.8) In 2019, transaction costs of USD 253 million (2018: USD 79 million) net of tax of USD 36 million (2018: USD 20 million), that are directly attributable to the distribution (spin-off) of Alcon Inc. to Novartis shareholders and that would otherwise have been avoided, were recorded as a deduction from equity. See Note 1 for further details. No transaction costs were recorded as a deduction from equity in 2020.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.9) At December 31, 2020, the market maker held 1 million (2019: 13 million; 2018: 11 million) written call options, originally issued as part of the share-based compensation for associates, that have not yet been exercised. The weighted average exercise price of these options is USD 60.09 (2019: USD 63.90; 2018: USD 62.70), and they have contractual lives of 10 years, with remaining lives up to three years (2019: four years; 2018: five years). </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In December 2018, Novartis entered into an agreement with the market maker for its employee options to repurchase a portion of the outstanding written call options that are not exercised in exchange for treasury shares. During 2019, this agreement was fully executed.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-46</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId001572762"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">19. Non-current financial debt</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&nbsp;298</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22&nbsp;167</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities to banks and other financial institutions<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 233</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 188</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total, including current portion of non-current financial debt</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28&nbsp;531</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;355</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion of non-current financial debt</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;272</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;002</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26&nbsp;259</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&nbsp;353</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Average interest rate 0.3% (2019: 0.2%)</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">All bonds are initially recorded at the amount of proceeds received, net of transaction costs. They are subsequently carried at amortized cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognized as a charge to the consolidated income statement over the period of the relevant bond. Financial debts, including current financial debts, contain only general default covenants. The Group is in compliance with these covenants.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The percentage of fixed-rate financial debt to total financial debt was 79% at December 31, 2020, and 82% at December 31, 2019.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The average interest rate on total financial debt in 2020 was 2.0% (2019: 2.4%).</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 29 contains a maturity table of the Group&#x2019;s future contractual interest payments commitments.</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides a breakdown of straight bonds:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>Coupon</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Currency</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Nominal <br> amount<br> (millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Issuance <br> year</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Maturity <br> year</div>
      </td>
      <td></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Issuer</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Issue price</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020<br> (USD<br> millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019<br> (USD<br> millions)</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4.400%</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2010</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div>
      </td>
      <td align="right" width="1%"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.237%</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.400%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;500</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2012</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.225%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;497</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;495</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3.700%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2012</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2042</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98.325%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 490</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 489</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3.400%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;150</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2014</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.287%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;142</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;139</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4.400%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;850</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2014</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2044</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.196%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;826</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;825</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.750%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 600</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2014</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.134%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 737</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 670</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.625%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 600</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2014</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2026</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.697%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 735</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 670</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.250%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis AG, Basel, Switzerland</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.640%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 568</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 517</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.625%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 550</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2029</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis AG, Basel, Switzerland</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.502%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 625</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 568</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.050%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 325</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2035</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis AG, Basel, Switzerland</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.479%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 369</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 336</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3.000%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;750</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.010%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;737</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;735</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4.000%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2045</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98.029%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;220</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;219</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.125%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2016</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.127%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;530</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;392</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.625%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2016</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2028</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98.480%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 607</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 553</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.800%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.609%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;000</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.400%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.449%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 998</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 996</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3.100%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2027</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.109%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 992</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 990</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.000%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.133%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;536</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;396</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.125%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 600</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2027</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.874%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 735</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 670</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.500%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 750</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.655%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 919</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 837</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.375%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 750</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2030</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.957%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 920</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 838</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.700%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 750</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2038</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.217%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 913</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 832</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.750%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.852%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 996</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.000%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2027</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.909%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;245</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.200%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;500</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2030</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.869%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;493</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.750%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2050</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 97.712%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;213</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.000%<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;850</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2028</div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.354%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;255</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total straight bonds</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td>
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28&nbsp;298</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;167</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> The EUR 1 850 million bond issued in 2020 features a coupon step-up of 0.25% commencing with the first interest payment date after December 31, 2025, if one or both of the 2025 Patient Access Targets are not met. These 2025 Patient Access Targets are the 2025 Flagship Programs Patient Reach Target and the 2025 Strategic Innovative Therapies Patient Reach Target, as defined in the bond prospectus. As of December 31, 2020, there is no indication that these 2025 Patient Access Targets will not be met.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-47</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables provide a breakdown of total non-current financial debt, including current portion by maturity and currency:</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Breakdown by maturity:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2020</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;002</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2021</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;272</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;067</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;631</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;583</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;546</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;321</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;142</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;139</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;302</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;252</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After 2025</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&nbsp;638</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;991</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28&nbsp;531</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;355</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Breakdown by currency:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&nbsp;848</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;889</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&nbsp;888</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;861</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 194</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 184</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;563</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;421</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28&nbsp;531</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;355</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The following table shows the comparison of balance sheet and fair value of total non-current financial debt, including current portion:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020<br> Balance<br> sheet</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020<br> Fair<br> values</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019<br> Balance<br> sheet</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019<br> Fair<br> values</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&nbsp;298</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31&nbsp;359</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22&nbsp;167</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23&nbsp;701</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 233</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 233</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 188</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 188</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28&nbsp;531</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 31&nbsp;592</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;355</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;889</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The fair values of straight bonds are determined by quoted market prices. Other financial debts are recorded at notional amounts, which are a reasonable approximation of the fair values.</div><a name="anchorId001574591"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">20. Provisions and other non-current liabilities</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued liability for employee benefits:</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit pension plans<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;538</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;469</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other long-term employee benefits and deferred compensation</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 637</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 546</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other post-employment benefits<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 543</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 612</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Environmental remediation provisions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 642</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 592</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for product liabilities, governmental investigations and other legal matters</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 181</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 200</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 984</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 958</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 409</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 255</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total provisions and other non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;934</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;632</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Note 25 provides additional disclosures related to post-employment benefits.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis believes that its total provisions are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities in this area, Novartis may incur additional costs beyond the amounts provided. Management believes that such additional amounts, if any, would not be material to the Group&#x2019;s financial condition but could be material to the results of operations or cash flows in a given period.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-48</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Environmental remediation provisions</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movements in the environmental liability provisions:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 714</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 692</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 761</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;48</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;27</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005; 83</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;21</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 82</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 124</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;7</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 809</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 714</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 692</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current provision</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;167</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;122</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;58</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current environmental remediation provisions at December 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">     642</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     592</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     634</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">  </div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Releases of provisions credited to the consolidated income statement from continuing operations were USD 21 million in 2018.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Additions to provisions charged to the consolidated income statement from continuing operations were USD 7 million in 2018.</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The material components of the environmental remediation provisions consist of costs to sufficiently clean and refurbish contaminated sites to the extent necessary and to continue surveillance at sites where the environmental remediation exposure is less significant. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A substantial portion of the environmental remediation provisions relate to the remediation of Basel regional landfills in the adjacent border areas in Switzerland, Germany and France. The provisions are reassessed on a yearly basis and adjusted as necessary.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the United States, Novartis has been named under federal legislation (the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended) as a potentially responsible party (PRP) in respect of certain sites. Novartis actively participates in, or monitors, the cleanup activities at the sites in which it is a PRP. The provision takes into consideration the number of other PRPs at each site as well as the identity and financial position of such parties in light of the joint and several nature of the liability. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The expected timing of the related cash outflows as of December 31, 2020, is currently projected as follows:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Expected <br> cash outflows</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due within two years</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 181</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due later than two years, but within five years</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 210</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due later than five years, but within 10 years</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 338</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due after 10 years</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 80</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total environmental remediation liability provisions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 809</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Provisions for product liabilities, governmental investigations and other legal matters </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has established provisions for certain product liabilities, governmental investigations and other legal matters where a potential cash outflow is probable and Novartis can make a reliable estimate of the amount of the outflow. These provisions represent the Group&#x2019;s current best estimate of the total financial effect for the matters described below and for other less significant matters. Potential cash outflows reflected in a provision might be fully or partially offset by insurance in certain circumstances.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis has not established provisions for potential damage awards for certain additional legal claims against its subsidiaries if Novartis currently believes that a payment is either not probable or cannot be reliably estimated. In total, these not-provisioned-for matters include more than 3&#xA0;000 individual product liability cases and certain other legal matters. Plaintiffs&#x2019; alleged claims in these matters, which Novartis does not believe to be entirely remote but which do not fulfill the conditions for the establishment of provisions, currently aggregate to, according to the current best belief of Novartis, approximately USD&nbsp;0.5 billion. In addition, in some of these matters there are claims for punitive or multiple (treble) damages, civil penalties and disgorgement of profits that in the view of Novartis are either wholly or partially unspecified, or wholly or partially unquantifiable at present; the Group believes that information about these amounts claimed by plaintiffs generally is not meaningful for purposes of determining a reliable estimate of a loss that is probable or more than remote.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A number of other legal matters are in such early stages or the issues presented are such that the Group has not made any provisions since it cannot currently estimate either a potential outcome or the amount of any potential losses. For these reasons, among others, the Group generally is unable to make a reliable estimate of possible loss with respect to such cases. It is therefore not practicable to provide information about the potential financial impact of those cases.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There might also be cases for which the Group was able to make a reliable estimate of the possible loss or the range of possible loss, but the Group believes that publication of such information on a case-by-case basis would seriously prejudice the Group&#x2019;s position in ongoing legal proceedings or in any related settlement discussions. Accordingly, in such cases, information has been disclosed with respect to the nature of the contingency, but no disclosure is provided as to an estimate of the possible loss or range of possible loss.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 28 contains additional information on contingencies.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Summary of significant legal proceedings</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following is a summary of significant legal proceedings to which Novartis or its subsidiaries are currently a party, or were a party and that concluded in 2020.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Investigations and related litigations</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Southern District of New York (S.D.N.Y.) Gilenya marketing practices investigation and litigation</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2013, Novartis Pharmaceuticals Corporation (NPC) received a civil investigative demand from the United States Attorney&#x2019;s Office (USAO) for the S.D.N.Y. requesting the production of documents and information relating to marketing practices for <i>Gilenya</i>, including the </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-49</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">remuneration of healthcare providers in connection therewith. In 2017, the S.D.N.Y. and New York State declined to intervene in claims raised by an individual relator in a <i>qui tam</i> complaint, which continue to be vigorously contested.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Government generic pricing antitrust investigations, antitrust class actions</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Since 2016, Sandoz Inc. has received a grand jury subpoena and a civil investigative demand and interrogatories from the Antitrust and Civil Divisions of the US Department of Justice (DOJ), and a subpoena and interrogatories from the Attorney General of the State of Connecticut in connection with those agencies&#x2019; investigation into alleged price fixing and market allocation of generic drugs in the US market as well as alleged federal False Claims Act (FCA) violations. In 2020, Sandoz Inc. reached a resolution with the DOJ Antitrust Division, pursuant to which Sandoz Inc. agreed to pay USD 195 million and entered into a deferred prosecution agreement. The Sandoz resolution related to instances of misconduct at the company between 2013 and 2015 with regard to certain generic drugs sold in the United States. Under the terms of that agreement, Sandoz Inc. will continue to take steps to enhance its compliance program, employee training and monitoring, and will continue to cooperate with the US government&#x2019;s ongoing investigation into the generic pharmaceutical industry. Sandoz Inc. is also in negotiations with the DOJ Civil Division to resolve potential related claims and has recorded a provision of USD 187 million.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Since the third quarter of 2016, Sandoz Inc. and Fougera Pharmaceuticals Inc. have been sued alongside other generic pharmaceutical companies in numerous individual and putative class action complaints by direct and indirect private purchasers and by 54 states and US territories, represented by their respective Attorneys General. Plaintiffs claim that defendants, including Sandoz, engaged in price fixing and market allocation of generic drugs in the US market, and seek damages and injunctive relief. The actions contain product-specific complaints as well as complaints alleging the existence of an overarching industry conspiracy, and assert violations of federal and state antitrust laws as well as consumer protection laws. The cases have been consolidated for pretrial purposes in the United States District Court (USDC) for the Eastern District of Pennsylvania, and the claims are being vigorously contested.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Lucentis/Avastin<sup>&#xAE;</sup> matters</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In connection with an investigation into whether Novartis entities, F. Hoffmann-La Roche AG, Genentech Inc. and Roche S.p.A. colluded to artificially preserve the market positions of Avastin<sup>&#xAE;</sup> and <i>Lucentis</i>, in 2014 the Italian Competition Authority (ICA) imposed a fine equivalent to USD 125 million on the Novartis entities. Novartis paid the fine, subject to the right to later claim recoupment, and appealed before the Consiglio di Stato (CdS). In 2014 and 2015, the Italian Ministry of Health and the Lombardia region sent letters with payment requests for a total equivalent of approximately USD&nbsp;1.3 billion in damages from Novartis and Roche entities based on these allegations. In 2019, the CdS upheld the ICA decision and fine. Following the CdS decision, several additional Italian regions and hospitals sent letters claiming damages for an aggregate amount of approximately USD 330 million. None of these claims has been asserted in legal proceedings.  Novartis continues to appeal the CdS decision. In 2019, the French Competition Authority (FCA) issued a Statement of Objections against Novartis entities, alleging anti-competitive practices on the French market for anti-vascular endothelial growth factor treatments for wet age-related macular degeneration from 2008 to 2013. In 2020, the FCA issued a decision finding that the Novartis entities had infringed competition law by abusing a dominant position and imposing a fine of EUR 385 million (equivalent to approximately USD 452 million). Novartis paid the fine, again subject to recoupment, and is appealing the FCA&#x2019;s decision. Novartis continues to vigorously contest all claims in Italy and France. Novartis is also challenging policies and regulations allowing off-label/unlicensed use and reimbursement for economic reasons in various countries, including Italy and Turkey.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Japan investigation</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2015, a trial started against a former Novartis Pharma K.K. (NPKK) employee, and also against NPKK under the dual liability concept in Japanese law, over allegations brought by the Tokyo District Public Prosecutor Office for alleged manipulation of data in sub-analysis publications of the Kyoto Heart Study regarding valsartan. The charges against NPKK are subject to a maximum total fine of JPY 4 million. In 2018, the Tokyo High Court upheld a not-guilty ruling of the Tokyo District Court for both the former NPKK employee and NPKK. A further appeal by the Tokyo High Public Prosecutor Office remains pending.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">South Korea investigation</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2016, the Seoul Western District Prosecutor initiated a criminal investigation into, among other things, allegations that Novartis Korea utilized medical journals to provide inappropriate economic benefits to healthcare professionals (HCPs). This resulted in a non-material fine in January 2020, and the Prosecutor has appealed the fine. The resolution of inquiries by the DOJ and the US Securities and Exchange Commission (SEC) regarding this matter is described below in &#x201C;Concluded legal matters - US Government Foreign Corrupt Practices Act (FCPA) investigations.&#x201D;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Greece investigation</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis is providing information to the Greek authorities investigating allegations of potentially inappropriate economic benefits to HCPs, government officials and others in Greece. These authorities include the Greek Coordinating Body for Inspection and Control, and the Greek Body of Prosecution of Financial Crime, from which the Company received a summons in 2018 and 2020. The resolution of inquiries by the DOJ and the SEC regarding this matter is described below in &#x201C;Concluded legal matters - US Government Foreign Corrupt Practices Act (FCPA) investigations.&#x201D;</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-50</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Antitrust class actions</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Exforge</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Since 2018, Novartis Group companies as well as other pharmaceutical companies have been sued by various direct and indirect purchasers of <i>Exforge</i> in multiple US individual and putative class action complaints. They claim that Novartis made a reverse payment in the form of an agreement not to launch an authorized generic, alleging violations of federal antitrust law and state antitrust, consumer protection and common laws, and seeking damages as well as injunctive relief. The cases have been consolidated in the S.D.N.Y. and the claims are being vigorously contested.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Product liability litigation</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Reclast  </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">NPC is a defendant in more than 20 US product liability actions involving <i>Reclast</i> and alleging atypical femur fracture injuries, all of which are in New Jersey state or federal court and in California state court, coordinated with claims against other bisphosphonate manufacturers. The claims are being vigorously contested.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Taxotere<sup>&#xAE;</sup> (docetaxel)</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sandoz is a defendant in more than 3&#xA0;000 US product liability actions involving Taxotere<sup>&#xAE;</sup> (docetaxel), an oncology product, many of which have been transferred to a multidistrict litigation in the Eastern District of Louisiana. The complaints allege misleading marketing and that Sanofi, as innovator, and several 505(b)(2) NDA holders (including Sandoz) failed to warn of the risk of permanent alopecia/hair loss. The claims are being vigorously contested.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Amiodarone</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sandoz entities are named in less than five individual and multi-plaintiff US product liability cases involving amiodarone, a cardiac drug indicated to treat life-threatening arrhythmias that have not responded to other treatment. The complaints allege failure to warn, off-label promotion and failure to include medication guides to pharmacies. The claims are being vigorously contested.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Sartans and ranitidine</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Since 2018, claims have been brought against Sandoz and other pharmaceutical companies alleging injury from carcinogenic impurities found in valsartan and valsartan/HCT film-coated tablets and/or losartan marketed or manufactured by Sandoz.  These claims include several putative class actions in Canada. Claims have also been brought alleging injury from carcinogenic impurities in ranitidine-containing medicines. These claims also include several putative class actions in Canada and a multidistrict litigation in Florida. All of these claims are being vigorously contested.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Tasigna</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">NPC is a defendant in more than 80 US product liability actions involving <i>Tasigna</i>, alleging that the product caused various cardiovascular effects and that NPC failed to provide adequate warnings about those alleged side effects. The actions are pending in New Jersey state court and in federal courts in various jurisdictions.  The claims are being vigorously contested.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other matters</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Average Wholesale Price (AWP) litigation</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Lawsuits have been brought, the latest in February 2016, by various US state governmental entities and private parties against various pharmaceutical companies, including NPC, alleging that they fraudulently overstated the AWP that is or has been used by payors, including state Medicaid agencies, to calculate reimbursements to healthcare providers. NPC remains a defendant in a putative class action brought by private payors in New Jersey, and vigorously contests those claims.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Aimovig&ndash;Amgen dispute</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2015 and 2017, Novartis and Amgen entered into agreements regarding the development and commercialization of <i>Aimovig</i>, which the companies co-commercialize in the US and to which Novartis has exclusive rights in all territories outside the US, excluding Japan. Amgen issued a termination notice in April 2019 based on an alleged material breach of the collaboration agreements, and this notice, as well as other ancillary matters, are the subject of legal proceedings between Novartis and Amgen. Novartis disputes Amgen&#x2019;s allegations vigorously. In 2020, the court ruled that Amgen did not have grounds to terminate the 2017 agreement and dismissed that portion of their lawsuit.  The collaboration continues during the litigation between the companies, and will remain in force until and unless a final court decision terminates the agreements.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Shareholder Derivative Lawsuit</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2021, NPC, Sandoz Inc., Novartis Capital Corporation and certain present and former directors and officers of Novartis were named as defendants, and Novartis was named as a nominal defendant, in a purported shareholder derivative lawsuit filed in New York state court. The plaintiff, derivatively as a purported Novartis shareholder on behalf of Novartis, seeks damages and other remedies based on alleged conduct by the corporate and individual defendants. The claims are being vigorously contested.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Concluded legal matters</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">S.D.N.Y. marketing practices investigation and litigation</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2013, the US government filed a civil complaint in intervention to an individual <i>qui tam</i> action against NPC in the USDC for the S.D.N.Y. The complaint, as subsequently amended, asserted federal FCA and common law claims with respect to speaker programs and other promotional activities for certain NPC cardiovascular medications (<i>Lotrel</i>, <i>Starlix</i> and <i>Valturna</i>) allegedly serving as mechanisms to provide kickbacks to HCPs. Also in 2013, New York State filed a civil complaint in intervention asserting similar claims. In 2020, Novartis finalized its settlement agreement with the S.D.N.Y, the New York State Attorney General and the individual relator to resolve their claims. As part of this settlement, Novartis agreed to pay USD 0.7 billion, and has agreed to new corporate integrity obligations with the Office of Inspector General of the US Department of Health and Human Services.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-51</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">U.S. Government Foreign Corrupt Practices Act (FCPA) investigations</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2020, Novartis reached settlements with the DOJ and the SEC resolving all FCPA investigations into historical conduct by Novartis and its subsidiaries. These investigations were previously disclosed in Note 20 to the Consolidated Financial Statements in our 2019 Annual Report and 2019 Form 20-F under the headings &#x201C;Investigations and related litigations &ndash; Greece investigation,&#x201D; &#x201C;Investigations and related litigations &ndash; South Korea investigation&#x201D; and &#x201C;Investigations and related litigations &ndash; Asia/Russia investigation.&#x201D; As part of the coordinated resolution of these investigations, Novartis and certain of its current and former subsidiaries agreed to pay USD 0.3 billion. To resolve the DOJ investigation, both Novartis Hellas S.A.C.I. and Alcon Pte Ltd., a former Novartis subsidiary, entered into separate deferred prosecution agreements (DPA) with the DOJ. The Novartis Hellas DPA contained no allegations relating to any bribery of Greek politicians, which is consistent with what Novartis found in its own internal investigation. To resolve the SEC investigation, Novartis AG reached an agreement pertaining to internal controls and books and records violations in Greece, Vietnam and South Korea, which also addressed certain internal controls and books and records issues related to Alcon China&#x2019;s placement of surgical devices. Other developments in Greece and South Korea are described above in &#x201C;Investigations and related litigations &ndash; Greece investigation&#x201D; and &#x201C;Investigations and related litigations &ndash; South Korea investigation,&#x201D; respectively. The matters disclosed in Note 20 to the Consolidated Financial Statements in our 2019 Annual Report and 2019 Form 20-F under the heading &#x201C;Investigations and related litigations &ndash; Asia/Russia investigation&#x201D; are now concluded.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Enoxaparin</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2015, Sandoz and Momenta Pharmaceuticals were sued in a putative antitrust class action in federal court in Tennessee alleging that Momenta and Sandoz engaged in anticompetitive and unfair business conduct with regard to sales of enoxaparin. In 2019, Sandoz  agreed to pay USD 85 million to resolve the class action. The matter is now concluded.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Summary of product liability, governmental investigations and other legal matters provision movements</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;369</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 340</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 351</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions related to  discontinued operations<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;42</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;863</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;116</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;118</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases of provisions<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;52</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;107</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to provisions<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;018</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;230</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 220</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 487</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;369</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 340</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;306</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;169</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;126</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current product  liabilities, governmental  investigations and other  legal matters provisions  at December 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">         181</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">         200</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">         214</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Notes 1, 2 and 30 provide information related to discontinued operations.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Releases of provisions credited to the consolidated income statement from continuing operations were USD 107 million in 2018.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Additions to provisions charged to the consolidated income statement from continuing operations were USD 220 million in 2018.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis believes that its total provisions for investigations, product liability, arbitration and other legal matters are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities, there can be no assurance that additional liabilities and costs will not be incurred beyond the amounts provided.</div><a name="anchorId001575559"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">21. Current financial debt and&nbsp;derivative&nbsp;financial&nbsp;instruments</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of associates  payable on demand<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   2&nbsp;085</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1&nbsp;836</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other financial debt<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 976</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 719</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;258</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;289</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current portion of non-current financial debt</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;272</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;002</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 194</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 185</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt and derivative  financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   9&nbsp;785</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   7&nbsp;031</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Weighted average interest rate 0.4% (2019: 0.5%)</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Weighted average interest rate 5.0% (2019: 12.9%)</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated balance sheet amounts of current financial debt, other than the current portion of non-current financial debt, approximate the estimated fair value due to the short-term nature of these instruments.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Details on commercial papers and short term borrowings are provided under &#x201C;Liquidity risk&#x201D; in Note&nbsp;29.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-52</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">  </div><a name="anchorId001575719"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">22. Provisions and other current liabilities</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes other than income taxes</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 749</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 471</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Restructuring provisions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 459</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 438</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued expenses for goods and services received but not invoiced</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;167</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;046</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accruals for royalties</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 732</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 653</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued interests on financial debt</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 133</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 98</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for deductions from revenue</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;256</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;595</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accruals for compensation and benefits, including social security</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;286</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;464</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Environmental remediation liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 167</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 122</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 56</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 114</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for product liabilities, governmental investigations and other legal matters<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 306</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;169</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued share-based payments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 269</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 326</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent considerations<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 62</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 78</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;769</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other payables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 716</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 764</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total provisions and other current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&nbsp;127</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;338</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Note 20 provides additional disclosures related to legal provisions.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Note 29 provides additional disclosures related to contingent considerations.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Note 18 provides additional disclosures related to commitment for repurchase of own shares.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Provisions are based upon management&#x2019;s best estimate and adjusted for actual experience. Such adjustments to historic estimates have not been material.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-53</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Provisions for deductions from revenue</font>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movement of the provisions for deductions from revenue:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income statement charge<sup>2</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Revenue<br> deductions<br> provisions at<br> January 1</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Revenue <br> deductions <br> provisions<br> related to <br> discontinued <br> operations<sup>1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Effect of<br> currency<br> translation <br> and business<br> combinations</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Payments/<br> utilizations</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Adjustments<br> of prior years</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> <br> Current year</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Change in <br> provisions<br> offset against<br> gross trade<br> receivables</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Revenue<br> deductions<br> provisions at<br> December 31</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">2020</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US-specific healthcare plans  and program rebates</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   1&nbsp;981</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;5&nbsp;560</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;107</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   5&nbsp;739</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   2&nbsp;053</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-US-specific healthcare plans  and program rebates</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   1&nbsp;769</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   167</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;2&nbsp;597</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   2&nbsp;940</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   2&nbsp;272</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-healthcare plans  and program-related rebates, returns and other deductions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     1&nbsp;845</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     67</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     &#x2013;&#x2005;11&nbsp;137</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     &#x2013;&#x2005;51</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     11&nbsp;094</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     113</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     1&nbsp;931</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;595</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 234</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;19&nbsp;294</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;151</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 19&nbsp;773</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 99</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;256</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US-specific healthcare plans  and program rebates</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1&nbsp;883</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;5&nbsp;183</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;193</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   5&nbsp;474</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1&nbsp;981</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-US-specific healthcare plans  and program rebates</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1&nbsp;625</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;28</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;2&nbsp;467</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   2&nbsp;659</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1&nbsp;769</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-healthcare plans  and program-related rebates, returns and other deductions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     1&nbsp;754</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2013;&#x2005;166</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2013;&#x2005;11&nbsp;698</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2013;&#x2005;25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     11&nbsp;868</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     103</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     1&nbsp;845</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;262</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;194</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;19&nbsp;348</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;220</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&nbsp;001</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 104</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;595</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">2018</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US-specific healthcare plans  and program rebates</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1&nbsp;590</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;4&nbsp;158</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;90</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   4&nbsp;541</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1&nbsp;883</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-US-specific healthcare plans  and program rebates</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1&nbsp;356</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;78</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;2&nbsp;182</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   83</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   2&nbsp;555</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;109</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1&nbsp;625</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-healthcare plans  and program-related rebates, returns and other deductions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     1&nbsp;726</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2013;&#x2005;51</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2013;&#x2005;12&nbsp;227</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2013;&#x2005;91</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     11&nbsp;956</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     441</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     1&nbsp;754</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total 2018</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;672</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;129</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;18&nbsp;567</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;98</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 19&nbsp;052</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 332</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;262</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Notes 1, 2 and 30 provide information related to discontinued operations.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="18">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Charges to the consolidated income statement from continuing operations were USD 18 248 million in 2018.</div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Restructuring provisions movements</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 438</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 507</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 153</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions related to  discontinued operations<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 354</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 492</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 534</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;268</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;479</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;145</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;87</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;72</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;33</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 459</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 438</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 507</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   </div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Notes 1, 2 and 30 provide information related to discontinued operations.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Additions to provisions charged to the consolidated income statement from continuing operations were USD 521 million in 2018.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Reversal of provisions credited to the consolidated income statement from continuing operations were USD 31 million in 2018.</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2020, additions to provisions of USD&nbsp;354 million were mainly related to the following reorganizations:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Innovative Medicines Division restructured its field force and supporting functions in Region Europe.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Sandoz Division initiatives to realign its organizational structures to improve competiveness that commenced in 2019 continued. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Group-wide initiatives to streamline Novartis Technical Operations through the setup of operations centers and implementation of new technologies, in the Innovative Medicines Division and the Sandoz Division, continued. In addition, Novartis Business Services continued the phased implementation of the new operating model to change outsourcing structures and transition activities to service centers.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2019, additions to provisions of USD 492 million were mainly related to the following reorganizations:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Innovative Medicines Division restructured its field force and supporting functions in Latin America, and following the <i>Xiidra</i> acquisition, its Ophthalmology field force in the US.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Sandoz Division initiatives to realign its organizational structures to improve competiveness. These ini-</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-54</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">tiatives include reduction in its headquarters, global functions and countries workforce, and the closure of its development center in Holzkirchen, Germany. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Group-wide initiatives to streamline Novartis Technical Operations and implement new technologies, mainly in the Innovative Medicines Division and in the Sandoz Division, continued. In addition, Novartis Business Services launched the next phase of the new operating model to change outsourcing structures and transition activities to service centers.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">In 2018, additions to provisions of USD&nbsp;534 million were mainly related to the following reorganizations:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Innovative Medicines Division&#x2019;s Oncology business unit initiative to streamline its organizational structure. The objective was to enhance agility and efficiency, resulting in an acceleration of operational execution. In addition, a program to reorganize the Japanese business model was launched. Region Europe transformed its approach to market in light of the changing product portfolio. The objective was to speed up patient access.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Group-wide initiatives to streamline Novartis Technical Operations and implement new technologies, mainly in the Innovative Medicines Division and in the Sandoz Division, continued. In addition, Novartis Business Services launched an initiative to reorganize its organizational structure to achieve cost efficiencies by shifting activities to global service centers.</div><a name="anchorId001577662"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"><b>23. Details to the consolidated statements of cash flows</b></div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.1) Reversal of non-cash items and other adjustments from continuing operations</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation, amortization and impairments on:</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;758</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;547</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;783</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 330</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 305</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;376</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;974</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;428</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial assets<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;335</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;38</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;411</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;871</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 895</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gains on disposal and other adjustments on property, plant and equipment; intangible assets;  financial assets; and other non-current assets, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;478</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;1&nbsp;234</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;902</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-settled compensation expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 738</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 758</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 673</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;673</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;659</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6&nbsp;438</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;807</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;793</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;295</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net financial expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 947</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 805</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 746</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;881</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;122</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;486</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Depreciation of right-of-use assets recognized from January 1, 2019, the date of implementation of IFRS 16 Leases. See Note 1.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Includes fair value adjustments</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> 2018 included a reversal of a pre-tax gain (USD 5.8 billion) recognized from the divestment of the investment in GSK Consumer Healthcare Holdings Ltd. (see Note 2). The net cash proceed of USD 13.0 billion from the divestment was included in the consolidated statements of cash flows in the line "Acquisitions and divestments of interests in associated companies, net."</div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.2) Total amount of taxes paid </font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2020, the total amount of taxes paid was USD&nbsp;1.9 billion, of which USD&nbsp;1.8 billion was included within &#x201C;Net cash flows from operating activities from continuing operations&#x201D;, and USD&nbsp;88 million was included within &#x201C;Net cash flows used in investing activities from discontinued operations.&#x201D;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2019, the total amount of taxes paid was USD&nbsp;2.0 billion, of which USD&nbsp;1.9 billion was included within &#x201C;Net cash flows from operating activities from continuing operations&#x201D;, USD&nbsp;38 million was included within &#x201C;Net cash flows from operating activities from discontinued operations,&#x201D; and USD&nbsp;79 million was included within &#x201C;Net cash flows used in investing activities from discontinued operations.&#x201D;</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2018, the total amount of taxes paid was USD&nbsp;1.8 billion, of which USD&nbsp;1.5 billion was included within &#x201C;Net cash flows from operating activities from continuing operations&#x201D;, USD&nbsp;164 million was included within &#x201C;Net cash flows from operating activities from discontinued operations,&#x201D; and USD&nbsp;139 million was included within &#x201C;Net cash flows used in investing activities from continuing operations.&#x201D;</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-55</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.3) Cash flows from changes in working capital and other operating items included in the net cash flows from operating activities from continuing operations</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Increase) in inventories</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;543</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;382</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;387</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Decrease/(increase) in trade receivables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 137</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;980</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;544</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Decrease)/increase in trade payables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;324</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 553</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 252</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 229</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;160</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 316</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 211</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;167</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 941</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other adjustments, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;291</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 199</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 576</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.4) Cash flows arising from acquisitions and divestments of interests in associated companies, net</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2018, acquisitions and divestments of interests in associated companies included USD 12&#xA0;855 million net of taxes (USD 12&#xA0;994 million before taxes) from the divestment of the investment in GSK Consumer Healthcare Holdings Ltd. (see Note 2).</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.5) Cash flows arising from acquisitions and divestments of businesses, net</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table is a summary of the cash flow impact of acquisitions and divestments of businesses. The most significant transactions are described in Note 2.</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of acquisitions of businesses</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;10&nbsp;173</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;124</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;13&nbsp;660</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value of previously held equity interests</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 242</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments, deferred consideration and other adjustments, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 62</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;36</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used for acquisitions of businesses</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;10&nbsp;006</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;851</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;13&nbsp;701</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows from divestments of businesses, net<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 49</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 91</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used for acquisitions and divestments of businesses, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;9&nbsp;957</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;760</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;13&nbsp;683</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> In 2020, USD 49 million represented the net cash inflows from divestments in previous years. <br>In 2019, the USD 91 million included USD 4 million of net cash outflows from divestments in previous years, and USD 95 million net cash inflows from business divestments in 2019. The net identifiable assets of the 2019 divested businesses amounted to USD 196 million, comprised of non-current assets of USD 159 million; current assets of USD 96 million, including USD 11 million cash and cash equivalents; non-current liabilities of USD 18 million; and current liabilities of USD 41 million.<br>In 2018, USD 18 million represented the net cash inflows from divestments in previous years.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Notes 2 and 24 provide further information regarding acquisitions and divestments of businesses. All acquisitions were for cash.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-56</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.6) Reconciliation of liabilities arising from financing activities</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> Non-current <br> financial <br> debts</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Current <br> financial <br> debts and <br> derivative <br> financial <br> instruments</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Non-current <br> lease liabilities</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> Current lease <br> liabilities</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2020</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20&nbsp;353</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;031</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;703</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 246</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;126</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of non-current financial debts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;003</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;261</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;312</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;56</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New leases</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 221</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 73</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, and other changes, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 65</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 832</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 392</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification from non-current to current, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;067</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;067</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 250</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26&nbsp;259</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;785</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;719</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 286</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> Non-current <br> financial <br> debts</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Current <br> financial <br> debts and <br> derivative <br> financial <br> instruments</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> <br> Non-current <br> lease liabilities</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> <br> Current lease <br> liabilities</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2019</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;470</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;678</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of adoption of IFRS 16 Leases continuing operations<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;471</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 268</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of adoption of IFRS 16 Leases discontinued operations<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;89</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 246</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 40</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debts and lease liabilities related to discontinued operations<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;47</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;246</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;40</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 93</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of non-current financial debts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;195</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;582</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;273</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;51</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New leases</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 362</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 131</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions and divestments of businesses</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, and other changes, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 129</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;141</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification from non-current to current, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;003</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;003</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;156</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 156</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&nbsp;353</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;031</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;703</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 246</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Lease liabilities recognized on January 1, 2019, the date of implementation of IFRS 16 Leases. See Note 1.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> In 2018, financial debts included USD 89 million for previously reported finance lease obligations of the Alcon business that were reclassified on January 1, 2019, to lease liabilities, with the adoption of IFRS 16 Leases. Note 30 provides additional disclosures.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Represents the financial debts and lease liabilities at January 1, 2019, related to the Alcon business reported as discontinued operations. See Notes 1, 2 and 30.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-57</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> Non-current <br> financial <br> debts</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Current <br> financial <br> debts and <br> derivative <br> financial <br> instruments</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2018</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;224</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;308</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;856</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of non-current financial debts<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;366</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;681</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, and other changes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;48</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;462</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;93</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current portion of non-current financial debt</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;190</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;190</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2018</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;470</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;678</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Increase in non-current financial debts was only recorded in the consolidated statements of cash flows from continuing operations.  </div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Repayment of non-current financial debts was only recorded in the consolidated statements of cash flows from continuing operations.  </div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Changes in current financial debts included in the consolidated statements of cash flows from continuing operations were USD 1 687 million.  </div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For net cash flows used in investing activities from discontinued operations, see Note 30.</div><a name="anchorId001579570"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">24. Acquisitions of businesses</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Fair value of assets and liabilities arising from acquisitions of businesses</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 137</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 196</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;550</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;531</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;600</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 342</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;224</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 218</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 476</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 60</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 381</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current financial and other assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 84</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 195</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables and financial and other current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 109</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 90</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;112</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;977</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;107</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;874</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current financial debts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current lease liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;44</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables and other liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;144</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;178</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;627</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net identifiable assets acquired</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;669</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;938</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;000</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired cash and cash equivalents</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;76</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;112</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-controlling interests</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;26</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;580</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 186</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;084</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of acquisitions of businesses<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&nbsp;173</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;124</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;946</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="8">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> In 2018, net assets recognized as a result of acquisitions of businesses in the consolidated balance sheet from continuing operations were USD 13 660 million.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Note 2 details significant acquisitions of businesses, specifically, The Medicines Company and the Japanese business of AGI in 2020; <i>Xiidra</i> and IFM Tre, Inc. in 2019; and AAA, AveXis and Endocyte in 2018. The goodwill arising out of these acquisitions is attributable to the buyer specific synergies, the assembled workforce, and the accounting for deferred tax liabilities on the acquired assets. Goodwill of USD&nbsp;74 million in 2020 (2019: USD 98 million, 2018: nil) is tax deductible. </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-58</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId001579975"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">25. Post-employment benefits for associates</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Defined benefit plans</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In addition to the legally required social security schemes, the Group has numerous independent pension and other post-employment benefit plans. In most cases, these plans are externally funded in entities that are legally separate from the Group. For certain Group companies, however, no independent plan assets exist for the pension and other post-employment benefit obligations of associates. In these cases, the related unfunded liability is included in the balance sheet. The defined benefit obligations (DBOs) of all major pension and other post-employment benefit plans are reappraised annually by independent actuaries. Plan assets are recognized at fair value. The major plans are based in Switzerland, the United States, the United Kingdom, Germany and Japan, which represent 95% of the Group&#x2019;s total DBO for pension plans. Details of the plans in the two most significant countries, Switzerland and the United States, which represent 81% of the Group&#x2019;s total DBO for post-employment benefit plans, are provided below.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Swiss-based pension plans represent the most significant portion of the Group&#x2019;s total DBO and plan assets. For the active insured members born on or after January 1, 1956, or having joined the plans after December 31, 2010, the benefits are partially linked to the contributions paid into the plan. Certain features of Swiss pension plans required by law preclude the plans from being categorized as defined contribution plans. These factors include a minimum interest guarantee on retirement savings accounts, a predetermined factor for converting the accumulated savings account balance into a pension, and embedded death and disability benefits.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">All benefits granted under Swiss-based pension plans are vested, and Swiss legislation prescribes that the employer has to contribute a fixed percentage of an associate&#x2019;s pay to an external pension fund. Additional employer contributions may be required whenever the plan&#x2019;s statutory funding ratio falls below a certain level. The associate also contributes to the plan. The pension plans are run by separate legal entities, each governed by a board of trustees that &ndash; for the principal plans &ndash; consists of representatives nominated by Novartis and the active insured associates. The boards of trustees are responsible for the plan design and asset investment strategy.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In December 2020 the Board of Trustees of the Novartis Swiss Pension Fund agreed to adjust the annuity conversion rate at retirement with effect from January 1, 2022. This amendment does not affect existing pensioners, and its impact on existing plan participants will be mitigated by way of defined compensatory measures. This amendment resulted in a net pre-tax curtailment gain of USD 101 million (CHF 90 million).</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The United States pension plans represent the second-largest component of the Group&#x2019;s total DBO and plan assets. The principal plans (Qualified Plans) are funded, whereas plans providing additional benefits for executives (Restoration Plans) are unfunded. Employer contributions are required for Qualified Plans whenever the statutory funding ratio falls below a certain level. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Furthermore, in certain countries, associates are covered under other post-employment benefit plans and post-retirement medical plans.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the US, other post-employment benefit plans consist primarily of post-employment healthcare benefits, which have been closed to new members since 2015. Part of the costs of these plans is reimbursable under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. There is no statutory funding requirement for these plans. The Group is funding these plans to the extent that it is tax efficient.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-59</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables are a summary of the funded and unfunded defined benefit obligation for pension and other post-employment benefit plans of associates at December 31, 2020 and 2019:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans  </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment  benefit plans</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at January 1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;066</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;179</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 746</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;073</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit obligations related to discontinued operations<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;662</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;385</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current service cost</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 372</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 336</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest cost</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 222</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 330</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 29</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past service costs and settlements</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;102</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;168</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Administrative expenses</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurement losses/(gains) arising from changes in financial assumptions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;166</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;791</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurement (gains)/losses arising from changes in demographic assumptions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;28</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;193</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Experience-related remeasurement losses/(gains)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 159</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 184</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;132</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;22</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;810</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 283</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit payments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;264</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;256</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;33</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;30</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions of associates</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 186</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 169</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 49</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 25&nbsp;602</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;066</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 632</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 746</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at January 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 19&nbsp;810</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;838</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 134</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 119</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Plan assets related to discontinued operations<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;424</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;40</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 166</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 257</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Return on plan assets excluding interest income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;318</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;656</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;620</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 304</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Group contributions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 464</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 420</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 74</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions of associates</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 186</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 169</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Settlements</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;193</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit payments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;264</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;256</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;33</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;30</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22&nbsp;317</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 19&nbsp;810</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 89</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 134</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;285</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;256</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;543</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;612</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Limitation on recognition of fund surplus at January 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;65</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;68</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in limitation on recognition of fund surplus (incl. exchange rate differences)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income on limitation of fund surplus</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Limitation on recognition of fund surplus at December 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;51</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;65</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability in the balance sheet at December 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;336</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;321</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;543</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;612</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Notes 1, 2 and 30 provide information related to discontinued operations.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-60</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The reconciliation of the net liability from January 1 to December 31 is as follows:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans  </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment  benefit plans</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability at January 1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;321</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;409</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;612</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;954</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less: net liability related to discontinued operations<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 238</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 345</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current service cost</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;372</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;336</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;13</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net interest expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;58</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;77</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;26</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Administrative expenses</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past service costs and settlements</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 117</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurements</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;126</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 109</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;35</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;190</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Group contributions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 464</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 420</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 74</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in limitation on recognition of fund surplus</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability at December 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;336</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;321</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;543</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;612</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Amounts recognized in the consolidated balance sheet</div>
      </td>
      <td align="right"></td>
      <td align="right"></td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right"></td>
      <td align="right"></td>
      <td align="right"></td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid benefit cost</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 202</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 148</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued benefit liability</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;538</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;469</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;543</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;612</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Notes 1, 2 and 30 provide information related to discontinued operations.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows a breakdown of the DBO for pension plans by geography and type of member, and the breakdown of plan assets into the geographical locations in which they are held:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="7" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td colspan="7" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Switzerland</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> United<br> States</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of<br> the world</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Total</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Switzerland</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> United<br> States</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rest of<br> the world</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&nbsp;807</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;788</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;007</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 25&nbsp;602</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&nbsp;106</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;552</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;408</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;066</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof unfunded</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 701</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 516</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 1&nbsp;217</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 670</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 466</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 1&nbsp;136</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">By type of member</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Active</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;837</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 665</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;573</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;075</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;167</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 630</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;400</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;197</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred pensioners</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;290</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;819</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;109</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;205</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;517</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;722</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Pensioners</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;970</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;833</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;615</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&nbsp;418</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;939</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;717</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;491</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;147</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&nbsp;396</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;487</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;434</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22&nbsp;317</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;457</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;311</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;042</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 19&nbsp;810</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;411</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;301</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;573</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;285</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;649</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;241</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;366</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;256</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
    </tr>
  </table>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows a breakdown of the DBO for other post-employment benefit plans by geography and type of member, and the breakdown of plan assets into the geographical locations in which they are held:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> United<br> States</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of<br> the world</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Total</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> United<br> States</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rest of<br> the world</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 543</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 89</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 632</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 658</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 88</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 746</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof unfunded</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 454</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 89</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 543</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 524</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 88</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 612</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">By type of member</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Active</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 80</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 105</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 121</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 36</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 157</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred pensioners</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Pensioners</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 446</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 510</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 522</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 52</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 574</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 89</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 89</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 134</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 134</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;454</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;89</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;543</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;524</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;88</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;612</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-61</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the principal weighted average actuarial assumptions used for calculating defined benefit plans and other post-employment benefits of associates:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans  </div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment  benefit plans</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Weighted average assumptions used to determine  benefit obligations at December 31</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Discount rate</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.6%</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.0%</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.6%</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.9%</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.6%</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.4%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected rate of pension increase</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.3%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.3%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.4%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected rate of salary increase</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.7%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.8%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.8%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest on savings account</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.1%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.3%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.8%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current average life expectancy  for a 65-year-old male in years</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   21</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current average life expectancy  for a 65-year-old female in years</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   23</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Changes in the aforementioned actuarial assumptions can result in significant volatility in the accounting for the Group&#x2019;s pension plans in the consolidated financial statements. This can result in substantial changes in the Group&#x2019;s other comprehensive income, long-term liabilities and prepaid pension assets.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The DBO is significantly impacted by assumptions regarding the rate that is used to discount the actuarially determined post-employment benefit liability. This rate is based on yields of high-quality corporate bonds in the country of the plan. Decreasing corporate bond yields decrease the discount rate, so that the DBO increases and the funded status decreases.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In Switzerland, an increase in the DBO due to lower discount rates is slightly offset by lower future benefits expected to be paid on the associate&#x2019;s savings account where the assumption on interest accrued changes in line with the discount rate.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The impact of decreasing interest rates on a plan&#x2019;s assets is more difficult to predict. A significant part of the plan assets is invested in bonds. Bond values usually rise when interest rates decrease and may therefore partially compensate for the decrease in the funded status. Furthermore, pension assets also include significant holdings of equity instruments. Share prices tend to rise when interest rates decrease and therefore often counteract the negative impact of the rising defined benefit obligation on the funded status (although the correlation of interest rates with equities is not as strong as with bonds, especially in the short term).</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The expected rate for pension increases significantly affects the DBO of most plans in Switzerland, Germany and the United Kingdom. Such pension increases also decrease the funded status, although there is no strong correlation between the value of the plan assets and pension/inflation increases.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Assumptions regarding life expectancy significantly impact the DBO. An increase in longevity increases the DBO. There is no offsetting impact from the plan assets, as no longevity bonds or swaps are held by the pension funds. Generational mortality tables are used where this data is available.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the sensitivity of the defined benefit pension obligation to the principal actuarial assumptions for the major plans in Switzerland, the United States, the United Kingdom, Germany and Japan on an aggregated basis:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in 2020 year-end<br> defined benefit pension obligation</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in discount rate</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;885</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in discount rate</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 942</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One-year increase in life expectancy</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 993</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in rate of pension increase</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 589</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in rate of pension increase</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;143</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase of interest on savings account</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 62</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease of interest on savings account</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;30</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in rate of salary increase</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 61</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in rate of salary increase</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;61</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The healthcare cost trend rate assumptions used for other post-employment benefits are as follows:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Healthcare cost trend rate assumed for next year</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   6.3%</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   6.5%</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   7.0%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rate to which the cost trend rate is assumed to decline</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   4.5%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   4.5%</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   4.5%</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Year that the rate reaches the ultimate trend rate</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   2028</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   2028</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   2028</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the weighted average plan asset allocation of funded defined benefit pension plans at December 31, 2020 and&nbsp;2019:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="7" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(as a percentage)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-term <br> target <br> minimum</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-term <br> target <br> maximum</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity securities</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 36</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Real estate</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alternative investments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and other investments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash and most of the equity and debt securities have a quoted market price in an active market. Real estate and </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-62</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">alternative investments, which include hedge fund, private equity, infrastructure and commodity investments, usually have a quoted market price or a regularly updated net asset value.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The strategic allocation of assets of the different pension plans is determined with the objective of achieving an investment return that, together with the contributions paid by the Group and its associates, is sufficient to maintain reasonable control over the various funding risks of the plans. Based upon the market and economic environments, actual asset allocations may temporarily be permitted to deviate from policy targets. The asset allocation currently includes investments in shares of Novartis AG as per the below table: </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> December 31, <br> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31, <br> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Investment in shares of Novartis AG</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Number of shares (in millions)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Market value (in USD billions)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The weighted average duration of the defined benefit obligation is 15.4 years (2019: 15.2 years).</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s ordinary contribution to the various pension plans is based on the rules of each plan. Additional contributions are made whenever this is required by statute or law (i.e., usually when statutory funding levels fall below predetermined thresholds). The only significant plans that are foreseen to require additional funding are those in the United Kingdom and Germany.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The expected future cash flows in respect of pension and other post-employment benefit plans at December 31, 2020, were as follows:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Pension plans</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-<br> employment<br> benefit plans</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis Group contributions</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2021 (estimated)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 404</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Expected future benefit payments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2021</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;245</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;198</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 41</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;191</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 41</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;182</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;165</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026&#x2013;2030</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;651</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 181</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Defined contribution plans</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In many subsidiaries, associates are covered by defined contribution plans. Contributions charged to the consolidated income statement for the defined contribution plans were: </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions for defined contribution plans continuing operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   501</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   422</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   443</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For defined contribution plans for discontinued operations, see Note 30.</div><a name="anchorId001583055"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">26. Equity-based participation plans for associates</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The expense related to all equity-based participation plans and the liabilities arising from equity-based payment transactions were as follows:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense related to equity-based  participation plans</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   958</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1&nbsp;067</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   918</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities arising from equity-based  payment transactions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   269</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   326</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   273</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Equity-based participation plans can be separated into the following plans:</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Annual Incentive</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Annual Incentive for the Novartis Group CEO and other Executive Committee members (ECN) is paid 50% in cash and 50% in Novartis restricted shares (RSs) or restricted share units (RSUs). For the Novartis Top Leaders (NTLs), the Annual Incentive is paid 70% in cash and 30% in RSs or RSUs. Both the ECN and NTLs can opt to invest up to the maximum cash portion of their Annual Incentive to receive further RSs or RSUs. Any cash is paid out during February or March in the year following the end of the performance period, and the shares are granted during January in the year following the end of the performance period.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Share savings plans</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Associates in certain countries and certain key executives worldwide are encouraged to invest their Annual Incentive in a share savings plan.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Under the share savings plan, participants may elect to receive their relevant compensation fully or partially in Novartis shares in lieu of cash. As a reward for their participation in the share savings plan, at no additional cost to the participant, Novartis matches their investments in shares after a holding period of three or five years. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Novartis operates share savings plans for which associates may only participate in one of the share savings </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-63</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">plans in any given year. The most significant are listed below:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; In Switzerland, Employee Share Ownership Plan (ESOP) participants may choose to receive their Annual Incentive (i) 100% in shares, (ii) 50% in shares and 50% in cash, or (iii) 100% in cash. After expiration of a three-year holding period for Novartis shares invested under the ESOP, participants will receive one matching share for every two invested shares. Associates eligible for the equity plan &#x201C;Select&#x201D; are not eligible to receive ESOP matching shares starting with the 2017 performance period.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Leveraged Share Savings Plan (LSSP) was available to key executives for performance periods prior to 2016. At the participant&#x2019;s election, the Annual Incentive was awarded partly or entirely in shares. The elected number of shares is subject to a holding period of five years. At the end of the holding period, Novartis will match the invested shares at a ratio of 1-to-1 (i.e., one share awarded for each invested share). In the United States, both the LSSP award and the corresponding match are cash settled.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Novartis Group CEO, the other Executive Committee members from 2014, and the NTLs from 2016 are not eligible to participate in the share savings plans. </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Novartis equity plan &#x201C;Select&#x201D;</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The equity plan &#x201C;Select&#x201D; is a global equity incentive plan under which eligible associates may annually be awarded a grant subject to a three-year, and for selected units a four-year, staggered vesting period. No awards are granted for performance ratings below a certain threshold. Executive Committee members and NTLs are not eligible to participate in the equity plan &#x201C;Select&#x201D;. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The equity plan &#x201C;Select&#x201D; currently allows participants in Switzerland to choose the form of their equity compensation in RSs or RSUs. In all other jurisdictions, RSs or RSUs are granted unilaterally. Until 2013, participants could also choose to receive part or the entire grant in the form of tradable share options.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Tradable share options expire on their 10<sup>th</sup> anniversary from the grant date. Each tradable share option entitles the holder to purchase after vesting (and before the 10<sup>th</sup> anniversary from the grant date) one Novartis share at a stated exercise price that equals the closing market price of the underlying share at the grant date. As the exercise price does not reflect the decrease in the Novartis share due to the Alcon spin, one-fifth of an Alcon share will also be awarded to the option holder upon exercise.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Options under Novartis equity plan &#x201C;Select&#x201D; outside North America</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the activity associated with the share options during the period. The weighted average prices in the table below are translated from Swiss francs into USD at historical rates.</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> Options<br> (millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted<br> average <br> exercise <br> price<br> (USD)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> Options<br> (millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted<br> average <br> exercise <br> price<br> (USD)</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Options outstanding  at January 1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   3.4</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   60.9</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   5.6</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   59.9</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sold or exercised</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;0.8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 58.4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 62.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 60.9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 62.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 60.9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">All share options were granted at an exercise price that was equal to the closing market price of the Group&#x2019;s shares at the grant date. The weighted average share price at the dates of sale or exercise was USD&nbsp;91.7.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table summarizes information about share options outstanding at December 31, 2020:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"><br>Options outstanding</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total/<br> weighted<br> average</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Number outstanding (millions)</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.4</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.8</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.4</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2.6</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remaining contractual life (years)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1.4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise price (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 66.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 62.0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Options under Novartis equity plan &#x201C;Select&#x201D; for North America</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the activity associated with the ADR options during the period:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> ADR<br> options<br> (millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted<br> average <br> exercise <br> price<br> (USD)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> ADR<br> options<br> (millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted<br> average <br> exercise <br> price<br> (USD)</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Options outstanding  at January 1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   9.6</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   61.9</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   15.2</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   60.7</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sold or exercised</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2.9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 59.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 58.6</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 62.9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 61.9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 62.9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 61.9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">All ADR options were granted at an exercise price that was equal to the closing market price of the ADRs at the grant date. The weighted average ADR price at the dates of sale or exercise was USD&nbsp;92.2.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table summarizes information about ADR options outstanding at December 31, 2020:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"><br>ADR options outstanding</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> </div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total/<br> weighted<br> average</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Number outstanding (millions)</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.4</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.0</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6.7</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remaining contractual life (years)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1.5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise price (USD)</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 58.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 66.1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 62.9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-64</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Long-Term Performance Plan</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Long-Term Performance Plan (LTPP) is an equity plan for the ECN, the NTLs and employees of Group units with specific targets.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Participants are granted a target number of performance share units (PSUs) at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. The actual payout depends on the achievement of the performance measures and ranges between 0% and 200% of the granted amount. PSUs granted under the LTPP do not carry voting rights, but do carry dividend equivalents that are paid in unrestricted Novartis shares at the end of the performance period.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The LTPP awards are subject to a three-year performance and vesting period. Until 2018, the performance criteria were based on Novartis internal performance metrics. Starting in 2019, for new grants the performance criteria are based on both Novartis internal performance metrics and variables that can be observed in the market, which is the ranking of the Novartis total shareholder return (TSR) relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">TSR for Novartis and the peer companies is calculated as the change in the company share price, which is translated to USD at the relevant exchange rate, including the reinvestment return of dividends, over the three-year performance period. The calculation is based on Bloomberg standard published TSR data, which is publicly available. The position of Novartis in the peer group determines the payout range based on a payout matrix. </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Long-Term Relative Performance Plan</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The LTRPP is an equity plan for the Novartis ECN and NTLs. The last grant under this plan was made in 2018. The LTRPP performance criteria are based on variables that can be observed in the market, which is the ranking of the Novartis TSR relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. The TSR for Novartis and the peer companies is calculated as described in the LTPP section above. </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Other share awards</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Selected associates, excluding the ECN members, may exceptionally receive Special Share Awards of RSs or RSUs. These Special Share Awards provide an opportunity to reward outstanding achievements or exceptional performance, and aim to retain key contributors. They are based on a formal internal selection process, through which the individual performance of each candidate is thoroughly assessed at several management levels. Special Share Awards have a minimum three-year vesting period. In exceptional circumstances, Special Share Awards may be awarded to attract special expertise and new talents to the organization. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Worldwide, associates at different levels in the organization were awarded RSs and RSUs in 2020, 2019 and 2018.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, in 2020, 2019 and 2018, Board members received unrestricted shares as part of their regular compensation.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Summary of non-vested share movements</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The table below provides a summary of non-vested share movements (RSs, RSUs and PSUs) for all plans: </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Number<br> of shares<br> in millions</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br> average fair<br> value at grant<br> date in USD</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Fair value at <br> grant date in<br> USD millions</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Number<br> of shares<br> in millions</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted <br> average fair<br> value at grant<br> date in USD</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Fair value at <br> grant date in<br> USD millions</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-vested shares at January 1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 25.8</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 71.1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;835</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25.7</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 77.1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;981</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Granted</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Annual Incentive</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 93.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 103</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 78.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 86</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Share savings plans</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 95.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 399</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 83.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 349</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Select North America</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 86.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 286</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 64.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 339</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Select outside North America</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 89.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 179</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 67.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 175</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Long-Term Performance Plan</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 85.1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 213</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 68.9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 172</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Long-Term Relative Performance Plan<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Other share awards</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 78.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 117</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 67.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 129</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vested</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13.8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 74.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;024</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;13.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 80.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;068</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forfeited</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2.0</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 75.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;151</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;328</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-vested shares at December 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 24.8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 78.9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;957</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25.8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71.1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;835</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> LTRPP grants in 2020 represent incremental payouts based on performance criteria under the plan. In 2019 the LTRPP grants are keep whole awards granted due to the spin-off of the Alcon business.</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-65</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At April 8, 2019, the Alcon spin-off date, all RSU and PSU holders, who were not entitled to the dividend in kind in the form of Alcon shares received keep whole awards in Novartis shares to compensate for the loss of the Alcon value from their Novartis shares. These keep whole awards were accounted for as a modification. As they did not increase the value of the original grant, they did not lead to additional expense. In the table above, this is reflected by a zero fair value at grant date amount.</div><a name="anchorId001584465"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">27. Transactions with related parties</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Roche Holding AG</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has two agreements with Genentech, Inc., United States (Genentech), and one agreement with Spark Therapeutics, Inc., United States (Spark). Both companies are subsidiaries of Roche Holding AG (Roche), which is indirectly included in the consolidated financial statements using equity accounting since Novartis holds 33.3% of the outstanding voting shares of Roche (see Note 4).</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"><i>Lucentis</i></font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has licensed from Genentech/Roche the exclusive rights to develop and market <i>Lucentis</i> outside the United States for indications related to diseases of the eye. Novartis pays royalties on the net sales of <i>Lucentis</i> products outside the United States. In 2020, <i>Lucentis</i> sales of USD&nbsp;1.9 billion (2019: USD&nbsp;2.1 billion; 2018: USD&nbsp;2.0 billion) were recognized by Novartis.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"><i>Xolair</i></font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis and Genentech/Roche are co-promoting <i>Xolair</i> in the United States, where Genentech/Roche records all sales. Novartis records sales outside the United States.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis markets <i>Xolair</i> and records all sales and related costs outside the United States as well as co-promotion costs in the US. Genentech/Roche and Novartis share the resulting profits from sales in the United States, Europe and other countries, according to agreed profit-sharing percentages. In 2020, Novartis recognized total sales of <i>Xolair</i> of USD&nbsp;1.3 billion (2019: USD&nbsp;1.2 billion; 2018: USD&nbsp;1.0 billion), including sales to Genentech/Roche for the United States market.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"><i>Luxturna</i></font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2018, Novartis entered into an exclusive licensing and commercialization agreement and a supply agreement with Spark for <i>Luxturna</i> outside the United States. The agreements include regulatory and sales milestones as well as royalties payable to Spark on ex-US sales. On December 17, 2019, Roche acquired Spark.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The net income for royalties, cost sharing and profit sharing arising out of the <i>Lucentis</i>, <i>Xolair</i> and <i>Luxturna</i> agreements with Roche totaled USD&nbsp;217 million in 2020 (net income in 2019: USD&nbsp;101 million; net expense in 2018: USD&nbsp;34 million).</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Furthermore, Novartis has several patent license, supply and distribution agreements with Roche.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Novartis Pension Fund</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2018, a Group subsidiary provided an uncommitted overnight credit facility to the Novartis Pension Fund, Switzerland, for up to USD 500 million with interest at the US Federal Funds Rate. This credit facility was not utilized during the years 2020, 2019 and 2018.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Executive Officers and Non-Executive Directors compensation</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2020, there were 13 Executive Committee members (&#x201C;Executive Officers&#x201D;). There were 15 Executive Officers in 2019 and 17 Executive Officers in 2018, including those who stepped down.</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The total compensation for Executive Committee members and the 14 Non-Executive Directors (13 in 2019 and 2018) using the Group&#x2019;s accounting policies for equity-based compensation and pension benefits was as follows:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Executive Officers</div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-Executive Directors</div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="20" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and other compensation</div>
      </td>
      <td align="right" width="5%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.6</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20.7</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22.5</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.6</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.0</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30.2</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24.8</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="5%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26.5</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="20" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Post-employment benefits</div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="20" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 41.1</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 40.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 42.5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 46.3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 45.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 47.3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="20" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 69.4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 63.9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 67.5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9.8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8.7</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8.8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 79.2</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 72.6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 76.3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="20" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-66</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2020, the IFRS compensation expense increased due to higher cash and other compensation. This increase in cash compensation is mainly attributable to ECN members who joined the ECN during 2019, as a result 2019 represented only a portion of their annual compensation. Other compensation increased on account of higher social security payments on vested equity-based compensation.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">During 2019, the IFRS compensation expense decreased due to lower cash buyout payments to new executive officers and the forfeiture of equity-based compensation as a result of the resignation of an executive officer. These effects were partially offset by higher equity based compensation of executive officers appointed over the last three years.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Annual Incentive award, which is fully included in equity-based compensation even when paid out in cash, is granted in January in the year following the reporting period.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The disclosures on Board and executive compensation required by the Swiss Code of Obligations and in accordance with the Swiss Ordinance against Excessive Compensation in Stock Exchange Listed Companies are shown in the Compensation Report of the Group.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Transactions with former members of the Board of Directors</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2020, 2019 and 2018, the following payments (or waivers of claims) were made to former Board members or to &#x201C;persons closely&#x201D; linked to them:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currency</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dr. Krauer</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 60&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 60&nbsp;000</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dr. Vasella</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&nbsp;228</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Dr. Alex Krauer, Honorary Chairman, is entitled to an amount of CHF&nbsp;60&#xA0;000 for annual periods from one AGM to the next. This amount was fixed in 1998 upon his departure from the Board in 1999, and has not been revised since that date.</div><a name="anchorId001584910"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">28. Commitments and contingencies</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Research and development commitments</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has entered into long-term research and development agreements with various institutions, which provide for potential milestone payments by Novartis that may be capitalized. As of December 31, 2020, the Group&#x2019;s commitments to make payments under those agreements, and their estimated timing, were as follows:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2021</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 449</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 691</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 325</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 483</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 281</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Thereafter</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;003</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;232</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In addition in November 2020 and in January 2021, Novartis entered into long-term research and development agreements, both of which did not close as of January 25, 2021. These agreements provide for potential milestones payments by Novartis that may be capitalized. Based on their estimated timing, the payments for these transactions are expected to amount to USD 549 million in 2021, USD 248 million in 2022, USD 160 million in 2023, USD 415 million in 2024, USD 515 million in 2025, USD 1&#xA0;409 million later than 2025, for a total of USD 3&#xA0;296 million.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Commitments for capital calls</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group holds investments in funds in which it has committed to invest further upon future capital calls. As of December 31, 2020, the total uncalled capital commitments for the Group&#x2019;s investments in funds amounts to USD 87 million. Note 29 contains further information on the Group&#x2019;s investments in funds.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Other commitments</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has entered into various purchase commitments for services and materials as well as for equipment in the ordinary course of business. These commitments are generally entered into at current market prices and reflect normal business operations. For disclosure of property, plant and equipment purchase commitments, see Note 9.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Guarantees issued</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has issued guarantees to third parties in the ordinary course of business, mostly for tax, customs or other governmental agencies. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, Novartis AG is guarantor of the Group&#x2019;s issued bonds, credit facilities and commercial paper programs.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-67</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Contingencies</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Group companies have to observe the laws, government orders and regulations of the country in which they operate.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A number of Novartis companies are, and will likely continue to be, subject to various legal proceedings and investigations that arise from time to time, including proceedings regarding product liability; sales and marketing practices; commercial disputes; employment and wrongful discharge; and antitrust, securities, health and safety, environmental, tax, international trade, privacy and intellectual property matters. As a result, the Group may become subject to substantial liabilities that may not be covered by insurance and that could affect our business, financial position and reputation. While Novartis does not believe that any of these legal proceedings will have a material adverse effect on its financial position, litigation is inherently unpredictable and large judgments sometimes occur. As a consequence, Novartis may in the future incur judgments or enter into settlements of claims that could have a material adverse effect on its results of operations or cash flow.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Governments and regulatory authorities around the world have been stepping up their compliance and law enforcement activities in recent years in key areas, including marketing practices, pricing, corruption, trade restrictions, embargo legislation, insider trading, antitrust, cyber security and data privacy. Further, when one government or regulatory authority undertakes an investigation, it is not uncommon for other governments or regulators to undertake investigations regarding the same or similar matters. Responding to such investigations is costly and requires an increasing amount of management&#x2019;s time and attention. In addition, such investigations may affect our reputation, create a risk of potential exclusion from government reimbursement programs in the United States and other countries, and lead to (or arise from) litigation. These factors have contributed to decisions by Novartis and other companies in the healthcare industry, when deemed in their interest, to enter into settlement agreements with governmental authorities around the world prior to any formal decision by the authorities or a court. These government settlements have involved and may in the future involve large cash payments, sometimes in the hundreds of millions of dollars or more, including the potential repayment of amounts allegedly obtained improperly and other penalties, including treble damages. In addition, settlements of government healthcare fraud cases often require companies to enter into corporate integrity agreements, which are intended to regulate company behavior for a period of years. Our affiliate Novartis Corporation is a party to such an agreement, which will expire in 2025. Also, matters underlying governmental investigations and settlements may be the subject of separate private litigation.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">While provisions have been made for probable losses, which management deems to be reasonable or appropriate, there are uncertainties connected with these estimates.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 20 contains additional information on these matters.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A number of Group companies are involved in legal proceedings concerning intellectual property rights. The inherent unpredictability of such proceedings means that there can be no assurances as to their ultimate outcome. A negative result in any such proceeding could potentially adversely affect the ability of certain Novartis companies to sell their products, or require the payment of substantial damages or royalties.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the opinion of management, however, the outcome of these actions will not materially affect the Group&#x2019;s financial position but could be material to the results of operations or cash flow in a given period.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s potential environmental remediation liability is assessed based on a risk assessment and investigation of the various sites identified by the Group as at risk for environmental remediation exposure. The Group&#x2019;s future remediation expenses are affected by a number of uncertainties. These uncertainties include, but are not limited to, the method and extent of remediation, the percentage of material attributable to the Group at the remediation sites relative to that attributable to other parties, and the financial capabilities of the other potentially responsible parties.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 20 contains additional information on environmental liabilities.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-68</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId001585072"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">29. Financial instruments &ndash; additional disclosures</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables show the carrying values of financial instruments by measurement categories as of December 31, 2020 and 2019. Except for straight bonds (see Note 19), the carrying values are equal to, or a reasonable approximation of, the fair values.</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td></td>
      <td colspan="7" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> <br> <br> Note</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> Financial<br> instruments at<br> amortized<br> costs</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> Financial<br> instruments at<br> fair value<br> through other<br> comprehensive<br> income</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Financial<br> instruments at<br> fair value<br> through the<br> consolidated<br> income<br> statement</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br> <br> <br> <br> Other<br> financial<br> liabilities</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;658</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;609</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;217</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 963</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities - debt securities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - equity securities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;111</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 466</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - debt securities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - fund investments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 366</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances, security deposits and other long-term receivables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 297</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Associated companies at fair value through profit and loss</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 211</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 159</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 625</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20&nbsp;744</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;173</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;827</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of associates payable on demand</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;085</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other short-term financial debt</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 976</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;258</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&nbsp;298</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term liabilities to banks and other financial institutions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 233</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;403</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18/22</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;769</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities (see Note 20/22) and other financial liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;069</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 194</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;005</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 43&nbsp;022</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;263</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;005</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-69</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div>
      </td>
      <td></td>
      <td colspan="7" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
      <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> <br> <br> <br> Note</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> Financial<br> instruments at<br> amortized<br> costs</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Financial<br> instruments at<br> fair value<br> through other<br> comprehensive<br> income</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Financial<br> instruments at<br> fair value<br> through the<br> consolidated<br> income<br> statement</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> <br> Other<br> financial<br> liabilities</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;112</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;301</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;036</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities - debt securities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities - fund investments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - equity securities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;158</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 366</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - debt securities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - fund investments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 233</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances, security deposits and other long-term receivables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 329</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Associated companies at fair value through profit and loss</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 186</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 399</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 21&nbsp;839</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;215</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;323</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of associates payable on demand</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;836</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other short-term financial debt</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 719</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;289</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22&nbsp;167</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term liabilities to banks and other financial institutions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 188</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;424</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities (see Note 20/22) and other financial liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;065</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 185</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;949</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 32&nbsp;623</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;949</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Derivative financial instruments</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables show the contract or underlying principal amounts and fair values of derivative financial instruments analyzed by type of contract at December&nbsp;31, 2020 and 2019. Contract or underlying principal amounts indicate the gross volume of business outstanding at the consolidated balance sheet date and do not represent amounts at risk. The fair values are determined by reference to market prices or standard pricing models that use observable market inputs at December 31,&nbsp;2020 and 2019. </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Contract or underlying  principal amount</div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Positive fair values  </div>
      </td>
      <td></td>
      <td colspan="3" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Negative fair values  </div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
      <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
      <td colspan="3" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&nbsp;679</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;779</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 151</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 96</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;165</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;75</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 269</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;29</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;110</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments included in  marketable securities and in current financial debts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   13&nbsp;760</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   11&nbsp;057</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   159</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   102</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   &#x2013;&#x2005;194</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   &#x2013;&#x2005;185</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows by currency contract or underlying principal amount the derivative financial instruments at December&nbsp;31,&nbsp;2020 and 2019:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="7" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> EUR</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;432</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;376</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;871</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&nbsp;679</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;432</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;457</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;871</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;760</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-70</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="7" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> EUR</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;373</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;760</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;646</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;779</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 250</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 269</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;373</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;665</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;057</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Derivative financial instruments effective for hedge accounting purposes</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At the end of 2020 and 2019, there were no open hedging instruments for anticipated transactions.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Fair value by hierarchy</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As required by IFRS, financial assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. There are three hierarchical levels, based on increasing subjectivity associated with the inputs to derive fair valuation for these assets and liabilities, which are as follows:</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The assets carried at Level 1 fair value are equity and debt securities listed in active markets.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The assets generally included in Level 2 fair value hierarchy are foreign exchange and interest rate derivatives, and certain debt securities. Foreign exchange and interest rate derivatives are valued using corroborated market data. The liabilities generally included in this fair value hierarchy consist of foreign exchange and interest rate derivatives.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Level 3 inputs are unobservable for the asset or liability. The assets generally included in Level 3 fair value hierarchy are various investments in hedge funds and unquoted equity security investments. Contingent consideration carried at fair value is included in this category.</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="7" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 1</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 2</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 3</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 159</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 159</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities and derivative financial instruments</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 185</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 185</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt and equity securities</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;153</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 460</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;613</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 366</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 366</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 625</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 625</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total long-term financial investments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;153</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;451</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;604</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit and loss</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 211</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 211</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;046</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;046</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;23</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;194</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;194</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities at fair value</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;194</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;069</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;263</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-71</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="7" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 1</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 2</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 3</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 61</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities and derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 126</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 163</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt and equity securities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 976</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 581</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;557</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 233</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 233</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 399</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 399</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total long-term financial investments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 976</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;213</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;189</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit and loss</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 186</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 186</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;036</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;036</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;29</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;29</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;185</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;185</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities at fair value</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;185</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;065</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;250</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The change in carrying values associated with Level 3 financial instruments, using significant unobservable inputs during the year ended December 31, is set forth below:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="13" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="13" height="3"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="13" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="13" height="3"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Associated <br> companies at <br> fair value  through<br> profit and loss</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Fund<br> investments</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Long-term <br> financial <br> investments</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Contingent <br> consideration <br> receivables</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Contingent <br> consideration <br> payables</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> Other <br> financial <br> liabilities</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 186</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 233</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 581</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 399</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;036</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;29</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value gains and other adjustments,  including from divestments recognized  in the consolidated income statement</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     57</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     151</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     34</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     173</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     206</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value losses (including impairments and   amortizations) and other adjustments recognized   in the consolidated income statement</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     &#x2013;&#x2005;18</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     &#x2013;&#x2005;8</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     &#x2013;&#x2005;39</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     &#x2013;&#x2005;90</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments recognized in the consolidated statement   of comprehensive income, including currency translation effects</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   33</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   40</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;62</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;2</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 123</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;123</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash receipts and payments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 63</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;23</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;61</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;109</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;163</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 211</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 366</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 460</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 625</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;046</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;23</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of fair value gains and losses recognized   in the consolidated income statement for assets   and liabilities held at December 31, 2020</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     39</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     143</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     173</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     116</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><b></b><b></b><b></b><b></b></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup><b></b><b></b><b></b></div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-72</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="13" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="13" height="3"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="13" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="13" height="3"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Associated <br> companies at <br> fair value  through<br> profit and loss</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Fund<br> investments</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Long-term <br> financial <br> investments</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Contingent <br> consideration <br> receivables</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Contingent <br> consideration <br> payables</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> Other <br> financial <br> liabilities</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 145</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 251</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 488</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 396</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;907</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;10</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact from discontinued operations<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;28</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 163</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value gains and other adjustments,   including from divestments recognized   in the consolidated income statement</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     35</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     195</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value losses (including impairments and   amortizations) and other adjustments recognized   in the consolidated income statement</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2013;&#x2005;15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2013;&#x2005;89</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2013;&#x2005;48</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments recognized in the consolidated statement   of comprehensive income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 49</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 229</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;401</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash receipts and payments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;30</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;53</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;64</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 186</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 233</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 581</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 399</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;036</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;29</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of fair value gains and losses recognized   in the consolidated income statement for assets   and liabilities held at December 31, 2019</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2013;&#x2005;15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     12</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     35</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     106</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2013;&#x2005;47</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="14">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Notes 1, 2 and 30 provide information related to discontinued operations.</div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2020, there were several individually non-significant transfers of financial investments from Level 3 to Level 1 for USD&nbsp;166  million (2019: USD&nbsp;64 million), mainly due to initial public offerings of the invested companies.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Realized gains and losses associated with Level 3 long-term financial investments measured at fair value through the consolidated income statement are recorded in the consolidated income statement under &#x201C;Other income&#x201D; or &#x201C;Other expense,&#x201D; respectively. Realized gains and losses associated with Level 3 long-term financial investments measured at fair value through other comprehensive income are not recycled through the consolidated income statement but are instead reclassified to retained earnings.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">During the year, the net loss and net gain recorded on associated companies, fund investments and long-term financial investments at fair value through profit and loss were USD 92 million and USD 427 million, respectively.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If the pricing parameters for the Level 3 input were to change for associated companies at fair value through profit and loss, fund investments and long-term financial investments by 10% positively or negatively, this would change the amounts recorded in the 2020 consolidated statement of comprehensive income by USD&nbsp;104 million.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To determine the fair value of a contingent consideration, various unobservable inputs are used. A change in these inputs might result in a significantly higher or lower fair value measurement. The inputs used are, among others, the probability of success, sales forecast and assumptions regarding the discount rate and timing and different scenarios of triggering events. The inputs are interrelated. The significance and usage of these inputs to each contingent consideration may vary due to differences in the timing and triggering events for payments or in the nature of the asset related to the contingent consideration. </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If the most significant parameters for the Level&nbsp;3 input were to change by 10% positively or negatively, or where the probability of success (POS) is the most significant input parameter, 10% were added or deducted from the applied probability of success, for contingent consideration payables, other financial liabilities and contingent consideration receivables, this would change the amounts recorded in the 2020 consolidated income statement by USD&nbsp;260 million and USD&nbsp;324 million, respectively.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Equity securities measured at fair value through other comprehensive income</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Equity securities held as strategic investments, typically held outside the Novartis Venture Fund, are generally designated at date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. Except for the investment in Alcon Inc. with a fair value of USD 71 million at December 31, 2020 (2019: USD 382 million), these are made up of individually non-significant investments. At December 31, 2020, the Group holds 56 non-listed equity securities (December 31, 2019: 53) and 34 listed equity securities (December 31, 2019: 29) in this category with the following fair values:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Listed equity securities</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 862</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 843</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-listed equity securities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 249</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 315</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity securities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;111</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;158</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There were no dividends recognized during 2020 and 2019 from these equity securities. In 2020, in accor-</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-73</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">dance with the consolidated foundations Alcon Inc. shares divestment plans, Alcon Inc. shares with a fair value of USD&nbsp;331 million were sold (2019: USD 976 million), and the USD&nbsp;13 million gain on disposal (2019: USD 62 million gain) was transferred from other comprehensive income to retained earnings during 2020. In addition, in 2020, equity securities that were no longer considered strategic, with a fair value of USD&nbsp;206 million (2019: USD&nbsp;33 million), were sold, and the USD&nbsp;137 million gain on disposal (2019: USD&nbsp;33 million gain) was transferred from other comprehensive income to retained earnings (see Note 8).</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Nature and extent of risks arising from financial instruments</font>
</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Market risk</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis is exposed to market risk, primarily related to foreign currency exchange rates, interest rates, and the market value of the investments of liquid funds. The Group actively monitors and seeks to reduce, where it deems it appropriate to do so, fluctuations in these exposures. It is the Group&#x2019;s policy and practice to enter into a variety of derivative financial instruments to manage the volatility of these exposures and to enhance the yield on the investment of liquid funds. It does not enter into any financial transactions containing a risk that cannot be quantified at the time the transaction is concluded. In addition, it does not sell short assets it does not have, or does not know it will have, in the future. The Group only sells existing assets or enters into transactions and future transactions (in the case of anticipatory hedges) that it confidently expects it will have in the future, based on past experience. In the case of liquid funds, the Group writes call options on assets it has, or writes put options on positions it wants to acquire and has the liquidity to acquire. The Group expects that any loss in value for these instruments generally would be offset by increases in the value of the underlying transactions.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Foreign currency exchange rate risk</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group uses the US dollar as its reporting currency. As a result, the Group is exposed to foreign currency exchange movements, primarily in European, Japanese and emerging market currencies. Fluctuations in the exchange rates between the US dollar and other currencies can have a significant effect on both the Group&#x2019;s results of operations, including reported sales and earnings, as well as on the reported value of our assets, liabilities and cash flows. This, in turn, may significantly affect the comparability of period-to-period results of operations.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Because our expenditures in Swiss francs are significantly higher than our revenues in Swiss francs, volatility in the value of the Swiss franc can have a significant impact on the reported value of our earnings, assets and liabilities, and the timing and extent of such volatility can be difficult to predict.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There is also a risk that certain countries could devalue their currency. If this occurs, it could impact the effective prices we would be able to charge for our products and also have an adverse impact on both our consolidated income statement and balance sheet.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Subsidiaries whose functional currencies have experienced a cumulative inflation rate of more than 100% over the past three years apply the rules of IAS 29 &#x201C;Financial reporting in Hyperinflationary Economies&#x201D;. The hyperinflationary economies in which Novartis operates are Argentina and Venezuela. Venezuela was hyperinflationary for all years presented, and Argentina became hyperinflationary effective July 1, 2018, requiring retroactive implementation of hyperinflation accounting as of January 1, 2018. The impacts of applying IAS 29 were not significant in all years presented.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group manages its global currency exposure by engaging in hedging transactions where management deems appropriate. Novartis may enter into various contracts that reflect the changes in the value of foreign currency exchange rates to preserve the value of assets, commitments and anticipated transactions. Novartis also uses forward contracts and foreign currency option contracts to hedge.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net investments in subsidiaries in foreign countries are long-term investments. Their fair value changes through movements of foreign currency exchange rates. The Group has designated a certain portion of its long-term euro-denominated straight bonds as hedges of the translation risk arising on certain of these net investments in foreign operations with euro functional currency. As of December 31, 2020, long-term financial debt with a carrying amount of EUR&nbsp;1.8 billion (USD&nbsp;2.3 billion) (December 31, 2019: USD 2.1 billion), has been designated as a hedge instrument. During 2020, USD&nbsp;201 million of unrealized loss (unrealized income in 2019: USD 44 million) was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge. The hedge remained effective since inception, and no amount was recognized in the consolidated income statement in 2020, 2019 and 2018.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Commodity price risk</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has only a very limited exposure to price risk related to anticipated purchases of certain commodities used as raw materials by the Group&#x2019;s businesses. A change in those prices may alter the gross margin of a specific business, but generally by not more than 10% of the margin and thus below the Group&#x2019;s risk management tolerance levels. Accordingly, the Group does not enter into significant commodity futures, forward or option contracts to manage fluctuations in prices of anticipated purchases.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest rate risk</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group addresses its net exposure to interest rate risk mainly through the ratio of its fixed-rate financial debt to variable-rate financial debt contained in its total financial debt portfolio. To manage this mix, Novartis may enter into interest rate swap agreements, in which it exchanges periodic payments based on a notional amount and agreed-upon fixed and variable interest rates.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Equity risk</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group may purchase equities as investments of its liquid funds. As a policy, it limits its holdings in an unrelated company to less than 5% of its liquid funds. Poten-</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-74</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">tial investments are thoroughly analyzed. Call options are written on equities that the Group owns, and put options are written on equities that the Group wants to buy and for which cash is available.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Credit risk</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Credit risks arise from the possibility that customers may not be able to settle their obligations as agreed. To manage this risk, the Group periodically assesses country and customer credit risk, assigns individual credit limits, and takes actions to mitigate credit risk where appropriate.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The provisions for expected credit losses for customers are based on a forward-looking expected credit loss, which includes possible default events on the trade receivables over the entire holding period of the trade receivables.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In measuring the expected credit losses, trade receivables are grouped based on shared credit risk characteristics (such as private versus public receivables) and days past due. In determining the expected credit loss rates, the Group considers current and forward-looking macroeconomic factors that may affect the ability of the customers to settle the receivables, and historical loss rates for each category of customers.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s largest customer accounted for approximately 17% of net sales, and the second largest and third largest customers accounted for 11% and 6% of net sales, respectively (2019: 18%,  13% and 8%, respectively; 2018: 18%, 14% and 8%, respectively).</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The highest amounts of trade receivables outstanding were for these same three customers and amounted to 14%, 12% and 6%, respectively, of the Group&#x2019;s trade receivables at December 31, 2020 (2019: 14%, 12% and 7%, respectively). There is no other significant concentration of customer credit risk.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Counterparty risk</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Counterparty risk encompasses issuer risk on marketable securities and money market instruments; credit risk on cash, time deposits and derivatives; as well as settlement risk for different instruments. Issuer risk is reduced by only buying securities that are at least A- rated. Counterparty credit risk and settlement risk are reduced by a policy of entering into transactions with counterparties (banks or financial institutions) that feature a strong credit rating. Exposure to these risks is closely monitored and kept within predetermined parameters. The limits are regularly assessed and determined based upon credit analysis, including financial statement and capital adequacy ratio reviews. In addition, reverse repurchasing agreements are contracted, and Novartis has entered into credit support agreements with various banks for derivative transactions. To further reduce the settlement risk, the Group has implemented a multi-currency system, CLS (Continuous Linked Settlement), providing multilateral netting (payment-versus-payment settlement) of cash flows from foreign exchange transactions.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s cash and cash equivalents are held with major regulated financial institutions; the three largest ones hold approximately 14.1%, 12.6% and 9.7%, respectively (2019: 12.6%, 10.4% and 8.3%, respectively).</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group does not expect any losses from non-performance by these counterparties and does not have any significant grouping of exposures to financial sector or country risk.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Liquidity risk</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Liquidity risk is defined as the risk that the Group could not be able to settle or meet its obligations associated with financial liabilities that are settled by delivering cash or another financial asset. Group Treasury is responsible for liquidity, funding and settlement management. In addition, liquidity and funding risks, and related processes and policies, are overseen by management. Novartis manages its liquidity risk on a consolidated basis according to business needs and tax, capital or regulatory considerations, if applicable, through numerous sources of financing in order to maintain flexibility. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Certain countries have legal or economic restrictions on the ability of subsidiaries to transfer funds to the Group in the form of cash dividends, loans or advances, but these restrictions do not have an impact on the ability of the Group to meet its cash obligations.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Management monitors the Group&#x2019;s net debt or liquidity position through rolling forecasts on the basis of expected cash flows.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis has two US commercial paper programs under which it can issue up to USD&nbsp;9.0 billion in the aggregate of unsecured commercial paper notes. Novartis also has a Japanese commercial paper program under which it can issue up to JPY&nbsp;150 billion (approximately USD&nbsp;1.5 billion) of unsecured commercial paper notes. Commercial paper notes totaling USD&nbsp;4.3 billion under these three programs were outstanding as per December 31, 2020 (2019: USD&nbsp;2.3 billion). Novartis further has a committed credit facility of USD&nbsp;6.0 billion, which was renewed in September 2019. This credit facility is provided by a syndicate of banks and is intended to be used as a backstop for the US commercial paper programs. The facility matures in September 2024 and was undrawn as per December 31, 2020, and December 31, 2019.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In December 2019, Novartis entered into a short-term credit facility of USD 7 billion, with a maturity date of June 30, 2020 with a syndicate of banks. On January 7, 2020, Novartis borrowed USD 7 billion under the facility with interest based on the USD LIBOR. On February 14, 2020, Novartis repaid the full USD 7 billion initially borrowed. The facility expired on June 30, 2020.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-75</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table sets forth how management monitors net debt or liquidity based on details of the remaining contractual maturities of current financial assets and liabilities, excluding trade receivables and payables as well as contingent considerations at December 31, 2020, and December 31, 2019:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="11" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="11" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="11" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="11" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Due within <br> one month</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br> one month <br> but less than <br> three months</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than<br>  three months <br> but less than <br> one year</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br> one year <br> but less than <br> five years</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Due after <br> five years</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> Total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, time deposits and short-term investments with original maturity more than 90 days</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   13</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   1&nbsp;571</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   25</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   5</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   21</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   1&nbsp;635</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 111</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 111</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments and accrued interest</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 110</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 159</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;558</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;100</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;658</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;609</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;781</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 135</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;563</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10&nbsp;621</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15&nbsp;638</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;26&nbsp;259</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;10&nbsp;661</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;15&nbsp;802</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;26&nbsp;463</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;10&nbsp;621</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;15&nbsp;638</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;26&nbsp;259</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4&nbsp;195</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;218</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;178</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9&nbsp;591</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;4&nbsp;195</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;2&nbsp;219</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;3&nbsp;179</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;9&nbsp;593</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;93</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;84</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;17</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;194</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;4&nbsp;288</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2&nbsp;302</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;195</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;9&nbsp;785</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;321</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 479</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;166</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;10&nbsp;612</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;15&nbsp;503</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;24&nbsp;481</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="11" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="11" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="11" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="11" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Due within <br> one month</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br> one month <br> but less than <br> three months</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than<br>  three months <br> but less than <br> one year</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br> one year <br> but less than <br> five years</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Due after <br> five years</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> Total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, time deposits and short-term investments with original maturity more than 90 days</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   20</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   26</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   16</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   3</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   57</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="7%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   122</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 110</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 110</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments and accrued interest</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 79</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;712</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;400</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;112</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;746</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;505</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 19</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 170</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;446</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9&nbsp;110</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11&nbsp;243</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;20&nbsp;353</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &#x2013;&#x2005;9&nbsp;150</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &#x2013;&#x2005;11&nbsp;355</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &#x2013;&#x2005;20&nbsp;505</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;9&nbsp;110</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;11&nbsp;243</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;20&nbsp;353</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4&nbsp;243</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;373</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;230</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6&nbsp;846</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &#x2013;&#x2005;4&nbsp;243</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &#x2013;&#x2005;1&nbsp;373</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &#x2013;&#x2005;1&nbsp;230</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &#x2013;&#x2005;6&nbsp;846</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;130</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;29</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;26</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;185</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;373</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;402</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;256</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;7&nbsp;031</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;373</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 103</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;237</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;9&nbsp;104</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;11&nbsp;073</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;15&nbsp;938</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated balance sheet amounts of financial liabilities included in the above analysis are not materially different to the contractual amounts due on maturity. The positive and negative fair values on derivative financial instruments represent the net contractual amounts to be exchanged at maturity.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-76</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s contractual undiscounted potential cash flows from derivative financial instruments to be settled on a gross basis are as follows:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="7" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Due within <br> one month</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br> one month <br> but less than <br> three months</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than<br>  three months <br> but less than <br> one year</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> Total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Derivative financial instruments and accrued interest on derivative  financial instruments</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="1%"></td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential outflows in various currencies - from financial derivative liabilities</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;930</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4&nbsp;096</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;719</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5&nbsp;745</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential inflows in various currencies - from financial derivative assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 904</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;114</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 710</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;728</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="7" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="7" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Due within <br> one month</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br> one month <br> but less than <br> three months</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than<br>  three months <br> but less than <br> one year</div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> </div>
      </td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> Total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Derivative financial instruments and accrued interest on derivative  financial instruments</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential outflows in various currencies - from financial derivative liabilities</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;814</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4&nbsp;624</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;952</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6&nbsp;390</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential inflows in various currencies - from financial derivative assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 807</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;656</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 922</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;385</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Other contractual liabilities that are not part of management&#x2019;s monitoring of the net debt or liquidity consist of the following items:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="9" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="9" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="9" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Due within <br> three months</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than<br>  three months <br> but less than <br> one year</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br> one year <br> but less than <br> five years</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Due after <br> five years</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> <br> Total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contractual interest on non-current liabilities</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;82</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;468</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;846</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4&nbsp;251</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6&nbsp;647</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;77</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;209</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;692</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;027</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;005</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5&nbsp;239</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;164</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5&nbsp;403</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;769</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;769</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;24</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;38</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;639</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;345</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;046</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="9" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="9" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="9" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br>(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Due within <br> three months</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than<br>  three months <br> but less than <br> one year</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br> one year <br> but less than <br> five years</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> Due after <br> five years</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br> <br> <br> Total</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contractual interest on non-current liabilities</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;36</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;428</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;531</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;439</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="8%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;434</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;65</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;181</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;622</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;081</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;949</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;222</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;202</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;424</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;62</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;582</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;383</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;036</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="12" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Capital risk management</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis strives to maintain a strong credit rating. In managing its capital, Novartis focuses on maintaining a strong balance sheet. As of December 31, 2020, Moody&#x2019;s Investor Service rated the Company A1 for long-term maturities and P-1 for short-term maturities and S&amp;P Global Ratings rated the company AA- for long-term maturities and A-1+ for short-term maturities. </div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Value at risk</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group uses a value at risk (VAR) computation to estimate the potential 10-day loss in the fair value of its financial instruments.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A 10-day period is used because of an assumption that not all positions could be undone in one day given the size of the positions. The VAR computation includes </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-77</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">all financial assets and financial liabilities as set forth in the table on page F-69, except:</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Trade receivables</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Other current assets</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Long-term loans and receivables, advances and security deposits</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Contingent considerations</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Lease liabilities</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Commitment for repurchase of own shares</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Trade payables</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The VAR estimates are made assuming normal market conditions, using a 95% confidence interval. The Group uses a &#x201C;Delta Normal&#x201D; model to determine the observed interrelationships between movements in interest rates, stock markets and various currencies. These interrelationships are determined by observing interest rate movements, stock market movements and foreign currency rate movements over a 60-day period for the calculation of VAR amounts.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimated potential 10-day loss in the fair value of the Group&#x2019;s foreign currency positions (including foreign exchange translation risk), the estimated potential 10-day loss of its equity holdings, and the estimated potential 10-day loss in fair value of its interest rate-sensitive instruments (primarily financial debt and investments of liquid funds under normal market conditions), as calculated in the VAR model, are the following:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">All financial instruments</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 587</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 355</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Analyzed by components:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to foreign  currency exchange rates</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   199</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   89</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to equity  market movements</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   62</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   31</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to interest rates</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 197</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 187</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The average, high and low VAR amounts are as follows:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Average</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> High</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Low</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">All financial instruments</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 568</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 659</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 322</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Analyzed by components:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to foreign  currency exchange rates</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   225</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   515</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   71</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to equity  market movements</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   78</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   261</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   21</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to  interest rates</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   329</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   912</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   173</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td></td>
      <td colspan="5" align="center" height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr>
      <td height="1"></td>
      <td height="1"></td>
      <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
      <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td>
    </tr>
    <tr bgcolor="white">
      <td height="3"></td>
      <td height="1"></td>
      <td colspan="5" height="3"></td>
      <td height="1"></td>
    </tr>
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Average</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> High</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Low</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">All financial instruments</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 348</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 385</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 303</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Analyzed by components:</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to foreign  currency exchange rates</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   143</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   195</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   86</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to equity  market movements</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   36</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   81</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   16</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to  interest rates</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   233</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   303</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   187</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The VAR computation is a risk analysis tool designed to statistically estimate the potential 10-day loss from adverse movements in foreign currency exchange rates, equity prices and interest rates under normal market conditions. The computation does not purport to represent actual losses in fair value on earnings to be incurred by the Group, nor does it consider the effect of favorable changes in market rates. The Group cannot predict actual future movements in such market rates, and it does not claim that these VAR results are indicative of future movements in such market rates or are representative of any actual impact that future changes in market rates may have on the Group&#x2019;s future results of operations or financial position.</div><a name="anchorId001592389"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">30. Discontinued operations</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Discontinued operations include the operational results from the Alcon eye care devices business and certain Corporate activities attributable to the Alcon business prior to the spin-off, the gain on distribution of Alcon Inc. to Novartis AG shareholders, and certain other expenses related to the Distribution (refer to Notes 1 and 2 for further details). </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Alcon eye care devices business researched, discovered, developed, manufactured, distributed and sold a broad range of eye care products. Alcon was organized into two global business franchises, Surgical and Vision Care. Alcon also provided services, training, education and technical support for both the Surgical and Vision Care businesses.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-78</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Consolidated income statement</font>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019<sup style="white-space: nowrap"> 1</sup></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from discontinued operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   1&nbsp;777</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   7&nbsp;149</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to continuing segments</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;809</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;153</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;860</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;983</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 949</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;170</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;638</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;754</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;142</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;585</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;113</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;126</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income/(loss) from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;234</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;25</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income/(loss) before taxes from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 58</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;260</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;159</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 74</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net loss from discontinued operations  before gain on distribution of Alcon Inc.  to Novartis AG shareholders</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     &#x2013;&#x2005;101</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     &#x2013;&#x2005;186</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc.  to Novartis AG shareholders<sup style="white-space: nowrap">&nbsp;2</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   4&nbsp;691</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income/(loss) from discontinued operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;590</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;186</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> The consolidated income statement amounts are for the period from January 1, 2019, to the completion of the spin-off.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> See Note 2 for further details on the non-taxable, non-cash gain on distribution of Alcon Inc. to Novartis AG shareholders.</div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Supplemental disclosures related to the Alcon business distributed to Novartis AG shareholders</font>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Additional significant accounting policies</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The accounting policies mentioned in Note 1 were used for the reporting of discontinued operations. The following additional significant accounting policies were applicable to discontinued operations.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Intangible assets available for use</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In addition to currently marketed products, technologies and other intangible assets (including computer software), discontinued operations intangible assets available for use also included marketing know-how and the Alcon brand name. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketing know-how represents the value attributable to the expertise acquired for marketing and distributing Alcon surgical products.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Alcon brand name was shown separately, as it was the only Novartis intangible asset that was available for use with an indefinite useful life. Novartis considers that it was appropriate that the Alcon brand name had an indefinite life since Alcon-branded products had a history of strong revenue and cash flow performance, and Novartis had the intent and ability to support the brand with spending to maintain its value for the foreseeable future. The Alcon brand name was not amortized as it had an indefinite useful life, but was evaluated for potential impairment annually. </div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the respective useful lives for available-for-use intangible assets and the location in the consolidated income statement in which the respective amortization and any potential impairment charge were recognized: </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br> <br> Useful life</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income statement location<br> for amortization and<br> impairment charges</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketing know-how</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25 years</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon brand name</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Not amortized,  indefinite useful life</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Other expense"  </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the activities and more specifically on appropriate royalty rate for the Alcon brand name.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Revenue recognition</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In the Alcon Division, which is reported as discontinued operations, surgical equipment may have been sold together with other products and services under a single contract. Revenues were recognized upon satisfaction of each of the performance obligations in the contract and the consideration was allocated based on the standalone selling price of each performance obligation.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For surgical equipment, in addition to cash and installment sales, revenue was recognized under finance and operating lease arrangements. Arrangements in which substantially all the risks and rewards incidental to ownership transfers to the customer were treated as finance lease arrangements. Revenue from finance lease arrangements was recognized at amounts equal to the fair value of the equipment, which approximated the present value of the minimum lease payments under the arrangements. As interest rates embedded in lease </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-79</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">arrangements were approximately market rates, revenue under finance lease arrangements was comparable to revenue for outright sales. Finance income for arrangements longer than 12 months was deferred and subsequently recognized based on a pattern that approximated to the use of the effective interest method and was recorded in &#x201C;Other income.&#x201D; Operating lease revenue for equipment rentals was recognized on a straight-line basis over the lease term.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Net income </font>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Included in net income from discontinued operations are:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of property, plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;42</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;235</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of right-of-use assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;174</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;052</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on property, plant and equipment</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on intangible assets<sup style="white-space: nowrap">&nbsp;1</sup></div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;391</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to restructuring provisions</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;13</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation of Novartis equity plans</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;93</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="6">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> 2018 includes an impairment of USD 337 million related to the write-down of the CyPass currently marketed product, which was acquired with the Alcon Division 2016 acquisition of Transcend Medical, Inc.</div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Balance sheet </font>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following were in the balance sheet from discontinued operations for the period from January 1, 2019, to the date of reclassification:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to property, plant and equipment</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 113</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to right-of-use assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to goodwill and intangible assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 36</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="4">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="4">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;</sup></div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Cash flows used in investing activities from discontinued operations</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash flows used in investing activities from discontinued operations include the investing activities of the Alcon business and cash outflows for transaction-related expenditures attributable to the series of portfolio transformation transactions completed in 2015. </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments attributable  to the spin-off of the  Alcon business</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     &#x2013;&#x2005;39</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2013;&#x2005;29</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="11%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     </div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Divested cash and cash equivalents</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;628</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows attributable to the  spin-off of the Alcon business</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   &#x2013;&#x2005;39</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   &#x2013;&#x2005;657</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   </div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other cash flows used in investing activities, net</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2013;&#x2005;88</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;502</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   &#x2013;&#x2005;1&nbsp;001</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows used in investing  activities from discontinued  operations</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">     &#x2013;&#x2005;127</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     &#x2013;&#x2005;1&nbsp;159</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">     &#x2013;&#x2005;1&nbsp;001</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Cash flows from financing activities from discontinued operations</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2020, the net cash outflows used in financing activities from discontinued operations of USD 50 million was for transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2019, the net cash inflows from financing activities from discontinued operations of USD 3.3 billion (2018: USD 167 million net cash outflows) included mainly USD 3.5 billion (2018: nil) cash inflows from Alcon borrowings in connection with the distribution (spin-off) of the Alcon business to Novartis AG shareholders, partly offset by USD 0.2 billion (2018: USD 0.1 billion) transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders (see Notes 1 and 2).</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Leases</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The lease liabilities recorded in discontinued operations on January 1, 2019, the date of implementation of IFRS 16 Leases (see Note 1), were USD 286 million, and the right-of-use assets were USD 276 million, including USD </div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-80</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">89 million and USD 75 million, respectively, for the previously reported finance lease obligations. For discontinued operations, there were no impairments or significant contract terminations of right-of-use assets for the period from January 1, 2019, to February 28, 2019, the date of shareholder approval for the Alcon spin-off.</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Net assets derecognized </font>
</div>
<div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table presents the Alcon business net assets at the date of spin-off at April 8, 2019:</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="20%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;858</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 269</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;906</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets other than goodwill</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;121</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 732</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial and other non-current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 526</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;469</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables and other current assets</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;787</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 628</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;713</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current lease liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;269</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current financial debts</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;538</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables, provisions and other liabilities</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;751</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets derecognized</div>
      </td>
      <td align="right"></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&nbsp;025</div>
      </td>
      <td align="right"></td>
    </tr>
    <tr>
      <td colspan="4" style="border-bottom: solid #000000 3px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td>
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
    </tr>
  </table>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Defined contribution plans</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In many subsidiaries, associates are covered by defined contribution plans. Contributions charged to the consolidated income statement for the defined contribution plans were: </div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div>
      </td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions for defined  contribution plans  discontinued operations</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     33</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="14%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     104</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
    </tr>
  </table>
</div><a name=""></a><div style=" padding-bottom: 10px;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In March 2019, Alcon acquired PowerVision, Inc. (PowerVision), a privately held, US-based medical device development company focused on developing accommodative, implantable intraocular lenses. The fair value of the total purchase consideration was USD 424 million. The amount consisted of an initial cash payment of USD 289 million and the fair value of the contingent consideration of USD 135 million, due to PowerVision shareholders, which they are eligible to receive upon the achievement of specified regulatory and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 418 million, consisting of intangible assets of USD 505 million, net deferred tax liabilities of USD 93 million, other net assets of USD 6 million, and goodwill of USD 6 million. The 2019 results of operations since the date of the acquisition were not material.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For additional information related to the distribution (spin-off) of the Alcon business to Novartis AG shareholders, effected through a dividend in kind distribution that was completed on April 8, 2019, refer to Note 1 and Note 2.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-81</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorId001593427"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">31. Events subsequent to the December 31, 2020, consolidated balance sheet date</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Significant transactions not closed as of January&nbsp;25,&nbsp;2021</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In November 2020 and in January 2021, Novartis entered into long-term research and development agreements, both of which did not close as of January 25, 2021. For additional information see Note 28. </div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Significant transaction closed in January 2021</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In December 2020, Novartis entered into a business acquisition agreement that closed on January 21, 2021, with an estimated fair value purchase price of USD 235 million.</div><a name=""></a><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Dividend proposal for 2020 and approval of&nbsp;the Group&#x2019;s 2020 consolidated financial statements </font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On January 25, 2021, the Novartis AG Board of Directors proposed the acceptance of the 2020 consolidated financial statements of the Novartis Group for approval by the Annual General Meeting on March 2, 2021. Furthermore, also on January 25, 2021, the Board proposed a dividend of CHF 3.00 per share to be approved at the Annual General Meeting on March 2, 2021. If approved, total dividend payments would amount to approximately USD 7.7 billion (2019: USD&nbsp;7.0  billion), using the CHF/USD December 31, 2020, exchange rate.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-82</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div><a name="anchorNote31"></a><a name="anchorId001593466"></a><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">32. Principal Group subsidiaries and&#xA0;associated&#xA0;companies</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table lists the principal subsidiaries controlled by Novartis, associated companies in which &#xAD;Novartis is deemed to have significant influence, and foundations required to be consolidated under IFRS. It includes all subsidiaries, associated companies and consolidated foundations with total assets or net sales to third parties in excess of USD&#xA0;25&#xA0;million. The equity interest percentage shown in the table also represents the share in voting rights in those entities, except where explicitly noted.</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"><br>As at December 31, 2020</div>
      </td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br> capital<sup style="white-space: nowrap">  1</sup></div>
      </td>
      <td></td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br> interest</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Algeria</div>
      </td>
      <td align="right" width="1%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Soci&#xE9;t&#xE9; par actions SANDOZ</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Algiers</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DZD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 650.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Argentina</div>
      </td>
      <td align="right" width="1%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Argentina S.A.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buenos Aires</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ARS</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 906.1</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Australia</div>
      </td>
      <td align="right" width="1%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Australia Pty Ltd</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Macquarie Park, NSW</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals Australia Pty Ltd</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Macquarie Park, NSW</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   AUD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   3.8</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Pty Ltd</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Macquarie Park, NSW</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.6</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Austria</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Austria GmbH</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vienna</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma GmbH</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vienna</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.1</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz GmbH</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Kundl</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32.7</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">EBEWE Pharma Ges.m.b.H Nfg. KG</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Unterach am Attersee</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Bangladesh</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Bangladesh) Limited</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gazipur</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BDT</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 162.5</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Belgium</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma NV</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vilvoorde</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.1</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz NV</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vilvoorde</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19.2</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon - Couvreur NV</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Puurs</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 110.6</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Bermuda</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Investment Ltd.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Securities Investment Ltd.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finance Services Ltd.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Triangle International Reinsurance Limited</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trinity River Insurance Co Ltd.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 370&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Brazil</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Bioci&#xEA;ncias S.A.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">S&#xE3;o Paulo</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRL</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 265.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz do Brasil Ind&#xFA;stria Farmac&#xEA;utica Ltda.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Camb&#xE9;, PR</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRL</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 190.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Canada</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals Canada Inc.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dorval, Quebec</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.2</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Canada Inc.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Boucherville, Quebec</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 80.8</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Manufacturing Inc.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Boucherville, Quebec</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Chile</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Chile S.A.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Santiago de Chile</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CLP</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">China</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Beijing Novartis Pharma Co., Ltd.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Beijing</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals (HK) Limited</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hong Kong</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HKD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 200</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">China Novartis Institutes for  BioMedical Research Co., Ltd.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Shanghai</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   320.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Suzhou Novartis Technical Development Co., Ltd.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Changshu</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   12.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shanghai Novartis Trading Ltd.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shanghai</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.2</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz (China) Pharmaceutical Co., Ltd.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Zhongshan</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   57.6</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Colombia</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis de Colombia S.A.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Santaf&#xE9; de Bogot&#xE1;</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> COP</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.9</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Croatia</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz d.o.o. farmaceutska industrija</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Zagreb</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HRK</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.6</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Czech Republic</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis s.r.o.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prague</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CZK</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 51.5</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz s.r.o.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prague</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CZK</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44.7</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Denmark</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Healthcare A/S</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Copenhagen</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DKK</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz A/S</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Copenhagen</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DKK</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ecuador</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Ecuador S.A.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Quito</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Egypt</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma S.A.E.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cairo</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EGP</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 193.8</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.77%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Egypt Pharma S.A.E.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New Cairo City</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EGP</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 250&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Finland</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finland Oy</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Espoo</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 459&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"><br>As at December 31, 2020</div>
      </td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br> capital<sup style="white-space: nowrap">  1</sup></div>
      </td>
      <td></td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br> interest</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">France</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Groupe France S.A.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rueil-Malmaison</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 903.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma S.A.S.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rueil-Malmaison</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43.4</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Advanced Accelerator Applications S.A.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Saint-Genis-Pouilly</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76&nbsp;734</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.2%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CELLforCURE</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Les Ulis</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.2</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz S.A.S.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Levallois-Perret</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.4</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Germany</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Deutschland GmbH</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nuremberg</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 155.5</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Business Services GmbH</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Wehr</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma GmbH</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nuremberg</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.6</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Produktions GmbH</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Wehr</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz International GmbH</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Holzkirchen</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 A Pharma GmbH</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Oberhaching</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">HEXAL AG</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Holzkirchen</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 93.7</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Salutas Pharma GmbH</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Barleben</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 42.1</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aeropharm GmbH</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rudolstadt</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Greece</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Hellas) S.A.C.I.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Metamorphosis / Athens</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 233.9</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Hungary</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Hungary Healthcare Limited Liability  Company</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Budapest</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   HUF</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   545.6</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Hungary Limited Liability Company</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Budapest</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HUF</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 883.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">India</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis India Limited</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mumbai</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 123.5</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70.68%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Healthcare Private Limited</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mumbai</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Private Limited</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mumbai</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Indonesia</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">PT. Novartis Indonesia</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Jakarta</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IDR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.7</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ireland</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Ireland Limited</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dublin</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Integrated Services Limited</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ringaskiddy, County Cork</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Ringaskiddy Limited</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ringaskiddy, County Cork</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Gene Therapies EU Limited</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dublin</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Israel</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Israel Ltd.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tel Aviv</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ILS</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Italy</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Farma S.p.A.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Origgio</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Advanced Accelerator Applications (Italy) S.r.l.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Pozzilli</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 119&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.2%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz S.p.A.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Origgio</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.7</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Japan</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma K.K.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tokyo</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ciba-Geigy Japan Limited</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tokyo</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.5</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz K.K.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tokyo</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aspen Japan K.K.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tokyo</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.2</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Latvia</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Baltics SIA</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Riga</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Luxembourg</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Investments S.&#xE0; r.l.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Luxembourg City</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finance S.A.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Luxembourg City</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Malaysia</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Corporation (Malaysia) Sdn. Bhd.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Kuala Lumpur</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MYR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.3</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Mexico</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Farmac&#xE9;utica, S.A. de C.V.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mexico City</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MXN</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 205.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz, S.A. de C.V.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mexico City</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MXN</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 468.2</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Morocco</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Maroc SA</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Casablanca</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MAD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 80.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Netherlands</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Netherlands B.V.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amsterdam</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.4</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma B.V.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amsterdam</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.5</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">IDB Holland BV</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Baarle-Nassau</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.2%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz B.V.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Almere</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 907&nbsp;560</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">New Zealand</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis New Zealand Ltd</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Auckland</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NZD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 820&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-83</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"><br>As at December 31, 2020</div>
      </td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br> capital<sup style="white-space: nowrap">  1</sup></div>
      </td>
      <td></td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br> interest</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Norway</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Norge AS</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Oslo</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NOK</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.5</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Pakistan</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma (Pakistan) Limited</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Karachi</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PKR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.7</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.99%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Panama</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma (Logistics), Inc.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Panama City</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Peru</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Biosciences Per&#xFA; S.A.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lima</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PEN</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.1</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Philippines</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Healthcare Philippines, Inc.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Makati City</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PHP</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 298.8</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Philippines Corporation</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Makati City</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PHP</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Poland</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Poland Sp. z o.o.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Warsaw</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44.2</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Polska Sp. z o.o.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Warsaw</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.6</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lek S.A.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Strykow</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.4</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Portugal</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Portugal, S.G.P.S., Lda.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Porto Salvo</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Farma - Produtos Farmac&#xEA;uticos, S.A.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Porto Salvo</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.4</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Farmac&#xEA;utica, Lda.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Porto Salvo</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 499&nbsp;900</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Romania</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Services Romania S.R.L.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bucharest</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RON</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz S.R.L.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Targu-Mures</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RON</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 105.2</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Russian Federation</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma LLC</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Moscow</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Neva LLC</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">St. Petersburg</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">ZAO Sandoz</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Moscow</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57.4</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Saudi Arabia</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Saudi Ltd.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Riyadh</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SAR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Singapore</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Singapore) Pte Ltd.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Singapore</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Singapore Pharmaceutical  Manufacturing Pte Ltd</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Singapore</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   SGD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   45.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Asia Pacific Pharmaceuticals Pte Ltd</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Singapore</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   SGD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   39.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Slovakia</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Slovakia s.r.o.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bratislava</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Slovenia</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lek Pharmaceuticals d.d.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ljubljana</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 48.4</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Pharmaceuticals d.d.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ljubljana</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.5</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">South Africa</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis South Africa (Pty) Ltd</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Midrand</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ZAR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 86.3</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz South Africa (Pty) Ltd</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Kempton Park</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ZAR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">South Korea</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Korea Ltd.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Seoul</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> KRW</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24.5</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98.55%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Spain</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Farmac&#xE9;utica, S.A.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Barcelona</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 63.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Advanced Accelerator Applications Iberica, S.L.U.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Barcelona</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   22.6</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   99.2%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Catalana de Dispensacion sau  (Cadisa)</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Esplugues de Llobregat</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   450&nbsp;750</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   99.2%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Farmac&#xE9;utica S.A.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Madrid</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 270&nbsp;450</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Industrial Products  S.A.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Les Franqueses del Vall&#xE9;s / Barcelona</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   9.3</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Cusi, S.A.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">El Masnou / Barcelona</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10.1</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Abadia Retuerta S.A.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sard&#xF3;n de Duero / Valladolid</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sweden</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Sverige AB</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Stockholm</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SEK</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Switzerland</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis International AG</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Holding AG</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.2</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis International Pharmaceutical Investment AG</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Bioventures AG</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Forschungsstiftung</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel<sup style="white-space: nowrap">&nbsp;4</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Stiftung f&#xFC;r Kaderausbildung</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel<sup style="white-space: nowrap">&nbsp;4</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Mitarbeiterbeteiligungsstiftung</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel<sup style="white-space: nowrap">&nbsp;4</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Stiftung f&#xFC;r Mensch und Umwelt</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel<sup style="white-space: nowrap">&nbsp;4</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Stiftung der Novartis AG f&#xFC;r Erziehung, Ausbildung und Bildung</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Basel<sup style="white-space: nowrap">&nbsp;4</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   --</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   --</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   --</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Overseas Investments AG</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japat AG</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma AG</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 350.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Services AG</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Schweizerhalle AG</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Muttenz</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.9</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Stein AG</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Stein</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 251&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Schweiz AG</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Risch</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Ophthalmics AG</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fribourg</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Advanced Accelerator Applications International SA</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Geneva</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9.3</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.2%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz AG</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Pharmaceuticals AG</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Risch</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Roche Holding AG</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 160.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33%/6%<sup style="white-space: nowrap"> 2</sup></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
  </table>
</div>
<div style="padding-top:10px; padding-bottom:30px;">
  <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
    <tr valign="bottom">
      <td height="12">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"><br>As at December 31, 2020</div>
      </td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br> capital<sup style="white-space: nowrap">  1</sup></div>
      </td>
      <td></td>
      <td></td>
      <td align="right">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br> interest</div>
      </td>
      <td></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Taiwan</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Taiwan) Co., Ltd.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taipei</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TWD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 170.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Thailand</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Thailand) Limited</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bangkok</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> THB</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 302.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Turkey</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Saglik, Gida ve Tarim &#xDC;r&#xFC;nleri Sanayi  ve Ticaret A.S.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Istanbul</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   TRY</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   98.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Farmanova Saglik Hizmetleri Ltd. Sti.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Istanbul</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.7</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Ila&#xE7; Sanayi ve Ticaret A.S.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Istanbul</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 265.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.99%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Grup Saglik &#xDC;r&#xFC;nleri Ila&#xE7;lari Sanayi ve Ticaret A.S.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Gebze - Kocaeli</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   TRY</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   50.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ukraine</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Ukraine LLC</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Kyiv</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> UAH</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United Arab Emirates</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Middle East FZE</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dubai</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AED</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United Kingdom</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis UK Limited</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">London</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.5</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals UK Limited</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">London</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.4</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Grimsby Limited</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">London</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 250.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Advanced Accelerator Applications (UK &amp; Ireland)</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">London</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.2%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Neutec Pharma Limited</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">London</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.7</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ziarco Group Limited</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">London</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;904</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Limited</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frimley / Camberley</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Coalesce Product Development Limited</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cambridge, Cambs</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United States of America</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Corporation</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 72.2</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finance Corporation</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Capital Corporation</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Services, Inc.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis US Foundation</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ<sup style="white-space: nowrap">&nbsp;4</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals Corporation</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ<sup style="white-space: nowrap">&nbsp;3</sup></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 650</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Advanced Accelerator Applications USA, Inc.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Millburn, NJ</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.2%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Gene Therapies, Inc.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bannockburn, IL</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Technology LLC</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Institutes for BioMedical  Research, Inc.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cambridge, MA</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   1</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Optogenetics Research, Inc.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CoStim Pharmaceuticals Inc.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cambridge, MA</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Endocyte, Inc.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Navigate BioPharma Services, Inc.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Carlsbad, CA</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">The Medicines Company</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Inc.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Princeton, NJ</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25&nbsp;000</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amblyotech Inc.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Oriel Therapeutics, Inc.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Durham, NC</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50.0</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fougera Pharmaceuticals Inc.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Melville, NY</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Eon Labs, Inc.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Princeton, NJ</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Vaccines and Diagnostics, Inc.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Venezuela</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis de Venezuela, S.A.</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Caracas</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VES</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Vietnam</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr valign="bottom" bgcolor="#ffffff">
      <td height="16">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Vietnam Company Limited</div>
      </td>
      <td align="right" width="9%"></td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ho Chi Minh City</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VND</div>
      </td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70</div>
      </td>
      <td width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
      </td>
      <td align="right" width="1%"></td>
      <td align="right" width="9%">
        <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div>
      </td>
      <td align="right" width="1%"></td>
    </tr>
    <tr>
      <td colspan="10" style="border-bottom: solid #000000 1px;"></td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">In addition, the Group is represented by subsidiaries and associated companies with total assets or net sales to third parties below USD 25 million in the following countries: Bosnia and Herzegovina, Bulgaria, Dominican Republic, Guatemala, Kenya, Kuwait, North Macedonia, Nigeria, Puerto Rico and Uruguay</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;1&nbsp;</sup> Share capital may not reflect the taxable share capital and does not include any paid-in surplus.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;2&nbsp;</sup> Approximately 33.3% of voting shares; approximately 6.2% of total net income and equity attributable to Novartis.</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;3&nbsp;</sup> Significant subsidiary under SEC Regulation S-X Rule 1-02(w)</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><sup>&nbsp;4&nbsp;</sup> Fully consolidated Foundation</div>
      </td>
    </tr>
    <tr valign="bottom">
      <td height="10px" colspan="10">
        <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">m = million; bn = billion</div>
      </td>
    </tr>
  </table>
</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-84</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
    <a name="anchorId001737515"></a><p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Report of Independent Registered Public Accounting Firm</p><a name=""></a><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">To the shareholders and Board of Directors of Novartis AG</font>
</div><a name=""></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Opinions on the Financial Statements and Internal Control over Financial Reporting</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">We have audited the accompanying consolidated balance sheets of Novartis AG and its subsidiaries (the &#x201C;Group&#x201D;) as of December 31, 2020 and December 31, 2019, and the related consolidated income statements, consolidated statements of comprehensive income, consolidated statements of changes in equity, and consolidated statements of cash flows, for each of the three years in the period ended December 31, 2020, including the related notes (collectively referred to as the &#x201C;consolidated financial statements&#x201D;). We also have audited the Group&#x2019;s internal control over financial reporting as of December 31, 2020, based on criteria established in <i>Internal Control &ndash; Integrated Framework</i> (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).  </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Group as of December 31, 2020 and December 31, 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020 in conformity with International Financial Reporting Standards (&#x201C;IFRS&#x201D;) as issued by the International Accounting Standards Board. Also in our opinion, the Group maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on criteria established in <i>Internal Control &ndash; Integrated Framework</i> (2013) issued by the COSO. </div>
<div>
  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;font-style:italic;">Change in Accounting Principle</div>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As discussed in Note 1 to the consolidated financial statements, the Group changed the manner in which it accounts for leases in 2019 in accordance with the provision of the new IFRS 16 Leases standard.</div><a name=""></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Basis for Opinions</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The Group&#x2019;s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in &#x201C;Report of Novartis Management on Internal Control Over Financial Reporting&#x201D; appearing under Item 15(b). The Board of Directors is also responsible for the preparation of the consolidated financial statements in accordance with IFRS, and for such internal control as the Board of Directors determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error. Our responsibility is to express opinions on the Group&#x2019;s consolidated financial statements and on the Group&#x2019;s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Group in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.  </div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</div><a name=""></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Definition and Limitations of Internal Control over Financial Reporting</font>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">A company&#x2019;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS. A company&#x2019;s internal control over financial reporting includes those policies and procedures that (i)&nbsp;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii)&nbsp;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with IFRS, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the com-</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-85</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">pany; and (iii)&nbsp;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#x2019;s assets that could have a material effect on the financial statements.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.  </div><a name=""></a><div>
  <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Critical Audit Matters</font>
</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</div>
<div>
  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;font-style:italic;">Intangible Assets Impairment Assessments &ndash; Innovative Medicines Division Currently Marketed Products</div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">As described in Notes 1 and 11 to the consolidated financial statements, the Group has intangible assets in its Innovative Medicines Division other than goodwill totaling USD 35.1 billion at December 31, 2020, including currently marketed products of USD 29.6 billion. The Group recognized impairments of intangible assets in its Innovative Medicines Division other than goodwill of USD 768 million during the year. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal that is used to determine if the asset is impaired. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. The estimates that management used in calculating the net present values depend on assumptions specific to the nature of the Innovative Medicines Division&#x2019;s activities with regard to the amount and timing of projected future cash flows; long-term sales forecasts; actions of competitors (launch of competing products, marketing initiatives, etc.); sales erosion rates after the end of patent or other intellectual property rights protection, and timing of the entry of generic competition; outcome of research and development activities (compound efficacy, results of clinical trials, etc.); amount and timing of projected costs to develop IPR&amp;D into commercially viable products; profit margins; probability of obtaining regulatory approval; future tax rate; and discount rate.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The principal considerations for our determination that performing procedures relating to the intangible assets impairment assessments of the Innovative Medicines Division currently marketed products is a critical audit matter are the significant judgment by management when developing the net present value of the intangible assets. This in turn led to a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management&#x2019;s significant assumptions related to the amount and timing of projected future cash flows (specifically the long-term sales forecasts and the probability of obtaining regulatory approval) and the discount rate. In addition, the audit effort involved the use of professionals with specialized skill and knowledge.</div>
<div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management&#x2019;s intangible assets impairment assessments, including controls over the Innovative Medicines Division currently marketed products. These procedures also included, among others, testing management&#x2019;s process for developing the fair value estimate; evaluating the appropriateness of the net present value techniques; testing the completeness and accuracy of underlying data used in the model; and evaluating the significant assumptions used by management, including the amount and timing of projected future cash flows and the discount rate. Evaluating management&#x2019;s assumptions related to the amount and timing of projected future cash flows and the discount rate involved evaluating whether the assumptions used by management were reasonable considering the current and past performance of the intangible assets, the consistency with external market and industry data, and whether these assumptions were consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in the evaluation of the discount rate.</div>
<div>
  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;font-style:italic;">US Managed Care, Medicare Part D and Medicaid Rebates</div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">As described in Note 1 and 22 to the consolidated financial statements, the consideration Novartis receives in exchange for its goods or services may be fixed or variable. Variable consideration is only recognized when it is highly probable that a significant reversal will not occur. Rebates and discounts granted to government agencies, wholesalers, retail pharmacies, managed healthcare organizations and other customers, as well as chargebacks, are provisioned and recorded as a revenue deduction at the time the related revenues are recorded or when the incentives are offered. They are calculated on the basis of historical experience, regulations, the specific terms in the individual agreements, product pricing and the mix of products, contracts, channels and payors. The provision reported as of December 31, 2020 for revenue deductions amounted to USD 6.3 billion, a significant portion of which related to US Managed Care, Medicare Part D and Medicaid rebates.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-86</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The principal considerations for our determination that performing procedures relating to the US Managed Care, Medicare Part D and Medicaid rebates is a critical audit matter are the significant judgment by management due to the significant measurement uncertainty involved in developing these provisions, as the provisions are based on assumptions developed using historical experience, regulations, the specific terms in the individual agreements, product pricing and the mix of products, contracts, channels and payors. This in turn led to a high degree of auditor judgment, subjectivity and effort in applying procedures relating to these assumptions.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to provisions for the US Managed Care, Medicare Part D and Medicaid rebate programs, including controls over the assumptions used to estimate these rebates. These procedures also included, among others, developing an independent estimate of the rebates by utilizing third-party information on price and market conditions in the US, the terms of the specific rebate programs, and the historical trend of actual rebate claims paid; comparing the independent estimate to management&#x2019;s estimates; and testing rebate claims processed by the Group, including evaluating those claims for consistency with the contractual and mandated terms of the Group&#x2019;s rebate arrangements.</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">/s/ PricewaterhouseCoopers AG</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Basel, Switzerland</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">January 25, 2021</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">We have served as the Group&#x2019;s or its predecessors&#x2019; auditor since at least 1940. We have not been able to determine the specific year we began serving as auditor of the Group&#x2019;s predecessors.</div>
<div style="padding-bottom:10px;"></div>
<div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
  <div style="TEXT-ALIGN: center; WIDTH: 100%">
    <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-87</font>
    <div style="padding-bottom:10px;"></div>
    <hr style="HEIGHT: 2px; WIDTH: 100%; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px" noshade size="3">
  </div>
  <div style="padding-bottom:30px;"></div>
</div>




<br>
<img src="x_coverback.jpg">
<br>
<br>




</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1
<SEQUENCE>2
<FILENAME>a21012620f-ex1_2.htm
<DESCRIPTION>EXHIBIT 1.2
<TEXT>

<html>
<head>
<title>EXHIBIT 1.2</title>
</head>
<body bgcolor="#ffffff">

  <div>
<div>&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">
<table id="z5497beb06e37450ab11a1bb36b8c8d5a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 12.68%; VERTICAL-ALIGN: top">&#160;<img src="deckblatt2.jpg"></td>
<td style="WIDTH: 87.32%; VERTICAL-ALIGN: top"><font style="FONT-FAMILY: 'Times New Roman'">&#160; </font>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; TEXT-ALIGN: right">Exhibit 1.2</div>

<div style="FONT-SIZE: 24pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left; MARGIN-TOP: 12pt"><img src="logo.jpg"></div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div><br>
<font style="FONT-FAMILY: 'Times New Roman'">&#160;</font></div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-SIZE: 24pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left; MARGIN-TOP: 12pt">
<div style="FONT-FAMILY: 'Times New Roman'">Regulations of the Board of Directors, <br>
 the Board Committees and the Executive Committee of Novartis AG</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-SIZE: 20pt; FONT-FAMILY: 'Times New Roman'">(Organisationsreglement)</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left; MARGIN-TOP: 486pt"><br>


<div style="FONT-SIZE: 24pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left; MARGIN-TOP: 12pt">&#160;</div>
</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>
</div>

<div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New Roman'; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>
</div>

<div>
<table id="zfb18c78136dc4d6497e94c70c6f3f075" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 108.15pt">Novartis AG</div>
</td>
</tr>

<tr>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; TEXT-ALIGN: left; MARGIN-LEFT: 108.15pt">4002 Basel, Switzerland</div>
</td>
</tr>

<tr>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 100%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; TEXT-ALIGN: left; MARGIN-LEFT: 108.15pt">&#169; 1 January 2021, Novartis AG</div>
</td>
</tr>
</table>
</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New Roman'; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div>
<table id="z70a0ee492bfc4bdf82f3802ad30e915b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 22.68%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 2.15%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 68.32%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">Table of Contents</div>
</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 6.85%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 22.68%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">Section 1</div>
</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 2.15%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 68.32%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 14pt; COLOR: #0460a9; TEXT-ALIGN: left">Scope of the Regulations, Organization in general</div>
</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 6.85%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 14pt; COLOR: #0460a9; TEXT-ALIGN: right">2</div>
</td>
</tr>

<tr>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 22.68%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">Section 2</div>
</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 2.15%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 68.32%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 14pt; COLOR: #0460a9; TEXT-ALIGN: left">General Provisions</div>
</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 6.85%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 14pt; COLOR: #0460a9; TEXT-ALIGN: right">2</div>
</td>
</tr>

<tr>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 22.68%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">Section 3</div>
</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 2.15%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 68.32%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 14pt; COLOR: #0460a9; TEXT-ALIGN: left">Meetings of the Board, the Board Committees and the Executive Committee</div>
</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 6.85%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 14pt; COLOR: #0460a9; TEXT-ALIGN: right">3</div>
</td>
</tr>

<tr>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 22.68%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">Section 4</div>
</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 2.15%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 68.32%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 14pt; COLOR: #0460a9; TEXT-ALIGN: left">Board of Directors</div>
</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 6.85%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 14pt; COLOR: #0460a9; TEXT-ALIGN: right">4</div>
</td>
</tr>

<tr>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 22.68%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">Section 5</div>
</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 2.15%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 68.32%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 14pt; COLOR: #0460a9; TEXT-ALIGN: left">Executive Committee</div>
</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 6.85%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 14pt; COLOR: #0460a9; TEXT-ALIGN: right">8</div>
</td>
</tr>

<tr>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 22.68%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">Section 6</div>
</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 2.15%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 68.32%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 14pt; COLOR: #0460a9; TEXT-ALIGN: left">Internal Audit</div>
</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 6.85%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 14pt; COLOR: #0460a9; TEXT-ALIGN: right">9</div>
</td>
</tr>

<tr>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 22.68%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">Section 7</div>
</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 2.15%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 68.32%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 14pt; COLOR: #0460a9; TEXT-ALIGN: left">Effectiveness, Amendments</div>
</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 6.85%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 14pt; COLOR: #0460a9; TEXT-ALIGN: right">10</div>
</td>
</tr>

<tr>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 22.68%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">Appendix I</div>
</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 2.15%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 68.32%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 14pt; COLOR: #0460a9; TEXT-ALIGN: left">Board Committees Charter</div>
</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 6.85%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 14pt; COLOR: #0460a9; TEXT-ALIGN: right">11</div>
</td>
</tr>

<tr>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 22.68%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">Appendix II</div>
</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 2.15%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 68.32%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 14pt; COLOR: #0460a9; TEXT-ALIGN: left">Independence Criteria for the Board and the Board Committees</div>
</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 6.85%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 14pt; COLOR: #0460a9; TEXT-ALIGN: right">23</div>
</td>
</tr>

<tr>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 22.68%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 2.15%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 68.32%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 14pt; COLOR: #0460a9; TEXT-ALIGN: left">Abbreviations and Definitions</div>
</td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 6.85%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 14pt; COLOR: #0460a9; TEXT-ALIGN: right">26</div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">All references to individuals apply to both male and female persons.</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">1</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New Roman'; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</div>

<div>
<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="z728c3dfd33ca418db042333142ba427a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">Section 1</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">Scope of the Regulations, Organization in general</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 1</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Scope</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">These Regulations govern the internal organization as well as the duties, powers and responsibilities of the following executive bodies and persons of the Company:</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#8211; Board and its Committees</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#8211; Chairman</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#8211; Vice-Chairman</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-VARIANT: normal; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: justify">&#8211; Lead Independent Director</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-VARIANT: normal; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: justify">
<div id="DSPFPageHeader">&#8211; CEO</div>
</div>
</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#8211; Executive Committee (including its sub-committees) and</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#8211; Internal Audit</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 2</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Company Structure</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The Company is a holding company, which directly or indirectly owns a global group of companies that conduct the Business. To ensure proper functioning of the Business in the interests of the Company and its shareholders and to comply with various requirements imposed by relevant laws and regulatory authorities, the Board shall supervise and, where necessary and appropriate, provide overall strategic direction for the Business.</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">Section 2</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">General Provisions</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 3</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Duty of Care and Loyalty</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Each Director or Executive is under the duty to carry out his/her responsibilities with due care and to safeguard and further the interests of the Group, the Company and its shareholders, including the creation of long-term value.</div>

<font style="FONT-SIZE: 14pt">&#160;</font></td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 4</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Conflict of Interest</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Each Director or Executive arranges his/her personal and business affairs so as to avoid an actual or apparent Conflict of Interest.</div>

<div>&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">No Director or Executive shall participate in decisions and resolutions on matters, which affect, or reasonably might affect, his/her interests or the interests of a person close to him/her (but he or she may participate in the discussion). If the Director or Executive is in a position of a permanent Conflict of Interest or any other non-solvable situation that hinders him/her in carrying out his/her duties to the full, he/she shall offer his/her resignation.</div>

<div>&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Each Director or Executive must make a notification immediately, if the circumstances change so that it might affect or appear to affect the Director&#8217;s or Executive&#8217;s independence. In case of a new mandate, notification must occur prior to accepting such new mandate.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">2</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="zbeadc73ef53a4f80a22b745cd305f197" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Required disclosures include (but are not limited to):</div>

<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 22pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(i)<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font></font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">a material change (or contemplated change) of his/her business or professional affiliations or responsibilities; and/or</font></div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 26pt; TEXT-INDENT: -26pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(ii)<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font></font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">any change of circumstances that may affect or appear to affect his/her independence or give rise to a Conflict of Interest.</font></div>

<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Disclosure must be made by:</div>

<div style="MARGIN-LEFT: 26pt; MARGIN-TOP: 3pt; TEXT-INDENT: -26pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(i)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">the Chairman to the Chairperson of the GNCRC; and by</font></div>

<div style="MARGIN-LEFT: 26pt; MARGIN-TOP: 3pt; TEXT-INDENT: -26pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(ii)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">a Director or the CEO to the Chairman; and by</font></div>

<div style="MARGIN-LEFT: 26pt; MARGIN-TOP: 3pt; TEXT-INDENT: -26pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(iii)&#160; </font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">an Executive to the CEO.</font></div>

<div>&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The Chairman, the CEO and the Chairperson of the GNCRC, respectively, must review the disclosures and inform the Board, respectively the ECN, with a corresponding proposal for appropriate mitigating measures, if any.</div>

<font style="FONT-SIZE: 14pt">&#160;</font></td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 5</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Confidentiality</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Each Director and Executive keeps at all times strictly confidential all information &#8211; except information already in the public domain &#8211; relating to the Company and/or the Group, which the member has learned during the exercise of the duties. This obligation and duty continues even after the expiration of the term of office.</div>

<div>&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Documents of the Company and/or the Group must be returned by the Director or Executive at the latest on expiry of the term of office. If required, e.g. in case of legal proceedings, the Director or Executive can access relevant documents at the office of the Corporate Secretary.</div>

<font style="FONT-SIZE: 14pt">&#160;</font></td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">Section 3</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">Meetings of the Board, the Board Committees and the Executive Committee</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 6</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">No Representation of Members</div>

<div>&#160;</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">A Director or Executive who is not able to participate in a Board, Board Committee or an Executive Committee meeting may not be represented by another Director or Executive or any other person.</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 7</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Quorum, Majority</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Requirements</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Unless stated otherwise in these Regulations, the presence in person, by telephone, by video conference or other technical means of a majority of the members is required for any meeting.</div>

<div>&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">If the chair does not participate, the meeting will be chaired by the deputy or, in his/her absence, by any member appointed by the other members as <font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-STYLE: italic">ad hoc </font>chair.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">3</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="zc75c14fea6ed4702940adf277acfd7cd" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.38%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Resolutions require the affirmative majority of the votes cast. If an item is, however, not on the agenda<font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">, </font>resolutions are passed by an affirmative vote of at least two thirds of the Directors or Executives, present at a meeting.</div>

<div>&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">In the event of a tie on any issue, (i) in a Board Committee, the full Board decides the issue, and (ii) in the Executive Committee, the CEO decides the issue.</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.38%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 8</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Circular Resolutions</div>

<div>&#160;</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.38%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">A proposal for a circular resolution must be communicated to all members, giving a deadline for responding, and is only deemed to have passed if:</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.38%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 14pt; MARGIN-LEFT: 22pt; TEXT-INDENT: -22pt">(i)&#160; more than two-thirds of all members cast a vote or give written notice that they abstain (written notice can include email notice);</div>

<div style="FONT-SIZE: 14pt; MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt">(ii)&#160; an absolute majority of all members casting a vote approve the proposed resolution; and</div>

<div style="FONT-SIZE: 14pt; MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt">(iii)&#160; no member requests a meeting within the deadline for responding in relation to the subject matter of the proposed resolution.</div>

<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-SIZE: 14pt; WIDTH: 75.38%; VERTICAL-ALIGN: top" colspan="2">
<div>A circular resolution must be recorded under a separate heading in the minutes of the following meeting.</div>

<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.38%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 9</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Secretary, Minutes</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.38%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The Board and the Board Committees each appoint a secretary, who need not be a member of the body.</div>

<div>&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The secretaries of the Board and the Board Committees, and the General Counsel in case of the Executive Committee, keep the meeting minutes, which contain all resolutions adopted at the meeting and the key decision-making factors.</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.38%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 10</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Application to other Bodies</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.38%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Articles 3&#8211;9 apply analogously to all other management committees of the Company and their members.</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">Section 4</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.38%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">Board of Directors</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.38%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 11</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Independence</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.38%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The majority of the Directors have to meet the independence criteria set forth in Appendix&#160;II.</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.38%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 12</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Duties of the Board</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.38%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The Board is the ultimate executive body of the Company.</div>

<div>&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">It shall resolve all Business matters, which are not reserved to the authority of the General Meeting or to other executive bodies of the Company by law, the Articles, or these Regulations.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">4</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="z4d3f0d3c0a254a4b8227bb6832b538d9" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.38%; VERTICAL-ALIGN: top" colspan="4">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">In particular, the Board has the following duties:</div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">a)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The ultimate direction of the Business, including, without limitation, the taking of resolutions and the giving of instructions or overall guidance regarding the following matters (where applicable, the duties of the Board are further defined and specified in internal regulations):</font></div>

<div style="MARGIN-LEFT: 40pt; MARGIN-TOP: 2pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font></font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The strategy upon recommendation of the Executive Committee.</font></div>

<div style="MARGIN-LEFT: 40pt; MARGIN-TOP: 2pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The entry into new areas of activity and withdrawal from existing areas of the Business; acquisitions and divestments of companies, participations in companies or businesses, or incorporations or liquidations of companies or businesses, if such matters are of fundamental significance to the Business.</font></div>

<div style="MARGIN-LEFT: 40pt; MARGIN-TOP: 2pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The opening and closing down of sites of fundamental significance to the Business.</font></div>

<div style="MARGIN-LEFT: 40pt; MARGIN-TOP: 2pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The initiation and settlement of legal proceedings of fundamental significance to the Business.</font></div>

<div style="MARGIN-LEFT: 40pt; MARGIN-TOP: 2pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The setting of financial targets.</font></div>

<div style="MARGIN-LEFT: 40pt; MARGIN-TOP: 2pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The review and approval of corporate policies that are fundamental to the Group, as determined by the Chairman and the CEO.</font></div>

<div style="MARGIN-LEFT: 40pt; MARGIN-TOP: 2pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The adoption from time to time of further regulations and instructions regarding the organization of the Business and the duties and responsibilities of the executive bodies.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.38%; VERTICAL-ALIGN: top" colspan="4">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">b)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The determination of the organization of the Company and the Group.</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">c)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The manner of governance of the Group.</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">d)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The regular review of the Group&#8217;s culture.</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">e)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The review of the Group&#8217;s risk management system and of the most significant risks and how these are managed.</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">f)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The determination of the Group&#8217;s accounting system, financial controls and financial planning.</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">g)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The review and approval of the annual report of the Company and of the Group, incl. the Compensation Report.</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">h)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The nomination or appointment, removal, determination of duties and responsibilities, and succession plans of the following persons (subject to the powers of the General Meeting):</font></div>

<div style="MARGIN-LEFT: 40pt; MARGIN-TOP: 2pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Vice-Chairman</font></div>

<div style="MARGIN-LEFT: 40pt; MARGIN-TOP: 2pt; TEXT-INDENT: -18pt">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#8211;<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font>Lead Independent Director</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Board Committee members and Chairpersons</font></div>
</div>

<div style="MARGIN-LEFT: 40pt; MARGIN-TOP: 2pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">CEO</font></div>

<div style="MARGIN-LEFT: 40pt; MARGIN-TOP: 2pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Executives</font></div>

<div style="MARGIN-LEFT: 40pt; MARGIN-TOP: 2pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Independent Proxy</font></div>

<div style="MARGIN-LEFT: 40pt; MARGIN-TOP: 2pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Such other persons as the Board may determine, from time to time, as having significant impact on the Business.</font></div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">5</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="zed5385f792ba4c588b392920f6bd661b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">i)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The composition of the Board, including the appropriate skills and experiences to be considered in succession planning.</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">j)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The designation of those persons who have signatory power for the Company and the manner in which such persons may sign on behalf of the Company.</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">k)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The ultimate supervision of the persons entrusted with the management of the Business, specifically in view of their compliance with laws, the Articles, these Regulations and other applicable regulations, directives and instructions.</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">l)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The preparations for the General Meeting and carrying out the resolutions of the General Meeting, including the preparation of the proposals to the General Meeting related to the compensation of the Board and of the Executive Committee and to the Compensation Report, as per the Articles.</font></div>

<div style="MARGIN-TOP: 3pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">m)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The notification of the court if liabilities exceed assets.</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">n)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The adoption of resolutions concerning an increase of the share capital to the extent that such power is vested in the Board (article&#160;651 paragraph 4 CO), as well as resolutions concerning confirmation of capital increases and related amendments to the Articles. The adoption of such resolutions shall be exempted from the majority requirement outlined in article 7.</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">o)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The determination of (i) the compensation strategy and of the principles, structure and design of compensation plans for the Executive Committee, (ii) the long-term incentive/equity plans, (iii)&#160;the compensation of the Directors and of the CEO to be presented to the shareholders, and of the terms of employment of the CEO, (iv) the Group and divisional financial, strategic and operational targets and the evaluation of target achievement.</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">p)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The determination of the maximum aggregate amount or maximum partial amounts of compensation, in the event the General Meeting has not approved a proposal of the Board, as per the Articles.</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">q)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The determination of (i) whether or not a Director is independent, based on a proposal by the GNCRC, and (ii) whether or not the ACC Directors meet the financial literacy and expertise standards.</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">r)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The decision on appropriate measures in case of a disclosure in accordance with article 4 of these Regulations.</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">s)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The approval of other business, if such business exceeds the authority delegated from time to time by the Board to the Board Committees or to the Executive Committee.</font></div>

<div style="MARGIN-TOP: 3pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 13</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Delegation of Management</div>

<div>&#160;</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Where not stipulated as a Board responsibility in the law, the Articles or these Regulations, the Board delegates the management of the Business to the Executive Committee, pursuant and subject to these Regulations.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">6</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="za6591fae7a844b8185b114f2f29e216d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5.21%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.77%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 14</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Meetings, Agenda</div>

<div>&#160;</div>
</td>
<td style="WIDTH: 5.21%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.77%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The Board meets at the invitation of the Chairman as often as may be required.</div>

<div>&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Invitations for Board meetings contain the meeting agenda and are sent out at least five business days in advance, except for urgent matters. Also, any Director may request a meeting for a specific purpose or the inclusion of a certain item on the agenda.</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5.21%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.77%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 15</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Right to Request</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Information</div>

<div>&#160;</div>
</td>
<td style="WIDTH: 5.21%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.77%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Directors have full and unrestricted access to the management and employees of the Group in the execution of their duties.<br>
 &#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5.21%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.77%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 16</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Independent Advisors</div>

<div>&#160;</div>
</td>
<td style="WIDTH: 5.21%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.77%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The Board has the authority to retain independent advisors for any matters within the scope of its responsibilities.</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5.21%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.77%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 17</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Evaluation of Board Performance</div>

<div>&#160;</div>
</td>
<td style="WIDTH: 5.21%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.77%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The Board conducts an annual evaluation of the performance of the Board, of the Board Committees and of the Chairman.</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5.21%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.77%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 18</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Board Committees</div>

<div>&#160;</div>
</td>
<td style="WIDTH: 5.21%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.77%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The Board may establish ad hoc Board Committees and has the following permanent Board Committees:</div>

<div style="MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Audit and Compliance Committee Compensation Committee Governance, Nomination and Corporate Responsibilities Committee</font></div>

<div style="MARGIN-LEFT: 22pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Risk Committee and</font></div>

<div style="MARGIN-LEFT: 22pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Science &amp; Technology Committee</font></div>

<div>&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The composition and duties of the permanent Board Committees are set forth in Appendix I.</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5.21%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.77%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 19</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Chairman</div>

<div>&#160;</div>
</td>
<td style="WIDTH: 5.21%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.77%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">In addition to other duties described in these Regulations and the Articles, the Chairman has the following duties:</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify; MARGIN-LEFT: 22pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">a)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Provides leadership to the Board in its governance role, coordinating the tasks within the Board.</font></div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify; MARGIN-LEFT: 22pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">b)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Coordinates, together with the Chairpersons, the work of the Board Committees.</font></div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify; MARGIN-LEFT: 22pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">c)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Establishes and keeps a close working relationship with the CEO, providing advice and support while respecting the fact that the day-to-day management responsibility is delegated to the Executive Committee led by the CEO.</font></div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify; MARGIN-LEFT: 22pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">d)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Promotes effective relationships and communication between the Board, the CEO and the Executive Committee.</font></div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify; MARGIN-LEFT: 22pt; TEXT-INDENT: -22pt">e)<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Takes the lead in crisis situations.</font></div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">7</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="z22abfe930a384b4788a97f5739fdd7f6" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Chairman</div>

<div>&#160;</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.2%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify; MARGIN-LEFT: 22pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">f)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Together with the CEO, ensures effective communication with shareholders, other stakeholders and the general public; and</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">g)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Works closely with the CEO in evaluating Executives and in establishing succession plans for key management positions.</font></div>

<div style="MARGIN-TOP: 3pt; TEXT-INDENT: 6.1pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.2%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 20</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Vice-Chairman</div>

<div>&#160;</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.2%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">In case and as long as the Chairman is incapacitated, the Vice-Chairman assumes all of the Chairman&#8217;s responsibilities.</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">
<div id="DSPFPageHeader"></div>

<div>Once a year, the Vice<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">-</font>Chairman leads the Board&#8217;s annual assessment of the Chairman.</div>
</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.2%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 20<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">bis</sup></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">Lead Independent Director</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.2%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">To support adequate control mechanisms, the Board can, if deemed appropriate and in the best interests of the Company, designate an experienced independent Director as Lead Independent Director with the following duties:</div>

<div id="DSPFPageFooter"></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">a)</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Chairs the sessions of the independent Directors; and</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">b)</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Leads the independent Directors in case of a crisis or matter requiring their separate consideration or decision.</font></div>

<div>&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Every independent Director may request separate meetings of the independent Directors if the need arises.</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">
<div id="DSPFPageHeader"></div>

<div>The roles of the Vice-Chairman and the Lead Independent Director can be held by two Directors or by one Director (combined role).</div>

<div>&#160;</div>
</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">Section 5</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.2%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">Executive Committee</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.2%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 21</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">CEO</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.2%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">In addition to other duties that may be assigned by the Board, the CEO, supported by the Executive Committee, has the following duties:</div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">a)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Overall responsibility for the management and performance of the Business.</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">b)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Leads the Executive Committee.</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">c)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Builds and maintains an effective Executive Committee and proposes adequate succession planning to the Board.</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">d)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Represents Novartis, in coordination with the Chairman, with major customers, financial analysts, investors and the media.</font></div>

<div style="MARGIN-TOP: 3pt; TEXT-INDENT: 0.7pt">&#160;</div>
</td>
</tr>

<tr style="HEIGHT: 22px">
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.2%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 22</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Members of</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Executive Committee</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.2%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The Executive Committee is headed by the CEO. It consists of such members as appointed or removed by the Board.</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.2%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 23</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Duties of Executive</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Committee</div>

<div>&#160;</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.2%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The Executive Committee is responsible for the management of the Business. In particular, and without limitation, the Executive Committee has the following duties:</div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">8</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="z02d410af7ae44fff842fb106ab064ba5" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>

<div>&#160;</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.2%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify; MARGIN-LEFT: 22pt; TEXT-INDENT: -22pt">
<div style="TEXT-ALIGN: left">a)<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font>Regularly assess the achievement of the targets for the Business. </div>

<div style="TEXT-ALIGN: left">b)<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font>Submit proposals to the Board or to one of the Board Committees for approval for items, requiring such approval based on these Regulations or further internal regulations. </div>

<div style="TEXT-ALIGN: left">c)<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font>Implement the decisions taken by the Board or the Board Committees. </div>

<div style="TEXT-ALIGN: left">d)<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font>Prepare and submit quarterly and annual reports for the attention of the Board or the Board Committees, and keep the Board or the Board Committees informed of all matters of fundamental significance to the Business and/or that are relevant to allow the Board or the Board Committees to fully perform their duties. </div>

<div style="TEXT-ALIGN: left">e)<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font>Implement modifications to the organization of the Business to ensure efficient operation of the Business and achievement of optimized consolidated results. </div>

<div style="TEXT-ALIGN: left">f)<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font>Ensure appropriate external stakeholder management, including an effective internal and external communication strategy. </div>

<div style="TEXT-ALIGN: left">g)<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font>Ensure that management capacity, financial and other resources are provided and used efficiently. </div>

<div style="TEXT-ALIGN: left">h)<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font>Deal with such other matters as are delegated by the Board or a Board Committee to the Executive Committee. </div>
</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.2%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.2%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 24</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Sub-committees of the Executive Committee</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.2%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The Executive Committee may delegate duties as stipulated in article&#160;23 above to other executives and committees and may empower them to further delegate their responsibilities and authorities. Each such delegation must be in writing, and clear responsibilities and accountabilities must be established. The CEO ensures proper reporting to the Executive Committee as needed.</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">Section 6</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.2%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">Internal Audit</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.2%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 25</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Duties of Internal Audit</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.2%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The Internal Audit has to:</div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">a)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Carry out operational and system audits, assisting the Divisions and Cross-Divisional Units in the accomplishment of objectives by providing an independent approach to the evaluation, improvement, and effectiveness of their risk management and internal control framework. All Divisions, Cross-Divisional Units and subsidiaries of the Group are subject to audit.</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">b)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Prepare reports regarding the audits it has performed, and report to the ACC and to the CEO material irregularities, whether actual or suspected, without delay.</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">c)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Perform such other functions and audits as assigned to it by the Board, the ACC or the CEO.</font></div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">9</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="z80c95b1384b3423b85b6e9bca483af9c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">Section 7</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.16%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">Effectiveness, Amendments</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.16%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 26</div>
</td>
</tr>

<tr style="HEIGHT: 97px">
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Effectiveness, Amendments</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.16%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">These Regulations come into effect on January 1, 2021 and replace former regulations of the Board, the Board Committees and the Executive Committee.</div>

<div>&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">These Regulations may only be amended or replaced by the Board.</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 31.18%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">
<div id="DSPFPageHeader"></div>

<div>
<div id="DSPFPageHeader"></div>

<div>
<div id="DSPFPageHeader"></div>

<div>Dr. Joerg Reinhardt</div>
</div>
</div>
</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Chairman</div>
</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">
<div id="DSPFPageHeader"></div>

<div>Dr. Charlotte Pamer-Wieser</div>
</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Corporate Secretary</div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">10</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="z143099373d6b40b9a136f15f03b7c526" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20.65%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">Appendix I:</div>
</td>
<td style="WIDTH: 3.92%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 69.68%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">Board Committees Charter</div>
</td>
<td style="WIDTH: 5.75%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 20.65%; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Section 1</div>
</td>
<td style="WIDTH: 3.92%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 69.68%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">General Provisions</div>
</td>
<td style="WIDTH: 5.75%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: right; MARGIN-TOP: 12pt">12</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.65%; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Section 2</div>
</td>
<td style="WIDTH: 3.92%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 69.68%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Roles and Responsibilities of the Board Committees</div>
</td>
<td style="WIDTH: 5.75%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 20.65%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 3.92%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 69.68%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 12pt; TEXT-INDENT: 18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9">-</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9">Roles and Responsibilities of the ACC</font></div>
</td>
<td style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-VARIANT: normal; WIDTH: 5.75%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: #0460a9; FONT-STYLE: normal">
<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: right; MARGIN-TOP: 12pt">13</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.65%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 3.92%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 69.68%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 12pt; TEXT-INDENT: 18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9">-</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9">Roles and Responsibilities of the CC</font></div>
</td>
<td style="WIDTH: 5.75%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: right; MARGIN-TOP: 12pt">16</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.65%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 3.92%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 69.68%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 12pt; TEXT-INDENT: 18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9">-</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9">Roles and Responsibilities of GNCRC</font></div>
</td>
<td style="WIDTH: 5.75%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: right; MARGIN-TOP: 12pt">19</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.65%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 3.92%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 69.68%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 12pt; TEXT-INDENT: 18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9">-</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9">Roles and Responsibilities of RC</font></div>
</td>
<td style="WIDTH: 5.75%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: right; MARGIN-TOP: 12pt">21</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.65%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 3.92%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 69.68%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 12pt; TEXT-INDENT: 18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9">-</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9">Roles and Responsibilities of the STC</font></div>
</td>
<td style="WIDTH: 5.75%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: right; MARGIN-TOP: 12pt">22</div>
</td>
</tr>
</table>

<div id="DSPFPageFooter"></div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">11</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="zd04ce7b9d61e47edb425725b59b7e54e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">Section 1</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">General Provisions</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">These General Provisions contain additional organizational requirements for Board Committees in addition to the rules set forth in the Regulations.</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 1</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Composition</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The ACC, the GNCRC, the RC and the&#160;STC each consist of a minimum of 3 members. The CC consists of a minimum of 3 and a maximum of 5 members.</div>

<div>&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The Board elects the Chairpersons of the Board Committees.</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 2</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Independence,</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Qualifications</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Each Director of the ACC, CC and GNCRC has to meet the independence criteria set forth in Appendix&#160;II.</div>

<div>&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Each ACC member must further be financially literate, including at least one member who has accounting and related financial management expertise (&#8220;audit committee financial expert&#8221;), as such qualifications are interpreted by the Board in its business judgment.</div>

<div>&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The &#8220;audit committee financial expert&#8221; must have</div>

<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(i)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#160;an understanding of generally accepted accounting principles and financial statements;</font></div>

<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(ii)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#160;the ability to assess the general application of such principles in connection with the accounting for estimates, accruals and reserves;</font></div>

<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(iii)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">experience preparing, auditing, analyzing or evaluating financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of issues that can reasonably be expected to be raised by the Group&#8217;s financial statements, or experience actively supervising one or more persons engaged in such activities;</font></div>

<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(iv)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">an understanding of internal control over financial reporting; and</font></div>

<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(v) </font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">an understanding of audit committee functions.</font></div>

<div style="MARGIN-TOP: 3pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 3</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Coordination between ACC and RC</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The Chairpersons of the RC and the ACC shall generally be appointed as members of the other Committee. To the extent appropriate, the Chairpersons of the ACC and the RC coordinate the work of the ACC and the RC, in particular to ensure that there are as few as possible overlaps.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">12</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="z5d4f751ec6a14e1487e3eba9f73a4034" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="VERTICAL-ALIGN: top" colspan="2">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 4</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Meeting Participations and Interactions</div>
</td>
<td style="VERTICAL-ALIGN: top" colspan="2">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Each Board Committee may invite to its meetings other Directors, Executives and such other persons, as the respective Board Committee deems appropriate to carry out its responsibilities. The Chairman may attend the Board Committee meetings in consultation with the relevant Chairperson.</div>

<div>&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Special rules apply to the presence of the following persons at Board Committee meetings:</div>

<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(i)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#160;An Executive shall not be present during the decision on his/her own pay at a CC meeting; or</font></div>

<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(ii)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Anyone with a personal interest in the matters to be discussed will be excluded from the ACC, GNCRC, RC and&#160;STC meeting, respectively.</font></div>

<div style="MARGIN-TOP: 3pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="VERTICAL-ALIGN: top" colspan="2">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 5</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Advisors, Investigations</div>
</td>
<td style="VERTICAL-ALIGN: top" colspan="2">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The Board Committees shall have the authority to obtain advice and assistance from internal or external legal, accounting or other advisors. The ACC shall have the authority to conduct or authorize investigations into any matter within the scope of its responsibilities.</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="VERTICAL-ALIGN: top" colspan="2">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 6</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Debriefing to the Board</div>
</td>
<td style="VERTICAL-ALIGN: top" colspan="2">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The Board Committees regularly report to the Board on its deliberations and decisions and on the items set forth in Section 2 of this Appendix I. Other matters will be reported, as the Board Committees deem appropriate.</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">Section 2</div>
</td>
<td style="VERTICAL-ALIGN: top" colspan="2">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">Roles and Responsibilities of the Board Committees</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">Roles and Responsibilities of the Audit and Compliance Committee (ACC)</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 7</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">ACC&#8217;s Mission Statement</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The ACC assists the Board in monitoring the:</div>

<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(i)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#160;integrity of the financial statements of the Group;</font></div>

<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(ii)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">External Auditor&#8217;s qualifications and independence;</font></div>

<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(iii)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">performance of the Internal Audit function and of the External Auditor; and</font></div>

<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(iv)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">compliance by the Group with legal and regulatory requirements.</font></div>

<div style="MARGIN-TOP: 3pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="VERTICAL-ALIGN: top" colspan="2">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 8</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">ACC&#8217;s Role and Responsibilities</div>
</td>
<td style="VERTICAL-ALIGN: top" colspan="2">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The ACC has the following roles and responsibilities:</div>

<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="VERTICAL-ALIGN: top" colspan="2">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-STYLE: italic; TEXT-ALIGN: justify">Regarding the External Auditor</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="VERTICAL-ALIGN: top" colspan="2">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">1.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Evaluate the qualifications, performance and independence of the External Auditor, including considering whether the External </font></div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">13</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="z4c9909a0a961460b817fe189c7dce065" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5.2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.84%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt">Auditor&#8217;s quality controls are adequate and whether the provision of permitted non-audit services is compatible with maintaining the External Auditor&#8217;s independence, taking into account the opinions of management and Internal Audit.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5.2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.84%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">2.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Ensure rotation of the audit partners of the External Auditor at least every five years. Consider whether, in order to ensure continuing auditor independence, it is appropriate to adopt a policy of rotating the external auditing firm on a regular basis.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5.2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.84%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">3.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">On behalf of the Board, which has fully delegated this task to the ACC, (1) select and nominate the External Auditor for election by the General Meeting, and (2) be directly responsible for the supervision and compensation of the External Auditor (including the resolution of any disagreement between management and the External Auditor regarding financial reporting).</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5.2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.84%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">4.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">On behalf of the Board, which has fully delegated this task to the ACC, pre-approve all auditing services, internal control-related services and non-audit services permitted under applicable statutory law, regulations and listing requirements to be performed for the Group by its External Auditor.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5.2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.84%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">5.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Obtain and review a report from the External Auditor at least annually regarding (1) the External Auditor&#8217;s internal quality-control procedures, (2) any material issues raised by the most recent quality-control review, or peer review, of the firm, or by any inquiry or investigation by governmental or professional authorities within the preceding five years respecting one or more independent audits carried out by the firm, (3) any steps taken to deal with any such issues, and (4) all relationships between the External Auditor and the Group.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5.2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.84%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">6.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Discuss with the External Auditor the results of their audits, any unusual items or disclosures contained in the audits and the matters required by Public Company Auditing Oversight Board Auditing Standards No.&#160;1301, as revised, and request a formal written statement from the External Auditor documenting such discussion<font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000">.</font></font></div>

<div style="MARGIN-TOP: 3pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5.2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.84%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-STYLE: italic; TEXT-ALIGN: justify">Regarding Internal Audit</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5.2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.84%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">7.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Review the significant reports to management, prepared by the Internal Audit department and management&#8217;s responses and supervise the remediation of open audit issues.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5.2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.84%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">8.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Review periodically the adequacy of the organizational structure, budget and appointment or replacement of the senior Internal Audit executives.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5.2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.84%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">9.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Discuss with the CEO, as needed, the Internal Audit department&#8217;s responsibilities, staffing and any recommended changes in the planned scope of the Internal Audit.</font></div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">14</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="z41f41dc414dc4a8fa44c35ccb09f9f43" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-STYLE: italic; TEXT-ALIGN: justify">Regarding Financial Reporting and internal controls</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">10.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Review and discuss with management and the External Auditor the Company&#8217;s and Group&#8217;s quarterly and annual financial statements (including the sections on Operating and Financial Review and Prospects) to consider significant financial reporting issues and judgments made in connection with the preparation of the Company&#8217;s and Group&#8217;s financial statements, including any significant changes in the Company&#8217;s or Group&#8217;s selection or application of accounting principles.</font></div>

<div style="MARGIN-TOP: 3pt">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">11.</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">On behalf of the Board, which has fully delegated this task to the ACC, approve the Company&#8217;s and Group&#8217;s quarterly financial statements for the first three quarters of each calendar year and the corresponding financial results releases. The Board remains responsible for the approval of the annual financial statements of the Company and the Group and of the corresponding financial results releases.</font></div>

<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">12.</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Review and discuss with management and the External Auditor their assessment of the effectiveness of the Group&#8217;s internal controls, disclosure controls and procedures for financial reporting and whether any changes are appropriate in light of such assessment.</font></div>

<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt">13.</font><font style="FONT-SIZE: 14pt; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'"><font style="FONT-SIZE: 14pt">Review and discuss (1) all significant deficiencies in the design or operation of internal controls which could adversely affect the Group&#8217;s ability to record, </font>process, summarize and report financial data, including any material weaknesses in internal controls, (2) any fraud, whether or not material, that involves management or other employees who have a significant role in the Group&#8217;s internal controls, and (3) any significant changes in internal controls or in other factors that could significantly affect internal controls, including any corrective actions with regards to significant deficiencies and material weaknesses.</font> </div>

<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">14.<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font></font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Review such other matters in relation to the Group&#8217;s accounting, auditing, financial reporting and compliance with law and internal policies.</font></div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt">&#160;</div>
</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-SIZE: 14pt; WIDTH: 75%; VERTICAL-ALIGN: top; FONT-STYLE: italic">Regarding Significant Legal Matters and Regulatory Risks</td>
</tr>

<tr style="HEIGHT: 54px">
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-SIZE: 10pt; WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">15.<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font></font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Review major issues regarding the status of the Group&#8217;s material legal matters, as well as major legislative and regulatory developments that may have significant impact on the Group.</font></div>

<div style="MARGIN-LEFT: 27pt; TEXT-INDENT: -27pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-SIZE: 14pt; WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-SIZE: 14pt; WIDTH: 75%; VERTICAL-ALIGN: top; FONT-STYLE: italic">Regarding an Effective Compliance Program</td>
</tr>

<tr style="HEIGHT: 52px">
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-SIZE: 10pt; WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-SIZE: 14pt; WIDTH: 75%; VERTICAL-ALIGN: top; MARGIN-LEFT: 27pt; TEXT-INDENT: -27pt">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt">16.<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font>Review at least annually the processes and procedures used by management to execute an effective compliance program.</div>

<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt">17.<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font>Review at least annually compliance by Novartis associates with those Group policies falling into the subject matter expertise of the ACC.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">15</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="z61bf6854f604495ca523a9cf0f2aa05c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-SIZE: 14pt; WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-TOP: 3pt">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">18.</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Review updates from the Company&#8217;s SpeakUp office regarding whistleblowing activities and trends.</font></div>

<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">19.</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Establish procedures for (a) the receipt, retention and treatment of complaints received by the Group regarding accounting, internal accounting controls or auditing matters, and (b) the confidential, anonymous submission by employees of the Group of concerns regarding questionable accounting or auditing matters to the SpeakUp office.</font></div>

<div style="MARGIN-TOP: 3pt">&#160;</div>
</div>
</td>
</tr>

<tr style="HEIGHT: 23px">
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-SIZE: 14pt; WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-SIZE: 14pt; WIDTH: 75%; VERTICAL-ALIGN: top; FONT-STYLE: italic">Other</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-SIZE: 14pt; WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">20.<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font></font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Annually review the financial literacy of each ACC member to determine whether he/she meets the applicable legal standards, confirm the audit committee financial expert, and propose to the Board the appropriate determination and its disclosure.</font></div>

<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">21.<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font></font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Annually review and reassess the adequacy of Articles 7 - 8 of this Appendix I and submit proposed changes to the Board for approval.</font></div>

<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="z835d37f1d81c454e8cccb34db6586bcf" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5.4%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.67%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">Roles and Responsibilities of the Compensation Committee (CC)</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5.4%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.67%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 9</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">CC&#8217;s Mission Statement</div>
</td>
<td style="WIDTH: 5.4%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.67%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The CC assists the Board concerning, but not limited to, the:</div>

<div><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(i)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#160;compensation philosophy and strategy;</font></div>

<div><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(ii)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">design of the compensation plans;</font></div>

<div style="MARGIN-LEFT: 28pt; TEXT-INDENT: -28pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(iii)</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">compensation of the Chairman, the Directors and of the CEO and other members of the Executive Committee. The CC has oversight of the remuneration policy for the wider employee population; </font></div>

<div style="MARGIN-LEFT: 28pt; TEXT-INDENT: -28pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(iv)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">preparation of the Compensation Report and other relevant disclosures. </font></div>

<div>&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Pay for performance is one of the guiding principles of the compensation strategy of the Group. The Group aims to reward those associates who achieve competitive business results and exemplify the Group values and behaviors. The compensation strategy strives to strengthen the performance-oriented culture and to reinforce entrepreneurial behavior resulting in contributions that motivated and dedicated associates make to sustain superior business results whilst holding executives accountable for behavior that displays innovation, quality, performance, collaboration, courage and integrity.</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5.4%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.67%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 10</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">CC&#8217;s Role and Responsibilities</div>
</td>
<td style="WIDTH: 5.4%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 74.67%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The CC has the following responsibilities:</div>

<div style="MARGIN-LEFT: 21pt; MARGIN-TOP: 3pt; TEXT-INDENT: -21pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">1.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Develop a compensation strategy in line with the principles described in the Articles, and submit to the Board for approval.</font></div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">16</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="z57cecc9e6e2b48cab5bd861fbdb01b15" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 21pt; MARGIN-TOP: 3pt; TEXT-INDENT: -21pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">2.</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Develop the principles and design of compensation plans, long-term incentive/equity plans, pension arrangements and benefits for the Executives and the Directors, and submit to the Board for approval. </font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 21pt; MARGIN-TOP: 3pt; TEXT-INDENT: -21pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">3.</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Support the Board in preparing the proposals to the General Meeting regarding the compensation of the Directors and the Executives.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top"></td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 21pt; MARGIN-TOP: 3pt; TEXT-INDENT: -21pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">4.</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Prepare the Compensation Report and submit to the Board for approval.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">5.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Propose to the Board the contractual terms (if any) and compensation of the Directors (incl. the Chairman) and the CEO.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">6.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Determine, after consulting with the CEO, the terms of employment, promotion or termination of the other Executives (except for the CEO).</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">7.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Develop the terms of, and administer, the Group&#8217;s long-term incentive/equity compensation plans, including the weightings, payout curves and caps for the chosen performance measures.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">8.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Together with the RC, assess whether the Group&#8217;s incentives for associates below Executive Committee level are appropriately aligned to business performance and do not encourage excessive risk taking.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">9.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Determine the critical performance measures (financial, strategic and operational) that inform how well the Group and its Divisions are performing in relation to the business strategy for incorporation into the incentive plans, as well as any measures relating to Environmental, Social and Governance (ESG).</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 26pt; MARGIN-TOP: 3pt; TEXT-INDENT: -26pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">10.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">At the start of each performance period, review, after Board approval, the Group and divisional financial, strategic, operational and individual targets for Executive Committee members and direct reports to the Chairman. Incorporate these targets into the short-term and long-term incentive/equity compensation plans.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">11.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Periodically review and propose to the Board for approval a peer group(s) of companies for executive compensation comparisons.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">12.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">At the start of each performance period, approve the target total direct compensation levels and the mix of compensation (fixed/variable, short/long-term, individual/Group/Division, and cash/equity) for Executive Committee members and direct reports to the Chairman taking into consideration pay and conditions for the wider population of Group associates.</font></div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">17</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="zf4ddfb9aa1804542afae972516f32c16" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">13.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">At the end of each performance period, taking into consideration the Board&#8217;s evaluation of Group and divisional performance against targets established at the beginning of the performance cycle, approve performance results under the incentive plans, evaluate individual performance, approve the amount of compensation earned by Executive Committee members and recommend the amount of compensation earned by the CEO to the Board for approval taking into account the overall performance of the Business and, if appropriate, making adjustments to the formulaic outcome of any incentive plans, within the plan Rules.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">14.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Consider and decide whether there is a need for malus and/or clawback provisions to be exercised and, if so, the extent and form of the malus and/or clawback.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">15.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Incorporate the recommendations of the STC for the establishment of innovation targets under incentive compensation plans at the start of each performance cycle and measurement of achievement thereof at the end.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">16.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Periodically assess the effectiveness of the executive short-term and long-term incentive plans in relation to the Group&#8217;s strategic objectives, values and pay-for-performance principles.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">17.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Work together with other Board Committees, including the ACC, RC and the STC to ensure that executive compensation is correctly aligned to performance and is not structured in a way that could lead to inappropriate risk taking.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">18.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Annually assess the level of Board compensation against the peer group and other relevant companies and submit to the Board its recommendations for the compensation of Directors and the compensation and terms of employment of the Chairman.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">19.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Establish executive and director stock ownership guidelines and stock trading policies, and monitor compliance with such policies.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">20.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Inform the Board about policies, programs and key decisions as well as statistical comparisons and benchmarking of compensation levels against key competitors and regularly report to the Board on the decisions and deliberations of the Compensation Committee.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">21.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">In collaboration with the Chairman, oversee communication and engagement on executive compensation matters with shareholders and their advisors, including shareholder voting on Board and Executive Committee compensation, and assess the voting results on executive compensation matters of the most recent General Meeting.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">22.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Be kept informed of the remuneration of the workforce and related policies and keep abreast of any developments.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">23.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Annually assess the engagement and performance of compensation consultants or other outside advisors engaged by the CC and their independence in relation to any potential conflicts of interest.</font></div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">18</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="z94bfbf6cf1d04f02b6d5d13de12451bf" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">24.</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Keep abreast of regulatory and corporate governance best practice requirements regarding Board, Executive Committee and other senior executive compensation.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">25.</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Keep abreast of market trends and consideration of external factors that may influence pay in terms of design, structure, quantum, disclosure etc.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">26.</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Establish an annual calendar of activities for the upcoming year, including special projects to be undertaken by the CC.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">27.</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Review and reassess the adequacy of Articles 9 - 10 of this Appendix I and submit proposed changes to the Board for approval.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">28.</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Assume other responsibilities assigned to it by law, the Articles and by the Board.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">&#160;

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">
<div id="DSPFPageHeader"></div>

<div>Roles and Responsibilities of the Governance, Nomination and Corporate Responsibilities Committee (GNCRC)</div>
</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify; MARGIN-TOP: 10px">Article 11</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">GNCRC&#8217;s Mission Statement</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The GNCRC assists the Board in fulfilling its responsibilities with respect to the:</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">
<div style="MARGIN-LEFT: 26pt; MARGIN-TOP: 3pt; TEXT-INDENT: -26pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(i)</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">governance of the Group;</font></div>

<div style="MARGIN-TOP: 3pt">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify; MARGIN-LEFT: 28pt; MARGIN-TOP: 3pt; TEXT-INDENT: -28pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(ii)</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">identification of individuals who are qualified to become (or be re-elected as) Directors or the CEO; and</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(iii)</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">corporate and social responsibilities of the Group.</font></div>
</div>
</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify; MARGIN-TOP: 10px">Article 12</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">GNCRC&#8217;s Roles and Responsibilities</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The GNCRC has the following roles and responsibilities:</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-STYLE: italic; TEXT-ALIGN: justify">In General</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">1.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Review periodically the Articles and the Regulations and recommend to the Board changes thereto in respect of good corporate governance and fostering shareholders&#8217; rights.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">2.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Consult with the Chairman in carrying out the duties of the GNCRC.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">3.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Prepare and annually review succession plans for the Chairman, the Vice-Chairman, the Lead Independent Director, Directors, Board Committee members, Chairpersons and the CEO, and make proposals to the Board for the election and the re-election by&#160; the Board respectively by the AGM for the Directors, the Chairman and the CC Directors.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">4.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Make proposals to the Board for the election of the Independent Proxy.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">5.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Recommend such other actions not set out below regarding the governance of the Group that are in the best interests of the Group and the Company&#8217;s shareholders, as the GNCRC deems appropriate.</font></div>

<div style="MARGIN-TOP: 3pt">&#160;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">19</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="zd4f69297226a440e9589d788b2b27129" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-STYLE: italic; TEXT-ALIGN: justify">Board Composition</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">6.</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Review the composition and size of the Board in order to ensure the Board has the proper expertise and consists of persons with sufficiently diverse backgrounds.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">7.</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Determine the criteria for selection of the Chairman, the Vice-Chairman, the Lead Independent Director, Directors and Board Committee members. The GNCRC considers factors such as (i) personality, skills and knowledge, (ii) diversity of viewpoints, professional backgrounds and expertise, (iii) business and other experience relevant to the Business, (iv) the ability and willingness to commit adequate time and effort to Board and Board Committee responsibilities, (v) the extent to which personality, background, expertise, knowledge and experience will interact with other Directors to build an effective and complementary Board, and (vi) any disclosures made under article 4 of the Regulations, in particular whether existing board memberships or other positions held by a candidate could lead to a Conflict of Interest.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">8.</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">With the participation of the Chairman, actively seek, interview and screen individuals qualified to become a candidate for the position as a Director, for recommendation to the Board.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">9.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Assess and recommend to the Board as to whether Directors should stand for re-election. For its assessment, the GNCRC considers, among other things, age limit, contributions to the Board and the Company, and ability and willingness to commit adequate time to the Board and Board Committee matters.</font></div>

<div style="MARGIN-TOP: 3pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-STYLE: italic; TEXT-ALIGN: justify">Board Committees</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">10.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">With the Chairman, make recommendations to the Board for the creation of additional Board Committees or a change in mandate or dissolution of Board Committees.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">11.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">With the Chairman, periodically review the composition of the Board Committees. When doing so, the GNCRC takes into account whether a Board Committee member is suitable for the tasks of the respective Board Committee, including an envisioned quorum of independent Committee members, if applicable.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">12.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">With the Chairman, periodically review the chairmanships of the Board Committees.</font></div>

<div style="MARGIN-TOP: 3pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-STYLE: italic; TEXT-ALIGN: justify">Conflicts, Other Directorships and Board member</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">13.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Review directorships and consulting agreements of Board members for conflicts of interest.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">14.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Annually submit to the Board a proposal concerning the determination of the independence status of the Directors and the corresponding disclosure.</font></div>

<div style="MARGIN-TOP: 3pt">&#160;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'"></div>

<div style="FONT-FAMILY: 'Times New Roman'">
<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">20</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="zd7bfbc9a410f434f8d4659592ec0949b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.07%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 76.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-STYLE: italic; TEXT-ALIGN: justify">Corporate Responsibilities of the Group</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.07%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 76.02%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">15.</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Oversee the Group&#8217;s strategy and governance on corporate and social responsibility.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.07%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 76.02%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">16.</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Oversee key issues related to corporate and social responsibility that may affect the Business and the Group&#8217;s reputation.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.07%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 76.02%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">17.</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Oversee the Company&#8217;s participation in the UN Global Compact.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.07%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 76.02%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">18.</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Review and discuss emerging trends with regard to corporate responsibility.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.07%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 76.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt">19.<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Advise the Board and provide counsel to the management on corporate responsibility.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.07%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 76.02%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">20.</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Approve the Novartis in Society Report.</font></div>

<div style="MARGIN-LEFT: 27pt; MARGIN-TOP: 3pt; TEXT-INDENT: -27pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.07%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 76.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">Roles and Responsibilities of the Risk Committee (RC)</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.07%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 76.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 13</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">RC&#8217;s Mission Statement</div>
</td>
<td style="WIDTH: 4.07%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 76.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The RC will assist the Board in ensuring that risks are properly assessed and professionally managed by:</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(i)</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">overseeing the Group&#8217;s risk management system and processes; and</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">(ii)</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">reviewing the Group&#8217;s risk portfolio and related actions implemented by management.</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt">&#160;</div>
</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.07%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 76.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 14</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">RC&#8217;s Role and Responsibilities</div>
</td>
<td style="WIDTH: 4.07%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 76.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The RC has the following role and responsibilities:</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.07%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 76.02%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">1.</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Ensure that the Group has implemented an appropriate and effective risk management system and process.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.07%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 76.02%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">2.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Ensure that all necessary steps are taken to foster a culture of risk-adjusted decision-making without constraining reasonable risk taking and innovation.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.07%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 76.02%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -23pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">3.</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Together with the CC, assess whether the Group&#8217;s incentives for associates below Executive Committee level are appropriately aligned to business performance and do not encourage excessive risk taking.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.07%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 76.02%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">4.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Review with management and Internal Audit the identification, prioritization and management of the risks, the accountabilities and roles of the functions involved with risk management, the risk portfolio and the related actions implemented by management.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.07%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 76.02%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">5.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Inform the Board on a periodic basis on the risk management system and on the most significant risks and how these are managed.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.07%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 76.02%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">6.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Review such other matters in relation to the Group&#8217;s risk management, as the RC may, in its own discretion, deem desirable in connection with its responsibilities described above.</font></div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">21</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="z57b9fd99c23644569b2fcc419217f656" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">7.</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">Keep itself up to date on risk management best practices. The Chief Ethics, Risk and Compliance Officer, or his/her designee, is expected to update the RC at least once a year on developments in this area.</font></div>

<div style="MARGIN-LEFT: 22pt; MARGIN-TOP: 3pt; TEXT-INDENT: -22pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">Roles and Responsibilities of the Science&#160;&amp; Technology&#160;Committee (STC)</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Article 15</div>
</td>
</tr>

<tr style="HEIGHT: 17px">
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">STC&#8217;s Mission Statement</div>
</td>
<td style="WIDTH: 4.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-SIZE: 14pt; WIDTH: 75%; VERTICAL-ALIGN: top">
<div>The STC (i) oversees the science and technology strategy, including digital and data related innovation, (ii) evaluates and challenges the effectiveness and competitiveness of innovation-related functions, (iii) reviews and discusses emerging scientific trends and activities critical to the success of science and innovation, and (iv) reviews the R&amp;D portfolio.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify; MARGIN-TOP: 10pt">Article 16</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">STC&#8217;s Role and Responsibilities</div>
</td>
<td style="WIDTH: 4.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt">The STC has the following role and responsibilities:</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 22pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">1.<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font></font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">Monitoring emerging scientific, data-related, technological and research trends and issues, and bringing recommendations to the Board.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 22pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">2.<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font></font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">Informing the Board on a periodic basis about critical developments for the success of the portfolio and for scientific, technological and research activities as well as benchmarking.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 22pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">3.<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font></font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">Assisting the Board with setting the Company&#8217;s strategy for science, data, technology and research.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 22pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">4.<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font></font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">Assisting the Board with oversight and evaluation of the performance of the scientific, technological and research teams within the Company in relation to the strategy.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 22pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">5.<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font></font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">Review of performance and proposed targets in the area of science, technology and research.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20.06%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 4.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 22pt; TEXT-INDENT: -22pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">6.<font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font></font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #231f20">Reviewing such other matters in relation to science, data, technology and research as the STC may, in its own discretion, deem desirable in connection with its responsibilities.</font></div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">22</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="z663abc062f694192a21e30bf60b779a2" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: justify">Appendix II</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">Independence Criteria for the Board and the Board Committees</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #0460a9; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">Independence of the Directors</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The GNCRC annually submits to the full Board a proposal concerning the determination of the independent status of all Directors. For purposes of such assessment, the GNCRC considers all relevant facts and circumstances of which it is aware.</div>

<div>&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">In order to be considered independent, a Director shall not have any material relationship with the Group other than his/her service as a Director.</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">I. Material Relationships</div>
</td>
</tr>

<tr style="HEIGHT: 27px">
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-STYLE: italic">1.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-STYLE: italic">A Director will not be considered independent if</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 18pt; MARGIN-TOP: 3pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The Director or his/her immediate Family Member owns more than 10% of the stock of the Company;</font></div>

<div style="MARGIN-LEFT: 18pt; MARGIN-TOP: 3pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The Director has received direct compensation (other than for former service as an interim Chairman ) of more than USD 120 000 p.a. (other than dividends or Board/Board Committee fees and retirement or deferred pay for prior service, provided such compensation is not contingent in any way on continued service) from the Group within the last three years;</font></div>

<div style="MARGIN-LEFT: 18pt; MARGIN-TOP: 3pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">A Family Member has received direct compensation of more than USD 120 000 p.a. (other than compensation received for service as an employee other than an executive officer) from the Group within the last three years;</font></div>

<div style="MARGIN-LEFT: 18pt; MARGIN-TOP: 3pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The Director is, or has been within the last three years, an employee of the Group;</font></div>

<div style="MARGIN-LEFT: 18pt; MARGIN-TOP: 3pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-STYLE: italic">&#8211;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">A Family Member is, or has been within the last three years, an executive officer of the Group;</font></div>

<div style="MARGIN-LEFT: 18pt; MARGIN-TOP: 3pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The Director is a current partner or employee of the External Auditor of the Group;</font></div>

<div style="MARGIN-TOP: 3pt">
<div style="MARGIN-LEFT: 18pt; MARGIN-TOP: 3pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">A Family Member is a partner of the External Auditor or is an employee of the External Auditor and works on the Group&#8217;s audit;</font></div>

<div style="MARGIN-LEFT: 18pt; MARGIN-TOP: 3pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The Director or a Family Member is a former partner or employee of the External Auditor who personally worked on the Group&#8217;s audit during the last three years;</font></div>

<div style="MARGIN-LEFT: 18pt; MARGIN-TOP: 3pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The Director or a Family Member is, or has been within the last three years, employed as an executive officer of an enterprise while any of the present Executives serves or has served on that enterprise&#8217;s compensation committee;</font></div>

<div style="MARGIN-LEFT: 18pt; MARGIN-TOP: 3pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">An enterprise has made payments to or received payments from the Group for goods, property or services in an amount that exceeds, in any of the last three fiscal years, the greater of </font></div>
</div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">23</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="z7c681e1d798d43ca84d116d8676c8a6b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 18pt; MARGIN-TOP: 3pt">USD&#160;1&#160;million or 2% of the enterprise&#8217;s consolidated gross revenues, and</div>

<div style="MARGIN-LEFT: 40pt; MARGIN-TOP: 3pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;&#160; </font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The Director is a board member or employee of that enterprise or holds more than 10% of the shares in that enterprise; or</font></div>

<div style="MARGIN-LEFT: 40pt; MARGIN-TOP: 3pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;&#160; </font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">A Family Member is a board member or executive officer or holds more than 10% of the shares in that enterprise.</font></div>

<div style="MARGIN-TOP: 3pt; TEXT-INDENT: 18pt">&#160;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="z383291138a4b40a39b27827d04fe3d4f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-STYLE: italic">2.&#160; </font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-STYLE: italic">In addition to the independence criteria set forth above for all Directors in Section 1, an ACC Director will not be considered independent if</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 18pt; MARGIN-TOP: 3pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The ACC Director or his/her spouse, minor child, minor stepchild, or child or stepchild sharing the ACC Directors&#8217; home, accepts any salary or consulting, advisory or other compensatory fee (other than Board/Board Committee compensation) from the Group;</font></div>

<div style="MARGIN-LEFT: 18pt; MARGIN-TOP: 3pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The ACC Director is a partner, a member, an officer such as a managing director, executive officer or occupies a similar position in an enterprise that provides advisory services such as accounting, legal, investment banking or financial advisory services to the Group;</font></div>

<div style="MARGIN-LEFT: 18pt; MARGIN-TOP: 3pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">If an ACC Director simultaneously serves on the audit committees of more than two public companies other than the Company&#8217;s, then the GNCRC must determine that such simultaneous service would not impair the ability of such Director to effectively serve on the ACC.</font></div>

<div style="MARGIN-TOP: 3pt">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-SIZE: 14pt; WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-STYLE: italic; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt">3.&#160; In addition to the independence criteria set forth for all Directors in Section 1, above, when making its assessment as to the independent status of a CC Director, the GNCRC considers whether the CC Director receives compensation from any person or entity that would impair his or her ability to make independent judgments about the Executive compensation.</div>

<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-SIZE: 14pt; WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; COLOR: #0460a9; TEXT-ALIGN: justify">II. Immaterial Relationships</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-SIZE: 14pt; WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div>Unless the GNCRC concludes in its assessment to the contrary, a relationship is presumed not to impair the independence of a Director if</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-SIZE: 14pt; WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="MARGIN-LEFT: 18pt; MARGIN-TOP: 3pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font style="FONT-SIZE: 1px; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The Director or a Family Member received from the Group, during the last fiscal year, personal benefits (other than the coverage of travel expenses incurred by a Family Member in connection with meetings of the Board) having an aggregate value of less than USD 5 000;</font></div>

<div style="MARGIN-LEFT: 18pt; MARGIN-TOP: 3pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;</font><font style="FONT-SIZE: 14pt; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">A Family Member is an employee but not an executive officer of the Group, unless the Family Member is an ACC Director&#8217;s spouse, minor child, minor stepchild or child or stepchild sharing the ACC Director&#8217;s home;</font></div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">24</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<table id="z5c18094d2c9c4a6d80b51462407dc7d3" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75.21%; VERTICAL-ALIGN: top">
<div style="MARGIN-TOP: 3pt">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 18pt; MARGIN-TOP: 3pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;<font style="FONT-SIZE: 14pt; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font></font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The Director or a Family Member is a board member or executive officer of a non-profit organization and the Group&#8217;s contributions to such organization did not exceed, in any of the last three fiscal years, the greater of USD 1 million or 2% of the organization&#8217;s consolidated gross revenues;</font></div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left; MARGIN-LEFT: 18pt; MARGIN-TOP: 3pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;<font style="FONT-SIZE: 14pt; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font></font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">An enterprise in which the Director or a Family Member is a director, executive officer or employee has been indebted to the Group in connection with a transaction in the ordinary course of business or in an amount that did not exceed USD 100 000 during the last fiscal year;</font></div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left; MARGIN-LEFT: 18pt; MARGIN-TOP: 3pt; TEXT-INDENT: -18pt"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">&#8211;<font style="FONT-SIZE: 14pt; WIDTH: 9pt; DISPLAY: inline-block">&#160;</font></font><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'">The Director or a Family Member serves on the board of another enterprise at which an Executive or another Director also serves as board member.</font></div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; MARGIN-TOP: 3pt"><br>
</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left; MARGIN-TOP: 3pt">The enumeration of relationships mentioned in this Section II is merely exemplary. The fact that a particular relationship is not listed does not mean that the relationship affects the independence of a Director.</div>
</div>
</td>
</tr>
</table>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">25</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">&#160;</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>

<div>
<div style="FONT-FAMILY: 'Times New Roman'">
<table id="zd1b5939b47ab4ae7a137c0f263ec54fd" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; TEXT-ALIGN: left">Abbreviations and Definitions</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">ACC</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Audit and Compliance Committee of the Board</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Appendix I</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Appendix I to these Regulations which forms an integral part of these Regulations (Board Committees Charter)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Appendix II</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Appendix II to these Regulations which forms an integral part of these Regulations (Independence Criteria for the Board and the Board Committees)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Articles</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Articles of Incorporation of the Company</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Board</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Board of directors of the Company</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Board Committee(s)</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Any or all committee(s) of the Board</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Business</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Business operations conducted by the Group</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">CC</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Compensation Committee of the Board</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Chairman</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Chairman of the Board</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Chairperson(s)</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Any or all Director(s) who chair(s) a / the Board Committee(s)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">CO</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Swiss Code of Obligations</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Cross-Divisional Unit(s)</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Any or all cross-divisional organizational unit(s) supporting the Divisions</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Company</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Novartis AG</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Compensation Report</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Compensation report of the Company</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Conflict of Interest</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Any personal interest, or the interest of a closely related person or company, that a Director or Executive might have in a particular matter which does or might be regarded to conflict with the interests of the Company or the Group</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Director(s)</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Any or all member(s) of the Board</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Division(s)</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Any or all global operating divisions of the Group, including its business units, if any</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Executive(s)</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Any or all Executive Committee member(s)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Executive Committee</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Executive committee of the Company</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">External Auditor</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">The Group&#8217;s external auditor</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Family Member</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">An immediate family member of a Director, i.e., including a person&#8217;s spouse, parents, children, stepchildren, siblings, mother-, father-, brothers-, sisters-, sons- and daughters-in-law and anyone (other than domestic employees) who share such person&#8217;s home</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">General Meeting</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">General meeting of shareholders of the Company</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">GNCRC</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Governance, Nomination and Corporate Responsibilities Committee of the Board</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Group</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Novartis and its subsidiaries</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Independence Criteria</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Independence criteria set forth in Appendix II</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Internal Audit</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">The Group&#8217;s internal audit</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Lead Independent Director</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">Lead Independent Director of the Board</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">RC</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Risk Committee of the Board</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Regulations</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">These Organizational Regulations of the Company, including Appendix I and Appendix II which form an integral part of these Regulations</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">STC</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">Science &amp; Technology Committee of the Board</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Vice-Chairman</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 75%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Vice-Chairman of the Board</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">&#160;</div>
</div>
</div>

<div style="FONT-FAMILY: 'Times New Roman'">
<div style="FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">26</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2
<SEQUENCE>3
<FILENAME>a21012620f-ex2_8.htm
<DESCRIPTION>EXHIBIT 2.8
<TEXT>

<html>
<head>
<title>EXHIBIT 2.8</title>
</head>
<body bgcolor="#ffffff">

  <div>&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; TEXT-ALIGN: right">Exhibit 2.8</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; TEXT-ALIGN: center">DESCRIPTION OF SECURITIES</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; TEXT-ALIGN: center">REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">As of December 31, 2020 Novartis&#160;AG (&#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) had the following series of securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;):</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>

<table id="zf3d380f10de04350b72b628de721e065" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 30%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Title of each class</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 30%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Trading symbol(s)</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 30%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Name of each exchange on which registered</div>
</td>
</tr>

<tr>
<td style="WIDTH: 30%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Ordinary shares, nominal value CHF 0.50 per share</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">American Depositary Shares,<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"><br>
</font> each representing 1 share</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 30%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">NOVN</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">NVS</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 30%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">New York Stock Exchange</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">&#160;</div>

<div>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">New York Stock Exchange</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify">Our shares are listed in Switzerland on the SIX Swiss Exchange (&#8220;SIX&#8221;). American Depositary Shares (&#8220;ADSs&#8221;), each representing one ordinary share, nominal value 0.50 Swiss Francs per share of Novartis&#160;AG (the &#8220;shares&#8221;), have been available in the US through an American Depositary Receipt (&#8220;ADR&#8221;) program since December 1996. This program was established pursuant to the deposit agreement that we entered into with JPMorgan Chase Bank, N.A., New York (&#8220;JPMorgan Chase&#8221;), as depositary (&#8220;Deposit Agreement&#8221;). Our ADRs have been listed on the New York Stock Exchange (&#8220;NYSE&#8221;) since May 2000 and are traded under the symbol NVS. In connection with this listing (but not for trading), the shares are registered under Section&#160;12(b) of the Exchange Act. This exhibit contains a description of the rights of (i) the holders of the shares and (ii) ADR holders. Shares underlying the ADSs are held by JPMorgan Chase, the depositary, and holders of ADSs will not be treated as holders of the shares.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">The following summary is subject to and qualified in its entirety by Novartis&#160;AG&#8217;s Articles of Incorporation (&#8220;Articles&#8221;), Regulations (&#8220;Board Regulations&#8221;) of the Novartis&#160;AG Board (the &#8220;Board&#8221;), and by Swiss law, particularly the Swiss Code of Obligations (&#8220;Swiss CO&#8221;). This is not a summary of all the significant provisions of the Articles, the Board Regulations, or of Swiss law and does not purport to be complete. Capitalized terms used but not defined herein have the meanings given to them in Novartis&#160;AG&#8217;s annual report on Form 20-F for the fiscal year ended December 31, 2020 and in the Deposit Agreement, which is an exhibit to our registration statement on Form F-6 filed with the SEC on May 3, 2001.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; TEXT-ALIGN: center">ORDINARY SHARES</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">Item 9. General</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Item 9.A.6. Limitations or qualifications</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify">Not applicable.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Item 9.A.7. Other rights</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify">Not applicable.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">9.A.5 Type and class of securities</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify">Each share has nominal value of 0.50 Swiss Francs per share. The respective number of shares that have been issued as of December 31, 2020 is given in Item 6.C of the annual report on Form 20-F for the fiscal year ended December 31, 2020. Novartis&#160;AG shares are issued as uncertificated securities (in the sense of the Swiss Code of Obligations) and as book entry securities (in terms of the Swiss Act on Intermediated Securities). All shares have equal voting rights and carry equal entitlements to dividends. No participation certificates, non-voting equity securities (Genussscheine) or profit-sharing certificates have been issued.</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">
<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: normal; TEXT-ALIGN: center">1</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>

<div>&#160;</div>
</div>
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">9.A.3 Pre-emptive rights</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify">If a capital increase is approved, then our shareholders would generally have certain pre-emptive rights to obtain newly issued shares in an amount proportional to the nominal value of the shares they already hold. These pre-emptive rights could be excluded in certain limited circumstances with the approval of a resolution adopted at a General Meeting of Shareholders (&#8220;General Meeting&#8221;) by a supermajority of two thirds of the votes. Pre-emptive rights, if not excluded, are transferable during the subscription period relating to a particular offering of shares and may be quoted on the SIX. US holders of shares, or US holders of ADRs, may not be able to exercise the pre-emptive rights attached to the shares or to the shares underlying their ADRs unless a registration statement under the US Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), is effective with respect to such rights and the related shares, or an exemption from this registration requirement is available. If pre-emptive rights could not be exercised by an ADR holder, the depositary would, if possible, sell the holder&#8217;s pre-emptive rights and distribute the net proceeds of the sale to the holder. If the depositary determines, in its discretion, that the rights could not be sold, the depositary might allow such rights to lapse.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold">Item 10.B Memorandum and articles of association</font></div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #272118; TEXT-ALIGN: left; MARGIN-TOP: 3pt">10.B.3 Shareholder rights</div>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Because Novartis&#160;AG has only one class of registered shares, the following information applies to all shareholders.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="z2594a8f351db471cbbf03c7b2bc4d6de" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 15.01%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: left">(a)</div>
</td>
<td style="WIDTH: 84.99%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Under the Swiss CO, we may only pay dividends out of balance sheet profits or out of distributable reserves. In any event, under the Swiss CO, while the Board may propose that a dividend be paid, we may only pay dividends upon shareholders&#8217; approval at a General Meeting. Furthermore, the Swiss CO requires us to accrue general legal reserves under certain circumstances so long as these reserves amount to less than 20% of our registered share capital, and Swiss law and the Articles permit us to accrue additional reserves beyond the statutory reserves. Our auditors must confirm that the dividend proposal of our Board conforms with the Swiss CO and the Articles. Our Board expects to recommend the payment of a dividend in respect of each financial year. See &#8220;Item&#160;3.&#160;Key Information&#8212;Item&#160;3.A. Selected financial data&#8212;Cash dividends per share&#8221; and &#8220;Item&#160;8.&#160;Financial Information&#8212;Item&#160;8.A. Consolidated statements and other financial information&#8212;Dividend policy&#8221; of our Form 20-F for the fiscal year ended December 31, 2020.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify; TEXT-INDENT: 14.15pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118">Dividends are usually due and payable shortly after the shareholders have passed a resolution approving the payment. Dividends that have not been claimed within five years after the due date revert to us and are allocated to our general reserves.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118">For information about deduction of the withholding tax or other duties from dividend payments, see &#8220;Item 10. Additional Information&#8212;Item&#160;10.E Taxation&#8221; of our Form 20-F for the fiscal year ended December 31, 2020.</font></div>

<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 15.01%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: left">(b)</div>
</td>
<td style="WIDTH: 84.99%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify">Each share is entitled to one vote at a General Meeting. Voting rights may only be exercised for shares registered with the right to vote on the record date for the applicable General Meeting. In order to do so, the shareholder must file&#160;a share registration form with us, setting forth the shareholder&#8217;s name, address and citizenship (or, in the case of a legal entity, its registered office). If the shareholder has not timely registered its shares, then the shareholder may not vote at, or participate in, a General Meeting.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify; TEXT-INDENT: 14.15pt">To vote its shares, the shareholder must also explicitly declare that it has acquired the shares in its own name and for its own account. If the shareholder refuses to make such a declaration, the shares may not be voted unless the Board recognizes such shareholder as a nominee.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify; TEXT-INDENT: 14.15pt">The Articles provide that no shareholder shall be registered with the right to vote shares comprising more than 2% of the registered share capital. The Board may, upon request, grant an exemption from this restriction. Considerations include whether the shareholder supports our goal of creating sustainable value and has a long<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#8209;</font>term investment horizon. Furthermore, the Articles provide that no nominee shall be registered with the right to vote shares comprising 0.5% or more of the registered share capital. The Board may, upon request, grant an exemption from this restriction if the nominee discloses the names, addresses and number of shares of the persons for whose account it holds 0.5% or more of the registered share capital. The same restrictions indirectly apply to ADR holders. We have in the past granted exemptions from the 2% rule for shareholders and the 0.5% rule for nominees.</div>
</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: center; MARGIN-TOP: 3pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">
<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">2</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">
<table id="z8dec3fedbf904a668c08b1524e1208c0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 15.01%; VERTICAL-ALIGN: top"></td>
<td style="FONT-FAMILY: 'Times New Roman'; WIDTH: 84.99%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-VARIANT: normal; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: #272118; FONT-STYLE: normal; TEXT-INDENT: 14.15pt">For purposes of the 2% rule for shareholders and the 0.5% rule for nominees, groups of companies and groups of shareholders acting in concert are considered to be one shareholder. These rules also apply to shares acquired or subscribed by the exercise of subscription, option or conversion rights.</div>

<div style="TEXT-INDENT: 14.15pt">After hearing the registered shareholder or nominee, the Board may cancel, with retroactive effect as of the date of registration, the registration of the shareholders if the registration was effected based on false information.</div>

<div style="TEXT-INDENT: 14.15pt">Registration restrictions in the Articles may only be removed upon a resolution carrying a two&#8209;thirds majority of the votes represented at a General Meeting.</div>

<div style="TEXT-INDENT: 14.15pt">Except as noted below, shareholders&#8217; resolutions require the approval of an absolute majority of the votes present at a General Meeting. As a result, abstentions have the effect of votes against such resolutions. Some examples of shareholders&#8217; resolutions requiring a vote by such &#8220;absolute majority of the votes&#8221; are:</div>

<ul>
<li>Adoption and amendment of the Articles </li>

<li>Election and removal of the Chairman, the Board and Compensation Committee members, the Independent Proxy and the external auditor </li>

<li>Approval of the management report and of the consolidated financial statements </li>

<li>
<div>Approval of the financial statements of Novartis&#160;AG, and decision on the appropriation of available earnings shown on the balancesheet, including dividends, if any</div>
</li>

<li>Approval of the maximum aggregate compensation of the Board (from an Annual General Meeting of Shareholders (&#8220;AGM&#8221;) until the next AGM) and of the Executive Committee (for the financial year following the AGM) </li>

<li>Discharge of Board and Executive Committee members from liability for matters disclosed to the General Meeting </li>

<li>Decision on other matters that are reserved by law or by the Articles (e.g., advisory vote on the Compensation Report) to the General Meeting </li>
</ul>

<div style="TEXT-INDENT: 14.15pt">According to the Articles and Swiss law, the following matters require the approval of a &#8220;supermajority&#8221; of at least two&#8209;thirds of the votes present at a General Meeting:</div>

<ul>
<li>Alteration of the purpose of Novartis&#160;AG </li>

<li>Creation of shares with increased voting powers </li>

<li>Implementation of restrictions on the transfer of registered shares, and the removal of such restrictions </li>

<li>Authorized or conditional increase of the share capital </li>

<li>Increase of the share capital out of equity, by contribution in kind, for the purpose of an acquisition of property or the grant of special rights </li>

<li>Restriction or cancellation of subscription rights </li>

<li>Change of the registered office of Novartis&#160;AG </li>

<li>Dissolution of Novartis&#160;AG </li>
</ul>

<div style="TEXT-INDENT: 14.15pt">In addition, the law provides for a qualified majority for other resolutions, such as a merger or demerger.</div>

<div style="TEXT-INDENT: 14.15pt">Our shareholders are required to annually elect all Directors (including the Chairman), the Compensation Committee members, the external auditor and the Independent Proxy. The Articles do not provide for cumulative voting of shares.</div>

<div style="TEXT-INDENT: 14.15pt">At a General Meeting, shareholders can be represented by a proxy, which must either be the shareholder&#8217;s legal representative, another shareholder with the right to vote, or the Independent</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">
<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">3</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">
<table id="zde2693d640274a6ca6b0182711f28a61" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 15.01%; VERTICAL-ALIGN: top"></td>
<td style="WIDTH: 84.99%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify">Proxy. Votes are taken either by a show of hands or by electronic voting, unless the General Meeting resolves to have a ballot or where a ballot is ordered by the chair of the meeting. However, in accordance with Swiss legislation passed in response to the COVID-19 pandemic, the Board has decided that voting rights at our 2021 AGM can only be exercised through the Independent Proxy. It will not be possible to physically attend our 2021 AGM.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify; TEXT-INDENT: 18pt">ADSs are issued by our depositary JPMorgan Chase, and not by us. The ADR is vested with rights defined and enumerated in the Deposit Agreement (such as the rights to vote, to receive a dividend and to receive a share in exchange for a certain number of ADRs). The enumeration of rights, including any limitations on those rights in the Deposit Agreement, is final. There are no other rights given to the ADR holders. Only the ADS depositary, holding our shares underlying the ADRs, is registered as a shareholder in our share register. An ADR is not a Novartis&#160;AG share and an ADR holder is not a Novartis&#160;AG shareholder.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify; TEXT-INDENT: 13.7pt">The Deposit Agreement between our depositary, the ADR holder and us has granted certain indirect rights to vote to the ADR holders. ADR holders may not attend a General Meeting in person. ADR holders exercise their voting rights by instructing JPMorgan Chase, our depositary, to exercise the voting rights attached to the registered shares underlying the ADRs. JPMorgan Chase, exercises the voting rights for registered shares underlying ADRs for which no voting instructions have been given by providing a discretionary proxy to an uninstructed independent designee. Such designee has to be a shareholder of Novartis&#160;AG. The same voting restrictions apply to ADR holders as to those holding Novartis&#160;AG shares (i.e., the right to vote up to 2% of the Novartis&#160;AG registered share capital &#8211; unless otherwise granted an exemption by the Board &#8211; and the disclosure requirement for nominees).</div>

<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 15.01%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: left">(c)</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: left">(d)</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: left">(e)</div>
</td>
<td style="WIDTH: 84.99%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify">Shareholders have the right to allocate the profit shown on our balance sheet and to distribute dividends by vote taken at the General Meeting, subject to the legal requirements described in &#8220;Item&#160;10.B.3(a) Shareholder rights.&#8221;</div>

<div>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify; MARGIN-RIGHT: 11.35pt">Under the Swiss CO, any surplus arising out of a liquidation of Novartis&#160;AG (i.e., after the settlement of all claims of all creditors) would be distributed to the shareholders in proportion to the paid-in nominal value of their shares.</div>

<div>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify">The Swiss CO limits a corporation&#8217;s ability to hold or repurchase its own shares. We and our subsidiaries may only repurchase shares if we have sufficient freely disposable equity in the amount of the purchase price of the acquired shares. The aggregate nominal value of all Novartis&#160;AG shares held by us and our subsidiaries may not exceed 10% of our registered share capital. However, it is accepted that a Swiss corporation may repurchase its own shares beyond the statutory limit of 10% if the repurchased shares are clearly earmarked for cancellation. In addition, we are required to recognize a negative position, or if our subsidiaries acquire our shares, to create a special reserve on our balance sheet in the amount of the purchase price of the acquired shares. Repurchased shares held by us or our subsidiaries do not carry any rights to vote at a General Meeting, but are entitled to the economic benefits generally connected with the shares. The definition of subsidiaries, and therefore, treasury shares, for purposes of the above described reserves requirement and voting restrictions differs from the definition of subsidiaries for purposes of consolidation in our consolidated financial statements. The definition in the consolidated financial statements requires consolidation for financial reporting purposes of special purpose entities in instances where we have the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities. Therefore, our consolidated financial statements include special purpose entities, mainly foundations, which do not qualify as subsidiaries subject to the reserve requirements and voting restrictions of the Swiss CO because we do not hold a majority participation in these special purpose entities. Accordingly, no reserve requirements apply to shares held by such special purpose entities, and such entities are not restricted from independently voting their shares.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify; TEXT-INDENT: 14.15pt">Under the Swiss CO, we may not cancel treasury shares without the approval of a capital reduction by our shareholders.</div>

<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 15.01%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: left">(f)</div>
</td>
<td style="WIDTH: 60.06%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify">Not applicable.</div>
</td>
<td style="WIDTH: 25.07%; VERTICAL-ALIGN: top">&#160;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">
<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">4</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>

<div>&#160;</div>
</div>
</div>
</div>
</div>
</div>
</div>

<table id="zdf03bce7cdb64fa08d67975b7e04003c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 15.01%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: left">(g)</div>
</td>
<td style="WIDTH: 84.99%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify">Since all of our issued and outstanding shares have been fully paid in, our shareholders are not obliged to make further contributions with respect to their shares.</div>

<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 15.01%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: left">(h)</div>
</td>
<td style="WIDTH: 84.99%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify">See &#8220;&#8212;Item&#160;10.B.3(b) Shareholder rights&#8221; and &#8220;&#8212;Item&#160;10.B.7 Change in control.&#8221;</div>

<div>&#160;</div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #272118; TEXT-ALIGN: left; MARGIN-TOP: 3pt">10.B.4 Changes to shareholder rights</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify; MARGIN-LEFT: 1.35pt">Under the Swiss CO, we may not issue new shares without the prior approval of a capital increase by our shareholders. If a capital increase is approved, then our shareholders would generally have certain pre-emptive rights to obtain newly issued shares in an amount proportional to the nominal value of the shares they already hold. These pre-emptive rights could be excluded in certain limited circumstances with the approval of a resolution adopted at a General Meeting by a supermajority of two<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#8209;</font>thirds of the votes. In addition, we may not create shares with increased voting powers or place restrictions on the transfer of registered shares without the approval of a resolution adopted at a General Meeting by a supermajority of votes. In addition, see &#8220;&#8212;Item&#160;10.B.3(b) Shareholder rights&#8221; with regard to the Board&#8217;s ability to cancel the registration of shares under limited circumstances.</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #272118; TEXT-ALIGN: left; MARGIN-TOP: 3pt">10.B.6 Limitations</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify; MARGIN-LEFT: 1.35pt">There are no limitations under the Swiss CO or our Articles on the right of non<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#8209;</font>Swiss residents or nationals to own or vote shares other than the restrictions applicable to all shareholders. But see &#8220;&#8212;Item&#160;10.B.3(b) Shareholder rights&#8221; regarding conditions for exercising an ADR holder&#8217;s right to vote at a shareholder meeting.</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #272118; TEXT-ALIGN: left; MARGIN-TOP: 3pt">10.B.7 Change in control</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify; MARGIN-LEFT: 1.35pt">The Articles and the Board Regulations contain no provision that would have an effect of delaying, deferring or preventing a change in control of Novartis&#160;AG and that would operate only with respect to a merger, acquisition or corporate restructuring involving us or any of our subsidiaries.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify; MARGIN-LEFT: 1.35pt; TEXT-INDENT: 14.15pt">According to the Swiss Merger Act, shareholders may pass a resolution to merge with another corporation at any time. Such a resolution would require the consent of at least two<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">&#8209;</font>thirds of all votes present at the necessary General Meeting.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify; MARGIN-LEFT: 1.35pt; TEXT-INDENT: 14.15pt">Under the Swiss Financial Market Infrastructure Act, shareholders and groups of shareholders acting in concert who acquire more than 33 1/3% of our shares would be under an obligation to make an offer to acquire all remaining Novartis&#160;AG shares. Novartis&#160;AG has neither opted out from the mandatory takeover offer obligation nor opted to increase the threshold for mandatory takeover offers in its Articles.</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #272118; TEXT-ALIGN: left; MARGIN-TOP: 3pt">10.B.8 Disclosure of shareholdings</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify; MARGIN-LEFT: 1.35pt">Under the Swiss Financial Market Infrastructure Act, persons who directly, indirectly or in concert with other parties acquire or dispose of our shares or purchase or sale rights relating to our shares are required to notify us and the SIX of the level of their holdings whenever such holdings reach, exceed or fall below certain thresholds &#8211; 3%, 5%, 10%, 15%, 20%, 25%, 33 1/3%, 50% and 66 2/3% &#8211; of the voting rights represented by our share capital (whether exercisable or not). This also applies to anyone who has discretionary power to exercise voting rights associated with our shares. Following receipt of such notification, we are required to inform the public by publishing the information via the electronic publication platform operated by the SIX.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify; MARGIN-LEFT: 1.35pt; TEXT-INDENT: 14.15pt">An additional disclosure obligation exists under the Swiss CO that requires us to disclose, once a year in the notes to the financial statements published in our Annual Report, the identity of all of our shareholders (or related groups of shareholders) who have been granted exemption entitling them to vote more than 2% of our registered share capital, as described in &#8220;&#8212;Item&#160;10.B.3(b) Shareholder rights.&#8221;</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #272118; TEXT-ALIGN: left; MARGIN-TOP: 3pt">10.B.9 Differences in the law</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">See the references to Swiss law throughout this &#8220;&#8212;Item&#160;10.B Memorandum and articles of association.&#8221;</div>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #272118; TEXT-ALIGN: left; MARGIN-TOP: 3pt">10.B.10 Changes in capital</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The requirements of the Articles regarding changes in capital are not more stringent than the requirements of Swiss law.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">
<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">5</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>

<div>&#160;</div>
</div>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center; MARGIN-TOP: 3pt">AMERICAN DEPOSITARY SHARES</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Item 12. Other securities</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Disclosures under Items 12.A, 12.B, and 12.C are not applicable.</div>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt">12.D.1 Depositary</div>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">JPMorgan Chase has been appointed as the depositary pursuant to the Deposit Agreement. JPMorgan Chase&#8217;s principal executive office is located at 4 New York Plaza, 13<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">th</sup> Floor, New York, NY 10004.</div>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">12.D.2 Provisions</div>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">ADSs are issued by the depositary, and not by us. The ADR is vested with rights defined and enumerated in the Deposit Agreement (such as the rights to vote, to receive a dividend and to receive a share of Novartis&#160;AG in exchange for a certain number of ADRs). The enumeration of rights, including any limitations on those rights in the Deposit Agreement, is final. There are no other rights given to the ADR holders. Only the depositary is registered as shareholder in our share register. An ADR is not a Novartis&#160;AG share and an ADR holder is not a Novartis&#160;AG shareholder.</div>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The following is a summary of the material provisions of the Deposit Agreement. For more complete information, you should read the Deposit Agreement and form of ADR. The amended and restated Deposit Agreement and Amendment No. 1 has been filed with the SEC as an exhibit to the Form F-6 filed with the SEC on September 8, 2000, and Amendment No. 2 has been filed with the SEC as an exhibit to the Form F-6 filed with the SEC on May 3, 2001.</div>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Voting rights</div>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify; MARGIN-LEFT: 1.35pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118">The</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000"> Deposit Agreement has granted certain indirect rights to vote to the ADR holders. ADR holders may not attend Novartis&#160;AG general meetings in person. ADR holders exercise their voting rights by instructing the depositary to exercise the voting rights attached to the registered shares underlying the ADRs. The depositary exercises the voting rights for registered shares underlying ADRs for which no voting instructions have been given by providing a discretionary proxy to an uninstructed independent designee pursuant to paragraph 13 of the form of ADR. Such designee has to be a shareholder of Novartis&#160;AG. The same voting restrictions apply to ADR holders as to those holding Novartis&#160;AG shares (i.e., the right to vote up to 2% of the Novartis&#160;AG registered share capital &#8211; unless otherwise granted an exemption by the Board &#8211; and the disclosure requirement for nominees).</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify; MARGIN-LEFT: 1.35pt; TEXT-INDENT: 14.15pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118">As</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000"> soon as practicable after receipt from Novartis&#160;AG of notice of any meeting or solicitation of consents or proxies of holders of shares or other deposited securities, the depositary will mail to holders a notice stating (a) such information as is contained in such notice and any solicitation materials (or a summary thereof), (b) that each holder on the record date set by the depositary therefor will be entitled, subject to applicable law and the provisions of or governing deposited securities to instruct the depositary as to the exercise of the voting rights, if any, pertaining to the deposited securities represented by the ADSs evidenced by such holder&#8217;s ADRs and (c) the manner in which such instructions may be given, including instructions to give a discretionary proxy to a person designated by Novartis&#160;AG. Upon receipt of instructions of a holder on such record date in the manner and on or before the date established by the depositary for such purpose, the depositary will endeavor insofar as practicable and permitted under the provisions of or governing deposited securities to vote or cause to be voted (or to grant a discretionary proxy to a person designated by Novartis&#160;AG) the deposited securities represented by the ADSs evidenced by such holder&#8217;s ADRs in accordance with such instructions. The depositary will not itself exercise any voting discretion in respect of any deposited securities. To the extent such instructions are not so received by the depositary from any holder, the depositary shall deem such holder to have so instructed the depositary to give a discretionary proxy to a person designated by Novartis&#160;AG and the depositary shall endeavor insofar as practicable and permitted under the provisions of or governing deposited securities to give a discretionary proxy to a person designated by Novartis&#160;AG to vote the deposited securities represented by the ADSs evidenced by such holder&#8217;s ADRs as to which such instructions are so given, provided that no such instruction shall be </font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify; MARGIN-LEFT: 1.35pt; TEXT-INDENT: 14.15pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify; MARGIN-LEFT: 1.35pt; TEXT-INDENT: 14.15pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify; MARGIN-LEFT: 1.35pt; TEXT-INDENT: 14.15pt">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">
<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">6</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center">&#160;</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000"><br>
 deemed given and no discretionary proxy shall be given with respect to any matter as to which the Novartis&#160;AG informs the depositary (and Novartis&#160;AG agrees to provide such information promptly in writing) that Novartis&#160;AG does not wish such proxy given.</div>
</div>
</div>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Share dividends and other distributions</div>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>&#160;</div>

<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff">The depositary will distribute as promptly as practicable by mail, to the extent distribution by mail is practicable, to each ADR holder on the record date set by the depositary at such ADR holder&#8217;s address shown on the ADR Register, in proportion to the number of deposited securities (on which the following distributions on deposited securities are received by the custodian) represented by ADSs evidenced by such holder&#8217;s ADRs:</font></font></div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>&#160;</div>

<table id="z20b246e3c7844c14968b878c38d4823d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 15.38%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: left">(a)</div>
</td>
<td style="WIDTH: 84.62%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-STYLE: italic; BACKGROUND-COLOR: #ffffff">Cash: </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff">Any US dollars available to the depositary resulting from a cash dividend or other cash distribution or the net proceeds of sales of any other distribution or portion thereof authorized in paragraph 10 (&#8220;Cash&#8221;) of the form of ADR, on an averaged or other reasonably practicable basis, subject to (i) appropriate adjustments for taxes withheld, (ii) such distribution being impermissible pursuant to applicable law with respect to certain holders, and (iii) deduction of the depositary&#8217;s expenses in (1) converting any foreign currency to US dollars by sale or in such other manner as the depositary may determine to the extent that it determines that such conversion may be made on a reasonable basis, (2) transferring foreign currency or US dollars to the US by such means as the depositary may determine to the extent that it determines that such transfer may be made on a reasonable basis, (3) obtaining any approval or license of any governmental authority required for such conversion or transfer, which is obtainable at a reasonable cost and within a reasonable time and (4) making any sale by public or private means in any commercially reasonable manner.</font></div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>&#160;</div>

<table id="z80f5e8df809942bd9fa772021814a174" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 15.38%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: left">(b)</div>
</td>
<td style="WIDTH: 84.62%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-STYLE: italic">Shares</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff">. (i) Additional ADRs evidencing whole ADSs representing any shares available to the depositary resulting from a dividend or free distribution on deposited securities consisting of shares (a &#8220;Share Distribution&#8221;) and (ii) US dollars available to it resulting from the net proceeds of sales of shares received in a Share Distribution, which shares would give rise to fractional ADSs if additional ADRs were issued therefor, as in the case of Cash.</font></div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"><br>
</font></div>

<table id="zf1eb8a4fbdb54d60b6befc6b5c4cc387" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 15.38%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: left">(c)</div>
</td>
<td style="WIDTH: 84.62%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-STYLE: italic">Rights</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff">. (i) Warrants or other instruments in the discretion of the depositary after consultation with Novartis&#160;AG if practicable representing rights to acquire additional ADRs in respect of any rights to subscribe for additional shares or rights of any nature available to the depositary as a result of a distribution on deposited securities (&#8220;Rights&#8221;), to the extent that Novartis&#160;AG timely furnishes to the depositary evidence satisfactory to the depositary that the depositary may lawfully distribute the same (Novartis&#160;AG has no obligation to so furnish such evidence), or (ii) to the extent Novartis&#160;AG does not so furnish such evidence and sales of Rights are practicable, any US dollars available to the depositary from the net proceeds of sales of Rights as in the case of Cash, or (iii) to the extent Novartis&#160;AG does not so furnish such evidence and such sales cannot practicably be accomplished by reason of the nontransferability of the Rights, limited markets therefor, their short duration or otherwise, nothing (and any Rights may lapse).</font></div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"><br>
</font></div>

<table id="zbdc0962b7c4545adae5d80ce14756133" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 15.38%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: left">(d)</div>
</td>
<td style="WIDTH: 84.62%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-STYLE: italic">Other Distributions</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff">. (i) Securities or property available to the depositary resulting from any distribution on deposited securities other than Cash, Share Distributions and Rights (&#8220;Other Distributions&#8221;), by any means that the depositary may deem equitable and practicable, or (ii) to the extent the depositary deems distribution of such securities or property not to be equitable and practicable, any US dollars available to the depositary from the net proceeds of sales of Other Distributions as in the case of Cash. The depositary shall endeavor to conduct any sales hereunder in a commercially reasonable manner.</font></div>
</td>
</tr>
</table>

<div style="BACKGROUND-COLOR: #ffffff"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"><br>
</font></div>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify; MARGIN-TOP: 3pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff">7</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>&#160;</div>

<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font></div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font><br>
 &#160;</div>
</div>
</div>
</div>
</div>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff">The depositary will distribute US dollars by checks drawn on a bank in the US for whole dollars and cents (any fractional cents being withheld without liability for interest and dealt with by the depositary in accordance with its then current procedures), pursuant to paragraph 10 of the form of ADR.</font></div>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Deposit, withdrawal and cancellation</div>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff">Subject to paragraphs 4 and 5 of the form of ADR, upon surrender of (i) a certificated ADR in form satisfactory to the depositary at the transfer office or (ii) proper instructions and documentation in the case of a Direct Registration ADR, the holder hereof is entitled to delivery at the custodian&#8217;s office of the deposited securities at the time represented by the ADSs evidenced by this ADR. At the request, risk and expense of the holder, the depositary may deliver such deposited securities at such other place as may have been requested by the holder. Notwithstanding any other provision of the deposit agreement or this ADR, the withdrawal of deposited securities may be restricted only for the reasons set forth in General Instruction I.A.(1) of Form F-6 (as such instructions may be amended from time to time) under the Securities Act.</font></div>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Reclassification, recapitalizations and mergers</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<font style="FONT-FAMILY: 'Times New Roman'">If Novartis&#160;AG takes certain actions that affect the deposited securities, including (i)&#160;any change in par value, split-up, consolidation, cancellation or other reclassification of deposited securities or (ii)&#160;any recapitalization, reorganization, merger, consolidation, liquidation, receivership, bankruptcy or sale of all or substantially all the assets of the company, then the depositary may choose to:</font></div>

<div>&#160;</div>

<table id="zd560187e1886484cba01b7aabf72547c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 15.38%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: left">(a)</div>
</td>
<td style="WIDTH: 84.62%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: left">issue and distribute additional ADRs;</div>
</td>
</tr>
</table>

<div style="BACKGROUND-COLOR: #ffffff">
<div id="DSPFPageHeader"></div>

<div>&#160;</div>
</div>

<table id="z0daa7dcd1c1e44dfa923db20fc666fe2" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 15.38%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: left">(b)</div>
</td>
<td style="WIDTH: 84.62%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: left">amend the deposit agreement and applicable ADRs;</div>
</td>
</tr>
</table>

<div style="BACKGROUND-COLOR: #ffffff">
<div id="DSPFPageHeader"></div>

<div>&#160;</div>
</div>

<table id="zdd3f09a6b01347b49ea65ef64575901b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 15.38%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: left">(c)</div>
</td>
<td style="WIDTH: 84.62%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify">call for the surrender of outstanding ADRs to be exchanged for new ADRs; and</div>
</td>
</tr>
</table>

<div style="BACKGROUND-COLOR: #ffffff">
<div id="DSPFPageHeader"></div>

<div>&#160;</div>
</div>

<table id="z6d0d3bdaa165409db84328cfd1a23948" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 15.38%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: left">(d)</div>
</td>
<td style="WIDTH: 84.62%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify">distribute cash, securities or property on the record date set by the depositary to reflect the transaction.</div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Amendment and termination</div>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 1.35pt">The ADRs and the Deposit Agreement may be amended by Novartis&#160;AG and the depositary, provided that any amendment that imposes or increases any fees or charges (other than stock transfer or other taxes and other governmental charges, transfer or registration fees, cable, telex or facsimile transmission costs, delivery costs or other such expenses), or that shall otherwise prejudice any substantial existing right of holders, shall become effective 30 days after notice of such amendment shall have been given to the holders. Every holder of an ADR at the time any amendment to the Deposit Agreement so becomes effective shall be deemed, by continuing to hold such ADR, to consent and agree to such amendment and to be bound by the Deposit Agreement as amended thereby.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 1.35pt; TEXT-INDENT: 14.15pt">The depositary may, and shall at the written direction of Novartis&#160;AG, terminate the Deposit Agreement and this ADR by mailing notice of such termination to the holders at least 30 days prior to the date fixed in such notice for such termination. After the date so fixed for termination, the depositary and its agents will perform no further acts under the Deposit Agreement and this ADR, except to receive and hold (or sell) distributions on deposited securities and deliver deposited securities being withdrawn. As soon as practicable after the expiration of six months from the date so fixed for termination, the depositary shall sell the deposited securities and shall thereafter (as long as it may lawfully do so) hold in a segregated account the net proceeds of such sales, together with any other cash then held by it under the Deposit Agreement, without liability for interest, in trust for the pro rata benefit of the holders of ADRs not theretofore surrendered. After making such sale, the Depositary shall be discharged from all obligations in respect of the Deposit</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 1.35pt; TEXT-INDENT: 14.15pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 1.35pt; MARGIN-TOP: 3pt; TEXT-INDENT: 14.15pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div style="BACKGROUND-COLOR: #ffffff"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify; MARGIN-TOP: 3pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff">8</font></font></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>&#160;</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>

<div><br>
 Agreement and this ADR, except for its obligations to Novartis&#160;AG under Section 16 of the Deposit Agreement and to account for such net proceeds and other cash. After the date so fixed for termination, Novartis&#160;AG will be discharged from all obligations under the Deposit Agreement except for its obligations to the depositary and its agents.</div>
</div>
</div>
</div>
</div>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Limitation on obligations and liability to ADR holders</div>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The depositary, Novartis&#160;AG, their respective directors, employees, officers, agents or affiliates and each of them shall: (a) incur no liability (i) if any present or future law, regulation, order, decree, moratorium, fiat, the provisions of or governing any deposited securities and the Memorandum and Articles, act of God, war or other circumstance beyond its control shall prevent, delay or subject to any civil or criminal penalty or restraint or any act which the Deposit Agreement or this ADR provides shall be done or performed by it, or (ii) by reason of any exercise or failure to exercise any discretion given it in the Deposit Agreement, this ADR or the Memorandum and Articles; (b) assume no liability except to perform its obligations to the extent they are specifically set forth in this ADR and the Deposit Agreement without gross negligence or bad faith; (c) be under no obligation to appear in, prosecute or defend any action, suit or other proceeding in respect of any Deposited Securities or this ADR; or (d) not be liable for any action or inaction by it in reliance upon the advice of or information from legal counsel, accountants, any person presenting shares for deposit, any holder, or any other person believed by it to be competent to give such advice or information. The depositary, its agents and Novartis&#160;AG may rely and shall be protected in acting upon any written notice, request, direction or other document believed by them to be genuine and to have been signed or presented by the proper party or parties. The depositary and its agents will not be responsible for any failure to carry out any instructions to vote any of the deposited securities, for the manner in which any such vote is cast or for the effect of any such vote. The depositary and its agents may own and deal in any class of securities of Novartis&#160;AG and its affiliates and in ADRs. Novartis&#160;AG has agreed to indemnify the depositary and its agents under certain circumstances and the depositary and its agents have agreed to indemnify Novartis&#160;AG under certain circumstances. No disclaimer of liability under the Securities Act is intended by any provision hereof.</div>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Books of depositary</div>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">The depositary will keep books at its principal office for the registration and transfer of ADRs, which will be open for inspection by owners of ADRs at all reasonable times. Such inspection shall not be for the purpose of communicating with other owners of ADRs in the interest of a business or object other than our business or other than a matter related to the deposit agreement or the ADRs.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>

<div id="DSPFPageFooter">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div style="BACKGROUND-COLOR: #ffffff"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; COLOR: #272118; TEXT-ALIGN: justify; MARGIN-TOP: 3pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff">9</font></font></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>&#160;</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font>

<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff"></font><br>
 &#160;</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12
<SEQUENCE>4
<FILENAME>a21012620f-ex12_1.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>

<html>
<head>
<title>EXHIBIT 12.1</title>
</head>
<body bgcolor="#ffffff">



    <div style="text-align:right;font-weight: bold;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Exhibit&#xA0;12.1 </div>
<div style="text-align:center;font-weight: bold;padding-bottom:30px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">CERTIFICATION </div>
<div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">I, Vasant Narasimhan, certify that: </div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">1.  I have reviewed this annual report on Form&#xA0;20-F of Novartis AG; </div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; </div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">4.  The company&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#xA0;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#xA0;13a-15(f) and 15d-15(f)) for the company and have: </div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">a)  designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">b)  designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">c)  evaluated the effectiveness of the company&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">d)  disclosed in this report any change in the company&#x2019;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#x2019;s internal control over financial reporting; and </div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">5.  The company&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#x2019;s auditors and the audit committee of the company&#x2019;s board of directors (or persons performing the equivalent functions): </div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">a)  all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#x2019;s ability to record, process, summarize and report financial information; and </div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">b)  any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#x2019;s internal control over financial reporting. </div>
<div style="padding-bottom:15px;padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Date: January&#xA0;26, 2021</div>
<div style="text-decoration:underline;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">By:&#xA0; /s/&#xA0;&#xA0;VASANT NARASIMHAN</div>
<div style="margin-left:22px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Name:&#xA0; Vasant Narasimhan</div>
<div style="margin-left:22px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Title:&#xA0; <i>Chief Executive Officer</i></div>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12
<SEQUENCE>5
<FILENAME>a21012620f-ex12_2.htm
<DESCRIPTION>EXHIBIT 12.2
<TEXT>

<html>
<head>
<title>EXHIBIT 12.2</title>
</head>
<body bgcolor="#ffffff">



    <div style="text-align:right;font-weight: bold;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Exhibit&#xA0;12.2 </div>
<div style="text-align:center;font-weight: bold;padding-bottom:30px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">CERTIFICATION </div>
<div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">I, Harry Kirsch, certify that: </div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">1.  I have reviewed this annual report on Form&#xA0;20-F of Novartis AG; </div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; </div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">4.  The company&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#xA0;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#xA0;13a-15(f) and 15d-15(f)) for the company and have: </div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">a)  designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">b)  designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">c)  evaluated the effectiveness of the company&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">d)  disclosed in this report any change in the company&#x2019;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#x2019;s internal control over financial reporting; and </div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">5.  The company&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#x2019;s auditors and the audit committee of the company&#x2019;s board of directors (or persons performing the equivalent functions): </div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">a)  all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#x2019;s ability to record, process, summarize and report financial information; and </div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">b)  any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#x2019;s internal control over financial reporting. </div>
<div style="padding-bottom:15px;padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Date: January&#xA0;26, 2021</div>
<div style="text-decoration:underline;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">By:&#xA0; /s/&#xA0;&#xA0;HARRY KIRSCH</div>
<div style="margin-left:22px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Name:&#xA0; Harry Kirsch</div>
<div style="margin-left:22px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Title:&#xA0; <i>Chief Financial Officer</i></div>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13
<SEQUENCE>6
<FILENAME>a21012620f-ex13_1.htm
<DESCRIPTION>EXHIBIT 13.1
<TEXT>

<html>
<head>
<title>EXHIBIT 13.1</title>
</head>
<body bgcolor="#ffffff">



    <div style="text-align:right;font-weight: bold;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Exhibit&#xA0;13.1 </div>
<div style="text-align:center;font-weight: bold;padding-bottom:30px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">CERTIFICATION OF VASANT NARASIMHAN, CHIEF EXECUTIVE OFFICER OF  NOVARTIS AG PURSUANT TO SECTION 18 U.S.C. SECTION 1350,  AS ADOPTED PURSUANT TO SECTION 906  OF THE SARBANES-OXLEY ACT OF 2002 </div>
<div style="padding-bottom:10px;text-indent:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"> Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), the undersigned officer of Novartis AG, a Swiss corporation (the &#x201C;Company&#x201D;), hereby certifies, to the best of such officer&#x2019;s knowledge, that: </div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">1.  The Annual Report on Form 20-F for the year ended December 31, 2020 (the &#x201C;Form 20-F&#x201D;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and </div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">2.  The information contained in the Form 20-F fairly presents, in all material respects, the financial condition and results of operations of the Company. </div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"> </div>
<div style="text-decoration:underline;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">By:&#xA0; /s/&#xA0;&#xA0;VASANT NARASIMHAN</div>
<div style="margin-left:22px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Name:&#xA0; Vasant Narasimhan</div>
<div style="margin-left:22px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Title:&#xA0; <i>Chief Executive Officer</i></div>
<div style="padding-bottom:15px;padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Date: January 26, 2021</div>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13
<SEQUENCE>7
<FILENAME>a21012620f-ex13_2.htm
<DESCRIPTION>EXHIBIT 13.2
<TEXT>

<html>
<head>
<title>EXHIBIT 13.2</title>
</head>
<body bgcolor="#ffffff">



    <div style="text-align:right;font-weight: bold;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Exhibit&#xA0;13.2 </div>
<div style="text-align:center;font-weight: bold;padding-bottom:30px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">CERTIFICATION OF HARRY KIRSCH, CHIEF FINANCIAL OFFICER OF  NOVARTIS AG PURSUANT TO SECTION 18 U.S.C. SECTION 1350,   AS ADOPTED PURSUANT TO SECTION 906  OF THE SARBANES-OXLEY ACT OF 2002 </div>
<div style="padding-bottom:10px;text-indent:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), the undersigned officer of Novartis AG, a Swiss corporation (the &#x201C;Company&#x201D;), hereby certifies, to the best of such officer&#x2019;s knowledge, that: </div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">1.  The Annual Report on Form 20-F for the year ended December 31, 2020 (the &#x201C;Form 20-F&#x201D;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and </div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">2.  The information contained in the Form 20-F fairly presents, in all material respects, the financial condition and results of operations of the Company. </div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"> </div>
<div style="text-decoration:underline;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">By:&#xA0; /s/&#xA0;&#xA0;HARRY KIRSCH</div>
<div style="margin-left:22px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Name:&#xA0; Harry Kirsch</div>
<div style="margin-left:22px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Title:&#xA0; <i>Chief Financial Officer</i></div>
<div style="padding-bottom:15px;padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Date: January 26, 2021</div>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15
<SEQUENCE>8
<FILENAME>a21012620f-ex15_1.htm
<DESCRIPTION>EXHIBIT 15.1
<TEXT>

<html>
<head>
<title>EXHIBIT 15.1</title>
</head>
<body bgcolor="#ffffff">





<br>
<img src="x_pwc.gif">
<br>


    <div style="text-align:right;font-weight: bold;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"> Exhibit&#xA0;15.1 </div>
<div style="text-align:center;font-weight: bold;padding-bottom:30px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">&#xA0;</div>
<div style="text-align:center;font-weight: bold;padding-bottom:30px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>
<div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-171739, 333-198706 and 333-250207) and Form F-3 (No. 333-236162) of Novartis AG of our report dated January 25, 2021 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 20-F.</div>
<div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">&#xA0;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">/s/ PricewaterhouseCoopers AG</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Basel, Switzerland</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">January 25, 2021</div>
<div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">&#xA0;</div>
<div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">&#xA0;</div>
<div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">&#xA0;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"> </div>



</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>nvs-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
   <link:roleRef roleURI="http://novartis.com/20201231/role/StatementsOfCashFlowParenthetical" xlink:href="nvs-20201231.xsd#statementsOfCashFlowParenthetical" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails" xlink:href="nvs-20201231.xsd#disclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/StatementOfComprehensiveIncomeCalc2" xlink:href="nvs-20201231.xsd#statementOfComprehensiveIncomeCalc2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/StatementOfIncomeCalc2" xlink:href="nvs-20201231.xsd#statementOfIncomeCalc2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureMarketableSecuritiesDetails" xlink:href="nvs-20201231.xsd#disclosureMarketableSecuritiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails" xlink:href="nvs-20201231.xsd#disclosureFinancialAndOtherNoncurrentAssetsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails" xlink:href="nvs-20201231.xsd#disclosureProvisionsAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureAcquisitionsOfBusinessesDetails" xlink:href="nvs-20201231.xsd#disclosureAcquisitionsOfBusinessesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:href="nvs-20201231.xsd#disclosureCommitmentsAndContingenciesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureOtherCurrentAssetsDetails" xlink:href="nvs-20201231.xsd#disclosureOtherCurrentAssetsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:href="nvs-20201231.xsd#disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:href="nvs-20201231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:href="nvs-20201231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityDetails" xlink:href="nvs-20201231.xsd#disclosureEquityDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4" xlink:href="nvs-20201231.xsd#disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedPartiesDetails2" xlink:href="nvs-20201231.xsd#disclosureTransactionsWithRelatedPartiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/StatementOfComprehensiveIncome" xlink:href="nvs-20201231.xsd#statementOfComprehensiveIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/StatementsOfCashFlow" xlink:href="nvs-20201231.xsd#statementsOfCashFlow" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails" xlink:href="nvs-20201231.xsd#disclosureNonCurrentFinancialDebtDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2" xlink:href="nvs-20201231.xsd#disclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/StatementOfIncome" xlink:href="nvs-20201231.xsd#statementOfIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:href="nvs-20201231.xsd#disclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2" xlink:href="nvs-20201231.xsd#disclosureFinancialAndOtherNoncurrentAssetsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureMarketableSecuritiesDetails2" xlink:href="nvs-20201231.xsd#disclosureMarketableSecuritiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEarningsPerShareDetails" xlink:href="nvs-20201231.xsd#disclosureEarningsPerShareDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/BalanceSheet" xlink:href="nvs-20201231.xsd#balanceSheet" xlink:type="simple"/>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/BalanceSheet" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="lbl_CurrentAssets" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Assets" xlink:label="lbl_Assets" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Assets" xlink:to="lbl_CurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="lbl_NoncurrentAssets" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Assets" xlink:to="lbl_NoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="lbl_EquityAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Equity" xlink:to="lbl_EquityAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncontrollingInterests" xlink:label="lbl_NoncontrollingInterests" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Equity" xlink:to="lbl_NoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_EquityAttributableToOwnersOfParent" xlink:to="lbl_IssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherReserves" xlink:label="lbl_OtherReserves" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_EquityAttributableToOwnersOfParent" xlink:to="lbl_OtherReserves" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_EquityAttributableToOwnersOfParent" xlink:to="lbl_TreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="lbl_CurrentLiabilities" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Liabilities" xlink:label="lbl_Liabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Liabilities" xlink:to="lbl_CurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="lbl_NoncurrentLiabilities" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Liabilities" xlink:to="lbl_NoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentLiabilities" xlink:to="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="lbl_EquityAndLiabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_EquityAndLiabilities" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_EquityAndLiabilities" xlink:to="lbl_Liabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Goodwill" xlink:label="lbl_Goodwill" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_Goodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="lbl_NoncurrentFinancialAssets" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_NoncurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_OtherNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentLiabilities" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilities" xlink:to="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilities" xlink:to="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_OtherCurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="lbl_CurrentAssets1" xlink:type="locator"/>
      <link:calculationArc order="10.2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssets1" xlink:to="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:calculationArc order="17.2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssets" xlink:to="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_Inventories" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="lbl_OtherCurrentFinancialAssets" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_OtherCurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_OtherCurrentNonfinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="lbl_NoncurrentLeaseLiabilities" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentLiabilities" xlink:to="lbl_NoncurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="lbl_CurrentLeaseLiabilities" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_CurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="lbl_CurrentTaxAssetsCurrent" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_CurrentTaxAssetsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentLiabilities" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/DisclosureEarningsPerShareDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="lbl_BasicEarningsLossPerShare" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_BasicEarningsLossPerShare" xlink:to="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_BasicEarningsLossPerShare" xlink:to="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="lbl_DilutedEarningsLossPerShare" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_DilutedEarningsLossPerShare" xlink:to="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_DilutedEarningsLossPerShare" xlink:to="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/DisclosureMarketableSecuritiesDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Cash" xlink:label="lbl_Cash" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashAndCashEquivalents" xlink:to="lbl_Cash" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashEquivalents" xlink:label="lbl_CashEquivalents" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashAndCashEquivalents" xlink:to="lbl_CashEquivalents" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DeferredCompensationPlansAssets" xlink:label="lbl_DeferredCompensationPlansAssets" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentAssets" xlink:to="lbl_DeferredCompensationPlansAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:label="lbl_OtherNoncurrentNonfinancialAssets" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentAssets" xlink:to="lbl_OtherNoncurrentNonfinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PrepaidPostemploymentBenefitPlansAssets" xlink:label="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentAssets" xlink:to="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CommercialPapersIssued" xlink:label="lbl_CommercialPapersIssued" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialLiabilities" xlink:to="lbl_CommercialPapersIssued" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShorttermBorrowings" xlink:label="lbl_ShorttermBorrowings" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialLiabilities" xlink:to="lbl_ShorttermBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialLiabilities" xlink:to="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="lbl_DerivativeFinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialLiabilities" xlink:to="lbl_DerivativeFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:label="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialLiabilities" xlink:to="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/StatementOfIncome" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="lbl_ProfitLossFromContinuingOperations" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLoss" xlink:to="lbl_ProfitLossFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLoss" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromContinuingOperations" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossBeforeTax" xlink:to="lbl_ProfitLossFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossBeforeTax" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_OtherIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossBeforeTax" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_GrossProfit" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GrossProfit" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GrossProfit" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_RevenueFromSaleOfGoods" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromContinuingOperations" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossBeforeTax" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_ResearchAndDevelopmentExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GrossProfit" xlink:to="lbl_CostOfSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:calculationArc order="1.5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_OtherExpenseByFunction" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_RevenueFromSaleOfGoods" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:label="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromDiscontinuedOperations" xlink:to="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromDiscontinuedOperations" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:label="lbl_GainsLossesOnAvailableforsaleFinancialAssets" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_GainsLossesOnAvailableforsaleFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnNetMonetaryPosition" xlink:label="lbl_GainsLossesOnNetMonetaryPosition" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_GainsLossesOnNetMonetaryPosition" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:label="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:type="locator"/>
      <link:calculationArc order="5.5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromInterest" xlink:label="lbl_RevenueFromInterest" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_RevenueFromInterest" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromDividends" xlink:label="lbl_RevenueFromDividends" xlink:type="locator"/>
      <link:calculationArc order="10.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_RevenueFromDividends" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherFinanceCost" xlink:label="lbl_OtherFinanceCost" xlink:type="locator"/>
      <link:calculationArc order="11.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_OtherFinanceCost" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeOnForwardContractsAndOptions" xlink:label="lbl_IncomeOnForwardContractsAndOptions" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_IncomeOnForwardContractsAndOptions" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Borrowings" xlink:to="lbl_BondsIssued" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LiabilitiesToBanksAndOtherInstitutions" xlink:label="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Borrowings" xlink:to="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/StatementsOfCashFlow" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivities" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivities" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="10.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="11.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="12.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="13.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:label="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:calculationArc order="15.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:calculationArc order="2.5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:to="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:label="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:to="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:calculationArc order="14.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivities" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="15.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivities" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:label="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:label="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TransactionCostsRecordedInEquityPaid" xlink:label="lbl_TransactionCostsRecordedInEquityPaid" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_TransactionCostsRecordedInEquityPaid" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:label="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:calculationArc order="10.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="arc"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="arc"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="arc"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/StatementOfComprehensiveIncome" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ComprehensiveIncome" xlink:to="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ComprehensiveIncome" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:calculationArc order="2.8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ComprehensiveIncome" xlink:to="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedPartiesDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="lbl_KeyManagementPersonnelCompensation" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_KeyManagementPersonnelCompensation" xlink:to="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_KeyManagementPersonnelCompensation" xlink:to="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="locator"/>
      <link:calculationArc order="1.5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_KeyManagementPersonnelCompensation" xlink:to="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:label="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OutstandingShareCapital" xlink:label="lbl_OutstandingShareCapital" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OutstandingShareCapital" xlink:to="lbl_IssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="lbl_SaleOrIssueOfTreasuryShares" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OutstandingShareCapitalMovement" xlink:label="lbl_OutstandingShareCapitalMovement" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OutstandingShareCapitalMovement" xlink:to="lbl_SaleOrIssueOfTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IssuedCapitalMovement" xlink:label="lbl_IssuedCapitalMovement" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OutstandingShareCapitalMovement" xlink:to="lbl_IssuedCapitalMovement" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OutstandingShareCapital" xlink:to="lbl_TreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TreasurySharesMovementOfPeriod" xlink:label="lbl_TreasurySharesMovementOfPeriod" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OutstandingShareCapitalMovement" xlink:to="lbl_TreasurySharesMovementOfPeriod" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:label="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:label="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherPostemploymentBenefits" xlink:label="lbl_OtherPostemploymentBenefits" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalRemediationProvisionNoncurrent" xlink:label="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationNonCurrent" xlink:label="lbl_ContingentConsiderationNonCurrent" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="lbl_OtherNoncurrentLiabilities" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:type="arc"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:type="arc"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_OtherPostemploymentBenefits" xlink:type="arc"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="arc"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_ContingentConsiderationNonCurrent" xlink:type="arc"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_OtherNoncurrentLiabilities" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome1" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:label="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:type="arc"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc"/>
      <link:calculationArc order="10.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:calculationArc order="11.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/DisclosureOtherCurrentAssetsDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentPrepaidExpensesAssociatedCompanies" xlink:label="lbl_CurrentPrepaidExpensesAssociatedCompanies" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_CurrentPrepaidExpensesAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentPrepaidExpensesThirdParty" xlink:label="lbl_CurrentPrepaidExpensesThirdParty" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_CurrentPrepaidExpensesThirdParty" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="lbl_CurrentValueAddedTaxReceivables" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_CurrentValueAddedTaxReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherReceivablesAndCurrentAssets" xlink:label="lbl_OtherReceivablesAndCurrentAssets" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_OtherReceivablesAndCurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReceivablesAssociatedCompanies" xlink:label="lbl_ReceivablesAssociatedCompanies" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_ReceivablesAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WithholdingTaxRecoverable" xlink:label="lbl_WithholdingTaxRecoverable" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_WithholdingTaxRecoverable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationReceivableCurrent" xlink:label="lbl_ContingentConsiderationReceivableCurrent" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_ContingentConsiderationReceivableCurrent" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CommitmentsUnderLongtermResearchAgreements" xlink:label="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:label="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:to="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherIntangiblePurchaseCommitments" xlink:label="lbl_OtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:to="lbl_OtherIntangiblePurchaseCommitments" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/DisclosureAcquisitionsOfBusinessesDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IdentifiableAssetsAcquired" xlink:label="lbl_IdentifiableAssetsAcquired" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialAndOtherAssets" xlink:label="lbl_FinancialAndOtherAssets" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_FinancialAndOtherAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="10.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="11.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradePayablesAndOtherLiabilities" xlink:label="lbl_TradePayablesAndOtherLiabilities" xlink:type="locator"/>
      <link:calculationArc order="12.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_TradePayablesAndOtherLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RightOfUseAssetsAsOfAcquisitionDate" xlink:label="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="13.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:label="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="14.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShorttermRestructuringProvision" xlink:label="lbl_ShorttermRestructuringProvision" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_ShorttermRestructuringProvision" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="lbl_AccrualsClassifiedAsCurrent" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_AccrualsClassifiedAsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:label="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentInterestPayable" xlink:label="lbl_CurrentInterestPayable" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_CurrentInterestPayable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RefundsProvision" xlink:label="lbl_RefundsProvision" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_RefundsProvision" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="lbl_ShorttermEmployeeBenefitsAccruals" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_ShorttermEmployeeBenefitsAccruals" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionCurrent" xlink:label="lbl_EnvironmentalProvisionCurrent" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_EnvironmentalProvisionCurrent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredIncomeClassifiedAsCurrent" xlink:label="lbl_DeferredIncomeClassifiedAsCurrent" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_DeferredIncomeClassifiedAsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="locator"/>
      <link:calculationArc order="10.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:label="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="locator"/>
      <link:calculationArc order="11.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationCurrentPortion" xlink:label="lbl_ContingentConsiderationCurrentPortion" xlink:type="locator"/>
      <link:calculationArc order="12.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_ContingentConsiderationCurrentPortion" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CommitmentForRepurchaseOwnShares" xlink:label="lbl_CommitmentForRepurchaseOwnShares" xlink:type="locator"/>
      <link:calculationArc order="13.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_CommitmentForRepurchaseOwnShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentPayables" xlink:label="lbl_OtherCurrentPayables" xlink:type="locator"/>
      <link:calculationArc order="14.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_OtherCurrentPayables" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentRefundsProvision" xlink:label="lbl_CurrentRefundsProvision" xlink:type="locator"/>
      <link:calculationArc order="15.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_CurrentRefundsProvision" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="lbl_NoncurrentFinancialAssets" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:label="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentTradeReceivables" xlink:label="lbl_NoncurrentTradeReceivables" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_NoncurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentFinanceLeaseReceivables" xlink:label="lbl_NoncurrentFinanceLeaseReceivables" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_NoncurrentFinanceLeaseReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationReceivable" xlink:label="lbl_ContingentConsiderationReceivable" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_ContingentConsiderationReceivable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLoansAndReceivables" xlink:label="lbl_NoncurrentLoansAndReceivables" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_NoncurrentLoansAndReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentFinancialAssetsEquityInvestments" xlink:label="lbl_NoncurrentFinancialAssetsEquityInvestments" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:to="lbl_NoncurrentFinancialAssetsEquityInvestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentFinancialAsstetsDebtSecurities" xlink:label="lbl_NoncurrentFinancialAsstetsDebtSecurities" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:to="lbl_NoncurrentFinancialAsstetsDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentFinancialAssetsFundInvestments" xlink:label="lbl_NoncurrentFinancialAssetsFundInvestments" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:to="lbl_NoncurrentFinancialAssetsFundInvestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LongTermReceivablesFromFinanceSubleases" xlink:label="lbl_LongTermReceivablesFromFinanceSubleases" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_LongTermReceivablesFromFinanceSubleases" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentReceivables" xlink:label="lbl_OtherNoncurrentReceivables" xlink:type="locator"/>
      <link:calculationArc order="10.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_OtherNoncurrentReceivables" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/DisclosureMarketableSecuritiesDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="lbl_OtherCurrentFinancialAssets" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MarketableSecurities" xlink:label="lbl_MarketableSecurities" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialAssets" xlink:to="lbl_MarketableSecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_Commodities" xlink:label="lbl_Commodities" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialAssets" xlink:to="lbl_Commodities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:label="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialAssets" xlink:to="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DerivativeFinancialAssets" xlink:label="lbl_DerivativeFinancialAssets" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialAssets" xlink:to="lbl_DerivativeFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestReceivable" xlink:label="lbl_InterestReceivable" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialAssets" xlink:to="lbl_InterestReceivable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DebtInstrumentsHeld" xlink:label="lbl_DebtInstrumentsHeld" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_MarketableSecurities" xlink:to="lbl_DebtInstrumentsHeld" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityInstrumentsHeld" xlink:label="lbl_EquityInstrumentsHeld" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_MarketableSecurities" xlink:to="lbl_EquityInstrumentsHeld" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FundInstrumentsHeld" xlink:label="lbl_FundInstrumentsHeld" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_MarketableSecurities" xlink:to="lbl_FundInstrumentsHeld" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/StatementOfIncomeCalc2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLoss" xlink:to="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLoss" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/StatementOfComprehensiveIncomeCalc2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ComprehensiveIncome" xlink:to="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ComprehensiveIncome" xlink:to="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:label="lbl_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_InterestExpense" xlink:to="lbl_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_InterestExpense" xlink:to="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:label="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_InterestExpense" xlink:to="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20201231/role/StatementsOfCashFlowParenthetical" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="lbl_ProfitLossFromContinuingOperations" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_ProfitLossFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsReceivedClassifiedAsOperatingActivities" xlink:label="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:calculationArc order="10.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:calculationArc order="11.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="arc"/>
   </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>nvs-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails10" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSubsequentEventsDetails2" xlink:href="nvs-20201231.xsd#disclosureSubsequentEventsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSubsequentEventsDetails" xlink:href="nvs-20201231.xsd#disclosureSubsequentEventsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails12" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresDetails12" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails" xlink:href="nvs-20201231.xsd#disclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails2" xlink:href="nvs-20201231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSignificantAccountingPoliciesDetails2" xlink:href="nvs-20201231.xsd#disclosureSignificantAccountingPoliciesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="nvs-20201231.xsd#disclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedPartiesDetails1" xlink:href="nvs-20201231.xsd#disclosureTransactionsWithRelatedPartiesDetails1_1df9063b" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DocumentAndEntityInformation" xlink:href="nvs-20201231.xsd#documentAndEntityInformation" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsTables" xlink:href="nvs-20201231.xsd#disclosureDiscontinuedOperationsTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5" xlink:href="nvs-20201231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails4" xlink:href="nvs-20201231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2" xlink:href="nvs-20201231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails2" xlink:href="nvs-20201231.xsd#disclosureNonCurrentFinancialDebtDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssetsDetails" xlink:href="nvs-20201231.xsd#disclosureGoodwillAndIntangibleAssetsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3" xlink:href="nvs-20201231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSignificantAccountingPoliciesDetails" xlink:href="nvs-20201231.xsd#disclosureSignificantAccountingPoliciesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSignificantTransactionsDetails" xlink:href="nvs-20201231.xsd#disclosureSignificantTransactionsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails7" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresDetails7" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/StatementOfIncome" xlink:href="nvs-20201231.xsd#statementOfIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4" xlink:href="nvs-20201231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3" xlink:href="nvs-20201231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3" xlink:href="nvs-20201231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails4" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureAcquisitionsOfBusinessesDetails" xlink:href="nvs-20201231.xsd#disclosureAcquisitionsOfBusinessesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureCommitmentsAndContingenciesDetails" xlink:href="nvs-20201231.xsd#disclosureCommitmentsAndContingenciesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:href="nvs-20201231.xsd#disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4" xlink:href="nvs-20201231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityDetails2" xlink:href="nvs-20201231.xsd#disclosureEquityDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePropertyPlantAndEquipmentDetails" xlink:href="nvs-20201231.xsd#disclosurePropertyPlantAndEquipmentDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails6" xlink:href="nvs-20201231.xsd#disclosureDiscontinuedOperationsDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails" xlink:href="nvs-20201231.xsd#disclosureDiscontinuedOperationsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails2" xlink:href="nvs-20201231.xsd#disclosureTradeReceivablesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5" xlink:href="nvs-20201231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTaxesDetails3" xlink:href="nvs-20201231.xsd#disclosureTaxesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDisposalGroupHeldForSaleDetails" xlink:href="nvs-20201231.xsd#disclosureDisposalGroupHeldForSaleDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails11" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresDetails11" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails9" xlink:href="nvs-20201231.xsd#disclosureDiscontinuedOperationsDetails9" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails5" xlink:href="nvs-20201231.xsd#disclosureDiscontinuedOperationsDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityDetails" xlink:href="nvs-20201231.xsd#disclosureEquityDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2" xlink:href="nvs-20201231.xsd#disclosureProvisionsAndOtherCurrentLiabilitiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails" xlink:href="nvs-20201231.xsd#disclosureTradeReceivablesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails5" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/StatementOfComprehensiveIncome" xlink:href="nvs-20201231.xsd#statementOfComprehensiveIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/StatementOfChangesInEquity" xlink:href="nvs-20201231.xsd#statementOfChangesInEquity" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails10" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresDetails10" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails8" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresDetails8" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/StatementsOfCashFlow" xlink:href="nvs-20201231.xsd#statementsOfCashFlow" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/BalanceSheet" xlink:href="nvs-20201231.xsd#balanceSheet" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="nvs-20201231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails8" xlink:href="nvs-20201231.xsd#disclosureDiscontinuedOperationsDetails8" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10" xlink:href="nvs-20201231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails10" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5" xlink:href="nvs-20201231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails13" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6" xlink:href="nvs-20201231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails6" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:href="nvs-20201231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSignificantTransactionsDetails2" xlink:href="nvs-20201231.xsd#disclosureSignificantTransactionsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails14" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails4" xlink:href="nvs-20201231.xsd#disclosureDiscontinuedOperationsDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails3" xlink:href="nvs-20201231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6" xlink:href="nvs-20201231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2" xlink:href="nvs-20201231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2" xlink:href="nvs-20201231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails3" xlink:href="nvs-20201231.xsd#disclosureDiscontinuedOperationsDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails2" xlink:href="nvs-20201231.xsd#disclosureDiscontinuedOperationsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails12" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails11" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails9" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails8" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails7" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:href="nvs-20201231.xsd#disclosureCommitmentsAndContingenciesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedPartiesDetails3" xlink:href="nvs-20201231.xsd#disclosureTransactionsWithRelatedPartiesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedPartiesDetails2" xlink:href="nvs-20201231.xsd#disclosureTransactionsWithRelatedPartiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6" xlink:href="nvs-20201231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5" xlink:href="nvs-20201231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2" xlink:href="nvs-20201231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails" xlink:href="nvs-20201231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9" xlink:href="nvs-20201231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails9" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8" xlink:href="nvs-20201231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails8" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7" xlink:href="nvs-20201231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails7" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6" xlink:href="nvs-20201231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5" xlink:href="nvs-20201231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4" xlink:href="nvs-20201231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3" xlink:href="nvs-20201231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails" xlink:href="nvs-20201231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails" xlink:href="nvs-20201231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3" xlink:href="nvs-20201231.xsd#disclosureProvisionsAndOtherCurrentLiabilitiesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:href="nvs-20201231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails5" xlink:href="nvs-20201231.xsd#disclosureNonCurrentFinancialDebtDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails4" xlink:href="nvs-20201231.xsd#disclosureNonCurrentFinancialDebtDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails3" xlink:href="nvs-20201231.xsd#disclosureNonCurrentFinancialDebtDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails5" xlink:href="nvs-20201231.xsd#disclosureTradeReceivablesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails4" xlink:href="nvs-20201231.xsd#disclosureTradeReceivablesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails3" xlink:href="nvs-20201231.xsd#disclosureTradeReceivablesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureInventoriesDetails" xlink:href="nvs-20201231.xsd#disclosureInventoriesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4" xlink:href="nvs-20201231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssetsDetails4" xlink:href="nvs-20201231.xsd#disclosureGoodwillAndIntangibleAssetsDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssetsDetails3" xlink:href="nvs-20201231.xsd#disclosureGoodwillAndIntangibleAssetsDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssetsDetails2" xlink:href="nvs-20201231.xsd#disclosureGoodwillAndIntangibleAssetsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4" xlink:href="nvs-20201231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2" xlink:href="nvs-20201231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEarningsPerShareDetails" xlink:href="nvs-20201231.xsd#disclosureEarningsPerShareDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTaxesDetails2" xlink:href="nvs-20201231.xsd#disclosureTaxesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTaxesDetails" xlink:href="nvs-20201231.xsd#disclosureTaxesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails6" xlink:href="nvs-20201231.xsd#disclosureAssociatedCompaniesDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails5" xlink:href="nvs-20201231.xsd#disclosureAssociatedCompaniesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails4" xlink:href="nvs-20201231.xsd#disclosureAssociatedCompaniesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails3" xlink:href="nvs-20201231.xsd#disclosureAssociatedCompaniesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails2" xlink:href="nvs-20201231.xsd#disclosureAssociatedCompaniesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails" xlink:href="nvs-20201231.xsd#disclosureAssociatedCompaniesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails3" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails2" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails1" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresDetails1" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables" xlink:href="nvs-20201231.xsd#disclosureEquityBasedParticipationPlansForAssociatesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesTables" xlink:href="nvs-20201231.xsd#disclosurePostEmploymentBenefitsForAssociatesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesTables" xlink:href="nvs-20201231.xsd#disclosureAssociatedCompaniesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresTables" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSignificantTransactions" xlink:href="nvs-20201231.xsd#disclosureSignificantTransactions" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="nvs-20201231.xsd#disclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityDetails3" xlink:href="nvs-20201231.xsd#disclosureEquityDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityDetails5" xlink:href="nvs-20201231.xsd#disclosureEquityDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails" xlink:href="nvs-20201231.xsd#disclosureNonCurrentFinancialDebtDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails6" xlink:href="nvs-20201231.xsd#disclosureNonCurrentFinancialDebtDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:href="nvs-20201231.xsd#disclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails3" xlink:href="nvs-20201231.xsd#disclosureFinancialAndOtherNoncurrentAssetsDetails3" xlink:type="simple"/>
   <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
   <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
   <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
   <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
   <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
   <link:definitionLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoryMember" xlink:label="lbl_InventoryMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoryAxis" xlink:label="lbl_InventoryAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_InventoryAxis" xlink:to="lbl_InventoryMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_RangeAxis" xlink:to="lbl_RangesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_AssetsAndLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_YearOfExpiryMember" xlink:label="lbl_YearOfExpiryMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_YearOfExpiryAxis" xlink:label="lbl_YearOfExpiryAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_YearOfExpiryAxis" xlink:to="lbl_YearOfExpiryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BalanceSheetTreatmentMember" xlink:label="lbl_BalanceSheetTreatmentMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BalanceSheetTreatmentAxis" xlink:label="lbl_BalanceSheetTreatmentAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_BalanceSheetTreatmentAxis" xlink:to="lbl_BalanceSheetTreatmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeStatementLocationMember" xlink:label="lbl_IncomeStatementLocationMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeStatementLocationAxis" xlink:label="lbl_IncomeStatementLocationAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_IncomeStatementLocationAxis" xlink:to="lbl_IncomeStatementLocationMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="lbl_ClassesOfShareCapitalMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="lbl_ClassesOfShareCapitalAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfShareCapitalAxis" xlink:to="lbl_ClassesOfShareCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SubsequentEventTypeMember" xlink:label="lbl_SubsequentEventTypeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SubsequentEventTypAxis" xlink:label="lbl_SubsequentEventTypAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_SubsequentEventTypAxis" xlink:to="lbl_SubsequentEventTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueByMeasurementBasisMember" xlink:label="lbl_FairValueByMeasurementBasisMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueByMeasurementBasisAxis" xlink:label="lbl_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_FairValueByMeasurementBasisAxis" xlink:to="lbl_FairValueByMeasurementBasisMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_LevelsOfFairValueHierarchyAxis" xlink:to="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="lbl_EntitysTotalForSubsidiariesMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lbl_EntitysTotalForSubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_OtherProvisionsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PastDueStatusAxis" xlink:label="lbl_PastDueStatusAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_PastDueStatusAxis" xlink:to="lbl_PastDueStatusMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="lbl_DefinedBenefitPlansMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="lbl_DefinedBenefitPlansAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_DefinedBenefitPlansAxis" xlink:to="lbl_DefinedBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ObligationByTypeMember" xlink:label="lbl_ObligationByTypeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ObligationByTypeAxis" xlink:label="lbl_ObligationByTypeAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ObligationByTypeAxis" xlink:to="lbl_ObligationByTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeInActuarialAssumptionMember" xlink:label="lbl_ChangeInActuarialAssumptionMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeInActuarialAssumptionAxis" xlink:label="lbl_ChangeInActuarialAssumptionAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ChangeInActuarialAssumptionAxis" xlink:to="lbl_ChangeInActuarialAssumptionMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="lbl_ActuarialAssumptionsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:label="lbl_ActuarialAssumptionsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ActuarialAssumptionsAxis" xlink:to="lbl_ActuarialAssumptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquisitionsAndDivestmentsMember" xlink:label="lbl_AcquisitionsAndDivestmentsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquisitionsAndDivestmentsAxis" xlink:label="lbl_AcquisitionsAndDivestmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_AcquisitionsAndDivestmentsAxis" xlink:to="lbl_AcquisitionsAndDivestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="lbl_EntitysTotalForBusinessCombinationsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="lbl_BusinessCombinationsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_BusinessCombinationsAxis" xlink:to="lbl_EntitysTotalForBusinessCombinationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PastDueStatusMember" xlink:label="lbl_PastDueStatusMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonvestingMember" xlink:label="lbl_NonvestingMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonvestingAxis" xlink:label="lbl_NonvestingAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_NonvestingAxis" xlink:to="lbl_NonvestingMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorCustomersMember" xlink:label="lbl_MajorCustomersMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="lbl_MajorCustomersAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_MajorCustomersAxis" xlink:to="lbl_MajorCustomersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FranchiseMember" xlink:label="lbl_FranchiseMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FranchiseAxis" xlink:label="lbl_FranchiseAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_FranchiseAxis" xlink:to="lbl_FranchiseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BusinessUnitMember" xlink:label="lbl_BusinessUnitMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BusinessUnitAxis" xlink:label="lbl_BusinessUnitAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_BusinessUnitAxis" xlink:to="lbl_BusinessUnitMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="lbl_FinancialLiabilitiesMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:to="lbl_FinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="lbl_FinancialLiabilitiesCategoryMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lbl_FinancialLiabilitiesCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BalanceSheetItemMember" xlink:label="lbl_BalanceSheetItemMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BalanceSheetItemAxis" xlink:label="lbl_BalanceSheetItemAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_BalanceSheetItemAxis" xlink:to="lbl_BalanceSheetItemMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="lbl_FinancialAssetsCategoryMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="lbl_CategoriesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_CategoriesOfFinancialAssetsAxis" xlink:to="lbl_FinancialAssetsCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsMember" xlink:label="lbl_FinancialAssetsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="lbl_ClassesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfFinancialAssetsAxis" xlink:to="lbl_FinancialAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsPrincipalAmountsMember" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsPrincipalAmountsAxis" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MeasurementAxis" xlink:label="lbl_MeasurementAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_MeasurementAxis" xlink:to="lbl_AggregatedMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="lbl_LiabilitiesMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="lbl_ClassesOfLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfLiabilitiesAxis" xlink:to="lbl_LiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="lbl_AggregatedMeasurementMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactLocationMember" xlink:label="lbl_ImpactLocationMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactLocationAxis" xlink:label="lbl_ImpactLocationAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ImpactLocationAxis" xlink:to="lbl_ImpactLocationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VendorMember" xlink:label="lbl_VendorMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VendorAxis" xlink:label="lbl_VendorAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_VendorAxis" xlink:to="lbl_VendorMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:to="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PlansAndProgramRebatesMember" xlink:label="lbl_PlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PlansAndProgramRebatesAxis" xlink:label="lbl_PlansAndProgramRebatesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_PlansAndProgramRebatesAxis" xlink:to="lbl_PlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis1" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_CurrencyAxis1" xlink:to="lbl_AllCurrenciesDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LitigationCaseMember" xlink:label="lbl_LitigationCaseMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="lbl_LitigationCaseAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_LitigationCaseAxis" xlink:to="lbl_LitigationCaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails3" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" xlink:label="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:label="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShorttermBorrowings" xlink:label="lbl_ShorttermBorrowings" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_ShorttermBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CommercialPapersIssued" xlink:label="lbl_CommercialPapersIssued" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CommercialPapersIssued" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="lbl_DerivativeFinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_OtherCurrentFinancialLiabilities" xlink:type="arc"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_WeightedAverageInterestRateAssociates" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WeightedAverageInterestRateAssociates" xlink:label="lbl_WeightedAverageInterestRateAssociates" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:label="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails6" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" xlink:label="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:label="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:to="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentFinancialDebtsCoveredByCollateral" xlink:label="lbl_NoncurrentFinancialDebtsCoveredByCollateral" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:to="lbl_NoncurrentFinancialDebtsCoveredByCollateral" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:label="lbl_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:to="lbl_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" xlink:label="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:label="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_BondsIssued" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AverageInterestRateOnLoansReceived" xlink:label="lbl_AverageInterestRateOnLoansReceived" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_AverageInterestRateOnLoansReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:label="lbl_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AverageInterestRateOnBorrowings" xlink:label="lbl_AverageInterestRateOnBorrowings" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_AverageInterestRateOnBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LiabilitiesToBanksAndOtherInstitutions" xlink:label="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:type="locator"/>
      <link:definitionArc order="2.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinanceLeaseLiabilities" xlink:label="lbl_FinanceLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_FinanceLeaseLiabilities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="lbl_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="lbl_StatementOfChangesInEquityAbstract1" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract1" xlink:to="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MaximalAmountOfShareBuybackProgramm" xlink:label="lbl_MaximalAmountOfShareBuybackProgramm" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_MaximalAmountOfShareBuybackProgramm" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WrittenCallOptionsHeldByMarketMaker" xlink:label="lbl_WrittenCallOptionsHeldByMarketMaker" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_WrittenCallOptionsHeldByMarketMaker" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WrittenCallOptionsContractualLive" xlink:label="lbl_WrittenCallOptionsContractualLive" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_WrittenCallOptionsContractualLive" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WrittenCallOptionsContractualLiveRemaining" xlink:label="lbl_WrittenCallOptionsContractualLiveRemaining" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_WrittenCallOptionsContractualLiveRemaining" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WrittenCallOptionsWeightedAverageExercisePrice" xlink:label="lbl_WrittenCallOptionsWeightedAverageExercisePrice" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_WrittenCallOptionsWeightedAverageExercisePrice" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountRecordedInEquityRelatedToHyperinflation" xlink:label="lbl_AmountRecordedInEquityRelatedToHyperinflation" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_AmountRecordedInEquityRelatedToHyperinflation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxOnTransactionCostsRecordedInEquity" xlink:label="lbl_TaxOnTransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:definitionArc order="2.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TaxOnTransactionCostsRecordedInEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TransactionCostsRecordedInEquity" xlink:label="lbl_TransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:definitionArc order="2.2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TransactionCostsRecordedInEquity" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DividendsPayableAmountPerShare" xlink:label="lbl_DividendsPayableAmountPerShare" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="lbl_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_DividendsPayableAmountPerShare" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPaid" xlink:label="lbl_DividendsPaid" xlink:type="locator"/>
      <link:definitionArc order="0.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_DividendsPaid" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureSignificantTransactions" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfSignificantTransactionsTextBlock" xlink:label="lbl_DisclosureOfSignificantTransactionsTextBlock" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfSignificantTransactionsTextBlock" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresTables" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="lbl_DisclosureOfOperatingSegmentsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesTables" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:label="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:label="lbl_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PurchasePriceAllocationAssociatesTableTextBlock" xlink:label="lbl_PurchasePriceAllocationAssociatesTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchasePriceAllocationAssociatesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:label="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="lbl_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:label="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:label="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:label="lbl_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:label="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:label="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:label="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ConsumerHealthMember" xlink:label="lbl_ConsumerHealthMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_ConsumerHealthMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfReportableSegments" xlink:label="lbl_NumberOfReportableSegments" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfReportableSegments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfBusinessUnits" xlink:label="lbl_NumberOfBusinessUnits" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfBusinessUnits" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfFranchises" xlink:label="lbl_NumberOfFranchises" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfFranchises" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails1" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_CostOfSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_GrossProfit" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ResearchAndDevelopmentExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdministrativeExpense" xlink:label="lbl_AdministrativeExpense" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherExpenseByFunction" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:label="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="lbl_ProfitLossFromContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:label="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromInterest" xlink:label="lbl_RevenueFromInterest" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromInterest" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="lbl_DepreciationAndAmortisationExpense" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DepreciationAndAmortisationExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:label="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdditionsToRestructuringProvisions" xlink:label="lbl_AdditionsToRestructuringProvisions" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsToRestructuringProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="lbl_RightofuseAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_RightofuseAssetsMember" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails3" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Assets" xlink:label="lbl_Assets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Assets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Liabilities" xlink:label="lbl_Liabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Liabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NetDebt" xlink:label="lbl_NetDebt" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NetDebt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetOperatingAssets" xlink:label="lbl_NetOperatingAssets" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NetOperatingAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="lbl_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdditionsToInvestmentInAssociatedCompanies" xlink:label="lbl_AdditionsToInvestmentInAssociatedCompanies" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsToInvestmentInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:label="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialDebtsAndDerivativeInstruments" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:label="lbl_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="7.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="lbl_AdditionsToRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="7.7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsToRightofuseAssets" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:label="lbl_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails3" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_RangeAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RangeAxis" xlink:to="lbl_RangesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="lbl_TopOfRangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesMember" xlink:to="lbl_TopOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="lbl_ProportionOfOwnershipInterestInAssociate" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ProportionOfOwnershipInterestInAssociate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsReceived" xlink:label="lbl_DividendsReceived" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_DividendsReceived" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished" xlink:label="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContributionOfBusinessToJointVenture" xlink:label="lbl_ContributionOfBusinessToJointVenture" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ContributionOfBusinessToJointVenture" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails4" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AssociatesSummarizedFinancialInformationTable" xlink:label="lbl_AssociatesSummarizedFinancialInformationTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_AssociatesSummarizedFinancialInformationTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_AssociatesSummarizedFinancialInformationTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="lbl_CurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_CurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="lbl_NoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_NoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="lbl_CurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_CurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="lbl_NoncurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_NoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Revenue" xlink:label="lbl_Revenue" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_Revenue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="lbl_OtherComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_OtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ComprehensiveIncome" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails5" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PurchasePriceAllocationAssociatesTable" xlink:label="lbl_PurchasePriceAllocationAssociatesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_PurchasePriceAllocationAssociatesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_PurchasePriceAllocationAssociatesTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ShareOfEstimatedNetAssets" xlink:label="lbl_ShareOfEstimatedNetAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfEstimatedNetAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:label="lbl_AdditionalRecognitionGoodwill" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_AdditionalRecognitionGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" xlink:label="lbl_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" xlink:label="lbl_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails6" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ConsolidatedIncomeStatementEffectsTable" xlink:label="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ShareOfCurrentYearNetIncome" xlink:label="lbl_ShareOfCurrentYearNetIncome" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfCurrentYearNetIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PriorYearAdjustment" xlink:label="lbl_PriorYearAdjustment" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_PriorYearAdjustment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:label="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:label="lbl_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:to="lbl_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:label="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:label="lbl_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:type="locator"/>
      <link:definitionArc order="4.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureTaxesDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_ForeignCountriesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccountingProfit" xlink:label="lbl_AccountingProfit" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AccountingProfit" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:definitionArc order="0.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureTaxesDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_ForeignCountriesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="lbl_CurrentTaxExpenseIncome" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentTaxExpenseIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="lbl_DeferredTaxExpenseIncome" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxExpenseIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxExpenseIncomeDiscontinuingOperations" xlink:label="lbl_TaxExpenseIncomeDiscontinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxExpenseIncomeDiscontinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeTaxExpense" xlink:label="lbl_IncomeTaxExpense" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:definitionArc order="0.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureEarningsPerShareDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EarningsPerShareTable" xlink:label="lbl_EarningsPerShareTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_EarningsPerShareTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EarningsPerShareLineItems" xlink:label="lbl_EarningsPerShareLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_EarningsPerShareTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="lbl_WeightedAverageShares" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_WeightedAverageShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:label="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="lbl_AdjustedWeightedAverageShares" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_AdjustedWeightedAverageShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="lbl_BasicEarningsLossPerShare" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_BasicEarningsLossPerShare" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="lbl_DilutedEarningsLossPerShare" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_DilutedEarningsLossPerShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OptionsExcludedFromTheCalculation" xlink:label="lbl_OptionsExcludedFromTheCalculation" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_OptionsExcludedFromTheCalculation" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LandMember" xlink:label="lbl_LandMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_LandMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BuildingsMember" xlink:label="lbl_BuildingsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_BuildingsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_VehiclesMember" xlink:label="lbl_VehiclesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_VehiclesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherAssetsMember" xlink:label="lbl_OtherAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_OtherAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="lbl_DepreciationRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_DepreciationRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:label="lbl_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LeaseLiabilitiesUndiscounted" xlink:label="lbl_LeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_LeaseLiabilitiesUndiscounted" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MostMaterialLeaseWithLeaseTermExtension" xlink:label="lbl_MostMaterialLeaseWithLeaseTermExtension" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_MostMaterialLeaseWithLeaseTermExtension" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="lbl_CurrentLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_CurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentLeaseLiabilitiesUndiscounted" xlink:label="lbl_CurrentLeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:definitionArc order="2.7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_CurrentLeaseLiabilitiesUndiscounted" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="lbl_NoncurrentLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_NoncurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentLeaseLiabilitiesUndiscounted" xlink:label="lbl_NoncurrentLeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:definitionArc order="2.9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_NoncurrentLeaseLiabilitiesUndiscounted" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssetsDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodwillMember" xlink:label="lbl_GoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_GoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquiredResearchAndDevelopmentMember" xlink:label="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconBrandNameMember" xlink:label="lbl_AlconBrandNameMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AlconBrandNameMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TechnologybasedIntangibleAssetsMember" xlink:label="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_CurrentlyMarketedProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MarketingRelatedIntangibleAssetsMember" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="lbl_OtherIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_OtherIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="lbl_UnallocatedAmountsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_UnallocatedAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="lbl_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssetsDetails3" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="lbl_UnallocatedAmountsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_UnallocatedAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:label="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:label="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssetsDetails4" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="lbl_UnallocatedAmountsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_UnallocatedAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VotrientMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SerelaxinMember" xlink:label="lbl_SerelaxinMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SerelaxinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CyPassMember" xlink:label="lbl_CyPassMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_CyPassMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:to="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodwillMember" xlink:label="lbl_GoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_GoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquiredResearchAndDevelopmentMember" xlink:label="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconBrandNameMember" xlink:label="lbl_AlconBrandNameMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AlconBrandNameMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TechnologybasedIntangibleAssetsMember" xlink:label="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_CurrentlyMarketedProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MarketingRelatedIntangibleAssetsMember" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="lbl_OtherIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_OtherIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:label="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherProductsMember" xlink:label="lbl_OtherProductsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:label="lbl_DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:label="lbl_DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:label="lbl_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionForIncomeTaxesOnUnremittedEarnings" xlink:label="lbl_ProvisionForIncomeTaxesOnUnremittedEarnings" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProvisionForIncomeTaxesOnUnremittedEarnings" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureInventoriesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoryAxis" xlink:label="lbl_InventoryAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoryCurrentTable" xlink:label="lbl_InventoryCurrentTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_InventoryCurrentTable" xlink:to="lbl_InventoryAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoryMember" xlink:label="lbl_InventoryMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_InventoryAxis" xlink:to="lbl_InventoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoryRawMaterialsGrossMember" xlink:label="lbl_InventoryRawMaterialsGrossMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InventoryMember" xlink:to="lbl_InventoryRawMaterialsGrossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoryWorkInProgressGrossMember" xlink:label="lbl_InventoryWorkInProgressGrossMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InventoryMember" xlink:to="lbl_InventoryWorkInProgressGrossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoryFinishedGoodsGrossMember" xlink:label="lbl_InventoryFinishedGoodsGrossMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InventoryMember" xlink:to="lbl_InventoryFinishedGoodsGrossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoryLineItems" xlink:label="lbl_InventoryLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_InventoryCurrentTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_Inventories" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:label="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InventoryWritedown2011" xlink:label="lbl_InventoryWritedown2011" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_InventoryWritedown2011" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReversalOfInventoryWritedown" xlink:label="lbl_ReversalOfInventoryWritedown" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_ReversalOfInventoryWritedown" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails3" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AnalysisOfOverdueAmountsTable" xlink:label="lbl_AnalysisOfOverdueAmountsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionForDoubtfulReceivableMember" xlink:label="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PastDueStatusAxis" xlink:label="lbl_PastDueStatusAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_PastDueStatusAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PastDueStatusMember" xlink:label="lbl_PastDueStatusMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_PastDueStatusAxis" xlink:to="lbl_PastDueStatusMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentMember" xlink:label="lbl_CurrentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_PastDueStatusMember" xlink:to="lbl_CurrentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="lbl_NotLaterThanOneMonthMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentMember" xlink:to="lbl_NotLaterThanOneMonthMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentMember" xlink:to="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:label="lbl_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentMember" xlink:to="lbl_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:label="lbl_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentMember" xlink:to="lbl_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="lbl_LaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentMember" xlink:to="lbl_LaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AnalysisOfOverdueAmountsLineItems" xlink:label="lbl_AnalysisOfOverdueAmountsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_AnalysisOfOverdueAmountsLineItems" xlink:to="lbl_AnalysisOfOverdueAmountsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AnalysisOfOverdueAmountsLineItems" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails4" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:label="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:to="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:to="lbl_CurrencyAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CurrencyAxis" xlink:to="lbl_AllCurrenciesDomain" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_USD" xlink:label="lbl_USD" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_USD" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="lbl_EUR" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_EUR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY" xlink:label="lbl_JPY" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_JPY" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CNY" xlink:label="lbl_CNY" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CNY" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_RUB" xlink:label="lbl_RUB" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_RUB" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_BRL" xlink:label="lbl_BRL" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_BRL" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP" xlink:label="lbl_GBP" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_GBP" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AUD" xlink:label="lbl_AUD" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_AUD" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CHF" xlink:label="lbl_CHF" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CHF" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CAD" xlink:label="lbl_CAD" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CAD" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrencyOthersMember" xlink:label="lbl_CurrencyOthersMember" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CurrencyOthersMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:label="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentTradeReceivablesFromCloselyMonitoredCountries" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountries" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountries" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails3" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:label="lbl_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LaterThanSixYearsMember" xlink:label="lbl_LaterThanSixYearsMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanSixYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="lbl_Borrowings" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails4" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:to="lbl_CurrencyAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CurrencyAxis" xlink:to="lbl_AllCurrenciesDomain" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_USD" xlink:label="lbl_USD" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_USD" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="lbl_EUR" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_EUR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY" xlink:label="lbl_JPY" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_JPY" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CHF" xlink:label="lbl_CHF" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CHF" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrencyOthersMember" xlink:label="lbl_CurrencyOthersMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CurrencyOthersMember" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueByMeasurementBasisAxis" xlink:label="lbl_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_FairValueByMeasurementBasisAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueByMeasurementBasisMember" xlink:label="lbl_FairValueByMeasurementBasisMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_FairValueByMeasurementBasisAxis" xlink:to="lbl_FairValueByMeasurementBasisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CarryingReportedAmountFairValueDisclosureMember" xlink:label="lbl_CarryingReportedAmountFairValueDisclosureMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FairValueByMeasurementBasisMember" xlink:to="lbl_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueDisclosureItemAmountsMember" xlink:label="lbl_FairValueDisclosureItemAmountsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FairValueByMeasurementBasisMember" xlink:to="lbl_FairValueDisclosureItemAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_BondsIssued" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherNoncurrentFinancialDebt" xlink:label="lbl_OtherNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_OtherNoncurrentFinancialDebt" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_Borrowings" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:label="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:label="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherPostemploymentBenefits" xlink:label="lbl_OtherPostemploymentBenefits" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_OtherPostemploymentBenefits" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalRemediationProvisionNoncurrent" xlink:label="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationNonCurrent" xlink:label="lbl_ContingentConsiderationNonCurrent" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ContingentConsiderationNonCurrent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="lbl_OtherNoncurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_OtherNoncurrentLiabilities" xlink:type="arc"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RestructuringProvisionsMovementsTable" xlink:label="lbl_RestructuringProvisionsMovementsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_RestructuringProvisionsMovementsTable" xlink:to="lbl_ClassesOfProvisionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_OtherProvisionsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestructuringProvisionMember" xlink:label="lbl_RestructuringProvisionMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_RestructuringProvisionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PlansAndProgramRebatesMember" xlink:label="lbl_PlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_PlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:label="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:to="lbl_RestructuringProvisionsMovementsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RestructuringProvisionsMovementsRollForward" xlink:label="lbl_RestructuringProvisionsMovementsRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:to="lbl_RestructuringProvisionsMovementsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherProvisions" xlink:label="lbl_OtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_OtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="lbl_AdditionalProvisionsOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_AdditionalProvisionsOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="lbl_ProvisionUsedOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_ProvisionUsedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:label="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="6.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_RestructuringProvisionsMovementsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsImpairedMember" xlink:label="lbl_FinancialAssetsImpairedMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_FinancialAssetsImpairedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:label="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="lbl_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:to="lbl_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:label="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:label="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="lbl_AdjustmentsForSharebasedPayments" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForSharebasedPayments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="lbl_AdjustmentsForFinanceIncomeCost" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:label="lbl_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="lbl_RightofuseAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_RightofuseAssetsMember" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="lbl_DefinedBenefitPlansAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_DefinedBenefitPlansAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="lbl_DefinedBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_DefinedBenefitPlansAxis" xlink:to="lbl_DefinedBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_ForeignCountriesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ConcentrationOfMajorPlansGeographic" xlink:label="lbl_ConcentrationOfMajorPlansGeographic" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ConcentrationOfMajorPlansGeographic" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements" xlink:label="lbl_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MajorPlansPercentageInGroupDBOPensions" xlink:label="lbl_MajorPlansPercentageInGroupDBOPensions" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_MajorPlansPercentageInGroupDBOPensions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:label="lbl_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:label="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:label="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:label="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:label="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeInLimitationOnRecognitionOfFundSurplus" xlink:label="lbl_ChangeInLimitationOnRecognitionOfFundSurplus" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_ChangeInLimitationOnRecognitionOfFundSurplus" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:label="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PrepaidPostemploymentBenefitPlansAssets" xlink:label="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:to="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:label="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:to="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReimbursmentsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReimbursmentsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="8.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_ReimbursmentsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_ForeignCountriesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ObligationByTypeAxis" xlink:label="lbl_ObligationByTypeAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_ObligationByTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ObligationByTypeMember" xlink:label="lbl_ObligationByTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ObligationByTypeAxis" xlink:to="lbl_ObligationByTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UnfundedMember" xlink:label="lbl_UnfundedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_UnfundedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ActiveMember" xlink:label="lbl_ActiveMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_ActiveMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DeferredPensionersMember" xlink:label="lbl_DeferredPensionersMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_DeferredPensionersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PensionersMember" xlink:label="lbl_PensionersMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_PensionersMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="lbl_PlanAssetsAtFairValue" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_PlanAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="lbl_SurplusDeficitInPlan" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_SurplusDeficitInPlan" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:label="lbl_ActuarialAssumptionOfDiscountRates" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ActuarialAssumptionOfDiscountRates" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitAssumptionLifeExpectancyMale" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyMale" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitAssumptionLifeExpectancyMale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:label="lbl_ActuarialAssumptionsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:label="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="lbl_ActuarialAssumptionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="lbl_ActuarialAssumptionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ActuarialAssumptionsAxis" xlink:to="lbl_ActuarialAssumptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:label="lbl_ActuarialAssumptionOfDiscountRatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_ActuarialAssumptionOfDiscountRatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LifeExpectancyMember" xlink:label="lbl_LifeExpectancyMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_LifeExpectancyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeInActuarialAssumptionAxis" xlink:label="lbl_ChangeInActuarialAssumptionAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="lbl_ChangeInActuarialAssumptionAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeInActuarialAssumptionMember" xlink:label="lbl_ChangeInActuarialAssumptionMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeInActuarialAssumptionAxis" xlink:to="lbl_ChangeInActuarialAssumptionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_Increase25BasisPointMember" xlink:label="lbl_Increase25BasisPointMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_Increase25BasisPointMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_Decrease25BasisPointMember" xlink:label="lbl_Decrease25BasisPointMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_Decrease25BasisPointMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_Change25BasisPointMember" xlink:label="lbl_Change25BasisPointMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_Change25BasisPointMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_Increase1YearMember" xlink:label="lbl_Increase1YearMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_Increase1YearMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:label="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:label="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:label="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfHealthCareCostTrendRatesTable" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:label="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfAllocationOfPlanAssetsTable" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityInvestmentsMember" xlink:label="lbl_EquityInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_EquityInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DebtSecuritiesMember" xlink:label="lbl_DebtSecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_DebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RealEstateMember" xlink:label="lbl_RealEstateMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_RealEstateMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlternativeInvestmentsMember" xlink:label="lbl_AlternativeInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_AlternativeInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashAndOtherInvestmentsMember" xlink:label="lbl_CashAndOtherInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_CashAndOtherInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:label="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:label="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanPlanAssetAllocations" xlink:label="lbl_DefinedBenefitPlanPlanAssetAllocations" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanPlanAssetAllocations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EmployerSharesHeldByDefinedBenefitPlan" xlink:label="lbl_EmployerSharesHeldByDefinedBenefitPlan" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_EmployerSharesHeldByDefinedBenefitPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:label="lbl_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:label="lbl_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfExpectedBenefitPaymentsTable" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:label="lbl_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:to="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:to="lbl_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:label="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationAnnualIncentivePlanMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentivePlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentivePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:label="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationUKShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationUKShareSavingsPlanMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationUKShareSavingsPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationLongTermPerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePlanMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermPerformancePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationOtherShareAwardsMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationRestrictedSharesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:to="lbl_EquityBasedParticipationRestrictedSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationSpecialShareAwardsMember" xlink:label="lbl_EquityBasedParticipationSpecialShareAwardsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:to="lbl_EquityBasedParticipationSpecialShareAwardsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_RangeAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RangeAxis" xlink:to="lbl_RangesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="lbl_BottomOfRangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesMember" xlink:to="lbl_BottomOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="lbl_TopOfRangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesMember" xlink:to="lbl_TopOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:label="lbl_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAnnualIncentive" xlink:label="lbl_DescriptionOfAnnualIncentive" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_DescriptionOfAnnualIncentive" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonvestingAxis" xlink:label="lbl_NonvestingAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:to="lbl_NonvestingAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonvestingMember" xlink:label="lbl_NonvestingMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_NonvestingAxis" xlink:to="lbl_NonvestingMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonvestedSharesGrantedMember" xlink:label="lbl_NonvestedSharesGrantedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NonvestingMember" xlink:to="lbl_NonvestedSharesGrantedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationAnnualIncentivePlanMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentivePlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentivePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationLongTermPerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePlanMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermPerformancePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationOtherShareAwardsMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="1.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="3.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="5.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="7.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:label="lbl_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:to="lbl_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:label="lbl_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:to="lbl_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="lbl_NumberOfOutstandingShareOptions" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedPartiesDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonExecutiveDirectorMember" xlink:label="lbl_NonExecutiveDirectorMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_NonExecutiveDirectorMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="lbl_KeyManagementPersonnelCompensation" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensation" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedPartiesDetails3" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProfDrBrodyMember" xlink:label="lbl_ProfDrBrodyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_ProfDrBrodyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProfDrZinkernagelMember" xlink:label="lbl_ProfDrZinkernagelMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_ProfDrZinkernagelMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DrAlexKrauerMember" xlink:label="lbl_DrAlexKrauerMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_DrAlexKrauerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DrDanielVasellaMember" xlink:label="lbl_DrDanielVasellaMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_DrDanielVasellaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DrJamesBradnerMember" xlink:label="lbl_DrJamesBradnerMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_DrJamesBradnerMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPensionFundMember" xlink:label="lbl_NovartisPensionFundMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NovartisPensionFundMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="lbl_KeyManagementPersonnelCompensation" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KeyManagementPersonnelCompensationDailyRate" xlink:label="lbl_KeyManagementPersonnelCompensationDailyRate" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationDailyRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:label="lbl_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KeyManagementPersonnelCompensationSharesAcquired" xlink:label="lbl_KeyManagementPersonnelCompensationSharesAcquired" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationSharesAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:label="lbl_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:label="lbl_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsCreditFacilityUncommitted" xlink:label="lbl_BorrowingsCreditFacilityUncommitted" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_BorrowingsCreditFacilityUncommitted" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:label="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:label="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CommitmentsUnderLongtermResearchAgreements" xlink:label="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherIntangiblePurchaseCommitments" xlink:label="lbl_OtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_OtherIntangiblePurchaseCommitments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:label="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:label="lbl_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:type="locator"/>
      <link:definitionArc order="1.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MeasurementAxis" xlink:label="lbl_MeasurementAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_MeasurementAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="lbl_AggregatedMeasurementMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MeasurementAxis" xlink:to="lbl_AggregatedMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RecurringFairValueMeasurementMember" xlink:label="lbl_RecurringFairValueMeasurementMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedMeasurementMember" xlink:to="lbl_RecurringFairValueMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_LevelsOfFairValueHierarchyAxis" xlink:to="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="lbl_Level1OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level1OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="lbl_Level2OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level2OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="lbl_Level3OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level3OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ValuedAtAmortizedCostMember" xlink:label="lbl_ValuedAtAmortizedCostMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_ValuedAtAmortizedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:label="lbl_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:label="lbl_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:label="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationReceivablesShorttermMember" xlink:label="lbl_ContingentConsiderationReceivablesShorttermMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_ContingentConsiderationReceivablesShorttermMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DebtSecuritiesMember" xlink:label="lbl_DebtSecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_DebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquitySecuritiesMember" xlink:label="lbl_EquitySecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_EquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FundInvestmentsMember" xlink:label="lbl_FundInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_FundInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TotalAvailableforsaleMarketableSecuritiesMember" xlink:label="lbl_TotalAvailableforsaleMarketableSecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_TotalAvailableforsaleMarketableSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:label="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:label="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AvailableforsaleFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationReceivablesMember" xlink:label="lbl_ContingentConsiderationReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_ContingentConsiderationReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:label="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="lbl_FinancialAssetsAtFairValue" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="lbl_FinancialAssetsAtFairValue" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MeasurementAxis" xlink:label="lbl_MeasurementAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_MeasurementAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="lbl_AggregatedMeasurementMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MeasurementAxis" xlink:to="lbl_AggregatedMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RecurringFairValueMeasurementMember" xlink:label="lbl_RecurringFairValueMeasurementMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedMeasurementMember" xlink:to="lbl_RecurringFairValueMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_LevelsOfFairValueHierarchyAxis" xlink:to="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="lbl_Level1OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level1OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="lbl_Level2OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level2OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="lbl_Level3OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level3OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ValuedAtAmortizedCostMember" xlink:label="lbl_ValuedAtAmortizedCostMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_ValuedAtAmortizedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="lbl_ClassesOfLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_ClassesOfLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="lbl_LiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfLiabilitiesAxis" xlink:to="lbl_LiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationPayablesMember" xlink:label="lbl_ContingentConsiderationPayablesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_ContingentConsiderationPayablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherFinancialLiabilitiesMember" xlink:label="lbl_OtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_OtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="lbl_FinancialLiabilitiesAtFairValue" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_FinancialLiabilitiesAtFairValue" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:label="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:label="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FundInvestmentsMember" xlink:label="lbl_FundInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FundInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AvailableforsaleFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LongTermFinancialInvestmentsMember" xlink:label="lbl_LongTermFinancialInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_LongTermFinancialInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationReceivablesMember" xlink:label="lbl_ContingentConsiderationReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_ContingentConsiderationReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationPayablesMember" xlink:label="lbl_ContingentConsiderationPayablesMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_ContingentConsiderationPayablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherFinancialLiabilitiesMember" xlink:label="lbl_OtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_OtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:to="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsCarryingValueLevel3" xlink:label="lbl_FinancialInstrumentsCarryingValueLevel3" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FinancialInstrumentsCarryingValueLevel3" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:label="lbl_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:label="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:label="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PurchaseFairValueMeasurementAssets" xlink:label="lbl_PurchaseFairValueMeasurementAssets" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_PurchaseFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:label="lbl_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisposalsFairValueMeasurementAssets" xlink:label="lbl_DisposalsFairValueMeasurementAssets" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DisposalsFairValueMeasurementAssets" xlink:type="arc"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReclassificationFairValueMeasurementAssets" xlink:label="lbl_ReclassificationFairValueMeasurementAssets" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_ReclassificationFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:label="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:label="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="lbl_NotLaterThanOneMonthMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneMonthMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:label="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MarketableSecuritiesAndTimeDepositsMember" xlink:label="lbl_MarketableSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_MarketableSecuritiesAndTimeDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CommoditiesMember" xlink:label="lbl_CommoditiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CommoditiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:label="lbl_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashAndCashEquivalentsMember" xlink:label="lbl_CashAndCashEquivalentsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CashAndCashEquivalentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialDebtMember" xlink:label="lbl_FinancialDebtMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FinancialDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialDebtUndiscountedMember" xlink:label="lbl_FinancialDebtUndiscountedMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FinancialDebtUndiscountedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MaturityOfNetDebtLineItems" xlink:label="lbl_MaturityOfNetDebtLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:label="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_OtherCurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NetDebt" xlink:label="lbl_NetDebt" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_NetDebt" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="lbl_NotLaterThanOneMonthMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneMonthMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:label="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:label="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:label="lbl_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TenDayLossFairValueVARModelTable" xlink:label="lbl_TenDayLossFairValueVARModelTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_TenDayLossFairValueVARModelTable" xlink:to="lbl_RangeAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RangeAxis" xlink:to="lbl_RangesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageMember" xlink:label="lbl_WeightedAverageMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesMember" xlink:to="lbl_WeightedAverageMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="lbl_TopOfRangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesMember" xlink:to="lbl_TopOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="lbl_BottomOfRangeMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesMember" xlink:to="lbl_BottomOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WorstCaseLossScenarioMember" xlink:label="lbl_WorstCaseLossScenarioMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesMember" xlink:to="lbl_WorstCaseLossScenarioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TenDayLossFairValueVARModelLineItems" xlink:label="lbl_TenDayLossFairValueVARModelLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_TenDayLossFairValueVARModelTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsValueAtRiskComputation" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputation" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VendorAxis" xlink:label="lbl_VendorAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:label="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:to="lbl_VendorAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VendorMember" xlink:label="lbl_VendorMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_VendorAxis" xlink:to="lbl_VendorMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LargestFinancialInstitutionMember" xlink:label="lbl_LargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_VendorMember" xlink:to="lbl_LargestFinancialInstitutionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SecondLargestFinancialInstitutionMember" xlink:label="lbl_SecondLargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_VendorMember" xlink:to="lbl_SecondLargestFinancialInstitutionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ThirdLargestFinancialInstitutionMember" xlink:label="lbl_ThirdLargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_VendorMember" xlink:to="lbl_ThirdLargestFinancialInstitutionMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:to="lbl_BorrowingsByNameAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_USCommercialPaperProgramsMember" xlink:label="lbl_USCommercialPaperProgramsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_USCommercialPaperProgramsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_JPCommercialPaperProgramsMember" xlink:label="lbl_JPCommercialPaperProgramsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_JPCommercialPaperProgramsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OpenHedgesForAnticipatedTransactions" xlink:label="lbl_OpenHedgesForAnticipatedTransactions" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_OpenHedgesForAnticipatedTransactions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:type="arc"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MostSignificantForeignExchangeLosses" xlink:label="lbl_MostSignificantForeignExchangeLosses" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_MostSignificantForeignExchangeLosses" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LongtermFinancialDebtWithACarryingAmount" xlink:label="lbl_LongtermFinancialDebtWithACarryingAmount" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_LongtermFinancialDebtWithACarryingAmount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:label="lbl_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MaximumHoldingInUnrelatedCompany" xlink:label="lbl_MaximumHoldingInUnrelatedCompany" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_MaximumHoldingInUnrelatedCompany" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:label="lbl_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:label="lbl_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:label="lbl_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:label="lbl_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:label="lbl_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:label="lbl_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsCommercialPaperNumberOfPrograms" xlink:label="lbl_BorrowingsCommercialPaperNumberOfPrograms" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCommercialPaperNumberOfPrograms" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsCreditFacilityCommitted" xlink:label="lbl_BorrowingsCreditFacilityCommitted" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCreditFacilityCommitted" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DebtEquityRatio" xlink:label="lbl_DebtEquityRatio" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DebtEquityRatio" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VAREstimateConfidenceInterval" xlink:label="lbl_VAREstimateConfidenceInterval" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_VAREstimateConfidenceInterval" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:label="lbl_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CounterpartyRiskAbstract" xlink:label="lbl_CounterpartyRiskAbstract" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CounterpartyRiskAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:label="lbl_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CounterpartyRiskAbstract" xlink:to="lbl_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsCreditFacilityShortTerm" xlink:label="lbl_BorrowingsCreditFacilityShortTerm" xlink:type="locator"/>
      <link:definitionArc order="18.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCreditFacilityShortTerm" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountBorrowedUnderTheCreditFacility" xlink:label="lbl_AmountBorrowedUnderTheCreditFacility" xlink:type="locator"/>
      <link:definitionArc order="18.7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_AmountBorrowedUnderTheCreditFacility" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueOfOtherFinancialAssetsSold" xlink:label="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="locator"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromInterest" xlink:label="lbl_RevenueFromInterest" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromInterest" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="lbl_DepreciationAndAmortisationExpense" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DepreciationAndAmortisationExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:label="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdditionsToRestructuringProvisions" xlink:label="lbl_AdditionsToRestructuringProvisions" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdditionsToRestructuringProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="lbl_RightofuseAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_RightofuseAssetsMember" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails3" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Goodwill" xlink:label="lbl_Goodwill" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_Goodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialAndOtherNoncurrentAssets" xlink:label="lbl_FinancialAndOtherNoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinancialAndOtherNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_Inventories" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradeReceivablesAndOtherCurrentAssets" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentAndNoncurrentFinancialDebt" xlink:label="lbl_CurrentAndNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentAndNoncurrentFinancialDebt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradePayablesProvisionsAndOtherLiabilities" xlink:label="lbl_TradePayablesProvisionsAndOtherLiabilities" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TradePayablesProvisionsAndOtherLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetAssetsDerecognized" xlink:label="lbl_NetAssetsDerecognized" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetAssetsDerecognized" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionRollForward" xlink:label="lbl_EnvironmentalProvisionRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvision" xlink:label="lbl_EnvironmentalProvision" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvision" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionPayments" xlink:label="lbl_EnvironmentalProvisionPayments" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionPayments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionReleases" xlink:label="lbl_EnvironmentalProvisionReleases" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionReleases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionAdditions" xlink:label="lbl_EnvironmentalProvisionAdditions" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionAdditions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:label="lbl_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionCurrent" xlink:label="lbl_EnvironmentalProvisionCurrent" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalRemediationProvisionNoncurrent" xlink:label="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefund" xlink:label="lbl_IncomeTaxesPaidRefund" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefund" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:label="lbl_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:label="lbl_OtherAdjustmentsToReconcileProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherAdjustmentsToReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_LegalEntityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GSKConsumerHealthcareMember" xlink:label="lbl_GSKConsumerHealthcareMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKConsumerHealthcareMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromSalesOfInterestsInAssociates" xlink:label="lbl_ProceedsFromSalesOfInterestsInAssociates" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfInterestsInAssociates" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails4" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DivestedCashAndCashEquivalents" xlink:label="lbl_DivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DivestedCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashFlowsAttributableToDivestedBusiness" xlink:label="lbl_CashFlowsAttributableToDivestedBusiness" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsAttributableToDivestedBusiness" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:to="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ListedEquitySecuritiesMember" xlink:label="lbl_ListedEquitySecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lbl_ListedEquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonlistedEquitySecuritiesMember" xlink:label="lbl_NonlistedEquitySecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lbl_NonlistedEquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TotalFairValueAdjustmentsMember" xlink:label="lbl_TotalFairValueAdjustmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalFairValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:label="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:type="arc"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GainLossOnSaleOfOtherFinancialAssets" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueOfOtherFinancialAssetsSold" xlink:label="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="locator"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureSignificantTransactionsDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetAssetsDerecognized" xlink:label="lbl_NetAssetsDerecognized" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NetAssetsDerecognized" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPayable" xlink:label="lbl_DividendsPayable" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DividendsPayable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DistributionOfDividendToDividendBearingShares" xlink:label="lbl_DistributionOfDividendToDividendBearingShares" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DistributionOfDividendToDividendBearingShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TransactionCosts" xlink:label="lbl_TransactionCosts" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TransactionCosts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails6" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="lbl_MajorCustomersAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMajorCustomersTable" xlink:label="lbl_DisclosureOfMajorCustomersTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfMajorCustomersTable" xlink:to="lbl_MajorCustomersAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorCustomersMember" xlink:label="lbl_MajorCustomersMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MajorCustomersAxis" xlink:to="lbl_MajorCustomersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LargestCustomerMember" xlink:label="lbl_LargestCustomerMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_LargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SecondLargestCustomerMember" xlink:label="lbl_SecondLargestCustomerMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_SecondLargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ThirdLargestCustomerMember" xlink:label="lbl_ThirdLargestCustomerMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_ThirdLargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:label="lbl_DisclosureOfMajorCustomersLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_DisclosureOfMajorCustomersTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="lbl_PercentageOfEntitysRevenue" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfEntitysRevenue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PercentageOfEntitysTradeReceivable" xlink:label="lbl_PercentageOfEntitysTradeReceivable" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfEntitysTradeReceivable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CustomersWithNetSalesOverFivePercent" xlink:label="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RealEstateMember" xlink:label="lbl_RealEstateMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lbl_RealEstateMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SaleAndLeaseBackMember" xlink:label="lbl_SaleAndLeaseBackMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lbl_SaleAndLeaseBackMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashInflowForLeases" xlink:label="lbl_CashInflowForLeases" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashInflowForLeases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashInflowForSaleAndLeaseback" xlink:label="lbl_CashInflowForSaleAndLeaseback" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashInflowForSaleAndLeaseback" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:label="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:label="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:to="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsPrincipalAmountsAxis" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsPrincipalAmountsMember" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContractOrUnderlyingPrincipalAmoutMember" xlink:label="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PositiveFairValuesMember" xlink:label="lbl_PositiveFairValuesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_PositiveFairValuesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NegativeFairValuesMember" xlink:label="lbl_NegativeFairValuesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_NegativeFairValuesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:label="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:label="lbl_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:label="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:label="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstruments" xlink:label="lbl_DerivativeFinancialInstruments" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstruments" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:label="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:to="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsPrincipalAmountsAxis" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsPrincipalAmountsMember" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContractOrUnderlyingPrincipalAmoutMember" xlink:label="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:label="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:label="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:label="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstruments" xlink:label="lbl_DerivativeFinancialInstruments" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_CurrencyAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CurrencyAxis" xlink:to="lbl_AllCurrenciesDomain" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="lbl_EUR" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_EUR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_USD" xlink:label="lbl_USD" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_USD" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY" xlink:label="lbl_JPY" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_JPY" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrencyOthersMember" xlink:label="lbl_CurrencyOthersMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CurrencyOthersMember" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="lbl_MajorCustomersAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMajorCustomersTable" xlink:label="lbl_DisclosureOfMajorCustomersTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfMajorCustomersTable" xlink:to="lbl_MajorCustomersAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorCustomersMember" xlink:label="lbl_MajorCustomersMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MajorCustomersAxis" xlink:to="lbl_MajorCustomersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LargestCustomerMember" xlink:label="lbl_LargestCustomerMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_LargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SecondLargestCustomerMember" xlink:label="lbl_SecondLargestCustomerMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_SecondLargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ThirdLargestCustomerMember" xlink:label="lbl_ThirdLargestCustomerMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_ThirdLargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:label="lbl_DisclosureOfMajorCustomersLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_DisclosureOfMajorCustomersTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="lbl_PercentageOfEntitysRevenue" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfEntitysRevenue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PercentageOfEntitysTradeReceivable" xlink:label="lbl_PercentageOfEntitysTradeReceivable" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfEntitysTradeReceivable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CustomersWithNetSalesOverFivePercent" xlink:label="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactLocationAxis" xlink:label="lbl_ImpactLocationAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ImpactLocationAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactLocationMember" xlink:label="lbl_ImpactLocationMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ImpactLocationAxis" xlink:to="lbl_ImpactLocationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeStatementMember" xlink:label="lbl_IncomeStatementMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ImpactLocationMember" xlink:to="lbl_IncomeStatementMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ImpactLocationMember" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:label="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:label="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:label="lbl_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:label="lbl_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:label="lbl_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:label="lbl_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:to="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="lbl_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:to="lbl_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails8" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:to="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="lbl_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:to="lbl_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_AssetsAndLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_AssetsAndLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:label="lbl_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoriesMember" xlink:label="lbl_InventoriesMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_InventoriesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxLossCarryforwardsMember" xlink:label="lbl_TaxLossCarryforwardsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_TaxLossCarryforwardsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherAssetsProvisionsAccrualsMember" xlink:label="lbl_OtherAssetsProvisionsAccrualsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_OtherAssetsProvisionsAccrualsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GrossDeferredTaxAssets" xlink:label="lbl_GrossDeferredTaxAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossDeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GrossDeferredTaxLiabilities" xlink:label="lbl_GrossDeferredTaxLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossDeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="lbl_DeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MovementInDeferredTaxBalanceRollForward" xlink:label="lbl_MovementInDeferredTaxBalanceRollForward" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_MovementInDeferredTaxBalanceRollForward" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:label="lbl_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/BalanceSheet" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="lbl_AssetsAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AssetsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="lbl_NoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_NoncurrentAssetsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Goodwill" xlink:label="lbl_Goodwill" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_Goodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="lbl_NoncurrentFinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_NoncurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_OtherNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="lbl_NoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_NoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="lbl_CurrentAssetsAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_CurrentAssetsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_Inventories" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentTaxAssetsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="lbl_OtherCurrentFinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_OtherCurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_OtherCurrentNonfinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="lbl_CurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Assets" xlink:label="lbl_Assets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_Assets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="lbl_EquityAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EquityAndLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="lbl_EquityAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_EquityAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_IssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_TreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherReserves" xlink:label="lbl_OtherReserves" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_OtherReserves" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="lbl_EquityAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_EquityAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncontrollingInterests" xlink:label="lbl_NoncontrollingInterests" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_NoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="lbl_LiabilitiesAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_LiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="lbl_NoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_NoncurrentLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="lbl_NoncurrentLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_NoncurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="lbl_NoncurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_NoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="lbl_CurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_CurrentLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_OtherCurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="lbl_CurrentLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="lbl_CurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Liabilities" xlink:label="lbl_Liabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_Liabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="lbl_EquityAndLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_EquityAndLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="lbl_CurrentTaxAssetsCurrent" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/StatementsOfCashFlow" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_YoYChangeMember" xlink:label="lbl_YoYChangeMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_YoYChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="lbl_ProfitLossFromContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsReceivedClassifiedAsOperatingActivities" xlink:label="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:label="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:label="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:label="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="30.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="locator"/>
      <link:definitionArc order="31.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:label="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="locator"/>
      <link:definitionArc order="32.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="33.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="34.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="35.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="36.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:label="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="locator"/>
      <link:definitionArc order="37.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="38.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="39.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="40.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="41.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="locator"/>
      <link:definitionArc order="42.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="44.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="45.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="46.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails8" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FranchiseAxis" xlink:label="lbl_FranchiseAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_FranchiseAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FranchiseMember" xlink:label="lbl_FranchiseMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_FranchiseAxis" xlink:to="lbl_FranchiseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetailGenericsMember" xlink:label="lbl_RetailGenericsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_RetailGenericsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BiopharmaceuticalsMember" xlink:label="lbl_BiopharmaceuticalsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_BiopharmaceuticalsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AntiInfectivesMember" xlink:label="lbl_AntiInfectivesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_AntiInfectivesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductPortfolioAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AntiInfectivesSoldUnderSandozNameMember" xlink:label="lbl_AntiInfectivesSoldUnderSandozNameMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_AntiInfectivesSoldUnderSandozNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails10" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProfitSharingIncome" xlink:label="lbl_ProfitSharingIncome" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitSharingIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromRoyalties" xlink:label="lbl_RevenueFromRoyalties" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromRoyalties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MilestoneIncome" xlink:label="lbl_MilestoneIncome" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_MilestoneIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherRevenueOther" xlink:label="lbl_OtherRevenueOther" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherRevenueOther" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/StatementOfChangesInEquity" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="lbl_StatementOfChangesInEquityTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementOfChangesInEquityTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="lbl_IssuedCapitalMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_IssuedCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TreasurySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="lbl_RetainedEarningsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_RetainedEarningsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="lbl_NoncontrollingInterestsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_NoncontrollingInterestsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementOfChangesInEquityTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RestatedValueAdjustmentsMember" xlink:label="lbl_RestatedValueAdjustmentsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_RestatedValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="lbl_StatementOfChangesInEquityLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_StatementOfChangesInEquityTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="lbl_OtherComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPaid" xlink:label="lbl_DividendsPaid" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_DividendsPaid" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DividendPaidNoncashAssetsDistribution" xlink:label="lbl_DividendPaidNoncashAssetsDistribution" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_DividendPaidNoncashAssetsDistribution" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="lbl_PurchaseOfTreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_PurchaseOfTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReductionOfIssuedCapital" xlink:label="lbl_ReductionOfIssuedCapital" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ReductionOfIssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherShareSales" xlink:label="lbl_OtherShareSales" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherShareSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxesOnTreasuryShares" xlink:label="lbl_TaxesOnTreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_TaxesOnTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TransactionCostsRecordedInEquity" xlink:label="lbl_TransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_TransactionCostsRecordedInEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsOnFinancialAssetsSold" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeMaketableSecurities" xlink:label="lbl_OtherComprehensiveIncomeMaketableSecurities" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherComprehensiveIncomeMaketableSecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:label="lbl_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseInNoncontrolingInterests" xlink:label="lbl_IncreaseDecreaseInNoncontrolingInterests" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseInNoncontrolingInterests" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsRelatedToDivestments" xlink:label="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ChangesInEquity" xlink:label="lbl_ChangesInEquity" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ChangesInEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:label="lbl_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RepurchaseOfOptions" xlink:label="lbl_RepurchaseOfOptions" xlink:type="locator"/>
      <link:definitionArc order="9.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_RepurchaseOfOptions" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/StatementOfComprehensiveIncome" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:to="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:to="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails5" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:label="lbl_EuropeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EuropeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AmericasMember" xlink:label="lbl_AmericasMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_AmericasMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AsiaAfricaAustralasiaMember" xlink:label="lbl_AsiaAfricaAustralasiaMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_AsiaAfricaAustralasiaMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SelectedNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixTable" xlink:label="lbl_DisclosureOfProvisionMatrixTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionForDoubtfulReceivableMember" xlink:label="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_DisclosureOfProvisionMatrixTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionForDoubtfulReceivable" xlink:label="lbl_ProvisionForDoubtfulReceivable" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_ProvisionForDoubtfulReceivable" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionForDeductionFromRevenueTable" xlink:label="lbl_ProvisionForDeductionFromRevenueTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ProvisionForDeductionFromRevenueTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PlansAndProgramRebatesAxis" xlink:label="lbl_PlansAndProgramRebatesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ProvisionForDeductionFromRevenueTable" xlink:to="lbl_PlansAndProgramRebatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PlansAndProgramRebatesMember" xlink:label="lbl_PlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_PlansAndProgramRebatesAxis" xlink:to="lbl_PlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_USspecificHealthcarePlansAndProgramRebatesMember" xlink:label="lbl_USspecificHealthcarePlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_PlansAndProgramRebatesMember" xlink:to="lbl_USspecificHealthcarePlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:label="lbl_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_PlansAndProgramRebatesMember" xlink:to="lbl_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:label="lbl_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_PlansAndProgramRebatesMember" xlink:to="lbl_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:label="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:to="lbl_ProvisionForDeductionFromRevenueTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionsForDeductionsFromRevenueRollForward" xlink:label="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:to="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentRefundsProvision" xlink:label="lbl_CurrentRefundsProvision" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_CurrentRefundsProvision" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentRefundsProvisionDiscontinuedOperations" xlink:label="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="lbl_ProvisionUsedOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_ProvisionUsedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeStatementAdjustmentsOfPriorYear" xlink:label="lbl_IncomeStatementAdjustmentsOfPriorYear" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_IncomeStatementAdjustmentsOfPriorYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeStatementAdjustmentsOfCurrentYear" xlink:label="lbl_IncomeStatementAdjustmentsOfCurrentYear" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_IncomeStatementAdjustmentsOfCurrentYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangesInOffsetAgainstGrossTradeReceivables" xlink:label="lbl_ChangesInOffsetAgainstGrossTradeReceivables" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_ChangesInOffsetAgainstGrossTradeReceivables" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_IssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OutstandingShareCapital" xlink:label="lbl_OutstandingShareCapital" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_OutstandingShareCapital" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IssuedCapitalMovement" xlink:label="lbl_IssuedCapitalMovement" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_IssuedCapitalMovement" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="lbl_SaleOrIssueOfTreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_SaleOrIssueOfTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TreasurySharesMovementOfPeriod" xlink:label="lbl_TreasurySharesMovementOfPeriod" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesMovementOfPeriod" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OutstandingShareCapitalMovement" xlink:label="lbl_OutstandingShareCapitalMovement" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_OutstandingShareCapitalMovement" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails5" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UndiscountedFinanceLeasePaymentsToBeReceived" xlink:label="lbl_UndiscountedFinanceLeasePaymentsToBeReceived" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_UndiscountedFinanceLeasePaymentsToBeReceived" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:label="lbl_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DecreaseInFinanceLeasesReceivableDueToUnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:label="lbl_DecreaseInFinanceLeasesReceivableDueToUnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DecreaseInFinanceLeasesReceivableDueToUnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MinimumFinaceLeasePaymentsReceivableAtPresentValue" xlink:label="lbl_MinimumFinaceLeasePaymentsReceivableAtPresentValue" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_MinimumFinaceLeasePaymentsReceivableAtPresentValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinanceLeaseProvision" xlink:label="lbl_FinanceLeaseProvision" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinanceLeaseProvision" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinanceLeaseReceivables" xlink:label="lbl_FinanceLeaseReceivables" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinanceLeaseReceivables" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails9" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_LegalEntityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PowerVisionInc.Member" xlink:label="lbl_PowerVisionInc.Member" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_PowerVisionInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:label="lbl_AdditionalRecognitionGoodwill" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AdditionalRecognitionGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherNetAssets" xlink:label="lbl_OtherNetAssets" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_OtherNetAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="lbl_DeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails11" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RestOfTheWorldMember" xlink:label="lbl_RestOfTheWorldMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_RestOfTheWorldMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BusinessUnitAxis" xlink:label="lbl_BusinessUnitAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_BusinessUnitAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BusinessUnitMember" xlink:label="lbl_BusinessUnitMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BusinessUnitAxis" xlink:to="lbl_BusinessUnitMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OncologyMember" xlink:label="lbl_OncologyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BusinessUnitMember" xlink:to="lbl_OncologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PharmaceuticalMember" xlink:label="lbl_PharmaceuticalMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BusinessUnitMember" xlink:to="lbl_PharmaceuticalMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FranchiseAxis" xlink:label="lbl_FranchiseAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_FranchiseAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FranchiseMember" xlink:label="lbl_FranchiseMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_FranchiseAxis" xlink:to="lbl_FranchiseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OphthalmologyMember" xlink:label="lbl_OphthalmologyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_OphthalmologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NeuroscienceMember" xlink:label="lbl_NeuroscienceMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_NeuroscienceMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RespiratoryMember" xlink:label="lbl_RespiratoryMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_RespiratoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CardioMetabolicMember" xlink:label="lbl_CardioMetabolicMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_CardioMetabolicMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EstablishedMedicinesMember" xlink:label="lbl_EstablishedMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_EstablishedMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImmunologyHepatologyAndDermatologyMember" xlink:label="lbl_ImmunologyHepatologyAndDermatologyMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_ImmunologyHepatologyAndDermatologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductPortfolioAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_Top20ProductsMember" xlink:label="lbl_Top20ProductsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_Top20ProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RestOfPortfolioMember" xlink:label="lbl_RestOfPortfolioMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_RestOfPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CosentyxMember" xlink:label="lbl_CosentyxMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_CosentyxMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GilenyaMember" xlink:label="lbl_GilenyaMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GilenyaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TasignaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EntrestoMember" xlink:label="lbl_EntrestoMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_EntrestoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandostatinMember" xlink:label="lbl_SandostatinMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SandostatinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AfinitorVotubiaMember" xlink:label="lbl_AfinitorVotubiaMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AfinitorVotubiaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PromactaRevoladeMember" xlink:label="lbl_PromactaRevoladeMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PromactaRevoladeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TafinlarMekinistMember" xlink:label="lbl_TafinlarMekinistMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TafinlarMekinistMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GalvusGroupMember" xlink:label="lbl_GalvusGroupMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GalvusGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GleevecGlivecMember" xlink:label="lbl_GleevecGlivecMember" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GleevecGlivecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XolairMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_JakaviMember" xlink:label="lbl_JakaviMember" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_JakaviMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DiovanGroupMember" xlink:label="lbl_DiovanGroupMember" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_DiovanGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExforgeGroupMember" xlink:label="lbl_ExforgeGroupMember" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExforgeGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExjadeJadenuMember" xlink:label="lbl_ExjadeJadenuMember" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExjadeJadenuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VotrientMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IlarisMember" xlink:label="lbl_IlarisMember" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_IlarisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ZortressCerticanMember" xlink:label="lbl_ZortressCerticanMember" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZortressCerticanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KisqaliMember" xlink:label="lbl_KisqaliMember" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KisqaliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TravoprostGroupMember" xlink:label="lbl_TravoprostGroupMember" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TravoprostGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NeoralSandimmunEMember" xlink:label="lbl_NeoralSandimmunEMember" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_NeoralSandimmunEMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VoltarenCataflamMember" xlink:label="lbl_VoltarenCataflamMember" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VoltarenCataflamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExelonExelonPatchMember" xlink:label="lbl_ExelonExelonPatchMember" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExelonExelonPatchMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ZolgensmaMember" xlink:label="lbl_ZolgensmaMember" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZolgensmaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdakveoMember" xlink:label="lbl_AdakveoMember" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AdakveoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KesimptaMember" xlink:label="lbl_KesimptaMember" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KesimptaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureDisposalGroupHeldForSaleDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:to="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisposalGroupHeldForSaleLineItems" xlink:label="lbl_DisposalGroupHeldForSaleLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisposalGroupHeldForSaleLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:label="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisposalGroupHeldForSaleLineItems" xlink:to="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_OtherNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_Inventories" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_OtherCurrentNonfinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:label="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisposalGroupHeldForSaleLineItems" xlink:to="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureTaxesDetails3" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ApplicableTaxRate" xlink:label="lbl_ApplicableTaxRate" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ApplicableTaxRate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxRateEffectOfTaxLosses" xlink:label="lbl_TaxRateEffectOfTaxLosses" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfTaxLosses" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:label="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:label="lbl_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxRateEffectOfCreditsAndAllowances" xlink:label="lbl_TaxRateEffectOfCreditsAndAllowances" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfCreditsAndAllowances" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:label="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxRateEffectFromChangeInTaxRate" xlink:label="lbl_TaxRateEffectFromChangeInTaxRate" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectFromChangeInTaxRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EffectOfWriteoffOfDeferredTaxAssets" xlink:label="lbl_EffectOfWriteoffOfDeferredTaxAssets" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfWriteoffOfDeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:label="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxRateEffectFromBenefitsExpiring" xlink:label="lbl_TaxRateEffectFromBenefitsExpiring" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectFromBenefitsExpiring" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxRateEffectFromNondeductibleLossesInRegion" xlink:label="lbl_TaxRateEffectFromNondeductibleLossesInRegion" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectFromNondeductibleLossesInRegion" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AverageEffectiveTaxRateContinuingOperations" xlink:label="lbl_AverageEffectiveTaxRateContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AverageEffectiveTaxRateContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AverageEffectiveTaxRateDiscontinuedOperations" xlink:label="lbl_AverageEffectiveTaxRateDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AverageEffectiveTaxRateDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AverageEffectiveTaxRate" xlink:label="lbl_AverageEffectiveTaxRate" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AverageEffectiveTaxRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:label="lbl_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="lbl_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="lbl_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:label="lbl_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:label="lbl_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EffectOfUSTaxReformLegislation" xlink:label="lbl_EffectOfUSTaxReformLegislation" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfUSTaxReformLegislation" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:label="lbl_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:label="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashOutflowForLeases" xlink:label="lbl_CashOutflowForLeases" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashOutflowForLeases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashOutflowsForShortTermAndLowValueLeases" xlink:label="lbl_CashOutflowsForShortTermAndLowValueLeases" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashOutflowsForShortTermAndLowValueLeases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashOutflowsForPaymentsOfLeasesInterest" xlink:label="lbl_CashOutflowsForPaymentsOfLeasesInterest" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashOutflowsForPaymentsOfLeasesInterest" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RepaymentOfLeaseLiability" xlink:label="lbl_RepaymentOfLeaseLiability" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_RepaymentOfLeaseLiability" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:label="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:label="lbl_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WeightedAverageInterestRateLeaseLiabilities" xlink:label="lbl_WeightedAverageInterestRateLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_WeightedAverageInterestRateLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LeaseIncentives" xlink:label="lbl_LeaseIncentives" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_LeaseIncentives" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixTable" xlink:label="lbl_DisclosureOfProvisionMatrixTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionForDoubtfulReceivableMember" xlink:label="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_DisclosureOfProvisionMatrixTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionForDoubtfulReceivable" xlink:label="lbl_ProvisionForDoubtfulReceivable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_ProvisionForDoubtfulReceivable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfDivestmentsOtherProvisions" xlink:label="lbl_ImpactOfDivestmentsOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_ImpactOfDivestmentsOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="lbl_AdditionalProvisionsOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_AdditionalProvisionsOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="lbl_ProvisionUsedOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_ProvisionUsedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:label="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="lbl_ClassesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="lbl_DisclosureOfFinancialAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_ClassesOfFinancialAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsMember" xlink:label="lbl_FinancialAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfFinancialAssetsAxis" xlink:to="lbl_FinancialAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashAndCashEquivalentsMember" xlink:label="lbl_CashAndCashEquivalentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialAssetsMember" xlink:to="lbl_CashAndCashEquivalentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueMember" xlink:label="lbl_FinancialAssetsAtFairValueMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialAssetsMember" xlink:to="lbl_FinancialAssetsAtFairValueMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="lbl_FinancialAssetsAtAmortisedCostMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialAssetsMember" xlink:to="lbl_FinancialAssetsAtAmortisedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="lbl_CategoriesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_CategoriesOfFinancialAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="lbl_FinancialAssetsCategoryMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CategoriesOfFinancialAssetsAxis" xlink:to="lbl_FinancialAssetsCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:label="lbl_FinancialAssetsAtAmortisedCostCategoryMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialAssetsCategoryMember" xlink:to="lbl_FinancialAssetsAtAmortisedCostCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:label="lbl_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialAssetsCategoryMember" xlink:to="lbl_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="lbl_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialAssetsCategoryMember" xlink:to="lbl_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AvailableForSaleMarketableSecuritiesMember" xlink:label="lbl_AvailableForSaleMarketableSecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AvailableForSaleMarketableSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentFinancialDebtMember" xlink:label="lbl_CurrentFinancialDebtMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CurrentFinancialDebtMember" xlink:type="arc"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CashAndCashEquivalentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BalanceSheetItemAxis" xlink:label="lbl_BalanceSheetItemAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_BalanceSheetItemAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BalanceSheetItemMember" xlink:label="lbl_BalanceSheetItemMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BalanceSheetItemAxis" xlink:to="lbl_BalanceSheetItemMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DebtSecuritiesMember" xlink:label="lbl_DebtSecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_DebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquitySecuritiesMember" xlink:label="lbl_EquitySecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_EquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FundInvestmentsMember" xlink:label="lbl_FundInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_FundInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationReceivablesMember" xlink:label="lbl_ContingentConsiderationReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_ContingentConsiderationReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherCurrentAssetsMember" xlink:label="lbl_OtherCurrentAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_OtherCurrentAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:label="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:label="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:label="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:label="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="lbl_DisclosureOfFinancialAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfFinancialAssetsLineItems" xlink:to="lbl_DisclosureOfFinancialAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssets" xlink:label="lbl_FinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFinancialAssetsLineItems" xlink:to="lbl_FinancialAssets" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CostOfSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossProfit" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ResearchAndDevelopmentExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherExpenseByFunction" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:label="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:label="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ApplicableTaxRateExcludingExceptionalItems" xlink:label="lbl_ApplicableTaxRateExcludingExceptionalItems" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ApplicableTaxRateExcludingExceptionalItems" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails6" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="lbl_AdditionsToRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsToRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosurePropertyPlantAndEquipmentDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LandMember" xlink:label="lbl_LandMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_LandMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BuildingsMember" xlink:label="lbl_BuildingsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_BuildingsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="lbl_ConstructionInProgressMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_ConstructionInProgressMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MachineryMember" xlink:label="lbl_MachineryMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_MachineryMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:label="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:label="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:label="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:label="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:label="lbl_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:label="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingCostsCapitalised" xlink:label="lbl_BorrowingCostsCapitalised" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_BorrowingCostsCapitalised" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:label="lbl_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:label="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:label="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="lbl_ClassesOfShareCapitalAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_ClassesOfShareCapitalAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="lbl_ClassesOfShareCapitalMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfShareCapitalAxis" xlink:to="lbl_ClassesOfShareCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OrdinarySharesMember" xlink:label="lbl_OrdinarySharesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_OrdinarySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_TreasurySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="lbl_NumberOfSharesIssued" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfSharesIssued" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfTreasuryShares" xlink:label="lbl_NumberOfTreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="lbl_NumberOfSharesOutstanding" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfSharesOutstanding" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharesCancelledForCapitalReduction" xlink:label="lbl_SharesCancelledForCapitalReduction" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_SharesCancelledForCapitalReduction" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TreasurySharesAcquiredToBeHeld" xlink:label="lbl_TreasurySharesAcquiredToBeHeld" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesAcquiredToBeHeld" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TreasurySharesAcquiredToBeCancelled" xlink:label="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherSharePurchases" xlink:label="lbl_OtherSharePurchases" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_OtherSharePurchases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:label="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedCompensationShares" xlink:label="lbl_EquityBasedCompensationShares" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_EquityBasedCompensationShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharesDeliveredToDivestedBusinessEmployees" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfOtherShareSales" xlink:label="lbl_NumberOfOtherShareSales" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfOtherShareSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ShareMovements" xlink:label="lbl_ShareMovements" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_ShareMovements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TreasurySharesWithRestrictedUse" xlink:label="lbl_TreasurySharesWithRestrictedUse" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesWithRestrictedUse" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StockRepurchaseProgramAuthorizedAmount1" xlink:label="lbl_StockRepurchaseProgramAuthorizedAmount1" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="lbl_FinancialLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:to="lbl_FinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="lbl_FinancialLiabilitiesAtAmortisedCostMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialLiabilitiesMember" xlink:to="lbl_FinancialLiabilitiesAtAmortisedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:label="lbl_FinancialLiabilitiesAtFairValueMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialLiabilitiesMember" xlink:to="lbl_FinancialLiabilitiesAtFairValueMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="lbl_FinancialLiabilitiesCategoryMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lbl_FinancialLiabilitiesCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:label="lbl_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialLiabilitiesCategoryMember" xlink:to="lbl_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="lbl_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialLiabilitiesCategoryMember" xlink:to="lbl_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherFinancialLiabilitiesCategoryMember" xlink:label="lbl_OtherFinancialLiabilitiesCategoryMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialLiabilitiesCategoryMember" xlink:to="lbl_OtherFinancialLiabilitiesCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentFinancialDebtMember" xlink:label="lbl_CurrentFinancialDebtMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CurrentFinancialDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentFinancialDebtMember" xlink:label="lbl_NoncurrentFinancialDebtMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_NoncurrentFinancialDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="lbl_LeaseLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_LeaseLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradePayablesMember" xlink:label="lbl_TradePayablesMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_TradePayablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CommitmentForRepurchaseOfOwnSharesMember" xlink:label="lbl_CommitmentForRepurchaseOfOwnSharesMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CommitmentForRepurchaseOfOwnSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherFinancialLiabilitiesMember" xlink:label="lbl_OtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_OtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BalanceSheetItemAxis" xlink:label="lbl_BalanceSheetItemAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_BalanceSheetItemAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BalanceSheetItemMember" xlink:label="lbl_BalanceSheetItemMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BalanceSheetItemAxis" xlink:to="lbl_BalanceSheetItemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:label="lbl_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BankAndOtherFinancialDebtMember" xlink:label="lbl_BankAndOtherFinancialDebtMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_BankAndOtherFinancialDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CommercialPaperMember" xlink:label="lbl_CommercialPaperMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_CommercialPaperMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentPortionOfNoncurrentDebtMember" xlink:label="lbl_CurrentPortionOfNoncurrentDebtMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_CurrentPortionOfNoncurrentDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StraightBondsMember" xlink:label="lbl_StraightBondsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_StraightBondsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:label="lbl_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinanceLeaseObligationsMember" xlink:label="lbl_FinanceLeaseObligationsMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_FinanceLeaseObligationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:label="lbl_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:label="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilities" xlink:label="lbl_FinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="lbl_FinancialLiabilities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ClassesOfProvisionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_OtherProvisionsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LegalProceedingsProvisionMember" xlink:label="lbl_LegalProceedingsProvisionMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_LegalProceedingsProvisionMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_IT" xlink:label="lbl_IT" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_IT" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="lbl_JP" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_JP" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CA" xlink:label="lbl_CA" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CA" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_KR" xlink:label="lbl_KR" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_KR" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_FR" xlink:label="lbl_FR" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_FR" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NAGAndNovartisPharmaSpAMember" xlink:label="lbl_NAGAndNovartisPharmaSpAMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NAGAndNovartisPharmaSpAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FHoffmanLaRocheAGAndRocheSpAMember" xlink:label="lbl_FHoffmanLaRocheAGAndRocheSpAMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_FHoffmanLaRocheAGAndRocheSpAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaKKMember" xlink:label="lbl_NovartisPharmaKKMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NovartisPharmaKKMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NAGMember" xlink:label="lbl_NAGMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NPCAndOthersMember" xlink:label="lbl_NPCAndOthersMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NPCAndOthersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisNCMember" xlink:label="lbl_NovartisNCMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NovartisNCMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SolodynMember" xlink:label="lbl_SolodynMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SolodynMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnoxaparinMember" xlink:label="lbl_EnoxaparinMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_EnoxaparinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContactLensesMember" xlink:label="lbl_ContactLensesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ContactLensesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GleevecMember" xlink:label="lbl_GleevecMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GleevecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReclastAclastaMember" xlink:label="lbl_ReclastAclastaMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ReclastAclastaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TekturnaRasilezValturnaMember" xlink:label="lbl_TekturnaRasilezValturnaMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TekturnaRasilezValturnaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxotereMember" xlink:label="lbl_TaxotereMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TaxotereMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmiodaroneMember" xlink:label="lbl_AmiodaroneMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AmiodaroneMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TasignaMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="lbl_LitigationCaseAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_LitigationCaseAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LitigationCaseMember" xlink:label="lbl_LitigationCaseMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_LitigationCaseAxis" xlink:to="lbl_LitigationCaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TennesseeClassActionMember" xlink:label="lbl_TennesseeClassActionMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LitigationCaseMember" xlink:to="lbl_TennesseeClassActionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MassachusettsCaseMember" xlink:label="lbl_MassachusettsCaseMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LitigationCaseMember" xlink:to="lbl_MassachusettsCaseMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:label="lbl_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:label="lbl_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountOfSettlementInPrinciple" xlink:label="lbl_AmountOfSettlementInPrinciple" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_AmountOfSettlementInPrinciple" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdditionalAmountOfSettlementInPrinciple" xlink:label="lbl_AdditionalAmountOfSettlementInPrinciple" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_AdditionalAmountOfSettlementInPrinciple" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountOfResolvedAction" xlink:label="lbl_AmountOfResolvedAction" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_AmountOfResolvedAction" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:label="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:label="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ActuarialLossesFromDefinedBenefitPlansMember" xlink:label="lbl_ActuarialLossesFromDefinedBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_ActuarialLossesFromDefinedBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CumulativeCurrencyTranslationEffectsMember" xlink:label="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="lbl_NoncontrollingInterestsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_NoncontrollingInterestsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TotalFairValueAdjustmentsMember" xlink:label="lbl_TotalFairValueAdjustmentsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_TotalFairValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:label="lbl_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RestatedValueAdjustmentsMember" xlink:label="lbl_RestatedValueAdjustmentsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_RestatedValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:label="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeDebtSecurities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GainLossOnSaleOfOtherFinancialAssets" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsOnFinancialAssetsSold" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsRelatedToDivestments" xlink:label="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:label="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:label="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:label="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:label="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:to="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:label="lbl_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:to="lbl_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureAcquisitionsOfBusinessesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RightOfUseAssetsAsOfAcquisitionDate" xlink:label="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialAndOtherAssets" xlink:label="lbl_FinancialAndOtherAssets" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_FinancialAndOtherAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:label="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradePayablesAndOtherLiabilities" xlink:label="lbl_TradePayablesAndOtherLiabilities" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_TradePayablesAndOtherLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IdentifiableAssetsAcquired" xlink:label="lbl_IdentifiableAssetsAcquired" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_IdentifiableAssetsAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquiredCashAndCashEquivalents" xlink:label="lbl_AcquiredCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_AcquiredCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:label="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="lbl_GoodwillRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_GoodwillRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodwillExpectedDeductibleForTaxPurposes" xlink:label="lbl_GoodwillExpectedDeductibleForTaxPurposes" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_GoodwillExpectedDeductibleForTaxPurposes" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails4" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_GB" xlink:label="lbl_GB" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_GB" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_FR" xlink:label="lbl_FR" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_FR" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DE" xlink:label="lbl_DE" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_DE" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="lbl_JP" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_JP" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CN" xlink:label="lbl_CN" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CN" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherCountriesMember" xlink:label="lbl_OtherCountriesMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_OtherCountriesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SelectedNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BalanceSheetTreatmentAxis" xlink:label="lbl_BalanceSheetTreatmentAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lbl_BalanceSheetTreatmentAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BalanceSheetTreatmentMember" xlink:label="lbl_BalanceSheetTreatmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BalanceSheetTreatmentAxis" xlink:to="lbl_BalanceSheetTreatmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CapitalizedMember" xlink:label="lbl_CapitalizedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetTreatmentMember" xlink:to="lbl_CapitalizedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NotCapitalizedMember" xlink:label="lbl_NotCapitalizedMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetTreatmentMember" xlink:to="lbl_NotCapitalizedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_YearOfExpiryAxis" xlink:label="lbl_YearOfExpiryAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lbl_YearOfExpiryAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_YearOfExpiryMember" xlink:label="lbl_YearOfExpiryMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_YearOfExpiryAxis" xlink:to="lbl_YearOfExpiryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OneYearMember" xlink:label="lbl_OneYearMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_OneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TwoYearsMember" xlink:label="lbl_TwoYearsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_TwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ThreeYearsMember" xlink:label="lbl_ThreeYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_ThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FourYearsMember" xlink:label="lbl_FourYearsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_FourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FiveYearsMember" xlink:label="lbl_FiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_FiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MoreThanFiveYearsMember" xlink:label="lbl_MoreThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_MoreThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NotSubjectToExpiryMember" xlink:label="lbl_NotSubjectToExpiryMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_NotSubjectToExpiryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lbl_LegalEntityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TheMedicinesCompanyMember" xlink:label="lbl_TheMedicinesCompanyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TheMedicinesCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:label="lbl_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ValueOfTaxLossCarryforwardsExpired" xlink:label="lbl_ValueOfTaxLossCarryforwardsExpired" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ValueOfTaxLossCarryforwardsExpired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxLossCarryForwards" xlink:label="lbl_TaxLossCarryForwards" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxLossCarryForwards" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice46.4Member" xlink:label="lbl_ExercisePrice46.4Member" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice46.4Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice46.7Member" xlink:label="lbl_ExercisePrice46.7Member" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice46.7Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice53.7Member" xlink:label="lbl_ExercisePrice53.7Member" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice53.7Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice54.5Member" xlink:label="lbl_ExercisePrice54.5Member" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice54.5Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice57.0Member" xlink:label="lbl_ExercisePrice57.0Member" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.0Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice57.1Member" xlink:label="lbl_ExercisePrice57.1Member" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.1Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice57.6Member" xlink:label="lbl_ExercisePrice57.6Member" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.6Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice58.3Member" xlink:label="lbl_ExercisePrice58.3Member" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice58.3Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice66.0Member" xlink:label="lbl_ExercisePrice66.0Member" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice66.0Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice66.1Member" xlink:label="lbl_ExercisePrice66.1Member" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice66.1Member" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="lbl_NumberOfOutstandingShareOptions" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice46.4Member" xlink:label="lbl_ExercisePrice46.4Member" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice46.4Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice46.7Member" xlink:label="lbl_ExercisePrice46.7Member" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice46.7Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice53.7Member" xlink:label="lbl_ExercisePrice53.7Member" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice53.7Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice54.5Member" xlink:label="lbl_ExercisePrice54.5Member" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice54.5Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice57.0Member" xlink:label="lbl_ExercisePrice57.0Member" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.0Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice57.1Member" xlink:label="lbl_ExercisePrice57.1Member" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.1Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice57.6Member" xlink:label="lbl_ExercisePrice57.6Member" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.6Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice58.3Member" xlink:label="lbl_ExercisePrice58.3Member" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice58.3Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice66.0Member" xlink:label="lbl_ExercisePrice66.0Member" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice66.0Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice66.1Member" xlink:label="lbl_ExercisePrice66.1Member" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice66.1Member" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="lbl_NumberOfOutstandingShareOptions" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/StatementOfIncome" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CostOfSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossProfit" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ResearchAndDevelopmentExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherExpenseByFunction" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="lbl_ProfitLossFromContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:label="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="lbl_ProfitLossAttributableToAbstract" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossAttributableToAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsPerShareAbstract" xlink:label="lbl_BasicEarningsPerShareAbstract" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_BasicEarningsPerShareAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BasicEarningsPerShareAbstract" xlink:to="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BasicEarningsPerShareAbstract" xlink:to="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="lbl_BasicEarningsLossPerShare" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BasicEarningsPerShareAbstract" xlink:to="lbl_BasicEarningsLossPerShare" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsPerShareAbstract" xlink:label="lbl_DilutedEarningsPerShareAbstract" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DilutedEarningsPerShareAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DilutedEarningsPerShareAbstract" xlink:to="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DilutedEarningsPerShareAbstract" xlink:to="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="lbl_DilutedEarningsLossPerShare" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DilutedEarningsPerShareAbstract" xlink:to="lbl_DilutedEarningsLossPerShare" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails7" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BusinessUnitAxis" xlink:label="lbl_BusinessUnitAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_BusinessUnitAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BusinessUnitMember" xlink:label="lbl_BusinessUnitMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BusinessUnitAxis" xlink:to="lbl_BusinessUnitMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OncologyMember" xlink:label="lbl_OncologyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BusinessUnitMember" xlink:to="lbl_OncologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PharmaceuticalMember" xlink:label="lbl_PharmaceuticalMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BusinessUnitMember" xlink:to="lbl_PharmaceuticalMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FranchiseAxis" xlink:label="lbl_FranchiseAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_FranchiseAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FranchiseMember" xlink:label="lbl_FranchiseMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_FranchiseAxis" xlink:to="lbl_FranchiseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImmunologyHepatologyAndDermatologyMember" xlink:label="lbl_ImmunologyHepatologyAndDermatologyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_ImmunologyHepatologyAndDermatologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OphthalmologyMember" xlink:label="lbl_OphthalmologyMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_OphthalmologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NeuroscienceMember" xlink:label="lbl_NeuroscienceMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_NeuroscienceMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CardioMetabolicMember" xlink:label="lbl_CardioMetabolicMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_CardioMetabolicMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RespiratoryMember" xlink:label="lbl_RespiratoryMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_RespiratoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EstablishedMedicinesMember" xlink:label="lbl_EstablishedMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_EstablishedMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductPortfolioAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_COPDMember" xlink:label="lbl_COPDMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_COPDMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TasignaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PromactaRevoladeMember" xlink:label="lbl_PromactaRevoladeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PromactaRevoladeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TafinlarMekinistMember" xlink:label="lbl_TafinlarMekinistMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TafinlarMekinistMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandostatinMember" xlink:label="lbl_SandostatinMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SandostatinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_JakaviMember" xlink:label="lbl_JakaviMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_JakaviMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GleevecGlivecMember" xlink:label="lbl_GleevecGlivecMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GleevecGlivecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AfinitorVotubiaMember" xlink:label="lbl_AfinitorVotubiaMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AfinitorVotubiaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KisqaliMember" xlink:label="lbl_KisqaliMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KisqaliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExjadeJadenuMember" xlink:label="lbl_ExjadeJadenuMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExjadeJadenuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VotrientMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KymriahMember" xlink:label="lbl_KymriahMember" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KymriahMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LutatheraMember" xlink:label="lbl_LutatheraMember" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LutatheraMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PiqrayMember" xlink:label="lbl_PiqrayMember" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PiqrayMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdakveoMember" xlink:label="lbl_AdakveoMember" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AdakveoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TabrectaMember" xlink:label="lbl_TabrectaMember" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TabrectaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CosentyxMember" xlink:label="lbl_CosentyxMember" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_CosentyxMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IlarisMember" xlink:label="lbl_IlarisMember" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_IlarisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_XiidraMember" xlink:label="lbl_XiidraMember" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XiidraMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BeovuMember" xlink:label="lbl_BeovuMember" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_BeovuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GilenyaMember" xlink:label="lbl_GilenyaMember" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GilenyaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ZolgensmaMember" xlink:label="lbl_ZolgensmaMember" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZolgensmaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MayzentMember" xlink:label="lbl_MayzentMember" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_MayzentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AimovigMember" xlink:label="lbl_AimovigMember" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AimovigMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KesimptaMember" xlink:label="lbl_KesimptaMember" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KesimptaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EntrestoMember" xlink:label="lbl_EntrestoMember" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_EntrestoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XolairMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UltibroGroupMember" xlink:label="lbl_UltibroGroupMember" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_UltibroGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UltibroBreezhalerMember" xlink:label="lbl_UltibroBreezhalerMember" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_UltibroBreezhalerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GalvusGroupMember" xlink:label="lbl_GalvusGroupMember" xlink:type="locator"/>
      <link:definitionArc order="30.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GalvusGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DiovanGroupMember" xlink:label="lbl_DiovanGroupMember" xlink:type="locator"/>
      <link:definitionArc order="31.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_DiovanGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExforgeGroupMember" xlink:label="lbl_ExforgeGroupMember" xlink:type="locator"/>
      <link:definitionArc order="32.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExforgeGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ZortressCerticanMember" xlink:label="lbl_ZortressCerticanMember" xlink:type="locator"/>
      <link:definitionArc order="33.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZortressCerticanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NeoralSandimmunEMember" xlink:label="lbl_NeoralSandimmunEMember" xlink:type="locator"/>
      <link:definitionArc order="34.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_NeoralSandimmunEMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VoltarenCataflamMember" xlink:label="lbl_VoltarenCataflamMember" xlink:type="locator"/>
      <link:definitionArc order="35.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VoltarenCataflamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TravoprostGroupMember" xlink:label="lbl_TravoprostGroupMember" xlink:type="locator"/>
      <link:definitionArc order="36.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TravoprostGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SeebriBreezhalerMember" xlink:label="lbl_SeebriBreezhalerMember" xlink:type="locator"/>
      <link:definitionArc order="37.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SeebriBreezhalerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OnbrezBreezhalerMember" xlink:label="lbl_OnbrezBreezhalerMember" xlink:type="locator"/>
      <link:definitionArc order="38.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OnbrezBreezhalerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SystaneGroupMember" xlink:label="lbl_SystaneGroupMember" xlink:type="locator"/>
      <link:definitionArc order="39.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SystaneGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TopicalOlopatadineGroupMember" xlink:label="lbl_TopicalOlopatadineGroupMember" xlink:type="locator"/>
      <link:definitionArc order="40.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TopicalOlopatadineGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MyforticMember" xlink:label="lbl_MyforticMember" xlink:type="locator"/>
      <link:definitionArc order="41.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_MyforticMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExelonExelonPatchMember" xlink:label="lbl_ExelonExelonPatchMember" xlink:type="locator"/>
      <link:definitionArc order="42.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExelonExelonPatchMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RitalinFocalinMember" xlink:label="lbl_RitalinFocalinMember" xlink:type="locator"/>
      <link:definitionArc order="43.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_RitalinFocalinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherProductsMember" xlink:label="lbl_OtherProductsMember" xlink:type="locator"/>
      <link:definitionArc order="44.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureSignificantTransactionsDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="lbl_EntitysTotalForSubsidiariesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lbl_EntitysTotalForSubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SubsidiariesMember" xlink:label="lbl_SubsidiariesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSubsidiariesMember" xlink:to="lbl_SubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeStatementLocationAxis" xlink:label="lbl_IncomeStatementLocationAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_IncomeStatementLocationAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeStatementLocationMember" xlink:label="lbl_IncomeStatementLocationMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_IncomeStatementLocationAxis" xlink:to="lbl_IncomeStatementLocationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OperatingIncomeMember" xlink:label="lbl_OperatingIncomeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IncomeStatementLocationMember" xlink:to="lbl_OperatingIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_LegalEntityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsAAAMember" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AspenGlobalIncorporatedMember" xlink:label="lbl_AspenGlobalIncorporatedMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AspenGlobalIncorporatedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TheMedicinesCompanyMember" xlink:label="lbl_TheMedicinesCompanyMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TheMedicinesCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AveXisIncMember" xlink:label="lbl_AveXisIncMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AveXisIncMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EndocyteMember" xlink:label="lbl_EndocyteMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EndocyteMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TranscendMedicalIncMember" xlink:label="lbl_TranscendMedicalIncMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TranscendMedicalIncMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SelexysPharmaceuticalsCorporationMember" xlink:label="lbl_SelexysPharmaceuticalsCorporationMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SelexysPharmaceuticalsCorporationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReprixysPharmaceuticalsCorporationMember" xlink:label="lbl_ReprixysPharmaceuticalsCorporationMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ReprixysPharmaceuticalsCorporationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ZiarcoGroupLimitedMember" xlink:label="lbl_ZiarcoGroupLimitedMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ZiarcoGroupLimitedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EncoreVisionIncMember" xlink:label="lbl_EncoreVisionIncMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EncoreVisionIncMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EliLillyAndCompanyMember" xlink:label="lbl_EliLillyAndCompanyMember" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EliLillyAndCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GSKOncologyProductsMember" xlink:label="lbl_GSKOncologyProductsMember" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKOncologyProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GSKVaccinesMember" xlink:label="lbl_GSKVaccinesMember" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKVaccinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GSKConsumerHealthcareMember" xlink:label="lbl_GSKConsumerHealthcareMember" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKConsumerHealthcareMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GSKTotalTransactionMember" xlink:label="lbl_GSKTotalTransactionMember" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKTotalTransactionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CSLMember" xlink:label="lbl_CSLMember" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CSLMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SpinifexMember" xlink:label="lbl_SpinifexMember" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SpinifexMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdmuneTheraputicsMember" xlink:label="lbl_AdmuneTheraputicsMember" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdmuneTheraputicsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="lbl_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IFMTreInc.Member" xlink:label="lbl_IFMTreInc.Member" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_IFMTreInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PowerVisionInc.Member" xlink:label="lbl_PowerVisionInc.Member" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_PowerVisionInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:label="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_BorrowingsByNameAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsUSDMember" xlink:label="lbl_BorrowingsUSDMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_BorrowingsUSDMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsEURMember" xlink:label="lbl_BorrowingsEURMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_BorrowingsEURMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DetailedInformationAboutSignificantTransaction" xlink:label="lbl_DetailedInformationAboutSignificantTransaction" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DetailedInformationAboutSignificantTransaction" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RepaymentOfIntercompanyBalances" xlink:label="lbl_RepaymentOfIntercompanyBalances" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RepaymentOfIntercompanyBalances" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:label="lbl_AdditionalRecognitionGoodwill" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AdditionalRecognitionGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:label="lbl_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="lbl_PercentageOfVotingEquityInterestsAcquired" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfVotingEquityInterestsAcquired" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:label="lbl_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PotentiallyRefundableConsiderationFromAcquisition" xlink:label="lbl_PotentiallyRefundableConsiderationFromAcquisition" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PotentiallyRefundableConsiderationFromAcquisition" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:label="lbl_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContractRightOfFirstNegotiationTerm" xlink:label="lbl_ContractRightOfFirstNegotiationTerm" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ContractRightOfFirstNegotiationTerm" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueOfAcquiree" xlink:label="lbl_RevenueOfAcquiree" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RevenueOfAcquiree" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueOfAcquireeFullYear" xlink:label="lbl_RevenueOfAcquireeFullYear" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RevenueOfAcquireeFullYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:label="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:label="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="lbl_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:label="lbl_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:label="lbl_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="lbl_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PercentageOfVotingEquityInterestsContributed" xlink:label="lbl_PercentageOfVotingEquityInterestsContributed" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfVotingEquityInterestsContributed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TransactionRelatedCosts" xlink:label="lbl_TransactionRelatedCosts" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TransactionRelatedCosts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TransactionRelatedCostsPaid" xlink:label="lbl_TransactionRelatedCostsPaid" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TransactionRelatedCostsPaid" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLoss" xlink:label="lbl_ImpairmentLoss" xlink:type="locator"/>
      <link:definitionArc order="30.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ImpairmentLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReversalOfImpairmentLoss" xlink:label="lbl_ReversalOfImpairmentLoss" xlink:type="locator"/>
      <link:definitionArc order="31.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ReversalOfImpairmentLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PreTaxProfitLossFromDivestmentOfBusiness" xlink:label="lbl_PreTaxProfitLossFromDivestmentOfBusiness" xlink:type="locator"/>
      <link:definitionArc order="32.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PreTaxProfitLossFromDivestmentOfBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:definitionArc order="33.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PotentialReceivableFromDivestment" xlink:label="lbl_PotentialReceivableFromDivestment" xlink:type="locator"/>
      <link:definitionArc order="34.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PotentialReceivableFromDivestment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DivestmentFairValueOfContingentConsiderationReceived" xlink:label="lbl_DivestmentFairValueOfContingentConsiderationReceived" xlink:type="locator"/>
      <link:definitionArc order="35.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DivestmentFairValueOfContingentConsiderationReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MilestonePaymentAlreadyReceived" xlink:label="lbl_MilestonePaymentAlreadyReceived" xlink:type="locator"/>
      <link:definitionArc order="36.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_MilestonePaymentAlreadyReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FuturePutOptionToSellBusiness" xlink:label="lbl_FuturePutOptionToSellBusiness" xlink:type="locator"/>
      <link:definitionArc order="37.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_FuturePutOptionToSellBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PaymentPutOption" xlink:label="lbl_PaymentPutOption" xlink:type="locator"/>
      <link:definitionArc order="38.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PaymentPutOption" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestExchanged" xlink:label="lbl_InterestExchanged" xlink:type="locator"/>
      <link:definitionArc order="39.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_InterestExchanged" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="lbl_ParValuePerShare" xlink:type="locator"/>
      <link:definitionArc order="40.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ParValuePerShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PercentageOfShareCapitalInTenderOffer" xlink:label="lbl_PercentageOfShareCapitalInTenderOffer" xlink:type="locator"/>
      <link:definitionArc order="41.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfShareCapitalInTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashOfferPerOrdinaryShare" xlink:label="lbl_CashOfferPerOrdinaryShare" xlink:type="locator"/>
      <link:definitionArc order="42.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CashOfferPerOrdinaryShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashOfferPerADS" xlink:label="lbl_CashOfferPerADS" xlink:type="locator"/>
      <link:definitionArc order="43.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CashOfferPerADS" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfOrdinarySharePerADS" xlink:label="lbl_NumberOfOrdinarySharePerADS" xlink:type="locator"/>
      <link:definitionArc order="44.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfOrdinarySharePerADS" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ValueOfEquity" xlink:label="lbl_ValueOfEquity" xlink:type="locator"/>
      <link:definitionArc order="45.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ValueOfEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:label="lbl_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:type="locator"/>
      <link:definitionArc order="46.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherNetAssets" xlink:label="lbl_OtherNetAssets" xlink:type="locator"/>
      <link:definitionArc order="47.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_OtherNetAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="lbl_DeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="48.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="49.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DivestmentCostToSell" xlink:label="lbl_DivestmentCostToSell" xlink:type="locator"/>
      <link:definitionArc order="50.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DivestmentCostToSell" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:definitionArc order="51.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:definitionArc order="52.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:definitionArc order="53.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CarryingValueOfTheDivestedBusiness" xlink:label="lbl_CarryingValueOfTheDivestedBusiness" xlink:type="locator"/>
      <link:definitionArc order="54.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CarryingValueOfTheDivestedBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfProductsInPortfolioToBeSold" xlink:label="lbl_NumberOfProductsInPortfolioToBeSold" xlink:type="locator"/>
      <link:definitionArc order="55.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfProductsInPortfolioToBeSold" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:definitionArc order="56.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProformaNetSales" xlink:label="lbl_ProformaNetSales" xlink:type="locator"/>
      <link:definitionArc order="57.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProformaNetSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherBorrowings" xlink:label="lbl_OtherBorrowings" xlink:type="locator"/>
      <link:definitionArc order="58.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_OtherBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPayable" xlink:label="lbl_DividendsPayable" xlink:type="locator"/>
      <link:definitionArc order="59.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DividendsPayable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:definitionArc order="60.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:label="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:definitionArc order="61.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="lbl_NetAssetsLiabilities" xlink:type="locator"/>
      <link:definitionArc order="62.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NetAssetsLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="lbl_FinancialAssetsAtFairValue" xlink:type="locator"/>
      <link:definitionArc order="63.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_FinancialAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="locator"/>
      <link:definitionArc order="64.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:definitionArc order="65.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:label="lbl_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:type="locator"/>
      <link:definitionArc order="66.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PotentialMilestoneMaximumPayments" xlink:label="lbl_PotentialMilestoneMaximumPayments" xlink:type="locator"/>
      <link:definitionArc order="67.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PotentialMilestoneMaximumPayments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:label="lbl_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:type="locator"/>
      <link:definitionArc order="68.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdditionalBorrowings" xlink:label="lbl_AdditionalBorrowings" xlink:type="locator"/>
      <link:definitionArc order="69.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AdditionalBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PercentageOfEquityInterestSharesReceived" xlink:label="lbl_PercentageOfEquityInterestSharesReceived" xlink:type="locator"/>
      <link:definitionArc order="70.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfEquityInterestSharesReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:label="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:type="locator"/>
      <link:definitionArc order="71.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator"/>
      <link:definitionArc order="72.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CustomaryPurchasePriceAdjustment" xlink:label="lbl_CustomaryPurchasePriceAdjustment" xlink:type="locator"/>
      <link:definitionArc order="73.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CustomaryPurchasePriceAdjustment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="74.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="75.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="76.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="lbl_IssuedCapitalMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_IssuedCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TreasurySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="lbl_RetainedEarningsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_RetainedEarningsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="lbl_NoncontrollingInterestsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_NoncontrollingInterestsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="lbl_ParValuePerShare" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ParValuePerShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:label="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UndiscountedOperatingLeaseCommitments" xlink:label="lbl_UndiscountedOperatingLeaseCommitments" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_UndiscountedOperatingLeaseCommitments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ShortTermLeasesAndLowValueLeases" xlink:label="lbl_ShortTermLeasesAndLowValueLeases" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ShortTermLeasesAndLowValueLeases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RemainingLeaseCommitments" xlink:label="lbl_RemainingLeaseCommitments" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RemainingLeaseCommitments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LeaseLiabilitiesToBeRecognized" xlink:label="lbl_LeaseLiabilitiesToBeRecognized" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_LeaseLiabilitiesToBeRecognized" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RightOfUseAssetsToBeRecognized" xlink:label="lbl_RightOfUseAssetsToBeRecognized" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RightOfUseAssetsToBeRecognized" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PrepaymentsAndAccruedLeasePayments" xlink:label="lbl_PrepaymentsAndAccruedLeasePayments" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PrepaymentsAndAccruedLeasePayments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="lbl_GrossLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:label="lbl_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NewLeaseArrangements" xlink:label="lbl_NewLeaseArrangements" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NewLeaseArrangements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UndiscountedFutureLeasePayments" xlink:label="lbl_UndiscountedFutureLeasePayments" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_UndiscountedFutureLeasePayments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EffectOfDiscounting" xlink:label="lbl_EffectOfDiscounting" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfDiscounting" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:label="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MovementsOfTheRightofuseAssetsRollForward" xlink:label="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="lbl_AdditionsToRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_AdditionsToRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="lbl_DepreciationRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_DepreciationRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LeaseContractTerminationsRightofuseAssets" xlink:label="lbl_LeaseContractTerminationsRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_LeaseContractTerminationsRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisposalsAndRetirementsRightofuseAssets" xlink:label="lbl_DisposalsAndRetirementsRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_DisposalsAndRetirementsRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssetsDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodwillMember" xlink:label="lbl_GoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_GoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquiredResearchAndDevelopmentMember" xlink:label="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconBrandNameMember" xlink:label="lbl_AlconBrandNameMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AlconBrandNameMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TechnologybasedIntangibleAssetsMember" xlink:label="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_CurrentlyMarketedProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MarketingRelatedIntangibleAssetsMember" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="lbl_OtherIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_OtherIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="lbl_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:label="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:label="lbl_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:label="lbl_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:label="lbl_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:label="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:label="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lbl_BorrowingsByNameAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:label="lbl_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:label="lbl_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:label="lbl_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:label="lbl_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:label="lbl_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:label="lbl_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:label="lbl_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:label="lbl_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:label="lbl_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:label="lbl_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:label="lbl_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:label="lbl_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:label="lbl_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:label="lbl_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:label="lbl_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:label="lbl_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:label="lbl_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:label="lbl_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:label="lbl_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:label="lbl_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:label="lbl_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:label="lbl_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:label="lbl_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:label="lbl_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:label="lbl_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:label="lbl_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:label="lbl_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:label="lbl_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:label="lbl_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="lbl_BorrowingsInterestRate" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsInterestRate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsOriginalCurrency" xlink:label="lbl_BorrowingsOriginalCurrency" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsOriginalCurrency" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotionalAmount" xlink:label="lbl_NotionalAmount" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_NotionalAmount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsIssuanceDate" xlink:label="lbl_BorrowingsIssuanceDate" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsIssuanceDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsMaturity" xlink:label="lbl_BorrowingsMaturity" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsMaturity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsLender" xlink:label="lbl_BorrowingsLender" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsLender" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsPremiumDiscount" xlink:label="lbl_BorrowingsPremiumDiscount" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsPremiumDiscount" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BondsIssued" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsInterestRateStepUp" xlink:label="lbl_BorrowingsInterestRateStepUp" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsInterestRateStepUp" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:label="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanInterestCost" xlink:label="lbl_DefinedBenefitPlanInterestCost" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_DefinedBenefitPlanInterestCost" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:label="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:label="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="lbl_PlanAssetsAtFairValue" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_PlanAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:label="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanSettlementsPlanAssets" xlink:label="lbl_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="lbl_SurplusDeficitInPlan" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_SurplusDeficitInPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LimitationOnRecognitionOfFundSurplus" xlink:label="lbl_LimitationOnRecognitionOfFundSurplus" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_LimitationOnRecognitionOfFundSurplus" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeInLimitationOnRecognitionOfFundSurplus" xlink:label="lbl_ChangeInLimitationOnRecognitionOfFundSurplus" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_ChangeInLimitationOnRecognitionOfFundSurplus" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestIncomeOnLimitationOfFundSurplus" xlink:label="lbl_InterestIncomeOnLimitationOfFundSurplus" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_InterestIncomeOnLimitationOfFundSurplus" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReimbursmentsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReimbursmentsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="5.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_ReimbursmentsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquisitionsAndDivestmentsAxis" xlink:label="lbl_AcquisitionsAndDivestmentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_AcquisitionsAndDivestmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquisitionsAndDivestmentsMember" xlink:label="lbl_AcquisitionsAndDivestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AcquisitionsAndDivestmentsAxis" xlink:to="lbl_AcquisitionsAndDivestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquisitionsMember" xlink:label="lbl_AcquisitionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AcquisitionsAndDivestmentsMember" xlink:to="lbl_AcquisitionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DivestmentsMember" xlink:label="lbl_DivestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AcquisitionsAndDivestmentsMember" xlink:to="lbl_DivestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="lbl_BusinessCombinationsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_BusinessCombinationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="lbl_EntitysTotalForBusinessCombinationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BusinessCombinationsAxis" xlink:to="lbl_EntitysTotalForBusinessCombinationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TranscendMedicalIncMember" xlink:label="lbl_TranscendMedicalIncMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForBusinessCombinationsMember" xlink:to="lbl_TranscendMedicalIncMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_AssetsAndLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_AssetsAndLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentAssetsMember" xlink:label="lbl_NoncurrentAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_NoncurrentAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentLiabilitiesMember" xlink:label="lbl_CurrentLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_CurrentLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentLiabilitiesMember" xlink:label="lbl_NoncurrentLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_NoncurrentLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashFlowFromNetIdentifiableAssets" xlink:label="lbl_CashFlowFromNetIdentifiableAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowFromNetIdentifiableAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:label="lbl_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReceivablesAndPayablesContingentConsiderationNet" xlink:label="lbl_ReceivablesAndPayablesContingentConsiderationNet" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ReceivablesAndPayablesContingentConsiderationNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherPaymentsAndDeferredConsiderationNet" xlink:label="lbl_OtherPaymentsAndDeferredConsiderationNet" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherPaymentsAndDeferredConsiderationNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationPaid" xlink:label="lbl_ContingentConsiderationPaid" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ContingentConsiderationPaid" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentAssetsDivested" xlink:label="lbl_NoncurrentAssetsDivested" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NoncurrentAssetsDivested" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="lbl_ConsiderationPaidReceived" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ConsiderationPaidReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetCashOutflowsFromDivestments" xlink:label="lbl_NetCashOutflowsFromDivestments" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashOutflowsFromDivestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentAssetsDivested" xlink:label="lbl_CurrentAssetsDivested" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentAssetsDivested" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentLiabilitiesDivested" xlink:label="lbl_CurrentLiabilitiesDivested" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentLiabilitiesDivested" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_AssetsAndLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_AssetsAndLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonCurrentFinancialDebtsMember" xlink:label="lbl_NonCurrentFinancialDebtsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_NonCurrentFinancialDebtsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:label="lbl_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentLeaseLiabilitiesMember" xlink:label="lbl_NoncurrentLeaseLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_NoncurrentLeaseLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentLeaseLiabilitiesMember" xlink:label="lbl_CurrentLeaseLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_CurrentLeaseLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialDebtsAndDerivativeInstruments" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LeaseLiabilitiesImpactOfAdoptionOfIFRS16" xlink:label="lbl_LeaseLiabilitiesImpactOfAdoptionOfIFRS16" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_LeaseLiabilitiesImpactOfAdoptionOfIFRS16" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:label="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:label="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:label="lbl_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmortizationOfBondsDiscount" xlink:label="lbl_AmortizationOfBondsDiscount" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AmortizationOfBondsDiscount" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReclassificationFromNoncurrentToCurrentNet" xlink:label="lbl_ReclassificationFromNoncurrentToCurrentNet" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ReclassificationFromNoncurrentToCurrentNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentPortionOfNoncurrentFinancialDebt" xlink:label="lbl_CurrentPortionOfNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentPortionOfNoncurrentFinancialDebt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:label="lbl_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsTables" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" xlink:label="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" xlink:label="lbl_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:label="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BalanceSheetAdditionalInformationTableTextBlock" xlink:label="lbl_BalanceSheetAdditionalInformationTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_BalanceSheetAdditionalInformationTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashFlowsUsedInInvestingActivitiesTableTextBlock" xlink:label="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:label="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNetAssetsDerecognizedTableTextBlock" xlink:label="lbl_DisclosureOfNetAssetsDerecognizedTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNetAssetsDerecognizedTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:label="lbl_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" xlink:label="lbl_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DocumentAndEntityInformation" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="lbl_DocumentInformationTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="lbl_DocumentInformationLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentInformationTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="lbl_DocumentType" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentType" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="lbl_AmendmentFlag" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_AmendmentFlag" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="lbl_DocumentAnnualReport" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentAnnualReport" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="lbl_DocumentTransitionReport" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentTransitionReport" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="lbl_DocumentShellCompanyReport" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentShellCompanyReport" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="lbl_DocumentPeriodEndDate" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentPeriodEndDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="lbl_DocumentFiscalYearFocus" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentFiscalYearFocus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="lbl_DocumentFiscalPeriodFocus" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentFiscalPeriodFocus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="lbl_TradingSymbol" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_TradingSymbol" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="lbl_EntityRegistrantName" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityRegistrantName" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="lbl_EntityCentralIndexKey" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityCentralIndexKey" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="lbl_CurrentFiscalYearEndDate" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_CurrentFiscalYearEndDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="lbl_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="lbl_EntityCurrentReportingStatus" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityCurrentReportingStatus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="lbl_EntityVoluntaryFilers" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityVoluntaryFilers" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="lbl_EntityFilerCategory" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityFilerCategory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="lbl_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="lbl_EntityPublicFloat" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityPublicFloat" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="lbl_EntityShellCompany" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityShellCompany" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="lbl_EntityEmergingGrowthCompany" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityEmergingGrowthCompany" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="lbl_EntityInteractiveDataCurrent" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityInteractiveDataCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="lbl_IcfrAuditorAttestationFlag" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_IcfrAuditorAttestationFlag" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedPartiesDetails1" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonExecutiveDirectorMember" xlink:label="lbl_NonExecutiveDirectorMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_NonExecutiveDirectorMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GenentechRocheMember" xlink:label="lbl_GenentechRocheMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GenentechRocheMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GenentechInc.USAMember" xlink:label="lbl_GenentechInc.USAMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GenentechInc.USAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SparkTherapeuticsInc.Member" xlink:label="lbl_SparkTherapeuticsInc.Member" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_SparkTherapeuticsInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XolairMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:label="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfContractsWithRelatedParties" xlink:label="lbl_NumberOfContractsWithRelatedParties" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_NumberOfContractsWithRelatedParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RelatedPartiesNumberOfExecutiveCommiteeMembers" xlink:label="lbl_RelatedPartiesNumberOfExecutiveCommiteeMembers" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_RelatedPartiesNumberOfExecutiveCommiteeMembers" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:label="lbl_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DistributionByWayOfDivindendInKindToShareholders" xlink:label="lbl_DistributionByWayOfDivindendInKindToShareholders" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DistributionByWayOfDivindendInKindToShareholders" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:label="lbl_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:label="lbl_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TransactionCostsRecordedInEquityTextBlock" xlink:label="lbl_TransactionCostsRecordedInEquityTextBlock" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TransactionCostsRecordedInEquityTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:label="lbl_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:type="locator"/>
      <link:definitionArc order="30.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:label="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="locator"/>
      <link:definitionArc order="31.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="32.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="33.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:type="locator"/>
      <link:definitionArc order="34.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:type="locator"/>
      <link:definitionArc order="35.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureSignificantAccountingPoliciesDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="lbl_AssetsAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AssetsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="lbl_NoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_NoncurrentAssetsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="lbl_EquityAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EquityAndLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="lbl_EquityAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_EquityAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherReserves" xlink:label="lbl_OtherReserves" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_OtherReserves" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="lbl_LiabilitiesAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_LiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="lbl_CurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_CurrentLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="lbl_CurrentLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLeaseLiabilities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_AssetsAndLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_AssetsAndLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InvestmentsInSubsidiariesMember" xlink:label="lbl_InvestmentsInSubsidiariesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_InvestmentsInSubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GoodwillFromAcquisitionsMember" xlink:label="lbl_GoodwillFromAcquisitionsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_GoodwillFromAcquisitionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DeductibleTemporaryDifferencesForWhichNoDeferredTaxLiabilityIsRecognised" xlink:label="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxLiabilityIsRecognised" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxLiabilityIsRecognised" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="lbl_EntitysTotalForSubsidiariesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lbl_EntitysTotalForSubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SubsidiariesMember" xlink:label="lbl_SubsidiariesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSubsidiariesMember" xlink:to="lbl_SubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lbl_LegalEntityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SocieteParActionsSANDOZAlgiersMember" xlink:label="lbl_SocieteParActionsSANDOZAlgiersMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SocieteParActionsSANDOZAlgiersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozManufacturingInc.Member" xlink:label="lbl_SandozManufacturingInc.Member" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozManufacturingInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:label="lbl_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:label="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisManufacturingGmbHMember" xlink:label="lbl_NovartisManufacturingGmbHMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisManufacturingGmbHMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisManufacturingGmbHMarburgMember" xlink:label="lbl_NovartisManufacturingGmbHMarburgMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisManufacturingGmbHMarburgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisTechnologyLLCMember" xlink:label="lbl_NovartisTechnologyLLCMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisTechnologyLLCMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInflammasomeResearchInc.Member" xlink:label="lbl_NovartisInflammasomeResearchInc.Member" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInflammasomeResearchInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:label="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:label="lbl_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:label="lbl_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImagingEquipmentLtdMember" xlink:label="lbl_ImagingEquipmentLtdMember" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ImagingEquipmentLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IDBHollandBVMember" xlink:label="lbl_IDBHollandBVMember" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_IDBHollandBVMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CELLforCUREMember" xlink:label="lbl_CELLforCUREMember" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CELLforCUREMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisArgentinaS.A.BuenosAiresMember" xlink:label="lbl_NovartisArgentinaS.A.BuenosAiresMember" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisArgentinaS.A.BuenosAiresMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriosS.A.BuenosAiresMember" xlink:label="lbl_AlconLaboratoriosS.A.BuenosAiresMember" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriosS.A.BuenosAiresMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozPtyLtdMacquarieParkNSWMember" xlink:label="lbl_SandozPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPtyLtdMacquarieParkNSWMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisAustriaGmbHViennaMember" xlink:label="lbl_NovartisAustriaGmbHViennaMember" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisAustriaGmbHViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaGmbHViennaMember" xlink:label="lbl_NovartisPharmaGmbHViennaMember" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaGmbHViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozGmbHViennaMember" xlink:label="lbl_SandozGmbHViennaMember" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozGmbHViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconOphthalmikaGmbHViennaMember" xlink:label="lbl_AlconOphthalmikaGmbHViennaMember" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconOphthalmikaGmbHViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:label="lbl_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisBangladeshLimitedGazipurMember" xlink:label="lbl_NovartisBangladeshLimitedGazipurMember" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBangladeshLimitedGazipurMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaNVVilvoordeMember" xlink:label="lbl_NovartisPharmaNVVilvoordeMember" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaNVVilvoordeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozNVVilvoordeMember" xlink:label="lbl_SandozNVVilvoordeMember" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozNVVilvoordeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconCouvreurNVPuursMember" xlink:label="lbl_AlconCouvreurNVPuursMember" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconCouvreurNVPuursMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:label="lbl_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:type="locator"/>
      <link:definitionArc order="30.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconNVVilvoordeMember" xlink:label="lbl_AlconNVVilvoordeMember" xlink:type="locator"/>
      <link:definitionArc order="31.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconNVVilvoordeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInvestmentLtd.HamiltonMember" xlink:label="lbl_NovartisInvestmentLtd.HamiltonMember" xlink:type="locator"/>
      <link:definitionArc order="32.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInvestmentLtd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:label="lbl_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:type="locator"/>
      <link:definitionArc order="33.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFinanceServicesLtd.HamiltonMember" xlink:label="lbl_NovartisFinanceServicesLtd.HamiltonMember" xlink:type="locator"/>
      <link:definitionArc order="34.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinanceServicesLtd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisB2Ltd.HamiltonMember" xlink:label="lbl_NovartisB2Ltd.HamiltonMember" xlink:type="locator"/>
      <link:definitionArc order="35.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisB2Ltd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisB3Ltd.HamiltonMember" xlink:label="lbl_NovartisB3Ltd.HamiltonMember" xlink:type="locator"/>
      <link:definitionArc order="36.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisB3Ltd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:label="lbl_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:type="locator"/>
      <link:definitionArc order="37.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:label="lbl_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:type="locator"/>
      <link:definitionArc order="38.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisBiocienciasS.A.SaoPauloMember" xlink:label="lbl_NovartisBiocienciasS.A.SaoPauloMember" xlink:type="locator"/>
      <link:definitionArc order="39.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBiocienciasS.A.SaoPauloMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:label="lbl_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:type="locator"/>
      <link:definitionArc order="40.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:label="lbl_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:type="locator"/>
      <link:definitionArc order="41.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozCanadaInc.BouchervilleQuebecMember" xlink:label="lbl_SandozCanadaInc.BouchervilleQuebecMember" xlink:type="locator"/>
      <link:definitionArc order="42.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozCanadaInc.BouchervilleQuebecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconCanadaInc.MississaugaOntarioMember" xlink:label="lbl_AlconCanadaInc.MississaugaOntarioMember" xlink:type="locator"/>
      <link:definitionArc order="43.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconCanadaInc.MississaugaOntarioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:label="lbl_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:type="locator"/>
      <link:definitionArc order="44.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisChileS.A.SantiagoDeChileMember" xlink:label="lbl_NovartisChileS.A.SantiagoDeChileMember" xlink:type="locator"/>
      <link:definitionArc order="45.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisChileS.A.SantiagoDeChileMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:label="lbl_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:type="locator"/>
      <link:definitionArc order="46.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:label="lbl_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:type="locator"/>
      <link:definitionArc order="47.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:label="lbl_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:type="locator"/>
      <link:definitionArc order="48.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:label="lbl_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:type="locator"/>
      <link:definitionArc order="49.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:label="lbl_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:type="locator"/>
      <link:definitionArc order="50.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:label="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:type="locator"/>
      <link:definitionArc order="51.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:label="lbl_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:type="locator"/>
      <link:definitionArc order="52.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:label="lbl_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:type="locator"/>
      <link:definitionArc order="53.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconHongKongLimitedHongKongMember" xlink:label="lbl_AlconHongKongLimitedHongKongMember" xlink:type="locator"/>
      <link:definitionArc order="54.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconHongKongLimitedHongKongMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:label="lbl_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:type="locator"/>
      <link:definitionArc order="55.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:label="lbl_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:type="locator"/>
      <link:definitionArc order="56.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:label="lbl_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:type="locator"/>
      <link:definitionArc order="57.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:label="lbl_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:type="locator"/>
      <link:definitionArc order="58.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisS.r.o.PragueMember" xlink:label="lbl_NovartisS.r.o.PragueMember" xlink:type="locator"/>
      <link:definitionArc order="59.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisS.r.o.PragueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozS.r.o.PragueMember" xlink:label="lbl_SandozS.r.o.PragueMember" xlink:type="locator"/>
      <link:definitionArc order="60.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.r.o.PragueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:label="lbl_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:type="locator"/>
      <link:definitionArc order="61.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisHealthcareASCopenhagenMember" xlink:label="lbl_NovartisHealthcareASCopenhagenMember" xlink:type="locator"/>
      <link:definitionArc order="62.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHealthcareASCopenhagenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozASCopenhagenMember" xlink:label="lbl_SandozASCopenhagenMember" xlink:type="locator"/>
      <link:definitionArc order="63.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozASCopenhagenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconNordicASCopenhagenMember" xlink:label="lbl_AlconNordicASCopenhagenMember" xlink:type="locator"/>
      <link:definitionArc order="64.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconNordicASCopenhagenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisEcuadorS.A.QuitoMember" xlink:label="lbl_NovartisEcuadorS.A.QuitoMember" xlink:type="locator"/>
      <link:definitionArc order="65.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisEcuadorS.A.QuitoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaS.A.E.CairoMember" xlink:label="lbl_NovartisPharmaS.A.E.CairoMember" xlink:type="locator"/>
      <link:definitionArc order="66.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaS.A.E.CairoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:label="lbl_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:type="locator"/>
      <link:definitionArc order="67.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFinlandOyEspooMember" xlink:label="lbl_NovartisFinlandOyEspooMember" xlink:type="locator"/>
      <link:definitionArc order="68.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinlandOyEspooMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:label="lbl_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:type="locator"/>
      <link:definitionArc order="69.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:label="lbl_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:definitionArc order="70.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember" xlink:label="lbl_AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember" xlink:type="locator"/>
      <link:definitionArc order="71.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CELLforCURELesUlisMember" xlink:label="lbl_CELLforCURELesUlisMember" xlink:type="locator"/>
      <link:definitionArc order="72.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CELLforCURELesUlisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozS.A.S.LevalloisPerretMember" xlink:label="lbl_SandozS.A.S.LevalloisPerretMember" xlink:type="locator"/>
      <link:definitionArc order="73.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.A.S.LevalloisPerretMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:label="lbl_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:definitionArc order="74.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisDeutschlandGmbHWehrMember" xlink:label="lbl_NovartisDeutschlandGmbHWehrMember" xlink:type="locator"/>
      <link:definitionArc order="75.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisDeutschlandGmbHWehrMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaGmbHNurembergMember" xlink:label="lbl_NovartisPharmaGmbHNurembergMember" xlink:type="locator"/>
      <link:definitionArc order="76.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaGmbHNurembergMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaProduktionsGmbHWehrMember" xlink:label="lbl_NovartisPharmaProduktionsGmbHWehrMember" xlink:type="locator"/>
      <link:definitionArc order="77.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaProduktionsGmbHWehrMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:label="lbl_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:type="locator"/>
      <link:definitionArc order="78.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WaveLightGmbHErlangenMember" xlink:label="lbl_WaveLightGmbHErlangenMember" xlink:type="locator"/>
      <link:definitionArc order="79.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_WaveLightGmbHErlangenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CIBAVisionGmbHGrosswallstadtMember" xlink:label="lbl_CIBAVisionGmbHGrosswallstadtMember" xlink:type="locator"/>
      <link:definitionArc order="80.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionGmbHGrosswallstadtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozInternationalGmbHHolzkirchenMember" xlink:label="lbl_SandozInternationalGmbHHolzkirchenMember" xlink:type="locator"/>
      <link:definitionArc order="81.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozInternationalGmbHHolzkirchenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1APharmaGmbHOberhachingMember" xlink:label="lbl_A1APharmaGmbHOberhachingMember" xlink:type="locator"/>
      <link:definitionArc order="82.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_A1APharmaGmbHOberhachingMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SalutasPharmaGmbHBarlebenMember" xlink:label="lbl_SalutasPharmaGmbHBarlebenMember" xlink:type="locator"/>
      <link:definitionArc order="83.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SalutasPharmaGmbHBarlebenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_HEXALAGHolzkirchenMember" xlink:label="lbl_HEXALAGHolzkirchenMember" xlink:type="locator"/>
      <link:definitionArc order="84.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_HEXALAGHolzkirchenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AeropharmGmbHRudolstadtMember" xlink:label="lbl_AeropharmGmbHRudolstadtMember" xlink:type="locator"/>
      <link:definitionArc order="85.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AeropharmGmbHRudolstadtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisDeutschlandGmbHNurembergMember" xlink:label="lbl_NovartisDeutschlandGmbHNurembergMember" xlink:type="locator"/>
      <link:definitionArc order="86.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisDeutschlandGmbHNurembergMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisBusinessServicesGmbHWehrMember" xlink:label="lbl_NovartisBusinessServicesGmbHWehrMember" xlink:type="locator"/>
      <link:definitionArc order="87.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBusinessServicesGmbHWehrMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovistaInsuranceLimitedGibraltarCityMember" xlink:label="lbl_NovistaInsuranceLimitedGibraltarCityMember" xlink:type="locator"/>
      <link:definitionArc order="88.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovistaInsuranceLimitedGibraltarCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:label="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:type="locator"/>
      <link:definitionArc order="89.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:label="lbl_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:type="locator"/>
      <link:definitionArc order="90.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:label="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:type="locator"/>
      <link:definitionArc order="91.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:label="lbl_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:type="locator"/>
      <link:definitionArc order="92.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisIndiaLimitedMumbaiMember" xlink:label="lbl_NovartisIndiaLimitedMumbaiMember" xlink:type="locator"/>
      <link:definitionArc order="93.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisIndiaLimitedMumbaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:label="lbl_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:type="locator"/>
      <link:definitionArc order="94.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozPrivateLimitedMumbaiMember" xlink:label="lbl_SandozPrivateLimitedMumbaiMember" xlink:type="locator"/>
      <link:definitionArc order="95.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPrivateLimitedMumbaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:label="lbl_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:type="locator"/>
      <link:definitionArc order="96.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PT.NovartisIndonesiaJakartaMember" xlink:label="lbl_PT.NovartisIndonesiaJakartaMember" xlink:type="locator"/>
      <link:definitionArc order="97.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_PT.NovartisIndonesiaJakartaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PT.CIBAVisionBatamBatamMember" xlink:label="lbl_PT.CIBAVisionBatamBatamMember" xlink:type="locator"/>
      <link:definitionArc order="98.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_PT.CIBAVisionBatamBatamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisIrelandLimitedDublinMember" xlink:label="lbl_NovartisIrelandLimitedDublinMember" xlink:type="locator"/>
      <link:definitionArc order="99.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisIrelandLimitedDublinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:label="lbl_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:type="locator"/>
      <link:definitionArc order="100.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:label="lbl_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:type="locator"/>
      <link:definitionArc order="101.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisGeneTherapiesEULimitedDublinMember" xlink:label="lbl_NovartisGeneTherapiesEULimitedDublinMember" xlink:type="locator"/>
      <link:definitionArc order="102.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGeneTherapiesEULimitedDublinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:label="lbl_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:type="locator"/>
      <link:definitionArc order="103.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisIsraelLtd.TelAvivMember" xlink:label="lbl_NovartisIsraelLtd.TelAvivMember" xlink:type="locator"/>
      <link:definitionArc order="104.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisIsraelLtd.TelAvivMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OptonolLtd.NeveIlanMember" xlink:label="lbl_OptonolLtd.NeveIlanMember" xlink:type="locator"/>
      <link:definitionArc order="105.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_OptonolLtd.NeveIlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFarmaS.p.A.OriggioMember" xlink:label="lbl_NovartisFarmaS.p.A.OriggioMember" xlink:type="locator"/>
      <link:definitionArc order="106.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFarmaS.p.A.OriggioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:label="lbl_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:type="locator"/>
      <link:definitionArc order="107.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozS.p.A.OriggioMember" xlink:label="lbl_SandozS.p.A.OriggioMember" xlink:type="locator"/>
      <link:definitionArc order="108.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.p.A.OriggioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:label="lbl_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:type="locator"/>
      <link:definitionArc order="109.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconItaliaS.p.A.MilanMember" xlink:label="lbl_AlconItaliaS.p.A.MilanMember" xlink:type="locator"/>
      <link:definitionArc order="110.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconItaliaS.p.A.MilanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisHoldingJapanK.K.TokyoMember" xlink:label="lbl_NovartisHoldingJapanK.K.TokyoMember" xlink:type="locator"/>
      <link:definitionArc order="111.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHoldingJapanK.K.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaK.K.TokyoMember" xlink:label="lbl_NovartisPharmaK.K.TokyoMember" xlink:type="locator"/>
      <link:definitionArc order="112.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaK.K.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CibaGeigyJapanLimitedTokyoMember" xlink:label="lbl_CibaGeigyJapanLimitedTokyoMember" xlink:type="locator"/>
      <link:definitionArc order="113.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CibaGeigyJapanLimitedTokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozK.K.TokyoMember" xlink:label="lbl_SandozK.K.TokyoMember" xlink:type="locator"/>
      <link:definitionArc order="114.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozK.K.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AspenJapanK.K.TokyoMember" xlink:label="lbl_AspenJapanK.K.TokyoMember" xlink:type="locator"/>
      <link:definitionArc order="115.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AspenJapanK.K.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconJapanLtd.TokyoMember" xlink:label="lbl_AlconJapanLtd.TokyoMember" xlink:type="locator"/>
      <link:definitionArc order="116.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconJapanLtd.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisBalticsSIARigaMember" xlink:label="lbl_NovartisBalticsSIARigaMember" xlink:type="locator"/>
      <link:definitionArc order="117.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBalticsSIARigaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:label="lbl_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:type="locator"/>
      <link:definitionArc order="118.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFinanceS.A.LuxembourgCityMember" xlink:label="lbl_NovartisFinanceS.A.LuxembourgCityMember" xlink:type="locator"/>
      <link:definitionArc order="119.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinanceS.A.LuxembourgCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember" xlink:label="lbl_NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember" xlink:type="locator"/>
      <link:definitionArc order="120.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:label="lbl_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="locator"/>
      <link:definitionArc order="121.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:label="lbl_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:type="locator"/>
      <link:definitionArc order="122.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:label="lbl_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:definitionArc order="123.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozS.A.DeC.V.MexicoCityMember" xlink:label="lbl_SandozS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:definitionArc order="124.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.A.DeC.V.MexicoCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:label="lbl_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:definitionArc order="125.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaMarocSACasablancaMember" xlink:label="lbl_NovartisPharmaMarocSACasablancaMember" xlink:type="locator"/>
      <link:definitionArc order="126.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaMarocSACasablancaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisNetherlandsB.V.ArnhemMember" xlink:label="lbl_NovartisNetherlandsB.V.ArnhemMember" xlink:type="locator"/>
      <link:definitionArc order="127.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNetherlandsB.V.ArnhemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisNetherlandsB.V.AmsterdamMember" xlink:label="lbl_NovartisNetherlandsB.V.AmsterdamMember" xlink:type="locator"/>
      <link:definitionArc order="128.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNetherlandsB.V.AmsterdamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaB.V.ArnhemMember" xlink:label="lbl_NovartisPharmaB.V.ArnhemMember" xlink:type="locator"/>
      <link:definitionArc order="129.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaB.V.ArnhemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaB.V.AmsterdamMember" xlink:label="lbl_NovartisPharmaB.V.AmsterdamMember" xlink:type="locator"/>
      <link:definitionArc order="130.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaB.V.AmsterdamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IDBHollandBVBaarleNassauMember" xlink:label="lbl_IDBHollandBVBaarleNassauMember" xlink:type="locator"/>
      <link:definitionArc order="131.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_IDBHollandBVBaarleNassauMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozB.V.AlmereMember" xlink:label="lbl_SandozB.V.AlmereMember" xlink:type="locator"/>
      <link:definitionArc order="132.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozB.V.AlmereMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconNederlandB.V.ArnhemMember" xlink:label="lbl_AlconNederlandB.V.ArnhemMember" xlink:type="locator"/>
      <link:definitionArc order="133.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconNederlandB.V.ArnhemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisNewZealandLtdAucklandMember" xlink:label="lbl_NovartisNewZealandLtdAucklandMember" xlink:type="locator"/>
      <link:definitionArc order="134.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNewZealandLtdAucklandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisNorgeASOsloMember" xlink:label="lbl_NovartisNorgeASOsloMember" xlink:type="locator"/>
      <link:definitionArc order="135.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNorgeASOsloMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaPakistanLimitedKarachiMember" xlink:label="lbl_NovartisPharmaPakistanLimitedKarachiMember" xlink:type="locator"/>
      <link:definitionArc order="136.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaPakistanLimitedKarachiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:label="lbl_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:type="locator"/>
      <link:definitionArc order="137.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconCentroamericaS.A.PanamaCityMember" xlink:label="lbl_AlconCentroamericaS.A.PanamaCityMember" xlink:type="locator"/>
      <link:definitionArc order="138.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconCentroamericaS.A.PanamaCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisBiosciencesPeruS.A.LimaMember" xlink:label="lbl_NovartisBiosciencesPeruS.A.LimaMember" xlink:type="locator"/>
      <link:definitionArc order="139.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBiosciencesPeruS.A.LimaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:label="lbl_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:type="locator"/>
      <link:definitionArc order="140.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozPhilippinesCorporationMakatiCityMember" xlink:label="lbl_SandozPhilippinesCorporationMakatiCityMember" xlink:type="locator"/>
      <link:definitionArc order="141.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPhilippinesCorporationMakatiCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPolandSp.ZO.o.WarsawMember" xlink:label="lbl_NovartisPolandSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:definitionArc order="142.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPolandSp.ZO.o.WarsawMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozPolskaSp.ZO.o.WarsawMember" xlink:label="lbl_SandozPolskaSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:definitionArc order="143.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPolskaSp.ZO.o.WarsawMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LekS.A.StrykowMember" xlink:label="lbl_LekS.A.StrykowMember" xlink:type="locator"/>
      <link:definitionArc order="144.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_LekS.A.StrykowMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconPolskaSp.ZO.o.WarsawMember" xlink:label="lbl_AlconPolskaSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:definitionArc order="145.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPolskaSp.ZO.o.WarsawMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:label="lbl_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:type="locator"/>
      <link:definitionArc order="146.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:label="lbl_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:type="locator"/>
      <link:definitionArc order="147.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozFarmaceuticaLda.PortoSalvoMember" xlink:label="lbl_SandozFarmaceuticaLda.PortoSalvoMember" xlink:type="locator"/>
      <link:definitionArc order="148.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozFarmaceuticaLda.PortoSalvoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:label="lbl_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:type="locator"/>
      <link:definitionArc order="149.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:label="lbl_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:type="locator"/>
      <link:definitionArc order="150.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozS.R.L.TarguMuresMember" xlink:label="lbl_SandozS.R.L.TarguMuresMember" xlink:type="locator"/>
      <link:definitionArc order="151.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.R.L.TarguMuresMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconRomaniaS.R.L.BucharestMember" xlink:label="lbl_AlconRomaniaS.R.L.BucharestMember" xlink:type="locator"/>
      <link:definitionArc order="152.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconRomaniaS.R.L.BucharestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaLLCMoscowMember" xlink:label="lbl_NovartisPharmaLLCMoscowMember" xlink:type="locator"/>
      <link:definitionArc order="153.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaLLCMoscowMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisNevaLLCSt.PetersburgMember" xlink:label="lbl_NovartisNevaLLCSt.PetersburgMember" xlink:type="locator"/>
      <link:definitionArc order="154.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNevaLLCSt.PetersburgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ZAOSandozMoscowMember" xlink:label="lbl_ZAOSandozMoscowMember" xlink:type="locator"/>
      <link:definitionArc order="155.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ZAOSandozMoscowMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconFarmacevtikaLLCMoscowMember" xlink:label="lbl_AlconFarmacevtikaLLCMoscowMember" xlink:type="locator"/>
      <link:definitionArc order="156.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconFarmacevtikaLLCMoscowMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:label="lbl_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:type="locator"/>
      <link:definitionArc order="157.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisSaudiLtd.RiyadhMember" xlink:label="lbl_NovartisSaudiLtd.RiyadhMember" xlink:type="locator"/>
      <link:definitionArc order="158.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSaudiLtd.RiyadhMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisSingaporePteLtd.SingaporeMember" xlink:label="lbl_NovartisSingaporePteLtd.SingaporeMember" xlink:type="locator"/>
      <link:definitionArc order="159.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSingaporePteLtd.SingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:label="lbl_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:type="locator"/>
      <link:definitionArc order="160.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:label="lbl_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:type="locator"/>
      <link:definitionArc order="161.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:label="lbl_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:type="locator"/>
      <link:definitionArc order="162.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconPteLtdSingaporeMember" xlink:label="lbl_AlconPteLtdSingaporeMember" xlink:type="locator"/>
      <link:definitionArc order="163.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:label="lbl_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:type="locator"/>
      <link:definitionArc order="164.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:label="lbl_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:type="locator"/>
      <link:definitionArc order="165.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisSlovakiaS.r.o.BratislavaMember" xlink:label="lbl_NovartisSlovakiaS.r.o.BratislavaMember" xlink:type="locator"/>
      <link:definitionArc order="166.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSlovakiaS.r.o.BratislavaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LekPharmaceuticalsD.d.LjubjanaMember" xlink:label="lbl_LekPharmaceuticalsD.d.LjubjanaMember" xlink:type="locator"/>
      <link:definitionArc order="167.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_LekPharmaceuticalsD.d.LjubjanaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:label="lbl_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:type="locator"/>
      <link:definitionArc order="168.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisSouthAfricaPtyLtdMidrandMember" xlink:label="lbl_NovartisSouthAfricaPtyLtdMidrandMember" xlink:type="locator"/>
      <link:definitionArc order="169.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSouthAfricaPtyLtdMidrandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozSouthAfricaPtyLtdKemptonParkMember" xlink:label="lbl_SandozSouthAfricaPtyLtdKemptonParkMember" xlink:type="locator"/>
      <link:definitionArc order="170.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozSouthAfricaPtyLtdKemptonParkMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:label="lbl_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:type="locator"/>
      <link:definitionArc order="171.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisKoreaLtd.SeoulMember" xlink:label="lbl_NovartisKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:definitionArc order="172.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisKoreaLtd.SeoulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozKoreaLtd.SeoulMember" xlink:label="lbl_SandozKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:definitionArc order="173.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozKoreaLtd.SeoulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconKoreaLtd.SeoulMember" xlink:label="lbl_AlconKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:definitionArc order="174.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconKoreaLtd.SeoulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:label="lbl_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:type="locator"/>
      <link:definitionArc order="175.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:label="lbl_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:type="locator"/>
      <link:definitionArc order="176.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozFarmaceuticaS.A.MadridMember" xlink:label="lbl_SandozFarmaceuticaS.A.MadridMember" xlink:type="locator"/>
      <link:definitionArc order="177.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozFarmaceuticaS.A.MadridMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozIndustrialProductsS.A.BarcelonaMember" xlink:label="lbl_SandozIndustrialProductsS.A.BarcelonaMember" xlink:type="locator"/>
      <link:definitionArc order="178.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozIndustrialProductsS.A.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:label="lbl_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:type="locator"/>
      <link:definitionArc order="179.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconHealthcareS.A.BarcelonaMember" xlink:label="lbl_AlconHealthcareS.A.BarcelonaMember" xlink:type="locator"/>
      <link:definitionArc order="180.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconHealthcareS.A.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconCusiS.A.BarcelonaMember" xlink:label="lbl_AlconCusiS.A.BarcelonaMember" xlink:type="locator"/>
      <link:definitionArc order="181.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconCusiS.A.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:label="lbl_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:type="locator"/>
      <link:definitionArc order="182.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisSverigeABStockholmMember" xlink:label="lbl_NovartisSverigeABStockholmMember" xlink:type="locator"/>
      <link:definitionArc order="183.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSverigeABStockholmMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisOverseasInvestmentsAGBaselMember" xlink:label="lbl_NovartisOverseasInvestmentsAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="184.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisOverseasInvestmentsAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_JapatAGBaselMember" xlink:label="lbl_JapatAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="185.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_JapatAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInternationalAGBaselMember" xlink:label="lbl_NovartisInternationalAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="186.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInternationalAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisHoldingAGBaselMember" xlink:label="lbl_NovartisHoldingAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="187.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHoldingAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:label="lbl_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="188.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisOphthalmicsAGFribourgMember" xlink:label="lbl_NovartisOphthalmicsAGFribourgMember" xlink:type="locator"/>
      <link:definitionArc order="189.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisOphthalmicsAGFribourgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisBioventuresAGBaselMember" xlink:label="lbl_NovartisBioventuresAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="190.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBioventuresAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisForschungsstiftungBaselMember" xlink:label="lbl_NovartisForschungsstiftungBaselMember" xlink:type="locator"/>
      <link:definitionArc order="191.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisForschungsstiftungBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisStiftungFuerKaderausbildungBaselMember" xlink:label="lbl_NovartisStiftungFuerKaderausbildungBaselMember" xlink:type="locator"/>
      <link:definitionArc order="192.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisStiftungFuerKaderausbildungBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:label="lbl_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:type="locator"/>
      <link:definitionArc order="193.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:label="lbl_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:type="locator"/>
      <link:definitionArc order="194.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:label="lbl_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:type="locator"/>
      <link:definitionArc order="195.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaAGBaselMember" xlink:label="lbl_NovartisPharmaAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="196.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInternationalPharmaceuticalAGBaselMember" xlink:label="lbl_NovartisInternationalPharmaceuticalAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="197.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInternationalPharmaceuticalAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaServicesAGBaselMember" xlink:label="lbl_NovartisPharmaServicesAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="198.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaServicesAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:label="lbl_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:type="locator"/>
      <link:definitionArc order="199.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaSteinAGSteinMember" xlink:label="lbl_NovartisPharmaSteinAGSteinMember" xlink:type="locator"/>
      <link:definitionArc order="200.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaSteinAGSteinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaSchweizAGRischMember" xlink:label="lbl_NovartisPharmaSchweizAGRischMember" xlink:type="locator"/>
      <link:definitionArc order="201.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaSchweizAGRischMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:label="lbl_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:type="locator"/>
      <link:definitionArc order="202.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:label="lbl_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:type="locator"/>
      <link:definitionArc order="203.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozAGBaselMember" xlink:label="lbl_SandozAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="204.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozPharmaceuticalsAGRischMember" xlink:label="lbl_SandozPharmaceuticalsAGRischMember" xlink:type="locator"/>
      <link:definitionArc order="205.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPharmaceuticalsAGRischMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconAGFribourgMember" xlink:label="lbl_AlconAGFribourgMember" xlink:type="locator"/>
      <link:definitionArc order="206.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconAGFribourgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconManagementSAGenevaMember" xlink:label="lbl_AlconManagementSAGenevaMember" xlink:type="locator"/>
      <link:definitionArc order="207.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconManagementSAGenevaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconSwitzerlandSARischMember" xlink:label="lbl_AlconSwitzerlandSARischMember" xlink:type="locator"/>
      <link:definitionArc order="208.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconSwitzerlandSARischMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconPharmaceuticalsLtd.FribourgMember" xlink:label="lbl_AlconPharmaceuticalsLtd.FribourgMember" xlink:type="locator"/>
      <link:definitionArc order="209.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPharmaceuticalsLtd.FribourgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RocheHoldingAGBaselMember" xlink:label="lbl_RocheHoldingAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="210.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_RocheHoldingAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:label="lbl_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:type="locator"/>
      <link:definitionArc order="211.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisThailandLimitedBangkokMember" xlink:label="lbl_NovartisThailandLimitedBangkokMember" xlink:type="locator"/>
      <link:definitionArc order="212.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisThailandLimitedBangkokMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesThailandLimitedBangkokMember" xlink:label="lbl_AlconLaboratoriesThailandLimitedBangkokMember" xlink:type="locator"/>
      <link:definitionArc order="213.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesThailandLimitedBangkokMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:label="lbl_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:definitionArc order="214.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:label="lbl_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:type="locator"/>
      <link:definitionArc order="215.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:label="lbl_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:type="locator"/>
      <link:definitionArc order="216.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:label="lbl_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:definitionArc order="217.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:label="lbl_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:type="locator"/>
      <link:definitionArc order="218.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:label="lbl_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:definitionArc order="219.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozUkraineLLCKievMember" xlink:label="lbl_SandozUkraineLLCKievMember" xlink:type="locator"/>
      <link:definitionArc order="220.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozUkraineLLCKievMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisMiddleEastFZEDubaiMember" xlink:label="lbl_NovartisMiddleEastFZEDubaiMember" xlink:type="locator"/>
      <link:definitionArc order="221.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisMiddleEastFZEDubaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisUKLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:definitionArc order="222.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisUKLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisUKLimitedLondonMember" xlink:label="lbl_NovartisUKLimitedLondonMember" xlink:type="locator"/>
      <link:definitionArc order="223.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisUKLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:definitionArc order="224.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:label="lbl_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:type="locator"/>
      <link:definitionArc order="225.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:definitionArc order="226.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisGrimsbyLimitedLondonMember" xlink:label="lbl_NovartisGrimsbyLimitedLondonMember" xlink:type="locator"/>
      <link:definitionArc order="227.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGrimsbyLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:type="locator"/>
      <link:definitionArc order="228.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NeutecPharmaLimitedLondonMember" xlink:label="lbl_NeutecPharmaLimitedLondonMember" xlink:type="locator"/>
      <link:definitionArc order="229.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NeutecPharmaLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImagingEquipmentLtdLondonMember" xlink:label="lbl_ImagingEquipmentLtdLondonMember" xlink:type="locator"/>
      <link:definitionArc order="230.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ImagingEquipmentLtdLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VivactaLimitedFrimleyCamberleySurreyMember" xlink:label="lbl_VivactaLimitedFrimleyCamberleySurreyMember" xlink:type="locator"/>
      <link:definitionArc order="231.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_VivactaLimitedFrimleyCamberleySurreyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:label="lbl_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:type="locator"/>
      <link:definitionArc order="232.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ZiarcoGroupLimitedLondonMember" xlink:label="lbl_ZiarcoGroupLimitedLondonMember" xlink:type="locator"/>
      <link:definitionArc order="233.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ZiarcoGroupLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozLimitedFrimleyCamberleyMember" xlink:label="lbl_SandozLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:definitionArc order="234.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:label="lbl_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:type="locator"/>
      <link:definitionArc order="235.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:label="lbl_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:definitionArc order="236.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:label="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="locator"/>
      <link:definitionArc order="237.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisCorporationEastHanoverNYMember" xlink:label="lbl_NovartisCorporationEastHanoverNYMember" xlink:type="locator"/>
      <link:definitionArc order="238.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisCorporationEastHanoverNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFinanceCorporationNewYorkNYMember" xlink:label="lbl_NovartisFinanceCorporationNewYorkNYMember" xlink:type="locator"/>
      <link:definitionArc order="239.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinanceCorporationNewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFinanceCorporationEastHanoverNJMember" xlink:label="lbl_NovartisFinanceCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="240.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinanceCorporationEastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisCapitalCorporationNewYorkNYMember" xlink:label="lbl_NovartisCapitalCorporationNewYorkNYMember" xlink:type="locator"/>
      <link:definitionArc order="241.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisCapitalCorporationNewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisCapitalCorporationEastHanoverNJMember" xlink:label="lbl_NovartisCapitalCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="242.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisCapitalCorporationEastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisServicesInc.EastHanoverNYMember" xlink:label="lbl_NovartisServicesInc.EastHanoverNYMember" xlink:type="locator"/>
      <link:definitionArc order="243.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisServicesInc.EastHanoverNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisUSFoundationNewYorkNYMember" xlink:label="lbl_NovartisUSFoundationNewYorkNYMember" xlink:type="locator"/>
      <link:definitionArc order="244.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisUSFoundationNewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisUSFoundationEastHanoverNJMember" xlink:label="lbl_NovartisUSFoundationEastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="245.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisUSFoundationEastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:label="lbl_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:type="locator"/>
      <link:definitionArc order="246.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:type="locator"/>
      <link:definitionArc order="247.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:label="lbl_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:type="locator"/>
      <link:definitionArc order="248.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CortheraInc.SanMateoCAMember" xlink:label="lbl_CortheraInc.SanMateoCAMember" xlink:type="locator"/>
      <link:definitionArc order="249.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CortheraInc.SanMateoCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:label="lbl_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:type="locator"/>
      <link:definitionArc order="250.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EncoreVisionInc.NewYorkNYMember" xlink:label="lbl_EncoreVisionInc.NewYorkNYMember" xlink:type="locator"/>
      <link:definitionArc order="251.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EncoreVisionInc.NewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EncoreVisionInc.EastHanoverNJMember" xlink:label="lbl_EncoreVisionInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="252.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EncoreVisionInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EndocyteInc.LafayetteINMember" xlink:label="lbl_EndocyteInc.LafayetteINMember" xlink:type="locator"/>
      <link:definitionArc order="253.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EndocyteInc.LafayetteINMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EndocyteInc.EastHanoverNJMember" xlink:label="lbl_EndocyteInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="254.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EndocyteInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:label="lbl_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:type="locator"/>
      <link:definitionArc order="255.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:label="lbl_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="256.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:label="lbl_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:type="locator"/>
      <link:definitionArc order="257.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:label="lbl_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="258.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:label="lbl_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:type="locator"/>
      <link:definitionArc order="259.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:type="locator"/>
      <link:definitionArc order="260.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AveXisInc.BannockburnILMember" xlink:label="lbl_AveXisInc.BannockburnILMember" xlink:type="locator"/>
      <link:definitionArc order="261.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AveXisInc.BannockburnILMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:label="lbl_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="262.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:label="lbl_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="263.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:label="lbl_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="264.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TheMedicinesCompanyMember" xlink:label="lbl_TheMedicinesCompanyMember" xlink:type="locator"/>
      <link:definitionArc order="265.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TheMedicinesCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozInc.PrincetonNJMember" xlink:label="lbl_SandozInc.PrincetonNJMember" xlink:type="locator"/>
      <link:definitionArc order="266.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozInc.PrincetonNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmblyotechInc.EastHanoverNJMember" xlink:label="lbl_AmblyotechInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="267.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AmblyotechInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OrielTherapeuticsInc.DurhamNCMember" xlink:label="lbl_OrielTherapeuticsInc.DurhamNCMember" xlink:type="locator"/>
      <link:definitionArc order="268.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_OrielTherapeuticsInc.DurhamNCMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:label="lbl_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:type="locator"/>
      <link:definitionArc order="269.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EonLabsInc.PrincetonNJMember" xlink:label="lbl_EonLabsInc.PrincetonNJMember" xlink:type="locator"/>
      <link:definitionArc order="270.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EonLabsInc.PrincetonNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesInc.FortWorthTXMember" xlink:label="lbl_AlconLaboratoriesInc.FortWorthTXMember" xlink:type="locator"/>
      <link:definitionArc order="271.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesInc.FortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:label="lbl_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:type="locator"/>
      <link:definitionArc order="272.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconResearchLtd.FortWorthTXMember" xlink:label="lbl_AlconResearchLtd.FortWorthTXMember" xlink:type="locator"/>
      <link:definitionArc order="273.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconResearchLtd.FortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLensxInc.AlisoViejoCAMember" xlink:label="lbl_AlconLensxInc.AlisoViejoCAMember" xlink:type="locator"/>
      <link:definitionArc order="274.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLensxInc.AlisoViejoCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:label="lbl_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:type="locator"/>
      <link:definitionArc order="275.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WaveLightInc.SterlingVAMember" xlink:label="lbl_WaveLightInc.SterlingVAMember" xlink:type="locator"/>
      <link:definitionArc order="276.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_WaveLightInc.SterlingVAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TearFilmInnovationsInc.FortWorthTXMember" xlink:label="lbl_TearFilmInnovationsInc.FortWorthTXMember" xlink:type="locator"/>
      <link:definitionArc order="277.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TearFilmInnovationsInc.FortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TrueVisionSystemsInc.FortWorthTXMember" xlink:label="lbl_TrueVisionSystemsInc.FortWorthTXMember" xlink:type="locator"/>
      <link:definitionArc order="278.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TrueVisionSystemsInc.FortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CIBAVisionCorporationLLCDuluthGAMember" xlink:label="lbl_CIBAVisionCorporationLLCDuluthGAMember" xlink:type="locator"/>
      <link:definitionArc order="279.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionCorporationLLCDuluthGAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:label="lbl_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:type="locator"/>
      <link:definitionArc order="280.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:label="lbl_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="281.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:label="lbl_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:type="locator"/>
      <link:definitionArc order="282.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TranscendMedicalInc.LakeForestILMember" xlink:label="lbl_TranscendMedicalInc.LakeForestILMember" xlink:type="locator"/>
      <link:definitionArc order="283.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TranscendMedicalInc.LakeForestILMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisDeVenezuelaS.A.CaracasMember" xlink:label="lbl_NovartisDeVenezuelaS.A.CaracasMember" xlink:type="locator"/>
      <link:definitionArc order="284.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisDeVenezuelaS.A.CaracasMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconPharmaceuticalC.A.CaracasMember" xlink:label="lbl_AlconPharmaceuticalC.A.CaracasMember" xlink:type="locator"/>
      <link:definitionArc order="285.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPharmaceuticalC.A.CaracasMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsAAAMember" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="locator"/>
      <link:definitionArc order="286.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:label="lbl_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:type="locator"/>
      <link:definitionArc order="287.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NameOfSubsidiary" xlink:label="lbl_NameOfSubsidiary" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_NameOfSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" xlink:label="lbl_PrincipalPlaceOfBusinessOfSubsidiary" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_PrincipalPlaceOfBusinessOfSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:label="lbl_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharePaidinCapital" xlink:label="lbl_SharePaidinCapital" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_SharePaidinCapital" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xlink:label="lbl_ProportionOfVotingPowerHeldInSubsidiary" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_ProportionOfVotingPowerHeldInSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:label="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails12" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:label="lbl_EuropeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EuropeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AsiaAfricaAustralasiaMember" xlink:label="lbl_AsiaAfricaAustralasiaMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_AsiaAfricaAustralasiaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CanadaAndLatinAmericaMember" xlink:label="lbl_CanadaAndLatinAmericaMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CanadaAndLatinAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EstablishedMarketsMember" xlink:label="lbl_EstablishedMarketsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EstablishedMarketsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EmergingGrowthMarketsMember" xlink:label="lbl_EmergingGrowthMarketsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EmergingGrowthMarketsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureSubsequentEventsDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SubsequentEventTypAxis" xlink:label="lbl_SubsequentEventTypAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_SubsequentEventTypAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SubsequentEventTypeMember" xlink:label="lbl_SubsequentEventTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SubsequentEventTypAxis" xlink:to="lbl_SubsequentEventTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SubsequentEventMember" xlink:label="lbl_SubsequentEventMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SubsequentEventTypeMember" xlink:to="lbl_SubsequentEventMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureSubsequentEventsDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SubsequentEventTypAxis" xlink:label="lbl_SubsequentEventTypAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_SubsequentEventTypAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SubsequentEventTypeMember" xlink:label="lbl_SubsequentEventTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SubsequentEventTypAxis" xlink:to="lbl_SubsequentEventTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SubsequentEventMember" xlink:label="lbl_SubsequentEventMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SubsequentEventTypeMember" xlink:to="lbl_SubsequentEventMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:label="lbl_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:label="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContractualInterestOnNoncurrentLiabilities" xlink:label="lbl_ContractualInterestOnNoncurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_ContractualInterestOnNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationLiabilities" xlink:label="lbl_ContingentConsiderationLiabilities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_ContingentConsiderationLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CommitmentForRepurchaseOwnShares" xlink:label="lbl_CommitmentForRepurchaseOwnShares" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CommitmentForRepurchaseOwnShares" xlink:type="arc"/>
   </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>11
<FILENAME>nvs-20201231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by MDD - e-reporting v3 -->
<!-- Created by MDD - Management Digital Data AG, Switzerland -->
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nvs="http://novartis.com/20201231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2019-03-27/ifrs-full" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ns0="http://www.novartis.com/custom-units">
  <link:schemaRef xlink:type="simple" xlink:href="nvs-20201231.xsd" />
  <xbrli:context id="AR_I-CurrentYearEnd-2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-Alcon-3-April-8">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-08</xbrli:startDate>
      <xbrli:endDate>2019-04-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearStart-1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYearStart-1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-01-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-08</xbrli:startDate>
      <xbrli:endDate>2019-04-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-08</xbrli:startDate>
      <xbrli:endDate>2019-04-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Alcon-1-March-6_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Alcon-4-April-9_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Alcon-2-March-31_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Alcon-1-March-6_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4BorrowingsUSDMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:BorrowingsUSDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Alcon-1-March-6_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4BorrowingsEURMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:BorrowingsEURMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:USspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonUSspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearStart-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearStart-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-PowerVision-1_dei-2020LegalEntityAxis_nvs-2020Q4PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:PowerVisionInc.Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-PowerVision-1_dei-2020LegalEntityAxis_nvs-2020Q4PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:PowerVisionInc.Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-03-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019BottomOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019BottomOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019TopOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019TopOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CommoditiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommoditiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CommoditiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommoditiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019USD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019USD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019EUR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019EUR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019JPY">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019JPY">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019RUB">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:RUB</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019RUB">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:RUB</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019CNY">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019CNY">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019GBP">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019GBP">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019AUD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019AUD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019BRL">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:BRL</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019BRL">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:BRL</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019CAD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019CAD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019CHF">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019CHF">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019CurrentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:CurrentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019CurrentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:CurrentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019NotLaterThanOneMonthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019NotLaterThanOneMonthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanThreeMonthsAndNotLaterThanSixMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanThreeMonthsAndNotLaterThanSixMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanSixMonthsAndNotLaterThanOneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanSixMonthsAndNotLaterThanOneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanOneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanOneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AlconBrandNameMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AlconBrandNameMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4MarketingRelatedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AlconBrandNameMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AlconBrandNameMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4MarketingRelatedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EnoxaparinMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember_srt-2020LitigationCaseAxis_nvs-2020Q4TennesseeClassActionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EnoxaparinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">nvs:TennesseeClassActionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AmiodaroneMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AmiodaroneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4NPCAndOthersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NPCAndOthersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ReclastAclastaMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4NPCAndOthersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NPCAndOthersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ReclastAclastaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TaxotereMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TaxotereMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TravoprostGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TravoprostGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TravoprostGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TravoprostGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EnoxaparinMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EnoxaparinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4NPCAndOthersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NPCAndOthersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_ifrsfull-2019ActuarialAssumptionOfDiscountRatesMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Change25BasisPointMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_ifrsfull-2019ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Change25BasisPointMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_ifrsfull-2019ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Change25BasisPointMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019EquityInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:EquityInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019EquityInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:EquityInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019EquityInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:EquityInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17IT_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IT</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17IT_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4NAGAndNovartisPharmaSpAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IT</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NAGAndNovartisPharmaSpAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4NovartisPharmaKKMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NovartisPharmaKKMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsAndNotLaterThanTenYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsAndNotLaterThanTenYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableForSaleMarketableSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableForSaleMarketableSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4FundInvestmentsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4ContingentConsiderationReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4EquitySecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:EquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4EquitySecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:EquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4EquitySecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:EquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4FundInvestmentsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4FundInvestmentsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableForSaleMarketableSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableForSaleMarketableSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4ContingentConsiderationReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableForSaleMarketableSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableForSaleMarketableSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4EquitySecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:EquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4TimeDepositsWithOriginalMaturityMoreThan90DaysMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:TimeDepositsWithOriginalMaturityMoreThan90DaysMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4OtherCurrentAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:OtherCurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4OtherCurrentAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:OtherCurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4TimeDepositsWithOriginalMaturityMoreThan90DaysMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:TimeDepositsWithOriginalMaturityMoreThan90DaysMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_ifrsfull-2019TradeReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_nvs-2020Q4CashAndCashEquivalentsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_nvs-2020Q4CashAndCashEquivalentsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TradePayablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TradePayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4BankAndOtherFinancialDebtMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:BankAndOtherFinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4CommercialPaperMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:CommercialPaperMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4StraightBondsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4NoncurrentFinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:StraightBondsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4LiabilitiesToBanksAndOtherFinancialInstitutionsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4NoncurrentFinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:LiabilitiesToBanksAndOtherFinancialInstitutionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4InterestBearningAccountsOfAssociatesPayableOnDemandMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:InterestBearningAccountsOfAssociatesPayableOnDemandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CommitmentForRepurchaseOfOwnSharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommitmentForRepurchaseOfOwnSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4InterestBearningAccountsOfAssociatesPayableOnDemandMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:InterestBearningAccountsOfAssociatesPayableOnDemandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4BankAndOtherFinancialDebtMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:BankAndOtherFinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4CommercialPaperMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:CommercialPaperMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4StraightBondsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4NoncurrentFinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:StraightBondsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4LiabilitiesToBanksAndOtherFinancialInstitutionsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4NoncurrentFinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:LiabilitiesToBanksAndOtherFinancialInstitutionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TradePayablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TradePayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_ifrsfull-2019LeaseLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">nvs:OtherFinancialLiabilitiesCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">nvs:OtherFinancialLiabilitiesCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_ifrsfull-2019LeaseLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">nvs:OtherFinancialLiabilitiesCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">nvs:OtherFinancialLiabilitiesCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4ContingentConsiderationAndOtherFinancialLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:ContingentConsiderationAndOtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4ContingentConsiderationAndOtherFinancialLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:ContingentConsiderationAndOtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4FundInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4FundInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4ContingentConsiderationReceivablesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4FundInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4FundInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4FundInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4ContingentConsiderationReceivablesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4ContingentConsiderationReceivablesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4FundInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4ContingentConsiderationReceivablesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis">ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis">ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis">ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis">ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019DisposalGroupsClassifiedAsHeldForSaleMember_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis">ifrs-full:DisposalGroupsClassifiedAsHeldForSaleMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019DisposalGroupsClassifiedAsHeldForSaleMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis">ifrs-full:DisposalGroupsClassifiedAsHeldForSaleMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019WeightedAverageMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:WeightedAverageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019WeightedAverageMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:WeightedAverageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeVenezuelaS.A.CaracasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AmblyotechInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AmblyotechInc.EastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AmblyotechInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AmblyotechInc.EastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisVietnamCompanyLimitedHoChiMinhCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CoalesceProductDevelopmentLimitedCambridgeCambsMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CoalesceProductDevelopmentLimitedCambridgeCambsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisVietnamCompanyLimitedHoChiMinhCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIsraelLtd.TelAvivMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIsraelLtd.TelAvivMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AspenJapanK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AspenJapanK.K.TokyoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AspenJapanK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AspenJapanK.K.TokyoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcarePhilippinesInc.MakatiCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcarePhilippinesInc.MakatiCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPhilippinesCorporationMakatiCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPhilippinesCorporationMakatiCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4RocheHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:RocheHoldingAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsUKIrelandLondonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsUKIrelandLondonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NeutecPharmaLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NeutecPharmaLimitedLondonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NeutecPharmaLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NeutecPharmaLimitedLondonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4CoalesceProductDevelopmentLimitedCambridgeCambsMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CoalesceProductDevelopmentLimitedCambridgeCambsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOptogeneticsResearchInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisOptogeneticsResearchInc.EastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOptogeneticsResearchInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisOptogeneticsResearchInc.EastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeVenezuelaS.A.CaracasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozManufacturingInc.Member_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozManufacturingInc.Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozManufacturingInc.Member_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozManufacturingInc.Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AlconCusiS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AlconCusiS.A.BarcelonaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AlconCusiS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AlconCusiS.A.BarcelonaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeutschlandGmbHNurembergMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeutschlandGmbHNurembergMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesEULimitedDublinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesEULimitedDublinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsCorporationEastHanoverNYMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AveXisInc.BannockburnILMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AveXisInc.BannockburnILMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AveXisInc.BannockburnILMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AveXisInc.BannockburnILMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4CoStimPharmaceuticalsInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CoStimPharmaceuticalsInc.CambridgeMAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CoStimPharmaceuticalsInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CoStimPharmaceuticalsInc.CambridgeMAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EndocyteInc.EastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EndocyteInc.EastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NavigateBioPharmaServicesInc.CarlsbadCAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NavigateBioPharmaServicesInc.CarlsbadCAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozInc.PrincetonNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozInc.PrincetonNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:OrielTherapeuticsInc.DurhamNCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:OrielTherapeuticsInc.DurhamNCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:FougeraPharmaceuticalsInc.MelvilleNYMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:FougeraPharmaceuticalsInc.MelvilleNYMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4EonLabsInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EonLabsInc.PrincetonNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EonLabsInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EonLabsInc.PrincetonNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsInternationalSAGeneveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsInternationalSAGeneveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPharmaceuticalsAGRischMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPharmaceuticalsAGRischMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4RocheHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:RocheHoldingAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisTaiwanCo.Ltd.TaipeiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisTaiwanCo.Ltd.TaipeiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisThailandLimitedBangkokMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisThailandLimitedBangkokMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisThailandLimitedBangkokMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisThailandLimitedBangkokMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozIlacSanayiVeTicaretA.S.IstanbulMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozIlacSanayiVeTicaretA.S.IstanbulMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozUkraineLLCKievMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozUkraineLLCKievMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozUkraineLLCKievMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozUkraineLLCKievMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisMiddleEastFZEDubaiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisMiddleEastFZEDubaiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisUKLimitedLondonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisUKLimitedLondonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsUKLimitedLondonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsUKLimitedLondonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGrimsbyLimitedLondonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGrimsbyLimitedLondonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4ZiarcoGroupLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ZiarcoGroupLimitedLondonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ZiarcoGroupLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ZiarcoGroupLimitedLondonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozLimitedFrimleyCamberleyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozLimitedFrimleyCamberleyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCorporationEastHanoverNYMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCorporationEastHanoverNYMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceCorporationEastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceCorporationEastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCapitalCorporationEastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCapitalCorporationEastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisServicesInc.EastHanoverNYMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisServicesInc.EastHanoverNYMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisUSFoundationEastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsCorporationEastHanoverNYMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaPakistanLimitedKarachiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaPakistanLimitedKarachiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaLogisticsInc.PanamaCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaLogisticsInc.PanamaCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiosciencesPeruS.A.LimaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBiosciencesPeruS.A.LimaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiosciencesPeruS.A.LimaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBiosciencesPeruS.A.LimaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPolandSp.ZO.o.WarsawMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPolandSp.ZO.o.WarsawMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPolskaSp.ZO.o.WarsawMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPolskaSp.ZO.o.WarsawMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4LekS.A.StrykowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:LekS.A.StrykowMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4LekS.A.StrykowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:LekS.A.StrykowMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPortugalSGPSLda.PortoSalvoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPortugalSGPSLda.PortoSalvoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozFarmaceuticaLda.PortoSalvoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozFarmaceuticaLda.PortoSalvoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaServicesRomaniaS.R.L.BucharestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaServicesRomaniaS.R.L.BucharestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.R.L.TarguMuresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.R.L.TarguMuresMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.R.L.TarguMuresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.R.L.TarguMuresMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLLCMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaLLCMoscowMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLLCMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaLLCMoscowMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNevaLLCSt.PetersburgMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNevaLLCSt.PetersburgMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4ZAOSandozMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ZAOSandozMoscowMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ZAOSandozMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ZAOSandozMoscowMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSaudiLtd.RiyadhMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSaudiLtd.RiyadhMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSingaporePteLtd.SingaporeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSingaporePteLtd.SingaporeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSlovakiaS.r.o.BratislavaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSlovakiaS.r.o.BratislavaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:LekPharmaceuticalsD.d.LjubjanaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:LekPharmaceuticalsD.d.LjubjanaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPharmaceuticalsD.d.LjubjanaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPharmaceuticalsD.d.LjubjanaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSouthAfricaPtyLtdMidrandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSouthAfricaPtyLtdMidrandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozSouthAfricaPtyLtdKemptonParkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozSouthAfricaPtyLtdKemptonParkMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozSouthAfricaPtyLtdKemptonParkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozSouthAfricaPtyLtdKemptonParkMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisKoreaLtd.SeoulMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisKoreaLtd.SeoulMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaceuticaS.A.BarcelonaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaceuticaS.A.BarcelonaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozFarmaceuticaS.A.MadridMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozFarmaceuticaS.A.MadridMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozIndustrialProductsS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozIndustrialProductsS.A.BarcelonaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozIndustrialProductsS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozIndustrialProductsS.A.BarcelonaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AbadiaRetuertaS.A.SardonDeDueroValladolidMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AbadiaRetuertaS.A.SardonDeDueroValladolidMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSverigeABStockholmMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSverigeABStockholmMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSverigeABStockholmMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSverigeABStockholmMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInternationalAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInternationalAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHoldingAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHoldingAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInternationalPharmaceuticalInvestmentAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInternationalPharmaceuticalInvestmentAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBioventuresAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBioventuresAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBioventuresAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBioventuresAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisForschungsstiftungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisForschungsstiftungBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisStiftungFuerKaderausbildungBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisMitarbeiterbeteiligungsstiftungBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisStiftungFuerMenschUndUmweltBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisOverseasInvestmentsAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisOverseasInvestmentsAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4JapatAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:JapatAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4JapatAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:JapatAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaServicesAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaServicesAGBaselMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSchweizerhalleAGMuttenzMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSchweizerhalleAGMuttenzMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSteinAGSteinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSteinAGSteinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSchweizAGRischMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSchweizAGRischMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOphthalmicsAGFribourgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisOphthalmicsAGFribourgMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOphthalmicsAGFribourgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisOphthalmicsAGFribourgMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SocieteParActionsSANDOZAlgiersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SocieteParActionsSANDOZAlgiersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisArgentinaS.A.BuenosAiresMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisArgentinaS.A.BuenosAiresMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAustraliaPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAustraliaPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustriaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAustriaGmbHViennaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustriaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAustriaGmbHViennaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaGmbHViennaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaGmbHViennaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozGmbHViennaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozGmbHViennaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EBEWEPharmaGes.m.b.HNfg.KGViennaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EBEWEPharmaGes.m.b.HNfg.KGViennaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBangladeshLimitedGazipurMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBangladeshLimitedGazipurMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaNVVilvoordeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaNVVilvoordeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozNVVilvoordeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozNVVilvoordeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AlconCouvreurNVPuursMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AlconCouvreurNVPuursMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AlconCouvreurNVPuursMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AlconCouvreurNVPuursMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInvestmentLtd.HamiltonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInvestmentLtd.HamiltonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSecuritiesInvestmentLtd.HamiltonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSecuritiesInvestmentLtd.HamiltonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceServicesLtd.HamiltonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceServicesLtd.HamiltonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TriangleInternationalReinsuranceLimitedHamiltonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TriangleInternationalReinsuranceLimitedHamiltonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TrinityRiverInsuranceCoLtd.HamiltonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TrinityRiverInsuranceCoLtd.HamiltonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBiocienciasS.A.SaoPauloMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBiocienciasS.A.SaoPauloMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozCanadaInc.BouchervilleQuebecMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozCanadaInc.BouchervilleQuebecMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisChileS.A.SantiagoDeChileMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisChileS.A.SantiagoDeChileMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:BeijingNovartisPharmaCo.Ltd.BeijingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:BeijingNovartisPharmaCo.Ltd.BeijingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsHKLimitedHongKongMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsHKLimitedHongKongMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ShanghaiNovartisTradingLtd.ShanghaiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ShanghaiNovartisTradingLtd.ShanghaiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeColombiaS.A.SantafeDeBobotaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeColombiaS.A.SantafeDeBobotaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozD.o.o.FarmaceutskaIndustrijaZagrebMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozD.o.o.FarmaceutskaIndustrijaZagrebMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisS.r.o.PragueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisS.r.o.PragueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.r.o.PragueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.r.o.PragueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcareASCopenhagenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcareASCopenhagenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozASCopenhagenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozASCopenhagenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisEcuadorS.A.QuitoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisEcuadorS.A.QuitoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaS.A.E.CairoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaS.A.E.CairoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozEgyptPharmaS.A.E.NewCairoCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozEgyptPharmaS.A.E.NewCairoCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinlandOyEspooMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinlandOyEspooMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinlandOyEspooMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinlandOyEspooMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGroupeFranceS.A.RueilMalmaisonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGroupeFranceS.A.RueilMalmaisonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaS.A.S.RueilMalmaisonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaS.A.S.RueilMalmaisonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4CELLforCURELesUlisMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CELLforCURELesUlisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CELLforCURELesUlisMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CELLforCURELesUlisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.A.S.LevalloisPerretMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.A.S.LevalloisPerretMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBusinessServicesGmbHWehrMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBusinessServicesGmbHWehrMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaGmbHNurembergMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaGmbHNurembergMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaProduktionsGmbHWehrMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaProduktionsGmbHWehrMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozInternationalGmbHHolzkirchenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozInternationalGmbHHolzkirchenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4A1APharmaGmbHOberhachingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:A1APharmaGmbHOberhachingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4A1APharmaGmbHOberhachingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:A1APharmaGmbHOberhachingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4HEXALAGHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:HEXALAGHolzkirchenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4HEXALAGHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:HEXALAGHolzkirchenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SalutasPharmaGmbHBarlebenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SalutasPharmaGmbHBarlebenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AeropharmGmbHRudolstadtMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AeropharmGmbHRudolstadtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AeropharmGmbHRudolstadtMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AeropharmGmbHRudolstadtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozHungaryLimitedLiabilityCompanyBudapestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozHungaryLimitedLiabilityCompanyBudapestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIndiaLimitedMumbaiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIndiaLimitedMumbaiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcarePrivateLimitedMumbaiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcarePrivateLimitedMumbaiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPrivateLimitedMumbaiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPrivateLimitedMumbaiMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:PT.NovartisIndonesiaJakartaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:PT.NovartisIndonesiaJakartaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIrelandLimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIrelandLimitedDublinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIrelandLimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIrelandLimitedDublinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaS.p.A.OriggioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaS.p.A.OriggioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.p.A.OriggioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.p.A.OriggioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaK.K.TokyoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaK.K.TokyoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CibaGeigyJapanLimitedTokyoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CibaGeigyJapanLimitedTokyoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozK.K.TokyoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozK.K.TokyoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBalticsSIARigaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBalticsSIARigaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBalticsSIARigaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBalticsSIARigaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInvestmentsS.aR.l.LuxembourgCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInvestmentsS.aR.l.LuxembourgCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceS.A.LuxembourgCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceS.A.LuxembourgCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.A.DeC.V.MexicoCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.A.DeC.V.MexicoCityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaMarocSACasablancaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaMarocSACasablancaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNetherlandsB.V.AmsterdamMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNetherlandsB.V.AmsterdamMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaB.V.AmsterdamMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaB.V.AmsterdamMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4IDBHollandBVBaarleNassauMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:IDBHollandBVBaarleNassauMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4IDBHollandBVBaarleNassauMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:IDBHollandBVBaarleNassauMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozB.V.AlmereMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozB.V.AlmereMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozB.V.AlmereMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozB.V.AlmereMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNewZealandLtdAucklandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNewZealandLtdAucklandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNorgeASOsloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNorgeASOsloMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNorgeASOsloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNorgeASOsloMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AimovigMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AimovigMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4BeovuMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:BeovuMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZolgensmaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KymriahMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PiqrayMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PiqrayMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XiidraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XiidraMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4BeovuMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:BeovuMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TabrectaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TabrectaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KesimptaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LutatheraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LutatheraMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LutatheraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LutatheraMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PiqrayMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PiqrayMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AdakveoMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AdakveoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AdakveoMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AdakveoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XiidraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XiidraMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZolgensmaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4MayzentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:MayzentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4MayzentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:MayzentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AimovigMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AimovigMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4UltibroGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4UltibroGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4UltibroGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LutatheraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LutatheraMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KymriahMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KymriahMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AimovigMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AimovigMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4FHoffmanLaRocheAGAndRocheSpAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:FHoffmanLaRocheAGAndRocheSpAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019FinancialAssetsImpairedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:FinancialAssetsImpairedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019FinancialAssetsImpairedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:FinancialAssetsImpairedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019FinancialAssetsImpairedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:FinancialAssetsImpairedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019LandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019VehiclesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019VehiclesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019VehiclesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019VehiclesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019OtherAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019OtherAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019OtherAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019OtherAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4MarketingRelatedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4MarketingRelatedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TravoprostGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TravoprostGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TravoprostGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TravoprostGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TravoprostGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TravoprostGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TravoprostGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TravoprostGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:CardioMetabolicMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:OphthalmologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:ImmunologyHepatologyAndDermatologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:EstablishedMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:PharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RespiratoryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:BusinessUnitAxis">nvs:OncologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-TheMedicinesCompany_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-11-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-TheMedicinesCompany_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-23</xbrli:startDate>
      <xbrli:endDate>2019-11-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-TheMedicinesCompany-2_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-TheMedicinesCompany-2_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-06</xbrli:startDate>
      <xbrli:endDate>2020-01-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-IFM-1_dei-2020LegalEntityAxis_nvs-2020Q4IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:IFMTreInc.Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-07</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-IFM-1_dei-2020LegalEntityAxis_nvs-2020Q4IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:IFMTreInc.Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-07</xbrli:startDate>
      <xbrli:endDate>2019-05-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2019-07-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-07-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-AspenGlobalIncorporation_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AspenGlobalIncorporatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-11</xbrli:startDate>
      <xbrli:endDate>2019-11-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-AspenGlobalIncorporation_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AspenGlobalIncorporatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-11-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AspenGlobalIncorporatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AspenGlobalIncorporatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-31</xbrli:startDate>
      <xbrli:endDate>2020-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RetailGenericsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RetailGenericsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4BiopharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:BiopharmaceuticalsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-03-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4AntiInfectivesSoldUnderSandozNameMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:AntiInfectivesSoldUnderSandozNameMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4AntiInfectivesSoldUnderSandozNameMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:AntiInfectivesSoldUnderSandozNameMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4AntiInfectivesSoldUnderSandozNameMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:AntiInfectivesSoldUnderSandozNameMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4BiopharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:BiopharmaceuticalsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4BiopharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:BiopharmaceuticalsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RetailGenericsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RetailGenericsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RetailGenericsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RetailGenericsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Sandoz-Divestment_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-09-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-Alcon-3-April-8_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-08</xbrli:startDate>
      <xbrli:endDate>2019-04-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-HY1-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-HY1-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4RealEstateMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:RealEstateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AlternativeInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AlternativeInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4CashAndOtherInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:CashAndOtherInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4RealEstateMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:RealEstateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4RealEstateMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:RealEstateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AlternativeInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AlternativeInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AlternativeInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AlternativeInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4CashAndOtherInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:CashAndOtherInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4CashAndOtherInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:CashAndOtherInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">nvs:ExercisePrice57.0Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.6Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">nvs:ExercisePrice57.6Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice66.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">nvs:ExercisePrice66.0Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">nvs:ExercisePrice57.0Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.6Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">nvs:ExercisePrice57.6Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice66.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">nvs:ExercisePrice66.0Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice66.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">nvs:ExercisePrice66.0Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">nvs:ExercisePrice57.0Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.6Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">nvs:ExercisePrice57.6Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice66.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">nvs:ExercisePrice66.0Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">nvs:ExercisePrice57.0Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.6Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">nvs:ExercisePrice57.6Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnEquitySecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnEquitySecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnEquitySecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnDeferredCashFlowHedgesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnDeferredCashFlowHedgesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnDeferredCashFlowHedgesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnDeferredCashFlowHedgesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InvestmentsInSubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InvestmentsInSubsidiariesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InvestmentsInSubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InvestmentsInSubsidiariesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4GoodwillFromAcquisitionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:GoodwillFromAcquisitionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4GoodwillFromAcquisitionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:GoodwillFromAcquisitionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4TwoYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4ThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4NotSubjectToExpiryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4NotSubjectToExpiryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4OneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4TwoYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4ThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FourYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FourYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4ThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4TwoYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4OneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4NotSubjectToExpiryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4NotSubjectToExpiryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FourYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4ThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4OneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4TwoYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4OneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4OneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4TwoYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4TwoYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4ThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4ThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FourYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FourYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4InventoryAxis_nvs-2020Q4InventoryRawMaterialsGrossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryRawMaterialsGrossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4InventoryAxis_nvs-2020Q4InventoryRawMaterialsGrossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryRawMaterialsGrossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4InventoryAxis_nvs-2020Q4InventoryWorkInProgressGrossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryWorkInProgressGrossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4InventoryAxis_nvs-2020Q4InventoryWorkInProgressGrossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryWorkInProgressGrossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4InventoryAxis_nvs-2020Q4InventoryFinishedGoodsGrossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryFinishedGoodsGrossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4InventoryAxis_nvs-2020Q4InventoryFinishedGoodsGrossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryFinishedGoodsGrossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanFiveYearsAndNotLaterThanSixYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanFiveYearsAndNotLaterThanSixYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanSixYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanSixYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4CarryingReportedAmountFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FairValueByMeasurementBasisAxis">nvs:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4CarryingReportedAmountFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FairValueByMeasurementBasisAxis">nvs:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4FairValueDisclosureItemAmountsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FairValueByMeasurementBasisAxis">nvs:FairValueDisclosureItemAmountsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4FairValueDisclosureItemAmountsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FairValueByMeasurementBasisAxis">nvs:FairValueDisclosureItemAmountsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_nvs-2020Q4LifeExpectancyMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Increase1YearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">nvs:LifeExpectancyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Increase1YearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_nvs-2020Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Change25BasisPointMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationAnnualIncentivePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationAnnualIncentivePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationShareSavingsPlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationShareSavingsPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationShareSavingsPlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationShareSavingsPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermPerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLongTermPerformancePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermPerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLongTermPerformancePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermRelativePerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLongTermRelativePerformancePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermRelativePerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLongTermRelativePerformancePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationOtherShareAwardsMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationOtherShareAwardsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationOtherShareAwardsMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationOtherShareAwardsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:NonvestingAxis">nvs:NonvestedSharesGrantedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4NonExecutiveDirectorMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:NonExecutiveDirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4NonExecutiveDirectorMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:NonExecutiveDirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4NonExecutiveDirectorMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:NonExecutiveDirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4DrAlexKrauerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:DrAlexKrauerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4DrAlexKrauerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:DrAlexKrauerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4DrAlexKrauerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:DrAlexKrauerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4DrDanielVasellaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:DrDanielVasellaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4NovartisPensionFundMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NovartisPensionFundMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CommoditiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommoditiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CommoditiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommoditiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4VendorAxis_nvs-2020Q4LargestFinancialInstitutionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:LargestFinancialInstitutionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4VendorAxis_nvs-2020Q4LargestFinancialInstitutionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:LargestFinancialInstitutionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4VendorAxis_nvs-2020Q4SecondLargestFinancialInstitutionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:SecondLargestFinancialInstitutionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4VendorAxis_nvs-2020Q4SecondLargestFinancialInstitutionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:SecondLargestFinancialInstitutionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4VendorAxis_nvs-2020Q4ThirdLargestFinancialInstitutionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:ThirdLargestFinancialInstitutionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4VendorAxis_nvs-2020Q4ThirdLargestFinancialInstitutionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:ThirdLargestFinancialInstitutionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4USCommercialPaperProgramsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:USCommercialPaperProgramsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4JPCommercialPaperProgramsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:JPCommercialPaperProgramsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4AlconMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearStart-1_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLiabilitiesMember_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLiabilitiesMember_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentAssetsMember_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2020Q4ListedEquitySecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:ListedEquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2020Q4ListedEquitySecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:ListedEquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2020Q4NonlistedEquitySecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:NonlistedEquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2020Q4NonlistedEquitySecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:NonlistedEquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4LargestCustomerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:LargestCustomerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4LargestCustomerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:LargestCustomerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4LargestCustomerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:LargestCustomerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4SecondLargestCustomerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:SecondLargestCustomerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4SecondLargestCustomerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:SecondLargestCustomerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4SecondLargestCustomerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:SecondLargestCustomerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4ThirdLargestCustomerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:ThirdLargestCustomerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4ThirdLargestCustomerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:ThirdLargestCustomerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4ThirdLargestCustomerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:ThirdLargestCustomerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:USspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:USspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:USspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:USspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:USspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:USspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:USspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonUSspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonUSspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonUSspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonUSspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonUSspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonUSspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonUSspecificHealthcarePlansAndProgramRebatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:PlansAndProgramRebatesAxis">nvs:NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4NegativeFairValuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:NegativeFairValuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4PositiveFairValuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:PositiveFairValuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019EUR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019USD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019USD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019EUR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4PositiveFairValuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:PositiveFairValuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4NegativeFairValuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:NegativeFairValuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019EUR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019USD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019EUR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019USD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4PositiveFairValuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:PositiveFairValuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4PositiveFairValuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:PositiveFairValuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4NegativeFairValuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:NegativeFairValuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4NegativeFairValuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:NegativeFairValuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4SubsequentEventTypAxis_nvs-2020Q4SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:SubsequentEventTypAxis">nvs:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_nvs-2020Q4SubsequentEventTypAxis_nvs-2020Q4SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:SubsequentEventTypAxis">nvs:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4ImpactLocationAxis_nvs-2020Q4IncomeStatementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ImpactLocationAxis">nvs:IncomeStatementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4ImpactLocationAxis_ifrsfull-2019EquityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:ImpactLocationAxis">ifrs-full:EquityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4NotSubjectToExpiryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4NotSubjectToExpiryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_srt-2020CurrencyAxis_currency-2019USD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_srt-2020CurrencyAxis_currency-2019USD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_srt-2020CurrencyAxis_currency-2019EUR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_srt-2020CurrencyAxis_currency-2019EUR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_srt-2020CurrencyAxis_currency-2019JPY">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_srt-2020CurrencyAxis_currency-2019JPY">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_srt-2020CurrencyAxis_currency-2019CHF">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_srt-2020CurrencyAxis_currency-2019CHF">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_srt-2020RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2020Q4SaleAndLeaseBackMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nvs:SaleAndLeaseBackMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_srt-2020RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2020Q4SaleAndLeaseBackMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nvs:SaleAndLeaseBackMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-GSK-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4GSKConsumerHealthcareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GSKConsumerHealthcareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-03-27</xbrli:startDate>
      <xbrli:endDate>2018-03-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-GSK-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4GSKConsumerHealthcareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GSKConsumerHealthcareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-AAA_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsAAAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-10-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsAAAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-01-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsAAAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-22</xbrli:startDate>
      <xbrli:endDate>2018-01-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-AAA-Dec2020_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsAAAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Avexis_dei-2020LegalEntityAxis_nvs-2020Q4AveXisIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AveXisIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-04-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-Avexis-2-May_dei-2020LegalEntityAxis_nvs-2020Q4AveXisIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AveXisIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-15</xbrli:startDate>
      <xbrli:endDate>2018-05-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Avexis-2-May_dei-2020LegalEntityAxis_nvs-2020Q4AveXisIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AveXisIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-05-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_I-Transaction-Endocyte-2-Dec_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EndocyteMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-Transaction-Endocyte-2-Dec_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EndocyteMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-12-21</xbrli:startDate>
      <xbrli:endDate>2018-12-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SparkTherapeuticsInc.Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SparkTherapeuticsInc.Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationAnnualIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationShareSavingsPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationShareSavingsPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationEmployeeShareOwnershipPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationEmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLeveragedShareSavingsPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLeveragedShareSavingsPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermPerformancePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLongTermPerformancePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermRelativePerformancePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLongTermRelativePerformancePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationSpecialShareAwardsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationSpecialShareAwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisTechnologyLLCInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisTechnologyLLCInc.EastHanoverNJMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USDPerShares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="CHFPerShares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:CHF</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="EUR">
    <xbrli:measure>iso4217:EUR</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="CHF">
    <xbrli:measure>iso4217:CHF</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Year">
    <xbrli:measure>ns0:year</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="JPY">
    <xbrli:measure>iso4217:JPY</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="VEF">
    <xbrli:measure>iso4217:VEF</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="VND">
    <xbrli:measure>iso4217:VND</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="ILS">
    <xbrli:measure>iso4217:ILS</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="PHP">
    <xbrli:measure>iso4217:PHP</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="GBP">
    <xbrli:measure>iso4217:GBP</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="CAD">
    <xbrli:measure>iso4217:CAD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="TWD">
    <xbrli:measure>iso4217:TWD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="THB">
    <xbrli:measure>iso4217:THB</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="TRY">
    <xbrli:measure>iso4217:TRY</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="UAH">
    <xbrli:measure>iso4217:UAH</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="AED">
    <xbrli:measure>iso4217:AED</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="PKR">
    <xbrli:measure>iso4217:PKR</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="PEN">
    <xbrli:measure>iso4217:PEN</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="PLN">
    <xbrli:measure>iso4217:PLN</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="RON">
    <xbrli:measure>iso4217:RON</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="RUB">
    <xbrli:measure>iso4217:RUB</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="SAR">
    <xbrli:measure>iso4217:SAR</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="SGD">
    <xbrli:measure>iso4217:SGD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="ZAR">
    <xbrli:measure>iso4217:ZAR</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="KRW">
    <xbrli:measure>iso4217:KRW</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="SEK">
    <xbrli:measure>iso4217:SEK</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="DZD">
    <xbrli:measure>iso4217:DZD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="ARS">
    <xbrli:measure>iso4217:ARS</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="AUD">
    <xbrli:measure>iso4217:AUD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="BDT">
    <xbrli:measure>iso4217:BDT</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="BRL">
    <xbrli:measure>iso4217:BRL</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="CLP">
    <xbrli:measure>iso4217:CLP</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="HKD">
    <xbrli:measure>iso4217:HKD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="COP">
    <xbrli:measure>iso4217:COP</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="HRK">
    <xbrli:measure>iso4217:HRK</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="CZK">
    <xbrli:measure>iso4217:CZK</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="DKK">
    <xbrli:measure>iso4217:DKK</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="EGP">
    <xbrli:measure>iso4217:EGP</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="HUF">
    <xbrli:measure>iso4217:HUF</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="INR">
    <xbrli:measure>iso4217:INR</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="IDR">
    <xbrli:measure>iso4217:IDR</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="MYR">
    <xbrli:measure>iso4217:MYR</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="MXN">
    <xbrli:measure>iso4217:MXN</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="MAD">
    <xbrli:measure>iso4217:MAD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="NZD">
    <xbrli:measure>iso4217:NZD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="NOK">
    <xbrli:measure>iso4217:NOK</xbrli:measure>
  </xbrli:unit>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">8782000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">7558000000</nvs:GrossDeferredTaxLiabilities>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">-1224000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">354000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-289000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">47000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-25000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">7952000000</nvs:GrossDeferredTaxAssets>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">-2042000000</ifrs-full:DeferredTaxLiabilityAsset>
  <nvs:OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">43000000</nvs:OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">5910000000</nvs:GrossDeferredTaxLiabilities>
  <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-83000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">6805000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">124000000</nvs:ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">7909000000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">5867000000</ifrs-full:DeferredTaxLiabilities>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">2986000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:ValueOfTaxLossCarryforwardsExpired contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">9000000</nvs:ValueOfTaxLossCarryforwardsExpired>
  <nvs:ValueOfTaxLossCarryforwardsExpired contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">8000000</nvs:ValueOfTaxLossCarryforwardsExpired>
  <nvs:DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-8">4300000000</nvs:DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months>
  <nvs:DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-8">5200000000</nvs:DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months>
  <nvs:ProvisionForIncomeTaxesOnUnremittedEarnings contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-9">0</nvs:ProvisionForIncomeTaxesOnUnremittedEarnings>
  <nvs:ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges contextRef="AR_I-CurrentYearEnd-1" unitRef="Pure" decimals="2">0.13</nvs:ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges>
  <nvs:ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges contextRef="AR_I-CurrentYearEnd-1" unitRef="Pure" decimals="2">0.13</nvs:ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges>
  <nvs:ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-234000000</nvs:ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="2">1.00</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1" unitRef="Pure" decimals="2">1.00</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2" unitRef="Pure" decimals="2">1.00</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">90379000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd" unitRef="Pure" decimals="2">1.00</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">77701000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="Pure" decimals="2">1.00</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet contextRef="AR_D-Transaction-Alcon-3-April-8" unitRef="USD" decimals="-6">4691000000</nvs:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet>
  <ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-8">7000000000</ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">48659000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">47445000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">44751000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:AmountBorrowedUnderTheCreditFacility contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-9">7000000000</nvs:AmountBorrowedUnderTheCreditFacility>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">2005000000</ifrs-full:LeaseLiabilities>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">3485000000</nvs:LeaseLiabilitiesUndiscounted>
  <nvs:CurrentLeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">295000000</nvs:CurrentLeaseLiabilitiesUndiscounted>
  <nvs:NoncurrentLeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">3190000000</nvs:NoncurrentLeaseLiabilitiesUndiscounted>
  <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">66000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
  <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">7000000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
  <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">8000000</ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed>
  <ifrs-full:CashOutflowForLeases contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">339000000</ifrs-full:CashOutflowForLeases>
  <nvs:CashOutflowsForShortTermAndLowValueLeases contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">15000000</nvs:CashOutflowsForShortTermAndLowValueLeases>
  <nvs:CashOutflowsForPaymentsOfLeasesInterest contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">51000000</nvs:CashOutflowsForPaymentsOfLeasesInterest>
  <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">273000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
  <ifrs-full:IncomeTaxesPaidRefund contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1993000000</ifrs-full:IncomeTaxesPaidRefund>
  <ifrs-full:IncomeTaxesPaidRefund contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1809000000</ifrs-full:IncomeTaxesPaidRefund>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">139000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsInvestingActivities>
  <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">44000000</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
  <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">137000000</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
  <nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">3550000000</nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate>
  <nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">2531000000</nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate>
  <nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">342000000</nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate>
  <nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">10224000000</nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate>
  <nvs:OtherIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">22000000</nvs:OtherIntangibleAssetsRecognisedAsOfAcquisitionDate>
  <nvs:OtherIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">1000000</nvs:OtherIntangibleAssetsRecognisedAsOfAcquisitionDate>
  <ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">60000000</ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate>
  <ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">381000000</ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate>
  <nvs:FinancialAndOtherAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">8000000</nvs:FinancialAndOtherAssets>
  <nvs:FinancialAndOtherAssets contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">19000000</nvs:FinancialAndOtherAssets>
  <ifrs-full:InventoryRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">195000000</ifrs-full:InventoryRecognisedAsOfAcquisitionDate>
  <ifrs-full:InventoryRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">20000000</ifrs-full:InventoryRecognisedAsOfAcquisitionDate>
  <nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">4000000</nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate>
  <nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">90000000</nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate>
  <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">1112000000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
  <ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">107000000</ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">2874000000</ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">2000000</ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">14000000</ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate>
  <nvs:TradePayablesAndOtherLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">178000000</nvs:TradePayablesAndOtherLiabilities>
  <nvs:TradePayablesAndOtherLiabilities contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">627000000</nvs:TradePayablesAndOtherLiabilities>
  <nvs:IdentifiableAssetsAcquired contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">7669000000</nvs:IdentifiableAssetsAcquired>
  <nvs:IdentifiableAssetsAcquired contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">3938000000</nvs:IdentifiableAssetsAcquired>
  <nvs:IdentifiableAssetsAcquired contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">11000000000</nvs:IdentifiableAssetsAcquired>
  <nvs:AcquiredCashAndCashEquivalents contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">1112000000</nvs:AcquiredCashAndCashEquivalents>
  <ifrs-full:NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">26000000</ifrs-full:NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate>
  <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">186000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
  <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">4084000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">10173000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">4124000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">13946000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:GoodwillExpectedDeductibleForTaxPurposes contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">98000000</ifrs-full:GoodwillExpectedDeductibleForTaxPurposes>
  <ifrs-full:GoodwillExpectedDeductibleForTaxPurposes contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">0</ifrs-full:GoodwillExpectedDeductibleForTaxPurposes>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1833000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1876000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1506000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-9957000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-3760000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-13683000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-127000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations>
  <ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-1159000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations>
  <ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-1001000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations>
  <nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases contextRef="AR_I-CurrentYearEnd" unitRef="Pure" decimals="0">3000</nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases>
  <nvs:ProductLiabilityContingencyLossExposureNotAccruedBestEstimate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-8">500000000</nvs:ProductLiabilityContingencyLossExposureNotAccruedBestEstimate>
  <nvs:ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">358000000</nvs:ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <nvs:MajorPlansPercentageInGroupDBOPensions contextRef="AR_I-CurrentYearEnd" unitRef="Pure" decimals="2">0.95</nvs:MajorPlansPercentageInGroupDBOPensions>
  <nvs:MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans contextRef="AR_I-CurrentYearEnd" unitRef="Pure" decimals="2">0.81</nvs:MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans>
  <nvs:CommitmentsUnderLongtermResearchAgreements contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">5232000000</nvs:CommitmentsUnderLongtermResearchAgreements>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-467000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-359000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <nvs:EnvironmentalProvisionExpectedCashOutflowAfterTenYears contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">80000000</nvs:EnvironmentalProvisionExpectedCashOutflowAfterTenYears>
  <nvs:PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">25000000</nvs:PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">53000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">82000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">48659000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">47498000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">44833000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1239000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1179000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1266000000</ifrs-full:OtherRevenue>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">15121000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">14425000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">14510000000</ifrs-full:CostOfSales>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">34777000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">34252000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">31589000000</ifrs-full:GrossProfit>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">14197000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">14369000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">13717000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">8980000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">9402000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">8489000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1742000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">2031000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1629000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">3190000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">3426000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">2609000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">10152000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">9086000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">8403000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">673000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">659000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">6438000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">869000000</ifrs-full:InterestExpense>
  <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">850000000</ifrs-full:InterestExpense>
  <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">932000000</ifrs-full:InterestExpense>
  <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-78000000</ifrs-full:OtherFinanceIncomeCost>
  <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">45000000</ifrs-full:OtherFinanceIncomeCost>
  <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">186000000</ifrs-full:OtherFinanceIncomeCost>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">9878000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">8940000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">14095000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1807000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1793000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1295000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:ProfitLossFromContinuingOperations contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">8071000000</ifrs-full:ProfitLossFromContinuingOperations>
  <ifrs-full:ProfitLossFromContinuingOperations contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">7147000000</ifrs-full:ProfitLossFromContinuingOperations>
  <ifrs-full:ProfitLossFromContinuingOperations contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">12800000000</ifrs-full:ProfitLossFromContinuingOperations>
  <nvs:NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-101000000</nvs:NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution>
  <nvs:NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-186000000</nvs:NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution>
  <ifrs-full:ProfitLossFromDiscontinuedOperations contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">4590000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
  <ifrs-full:ProfitLossFromDiscontinuedOperations contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-186000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">8071000000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">11737000000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">12614000000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">8072000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
  <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">11732000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
  <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">12611000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
  <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-1000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
  <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">5000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
  <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">3000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
  <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations contextRef="AR_D-CurrentYear" unitRef="USDPerShares" decimals="2">3.55</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
  <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations contextRef="AR_D-CurrentYear-1" unitRef="USDPerShares" decimals="2">3.12</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
  <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations contextRef="AR_D-CurrentYear-2" unitRef="USDPerShares" decimals="2">5.52</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
  <ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations contextRef="AR_D-CurrentYear-1" unitRef="USDPerShares" decimals="2">2.00</ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations>
  <ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations contextRef="AR_D-CurrentYear-2" unitRef="USDPerShares" decimals="2">-0.08</ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations>
  <ifrs-full:BasicEarningsLossPerShare contextRef="AR_D-CurrentYear" unitRef="USDPerShares" decimals="2">3.55</ifrs-full:BasicEarningsLossPerShare>
  <ifrs-full:BasicEarningsLossPerShare contextRef="AR_D-CurrentYear-1" unitRef="USDPerShares" decimals="2">5.12</ifrs-full:BasicEarningsLossPerShare>
  <ifrs-full:BasicEarningsLossPerShare contextRef="AR_D-CurrentYear-2" unitRef="USDPerShares" decimals="2">5.44</ifrs-full:BasicEarningsLossPerShare>
  <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations contextRef="AR_D-CurrentYear" unitRef="USDPerShares" decimals="2">3.52</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
  <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations contextRef="AR_D-CurrentYear-1" unitRef="USDPerShares" decimals="2">3.08</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
  <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations contextRef="AR_D-CurrentYear-2" unitRef="USDPerShares" decimals="2">5.46</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
  <ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations contextRef="AR_D-CurrentYear-1" unitRef="USDPerShares" decimals="2">1.98</ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations>
  <ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations contextRef="AR_D-CurrentYear-2" unitRef="USDPerShares" decimals="2">-0.08</ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations>
  <ifrs-full:DilutedEarningsLossPerShare contextRef="AR_D-CurrentYear" unitRef="USDPerShares" decimals="2">3.52</ifrs-full:DilutedEarningsLossPerShare>
  <ifrs-full:DilutedEarningsLossPerShare contextRef="AR_D-CurrentYear-1" unitRef="USDPerShares" decimals="2">5.06</ifrs-full:DilutedEarningsLossPerShare>
  <ifrs-full:DilutedEarningsLossPerShare contextRef="AR_D-CurrentYear-2" unitRef="USDPerShares" decimals="2">5.38</ifrs-full:DilutedEarningsLossPerShare>
  <ifrs-full:ParValuePerShare contextRef="AR_I-CurrentYearEnd" unitRef="CHFPerShares" decimals="2">0.50</ifrs-full:ParValuePerShare>
  <nvs:NumberOfReportableSegments contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="0">2</nvs:NumberOfReportableSegments>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">12263000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">12069000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">1676000000</ifrs-full:RightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1677000000</ifrs-full:RightofuseAssets>
  <ifrs-full:Goodwill contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">29999000000</ifrs-full:Goodwill>
  <ifrs-full:Goodwill contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">26524000000</ifrs-full:Goodwill>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">36809000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">28787000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">9632000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">8644000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <ifrs-full:DeferredTaxAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">8214000000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:NoncurrentFinancialAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">2901000000</ifrs-full:NoncurrentFinancialAssets>
  <ifrs-full:NoncurrentFinancialAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">2518000000</ifrs-full:NoncurrentFinancialAssets>
  <ifrs-full:OtherNoncurrentAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">892000000</ifrs-full:OtherNoncurrentAssets>
  <ifrs-full:OtherNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">738000000</ifrs-full:OtherNoncurrentAssets>
  <ifrs-full:NoncurrentAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">102386000000</ifrs-full:NoncurrentAssets>
  <ifrs-full:NoncurrentAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">88866000000</ifrs-full:NoncurrentAssets>
  <ifrs-full:Inventories contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">7131000000</ifrs-full:Inventories>
  <ifrs-full:Inventories contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">5982000000</ifrs-full:Inventories>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">8217000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">8301000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTaxAssetsCurrent contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">239000000</ifrs-full:CurrentTaxAssetsCurrent>
  <ifrs-full:CurrentTaxAssetsCurrent contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">254000000</ifrs-full:CurrentTaxAssetsCurrent>
  <ifrs-full:OtherCurrentFinancialAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">1905000000</ifrs-full:OtherCurrentFinancialAssets>
  <ifrs-full:OtherCurrentFinancialAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">334000000</ifrs-full:OtherCurrentFinancialAssets>
  <ifrs-full:CashAndCashEquivalents contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">9658000000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">11112000000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:OtherCurrentNonfinancialAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">2523000000</ifrs-full:OtherCurrentNonfinancialAssets>
  <ifrs-full:OtherCurrentNonfinancialAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">2680000000</ifrs-full:OtherCurrentNonfinancialAssets>
  <ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">29673000000</ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
  <ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">28663000000</ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
  <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">841000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale>
  <ifrs-full:CurrentAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">29673000000</ifrs-full:CurrentAssets>
  <ifrs-full:CurrentAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">29504000000</ifrs-full:CurrentAssets>
  <ifrs-full:Assets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">132059000000</ifrs-full:Assets>
  <ifrs-full:Assets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">118370000000</ifrs-full:Assets>
  <ifrs-full:IssuedCapital contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">913000000</ifrs-full:IssuedCapital>
  <ifrs-full:IssuedCapital contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">936000000</ifrs-full:IssuedCapital>
  <ifrs-full:TreasuryShares contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">53000000</ifrs-full:TreasuryShares>
  <ifrs-full:TreasuryShares contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">80000000</ifrs-full:TreasuryShares>
  <ifrs-full:OtherReserves contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">55738000000</ifrs-full:OtherReserves>
  <ifrs-full:OtherReserves contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">54618000000</ifrs-full:OtherReserves>
  <ifrs-full:EquityAttributableToOwnersOfParent contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">56598000000</ifrs-full:EquityAttributableToOwnersOfParent>
  <ifrs-full:EquityAttributableToOwnersOfParent contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">55474000000</ifrs-full:EquityAttributableToOwnersOfParent>
  <ifrs-full:NoncontrollingInterests contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">68000000</ifrs-full:NoncontrollingInterests>
  <ifrs-full:NoncontrollingInterests contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">77000000</ifrs-full:NoncontrollingInterests>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">56666000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">55551000000</ifrs-full:Equity>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">26259000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">20353000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:NoncurrentLeaseLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">1719000000</ifrs-full:NoncurrentLeaseLiabilities>
  <ifrs-full:NoncurrentLeaseLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1703000000</ifrs-full:NoncurrentLeaseLiabilities>
  <ifrs-full:DeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">7422000000</ifrs-full:DeferredTaxLiabilities>
  <ifrs-full:OtherNoncurrentNonfinancialLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">6934000000</ifrs-full:OtherNoncurrentNonfinancialLiabilities>
  <ifrs-full:OtherNoncurrentNonfinancialLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">6632000000</ifrs-full:OtherNoncurrentNonfinancialLiabilities>
  <ifrs-full:NoncurrentLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">42334000000</ifrs-full:NoncurrentLiabilities>
  <ifrs-full:NoncurrentLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">34555000000</ifrs-full:NoncurrentLiabilities>
  <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">5403000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
  <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">5424000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">9785000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">7031000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:CurrentLeaseLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">286000000</ifrs-full:CurrentLeaseLiabilities>
  <ifrs-full:CurrentLeaseLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">246000000</ifrs-full:CurrentLeaseLiabilities>
  <ifrs-full:CurrentTaxLiabilitiesCurrent contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">2458000000</ifrs-full:CurrentTaxLiabilitiesCurrent>
  <ifrs-full:CurrentTaxLiabilitiesCurrent contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">2194000000</ifrs-full:CurrentTaxLiabilitiesCurrent>
  <ifrs-full:OtherCurrentNonfinancialLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">15127000000</ifrs-full:OtherCurrentNonfinancialLiabilities>
  <ifrs-full:OtherCurrentNonfinancialLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">13338000000</ifrs-full:OtherCurrentNonfinancialLiabilities>
  <ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">33059000000</ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
  <ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">28233000000</ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
  <ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">31000000</ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
  <ifrs-full:CurrentLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">33059000000</ifrs-full:CurrentLiabilities>
  <ifrs-full:CurrentLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">28264000000</ifrs-full:CurrentLiabilities>
  <ifrs-full:Liabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">75393000000</ifrs-full:Liabilities>
  <ifrs-full:Liabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">62819000000</ifrs-full:Liabilities>
  <ifrs-full:EquityAndLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">132059000000</ifrs-full:EquityAndLiabilities>
  <ifrs-full:EquityAndLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">118370000000</ifrs-full:EquityAndLiabilities>
  <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">9881000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
  <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">9122000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
  <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1486000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
  <ifrs-full:DividendsReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">490000000</ifrs-full:DividendsReceivedClassifiedAsOperatingActivities>
  <ifrs-full:DividendsReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">463000000</ifrs-full:DividendsReceivedClassifiedAsOperatingActivities>
  <ifrs-full:DividendsReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">719000000</ifrs-full:DividendsReceivedClassifiedAsOperatingActivities>
  <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">47000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
  <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">214000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
  <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">241000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
  <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">703000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
  <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">793000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
  <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">816000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
  <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">464000000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
  <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">28000000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
  <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">218000000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
  <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">39000000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
  <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">33000000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
  <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">31000000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
  <nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">16378000000</nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges>
  <nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">14272000000</nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges>
  <nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">13111000000</nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges>
  <nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">2437000000</nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities>
  <nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">924000000</nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities>
  <nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">638000000</nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities>
  <nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-291000000</nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems>
  <nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">199000000</nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems>
  <nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">576000000</nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems>
  <ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">13650000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">13547000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">13049000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">78000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations>
  <ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1223000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">13650000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">13625000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">14272000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1275000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1379000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1254000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">88000000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">857000000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">102000000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1310000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">878000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1394000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">380000000</ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">973000000</ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">823000000</ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities>
  <nvs:PurchaseOfFinancialAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">230000000</nvs:PurchaseOfFinancialAssetsClassifiedAsInvestingActivities>
  <nvs:PurchaseOfFinancialAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">302000000</nvs:PurchaseOfFinancialAssetsClassifiedAsInvestingActivities>
  <nvs:PurchaseOfFinancialAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">205000000</nvs:PurchaseOfFinancialAssetsClassifiedAsInvestingActivities>
  <nvs:ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">723000000</nvs:ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities>
  <nvs:ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1152000000</nvs:ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities>
  <nvs:ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">165000000</nvs:ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">61000000</ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">60000000</ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">39000000</ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">2000000</ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">3000000</ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">9000000</ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities>
  <nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-7000000</nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies>
  <nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-6000000</nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies>
  <nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">12854000000</nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies>
  <ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1900000000</ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
  <ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">228000000</ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
  <ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">2440000000</ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
  <ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">492000000</ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
  <ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">2561000000</ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
  <ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">472000000</ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-13055000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-1067000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-4590000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-13182000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-2226000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-5591000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">6987000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
  <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">6645000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
  <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">6966000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
  <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">2842000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
  <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">5533000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
  <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">2036000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
  <nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">748000000</nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions>
  <nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">201000000</nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions>
  <nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">700000000</nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions>
  <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">7126000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
  <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">93000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
  <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">2856000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
  <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">2003000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
  <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">3195000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
  <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">366000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
  <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">2261000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
  <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-1582000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
  <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1687000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
  <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">312000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
  <ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">2000000</ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries>
  <ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">6000000</ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries>
  <ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">19000000</ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-147000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">56000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">67000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-2158000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-16884000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-4077000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations>
  <ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-50000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations>
  <ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">3257000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations>
  <ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-167000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-2208000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-13627000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-4244000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-1740000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-2228000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">4437000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">286000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">69000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-26000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-1454000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-2159000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">4411000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="AR_I-CurrentYearEnd-3" unitRef="USD" decimals="-6">8860000000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">13271000000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:RevenueFromInterest contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">91000000</ifrs-full:RevenueFromInterest>
  <ifrs-full:RevenueFromInterest contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">245000000</ifrs-full:RevenueFromInterest>
  <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">335000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
  <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">38000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">354000000</nvs:AdditionsToRestructuringProvisions>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">492000000</nvs:AdditionsToRestructuringProvisions>
  <ifrs-full:RevenueFromInterest contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">292000000</ifrs-full:RevenueFromInterest>
  <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-6000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">521000000</nvs:AdditionsToRestructuringProvisions>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">24481000000</ifrs-full:NetDebt>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">15938000000</ifrs-full:NetDebt>
  <nvs:NetOperatingAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">81147000000</nvs:NetOperatingAssets>
  <nvs:NetOperatingAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">71489000000</nvs:NetOperatingAssets>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1265000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1474000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">66808000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">55311000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1425000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">767000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <nvs:AdditionsToInvestmentInAssociatedCompanies contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-31000000</nvs:AdditionsToInvestmentInAssociatedCompanies>
  <nvs:AdditionsToInvestmentInAssociatedCompanies contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-55000000</nvs:AdditionsToInvestmentInAssociatedCompanies>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">11563000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">11446000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">36044000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">27384000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <nvs:CurrentIncomeTaxAndDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">9880000000</nvs:CurrentIncomeTaxAndDeferredTaxLiabilities>
  <nvs:CurrentIncomeTaxAndDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">8061000000</nvs:CurrentIncomeTaxAndDeferredTaxLiabilities>
  <nvs:ProfitSharingIncome contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">835000000</nvs:ProfitSharingIncome>
  <nvs:ProfitSharingIncome contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">734000000</nvs:ProfitSharingIncome>
  <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">300000000</ifrs-full:RevenueFromRoyalties>
  <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">147000000</ifrs-full:RevenueFromRoyalties>
  <nvs:MilestoneIncome contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">50000000</nvs:MilestoneIncome>
  <nvs:MilestoneIncome contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">231000000</nvs:MilestoneIncome>
  <nvs:OtherRevenueOther contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">54000000</nvs:OtherRevenueOther>
  <nvs:OtherRevenueOther contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">67000000</nvs:OtherRevenueOther>
  <nvs:ProfitSharingIncome contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">877000000</nvs:ProfitSharingIncome>
  <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">617000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">565000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">5956000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">708000000</nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions>
  <nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">714000000</nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions>
  <nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">877000000</nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions>
  <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">67000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
  <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">94000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
  <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">70000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
  <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">55000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
  <ifrs-full:RevenueFromDividends contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">18000000</ifrs-full:RevenueFromDividends>
  <ifrs-full:RevenueFromDividends contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">12000000</ifrs-full:RevenueFromDividends>
  <ifrs-full:RevenueFromDividends contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1000000</ifrs-full:RevenueFromDividends>
  <ifrs-full:OtherFinanceCost contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">52000000</ifrs-full:OtherFinanceCost>
  <ifrs-full:OtherFinanceCost contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">52000000</ifrs-full:OtherFinanceCost>
  <ifrs-full:OtherFinanceCost contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">39000000</ifrs-full:OtherFinanceCost>
  <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-135000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
  <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-160000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
  <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-68000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
  <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">188000000</ifrs-full:RevenueFromRoyalties>
  <nvs:OtherRevenueOther contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">28000000</nvs:OtherRevenueOther>
  <nvs:MilestoneIncome contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">173000000</nvs:MilestoneIncome>
  <ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">256000000</ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment>
  <ifrs-full:BorrowingCostsCapitalised contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">2000000</ifrs-full:BorrowingCostsCapitalised>
  <ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">220000000</ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment>
  <ifrs-full:BorrowingCostsCapitalised contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">4000000</ifrs-full:BorrowingCostsCapitalised>
  <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">330000000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">0</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
  <nvs:DeferredCompensationPlansAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">471000000</nvs:DeferredCompensationPlansAssets>
  <nvs:DeferredCompensationPlansAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">414000000</nvs:DeferredCompensationPlansAssets>
  <nvs:PrepaidPostemploymentBenefitPlansAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">202000000</nvs:PrepaidPostemploymentBenefitPlansAssets>
  <nvs:PrepaidPostemploymentBenefitPlansAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">148000000</nvs:PrepaidPostemploymentBenefitPlansAssets>
  <ifrs-full:OtherNoncurrentNonfinancialAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">219000000</ifrs-full:OtherNoncurrentNonfinancialAssets>
  <ifrs-full:OtherNoncurrentNonfinancialAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">176000000</ifrs-full:OtherNoncurrentNonfinancialAssets>
  <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-8">8500000000</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
  <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-8">8500000000</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
  <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-8">8300000000</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
  <ifrs-full:InventoryWritedown2011 contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">752000000</ifrs-full:InventoryWritedown2011>
  <ifrs-full:InventoryWritedown2011 contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">603000000</ifrs-full:InventoryWritedown2011>
  <ifrs-full:ReversalOfInventoryWritedown contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">218000000</ifrs-full:ReversalOfInventoryWritedown>
  <ifrs-full:ReversalOfInventoryWritedown contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">216000000</ifrs-full:ReversalOfInventoryWritedown>
  <ifrs-full:CurrentValueAddedTaxReceivables contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">544000000</ifrs-full:CurrentValueAddedTaxReceivables>
  <ifrs-full:CurrentValueAddedTaxReceivables contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">508000000</ifrs-full:CurrentValueAddedTaxReceivables>
  <nvs:WithholdingTaxRecoverable contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">73000000</nvs:WithholdingTaxRecoverable>
  <nvs:WithholdingTaxRecoverable contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">108000000</nvs:WithholdingTaxRecoverable>
  <nvs:CurrentPrepaidExpensesThirdParty contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">943000000</nvs:CurrentPrepaidExpensesThirdParty>
  <nvs:CurrentPrepaidExpensesThirdParty contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">898000000</nvs:CurrentPrepaidExpensesThirdParty>
  <nvs:ReceivablesAssociatedCompanies contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1000000</nvs:ReceivablesAssociatedCompanies>
  <nvs:OtherReceivablesAndCurrentAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">963000000</nvs:OtherReceivablesAndCurrentAssets>
  <nvs:OtherReceivablesAndCurrentAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1165000000</nvs:OtherReceivablesAndCurrentAssets>
  <ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">3538000000</ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan>
  <ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">3469000000</ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan>
  <nvs:OtherLongtermEmployeeBenefitsAndDeferredCompensation contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">637000000</nvs:OtherLongtermEmployeeBenefitsAndDeferredCompensation>
  <nvs:OtherLongtermEmployeeBenefitsAndDeferredCompensation contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">546000000</nvs:OtherLongtermEmployeeBenefitsAndDeferredCompensation>
  <nvs:OtherPostemploymentBenefits contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">543000000</nvs:OtherPostemploymentBenefits>
  <nvs:OtherPostemploymentBenefits contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">612000000</nvs:OtherPostemploymentBenefits>
  <nvs:EnvironmentalRemediationProvisionNoncurrent contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">642000000</nvs:EnvironmentalRemediationProvisionNoncurrent>
  <nvs:EnvironmentalRemediationProvisionNoncurrent contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">592000000</nvs:EnvironmentalRemediationProvisionNoncurrent>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">181000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">200000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent>
  <nvs:ContingentConsiderationNonCurrent contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">984000000</nvs:ContingentConsiderationNonCurrent>
  <nvs:ContingentConsiderationNonCurrent contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">958000000</nvs:ContingentConsiderationNonCurrent>
  <ifrs-full:OtherNoncurrentLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">409000000</ifrs-full:OtherNoncurrentLiabilities>
  <ifrs-full:OtherNoncurrentLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">255000000</ifrs-full:OtherNoncurrentLiabilities>
  <nvs:EnvironmentalProvision contextRef="AR_I-CurrentYearEnd-3" unitRef="USD" decimals="-6">761000000</nvs:EnvironmentalProvision>
  <nvs:EnvironmentalProvisionPayments contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-10000000</nvs:EnvironmentalProvisionPayments>
  <nvs:EnvironmentalProvisionPayments contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-30000000</nvs:EnvironmentalProvisionPayments>
  <nvs:EnvironmentalProvisionPayments contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-48000000</nvs:EnvironmentalProvisionPayments>
  <nvs:EnvironmentalProvisionReleases contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">27000000</nvs:EnvironmentalProvisionReleases>
  <nvs:EnvironmentalProvisionReleases contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">83000000</nvs:EnvironmentalProvisionReleases>
  <nvs:EnvironmentalProvisionReleases contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">21000000</nvs:EnvironmentalProvisionReleases>
  <nvs:EnvironmentalProvisionAdditions contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">82000000</nvs:EnvironmentalProvisionAdditions>
  <nvs:EnvironmentalProvisionAdditions contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">124000000</nvs:EnvironmentalProvisionAdditions>
  <nvs:EnvironmentalProvisionAdditions contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">7000000</nvs:EnvironmentalProvisionAdditions>
  <nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">50000000</nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss>
  <nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">11000000</nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss>
  <nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-7000000</nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss>
  <nvs:EnvironmentalProvision contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">809000000</nvs:EnvironmentalProvision>
  <nvs:EnvironmentalProvision contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">714000000</nvs:EnvironmentalProvision>
  <nvs:EnvironmentalProvision contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">692000000</nvs:EnvironmentalProvision>
  <nvs:EnvironmentalProvisionCurrent contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">167000000</nvs:EnvironmentalProvisionCurrent>
  <nvs:EnvironmentalProvisionCurrent contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">122000000</nvs:EnvironmentalProvisionCurrent>
  <nvs:EnvironmentalProvisionCurrent contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">58000000</nvs:EnvironmentalProvisionCurrent>
  <nvs:EnvironmentalRemediationProvisionNoncurrent contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">634000000</nvs:EnvironmentalRemediationProvisionNoncurrent>
  <nvs:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">749000000</nvs:AccrualForTaxesOtherThanIncomeTaxesCurrent>
  <nvs:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">471000000</nvs:AccrualForTaxesOtherThanIncomeTaxesCurrent>
  <ifrs-full:ShorttermRestructuringProvision contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">459000000</ifrs-full:ShorttermRestructuringProvision>
  <ifrs-full:ShorttermRestructuringProvision contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">438000000</ifrs-full:ShorttermRestructuringProvision>
  <ifrs-full:AccrualsClassifiedAsCurrent contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">1167000000</ifrs-full:AccrualsClassifiedAsCurrent>
  <ifrs-full:AccrualsClassifiedAsCurrent contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1046000000</ifrs-full:AccrualsClassifiedAsCurrent>
  <nvs:AccruedRoyaltiesPayableClassifiedAsCurrent contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">732000000</nvs:AccruedRoyaltiesPayableClassifiedAsCurrent>
  <nvs:AccruedRoyaltiesPayableClassifiedAsCurrent contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">653000000</nvs:AccruedRoyaltiesPayableClassifiedAsCurrent>
  <ifrs-full:CurrentInterestPayable contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">133000000</ifrs-full:CurrentInterestPayable>
  <ifrs-full:CurrentInterestPayable contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">98000000</ifrs-full:CurrentInterestPayable>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">6256000000</ifrs-full:CurrentRefundsProvision>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">5595000000</ifrs-full:CurrentRefundsProvision>
  <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">2286000000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
  <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">2464000000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
  <ifrs-full:DeferredIncomeClassifiedAsCurrent contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">56000000</ifrs-full:DeferredIncomeClassifiedAsCurrent>
  <ifrs-full:DeferredIncomeClassifiedAsCurrent contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">114000000</ifrs-full:DeferredIncomeClassifiedAsCurrent>
  <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011 contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">269000000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
  <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011 contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">326000000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
  <nvs:ContingentConsiderationCurrentPortion contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">62000000</nvs:ContingentConsiderationCurrentPortion>
  <nvs:ContingentConsiderationCurrentPortion contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">78000000</nvs:ContingentConsiderationCurrentPortion>
  <ifrs-full:OtherCurrentPayables contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">716000000</ifrs-full:OtherCurrentPayables>
  <ifrs-full:OtherCurrentPayables contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">764000000</ifrs-full:OtherCurrentPayables>
  <nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">234000000</nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">19294000000</ifrs-full:ProvisionUsedOtherProvisions>
  <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-151000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">19773000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <nvs:ChangesInOffsetAgainstGrossTradeReceivables contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-99000000</nvs:ChangesInOffsetAgainstGrossTradeReceivables>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">5262000000</ifrs-full:CurrentRefundsProvision>
  <nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-10000000</nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">19348000000</ifrs-full:ProvisionUsedOtherProvisions>
  <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-220000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">20001000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <nvs:ChangesInOffsetAgainstGrossTradeReceivables contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-104000000</nvs:ChangesInOffsetAgainstGrossTradeReceivables>
  <nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1411000000</nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities>
  <nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1871000000</nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities>
  <nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">895000000</nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities>
  <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-478000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
  <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-1234000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
  <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-902000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
  <ifrs-full:AdjustmentsForSharebasedPayments contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">738000000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:AdjustmentsForSharebasedPayments contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">758000000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:AdjustmentsForSharebasedPayments contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">673000000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-947000000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-805000000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-746000000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-543000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-382000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-387000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">137000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-980000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-544000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-324000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">553000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">252000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">229000000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-160000000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">316000000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">211000000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1167000000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">941000000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities>
  <ifrs-full:OtherAdjustmentsToReconcileProfitLoss contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-1000000</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
  <ifrs-full:OtherAdjustmentsToReconcileProfitLoss contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1000000</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
  <ifrs-full:OtherAdjustmentsToReconcileProfitLoss contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-2000000</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd-3" unitRef="USD" decimals="-6">4672000000</ifrs-full:CurrentRefundsProvision>
  <nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-129000000</nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">18567000000</ifrs-full:ProvisionUsedOtherProvisions>
  <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-98000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">19052000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <nvs:ChangesInOffsetAgainstGrossTradeReceivables contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-332000000</nvs:ChangesInOffsetAgainstGrossTradeReceivables>
  <nvs:NoncurrentFinancialAssetsEquityInvestments contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1524000000</nvs:NoncurrentFinancialAssetsEquityInvestments>
  <nvs:NoncurrentFinancialAsstetsDebtSecurities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">33000000</nvs:NoncurrentFinancialAsstetsDebtSecurities>
  <nvs:NoncurrentFinancialAssetsFundInvestments contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">233000000</nvs:NoncurrentFinancialAssetsFundInvestments>
  <nvs:NoncurrentFinancialAssetsTotalFinancialInvestments contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">1979000000</nvs:NoncurrentFinancialAssetsTotalFinancialInvestments>
  <nvs:NoncurrentFinancialAssetsTotalFinancialInvestments contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1790000000</nvs:NoncurrentFinancialAssetsTotalFinancialInvestments>
  <nvs:LongTermReceivablesFromFinanceSubleases contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">66000000</nvs:LongTermReceivablesFromFinanceSubleases>
  <ifrs-full:OtherNoncurrentReceivables contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">104000000</ifrs-full:OtherNoncurrentReceivables>
  <nvs:ContingentConsiderationReceivable contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">399000000</nvs:ContingentConsiderationReceivable>
  <ifrs-full:NoncurrentLoansAndReceivables contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">159000000</ifrs-full:NoncurrentLoansAndReceivables>
  <nvs:MarketableSecurities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">61000000</nvs:MarketableSecurities>
  <nvs:Commodities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">110000000</nvs:Commodities>
  <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">61000000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
  <ifrs-full:DerivativeFinancialAssets contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">102000000</ifrs-full:DerivativeFinancialAssets>
  <ifrs-full:Cash contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">3247000000</ifrs-full:Cash>
  <ifrs-full:CashEquivalents contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">7865000000</ifrs-full:CashEquivalents>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">22167000000</ifrs-full:BondsIssued>
  <nvs:LiabilitiesToBanksAndOtherInstitutions contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">188000000</nvs:LiabilitiesToBanksAndOtherInstitutions>
  <ifrs-full:CurrentPortionOfLongtermBorrowings contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">2002000000</ifrs-full:CurrentPortionOfLongtermBorrowings>
  <nvs:AverageInterestRateOnLoansReceived contextRef="AR_D-CurrentYear-1" unitRef="Pure" decimals="3">0.002</nvs:AverageInterestRateOnLoansReceived>
  <nvs:RatioFixedRateFinancialDebtToTotalFinancialDebt contextRef="AR_I-CurrentYearEnd-1" unitRef="Pure" decimals="2">0.82</nvs:RatioFixedRateFinancialDebtToTotalFinancialDebt>
  <nvs:AverageInterestRateOnBorrowings contextRef="AR_D-CurrentYear-1" unitRef="Pure" decimals="3">0.024</nvs:AverageInterestRateOnBorrowings>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd-3" unitRef="USD" decimals="-6">28532000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">43000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
  <nvs:AmortizationOfBondsDiscount contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-29000000</nvs:AmortizationOfBondsDiscount>
  <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-555000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
  <nvs:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">4691000000</nvs:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet>
  <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-56000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-94000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-482000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">28531000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">22355000000</ifrs-full:Borrowings>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1169000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent>
  <nvs:InterestBearningAccountsOfAssociatesPayableOnDemand contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1836000000</nvs:InterestBearningAccountsOfAssociatesPayableOnDemand>
  <ifrs-full:ShorttermBorrowings contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">719000000</ifrs-full:ShorttermBorrowings>
  <ifrs-full:CommercialPapersIssued contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">2289000000</ifrs-full:CommercialPapersIssued>
  <ifrs-full:DerivativeFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">185000000</ifrs-full:DerivativeFinancialLiabilities>
  <nvs:WeightedAverageInterestRateAssociates contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="3">0.004</nvs:WeightedAverageInterestRateAssociates>
  <nvs:WeightedAverageInterestRateAssociates contextRef="AR_D-CurrentYear-1" unitRef="Pure" decimals="3">0.005</nvs:WeightedAverageInterestRateAssociates>
  <nvs:WeightedAverageInterestRateOnBankAndOtherFinancialDebt contextRef="AR_D-CurrentYear-1" unitRef="Pure" decimals="3">0.129</nvs:WeightedAverageInterestRateOnBankAndOtherFinancialDebt>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions contextRef="AR_I-CurrentYearEnd-3" unitRef="USD" decimals="-6">351000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-42000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">10000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-116000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-118000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">52000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">107000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1230000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">220000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-1000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-6000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">487000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1369000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">340000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">126000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">214000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent>
  <nvs:RelatedPartiesNumberOfExecutiveCommiteeMembers contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="0">13</nvs:RelatedPartiesNumberOfExecutiveCommiteeMembers>
  <nvs:RelatedPartiesNumberOfExecutiveCommiteeMembers contextRef="AR_D-CurrentYear-1" unitRef="Pure" decimals="0">15</nvs:RelatedPartiesNumberOfExecutiveCommiteeMembers>
  <nvs:RelatedPartiesNumberOfExecutiveCommiteeMembers contextRef="AR_D-CurrentYear-2" unitRef="Pure" decimals="0">17</nvs:RelatedPartiesNumberOfExecutiveCommiteeMembers>
  <nvs:RelatedPartiesNumberOfNonexecutiveDirectors contextRef="AR_D-CurrentYear-1" unitRef="Pure" decimals="0">13</nvs:RelatedPartiesNumberOfNonexecutiveDirectors>
  <nvs:RelatedPartiesNumberOfNonexecutiveDirectors contextRef="AR_D-CurrentYear-2" unitRef="Pure" decimals="0">13</nvs:RelatedPartiesNumberOfNonexecutiveDirectors>
  <ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">166000000</ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets>
  <ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">64000000</ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets>
  <nvs:NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">92000000</nvs:NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement>
  <nvs:NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">427000000</nvs:NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement>
  <nvs:AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10 contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">104000000</nvs:AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10>
  <nvs:AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10 contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">260000000</nvs:AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10>
  <nvs:AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10 contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-324000000</nvs:AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10>
  <nvs:LongtermFinancialDebtWithACarryingAmount contextRef="AR_I-CurrentYearEnd" unitRef="EUR" decimals="-8">1800000000</nvs:LongtermFinancialDebtWithACarryingAmount>
  <nvs:LongtermFinancialDebtWithACarryingAmount contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-8">2300000000</nvs:LongtermFinancialDebtWithACarryingAmount>
  <nvs:LongtermFinancialDebtWithACarryingAmount contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-8">2100000000</nvs:LongtermFinancialDebtWithACarryingAmount>
  <nvs:UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">44000000</nvs:UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge>
  <nvs:NetInvestmentHedgeRecognizedInTheIncomeStatement contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">0</nvs:NetInvestmentHedgeRecognizedInTheIncomeStatement>
  <nvs:BorrowingsCommercialPaperNumberOfPrograms contextRef="AR_I-CurrentYearEnd" unitRef="Pure" decimals="0">3</nvs:BorrowingsCommercialPaperNumberOfPrograms>
  <nvs:BorrowingsCommercialPaperMaximumBorrowingAmount contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-8">4300000000</nvs:BorrowingsCommercialPaperMaximumBorrowingAmount>
  <nvs:BorrowingsCommercialPaperMaximumBorrowingAmount contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-8">2300000000</nvs:BorrowingsCommercialPaperMaximumBorrowingAmount>
  <nvs:BorrowingsCreditFacilityCommitted contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-9">6000000000</nvs:BorrowingsCreditFacilityCommitted>
  <nvs:VAREstimateConfidenceInterval contextRef="AR_I-CurrentYearEnd" unitRef="Pure" decimals="2">0.95</nvs:VAREstimateConfidenceInterval>
  <nvs:MaximumMarginPercentageImpactOfCommodityPriceChange contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="2">0.10</nvs:MaximumMarginPercentageImpactOfCommodityPriceChange>
  <nvs:MaximumHoldingInUnrelatedCompany contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="2">0.05</nvs:MaximumHoldingInUnrelatedCompany>
  <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">1111000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
  <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1158000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
  <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">5745000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
  <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">5728000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
  <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">6390000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
  <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">6385000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
  <nvs:ContractualInterestOnNoncurrentLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">-6647000000</nvs:ContractualInterestOnNoncurrentLiabilities>
  <nvs:ContingentConsiderationLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">1046000000</nvs:ContingentConsiderationLiabilities>
  <nvs:ContractualInterestOnNoncurrentLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">-5434000000</nvs:ContractualInterestOnNoncurrentLiabilities>
  <nvs:ContingentConsiderationLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1036000000</nvs:ContingentConsiderationLiabilities>
  <nvs:FinancialInstrumentsValueAtRiskComputation contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">355000000</nvs:FinancialInstrumentsValueAtRiskComputation>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">89000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">31000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">187000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates>
  <ifrs-full:WeightedAverageShares contextRef="AR_D-CurrentYear-1" unitRef="Shares" decimals="-6">2291000000</ifrs-full:WeightedAverageShares>
  <ifrs-full:WeightedAverageShares contextRef="AR_D-CurrentYear-2" unitRef="Shares" decimals="-6">2319000000</ifrs-full:WeightedAverageShares>
  <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares contextRef="AR_D-CurrentYear-1" unitRef="Shares" decimals="-6">28000000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
  <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares contextRef="AR_D-CurrentYear-2" unitRef="Shares" decimals="-6">25000000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
  <ifrs-full:AdjustedWeightedAverageShares contextRef="AR_D-CurrentYear" unitRef="Shares" decimals="-6">2296000000</ifrs-full:AdjustedWeightedAverageShares>
  <ifrs-full:AdjustedWeightedAverageShares contextRef="AR_D-CurrentYear-1" unitRef="Shares" decimals="-6">2319000000</ifrs-full:AdjustedWeightedAverageShares>
  <ifrs-full:AdjustedWeightedAverageShares contextRef="AR_D-CurrentYear-2" unitRef="Shares" decimals="-6">2344000000</ifrs-full:AdjustedWeightedAverageShares>
  <nvs:OptionsExcludedFromTheCalculation contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="0">0</nvs:OptionsExcludedFromTheCalculation>
  <nvs:OptionsExcludedFromTheCalculation contextRef="AR_D-CurrentYear-1" unitRef="Pure" decimals="0">0</nvs:OptionsExcludedFromTheCalculation>
  <nvs:OptionsExcludedFromTheCalculation contextRef="AR_D-CurrentYear-2" unitRef="Pure" decimals="0">0</nvs:OptionsExcludedFromTheCalculation>
  <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011 contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">273000000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-5">30200000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-5">24800000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-5">26500000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-5">2700000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-5">2600000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-5">2500000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-5">46300000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-5">45200000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-5">47300000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-5">79200000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-5">72600000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-5">76300000</ifrs-full:KeyManagementPersonnelCompensation>
  <nvs:CurrentTradeReceivablesFromCloselyMonitoredCountries contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1588000000</nvs:CurrentTradeReceivablesFromCloselyMonitoredCountries>
  <nvs:CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">61000000</nvs:CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear>
  <nvs:CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">-24000000</nvs:CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded>
  <nvs:OtherComprehensiveIncomeNetOfTaxDebtSecurities contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1000000</nvs:OtherComprehensiveIncomeNetOfTaxDebtSecurities>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">1000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">12000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges>
  <nvs:OtherComprehensiveIncomeNetOfTaxFinancialInstruments contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">2000000</nvs:OtherComprehensiveIncomeNetOfTaxFinancialInstruments>
  <nvs:OtherComprehensiveIncomeNetOfTaxFinancialInstruments contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">12000000</nvs:OtherComprehensiveIncomeNetOfTaxFinancialInstruments>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">44000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">95000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">352000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">315000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">2937000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">304000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-60000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-47000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">13000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
  <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">393000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-514000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-346000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">11401000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">11527000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">12208000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">11403000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">11525000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">12210000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">2000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
  <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-2000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-406000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">6966000000</ifrs-full:DividendsPaid>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1973000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">434000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <nvs:OtherShareSales contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">263000000</nvs:OtherShareSales>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">756000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-284000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
  <nvs:TransactionCostsRecordedInEquity contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">79000000</nvs:TransactionCostsRecordedInEquity>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">9000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <nvs:IncreaseDecreaseInNoncontrolingInterests contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-1000000</nvs:IncreaseDecreaseInNoncontrolingInterests>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">38000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-7803000000</ifrs-full:ChangesInEquity>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-210000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">6645000000</ifrs-full:DividendsPaid>
  <nvs:DividendPaidNoncashAssetsDistribution contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">23434000000</nvs:DividendPaidNoncashAssetsDistribution>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">5511000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">210000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">833000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">18000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <nvs:TaxesOnTreasuryShares contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">189000000</nvs:TaxesOnTreasuryShares>
  <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">284000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
  <nvs:TransactionCostsRecordedInEquity contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">253000000</nvs:TransactionCostsRecordedInEquity>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-5000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <nvs:IncreaseDecreaseInNoncontrolingInterests contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-1000000</nvs:IncreaseDecreaseInNoncontrolingInterests>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">22000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-34671000000</ifrs-full:ChangesInEquity>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">3330000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">806000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">730000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">30000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">6987000000</ifrs-full:DividendsPaid>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">3056000000</ifrs-full:PurchaseOfTreasuryShares>
  <nvs:TaxesOnTreasuryShares contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-32000000</nvs:TaxesOnTreasuryShares>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">18000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-10286000000</ifrs-full:ChangesInEquity>
  <ifrs-full:IssuedCapital contextRef="AR_I-CurrentYearEnd-3" unitRef="USD" decimals="-6">969000000</ifrs-full:IssuedCapital>
  <nvs:IssuedCapitalMovement contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-25000000</nvs:IssuedCapitalMovement>
  <ifrs-full:IssuedCapital contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">944000000</ifrs-full:IssuedCapital>
  <nvs:IssuedCapitalMovement contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-8000000</nvs:IssuedCapitalMovement>
  <nvs:IssuedCapitalMovement contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-23000000</nvs:IssuedCapitalMovement>
  <ifrs-full:TreasuryShares contextRef="AR_I-CurrentYearEnd-3" unitRef="USD" decimals="-6">100000000</ifrs-full:TreasuryShares>
  <ifrs-full:TreasuryShares contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">69000000</ifrs-full:TreasuryShares>
  <nvs:OutstandingShareCapital contextRef="AR_I-CurrentYearEnd-3" unitRef="USD" decimals="-6">869000000</nvs:OutstandingShareCapital>
  <nvs:OutstandingShareCapitalMovement contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">6000000</nvs:OutstandingShareCapitalMovement>
  <nvs:OutstandingShareCapital contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">875000000</nvs:OutstandingShareCapital>
  <nvs:OutstandingShareCapitalMovement contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-19000000</nvs:OutstandingShareCapitalMovement>
  <nvs:OutstandingShareCapital contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">856000000</nvs:OutstandingShareCapital>
  <nvs:OutstandingShareCapitalMovement contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">4000000</nvs:OutstandingShareCapitalMovement>
  <nvs:OutstandingShareCapital contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">860000000</nvs:OutstandingShareCapital>
  <ifrs-full:NumberOfSharesOutstanding contextRef="AR_I-CurrentYearEnd-3" unitRef="Shares" decimals="-5">2317500000</ifrs-full:NumberOfSharesOutstanding>
  <nvs:TreasurySharesAcquiredToBeCancelled contextRef="AR_D-CurrentYear" unitRef="Shares" decimals="-5">-32600000</nvs:TreasurySharesAcquiredToBeCancelled>
  <nvs:TreasurySharesAcquiredToBeCancelled contextRef="AR_D-CurrentYear-1" unitRef="Shares" decimals="-5">-60300000</nvs:TreasurySharesAcquiredToBeCancelled>
  <nvs:ShareMovements contextRef="AR_D-CurrentYear-2" unitRef="Shares" decimals="-5">-6300000</nvs:ShareMovements>
  <ifrs-full:NumberOfSharesOutstanding contextRef="AR_I-CurrentYearEnd" unitRef="Shares" decimals="-5">2256800000</ifrs-full:NumberOfSharesOutstanding>
  <ifrs-full:NumberOfSharesOutstanding contextRef="AR_I-CurrentYearEnd-1" unitRef="Shares" decimals="-5">2265000000</ifrs-full:NumberOfSharesOutstanding>
  <ifrs-full:NumberOfSharesOutstanding contextRef="AR_I-CurrentYearEnd-2" unitRef="Shares" decimals="-5">2311200000</ifrs-full:NumberOfSharesOutstanding>
  <nvs:StockRepurchaseProgramAuthorizedAmount1 contextRef="AR_I-CurrentYearEnd" unitRef="CHF" decimals="-9">10000000000</nvs:StockRepurchaseProgramAuthorizedAmount1>
  <nvs:StockRepurchaseProgramAuthorizedAmount1 contextRef="AR_I-CurrentYearEnd-1" unitRef="CHF" decimals="-9">10000000000</nvs:StockRepurchaseProgramAuthorizedAmount1>
  <nvs:StockRepurchaseProgramAuthorizedAmount1 contextRef="AR_I-CurrentYearEnd-2" unitRef="CHF" decimals="-9">10000000000</nvs:StockRepurchaseProgramAuthorizedAmount1>
  <nvs:WrittenCallOptionsHeldByMarketMaker contextRef="AR_I-CurrentYearEnd-1" unitRef="Pure" decimals="-6">13000000</nvs:WrittenCallOptionsHeldByMarketMaker>
  <nvs:WrittenCallOptionsHeldByMarketMaker contextRef="AR_I-CurrentYearEnd-2" unitRef="Pure" decimals="-6">11000000</nvs:WrittenCallOptionsHeldByMarketMaker>
  <nvs:WrittenCallOptionsWeightedAverageExercisePrice contextRef="AR_I-CurrentYearEnd-1" unitRef="USDPerShares" decimals="2">63.90</nvs:WrittenCallOptionsWeightedAverageExercisePrice>
  <nvs:WrittenCallOptionsWeightedAverageExercisePrice contextRef="AR_I-CurrentYearEnd-2" unitRef="USDPerShares" decimals="2">62.70</nvs:WrittenCallOptionsWeightedAverageExercisePrice>
  <nvs:WrittenCallOptionsContractualLive contextRef="AR_I-CurrentYearEnd" unitRef="Year" decimals="0">10</nvs:WrittenCallOptionsContractualLive>
  <nvs:WrittenCallOptionsContractualLiveRemaining contextRef="AR_I-CurrentYearEnd" unitRef="Year" decimals="0">3</nvs:WrittenCallOptionsContractualLiveRemaining>
  <nvs:WrittenCallOptionsContractualLiveRemaining contextRef="AR_I-CurrentYearEnd-1" unitRef="Year" decimals="0">4</nvs:WrittenCallOptionsContractualLiveRemaining>
  <nvs:WrittenCallOptionsContractualLiveRemaining contextRef="AR_I-CurrentYearEnd-2" unitRef="Year" decimals="0">5</nvs:WrittenCallOptionsContractualLiveRemaining>
  <nvs:MaximalAmountOfShareBuybackProgramm contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-8">2500000000</nvs:MaximalAmountOfShareBuybackProgramm>
  <nvs:TaxOnTransactionCostsRecordedInEquity contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">36000000</nvs:TaxOnTransactionCostsRecordedInEquity>
  <nvs:TaxOnTransactionCostsRecordedInEquity contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">20000000</nvs:TaxOnTransactionCostsRecordedInEquity>
  <nvs:AmountRecordedInEquityRelatedToHyperinflation contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">22000000</nvs:AmountRecordedInEquityRelatedToHyperinflation>
  <nvs:AmountRecordedInEquityRelatedToHyperinflation contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">38000000</nvs:AmountRecordedInEquityRelatedToHyperinflation>
  <nvs:DividendsPayableAmountPerShare contextRef="AR_I-CurrentYearEnd-1" unitRef="CHFPerShares" decimals="2">2.85</nvs:DividendsPayableAmountPerShare>
  <nvs:DividendsPayableAmountPerShare contextRef="AR_I-CurrentYearEnd-2" unitRef="CHFPerShares" decimals="2">2.80</nvs:DividendsPayableAmountPerShare>
  <nvs:TreasurySharesAcquiredForCancellationValue contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">5351000000</nvs:TreasurySharesAcquiredForCancellationValue>
  <nvs:TreasurySharesAcquiredForCancellationValue contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">1859000000</nvs:TreasurySharesAcquiredForCancellationValue>
  <nvs:OtherSharePurchasesValue contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">160000000</nvs:OtherSharePurchasesValue>
  <nvs:OtherSharePurchasesValue contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">114000000</nvs:OtherSharePurchasesValue>
  <nvs:SharepurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-1" unitRef="Shares" decimals="-5">-62000000</nvs:SharepurchaseOfTreasuryShares>
  <nvs:SharepurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-2" unitRef="Shares" decimals="-5">-24500000</nvs:SharepurchaseOfTreasuryShares>
  <nvs:SharesDeliveredToDivestedBusinessEmployees contextRef="AR_D-CurrentYear-1" unitRef="Shares" decimals="-5">900000</nvs:SharesDeliveredToDivestedBusinessEmployees>
  <nvs:NumberOfOtherShareSales contextRef="AR_D-CurrentYear-2" unitRef="Shares" decimals="-5">3000000</nvs:NumberOfOtherShareSales>
  <nvs:OtherShareSalesEquityImpact contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">263000000</nvs:OtherShareSalesEquityImpact>
  <nvs:EquityImpactOfTreasuryShareMovements contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1490000000</nvs:EquityImpactOfTreasuryShareMovements>
  <nvs:TreasurySharesMovement contextRef="AR_D-CurrentYear-1" unitRef="Shares" decimals="-5">-46200000</nvs:TreasurySharesMovement>
  <nvs:EquityImpactOfTreasuryShareMovements contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">4450000000</nvs:EquityImpactOfTreasuryShareMovements>
  <nvs:TreasurySharesMovement contextRef="AR_D-CurrentYear-2" unitRef="Shares" decimals="-5">-6300000</nvs:TreasurySharesMovement>
  <nvs:EquityImpactOfTreasuryShareMovements contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">520000000</nvs:EquityImpactOfTreasuryShareMovements>
  <nvs:TreasurySharesAcquiredToBeCancelled contextRef="AR_D-CurrentYear-2" unitRef="Shares" decimals="-5">-23300000</nvs:TreasurySharesAcquiredToBeCancelled>
  <nvs:OtherSharePurchases contextRef="AR_D-CurrentYear" unitRef="Shares" decimals="-5">-1700000</nvs:OtherSharePurchases>
  <nvs:OtherSharePurchases contextRef="AR_D-CurrentYear-1" unitRef="Shares" decimals="-5">-1700000</nvs:OtherSharePurchases>
  <nvs:OtherSharePurchases contextRef="AR_D-CurrentYear-2" unitRef="Shares" decimals="-5">-1200000</nvs:OtherSharePurchases>
  <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares contextRef="AR_D-CurrentYear" unitRef="Shares" decimals="-5">14700000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
  <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares contextRef="AR_D-CurrentYear-1" unitRef="Shares" decimals="-5">5500000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
  <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares contextRef="AR_D-CurrentYear-2" unitRef="Shares" decimals="-5">7800000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
  <nvs:EquityBasedCompensationShares contextRef="AR_D-CurrentYear" unitRef="Shares" decimals="-5">11000000</nvs:EquityBasedCompensationShares>
  <nvs:EquityBasedCompensationShares contextRef="AR_D-CurrentYear-1" unitRef="Shares" decimals="-5">9400000</nvs:EquityBasedCompensationShares>
  <nvs:EquityBasedCompensationShares contextRef="AR_D-CurrentYear-2" unitRef="Shares" decimals="-5">7400000</nvs:EquityBasedCompensationShares>
  <nvs:SharesDeliveredToDivestedBusinessEmployees contextRef="AR_D-CurrentYear" unitRef="Shares" decimals="-5">400000</nvs:SharesDeliveredToDivestedBusinessEmployees>
  <nvs:ShareMovements contextRef="AR_D-CurrentYear" unitRef="Shares" decimals="-5">-8200000</nvs:ShareMovements>
  <nvs:ShareMovements contextRef="AR_D-CurrentYear-1" unitRef="Shares" decimals="-5">-46200000</nvs:ShareMovements>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">78692000000</ifrs-full:Equity>
  <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">37000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
  <nvs:TreasurySharesMovementOfPeriod contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">31000000</nvs:TreasurySharesMovementOfPeriod>
  <nvs:TreasurySharesMovementOfPeriod contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">-11000000</nvs:TreasurySharesMovementOfPeriod>
  <nvs:TreasurySharesMovementOfPeriod contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">27000000</nvs:TreasurySharesMovementOfPeriod>
  <nvs:WeightedAverageInterestRateLeaseLiabilities contextRef="AR_D-CurrentYear-1" unitRef="Pure" decimals="3">0.039</nvs:WeightedAverageInterestRateLeaseLiabilities>
  <nvs:LeaseIncentives contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">33000000</nvs:LeaseIncentives>
  <nvs:MostMaterialLeaseWithLeaseTermExtension contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-8">600000000</nvs:MostMaterialLeaseWithLeaseTermExtension>
  <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">537000000</ifrs-full:AdditionsToRightofuseAssets>
  <nvs:LeaseContractTerminationsRightofuseAssets contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">98000000</nvs:LeaseContractTerminationsRightofuseAssets>
  <nvs:DisposalsAndRetirementsRightofuseAssets contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">17000000</nvs:DisposalsAndRetirementsRightofuseAssets>
  <nvs:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">6000000</nvs:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearStart-1" unitRef="USD" decimals="-6">1554000000</ifrs-full:RightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">305000000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">346000000</ifrs-full:AdditionsToRightofuseAssets>
  <nvs:LeaseContractTerminationsRightofuseAssets contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">63000000</nvs:LeaseContractTerminationsRightofuseAssets>
  <nvs:DisposalsAndRetirementsRightofuseAssets contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">32000000</nvs:DisposalsAndRetirementsRightofuseAssets>
  <nvs:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">46000000</nvs:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
  <nvs:FairValueOfOtherFinancialAssetsSold contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">33000000</nvs:FairValueOfOtherFinancialAssetsSold>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">-792000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-1000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <nvs:DividendsPayableAmountPerShare contextRef="AR_I-CurrentYearEnd" unitRef="CHFPerShares" decimals="2">2.95</nvs:DividendsPayableAmountPerShare>
  <nvs:RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-511000000</nvs:RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">28298000000</ifrs-full:BondsIssued>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">306000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-6">1949000000</ifrs-full:LeaseLiabilities>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-201000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">3194000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">143000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">250000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
  <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-2000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
  <nvs:AmountRecordedInEquityRelatedToHyperinflation contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">18000000</nvs:AmountRecordedInEquityRelatedToHyperinflation>
  <nvs:TreasurySharesAcquiredForCancellationValue contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">2897000000</nvs:TreasurySharesAcquiredForCancellationValue>
  <nvs:OtherSharePurchasesValue contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">159000000</nvs:OtherSharePurchasesValue>
  <nvs:SharepurchaseOfTreasuryShares contextRef="AR_D-CurrentYear" unitRef="Shares" decimals="-5">-34300000</nvs:SharepurchaseOfTreasuryShares>
  <nvs:TreasurySharesMovement contextRef="AR_D-CurrentYear" unitRef="Shares" decimals="-5">-8200000</nvs:TreasurySharesMovement>
  <nvs:WrittenCallOptionsHeldByMarketMaker contextRef="AR_I-CurrentYearEnd" unitRef="Pure" decimals="-6">1000000</nvs:WrittenCallOptionsHeldByMarketMaker>
  <nvs:WrittenCallOptionsWeightedAverageExercisePrice contextRef="AR_I-CurrentYearEnd" unitRef="USDPerShares" decimals="2">60.09</nvs:WrittenCallOptionsWeightedAverageExercisePrice>
  <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">26000000</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
  <nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">196000000</nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate>
  <nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">8600000000</nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate>
  <nvs:OtherIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">218000000</nvs:OtherIntangibleAssetsRecognisedAsOfAcquisitionDate>
  <ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">476000000</ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate>
  <nvs:FinancialAndOtherAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">49000000</nvs:FinancialAndOtherAssets>
  <ifrs-full:InventoryRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">84000000</ifrs-full:InventoryRecognisedAsOfAcquisitionDate>
  <nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">109000000</nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate>
  <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">76000000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
  <ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">1977000000</ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">32000000</ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate>
  <nvs:TradePayablesAndOtherLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">144000000</nvs:TradePayablesAndOtherLiabilities>
  <nvs:AcquiredCashAndCashEquivalents contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">76000000</nvs:AcquiredCashAndCashEquivalents>
  <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">2580000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
  <ifrs-full:CashOutflowForLeases contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">379000000</ifrs-full:CashOutflowForLeases>
  <nvs:CashOutflowsForPaymentsOfLeasesInterest contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">56000000</nvs:CashOutflowsForPaymentsOfLeasesInterest>
  <nvs:WeightedAverageInterestRateLeaseLiabilities contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="3">0.034</nvs:WeightedAverageInterestRateLeaseLiabilities>
  <nvs:LeaseIncentives contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">0</nvs:LeaseIncentives>
  <nvs:MostMaterialLeaseWithLeaseTermExtension contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-8">600000000</nvs:MostMaterialLeaseWithLeaseTermExtension>
  <nvs:CurrentTradeReceivablesFromCloselyMonitoredCountries contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">1505000000</nvs:CurrentTradeReceivablesFromCloselyMonitoredCountries>
  <nvs:CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">55000000</nvs:CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear>
  <nvs:CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">-27000000</nvs:CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded>
  <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">14000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
  <nvs:RepurchaseOfOptions contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">89000000</nvs:RepurchaseOfOptions>
  <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-1769000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
  <nvs:RightOfUseAssetsAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">32000000</nvs:RightOfUseAssetsAsOfAcquisitionDate>
  <nvs:CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">44000000</nvs:CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate>
  <ifrs-full:GrossLeaseLiabilities contextRef="AR_I-CurrentYearEnd-2" unitRef="USD" decimals="-6">3612000000</ifrs-full:GrossLeaseLiabilities>
  <nvs:NewLeaseArrangements contextRef="AR_D-CurrentYear-2" unitRef="USD" decimals="-6">-65000000</nvs:NewLeaseArrangements>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearStart-1" unitRef="USD" decimals="-6">1736000000</ifrs-full:LeaseLiabilities>
  <nvs:ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges contextRef="AR_I-CurrentYearEnd-2" unitRef="Pure" decimals="2">0.22</nvs:ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges>
  <nvs:ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges contextRef="AR_I-CurrentYearEnd-2" unitRef="Pure" decimals="2">0.08</nvs:ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges>
  <nvs:AcquisitionsThroughBusinessCombinationsRightofuseAssets contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">32000000</nvs:AcquisitionsThroughBusinessCombinationsRightofuseAssets>
  <nvs:UndiscountedFutureLeasePayments contextRef="AR_D-CurrentYearStart-1" unitRef="USD" decimals="-6">3283000000</nvs:UndiscountedFutureLeasePayments>
  <nvs:MaximalAmountOfShareBuybackProgramm contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-9">5000000000</nvs:MaximalAmountOfShareBuybackProgramm>
  <nvs:NumberOfOptionsRepurchased contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="-5">-3700000</nvs:NumberOfOptionsRepurchased>
  <nvs:EnvironmentalProvisionExpectedCashOutflowNextTwoYears contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">181000000</nvs:EnvironmentalProvisionExpectedCashOutflowNextTwoYears>
  <nvs:EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">210000000</nvs:EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears>
  <nvs:EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">338000000</nvs:EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears>
  <nvs:NoncurrentFinancialAssetsEquityInvestments contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">1577000000</nvs:NoncurrentFinancialAssetsEquityInvestments>
  <nvs:NoncurrentFinancialAsstetsDebtSecurities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">36000000</nvs:NoncurrentFinancialAsstetsDebtSecurities>
  <nvs:NoncurrentFinancialAssetsFundInvestments contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">366000000</nvs:NoncurrentFinancialAssetsFundInvestments>
  <nvs:LongTermReceivablesFromFinanceSubleases contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">83000000</nvs:LongTermReceivablesFromFinanceSubleases>
  <ifrs-full:OtherNoncurrentReceivables contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">125000000</ifrs-full:OtherNoncurrentReceivables>
  <nvs:ContingentConsiderationReceivable contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">625000000</nvs:ContingentConsiderationReceivable>
  <ifrs-full:NoncurrentLoansAndReceivables contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">89000000</ifrs-full:NoncurrentLoansAndReceivables>
  <nvs:MarketableSecurities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">26000000</nvs:MarketableSecurities>
  <nvs:Commodities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">111000000</nvs:Commodities>
  <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">1609000000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
  <ifrs-full:DerivativeFinancialAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">159000000</ifrs-full:DerivativeFinancialAssets>
  <ifrs-full:Cash contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">3750000000</ifrs-full:Cash>
  <ifrs-full:CashEquivalents contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">5908000000</ifrs-full:CashEquivalents>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">11000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-1863000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">31000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1018000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-17000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">3507000000</nvs:LeaseLiabilitiesUndiscounted>
  <nvs:CurrentLeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">338000000</nvs:CurrentLeaseLiabilitiesUndiscounted>
  <nvs:NoncurrentLeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">3169000000</nvs:NoncurrentLeaseLiabilitiesUndiscounted>
  <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">4000000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
  <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">7000000</ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed>
  <nvs:CashOutflowsForShortTermAndLowValueLeases contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">11000000</nvs:CashOutflowsForShortTermAndLowValueLeases>
  <nvs:LiabilitiesToBanksAndOtherInstitutions contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">233000000</nvs:LiabilitiesToBanksAndOtherInstitutions>
  <ifrs-full:CurrentPortionOfLongtermBorrowings contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">2272000000</ifrs-full:CurrentPortionOfLongtermBorrowings>
  <nvs:InterestBearningAccountsOfAssociatesPayableOnDemand contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">2085000000</nvs:InterestBearningAccountsOfAssociatesPayableOnDemand>
  <ifrs-full:ShorttermBorrowings contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">976000000</ifrs-full:ShorttermBorrowings>
  <ifrs-full:CommercialPapersIssued contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">4258000000</ifrs-full:CommercialPapersIssued>
  <ifrs-full:DerivativeFinancialLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">194000000</ifrs-full:DerivativeFinancialLiabilities>
  <ifrs-full:WeightedAverageShares contextRef="AR_D-CurrentYear" unitRef="Shares" decimals="-6">2277000000</ifrs-full:WeightedAverageShares>
  <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares contextRef="AR_D-CurrentYear" unitRef="Shares" decimals="-6">19000000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
  <nvs:CommitmentForRepurchaseOwnShares contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">1769000000</nvs:CommitmentForRepurchaseOwnShares>
  <nvs:FinancialInstrumentsValueAtRiskComputation contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">587000000</nvs:FinancialInstrumentsValueAtRiskComputation>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">199000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">62000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">197000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates>
  <nvs:UncalledCapitalCommitmentsForInvestmentsInFunds contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">87000000</nvs:UncalledCapitalCommitmentsForInvestmentsInFunds>
  <nvs:FairValueOfOtherFinancialAssetsSold contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">206000000</nvs:FairValueOfOtherFinancialAssetsSold>
  <nvs:UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">201000000</nvs:UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge>
  <nvs:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">101000000</nvs:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
  <nvs:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments contextRef="AR_D-CurrentYear" unitRef="CHF" decimals="-6">90000000</nvs:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
  <ifrs-full:IncomeTaxesPaidRefund contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1921000000</ifrs-full:IncomeTaxesPaidRefund>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">293000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">-39000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">1501000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">12000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">8344000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">7552000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">130000000</nvs:OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction>
  <ifrs-full:InventoryWritedown2011 contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">702000000</ifrs-full:InventoryWritedown2011>
  <ifrs-full:ReversalOfInventoryWritedown contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">255000000</ifrs-full:ReversalOfInventoryWritedown>
  <ifrs-full:GoodwillExpectedDeductibleForTaxPurposes contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">74000000</ifrs-full:GoodwillExpectedDeductibleForTaxPurposes>
  <nvs:AverageInterestRateOnLoansReceived contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="3">0.003</nvs:AverageInterestRateOnLoansReceived>
  <nvs:RatioFixedRateFinancialDebtToTotalFinancialDebt contextRef="AR_I-CurrentYearEnd" unitRef="Pure" decimals="2">0.79</nvs:RatioFixedRateFinancialDebtToTotalFinancialDebt>
  <nvs:AverageInterestRateOnBorrowings contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="3">0.020</nvs:AverageInterestRateOnBorrowings>
  <nvs:WeightedAverageInterestRateOnBankAndOtherFinancialDebt contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="3">0.050</nvs:WeightedAverageInterestRateOnBankAndOtherFinancialDebt>
  <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">9000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
  <nvs:ValueOfTaxLossCarryforwardsExpired contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">14000000</nvs:ValueOfTaxLossCarryforwardsExpired>
  <nvs:DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-8">4500000000</nvs:DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months>
  <nvs:DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-8">7000000000</nvs:DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months>
  <nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd contextRef="AR_I-CurrentYearEnd" unitRef="USD" decimals="-6">3296000000</nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd>
  <nvs:UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-9">27000000000</nvs:UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment>
  <nvs:UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-9">26000000000</nvs:UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment>
  <ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-8">7700000000</ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners>
  <nvs:ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets contextRef="AR_D-CurrentYear" unitRef="USD" decimals="-6">0</nvs:ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets>
  <nvs:ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets contextRef="AR_D-CurrentYear-1" unitRef="USD" decimals="-6">0</nvs:ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets>
  <nvs:RelatedPartiesNumberOfNonexecutiveDirectors contextRef="AR_D-CurrentYear" unitRef="Pure" decimals="0">14</nvs:RelatedPartiesNumberOfNonexecutiveDirectors>
  <nvs:BorrowingsCreditFacilityShortTerm contextRef="AR_I-CurrentYearEnd-1" unitRef="USD" decimals="-9">7000000000</nvs:BorrowingsCreditFacilityShortTerm>
  <dei:EntityCommonStockSharesOutstanding contextRef="AR_I-CurrentYearEnd" unitRef="Shares" decimals="0">2256822048</dei:EntityCommonStockSharesOutstanding>
  <nvs:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.020</nvs:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
  <nvs:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.001</nvs:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <ifrs-full:DeferredTaxExpenseIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember" unitRef="USD" decimals="-6">-430000000</ifrs-full:DeferredTaxExpenseIncome>
  <ifrs-full:CurrentTaxExpenseIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember" unitRef="USD" decimals="-6">1168000000</ifrs-full:CurrentTaxExpenseIncome>
  <ifrs-full:DeferredTaxExpenseIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">137000000</ifrs-full:DeferredTaxExpenseIncome>
  <ifrs-full:ApplicableTaxRate contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.136</ifrs-full:ApplicableTaxRate>
  <ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.046</ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
  <ifrs-full:TaxRateEffectOfTaxLosses contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.003</ifrs-full:TaxRateEffectOfTaxLosses>
  <nvs:TaxRateEffectOfIncomeTaxedAtReducedRates contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.003</nvs:TaxRateEffectOfIncomeTaxedAtReducedRates>
  <ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.007</ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation>
  <nvs:TaxRateEffectOfCreditsAndAllowances contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.023</nvs:TaxRateEffectOfCreditsAndAllowances>
  <nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.002</nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability>
  <ifrs-full:TaxRateEffectFromChangeInTaxRate contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.003</ifrs-full:TaxRateEffectFromChangeInTaxRate>
  <nvs:EffectOfWriteoffOfDeferredTaxAssets contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.002</nvs:EffectOfWriteoffOfDeferredTaxAssets>
  <nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.008</nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries>
  <ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.023</ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods>
  <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.019</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
  <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">29000000</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">9786000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember" unitRef="USD" decimals="-6">92000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:CurrentTaxExpenseIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">932000000</ifrs-full:CurrentTaxExpenseIncome>
  <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">8072000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
  <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">501000000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
  <nvs:EnvironmentalProvisionReleases contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">21000000</nvs:EnvironmentalProvisionReleases>
  <nvs:EnvironmentalProvisionAdditions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">7000000</nvs:EnvironmentalProvisionAdditions>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">18248000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">1687000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
  <ifrs-full:UnusedProvisionReversedOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">44000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
  <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">30000000</ifrs-full:AdditionalProvisionsOtherProvisions>
  <nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16 contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">-2000000</nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16>
  <nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16 contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">-1000000</nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16>
  <nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16 contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">1471000000</nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16>
  <nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16 contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">268000000</nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16>
  <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">521000000</ifrs-full:AdditionalProvisionsOtherProvisions>
  <ifrs-full:UnusedProvisionReversedOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">31000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">11403000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">6948000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">12417000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">7142000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
  <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">12797000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">107000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">220000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions>
  <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">89000000</ifrs-full:AdditionalProvisionsOtherProvisions>
  <ifrs-full:UnusedProvisionReversedOtherProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">53000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">645000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">53000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">220000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">395000000</nvs:AdditionsToRestructuringProvisions>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">32000000</nvs:AdditionsToRestructuringProvisions>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">94000000</nvs:AdditionsToRestructuringProvisions>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">918000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">7000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">239000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">60000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">2000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">592000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">249000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">107000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
  <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-113000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1075000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">285000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">122000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">2214000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">366000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">714000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">761000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">64000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">98000000</nvs:AdditionsToRestructuringProvisions>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">165000000</nvs:AdditionsToRestructuringProvisions>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">39000000</nvs:AdditionsToRestructuringProvisions>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">98000000</nvs:AdditionsToRestructuringProvisions>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">217000000</nvs:AdditionsToRestructuringProvisions>
  <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">20000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">229000000</nvs:AdditionsToRestructuringProvisions>
  <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">153000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
  <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">18000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
  <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">182000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">67000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">180000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">958000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">1067000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">239000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">912000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">952000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">282000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">283000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">124000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">110000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">273000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">247000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">41000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">41000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">16000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">17000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">3080000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">2509000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">370000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">315000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">12000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">12000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">324000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">100000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">116000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">101000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">1000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">768000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">632000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">141000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">506000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">5000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">422000000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
  <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">443000000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">13660000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:DeferredTaxExpenseIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember" unitRef="USD" decimals="-6">-447000000</ifrs-full:DeferredTaxExpenseIncome>
  <ifrs-full:DeferredTaxExpenseIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember" unitRef="USD" decimals="-6">-428000000</ifrs-full:DeferredTaxExpenseIncome>
  <ifrs-full:CurrentTaxExpenseIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">2100000000</ifrs-full:CurrentTaxExpenseIncome>
  <ifrs-full:CurrentTaxExpenseIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">2147000000</ifrs-full:CurrentTaxExpenseIncome>
  <ifrs-full:CurrentTaxExpenseIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">1603000000</ifrs-full:CurrentTaxExpenseIncome>
  <ifrs-full:DeferredTaxExpenseIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">93000000</ifrs-full:DeferredTaxExpenseIncome>
  <ifrs-full:CurrentTaxExpenseIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember" unitRef="USD" decimals="-6">988000000</ifrs-full:CurrentTaxExpenseIncome>
  <ifrs-full:DeferredTaxExpenseIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">120000000</ifrs-full:DeferredTaxExpenseIncome>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">8097000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">11887000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember" unitRef="USD" decimals="-6">843000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember" unitRef="USD" decimals="-6">2208000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">9878000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">8940000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">14095000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:CurrentTaxExpenseIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">1186000000</ifrs-full:CurrentTaxExpenseIncome>
  <ifrs-full:CurrentTaxExpenseIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">615000000</ifrs-full:CurrentTaxExpenseIncome>
  <ifrs-full:CurrentTaxExpenseIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember" unitRef="USD" decimals="-6">961000000</ifrs-full:CurrentTaxExpenseIncome>
  <ifrs-full:DeferredTaxExpenseIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">-293000000</ifrs-full:DeferredTaxExpenseIncome>
  <ifrs-full:DeferredTaxExpenseIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">-354000000</ifrs-full:DeferredTaxExpenseIncome>
  <ifrs-full:DeferredTaxExpenseIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">-308000000</ifrs-full:DeferredTaxExpenseIncome>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">1807000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">1793000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">1295000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:ApplicableTaxRate contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.117</ifrs-full:ApplicableTaxRate>
  <ifrs-full:ApplicableTaxRate contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.143</ifrs-full:ApplicableTaxRate>
  <ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.048</ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
  <ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.017</ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
  <ifrs-full:TaxRateEffectOfTaxLosses contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.001</ifrs-full:TaxRateEffectOfTaxLosses>
  <ifrs-full:TaxRateEffectOfTaxLosses contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.001</ifrs-full:TaxRateEffectOfTaxLosses>
  <nvs:TaxRateEffectOfIncomeTaxedAtReducedRates contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.007</nvs:TaxRateEffectOfIncomeTaxedAtReducedRates>
  <nvs:TaxRateEffectOfIncomeTaxedAtReducedRates contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.004</nvs:TaxRateEffectOfIncomeTaxedAtReducedRates>
  <ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.000</ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation>
  <ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.037</ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation>
  <nvs:TaxRateEffectOfCreditsAndAllowances contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.023</nvs:TaxRateEffectOfCreditsAndAllowances>
  <nvs:TaxRateEffectOfCreditsAndAllowances contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.023</nvs:TaxRateEffectOfCreditsAndAllowances>
  <nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.005</nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability>
  <nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.002</nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability>
  <ifrs-full:TaxRateEffectFromChangeInTaxRate contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.014</ifrs-full:TaxRateEffectFromChangeInTaxRate>
  <ifrs-full:TaxRateEffectFromChangeInTaxRate contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.001</ifrs-full:TaxRateEffectFromChangeInTaxRate>
  <nvs:EffectOfWriteoffOfDeferredTaxAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.040</nvs:EffectOfWriteoffOfDeferredTaxAssets>
  <nvs:EffectOfWriteoffOfDeferredTaxAssets contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.002</nvs:EffectOfWriteoffOfDeferredTaxAssets>
  <nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.006</nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries>
  <nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.000</nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries>
  <ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.022</ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods>
  <ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.005</ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods>
  <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.030</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
  <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.003</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
  <ifrs-full:AverageEffectiveTaxRate contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.183</ifrs-full:AverageEffectiveTaxRate>
  <ifrs-full:AverageEffectiveTaxRate contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.201</ifrs-full:AverageEffectiveTaxRate>
  <ifrs-full:AverageEffectiveTaxRate contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.092</ifrs-full:AverageEffectiveTaxRate>
  <nvs:EffectOfIncomeNotSubjectToTaxOnDivestmentGain contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">-0.037</nvs:EffectOfIncomeNotSubjectToTaxOnDivestmentGain>
  <nvs:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.026</nvs:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
  <nvs:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="Pure" decimals="3">0.004</nvs:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">11000000</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense>
  <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019ContinuingOperationsMember" unitRef="USD" decimals="-6">19000000</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense>
  <nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16 contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">40000000</nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-858000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-82000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-1403000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">123000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">248000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">39000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">217000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">38000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">164000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">79000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsInvestingActivities>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">2858000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:RightofuseAssets contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">269000000</ifrs-full:RightofuseAssets>
  <ifrs-full:Goodwill contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">8906000000</ifrs-full:Goodwill>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">11121000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DeferredTaxAssets contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">732000000</ifrs-full:DeferredTaxAssets>
  <nvs:FinancialAndOtherNoncurrentAssets contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">526000000</nvs:FinancialAndOtherNoncurrentAssets>
  <ifrs-full:Inventories contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">1469000000</ifrs-full:Inventories>
  <nvs:TradeReceivablesAndOtherCurrentAssets contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">1787000000</nvs:TradeReceivablesAndOtherCurrentAssets>
  <ifrs-full:CashAndCashEquivalents contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">628000000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:DeferredTaxLiabilities contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">1713000000</ifrs-full:DeferredTaxLiabilities>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">269000000</ifrs-full:LeaseLiabilities>
  <nvs:CurrentAndNoncurrentFinancialDebt contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">3538000000</nvs:CurrentAndNoncurrentFinancialDebt>
  <nvs:TradePayablesProvisionsAndOtherLiabilities contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">2751000000</nvs:TradePayablesProvisionsAndOtherLiabilities>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">9000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">113000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">36000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <nvs:NetAssetsDerecognized contextRef="AR_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-20025000000</nvs:NetAssetsDerecognized>
  <ifrs-full:DividendsPayable contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">23434000000</ifrs-full:DividendsPayable>
  <ifrs-full:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed contextRef="AR_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">3409000000</ifrs-full:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed>
  <nvs:DistributionOfDividendToDividendBearingShares contextRef="AR_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">1273000000</nvs:DistributionOfDividendToDividendBearingShares>
  <nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement contextRef="AR_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">123000000</nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement>
  <nvs:TransactionCosts contextRef="AR_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">114000000</nvs:TransactionCosts>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">1777000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">32000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">1809000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">860000000</ifrs-full:CostOfSales>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">949000000</ifrs-full:GrossProfit>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">638000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">142000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">15000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">113000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">71000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">10000000</ifrs-full:InterestExpense>
  <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:OtherFinanceIncomeCost>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">58000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">159000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <nvs:NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-101000000</nvs:NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution>
  <ifrs-full:ProfitLossFromDiscontinuedOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">4590000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">42000000</ifrs-full:DepreciationAndAmortisationExpense>
  <nvs:CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-29000000</nvs:CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents>
  <nvs:DivestedCashAndCashEquivalents contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">628000000</nvs:DivestedCashAndCashEquivalents>
  <nvs:CashFlowsAttributableToDivestedBusiness contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-39000000</nvs:CashFlowsAttributableToDivestedBusiness>
  <nvs:CashFlowsAttributableToDivestedBusiness contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-657000000</nvs:CashFlowsAttributableToDivestedBusiness>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-502000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-1001000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities>
  <nvs:ProceedsFromCurrentAndNoncurrentBorrowings contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">3492000000</nvs:ProceedsFromCurrentAndNoncurrentBorrowings>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">212000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">57000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">174000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-424000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-40000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">0</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-238000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">0</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-345000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">33000000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
  <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">104000000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
  <nvs:DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-47000000</nvs:DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations>
  <nvs:DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-246000000</nvs:DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations>
  <nvs:DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-40000000</nvs:DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations>
  <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">4590000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
  <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-186000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
  <nvs:RepaymentOfIntercompanyBalances contextRef="AR_D-Transaction-Alcon-3-April-8_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-8">3100000000</nvs:RepaymentOfIntercompanyBalances>
  <ifrs-full:Borrowings contextRef="AR_I-Transaction-Alcon-1-March-6_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-8">3500000000</ifrs-full:Borrowings>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-Transaction-Alcon-4-April-9_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-8">1300000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:DividendsPayable contextRef="AR_I-Transaction-Alcon-2-March-31_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-8">26400000000</ifrs-full:DividendsPayable>
  <ifrs-full:NetAssetsLiabilities contextRef="AR_I-Transaction-Alcon-2-March-31_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-8">23100000000</ifrs-full:NetAssetsLiabilities>
  <ifrs-full:OtherBorrowings contextRef="AR_I-Transaction-Alcon-1-March-6_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-8">3200000000</ifrs-full:OtherBorrowings>
  <ifrs-full:OtherBorrowings contextRef="AR_I-Transaction-Alcon-1-March-6_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4BorrowingsUSDMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-8">2800000000</ifrs-full:OtherBorrowings>
  <ifrs-full:OtherBorrowings contextRef="AR_I-Transaction-Alcon-1-March-6_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4BorrowingsEURMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-8">400000000</ifrs-full:OtherBorrowings>
  <nvs:AdditionalBorrowings contextRef="AR_I-Transaction-Alcon-1-March-6_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-8">300000000</nvs:AdditionalBorrowings>
  <nvs:CurrentRefundsProvisionDiscontinuedOperations contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">0</nvs:CurrentRefundsProvisionDiscontinuedOperations>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">4577000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-207000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
  <nvs:CurrentRefundsProvisionDiscontinuedOperations contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">-28000000</nvs:CurrentRefundsProvisionDiscontinuedOperations>
  <nvs:CurrentRefundsProvisionDiscontinuedOperations contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">-166000000</nvs:CurrentRefundsProvisionDiscontinuedOperations>
  <nvs:CurrentRefundsProvisionDiscontinuedOperations contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-194000000</nvs:CurrentRefundsProvisionDiscontinuedOperations>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">7149000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">4000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">7153000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">3983000000</ifrs-full:CostOfSales>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">3170000000</ifrs-full:GrossProfit>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">2754000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">585000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">61000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">126000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-234000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">25000000</ifrs-full:InterestExpense>
  <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-1000000</ifrs-full:OtherFinanceIncomeCost>
  <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-260000000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-74000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <nvs:NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-186000000</nvs:NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution>
  <nvs:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">4691000000</nvs:DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet>
  <ifrs-full:ProfitLossFromDiscontinuedOperations contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-186000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
  <ifrs-full:RevenueFromInterest contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">2000000</ifrs-full:RevenueFromInterest>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">235000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">1052000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">3000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">391000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <nvs:AdditionsToRestructuringProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">13000000</nvs:AdditionsToRestructuringProvisions>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">93000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">3000000</ifrs-full:AdditionsToRightofuseAssets>
  <nvs:DefinedBenefitObligationDiscontinuedOperationsAtPresentValue contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-662000000</nvs:DefinedBenefitObligationDiscontinuedOperationsAtPresentValue>
  <nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16 contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-89000000</nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16>
  <nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16 contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">246000000</nvs:LeaseLiabilitiesImpactOfAdoptionOfIFRS16>
  <nvs:DefinedBenefitObligationDiscontinuedOperationsAtPresentValue contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-385000000</nvs:DefinedBenefitObligationDiscontinuedOperationsAtPresentValue>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">9000000</ifrs-full:DepreciationAndAmortisationExpense>
  <nvs:ProceedsFromCurrentAndNoncurrentBorrowings contextRef="AR_D-CurrentYear-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">0</nvs:ProceedsFromCurrentAndNoncurrentBorrowings>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">-19000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">163000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">-28000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">286000000</ifrs-full:LeaseLiabilities>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">276000000</ifrs-full:RightofuseAssets>
  <nvs:GrossLeaseLiabilitiesDiscontinuedOperations contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">222000000</nvs:GrossLeaseLiabilitiesDiscontinuedOperations>
  <nvs:ProvisionForDoubtfulReceivable contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">54000000</nvs:ProvisionForDoubtfulReceivable>
  <nvs:CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-39000000</nvs:CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents>
  <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">-88000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember" unitRef="USD" decimals="-6">88000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsInvestingActivities>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">89000000</ifrs-full:LeaseLiabilities>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">75000000</ifrs-full:RightofuseAssets>
  <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="AR_I-Transaction-PowerVision-1_dei-2020LegalEntityAxis_nvs-2020Q4PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">424000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-PowerVision-1_dei-2020LegalEntityAxis_nvs-2020Q4PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">289000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-Transaction-PowerVision-1_dei-2020LegalEntityAxis_nvs-2020Q4PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">135000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-Transaction-PowerVision-1_dei-2020LegalEntityAxis_nvs-2020Q4PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">418000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-Transaction-PowerVision-1_dei-2020LegalEntityAxis_nvs-2020Q4PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">505000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-Transaction-PowerVision-1_dei-2020LegalEntityAxis_nvs-2020Q4PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">93000000</ifrs-full:DeferredTaxLiabilityAsset>
  <nvs:OtherNetAssets contextRef="AR_I-Transaction-PowerVision-1_dei-2020LegalEntityAxis_nvs-2020Q4PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">6000000</nvs:OtherNetAssets>
  <ifrs-full:AdditionalRecognitionGoodwill contextRef="AR_D-Transaction-PowerVision-1_dei-2020LegalEntityAxis_nvs-2020Q4PowerVisionInc.Member_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">6000000</ifrs-full:AdditionalRecognitionGoodwill>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019BottomOfRangeMember" unitRef="USD" decimals="-6">173000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019BottomOfRangeMember" unitRef="USD" decimals="-6">71000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019BottomOfRangeMember" unitRef="USD" decimals="-6">21000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements>
  <nvs:FinancialInstrumentsValueAtRiskComputation contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019BottomOfRangeMember" unitRef="USD" decimals="-6">322000000</nvs:FinancialInstrumentsValueAtRiskComputation>
  <nvs:FinancialInstrumentsValueAtRiskComputation contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019BottomOfRangeMember" unitRef="USD" decimals="-6">303000000</nvs:FinancialInstrumentsValueAtRiskComputation>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019BottomOfRangeMember" unitRef="USD" decimals="-6">86000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019BottomOfRangeMember" unitRef="USD" decimals="-6">16000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019BottomOfRangeMember" unitRef="USD" decimals="-6">187000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019TopOfRangeMember" unitRef="USD" decimals="-6">195000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019TopOfRangeMember" unitRef="USD" decimals="-6">81000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements>
  <nvs:FinancialInstrumentsValueAtRiskComputation contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019TopOfRangeMember" unitRef="USD" decimals="-6">385000000</nvs:FinancialInstrumentsValueAtRiskComputation>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019TopOfRangeMember" unitRef="USD" decimals="-6">303000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates>
  <nvs:FinancialInstrumentsValueAtRiskComputation contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019TopOfRangeMember" unitRef="USD" decimals="-6">659000000</nvs:FinancialInstrumentsValueAtRiskComputation>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019TopOfRangeMember" unitRef="USD" decimals="-6">515000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019TopOfRangeMember" unitRef="USD" decimals="-6">261000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019TopOfRangeMember" unitRef="USD" decimals="-6">912000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates>
  <nvs:DepreciationChargePriorToClassificationToAssetsHeldForSale contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">20000000</nvs:DepreciationChargePriorToClassificationToAssetsHeldForSale>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">-117000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">-58000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">3000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">2000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">19000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">433000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">115000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">11463000000</ifrs-full:PropertyPlantAndEquipment>
  <nvs:DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">3000000</nvs:DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">-6328000000</ifrs-full:PropertyPlantAndEquipment>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">-562000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment>
  <nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">1170000000</nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">447000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">51000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">1000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">-33000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">-5124000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">6339000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">14135000000</ifrs-full:PropertyPlantAndEquipment>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">1615000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">24000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">332000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">112000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">1551000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">32000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">465000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">695000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">12377000000</ifrs-full:PropertyPlantAndEquipment>
  <nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">433000000</nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">491000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">194000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">-373000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">-5807000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">6570000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">3975000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">-10063000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">-731000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">228000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">827000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">1543000000</nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">14038000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">956000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">1656000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">-13000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">1774000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">355000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">630000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">9000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">2678000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment>
  <nvs:DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">2000000</nvs:DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">17155000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">-9726000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">-9000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">110000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">898000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">1674000000</nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">-1541000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">-11924000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">13674000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">3948000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">296000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">595000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">5000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">-101000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">-168000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
  <nvs:DepreciationChargePriorToClassificationToAssetsHeldForSale contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">18000000</nvs:DepreciationChargePriorToClassificationToAssetsHeldForSale>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">8000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
  <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019MachineryMember" unitRef="USD" decimals="-6">7000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">16807000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">6837000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">9970000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">16396000000</ifrs-full:PlanAssetsAtFairValue>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">800000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="Pure" decimals="2">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">34904000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="Pure" decimals="2">0.39</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">15106000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">6167000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">8939000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">14457000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-411000000</ifrs-full:SurplusDeficitInPlan>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-649000000</ifrs-full:SurplusDeficitInPlan>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">848000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="Pure" decimals="2">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">795000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="Pure" decimals="2">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="USD" decimals="-6">33032000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019CountryOfDomicileMember" unitRef="Pure" decimals="2">0.43</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-1573000000</ifrs-full:SurplusDeficitInPlan>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">3042000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-1366000000</ifrs-full:SurplusDeficitInPlan>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">89000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">88000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">89000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">88000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">25000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">36000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">0</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">0</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">64000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1615000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1517000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1491000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">3434000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1573000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1400000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1819000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">5007000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">4408000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">516000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">466000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">52000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">0</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">0</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-89000000</ifrs-full:SurplusDeficitInPlan>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_ifrsfull-2019ForeignCountriesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-88000000</ifrs-full:SurplusDeficitInPlan>
  <nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember" unitRef="USD" decimals="-6">549000000</nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember" unitRef="USD" decimals="-6">338000000</nvs:LeaseLiabilitiesUndiscounted>
  <nvs:CommitmentsUnderLongtermResearchAgreements contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember" unitRef="USD" decimals="-6">449000000</nvs:CommitmentsUnderLongtermResearchAgreements>
  <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1245000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
  <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">40000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember" unitRef="USD" decimals="-6">286000000</ifrs-full:LeaseLiabilities>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember" unitRef="USD" decimals="-6">246000000</ifrs-full:LeaseLiabilities>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember" unitRef="USD" decimals="-6">295000000</nvs:LeaseLiabilitiesUndiscounted>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember" unitRef="USD" decimals="-6">2002000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneYearMember" unitRef="USD" decimals="-6">2272000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember" unitRef="USD" decimals="-6">2067000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember" unitRef="USD" decimals="-6">2631000000</ifrs-full:Borrowings>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember" unitRef="USD" decimals="-6">202000000</ifrs-full:LeaseLiabilities>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember" unitRef="USD" decimals="-6">246000000</nvs:LeaseLiabilitiesUndiscounted>
  <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1198000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
  <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">41000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
  <nvs:CommitmentsUnderLongtermResearchAgreements contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember" unitRef="USD" decimals="-6">691000000</nvs:CommitmentsUnderLongtermResearchAgreements>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember" unitRef="USD" decimals="-6">229000000</ifrs-full:LeaseLiabilities>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember" unitRef="USD" decimals="-6">274000000</nvs:LeaseLiabilitiesUndiscounted>
  <nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanTwoYearsMember" unitRef="USD" decimals="-6">248000000</nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd>
  <nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember" unitRef="USD" decimals="-6">160000000</nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember" unitRef="USD" decimals="-6">186000000</ifrs-full:LeaseLiabilities>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember" unitRef="USD" decimals="-6">226000000</nvs:LeaseLiabilitiesUndiscounted>
  <nvs:CommitmentsUnderLongtermResearchAgreements contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember" unitRef="USD" decimals="-6">325000000</nvs:CommitmentsUnderLongtermResearchAgreements>
  <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1191000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
  <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">41000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember" unitRef="USD" decimals="-6">163000000</ifrs-full:LeaseLiabilities>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember" unitRef="USD" decimals="-6">202000000</nvs:LeaseLiabilitiesUndiscounted>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember" unitRef="USD" decimals="-6">2583000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanTwoYearsAndNotLaterThanThreeYearsMember" unitRef="USD" decimals="-6">2546000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember" unitRef="USD" decimals="-6">2321000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember" unitRef="USD" decimals="-6">2142000000</ifrs-full:Borrowings>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember" unitRef="USD" decimals="-6">138000000</ifrs-full:LeaseLiabilities>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember" unitRef="USD" decimals="-6">173000000</nvs:LeaseLiabilitiesUndiscounted>
  <nvs:CommitmentsUnderLongtermResearchAgreements contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember" unitRef="USD" decimals="-6">483000000</nvs:CommitmentsUnderLongtermResearchAgreements>
  <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1182000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
  <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">40000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember" unitRef="USD" decimals="-6">148000000</ifrs-full:LeaseLiabilities>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember" unitRef="USD" decimals="-6">183000000</nvs:LeaseLiabilitiesUndiscounted>
  <nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanThreeYearsAndNotLaterThanFourYearsMember" unitRef="USD" decimals="-6">415000000</nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd>
  <nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">515000000</nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">129000000</ifrs-full:LeaseLiabilities>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">160000000</nvs:LeaseLiabilitiesUndiscounted>
  <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1165000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
  <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">40000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
  <nvs:CommitmentsUnderLongtermResearchAgreements contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">281000000</nvs:CommitmentsUnderLongtermResearchAgreements>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">119000000</ifrs-full:LeaseLiabilities>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">150000000</nvs:LeaseLiabilitiesUndiscounted>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">2139000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFourYearsAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">3302000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">15638000000</ifrs-full:Borrowings>
  <nvs:ContingentConsiderationLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">383000000</nvs:ContingentConsiderationLiabilities>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">11073000000</ifrs-full:NetDebt>
  <nvs:ContractualInterestOnNoncurrentLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">-3439000000</nvs:ContractualInterestOnNoncurrentLiabilities>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">11243000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember" unitRef="USD" decimals="-6">57000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CommoditiesMember" unitRef="USD" decimals="-6">110000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" unitRef="USD" decimals="-6">3000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">170000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">11243000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">11355000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">15638000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">135000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">15503000000</ifrs-full:NetDebt>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">2419000000</nvs:LeaseLiabilitiesUndiscounted>
  <nvs:CommitmentsUnderLongtermResearchAgreements contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">3003000000</nvs:CommitmentsUnderLongtermResearchAgreements>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">1027000000</ifrs-full:LeaseLiabilities>
  <nvs:LeaseLiabilitiesUndiscounted contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">2326000000</nvs:LeaseLiabilitiesUndiscounted>
  <nvs:ContractualInterestOnNoncurrentLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">-4251000000</nvs:ContractualInterestOnNoncurrentLiabilities>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember" unitRef="USD" decimals="-6">21000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CommoditiesMember" unitRef="USD" decimals="-6">111000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" unitRef="USD" decimals="-6">3000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">15638000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">15802000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">1409000000</nvs:ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">1081000000</ifrs-full:LeaseLiabilities>
  <nvs:ContingentConsiderationLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsMember" unitRef="USD" decimals="-6">345000000</nvs:ContingentConsiderationLiabilities>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019USD" unitRef="USD" decimals="-6">3311000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019USD" unitRef="USD" decimals="-6">3466000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019EUR" unitRef="USD" decimals="-6">1668000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019EUR" unitRef="USD" decimals="-6">1384000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019JPY" unitRef="USD" decimals="-6">437000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019JPY" unitRef="USD" decimals="-6">466000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019RUB" unitRef="USD" decimals="-6">288000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019RUB" unitRef="USD" decimals="-6">341000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019CNY" unitRef="USD" decimals="-6">208000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019CNY" unitRef="USD" decimals="-6">279000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019GBP" unitRef="USD" decimals="-6">191000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019GBP" unitRef="USD" decimals="-6">202000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019AUD" unitRef="USD" decimals="-6">153000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019AUD" unitRef="USD" decimals="-6">125000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019BRL" unitRef="USD" decimals="-6">148000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019BRL" unitRef="USD" decimals="-6">165000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019CAD" unitRef="USD" decimals="-6">125000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019CAD" unitRef="USD" decimals="-6">129000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019CHF" unitRef="USD" decimals="-6">124000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_currency-2019CHF" unitRef="USD" decimals="-6">89000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember" unitRef="USD" decimals="-6">1564000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember" unitRef="USD" decimals="-6">1655000000</ifrs-full:CurrentTradeReceivables>
  <nvs:ProvisionForDoubtfulReceivable contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">-93000000</nvs:ProvisionForDoubtfulReceivable>
  <nvs:ProvisionForDoubtfulReceivable contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">-95000000</nvs:ProvisionForDoubtfulReceivable>
  <nvs:ProvisionForDoubtfulReceivable contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">-190000000</nvs:ProvisionForDoubtfulReceivable>
  <nvs:ProvisionForDoubtfulReceivable contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">-126000000</nvs:ProvisionForDoubtfulReceivable>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">8310000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019CurrentMember" unitRef="USD" decimals="-6">7714000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019CurrentMember" unitRef="USD" decimals="-6">7763000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019NotLaterThanOneMonthMember" unitRef="USD" decimals="-6">150000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019NotLaterThanOneMonthMember" unitRef="USD" decimals="-6">161000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">118000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">123000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">8396000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">8217000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">8301000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">1000000</ifrs-full:AcquisitionsThroughBusinessCombinationsOtherProvisions>
  <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">59000000</ifrs-full:AdditionalProvisionsOtherProvisions>
  <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">89000000</ifrs-full:AdditionalProvisionsOtherProvisions>
  <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">47000000</ifrs-full:AdditionalProvisionsOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">13000000</ifrs-full:ProvisionUsedOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">12000000</ifrs-full:ProvisionUsedOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">39000000</ifrs-full:ProvisionUsedOtherProvisions>
  <ifrs-full:UnusedProvisionReversedOtherProvisions contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">53000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
  <ifrs-full:UnusedProvisionReversedOtherProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">53000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
  <ifrs-full:UnusedProvisionReversedOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">61000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">5000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">-1000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2020Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">-12000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" unitRef="USD" decimals="-6">102000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" unitRef="USD" decimals="-6">103000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanSixMonthsAndNotLaterThanOneYearMember" unitRef="USD" decimals="-6">77000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanSixMonthsAndNotLaterThanOneYearMember" unitRef="USD" decimals="-6">96000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanOneYearMember" unitRef="USD" decimals="-6">149000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:CurrentTradeReceivables contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfFinancialInstrumentsAxis_ifrsfull-2019TradeReceivablesMember_ifrsfull-2019PastDueStatusAxis_ifrsfull-2019LaterThanOneYearMember" unitRef="USD" decimals="-6">150000000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">53419000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">57333000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">2384000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">67725000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">35700000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">16167000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AlconBrandNameMember" unitRef="USD" decimals="-6">2980000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">6253000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">35412000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4MarketingRelatedIntangibleAssetsMember" unitRef="USD" decimals="-6">5960000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">2253000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">69025000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">186000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">342000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">3550000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">22000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">3914000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">-9069000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">9069000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">265000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">243000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">259000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">767000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">75000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
  <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">544000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
  <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">436000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
  <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">1055000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">-61000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">49000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">254000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">32000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">335000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">26825000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">7429000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">884000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">43548000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">1558000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">2580000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">8600000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">196000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">218000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">9014000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">-9272000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">-2000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">9274000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">339000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">674000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">412000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">1425000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">421000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
  <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">101000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
  <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">39000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
  <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">11000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
  <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">572000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">916000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">208000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">58000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">2568000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">205000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">3039000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">30321000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">6893000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">1115000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">26999000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">1350000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">34028000000</ifrs-full:PropertyPlantAndEquipment>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">61000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">655000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">2042000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">696000000</ifrs-full:PropertyPlantAndEquipment>
  <nvs:DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">127000000</nvs:DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">10000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">5009000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment>
  <nvs:DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">122000000</nvs:DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">44000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">57000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">1000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">6000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">-1019000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">1474000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">75000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">1001000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">3409000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">1000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">9000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">21000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">512000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">1000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">2201000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">36000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">57000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">1797000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">555000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">110000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">28218000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">1248000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">26000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">10000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">7000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">-1038000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">1265000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">23000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">847000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">2000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">23000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
  <nvs:AdditionsIncludedInDisposalGroupToTheDateOfReclassification contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">0</nvs:AdditionsIncludedInDisposalGroupToTheDateOfReclassification>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember" unitRef="USD" decimals="-6">-332000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">-11000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">-36000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">12000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">-10000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">-276000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">-1112000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">-2000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">-1400000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">9000000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">249000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AlconBrandNameMember" unitRef="USD" decimals="-6">2980000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">5369000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">4440000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4MarketingRelatedIntangibleAssetsMember" unitRef="USD" decimals="-6">5960000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">572000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">19570000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">1000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">-4000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill>
  <nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019GrossCarryingAmountMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">-3000000</nvs:IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill>
  <nvs:AmountOfSettlementInPrinciple contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EnoxaparinMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember_srt-2020LitigationCaseAxis_nvs-2020Q4TennesseeClassActionMember" unitRef="USD" decimals="-6">85000000</nvs:AmountOfSettlementInPrinciple>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">11126000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">2220000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="USD" decimals="-6">16484000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">14342000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">13789000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">11864000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">2142000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">2491000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">2754000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">-0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="USD" decimals="-6">16280000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="Pure" decimals="2">0.34</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="USD" decimals="-6">14618000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="Pure" decimals="2">0.33</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="USD" decimals="-6">28893000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="Pure" decimals="2">0.37</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">670000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">3552000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1205000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">630000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1717000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">15000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">121000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">524000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">658000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">2311000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-1301000000</ifrs-full:SurplusDeficitInPlan>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-1241000000</ifrs-full:SurplusDeficitInPlan>
  <nvs:DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember" unitRef="Pure" decimals="0">54</nvs:DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations>
  <nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AmiodaroneMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember" unitRef="Pure" decimals="0">5</nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases>
  <nvs:AmountOfSettlementInPrinciple contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4NPCAndOthersMember" unitRef="USD" decimals="-8">700000000</nvs:AmountOfSettlementInPrinciple>
  <nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ReclastAclastaMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4NPCAndOthersMember" unitRef="Pure" decimals="0">20</nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases>
  <nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TaxotereMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember" unitRef="Pure" decimals="0">3000</nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-524000000</ifrs-full:SurplusDeficitInPlan>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-454000000</ifrs-full:SurplusDeficitInPlan>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">134000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">522000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">9654000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember" unitRef="USD" decimals="-6">2210000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TravoprostGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">404000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">262000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">194000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">145000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">806000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">817000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">440000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">929000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">581000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">457000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">521000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">556000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">84000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">19000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1736000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">804000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">925000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">881000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1003000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">691000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">481000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">334000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">86000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">13000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">450000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">332000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">304000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TravoprostGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">169000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">250000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">10679000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember" unitRef="USD" decimals="-6">3110000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1765000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1674000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EnoxaparinMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember" unitRef="Pure" decimals="0">1</nvs:DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt>
  <nvs:AmountOfSettlementInPrinciple contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="USD" decimals="-8">300000000</nvs:AmountOfSettlementInPrinciple>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="Pure" decimals="2">0.34</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="USD" decimals="-6">39889000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US" unitRef="Pure" decimals="2">0.44</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">2516000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1562000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1277000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">859000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">833000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">17000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">446000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">89000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">543000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">454000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">80000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1833000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1290000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">2487000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">665000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">3788000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">701000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember" unitRef="USD" decimals="-6">3216000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">400000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">318000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">138000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">259000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">569000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">837000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">315000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">644000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">124000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">16000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">459000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">-0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">187000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent>
  <nvs:AmountOfSettlementInPrinciple contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">195000000</nvs:AmountOfSettlementInPrinciple>
  <nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17US_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4NPCAndOthersMember" unitRef="Pure" decimals="0">80</nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases>
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_ifrsfull-2019ActuarialAssumptionOfDiscountRatesMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Change25BasisPointMember" unitRef="USD" decimals="-6">-885000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_ifrsfull-2019ActuarialAssumptionOfDiscountRatesMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Change25BasisPointMember" unitRef="USD" decimals="-6">942000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_ifrsfull-2019ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Change25BasisPointMember" unitRef="USD" decimals="-6">589000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_ifrsfull-2019ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Change25BasisPointMember" unitRef="USD" decimals="-6">-143000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_ifrsfull-2019ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Change25BasisPointMember" unitRef="USD" decimals="-6">61000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_ifrsfull-2019ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Change25BasisPointMember" unitRef="USD" decimals="-6">-61000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
  <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019EquityInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.15</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum>
  <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019EquityInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.40</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum>
  <nvs:DefinedBenefitPlanPlanAssetAllocations contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019EquityInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.28</nvs:DefinedBenefitPlanPlanAssetAllocations>
  <nvs:DefinedBenefitPlanPlanAssetAllocations contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019EquityInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.27</nvs:DefinedBenefitPlanPlanAssetAllocations>
  <nvs:DefinedBenefitPlanPlanAssetAllocations contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.36</nvs:DefinedBenefitPlanPlanAssetAllocations>
  <nvs:DefinedBenefitPlanPlanAssetAllocations contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.34</nvs:DefinedBenefitPlanPlanAssetAllocations>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">26000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">24000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">24000000</ifrs-full:FinancialAssetsAtFairValue>
  <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.60</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum>
  <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.20</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019DebtSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">26000000</ifrs-full:FinancialAssetsAtFairValue>
  <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-1769000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
  <nvs:RepurchaseOfOptions contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">89000000</nvs:RepurchaseOfOptions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">730000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">3331000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">3056000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">806000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">30000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">8072000000</ifrs-full:ProfitLoss>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">6000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">74168000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" unitRef="USD" decimals="-6">60000000</ifrs-full:Equity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-10279000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">56598000000</ifrs-full:Equity>
  <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">6987000000</ifrs-full:DividendsPaid>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">18000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <nvs:TaxesOnTreasuryShares contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-32000000</nvs:TaxesOnTreasuryShares>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">11403000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-34668000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">55474000000</ifrs-full:Equity>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">22000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <nvs:TransactionCostsRecordedInEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">253000000</nvs:TransactionCostsRecordedInEquity>
  <nvs:TaxesOnTreasuryShares contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">189000000</nvs:TaxesOnTreasuryShares>
  <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">284000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">833000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">18000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">210000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <nvs:DividendPaidNoncashAssetsDistribution contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">23434000000</nvs:DividendPaidNoncashAssetsDistribution>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">5511000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">11525000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">6645000000</ifrs-full:DividendsPaid>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-207000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">11732000000</ifrs-full:ProfitLoss>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" unitRef="USD" decimals="-6">3000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">78617000000</ifrs-full:Equity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-7824000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">78614000000</ifrs-full:Equity>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">38000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-13000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-284000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
  <nvs:TransactionCostsRecordedInEquity contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">79000000</nvs:TransactionCostsRecordedInEquity>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">756000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <nvs:OtherShareSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">263000000</nvs:OtherShareSales>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">434000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">1973000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">6966000000</ifrs-full:DividendsPaid>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">12210000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">-401000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">74228000000</ifrs-full:Equity>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019EquityAttributableToOwnersOfParentMember" unitRef="USD" decimals="-6">12611000000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">3000000</ifrs-full:ProfitLoss>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-5000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">59000000</ifrs-full:Equity>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-2000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">22000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <nvs:IncreaseDecreaseInNoncontrolingInterests contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-1000000</nvs:IncreaseDecreaseInNoncontrolingInterests>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">78000000</ifrs-full:Equity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">21000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">78000000</ifrs-full:Equity>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">5000000</ifrs-full:ProfitLoss>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">2000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-2000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <nvs:IncreaseDecreaseInNoncontrolingInterests contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-1000000</nvs:IncreaseDecreaseInNoncontrolingInterests>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">77000000</ifrs-full:Equity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-2000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">68000000</ifrs-full:Equity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-7000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">59000000</ifrs-full:Equity>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-1000000</ifrs-full:ProfitLoss>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-1000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-7000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">1000000</nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-1000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-2000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-29000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-3000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">1000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-1000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-29000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">-21000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-21000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-5000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-5000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-26000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019NoncontrollingInterestsMember" unitRef="USD" decimals="-6">-2000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <nvs:EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17IT_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember" unitRef="USD" decimals="-6">330000000</nvs:EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed>
  <ifrs-full:EstimatedFinancialEffectOfContingentLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17IT_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4NAGAndNovartisPharmaSpAMember" unitRef="USD" decimals="-6">125000000</ifrs-full:EstimatedFinancialEffectOfContingentLiabilities>
  <nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17IT_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember" unitRef="USD" decimals="-8">1300000000</nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine>
  <nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4NovartisPharmaKKMember" unitRef="JPY" decimals="-6">4000000</nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP" unitRef="USD" decimals="-6">2656000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP" unitRef="Pure" decimals="2">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP" unitRef="USD" decimals="-6">2575000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP" unitRef="Pure" decimals="2">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP" unitRef="USD" decimals="-6">309000000</nvs:SelectedNoncurrentAssets>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP" unitRef="USD" decimals="-6">2804000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP" unitRef="Pure" decimals="2">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17JP" unitRef="USD" decimals="-6">313000000</nvs:SelectedNoncurrentAssets>
  <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsAndNotLaterThanTenYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">5651000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
  <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanFiveYearsAndNotLaterThanTenYearsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">181000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableForSaleMarketableSecuritiesMember" unitRef="USD" decimals="-6">26000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember" unitRef="USD" decimals="-6">36000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4FundInvestmentsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember" unitRef="USD" decimals="-6">366000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">159000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">625000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember" unitRef="USD" decimals="-6">1173000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember" unitRef="USD" decimals="-6">1827000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4EquitySecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember" unitRef="USD" decimals="-6">1111000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4EquitySecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember" unitRef="USD" decimals="-6">466000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">211000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4EquitySecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember" unitRef="USD" decimals="-6">366000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4FundInvestmentsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember" unitRef="USD" decimals="-6">233000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4FundInvestmentsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableForSaleMarketableSecuritiesMember" unitRef="USD" decimals="-6">37000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">399000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableForSaleMarketableSecuritiesMember" unitRef="USD" decimals="-6">24000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4EquitySecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember" unitRef="USD" decimals="-6">1158000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_ifrsfull-2019DebtSecuritiesMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AvailableforsaleLongtermFinancialInvestmentsMember" unitRef="USD" decimals="-6">33000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember" unitRef="USD" decimals="-6">1215000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">186000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">102000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtFairValueMember" unitRef="USD" decimals="-6">1323000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4TimeDepositsWithOriginalMaturityMoreThan90DaysMember" unitRef="USD" decimals="-6">61000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" unitRef="USD" decimals="-6">329000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember" unitRef="USD" decimals="-6">21839000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">8301000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4OtherCurrentAssetsMember" unitRef="USD" decimals="-6">2036000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember" unitRef="USD" decimals="-6">20744000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4OtherCurrentAssetsMember" unitRef="USD" decimals="-6">963000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" unitRef="USD" decimals="-6">297000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4TimeDepositsWithOriginalMaturityMoreThan90DaysMember" unitRef="USD" decimals="-6">1609000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_ifrsfull-2019TradeReceivablesMember" unitRef="USD" decimals="-6">8217000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_nvs-2020Q4CashAndCashEquivalentsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember" unitRef="USD" decimals="-6">9658000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialAssetsAxis_ifrsfull-2019FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialAssetsAxis_nvs-2020Q4CashAndCashEquivalentsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember" unitRef="USD" decimals="-6">11112000000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TradePayablesMember" unitRef="USD" decimals="-6">5424000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember" unitRef="USD" decimals="-6">32623000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4BankAndOtherFinancialDebtMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtMember" unitRef="USD" decimals="-6">719000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4CommercialPaperMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtMember" unitRef="USD" decimals="-6">2289000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4StraightBondsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4NoncurrentFinancialDebtMember" unitRef="USD" decimals="-6">22167000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4LiabilitiesToBanksAndOtherFinancialInstitutionsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4NoncurrentFinancialDebtMember" unitRef="USD" decimals="-6">188000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4InterestBearningAccountsOfAssociatesPayableOnDemandMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtMember" unitRef="USD" decimals="-6">1836000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CommitmentForRepurchaseOfOwnSharesMember" unitRef="USD" decimals="-6">1769000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4InterestBearningAccountsOfAssociatesPayableOnDemandMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtMember" unitRef="USD" decimals="-6">2085000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4BankAndOtherFinancialDebtMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtMember" unitRef="USD" decimals="-6">976000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4CommercialPaperMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtMember" unitRef="USD" decimals="-6">4258000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4StraightBondsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4NoncurrentFinancialDebtMember" unitRef="USD" decimals="-6">28298000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4LiabilitiesToBanksAndOtherFinancialInstitutionsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4NoncurrentFinancialDebtMember" unitRef="USD" decimals="-6">233000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TradePayablesMember" unitRef="USD" decimals="-6">5403000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_ifrsfull-2019LeaseLiabilitiesMember" unitRef="USD" decimals="-6">2005000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember" unitRef="USD" decimals="-6">43022000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">2005000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_ifrsfull-2019LeaseLiabilitiesMember" unitRef="USD" decimals="-6">1949000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtAmortisedCostMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">1949000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueMember" unitRef="USD" decimals="-6">1263000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">194000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4ContingentConsiderationAndOtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">1069000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4ContingentConsiderationAndOtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">1065000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueMember" unitRef="USD" decimals="-6">1250000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2019ClassesOfFinancialLiabilitiesAxis_ifrsfull-2019FinancialLiabilitiesAtFairValueMember_nvs-2020Q4BalanceSheetItemAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">185000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">26000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">26000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">159000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">185000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">185000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">1613000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4FundInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">366000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">1263000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4FundInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">37000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">194000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">1069000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4ContingentConsiderationReceivablesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">625000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">1153000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">1451000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">2604000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">211000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">1046000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">23000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">194000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">37000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">24000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4FundInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">37000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">61000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">102000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">102000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">37000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">126000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">163000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">976000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">581000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4FundInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">233000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">1557000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4FundInvestmentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">233000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4ContingentConsiderationReceivablesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">399000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4ContingentConsiderationReceivablesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">399000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">976000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">1213000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">2189000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">186000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">186000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">1036000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">1036000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">29000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">29000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">185000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">185000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">185000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">1065000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">1250000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" unitRef="USD" decimals="-6">159000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level1OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">1153000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">460000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4FundInvestmentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">366000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4ContingentConsiderationReceivablesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialInvestmentsAndLongtermLoansGroupMember" unitRef="USD" decimals="-6">625000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">211000000</ifrs-full:FinancialAssetsAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">1046000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level3OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">23000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember_ifrsfull-2019LevelsOfFairValueHierarchyAxis_ifrsfull-2019Level2OfFairValueHierarchyMember_ifrsfull-2019MeasurementAxis_ifrsfull-2019RecurringFairValueMeasurementMember" unitRef="USD" decimals="-6">194000000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">622000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">191000000</nvs:GrossDeferredTaxAssets>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">431000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">74000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">10000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">282000000</ifrs-full:DeferredTaxLiabilityAsset>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">390000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">108000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">430000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">189000000</nvs:GrossDeferredTaxAssets>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">53000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">-5000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">89000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">241000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">3918000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">110000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">1945000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">-58000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">1351000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">5269000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">1469000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">3610000000</nvs:GrossDeferredTaxLiabilities>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">2141000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">45000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">-39000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">605000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">8000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">4151000000</ifrs-full:DeferredTaxLiabilityAsset>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">1233000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">5384000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:AmortizationPriorToClassificationToAssetsHeldForSale contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">102000000</nvs:AmortizationPriorToClassificationToAssetsHeldForSale>
  <nvs:AmortizationPriorToClassificationToAssetsHeldForSale contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">73000000</nvs:AmortizationPriorToClassificationToAssetsHeldForSale>
  <nvs:AmortizationPriorToClassificationToAssetsHeldForSale contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">29000000</nvs:AmortizationPriorToClassificationToAssetsHeldForSale>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">169000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">475000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DeferredTaxAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">11000000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:OtherNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">2000000</ifrs-full:OtherNoncurrentAssets>
  <ifrs-full:Inventories contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">181000000</ifrs-full:Inventories>
  <ifrs-full:OtherCurrentNonfinancialAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">3000000</ifrs-full:OtherCurrentNonfinancialAssets>
  <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">841000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale>
  <ifrs-full:DeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">2000000</ifrs-full:DeferredTaxLiabilities>
  <ifrs-full:OtherNoncurrentNonfinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">4000000</ifrs-full:OtherNoncurrentNonfinancialLiabilities>
  <ifrs-full:OtherCurrentNonfinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">25000000</ifrs-full:OtherCurrentNonfinancialLiabilities>
  <ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" unitRef="USD" decimals="-6">31000000</ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019DisposalGroupsClassifiedAsHeldForSaleMember_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">37000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfull-2019DisposalGroupsClassifiedAsHeldForSaleMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">220000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember" unitRef="USD" decimals="-6">13000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">4195000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember" unitRef="USD" decimals="-6">8558000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" unitRef="USD" decimals="-6">38000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">4195000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">93000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities contextRef="AR_D-CurrentYear_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember" unitRef="USD" decimals="-6">930000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
  <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets contextRef="AR_D-CurrentYear_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember" unitRef="USD" decimals="-6">904000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember" unitRef="USD" decimals="-6">20000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember" unitRef="USD" decimals="-6">-4321000000</ifrs-full:NetDebt>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember" unitRef="USD" decimals="-6">4288000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember" unitRef="USD" decimals="-6">8609000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember" unitRef="USD" decimals="-6">9712000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember" unitRef="USD" decimals="-6">9746000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" unitRef="USD" decimals="-6">14000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">4243000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">4243000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">130000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember" unitRef="USD" decimals="-6">807000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
  <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities contextRef="AR_D-CurrentYear-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember" unitRef="USD" decimals="-6">814000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember" unitRef="USD" decimals="-6">4373000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019NotLaterThanOneMonthMember" unitRef="USD" decimals="-6">-5373000000</ifrs-full:NetDebt>
  <nvs:CommitmentForRepurchaseOwnShares contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">1769000000</nvs:CommitmentForRepurchaseOwnShares>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">-103000000</ifrs-full:NetDebt>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">1402000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">29000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities contextRef="AR_D-CurrentYear-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">4624000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
  <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">4656000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">1373000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">1373000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" unitRef="USD" decimals="-6">79000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">1505000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember" unitRef="USD" decimals="-6">1400000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">2781000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">2302000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">-479000000</ifrs-full:NetDebt>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember" unitRef="USD" decimals="-6">26000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:ContractualInterestOnNoncurrentLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">-36000000</nvs:ContractualInterestOnNoncurrentLiabilities>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">65000000</ifrs-full:LeaseLiabilities>
  <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">5222000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
  <nvs:ContingentConsiderationLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">62000000</nvs:ContingentConsiderationLiabilities>
  <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets contextRef="AR_D-CurrentYear_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">4114000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
  <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities contextRef="AR_D-CurrentYear_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">4096000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">84000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">2219000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">77000000</ifrs-full:LeaseLiabilities>
  <nvs:ContractualInterestOnNoncurrentLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">-82000000</nvs:ContractualInterestOnNoncurrentLiabilities>
  <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">5239000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" unitRef="USD" decimals="-6">110000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">2218000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember" unitRef="USD" decimals="-6">1100000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember" unitRef="USD" decimals="-6">1571000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:ContingentConsiderationLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneMonthAndNotLaterThanThreeMonthsMember" unitRef="USD" decimals="-6">24000000</nvs:ContingentConsiderationLiabilities>
  <nvs:ContingentConsiderationLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">639000000</nvs:ContingentConsiderationLiabilities>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">10621000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">10661000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" unitRef="USD" decimals="-6">4000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:ContractualInterestOnNoncurrentLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">-1846000000</nvs:ContractualInterestOnNoncurrentLiabilities>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">692000000</ifrs-full:LeaseLiabilities>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember" unitRef="USD" decimals="-6">5000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">622000000</ifrs-full:LeaseLiabilities>
  <nvs:ContingentConsiderationLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">582000000</nvs:ContingentConsiderationLiabilities>
  <nvs:ContractualInterestOnNoncurrentLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">-1531000000</nvs:ContractualInterestOnNoncurrentLiabilities>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">9104000000</ifrs-full:NetDebt>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">10621000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">10612000000</ifrs-full:NetDebt>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">9000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">9150000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">9110000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" unitRef="USD" decimals="-6">3000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember" unitRef="USD" decimals="-6">3000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">6000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_ifrsfull-2019LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="USD" decimals="-6">9110000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019WeightedAverageMember" unitRef="USD" decimals="-6">143000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates>
  <nvs:FinancialInstrumentsValueAtRiskComputation contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019WeightedAverageMember" unitRef="USD" decimals="-6">348000000</nvs:FinancialInstrumentsValueAtRiskComputation>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019WeightedAverageMember" unitRef="USD" decimals="-6">36000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019RangeAxis_ifrsfull-2019WeightedAverageMember" unitRef="USD" decimals="-6">233000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019WeightedAverageMember" unitRef="USD" decimals="-6">329000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019WeightedAverageMember" unitRef="USD" decimals="-6">78000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements>
  <nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019WeightedAverageMember" unitRef="USD" decimals="-6">225000000</nvs:FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates>
  <nvs:FinancialInstrumentsValueAtRiskComputation contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangeAxis_ifrsfull-2019WeightedAverageMember" unitRef="USD" decimals="-6">568000000</nvs:FinancialInstrumentsValueAtRiskComputation>
  <ifrs-full:NumberOfSharesIssued contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember" unitRef="Shares" decimals="-5">2616800000</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:NumberOfSharesIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember" unitRef="Shares" decimals="-5">2467000000</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:NumberOfSharesIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember" unitRef="Shares" decimals="-5">2527300000</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:NumberOfSharesIssued contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember" unitRef="Shares" decimals="-5">2550600000</ifrs-full:NumberOfSharesIssued>
  <nvs:SharesCancelledForCapitalReduction contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember" unitRef="Shares" decimals="-5">-23300000</nvs:SharesCancelledForCapitalReduction>
  <nvs:SharesCancelledForCapitalReduction contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember" unitRef="Shares" decimals="-5">-66200000</nvs:SharesCancelledForCapitalReduction>
  <nvs:SharesCancelledForCapitalReduction contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember" unitRef="Shares" decimals="-5">-60300000</nvs:SharesCancelledForCapitalReduction>
  <nvs:ShareMovements contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember" unitRef="Shares" decimals="-5">-66200000</nvs:ShareMovements>
  <nvs:ShareMovements contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember" unitRef="Shares" decimals="-5">-23300000</nvs:ShareMovements>
  <nvs:ShareMovements contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019OrdinarySharesMember" unitRef="Shares" decimals="-5">-60300000</nvs:ShareMovements>
  <nvs:TreasurySharesWithRestrictedUse contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">103000000</nvs:TreasurySharesWithRestrictedUse>
  <nvs:TreasurySharesWithRestrictedUse contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">117600000</nvs:TreasurySharesWithRestrictedUse>
  <nvs:TreasurySharesWithRestrictedUse contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">121600000</nvs:TreasurySharesWithRestrictedUse>
  <nvs:ShareMovements contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">52100000</nvs:ShareMovements>
  <nvs:EquityBasedCompensationShares contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">7400000</nvs:EquityBasedCompensationShares>
  <nvs:EquityBasedCompensationShares contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">9400000</nvs:EquityBasedCompensationShares>
  <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">7800000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
  <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">5500000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
  <nvs:OtherSharePurchases contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">-1200000</nvs:OtherSharePurchases>
  <nvs:OtherSharePurchases contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">-1700000</nvs:OtherSharePurchases>
  <nvs:ShareMovements contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">-22900000</nvs:ShareMovements>
  <nvs:ShareMovements contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">59900000</nvs:ShareMovements>
  <nvs:SharesCancelledForCapitalReduction contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">60300000</nvs:SharesCancelledForCapitalReduction>
  <nvs:SharesCancelledForCapitalReduction contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">66200000</nvs:SharesCancelledForCapitalReduction>
  <nvs:SharesCancelledForCapitalReduction contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">23300000</nvs:SharesCancelledForCapitalReduction>
  <nvs:TreasurySharesAcquiredToBeCancelled contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">-23300000</nvs:TreasurySharesAcquiredToBeCancelled>
  <nvs:TreasurySharesAcquiredToBeCancelled contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">-60300000</nvs:TreasurySharesAcquiredToBeCancelled>
  <nvs:NumberOfTreasuryShares contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">-239400000</nvs:NumberOfTreasuryShares>
  <nvs:NumberOfTreasuryShares contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">-262300000</nvs:NumberOfTreasuryShares>
  <nvs:NumberOfTreasuryShares contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">-210200000</nvs:NumberOfTreasuryShares>
  <nvs:NumberOfTreasuryShares contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">-299300000</nvs:NumberOfTreasuryShares>
  <nvs:SharesDeliveredToDivestedBusinessEmployees contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">900000</nvs:SharesDeliveredToDivestedBusinessEmployees>
  <nvs:NumberOfOtherShareSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">3000000</nvs:NumberOfOtherShareSales>
  <nvs:TreasurySharesAcquiredToBeCancelled contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">-32600000</nvs:TreasurySharesAcquiredToBeCancelled>
  <nvs:OtherSharePurchases contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">-1700000</nvs:OtherSharePurchases>
  <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">14700000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
  <nvs:EquityBasedCompensationShares contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">11000000</nvs:EquityBasedCompensationShares>
  <nvs:SharesDeliveredToDivestedBusinessEmployees contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfShareCapitalAxis_ifrsfull-2019TreasurySharesMember" unitRef="Shares" decimals="-5">400000</nvs:SharesDeliveredToDivestedBusinessEmployees>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="VEF" decimals="-5">1400000</nvs:SharePaidinCapital>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AmblyotechInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">50</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AmblyotechInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AmblyotechInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">450750</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CoalesceProductDevelopmentLimitedCambridgeCambsMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">0.40</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="VND" decimals="-9">70000000000</nvs:SharePaidinCapital>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="ILS" decimals="0">1000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AspenJapanK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="JPY" decimals="-5">2200000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AspenJapanK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AspenJapanK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="PHP" decimals="-5">298800000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="PHP" decimals="-5">30000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">22600000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4RocheHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.060</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="GBP" decimals="0">100</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NeutecPharmaLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="GBP" decimals="-5">7700000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NeutecPharmaLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NeutecPharmaLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4CoalesceProductDevelopmentLimitedCambridgeCambsMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="GBP" decimals="-5">6000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CoalesceProductDevelopmentLimitedCambridgeCambsMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">0.40</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOptogeneticsResearchInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOptogeneticsResearchInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOptogeneticsResearchInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozManufacturingInc.Member_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CAD" decimals="0">100</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozManufacturingInc.Member_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozManufacturingInc.Member_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AlconCusiS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">10100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AlconCusiS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AlconCusiS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="1">155.5</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">100</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">100</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AveXisInc.BannockburnILMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AveXisInc.BannockburnILMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AveXisInc.BannockburnILMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4CoStimPharmaceuticalsInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CoStimPharmaceuticalsInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CoStimPharmaceuticalsInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">25000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="-5">50000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4EonLabsInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EonLabsInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EonLabsInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">3</nvs:SharePaidinCapital>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="-5">9300000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="-5">5000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="0">100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4RocheHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="-5">160000000</nvs:SharePaidinCapital>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="TWD" decimals="-5">170000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisThailandLimitedBangkokMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="THB" decimals="-5">302000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisThailandLimitedBangkokMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisThailandLimitedBangkokMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="TRY" decimals="-5">98000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="TRY" decimals="-5">6700000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="TRY" decimals="-5">265000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="4">0.9999</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="4">0.9999</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="TRY" decimals="-5">50000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozUkraineLLCKievMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="UAH" decimals="-5">8000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozUkraineLLCKievMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozUkraineLLCKievMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="AED" decimals="-5">7000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="GBP" decimals="-5">25500000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="GBP" decimals="-5">5400000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="GBP" decimals="-5">250000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4ZiarcoGroupLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="GBP" decimals="0">3904</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ZiarcoGroupLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ZiarcoGroupLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="GBP" decimals="-5">2000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="-5">72200000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">1</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">650</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="PKR" decimals="-8">6700000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="4">0.9999</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="4">0.9999</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">10000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiosciencesPeruS.A.LimaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="PEN" decimals="-5">6100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiosciencesPeruS.A.LimaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiosciencesPeruS.A.LimaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="PLN" decimals="-5">44200000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="PLN" decimals="-5">25600000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4LekS.A.StrykowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="PLN" decimals="-5">11400000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4LekS.A.StrykowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4LekS.A.StrykowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">500000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">2400000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">499900</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="RON" decimals="-5">3000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.R.L.TarguMuresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="RON" decimals="-5">105200000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.R.L.TarguMuresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.R.L.TarguMuresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLLCMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="RUB" decimals="-5">20000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLLCMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLLCMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="RUB" decimals="-5">500000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4ZAOSandozMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="RUB" decimals="-5">57400000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ZAOSandozMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ZAOSandozMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="SAR" decimals="-5">30000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="SGD" decimals="0">100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="SGD" decimals="-5">45000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="SGD" decimals="-5">39000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">2000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">48400000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">1500000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="ZAR" decimals="-5">86300000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozSouthAfricaPtyLtdKemptonParkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="ZAR" decimals="-5">3000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozSouthAfricaPtyLtdKemptonParkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozSouthAfricaPtyLtdKemptonParkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="KRW" decimals="-8">24500000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="4">0.9855</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="4">0.9855</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">63000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">270450</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozIndustrialProductsS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">9300000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozIndustrialProductsS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozIndustrialProductsS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">6000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSverigeABStockholmMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="SEK" decimals="-5">5000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSverigeABStockholmMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSverigeABStockholmMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="-5">10000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="-5">100200000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="0">100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBioventuresAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="0">100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBioventuresAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBioventuresAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisForschungsstiftungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="-5">1000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4JapatAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="0">50000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4JapatAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4JapatAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="-5">350000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="-5">20000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="-5">18900000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="0">251000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="-5">5000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOphthalmicsAGFribourgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="0">100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOphthalmicsAGFribourgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOphthalmicsAGFribourgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="DZD" decimals="-5">650000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="ARS" decimals="-5">906100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="AUD" decimals="0">2</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="AUD" decimals="-5">3800000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="AUD" decimals="-5">11600000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustriaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">1000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustriaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustriaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">1100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">32700000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">1000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="BDT" decimals="-5">162500000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">0.60</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">0.60</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">7100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">19200000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AlconCouvreurNVPuursMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">110600000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AlconCouvreurNVPuursMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AlconCouvreurNVPuursMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">12000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="0">30000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="0">20000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CHF" decimals="-5">1000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">370000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="BRL" decimals="-5">265000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="BRL" decimals="-5">190000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CAD" decimals="-5">1200000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CAD" decimals="-5">80800000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CLP" decimals="-8">2000000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="-5">30000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="HKD" decimals="0">200</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="-5">320000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="-5">12000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="-5">3200000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="-5">57600000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="COP" decimals="-8">7900000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="HRK" decimals="-5">25600000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CZK" decimals="-5">51500000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="CZK" decimals="-5">44700000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="DKK" decimals="-5">14000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="DKK" decimals="-5">12000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="-5">4000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EGP" decimals="-5">193800000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="4">0.9977</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="4">0.9977</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EGP" decimals="0">250000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinlandOyEspooMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">459000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinlandOyEspooMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinlandOyEspooMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">903000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">43400000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">76734</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4CELLforCURELesUlisMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">4200000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CELLforCURELesUlisMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CELLforCURELesUlisMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">5400000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">25000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">25600000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">2000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4A1APharmaGmbHOberhachingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">26000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4A1APharmaGmbHOberhachingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4A1APharmaGmbHOberhachingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4HEXALAGHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">93700000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4HEXALAGHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4HEXALAGHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">42100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AeropharmGmbHRudolstadtMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">26000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AeropharmGmbHRudolstadtMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AeropharmGmbHRudolstadtMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">233900000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="HUF" decimals="-5">545600000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="HUF" decimals="-5">883000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="INR" decimals="-5">123500000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="4">0.7068</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="4">0.7068</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="INR" decimals="-5">60000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="INR" decimals="-5">32000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="IDR" decimals="-8">7700000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIrelandLimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">25000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIrelandLimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIrelandLimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">2000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">18200000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">119000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">1700000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="JPY" decimals="-8">6000000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="JPY" decimals="-5">8500000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="JPY" decimals="-5">100000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBalticsSIARigaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">3000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBalticsSIARigaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBalticsSIARigaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="-5">100000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="USD" decimals="0">100000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="MYR" decimals="-5">3300000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="MXN" decimals="-5">205000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="MXN" decimals="-5">468200000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="MAD" decimals="-5">80000000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">1400000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="-5">4500000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4IDBHollandBVBaarleNassauMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">18000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4IDBHollandBVBaarleNassauMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4IDBHollandBVBaarleNassauMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4SandozB.V.AlmereMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="EUR" decimals="0">907560</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozB.V.AlmereMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozB.V.AlmereMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="NZD" decimals="0">820000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:SharePaidinCapital contextRef="AR_I-CurrentYearEnd_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNorgeASOsloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="NOK" decimals="-5">1500000</nvs:SharePaidinCapital>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNorgeASOsloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNorgeASOsloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember" unitRef="Pure" decimals="2">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">395000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">-4361000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">74227000000</ifrs-full:Equity>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">-5064000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">329000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">-4340000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">-100000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">77639000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">-4340000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019PreviouslyStatedMember" unitRef="USD" decimals="-6">969000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" unitRef="USD" decimals="-6">-177000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" unitRef="USD" decimals="-6">237000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" unitRef="USD" decimals="-6">60000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" unitRef="USD" decimals="-6">3000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrsfull-2019IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" unitRef="USD" decimals="-6">3000000</ifrs-full:Equity>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-56000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">8072000000</ifrs-full:ProfitLoss>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">150000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">18000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">6987000000</ifrs-full:DividendsPaid>
  <nvs:TaxesOnTreasuryShares contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-32000000</nvs:TaxesOnTreasuryShares>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">7000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">3038000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">798000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">30000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">724000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <nvs:FairValueAdjustmentsRelatedToDivestments contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-2000000</nvs:FairValueAdjustmentsRelatedToDivestments>
  <nvs:RepurchaseOfOptions contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">89000000</nvs:RepurchaseOfOptions>
  <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-1769000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-13000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">38000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-7814000000</ifrs-full:ChangesInEquity>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">16000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">752000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <nvs:TransactionCostsRecordedInEquity contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">79000000</nvs:TransactionCostsRecordedInEquity>
  <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-284000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
  <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">6966000000</ifrs-full:DividendsPaid>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">12129000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-482000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">12611000000</ifrs-full:ProfitLoss>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">1960000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">430000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:ReductionOfIssuedCapital contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">9000000</ifrs-full:ReductionOfIssuedCapital>
  <nvs:OtherShareSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">261000000</nvs:OtherShareSales>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">82191000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">82194000000</ifrs-full:Equity>
  <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">6645000000</ifrs-full:DividendsPaid>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">11732000000</ifrs-full:ProfitLoss>
  <nvs:DividendPaidNoncashAssetsDistribution contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">23434000000</nvs:DividendPaidNoncashAssetsDistribution>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">11638000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-94000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">95000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <nvs:TransactionCostsRecordedInEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">253000000</nvs:TransactionCostsRecordedInEquity>
  <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">284000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
  <nvs:TaxesOnTreasuryShares contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">189000000</nvs:TaxesOnTreasuryShares>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">207000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:ReductionOfIssuedCapital contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">4000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">5480000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">828000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">18000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-10134000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">57157000000</ifrs-full:Equity>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">8016000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ReductionOfIssuedCapital contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">8000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">59275000000</ifrs-full:Equity>
  <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">22000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
  <nvs:FairValueAdjustmentsRelatedToDivestments contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-3000000</nvs:FairValueAdjustmentsRelatedToDivestments>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember" unitRef="USD" decimals="-6">-34557000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019RetainedEarningsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">77876000000</ifrs-full:Equity>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember" unitRef="USD" decimals="-5">69400000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear-1_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember" unitRef="USD" decimals="-5">63900000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember" unitRef="USD" decimals="-5">67500000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember" unitRef="USD" decimals="-5">40600000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember" unitRef="USD" decimals="-5">42500000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="AR_D-CurrentYear-1_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember" unitRef="USD" decimals="-5">2600000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember" unitRef="USD" decimals="-5">2500000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="AR_D-CurrentYear-1_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember" unitRef="USD" decimals="-5">20700000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember" unitRef="USD" decimals="-5">22500000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="AR_D-CurrentYear_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember" unitRef="USD" decimals="-5">25600000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="AR_D-CurrentYear_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember" unitRef="USD" decimals="-5">2700000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="AR_D-CurrentYear_ifrsfull-2019CategoriesOfRelatedPartiesAxis_ifrsfull-2019KeyManagementPersonnelOfEntityOrParentMember" unitRef="USD" decimals="-5">41100000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">5000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AimovigMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="Pure" decimals="2">0.59</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4BeovuMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">35000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZolgensmaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="Pure" decimals="2">1.55</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KymriahMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.71</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PiqrayMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">1.76</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XiidraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="Pure" decimals="2">0.96</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="Pure" decimals="3">0.015</ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4BeovuMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">190000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="USD" decimals="-6">1000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TabrectaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">35000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="Pure" decimals="3">0.065</ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal>
  <ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="Pure" decimals="3">0.065</ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember" unitRef="USD" decimals="-6">442000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KesimptaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">15000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="Pure" decimals="3">0.015</ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1958000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1738000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1542000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1439000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1339000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1188000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1083000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">687000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">1.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">653000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">635000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KymriahMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">474000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LutatheraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">445000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LutatheraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">1.64</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PiqrayMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">320000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PiqrayMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">116000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AdakveoMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">105000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AdakveoMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1070000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">3995000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">873000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">1933000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XiidraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">376000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XiidraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">192000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">1911000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">3003000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZolgensmaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">920000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">1916000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">980000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">452000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">393000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">360000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZolgensmaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">361000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4MayzentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">170000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4MayzentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">26000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AimovigMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">164000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AimovigMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">8000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">51000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="USD" decimals="-6">2497000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="USD" decimals="-6">1251000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4UltibroGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="USD" decimals="-6">623000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4UltibroGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="USD" decimals="-6">630000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4UltibroGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="Pure" decimals="2">-0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4UltibroGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="USD" decimals="-6">703000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4UltibroGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="Pure" decimals="2">-0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="USD" decimals="-6">26000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">1199000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">1003000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember" unitRef="USD" decimals="-6">841000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1487000000</ifrs-full:RightofuseAssets>
  <nvs:NetOperatingAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">468000000</nvs:NetOperatingAssets>
  <nvs:NetOperatingAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">2932000000</nvs:NetOperatingAssets>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">145000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">145000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">24481000000</ifrs-full:NetDebt>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">15938000000</ifrs-full:NetDebt>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">227000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">1122000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">42000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">1543000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">7000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">0</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">0</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">0</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">136000000</ifrs-full:RightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">54000000</ifrs-full:RightofuseAssets>
  <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">454000000</ifrs-full:AdditionsToRightofuseAssets>
  <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">49000000</ifrs-full:AdditionsToRightofuseAssets>
  <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">34000000</ifrs-full:AdditionsToRightofuseAssets>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">21718000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">4548000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">29645000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">925000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">35121000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">8274000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">152000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">592000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">249000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">506000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1880000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1874000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.00</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1585000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1587000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.00</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1539000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">-0.30</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1556000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">-0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1416000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.23</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1174000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1338000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.15</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1155000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1263000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">-0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1561000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">-0.19</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1114000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.20</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">977000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">975000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">-0.33</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1099000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">-0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">755000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">-0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">828000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">480000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.43</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">235000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LutatheraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">441000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LutatheraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LutatheraMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">167000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KymriahMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">278000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KymriahMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">76000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1189000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">-0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">1139000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">14711000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">14370000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="USD" decimals="-6">13428000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">6998000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">7268000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember" unitRef="Pure" decimals="2">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember" unitRef="USD" decimals="-6">24302000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember" unitRef="USD" decimals="-6">23344000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember" unitRef="USD" decimals="-6">21464000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember" unitRef="Pure" decimals="2">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="Pure" decimals="2">0.43</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="USD" decimals="-6">1050000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="Pure" decimals="2">0.67</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">1297000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">1284000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">1064000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">1023000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">1025000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">1002000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">485000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">464000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">419000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">463000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">417000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">445000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">2291000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">2587000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="Pure" decimals="2">-0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember" unitRef="USD" decimals="-6">6303000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">2086000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="Pure" decimals="2">-0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">2046000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="Pure" decimals="2">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">2463000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="Pure" decimals="2">-0.22</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">1995000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="Pure" decimals="2">0.23</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">4410000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">4776000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="Pure" decimals="2">-0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="USD" decimals="-6">4558000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">3551000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="Pure" decimals="2">0.13</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">2837000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="Pure" decimals="2">0.25</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">671000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="Pure" decimals="2">0.30</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">554000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="Pure" decimals="2">0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">1000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">4868000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">4222000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="Pure" decimals="2">0.15</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="USD" decimals="-6">3392000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember" unitRef="Pure" decimals="2">0.24</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">3223000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="Pure" decimals="2">-0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">3341000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="Pure" decimals="2">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AimovigMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">103000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">60000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="Pure" decimals="2">-0.15</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">80000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="Pure" decimals="2">-0.25</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">4323000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">3773000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="Pure" decimals="2">0.15</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="USD" decimals="-6">3429000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember" unitRef="Pure" decimals="2">0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="USD" decimals="-6">1173000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="Pure" decimals="2">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="USD" decimals="-6">1039000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="Pure" decimals="2">0.13</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="USD" decimals="-6">22000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="Pure" decimals="2">0.18</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="USD" decimals="-6">25000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="Pure" decimals="2">-0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="USD" decimals="-6">1900000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="USD" decimals="-6">1825000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="USD" decimals="-6">1767000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember" unitRef="Pure" decimals="2">0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="USD" decimals="-6">1726000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="Pure" decimals="2">0.45</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="USD" decimals="-6">1028000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="Pure" decimals="2">0.68</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="USD" decimals="-6">24000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="Pure" decimals="2">-0.96</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="USD" decimals="-6">22000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="Pure" decimals="2">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="USD" decimals="-6">2498000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember" unitRef="USD" decimals="-6">1750000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">39013000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">2000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">2000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">670000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">656000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">37714000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">9646000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">9731000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">792000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">783000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">189000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">141000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-981000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-871000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">39805000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">38497000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">9835000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">9872000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-981000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-871000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1018000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1092000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">53000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">63000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">168000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">24000000</ifrs-full:OtherRevenue>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">10927000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">10050000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">5252000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">5334000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-1058000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-959000000</ifrs-full:CostOfSales>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">29896000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">29539000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">4636000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">4601000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">245000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">112000000</ifrs-full:GrossProfit>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">11657000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">11617000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">2076000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">2218000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">464000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">534000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">8118000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">8152000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">862000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">1250000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">922000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1586000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">176000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">167000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">644000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">278000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1871000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">2069000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">831000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">749000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">488000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">608000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">9172000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">9287000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">1043000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">551000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-63000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-752000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">27384000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <nvs:CurrentIncomeTaxAndDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">8061000000</nvs:CurrentIncomeTaxAndDeferredTaxLiabilities>
  <nvs:CurrentIncomeTaxAndDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">9880000000</nvs:CurrentIncomeTaxAndDeferredTaxLiabilities>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">36044000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">11563000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:AdditionsToInvestmentInAssociatedCompanies contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-11000000</nvs:AdditionsToInvestmentInAssociatedCompanies>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">11446000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">8509000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <nvs:AdditionsToInvestmentInAssociatedCompanies contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">-24000000</nvs:AdditionsToInvestmentInAssociatedCompanies>
  <nvs:AdditionsToInvestmentInAssociatedCompanies contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">-44000000</nvs:AdditionsToInvestmentInAssociatedCompanies>
  <nvs:AdditionsToInvestmentInAssociatedCompanies contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-7000000</nvs:AdditionsToInvestmentInAssociatedCompanies>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">194000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">85000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">52000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">128000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">8000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">7000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">9430000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1235000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">8892000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">152000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">83000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">647000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">105000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">68000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">9859000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">741000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">177000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">34892000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-836000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">35633000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">10036000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-836000000</ifrs-full:RevenueFromSaleOfGoods>
  <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1188000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">62000000</ifrs-full:OtherRevenue>
  <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">16000000</ifrs-full:OtherRevenue>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">9870000000</ifrs-full:CostOfSales>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">5000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">6432000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">7871000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">1332000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-800000000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">5530000000</ifrs-full:CostOfSales>
  <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">-890000000</ifrs-full:CostOfSales>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">26951000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">4568000000</ifrs-full:GrossProfit>
  <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">70000000</ifrs-full:GrossProfit>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">10907000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">2305000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">505000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">7675000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">814000000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">977000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">505000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">147000000</ifrs-full:OtherIncome>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1475000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">622000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">512000000</ifrs-full:OtherExpenseByFunction>
  <ifrs-full:Assets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">83112000000</ifrs-full:Assets>
  <ifrs-full:Assets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">71225000000</ifrs-full:Assets>
  <ifrs-full:Assets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">16825000000</ifrs-full:Assets>
  <ifrs-full:Assets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">16468000000</ifrs-full:Assets>
  <ifrs-full:Assets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">32122000000</ifrs-full:Assets>
  <ifrs-full:Assets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">30677000000</ifrs-full:Assets>
  <ifrs-full:Liabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">15472000000</ifrs-full:Liabilities>
  <ifrs-full:Liabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">15332000000</ifrs-full:Liabilities>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1489000000</ifrs-full:RightofuseAssets>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">110000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">143000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">926000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">1114000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">229000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">217000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">133000000</ifrs-full:RightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">54000000</ifrs-full:RightofuseAssets>
  <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">264000000</ifrs-full:AdditionsToRightofuseAssets>
  <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">67000000</ifrs-full:AdditionsToRightofuseAssets>
  <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">15000000</ifrs-full:AdditionsToRightofuseAssets>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">56839000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">46336000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">9817000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">9863000000</ifrs-full:PropertyPlantAndEquipment>
  <nvs:NetOperatingAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">12664000000</nvs:NetOperatingAssets>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">9632000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">1849000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">1888000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">551000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">549000000</ifrs-full:PropertyPlantAndEquipment>
  <nvs:NetOperatingAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">67640000000</nvs:NetOperatingAssets>
  <nvs:NetOperatingAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">55893000000</nvs:NetOperatingAssets>
  <nvs:NetOperatingAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">13039000000</nvs:NetOperatingAssets>
  <ifrs-full:Liabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">3786000000</ifrs-full:Liabilities>
  <ifrs-full:Liabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">3804000000</ifrs-full:Liabilities>
  <ifrs-full:Liabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">56135000000</ifrs-full:Liabilities>
  <ifrs-full:Liabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">43683000000</ifrs-full:Liabilities>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">7000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">76000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">76000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">768000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">669000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">141000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember" unitRef="USD" decimals="-6">914000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember" unitRef="USD" decimals="-6">1175000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">3000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">18750000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">5339000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">7000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">21720000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">520000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">27586000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">7767000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">85000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">156000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">859000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">25000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2019SegmentConsolidationItemsAxis_ifrsfull-2019OperatingSegmentsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">1125000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">1482000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">301000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">1318000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">1345000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">440000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">202000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">1758000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">1547000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019PropertyPlantAndEquipmentMember" unitRef="USD" decimals="-6">1783000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">4376000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">3974000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">3428000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">3462000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">2836000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">914000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">1138000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">841000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019IntangibleAssetsAndGoodwillMember" unitRef="USD" decimals="-6">2587000000</ifrs-full:DepreciationAndAmortisationExpense>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE" unitRef="USD" decimals="-6">4120000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE" unitRef="Pure" decimals="2">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE" unitRef="USD" decimals="-6">3972000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE" unitRef="Pure" decimals="2">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE" unitRef="USD" decimals="-6">2554000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE" unitRef="Pure" decimals="2">0.03</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE" unitRef="USD" decimals="-6">4518000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE" unitRef="Pure" decimals="2">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE" unitRef="USD" decimals="-6">2607000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17DE" unitRef="Pure" decimals="2">0.03</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR" unitRef="USD" decimals="-6">2442000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR" unitRef="USD" decimals="-6">4115000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR" unitRef="Pure" decimals="2">0.05</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4FHoffmanLaRocheAGAndRocheSpAMember" unitRef="USD" decimals="-6">452000000</nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine>
  <nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4FHoffmanLaRocheAGAndRocheSpAMember" unitRef="EUR" decimals="-6">385000000</nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR" unitRef="USD" decimals="-6">2442000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR" unitRef="USD" decimals="-6">2505000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR" unitRef="Pure" decimals="2">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR" unitRef="USD" decimals="-6">3933000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17FR" unitRef="Pure" decimals="2">0.05</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019FinancialAssetsImpairedMember" unitRef="USD" decimals="-6">-335000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019FinancialAssetsImpairedMember" unitRef="USD" decimals="-6">-38000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019FinancialAssetsImpairedMember" unitRef="USD" decimals="-6">6000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">26524000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">-406000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">4000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">-301000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">29999000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">-21000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">-322000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019GoodwillMember" unitRef="USD" decimals="-6">101000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">-925000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill>
  <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">37000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">8813000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">-1550000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">36809000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">-30916000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">3462000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">567000000</nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">914000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">-148000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">-24632000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">1175000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">-30306000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">2836000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">983000000</nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019IntangibleAssetsOtherThanGoodwillMember" unitRef="USD" decimals="-6">28787000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">163000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">42000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">-4758000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">105000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">-721000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">40000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">101000000</nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">72000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">-885000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">230000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">-46000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">-107000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019TechnologybasedIntangibleAssetsMember" unitRef="USD" decimals="-6">4184000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">128000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">-145000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">1112000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">-1272000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">21000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">175000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">6000000</nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">-937000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">-11000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">419000000</nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">32000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">-1304000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">137000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2019OtherIntangibleAssetsMember" unitRef="USD" decimals="-6">621000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">492000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">-43000000</ifrs-full:PropertyPlantAndEquipment>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">-8000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment>
  <nvs:DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">-26000000</nvs:DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">10000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">-20000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">-1000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">17000000</nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">0</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">15000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">-1000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">-19000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">536000000</ifrs-full:PropertyPlantAndEquipment>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">0</nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">-4000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">1182000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">-66000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">10000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">11000000</nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">1290000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">-60000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">34000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">2000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">2000000</nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">-7000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2019ConstructionInProgressMember" unitRef="USD" decimals="-6">-37000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">354000000</ifrs-full:AdditionalProvisionsOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">268000000</ifrs-full:ProvisionUsedOtherProvisions>
  <ifrs-full:UnusedProvisionReversedOtherProvisions contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">87000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">22000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:OtherProvisions contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">153000000</ifrs-full:OtherProvisions>
  <ifrs-full:DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">8000000</ifrs-full:DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions>
  <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">492000000</ifrs-full:AdditionalProvisionsOtherProvisions>
  <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">534000000</ifrs-full:AdditionalProvisionsOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">479000000</ifrs-full:ProvisionUsedOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">145000000</ifrs-full:ProvisionUsedOtherProvisions>
  <ifrs-full:UnusedProvisionReversedOtherProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">72000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
  <ifrs-full:UnusedProvisionReversedOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">33000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">-2000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">-2000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:OtherProvisions contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">459000000</ifrs-full:OtherProvisions>
  <ifrs-full:OtherProvisions contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">438000000</ifrs-full:OtherProvisions>
  <ifrs-full:OtherProvisions contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ClassesOfProvisionsAxis_ifrsfull-2019RestructuringProvisionMember" unitRef="USD" decimals="-6">507000000</ifrs-full:OtherProvisions>
  <ifrs-full:ReductionOfIssuedCapital contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">23000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">969000000</ifrs-full:Equity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">-8000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">936000000</ifrs-full:Equity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">-23000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">913000000</ifrs-full:Equity>
  <ifrs-full:ReductionOfIssuedCapital contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">8000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">944000000</ifrs-full:Equity>
  <ifrs-full:ReductionOfIssuedCapital contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">25000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">-25000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019IssuedCapitalMember" unitRef="USD" decimals="-6">944000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">-69000000</ifrs-full:Equity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">31000000</ifrs-full:ChangesInEquity>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">4000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:ReductionOfIssuedCapital contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">-34000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">13000000</ifrs-full:PurchaseOfTreasuryShares>
  <nvs:OtherShareSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">2000000</nvs:OtherShareSales>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">4000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">-100000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">-69000000</ifrs-full:Equity>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">31000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:ReductionOfIssuedCapital contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">-12000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">3000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">5000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">-53000000</ifrs-full:Equity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">27000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">-80000000</ifrs-full:Equity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">-11000000</ifrs-full:ChangesInEquity>
  <ifrs-full:ReductionOfIssuedCapital contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">-31000000</ifrs-full:ReductionOfIssuedCapital>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">8000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">18000000</ifrs-full:PurchaseOfTreasuryShares>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">6000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_ifrsfull-2019TreasurySharesMember" unitRef="USD" decimals="-6">0</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">537000000</ifrs-full:RightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">14000000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">528000000</ifrs-full:RightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019LandMember" unitRef="USD" decimals="-6">11000000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">963000000</ifrs-full:RightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">207000000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">990000000</ifrs-full:RightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019BuildingsMember" unitRef="USD" decimals="-6">194000000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019VehiclesMember" unitRef="USD" decimals="-6">129000000</ifrs-full:RightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019VehiclesMember" unitRef="USD" decimals="-6">87000000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019VehiclesMember" unitRef="USD" decimals="-6">155000000</ifrs-full:RightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019VehiclesMember" unitRef="USD" decimals="-6">100000000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019OtherAssetsMember" unitRef="USD" decimals="-6">30000000</ifrs-full:RightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019OtherAssetsMember" unitRef="USD" decimals="-6">12000000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019OtherAssetsMember" unitRef="USD" decimals="-6">21000000</ifrs-full:RightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019OtherAssetsMember" unitRef="USD" decimals="-6">10000000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember" unitRef="USD" decimals="-6">330000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember" unitRef="USD" decimals="-6">305000000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember" unitRef="USD" decimals="-6">330000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019ClassesOfAssetsAxis_ifrsfull-2019RightofuseAssetsMember" unitRef="USD" decimals="-6">305000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
  <nvs:ImpairmentChargePriorToClassificationToAssetsHeldForSale contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">2000000</nvs:ImpairmentChargePriorToClassificationToAssetsHeldForSale>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">-18332000000</ifrs-full:PropertyPlantAndEquipment>
  <nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">-2118000000</nvs:DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment>
  <nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">2846000000</nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment>
  <nvs:DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">-26000000</nvs:DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment>
  <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">3000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">205000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">1345000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">-14930000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">-43000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">2004000000</nvs:AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">447000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">1318000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">-1108000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">-15955000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">485000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">494000000</nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">984000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">2657000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">70000000</nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4MarketingRelatedIntangibleAssetsMember" unitRef="USD" decimals="-6">-1906000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">-21218000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">-1120000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">54000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">-126000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">-11000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">-2005000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">-20969000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">515000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">338000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">3215000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">39000000</nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions>
  <nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">421000000</nvs:AccumulatedImpairmentsOnDisposalsAndDerecognitions>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">-26566000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">-2193000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">-1267000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">-92000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">416000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-2_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">400000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4OtherProductsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">108000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">37000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">-163000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">-816000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">2000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">-2000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill>
  <nvs:ImpairmentChargesRelatedToDisposalGroupHeldForSale contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">-42000000</nvs:ImpairmentChargesRelatedToDisposalGroupHeldForSale>
  <nvs:DepreciationChargePriorToClassificationToAssetsHeldForSale contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">38000000</nvs:DepreciationChargePriorToClassificationToAssetsHeldForSale>
  <nvs:DepreciationChargePriorToClassificationToAssetsHeldForSale contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">0</nvs:DepreciationChargePriorToClassificationToAssetsHeldForSale>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4MarketingRelatedIntangibleAssetsMember" unitRef="USD" decimals="-6">1906000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">2592000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations>
  <nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">3000000</nvs:AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations>
  <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember" unitRef="USD" decimals="-6">7000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2019AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">181000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">12818000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">12296000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:NumberOfBusinessUnits contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="Pure" decimals="0">2</nvs:NumberOfBusinessUnits>
  <nvs:OtherRevenueOther contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">24000000</nvs:OtherRevenueOther>
  <nvs:MilestoneIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">128000000</nvs:MilestoneIncome>
  <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">162000000</ifrs-full:RevenueFromRoyalties>
  <nvs:ProfitSharingIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">874000000</nvs:ProfitSharingIncome>
  <nvs:OtherRevenueOther contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">37000000</nvs:OtherRevenueOther>
  <nvs:OtherRevenueOther contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">55000000</nvs:OtherRevenueOther>
  <nvs:MilestoneIncome contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">39000000</nvs:MilestoneIncome>
  <nvs:MilestoneIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">201000000</nvs:MilestoneIncome>
  <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">107000000</ifrs-full:RevenueFromRoyalties>
  <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">104000000</ifrs-full:RevenueFromRoyalties>
  <nvs:ProfitSharingIncome contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">835000000</nvs:ProfitSharingIncome>
  <nvs:ProfitSharingIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">732000000</nvs:ProfitSharingIncome>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">9370000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">9141000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">8634000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">8718000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">8458000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">8097000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">2469000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">2649000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">2635000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">29643000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">28573000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">26258000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">3995000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">3003000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1933000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1958000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">2497000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1439000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1083000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1738000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1542000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">18790000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">29916000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">873000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">687000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember" unitRef="USD" decimals="-6">9097000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">24671000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1331000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">3551000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1199000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1188000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1251000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1339000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1003000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">980000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">653000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">635000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1479000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">905000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1099000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1933000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1220000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1441000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember" unitRef="USD" decimals="-6">5736000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember" unitRef="USD" decimals="-6">7946000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">23028000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">23925000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">17292000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">26946000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">517000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">319000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VoltarenCataflamMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">464000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4NeoralSandimmunEMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">323000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">292000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">554000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TravoprostGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">828000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TravoprostGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">424000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">983000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1002000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">977000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">977000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1023000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">939000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1039000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">472000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1028000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">578000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1099000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1039000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1174000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">698000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1155000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">593000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1284000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1284000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1561000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">627000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1556000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1121000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">770000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1587000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1874000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1068000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">3341000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GilenyaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1576000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1163000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">2837000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">2046000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">2046000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">28646000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember" unitRef="USD" decimals="-6">5958000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember" unitRef="USD" decimals="-6">9068000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">17967000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">480000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZortressCerticanMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">230000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TravoprostGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">316000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TravoprostGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">485000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">671000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">367000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">975000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">423000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">755000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">525000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1012000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1025000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1064000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">978000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1297000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">929000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1263000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1173000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1173000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1114000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4EntrestoMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4CardioMetabolicMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1114000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">857000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4PromactaRevoladeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1338000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1297000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1539000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">725000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1416000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">536000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">704000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1585000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1726000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">801000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">2086000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1076000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TasignaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1880000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1487000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4CosentyxMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">3223000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4OphthalmologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">2086000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">-0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">920000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4RestOfPortfolioMember" unitRef="USD" decimals="-6">5881000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4VotrientMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">376000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExjadeJadenuMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">515000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4KisqaliMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">369000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4IlarisMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4ImmunologyHepatologyAndDermatologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">473000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ZolgensmaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4NeuroscienceMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">461000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4ExforgeGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">964000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4DiovanGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">879000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4AfinitorVotubiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">439000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GleevecGlivecMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">873000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4GalvusGroupMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4EstablishedMedicinesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1199000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4JakaviMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1339000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4PharmaceuticalMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RespiratoryMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">1251000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4SandostatinMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">602000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4RestOfTheWorldMember_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4TafinlarMekinistMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember_nvs-2020Q4BusinessUnitAxis_nvs-2020Q4OncologyMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4Top20ProductsMember" unitRef="USD" decimals="-6">973000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:CashOfferPerOrdinaryShare contextRef="AR_I-Transaction-TheMedicinesCompany_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="1">85.0</nvs:CashOfferPerOrdinaryShare>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-TheMedicinesCompany_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">9600000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">9600000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">7100000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">8500000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">1400000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:AdditionalRecognitionGoodwill contextRef="AR_D-Transaction-TheMedicinesCompany-2_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">2500000000</ifrs-full:AdditionalRecognitionGoodwill>
  <nvs:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage contextRef="AR_I-Transaction-IFM-1_dei-2020LegalEntityAxis_nvs-2020Q4IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.09</nvs:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
  <ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate contextRef="AR_I-Transaction-IFM-1_dei-2020LegalEntityAxis_nvs-2020Q4IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">33000000</ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate>
  <ifrs-full:GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination contextRef="AR_D-Transaction-IFM-1_dei-2020LegalEntityAxis_nvs-2020Q4IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">14000000</ifrs-full:GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination>
  <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="AR_I-Transaction-IFM-1_dei-2020LegalEntityAxis_nvs-2020Q4IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">361000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
  <ifrs-full:PercentageOfVotingEquityInterestsAcquired contextRef="AR_I-Transaction-IFM-1_dei-2020LegalEntityAxis_nvs-2020Q4IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="Pure" decimals="2">0.91</ifrs-full:PercentageOfVotingEquityInterestsAcquired>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-IFM-1_dei-2020LegalEntityAxis_nvs-2020Q4IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">285000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-Transaction-IFM-1_dei-2020LegalEntityAxis_nvs-2020Q4IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">76000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-Transaction-IFM-1_dei-2020LegalEntityAxis_nvs-2020Q4IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">355000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:AdditionalRecognitionGoodwill contextRef="AR_D-Transaction-IFM-1_dei-2020LegalEntityAxis_nvs-2020Q4IFMTreInc.Member_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">39000000</ifrs-full:AdditionalRecognitionGoodwill>
  <nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment contextRef="AR_D-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">3400000000</nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment>
  <nvs:PotentialMilestoneMaximumPayments contextRef="AR_D-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">1900000000</nvs:PotentialMilestoneMaximumPayments>
  <nvs:CustomaryPurchasePriceAdjustment contextRef="AR_D-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">100000000</nvs:CustomaryPurchasePriceAdjustment>
  <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="AR_I-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">3700000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">3500000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">200000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">3600000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">3600000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionalRecognitionGoodwill contextRef="AR_D-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">100000000</ifrs-full:AdditionalRecognitionGoodwill>
  <ifrs-full:RevenueOfAcquiree contextRef="AR_D-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">200000000</ifrs-full:RevenueOfAcquiree>
  <nvs:RevenueOfAcquireeFullYear contextRef="AR_D-Transaction-Takeda-2_dei-2020LegalEntityAxis_nvs-2020Q4TakedaPharmaceuticalCompanyLimitedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-8">300000000</nvs:RevenueOfAcquireeFullYear>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember" unitRef="USD" decimals="-6">13484000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">5231000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">5115000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">4963000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-AspenGlobalIncorporation_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="EUR" decimals="-6">300000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-AspenGlobalIncorporation_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">336000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-Transaction-AspenGlobalIncorporation_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="EUR" decimals="-6">100000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-Transaction-AspenGlobalIncorporation_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">112000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">196000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <nvs:OtherNetAssets contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">26000000</nvs:OtherNetAssets>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">16000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:AdditionalRecognitionGoodwill contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">86000000</ifrs-full:AdditionalRecognitionGoodwill>
  <nvs:PotentialMilestoneMaximumPayments contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">77000000</nvs:PotentialMilestoneMaximumPayments>
  <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="EUR" decimals="-5">294000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
  <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">324000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="EUR" decimals="-5">247000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">273000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="EUR" decimals="-5">47000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">51000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">238000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="EUR" decimals="-5">274000000</nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment>
  <nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">303000000</nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment>
  <nvs:CustomaryPurchasePriceAdjustment contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="EUR" decimals="-5">27000000</nvs:CustomaryPurchasePriceAdjustment>
  <nvs:CustomaryPurchasePriceAdjustment contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">30000000</nvs:CustomaryPurchasePriceAdjustment>
  <nvs:PotentialMilestoneMaximumPayments contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2020LegalEntityAxis_nvs-2020Q4AspenGlobalIncorporatedMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="EUR" decimals="-5">70000000</nvs:PotentialMilestoneMaximumPayments>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember" unitRef="USD" decimals="-6">474000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RetailGenericsMember" unitRef="USD" decimals="-6">7244000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4BiopharmaceuticalsMember" unitRef="USD" decimals="-6">1928000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">38000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">102000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill contextRef="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-5">42000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">-0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.00</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="Pure" decimals="2">-0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="Pure" decimals="2">-0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4AntiInfectivesSoldUnderSandozNameMember" unitRef="USD" decimals="-6">694000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4AntiInfectivesSoldUnderSandozNameMember" unitRef="USD" decimals="-6">784000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember_nvs-2020Q4ProductPortfolioAxis_nvs-2020Q4AntiInfectivesSoldUnderSandozNameMember" unitRef="USD" decimals="-6">826000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4BiopharmaceuticalsMember" unitRef="USD" decimals="-6">1607000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4BiopharmaceuticalsMember" unitRef="Pure" decimals="2">0.20</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4BiopharmaceuticalsMember" unitRef="USD" decimals="-6">1436000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4BiopharmaceuticalsMember" unitRef="Pure" decimals="2">0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember" unitRef="USD" decimals="-6">534000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember" unitRef="Pure" decimals="2">-0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember" unitRef="USD" decimals="-6">543000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4AntiInfectivesMember" unitRef="Pure" decimals="2">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RetailGenericsMember" unitRef="USD" decimals="-6">7590000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RetailGenericsMember" unitRef="Pure" decimals="2">-0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RetailGenericsMember" unitRef="USD" decimals="-6">7880000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4FranchiseAxis_nvs-2020Q4RetailGenericsMember" unitRef="Pure" decimals="2">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:DivestmentDateFairValueOfTotalConsiderationTransferred contextRef="AR_I-Transaction-Sandoz-Divestment_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-8">800000000</nvs:DivestmentDateFairValueOfTotalConsiderationTransferred>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">1501000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">1341000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">1363000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">772000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">784000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">779000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:ProfitSharingIncome contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">0</nvs:ProfitSharingIncome>
  <nvs:ProfitSharingIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">2000000</nvs:ProfitSharingIncome>
  <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">25000000</ifrs-full:RevenueFromRoyalties>
  <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">19000000</ifrs-full:RevenueFromRoyalties>
  <nvs:MilestoneIncome contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">11000000</nvs:MilestoneIncome>
  <nvs:MilestoneIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">30000000</nvs:MilestoneIncome>
  <nvs:OtherRevenueOther contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">17000000</nvs:OtherRevenueOther>
  <nvs:OtherRevenueOther contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">12000000</nvs:OtherRevenueOther>
  <nvs:ProfitSharingIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">3000000</nvs:ProfitSharingIncome>
  <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">10000000</ifrs-full:RevenueFromRoyalties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.00</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">-0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">7089000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">7111000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">7233000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">2557000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">2620000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">2626000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:MilestoneIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">45000000</nvs:MilestoneIncome>
  <nvs:OtherRevenueOther contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="USD" decimals="-6">4000000</nvs:OtherRevenueOther>
  <nvs:NumberOfFranchises contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember" unitRef="Pure" decimals="0">3</nvs:NumberOfFranchises>
  <ifrs-full:IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners contextRef="AR_D-Transaction-Alcon-3-April-8_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-9">3000000000</ifrs-full:IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners>
  <nvs:PercentageOfEquityInterestSharesReceived contextRef="AR_I-Transaction-Alcon-3-April-8_ifrsfull-2019SegmentsAxis_nvs-2020Q4AlconMember" unitRef="Pure" decimals="3">0.047</nvs:PercentageOfEquityInterestSharesReceived>
  <ifrs-full:CurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">31300000000</ifrs-full:CurrentAssets>
  <ifrs-full:NoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">56400000000</ifrs-full:NoncurrentAssets>
  <ifrs-full:CurrentLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">24100000000</ifrs-full:CurrentLiabilities>
  <ifrs-full:NoncurrentLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">23100000000</ifrs-full:NoncurrentLiabilities>
  <ifrs-full:CurrentAssets contextRef="AR_I-HY1-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">27700000000</ifrs-full:CurrentAssets>
  <ifrs-full:NoncurrentAssets contextRef="AR_I-HY1-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">55700000000</ifrs-full:NoncurrentAssets>
  <ifrs-full:CurrentLiabilities contextRef="AR_I-HY1-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">22500000000</ifrs-full:CurrentLiabilities>
  <ifrs-full:NoncurrentLiabilities contextRef="AR_I-HY1-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">23100000000</ifrs-full:NoncurrentLiabilities>
  <ifrs-full:Revenue contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">63800000000</ifrs-full:Revenue>
  <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">12300000000</ifrs-full:ProfitLoss>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">-900000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">11400000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:Revenue contextRef="AR_D-HY1-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">30400000000</ifrs-full:Revenue>
  <ifrs-full:ProfitLoss contextRef="AR_D-HY1-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">7200000000</ifrs-full:ProfitLoss>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-HY1-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">-700000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-HY1-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">6500000000</ifrs-full:ComprehensiveIncome>
  <nvs:PriorYearAdjustment contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">-64000000</nvs:PriorYearAdjustment>
  <nvs:ShareOfEstimatedNetAssets contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">2585000000</nvs:ShareOfEstimatedNetAssets>
  <ifrs-full:RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">117000000</ifrs-full:RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdditionalRecognitionGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">3233000000</ifrs-full:AdditionalRecognitionGoodwill>
  <nvs:ShareOfCurrentYearNetIncome contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">913000000</nvs:ShareOfCurrentYearNetIncome>
  <nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">-172000000</nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets>
  <ifrs-full:FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">18800000000</ifrs-full:FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished>
  <nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">26000000</nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax>
  <nvs:CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">5935000000</nvs:CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill>
  <nvs:AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">3472000000</nvs:AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived>
  <nvs:ShareOfCurrentYearNetIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">910000000</nvs:ShareOfCurrentYearNetIncome>
  <nvs:ShareOfCurrentYearNetIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">799000000</nvs:ShareOfCurrentYearNetIncome>
  <nvs:PriorYearAdjustment contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">-129000000</nvs:PriorYearAdjustment>
  <nvs:PriorYearAdjustment contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">-125000000</nvs:PriorYearAdjustment>
  <nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">-162000000</nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets>
  <nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">-148000000</nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets>
  <nvs:PartialReleaseOfDeferredTaxLiabilityRecognized contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">43000000</nvs:PartialReleaseOfDeferredTaxLiabilityRecognized>
  <nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">24000000</nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax>
  <nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">40000000</nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax>
  <ifrs-full:ProportionOfVotingPowerHeldInAssociate contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="Pure" decimals="3">0.333</ifrs-full:ProportionOfVotingPowerHeldInAssociate>
  <ifrs-full:ProportionOfVotingPowerHeldInAssociate contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="Pure" decimals="3">0.333</ifrs-full:ProportionOfVotingPowerHeldInAssociate>
  <ifrs-full:ProportionOfVotingPowerHeldInAssociate contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="Pure" decimals="3">0.333</ifrs-full:ProportionOfVotingPowerHeldInAssociate>
  <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="Pure" decimals="3">0.062</ifrs-full:ProportionOfOwnershipInterestInAssociate>
  <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="Pure" decimals="3">0.062</ifrs-full:ProportionOfOwnershipInterestInAssociate>
  <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="Pure" decimals="3">0.062</ifrs-full:ProportionOfOwnershipInterestInAssociate>
  <ifrs-full:DividendsReceived contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">487000000</ifrs-full:DividendsReceived>
  <ifrs-full:DividendsReceived contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">460000000</ifrs-full:DividendsReceived>
  <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember">P20Y0M0D</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-8">16900000000</ifrs-full:FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">9407000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">8445000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">677000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">662000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">526000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">-56000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">-94000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">75000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">621000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">568000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember" unitRef="USD" decimals="-6">601000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" unitRef="USD" decimals="-6">5910000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" unitRef="USD" decimals="-6">-557000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
  <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" unitRef="USD" decimals="-6">5353000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" unitRef="USD" decimals="-6">1000000</nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax>
  <nvs:ShareOfCurrentYearNetIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" unitRef="USD" decimals="-6">119000000</nvs:ShareOfCurrentYearNetIncome>
  <nvs:PriorYearAdjustment contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" unitRef="USD" decimals="-6">4000000</nvs:PriorYearAdjustment>
  <nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" unitRef="USD" decimals="-6">-3000000</nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets>
  <nvs:GainOnDivestmentOfInterestsInAssociatedCompanies contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" unitRef="USD" decimals="-6">5790000000</nvs:GainOnDivestmentOfInterestsInAssociatedCompanies>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember" unitRef="USD" decimals="-6">-4000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember" unitRef="USD" decimals="-6">2000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember" unitRef="USD" decimals="-6">-4000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember" unitRef="USD" decimals="-6">2000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember" unitRef="USD" decimals="-6">225000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember" unitRef="USD" decimals="-6">199000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
  <nvs:GainLossOnSaleOfOtherFinancialAssets contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember" unitRef="USD" decimals="-6">137000000</nvs:GainLossOnSaleOfOtherFinancialAssets>
  <nvs:GainLossOnSaleOfOtherFinancialAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4OthersAssociatesMember" unitRef="USD" decimals="-6">33000000</nvs:GainLossOnSaleOfOtherFinancialAssets>
  <nvs:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">169000000</nvs:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation>
  <nvs:EmployerSharesHeldByDefinedBenefitPlan contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Shares" decimals="-5">2300000</nvs:EmployerSharesHeldByDefinedBenefitPlan>
  <nvs:ValueOfEmployerSharesHeldByDefinedBenefitPlan contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-8">200000000</nvs:ValueOfEmployerSharesHeldByDefinedBenefitPlan>
  <nvs:WeightedAverageDurationOfDefinedBenefitObligationYears contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">P15Y4M25D</nvs:WeightedAverageDurationOfDefinedBenefitObligationYears>
  <nvs:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">404000000</nvs:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
  <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4RealEstateMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.20</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum>
  <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4RealEstateMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.05</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum>
  <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AlternativeInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.00</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum>
  <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AlternativeInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.20</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum>
  <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4CashAndOtherInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.00</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum>
  <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum contextRef="AR_D-CurrentYear_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4CashAndOtherInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.15</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum>
  <nvs:DefinedBenefitAssumptionLifeExpectancyFemale contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">P24Y0M0D</nvs:DefinedBenefitAssumptionLifeExpectancyFemale>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">13418000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <nvs:ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1318000000</nvs:ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">9075000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1217000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:ActuarialAssumptionOfDiscountRates contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="3">0.006</ifrs-full:ActuarialAssumptionOfDiscountRates>
  <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="3">0.003</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
  <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="3">0.027</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
  <nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="3">0.001</nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount>
  <nvs:DefinedBenefitAssumptionLifeExpectancyMale contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">P22Y0M0D</nvs:DefinedBenefitAssumptionLifeExpectancyMale>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">3109000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <nvs:DefinedBenefitPlanInterestCost contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">222000000</nvs:DefinedBenefitPlanInterestCost>
  <nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-102000000</nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset>
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-1166000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">28000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
  <nvs:ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-159000000</nvs:ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset>
  <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1810000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability>
  <nvs:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">186000000</nvs:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation>
  <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1 contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-9000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1>
  <nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-166000000</nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset>
  <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-1620000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset>
  <nvs:DefinedBenefitPlanSettlementsPlanAssets contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-15000000</nvs:DefinedBenefitPlanSettlementsPlanAssets>
  <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1 contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-2000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1>
  <nvs:InterestIncomeOnLimitationOfFundSurplus contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">2000000</nvs:InterestIncomeOnLimitationOfFundSurplus>
  <nvs:PrepaidPostemploymentBenefitPlansAssets contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">202000000</nvs:PrepaidPostemploymentBenefitPlansAssets>
  <nvs:AdministrativeExpenseNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">24000000</nvs:AdministrativeExpenseNetDefinedBenefitLiabilityAsset>
  <nvs:DefinedBenefitPlanPlanAssetAllocations contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4RealEstateMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.17</nvs:DefinedBenefitPlanPlanAssetAllocations>
  <nvs:DefinedBenefitPlanPlanAssetAllocations contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4RealEstateMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.17</nvs:DefinedBenefitPlanPlanAssetAllocations>
  <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">186000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1264000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
  <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">372000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
  <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">464000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
  <nvs:ChangeInLimitationOnRecognitionOfFundSurplus contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-16000000</nvs:ChangeInLimitationOnRecognitionOfFundSurplus>
  <nvs:DefinedBenefitPlanPlanAssetAllocations contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AlternativeInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.13</nvs:DefinedBenefitPlanPlanAssetAllocations>
  <nvs:DefinedBenefitPlanPlanAssetAllocations contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4AlternativeInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.15</nvs:DefinedBenefitPlanPlanAssetAllocations>
  <nvs:DefinedBenefitPlanPlanAssetAllocations contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4CashAndOtherInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.08</nvs:DefinedBenefitPlanPlanAssetAllocations>
  <nvs:DefinedBenefitPlanPlanAssetAllocations contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfAssetsAxis_nvs-2020Q4CashAndOtherInvestmentsMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">0.05</nvs:DefinedBenefitPlanPlanAssetAllocations>
  <nvs:DefinedBenefitPlanPlanAssetAllocations contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">1.00</nvs:DefinedBenefitPlanPlanAssetAllocations>
  <nvs:DefinedBenefitPlanPlanAssetAllocations contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="2">1.00</nvs:DefinedBenefitPlanPlanAssetAllocations>
  <nvs:EmployerSharesHeldByDefinedBenefitPlan contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Shares" decimals="-5">2300000</nvs:EmployerSharesHeldByDefinedBenefitPlan>
  <nvs:ValueOfEmployerSharesHeldByDefinedBenefitPlan contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-8">200000000</nvs:ValueOfEmployerSharesHeldByDefinedBenefitPlan>
  <nvs:WeightedAverageDurationOfDefinedBenefitObligationYears contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">P15Y2M13D</nvs:WeightedAverageDurationOfDefinedBenefitObligationYears>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">23066000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">22179000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">3409000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">58000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
  <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">77000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
  <ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-117000000</ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">25000000</ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
  <nvs:DefinedBenefitPlanSettlementsPlanAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">193000000</nvs:DefinedBenefitPlanSettlementsPlanAssets>
  <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1 contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-39000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">22317000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">3285000000</ifrs-full:SurplusDeficitInPlan>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">3256000000</ifrs-full:SurplusDeficitInPlan>
  <nvs:LimitationOnRecognitionOfFundSurplus contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-65000000</nvs:LimitationOnRecognitionOfFundSurplus>
  <nvs:LimitationOnRecognitionOfFundSurplus contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-68000000</nvs:LimitationOnRecognitionOfFundSurplus>
  <nvs:ChangeInLimitationOnRecognitionOfFundSurplus contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-7000000</nvs:ChangeInLimitationOnRecognitionOfFundSurplus>
  <nvs:InterestIncomeOnLimitationOfFundSurplus contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">4000000</nvs:InterestIncomeOnLimitationOfFundSurplus>
  <nvs:LimitationOnRecognitionOfFundSurplus contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-51000000</nvs:LimitationOnRecognitionOfFundSurplus>
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">3336000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">3321000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-257000000</nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset>
  <nvs:ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1656000000</nvs:ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset>
  <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-304000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset>
  <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">420000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">25602000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">19810000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">18838000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">336000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
  <nvs:DefinedBenefitPlanInterestCost contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">330000000</nvs:DefinedBenefitPlanInterestCost>
  <nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-168000000</nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset>
  <nvs:AdministrativeExpenseNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">24000000</nvs:AdministrativeExpenseNetDefinedBenefitLiabilityAsset>
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-1791000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">193000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
  <nvs:ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-184000000</nvs:ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset>
  <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">283000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability>
  <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1256000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
  <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">169000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
  <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1 contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">49000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1>
  <ifrs-full:ActuarialAssumptionOfDiscountRates contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="3">0.010</ifrs-full:ActuarialAssumptionOfDiscountRates>
  <ifrs-full:ActuarialAssumptionOfDiscountRates contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="3">0.016</ifrs-full:ActuarialAssumptionOfDiscountRates>
  <nvs:DefinedBenefitAssumptionLifeExpectancyFemale contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">P24Y0M0D</nvs:DefinedBenefitAssumptionLifeExpectancyFemale>
  <nvs:DefinedBenefitAssumptionLifeExpectancyFemale contextRef="AR_D-CurrentYear-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">P24Y0M0D</nvs:DefinedBenefitAssumptionLifeExpectancyFemale>
  <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="3">0.003</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
  <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="3">0.004</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
  <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="3">0.028</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
  <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="3">0.028</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
  <nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="3">0.003</nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount>
  <nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="Pure" decimals="3">0.008</nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount>
  <nvs:DefinedBenefitAssumptionLifeExpectancyMale contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">P22Y0M0D</nvs:DefinedBenefitAssumptionLifeExpectancyMale>
  <nvs:DefinedBenefitAssumptionLifeExpectancyMale contextRef="AR_D-CurrentYear-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">P22Y0M0D</nvs:DefinedBenefitAssumptionLifeExpectancyMale>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">12147000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">2722000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">1136000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">8197000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">21000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
  <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-126000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">190000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-21000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
  <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1 contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">-11000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1>
  <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1 contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">10000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1>
  <nvs:PrepaidPostemploymentBenefitPlansAssets contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">148000000</nvs:PrepaidPostemploymentBenefitPlansAssets>
  <nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">3538000000</nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities>
  <nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember" unitRef="USD" decimals="-6">3469000000</nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities>
  <nvs:ReimbursmentsFromPlanToEmployerNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-20000000</nvs:ReimbursmentsFromPlanToEmployerNetDefinedBenefitLiabilityAsset>
  <nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">543000000</nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities>
  <nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">612000000</nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities>
  <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1 contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-1000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1>
  <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1 contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">3000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1>
  <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-7000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">0</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
  <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">109000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
  <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-35000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
  <nvs:DefinedBenefitAssumptionLifeExpectancyMale contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">P21Y0M0D</nvs:DefinedBenefitAssumptionLifeExpectancyMale>
  <nvs:DefinedBenefitAssumptionLifeExpectancyMale contextRef="AR_D-CurrentYear-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">P21Y0M0D</nvs:DefinedBenefitAssumptionLifeExpectancyMale>
  <nvs:DefinedBenefitAssumptionLifeExpectancyFemale contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">P23Y0M0D</nvs:DefinedBenefitAssumptionLifeExpectancyFemale>
  <nvs:DefinedBenefitAssumptionLifeExpectancyFemale contextRef="AR_D-CurrentYear-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">P23Y0M0D</nvs:DefinedBenefitAssumptionLifeExpectancyFemale>
  <ifrs-full:ActuarialAssumptionOfDiscountRates contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="Pure" decimals="3">0.036</ifrs-full:ActuarialAssumptionOfDiscountRates>
  <ifrs-full:ActuarialAssumptionOfDiscountRates contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="Pure" decimals="3">0.044</ifrs-full:ActuarialAssumptionOfDiscountRates>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">612000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">157000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">15000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1 contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">1000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1>
  <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">30000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
  <nvs:ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">22000000</nvs:ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">9000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-76000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
  <nvs:DefinedBenefitPlanInterestCost contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">29000000</nvs:DefinedBenefitPlanInterestCost>
  <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">13000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">134000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">119000000</ifrs-full:PlanAssetsAtFairValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">632000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">74000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
  <nvs:ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">10000000</nvs:ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset>
  <nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-3000000</nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset>
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">543000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">612000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">543000000</ifrs-full:SurplusDeficitInPlan>
  <ifrs-full:SurplusDeficitInPlan contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">612000000</ifrs-full:SurplusDeficitInPlan>
  <ifrs-full:PlanAssetsAtFairValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">89000000</ifrs-full:PlanAssetsAtFairValue>
  <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1 contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">2000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1>
  <ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">1000000</ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">0</ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">16000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
  <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">26000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">954000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">746000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">1073000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="Pure" decimals="3">0.065</nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
  <nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear contextRef="AR_D-CurrentYear-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="Pure" decimals="3">0.070</nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
  <nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="Pure" decimals="3">0.045</nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline>
  <nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline contextRef="AR_D-CurrentYear-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="Pure" decimals="3">0.045</nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline>
  <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">11000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
  <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">33000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
  <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">0</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">574000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-4000000</nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset>
  <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1 contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-1000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1>
  <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-7000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability>
  <nvs:ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">132000000</nvs:ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">13000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">-40000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
  <nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">1000000</nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset>
  <nvs:DefinedBenefitPlanInterestCost contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">20000000</nvs:DefinedBenefitPlanInterestCost>
  <nvs:DefinedBenefitAssumptionLifeExpectancyMale contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">P21Y0M0D</nvs:DefinedBenefitAssumptionLifeExpectancyMale>
  <nvs:ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">4000000</nvs:ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset>
  <nvs:DefinedBenefitAssumptionLifeExpectancyFemale contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">P23Y0M0D</nvs:DefinedBenefitAssumptionLifeExpectancyFemale>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4UnfundedMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">543000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4PensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">510000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4DeferredPensionersMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">17000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4ObligationByTypeAxis_nvs-2020Q4ActiveMember_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">105000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <nvs:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="USD" decimals="-6">40000000</nvs:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
  <nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="Pure" decimals="3">0.063</nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
  <nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="Pure" decimals="3">0.045</nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline>
  <ifrs-full:ActuarialAssumptionOfDiscountRates contextRef="AR_I-CurrentYearEnd_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember" unitRef="Pure" decimals="3">0.029</ifrs-full:ActuarialAssumptionOfDiscountRates>
  <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="Pure" decimals="-5">800000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="USDPerShares" decimals="1">57.3</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="Pure" decimals="-5">400000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.6Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="Pure" decimals="-5">800000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice66.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="Pure" decimals="-5">1400000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="AR_D-CurrentYear_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">P0Y0M0D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="AR_D-CurrentYear_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.6Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">P1Y0M0D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="AR_D-CurrentYear_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice66.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">P2Y0M0D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">P1Y4M26D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="USDPerShares" decimals="1">57.0</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.6Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="USDPerShares" decimals="1">57.6</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice66.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="USDPerShares" decimals="1">66.0</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">2000000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">89.4</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="USDPerShares" decimals="1">91.7</ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="Pure" decimals="-5">5600000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="USDPerShares" decimals="1">59.9</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="Pure" decimals="-5">2200000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="USDPerShares" decimals="1">58.4</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="AR_I-CurrentYearEnd_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="Pure" decimals="-5">2600000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="USDPerShares" decimals="1">62.0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="Pure" decimals="-5">3400000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="USDPerShares" decimals="1">60.9</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="AR_I-CurrentYearEnd_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="Pure" decimals="-5">2600000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="USDPerShares" decimals="1">62.0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="Pure" decimals="-5">3400000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" unitRef="USDPerShares" decimals="1">60.9</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">179000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">2600000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">67.4</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">175000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">339000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">5300000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">64.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="USDPerShares" decimals="1">60.7</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="Pure" decimals="-5">15200000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="Pure" decimals="-5">5600000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="USDPerShares" decimals="1">58.6</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="AR_I-CurrentYearEnd_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="Pure" decimals="-5">6700000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="USDPerShares" decimals="1">62.9</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="Pure" decimals="-5">9600000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="USDPerShares" decimals="1">61.9</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="AR_I-CurrentYearEnd_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="Pure" decimals="-5">6700000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="USDPerShares" decimals="1">62.9</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="Pure" decimals="-5">9600000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="USDPerShares" decimals="1">61.9</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">286000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="USDPerShares" decimals="1">92.2</ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">86.7</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">3300000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice66.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="Pure" decimals="-5">4000000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="AR_D-CurrentYear_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">P0Y0M0D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="AR_D-CurrentYear_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.6Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">P1Y0M0D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="AR_D-CurrentYear_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice66.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">P2Y0M0D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">P1Y6M1D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="USDPerShares" decimals="1">57.0</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.6Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="USDPerShares" decimals="1">58.3</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice66.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="USDPerShares" decimals="1">66.1</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.6Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="Pure" decimals="-5">2300000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="Pure" decimals="-5">2900000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="USDPerShares" decimals="1">59.6</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="AR_I-CurrentYearEnd_ifrsfull-2019RangesOfExercisePricesForOutstandingShareOptionsAxis_nvs-2020Q4ExercisePrice57.0Member_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" unitRef="Pure" decimals="-5">400000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear-2_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">16000000</ifrs-full:RevenueFromRoyalties>
  <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">168000000</ifrs-full:RevenueFromRoyalties>
  <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear-1_ifrsfull-2019SegmentsAxis_nvs-2020Q4CorporateMember" unitRef="USD" decimals="-6">24000000</ifrs-full:RevenueFromRoyalties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember" unitRef="USD" decimals="-6">18885000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember" unitRef="Pure" decimals="2">0.39</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember" unitRef="USD" decimals="-6">18333000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember" unitRef="Pure" decimals="2">0.40</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember" unitRef="USD" decimals="-6">8296000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember" unitRef="Pure" decimals="2">0.11</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember" unitRef="USD" decimals="-6">19038000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember" unitRef="Pure" decimals="2">0.39</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember" unitRef="USD" decimals="-6">7837000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4OtherCountriesMember" unitRef="Pure" decimals="2">0.08</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">-0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember_nvs-2020Q4ChangeOverPeriodAxis_nvs-2020Q4PoPYEChangeMember" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
  <nvs:OtherComprehensiveIncomeNetOfTaxDebtSecurities contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnDebtSecuritiesMember" unitRef="USD" decimals="-6">1000000</nvs:OtherComprehensiveIncomeNetOfTaxDebtSecurities>
  <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnEquitySecuritiesMember" unitRef="USD" decimals="-6">13000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
  <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnEquitySecuritiesMember" unitRef="USD" decimals="-6">-47000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
  <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnEquitySecuritiesMember" unitRef="USD" decimals="-6">250000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnEquitySecuritiesMember" unitRef="USD" decimals="-6">-16000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnEquitySecuritiesMember" unitRef="USD" decimals="-6">-95000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnEquitySecuritiesMember" unitRef="USD" decimals="-6">-150000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnEquitySecuritiesMember" unitRef="USD" decimals="-6">47000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnEquitySecuritiesMember" unitRef="USD" decimals="-6">-5000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnEquitySecuritiesMember" unitRef="USD" decimals="-6">-36000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnDeferredCashFlowHedgesMember" unitRef="USD" decimals="-6">-1000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnDeferredCashFlowHedgesMember" unitRef="USD" decimals="-6">12000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnDeferredCashFlowHedgesMember" unitRef="USD" decimals="-6">1000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">76000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:OtherComprehensiveIncomeNetOfTaxDebtSecurities contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">1000000</nvs:OtherComprehensiveIncomeNetOfTaxDebtSecurities>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">-150000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">-95000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">-16000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">12000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges>
  <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">250000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">1000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">143000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">-1448000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">3386000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:FairValueAdjustmentsRelatedToDivestments contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">2000000</nvs:FairValueAdjustmentsRelatedToDivestments>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">3194000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">-116000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:FairValueAdjustmentsRelatedToDivestments contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">3000000</nvs:FairValueAdjustmentsRelatedToDivestments>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">-4686000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">-201000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">352000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">-467000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">-47000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
  <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">13000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" unitRef="USD" decimals="-6">-177000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">-359000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">315000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">-4538000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">95000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">-4478000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember" unitRef="USD" decimals="-6">44000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <nvs:GainLossOnSaleOfOtherFinancialAssets contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">13000000</nvs:GainLossOnSaleOfOtherFinancialAssets>
  <nvs:GainLossOnSaleOfOtherFinancialAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalFairValueAdjustmentsMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">62000000</nvs:GainLossOnSaleOfOtherFinancialAssets>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">-4517000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">78695000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">74287000000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4RestatedValueAdjustmentsMember" unitRef="USD" decimals="-6">-4452000000</ifrs-full:Equity>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">5424000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4AcquiredResearchAndDevelopmentMember" unitRef="USD" decimals="-6">4700000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">30767000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2020Q4CurrentlyMarketedProductsMember" unitRef="USD" decimals="-6">22579000000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InvestmentsInSubsidiariesMember" unitRef="USD" decimals="-9">3000000000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
  <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InvestmentsInSubsidiariesMember" unitRef="USD" decimals="-9">5000000000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
  <nvs:DeductibleTemporaryDifferencesForWhichNoDeferredTaxLiabilityIsRecognised contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4GoodwillFromAcquisitionsMember" unitRef="USD" decimals="-9">27000000000</nvs:DeductibleTemporaryDifferencesForWhichNoDeferredTaxLiabilityIsRecognised>
  <nvs:DeductibleTemporaryDifferencesForWhichNoDeferredTaxLiabilityIsRecognised contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4GoodwillFromAcquisitionsMember" unitRef="USD" decimals="-9">24000000000</nvs:DeductibleTemporaryDifferencesForWhichNoDeferredTaxLiabilityIsRecognised>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4TwoYearsMember" unitRef="USD" decimals="-6">5000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4ThreeYearsMember" unitRef="USD" decimals="-6">6000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4NotSubjectToExpiryMember" unitRef="USD" decimals="-6">683000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FiveYearsMember" unitRef="USD" decimals="-6">40000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember" unitRef="USD" decimals="-6">2291000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4NotSubjectToExpiryMember" unitRef="USD" decimals="-6">35000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember" unitRef="USD" decimals="-6">3025000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4OneYearMember" unitRef="USD" decimals="-6">0</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4TwoYearsMember" unitRef="USD" decimals="-6">0</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember" unitRef="USD" decimals="-6">2338000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4ThreeYearsMember" unitRef="USD" decimals="-6">6000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FourYearsMember" unitRef="USD" decimals="-6">46000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FiveYearsMember" unitRef="USD" decimals="-6">37000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4CapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember" unitRef="USD" decimals="-6">2214000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember" unitRef="USD" decimals="-6">125000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FiveYearsMember" unitRef="USD" decimals="-6">127000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FourYearsMember" unitRef="USD" decimals="-6">16000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4ThreeYearsMember" unitRef="USD" decimals="-6">28000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember" unitRef="USD" decimals="-6">648000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4TwoYearsMember" unitRef="USD" decimals="-6">28000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4OneYearMember" unitRef="USD" decimals="-6">14000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember" unitRef="USD" decimals="-6">3780000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4NotSubjectToExpiryMember" unitRef="USD" decimals="-6">310000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember" unitRef="USD" decimals="-6">3400000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FiveYearsMember" unitRef="USD" decimals="-6">11000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4NotSubjectToExpiryMember" unitRef="USD" decimals="-6">323000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FourYearsMember" unitRef="USD" decimals="-6">23000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4ThreeYearsMember" unitRef="USD" decimals="-6">2000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4OneYearMember" unitRef="USD" decimals="-6">20000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4TwoYearsMember" unitRef="USD" decimals="-6">1000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:TaxLossCarryForwards contextRef="AR_D-CurrentYear_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember" unitRef="USD" decimals="-8">3200000000</nvs:TaxLossCarryForwards>
  <nvs:TaxLossCarryForwards contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_nvs-2020Q4BalanceSheetTreatmentAxis_nvs-2020Q4NotCapitalizedMember_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember" unitRef="USD" decimals="-8">1600000000</nvs:TaxLossCarryForwards>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4OneYearMember" unitRef="USD" decimals="-6">14000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4OneYearMember" unitRef="USD" decimals="-6">20000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4TwoYearsMember" unitRef="USD" decimals="-6">6000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4TwoYearsMember" unitRef="USD" decimals="-6">28000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4ThreeYearsMember" unitRef="USD" decimals="-6">8000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4ThreeYearsMember" unitRef="USD" decimals="-6">34000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FourYearsMember" unitRef="USD" decimals="-6">62000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FourYearsMember" unitRef="USD" decimals="-6">23000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FiveYearsMember" unitRef="USD" decimals="-6">51000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4FiveYearsMember" unitRef="USD" decimals="-6">164000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember" unitRef="USD" decimals="-6">2339000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4MoreThanFiveYearsMember" unitRef="USD" decimals="-6">5691000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <ifrs-full:Inventories contextRef="AR_I-CurrentYearEnd_nvs-2020Q4InventoryAxis_nvs-2020Q4InventoryRawMaterialsGrossMember" unitRef="USD" decimals="-6">967000000</ifrs-full:Inventories>
  <ifrs-full:Inventories contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4InventoryAxis_nvs-2020Q4InventoryRawMaterialsGrossMember" unitRef="USD" decimals="-6">751000000</ifrs-full:Inventories>
  <ifrs-full:Inventories contextRef="AR_I-CurrentYearEnd_nvs-2020Q4InventoryAxis_nvs-2020Q4InventoryWorkInProgressGrossMember" unitRef="USD" decimals="-6">3324000000</ifrs-full:Inventories>
  <ifrs-full:Inventories contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4InventoryAxis_nvs-2020Q4InventoryWorkInProgressGrossMember" unitRef="USD" decimals="-6">3024000000</ifrs-full:Inventories>
  <ifrs-full:Inventories contextRef="AR_I-CurrentYearEnd_nvs-2020Q4InventoryAxis_nvs-2020Q4InventoryFinishedGoodsGrossMember" unitRef="USD" decimals="-6">2840000000</ifrs-full:Inventories>
  <ifrs-full:Inventories contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4InventoryAxis_nvs-2020Q4InventoryFinishedGoodsGrossMember" unitRef="USD" decimals="-6">2207000000</ifrs-full:Inventories>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" unitRef="Pure" decimals="5">0.04400</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" unitRef="USD" decimals="-6">1000000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" unitRef="Pure" decimals="5">0.99237</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" unitRef="USD" decimals="-6">1000000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" unitRef="Pure" decimals="5">0.02400</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" unitRef="USD" decimals="-6">1500000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" unitRef="Pure" decimals="5">0.99225</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" unitRef="USD" decimals="-6">1495000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" unitRef="USD" decimals="-6">1497000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" unitRef="USD" decimals="-6">490000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" unitRef="Pure" decimals="5">0.03700</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" unitRef="USD" decimals="-6">500000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" unitRef="Pure" decimals="5">0.98325</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" unitRef="USD" decimals="-6">489000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" unitRef="Pure" decimals="5">0.03400</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" unitRef="USD" decimals="-6">2150000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" unitRef="Pure" decimals="5">0.99287</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" unitRef="USD" decimals="-6">2139000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" unitRef="USD" decimals="-6">2142000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" unitRef="USD" decimals="-6">1826000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" unitRef="Pure" decimals="5">0.04400</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" unitRef="USD" decimals="-6">1850000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" unitRef="Pure" decimals="5">0.99196</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" unitRef="USD" decimals="-6">1825000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" unitRef="Pure" decimals="5">0.00750</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" unitRef="EUR" decimals="-6">600000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" unitRef="Pure" decimals="5">0.99134</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" unitRef="USD" decimals="-6">670000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" unitRef="USD" decimals="-6">737000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" unitRef="USD" decimals="-6">735000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" unitRef="Pure" decimals="5">0.01625</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" unitRef="EUR" decimals="-6">600000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" unitRef="Pure" decimals="5">0.99697</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" unitRef="USD" decimals="-6">670000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" unitRef="Pure" decimals="5">0.00250</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" unitRef="CHF" decimals="-6">500000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" unitRef="Pure" decimals="5">1.00640</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" unitRef="USD" decimals="-6">517000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" unitRef="USD" decimals="-6">568000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" unitRef="USD" decimals="-6">625000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" unitRef="Pure" decimals="5">0.00625</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" unitRef="CHF" decimals="-6">550000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" unitRef="Pure" decimals="5">1.00502</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" unitRef="USD" decimals="-6">568000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" unitRef="Pure" decimals="5">0.01050</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" unitRef="CHF" decimals="-6">325000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" unitRef="Pure" decimals="5">1.00479</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" unitRef="USD" decimals="-6">336000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" unitRef="USD" decimals="-6">369000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" unitRef="USD" decimals="-6">1737000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" unitRef="Pure" decimals="5">0.03000</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" unitRef="USD" decimals="-6">1750000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" unitRef="Pure" decimals="5">0.99010</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" unitRef="USD" decimals="-6">1735000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" unitRef="Pure" decimals="5">0.04000</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" unitRef="USD" decimals="-6">1250000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" unitRef="Pure" decimals="5">0.98029</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" unitRef="USD" decimals="-6">1219000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" unitRef="USD" decimals="-6">1220000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" unitRef="USD" decimals="-6">1530000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" unitRef="Pure" decimals="5">0.00125</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" unitRef="EUR" decimals="-6">1250000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" unitRef="Pure" decimals="5">0.99127</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" unitRef="USD" decimals="-6">1392000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" unitRef="Pure" decimals="5">0.00625</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" unitRef="EUR" decimals="-6">500000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" unitRef="Pure" decimals="5">0.98480</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" unitRef="USD" decimals="-6">553000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" unitRef="USD" decimals="-6">607000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" unitRef="Pure" decimals="5">0.01800</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" unitRef="USD" decimals="-6">1000000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" unitRef="Pure" decimals="5">0.99609</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" unitRef="USD" decimals="-6">1000000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" unitRef="Pure" decimals="5">0.02400</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" unitRef="USD" decimals="-6">1000000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" unitRef="Pure" decimals="5">0.99449</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" unitRef="USD" decimals="-6">996000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" unitRef="USD" decimals="-6">998000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" unitRef="USD" decimals="-6">992000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" unitRef="Pure" decimals="5">0.03100</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" unitRef="USD" decimals="-6">1000000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" unitRef="Pure" decimals="5">0.99109</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" unitRef="USD" decimals="-6">990000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" unitRef="Pure" decimals="5">0.00000</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" unitRef="EUR" decimals="-6">1250000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" unitRef="Pure" decimals="5">0.99133</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" unitRef="USD" decimals="-6">1396000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" unitRef="USD" decimals="-6">1536000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" unitRef="USD" decimals="-6">735000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" unitRef="Pure" decimals="5">0.01125</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" unitRef="EUR" decimals="-6">600000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" unitRef="Pure" decimals="5">0.99874</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" unitRef="USD" decimals="-6">670000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" unitRef="Pure" decimals="5">0.00500</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" unitRef="EUR" decimals="-6">750000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" unitRef="Pure" decimals="5">0.99655</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" unitRef="USD" decimals="-6">837000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" unitRef="USD" decimals="-6">919000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" unitRef="USD" decimals="-6">920000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" unitRef="Pure" decimals="5">0.01375</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" unitRef="EUR" decimals="-6">750000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" unitRef="Pure" decimals="5">0.99957</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" unitRef="USD" decimals="-6">838000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" unitRef="Pure" decimals="5">0.01700</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" unitRef="EUR" decimals="-6">750000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" unitRef="Pure" decimals="5">0.99217</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" unitRef="USD" decimals="-6">832000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" unitRef="USD" decimals="-6">913000000</ifrs-full:BondsIssued>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanFiveYearsAndNotLaterThanSixYearsMember" unitRef="USD" decimals="-6">2252000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanSixYearsMember" unitRef="USD" decimals="-6">8991000000</ifrs-full:Borrowings>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4CarryingReportedAmountFairValueDisclosureMember" unitRef="USD" decimals="-6">28298000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4CarryingReportedAmountFairValueDisclosureMember" unitRef="USD" decimals="-6">22167000000</ifrs-full:BondsIssued>
  <nvs:OtherNoncurrentFinancialDebt contextRef="AR_I-CurrentYearEnd_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4CarryingReportedAmountFairValueDisclosureMember" unitRef="USD" decimals="-6">233000000</nvs:OtherNoncurrentFinancialDebt>
  <nvs:OtherNoncurrentFinancialDebt contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4CarryingReportedAmountFairValueDisclosureMember" unitRef="USD" decimals="-6">188000000</nvs:OtherNoncurrentFinancialDebt>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4CarryingReportedAmountFairValueDisclosureMember" unitRef="USD" decimals="-6">28531000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4CarryingReportedAmountFairValueDisclosureMember" unitRef="USD" decimals="-6">22355000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4FairValueDisclosureItemAmountsMember" unitRef="USD" decimals="-6">23889000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4FairValueDisclosureItemAmountsMember" unitRef="USD" decimals="-6">31592000000</ifrs-full:Borrowings>
  <nvs:OtherNoncurrentFinancialDebt contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4FairValueDisclosureItemAmountsMember" unitRef="USD" decimals="-6">188000000</nvs:OtherNoncurrentFinancialDebt>
  <nvs:OtherNoncurrentFinancialDebt contextRef="AR_I-CurrentYearEnd_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4FairValueDisclosureItemAmountsMember" unitRef="USD" decimals="-6">233000000</nvs:OtherNoncurrentFinancialDebt>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4FairValueDisclosureItemAmountsMember" unitRef="USD" decimals="-6">23701000000</ifrs-full:BondsIssued>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_nvs-2020Q4FairValueByMeasurementBasisAxis_nvs-2020Q4FairValueDisclosureItemAmountsMember" unitRef="USD" decimals="-6">31359000000</ifrs-full:BondsIssued>
  <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">10000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
  <nvs:CurrentPortionOfNoncurrentFinancialDebt contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">-3190000000</nvs:CurrentPortionOfNoncurrentFinancialDebt>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">22470000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">-462000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
  <nvs:AmortizationOfBondsDiscount contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">-27000000</nvs:AmortizationOfBondsDiscount>
  <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">2856000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">23224000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">-5000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
  <nvs:ReclassificationFromNoncurrentToCurrentNet contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">-2003000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">20353000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">1000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
  <nvs:AmortizationOfBondsDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">-16000000</nvs:AmortizationOfBondsDiscount>
  <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">93000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
  <nvs:AmortizationOfBondsDiscount contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">-25000000</nvs:AmortizationOfBondsDiscount>
  <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">-141000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">26259000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">832000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
  <nvs:ReclassificationFromNoncurrentToCurrentNet contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">-2067000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
  <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NonCurrentFinancialDebtsMember" unitRef="USD" decimals="-6">7126000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
  <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">2003000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
  <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">2261000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
  <nvs:ReclassificationFromNoncurrentToCurrentNet contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">2067000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
  <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">392000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">9785000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">44000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">2000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
  <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">-129000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
  <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">3195000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
  <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">-1582000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
  <nvs:AmortizationOfBondsDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">-5000000</nvs:AmortizationOfBondsDiscount>
  <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">32000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">7031000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <nvs:ReclassificationFromNoncurrentToCurrentNet contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">2003000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
  <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">48000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">5308000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">366000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
  <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">1681000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
  <nvs:AmortizationOfBondsDiscount contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">-2000000</nvs:AmortizationOfBondsDiscount>
  <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">-93000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">9678000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <nvs:CurrentPortionOfNoncurrentFinancialDebt contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">3190000000</nvs:CurrentPortionOfNoncurrentFinancialDebt>
  <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">4000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
  <nvs:ReclassificationFromNoncurrentToCurrentNet contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">-156000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">1703000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">36000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">221000000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
  <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">30000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
  <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">362000000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
  <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">-33000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
  <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">-11000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">4000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">1719000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">39000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
  <nvs:ReclassificationFromNoncurrentToCurrentNet contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">-250000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
  <nvs:ReclassificationFromNoncurrentToCurrentNet contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">250000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
  <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">12000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">286000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">1000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">-6000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
  <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">-20000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
  <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">131000000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">273000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
  <nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">-51000000</nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities>
  <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">-65000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
  <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">73000000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">8000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">312000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
  <nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">-56000000</nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities>
  <nvs:FinancialDebtsAndDerivativeInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">246000000</nvs:FinancialDebtsAndDerivativeInstruments>
  <nvs:ReclassificationFromNoncurrentToCurrentNet contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLeaseLiabilitiesMember" unitRef="USD" decimals="-6">156000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_nvs-2020Q4LifeExpectancyMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Increase1YearMember" unitRef="USD" decimals="-6">993000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_nvs-2020Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Change25BasisPointMember" unitRef="USD" decimals="-6">62000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ActuarialAssumptionsAxis_nvs-2020Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2020Q4ChangeInActuarialAssumptionAxis_nvs-2020Q4Change25BasisPointMember" unitRef="USD" decimals="-6">-30000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationAnnualIncentivePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">1100000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationAnnualIncentivePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">78.4</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationAnnualIncentivePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">86000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationAnnualIncentivePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">103000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationAnnualIncentivePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">1100000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationAnnualIncentivePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">93.7</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationShareSavingsPlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">4200000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationShareSavingsPlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">95.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationShareSavingsPlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">399000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationShareSavingsPlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">349000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationShareSavingsPlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">4200000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationShareSavingsPlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">83.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermPerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">213000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermPerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">2500000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermPerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">68.9</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermPerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">172000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermPerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">2500000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermPerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">85.1</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermRelativePerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">200000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermRelativePerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">0.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermRelativePerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">0</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermRelativePerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">100000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermRelativePerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">0.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermRelativePerformancePlanMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">0</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationOtherShareAwardsMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">117000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationOtherShareAwardsMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">1900000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationOtherShareAwardsMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">67.7</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue contextRef="AR_D-CurrentYear-1_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationOtherShareAwardsMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">129000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationOtherShareAwardsMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">1500000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationOtherShareAwardsMember_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">78.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">13800000</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">74.2</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
  <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">2000000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">75.3</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue contextRef="AR_D-CurrentYear_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">1024000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue>
  <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear-1_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">13300000</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear-1_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">80.3</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue contextRef="AR_D-CurrentYear-1_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">1068000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue contextRef="AR_D-CurrentYear_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">151000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue>
  <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear-1_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">4300000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019 contextRef="AR_D-CurrentYear-1_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">76.3</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue contextRef="AR_D-CurrentYear-1_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">328000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue>
  <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="AR_I-CurrentYearEnd_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">24800000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">78.9</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue contextRef="AR_I-CurrentYearEnd_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">1957000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue>
  <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">25800000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">71.1</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">1835000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue>
  <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="Pure" decimals="-5">25700000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019 contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USDPerShares" decimals="1">77.1</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
  <nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4NonvestingAxis_nvs-2020Q4NonvestedSharesGrantedMember" unitRef="USD" decimals="-6">1981000000</nvs:SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="AR_D-CurrentYear-1_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4NonExecutiveDirectorMember" unitRef="USD" decimals="-5">4100000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4NonExecutiveDirectorMember" unitRef="USD" decimals="-5">4000000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="AR_D-CurrentYear-1_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4NonExecutiveDirectorMember" unitRef="USD" decimals="-5">4600000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4NonExecutiveDirectorMember" unitRef="USD" decimals="-5">4800000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4NonExecutiveDirectorMember" unitRef="USD" decimals="-5">9800000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear-1_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4NonExecutiveDirectorMember" unitRef="USD" decimals="-5">8700000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4NonExecutiveDirectorMember" unitRef="USD" decimals="-5">8800000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="AR_D-CurrentYear_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4NonExecutiveDirectorMember" unitRef="USD" decimals="-5">5200000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="AR_D-CurrentYear_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4NonExecutiveDirectorMember" unitRef="USD" decimals="-5">4600000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember" unitRef="USD" decimals="-8">2100000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember" unitRef="USD" decimals="-8">2000000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember" unitRef="USD" decimals="-8">1300000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember" unitRef="USD" decimals="-8">1200000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4XolairMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember" unitRef="USD" decimals="-9">1000000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:NetExpenseRoyaltiesCostSharingAndProfitSharing contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember" unitRef="USD" decimals="-6">217000000</nvs:NetExpenseRoyaltiesCostSharingAndProfitSharing>
  <nvs:NetExpenseRoyaltiesCostSharingAndProfitSharing contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember" unitRef="USD" decimals="-6">101000000</nvs:NetExpenseRoyaltiesCostSharingAndProfitSharing>
  <nvs:NetExpenseRoyaltiesCostSharingAndProfitSharing contextRef="AR_D-CurrentYear-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember" unitRef="USD" decimals="-6">34000000</nvs:NetExpenseRoyaltiesCostSharingAndProfitSharing>
  <nvs:NumberOfContractsWithRelatedParties contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember" unitRef="Pure" decimals="0">2</nvs:NumberOfContractsWithRelatedParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019ProductsAndServicesAxis_nvs-2020Q4LucentisMember_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GenentechRocheMember" unitRef="USD" decimals="-8">1900000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear-1_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4DrAlexKrauerMember" unitRef="CHF" decimals="0">60000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4DrAlexKrauerMember" unitRef="CHF" decimals="0">60000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4DrAlexKrauerMember" unitRef="CHF" decimals="0">60000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear-2_ifrsfull-2019CategoriesOfRelatedPartiesAxis_nvs-2020Q4DrDanielVasellaMember" unitRef="CHF" decimals="0">18228</ifrs-full:KeyManagementPersonnelCompensation>
  <nvs:BorrowingsCreditFacilityUncommitted contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4NovartisPensionFundMember" unitRef="USD" decimals="-6">500000000</nvs:BorrowingsCreditFacilityUncommitted>
  <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">57000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">18000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:DisposalsFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">23000000</nvs:DisposalsFairValueMeasurementAssets>
  <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">4000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
  <nvs:PurchaseFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">24000000</nvs:PurchaseFairValueMeasurementAssets>
  <nvs:ReclassificationFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">-19000000</nvs:ReclassificationFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">211000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">39000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">145000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:PurchaseFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">49000000</nvs:PurchaseFairValueMeasurementAssets>
  <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">15000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">-15000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
  <nvs:DisposalsFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">3000000</nvs:DisposalsFairValueMeasurementAssets>
  <nvs:ReclassificationFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">10000000</nvs:ReclassificationFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" unitRef="USD" decimals="-6">186000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">143000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">366000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:PurchaseFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">28000000</nvs:PurchaseFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">251000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">12000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">233000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:DisposalsFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">30000000</nvs:DisposalsFairValueMeasurementAssets>
  <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">12000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
  <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">8000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">151000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:ReclassificationFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">31000000</nvs:ReclassificationFairValueMeasurementAssets>
  <nvs:PurchaseFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">17000000</nvs:PurchaseFairValueMeasurementAssets>
  <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">3000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
  <nvs:DisposalsFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FundInvestmentsMember" unitRef="USD" decimals="-6">61000000</nvs:DisposalsFairValueMeasurementAssets>
  <nvs:DisposalsFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">109000000</nvs:DisposalsFairValueMeasurementAssets>
  <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">33000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
  <nvs:PurchaseFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">123000000</nvs:PurchaseFairValueMeasurementAssets>
  <nvs:ReclassificationFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">-163000000</nvs:ReclassificationFairValueMeasurementAssets>
  <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">34000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">39000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">6000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
  <nvs:DisposalsFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">53000000</nvs:DisposalsFairValueMeasurementAssets>
  <nvs:ReclassificationFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">-64000000</nvs:ReclassificationFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">581000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">-6000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
  <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">6000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">488000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:PurchaseFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">229000000</nvs:PurchaseFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">460000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4LongTermFinancialInvestmentsMember" unitRef="USD" decimals="-6">-5000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
  <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">173000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">625000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">-32000000</nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">396000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">35000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">399000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">35000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
  <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">173000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">40000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
  <nvs:PurchaseFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">43000000</nvs:PurchaseFairValueMeasurementAssets>
  <nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationReceivablesMember" unitRef="USD" decimals="-6">-30000000</nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets>
  <nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">63000000</nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets>
  <nvs:PurchaseFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">-123000000</nvs:PurchaseFairValueMeasurementAssets>
  <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">-62000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
  <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">206000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">90000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:ReclassificationFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">-4000000</nvs:ReclassificationFairValueMeasurementAssets>
  <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">106000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">-1036000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">195000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">-907000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">3000000</nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets>
  <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">89000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:PurchaseFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">-401000000</nvs:PurchaseFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">-1046000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4ContingentConsiderationPayablesMember" unitRef="USD" decimals="-6">116000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
  <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">-3000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">-23000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:PurchaseFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">-5000000</nvs:PurchaseFairValueMeasurementAssets>
  <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">48000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">33000000</nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">-10000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">1000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:FinancialInstrumentsCarryingValueLevel3 contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">-29000000</nvs:FinancialInstrumentsCarryingValueLevel3>
  <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">-47000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
  <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">3000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
  <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">-2000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
  <nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets contextRef="AR_D-CurrentYear_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4OtherFinancialLiabilitiesMember" unitRef="USD" decimals="-6">11000000</nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember" unitRef="USD" decimals="-6">25000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">164000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
  <nvs:ContractualInterestOnNoncurrentLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">-468000000</nvs:ContractualInterestOnNoncurrentLiabilities>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">209000000</ifrs-full:LeaseLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">3179000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">17000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities contextRef="AR_D-CurrentYear_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">719000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
  <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets contextRef="AR_D-CurrentYear_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">710000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" unitRef="USD" decimals="-6">4000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">3178000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <nvs:ContingentConsiderationLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">38000000</nvs:ContingentConsiderationLiabilities>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">29000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">3166000000</ifrs-full:NetDebt>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">3195000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">1230000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">1230000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets contextRef="AR_D-CurrentYear-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">922000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
  <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities contextRef="AR_D-CurrentYear-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">952000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">26000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">1256000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:NetDebt contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">1237000000</ifrs-full:NetDebt>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember" unitRef="USD" decimals="-6">16000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" unitRef="USD" decimals="-6">3000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">19000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:ContractualInterestOnNoncurrentLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">-428000000</nvs:ContractualInterestOnNoncurrentLiabilities>
  <nvs:ContingentConsiderationLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">9000000</nvs:ContingentConsiderationLiabilities>
  <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">202000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019MaturityAxis_nvs-2020Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" unitRef="USD" decimals="-6">181000000</ifrs-full:LeaseLiabilities>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember" unitRef="USD" decimals="-6">122000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4MarketableSecuritiesAndTimeDepositsMember" unitRef="USD" decimals="-6">1635000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CommoditiesMember" unitRef="USD" decimals="-6">111000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CommoditiesMember" unitRef="USD" decimals="-6">110000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" unitRef="USD" decimals="-6">102000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" unitRef="USD" decimals="-6">159000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember" unitRef="USD" decimals="-6">9658000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4CashAndCashEquivalentsMember" unitRef="USD" decimals="-6">11112000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">20353000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">6846000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">26259000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtMember" unitRef="USD" decimals="-6">9591000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">9593000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">26463000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">6846000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4FinancialDebtUndiscountedMember" unitRef="USD" decimals="-6">20505000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">185000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <ifrs-full:OtherCurrentFinancialLiabilities contextRef="AR_I-CurrentYearEnd_nvs-2020Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2020Q4DerivativeFinancialInstrumentsMember" unitRef="USD" decimals="-6">194000000</ifrs-full:OtherCurrentFinancialLiabilities>
  <nvs:CashAndCashEquivalentsHeldWithFinancialInstitution contextRef="AR_D-CurrentYear_nvs-2020Q4VendorAxis_nvs-2020Q4LargestFinancialInstitutionMember" unitRef="Pure" decimals="3">0.141</nvs:CashAndCashEquivalentsHeldWithFinancialInstitution>
  <nvs:CashAndCashEquivalentsHeldWithFinancialInstitution contextRef="AR_D-CurrentYear-1_nvs-2020Q4VendorAxis_nvs-2020Q4LargestFinancialInstitutionMember" unitRef="Pure" decimals="3">0.126</nvs:CashAndCashEquivalentsHeldWithFinancialInstitution>
  <nvs:CashAndCashEquivalentsHeldWithFinancialInstitution contextRef="AR_D-CurrentYear_nvs-2020Q4VendorAxis_nvs-2020Q4SecondLargestFinancialInstitutionMember" unitRef="Pure" decimals="3">0.126</nvs:CashAndCashEquivalentsHeldWithFinancialInstitution>
  <nvs:CashAndCashEquivalentsHeldWithFinancialInstitution contextRef="AR_D-CurrentYear-1_nvs-2020Q4VendorAxis_nvs-2020Q4SecondLargestFinancialInstitutionMember" unitRef="Pure" decimals="3">0.104</nvs:CashAndCashEquivalentsHeldWithFinancialInstitution>
  <nvs:CashAndCashEquivalentsHeldWithFinancialInstitution contextRef="AR_D-CurrentYear_nvs-2020Q4VendorAxis_nvs-2020Q4ThirdLargestFinancialInstitutionMember" unitRef="Pure" decimals="3">0.097</nvs:CashAndCashEquivalentsHeldWithFinancialInstitution>
  <nvs:CashAndCashEquivalentsHeldWithFinancialInstitution contextRef="AR_D-CurrentYear-1_nvs-2020Q4VendorAxis_nvs-2020Q4ThirdLargestFinancialInstitutionMember" unitRef="Pure" decimals="3">0.083</nvs:CashAndCashEquivalentsHeldWithFinancialInstitution>
  <nvs:BorrowingsCommercialPaperNumberOfPrograms contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4USCommercialPaperProgramsMember" unitRef="Pure" decimals="0">2</nvs:BorrowingsCommercialPaperNumberOfPrograms>
  <nvs:BorrowingsCommercialPaperMaximumBorrowingAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4USCommercialPaperProgramsMember" unitRef="USD" decimals="-9">9000000000</nvs:BorrowingsCommercialPaperMaximumBorrowingAmount>
  <nvs:BorrowingsCommercialPaperMaximumBorrowingAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4JPCommercialPaperProgramsMember" unitRef="JPY" decimals="-9">150000000000</nvs:BorrowingsCommercialPaperMaximumBorrowingAmount>
  <nvs:BorrowingsCommercialPaperMaximumBorrowingAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4JPCommercialPaperProgramsMember" unitRef="USD" decimals="-8">1500000000</nvs:BorrowingsCommercialPaperMaximumBorrowingAmount>
  <nvs:BorrowingsCommercialPaperNumberOfPrograms contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4JPCommercialPaperProgramsMember" unitRef="Pure" decimals="0">1</nvs:BorrowingsCommercialPaperNumberOfPrograms>
  <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="AR_I-CurrentYearEnd_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">71000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
  <nvs:FairValueOfOtherFinancialAssetsSold contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">331000000</nvs:FairValueOfOtherFinancialAssetsSold>
  <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">382000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
  <nvs:FairValueOfOtherFinancialAssetsSold contextRef="AR_D-CurrentYear-1_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4AlconMember" unitRef="USD" decimals="-6">976000000</nvs:FairValueOfOtherFinancialAssetsSold>
  <ifrs-full:PropertyPlantAndEquipment contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" unitRef="USD" decimals="-6">-101000000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:OtherReserves contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" unitRef="USD" decimals="-6">3000000</ifrs-full:OtherReserves>
  <ifrs-full:CurrentLeaseLiabilities contextRef="AR_I-CurrentYearStart-1_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" unitRef="USD" decimals="-6">268000000</ifrs-full:CurrentLeaseLiabilities>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-466000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">145000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-5773000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-5064000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-359000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:FairValueAdjustmentsRelatedToDivestments contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-30000000</nvs:FairValueAdjustmentsRelatedToDivestments>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-5919000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">145000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <nvs:FairValueAdjustmentsRelatedToDivestments contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">2000000</nvs:FairValueAdjustmentsRelatedToDivestments>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-313000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">69000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-466000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-5423000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-359000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-1000000</nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <nvs:ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4ActuarialLossesFromDefinedBenefitPlansMember" unitRef="USD" decimals="-6">-358000000</nvs:ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">95000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">744000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">44000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">3193000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">0</nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement>
  <nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">129000000</nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement>
  <nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">-946000000</nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">1142000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">320000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">354000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">415000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">329000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">4134000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">2992000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">398000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4CumulativeCurrencyTranslationEffectsMember" unitRef="USD" decimals="-6">-201000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-201000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">3193000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-113000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">3387000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-1419000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-1419000000</ifrs-full:Equity>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-149000000</ifrs-full:ChangesInEquity>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-4517000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">95000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">81000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">44000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">354000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">320000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-4657000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-92000000</ifrs-full:ChangesInEquity>
  <nvs:FairValueAdjustmentsRelatedToDivestments contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">3000000</nvs:FairValueAdjustmentsRelatedToDivestments>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-4657000000</ifrs-full:Equity>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-150000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">3387000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">81000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">81000000</ifrs-full:OtherComprehensiveIncome>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-16000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-16000000</ifrs-full:ChangesInEquity>
  <ifrs-full:Equity contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-4452000000</ifrs-full:Equity>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-113000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-113000000</ifrs-full:ComprehensiveIncome>
  <nvs:FairValueAdjustmentsOnFinancialAssetsSold contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-95000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
  <nvs:FairValueAdjustmentsRelatedToDivestments contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">2000000</nvs:FairValueAdjustmentsRelatedToDivestments>
  <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-1000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">3387000000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-466000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-4452000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-359000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" unitRef="USD" decimals="-6">-177000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-1000000</nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
  <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">-47000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
  <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">13000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">145000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <nvs:OtherComprehensiveIncomeNetOfTaxDebtSecurities contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">1000000</nvs:OtherComprehensiveIncomeNetOfTaxDebtSecurities>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">1000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">12000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges>
  <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" unitRef="USD" decimals="-6">250000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember_ifrsfull-2019RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2020Q4IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" unitRef="USD" decimals="-6">-177000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:CashFlowFromNetIdentifiableAssets contextRef="AR_D-CurrentYear_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">10173000000</nvs:CashFlowFromNetIdentifiableAssets>
  <ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate contextRef="AR_I-CurrentYearEnd_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">7000000</ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate>
  <nvs:ReceivablesAndPayablesContingentConsiderationNet contextRef="AR_D-CurrentYear_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">98000000</nvs:ReceivablesAndPayablesContingentConsiderationNet>
  <nvs:OtherPaymentsAndDeferredConsiderationNet contextRef="AR_D-CurrentYear_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">62000000</nvs:OtherPaymentsAndDeferredConsiderationNet>
  <nvs:CashFlowFromNetIdentifiableAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">4124000000</nvs:CashFlowFromNetIdentifiableAssets>
  <nvs:CashFlowFromNetIdentifiableAssets contextRef="AR_D-CurrentYear-2_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">13660000000</nvs:CashFlowFromNetIdentifiableAssets>
  <ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">33000000</ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate>
  <nvs:ReceivablesAndPayablesContingentConsiderationNet contextRef="AR_D-CurrentYear-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">242000000</nvs:ReceivablesAndPayablesContingentConsiderationNet>
  <nvs:ReceivablesAndPayablesContingentConsiderationNet contextRef="AR_D-CurrentYear-2_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">-5000000</nvs:ReceivablesAndPayablesContingentConsiderationNet>
  <nvs:OtherPaymentsAndDeferredConsiderationNet contextRef="AR_D-CurrentYear-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">-2000000</nvs:OtherPaymentsAndDeferredConsiderationNet>
  <nvs:OtherPaymentsAndDeferredConsiderationNet contextRef="AR_D-CurrentYear-2_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">-36000000</nvs:OtherPaymentsAndDeferredConsiderationNet>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">-10006000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">-3851000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4AcquisitionsMember" unitRef="USD" decimals="-6">-13701000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember" unitRef="USD" decimals="-6">91000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember" unitRef="USD" decimals="-6">18000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember" unitRef="USD" decimals="-6">49000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
  <ifrs-full:LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013 contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4CurrentLiabilitiesMember_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember" unitRef="USD" decimals="-6">41000000</ifrs-full:LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013>
  <ifrs-full:ConsiderationPaidReceived contextRef="AR_D-CurrentYear-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember" unitRef="USD" decimals="-6">95000000</ifrs-full:ConsiderationPaidReceived>
  <nvs:NetCashOutflowsFromDivestments contextRef="AR_D-CurrentYear-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember" unitRef="USD" decimals="-6">4000000</nvs:NetCashOutflowsFromDivestments>
  <ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember" unitRef="USD" decimals="-6">196000000</ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
  <nvs:CurrentAssetsDivested contextRef="AR_D-CurrentYear-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember" unitRef="USD" decimals="-6">96000000</nvs:CurrentAssetsDivested>
  <ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013 contextRef="AR_D-CurrentYear-1_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember" unitRef="USD" decimals="-6">11000000</ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013>
  <ifrs-full:LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013 contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentLiabilitiesMember_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember" unitRef="USD" decimals="-6">18000000</ifrs-full:LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013>
  <ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4NoncurrentAssetsMember_nvs-2020Q4AcquisitionsAndDivestmentsAxis_nvs-2020Q4DivestmentsMember" unitRef="USD" decimals="-6">159000000</ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
  <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="AR_I-CurrentYearEnd_ifrsfull-2019InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2020Q4ListedEquitySecuritiesMember" unitRef="USD" decimals="-6">862000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
  <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2020Q4ListedEquitySecuritiesMember" unitRef="USD" decimals="-6">843000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
  <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2020Q4NonlistedEquitySecuritiesMember" unitRef="USD" decimals="-6">315000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
  <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="AR_I-CurrentYearEnd_ifrsfull-2019InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2020Q4NonlistedEquitySecuritiesMember" unitRef="USD" decimals="-6">249000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
  <ifrs-full:PercentageOfEntitysRevenue contextRef="AR_D-CurrentYear_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4LargestCustomerMember" unitRef="Pure" decimals="2">0.17</ifrs-full:PercentageOfEntitysRevenue>
  <ifrs-full:PercentageOfEntitysRevenue contextRef="AR_D-CurrentYear-1_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4LargestCustomerMember" unitRef="Pure" decimals="2">0.18</ifrs-full:PercentageOfEntitysRevenue>
  <ifrs-full:PercentageOfEntitysRevenue contextRef="AR_D-CurrentYear-2_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4LargestCustomerMember" unitRef="Pure" decimals="2">0.18</ifrs-full:PercentageOfEntitysRevenue>
  <nvs:PercentageOfEntitysTradeReceivable contextRef="AR_D-CurrentYear_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4LargestCustomerMember" unitRef="Pure" decimals="2">0.14</nvs:PercentageOfEntitysTradeReceivable>
  <nvs:PercentageOfEntitysTradeReceivable contextRef="AR_D-CurrentYear-1_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4LargestCustomerMember" unitRef="Pure" decimals="2">0.14</nvs:PercentageOfEntitysTradeReceivable>
  <ifrs-full:PercentageOfEntitysRevenue contextRef="AR_D-CurrentYear_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4SecondLargestCustomerMember" unitRef="Pure" decimals="2">0.11</ifrs-full:PercentageOfEntitysRevenue>
  <ifrs-full:PercentageOfEntitysRevenue contextRef="AR_D-CurrentYear-1_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4SecondLargestCustomerMember" unitRef="Pure" decimals="2">0.13</ifrs-full:PercentageOfEntitysRevenue>
  <ifrs-full:PercentageOfEntitysRevenue contextRef="AR_D-CurrentYear-2_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4SecondLargestCustomerMember" unitRef="Pure" decimals="2">0.14</ifrs-full:PercentageOfEntitysRevenue>
  <nvs:PercentageOfEntitysTradeReceivable contextRef="AR_D-CurrentYear_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4SecondLargestCustomerMember" unitRef="Pure" decimals="2">0.12</nvs:PercentageOfEntitysTradeReceivable>
  <nvs:PercentageOfEntitysTradeReceivable contextRef="AR_D-CurrentYear-1_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4SecondLargestCustomerMember" unitRef="Pure" decimals="2">0.12</nvs:PercentageOfEntitysTradeReceivable>
  <ifrs-full:PercentageOfEntitysRevenue contextRef="AR_D-CurrentYear_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4ThirdLargestCustomerMember" unitRef="Pure" decimals="2">0.06</ifrs-full:PercentageOfEntitysRevenue>
  <ifrs-full:PercentageOfEntitysRevenue contextRef="AR_D-CurrentYear-1_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4ThirdLargestCustomerMember" unitRef="Pure" decimals="2">0.08</ifrs-full:PercentageOfEntitysRevenue>
  <ifrs-full:PercentageOfEntitysRevenue contextRef="AR_D-CurrentYear-2_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4ThirdLargestCustomerMember" unitRef="Pure" decimals="2">0.08</ifrs-full:PercentageOfEntitysRevenue>
  <nvs:PercentageOfEntitysTradeReceivable contextRef="AR_D-CurrentYear_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4ThirdLargestCustomerMember" unitRef="Pure" decimals="2">0.06</nvs:PercentageOfEntitysTradeReceivable>
  <nvs:PercentageOfEntitysTradeReceivable contextRef="AR_D-CurrentYear-1_ifrsfull-2019MajorCustomersAxis_nvs-2020Q4ThirdLargestCustomerMember" unitRef="Pure" decimals="2">0.07</nvs:PercentageOfEntitysTradeReceivable>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd-3_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">1590000000</ifrs-full:CurrentRefundsProvision>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">4158000000</ifrs-full:ProvisionUsedOtherProvisions>
  <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">-90000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">4541000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">1883000000</ifrs-full:CurrentRefundsProvision>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">5183000000</ifrs-full:ProvisionUsedOtherProvisions>
  <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">-193000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">5474000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">1981000000</ifrs-full:CurrentRefundsProvision>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">5560000000</ifrs-full:ProvisionUsedOtherProvisions>
  <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">-107000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">5739000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4USspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">2053000000</ifrs-full:CurrentRefundsProvision>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">1769000000</ifrs-full:CurrentRefundsProvision>
  <nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">167000000</nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">2597000000</ifrs-full:ProvisionUsedOtherProvisions>
  <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">7000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">2940000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <nvs:ChangesInOffsetAgainstGrossTradeReceivables contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">14000000</nvs:ChangesInOffsetAgainstGrossTradeReceivables>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">2272000000</ifrs-full:CurrentRefundsProvision>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">1625000000</ifrs-full:CurrentRefundsProvision>
  <nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">-19000000</nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">2467000000</ifrs-full:ProvisionUsedOtherProvisions>
  <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">-2000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">2659000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <nvs:ChangesInOffsetAgainstGrossTradeReceivables contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">-1000000</nvs:ChangesInOffsetAgainstGrossTradeReceivables>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd-3_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">1356000000</ifrs-full:CurrentRefundsProvision>
  <nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">-78000000</nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">2182000000</ifrs-full:ProvisionUsedOtherProvisions>
  <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">83000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">2555000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <nvs:ChangesInOffsetAgainstGrossTradeReceivables contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonUSspecificHealthcarePlansAndProgramRebatesMember" unitRef="USD" decimals="-6">109000000</nvs:ChangesInOffsetAgainstGrossTradeReceivables>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd-3_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">1726000000</ifrs-full:CurrentRefundsProvision>
  <nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">-51000000</nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">12227000000</ifrs-full:ProvisionUsedOtherProvisions>
  <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">-91000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">11956000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <nvs:ChangesInOffsetAgainstGrossTradeReceivables contextRef="AR_D-CurrentYear-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">-441000000</nvs:ChangesInOffsetAgainstGrossTradeReceivables>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd-2_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">1754000000</ifrs-full:CurrentRefundsProvision>
  <nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">9000000</nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">11698000000</ifrs-full:ProvisionUsedOtherProvisions>
  <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">-25000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">11868000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <nvs:ChangesInOffsetAgainstGrossTradeReceivables contextRef="AR_D-CurrentYear-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">-103000000</nvs:ChangesInOffsetAgainstGrossTradeReceivables>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">1845000000</ifrs-full:CurrentRefundsProvision>
  <nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">67000000</nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
  <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">11137000000</ifrs-full:ProvisionUsedOtherProvisions>
  <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">-51000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
  <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">11094000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
  <nvs:ChangesInOffsetAgainstGrossTradeReceivables contextRef="AR_D-CurrentYear_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">-113000000</nvs:ChangesInOffsetAgainstGrossTradeReceivables>
  <ifrs-full:CurrentRefundsProvision contextRef="AR_I-CurrentYearEnd_nvs-2020Q4PlansAndProgramRebatesAxis_nvs-2020Q4NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" unitRef="USD" decimals="-6">1931000000</ifrs-full:CurrentRefundsProvision>
  <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4NegativeFairValuesMember" unitRef="USD" decimals="-6">-110000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
  <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4NegativeFairValuesMember" unitRef="USD" decimals="-6">-75000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
  <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember" unitRef="USD" decimals="-6">9000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
  <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4PositiveFairValuesMember" unitRef="USD" decimals="-6">6000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
  <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember" unitRef="USD" decimals="-6">269000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
  <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4PositiveFairValuesMember" unitRef="USD" decimals="-6">96000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
  <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember" unitRef="USD" decimals="-6">10779000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
  <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract contextRef="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember" unitRef="USD" decimals="-6">11000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
  <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities contextRef="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember" unitRef="USD" decimals="-6">70000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
  <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts contextRef="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember" unitRef="USD" decimals="-6">13679000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
  <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts contextRef="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019EUR" unitRef="USD" decimals="-6">2432000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
  <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts contextRef="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019USD" unitRef="USD" decimals="-6">6376000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
  <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts contextRef="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember" unitRef="USD" decimals="-6">4871000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
  <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019USD" unitRef="USD" decimals="-6">9000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
  <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019USD" unitRef="USD" decimals="-6">250000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
  <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember" unitRef="USD" decimals="-6">19000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
  <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract contextRef="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019USD" unitRef="USD" decimals="-6">11000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
  <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities contextRef="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019USD" unitRef="USD" decimals="-6">70000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
  <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019EUR" unitRef="USD" decimals="-6">1373000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
  <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019USD" unitRef="USD" decimals="-6">7760000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
  <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember" unitRef="USD" decimals="-6">1646000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
  <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts contextRef="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4PositiveFairValuesMember" unitRef="USD" decimals="-6">151000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
  <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts contextRef="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4NegativeFairValuesMember" unitRef="USD" decimals="-6">-165000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
  <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract contextRef="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4PositiveFairValuesMember" unitRef="USD" decimals="-6">8000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
  <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities contextRef="AR_I-CurrentYearEnd_nvs-2020Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2020Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4NegativeFairValuesMember" unitRef="USD" decimals="-6">-29000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
  <nvs:DerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember" unitRef="USD" decimals="-6">4871000000</nvs:DerivativeFinancialInstruments>
  <nvs:DerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019EUR" unitRef="USD" decimals="-6">2432000000</nvs:DerivativeFinancialInstruments>
  <nvs:DerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019USD" unitRef="USD" decimals="-6">6457000000</nvs:DerivativeFinancialInstruments>
  <nvs:DerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019EUR" unitRef="USD" decimals="-6">1373000000</nvs:DerivativeFinancialInstruments>
  <nvs:DerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_currency-2019USD" unitRef="USD" decimals="-6">8019000000</nvs:DerivativeFinancialInstruments>
  <nvs:DerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember" unitRef="USD" decimals="-6">1665000000</nvs:DerivativeFinancialInstruments>
  <nvs:DerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember" unitRef="USD" decimals="-6">13760000000</nvs:DerivativeFinancialInstruments>
  <nvs:DerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4ContractOrUnderlyingPrincipalAmoutMember" unitRef="USD" decimals="-6">11057000000</nvs:DerivativeFinancialInstruments>
  <nvs:DerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4PositiveFairValuesMember" unitRef="USD" decimals="-6">159000000</nvs:DerivativeFinancialInstruments>
  <nvs:DerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4PositiveFairValuesMember" unitRef="USD" decimals="-6">102000000</nvs:DerivativeFinancialInstruments>
  <nvs:DerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4NegativeFairValuesMember" unitRef="USD" decimals="-6">-194000000</nvs:DerivativeFinancialInstruments>
  <nvs:DerivativeFinancialInstruments contextRef="AR_I-CurrentYearEnd-1_nvs-2020Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2020Q4NegativeFairValuesMember" unitRef="USD" decimals="-6">-185000000</nvs:DerivativeFinancialInstruments>
  <ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare contextRef="AR_D-CurrentYear_nvs-2020Q4SubsequentEventTypAxis_nvs-2020Q4SubsequentEventMember" unitRef="CHFPerShares" decimals="2">3.00</ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare>
  <nvs:EstimatedAcquisitionFairValueOfTotalConsideration contextRef="AR_I-CurrentYearEnd_nvs-2020Q4SubsequentEventTypAxis_nvs-2020Q4SubsequentEventMember" unitRef="USD" decimals="-6">235000000</nvs:EstimatedAcquisitionFairValueOfTotalConsideration>
  <nvs:ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4ImpactLocationAxis_nvs-2020Q4IncomeStatementMember" unitRef="USD" decimals="-6">-234000000</nvs:ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset>
  <nvs:ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_nvs-2020Q4ImpactLocationAxis_nvs-2020Q4IncomeStatementMember" unitRef="USD" decimals="-6">-234000000</nvs:ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <nvs:ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear-1_nvs-2020Q4ImpactLocationAxis_ifrsfull-2019EquityMember" unitRef="USD" decimals="-6">358000000</nvs:ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <nvs:ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1_nvs-2020Q4ImpactLocationAxis_ifrsfull-2019EquityMember" unitRef="USD" decimals="-6">358000000</nvs:ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">291000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">1078000000</nvs:GrossDeferredTaxAssets>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">-313000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">-787000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">-915000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">308000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">273000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">1188000000</nvs:GrossDeferredTaxAssets>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">-3000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">340000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">1137000000</nvs:GrossDeferredTaxAssets>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">-38000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">-25000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" unitRef="USD" decimals="-6">-797000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">-2343000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">212000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">25000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">3000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">2502000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">159000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">3722000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">474000000</nvs:GrossDeferredTaxLiabilities>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">-818000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">23000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">-3248000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">-2159000000</ifrs-full:DeferredTaxLiabilityAsset>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">2446000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4InventoriesMember" unitRef="USD" decimals="-6">287000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">7000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">255000000</nvs:GrossDeferredTaxAssets>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">-248000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">-273000000</ifrs-full:DeferredTaxLiabilityAsset>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">-31000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">-21000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">-113000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">75000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">273000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">10000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">507000000</nvs:GrossDeferredTaxAssets>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">-408000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">-5000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">-164000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4TaxLossCarryforwardsMember" unitRef="USD" decimals="-6">-497000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">-1314000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">71000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">35000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">-34000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">9000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">2658000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">1344000000</nvs:GrossDeferredTaxLiabilities>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">-36000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">2175000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">805000000</nvs:GrossDeferredTaxLiabilities>
  <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">-166000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
  <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">298000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
  <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">26000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
  <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">12000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">-1370000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">-1271000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">24000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <nvs:GrossDeferredTaxAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">2596000000</nvs:GrossDeferredTaxAssets>
  <nvs:GrossDeferredTaxLiabilities contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019AssetsAndLiabilitiesAxis_nvs-2020Q4OtherAssetsProvisionsAccrualsMember" unitRef="USD" decimals="-6">1325000000</nvs:GrossDeferredTaxLiabilities>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember" unitRef="Pure" decimals="2">0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember" unitRef="Pure" decimals="2">0.22</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember" unitRef="USD" decimals="-6">2209000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember" unitRef="Pure" decimals="2">0.03</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember" unitRef="USD" decimals="-6">9799000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember" unitRef="USD" decimals="-6">9460000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember" unitRef="USD" decimals="-6">10219000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember" unitRef="Pure" decimals="2">0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember" unitRef="USD" decimals="-6">2190000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4AsiaAfricaAustralasiaMember" unitRef="Pure" decimals="2">0.02</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember" unitRef="USD" decimals="-6">3241000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember" unitRef="USD" decimals="-6">3433000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4CanadaAndLatinAmericaMember" unitRef="USD" decimals="-6">3414000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember" unitRef="USD" decimals="-6">36732000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember" unitRef="USD" decimals="-6">35684000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EstablishedMarketsMember" unitRef="USD" decimals="-6">33491000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember" unitRef="USD" decimals="-6">11927000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember" unitRef="USD" decimals="-6">11761000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_nvs-2020Q4EmergingGrowthMarketsMember" unitRef="USD" decimals="-6">11260000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember" unitRef="USD" decimals="-6">218000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember" unitRef="USD" decimals="-6">25000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember" unitRef="USD" decimals="-6">227000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember" unitRef="USD" decimals="-6">-45000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:FairValueAdjustmentsRelatedToDivestments contextRef="AR_D-CurrentYear-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember" unitRef="USD" decimals="-6">33000000</nvs:FairValueAdjustmentsRelatedToDivestments>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember" unitRef="USD" decimals="-6">120000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome contextRef="AR_D-CurrentYear_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember" unitRef="USD" decimals="-6">250000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
  <nvs:ValueAdjustmentOnComprehensiveIncome contextRef="AR_I-CurrentYearEnd_ifrsfull-2019ComponentsOfEquityAxis_nvs-2020Q4FairValueAdjustmentsOnFinancialInstrumentsMember" unitRef="USD" decimals="-6">220000000</nvs:ValueAdjustmentOnComprehensiveIncome>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" unitRef="USD" decimals="-6">1000000000</ifrs-full:NotionalAmount>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" unitRef="Pure" decimals="5">0.01750</ifrs-full:BorrowingsInterestRate>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" unitRef="Pure" decimals="5">0.99852</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" unitRef="USD" decimals="-6">996000000</ifrs-full:BondsIssued>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" unitRef="USD" decimals="-6">1250000000</ifrs-full:NotionalAmount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" unitRef="USD" decimals="-6">1245000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" unitRef="Pure" decimals="5">0.02000</ifrs-full:BorrowingsInterestRate>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" unitRef="Pure" decimals="5">0.99909</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" unitRef="USD" decimals="-6">1500000000</ifrs-full:NotionalAmount>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" unitRef="Pure" decimals="5">0.02200</ifrs-full:BorrowingsInterestRate>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" unitRef="Pure" decimals="5">0.99869</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" unitRef="USD" decimals="-6">1493000000</ifrs-full:BondsIssued>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" unitRef="USD" decimals="-6">1250000000</ifrs-full:NotionalAmount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" unitRef="USD" decimals="-6">1213000000</ifrs-full:BondsIssued>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" unitRef="Pure" decimals="5">0.02750</ifrs-full:BorrowingsInterestRate>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" unitRef="Pure" decimals="5">0.97712</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BorrowingsInterestRate contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" unitRef="Pure" decimals="5">0.00000</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:NotionalAmount contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" unitRef="EUR" decimals="-6">1850000000</ifrs-full:NotionalAmount>
  <nvs:BorrowingsPremiumDiscount contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" unitRef="Pure" decimals="5">0.99354</nvs:BorrowingsPremiumDiscount>
  <ifrs-full:BondsIssued contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" unitRef="USD" decimals="-6">2255000000</ifrs-full:BondsIssued>
  <nvs:BorrowingsInterestRateStepUp contextRef="AR_I-CurrentYearEnd_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" unitRef="Pure" decimals="4">0.0025</nvs:BorrowingsInterestRateStepUp>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4NotSubjectToExpiryMember" unitRef="USD" decimals="-6">1006000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1_nvs-2020Q4YearOfExpiryAxis_nvs-2020Q4NotSubjectToExpiryMember" unitRef="USD" decimals="-6">345000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN" unitRef="USD" decimals="-6">2573000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN" unitRef="USD" decimals="-6">2214000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN" unitRef="Pure" decimals="2">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN" unitRef="USD" decimals="-6">1953000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN" unitRef="Pure" decimals="2">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN" unitRef="USD" decimals="-6">714000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN" unitRef="Pure" decimals="2">0.01</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN" unitRef="USD" decimals="-6">684000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_country-2017-2Q17CN" unitRef="Pure" decimals="2">0.01</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_srt-2020CurrencyAxis_currency-2019USD" unitRef="USD" decimals="-6">15848000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_srt-2020CurrencyAxis_currency-2019USD" unitRef="USD" decimals="-6">12889000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_srt-2020CurrencyAxis_currency-2019EUR" unitRef="USD" decimals="-6">10888000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_srt-2020CurrencyAxis_currency-2019EUR" unitRef="USD" decimals="-6">7861000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_srt-2020CurrencyAxis_currency-2019JPY" unitRef="USD" decimals="-6">194000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_srt-2020CurrencyAxis_currency-2019JPY" unitRef="USD" decimals="-6">184000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_srt-2020CurrencyAxis_currency-2019CHF" unitRef="USD" decimals="-6">1563000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd-1_srt-2020CurrencyAxis_currency-2019CHF" unitRef="USD" decimals="-6">1421000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="AR_I-CurrentYearEnd_srt-2020CurrencyAxis_nvs-2020Q4CurrencyOthersMember" unitRef="USD" decimals="-6">38000000</ifrs-full:Borrowings>
  <nvs:CashInflowForSaleAndLeaseback contextRef="AR_D-CurrentYear-1_srt-2020RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2020Q4SaleAndLeaseBackMember" unitRef="USD" decimals="-8">-700000000</nvs:CashInflowForSaleAndLeaseback>
  <ifrs-full:LeaseLiabilities contextRef="AR_I-CurrentYearEnd-1_srt-2020RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2020Q4SaleAndLeaseBackMember" unitRef="USD" decimals="-6">96000000</ifrs-full:LeaseLiabilities>
  <ifrs-full:RightofuseAssets contextRef="AR_I-CurrentYearEnd-1_srt-2020RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2020Q4SaleAndLeaseBackMember" unitRef="USD" decimals="-6">37000000</ifrs-full:RightofuseAssets>
  <ifrs-full:GainsLossesArisingFromSaleAndLeasebackTransactions contextRef="AR_D-CurrentYear-1_srt-2020RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2020Q4SaleAndLeaseBackMember" unitRef="USD" decimals="-6">478000000</ifrs-full:GainsLossesArisingFromSaleAndLeasebackTransactions>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember" unitRef="Pure" decimals="2">0.38</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember" unitRef="Pure" decimals="2">0.38</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember" unitRef="Pure" decimals="2">0.39</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember" unitRef="USD" decimals="-6">47798000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember" unitRef="Pure" decimals="2">0.53</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember" unitRef="USD" decimals="-6">46103000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember" unitRef="Pure" decimals="2">0.59</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember" unitRef="USD" decimals="-6">17259000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember" unitRef="USD" decimals="-6">18715000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020EuropeMember" unitRef="USD" decimals="-6">17933000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember" unitRef="USD" decimals="-6">19725000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember" unitRef="Pure" decimals="2">0.41</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember" unitRef="USD" decimals="-6">19713000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember" unitRef="Pure" decimals="2">0.41</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember" unitRef="USD" decimals="-6">18032000000</nvs:RevenueFromSaleOfGoodsThirdParties>
  <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember" unitRef="Pure" decimals="2">0.39</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember" unitRef="USD" decimals="-6">40391000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember" unitRef="Pure" decimals="2">0.45</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember" unitRef="USD" decimals="-6">29389000000</nvs:SelectedNoncurrentAssets>
  <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2019GeographicalAreasAxis_srt-2020AmericasMember" unitRef="Pure" decimals="2">0.38</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
  <ifrs-full:ProceedsFromSalesOfInterestsInAssociates contextRef="AR_D-Transaction-GSK-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4GSKConsumerHealthcareMember" unitRef="USD" decimals="-6">12855000000</ifrs-full:ProceedsFromSalesOfInterestsInAssociates>
  <ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations contextRef="AR_D-Transaction-GSK-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4GSKConsumerHealthcareMember" unitRef="USD" decimals="-6">12994000000</ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations>
  <nvs:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage contextRef="AR_I-Transaction-GSK-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4GSKConsumerHealthcareMember" unitRef="Pure" decimals="3">0.365</nvs:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
  <nvs:PreTaxProfitLossFromDivestmentOfBusiness contextRef="AR_I-Transaction-GSK-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4GSKConsumerHealthcareMember" unitRef="USD" decimals="-8">5800000000</nvs:PreTaxProfitLossFromDivestmentOfBusiness>
  <nvs:PercentageOfShareCapitalInTenderOffer contextRef="AR_I-Transaction-AAA_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="Pure" decimals="2">1.00</nvs:PercentageOfShareCapitalInTenderOffer>
  <nvs:CashOfferPerOrdinaryShare contextRef="AR_I-Transaction-AAA_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="USD" decimals="0">41</nvs:CashOfferPerOrdinaryShare>
  <nvs:CashOfferPerADS contextRef="AR_I-Transaction-AAA_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="USD" decimals="0">82</nvs:CashOfferPerADS>
  <nvs:NumberOfOrdinarySharePerADS contextRef="AR_I-Transaction-AAA_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="Pure" decimals="0">2</nvs:NumberOfOrdinarySharePerADS>
  <nvs:ValueOfEquity contextRef="AR_I-Transaction-AAA_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="USD" decimals="-8">3900000000</nvs:ValueOfEquity>
  <nvs:PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer contextRef="AR_I-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="Pure" decimals="2">0.97</nvs:PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="USD" decimals="-8">3900000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <nvs:PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer contextRef="AR_I-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="Pure" decimals="3">0.018</nvs:PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer>
  <nvs:ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer contextRef="AR_I-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="USD" decimals="-6">60000000</nvs:ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer>
  <nvs:TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer contextRef="AR_I-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="Pure" decimals="3">0.987</nvs:TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="USD" decimals="-8">1900000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:AdditionalRecognitionGoodwill contextRef="AR_D-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="USD" decimals="-8">2000000000</ifrs-full:AdditionalRecognitionGoodwill>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="USD" decimals="-8">2500000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="USD" decimals="-8">600000000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:RevenueOfAcquiree contextRef="AR_D-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="USD" decimals="-8">400000000</ifrs-full:RevenueOfAcquiree>
  <nvs:RevenueOfAcquireeFullYear contextRef="AR_D-Transaction-AAA-2-2018_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="USD" decimals="-8">400000000</nvs:RevenueOfAcquireeFullYear>
  <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="AR_D-Transaction-AAA-Dec2020_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsAAAMember" unitRef="Pure" decimals="3">0.992</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
  <nvs:CashOfferPerOrdinaryShare contextRef="AR_I-Transaction-Avexis_dei-2020LegalEntityAxis_nvs-2020Q4AveXisIncMember" unitRef="USD" decimals="0">218</nvs:CashOfferPerOrdinaryShare>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-Avexis-2-May_dei-2020LegalEntityAxis_nvs-2020Q4AveXisIncMember" unitRef="USD" decimals="-8">8700000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-Transaction-Avexis-2-May_dei-2020LegalEntityAxis_nvs-2020Q4AveXisIncMember" unitRef="USD" decimals="-8">7200000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:AdditionalRecognitionGoodwill contextRef="AR_D-Transaction-Avexis-2-May_dei-2020LegalEntityAxis_nvs-2020Q4AveXisIncMember" unitRef="USD" decimals="-8">1500000000</ifrs-full:AdditionalRecognitionGoodwill>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-Transaction-Avexis-2-May_dei-2020LegalEntityAxis_nvs-2020Q4AveXisIncMember" unitRef="USD" decimals="-8">8500000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-Transaction-Avexis-2-May_dei-2020LegalEntityAxis_nvs-2020Q4AveXisIncMember" unitRef="USD" decimals="-8">1600000000</ifrs-full:DeferredTaxLiabilityAsset>
  <nvs:OtherNetAssets contextRef="AR_I-Transaction-Avexis-2-May_dei-2020LegalEntityAxis_nvs-2020Q4AveXisIncMember" unitRef="USD" decimals="-8">300000000</nvs:OtherNetAssets>
  <nvs:CashOfferPerOrdinaryShare contextRef="AR_I-Transaction-Endocyte-2-Dec_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteMember" unitRef="USD" decimals="0">24</nvs:CashOfferPerOrdinaryShare>
  <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="AR_D-Transaction-Endocyte-2-Dec_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteMember" unitRef="USD" decimals="-8">2100000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
  <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="AR_I-Transaction-Endocyte-2-Dec_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteMember" unitRef="USD" decimals="-8">2100000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
  <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AR_I-Transaction-Endocyte-2-Dec_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteMember" unitRef="USD" decimals="-8">1500000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AR_I-Transaction-Endocyte-2-Dec_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteMember" unitRef="USD" decimals="-8">1500000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="AR_I-Transaction-Endocyte-2-Dec_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteMember" unitRef="USD" decimals="-8">300000000</ifrs-full:DeferredTaxLiabilityAsset>
  <nvs:OtherNetAssets contextRef="AR_I-Transaction-Endocyte-2-Dec_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteMember" unitRef="USD" decimals="-8">300000000</nvs:OtherNetAssets>
  <ifrs-full:AdditionalRecognitionGoodwill contextRef="AR_D-Transaction-Endocyte-2-Dec_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteMember" unitRef="USD" decimals="-8">600000000</ifrs-full:AdditionalRecognitionGoodwill>
  <nvs:NumberOfContractsWithRelatedParties contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4SparkTherapeuticsInc.Member" unitRef="Pure" decimals="0">1</nvs:NumberOfContractsWithRelatedParties>
  <nvs:CustomersWithNetSalesOverFivePercent contextRef="AR_D-CurrentYear">The Group&#x2019;s largest, second-largest and third-largest customers account for approximately 17%, 11% and 6% of net sales, respectively (2019: 18%, 13% and 8%, respectively; 2018: 18%, 14% and 8%, respectively). All segments had sales to these customers in 2020, 2019 and 2018. The highest amounts of trade receivables outstanding were for these same three customers and amounted to approximately 14%, 12% and 6%, respectively, of the trade receivables at December 31, 2020 (2019: 14%, 12% and 7%, respectively).</nvs:CustomersWithNetSalesOverFivePercent>
  <nvs:ConcentrationOfMajorPlansGeographic contextRef="AR_D-CurrentYear">The major plans are based in Switzerland, the United States, the United Kingdom, Germany and Japan, which represent 95% of the Group&#x2019;s total DBO for pension plans.</nvs:ConcentrationOfMajorPlansGeographic>
  <nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">2028</nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate>
  <nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate contextRef="AR_D-CurrentYear-1_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">2028</nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate>
  <nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate contextRef="AR_D-CurrentYear-2_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">2028</nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member">2010</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member">2020</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">2012</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">2022</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">2012</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">2042</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">2014</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">2024</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">2014</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">2044</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member">2014</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member">2021</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">2014</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">2026</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">CHF</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">2015</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">2025</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">Novartis AG, Basel, Switzerland</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">CHF</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">2015</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">2029</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">Novartis AG, Basel, Switzerland</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">CHF</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">2015</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">2035</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">Novartis AG, Basel, Switzerland</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">2015</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">2025</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">2015</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">2045</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">2016</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">2023</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">2016</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">2028</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member">2017</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member">2020</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">2017</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">2022</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">2017</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">2027</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member">2017</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member">2021</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">2017</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">2027</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">2018</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">2023</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">2018</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">2030</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">2018</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">2038</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
  <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationAnnualIncentivePlanMember">The Annual Incentive for the Novartis Group CEO and other Executive Committee members (ECN) is paid 50% in cash and 50% in Novartis restricted shares (RSs) or restricted share units (RSUs). For the Novartis Top Leaders (NTLs), the Annual Incentive is paid 70% in cash and 30% in RSs or RSUs. Both the ECN and NTLs can opt to invest up to the maximum cash portion of their Annual Incentive to receive further RSs or RSUs. Any cash is paid out during February or March in the year following the end of the performance period, and the shares are granted during January in the year following the end of the performance period.</ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
  <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationShareSavingsPlanMember">Associates in certain countries and certain key executives worldwide are encouraged to invest their Annual Incentive in a share savings plan. Under the share savings plan, participants may elect to receive their relevant compensation fully or partially in Novartis shares in lieu of cash. As a reward for their participation in the share savings plan, at no additional cost to the participant, Novartis matches their investments in shares after a holding period of three or five years.</ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
  <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationEmployeeShareOwnershipPlanMember">In Switzerland, Employee Share Ownership Plan (ESOP) participants may choose to receive their Annual Incentive (i) 100% in shares, (ii) 50% in shares and 50% in cash, or (iii) 100% in cash. After expiration of a three-year holding period for Novartis shares invested under the ESOP, participants will receive one matching share for every two invested shares. Associates eligible for the equity plan &#x201C;Select&#x201D; are not eligible to receive ESOP matching shares starting with the 2017 performance period.</ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
  <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLeveragedShareSavingsPlanMember">The Leveraged Share Savings Plan (LSSP) was available to key executives for performance periods prior to 2016. At the participant&#x2019;s election, the Annual Incentive was awarded partly or entirely in shares. The elected number of shares is subject to a holding period of five years. At the end of the holding period, Novartis will match the invested shares at a ratio of 1-to-1 (i.e., one share awarded for each invested share). In the United States, both the LSSP award and the corresponding match are cash settled.</ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
  <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectMember">The equity plan &#x201C;Select&#x201D; is a global equity incentive plan under which eligible associates may annually be awarded a grant subject to a three-year, and for selected units a four-year, staggered vesting period. No awards are granted for performance ratings below a certain threshold. Executive Committee members and NTLs are not eligible to participate in the equity plan &#x201C;Select&#x201D;. The equity plan &#x201C;Select&#x201D; currently allows participants in Switzerland to choose the form of their equity compensation in RSs or RSUs. In all other jurisdictions, RSs or RSUs are granted unilaterally. Until 2013, participants could also choose to receive part or the entire grant in the form of tradable share options. Tradable share options expire on their 10th anniversary from the grant date. Each tradable share option entitles the holder to purchase after vesting (and before the 10th anniversary from the grant date) one Novartis share at a stated exercise price that equals the closing market price of the underlying share at the grant date. As the exercise price does not reflect the decrease in the Novartis share due to the Alcon spin, one-fifth of an Alcon share will also be awarded to the option holder upon exercise.</ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
  <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermPerformancePlanMember">The Long-Term Performance Plan (LTPP) is an equity plan for the ECN, the NTLs and employees of Group units with specific targets. Participants are granted a target number of performance share units (PSUs) at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. The actual payout depends on the achievement of the performance measures and ranges between 0% and 200% of the granted amount. PSUs granted under the LTPP do not carry voting rights, but do carry dividend equivalents that are paid in unrestricted Novartis shares at the end of the performance period. The LTPP awards are subject to a three-year performance and vesting period. Until 2018, the performance criteria were based on Novartis internal performance metrics. Starting in 2019, for new grants the performance criteria are based on both Novartis internal performance metrics and variables that can be observed in the market, which is the ranking of the Novartis total shareholder return (TSR) relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. TSR for Novartis and the peer companies is calculated as the change in the company share price, which is translated to USD at the relevant exchange rate, including the reinvestment return of dividends, over the three-year performance period. The calculation is based on Bloomberg standard published TSR data, which is publicly available. The position of Novartis in the peer group determines the payout range based on a payout matrix.</ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
  <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationLongTermRelativePerformancePlanMember">The LTRPP is an equity plan for the Novartis ECN and NTLs. The last grant under this plan was made in 2018. The LTRPP performance criteria are based on variables that can be observed in the market, which is the ranking of the Novartis TSR relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. The TSR for Novartis and the peer companies is calculated as described in the LTPP section above.</ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
  <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationSpecialShareAwardsMember">Selected associates, excluding the ECN members, may exceptionally receive Special Share Awards of RSs or RSUs. These Special Share Awards provide an opportunity to reward outstanding achievements or exceptional performance, and aim to retain key contributors. They are based on a formal internal selection process, through which the individual performance of each candidate is thoroughly assessed at several management levels. Special Share Awards have a minimum three-year vesting period. In exceptional circumstances, Special Share Awards may be awarded to attract special expertise and new talents to the &#xAC;organization. Worldwide, associates at different levels in the organization were awarded RSs and RSUs in 2020, 2019 and 2018. In addition, in 2020, 2019 and 2018, Board members received &#xAC;unrestricted shares as part of their regular compensation.</ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
  <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;1. Significant accounting policies&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Novartis Group (Novartis or Group) is a multinational group of companies specializing in the research, development, manufacturing and marketing of a broad range of innovative pharmaceuticals and cost-saving generic medicines. The Group is headquartered in Basel, Switzerland. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The consolidated financial statements of the Group are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). They are prepared in accordance with the historical cost convention, except for items that are required to be accounted for at fair value. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&amp;#x2019;s financial year-end is December 31, which is also the annual closing date of the individual entities&amp;#x2019; financial statements incorporated into the Group&amp;#x2019;s consolidated financial statements. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The preparation of financial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the year, which affect the reported amounts of revenues, expenses, assets, liabilities and contingent amounts. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Estimates are based on historical experience and other assumptions that are considered reasonable under the given circumstances and are regularly monitored. Actual outcomes and results could differ from those estimates and assumptions. Revisions to estimates are recognized in the period in which the estimate is revised. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;Listed below are accounting policies of significance to Novartis or, in cases where IFRS provides alternatives, the option adopted by Novartis. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Scope of consolidation &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The consolidated financial statements include all entities, including structured entities, over which Novartis AG, Basel, Switzerland, directly or indirectly has control (generally as a result of owning more than 50% of the entity&amp;#x2019;s voting interest). Consolidated entities are also referred to as &amp;#x201c;subsidiaries.&amp;#x201d; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In cases where Novartis does not fully own a subsidiary, it has elected to value any remaining outstanding non-controlling interest at the time of acquiring control of the subsidiary at its proportionate share of the fair value of the net identified assets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The contribution of a business to an associate or joint venture is accounted for by applying the option under IFRS that permits the accounting for the retained interest of the business contributed at its net book value at the time of the contribution. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Investments in associated companies (generally defined as investments in entities in which Novartis holds between 20% and 50% of voting shares or over which it otherwise has significant influence) and joint ventures are accounted for using the equity method, except for selected venture fund investments for which the Group has elected to apply the method of fair value through the consolidated income statement. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Foreign currencies&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The consolidated financial statements of Novartis are presented in US dollars (USD). The functional currency of subsidiaries is generally the local currency of the respective entity. The functional currency used for the reporting of certain Swiss and foreign finance entities is USD instead of their respective local currencies. This reflects the fact that the cash flows and transactions of these entities are primarily denominated in these currencies. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For subsidiaries not operating in hyperinflationary economies, the subsidiary&amp;#x2019;s results, financial position and cash flows that do not have USD as their functional currency are translated into USD using the following exchange rates: &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Income, expense and cash flows using for each month the average exchange rate, with the US dollar values for each month being aggregated during the year &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Balance sheets using year-end exchange rates&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Resulting exchange rate differences are recognized in other comprehensive income&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;For subsidiaries operating in hyperinflationary economies, the impact of the restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period is recorded in retained earnings in equity. The subsequent gains or losses resulting from the restatement of non-monetary assets are recorded in &amp;#x201c;Other financial income and expense&amp;#x201d; in the consolidated income statement. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Non-current assets held for sale or held for distribution to owners&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Non-current assets are accounted for as assets held for sale or related to discontinued operations when their carrying amount is to be recovered principally through a sale transaction or distribution to owners and a sale or distribution to owners is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell with any resulting impairment recognized. Assets related to discontinued operations and assets of disposal group held for sale are not depreciated or amortized. The prior year consolidated balance sheet is not restated. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If in a subsequent period, the criteria for classification as held for sale are no longer met, the recoverable amount of assets and liabilities are reclassified out of assets held for sale into the respective balance sheet lines, prior year consolidated balance sheet is not restated. The cumulative amount of depreciation and amortization not recorded since the date of their classification to assets held for sale, and any required adjustments to the recoverable amounts of assets are recognized in the consolidated income statement. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Distribution of Alcon Inc. to Novartis AG shareholders &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During the first quarter of 2019, at the Annual General Meeting (AGM) of Novartis AG shareholders, held on February 28, 2019, the Novartis AG shareholders approved a special distribution by way of a dividend in kind to effect the spin-off of Alcon Inc. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The February 28, 2019, shareholder approval for the spin-off required the Alcon Division and selected portions of corporate activities attributable to Alcon&amp;#x2019;s business (the &amp;#x201c;Alcon business&amp;#x201d;) to be reported as discontinued operations. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The shareholder approval to spin off the Alcon business also required the recognition of a distribution liability at the fair value of the Alcon business. The Group elected to measure the distribution liability at the fair value of the Alcon business net assets taken as a whole. The distribution liability was recognized through a reduction in retained earnings. It was required to be adjusted at each balance sheet date for changes in its estimated fair value, up to the date of the distribution to shareholders through retained earnings. Any resulting impairment of the business assets to be distributed would have been recognized in the consolidated income statements in &amp;#x201c;Other expense&amp;#x201d; of discontinued operations, at the date of initial recognition of the distribution liability or at subsequent dates resulting from changes of the distribution liability valuation. At the April 8, 2019 distribution settlement date, the resulting gain, which was measured as the excess amount of the distribution liability over the then-carrying value of the net assets of the business distributed, was recognized on the line &amp;#x201c;Gain on distribution of Alcon Inc. to Novartis AG shareholders&amp;#x201d; in the income statement of discontinued operations. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The recognition of the distribution liability required the use of valuation techniques for purposes of impairment testing of the Alcon business&amp;#x2019; assets to be distributed and for the measurement of the fair value of the distribution liability. These valuations required the use of management assumptions and estimates related to the Alcon business&amp;#x2019; future cash flows, market multiples to estimate day one market value, and control premiums to apply in estimating the Alcon business fair value. These fair value measurements were classified as &amp;#x201c;Level 3&amp;#x201d; in the fair value hierarchy. The section &amp;#x201c;&amp;mdash;Impairment of goodwill and intangible assets&amp;#x201d; in this Note 1 provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Transaction costs that were directly attributable to the distribution (spin-off) of Alcon to the Novartis shareholders, and that would otherwise have been avoided, were recorded as a deduction from equity. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For additional disclosures, refer to &amp;#x201c;Note 2. Significant transactions&amp;mdash;Significant transactions in 2019&amp;mdash;Completion of the spin-off of the Alcon business through a dividend in kind distribution to Novartis AG shareholders,&amp;#x201d; and &amp;#x201c;Note 30. Discontinued operations.&amp;#x201d; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Acquisition of assets and businesses&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Assets separately acquired are recorded at cost, which includes the purchase price and any directly attributable costs for bringing the asset into the condition to operate as intended. Expected costs for obligations to dismantle and remove property, plant and equipment when they are no longer used are included in their cost. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Acquired businesses are accounted for using the acquisition method, unless the optional concentration test is applied. The optional concentration test allows for the election on a transaction-by-transaction basis to account for the acquired business as an asset separately acquired when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The acquisition method requires that the assets acquired and liabilities assumed be recorded at their respective fair values on the date the Group obtains control. The excess of the fair value of the total purchase consideration transferred and the fair value of the acquired assets and assumed liabilities is recognized as goodwill. The related valuations are based on information available at the acquisition date. Acquisition related costs are expensed as incurred. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The application of the acquisition method requires certain estimates and assumptions to be made, especially concerning the fair values of the acquired intangible assets, inventories, property, plant and equipment and the liabilities assumed at the acquisition date, and the useful lives of the intangible assets and property, plant and equipment. Estimates of fair value require the use of valuation techniques. These valuations require the use of management assumptions and estimates, including value of comparable assets in the market, amount and timing of future cash flows, outcomes and costs of research and development activities, probability of obtaining regulatory approval, long-term sales forecasts, actions of competitors, discount rates and terminal growth rates. The section &amp;#x201c;&amp;mdash;Impairment of goodwill and intangible assets&amp;#x201d; in this Note 1 provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Property, plant and equipment&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Property, plant and equipment are depreciated on a straight-line basis in the consolidated income statement over their estimated useful lives. Freehold land is not depreciated. The related depreciation expense is included in the costs of the functions using the asset. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Property, plant and equipment are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the respective useful lives for property, plant and equipment:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Useful life&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Buildings&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20 to 40 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and other equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7 to 20 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Furniture and vehicles&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5 to 10 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Computer hardware&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3 to 7 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Government grants obtained for construction activities, including any related equipment, are deducted from the gross acquisition cost to arrive at the balance sheet carrying value of the related assets. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Leases and right-of-use assets&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;From January 1, 2019, with the adoption of IFRS 16 Leases, the Group adopted the following accounting policies for leases and right-of-use assets: &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;As lessee, the Group assesses whether a contract contains a lease at inception of a contract and upon the modification of a contract. The Group elected to allocate the consideration in the contract to the lease and non-lease components on the basis of the relative standalone price. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a lessee, except for leases with a term of 12 months or less (short-term leases) and low-value leases. For these short-term and low-value leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease to the end of the lease term. The lease term includes the period of any lease extension that in management&amp;#x2019;s assessment is highly probable to be exercised by the Group. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the Novartis incremental borrowing rate for the asset subject to the lease in the respective markets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever there is a change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The portion of the lease payments attributable to the repayment of lease liabilities is recognized in cash flows used in financing activities, and the portion attributable to the payment of interest is included in cash flows from operating activities. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Right-of-use assets are initially recognized on the balance sheet at cost, which comprises the amount of the initial measurement of the corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease incentive received and any initial direct costs incurred by Novartis, and expected costs for obligations to dismantle and remove right-of-use assets when they are no longer used. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease over the shorter of the useful life of the right-of-use asset or the end of the lease term. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In arrangements where the Group is the lessor, it determines at lease inception whether the lease is a finance lease or an operating lease. Leases that transfer substantially all of the risk and rewards incidental to ownership of the underlying asset to the counterparty (the lessee) are accounted for as finance leases. Leases that do not transfer substantially all of the risks and rewards of ownership are accounted for as operating leases. Lease payments received under operating leases are recognized on a straight-line basis over the lease term in the consolidated income statement in either &amp;#x201c;net sales&amp;#x201d; or &amp;#x201c;other income,&amp;#x201d; depending on the nature of and underlying asset to the lease arrangement. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;Prior to January 1, 2019, the Group applied the following accounting policies for leases: &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Leases that transferred substantially all of the risks and rewards of ownership were recognized as finance leases, with the leased asset measured initially at an amount equal to the lower of their fair value and the present value of the minimum lease payments. Minimum lease payments were the payments over the lease term that the Group, as leasee, was required to make, excluding contingent rent. The underlying asset was accounted for in accordance with the accounting policy applicable to that asset. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Leases that did not transfer substantially all of the risks and rewards of ownership were accounted for as operating leases and were not recognized in the consolidated balance sheet. Payments made under operating leases were recognized in the consolidated income statement on a straight-line basis over the term of the lease. Lease incentives received were deferred and recognized as a component of lease expense over the term of the lease. The future undiscounted lease payments under operating leases were disclosed as commitments in the notes to the consolidated financial statements. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Lessor accounting policies were not substantially different from those applied upon the adoption of IFRS 16 Leases, as described above. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;The section &amp;#x201c;&amp;mdash;Impact of adopting significant new IFRS standards in 2019&amp;#x201d; in this Note 1 provides additional disclosures on the impact of adoption of IFRS 16 Leases. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Goodwill and intangible assets&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Goodwill&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Goodwill arises in the acquisition of a business when applying the acquisition method and is the excess of the fair value of the consideration transferred to acquire a business over the underlying fair value of the net identified assets acquired. It is allocated to groups of cash-generating units (CGUs), which are usually represented by the reported segments. Goodwill is tested for impairment annually at the level of these groups of CGUs, and any impairment charges are recorded under &amp;#x201c;Other expense&amp;#x201d; in the consolidated income statement. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Intangible assets available for use&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has the following classes of available for use intangible assets: currently marketed products; technologies; other intangible assets (including computer software). &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Currently marketed products represent the composite value of acquired intellectual property (IP), patents, distribution rights and product trade names. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Technologies represent identified and separable acquired know-how used in the research, development and production processes. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Significant investments in internally developed and acquired computer software are capitalized and included in the &amp;#x201c;Other&amp;#x201d; category, and amortized once available for use. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Intangible assets available for use with a definite useful life are amortized over their estimated useful lives on a straight-line basis and are evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the respective useful lives for intangible assets available for use and the location in the consolidated income statement in which the respective amortization and any potential impairment charge is recognized: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Useful life &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Income statement location &lt;br&gt;&lt;/br&gt; for amortization and &lt;br&gt;&lt;/br&gt; impairment charges &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currently marketed products&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5 to 20 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold"&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Technologies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10 to 20 years &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold" &lt;br&gt;&lt;/br&gt; or "Research &lt;br&gt;&lt;/br&gt; and development" &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other (including &lt;br&gt;&lt;/br&gt;computer software) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3 to 7 years &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; In the respective &lt;br&gt;&lt;/br&gt; functional expense &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Intangible assets not yet available for use&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Acquired research and development intangible assets that are still under development and have accordingly not yet obtained marketing approval are recognized as in-process research and development (IPR&amp;amp;D). &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;IPR&amp;amp;D is not amortized, but is evaluated for potential impairment on an annual basis or when facts and circumstances warrant. Any impairment charge is recorded in the consolidated income statement under &amp;#x201c;Research and development.&amp;#x201d; Once a project included in IPR&amp;amp;D has been successfully developed, it is transferred to the &amp;#x201c;Currently marketed products&amp;#x201d; category. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impairment of goodwill and intangible assets&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;An asset is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value-in-use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or CGUs, and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group&amp;#x2019;s activities with regard to: &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Amount and timing of projected future cash flows&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Long-term sales forecasts &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Actions of competitors (launch of competing products, marketing initiatives, etc.)&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Sales erosion rates after the end of patent or other intellectual property rights protection, and timing of the entry of generic competition &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Outcome of research and development activities (compound efficacy, results of clinical trials, etc.)&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Amount and timing of projected costs to develop IPR&amp;amp;D into commercially viable products&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Profit margins&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Probability of obtaining regulatory approval&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Future tax rate&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Appropriate terminal growth rate&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Appropriate discount rate&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Generally, for intangible assets with a definite useful life, Novartis uses cash flow projections for the whole useful life of these assets. For goodwill, Novartis generally utilizes cash flow projections for a five-year period based on management forecasts, with a terminal value based on cash flow projections usually in line with inflation rates for later periods. Probability-weighted scenarios are typically used. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Discount rates used consider the Group&amp;#x2019;s estimated weighted average cost of capital, adjusted for specific asset, country and currency risks associated with cash flow projections, to approximate the discount rate that market participants would use to value the asset. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Due to the above factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impairment of associated companies accounted for at equity&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis considers investments in associated companies for impairment evaluation whenever objective evidence indicates the net investment may be impaired, including when a quoted share price indicates a fair value less than the per-share balance sheet carrying value for the investment. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If the recoverable amount of the investment is estimated to be lower than the balance sheet carrying amount, an impairment charge is recognized for the difference in the consolidated income statement under &amp;#x201c;Income from associated companies.&amp;#x201d; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Cash and cash equivalents&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Cash and cash equivalents include highly liquid investments with original maturities of three months or less, which are readily convertible to known amounts of cash. Bank overdrafts are usually presented within current financial debts on the consolidated balance sheet, except in cases where a right of offset has been agreed with a bank, which then allows for presentation on a net basis. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Marketable securities, commodities and non-current financial assets &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Commodities, which include gold bullion or coins, are valued at the lower of cost or fair value using current market prices. The changes in fair value below cost are immediately recorded in &amp;#x201c;Other financial income and expense.&amp;#x201d; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Marketable securities are financial assets held for short-term purposes which are principally traded in liquid markets and are classified within current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &amp;#x201c;Other financial income and expense&amp;#x201d; in the consolidated income statement. Non-current financial assets held for long-term strategic purposes are classified within non-current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &amp;#x201c;Other income&amp;#x201d; and &amp;#x201c;Other expense&amp;#x201d; in the consolidated income statement. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Marketable securities and non-current financial assets are initially recorded at fair value on their trade date, which is different from the settlement date when the transaction is ultimately effected. Quoted securities are remeasured at each reporting date to fair value based on current market prices. If the market for a financial asset is not active or no market is available, fair values are established using valuation techniques. The majority of non-quoted investments are valued initially at fair value through the established purchase price between a willing buyer and seller. Non-quoted investments are subsequently adjusted based on values derived from discounted cash flow analysis or other pricing models. These investment values are classified as &amp;#x201c;Level 3&amp;#x201d; in the fair value hierarchy. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group classifies and accounts for its marketable securities and non-current financial assets in the following categories: &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Debt securities are valued at fair value through other comprehensive income with subsequent recycling into the consolidated income statement, as they meet both the &amp;#x201c;solely payment of principal and interest&amp;#x201d; and the business model criteria. Unrealized gains and losses, except exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are recognized in the consolidated income statement when the debt instrument is sold, at which time the gain is transferred to &amp;#x201c;Other financial income and expense.&amp;#x201d; Exchange gains and losses related to debt instruments are immediately recognized in the consolidated income statement to &amp;#x201c;Other financial income and expense.&amp;#x201d; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Fund investments and equity securities of the Novartis venture fund are valued at fair value through profit and loss (FVPL). Unrealized gains and losses, including exchange gains and losses, are recognized in the consolidated income statement to &amp;#x201c;Other income&amp;#x201d; for gains and &amp;#x201c;Other expense&amp;#x201d; for losses. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Equity securities held as strategic investments, typically held outside of the Novartis venture fund, are generally designated at the date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. Unrealized gains and losses, including exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are reclassified to retained earnings when the equity security is sold. If these equity securities are not designated at the date of acquisition as financial assets valued at fair value through other comprehensive income, they are valued at FVPL, as described above. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Other non-current financial assets, such as loans and long-term receivables from customers, advances and other deposits, are valued at amortized cost, which reflects the time value of money less any allowances for expected credit losses. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group assesses on a forward-looking basis the expected credit losses associated with its debt securities valued at fair value through other comprehensive income. Impairments on debt securities are recorded in &amp;#x201c;Other financial income and expense.&amp;#x201d; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For other financial assets valued at amortized cost, impairments, which are based on their expected credit losses, and exchange rate losses are included in &amp;#x201c;Other expense&amp;#x201d; in the consolidated income statement. Exchange rate gains and interest income, using the effective interest rate method, are included in &amp;#x201c;Other income&amp;#x201d; or &amp;#x201c;Other financial income&amp;#x201d; in the consolidated income statement, depending on the nature of the item. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Derivative financial instruments&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Derivative financial instruments are initially recognized in the balance sheet at fair value and are remeasured to their current fair value at the end of each subsequent reporting period. The valuation of a forward exchange rate contract is based on the discounted cash flow model, using interest curves and spot rates at the reporting date as observable inputs. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Options are valued based on a modified Black-Scholes model using volatility and exercise prices as major observable inputs. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group utilizes derivative financial instruments for the purpose of hedging to reduce the volatility in the Group&amp;#x2019;s performance due to the exposure to various business related risks. To mitigate these risks, the Group enters into certain derivative financial instruments. The risk reduction is obtained because the derivative&amp;#x2019;s value or cash flows are expected, wholly or partly, to offset changes in the value or cash flows of the recognized assets or liabilities. The overall strategy is aiming to mitigate the currency and interest rate risk of positions that are contractually agreed, and to partially mitigate the exposure risk of selected anticipated transactions. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Certain derivative financial instruments meet the criteria for hedge accounting treatment. A prerequisite for obtaining this accounting-hedge relationship is extensive documentation on inception and proving on a regular basis that the economic hedge is effective for accounting purposes. Other derivative financial instruments do not meet the criteria to qualify for hedge accounting. Changes in the fair value of these derivative instruments are recognized immediately in &amp;#x201c;Other financial income and expense&amp;#x201d; in the consolidated income statement. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In addition, the Group has designated certain long-term debt components as hedges of the translation risk arising on certain net investments in foreign operations. On consolidation, foreign currency differences arising on long-term debt designated as net investment hedges of a foreign operation are recognized in other comprehensive income and accumulated in currency translation effects, to the extent that the hedge is effective. The foreign currency differences arising from hedge ineffectiveness are recognized in the income statement in &amp;#x201c;Other financial income and expense.&amp;#x201d; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;When a hedged net investment is disposed of, the proportionate portion of the cumulative amount recognized in equity in relation to the hedged net investment is transferred to the consolidated income statement as an adjustment to the gain or loss on disposal. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Inventories&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Inventory is valued at the lower of acquisition or production cost determined on a first-in, first-out basis and net realizable value. This value is used for the &amp;#x201c;Cost of goods sold&amp;#x201d; in the consolidated income statement. Unsaleable inventory is fully written off in the consolidated income statement under &amp;#x201c;Cost of goods sold.&amp;#x201d; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Trade receivables&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Trade receivables are initially recognized at their invoiced amounts, including any related sales taxes less adjustments for estimated revenue deductions such as rebates, chargebacks and cash discounts. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The provisions for doubtful trade receivables are established using an expected credit loss model (ECL). The provisions are based on a forward-looking ECL, which includes possible default events on the trade receivables over the entire holding period of the trade receivable. These provisions represent the difference between the trade receivable&amp;#x2019;s carrying amount in the consolidated balance sheet and the estimated collectible amount. Charges for doubtful trade receivables are recorded as marketing and selling costs recognized in the consolidated income statement within &amp;#x201c;Selling, general and administration&amp;#x201d; expenses. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Legal and environmental liabilities&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis and its subsidiaries are subject to contingencies arising in the ordinary course of business, such as patent litigation, environmental remediation liabilities and other product-related litigation, commercial litigation, and governmental investigations and proceedings. Provisions are recorded where a reliable estimate can be made of the probable outcome of legal or other disputes against the subsidiary. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Contingent consideration&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In an acquisition or a divestment of a business, it is necessary to recognize contingent future amounts due to previous owners, representing contractually defined potential amounts as a liability or an asset. Usually for Novartis, these are linked to milestone or royalty payments related to certain assets and are recognized as a financial liability or financial asset at fair value, which is then remeasured at each subsequent reporting date. These estimations typically depend on factors such as technical milestones or market performance, and are adjusted for the probability of their likelihood of payment, and are appropriately discounted to reflect the impact of time. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the consolidated income statement in &amp;#x201c;Cost of goods sold&amp;#x201d; for currently marketed products and in &amp;#x201c;Research and development&amp;#x201d; for IPR&amp;amp;D. Changes in contingent consideration assets are recognized in &amp;#x201c;Other income&amp;#x201d; or &amp;#x201c;Other expense,&amp;#x201d; depending on their nature. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The effect of unwinding the discount over time is recognized for contingent liabilities in &amp;#x201c;Interest expense&amp;#x201d; and for contingent assets as interest income recognized in the consolidated income statement within &amp;#x201c;Other financial income and expense.&amp;#x201d; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Defined ben&lt;/font&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;efit pension plans and&amp;nbsp;other&amp;nbsp;post-employment benefits&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The liability in respect of defined benefit pension plans and other post-employment benefits is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions in which associates are employed, while the net interest on the net defined benefit liability or asset is recognized as &amp;#x201c;Other expense&amp;#x201d; or &amp;#x201c;Other income.&amp;#x201d; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Treasury shares&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Treasury shares are initially recorded at fair value on their trade date, which is different from the settlement date, when the transaction is ultimately effected. Treasury shares are deducted from consolidated equity at their nominal value of CHF&amp;nbsp;0.50 per share. Differences between the nominal amount and the transaction price on purchases or sales of treasury shares with third parties, or the value of services received for the shares allocated to associates as part of share-based compensation arrangements, are recorded in &amp;#x201c;Retained earnings&amp;#x201d; in the consolidated statement of changes in equity. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Revenue recognition&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Revenue on the sale of Novartis Group products and services, which is recorded as &amp;#x201c;Net sales&amp;#x201d; in the consolidated income statement, is recognized when a contractual promise to a customer (performance obligation) has been fulfilled by transferring control over the promised goods and services to the customer, substantially all of which is at the point in time of shipment to or receipt of the products by the customer or when the services are performed. If contracts contain customer acceptance provisions, revenue is recognized upon the satisfaction of the acceptance criteria. If products are stockpiled at the request of the customer, revenue is only recognized once the products have been inspected and accepted by the customer, and there is no right of return or replenishment on product expiry. The amount of revenue recognized is based on the consideration Novartis expects to receive in exchange for its goods and services, when it is highly probable that a significant reversal will not occur. If a contract contains more than one performance obligation, the consideration is allocated based on the standalone selling price of each performance obligation. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The consideration Novartis receives in exchange for its goods or services may be fixed or variable. Variable consideration is only recognized when it is highly probable that a significant reversal will not occur. The most common elements of variable consideration are listed below. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Rebates and discounts granted to government agencies, wholesalers, retail pharmacies, managed healthcare organizations and other customers, as well as chargebacks are provisioned and recorded as a revenue deduction at the time the related revenues are recorded or when the incentives are offered. They are calculated on the basis of historical experience, regulations, the specific terms in the individual agreements, product pricing and the mix of products, contracts, channels and payors. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Refunds granted to healthcare providers under innovative pay-for-performance agreements (i.e., outcome based arrangements) are provisioned and recorded as a revenue deduction at the time the related sales are recorded. They are calculated on the basis of historical experience and clinical data available for the product, as well as the specific terms in the individual agreements. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until the uncertainty is resolved or until such history is available. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Cash discounts are offered to customers to encourage prompt payment and are provisioned and recorded as revenue deductions at the time the related sales are recorded. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Shelf stock adjustments are generally granted to customers, primarily of the Sandoz Division, to cover the inventory held by them at the time a price decline becomes effective. Revenue deduction provisions for shelf stock adjustments are recorded when the price decline is anticipated, based on the impact of the price decline on the customer&amp;#x2019;s estimated inventory levels. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Sales returns provisions are recognized and recorded as revenue deductions when there is historical experience of Novartis agreeing to customer returns and Novartis can reasonably estimate expected future returns. In doing so, the estimated rate of return is applied, determined on the basis of historical experience of customer returns and considering any other relevant factors. This is applied to the amounts invoiced, also considering the amount of returned products to be destroyed versus products that can be placed back in inventory for resale. Where shipments are made on a resale or return basis, without sufficient historical experience for estimating sales returns, revenue is only recorded when there is evidence of consumption or when the right of return has expired. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Net sales and provisions for revenue deductions are adjusted to actual amounts as rebates, refunds, discounts and returns are processed. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these sales deductions. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;&amp;#x201c;Other revenue&amp;#x201d; includes income from profit-sharing arrangements with our collaboration partners, and royalty and milestone income from the out-licensing of intellectual property when Novartis retains an interest in the intellectual property through a license. Royalty income earned through a license is recognized when the underlying sales have occurred. Milestone income is recognized at the point in time when it is highly probable that the relevant milestone event criteria are met, and the risk of reversal of revenue recognition is remote. Other revenue also includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales, and is recognized when control transfers to the third party and our performance obligations are satisfied. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Research and development&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Internal research and development (R&amp;amp;D) costs are fully charged to &amp;#x201c;Research and development&amp;#x201d; in the consolidated income statement in the period in which they are incurred. The Group considers that regulatory and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained in a major market such as the United States, the European Union, Switzerland or Japan. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Payments made to third parties, such as contract research and development organizations in compensation for subcontracted R&amp;amp;D, that are deemed not to transfer intellectual property to Novartis are expensed as internal R&amp;amp;D expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been achieved from a regulatory authority in a major market. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Payments made to third parties to in-license or acquire intellectual property rights, compounds and products, including initial upfront and subsequent milestone payments, are capitalized, as are payments for other assets, such as technologies to be used in R&amp;amp;D activities. If additional payments are made to the originator company to continue to perform R&amp;amp;D activities, an evaluation is made as to the nature of the payments. Such additional payments will be expensed if they are deemed to be compensation for subcontracted R&amp;amp;D services not resulting in an additional transfer of intellectual property rights to Novartis. Such additional payments will be capitalized if they are deemed to be compensation for the transfer to Novartis of additional intellectual property developed at the risk of the originator company. Subsequent internal R&amp;amp;D costs in relation to IPR&amp;amp;D and other assets are expensed, since the technical feasibility of the internal R&amp;amp;D activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Costs for post-approval studies performed to support the continued registration of a marketed product are recognized as marketing expenses. Costs for activities that are required by regulatory authorities as a condition for obtaining marketing approval are capitalized and recognized as currently marketed products. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Inventory produced ahead of regulatory approval is fully provisioned, and the charge is included in &amp;#x201c;Other expense&amp;#x201d; in the consolidated income statement, as its ultimate use cannot be assured. If this inventory can be subsequently sold, the provision is released to &amp;#x201c;Other income&amp;#x201d; in the consolidated income statement, either on approval by the appropriate regulatory authority or, exceptionally in Europe, on recommendation by the Committee for Medicinal Products for Human Use (CHMP), if approval is virtually certain. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Share-based compensation&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Vested Novartis shares and American Depositary Receipts (ADRs) that are granted as compensation are valued at their market value on the grant date and are immediately expensed in the consolidated income statement. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair values of unvested restricted shares (RSs), restricted share units (RSUs) and performance share units (PSUs) in Novartis shares and ADRs granted to associates as compensation are recognized as an expense over the related vesting period. The expense recorded in the consolidated income statement is included in the personnel expenses of the various functions in which the associates are employed. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Unvested restricted shares, restricted ADRs and RSUs are only conditional on the provision of services by the plan participant during the vesting period. They are valued at fair value on the grant date. As RSUs do not entitle the holder to dividends, the fair value is based on the Novartis share price at the grant date adjusted for the net present value of the dividends expected to be paid during the holding period. The fair value of these grants, after making adjustments for assumptions related to forfeiture during the vesting period, is expensed on a straight-line basis over the respective vesting period. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;PSUs are subject to the achievement of certain performance criteria during the vesting period and require plan participants to provide services during this period. The following paragraphs provide an overview of the accounting policies for the share-based compensation plans that grant PSUs. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For PSUs granted under plans that are subject to performance criteria based on Novartis internal performance metrics and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on assumptions concerning the expected performance against the internal performance metrics throughout the vesting period. The assumptions are based on the Group&amp;#x2019;s targets for those performance metrics, and the expected forfeitures due to plan participants not meeting their service conditions. The assumptions are periodically adjusted over the vesting period. Any change in estimates for past services is recorded immediately as an expense or income in the consolidated income statement, and amounts for the remaining vesting period are expensed on a straight-line basis. As a result, at the end of the vesting period, the charge during the entire vesting period represents the amount that will finally vest. The number of equity instruments that finally vest is determined at the vesting date. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For PSUs granted under plans that are subject to performance criteria based on variables that can be observed in the market, which for Novartis plans is the Novartis total shareholder return (TSR) relative to a specific peer group of companies over the vesting period, and that are conditional on the provision of services by the plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on the total fair value of the grant over the vesting period. IFRS requires that these variables that can be observed in the market are taken into account in determining the fair value of the PSUs at the grant date. Novartis determined the fair value of these PSUs at the date of grant using a Monte Carlo simulation model. Adjustments to the number of equity instruments granted are only made if a plan participant does not fulfill the service conditions. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For PSUs granted under plans that are subject to both performance criteria based on Novartis internal performance metrics and Novartis TSR relative to a specific peer group of companies over the vesting period and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on a bifurcation into the components based on the performance criteria related to Novartis internal performance metrics and TSR, as described in the paragraphs above. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Measuring the fair values of PSUs granted that include TSR performance criteria requires use of estimates. The Monte Carlo simulation used to determine the fair value of the PSUs TSR performance criteria requires the probability of factors related to uncertain future events; the term of the award; the grant price of underlying shares or ADRs; expected volatilities; the expected correlation matrix of the underlying equity instruments with those of the peer group of companies; and the risk-free interest rate as input parameters. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If a plan participant leaves Novartis for reasons other than retirement, disability or death, then unvested restricted shares, restricted ADRs, RSUs and PSUs are forfeited, unless determined otherwise by the provision of the plan rules or by the Compensation Committee of the Novartis Board of Directors, for example, in connection with a reorganization or divestment. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Government grants&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Grants from governments or similar organizations are recognized at their fair value when there is a reasonable assurance that the grant will be received and the Group will comply with all attached conditions. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Government grants received to compensate for cost are deferred and recognized in the consolidated income statement over the period necessary to match them against the related costs that they are intended to compensate. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The accounting policy for property, plant and equipment describes the treatment of any related grants. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Restructuring charges&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Restructuring provisions are recognized for the direct expenditures arising from the restructuring, where the plans are sufficiently detailed and where appropriate communication to those affected has been made. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Charges to increase restructuring provisions are included in &amp;#x201c;Other expense&amp;#x201d; in the consolidated income statements. Corresponding releases are recorded in &amp;#x201c;Other income&amp;#x201d; in the consolidated income statement. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Healthcare contributions&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Healthcare contribution levies and fees under governmental programs that require the Group to contribute to a country&amp;#x2019;s healthcare costs, other than programs described in Revenue recognition in this Note 1, are recognized in Other expense in the consolidated income statement. Provisions for healthcare contributions are adjusted to the actual amounts levied. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these healthcare contributions. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Taxes&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Taxes on income are provided in the same periods as the revenues and expenses to which they relate and include interest and penalties incurred during the period. Deferred taxes are determined using the comprehensive liability method and are calculated on the temporary differences that arise between the tax base of an asset or liability and its carrying value in the balance sheet prepared for consolidation purposes, except for those temporary differences related to investments in subsidiaries and associated companies, where the timing of their reversal can be controlled and it is probable that the difference will not reverse in the foreseeable future. Since the retained earnings are reinvested, withholding or other taxes on eventual distribution of a subsidiary&amp;#x2019;s retained earnings are only taken into account when a dividend has been planned. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The estimated amounts for current and deferred tax assets or liabilities, including any amounts related to any uncertain tax positions, are based on currently known facts and circumstances. Tax returns are based on an interpretation of tax laws and regulations, and reflect estimates based on these judgments and interpretations. The tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made requiring payments of additional tax, interest or penalties. Inherent uncertainties exist in the estimates of the tax positions. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impact of adopting significant new IFRS standard in 2020&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following new IFRS standard has been adopted by Novartis from January 1, 2020:&lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;IFRS 3 Business Combination amendments&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The IASB issued amendments to IFRS 3 Business Combinations that revised the definition of a business, which assist entities with the evaluation of when an asset or group of assets acquired should be considered a business. This amended standard has been applied to transactions entered into on or after January 1, 2020. The amended standard allows an entity to apply an optional concentration test, on a transaction-by-transaction basis, to evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this optional concentration test is met, the set of activities and assets is determined not to be a business. The adoption of this amended standard on January 1, 2020 did not have a significant impact on our consolidated financial statements and is not expected to have a significant impact in future periods. However, this will depend on the facts and circumstances of future transactions and if the Group decides to apply the optional concentration test in the assessment of whether an acquired set of activities and assets is or is not a business. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;There are no other IFRS standards or interpretations not yet effective that would be expected to have a material impact on the Group. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impact of adopting significant new IFRS standard in 2019&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following new IFRS standard has been adopted by Novartis from January 1, 2019: &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;IFRS 16 Leases&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;IFRS 16 Leases substantially changed the financial statements, as the majority of leases for which the Group is the lessee became on-balance sheet liabilities with corresponding right-of-use assets also recognized on the balance sheet. The lease liability reflects the net present value of the remaining lease payments, and the right-of-use asset corresponds to the lease liability, adjusted for payments made before the commencement date, lease incentives and other items related to the lease agreement. The standard replaces IAS 17 Leases and related interpretations. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Upon adoption of the new standard, a portion of the annual operating lease costs, which was previously fully recognized as functional expenses, as a component of operating income, is recorded as interest expense. In addition, the portion of the lease payments that represents the reduction of the lease liability is recognized in the cash flow statement as an outflow from financing activities, which was previously fully recognized as an outflow from operating activities. Given the leases involved, these effects are not significant to the consolidated income statement and consolidated statement of cash flow. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group implemented the new standard on January 1, 2019, and applied the modified retrospective method, with right-of-use assets measured at an amount equal to the lease liability, adjusted by the amount of the prepaid or accrued lease payments relating to those leases recognized in the balance sheet immediately before the date of initial application and did not restate prior years. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Results of our impact assessment: &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The undiscounted operating lease commitments as of December 31, 2018, amounted to USD 3.6 billion. This includes approximately USD 0.1 billion of leases with a commencement date in 2019, as well as short-term leases and low-value leases that are recognized from January 1, 2019, upon adoption of IFRS 16, on a straight-line basis as expense in profit and loss. This also includes USD 0.2 billion lease commitments related to the Alcon Division, which is attributable to discontinued operation in 2019. For the remaining undiscounted lease commitments attributable to continuing operations of USD 3.3 billion, the Group recognized on January 1, 2019, lease liabilities of USD 1.74 billion and right-of-use assets of USD 1.55 billion (after the reclassification of USD 0.1 billion from property, plant and equipment, and net adjustments for the USD 0.3 billion recognition of sublease receivables, prepayments, and accrued lease payments recognized as at December 31, 2018). For the lease commitments attributable to discontinued operations, the Group recognized on January 1, 2019, lease liabilities and right-of-use assets of USD 0.2 billion. This does not include the discontinued operations right-of-use assets and lease liability on finance lease agreements of USD 75 million and USD 89 million, respectively. There was an insignificant increase to retained earnings upon adoption of IFRS 16 of USD 3 million that arose from subleases that were accounted for as operating lease agreements under IAS 17 and are accounted for as finance leases under IFRS 16. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;As a lessor, the Group had no significant impact upon adoption. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;For additional significant accounting policies applicable to the discontinued operations business see Note 30. &lt;/div&gt;</ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForSubsidiariesExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Scope of consolidation &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The consolidated financial statements include all entities, including structured entities, over which Novartis AG, Basel, Switzerland, directly or indirectly has control (generally as a result of owning more than 50% of the entity&amp;#x2019;s voting interest). Consolidated entities are also referred to as &amp;#x201c;subsidiaries.&amp;#x201d; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In cases where Novartis does not fully own a subsidiary, it has elected to value any remaining outstanding non-controlling interest at the time of acquiring control of the subsidiary at its proportionate share of the fair value of the net identified assets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The contribution of a business to an associate or joint venture is accounted for by applying the option under IFRS that permits the accounting for the retained interest of the business contributed at its net book value at the time of the contribution. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Investments in associated companies (generally defined as investments in entities in which Novartis holds between 20% and 50% of voting shares or over which it otherwise has significant influence) and joint ventures are accounted for using the equity method, except for selected venture fund investments for which the Group has elected to apply the method of fair value through the consolidated income statement. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForSubsidiariesExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Foreign currencies&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The consolidated financial statements of Novartis are presented in US dollars (USD). The functional currency of subsidiaries is generally the local currency of the respective entity. The functional currency used for the reporting of certain Swiss and foreign finance entities is USD instead of their respective local currencies. This reflects the fact that the cash flows and transactions of these entities are primarily denominated in these currencies. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For subsidiaries not operating in hyperinflationary economies, the subsidiary&amp;#x2019;s results, financial position and cash flows that do not have USD as their functional currency are translated into USD using the following exchange rates: &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Income, expense and cash flows using for each month the average exchange rate, with the US dollar values for each month being aggregated during the year &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Balance sheets using year-end exchange rates&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Resulting exchange rate differences are recognized in other comprehensive income&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;For subsidiaries operating in hyperinflationary economies, the impact of the restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period is recorded in retained earnings in equity. The subsequent gains or losses resulting from the restatement of non-monetary assets are recorded in &amp;#x201c;Other financial income and expense&amp;#x201d; in the consolidated income statement. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Non-current assets held for sale or held for distribution to owners&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Non-current assets are accounted for as assets held for sale or related to discontinued operations when their carrying amount is to be recovered principally through a sale transaction or distribution to owners and a sale or distribution to owners is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell with any resulting impairment recognized. Assets related to discontinued operations and assets of disposal group held for sale are not depreciated or amortized. The prior year consolidated balance sheet is not restated. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If in a subsequent period, the criteria for classification as held for sale are no longer met, the recoverable amount of assets and liabilities are reclassified out of assets held for sale into the respective balance sheet lines, prior year consolidated balance sheet is not restated. The cumulative amount of depreciation and amortization not recorded since the date of their classification to assets held for sale, and any required adjustments to the recoverable amounts of assets are recognized in the consolidated income statement. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory>
  <nvs:DistributionByWayOfDivindendInKindToShareholders contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Distribution of Alcon Inc. to Novartis AG shareholders &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During the first quarter of 2019, at the Annual General Meeting (AGM) of Novartis AG shareholders, held on February 28, 2019, the Novartis AG shareholders approved a special distribution by way of a dividend in kind to effect the spin-off of Alcon Inc. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The February 28, 2019, shareholder approval for the spin-off required the Alcon Division and selected portions of corporate activities attributable to Alcon&amp;#x2019;s business (the &amp;#x201c;Alcon business&amp;#x201d;) to be reported as discontinued operations. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The shareholder approval to spin off the Alcon business also required the recognition of a distribution liability at the fair value of the Alcon business. The Group elected to measure the distribution liability at the fair value of the Alcon business net assets taken as a whole. The distribution liability was recognized through a reduction in retained earnings. It was required to be adjusted at each balance sheet date for changes in its estimated fair value, up to the date of the distribution to shareholders through retained earnings. Any resulting impairment of the business assets to be distributed would have been recognized in the consolidated income statements in &amp;#x201c;Other expense&amp;#x201d; of discontinued operations, at the date of initial recognition of the distribution liability or at subsequent dates resulting from changes of the distribution liability valuation. At the April 8, 2019 distribution settlement date, the resulting gain, which was measured as the excess amount of the distribution liability over the then-carrying value of the net assets of the business distributed, was recognized on the line &amp;#x201c;Gain on distribution of Alcon Inc. to Novartis AG shareholders&amp;#x201d; in the income statement of discontinued operations. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The recognition of the distribution liability required the use of valuation techniques for purposes of impairment testing of the Alcon business&amp;#x2019; assets to be distributed and for the measurement of the fair value of the distribution liability. These valuations required the use of management assumptions and estimates related to the Alcon business&amp;#x2019; future cash flows, market multiples to estimate day one market value, and control premiums to apply in estimating the Alcon business fair value. These fair value measurements were classified as &amp;#x201c;Level 3&amp;#x201d; in the fair value hierarchy. The section &amp;#x201c;&amp;mdash;Impairment of goodwill and intangible assets&amp;#x201d; in this Note 1 provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Transaction costs that were directly attributable to the distribution (spin-off) of Alcon to the Novartis shareholders, and that would otherwise have been avoided, were recorded as a deduction from equity. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For additional disclosures, refer to &amp;#x201c;Note 2. Significant transactions&amp;mdash;Significant transactions in 2019&amp;mdash;Completion of the spin-off of the Alcon business through a dividend in kind distribution to Novartis AG shareholders,&amp;#x201d; and &amp;#x201c;Note 30. Discontinued operations.&amp;#x201d; &lt;/div&gt;</nvs:DistributionByWayOfDivindendInKindToShareholders>
  <ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Acquisition of assets and businesses&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Assets separately acquired are recorded at cost, which includes the purchase price and any directly attributable costs for bringing the asset into the condition to operate as intended. Expected costs for obligations to dismantle and remove property, plant and equipment when they are no longer used are included in their cost. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Acquired businesses are accounted for using the acquisition method, unless the optional concentration test is applied. The optional concentration test allows for the election on a transaction-by-transaction basis to account for the acquired business as an asset separately acquired when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The acquisition method requires that the assets acquired and liabilities assumed be recorded at their respective fair values on the date the Group obtains control. The excess of the fair value of the total purchase consideration transferred and the fair value of the acquired assets and assumed liabilities is recognized as goodwill. The related valuations are based on information available at the acquisition date. Acquisition related costs are expensed as incurred. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The application of the acquisition method requires certain estimates and assumptions to be made, especially concerning the fair values of the acquired intangible assets, inventories, property, plant and equipment and the liabilities assumed at the acquisition date, and the useful lives of the intangible assets and property, plant and equipment. Estimates of fair value require the use of valuation techniques. These valuations require the use of management assumptions and estimates, including value of comparable assets in the market, amount and timing of future cash flows, outcomes and costs of research and development activities, probability of obtaining regulatory approval, long-term sales forecasts, actions of competitors, discount rates and terminal growth rates. The section &amp;#x201c;&amp;mdash;Impairment of goodwill and intangible assets&amp;#x201d; in this Note 1 provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Property, plant and equipment&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Property, plant and equipment are depreciated on a straight-line basis in the consolidated income statement over their estimated useful lives. Freehold land is not depreciated. The related depreciation expense is included in the costs of the functions using the asset. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Property, plant and equipment are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the respective useful lives for property, plant and equipment:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Useful life&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Buildings&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20 to 40 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and other equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7 to 20 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Furniture and vehicles&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5 to 10 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Computer hardware&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3 to 7 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Government grants obtained for construction activities, including any related equipment, are deducted from the gross acquisition cost to arrive at the balance sheet carrying value of the related assets. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
  <nvs:RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Useful life&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Buildings&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20 to 40 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and other equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7 to 20 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Furniture and vehicles&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5 to 10 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Computer hardware&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3 to 7 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock>
  <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Leases and right-of-use assets&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;From January 1, 2019, with the adoption of IFRS 16 Leases, the Group adopted the following accounting policies for leases and right-of-use assets: &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;As lessee, the Group assesses whether a contract contains a lease at inception of a contract and upon the modification of a contract. The Group elected to allocate the consideration in the contract to the lease and non-lease components on the basis of the relative standalone price. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a lessee, except for leases with a term of 12 months or less (short-term leases) and low-value leases. For these short-term and low-value leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease to the end of the lease term. The lease term includes the period of any lease extension that in management&amp;#x2019;s assessment is highly probable to be exercised by the Group. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the Novartis incremental borrowing rate for the asset subject to the lease in the respective markets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever there is a change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The portion of the lease payments attributable to the repayment of lease liabilities is recognized in cash flows used in financing activities, and the portion attributable to the payment of interest is included in cash flows from operating activities. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Right-of-use assets are initially recognized on the balance sheet at cost, which comprises the amount of the initial measurement of the corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease incentive received and any initial direct costs incurred by Novartis, and expected costs for obligations to dismantle and remove right-of-use assets when they are no longer used. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease over the shorter of the useful life of the right-of-use asset or the end of the lease term. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In arrangements where the Group is the lessor, it determines at lease inception whether the lease is a finance lease or an operating lease. Leases that transfer substantially all of the risk and rewards incidental to ownership of the underlying asset to the counterparty (the lessee) are accounted for as finance leases. Leases that do not transfer substantially all of the risks and rewards of ownership are accounted for as operating leases. Lease payments received under operating leases are recognized on a straight-line basis over the lease term in the consolidated income statement in either &amp;#x201c;net sales&amp;#x201d; or &amp;#x201c;other income,&amp;#x201d; depending on the nature of and underlying asset to the lease arrangement. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;Prior to January 1, 2019, the Group applied the following accounting policies for leases: &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Leases that transferred substantially all of the risks and rewards of ownership were recognized as finance leases, with the leased asset measured initially at an amount equal to the lower of their fair value and the present value of the minimum lease payments. Minimum lease payments were the payments over the lease term that the Group, as leasee, was required to make, excluding contingent rent. The underlying asset was accounted for in accordance with the accounting policy applicable to that asset. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Leases that did not transfer substantially all of the risks and rewards of ownership were accounted for as operating leases and were not recognized in the consolidated balance sheet. Payments made under operating leases were recognized in the consolidated income statement on a straight-line basis over the term of the lease. Lease incentives received were deferred and recognized as a component of lease expense over the term of the lease. The future undiscounted lease payments under operating leases were disclosed as commitments in the notes to the consolidated financial statements. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Lessor accounting policies were not substantially different from those applied upon the adoption of IFRS 16 Leases, as described above. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;The section &amp;#x201c;&amp;mdash;Impact of adopting significant new IFRS standards in 2019&amp;#x201d; in this Note 1 provides additional disclosures on the impact of adoption of IFRS 16 Leases. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Goodwill and intangible assets&lt;/font&gt; &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Goodwill&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Goodwill arises in the acquisition of a business when applying the acquisition method and is the excess of the fair value of the consideration transferred to acquire a business over the underlying fair value of the net identified assets acquired. It is allocated to groups of cash-generating units (CGUs), which are usually represented by the reported segments. Goodwill is tested for impairment annually at the level of these groups of CGUs, and any impairment charges are recorded under &amp;#x201c;Other expense&amp;#x201d; in the consolidated income statement. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory>
  <nvs:DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Intangible assets available for use&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has the following classes of available for use intangible assets: currently marketed products; technologies; other intangible assets (including computer software). &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Currently marketed products represent the composite value of acquired intellectual property (IP), patents, distribution rights and product trade names. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Technologies represent identified and separable acquired know-how used in the research, development and production processes. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Significant investments in internally developed and acquired computer software are capitalized and included in the &amp;#x201c;Other&amp;#x201d; category, and amortized once available for use. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Intangible assets available for use with a definite useful life are amortized over their estimated useful lives on a straight-line basis and are evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the respective useful lives for intangible assets available for use and the location in the consolidated income statement in which the respective amortization and any potential impairment charge is recognized: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Useful life &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Income statement location &lt;br&gt;&lt;/br&gt; for amortization and &lt;br&gt;&lt;/br&gt; impairment charges &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currently marketed products&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5 to 20 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold"&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Technologies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10 to 20 years &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold" &lt;br&gt;&lt;/br&gt; or "Research &lt;br&gt;&lt;/br&gt; and development" &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other (including &lt;br&gt;&lt;/br&gt;computer software) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3 to 7 years &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; In the respective &lt;br&gt;&lt;/br&gt; functional expense &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock>
  <nvs:RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Useful life &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Income statement location &lt;br&gt;&lt;/br&gt; for amortization and &lt;br&gt;&lt;/br&gt; impairment charges &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currently marketed products&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5 to 20 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold"&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Technologies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10 to 20 years &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold" &lt;br&gt;&lt;/br&gt; or "Research &lt;br&gt;&lt;/br&gt; and development" &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other (including &lt;br&gt;&lt;/br&gt;computer software) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3 to 7 years &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; In the respective &lt;br&gt;&lt;/br&gt; functional expense &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock>
  <nvs:DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock contextRef="AR_D-CurrentYear">&lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Intangible assets not yet available for use&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Acquired research and development intangible assets that are still under development and have accordingly not yet obtained marketing approval are recognized as in-process research and development (IPR&amp;amp;D). &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;IPR&amp;amp;D is not amortized, but is evaluated for potential impairment on an annual basis or when facts and circumstances warrant. Any impairment charge is recorded in the consolidated income statement under &amp;#x201c;Research and development.&amp;#x201d; Once a project included in IPR&amp;amp;D has been successfully developed, it is transferred to the &amp;#x201c;Currently marketed products&amp;#x201d; category. &lt;/div&gt;</nvs:DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock>
  <nvs:DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impairment of goodwill and intangible assets&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;An asset is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value-in-use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or CGUs, and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group&amp;#x2019;s activities with regard to: &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Amount and timing of projected future cash flows&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Long-term sales forecasts &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Actions of competitors (launch of competing products, marketing initiatives, etc.)&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Sales erosion rates after the end of patent or other intellectual property rights protection, and timing of the entry of generic competition &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Outcome of research and development activities (compound efficacy, results of clinical trials, etc.)&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Amount and timing of projected costs to develop IPR&amp;amp;D into commercially viable products&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Profit margins&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Probability of obtaining regulatory approval&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Future tax rate&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Appropriate terminal growth rate&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Appropriate discount rate&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Generally, for intangible assets with a definite useful life, Novartis uses cash flow projections for the whole useful life of these assets. For goodwill, Novartis generally utilizes cash flow projections for a five-year period based on management forecasts, with a terminal value based on cash flow projections usually in line with inflation rates for later periods. Probability-weighted scenarios are typically used. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Discount rates used consider the Group&amp;#x2019;s estimated weighted average cost of capital, adjusted for specific asset, country and currency risks associated with cash flow projections, to approximate the discount rate that market participants would use to value the asset. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Due to the above factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques. &lt;/div&gt;</nvs:DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock>
  <nvs:DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impairment of associated companies accounted for at equity&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis considers investments in associated companies for impairment evaluation whenever objective evidence indicates the net investment may be impaired, including when a quoted share price indicates a fair value less than the per-share balance sheet carrying value for the investment. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If the recoverable amount of the investment is estimated to be lower than the balance sheet carrying amount, an impairment charge is recognized for the difference in the consolidated income statement under &amp;#x201c;Income from associated companies.&amp;#x201d; &lt;/div&gt;</nvs:DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock>
  <nvs:DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Cash and cash equivalents&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Cash and cash equivalents include highly liquid investments with original maturities of three months or less, which are readily convertible to known amounts of cash. Bank overdrafts are usually presented within current financial debts on the consolidated balance sheet, except in cases where a right of offset has been agreed with a bank, which then allows for presentation on a net basis. &lt;/div&gt;</nvs:DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock>
  <nvs:DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Marketable securities, commodities and non-current financial assets &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Commodities, which include gold bullion or coins, are valued at the lower of cost or fair value using current market prices. The changes in fair value below cost are immediately recorded in &amp;#x201c;Other financial income and expense.&amp;#x201d; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Marketable securities are financial assets held for short-term purposes which are principally traded in liquid markets and are classified within current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &amp;#x201c;Other financial income and expense&amp;#x201d; in the consolidated income statement. Non-current financial assets held for long-term strategic purposes are classified within non-current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &amp;#x201c;Other income&amp;#x201d; and &amp;#x201c;Other expense&amp;#x201d; in the consolidated income statement. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Marketable securities and non-current financial assets are initially recorded at fair value on their trade date, which is different from the settlement date when the transaction is ultimately effected. Quoted securities are remeasured at each reporting date to fair value based on current market prices. If the market for a financial asset is not active or no market is available, fair values are established using valuation techniques. The majority of non-quoted investments are valued initially at fair value through the established purchase price between a willing buyer and seller. Non-quoted investments are subsequently adjusted based on values derived from discounted cash flow analysis or other pricing models. These investment values are classified as &amp;#x201c;Level 3&amp;#x201d; in the fair value hierarchy. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group classifies and accounts for its marketable securities and non-current financial assets in the following categories: &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Debt securities are valued at fair value through other comprehensive income with subsequent recycling into the consolidated income statement, as they meet both the &amp;#x201c;solely payment of principal and interest&amp;#x201d; and the business model criteria. Unrealized gains and losses, except exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are recognized in the consolidated income statement when the debt instrument is sold, at which time the gain is transferred to &amp;#x201c;Other financial income and expense.&amp;#x201d; Exchange gains and losses related to debt instruments are immediately recognized in the consolidated income statement to &amp;#x201c;Other financial income and expense.&amp;#x201d; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Fund investments and equity securities of the Novartis venture fund are valued at fair value through profit and loss (FVPL). Unrealized gains and losses, including exchange gains and losses, are recognized in the consolidated income statement to &amp;#x201c;Other income&amp;#x201d; for gains and &amp;#x201c;Other expense&amp;#x201d; for losses. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Equity securities held as strategic investments, typically held outside of the Novartis venture fund, are generally designated at the date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. Unrealized gains and losses, including exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are reclassified to retained earnings when the equity security is sold. If these equity securities are not designated at the date of acquisition as financial assets valued at fair value through other comprehensive income, they are valued at FVPL, as described above. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Other non-current financial assets, such as loans and long-term receivables from customers, advances and other deposits, are valued at amortized cost, which reflects the time value of money less any allowances for expected credit losses. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group assesses on a forward-looking basis the expected credit losses associated with its debt securities valued at fair value through other comprehensive income. Impairments on debt securities are recorded in &amp;#x201c;Other financial income and expense.&amp;#x201d; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For other financial assets valued at amortized cost, impairments, which are based on their expected credit losses, and exchange rate losses are included in &amp;#x201c;Other expense&amp;#x201d; in the consolidated income statement. Exchange rate gains and interest income, using the effective interest rate method, are included in &amp;#x201c;Other income&amp;#x201d; or &amp;#x201c;Other financial income&amp;#x201d; in the consolidated income statement, depending on the nature of the item. &lt;/div&gt;</nvs:DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock>
  <ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Derivative financial instruments&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Derivative financial instruments are initially recognized in the balance sheet at fair value and are remeasured to their current fair value at the end of each subsequent reporting period. The valuation of a forward exchange rate contract is based on the discounted cash flow model, using interest curves and spot rates at the reporting date as observable inputs. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Options are valued based on a modified Black-Scholes model using volatility and exercise prices as major observable inputs. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group utilizes derivative financial instruments for the purpose of hedging to reduce the volatility in the Group&amp;#x2019;s performance due to the exposure to various business related risks. To mitigate these risks, the Group enters into certain derivative financial instruments. The risk reduction is obtained because the derivative&amp;#x2019;s value or cash flows are expected, wholly or partly, to offset changes in the value or cash flows of the recognized assets or liabilities. The overall strategy is aiming to mitigate the currency and interest rate risk of positions that are contractually agreed, and to partially mitigate the exposure risk of selected anticipated transactions. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Certain derivative financial instruments meet the criteria for hedge accounting treatment. A prerequisite for obtaining this accounting-hedge relationship is extensive documentation on inception and proving on a regular basis that the economic hedge is effective for accounting purposes. Other derivative financial instruments do not meet the criteria to qualify for hedge accounting. Changes in the fair value of these derivative instruments are recognized immediately in &amp;#x201c;Other financial income and expense&amp;#x201d; in the consolidated income statement. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In addition, the Group has designated certain long-term debt components as hedges of the translation risk arising on certain net investments in foreign operations. On consolidation, foreign currency differences arising on long-term debt designated as net investment hedges of a foreign operation are recognized in other comprehensive income and accumulated in currency translation effects, to the extent that the hedge is effective. The foreign currency differences arising from hedge ineffectiveness are recognized in the income statement in &amp;#x201c;Other financial income and expense.&amp;#x201d; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;When a hedged net investment is disposed of, the proportionate portion of the cumulative amount recognized in equity in relation to the hedged net investment is transferred to the consolidated income statement as an adjustment to the gain or loss on disposal. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Inventories&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Inventory is valued at the lower of acquisition or production cost determined on a first-in, first-out basis and net realizable value. This value is used for the &amp;#x201c;Cost of goods sold&amp;#x201d; in the consolidated income statement. Unsaleable inventory is fully written off in the consolidated income statement under &amp;#x201c;Cost of goods sold.&amp;#x201d; &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories>
  <ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Trade receivables&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Trade receivables are initially recognized at their invoiced amounts, including any related sales taxes less adjustments for estimated revenue deductions such as rebates, chargebacks and cash discounts. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The provisions for doubtful trade receivables are established using an expected credit loss model (ECL). The provisions are based on a forward-looking ECL, which includes possible default events on the trade receivables over the entire holding period of the trade receivable. These provisions represent the difference between the trade receivable&amp;#x2019;s carrying amount in the consolidated balance sheet and the estimated collectible amount. Charges for doubtful trade receivables are recorded as marketing and selling costs recognized in the consolidated income statement within &amp;#x201c;Selling, general and administration&amp;#x201d; expenses. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Legal and environmental liabilities&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis and its subsidiaries are subject to contingencies arising in the ordinary course of business, such as patent litigation, environmental remediation liabilities and other product-related litigation, commercial litigation, and governmental investigations and proceedings. Provisions are recorded where a reliable estimate can be made of the probable outcome of legal or other disputes against the subsidiary. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Contingent consideration&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In an acquisition or a divestment of a business, it is necessary to recognize contingent future amounts due to previous owners, representing contractually defined potential amounts as a liability or an asset. Usually for Novartis, these are linked to milestone or royalty payments related to certain assets and are recognized as a financial liability or financial asset at fair value, which is then remeasured at each subsequent reporting date. These estimations typically depend on factors such as technical milestones or market performance, and are adjusted for the probability of their likelihood of payment, and are appropriately discounted to reflect the impact of time. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the consolidated income statement in &amp;#x201c;Cost of goods sold&amp;#x201d; for currently marketed products and in &amp;#x201c;Research and development&amp;#x201d; for IPR&amp;amp;D. Changes in contingent consideration assets are recognized in &amp;#x201c;Other income&amp;#x201d; or &amp;#x201c;Other expense,&amp;#x201d; depending on their nature. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The effect of unwinding the discount over time is recognized for contingent liabilities in &amp;#x201c;Interest expense&amp;#x201d; and for contingent assets as interest income recognized in the consolidated income statement within &amp;#x201c;Other financial income and expense.&amp;#x201d; &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Defined ben&lt;/font&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;efit pension plans and&amp;nbsp;other&amp;nbsp;post-employment benefits&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The liability in respect of defined benefit pension plans and other post-employment benefits is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions in which associates are employed, while the net interest on the net defined benefit liability or asset is recognized as &amp;#x201c;Other expense&amp;#x201d; or &amp;#x201c;Other income.&amp;#x201d; &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForTreasurySharesExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Treasury shares&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Treasury shares are initially recorded at fair value on their trade date, which is different from the settlement date, when the transaction is ultimately effected. Treasury shares are deducted from consolidated equity at their nominal value of CHF&amp;nbsp;0.50 per share. Differences between the nominal amount and the transaction price on purchases or sales of treasury shares with third parties, or the value of services received for the shares allocated to associates as part of share-based compensation arrangements, are recorded in &amp;#x201c;Retained earnings&amp;#x201d; in the consolidated statement of changes in equity. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForTreasurySharesExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Revenue recognition&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Revenue on the sale of Novartis Group products and services, which is recorded as &amp;#x201c;Net sales&amp;#x201d; in the consolidated income statement, is recognized when a contractual promise to a customer (performance obligation) has been fulfilled by transferring control over the promised goods and services to the customer, substantially all of which is at the point in time of shipment to or receipt of the products by the customer or when the services are performed. If contracts contain customer acceptance provisions, revenue is recognized upon the satisfaction of the acceptance criteria. If products are stockpiled at the request of the customer, revenue is only recognized once the products have been inspected and accepted by the customer, and there is no right of return or replenishment on product expiry. The amount of revenue recognized is based on the consideration Novartis expects to receive in exchange for its goods and services, when it is highly probable that a significant reversal will not occur. If a contract contains more than one performance obligation, the consideration is allocated based on the standalone selling price of each performance obligation. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The consideration Novartis receives in exchange for its goods or services may be fixed or variable. Variable consideration is only recognized when it is highly probable that a significant reversal will not occur. The most common elements of variable consideration are listed below. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Rebates and discounts granted to government agencies, wholesalers, retail pharmacies, managed healthcare organizations and other customers, as well as chargebacks are provisioned and recorded as a revenue deduction at the time the related revenues are recorded or when the incentives are offered. They are calculated on the basis of historical experience, regulations, the specific terms in the individual agreements, product pricing and the mix of products, contracts, channels and payors. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Refunds granted to healthcare providers under innovative pay-for-performance agreements (i.e., outcome based arrangements) are provisioned and recorded as a revenue deduction at the time the related sales are recorded. They are calculated on the basis of historical experience and clinical data available for the product, as well as the specific terms in the individual agreements. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until the uncertainty is resolved or until such history is available. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Cash discounts are offered to customers to encourage prompt payment and are provisioned and recorded as revenue deductions at the time the related sales are recorded. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Shelf stock adjustments are generally granted to customers, primarily of the Sandoz Division, to cover the inventory held by them at the time a price decline becomes effective. Revenue deduction provisions for shelf stock adjustments are recorded when the price decline is anticipated, based on the impact of the price decline on the customer&amp;#x2019;s estimated inventory levels. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Sales returns provisions are recognized and recorded as revenue deductions when there is historical experience of Novartis agreeing to customer returns and Novartis can reasonably estimate expected future returns. In doing so, the estimated rate of return is applied, determined on the basis of historical experience of customer returns and considering any other relevant factors. This is applied to the amounts invoiced, also considering the amount of returned products to be destroyed versus products that can be placed back in inventory for resale. Where shipments are made on a resale or return basis, without sufficient historical experience for estimating sales returns, revenue is only recorded when there is evidence of consumption or when the right of return has expired. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Net sales and provisions for revenue deductions are adjusted to actual amounts as rebates, refunds, discounts and returns are processed. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these sales deductions. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;&amp;#x201c;Other revenue&amp;#x201d; includes income from profit-sharing arrangements with our collaboration partners, and royalty and milestone income from the out-licensing of intellectual property when Novartis retains an interest in the intellectual property through a license. Royalty income earned through a license is recognized when the underlying sales have occurred. Milestone income is recognized at the point in time when it is highly probable that the relevant milestone event criteria are met, and the risk of reversal of revenue recognition is remote. Other revenue also includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales, and is recognized when control transfers to the third party and our performance obligations are satisfied. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
  <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Research and development&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Internal research and development (R&amp;amp;D) costs are fully charged to &amp;#x201c;Research and development&amp;#x201d; in the consolidated income statement in the period in which they are incurred. The Group considers that regulatory and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained in a major market such as the United States, the European Union, Switzerland or Japan. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Payments made to third parties, such as contract research and development organizations in compensation for subcontracted R&amp;amp;D, that are deemed not to transfer intellectual property to Novartis are expensed as internal R&amp;amp;D expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been achieved from a regulatory authority in a major market. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Payments made to third parties to in-license or acquire intellectual property rights, compounds and products, including initial upfront and subsequent milestone payments, are capitalized, as are payments for other assets, such as technologies to be used in R&amp;amp;D activities. If additional payments are made to the originator company to continue to perform R&amp;amp;D activities, an evaluation is made as to the nature of the payments. Such additional payments will be expensed if they are deemed to be compensation for subcontracted R&amp;amp;D services not resulting in an additional transfer of intellectual property rights to Novartis. Such additional payments will be capitalized if they are deemed to be compensation for the transfer to Novartis of additional intellectual property developed at the risk of the originator company. Subsequent internal R&amp;amp;D costs in relation to IPR&amp;amp;D and other assets are expensed, since the technical feasibility of the internal R&amp;amp;D activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Costs for post-approval studies performed to support the continued registration of a marketed product are recognized as marketing expenses. Costs for activities that are required by regulatory authorities as a condition for obtaining marketing approval are capitalized and recognized as currently marketed products. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Inventory produced ahead of regulatory approval is fully provisioned, and the charge is included in &amp;#x201c;Other expense&amp;#x201d; in the consolidated income statement, as its ultimate use cannot be assured. If this inventory can be subsequently sold, the provision is released to &amp;#x201c;Other income&amp;#x201d; in the consolidated income statement, either on approval by the appropriate regulatory authority or, exceptionally in Europe, on recommendation by the Committee for Medicinal Products for Human Use (CHMP), if approval is virtually certain. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Share-based compensation&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Vested Novartis shares and American Depositary Receipts (ADRs) that are granted as compensation are valued at their market value on the grant date and are immediately expensed in the consolidated income statement. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair values of unvested restricted shares (RSs), restricted share units (RSUs) and performance share units (PSUs) in Novartis shares and ADRs granted to associates as compensation are recognized as an expense over the related vesting period. The expense recorded in the consolidated income statement is included in the personnel expenses of the various functions in which the associates are employed. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Unvested restricted shares, restricted ADRs and RSUs are only conditional on the provision of services by the plan participant during the vesting period. They are valued at fair value on the grant date. As RSUs do not entitle the holder to dividends, the fair value is based on the Novartis share price at the grant date adjusted for the net present value of the dividends expected to be paid during the holding period. The fair value of these grants, after making adjustments for assumptions related to forfeiture during the vesting period, is expensed on a straight-line basis over the respective vesting period. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;PSUs are subject to the achievement of certain performance criteria during the vesting period and require plan participants to provide services during this period. The following paragraphs provide an overview of the accounting policies for the share-based compensation plans that grant PSUs. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For PSUs granted under plans that are subject to performance criteria based on Novartis internal performance metrics and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on assumptions concerning the expected performance against the internal performance metrics throughout the vesting period. The assumptions are based on the Group&amp;#x2019;s targets for those performance metrics, and the expected forfeitures due to plan participants not meeting their service conditions. The assumptions are periodically adjusted over the vesting period. Any change in estimates for past services is recorded immediately as an expense or income in the consolidated income statement, and amounts for the remaining vesting period are expensed on a straight-line basis. As a result, at the end of the vesting period, the charge during the entire vesting period represents the amount that will finally vest. The number of equity instruments that finally vest is determined at the vesting date. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For PSUs granted under plans that are subject to performance criteria based on variables that can be observed in the market, which for Novartis plans is the Novartis total shareholder return (TSR) relative to a specific peer group of companies over the vesting period, and that are conditional on the provision of services by the plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on the total fair value of the grant over the vesting period. IFRS requires that these variables that can be observed in the market are taken into account in determining the fair value of the PSUs at the grant date. Novartis determined the fair value of these PSUs at the date of grant using a Monte Carlo simulation model. Adjustments to the number of equity instruments granted are only made if a plan participant does not fulfill the service conditions. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For PSUs granted under plans that are subject to both performance criteria based on Novartis internal performance metrics and Novartis TSR relative to a specific peer group of companies over the vesting period and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on a bifurcation into the components based on the performance criteria related to Novartis internal performance metrics and TSR, as described in the paragraphs above. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Measuring the fair values of PSUs granted that include TSR performance criteria requires use of estimates. The Monte Carlo simulation used to determine the fair value of the PSUs TSR performance criteria requires the probability of factors related to uncertain future events; the term of the award; the grant price of underlying shares or ADRs; expected volatilities; the expected correlation matrix of the underlying equity instruments with those of the peer group of companies; and the risk-free interest rate as input parameters. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If a plan participant leaves Novartis for reasons other than retirement, disability or death, then unvested restricted shares, restricted ADRs, RSUs and PSUs are forfeited, unless determined otherwise by the provision of the plan rules or by the Compensation Committee of the Novartis Board of Directors, for example, in connection with a reorganization or divestment. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Government grants&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Grants from governments or similar organizations are recognized at their fair value when there is a reasonable assurance that the grant will be received and the Group will comply with all attached conditions. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Government grants received to compensate for cost are deferred and recognized in the consolidated income statement over the period necessary to match them against the related costs that they are intended to compensate. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The accounting policy for property, plant and equipment describes the treatment of any related grants. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants>
  <ifrs-full:DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Restructuring charges&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Restructuring provisions are recognized for the direct expenditures arising from the restructuring, where the plans are sufficiently detailed and where appropriate communication to those affected has been made. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Charges to increase restructuring provisions are included in &amp;#x201c;Other expense&amp;#x201d; in the consolidated income statements. Corresponding releases are recorded in &amp;#x201c;Other income&amp;#x201d; in the consolidated income statement. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Taxes&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Taxes on income are provided in the same periods as the revenues and expenses to which they relate and include interest and penalties incurred during the period. Deferred taxes are determined using the comprehensive liability method and are calculated on the temporary differences that arise between the tax base of an asset or liability and its carrying value in the balance sheet prepared for consolidation purposes, except for those temporary differences related to investments in subsidiaries and associated companies, where the timing of their reversal can be controlled and it is probable that the difference will not reverse in the foreseeable future. Since the retained earnings are reinvested, withholding or other taxes on eventual distribution of a subsidiary&amp;#x2019;s retained earnings are only taken into account when a dividend has been planned. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The estimated amounts for current and deferred tax assets or liabilities, including any amounts related to any uncertain tax positions, are based on currently known facts and circumstances. Tax returns are based on an interpretation of tax laws and regulations, and reflect estimates based on these judgments and interpretations. The tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made requiring payments of additional tax, interest or penalties. Inherent uncertainties exist in the estimates of the tax positions. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
  <ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impact of adopting significant new IFRS standard in 2020&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following new IFRS standard has been adopted by Novartis from January 1, 2020:&lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;IFRS 3 Business Combination amendments&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The IASB issued amendments to IFRS 3 Business Combinations that revised the definition of a business, which assist entities with the evaluation of when an asset or group of assets acquired should be considered a business. This amended standard has been applied to transactions entered into on or after January 1, 2020. The amended standard allows an entity to apply an optional concentration test, on a transaction-by-transaction basis, to evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this optional concentration test is met, the set of activities and assets is determined not to be a business. The adoption of this amended standard on January 1, 2020 did not have a significant impact on our consolidated financial statements and is not expected to have a significant impact in future periods. However, this will depend on the facts and circumstances of future transactions and if the Group decides to apply the optional concentration test in the assessment of whether an acquired set of activities and assets is or is not a business. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;There are no other IFRS standards or interpretations not yet effective that would be expected to have a material impact on the Group. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impact of adopting significant new IFRS standard in 2019&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following new IFRS standard has been adopted by Novartis from January 1, 2019: &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;IFRS 16 Leases&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;IFRS 16 Leases substantially changed the financial statements, as the majority of leases for which the Group is the lessee became on-balance sheet liabilities with corresponding right-of-use assets also recognized on the balance sheet. The lease liability reflects the net present value of the remaining lease payments, and the right-of-use asset corresponds to the lease liability, adjusted for payments made before the commencement date, lease incentives and other items related to the lease agreement. The standard replaces IAS 17 Leases and related interpretations. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Upon adoption of the new standard, a portion of the annual operating lease costs, which was previously fully recognized as functional expenses, as a component of operating income, is recorded as interest expense. In addition, the portion of the lease payments that represents the reduction of the lease liability is recognized in the cash flow statement as an outflow from financing activities, which was previously fully recognized as an outflow from operating activities. Given the leases involved, these effects are not significant to the consolidated income statement and consolidated statement of cash flow. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group implemented the new standard on January 1, 2019, and applied the modified retrospective method, with right-of-use assets measured at an amount equal to the lease liability, adjusted by the amount of the prepaid or accrued lease payments relating to those leases recognized in the balance sheet immediately before the date of initial application and did not restate prior years. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Results of our impact assessment: &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The undiscounted operating lease commitments as of December 31, 2018, amounted to USD 3.6 billion. This includes approximately USD 0.1 billion of leases with a commencement date in 2019, as well as short-term leases and low-value leases that are recognized from January 1, 2019, upon adoption of IFRS 16, on a straight-line basis as expense in profit and loss. This also includes USD 0.2 billion lease commitments related to the Alcon Division, which is attributable to discontinued operation in 2019. For the remaining undiscounted lease commitments attributable to continuing operations of USD 3.3 billion, the Group recognized on January 1, 2019, lease liabilities of USD 1.74 billion and right-of-use assets of USD 1.55 billion (after the reclassification of USD 0.1 billion from property, plant and equipment, and net adjustments for the USD 0.3 billion recognition of sublease receivables, prepayments, and accrued lease payments recognized as at December 31, 2018). For the lease commitments attributable to discontinued operations, the Group recognized on January 1, 2019, lease liabilities and right-of-use assets of USD 0.2 billion. This does not include the discontinued operations right-of-use assets and lease liability on finance lease agreements of USD 75 million and USD 89 million, respectively. There was an insignificant increase to retained earnings upon adoption of IFRS 16 of USD 3 million that arose from subleases that were accounted for as operating lease agreements under IAS 17 and are accounted for as finance leases under IFRS 16. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;As a lessor, the Group had no significant impact upon adoption. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;For additional significant accounting policies applicable to the discontinued operations business see Note 30. &lt;/div&gt;</ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations>
  <nvs:DisclosureOfSignificantTransactionsTextBlock contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;2. Significant transactions&lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Significant transactions in 2020&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group applied the acquisition method of accounting for businesses acquired, and did not elect to apply the optional concentration test to account for acquired business as an asset separately acquired. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines &amp;ndash; acquisition of The&amp;nbsp;Medicines Company&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On November 23, 2019, Novartis entered into an agreement and plan of merger (the Merger Agreement) with The Medicines Company, a US-based pharmaceutical company headquartered in Parsippany, New Jersey USA. Pursuant to the Merger Agreement, on December 5, 2019, Novartis, through a subsidiary, commenced a tender offer to acquire all outstanding shares of The Medicines Company for USD 85 per share, or a total consideration of approximately USD 9.6 billion in cash on a fully diluted basis, including the equivalent share value related to The Medicines Company&amp;#x2019;s convertible notes, in accordance with their terms. The tender offer expired on January 3, 2020, and on January 6, 2020, the acquiring subsidiary merged with and into The Medicines Company, resulting in The Medicines Company becoming an indirect wholly owned subsidiary of Novartis. Novartis financed the transaction through available cash, and short- and long-term borrowings. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Medicines Company is focused on the development of inclisiran, a potentially first-in-class, twice yearly therapy that allows administration during patients&amp;#x2019; routine visits to their healthcare professionals and will potentially contribute to improved patient adherence and sustained lower LDL-C levels. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of the total purchase consideration was USD 9.6 billion. The purchase price allocation resulted in net identifiable assets of approximately USD 7.1 billion, consisting of USD 8.5 billion intangible assets, USD 1.4 billion net deferred tax liabilities and goodwill of approximately USD 2.5 billion. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Results of operations since the date of acquisition were not material.&lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Sandoz &amp;ndash; acquisition of the Japanese business of Aspen Global Incorporated &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On November 11, 2019, Sandoz entered into an agreement for the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. Under the agreement, Sandoz acquired the shares in Aspen Japan K.K. and associated assets held by AGI. The transaction closed on January 31, 2020. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Aspen&amp;#x2019;s portfolio in Japan consists of off-patent medicines with a focus on anesthetics and specialty brands. The acquisition will enable Sandoz to expand its presence in the third-largest worldwide generics marketplace. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The purchase price consists of EUR 274 million (USD 303 million) upfront payment, less customary purchase price adjustment of EUR 27 million (USD 30 million), plus potential milestone payments of up to EUR 70 million (USD 77 million), which AGI is eligible to receive upon the achievement of specified milestones.&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of the total purchase consideration was EUR 294 million (USD 324 million). The amount consisted of a cash payment of EUR 247 million (USD 273 million) and the fair value of contingent consideration of EUR 47 million (USD 51 million), which AGI is eligible to receive upon the achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD 238 million, consisting of USD 196 million intangible assets, USD 26 million other net assets, USD 16 million net deferred tax assets. Goodwill amounted to USD 86 million. Results of operations since the date of acquisition were not material. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Sandoz &amp;ndash; retention of US dermatology business and generic US oral solids portfolio, previously planned to be divested &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On September 6, 2018, Novartis announced that it entered into a stock and asset purchase agreement (SAPA) with Aurobindo Pharma USA Inc. (Aurobindo) for the sale of selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, for USD 0.8 billion in cash and potential earnouts. The closing was conditional on obtaining regulatory approval. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In March 2020, Novartis took the decision to retain the Sandoz US generic oral solids and dermatology businesses and on April 2, 2020 entered into a mutual agreement with Aurobindo to terminate the transaction. The decision was taken as approval from the US Federal Trade Commission for the transaction was not obtained within the agreed timelines. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The cumulative amount of the depreciation on property, plant and equipment (USD 38 million) and amortization on intangible assets (USD 102 million), not recorded in the consolidated income statement since the date of classification as held for sale was recognized in the consolidated income statement in the first quarter of 2020. In addition, an impairment of currently marketed products of USD 42 million was recognized in the first quarter of 2020 consolidated income statement. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;As at March 31, 2020, the assets and liabilities of the Sandoz US generic oral solids and dermatology businesses were reclassified out of assets and liabilities of disposal group held for sale. The prior year balance sheet is not required to be restated. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In the Group&amp;#x2019;s consolidated balance sheet at December 31, 2019, the assets and liabilities classified as disposal group assets and liabilities held for sale consisted of the following: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Assets of disposal group classified as held for sale&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 169&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 475&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other non-current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 841&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Liabilities of disposal group classified as held for sale&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions and other non-current &lt;br&gt;&lt;/br&gt;liabilities &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions and other current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;There were no cumulative income or expenses included in the other comprehensive income relating to the disposal group. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Significant transactions in 2019&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Completion of the spin-off of the Alcon business through a dividend in kind distribution to Novartis AG shareholders &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On June 29, 2018, Novartis announced its intention to seek shareholder approval for the spin-off of the Alcon business into a separately traded standalone company, following the complete structural separation of the Alcon business into a standalone company (the Alcon business or Alcon Inc.). &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Novartis AG shareholders approved the spin-off of the Alcon business at the 2019 Annual General Meeting held on February 28, 2019, subject to completion of certain conditions precedent to the distribution. Upon shareholder approval, the Alcon business was reported as discontinued operations, and the fair value of the Alcon business exceeded the carrying value of its net assets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The conditions precedent to the spin-off were met and on April 8, 2019 the spin-off of the Alcon business was effected by way of a distribution of a dividend in kind of Alcon Inc. shares to Novartis AG shareholders and ADR (American Depositary Receipt) holders (the Distribution), which amounted to USD 23.4 billion and is recognized as a reduction to retained earnings. Through the Distribution, each Novartis AG shareholder received one Alcon Inc. share for every five Novartis AG shares/ADRs they held on April 8, 2019, close of business. As of April 9, 2019, the shares of Alcon Inc. are listed on the SIX Swiss Exchange (SIX) and on the New York Stock Exchange (NYSE) under the symbol &amp;#x201c;ALC.&amp;#x201d; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The dividend in kind distribution liability to effect the spin-off of the Alcon business (the distribution liability) amounted to USD 26.4 billion at March 31, 2019, unchanged from its initial recognition on February 28, 2019, and was in excess of the carrying value of the Alcon business net assets as of February 28, 2019, and as of March 31, 2019. The net assets of the Alcon business amounted to USD 23.1 billion as at March 31, 2019. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;On March 6, 2019, Alcon entered into financing arrangements with a syndicate of banks under which it borrowed on April 2, 2019, a total amount of USD 3.2 billion. These borrowings consisted of approximately USD 2.8 billion and the equivalent of USD 0.4 billion in EUR in bridge and other term loans under such Alcon facilities agreement. In addition, approximately USD 0.3 billion of borrowings under a number of local bilateral facilities in different countries, with the largest share of borrowings in Japan, were raised. This resulted in a total gross debt of USD 3.5 billion. These outstanding borrowings of the Alcon legal entities were recorded in the balance sheet and financing cash flow from discontinued operations. Prior to the spin-off, through a series of intercompany transactions, Alcon legal entities paid approximately USD 3.1 billion in cash to Novartis and its affiliates. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;At the April 8, 2019 Distribution, the fair value of the distribution liability of the Alcon business amounted to USD 23.4 billion, a decrease of USD 3.0 billion from March 31, 2019. As mentioned above, prior to the spin-off, through a series of intercompany transactions, Alcon legal entities incurred additional net financial debt and paid approximately USD 3.1 billion in cash to Novartis and its affiliates. This additional net debt and transactions resulted in a decrease in Alcon&amp;#x2019;s net assets to USD 20.0 billion at the date of the Distribution of the dividend in kind to Novartis AG shareholders on April 8, 2019. The distribution liability at April 8, 2019, remained in excess of the then-carrying value of the Alcon business net assets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Certain consolidated foundations own Novartis AG dividend-bearing shares restricting their availability for use by the Group. These Novartis AG shares are accounted for as treasury shares. Through the Distribution, these foundations received Alcon Inc. shares representing an approximate 4.7% equity interest in Alcon Inc. Upon the loss of control of Alcon Inc. through the Distribution, the financial investment in Alcon Inc. was recognized at its fair value based on the opening traded share price of Alcon Inc. on April 9, 2019 (a Level 1 hierarchy valuation). At initial recognition, its fair value of USD 1.3 billion was reported on the Group&amp;#x2019;s consolidated balance sheet as a financial asset. Management has designated this investment at fair value through other comprehensive income. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The total non-taxable, non-cash gain recognized at the distribution date of the spin-off of the Alcon business amounted to USD 4.7 billion consisting of: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; April 8, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net assets derecognized &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derecognition of distribution liability&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 23&amp;nbsp;434&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Difference between net assets and distribution liability&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;409&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Recognition of Alcon Inc. shares obtained &lt;br&gt;&lt;/br&gt;through consolidated foundations &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;273 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation gains recycled into &lt;br&gt;&lt;/br&gt;the consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 123 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Transaction costs recognized in the consolidated income statement&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;114&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gain on distribution of Alcon Inc. to Novartis AG shareholders&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="4"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="4"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; See Note 30 for additional information. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;For additional disclosures on discontinued operations, refer to Note 30.&lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines &amp;ndash; acquisition of IFM Tre, Inc. &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On May 7, 2019, Novartis acquired IFM Tre, Inc., a privately held, US-based biopharmaceutical company focused on developing anti-inflammatory medicines targeting the NLRP3 inflammasome. The acquisition gives Novartis full rights to IFM Tre, Inc.&amp;#x2019;s portfolio of NLRP3 antagonists. The NLRP3 antagonists portfolio consists of one clinical program and two preclinical programs: IFM-2427, a first-in-class, clinical-stage systemic antagonist for an array of chronic inflammatory disorders, including atherosclerosis and nonalcoholic steatohepatitis (NASH); a preclinical-stage gut-directed molecule for the treatment of inflammatory bowel disease; and a preclinical-stage central nervous system (CNS)-penetrant molecule. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The previously held interest of 9% was adjusted to its fair value of USD 33 million through the consolidated income statement at acquisition date. This remeasurement resulted in a gain of USD 14 million. The fair value of the total purchase consideration for acquiring the 91% stake Novartis did not already own amounted to USD 361 million. The amount consisted of an initial cash payment of USD 285 million, and the fair value of the contingent consideration of USD 76 million due to the IFM Tre, Inc. shareholders, which they are eligible to receive upon the achievement of specified development and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 355 million, mainly intangible assets, and goodwill of USD 39 million. The 2019 results of operations since the date of acquisition were not material. &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines &amp;ndash; acquisition of &lt;i&gt;Xiidra&lt;/i&gt; &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On May 8, 2019, Novartis entered into an agreement with Takeda Pharmaceutical Company Limited (Takeda) to acquire the assets associated with &lt;i&gt;Xiidra&lt;/i&gt; (lifitegrast ophthalmic solution) 5% worldwide. &lt;i&gt;Xiidra&lt;/i&gt; is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease. The transaction bolsters the Novartis front-of-the-eye portfolio and ophthalmic leadership. The transaction closed on July 1, 2019. The purchase price consists of a USD 3.4 billion upfront payment, customary purchase price adjustments of USD 0.1 billion, and the potential milestone payments of up to USD 1.9 billion, which Takeda is eligible to receive upon the achievement of specified commercialization milestones. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of the total purchase consideration is USD 3.7 billion. The amount consists of an initial cash payment of USD 3.5 billion, and the fair value of the contingent consideration of USD 0.2 billion, which Takeda is eligible to receive upon the achievement of specified commercialization milestones. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The purchase price allocation resulted in net identifiable assets of approximately USD 3.6 billion, consisting mainly of intangible assets of USD 3.6 billion, and goodwill amounted to approximately USD 0.1 billion. In 2019, from the date of acquisition, the business generated net sales of USD 0.2 billion. Management estimates that net sales for the entire year of 2019 would have amounted to USD 0.3 billion, had the business been acquired at the beginning of the 2019 reporting period. The 2019 results of operations since the date of acquisition were not material. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Significant transactions in 2018&lt;/font&gt; &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines &amp;ndash; acquisition of Advanced Accelerator Applications S.A.&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On October 30, 2017, Novartis entered into a binding memorandum of understanding with Advanced Accelerator Applications S.A. (AAA), a company headquartered in Saint-Genis-Pouilly, France, under which Novartis agreed to commence a tender offer for 100% of the share capital of AAA subject to certain conditions. Novartis commenced the tender offer on December 7, 2017, to purchase all of the outstanding ordinary shares for a price of USD&amp;nbsp;41 per share and USD&amp;nbsp;82 per American Depositary Share (ADS), each representing two ordinary shares of AAA, which expired on January 19, 2018. The offer valued AAA&amp;#x2019;s equity at USD&amp;nbsp;3.9 billion, on a fully diluted basis. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;As of January 19, 2018, the expiration date of the tender offer, approximately 97% of the then-outstanding fully diluted ordinary shares, including ordinary shares represented by ADSs (hereinafter collectively referred to as &amp;#x201c;the outstanding shares&amp;#x201d;), were validly tendered. On January 22, 2018, Novartis accepted and paid USD 3.9 billion for the outstanding shares tendered in the offer. On January 22, 2018, Novartis commenced a subsequent offering period that expired on January 31, 2018. As of the expiration of the subsequent offering period, an additional 1.8% of the outstanding shares were validly tendered. Novartis accepted and paid approximately USD 60 million, resulting in an increase in Novartis ownership in AAA to 98.7%. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of the total purchase consideration was USD 3.9 billion. The purchase price allocation resulted in net identifiable assets of approximately USD 1.9 billion, consisting of USD 2.5 billion intangible assets, USD 0.6 billion net deferred tax liabilities, and goodwill of approximately USD 2.0 billion. In 2018, from the date of the acquisition, the business generated net sales of USD 0.4 billion. Management estimated that net sales for the entire year of 2018 would have amounted to USD 0.4 billion had AAA been acquired at the beginning of 2018. The 2018 results from operations since the acquisition were not material. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;As of December 31, 2020, Novartis held 99.2% of the then-outstanding fully diluted ordinary shares, including ordinary shares represented by ADSs. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;AAA is a radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicines &amp;ndash; including &lt;i&gt;Lutathera&lt;/i&gt; (USAN: lutetium Lu 177 dotatate/INN: lutetium ( &lt;sup&gt;177&lt;/sup&gt;Lu) oxodotreotide), a first-in-class radioligand therapy product for neuroendocrine tumors &amp;ndash; and a portfolio of diagnostic products. Radiopharmaceuticals, such as &lt;i&gt;Lutathera&lt;/i&gt;, are unique medicinal formulations containing radioisotopes, which are used clinically for both diagnosis and therapy. &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines &amp;ndash; acquisition of AveXis, Inc.&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On April 6, 2018, Novartis entered into an agreement and plan of merger with AveXis, Inc., a US-based clinical stage gene therapy company, under which Novartis commenced on April 17, 2018, a tender offer to purchase all outstanding common stock of AveXis, Inc. for USD 218 per share in cash. On May 15, 2018, Novartis completed the acquisition of the common stock of AveXis, Inc. and paid a total of USD 8.7 billion. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of the total purchase consideration was USD 8.7 billion. The purchase price allocation resulted in net identifiable assets of approximately USD 7.2 billion, consisting of USD 8.5 billion intangible assets, USD 1.6 billion net deferred tax liabilities and other net assets of USD 0.3 billion, and goodwill of approximately USD 1.5 billion. The 2018 results of operations since the date of acquisition were not material. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;AveXis, Inc. is focused on developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. AveXis, Inc.&amp;#x2019;s initial product candidate, AVXS-101, is a proprietary gene therapy currently in development for the treatment of spinal muscular atrophy (SMA) type 1 &amp;ndash; the leading genetic cause of infant mortality &amp;ndash; and SMA types 2 and 3. In addition, AveXis, Inc. has a pipeline of other novel treatments for rare neurological diseases, including Rett syndrome (RTT) and a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene. &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines &amp;ndash; acquisition of Endocyte, Inc.&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On October 18, 2018, Novartis entered into an agreement and plan of merger with Endocyte, Inc. (Endocyte), a US-based biopharmaceutical company focused on developing targeted therapeutics for cancer treatment. The transaction was completed on December 21, 2018. Under the terms of the agreement, Novartis acquired all outstanding shares of Endocyte common stock for USD 24 per share. The total consideration amounted to USD 2.1 billion. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of the total purchase consideration was USD 2.1 billion. The purchase price allocation resulted in net identifiable assets of approximately USD 1.5 billion, consisting of USD 1.5 billion intangible assets, USD 0.3 billion net deferred tax liabilities and other net assets of USD 0.3 billion, and goodwill of approximately USD 0.6 billion. The purchase price allocation was preliminary at December 31, 2018, as the transaction closed on December 21, 2018, which was close to the Group&amp;#x2019;s year-end and therefore did not provide sufficient time to complete the valuation of the intangible assets, deferred taxes, assumed liabilities and goodwill. During 2019, there were no significant revisions to the purchase price allocation. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Endocyte uses drug conjugation technology to develop targeted therapies with companion imaging agents, including 177Lu-PSMA-617, a potential first-in-class investigational radioligand therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC). &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Corporate &amp;ndash; divestment of 36.5% stake in GlaxoSmithKline Consumer Healthcare Holdings Ltd. &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On March 27, 2018, Novartis entered into an agreement with GlaxoSmithKline plc (GSK) to divest its 36.5% stake in GlaxoSmithKline Consumer Healthcare Holdings Ltd. to GSK for USD 13.0 billion in cash. As a result, Novartis discontinued the use of equity method accounting starting from April 1, 2018. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;On June 1, 2018, the transaction closed and Novartis realized a pre-tax gain of USD 5.8 billion, recorded in income from associated companies. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;For significant transactions in 2019 for discontinued operations, see Note 30. There were no significant transactions in 2020 for discontinued operations. &lt;/div&gt;</nvs:DisclosureOfSignificantTransactionsTextBlock>
  <nvs:DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; April 8, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net assets derecognized &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derecognition of distribution liability&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 23&amp;nbsp;434&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Difference between net assets and distribution liability&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;409&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Recognition of Alcon Inc. shares obtained &lt;br&gt;&lt;/br&gt;through consolidated foundations &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;273 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation gains recycled into &lt;br&gt;&lt;/br&gt;the consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 123 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Transaction costs recognized in the consolidated income statement&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;114&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gain on distribution of Alcon Inc. to Novartis AG shareholders&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="4"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="4"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; See Note 30 for additional information. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock>
  <nvs:DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Assets of disposal group classified as held for sale&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 169&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 475&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other non-current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 841&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Liabilities of disposal group classified as held for sale&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions and other non-current &lt;br&gt;&lt;/br&gt;liabilities &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions and other current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;There were no cumulative income or expenses included in the other comprehensive income relating to the disposal group. &lt;/div&gt;</nvs:DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock>
  <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;3. Segmentation of key figures 2020, 2019 and 2018&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The businesses of Novartis are divided operationally on a worldwide basis into two identified reporting segments: Innovative Medicines and Sandoz. In addition, we separately report Corporate activities. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Reporting segments are presented in a manner consistent with the internal reporting to the chief operating decision-maker, which is the Executive Committee of Novartis. The reporting segments are managed separately because they each research, develop, manufacture, distribute and sell distinct products that require differing marketing strategies. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Executive Committee of Novartis is responsible for allocating resources and assessing the performance of the reporting segments. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The reporting segments are as follows:&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines. The Innovative Medicines Division is organized into two global business units: Novartis Oncology and Novartis Pharmaceuticals. Novartis Oncology consists of the global business franchise Oncology, and Novartis Pharmaceuticals consists of the global business franchises Immunology, Hepatology and Dermatology; Ophthalmology; Neuroscience; Cardiovascular, Renal and Metabolism; Respiratory; and Established Medicines. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Sandoz develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. Sandoz is organized globally into three franchises: Retail Generics, Anti-Infectives and Biopharmaceuticals. In Retail Generics, Sandoz develops, manufactures and markets active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a broad range of therapeutic areas, as well as finished dosage form of anti-infectives sold to third parties. In Anti-Infectives, Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by Retail Generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products, including biosimilars, and provides biotechnology manufacturing services to other companies. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Income and expenses relating to Corporate include the costs of the Group headquarters and those of corporate coordination functions in major countries. In addition, Corporate includes other items of income and expense that are not attributable to specific segments, such as certain revenues from intellectual property rights, certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations and sponsorships. Usually, no allocation of Corporate items is made to the segments. As a result, Corporate assets and liabilities principally consist of net liquidity (cash and cash equivalents, marketable securities less financial debts), investments in associated companies, and current and deferred taxes and non-segment-specific environmental remediation and post-employment benefit liabilities. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;Our divisions are supported by the Novartis Institutes for BioMedical Research, Global Drug Development, Novartis Technical Operations and Novartis Business Services organizations. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; The Novartis Institutes for BioMedical Research (NIBR) conducts research activities for the Innovative Medicines Division and also collaborates with Sandoz. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; The Global Drug Development organization oversees all drug development activities for our Innovative Medicines Division and collaborates with our Sandoz Division on the development of its biosimilars portfolio. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; The Novartis Technical Operations organization manages our manufacturing operations across our Innovative Medicines and Sandoz Divisions. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Novartis Business Services (NBS) is our shared services organization that delivers business support services across the Group, such as information technology, real estate and facility services, procurement, product lifecycle services, human resources, and financial reporting and accounting operations. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Following the February 28, 2019, shareholders&amp;#x2019; approval of the spin-off of the Alcon business (refer to Notes 1, 2 and 30 for further details), the Group reported its consolidated financial statements as &amp;#x201c;continuing operations&amp;#x201d; and &amp;#x201c;discontinued operations.&amp;#x201d; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Continuing operations comprise the activities of the Innovative Medicines and Sandoz Divisions, and the continuing Corporate activities. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Discontinued operations include the operational results from the Alcon eye care devices business and certain corporate activities attributable to the Alcon business prior to the spin-off, the gain on distribution of Alcon Inc. to Novartis AG shareholders, and certain other expenses related to the Distribution (refer to Notes 1, 2 and 30 for further details). &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The accounting policies mentioned in Note 1 are used in the reporting of segment results. Inter-segmental sales are made at amounts that are considered to approximate arm&amp;#x2019;s length transactions. The Executive Committee of Novartis evaluates segmental performance and allocates resources among the segments based on a number of measures, including net sales, operating income and net operating assets. Segment net operating assets consist primarily of property, plant and equipment; right-of-use assets; intangible assets; goodwill; inventories; and trade and other operating receivables less operating liabilities. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Segmentation &amp;ndash; consolidated income statements&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 39&amp;nbsp;013&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&amp;nbsp;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;646&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;731&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 48&amp;nbsp;659&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;445&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to continuing and discontinued segments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 792&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 783&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 189&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;981&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 39&amp;nbsp;805&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 38&amp;nbsp;497&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;835&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;872&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;981&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 48&amp;nbsp;659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;498&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other revenues&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;092&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 168&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;927&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;050&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;252&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;334&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;058&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 959&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;121&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;425&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 29&amp;nbsp;896&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 29&amp;nbsp;539&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;636&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;601&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 245&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 34&amp;nbsp;777&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;252&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;657&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;617&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;076&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;534&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;197&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;369&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&amp;nbsp;118&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8&amp;nbsp;152&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;862&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&amp;nbsp;980&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;402&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 922&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;586&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 176&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 644&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 278&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;742&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;831&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;749&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;488&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;608&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;426&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;172&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;287&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;043&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 551&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;752&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 10&amp;nbsp;152&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;086&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income from associated companies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 670&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 673&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;869&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;850&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;78&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;878&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;940&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;807&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;793&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;071&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net loss from discontinued operations before gain on &lt;br&gt;&lt;/br&gt;distribution of Alcon Inc. to Novartis AG shareholders &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gain on distribution of Alcon Inc. to Novartis AG shareholders&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;071&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;737&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Attributable to:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Shareholders of Novartis AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 8&amp;nbsp;072&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 11&amp;nbsp;732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Non-controlling interests&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in net income from continuing operations are:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 91&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 245&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;912&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;952&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;282&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;283&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;318&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;247&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;330&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;305&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;080&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;509&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;315&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;462&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;836&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on property, plant and equipment, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;324&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;116&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;101&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;440&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on intangible assets, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;768&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;506&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;914&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;138&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges and fair value &lt;br&gt;&lt;/br&gt;changes on financial assets, net &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 153 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 18 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 182 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 20 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 335 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 38 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to restructuring provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;229&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;165&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;354&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;492&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation of Novartis equity plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;761&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;64&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;180&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;958&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;067&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&amp;nbsp;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;892&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;731&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;859&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;445&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 44&amp;nbsp;751&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to continuing and discontinued segments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 783&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 741&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 177&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;836&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 82&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 38&amp;nbsp;497&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 35&amp;nbsp;633&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;872&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 10&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;836&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;498&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 44&amp;nbsp;833&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other revenues&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;092&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;266&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;050&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;870&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;334&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;530&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 959&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 890&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;425&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;510&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 29&amp;nbsp;539&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&amp;nbsp;951&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;601&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;568&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 70&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;252&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 31&amp;nbsp;589&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;617&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;907&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;305&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;534&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;505&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;369&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&amp;nbsp;717&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8&amp;nbsp;152&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;7&amp;nbsp;675&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;814&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;402&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8&amp;nbsp;489&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;586&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 977&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 505&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 278&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;629&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;475&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;749&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;622&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;608&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;512&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;426&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;609&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;287&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 551&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;332&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;752&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;800&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;086&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;403&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income from associated companies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&amp;nbsp;432&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&amp;nbsp;438&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;850&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;932&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;940&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 14&amp;nbsp;095&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;793&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;295&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 12&amp;nbsp;800&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net loss from discontinued operations before gain on &lt;br&gt;&lt;/br&gt;distribution of Alcon Inc. to Novartis AG shareholders &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;186 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gain on distribution of Alcon Inc. to Novartis AG shareholders&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income/(loss) from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;737&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 12&amp;nbsp;614&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Attributable to:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Shareholders of Novartis AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 11&amp;nbsp;732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 12&amp;nbsp;611&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Non-controlling interests&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in net income from continuing operations are:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 245&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 292&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;952&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;075&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;283&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;285&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;482&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of right-of-use assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;247&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;305&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;509&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;214&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;315&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;836&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;587&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on property, plant and equipment, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;101&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on intangible assets, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;592&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;506&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;249&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;138&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;841&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges and fair value &lt;br&gt;&lt;/br&gt;changes on financial assets, net &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 18 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 107 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 20 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;113 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 38 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to restructuring provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;229&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;395&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;165&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;94&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;492&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;521&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation of Novartis equity plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;761&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;645&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;067&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;918&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Depreciation of right-of-use assets recognized from January 1, 2019, the date of implementation of IFRS 16 Leases. Note 1 provides additional disclosures. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Segmentation &amp;ndash; consolidated balance sheets&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 83&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 71&amp;nbsp;225&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 16&amp;nbsp;825&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 16&amp;nbsp;468&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 32&amp;nbsp;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 30&amp;nbsp;677&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 132&amp;nbsp;059&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 118&amp;nbsp;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;472&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;332&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;786&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;804&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;56&amp;nbsp;135&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;43&amp;nbsp;683&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;75&amp;nbsp;393&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;62&amp;nbsp;819&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total equity&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 56&amp;nbsp;666&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 55&amp;nbsp;551&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net debt &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&amp;nbsp;481&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&amp;nbsp;938&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&amp;nbsp;481&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&amp;nbsp;938&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net operating assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 67&amp;nbsp;640&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 55&amp;nbsp;893&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 13&amp;nbsp;039&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 12&amp;nbsp;664&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 468&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;932&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 81&amp;nbsp;147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 71&amp;nbsp;489&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in assets and liabilities are:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;863&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;849&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;888&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 551&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 549&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&amp;nbsp;263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to property, plant &lt;br&gt;&lt;/br&gt;and equipment &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 926 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;114 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 229 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 217 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 110 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 143 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;265 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;474 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;489&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;487&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 133&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 136&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 54&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 54&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;676&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;677&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to right-of-use assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 264&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 454&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 346&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 537&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total goodwill and intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 56&amp;nbsp;839&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 46&amp;nbsp;336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;817&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;892&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 152&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 83&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 66&amp;nbsp;808&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 55&amp;nbsp;311&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to goodwill and &lt;br&gt;&lt;/br&gt;intangible assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;235 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 647 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 105 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 68 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 85 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 52 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;425 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 767 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total investment in associated &lt;br&gt;&lt;/br&gt;companies &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 194 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 128 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 9&amp;nbsp;430 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 8&amp;nbsp;509 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 9&amp;nbsp;632 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 8&amp;nbsp;644 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to investment in associated &lt;br&gt;&lt;/br&gt;companies &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 24 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 44 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 11 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 31 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 55 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents, marketable securities, &lt;br&gt;&lt;/br&gt;commodities, time deposits and derivative &lt;br&gt;&lt;/br&gt;financial instruments &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 11&amp;nbsp;563 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 11&amp;nbsp;446 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 11&amp;nbsp;563 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 11&amp;nbsp;446 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debts and derivative &lt;br&gt;&lt;/br&gt;financial instruments &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 36&amp;nbsp;044 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 27&amp;nbsp;384 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 36&amp;nbsp;044 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 27&amp;nbsp;384 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current income tax and deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;880&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;061&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;880&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;061&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Note 29 provides additional disclosures related to net debt &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Excluding the impact of business acquisitions &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows countries that accounted for more than 5% of at least one of the respective Group totals, as well as regional information for net sales to third parties for the years ended December 31, 2020, 2019 and 2018, and for selected non-current assets for the years ended December 31, 2020 and 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="11" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Net sales&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total of selected non-current assets&lt;sup&gt;2&lt;/sup&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; %&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; %&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; %&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; %&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; %&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Country&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 800&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 848&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 795&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&amp;nbsp;904&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&amp;nbsp;032&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&amp;nbsp;484&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&amp;nbsp;280&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&amp;nbsp;618&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 39&amp;nbsp;889&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&amp;nbsp;893&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;France&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;442&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;442&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;505&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;115&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;933&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Germany&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;518&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;120&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;972&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;607&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;554&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japan&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;804&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;575&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 313&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 309&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;China&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;573&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;214&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;953&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 714&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 684&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&amp;nbsp;038&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&amp;nbsp;885&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&amp;nbsp;333&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&amp;nbsp;837&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;296&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 48&amp;nbsp;659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;445&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 44&amp;nbsp;751&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 90&amp;nbsp;379&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 77&amp;nbsp;701&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Region&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18&amp;nbsp;715&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 17&amp;nbsp;933&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 17&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 47&amp;nbsp;798&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 46&amp;nbsp;103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 59&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Americas&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&amp;nbsp;725&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 19&amp;nbsp;713&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&amp;nbsp;032&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&amp;nbsp;391&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 29&amp;nbsp;389&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&amp;nbsp;219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;799&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;460&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;209&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 48&amp;nbsp;659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;445&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 44&amp;nbsp;751&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 90&amp;nbsp;379&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 77&amp;nbsp;701&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales to third party from continuing operations by location of customer &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Total of property, plant and equipment; right-of-use assets; goodwill; intangible assets and investment in associated companies &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group&amp;#x2019;s largest, second-largest and third-largest customers account for approximately 17%, 11% and 6% of net sales, respectively (2019: 18%, 13% and 8%, respectively; 2018: 18%, 14% and 8%, respectively). All segments had sales to these customers in 2020, 2019 and 2018. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The highest amounts of trade receivables outstanding were for these same three customers and amounted to approximately 14%, 12% and 6%, respectively, of the trade receivables at December 31, 2020 (2019: 14%, 12% and 7%, respectively). &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Segmentation &amp;ndash; Net sales by region &lt;sup&gt;1&lt;/sup&gt; &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2020 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2019 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change &lt;br&gt;&lt;/br&gt; (2019 &lt;br&gt;&lt;/br&gt; to 2020) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2018 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change &lt;br&gt;&lt;/br&gt; (2018 &lt;br&gt;&lt;/br&gt; to 2019) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&amp;nbsp;484&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;818&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;296&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14&amp;nbsp;342&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 13&amp;nbsp;789&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;864&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;718&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;458&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;097&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;649&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;635&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 39&amp;nbsp;013&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&amp;nbsp;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;892&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Established Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 29&amp;nbsp;643&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&amp;nbsp;573&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26&amp;nbsp;258&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Emerging Growth Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;634&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;231&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;115&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;963&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;491&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;754&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;501&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;341&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;363&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 772&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 784&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 779&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;646&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;731&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;859&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Established Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&amp;nbsp;089&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Emerging Growth Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;557&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;620&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;626&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18&amp;nbsp;715&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 17&amp;nbsp;933&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 17&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&amp;nbsp;484&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&amp;nbsp;280&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&amp;nbsp;618&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&amp;nbsp;219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;799&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;460&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;241&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;433&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;414&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 48&amp;nbsp;659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;445&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 44&amp;nbsp;751&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Established Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&amp;nbsp;732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 35&amp;nbsp;684&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&amp;nbsp;491&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Emerging Growth Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&amp;nbsp;927&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;761&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;260&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales to third parties from continuing operations by location of customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines Division net sales by business franchise&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2020 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2019 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change &lt;br&gt;&lt;/br&gt; (2019 to &lt;br&gt;&lt;/br&gt; 2020) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2018 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change &lt;br&gt;&lt;/br&gt; (2018 to &lt;br&gt;&lt;/br&gt; 2019) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;958&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;880&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;874&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Promacta/Revolade&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;738&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;416&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;174&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;542&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;338&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;155&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;439&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;585&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;587&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Jakavi&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;339&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;114&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 977&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;561&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;083&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;539&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;556&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 687&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 480&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 235&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 653&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 975&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;099&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 635&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 755&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 828&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kymriah&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 474&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 278&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 71&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lutathera&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 445&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 441&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 164&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Piqray&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 320&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 116&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 176&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Adakveo&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 105&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tabrecta&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;070&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;189&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;139&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Novartis Oncology business unit&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 14&amp;nbsp;711&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 14&amp;nbsp;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 13&amp;nbsp;428&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Immunology, Hepatology and Dermatology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cosentyx&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;995&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;551&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;837&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Ilaris&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 873&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 671&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 554&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Immunology, Hepatology and Dermatology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;868&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;222&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;392&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;933&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;086&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xiidra&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 376&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 192&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 96&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Beovu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;911&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;463&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;995&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;410&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;776&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;558&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;223&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;341&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 920&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 361&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 155&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Mayzent&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 170&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Aimovig&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 164&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 59&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kesimpta&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 80&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;323&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;773&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;429&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2020 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2019 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change &lt;br&gt;&lt;/br&gt; (2019 to &lt;br&gt;&lt;/br&gt; 2020) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2018 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change &lt;br&gt;&lt;/br&gt; (2018 to &lt;br&gt;&lt;/br&gt; 2019) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cardiovascular, Renal and Metabolism&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Entresto&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;497&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;726&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;028&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 68&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;96&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Cardiovascular, Renal and Metabolism&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;498&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;750&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;050&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Respiratory&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xolair &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;251&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;173&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;039&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Ultibro&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 623&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 630&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 703&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Respiratory&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;900&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;825&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;767&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;199&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;297&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;284&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;064&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 980&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;002&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zortress/Certican&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 452&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 485&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Neoral/Sandimmun(e)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 393&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 419&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 463&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Voltaren/Cataflam&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 360&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 417&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 445&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;916&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;291&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;587&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;303&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&amp;nbsp;998&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;268&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Novartis Pharmaceuticals business unit&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 24&amp;nbsp;302&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;344&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 21&amp;nbsp;464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 39&amp;nbsp;013&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&amp;nbsp;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;892&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;nm = not meaningful&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Top 20 Innovative Medicines Division product net sales &amp;ndash; 2020&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Brands &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Business franchise &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Key indication &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; US &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Rest of &lt;br&gt;&lt;/br&gt; world &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td width="21%" height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Cosentyx &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="21%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Immunology, Hepatology &lt;br&gt;&lt;/br&gt; and Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="21%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis, ankylosing &lt;br&gt;&lt;/br&gt; spondylitis, psoriatic &lt;br&gt;&lt;/br&gt; arthritis and &lt;br&gt;&lt;/br&gt; non-radiographic axial &lt;br&gt;&lt;/br&gt; spondyloarthritis &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;516 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;479 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 3&amp;nbsp;995 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;562&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;441&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Entresto &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular, Renal &lt;br&gt;&lt;/br&gt; and Metabolism &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Chronic heart failure &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;277 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;220 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;497 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 859&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;099&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;958&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related macular degeneration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;933&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;933&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Promacta/Revolade &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune thrombocytopenia (ITP), &lt;br&gt;&lt;/br&gt; severe aplastic anemia (SAA) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 833 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 905 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;738 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;&lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic and &lt;br&gt;&lt;/br&gt; adjuvant melanoma; advanced &lt;br&gt;&lt;/br&gt; non-small cell lung cancer (NSCLC) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 569 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 973 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;542 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors and acromegaly&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 837&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 602&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;439&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Jakavi &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF), &lt;br&gt;&lt;/br&gt; polycythemia vera (PV) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;339 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;339 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Xolair &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Respiratory &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe allergic asthma (SAA) &lt;br&gt;&lt;/br&gt; and chronic spontaneous urticaria &lt;br&gt;&lt;/br&gt; (CSU) and nasal polyps &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;251 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;251 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Type 2 diabetes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;199&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;199&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia and GIST&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 315&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 873&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/TSC&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 644&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 439&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;083&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 879&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 964&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 980&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Spinal muscular atrophy (SMA)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 459&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 461&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 920&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Ilaris &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Immunology, Hepatology &lt;br&gt;&lt;/br&gt; and Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS, &lt;br&gt;&lt;/br&gt; TRAPS, HIDS/MKD, FMF, SJIA, &lt;br&gt;&lt;/br&gt; AOSD and gout) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 400 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 473 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 873 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HR+/HER2- metastatic breast cancer&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 318&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 369&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 687&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic iron overload&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 138&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 515&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 653&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Renal cell carcinoma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 376&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 635&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 products total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 11&amp;nbsp;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 18&amp;nbsp;790&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 29&amp;nbsp;916&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;216&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;881&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;097&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 14&amp;nbsp;342&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 24&amp;nbsp;671&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 39&amp;nbsp;013&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Top 20 Innovative Medicines Division product net sales &amp;ndash; 2019&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Brands &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Business franchise &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Key indication &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; US &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rest of &lt;br&gt;&lt;/br&gt; world &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td width="21%" height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Cosentyx &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="21%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology, Hepatology &lt;br&gt;&lt;/br&gt; and Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="21%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis, ankylosing &lt;br&gt;&lt;/br&gt; spondylitis and psoriatic arthritis &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;220 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;331 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 3&amp;nbsp;551 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;736&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;487&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;223&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related macular degeneration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;086&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;086&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 804&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;076&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;880&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Entresto &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular, Renal &lt;br&gt;&lt;/br&gt; and Metabolism &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Chronic heart failure &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 925 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 801 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;726 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors and acromegaly&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 881&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 704&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;585&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/TSC&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 536&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;539&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Promacta/Revolade &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune thrombocytopenia (ITP), &lt;br&gt;&lt;/br&gt; severe aplastic anemia (SAA) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 691 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 725 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;416 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;&lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic and &lt;br&gt;&lt;/br&gt; adjuvant melanoma; advanced &lt;br&gt;&lt;/br&gt; non-small cell lung cancer (NSCLC) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 481 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 857 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;338 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Type 2 diabetes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;297&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;297&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia and GIST&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 334&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 929&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Xolair &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Respiratory &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe allergic asthma (SAA) &lt;br&gt;&lt;/br&gt; and chronic spontaneous urticaria &lt;br&gt;&lt;/br&gt; (CSU) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;173 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;173 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Jakavi &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF), &lt;br&gt;&lt;/br&gt; polycythemia vera (PV) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;114 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;114 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 86&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 978&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;064&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;012&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic iron overload&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 450&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 525&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 975&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Renal cell carcinoma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 332&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 423&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 755&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Ilaris &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Immunology, Hepatology &lt;br&gt;&lt;/br&gt; and Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS, &lt;br&gt;&lt;/br&gt; TRAPS, HIDS/MKD, FMF, SJIA, &lt;br&gt;&lt;/br&gt; AOSD and gout) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 304 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 367 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 671 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zortress/Certican&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Transplantation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 316&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 485&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HR+/HER2- metastatic breast cancer&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 480&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 products total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 10&amp;nbsp;679&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 17&amp;nbsp;967&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 28&amp;nbsp;646&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;958&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;068&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 13&amp;nbsp;789&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;925&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&amp;nbsp;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Top 20 Innovative Medicines Division product net sales &amp;ndash; 2018&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Brands &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Business franchise &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Key indication &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; US &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rest of &lt;br&gt;&lt;/br&gt; world &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td width="21%" height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="21%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="21%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;765&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;576&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;341&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Cosentyx &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology, Hepatology &lt;br&gt;&lt;/br&gt; and Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis, ankylosing &lt;br&gt;&lt;/br&gt; spondylitis and psoriatic arthritis &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;674 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;163 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;837 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related macular degeneration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 806&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;068&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;874&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors and acromegaly&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 817&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 770&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;587&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia and GIST&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 440&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;121&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;561&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/TSC&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 929&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 627&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;556&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Type 2 diabetes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;284&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;284&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Promacta/Revolade &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune thrombocytopenia (ITP), &lt;br&gt;&lt;/br&gt; severe aplastic anemia (SAA) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 581 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 593 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;174 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;&lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic and &lt;br&gt;&lt;/br&gt; adjuvant melanoma; advanced &lt;br&gt;&lt;/br&gt; non-small cell lung cancer (NSCLC) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 457 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 698 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;155 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic iron overload&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 521&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 578&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;099&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Xolair &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Respiratory &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe allergic asthma (SAA) &lt;br&gt;&lt;/br&gt; and chronic spontaneous urticaria &lt;br&gt;&lt;/br&gt; (CSU) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;039 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;039 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Entresto &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular, Renal &lt;br&gt;&lt;/br&gt; and Metabolism &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Chronic heart failure &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 556 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 472 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;028 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 84&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 939&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 983&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;002&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Jakavi &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF), &lt;br&gt;&lt;/br&gt; polycythemia vera (PV) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 977 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 977 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Renal cell carcinoma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 404&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 828&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Ilaris &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Immunology, Hepatology &lt;br&gt;&lt;/br&gt; and Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS, &lt;br&gt;&lt;/br&gt; TRAPS, HIDS/MKD, FMF, SJIA, &lt;br&gt;&lt;/br&gt; AOSD and gout) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 262 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 292 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 554 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Travoprost Group &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Ophthalmology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Reduction of elevated intraocular &lt;br&gt;&lt;/br&gt; pressure &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 194 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 323 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 517 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zortress/Certican&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Transplantation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 145&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 319&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 products total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;654&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 17&amp;nbsp;292&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&amp;nbsp;946&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;210&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;736&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;946&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;864&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;028&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;892&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Sandoz Division net sales by business franchise&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2020 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2019 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change &lt;br&gt;&lt;/br&gt; (2019 to &lt;br&gt;&lt;/br&gt; 2020) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2018 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change &lt;br&gt;&lt;/br&gt; (2018 to &lt;br&gt;&lt;/br&gt; 2019) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Retail Generics &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&amp;nbsp;244&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;880&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Biopharmaceuticals&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;928&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;607&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;436&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Anti-Infectives&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 474&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 534&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;646&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;731&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;859&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Of which USD 694 million (2019: USD 784 million; 2018: USD 826 million) represents anti-infectives sold under the Sandoz name &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The product portfolio of Sandoz is widely spread in 2020, 2019 and 2018.&lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Segmentation &amp;ndash; other revenue&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Profit-sharing income&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 835&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 732&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 835&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 734&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Royalty income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 107&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 168&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 300&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Milestone income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 231&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 54&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other revenues&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;092&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 168&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Innovative Medicines &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Profit-sharing income&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 732&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 874&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 734&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 877&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Royalty income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 162&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Milestone income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 128&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 231&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 173&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other revenues&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;092&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;266&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
  <ifrs-full:DisclosureOfOperatingSegmentsExplanatory contextRef="AR_D-CurrentYear">&lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Segmentation &amp;ndash; consolidated income statements&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 39&amp;nbsp;013&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&amp;nbsp;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;646&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;731&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 48&amp;nbsp;659&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;445&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to continuing and discontinued segments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 792&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 783&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 189&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;981&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 39&amp;nbsp;805&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 38&amp;nbsp;497&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;835&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;872&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;981&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 48&amp;nbsp;659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;498&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other revenues&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;092&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 168&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;927&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;050&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;252&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;334&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;058&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 959&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;121&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;425&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 29&amp;nbsp;896&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 29&amp;nbsp;539&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;636&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;601&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 245&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 34&amp;nbsp;777&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;252&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;657&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;617&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;076&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;534&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;197&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;369&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&amp;nbsp;118&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8&amp;nbsp;152&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;862&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&amp;nbsp;980&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;402&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 922&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;586&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 176&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 644&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 278&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;742&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;831&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;749&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;488&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;608&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;426&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;172&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;287&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;043&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 551&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;752&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 10&amp;nbsp;152&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;086&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income from associated companies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 670&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 673&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;869&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;850&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;78&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;878&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;940&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;807&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;793&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;071&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net loss from discontinued operations before gain on &lt;br&gt;&lt;/br&gt;distribution of Alcon Inc. to Novartis AG shareholders &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gain on distribution of Alcon Inc. to Novartis AG shareholders&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;071&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;737&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Attributable to:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Shareholders of Novartis AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 8&amp;nbsp;072&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 11&amp;nbsp;732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Non-controlling interests&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in net income from continuing operations are:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 91&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 245&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;912&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;952&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;282&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;283&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;318&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;247&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;330&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;305&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;080&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;509&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;315&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;462&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;836&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on property, plant and equipment, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;324&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;116&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;101&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;440&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on intangible assets, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;768&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;506&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;914&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;138&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges and fair value &lt;br&gt;&lt;/br&gt;changes on financial assets, net &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 153 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 18 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 182 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 20 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 335 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 38 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to restructuring provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;229&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;165&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;354&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;492&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation of Novartis equity plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;761&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;64&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;180&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;958&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;067&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&amp;nbsp;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;892&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;731&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;859&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;445&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 44&amp;nbsp;751&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to continuing and discontinued segments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 783&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 741&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 177&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;836&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 82&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 38&amp;nbsp;497&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 35&amp;nbsp;633&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;872&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 10&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;836&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;498&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 44&amp;nbsp;833&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other revenues&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;092&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;266&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;050&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;870&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;334&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;530&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 959&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 890&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;425&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;510&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 29&amp;nbsp;539&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&amp;nbsp;951&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;601&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;568&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 70&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;252&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 31&amp;nbsp;589&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;617&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;907&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;305&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;534&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;505&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;369&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&amp;nbsp;717&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8&amp;nbsp;152&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;7&amp;nbsp;675&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;814&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;402&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8&amp;nbsp;489&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;586&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 977&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 505&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 278&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;629&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;475&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;749&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;622&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;608&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;512&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;426&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;609&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;287&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 551&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;332&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;752&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;800&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;086&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;403&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income from associated companies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&amp;nbsp;432&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&amp;nbsp;438&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;850&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;932&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;940&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 14&amp;nbsp;095&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;793&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;295&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 12&amp;nbsp;800&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net loss from discontinued operations before gain on &lt;br&gt;&lt;/br&gt;distribution of Alcon Inc. to Novartis AG shareholders &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;186 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gain on distribution of Alcon Inc. to Novartis AG shareholders&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income/(loss) from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;737&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 12&amp;nbsp;614&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Attributable to:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Shareholders of Novartis AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 11&amp;nbsp;732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 12&amp;nbsp;611&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Non-controlling interests&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in net income from continuing operations are:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 245&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 292&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;952&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;075&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;283&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;285&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;482&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of right-of-use assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;247&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;305&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;509&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;214&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;315&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;836&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;587&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on property, plant and equipment, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;101&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on intangible assets, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;592&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;506&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;249&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;138&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;841&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges and fair value &lt;br&gt;&lt;/br&gt;changes on financial assets, net &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 18 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 107 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 20 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;113 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 38 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to restructuring provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;229&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;395&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;165&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;94&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;492&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;521&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation of Novartis equity plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;761&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;645&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;067&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;918&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Depreciation of right-of-use assets recognized from January 1, 2019, the date of implementation of IFRS 16 Leases. Note 1 provides additional disclosures. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
  <nvs:DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Segmentation &amp;ndash; consolidated balance sheets&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 83&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 71&amp;nbsp;225&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 16&amp;nbsp;825&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 16&amp;nbsp;468&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 32&amp;nbsp;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 30&amp;nbsp;677&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 132&amp;nbsp;059&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 118&amp;nbsp;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;472&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;332&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;786&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;804&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;56&amp;nbsp;135&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;43&amp;nbsp;683&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;75&amp;nbsp;393&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;62&amp;nbsp;819&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total equity&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 56&amp;nbsp;666&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 55&amp;nbsp;551&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net debt &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&amp;nbsp;481&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&amp;nbsp;938&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&amp;nbsp;481&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&amp;nbsp;938&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net operating assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 67&amp;nbsp;640&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 55&amp;nbsp;893&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 13&amp;nbsp;039&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 12&amp;nbsp;664&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 468&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;932&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 81&amp;nbsp;147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 71&amp;nbsp;489&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in assets and liabilities are:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;863&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;849&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;888&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 551&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 549&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&amp;nbsp;263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to property, plant &lt;br&gt;&lt;/br&gt;and equipment &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 926 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;114 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 229 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 217 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 110 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 143 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;265 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;474 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;489&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;487&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 133&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 136&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 54&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 54&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;676&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;677&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to right-of-use assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 264&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 454&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 346&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 537&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total goodwill and intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 56&amp;nbsp;839&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 46&amp;nbsp;336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;817&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;892&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 152&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 83&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 66&amp;nbsp;808&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 55&amp;nbsp;311&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to goodwill and &lt;br&gt;&lt;/br&gt;intangible assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;235 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 647 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 105 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 68 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 85 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 52 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;425 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 767 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total investment in associated &lt;br&gt;&lt;/br&gt;companies &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 194 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 128 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 9&amp;nbsp;430 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 8&amp;nbsp;509 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 9&amp;nbsp;632 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 8&amp;nbsp;644 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to investment in associated &lt;br&gt;&lt;/br&gt;companies &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 24 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 44 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 11 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 31 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 55 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents, marketable securities, &lt;br&gt;&lt;/br&gt;commodities, time deposits and derivative &lt;br&gt;&lt;/br&gt;financial instruments &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 11&amp;nbsp;563 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 11&amp;nbsp;446 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 11&amp;nbsp;563 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 11&amp;nbsp;446 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debts and derivative &lt;br&gt;&lt;/br&gt;financial instruments &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 36&amp;nbsp;044 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 27&amp;nbsp;384 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 36&amp;nbsp;044 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 27&amp;nbsp;384 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current income tax and deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;880&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;061&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;880&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;061&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Note 29 provides additional disclosures related to net debt &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Excluding the impact of business acquisitions &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock>
  <nvs:DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="11" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Net sales&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total of selected non-current assets&lt;sup&gt;2&lt;/sup&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; %&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; %&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; %&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; %&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; %&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Country&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 800&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 848&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 795&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&amp;nbsp;904&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&amp;nbsp;032&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&amp;nbsp;484&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&amp;nbsp;280&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&amp;nbsp;618&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 39&amp;nbsp;889&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&amp;nbsp;893&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;France&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;442&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;442&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;505&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;115&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;933&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Germany&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;518&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;120&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;972&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;607&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;554&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japan&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;804&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;575&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 313&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 309&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;China&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;573&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;214&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;953&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 714&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 684&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&amp;nbsp;038&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&amp;nbsp;885&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&amp;nbsp;333&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&amp;nbsp;837&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;296&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 48&amp;nbsp;659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;445&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 44&amp;nbsp;751&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 90&amp;nbsp;379&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 77&amp;nbsp;701&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Region&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18&amp;nbsp;715&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 17&amp;nbsp;933&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 17&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 47&amp;nbsp;798&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 46&amp;nbsp;103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 59&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Americas&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&amp;nbsp;725&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 19&amp;nbsp;713&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&amp;nbsp;032&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&amp;nbsp;391&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 29&amp;nbsp;389&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&amp;nbsp;219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;799&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;460&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;209&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 48&amp;nbsp;659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;445&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 44&amp;nbsp;751&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 90&amp;nbsp;379&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 77&amp;nbsp;701&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales to third party from continuing operations by location of customer &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Total of property, plant and equipment; right-of-use assets; goodwill; intangible assets and investment in associated companies &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock>
  <nvs:DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Segmentation &amp;ndash; Net sales by region &lt;sup&gt;1&lt;/sup&gt; &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2020 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2019 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change &lt;br&gt;&lt;/br&gt; (2019 &lt;br&gt;&lt;/br&gt; to 2020) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2018 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change &lt;br&gt;&lt;/br&gt; (2018 &lt;br&gt;&lt;/br&gt; to 2019) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&amp;nbsp;484&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;818&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;296&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14&amp;nbsp;342&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 13&amp;nbsp;789&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;864&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;718&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;458&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;097&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;649&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;635&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 39&amp;nbsp;013&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&amp;nbsp;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;892&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Established Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 29&amp;nbsp;643&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&amp;nbsp;573&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26&amp;nbsp;258&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Emerging Growth Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;634&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;231&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;115&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;963&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;491&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;754&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;501&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;341&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;363&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 772&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 784&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 779&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;646&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;731&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;859&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Established Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&amp;nbsp;089&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Emerging Growth Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;557&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;620&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;626&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18&amp;nbsp;715&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 17&amp;nbsp;933&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 17&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&amp;nbsp;484&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&amp;nbsp;280&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&amp;nbsp;618&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&amp;nbsp;219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;799&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;460&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;241&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;433&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;414&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 48&amp;nbsp;659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 47&amp;nbsp;445&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 44&amp;nbsp;751&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Established Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&amp;nbsp;732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 35&amp;nbsp;684&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&amp;nbsp;491&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Of which in Emerging Growth Markets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&amp;nbsp;927&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;761&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;260&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales to third parties from continuing operations by location of customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock>
  <nvs:DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">&lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines Division net sales by business franchise&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2020 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2019 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change &lt;br&gt;&lt;/br&gt; (2019 to &lt;br&gt;&lt;/br&gt; 2020) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2018 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change &lt;br&gt;&lt;/br&gt; (2018 to &lt;br&gt;&lt;/br&gt; 2019) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;958&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;880&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;874&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Promacta/Revolade&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;738&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;416&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;174&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;542&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;338&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;155&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;439&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;585&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;587&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Jakavi&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;339&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;114&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 977&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;561&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;083&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;539&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;556&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 687&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 480&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 235&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 653&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 975&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;099&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 635&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 755&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 828&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kymriah&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 474&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 278&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 71&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lutathera&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 445&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 441&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 164&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Piqray&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 320&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 116&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 176&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Adakveo&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 105&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tabrecta&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;070&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;189&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;139&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Novartis Oncology business unit&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 14&amp;nbsp;711&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 14&amp;nbsp;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 13&amp;nbsp;428&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Immunology, Hepatology and Dermatology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cosentyx&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;995&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;551&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;837&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Ilaris&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 873&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 671&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 554&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Immunology, Hepatology and Dermatology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;868&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;222&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;392&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;933&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;086&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xiidra&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 376&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 192&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 96&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Beovu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;911&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;463&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;995&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;410&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;776&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;558&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;223&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;341&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 920&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 361&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 155&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Mayzent&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 170&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Aimovig&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 164&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 59&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kesimpta&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 80&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;323&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;773&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;429&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2020 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2019 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change &lt;br&gt;&lt;/br&gt; (2019 to &lt;br&gt;&lt;/br&gt; 2020) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2018 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change &lt;br&gt;&lt;/br&gt; (2018 to &lt;br&gt;&lt;/br&gt; 2019) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cardiovascular, Renal and Metabolism&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Entresto&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;497&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;726&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;028&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 68&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;96&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Cardiovascular, Renal and Metabolism&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;498&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;750&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;050&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Respiratory&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xolair &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;251&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;173&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;039&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Ultibro&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 623&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 630&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 703&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Respiratory&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;900&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;825&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;767&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;199&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;297&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;284&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;064&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 980&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;002&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zortress/Certican&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 452&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 485&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Neoral/Sandimmun(e)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 393&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 419&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 463&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Voltaren/Cataflam&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 360&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 417&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 445&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;916&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;291&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;587&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;303&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&amp;nbsp;998&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;268&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Novartis Pharmaceuticals business unit&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 24&amp;nbsp;302&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;344&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 21&amp;nbsp;464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 39&amp;nbsp;013&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&amp;nbsp;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;892&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;nm = not meaningful&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock>
  <nvs:DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4InnovativeMedicinesMember">&lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Top 20 Innovative Medicines Division product net sales &amp;ndash; 2020&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Brands &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Business franchise &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Key indication &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; US &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Rest of &lt;br&gt;&lt;/br&gt; world &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td width="21%" height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Cosentyx &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="21%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Immunology, Hepatology &lt;br&gt;&lt;/br&gt; and Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="21%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis, ankylosing &lt;br&gt;&lt;/br&gt; spondylitis, psoriatic &lt;br&gt;&lt;/br&gt; arthritis and &lt;br&gt;&lt;/br&gt; non-radiographic axial &lt;br&gt;&lt;/br&gt; spondyloarthritis &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;516 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;479 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 3&amp;nbsp;995 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;562&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;441&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Entresto &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular, Renal &lt;br&gt;&lt;/br&gt; and Metabolism &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Chronic heart failure &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;277 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;220 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;497 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 859&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;099&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;958&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related macular degeneration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;933&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;933&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Promacta/Revolade &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune thrombocytopenia (ITP), &lt;br&gt;&lt;/br&gt; severe aplastic anemia (SAA) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 833 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 905 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;738 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;&lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic and &lt;br&gt;&lt;/br&gt; adjuvant melanoma; advanced &lt;br&gt;&lt;/br&gt; non-small cell lung cancer (NSCLC) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 569 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 973 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;542 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors and acromegaly&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 837&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 602&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;439&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Jakavi &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF), &lt;br&gt;&lt;/br&gt; polycythemia vera (PV) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;339 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;339 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Xolair &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Respiratory &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe allergic asthma (SAA) &lt;br&gt;&lt;/br&gt; and chronic spontaneous urticaria &lt;br&gt;&lt;/br&gt; (CSU) and nasal polyps &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;251 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;251 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Type 2 diabetes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;199&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;199&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia and GIST&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 315&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 873&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/TSC&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 644&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 439&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;083&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 879&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 964&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 980&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Spinal muscular atrophy (SMA)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 459&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 461&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 920&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Ilaris &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Immunology, Hepatology &lt;br&gt;&lt;/br&gt; and Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS, &lt;br&gt;&lt;/br&gt; TRAPS, HIDS/MKD, FMF, SJIA, &lt;br&gt;&lt;/br&gt; AOSD and gout) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 400 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 473 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 873 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HR+/HER2- metastatic breast cancer&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 318&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 369&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 687&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic iron overload&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 138&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 515&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 653&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Renal cell carcinoma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 376&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 635&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 products total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 11&amp;nbsp;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 18&amp;nbsp;790&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 29&amp;nbsp;916&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;216&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;881&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;097&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 14&amp;nbsp;342&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 24&amp;nbsp;671&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 39&amp;nbsp;013&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Top 20 Innovative Medicines Division product net sales &amp;ndash; 2019&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Brands &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Business franchise &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Key indication &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; US &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rest of &lt;br&gt;&lt;/br&gt; world &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td width="21%" height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Cosentyx &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="21%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology, Hepatology &lt;br&gt;&lt;/br&gt; and Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="21%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis, ankylosing &lt;br&gt;&lt;/br&gt; spondylitis and psoriatic arthritis &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;220 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;331 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 3&amp;nbsp;551 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;736&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;487&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;223&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related macular degeneration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;086&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;086&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 804&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;076&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;880&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Entresto &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular, Renal &lt;br&gt;&lt;/br&gt; and Metabolism &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Chronic heart failure &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 925 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 801 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;726 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors and acromegaly&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 881&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 704&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;585&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/TSC&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 536&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;539&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Promacta/Revolade &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune thrombocytopenia (ITP), &lt;br&gt;&lt;/br&gt; severe aplastic anemia (SAA) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 691 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 725 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;416 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;&lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic and &lt;br&gt;&lt;/br&gt; adjuvant melanoma; advanced &lt;br&gt;&lt;/br&gt; non-small cell lung cancer (NSCLC) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 481 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 857 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;338 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Type 2 diabetes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;297&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;297&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia and GIST&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 334&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 929&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Xolair &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Respiratory &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe allergic asthma (SAA) &lt;br&gt;&lt;/br&gt; and chronic spontaneous urticaria &lt;br&gt;&lt;/br&gt; (CSU) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;173 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;173 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Jakavi &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF), &lt;br&gt;&lt;/br&gt; polycythemia vera (PV) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;114 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;114 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 86&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 978&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;064&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;012&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic iron overload&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 450&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 525&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 975&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Renal cell carcinoma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 332&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 423&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 755&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Ilaris &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Immunology, Hepatology &lt;br&gt;&lt;/br&gt; and Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS, &lt;br&gt;&lt;/br&gt; TRAPS, HIDS/MKD, FMF, SJIA, &lt;br&gt;&lt;/br&gt; AOSD and gout) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 304 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 367 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 671 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zortress/Certican&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Transplantation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 316&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 485&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HR+/HER2- metastatic breast cancer&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 480&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 products total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 10&amp;nbsp;679&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 17&amp;nbsp;967&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 28&amp;nbsp;646&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;958&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;068&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 13&amp;nbsp;789&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;925&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&amp;nbsp;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Top 20 Innovative Medicines Division product net sales &amp;ndash; 2018&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Brands &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Business franchise &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Key indication &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; US &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rest of &lt;br&gt;&lt;/br&gt; world &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td width="21%" height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="21%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="21%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;765&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;576&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;341&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Cosentyx &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology, Hepatology &lt;br&gt;&lt;/br&gt; and Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis, ankylosing &lt;br&gt;&lt;/br&gt; spondylitis and psoriatic arthritis &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;674 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;163 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;837 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Ophthalmology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related macular degeneration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 806&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;068&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;874&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors and acromegaly&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 817&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 770&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;587&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia and GIST&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 440&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;121&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;561&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/TSC&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 929&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 627&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;556&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Type 2 diabetes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;284&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;284&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Promacta/Revolade &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune thrombocytopenia (ITP), &lt;br&gt;&lt;/br&gt; severe aplastic anemia (SAA) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 581 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 593 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;174 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;&lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic and &lt;br&gt;&lt;/br&gt; adjuvant melanoma; advanced &lt;br&gt;&lt;/br&gt; non-small cell lung cancer (NSCLC) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 457 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 698 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;155 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic iron overload&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 521&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 578&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;099&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Xolair &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Respiratory &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe allergic asthma (SAA) &lt;br&gt;&lt;/br&gt; and chronic spontaneous urticaria &lt;br&gt;&lt;/br&gt; (CSU) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;039 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;039 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Entresto &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular, Renal &lt;br&gt;&lt;/br&gt; and Metabolism &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Chronic heart failure &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 556 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 472 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;028 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 84&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 939&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 983&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;002&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Jakavi &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Oncology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF), &lt;br&gt;&lt;/br&gt; polycythemia vera (PV) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 977 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 977 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Oncology&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Renal cell carcinoma&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 404&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 828&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Ilaris &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Immunology, Hepatology &lt;br&gt;&lt;/br&gt; and Dermatology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS, &lt;br&gt;&lt;/br&gt; TRAPS, HIDS/MKD, FMF, SJIA, &lt;br&gt;&lt;/br&gt; AOSD and gout) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 262 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 292 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 554 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Travoprost Group &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Ophthalmology &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Reduction of elevated intraocular &lt;br&gt;&lt;/br&gt; pressure &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 194 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 323 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 517 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zortress/Certican&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Transplantation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 145&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 319&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 products total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;654&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 17&amp;nbsp;292&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&amp;nbsp;946&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;210&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;736&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;946&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;864&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;028&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;892&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Net sales reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock>
  <nvs:DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019SegmentsAxis_nvs-2020Q4SandozMember">&lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Sandoz Division net sales by business franchise&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2020 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2019 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change &lt;br&gt;&lt;/br&gt; (2019 to &lt;br&gt;&lt;/br&gt; 2020) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2018 &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change &lt;br&gt;&lt;/br&gt; (2018 to &lt;br&gt;&lt;/br&gt; 2019) &lt;br&gt;&lt;/br&gt; USD % &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Retail Generics &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&amp;nbsp;244&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;880&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Biopharmaceuticals&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;928&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;607&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;436&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Anti-Infectives&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 474&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 534&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;646&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;731&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;859&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Of which USD 694 million (2019: USD 784 million; 2018: USD 826 million) represents anti-infectives sold under the Sandoz name &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock>
  <nvs:DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Segmentation &amp;ndash; other revenue&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Profit-sharing income&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 835&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 732&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 835&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 734&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Royalty income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 107&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 168&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 300&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Milestone income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 231&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 54&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other revenues&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;092&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 168&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Innovative Medicines &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Corporate (including eliminations)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Group &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Profit-sharing income&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 732&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 874&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 734&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 877&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Royalty income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 162&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Milestone income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 128&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 231&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 173&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other revenues&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;092&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;266&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock>
  <ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;4. Associated companies&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Net income statement effect&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other comprehensive income effect&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total comprehensive income effect&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018 &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Roche Holding AG, Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 677&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 662&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 526&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;56&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;94&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 621&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 568&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 601&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;GlaxoSmithKline Consumer &lt;br&gt;&lt;/br&gt;Healthcare Holdings Ltd., UK &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 5&amp;nbsp;910 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;557 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 5&amp;nbsp;353 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies related to continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 673&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&amp;nbsp;438&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;56&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;94&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;482&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 617&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 565&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;956&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="20"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="20"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; In 2018, Novartis share of other comprehensive income recognized by associated companies, net of taxes of USD 511 million was recycled into the consolidated income statement as a result of the divestment of the investment in GSK Consumer Healthcare Holdings Ltd. No Novartis share of other comprehensive income recognized by associated companies, net of taxes was recycled into the consolidated income statement in 2020 and 2019. &lt;b&gt;&lt;/b&gt; &lt;b&gt;&lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has a significant investment in Roche Holding AG, Basel (Roche), as well as certain other smaller investments that are accounted for as associated companies. The investment in GlaxoSmithKline Consumer Healthcare Holdings Ltd., Brentford, Middlesex, UK, was divested on June 1, 2018, to GlaxoSmithKline plc, Great Britain. &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Balance sheet value&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Roche Holding AG, Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;407&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;445&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 225&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 199&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;644&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Roche Holding AG &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group&amp;#x2019;s holding in Roche voting shares was 33.3% at December 31, 2020, 2019 and 2018. This investment represents approximately 6.2% of Roche&amp;#x2019;s total outstanding voting and non-voting equity instruments at December 31, 2020, 2019 and 2018. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Since full-year 2020 financial data for Roche is not available when Novartis produces its consolidated financial results, a survey of analyst estimates is used to estimate the Group&amp;#x2019;s share of Roche&amp;#x2019;s net income. Any differences between these estimates and actual results will be adjusted in the Group&amp;#x2019;s 2021 consolidated financial statements when available. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following tables show summarized financial information for Roche, including current values of fair value adjustments made at the time of the acquisition of the shares, for the year ended December 31, 2019, and for the six months ended June 30, 2020 (since full-year 2020 data is not yet available): &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(CHF billions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Current assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Non-current &lt;br&gt;&lt;/br&gt; assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Current &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Non-current &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 31.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 56.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 23.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;June 30, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 27.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 55.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 22.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(CHF billions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Revenue &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Net income &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other &lt;br&gt;&lt;/br&gt; comprehen- &lt;br&gt;&lt;/br&gt; sive income &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br&gt;&lt;/br&gt; comprehen- &lt;br&gt;&lt;/br&gt; sive income &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 63.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;0.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;June 30, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;0.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;A purchase price allocation was performed on the basis of publicly available information at the time of acquisition of the investment. The December 31, 2020, balance sheet value allocation is as follows: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis share of Roche&amp;#x2019;s estimated net assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;585&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis share of reappraised intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 117&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Implicit Novartis goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current value of share in net identifiable assets &lt;br&gt;&lt;/br&gt;and goodwill &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 5&amp;nbsp;935 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated equity accounting adjustments and translation effects less dividends received&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;472&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Balance sheet value&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;407&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The identified intangible assets principally relate to the value of currently marketed products and are amortized on a straight-line basis over their estimated average useful life of 20 years. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2020, dividends received from Roche in relation to the distribution of its 2019 net income amounted to USD&amp;nbsp;487 million (2019: USD 460 million in relation to the distribution of its 2018 net income). &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The consolidated income statement effects from applying Novartis accounting principles for this investment in 2020, 2019 and 2018 are as follows: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis share of Roche's &lt;br&gt;&lt;/br&gt;estimated current-year &lt;br&gt;&lt;/br&gt;consolidated net income &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 913 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 910 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 799 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prior-year adjustment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;64&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of fair value &lt;br&gt;&lt;/br&gt;adjustments relating to &lt;br&gt;&lt;/br&gt;intangible assets, net of taxes &lt;br&gt;&lt;/br&gt;of USD 26 million (2019: USD 24 &lt;br&gt;&lt;/br&gt;million; 2018: USD 40 million) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;172 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;162 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;148 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Partial release of deferred tax liability recognized&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income effect&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 677&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 662&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 526&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The publicly quoted market value of the Novartis interest in Roche (SIX symbol: RO) at December&amp;nbsp;31, 2020, was USD&amp;nbsp;18.8 billion (2019: USD&amp;nbsp;16.9 billion). &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;GlaxoSmithKline Consumer Healthcare Holdings&amp;nbsp;Ltd.&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On March 27, 2018, Novartis entered into an agreement with GlaxoSmithKline plc, Great Britain (GSK), to divest its 36.5% stake in GSK Consumer Healthcare Holdings Ltd. (GSK Consumer Healthcare) to GSK for USD 13.0 billion in cash. As a result, Novartis discontinued the use of equity method accounting starting from April 1, 2018. The divestment transaction closed on June 1, 2018, and Novartis realized a pre-tax gain of USD 5.8 billion, recorded in income from associated companies. See Note 2. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;GSK Consumer Healthcare was formed in March 2015 via contribution of businesses from both Novartis and GSK. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Until June 1, 2018, Novartis had a 36.5% interest in GSK Consumer Healthcare and had four of 11 seats on the GSK Consumer Healthcare board of directors. Furthermore, Novartis had customary minority rights as well as exit rights at a predefined, market-based pricing mechanism. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The consolidated income statement effects from applying Novartis accounting principles for this investment in 2018 are as follows: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis share of &lt;br&gt;&lt;/br&gt;GSK Consumer Healthcare's &lt;br&gt;&lt;/br&gt;estimated current-year &lt;br&gt;&lt;/br&gt;consolidated net income &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 119 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prior-year adjustment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of fair value &lt;br&gt;&lt;/br&gt;adjustments relating to &lt;br&gt;&lt;/br&gt;intangible assets and inventory, &lt;br&gt;&lt;/br&gt;net of taxes of USD 1 million &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Pre-tax gain on divestment of GSK Consumer Healthcare&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;790&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income effect&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;910&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory>
  <ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Net income statement effect&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other comprehensive income effect&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total comprehensive income effect&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018 &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Roche Holding AG, Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 677&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 662&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 526&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;56&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;94&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 621&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 568&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 601&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;GlaxoSmithKline Consumer &lt;br&gt;&lt;/br&gt;Healthcare Holdings Ltd., UK &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 5&amp;nbsp;910 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;557 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 5&amp;nbsp;353 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies related to continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 673&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&amp;nbsp;438&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;56&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;94&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;482&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 617&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 565&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;956&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="20"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="20"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; In 2018, Novartis share of other comprehensive income recognized by associated companies, net of taxes of USD 511 million was recycled into the consolidated income statement as a result of the divestment of the investment in GSK Consumer Healthcare Holdings Ltd. No Novartis share of other comprehensive income recognized by associated companies, net of taxes was recycled into the consolidated income statement in 2020 and 2019. &lt;b&gt;&lt;/b&gt; &lt;b&gt;&lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory>
  <nvs:DisclosureOfAssociatesBalanceSheetTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Balance sheet value&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Roche Holding AG, Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;407&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;445&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 225&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 199&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;644&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfAssociatesBalanceSheetTableTextBlock>
  <nvs:AssociatesSummarizedFinancialInformationTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(CHF billions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Current assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Non-current &lt;br&gt;&lt;/br&gt; assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Current &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Non-current &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 31.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 56.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 23.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;June 30, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 27.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 55.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 22.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(CHF billions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Revenue &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Net income &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other &lt;br&gt;&lt;/br&gt; comprehen- &lt;br&gt;&lt;/br&gt; sive income &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br&gt;&lt;/br&gt; comprehen- &lt;br&gt;&lt;/br&gt; sive income &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 63.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;0.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;June 30, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;0.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:AssociatesSummarizedFinancialInformationTableTextBlock>
  <nvs:PurchasePriceAllocationAssociatesTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis share of Roche&amp;#x2019;s estimated net assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;585&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis share of reappraised intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 117&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Implicit Novartis goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current value of share in net identifiable assets &lt;br&gt;&lt;/br&gt;and goodwill &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 5&amp;nbsp;935 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated equity accounting adjustments and translation effects less dividends received&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;472&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Balance sheet value&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;407&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:PurchasePriceAllocationAssociatesTableTextBlock>
  <nvs:DisclosureOfAssociatesNetIncomeEffectTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4RocheHoldingAGMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis share of Roche's &lt;br&gt;&lt;/br&gt;estimated current-year &lt;br&gt;&lt;/br&gt;consolidated net income &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 913 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 910 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 799 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prior-year adjustment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;64&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of fair value &lt;br&gt;&lt;/br&gt;adjustments relating to &lt;br&gt;&lt;/br&gt;intangible assets, net of taxes &lt;br&gt;&lt;/br&gt;of USD 26 million (2019: USD 24 &lt;br&gt;&lt;/br&gt;million; 2018: USD 40 million) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;172 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;162 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;148 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Partial release of deferred tax liability recognized&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income effect&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 677&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 662&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 526&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfAssociatesNetIncomeEffectTableTextBlock>
  <nvs:DisclosureOfAssociatesNetIncomeEffectTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019SignificantInvestmentsInAssociatesAxis_nvs-2020Q4GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis share of &lt;br&gt;&lt;/br&gt;GSK Consumer Healthcare's &lt;br&gt;&lt;/br&gt;estimated current-year &lt;br&gt;&lt;/br&gt;consolidated net income &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 119 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prior-year adjustment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of fair value &lt;br&gt;&lt;/br&gt;adjustments relating to &lt;br&gt;&lt;/br&gt;intangible assets and inventory, &lt;br&gt;&lt;/br&gt;net of taxes of USD 1 million &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Pre-tax gain on divestment of GSK Consumer Healthcare&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;790&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income effect&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;910&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfAssociatesNetIncomeEffectTableTextBlock>
  <ifrs-full:DisclosureOfInterestExpenseExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;5. Interest expense and&amp;nbsp;other&amp;nbsp;financial&amp;nbsp;income&amp;nbsp;and&amp;nbsp;expense&lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Interest expense&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;708&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;877&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense on lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;66&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense arising from discounting long-term liabilities and capitalized borrowing costs&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;94&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;70&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total interest expense from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;869&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;850&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;932&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Other financial income and expense&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 91&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 245&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 292&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency result, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;135&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;160&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;68&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other financial income and expense from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;78&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfInterestExpenseExplanatory>
  <nvs:InterestExpenseTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;708&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;877&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense on lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;66&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense arising from discounting long-term liabilities and capitalized borrowing costs&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;94&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;70&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total interest expense from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;869&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;850&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;932&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:InterestExpenseTableTextBlock>
  <nvs:OtherFinancialIncomeAndExpenseTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 91&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 245&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 292&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency result, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;135&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;160&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;68&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other financial income and expense from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;78&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:OtherFinancialIncomeAndExpenseTableTextBlock>
  <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;6. Taxes&lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Income before taxes&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;786&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;097&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;887&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Foreign&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 92&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 843&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;208&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;878&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;940&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 14&amp;nbsp;095&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Current and deferred income tax expense&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;932&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;186&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;615&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Foreign&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;168&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;961&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;988&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current income tax expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;603&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;137&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;120&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Foreign&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 430&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 447&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 428&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Deferred tax income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 293&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 354&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 308&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income tax expense from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;807&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;793&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;295&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Analysis of tax rate&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has a substantial business presence in many countries and is therefore subject to different income and expense items that are non-taxable (permanent differences) or are taxed at different rates in those tax jurisdictions. This results in a difference between our applicable tax rate and effective tax rate. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The main elements contributing to the difference between the Group&amp;#x2019;s overall applicable tax rate (which can change each year since it is calculated as the weighted average tax rate based on the pre-tax income of each subsidiary) and the effective tax rate are shown in the following table: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(As a percentage)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Applicable tax rate&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of disallowed expenditures&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of utilization of tax losses &lt;br&gt;&lt;/br&gt;brought forward from prior periods &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of income taxed at reduced rates&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;0.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;0.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;0.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of income not subject to tax &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;0.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of tax credits and allowances&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of release of &lt;br&gt;&lt;/br&gt;contingent consideration liability &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.5 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of tax rate change &lt;br&gt;&lt;/br&gt;on current and deferred &lt;br&gt;&lt;/br&gt;tax assets and liabilities &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 0.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;1.4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of write-off of deferred tax assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of write-down and reversal of &lt;br&gt;&lt;/br&gt;write-down of investments in subsidiaries &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 0.0 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of prior-year items&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;0.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of other items &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Effective tax rate for continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 18.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 20.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;b&gt; &lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Included in 2018 is the effect of income not subject to tax (-3.7%) arising from the portion of the non-taxable gain on the divestment of the Group's investment in GSK Consumer Healthcare Holdings Ltd. attributable to Switzerland. &lt;b&gt; &lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; 2019 is mainly related to the revaluation of the deferred tax assets and liabilities resulting from the tax reforms enacted in Switzerland in 2019. Refer to Note 12 for additional disclosures. &lt;b&gt; &lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; 2019 is primarily related to a non-cash, one-time deferred tax expense for the write-off of a deferred tax asset resulting from legal entity reorganizations. &lt;b&gt; &lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; In 2020, other items (+1.9%) include changes in uncertain tax positions (+2.0%) and other items (-0.1%). &lt;br&gt;&lt;/br&gt; In 2019, other items (+3.0%) include changes in uncertain tax positions (+2.6%) and other items (+0.4%). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The utilization of tax-loss carry-forwards lowered the tax charge by USD&amp;nbsp;29 million in 2020, by USD&amp;nbsp;11 million in 2019, and by USD&amp;nbsp;19 million in 2018.&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For the amount of taxes attributable to discontinued operations, see Note 30.&lt;/div&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
  <nvs:IncomeBeforeTaxesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;786&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;097&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;887&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Foreign&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 92&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 843&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;208&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;878&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;940&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 14&amp;nbsp;095&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:IncomeBeforeTaxesTableTextBlock>
  <nvs:CurrentAndDeferredIncomeTaxExpenseTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;932&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;186&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;615&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Foreign&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;168&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;961&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;988&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current income tax expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;603&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;137&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;120&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Foreign&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 430&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 447&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 428&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Deferred tax income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 293&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 354&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 308&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income tax expense from continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;807&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;793&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;295&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:CurrentAndDeferredIncomeTaxExpenseTableTextBlock>
  <nvs:AnalysisOfTaxRateTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(As a percentage)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Applicable tax rate&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of disallowed expenditures&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of utilization of tax losses &lt;br&gt;&lt;/br&gt;brought forward from prior periods &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of income taxed at reduced rates&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;0.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;0.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;0.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of income not subject to tax &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;0.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of tax credits and allowances&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of release of &lt;br&gt;&lt;/br&gt;contingent consideration liability &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.5 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of tax rate change &lt;br&gt;&lt;/br&gt;on current and deferred &lt;br&gt;&lt;/br&gt;tax assets and liabilities &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 0.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;1.4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of write-off of deferred tax assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of write-down and reversal of &lt;br&gt;&lt;/br&gt;write-down of investments in subsidiaries &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;0.6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 0.0 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of prior-year items&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;0.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of other items &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Effective tax rate for continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 18.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 20.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;b&gt; &lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Included in 2018 is the effect of income not subject to tax (-3.7%) arising from the portion of the non-taxable gain on the divestment of the Group's investment in GSK Consumer Healthcare Holdings Ltd. attributable to Switzerland. &lt;b&gt; &lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; 2019 is mainly related to the revaluation of the deferred tax assets and liabilities resulting from the tax reforms enacted in Switzerland in 2019. Refer to Note 12 for additional disclosures. &lt;b&gt; &lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; 2019 is primarily related to a non-cash, one-time deferred tax expense for the write-off of a deferred tax asset resulting from legal entity reorganizations. &lt;b&gt; &lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; In 2020, other items (+1.9%) include changes in uncertain tax positions (+2.0%) and other items (-0.1%). &lt;br&gt;&lt;/br&gt; In 2019, other items (+3.0%) include changes in uncertain tax positions (+2.6%) and other items (+0.4%). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:AnalysisOfTaxRateTableTextBlock>
  <ifrs-full:EarningsPerShareExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;7. Earnings per share&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income attributable to shareholders of Novartis AG (USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;- Continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;072&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;797&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;- Discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;072&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 12&amp;nbsp;611&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Number of shares (in millions)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Weighted average number of shares outstanding used in basic earnings per share&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;277&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;291&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;319&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Weighted average number of shares in diluted earnings per share&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;296&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;319&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;344&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Basic earnings per share (USD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;- Continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5.52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;- Discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.00&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;0.08&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3.55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5.12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5.44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Diluted earnings per share (USD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;- Continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.08&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5.46&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;- Discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1.98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;0.08&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3.52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5.06&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5.38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Basic earnings per share (EPS) is calculated by dividing net income attributable to shareholders of Novartis AG by the weighted average number of shares outstanding in a reporting period. This calculation excludes the average number of issued shares purchased by the Group and held as treasury shares. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For diluted EPS, the weighted average number of shares outstanding is adjusted to assume the vesting of all restricted shares, restricted share units, and the conversion of all potentially dilutive shares arising from options on Novartis shares that have been issued. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;No options were excluded from the calculation of diluted EPS in 2020, 2019 or 2018, as all options were dilutive in all years. &lt;/div&gt;</ifrs-full:EarningsPerShareExplanatory>
  <nvs:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income attributable to shareholders of Novartis AG (USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;- Continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;072&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;797&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;- Discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;072&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 12&amp;nbsp;611&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Number of shares (in millions)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Weighted average number of shares outstanding used in basic earnings per share&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;277&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;291&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;319&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Weighted average number of shares in diluted earnings per share&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;296&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;319&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;344&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Basic earnings per share (USD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;- Continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5.52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;- Discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.00&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;0.08&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3.55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5.12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5.44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Diluted earnings per share (USD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;- Continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.08&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5.46&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;- Discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1.98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;0.08&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3.52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5.06&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5.38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <nvs:ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;8. Changes in consolidated statements of&amp;nbsp;comprehensive income&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The consolidated statements of comprehensive income include the Group&amp;#x2019;s net income for the year as well as all other valuation adjustments recorded in the Group&amp;#x2019;s consolidated balance sheet which under IFRS are not recorded in the consolidated income statement. These include fair value adjustments to financial instruments, actuarial gains or losses on defined benefit pension plans, and currency translation effects, net of tax. &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Note &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Fair value &lt;br&gt;&lt;/br&gt; adjustments &lt;br&gt;&lt;/br&gt; on financial &lt;br&gt;&lt;/br&gt; instruments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Actuarial &lt;br&gt;&lt;/br&gt; gains/(losses) &lt;br&gt;&lt;/br&gt; from defined &lt;br&gt;&lt;/br&gt; benefit plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Cumulative &lt;br&gt;&lt;/br&gt; currency &lt;br&gt;&lt;/br&gt; translation &lt;br&gt;&lt;/br&gt; effects &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total value &lt;br&gt;&lt;/br&gt; adjustments &lt;br&gt;&lt;/br&gt; attributable to &lt;br&gt;&lt;/br&gt; Novartis AG &lt;br&gt;&lt;/br&gt; shareholders &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Non- &lt;br&gt;&lt;/br&gt; controlling &lt;br&gt;&lt;/br&gt; interest &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total value &lt;br&gt;&lt;/br&gt; adjustments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2017, as previously reported&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 395&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;064&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 329&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;340&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;361&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of adoption of IFRS 9 on retained &lt;br&gt;&lt;/br&gt;earnings and OCI &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;177 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;177 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;177 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Restated value adjustments at January 1, 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;064&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 329&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;517&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;538&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on deferred cash flow &lt;br&gt;&lt;/br&gt;hedges, net of taxes of USD -1 million &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities, &lt;br&gt;&lt;/br&gt;net of taxes of USD -5 million &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 13 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 13 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 13 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net investment hedge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit plans, net of taxes &lt;br&gt;&lt;/br&gt;of USD 69 million &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;359 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;359 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;359 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 320&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 320&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 315&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total value adjustments in 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;359&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 415&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 81&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities sold, reclassified to retained earnings&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 227&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;423&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 744&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;452&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;478&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on deferred cash &lt;br&gt;&lt;/br&gt;flow hedges &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities, &lt;br&gt;&lt;/br&gt;net of taxes of USD 47 million &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;47 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;47 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;47 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net investment hedge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit plans, net of taxes &lt;br&gt;&lt;/br&gt;of USD -313 million &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;466 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;466 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;467 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 354&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 354&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 352&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total value adjustments in 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;466&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 398&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;113&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;116&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities &lt;br&gt;&lt;/br&gt;sold, reclassified to retained earnings &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;95 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;95 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;95 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments related to divestments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 120&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;919&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;657&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;686&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities, &lt;br&gt;&lt;/br&gt;net of taxes of USD -36 million &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 250 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 250 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 250 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net investment hedge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit plans, net of taxes &lt;br&gt;&lt;/br&gt;of USD -3 million &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 145 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 145 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 143 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total value adjustments in 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 145&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;992&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;387&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;386&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities &lt;br&gt;&lt;/br&gt;sold, reclassified to retained earnings &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;150 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;150 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;150 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments related to divestments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of change in ownership of consolidated entities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;773&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;134&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;419&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;448&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Includes fair value adjustments on equity securities designated as financial assets valued at fair value through other comprehensive income with no subsequent recycling into the &lt;br&gt;&lt;/br&gt;consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Included in 2019 is a USD -358 million impact related to the revaluation of deferred tax assets on Swiss post-employment benefits that were previously recognized through other &lt;br&gt;&lt;/br&gt;comprehensive income. This revaluation resulted from the Swiss tax reforms enacted by the voters in 2019. Refer to Note 12 for additional disclosures. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;8.1) In 2020, no currency translation losses or gains were recycled through the income statement. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2019, cumulative currency translation gains of USD&amp;nbsp;129 million were recycled through the income statement mainly as a result of the spin-off of the Alcon business through a dividend in kind distribution to Novartis AG shareholders. See Notes 2 and 30. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2018, cumulative currency translation losses of USD&amp;nbsp;946 million were recycled through the income statement as a result of the divestment of the investment in GSK Consumer Healthcare Holdings Ltd. See Notes 2 and 4. &lt;/div&gt;</nvs:ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock>
  <nvs:ScheduleOfComprehensiveIncomeTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Note &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Fair value &lt;br&gt;&lt;/br&gt; adjustments &lt;br&gt;&lt;/br&gt; on financial &lt;br&gt;&lt;/br&gt; instruments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Actuarial &lt;br&gt;&lt;/br&gt; gains/(losses) &lt;br&gt;&lt;/br&gt; from defined &lt;br&gt;&lt;/br&gt; benefit plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Cumulative &lt;br&gt;&lt;/br&gt; currency &lt;br&gt;&lt;/br&gt; translation &lt;br&gt;&lt;/br&gt; effects &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total value &lt;br&gt;&lt;/br&gt; adjustments &lt;br&gt;&lt;/br&gt; attributable to &lt;br&gt;&lt;/br&gt; Novartis AG &lt;br&gt;&lt;/br&gt; shareholders &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Non- &lt;br&gt;&lt;/br&gt; controlling &lt;br&gt;&lt;/br&gt; interest &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total value &lt;br&gt;&lt;/br&gt; adjustments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2017, as previously reported&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 395&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;064&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 329&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;340&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;361&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of adoption of IFRS 9 on retained &lt;br&gt;&lt;/br&gt;earnings and OCI &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;177 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;177 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;177 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Restated value adjustments at January 1, 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;064&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 329&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;517&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;538&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on deferred cash flow &lt;br&gt;&lt;/br&gt;hedges, net of taxes of USD -1 million &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities, &lt;br&gt;&lt;/br&gt;net of taxes of USD -5 million &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 13 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 13 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 13 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net investment hedge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit plans, net of taxes &lt;br&gt;&lt;/br&gt;of USD 69 million &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;359 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;359 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;359 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 320&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 320&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 315&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total value adjustments in 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;359&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 415&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 81&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities sold, reclassified to retained earnings&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 227&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;423&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 744&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;452&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;478&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on deferred cash &lt;br&gt;&lt;/br&gt;flow hedges &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities, &lt;br&gt;&lt;/br&gt;net of taxes of USD 47 million &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;47 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;47 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;47 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net investment hedge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit plans, net of taxes &lt;br&gt;&lt;/br&gt;of USD -313 million &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;466 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;466 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;467 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 354&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 354&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 352&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total value adjustments in 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;466&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 398&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;113&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;116&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities &lt;br&gt;&lt;/br&gt;sold, reclassified to retained earnings &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;95 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;95 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;95 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments related to divestments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 120&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;919&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;657&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;686&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities, &lt;br&gt;&lt;/br&gt;net of taxes of USD -36 million &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 250 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 250 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 250 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net investment hedge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit plans, net of taxes &lt;br&gt;&lt;/br&gt;of USD -3 million &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 145 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 145 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 143 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total value adjustments in 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 145&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;992&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;387&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;386&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities &lt;br&gt;&lt;/br&gt;sold, reclassified to retained earnings &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;150 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;150 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;150 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments related to divestments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of change in ownership of consolidated entities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;773&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;134&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;419&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;448&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Includes fair value adjustments on equity securities designated as financial assets valued at fair value through other comprehensive income with no subsequent recycling into the &lt;br&gt;&lt;/br&gt;consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Included in 2019 is a USD -358 million impact related to the revaluation of deferred tax assets on Swiss post-employment benefits that were previously recognized through other &lt;br&gt;&lt;/br&gt;comprehensive income. This revaluation resulted from the Swiss tax reforms enacted by the voters in 2019. Refer to Note 12 for additional disclosures. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfComprehensiveIncomeTableTextBlock>
  <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;9. Property, plant and equipment&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of property, plant and equipment during 2020: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Land &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Buildings &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Construction &lt;br&gt;&lt;/br&gt; in progress &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Machinery &lt;br&gt;&lt;/br&gt; and other &lt;br&gt;&lt;/br&gt; equipment &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 512&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 11&amp;nbsp;463&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;350&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 13&amp;nbsp;674&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&amp;nbsp;999&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of assets reclassified out of assets of &lt;br&gt;&lt;/br&gt;disposal group held for sale &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 11 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 117 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 36 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 168 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 332 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 433&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;038&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 595&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 115&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 847&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 296&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;265&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;465&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;57&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 695&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 956&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;797&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 555&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 12&amp;nbsp;377&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 14&amp;nbsp;038&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 28&amp;nbsp;218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Accumulated depreciation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;726&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;930&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation on assets reclassified out of assets of &lt;br&gt;&lt;/br&gt;disposal group held for sale &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;58 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;163 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation on disposals and derecognitions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 433&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;004&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;491&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;827&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;318&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;228&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;447&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of impairment charge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;731&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;108&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;807&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;66&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;063&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;955&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 536&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;570&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;182&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;975&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 12&amp;nbsp;263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Commitments for purchases of property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Capitalized borrowing costs&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Note 2 provides additional disclosures related to the reclassification out of assets of the disposal group held for sale. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Depreciation charge includes USD 38 million (USD 20 million for buildings and USD 18 million for machinery and other equipment), representing the cumulative amount of depreciation charge on the disposal group held for sale for property, plant and equipment from the date of classification to held for sale, September 2018, to March 31, 2020, the date of reclassification out of assets of disposal group held for sale. See Note 2 for further details. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of property, plant and equipment during 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Land &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Buildings &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Construction &lt;br&gt;&lt;/br&gt; in progress &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Machinery &lt;br&gt;&lt;/br&gt; and other &lt;br&gt;&lt;/br&gt; equipment &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 696&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 14&amp;nbsp;135&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 17&amp;nbsp;155&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;028&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of assets related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;615&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;655&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;678&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;009&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification to right-of-use assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;127&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of assets related to disposal group held for sale &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 57&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 332&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 630&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;001&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 355&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;474&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;551&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;774&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;409&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 512&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;463&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;350&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 13&amp;nbsp;674&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&amp;nbsp;999&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Accumulated depreciation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;328&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;924&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;18&amp;nbsp;332&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation on assets related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 562&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;541&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;118&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification to right-of-use assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation on assets related to disposal group held for sale &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation on disposals and derecognitions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;170&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;674&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;846&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;447&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;898&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;205&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of impairment charge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;726&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;930&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 492&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&amp;nbsp;339&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;290&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;948&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 12&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Commitments for purchases of property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Capitalized borrowing costs&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Represents the cost of assets and accumulated depreciation at January 1, 2019, related to the Alcon business reported as discontinued operations. Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Reclassification to right-of-use assets at January 1, 2019, upon adoption of IFRS 16 Leases. Refer to Note 1 for additional disclosure. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Note 2 provides additional disclosures related to disposal group held for sale. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; No depreciation charge in the disposal group held for sale for the period from January 1, 2019, to December 31, 2019, was recorded. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;5&amp;nbsp;&lt;/sup&gt; Impairments in the disposal group held for sale for the period from January 1, 2019, to December 31, 2019, were USD 2 million. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
  <nvs:PropertyPlantAndEquipmentTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of property, plant and equipment during 2020: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Land &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Buildings &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Construction &lt;br&gt;&lt;/br&gt; in progress &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Machinery &lt;br&gt;&lt;/br&gt; and other &lt;br&gt;&lt;/br&gt; equipment &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 512&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 11&amp;nbsp;463&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;350&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 13&amp;nbsp;674&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&amp;nbsp;999&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of assets reclassified out of assets of &lt;br&gt;&lt;/br&gt;disposal group held for sale &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 11 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 117 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 36 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 168 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 332 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 433&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;038&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 595&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 115&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 847&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 296&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;265&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;465&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;57&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;201&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 695&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 956&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;797&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 555&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 12&amp;nbsp;377&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 14&amp;nbsp;038&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 28&amp;nbsp;218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Accumulated depreciation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;726&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;930&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation on assets reclassified out of assets of &lt;br&gt;&lt;/br&gt;disposal group held for sale &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;58 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;163 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation on disposals and derecognitions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 433&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;004&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;491&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;827&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;318&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;228&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;447&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of impairment charge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;731&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;108&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;807&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;66&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;063&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;955&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 536&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;570&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;182&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;975&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 12&amp;nbsp;263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Commitments for purchases of property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Capitalized borrowing costs&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Note 2 provides additional disclosures related to the reclassification out of assets of the disposal group held for sale. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Depreciation charge includes USD 38 million (USD 20 million for buildings and USD 18 million for machinery and other equipment), representing the cumulative amount of depreciation charge on the disposal group held for sale for property, plant and equipment from the date of classification to held for sale, September 2018, to March 31, 2020, the date of reclassification out of assets of disposal group held for sale. See Note 2 for further details. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of property, plant and equipment during 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Land &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Buildings &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Construction &lt;br&gt;&lt;/br&gt; in progress &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Machinery &lt;br&gt;&lt;/br&gt; and other &lt;br&gt;&lt;/br&gt; equipment &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 696&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 14&amp;nbsp;135&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 17&amp;nbsp;155&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 34&amp;nbsp;028&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of assets related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;615&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;655&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;678&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;009&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification to right-of-use assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;127&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of assets related to disposal group held for sale &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 57&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 332&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 630&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;001&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 355&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;474&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;551&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;774&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;409&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 512&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;463&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;350&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 13&amp;nbsp;674&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&amp;nbsp;999&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Accumulated depreciation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;328&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;924&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;18&amp;nbsp;332&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation on assets related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 562&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;541&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;118&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification to right-of-use assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation on assets related to disposal group held for sale &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation on disposals and derecognitions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;170&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;674&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;846&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;447&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;898&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;205&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of impairment charge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;726&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&amp;nbsp;930&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 492&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&amp;nbsp;339&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;290&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;948&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 12&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Commitments for purchases of property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Capitalized borrowing costs&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Represents the cost of assets and accumulated depreciation at January 1, 2019, related to the Alcon business reported as discontinued operations. Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Reclassification to right-of-use assets at January 1, 2019, upon adoption of IFRS 16 Leases. Refer to Note 1 for additional disclosure. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Note 2 provides additional disclosures related to disposal group held for sale. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; No depreciation charge in the disposal group held for sale for the period from January 1, 2019, to December 31, 2019, was recorded. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;5&amp;nbsp;&lt;/sup&gt; Impairments in the disposal group held for sale for the period from January 1, 2019, to December 31, 2019, were USD 2 million. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:PropertyPlantAndEquipmentTableTextBlock>
  <ifrs-full:DisclosureOfLeasesExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;10. Right-of-use assets and lease liabilities&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of the right-of-use assets of continuing operations: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Right-of-use assets at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;677&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;554&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 346&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 537&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation charge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;330&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;305&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease contract terminations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of divestments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 46&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total right-of-use assets at December 31 &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;676&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;677&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Lease contract terminations also includes modifications to existing leases that result in reductions to the right-of-use assets, and reductions due to sub-leasing. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; No impairment charge was recorded in 2020 (2019: nil). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the right-of-use assets carrying value and depreciation charge of continuing operations at December 31, 2020 and 2019, by underlying class of asset: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2020 &lt;br&gt;&lt;/br&gt; carrying value &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Depreciation &lt;br&gt;&lt;/br&gt; charge &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;br&gt;&lt;/br&gt; carrying value &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Depreciation &lt;br&gt;&lt;/br&gt; charge &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Land&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 528&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 537&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Buildings&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 963&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 207&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 990&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vehicles&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 155&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 87&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and equipment, and other assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;676&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 330&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;677&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 305&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the lease liabilities of continuing operations by maturity at December 31, 2020 and 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Lease liabilities &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Lease liabilities &lt;br&gt;&lt;/br&gt; undiscounted &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Lease liabilities &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Lease liabilities &lt;br&gt;&lt;/br&gt; undiscounted &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less than one year&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 286&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 338&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 246&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 295&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between one and two years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 229&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 274&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 246&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between two and three years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 226&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between three and four years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 148&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 183&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 138&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 173&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between four and five years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 160&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 119&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 150&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After five years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;027&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;326&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;081&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;419&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;005&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;507&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;949&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;485&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current portion of lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;286&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;338&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;246&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;295&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current portion of lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;719&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;703&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;At December 31, 2020 and December 31, 2019, there were no material future cash outflows, including extension options, excluded from the measurement of lease liabilities. The Group&amp;#x2019;s most material lease with a lease term extension, representing a lease liability value of USD 0.6 billion (2019: USD 0.6 billion), has a determined lease term end date of 2071 (2019: 2071). &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2019, the Group completed sale and leaseback transactions for certain property, plant and equipment as part of its plans to consolidate sites. Transactions resulted in net cash inflows of USD 0.7 billion and the recognition of USD 96 million of lease liabilities, and USD 37 million of right-of-use assets. The right-of-use assets value reflects the proportion of the property, plant and equipment retained for a period of one to five years, with two five-year extension periods for certain right-of-use assets. The liabilities reflect the net present value of future lease payments. The net gain on the sale and leaseback transactions amounted to USD 478 million. There were no significant sale and leaseback transactions completed in 2020. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table provides additional disclosures related to right-of-use assets and lease liabilities of continuing operations for 2020 and 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense on lease liabilities &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 67&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 66&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense on short-term leases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense on low-value leases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total cash outflows for leases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 379&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 339&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Thereof:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cash outflows for short-term leases &lt;br&gt;&lt;/br&gt;and low-value leases &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 11 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 15 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Payments of interest &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 56&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Payments of lease liabilities &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 312&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; The weighted average interest rate is 3.4% (2019: 3.9%). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Cash flows from short-term and low-value leases are included within total net cash flows from operating activities. The portfolio of short-term leases to which the Group is committed to at December 31, 2020 and 2019, is similar to the portfolio of short-term leases the Group entered into during 2020 and 2019. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Included within total net cash flows from operating activities. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; Reported as cash outflows used in financing activities net of lease incentives received of USD nil (2019: USD 33 million). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The net investment held and income from subleasing right-of-use assets were not significant for 2020 and 2019. Income from leasing Novartis property, plant and equipment to third parties for both 2020 and 2019 was not significant. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Note 30 provides additional disclosures on discontinued operations.&lt;/div&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
  <nvs:DisclosureOfRightofuseAssetsRollForwardTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Right-of-use assets at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;677&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;554&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 346&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 537&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation charge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;330&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;305&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease contract terminations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of divestments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 46&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total right-of-use assets at December 31 &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;676&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;677&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Lease contract terminations also includes modifications to existing leases that result in reductions to the right-of-use assets, and reductions due to sub-leasing. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; No impairment charge was recorded in 2020 (2019: nil). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfRightofuseAssetsRollForwardTableTextBlock>
  <nvs:DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2020 &lt;br&gt;&lt;/br&gt; carrying value &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Depreciation &lt;br&gt;&lt;/br&gt; charge &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;br&gt;&lt;/br&gt; carrying value &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Depreciation &lt;br&gt;&lt;/br&gt; charge &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Land&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 528&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 537&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Buildings&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 963&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 207&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 990&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vehicles&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 155&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 87&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and equipment, and other assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;676&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 330&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;677&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 305&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock>
  <nvs:DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Lease liabilities &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Lease liabilities &lt;br&gt;&lt;/br&gt; undiscounted &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Lease liabilities &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Lease liabilities &lt;br&gt;&lt;/br&gt; undiscounted &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less than one year&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 286&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 338&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 246&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 295&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between one and two years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 229&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 274&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 246&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between two and three years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 226&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between three and four years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 148&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 183&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 138&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 173&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between four and five years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 160&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 119&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 150&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After five years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;027&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;326&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;081&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;419&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;005&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;507&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;949&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;485&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current portion of lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;286&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;338&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;246&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;295&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current portion of lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;719&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;703&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock>
  <nvs:AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense on lease liabilities &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 67&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 66&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense on short-term leases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense on low-value leases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total cash outflows for leases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 379&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 339&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Thereof:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cash outflows for short-term leases &lt;br&gt;&lt;/br&gt;and low-value leases &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 11 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 15 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Payments of interest &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 56&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Payments of lease liabilities &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 312&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; The weighted average interest rate is 3.4% (2019: 3.9%). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Cash flows from short-term and low-value leases are included within total net cash flows from operating activities. The portfolio of short-term leases to which the Group is committed to at December 31, 2020 and 2019, is similar to the portfolio of short-term leases the Group entered into during 2020 and 2019. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Included within total net cash flows from operating activities. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; Reported as cash outflows used in financing activities net of lease incentives received of USD nil (2019: USD 33 million). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock>
  <ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;11. Goodwill and intangible assets&lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of goodwill and intangible assets in 2020: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="1" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="9" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; In-process &lt;br&gt;&lt;/br&gt; research and &lt;br&gt;&lt;/br&gt; development &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Technologies &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Currently &lt;br&gt;&lt;/br&gt; marketed &lt;br&gt;&lt;/br&gt; products &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other &lt;br&gt;&lt;/br&gt; intangible &lt;br&gt;&lt;/br&gt; assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&amp;nbsp;825&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;429&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 884&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 43&amp;nbsp;548&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;558&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 53&amp;nbsp;419&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of assets reclassified out of assets of &lt;br&gt;&lt;/br&gt;disposal group held for sale &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 10 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 276 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;112 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;400 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;580&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;600&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 196&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;014&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;272&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;274&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 339&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 674&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 412&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;425&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;421&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;101&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;572&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 916&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 208&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;568&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 205&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;039&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 30&amp;nbsp;321&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;893&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;115&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 57&amp;nbsp;333&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;384&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 67&amp;nbsp;725&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Accumulated amortization&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;005&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;721&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;969&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;937&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;24&amp;nbsp;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization on assets reclassified &lt;br&gt;&lt;/br&gt;out of assets of disposal group held for sale &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;107 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;816 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;925 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;72&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;215&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;175&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;462&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization on disposals &lt;br&gt;&lt;/br&gt;and derecognitions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 421 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 39 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 567 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;6&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;515&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;338&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;914&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;92&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;46&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;267&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;145&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;550&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;322&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;885&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;26&amp;nbsp;566&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;272&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;30&amp;nbsp;916&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 29&amp;nbsp;999&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;700&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 30&amp;nbsp;767&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 36&amp;nbsp;809&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Note 2 provides additional disclosures related to the reclassification out of assets of disposal group held for sale as of March 31, 2020. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; No addition for the disposal group held for sale for the period from January 1, 2020, to March 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;5&amp;nbsp;&lt;/sup&gt; Amortization charge includes USD 102 million (USD 73 million for currently marketed products and USD 29 million for technologies), representing the cumulative amount of amortization charge for the disposal group held for sale for intangible assets from the date of reclassification to held for sale, September 6, 2018, to March 31, 2020, the date of reclassification out of assets of disposal group held for sale. See Note 2 for further details. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;6&amp;nbsp;&lt;/sup&gt; Impairment charge includes USD 42 million on currently marketed products that were previously classified within assets of disposal group held for sale. See Note 2 for further details. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of goodwill and intangible assets in 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="1" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="13" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; In-process &lt;br&gt;&lt;/br&gt; research and &lt;br&gt;&lt;/br&gt; development &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Alcon &lt;br&gt;&lt;/br&gt; brand name &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Technologies &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Currently &lt;br&gt;&lt;/br&gt; marketed &lt;br&gt;&lt;/br&gt; products &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Marketing &lt;br&gt;&lt;/br&gt; know-how &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Other &lt;br&gt;&lt;/br&gt; intangible &lt;br&gt;&lt;/br&gt; assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 35&amp;nbsp;700&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 16&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;980&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&amp;nbsp;253&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 35&amp;nbsp;412&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;960&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;253&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 69&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of assets related to &lt;br&gt;&lt;/br&gt;discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;000 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;249 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;980 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;369 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;440 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;960 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;572 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;19&amp;nbsp;570 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of assets related to disposal group &lt;br&gt;&lt;/br&gt;held for sale, net &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 342&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;550&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;914&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 265&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 243&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 767&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;544&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;436&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;055&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 254&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 335&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&amp;nbsp;825&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;429&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 884&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 43&amp;nbsp;548&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;558&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 53&amp;nbsp;419&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Accumulated amortization&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;406&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;120&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;758&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;21&amp;nbsp;218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;906&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;304&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;30&amp;nbsp;306&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization &lt;br&gt;&lt;/br&gt;on assets related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4&amp;nbsp;184 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;592 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;906 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 128 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 8&amp;nbsp;813 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;6&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;42&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;657&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;137&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;836&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization on disposals &lt;br&gt;&lt;/br&gt;and derecognitions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 70 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 494 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 419 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 983 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;6&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;984&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;105&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;54&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;175&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of impairment charge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;148&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;005&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;721&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;969&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;937&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;24&amp;nbsp;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&amp;nbsp;524&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;579&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 621&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 28&amp;nbsp;787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Represents the cost of assets and accumulated amortization at January 1, 2019, related to the Alcon business reported as discontinued operations. Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Note 2 provides additional disclosures related to assets of disposal group held for sale. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; No addition in the disposal group held for sale for the period from January 1, 2019, to December 31, 2019 &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;5&amp;nbsp;&lt;/sup&gt; Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;6&amp;nbsp;&lt;/sup&gt; No amortization or impairment charges related to the disposal group held for sale for the period from January 1, 2019, to December 31, 2019. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2020: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="1" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="9" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; In-process &lt;br&gt;&lt;/br&gt; research and &lt;br&gt;&lt;/br&gt; development &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Technologies &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Currently &lt;br&gt;&lt;/br&gt; marketed &lt;br&gt;&lt;/br&gt; products &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other &lt;br&gt;&lt;/br&gt; intangible &lt;br&gt;&lt;/br&gt; assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&amp;nbsp;718&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;548&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 29&amp;nbsp;645&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 925&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 35&amp;nbsp;121&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;274&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 152&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 227&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 42&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 145&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 145&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 29&amp;nbsp;999&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;700&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 30&amp;nbsp;767&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 36&amp;nbsp;809&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="1" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="9" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; In-process &lt;br&gt;&lt;/br&gt; research and &lt;br&gt;&lt;/br&gt; development &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Technologies &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Currently &lt;br&gt;&lt;/br&gt; marketed &lt;br&gt;&lt;/br&gt; products &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Other &lt;br&gt;&lt;/br&gt; intangible &lt;br&gt;&lt;/br&gt; assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&amp;nbsp;750&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;339&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&amp;nbsp;720&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 520&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 27&amp;nbsp;586&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;767&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 85&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 156&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 859&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&amp;nbsp;524&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;579&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 621&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 28&amp;nbsp;787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Innovative Medicines and Sandoz Divisions&amp;#x2019; cash-generating units, to which goodwill is allocated, each comprise a group of smaller cash-generating units. The valuation method of the recoverable amount of the cash-generating units, to which goodwill is allocated, is based on the fair value less costs of disposal. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following assumptions are used in the calculations:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(As a percentage) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative &lt;br&gt;&lt;/br&gt; Medicines &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Terminal growth rate&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Discount rate (post-tax)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The discount rates for all divisions consider the Group&amp;#x2019;s weighted average cost of capital, adjusted to approximate the weighted average cost of capital of a comparable market participant. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value less costs of disposal, for all cash-generating units containing goodwill, is reviewed for the impact of reasonably possible changes in key assumptions. In particular, we considered an increase in the discount rate, a decrease in the terminal growth rate, and certain negative impacts on the forecasted cash flows. These reasonably possible changes in key assumptions did not indicate an impairment. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;&amp;#x201c;Note 1. Significant accounting policies&amp;mdash;Impairment of goodwill and intangible assets&amp;#x201d; provides additional disclosures on how the Group performs goodwill and intangible asset impairment testing. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the intangible asset and goodwill impairment charges for continuing operations for 2020, 2019 and 2018: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;768&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;669&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;592&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;506&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;249&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;914&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;175&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;841&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; 2020 includes an impairment of USD 485 million related to the write-down of IPR&amp;amp;D related to cessation of clinical development program ZPL389 for atopic dermatitis and USD 181 million related to a partial write-down of the &lt;i&gt;Votrient&lt;/i&gt; currently marketed product. &lt;br&gt;&lt;/br&gt;2019 includes an impairment of USD 416 million related to the write-down of IPR&amp;amp;D related to cessation of clinical development program EMA401 and a USD 108 million write-down related to the cessation of clinical development program for MOR106 for atopic dermatitis. &lt;br&gt;&lt;/br&gt;2018 includes an impairment of USD 400 million related to a partial write-down of the &lt;i&gt;Votrient&lt;/i&gt; currently marketed product. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; 2019 includes an impairment of USD 442 million related to the write-down of IPR&amp;amp;D related to the discontinuation of the generic Advair&amp;#xae; development program. &lt;br&gt;&lt;/br&gt;2018 includes impairments of USD 220 million related to the write-down of the allocated goodwill (USD 183 million) and the currently marketed products (USD 37 million) related to the retained Sandoz US dermatology business and generic US oral solids portfolio. See Note 2. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2020, there were no reversals of prior-year impairment charges (2019: USD 37 million; 2018: nil).&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;Note 30 provides additional disclosures on discontinued operations.&lt;/div&gt;</ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory>
  <nvs:DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of goodwill and intangible assets in 2020: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="1" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="9" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; In-process &lt;br&gt;&lt;/br&gt; research and &lt;br&gt;&lt;/br&gt; development &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Technologies &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Currently &lt;br&gt;&lt;/br&gt; marketed &lt;br&gt;&lt;/br&gt; products &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other &lt;br&gt;&lt;/br&gt; intangible &lt;br&gt;&lt;/br&gt; assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&amp;nbsp;825&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;429&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 884&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 43&amp;nbsp;548&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;558&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 53&amp;nbsp;419&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of assets reclassified out of assets of &lt;br&gt;&lt;/br&gt;disposal group held for sale &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 10 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 276 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;112 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;400 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;580&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;600&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 196&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;014&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;272&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;274&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 339&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 674&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 412&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;425&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;421&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;101&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;572&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 916&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 208&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;568&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 205&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;039&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 30&amp;nbsp;321&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;893&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;115&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 57&amp;nbsp;333&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;384&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 67&amp;nbsp;725&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Accumulated amortization&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;005&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;721&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;969&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;937&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;24&amp;nbsp;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization on assets reclassified &lt;br&gt;&lt;/br&gt;out of assets of disposal group held for sale &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;107 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;816 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;925 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;72&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;215&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;175&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;462&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization on disposals &lt;br&gt;&lt;/br&gt;and derecognitions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 421 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 39 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 567 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;6&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;515&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;338&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;914&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;92&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;46&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;267&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;145&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;550&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;322&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;885&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;26&amp;nbsp;566&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;272&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;30&amp;nbsp;916&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 29&amp;nbsp;999&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;700&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 30&amp;nbsp;767&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 36&amp;nbsp;809&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Note 2 provides additional disclosures related to the reclassification out of assets of disposal group held for sale as of March 31, 2020. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; No addition for the disposal group held for sale for the period from January 1, 2020, to March 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;5&amp;nbsp;&lt;/sup&gt; Amortization charge includes USD 102 million (USD 73 million for currently marketed products and USD 29 million for technologies), representing the cumulative amount of amortization charge for the disposal group held for sale for intangible assets from the date of reclassification to held for sale, September 6, 2018, to March 31, 2020, the date of reclassification out of assets of disposal group held for sale. See Note 2 for further details. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;6&amp;nbsp;&lt;/sup&gt; Impairment charge includes USD 42 million on currently marketed products that were previously classified within assets of disposal group held for sale. See Note 2 for further details. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of goodwill and intangible assets in 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="1" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="13" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; In-process &lt;br&gt;&lt;/br&gt; research and &lt;br&gt;&lt;/br&gt; development &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Alcon &lt;br&gt;&lt;/br&gt; brand name &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Technologies &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Currently &lt;br&gt;&lt;/br&gt; marketed &lt;br&gt;&lt;/br&gt; products &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Marketing &lt;br&gt;&lt;/br&gt; know-how &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Other &lt;br&gt;&lt;/br&gt; intangible &lt;br&gt;&lt;/br&gt; assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 35&amp;nbsp;700&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 16&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;980&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&amp;nbsp;253&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 35&amp;nbsp;412&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;960&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;253&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 69&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of assets related to &lt;br&gt;&lt;/br&gt;discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;000 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;249 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;980 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;369 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;440 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;960 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;572 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;19&amp;nbsp;570 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of assets related to disposal group &lt;br&gt;&lt;/br&gt;held for sale, net &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 342&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;550&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;914&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 265&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 243&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 767&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;544&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;436&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;055&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 254&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 335&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&amp;nbsp;825&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;429&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 884&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 43&amp;nbsp;548&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;558&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 53&amp;nbsp;419&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Accumulated amortization&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;406&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;120&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;758&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;21&amp;nbsp;218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;906&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;304&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;30&amp;nbsp;306&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization &lt;br&gt;&lt;/br&gt;on assets related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4&amp;nbsp;184 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;592 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;906 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 128 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 8&amp;nbsp;813 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;6&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;42&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;657&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;137&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;836&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization on disposals &lt;br&gt;&lt;/br&gt;and derecognitions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 70 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 494 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 419 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 983 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;6&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;984&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;105&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;54&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;175&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of impairment charge&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;148&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;005&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;721&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;969&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;937&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;24&amp;nbsp;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&amp;nbsp;524&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;579&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 621&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 28&amp;nbsp;787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Represents the cost of assets and accumulated amortization at January 1, 2019, related to the Alcon business reported as discontinued operations. Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Note 2 provides additional disclosures related to assets of disposal group held for sale. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; No addition in the disposal group held for sale for the period from January 1, 2019, to December 31, 2019 &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;5&amp;nbsp;&lt;/sup&gt; Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;6&amp;nbsp;&lt;/sup&gt; No amortization or impairment charges related to the disposal group held for sale for the period from January 1, 2019, to December 31, 2019. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock>
  <nvs:AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="1" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="9" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; In-process &lt;br&gt;&lt;/br&gt; research and &lt;br&gt;&lt;/br&gt; development &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Technologies &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Currently &lt;br&gt;&lt;/br&gt; marketed &lt;br&gt;&lt;/br&gt; products &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other &lt;br&gt;&lt;/br&gt; intangible &lt;br&gt;&lt;/br&gt; assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&amp;nbsp;718&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;548&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 29&amp;nbsp;645&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 925&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 35&amp;nbsp;121&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;274&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 152&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 227&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 42&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 145&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 145&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 29&amp;nbsp;999&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;700&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 30&amp;nbsp;767&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 36&amp;nbsp;809&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="1" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="9" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="1" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; In-process &lt;br&gt;&lt;/br&gt; research and &lt;br&gt;&lt;/br&gt; development &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Technologies &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Currently &lt;br&gt;&lt;/br&gt; marketed &lt;br&gt;&lt;/br&gt; products &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Other &lt;br&gt;&lt;/br&gt; intangible &lt;br&gt;&lt;/br&gt; assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&amp;nbsp;750&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;339&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&amp;nbsp;720&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 520&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 27&amp;nbsp;586&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;767&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 85&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 156&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 859&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 26&amp;nbsp;524&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;579&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 621&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 28&amp;nbsp;787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock>
  <nvs:AssumptionsUsedInTheCalculationOfValuationTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(As a percentage) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative &lt;br&gt;&lt;/br&gt; Medicines &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Sandoz &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Terminal growth rate&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Discount rate (post-tax)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:AssumptionsUsedInTheCalculationOfValuationTextBlock>
  <nvs:IntangibleAssetImpairmentChargesTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;768&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;669&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;592&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;506&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;249&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;914&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;175&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;841&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; 2020 includes an impairment of USD 485 million related to the write-down of IPR&amp;amp;D related to cessation of clinical development program ZPL389 for atopic dermatitis and USD 181 million related to a partial write-down of the &lt;i&gt;Votrient&lt;/i&gt; currently marketed product. &lt;br&gt;&lt;/br&gt;2019 includes an impairment of USD 416 million related to the write-down of IPR&amp;amp;D related to cessation of clinical development program EMA401 and a USD 108 million write-down related to the cessation of clinical development program for MOR106 for atopic dermatitis. &lt;br&gt;&lt;/br&gt;2018 includes an impairment of USD 400 million related to a partial write-down of the &lt;i&gt;Votrient&lt;/i&gt; currently marketed product. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; 2019 includes an impairment of USD 442 million related to the write-down of IPR&amp;amp;D related to the discontinuation of the generic Advair&amp;#xae; development program. &lt;br&gt;&lt;/br&gt;2018 includes impairments of USD 220 million related to the write-down of the allocated goodwill (USD 183 million) and the currently marketed products (USD 37 million) related to the retained Sandoz US dermatology business and generic US oral solids portfolio. See Note 2. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:IntangibleAssetImpairmentChargesTextBlock>
  <ifrs-full:DisclosureOfDeferredTaxesExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;12. Deferred tax assets and liabilities &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Property, &lt;br&gt;&lt;/br&gt; plant and &lt;br&gt;&lt;/br&gt; equipment &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Intangible &lt;br&gt;&lt;/br&gt; assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pensions and &lt;br&gt;&lt;/br&gt; other benefit &lt;br&gt;&lt;/br&gt; obligations &lt;br&gt;&lt;/br&gt; of associates &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Inventories &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Tax loss &lt;br&gt;&lt;/br&gt; carry- &lt;br&gt;&lt;/br&gt; forwards &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Other assets, &lt;br&gt;&lt;/br&gt; provisions &lt;br&gt;&lt;/br&gt; and accruals &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax assets at January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 108&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;078&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;446&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 255&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;596&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;952&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax liabilities at January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;390&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;610&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;291&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;287&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;325&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;910&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;282&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;271&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;282&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;271&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Credited/(charged) to income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 212&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;164&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 71&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 293&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Charged to equity&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Charged to other comprehensive income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;945&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 408&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;501&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other movements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;241&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;918&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 797&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;343&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 497&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;314&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 792&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax assets at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 189&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;351&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;137&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;502&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 507&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;658&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;344&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax liabilities at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;430&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;340&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;344&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&amp;nbsp;552&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;241&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;918&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 797&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;343&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 497&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;314&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 792&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After offsetting the following amount of deferred tax assets and liabilities within the same tax jurisdiction, the balance amounts to: &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 130&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;214&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&amp;nbsp;422&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 792&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax assets at January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 191&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;722&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;175&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;782&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax liabilities at January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;622&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;384&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;474&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;805&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;7&amp;nbsp;558&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;431&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;151&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 915&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;224&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;431&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;151&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 915&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;224&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net deferred tax balance related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 82&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;403&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;123&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 858&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Credited/(charged) to income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 74&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 605&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 308&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;818&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;113&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 298&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 354&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Charged to equity&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;83&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Charged to other comprehensive income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;313&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;289&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;47&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other movements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;282&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;271&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax assets at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 108&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;078&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;446&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 255&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;596&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;952&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax liabilities at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;390&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;610&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;291&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;287&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;325&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;910&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;282&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;271&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After offsetting the following amount of deferred tax assets and liabilities within the same tax jurisdiction, the balance amounts to: &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;909&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;867&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;b&gt; &lt;/b&gt; &lt;b&gt; &lt;/b&gt; &lt;b&gt; &lt;/b&gt; &lt;b&gt; &lt;/b&gt; &lt;b&gt; &lt;/b&gt; &lt;b&gt; &lt;/b&gt; &lt;b&gt; &lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;b&gt; &lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;b&gt;&lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table presents deferred tax assets and deferred tax liabilities, which are expected to have an impact on current taxes payable after more than 12&amp;nbsp;months:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD billions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expected to have an impact on current tax payable after more than 12 months&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Deferred tax liabilities have not been recognized for the withholding tax and other taxes that would be payable on the remittance of earnings of foreign subsidiaries, as the Group has the ability to control any future reversal and the unremitted earnings are retained in the foreign subsidiaries for reinvestment. The total unremitted earnings retained for reinvestment in the Group&amp;#x2019;s foreign subsidiaries that would be subject to withholding tax or other taxes if remitted to the Group are estimated at approximately USD 27 billion in 2020 (2019: USD 26 billion). &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;Temporary differences on which no deferred tax has been provided as they are permanent in nature related to: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD billions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Investments in subsidiaries&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Goodwill from acquisitions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The gross value of tax-loss carry-forwards that have or have not been capitalized as deferred tax assets, with their expiry dates, is as follows: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Not capitalized&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Capitalized&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020 total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;One year&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Two years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Three years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Four years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Five years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;More than five years &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;400&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;291&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Not subject to expiry&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 323&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 683&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;006&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;780&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;805&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Not capitalized more than five years includes USD 3.2 billion attributable to US state tax-loss carry-forwards, of which USD 1.6 billion relates to The Medicines Company, which was acquired in 2020 (see Note 2). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Not capitalized&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Capitalized&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019 total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;One year&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Two years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Three years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Four years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 46&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Five years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 127&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 164&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;More than five years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;214&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;339&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Not subject to expiry&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 310&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 648&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;338&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;986&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tax losses carried forward &lt;br&gt;&lt;/br&gt;that expired &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 14 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Deferred tax assets related to taxable losses of relevant Group entities are recognized to the extent it is considered probable that future taxable profits will be available against which such losses can be utilized in the foreseeable future. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;The Basel-Stadt cantonal tax reform was approved by voters in February 2019, with parts of the reform retroactively enacted per January 1, 2019. The newly enacted tax rate resulted in a decrease of the blended cantonal and federal tax rate from 22% to 13%. This change impacted the Group&amp;#x2019;s Basel-Stadt-domiciled operating subsidiaries. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Swiss federal tax reform was approved by voters in May 2019. The enactment of the Swiss federal tax reform required the abolishment of the holding company tax regimes as of January 1, 2020. As a result, the holding company tax rate increased from the current 8% to 13%, effective January 1, 2020. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The enactment of these Swiss tax reforms required a revaluation of the deferred tax assets and liabilities to the newly enacted tax rates at the date of enactment. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the impact on the revaluation of deferred assets and liabilities in 2019, as at the respective dates of the enactment of the Swiss tax reforms: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Income &lt;br&gt;&lt;/br&gt; statement &lt;br&gt;&lt;/br&gt; continuing &lt;br&gt;&lt;/br&gt; operations &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Equity &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax asset &lt;br&gt;&lt;/br&gt;and liability revaluation &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Items previously recognized &lt;br&gt;&lt;/br&gt;in consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 234 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 234 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Items previously recognized in other comprehensive income &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;358&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;358&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total revaluation of deferred tax assets and liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 234&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;358&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Related to post-employment benefits &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfDeferredTaxesExplanatory>
  <nvs:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Property, &lt;br&gt;&lt;/br&gt; plant and &lt;br&gt;&lt;/br&gt; equipment &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Intangible &lt;br&gt;&lt;/br&gt; assets &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pensions and &lt;br&gt;&lt;/br&gt; other benefit &lt;br&gt;&lt;/br&gt; obligations &lt;br&gt;&lt;/br&gt; of associates &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Inventories &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Tax loss &lt;br&gt;&lt;/br&gt; carry- &lt;br&gt;&lt;/br&gt; forwards &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Other assets, &lt;br&gt;&lt;/br&gt; provisions &lt;br&gt;&lt;/br&gt; and accruals &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax assets at January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 108&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;078&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;446&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 255&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;596&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;952&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax liabilities at January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;390&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;610&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;291&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;287&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;325&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;910&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;282&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;271&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;282&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;271&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Credited/(charged) to income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 212&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;164&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 71&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 293&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Charged to equity&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Charged to other comprehensive income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;945&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 408&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;501&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other movements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;241&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;918&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 797&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;343&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 497&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;314&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 792&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax assets at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 189&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;351&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;137&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;502&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 507&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;658&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;344&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax liabilities at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;430&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;340&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;344&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&amp;nbsp;552&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;241&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;918&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 797&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;343&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 497&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;314&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 792&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After offsetting the following amount of deferred tax assets and liabilities within the same tax jurisdiction, the balance amounts to: &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 130&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;214&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&amp;nbsp;422&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 792&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax assets at January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 191&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;722&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;175&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;782&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax liabilities at January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;622&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;384&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;474&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;805&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;7&amp;nbsp;558&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;431&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;151&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 915&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;224&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;431&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;151&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 915&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;370&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;224&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net deferred tax balance related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 82&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;403&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;123&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 858&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Credited/(charged) to income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 74&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 605&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 308&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;818&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;113&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 298&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 354&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Charged to equity&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 75&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;83&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Charged to other comprehensive income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;313&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;289&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;45&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;47&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other movements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;282&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;271&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax assets at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 108&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;078&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;446&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 255&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;596&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;952&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax liabilities at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;390&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;610&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;291&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;287&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;325&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;910&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;282&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 248&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;271&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After offsetting the following amount of deferred tax assets and liabilities within the same tax jurisdiction, the balance amounts to: &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;909&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;867&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;b&gt; &lt;/b&gt; &lt;b&gt; &lt;/b&gt; &lt;b&gt; &lt;/b&gt; &lt;b&gt; &lt;/b&gt; &lt;b&gt; &lt;/b&gt; &lt;b&gt; &lt;/b&gt; &lt;b&gt; &lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;b&gt; &lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;b&gt;&lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <nvs:DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD billions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expected to have an impact on current tax payable after more than 12 months&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock>
  <nvs:TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD billions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Investments in subsidiaries&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Goodwill from acquisitions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock>
  <ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Not capitalized&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Capitalized&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020 total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;One year&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Two years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Three years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Four years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Five years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;More than five years &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;400&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;291&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Not subject to expiry&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 323&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 683&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;006&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;780&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;805&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Not capitalized more than five years includes USD 3.2 billion attributable to US state tax-loss carry-forwards, of which USD 1.6 billion relates to The Medicines Company, which was acquired in 2020 (see Note 2). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Not capitalized&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Capitalized&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019 total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;One year&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Two years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Three years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Four years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 46&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Five years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 127&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 164&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;More than five years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;214&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;339&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Not subject to expiry&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 310&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 648&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;338&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;986&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tax losses carried forward &lt;br&gt;&lt;/br&gt;that expired &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 14 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory>
  <nvs:CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Income &lt;br&gt;&lt;/br&gt; statement &lt;br&gt;&lt;/br&gt; continuing &lt;br&gt;&lt;/br&gt; operations &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Equity &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax asset &lt;br&gt;&lt;/br&gt;and liability revaluation &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Items previously recognized &lt;br&gt;&lt;/br&gt;in consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 234 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 234 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Items previously recognized in other comprehensive income &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;358&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;358&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total revaluation of deferred tax assets and liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 234&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;358&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Related to post-employment benefits &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock>
  <nvs:DisclosureOfFinancialAssetsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;577&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;524&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;979&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;790&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term receivables from finance subleases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 83&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 66&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other long-term receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 625&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term loans, advances and security deposits&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;901&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;518&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent considerations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfFinancialAssetsTableTextBlock>
  <nvs:DisclosureOfOtherNoncurrentAssetsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred compensation plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 471&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 414&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prepaid post-employment benefit plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 148&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other non-current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 176&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other non-current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 892&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 738&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfOtherNoncurrentAssetsTableTextBlock>
  <ifrs-full:DisclosureOfInventoriesExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;14. Inventories&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Raw material, consumables&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 967&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 751&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Work in progress&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;324&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;024&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Finished products&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;840&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;207&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;131&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;982&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the amount of inventory recognized as an expense in &amp;#x201c;Cost of goods sold&amp;#x201d; in the consolidated income statements from continuing operations: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD billions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the recognized amount of inventory provision and reversals of inventory provision recorded in the consolidated income statements from continuing operations: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventory provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;702&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;752&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;603&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversals of inventory provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 255&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 216&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The reversals mainly result from the release of products initially requiring additional quality control inspections and from the reassessment of inventory values manufactured prior to regulatory approval but for which approval was subsequently received. &lt;/div&gt;</ifrs-full:DisclosureOfInventoriesExplanatory>
  <nvs:ScheduleOfInventoryCurrentTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Raw material, consumables&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 967&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 751&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Work in progress&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;324&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;024&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Finished products&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;840&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;207&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;131&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;982&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfInventoryCurrentTableTextBlock>
  <nvs:DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD billions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock>
  <nvs:DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventory provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;702&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;752&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;603&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversals of inventory provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 255&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 216&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock>
  <nvs:DisclosureOfTradeReceivablesExplanatoryTextBlock contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;15. Trade receivables&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total gross trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;310&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;396&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for doubtful trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total trade receivables, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movement in the provision for doubtful trade receivables:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;95&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 54&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for doubtful trade receivables charged to the consolidated income statement &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;59&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;47&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Utilization of provisions for doubtful trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of provisions for doubtful trade receivables credited to the consolidated income statement &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Provisions charged to the consolidated income statement from continuing operations were USD 30 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Reversal of provisions credited to the consolidated income statement from continuing operations were USD 44 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the trade receivables that are not overdue as specified in the payment terms and conditions established with Novartis customers, as well as an analysis of overdue amounts and related provisions for doubtful trade receivables: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Not overdue&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&amp;nbsp;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;763&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for not more than one month&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 150&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 161&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than one month &lt;br&gt;&lt;/br&gt;but less than three months &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 118 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 123 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than three months &lt;br&gt;&lt;/br&gt;but less than six months &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 102 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 103 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than six months &lt;br&gt;&lt;/br&gt;but less than one year &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 77 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 96 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than one year&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 149&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 150&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for doubtful trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total trade receivables, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Trade receivable balances represent amounts due from our customers, which are mainly drug wholesalers, retailers, private health systems, government agencies, managed care providers, pharmacy benefit managers and government-supported healthcare systems. Novartis continues to monitor sovereign debt issues and economic conditions in the countries in which it operates, particularly in Argentina, Brazil, Greece, Italy, Portugal, Russia, Saudi Arabia, Spain and Turkey, and evaluates trade receivables in these countries for potential collection risks. The majority of the outstanding trade receivables from Portugal, Saudi Arabia, Spain and Greece are due directly from local governments or from government-funded entities. Deteriorating credit and economic conditions as well as other factors in these closely monitored countries have resulted in, and may continue to result in, an increase in the average length of time that it takes to collect these trade receivables, and may require the Group to re-evaluate the expected credit loss amount of these trade receivables in future periods. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the gross trade receivables balance from these closely monitored countries at December 31, 2020 and 2019; the amounts that are past due for more than one year; and the related provisions that have been recorded: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total balance of gross trade &lt;br&gt;&lt;/br&gt;receivables from closely &lt;br&gt;&lt;/br&gt;monitored countries &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;505 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;588 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than one year&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;At December 31, 2020, amounts past due for more than one year are not significant in any of these countries on a standalone basis. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Total trade receivables include amounts denominated in the following major currencies:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US dollar (USD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;311&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;466&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Euro (EUR)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;668&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;384&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japanese yen (JPY)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 437&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 466&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Russian ruble (RUB)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 288&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 341&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Chinese yuan (CNY)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 208&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 279&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;British pound (GBP)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 191&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Australian dollar (AUD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 153&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Brazilian real (BRL)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 148&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 165&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canadian dollar (CAD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Swiss franc (CHF)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other currencies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;564&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;655&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total trade receivables, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfTradeReceivablesExplanatoryTextBlock>
  <nvs:ProvisionsForTradeReceivablesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total gross trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;310&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;396&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for doubtful trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total trade receivables, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ProvisionsForTradeReceivablesTableTextBlock>
  <nvs:TradeReceivablesProvisionMovementsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;95&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 54&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for doubtful trade receivables charged to the consolidated income statement &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;59&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;47&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Utilization of provisions for doubtful trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of provisions for doubtful trade receivables credited to the consolidated income statement &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Provisions charged to the consolidated income statement from continuing operations were USD 30 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Reversal of provisions credited to the consolidated income statement from continuing operations were USD 44 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:TradeReceivablesProvisionMovementsTableTextBlock>
  <nvs:OverdueAmountsAndRelatedProvisionsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Not overdue&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&amp;nbsp;714&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;763&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for not more than one month&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 150&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 161&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than one month &lt;br&gt;&lt;/br&gt;but less than three months &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 118 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 123 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than three months &lt;br&gt;&lt;/br&gt;but less than six months &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 102 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 103 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than six months &lt;br&gt;&lt;/br&gt;but less than one year &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 77 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 96 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than one year&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 149&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 150&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for doubtful trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;95&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total trade receivables, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:OverdueAmountsAndRelatedProvisionsTableTextBlock>
  <nvs:GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total balance of gross trade &lt;br&gt;&lt;/br&gt;receivables from closely &lt;br&gt;&lt;/br&gt;monitored countries &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;505 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;588 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than one year&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 55&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock>
  <nvs:TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US dollar (USD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;311&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;466&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Euro (EUR)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;668&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;384&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japanese yen (JPY)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 437&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 466&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Russian ruble (RUB)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 288&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 341&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Chinese yuan (CNY)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 208&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 279&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;British pound (GBP)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 191&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Australian dollar (AUD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 153&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Brazilian real (BRL)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 148&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 165&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canadian dollar (CAD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Swiss franc (CHF)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other currencies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;564&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;655&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total trade receivables, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock>
  <nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;16. Marketable securities, commodities, time&amp;nbsp;deposits, derivative financial instruments, and&amp;nbsp;cash and cash equivalents&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Marketable securities, commodities, time&amp;nbsp;deposits and derivative financial instruments&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity more than 90 days&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;609&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities, commodities, time deposits and derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;905&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 334&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Cash and cash equivalents&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current accounts&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;750&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;247&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity less than 90 days&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;908&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;865&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;658&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock>
  <nvs:MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity more than 90 days&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;609&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities, commodities, time deposits and derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;905&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 334&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock>
  <nvs:CashAndCashEquivalentsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current accounts&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;750&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;247&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity less than 90 days&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;908&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;865&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;658&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:CashAndCashEquivalentsTableTextBlock>
  <ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;17. Other current assets&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;VAT receivable&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 544&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 508&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Withholding tax recoverable&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 73&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 108&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prepaid expenses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 943&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 898&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Receivables from associated companies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other receivables and current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 963&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;165&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;523&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;680&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory>
  <nvs:OtherCurrentAssetsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;VAT receivable&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 544&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 508&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Withholding tax recoverable&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 73&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 108&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prepaid expenses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 943&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 898&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Receivables from associated companies&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other receivables and current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 963&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;165&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;523&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;680&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:OtherCurrentAssetsTableTextBlock>
  <nvs:DisclosureOfEquityTextBlock contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;18. Equity&lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the movement in the share capital:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Jan 1, 2018 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Movement &lt;br&gt;&lt;/br&gt; in year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Dec 31, 2018 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Movement &lt;br&gt;&lt;/br&gt; in year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Dec 31, 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Movement &lt;br&gt;&lt;/br&gt; in year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Dec 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Share capital&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 969&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 944&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 936&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 913&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Treasury shares&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;69&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;80&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Outstanding share capital&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 869&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 875&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 856&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 860&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the movement in the shares:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Number of outstanding shares &lt;br&gt;&lt;/br&gt;(in millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Note &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br&gt;&lt;/br&gt; Novartis &lt;br&gt;&lt;/br&gt; shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br&gt;&lt;/br&gt; treasury &lt;br&gt;&lt;/br&gt; shares &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br&gt;&lt;/br&gt; outstanding &lt;br&gt;&lt;/br&gt; shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br&gt;&lt;/br&gt; Novartis &lt;br&gt;&lt;/br&gt; shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br&gt;&lt;/br&gt; treasury &lt;br&gt;&lt;/br&gt; shares &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br&gt;&lt;/br&gt; outstanding &lt;br&gt;&lt;/br&gt; shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br&gt;&lt;/br&gt; Novartis &lt;br&gt;&lt;/br&gt; shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br&gt;&lt;/br&gt; treasury &lt;br&gt;&lt;/br&gt; shares &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br&gt;&lt;/br&gt; outstanding &lt;br&gt;&lt;/br&gt; shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Balance at beginning of year&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;527.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;262.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;265.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;550.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;239.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;311.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;616.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;299.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;317.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares canceled for capital &lt;br&gt;&lt;/br&gt;reduction &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;60.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 60.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;23.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 23.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;66.2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 66.2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares acquired to be &lt;br&gt;&lt;/br&gt;canceled &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;32.6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;32.6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;60.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;60.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;23.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;23.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share purchases &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise of options &lt;br&gt;&lt;/br&gt;and employee transactions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 18.9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 14.7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 14.7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 5.5 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 5.5 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 7.8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 7.8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares delivered to Alcon &lt;br&gt;&lt;/br&gt;employees &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 0.4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 0.4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 0.9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 0.9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total movements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;60.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 52.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;23.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;22.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;46.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;66.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 59.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Balance at end of year&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;467.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;210.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;256.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;527.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;262.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;265.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;550.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;239.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;311.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Approximately 103.0 million treasury shares (2019: 117.6 million; 2018: 121.6 million) are held in Novartis entities that restrict their availability for use. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Novartis reduced its share capital by canceling shares that were repurchased on the SIX Swiss Exchange second trading line during previous years. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2016 Annual General Meeting (AGM) for transactions before February 28, 2019, and under a new CHF 10 billion share buyback authority approved at the 2019 AGM for transactions after such date &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;5&amp;nbsp;&lt;/sup&gt; Shares delivered as a result of options being exercised and physical share deliveries related to equity-based participation plans. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;18.1) The amount available for distribution as a dividend to shareholders is based on the available distributable retained earnings of Novartis AG determined in accordance with the legal provisions of the Swiss Code of Obligations. &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dividend per share (in CHF)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.95&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.85&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.80&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total dividend payment &lt;br&gt;&lt;/br&gt;(in USD billion) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 7.0 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 6.6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 7.0 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;18.2) The following table summarizes the treasury shares movements:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Note &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Number of &lt;br&gt;&lt;/br&gt; outstanding &lt;br&gt;&lt;/br&gt; shares &lt;br&gt;&lt;/br&gt; (in millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Equity impact &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Number of &lt;br&gt;&lt;/br&gt; outstanding &lt;br&gt;&lt;/br&gt; shares &lt;br&gt;&lt;/br&gt; (in millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Equity impact &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Number of &lt;br&gt;&lt;/br&gt; outstanding &lt;br&gt;&lt;/br&gt; shares &lt;br&gt;&lt;/br&gt; (in millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Equity impact &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares acquired to be canceled &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;32.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;897&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;60.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;351&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;23.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;859&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share purchases &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;160&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;114&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Purchase of treasury shares&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;34.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;056&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;62.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;511&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;24.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;973&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise of options and employee transactions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 806&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 210&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 434&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 730&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 833&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 756&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares delivered to Alcon employees&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;490&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;46.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;450&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;520&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2016 AGM for transactions before February 28, 2019, and under a new CHF 10 billion share buyback authority approved at the 2019 AGM for transactions after such date &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Shares delivered as a result of options being exercised related to equity-based participation plans and the delivery of treasury shares. The average share price of the shares delivered was significantly below market price, reflecting the strike price of the options exercised. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; Equity-settled share-based compensation is expensed in the consolidated income statement in accordance with the vesting period of the share-based compensation plans. The value for the shares and options granted is credited to consolidated equity over the respective vesting period. In addition, tax benefits arising from tax-deductible amounts exceeding the expense recognized in the income statement are credited to equity. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.3) In November 2020, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD 2.5 billion share buyback. Novartis is able to cancel this arrangement at any time but could be subject to a 90-day waiting period. The commitment under this arrangement therefore reflects the obligated purchases by the bank under such trading plan over a rolling 90-day period, or if shorter, until the maturity date of such trading plan. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The commitment under this arrangement amounted to USD 1.8 billion as of December 31, 2020.&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In August 2020, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares to mitigate dilution related to participation plans of associates. Novartis was able to cancel this arrangement at any time but would have been subjected to a 90-day waiting period. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;This trading plan commitment was fully executed and expired, and as a consequence, there is no contingent liability related to this plan recognized as of December 31, 2020. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2019, Novartis entered into a similar irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD&amp;nbsp;5 billion share buyback and to repurchase Novartis shares to mitigate dilution related to participation plans of associates. The commitment under this arrangement therefore reflects the obligated purchases by the bank under such trading plan over a rolling 90-day period, or if shorter, until the maturity date of such trading plan. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The trading plan commitment was fully executed and expired, and as a consequence, there is no contingent liability related to this plan recognized as of December 31, 2019. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2018, Novartis entered into a similar irrevocable, non-discretionary arrangements with a bank to repurchase Novartis shares. The commitments under this arrangement reflected the expected purchases by the bank under such trading plan over a rolling 90-day period. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The commitment under this arrangement amounted to USD 284 million as of December 31, 2018. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.4) In October 2020, Novartis entered into an agreement with the market maker for its employee options to repurchase a portion of the outstanding written call options. A total of 3.7 million options were repurchased under this agreement. This agreement was terminated in November 2020. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.5) The impact of change in ownership of consolidated entities represents the excess of the amount paid to non-controlling interest over their carrying value and equity allocation to non-controlling interest due to change in ownership percentage. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.6) Changes in non-controlling interests represent the impact on the non-controlling interest of transactions with minority shareholders, such as change in ownership percentage, dividend payments and other equity transactions. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.7) Other movements includes, for subsidiaries in hyperinflationary economies, the impact of the restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period as well as the restatement of the equity balances of the current year. In 2020, the amount recorded in equity related to hyperinflation accounting was USD 18 million (2019: USD 22 million; 2018: USD 38 million). See Note 29 for additional disclosures. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.8) In 2019, transaction costs of USD 253 million (2018: USD 79 million) net of tax of USD 36 million (2018: USD 20 million), that are directly attributable to the distribution (spin-off) of Alcon Inc. to Novartis shareholders and that would otherwise have been avoided, were recorded as a deduction from equity. See Note 1 for further details. No transaction costs were recorded as a deduction from equity in 2020. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.9) At December 31, 2020, the market maker held 1 million (2019: 13 million; 2018: 11 million) written call options, originally issued as part of the share-based compensation for associates, that have not yet been exercised. The weighted average exercise price of these options is USD 60.09 (2019: USD 63.90; 2018: USD 62.70), and they have contractual lives of 10 years, with remaining lives up to three years (2019: four years; 2018: five years). &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In December 2018, Novartis entered into an agreement with the market maker for its employee options to repurchase a portion of the outstanding written call options that are not exercised in exchange for treasury shares. During 2019, this agreement was fully executed. &lt;/div&gt;</nvs:DisclosureOfEquityTextBlock>
  <nvs:MovementInTheShareCapitalTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Jan 1, 2018 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Movement &lt;br&gt;&lt;/br&gt; in year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Dec 31, 2018 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Movement &lt;br&gt;&lt;/br&gt; in year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Dec 31, 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Movement &lt;br&gt;&lt;/br&gt; in year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Dec 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Share capital&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 969&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 944&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 936&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 913&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Treasury shares&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;69&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;80&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Outstanding share capital&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 869&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 875&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 856&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 860&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:MovementInTheShareCapitalTableTextBlock>
  <nvs:MovementInTheShareslTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Number of outstanding shares &lt;br&gt;&lt;/br&gt;(in millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Note &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br&gt;&lt;/br&gt; Novartis &lt;br&gt;&lt;/br&gt; shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br&gt;&lt;/br&gt; treasury &lt;br&gt;&lt;/br&gt; shares &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br&gt;&lt;/br&gt; outstanding &lt;br&gt;&lt;/br&gt; shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br&gt;&lt;/br&gt; Novartis &lt;br&gt;&lt;/br&gt; shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br&gt;&lt;/br&gt; treasury &lt;br&gt;&lt;/br&gt; shares &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br&gt;&lt;/br&gt; outstanding &lt;br&gt;&lt;/br&gt; shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br&gt;&lt;/br&gt; Novartis &lt;br&gt;&lt;/br&gt; shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br&gt;&lt;/br&gt; treasury &lt;br&gt;&lt;/br&gt; shares &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br&gt;&lt;/br&gt; outstanding &lt;br&gt;&lt;/br&gt; shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Balance at beginning of year&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;527.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;262.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;265.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;550.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;239.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;311.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;616.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;299.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="4%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;317.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares canceled for capital &lt;br&gt;&lt;/br&gt;reduction &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;60.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 60.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;23.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 23.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;66.2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 66.2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares acquired to be &lt;br&gt;&lt;/br&gt;canceled &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;32.6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;32.6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;60.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;60.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;23.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;23.3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share purchases &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise of options &lt;br&gt;&lt;/br&gt;and employee transactions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 18.9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 14.7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 14.7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 5.5 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 5.5 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 7.8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 7.8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;5&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares delivered to Alcon &lt;br&gt;&lt;/br&gt;employees &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 0.4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 0.4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 0.9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 0.9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total movements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;60.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 52.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;23.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;22.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;46.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;66.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 59.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Balance at end of year&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;467.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;210.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;256.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;527.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;262.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;265.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;550.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;239.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;311.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="22" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Approximately 103.0 million treasury shares (2019: 117.6 million; 2018: 121.6 million) are held in Novartis entities that restrict their availability for use. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Novartis reduced its share capital by canceling shares that were repurchased on the SIX Swiss Exchange second trading line during previous years. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2016 Annual General Meeting (AGM) for transactions before February 28, 2019, and under a new CHF 10 billion share buyback authority approved at the 2019 AGM for transactions after such date &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;5&amp;nbsp;&lt;/sup&gt; Shares delivered as a result of options being exercised and physical share deliveries related to equity-based participation plans. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="22"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:MovementInTheShareslTableTextBlock>
  <nvs:DividendTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dividend per share (in CHF)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.95&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.85&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.80&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total dividend payment &lt;br&gt;&lt;/br&gt;(in USD billion) &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 7.0 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 6.6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 7.0 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DividendTableTextBlock>
  <nvs:SummaryOfTreasurySharesMovementsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Note &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Number of &lt;br&gt;&lt;/br&gt; outstanding &lt;br&gt;&lt;/br&gt; shares &lt;br&gt;&lt;/br&gt; (in millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Equity impact &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Number of &lt;br&gt;&lt;/br&gt; outstanding &lt;br&gt;&lt;/br&gt; shares &lt;br&gt;&lt;/br&gt; (in millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Equity impact &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Number of &lt;br&gt;&lt;/br&gt; outstanding &lt;br&gt;&lt;/br&gt; shares &lt;br&gt;&lt;/br&gt; (in millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Equity impact &lt;br&gt;&lt;/br&gt; USD m &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares acquired to be canceled &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;32.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;897&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;60.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;351&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;23.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="6%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;859&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share purchases &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;160&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;114&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Purchase of treasury shares&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;34.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;056&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;62.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;511&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;24.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;973&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise of options and employee transactions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 806&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 210&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 434&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 730&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 833&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 756&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares delivered to Alcon employees&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share sales&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;8.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;490&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;46.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;450&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;520&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="16" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2016 AGM for transactions before February 28, 2019, and under a new CHF 10 billion share buyback authority approved at the 2019 AGM for transactions after such date &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Shares delivered as a result of options being exercised related to equity-based participation plans and the delivery of treasury shares. The average share price of the shares delivered was significantly below market price, reflecting the strike price of the options exercised. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; Equity-settled share-based compensation is expensed in the consolidated income statement in accordance with the vesting period of the share-based compensation plans. The value for the shares and options granted is credited to consolidated equity over the respective vesting period. In addition, tax benefits arising from tax-deductible amounts exceeding the expense recognized in the income statement are credited to equity. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:SummaryOfTreasurySharesMovementsTableTextBlock>
  <ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;19. Non-current financial debt&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 28&amp;nbsp;298&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Liabilities to banks and other financial institutions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total, including current portion of non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 28&amp;nbsp;531&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;355&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current portion of non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;272&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;002&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 20&amp;nbsp;353&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Average interest rate 0.3% (2019: 0.2%) &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;All bonds are initially recorded at the amount of proceeds received, net of transaction costs. They are subsequently carried at amortized cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognized as a charge to the consolidated income statement over the period of the relevant bond. Financial debts, including current financial debts, contain only general default covenants. The Group is in compliance with these covenants. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The percentage of fixed-rate financial debt to total financial debt was 79% at December 31, 2020, and 82% at December 31, 2019.&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The average interest rate on total financial debt in 2020 was 2.0% (2019: 2.4%).&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Note 29 contains a maturity table of the Group&amp;#x2019;s future contractual interest payments commitments. &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table provides a breakdown of straight bonds:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Coupon &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Currency &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Nominal &lt;br&gt;&lt;/br&gt; amount &lt;br&gt;&lt;/br&gt; (millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Issuance &lt;br&gt;&lt;/br&gt; year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Maturity &lt;br&gt;&lt;/br&gt; year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Issuer &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Issue price &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020 &lt;br&gt;&lt;/br&gt; (USD &lt;br&gt;&lt;/br&gt; millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019 &lt;br&gt;&lt;/br&gt; (USD &lt;br&gt;&lt;/br&gt; millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;4.400%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2010&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.237%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.400%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2012&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2022&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.225%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;497&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;495&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;3.700%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2012&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 98.325%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 490&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 489&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;3.400%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;150&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2014&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2024&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.287%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;139&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;4.400%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;850&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2014&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2044&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.196%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;826&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;825&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.750%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 600&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2014&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2021&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.134%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 737&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 670&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.625%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 600&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2014&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2026&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.697%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 735&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 670&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.250%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2015&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis AG, Basel, Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100.640%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 568&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 517&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.625%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 550&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2015&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2029&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis AG, Basel, Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100.502%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 625&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 568&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.050%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 325&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2015&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2035&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis AG, Basel, Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100.479%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 369&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;3.000%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;750&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2015&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.010%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;737&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;735&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;4.000%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2015&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2045&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 98.029%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.125%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2016&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.127%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;530&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;392&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.625%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2016&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2028&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 98.480%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 607&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 553&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.800%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2017&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.609%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.400%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2017&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2022&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.449%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 998&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 996&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;3.100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2017&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2027&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.109%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 992&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 990&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.000%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2017&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2021&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.133%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;536&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;396&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.125%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 600&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2017&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2027&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.874%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 735&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 670&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.500%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 750&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.655%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 919&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 837&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.375%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 750&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2030&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.957%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 920&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 838&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.700%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 750&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2038&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.217%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 913&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 832&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.750%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.852%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 996&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.000%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2027&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.909%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;245&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.200%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2030&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.869%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;493&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.750%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2050&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 97.712%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;213&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.000% &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;850&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2028&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.354%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;255&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total straight bonds&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 28&amp;nbsp;298&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; The EUR 1 850 million bond issued in 2020 features a coupon step-up of 0.25% commencing with the first interest payment date after December 31, 2025, if one or both of the 2025 Patient Access Targets are not met. These 2025 Patient Access Targets are the 2025 Flagship Programs Patient Reach Target and the 2025 Strategic Innovative Therapies Patient Reach Target, as defined in the bond prospectus. As of December 31, 2020, there is no indication that these 2025 Patient Access Targets will not be met. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following tables provide a breakdown of total non-current financial debt, including current portion by maturity and currency: &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Breakdown by maturity:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;002&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;272&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;067&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;631&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;583&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;546&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;321&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2024&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;139&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;302&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;252&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After 2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&amp;nbsp;638&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;991&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 28&amp;nbsp;531&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;355&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Breakdown by currency:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US dollar (USD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&amp;nbsp;848&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;889&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Euro (EUR)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&amp;nbsp;888&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;861&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japanese yen (JPY)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 184&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Swiss franc (CHF)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;563&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;421&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 28&amp;nbsp;531&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;355&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;The following table shows the comparison of balance sheet and fair value of total non-current financial debt, including current portion: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020 &lt;br&gt;&lt;/br&gt; Balance &lt;br&gt;&lt;/br&gt; sheet &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020 &lt;br&gt;&lt;/br&gt; Fair &lt;br&gt;&lt;/br&gt; values &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019 &lt;br&gt;&lt;/br&gt; Balance &lt;br&gt;&lt;/br&gt; sheet &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019 &lt;br&gt;&lt;/br&gt; Fair &lt;br&gt;&lt;/br&gt; values &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 28&amp;nbsp;298&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 31&amp;nbsp;359&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 23&amp;nbsp;701&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 28&amp;nbsp;531&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 31&amp;nbsp;592&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;355&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;889&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The fair values of straight bonds are determined by quoted market prices. Other financial debts are recorded at notional amounts, which are a reasonable approximation of the fair values. &lt;/div&gt;</ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory>
  <nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 28&amp;nbsp;298&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Liabilities to banks and other financial institutions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total, including current portion of non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 28&amp;nbsp;531&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;355&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current portion of non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;272&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;002&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 20&amp;nbsp;353&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Average interest rate 0.3% (2019: 0.2%) &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock>
  <nvs:DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Coupon &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Currency &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Nominal &lt;br&gt;&lt;/br&gt; amount &lt;br&gt;&lt;/br&gt; (millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Issuance &lt;br&gt;&lt;/br&gt; year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Maturity &lt;br&gt;&lt;/br&gt; year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Issuer &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Issue price &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020 &lt;br&gt;&lt;/br&gt; (USD &lt;br&gt;&lt;/br&gt; millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019 &lt;br&gt;&lt;/br&gt; (USD &lt;br&gt;&lt;/br&gt; millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;4.400%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2010&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.237%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.400%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2012&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2022&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.225%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;497&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;495&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;3.700%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2012&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 98.325%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 490&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 489&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;3.400%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;150&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2014&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2024&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.287%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;139&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;4.400%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;850&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2014&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2044&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.196%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;826&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;825&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.750%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 600&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2014&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2021&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.134%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 737&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 670&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.625%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 600&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2014&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2026&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.697%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 735&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 670&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.250%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2015&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis AG, Basel, Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100.640%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 568&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 517&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.625%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 550&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2015&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2029&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis AG, Basel, Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100.502%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 625&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 568&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.050%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 325&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2015&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2035&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis AG, Basel, Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100.479%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 369&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;3.000%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;750&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2015&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.010%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;737&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;735&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;4.000%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2015&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2045&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 98.029%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.125%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2016&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.127%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;530&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;392&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.625%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2016&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2028&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 98.480%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 607&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 553&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.800%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2017&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.609%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.400%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2017&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2022&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.449%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 998&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 996&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;3.100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2017&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2027&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.109%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 992&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 990&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.000%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2017&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2021&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.133%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;536&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;396&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.125%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 600&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2017&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2027&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.874%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 735&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 670&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.500%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 750&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.655%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 919&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 837&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.375%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 750&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2030&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.957%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 920&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 838&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.700%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 750&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2038&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.217%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 913&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 832&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1.750%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.852%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 996&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.000%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2027&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.909%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;245&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.200%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;500&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2030&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.869%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;493&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2.750%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2050&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Capital Corporation, New York, United States&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 97.712%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;213&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;0.000% &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;850&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2028&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Novartis Finance S.A., Luxembourg, Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.354%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;255&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total straight bonds&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 28&amp;nbsp;298&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; The EUR 1 850 million bond issued in 2020 features a coupon step-up of 0.25% commencing with the first interest payment date after December 31, 2025, if one or both of the 2025 Patient Access Targets are not met. These 2025 Patient Access Targets are the 2025 Flagship Programs Patient Reach Target and the 2025 Strategic Innovative Therapies Patient Reach Target, as defined in the bond prospectus. As of December 31, 2020, there is no indication that these 2025 Patient Access Targets will not be met. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock>
  <nvs:DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;002&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;272&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;067&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;631&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;583&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;546&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;321&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2024&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;139&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;302&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;252&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After 2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&amp;nbsp;638&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;991&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 28&amp;nbsp;531&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;355&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock>
  <nvs:DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US dollar (USD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&amp;nbsp;848&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;889&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Euro (EUR)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&amp;nbsp;888&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;861&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japanese yen (JPY)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 184&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Swiss franc (CHF)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;563&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;421&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 28&amp;nbsp;531&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;355&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock>
  <nvs:DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020 &lt;br&gt;&lt;/br&gt; Balance &lt;br&gt;&lt;/br&gt; sheet &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020 &lt;br&gt;&lt;/br&gt; Fair &lt;br&gt;&lt;/br&gt; values &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019 &lt;br&gt;&lt;/br&gt; Balance &lt;br&gt;&lt;/br&gt; sheet &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019 &lt;br&gt;&lt;/br&gt; Fair &lt;br&gt;&lt;/br&gt; values &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 28&amp;nbsp;298&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 31&amp;nbsp;359&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 23&amp;nbsp;701&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 28&amp;nbsp;531&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 31&amp;nbsp;592&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;355&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;889&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock>
  <ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;20. Provisions and other non-current liabilities&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued liability for employee benefits:&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit pension plans &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;538&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other long-term employee benefits and deferred compensation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 637&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 546&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other post-employment benefits &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Environmental remediation provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 642&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 592&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for product liabilities, governmental investigations and other legal matters&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 200&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 984&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 958&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 409&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 255&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total provisions and other non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;934&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&amp;nbsp;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Note 25 provides additional disclosures related to post-employment benefits. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent consideration. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis believes that its total provisions are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities in this area, Novartis may incur additional costs beyond the amounts provided. Management believes that such additional amounts, if any, would not be material to the Group&amp;#x2019;s financial condition but could be material to the results of operations or cash flows in a given period. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Environmental remediation provisions&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the movements in the environmental liability provisions:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 714&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 692&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 761&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;48&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Releases &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005; 83&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 82&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 809&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 714&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 692&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current provision&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current environmental remediation provisions at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 642&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 592&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 634&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Releases of provisions credited to the consolidated income statement from continuing operations were USD 21 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Additions to provisions charged to the consolidated income statement from continuing operations were USD 7 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The material components of the environmental remediation provisions consist of costs to sufficiently clean and refurbish contaminated sites to the extent necessary and to continue surveillance at sites where the environmental remediation exposure is less significant. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;A substantial portion of the environmental remediation provisions relate to the remediation of Basel regional landfills in the adjacent border areas in Switzerland, Germany and France. The provisions are reassessed on a yearly basis and adjusted as necessary. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In the United States, Novartis has been named under federal legislation (the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended) as a potentially responsible party (PRP) in respect of certain sites. Novartis actively participates in, or monitors, the cleanup activities at the sites in which it is a PRP. The provision takes into consideration the number of other PRPs at each site as well as the identity and financial position of such parties in light of the joint and several nature of the liability. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The expected timing of the related cash outflows as of December 31, 2020, is currently projected as follows: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Expected &lt;br&gt;&lt;/br&gt; cash outflows &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due within two years&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due later than two years, but within five years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 210&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due later than five years, but within 10 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 338&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due after 10 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 80&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total environmental remediation liability provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 809&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Provisions for product liabilities, governmental investigations and other legal matters &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has established provisions for certain product liabilities, governmental investigations and other legal matters where a potential cash outflow is probable and Novartis can make a reliable estimate of the amount of the outflow. These provisions represent the Group&amp;#x2019;s current best estimate of the total financial effect for the matters described below and for other less significant matters. Potential cash outflows reflected in a provision might be fully or partially offset by insurance in certain circumstances. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Novartis has not established provisions for potential damage awards for certain additional legal claims against its subsidiaries if Novartis currently believes that a payment is either not probable or cannot be reliably estimated. In total, these not-provisioned-for matters include more than 3&amp;#xa0;000 individual product liability cases and certain other legal matters. Plaintiffs&amp;#x2019; alleged claims in these matters, which Novartis does not believe to be entirely remote but which do not fulfill the conditions for the establishment of provisions, currently aggregate to, according to the current best belief of Novartis, approximately USD&amp;nbsp;0.5 billion. In addition, in some of these matters there are claims for punitive or multiple (treble) damages, civil penalties and disgorgement of profits that in the view of Novartis are either wholly or partially unspecified, or wholly or partially unquantifiable at present; the Group believes that information about these amounts claimed by plaintiffs generally is not meaningful for purposes of determining a reliable estimate of a loss that is probable or more than remote. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;A number of other legal matters are in such early stages or the issues presented are such that the Group has not made any provisions since it cannot currently estimate either a potential outcome or the amount of any potential losses. For these reasons, among others, the Group generally is unable to make a reliable estimate of possible loss with respect to such cases. It is therefore not practicable to provide information about the potential financial impact of those cases. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;There might also be cases for which the Group was able to make a reliable estimate of the possible loss or the range of possible loss, but the Group believes that publication of such information on a case-by-case basis would seriously prejudice the Group&amp;#x2019;s position in ongoing legal proceedings or in any related settlement discussions. Accordingly, in such cases, information has been disclosed with respect to the nature of the contingency, but no disclosure is provided as to an estimate of the possible loss or range of possible loss. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Note 28 contains additional information on contingencies.&lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Summary of significant legal proceedings&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following is a summary of significant legal proceedings to which Novartis or its subsidiaries are currently a party, or were a party and that concluded in 2020. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Investigations and related litigations&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Southern District of New York (S.D.N.Y.) Gilenya marketing practices investigation and litigation &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2013, Novartis Pharmaceuticals Corporation (NPC) received a civil investigative demand from the United States Attorney&amp;#x2019;s Office (USAO) for the S.D.N.Y. requesting the production of documents and information relating to marketing practices for &lt;i&gt;Gilenya&lt;/i&gt;, including the remuneration of healthcare providers in connection therewith. In 2017, the S.D.N.Y. and New York State declined to intervene in claims raised by an individual relator in a &lt;i&gt;qui tam&lt;/i&gt; complaint, which continue to be vigorously contested. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Government generic pricing antitrust investigations, antitrust class actions&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Since 2016, Sandoz Inc. has received a grand jury subpoena and a civil investigative demand and interrogatories from the Antitrust and Civil Divisions of the US Department of Justice (DOJ), and a subpoena and interrogatories from the Attorney General of the State of Connecticut in connection with those agencies&amp;#x2019; investigation into alleged price fixing and market allocation of generic drugs in the US market as well as alleged federal False Claims Act (FCA) violations. In 2020, Sandoz Inc. reached a resolution with the DOJ Antitrust Division, pursuant to which Sandoz Inc. agreed to pay USD 195 million and entered into a deferred prosecution agreement. The Sandoz resolution related to instances of misconduct at the company between 2013 and 2015 with regard to certain generic drugs sold in the United States. Under the terms of that agreement, Sandoz Inc. will continue to take steps to enhance its compliance program, employee training and monitoring, and will continue to cooperate with the US government&amp;#x2019;s ongoing investigation into the generic pharmaceutical industry. Sandoz Inc. is also in negotiations with the DOJ Civil Division to resolve potential related claims and has recorded a provision of USD 187 million. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Since the third quarter of 2016, Sandoz Inc. and Fougera Pharmaceuticals Inc. have been sued alongside other generic pharmaceutical companies in numerous individual and putative class action complaints by direct and indirect private purchasers and by 54 states and US territories, represented by their respective Attorneys General. Plaintiffs claim that defendants, including Sandoz, engaged in price fixing and market allocation of generic drugs in the US market, and seek damages and injunctive relief. The actions contain product-specific complaints as well as complaints alleging the existence of an overarching industry conspiracy, and assert violations of federal and state antitrust laws as well as consumer protection laws. The cases have been consolidated for pretrial purposes in the United States District Court (USDC) for the Eastern District of Pennsylvania, and the claims are being vigorously contested. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Lucentis/Avastin &lt;sup&gt;&amp;#xae;&lt;/sup&gt; matters &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In connection with an investigation into whether Novartis entities, F. Hoffmann-La Roche AG, Genentech Inc. and Roche S.p.A. colluded to artificially preserve the market positions of Avastin &lt;sup&gt;&amp;#xae;&lt;/sup&gt; and &lt;i&gt;Lucentis&lt;/i&gt;, in 2014 the Italian Competition Authority (ICA) imposed a fine equivalent to USD 125 million on the Novartis entities. Novartis paid the fine, subject to the right to later claim recoupment, and appealed before the Consiglio di Stato (CdS). In 2014 and 2015, the Italian Ministry of Health and the Lombardia region sent letters with payment requests for a total equivalent of approximately USD&amp;nbsp;1.3 billion in damages from Novartis and Roche entities based on these allegations. In 2019, the CdS upheld the ICA decision and fine. Following the CdS decision, several additional Italian regions and hospitals sent letters claiming damages for an aggregate amount of approximately USD 330 million. None of these claims has been asserted in legal proceedings. Novartis continues to appeal the CdS decision. In 2019, the French Competition Authority (FCA) issued a Statement of Objections against Novartis entities, alleging anti-competitive practices on the French market for anti-vascular endothelial growth factor treatments for wet age-related macular degeneration from 2008 to 2013. In 2020, the FCA issued a decision finding that the Novartis entities had infringed competition law by abusing a dominant position and imposing a fine of EUR 385 million (equivalent to approximately USD 452 million). Novartis paid the fine, again subject to recoupment, and is appealing the FCA&amp;#x2019;s decision. Novartis continues to vigorously contest all claims in Italy and France. Novartis is also challenging policies and regulations allowing off-label/unlicensed use and reimbursement for economic reasons in various countries, including Italy and Turkey. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Japan investigation&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2015, a trial started against a former Novartis Pharma K.K. (NPKK) employee, and also against NPKK under the dual liability concept in Japanese law, over allegations brought by the Tokyo District Public Prosecutor Office for alleged manipulation of data in sub-analysis publications of the Kyoto Heart Study regarding valsartan. The charges against NPKK are subject to a maximum total fine of JPY 4 million. In 2018, the Tokyo High Court upheld a not-guilty ruling of the Tokyo District Court for both the former NPKK employee and NPKK. A further appeal by the Tokyo High Public Prosecutor Office remains pending. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;South Korea investigation&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2016, the Seoul Western District Prosecutor initiated a criminal investigation into, among other things, allegations that Novartis Korea utilized medical journals to provide inappropriate economic benefits to healthcare professionals (HCPs). This resulted in a non-material fine in January 2020, and the Prosecutor has appealed the fine. The resolution of inquiries by the DOJ and the US Securities and Exchange Commission (SEC) regarding this matter is described below in &amp;#x201c;Concluded legal matters - US Government Foreign Corrupt Practices Act (FCPA) investigations.&amp;#x201d; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Greece investigation&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis is providing information to the Greek authorities investigating allegations of potentially inappropriate economic benefits to HCPs, government officials and others in Greece. These authorities include the Greek Coordinating Body for Inspection and Control, and the Greek Body of Prosecution of Financial Crime, from which the Company received a summons in 2018 and 2020. The resolution of inquiries by the DOJ and the SEC regarding this matter is described below in &amp;#x201c;Concluded legal matters - US Government Foreign Corrupt Practices Act (FCPA) investigations.&amp;#x201d; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Antitrust class actions&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Exforge&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Since 2018, Novartis Group companies as well as other pharmaceutical companies have been sued by various direct and indirect purchasers of &lt;i&gt;Exforge&lt;/i&gt; in multiple US individual and putative class action complaints. They claim that Novartis made a reverse payment in the form of an agreement not to launch an authorized generic, alleging violations of federal antitrust law and state antitrust, consumer protection and common laws, and seeking damages as well as injunctive relief. The cases have been consolidated in the S.D.N.Y. and the claims are being vigorously contested. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Product liability litigation&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Reclast &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;NPC is a defendant in more than 20 US product liability actions involving &lt;i&gt;Reclast&lt;/i&gt; and alleging atypical femur fracture injuries, all of which are in New Jersey state or federal court and in California state court, coordinated with claims against other bisphosphonate manufacturers. The claims are being vigorously contested. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Taxotere&amp;#xae; (docetaxel)&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Sandoz is a defendant in more than 3&amp;#xa0;000 US product liability actions involving Taxotere &lt;sup&gt;&amp;#xae;&lt;/sup&gt; (docetaxel), an oncology product, many of which have been transferred to a multidistrict litigation in the Eastern District of Louisiana. The complaints allege misleading marketing and that Sanofi, as innovator, and several 505(b)(2) NDA holders (including Sandoz) failed to warn of the risk of permanent alopecia/hair loss. The claims are being vigorously contested. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Amiodarone&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Sandoz entities are named in less than five individual and multi-plaintiff US product liability cases involving amiodarone, a cardiac drug indicated to treat life-threatening arrhythmias that have not responded to other treatment. The complaints allege failure to warn, off-label promotion and failure to include medication guides to pharmacies. The claims are being vigorously contested. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Sartans and ranitidine&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Since 2018, claims have been brought against Sandoz and other pharmaceutical companies alleging injury from carcinogenic impurities found in valsartan and valsartan/HCT film-coated tablets and/or losartan marketed or manufactured by Sandoz. These claims include several putative class actions in Canada. Claims have also been brought alleging injury from carcinogenic impurities in ranitidine-containing medicines. These claims also include several putative class actions in Canada and a multidistrict litigation in Florida. All of these claims are being vigorously contested. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Tasigna&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;NPC is a defendant in more than 80 US product liability actions involving &lt;i&gt;Tasigna&lt;/i&gt;, alleging that the product caused various cardiovascular effects and that NPC failed to provide adequate warnings about those alleged side effects. The actions are pending in New Jersey state court and in federal courts in various jurisdictions. The claims are being vigorously contested. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Other matters&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Average Wholesale Price (AWP) litigation&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Lawsuits have been brought, the latest in February 2016, by various US state governmental entities and private parties against various pharmaceutical companies, including NPC, alleging that they fraudulently overstated the AWP that is or has been used by payors, including state Medicaid agencies, to calculate reimbursements to healthcare providers. NPC remains a defendant in a putative class action brought by private payors in New Jersey, and vigorously contests those claims. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Aimovig&amp;ndash;Amgen dispute&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2015 and 2017, Novartis and Amgen entered into agreements regarding the development and commercialization of &lt;i&gt;Aimovig&lt;/i&gt;, which the companies co-commercialize in the US and to which Novartis has exclusive rights in all territories outside the US, excluding Japan. Amgen issued a termination notice in April 2019 based on an alleged material breach of the collaboration agreements, and this notice, as well as other ancillary matters, are the subject of legal proceedings between Novartis and Amgen. Novartis disputes Amgen&amp;#x2019;s allegations vigorously. In 2020, the court ruled that Amgen did not have grounds to terminate the 2017 agreement and dismissed that portion of their lawsuit. The collaboration continues during the litigation between the companies, and will remain in force until and unless a final court decision terminates the agreements. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Shareholder Derivative Lawsuit&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2021, NPC, Sandoz Inc., Novartis Capital Corporation and certain present and former directors and officers of Novartis were named as defendants, and Novartis was named as a nominal defendant, in a purported shareholder derivative lawsuit filed in New York state court. The plaintiff, derivatively as a purported Novartis shareholder on behalf of Novartis, seeks damages and other remedies based on alleged conduct by the corporate and individual defendants. The claims are being vigorously contested. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Concluded legal matters&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;S.D.N.Y. marketing practices investigation and litigation&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2013, the US government filed a civil complaint in intervention to an individual &lt;i&gt;qui tam&lt;/i&gt; action against NPC in the USDC for the S.D.N.Y. The complaint, as subsequently amended, asserted federal FCA and common law claims with respect to speaker programs and other promotional activities for certain NPC cardiovascular medications ( &lt;i&gt;Lotrel&lt;/i&gt;, &lt;i&gt;Starlix&lt;/i&gt; and &lt;i&gt;Valturna&lt;/i&gt;) allegedly serving as mechanisms to provide kickbacks to HCPs. Also in 2013, New York State filed a civil complaint in intervention asserting similar claims. In 2020, Novartis finalized its settlement agreement with the S.D.N.Y, the New York State Attorney General and the individual relator to resolve their claims. As part of this settlement, Novartis agreed to pay USD 0.7 billion, and has agreed to new corporate integrity obligations with the Office of Inspector General of the US Department of Health and Human Services. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;U.S. Government Foreign Corrupt Practices Act (FCPA) investigations&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2020, Novartis reached settlements with the DOJ and the SEC resolving all FCPA investigations into historical conduct by Novartis and its subsidiaries. These investigations were previously disclosed in Note 20 to the Consolidated Financial Statements in our 2019 Annual Report and 2019 Form 20-F under the headings &amp;#x201c;Investigations and related litigations &amp;ndash; Greece investigation,&amp;#x201d; &amp;#x201c;Investigations and related litigations &amp;ndash; South Korea investigation&amp;#x201d; and &amp;#x201c;Investigations and related litigations &amp;ndash; Asia/Russia investigation.&amp;#x201d; As part of the coordinated resolution of these investigations, Novartis and certain of its current and former subsidiaries agreed to pay USD 0.3 billion. To resolve the DOJ investigation, both Novartis Hellas S.A.C.I. and Alcon Pte Ltd., a former Novartis subsidiary, entered into separate deferred prosecution agreements (DPA) with the DOJ. The Novartis Hellas DPA contained no allegations relating to any bribery of Greek politicians, which is consistent with what Novartis found in its own internal investigation. To resolve the SEC investigation, Novartis AG reached an agreement pertaining to internal controls and books and records violations in Greece, Vietnam and South Korea, which also addressed certain internal controls and books and records issues related to Alcon China&amp;#x2019;s placement of surgical devices. Other developments in Greece and South Korea are described above in &amp;#x201c;Investigations and related litigations &amp;ndash; Greece investigation&amp;#x201d; and &amp;#x201c;Investigations and related litigations &amp;ndash; South Korea investigation,&amp;#x201d; respectively. The matters disclosed in Note 20 to the Consolidated Financial Statements in our 2019 Annual Report and 2019 Form 20-F under the heading &amp;#x201c;Investigations and related litigations &amp;ndash; Asia/Russia investigation&amp;#x201d; are now concluded. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Enoxaparin&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2015, Sandoz and Momenta Pharmaceuticals were sued in a putative antitrust class action in federal court in Tennessee alleging that Momenta and Sandoz engaged in anticompetitive and unfair business conduct with regard to sales of enoxaparin. In 2019, Sandoz agreed to pay USD 85 million to resolve the class action. The matter is now concluded. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Summary of product liability, governmental investigations and other legal matters provision movements &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;369&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 340&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 351&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions related to &lt;br&gt;&lt;/br&gt;discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;42 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;863&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;116&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;118&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Releases of provisions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;107&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to provisions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 487&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;369&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 340&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current portion&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;306&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current product liabilities, governmental investigations and other legal matters provisions at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 200&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 214&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Releases of provisions credited to the consolidated income statement from continuing operations were USD 107 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Additions to provisions charged to the consolidated income statement from continuing operations were USD 220 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis believes that its total provisions for investigations, product liability, arbitration and other legal matters are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities, there can be no assurance that additional liabilities and costs will not be incurred beyond the amounts provided. &lt;/div&gt;</ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory>
  <ifrs-full:DisclosureOfOtherProvisionsExplanatory contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued liability for employee benefits:&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit pension plans &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;538&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other long-term employee benefits and deferred compensation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 637&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 546&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other post-employment benefits &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Environmental remediation provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 642&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 592&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for product liabilities, governmental investigations and other legal matters&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 200&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 984&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 958&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 409&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 255&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total provisions and other non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;934&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&amp;nbsp;632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Note 25 provides additional disclosures related to post-employment benefits. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent consideration. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfOtherProvisionsExplanatory>
  <nvs:AccrualForEnvironmentalLossContingenciesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 714&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 692&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 761&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;48&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Releases &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005; 83&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 82&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 809&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 714&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 692&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current provision&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current environmental remediation provisions at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 642&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 592&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 634&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Releases of provisions credited to the consolidated income statement from continuing operations were USD 21 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Additions to provisions charged to the consolidated income statement from continuing operations were USD 7 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:AccrualForEnvironmentalLossContingenciesTableTextBlock>
  <nvs:AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Expected &lt;br&gt;&lt;/br&gt; cash outflows &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due within two years&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due later than two years, but within five years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 210&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due later than five years, but within 10 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 338&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due after 10 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 80&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total environmental remediation liability provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 809&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock>
  <nvs:AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;369&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 340&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 351&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions related to &lt;br&gt;&lt;/br&gt;discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;42 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;863&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;116&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;118&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Releases of provisions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;107&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to provisions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 487&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;369&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 340&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current portion&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;306&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current product liabilities, governmental investigations and other legal matters provisions at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 200&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 214&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Releases of provisions credited to the consolidated income statement from continuing operations were USD 107 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Additions to provisions charged to the consolidated income statement from continuing operations were USD 220 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock>
  <nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;21. Current financial debt and&amp;nbsp;derivative&amp;nbsp;financial&amp;nbsp;instruments&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest-bearing accounts of associates &lt;br&gt;&lt;/br&gt;payable on demand &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;085 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;836 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bank and other financial debt &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 976&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 719&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commercial paper&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;258&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;289&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current portion of non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;272&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;002&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial debt and derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;785&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Weighted average interest rate 0.4% (2019: 0.5%) &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Weighted average interest rate 5.0% (2019: 12.9%) &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The consolidated balance sheet amounts of current financial debt, other than the current portion of non-current financial debt, approximate the estimated fair value due to the short-term nature of these instruments. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Details on commercial papers and short term borrowings are provided under &amp;#x201c;Liquidity risk&amp;#x201d; in Note&amp;nbsp;29.&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt; &lt;/div&gt;</nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock>
  <nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest-bearing accounts of associates &lt;br&gt;&lt;/br&gt;payable on demand &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;085 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;836 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bank and other financial debt &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 976&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 719&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commercial paper&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;258&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;289&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current portion of non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;272&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;002&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial debt and derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;785&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Weighted average interest rate 0.4% (2019: 0.5%) &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Weighted average interest rate 5.0% (2019: 12.9%) &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock>
  <nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;22. Provisions and other current liabilities&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes other than income taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 749&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 471&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Restructuring provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 459&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 438&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued expenses for goods and services received but not invoiced&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accruals for royalties&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 653&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued interests on financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 133&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for deductions from revenue&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;595&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accruals for compensation and benefits, including social security&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;286&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Environmental remediation liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 56&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 114&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for product liabilities, governmental investigations and other legal matters &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 306&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued share-based payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 326&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent considerations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 78&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commitment for repurchase of own shares &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;769&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 716&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 764&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total provisions and other current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 15&amp;nbsp;127&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 13&amp;nbsp;338&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Note 20 provides additional disclosures related to legal provisions. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent considerations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Note 18 provides additional disclosures related to commitment for repurchase of own shares. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Provisions are based upon management&amp;#x2019;s best estimate and adjusted for actual experience. Such adjustments to historic estimates have not been material. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Provisions for deductions from revenue&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the movement of the provisions for deductions from revenue:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Income statement charge&lt;sup&gt;2&lt;/sup&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Revenue &lt;br&gt;&lt;/br&gt; deductions &lt;br&gt;&lt;/br&gt; provisions at &lt;br&gt;&lt;/br&gt; January 1 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Revenue &lt;br&gt;&lt;/br&gt; deductions &lt;br&gt;&lt;/br&gt; provisions &lt;br&gt;&lt;/br&gt; related to &lt;br&gt;&lt;/br&gt; discontinued &lt;br&gt;&lt;/br&gt; operations&lt;sup&gt;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Effect of &lt;br&gt;&lt;/br&gt; currency &lt;br&gt;&lt;/br&gt; translation &lt;br&gt;&lt;/br&gt; and business &lt;br&gt;&lt;/br&gt; combinations &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Payments/ &lt;br&gt;&lt;/br&gt; utilizations &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Adjustments &lt;br&gt;&lt;/br&gt; of prior years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Current year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Change in &lt;br&gt;&lt;/br&gt; provisions &lt;br&gt;&lt;/br&gt; offset against &lt;br&gt;&lt;/br&gt; gross trade &lt;br&gt;&lt;/br&gt; receivables &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Revenue &lt;br&gt;&lt;/br&gt; deductions &lt;br&gt;&lt;/br&gt; provisions at &lt;br&gt;&lt;/br&gt; December 31 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US-specific healthcare plans &lt;br&gt;&lt;/br&gt;and program rebates &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;981 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;560 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;107 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 5&amp;nbsp;739 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;053 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-US-specific healthcare plans &lt;br&gt;&lt;/br&gt;and program rebates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;769 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 167 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;597 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;940 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;14 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;272 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-healthcare plans and program-related rebates, returns and other deductions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;845&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;137&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&amp;nbsp;094&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 113&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;931&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&amp;nbsp;595&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 234&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;19&amp;nbsp;294&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;151&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 19&amp;nbsp;773&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 99&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US-specific healthcare plans &lt;br&gt;&lt;/br&gt;and program rebates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;883 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 0 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;183 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;193 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 5&amp;nbsp;474 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;981 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-US-specific healthcare plans &lt;br&gt;&lt;/br&gt;and program rebates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;625 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;28 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;19 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;467 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;659 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;769 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-healthcare plans and program-related rebates, returns and other deductions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;754&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;698&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;868&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;845&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;262&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;19&amp;nbsp;348&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 20&amp;nbsp;001&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;595&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US-specific healthcare plans &lt;br&gt;&lt;/br&gt;and program rebates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;590 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;158 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;90 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4&amp;nbsp;541 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;883 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-US-specific healthcare plans &lt;br&gt;&lt;/br&gt;and program rebates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;356 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;78 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;182 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 83 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;555 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;109 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;625 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-healthcare plans and program-related rebates, returns and other deductions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;726&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&amp;nbsp;227&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;91&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;956&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 441&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;754&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;672&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;18&amp;nbsp;567&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 19&amp;nbsp;052&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 332&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;262&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Charges to the consolidated income statement from continuing operations were USD 18 248 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Restructuring provisions movements&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 438&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 507&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 153&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions related to &lt;br&gt;&lt;/br&gt;discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 354&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 492&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 534&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;268&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;479&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;145&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Releases &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;87&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;72&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 459&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 438&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 507&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Additions to provisions charged to the consolidated income statement from continuing operations were USD 521 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Reversal of provisions credited to the consolidated income statement from continuing operations were USD 31 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2020, additions to provisions of USD&amp;nbsp;354 million were mainly related to the following reorganizations:&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; The Innovative Medicines Division restructured its field force and supporting functions in Region Europe. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; The Sandoz Division initiatives to realign its organizational structures to improve competiveness that commenced in 2019 continued. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Group-wide initiatives to streamline Novartis Technical Operations through the setup of operations centers and implementation of new technologies, in the Innovative Medicines Division and the Sandoz Division, continued. In addition, Novartis Business Services continued the phased implementation of the new operating model to change outsourcing structures and transition activities to service centers. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2019, additions to provisions of USD 492 million were mainly related to the following reorganizations:&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; The Innovative Medicines Division restructured its field force and supporting functions in Latin America, and following the &lt;i&gt;Xiidra&lt;/i&gt; acquisition, its Ophthalmology field force in the US. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; The Sandoz Division initiatives to realign its organizational structures to improve competiveness. These initiatives include reduction in its headquarters, global functions and countries workforce, and the closure of its development center in Holzkirchen, Germany. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Group-wide initiatives to streamline Novartis Technical Operations and implement new technologies, mainly in the Innovative Medicines Division and in the Sandoz Division, continued. In addition, Novartis Business Services launched the next phase of the new operating model to change outsourcing structures and transition activities to service centers. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;In 2018, additions to provisions of USD&amp;nbsp;534 million were mainly related to the following reorganizations:&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; The Innovative Medicines Division&amp;#x2019;s Oncology business unit initiative to streamline its organizational structure. The objective was to enhance agility and efficiency, resulting in an acceleration of operational execution. In addition, a program to reorganize the Japanese business model was launched. Region Europe transformed its approach to market in light of the changing product portfolio. The objective was to speed up patient access. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Group-wide initiatives to streamline Novartis Technical Operations and implement new technologies, mainly in the Innovative Medicines Division and in the Sandoz Division, continued. In addition, Novartis Business Services launched an initiative to reorganize its organizational structure to achieve cost efficiencies by shifting activities to global service centers. &lt;/div&gt;</nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock>
  <nvs:ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes other than income taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 749&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 471&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Restructuring provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 459&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 438&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued expenses for goods and services received but not invoiced&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accruals for royalties&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 653&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued interests on financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 133&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for deductions from revenue&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;595&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accruals for compensation and benefits, including social security&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;286&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Environmental remediation liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 56&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 114&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for product liabilities, governmental investigations and other legal matters &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 306&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued share-based payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 326&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent considerations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 78&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commitment for repurchase of own shares &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;769&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 716&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 764&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total provisions and other current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 15&amp;nbsp;127&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 13&amp;nbsp;338&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Note 20 provides additional disclosures related to legal provisions. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent considerations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Note 18 provides additional disclosures related to commitment for repurchase of own shares. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock>
  <nvs:ProvisionsForReductionOfRevenueTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Income statement charge&lt;sup&gt;2&lt;/sup&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Revenue &lt;br&gt;&lt;/br&gt; deductions &lt;br&gt;&lt;/br&gt; provisions at &lt;br&gt;&lt;/br&gt; January 1 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Revenue &lt;br&gt;&lt;/br&gt; deductions &lt;br&gt;&lt;/br&gt; provisions &lt;br&gt;&lt;/br&gt; related to &lt;br&gt;&lt;/br&gt; discontinued &lt;br&gt;&lt;/br&gt; operations&lt;sup&gt;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Effect of &lt;br&gt;&lt;/br&gt; currency &lt;br&gt;&lt;/br&gt; translation &lt;br&gt;&lt;/br&gt; and business &lt;br&gt;&lt;/br&gt; combinations &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Payments/ &lt;br&gt;&lt;/br&gt; utilizations &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Adjustments &lt;br&gt;&lt;/br&gt; of prior years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Current year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Change in &lt;br&gt;&lt;/br&gt; provisions &lt;br&gt;&lt;/br&gt; offset against &lt;br&gt;&lt;/br&gt; gross trade &lt;br&gt;&lt;/br&gt; receivables &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Revenue &lt;br&gt;&lt;/br&gt; deductions &lt;br&gt;&lt;/br&gt; provisions at &lt;br&gt;&lt;/br&gt; December 31 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US-specific healthcare plans &lt;br&gt;&lt;/br&gt;and program rebates &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;981 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;560 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;107 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 5&amp;nbsp;739 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;053 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-US-specific healthcare plans &lt;br&gt;&lt;/br&gt;and program rebates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;769 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 167 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;597 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;940 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;14 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;272 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-healthcare plans and program-related rebates, returns and other deductions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;845&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 67&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;137&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&amp;nbsp;094&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 113&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;931&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&amp;nbsp;595&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 234&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;19&amp;nbsp;294&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;151&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 19&amp;nbsp;773&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 99&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US-specific healthcare plans &lt;br&gt;&lt;/br&gt;and program rebates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;883 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 0 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;183 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;193 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 5&amp;nbsp;474 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;981 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-US-specific healthcare plans &lt;br&gt;&lt;/br&gt;and program rebates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;625 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;28 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;19 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;467 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;659 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;769 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-healthcare plans and program-related rebates, returns and other deductions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;754&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;698&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;868&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;845&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;262&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;19&amp;nbsp;348&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;220&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 20&amp;nbsp;001&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;595&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US-specific healthcare plans &lt;br&gt;&lt;/br&gt;and program rebates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;590 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;158 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;90 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4&amp;nbsp;541 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;883 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-US-specific healthcare plans &lt;br&gt;&lt;/br&gt;and program rebates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;356 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;78 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;182 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 83 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2&amp;nbsp;555 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;109 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;625 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-healthcare plans and program-related rebates, returns and other deductions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;726&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;12&amp;nbsp;227&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;91&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;956&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 441&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;754&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;672&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;18&amp;nbsp;567&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 19&amp;nbsp;052&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 332&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;262&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="18"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Charges to the consolidated income statement from continuing operations were USD 18 248 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ProvisionsForReductionOfRevenueTableTextBlock>
  <nvs:RestructuringProvisionsMovementsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 438&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 507&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 153&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions related to &lt;br&gt;&lt;/br&gt;discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 354&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 492&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 534&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;268&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;479&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;145&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Releases &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;87&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;72&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 459&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 438&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 507&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Additions to provisions charged to the consolidated income statement from continuing operations were USD 521 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Reversal of provisions credited to the consolidated income statement from continuing operations were USD 31 million in 2018. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:RestructuringProvisionsMovementsTableTextBlock>
  <ifrs-full:DisclosureOfCashFlowStatementExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt; &lt;b&gt;23. Details to the consolidated statements of cash flows&lt;/b&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.1) Reversal of non-cash items and other adjustments from continuing operations&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation, amortization and impairments on:&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;758&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;547&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;783&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Right-of-use assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 330&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 305&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;376&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;974&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;428&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;335&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in provisions and other non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;411&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 895&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gains on disposal and other adjustments on property, plant and equipment; intangible assets; &lt;br&gt;&lt;/br&gt;financial assets; and other non-current assets, net &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;478 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;234 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;902 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-settled compensation expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 738&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 758&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 673&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income from associated companies &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;673&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;438&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;807&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;793&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;295&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net financial expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 947&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 805&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 746&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;881&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;486&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Depreciation of right-of-use assets recognized from January 1, 2019, the date of implementation of IFRS 16 Leases. See Note 1. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Includes fair value adjustments &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; 2018 included a reversal of a pre-tax gain (USD 5.8 billion) recognized from the divestment of the investment in GSK Consumer Healthcare Holdings Ltd. (see Note 2). The net cash proceed of USD 13.0 billion from the divestment was included in the consolidated statements of cash flows in the line "Acquisitions and divestments of interests in associated companies, net." &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.2) Total amount of taxes paid &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2020, the total amount of taxes paid was USD&amp;nbsp;1.9 billion, of which USD&amp;nbsp;1.8 billion was included within &amp;#x201c;Net cash flows from operating activities from continuing operations&amp;#x201d;, and USD&amp;nbsp;88 million was included within &amp;#x201c;Net cash flows used in investing activities from discontinued operations.&amp;#x201d; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2019, the total amount of taxes paid was USD&amp;nbsp;2.0 billion, of which USD&amp;nbsp;1.9 billion was included within &amp;#x201c;Net cash flows from operating activities from continuing operations&amp;#x201d;, USD&amp;nbsp;38 million was included within &amp;#x201c;Net cash flows from operating activities from discontinued operations,&amp;#x201d; and USD&amp;nbsp;79 million was included within &amp;#x201c;Net cash flows used in investing activities from discontinued operations.&amp;#x201d; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2018, the total amount of taxes paid was USD&amp;nbsp;1.8 billion, of which USD&amp;nbsp;1.5 billion was included within &amp;#x201c;Net cash flows from operating activities from continuing operations&amp;#x201d;, USD&amp;nbsp;164 million was included within &amp;#x201c;Net cash flows from operating activities from discontinued operations,&amp;#x201d; and USD&amp;nbsp;139 million was included within &amp;#x201c;Net cash flows used in investing activities from continuing operations.&amp;#x201d; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.3) Cash flows from changes in working capital and other operating items included in the net cash flows from operating activities from continuing operations &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;(Increase) in inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;382&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;387&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Decrease/(increase) in trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 137&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;980&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;544&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;(Decrease)/increase in trade payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;324&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 553&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 252&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 229&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;160&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 316&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in other current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 211&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 941&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other adjustments, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;291&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 199&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 576&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.4) Cash flows arising from acquisitions and divestments of interests in associated companies, net &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2018, acquisitions and divestments of interests in associated companies included USD 12&amp;#xa0;855 million net of taxes (USD 12&amp;#xa0;994 million before taxes) from the divestment of the investment in GSK Consumer Healthcare Holdings Ltd. (see Note 2). &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.5) Cash flows arising from acquisitions and divestments of businesses, net&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table is a summary of the cash flow impact of acquisitions and divestments of businesses. The most significant transactions are described in Note 2. &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Note&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets recognized as a result of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;173&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&amp;nbsp;660&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value of previously held equity interests&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration payables, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 242&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments, deferred consideration and other adjustments, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows used for acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;006&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;851&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&amp;nbsp;701&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows from divestments of businesses, net &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 91&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 18&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows used for acquisitions and divestments of businesses, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;957&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;760&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&amp;nbsp;683&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; In 2020, USD 49 million represented the net cash inflows from divestments in previous years. &lt;br&gt;&lt;/br&gt;In 2019, the USD 91 million included USD 4 million of net cash outflows from divestments in previous years, and USD 95 million net cash inflows from business divestments in 2019. The net identifiable assets of the 2019 divested businesses amounted to USD 196 million, comprised of non-current assets of USD 159 million; current assets of USD 96 million, including USD 11 million cash and cash equivalents; non-current liabilities of USD 18 million; and current liabilities of USD 41 million. &lt;br&gt;&lt;/br&gt;In 2018, USD 18 million represented the net cash inflows from divestments in previous years. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Notes 2 and 24 provide further information regarding acquisitions and divestments of businesses. All acquisitions were for cash. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.6) Reconciliation of liabilities arising from financing activities&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Non-current &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; debts &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Current &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; debts and &lt;br&gt;&lt;/br&gt; derivative &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; instruments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Non-current &lt;br&gt;&lt;/br&gt; lease liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Current lease &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 20&amp;nbsp;353&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;703&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 246&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase in non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&amp;nbsp;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Repayments of non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;261&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments of lease liabilities, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;312&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest payments for amounts included in lease liabilities &lt;br&gt;&lt;/br&gt;classified as cash flows from operating activities &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;56 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;New leases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 221&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 73&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Changes in fair values, and other changes, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 65&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of bonds discount&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 832&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 392&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification from non-current to current, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;067&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;067&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;785&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;719&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 286&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Non-current &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; debts &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Current &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; debts and &lt;br&gt;&lt;/br&gt; derivative &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; instruments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Non-current &lt;br&gt;&lt;/br&gt; lease liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Current lease &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;470&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;678&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of adoption of IFRS 16 Leases continuing operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;471&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 268&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of adoption of IFRS 16 Leases discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 246&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debts and lease liabilities related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;47&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;246&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase in non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Repayments of non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;195&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;582&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments of lease liabilities, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest payments for amounts included in lease liabilities &lt;br&gt;&lt;/br&gt;classified as cash flows from operating activities &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;51 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;New leases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 362&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 131&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions and divestments of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Changes in fair values, and other changes, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of bonds discount&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification from non-current to current, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;156&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 156&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 20&amp;nbsp;353&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;703&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 246&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Lease liabilities recognized on January 1, 2019, the date of implementation of IFRS 16 Leases. See Note 1. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; In 2018, financial debts included USD 89 million for previously reported finance lease obligations of the Alcon business that were reclassified on January 1, 2019, to lease liabilities, with the adoption of IFRS 16 Leases. Note 30 provides additional disclosures. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Represents the financial debts and lease liabilities at January 1, 2019, related to the Alcon business reported as discontinued operations. See Notes 1, 2 and 30. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Non-current &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; debts &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Current &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; debts and &lt;br&gt;&lt;/br&gt; derivative &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; instruments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;224&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;308&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase in non-current financial debts &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;856&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Repayments of non-current financial debts &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in current financial debts &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;681&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Changes in fair values, and other changes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;48&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of bonds discount&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;462&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current portion of non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;470&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;678&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Increase in non-current financial debts was only recorded in the consolidated statements of cash flows from continuing operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Repayment of non-current financial debts was only recorded in the consolidated statements of cash flows from continuing operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Changes in current financial debts included in the consolidated statements of cash flows from continuing operations were USD 1 687 million. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;For net cash flows used in investing activities from discontinued operations, see Note 30. &lt;/div&gt;</ifrs-full:DisclosureOfCashFlowStatementExplanatory>
  <nvs:AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation, amortization and impairments on:&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;758&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;547&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;783&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Right-of-use assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 330&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 305&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;376&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;974&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;428&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;335&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in provisions and other non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;411&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 895&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gains on disposal and other adjustments on property, plant and equipment; intangible assets; &lt;br&gt;&lt;/br&gt;financial assets; and other non-current assets, net &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;478 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;234 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;902 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-settled compensation expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 738&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 758&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 673&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income from associated companies &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;673&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;659&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;438&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;807&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;793&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;295&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net financial expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 947&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 805&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 746&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;881&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;122&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;486&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Depreciation of right-of-use assets recognized from January 1, 2019, the date of implementation of IFRS 16 Leases. See Note 1. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Includes fair value adjustments &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; 2018 included a reversal of a pre-tax gain (USD 5.8 billion) recognized from the divestment of the investment in GSK Consumer Healthcare Holdings Ltd. (see Note 2). The net cash proceed of USD 13.0 billion from the divestment was included in the consolidated statements of cash flows in the line "Acquisitions and divestments of interests in associated companies, net." &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock>
  <nvs:CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;(Increase) in inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;382&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;387&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Decrease/(increase) in trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 137&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;980&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;544&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;(Decrease)/increase in trade payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;324&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 553&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 252&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 229&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;160&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 316&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in other current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 211&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 941&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other adjustments, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;291&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 199&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 576&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock>
  <nvs:CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Note&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets recognized as a result of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;173&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&amp;nbsp;660&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value of previously held equity interests&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration payables, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 98&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 242&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments, deferred consideration and other adjustments, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows used for acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;006&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;851&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&amp;nbsp;701&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows from divestments of businesses, net &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 91&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 18&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows used for acquisitions and divestments of businesses, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;957&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;760&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&amp;nbsp;683&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; In 2020, USD 49 million represented the net cash inflows from divestments in previous years. &lt;br&gt;&lt;/br&gt;In 2019, the USD 91 million included USD 4 million of net cash outflows from divestments in previous years, and USD 95 million net cash inflows from business divestments in 2019. The net identifiable assets of the 2019 divested businesses amounted to USD 196 million, comprised of non-current assets of USD 159 million; current assets of USD 96 million, including USD 11 million cash and cash equivalents; non-current liabilities of USD 18 million; and current liabilities of USD 41 million. &lt;br&gt;&lt;/br&gt;In 2018, USD 18 million represented the net cash inflows from divestments in previous years. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock>
  <nvs:ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Non-current &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; debts &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Current &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; debts and &lt;br&gt;&lt;/br&gt; derivative &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; instruments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Non-current &lt;br&gt;&lt;/br&gt; lease liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Current lease &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 20&amp;nbsp;353&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;703&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 246&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase in non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&amp;nbsp;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Repayments of non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;261&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments of lease liabilities, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;312&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest payments for amounts included in lease liabilities &lt;br&gt;&lt;/br&gt;classified as cash flows from operating activities &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;56 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;New leases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 221&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 73&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Changes in fair values, and other changes, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 65&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of bonds discount&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 832&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 392&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification from non-current to current, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;067&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;067&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&amp;nbsp;785&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;719&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 286&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Non-current &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; debts &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Current &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; debts and &lt;br&gt;&lt;/br&gt; derivative &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; instruments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Non-current &lt;br&gt;&lt;/br&gt; lease liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Current lease &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;470&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;678&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of adoption of IFRS 16 Leases continuing operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;471&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 268&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of adoption of IFRS 16 Leases discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 246&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debts and lease liabilities related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;47&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;246&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase in non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Repayments of non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;195&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;582&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments of lease liabilities, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest payments for amounts included in lease liabilities &lt;br&gt;&lt;/br&gt;classified as cash flows from operating activities &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;51 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;New leases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 362&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 131&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions and divestments of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Changes in fair values, and other changes, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of bonds discount&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;141&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification from non-current to current, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;156&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 156&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 20&amp;nbsp;353&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;703&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 246&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Lease liabilities recognized on January 1, 2019, the date of implementation of IFRS 16 Leases. See Note 1. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; In 2018, financial debts included USD 89 million for previously reported finance lease obligations of the Alcon business that were reclassified on January 1, 2019, to lease liabilities, with the adoption of IFRS 16 Leases. Note 30 provides additional disclosures. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Represents the financial debts and lease liabilities at January 1, 2019, related to the Alcon business reported as discontinued operations. See Notes 1, 2 and 30. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Non-current &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; debts &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Current &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; debts and &lt;br&gt;&lt;/br&gt; derivative &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; instruments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;224&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;308&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase in non-current financial debts &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;856&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Repayments of non-current financial debts &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in current financial debts &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;681&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Changes in fair values, and other changes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;48&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of bonds discount&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 27&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;462&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current portion of non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;470&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;678&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Increase in non-current financial debts was only recorded in the consolidated statements of cash flows from continuing operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Repayment of non-current financial debts was only recorded in the consolidated statements of cash flows from continuing operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Changes in current financial debts included in the consolidated statements of cash flows from continuing operations were USD 1 687 million. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock>
  <ifrs-full:DisclosureOfBusinessCombinationsExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;24. Acquisitions of businesses&lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Fair value of assets and liabilities arising from acquisitions of businesses&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 137&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currently marketed products&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 196&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;550&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;531&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Acquired research and development&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;600&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 342&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&amp;nbsp;224&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 476&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 381&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-current financial and other assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 84&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 195&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables and financial and other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 109&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 90&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;977&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;107&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;874&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables and other liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;144&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;178&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;627&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net identifiable assets acquired&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;669&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;938&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Acquired cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-controlling interests&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;580&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;084&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets recognized as a result of acquisitions of businesses &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 10&amp;nbsp;173&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 13&amp;nbsp;946&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; In 2018, net assets recognized as a result of acquisitions of businesses in the consolidated balance sheet from continuing operations were USD 13 660 million. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Note 2 details significant acquisitions of businesses, specifically, The Medicines Company and the Japanese business of AGI in 2020; &lt;i&gt;Xiidra&lt;/i&gt; and IFM Tre, Inc. in 2019; and AAA, AveXis and Endocyte in 2018. The goodwill arising out of these acquisitions is attributable to the buyer specific synergies, the assembled workforce, and the accounting for deferred tax liabilities on the acquired assets. Goodwill of USD&amp;nbsp;74 million in 2020 (2019: USD 98 million, 2018: nil) is tax deductible. &lt;/div&gt;</ifrs-full:DisclosureOfBusinessCombinationsExplanatory>
  <nvs:FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 44&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 137&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currently marketed products&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 196&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&amp;nbsp;550&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;531&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Acquired research and development&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;600&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 342&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&amp;nbsp;224&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 476&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 381&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-current financial and other assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 84&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 195&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables and financial and other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 109&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 90&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;977&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;107&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;874&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;44&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables and other liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;144&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;178&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;627&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net identifiable assets acquired&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 7&amp;nbsp;669&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;938&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Acquired cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-controlling interests&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;580&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;084&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets recognized as a result of acquisitions of businesses &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 10&amp;nbsp;173&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;124&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 13&amp;nbsp;946&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="8"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; In 2018, net assets recognized as a result of acquisitions of businesses in the consolidated balance sheet from continuing operations were USD 13 660 million. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock>
  <ifrs-full:DisclosureOfEmployeeBenefitsExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;25. Post-employment benefits for associates&lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Defined benefit plans&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In addition to the legally required social security schemes, the Group has numerous independent pension and other post-employment benefit plans. In most cases, these plans are externally funded in entities that are legally separate from the Group. For certain Group companies, however, no independent plan assets exist for the pension and other post-employment benefit obligations of associates. In these cases, the related unfunded liability is included in the balance sheet. The defined benefit obligations (DBOs) of all major pension and other post-employment benefit plans are reappraised annually by independent actuaries. Plan assets are recognized at fair value. The major plans are based in Switzerland, the United States, the United Kingdom, Germany and Japan, which represent 95% of the Group&amp;#x2019;s total DBO for pension plans. Details of the plans in the two most significant countries, Switzerland and the United States, which represent 81% of the Group&amp;#x2019;s total DBO for post-employment benefit plans, are provided below. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Swiss-based pension plans represent the most significant portion of the Group&amp;#x2019;s total DBO and plan assets. For the active insured members born on or after January 1, 1956, or having joined the plans after December 31, 2010, the benefits are partially linked to the contributions paid into the plan. Certain features of Swiss pension plans required by law preclude the plans from being categorized as defined contribution plans. These factors include a minimum interest guarantee on retirement savings accounts, a predetermined factor for converting the accumulated savings account balance into a pension, and embedded death and disability benefits. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;All benefits granted under Swiss-based pension plans are vested, and Swiss legislation prescribes that the employer has to contribute a fixed percentage of an associate&amp;#x2019;s pay to an external pension fund. Additional employer contributions may be required whenever the plan&amp;#x2019;s statutory funding ratio falls below a certain level. The associate also contributes to the plan. The pension plans are run by separate legal entities, each governed by a board of trustees that &amp;ndash; for the principal plans &amp;ndash; consists of representatives nominated by Novartis and the active insured associates. The boards of trustees are responsible for the plan design and asset investment strategy. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In December 2020 the Board of Trustees of the Novartis Swiss Pension Fund agreed to adjust the annuity conversion rate at retirement with effect from January 1, 2022. This amendment does not affect existing pensioners, and its impact on existing plan participants will be mitigated by way of defined compensatory measures. This amendment resulted in a net pre-tax curtailment gain of USD 101 million (CHF 90 million). &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The United States pension plans represent the second-largest component of the Group&amp;#x2019;s total DBO and plan assets. The principal plans (Qualified Plans) are funded, whereas plans providing additional benefits for executives (Restoration Plans) are unfunded. Employer contributions are required for Qualified Plans whenever the statutory funding ratio falls below a certain level. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Furthermore, in certain countries, associates are covered under other post-employment benefit plans and post-retirement medical plans. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In the US, other post-employment benefit plans consist primarily of post-employment healthcare benefits, which have been closed to new members since 2015. Part of the costs of these plans is reimbursable under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. There is no statutory funding requirement for these plans. The Group is funding these plans to the extent that it is tax efficient. &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following tables are a summary of the funded and unfunded defined benefit obligation for pension and other post-employment benefit plans of associates at December 31, 2020 and 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-employment benefit plans&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 23&amp;nbsp;066&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 746&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;073&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Benefit obligations related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;662&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;385&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current service cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 372&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 222&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 330&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past service costs and settlements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;168&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Administrative expenses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remeasurement losses/(gains) arising from changes in financial assumptions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;791&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remeasurement (gains)/losses arising from changes in demographic assumptions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Experience-related remeasurement losses/(gains)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 184&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;132&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;810&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 283&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Benefit payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;264&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions of associates&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of acquisitions, divestments or transfers&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 25&amp;nbsp;602&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;066&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 746&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 19&amp;nbsp;810&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 18&amp;nbsp;838&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 134&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 119&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Plan assets related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 257&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Return on plan assets excluding interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;318&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;620&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 304&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Group contributions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 420&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 74&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions of associates&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Settlements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Benefit payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;264&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of acquisitions, divestments or transfers&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 22&amp;nbsp;317&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 19&amp;nbsp;810&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 134&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Funded status&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;285&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Limitation on recognition of fund surplus at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;65&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;68&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in limitation on recognition of fund surplus (incl. exchange rate differences)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income on limitation of fund surplus&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Limitation on recognition of fund surplus at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;65&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net liability in the balance sheet at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;321&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The reconciliation of the net liability from January 1 to December 31 is as follows:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-employment benefit plans&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net liability at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;321&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;409&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;954&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less: net liability related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 238&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current service cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;372&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;77&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Administrative expenses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past service costs and settlements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 117&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remeasurements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 109&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Group contributions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 420&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 74&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of acquisitions, divestments or transfers&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in limitation on recognition of fund surplus&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net liability at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;321&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Amounts recognized in the consolidated balance sheet&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prepaid benefit cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 148&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued benefit liability&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;538&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows a breakdown of the DBO for pension plans by geography and type of member, and the breakdown of plan assets into the geographical locations in which they are held: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Switzerland &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; United &lt;br&gt;&lt;/br&gt; States &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Rest of &lt;br&gt;&lt;/br&gt; the world &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Switzerland &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; United &lt;br&gt;&lt;/br&gt; States &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rest of &lt;br&gt;&lt;/br&gt; the world &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 16&amp;nbsp;807&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;788&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&amp;nbsp;007&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 25&amp;nbsp;602&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 15&amp;nbsp;106&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;552&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;408&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;066&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Thereof unfunded&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 701&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 516&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 1&amp;nbsp;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 670&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 466&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 1&amp;nbsp;136&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;By type of member&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Active&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&amp;nbsp;837&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 665&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;573&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;075&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 630&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;400&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;197&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred pensioners&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;290&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;819&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;109&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;205&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;517&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;722&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Pensioners&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;970&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;833&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;615&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&amp;nbsp;418&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;939&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;717&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;491&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 16&amp;nbsp;396&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;487&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;434&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 22&amp;nbsp;317&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 14&amp;nbsp;457&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;311&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 19&amp;nbsp;810&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Funded status&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;411&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;573&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;285&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;649&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;241&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows a breakdown of the DBO for other post-employment benefit plans by geography and type of member, and the breakdown of plan assets into the geographical locations in which they are held: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; United &lt;br&gt;&lt;/br&gt; States &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Rest of &lt;br&gt;&lt;/br&gt; the world &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; United &lt;br&gt;&lt;/br&gt; States &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rest of &lt;br&gt;&lt;/br&gt; the world &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 543&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 632&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 658&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 88&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 746&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Thereof unfunded&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 454&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 524&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 88&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;By type of member&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Active&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 80&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 105&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 121&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 157&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred pensioners&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Pensioners&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 446&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 64&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 510&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 522&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 574&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 134&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 134&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Funded status&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;454&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;524&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;88&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the principal weighted average actuarial assumptions used for calculating defined benefit plans and other post-employment benefits of associates: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-employment benefit plans&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Weighted average assumptions used to determine benefit obligations at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Discount rate&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.6%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1.0%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1.6%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.9%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.6%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.4%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expected rate of pension increase&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.3%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.3%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.4%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expected rate of salary increase&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.7%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.8%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.8%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest on savings account&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.1%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.3%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.8%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current average life expectancy &lt;br&gt;&lt;/br&gt;for a 65-year-old male in years &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 22 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 22 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 22 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current average life expectancy &lt;br&gt;&lt;/br&gt;for a 65-year-old female in years &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 24 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 24 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 24 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 23 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 23 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 23 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Changes in the aforementioned actuarial assumptions can result in significant volatility in the accounting for the Group&amp;#x2019;s pension plans in the consolidated financial statements. This can result in substantial changes in the Group&amp;#x2019;s other comprehensive income, long-term liabilities and prepaid pension assets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The DBO is significantly impacted by assumptions regarding the rate that is used to discount the actuarially determined post-employment benefit liability. This rate is based on yields of high-quality corporate bonds in the country of the plan. Decreasing corporate bond yields decrease the discount rate, so that the DBO increases and the funded status decreases. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In Switzerland, an increase in the DBO due to lower discount rates is slightly offset by lower future benefits expected to be paid on the associate&amp;#x2019;s savings account where the assumption on interest accrued changes in line with the discount rate. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The impact of decreasing interest rates on a plan&amp;#x2019;s assets is more difficult to predict. A significant part of the plan assets is invested in bonds. Bond values usually rise when interest rates decrease and may therefore partially compensate for the decrease in the funded status. Furthermore, pension assets also include significant holdings of equity instruments. Share prices tend to rise when interest rates decrease and therefore often counteract the negative impact of the rising defined benefit obligation on the funded status (although the correlation of interest rates with equities is not as strong as with bonds, especially in the short term). &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The expected rate for pension increases significantly affects the DBO of most plans in Switzerland, Germany and the United Kingdom. Such pension increases also decrease the funded status, although there is no strong correlation between the value of the plan assets and pension/inflation increases. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Assumptions regarding life expectancy significantly impact the DBO. An increase in longevity increases the DBO. There is no offsetting impact from the plan assets, as no longevity bonds or swaps are held by the pension funds. Generational mortality tables are used where this data is available. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the sensitivity of the defined benefit pension obligation to the principal actuarial assumptions for the major plans in Switzerland, the United States, the United Kingdom, Germany and Japan on an aggregated basis: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change in 2020 year-end &lt;br&gt;&lt;/br&gt; defined benefit pension obligation &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase in discount rate&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;885&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease in discount rate&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 942&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;One-year increase in life expectancy&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 993&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase in rate of pension increase&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 589&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease in rate of pension increase&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;143&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase of interest on savings account&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease of interest on savings account&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase in rate of salary increase&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease in rate of salary increase&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The healthcare cost trend rate assumptions used for other post-employment benefits are as follows:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Healthcare cost trend rate &lt;br&gt;&lt;/br&gt;assumed for next year &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 6.3% &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 6.5% &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 7.0% &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rate to which the cost trend &lt;br&gt;&lt;/br&gt;rate is assumed to decline &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 4.5% &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4.5% &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4.5% &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Year that the rate reaches &lt;br&gt;&lt;/br&gt;the ultimate trend rate &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2028 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2028 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2028 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the weighted average plan asset allocation of funded defined benefit pension plans at December 31, 2020 and&amp;nbsp;2019:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(as a percentage) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Long-term &lt;br&gt;&lt;/br&gt; target &lt;br&gt;&lt;/br&gt; minimum &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Long-term &lt;br&gt;&lt;/br&gt; target &lt;br&gt;&lt;/br&gt; maximum &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 27&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Real estate&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Alternative investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and other investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Cash and most of the equity and debt securities have a quoted market price in an active market. Real estate and alternative investments, which include hedge fund, private equity, infrastructure and commodity investments, usually have a quoted market price or a regularly updated net asset value. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The strategic allocation of assets of the different pension plans is determined with the objective of achieving an investment return that, together with the contributions paid by the Group and its associates, is sufficient to maintain reasonable control over the various funding risks of the plans. Based upon the market and economic environments, actual asset allocations may temporarily be permitted to deviate from policy targets. The asset allocation currently includes investments in shares of Novartis AG as per the below table: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Investment in shares of Novartis AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Number of shares (in millions)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Market value (in USD billions)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The weighted average duration of the defined benefit obligation is 15.4 years (2019: 15.2 years).&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&amp;#x2019;s ordinary contribution to the various pension plans is based on the rules of each plan. Additional contributions are made whenever this is required by statute or law (i.e., usually when statutory funding levels fall below predetermined thresholds). The only significant plans that are foreseen to require additional funding are those in the United Kingdom and Germany. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The expected future cash flows in respect of pension and other post-employment benefit plans at December 31, 2020, were as follows: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Pension plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post- &lt;br&gt;&lt;/br&gt; employment &lt;br&gt;&lt;/br&gt; benefit plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Novartis Group contributions&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2021 (estimated)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 404&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Expected future benefit payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;245&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;198&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;191&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2024&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;182&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;165&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2026&amp;#x2013;2030&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;651&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Defined contribution plans&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In many subsidiaries, associates are covered by defined contribution plans. Contributions charged to the consolidated income statement for the defined contribution plans were: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions for defined contribution plans continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 501&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 422&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 443&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;For defined contribution plans for discontinued operations, see Note 30.&lt;/div&gt;</ifrs-full:DisclosureOfEmployeeBenefitsExplanatory>
  <nvs:DisclosureOfDefinedBenefitPlansTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-employment benefit plans&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 23&amp;nbsp;066&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 22&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 746&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;073&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Benefit obligations related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;662&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;385&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current service cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 372&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 222&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 330&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past service costs and settlements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;168&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Administrative expenses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remeasurement losses/(gains) arising from changes in financial assumptions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;791&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remeasurement (gains)/losses arising from changes in demographic assumptions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Experience-related remeasurement losses/(gains)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 184&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;132&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;810&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 283&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Benefit payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;264&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions of associates&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of acquisitions, divestments or transfers&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 25&amp;nbsp;602&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;066&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 632&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 746&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 19&amp;nbsp;810&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 18&amp;nbsp;838&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 134&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 119&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Plan assets related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 257&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Return on plan assets excluding interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;318&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;620&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 304&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Group contributions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 420&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 74&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions of associates&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 169&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Settlements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;193&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Benefit payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;264&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of acquisitions, divestments or transfers&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 22&amp;nbsp;317&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 19&amp;nbsp;810&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 134&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Funded status&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;285&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Limitation on recognition of fund surplus at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;65&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;68&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in limitation on recognition of fund surplus (incl. exchange rate differences)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income on limitation of fund surplus&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Limitation on recognition of fund surplus at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;51&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;65&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net liability in the balance sheet at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;321&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfDefinedBenefitPlansTableTextBlock>
  <nvs:DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-employment benefit plans&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net liability at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;321&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;409&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;954&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less: net liability related to discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 238&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current service cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;372&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;77&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Administrative expenses&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past service costs and settlements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 117&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remeasurements&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 109&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;35&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;190&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Group contributions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 464&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 420&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 74&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of acquisitions, divestments or transfers&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in limitation on recognition of fund surplus&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net liability at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;336&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;321&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Amounts recognized in the consolidated balance sheet&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prepaid benefit cost&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 148&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued benefit liability&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;538&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock>
  <nvs:BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4PensionPlanMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Switzerland &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; United &lt;br&gt;&lt;/br&gt; States &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Rest of &lt;br&gt;&lt;/br&gt; the world &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Switzerland &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; United &lt;br&gt;&lt;/br&gt; States &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rest of &lt;br&gt;&lt;/br&gt; the world &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 16&amp;nbsp;807&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;788&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&amp;nbsp;007&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 25&amp;nbsp;602&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 15&amp;nbsp;106&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;552&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;408&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 23&amp;nbsp;066&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Thereof unfunded&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 701&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 516&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 1&amp;nbsp;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 670&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 466&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 1&amp;nbsp;136&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;By type of member&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Active&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&amp;nbsp;837&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 665&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;573&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;075&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 630&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;400&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;197&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred pensioners&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;290&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;819&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;109&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;205&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;517&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;722&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Pensioners&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;970&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;833&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;615&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&amp;nbsp;418&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;939&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;717&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;491&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 12&amp;nbsp;147&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 16&amp;nbsp;396&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;487&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 3&amp;nbsp;434&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 22&amp;nbsp;317&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 14&amp;nbsp;457&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;311&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;042&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 19&amp;nbsp;810&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Funded status&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;411&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;573&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;285&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;649&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;241&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="18" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock>
  <nvs:BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock contextRef="AR_D-CurrentYear_nvs-2020Q4RetirementPlanTypeAxis_nvs-2020Q4OtherPostemploymentBenefitPlansMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; United &lt;br&gt;&lt;/br&gt; States &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Rest of &lt;br&gt;&lt;/br&gt; the world &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; United &lt;br&gt;&lt;/br&gt; States &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rest of &lt;br&gt;&lt;/br&gt; the world &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 543&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 632&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 658&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 88&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 746&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Thereof unfunded&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 454&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; 543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 524&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 88&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; 612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;By type of member&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Active&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 80&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 105&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 121&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 157&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred pensioners&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Pensioners&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 446&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 64&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 510&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 522&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 52&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 574&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 134&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 134&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Funded status&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;454&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;543&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;524&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;88&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock>
  <nvs:ScheduleOfAssumptionsUsedTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-employment benefit plans&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Weighted average assumptions used to determine benefit obligations at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Discount rate&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.6%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1.0%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1.6%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.9%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3.6%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.4%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expected rate of pension increase&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.3%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.3%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.4%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expected rate of salary increase&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.7%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.8%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.8%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest on savings account&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.1%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.3%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.8%&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current average life expectancy &lt;br&gt;&lt;/br&gt;for a 65-year-old male in years &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 22 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 22 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 22 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current average life expectancy &lt;br&gt;&lt;/br&gt;for a 65-year-old female in years &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 24 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 24 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 24 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 23 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 23 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 23 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfAssumptionsUsedTableTextBlock>
  <nvs:ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change in 2020 year-end &lt;br&gt;&lt;/br&gt; defined benefit pension obligation &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase in discount rate&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;885&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease in discount rate&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 942&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;One-year increase in life expectancy&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 993&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase in rate of pension increase&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 589&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease in rate of pension increase&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;143&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase of interest on savings account&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease of interest on savings account&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase in rate of salary increase&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease in rate of salary increase&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock>
  <nvs:ScheduleOfHealthCareCostTrendRatesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Healthcare cost trend rate &lt;br&gt;&lt;/br&gt;assumed for next year &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 6.3% &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 6.5% &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 7.0% &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rate to which the cost trend &lt;br&gt;&lt;/br&gt;rate is assumed to decline &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 4.5% &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4.5% &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 4.5% &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Year that the rate reaches &lt;br&gt;&lt;/br&gt;the ultimate trend rate &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 2028 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2028 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 2028 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfHealthCareCostTrendRatesTableTextBlock>
  <nvs:ScheduleOfAllocationOfPlanAssetsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(as a percentage) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Long-term &lt;br&gt;&lt;/br&gt; target &lt;br&gt;&lt;/br&gt; minimum &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Long-term &lt;br&gt;&lt;/br&gt; target &lt;br&gt;&lt;/br&gt; maximum &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 27&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 60&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 34&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Real estate&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Alternative investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and other investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
  <nvs:ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31, &lt;br&gt;&lt;/br&gt; 2019 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Investment in shares of Novartis AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Number of shares (in millions)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Market value (in USD billions)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock>
  <nvs:ScheduleOfExpectedBenefitPaymentsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Pension plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post- &lt;br&gt;&lt;/br&gt; employment &lt;br&gt;&lt;/br&gt; benefit plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Novartis Group contributions&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2021 (estimated)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 404&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Expected future benefit payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;245&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;198&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;191&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 41&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2024&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;182&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;165&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2026&amp;#x2013;2030&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;651&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
  <nvs:ScheduleOfDefinedContributionPlansTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions for defined contribution plans continuing operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 501&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 422&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 443&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfDefinedContributionPlansTableTextBlock>
  <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;26. Equity-based participation plans for associates&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The expense related to all equity-based participation plans and the liabilities arising from equity-based payment transactions were as follows: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense related to equity-based &lt;br&gt;&lt;/br&gt;participation plans &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 958 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;067 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 918 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Liabilities arising from equity-based payment transactions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 326&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Equity-based participation plans can be separated into the following plans:&lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Annual Incentive&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Annual Incentive for the Novartis Group CEO and other Executive Committee members (ECN) is paid 50% in cash and 50% in Novartis restricted shares (RSs) or restricted share units (RSUs). For the Novartis Top Leaders (NTLs), the Annual Incentive is paid 70% in cash and 30% in RSs or RSUs. Both the ECN and NTLs can opt to invest up to the maximum cash portion of their Annual Incentive to receive further RSs or RSUs. Any cash is paid out during February or March in the year following the end of the performance period, and the shares are granted during January in the year following the end of the performance period. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Share savings plans&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Associates in certain countries and certain key executives worldwide are encouraged to invest their Annual Incentive in a share savings plan. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Under the share savings plan, participants may elect to receive their relevant compensation fully or partially in Novartis shares in lieu of cash. As a reward for their participation in the share savings plan, at no additional cost to the participant, Novartis matches their investments in shares after a holding period of three or five years. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;Novartis operates share savings plans for which associates may only participate in one of the share savings plans in any given year. The most significant are listed below: &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; In Switzerland, Employee Share Ownership Plan (ESOP) participants may choose to receive their Annual Incentive (i) 100% in shares, (ii) 50% in shares and 50% in cash, or (iii) 100% in cash. After expiration of a three-year holding period for Novartis shares invested under the ESOP, participants will receive one matching share for every two invested shares. Associates eligible for the equity plan &amp;#x201c;Select&amp;#x201d; are not eligible to receive ESOP matching shares starting with the 2017 performance period. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; The Leveraged Share Savings Plan (LSSP) was available to key executives for performance periods prior to 2016. At the participant&amp;#x2019;s election, the Annual Incentive was awarded partly or entirely in shares. The elected number of shares is subject to a holding period of five years. At the end of the holding period, Novartis will match the invested shares at a ratio of 1-to-1 (i.e., one share awarded for each invested share). In the United States, both the LSSP award and the corresponding match are cash settled. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Novartis Group CEO, the other Executive Committee members from 2014, and the NTLs from 2016 are not eligible to participate in the share savings plans. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Novartis equity plan &amp;#x201c;Select&amp;#x201d;&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The equity plan &amp;#x201c;Select&amp;#x201d; is a global equity incentive plan under which eligible associates may annually be awarded a grant subject to a three-year, and for selected units a four-year, staggered vesting period. No awards are granted for performance ratings below a certain threshold. Executive Committee members and NTLs are not eligible to participate in the equity plan &amp;#x201c;Select&amp;#x201d;. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The equity plan &amp;#x201c;Select&amp;#x201d; currently allows participants in Switzerland to choose the form of their equity compensation in RSs or RSUs. In all other jurisdictions, RSs or RSUs are granted unilaterally. Until 2013, participants could also choose to receive part or the entire grant in the form of tradable share options. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Tradable share options expire on their 10 &lt;sup&gt;th&lt;/sup&gt; anniversary from the grant date. Each tradable share option entitles the holder to purchase after vesting (and before the 10 &lt;sup&gt;th&lt;/sup&gt; anniversary from the grant date) one Novartis share at a stated exercise price that equals the closing market price of the underlying share at the grant date. As the exercise price does not reflect the decrease in the Novartis share due to the Alcon spin, one-fifth of an Alcon share will also be awarded to the option holder upon exercise. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Options under Novartis equity plan &amp;#x201c;Select&amp;#x201d; outside North America&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the activity associated with the share options during the period. The weighted average prices in the table below are translated from Swiss francs into USD at historical rates. &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Options &lt;br&gt;&lt;/br&gt; (millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Weighted &lt;br&gt;&lt;/br&gt; average &lt;br&gt;&lt;/br&gt; exercise &lt;br&gt;&lt;/br&gt; price &lt;br&gt;&lt;/br&gt; (USD) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Options &lt;br&gt;&lt;/br&gt; (millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Weighted &lt;br&gt;&lt;/br&gt; average &lt;br&gt;&lt;/br&gt; exercise &lt;br&gt;&lt;/br&gt; price &lt;br&gt;&lt;/br&gt; (USD) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Options outstanding &lt;br&gt;&lt;/br&gt;at January 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 3.4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 60.9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 5.6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 59.9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sold or exercised&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;0.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 57.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 58.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Outstanding at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 62.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 60.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Exercisable at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 62.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 60.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;All share options were granted at an exercise price that was equal to the closing market price of the Group&amp;#x2019;s shares at the grant date. The weighted average share price at the dates of sale or exercise was USD&amp;nbsp;91.7. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table summarizes information about share options outstanding at December 31, 2020: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Options outstanding &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Total/ &lt;br&gt;&lt;/br&gt; weighted &lt;br&gt;&lt;/br&gt; average &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Number outstanding (millions)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remaining contractual life (years)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise price (USD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 57.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 57.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 66.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 62.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Options under Novartis equity plan &amp;#x201c;Select&amp;#x201d; for North America&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the activity associated with the ADR options during the period: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; ADR &lt;br&gt;&lt;/br&gt; options &lt;br&gt;&lt;/br&gt; (millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Weighted &lt;br&gt;&lt;/br&gt; average &lt;br&gt;&lt;/br&gt; exercise &lt;br&gt;&lt;/br&gt; price &lt;br&gt;&lt;/br&gt; (USD) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; ADR &lt;br&gt;&lt;/br&gt; options &lt;br&gt;&lt;/br&gt; (millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Weighted &lt;br&gt;&lt;/br&gt; average &lt;br&gt;&lt;/br&gt; exercise &lt;br&gt;&lt;/br&gt; price &lt;br&gt;&lt;/br&gt; (USD) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Options outstanding &lt;br&gt;&lt;/br&gt;at January 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 9.6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 61.9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 15.2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 60.7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sold or exercised&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 59.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 58.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Outstanding at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 62.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 61.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Exercisable at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 62.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 61.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;All ADR options were granted at an exercise price that was equal to the closing market price of the ADRs at the grant date. The weighted average ADR price at the dates of sale or exercise was USD&amp;nbsp;92.2. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table summarizes information about ADR options outstanding at December 31, 2020: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;ADR options outstanding &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Total/ &lt;br&gt;&lt;/br&gt; weighted &lt;br&gt;&lt;/br&gt; average &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Number outstanding (millions)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remaining contractual life (years)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise price (USD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 57.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 58.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 66.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 62.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Long-Term Performance Plan&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Long-Term Performance Plan (LTPP) is an equity plan for the ECN, the NTLs and employees of Group units with specific targets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Participants are granted a target number of performance share units (PSUs) at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. The actual payout depends on the achievement of the performance measures and ranges between 0% and 200% of the granted amount. PSUs granted under the LTPP do not carry voting rights, but do carry dividend equivalents that are paid in unrestricted Novartis shares at the end of the performance period. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The LTPP awards are subject to a three-year performance and vesting period. Until 2018, the performance criteria were based on Novartis internal performance metrics. Starting in 2019, for new grants the performance criteria are based on both Novartis internal performance metrics and variables that can be observed in the market, which is the ranking of the Novartis total shareholder return (TSR) relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;TSR for Novartis and the peer companies is calculated as the change in the company share price, which is translated to USD at the relevant exchange rate, including the reinvestment return of dividends, over the three-year performance period. The calculation is based on Bloomberg standard published TSR data, which is publicly available. The position of Novartis in the peer group determines the payout range based on a payout matrix. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Long-Term Relative Performance Plan&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The LTRPP is an equity plan for the Novartis ECN and NTLs. The last grant under this plan was made in 2018. The LTRPP performance criteria are based on variables that can be observed in the market, which is the ranking of the Novartis TSR relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. The TSR for Novartis and the peer companies is calculated as described in the LTPP section above. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Other share awards&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Selected associates, excluding the ECN members, may exceptionally receive Special Share Awards of RSs or RSUs. These Special Share Awards provide an opportunity to reward outstanding achievements or exceptional performance, and aim to retain key contributors. They are based on a formal internal selection process, through which the individual performance of each candidate is thoroughly assessed at several management levels. Special Share Awards have a minimum three-year vesting period. In exceptional circumstances, Special Share Awards may be awarded to attract special expertise and new talents to the organization. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Worldwide, associates at different levels in the organization were awarded RSs and RSUs in 2020, 2019 and 2018. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In addition, in 2020, 2019 and 2018, Board members received unrestricted shares as part of their regular compensation.&lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Summary of non-vested share movements&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The table below provides a summary of non-vested share movements (RSs, RSUs and PSUs) for all plans: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Number &lt;br&gt;&lt;/br&gt; of shares &lt;br&gt;&lt;/br&gt; in millions &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Weighted &lt;br&gt;&lt;/br&gt; average fair &lt;br&gt;&lt;/br&gt; value at grant &lt;br&gt;&lt;/br&gt; date in USD &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Fair value at &lt;br&gt;&lt;/br&gt; grant date in &lt;br&gt;&lt;/br&gt; USD millions &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Number &lt;br&gt;&lt;/br&gt; of shares &lt;br&gt;&lt;/br&gt; in millions &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Weighted &lt;br&gt;&lt;/br&gt; average fair &lt;br&gt;&lt;/br&gt; value at grant &lt;br&gt;&lt;/br&gt; date in USD &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Fair value at &lt;br&gt;&lt;/br&gt; grant date in &lt;br&gt;&lt;/br&gt; USD millions &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-vested shares at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 25.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 71.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;835&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 25.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 77.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;981&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Annual Incentive&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 93.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 78.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 86&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Share savings plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 95.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 83.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 349&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Select North America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 86.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 286&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 64.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 339&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Select outside North America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 89.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 67.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 175&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Long-Term Performance Plan&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 85.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 213&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 68.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 172&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Long-Term Relative Performance Plan &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Other share awards&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 78.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 117&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 67.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vested&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 74.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;024&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 80.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;068&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 75.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;151&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;328&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-vested shares at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 24.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 78.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;957&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 25.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 71.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;835&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; LTRPP grants in 2020 represent incremental payouts based on performance criteria under the plan. In 2019 the LTRPP grants are keep whole awards granted due to the spin-off of the Alcon business. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;At April 8, 2019, the Alcon spin-off date, all RSU and PSU holders, who were not entitled to the dividend in kind in the form of Alcon shares received keep whole awards in Novartis shares to compensate for the loss of the Alcon value from their Novartis shares. These keep whole awards were accounted for as a modification. As they did not increase the value of the original grant, they did not lead to additional expense. In the table above, this is reflected by a zero fair value at grant date amount. &lt;/div&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
  <nvs:ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense related to equity-based &lt;br&gt;&lt;/br&gt;participation plans &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 958 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;067 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 918 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Liabilities arising from equity-based payment transactions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 326&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 273&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock>
  <ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Options &lt;br&gt;&lt;/br&gt; (millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Weighted &lt;br&gt;&lt;/br&gt; average &lt;br&gt;&lt;/br&gt; exercise &lt;br&gt;&lt;/br&gt; price &lt;br&gt;&lt;/br&gt; (USD) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Options &lt;br&gt;&lt;/br&gt; (millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Weighted &lt;br&gt;&lt;/br&gt; average &lt;br&gt;&lt;/br&gt; exercise &lt;br&gt;&lt;/br&gt; price &lt;br&gt;&lt;/br&gt; (USD) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Options outstanding &lt;br&gt;&lt;/br&gt;at January 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 3.4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 60.9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 5.6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 59.9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sold or exercised&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;0.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 57.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 58.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Outstanding at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 62.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 60.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Exercisable at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 62.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 60.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
  <ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;Options outstanding &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Total/ &lt;br&gt;&lt;/br&gt; weighted &lt;br&gt;&lt;/br&gt; average &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Number outstanding (millions)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remaining contractual life (years)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise price (USD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 57.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 57.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 66.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 62.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory>
  <ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; ADR &lt;br&gt;&lt;/br&gt; options &lt;br&gt;&lt;/br&gt; (millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Weighted &lt;br&gt;&lt;/br&gt; average &lt;br&gt;&lt;/br&gt; exercise &lt;br&gt;&lt;/br&gt; price &lt;br&gt;&lt;/br&gt; (USD) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; ADR &lt;br&gt;&lt;/br&gt; options &lt;br&gt;&lt;/br&gt; (millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Weighted &lt;br&gt;&lt;/br&gt; average &lt;br&gt;&lt;/br&gt; exercise &lt;br&gt;&lt;/br&gt; price &lt;br&gt;&lt;/br&gt; (USD) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Options outstanding &lt;br&gt;&lt;/br&gt;at January 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 9.6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 61.9 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 15.2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 60.7 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sold or exercised&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 59.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 58.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Outstanding at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 62.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 61.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Exercisable at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 62.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 61.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
  <ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory contextRef="AR_D-CurrentYear_ifrsfull-2019TypesOfSharebasedPaymentArrangementsAxis_nvs-2020Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;ADR options outstanding &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Total/ &lt;br&gt;&lt;/br&gt; weighted &lt;br&gt;&lt;/br&gt; average &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Number outstanding (millions)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remaining contractual life (years)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise price (USD)&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 57.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 58.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 66.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 62.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory>
  <nvs:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Number &lt;br&gt;&lt;/br&gt; of shares &lt;br&gt;&lt;/br&gt; in millions &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Weighted &lt;br&gt;&lt;/br&gt; average fair &lt;br&gt;&lt;/br&gt; value at grant &lt;br&gt;&lt;/br&gt; date in USD &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Fair value at &lt;br&gt;&lt;/br&gt; grant date in &lt;br&gt;&lt;/br&gt; USD millions &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Number &lt;br&gt;&lt;/br&gt; of shares &lt;br&gt;&lt;/br&gt; in millions &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Weighted &lt;br&gt;&lt;/br&gt; average fair &lt;br&gt;&lt;/br&gt; value at grant &lt;br&gt;&lt;/br&gt; date in USD &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Fair value at &lt;br&gt;&lt;/br&gt; grant date in &lt;br&gt;&lt;/br&gt; USD millions &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-vested shares at January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 25.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 71.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;835&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 25.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 77.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;981&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Annual Incentive&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 93.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 78.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 86&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Share savings plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 95.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 83.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 349&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Select North America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 86.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 286&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 64.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 339&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Select outside North America&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 89.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 67.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 175&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Long-Term Performance Plan&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 85.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 213&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 68.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 172&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Long-Term Relative Performance Plan &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&amp;#x2013; Other share awards&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 78.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 117&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 67.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 129&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vested&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;13.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 74.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;024&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 80.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;068&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 75.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;151&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 76.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;328&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-vested shares at December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 24.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 78.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;957&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 25.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 71.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;835&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; LTRPP grants in 2020 represent incremental payouts based on performance criteria under the plan. In 2019 the LTRPP grants are keep whole awards granted due to the spin-off of the Alcon business. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;At April 8, 2019, the Alcon spin-off date, all RSU and PSU holders, who were not entitled to the dividend in kind in the form of Alcon shares received keep whole awards in Novartis shares to compensate for the loss of the Alcon value from their Novartis shares. These keep whole awards were accounted for as a modification. As they did not increase the value of the original grant, they did not lead to additional expense. In the table above, this is reflected by a zero fair value at grant date amount. &lt;/div&gt;</nvs:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
  <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;27. Transactions with related parties&lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Roche Holding AG&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has two agreements with Genentech, Inc., United States (Genentech), and one agreement with Spark Therapeutics, Inc., United States (Spark). Both companies are subsidiaries of Roche Holding AG (Roche), which is indirectly included in the consolidated financial statements using equity accounting since Novartis holds 33.3% of the outstanding voting shares of Roche (see Note 4). &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;i&gt;Lucentis&lt;/i&gt; &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has licensed from Genentech/Roche the exclusive rights to develop and market &lt;i&gt;Lucentis&lt;/i&gt; outside the United States for indications related to diseases of the eye. Novartis pays royalties on the net sales of &lt;i&gt;Lucentis&lt;/i&gt; products outside the United States. In 2020, &lt;i&gt;Lucentis&lt;/i&gt; sales of USD&amp;nbsp;1.9 billion (2019: USD&amp;nbsp;2.1 billion; 2018: USD&amp;nbsp;2.0 billion) were recognized by Novartis. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;i&gt;Xolair&lt;/i&gt; &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis and Genentech/Roche are co-promoting &lt;i&gt;Xolair&lt;/i&gt; in the United States, where Genentech/Roche records all sales. Novartis records sales outside the United States. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Novartis markets &lt;i&gt;Xolair&lt;/i&gt; and records all sales and related costs outside the United States as well as co-promotion costs in the US. Genentech/Roche and Novartis share the resulting profits from sales in the United States, Europe and other countries, according to agreed profit-sharing percentages. In 2020, Novartis recognized total sales of &lt;i&gt;Xolair&lt;/i&gt; of USD&amp;nbsp;1.3 billion (2019: USD&amp;nbsp;1.2 billion; 2018: USD&amp;nbsp;1.0 billion), including sales to Genentech/Roche for the United States market. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;i&gt;Luxturna&lt;/i&gt; &lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2018, Novartis entered into an exclusive licensing and commercialization agreement and a supply agreement with Spark for &lt;i&gt;Luxturna&lt;/i&gt; outside the United States. The agreements include regulatory and sales milestones as well as royalties payable to Spark on ex-US sales. On December 17, 2019, Roche acquired Spark. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;The net income for royalties, cost sharing and profit sharing arising out of the &lt;i&gt;Lucentis&lt;/i&gt;, &lt;i&gt;Xolair&lt;/i&gt; and &lt;i&gt;Luxturna&lt;/i&gt; agreements with Roche totaled USD&amp;nbsp;217 million in 2020 (net income in 2019: USD&amp;nbsp;101 million; net expense in 2018: USD&amp;nbsp;34 million). &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Furthermore, Novartis has several patent license, supply and distribution agreements with Roche. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Novartis Pension Fund&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2018, a Group subsidiary provided an uncommitted overnight credit facility to the Novartis Pension Fund, Switzerland, for up to USD 500 million with interest at the US Federal Funds Rate. This credit facility was not utilized during the years 2020, 2019 and 2018. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Executive Officers and Non-Executive Directors compensation&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During 2020, there were 13 Executive Committee members (&amp;#x201c;Executive Officers&amp;#x201d;). There were 15 Executive Officers in 2019 and 17 Executive Officers in 2018, including those who stepped down. &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The total compensation for Executive Committee members and the 14 Non-Executive Directors (13 in 2019 and 2018) using the Group&amp;#x2019;s accounting policies for equity-based compensation and pension benefits was as follows: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Executive Officers&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Non-Executive Directors&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and other compensation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 20.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Post-employment benefits&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 41.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 40.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 42.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 46.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 45.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 47.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 69.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 63.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 67.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 79.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 72.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 76.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During 2020, the IFRS compensation expense increased due to higher cash and other compensation. This increase in cash compensation is mainly attributable to ECN members who joined the ECN during 2019, as a result 2019 represented only a portion of their annual compensation. Other compensation increased on account of higher social security payments on vested equity-based compensation. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;During 2019, the IFRS compensation expense decreased due to lower cash buyout payments to new executive officers and the forfeiture of equity-based compensation as a result of the resignation of an executive officer. These effects were partially offset by higher equity based compensation of executive officers appointed over the last three years. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Annual Incentive award, which is fully included in equity-based compensation even when paid out in cash, is granted in January in the year following the reporting period. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The disclosures on Board and executive compensation required by the Swiss Code of Obligations and in accordance with the Swiss Ordinance against Excessive Compensation in Stock Exchange Listed Companies are shown in the Compensation Report of the Group. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Transactions with former members of the Board of Directors&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During 2020, 2019 and 2018, the following payments (or waivers of claims) were made to former Board members or to &amp;#x201c;persons closely&amp;#x201d; linked to them: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Currency&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dr. Krauer&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 60&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 60&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 60&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dr. Vasella&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&amp;nbsp;228&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Dr. Alex Krauer, Honorary Chairman, is entitled to an amount of CHF&amp;nbsp;60&amp;#xa0;000 for annual periods from one AGM to the next. This amount was fixed in 1998 upon his departure from the Board in 1999, and has not been revised since that date. &lt;/div&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
  <nvs:OfficerAndDirectorCompensationTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Executive Officers&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Non-Executive Directors&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and other compensation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 20.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.0&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="5%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 26.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Post-employment benefits&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 41.1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 40.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 42.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 46.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 45.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 47.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 69.4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 63.9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 67.5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8.7&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8.8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 79.2&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 72.6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 76.3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="20" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:OfficerAndDirectorCompensationTableTextBlock>
  <nvs:TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Currency&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dr. Krauer&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 60&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 60&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 60&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dr. Vasella&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 18&amp;nbsp;228&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock>
  <nvs:DisclosureOfCommitmentsAndContingenciesTextBlock contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;28. Commitments and contingencies&lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Research and development commitments&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group has entered into long-term research and development agreements with various institutions, which provide for potential milestone payments by Novartis that may be capitalized. As of December 31, 2020, the Group&amp;#x2019;s commitments to make payments under those agreements, and their estimated timing, were as follows: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 449&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 325&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2024&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 483&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 281&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Thereafter&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&amp;nbsp;232&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In addition in November 2020 and in January 2021, Novartis entered into long-term research and development agreements, both of which did not close as of January 25, 2021. These agreements provide for potential milestones payments by Novartis that may be capitalized. Based on their estimated timing, the payments for these transactions are expected to amount to USD 549 million in 2021, USD 248 million in 2022, USD 160 million in 2023, USD 415 million in 2024, USD 515 million in 2025, USD 1&amp;#xa0;409 million later than 2025, for a total of USD 3&amp;#xa0;296 million. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Commitments for capital calls&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group holds investments in funds in which it has committed to invest further upon future capital calls. As of December 31, 2020, the total uncalled capital commitments for the Group&amp;#x2019;s investments in funds amounts to USD 87 million. Note 29 contains further information on the Group&amp;#x2019;s investments in funds. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Other commitments&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group has entered into various purchase commitments for services and materials as well as for equipment in the ordinary course of business. These commitments are generally entered into at current market prices and reflect normal business operations. For disclosure of property, plant and equipment purchase commitments, see Note 9. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Guarantees issued&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group has issued guarantees to third parties in the ordinary course of business, mostly for tax, customs or other governmental agencies. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In addition, Novartis AG is guarantor of the Group&amp;#x2019;s issued bonds, credit facilities and commercial paper programs. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Contingencies&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Group companies have to observe the laws, government orders and regulations of the country in which they operate. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;A number of Novartis companies are, and will likely continue to be, subject to various legal proceedings and investigations that arise from time to time, including proceedings regarding product liability; sales and marketing practices; commercial disputes; employment and wrongful discharge; and antitrust, securities, health and safety, environmental, tax, international trade, privacy and intellectual property matters. As a result, the Group may become subject to substantial liabilities that may not be covered by insurance and that could affect our business, financial position and reputation. While Novartis does not believe that any of these legal proceedings will have a material adverse effect on its financial position, litigation is inherently unpredictable and large judgments sometimes occur. As a consequence, Novartis may in the future incur judgments or enter into settlements of claims that could have a material adverse effect on its results of operations or cash flow. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Governments and regulatory authorities around the world have been stepping up their compliance and law enforcement activities in recent years in key areas, including marketing practices, pricing, corruption, trade restrictions, embargo legislation, insider trading, antitrust, cyber security and data privacy. Further, when one government or regulatory authority undertakes an investigation, it is not uncommon for other governments or regulators to undertake investigations regarding the same or similar matters. Responding to such investigations is costly and requires an increasing amount of management&amp;#x2019;s time and attention. In addition, such investigations may affect our reputation, create a risk of potential exclusion from government reimbursement programs in the United States and other countries, and lead to (or arise from) litigation. These factors have contributed to decisions by Novartis and other companies in the healthcare industry, when deemed in their interest, to enter into settlement agreements with governmental authorities around the world prior to any formal decision by the authorities or a court. These government settlements have involved and may in the future involve large cash payments, sometimes in the hundreds of millions of dollars or more, including the potential repayment of amounts allegedly obtained improperly and other penalties, including treble damages. In addition, settlements of government healthcare fraud cases often require companies to enter into corporate integrity agreements, which are intended to regulate company behavior for a period of years. Our affiliate Novartis Corporation is a party to such an agreement, which will expire in 2025. Also, matters underlying governmental investigations and settlements may be the subject of separate private litigation. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;While provisions have been made for probable losses, which management deems to be reasonable or appropriate, there are uncertainties connected with these estimates. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Note 20 contains additional information on these matters.&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;A number of Group companies are involved in legal proceedings concerning intellectual property rights. The inherent unpredictability of such proceedings means that there can be no assurances as to their ultimate outcome. A negative result in any such proceeding could potentially adversely affect the ability of certain Novartis companies to sell their products, or require the payment of substantial damages or royalties. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In the opinion of management, however, the outcome of these actions will not materially affect the Group&amp;#x2019;s financial position but could be material to the results of operations or cash flow in a given period. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&amp;#x2019;s potential environmental remediation liability is assessed based on a risk assessment and investigation of the various sites identified by the Group as at risk for environmental remediation exposure. The Group&amp;#x2019;s future remediation expenses are affected by a number of uncertainties. These uncertainties include, but are not limited to, the method and extent of remediation, the percentage of material attributable to the Group at the remediation sites relative to that attributable to other parties, and the financial capabilities of the other potentially responsible parties. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Note 20 contains additional information on environmental liabilities.&lt;/div&gt;</nvs:DisclosureOfCommitmentsAndContingenciesTextBlock>
  <nvs:DisclosureOfLeasingCommitmentsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 449&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 325&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2024&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 483&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 281&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Thereafter&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;003&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 5&amp;nbsp;232&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfLeasingCommitmentsTableTextBlock>
  <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;29. Financial instruments &amp;ndash; additional disclosures&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following tables show the carrying values of financial instruments by measurement categories as of December 31, 2020 and 2019. Except for straight bonds (see Note 19), the carrying values are equal to, or a reasonable approximation of, the fair values. &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Note &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Financial &lt;br&gt;&lt;/br&gt; instruments at &lt;br&gt;&lt;/br&gt; amortized &lt;br&gt;&lt;/br&gt; costs &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Financial &lt;br&gt;&lt;/br&gt; instruments at &lt;br&gt;&lt;/br&gt; fair value &lt;br&gt;&lt;/br&gt; through other &lt;br&gt;&lt;/br&gt; comprehensive &lt;br&gt;&lt;/br&gt; income &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Financial &lt;br&gt;&lt;/br&gt; instruments at &lt;br&gt;&lt;/br&gt; fair value &lt;br&gt;&lt;/br&gt; through the &lt;br&gt;&lt;/br&gt; consolidated &lt;br&gt;&lt;/br&gt; income &lt;br&gt;&lt;/br&gt; statement &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Other &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;658&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity more than 90 days&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;609&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 963&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities - debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 466&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term loans, advances, security deposits and other long-term receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 297&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 211&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 625&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 20&amp;nbsp;744&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;173&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;827&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest-bearing accounts of associates payable on demand&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;085&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bank and other short-term financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 976&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commercial paper&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;258&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 28&amp;nbsp;298&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term liabilities to banks and other financial institutions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;403&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commitment for repurchase of own shares&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18/22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;769&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities (see Note 20/22) and other financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;005&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 43&amp;nbsp;022&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;005&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Note &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Financial &lt;br&gt;&lt;/br&gt; instruments at &lt;br&gt;&lt;/br&gt; amortized &lt;br&gt;&lt;/br&gt; costs &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Financial &lt;br&gt;&lt;/br&gt; instruments at &lt;br&gt;&lt;/br&gt; fair value &lt;br&gt;&lt;/br&gt; through other &lt;br&gt;&lt;/br&gt; comprehensive &lt;br&gt;&lt;/br&gt; income &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Financial &lt;br&gt;&lt;/br&gt; instruments at &lt;br&gt;&lt;/br&gt; fair value &lt;br&gt;&lt;/br&gt; through the &lt;br&gt;&lt;/br&gt; consolidated &lt;br&gt;&lt;/br&gt; income &lt;br&gt;&lt;/br&gt; statement &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Other &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity more than 90 days&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities - debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities - fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;158&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term loans, advances, security deposits and other long-term receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 329&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 21&amp;nbsp;839&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;215&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;323&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest-bearing accounts of associates payable on demand&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;836&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bank and other short-term financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 719&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commercial paper&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;289&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term liabilities to banks and other financial institutions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities (see Note 20/22) and other financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;065&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;949&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 32&amp;nbsp;623&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;949&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Derivative financial instruments&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following tables show the contract or underlying principal amounts and fair values of derivative financial instruments analyzed by type of contract at December&amp;nbsp;31, 2020 and 2019. Contract or underlying principal amounts indicate the gross volume of business outstanding at the consolidated balance sheet date and do not represent amounts at risk. The fair values are determined by reference to market prices or standard pricing models that use observable market inputs at December 31,&amp;nbsp;2020 and 2019. &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Contract or underlying principal amount&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Positive fair values &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Negative fair values &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forward foreign exchange rate contracts&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&amp;nbsp;679&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&amp;nbsp;779&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 151&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 96&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;165&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;75&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodity purchase contract&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Options on equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 70&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total derivative financial instruments included in marketable securities and in current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 13&amp;nbsp;760&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;057&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows by currency contract or underlying principal amount the derivative financial instruments at December&amp;nbsp;31,&amp;nbsp;2020 and 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forward foreign exchange rate contracts&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;432&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&amp;nbsp;376&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&amp;nbsp;679&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodity purchase contract&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Options on equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 70&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 70&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;432&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;457&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 13&amp;nbsp;760&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Other&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forward foreign exchange rate contracts&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;760&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;646&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&amp;nbsp;779&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodity purchase contract&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Options on equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;665&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;057&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Derivative financial instruments effective for hedge accounting purposes&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;At the end of 2020 and 2019, there were no open hedging instruments for anticipated transactions. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Fair value by hierarchy&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;As required by IFRS, financial assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. There are three hierarchical levels, based on increasing subjectivity associated with the inputs to derive fair valuation for these assets and liabilities, which are as follows: &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The assets carried at Level 1 fair value are equity and debt securities listed in active markets. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The assets generally included in Level 2 fair value hierarchy are foreign exchange and interest rate derivatives, and certain debt securities. Foreign exchange and interest rate derivatives are valued using corroborated market data. The liabilities generally included in this fair value hierarchy consist of foreign exchange and interest rate derivatives. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Level 3 inputs are unobservable for the asset or liability. The assets generally included in Level 3 fair value hierarchy are various investments in hedge funds and unquoted equity security investments. Contingent consideration carried at fair value is included in this category. &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Level 1&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Level 2&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Level 3&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities and derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 185&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 185&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt and equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;153&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 460&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;613&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 625&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 625&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total long-term financial investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;153&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;451&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;604&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 211&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 211&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities at fair value&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Level 1&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Level 2&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Level 3&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities and derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt and equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 976&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 581&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;557&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total long-term financial investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 976&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;213&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;189&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities at fair value&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;065&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The change in carrying values associated with Level 3 financial instruments, using significant unobservable inputs during the year ended December 31, is set forth below: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="13" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" height="3"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" height="3"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Associated &lt;br&gt;&lt;/br&gt; companies at &lt;br&gt;&lt;/br&gt; fair value through &lt;br&gt;&lt;/br&gt; profit and loss &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Fund &lt;br&gt;&lt;/br&gt; investments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Long-term &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; investments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Contingent &lt;br&gt;&lt;/br&gt; consideration &lt;br&gt;&lt;/br&gt; receivables &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Contingent &lt;br&gt;&lt;/br&gt; consideration &lt;br&gt;&lt;/br&gt; payables &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Other &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 581&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value gains and other adjustments, &lt;br&gt;&lt;/br&gt;including from divestments recognized &lt;br&gt;&lt;/br&gt;in the consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 57 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 151 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 34 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 173 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 206 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value losses (including impairments and &lt;br&gt;&lt;/br&gt;amortizations) and other adjustments recognized &lt;br&gt;&lt;/br&gt;in the consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;18 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;39 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;90 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments recognized in the consolidated statement &lt;br&gt;&lt;/br&gt;of comprehensive income, including currency translation effects &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 33 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 40 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;62 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Purchases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 123&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;123&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash receipts and payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;109&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 211&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 460&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 625&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total of fair value gains and losses recognized &lt;br&gt;&lt;/br&gt;in the consolidated income statement for assets &lt;br&gt;&lt;/br&gt;and liabilities held at December 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 39 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 143 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;5 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 173 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 116 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;b&gt;&lt;/b&gt; &lt;b&gt;&lt;/b&gt; &lt;b&gt;&lt;/b&gt; &lt;b&gt;&lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;b&gt;&lt;/b&gt; &lt;b&gt;&lt;/b&gt; &lt;b&gt;&lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="13" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" height="3"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" height="3"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Associated &lt;br&gt;&lt;/br&gt; companies at &lt;br&gt;&lt;/br&gt; fair value through &lt;br&gt;&lt;/br&gt; profit and loss &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Fund &lt;br&gt;&lt;/br&gt; investments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Long-term &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; investments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Contingent &lt;br&gt;&lt;/br&gt; consideration &lt;br&gt;&lt;/br&gt; receivables &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Contingent &lt;br&gt;&lt;/br&gt; consideration &lt;br&gt;&lt;/br&gt; payables &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Other &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 145&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 251&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 488&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 396&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;907&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact from discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value gains and other adjustments, &lt;br&gt;&lt;/br&gt;including from divestments recognized &lt;br&gt;&lt;/br&gt;in the consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 35 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 195 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value losses (including impairments and &lt;br&gt;&lt;/br&gt;amortizations) and other adjustments recognized &lt;br&gt;&lt;/br&gt;in the consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;15 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;89 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;48 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments recognized in the consolidated statement &lt;br&gt;&lt;/br&gt;of comprehensive income &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Purchases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 229&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;401&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash receipts and payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;64&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 581&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total of fair value gains and losses recognized &lt;br&gt;&lt;/br&gt;in the consolidated income statement for assets &lt;br&gt;&lt;/br&gt;and liabilities held at December 31, 2019 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;15 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 35 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 106 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;47 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During 2020, there were several individually non-significant transfers of financial investments from Level 3 to Level 1 for USD&amp;nbsp;166 million (2019: USD&amp;nbsp;64 million), mainly due to initial public offerings of the invested companies. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Realized gains and losses associated with Level 3 long-term financial investments measured at fair value through the consolidated income statement are recorded in the consolidated income statement under &amp;#x201c;Other income&amp;#x201d; or &amp;#x201c;Other expense,&amp;#x201d; respectively. Realized gains and losses associated with Level 3 long-term financial investments measured at fair value through other comprehensive income are not recycled through the consolidated income statement but are instead reclassified to retained earnings. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;During the year, the net loss and net gain recorded on associated companies, fund investments and long-term financial investments at fair value through profit and loss were USD 92 million and USD 427 million, respectively. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If the pricing parameters for the Level 3 input were to change for associated companies at fair value through profit and loss, fund investments and long-term financial investments by 10% positively or negatively, this would change the amounts recorded in the 2020 consolidated statement of comprehensive income by USD&amp;nbsp;104 million. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;To determine the fair value of a contingent consideration, various unobservable inputs are used. A change in these inputs might result in a significantly higher or lower fair value measurement. The inputs used are, among others, the probability of success, sales forecast and assumptions regarding the discount rate and timing and different scenarios of triggering events. The inputs are interrelated. The significance and usage of these inputs to each contingent consideration may vary due to differences in the timing and triggering events for payments or in the nature of the asset related to the contingent consideration. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If the most significant parameters for the Level&amp;nbsp;3 input were to change by 10% positively or negatively, or where the probability of success (POS) is the most significant input parameter, 10% were added or deducted from the applied probability of success, for contingent consideration payables, other financial liabilities and contingent consideration receivables, this would change the amounts recorded in the 2020 consolidated income statement by USD&amp;nbsp;260 million and USD&amp;nbsp;324 million, respectively. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Equity securities measured at fair value through other comprehensive income&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Equity securities held as strategic investments, typically held outside the Novartis Venture Fund, are generally designated at date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. Except for the investment in Alcon Inc. with a fair value of USD 71 million at December 31, 2020 (2019: USD 382 million), these are made up of individually non-significant investments. At December 31, 2020, the Group holds 56 non-listed equity securities (December 31, 2019: 53) and 34 listed equity securities (December 31, 2019: 29) in this category with the following fair values: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Listed equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 862&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 843&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-listed equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 249&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 315&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;158&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;There were no dividends recognized during 2020 and 2019 from these equity securities. In 2020, in accordance with the consolidated foundations Alcon Inc. shares divestment plans, Alcon Inc. shares with a fair value of USD&amp;nbsp;331 million were sold (2019: USD 976 million), and the USD&amp;nbsp;13 million gain on disposal (2019: USD 62 million gain) was transferred from other comprehensive income to retained earnings during 2020. In addition, in 2020, equity securities that were no longer considered strategic, with a fair value of USD&amp;nbsp;206 million (2019: USD&amp;nbsp;33 million), were sold, and the USD&amp;nbsp;137 million gain on disposal (2019: USD&amp;nbsp;33 million gain) was transferred from other comprehensive income to retained earnings (see Note 8). &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Nature and extent of risks arising from financial instruments&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Market risk&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis is exposed to market risk, primarily related to foreign currency exchange rates, interest rates, and the market value of the investments of liquid funds. The Group actively monitors and seeks to reduce, where it deems it appropriate to do so, fluctuations in these exposures. It is the Group&amp;#x2019;s policy and practice to enter into a variety of derivative financial instruments to manage the volatility of these exposures and to enhance the yield on the investment of liquid funds. It does not enter into any financial transactions containing a risk that cannot be quantified at the time the transaction is concluded. In addition, it does not sell short assets it does not have, or does not know it will have, in the future. The Group only sells existing assets or enters into transactions and future transactions (in the case of anticipatory hedges) that it confidently expects it will have in the future, based on past experience. In the case of liquid funds, the Group writes call options on assets it has, or writes put options on positions it wants to acquire and has the liquidity to acquire. The Group expects that any loss in value for these instruments generally would be offset by increases in the value of the underlying transactions. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Foreign currency exchange rate risk&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group uses the US dollar as its reporting currency. As a result, the Group is exposed to foreign currency exchange movements, primarily in European, Japanese and emerging market currencies. Fluctuations in the exchange rates between the US dollar and other currencies can have a significant effect on both the Group&amp;#x2019;s results of operations, including reported sales and earnings, as well as on the reported value of our assets, liabilities and cash flows. This, in turn, may significantly affect the comparability of period-to-period results of operations. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Because our expenditures in Swiss francs are significantly higher than our revenues in Swiss francs, volatility in the value of the Swiss franc can have a significant impact on the reported value of our earnings, assets and liabilities, and the timing and extent of such volatility can be difficult to predict. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;There is also a risk that certain countries could devalue their currency. If this occurs, it could impact the effective prices we would be able to charge for our products and also have an adverse impact on both our consolidated income statement and balance sheet. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Subsidiaries whose functional currencies have experienced a cumulative inflation rate of more than 100% over the past three years apply the rules of IAS 29 &amp;#x201c;Financial reporting in Hyperinflationary Economies&amp;#x201d;. The hyperinflationary economies in which Novartis operates are Argentina and Venezuela. Venezuela was hyperinflationary for all years presented, and Argentina became hyperinflationary effective July 1, 2018, requiring retroactive implementation of hyperinflation accounting as of January 1, 2018. The impacts of applying IAS 29 were not significant in all years presented. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group manages its global currency exposure by engaging in hedging transactions where management deems appropriate. Novartis may enter into various contracts that reflect the changes in the value of foreign currency exchange rates to preserve the value of assets, commitments and anticipated transactions. Novartis also uses forward contracts and foreign currency option contracts to hedge. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Net investments in subsidiaries in foreign countries are long-term investments. Their fair value changes through movements of foreign currency exchange rates. The Group has designated a certain portion of its long-term euro-denominated straight bonds as hedges of the translation risk arising on certain of these net investments in foreign operations with euro functional currency. As of December 31, 2020, long-term financial debt with a carrying amount of EUR&amp;nbsp;1.8 billion (USD&amp;nbsp;2.3 billion) (December 31, 2019: USD 2.1 billion), has been designated as a hedge instrument. During 2020, USD&amp;nbsp;201 million of unrealized loss (unrealized income in 2019: USD 44 million) was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge. The hedge remained effective since inception, and no amount was recognized in the consolidated income statement in 2020, 2019 and 2018. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Commodity price risk&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group has only a very limited exposure to price risk related to anticipated purchases of certain commodities used as raw materials by the Group&amp;#x2019;s businesses. A change in those prices may alter the gross margin of a specific business, but generally by not more than 10% of the margin and thus below the Group&amp;#x2019;s risk management tolerance levels. Accordingly, the Group does not enter into significant commodity futures, forward or option contracts to manage fluctuations in prices of anticipated purchases. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Interest rate risk&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group addresses its net exposure to interest rate risk mainly through the ratio of its fixed-rate financial debt to variable-rate financial debt contained in its total financial debt portfolio. To manage this mix, Novartis may enter into interest rate swap agreements, in which it exchanges periodic payments based on a notional amount and agreed-upon fixed and variable interest rates. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Equity risk&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group may purchase equities as investments of its liquid funds. As a policy, it limits its holdings in an unrelated company to less than 5% of its liquid funds. Potential investments are thoroughly analyzed. Call options are written on equities that the Group owns, and put options are written on equities that the Group wants to buy and for which cash is available. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Credit risk&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Credit risks arise from the possibility that customers may not be able to settle their obligations as agreed. To manage this risk, the Group periodically assesses country and customer credit risk, assigns individual credit limits, and takes actions to mitigate credit risk where appropriate. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The provisions for expected credit losses for customers are based on a forward-looking expected credit loss, which includes possible default events on the trade receivables over the entire holding period of the trade receivables. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In measuring the expected credit losses, trade receivables are grouped based on shared credit risk characteristics (such as private versus public receivables) and days past due. In determining the expected credit loss rates, the Group considers current and forward-looking macroeconomic factors that may affect the ability of the customers to settle the receivables, and historical loss rates for each category of customers. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&amp;#x2019;s largest customer accounted for approximately 17% of net sales, and the second largest and third largest customers accounted for 11% and 6% of net sales, respectively (2019: 18%, 13% and 8%, respectively; 2018: 18%, 14% and 8%, respectively).&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The highest amounts of trade receivables outstanding were for these same three customers and amounted to 14%, 12% and 6%, respectively, of the Group&amp;#x2019;s trade receivables at December 31, 2020 (2019: 14%, 12% and 7%, respectively). There is no other significant concentration of customer credit risk. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Counterparty risk&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Counterparty risk encompasses issuer risk on marketable securities and money market instruments; credit risk on cash, time deposits and derivatives; as well as settlement risk for different instruments. Issuer risk is reduced by only buying securities that are at least A- rated. Counterparty credit risk and settlement risk are reduced by a policy of entering into transactions with counterparties (banks or financial institutions) that feature a strong credit rating. Exposure to these risks is closely monitored and kept within predetermined parameters. The limits are regularly assessed and determined based upon credit analysis, including financial statement and capital adequacy ratio reviews. In addition, reverse repurchasing agreements are contracted, and Novartis has entered into credit support agreements with various banks for derivative transactions. To further reduce the settlement risk, the Group has implemented a multi-currency system, CLS (Continuous Linked Settlement), providing multilateral netting (payment-versus-payment settlement) of cash flows from foreign exchange transactions. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&amp;#x2019;s cash and cash equivalents are held with major regulated financial institutions; the three largest ones hold approximately 14.1%, 12.6% and 9.7%, respectively (2019: 12.6%, 10.4% and 8.3%, respectively). &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group does not expect any losses from non-performance by these counterparties and does not have any significant grouping of exposures to financial sector or country risk. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Liquidity risk&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Liquidity risk is defined as the risk that the Group could not be able to settle or meet its obligations associated with financial liabilities that are settled by delivering cash or another financial asset. Group Treasury is responsible for liquidity, funding and settlement management. In addition, liquidity and funding risks, and related processes and policies, are overseen by management. Novartis manages its liquidity risk on a consolidated basis according to business needs and tax, capital or regulatory considerations, if applicable, through numerous sources of financing in order to maintain flexibility. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Certain countries have legal or economic restrictions on the ability of subsidiaries to transfer funds to the Group in the form of cash dividends, loans or advances, but these restrictions do not have an impact on the ability of the Group to meet its cash obligations. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Management monitors the Group&amp;#x2019;s net debt or liquidity position through rolling forecasts on the basis of expected cash flows. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Novartis has two US commercial paper programs under which it can issue up to USD&amp;nbsp;9.0 billion in the aggregate of unsecured commercial paper notes. Novartis also has a Japanese commercial paper program under which it can issue up to JPY&amp;nbsp;150 billion (approximately USD&amp;nbsp;1.5 billion) of unsecured commercial paper notes. Commercial paper notes totaling USD&amp;nbsp;4.3 billion under these three programs were outstanding as per December 31, 2020 (2019: USD&amp;nbsp;2.3 billion). Novartis further has a committed credit facility of USD&amp;nbsp;6.0 billion, which was renewed in September 2019. This credit facility is provided by a syndicate of banks and is intended to be used as a backstop for the US commercial paper programs. The facility matures in September 2024 and was undrawn as per December 31, 2020, and December 31, 2019. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In December 2019, Novartis entered into a short-term credit facility of USD 7 billion, with a maturity date of June 30, 2020 with a syndicate of banks. On January 7, 2020, Novartis borrowed USD 7 billion under the facility with interest based on the USD LIBOR. On February 14, 2020, Novartis repaid the full USD 7 billion initially borrowed. The facility expired on June 30, 2020. &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table sets forth how management monitors net debt or liquidity based on details of the remaining contractual maturities of current financial assets and liabilities, excluding trade receivables and payables as well as contingent considerations at December 31, 2020, and December 31, 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="11" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due within &lt;br&gt;&lt;/br&gt; one month &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one month &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; three months &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; three months &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; one year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one year &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due after &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities, time deposits and short-term &lt;br&gt;&lt;/br&gt;investments with original maturity more than 90 days &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 13 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;571 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 25 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 5 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;635 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments and accrued interest&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;558&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;658&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;609&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;781&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 135&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 11&amp;nbsp;563&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;621&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;638&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;26&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;661&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;802&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;26&amp;nbsp;463&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;621&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;638&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;26&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;195&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;178&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;591&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;195&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;593&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;84&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;288&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;302&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;195&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;785&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;321&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 479&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;503&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;24&amp;nbsp;481&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="11" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due within &lt;br&gt;&lt;/br&gt; one month &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one month &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; three months &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; three months &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; one year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one year &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due after &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities, time deposits and short-term &lt;br&gt;&lt;/br&gt;investments with original maturity more than 90 days &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 20 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 26 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 16 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 57 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 122 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments and accrued interest&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 79&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;712&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;400&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;746&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;505&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 170&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;446&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;243&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;353&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;150&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;355&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;505&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;243&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;353&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;243&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;846&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;243&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;846&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;130&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;402&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;7&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;237&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;073&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;938&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The consolidated balance sheet amounts of financial liabilities included in the above analysis are not materially different to the contractual amounts due on maturity. The positive and negative fair values on derivative financial instruments represent the net contractual amounts to be exchanged at maturity. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&amp;#x2019;s contractual undiscounted potential cash flows from derivative financial instruments to be settled on a gross basis are as follows: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due within &lt;br&gt;&lt;/br&gt; one month &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one month &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; three months &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; three months &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; one year &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Derivative financial instruments and accrued interest on derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential outflows in various currencies - from financial derivative liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;930&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;096&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;719&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;745&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential inflows in various currencies - from financial derivative assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 904&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;114&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 710&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;728&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due within &lt;br&gt;&lt;/br&gt; one month &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one month &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; three months &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; three months &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; one year &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Derivative financial instruments and accrued interest on derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential outflows in various currencies - from financial derivative liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;814&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;624&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;952&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;390&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential inflows in various currencies - from financial derivative assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 807&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 922&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&amp;nbsp;385&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Other contractual liabilities that are not part of management&amp;#x2019;s monitoring of the net debt or liquidity consist of the following items: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="9" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due within &lt;br&gt;&lt;/br&gt; three months &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; three months &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; one year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one year &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due after &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contractual interest on non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;82&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;468&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;846&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;251&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;647&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;77&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;209&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;692&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;027&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;005&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;164&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;403&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commitment for repurchase of own shares&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;769&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;769&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;639&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="9" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due within &lt;br&gt;&lt;/br&gt; three months &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; three months &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; one year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one year &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due after &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contractual interest on non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;36&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;428&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;531&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;439&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;434&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;65&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;622&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;081&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;949&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;222&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;582&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;383&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Capital risk management&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis strives to maintain a strong credit rating. In managing its capital, Novartis focuses on maintaining a strong balance sheet. As of December 31, 2020, Moody&amp;#x2019;s Investor Service rated the Company A1 for long-term maturities and P-1 for short-term maturities and S&amp;amp;P Global Ratings rated the company AA- for long-term maturities and A-1+ for short-term maturities. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Value at risk&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group uses a value at risk (VAR) computation to estimate the potential 10-day loss in the fair value of its financial instruments. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;A 10-day period is used because of an assumption that not all positions could be undone in one day given the size of the positions. The VAR computation includes all financial assets and financial liabilities as set forth in the table on page F-69, except: &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Trade receivables&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Other current assets&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Long-term loans and receivables, advances and security deposits&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Contingent considerations&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Lease liabilities&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Commitment for repurchase of own shares&lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&amp;#x2022; Trade payables&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The VAR estimates are made assuming normal market conditions, using a 95% confidence interval. The Group uses a &amp;#x201c;Delta Normal&amp;#x201d; model to determine the observed interrelationships between movements in interest rates, stock markets and various currencies. These interrelationships are determined by observing interest rate movements, stock market movements and foreign currency rate movements over a 60-day period for the calculation of VAR amounts. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The estimated potential 10-day loss in the fair value of the Group&amp;#x2019;s foreign currency positions (including foreign exchange translation risk), the estimated potential 10-day loss of its equity holdings, and the estimated potential 10-day loss in fair value of its interest rate-sensitive instruments (primarily financial debt and investments of liquid funds under normal market conditions), as calculated in the VAR model, are the following: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;All financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 587&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 355&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Analyzed by components:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to foreign &lt;br&gt;&lt;/br&gt;currency exchange rates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 199 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 89 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to equity &lt;br&gt;&lt;/br&gt;market movements &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 62 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 31 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to interest rates&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 197&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 187&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The average, high and low VAR amounts are as follows:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Average&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; High&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Low&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;All financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 568&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 659&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 322&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Analyzed by components:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to foreign &lt;br&gt;&lt;/br&gt;currency exchange rates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 225 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 515 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 71 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to equity &lt;br&gt;&lt;/br&gt;market movements &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 78 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 261 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to &lt;br&gt;&lt;/br&gt;interest rates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 329 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 912 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 173 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Average&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; High&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Low&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;All financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 348&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 385&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 303&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Analyzed by components:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to foreign &lt;br&gt;&lt;/br&gt;currency exchange rates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 143 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 195 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 86 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to equity &lt;br&gt;&lt;/br&gt;market movements &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 36 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 81 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 16 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to &lt;br&gt;&lt;/br&gt;interest rates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 233 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 303 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 187 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The VAR computation is a risk analysis tool designed to statistically estimate the potential 10-day loss from adverse movements in foreign currency exchange rates, equity prices and interest rates under normal market conditions. The computation does not purport to represent actual losses in fair value on earnings to be incurred by the Group, nor does it consider the effect of favorable changes in market rates. The Group cannot predict actual future movements in such market rates, and it does not claim that these VAR results are indicative of future movements in such market rates or are representative of any actual impact that future changes in market rates may have on the Group&amp;#x2019;s future results of operations or financial position. &lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
  <nvs:DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Note &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Financial &lt;br&gt;&lt;/br&gt; instruments at &lt;br&gt;&lt;/br&gt; amortized &lt;br&gt;&lt;/br&gt; costs &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Financial &lt;br&gt;&lt;/br&gt; instruments at &lt;br&gt;&lt;/br&gt; fair value &lt;br&gt;&lt;/br&gt; through other &lt;br&gt;&lt;/br&gt; comprehensive &lt;br&gt;&lt;/br&gt; income &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Financial &lt;br&gt;&lt;/br&gt; instruments at &lt;br&gt;&lt;/br&gt; fair value &lt;br&gt;&lt;/br&gt; through the &lt;br&gt;&lt;/br&gt; consolidated &lt;br&gt;&lt;/br&gt; income &lt;br&gt;&lt;/br&gt; statement &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Other &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;658&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity more than 90 days&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;609&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;217&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 963&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities - debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 466&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term loans, advances, security deposits and other long-term receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 297&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 211&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 625&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 20&amp;nbsp;744&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;173&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;827&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest-bearing accounts of associates payable on demand&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;085&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bank and other short-term financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 976&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commercial paper&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;258&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 28&amp;nbsp;298&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term liabilities to banks and other financial institutions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;403&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commitment for repurchase of own shares&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18/22&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;769&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities (see Note 20/22) and other financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;005&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 43&amp;nbsp;022&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;005&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Note &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Financial &lt;br&gt;&lt;/br&gt; instruments at &lt;br&gt;&lt;/br&gt; amortized &lt;br&gt;&lt;/br&gt; costs &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Financial &lt;br&gt;&lt;/br&gt; instruments at &lt;br&gt;&lt;/br&gt; fair value &lt;br&gt;&lt;/br&gt; through other &lt;br&gt;&lt;/br&gt; comprehensive &lt;br&gt;&lt;/br&gt; income &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Financial &lt;br&gt;&lt;/br&gt; instruments at &lt;br&gt;&lt;/br&gt; fair value &lt;br&gt;&lt;/br&gt; through the &lt;br&gt;&lt;/br&gt; consolidated &lt;br&gt;&lt;/br&gt; income &lt;br&gt;&lt;/br&gt; statement &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Other &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity more than 90 days&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;301&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities - debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities - fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;158&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term loans, advances, security deposits and other long-term receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 329&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 21&amp;nbsp;839&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;215&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;323&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest-bearing accounts of associates payable on demand&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;836&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bank and other short-term financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 719&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commercial paper&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;289&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 22&amp;nbsp;167&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term liabilities to banks and other financial institutions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 188&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 5&amp;nbsp;424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities (see Note 20/22) and other financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;065&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;949&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 32&amp;nbsp;623&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;949&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock>
  <ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Contract or underlying principal amount&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Positive fair values &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="3" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Negative fair values &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="3" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forward foreign exchange rate contracts&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&amp;nbsp;679&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&amp;nbsp;779&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 151&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 96&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;165&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;75&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodity purchase contract&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Options on equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 70&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total derivative financial instruments included in marketable securities and in current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 13&amp;nbsp;760&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;057&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory>
  <nvs:DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forward foreign exchange rate contracts&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&amp;nbsp;432&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6&amp;nbsp;376&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&amp;nbsp;679&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodity purchase contract&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Options on equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 70&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 70&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;432&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 6&amp;nbsp;457&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;871&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 13&amp;nbsp;760&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Other&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forward foreign exchange rate contracts&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 7&amp;nbsp;760&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;646&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&amp;nbsp;779&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodity purchase contract&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Options on equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 8&amp;nbsp;019&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;665&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;057&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock>
  <ifrs-full:DisclosureOfFairValueMeasurementExplanatory contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Level 1&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Level 2&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Level 3&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 26&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities and derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 185&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 185&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt and equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;153&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 460&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;613&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 625&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 625&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total long-term financial investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;153&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;451&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;604&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 211&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 211&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities at fair value&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;069&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;263&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Level 1&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Level 2&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Level 3&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities and derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 37&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt and equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 976&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 581&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;557&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total long-term financial investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 976&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;213&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;189&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities at fair value&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;065&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;250&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfFairValueMeasurementExplanatory>
  <nvs:DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="13" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" height="3"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" height="3"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Associated &lt;br&gt;&lt;/br&gt; companies at &lt;br&gt;&lt;/br&gt; fair value through &lt;br&gt;&lt;/br&gt; profit and loss &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Fund &lt;br&gt;&lt;/br&gt; investments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Long-term &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; investments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Contingent &lt;br&gt;&lt;/br&gt; consideration &lt;br&gt;&lt;/br&gt; receivables &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Contingent &lt;br&gt;&lt;/br&gt; consideration &lt;br&gt;&lt;/br&gt; payables &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; Other &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 581&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value gains and other adjustments, &lt;br&gt;&lt;/br&gt;including from divestments recognized &lt;br&gt;&lt;/br&gt;in the consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 57 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 151 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 34 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 173 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 206 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value losses (including impairments and &lt;br&gt;&lt;/br&gt;amortizations) and other adjustments recognized &lt;br&gt;&lt;/br&gt;in the consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;18 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;8 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;39 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;90 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments recognized in the consolidated statement &lt;br&gt;&lt;/br&gt;of comprehensive income, including currency translation effects &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 4 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 33 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 40 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;62 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;2 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Purchases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 123&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 43&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;123&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash receipts and payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 63&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;109&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 211&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 460&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 625&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;23&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total of fair value gains and losses recognized &lt;br&gt;&lt;/br&gt;in the consolidated income statement for assets &lt;br&gt;&lt;/br&gt;and liabilities held at December 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 39 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 143 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;5 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 173 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 116 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;b&gt;&lt;/b&gt; &lt;b&gt;&lt;/b&gt; &lt;b&gt;&lt;/b&gt; &lt;b&gt;&lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;b&gt;&lt;/b&gt; &lt;b&gt;&lt;/b&gt; &lt;b&gt;&lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="13" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" height="3"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="13" height="3"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Associated &lt;br&gt;&lt;/br&gt; companies at &lt;br&gt;&lt;/br&gt; fair value through &lt;br&gt;&lt;/br&gt; profit and loss &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Fund &lt;br&gt;&lt;/br&gt; investments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Long-term &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; investments &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Contingent &lt;br&gt;&lt;/br&gt; consideration &lt;br&gt;&lt;/br&gt; receivables &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Contingent &lt;br&gt;&lt;/br&gt; consideration &lt;br&gt;&lt;/br&gt; payables &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; Other &lt;br&gt;&lt;/br&gt; financial &lt;br&gt;&lt;/br&gt; liabilities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 145&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 251&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 488&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 396&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;907&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact from discontinued operations &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 163&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value gains and other adjustments, &lt;br&gt;&lt;/br&gt;including from divestments recognized &lt;br&gt;&lt;/br&gt;in the consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 35 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 195 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 1 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value losses (including impairments and &lt;br&gt;&lt;/br&gt;amortizations) and other adjustments recognized &lt;br&gt;&lt;/br&gt;in the consolidated income statement &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;15 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;89 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;48 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments recognized in the consolidated statement &lt;br&gt;&lt;/br&gt;of comprehensive income &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Purchases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 49&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 28&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 229&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;401&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash receipts and payments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;30&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;53&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;64&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 581&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total of fair value gains and losses recognized &lt;br&gt;&lt;/br&gt;in the consolidated income statement for assets &lt;br&gt;&lt;/br&gt;and liabilities held at December 31, 2019 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;15 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 12 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 6 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 35 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; 106 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;47 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="14"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Notes 1, 2 and 30 provide information related to discontinued operations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock>
  <ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Listed equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 862&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 843&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-listed equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 249&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 315&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;158&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory>
  <nvs:DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="11" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due within &lt;br&gt;&lt;/br&gt; one month &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one month &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; three months &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; three months &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; one year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one year &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due after &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities, time deposits and short-term &lt;br&gt;&lt;/br&gt;investments with original maturity more than 90 days &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 13 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;571 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 25 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 5 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;635 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 111&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments and accrued interest&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8&amp;nbsp;558&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;100&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9&amp;nbsp;658&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 8&amp;nbsp;609&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;781&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 135&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 11&amp;nbsp;563&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;621&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;638&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;26&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;661&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;802&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;26&amp;nbsp;463&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;621&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;638&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;26&amp;nbsp;259&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;195&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;218&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;178&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;591&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;195&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;179&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;593&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;84&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;17&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;194&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;288&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;302&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;195&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;785&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 4&amp;nbsp;321&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 479&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;166&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;10&amp;nbsp;612&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;503&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;24&amp;nbsp;481&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="11" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="11" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due within &lt;br&gt;&lt;/br&gt; one month &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one month &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; three months &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; three months &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; one year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one year &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due after &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities, time deposits and short-term &lt;br&gt;&lt;/br&gt;investments with original maturity more than 90 days &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 20 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 26 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 16 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 3 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 57 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="7%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 122 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments and accrued interest&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 79&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 102&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 9&amp;nbsp;712&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;400&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;112&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 9&amp;nbsp;746&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;505&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 19&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 6&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 170&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 11&amp;nbsp;446&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;243&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;353&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;150&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;355&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;505&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;110&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;243&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;20&amp;nbsp;353&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;243&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;846&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;243&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;230&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;846&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;130&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;29&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;26&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;185&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;402&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;256&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;7&amp;nbsp;031&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net debt&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 5&amp;nbsp;373&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 103&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;237&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&amp;nbsp;104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;11&amp;nbsp;073&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;15&amp;nbsp;938&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="14" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock>
  <nvs:DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due within &lt;br&gt;&lt;/br&gt; one month &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one month &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; three months &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; three months &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; one year &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Derivative financial instruments and accrued interest on derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential outflows in various currencies - from financial derivative liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;930&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;096&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;719&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;745&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential inflows in various currencies - from financial derivative assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 904&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4&amp;nbsp;114&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 710&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5&amp;nbsp;728&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="7" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="7" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due within &lt;br&gt;&lt;/br&gt; one month &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one month &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; three months &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; three months &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; one year &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Derivative financial instruments and accrued interest on derivative financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential outflows in various currencies - from financial derivative liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;814&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;624&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;952&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;390&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential inflows in various currencies - from financial derivative assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 807&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;656&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 922&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 6&amp;nbsp;385&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock>
  <nvs:DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="9" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due within &lt;br&gt;&lt;/br&gt; three months &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; three months &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; one year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one year &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due after &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contractual interest on non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;82&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;468&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;846&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;4&amp;nbsp;251&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;6&amp;nbsp;647&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;77&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;209&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;692&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;027&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;005&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;239&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;164&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;403&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commitment for repurchase of own shares&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;769&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;769&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;24&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;38&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;639&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;345&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;046&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="9" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="9" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;(USD millions) &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due within &lt;br&gt;&lt;/br&gt; three months &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; three months &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; one year &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br&gt;&lt;/br&gt; one year &lt;br&gt;&lt;/br&gt; but less than &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Due after &lt;br&gt;&lt;/br&gt; five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contractual interest on non-current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;36&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;428&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;531&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;439&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="8%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;434&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;65&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;181&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;622&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;081&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;949&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;222&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;5&amp;nbsp;424&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;62&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;582&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;383&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;036&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="12" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock>
  <nvs:DisclosureOfTenDayLossFairValueVARModelTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;All financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 587&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 355&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Analyzed by components:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to foreign &lt;br&gt;&lt;/br&gt;currency exchange rates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 199 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 89 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to equity &lt;br&gt;&lt;/br&gt;market movements &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 62 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 31 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to interest rates&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 197&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 187&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfTenDayLossFairValueVARModelTableTextBlock>
  <nvs:DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Average&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; High&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Low&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;All financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 568&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 659&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 322&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Analyzed by components:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to foreign &lt;br&gt;&lt;/br&gt;currency exchange rates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 225 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 515 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 71 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to equity &lt;br&gt;&lt;/br&gt;market movements &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 78 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 261 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 21 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to &lt;br&gt;&lt;/br&gt;interest rates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 329 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 912 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; 173 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="center" colspan="5" height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;td colspan="5" height="3"&gt;&lt;/td&gt; &lt;td height="1"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Average&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; High&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Low&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;All financial instruments&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 348&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 385&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 303&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Analyzed by components:&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to foreign &lt;br&gt;&lt;/br&gt;currency exchange rates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 143 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 195 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 86 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to equity &lt;br&gt;&lt;/br&gt;market movements &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 36 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 81 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 16 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Instruments sensitive to &lt;br&gt;&lt;/br&gt;interest rates &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 233 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 303 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 187 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock>
  <ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;30. Discontinued operations&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Discontinued operations include the operational results from the Alcon eye care devices business and certain Corporate activities attributable to the Alcon business prior to the spin-off, the gain on distribution of Alcon Inc. to Novartis AG shareholders, and certain other expenses related to the Distribution (refer to Notes 1 and 2 for further details). &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Alcon eye care devices business researched, discovered, developed, manufactured, distributed and sold a broad range of eye care products. Alcon was organized into two global business franchises, Surgical and Vision Care. Alcon also provided services, training, education and technical support for both the Surgical and Vision Care businesses. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Consolidated income statement&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019 &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties from &lt;br&gt;&lt;/br&gt;discontinued operations &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;777 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 7&amp;nbsp;149 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to continuing segments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;809&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;153&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;860&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;983&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 949&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;170&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;638&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;754&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;585&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;113&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income/(loss) from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 71&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;234&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income/(loss) before taxes from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;260&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 74&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net loss from discontinued operations &lt;br&gt;&lt;/br&gt;before gain on distribution of Alcon Inc. &lt;br&gt;&lt;/br&gt;to Novartis AG shareholders &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;186 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gain on distribution of Alcon Inc. to Novartis AG shareholders &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income/(loss) from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; The consolidated income statement amounts are for the period from January 1, 2019, to the completion of the spin-off. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; See Note 2 for further details on the non-taxable, non-cash gain on distribution of Alcon Inc. to Novartis AG shareholders. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Supplemental disclosures related to the Alcon business distributed to Novartis AG shareholders &lt;/font&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Additional significant accounting policies&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The accounting policies mentioned in Note 1 were used for the reporting of discontinued operations. The following additional significant accounting policies were applicable to discontinued operations. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Intangible assets available for use&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In addition to currently marketed products, technologies and other intangible assets (including computer software), discontinued operations intangible assets available for use also included marketing know-how and the Alcon brand name. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Marketing know-how represents the value attributable to the expertise acquired for marketing and distributing Alcon surgical products. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Alcon brand name was shown separately, as it was the only Novartis intangible asset that was available for use with an indefinite useful life. Novartis considers that it was appropriate that the Alcon brand name had an indefinite life since Alcon-branded products had a history of strong revenue and cash flow performance, and Novartis had the intent and ability to support the brand with spending to maintain its value for the foreseeable future. The Alcon brand name was not amortized as it had an indefinite useful life, but was evaluated for potential impairment annually. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the respective useful lives for available-for-use intangible assets and the location in the consolidated income statement in which the respective amortization and any potential impairment charge were recognized: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Useful life &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Income statement location &lt;br&gt;&lt;/br&gt; for amortization and &lt;br&gt;&lt;/br&gt; impairment charges &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketing know-how&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold"&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Alcon brand name&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Not amortized, &lt;br&gt;&lt;/br&gt; indefinite useful life &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Other expense" &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the activities and more specifically on appropriate royalty rate for the Alcon brand name. &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Revenue recognition&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In the Alcon Division, which is reported as discontinued operations, surgical equipment may have been sold together with other products and services under a single contract. Revenues were recognized upon satisfaction of each of the performance obligations in the contract and the consideration was allocated based on the standalone selling price of each performance obligation. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For surgical equipment, in addition to cash and installment sales, revenue was recognized under finance and operating lease arrangements. Arrangements in which substantially all the risks and rewards incidental to ownership transfers to the customer were treated as finance lease arrangements. Revenue from finance lease arrangements was recognized at amounts equal to the fair value of the equipment, which approximated the present value of the minimum lease payments under the arrangements. As interest rates embedded in lease arrangements were approximately market rates, revenue under finance lease arrangements was comparable to revenue for outright sales. Finance income for arrangements longer than 12 months was deferred and subsequently recognized based on a pattern that approximated to the use of the effective interest method and was recorded in &amp;#x201c;Other income.&amp;#x201d; Operating lease revenue for equipment rentals was recognized on a straight-line basis over the lease term. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Net income &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Included in net income from discontinued operations are:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;42&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;235&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;174&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;052&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on intangible assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;391&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to restructuring provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation of Novartis equity plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; 2018 includes an impairment of USD 337 million related to the write-down of the CyPass currently marketed product, which was acquired with the Alcon Division 2016 acquisition of Transcend Medical, Inc. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Balance sheet &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following were in the balance sheet from discontinued operations for the period from January 1, 2019, to the date of reclassification: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 113&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to goodwill and intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="4"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="4"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Cash flows used in investing activities from discontinued operations&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Cash flows used in investing activities from discontinued operations include the investing activities of the Alcon business and cash outflows for transaction-related expenditures attributable to the series of portfolio transformation transactions completed in 2015. &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments attributable &lt;br&gt;&lt;/br&gt;to the spin-off of the &lt;br&gt;&lt;/br&gt;Alcon business &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;39 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;29 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Divested cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;628&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows attributable to the spin-off of the Alcon business&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;657&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other cash flows used in investing activities, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;88&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;502&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;001&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net cash flows used in investing activities from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;127&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;001&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Cash flows from financing activities from discontinued operations&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2020, the net cash outflows used in financing activities from discontinued operations of USD 50 million was for transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2019, the net cash inflows from financing activities from discontinued operations of USD 3.3 billion (2018: USD 167 million net cash outflows) included mainly USD 3.5 billion (2018: nil) cash inflows from Alcon borrowings in connection with the distribution (spin-off) of the Alcon business to Novartis AG shareholders, partly offset by USD 0.2 billion (2018: USD 0.1 billion) transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders (see Notes 1 and 2). &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Leases&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The lease liabilities recorded in discontinued operations on January 1, 2019, the date of implementation of IFRS 16 Leases (see Note 1), were USD 286 million, and the right-of-use assets were USD 276 million, including USD 89 million and USD 75 million, respectively, for the previously reported finance lease obligations. For discontinued operations, there were no impairments or significant contract terminations of right-of-use assets for the period from January 1, 2019, to February 28, 2019, the date of shareholder approval for the Alcon spin-off. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Net assets derecognized &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table presents the Alcon business net assets at the date of spin-off at April 8, 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;858&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;906&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;121&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial and other non-current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 526&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables and other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 628&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;713&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;538&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables, provisions and other liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;751&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets derecognized&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 20&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Defined contribution plans&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In many subsidiaries, associates are covered by defined contribution plans. Contributions charged to the consolidated income statement for the defined contribution plans were: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions for defined contribution plans discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Significant transactions&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In March 2019, Alcon acquired PowerVision, Inc. (PowerVision), a privately held, US-based medical device development company focused on developing accommodative, implantable intraocular lenses. The fair value of the total purchase consideration was USD 424 million. The amount consisted of an initial cash payment of USD 289 million and the fair value of the contingent consideration of USD 135 million, due to PowerVision shareholders, which they are eligible to receive upon the achievement of specified regulatory and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 418 million, consisting of intangible assets of USD 505 million, net deferred tax liabilities of USD 93 million, other net assets of USD 6 million, and goodwill of USD 6 million. The 2019 results of operations since the date of the acquisition were not material. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For additional information related to the distribution (spin-off) of the Alcon business to Novartis AG shareholders, effected through a dividend in kind distribution that was completed on April 8, 2019, refer to Note 1 and Note 2. &lt;/div&gt;</ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory>
  <nvs:ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019 &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties from &lt;br&gt;&lt;/br&gt;discontinued operations &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 1&amp;nbsp;777 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; 7&amp;nbsp;149 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to continuing segments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 32&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;809&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 7&amp;nbsp;153&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;860&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;983&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 949&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 3&amp;nbsp;170&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;638&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;754&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;142&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;585&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 15&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 61&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;113&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;126&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income/(loss) from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 71&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;234&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;10&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;25&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income/(loss) before taxes from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 58&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;260&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 74&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net loss from discontinued operations &lt;br&gt;&lt;/br&gt;before gain on distribution of Alcon Inc. &lt;br&gt;&lt;/br&gt;to Novartis AG shareholders &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;101 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;186 &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gain on distribution of Alcon Inc. to Novartis AG shareholders &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 4&amp;nbsp;691&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income/(loss) from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 4&amp;nbsp;590&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;186&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; The consolidated income statement amounts are for the period from January 1, 2019, to the completion of the spin-off. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; See Note 2 for further details on the non-taxable, non-cash gain on distribution of Alcon Inc. to Novartis AG shareholders. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock>
  <nvs:ConsolidatedIncomeStatementAdditionalInformationTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;42&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;235&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;174&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;052&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on intangible assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;391&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to restructuring provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation of Novartis equity plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; 2018 includes an impairment of USD 337 million related to the write-down of the CyPass currently marketed product, which was acquired with the Alcon Division 2016 acquisition of Transcend Medical, Inc. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ConsolidatedIncomeStatementAdditionalInformationTableTextBlock>
  <nvs:BalanceSheetAdditionalInformationTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 113&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to goodwill and intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="4"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="4"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:BalanceSheetAdditionalInformationTableTextBlock>
  <nvs:CashFlowsUsedInInvestingActivitiesTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments attributable &lt;br&gt;&lt;/br&gt;to the spin-off of the &lt;br&gt;&lt;/br&gt;Alcon business &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;39 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;29 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Divested cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;628&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows attributable to the spin-off of the Alcon business&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;657&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other cash flows used in investing activities, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;88&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;502&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;001&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net cash flows used in investing activities from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;127&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;001&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:CashFlowsUsedInInvestingActivitiesTableTextBlock>
  <nvs:DisclosureOfNetAssetsDerecognizedTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;858&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;906&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;121&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial and other non-current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 526&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables and other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 628&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;713&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;538&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables, provisions and other liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;751&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets derecognized&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 20&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfNetAssetsDerecognizedTableTextBlock>
  <nvs:ScheduleOfDefinedContributionPlansTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions for defined contribution plans discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:ScheduleOfDefinedContributionPlansTableTextBlock>
  <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;31. Events subsequent to the December 31, 2020, consolidated balance sheet date&lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Significant transactions not closed as of January&amp;nbsp;25,&amp;nbsp;2021&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In November 2020 and in January 2021, Novartis entered into long-term research and development agreements, both of which did not close as of January 25, 2021. For additional information see Note 28. &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Significant transaction closed in January 2021&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In December 2020, Novartis entered into a business acquisition agreement that closed on January 21, 2021, with an estimated fair value purchase price of USD 235 million. &lt;/div&gt; &lt;div&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Dividend proposal for 2020 and approval of&amp;nbsp;the Group&amp;#x2019;s 2020 consolidated financial statements &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On January 25, 2021, the Novartis AG Board of Directors proposed the acceptance of the 2020 consolidated financial statements of the Novartis Group for approval by the Annual General Meeting on March 2, 2021. Furthermore, also on January 25, 2021, the Board proposed a dividend of CHF 3.00 per share to be approved at the Annual General Meeting on March 2, 2021. If approved, total dividend payments would amount to approximately USD 7.7 billion (2019: USD&amp;nbsp;7.0 billion), using the CHF/USD December 31, 2020, exchange rate. &lt;/div&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
  <ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory contextRef="AR_D-CurrentYear">&lt;a name="anchorNote31"&gt;&lt;/a&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;32. Principal Group subsidiaries and&amp;#xa0;associated&amp;#xa0;companies&lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table lists the principal subsidiaries controlled by Novartis, associated companies in which &amp;#xad;Novartis is deemed to have significant influence, and foundations required to be consolidated under IFRS. It includes all subsidiaries, associated companies and consolidated foundations with total assets or net sales to third parties in excess of USD&amp;#xa0;25&amp;#xa0;million. The equity interest percentage shown in the table also represents the share in voting rights in those entities, except where explicitly noted. &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;As at December 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share &lt;br&gt;&lt;/br&gt; capital &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br&gt;&lt;/br&gt; interest &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Algeria&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Soci&amp;#xe9;t&amp;#xe9; par actions SANDOZ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Algiers&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; DZD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 650.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Argentina&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Argentina S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Buenos Aires&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ARS&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 906.1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Australia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Australia Pty Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Macquarie Park, NSW&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AUD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharmaceuticals Australia Pty Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Macquarie Park, NSW&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AUD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.8&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Pty Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Macquarie Park, NSW&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AUD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Austria&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Austria GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vienna&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vienna&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Kundl&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;EBEWE Pharma Ges.m.b.H Nfg. KG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Unterach am Attersee&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Bangladesh&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis (Bangladesh) Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gazipur&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BDT&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 162.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 60%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Belgium&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma NV&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vilvoorde&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz NV&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vilvoorde&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Alcon - Couvreur NV&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Puurs&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 110.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Bermuda&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Investment Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Hamilton&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Securities Investment Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Hamilton&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Finance Services Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Hamilton&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Triangle International Reinsurance Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Hamilton&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trinity River Insurance Co Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Hamilton&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 370&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Brazil&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Bioci&amp;#xea;ncias S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;S&amp;#xe3;o Paulo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRL&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 265.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz do Brasil Ind&amp;#xfa;stria Farmac&amp;#xea;utica Ltda.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Camb&amp;#xe9;, PR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRL&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 190.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Canada&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharmaceuticals Canada Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dorval, Quebec&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CAD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Canada Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Boucherville, Quebec&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CAD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 80.8&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Manufacturing Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Boucherville, Quebec&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CAD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Chile&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Chile S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Santiago de Chile&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CLP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;China&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Beijing Novartis Pharma Co., Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Beijing&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharmaceuticals (HK) Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Hong Kong&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HKD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 200&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;China Novartis Institutes for BioMedical Research Co., Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Shanghai&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 320.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Suzhou Novartis Technical Development Co., Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Changshu&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shanghai Novartis Trading Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shanghai&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz (China) Pharmaceutical Co., Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Zhongshan&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 57.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Colombia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis de Colombia S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Santaf&amp;#xe9; de Bogot&amp;#xe1;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; COP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.9&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Croatia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz d.o.o. farmaceutska industrija&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Zagreb&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HRK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Czech Republic&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis s.r.o.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prague&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CZK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 51.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz s.r.o.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prague&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CZK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 44.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Denmark&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Healthcare A/S&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Copenhagen&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; DKK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz A/S&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Copenhagen&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; DKK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ecuador&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Ecuador S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Quito&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Egypt&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma S.A.E.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cairo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EGP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 193.8&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.77%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Egypt Pharma S.A.E.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;New Cairo City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EGP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 250&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Finland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Finland Oy&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Espoo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 459&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;As at December 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share &lt;br&gt;&lt;/br&gt; capital &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br&gt;&lt;/br&gt; interest &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;France&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Groupe France S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rueil-Malmaison&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 903.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma S.A.S.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rueil-Malmaison&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 43.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Advanced Accelerator Applications S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Saint-Genis-Pouilly&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 76&amp;nbsp;734&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;CELLforCURE&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Les Ulis&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz S.A.S.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Levallois-Perret&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Germany&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Deutschland GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Nuremberg&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 155.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Business Services GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Wehr&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Nuremberg&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Produktions GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Wehr&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz International GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Holzkirchen&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1 A Pharma GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Oberhaching&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;HEXAL AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Holzkirchen&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 93.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Salutas Pharma GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Barleben&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 42.1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Aeropharm GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rudolstadt&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Greece&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis (Hellas) S.A.C.I.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Metamorphosis / Athens&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 233.9&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Hungary&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Hungary Healthcare Limited Liability Company&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Budapest&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HUF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 545.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Hungary Limited Liability Company&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Budapest&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HUF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 883.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;India&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis India Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Mumbai&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; INR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 123.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 70.68%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Healthcare Private Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Mumbai&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; INR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 60.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Private Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Mumbai&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; INR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Indonesia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;PT. Novartis Indonesia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Jakarta&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; IDR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ireland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Ireland Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dublin&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Integrated Services Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ringaskiddy, County Cork&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Ringaskiddy Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ringaskiddy, County Cork&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Gene Therapies EU Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dublin&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Israel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Israel Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tel Aviv&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ILS&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Italy&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Farma S.p.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Origgio&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Advanced Accelerator Applications (Italy) S.r.l.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Pozzilli&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 119&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz S.p.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Origgio&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Japan&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma K.K.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tokyo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ciba-Geigy Japan Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tokyo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz K.K.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tokyo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Aspen Japan K.K.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tokyo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Latvia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Baltics SIA&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Riga&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Investments S.&amp;#xe0; r.l.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Luxembourg City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Finance S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Luxembourg City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Malaysia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Corporation (Malaysia) Sdn. Bhd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Kuala Lumpur&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MYR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.3&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Mexico&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Farmac&amp;#xe9;utica, S.A. de C.V.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Mexico City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MXN&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 205.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz, S.A. de C.V.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Mexico City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MXN&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 468.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Morocco&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Maroc SA&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Casablanca&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MAD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 80.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Netherlands&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Netherlands B.V.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amsterdam&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma B.V.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amsterdam&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;IDB Holland BV&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Baarle-Nassau&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz B.V.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Almere&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 907&amp;nbsp;560&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;New Zealand&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis New Zealand Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Auckland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; NZD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 820&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;As at December 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share &lt;br&gt;&lt;/br&gt; capital &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br&gt;&lt;/br&gt; interest &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Norway&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Norge AS&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Oslo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; NOK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Pakistan&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma (Pakistan) Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Karachi&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PKR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.99%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Panama&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma (Logistics), Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Panama City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Peru&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Biosciences Per&amp;#xfa; S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lima&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PEN&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Philippines&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Healthcare Philippines, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Makati City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PHP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 298.8&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Philippines Corporation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Makati City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PHP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Poland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Poland Sp. z o.o.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Warsaw&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PLN&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 44.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Polska Sp. z o.o.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Warsaw&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PLN&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lek S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Strykow&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PLN&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Portugal&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Portugal, S.G.P.S., Lda.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Porto Salvo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 500&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Farma - Produtos Farmac&amp;#xea;uticos, S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Porto Salvo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Farmac&amp;#xea;utica, Lda.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Porto Salvo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 499&amp;nbsp;900&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Romania&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Services Romania S.R.L.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bucharest&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RON&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz S.R.L.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Targu-Mures&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RON&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 105.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Russian Federation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma LLC&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Moscow&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RUB&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Neva LLC&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;St. Petersburg&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RUB&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 500.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;ZAO Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Moscow&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RUB&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 57.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Saudi Arabia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Saudi Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Riyadh&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SAR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Singapore&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis (Singapore) Pte Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Singapore&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SGD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Singapore Pharmaceutical Manufacturing Pte Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Singapore&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SGD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 45.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Asia Pacific Pharmaceuticals Pte Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Singapore&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SGD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 39.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Slovakia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Slovakia s.r.o.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bratislava&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Slovenia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lek Pharmaceuticals d.d.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ljubljana&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 48.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Pharmaceuticals d.d.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ljubljana&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;South Africa&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis South Africa (Pty) Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Midrand&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ZAR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 86.3&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz South Africa (Pty) Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Kempton Park&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ZAR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;South Korea&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Korea Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Seoul&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; KRW&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 98.55%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Spain&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Farmac&amp;#xe9;utica, S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Barcelona&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 63.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Advanced Accelerator Applications Iberica, S.L.U.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Barcelona&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 22.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Catalana de Dispensacion sau (Cadisa)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Esplugues de Llobregat&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 450&amp;nbsp;750&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Farmac&amp;#xe9;utica S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Madrid&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 270&amp;nbsp;450&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Industrial Products S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Les Franqueses del Vall&amp;#xe9;s / Barcelona&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9.3&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Alcon Cusi, S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;El Masnou / Barcelona&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10.1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Abadia Retuerta S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sard&amp;#xf3;n de Duero / Valladolid&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Sweden&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Sverige AB&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Stockholm&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SEK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis International AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Holding AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis International Pharmaceutical Investment AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Bioventures AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Forschungsstiftung&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Stiftung f&amp;#xfc;r Kaderausbildung&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Mitarbeiterbeteiligungsstiftung&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Stiftung f&amp;#xfc;r Mensch und Umwelt&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Stiftung der Novartis AG f&amp;#xfc;r Erziehung, Ausbildung und Bildung&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Overseas Investments AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japat AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 350.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Services AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Schweizerhalle AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Muttenz&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18.9&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Stein AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Stein&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 251&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Schweiz AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Risch&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Ophthalmics AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fribourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Advanced Accelerator Applications International SA&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Geneva&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9.3&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Pharmaceuticals AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Risch&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Roche Holding AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 160.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 33%/6% &lt;sup style="white-space: nowrap"&gt; 2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;As at December 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share &lt;br&gt;&lt;/br&gt; capital &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br&gt;&lt;/br&gt; interest &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Taiwan&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis (Taiwan) Co., Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taipei&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TWD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 170.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Thailand&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis (Thailand) Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bangkok&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; THB&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 302.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Turkey&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Saglik, Gida ve Tarim &amp;#xdc;r&amp;#xfc;nleri Sanayi ve Ticaret A.S.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Istanbul&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 98.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Farmanova Saglik Hizmetleri Ltd. Sti.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Istanbul&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Ila&amp;#xe7; Sanayi ve Ticaret A.S.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Istanbul&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 265.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.99%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Grup Saglik &amp;#xdc;r&amp;#xfc;nleri Ila&amp;#xe7;lari Sanayi ve Ticaret A.S.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Gebze - Kocaeli&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ukraine&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Ukraine LLC&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Kyiv&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; UAH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;United Arab Emirates&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Middle East FZE&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dubai&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AED&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;United Kingdom&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis UK Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;London&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharmaceuticals UK Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;London&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Grimsby Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;London&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 250.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Advanced Accelerator Applications (UK &amp;amp; Ireland)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;London&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Neutec Pharma Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;London&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ziarco Group Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;London&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;904&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Frimley / Camberley&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Coalesce Product Development Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cambridge, Cambs&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;United States of America&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Corporation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 72.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Finance Corporation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Capital Corporation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Services, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis US Foundation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharmaceuticals Corporation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 650&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Advanced Accelerator Applications USA, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Millburn, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Gene Therapies, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bannockburn, IL&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Technology LLC&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cambridge, MA&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Optogenetics Research, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;CoStim Pharmaceuticals Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cambridge, MA&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Endocyte, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Navigate BioPharma Services, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Carlsbad, CA&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;The Medicines Company&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Princeton, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amblyotech Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Oriel Therapeutics, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Durham, NC&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fougera Pharmaceuticals Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Melville, NY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Eon Labs, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Princeton, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Vaccines and Diagnostics, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Venezuela&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis de Venezuela, S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Caracas&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; VES&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Vietnam&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Vietnam Company Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ho Chi Minh City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; VND&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 70&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;In addition, the Group is represented by subsidiaries and associated companies with total assets or net sales to third parties below USD 25 million in the following countries: Bosnia and Herzegovina, Bulgaria, Dominican Republic, Guatemala, Kenya, Kuwait, North Macedonia, Nigeria, Puerto Rico and Uruguay &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Share capital may not reflect the taxable share capital and does not include any paid-in surplus. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Approximately 33.3% of voting shares; approximately 6.2% of total net income and equity attributable to Novartis. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Significant subsidiary under SEC Regulation S-X Rule 1-02(w) &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; Fully consolidated Foundation &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;m = million; bn = billion&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory>
  <nvs:PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock contextRef="AR_D-CurrentYear">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;As at December 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share &lt;br&gt;&lt;/br&gt; capital &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br&gt;&lt;/br&gt; interest &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Algeria&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Soci&amp;#xe9;t&amp;#xe9; par actions SANDOZ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Algiers&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; DZD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 650.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Argentina&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Argentina S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Buenos Aires&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ARS&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 906.1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Australia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Australia Pty Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Macquarie Park, NSW&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AUD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharmaceuticals Australia Pty Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Macquarie Park, NSW&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AUD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.8&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Pty Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Macquarie Park, NSW&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AUD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Austria&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Austria GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vienna&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vienna&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Kundl&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;EBEWE Pharma Ges.m.b.H Nfg. KG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Unterach am Attersee&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Bangladesh&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis (Bangladesh) Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gazipur&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BDT&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 162.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 60%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Belgium&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma NV&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vilvoorde&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz NV&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vilvoorde&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Alcon - Couvreur NV&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Puurs&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 110.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Bermuda&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Investment Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Hamilton&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Securities Investment Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Hamilton&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Finance Services Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Hamilton&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Triangle International Reinsurance Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Hamilton&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trinity River Insurance Co Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Hamilton&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 370&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Brazil&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Bioci&amp;#xea;ncias S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;S&amp;#xe3;o Paulo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRL&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 265.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz do Brasil Ind&amp;#xfa;stria Farmac&amp;#xea;utica Ltda.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Camb&amp;#xe9;, PR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRL&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 190.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Canada&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharmaceuticals Canada Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dorval, Quebec&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CAD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Canada Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Boucherville, Quebec&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CAD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 80.8&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Manufacturing Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Boucherville, Quebec&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CAD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Chile&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Chile S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Santiago de Chile&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CLP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;China&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Beijing Novartis Pharma Co., Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Beijing&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharmaceuticals (HK) Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Hong Kong&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HKD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 200&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;China Novartis Institutes for BioMedical Research Co., Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Shanghai&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 320.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Suzhou Novartis Technical Development Co., Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Changshu&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shanghai Novartis Trading Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shanghai&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz (China) Pharmaceutical Co., Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Zhongshan&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 57.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Colombia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis de Colombia S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Santaf&amp;#xe9; de Bogot&amp;#xe1;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; COP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.9&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Croatia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz d.o.o. farmaceutska industrija&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Zagreb&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HRK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Czech Republic&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis s.r.o.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prague&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CZK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 51.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz s.r.o.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prague&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CZK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 44.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Denmark&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Healthcare A/S&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Copenhagen&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; DKK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz A/S&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Copenhagen&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; DKK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 12.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ecuador&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Ecuador S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Quito&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Egypt&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma S.A.E.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cairo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EGP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 193.8&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.77%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Egypt Pharma S.A.E.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;New Cairo City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EGP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 250&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Finland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Finland Oy&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Espoo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 459&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;As at December 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share &lt;br&gt;&lt;/br&gt; capital &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br&gt;&lt;/br&gt; interest &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;France&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Groupe France S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rueil-Malmaison&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 903.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma S.A.S.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rueil-Malmaison&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 43.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Advanced Accelerator Applications S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Saint-Genis-Pouilly&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 76&amp;nbsp;734&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;CELLforCURE&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Les Ulis&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz S.A.S.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Levallois-Perret&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Germany&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Deutschland GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Nuremberg&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 155.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Business Services GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Wehr&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Nuremberg&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Produktions GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Wehr&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz International GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Holzkirchen&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;1 A Pharma GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Oberhaching&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;HEXAL AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Holzkirchen&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 93.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Salutas Pharma GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Barleben&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 42.1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Aeropharm GmbH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rudolstadt&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 26&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Greece&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis (Hellas) S.A.C.I.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Metamorphosis / Athens&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 233.9&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Hungary&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Hungary Healthcare Limited Liability Company&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Budapest&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HUF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 545.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Hungary Limited Liability Company&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Budapest&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HUF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 883.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;India&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis India Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Mumbai&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; INR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 123.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 70.68%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Healthcare Private Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Mumbai&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; INR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 60.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Private Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Mumbai&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; INR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 32.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Indonesia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;PT. Novartis Indonesia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Jakarta&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; IDR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ireland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Ireland Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dublin&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Integrated Services Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ringaskiddy, County Cork&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Ringaskiddy Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ringaskiddy, County Cork&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Gene Therapies EU Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dublin&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Israel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Israel Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tel Aviv&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ILS&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Italy&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Farma S.p.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Origgio&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Advanced Accelerator Applications (Italy) S.r.l.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Pozzilli&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 119&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz S.p.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Origgio&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Japan&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma K.K.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tokyo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ciba-Geigy Japan Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tokyo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz K.K.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tokyo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Aspen Japan K.K.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tokyo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Latvia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Baltics SIA&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Riga&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Luxembourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Investments S.&amp;#xe0; r.l.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Luxembourg City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Finance S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Luxembourg City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Malaysia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Corporation (Malaysia) Sdn. Bhd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Kuala Lumpur&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MYR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.3&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Mexico&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Farmac&amp;#xe9;utica, S.A. de C.V.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Mexico City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MXN&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 205.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz, S.A. de C.V.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Mexico City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MXN&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 468.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Morocco&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Maroc SA&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Casablanca&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MAD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 80.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Netherlands&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Netherlands B.V.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amsterdam&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma B.V.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amsterdam&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 4.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;IDB Holland BV&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Baarle-Nassau&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz B.V.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Almere&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 907&amp;nbsp;560&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;New Zealand&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis New Zealand Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Auckland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; NZD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 820&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;As at December 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share &lt;br&gt;&lt;/br&gt; capital &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br&gt;&lt;/br&gt; interest &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Norway&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Norge AS&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Oslo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; NOK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Pakistan&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma (Pakistan) Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Karachi&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PKR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.99%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Panama&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma (Logistics), Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Panama City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Peru&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Biosciences Per&amp;#xfa; S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lima&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PEN&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Philippines&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Healthcare Philippines, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Makati City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PHP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 298.8&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Philippines Corporation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Makati City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PHP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Poland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Poland Sp. z o.o.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Warsaw&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PLN&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 44.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Polska Sp. z o.o.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Warsaw&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PLN&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lek S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Strykow&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PLN&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 11.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Portugal&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Portugal, S.G.P.S., Lda.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Porto Salvo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 500&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Farma - Produtos Farmac&amp;#xea;uticos, S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Porto Salvo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Farmac&amp;#xea;utica, Lda.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Porto Salvo&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 499&amp;nbsp;900&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Romania&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Services Romania S.R.L.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bucharest&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RON&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz S.R.L.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Targu-Mures&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RON&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 105.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Russian Federation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma LLC&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Moscow&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RUB&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Neva LLC&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;St. Petersburg&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RUB&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 500.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;ZAO Sandoz&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Moscow&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RUB&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 57.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Saudi Arabia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Saudi Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Riyadh&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SAR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 30.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Singapore&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis (Singapore) Pte Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Singapore&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SGD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Singapore Pharmaceutical Manufacturing Pte Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Singapore&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SGD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 45.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Asia Pacific Pharmaceuticals Pte Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Singapore&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SGD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 39.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Slovakia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Slovakia s.r.o.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bratislava&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Slovenia&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lek Pharmaceuticals d.d.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ljubljana&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 48.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Pharmaceuticals d.d.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ljubljana&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;South Africa&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis South Africa (Pty) Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Midrand&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ZAR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 86.3&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz South Africa (Pty) Ltd&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Kempton Park&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ZAR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;South Korea&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Korea Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Seoul&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; KRW&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 98.55%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Spain&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Farmac&amp;#xe9;utica, S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Barcelona&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 63.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Advanced Accelerator Applications Iberica, S.L.U.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Barcelona&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 22.6&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Catalana de Dispensacion sau (Cadisa)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Esplugues de Llobregat&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 450&amp;nbsp;750&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Farmac&amp;#xe9;utica S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Madrid&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 270&amp;nbsp;450&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Industrial Products S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Les Franqueses del Vall&amp;#xe9;s / Barcelona&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9.3&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Alcon Cusi, S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;El Masnou / Barcelona&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10.1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Abadia Retuerta S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sard&amp;#xf3;n de Duero / Valladolid&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Sweden&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Sverige AB&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Stockholm&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SEK&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Switzerland&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis International AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Holding AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis International Pharmaceutical Investment AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Bioventures AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Forschungsstiftung&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Stiftung f&amp;#xfc;r Kaderausbildung&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Mitarbeiterbeteiligungsstiftung&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Stiftung f&amp;#xfc;r Mensch und Umwelt&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Stiftung der Novartis AG f&amp;#xfc;r Erziehung, Ausbildung und Bildung&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Overseas Investments AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japat AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 350.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Services AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Schweizerhalle AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Muttenz&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18.9&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Stein AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Stein&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 251&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharma Schweiz AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Risch&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Ophthalmics AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fribourg&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Advanced Accelerator Applications International SA&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Geneva&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 9.3&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Pharmaceuticals AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Risch&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Roche Holding AG&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Basel&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 160.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 33%/6% &lt;sup style="white-space: nowrap"&gt; 2&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt;As at December 31, 2020 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share &lt;br&gt;&lt;/br&gt; capital &lt;sup style="white-space: nowrap"&gt; 1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br&gt;&lt;/br&gt; interest &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Taiwan&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis (Taiwan) Co., Ltd.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taipei&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TWD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 170.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Thailand&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis (Thailand) Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bangkok&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; THB&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 302.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Turkey&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Saglik, Gida ve Tarim &amp;#xdc;r&amp;#xfc;nleri Sanayi ve Ticaret A.S.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Istanbul&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 98.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Farmanova Saglik Hizmetleri Ltd. Sti.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Istanbul&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Ila&amp;#xe7; Sanayi ve Ticaret A.S.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Istanbul&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 265.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.99%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Grup Saglik &amp;#xdc;r&amp;#xfc;nleri Ila&amp;#xe7;lari Sanayi ve Ticaret A.S.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Gebze - Kocaeli&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ukraine&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Ukraine LLC&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Kyiv&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; UAH&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 8.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;United Arab Emirates&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Middle East FZE&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dubai&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AED&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;United Kingdom&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis UK Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;London&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25.5&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharmaceuticals UK Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;London&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5.4&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Grimsby Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;London&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 250.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Advanced Accelerator Applications (UK &amp;amp; Ireland)&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;London&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Neutec Pharma Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;London&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7.7&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ziarco Group Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;London&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&amp;nbsp;904&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Frimley / Camberley&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 2.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Coalesce Product Development Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cambridge, Cambs&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 6.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 40%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;United States of America&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Corporation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 72.2&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Finance Corporation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Capital Corporation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Services, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis US Foundation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;4&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Pharmaceuticals Corporation&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;3&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 650&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Advanced Accelerator Applications USA, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Millburn, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 99.2%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Gene Therapies, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bannockburn, IL&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Technology LLC&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cambridge, MA&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Optogenetics Research, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;CoStim Pharmaceuticals Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cambridge, MA&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Endocyte, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Navigate BioPharma Services, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Carlsbad, CA&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;The Medicines Company&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Princeton, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25&amp;nbsp;000&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amblyotech Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Oriel Therapeutics, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Durham, NC&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 50.0&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fougera Pharmaceuticals Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Melville, NY&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Eon Labs, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Princeton, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Vaccines and Diagnostics, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;East Hanover, NJ&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Venezuela&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis de Venezuela, S.A.&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Caracas&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; VES&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 14&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Vietnam&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Vietnam Company Limited&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt;&lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Ho Chi Minh City&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; VND&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 70&lt;/div&gt; &lt;/td&gt; &lt;td width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="9%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 100%&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="10" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;In addition, the Group is represented by subsidiaries and associated companies with total assets or net sales to third parties below USD 25 million in the following countries: Bosnia and Herzegovina, Bulgaria, Dominican Republic, Guatemala, Kenya, Kuwait, North Macedonia, Nigeria, Puerto Rico and Uruguay &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Share capital may not reflect the taxable share capital and does not include any paid-in surplus. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;2&amp;nbsp;&lt;/sup&gt; Approximately 33.3% of voting shares; approximately 6.2% of total net income and equity attributable to Novartis. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;3&amp;nbsp;&lt;/sup&gt; Significant subsidiary under SEC Regulation S-X Rule 1-02(w) &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;4&amp;nbsp;&lt;/sup&gt; Fully consolidated Foundation &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="10"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;m = million; bn = billion&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">2020</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">2025</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">2020</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">2027</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">2020</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">2030</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">USD</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">2020</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">2050</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
  <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
  <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">2020</nvs:BorrowingsIssuanceDate>
  <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">2028</ifrs-full:BorrowingsMaturity>
  <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2019BorrowingsByNameAxis_nvs-2020Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
  <nvs:DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock contextRef="AR_D-CurrentYear">&lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Healthcare contributions&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Healthcare contribution levies and fees under governmental programs that require the Group to contribute to a country&amp;#x2019;s healthcare costs, other than programs described in Revenue recognition in this Note 1, are recognized in Other expense in the consolidated income statement. Provisions for healthcare contributions are adjusted to the actual amounts levied. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these healthcare contributions. &lt;/div&gt;</nvs:DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock>
  <nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock contextRef="AR_D-CurrentYear">&lt;div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;13. Financial and other non-current assets&lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Financial assets&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 1&amp;nbsp;577&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;524&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 366&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 233&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial investments&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 1&amp;nbsp;979&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 1&amp;nbsp;790&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term receivables from finance subleases&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 83&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 66&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other long-term receivables&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 125&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 625&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 399&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term loans, advances and security deposits&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 89&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 2&amp;nbsp;901&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 2&amp;nbsp;518&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent considerations. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Other non-current assets&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred compensation plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 471&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 414&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prepaid post-employment benefit plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 202&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 148&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other non-current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 219&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 176&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other non-current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; 892&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 738&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock>
  <nvs:RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">&lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Useful life &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Income statement location &lt;br&gt;&lt;/br&gt; for amortization and &lt;br&gt;&lt;/br&gt; impairment charges &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketing know-how&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold"&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Alcon brand name&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Not amortized, &lt;br&gt;&lt;/br&gt; indefinite useful life &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Other expense" &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;</nvs:RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock>
  <dei:EntityRegistrantName contextRef="AR_D-CurrentYear">NOVARTIS AG</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey contextRef="AR_D-CurrentYear">0001114448</dei:EntityCentralIndexKey>
  <dei:DocumentType contextRef="AR_D-CurrentYear">20-F</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="AR_D-CurrentYear">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:AmendmentFlag contextRef="AR_D-CurrentYear">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="AR_D-CurrentYear">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityWellKnownSeasonedIssuer contextRef="AR_D-CurrentYear">Yes</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityVoluntaryFilers contextRef="AR_D-CurrentYear">No</dei:EntityVoluntaryFilers>
  <dei:EntityCurrentReportingStatus contextRef="AR_D-CurrentYear">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="AR_D-CurrentYear">Large Accelerated Filer</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="AR_D-CurrentYear">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus contextRef="AR_D-CurrentYear">FY</dei:DocumentFiscalPeriodFocus>
  <dei:EntityInteractiveDataCurrent contextRef="AR_D-CurrentYear">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityShellCompany contextRef="AR_D-CurrentYear">false</dei:EntityShellCompany>
  <dei:EntityEmergingGrowthCompany contextRef="AR_D-CurrentYear">false</dei:EntityEmergingGrowthCompany>
  <dei:DocumentAnnualReport contextRef="AR_D-CurrentYear">true</dei:DocumentAnnualReport>
  <dei:DocumentShellCompanyReport contextRef="AR_D-CurrentYear">false</dei:DocumentShellCompanyReport>
  <dei:DocumentTransitionReport contextRef="AR_D-CurrentYear">false</dei:DocumentTransitionReport>
  <dei:IcfrAuditorAttestationFlag contextRef="AR_D-CurrentYear">true</dei:IcfrAuditorAttestationFlag>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Soci&#xE9;t&#xE9; par actions SANDOZ</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Algiers</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Algeria</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Argentina S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Buenos Aires</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Argentina</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Australia Pty Ltd</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Macquarie Park, NSW</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Australia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Macquarie Park, NSW</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Australia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharmaceuticals Australia Pty Ltd</ifrs-full:NameOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Pty Ltd</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Macquarie Park, NSW</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Australia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustriaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Austria GmbH</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustriaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Vienna</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAustriaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Austria</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma GmbH</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Vienna</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Austria</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz GmbH</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Kundl</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozGmbHViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Austria</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">EBEWE Pharma Ges.m.b.H Nfg. KG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Unterach am Attersee</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Austria</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis (Bangladesh) Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Gazipur</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Bangladesh</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma NV</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Vilvoorde</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Belgium</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz NV</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Vilvoorde</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozNVVilvoordeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Belgium</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AlconCouvreurNVPuursMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Alcon - Couvreur NV</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AlconCouvreurNVPuursMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Puurs</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AlconCouvreurNVPuursMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Belgium</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Investment Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Hamilton</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Bermuda</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Securities Investment Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Hamilton</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Bermuda</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Finance Services Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Hamilton</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Bermuda</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Triangle International Reinsurance Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Hamilton</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Bermuda</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Trinity River Insurance Co Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Hamilton</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Bermuda</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Bioci&#xEA;ncias S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">S&#xE3;o Paulo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Brazil</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz do Brasil Ind&#xFA;stria Farmac&#xEA;utica Ltda.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Camb&#xE9;, PR</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Brazil</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharmaceuticals Canada Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Dorval, Quebec</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Canada</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Canada Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Boucherville, Quebec</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Canada</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Chile S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Santiago de Chile</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Chile</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Beijing Novartis Pharma Co., Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Beijing</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharmaceuticals (HK) Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Hong Kong</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Shanghai</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Changshu</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Shanghai Novartis Trading Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Shanghai</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Zhongshan</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis de Colombia S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Santaf&#xE9; de Bogot&#xE1;</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Colombia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz d.o.o. farmaceutska industrija</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Zagreb</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Croatia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis s.r.o.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Prague</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Czech Republic</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz s.r.o.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Prague</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.r.o.PragueMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Czech Republic</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Healthcare A/S</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Copenhagen</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Denmark</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz A/S</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Copenhagen</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozASCopenhagenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Denmark</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Ecuador S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Quito</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ecuador</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma S.A.E.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Cairo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Egypt</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Egypt Pharma S.A.E.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">New Cairo City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Egypt</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinlandOyEspooMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Finland Oy</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinlandOyEspooMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Espoo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinlandOyEspooMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Finland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Groupe France S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Rueil-Malmaison</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma S.A.S.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Rueil-Malmaison</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Advanced Accelerator Applications S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Saint-Genis-Pouilly</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CELLforCURELesUlisMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">CELLforCURE</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CELLforCURELesUlisMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Les Ulis</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CELLforCURELesUlisMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz S.A.S.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Levallois-Perret</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Business Services GmbH</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Wehr</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma GmbH</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Nuremberg</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma Produktions GmbH</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Wehr</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz International GmbH</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Holzkirchen</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4A1APharmaGmbHOberhachingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">1 A Pharma GmbH</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4A1APharmaGmbHOberhachingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Oberhaching</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4A1APharmaGmbHOberhachingMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4HEXALAGHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">HEXAL AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4HEXALAGHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Holzkirchen</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4HEXALAGHolzkirchenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Salutas Pharma GmbH</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Barleben</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AeropharmGmbHRudolstadtMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Aeropharm GmbH</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AeropharmGmbHRudolstadtMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Rudolstadt</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AeropharmGmbHRudolstadtMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis (Hellas) S.A.C.I.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Metamorphosis / Athens</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Greece</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Budapest</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Hungary</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Hungary Limited Liability Company</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Budapest</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Hungary</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis India Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Mumbai</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Healthcare Private Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Mumbai</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Private Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Mumbai</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">PT. Novartis Indonesia</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Jakarta</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Indonesia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIrelandLimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Ireland Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIrelandLimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Dublin</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIrelandLimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ireland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Ringaskiddy Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ringaskiddy, County Cork</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ireland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Farma S.p.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Origgio</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Italy</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Advanced Accelerator Applications (Italy) S.r.l.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Pozzilli</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Italy</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz S.p.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Origgio</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.p.A.OriggioMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Italy</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma K.K.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Tokyo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Japan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ciba-Geigy Japan Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Tokyo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Japan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz K.K.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Tokyo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Japan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBalticsSIARigaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Baltics SIA</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBalticsSIARigaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Riga</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBalticsSIARigaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Latvia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Investments S.&#xE0; r.l.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Luxembourg City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Luxembourg</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Finance S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Luxembourg City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Luxembourg</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Corporation (Malaysia) Sdn. Bhd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Kuala Lumpur</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Malaysia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Farmac&#xE9;utica, S.A. de C.V.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Mexico City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Mexico</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz, S.A. de C.V.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Mexico City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Mexico</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma Maroc SA</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Casablanca</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Morocco</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Netherlands B.V.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Amsterdam</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Netherlands</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma B.V.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Amsterdam</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Netherlands</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4IDBHollandBVBaarleNassauMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">IDB Holland BV</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4IDBHollandBVBaarleNassauMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Baarle-Nassau</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4IDBHollandBVBaarleNassauMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Netherlands</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozB.V.AlmereMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz B.V.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozB.V.AlmereMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Almere</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozB.V.AlmereMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Netherlands</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis New Zealand Ltd</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Auckland</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">New Zealand</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNorgeASOsloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Norge AS</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNorgeASOsloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Oslo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNorgeASOsloMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Norway</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma (Pakistan) Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Karachi</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Pakistan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma (Logistics), Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Panama City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Panama</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiosciencesPeruS.A.LimaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Biosciences Per&#xFA; S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiosciencesPeruS.A.LimaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Lima</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBiosciencesPeruS.A.LimaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Peru</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Poland Sp. z o.o.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Warsaw</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Poland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Polska Sp. z o.o.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Warsaw</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Poland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4LekS.A.StrykowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Lek S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4LekS.A.StrykowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Strykow</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4LekS.A.StrykowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Poland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Portugal, S.G.P.S., Lda.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Porto Salvo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Portugal</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Farma - Produtos Farmac&#xEA;uticos, S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Porto Salvo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Portugal</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Farmac&#xEA;utica, Lda.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Porto Salvo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Portugal</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma Services Romania S.R.L.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Bucharest</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Romania</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.R.L.TarguMuresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz S.R.L.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.R.L.TarguMuresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Targu-Mures</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozS.R.L.TarguMuresMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Romania</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLLCMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma LLC</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLLCMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Moscow</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaLLCMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Russian Federation</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Neva LLC</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">St. Petersburg</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Russian Federation</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ZAOSandozMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">ZAO Sandoz</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ZAOSandozMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Moscow</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ZAOSandozMoscowMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Russian Federation</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Saudi Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Riyadh</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Saudi Arabia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis (Singapore) Pte Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Singapore</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Singapore</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Singapore</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Singapore</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Singapore</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Singapore</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Slovakia s.r.o.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Bratislava</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Slovakia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Lek Pharmaceuticals d.d.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ljubljana</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Slovenia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Pharmaceuticals d.d.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ljubljana</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Slovenia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis South Africa (Pty) Ltd</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Midrand</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">South Africa</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozSouthAfricaPtyLtdKemptonParkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz South Africa (Pty) Ltd</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozSouthAfricaPtyLtdKemptonParkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Kempton Park</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozSouthAfricaPtyLtdKemptonParkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">South Africa</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Korea Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Seoul</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">South Korea</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Farmac&#xE9;utica, S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Barcelona</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Farmac&#xE9;utica S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Madrid</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozIndustrialProductsS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Les Franqueses del Vall&#xE9;s / Barcelona</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozIndustrialProductsS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Abadia Retuerta S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sard&#xF3;n de Duero / Valladolid</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSverigeABStockholmMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Sverige AB</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSverigeABStockholmMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Stockholm</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSverigeABStockholmMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sweden</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis International AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Holding AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis International Pharmaceutical Investment AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBioventuresAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Bioventures AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBioventuresAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisBioventuresAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisForschungsstiftungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Forschungsstiftung</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisForschungsstiftungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisForschungsstiftungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Stiftung f&#xFC;r Kaderausbildung</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Mitarbeiterbeteiligungsstiftung</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Stiftung f&#xFC;r Mensch und Umwelt</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Overseas Investments AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4JapatAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Japat AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4JapatAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4JapatAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma Services AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma Schweizerhalle AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Muttenz</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma Stein AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Stein</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharma Schweiz AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Risch</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOphthalmicsAGFribourgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Ophthalmics AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOphthalmicsAGFribourgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Fribourg</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOphthalmicsAGFribourgMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Advanced Accelerator Applications International SA</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Geneva</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Pharmaceuticals AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Risch</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4RocheHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Roche Holding AG</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4RocheHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4RocheHoldingAGBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis (Taiwan) Co., Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Taipei</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Taiwan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisThailandLimitedBangkokMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis (Thailand) Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisThailandLimitedBangkokMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Bangkok</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisThailandLimitedBangkokMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Thailand</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Istanbul</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Turkey</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Farmanova Saglik Hizmetleri Ltd. Sti.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Istanbul</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Turkey</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Ila&#xE7; Sanayi ve Ticaret A.S.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Istanbul</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Turkey</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Gebze - Kocaeli</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Turkey</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozUkraineLLCKievMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Ukraine LLC</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozUkraineLLCKievMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Kyiv</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozUkraineLLCKievMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ukraine</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Middle East FZE</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Dubai</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">United Arab Emirates</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis UK Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">London</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharmaceuticals UK Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">London</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Grimsby Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">London</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ZiarcoGroupLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ziarco Group Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ZiarcoGroupLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">London</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ZiarcoGroupLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Frimley / Camberley</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Corporation</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Finance Corporation</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Capital Corporation</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Services, Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis US Foundation</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Pharmaceuticals Corporation</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Advanced Accelerator Applications USA, Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Millburn, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AveXisInc.BannockburnILMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Gene Therapies, Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AveXisInc.BannockburnILMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Bannockburn, IL</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AveXisInc.BannockburnILMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisTechnologyLLCInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Technology LLC</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisTechnologyLLCInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisTechnologyLLCInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Cambridge, MA</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CoStimPharmaceuticalsInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">CoStim Pharmaceuticals Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CoStimPharmaceuticalsInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Cambridge, MA</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CoStimPharmaceuticalsInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Endocyte, Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Navigate BioPharma Services, Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Carlsbad, CA</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Princeton, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Oriel Therapeutics, Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Durham, NC</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Fougera Pharmaceuticals Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Melville, NY</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EonLabsInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Eon Labs, Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EonLabsInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Princeton, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4EonLabsInc.PrincetonNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Vaccines and Diagnostics, Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis de Venezuela, S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Caracas</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Venezuela</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozManufacturingInc.Member_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Manufacturing Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozManufacturingInc.Member_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Boucherville, Quebec</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozManufacturingInc.Member_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Canada</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AlconCusiS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Alcon Cusi, S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AlconCusiS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">El Masnou / Barcelona</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AlconCusiS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">China Novartis Institutes for BioMedical Research Co., Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Suzhou Novartis Technical Development Co., Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz (China) Pharmaceutical Co., Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Deutschland GmbH</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Nuremberg</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Hungary Healthcare Limited Liability Company</ifrs-full:NameOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Integrated Services Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ringaskiddy, County Cork</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ireland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Gene Therapies EU Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Dublin</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ireland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Israel Ltd.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Tel Aviv</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Israel</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AspenJapanK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Aspen Japan K.K.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AspenJapanK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Tokyo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AspenJapanK.K.TokyoMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Japan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Healthcare Philippines, Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Makati City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Philippines</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Philippines Corporation</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Makati City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Philippines</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Singapore Pharmaceutical Manufacturing Pte Ltd</ifrs-full:NameOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Asia Pacific Pharmaceuticals Pte Ltd</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Barcelona</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Advanced Accelerator Applications Iberica, S.L.U.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Esplugues de Llobregat</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Catalana de Dispensacion sau (Cadisa)</ifrs-full:NameOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozIndustrialProductsS.A.BarcelonaMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Industrial Products S.A.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Stiftung der Novartis AG f&#xFC;r Erziehung, Ausbildung und Bildung</ifrs-full:NameOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Saglik, Gida ve Tarim &#xDC;r&#xFC;nleri Sanayi ve Ticaret A.S.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Sandoz Grup Saglik &#xDC;r&#xFC;nleri Ila&#xE7;lari Sanayi ve Ticaret A.S.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Advanced Accelerator Applications (UK &amp; Ireland)</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">London</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NeutecPharmaLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Neutec Pharma Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NeutecPharmaLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">London</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NeutecPharmaLimitedLondonMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CoalesceProductDevelopmentLimitedCambridgeCambsMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Coalesce Product Development Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CoalesceProductDevelopmentLimitedCambridgeCambsMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Cambridge, Cambs</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4CoalesceProductDevelopmentLimitedCambridgeCambsMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Institutes for BioMedical Research, Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOptogeneticsResearchInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Optogenetics Research, Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOptogeneticsResearchInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisOptogeneticsResearchInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">The Medicines Company</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4TheMedicinesCompanyMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AmblyotechInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Amblyotech Inc.</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AmblyotechInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4AmblyotechInc.EastHanoverNJMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Novartis Vietnam Company Limited</ifrs-full:NameOfSubsidiary>
  <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Ho Chi Minh City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
  <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2020LegalEntityAxis_nvs-2020Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2019SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2019SubsidiariesMember">Vietnam</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
  <nvs:DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">&lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Intangible assets available for use&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In addition to currently marketed products, technologies and other intangible assets (including computer software), discontinued operations intangible assets available for use also included marketing know-how and the Alcon brand name. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Marketing know-how represents the value attributable to the expertise acquired for marketing and distributing Alcon surgical products. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Alcon brand name was shown separately, as it was the only Novartis intangible asset that was available for use with an indefinite useful life. Novartis considers that it was appropriate that the Alcon brand name had an indefinite life since Alcon-branded products had a history of strong revenue and cash flow performance, and Novartis had the intent and ability to support the brand with spending to maintain its value for the foreseeable future. The Alcon brand name was not amortized as it had an indefinite useful life, but was evaluated for potential impairment annually. &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the respective useful lives for available-for-use intangible assets and the location in the consolidated income statement in which the respective amortization and any potential impairment charge were recognized: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; Useful life &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Income statement location &lt;br&gt;&lt;/br&gt; for amortization and &lt;br&gt;&lt;/br&gt; impairment charges &lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketing know-how&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 25 years&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold"&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Alcon brand name&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Not amortized, &lt;br&gt;&lt;/br&gt; indefinite useful life &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Other expense" &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the activities and more specifically on appropriate royalty rate for the Alcon brand name. &lt;/div&gt;</nvs:DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock>
  <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="AR_D-CurrentYear_ifrsfull-2019ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2019DiscontinuedOperationsMember">&lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Revenue recognition&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In the Alcon Division, which is reported as discontinued operations, surgical equipment may have been sold together with other products and services under a single contract. Revenues were recognized upon satisfaction of each of the performance obligations in the contract and the consideration was allocated based on the standalone selling price of each performance obligation. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For surgical equipment, in addition to cash and installment sales, revenue was recognized under finance and operating lease arrangements. Arrangements in which substantially all the risks and rewards incidental to ownership transfers to the customer were treated as finance lease arrangements. Revenue from finance lease arrangements was recognized at amounts equal to the fair value of the equipment, which approximated the present value of the minimum lease payments under the arrangements. As interest rates embedded in lease arrangements were approximately market rates, revenue under finance lease arrangements was comparable to revenue for outright sales. Finance income for arrangements longer than 12 months was deferred and subsequently recognized based on a pattern that approximated to the use of the effective interest method and was recorded in &amp;#x201c;Other income.&amp;#x201d; Operating lease revenue for equipment rentals was recognized on a straight-line basis over the lease term. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Net income &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Included in net income from discontinued operations are:&lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;42&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;235&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation of right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;174&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;052&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charges on intangible assets &lt;sup style="white-space: nowrap"&gt;&amp;nbsp;1&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;391&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to restructuring provisions&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;13&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation of Novartis equity plans&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;9&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;93&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="6"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;1&amp;nbsp;&lt;/sup&gt; 2018 includes an impairment of USD 337 million related to the write-down of the CyPass currently marketed product, which was acquired with the Alcon Division 2016 acquisition of Transcend Medical, Inc. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Balance sheet &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following were in the balance sheet from discontinued operations for the period from January 1, 2019, to the date of reclassification: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 113&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 3&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to goodwill and intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 36&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px" colspan="4"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td colspan="4"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt; &lt;sup&gt;&amp;nbsp;&lt;/sup&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Cash flows used in investing activities from discontinued operations&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Cash flows used in investing activities from discontinued operations include the investing activities of the Alcon business and cash outflows for transaction-related expenditures attributable to the series of portfolio transformation transactions completed in 2015. &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments attributable &lt;br&gt;&lt;/br&gt;to the spin-off of the &lt;br&gt;&lt;/br&gt;Alcon business &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;39 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &amp;#x2013;&amp;#x2005;29 &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="11%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Divested cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;628&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows attributable to the spin-off of the Alcon business&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;39&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;657&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other cash flows used in investing activities, net&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;88&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;502&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;001&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net cash flows used in investing activities from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt; &amp;#x2013;&amp;#x2005;127&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;159&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;001&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="8" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Cash flows from financing activities from discontinued operations&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2020, the net cash outflows used in financing activities from discontinued operations of USD 50 million was for transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2019, the net cash inflows from financing activities from discontinued operations of USD 3.3 billion (2018: USD 167 million net cash outflows) included mainly USD 3.5 billion (2018: nil) cash inflows from Alcon borrowings in connection with the distribution (spin-off) of the Alcon business to Novartis AG shareholders, partly offset by USD 0.2 billion (2018: USD 0.1 billion) transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders (see Notes 1 and 2). &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Leases&lt;/font&gt; &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The lease liabilities recorded in discontinued operations on January 1, 2019, the date of implementation of IFRS 16 Leases (see Note 1), were USD 286 million, and the right-of-use assets were USD 276 million, including USD 89 million and USD 75 million, respectively, for the previously reported finance lease obligations. For discontinued operations, there were no impairments or significant contract terminations of right-of-use assets for the period from January 1, 2019, to February 28, 2019, the date of shareholder approval for the Alcon spin-off. &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Net assets derecognized &lt;/font&gt; &lt;/div&gt; &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table presents the Alcon business net assets at the date of spin-off at April 8, 2019: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="20%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 2&amp;nbsp;858&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Right-of-use assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 8&amp;nbsp;906&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Intangible assets other than goodwill&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 11&amp;nbsp;121&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 732&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial and other non-current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 526&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventories&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;469&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables and other current assets&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 1&amp;nbsp;787&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 628&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;1&amp;nbsp;713&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current lease liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;269&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current financial debts&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;3&amp;nbsp;538&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 1px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables, provisions and other liabilities&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; &amp;#x2013;&amp;#x2005;2&amp;nbsp;751&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets derecognized&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt; 20&amp;nbsp;025&lt;/div&gt; &lt;/td&gt; &lt;td align="right"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="4" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td height="10px"&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Defined contribution plans&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In many subsidiaries, associates are covered by defined contribution plans. Contributions charged to the consolidated income statement for the defined contribution plans were: &lt;/div&gt; &lt;div style="padding-top:10px; padding-bottom:30px;"&gt; &lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"&gt; &lt;tr valign="bottom"&gt; &lt;td height="12"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;td align="right"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 2px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" bgcolor="#ffffff"&gt; &lt;td height="16"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions for defined contribution plans discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 33&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;td align="right" width="14%"&gt; &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; 104&lt;/div&gt; &lt;/td&gt; &lt;td align="right" width="1%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td colspan="6" style="border-bottom: solid #000000 3px;"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" padding-bottom: 10px;"&gt; &lt;font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Significant transactions&lt;/font&gt; &lt;/div&gt; &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In March 2019, Alcon acquired PowerVision, Inc. (PowerVision), a privately held, US-based medical device development company focused on developing accommodative, implantable intraocular lenses. The fair value of the total purchase consideration was USD 424 million. The amount consisted of an initial cash payment of USD 289 million and the fair value of the contingent consideration of USD 135 million, due to PowerVision shareholders, which they are eligible to receive upon the achievement of specified regulatory and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 418 million, consisting of intangible assets of USD 505 million, net deferred tax liabilities of USD 93 million, other net assets of USD 6 million, and goodwill of USD 6 million. The 2019 results of operations since the date of the acquisition were not material. &lt;/div&gt; &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For additional information related to the distribution (spin-off) of the Alcon business to Novartis AG shareholders, effected through a dividend in kind distribution that was completed on April 8, 2019, refer to Note 1 and Note 2. &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>nvs-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
   <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
   <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
   <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
   <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
   <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
   <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
      <link:label id="id_33621d8b" xlink:label="lbl_CHF_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland, Francs</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CHF" xlink:label="lbl_CHF" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CHF" xlink:to="lbl_CHF_labels" xlink:type="arc"/>
      <link:label id="id_2109f0bd" xlink:label="lbl_label554299581" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland</link:label>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CH" xlink:label="lbl_CH" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CH" xlink:to="lbl_label554299581" xlink:type="arc"/>
      <link:label id="id_30237143" xlink:label="lbl_label807629123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="lbl_DocumentType" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentType" xlink:to="lbl_label807629123" xlink:type="arc"/>
      <link:label id="id_bb438c4" xlink:label="lbl_NoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="lbl_NoncurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_NoncurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_7fdd0dd5" xlink:label="lbl_NoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current assets</link:label>
      <link:label id="id_18b26df5" xlink:label="lbl_CurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="lbl_CurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAssets" xlink:to="lbl_CurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_2d4bde06" xlink:label="lbl_CurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
      <link:label id="id_e8d83cc" xlink:label="lbl_Assets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Assets" xlink:label="lbl_Assets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Assets" xlink:to="lbl_Assets_labels" xlink:type="arc"/>
      <link:label id="id_1c011115" xlink:label="lbl_Assets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
      <link:label id="id_17d32c44" xlink:label="lbl_TreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasuryShares" xlink:to="lbl_TreasuryShares_labels" xlink:type="arc"/>
      <link:label id="id_210754dc" xlink:label="lbl_EquityAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity attributable to owners of parent</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="lbl_EquityAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityAttributableToOwnersOfParent" xlink:to="lbl_EquityAttributableToOwnersOfParent_labels" xlink:type="arc"/>
      <link:label id="id_5c95b1b" xlink:label="lbl_EquityAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Equity attributable to Novartis AG shareholders</link:label>
      <link:label id="id_6ada4c7f" xlink:label="lbl_Equity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Equity" xlink:to="lbl_Equity_labels" xlink:type="arc"/>
      <link:label id="id_217508c4" xlink:label="lbl_Equity_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
      <link:label id="id_202888aa" xlink:label="lbl_NoncurrentProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current provisions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentProvisions" xlink:label="lbl_NoncurrentProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentProvisions" xlink:to="lbl_NoncurrentProvisions_labels" xlink:type="arc"/>
      <link:label id="id_30c761c7" xlink:label="lbl_NoncurrentProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current provisions</link:label>
      <link:label id="id_70a3cca2" xlink:label="lbl_NoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="lbl_NoncurrentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLiabilities" xlink:to="lbl_NoncurrentLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_46c178af" xlink:label="lbl_NoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
      <link:label id="id_37698457" xlink:label="lbl_CurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="lbl_CurrentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLiabilities" xlink:to="lbl_CurrentLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_422c0184" xlink:label="lbl_CurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
      <link:label id="id_6a28968d" xlink:label="lbl_Liabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Liabilities" xlink:label="lbl_Liabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Liabilities" xlink:to="lbl_Liabilities_labels" xlink:type="arc"/>
      <link:label id="id_35c7371a" xlink:label="lbl_Liabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
      <link:label id="id_6baaabed" xlink:label="lbl_EquityAndLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="lbl_EquityAndLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityAndLiabilities" xlink:to="lbl_EquityAndLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_3794ff9e" xlink:label="lbl_EquityAndLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity and liabilities</link:label>
      <link:label id="id_5ecd50fe" xlink:label="lbl_PropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipment" xlink:to="lbl_PropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_5f7f6e84" xlink:label="lbl_label1602186884" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Goodwill" xlink:label="lbl_Goodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Goodwill" xlink:to="lbl_label1602186884" xlink:type="arc"/>
      <link:label id="id_78569540" xlink:label="lbl_label2018940224" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IntangibleAssetsOtherThanGoodwill" xlink:to="lbl_label2018940224" xlink:type="arc"/>
      <link:label id="id_600994ad" xlink:label="lbl_DeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxAssets" xlink:to="lbl_DeferredTaxAssets_labels" xlink:type="arc"/>
      <link:label id="id_76aa2451" xlink:label="lbl_OtherNoncurrentNonfinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current non-financial assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:label="lbl_OtherNoncurrentNonfinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentNonfinancialAssets" xlink:to="lbl_OtherNoncurrentNonfinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_2dffac3d" xlink:label="lbl_Inventories_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current inventories</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Inventories" xlink:to="lbl_Inventories_labels" xlink:type="arc"/>
      <link:label id="id_3b71d990" xlink:label="lbl_OtherCurrentFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current financial assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="lbl_OtherCurrentFinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentFinancialAssets" xlink:to="lbl_OtherCurrentFinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_47798f64" xlink:label="lbl_CashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalents" xlink:to="lbl_CashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_c46389d" xlink:label="lbl_IssuedCapital_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IssuedCapital" xlink:to="lbl_IssuedCapital_labels" xlink:type="arc"/>
      <link:label id="id_7fe108cb" xlink:label="lbl_OtherReserves_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other reserves</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherReserves" xlink:label="lbl_OtherReserves" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherReserves" xlink:to="lbl_OtherReserves_labels" xlink:type="arc"/>
      <link:label id="id_62ed78ce" xlink:label="lbl_label1659730126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncontrollingInterests" xlink:label="lbl_NoncontrollingInterests" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncontrollingInterests" xlink:to="lbl_label1659730126" xlink:type="arc"/>
      <link:label id="id_40cd0a97" xlink:label="lbl_label1087179415" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other non-current payables</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentPayables" xlink:label="lbl_NoncurrentPayables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentPayables" xlink:to="lbl_label1087179415" xlink:type="arc"/>
      <link:label id="id_314a7125" xlink:label="lbl_DeferredTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxLiabilities" xlink:to="lbl_DeferredTaxLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_15149ace" xlink:label="lbl_OtherNoncurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current financial liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentFinancialLiabilities" xlink:to="lbl_OtherNoncurrentFinancialLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_48a2d168" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current non-financial liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_65fe4156" xlink:label="lbl_OtherCurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current financial liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentFinancialLiabilities" xlink:to="lbl_OtherCurrentFinancialLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_4f6a78d8" xlink:label="lbl_CurrentTaxLiabilitiesCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax liabilities, current</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTaxLiabilitiesCurrent" xlink:to="lbl_CurrentTaxLiabilitiesCurrent_labels" xlink:type="arc"/>
      <link:label id="id_63598632" xlink:label="lbl_OtherCurrentNonfinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current non-financial liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_OtherCurrentNonfinancialLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_654cedce" xlink:label="lbl_Inventories_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
      <link:label id="id_288deb92" xlink:label="lbl_IssuedCapital_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
      <link:label id="id_b623bea" xlink:label="lbl_OtherReserves_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserves</link:label>
      <link:label id="id_3c0375d2" xlink:label="lbl_OtherNoncurrentNonfinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
      <link:label id="id_5eaf97e4" xlink:label="lbl_NoncurrentProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions and other non-current liabilities</link:label>
      <link:label id="id_48a98684" xlink:label="lbl_OtherNoncurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial debts</link:label>
      <link:label id="id_126c9e67" xlink:label="lbl_OtherCurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial debts and derivative financial instruments</link:label>
      <link:label id="id_4f2ac258" xlink:label="lbl_CurrentTaxLiabilitiesCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current income tax liabilities</link:label>
      <link:label id="id_1abd43d3" xlink:label="lbl_label448611283" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DocumentAndEntityInformationAbstract" xlink:label="lbl_DocumentAndEntityInformationAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentAndEntityInformationAbstract" xlink:to="lbl_label448611283" xlink:type="arc"/>
      <link:label id="id_3da2017e" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments accounted for using equity method</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InvestmentAccountedForUsingEquityMethod" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod_labels" xlink:type="arc"/>
      <link:label id="id_6c3d0a" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in associated companies</link:label>
      <link:label id="id_551c0fc4" xlink:label="lbl_label1427902404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="lbl_NoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_label1427902404" xlink:type="arc"/>
      <link:label id="id_42437f89" xlink:label="lbl_label1111719817" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="lbl_CurrentAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_label1111719817" xlink:type="arc"/>
      <link:label id="id_6e6b7ee6" xlink:label="lbl_TreasuryShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares</link:label>
      <link:label id="id_47a37331" xlink:label="lbl_label1201894193" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="lbl_EquityAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_label1201894193" xlink:type="arc"/>
      <link:label id="id_131d39b3" xlink:label="lbl_label320682419" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="lbl_EquityAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityAbstract" xlink:to="lbl_label320682419" xlink:type="arc"/>
      <link:label id="id_7f542d" xlink:label="lbl_label8344621" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="lbl_LiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_label8344621" xlink:type="arc"/>
      <link:label id="id_622df1d" xlink:label="lbl_label102948637" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="lbl_NoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_label102948637" xlink:type="arc"/>
      <link:label id="id_7ba5a5ef" xlink:label="lbl_label2074453487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="lbl_CurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_label2074453487" xlink:type="arc"/>
      <link:label id="id_88ddaa5" xlink:label="lbl_label143514277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lbl_label143514277" xlink:type="arc"/>
      <link:label id="id_47732be6" xlink:label="lbl_label1198730214" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_label1198730214" xlink:type="arc"/>
      <link:label id="id_47bd73ec" xlink:label="lbl_label1203598316" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lbl_label1203598316" xlink:type="arc"/>
      <link:label id="id_bca487e" xlink:label="lbl_PropertyPlantAndEquipmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_PropertyPlantAndEquipmentMember_labels" xlink:type="arc"/>
      <link:label id="id_567bb83c" xlink:label="lbl_LandMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LandMember" xlink:label="lbl_LandMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LandMember" xlink:to="lbl_LandMember_labels" xlink:type="arc"/>
      <link:label id="id_16f548da" xlink:label="lbl_LandMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
      <link:label id="id_a7eb90b" xlink:label="lbl_BuildingsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Buildings [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BuildingsMember" xlink:label="lbl_BuildingsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BuildingsMember" xlink:to="lbl_BuildingsMember_labels" xlink:type="arc"/>
      <link:label id="id_4d69998b" xlink:label="lbl_BuildingsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings</link:label>
      <link:label id="id_62ebaccc" xlink:label="lbl_ConstructionInProgressMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in progress [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="lbl_ConstructionInProgressMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConstructionInProgressMember" xlink:to="lbl_ConstructionInProgressMember_labels" xlink:type="arc"/>
      <link:label id="id_74f44044" xlink:label="lbl_ConstructionInProgressMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
      <link:label id="id_451f7511" xlink:label="lbl_MachineryMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MachineryMember" xlink:label="lbl_MachineryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MachineryMember" xlink:to="lbl_MachineryMember_labels" xlink:type="arc"/>
      <link:label id="id_50dda083" xlink:label="lbl_MachineryMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and other equipment</link:label>
      <link:label id="id_6f28e51b" xlink:label="lbl_label1864951067" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_label1864951067" xlink:type="arc"/>
      <link:label id="id_7c438c3d" xlink:label="lbl_label2084801597" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_label2084801597" xlink:type="arc"/>
      <link:label id="id_5e0af6ee" xlink:label="lbl_label1577776878" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_label1577776878" xlink:type="arc"/>
      <link:label id="id_345f7738" xlink:label="lbl_GrossCarryingAmountMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross carrying amount [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossCarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember_labels" xlink:type="arc"/>
      <link:label id="id_77df9cb5" xlink:label="lbl_PropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment at beginning of period</link:label>
      <link:label id="id_4145517b" xlink:label="lbl_PropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment at end of period</link:label>
      <link:label id="id_1f5560c5" xlink:label="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers from construction in progress, property, plant and equipment</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:to="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_7baa32ee" xlink:label="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
      <link:label id="id_3eb55d39" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_31501db" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
      <link:label id="id_53833bce" xlink:label="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals and retirements, property, plant and equipment</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:label="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:to="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_648c3365" xlink:label="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposals and derecognitions</link:label>
      <link:label id="id_5803c369" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_54f4afbb" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, property, plant and equipment</link:label>
      <link:label id="id_f07d187" xlink:label="lbl_DepreciationPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, property, plant and equipment</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DepreciationPropertyPlantAndEquipment" xlink:to="lbl_DepreciationPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_57f67848" xlink:label="lbl_DepreciationPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation charge</link:label>
      <link:label id="id_6a50bcb" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_4bc845d6" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, property, plant and equipment</link:label>
      <link:label id="id_6bc0d1d9" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reversal of impairment loss recognised in profit or loss, property, plant and equipment</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_3cc1cda9" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reversal of impairment charge</link:label>
      <link:label id="id_2b7f313a" xlink:label="lbl_label729755962" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net book value of Property, plant and equipment under finance lease contracts</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:label="lbl_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:to="lbl_label729755962" xlink:type="arc"/>
      <link:label id="id_260ca259" xlink:label="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual commitments for acquisition of property, plant and equipment</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:label="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:to="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_34818382" xlink:label="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments for purchases of property, plant and equipment</link:label>
      <link:label id="id_54bcbe9d" xlink:label="lbl_BorrowingCostsCapitalised_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowing costs capitalised</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingCostsCapitalised" xlink:label="lbl_BorrowingCostsCapitalised" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingCostsCapitalised" xlink:to="lbl_BorrowingCostsCapitalised_labels" xlink:type="arc"/>
      <link:label id="id_555c8c31" xlink:label="lbl_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalisation rate of borrowing costs eligible for capitalisation</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:label="lbl_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:to="lbl_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_labels" xlink:type="arc"/>
      <link:label id="id_4c298205" xlink:label="lbl_BorrowingsInterestRate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, interest rate</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="lbl_BorrowingsInterestRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsInterestRate" xlink:to="lbl_BorrowingsInterestRate_labels" xlink:type="arc"/>
      <link:label id="id_4611e1b4" xlink:label="lbl_BorrowingsInterestRate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate on borrowings for new additions</link:label>
      <link:label id="id_3caaa61e" xlink:label="lbl_BorrowingCostsCapitalised_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized borrowing costs</link:label>
      <link:label id="id_5cb7a23f" xlink:label="lbl_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalization rate used to determine the amount of borrowing costs eligible for capitalization</link:label>
      <link:label id="id_556c754b" xlink:label="lbl_label1433171275" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementTable" xlink:to="lbl_label1433171275" xlink:type="arc"/>
      <link:label id="id_17e10fbe" xlink:label="lbl_label241915143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [line items]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementLineItems" xlink:to="lbl_label241915143" xlink:type="arc"/>
      <link:label id="id_556e2a5d" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_62e43be9" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
      <link:label id="id_7abef04f" xlink:label="lbl_PropertyPlantAndEquipmentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PropertyPlantAndEquipmentTableTextBlock" xlink:label="lbl_PropertyPlantAndEquipmentTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentTableTextBlock" xlink:to="lbl_PropertyPlantAndEquipmentTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_37009913" xlink:label="lbl_PropertyPlantAndEquipmentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Movements of property, plant and equipment</link:label>
      <link:label id="id_611528f2" xlink:label="lbl_label1628776690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories Disclosure [abstract]</link:label>
      <link:label id="id_7f461082" xlink:label="lbl_DisclosureOfInventoriesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of inventories [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="lbl_DisclosureOfInventoriesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfInventoriesExplanatory" xlink:to="lbl_DisclosureOfInventoriesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_6d592b5d" xlink:label="lbl_DisclosureOfInventoriesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoriesDisclosureAbstract" xlink:label="lbl_InventoriesDisclosureAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoriesDisclosureAbstract" xlink:to="lbl_label1628776690" xlink:type="arc"/>
      <link:label id="id_47e475f1" xlink:label="lbl_ScheduleOfInventoryCurrentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="lbl_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lbl_ScheduleOfInventoryCurrentTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1795799b" xlink:label="lbl_ScheduleOfInventoryCurrentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories by class</link:label>
      <link:label id="id_543a8d3d" xlink:label="lbl_label1413123389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Current [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoryCurrentTable" xlink:label="lbl_InventoryCurrentTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryCurrentTable" xlink:to="lbl_label1413123389" xlink:type="arc"/>
      <link:label id="id_781cb00d" xlink:label="lbl_label2015145997" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoryAxis" xlink:label="lbl_InventoryAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryAxis" xlink:to="lbl_label2015145997" xlink:type="arc"/>
      <link:label id="id_b0e25e5" xlink:label="lbl_label185476581" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoryMember" xlink:label="lbl_InventoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryMember" xlink:to="lbl_label185476581" xlink:type="arc"/>
      <link:label id="id_1b583e85" xlink:label="lbl_InventoryRawMaterialsGrossMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoryRawMaterialsGrossMember" xlink:label="lbl_InventoryRawMaterialsGrossMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryRawMaterialsGrossMember" xlink:to="lbl_InventoryRawMaterialsGrossMember_labels" xlink:type="arc"/>
      <link:label id="id_2bb8c828" xlink:label="lbl_InventoryRawMaterialsGrossMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw material, consumables</link:label>
      <link:label id="id_9dcab16" xlink:label="lbl_InventoryWorkInProgressGrossMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in progress, Gross [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoryWorkInProgressGrossMember" xlink:label="lbl_InventoryWorkInProgressGrossMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryWorkInProgressGrossMember" xlink:to="lbl_InventoryWorkInProgressGrossMember_labels" xlink:type="arc"/>
      <link:label id="id_696df603" xlink:label="lbl_InventoryWorkInProgressGrossMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in progress</link:label>
      <link:label id="id_5b4c39ad" xlink:label="lbl_label1531722157" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished products</link:label>
      <link:label id="id_2f569fbd" xlink:label="lbl_label794206141" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished goods, Gross [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoryFinishedGoodsGrossMember" xlink:label="lbl_InventoryFinishedGoodsGrossMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryFinishedGoodsGrossMember" xlink:to="lbl_label794206141" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryFinishedGoodsGrossMember" xlink:to="lbl_label1531722157" xlink:type="arc"/>
      <link:label id="id_4819bb17" xlink:label="lbl_InventoryLineItems_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [line items]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoryLineItems" xlink:label="lbl_InventoryLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_InventoryLineItems_labels" xlink:type="arc"/>
      <link:label id="id_29f36af5" xlink:label="lbl_InventoryLineItems_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
      <link:label id="id_4b29af41" xlink:label="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of inventories recognised as expense during period</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:label="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:to="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod_labels" xlink:type="arc"/>
      <link:label id="id_2b41374" xlink:label="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amount of inventory recognized as expense</link:label>
      <link:label id="id_11cae639" xlink:label="lbl_InventoryWritedown2011_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory write-down</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InventoryWritedown2011" xlink:label="lbl_InventoryWritedown2011" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryWritedown2011" xlink:to="lbl_InventoryWritedown2011_labels" xlink:type="arc"/>
      <link:label id="id_1fa3a1d8" xlink:label="lbl_InventoryWritedown2011_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory provisions</link:label>
      <link:label id="id_6f7b4a87" xlink:label="lbl_ReversalOfInventoryWritedown_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reversed inventory Provisions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReversalOfInventoryWritedown" xlink:label="lbl_ReversalOfInventoryWritedown" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReversalOfInventoryWritedown" xlink:to="lbl_ReversalOfInventoryWritedown_labels" xlink:type="arc"/>
      <link:label id="id_56e8eb36" xlink:label="lbl_ReversalOfInventoryWritedown_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reversal of inventory write-down</link:label>
      <link:label id="id_39ec1db2" xlink:label="lbl_label971775410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="lbl_EarningsPerShareAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EarningsPerShareAbstract" xlink:to="lbl_label971775410" xlink:type="arc"/>
      <link:label id="id_58dc47d3" xlink:label="lbl_EarningsPerShareExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="lbl_EarningsPerShareExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EarningsPerShareExplanatory" xlink:to="lbl_EarningsPerShareExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_20fad442" xlink:label="lbl_EarningsPerShareExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share</link:label>
      <link:label id="id_5ead42de" xlink:label="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5719e1f6" xlink:label="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share</link:label>
      <link:label id="id_531039b4" xlink:label="lbl_label1393572276" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EarningsPerShareTable" xlink:label="lbl_EarningsPerShareTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EarningsPerShareTable" xlink:to="lbl_label1393572276" xlink:type="arc"/>
      <link:label id="id_6cb953c7" xlink:label="lbl_label1824084935" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EarningsPerShareLineItems" xlink:label="lbl_EarningsPerShareLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_label1824084935" xlink:type="arc"/>
      <link:label id="id_1efe1d89" xlink:label="lbl_label519970185" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Continuing and discontinued operations [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_label519970185" xlink:type="arc"/>
      <link:label id="id_26f22885" xlink:label="lbl_label653404293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate continuing and discontinued operations [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_label653404293" xlink:type="arc"/>
      <link:label id="id_a503764" xlink:label="lbl_ContinuingOperationsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Continuing operations [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContinuingOperationsMember" xlink:to="lbl_ContinuingOperationsMember_labels" xlink:type="arc"/>
      <link:label id="id_64674183" xlink:label="lbl_DiscontinuedOperationsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued operations [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember_labels" xlink:type="arc"/>
      <link:label id="id_7aa601bd" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit/loss attributable to shareholders of Novartis AG</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossAttributableToOwnersOfParent" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent_labels" xlink:type="arc"/>
      <link:label id="id_68d30e6d" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to owners of parent</link:label>
      <link:label id="id_5a4aec87" xlink:label="lbl_WeightedAverageShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares outstanding</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="lbl_WeightedAverageShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageShares" xlink:to="lbl_WeightedAverageShares_labels" xlink:type="arc"/>
      <link:label id="id_1d84ebe1" xlink:label="lbl_WeightedAverageShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares outstanding used in the basic earnings per share</link:label>
      <link:label id="id_4e4dd4b7" xlink:label="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive effect of share options on number of ordinary shares</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:label="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:to="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_labels" xlink:type="arc"/>
      <link:label id="id_4486a95d" xlink:label="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options</link:label>
      <link:label id="id_627adbc2" xlink:label="lbl_AdjustedWeightedAverageShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjusted weighted average number of ordinary shares outstanding</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="lbl_AdjustedWeightedAverageShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustedWeightedAverageShares" xlink:to="lbl_AdjustedWeightedAverageShares_labels" xlink:type="arc"/>
      <link:label id="id_3ec2f3b5" xlink:label="lbl_AdjustedWeightedAverageShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares in diluted earnings per share</link:label>
      <link:label id="id_75396e0c" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share from continuing operation</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:to="lbl_BasicEarningsLossPerShareFromContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_35298166" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share, Continuing operations</link:label>
      <link:label id="id_4d75874f" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share from discontinued operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:to="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_57208e0e" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share, Discontinued operations</link:label>
      <link:label id="id_3bf5aca3" xlink:label="lbl_BasicEarningsLossPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="lbl_BasicEarningsLossPerShare" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BasicEarningsLossPerShare" xlink:to="lbl_BasicEarningsLossPerShare_labels" xlink:type="arc"/>
      <link:label id="id_51010c7c" xlink:label="lbl_BasicEarningsLossPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total basic earnings per share</link:label>
      <link:label id="id_48b2fef8" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share from continuing operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:to="lbl_DilutedEarningsLossPerShareFromContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_2cf2996b" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share from discontinued operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:to="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_4e26e1ff" xlink:label="lbl_DilutedEarningsLossPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="lbl_DilutedEarningsLossPerShare" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DilutedEarningsLossPerShare" xlink:to="lbl_DilutedEarningsLossPerShare_labels" xlink:type="arc"/>
      <link:label id="id_28929982" xlink:label="lbl_DilutedEarningsLossPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total diluted earnings per share</link:label>
      <link:label id="id_3969c29" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share, Continuing operations</link:label>
      <link:label id="id_aa58d2a" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share, Discontinued operations</link:label>
      <link:label id="id_10d604a9" xlink:label="lbl_label282461353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="lbl_AssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_label282461353" xlink:type="arc"/>
      <link:label id="id_6b10381b" xlink:label="lbl_label1796225051" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="lbl_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementOfFinancialPositionAbstract" xlink:to="lbl_label1796225051" xlink:type="arc"/>
      <link:label id="id_40fad394" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfIntangibleAssetsAbstract_labels" xlink:type="arc"/>
      <link:label id="id_43e147c6" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and intangible assets</link:label>
      <link:label id="id_56bb2315" xlink:label="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and intangible assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:label="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:to="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_51b234f9" xlink:label="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of intangible assets and goodwill [text block]</link:label>
      <link:label id="id_4c34e5bc" xlink:label="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Movements of goodwill and intangible assets [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" xlink:label="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" xlink:to="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_49099ca4" xlink:label="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Movements of goodwill and intangible assets</link:label>
      <link:label id="id_73128ea8" xlink:label="lbl_label1930596008" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocation of net book values of goodwill and intangible assets by reporting segment</link:label>
      <link:label id="id_4a2c58f" xlink:label="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assumptions used in the calculation of valuation [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AssumptionsUsedInTheCalculationOfValuationTextBlock" xlink:label="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock" xlink:to="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_77ac0526" xlink:label="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumptions used in the calculation of valuation</link:label>
      <link:label id="id_63728238" xlink:label="lbl_label1668448824" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocation of net book values of goodwill and intangible assets by reporting segment [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:label="lbl_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:to="lbl_label1668448824" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:to="lbl_label1930596008" xlink:type="arc"/>
      <link:label id="id_db941d3" xlink:label="lbl_label230244819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of IncomeTax [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfIncomeTaxAbstract" xlink:label="lbl_DisclosureOfIncomeTaxAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfIncomeTaxAbstract" xlink:to="lbl_label230244819" xlink:type="arc"/>
      <link:label id="id_21d3fbe0" xlink:label="lbl_DisclosureOfIncomeTaxExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="lbl_DisclosureOfIncomeTaxExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfIncomeTaxExplanatory" xlink:to="lbl_DisclosureOfIncomeTaxExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_3e9356c7" xlink:label="lbl_DisclosureOfIncomeTaxExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes</link:label>
      <link:label id="id_78295b76" xlink:label="lbl_IncomeBeforeTaxesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Before Taxes [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeBeforeTaxesTableTextBlock" xlink:label="lbl_IncomeBeforeTaxesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeBeforeTaxesTableTextBlock" xlink:to="lbl_IncomeBeforeTaxesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4c349cd3" xlink:label="lbl_IncomeBeforeTaxesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before taxes</link:label>
      <link:label id="id_12bf41b8" xlink:label="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current and deferred Income Tax Expense [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" xlink:label="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" xlink:to="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_47b0c493" xlink:label="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current and deferred income tax expense</link:label>
      <link:label id="id_553ce855" xlink:label="lbl_AnalysisOfTaxRateTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of Tax Rate [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AnalysisOfTaxRateTableTextBlock" xlink:label="lbl_AnalysisOfTaxRateTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AnalysisOfTaxRateTableTextBlock" xlink:to="lbl_AnalysisOfTaxRateTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3410484d" xlink:label="lbl_AnalysisOfTaxRateTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Analysis of tax rate</link:label>
      <link:label id="id_58de322f" xlink:label="lbl_label1490956847" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Interest Expense and Other Financial Income and Expense [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:label="lbl_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_label1490956847" xlink:type="arc"/>
      <link:label id="id_643ddbd0" xlink:label="lbl_DisclosureOfInterestExpenseExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of interest expense [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInterestExpenseExplanatory" xlink:label="lbl_DisclosureOfInterestExpenseExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfInterestExpenseExplanatory" xlink:to="lbl_DisclosureOfInterestExpenseExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_54a1e622" xlink:label="lbl_DisclosureOfInterestExpenseExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense and other financial income and expense</link:label>
      <link:label id="id_1f6de87d" xlink:label="lbl_InterestExpenseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestExpenseTableTextBlock" xlink:label="lbl_InterestExpenseTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseTableTextBlock" xlink:to="lbl_InterestExpenseTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6f7654df" xlink:label="lbl_InterestExpenseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
      <link:label id="id_3d171b85" xlink:label="lbl_OtherFinancialIncomeAndExpenseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financial Income and Expense [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherFinancialIncomeAndExpenseTableTextBlock" xlink:label="lbl_OtherFinancialIncomeAndExpenseTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherFinancialIncomeAndExpenseTableTextBlock" xlink:to="lbl_OtherFinancialIncomeAndExpenseTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_94ad887" xlink:label="lbl_OtherFinancialIncomeAndExpenseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial income and expense</link:label>
      <link:label id="id_4a94ff2f" xlink:label="lbl_label1934317586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Deferred Tax Assets and Liabilities [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_label1934317586" xlink:type="arc"/>
      <link:label id="id_7354dcb2" xlink:label="lbl_DisclosureOfDeferredTaxesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of deferred taxes [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:label="lbl_DisclosureOfDeferredTaxesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDeferredTaxesExplanatory" xlink:to="lbl_DisclosureOfDeferredTaxesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_7f591b1f" xlink:label="lbl_DisclosureOfDeferredTaxesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets and liablities</link:label>
      <link:label id="id_1f4ff3aa" xlink:label="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_21fac415" xlink:label="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
      <link:label id="id_36d33958" xlink:label="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</link:label>
      <link:label id="id_59f2fa2f" xlink:label="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Differences On Which No Deferred Tax Assets Have Been Provided [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" xlink:label="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" xlink:to="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_73861c88" xlink:label="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary differences on which no deferred tax assets have been provided</link:label>
      <link:label id="id_34022912" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:to="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_1ccd7026" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross value of tax-loss carry-forwards</link:label>
      <link:label id="id_3232a79c" xlink:label="lbl_label842180508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SignificantAccountingPoliciesAbstract" xlink:label="lbl_SignificantAccountingPoliciesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SignificantAccountingPoliciesAbstract" xlink:to="lbl_label842180508" xlink:type="arc"/>
      <link:label id="id_4b3b4099" xlink:label="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of significant accounting policies [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_3f1625ed" xlink:label="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant accounting policies</link:label>
      <link:label id="id_3d96e2f9" xlink:label="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Respective Useful Lives of property, plant and equipment [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:to="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_56feb2c8" xlink:label="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Respective Useful Lives of property, plant and equipment</link:label>
      <link:label id="id_8ac126c" xlink:label="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Respective Useful Lives of Available-for-Use Intangible Assets [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:label="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:to="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4312f4e1" xlink:label="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Respective Useful Lives of Available-for-Use Intangible Assets</link:label>
      <link:label id="id_16da82f9" xlink:label="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for subsidiaries [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_61c4e7e5" xlink:label="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scope of consolidation</link:label>
      <link:label id="id_2b17ff8e" xlink:label="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_57c3715e" xlink:label="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currencies</link:label>
      <link:label id="id_18360a81" xlink:label="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for business combinations [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_6b7df679" xlink:label="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of assets</link:label>
      <link:label id="id_9c406cf" xlink:label="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_634a44d" xlink:label="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property plant and equipment</link:label>
      <link:label id="id_785c05c7" xlink:label="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for goodwill [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_64f7217c" xlink:label="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
      <link:label id="id_5fb6702a" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for Intangible assets available-for-use [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_27c2e0c0" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets available-for-use</link:label>
      <link:label id="id_980511b" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for Intangible assets not yet available-for-use [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_31c63f04" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets not yet available-for-use</link:label>
      <link:label id="id_1a22e85b" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for Impairment of goodwill and intangible assets [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5ecba446" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of goodwill and intangible assets</link:label>
      <link:label id="id_35764af6" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for Impairment of associated companies accounted for at equity [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_547afa65" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of associated companies accounted for at equity</link:label>
      <link:label id="id_2741bbc2" xlink:label="lbl_label710888359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial assets [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:to="lbl_label710888359" xlink:type="arc"/>
      <link:label id="id_4c9d021c" xlink:label="lbl_DescriptionOfAccountingPolicyForMeasuringInventories_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for measuring inventories [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:label="lbl_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:to="lbl_DescriptionOfAccountingPolicyForMeasuringInventories_labels" xlink:type="arc"/>
      <link:label id="id_2dc53cba" xlink:label="lbl_DescriptionOfAccountingPolicyForMeasuringInventories_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
      <link:label id="id_4f18679b" xlink:label="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for trade and other receivables [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_7ee3df7f" xlink:label="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables</link:label>
      <link:label id="id_5def73f" xlink:label="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for provisions [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_63d0690f" xlink:label="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal and environmental liabilities</link:label>
      <link:label id="id_7371c5cb" xlink:label="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for contingent liabilities and contingent assets [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_55214b7d" xlink:label="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
      <link:label id="id_7e49b25a" xlink:label="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for employee benefits [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_23e7bf92" xlink:label="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit pension plans and other post retirement benefits</link:label>
      <link:label id="id_f50de43" xlink:label="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for treasury shares [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_21b13d04" xlink:label="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Shares</link:label>
      <link:label id="id_7b5ef0a7" xlink:label="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue_labels" xlink:type="arc"/>
      <link:label id="id_4f9fa5aa" xlink:label="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition</link:label>
      <link:label id="id_7912cc37" xlink:label="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_28239f2f" xlink:label="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
      <link:label id="id_20541755" xlink:label="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_6b599b81" xlink:label="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
      <link:label id="id_1cb64794" xlink:label="lbl_DescriptionOfAccountingPolicyForGovernmentGrants_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for government grants [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:label="lbl_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:to="lbl_DescriptionOfAccountingPolicyForGovernmentGrants_labels" xlink:type="arc"/>
      <link:label id="id_35eedb65" xlink:label="lbl_DescriptionOfAccountingPolicyForGovernmentGrants_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government grants</link:label>
      <link:label id="id_11f1b42e" xlink:label="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for decommissioning, restoration and rehabilitation provisions [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_40e153e3" xlink:label="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
      <link:label id="id_2726a264" xlink:label="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for income tax [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_13936f53" xlink:label="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes</link:label>
      <link:label id="id_4a557154" xlink:label="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for non-current assets or disposal groups classified as held for sale [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_7d2f6bd5" xlink:label="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets held for sale or held for distribution to owners</link:label>
      <link:label id="id_27c082e4" xlink:label="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:label="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:to="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_labels" xlink:type="arc"/>
      <link:label id="id_455ebc" xlink:label="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of adopting significant new IFRS standards</link:label>
      <link:label id="id_11c5047" xlink:label="lbl_label18632775" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:label="lbl_PropertyPlantAndEquipmentAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentAbstract" xlink:to="lbl_label18632775" xlink:type="arc"/>
      <link:label id="id_7e2f70e6" xlink:label="lbl_label2117038310" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RangeAxis" xlink:to="lbl_label2117038310" xlink:type="arc"/>
      <link:label id="id_6a60d490" xlink:label="lbl_label1784730768" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RangesMember" xlink:to="lbl_label1784730768" xlink:type="arc"/>
      <link:label id="id_64d1e224" xlink:label="lbl_BottomOfRangeMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bottom of range [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="lbl_BottomOfRangeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BottomOfRangeMember" xlink:to="lbl_BottomOfRangeMember_labels" xlink:type="arc"/>
      <link:label id="id_5e09e4ca" xlink:label="lbl_TopOfRangeMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top of range [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="lbl_TopOfRangeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TopOfRangeMember" xlink:to="lbl_TopOfRangeMember_labels" xlink:type="arc"/>
      <link:label id="id_28553079" xlink:label="lbl_ComputerEquipmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer equipment [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="lbl_ComputerEquipmentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComputerEquipmentMember" xlink:to="lbl_ComputerEquipmentMember_labels" xlink:type="arc"/>
      <link:label id="id_2be121a7" xlink:label="lbl_FurnitureAndVehiclesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and vehicles [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FurnitureAndVehiclesMember" xlink:label="lbl_FurnitureAndVehiclesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FurnitureAndVehiclesMember" xlink:to="lbl_FurnitureAndVehiclesMember_labels" xlink:type="arc"/>
      <link:label id="id_613b73ea" xlink:label="lbl_FurnitureAndVehiclesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and vehicles</link:label>
      <link:label id="id_593b0650" xlink:label="lbl_label1497040464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lbl_label1497040464" xlink:type="arc"/>
      <link:label id="id_42d9f411" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember_labels" xlink:type="arc"/>
      <link:label id="id_3c815062" xlink:label="lbl_BrandNamesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Brand names [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BrandNamesMember" xlink:label="lbl_BrandNamesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BrandNamesMember" xlink:to="lbl_BrandNamesMember_labels" xlink:type="arc"/>
      <link:label id="id_37b4dbd2" xlink:label="lbl_OtherIntangibleAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other intangible assets [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="lbl_OtherIntangibleAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherIntangibleAssetsMember" xlink:to="lbl_OtherIntangibleAssetsMember_labels" xlink:type="arc"/>
      <link:label id="id_7fe96854" xlink:label="lbl_TechnologybasedIntangibleAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology-based intangible assets [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TechnologybasedIntangibleAssetsMember" xlink:label="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TechnologybasedIntangibleAssetsMember" xlink:to="lbl_TechnologybasedIntangibleAssetsMember_labels" xlink:type="arc"/>
      <link:label id="id_2340963a" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketing related intangible assets [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MarketingRelatedIntangibleAssetsMember" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MarketingRelatedIntangibleAssetsMember" xlink:to="lbl_MarketingRelatedIntangibleAssetsMember_labels" xlink:type="arc"/>
      <link:label id="id_44d0b847" xlink:label="lbl_CurrentlyMarketedProductsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currently marketed products [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentlyMarketedProductsMember" xlink:to="lbl_CurrentlyMarketedProductsMember_labels" xlink:type="arc"/>
      <link:label id="id_796a6b5e" xlink:label="lbl_label2037017438" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income statement location [axis]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeStatementLocationAxis" xlink:label="lbl_IncomeStatementLocationAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeStatementLocationAxis" xlink:to="lbl_label2037017438" xlink:type="arc"/>
      <link:label id="id_bc5c8b8" xlink:label="lbl_label197511352" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income statement location [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeStatementLocationMember" xlink:label="lbl_IncomeStatementLocationMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeStatementLocationMember" xlink:to="lbl_label197511352" xlink:type="arc"/>
      <link:label id="id_2aedaf69" xlink:label="lbl_label720220009" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of sales [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CostOfSalesMember" xlink:label="lbl_CostOfSalesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CostOfSalesMember" xlink:to="lbl_label720220009" xlink:type="arc"/>
      <link:label id="id_2449d337" xlink:label="lbl_label608817975" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of sales or Research and Development [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CostOfSalesOrResearchAndDevelopmentMember" xlink:label="lbl_CostOfSalesOrResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CostOfSalesOrResearchAndDevelopmentMember" xlink:to="lbl_label608817975" xlink:type="arc"/>
      <link:label id="id_5073642b" xlink:label="lbl_label1349739563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestExpenseAbstract" xlink:label="lbl_InterestExpenseAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseAbstract" xlink:to="lbl_label1349739563" xlink:type="arc"/>
      <link:label id="id_7fef39d4" xlink:label="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense due to unwinding of discount on provisions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:label="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:to="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions_labels" xlink:type="arc"/>
      <link:label id="id_1de5231e" xlink:label="lbl_InterestExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpense" xlink:to="lbl_InterestExpense_labels" xlink:type="arc"/>
      <link:label id="id_f4773bc" xlink:label="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income/expense arising from discounting long-term liabilities</link:label>
      <link:label id="id_5a15aac0" xlink:label="lbl_label1549022431" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
      <link:label id="id_7a288c00" xlink:label="lbl_InterestExpense_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Interest Expense</link:label>
      <link:label id="id_55d5704a" xlink:label="lbl_label1440051274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other financial income and expense [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherFinancialIncomeAndExpenseAbstract" xlink:label="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_label1440051274" xlink:type="arc"/>
      <link:label id="id_1c654137" xlink:label="lbl_label476397879" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income on forward contracts and options</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeOnForwardContractsAndOptions" xlink:label="lbl_IncomeOnForwardContractsAndOptions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeOnForwardContractsAndOptions" xlink:to="lbl_label476397879" xlink:type="arc"/>
      <link:label id="id_545ae83" xlink:label="lbl_GainsLossesOnNetMonetaryPosition_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on net monetary position</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnNetMonetaryPosition" xlink:label="lbl_GainsLossesOnNetMonetaryPosition" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsLossesOnNetMonetaryPosition" xlink:to="lbl_GainsLossesOnNetMonetaryPosition_labels" xlink:type="arc"/>
      <link:label id="id_550f9fc0" xlink:label="lbl_GainsLossesOnNetMonetaryPosition_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monetary loss from hyperinflation</link:label>
      <link:label id="id_76a4da02" xlink:label="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_labels" xlink:type="arc"/>
      <link:label id="id_26393d9c" xlink:label="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency result, net</link:label>
      <link:label id="id_32d2b6d5" xlink:label="lbl_label852670165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major components of tax expense (income) [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="lbl_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="lbl_label852670165" xlink:type="arc"/>
      <link:label id="id_66ab5be5" xlink:label="lbl_label1722506213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical areas [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_label1722506213" xlink:type="arc"/>
      <link:label id="id_4667b9e2" xlink:label="lbl_label1181202914" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical areas [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_label1181202914" xlink:type="arc"/>
      <link:label id="id_3f3ab48" xlink:label="lbl_CountryOfDomicileMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Country of domicile [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CountryOfDomicileMember" xlink:to="lbl_CountryOfDomicileMember_labels" xlink:type="arc"/>
      <link:label id="id_14841da" xlink:label="lbl_ForeignCountriesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign countries [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ForeignCountriesMember" xlink:to="lbl_ForeignCountriesMember_labels" xlink:type="arc"/>
      <link:label id="id_56fc0dcb" xlink:label="lbl_CountryOfDomicileMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Switzerland</link:label>
      <link:label id="id_7d96a380" xlink:label="lbl_ForeignCountriesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
      <link:label id="id_58ec016" xlink:label="lbl_ProfitLossBeforeTax_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) before tax</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossBeforeTax" xlink:to="lbl_ProfitLossBeforeTax_labels" xlink:type="arc"/>
      <link:label id="id_55d23fd3" xlink:label="lbl_AccountingProfit_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting profit</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccountingProfit" xlink:label="lbl_AccountingProfit" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccountingProfit" xlink:to="lbl_AccountingProfit_labels" xlink:type="arc"/>
      <link:label id="id_1207c251" xlink:label="lbl_ProfitLossBeforeTax_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before taxes from continuing operations</link:label>
      <link:label id="id_d3303df" xlink:label="lbl_AccountingProfit_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Income before taxes</link:label>
      <link:label id="id_5fb2cb43" xlink:label="lbl_IncomeTaxExpenseContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income), continuing operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxExpenseContinuingOperations" xlink:to="lbl_IncomeTaxExpenseContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_477ea68" xlink:label="lbl_IncomeTaxExpenseContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
      <link:label id="id_4390e563" xlink:label="lbl_IncomeTaxExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeTaxExpense" xlink:label="lbl_IncomeTaxExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxExpense" xlink:to="lbl_IncomeTaxExpense_labels" xlink:type="arc"/>
      <link:label id="id_c99559f" xlink:label="lbl_IncomeTaxExpense_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Income Tax Expense</link:label>
      <link:label id="id_750153b3" xlink:label="lbl_label1963021235" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of average effective tax rate and applicable tax rate [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract" xlink:label="lbl_ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract" xlink:to="lbl_label1963021235" xlink:type="arc"/>
      <link:label id="id_5d2df8ac" xlink:label="lbl_ApplicableTaxRate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Applicable tax rate</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ApplicableTaxRate" xlink:label="lbl_ApplicableTaxRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ApplicableTaxRate" xlink:to="lbl_ApplicableTaxRate_labels" xlink:type="arc"/>
      <link:label id="id_74bd6dfe" xlink:label="lbl_ApplicableTaxRate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Applicable tax rate</link:label>
      <link:label id="id_2c804df7" xlink:label="lbl_TaxRateEffectOfCreditsAndAllowances_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of credits and allowances</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxRateEffectOfCreditsAndAllowances" xlink:label="lbl_TaxRateEffectOfCreditsAndAllowances" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfCreditsAndAllowances" xlink:to="lbl_TaxRateEffectOfCreditsAndAllowances_labels" xlink:type="arc"/>
      <link:label id="id_1d59fda1" xlink:label="lbl_TaxRateEffectOfCreditsAndAllowances_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of tax credits and allowances</link:label>
      <link:label id="id_682f727c" xlink:label="lbl_TaxRateEffectOfWriteOffOfDeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of write off of deferred tax assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxRateEffectOfWriteOffOfDeferredTaxAssets" xlink:label="lbl_TaxRateEffectOfWriteOffOfDeferredTaxAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfWriteOffOfDeferredTaxAssets" xlink:to="lbl_TaxRateEffectOfWriteOffOfDeferredTaxAssets_labels" xlink:type="arc"/>
      <link:label id="id_514b6bd9" xlink:label="lbl_TaxRateEffectOfWriteOffOfDeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of write off of deferred tax assets</link:label>
      <link:label id="id_6710a9a" xlink:label="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect from write down and reversal of write down of invest subsidiaries</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:label="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:to="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries_labels" xlink:type="arc"/>
      <link:label id="id_175786ff" xlink:label="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of write down and reversal of write down of investments in subsidiaries</link:label>
      <link:label id="id_574b8256" xlink:label="lbl_label1464566358" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of tax benefits expiring in 2017</link:label>
      <link:label id="id_5de8eaa3" xlink:label="lbl_label1575545507" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect from benefits expiring</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxRateEffectFromBenefitsExpiring" xlink:label="lbl_TaxRateEffectFromBenefitsExpiring" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectFromBenefitsExpiring" xlink:to="lbl_label1575545507" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectFromBenefitsExpiring" xlink:to="lbl_label1464566358" xlink:type="arc"/>
      <link:label id="id_536d84ea" xlink:label="lbl_label1131311877" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of non-deductible losses in Venezuela</link:label>
      <link:label id="id_4741211a" xlink:label="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate effect of adjustments for current tax of prior periods</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:to="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods_labels" xlink:type="arc"/>
      <link:label id="id_3fc4f53a" xlink:label="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of prior year items</link:label>
      <link:label id="id_665323a" xlink:label="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of other items</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_labels" xlink:type="arc"/>
      <link:label id="id_dea5852" xlink:label="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other tax rate effects for reconciliation between accounting profit and tax expense (income)</link:label>
      <link:label id="id_ee48bb4" xlink:label="lbl_AverageEffectiveTaxRateContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average effective tax rate continuing operations</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AverageEffectiveTaxRateContinuingOperations" xlink:label="lbl_AverageEffectiveTaxRateContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AverageEffectiveTaxRateContinuingOperations" xlink:to="lbl_AverageEffectiveTaxRateContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_37da283b" xlink:label="lbl_AverageEffectiveTaxRateContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate for continuing operations</link:label>
      <link:label id="id_47841719" xlink:label="lbl_label1199839001" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate for discontinued operations</link:label>
      <link:label id="id_f9778dc" xlink:label="lbl_label261585116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average effective tax rate discontinued operations</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AverageEffectiveTaxRateDiscontinuedOperations" xlink:label="lbl_AverageEffectiveTaxRateDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AverageEffectiveTaxRateDiscontinuedOperations" xlink:to="lbl_label261585116" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AverageEffectiveTaxRateDiscontinuedOperations" xlink:to="lbl_label1199839001" xlink:type="arc"/>
      <link:label id="id_51bf64bc" xlink:label="lbl_AverageEffectiveTaxRate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AverageEffectiveTaxRate" xlink:label="lbl_AverageEffectiveTaxRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AverageEffectiveTaxRate" xlink:to="lbl_AverageEffectiveTaxRate_labels" xlink:type="arc"/>
      <link:label id="id_4e4514d0" xlink:label="lbl_AverageEffectiveTaxRate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average effective tax rate</link:label>
      <link:label id="id_65d06a2f" xlink:label="lbl_label1708157487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax assets and liabilities [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_label1708157487" xlink:type="arc"/>
      <link:label id="id_482aa0f2" xlink:label="lbl_label1210753266" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_label1210753266" xlink:type="arc"/>
      <link:label id="id_75d207b8" xlink:label="lbl_label1976698808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_label1976698808" xlink:type="arc"/>
      <link:label id="id_1bb2f625" xlink:label="lbl_label464713253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pensions and other benefit obligations of associates [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:label="lbl_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:to="lbl_label464713253" xlink:type="arc"/>
      <link:label id="id_6d0f55ad" xlink:label="lbl_InventoriesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoriesMember" xlink:label="lbl_InventoriesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoriesMember" xlink:to="lbl_InventoriesMember_labels" xlink:type="arc"/>
      <link:label id="id_7e43c96a" xlink:label="lbl_label2118371690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax loss carryforwards [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxLossCarryforwardsMember" xlink:label="lbl_TaxLossCarryforwardsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxLossCarryforwardsMember" xlink:to="lbl_label2118371690" xlink:type="arc"/>
      <link:label id="id_112eae32" xlink:label="lbl_label288271922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets, provisions and accruals [member]</link:label>
      <link:label id="id_4d44190d" xlink:label="lbl_DeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
      <link:label id="id_69dcdf60" xlink:label="lbl_DeferredTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:label id="id_65498be7" xlink:label="lbl_DeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="lbl_DeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxLiabilityAsset" xlink:to="lbl_DeferredTaxLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_46ad922f" xlink:label="lbl_DeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax balance</link:label>
      <link:label id="id_637b5bc7" xlink:label="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credited/(charged) to income</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:to="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_labels" xlink:type="arc"/>
      <link:label id="id_50e2e919" xlink:label="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax expense (income) recognised in profit or loss</link:label>
      <link:label id="id_54101181" xlink:label="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax relating to items credited (charged) directly to equity</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:to="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_labels" xlink:type="arc"/>
      <link:label id="id_8409b0d" xlink:label="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charged to equity</link:label>
      <link:label id="id_5e5bb1e8" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax relating to components of other comprehensive income</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:to="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:type="arc"/>
      <link:label id="id_495f93f4" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credited/(charged) to other comprehensive income</link:label>
      <link:label id="id_22e658d6" xlink:label="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through business combinations, deferred tax liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:to="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_36e0af13" xlink:label="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_35a4b23c" xlink:label="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through other movements deferred tax liability (asset)</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:to="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_6e9211d6" xlink:label="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other movements</link:label>
      <link:label id="id_1e95490a" xlink:label="lbl_label513100042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offsetting of deferred tax assets and liabilities within the same tax jurisdiction</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:label="lbl_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:to="lbl_label513100042" xlink:type="arc"/>
      <link:label id="id_7845a7b2" xlink:label="lbl_label2017830834" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary differences on which no deferred tax assets have been provided [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedAbstract" xlink:label="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedAbstract" xlink:to="lbl_label2017830834" xlink:type="arc"/>
      <link:label id="id_76d7af65" xlink:label="lbl_label1993846629" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in subsidiaries [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InvestmentsInSubsidiariesMember" xlink:label="lbl_InvestmentsInSubsidiariesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InvestmentsInSubsidiariesMember" xlink:to="lbl_label1993846629" xlink:type="arc"/>
      <link:label id="id_155fe654" xlink:label="lbl_label358606420" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill from acquisitions [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GoodwillFromAcquisitionsMember" xlink:label="lbl_GoodwillFromAcquisitionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GoodwillFromAcquisitionsMember" xlink:to="lbl_label358606420" xlink:type="arc"/>
      <link:label id="id_2439e7db" xlink:label="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deductible temporary differences for which no deferred tax asset is recognised</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:to="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_labels" xlink:type="arc"/>
      <link:label id="id_720fdd61" xlink:label="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary differences on which no deferred tax has been provided as they are permanent in nature</link:label>
      <link:label id="id_193f7081" xlink:label="lbl_label423587969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:to="lbl_label423587969" xlink:type="arc"/>
      <link:label id="id_6b884d65" xlink:label="lbl_label1804094821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lbl_label1804094821" xlink:type="arc"/>
      <link:label id="id_37fff575" xlink:label="lbl_label939521397" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance sheet treatment [axis]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BalanceSheetTreatmentAxis" xlink:label="lbl_BalanceSheetTreatmentAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BalanceSheetTreatmentAxis" xlink:to="lbl_label939521397" xlink:type="arc"/>
      <link:label id="id_53909ff0" xlink:label="lbl_label1401987056" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance sheet treatment [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BalanceSheetTreatmentMember" xlink:label="lbl_BalanceSheetTreatmentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BalanceSheetTreatmentMember" xlink:to="lbl_label1401987056" xlink:type="arc"/>
      <link:label id="id_439c0ffd" xlink:label="lbl_label1134301181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CapitalizedMember" xlink:label="lbl_CapitalizedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CapitalizedMember" xlink:to="lbl_label1134301181" xlink:type="arc"/>
      <link:label id="id_4f2ca3b1" xlink:label="lbl_label1328325553" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not capitalized [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NotCapitalizedMember" xlink:label="lbl_NotCapitalizedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NotCapitalizedMember" xlink:to="lbl_label1328325553" xlink:type="arc"/>
      <link:label id="id_2654c6dd" xlink:label="lbl_label643090141" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year of expiry [axis]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_YearOfExpiryAxis" xlink:label="lbl_YearOfExpiryAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_YearOfExpiryAxis" xlink:to="lbl_label643090141" xlink:type="arc"/>
      <link:label id="id_4110ec53" xlink:label="lbl_label1091628115" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year of expiry [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_YearOfExpiryMember" xlink:label="lbl_YearOfExpiryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_label1091628115" xlink:type="arc"/>
      <link:label id="id_5e6070e2" xlink:label="lbl_label1583378658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One year [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OneYearMember" xlink:label="lbl_OneYearMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OneYearMember" xlink:to="lbl_label1583378658" xlink:type="arc"/>
      <link:label id="id_4ad3dc4f" xlink:label="lbl_label1255398479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two years [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TwoYearsMember" xlink:label="lbl_TwoYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TwoYearsMember" xlink:to="lbl_label1255398479" xlink:type="arc"/>
      <link:label id="id_5915ca9f" xlink:label="lbl_label1494600351" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Three years [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ThreeYearsMember" xlink:label="lbl_ThreeYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ThreeYearsMember" xlink:to="lbl_label1494600351" xlink:type="arc"/>
      <link:label id="id_7bb728cd" xlink:label="lbl_label2075601101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Four years [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FourYearsMember" xlink:label="lbl_FourYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FourYearsMember" xlink:to="lbl_label2075601101" xlink:type="arc"/>
      <link:label id="id_742ed8cf" xlink:label="lbl_label1949227215" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Five years [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FiveYearsMember" xlink:label="lbl_FiveYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FiveYearsMember" xlink:to="lbl_label1949227215" xlink:type="arc"/>
      <link:label id="id_347afbb1" xlink:label="lbl_label880475057" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">More than five years [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MoreThanFiveYearsMember" xlink:label="lbl_MoreThanFiveYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MoreThanFiveYearsMember" xlink:to="lbl_label880475057" xlink:type="arc"/>
      <link:label id="id_74c41296" xlink:label="lbl_label94266701" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</link:label>
      <link:label id="id_14f7a19b" xlink:label="lbl_ValueOfTaxLossCarryforwardsExpired_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value of tax loss carryforwards expired</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ValueOfTaxLossCarryforwardsExpired" xlink:label="lbl_ValueOfTaxLossCarryforwardsExpired" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueOfTaxLossCarryforwardsExpired" xlink:to="lbl_ValueOfTaxLossCarryforwardsExpired_labels" xlink:type="arc"/>
      <link:label id="id_6a5eff98" xlink:label="lbl_ValueOfTaxLossCarryforwardsExpired_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax loss carryforwards expired</link:label>
      <link:label id="id_70fd1364" xlink:label="lbl_label1895633764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax asset expected to have an impact on current taxes payable after more than 12 months</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:label="lbl_DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:to="lbl_label1895633764" xlink:type="arc"/>
      <link:label id="id_522d9018" xlink:label="lbl_label1378717720" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities expected to have an impact on current taxes payable after more than 12 months</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:label="lbl_DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:to="lbl_label1378717720" xlink:type="arc"/>
      <link:label id="id_2f7867e" xlink:label="lbl_label49776254" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unremitted earnings retained by consolidated entities for reinvestment</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:label="lbl_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:to="lbl_label49776254" xlink:type="arc"/>
      <link:label id="id_5d6e151" xlink:label="lbl_label97968465" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for income taxes on unremitted earnings</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionForIncomeTaxesOnUnremittedEarnings" xlink:label="lbl_ProvisionForIncomeTaxesOnUnremittedEarnings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionForIncomeTaxesOnUnremittedEarnings" xlink:to="lbl_label97968465" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:label="lbl_GainsLossesOnAvailableforsaleFinancialAssets1" xlink:type="locator"/>
      <link:label id="id_7db0af99" xlink:label="lbl_GainsLossesOnAvailableforsaleFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net capital losses on available-for-sale securities</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsLossesOnAvailableforsaleFinancialAssets1" xlink:to="lbl_GainsLossesOnAvailableforsaleFinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_27062936" xlink:label="lbl_GainsLossesOnAvailableforsaleFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on available-for-sale financial assets</link:label>
      <link:label id="id_71a78a3a" xlink:label="lbl_label1906805306" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial and other non-current assets [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:to="lbl_label1906805306" xlink:type="arc"/>
      <link:label id="id_52927dd" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial and other non-current assets [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" xlink:to="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4f2bb8aa" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial and other non-current assets</link:label>
      <link:label id="id_67e73888" xlink:label="lbl_DisclosureOfFinancialAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfFinancialAssetsTableTextBlock" xlink:label="lbl_DisclosureOfFinancialAssetsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAssetsTableTextBlock" xlink:to="lbl_DisclosureOfFinancialAssetsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_634e228d" xlink:label="lbl_DisclosureOfFinancialAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
      <link:label id="id_57b4381e" xlink:label="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other non-current assets [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:label="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:to="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6832ec2" xlink:label="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
      <link:label id="id_1f868b2b" xlink:label="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of minimum finance lease payments [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:label="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:to="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2e528ce3" xlink:label="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum finance lease payments</link:label>
      <link:label id="id_6a1e58d8" xlink:label="lbl_label1780373720" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current assets [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherCurrentAssetsAbstract" xlink:label="lbl_OtherCurrentAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_label1780373720" xlink:type="arc"/>
      <link:label id="id_574b2687" xlink:label="lbl_DisclosureOfOtherCurrentAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other current assets [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:label="lbl_DisclosureOfOtherCurrentAssetsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherCurrentAssetsExplanatory" xlink:to="lbl_DisclosureOfOtherCurrentAssetsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_2fe53b2a" xlink:label="lbl_DisclosureOfOtherCurrentAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
      <link:label id="id_2f9ef8c8" xlink:label="lbl_OtherCurrentAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current assets [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherCurrentAssetsTableTextBlock" xlink:label="lbl_OtherCurrentAssetsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentAssetsTableTextBlock" xlink:to="lbl_OtherCurrentAssetsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6c3d724c" xlink:label="lbl_OtherCurrentAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
      <link:label id="id_229f76b0" xlink:label="lbl_CurrentValueAddedTaxReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current value added tax receivables</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="lbl_CurrentValueAddedTaxReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentValueAddedTaxReceivables" xlink:to="lbl_CurrentValueAddedTaxReceivables_labels" xlink:type="arc"/>
      <link:label id="id_5dea7085" xlink:label="lbl_CurrentValueAddedTaxReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VAT Receivable</link:label>
      <link:label id="id_68e173a" xlink:label="lbl_label1024297901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Withholding tax recoverable</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WithholdingTaxRecoverable" xlink:label="lbl_WithholdingTaxRecoverable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WithholdingTaxRecoverable" xlink:to="lbl_label1024297901" xlink:type="arc"/>
      <link:label id="id_7437ef3d" xlink:label="lbl_label905656156" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses - third party</link:label>
      <link:label id="id_6210dea9" xlink:label="lbl_CurrentPrepaidExpensesAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current prepaid expenses associated companies</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentPrepaidExpensesAssociatedCompanies" xlink:label="lbl_CurrentPrepaidExpensesAssociatedCompanies" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentPrepaidExpensesAssociatedCompanies" xlink:to="lbl_CurrentPrepaidExpensesAssociatedCompanies_labels" xlink:type="arc"/>
      <link:label id="id_2201baf2" xlink:label="lbl_CurrentPrepaidExpensesAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses - associated companies</link:label>
      <link:label id="id_61baeb33" xlink:label="lbl_label1639639859" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables associated companies</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReceivablesAssociatedCompanies" xlink:label="lbl_ReceivablesAssociatedCompanies" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReceivablesAssociatedCompanies" xlink:to="lbl_label1639639859" xlink:type="arc"/>
      <link:label id="id_3ac7e1da" xlink:label="lbl_label986178010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other receivables and current assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherReceivablesAndCurrentAssets" xlink:label="lbl_OtherReceivablesAndCurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherReceivablesAndCurrentAssets" xlink:to="lbl_label986178010" xlink:type="arc"/>
      <link:label id="id_4072377e" xlink:label="lbl_OtherCurrentNonfinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other current assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_OtherCurrentNonfinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_e3db8e7" xlink:label="lbl_OtherCurrentNonfinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current non-financial assets</link:label>
      <link:label id="id_d18502c" xlink:label="lbl_label219697196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of marketable securities commodities deposits derivative instruments and cash [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_label219697196" xlink:type="arc"/>
      <link:label id="id_69021d0e" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of marketable securities commodities deposits derivative instruments and cash [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" xlink:to="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4984da50" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of marketable securities commodities deposits derivative instruments and cash</link:label>
      <link:label id="id_24a0b3b8" xlink:label="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities, commodities, timedeposits, and derivative financial instruments [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" xlink:label="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" xlink:to="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_443173b3" xlink:label="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, commodities, timedeposits, and derivative financial instruments</link:label>
      <link:label id="id_34fe6088" xlink:label="lbl_CashAndCashEquivalentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashAndCashEquivalentsTableTextBlock" xlink:label="lbl_CashAndCashEquivalentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsTableTextBlock" xlink:to="lbl_CashAndCashEquivalentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1b8f74ee" xlink:label="lbl_CashAndCashEquivalentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:label id="id_808126e" xlink:label="lbl_DebtInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt instruments held</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DebtInstrumentsHeld" xlink:label="lbl_DebtInstrumentsHeld" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DebtInstrumentsHeld" xlink:to="lbl_DebtInstrumentsHeld_labels" xlink:type="arc"/>
      <link:label id="id_6e00ca4f" xlink:label="lbl_DebtInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities</link:label>
      <link:label id="id_22a6b8a5" xlink:label="lbl_EquityInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity instruments held</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityInstrumentsHeld" xlink:label="lbl_EquityInstrumentsHeld" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityInstrumentsHeld" xlink:to="lbl_EquityInstrumentsHeld_labels" xlink:type="arc"/>
      <link:label id="id_724851f6" xlink:label="lbl_EquityInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities</link:label>
      <link:label id="id_419c6f6a" xlink:label="lbl_FundInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fund instruments held</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FundInstrumentsHeld" xlink:label="lbl_FundInstrumentsHeld" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FundInstrumentsHeld" xlink:to="lbl_FundInstrumentsHeld_labels" xlink:type="arc"/>
      <link:label id="id_53712316" xlink:label="lbl_FundInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fund investments</link:label>
      <link:label id="id_17079bd" xlink:label="lbl_label1789088932" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commodities</link:label>
      <link:label id="id_6c508a7b" xlink:label="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term deposits, not classified as cash equivalents</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:label="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:to="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_24ec6e77" xlink:label="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time deposits with original maturity more than 90 days</link:label>
      <link:label id="id_ef5ab87" xlink:label="lbl_DerivativeFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial instruments</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DerivativeFinancialAssets" xlink:label="lbl_DerivativeFinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialAssets" xlink:to="lbl_DerivativeFinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_4954716a" xlink:label="lbl_DerivativeFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial assets</link:label>
      <link:label id="id_57e2aa2d" xlink:label="lbl_InterestReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest receivable</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestReceivable" xlink:label="lbl_InterestReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestReceivable" xlink:to="lbl_InterestReceivable_labels" xlink:type="arc"/>
      <link:label id="id_6996ac87" xlink:label="lbl_InterestReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest on debt securities and time deposits</link:label>
      <link:label id="id_70ff77e4" xlink:label="lbl_Cash_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current accounts</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Cash" xlink:label="lbl_Cash" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Cash" xlink:to="lbl_Cash_labels" xlink:type="arc"/>
      <link:label id="id_502a929f" xlink:label="lbl_Cash_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash</link:label>
      <link:label id="id_436c5591" xlink:label="lbl_label1131173265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:label="lbl_CashAndCashEquivalentsAbstract1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsAbstract1" xlink:to="lbl_label1131173265" xlink:type="arc"/>
      <link:label id="id_20053f5" xlink:label="lbl_CashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash and cash equivalents</link:label>
      <link:label id="id_47b73cba" xlink:label="lbl_CashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time deposits and short term investments with original maturity less than 90 days</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashEquivalents" xlink:label="lbl_CashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashEquivalents" xlink:to="lbl_CashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_178a6550" xlink:label="lbl_CashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
      <link:label id="id_25a7d307" xlink:label="lbl_label631755527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt securities denominations [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DebtSecuritiesDenominationsAbstract" xlink:label="lbl_DebtSecuritiesDenominationsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DebtSecuritiesDenominationsAbstract" xlink:to="lbl_label631755527" xlink:type="arc"/>
      <link:label id="id_6e4a0bf9" xlink:label="lbl_DebtInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt securities held</link:label>
      <link:label id="id_3758e5ae" xlink:label="lbl_ComputerEquipmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
      <link:label id="id_487fbdc1" xlink:label="lbl_label1216331201" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in deferred tax balance [roll forward]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MovementInDeferredTaxBalanceRollForward" xlink:label="lbl_MovementInDeferredTaxBalanceRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_label1216331201" xlink:type="arc"/>
      <link:label id="id_41df7536" xlink:label="lbl_DeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax balance at beginning of period</link:label>
      <link:label id="id_2e28206a" xlink:label="lbl_DeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax balance at end of period</link:label>
      <link:label id="id_4c171394" xlink:label="lbl_label1276580756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="lbl_DisclosureOfFinancialAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_label1276580756" xlink:type="arc"/>
      <link:label id="id_767010e4" xlink:label="lbl_ContingentConsiderationReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Receivable</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationReceivable" xlink:label="lbl_ContingentConsiderationReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationReceivable" xlink:to="lbl_ContingentConsiderationReceivable_labels" xlink:type="arc"/>
      <link:label id="id_1c964d9b" xlink:label="lbl_ContingentConsiderationReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration receivables</link:label>
      <link:label id="id_1cc013c7" xlink:label="lbl_NoncurrentFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="lbl_NoncurrentFinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_NoncurrentFinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_47c06050" xlink:label="lbl_NoncurrentFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial assets</link:label>
      <link:label id="id_2038ebb3" xlink:label="lbl_NoncurrentFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total financial assets</link:label>
      <link:label id="id_7a406b1b" xlink:label="lbl_NoncurrentLoansAndReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current loans and receivables</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLoansAndReceivables" xlink:label="lbl_NoncurrentLoansAndReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLoansAndReceivables" xlink:to="lbl_NoncurrentLoansAndReceivables_labels" xlink:type="arc"/>
      <link:label id="id_69fe82c8" xlink:label="lbl_NoncurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current trade receivables</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentTradeReceivables" xlink:label="lbl_NoncurrentTradeReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentTradeReceivables" xlink:to="lbl_NoncurrentTradeReceivables_labels" xlink:type="arc"/>
      <link:label id="id_56c9fa84" xlink:label="lbl_NoncurrentFinancialAssetsAvailableforsale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial assets available-for-sale</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentFinancialAssetsAvailableforsale" xlink:label="lbl_NoncurrentFinancialAssetsAvailableforsale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialAssetsAvailableforsale" xlink:to="lbl_NoncurrentFinancialAssetsAvailableforsale_labels" xlink:type="arc"/>
      <link:label id="id_7f86a75a" xlink:label="lbl_NoncurrentFinancialAssetsAvailableforsale_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale long-term financial investments</link:label>
      <link:label id="id_416abfec" xlink:label="lbl_NoncurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term receivables from customers</link:label>
      <link:label id="id_614e0e43" xlink:label="lbl_NoncurrentLoansAndReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term loans, advances and security deposits</link:label>
      <link:label id="id_2adc1935" xlink:label="lbl_label719067445" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other non-current assets [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:label="lbl_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:to="lbl_label719067445" xlink:type="arc"/>
      <link:label id="id_372134b4" xlink:label="lbl_OtherNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentAssets" xlink:to="lbl_OtherNoncurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_36e85d79" xlink:label="lbl_OtherNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other non-current assets</link:label>
      <link:label id="id_3d890a89" xlink:label="lbl_label503420728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred compensation plans assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DeferredCompensationPlansAssets" xlink:label="lbl_DeferredCompensationPlansAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredCompensationPlansAssets" xlink:to="lbl_label503420728" xlink:type="arc"/>
      <link:label id="id_5743c2dd" xlink:label="lbl_PrepaidPostemploymentBenefitPlansAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid post-employment benefit plans assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PrepaidPostemploymentBenefitPlansAssets" xlink:label="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:to="lbl_PrepaidPostemploymentBenefitPlansAssets_labels" xlink:type="arc"/>
      <link:label id="id_509c8962" xlink:label="lbl_label1352436066" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MaturityAxis" xlink:to="lbl_label1352436066" xlink:type="arc"/>
      <link:label id="id_36becdba" xlink:label="lbl_label918474170" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregated time bands [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_label918474170" xlink:type="arc"/>
      <link:label id="id_19bac06a" xlink:label="lbl_NotLaterThanOneYearMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than one year [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NotLaterThanOneYearMember" xlink:to="lbl_NotLaterThanOneYearMember_labels" xlink:type="arc"/>
      <link:label id="id_40351209" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than five years [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember_labels" xlink:type="arc"/>
      <link:label id="id_26dc6723" xlink:label="lbl_LaterThanFiveYearsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than five years [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanFiveYearsMember" xlink:to="lbl_LaterThanFiveYearsMember_labels" xlink:type="arc"/>
      <link:label id="id_678942b3" xlink:label="lbl_NotLaterThanOneYearMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not later than one year</link:label>
      <link:label id="id_65bceee2" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Between one and five years</link:label>
      <link:label id="id_2043ab6e" xlink:label="lbl_LaterThanFiveYearsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Later than five years</link:label>
      <link:label id="id_1c8984aa" xlink:label="lbl_FinanceLeaseProvision_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance lease provision</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinanceLeaseProvision" xlink:label="lbl_FinanceLeaseProvision" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinanceLeaseProvision" xlink:to="lbl_FinanceLeaseProvision_labels" xlink:type="arc"/>
      <link:label id="id_4a3761d0" xlink:label="lbl_FinanceLeaseProvision_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Provision</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentFinanceLeaseReceivables" xlink:label="lbl_NoncurrentFinanceLeaseReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinanceLeaseReceivables" xlink:to="lbl_NoncurrentFinanceLeaseReceivables_labels" xlink:type="arc"/>
      <link:label id="id_5712ddf0" xlink:label="lbl_NoncurrentFinanceLeaseReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current finance lease receivables</link:label>
      <link:label id="id_3c5105da" xlink:label="lbl_IncomeStatementAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit or loss [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="lbl_IncomeStatementAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeStatementAbstract" xlink:to="lbl_IncomeStatementAbstract_labels" xlink:type="arc"/>
      <link:label id="id_3f03b5f7" xlink:label="lbl_IncomeStatementAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated income statements [abstract]</link:label>
      <link:label id="id_6acd9405" xlink:label="lbl_RevenueFromSaleOfGoods_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoods" xlink:to="lbl_RevenueFromSaleOfGoods_labels" xlink:type="arc"/>
      <link:label id="id_3a842f2" xlink:label="lbl_RevenueFromSaleOfGoods_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales</link:label>
      <link:label id="id_150c2b7f" xlink:label="lbl_OtherRevenue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherRevenue" xlink:to="lbl_OtherRevenue_labels" xlink:type="arc"/>
      <link:label id="id_127d952" xlink:label="lbl_OtherRevenue_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues</link:label>
      <link:label id="id_2760bdf6" xlink:label="lbl_CostOfSales_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CostOfSales" xlink:to="lbl_CostOfSales_labels" xlink:type="arc"/>
      <link:label id="id_2b80a016" xlink:label="lbl_CostOfSales_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</link:label>
      <link:label id="id_57c5a20d" xlink:label="lbl_GrossProfit_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossProfit" xlink:to="lbl_GrossProfit_labels" xlink:type="arc"/>
      <link:label id="id_526b4f9e" xlink:label="lbl_GrossProfit_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit from continuing operations</link:label>
      <link:label id="id_39d76e39" xlink:label="lbl_SalesAndMarketingExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales and marketing expense</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="lbl_SalesAndMarketingExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SalesAndMarketingExpense" xlink:to="lbl_SalesAndMarketingExpense_labels" xlink:type="arc"/>
      <link:label id="id_28a0f9b9" xlink:label="lbl_SalesAndMarketingExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Marketing and Sales</link:label>
      <link:label id="id_10d069b8" xlink:label="lbl_ResearchAndDevelopmentExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ResearchAndDevelopmentExpense" xlink:to="lbl_ResearchAndDevelopmentExpense_labels" xlink:type="arc"/>
      <link:label id="id_6d2fdc24" xlink:label="lbl_ResearchAndDevelopmentExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
      <link:label id="id_57c6dbd9" xlink:label="lbl_label1472650201" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherIncome" xlink:to="lbl_label1472650201" xlink:type="arc"/>
      <link:label id="id_5f87ab8e" xlink:label="lbl_ProfitLossFromOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from operating activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_ProfitLossFromOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_17803288" xlink:label="lbl_ProfitLossFromOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income from continuing operations</link:label>
      <link:label id="id_1fe0c0c6" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share of profit (loss) of associates and joint ventures accounted for using equity method</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:type="arc"/>
      <link:label id="id_487c7d01" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from associated companies</link:label>
      <link:label id="id_36251eec" xlink:label="lbl_ProfitLossFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from continuing operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="lbl_ProfitLossFromContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossFromContinuingOperations" xlink:to="lbl_ProfitLossFromContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_6dd27571" xlink:label="lbl_ProfitLossFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
      <link:label id="id_706453ab" xlink:label="lbl_IncomeTaxExpenseContinuingOperations_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes</link:label>
      <link:label id="id_1efbdca8" xlink:label="lbl_ProfitLossFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from discontinued operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossFromDiscontinuedOperations" xlink:to="lbl_ProfitLossFromDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_1ee0d5e9" xlink:label="lbl_ProfitLossFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income/loss from discontinued operations</link:label>
      <link:label id="id_390e92f5" xlink:label="lbl_ProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLoss" xlink:to="lbl_ProfitLoss_labels" xlink:type="arc"/>
      <link:label id="id_62e876b4" xlink:label="lbl_ProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
      <link:label id="id_6b81cf74" xlink:label="lbl_ProfitLossAttributableToAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="lbl_ProfitLossAttributableToAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToAbstract_labels" xlink:type="arc"/>
      <link:label id="id_1f2a4c4f" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to non-controlling interests</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:to="lbl_ProfitLossAttributableToNoncontrollingInterests_labels" xlink:type="arc"/>
      <link:label id="id_41604097" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
      <link:label id="id_68a67dec" xlink:label="lbl_label1755741676" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings per share [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsPerShareAbstract" xlink:label="lbl_BasicEarningsPerShareAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BasicEarningsPerShareAbstract" xlink:to="lbl_label1755741676" xlink:type="arc"/>
      <link:label id="id_4e036998" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Continuing operations</link:label>
      <link:label id="id_fc632c9" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations</link:label>
      <link:label id="id_6d6e73d7" xlink:label="lbl_label1835955159" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings per share [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsPerShareAbstract" xlink:label="lbl_DilutedEarningsPerShareAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DilutedEarningsPerShareAbstract" xlink:to="lbl_label1835955159" xlink:type="arc"/>
      <link:label id="id_78a7e003" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Continuing operations</link:label>
      <link:label id="id_2685ed2a" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations</link:label>
      <link:label id="id_506c062c" xlink:label="lbl_ProfitLossBeforeTax_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before taxes</link:label>
      <link:label id="id_4ec1d679" xlink:label="lbl_label1321326201" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="lbl_DisclosureOfClassesOfShareCapitalAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="lbl_label1321326201" xlink:type="arc"/>
      <link:label id="id_28aa5281" xlink:label="lbl_MovementInTheShareCapitalTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in the share capital [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MovementInTheShareCapitalTableTextBlock" xlink:label="lbl_MovementInTheShareCapitalTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MovementInTheShareCapitalTableTextBlock" xlink:to="lbl_MovementInTheShareCapitalTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_61f390ae" xlink:label="lbl_MovementInTheShareCapitalTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to movement in the share capital</link:label>
      <link:label id="id_696322e3" xlink:label="lbl_MovementInTheShareslTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in the shares [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MovementInTheShareslTableTextBlock" xlink:label="lbl_MovementInTheShareslTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MovementInTheShareslTableTextBlock" xlink:to="lbl_MovementInTheShareslTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3b7d854" xlink:label="lbl_MovementInTheShareslTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to movement in the shares</link:label>
      <link:label id="id_21fc0b5b" xlink:label="lbl_label570166107" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_label570166107" xlink:type="arc"/>
      <link:label id="id_69f171dc" xlink:label="lbl_label1777431004" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_label1777431004" xlink:type="arc"/>
      <link:label id="id_66229f4a" xlink:label="lbl_label1713545034" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="lbl_ClassesOfShareCapitalAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfShareCapitalAxis" xlink:to="lbl_label1713545034" xlink:type="arc"/>
      <link:label id="id_6258cf3f" xlink:label="lbl_ClassesOfShareCapitalMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share capital [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="lbl_ClassesOfShareCapitalMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_ClassesOfShareCapitalMember_labels" xlink:type="arc"/>
      <link:label id="id_45684f10" xlink:label="lbl_ChangesInEquity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in equity</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ChangesInEquity" xlink:label="lbl_ChangesInEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangesInEquity" xlink:to="lbl_ChangesInEquity_labels" xlink:type="arc"/>
      <link:label id="id_29e71b73" xlink:label="lbl_ChangesInEquity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Movement in the year</link:label>
      <link:label id="id_4ed5effa" xlink:label="lbl_TreasurySharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesMember" xlink:to="lbl_TreasurySharesMember_labels" xlink:type="arc"/>
      <link:label id="id_17794e38" xlink:label="lbl_OrdinarySharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary shares [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OrdinarySharesMember" xlink:label="lbl_OrdinarySharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OrdinarySharesMember" xlink:to="lbl_OrdinarySharesMember_labels" xlink:type="arc"/>
      <link:label id="id_b03287e" xlink:label="lbl_NumberOfSharesIssuedAndFullyPaid_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares issued and fully paid</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="lbl_NumberOfSharesIssuedAndFullyPaid" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfSharesIssuedAndFullyPaid" xlink:to="lbl_NumberOfSharesIssuedAndFullyPaid_labels" xlink:type="arc"/>
      <link:label id="id_1d73737e" xlink:label="lbl_NumberOfSharesOutstanding_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares outstanding</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="lbl_NumberOfSharesOutstanding" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfSharesOutstanding" xlink:to="lbl_NumberOfSharesOutstanding_labels" xlink:type="arc"/>
      <link:label id="id_4825d127" xlink:label="lbl_label1210437927" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in number of shares outstanding</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:label="lbl_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:to="lbl_label1210437927" xlink:type="arc"/>
      <link:label id="id_4881ff43" xlink:label="lbl_NumberOfSharesOutstanding_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of shares outstanding at beginning of period</link:label>
      <link:label id="id_40051e5a" xlink:label="lbl_NumberOfSharesOutstanding_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of shares outstanding at end of period</link:label>
      <link:label id="id_3bcbca2a" xlink:label="lbl_NumberOfSharesIssuedAndFullyPaid_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued and fully paid at beginning of period</link:label>
      <link:label id="id_733911db" xlink:label="lbl_NumberOfSharesIssuedAndFullyPaid_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued and fully paid at end of period</link:label>
      <link:label id="id_623febca" xlink:label="lbl_IssuedCapital_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Share capital at beginning of period</link:label>
      <link:label id="id_35d913cc" xlink:label="lbl_IssuedCapital_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Share capital at end of period</link:label>
      <link:label id="id_288f270c" xlink:label="lbl_TreasuryShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Treasury shares at end of period</link:label>
      <link:label id="id_140833fe" xlink:label="lbl_TreasuryShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Treasury shares at beginning of period</link:label>
      <link:label id="id_c7e7a97" xlink:label="lbl_Equity_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Equity at end of period</link:label>
      <link:label id="id_81b3b28" xlink:label="lbl_Equity_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Equity at beginning of period</link:label>
      <link:label id="id_102df8b6" xlink:label="lbl_PurchaseOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="lbl_PurchaseOfTreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfTreasuryShares" xlink:to="lbl_PurchaseOfTreasuryShares_labels" xlink:type="arc"/>
      <link:label id="id_151d9a8b" xlink:label="lbl_SaleOrIssueOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale or issue of treasury shares</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="lbl_SaleOrIssueOfTreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOrIssueOfTreasuryShares" xlink:to="lbl_SaleOrIssueOfTreasuryShares_labels" xlink:type="arc"/>
      <link:label id="id_20b3b802" xlink:label="lbl_label548648962" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="lbl_label548648962" xlink:type="arc"/>
      <link:label id="id_435514ee" xlink:label="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of events after reporting period [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_176c4f1e" xlink:label="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Events subsequent to the December 31 consolidated balance sheet date</link:label>
      <link:label id="id_34460981" xlink:label="lbl_label877005185" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Typ [axis]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SubsequentEventTypAxis" xlink:label="lbl_SubsequentEventTypAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SubsequentEventTypAxis" xlink:to="lbl_label877005185" xlink:type="arc"/>
      <link:label id="id_72e1dec5" xlink:label="lbl_label1927405253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SubsequentEventTypeMember" xlink:label="lbl_SubsequentEventTypeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SubsequentEventTypeMember" xlink:to="lbl_label1927405253" xlink:type="arc"/>
      <link:label id="id_1da2a9c4" xlink:label="lbl_label497199556" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SubsequentEventMember" xlink:label="lbl_SubsequentEventMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SubsequentEventMember" xlink:to="lbl_label497199556" xlink:type="arc"/>
      <link:label id="id_7f877b78" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:to="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners_labels" xlink:type="arc"/>
      <link:label id="id_7b380046" xlink:label="lbl_label2067267654" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and contingencies [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CommitmentsAndContingenciesAbstract" xlink:label="lbl_CommitmentsAndContingenciesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommitmentsAndContingenciesAbstract" xlink:to="lbl_label2067267654" xlink:type="arc"/>
      <link:label id="id_16b78de2" xlink:label="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of commitments and contingencies [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfCommitmentsAndContingenciesTextBlock" xlink:label="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock" xlink:to="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4488d3fd" xlink:label="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:label id="id_2de2541f" xlink:label="lbl_label769807391" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of significant transactions [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfSignificantTransactionsAbstract" xlink:label="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:to="lbl_label769807391" xlink:type="arc"/>
      <link:label id="id_157aa47d" xlink:label="lbl_DisclosureOfSignificantTransactionsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Significant transactions [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfSignificantTransactionsTextBlock" xlink:label="lbl_DisclosureOfSignificantTransactionsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantTransactionsTextBlock" xlink:to="lbl_DisclosureOfSignificantTransactionsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_17fcde6d" xlink:label="lbl_DisclosureOfSignificantTransactionsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant transactions</link:label>
      <link:label id="id_60f273a7" xlink:label="lbl_label1626502055" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:label="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_label1626502055" xlink:type="arc"/>
      <link:label id="id_7edd823a" xlink:label="lbl_DisclosureOfFinancialLiabilitiesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:label="lbl_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="lbl_DisclosureOfFinancialLiabilitiesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_7e94d6aa" xlink:label="lbl_DisclosureOfFinancialLiabilitiesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial debt</link:label>
      <link:label id="id_594cd676" xlink:label="lbl_label1498207862" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of current financial debt and derivative instruments [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_label1498207862" xlink:type="arc"/>
      <link:label id="id_716dfcd6" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of current financial debt and derivative instruments [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" xlink:to="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4ab48078" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current financial debt and derivative financial instruments</link:label>
      <link:label id="id_3d80ff4e" xlink:label="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-current portion of non-current borrowings by type [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" xlink:label="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" xlink:to="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5bcb7f48" xlink:label="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-current portion of non-current borrowings by type</link:label>
      <link:label id="id_84597e5" xlink:label="lbl_label138778597" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings</link:label>
      <link:label id="id_77855829" xlink:label="lbl_label2005227561" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:to="lbl_label2005227561" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:to="lbl_label138778597" xlink:type="arc"/>
      <link:label id="id_689e379d" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-current financial debt including current portion by maturity [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" xlink:to="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4824ba8c" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial debt including current portion by maturity</link:label>
      <link:label id="id_780939b8" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-current financial debt including current portion by currency [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" xlink:to="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_43204093" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial debt including current portion by currency</link:label>
      <link:label id="id_75f0b654" xlink:label="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of comparison of balance sheet and fair value of total non-current financial debt including current portion [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" xlink:label="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" xlink:to="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_18f19ce6" xlink:label="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comparison of balance sheet and fair value of total non-current financial debt including current portion</link:label>
      <link:label id="id_6962ebc4" xlink:label="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of collaerallized non-current financial debt and pledged assets [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" xlink:label="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" xlink:to="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1220efab" xlink:label="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaerallized non-current financial debt and pledged assets</link:label>
      <link:label id="id_4abca4e3" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of current financial debt and derivative instruments [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" xlink:to="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1f8d2d9c" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current financial debt and derivative instruments</link:label>
      <link:label id="id_8188b7e" xlink:label="lbl_DisclosureOfLeasingCommitmentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Leasing commitments [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfLeasingCommitmentsTableTextBlock" xlink:label="lbl_DisclosureOfLeasingCommitmentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfLeasingCommitmentsTableTextBlock" xlink:to="lbl_DisclosureOfLeasingCommitmentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_77b05f18" xlink:label="lbl_DisclosureOfLeasingCommitmentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasing commitments</link:label>
      <link:label id="id_6662e9d6" xlink:label="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of research and development commitments [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" xlink:label="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" xlink:to="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3f2ee562" xlink:label="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development and other intangible purchase commitments</link:label>
      <link:label id="id_2a65b84f" xlink:label="lbl_label711309391" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasing commitments [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LeasingCommitmentsAbstract" xlink:label="lbl_LeasingCommitmentsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeasingCommitmentsAbstract" xlink:to="lbl_label711309391" xlink:type="arc"/>
      <link:label id="id_1173f4bb" xlink:label="lbl_label292811963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule for commitments under fixed term operating leases [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:label="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:to="lbl_label292811963" xlink:type="arc"/>
      <link:label id="id_59b1ae19" xlink:label="lbl_label1504816665" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule for commitments under fixed term operating leases [line items]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:label="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:to="lbl_label1504816665" xlink:type="arc"/>
      <link:label id="id_a4d7aae" xlink:label="lbl_label172849838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than two years [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="lbl_label172849838" xlink:type="arc"/>
      <link:label id="id_717d4be6" xlink:label="lbl_label1904036838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than two years and not later than three years [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:to="lbl_label1904036838" xlink:type="arc"/>
      <link:label id="id_4d7a925b" xlink:label="lbl_label1299878491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than three years and not later than four years [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:to="lbl_label1299878491" xlink:type="arc"/>
      <link:label id="id_3b47450e" xlink:label="lbl_label994526478" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than four years and not later than five years [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:to="lbl_label994526478" xlink:type="arc"/>
      <link:label id="id_4b9f759a" xlink:label="lbl_label1268741530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development and other intangible asset purchase commitments [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ResearchAndDevelopmentCommitmentsAbstract" xlink:label="lbl_ResearchAndDevelopmentCommitmentsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ResearchAndDevelopmentCommitmentsAbstract" xlink:to="lbl_label1268741530" xlink:type="arc"/>
      <link:label id="id_714a8ba3" xlink:label="lbl_label1900710819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule for commitments under research and development and other intangible asset purchase [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:label="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:to="lbl_label1900710819" xlink:type="arc"/>
      <link:label id="id_36fa2fba" xlink:label="lbl_label922365882" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule for commitments under research and development and other intangible asset purchase [line items]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:label="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_label922365882" xlink:type="arc"/>
      <link:label id="id_5ab4de42" xlink:label="lbl_label632134259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments under long-term research and development agreements</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CommitmentsUnderLongtermResearchAgreements" xlink:label="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:to="lbl_label632134259" xlink:type="arc"/>
      <link:label id="id_2ceef672" xlink:label="lbl_label753858162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current financial debt and derivative financial instruments [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" xlink:label="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" xlink:to="lbl_label753858162" xlink:type="arc"/>
      <link:label id="id_68d6c1f6" xlink:label="lbl_label1758904822" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current financial debt and derivative financial instruments [line items]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_label1758904822" xlink:type="arc"/>
      <link:label id="id_797bb3cc" xlink:label="lbl_label2038150092" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest bearning accounts of associates payable on demand</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:label="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:to="lbl_label2038150092" xlink:type="arc"/>
      <link:label id="id_7b1552fe" xlink:label="lbl_ShorttermBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current borrowings</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShorttermBorrowings" xlink:label="lbl_ShorttermBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShorttermBorrowings" xlink:to="lbl_ShorttermBorrowings_labels" xlink:type="arc"/>
      <link:label id="id_5020629f" xlink:label="lbl_ShorttermBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bank and other financial debt</link:label>
      <link:label id="id_13e39c07" xlink:label="lbl_CommercialPapersIssued_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial papers issued</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CommercialPapersIssued" xlink:label="lbl_CommercialPapersIssued" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommercialPapersIssued" xlink:to="lbl_CommercialPapersIssued_labels" xlink:type="arc"/>
      <link:label id="id_4fdebda8" xlink:label="lbl_CommercialPapersIssued_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Papers</link:label>
      <link:label id="id_46dd5b19" xlink:label="lbl_CurrentPortionOfLongtermBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current portion of non-current borrowings</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentPortionOfLongtermBorrowings" xlink:to="lbl_CurrentPortionOfLongtermBorrowings_labels" xlink:type="arc"/>
      <link:label id="id_7558c2a6" xlink:label="lbl_CurrentPortionOfLongtermBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of non-current financial debt</link:label>
      <link:label id="id_36b8e550" xlink:label="lbl_label918086992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit derivative, fair value</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CreditDerivativeFairValue" xlink:label="lbl_CreditDerivativeFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CreditDerivativeFairValue" xlink:to="lbl_label918086992" xlink:type="arc"/>
      <link:label id="id_3a9947a0" xlink:label="lbl_DerivativeFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="lbl_DerivativeFinancialLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialLiabilities" xlink:to="lbl_DerivativeFinancialLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_6dcd1b42" xlink:label="lbl_DerivativeFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of derivative financial instruments</link:label>
      <link:label id="id_1dcb5ef8" xlink:label="lbl_WeightedAverageInterestRateAssociates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average interest rate, associates</link:label>
      <link:label id="id_2863fd2b" xlink:label="lbl_OtherCurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current financial debt and derivative financial instruments</link:label>
      <link:label id="id_5aca2f89" xlink:label="lbl_InterestExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
      <link:label id="id_74374cb6" xlink:label="lbl_label1949781174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of components of non-current financial debts [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:label="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_label1949781174" xlink:type="arc"/>
      <link:label id="id_7edb9957" xlink:label="lbl_label2128320855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of components of non-current financial debts [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" xlink:label="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" xlink:to="lbl_label2128320855" xlink:type="arc"/>
      <link:label id="id_10bc1963" xlink:label="lbl_label280762723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of components of non-current financial debts [line items]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:label="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_label280762723" xlink:type="arc"/>
      <link:label id="id_300b69ab" xlink:label="lbl_BondsIssued_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Straight bonds</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BondsIssued" xlink:to="lbl_BondsIssued_labels" xlink:type="arc"/>
      <link:label id="id_1e4e0830" xlink:label="lbl_BondsIssued_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bonds issued</link:label>
      <link:label id="id_203f2415" xlink:label="lbl_Borrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total including current portion of non-current financial debt</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Borrowings" xlink:to="lbl_Borrowings_labels" xlink:type="arc"/>
      <link:label id="id_1bc6ed35" xlink:label="lbl_Borrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
      <link:label id="id_2e986311" xlink:label="lbl_CurrentPortionOfLongtermBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Less current portion of non-current financial debt</link:label>
      <link:label id="id_355479bd" xlink:label="lbl_OtherNoncurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current financial debts</link:label>
      <link:label id="id_162b1eed" xlink:label="lbl_Borrowings_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">The amount of outstanding funds that the entity is obligated to repay</link:label>
      <link:label id="id_9d2aa80" xlink:label="lbl_label164801152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than five years and not later than six years [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:label="lbl_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:to="lbl_label164801152" xlink:type="arc"/>
      <link:label id="id_adae114" xlink:label="lbl_LaterThanSixYearsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than six years [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LaterThanSixYearsMember" xlink:label="lbl_LaterThanSixYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanSixYearsMember" xlink:to="lbl_LaterThanSixYearsMember_labels" xlink:type="arc"/>
      <link:label id="id_2050f0fd" xlink:label="lbl_LaterThanSixYearsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Later than six years</link:label>
      <link:label id="id_7e44b35f" xlink:label="lbl_label72836716" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Others</link:label>
      <link:label id="id_6a9e2b6" xlink:label="lbl_label111796918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of the collateralized non-current financial debt and pledged assets [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" xlink:label="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" xlink:to="lbl_label111796918" xlink:type="arc"/>
      <link:label id="id_57bebc13" xlink:label="lbl_label1472117779" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of the collateralized non-current financial debt and pledged assets [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" xlink:label="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" xlink:to="lbl_label1472117779" xlink:type="arc"/>
      <link:label id="id_6cdc708" xlink:label="lbl_label114149128" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of the collateralized non-current financial debt and pledged assets [line items]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:label="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:to="lbl_label114149128" xlink:type="arc"/>
      <link:label id="id_1ad42498" xlink:label="lbl_PropertyPlantAndEquipmentPledgedAsSecurity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, pledged as security</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:label="lbl_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:to="lbl_PropertyPlantAndEquipmentPledgedAsSecurity_labels" xlink:type="arc"/>
      <link:label id="id_4cf075ff" xlink:label="lbl_NoncurrentFinancialDebtsCoveredByCollateral_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial debts covered by collateral</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentFinancialDebtsCoveredByCollateral" xlink:label="lbl_NoncurrentFinancialDebtsCoveredByCollateral" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialDebtsCoveredByCollateral" xlink:to="lbl_NoncurrentFinancialDebtsCoveredByCollateral_labels" xlink:type="arc"/>
      <link:label id="id_cf0451a" xlink:label="lbl_NoncurrentFinancialDebtsCoveredByCollateral_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total amount of collateralized non-current financial debts</link:label>
      <link:label id="id_6e3a2d82" xlink:label="lbl_PropertyPlantAndEquipmentPledgedAsSecurity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total net book value of property, plant and equipment pledged as collateral for non-current financial debts</link:label>
      <link:label id="id_139c747e" xlink:label="lbl_label329020542" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:to="lbl_label329020542" xlink:type="arc"/>
      <link:label id="id_75a8b438" xlink:label="lbl_label1973990456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lbl_label1973990456" xlink:type="arc"/>
      <link:label id="id_3e0c6c47" xlink:label="lbl_label1041001543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_label1041001543" xlink:type="arc"/>
      <link:label id="id_776f09d7" xlink:label="lbl_label2003765719" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_label2003765719" xlink:type="arc"/>
      <link:label id="id_227fd573" xlink:label="lbl_label578803059" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_label578803059" xlink:type="arc"/>
      <link:label id="id_40a70df4" xlink:label="lbl_label1084689908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.25% EUR 1 500 million bond 2009/2016 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.757% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:label="lbl_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:to="lbl_label1084689908" xlink:type="arc"/>
      <link:label id="id_59ab4811" xlink:label="lbl_label1504397329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.4% USD 1 000 million bond 2010/2020 of Novartis Capital Corporation, New York United States, issued at 99.237% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:label="lbl_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:to="lbl_label1504397329" xlink:type="arc"/>
      <link:label id="id_57804983" xlink:label="lbl_label1468025219" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.4% USD 1 500 million bond 2012/2022 of Novartis Capital Corporation, New York United States, issued at 99.225% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:label="lbl_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:to="lbl_label1468025219" xlink:type="arc"/>
      <link:label id="id_7920acbc" xlink:label="lbl_label2032184508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.7% USD 500 million bond 2012/2042 of Novartis Capital Corporation, New York United States, issued at 98.325% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:label="lbl_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:to="lbl_label2032184508" xlink:type="arc"/>
      <link:label id="id_3ab016cd" xlink:label="lbl_label984618701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.4% USD 2 150 million bond 2014/2024 of Novartis Capital Corporation, New York United States, issued at 99.287% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:label="lbl_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:to="lbl_label984618701" xlink:type="arc"/>
      <link:label id="id_40a1b86b" xlink:label="lbl_label1084340331" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.4% USD 1 850 million bond 2014/2044 of Novartis Capital Corporation, New York United States, issued at 99.196% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:label="lbl_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:to="lbl_label1084340331" xlink:type="arc"/>
      <link:label id="id_78372e25" xlink:label="lbl_label2016882213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.75% EUR 600 million bond 2014/2021 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.134% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:label="lbl_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:to="lbl_label2016882213" xlink:type="arc"/>
      <link:label id="id_6e2b28f3" xlink:label="lbl_label1848322291" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.625% EUR 600 million bond 2014/2026 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.697% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:label="lbl_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:to="lbl_label1848322291" xlink:type="arc"/>
      <link:label id="id_7c889c9" xlink:label="lbl_label130582985" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.25% CHF 500 million bond 2015/2025 of Novartis AG Basel Switzerland, issued at 100.64% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:label="lbl_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:to="lbl_label130582985" xlink:type="arc"/>
      <link:label id="id_1321f0b" xlink:label="lbl_label20061963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.625% CHF 550 million bond 2015/2029 of Novartis AG Basel Switzerland, issued at 100.502% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:label="lbl_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:to="lbl_label20061963" xlink:type="arc"/>
      <link:label id="id_66ae9900" xlink:label="lbl_label1722718464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.050% CHF 325 million bond 2015/2035 of Novartis AG Basel Switzerland, issued at 100.479% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:label="lbl_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:to="lbl_label1722718464" xlink:type="arc"/>
      <link:label id="id_45d38312" xlink:label="lbl_label1171489554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.0% USD 1 750 million bond 2015/2025 of Novartis Capital Corporation, New York United States, issued at 99.010% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:label="lbl_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:to="lbl_label1171489554" xlink:type="arc"/>
      <link:label id="id_63c4e1e7" xlink:label="lbl_label1673847271" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.0% USD 1 250 million bond 2015/2045 of Novartis Capital Corporation, New York United States, issued at 98.029% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:label="lbl_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:to="lbl_label1673847271" xlink:type="arc"/>
      <link:label id="id_497f0505" xlink:label="lbl_label1233061125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.125% EUR 1 250 million bond 2016/2023 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.127% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:label="lbl_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:to="lbl_label1233061125" xlink:type="arc"/>
      <link:label id="id_5233650c" xlink:label="lbl_label1379099916" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.625% EUR 500 million bond 2016/2028 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 98.48% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:label="lbl_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:to="lbl_label1379099916" xlink:type="arc"/>
      <link:label id="id_5f125bc1" xlink:label="lbl_label1595038657" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notional amount</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotionalAmount" xlink:label="lbl_NotionalAmount" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NotionalAmount" xlink:to="lbl_label1595038657" xlink:type="arc"/>
      <link:label id="id_4a9f133" xlink:label="lbl_label78246195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, original currency</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsOriginalCurrency" xlink:label="lbl_BorrowingsOriginalCurrency" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsOriginalCurrency" xlink:to="lbl_label78246195" xlink:type="arc"/>
      <link:label id="id_3d3b01c0" xlink:label="lbl_BorrowingsMaturity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, maturity</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsMaturity" xlink:label="lbl_BorrowingsMaturity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsMaturity" xlink:to="lbl_BorrowingsMaturity_labels" xlink:type="arc"/>
      <link:label id="id_6970167" xlink:label="lbl_BorrowingsLender_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, lender</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsLender" xlink:label="lbl_BorrowingsLender" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsLender" xlink:to="lbl_BorrowingsLender_labels" xlink:type="arc"/>
      <link:label id="id_2d26d7a1" xlink:label="lbl_BorrowingsPremiumDiscount_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, premium discount</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsPremiumDiscount" xlink:label="lbl_BorrowingsPremiumDiscount" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsPremiumDiscount" xlink:to="lbl_BorrowingsPremiumDiscount_labels" xlink:type="arc"/>
      <link:label id="id_43d0ad58" xlink:label="lbl_label1137749336" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:to="lbl_label1137749336" xlink:type="arc"/>
      <link:label id="id_5168eb51" xlink:label="lbl_label1365830481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_label1365830481" xlink:type="arc"/>
      <link:label id="id_6ac35618" xlink:label="lbl_label1791186456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_label1791186456" xlink:type="arc"/>
      <link:label id="id_34e65236" xlink:label="lbl_label887509558" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LevelsOfFairValueHierarchyAxis" xlink:to="lbl_label887509558" xlink:type="arc"/>
      <link:label id="id_71bada1c" xlink:label="lbl_label1908070940" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All levels of fair value hierarchy [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_label1908070940" xlink:type="arc"/>
      <link:label id="id_7515173f" xlink:label="lbl_label1964316479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Level 1 of fair value hierarchy [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="lbl_Level1OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Level1OfFairValueHierarchyMember" xlink:to="lbl_label1964316479" xlink:type="arc"/>
      <link:label id="id_17ccd63f" xlink:label="lbl_label399300159" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Level 2 of fair value hierarchy [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="lbl_Level2OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Level2OfFairValueHierarchyMember" xlink:to="lbl_label399300159" xlink:type="arc"/>
      <link:label id="id_93d606b" xlink:label="lbl_label155017323" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Level 3 of fair value hierarchy [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="lbl_Level3OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Level3OfFairValueHierarchyMember" xlink:to="lbl_label155017323" xlink:type="arc"/>
      <link:label id="id_7c0df05a" xlink:label="lbl_OtherNoncurrentFinancialDebt_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current financial debt</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherNoncurrentFinancialDebt" xlink:label="lbl_OtherNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentFinancialDebt" xlink:to="lbl_OtherNoncurrentFinancialDebt_labels" xlink:type="arc"/>
      <link:label id="id_3aec21a3" xlink:label="lbl_OtherNoncurrentFinancialDebt_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Others</link:label>
      <link:label id="id_661a115" xlink:label="lbl_Borrowings_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
      <link:label id="id_45aae97f" xlink:label="lbl_label1168828799" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value by measurement basis [axis]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueByMeasurementBasisAxis" xlink:label="lbl_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueByMeasurementBasisAxis" xlink:to="lbl_label1168828799" xlink:type="arc"/>
      <link:label id="id_374d1399" xlink:label="lbl_label927798169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value by measurement basis [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueByMeasurementBasisMember" xlink:label="lbl_FairValueByMeasurementBasisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueByMeasurementBasisMember" xlink:to="lbl_label927798169" xlink:type="arc"/>
      <link:label id="id_5786569c" xlink:label="lbl_CarryingReportedAmountFairValueDisclosureMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying reported amount fair value disclosure [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CarryingReportedAmountFairValueDisclosureMember" xlink:label="lbl_CarryingReportedAmountFairValueDisclosureMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lbl_CarryingReportedAmountFairValueDisclosureMember_labels" xlink:type="arc"/>
      <link:label id="id_53a58f58" xlink:label="lbl_FairValueDisclosureItemAmountsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value disclosure item amounts [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueDisclosureItemAmountsMember" xlink:label="lbl_FairValueDisclosureItemAmountsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueDisclosureItemAmountsMember" xlink:to="lbl_FairValueDisclosureItemAmountsMember_labels" xlink:type="arc"/>
      <link:label id="id_5d4ffc36" xlink:label="lbl_FairValueDisclosureItemAmountsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair values</link:label>
      <link:label id="id_749b453a" xlink:label="lbl_CarryingReportedAmountFairValueDisclosureMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance sheet</link:label>
      <link:label id="id_670f6333" xlink:label="lbl_label1729061683" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of comprehensive income [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="lbl_StatementOfComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementOfComprehensiveIncomeAbstract" xlink:to="lbl_label1729061683" xlink:type="arc"/>
      <link:label id="id_2d51324" xlink:label="lbl_ProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
      <link:label id="id_669b15d1" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_labels" xlink:type="arc"/>
      <link:label id="id_624c557e" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income never to be recycled into the consolidated income statement</link:label>
      <link:label id="id_543798f6" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, available-for-sale financial assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_6e3138d0" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on marketable securities, net of taxes</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges_labels" xlink:type="arc"/>
      <link:label id="id_f9a3fe1" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on deferred cash flow hedges, net of taxes</link:label>
      <link:label id="id_63d7965" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, financial instruments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments_labels" xlink:type="arc"/>
      <link:label id="id_57f5d574" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total fair value adjustments on financial instruments, net of taxes</link:label>
      <link:label id="id_4fc35e7b" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_labels" xlink:type="arc"/>
      <link:label id="id_5227f572" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_6b11bff3" xlink:label="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income that will be reclassified to profit or loss, net of tax</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:type="arc"/>
      <link:label id="id_1e6e2048" xlink:label="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total of items to eventually recycle</link:label>
      <link:label id="id_485691e" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_labels1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_labels1" xlink:type="arc"/>
      <link:label id="id_6465e8d4" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_labels1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income to be eventually recycled into the consolidated income statement</link:label>
      <link:label id="id_2f7e508d" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:type="arc"/>
      <link:label id="id_7c43d9ec" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains/losses from defined benefit plans, net of taxes</link:label>
      <link:label id="id_20ffa710" xlink:label="lbl_ComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComprehensiveIncome" xlink:to="lbl_ComprehensiveIncome_labels" xlink:type="arc"/>
      <link:label id="id_27277ccb" xlink:label="lbl_ComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive income</link:label>
      <link:label id="id_5e2ce732" xlink:label="lbl_ComprehensiveIncomeAttributableToAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:to="lbl_ComprehensiveIncomeAttributableToAbstract_labels" xlink:type="arc"/>
      <link:label id="id_5ce83165" xlink:label="lbl_ComprehensiveIncomeAttributableToAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to</link:label>
      <link:label id="id_37725a9f" xlink:label="lbl_ComprehensiveIncomeAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income, attributable to owners of parent</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="lbl_ComprehensiveIncomeAttributableToOwnersOfParent_labels" xlink:type="arc"/>
      <link:label id="id_31bd4ac6" xlink:label="lbl_ComprehensiveIncomeAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders of Novartis AG</link:label>
      <link:label id="id_77aebdaf" xlink:label="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income, attributable to non-controlling interests</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:to="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests_labels" xlink:type="arc"/>
      <link:label id="id_30557ca" xlink:label="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
      <link:label id="id_3783d7c" xlink:label="lbl_ContinuingOperationsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Continuing operations</link:label>
      <link:label id="id_411d9c7f" xlink:label="lbl_DiscontinuedOperationsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations</link:label>
      <link:label id="id_4c054c08" xlink:label="lbl_OtherFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other financial income and expense</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_OtherFinanceIncomeCost_labels" xlink:type="arc"/>
      <link:label id="id_f2e2db3" xlink:label="lbl_OtherFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other financial income and expense from continuing operations</link:label>
      <link:label id="id_53dc86a1" xlink:label="lbl_OtherFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial income and expense</link:label>
      <link:label id="id_12f9d391" xlink:label="lbl_OtherFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other financial income and expense</link:label>
      <link:label id="id_76e0ee52" xlink:label="lbl_ProfitLossAttributableToAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to</link:label>
      <link:label id="id_533d4513" xlink:label="lbl_label1396524307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="lbl_StatementOfCashFlowsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementOfCashFlowsAbstract" xlink:to="lbl_label1396524307" xlink:type="arc"/>
      <link:label id="id_1706da9a" xlink:label="lbl_label386325146" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="lbl_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_label386325146" xlink:type="arc"/>
      <link:label id="id_23f6c7e5" xlink:label="lbl_label603375589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="lbl_StatementOfChangesInEquityTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementOfChangesInEquityTable" xlink:to="lbl_label603375589" xlink:type="arc"/>
      <link:label id="id_37845a12" xlink:label="lbl_label931420690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_label931420690" xlink:type="arc"/>
      <link:label id="id_ba7f520" xlink:label="lbl_label160680069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityMember" xlink:to="lbl_label160680069" xlink:type="arc"/>
      <link:label id="id_3004ac5a" xlink:label="lbl_label805612634" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity attributable to owners of parent [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_label805612634" xlink:type="arc"/>
      <link:label id="id_4221701b" xlink:label="lbl_label1109487643" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-controlling interests [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="lbl_NoncontrollingInterestsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncontrollingInterestsMember" xlink:to="lbl_label1109487643" xlink:type="arc"/>
      <link:label id="id_6ac2ea98" xlink:label="lbl_IssuedCapitalMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="lbl_IssuedCapitalMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IssuedCapitalMember" xlink:to="lbl_IssuedCapitalMember_labels" xlink:type="arc"/>
      <link:label id="id_37852f90" xlink:label="lbl_RetainedEarningsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="lbl_RetainedEarningsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RetainedEarningsMember" xlink:to="lbl_RetainedEarningsMember_labels" xlink:type="arc"/>
      <link:label id="id_3014527f" xlink:label="lbl_label806638207" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="lbl_StatementOfChangesInEquityLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_label806638207" xlink:type="arc"/>
      <link:label id="id_7cb9019e" xlink:label="lbl_label2092499358" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="lbl_OtherComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncome" xlink:to="lbl_label2092499358" xlink:type="arc"/>
      <link:label id="id_14c74049" xlink:label="lbl_DividendsPaid_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends recognised as distributions to owners</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPaid" xlink:label="lbl_DividendsPaid" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsPaid" xlink:to="lbl_DividendsPaid_labels" xlink:type="arc"/>
      <link:label id="id_55c8d5fc" xlink:label="lbl_DividendsPaid_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividends</link:label>
      <link:label id="id_290fddfc" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase/decrease of treasury share repurchase obligation under a share buyback trading plan</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:to="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan_labels" xlink:type="arc"/>
      <link:label id="id_35016d1a" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:to="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:type="arc"/>
      <link:label id="id_4817c0e9" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of change in ownership of consolidated entities</link:label>
      <link:label id="id_4d8eb67a" xlink:label="lbl_ChangesInEquity_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total of other equity movements</link:label>
      <link:label id="id_67a41ed4" xlink:label="lbl_label1738809044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments related to divestments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsRelatedToDivestments" xlink:label="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:to="lbl_label1738809044" xlink:type="arc"/>
      <link:label id="id_63274027" xlink:label="lbl_IssuedCapitalMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
      <link:label id="id_403fccbc" xlink:label="lbl_TreasurySharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares</link:label>
      <link:label id="id_74d7e6ee" xlink:label="lbl_RetainedEarningsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
      <link:label id="id_b4d100c" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, fair value adjustments on deferred cash flow hedges</link:label>
      <link:label id="id_780100c2" xlink:label="lbl_InterestReceivedClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest received, classified as operating activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:to="lbl_InterestReceivedClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_62d0936a" xlink:label="lbl_InterestReceivedClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest received</link:label>
      <link:label id="id_7b5cb6f6" xlink:label="lbl_InterestPaidClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest paid, classified as operating activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:to="lbl_InterestPaidClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_39ba29d5" xlink:label="lbl_InterestPaidClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
      <link:label id="id_1c3cdb2b" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund), classified as operating activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_66b0d29c" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid</link:label>
      <link:label id="id_72973404" xlink:label="lbl_label1922511876" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows from operating activities from continuing operations before working capital and provision changes</link:label>
      <link:label id="id_2f19480a" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments out of provisions and other net cash movements in non-current liabilities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:to="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_2fccc455" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in net current assets and other operating cash flow items</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems_labels" xlink:type="arc"/>
      <link:label id="id_7e94f37" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities, continuing operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_364038a2" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows from operating activities from continuing operations</link:label>
      <link:label id="id_2c0f5fb2" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities, discontinued operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_658b02cd" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows from operating activities from discontinued operations</link:label>
      <link:label id="id_77c3c41b" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_CashFlowsFromUsedInOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_4017c1c6" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total net cash flows from operating activities</link:label>
      <link:label id="id_668e4218" xlink:label="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_6c172e00" xlink:label="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
      <link:label id="id_79511d66" xlink:label="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales of property, plant and equipment</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_5310686b" xlink:label="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of intangible assets, classified as investing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_4e39a447" xlink:label="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of intangible assets</link:label>
      <link:label id="id_209f49b7" xlink:label="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales of intangible assets, classified as investing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_2fc66d2d" xlink:label="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of intangible assets</link:label>
      <link:label id="id_eed6ef4" xlink:label="lbl_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of financial assets, classified as investing activities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" xlink:to="lbl_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_7b96e87e" xlink:label="lbl_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of financial assets</link:label>
      <link:label id="id_674ec417" xlink:label="lbl_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales of financial assets, classified as investing activities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" xlink:to="lbl_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_3a72549d" xlink:label="lbl_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of financial assets</link:label>
      <link:label id="id_4799c790" xlink:label="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of other long-term assets, classified as investing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:to="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_5d62cc13" xlink:label="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of other non-current assets</link:label>
      <link:label id="id_4b05fa70" xlink:label="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales of other long-term assets, classified as investing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:to="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_2f0edb6a" xlink:label="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of other non-current assets</link:label>
      <link:label id="id_5354701a" xlink:label="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other cash payments to acquire equity or debt instruments of other entities, classified as investing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:to="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_2333df3a" xlink:label="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities and commodities</link:label>
      <link:label id="id_8f147c1" xlink:label="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other cash receipts from sales of equity or debt instruments of other entities, classified as investing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:to="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_c3ff34a" xlink:label="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of marketable securities and commodities</link:label>
      <link:label id="id_220d8b31" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities, continuing operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_1940f2ef" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash flows used in investing activities from continuing operations</link:label>
      <link:label id="id_bda8617" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities, discontinued operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_741f077b" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows used in/from investing activities from discontinued operations</link:label>
      <link:label id="id_34225142" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInInvestingActivities" xlink:to="lbl_CashFlowsFromUsedInInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_140f33b4" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash flows used in investing activities</link:label>
      <link:label id="id_643efdb2" xlink:label="lbl_PaymentsToAcquireOrRedeemEntitysShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to acquire or redeem entity's shares</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:to="lbl_PaymentsToAcquireOrRedeemEntitysShares_labels" xlink:type="arc"/>
      <link:label id="id_6226a1d0" xlink:label="lbl_PaymentsToAcquireOrRedeemEntitysShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of treasury shares</link:label>
      <link:label id="id_4f16d177" xlink:label="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of options and other treasury share transactions</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:label="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:to="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions_labels" xlink:type="arc"/>
      <link:label id="id_1e868ebc" xlink:label="lbl_CashFlowsFromUsedInFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInFinancingActivities" xlink:to="lbl_CashFlowsFromUsedInFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_2bab504d" xlink:label="lbl_CashFlowsFromUsedInFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total net cash flows used in financing activities</link:label>
      <link:label id="id_5774a6d0" xlink:label="lbl_label1467262672" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lbl_label1467262672" xlink:type="arc"/>
      <link:label id="id_649add65" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_605d8076" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total net change in cash and cash equivalents</link:label>
      <link:label id="id_153736f0" xlink:label="lbl_CashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
      <link:label id="id_354ffdea" xlink:label="lbl_CashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
      <link:label id="id_433b1725" xlink:label="lbl_label1127946021" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows before working capital and provision changes</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:label="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:to="lbl_label1127946021" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:to="lbl_label1922511876" xlink:type="arc"/>
      <link:label id="id_7f2f5c65" xlink:label="lbl_label2133810277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">5.125% USD 3 000 million bond 2009/2019 of Novaritis Securities Investment Ltd., Hamilton, Bermuda issued at 99.822% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:label="lbl_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:to="lbl_label2133810277" xlink:type="arc"/>
      <link:label id="id_429c1826" xlink:label="lbl_BorrowingsIssuanceDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, issuance date</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsIssuanceDate" xlink:label="lbl_BorrowingsIssuanceDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsIssuanceDate" xlink:to="lbl_BorrowingsIssuanceDate_labels" xlink:type="arc"/>
      <link:label id="id_2669d99c" xlink:label="lbl_label644471196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency, others [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrencyOthersMember" xlink:label="lbl_CurrencyOthersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrencyOthersMember" xlink:to="lbl_label644471196" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrencyOthersMember" xlink:to="lbl_label72836716" xlink:type="arc"/>
      <link:label id="id_27412435" xlink:label="lbl_CurrentPortionOfLongtermBorrowings_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less current portion of non-current financial debt</link:label>
      <link:label id="id_45c60d00" xlink:label="lbl_label1170607360" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:to="lbl_label1170607360" xlink:type="arc"/>
      <link:label id="id_388165d3" xlink:label="lbl_label948004307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_label948004307" xlink:type="arc"/>
      <link:label id="id_7de10318" xlink:label="lbl_label2111898392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_label2111898392" xlink:type="arc"/>
      <link:label id="id_1b1dbf0c" xlink:label="lbl_label454934284" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiaries [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lbl_label454934284" xlink:type="arc"/>
      <link:label id="id_1eb1092a" xlink:label="lbl_label514918698" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for subsidiaries [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="lbl_EntitysTotalForSubsidiariesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntitysTotalForSubsidiariesMember" xlink:to="lbl_label514918698" xlink:type="arc"/>
      <link:label id="id_3d371bfe" xlink:label="lbl_label1027021822" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiaries [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SubsidiariesMember" xlink:label="lbl_SubsidiariesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SubsidiariesMember" xlink:to="lbl_label1027021822" xlink:type="arc"/>
      <link:label id="id_644266d7" xlink:label="lbl_label1682073303" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating income [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OperatingIncomeMember" xlink:label="lbl_OperatingIncomeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OperatingIncomeMember" xlink:to="lbl_label1682073303" xlink:type="arc"/>
      <link:label id="id_41ead269" xlink:label="lbl_TranscendMedicalIncMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transcend Medical Inc [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TranscendMedicalIncMember" xlink:label="lbl_TranscendMedicalIncMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TranscendMedicalIncMember" xlink:to="lbl_TranscendMedicalIncMember_labels" xlink:type="arc"/>
      <link:label id="id_7cc6732" xlink:label="lbl_TranscendMedicalIncMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transcend Medical Inc.</link:label>
      <link:label id="id_5c37cd24" xlink:label="lbl_SelexysPharmaceuticalsCorporationMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selexys Pharmaceuticals Corporation [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SelexysPharmaceuticalsCorporationMember" xlink:label="lbl_SelexysPharmaceuticalsCorporationMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SelexysPharmaceuticalsCorporationMember" xlink:to="lbl_SelexysPharmaceuticalsCorporationMember_labels" xlink:type="arc"/>
      <link:label id="id_26bb8728" xlink:label="lbl_SelexysPharmaceuticalsCorporationMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selexys Pharmaceuticals Corporation</link:label>
      <link:label id="id_f0f7125" xlink:label="lbl_ZiarcoGroupLimitedMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ziarco Group Limited [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ZiarcoGroupLimitedMember" xlink:label="lbl_ZiarcoGroupLimitedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZiarcoGroupLimitedMember" xlink:to="lbl_ZiarcoGroupLimitedMember_labels" xlink:type="arc"/>
      <link:label id="id_74cc0f0d" xlink:label="lbl_ZiarcoGroupLimitedMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ziarco Group Limited</link:label>
      <link:label id="id_2cf9a6d0" xlink:label="lbl_EncoreVisionIncMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Encore Vision, Inc [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EncoreVisionIncMember" xlink:label="lbl_EncoreVisionIncMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EncoreVisionIncMember" xlink:to="lbl_EncoreVisionIncMember_labels" xlink:type="arc"/>
      <link:label id="id_14700202" xlink:label="lbl_EncoreVisionIncMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Encore Vision, Inc.</link:label>
      <link:label id="id_4323a92b" xlink:label="lbl_EliLillyAndCompanyMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eli Lilly and Company [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EliLillyAndCompanyMember" xlink:label="lbl_EliLillyAndCompanyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EliLillyAndCompanyMember" xlink:to="lbl_EliLillyAndCompanyMember_labels" xlink:type="arc"/>
      <link:label id="id_7d1163f7" xlink:label="lbl_EliLillyAndCompanyMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eli Lilly and Company</link:label>
      <link:label id="id_406cf0bb" xlink:label="lbl_GSKOncologyProductsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK Oncology Products [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GSKOncologyProductsMember" xlink:label="lbl_GSKOncologyProductsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GSKOncologyProductsMember" xlink:to="lbl_GSKOncologyProductsMember_labels" xlink:type="arc"/>
      <link:label id="id_4dee8051" xlink:label="lbl_GSKOncologyProductsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK Oncology Products</link:label>
      <link:label id="id_543b3534" xlink:label="lbl_GSKVaccinesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK Vaccines [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GSKVaccinesMember" xlink:label="lbl_GSKVaccinesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GSKVaccinesMember" xlink:to="lbl_GSKVaccinesMember_labels" xlink:type="arc"/>
      <link:label id="id_50145ee" xlink:label="lbl_GSKVaccinesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK Vaccines</link:label>
      <link:label id="id_258b2077" xlink:label="lbl_GSKConsumerHealthcareMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK Consumer Healthcare [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GSKConsumerHealthcareMember" xlink:label="lbl_GSKConsumerHealthcareMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GSKConsumerHealthcareMember" xlink:to="lbl_GSKConsumerHealthcareMember_labels" xlink:type="arc"/>
      <link:label id="id_5cb81481" xlink:label="lbl_GSKConsumerHealthcareMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK Consumer Healthcare</link:label>
      <link:label id="id_2c752dc" xlink:label="lbl_GSKTotalTransactionMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK Total Transaction [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GSKTotalTransactionMember" xlink:label="lbl_GSKTotalTransactionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GSKTotalTransactionMember" xlink:to="lbl_GSKTotalTransactionMember_labels" xlink:type="arc"/>
      <link:label id="id_366ab1d6" xlink:label="lbl_GSKTotalTransactionMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK Total Transaction</link:label>
      <link:label id="id_2144f8b2" xlink:label="lbl_CSLMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CSL [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CSLMember" xlink:label="lbl_CSLMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CSLMember" xlink:to="lbl_CSLMember_labels" xlink:type="arc"/>
      <link:label id="id_5f983746" xlink:label="lbl_CSLMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CSL</link:label>
      <link:label id="id_1961772e" xlink:label="lbl_SpinifexMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Spinifex [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SpinifexMember" xlink:label="lbl_SpinifexMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SpinifexMember" xlink:to="lbl_SpinifexMember_labels" xlink:type="arc"/>
      <link:label id="id_7bf72331" xlink:label="lbl_SpinifexMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Spinifex</link:label>
      <link:label id="id_72aed040" xlink:label="lbl_AdmuneTheraputicsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Admune Theraputics [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdmuneTheraputicsMember" xlink:label="lbl_AdmuneTheraputicsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdmuneTheraputicsMember" xlink:to="lbl_AdmuneTheraputicsMember_labels" xlink:type="arc"/>
      <link:label id="id_1b618d38" xlink:label="lbl_AdmuneTheraputicsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Admune Theraputics</link:label>
      <link:label id="id_2608381e" xlink:label="lbl_label638072862" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration transferred, acquisition-date fair value</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:to="lbl_label638072862" xlink:type="arc"/>
      <link:label id="id_6adf03f3" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion of consideration paid (received) consisting of cash and cash equivalents</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_29fb9219" xlink:label="lbl_label704352793" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent liabilities recognised as of acquisition date</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lbl_label704352793" xlink:type="arc"/>
      <link:label id="id_7589cc7b" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Identifiable assets acquired (liabilities assumed)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed_labels" xlink:type="arc"/>
      <link:label id="id_770a51dc" xlink:label="lbl_AdditionalRecognitionGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional recognition, goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:label="lbl_AdditionalRecognitionGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionalRecognitionGoodwill" xlink:to="lbl_AdditionalRecognitionGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_159fb0c8" xlink:label="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_labels" xlink:type="arc"/>
      <link:label id="id_bb4840e" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition-date fair value of equity interest in acquiree held by acquirer immediately before acquisition date</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:to="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_1f8e7785" xlink:label="lbl_label529430405" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (loss) recognised as result of remeasuring to fair value equity interest in acquiree held by acquirer before business combination</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:label="lbl_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:to="lbl_label529430405" xlink:type="arc"/>
      <link:label id="id_7a59b5df" xlink:label="lbl_label2052699615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of voting equity interests acquired</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="lbl_PercentageOfVotingEquityInterestsAcquired" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfVotingEquityInterestsAcquired" xlink:to="lbl_label2052699615" xlink:type="arc"/>
      <link:label id="id_3ce5a3b3" xlink:label="lbl_label1021682611" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:to="lbl_label1021682611" xlink:type="arc"/>
      <link:label id="id_4e581a" xlink:label="lbl_label5134362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of arrangement for contingent consideration arrangements and indemnification assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:label="lbl_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:to="lbl_label5134362" xlink:type="arc"/>
      <link:label id="id_3ebaa53a" xlink:label="lbl_label1052419386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of provisions and other current liabilities [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_label1052419386" xlink:type="arc"/>
      <link:label id="id_280373ad" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of provisions and other current liabilities explanatory [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" xlink:to="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_58be9555" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions and other current liabilities</link:label>
      <link:label id="id_6f3dfdd7" xlink:label="lbl_label1866333655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of acquisition of businesses [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:label="lbl_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:to="lbl_label1866333655" xlink:type="arc"/>
      <link:label id="id_74ec4e33" xlink:label="lbl_DisclosureOfBusinessCombinationsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of business combinations [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:label="lbl_DisclosureOfBusinessCombinationsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfBusinessCombinationsExplanatory" xlink:to="lbl_DisclosureOfBusinessCombinationsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_1fdc2fef" xlink:label="lbl_DisclosureOfBusinessCombinationsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of businesses</link:label>
      <link:label id="id_32cb811d" xlink:label="lbl_label852197661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_label852197661" xlink:type="arc"/>
      <link:label id="id_503f4b80" xlink:label="lbl_DisclosureOfEmployeeBenefitsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of employee benefits [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:label="lbl_DisclosureOfEmployeeBenefitsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="lbl_DisclosureOfEmployeeBenefitsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_4572e29d" xlink:label="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of provisions and other current liabilities [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7df1458c" xlink:label="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions and other current liabilities</link:label>
      <link:label id="id_330b4ffd" xlink:label="lbl_ProvisionsForReductionOfRevenueTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions for reduction of revenue [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionsForReductionOfRevenueTableTextBlock" xlink:label="lbl_ProvisionsForReductionOfRevenueTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionsForReductionOfRevenueTableTextBlock" xlink:to="lbl_ProvisionsForReductionOfRevenueTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2487cf91" xlink:label="lbl_ProvisionsForReductionOfRevenueTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for reduction of revenue</link:label>
      <link:label id="id_cda5e36" xlink:label="lbl_RestructuringProvisionsMovementsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring provisions movements [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RestructuringProvisionsMovementsTableTextBlock" xlink:label="lbl_RestructuringProvisionsMovementsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestructuringProvisionsMovementsTableTextBlock" xlink:to="lbl_RestructuringProvisionsMovementsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_50653a58" xlink:label="lbl_RestructuringProvisionsMovementsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring provisions movements</link:label>
      <link:label id="id_51adf498" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of assets and liabilities arising from acquisitions [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" xlink:to="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_55fc13ca" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of assets and liabilities arising from acquisitions</link:label>
      <link:label id="id_43a17f70" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:to="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4ac74a65" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of the funded and unfunded defined benefit obligation for pension and other post retirement benefit plans table</link:label>
      <link:label id="id_7580bb7" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:to="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5d57abea" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of the net liability table</link:label>
      <link:label id="id_8f2e3e1" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Breakdown of defined benefit obligation for pension plans and other post-employment benefit [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:to="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_26221373" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Breakdown of defined benefit obligation for pension plans and other post-employment benefit</link:label>
      <link:label id="id_7b5fd886" xlink:label="lbl_ScheduleOfAssumptionsUsedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of assumptions used [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="lbl_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lbl_ScheduleOfAssumptionsUsedTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_83b4487" xlink:label="lbl_ScheduleOfAssumptionsUsedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal weighted average actuarial assumptions</link:label>
      <link:label id="id_5a767463" xlink:label="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of sensitivity analysis for actuarial assumptions [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:label="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:to="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7c6a492e" xlink:label="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The sensitivity of the defined benefit pension obligation to the principal actuarial assumptions</link:label>
      <link:label id="id_40d21ce7" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of health care cost trend rates [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:to="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_28fc355" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The healthcare cost trend rate assumptions used for other post-employment benefits</link:label>
      <link:label id="id_37e4cfa4" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of allocation of plan assets [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:to="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_a47f671" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The weighted average plan asset allocation of funded defined benefit pension plans</link:label>
      <link:label id="id_14ebebe1" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of expected benefit payments [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7cfc7cde" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The expected future cash flows in respect of pension and other post- employment benefit plans</link:label>
      <link:label id="id_5cc7b4f2" xlink:label="lbl_label1556591858" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="lbl_label1556591858" xlink:type="arc"/>
      <link:label id="id_751ab231" xlink:label="lbl_label1964683825" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:to="lbl_label1964683825" xlink:type="arc"/>
      <link:label id="id_4f2027d2" xlink:label="lbl_label1327507410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_label1327507410" xlink:type="arc"/>
      <link:label id="id_44180645" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currently marketed products intangible assets recognised as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_7b396a57" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currently marketed products</link:label>
      <link:label id="id_2a66227f" xlink:label="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired research and development intangible assets recognised as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_520a49db" xlink:label="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired research and development</link:label>
      <link:label id="id_79560b48" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other intangible assets recognised as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_2e2e2336" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
      <link:label id="id_2367c616" xlink:label="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax assets recognised as of acquisition date</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:to="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_5161ba57" xlink:label="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
      <link:label id="id_62ae6b6f" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory recognised as of acquisition date</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:to="lbl_InventoryRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_4affdfb9" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
      <link:label id="id_5c47e1cf" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables and other current assets recognised as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_59b962bd" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables and financial and other current assets</link:label>
      <link:label id="id_13b05f40" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents recognised as of acquisition date</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:to="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_33b144aa" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:label id="id_262ed31" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net assets recognized as a result of acquisitions of business</link:label>
      <link:label id="id_7c2d8d71" xlink:label="lbl_label2083360113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill expected to be deductible for tax purposes</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodwillExpectedDeductibleForTaxPurposes" xlink:label="lbl_GoodwillExpectedDeductibleForTaxPurposes" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GoodwillExpectedDeductibleForTaxPurposes" xlink:to="lbl_label2083360113" xlink:type="arc"/>
      <link:label id="id_1e18b9d2" xlink:label="lbl_label504936914" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions and other current liabilities [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionsAndOtherCurrentLiabilitiesTable" xlink:label="lbl_ProvisionsAndOtherCurrentLiabilitiesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesTable" xlink:to="lbl_label504936914" xlink:type="arc"/>
      <link:label id="id_77fdfffd" xlink:label="lbl_label2013134845" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potentially refundable consideration from acquisition</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PotentiallyRefundableConsiderationFromAcquisition" xlink:label="lbl_PotentiallyRefundableConsiderationFromAcquisition" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentiallyRefundableConsiderationFromAcquisition" xlink:to="lbl_label2013134845" xlink:type="arc"/>
      <link:label id="id_240ec6" xlink:label="lbl_label2363078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of potentially refundable contingent consideration</link:label>
      <link:label id="id_5bb1899c" xlink:label="lbl_label1538361756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract right of first negotiation term</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContractRightOfFirstNegotiationTerm" xlink:label="lbl_ContractRightOfFirstNegotiationTerm" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContractRightOfFirstNegotiationTerm" xlink:to="lbl_label1538361756" xlink:type="arc"/>
      <link:label id="id_3eeb75f2" xlink:label="lbl_label1055618546" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue of acquiree since acquisition date</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueOfAcquiree" xlink:label="lbl_RevenueOfAcquiree" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueOfAcquiree" xlink:to="lbl_label1055618546" xlink:type="arc"/>
      <link:label id="id_742dd0f8" xlink:label="lbl_label1949159672" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue of acquiree full year</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueOfAcquireeFullYear" xlink:label="lbl_RevenueOfAcquireeFullYear" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueOfAcquireeFullYear" xlink:to="lbl_label1949159672" xlink:type="arc"/>
      <link:label id="id_37ba66ca" xlink:label="lbl_label934962890" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of business assets arising from contingencies amount recognized</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:label="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:to="lbl_label934962890" xlink:type="arc"/>
      <link:label id="id_53d61f56" xlink:label="lbl_label1406541654" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of business assets arising from contingencies amount recognized other than at fair value</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:label="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:to="lbl_label1406541654" xlink:type="arc"/>
      <link:label id="id_6acd7a2d" xlink:label="lbl_label1791851053" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of business, contingent consideration arrangements, range of outcomes, value, high</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="lbl_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lbl_label1791851053" xlink:type="arc"/>
      <link:label id="id_c33fcc1" xlink:label="lbl_label204733633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of business, contingent option arrangements, range of outcomes, value, high</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:label="lbl_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:to="lbl_label204733633" xlink:type="arc"/>
      <link:label id="id_22e7f31e" xlink:label="lbl_label585626398" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of business, contingent option arrangements, fee paid</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:label="lbl_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:to="lbl_label585626398" xlink:type="arc"/>
      <link:label id="id_4739cf42" xlink:label="lbl_label1194970946" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in subsidiaries, joint ventures and associates</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="lbl_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:to="lbl_label1194970946" xlink:type="arc"/>
      <link:label id="id_7e1ee3b5" xlink:label="lbl_label2115953589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of voting equity interests contributed</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PercentageOfVotingEquityInterestsContributed" xlink:label="lbl_PercentageOfVotingEquityInterestsContributed" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfVotingEquityInterestsContributed" xlink:to="lbl_label2115953589" xlink:type="arc"/>
      <link:label id="id_376f146e" xlink:label="lbl_TransactionRelatedCosts_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction related costs</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TransactionRelatedCosts" xlink:label="lbl_TransactionRelatedCosts" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionRelatedCosts" xlink:to="lbl_TransactionRelatedCosts_labels" xlink:type="arc"/>
      <link:label id="id_2d34f9e9" xlink:label="lbl_TransactionRelatedCostsPaid_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction related costs paid</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TransactionRelatedCostsPaid" xlink:label="lbl_TransactionRelatedCostsPaid" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionRelatedCostsPaid" xlink:to="lbl_TransactionRelatedCostsPaid_labels" xlink:type="arc"/>
      <link:label id="id_7a2e51fc" xlink:label="lbl_label690911032" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLoss" xlink:label="lbl_ImpairmentLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLoss" xlink:to="lbl_label690911032" xlink:type="arc"/>
      <link:label id="id_67f3701a" xlink:label="lbl_label1744007194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reversal of impairment loss</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReversalOfImpairmentLoss" xlink:label="lbl_ReversalOfImpairmentLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReversalOfImpairmentLoss" xlink:to="lbl_label1744007194" xlink:type="arc"/>
      <link:label id="id_7cff95a1" xlink:label="lbl_label2097124769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions and other current liabilities [line items]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:label="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:to="lbl_label2097124769" xlink:type="arc"/>
      <link:label id="id_772301d6" xlink:label="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for taxes other than income taxes, current</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent_labels" xlink:type="arc"/>
      <link:label id="id_2dc3de10" xlink:label="lbl_ShorttermRestructuringProvision_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current restructuring provision</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShorttermRestructuringProvision" xlink:label="lbl_ShorttermRestructuringProvision" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShorttermRestructuringProvision" xlink:to="lbl_ShorttermRestructuringProvision_labels" xlink:type="arc"/>
      <link:label id="id_5b202ec3" xlink:label="lbl_ShorttermRestructuringProvision_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring provisions</link:label>
      <link:label id="id_6d2493bb" xlink:label="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued royalties payable classified as current</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:label="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:to="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent_labels" xlink:type="arc"/>
      <link:label id="id_198471b1" xlink:label="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals for royalties</link:label>
      <link:label id="id_3eae10b2" xlink:label="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes other than income taxes</link:label>
      <link:label id="id_4d2d81e4" xlink:label="lbl_ShorttermEmployeeBenefitsAccruals_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term employee benefits accruals</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="lbl_ShorttermEmployeeBenefitsAccruals" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShorttermEmployeeBenefitsAccruals" xlink:to="lbl_ShorttermEmployeeBenefitsAccruals_labels" xlink:type="arc"/>
      <link:label id="id_28ce7ee" xlink:label="lbl_ShorttermEmployeeBenefitsAccruals_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accurals for compensation and benefits including social security</link:label>
      <link:label id="id_72d5fdf0" xlink:label="lbl_DeferredIncomeClassifiedAsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred income classified as current</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredIncomeClassifiedAsCurrent" xlink:label="lbl_DeferredIncomeClassifiedAsCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredIncomeClassifiedAsCurrent" xlink:to="lbl_DeferredIncomeClassifiedAsCurrent_labels" xlink:type="arc"/>
      <link:label id="id_315adc93" xlink:label="lbl_DeferredIncomeClassifiedAsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income</link:label>
      <link:label id="id_dfd6824" xlink:label="lbl_ShorttermLegalProceedingsProvision_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current legal proceedings provision</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShorttermLegalProceedingsProvision" xlink:label="lbl_ShorttermLegalProceedingsProvision" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShorttermLegalProceedingsProvision" xlink:to="lbl_ShorttermLegalProceedingsProvision_labels" xlink:type="arc"/>
      <link:label id="id_3dc37367" xlink:label="lbl_ShorttermLegalProceedingsProvision_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for product liabilities, governmental investigations and other legal matters</link:label>
      <link:label id="id_7364ea66" xlink:label="lbl_OtherCurrentPayables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current payables</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentPayables" xlink:label="lbl_OtherCurrentPayables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentPayables" xlink:to="lbl_OtherCurrentPayables_labels" xlink:type="arc"/>
      <link:label id="id_53bd8e15" xlink:label="lbl_OtherCurrentPayables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other payables</link:label>
      <link:label id="id_16646c9e" xlink:label="lbl_label375680158" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue [roll forward]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionsForDeductionsFromRevenueRollForward" xlink:label="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_label375680158" xlink:type="arc"/>
      <link:label id="id_236d2862" xlink:label="lbl_label594356322" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of other provisions [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_label594356322" xlink:type="arc"/>
      <link:label id="id_4ebad11d" xlink:label="lbl_label1320866077" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other provisions [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_label1320866077" xlink:type="arc"/>
      <link:label id="id_40fd93ca" xlink:label="lbl_RefundsProvisionMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Refunds provision [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RefundsProvisionMember" xlink:label="lbl_RefundsProvisionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RefundsProvisionMember" xlink:to="lbl_RefundsProvisionMember_labels" xlink:type="arc"/>
      <link:label id="id_134ebfe2" xlink:label="lbl_RefundsProvisionMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deductions from revenue</link:label>
      <link:label id="id_5e5b3081" xlink:label="lbl_OtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other provisions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherProvisions" xlink:label="lbl_OtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherProvisions" xlink:to="lbl_OtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_21da05f2" xlink:label="lbl_OtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Provision at end of period</link:label>
      <link:label id="id_3b690ec5" xlink:label="lbl_OtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Provision at beginning of period</link:label>
      <link:label id="id_7d787c31" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through loss of control of subsidiary, other provisions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:to="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_ff50d0a" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Provisions related to discontinued operations</link:label>
      <link:label id="id_5bf5caac" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations, other provisions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_2a95f348" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_27eafa" xlink:label="lbl_AdditionalProvisionsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional provisions, other provisions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="lbl_AdditionalProvisionsOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionalProvisionsOtherProvisions" xlink:to="lbl_AdditionalProvisionsOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_2c66d271" xlink:label="lbl_AdditionalProvisionsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
      <link:label id="id_fe1b238" xlink:label="lbl_ProvisionUsedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision used, other provisions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="lbl_ProvisionUsedOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionUsedOtherProvisions" xlink:to="lbl_ProvisionUsedOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_36a5293f" xlink:label="lbl_ProvisionUsedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/utilizations</link:label>
      <link:label id="id_359f477c" xlink:label="lbl_ChangesInOffsetAgainstGrossTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in offset against gross trade receivables</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangesInOffsetAgainstGrossTradeReceivables" xlink:label="lbl_ChangesInOffsetAgainstGrossTradeReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangesInOffsetAgainstGrossTradeReceivables" xlink:to="lbl_ChangesInOffsetAgainstGrossTradeReceivables_labels" xlink:type="arc"/>
      <link:label id="id_18735dbe" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, other provisions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_16f119f6" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_482a71cf" xlink:label="lbl_UnusedProvisionReversedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused provision reversed, other provisions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:label="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnusedProvisionReversedOtherProvisions" xlink:to="lbl_UnusedProvisionReversedOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_28d3a14e" xlink:label="lbl_ProvisionUsedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash payments</link:label>
      <link:label id="id_45b7ba0b" xlink:label="lbl_UnusedProvisionReversedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Releases</link:label>
      <link:label id="id_26660dfe" xlink:label="lbl_RestructuringProvisionMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring provision [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestructuringProvisionMember" xlink:label="lbl_RestructuringProvisionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestructuringProvisionMember" xlink:to="lbl_RestructuringProvisionMember_labels" xlink:type="arc"/>
      <link:label id="id_23d5363a" xlink:label="lbl_RestructuringProvisionMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring provision</link:label>
      <link:label id="id_79614e6" xlink:label="lbl_label127276262" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring provisions movements [roll forward]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RestructuringProvisionsMovementsRollForward" xlink:label="lbl_RestructuringProvisionsMovementsRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_label127276262" xlink:type="arc"/>
      <link:label id="id_51cb80cd" xlink:label="lbl_label1372291277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of trade receivables [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfTradeReceivablesAbstract" xlink:label="lbl_DisclosureOfTradeReceivablesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTradeReceivablesAbstract" xlink:to="lbl_label1372291277" xlink:type="arc"/>
      <link:label id="id_2ea0d5c3" xlink:label="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of trade receivables explanatory [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfTradeReceivablesExplanatoryTextBlock" xlink:label="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock" xlink:to="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6dd7d3e3" xlink:label="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables</link:label>
      <link:label id="id_2c1cad42" xlink:label="lbl_ProvisionsForTradeReceivablesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions for trade receivables [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionsForTradeReceivablesTableTextBlock" xlink:label="lbl_ProvisionsForTradeReceivablesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionsForTradeReceivablesTableTextBlock" xlink:to="lbl_ProvisionsForTradeReceivablesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3b131312" xlink:label="lbl_ProvisionsForTradeReceivablesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for trade receivables</link:label>
      <link:label id="id_2ef5991b" xlink:label="lbl_TradeReceivablesProvisionMovementsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables provision movements [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradeReceivablesProvisionMovementsTableTextBlock" xlink:label="lbl_TradeReceivablesProvisionMovementsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesProvisionMovementsTableTextBlock" xlink:to="lbl_TradeReceivablesProvisionMovementsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_77f758ca" xlink:label="lbl_TradeReceivablesProvisionMovementsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables provision movements</link:label>
      <link:label id="id_5d967f7b" xlink:label="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Overdue amounts and related provisions [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OverdueAmountsAndRelatedProvisionsTableTextBlock" xlink:label="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock" xlink:to="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2b0e9f8f" xlink:label="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overdue amounts and related provision</link:label>
      <link:label id="id_22339022" xlink:label="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables denominated in other currencies [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" xlink:label="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" xlink:to="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1c976f04" xlink:label="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables denominated in other currencies</link:label>
      <link:label id="id_3cb8d68f" xlink:label="lbl_label1018746511" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of provision matrix [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixAbstract" xlink:label="lbl_DisclosureOfProvisionMatrixAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfProvisionMatrixAbstract" xlink:to="lbl_label1018746511" xlink:type="arc"/>
      <link:label id="id_43d6f278" xlink:label="lbl_label1138160248" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of provision matrix [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixTable" xlink:label="lbl_DisclosureOfProvisionMatrixTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_label1138160248" xlink:type="arc"/>
      <link:label id="id_4c9afaa7" xlink:label="lbl_label1285225127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of provision matrix [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_label1285225127" xlink:type="arc"/>
      <link:label id="id_3182649e" xlink:label="lbl_label830629022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_label830629022" xlink:type="arc"/>
      <link:label id="id_5ff48884" xlink:label="lbl_label1609861252" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, class [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_label1609861252" xlink:type="arc"/>
      <link:label id="id_75e5081d" xlink:label="lbl_label123214748" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesMember" xlink:to="lbl_label123214748" xlink:type="arc"/>
      <link:label id="id_2e086500" xlink:label="lbl_CurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTradeReceivables" xlink:to="lbl_CurrentTradeReceivables_labels" xlink:type="arc"/>
      <link:label id="id_79f9d46a" xlink:label="lbl_CurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total trade receivables, net</link:label>
      <link:label id="id_3425f2e0" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for doubtful trade receivables related to discontinued operations</link:label>
      <link:label id="id_4ce7ed6d" xlink:label="lbl_AdditionalProvisionsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Provisions for doubtful trade receivables charged to the consolidated income statement</link:label>
      <link:label id="id_53792c91" xlink:label="lbl_ProvisionUsedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Utilization of reversal of provisions for doubtful trade receivables</link:label>
      <link:label id="id_74c340b1" xlink:label="lbl_label1958953137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of overdue amounts [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AnalysisOfOverdueAmountsTable" xlink:label="lbl_AnalysisOfOverdueAmountsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_label1958953137" xlink:type="arc"/>
      <link:label id="id_6ce050f6" xlink:label="lbl_label1826640118" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Past due status [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PastDueStatusAxis" xlink:label="lbl_PastDueStatusAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PastDueStatusAxis" xlink:to="lbl_label1826640118" xlink:type="arc"/>
      <link:label id="id_3284c13a" xlink:label="lbl_label847561018" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Past due status [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PastDueStatusMember" xlink:label="lbl_PastDueStatusMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PastDueStatusMember" xlink:to="lbl_label847561018" xlink:type="arc"/>
      <link:label id="id_21859e37" xlink:label="lbl_label562404919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentMember" xlink:label="lbl_CurrentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentMember" xlink:to="lbl_label562404919" xlink:type="arc"/>
      <link:label id="id_36a38547" xlink:label="lbl_label916686151" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of overdue amounts [line items]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AnalysisOfOverdueAmountsLineItems" xlink:label="lbl_AnalysisOfOverdueAmountsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AnalysisOfOverdueAmountsLineItems" xlink:to="lbl_label916686151" xlink:type="arc"/>
      <link:label id="id_5fbcb687" xlink:label="lbl_label1606203015" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of receivables denominated in various currencies [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:label="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:to="lbl_label1606203015" xlink:type="arc"/>
      <link:label id="id_2efadcc4" xlink:label="lbl_label788192452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables from closely monitored countries</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentTradeReceivablesFromCloselyMonitoredCountries" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountries" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountries" xlink:to="lbl_label788192452" xlink:type="arc"/>
      <link:label id="id_d85c974" xlink:label="lbl_label226871668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables from closely monitored countries past due more than one year</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" xlink:to="lbl_label226871668" xlink:type="arc"/>
      <link:label id="id_5358f3b4" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables from closely monitored countries past due more than one year, provisions recorded</link:label>
      <link:label id="id_7e49d670" xlink:label="lbl_label2118768240" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="lbl_label2118768240" xlink:type="arc"/>
      <link:label id="id_5081e337" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:to="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_172e52ca" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Group subsidiaries and associated companies</link:label>
      <link:label id="id_2f049798" xlink:label="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal Group subsidiaries and associated companies [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" xlink:label="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" xlink:to="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_678c8520" xlink:label="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Group subsidiaries and associated companies</link:label>
      <link:label id="id_171309e1" xlink:label="lbl_label387123681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lbl_label387123681" xlink:type="arc"/>
      <link:label id="id_7e6d2d55" xlink:label="lbl_label2121084245" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_label2121084245" xlink:type="arc"/>
      <link:label id="id_5b223713" xlink:label="lbl_label1528968979" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of subsidiary</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NameOfSubsidiary" xlink:label="lbl_NameOfSubsidiary" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NameOfSubsidiary" xlink:to="lbl_label1528968979" xlink:type="arc"/>
      <link:label id="id_2bc20f05" xlink:label="lbl_label734138117" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal place of business of subsidiary</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" xlink:label="lbl_PrincipalPlaceOfBusinessOfSubsidiary" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PrincipalPlaceOfBusinessOfSubsidiary" xlink:to="lbl_label734138117" xlink:type="arc"/>
      <link:label id="id_5cbe6246" xlink:label="lbl_label1555980870" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Country of incorporation of subsidiary</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:label="lbl_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:to="lbl_label1555980870" xlink:type="arc"/>
      <link:label id="id_77c5a25c" xlink:label="lbl_label2009440860" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in subsidiary</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:to="lbl_label2009440860" xlink:type="arc"/>
      <link:label id="id_64c53647" xlink:label="lbl_label1690646087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of voting rights held in subsidiary</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xlink:label="lbl_ProportionOfVotingPowerHeldInSubsidiary" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProportionOfVotingPowerHeldInSubsidiary" xlink:to="lbl_label1690646087" xlink:type="arc"/>
      <link:label id="id_5c37870a" xlink:label="lbl_label1547142922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share/paid-in capital</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharePaidinCapital" xlink:label="lbl_SharePaidinCapital" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharePaidinCapital" xlink:to="lbl_label1547142922" xlink:type="arc"/>
      <link:label id="id_3c7cb5b5" xlink:label="lbl_label1014805941" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Societe par actions SANDOZ, Algiers [member]</link:label>
      <link:label id="id_1fee848b" xlink:label="lbl_label535725195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Argentina S.A., Buenos Aires [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisArgentinaS.A.BuenosAiresMember" xlink:label="lbl_NovartisArgentinaS.A.BuenosAiresMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisArgentinaS.A.BuenosAiresMember" xlink:to="lbl_label535725195" xlink:type="arc"/>
      <link:label id="id_37e7fad0" xlink:label="lbl_label937949904" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratorios S.A., Buenos Aires [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriosS.A.BuenosAiresMember" xlink:label="lbl_AlconLaboratoriosS.A.BuenosAiresMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriosS.A.BuenosAiresMember" xlink:to="lbl_label937949904" xlink:type="arc"/>
      <link:label id="id_3ea304fe" xlink:label="lbl_label1050871038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche Holding AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RocheHoldingAGBaselMember" xlink:label="lbl_RocheHoldingAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RocheHoldingAGBaselMember" xlink:to="lbl_label1050871038" xlink:type="arc"/>
      <link:label id="id_6ed1f5c4" xlink:label="lbl_label1859253700" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_label1859253700" xlink:type="arc"/>
      <link:label id="id_258b1d67" xlink:label="lbl_label629874023" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_label629874023" xlink:type="arc"/>
      <link:label id="id_d3021ba" xlink:label="lbl_label221258170" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_label221258170" xlink:type="arc"/>
      <link:label id="id_7226aa6a" xlink:label="lbl_ForeignCountriesMember_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Rest of the world</link:label>
      <link:label id="id_494ba6f4" xlink:label="lbl_label1229694708" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plans [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="lbl_DefinedBenefitPlansMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlansMember" xlink:to="lbl_label1229694708" xlink:type="arc"/>
      <link:label id="id_1d4af2d7" xlink:label="lbl_label491451095" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic defined benefit plans [member]</link:label>
      <link:label id="id_48d21535" xlink:label="lbl_label1221727541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign defined benefit plans [member]</link:label>
      <link:label id="id_53109a65" xlink:label="lbl_ConcentrationOfMajorPlansGeographic_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration of major plans, geographic</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ConcentrationOfMajorPlansGeographic" xlink:label="lbl_ConcentrationOfMajorPlansGeographic" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConcentrationOfMajorPlansGeographic" xlink:to="lbl_ConcentrationOfMajorPlansGeographic_labels" xlink:type="arc"/>
      <link:label id="id_6dd86874" xlink:label="lbl_ConcentrationOfMajorPlansGeographic_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description of the major plans and the concentration of the Group's DBO by geography.</link:label>
      <link:label id="id_55c3f642" xlink:label="lbl_label1438905922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of plan amendments, curtailments and settlements</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements" xlink:label="lbl_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements1" xlink:to="lbl_label1438905922" xlink:type="arc"/>
      <link:label id="id_5774006e" xlink:label="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, recognized net gain (loss) due to curtailments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:label="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:to="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_labels" xlink:type="arc"/>
      <link:label id="id_1a9c795a" xlink:label="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Pre-tax curtailment gain (loss)</link:label>
      <link:label id="id_3ccdda27" xlink:label="lbl_label1020123687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plans [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="lbl_DefinedBenefitPlansAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlansAxis" xlink:to="lbl_label1020123687" xlink:type="arc"/>
      <link:label id="id_66c824b2" xlink:label="lbl_label1724392626" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement plan type [axis]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_label1724392626" xlink:type="arc"/>
      <link:label id="id_1c17a6ba" xlink:label="lbl_label471312058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement plan type [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_label471312058" xlink:type="arc"/>
      <link:label id="id_2219e14f" xlink:label="lbl_PensionPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension plan [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PensionPlanMember" xlink:to="lbl_PensionPlanMember_labels" xlink:type="arc"/>
      <link:label id="id_35fad562" xlink:label="lbl_OtherPostemploymentBenefitPlansMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other post-employment benefit plans [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherPostemploymentBenefitPlansMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember_labels" xlink:type="arc"/>
      <link:label id="id_2e4ea0d1" xlink:label="lbl_PensionPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension plans</link:label>
      <link:label id="id_67c584f7" xlink:label="lbl_OtherPostemploymentBenefitPlansMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other post-employment benefit plans</link:label>
      <link:label id="id_3d342709" xlink:label="lbl_DefinedBenefitObligationAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit obligation, at present value</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitObligationAtPresentValue" xlink:to="lbl_DefinedBenefitObligationAtPresentValue_labels" xlink:type="arc"/>
      <link:label id="id_22ca7a55" xlink:label="lbl_DefinedBenefitObligationAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Benefit obligation at beginning of period</link:label>
      <link:label id="id_7de6506d" xlink:label="lbl_DefinedBenefitObligationAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Benefit obligation at end of period</link:label>
      <link:label id="id_30925057" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current service cost, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:to="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_38d91a7e" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current service cost</link:label>
      <link:label id="id_2bef8750" xlink:label="lbl_DefinedBenefitPlanInterestCost_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, interest cost</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanInterestCost" xlink:label="lbl_DefinedBenefitPlanInterestCost" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanInterestCost" xlink:to="lbl_DefinedBenefitPlanInterestCost_labels" xlink:type="arc"/>
      <link:label id="id_6cf59b38" xlink:label="lbl_DefinedBenefitPlanInterestCost_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest cost</link:label>
      <link:label id="id_d5fe3e9" xlink:label="lbl_DefinedBenefitPlanInterestCost_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase in a defined benefit pension plan's projected benefit obligation or a defined benefit postretirement plan's accumulated postretirement benefit obligation due to the passage of time.</link:label>
      <link:label id="id_4281521a" xlink:label="lbl_AdministrativeExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Administrative expenses</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdministrativeExpense" xlink:label="lbl_AdministrativeExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdministrativeExpense" xlink:to="lbl_AdministrativeExpense_labels" xlink:type="arc"/>
      <link:label id="id_603d3cd8" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial gains (losses) arising from changes in financial assumptions, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_48f72a8" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Remeasurement losses/(gains) arising from changes in financial assumptions</link:label>
      <link:label id="id_3f236d51" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial gains (losses) arising from changes in demographic assumptions, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_78d171f" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Remeasurement (gains) arising from changes in demographic assumptions</link:label>
      <link:label id="id_7a970ce2" xlink:label="lbl_label783050349" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Experience-related remeasurement losses/(gains)</link:label>
      <link:label id="id_783c6ad8" xlink:label="lbl_label220841955" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_45220e6b" xlink:label="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments from plan, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:label="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:to="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_1ebcfd45" xlink:label="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Benefit payments</link:label>
      <link:label id="id_6368b27" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contributions to plan by plan participants, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:to="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_481bb1bf" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributions of associates</link:label>
      <link:label id="id_8f2ae87" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through acquisitions, divestments or transfers, benefit obligation</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1_labels" xlink:type="arc"/>
      <link:label id="id_474719e9" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of acquisitions, divestments or transfers</link:label>
      <link:label id="id_26d72366" xlink:label="lbl_PlanAssetsAtFairValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan assets, at fair value</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="lbl_PlanAssetsAtFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PlanAssetsAtFairValue" xlink:to="lbl_PlanAssetsAtFairValue_labels" xlink:type="arc"/>
      <link:label id="id_753e351c" xlink:label="lbl_PlanAssetsAtFairValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value of plan assets at beginning of period</link:label>
      <link:label id="id_432fa1b8" xlink:label="lbl_PlanAssetsAtFairValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value of plan assets at end of period</link:label>
      <link:label id="id_5996aa5" xlink:label="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense (income), defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:label="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:to="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_f38ab5e" xlink:label="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
      <link:label id="id_72396f28" xlink:label="lbl_ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Return on plan assets excluding interest income, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset" xlink:to="lbl_ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_3dae186e" xlink:label="lbl_ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Return on plan assets excluding interest income</link:label>
      <link:label id="id_66d6f9ff" xlink:label="lbl_label1273555602" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_37b55377" xlink:label="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contributions to plan by employer, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:to="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_12bfbc9" xlink:label="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis Group contributions</link:label>
      <link:label id="id_2adf4a42" xlink:label="lbl_DefinedBenefitPlanSettlementsPlanAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Settlements, Plan Assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanSettlementsPlanAssets" xlink:label="lbl_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanSettlementsPlanAssets" xlink:to="lbl_DefinedBenefitPlanSettlementsPlanAssets_labels" xlink:type="arc"/>
      <link:label id="id_6615f676" xlink:label="lbl_DefinedBenefitPlanSettlementsPlanAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
      <link:label id="id_4cd3f00b" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through acquisitions, divestments or transfers, defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1_labels" xlink:type="arc"/>
      <link:label id="id_410b8f27" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect of acquisitions, divestments or transfers</link:label>
      <link:label id="id_c41cf6c" xlink:label="lbl_label205639532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, change in benefit obligation [roll forward]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_label205639532" xlink:type="arc"/>
      <link:label id="id_3bf9f9ba" xlink:label="lbl_label1006238138" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, change in fair value of plan assets [roll forward]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_label1006238138" xlink:type="arc"/>
      <link:label id="id_290f00a6" xlink:label="lbl_SurplusDeficitInPlan_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Surplus (deficit) in plan</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="lbl_SurplusDeficitInPlan" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SurplusDeficitInPlan" xlink:to="lbl_SurplusDeficitInPlan_labels" xlink:type="arc"/>
      <link:label id="id_9610a9f" xlink:label="lbl_SurplusDeficitInPlan_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Funded status</link:label>
      <link:label id="id_5aa411ee" xlink:label="lbl_label1520701934" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, change in limitation on recognition of fund surplus [roll forward]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_label1520701934" xlink:type="arc"/>
      <link:label id="id_161add1b" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:to="lbl_LiabilityAssetOfDefinedBenefitPlans_labels" xlink:type="arc"/>
      <link:label id="id_37321747" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net liability in the balance sheet at end of period</link:label>
      <link:label id="id_5bdc9111" xlink:label="lbl_LimitationOnRecognitionOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Limitation on recognition of fund surplus</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LimitationOnRecognitionOfFundSurplus" xlink:label="lbl_LimitationOnRecognitionOfFundSurplus" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LimitationOnRecognitionOfFundSurplus" xlink:to="lbl_LimitationOnRecognitionOfFundSurplus_labels" xlink:type="arc"/>
      <link:label id="id_76d185b5" xlink:label="lbl_LimitationOnRecognitionOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Limitation on recognition of fund surplus at beginning of period</link:label>
      <link:label id="id_1ada4e58" xlink:label="lbl_LimitationOnRecognitionOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Limitation on recognition of fund surplus at end of period</link:label>
      <link:label id="id_6ef6a13c" xlink:label="lbl_ChangeInLimitationOnRecognitionOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in limitation on recognition of fund surplus</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeInLimitationOnRecognitionOfFundSurplus" xlink:label="lbl_ChangeInLimitationOnRecognitionOfFundSurplus" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangeInLimitationOnRecognitionOfFundSurplus" xlink:to="lbl_ChangeInLimitationOnRecognitionOfFundSurplus_labels" xlink:type="arc"/>
      <link:label id="id_203a6ebf" xlink:label="lbl_ChangeInLimitationOnRecognitionOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in limitation on recognition of fund surplus (incl. exchange rate differences)</link:label>
      <link:label id="id_5d578703" xlink:label="lbl_label1566017283" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income on limitation of fund surplus</link:label>
      <link:label id="id_1c085865" xlink:label="lbl_InterestIncomeOnLimitationOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income on limitation of fund surplus</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestIncomeOnLimitationOfFundSurplus" xlink:label="lbl_InterestIncomeOnLimitationOfFundSurplus" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestIncomeOnLimitationOfFundSurplus" xlink:to="lbl_InterestIncomeOnLimitationOfFundSurplus_labels" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestIncomeOnLimitationOfFundSurplus" xlink:to="lbl_label1566017283" xlink:type="arc"/>
      <link:label id="id_155f6c71" xlink:label="lbl_label358575217" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lbl_label358575217" xlink:type="arc"/>
      <link:label id="id_25ebb8ae" xlink:label="lbl_label636205230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, change in net liability [roll forward]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_label636205230" xlink:type="arc"/>
      <link:label id="id_54f9f34f" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Net liability at end of period</link:label>
      <link:label id="id_56e703b2" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Net liability at beginning of period</link:label>
      <link:label id="id_4c3018ba" xlink:label="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense (income), net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:label="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:to="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_493d88c7" xlink:label="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net interest expense</link:label>
      <link:label id="id_58444b6a" xlink:label="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (loss) on remeasurement, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:label="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:to="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_b032860" xlink:label="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remeasurements</link:label>
      <link:label id="id_16e626ad" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through changes in foreign exchange rates, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_6f51c69e" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_3d05f86e" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through acquisitions, divestments or transfers, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1_labels" xlink:type="arc"/>
      <link:label id="id_594017b5" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of acquisitions, divestments or transfers</link:label>
      <link:label id="id_f5fa1d1" xlink:label="lbl_label257925585" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts recognized in the consolidated balance sheet [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:label="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:to="lbl_label257925585" xlink:type="arc"/>
      <link:label id="id_5b08b7db" xlink:label="lbl_label1527298011" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued benefit liability</link:label>
      <link:label id="id_1ec53fdb" xlink:label="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit pension plan, accrued benefit liability</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:label="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:to="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities_labels" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:to="lbl_label1527298011" xlink:type="arc"/>
      <link:label id="id_1b1c172d" xlink:label="lbl_label454825773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Breakdown of defined benefit obligation for pension plans [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_label454825773" xlink:type="arc"/>
      <link:label id="id_574cbf67" xlink:label="lbl_label1464647527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Obligation by type [axis]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ObligationByTypeAxis" xlink:label="lbl_ObligationByTypeAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ObligationByTypeAxis" xlink:to="lbl_label1464647527" xlink:type="arc"/>
      <link:label id="id_59c768c3" xlink:label="lbl_ObligationByTypeMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Obligation by type [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ObligationByTypeMember" xlink:label="lbl_ObligationByTypeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_ObligationByTypeMember_labels" xlink:type="arc"/>
      <link:label id="id_e411de0" xlink:label="lbl_UnfundedMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unfunded [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UnfundedMember" xlink:label="lbl_UnfundedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnfundedMember" xlink:to="lbl_UnfundedMember_labels" xlink:type="arc"/>
      <link:label id="id_206ca87f" xlink:label="lbl_ObligationByTypeMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Obligation by type</link:label>
      <link:label id="id_4964c411" xlink:label="lbl_UnfundedMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unfunded</link:label>
      <link:label id="id_15c93075" xlink:label="lbl_ActiveMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Active [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ActiveMember" xlink:label="lbl_ActiveMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActiveMember" xlink:to="lbl_ActiveMember_labels" xlink:type="arc"/>
      <link:label id="id_4cc31394" xlink:label="lbl_ActiveMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Active</link:label>
      <link:label id="id_4cfa00d5" xlink:label="lbl_DeferredPensionersMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred pensioners [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DeferredPensionersMember" xlink:label="lbl_DeferredPensionersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredPensionersMember" xlink:to="lbl_DeferredPensionersMember_labels" xlink:type="arc"/>
      <link:label id="id_452ea3f3" xlink:label="lbl_DeferredPensionersMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred pensioners</link:label>
      <link:label id="id_9ccd7d0" xlink:label="lbl_PensionersMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pensioners [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PensionersMember" xlink:label="lbl_PensionersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PensionersMember" xlink:to="lbl_PensionersMember_labels" xlink:type="arc"/>
      <link:label id="id_77f4d5bf" xlink:label="lbl_PensionersMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pensioners</link:label>
      <link:label id="id_41aa0977" xlink:label="lbl_label1101662583" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of defined benefit plans disclosures [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lbl_label1101662583" xlink:type="arc"/>
      <link:label id="id_70b19e47" xlink:label="lbl_ActuarialAssumptionOfDiscountRates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of discount rates</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:label="lbl_ActuarialAssumptionOfDiscountRates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfDiscountRates" xlink:to="lbl_ActuarialAssumptionOfDiscountRates_labels" xlink:type="arc"/>
      <link:label id="id_30e2ed44" xlink:label="lbl_ActuarialAssumptionOfDiscountRates_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
      <link:label id="id_228400f7" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of pension increases</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_labels" xlink:type="arc"/>
      <link:label id="id_5ba9eb34" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected rate of pension increase</link:label>
      <link:label id="id_4f7f1dac" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of salary increases</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_labels" xlink:type="arc"/>
      <link:label id="id_2cc2bb1f" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected rate of salary increase</link:label>
      <link:label id="id_1baffc03" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of interest on savings account</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount_labels" xlink:type="arc"/>
      <link:label id="id_56eba13" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on savings account</link:label>
      <link:label id="id_646262cf" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyMale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit assumption life expectancy, male</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitAssumptionLifeExpectancyMale" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyMale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitAssumptionLifeExpectancyMale" xlink:to="lbl_DefinedBenefitAssumptionLifeExpectancyMale_labels" xlink:type="arc"/>
      <link:label id="id_32829bee" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyMale_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current life expectancy for a 65-year-old male</link:label>
      <link:label id="id_d9d966" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyFemale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit assumption life expectancy, female</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:to="lbl_DefinedBenefitAssumptionLifeExpectancyFemale_labels" xlink:type="arc"/>
      <link:label id="id_5516dd19" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyFemale_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current life expectancy for a 65-year-old female</link:label>
      <link:label id="id_5918de81" xlink:label="lbl_label1494802049" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:label="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="lbl_label1494802049" xlink:type="arc"/>
      <link:label id="id_689d3554" xlink:label="lbl_label1755133268" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:label="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="lbl_label1755133268" xlink:type="arc"/>
      <link:label id="id_3e1a9660" xlink:label="lbl_label1041929824" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumptions [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:label="lbl_ActuarialAssumptionsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionsAxis" xlink:to="lbl_label1041929824" xlink:type="arc"/>
      <link:label id="id_2737de6b" xlink:label="lbl_label657972843" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumptions [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="lbl_ActuarialAssumptionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_label657972843" xlink:type="arc"/>
      <link:label id="id_70f6e61c" xlink:label="lbl_ActuarialAssumptionOfDiscountRatesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of discount rates [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:label="lbl_ActuarialAssumptionOfDiscountRatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfDiscountRatesMember" xlink:to="lbl_ActuarialAssumptionOfDiscountRatesMember_labels" xlink:type="arc"/>
      <link:label id="id_1b153ebb" xlink:label="lbl_ActuarialAssumptionOfDiscountRatesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
      <link:label id="id_761309a6" xlink:label="lbl_LifeExpectancyMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Life expectancy [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LifeExpectancyMember" xlink:label="lbl_LifeExpectancyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LifeExpectancyMember" xlink:to="lbl_LifeExpectancyMember_labels" xlink:type="arc"/>
      <link:label id="id_527cf7bb" xlink:label="lbl_LifeExpectancyMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Life expectancy</link:label>
      <link:label id="id_70b51d3d" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of pension increases [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_labels" xlink:type="arc"/>
      <link:label id="id_5b5a9ebb" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate of pension increase</link:label>
      <link:label id="id_47824990" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of interest on savings account [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_labels" xlink:type="arc"/>
      <link:label id="id_32d0ccd0" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on savings account</link:label>
      <link:label id="id_742d5c34" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of salary increases [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_labels" xlink:type="arc"/>
      <link:label id="id_795db79c" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Salary increase</link:label>
      <link:label id="id_72dd0a47" xlink:label="lbl_label1927088711" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in actuarial assumption [axis]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeInActuarialAssumptionAxis" xlink:label="lbl_ChangeInActuarialAssumptionAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangeInActuarialAssumptionAxis" xlink:to="lbl_label1927088711" xlink:type="arc"/>
      <link:label id="id_6778fca" xlink:label="lbl_label108498890" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in actuarial assumption [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeInActuarialAssumptionMember" xlink:label="lbl_ChangeInActuarialAssumptionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_label108498890" xlink:type="arc"/>
      <link:label id="id_47ad1e48" xlink:label="lbl_Decrease25BasisPointMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease, 25 basis point [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_Decrease25BasisPointMember" xlink:label="lbl_Decrease25BasisPointMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Decrease25BasisPointMember" xlink:to="lbl_Decrease25BasisPointMember_labels" xlink:type="arc"/>
      <link:label id="id_56d62cdb" xlink:label="lbl_Decrease25BasisPointMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">25 basis point decrease</link:label>
      <link:label id="id_3867e568" xlink:label="lbl_Increase25BasisPointMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase, 25 basis point [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_Increase25BasisPointMember" xlink:label="lbl_Increase25BasisPointMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Increase25BasisPointMember" xlink:to="lbl_Increase25BasisPointMember_labels" xlink:type="arc"/>
      <link:label id="id_5197441d" xlink:label="lbl_Increase25BasisPointMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">25 basis point increase</link:label>
      <link:label id="id_1471972b" xlink:label="lbl_Increase1YearMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase, 1 year [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_Increase1YearMember" xlink:label="lbl_Increase1YearMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Increase1YearMember" xlink:to="lbl_Increase1YearMember_labels" xlink:type="arc"/>
      <link:label id="id_4ce59d83" xlink:label="lbl_Increase1YearMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1 year increase</link:label>
      <link:label id="id_290932d1" xlink:label="lbl_label688468689" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:label="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:to="lbl_label688468689" xlink:type="arc"/>
      <link:label id="id_7dde43af" xlink:label="lbl_label2111718319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:label="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:to="lbl_label2111718319" xlink:type="arc"/>
      <link:label id="id_a6a337a" xlink:label="lbl_label174732154" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of health care cost trend rates [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfHealthCareCostTrendRatesTable" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:to="lbl_label174732154" xlink:type="arc"/>
      <link:label id="id_3aac73e2" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:to="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_labels" xlink:type="arc"/>
      <link:label id="id_6a35725f" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Healthcare cost trend rate assumed for next year</link:label>
      <link:label id="id_41b83777" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Health Care Cost Trend Rate Assumed to Decline</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:to="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline_labels" xlink:type="arc"/>
      <link:label id="id_4f8e05fa" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate to which the cost trend rate is assumed to decline</link:label>
      <link:label id="id_6b154ebb" xlink:label="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Year that Rate Reaches Ultimate Trend Rate</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:label="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:to="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_labels" xlink:type="arc"/>
      <link:label id="id_1990f79d" xlink:label="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year that the rate reaches the ultimate trend rate</link:label>
      <link:label id="id_6d01266f" xlink:label="lbl_label1828791919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of allocation of plan assets [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfAllocationOfPlanAssetsTable" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:to="lbl_label1828791919" xlink:type="arc"/>
      <link:label id="id_546e2ee7" xlink:label="lbl_label1416507111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of assets [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_label1416507111" xlink:type="arc"/>
      <link:label id="id_351e0eb0" xlink:label="lbl_label891162288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_label891162288" xlink:type="arc"/>
      <link:label id="id_124636b7" xlink:label="lbl_EquityInvestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity investments [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityInvestmentsMember" xlink:label="lbl_EquityInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityInvestmentsMember" xlink:to="lbl_EquityInvestmentsMember_labels" xlink:type="arc"/>
      <link:label id="id_77cea25b" xlink:label="lbl_EquityInvestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities</link:label>
      <link:label id="id_1387f503" xlink:label="lbl_DebtSecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt securities [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DebtSecuritiesMember" xlink:label="lbl_DebtSecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DebtSecuritiesMember" xlink:to="lbl_DebtSecuritiesMember_labels" xlink:type="arc"/>
      <link:label id="id_3f4271a5" xlink:label="lbl_DebtSecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities</link:label>
      <link:label id="id_3fb49996" xlink:label="lbl_RealEstateMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Real estate [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RealEstateMember" xlink:label="lbl_RealEstateMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RealEstateMember" xlink:to="lbl_RealEstateMember_labels" xlink:type="arc"/>
      <link:label id="id_3b683c06" xlink:label="lbl_RealEstateMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Real estate</link:label>
      <link:label id="id_40e14f9f" xlink:label="lbl_AlternativeInvestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alternative investments [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlternativeInvestmentsMember" xlink:label="lbl_AlternativeInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlternativeInvestmentsMember" xlink:to="lbl_AlternativeInvestmentsMember_labels" xlink:type="arc"/>
      <link:label id="id_63169a31" xlink:label="lbl_AlternativeInvestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alternative investments</link:label>
      <link:label id="id_2f33748b" xlink:label="lbl_CashAndOtherInvestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and other investments [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashAndOtherInvestmentsMember" xlink:label="lbl_CashAndOtherInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndOtherInvestmentsMember" xlink:to="lbl_CashAndOtherInvestmentsMember_labels" xlink:type="arc"/>
      <link:label id="id_6087023c" xlink:label="lbl_CashAndOtherInvestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and other investments</link:label>
      <link:label id="id_36f85bd1" xlink:label="lbl_label922246097" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, target plan asset allocations range minimum</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:label="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:to="lbl_label922246097" xlink:type="arc"/>
      <link:label id="id_568969aa" xlink:label="lbl_label1451846058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, target plan asset allocations range maximum</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:label="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:to="lbl_label1451846058" xlink:type="arc"/>
      <link:label id="id_73a6e694" xlink:label="lbl_label1940317844" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, plan asset allocations</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanPlanAssetAllocations" xlink:label="lbl_DefinedBenefitPlanPlanAssetAllocations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanPlanAssetAllocations" xlink:to="lbl_label1940317844" xlink:type="arc"/>
      <link:label id="id_7df88f41" xlink:label="lbl_label2113441601" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares held by defined benefit plan</link:label>
      <link:label id="id_638e4e2e" xlink:label="lbl_label1670270510" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value of shares held by defined benefit plan</link:label>
      <link:label id="id_1fe80675" xlink:label="lbl_label535299701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average duration of defined benefit obligation years</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:label="lbl_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:to="lbl_label535299701" xlink:type="arc"/>
      <link:label id="id_3b7d1376" xlink:label="lbl_label998052726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined contribution pension and other post-retirement plans disclosure [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="lbl_label998052726" xlink:type="arc"/>
      <link:label id="id_3dd16606" xlink:label="lbl_label1037133318" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined contribution pension and other post-retirement plans disclosure [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:to="lbl_label1037133318" xlink:type="arc"/>
      <link:label id="id_123e0aae" xlink:label="lbl_label306055854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined contribution pension and other post-retirement plans disclosure [line items]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:to="lbl_label306055854" xlink:type="arc"/>
      <link:label id="id_f1ad7e6" xlink:label="lbl_label253417446" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Post-employment benefit expense, defined contribution plans</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="lbl_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:to="lbl_label253417446" xlink:type="arc"/>
      <link:label id="id_103a32b5" xlink:label="lbl_label272249525" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of expected benefit payments [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfExpectedBenefitPaymentsTable" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:to="lbl_label272249525" xlink:type="arc"/>
      <link:label id="id_3fa24799" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, expected future benefit payment [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:to="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract_labels" xlink:type="arc"/>
      <link:label id="id_7a2e1ca0" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, expected future employer contributions [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:to="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract_labels" xlink:type="arc"/>
      <link:label id="id_6e3282e0" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis Group contributions</link:label>
      <link:label id="id_723df25e" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future benefit payments</link:label>
      <link:label id="id_b004db7" xlink:label="lbl_label910647463" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributions, next fiscal year (estimated)</link:label>
      <link:label id="id_489bf9be" xlink:label="lbl_label839490648" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future benefit payment</link:label>
      <link:label id="id_20bc42c3" xlink:label="lbl_label549208771" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Past service cost and settlements</link:label>
      <link:label id="id_12ce3901" xlink:label="lbl_label315504897" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Past service cost and gains losses arising from settlements, defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:to="lbl_label315504897" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:to="lbl_label549208771" xlink:type="arc"/>
      <link:label id="id_47519d57" xlink:label="lbl_label1196531031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, expected future employer contributions, next fiscal year</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="lbl_label1196531031" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="lbl_label910647463" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SocieteParActionsSANDOZAlgiersMember" xlink:label="lbl_SocieteParActionsSANDOZAlgiersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SocieteParActionsSANDOZAlgiersMember" xlink:to="lbl_label1014805941" xlink:type="arc"/>
      <link:label id="id_1b677399" xlink:label="lbl_label459764633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:label="lbl_AnalysisOfIncomeAndExpenseAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AnalysisOfIncomeAndExpenseAbstract" xlink:to="lbl_label459764633" xlink:type="arc"/>
      <link:label id="id_33287a64" xlink:label="lbl_DisclosureOfDiscontinuedOperationsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of discontinued operations [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDiscontinuedOperationsExplanatory" xlink:label="lbl_DisclosureOfDiscontinuedOperationsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDiscontinuedOperationsExplanatory" xlink:to="lbl_DisclosureOfDiscontinuedOperationsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_2e310112" xlink:label="lbl_DisclosureOfDiscontinuedOperationsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations</link:label>
      <link:label id="id_6868ef6e" xlink:label="lbl_label1751707502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of details to the consolidated statements of cash flows [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_label1751707502" xlink:type="arc"/>
      <link:label id="id_6b1bab45" xlink:label="lbl_DisclosureOfCashFlowStatementExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Details to the consolidated statements of cash flows</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:label="lbl_DisclosureOfCashFlowStatementExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfCashFlowStatementExplanatory" xlink:to="lbl_DisclosureOfCashFlowStatementExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_d3696d1" xlink:label="lbl_DisclosureOfCashFlowStatementExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of cash flow statement [text block]</link:label>
      <link:label id="id_5827fd3a" xlink:label="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for non-cash items from continuing operations [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" xlink:label="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" xlink:to="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4b12a0b7" xlink:label="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for non-cash items from continuing operations</link:label>
      <link:label id="id_31e67efa" xlink:label="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from changes in working capital and other operating items included in operating cash flow from continuing operations [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" xlink:label="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" xlink:to="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3971a54e" xlink:label="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from changes in working capital and other operating items included in operating cash flow from continuing operations</link:label>
      <link:label id="id_1118f1b5" xlink:label="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows arising from acquisitions and divestments of businesses [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" xlink:label="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" xlink:to="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4c64ba26" xlink:label="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows arising from acquisitions and divestments of businesses</link:label>
      <link:label id="id_4c022ee6" xlink:label="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from discontinued operations [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashFlowsFromDiscontinuedOperationsTableTextBlock" xlink:label="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock" xlink:to="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5bd72b36" xlink:label="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from discontinued operations</link:label>
      <link:label id="id_2f1afbf8" xlink:label="lbl_ConsolidatedIncomeStatementSegmentationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated income statement segmentation [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ConsolidatedIncomeStatementSegmentationTableTextBlock" xlink:label="lbl_ConsolidatedIncomeStatementSegmentationTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsolidatedIncomeStatementSegmentationTableTextBlock" xlink:to="lbl_ConsolidatedIncomeStatementSegmentationTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5cbbe15" xlink:label="lbl_ConsolidatedIncomeStatementSegmentationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated income statement segmentation</link:label>
      <link:label id="id_5a01c254" xlink:label="lbl_ExpensesIncludedInNetIncomeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses included in net income [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExpensesIncludedInNetIncomeTableTextBlock" xlink:label="lbl_ExpensesIncludedInNetIncomeTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExpensesIncludedInNetIncomeTableTextBlock" xlink:to="lbl_ExpensesIncludedInNetIncomeTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2004e8bf" xlink:label="lbl_ExpensesIncludedInNetIncomeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses included in net income</link:label>
      <link:label id="id_10dd18ca" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToContinuingSegments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, sales to continuing segments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsSalesToContinuingSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToContinuingSegments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsSalesToContinuingSegments" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToContinuingSegments_labels" xlink:type="arc"/>
      <link:label id="id_2d4849c4" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToContinuingSegments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales to continuing segments</link:label>
      <link:label id="id_398e8ede" xlink:label="lbl_label965643998" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_label965643998" xlink:type="arc"/>
      <link:label id="id_136ba9dd" xlink:label="lbl_label325822941" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SegmentsMember" xlink:to="lbl_label325822941" xlink:type="arc"/>
      <link:label id="id_211fcf4d" xlink:label="lbl_VaccinesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vaccines [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VaccinesMember" xlink:label="lbl_VaccinesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VaccinesMember" xlink:to="lbl_VaccinesMember_labels" xlink:type="arc"/>
      <link:label id="id_5b74f3f8" xlink:label="lbl_ConsumerHealthMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consumer Health [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ConsumerHealthMember" xlink:label="lbl_ConsumerHealthMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsumerHealthMember" xlink:to="lbl_ConsumerHealthMember_labels" xlink:type="arc"/>
      <link:label id="id_56f765a5" xlink:label="lbl_CorporateMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CorporateMember" xlink:to="lbl_CorporateMember_labels" xlink:type="arc"/>
      <link:label id="id_18ef0ff6" xlink:label="lbl_VaccinesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vaccines</link:label>
      <link:label id="id_461a031f" xlink:label="lbl_ConsumerHealthMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consumer Health</link:label>
      <link:label id="id_53139d8a" xlink:label="lbl_CorporateMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate</link:label>
      <link:label id="id_448d3c2a" xlink:label="lbl_OperatingIncomeLossOfDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating income/loss of discontinued operations</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OperatingIncomeLossOfDiscontinuedOperations" xlink:label="lbl_OperatingIncomeLossOfDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OperatingIncomeLossOfDiscontinuedOperations" xlink:to="lbl_OperatingIncomeLossOfDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_720983c3" xlink:label="lbl_OperatingIncomeLossOfDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income/loss of discontinued operations</link:label>
      <link:label id="id_72fd7ee5" xlink:label="lbl_IncomeTaxExpenseOfDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax expense of discontinued operations</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeTaxExpenseOfDiscontinuedOperations" xlink:label="lbl_IncomeTaxExpenseOfDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxExpenseOfDiscontinuedOperations" xlink:to="lbl_IncomeTaxExpenseOfDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_28dd046" xlink:label="lbl_IncomeTaxExpenseOfDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense of discontinued operations</link:label>
      <link:label id="id_1f5a1a52" xlink:label="lbl_ProfitLossFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income from discontinued operations</link:label>
      <link:label id="id_6a72e089" xlink:label="lbl_label1785913481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationExpense" xlink:label="lbl_DepreciationExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DepreciationExpense" xlink:to="lbl_label1785913481" xlink:type="arc"/>
      <link:label id="id_25726f06" xlink:label="lbl_label628256518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortisation expense</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AmortisationExpense" xlink:label="lbl_AmortisationExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmortisationExpense" xlink:to="lbl_label628256518" xlink:type="arc"/>
      <link:label id="id_411f99ec" xlink:label="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss (reversal of impairment loss) recognised in profit or loss</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_labels" xlink:type="arc"/>
      <link:label id="id_3b138d2b" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions with employees</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees_labels" xlink:type="arc"/>
      <link:label id="id_16efc802" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation of Novartis equity plans</link:label>
      <link:label id="id_1bd6fe9" xlink:label="lbl_IntangibleAssetsAndGoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember_labels" xlink:type="arc"/>
      <link:label id="id_1b76fc8a" xlink:label="lbl_IntangibleAssetsAndGoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
      <link:label id="id_7b8e06f2" xlink:label="lbl_PropertyPlantAndEquipmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
      <link:label id="id_199a6c29" xlink:label="lbl_FinancialAssetsImpairedMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets impaired [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsImpairedMember" xlink:label="lbl_FinancialAssetsImpairedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsImpairedMember" xlink:to="lbl_FinancialAssetsImpairedMember_labels" xlink:type="arc"/>
      <link:label id="id_430aa9fa" xlink:label="lbl_FinancialAssetsImpairedMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
      <link:label id="id_580bc98f" xlink:label="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:label="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:to="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract_labels" xlink:type="arc"/>
      <link:label id="id_12db58d" xlink:label="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and impairments on:</link:label>
      <link:label id="id_7cae4caa" xlink:label="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for losses (gains) on disposal of non-current assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:label="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:to="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_7ed21581" xlink:label="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains on disposal and other adjustments on property, plant and equipment; intangible assets;financial assets; and other non-current assets, net</link:label>
      <link:label id="id_353f4e60" xlink:label="lbl_AdjustmentsForSharebasedPayments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment for share based payments</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="lbl_AdjustmentsForSharebasedPayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForSharebasedPayments" xlink:to="lbl_AdjustmentsForSharebasedPayments_labels" xlink:type="arc"/>
      <link:label id="id_728a3fc5" xlink:label="lbl_AdjustmentsForSharebasedPayments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-settled compensation expense</link:label>
      <link:label id="id_71026a6c" xlink:label="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment for change in provisions and other non-current liabilities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:label="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:to="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_7a811d6" xlink:label="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in provisions and other non-current liabilities</link:label>
      <link:label id="id_5215d26" xlink:label="lbl_AdjustmentsForFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for finance income (cost)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="lbl_AdjustmentsForFinanceIncomeCost" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForFinanceIncomeCost" xlink:to="lbl_AdjustmentsForFinanceIncomeCost_labels" xlink:type="arc"/>
      <link:label id="id_1e915c0" xlink:label="lbl_AdjustmentsForFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net financial expense</link:label>
      <link:label id="id_162e6aad" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInInventories_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in inventories</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInInventories_labels" xlink:type="arc"/>
      <link:label id="id_7b5bcf12" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInInventories_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase) in inventories</link:label>
      <link:label id="id_672b8eea" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_labels" xlink:type="arc"/>
      <link:label id="id_47cff5e1" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease/(Increase) in trade receivables</link:label>
      <link:label id="id_543bdc2c" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts payable</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_labels" xlink:type="arc"/>
      <link:label id="id_4059a0ed" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Decrease)/increase in trade payables</link:label>
      <link:label id="id_b388f81" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other inflows (outflows) of cash</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_64e8a2fc" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in other net current assets and other operating cash flow items</link:label>
      <link:label id="id_63e2f9e4" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
      <link:label id="id_118bdd59" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents, discontinued operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_671e3a1e" xlink:label="lbl_label1730034206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions and divestments [axis]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquisitionsAndDivestmentsAxis" xlink:label="lbl_AcquisitionsAndDivestmentsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsAndDivestmentsAxis" xlink:to="lbl_label1730034206" xlink:type="arc"/>
      <link:label id="id_141b97fd" xlink:label="lbl_label337352701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions and divestments [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquisitionsAndDivestmentsMember" xlink:label="lbl_AcquisitionsAndDivestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsAndDivestmentsMember" xlink:to="lbl_label337352701" xlink:type="arc"/>
      <link:label id="id_12050514" xlink:label="lbl_AcquisitionsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquisitionsMember" xlink:label="lbl_AcquisitionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsMember" xlink:to="lbl_AcquisitionsMember_labels" xlink:type="arc"/>
      <link:label id="id_7f5f8169" xlink:label="lbl_AcquisitionsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
      <link:label id="id_415fd821" xlink:label="lbl_DivestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divestments [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DivestmentsMember" xlink:label="lbl_DivestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DivestmentsMember" xlink:to="lbl_DivestmentsMember_labels" xlink:type="arc"/>
      <link:label id="id_7b19873c" xlink:label="lbl_DivestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divestments</link:label>
      <link:label id="id_177d8886" xlink:label="lbl_OtherAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial and other assets including deferred tax assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherAssetsMember" xlink:label="lbl_OtherAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherAssetsMember" xlink:to="lbl_OtherAssetsMember_labels" xlink:type="arc"/>
      <link:label id="id_fdd065b" xlink:label="lbl_OtherAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets [member]</link:label>
      <link:label id="id_7f9f59b1" xlink:label="lbl_OtherIntangibleAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
      <link:label id="id_1a3864c5" xlink:label="lbl_TechnologybasedIntangibleAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technologies</link:label>
      <link:label id="id_5b13ac00" xlink:label="lbl_BrandNamesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Brand names</link:label>
      <link:label id="id_7d41899d" xlink:label="lbl_InventoriesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
      <link:label id="id_50dd9de4" xlink:label="lbl_CashFlowFromNetIdentifiableAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net identifiable assets (acquired) or divested</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashFlowFromNetIdentifiableAssets" xlink:label="lbl_CashFlowFromNetIdentifiableAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowFromNetIdentifiableAssets" xlink:to="lbl_CashFlowFromNetIdentifiableAssets_labels" xlink:type="arc"/>
      <link:label id="id_4169909f" xlink:label="lbl_CashFlowFromNetIdentifiableAssets_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow) from Net identifiable assets (acquired) or divested</link:label>
      <link:label id="id_6da3acb5" xlink:label="lbl_CashInflowOutflowCurrencyTranslationEffects_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow), currency translation effects</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashInflowOutflowCurrencyTranslationEffects" xlink:label="lbl_CashInflowOutflowCurrencyTranslationEffects" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowCurrencyTranslationEffects" xlink:to="lbl_CashInflowOutflowCurrencyTranslationEffects_labels" xlink:type="arc"/>
      <link:label id="id_28a59cd9" xlink:label="lbl_CashInflowOutflowCurrencyTranslationEffects_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_6046e1a8" xlink:label="lbl_CashInflowOutflowCurrencyTranslationEffects_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_4ec913e7" xlink:label="lbl_CashInflowOutflowAcquiredDivestedLiquity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow), acquired/(divested) liquity</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashInflowOutflowAcquiredDivestedLiquity" xlink:label="lbl_CashInflowOutflowAcquiredDivestedLiquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowAcquiredDivestedLiquity" xlink:to="lbl_CashInflowOutflowAcquiredDivestedLiquity_labels" xlink:type="arc"/>
      <link:label id="id_470c377e" xlink:label="lbl_CashInflowOutflowAcquiredDivestedLiquity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired/(divested) liquity</link:label>
      <link:label id="id_50fcd8ec" xlink:label="lbl_CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
      <link:label id="id_51ec5468" xlink:label="lbl_CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow) from Net identifiable assets (acquired) or divested, currency translation effects, Acquired/(divested) liquidity and fair value of previously held equity interests.</link:label>
      <link:label id="id_33a842e" xlink:label="lbl_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash provided by refinancing of intercompany financial debt, net</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet" xlink:label="lbl_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet" xlink:to="lbl_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet_labels" xlink:type="arc"/>
      <link:label id="id_cbc3f6c" xlink:label="lbl_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Refinancing of intercompany financial debt, net</link:label>
      <link:label id="id_2f2298e2" xlink:label="lbl_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash provided by refinancing of intercompany financial debt, net.</link:label>
      <link:label id="id_7e82bd81" xlink:label="lbl_CashInflowOutflowGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow), Goodwill</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashInflowOutflowGoodwill" xlink:label="lbl_CashInflowOutflowGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowGoodwill" xlink:to="lbl_CashInflowOutflowGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_3c41ff79" xlink:label="lbl_CashInflowOutflowGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
      <link:label id="id_4f404f29" xlink:label="lbl_label1329614633" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divestment gain</link:label>
      <link:label id="id_250b8244" xlink:label="lbl_label621511236" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow), Divestment gain (loss)</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashInflowOutflowDivestmentGainLoss" xlink:label="lbl_CashInflowOutflowDivestmentGainLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowDivestmentGainLoss" xlink:to="lbl_label621511236" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowDivestmentGainLoss" xlink:to="lbl_label1329614633" xlink:type="arc"/>
      <link:label id="id_48ec9225" xlink:label="lbl_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes paid and other portfolio transformation related cash flows</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows" xlink:label="lbl_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows" xlink:to="lbl_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows_labels" xlink:type="arc"/>
      <link:label id="id_69b7f35f" xlink:label="lbl_ReceivablesAndPayablesContingentConsiderationNet_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables and payables contingent consideration, net</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReceivablesAndPayablesContingentConsiderationNet" xlink:label="lbl_ReceivablesAndPayablesContingentConsiderationNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReceivablesAndPayablesContingentConsiderationNet" xlink:to="lbl_ReceivablesAndPayablesContingentConsiderationNet_labels" xlink:type="arc"/>
      <link:label id="id_66ca8618" xlink:label="lbl_OtherPaymentsAndDeferredConsiderationNet_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other payments and deferred consideration, net</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherPaymentsAndDeferredConsiderationNet" xlink:label="lbl_OtherPaymentsAndDeferredConsiderationNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherPaymentsAndDeferredConsiderationNet" xlink:to="lbl_OtherPaymentsAndDeferredConsiderationNet_labels" xlink:type="arc"/>
      <link:label id="id_7403ad6c" xlink:label="lbl_DeferredPrepaidPortionOfSalesPrice_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">(Deferred)/prepaid portion of sales price</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DeferredPrepaidPortionOfSalesPrice" xlink:label="lbl_DeferredPrepaidPortionOfSalesPrice" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredPrepaidPortionOfSalesPrice" xlink:to="lbl_DeferredPrepaidPortionOfSalesPrice_labels" xlink:type="arc"/>
      <link:label id="id_7290427c" xlink:label="lbl_DeferredPrepaidPortionOfSalesPrice_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">(Deferred)/prepaid portion of sales price to cash flows (used in) provided by acquisitions/divestments of businesses.</link:label>
      <link:label id="id_55c25b5" xlink:label="lbl_label1423033786" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows</link:label>
      <link:label id="id_35ffff76" xlink:label="lbl_label905969526" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration paid</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationPaid" xlink:label="lbl_ContingentConsiderationPaid" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationPaid" xlink:to="lbl_label905969526" xlink:type="arc"/>
      <link:label id="id_344a7417" xlink:label="lbl_label877294615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business combinations [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="lbl_BusinessCombinationsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BusinessCombinationsAxis" xlink:to="lbl_label877294615" xlink:type="arc"/>
      <link:label id="id_2a937996" xlink:label="lbl_label714307990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for business combinations [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="lbl_EntitysTotalForBusinessCombinationsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntitysTotalForBusinessCombinationsMember" xlink:to="lbl_label714307990" xlink:type="arc"/>
      <link:label id="id_e12f433" xlink:label="lbl_Change25BasisPointMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change, 25 basis point [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_Change25BasisPointMember" xlink:label="lbl_Change25BasisPointMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Change25BasisPointMember" xlink:to="lbl_Change25BasisPointMember_labels" xlink:type="arc"/>
      <link:label id="id_a3f5c53" xlink:label="lbl_Change25BasisPointMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">25 basis point change</link:label>
      <link:label id="id_375463d0" xlink:label="lbl_label928277456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends payable, amount per share</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DividendsPayableAmountPerShare" xlink:label="lbl_DividendsPayableAmountPerShare" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsPayableAmountPerShare" xlink:to="lbl_label928277456" xlink:type="arc"/>
      <link:label id="id_43bd571e" xlink:label="lbl_label1136482078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares acquired to be held</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TreasurySharesAcquiredToBeHeld" xlink:label="lbl_TreasurySharesAcquiredToBeHeld" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesAcquiredToBeHeld" xlink:to="lbl_label1136482078" xlink:type="arc"/>
      <link:label id="id_57fc5a54" xlink:label="lbl_TreasurySharesAcquiredToBeCancelled_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares acquired to be cancelled</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TreasurySharesAcquiredToBeCancelled" xlink:label="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesAcquiredToBeCancelled" xlink:to="lbl_TreasurySharesAcquiredToBeCancelled_labels" xlink:type="arc"/>
      <link:label id="id_324c0bd9" xlink:label="lbl_label843844569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other share purchases</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherSharePurchases" xlink:label="lbl_OtherSharePurchases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherSharePurchases" xlink:to="lbl_label843844569" xlink:type="arc"/>
      <link:label id="id_4ae190e3" xlink:label="lbl_SharepurchaseOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-purchase of treasury shares</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharepurchaseOfTreasuryShares" xlink:label="lbl_SharepurchaseOfTreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharepurchaseOfTreasuryShares" xlink:to="lbl_SharepurchaseOfTreasuryShares_labels" xlink:type="arc"/>
      <link:label id="id_191f6daa" xlink:label="lbl_label421490090" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares acquired to be held, equity impact</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TreasurySharesAcquiredToBeHeldValue" xlink:label="lbl_TreasurySharesAcquiredToBeHeldValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesAcquiredToBeHeldValue" xlink:to="lbl_label421490090" xlink:type="arc"/>
      <link:label id="id_3ea88f28" xlink:label="lbl_TreasurySharesAcquiredForCancellationValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares acquired for cancellation, equity impact</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TreasurySharesAcquiredForCancellationValue" xlink:label="lbl_TreasurySharesAcquiredForCancellationValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesAcquiredForCancellationValue" xlink:to="lbl_TreasurySharesAcquiredForCancellationValue_labels" xlink:type="arc"/>
      <link:label id="id_6fbbc8cc" xlink:label="lbl_OtherSharePurchasesValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other share purchases, equity impact</link:label>
      <link:label id="id_5d0bb4f" xlink:label="lbl_label97565519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAbstract" xlink:label="lbl_ComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_label97565519" xlink:type="arc"/>
      <link:label id="id_663e6f69" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in consolidated statements of comprehensive income [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" xlink:to="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1fe06852" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in consolidated statements of comprehensive income</link:label>
      <link:label id="id_72bd6f82" xlink:label="lbl_ScheduleOfComprehensiveIncomeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of comprehensive income [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfComprehensiveIncomeTableTextBlock" xlink:label="lbl_ScheduleOfComprehensiveIncomeTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfComprehensiveIncomeTableTextBlock" xlink:to="lbl_ScheduleOfComprehensiveIncomeTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3ec5912e" xlink:label="lbl_ScheduleOfComprehensiveIncomeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
      <link:label id="id_72f6c7af" xlink:label="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of share value adjustments currency translation effects [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" xlink:label="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" xlink:to="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_570bfee5" xlink:label="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of share value adjustments currency translation effects</link:label>
      <link:label id="id_55c48a63" xlink:label="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments financial instruments reconciliation [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" xlink:label="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" xlink:to="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_b6f9702" xlink:label="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments financial instruments reconciliation</link:label>
      <link:label id="id_56e22f6a" xlink:label="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of defined benefit plan amounts recognized in other comprehensive income [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" xlink:label="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" xlink:to="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_8052d36" xlink:label="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of defined benefit plan amounts recognized in other comprehensive income</link:label>
      <link:label id="id_639839a6" xlink:label="lbl_label1670920614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_label1670920614" xlink:type="arc"/>
      <link:label id="id_46f3d26a" xlink:label="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_3abc74f9" xlink:label="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based participation plans for associates</link:label>
      <link:label id="id_36b95a30" xlink:label="lbl_label918116912" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lbl_label918116912" xlink:type="arc"/>
      <link:label id="id_4f551c1c" xlink:label="lbl_DisclosureOfRelatedPartyExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of related party [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="lbl_DisclosureOfRelatedPartyExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfRelatedPartyExplanatory" xlink:to="lbl_DisclosureOfRelatedPartyExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_2142f37a" xlink:label="lbl_DisclosureOfRelatedPartyExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transactions with related parties</link:label>
      <link:label id="id_21a37a9f" xlink:label="lbl_DisclosureOfEmployeeBenefitsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Post-employment benefits for associates</link:label>
      <link:label id="id_250e99ed" xlink:label="lbl_OfficerAndDirectorCompensationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Officer and director compensation [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OfficerAndDirectorCompensationTableTextBlock" xlink:label="lbl_OfficerAndDirectorCompensationTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OfficerAndDirectorCompensationTableTextBlock" xlink:to="lbl_OfficerAndDirectorCompensationTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_30161311" xlink:label="lbl_OfficerAndDirectorCompensationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Officers and Non-Executive Directors Compensation</link:label>
      <link:label id="id_332db2e6" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_5ba16f3" xlink:label="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:label="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:to="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_23eec797" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of unvested restricted stock units roll forward [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4f141a24" xlink:label="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of share-based compensation, activity [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:label="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:to="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2cdc96dc" xlink:label="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of share-based compensation, activity</link:label>
      <link:label id="id_5c5154d5" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of unvested restricted stock units roll forward</link:label>
      <link:label id="id_44099e5b" xlink:label="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options</link:label>
      <link:label id="id_2a634859" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options</link:label>
      <link:label id="id_2b301a02" xlink:label="lbl_label724572674" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_label724572674" xlink:type="arc"/>
      <link:label id="id_499d66e9" xlink:label="lbl_label1235052265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_label1235052265" xlink:type="arc"/>
      <link:label id="id_4bff5af2" xlink:label="lbl_label1275026162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of related parties [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_label1275026162" xlink:type="arc"/>
      <link:label id="id_4175504c" xlink:label="lbl_label1098207308" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for related parties [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_label1098207308" xlink:type="arc"/>
      <link:label id="id_52e5607c" xlink:label="lbl_label1390764156" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel of entity or parent [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_label1390764156" xlink:type="arc"/>
      <link:label id="id_51571277" xlink:label="lbl_label1364660855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Executive Director [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonExecutiveDirectorMember" xlink:label="lbl_NonExecutiveDirectorMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonExecutiveDirectorMember" xlink:to="lbl_label1364660855" xlink:type="arc"/>
      <link:label id="id_77564460" xlink:label="lbl_label2002142304" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associates [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_label2002142304" xlink:type="arc"/>
      <link:label id="id_7f01623c" xlink:label="lbl_label2130797116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for associates [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_label2130797116" xlink:type="arc"/>
      <link:label id="id_2d55a2fa" xlink:label="lbl_RocheHoldingAGMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche Holding AG [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RocheHoldingAGMember" xlink:to="lbl_RocheHoldingAGMember_labels" xlink:type="arc"/>
      <link:label id="id_102c1151" xlink:label="lbl_label271323473" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and services [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_label271323473" xlink:type="arc"/>
      <link:label id="id_7a1d10b6" xlink:label="lbl_label2048725174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and services [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_label2048725174" xlink:type="arc"/>
      <link:label id="id_4b6874" xlink:label="lbl_label4941940" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lucentis [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LucentisMember" xlink:to="lbl_label4941940" xlink:type="arc"/>
      <link:label id="id_4da120c0" xlink:label="lbl_label1302405312" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xolair [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_XolairMember" xlink:to="lbl_label1302405312" xlink:type="arc"/>
      <link:label id="id_40080a70" xlink:label="lbl_label1074268784" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of voting rights held in associate</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:to="lbl_label1074268784" xlink:type="arc"/>
      <link:label id="id_4fef4e77" xlink:label="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net expense, royalties cost sharing and profit sharing</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:label="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:to="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing_labels" xlink:type="arc"/>
      <link:label id="id_5866119e" xlink:label="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, post-employment benefits</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:to="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits_labels" xlink:type="arc"/>
      <link:label id="id_32134034" xlink:label="lbl_KeyManagementPersonnelCompensationSharebasedPayment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, share-based payment</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="lbl_KeyManagementPersonnelCompensationSharebasedPayment_labels" xlink:type="arc"/>
      <link:label id="id_40914b3d" xlink:label="lbl_KeyManagementPersonnelCompensation_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="lbl_KeyManagementPersonnelCompensation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensation" xlink:to="lbl_KeyManagementPersonnelCompensation_labels" xlink:type="arc"/>
      <link:label id="id_34c1eea8" xlink:label="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Post-employment benefits</link:label>
      <link:label id="id_24fee3be" xlink:label="lbl_KeyManagementPersonnelCompensationSharebasedPayment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation</link:label>
      <link:label id="id_5994538d" xlink:label="lbl_KeyManagementPersonnelCompensation_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
      <link:label id="id_a202e7c" xlink:label="lbl_label169881212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genentech, Inc., USA [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GenentechInc.USAMember" xlink:label="lbl_GenentechInc.USAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GenentechInc.USAMember" xlink:to="lbl_label169881212" xlink:type="arc"/>
      <link:label id="id_3ecec9c1" xlink:label="lbl_label1053739457" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prof. Dr. Brody [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProfDrBrodyMember" xlink:label="lbl_ProfDrBrodyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfDrBrodyMember" xlink:to="lbl_label1053739457" xlink:type="arc"/>
      <link:label id="id_60abf97a" xlink:label="lbl_label1621883258" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prof. Dr. Zinkernagel [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProfDrZinkernagelMember" xlink:label="lbl_ProfDrZinkernagelMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfDrZinkernagelMember" xlink:to="lbl_label1621883258" xlink:type="arc"/>
      <link:label id="id_707fbae9" xlink:label="lbl_label1887419113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dr. Alex Krauer [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DrAlexKrauerMember" xlink:label="lbl_DrAlexKrauerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DrAlexKrauerMember" xlink:to="lbl_label1887419113" xlink:type="arc"/>
      <link:label id="id_5f1c0cdd" xlink:label="lbl_label1595673821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dr. Daniel Vasella [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DrDanielVasellaMember" xlink:label="lbl_DrDanielVasellaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DrDanielVasellaMember" xlink:to="lbl_label1595673821" xlink:type="arc"/>
      <link:label id="id_49199deb" xlink:label="lbl_label1226415595" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dr. James Bradner [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DrJamesBradnerMember" xlink:label="lbl_DrJamesBradnerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DrJamesBradnerMember" xlink:to="lbl_label1226415595" xlink:type="arc"/>
      <link:label id="id_12139c9c" xlink:label="lbl_label303275164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, daily rate</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KeyManagementPersonnelCompensationDailyRate" xlink:label="lbl_KeyManagementPersonnelCompensationDailyRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationDailyRate" xlink:to="lbl_label303275164" xlink:type="arc"/>
      <link:label id="id_34648bf4" xlink:label="lbl_label879004660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, annual guaranteed minimum</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:label="lbl_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:to="lbl_label879004660" xlink:type="arc"/>
      <link:label id="id_475cd1c7" xlink:label="lbl_label1197265351" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, shares acquired</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KeyManagementPersonnelCompensationSharesAcquired" xlink:label="lbl_KeyManagementPersonnelCompensationSharesAcquired" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationSharesAcquired" xlink:to="lbl_label1197265351" xlink:type="arc"/>
      <link:label id="id_7d46110e" xlink:label="lbl_label2101743886" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, ownership interest acquired</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:label="lbl_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:to="lbl_label2101743886" xlink:type="arc"/>
      <link:label id="id_41061f2c" xlink:label="lbl_label1090920236" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in consolidated statements of comprehensive income [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:to="lbl_label1090920236" xlink:type="arc"/>
      <link:label id="id_2d82d11f" xlink:label="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on marketable securities [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:to="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember_labels" xlink:type="arc"/>
      <link:label id="id_2c74381f" xlink:label="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on marketable securities</link:label>
      <link:label id="id_1315ebbc" xlink:label="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on deferred cash flow hedges [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:label="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:to="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember_labels" xlink:type="arc"/>
      <link:label id="id_2feb765f" xlink:label="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on deferred cash flow hedges</link:label>
      <link:label id="id_41098a9f" xlink:label="lbl_ActuarialLossesFromDefinedBenefitPlansMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial gains/losses from defined benefit plans [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ActuarialLossesFromDefinedBenefitPlansMember" xlink:label="lbl_ActuarialLossesFromDefinedBenefitPlansMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialLossesFromDefinedBenefitPlansMember" xlink:to="lbl_ActuarialLossesFromDefinedBenefitPlansMember_labels" xlink:type="arc"/>
      <link:label id="id_66cb76c9" xlink:label="lbl_ActuarialLossesFromDefinedBenefitPlansMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains/losses from defined benefit plans</link:label>
      <link:label id="id_2dc02a48" xlink:label="lbl_CumulativeCurrencyTranslationEffectsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative currency translation effects [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CumulativeCurrencyTranslationEffectsMember" xlink:label="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:to="lbl_CumulativeCurrencyTranslationEffectsMember_labels" xlink:type="arc"/>
      <link:label id="id_167b29ff" xlink:label="lbl_CumulativeCurrencyTranslationEffectsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative currency translation effects</link:label>
      <link:label id="id_23f99baf" xlink:label="lbl_label603560879" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in consolidated statements of comprehensive income [line items]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_label603560879" xlink:type="arc"/>
      <link:label id="id_525fbfa4" xlink:label="lbl_label98094011" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Value adjustments on comprehensive income at end of period</link:label>
      <link:label id="id_5f2ad26f" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net actuarial gains/losses from defined benefit plans, net of taxes</link:label>
      <link:label id="id_56084e2" xlink:label="lbl_label492438188" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total value adjustments</link:label>
      <link:label id="id_4f1abe21" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on financial instruments</link:label>
      <link:label id="id_44ea9064" xlink:label="lbl_label521267934" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale financial investments</link:label>
      <link:label id="id_172d7365" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale marketable securities</link:label>
      <link:label id="id_1d877185" xlink:label="lbl_GainLossOnSaleOfMarketableInvestments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (loss) on sale of marketable investments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GainLossOnSaleOfMarketableInvestments" xlink:label="lbl_GainLossOnSaleOfMarketableInvestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainLossOnSaleOfMarketableInvestments" xlink:to="lbl_GainLossOnSaleOfMarketableInvestments_labels" xlink:type="arc"/>
      <link:label id="id_67ba82da" xlink:label="lbl_GainLossOnSaleOfMarketableInvestments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities sold</link:label>
      <link:label id="id_2adbb944" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (loss) on sale of other financial assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GainLossOnSaleOfOtherFinancialAssets" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:to="lbl_GainLossOnSaleOfOtherFinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_24c923e8" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial assets sold</link:label>
      <link:label id="id_334897f4" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments during the year</link:label>
      <link:label id="id_36328be7" xlink:label="lbl_label909282279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remeasurements from defined benefit plans [line items]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RemeasurementsFromDefinedBenefitPlansLineItems" xlink:label="lbl_RemeasurementsFromDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RemeasurementsFromDefinedBenefitPlansLineItems" xlink:to="lbl_label909282279" xlink:type="arc"/>
      <link:label id="id_598b1d0a" xlink:label="lbl_label1502289162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_label1502289162" xlink:type="arc"/>
      <link:label id="id_42afb056" xlink:label="lbl_label1118810198" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets and goodwill [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_label1118810198" xlink:type="arc"/>
      <link:label id="id_4854e53b" xlink:label="lbl_GoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodwillMember" xlink:label="lbl_GoodwillMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GoodwillMember" xlink:to="lbl_GoodwillMember_labels" xlink:type="arc"/>
      <link:label id="id_5a809ba7" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets other than Goodwill</link:label>
      <link:label id="id_6fcb9ca9" xlink:label="lbl_GoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
      <link:label id="id_789924e3" xlink:label="lbl_CurrentlyMarketedProductsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currently marketed products</link:label>
      <link:label id="id_6768eaf7" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketing know-how</link:label>
      <link:label id="id_1878d8ce" xlink:label="lbl_label410573006" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_label410573006" xlink:type="arc"/>
      <link:label id="id_5927b5e9" xlink:label="lbl_IntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="lbl_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IntangibleAssetsAndGoodwill" xlink:to="lbl_IntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_7c0ed12" xlink:label="lbl_IntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill at beginning of period</link:label>
      <link:label id="id_747bc8d6" xlink:label="lbl_IntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill at end of period</link:label>
      <link:label id="id_4eee4a8f" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations, intangible assets and goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_4295643b" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_fd8bae8" xlink:label="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers, intangible assets and goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:to="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_2975d791" xlink:label="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
      <link:label id="id_37bb77c5" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, intangible assets other than goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_31d55821" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
      <link:label id="id_4b244fff" xlink:label="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals and retirements, intangible assets and goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:label="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:to="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_c2fe7ed" xlink:label="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Disposals and derecognitions</link:label>
      <link:label id="id_13c2a444" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, intangible assets and goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_7e269b8c" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_3f53b387" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortisation, intangible assets other than goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="lbl_AmortisationIntangibleAssetsOtherThanGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_6e93cf7f" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization charge</link:label>
      <link:label id="id_4895c20f" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets and goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_31bd23bf" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge</link:label>
      <link:label id="id_4c0505b8" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reversal of impairment loss recognised in profit or loss, intangible assets other than goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_3a8c745b" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reversal of impairment charge</link:label>
      <link:label id="id_46823638" xlink:label="lbl_IntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net book value</link:label>
      <link:label id="id_71feba23" xlink:label="lbl_label1912519203" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment consolidation items [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_label1912519203" xlink:type="arc"/>
      <link:label id="id_76bd9383" xlink:label="lbl_label1992135555" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for segment consolidation items [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_label1992135555" xlink:type="arc"/>
      <link:label id="id_e23d9e6" xlink:label="lbl_label237230566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating segments [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OperatingSegmentsMember" xlink:to="lbl_label237230566" xlink:type="arc"/>
      <link:label id="id_4e99f014" xlink:label="lbl_InnovativeMedicinesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Innovative Medicines [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InnovativeMedicinesMember" xlink:to="lbl_InnovativeMedicinesMember_labels" xlink:type="arc"/>
      <link:label id="id_5cce9bca" xlink:label="lbl_InnovativeMedicinesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Innovative Medicines</link:label>
      <link:label id="id_62947297" xlink:label="lbl_SandozMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozMember" xlink:to="lbl_SandozMember_labels" xlink:type="arc"/>
      <link:label id="id_2d171b79" xlink:label="lbl_SandozMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sandoz</link:label>
      <link:label id="id_19f7b763" xlink:label="lbl_AlconMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconMember" xlink:to="lbl_AlconMember_labels" xlink:type="arc"/>
      <link:label id="id_82cbe5b" xlink:label="lbl_AlconMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alcon</link:label>
      <link:label id="id_40af0c2d" xlink:label="lbl_label1085213741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unallocated amounts [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="lbl_UnallocatedAmountsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnallocatedAmountsMember" xlink:to="lbl_label1085213741" xlink:type="arc"/>
      <link:label id="id_2f427f57" xlink:label="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Growth rate used to extrapolate cash flow projections</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:label="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:to="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_labels" xlink:type="arc"/>
      <link:label id="id_1f6b21d" xlink:label="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Terminal Growth Rate</link:label>
      <link:label id="id_6e31860b" xlink:label="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discount rate used in current measurement of fair value less costs of disposal</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:label="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:to="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal_labels" xlink:type="arc"/>
      <link:label id="id_59daa167" xlink:label="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount Rate (post-tax)</link:label>
      <link:label id="id_32f31c92" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets other than goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_6067b5a3" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairment charges</link:label>
      <link:label id="id_6697be1e" xlink:label="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of justification for using growth rate that exceeds long-term average growth rate</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:label="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:to="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate_labels" xlink:type="arc"/>
      <link:label id="id_576cfb66" xlink:label="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of growth rate</link:label>
      <link:label id="id_645c105b" xlink:label="lbl_label1683755099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_label1683755099" xlink:type="arc"/>
      <link:label id="id_86ca8ac" xlink:label="lbl_label141338796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_label141338796" xlink:type="arc"/>
      <link:label id="id_3cced209" xlink:label="lbl_label1020187145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_label1020187145" xlink:type="arc"/>
      <link:label id="id_b0eee5a" xlink:label="lbl_label185527898" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_label185527898" xlink:type="arc"/>
      <link:label id="id_7bf97c21" xlink:label="lbl_EquityBasedParticipationAnnualIncentivePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Annual Incentive Plan [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationAnnualIncentivePlanMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentivePlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationAnnualIncentivePlanMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentivePlanMember_labels" xlink:type="arc"/>
      <link:label id="id_2ae4d862" xlink:label="lbl_EquityBasedParticipationShareSavingsPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Share Savings Plan [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationShareSavingsPlanMember_labels" xlink:type="arc"/>
      <link:label id="id_6fae6c02" xlink:label="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Leveraged Share Savings Plan [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember_labels" xlink:type="arc"/>
      <link:label id="id_4b1054ab" xlink:label="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Employee Share Ownership Plan [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:label="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:to="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember_labels" xlink:type="arc"/>
      <link:label id="id_28d147a5" xlink:label="lbl_EquityBasedParticipationUKShareSavingsPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation UK Share Savings Plan [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationUKShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationUKShareSavingsPlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationUKShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationUKShareSavingsPlanMember_labels" xlink:type="arc"/>
      <link:label id="id_43a6ccb8" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Novartis Equity Plan "Select" [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember_labels" xlink:type="arc"/>
      <link:label id="id_3073fb0" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Long-Term Performance Plan [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationLongTermPerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationLongTermPerformancePlanMember" xlink:to="lbl_EquityBasedParticipationLongTermPerformancePlanMember_labels" xlink:type="arc"/>
      <link:label id="id_547a9da" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Long-Term Relative Performance Plan [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:to="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember_labels" xlink:type="arc"/>
      <link:label id="id_1f01ff40" xlink:label="lbl_EquityBasedParticipationSpecialShareAwardsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Special Share Awards [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationSpecialShareAwardsMember" xlink:label="lbl_EquityBasedParticipationSpecialShareAwardsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationSpecialShareAwardsMember" xlink:to="lbl_EquityBasedParticipationSpecialShareAwardsMember_labels" xlink:type="arc"/>
      <link:label id="id_89e9c6a" xlink:label="lbl_label144612458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:label="lbl_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:to="lbl_label144612458" xlink:type="arc"/>
      <link:label id="id_25616927" xlink:label="lbl_label627140903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of method of settlement for share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" xlink:label="lbl_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" xlink:to="lbl_label627140903" xlink:type="arc"/>
      <link:label id="id_7e605438" xlink:label="lbl_label2120242232" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of vesting requirements for share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:label="lbl_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:to="lbl_label2120242232" xlink:type="arc"/>
      <link:label id="id_73de771d" xlink:label="lbl_LiabilitiesFromSharebasedPaymentTransactions2011_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities from share-based payment transactions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:label="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:to="lbl_LiabilitiesFromSharebasedPaymentTransactions2011_labels" xlink:type="arc"/>
      <link:label id="id_41659fd5" xlink:label="lbl_label1097179093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_label1097179093" xlink:type="arc"/>
      <link:label id="id_70e32ac1" xlink:label="lbl_label1893935809" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_label1893935809" xlink:type="arc"/>
      <link:label id="id_1e53f765" xlink:label="lbl_NumberOfOutstandingShareOptions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="lbl_NumberOfOutstandingShareOptions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOutstandingShareOptions" xlink:to="lbl_NumberOfOutstandingShareOptions_labels" xlink:type="arc"/>
      <link:label id="id_71aeacaf" xlink:label="lbl_NumberOfOutstandingShareOptions_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of share options outstanding at beginning of period</link:label>
      <link:label id="id_5962c0d" xlink:label="lbl_NumberOfOutstandingShareOptions_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of share options outstanding at end of period</link:label>
      <link:label id="id_7fce5b76" xlink:label="lbl_label2144230262" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [roll forward]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_label2144230262" xlink:type="arc"/>
      <link:label id="id_3d4fe5a6" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_labels" xlink:type="arc"/>
      <link:label id="id_18341635" xlink:label="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_labels" xlink:type="arc"/>
      <link:label id="id_1df4b58c" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_labels" xlink:type="arc"/>
      <link:label id="id_4c6be67e" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share options exercised or sold</link:label>
      <link:label id="id_476e4360" xlink:label="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share options forfeited or expired</link:label>
      <link:label id="id_3c8a636c" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share options exercisable</link:label>
      <link:label id="id_18fcb954" xlink:label="lbl_label419215700" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_label419215700" xlink:type="arc"/>
      <link:label id="id_3e8e4697" xlink:label="lbl_label1049511575" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lbl_label1049511575" xlink:type="arc"/>
      <link:label id="id_2cfcdafb" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember_labels" xlink:type="arc"/>
      <link:label id="id_5fb4ce8d" xlink:label="lbl_EquityBasedParticipationRestrictedSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Restricted Shares [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationRestrictedSharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationRestrictedSharesMember" xlink:to="lbl_EquityBasedParticipationRestrictedSharesMember_labels" xlink:type="arc"/>
      <link:label id="id_6a904dd3" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Remeasurements from defined benefit plans, total after tax</link:label>
      <link:label id="id_77782278" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, before taxes, gains (losses) on remeasurements of defined benefit plans</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:type="arc"/>
      <link:label id="id_5e993e53" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit pension plans before tax</link:label>
      <link:label id="id_70219b11" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, before taxes, gains (losses) on remeasurements of other post-employment benefit plans</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" xlink:to="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans_labels" xlink:type="arc"/>
      <link:label id="id_24653928" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other post-employment benefit plans before tax</link:label>
      <link:label id="id_2e31d75a" xlink:label="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, gains (losses) on remeasurements of defined and other post-employment benefit plans, taxation</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:label="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:to="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation_labels" xlink:type="arc"/>
      <link:label id="id_258900b0" xlink:label="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxation on above items</link:label>
      <link:label id="id_7496cde" xlink:label="lbl_label122252510" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, shares acquired, price</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:label="lbl_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:to="lbl_label122252510" xlink:type="arc"/>
      <link:label id="id_77be955a" xlink:label="lbl_ValueAdjustmentOnComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value adjustment on comprehensive income</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_ValueAdjustmentOnComprehensiveIncome_labels" xlink:type="arc"/>
      <link:label id="id_19d019b2" xlink:label="lbl_ValueAdjustmentOnComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Value adjustments on comprehensive income at beginning of period</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_label98094011" xlink:type="arc"/>
      <link:label id="id_53394b08" xlink:label="lbl_label1396263688" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on value adjustment on comprehensive income</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_label1396263688" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_label492438188" xlink:type="arc"/>
      <link:label id="id_5127c80" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total value adjustments attributable to Novartis shareholders [Member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:to="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember_labels" xlink:type="arc"/>
      <link:label id="id_11f1c5d1" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total value adjustments</link:label>
      <link:label id="id_4fa34414" xlink:label="lbl_label1336099860" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon, Inc., equity plan, converted, Novartis share options [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:label="lbl_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:to="lbl_label1336099860" xlink:type="arc"/>
      <link:label id="id_47c79757" xlink:label="lbl_label1204262743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon, Inc., equity plan, converted, Share-settled appreciation rights (SSAR) [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:label="lbl_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:to="lbl_label1204262743" xlink:type="arc"/>
      <link:label id="id_5c4a8ca3" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of share options exercised</link:label>
      <link:label id="id_5368a3e4" xlink:label="lbl_label1399366628" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of unvested restricted stock units roll forward [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:to="lbl_label1399366628" xlink:type="arc"/>
      <link:label id="id_54d97aaa" xlink:label="lbl_label1423538858" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-vesting [axis]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonvestingAxis" xlink:label="lbl_NonvestingAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonvestingAxis" xlink:to="lbl_label1423538858" xlink:type="arc"/>
      <link:label id="id_129e3bed" xlink:label="lbl_label312359917" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-vesting [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonvestingMember" xlink:label="lbl_NonvestingMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonvestingMember" xlink:to="lbl_label312359917" xlink:type="arc"/>
      <link:label id="id_768fac4" xlink:label="lbl_label124320452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-vested shares granted [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonvestedSharesGrantedMember" xlink:label="lbl_NonvestedSharesGrantedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonvestedSharesGrantedMember" xlink:to="lbl_label124320452" xlink:type="arc"/>
      <link:label id="id_2ded6718" xlink:label="lbl_EquityBasedParticipationAnnualIncentivePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual incentive</link:label>
      <link:label id="id_5e84f23d" xlink:label="lbl_EquityBasedParticipationShareSavingsPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share savings plans</link:label>
      <link:label id="id_47fd4dbd" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Select</link:label>
      <link:label id="id_779d196a" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Performance Plan</link:label>
      <link:label id="id_39c41311" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Relative Performance Plan</link:label>
      <link:label id="id_1cf8204b" xlink:label="lbl_EquityBasedParticipationSpecialShareAwardsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Special share awards</link:label>
      <link:label id="id_4b5d1837" xlink:label="lbl_label679367036" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value at grante date at end of period</link:label>
      <link:label id="id_569121e3" xlink:label="lbl_label1373999706" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested, fair value at grante date</link:label>
      <link:label id="id_6bf6969c" xlink:label="lbl_label766376780" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited, fair value at grante date</link:label>
      <link:label id="id_6a253a0a" xlink:label="lbl_label1695476906" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted, fair value at grante date</link:label>
      <link:label id="id_5dafe477" xlink:label="lbl_label1571808375" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_label1571808375" xlink:type="arc"/>
      <link:label id="id_64b72c46" xlink:label="lbl_label1689726022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_label1689726022" xlink:type="arc"/>
      <link:label id="id_195ec04a" xlink:label="lbl_label425640010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_label425640010" xlink:type="arc"/>
      <link:label id="id_776b087e" xlink:label="lbl_label2003503230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material reconciling items [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MaterialReconcilingItemsMember" xlink:to="lbl_label2003503230" xlink:type="arc"/>
      <link:label id="id_13fb62a8" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, sales to other segments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments_labels" xlink:type="arc"/>
      <link:label id="id_71f1654a" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales to discontinued segment</link:label>
      <link:label id="id_425f6b3f" xlink:label="lbl_label1113549631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromInterest" xlink:label="lbl_RevenueFromInterest" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromInterest" xlink:to="lbl_label1113549631" xlink:type="arc"/>
      <link:label id="id_6ed59bdd" xlink:label="lbl_DepreciationAndAmortisationExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortisation expense</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="lbl_DepreciationAndAmortisationExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DepreciationAndAmortisationExpense" xlink:to="lbl_DepreciationAndAmortisationExpense_labels" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:label="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:to="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet_labels" xlink:type="arc"/>
      <link:label id="id_60788cbc" xlink:label="lbl_Liabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
      <link:label id="id_2bf65413" xlink:label="lbl_NetOperatingAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net operating assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetOperatingAssets" xlink:label="lbl_NetOperatingAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetOperatingAssets" xlink:to="lbl_NetOperatingAssets_labels" xlink:type="arc"/>
      <link:label id="id_3832e6c2" xlink:label="lbl_NetOperatingAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net operating assets</link:label>
      <link:label id="id_216a6d7c" xlink:label="lbl_PurchaseOfInterestsInAssociates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of interests in associates</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfInterestsInAssociates" xlink:label="lbl_PurchaseOfInterestsInAssociates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfInterestsInAssociates" xlink:to="lbl_PurchaseOfInterestsInAssociates_labels" xlink:type="arc"/>
      <link:label id="id_41f96a5e" xlink:label="lbl_PurchaseOfInterestsInAssociates_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions to investment in associated companies</link:label>
      <link:label id="id_5e202521" xlink:label="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:label="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:to="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments_labels" xlink:type="arc"/>
      <link:label id="id_3b72597a" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial debts and derivative instruments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialDebtsAndDerivativeInstruments" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialDebtsAndDerivativeInstruments" xlink:to="lbl_FinancialDebtsAndDerivativeInstruments_labels" xlink:type="arc"/>
      <link:label id="id_6e43b10" xlink:label="lbl_label1241182885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current income tax and deferred tax liabilities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:label="lbl_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:to="lbl_label1241182885" xlink:type="arc"/>
      <link:label id="id_2c7e10a7" xlink:label="lbl_label102429242" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales (in % of total net sales)</link:label>
      <link:label id="id_7f20a04d" xlink:label="lbl_SelectedNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total of selected non-current assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SelectedNoncurrentAssets" xlink:to="lbl_SelectedNoncurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_615b5ab6" xlink:label="lbl_SelectedNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies</link:label>
      <link:label id="id_46b9a3b0" xlink:label="lbl_label1358337308" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies. As percent of total selected non-current assets.</link:label>
      <link:label id="id_439913bb" xlink:label="lbl_label1134105531" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
      <link:label id="id_557072dd" xlink:label="lbl_label1433432797" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other countries [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherCountriesMember" xlink:label="lbl_OtherCountriesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCountriesMember" xlink:to="lbl_label1433432797" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCountriesMember" xlink:to="lbl_label1134105531" xlink:type="arc"/>
      <link:label id="id_56b7dac7" xlink:label="lbl_label1638353244" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asia/Africa/Australasia [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AsiaAfricaAustralasiaMember" xlink:label="lbl_AsiaAfricaAustralasiaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AsiaAfricaAustralasiaMember" xlink:to="lbl_label1638353244" xlink:type="arc"/>
      <link:label id="id_7ec1f871" xlink:label="lbl_label2126641265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of entity's revenue</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="lbl_PercentageOfEntitysRevenue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfEntitysRevenue" xlink:to="lbl_label2126641265" xlink:type="arc"/>
      <link:label id="id_4a42fa89" xlink:label="lbl_label1245903497" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of major customers [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMajorCustomersAbstract" xlink:label="lbl_DisclosureOfMajorCustomersAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMajorCustomersAbstract" xlink:to="lbl_label1245903497" xlink:type="arc"/>
      <link:label id="id_77148ff4" xlink:label="lbl_label1997836276" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of major customers [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMajorCustomersTable" xlink:label="lbl_DisclosureOfMajorCustomersTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMajorCustomersTable" xlink:to="lbl_label1997836276" xlink:type="arc"/>
      <link:label id="id_3a785089" xlink:label="lbl_label980963465" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of major customers [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:label="lbl_DisclosureOfMajorCustomersLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_label980963465" xlink:type="arc"/>
      <link:label id="id_7a5a32d3" xlink:label="lbl_label2052731603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major customers [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="lbl_MajorCustomersAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MajorCustomersAxis" xlink:to="lbl_label2052731603" xlink:type="arc"/>
      <link:label id="id_54ab46d" xlink:label="lbl_label88781933" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customers [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorCustomersMember" xlink:label="lbl_MajorCustomersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_label88781933" xlink:type="arc"/>
      <link:label id="id_329eef9f" xlink:label="lbl_label849276831" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Largest customer [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LargestCustomerMember" xlink:label="lbl_LargestCustomerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LargestCustomerMember" xlink:to="lbl_label849276831" xlink:type="arc"/>
      <link:label id="id_3eacc0a0" xlink:label="lbl_label1051508896" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second largest customer [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SecondLargestCustomerMember" xlink:label="lbl_SecondLargestCustomerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SecondLargestCustomerMember" xlink:to="lbl_label1051508896" xlink:type="arc"/>
      <link:label id="id_54e36398" xlink:label="lbl_label1424188312" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third largest customer [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ThirdLargestCustomerMember" xlink:label="lbl_ThirdLargestCustomerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ThirdLargestCustomerMember" xlink:to="lbl_label1424188312" xlink:type="arc"/>
      <link:label id="id_51bc0ac2" xlink:label="lbl_DisclosureOfEntitysReportableSegmentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of entity's operating segments [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:label="lbl_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="lbl_DisclosureOfEntitysReportableSegmentsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_76ba88df" xlink:label="lbl_DisclosureOfEntitysReportableSegmentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segmentation of key figures</link:label>
      <link:label id="id_596e3d72" xlink:label="lbl_DisclosureOfOperatingSegmentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="lbl_DisclosureOfOperatingSegmentsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsExplanatory" xlink:to="lbl_DisclosureOfOperatingSegmentsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_3d44b3a2" xlink:label="lbl_DisclosureOfOperatingSegmentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segmentation - Consolidated income statements</link:label>
      <link:label id="id_910173d" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments, balance sheet [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:to="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_f1f9461" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segmentation - Consolidated balance sheets</link:label>
      <link:label id="id_68241853" xlink:label="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments, by countries and regions [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:to="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_8ba3eb7" xlink:label="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales and total of selected non-current assets, by countries and regions</link:label>
      <link:label id="id_6d6e90e5" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments, net sales by business franchise [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock" xlink:to="lbl_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_11d66710" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales by business franchise</link:label>
      <link:label id="id_1b7ab5f2" xlink:label="lbl_label461026802" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of associates [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="lbl_label461026802" xlink:type="arc"/>
      <link:label id="id_15494420" xlink:label="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of investments accounted for using equity method [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:label="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_2bcfd6a6" xlink:label="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Associated companies</link:label>
      <link:label id="id_113707b2" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of associates [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_38388c12" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to associates</link:label>
      <link:label id="id_27f02648" xlink:label="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of associates balance sheet [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:label="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:to="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_ebb669f" xlink:label="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to associates, balance sheet value</link:label>
      <link:label id="id_52795c5f" xlink:label="lbl_AssociatesSummarizedFinancialInformationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associates summarized financial information [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:label="lbl_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:to="lbl_AssociatesSummarizedFinancialInformationTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6a736cd0" xlink:label="lbl_PurchasePriceAllocationAssociatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase price allocation associates [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PurchasePriceAllocationAssociatesTableTextBlock" xlink:label="lbl_PurchasePriceAllocationAssociatesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchasePriceAllocationAssociatesTableTextBlock" xlink:to="lbl_PurchasePriceAllocationAssociatesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_467a3bcc" xlink:label="lbl_label1182415820" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of associates [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_label1182415820" xlink:type="arc"/>
      <link:label id="id_3a1d7e" xlink:label="lbl_label3808638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of associates [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_label3808638" xlink:type="arc"/>
      <link:label id="id_6360193f" xlink:label="lbl_RocheHoldingAGMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Roche Holding AG, Switzerland</link:label>
      <link:label id="id_5e0c8ce9" xlink:label="lbl_label1577880809" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GlaxoSmithKline Consumer Healthcare Holdings Ltd., UK</link:label>
      <link:label id="id_197b34b2" xlink:label="lbl_label427504818" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GlaxoSmithKline Consumer Healthcare Holdings Ltd. [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:to="lbl_label427504818" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:to="lbl_label1577880809" xlink:type="arc"/>
      <link:label id="id_49715fd2" xlink:label="lbl_OthersAssociatesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Others associates [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OthersAssociatesMember" xlink:to="lbl_OthersAssociatesMember_labels" xlink:type="arc"/>
      <link:label id="id_4dbe4327" xlink:label="lbl_OthersAssociatesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Others</link:label>
      <link:label id="id_54a1c758" xlink:label="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share of total comprehensive income of associates and joint ventures accounted for using equity method</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:type="arc"/>
      <link:label id="id_33c07958" xlink:label="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive income effect</link:label>
      <link:label id="id_4b6b0442" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Balance sheet value</link:label>
      <link:label id="id_2f5ba89e" xlink:label="lbl_label794536094" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in associate</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="lbl_ProportionOfOwnershipInterestInAssociate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProportionOfOwnershipInterestInAssociate" xlink:to="lbl_label794536094" xlink:type="arc"/>
      <link:label id="id_5dfb85ae" xlink:label="lbl_label1576764846" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends received</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsReceived" xlink:label="lbl_DividendsReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsReceived" xlink:to="lbl_label1576764846" xlink:type="arc"/>
      <link:label id="id_404e569d" xlink:label="lbl_label1078875805" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associates summarized financial information [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AssociatesSummarizedFinancialInformationTable" xlink:label="lbl_AssociatesSummarizedFinancialInformationTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssociatesSummarizedFinancialInformationTable" xlink:to="lbl_label1078875805" xlink:type="arc"/>
      <link:label id="id_53734bbc" xlink:label="lbl_label1400064956" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase price allocation associates [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PurchasePriceAllocationAssociatesTable" xlink:label="lbl_PurchasePriceAllocationAssociatesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchasePriceAllocationAssociatesTable" xlink:to="lbl_label1400064956" xlink:type="arc"/>
      <link:label id="id_6e7640ef" xlink:label="lbl_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revaluation increase (decrease), intangible assets other than goodwil</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill" xlink:to="lbl_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_20824625" xlink:label="lbl_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis share of re-appraised intangible assets</link:label>
      <link:label id="id_3ec70a2" xlink:label="lbl_AdditionalRecognitionGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Implicit Novartis goodwill</link:label>
      <link:label id="id_2f773be1" xlink:label="lbl_ShareOfEstimatedNetAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share of estimated net assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ShareOfEstimatedNetAssets" xlink:label="lbl_ShareOfEstimatedNetAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShareOfEstimatedNetAssets" xlink:to="lbl_ShareOfEstimatedNetAssets_labels" xlink:type="arc"/>
      <link:label id="id_7ae8d097" xlink:label="lbl_ShareOfEstimatedNetAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis share of estimated net assets</link:label>
      <link:label id="id_df32051" xlink:label="lbl_label234037329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current value of share in net identifiable assets and goodwill</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" xlink:label="lbl_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" xlink:to="lbl_label234037329" xlink:type="arc"/>
      <link:label id="id_2274c64a" xlink:label="lbl_label578078282" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated equity accounting adjustments and translation effects less dividends received</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" xlink:label="lbl_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" xlink:to="lbl_label578078282" xlink:type="arc"/>
      <link:label id="id_4dcb8141" xlink:label="lbl_label1305182529" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated income statement effects [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ConsolidatedIncomeStatementEffectsTable" xlink:label="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:to="lbl_label1305182529" xlink:type="arc"/>
      <link:label id="id_139af9b9" xlink:label="lbl_label328923577" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis share of current year consolidated net income</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ShareOfCurrentYearNetIncome" xlink:label="lbl_ShareOfCurrentYearNetIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShareOfCurrentYearNetIncome" xlink:to="lbl_label328923577" xlink:type="arc"/>
      <link:label id="id_9a810fe" xlink:label="lbl_label162009342" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior year adjustment</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PriorYearAdjustment" xlink:label="lbl_PriorYearAdjustment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PriorYearAdjustment" xlink:to="lbl_label162009342" xlink:type="arc"/>
      <link:label id="id_78fa72de" xlink:label="lbl_label2029679326" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of fair value adjustments relating to intangible assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:label="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:to="lbl_label2029679326" xlink:type="arc"/>
      <link:label id="id_691026f" xlink:label="lbl_label110166639" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes on Amortization of fair value adjustments relating to intangible assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:label="lbl_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:to="lbl_label110166639" xlink:type="arc"/>
      <link:label id="id_7f5dcb1f" xlink:label="lbl_label2136853279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about provisions and non-current liabilities [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_label2136853279" xlink:type="arc"/>
      <link:label id="id_ff7eee9" xlink:label="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions, contingent liabilities and contingent assets [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:label="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:to="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_3d543140" xlink:label="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions and other non-current liabilities</link:label>
      <link:label id="id_55d4757f" xlink:label="lbl_label1439987071" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsExplanatory" xlink:label="lbl_DisclosureOfOtherProvisionsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherProvisionsExplanatory" xlink:to="lbl_label1439987071" xlink:type="arc"/>
      <link:label id="id_5b6a3526" xlink:label="lbl_label1533687078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccrualForEnvironmentalLossContingenciesTableTextBlock" xlink:label="lbl_AccrualForEnvironmentalLossContingenciesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccrualForEnvironmentalLossContingenciesTableTextBlock" xlink:to="lbl_label1533687078" xlink:type="arc"/>
      <link:label id="id_60a92ef1" xlink:label="lbl_label1621700337" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies, fiscal year maturity [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" xlink:label="lbl_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" xlink:to="lbl_label1621700337" xlink:type="arc"/>
      <link:label id="id_345b34eb" xlink:label="lbl_label878392555" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for product liabilities government investigations other legal matters loss contingencies [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" xlink:label="lbl_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" xlink:to="lbl_label878392555" xlink:type="arc"/>
      <link:label id="id_48374a1f" xlink:label="lbl_label1211583007" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_label1211583007" xlink:type="arc"/>
      <link:label id="id_31459c86" xlink:label="lbl_label826645638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_label826645638" xlink:type="arc"/>
      <link:label id="id_2ad08cd6" xlink:label="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current net defined benefit liability</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:label="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:to="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_labels" xlink:type="arc"/>
      <link:label id="id_7487a2cd" xlink:label="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit pension plans</link:label>
      <link:label id="id_74710a33" xlink:label="lbl_label1953565235" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other long-term employee benefits and deferred compensation</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:label="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:to="lbl_label1953565235" xlink:type="arc"/>
      <link:label id="id_26d5ce13" xlink:label="lbl_label651546131" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other post-employment benefits</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherPostemploymentBenefits" xlink:label="lbl_OtherPostemploymentBenefits" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherPostemploymentBenefits" xlink:to="lbl_label651546131" xlink:type="arc"/>
      <link:label id="id_70976fa3" xlink:label="lbl_label304425068" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental remediation provisions, non-current</link:label>
      <link:label id="id_5e14a65" xlink:label="lbl_label98650725" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
      <link:label id="id_5ed0917e" xlink:label="lbl_label1590727038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental provision [roll forward]</link:label>
      <link:label id="id_6aa8f98d" xlink:label="lbl_label448335871" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash payments</link:label>
      <link:label id="id_70108f36" xlink:label="lbl_label2143979670" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Releases</link:label>
      <link:label id="id_52a74241" xlink:label="lbl_label1560928630" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
      <link:label id="id_57e9d2a0" xlink:label="lbl_label42481781" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_5d09f298" xlink:label="lbl_label1902698328" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less current provision</link:label>
      <link:label id="id_6048622c" xlink:label="lbl_label1615356460" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental provision, fiscal year maturity [abstract]</link:label>
      <link:label id="id_f98ea01" xlink:label="lbl_label1750372676" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total environmental remediation liability provisions</link:label>
      <link:label id="id_2ccb9fb2" xlink:label="lbl_label1351152500" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due within two years</link:label>
      <link:label id="id_78ad40b" xlink:label="lbl_label771700847" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due later than two years, but within five years</link:label>
      <link:label id="id_7cc5fad5" xlink:label="lbl_label1968177093" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due later than five years, but within ten years</link:label>
      <link:label id="id_6e61547b" xlink:label="lbl_label757561900" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after ten years</link:label>
      <link:label id="id_4bc380f7" xlink:label="lbl_label1271103735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions [roll forward]</link:label>
      <link:label id="id_68422c0a" xlink:label="lbl_label1583004694" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions related to discontinued operations</link:label>
      <link:label id="id_efc629e" xlink:label="lbl_label1339267684" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash payments</link:label>
      <link:label id="id_6285ec7c" xlink:label="lbl_label1568927014" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Releases</link:label>
      <link:label id="id_3f37b15b" xlink:label="lbl_label1379712140" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
      <link:label id="id_50e2f2bd" xlink:label="lbl_label1424862979" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_73b301e7" xlink:label="lbl_label252843510" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Product liabilities government investigations other legal matters provisions at end of period</link:label>
      <link:label id="id_29a7abc" xlink:label="lbl_label438797926" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less current provision</link:label>
      <link:label id="id_2ace6c03" xlink:label="lbl_label1363494370" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Non-current product liabilities, governmental investigations and other legal matters provisions at end of period</link:label>
      <link:label id="id_39eddf10" xlink:label="lbl_label971890448" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal proceedings provision [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LegalProceedingsProvisionMember" xlink:label="lbl_LegalProceedingsProvisionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LegalProceedingsProvisionMember" xlink:to="lbl_label971890448" xlink:type="arc"/>
      <link:label id="id_1f2f7122" xlink:label="lbl_label523202850" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Solodyn [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SolodynMember" xlink:label="lbl_SolodynMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SolodynMember" xlink:to="lbl_label523202850" xlink:type="arc"/>
      <link:label id="id_10d3ac94" xlink:label="lbl_label282307732" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contact Lenses [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContactLensesMember" xlink:label="lbl_ContactLensesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContactLensesMember" xlink:to="lbl_label282307732" xlink:type="arc"/>
      <link:label id="id_3e0809a2" xlink:label="lbl_label1040714146" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gleevec [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GleevecMember" xlink:label="lbl_GleevecMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GleevecMember" xlink:to="lbl_label1040714146" xlink:type="arc"/>
      <link:label id="id_7edbae34" xlink:label="lbl_label2128326196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclast/Aclasta [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReclastAclastaMember" xlink:label="lbl_ReclastAclastaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclastAclastaMember" xlink:to="lbl_label2128326196" xlink:type="arc"/>
      <link:label id="id_2b94eceb" xlink:label="lbl_label731180267" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tekturna/Rasilez/Valturna [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TekturnaRasilezValturnaMember" xlink:label="lbl_TekturnaRasilezValturnaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TekturnaRasilezValturnaMember" xlink:to="lbl_label731180267" xlink:type="arc"/>
      <link:label id="id_6962e490" xlink:label="lbl_label1392715101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NAG and Novartis Pharma SpA [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NAGAndNovartisPharmaSpAMember" xlink:label="lbl_NAGAndNovartisPharmaSpAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NAGAndNovartisPharmaSpAMember" xlink:to="lbl_label1392715101" xlink:type="arc"/>
      <link:label id="id_13f125ec" xlink:label="lbl_label400121727" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">F Hoffman La Roche AG and Roche SpA [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FHoffmanLaRocheAGAndRocheSpAMember" xlink:label="lbl_FHoffmanLaRocheAGAndRocheSpAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FHoffmanLaRocheAGAndRocheSpAMember" xlink:to="lbl_label400121727" xlink:type="arc"/>
      <link:label id="id_5ce126b6" xlink:label="lbl_label1365859055" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma K.K. [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaKKMember" xlink:label="lbl_NovartisPharmaKKMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaKKMember" xlink:to="lbl_label1365859055" xlink:type="arc"/>
      <link:label id="id_4f6a2c55" xlink:label="lbl_label1494155554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NAG [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NAGMember" xlink:label="lbl_NAGMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NAGMember" xlink:to="lbl_label1494155554" xlink:type="arc"/>
      <link:label id="id_514c724a" xlink:label="lbl_label201735145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NPC and others [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NPCAndOthersMember" xlink:label="lbl_NPCAndOthersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NPCAndOthersMember" xlink:to="lbl_label201735145" xlink:type="arc"/>
      <link:label id="id_41e7b3b9" xlink:label="lbl_label770853776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis NC [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisNCMember" xlink:label="lbl_NovartisNCMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisNCMember" xlink:to="lbl_label770853776" xlink:type="arc"/>
      <link:label id="id_51394769" xlink:label="lbl_label1362708329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability contingency, loss exposure not accrued, number of cases</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:label="lbl_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:to="lbl_label1362708329" xlink:type="arc"/>
      <link:label id="id_241b918a" xlink:label="lbl_label605786506" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability contingency, loss exposure not accrued, best estimate</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:label="lbl_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:to="lbl_label605786506" xlink:type="arc"/>
      <link:label id="id_2225e7d2" xlink:label="lbl_label572909522" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated financial effect of contingent liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstimatedFinancialEffectOfContingentLiabilities" xlink:to="lbl_label572909522" xlink:type="arc"/>
      <link:label id="id_7a029719" xlink:label="lbl_label2046990105" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of nature of obligation contingent liabilities, number of legal questions referred to court</link:label>
      <link:label id="id_5477d4dd" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated financial effect of contingent liabilities, maximum fine</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine_labels" xlink:type="arc"/>
      <link:label id="id_4b15d12d" xlink:label="lbl_label1259721005" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of nature of obligation contingent liabilities, number of putative cases referred to court</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:to="lbl_label1259721005" xlink:type="arc"/>
      <link:label id="id_2dbbe7e6" xlink:label="lbl_label767289318" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of nature of obligation contingent liabilities, number of other cases referred to court</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:to="lbl_label767289318" xlink:type="arc"/>
      <link:label id="id_2ca8b224" xlink:label="lbl_label749253156" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of nature of obligation contingent liabilities, number of states with alleged violations</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:to="lbl_label749253156" xlink:type="arc"/>
      <link:label id="id_5f79ad81" xlink:label="lbl_label1601809793" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of nature of obligation contingent liabilities, number of cases still pending</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:to="lbl_label1601809793" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:to="lbl_label2046990105" xlink:type="arc"/>
      <link:label id="id_206c121e" xlink:label="lbl_label543953438" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Revenue" xlink:label="lbl_Revenue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Revenue" xlink:to="lbl_label543953438" xlink:type="arc"/>
      <link:label id="id_16a8694f" xlink:label="lbl_label380135759" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.800% USD 1'000 million 2017/2020 of Novartis Capital Corporation, New York, United States, issued at 99.609% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:label="lbl_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:to="lbl_label380135759" xlink:type="arc"/>
      <link:label id="id_37595e6f" xlink:label="lbl_label928603759" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.400% USD 1'000 million 2017/2022 of Novartis Capital Corporation, New York, United States, issued at 99.449% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:label="lbl_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:to="lbl_label928603759" xlink:type="arc"/>
      <link:label id="id_3742c395" xlink:label="lbl_label927122325" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.100% USD 1'000 million 2017/2027 of Novartis Capital Corporation, New York, United States, issued at 99.109% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:label="lbl_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:to="lbl_label927122325" xlink:type="arc"/>
      <link:label id="id_5358e820" xlink:label="lbl_label1398335520" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.000% EUR 1'250 million 2017/2021 of Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.133% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:label="lbl_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:to="lbl_label1398335520" xlink:type="arc"/>
      <link:label id="id_7779807a" xlink:label="lbl_label2004451450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.125% EUR 600 million 2017/2027 of Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.874% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:label="lbl_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:to="lbl_label2004451450" xlink:type="arc"/>
      <link:label id="id_2af5dc98" xlink:label="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transactions with former members of the Board of Directors [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" xlink:label="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" xlink:to="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3ade93c7" xlink:label="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transactions with former members of the Board of Directors</link:label>
      <link:label id="id_3e931ad0" xlink:label="lbl_TotalFairValueAdjustmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total fair value adjustments [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TotalFairValueAdjustmentsMember" xlink:label="lbl_TotalFairValueAdjustmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TotalFairValueAdjustmentsMember" xlink:to="lbl_TotalFairValueAdjustmentsMember_labels" xlink:type="arc"/>
      <link:label id="id_5fef6f2d" xlink:label="lbl_TotalFairValueAdjustmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value adjustments</link:label>
      <link:label id="id_2b0a5355" xlink:label="lbl_CurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Provisions at beginning of period</link:label>
      <link:label id="id_7633694e" xlink:label="lbl_CurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Provisions at end of period</link:label>
      <link:label id="id_55d5426d" xlink:label="lbl_label1440039533" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current prepaid expenses, third party</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentPrepaidExpensesThirdParty" xlink:label="lbl_CurrentPrepaidExpensesThirdParty" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentPrepaidExpensesThirdParty" xlink:to="lbl_label1440039533" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentPrepaidExpensesThirdParty" xlink:to="lbl_label905656156" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract1" xlink:type="locator"/>
      <link:label id="id_4ecd5cc2" xlink:label="lbl_label1322081474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [abstract]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract1" xlink:to="lbl_label1322081474" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:type="locator"/>
      <link:label id="id_3ada3bfa" xlink:label="lbl_label987380730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [line items]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:to="lbl_label987380730" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:type="locator"/>
      <link:label id="id_7e01564" xlink:label="lbl_label132126052" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [table]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:to="lbl_label132126052" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember1" xlink:type="locator"/>
      <link:label id="id_545eb47a" xlink:label="lbl_label1415492730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one month and not later than three months [member]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember1" xlink:to="lbl_label1415492730" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="lbl_LaterThanOneYearMember1" xlink:type="locator"/>
      <link:label id="id_7cfc55ea" xlink:label="lbl_label2096911850" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year [member]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanOneYearMember1" xlink:to="lbl_label2096911850" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:label="lbl_LaterThanSixMonthsAndNotLaterThanOneYearMember1" xlink:type="locator"/>
      <link:label id="id_22980743" xlink:label="lbl_label580388675" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than six months and not later than one year [member]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanSixMonthsAndNotLaterThanOneYearMember1" xlink:to="lbl_label580388675" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:label="lbl_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember1" xlink:type="locator"/>
      <link:label id="id_1f823f0f" xlink:label="lbl_label528629519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than three months and not later than six months [member]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember1" xlink:to="lbl_label528629519" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="lbl_NotLaterThanOneMonthMember" xlink:type="locator"/>
      <link:label id="id_1d54f07" xlink:label="lbl_label30756615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than one month [member]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NotLaterThanOneMonthMember" xlink:to="lbl_label30756615" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="lbl_OtherNoncurrentLiabilities1" xlink:type="locator"/>
      <link:label id="id_69518" xlink:label="lbl_label431384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentLiabilities1" xlink:to="lbl_label431384" xlink:type="arc"/>
      <link:label id="id_7b946bcb" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Past service cost and gains losses arising from settlements, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset1" xlink:to="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_11be10a7" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Past service cost and settlements</link:label>
      <link:label id="id_529b4b2a" xlink:label="lbl_TaxRateEffectFromChangeInTaxRate_labels1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect from change in tax rate</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxRateEffectFromChangeInTaxRate" xlink:label="lbl_TaxRateEffectFromChangeInTaxRate1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectFromChangeInTaxRate1" xlink:to="lbl_TaxRateEffectFromChangeInTaxRate_labels1" xlink:type="arc"/>
      <link:label id="id_9416195" xlink:label="lbl_TaxRateEffectFromChangeInTaxRate_labels1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of tax rate change on current and deferred tax assets and liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss1" xlink:type="locator"/>
      <link:label id="id_753a14cc" xlink:label="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of expense not deductible in determining taxable profit tax loss</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss1" xlink:to="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_labels" xlink:type="arc"/>
      <link:label id="id_4ff9c19a" xlink:label="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of disallowed expenditures</link:label>
      <link:label id="id_72f99baf" xlink:label="lbl_TaxRateEffectOfTaxLosses_labels1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of tax losses</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxRateEffectOfTaxLosses" xlink:label="lbl_TaxRateEffectOfTaxLosses1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfTaxLosses1" xlink:to="lbl_TaxRateEffectOfTaxLosses_labels1" xlink:type="arc"/>
      <link:label id="id_3858f2af" xlink:label="lbl_TaxRateEffectOfTaxLosses_labels1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of utilization of tax losses brought forward from prior periods</link:label>
      <link:label id="id_6100ccc9" xlink:label="lbl_OtherExpenseByFunction_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other expense</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherExpenseByFunction" xlink:to="lbl_OtherExpenseByFunction_labels" xlink:type="arc"/>
      <link:label id="id_7b7f0633" xlink:label="lbl_OtherExpenseByFunction_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other expense, by function</link:label>
      <link:label id="id_295deb1d" xlink:label="lbl_label694020893" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Par value per share</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="lbl_ParValuePerShare" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ParValuePerShare" xlink:to="lbl_label694020893" xlink:type="arc"/>
      <link:label id="id_223c2b0a" xlink:label="lbl_OtherCurrentNonfinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
      <link:label id="id_7418af90" xlink:label="lbl_OtherCurrentFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, commodities, time deposits and derivative financial instruments</link:label>
      <link:label id="id_7592952b" xlink:label="lbl_OtherCurrentFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total marketable securities, commodities, time deposits and derivative financial instruments</link:label>
      <link:label id="id_6a995f9c" xlink:label="lbl_label1788436380" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxotere [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxotereMember" xlink:label="lbl_TaxotereMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxotereMember" xlink:to="lbl_label1788436380" xlink:type="arc"/>
      <link:label id="id_578eb571" xlink:label="lbl_label1468970353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amiodarone [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmiodaroneMember" xlink:label="lbl_AmiodaroneMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmiodaroneMember" xlink:to="lbl_label1468970353" xlink:type="arc"/>
      <link:label id="id_3bc6fd49" xlink:label="lbl_label1002896713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of equity [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfEquityAbstract" xlink:label="lbl_DisclosureOfEquityAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfEquityAbstract" xlink:to="lbl_label1002896713" xlink:type="arc"/>
      <link:label id="id_5120693" xlink:label="lbl_DisclosureOfEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of equity [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfEquityTextBlock" xlink:label="lbl_DisclosureOfEquityTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfEquityTextBlock" xlink:to="lbl_DisclosureOfEquityTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6726d861" xlink:label="lbl_DisclosureOfEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
      <link:label id="id_3dc60187" xlink:label="lbl_DividendTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DividendTableTextBlock" xlink:label="lbl_DividendTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendTableTextBlock" xlink:to="lbl_DividendTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_258e3af2" xlink:label="lbl_DividendTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to Dividend</link:label>
      <link:label id="id_cb435c9" xlink:label="lbl_label213136841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="lbl_AmendmentFlag" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmendmentFlag" xlink:to="lbl_label213136841" xlink:type="arc"/>
      <link:label id="id_5d388f3d" xlink:label="lbl_label1563987773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="lbl_DocumentPeriodEndDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentPeriodEndDate" xlink:to="lbl_label1563987773" xlink:type="arc"/>
      <link:label id="id_1e619d64" xlink:label="lbl_label509713764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="lbl_DocumentFiscalYearFocus" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentFiscalYearFocus" xlink:to="lbl_label509713764" xlink:type="arc"/>
      <link:label id="id_7fb4d619" xlink:label="lbl_label2142557721" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="lbl_DocumentFiscalPeriodFocus" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentFiscalPeriodFocus" xlink:to="lbl_label2142557721" xlink:type="arc"/>
      <link:label id="id_29f6dab9" xlink:label="lbl_label704043705" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="lbl_TradingSymbol" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradingSymbol" xlink:to="lbl_label704043705" xlink:type="arc"/>
      <link:label id="id_30c984d" xlink:label="lbl_label51157069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="lbl_EntityRegistrantName" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityRegistrantName" xlink:to="lbl_label51157069" xlink:type="arc"/>
      <link:label id="id_387f1769" xlink:label="lbl_label947853161" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="lbl_EntityCentralIndexKey" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityCentralIndexKey" xlink:to="lbl_label947853161" xlink:type="arc"/>
      <link:label id="id_6f6c1fbf" xlink:label="lbl_label1869356991" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="lbl_CurrentFiscalYearEndDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentFiscalYearEndDate" xlink:to="lbl_label1869356991" xlink:type="arc"/>
      <link:label id="id_6f81ea6f" xlink:label="lbl_label1870785135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="lbl_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityWellKnownSeasonedIssuer" xlink:to="lbl_label1870785135" xlink:type="arc"/>
      <link:label id="id_593907e" xlink:label="lbl_label93556862" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="lbl_EntityCurrentReportingStatus" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityCurrentReportingStatus" xlink:to="lbl_label93556862" xlink:type="arc"/>
      <link:label id="id_a350bde" xlink:label="lbl_label171248606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="lbl_EntityVoluntaryFilers" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityVoluntaryFilers" xlink:to="lbl_label171248606" xlink:type="arc"/>
      <link:label id="id_1ebbff8e" xlink:label="lbl_label515637134" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="lbl_EntityFilerCategory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityFilerCategory" xlink:to="lbl_label515637134" xlink:type="arc"/>
      <link:label id="id_2df8f48d" xlink:label="lbl_label771290253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="lbl_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityCommonStockSharesOutstanding" xlink:to="lbl_label771290253" xlink:type="arc"/>
      <link:label id="id_6a10c99a" xlink:label="lbl_label1779485082" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="lbl_EntityPublicFloat" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityPublicFloat" xlink:to="lbl_label1779485082" xlink:type="arc"/>
      <link:label id="id_60ad1327" xlink:label="lbl_US_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_US" xlink:to="lbl_US_labels" xlink:type="arc"/>
      <link:label id="id_45b4f0b8" xlink:label="lbl_GB_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED KINGDOM</link:label>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_GB" xlink:label="lbl_GB" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GB" xlink:to="lbl_GB_labels" xlink:type="arc"/>
      <link:label id="id_fa4133c" xlink:label="lbl_DE_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GERMANY</link:label>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DE" xlink:label="lbl_DE" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DE" xlink:to="lbl_DE_labels" xlink:type="arc"/>
      <link:label id="id_4fab4920" xlink:label="lbl_FR_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FRANCE</link:label>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_FR" xlink:label="lbl_FR" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FR" xlink:to="lbl_FR_labels" xlink:type="arc"/>
      <link:label id="id_2409370a" xlink:label="lbl_JP_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="lbl_JP" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_JP" xlink:to="lbl_JP_labels" xlink:type="arc"/>
      <link:label id="id_7e84627" xlink:label="lbl_US_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US</link:label>
      <link:label id="id_35cc0588" xlink:label="lbl_GB_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UK</link:label>
      <link:label id="id_11499416" xlink:label="lbl_DE_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Germany</link:label>
      <link:label id="id_50732a2" xlink:label="lbl_FR_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">France</link:label>
      <link:label id="id_16ecebec" xlink:label="lbl_JP_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan</link:label>
      <link:label id="id_47d2ec01" xlink:label="lbl_IT_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ITALY</link:label>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_IT" xlink:label="lbl_IT" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IT" xlink:to="lbl_IT_labels" xlink:type="arc"/>
      <link:label id="id_3b372d9d" xlink:label="lbl_IT_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Italy</link:label>
      <link:label id="id_53d1a5ee" xlink:label="lbl_CA_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CANADA</link:label>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CA" xlink:label="lbl_CA" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CA" xlink:to="lbl_CA_labels" xlink:type="arc"/>
      <link:label id="id_68cbde64" xlink:label="lbl_CA_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canada</link:label>
      <link:label id="id_87623f2" xlink:label="lbl_USD_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United States of America, Dollars</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_USD" xlink:label="lbl_USD" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_USD" xlink:to="lbl_USD_labels" xlink:type="arc"/>
      <link:label id="id_73a7c19e" xlink:label="lbl_USD_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">USD</link:label>
      <link:label id="id_78126268" xlink:label="lbl_EUR_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="lbl_EUR" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EUR" xlink:to="lbl_EUR_labels" xlink:type="arc"/>
      <link:label id="id_70708ef7" xlink:label="lbl_EUR_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EUR</link:label>
      <link:label id="id_12746a38" xlink:label="lbl_JPY_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY" xlink:label="lbl_JPY" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_JPY" xlink:to="lbl_JPY_labels" xlink:type="arc"/>
      <link:label id="id_7b8f8056" xlink:label="lbl_JPY_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">JPY</link:label>
      <link:label id="id_7a7394c2" xlink:label="lbl_CNY_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">China, Yuan Renminbi</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CNY" xlink:label="lbl_CNY" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CNY" xlink:to="lbl_CNY_labels" xlink:type="arc"/>
      <link:label id="id_4d265dd0" xlink:label="lbl_CNY_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CNY</link:label>
      <link:label id="id_1c17f7c4" xlink:label="lbl_GBP_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United Kingdom, Pounds</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP" xlink:label="lbl_GBP" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GBP" xlink:to="lbl_GBP_labels" xlink:type="arc"/>
      <link:label id="id_1728da67" xlink:label="lbl_GBP_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GBP</link:label>
      <link:label id="id_436074ee" xlink:label="lbl_CHF_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CHF</link:label>
      <link:label id="id_1da98c1e" xlink:label="lbl_label497650718" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="lbl_DocumentInformationTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentInformationTable" xlink:to="lbl_label497650718" xlink:type="arc"/>
      <link:label id="id_12b84aa7" xlink:label="lbl_label314067623" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="lbl_DocumentInformationLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_label314067623" xlink:type="arc"/>
      <link:label id="id_165ab5d4" xlink:label="lbl_label375043540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_label375043540" xlink:type="arc"/>
      <link:label id="id_238135db" xlink:label="lbl_label595670491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityDomain" xlink:to="lbl_label595670491" xlink:type="arc"/>
      <link:label id="id_1d17e2f2" xlink:label="lbl_label488104690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_label488104690" xlink:type="arc"/>
      <link:label id="id_1d7da856" xlink:label="lbl_AdministrativeExpense_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Need new ITEM here</link:label>
      <link:label id="id_751ef3e9" xlink:label="lbl_AdministrativeExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">General and Administration</link:label>
      <link:label id="id_20c355f9" xlink:label="lbl_IncreaseDecreaseInNoncontrolingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in non-controling interests</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseInNoncontrolingInterests" xlink:label="lbl_IncreaseDecreaseInNoncontrolingInterests" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInNoncontrolingInterests" xlink:to="lbl_IncreaseDecreaseInNoncontrolingInterests_labels" xlink:type="arc"/>
      <link:label id="id_71d21c6b" xlink:label="lbl_IncreaseDecreaseInNoncontrolingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in non-controlling interests</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsReceivedClassifiedAsOperatingActivities" xlink:label="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:label id="id_7d6a6449" xlink:label="lbl_DividendsReceivedClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends received from associated companies and others</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:to="lbl_DividendsReceivedClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_4bdcb2fd" xlink:label="lbl_DividendsReceivedClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends received, classified as operating activities</link:label>
      <link:label id="id_d7b5832" xlink:label="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance income received, classified as operating activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:to="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_7e7ea58d" xlink:label="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial receipts</link:label>
      <link:label id="id_44baadd4" xlink:label="lbl_FinanceCostsPaidClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance costs paid, classified as operating activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:to="lbl_FinanceCostsPaidClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_68d65042" xlink:label="lbl_FinanceCostsPaidClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other financial payments</link:label>
      <link:label id="id_36d7aeb1" xlink:label="lbl_ProceedsFromSalesOfInterestsInAssociates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales of interests in associates</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromSalesOfInterestsInAssociates" xlink:label="lbl_ProceedsFromSalesOfInterestsInAssociates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromSalesOfInterestsInAssociates" xlink:to="lbl_ProceedsFromSalesOfInterestsInAssociates_labels" xlink:type="arc"/>
      <link:label id="id_df43529" xlink:label="lbl_ProceedsFromSalesOfInterestsInAssociates_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and divestments of interests in associated companies, net</link:label>
      <link:label id="id_789b89ac" xlink:label="lbl_label1718040268" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and divestments of businesses, net</link:label>
      <link:label id="id_197c150c" xlink:label="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividends paid to shareholders of Novartis AG</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:label="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:to="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_3ec8bcea" xlink:label="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends paid to equity holders of parent, classified as financing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="locator"/>
      <link:label id="id_7cc199f7" xlink:label="lbl_ProceedsFromNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from non-current financial debts</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromNoncurrentBorrowings" xlink:to="lbl_ProceedsFromNoncurrentBorrowings_labels" xlink:type="arc"/>
      <link:label id="id_2e7bd9f2" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of non-current borrowings</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RepaymentsOfNoncurrentBorrowings" xlink:to="lbl_RepaymentsOfNoncurrentBorrowings_labels" xlink:type="arc"/>
      <link:label id="id_106de250" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of non-current financial debts</link:label>
      <link:label id="id_40f4d6a8" xlink:label="lbl_ProceedsFromNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from non-current borrowings</link:label>
      <link:label id="id_1bde8770" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) increase (decrease) in current borrowings</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:to="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_labels" xlink:type="arc"/>
      <link:label id="id_104baa70" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in current financial debts</link:label>
      <link:label id="id_367ad3ce" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financing cash flows, net</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_2a649f3d" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other inflows (outflows) of cash, classified as financing activities</link:label>
      <link:label id="id_3f82a721" xlink:label="lbl_IncomeTaxesPaidRefund_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefund" xlink:label="lbl_IncomeTaxesPaidRefund" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxesPaidRefund" xlink:to="lbl_IncomeTaxesPaidRefund_labels" xlink:type="arc"/>
      <link:label id="id_53191c38" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund), classified as investing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_16a1607" xlink:label="lbl_label23729671" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfReportableSegments" xlink:label="lbl_NumberOfReportableSegments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfReportableSegments" xlink:to="lbl_label23729671" xlink:type="arc"/>
      <link:label id="id_ff1b344" xlink:label="lbl_label267498308" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Business Units</link:label>
      <link:label id="id_19aaa924" xlink:label="lbl_label430614820" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Franchises</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfFranchises" xlink:label="lbl_NumberOfFranchises" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfFranchises" xlink:to="lbl_label430614820" xlink:type="arc"/>
      <link:label id="id_4ccf5884" xlink:label="lbl_AdditionsToRestructuringProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions to restructuring provisions</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdditionsToRestructuringProvisions" xlink:label="lbl_AdditionsToRestructuringProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsToRestructuringProvisions" xlink:to="lbl_AdditionsToRestructuringProvisions_labels" xlink:type="arc"/>
      <link:label id="id_3b0ef23" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additions to property, plant and equipment</link:label>
      <link:label id="id_528839cf" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additions to intangible assets and goodwill</link:label>
      <link:label id="id_40106876" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, third parties and other segments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties_labels" xlink:type="arc"/>
      <link:label id="id_7458433e" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales to third parties from continuing operations</link:label>
      <link:label id="id_541cacbc" xlink:label="lbl_label1411165372" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, third parties and other segments, as percent of total net sales</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:to="lbl_label1411165372" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:to="lbl_label102429242" xlink:type="arc"/>
      <link:label id="id_5aa03955" xlink:label="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selected non-current assets, as percent</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:to="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_6c200908" xlink:label="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selected non-current assets (in % of total selected non-current assets)</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:to="lbl_label1358337308" xlink:type="arc"/>
      <link:label id="id_6d471c75" xlink:label="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of investments in associates for which there are quoted market prices</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished" xlink:label="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished" xlink:to="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished_labels" xlink:type="arc"/>
      <link:label id="id_6319607c" xlink:label="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in subsidiaries, joint ventures and associates</link:label>
      <link:label id="id_51c4430d" xlink:label="lbl_label1371816717" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense, gross</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:label="lbl_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:to="lbl_label1371816717" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:to="lbl_label1549022431" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromDividends" xlink:label="lbl_RevenueFromDividends" xlink:type="locator"/>
      <link:label id="id_752e4898" xlink:label="lbl_label1965967512" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend income</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromDividends" xlink:to="lbl_label1965967512" xlink:type="arc"/>
      <link:label id="id_6b7200d3" xlink:label="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss on commodities and available-for-sale securities, net</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:label="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:to="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet_labels" xlink:type="arc"/>
      <link:label id="id_4fa6704a" xlink:label="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment of commodities and available-for-sale securities, net</link:label>
      <link:label id="id_6fd24c63" xlink:label="lbl_OtherFinanceCost_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other finance cost</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherFinanceCost" xlink:label="lbl_OtherFinanceCost" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherFinanceCost" xlink:to="lbl_OtherFinanceCost_labels" xlink:type="arc"/>
      <link:label id="id_2d3e7598" xlink:label="lbl_OtherFinanceCost_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other financial expense</link:label>
      <link:label id="id_2b07fd1f" xlink:label="lbl_TaxExpenseIncomeDiscontinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income), discontinuing operations</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxExpenseIncomeDiscontinuingOperations" xlink:label="lbl_TaxExpenseIncomeDiscontinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxExpenseIncomeDiscontinuingOperations" xlink:to="lbl_TaxExpenseIncomeDiscontinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_671db01c" xlink:label="lbl_TaxExpenseIncomeDiscontinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense from discontinued operations</link:label>
      <link:label id="id_772c2e3e" xlink:label="lbl_label1999384126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect from non-deductible losses</link:label>
      <link:label id="id_199436bd" xlink:label="lbl_label429143741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation change in uncertain tax positions</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:label="lbl_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:to="lbl_label429143741" xlink:type="arc"/>
      <link:label id="id_80d3caa" xlink:label="lbl_label135085226" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation other adjustments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="lbl_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lbl_label135085226" xlink:type="arc"/>
      <link:label id="id_2016529c" xlink:label="lbl_label538333852" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation change in enacted tax rate</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="lbl_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lbl_label538333852" xlink:type="arc"/>
      <link:label id="id_2aa51152" xlink:label="lbl_label1640547073" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income net of tax gains/losses on remeasurements of defined benefit plans related to discontinued operations</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:to="lbl_label1640547073" xlink:type="arc"/>
      <link:label id="id_596243a4" xlink:label="lbl_label1689586548" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income net of tax exchange differences on translation related to discontinued operations</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:to="lbl_label1689586548" xlink:type="arc"/>
      <link:label id="id_1a035b8a" xlink:label="lbl_label436427658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business unit [axis]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BusinessUnitAxis" xlink:label="lbl_BusinessUnitAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BusinessUnitAxis" xlink:to="lbl_label436427658" xlink:type="arc"/>
      <link:label id="id_7dfe6553" xlink:label="lbl_label2113824083" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business unit [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BusinessUnitMember" xlink:label="lbl_BusinessUnitMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BusinessUnitMember" xlink:to="lbl_label2113824083" xlink:type="arc"/>
      <link:label id="id_1c8ae042" xlink:label="lbl_label478863426" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oncology [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OncologyMember" xlink:label="lbl_OncologyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OncologyMember" xlink:to="lbl_label478863426" xlink:type="arc"/>
      <link:label id="id_6b138679" xlink:label="lbl_label1796441721" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pharmaceutical [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PharmaceuticalMember" xlink:label="lbl_PharmaceuticalMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PharmaceuticalMember" xlink:to="lbl_label1796441721" xlink:type="arc"/>
      <link:label id="id_73d27a10" xlink:label="lbl_label1943173648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Franchise [axis]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FranchiseAxis" xlink:label="lbl_FranchiseAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FranchiseAxis" xlink:to="lbl_label1943173648" xlink:type="arc"/>
      <link:label id="id_578f16d9" xlink:label="lbl_label1468995289" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Franchise [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FranchiseMember" xlink:label="lbl_FranchiseMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FranchiseMember" xlink:to="lbl_label1468995289" xlink:type="arc"/>
      <link:label id="id_7a3bb683" xlink:label="lbl_label2050733699" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ophthalmology [member]</link:label>
      <link:label id="id_29ccb106" xlink:label="lbl_label701280518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neuroscience [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NeuroscienceMember" xlink:label="lbl_NeuroscienceMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NeuroscienceMember" xlink:to="lbl_label701280518" xlink:type="arc"/>
      <link:label id="id_1b0191fc" xlink:label="lbl_label453087740" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Respiratory [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RespiratoryMember" xlink:label="lbl_RespiratoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RespiratoryMember" xlink:to="lbl_label453087740" xlink:type="arc"/>
      <link:label id="id_43a1daf0" xlink:label="lbl_label1134680816" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cardiovascular, Renal and Metabolism [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CardioMetabolicMember" xlink:label="lbl_CardioMetabolicMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CardioMetabolicMember" xlink:to="lbl_label1134680816" xlink:type="arc"/>
      <link:label id="id_393ea837" xlink:label="lbl_label960407607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Established Medicines [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EstablishedMedicinesMember" xlink:label="lbl_EstablishedMedicinesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstablishedMedicinesMember" xlink:to="lbl_label960407607" xlink:type="arc"/>
      <link:label id="id_5bf06316" xlink:label="lbl_label1542480662" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product portfolio [axis]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_label1542480662" xlink:type="arc"/>
      <link:label id="id_38b2f5ea" xlink:label="lbl_label951252458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product portfolio [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_label951252458" xlink:type="arc"/>
      <link:label id="id_77b41933" xlink:label="lbl_label2008291635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">COPD [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_COPDMember" xlink:label="lbl_COPDMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_COPDMember" xlink:to="lbl_label2008291635" xlink:type="arc"/>
      <link:label id="id_7bd53aee" xlink:label="lbl_label2077571822" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gleevec/Glivec [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GleevecGlivecMember" xlink:label="lbl_GleevecGlivecMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GleevecGlivecMember" xlink:to="lbl_label2077571822" xlink:type="arc"/>
      <link:label id="id_b0600c4" xlink:label="lbl_label184942788" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tasigna [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TasignaMember" xlink:to="lbl_label184942788" xlink:type="arc"/>
      <link:label id="id_3f81d4ef" xlink:label="lbl_label1065473263" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandostatin [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandostatinMember" xlink:label="lbl_SandostatinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandostatinMember" xlink:to="lbl_label1065473263" xlink:type="arc"/>
      <link:label id="id_b64c3a5" xlink:label="lbl_label191153061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Afinitor/Votubia [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AfinitorVotubiaMember" xlink:label="lbl_AfinitorVotubiaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AfinitorVotubiaMember" xlink:to="lbl_label191153061" xlink:type="arc"/>
      <link:label id="id_7ee4b441" xlink:label="lbl_label2128917569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exjade/Jadenu [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExjadeJadenuMember" xlink:label="lbl_ExjadeJadenuMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExjadeJadenuMember" xlink:to="lbl_label2128917569" xlink:type="arc"/>
      <link:label id="id_28e14893" xlink:label="lbl_label685852819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tafinlar + Mekinist [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TafinlarMekinistMember" xlink:label="lbl_TafinlarMekinistMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TafinlarMekinistMember" xlink:to="lbl_label685852819" xlink:type="arc"/>
      <link:label id="id_67d8ca2f" xlink:label="lbl_label1742260783" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Promacta/Revolade [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PromactaRevoladeMember" xlink:label="lbl_PromactaRevoladeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PromactaRevoladeMember" xlink:to="lbl_label1742260783" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OphthalmologyMember" xlink:label="lbl_OphthalmologyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OphthalmologyMember" xlink:to="lbl_label2050733699" xlink:type="arc"/>
      <link:label id="id_647651d6" xlink:label="lbl_label1685475798" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Votrient [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VotrientMember" xlink:to="lbl_label1685475798" xlink:type="arc"/>
      <link:label id="id_2746717b" xlink:label="lbl_label658927995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jakavi [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_JakaviMember" xlink:label="lbl_JakaviMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_JakaviMember" xlink:to="lbl_label658927995" xlink:type="arc"/>
      <link:label id="id_72117eb7" xlink:label="lbl_label1913749175" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kisqali [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KisqaliMember" xlink:label="lbl_KisqaliMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KisqaliMember" xlink:to="lbl_label1913749175" xlink:type="arc"/>
      <link:label id="id_4dee8d50" xlink:label="lbl_label1307479376" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherProductsMember" xlink:label="lbl_OtherProductsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherProductsMember" xlink:to="lbl_label1307479376" xlink:type="arc"/>
      <link:label id="id_6a7a37e6" xlink:label="lbl_label1786394598" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Travoprost Group [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TravoprostGroupMember" xlink:label="lbl_TravoprostGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TravoprostGroupMember" xlink:to="lbl_label1786394598" xlink:type="arc"/>
      <link:label id="id_3e01b08f" xlink:label="lbl_label1040298127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Systane Group [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SystaneGroupMember" xlink:label="lbl_SystaneGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SystaneGroupMember" xlink:to="lbl_label1040298127" xlink:type="arc"/>
      <link:label id="id_3ffa23d" xlink:label="lbl_label67084861" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Topical Olopatadine Group [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TopicalOlopatadineGroupMember" xlink:label="lbl_TopicalOlopatadineGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TopicalOlopatadineGroupMember" xlink:to="lbl_label67084861" xlink:type="arc"/>
      <link:label id="id_931b1f9" xlink:label="lbl_label154251769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cosentyx [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CosentyxMember" xlink:label="lbl_CosentyxMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CosentyxMember" xlink:to="lbl_label154251769" xlink:type="arc"/>
      <link:label id="id_31cd0397" xlink:label="lbl_label835519383" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neoral/Sandimmun(e) [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NeoralSandimmunEMember" xlink:label="lbl_NeoralSandimmunEMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NeoralSandimmunEMember" xlink:to="lbl_label835519383" xlink:type="arc"/>
      <link:label id="id_48585481" xlink:label="lbl_label1213748353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zortress/Certican [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ZortressCerticanMember" xlink:label="lbl_ZortressCerticanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZortressCerticanMember" xlink:to="lbl_label1213748353" xlink:type="arc"/>
      <link:label id="id_d8aed9" xlink:label="lbl_label14200537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ilaris [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IlarisMember" xlink:label="lbl_IlarisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IlarisMember" xlink:to="lbl_label14200537" xlink:type="arc"/>
      <link:label id="id_612117f4" xlink:label="lbl_label1629558772" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Myfortic [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MyforticMember" xlink:label="lbl_MyforticMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MyforticMember" xlink:to="lbl_label1629558772" xlink:type="arc"/>
      <link:label id="id_63153a75" xlink:label="lbl_label1662335605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gilenya [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GilenyaMember" xlink:label="lbl_GilenyaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GilenyaMember" xlink:to="lbl_label1662335605" xlink:type="arc"/>
      <link:label id="id_79c9c9f8" xlink:label="lbl_label2043267576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ultibro Breezhaler [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UltibroBreezhalerMember" xlink:label="lbl_UltibroBreezhalerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UltibroBreezhalerMember" xlink:to="lbl_label2043267576" xlink:type="arc"/>
      <link:label id="id_39edf745" xlink:label="lbl_label971896645" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seebri Breezhaler [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SeebriBreezhalerMember" xlink:label="lbl_SeebriBreezhalerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SeebriBreezhalerMember" xlink:to="lbl_label971896645" xlink:type="arc"/>
      <link:label id="id_3093cd1d" xlink:label="lbl_label814992669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Onbrez Breezhaler [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OnbrezBreezhalerMember" xlink:label="lbl_OnbrezBreezhalerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OnbrezBreezhalerMember" xlink:to="lbl_label814992669" xlink:type="arc"/>
      <link:label id="id_61b9d990" xlink:label="lbl_label1639569808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entresto [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EntrestoMember" xlink:label="lbl_EntrestoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntrestoMember" xlink:to="lbl_label1639569808" xlink:type="arc"/>
      <link:label id="id_ba5bf3e" xlink:label="lbl_label195411774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Galvus Group [member]</link:label>
      <link:label id="id_4a18d85e" xlink:label="lbl_label1243142238" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exforge Group [member]</link:label>
      <link:label id="id_75a7ce71" xlink:label="lbl_label1973931633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diovan Group [member]</link:label>
      <link:label id="id_2e0075fc" xlink:label="lbl_label771782140" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Voltaren/Cataflam [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VoltarenCataflamMember" xlink:label="lbl_VoltarenCataflamMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VoltarenCataflamMember" xlink:to="lbl_label771782140" xlink:type="arc"/>
      <link:label id="id_5304aa12" xlink:label="lbl_label1392814610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exelon/Exelon Patch [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExelonExelonPatchMember" xlink:label="lbl_ExelonExelonPatchMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExelonExelonPatchMember" xlink:to="lbl_label1392814610" xlink:type="arc"/>
      <link:label id="id_10a15386" xlink:label="lbl_label279008134" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ritalin/Focalin [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RitalinFocalinMember" xlink:label="lbl_RitalinFocalinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RitalinFocalinMember" xlink:to="lbl_label279008134" xlink:type="arc"/>
      <link:label id="id_26f1359c" xlink:label="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated depreciation on disposals, property plant and equipment</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:label="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:to="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_1c74ede2" xlink:label="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation on disposals and derecognitions</link:label>
      <link:label id="id_22aa91df" xlink:label="lbl_label1255943452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated impairments on disposals and derecognition</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:label="lbl_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:to="lbl_label1255943452" xlink:type="arc"/>
      <link:label id="id_626451ea" xlink:label="lbl_AcquiredResearchAndDevelopmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired research and development [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquiredResearchAndDevelopmentMember" xlink:label="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquiredResearchAndDevelopmentMember" xlink:to="lbl_AcquiredResearchAndDevelopmentMember_labels" xlink:type="arc"/>
      <link:label id="id_d6a6395" xlink:label="lbl_AcquiredResearchAndDevelopmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired research and development</link:label>
      <link:label id="id_52b9d0b7" xlink:label="lbl_AlconBrandNameMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon brand name [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconBrandNameMember" xlink:label="lbl_AlconBrandNameMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconBrandNameMember" xlink:to="lbl_AlconBrandNameMember_labels" xlink:type="arc"/>
      <link:label id="id_4db335d9" xlink:label="lbl_AlconBrandNameMember_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Alcon brand name</link:label>
      <link:label id="id_52290b49" xlink:label="lbl_label1378421577" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross value of tax loss carry forwards expiring in future years</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:label="lbl_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:to="lbl_label1378421577" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:to="lbl_label94266701" xlink:type="arc"/>
      <link:label id="id_70e22198" xlink:label="lbl_label198642827" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales, change in %</link:label>
      <link:label id="id_330af3ff" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shareholders of Novartis AG</link:label>
      <link:label id="id_2b7d0eda" xlink:label="lbl_label729616090" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative currency translation gains/losses recycled through income statement</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:to="lbl_label729616090" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" xlink:label="lbl_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" xlink:type="locator"/>
      <link:label id="id_19f22bed" xlink:label="lbl_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impaired loss on financial assets transferred to the income statement</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" xlink:to="lbl_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax_labels" xlink:type="arc"/>
      <link:label id="id_2ac3f739" xlink:label="lbl_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification adjustments on financial assets measured at fair value through other comprehensive income, net of tax</link:label>
      <link:label id="id_1bf8cda2" xlink:label="lbl_label469290402" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, available-for-sale financial investments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeAvailableforsaleFinancialInvestments" xlink:label="lbl_OtherComprehensiveIncomeAvailableforsaleFinancialInvestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeAvailableforsaleFinancialInvestments" xlink:to="lbl_label469290402" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeAvailableforsaleFinancialInvestments" xlink:to="lbl_label521267934" xlink:type="arc"/>
      <link:label id="id_523cf50c" xlink:label="lbl_OtherComprehensiveIncomeMaketableSecurities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, maketable securities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeMaketableSecurities" xlink:label="lbl_OtherComprehensiveIncomeMaketableSecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeMaketableSecurities" xlink:to="lbl_OtherComprehensiveIncomeMaketableSecurities_labels" xlink:type="arc"/>
      <link:label id="id_64b0e4db" xlink:label="lbl_OtherComprehensiveIncomeMaketableSecurities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale marketable securities</link:label>
      <link:label id="id_37e931e5" xlink:label="lbl_FinanceLeaseReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net book value</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinanceLeaseReceivables" xlink:label="lbl_FinanceLeaseReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinanceLeaseReceivables" xlink:to="lbl_FinanceLeaseReceivables_labels" xlink:type="arc"/>
      <link:label id="id_f9fb296" xlink:label="lbl_FinanceLeaseReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance lease receivables</link:label>
      <link:label id="id_18330ebd" xlink:label="lbl_NoncurrentFinanceLeaseReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments from finance lease agreements</link:label>
      <link:label id="id_5342799f" xlink:label="lbl_label1396865439" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for doubtful receivable [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionForDoubtfulReceivableMember" xlink:label="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionForDoubtfulReceivableMember" xlink:to="lbl_label1396865439" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" xlink:to="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded_labels" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_Commodities" xlink:label="lbl_Commodities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Commodities" xlink:to="lbl_label1789088932" xlink:type="arc"/>
      <link:label id="id_2985d64f" xlink:label="lbl_OutstandingShareCapital_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding share capital</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OutstandingShareCapital" xlink:label="lbl_OutstandingShareCapital" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OutstandingShareCapital" xlink:to="lbl_OutstandingShareCapital_labels" xlink:type="arc"/>
      <link:label id="id_550535ae" xlink:label="lbl_OutstandingShareCapital_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Total outstanding share capital at beginning of period</link:label>
      <link:label id="id_75bd4d3d" xlink:label="lbl_OutstandingShareCapital_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Total outstanding share capital at end of period</link:label>
      <link:label id="id_551db3e0" xlink:label="lbl_SaleOrIssueOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares movement of period</link:label>
      <link:label id="id_736416f8" xlink:label="lbl_IssuedCapitalMovement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital, movement</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IssuedCapitalMovement" xlink:label="lbl_IssuedCapitalMovement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IssuedCapitalMovement" xlink:to="lbl_IssuedCapitalMovement_labels" xlink:type="arc"/>
      <link:label id="id_58515153" xlink:label="lbl_IssuedCapitalMovement_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital movement of period</link:label>
      <link:label id="id_416f3b0f" xlink:label="lbl_OutstandingShareCapitalMovement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding share capital, movement</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OutstandingShareCapitalMovement" xlink:label="lbl_OutstandingShareCapitalMovement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OutstandingShareCapitalMovement" xlink:to="lbl_OutstandingShareCapitalMovement_labels" xlink:type="arc"/>
      <link:label id="id_578dd06d" xlink:label="lbl_OutstandingShareCapitalMovement_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total shares outstanding movement of period</link:label>
      <link:label id="id_6cc370cc" xlink:label="lbl_label1824747724" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares cancelled for capital reduction</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharesCancelledForCapitalReduction" xlink:label="lbl_SharesCancelledForCapitalReduction" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharesCancelledForCapitalReduction" xlink:to="lbl_label1824747724" xlink:type="arc"/>
      <link:label id="id_138eeec4" xlink:label="lbl_TreasurySharesMovement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares, movement</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TreasurySharesMovement" xlink:label="lbl_TreasurySharesMovement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesMovement" xlink:to="lbl_TreasurySharesMovement_labels" xlink:type="arc"/>
      <link:label id="id_296c7c9b" xlink:label="lbl_TreasurySharesMovement_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total number of outstanding treasury shares</link:label>
      <link:label id="id_3fd2a1c9" xlink:label="lbl_SharepurchaseOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares</link:label>
      <link:label id="id_4f72913c" xlink:label="lbl_PurchaseOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares, equity impact</link:label>
      <link:label id="id_10472e97" xlink:label="lbl_EquityImpactOfTreasuryShareMovements_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity impact of treasury share movements</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityImpactOfTreasuryShareMovements" xlink:label="lbl_EquityImpactOfTreasuryShareMovements" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityImpactOfTreasuryShareMovements" xlink:to="lbl_EquityImpactOfTreasuryShareMovements_labels" xlink:type="arc"/>
      <link:label id="id_1cdf067d" xlink:label="lbl_EquityImpactOfTreasuryShareMovements_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity impact of treasury share movements</link:label>
      <link:label id="id_495f6f85" xlink:label="lbl_label903405960" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average interest rate on loans received</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AverageInterestRateOnLoansReceived" xlink:label="lbl_AverageInterestRateOnLoansReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AverageInterestRateOnLoansReceived" xlink:to="lbl_label903405960" xlink:type="arc"/>
      <link:label id="id_57858aea" xlink:label="lbl_label1766025212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ratio fixed rate financial debt to total financial debt</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:label="lbl_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:to="lbl_label1766025212" xlink:type="arc"/>
      <link:label id="id_10cf25f4" xlink:label="lbl_label1048419104" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average interest rate on borrowings</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AverageInterestRateOnBorrowings" xlink:label="lbl_AverageInterestRateOnBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AverageInterestRateOnBorrowings" xlink:to="lbl_label1048419104" xlink:type="arc"/>
      <link:label id="id_2aee42a4" xlink:label="lbl_BorrowingsInterestRate_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, coupon</link:label>
      <link:label id="id_176fa55a" xlink:label="lbl_BorrowingsIssuanceDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, issuance year</link:label>
      <link:label id="id_6ff69971" xlink:label="lbl_BorrowingsMaturity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, maturity year</link:label>
      <link:label id="id_7a5c6046" xlink:label="lbl_BorrowingsLender_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, issuer</link:label>
      <link:label id="id_30da0d60" xlink:label="lbl_BorrowingsPremiumDiscount_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, issue price</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationNonCurrent" xlink:label="lbl_ContingentConsiderationNonCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationNonCurrent" xlink:to="lbl_label98650725" xlink:type="arc"/>
      <link:label id="id_38f01585" xlink:label="lbl_label955258245" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Environmental remediation provisions</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionRollForward" xlink:label="lbl_EnvironmentalProvisionRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_label1590727038" xlink:type="arc"/>
      <link:label id="id_26f523d7" xlink:label="lbl_EnvironmentalProvision_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvision" xlink:label="lbl_EnvironmentalProvision" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvision" xlink:to="lbl_EnvironmentalProvision_labels" xlink:type="arc"/>
      <link:label id="id_2f8c0636" xlink:label="lbl_EnvironmentalProvision_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Environmental liabilities provision at beginning of period</link:label>
      <link:label id="id_3ca05f15" xlink:label="lbl_EnvironmentalProvision_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Environmental liabilities provision at end of period</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvision" xlink:to="lbl_label1750372676" xlink:type="arc"/>
      <link:label id="id_5bf2bac7" xlink:label="lbl_label1542634183" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies, payments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionPayments" xlink:label="lbl_EnvironmentalProvisionPayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionPayments" xlink:to="lbl_label1542634183" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionPayments" xlink:to="lbl_label448335871" xlink:type="arc"/>
      <link:label id="id_1bbf0a1c" xlink:label="lbl_label465504796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies, releases</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionReleases" xlink:label="lbl_EnvironmentalProvisionReleases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionReleases" xlink:to="lbl_label465504796" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionReleases" xlink:to="lbl_label2143979670" xlink:type="arc"/>
      <link:label id="id_30109c5e" xlink:label="lbl_label806394974" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies, additions</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionAdditions" xlink:label="lbl_EnvironmentalProvisionAdditions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionAdditions" xlink:to="lbl_label806394974" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionAdditions" xlink:to="lbl_label1560928630" xlink:type="arc"/>
      <link:label id="id_6528e847" xlink:label="lbl_label1697179719" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies, foreign currency translation gain (loss)</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:label="lbl_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:to="lbl_label1697179719" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:to="lbl_label42481781" xlink:type="arc"/>
      <link:label id="id_69c992c5" xlink:label="lbl_EnvironmentalProvisionCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies, Current</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionCurrent" xlink:label="lbl_EnvironmentalProvisionCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionCurrent" xlink:to="lbl_EnvironmentalProvisionCurrent_labels" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionCurrent" xlink:to="lbl_label1902698328" xlink:type="arc"/>
      <link:label id="id_76c21b8c" xlink:label="lbl_label1992432524" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Non-current environmental remediation provisions at end of period</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalRemediationProvisionNoncurrent" xlink:label="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:to="lbl_label1992432524" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:to="lbl_label955258245" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:to="lbl_label304425068" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:label="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:to="lbl_label1615356460" xlink:type="arc"/>
      <link:label id="id_6deab0eb" xlink:label="lbl_label1844097259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental provision, expected cash outflow, next two years</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:to="lbl_label1844097259" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:to="lbl_label1351152500" xlink:type="arc"/>
      <link:label id="id_54b46e40" xlink:label="lbl_label1421110848" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental provision, expected cash outflow, later than two years, but within five years</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:to="lbl_label1421110848" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:to="lbl_label771700847" xlink:type="arc"/>
      <link:label id="id_366842e4" xlink:label="lbl_label912802532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental provision, expected cash outflow, later than five years, but within ten years</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:to="lbl_label912802532" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:to="lbl_label1968177093" xlink:type="arc"/>
      <link:label id="id_53179e3c" xlink:label="lbl_label1394056764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental provision, expected cash outflow, after ten years</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:to="lbl_label1394056764" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:to="lbl_label757561900" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_label1271103735" xlink:type="arc"/>
      <link:label id="id_5e9e598e" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions_labels" xlink:type="arc"/>
      <link:label id="id_1dcf084" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Product liabilities government investigations other legal matters provisions at beginning of period</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:to="lbl_label252843510" xlink:type="arc"/>
      <link:label id="id_71839c4e" xlink:label="lbl_label1904450638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, discontinued operations</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:to="lbl_label1904450638" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:to="lbl_label1583004694" xlink:type="arc"/>
      <link:label id="id_53472504" xlink:label="lbl_label1397171460" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, payments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:to="lbl_label1397171460" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:to="lbl_label1339267684" xlink:type="arc"/>
      <link:label id="id_3e905f98" xlink:label="lbl_label1049649048" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, releases</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:to="lbl_label1049649048" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:to="lbl_label1568927014" xlink:type="arc"/>
      <link:label id="id_61e84c26" xlink:label="lbl_label1642613798" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, additions</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:to="lbl_label1642613798" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:to="lbl_label1379712140" xlink:type="arc"/>
      <link:label id="id_6c695b53" xlink:label="lbl_label1818843987" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, foreign currency translation gain (loss)</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:to="lbl_label1818843987" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:to="lbl_label1424862979" xlink:type="arc"/>
      <link:label id="id_54a4e6a7" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, current</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent_labels" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:to="lbl_label438797926" xlink:type="arc"/>
      <link:label id="id_acc6217" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, non-current</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent_labels" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:to="lbl_label1363494370" xlink:type="arc"/>
      <link:label id="id_d93a8b" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WeightedAverageInterestRateAssociates" xlink:label="lbl_WeightedAverageInterestRateAssociates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageInterestRateAssociates" xlink:to="lbl_WeightedAverageInterestRateAssociates_labels" xlink:type="arc"/>
      <link:label id="id_6be37912" xlink:label="lbl_WeightedAverageInterestRateAssociates_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average interest rate on interest bearning accounts of associates payable on demand.</link:label>
      <link:label id="id_1a1c62e1" xlink:label="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average interest rate on Bank and other financial debt</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:label="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:to="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt_labels" xlink:type="arc"/>
      <link:label id="id_1401b9c9" xlink:label="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average interest rate on Bank and other financial debt</link:label>
      <link:label id="id_7df4e11d" xlink:label="lbl_EnvironmentalProvisionCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Environmental remediation liabilities</link:label>
      <link:label id="id_19219108" xlink:label="lbl_AccrualsClassifiedAsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses for goods and services received but not invoiced</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="lbl_AccrualsClassifiedAsCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccrualsClassifiedAsCurrent" xlink:to="lbl_AccrualsClassifiedAsCurrent_labels" xlink:type="arc"/>
      <link:label id="id_2731b8ee" xlink:label="lbl_AccrualsClassifiedAsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accruals classified as current</link:label>
      <link:label id="id_1dcdc504" xlink:label="lbl_ContingentConsiderationCurrentPortion_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration, current portion</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationCurrentPortion" xlink:label="lbl_ContingentConsiderationCurrentPortion" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationCurrentPortion" xlink:to="lbl_ContingentConsiderationCurrentPortion_labels" xlink:type="arc"/>
      <link:label id="id_cecd050" xlink:label="lbl_ContingentConsiderationCurrentPortion_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent considerations</link:label>
      <link:label id="id_66cb3d62" xlink:label="lbl_label1724595554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for deduction from revenue [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionForDeductionFromRevenueTable" xlink:label="lbl_ProvisionForDeductionFromRevenueTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionForDeductionFromRevenueTable" xlink:to="lbl_label1724595554" xlink:type="arc"/>
      <link:label id="id_62196d01" xlink:label="lbl_label1645833473" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring provisions movements [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RestructuringProvisionsMovementsTable" xlink:label="lbl_RestructuringProvisionsMovementsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestructuringProvisionsMovementsTable" xlink:to="lbl_label1645833473" xlink:type="arc"/>
      <link:label id="id_5c0c0960" xlink:label="lbl_RestructuringProvisionTransfers_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring provision transfers</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RestructuringProvisionTransfers" xlink:label="lbl_RestructuringProvisionTransfers" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestructuringProvisionTransfers" xlink:to="lbl_RestructuringProvisionTransfers_labels" xlink:type="arc"/>
      <link:label id="id_2238ed4d" xlink:label="lbl_RestructuringProvisionTransfers_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transfers</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xlink:label="lbl_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xlink:type="locator"/>
      <link:label id="id_78c7fbb0" xlink:label="lbl_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification adjustments on cash flow hedges, net of tax</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xlink:to="lbl_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_labels" xlink:type="arc"/>
      <link:label id="id_b7c54f9" xlink:label="lbl_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized net losses on cash flow hedges transferred to the consolidated income statement</link:label>
      <link:label id="id_58b3a333" xlink:label="lbl_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other payables and deferred tax liabilities recognised as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lbl_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_5a90c79" xlink:label="lbl_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payables and other liabilities including deferred tax liabilities</link:label>
      <link:label id="id_2856a2a3" xlink:label="lbl_IdentifiableAssetsAcquired_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Identifiable assets acquired</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IdentifiableAssetsAcquired" xlink:label="lbl_IdentifiableAssetsAcquired" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_IdentifiableAssetsAcquired_labels" xlink:type="arc"/>
      <link:label id="id_205b065c" xlink:label="lbl_IdentifiableAssetsAcquired_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net identifiable assets acquired</link:label>
      <link:label id="id_62f623d2" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property plant and equipment recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_59f5d7c5" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
      <link:label id="id_28728c08" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currently marketed products intangible assets recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_4dd002d2" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currently marketed products</link:label>
      <link:label id="id_3be633c" xlink:label="lbl_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired divested research and development intangible assets recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_3369d331" xlink:label="lbl_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Acquired)/divested research and development</link:label>
      <link:label id="id_44229a8b" xlink:label="lbl_TechnologiesRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technologies recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TechnologiesRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_TechnologiesRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TechnologiesRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_TechnologiesRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_3e9ce44a" xlink:label="lbl_TechnologiesRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technologies</link:label>
      <link:label id="id_33f9a377" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other intangible assets recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_52667216" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
      <link:label id="id_2879f83e" xlink:label="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and other assets including deferred tax assets recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_64556efa" xlink:label="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial and other assets including deferred tax assets</link:label>
      <link:label id="id_63e0564e" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoryRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_InventoryRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_7a3f0241" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
      <link:label id="id_4427bc74" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables and other current assets recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_5681fbbf" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables and other current assets</link:label>
      <link:label id="id_6359834c" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_47a6ced3" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:label id="id_4d854151" xlink:label="lbl_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current and non-current financial debts recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_3ea67aa0" xlink:label="lbl_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current and non-current financial debts</link:label>
      <link:label id="id_1be55693" xlink:label="lbl_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other payables recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_65a5731d" xlink:label="lbl_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Trade payables and other liabilities including deferred tax liabilities</link:label>
      <link:label id="id_5d12057a" xlink:label="lbl_label1419113480" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Animal health [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AnimalHealthMember" xlink:label="lbl_AnimalHealthMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AnimalHealthMember" xlink:to="lbl_label1419113480" xlink:type="arc"/>
      <link:label id="id_6ab963bf" xlink:label="lbl_label1790534591" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sale of business</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProceedsFromSaleOfBusiness" xlink:label="lbl_ProceedsFromSaleOfBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromSaleOfBusiness" xlink:to="lbl_label1790534591" xlink:type="arc"/>
      <link:label id="id_2cda3a42" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash flows used in/from investing activities from discontinued operations</link:label>
      <link:label id="id_7f35ae76" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Financial debts and derivative instruments at beginning of period</link:label>
      <link:label id="id_5e88cc26" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Financial debts and derivative instruments at end of period</link:label>
      <link:label id="id_32b354fd" xlink:label="lbl_label1199806184" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair values, and other changes, net</link:label>
      <link:label id="id_3eaf2bac" xlink:label="lbl_AmortizationOfBondsDiscount_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of bonds discount</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmortizationOfBondsDiscount" xlink:label="lbl_AmortizationOfBondsDiscount" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmortizationOfBondsDiscount" xlink:to="lbl_AmortizationOfBondsDiscount_labels" xlink:type="arc"/>
      <link:label id="id_4b9e2882" xlink:label="lbl_label1268656258" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial debts [member]</link:label>
      <link:label id="id_24db2ae3" xlink:label="lbl_label618343139" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current financial debts and derivative financial instruments [member]</link:label>
      <link:label id="id_20254569" xlink:label="lbl_label539313513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current portion of non-current financial debt</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentPortionOfNoncurrentFinancialDebt" xlink:label="lbl_CurrentPortionOfNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentPortionOfNoncurrentFinancialDebt" xlink:to="lbl_label539313513" xlink:type="arc"/>
      <link:label id="id_4171dffa" xlink:label="lbl_label1097981946" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genentech / Roche [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GenentechRocheMember" xlink:label="lbl_GenentechRocheMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GenentechRocheMember" xlink:to="lbl_label1097981946" xlink:type="arc"/>
      <link:label id="id_21b59c45" xlink:label="lbl_label565550149" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of contracts with related parties</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfContractsWithRelatedParties" xlink:label="lbl_NumberOfContractsWithRelatedParties" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfContractsWithRelatedParties" xlink:to="lbl_label565550149" xlink:type="arc"/>
      <link:label id="id_140db491" xlink:label="lbl_RelatedPartiesNumberOfExecutiveCommiteeMembers_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related parties, number of executive commitee members</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RelatedPartiesNumberOfExecutiveCommiteeMembers" xlink:label="lbl_RelatedPartiesNumberOfExecutiveCommiteeMembers" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RelatedPartiesNumberOfExecutiveCommiteeMembers" xlink:to="lbl_RelatedPartiesNumberOfExecutiveCommiteeMembers_labels" xlink:type="arc"/>
      <link:label id="id_12cdd92b" xlink:label="lbl_RelatedPartiesNumberOfExecutiveCommiteeMembers_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Commitee members</link:label>
      <link:label id="id_4d39a061" xlink:label="lbl_RelatedPartiesNumberOfNonexecutiveDirectors_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related parties, number of non-executive directors</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:label="lbl_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:to="lbl_RelatedPartiesNumberOfNonexecutiveDirectors_labels" xlink:type="arc"/>
      <link:label id="id_2b93879e" xlink:label="lbl_RelatedPartiesNumberOfNonexecutiveDirectors_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-executive directors</link:label>
      <link:label id="id_4c2ae7af" xlink:label="lbl_label1277880239" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, expected future benefit payment</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:to="lbl_label1277880239" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:to="lbl_label839490648" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EmployerSharesHeldByDefinedBenefitPlan" xlink:label="lbl_EmployerSharesHeldByDefinedBenefitPlan" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EmployerSharesHeldByDefinedBenefitPlan" xlink:to="lbl_label2113441601" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:label="lbl_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:to="lbl_label1670270510" xlink:type="arc"/>
      <link:label id="id_2111657b" xlink:label="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Administrative expense net defined benefit liability asset</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:label="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:to="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_6b50d402" xlink:label="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Administrative expenses</link:label>
      <link:label id="id_2605ce0d" xlink:label="lbl_label637914637" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial gains (losses) arising from changes in expreience related assumptions, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="lbl_label637914637" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="lbl_label783050349" xlink:type="arc"/>
      <link:label id="id_45a2931c" xlink:label="lbl_label1168282396" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, foreign currency exchange rate gain (loss)</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:to="lbl_label1168282396" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:to="lbl_label220841955" xlink:type="arc"/>
      <link:label id="id_329368f1" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through changes in foreign exchange rates, defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset_labels" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:to="lbl_label1273555602" xlink:type="arc"/>
      <link:label id="id_5b9bb55e" xlink:label="lbl_label1536931166" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than five years and not later than ten years [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:label="lbl_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:to="lbl_label1536931166" xlink:type="arc"/>
      <link:label id="id_7cbb695f" xlink:label="lbl_label2092656991" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="lbl_DisclosureOfFinancialAssetsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_label2092656991" xlink:type="arc"/>
      <link:label id="id_675e88e3" xlink:label="lbl_label1734248675" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="lbl_DisclosureOfFinancialAssetsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAssetsLineItems" xlink:to="lbl_label1734248675" xlink:type="arc"/>
      <link:label id="id_6f8cf207" xlink:label="lbl_label1871507975" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssets" xlink:label="lbl_FinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssets" xlink:to="lbl_label1871507975" xlink:type="arc"/>
      <link:label id="id_31c4b50a" xlink:label="lbl_label834974986" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial assets [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="lbl_ClassesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfFinancialAssetsAxis" xlink:to="lbl_label834974986" xlink:type="arc"/>
      <link:label id="id_3b500f38" xlink:label="lbl_label995102520" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets, class [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsMember" xlink:label="lbl_FinancialAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsMember" xlink:to="lbl_label995102520" xlink:type="arc"/>
      <link:label id="id_5853963a" xlink:label="lbl_label1481872954" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at amortised cost, class [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="lbl_FinancialAssetsAtAmortisedCostMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsAtAmortisedCostMember" xlink:to="lbl_label1481872954" xlink:type="arc"/>
      <link:label id="id_15228c3a" xlink:label="lbl_label354585658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashAndCashEquivalentsMember" xlink:label="lbl_CashAndCashEquivalentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsMember" xlink:to="lbl_label354585658" xlink:type="arc"/>
      <link:label id="id_2ea70" xlink:label="lbl_label191088" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial assets [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="lbl_CategoriesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CategoriesOfFinancialAssetsAxis" xlink:to="lbl_label191088" xlink:type="arc"/>
      <link:label id="id_5fa2081d" xlink:label="lbl_label1604454429" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets, category [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="lbl_FinancialAssetsCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsCategoryMember" xlink:to="lbl_label1604454429" xlink:type="arc"/>
      <link:label id="id_7ddd290" xlink:label="lbl_label131977872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale marketable securities [member]</link:label>
      <link:label id="id_36737cf8" xlink:label="lbl_label913538296" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale long-term financial investments [member]</link:label>
      <link:label id="id_5632a636" xlink:label="lbl_label1446159926" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance sheet item [axis]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BalanceSheetItemAxis" xlink:label="lbl_BalanceSheetItemAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BalanceSheetItemAxis" xlink:to="lbl_label1446159926" xlink:type="arc"/>
      <link:label id="id_77e6aae0" xlink:label="lbl_label2011605728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance sheet item [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BalanceSheetItemMember" xlink:label="lbl_BalanceSheetItemMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_label2011605728" xlink:type="arc"/>
      <link:label id="id_39f42abc" xlink:label="lbl_label972303036" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity securities [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquitySecuritiesMember" xlink:label="lbl_EquitySecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquitySecuritiesMember" xlink:to="lbl_label972303036" xlink:type="arc"/>
      <link:label id="id_34461243" xlink:label="lbl_label877007427" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fund investments [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FundInvestmentsMember" xlink:label="lbl_FundInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FundInvestmentsMember" xlink:to="lbl_label877007427" xlink:type="arc"/>
      <link:label id="id_3c80f6bd" xlink:label="lbl_label1015084733" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables and other current assets excluding pre-payments [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:to="lbl_label1015084733" xlink:type="arc"/>
      <link:label id="id_71d621f1" xlink:label="lbl_label1909858801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration receivables [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationReceivablesMember" xlink:label="lbl_ContingentConsiderationReceivablesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationReceivablesMember" xlink:to="lbl_label1909858801" xlink:type="arc"/>
      <link:label id="id_266ee04f" xlink:label="lbl_label644800591" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued interest on debt securities and time deposits [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:label="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:to="lbl_label644800591" xlink:type="arc"/>
      <link:label id="id_462cba41" xlink:label="lbl_label1177336385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time deposits with original maturity more than 90 days [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:label="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:to="lbl_label1177336385" xlink:type="arc"/>
      <link:label id="id_1ada2efd" xlink:label="lbl_label450506493" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term loans and receivables from customers and finance lease, advances, security deposits [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:label="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:to="lbl_label450506493" xlink:type="arc"/>
      <link:label id="id_7c347590" xlink:label="lbl_label2083812752" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associated companies at fair value through profit and loss [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:label="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:to="lbl_label2083812752" xlink:type="arc"/>
      <link:label id="id_533b50d9" xlink:label="lbl_label1396396249" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsMember" xlink:to="lbl_label1396396249" xlink:type="arc"/>
      <link:label id="id_551fe4b1" xlink:label="lbl_label1428153521" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_label1428153521" xlink:type="arc"/>
      <link:label id="id_114f7584" xlink:label="lbl_label290420100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial liabilities [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:to="lbl_label290420100" xlink:type="arc"/>
      <link:label id="id_3b35b195" xlink:label="lbl_label993374613" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities, class [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="lbl_FinancialLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesMember" xlink:to="lbl_label993374613" xlink:type="arc"/>
      <link:label id="id_68a64911" xlink:label="lbl_label1755728145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at amortised cost, class [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="lbl_FinancialLiabilitiesAtAmortisedCostMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesAtAmortisedCostMember" xlink:to="lbl_label1755728145" xlink:type="arc"/>
      <link:label id="id_6d1d78f2" xlink:label="lbl_label1830648050" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at fair value, class [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:label="lbl_FinancialLiabilitiesAtFairValueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesAtFairValueMember" xlink:to="lbl_label1830648050" xlink:type="arc"/>
      <link:label id="id_27bb9ea8" xlink:label="lbl_label666607272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Groups of financial assets/liabilities [axis]</link:label>
      <link:label id="id_7cf4bc91" xlink:label="lbl_label2096413841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Groups of financial assets/liabilities [member]</link:label>
      <link:label id="id_68ba85b6" xlink:label="lbl_label1757054390" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at fair value, class [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueMember" xlink:label="lbl_FinancialAssetsAtFairValueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsAtFairValueMember" xlink:to="lbl_label1757054390" xlink:type="arc"/>
      <link:label id="id_3cee5982" xlink:label="lbl_label1022253442" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at fair value through profit or loss, category [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="lbl_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:to="lbl_label1022253442" xlink:type="arc"/>
      <link:label id="id_2d611cc9" xlink:label="lbl_label761339081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at fair value through other comprehensive income, category [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:label="lbl_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:to="lbl_label761339081" xlink:type="arc"/>
      <link:label id="id_2c7b189f" xlink:label="lbl_label746264735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities, category [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="lbl_FinancialLiabilitiesCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesCategoryMember" xlink:to="lbl_label746264735" xlink:type="arc"/>
      <link:label id="id_153859c4" xlink:label="lbl_label356014532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial liabilities [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lbl_label356014532" xlink:type="arc"/>
      <link:label id="id_14968138" xlink:label="lbl_label345407800" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at fair value through profit or loss, category [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="lbl_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:to="lbl_label345407800" xlink:type="arc"/>
      <link:label id="id_2576e32b" xlink:label="lbl_label628548395" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at amortised cost, category [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:label="lbl_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:to="lbl_label628548395" xlink:type="arc"/>
      <link:label id="id_5a840ece" xlink:label="lbl_label1518603982" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at amortised cost, category [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:label="lbl_FinancialAssetsAtAmortisedCostCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsAtAmortisedCostCategoryMember" xlink:to="lbl_label1518603982" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_label666607272" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_label2096413841" xlink:type="arc"/>
      <link:label id="id_4718921c" xlink:label="lbl_label1192792604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current financial debt [member]</link:label>
      <link:label id="id_1748f73f" xlink:label="lbl_label390657855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial debt [member]</link:label>
      <link:label id="id_7d47f3b5" xlink:label="lbl_label2101867445" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade payables [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradePayablesMember" xlink:label="lbl_TradePayablesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradePayablesMember" xlink:to="lbl_label2101867445" xlink:type="arc"/>
      <link:label id="id_1ed425bd" xlink:label="lbl_label517219773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest bearning accounts of associates payable on demand [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:label="lbl_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:to="lbl_label517219773" xlink:type="arc"/>
      <link:label id="id_7fb53de5" xlink:label="lbl_label2142584293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bank and other financial debt [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BankAndOtherFinancialDebtMember" xlink:label="lbl_BankAndOtherFinancialDebtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BankAndOtherFinancialDebtMember" xlink:to="lbl_label2142584293" xlink:type="arc"/>
      <link:label id="id_36f483b7" xlink:label="lbl_label921994167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial paper [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CommercialPaperMember" xlink:label="lbl_CommercialPaperMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommercialPaperMember" xlink:to="lbl_label921994167" xlink:type="arc"/>
      <link:label id="id_2993bf16" xlink:label="lbl_label697548566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current portion of non-current debt [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentPortionOfNoncurrentDebtMember" xlink:label="lbl_CurrentPortionOfNoncurrentDebtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentPortionOfNoncurrentDebtMember" xlink:to="lbl_label697548566" xlink:type="arc"/>
      <link:label id="id_7aa4522e" xlink:label="lbl_label2057589294" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Straight bonds [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StraightBondsMember" xlink:label="lbl_StraightBondsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StraightBondsMember" xlink:to="lbl_label2057589294" xlink:type="arc"/>
      <link:label id="id_2e89197f" xlink:label="lbl_label780736895" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities to banks and other financial institutions [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:label="lbl_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:to="lbl_label780736895" xlink:type="arc"/>
      <link:label id="id_3cfbed2" xlink:label="lbl_label63946450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance lease obligations [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinanceLeaseObligationsMember" xlink:label="lbl_FinanceLeaseObligationsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinanceLeaseObligationsMember" xlink:to="lbl_label63946450" xlink:type="arc"/>
      <link:label id="id_47b3aade" xlink:label="lbl_label1202957022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration and other financial liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:label="lbl_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:to="lbl_label1202957022" xlink:type="arc"/>
      <link:label id="id_74b2144b" xlink:label="lbl_label1957827659" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments, by type of contract [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:to="lbl_label1957827659" xlink:type="arc"/>
      <link:label id="id_11a7e82b" xlink:label="lbl_label296216619" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instrument, nature of instrument [axis]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:to="lbl_label296216619" xlink:type="arc"/>
      <link:label id="id_5a462aee" xlink:label="lbl_label1514547950" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instrument, nature of instrument [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:to="lbl_label1514547950" xlink:type="arc"/>
      <link:label id="id_75469247" xlink:label="lbl_label1967559239" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments, at fair value currency related [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:label="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:to="lbl_label1967559239" xlink:type="arc"/>
      <link:label id="id_3583f9fa" xlink:label="lbl_label897841658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, principal amounts [axis]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsPrincipalAmountsAxis" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:to="lbl_label897841658" xlink:type="arc"/>
      <link:label id="id_102b0f85" xlink:label="lbl_label271257477" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, principal amounts [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsPrincipalAmountsMember" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_label271257477" xlink:type="arc"/>
      <link:label id="id_3f464064" xlink:label="lbl_label1061568612" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract or underlying principal amout [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContractOrUnderlyingPrincipalAmoutMember" xlink:label="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:to="lbl_label1061568612" xlink:type="arc"/>
      <link:label id="id_24f6d45c" xlink:label="lbl_label620155996" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Positive fair values [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PositiveFairValuesMember" xlink:label="lbl_PositiveFairValuesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PositiveFairValuesMember" xlink:to="lbl_label620155996" xlink:type="arc"/>
      <link:label id="id_42b35305" xlink:label="lbl_label1119048453" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Negative fair values [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NegativeFairValuesMember" xlink:label="lbl_NegativeFairValuesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NegativeFairValuesMember" xlink:to="lbl_label1119048453" xlink:type="arc"/>
      <link:label id="id_4c8abefe" xlink:label="lbl_label1284161278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments [line items]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_label1284161278" xlink:type="arc"/>
      <link:label id="id_5286c358" xlink:label="lbl_label1384563544" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="lbl_label1384563544" xlink:type="arc"/>
      <link:label id="id_487fc207" xlink:label="lbl_label1216332295" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilities" xlink:label="lbl_FinancialLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilities" xlink:to="lbl_label1216332295" xlink:type="arc"/>
      <link:label id="id_453bddb" xlink:label="lbl_label72596955" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstruments" xlink:label="lbl_DerivativeFinancialInstruments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstruments" xlink:to="lbl_label72596955" xlink:type="arc"/>
      <link:label id="id_397d852b" xlink:label="lbl_label964527403" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments, forward foreign exchange rate contracts</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:label="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:to="lbl_label964527403" xlink:type="arc"/>
      <link:label id="id_b3aed83" xlink:label="lbl_label188411267" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments, over-the-counter currency options</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:label="lbl_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:to="lbl_label188411267" xlink:type="arc"/>
      <link:label id="id_24aeca58" xlink:label="lbl_label615434840" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments, by currency contract [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_label615434840" xlink:type="arc"/>
      <link:label id="id_3d32bab6" xlink:label="lbl_label1026734774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of assets [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_label1026734774" xlink:type="arc"/>
      <link:label id="id_3f252a8f" xlink:label="lbl_label1059400335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MeasurementAxis" xlink:label="lbl_MeasurementAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MeasurementAxis" xlink:to="lbl_label1059400335" xlink:type="arc"/>
      <link:label id="id_59852144" xlink:label="lbl_label1501897028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregated measurement [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="lbl_AggregatedMeasurementMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AggregatedMeasurementMember" xlink:to="lbl_label1501897028" xlink:type="arc"/>
      <link:label id="id_640cd1b3" xlink:label="lbl_label1678561715" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recurring fair value measurement [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RecurringFairValueMeasurementMember" xlink:label="lbl_RecurringFairValueMeasurementMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RecurringFairValueMeasurementMember" xlink:to="lbl_label1678561715" xlink:type="arc"/>
      <link:label id="id_6df52bda" xlink:label="lbl_label1844784090" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities, time deposits and derivative financial instruments [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:label="lbl_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:to="lbl_label1844784090" xlink:type="arc"/>
      <link:label id="id_469d8a26" xlink:label="lbl_label1184729638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial investments and long-term loans [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:label="lbl_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:to="lbl_label1184729638" xlink:type="arc"/>
      <link:label id="id_3e1a7df6" xlink:label="lbl_label1041923574" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total available-for-sale marketable securities [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TotalAvailableforsaleMarketableSecuritiesMember" xlink:label="lbl_TotalAvailableforsaleMarketableSecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TotalAvailableforsaleMarketableSecuritiesMember" xlink:to="lbl_label1041923574" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AvailableForSaleMarketableSecuritiesMember" xlink:label="lbl_AvailableForSaleMarketableSecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AvailableForSaleMarketableSecuritiesMember" xlink:to="lbl_label131977872" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:to="lbl_label913538296" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentFinancialDebtMember" xlink:label="lbl_CurrentFinancialDebtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentFinancialDebtMember" xlink:to="lbl_label1192792604" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentFinancialDebtMember" xlink:label="lbl_NoncurrentFinancialDebtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialDebtMember" xlink:to="lbl_label390657855" xlink:type="arc"/>
      <link:label id="id_55c289f5" xlink:label="lbl_label1438812661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale financial investments [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AvailableforsaleFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:to="lbl_label1438812661" xlink:type="arc"/>
      <link:label id="id_4af993b7" xlink:label="lbl_label1257870263" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of assets [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="lbl_label1257870263" xlink:type="arc"/>
      <link:label id="id_5b807bec" xlink:label="lbl_label1535146988" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valued at amortized cost [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ValuedAtAmortizedCostMember" xlink:label="lbl_ValuedAtAmortizedCostMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValuedAtAmortizedCostMember" xlink:to="lbl_label1535146988" xlink:type="arc"/>
      <link:label id="id_6163f2e6" xlink:label="lbl_label1633940198" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of liabilities [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="lbl_ClassesOfLiabilitiesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfLiabilitiesAxis" xlink:to="lbl_label1633940198" xlink:type="arc"/>
      <link:label id="id_39b2a3b6" xlink:label="lbl_label968008630" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="lbl_LiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_label968008630" xlink:type="arc"/>
      <link:label id="id_2dde0229" xlink:label="lbl_label769524265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration payables [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationPayablesMember" xlink:label="lbl_ContingentConsiderationPayablesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationPayablesMember" xlink:to="lbl_label769524265" xlink:type="arc"/>
      <link:label id="id_648479c6" xlink:label="lbl_label1686403526" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other financial liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherFinancialLiabilitiesMember" xlink:label="lbl_OtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherFinancialLiabilitiesMember" xlink:to="lbl_label1686403526" xlink:type="arc"/>
      <link:label id="id_7d19861f" xlink:label="lbl_label2098824735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">China Novartis Institutes for BioMedical Research Co., Ltd., Shanghai [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:label="lbl_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:to="lbl_label2098824735" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare1" xlink:type="locator"/>
      <link:label id="id_6e8d8711" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends proposed, cash per share</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare1" xlink:to="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare_labels" xlink:type="arc"/>
      <link:label id="id_5643fad7" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners per share</link:label>
      <link:label id="id_65bb0a73" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends proposed</link:label>
      <link:label id="id_738a993" xlink:label="lbl_label121153939" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase/decrease in fair value measurement liabilities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:label="lbl_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:to="lbl_label121153939" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:to="lbl_label1199806184" xlink:type="arc"/>
      <link:label id="id_7ebb8632" xlink:label="lbl_label2126218802" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets, at fair value</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="lbl_FinancialAssetsAtFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsAtFairValue" xlink:to="lbl_label2126218802" xlink:type="arc"/>
      <link:label id="id_5083795f" xlink:label="lbl_FinancialLiabilitiesAtFairValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities, at fair value</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="lbl_FinancialLiabilitiesAtFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesAtFairValue" xlink:to="lbl_FinancialLiabilitiesAtFairValue_labels" xlink:type="arc"/>
      <link:label id="id_2d43301f" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, hedges of net investments in foreign operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations_labels" xlink:type="arc"/>
      <link:label id="id_43e5ded1" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net investment hedge</link:label>
      <link:label id="id_72a89a91" xlink:label="lbl_label1923652241" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Australia Pty Ltd, Macquarie Park, NSW [member]</link:label>
      <link:label id="id_731902b7" xlink:label="lbl_label1931018935" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharmaceuticals Australia Pty Ltd, Macquarie Park, NSW [member]</link:label>
      <link:label id="id_1867bb0f" xlink:label="lbl_label409451279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories (Australia) Pty Ltd, Macquarie Park, NSW [member]</link:label>
      <link:label id="id_3d795141" xlink:label="lbl_label1031360833" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Pty Ltd, Macquarie Park, NSW [member]</link:label>
      <link:label id="id_5d546db3" xlink:label="lbl_label1565814195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Austria GmbH, Vienna [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisAustriaGmbHViennaMember" xlink:label="lbl_NovartisAustriaGmbHViennaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisAustriaGmbHViennaMember" xlink:to="lbl_label1565814195" xlink:type="arc"/>
      <link:label id="id_2234921c" xlink:label="lbl_label573870620" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma GmbH, Vienna [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaGmbHViennaMember" xlink:label="lbl_NovartisPharmaGmbHViennaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaGmbHViennaMember" xlink:to="lbl_label573870620" xlink:type="arc"/>
      <link:label id="id_7dcc65cd" xlink:label="lbl_label2110547405" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Ophthalmika GmbH, Vienna [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconOphthalmikaGmbHViennaMember" xlink:label="lbl_AlconOphthalmikaGmbHViennaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconOphthalmikaGmbHViennaMember" xlink:to="lbl_label2110547405" xlink:type="arc"/>
      <link:label id="id_6649a095" xlink:label="lbl_label1716101269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz GmbH, Kundl [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozGmbHViennaMember" xlink:label="lbl_SandozGmbHViennaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozGmbHViennaMember" xlink:to="lbl_label1716101269" xlink:type="arc"/>
      <link:label id="id_2af5dc99" xlink:label="lbl_label720755864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EBEWE Pharma Ges.m.b.H Nfg. KG, Unterach am Attersee [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:label="lbl_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:to="lbl_label720755864" xlink:type="arc"/>
      <link:label id="id_710ef91f" xlink:label="lbl_label1896806687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis (Bangladesh) Limited, Gazipur [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisBangladeshLimitedGazipurMember" xlink:label="lbl_NovartisBangladeshLimitedGazipurMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisBangladeshLimitedGazipurMember" xlink:to="lbl_label1896806687" xlink:type="arc"/>
      <link:label id="id_33533709" xlink:label="lbl_label861091593" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma NV, Vilvoorde [member]</link:label>
      <link:label id="id_6bd26090" xlink:label="lbl_label1808949392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon - Couvreur NV, Puurs [member]</link:label>
      <link:label id="id_471d9dcf" xlink:label="lbl_label1193123279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon NV, Vilvoorde [member]</link:label>
      <link:label id="id_61e985d" xlink:label="lbl_label102668381" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz NV, Vilvoorde [member]</link:label>
      <link:label id="id_3d34517c" xlink:label="lbl_label1026838908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Securities Investment Ltd., Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:label="lbl_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:to="lbl_label1026838908" xlink:type="arc"/>
      <link:label id="id_2e061bfd" xlink:label="lbl_label772152317" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Biociencias S.A., Sao Paulo [member]</link:label>
      <link:label id="id_608a61f5" xlink:label="lbl_label1619681781" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz do Brasil Industria Farmaceutica Ltda., Cambe, PR [member]</link:label>
      <link:label id="id_20501724" xlink:label="lbl_label542119716" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharmaceuticals Canada Inc., Dorval, Quebec [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:label="lbl_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:to="lbl_label542119716" xlink:type="arc"/>
      <link:label id="id_b170914" xlink:label="lbl_label186059028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Canada Inc., Mississauga, Ontario [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconCanadaInc.MississaugaOntarioMember" xlink:label="lbl_AlconCanadaInc.MississaugaOntarioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconCanadaInc.MississaugaOntarioMember" xlink:to="lbl_label186059028" xlink:type="arc"/>
      <link:label id="id_3382e919" xlink:label="lbl_label864217369" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIBA Vision Canada Inc., Mississauga, Ontario [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:label="lbl_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:to="lbl_label864217369" xlink:type="arc"/>
      <link:label id="id_4aad4cdd" xlink:label="lbl_label1252871389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Canada Inc., Boucherville, Quebec [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozCanadaInc.BouchervilleQuebecMember" xlink:label="lbl_SandozCanadaInc.BouchervilleQuebecMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozCanadaInc.BouchervilleQuebecMember" xlink:to="lbl_label1252871389" xlink:type="arc"/>
      <link:label id="id_467b0e02" xlink:label="lbl_label1182469634" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Chile S.A., Santiago de Chile [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisChileS.A.SantiagoDeChileMember" xlink:label="lbl_NovartisChileS.A.SantiagoDeChileMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisChileS.A.SantiagoDeChileMember" xlink:to="lbl_label1182469634" xlink:type="arc"/>
      <link:label id="id_4a31b636" xlink:label="lbl_label1244771894" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratorios Chile Ltd., Santiago de Chile [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:label="lbl_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:to="lbl_label1244771894" xlink:type="arc"/>
      <link:label id="id_61f8aada" xlink:label="lbl_label1643686618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Beijing Novartis Pharma Co., Ltd., Beijing [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:label="lbl_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:to="lbl_label1643686618" xlink:type="arc"/>
      <link:label id="id_344a1881" xlink:label="lbl_label877271169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharmaceuticals (HK) Limited, Hong Kong [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:label="lbl_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:to="lbl_label877271169" xlink:type="arc"/>
      <link:label id="id_2c879a70" xlink:label="lbl_label747084400" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Suzhou Novartis Pharma Technology Co., Ltd., Changshu [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:label="lbl_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:to="lbl_label747084400" xlink:type="arc"/>
      <link:label id="id_44f2dcf0" xlink:label="lbl_label1156766960" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shanghai Novartis Trading Ltd., Shanghai [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:label="lbl_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:to="lbl_label1156766960" xlink:type="arc"/>
      <link:label id="id_2b1815d1" xlink:label="lbl_label722998737" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Hong Kong Limited, Hong Kong [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconHongKongLimitedHongKongMember" xlink:label="lbl_AlconHongKongLimitedHongKongMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconHongKongLimitedHongKongMember" xlink:to="lbl_label722998737" xlink:type="arc"/>
      <link:label id="id_57ba8d14" xlink:label="lbl_label1471843604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon (China) Ophthalmic Product Co., Ltd., Beijing [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:label="lbl_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:to="lbl_label1471843604" xlink:type="arc"/>
      <link:label id="id_252cd53d" xlink:label="lbl_label623695165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz (China) Pharmaceutical Co., Ltd., Zhongshan [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:label="lbl_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:to="lbl_label623695165" xlink:type="arc"/>
      <link:label id="id_65e89b36" xlink:label="lbl_label1709742902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis de Colombia S.A., Santafe de Bogota [member]</link:label>
      <link:label id="id_1522bd0" xlink:label="lbl_label22162384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratorios Alcon de Colombia S.A., Santafe de Bogota [member]</link:label>
      <link:label id="id_2d82460" xlink:label="lbl_label47719520" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz d.o.o. farmaceutska industrija, Zagreb [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:label="lbl_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:to="lbl_label47719520" xlink:type="arc"/>
      <link:label id="id_c60eb2a" xlink:label="lbl_label207678250" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis s.r.o., Prague [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisS.r.o.PragueMember" xlink:label="lbl_NovartisS.r.o.PragueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisS.r.o.PragueMember" xlink:to="lbl_label207678250" xlink:type="arc"/>
      <link:label id="id_402474ef" xlink:label="lbl_label1076131055" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Pharmaceuticals (Czech Republic) s.r.o., Prague [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:label="lbl_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:to="lbl_label1076131055" xlink:type="arc"/>
      <link:label id="id_f1c4dd" xlink:label="lbl_label15844573" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz s.r.o., Prague [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozS.r.o.PragueMember" xlink:label="lbl_SandozS.r.o.PragueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozS.r.o.PragueMember" xlink:to="lbl_label15844573" xlink:type="arc"/>
      <link:label id="id_6ea1eef6" xlink:label="lbl_label1856106230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Healthcare A/S, Copenhagen [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisHealthcareASCopenhagenMember" xlink:label="lbl_NovartisHealthcareASCopenhagenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHealthcareASCopenhagenMember" xlink:to="lbl_label1856106230" xlink:type="arc"/>
      <link:label id="id_2dbeb314" xlink:label="lbl_label767472404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Nordic A/S, Copenhagen [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconNordicASCopenhagenMember" xlink:label="lbl_AlconNordicASCopenhagenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconNordicASCopenhagenMember" xlink:to="lbl_label767472404" xlink:type="arc"/>
      <link:label id="id_1e75de5c" xlink:label="lbl_label511041116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz A/S, Copenhagen [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozASCopenhagenMember" xlink:label="lbl_SandozASCopenhagenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozASCopenhagenMember" xlink:to="lbl_label511041116" xlink:type="arc"/>
      <link:label id="id_574d51cf" xlink:label="lbl_label1464685007" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Ecuador S.A., Quito [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisEcuadorS.A.QuitoMember" xlink:label="lbl_NovartisEcuadorS.A.QuitoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisEcuadorS.A.QuitoMember" xlink:to="lbl_label1464685007" xlink:type="arc"/>
      <link:label id="id_679520f0" xlink:label="lbl_label1737826544" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma S.A.E., Cairo [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaS.A.E.CairoMember" xlink:label="lbl_NovartisPharmaS.A.E.CairoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaS.A.E.CairoMember" xlink:to="lbl_label1737826544" xlink:type="arc"/>
      <link:label id="id_575ca2d" xlink:label="lbl_label91605549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Egypt Pharma S.A.E., New Cairo City [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:label="lbl_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:to="lbl_label91605549" xlink:type="arc"/>
      <link:label id="id_37f4e561" xlink:label="lbl_label938796385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Finland Oy, Espoo [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFinlandOyEspooMember" xlink:label="lbl_NovartisFinlandOyEspooMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFinlandOyEspooMember" xlink:to="lbl_label938796385" xlink:type="arc"/>
      <link:label id="id_42a0d3e7" xlink:label="lbl_label1117836263" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Groupe France S.A., Rueil-Malmaison [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:label="lbl_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:to="lbl_label1117836263" xlink:type="arc"/>
      <link:label id="id_7ba00702" xlink:label="lbl_label2074085122" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma S.A.S., Rueil-Malmaison [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:label="lbl_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:to="lbl_label2074085122" xlink:type="arc"/>
      <link:label id="id_d3dae7a" xlink:label="lbl_label222146170" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratoires Alcon S.A.S., Rueil-Malmaison [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:label="lbl_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:to="lbl_label222146170" xlink:type="arc"/>
      <link:label id="id_3116dc5e" xlink:label="lbl_label823581790" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz S.A.S., Levallois-Perret [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozS.A.S.LevalloisPerretMember" xlink:label="lbl_SandozS.A.S.LevalloisPerretMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozS.A.S.LevalloisPerretMember" xlink:to="lbl_label823581790" xlink:type="arc"/>
      <link:label id="id_6e409e90" xlink:label="lbl_label1849728656" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Deutschland GmbH, Wehr [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisDeutschlandGmbHWehrMember" xlink:label="lbl_NovartisDeutschlandGmbHWehrMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisDeutschlandGmbHWehrMember" xlink:to="lbl_label1849728656" xlink:type="arc"/>
      <link:label id="id_17634123" xlink:label="lbl_label392380707" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma GmbH, Nuremberg [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaGmbHNurembergMember" xlink:label="lbl_NovartisPharmaGmbHNurembergMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaGmbHNurembergMember" xlink:to="lbl_label392380707" xlink:type="arc"/>
      <link:label id="id_1cd787d" xlink:label="lbl_label30242941" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Produktions GmbH, Wehr [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaProduktionsGmbHWehrMember" xlink:label="lbl_NovartisPharmaProduktionsGmbHWehrMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaProduktionsGmbHWehrMember" xlink:to="lbl_label30242941" xlink:type="arc"/>
      <link:label id="id_401bb4ef" xlink:label="lbl_label1075557615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Business Services GmbH, Wehr [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisBusinessServicesGmbHWehrMember" xlink:label="lbl_NovartisBusinessServicesGmbHWehrMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisBusinessServicesGmbHWehrMember" xlink:to="lbl_label1075557615" xlink:type="arc"/>
      <link:label id="id_3672a73d" xlink:label="lbl_label913483581" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Pharma GmbH, Freiburg im Breisgau [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:label="lbl_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:to="lbl_label913483581" xlink:type="arc"/>
      <link:label id="id_1fd8572e" xlink:label="lbl_label534271790" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">WaveLight GmbH, Erlangen [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WaveLightGmbHErlangenMember" xlink:label="lbl_WaveLightGmbHErlangenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WaveLightGmbHErlangenMember" xlink:to="lbl_label534271790" xlink:type="arc"/>
      <link:label id="id_4649f215" xlink:label="lbl_label1179251221" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIBA Vision GmbH, Grosswallstadt [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CIBAVisionGmbHGrosswallstadtMember" xlink:label="lbl_CIBAVisionGmbHGrosswallstadtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CIBAVisionGmbHGrosswallstadtMember" xlink:to="lbl_label1179251221" xlink:type="arc"/>
      <link:label id="id_72338a4a" xlink:label="lbl_label1915980362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz International GmbH, Holzkirchen [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozInternationalGmbHHolzkirchenMember" xlink:label="lbl_SandozInternationalGmbHHolzkirchenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozInternationalGmbHHolzkirchenMember" xlink:to="lbl_label1915980362" xlink:type="arc"/>
      <link:label id="id_2c6debd5" xlink:label="lbl_label745401301" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">HEXAL AG, Holzkirchen [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_HEXALAGHolzkirchenMember" xlink:label="lbl_HEXALAGHolzkirchenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_HEXALAGHolzkirchenMember" xlink:to="lbl_label745401301" xlink:type="arc"/>
      <link:label id="id_3b790099" xlink:label="lbl_label997785753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Salutas Pharma GmbH, Barleben [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SalutasPharmaGmbHBarlebenMember" xlink:label="lbl_SalutasPharmaGmbHBarlebenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SalutasPharmaGmbHBarlebenMember" xlink:to="lbl_label997785753" xlink:type="arc"/>
      <link:label id="id_5a59fba6" xlink:label="lbl_label1515846566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1 A Pharma GmbH, Oberhaching [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1APharmaGmbHOberhachingMember" xlink:label="lbl_A1APharmaGmbHOberhachingMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1APharmaGmbHOberhachingMember" xlink:to="lbl_label1515846566" xlink:type="arc"/>
      <link:label id="id_63faa754" xlink:label="lbl_label1677371220" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aeropharm GmbH, Rudolstadt [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AeropharmGmbHRudolstadtMember" xlink:label="lbl_AeropharmGmbHRudolstadtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AeropharmGmbHRudolstadtMember" xlink:to="lbl_label1677371220" xlink:type="arc"/>
      <link:label id="id_53a147c7" xlink:label="lbl_label1403078599" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novista Insurance Limited, Gibraltar City [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovistaInsuranceLimitedGibraltarCityMember" xlink:label="lbl_NovistaInsuranceLimitedGibraltarCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovistaInsuranceLimitedGibraltarCityMember" xlink:to="lbl_label1403078599" xlink:type="arc"/>
      <link:label id="id_2881adea" xlink:label="lbl_label679587306" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis (Hellas) S.A.C.I., Metamorphosis/Athens [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:label="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:to="lbl_label679587306" xlink:type="arc"/>
      <link:label id="id_24c810e" xlink:label="lbl_label38568206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories Hellas Commercial and Industrial S.A., Maroussi, Athens [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:label="lbl_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:to="lbl_label38568206" xlink:type="arc"/>
      <link:label id="id_20010fd1" xlink:label="lbl_label536940497" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Hungary Healthcare Limited Liability Company, Budapest [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:label="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:to="lbl_label536940497" xlink:type="arc"/>
      <link:label id="id_3e0a5b35" xlink:label="lbl_label1040866101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Hungary Limited Liability Company, Budapest [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:label="lbl_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:to="lbl_label1040866101" xlink:type="arc"/>
      <link:label id="id_866e747" xlink:label="lbl_label140961607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis India Limited, Mumbai [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisIndiaLimitedMumbaiMember" xlink:label="lbl_NovartisIndiaLimitedMumbaiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisIndiaLimitedMumbaiMember" xlink:to="lbl_label140961607" xlink:type="arc"/>
      <link:label id="id_5d283d4e" xlink:label="lbl_label1562918222" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Healthcare Private Limited, Mumbai [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:label="lbl_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:to="lbl_label1562918222" xlink:type="arc"/>
      <link:label id="id_209ec8c8" xlink:label="lbl_label547277000" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories (India) Private Limited, Bangalore [member]</link:label>
      <link:label id="id_2bccb2e" xlink:label="lbl_label45927214" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Private Limited, Mumbai [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozPrivateLimitedMumbaiMember" xlink:label="lbl_SandozPrivateLimitedMumbaiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozPrivateLimitedMumbaiMember" xlink:to="lbl_label45927214" xlink:type="arc"/>
      <link:label id="id_30564a91" xlink:label="lbl_label810961553" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PT. Novartis Indonesia, Jakarta [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PT.NovartisIndonesiaJakartaMember" xlink:label="lbl_PT.NovartisIndonesiaJakartaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PT.NovartisIndonesiaJakartaMember" xlink:to="lbl_label810961553" xlink:type="arc"/>
      <link:label id="id_bca100f" xlink:label="lbl_label197791759" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PT. CIBA Vision Batam, Batam [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PT.CIBAVisionBatamBatamMember" xlink:label="lbl_PT.CIBAVisionBatamBatamMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PT.CIBAVisionBatamBatamMember" xlink:to="lbl_label197791759" xlink:type="arc"/>
      <link:label id="id_4fcc5f83" xlink:label="lbl_label1338793859" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Ireland Limited, Dublin [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisIrelandLimitedDublinMember" xlink:label="lbl_NovartisIrelandLimitedDublinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisIrelandLimitedDublinMember" xlink:to="lbl_label1338793859" xlink:type="arc"/>
      <link:label id="id_74708b2c" xlink:label="lbl_label1953532716" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Ringaskiddy Limited, Ringaskiddy, County Cork [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:label="lbl_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:to="lbl_label1953532716" xlink:type="arc"/>
      <link:label id="id_169e129" xlink:label="lbl_label23716137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories Ireland Limited, Cork City [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:label="lbl_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:to="lbl_label23716137" xlink:type="arc"/>
      <link:label id="id_1a15ed68" xlink:label="lbl_label437644648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Israel Ltd., Tel Aviv [member]</link:label>
      <link:label id="id_79225a64" xlink:label="lbl_label2032294500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Optonol Ltd., Neve-Ilan [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OptonolLtd.NeveIlanMember" xlink:label="lbl_OptonolLtd.NeveIlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OptonolLtd.NeveIlanMember" xlink:to="lbl_label2032294500" xlink:type="arc"/>
      <link:label id="id_572859e2" xlink:label="lbl_label1462262242" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Farma S.p.A., Origgio [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFarmaS.p.A.OriggioMember" xlink:label="lbl_NovartisFarmaS.p.A.OriggioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFarmaS.p.A.OriggioMember" xlink:to="lbl_label1462262242" xlink:type="arc"/>
      <link:label id="id_51e555ae" xlink:label="lbl_label1373984174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Italia S.p.A., Milan [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconItaliaS.p.A.MilanMember" xlink:label="lbl_AlconItaliaS.p.A.MilanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconItaliaS.p.A.MilanMember" xlink:to="lbl_label1373984174" xlink:type="arc"/>
      <link:label id="id_39182a7" xlink:label="lbl_label59867815" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz S.p.A., Origgio [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozS.p.A.OriggioMember" xlink:label="lbl_SandozS.p.A.OriggioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozS.p.A.OriggioMember" xlink:to="lbl_label59867815" xlink:type="arc"/>
      <link:label id="id_23768229" xlink:label="lbl_label594969129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Industrial Products S.p.A., Rovereto [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:label="lbl_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:to="lbl_label594969129" xlink:type="arc"/>
      <link:label id="id_46070173" xlink:label="lbl_label1174864243" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Holding Japan K.K., Tokyo [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisHoldingJapanK.K.TokyoMember" xlink:label="lbl_NovartisHoldingJapanK.K.TokyoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHoldingJapanK.K.TokyoMember" xlink:to="lbl_label1174864243" xlink:type="arc"/>
      <link:label id="id_30b5637" xlink:label="lbl_label51074615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma K.K., Tokyo [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaK.K.TokyoMember" xlink:label="lbl_NovartisPharmaK.K.TokyoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaK.K.TokyoMember" xlink:to="lbl_label51074615" xlink:type="arc"/>
      <link:label id="id_2358b28" xlink:label="lbl_label37063464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Japan Ltd., Tokyo [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconJapanLtd.TokyoMember" xlink:label="lbl_AlconJapanLtd.TokyoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconJapanLtd.TokyoMember" xlink:to="lbl_label37063464" xlink:type="arc"/>
      <link:label id="id_90ace63" xlink:label="lbl_label151703139" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz K.K., Tokyo [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozK.K.TokyoMember" xlink:label="lbl_SandozK.K.TokyoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozK.K.TokyoMember" xlink:to="lbl_label151703139" xlink:type="arc"/>
      <link:label id="id_2d24611e" xlink:label="lbl_label757358878" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Investments S.a r.l., Luxembourg City [member]</link:label>
      <link:label id="id_6373cce9" xlink:label="lbl_label1668533481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Finance S.A., Luxembourg City [member]</link:label>
      <link:label id="id_495a738b" xlink:label="lbl_label1230664587" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Corporation (Malaysia) Sdn. Bhd., Kuala Lumpur [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember" xlink:label="lbl_NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember" xlink:to="lbl_label1230664587" xlink:type="arc"/>
      <link:label id="id_30ea85e" xlink:label="lbl_label51292254" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories (Malaysia) Sdn. Bhd., Petaling Jaya [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:label="lbl_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:to="lbl_label51292254" xlink:type="arc"/>
      <link:label id="id_2040f9e0" xlink:label="lbl_label541129184" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIBA Vision Johor Sdn. Bhd., Kuala Lumpur [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:label="lbl_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:to="lbl_label541129184" xlink:type="arc"/>
      <link:label id="id_23d9a520" xlink:label="lbl_label601466144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Farmaceutica, S.A. de C.V., Mexico City [member]</link:label>
      <link:label id="id_7bc6228f" xlink:label="lbl_label2076582543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratorios, S.A. de C.V., Mexico City [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:label="lbl_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:to="lbl_label2076582543" xlink:type="arc"/>
      <link:label id="id_77370b0a" xlink:label="lbl_label2000096010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz, S.A. de C.V., Mexico City [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozS.A.DeC.V.MexicoCityMember" xlink:label="lbl_SandozS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozS.A.DeC.V.MexicoCityMember" xlink:to="lbl_label2000096010" xlink:type="arc"/>
      <link:label id="id_7143fa4f" xlink:label="lbl_label1900280399" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Maroc SA, Casablanca [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaMarocSACasablancaMember" xlink:label="lbl_NovartisPharmaMarocSACasablancaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaMarocSACasablancaMember" xlink:to="lbl_label1900280399" xlink:type="arc"/>
      <link:label id="id_30236580" xlink:label="lbl_label807626112" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Netherlands B.V., Arnhem [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisNetherlandsB.V.ArnhemMember" xlink:label="lbl_NovartisNetherlandsB.V.ArnhemMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisNetherlandsB.V.ArnhemMember" xlink:to="lbl_label807626112" xlink:type="arc"/>
      <link:label id="id_1fa13a8d" xlink:label="lbl_label530659981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma B.V., Arnhem [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaB.V.ArnhemMember" xlink:label="lbl_NovartisPharmaB.V.ArnhemMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaB.V.ArnhemMember" xlink:to="lbl_label530659981" xlink:type="arc"/>
      <link:label id="id_6a5dd736" xlink:label="lbl_label1784534838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Nederland B.V., Arnhem [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconNederlandB.V.ArnhemMember" xlink:label="lbl_AlconNederlandB.V.ArnhemMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconNederlandB.V.ArnhemMember" xlink:to="lbl_label1784534838" xlink:type="arc"/>
      <link:label id="id_89b7931" xlink:label="lbl_label144406833" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz B.V., Almere [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozB.V.AlmereMember" xlink:label="lbl_SandozB.V.AlmereMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozB.V.AlmereMember" xlink:to="lbl_label144406833" xlink:type="arc"/>
      <link:label id="id_7ae0d9be" xlink:label="lbl_label2061556158" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis New Zealand Ltd, Auckland [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisNewZealandLtdAucklandMember" xlink:label="lbl_NovartisNewZealandLtdAucklandMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisNewZealandLtdAucklandMember" xlink:to="lbl_label2061556158" xlink:type="arc"/>
      <link:label id="id_659fd8fc" xlink:label="lbl_label1704974588" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Norge AS, Oslo [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisNorgeASOsloMember" xlink:label="lbl_NovartisNorgeASOsloMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisNorgeASOsloMember" xlink:to="lbl_label1704974588" xlink:type="arc"/>
      <link:label id="id_53e6555" xlink:label="lbl_label87975253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma (Pakistan) Limited, Karachi [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaPakistanLimitedKarachiMember" xlink:label="lbl_NovartisPharmaPakistanLimitedKarachiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaPakistanLimitedKarachiMember" xlink:to="lbl_label87975253" xlink:type="arc"/>
      <link:label id="id_2f1259ff" xlink:label="lbl_label789731839" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma (Logistics), Inc., Panama City [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:label="lbl_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:to="lbl_label789731839" xlink:type="arc"/>
      <link:label id="id_51335372" xlink:label="lbl_label1362318194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Centroamerica S.A., Panama City [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconCentroamericaS.A.PanamaCityMember" xlink:label="lbl_AlconCentroamericaS.A.PanamaCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconCentroamericaS.A.PanamaCityMember" xlink:to="lbl_label1362318194" xlink:type="arc"/>
      <link:label id="id_240f2db1" xlink:label="lbl_label604974513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Healthcare Philippines, Inc., Makati City [member]</link:label>
      <link:label id="id_2050b70f" xlink:label="lbl_label542160655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Philippines Corporation, Makati City [member]</link:label>
      <link:label id="id_5fffa6cd" xlink:label="lbl_label1610589901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Poland Sp. z o.o., Warsaw [member]</link:label>
      <link:label id="id_74c896dd" xlink:label="lbl_label1959302877" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Polska Sp. z o.o., Warsaw [member]</link:label>
      <link:label id="id_712c39fe" xlink:label="lbl_label1898723838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Polska Sp. z o.o., Warsaw [member]</link:label>
      <link:label id="id_4ba5de33" xlink:label="lbl_label1269161523" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lek S.A., Strykow [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LekS.A.StrykowMember" xlink:label="lbl_LekS.A.StrykowMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LekS.A.StrykowMember" xlink:to="lbl_label1269161523" xlink:type="arc"/>
      <link:label id="id_520521db" xlink:label="lbl_label1376068059" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Portugal SGPS Lda., Porto Salvo [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:label="lbl_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:to="lbl_label1376068059" xlink:type="arc"/>
      <link:label id="id_c95dd37" xlink:label="lbl_label211148087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Farma - Produtos Farmaceuticos S.A., Porto Salvo [member]</link:label>
      <link:label id="id_881ce5c" xlink:label="lbl_label142724700" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Portugal-Produtos e Equipamentos Oftalmologicos Lda., Porto Salvo [member]</link:label>
      <link:label id="id_1c2378c4" xlink:label="lbl_label472086724" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Farmaceutica Lda., Porto Salvo [member]</link:label>
      <link:label id="id_4a9bb1ea" xlink:label="lbl_label1251717610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Services Romania S.R.L., Bucharest [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:label="lbl_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:to="lbl_label1251717610" xlink:type="arc"/>
      <link:label id="id_30d12469" xlink:label="lbl_label819012713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Romania S.R.L., Bucharest [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconRomaniaS.R.L.BucharestMember" xlink:label="lbl_AlconRomaniaS.R.L.BucharestMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconRomaniaS.R.L.BucharestMember" xlink:to="lbl_label819012713" xlink:type="arc"/>
      <link:label id="id_1a1b1a89" xlink:label="lbl_label437983881" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz S.R.L., Targu-Mures [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozS.R.L.TarguMuresMember" xlink:label="lbl_SandozS.R.L.TarguMuresMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozS.R.L.TarguMuresMember" xlink:to="lbl_label437983881" xlink:type="arc"/>
      <link:label id="id_620cd72f" xlink:label="lbl_label1645008687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma LLC, Moscow [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaLLCMoscowMember" xlink:label="lbl_NovartisPharmaLLCMoscowMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaLLCMoscowMember" xlink:to="lbl_label1645008687" xlink:type="arc"/>
      <link:label id="id_a4d4ccd" xlink:label="lbl_label172838093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Farmacevtika LLC, Moscow [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconFarmacevtikaLLCMoscowMember" xlink:label="lbl_AlconFarmacevtikaLLCMoscowMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconFarmacevtikaLLCMoscowMember" xlink:to="lbl_label172838093" xlink:type="arc"/>
      <link:label id="id_4f8c203f" xlink:label="lbl_label1334583359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZAO Sandoz, Moscow [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ZAOSandozMoscowMember" xlink:label="lbl_ZAOSandozMoscowMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZAOSandozMoscowMember" xlink:to="lbl_label1334583359" xlink:type="arc"/>
      <link:label id="id_3b17514" xlink:label="lbl_label61961492" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Neva LLC, St. Petersburg [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisNevaLLCSt.PetersburgMember" xlink:label="lbl_NovartisNevaLLCSt.PetersburgMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisNevaLLCSt.PetersburgMember" xlink:to="lbl_label61961492" xlink:type="arc"/>
      <link:label id="id_2d25f558" xlink:label="lbl_label757462360" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Saudi Pharmaceutical Distribution Co. Ltd., Riyadh [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:label="lbl_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:to="lbl_label757462360" xlink:type="arc"/>
      <link:label id="id_ef37254" xlink:label="lbl_label250835540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis (Singapore) Pte Ltd., Singapore [member]</link:label>
      <link:label id="id_27535d56" xlink:label="lbl_label659774806" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Singapore Pharmaceutical Manufacturing Pte Ltd, Singapore [member]</link:label>
      <link:label id="id_73caa11d" xlink:label="lbl_label1942659357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Asia Pacific Pharmaceuticals Pte Ltd, Singapore [member]</link:label>
      <link:label id="id_5ac408db" xlink:label="lbl_label1522796763" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Institute for Tropical Diseases Pte Ltd, Singapore [member]</link:label>
      <link:label id="id_405feadd" xlink:label="lbl_label1080027869" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Singapore Manufacturing Pte. Ltd., Singapore [member]</link:label>
      <link:label id="id_5ad357d3" xlink:label="lbl_label1523800019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIBA Vision Asian Manufacturing and Logistics Pte Ltd., Singapore [member]</link:label>
      <link:label id="id_5654aaaa" xlink:label="lbl_label1448389290" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Pte Ltd, Singapore [member]</link:label>
      <link:label id="id_1f0269e9" xlink:label="lbl_label520251881" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Slovakia s.r.o., Bratislava [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisSlovakiaS.r.o.BratislavaMember" xlink:label="lbl_NovartisSlovakiaS.r.o.BratislavaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSlovakiaS.r.o.BratislavaMember" xlink:to="lbl_label520251881" xlink:type="arc"/>
      <link:label id="id_3337da30" xlink:label="lbl_label859298352" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lek Pharmaceuticals d.d., Ljubjana [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LekPharmaceuticalsD.d.LjubjanaMember" xlink:label="lbl_LekPharmaceuticalsD.d.LjubjanaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LekPharmaceuticalsD.d.LjubjanaMember" xlink:to="lbl_label859298352" xlink:type="arc"/>
      <link:label id="id_24583ab1" xlink:label="lbl_label609761969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Pharmaceuticals d.d., Ljubjana [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:label="lbl_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:to="lbl_label609761969" xlink:type="arc"/>
      <link:label id="id_25162424" xlink:label="lbl_label622208036" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis South Africa (Pty) Ltd, Midrand [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisSouthAfricaPtyLtdMidrandMember" xlink:label="lbl_NovartisSouthAfricaPtyLtdMidrandMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSouthAfricaPtyLtdMidrandMember" xlink:to="lbl_label622208036" xlink:type="arc"/>
      <link:label id="id_c4640a" xlink:label="lbl_label12870666" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories (South Africa) (Pty) Ltd., Midrand [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:label="lbl_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:to="lbl_label12870666" xlink:type="arc"/>
      <link:label id="id_44cecbf4" xlink:label="lbl_label1154403316" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz South Africa (Pty) Ltd, Kempton Park [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozSouthAfricaPtyLtdKemptonParkMember" xlink:label="lbl_SandozSouthAfricaPtyLtdKemptonParkMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozSouthAfricaPtyLtdKemptonParkMember" xlink:to="lbl_label1154403316" xlink:type="arc"/>
      <link:label id="id_51e9e54d" xlink:label="lbl_label1374283085" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Korea Ltd., Seoul [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisKoreaLtd.SeoulMember" xlink:label="lbl_NovartisKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisKoreaLtd.SeoulMember" xlink:to="lbl_label1374283085" xlink:type="arc"/>
      <link:label id="id_2fbc9bcb" xlink:label="lbl_label800889803" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Korea Ltd., Seoul [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconKoreaLtd.SeoulMember" xlink:label="lbl_AlconKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconKoreaLtd.SeoulMember" xlink:to="lbl_label800889803" xlink:type="arc"/>
      <link:label id="id_3acd65c6" xlink:label="lbl_label986539462" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Korea Ltd., Seoul [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozKoreaLtd.SeoulMember" xlink:label="lbl_SandozKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozKoreaLtd.SeoulMember" xlink:to="lbl_label986539462" xlink:type="arc"/>
      <link:label id="id_2cb12411" xlink:label="lbl_label749806609" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Farmaceutica, S.A., Barcelona [member]</link:label>
      <link:label id="id_1788ee4f" xlink:label="lbl_label394849871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Cusi S.A., Barcelona [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconCusiS.A.BarcelonaMember" xlink:label="lbl_AlconCusiS.A.BarcelonaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconCusiS.A.BarcelonaMember" xlink:to="lbl_label394849871" xlink:type="arc"/>
      <link:label id="id_25c7e6c1" xlink:label="lbl_label633857729" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Farmaceutica S.A., Madrid [member]</link:label>
      <link:label id="id_578d972e" xlink:label="lbl_label1468897070" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Industrial Products S.A., Barcelona [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozIndustrialProductsS.A.BarcelonaMember" xlink:label="lbl_SandozIndustrialProductsS.A.BarcelonaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozIndustrialProductsS.A.BarcelonaMember" xlink:to="lbl_label1468897070" xlink:type="arc"/>
      <link:label id="id_6a673c57" xlink:label="lbl_label1785150551" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Abadia Retuerta S.A., Sardon de Duero/Valladolid [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:label="lbl_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:to="lbl_label1785150551" xlink:type="arc"/>
      <link:label id="id_6cfceac6" xlink:label="lbl_label1828514502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Sverige AB, Stockholm [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisSverigeABStockholmMember" xlink:label="lbl_NovartisSverigeABStockholmMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSverigeABStockholmMember" xlink:to="lbl_label1828514502" xlink:type="arc"/>
      <link:label id="id_1784eaf5" xlink:label="lbl_label394586869" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis International AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInternationalAGBaselMember" xlink:label="lbl_NovartisInternationalAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInternationalAGBaselMember" xlink:to="lbl_label394586869" xlink:type="arc"/>
      <link:label id="id_1cfce538" xlink:label="lbl_label486335800" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Holding AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisHoldingAGBaselMember" xlink:label="lbl_NovartisHoldingAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHoldingAGBaselMember" xlink:to="lbl_label486335800" xlink:type="arc"/>
      <link:label id="id_523c2f36" xlink:label="lbl_label1379675958" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis International Pharmaceutical AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInternationalPharmaceuticalAGBaselMember" xlink:label="lbl_NovartisInternationalPharmaceuticalAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInternationalPharmaceuticalAGBaselMember" xlink:to="lbl_label1379675958" xlink:type="arc"/>
      <link:label id="id_31c15b81" xlink:label="lbl_label834755457" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaAGBaselMember" xlink:label="lbl_NovartisPharmaAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaAGBaselMember" xlink:to="lbl_label834755457" xlink:type="arc"/>
      <link:label id="id_6bb5d046" xlink:label="lbl_label1807077446" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Services AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaServicesAGBaselMember" xlink:label="lbl_NovartisPharmaServicesAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaServicesAGBaselMember" xlink:to="lbl_label1807077446" xlink:type="arc"/>
      <link:label id="id_151ca66f" xlink:label="lbl_label354199151" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Schweizerhalle AG, Muttenz [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:label="lbl_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:to="lbl_label354199151" xlink:type="arc"/>
      <link:label id="id_7888d993" xlink:label="lbl_label2022234515" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Stein AG, Stein [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaSteinAGSteinMember" xlink:label="lbl_NovartisPharmaSteinAGSteinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaSteinAGSteinMember" xlink:to="lbl_label2022234515" xlink:type="arc"/>
      <link:label id="id_46b0e62c" xlink:label="lbl_label1185998380" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Schweiz AG, Risch [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaSchweizAGRischMember" xlink:label="lbl_NovartisPharmaSchweizAGRischMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaSchweizAGRischMember" xlink:to="lbl_label1185998380" xlink:type="arc"/>
      <link:label id="id_175b3164" xlink:label="lbl_label391852388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Switzerland SA, Risch [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconSwitzerlandSARischMember" xlink:label="lbl_AlconSwitzerlandSARischMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconSwitzerlandSARischMember" xlink:to="lbl_label391852388" xlink:type="arc"/>
      <link:label id="id_6dde1079" xlink:label="lbl_label1843269753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Pharmaceuticals Ltd., Fribourg [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconPharmaceuticalsLtd.FribourgMember" xlink:label="lbl_AlconPharmaceuticalsLtd.FribourgMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPharmaceuticalsLtd.FribourgMember" xlink:to="lbl_label1843269753" xlink:type="arc"/>
      <link:label id="id_2056dcf1" xlink:label="lbl_label542563569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozAGBaselMember" xlink:label="lbl_SandozAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozAGBaselMember" xlink:to="lbl_label542563569" xlink:type="arc"/>
      <link:label id="id_c4607df" xlink:label="lbl_label205916127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Pharmaceuticals AG, Risch [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozPharmaceuticalsAGRischMember" xlink:label="lbl_SandozPharmaceuticalsAGRischMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozPharmaceuticalsAGRischMember" xlink:to="lbl_label205916127" xlink:type="arc"/>
      <link:label id="id_2bda8165" xlink:label="lbl_label735740261" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis (Taiwan) Co., Ltd., Taipei [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:label="lbl_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:to="lbl_label735740261" xlink:type="arc"/>
      <link:label id="id_1cc3a1bc" xlink:label="lbl_label482582972" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis (Thailand) Limited, Bangkok [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisThailandLimitedBangkokMember" xlink:label="lbl_NovartisThailandLimitedBangkokMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisThailandLimitedBangkokMember" xlink:to="lbl_label482582972" xlink:type="arc"/>
      <link:label id="id_1e10820d" xlink:label="lbl_label504398349" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories (Thailand) Limited, Bangkok [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesThailandLimitedBangkokMember" xlink:label="lbl_AlconLaboratoriesThailandLimitedBangkokMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesThailandLimitedBangkokMember" xlink:to="lbl_label504398349" xlink:type="arc"/>
      <link:label id="id_76d30813" xlink:label="lbl_label1993541651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Saglik, Gida ve Tarim Urunleri Sanayi ve Ticaret A.S., Istanbul [member]</link:label>
      <link:label id="id_7653b21e" xlink:label="lbl_label1985196574" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratuvarlari Ticaret A.S., Istanbul [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:label="lbl_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:to="lbl_label1985196574" xlink:type="arc"/>
      <link:label id="id_6083f415" xlink:label="lbl_label1619260437" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Ilac Sanayi ve Ticaret A.S., Istanbul [member]</link:label>
      <link:label id="id_2c3cd0a2" xlink:label="lbl_label742183074" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Grup Saglik Urunleri Ilaclari Sanayi ve Ticaret A.S., Gebze - Kocaeli [member]</link:label>
      <link:label id="id_775d02f4" xlink:label="lbl_label2002584308" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Middle East FZE, Dubai [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisMiddleEastFZEDubaiMember" xlink:label="lbl_NovartisMiddleEastFZEDubaiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisMiddleEastFZEDubaiMember" xlink:to="lbl_label2002584308" xlink:type="arc"/>
      <link:label id="id_629f2d5a" xlink:label="lbl_label1654599002" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis UK Limited, Frimley/Camberley [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisUKLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisUKLimitedFrimleyCamberleyMember" xlink:to="lbl_label1654599002" xlink:type="arc"/>
      <link:label id="id_24628050" xlink:label="lbl_label610435152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharmaceuticals UK Limited, Frimley/Camberley [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:to="lbl_label610435152" xlink:type="arc"/>
      <link:label id="id_72101279" xlink:label="lbl_label1913655929" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Grimsby Limited, Frimley/Camberley [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:to="lbl_label1913655929" xlink:type="arc"/>
      <link:label id="id_41ed60da" xlink:label="lbl_label1106075866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Eye Care UK Limited, Frimley/Camberley [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:label="lbl_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:to="lbl_label1106075866" xlink:type="arc"/>
      <link:label id="id_61fe5165" xlink:label="lbl_label1644056933" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Limited, Frimley/Camberley [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozLimitedFrimleyCamberleyMember" xlink:label="lbl_SandozLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozLimitedFrimleyCamberleyMember" xlink:to="lbl_label1644056933" xlink:type="arc"/>
      <link:label id="id_5fa82378" xlink:label="lbl_label1604854648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Glaxosmithkline Consumer Healthcare Holdings Limited, Brentford, Middlesex [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:label="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:to="lbl_label1604854648" xlink:type="arc"/>
      <link:label id="id_4687124a" xlink:label="lbl_label1183257162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Corporation, East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisCorporationEastHanoverNYMember" xlink:label="lbl_NovartisCorporationEastHanoverNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCorporationEastHanoverNYMember" xlink:to="lbl_label1183257162" xlink:type="arc"/>
      <link:label id="id_739f0d6b" xlink:label="lbl_label1939803499" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Finance Corporation, New York, NY [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFinanceCorporationNewYorkNYMember" xlink:label="lbl_NovartisFinanceCorporationNewYorkNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFinanceCorporationNewYorkNYMember" xlink:to="lbl_label1939803499" xlink:type="arc"/>
      <link:label id="id_6a2defad" xlink:label="lbl_label1781395373" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Capital Corporation, New York, NY [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisCapitalCorporationNewYorkNYMember" xlink:label="lbl_NovartisCapitalCorporationNewYorkNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCapitalCorporationNewYorkNYMember" xlink:to="lbl_label1781395373" xlink:type="arc"/>
      <link:label id="id_2951cebe" xlink:label="lbl_label693227198" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharmaceuticals Corporation, East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:label="lbl_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:to="lbl_label693227198" xlink:type="arc"/>
      <link:label id="id_10d13d66" xlink:label="lbl_label282148198" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Institutes for BioMedical Research, Inc., Cambridge, MA [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:label="lbl_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:to="lbl_label282148198" xlink:type="arc"/>
      <link:label id="id_2e63ddd" xlink:label="lbl_label48643549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Institute for Functional Genomics, Inc., San Diego, CA [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:label="lbl_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:to="lbl_label48643549" xlink:type="arc"/>
      <link:label id="id_13ee6af1" xlink:label="lbl_label334392049" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Vaccines and Diagnostics, Inc., Cambridge, MA [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:label="lbl_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:to="lbl_label334392049" xlink:type="arc"/>
      <link:label id="id_5eea5c27" xlink:label="lbl_label1592417319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Services, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisServicesInc.EastHanoverNYMember" xlink:label="lbl_NovartisServicesInc.EastHanoverNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisServicesInc.EastHanoverNYMember" xlink:to="lbl_label1592417319" xlink:type="arc"/>
      <link:label id="id_51dba865" xlink:label="lbl_label1373349989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories Holding Corporation, Fort Worth, TX [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:label="lbl_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:to="lbl_label1373349989" xlink:type="arc"/>
      <link:label id="id_31a31f0b" xlink:label="lbl_label832773899" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories, Inc., Fort Worth, TX [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesInc.FortWorthTXMember" xlink:label="lbl_AlconLaboratoriesInc.FortWorthTXMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesInc.FortWorthTXMember" xlink:to="lbl_label832773899" xlink:type="arc"/>
      <link:label id="id_c4acd60" xlink:label="lbl_label206228832" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Refractivehorizons, LLC, Fort Worth, TX [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:label="lbl_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:to="lbl_label206228832" xlink:type="arc"/>
      <link:label id="id_48c065e" xlink:label="lbl_label76285534" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Research, Ltd., Fort Worth, TX [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconResearchLtd.FortWorthTXMember" xlink:label="lbl_AlconResearchLtd.FortWorthTXMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconResearchLtd.FortWorthTXMember" xlink:to="lbl_label76285534" xlink:type="arc"/>
      <link:label id="id_17312f5" xlink:label="lbl_label24318709" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Lensx, Inc., Aliso Viejo, CA [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLensxInc.AlisoViejoCAMember" xlink:label="lbl_AlconLensxInc.AlisoViejoCAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLensxInc.AlisoViejoCAMember" xlink:to="lbl_label24318709" xlink:type="arc"/>
      <link:label id="id_305f2824" xlink:label="lbl_label811542564" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Inc., Princeton, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozInc.PrincetonNJMember" xlink:label="lbl_SandozInc.PrincetonNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozInc.PrincetonNJMember" xlink:to="lbl_label811542564" xlink:type="arc"/>
      <link:label id="id_1810f51f" xlink:label="lbl_label403764511" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eon Labs, Inc., Princeton, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EonLabsInc.PrincetonNJMember" xlink:label="lbl_EonLabsInc.PrincetonNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EonLabsInc.PrincetonNJMember" xlink:to="lbl_label403764511" xlink:type="arc"/>
      <link:label id="id_1c839601" xlink:label="lbl_label478385665" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fougera Pharmaceuticals Inc., Melville, NY [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:label="lbl_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:to="lbl_label478385665" xlink:type="arc"/>
      <link:label id="id_7af3c86c" xlink:label="lbl_label2062796908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis de Venezuela, S.A., Caracas [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisDeVenezuelaS.A.CaracasMember" xlink:label="lbl_NovartisDeVenezuelaS.A.CaracasMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisDeVenezuelaS.A.CaracasMember" xlink:to="lbl_label2062796908" xlink:type="arc"/>
      <link:label id="id_51d78d0e" xlink:label="lbl_label1373080846" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Pharmaceutical, C.A., Caracas [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconPharmaceuticalC.A.CaracasMember" xlink:label="lbl_AlconPharmaceuticalC.A.CaracasMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPharmaceuticalC.A.CaracasMember" xlink:to="lbl_label1373080846" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisBiocienciasS.A.SaoPauloMember" xlink:label="lbl_NovartisBiocienciasS.A.SaoPauloMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisBiocienciasS.A.SaoPauloMember" xlink:to="lbl_label772152317" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:label="lbl_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:to="lbl_label1619681781" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:label="lbl_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:to="lbl_label1709742902" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:label="lbl_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:to="lbl_label22162384" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:label="lbl_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:to="lbl_label601466144" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:label="lbl_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:to="lbl_label211148087" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:label="lbl_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:to="lbl_label142724700" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozFarmaceuticaLda.PortoSalvoMember" xlink:label="lbl_SandozFarmaceuticaLda.PortoSalvoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozFarmaceuticaLda.PortoSalvoMember" xlink:to="lbl_label472086724" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:label="lbl_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:to="lbl_label749806609" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozFarmaceuticaS.A.MadridMember" xlink:label="lbl_SandozFarmaceuticaS.A.MadridMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozFarmaceuticaS.A.MadridMember" xlink:to="lbl_label633857729" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:label="lbl_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:to="lbl_label1993541651" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:label="lbl_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:to="lbl_label1619260437" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:label="lbl_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:to="lbl_label742183074" xlink:type="arc"/>
      <link:label id="id_5219f8cb" xlink:label="lbl_label1377433803" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments - additional disclosure [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_label1377433803" xlink:type="arc"/>
      <link:label id="id_7be99054" xlink:label="lbl_label2078904404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in fair value measurement [table]</link:label>
      <link:label id="id_373151e5" xlink:label="lbl_FinancialInstrumentsCarryingValueLevel3_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value measurement, carrying value, level 3</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsCarryingValueLevel3" xlink:label="lbl_FinancialInstrumentsCarryingValueLevel3" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsCarryingValueLevel3" xlink:to="lbl_FinancialInstrumentsCarryingValueLevel3_labels" xlink:type="arc"/>
      <link:label id="id_3bebbf6d" xlink:label="lbl_FinancialInstrumentsCarryingValueLevel3_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value measurement, carrying value, level 3, at beginning of period</link:label>
      <link:label id="id_fde9a71" xlink:label="lbl_FinancialInstrumentsCarryingValueLevel3_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value measurement, carrying value, level 3, at end of period</link:label>
      <link:label id="id_38539773" xlink:label="lbl_label945002355" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value gains and other adjustments including from divestments recognized in the consolidated income statement</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:label="lbl_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:to="lbl_label945002355" xlink:type="arc"/>
      <link:label id="id_3f162228" xlink:label="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:label="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:to="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets_labels" xlink:type="arc"/>
      <link:label id="id_34d2b17f" xlink:label="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments recognized in the consolidated statement of comprehensive income</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:label="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:to="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome_labels" xlink:type="arc"/>
      <link:label id="id_1f17c4f4" xlink:label="lbl_label521651444" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchases fair value measurement assets</link:label>
      <link:label id="id_712f0e18" xlink:label="lbl_DisposalsFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals fair value measurement assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisposalsFairValueMeasurementAssets" xlink:label="lbl_DisposalsFairValueMeasurementAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalsFairValueMeasurementAssets" xlink:to="lbl_DisposalsFairValueMeasurementAssets_labels" xlink:type="arc"/>
      <link:label id="id_6183f24" xlink:label="lbl_ReclassificationFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification fair value measurement assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReclassificationFairValueMeasurementAssets" xlink:label="lbl_ReclassificationFairValueMeasurementAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclassificationFairValueMeasurementAssets" xlink:to="lbl_ReclassificationFairValueMeasurementAssets_labels" xlink:type="arc"/>
      <link:label id="id_21602cfa" xlink:label="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value gains and losses recognized in the consolidated income statement for assets and liabilities held</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:label="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:to="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld_labels" xlink:type="arc"/>
      <link:label id="id_d0e5228" xlink:label="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end</link:label>
      <link:label id="id_28030b1e" xlink:label="lbl_label671288094" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Monitoring of net debt or liquidity based on contractual maturities [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:label="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:to="lbl_label671288094" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:label="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_label2078904404" xlink:type="arc"/>
      <link:label id="id_2f39f660" xlink:label="lbl_label792327776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity of net debt [line items]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MaturityOfNetDebtLineItems" xlink:label="lbl_MaturityOfNetDebtLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_label792327776" xlink:type="arc"/>
      <link:label id="id_58c89014" xlink:label="lbl_OtherNoncurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial debts</link:label>
      <link:label id="id_7d6c1038" xlink:label="lbl_OtherCurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current financial debt</link:label>
      <link:label id="id_2fc36503" xlink:label="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current financial assets</link:label>
      <link:label id="id_54e7be06" xlink:label="lbl_label1424473606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities and time deposits [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MarketableSecuritiesAndTimeDepositsMember" xlink:label="lbl_MarketableSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MarketableSecuritiesAndTimeDepositsMember" xlink:to="lbl_label1424473606" xlink:type="arc"/>
      <link:label id="id_2cb9fd3b" xlink:label="lbl_label750386491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commodities [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CommoditiesMember" xlink:label="lbl_CommoditiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommoditiesMember" xlink:to="lbl_label750386491" xlink:type="arc"/>
      <link:label id="id_31b4a926" xlink:label="lbl_label833923366" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deriviative financial instruments and accrued interest [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:label="lbl_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:to="lbl_label833923366" xlink:type="arc"/>
      <link:label id="id_75dba3db" xlink:label="lbl_label1977328603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial debt [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialDebtMember" xlink:label="lbl_FinancialDebtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialDebtMember" xlink:to="lbl_label1977328603" xlink:type="arc"/>
      <link:label id="id_24faa4a5" xlink:label="lbl_label620405925" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial debt - undiscounted [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialDebtUndiscountedMember" xlink:label="lbl_FinancialDebtUndiscountedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialDebtUndiscountedMember" xlink:to="lbl_label620405925" xlink:type="arc"/>
      <link:label id="id_2e5c234f" xlink:label="lbl_label777790287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than three month and not later than twelve months [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:label="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:to="lbl_label777790287" xlink:type="arc"/>
      <link:label id="id_106ff37d" xlink:label="lbl_label275772285" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments and accrued interest on derivative financial instruments [line items]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_label275772285" xlink:type="arc"/>
      <link:label id="id_7c18c756" xlink:label="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential outflows in various currencies - from financial derivative liabilities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:label="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:to="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_4ab97cb3" xlink:label="lbl_label1253670067" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential inflows in various currencies - from financial derivative assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:label="lbl_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:to="lbl_label1253670067" xlink:type="arc"/>
      <link:label id="id_68a3968f" xlink:label="lbl_label1755551375" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments and accrued interest on derivative financial instruments [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:to="lbl_label1755551375" xlink:type="arc"/>
      <link:label id="id_6f45bf77" xlink:label="lbl_ContractualInterestOnNoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual interest on non-current liabilities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContractualInterestOnNoncurrentLiabilities" xlink:label="lbl_ContractualInterestOnNoncurrentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContractualInterestOnNoncurrentLiabilities" xlink:to="lbl_ContractualInterestOnNoncurrentLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_60f25e47" xlink:label="lbl_ContractualInterestOnNoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual interest on non-current liabilities</link:label>
      <link:label id="id_26c3488c" xlink:label="lbl_label650332300" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ten day loss fair value VAR model [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TenDayLossFairValueVARModelTable" xlink:label="lbl_TenDayLossFairValueVARModelTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TenDayLossFairValueVARModelTable" xlink:to="lbl_label650332300" xlink:type="arc"/>
      <link:label id="id_3ecf37ac" xlink:label="lbl_label1053767596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ten day loss fair value VAR model [line items]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TenDayLossFairValueVARModelLineItems" xlink:label="lbl_TenDayLossFairValueVARModelLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_label1053767596" xlink:type="arc"/>
      <link:label id="id_1d7eaa93" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputation_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, value at risk computation</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsValueAtRiskComputation" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsValueAtRiskComputation" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputation_labels" xlink:type="arc"/>
      <link:label id="id_4d7520d9" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, value at risk computation, sensitive to foreign currency exchange rates</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates_labels" xlink:type="arc"/>
      <link:label id="id_bc6d63c" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, value at risk computation, sensitive to equity market movements</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements_labels" xlink:type="arc"/>
      <link:label id="id_7e591031" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, value at risk computation, sensitive to interest rates</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates_labels" xlink:type="arc"/>
      <link:label id="id_1a9805f" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputation_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All financial instruments</link:label>
      <link:label id="id_2ef01715" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instruments sensitive to foreign currency exchange rates</link:label>
      <link:label id="id_74cd5fab" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instruments sensitive to equity market movements</link:label>
      <link:label id="id_3073f174" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instruments sensitive to interest rates</link:label>
      <link:label id="id_69bd9251" xlink:label="lbl_WeightedAverageMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageMember" xlink:label="lbl_WeightedAverageMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageMember" xlink:to="lbl_WeightedAverageMember_labels" xlink:type="arc"/>
      <link:label id="id_301d16c7" xlink:label="lbl_WeightedAverageMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average</link:label>
      <link:label id="id_2a5fb07c" xlink:label="lbl_TopOfRangeMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">High</link:label>
      <link:label id="id_6654bf44" xlink:label="lbl_BottomOfRangeMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Low</link:label>
      <link:label id="id_405da1b9" xlink:label="lbl_WorstCaseLossScenarioMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Worst case loss scenario [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WorstCaseLossScenarioMember" xlink:label="lbl_WorstCaseLossScenarioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WorstCaseLossScenarioMember" xlink:to="lbl_WorstCaseLossScenarioMember_labels" xlink:type="arc"/>
      <link:label id="id_2e992db9" xlink:label="lbl_WorstCaseLossScenarioMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Worst case loss scenario</link:label>
      <link:label id="id_4ee2f2eb" xlink:label="lbl_label1323496171" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash receipts and payments fair value measurement assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:label="lbl_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:to="lbl_label1323496171" xlink:type="arc"/>
      <link:label id="id_2d2549bd" xlink:label="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Potential outflows in various currencies - from financial derivative liabilities</link:label>
      <link:label id="id_6773649" xlink:label="lbl_DeferredTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:label id="id_7a7f8744" xlink:label="lbl_Liabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
      <link:label id="id_5793c543" xlink:label="lbl_DeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax balance</link:label>
      <link:label id="id_786524e" xlink:label="lbl_UnusedProvisionReversedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reversal of provisions for doubtful trade receivables</link:label>
      <link:label id="id_6744ae33" xlink:label="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Publicly quoted market value of the Novartis interest</link:label>
      <link:label id="id_24696e1c" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current service cost</link:label>
      <link:label id="id_471bbf88" xlink:label="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net interest expense</link:label>
      <link:label id="id_1439e3a2" xlink:label="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Administrative expenses</link:label>
      <link:label id="id_2f35efb7" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Novartis Equity Plan "Select", outside North America [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_labels" xlink:type="arc"/>
      <link:label id="id_58a34798" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Select outside North America</link:label>
      <link:label id="id_5e36913a" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Novartis Equity Plan "Select", North America [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_labels" xlink:type="arc"/>
      <link:label id="id_49d8c8f7" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Select North America</link:label>
      <link:label id="id_7c2b7da9" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon, Inc., equity plans, granted to associates prior merger [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:to="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember_labels" xlink:type="arc"/>
      <link:label id="id_3be795e9" xlink:label="lbl_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="lbl_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_labels" xlink:type="arc"/>
      <link:label id="id_3e622c14" xlink:label="lbl_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited, number of shares</link:label>
      <link:label id="id_179f71dc" xlink:label="lbl_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding, Number</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="lbl_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_labels" xlink:type="arc"/>
      <link:label id="id_13e82d94" xlink:label="lbl_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested, number of shares</link:label>
      <link:label id="id_676b945a" xlink:label="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Granted, Number of Shares</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted_labels" xlink:type="arc"/>
      <link:label id="id_7c12048" xlink:label="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted, number of shares</link:label>
      <link:label id="id_36172efd" xlink:label="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of shares at end of period</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_labels" xlink:type="arc"/>
      <link:label id="id_60b0a4e9" xlink:label="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of shares at beginning of period</link:label>
      <link:label id="id_3531edda" xlink:label="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
      <link:label id="id_5e461d76" xlink:label="lbl_label1581653366" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of unvested restricted stock units [roll forward]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_label1581653366" xlink:type="arc"/>
      <link:label id="id_7874e637" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income from associated companies</link:label>
      <link:label id="id_32b80bd7" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Other Share Awards [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationOtherShareAwardsMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsMember_labels" xlink:type="arc"/>
      <link:label id="id_18282520" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other share awards</link:label>
      <link:label id="id_46ef7a38" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alcon equity plans granted to associates prior merger</link:label>
      <link:label id="id_5f28436" xlink:label="lbl_EquityBasedParticipationRestrictedSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Shares</link:label>
      <link:label id="id_68171cd3" xlink:label="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leveraged Share Savings Plan (LSSP)</link:label>
      <link:label id="id_33a3b55c" xlink:label="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Share Ownership Plan (ESOP)</link:label>
      <link:label id="id_48de40b0" xlink:label="lbl_EquityBasedParticipationUKShareSavingsPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UK Share Savings Plan</link:label>
      <link:label id="id_71e8eb1f" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for product liabilities, governmental investigations and other legal matters</link:label>
      <link:label id="id_68f6d949" xlink:label="lbl_ShareMovements_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share movements in period</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ShareMovements" xlink:label="lbl_ShareMovements" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShareMovements" xlink:to="lbl_ShareMovements_labels" xlink:type="arc"/>
      <link:label id="id_10047f77" xlink:label="lbl_ShareMovements_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total movements</link:label>
      <link:label id="id_5da2c69" xlink:label="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net expense, royalties cost sharing and profit sharing</link:label>
      <link:label id="id_1b2e9a2e" xlink:label="lbl_label2088768931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net investment hedge [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetInvestmentHedgeMember" xlink:label="lbl_NetInvestmentHedgeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetInvestmentHedgeMember" xlink:to="lbl_label2088768931" xlink:type="arc"/>
      <link:label id="id_6aadffe9" xlink:label="lbl_label1789788137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written call options held by market maker</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WrittenCallOptionsHeldByMarketMaker" xlink:label="lbl_WrittenCallOptionsHeldByMarketMaker" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WrittenCallOptionsHeldByMarketMaker" xlink:to="lbl_label1789788137" xlink:type="arc"/>
      <link:label id="id_29617d6b" xlink:label="lbl_label694254955" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written call options, contractual live</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WrittenCallOptionsContractualLive" xlink:label="lbl_WrittenCallOptionsContractualLive" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WrittenCallOptionsContractualLive" xlink:to="lbl_label694254955" xlink:type="arc"/>
      <link:label id="id_b107ceb" xlink:label="lbl_label185629931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written call options, contractual live, remaining</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WrittenCallOptionsContractualLiveRemaining" xlink:label="lbl_WrittenCallOptionsContractualLiveRemaining" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WrittenCallOptionsContractualLiveRemaining" xlink:to="lbl_label185629931" xlink:type="arc"/>
      <link:label id="id_292f5855" xlink:label="lbl_label690968661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written call options, weighted average exercise price</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WrittenCallOptionsWeightedAverageExercisePrice" xlink:label="lbl_WrittenCallOptionsWeightedAverageExercisePrice" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WrittenCallOptionsWeightedAverageExercisePrice" xlink:to="lbl_label690968661" xlink:type="arc"/>
      <link:label id="id_1e74829a" xlink:label="lbl_InterestExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total interest expense from continuing operations</link:label>
      <link:label id="id_764458f" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in current financial debts</link:label>
      <link:label id="id_657faa04" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividends paid to non-controlling interests and other financing cash flows</link:label>
      <link:label id="id_4f246ab" xlink:label="lbl_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables and other liabilities including deferred tax liabilities</link:label>
      <link:label id="id_3f1c8d8f" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PurchaseFairValueMeasurementAssets" xlink:label="lbl_PurchaseFairValueMeasurementAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseFairValueMeasurementAssets" xlink:to="lbl_label521651444" xlink:type="arc"/>
      <link:label id="id_cca13ad" xlink:label="lbl_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid and other portfolio transformation related cash flows</link:label>
      <link:label id="id_7ef7b9ed" xlink:label="lbl_OtherPaymentsAndDeferredConsiderationNet_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments, deferred consideration and other adjustments, net</link:label>
      <link:label id="id_47b366a2" xlink:label="lbl_DeferredPrepaidPortionOfSalesPrice_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred portion of sales price</link:label>
      <link:label id="id_547e2ca5" xlink:label="lbl_StockRepurchaseProgramAuthorizedAmount1_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StockRepurchaseProgramAuthorizedAmount1" xlink:label="lbl_StockRepurchaseProgramAuthorizedAmount1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lbl_StockRepurchaseProgramAuthorizedAmount1_labels" xlink:type="arc"/>
      <link:label id="id_73838734" xlink:label="lbl_StockRepurchaseProgramAuthorizedAmount1_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares repurchased on the SIX Swiss Exchange second trading line under the share buyback authority approved</link:label>
      <link:label id="id_56c435e" xlink:label="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement</link:label>
      <link:label id="id_12b02f16" xlink:label="lbl_DisposalsFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Disposals fair value measurement assets</link:label>
      <link:label id="id_26be22ce" xlink:label="lbl_AdjustmentsForReconcileProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reversal of non-cash items and other adjustments</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForReconcileProfitLoss" xlink:to="lbl_AdjustmentsForReconcileProfitLoss_labels" xlink:type="arc"/>
      <link:label id="id_2cafaaf8" xlink:label="lbl_AdjustmentsForReconcileProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total reversal of non-cash items</link:label>
      <link:label id="id_4b753731" xlink:label="lbl_AdjustmentsForReconcileProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile profit (loss)</link:label>
      <link:label id="id_38c3816c" xlink:label="lbl_IncomeTaxesPaidRefund_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income taxes (paid)/refund</link:label>
      <link:label id="id_156023e7" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income taxes (paid)/refund, classified as investing activities</link:label>
      <link:label id="id_4b858d4a" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income taxes refund/(paid), classified as operating activities</link:label>
      <link:label id="id_486e2543" xlink:label="lbl_DepreciationAndAmortisationExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortisation expense</link:label>
      <link:label id="id_bf2d3c0" xlink:label="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss (reversal of impairment loss) recognised in profit or loss</link:label>
      <link:label id="id_555a0937" xlink:label="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges and fair value gains on financial assets, net</link:label>
      <link:label id="id_498c02d2" xlink:label="lbl_AdditionsToRestructuringProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Additions to restructuring provisions</link:label>
      <link:label id="id_775477cb" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation of Novartis equity plans</link:label>
      <link:label id="id_408b9f0d" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income statement effect</link:label>
      <link:label id="id_2a46b40e" xlink:label="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of income taxed at reduced rates</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:label="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:to="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates_labels" xlink:type="arc"/>
      <link:label id="id_55aa23f7" xlink:label="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of income taxed at reduced rates</link:label>
      <link:label id="id_17e76531" xlink:label="lbl_label401040689" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movements of property, plant and equipment [roll forward]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:label="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_label401040689" xlink:type="arc"/>
      <link:label id="id_3d749f5d" xlink:label="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Disposals and derecognitions</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherAssetsProvisionsAccrualsMember" xlink:label="lbl_OtherAssetsProvisionsAccrualsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherAssetsProvisionsAccrualsMember" xlink:to="lbl_label288271922" xlink:type="arc"/>
      <link:label id="id_5ac948f0" xlink:label="lbl_IntangibleAssetsAndGoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets [member]</link:label>
      <link:label id="id_6dbb9ba2" xlink:label="lbl_label1841011618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="lbl_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="lbl_label1841011618" xlink:type="arc"/>
      <link:label id="id_44d33d7" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, NonVested in Period, Fair Value</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" xlink:to="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue_labels" xlink:type="arc"/>
      <link:label id="id_46c4badd" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value at grante date at beginning of period</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" xlink:to="lbl_label679367036" xlink:type="arc"/>
      <link:label id="id_1c16a93d" xlink:label="lbl_label471247165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Fair Value</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" xlink:to="lbl_label471247165" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" xlink:to="lbl_label1695476906" xlink:type="arc"/>
      <link:label id="id_657887a0" xlink:label="lbl_label1702397856" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" xlink:to="lbl_label1702397856" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" xlink:to="lbl_label1373999706" xlink:type="arc"/>
      <link:label id="id_6cec499" xlink:label="lbl_label114214041" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited in Period, Fair Value</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" xlink:to="lbl_label114214041" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" xlink:to="lbl_label766376780" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisSingaporePteLtd.SingaporeMember" xlink:label="lbl_NovartisSingaporePteLtd.SingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSingaporePteLtd.SingaporeMember" xlink:to="lbl_label250835540" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:label="lbl_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:to="lbl_label659774806" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:label="lbl_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:to="lbl_label1942659357" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:label="lbl_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:to="lbl_label1522796763" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:label="lbl_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:to="lbl_label1080027869" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:label="lbl_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:to="lbl_label1523800019" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconPteLtdSingaporeMember" xlink:label="lbl_AlconPteLtdSingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPteLtdSingaporeMember" xlink:to="lbl_label1448389290" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:label="lbl_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:to="lbl_label547277000" xlink:type="arc"/>
      <link:label id="id_3f303d9f" xlink:label="lbl_label1060126111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Spinifex Pharmaceuticals, Inc., Wilmington, NC [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:label="lbl_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:to="lbl_label1060126111" xlink:type="arc"/>
      <link:label id="id_7ab53501" xlink:label="lbl_label2058695937" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Encore Vision, Inc., New York, NY [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EncoreVisionInc.NewYorkNYMember" xlink:label="lbl_EncoreVisionInc.NewYorkNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EncoreVisionInc.NewYorkNYMember" xlink:to="lbl_label2058695937" xlink:type="arc"/>
      <link:label id="id_71637428" xlink:label="lbl_label1902343208" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Investment Ltd., Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInvestmentLtd.HamiltonMember" xlink:label="lbl_NovartisInvestmentLtd.HamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInvestmentLtd.HamiltonMember" xlink:to="lbl_label1902343208" xlink:type="arc"/>
      <link:label id="id_631dbefb" xlink:label="lbl_label1662893819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Finance Services Ltd., Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFinanceServicesLtd.HamiltonMember" xlink:label="lbl_NovartisFinanceServicesLtd.HamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFinanceServicesLtd.HamiltonMember" xlink:to="lbl_label1662893819" xlink:type="arc"/>
      <link:label id="id_682001cf" xlink:label="lbl_label1746928079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis B2 Ltd., Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisB2Ltd.HamiltonMember" xlink:label="lbl_NovartisB2Ltd.HamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisB2Ltd.HamiltonMember" xlink:to="lbl_label1746928079" xlink:type="arc"/>
      <link:label id="id_60c6aa6" xlink:label="lbl_label101477030" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis B3 Ltd., Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisB3Ltd.HamiltonMember" xlink:label="lbl_NovartisB3Ltd.HamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisB3Ltd.HamiltonMember" xlink:to="lbl_label101477030" xlink:type="arc"/>
      <link:label id="id_4bc526b5" xlink:label="lbl_label1271211701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ciba-Geigy Japan Limited, Tokyo [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CibaGeigyJapanLimitedTokyoMember" xlink:label="lbl_CibaGeigyJapanLimitedTokyoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CibaGeigyJapanLimitedTokyoMember" xlink:to="lbl_label1271211701" xlink:type="arc"/>
      <link:label id="id_518a9aeb" xlink:label="lbl_label1368038123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis International Pharmaceutical Investment AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:label="lbl_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:to="lbl_label1368038123" xlink:type="arc"/>
      <link:label id="id_614bc25c" xlink:label="lbl_label1632354908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Bioventures AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisBioventuresAGBaselMember" xlink:label="lbl_NovartisBioventuresAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisBioventuresAGBaselMember" xlink:to="lbl_label1632354908" xlink:type="arc"/>
      <link:label id="id_8fecb9d" xlink:label="lbl_label150915997" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Forschungsstiftung, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisForschungsstiftungBaselMember" xlink:label="lbl_NovartisForschungsstiftungBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisForschungsstiftungBaselMember" xlink:to="lbl_label150915997" xlink:type="arc"/>
      <link:label id="id_600bda82" xlink:label="lbl_label1611389570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Stiftung fuer Kaderausbildung, Basel [member]</link:label>
      <link:label id="id_6fd3a22a" xlink:label="lbl_label1876140586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Mitarbeiterbeteiligungsstiftung, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:label="lbl_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:to="lbl_label1876140586" xlink:type="arc"/>
      <link:label id="id_2d8acaf0" xlink:label="lbl_label764070640" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Stiftung fuer Mensch und Umwelt, Basel [member]</link:label>
      <link:label id="id_7d992496" xlink:label="lbl_label2107188374" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stiftung der Novartis AG fuer Erziehung, Ausbildung und Bildung, Basel [member]</link:label>
      <link:label id="id_2bb02e62" xlink:label="lbl_label732966498" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Farmanova Saglik Hizmetleri Ltd. Sti., Istanbul [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:label="lbl_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:to="lbl_label732966498" xlink:type="arc"/>
      <link:label id="id_6c99f32" xlink:label="lbl_label113876786" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ziarco Group Limited, Frimley/Camberley [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:label="lbl_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:to="lbl_label113876786" xlink:type="arc"/>
      <link:label id="id_7dfa0e77" xlink:label="lbl_label2113539703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vivacta Limited, Frimley/Camberley, Surrey [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VivactaLimitedFrimleyCamberleySurreyMember" xlink:label="lbl_VivactaLimitedFrimleyCamberleySurreyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VivactaLimitedFrimleyCamberleySurreyMember" xlink:to="lbl_label2113539703" xlink:type="arc"/>
      <link:label id="id_5489f125" xlink:label="lbl_label1418326309" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis US Foundation, New York, NY [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisUSFoundationNewYorkNYMember" xlink:label="lbl_NovartisUSFoundationNewYorkNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisUSFoundationNewYorkNYMember" xlink:to="lbl_label1418326309" xlink:type="arc"/>
      <link:label id="id_1c9b37d8" xlink:label="lbl_label479934424" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corthera, Inc., San Mateo, CA [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CortheraInc.SanMateoCAMember" xlink:label="lbl_CortheraInc.SanMateoCAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CortheraInc.SanMateoCAMember" xlink:to="lbl_label479934424" xlink:type="arc"/>
      <link:label id="id_32e0fe6b" xlink:label="lbl_label853605995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CoStim Pharmaceuticals Inc., Cambridge, MA [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:label="lbl_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:to="lbl_label853605995" xlink:type="arc"/>
      <link:label id="id_39cff8c0" xlink:label="lbl_label969930944" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Navigate BioPharma Services, Inc., Carlsbad, CA [member]</link:label>
      <link:label id="id_196cf67c" xlink:label="lbl_label426571388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reprixys Pharmaceuticals Corporation, East Hanover, NJ [member]</link:label>
      <link:label id="id_72f336af" xlink:label="lbl_label1928541871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ClarVista Medical, Inc., Aliso Viejo, CA [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:label="lbl_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:to="lbl_label1928541871" xlink:type="arc"/>
      <link:label id="id_55c01a35" xlink:label="lbl_label1438652981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transcend Medical, Inc., Lake Forest, IL [member]</link:label>
      <link:label id="id_4148f290" xlink:label="lbl_label1095299728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Triangle International Reinsurance Limited, Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:label="lbl_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:to="lbl_label1095299728" xlink:type="arc"/>
      <link:label id="id_75fcbca" xlink:label="lbl_label123718602" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trinity River Insurance Co Ltd., Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:label="lbl_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:to="lbl_label123718602" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisStiftungFuerKaderausbildungBaselMember" xlink:label="lbl_NovartisStiftungFuerKaderausbildungBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisStiftungFuerKaderausbildungBaselMember" xlink:to="lbl_label1611389570" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:label="lbl_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:to="lbl_label764070640" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:label="lbl_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:to="lbl_label2107188374" xlink:type="arc"/>
      <link:label id="id_7fb34e52" xlink:label="lbl_label2142457426" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Syntek Ilac Hammaddeleri Sanayi ve Ticaret A.S., Istanbul [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:label="lbl_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:to="lbl_label2142457426" xlink:type="arc"/>
      <link:label id="id_48e7e2a8" xlink:label="lbl_RUB_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Russia, Rubles</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_RUB" xlink:label="lbl_RUB" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RUB" xlink:to="lbl_RUB_labels" xlink:type="arc"/>
      <link:label id="id_2b6714e7" xlink:label="lbl_RUB_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RUB</link:label>
      <link:label id="id_6b134c2" xlink:label="lbl_BRL_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BRL</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_BRL" xlink:label="lbl_BRL" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BRL" xlink:to="lbl_BRL_labels" xlink:type="arc"/>
      <link:label id="id_19bb001f" xlink:label="lbl_BRL_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Brazil, Brazil Real</link:label>
      <link:label id="id_26408b72" xlink:label="lbl_AUD_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Australia, Dollars</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AUD" xlink:label="lbl_AUD" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AUD" xlink:to="lbl_AUD_labels" xlink:type="arc"/>
      <link:label id="id_1c95476e" xlink:label="lbl_AUD_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AUD</link:label>
      <link:label id="id_547736b0" xlink:label="lbl_CAD_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CAD</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CAD" xlink:label="lbl_CAD" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CAD" xlink:to="lbl_CAD_labels" xlink:type="arc"/>
      <link:label id="id_5eb5601a" xlink:label="lbl_CAD_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada, Dollars</link:label>
      <link:label id="id_58b8f0b8" xlink:label="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_435d0149" xlink:label="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of associates, net income effect [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:label="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:to="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_71b428a4" xlink:label="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to associates, net income effect</link:label>
      <link:label id="id_d71a4cc" xlink:label="lbl_AssociatesSummarizedFinancialInformationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Associates summarized financial information</link:label>
      <link:label id="id_303f5b81" xlink:label="lbl_PurchasePriceAllocationAssociatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price allocation associates</link:label>
      <link:label id="id_3ea56c51" xlink:label="lbl_label1051028561" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets/liabilities, expected to have impact on current taxes payable</link:label>
      <link:label id="id_549c77e3" xlink:label="lbl_label1419540451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of deferred tax assets and liabilities, expected to have impact on current taxes payable [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:label="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:to="lbl_label1419540451" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:to="lbl_label1051028561" xlink:type="arc"/>
      <link:label id="id_686d8bfd" xlink:label="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of unremitted earnings retained by consolidated entities for reinvestment [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" xlink:label="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" xlink:to="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4726a0d4" xlink:label="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unremitted earnings retained by consolidated entities for reinvestment</link:label>
      <link:label id="id_2be0cf3f" xlink:label="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of amount of inventory recognized as an expense in cost of goods sold [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" xlink:label="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" xlink:to="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_26e57cfe" xlink:label="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of inventory recognized as an expense in cost of goods sold</link:label>
      <link:label id="id_30833089" xlink:label="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of recognized amount of inventory provisions and reversals of inventory provision [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" xlink:label="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" xlink:to="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3124df13" xlink:label="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognized amount of inventory provisions and reversals of inventory provision</link:label>
      <link:label id="id_4d23afdc" xlink:label="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross trade receivable from closely monitored countries [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" xlink:label="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" xlink:to="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5f55c02d" xlink:label="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross trade receivable from closely monitored countries</link:label>
      <link:label id="id_540d35ce" xlink:label="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt securities, breakdown by currency [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DebtSecuritiesBreakdownByCurrencyTableTextBlock" xlink:label="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock" xlink:to="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_295129f0" xlink:label="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, breakdown by currency</link:label>
      <link:label id="id_22b42dd0" xlink:label="lbl_SummaryOfTreasurySharesMovementsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of treasury shares movements [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SummaryOfTreasurySharesMovementsTableTextBlock" xlink:label="lbl_SummaryOfTreasurySharesMovementsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SummaryOfTreasurySharesMovementsTableTextBlock" xlink:to="lbl_SummaryOfTreasurySharesMovementsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7493f0ce" xlink:label="lbl_SummaryOfTreasurySharesMovementsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related treasury shares movements</link:label>
      <link:label id="id_28836a6a" xlink:label="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" xlink:label="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" xlink:to="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_77bb4dc1" xlink:label="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities</link:label>
      <link:label id="id_63da54e2" xlink:label="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of liabilities arising from financing activities [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" xlink:label="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" xlink:to="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_ea1dc4a" xlink:label="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of liabilities arising from financing activities</link:label>
      <link:label id="id_ecb4868" xlink:label="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of asset allocation, investments in shares of Novartis AG [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:label="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:to="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6d5c5887" xlink:label="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset allocation, investments in shares of Novartis AG</link:label>
      <link:label id="id_583fe5ec" xlink:label="lbl_ScheduleOfDefinedContributionPlansTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of defined contribution plans [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:label="lbl_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:to="lbl_ScheduleOfDefinedContributionPlansTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4176cd8b" xlink:label="lbl_ScheduleOfDefinedContributionPlansTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined contribution plans</link:label>
      <link:label id="id_5864530c" xlink:label="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of expense related to all equity-based participation and liabilities arising from equity-based payment transactions [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:label="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:to="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_19e39c55" xlink:label="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense related to all equity-based participation and liabilities arising from equity-based payment transactions</link:label>
      <link:label id="id_12c92048" xlink:label="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets and financial liabilities [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:label="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:to="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6a3159a6" xlink:label="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets and financial liabilities</link:label>
      <link:label id="id_5070bcfa" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_5e4ef11c" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial instruments</link:label>
      <link:label id="id_4b298c60" xlink:label="lbl_label1261014112" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract or underlying principal amount the derivative financial instruments, by currency</link:label>
      <link:label id="id_6bba442" xlink:label="lbl_label112960578" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments, contract or underlying principal amount the derivative financial instruments, by currency [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:to="lbl_label112960578" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:to="lbl_label1261014112" xlink:type="arc"/>
      <link:label id="id_7def025f" xlink:label="lbl_DisclosureOfFairValueMeasurementExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:label="lbl_DisclosureOfFairValueMeasurementExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueMeasurementExplanatory" xlink:to="lbl_DisclosureOfFairValueMeasurementExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_77677ae5" xlink:label="lbl_DisclosureOfFairValueMeasurementExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value by hierarchy</link:label>
      <link:label id="id_3e022541" xlink:label="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in fair value measurement [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" xlink:label="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" xlink:to="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1b36ee5a" xlink:label="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in fair value measurement</link:label>
      <link:label id="id_fde92c1" xlink:label="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of monitoring of net debt or liquidity based on contractual maturities [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" xlink:label="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" xlink:to="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2293ad67" xlink:label="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monitoring of net debt or liquidity based on contractual maturities</link:label>
      <link:label id="id_1cfe8d17" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments and accrued interest on derivative financial instruments [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5ab7d205" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial instruments and accrued interest on derivative financial instruments</link:label>
      <link:label id="id_36cdbc5" xlink:label="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other contractual liabilities of the net debt or liquidity [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" xlink:label="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" xlink:to="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_36a9094b" xlink:label="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other contractual liabilities of the net debt or liquidity</link:label>
      <link:label id="id_6873d3e4" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of ten day loss fair value VAR model [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" xlink:to="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_52a21cc6" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ten day loss fair value VAR model</link:label>
      <link:label id="id_5cc8b03e" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of ten day loss fair value VAR model, average, high, and low VAR amounts [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" xlink:to="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_13881ac7" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ten day loss fair value VAR model, average, high, and low VAR amounts</link:label>
      <link:label id="id_41e588b8" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of ten day loss fair value VAR model, worst case loss scenario [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" xlink:to="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7c01a973" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ten day loss fair value VAR model, worst case loss scenario</link:label>
      <link:label id="id_5ec493de" xlink:label="lbl_KR_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">KOREA, REPUBLIC OF</link:label>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_KR" xlink:label="lbl_KR" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KR" xlink:to="lbl_KR_labels" xlink:type="arc"/>
      <link:label id="id_685d93ad" xlink:label="lbl_KR_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">South Korea</link:label>
      <link:label id="id_25a8beb4" xlink:label="lbl_PurchaseOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares</link:label>
      <link:label id="id_43c445c8" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of change in ownership of consolidated entities</link:label>
      <link:label id="id_53037399" xlink:label="lbl_PurchaseOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares, equity impact</link:label>
      <link:label id="id_449dfef2" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments out of provisions and other net cash movements in non-current liabilities</link:label>
      <link:label id="id_5f336b49" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Portion of consideration paid (received) consisting of cash and cash equivalents</link:label>
      <link:label id="id_1ebe8e22" xlink:label="lbl_ReprixysPharmaceuticalsCorporationMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reprixys Pharmaceuticals Corporation [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReprixysPharmaceuticalsCorporationMember" xlink:label="lbl_ReprixysPharmaceuticalsCorporationMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReprixysPharmaceuticalsCorporationMember" xlink:to="lbl_ReprixysPharmaceuticalsCorporationMember_labels" xlink:type="arc"/>
      <link:label id="id_7c3b4ddb" xlink:label="lbl_ReprixysPharmaceuticalsCorporationMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reprixys Pharmaceuticals Corporation</link:label>
      <link:label id="id_37f79dee" xlink:label="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of release of contingent consideration liability</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:label="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:to="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability_labels" xlink:type="arc"/>
      <link:label id="id_7767d800" xlink:label="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of release of contingent consideration liability</link:label>
      <link:label id="id_3fbded99" xlink:label="lbl_IncomeTaxExpenseContinuingOperations_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxRateEffectFromNondeductibleLossesInRegion" xlink:label="lbl_TaxRateEffectFromNondeductibleLossesInRegion" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectFromNondeductibleLossesInRegion" xlink:to="lbl_label1999384126" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectFromNondeductibleLossesInRegion" xlink:to="lbl_label1131311877" xlink:type="arc"/>
      <link:label id="id_7da827c0" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_45122075" xlink:label="lbl_AdditionalProvisionsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Provisions for doubtful trade receivables charged to the consolidated income statement</link:label>
      <link:label id="id_3b199e63" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_9457980" xlink:label="lbl_label155548032" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax asset and liability valuation [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:label="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_label155548032" xlink:type="arc"/>
      <link:label id="id_1c2a973a" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law deferred tax expense income recognised in profit or loss</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:to="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss_labels" xlink:type="arc"/>
      <link:label id="id_44e2d573" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law deferred tax relating to components of other comprehensive income</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:to="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:type="arc"/>
      <link:label id="id_31998635" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law increase decrease in deferred tax liability asset</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:to="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_3ecc5b67" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law increase decrease in current income tax liability</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:to="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability_labels" xlink:type="arc"/>
      <link:label id="id_16a647a9" xlink:label="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law change in deferred tax assets and liabilities and current tax liabilities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:label="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:to="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_549d9bf8" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Items previously recognized in consolidated income statement</link:label>
      <link:label id="id_5370a381" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Items previously recognized in other comprehensive income</link:label>
      <link:label id="id_584b4926" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Total revaluation of deferred tax assets and liabilities</link:label>
      <link:label id="id_1d65bc0" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Total revaluation of current income tax liabilities</link:label>
      <link:label id="id_67c3f632" xlink:label="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Total revaluation of deferred tax assets and liabilities and current income tax liabilities</link:label>
      <link:label id="id_25c7d443" xlink:label="lbl_label633852995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact location [axis]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactLocationAxis" xlink:label="lbl_ImpactLocationAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactLocationAxis" xlink:to="lbl_label633852995" xlink:type="arc"/>
      <link:label id="id_49f0b616" xlink:label="lbl_label1240512022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact location [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactLocationMember" xlink:label="lbl_ImpactLocationMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactLocationMember" xlink:to="lbl_label1240512022" xlink:type="arc"/>
      <link:label id="id_2bcc20cf" xlink:label="lbl_label734798031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income statement [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeStatementMember" xlink:label="lbl_IncomeStatementMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeStatementMember" xlink:to="lbl_label734798031" xlink:type="arc"/>
      <link:label id="id_5659c922" xlink:label="lbl_label1448724770" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase to retained earnings arising from first application of IFRS 9</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:label="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:to="lbl_label1448724770" xlink:type="arc"/>
      <link:label id="id_2a7f4c39" xlink:label="lbl_label712985657" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undiscounted operating lease commitments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UndiscountedOperatingLeaseCommitments" xlink:label="lbl_UndiscountedOperatingLeaseCommitments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UndiscountedOperatingLeaseCommitments" xlink:to="lbl_label712985657" xlink:type="arc"/>
      <link:label id="id_78817d05" xlink:label="lbl_label2021752069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contribution of business to joint venture</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContributionOfBusinessToJointVenture" xlink:label="lbl_ContributionOfBusinessToJointVenture" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContributionOfBusinessToJointVenture" xlink:to="lbl_label2021752069" xlink:type="arc"/>
      <link:label id="id_77130f8a" xlink:label="lbl_label1997737866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of income not subject to tax on the divestment gain on GSK investment</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:label="lbl_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:to="lbl_label1997737866" xlink:type="arc"/>
      <link:label id="id_5b6d1716" xlink:label="lbl_label1533875990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:label="lbl_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:to="lbl_label1533875990" xlink:type="arc"/>
      <link:label id="id_11cc9e15" xlink:label="lbl_label298622485" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to available-for-sale financia investments previously recognized through OCI</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToAvailableforsaleFinanciaInvestmentsPreviouslyRecognizedThroughOCI" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToAvailableforsaleFinanciaInvestmentsPreviouslyRecognizedThroughOCI" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToAvailableforsaleFinanciaInvestmentsPreviouslyRecognizedThroughOCI" xlink:to="lbl_label298622485" xlink:type="arc"/>
      <link:label id="id_7418c9fe" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to deferred tax assets on US post retirement previously recognized through OCI</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI_labels" xlink:type="arc"/>
      <link:label id="id_12e2c645" xlink:label="lbl_label316851781" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law effective tax rate after implemetation of new law changes</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:label="lbl_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:to="lbl_label316851781" xlink:type="arc"/>
      <link:label id="id_2bfd3952" xlink:label="lbl_label738015570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law tax on unremitted earnings period allowed for payment</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:label="lbl_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:to="lbl_label738015570" xlink:type="arc"/>
      <link:label id="id_34cb50dd" xlink:label="lbl_label885739741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to deferred tax assets on unremitted earnings</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:to="lbl_label885739741" xlink:type="arc"/>
      <link:label id="id_73b04098" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to revaluation of deferred tax assets on equity based compensation that were previously recognized through retained earnings</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings_labels" xlink:type="arc"/>
      <link:label id="id_75b59f04" xlink:label="lbl_label1713201135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through finance lease contracts property plant and equipment</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:label="lbl_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:to="lbl_label1713201135" xlink:type="arc"/>
      <link:label id="id_3eec7519" xlink:label="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal group companies materiality of assets or sales to third parties</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:label="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:to="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties_labels" xlink:type="arc"/>
      <link:label id="id_c93c456" xlink:label="lbl_label211010646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other intangible asset purchase commitments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherIntangiblePurchaseCommitments" xlink:label="lbl_OtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherIntangiblePurchaseCommitments" xlink:to="lbl_label211010646" xlink:type="arc"/>
      <link:label id="id_6759fd06" xlink:label="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development and other intangible asset purchase commitments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:label="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:to="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments_labels" xlink:type="arc"/>
      <link:label id="id_624861c8" xlink:label="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
      <link:label id="id_2f002958" xlink:label="lbl_label788539736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial instruments - narrative [table]</link:label>
      <link:label id="id_684e1ed4" xlink:label="lbl_label1749950164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Open hedges for anticipated transactions</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OpenHedgesForAnticipatedTransactions" xlink:label="lbl_OpenHedgesForAnticipatedTransactions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OpenHedgesForAnticipatedTransactions" xlink:to="lbl_label1749950164" xlink:type="arc"/>
      <link:label id="id_38f600d1" xlink:label="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transfers out of Level 3 of fair value hierarchy, assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:to="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets_labels" xlink:type="arc"/>
      <link:label id="id_24d61d6" xlink:label="lbl_label38625750" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount of change in OCI when pricing parameters for level 3 change more than 10%</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:to="lbl_label38625750" xlink:type="arc"/>
      <link:label id="id_8d1d7d" xlink:label="lbl_label9248125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Most significant foreign exchange losses</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MostSignificantForeignExchangeLosses" xlink:label="lbl_MostSignificantForeignExchangeLosses" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MostSignificantForeignExchangeLosses" xlink:to="lbl_label9248125" xlink:type="arc"/>
      <link:label id="id_75c586da" xlink:label="lbl_label1975879386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term financial debt with a carrying amount</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LongtermFinancialDebtWithACarryingAmount" xlink:label="lbl_LongtermFinancialDebtWithACarryingAmount" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LongtermFinancialDebtWithACarryingAmount" xlink:to="lbl_label1975879386" xlink:type="arc"/>
      <link:label id="id_189f8e8f" xlink:label="lbl_label413109903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized loss was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:label="lbl_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:to="lbl_label413109903" xlink:type="arc"/>
      <link:label id="id_19e141a6" xlink:label="lbl_label434192806" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net investment hedge recognized in the income statement</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:label="lbl_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:to="lbl_label434192806" xlink:type="arc"/>
      <link:label id="id_7d454e3e" xlink:label="lbl_label2101694014" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upper limit on holdings on unrelated company</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:label="lbl_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:to="lbl_label2101694014" xlink:type="arc"/>
      <link:label id="id_1ccfbaa5" xlink:label="lbl_label483375781" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings commercial paper maximum borrowing amount</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:label="lbl_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:to="lbl_label483375781" xlink:type="arc"/>
      <link:label id="id_665a2289" xlink:label="lbl_label1717183113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt/equity ratio</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DebtEquityRatio" xlink:label="lbl_DebtEquityRatio" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DebtEquityRatio" xlink:to="lbl_label1717183113" xlink:type="arc"/>
      <link:label id="id_5597d347" xlink:label="lbl_label1436013383" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">VAR estimate confidence interval</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VAREstimateConfidenceInterval" xlink:label="lbl_VAREstimateConfidenceInterval" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VAREstimateConfidenceInterval" xlink:to="lbl_label1436013383" xlink:type="arc"/>
      <link:label id="id_42729374" xlink:label="lbl_label1114805108" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings commercial paper maximum amount outstanding</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:label="lbl_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:to="lbl_label1114805108" xlink:type="arc"/>
      <link:label id="id_6e4f3f5e" xlink:label="lbl_label1850687326" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings credit facility committed</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsCreditFacilityCommitted" xlink:label="lbl_BorrowingsCreditFacilityCommitted" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsCreditFacilityCommitted" xlink:to="lbl_label1850687326" xlink:type="arc"/>
      <link:label id="id_40060c01" xlink:label="lbl_label1074138113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty risk [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CounterpartyRiskAbstract" xlink:label="lbl_CounterpartyRiskAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CounterpartyRiskAbstract" xlink:to="lbl_label1074138113" xlink:type="arc"/>
      <link:label id="id_16edbe31" xlink:label="lbl_label384679473" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of entity's cash and cash equivalents held with financial institution</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:label="lbl_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:to="lbl_label384679473" xlink:type="arc"/>
      <link:label id="id_367e78c8" xlink:label="lbl_label914258120" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vendor [axis]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VendorAxis" xlink:label="lbl_VendorAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VendorAxis" xlink:to="lbl_label914258120" xlink:type="arc"/>
      <link:label id="id_45057e7f" xlink:label="lbl_label1157987967" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vendor [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VendorMember" xlink:label="lbl_VendorMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VendorMember" xlink:to="lbl_label1157987967" xlink:type="arc"/>
      <link:label id="id_bcf5c90" xlink:label="lbl_label198139024" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Largest financial institution [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LargestFinancialInstitutionMember" xlink:label="lbl_LargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LargestFinancialInstitutionMember" xlink:to="lbl_label198139024" xlink:type="arc"/>
      <link:label id="id_561f18c8" xlink:label="lbl_label1444878536" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second largest financial institution [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SecondLargestFinancialInstitutionMember" xlink:label="lbl_SecondLargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SecondLargestFinancialInstitutionMember" xlink:to="lbl_label1444878536" xlink:type="arc"/>
      <link:label id="id_cbf0fed" xlink:label="lbl_label213848045" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third largest financial institution [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ThirdLargestFinancialInstitutionMember" xlink:label="lbl_ThirdLargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ThirdLargestFinancialInstitutionMember" xlink:to="lbl_label213848045" xlink:type="arc"/>
      <link:label id="id_3a76e486" xlink:label="lbl_label980870278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre tax profit (loss) from divestment of business</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PreTaxProfitLossFromDivestmentOfBusiness" xlink:label="lbl_PreTaxProfitLossFromDivestmentOfBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PreTaxProfitLossFromDivestmentOfBusiness" xlink:to="lbl_label980870278" xlink:type="arc"/>
      <link:label id="id_5810372f" xlink:label="lbl_label1477457711" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration transferred, divestment-date fair value</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:to="lbl_label1477457711" xlink:type="arc"/>
      <link:label id="id_4121b29e" xlink:label="lbl_label1092727454" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential receivable from divestment</link:label>
      <link:label id="id_3cc9e79a" xlink:label="lbl_label1019864986" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration received</link:label>
      <link:label id="id_5b569e4" xlink:label="lbl_label95775204" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone payment already received</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MilestonePaymentAlreadyReceived" xlink:label="lbl_MilestonePaymentAlreadyReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MilestonePaymentAlreadyReceived" xlink:to="lbl_label95775204" xlink:type="arc"/>
      <link:label id="id_63dee19f" xlink:label="lbl_label1675551135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future put option to sell business</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FuturePutOptionToSellBusiness" xlink:label="lbl_FuturePutOptionToSellBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FuturePutOptionToSellBusiness" xlink:to="lbl_label1675551135" xlink:type="arc"/>
      <link:label id="id_7e35f229" xlink:label="lbl_label2117464617" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment put option</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PaymentPutOption" xlink:label="lbl_PaymentPutOption" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentPutOption" xlink:to="lbl_label2117464617" xlink:type="arc"/>
      <link:label id="id_4b717d8e" xlink:label="lbl_label1265728910" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest exchanged</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestExchanged" xlink:label="lbl_InterestExchanged" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExchanged" xlink:to="lbl_label1265728910" xlink:type="arc"/>
      <link:label id="id_8fd1ef1" xlink:label="lbl_ChangesInOffsetAgainstGrossTradeReceivables_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Changes in offset against gross trade receivables</link:label>
      <link:label id="id_2ef82d23" xlink:label="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefit payments</link:label>
      <link:label id="id_7c796053" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Number of share options exercised</link:label>
      <link:label id="id_64515558" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Number of share options exercised or sold</link:label>
      <link:label id="id_79b0131b" xlink:label="lbl_FinancialLiabilitiesAtFairValue_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities, at fair value</link:label>
      <link:label id="id_18855477" xlink:label="lbl_ClassesOfShareCapitalMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total outstanding shares</link:label>
      <link:label id="id_34b6a8cb" xlink:label="lbl_OrdinarySharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Novartis shares</link:label>
      <link:label id="id_20b38808" xlink:label="lbl_TreasurySharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total treasury shares</link:label>
      <link:label id="id_5dca543c" xlink:label="lbl_LiabilitiesToBanksAndOtherInstitutions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities to banks and other institutions</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LiabilitiesToBanksAndOtherInstitutions" xlink:label="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:to="lbl_LiabilitiesToBanksAndOtherInstitutions_labels" xlink:type="arc"/>
      <link:label id="id_3901e819" xlink:label="lbl_LiabilitiesToBanksAndOtherInstitutions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Liabilities to banks and other financial institutions</link:label>
      <link:label id="id_551ca7d0" xlink:label="lbl_ContingentConsiderationReceivableCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration receivable, current</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationReceivableCurrent" xlink:label="lbl_ContingentConsiderationReceivableCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationReceivableCurrent" xlink:to="lbl_ContingentConsiderationReceivableCurrent_labels" xlink:type="arc"/>
      <link:label id="id_15fc798c" xlink:label="lbl_ContingentConsiderationReceivableCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration receivable</link:label>
      <link:label id="id_249fb0f8" xlink:label="lbl_ImpactOfDivestmentsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of divestments, other provisions</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfDivestmentsOtherProvisions" xlink:label="lbl_ImpactOfDivestmentsOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfDivestmentsOtherProvisions" xlink:to="lbl_ImpactOfDivestmentsOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_77b9898f" xlink:label="lbl_ImpactOfDivestmentsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of divestments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:label="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:to="lbl_label788539736" xlink:type="arc"/>
      <link:label id="id_4241ab2c" xlink:label="lbl_GrossCarryingAmountMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross carrying amount</link:label>
      <link:label id="id_1264a0dc" xlink:label="lbl_label308584668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customers with net sales over five percent</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CustomersWithNetSalesOverFivePercent" xlink:label="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CustomersWithNetSalesOverFivePercent" xlink:to="lbl_label308584668" xlink:type="arc"/>
      <link:label id="id_2af199bf" xlink:label="lbl_label720476607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net cash flows used in acquisitions and divestments of businesses, classified as investing activities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:to="lbl_label720476607" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:to="lbl_label1718040268" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:to="lbl_label1423033786" xlink:type="arc"/>
      <link:label id="id_2cbb9926" xlink:label="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Impairment (loss) reversal of impairment loss recognised in profit or loss</link:label>
      <link:label id="id_eadbcd2" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquired cash and cash equivalents</link:label>
      <link:label id="id_36976720" xlink:label="lbl_PrepaidPostemploymentBenefitPlansAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid benefit cost</link:label>
      <link:label id="id_1c757af9" xlink:label="lbl_LiabilitiesFromSharebasedPaymentTransactions2011_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued share-based payments</link:label>
      <link:label id="id_79c38d68" xlink:label="lbl_Inventories_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
      <link:label id="id_1dbfe68b" xlink:label="lbl_CurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables</link:label>
      <link:label id="id_7bc2e092" xlink:label="lbl_label2076369042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration receivables short-term [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationReceivablesShorttermMember" xlink:label="lbl_ContingentConsiderationReceivablesShorttermMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationReceivablesShorttermMember" xlink:to="lbl_label2076369042" xlink:type="arc"/>
      <link:label id="id_1fd99bd1" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase)/decrease of treasury share repurchase obligation under a share buyback trading plan</link:label>
      <link:label id="id_2da8b675" xlink:label="lbl_label329619167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options excluded from the calculation</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OptionsExcludedFromTheCalculation" xlink:label="lbl_OptionsExcludedFromTheCalculation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OptionsExcludedFromTheCalculation" xlink:to="lbl_label329619167" xlink:type="arc"/>
      <link:label id="id_171116a0" xlink:label="lbl_label386995872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US commercial paper programs [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_USCommercialPaperProgramsMember" xlink:label="lbl_USCommercialPaperProgramsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_USCommercialPaperProgramsMember" xlink:to="lbl_label386995872" xlink:type="arc"/>
      <link:label id="id_1fb8b12f" xlink:label="lbl_label532197679" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JP commercial paper programs [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_JPCommercialPaperProgramsMember" xlink:label="lbl_JPCommercialPaperProgramsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_JPCommercialPaperProgramsMember" xlink:to="lbl_label532197679" xlink:type="arc"/>
      <link:label id="id_68bfdd9c" xlink:label="lbl_label1757404572" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings commercial paper, number of programs</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsCommercialPaperNumberOfPrograms" xlink:label="lbl_BorrowingsCommercialPaperNumberOfPrograms" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsCommercialPaperNumberOfPrograms" xlink:to="lbl_label1757404572" xlink:type="arc"/>
      <link:label id="id_4e21d3c" xlink:label="lbl_label81927484" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount of change in OCI when most significant parameters for level 3 change more than 10%</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:to="lbl_label81927484" xlink:type="arc"/>
      <link:label id="id_5ccfc0db" xlink:label="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount of change in OCI when POS for level 3 change more than 10%</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:to="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10_labels" xlink:type="arc"/>
      <link:label id="id_17ec29fe" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications (AAA) [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsAAAMember" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:to="lbl_AdvancedAcceleratorApplicationsAAAMember_labels" xlink:type="arc"/>
      <link:label id="id_4991ae50" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications (AAA)</link:label>
      <link:label id="id_69548c9f" xlink:label="lbl_label1767148703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Share capital in tender offer</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PercentageOfShareCapitalInTenderOffer" xlink:label="lbl_PercentageOfShareCapitalInTenderOffer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfShareCapitalInTenderOffer" xlink:to="lbl_label1767148703" xlink:type="arc"/>
      <link:label id="id_5c76d079" xlink:label="lbl_CashOfferPerOrdinaryShare_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash offer per ordinary share</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashOfferPerOrdinaryShare" xlink:label="lbl_CashOfferPerOrdinaryShare" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashOfferPerOrdinaryShare" xlink:to="lbl_CashOfferPerOrdinaryShare_labels" xlink:type="arc"/>
      <link:label id="id_741421fb" xlink:label="lbl_CashOfferPerADS_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash offer per ADS</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashOfferPerADS" xlink:label="lbl_CashOfferPerADS" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashOfferPerADS" xlink:to="lbl_CashOfferPerADS_labels" xlink:type="arc"/>
      <link:label id="id_4236be0f" xlink:label="lbl_label1110883855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of ordinary share per ADS</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfOrdinarySharePerADS" xlink:label="lbl_NumberOfOrdinarySharePerADS" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOrdinarySharePerADS" xlink:to="lbl_label1110883855" xlink:type="arc"/>
      <link:label id="id_471c5e7e" xlink:label="lbl_label1193041534" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value of equity</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ValueOfEquity" xlink:label="lbl_ValueOfEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueOfEquity" xlink:to="lbl_label1193041534" xlink:type="arc"/>
      <link:label id="id_72ec4d21" xlink:label="lbl_label454367578" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximal amount of share buyback programm</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MaximalAmountOfShareBuybackProgramm" xlink:label="lbl_MaximalAmountOfShareBuybackProgramm" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MaximalAmountOfShareBuybackProgramm" xlink:to="lbl_label454367578" xlink:type="arc"/>
      <link:label id="id_6eb334f8" xlink:label="lbl_label1857238264" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of Annual Incentive</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAnnualIncentive" xlink:label="lbl_DescriptionOfAnnualIncentive" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAnnualIncentive" xlink:to="lbl_label1857238264" xlink:type="arc"/>
      <link:label id="id_5c74f412" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade payables</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:to="lbl_TradeAndOtherPayablesToTradeSuppliers_labels" xlink:type="arc"/>
      <link:label id="id_5ba6657f" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Trade payables</link:label>
      <link:label id="id_7ae769dd" xlink:label="lbl_OtherCurrentNonfinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions and other current liabilities</link:label>
      <link:label id="id_49cb7900" xlink:label="lbl_OtherCurrentNonfinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total provisions and other current liabilities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfBusinessUnits" xlink:label="lbl_NumberOfBusinessUnits" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfBusinessUnits" xlink:to="lbl_label267498308" xlink:type="arc"/>
      <link:label id="id_8b05ce2" xlink:label="lbl_label145775842" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, third parties, change in percent</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:to="lbl_label145775842" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:to="lbl_label198642827" xlink:type="arc"/>
      <link:label id="id_5eb218a8" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to deferred tax assets on US post retirement previously recognized through OCI</link:label>
      <link:label id="id_4b99efa9" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax on above items</link:label>
      <link:label id="id_5952def9" xlink:label="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefits other than equity-based compensation</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_labels" xlink:type="arc"/>
      <link:label id="id_389a5b52" xlink:label="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonCurrentFinancialDebtsMember" xlink:label="lbl_NonCurrentFinancialDebtsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonCurrentFinancialDebtsMember" xlink:to="lbl_label1268656258" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:label="lbl_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:to="lbl_label618343139" xlink:type="arc"/>
      <link:label id="id_6987695e" xlink:label="lbl_IntangibleAssetImpairmentChargesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible asset impairment charges [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IntangibleAssetImpairmentChargesTextBlock" xlink:label="lbl_IntangibleAssetImpairmentChargesTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IntangibleAssetImpairmentChargesTextBlock" xlink:to="lbl_IntangibleAssetImpairmentChargesTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_76ff2ee3" xlink:label="lbl_IntangibleAssetImpairmentChargesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairment charges</link:label>
      <link:label id="id_2dd3bece" xlink:label="lbl_label768851662" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of share capital tendered at the expiration of the tender offer</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:label="lbl_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:to="lbl_label768851662" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:label="lbl_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:to="lbl_label2363078" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DivestmentFairValueOfContingentConsiderationReceived" xlink:label="lbl_DivestmentFairValueOfContingentConsiderationReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DivestmentFairValueOfContingentConsiderationReceived" xlink:to="lbl_label1019864986" xlink:type="arc"/>
      <link:label id="id_4875601b" xlink:label="lbl_TransactionRelatedCostsPaid_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction related costs paid</link:label>
      <link:label id="id_5201dd1d" xlink:label="lbl_TransactionRelatedCosts_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction related costs</link:label>
      <link:label id="id_b9d0509" xlink:label="lbl_label770091111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of fair value adjustments relating to intangible assets tax</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:label="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:to="lbl_label770091111" xlink:type="arc"/>
      <link:label id="id_55cbca11" xlink:label="lbl_label1439418897" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum margin percentage impact of commodity price change</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:label="lbl_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:to="lbl_label1439418897" xlink:type="arc"/>
      <link:label id="id_a88bf0e" xlink:label="lbl_label176733966" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum holding in unrelated company</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MaximumHoldingInUnrelatedCompany" xlink:label="lbl_MaximumHoldingInUnrelatedCompany" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MaximumHoldingInUnrelatedCompany" xlink:to="lbl_label176733966" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PotentialReceivableFromDivestment" xlink:label="lbl_PotentialReceivableFromDivestment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialReceivableFromDivestment" xlink:to="lbl_label1092727454" xlink:type="arc"/>
      <link:label id="id_2fe8aa88" xlink:label="lbl_CashOfferPerADS_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This expresses the amount of cash Novartis paid to the owners of AAA per ADS.</link:label>
      <link:label id="id_74cb8111" xlink:label="lbl_CashOfferPerOrdinaryShare_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This expresses the amount of cash Novartis paid to the owners of AAA per ordinary share.</link:label>
      <link:label id="id_4036843c" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This expresses a maximal amount.</link:label>
      <link:label id="id_64640b79" xlink:label="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This expresses a limit.</link:label>
      <link:label id="id_177cac6" xlink:label="lbl_ReclassificationFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This is a reclassification that can be debit or credit.</link:label>
      <link:label id="id_5fdbc2b7" xlink:label="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This amount can be a debit or a credit as the table discloses the fair value gain and loses on assets and liabilities.</link:label>
      <link:label id="id_314a813f" xlink:label="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This amount can be a debit or a credit as the table discloses the fair value gain and loses on assets and liabilities.</link:label>
      <link:label id="id_4962d3fd" xlink:label="lbl_SellingGeneralAndAdministrativeExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expense</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SellingGeneralAndAdministrativeExpense" xlink:to="lbl_SellingGeneralAndAdministrativeExpense_labels" xlink:type="arc"/>
      <link:label id="id_1f242104" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through other changes, equity</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:to="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_labels" xlink:type="arc"/>
      <link:label id="id_5aa89188" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other movements</link:label>
      <link:label id="id_94ddbe4" xlink:label="lbl_label156097508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change over period [axis]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_label156097508" xlink:type="arc"/>
      <link:label id="id_4cdc11a9" xlink:label="lbl_label1289490857" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reported value [member]</link:label>
      <link:label id="id_501954f0" xlink:label="lbl_label1343837424" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change over period [member]</link:label>
      <link:label id="id_22153d9b" xlink:label="lbl_label571817371" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change to prior year-end [member]</link:label>
      <link:label id="id_dc043" xlink:label="lbl_NetDebt_labels2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net debt</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NetDebt" xlink:label="lbl_NetDebt1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetDebt1" xlink:to="lbl_NetDebt_labels2" xlink:type="arc"/>
      <link:label id="id_8969c68" xlink:label="lbl_NetDebt_labels2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net debt</link:label>
      <link:label id="id_641074d9" xlink:label="lbl_NetDebt_labels2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net debt</link:label>
      <link:label id="id_476a5a91" xlink:label="lbl_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="lbl_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="lbl_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_1548f70e" xlink:label="lbl_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of preparation</link:label>
      <link:label id="id_2c18deb" xlink:label="lbl_label46239211" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of preparation [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BasisOfPreparationAbstract" xlink:label="lbl_BasisOfPreparationAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BasisOfPreparationAbstract" xlink:to="lbl_label46239211" xlink:type="arc"/>
      <link:label id="id_2df428b0" xlink:label="lbl_label770975920" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selected critical accounting policies [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SelectedCriticalAccountingPoliciesAbstract" xlink:label="lbl_SelectedCriticalAccountingPoliciesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SelectedCriticalAccountingPoliciesAbstract" xlink:to="lbl_label770975920" xlink:type="arc"/>
      <link:label id="id_2a3a2ba4" xlink:label="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selected critical accounting policies</link:label>
      <link:label id="id_6b45f171" xlink:label="lbl_DisclosureOfEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of equity attributable to Novartis AG shareholders</link:label>
      <link:label id="id_2c2ab3f2" xlink:label="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial instruments</link:label>
      <link:label id="id_4dd6c758" xlink:label="lbl_label1305921368" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal proceedings update [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LegalProceedingsUpdateAbstract" xlink:label="lbl_LegalProceedingsUpdateAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LegalProceedingsUpdateAbstract" xlink:to="lbl_label1305921368" xlink:type="arc"/>
      <link:label id="id_62d75963" xlink:label="lbl_LegalProceedingsUpdateTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal proceedings update [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LegalProceedingsUpdateTextBlock" xlink:label="lbl_LegalProceedingsUpdateTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LegalProceedingsUpdateTextBlock" xlink:to="lbl_LegalProceedingsUpdateTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_47116fe6" xlink:label="lbl_LegalProceedingsUpdateTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal proceedings update</link:label>
      <link:label id="id_6f65ab76" xlink:label="lbl_label1868934006" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impacts of adoption of new IFRS standards [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactsOfAdoptionOfNewIFRSStandardsAbstract" xlink:label="lbl_ImpactsOfAdoptionOfNewIFRSStandardsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactsOfAdoptionOfNewIFRSStandardsAbstract" xlink:to="lbl_label1868934006" xlink:type="arc"/>
      <link:label id="id_73aff3ab" xlink:label="lbl_label200796173" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impacts of adoption of new IFRS standards [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactsOfAdoptionOfNewIFRSStandardsTextBlock" xlink:label="lbl_ImpactsOfAdoptionOfNewIFRSStandardsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactsOfAdoptionOfNewIFRSStandardsTextBlock" xlink:to="lbl_label200796173" xlink:type="arc"/>
      <link:label id="id_9aad709" xlink:label="lbl_label162191113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for available-for-sale financial assets [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:to="lbl_label162191113" xlink:type="arc"/>
      <link:label id="id_59f07686" xlink:label="lbl_label1508931206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial instruments [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="lbl_label1508931206" xlink:type="arc"/>
      <link:label id="id_4a00f82a" xlink:label="lbl_label1241577514" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for Revenue from Contracts with Customers [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:to="lbl_label1241577514" xlink:type="arc"/>
      <link:label id="id_68958299" xlink:label="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for other revenue [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_68991831" xlink:label="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
      <link:label id="id_5460feda" xlink:label="lbl_label1415642842" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated balance sheet by the adoption of IFRS 15 [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ConsolidatedBalanceSheetByTheAdoptionOfIFRS15TableTextBlock" xlink:label="lbl_ConsolidatedBalanceSheetByTheAdoptionOfIFRS15TableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsolidatedBalanceSheetByTheAdoptionOfIFRS15TableTextBlock" xlink:to="lbl_label1415642842" xlink:type="arc"/>
      <link:label id="id_5b4e8ef2" xlink:label="lbl_label1531875058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated statement of changes in equity by the adoption of IFRS 9 and IFRS 15 [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ConsolidatedStatementOfChangesInEquityByTheAdoptionOfIFRS9AndIFRS15TableTextBlock" xlink:label="lbl_ConsolidatedStatementOfChangesInEquityByTheAdoptionOfIFRS9AndIFRS15TableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsolidatedStatementOfChangesInEquityByTheAdoptionOfIFRS9AndIFRS15TableTextBlock" xlink:to="lbl_label1531875058" xlink:type="arc"/>
      <link:label id="id_e7f3472" xlink:label="lbl_label243217522" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments additional disclosures table by the adoption of IFRS 9 [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsAdditionalDisclosuresTableByTheAdoptionOfIFRS9TableTextBlock" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosuresTableByTheAdoptionOfIFRS9TableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosuresTableByTheAdoptionOfIFRS9TableTextBlock" xlink:to="lbl_label243217522" xlink:type="arc"/>
      <link:label id="id_71771d90" xlink:label="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net sales by region</link:label>
      <link:label id="id_4f219465" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments, net sales of Top 20 products [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:to="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2b8de385" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales of Top 20 products</link:label>
      <link:label id="id_45ec2147" xlink:label="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments, other revenue [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:to="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7f01fd05" xlink:label="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
      <link:label id="id_1894478a" xlink:label="lbl_AveXisIncMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AveXis, Inc. [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AveXisIncMember" xlink:label="lbl_AveXisIncMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AveXisIncMember" xlink:to="lbl_AveXisIncMember_labels" xlink:type="arc"/>
      <link:label id="id_43b60602" xlink:label="lbl_AveXisIncMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AveXis, Inc.</link:label>
      <link:label id="id_6a7073ad" xlink:label="lbl_label1785754541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retrospective application and retrospective restatement [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_label1785754541" xlink:type="arc"/>
      <link:label id="id_33459cb3" xlink:label="lbl_label860200115" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currently stated [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestatedMember" xlink:to="lbl_label860200115" xlink:type="arc"/>
      <link:label id="id_41804a67" xlink:label="lbl_label1098926695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previously stated [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PreviouslyStatedMember" xlink:to="lbl_label1098926695" xlink:type="arc"/>
      <link:label id="id_d0e08b6" xlink:label="lbl_label217930333" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy and corrections of prior period errors [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_label217930333" xlink:type="arc"/>
      <link:label id="id_4a438f95" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy, IFRS 9 [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member_labels" xlink:type="arc"/>
      <link:label id="id_68a9252d" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment, IFRS 9</link:label>
      <link:label id="id_3803c2cc" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy, IFRS 15 [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member_labels" xlink:type="arc"/>
      <link:label id="id_7f440478" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment, IFRS 15</link:label>
      <link:label id="id_6cbd5ed8" xlink:label="lbl_OCIReservesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI reserves [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OCIReservesMember" xlink:label="lbl_OCIReservesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OCIReservesMember" xlink:to="lbl_OCIReservesMember_labels" xlink:type="arc"/>
      <link:label id="id_37bd32c4" xlink:label="lbl_OCIReservesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OCI reserves</link:label>
      <link:label id="id_3071cdbf" xlink:label="lbl_label812764607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retail Generics [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetailGenericsMember" xlink:label="lbl_RetailGenericsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RetailGenericsMember" xlink:to="lbl_label812764607" xlink:type="arc"/>
      <link:label id="id_22d00e67" xlink:label="lbl_label584060519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biopharmaceuticals [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BiopharmaceuticalsMember" xlink:label="lbl_BiopharmaceuticalsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BiopharmaceuticalsMember" xlink:to="lbl_label584060519" xlink:type="arc"/>
      <link:label id="id_74e760f" xlink:label="lbl_label122582543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anti Infectives [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AntiInfectivesMember" xlink:label="lbl_AntiInfectivesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AntiInfectivesMember" xlink:to="lbl_label122582543" xlink:type="arc"/>
      <link:label id="id_2e5631da" xlink:label="lbl_label777400794" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Surgical [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SurgicalMember" xlink:label="lbl_SurgicalMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SurgicalMember" xlink:to="lbl_label777400794" xlink:type="arc"/>
      <link:label id="id_5a63105" xlink:label="lbl_label94777605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vision Care [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VisionCareMember" xlink:label="lbl_VisionCareMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VisionCareMember" xlink:to="lbl_label94777605" xlink:type="arc"/>
      <link:label id="id_33d2b620" xlink:label="lbl_label869447200" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consumables [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ConsumablesMember" xlink:label="lbl_ConsumablesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsumablesMember" xlink:to="lbl_label869447200" xlink:type="arc"/>
      <link:label id="id_3fe1336c" xlink:label="lbl_label1071723372" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Implantables [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImplantablesMember" xlink:label="lbl_ImplantablesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImplantablesMember" xlink:to="lbl_label1071723372" xlink:type="arc"/>
      <link:label id="id_6d32d4c6" xlink:label="lbl_label1832047814" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment/Other [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquipmentOtherMember" xlink:label="lbl_EquipmentOtherMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquipmentOtherMember" xlink:to="lbl_label1832047814" xlink:type="arc"/>
      <link:label id="id_9208315" xlink:label="lbl_label153125653" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ophthalmic OTC [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OphthalmicOTCMember" xlink:label="lbl_OphthalmicOTCMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OphthalmicOTCMember" xlink:to="lbl_label153125653" xlink:type="arc"/>
      <link:label id="id_3d77d223" xlink:label="lbl_label1031262755" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contact lens care [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContactLensCareMember" xlink:label="lbl_ContactLensCareMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContactLensCareMember" xlink:to="lbl_label1031262755" xlink:type="arc"/>
      <link:label id="id_5ff6168e" xlink:label="lbl_label1609963150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top 20 products [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_Top20ProductsMember" xlink:label="lbl_Top20ProductsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Top20ProductsMember" xlink:to="lbl_label1609963150" xlink:type="arc"/>
      <link:label id="id_1bc8878f" xlink:label="lbl_label466126735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rest of portfolio [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RestOfPortfolioMember" xlink:label="lbl_RestOfPortfolioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestOfPortfolioMember" xlink:to="lbl_label466126735" xlink:type="arc"/>
      <link:label id="id_60f02df8" xlink:label="lbl_label1626353144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty income</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromRoyalties" xlink:label="lbl_RevenueFromRoyalties" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromRoyalties" xlink:to="lbl_label1626353144" xlink:type="arc"/>
      <link:label id="id_132c5856" xlink:label="lbl_label321673302" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit sharing income</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProfitSharingIncome" xlink:label="lbl_ProfitSharingIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitSharingIncome" xlink:to="lbl_label321673302" xlink:type="arc"/>
      <link:label id="id_dd742a8" xlink:label="lbl_label232211112" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone income</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MilestoneIncome" xlink:label="lbl_MilestoneIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MilestoneIncome" xlink:to="lbl_label232211112" xlink:type="arc"/>
      <link:label id="id_31af75cd" xlink:label="lbl_OtherRevenueOther_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenue, other</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherRevenueOther" xlink:label="lbl_OtherRevenueOther" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherRevenueOther" xlink:to="lbl_OtherRevenueOther_labels" xlink:type="arc"/>
      <link:label id="id_41473bf" xlink:label="lbl_OtherRevenueOther_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
      <link:label id="id_22e4d15f" xlink:label="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from operating activities, as a percentage from net sales</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:label="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:to="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales_labels" xlink:type="arc"/>
      <link:label id="id_3e5bb44f" xlink:label="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating income as % of net sales</link:label>
      <link:label id="id_3761b8d8" xlink:label="lbl_label929151192" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada and Latin America [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CanadaAndLatinAmericaMember" xlink:label="lbl_CanadaAndLatinAmericaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CanadaAndLatinAmericaMember" xlink:to="lbl_label929151192" xlink:type="arc"/>
      <link:label id="id_35dc7c05" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, third parties, change in percent, cc</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc_labels" xlink:type="arc"/>
      <link:label id="id_2402bc9" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales, change in %, cc</link:label>
      <link:label id="id_11578a03" xlink:label="lbl_label290949635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Established Markets [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EstablishedMarketsMember" xlink:label="lbl_EstablishedMarketsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstablishedMarketsMember" xlink:to="lbl_label290949635" xlink:type="arc"/>
      <link:label id="id_1e6859ac" xlink:label="lbl_label510155180" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Emerging Growth Markets [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EmergingGrowthMarketsMember" xlink:label="lbl_EmergingGrowthMarketsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EmergingGrowthMarketsMember" xlink:to="lbl_label510155180" xlink:type="arc"/>
      <link:label id="id_395d61a2" xlink:label="lbl_label962421154" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rest of the world [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RestOfTheWorldMember" xlink:label="lbl_RestOfTheWorldMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestOfTheWorldMember" xlink:to="lbl_label962421154" xlink:type="arc"/>
      <link:label id="id_2aeb33db" xlink:label="lbl_TreasurySharesAcquiredToBeCancelled_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares acquired to be cancelled</link:label>
      <link:label id="id_16be2f1a" xlink:label="lbl_TreasurySharesAcquiredForCancellationValue_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares acquired for cancellation, equity impact</link:label>
      <link:label id="id_14bac1b3" xlink:label="lbl_StockRepurchaseProgramAuthorizedAmount1_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase of treasury share repurchase obligation under a share buyback trading plan</link:label>
      <link:label id="id_10768f17" xlink:label="lbl_label276205335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.5% EUR 750 million 2018/2023 of Novartis [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.5EUR750Million20182023OfNovartisMember" xlink:label="lbl_A0.5EUR750Million20182023OfNovartisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.5EUR750Million20182023OfNovartisMember" xlink:to="lbl_label276205335" xlink:type="arc"/>
      <link:label id="id_6c222bbb" xlink:label="lbl_label1814178747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.375% EUR 750 million 2018/2030 of Novartis [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1.375EUR750Million20182030OfNovartisMember" xlink:label="lbl_A1.375EUR750Million20182030OfNovartisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.375EUR750Million20182030OfNovartisMember" xlink:to="lbl_label1814178747" xlink:type="arc"/>
      <link:label id="id_42e49e27" xlink:label="lbl_label1122278951" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.7% EUR 750 million 2018/2038 of Novartis [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1.7EUR750Million20182038OfNovartisMember" xlink:label="lbl_A1.7EUR750Million20182038OfNovartisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.7EUR750Million20182038OfNovartisMember" xlink:to="lbl_label1122278951" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GalvusGroupMember" xlink:label="lbl_GalvusGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GalvusGroupMember" xlink:to="lbl_label195411774" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DiovanGroupMember" xlink:label="lbl_DiovanGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DiovanGroupMember" xlink:to="lbl_label1973931633" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExforgeGroupMember" xlink:label="lbl_ExforgeGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExforgeGroupMember" xlink:to="lbl_label1243142238" xlink:type="arc"/>
      <link:label id="id_15727011" xlink:label="lbl_label359821329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Immunology, Hepatology and Dermatology [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImmunologyHepatologyAndDermatologyMember" xlink:label="lbl_ImmunologyHepatologyAndDermatologyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImmunologyHepatologyAndDermatologyMember" xlink:to="lbl_label359821329" xlink:type="arc"/>
      <link:label id="id_86e5c43" xlink:label="lbl_label141450307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anti Infectives sold under Sandoz name [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AntiInfectivesSoldUnderSandozNameMember" xlink:label="lbl_AntiInfectivesSoldUnderSandozNameMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AntiInfectivesSoldUnderSandozNameMember" xlink:to="lbl_label141450307" xlink:type="arc"/>
      <link:label id="id_194d5f34" xlink:label="lbl_label424501044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combinations [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:label="lbl_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:to="lbl_label424501044" xlink:type="arc"/>
      <link:label id="id_4f78aa77" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on financial assets sold</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsOnFinancialAssetsSold" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:to="lbl_FairValueAdjustmentsOnFinancialAssetsSold_labels" xlink:type="arc"/>
      <link:label id="id_73e25c53" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets or disposal groups classified as held for sale</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_labels" xlink:type="arc"/>
      <link:label id="id_7e4ea322" xlink:label="lbl_label2119082786" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_label2119082786" xlink:type="arc"/>
      <link:label id="id_306dde36" xlink:label="lbl_label812506678" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy required by IFRSs [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:to="lbl_label812506678" xlink:type="arc"/>
      <link:label id="id_474e15ff" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets of disposal group held for sale</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherSharePurchasesValue" xlink:label="lbl_OtherSharePurchasesValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherSharePurchasesValue" xlink:to="lbl_OtherSharePurchasesValue_labels" xlink:type="arc"/>
      <link:label id="id_6ae68310" xlink:label="lbl_label1793491728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lutathera [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LutatheraMember" xlink:label="lbl_LutatheraMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LutatheraMember" xlink:to="lbl_label1793491728" xlink:type="arc"/>
      <link:label id="id_5ba5546c" xlink:label="lbl_label1537561708" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kymriah [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KymriahMember" xlink:label="lbl_KymriahMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KymriahMember" xlink:to="lbl_label1537561708" xlink:type="arc"/>
      <link:label id="id_6c54b8f7" xlink:label="lbl_label1817491703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of share capital tendered at the subsequent offering period of the tender offer</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:to="lbl_label1817491703" xlink:type="arc"/>
      <link:label id="id_a269182" xlink:label="lbl_label170299778" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration paid for share capital tendered at the subsequent offering period of the tender offer</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:to="lbl_label170299778" xlink:type="arc"/>
      <link:label id="id_7317bbcb" xlink:label="lbl_label1930935243" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total percentage of share capital tendered after the subsequent offering period of the tender offer</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:to="lbl_label1930935243" xlink:type="arc"/>
      <link:label id="id_57adc4f7" xlink:label="lbl_TransactionCostsRecordedInEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction costs recorded in Equity [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TransactionCostsRecordedInEquityTextBlock" xlink:label="lbl_TransactionCostsRecordedInEquityTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionCostsRecordedInEquityTextBlock" xlink:to="lbl_TransactionCostsRecordedInEquityTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_281ffdcd" xlink:label="lbl_TransactionCostsRecordedInEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs recorded in Equity</link:label>
      <link:label id="id_2cc49159" xlink:label="lbl_TransactionCostsRecordedInEquityPaid_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction costs recorded in equity paid</link:label>
      <link:label id="id_7df5c0c1" xlink:label="lbl_label2113257665" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transactions with related parties [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TransactionsWithRelatedPartiesAbstract" xlink:label="lbl_TransactionsWithRelatedPartiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionsWithRelatedPartiesAbstract" xlink:to="lbl_label2113257665" xlink:type="arc"/>
      <link:label id="id_5c1d5da7" xlink:label="lbl_label1309162706" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transactions with related parties [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TransactionsWithRelatedPartiesTextBlock" xlink:label="lbl_TransactionsWithRelatedPartiesTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionsWithRelatedPartiesTextBlock" xlink:to="lbl_label1309162706" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TransactionCostsRecordedInEquityPaid" xlink:label="lbl_TransactionCostsRecordedInEquityPaid" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionCostsRecordedInEquityPaid" xlink:to="lbl_TransactionCostsRecordedInEquityPaid_labels" xlink:type="arc"/>
      <link:label id="id_5de3849f" xlink:label="lbl_TransactionCostsRecordedInEquity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction costs recorded in equity</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TransactionCostsRecordedInEquity" xlink:label="lbl_TransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionCostsRecordedInEquity" xlink:to="lbl_TransactionCostsRecordedInEquity_labels" xlink:type="arc"/>
      <link:label id="id_154fa58" xlink:label="lbl_label22346328" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income recycled into the consolidated income statement</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:label="lbl_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:to="lbl_label22346328" xlink:type="arc"/>
      <link:label id="id_7c9a09e2" xlink:label="lbl_label2090469858" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase to retained earnings arising from first application of IFRS 9 fund investments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9FundInvestments" xlink:label="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9FundInvestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9FundInvestments" xlink:to="lbl_label2090469858" xlink:type="arc"/>
      <link:label id="id_36de49a0" xlink:label="lbl_label920537504" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase to retained earnings arising from first application of IFRS 9 equity securities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9EquitySecurities" xlink:label="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9EquitySecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9EquitySecurities" xlink:to="lbl_label920537504" xlink:type="arc"/>
      <link:label id="id_1e72baf" xlink:label="lbl_label31927215" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pension Fund [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPensionFundMember" xlink:label="lbl_NovartisPensionFundMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPensionFundMember" xlink:to="lbl_label31927215" xlink:type="arc"/>
      <link:label id="id_6d9924d1" xlink:label="lbl_label1838752977" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings credit facility uncommitted</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsCreditFacilityUncommitted" xlink:label="lbl_BorrowingsCreditFacilityUncommitted" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsCreditFacilityUncommitted" xlink:to="lbl_label1838752977" xlink:type="arc"/>
      <link:label id="id_60aed585" xlink:label="lbl_label1622070661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other net assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherNetAssets" xlink:label="lbl_OtherNetAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNetAssets" xlink:to="lbl_label1622070661" xlink:type="arc"/>
      <link:label id="id_25566515" xlink:label="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments from changes in ownership interests in subsidiaries that do not result in loss of control</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:label="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:to="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries_labels" xlink:type="arc"/>
      <link:label id="id_73ce5e23" xlink:label="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of change in ownership of consolidated entities</link:label>
      <link:label id="id_68208ecc" xlink:label="lbl_label1746964172" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ocular health [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OcularHealthMember" xlink:label="lbl_OcularHealthMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OcularHealthMember" xlink:to="lbl_label1746964172" xlink:type="arc"/>
      <link:label id="id_7d654567" xlink:label="lbl_label2103788903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.500% EUR 750 million 2018/2023 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.655% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:label="lbl_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:to="lbl_label2103788903" xlink:type="arc"/>
      <link:label id="id_a1b491f" xlink:label="lbl_label169560351" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.375% EUR 750 million 2018/2030 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.957% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:label="lbl_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:to="lbl_label169560351" xlink:type="arc"/>
      <link:label id="id_1f1416" xlink:label="lbl_label2036758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.700% EUR 750 million 2018/2038 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.217% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:label="lbl_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:to="lbl_label2036758" xlink:type="arc"/>
      <link:label id="id_63baf8ea" xlink:label="lbl_label1673197802" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications International SA, Geneve [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:label="lbl_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:to="lbl_label1673197802" xlink:type="arc"/>
      <link:label id="id_4bc832fa" xlink:label="lbl_label1271411450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications Switzerland SA, Geneve [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:label="lbl_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:to="lbl_label1271411450" xlink:type="arc"/>
      <link:label id="id_2658ed55" xlink:label="lbl_label643362133" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AveXis, Inc., Bannockburn, IL [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AveXisInc.BannockburnILMember" xlink:label="lbl_AveXisInc.BannockburnILMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AveXisInc.BannockburnILMember" xlink:to="lbl_label643362133" xlink:type="arc"/>
      <link:label id="id_358de13" xlink:label="lbl_label56155667" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications S.A., Saint Genis Pouilly [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember" xlink:label="lbl_AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember" xlink:to="lbl_label56155667" xlink:type="arc"/>
      <link:label id="id_480bc7a" xlink:label="lbl_BasicEarningsLossPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share</link:label>
      <link:label id="id_4f788787" xlink:label="lbl_DilutedEarningsLossPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share</link:label>
      <link:label id="id_579c77e7" xlink:label="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets other than non-current assets or disposal groups classified as held for sale or as held for distribution to owners</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_labels" xlink:type="arc"/>
      <link:label id="id_6e4a53e8" xlink:label="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets without disposal group</link:label>
      <link:label id="id_4c7ed954" xlink:label="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities other than liabilities included in disposal groups classified as held for sale</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_labels" xlink:type="arc"/>
      <link:label id="id_6f67d848" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities included in disposal groups classified as held for sale</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_labels" xlink:type="arc"/>
      <link:label id="id_41ef90c7" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities of disposal group held for sale</link:label>
      <link:label id="id_15dcecbd" xlink:label="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities without disposal group</link:label>
      <link:label id="id_6be52fb3" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share of other comprehensive income of associates and joint ventures accounted for using equity method that will be reclassified to profit or loss, net of tax</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:type="arc"/>
      <link:label id="id_2cc5f4f3" xlink:label="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income that will not be reclassified to profit or loss, net of tax</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:type="arc"/>
      <link:label id="id_4201ce33" xlink:label="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total of items never to be recycled</link:label>
      <link:label id="id_3dedbea0" xlink:label="lbl_SellingGeneralAndAdministrativeExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administration</link:label>
      <link:label id="id_24ee551" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations, property, plant and equipment</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_50cb4109" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_24ba2cbb" xlink:label="lbl_label616180923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal group held for sale [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisposalGroupHeldForSaleAbstract" xlink:label="lbl_DisposalGroupHeldForSaleAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalGroupHeldForSaleAbstract" xlink:to="lbl_label616180923" xlink:type="arc"/>
      <link:label id="id_2e51c9a9" xlink:label="lbl_label777111977" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities not classified as held for sale [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_label777111977" xlink:type="arc"/>
      <link:label id="id_54b5ab16" xlink:label="lbl_label1421191958" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities classified as held for sale [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:to="lbl_label1421191958" xlink:type="arc"/>
      <link:label id="id_620a76ae" xlink:label="lbl_label1644852910" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets held for sale [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsHeldForSaleMember" xlink:label="lbl_NoncurrentAssetsHeldForSaleMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAssetsHeldForSaleMember" xlink:to="lbl_label1644852910" xlink:type="arc"/>
      <link:label id="id_35b1993" xlink:label="lbl_label56301971" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal groups classified as held for sale [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:to="lbl_label56301971" xlink:type="arc"/>
      <link:label id="id_775bbb23" xlink:label="lbl_label2002500387" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities classified as held for sale [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_label2002500387" xlink:type="arc"/>
      <link:label id="id_76d4000c" xlink:label="lbl_label1993605132" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal group held for sale [line items]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisposalGroupHeldForSaleLineItems" xlink:label="lbl_DisposalGroupHeldForSaleLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalGroupHeldForSaleLineItems" xlink:to="lbl_label1993605132" xlink:type="arc"/>
      <link:label id="id_511c252" xlink:label="lbl_label85049938" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets of disposal group classified as held for sale [abstract]</link:label>
      <link:label id="id_3a8a761b" xlink:label="lbl_label982152731" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities of disposal group classified as held for sale [abstract]</link:label>
      <link:label id="id_7ebdc3d3" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in other current assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_196d02a3" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in other current assets</link:label>
      <link:label id="id_2004a2a3" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in other current liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_5c1266c3" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in other current liabilities</link:label>
      <link:label id="id_1b44e5e7" xlink:label="lbl_OtherAdjustmentsToReconcileProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other adjustments to reconcile profit (loss)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:label="lbl_OtherAdjustmentsToReconcileProfitLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherAdjustmentsToReconcileProfitLoss" xlink:to="lbl_OtherAdjustmentsToReconcileProfitLoss_labels" xlink:type="arc"/>
      <link:label id="id_753e354c" xlink:label="lbl_label1967011148" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in cash settled share based payments liabilities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:label="lbl_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:to="lbl_label1967011148" xlink:type="arc"/>
      <link:label id="id_3fb8017" xlink:label="lbl_OtherAdjustmentsToReconcileProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other adjustments, net</link:label>
      <link:label id="id_45184c03" xlink:label="lbl_CashInflowOutflowNoncontrollingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow), Non-controlling interests</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashInflowOutflowNoncontrollingInterests" xlink:label="lbl_CashInflowOutflowNoncontrollingInterests" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowNoncontrollingInterests" xlink:to="lbl_CashInflowOutflowNoncontrollingInterests_labels" xlink:type="arc"/>
      <link:label id="id_3e6c4694" xlink:label="lbl_CashInflowOutflowNoncontrollingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
      <link:label id="id_773be135" xlink:label="lbl_label1852230229" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount recorded in equity related to hyperinflation</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountRecordedInEquityRelatedToHyperinflation" xlink:label="lbl_AmountRecordedInEquityRelatedToHyperinflation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountRecordedInEquityRelatedToHyperinflation" xlink:to="lbl_label1852230229" xlink:type="arc"/>
      <link:label id="id_73d5e167" xlink:label="lbl_AdditionsToInvestmentInAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions to investment in associated companies</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdditionsToInvestmentInAssociatedCompanies" xlink:label="lbl_AdditionsToInvestmentInAssociatedCompanies" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsToInvestmentInAssociatedCompanies" xlink:to="lbl_AdditionsToInvestmentInAssociatedCompanies_labels" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:label id="id_1341dbff" xlink:label="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:to="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_346b395c" xlink:label="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_4b1ad4e8" xlink:label="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through obtaining or losing control of subsidiaries or other businesses, liabilities arising from financing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:to="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_2fcaf057" xlink:label="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations and divestments</link:label>
      <link:label id="id_17118b46" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment recognised as of acquisition date</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:to="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_1d85e3c0" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
      <link:label id="id_4b8f7d44" xlink:label="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and other assets including deferred tax assets recognised as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:to="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_2918e43e" xlink:label="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial and other assets including deferred tax assets</link:label>
      <link:label id="id_5abfc6c6" xlink:label="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities recognised as of acquisition date</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_40924196" xlink:label="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current and non-current financial debts</link:label>
      <link:label id="id_4016f674" xlink:label="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-controlling interest in acquiree recognised at acquisition date</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:label="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:to="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_2ea65efd" xlink:label="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
      <link:label id="id_2375ce31" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, debt securities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities_labels" xlink:type="arc"/>
      <link:label id="id_56d0df79" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on debt securities, net of taxes</link:label>
      <link:label id="id_4663183e" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="locator"/>
      <link:label id="id_40c6b8fb" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions_labels" xlink:type="arc"/>
      <link:label id="id_3261fe4" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation, equity impact</link:label>
      <link:label id="id_cb4c548" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</link:label>
      <link:label id="id_2a76513b" xlink:label="lbl_TransactionCosts_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction costs</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TransactionCosts" xlink:label="lbl_TransactionCosts" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionCosts" xlink:to="lbl_TransactionCosts_labels" xlink:type="arc"/>
      <link:label id="id_19c4929e" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain on divestment of interests in associated companies</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:to="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies_labels" xlink:type="arc"/>
      <link:label id="id_2500459a" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on divestment</link:label>
      <link:label id="id_198075f2" xlink:label="lbl_FairValueAdjustmentsOnDebtSecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on debt securities [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:to="lbl_FairValueAdjustmentsOnDebtSecuritiesMember_labels" xlink:type="arc"/>
      <link:label id="id_3f9715cf" xlink:label="lbl_FairValueAdjustmentsOnDebtSecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on debt securities</link:label>
      <link:label id="id_76d81b48" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on equity securities [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:to="lbl_FairValueAdjustmentsOnEquitySecuritiesMember_labels" xlink:type="arc"/>
      <link:label id="id_57bce160" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on equity securities</link:label>
      <link:label id="id_1fb67de2" xlink:label="lbl_label532053474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification to presentation required under IFRS 9 [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:label="lbl_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:to="lbl_label532053474" xlink:type="arc"/>
      <link:label id="id_714a2d9" xlink:label="lbl_label118792921" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restated Value Adjustments [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RestatedValueAdjustmentsMember" xlink:label="lbl_RestatedValueAdjustmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestatedValueAdjustmentsMember" xlink:to="lbl_label118792921" xlink:type="arc"/>
      <link:label id="id_4587be64" xlink:label="lbl_label1595406142" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial assets, equity investments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentFinancialAssetsEquityInvestments" xlink:label="lbl_NoncurrentFinancialAssetsEquityInvestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialAssetsEquityInvestments" xlink:to="lbl_label1595406142" xlink:type="arc"/>
      <link:label id="id_2b6a8c9e" xlink:label="lbl_label858249235" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial assets, fund investments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentFinancialAssetsFundInvestments" xlink:label="lbl_NoncurrentFinancialAssetsFundInvestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialAssetsFundInvestments" xlink:to="lbl_label858249235" xlink:type="arc"/>
      <link:label id="id_6be6dda0" xlink:label="lbl_label1810292128" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:to="lbl_label1810292128" xlink:type="arc"/>
      <link:label id="id_ea4af2a" xlink:label="lbl_label245673770" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_label245673770" xlink:type="arc"/>
      <link:label id="id_341eabcf" xlink:label="lbl_label874425295" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_label874425295" xlink:type="arc"/>
      <link:label id="id_2ef67b59" xlink:label="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in equity instruments designated at fair value through other comprehensive income</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:label="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:to="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_labels" xlink:type="arc"/>
      <link:label id="id_2bbf6984" xlink:label="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities</link:label>
      <link:label id="id_5be6a6ba" xlink:label="lbl_label1541842618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in equity instruments designated at fair value through other comprehensive income [axis]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:to="lbl_label1541842618" xlink:type="arc"/>
      <link:label id="id_5b1cb05e" xlink:label="lbl_label1528606814" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in equity instruments designated at fair value through other comprehensive income [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lbl_label1528606814" xlink:type="arc"/>
      <link:label id="id_131c72f5" xlink:label="lbl_label320631541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Listed equity securities [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ListedEquitySecuritiesMember" xlink:label="lbl_ListedEquitySecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ListedEquitySecuritiesMember" xlink:to="lbl_label320631541" xlink:type="arc"/>
      <link:label id="id_58943bff" xlink:label="lbl_label1486109695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-listed equity securities [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonlistedEquitySecuritiesMember" xlink:label="lbl_NonlistedEquitySecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonlistedEquitySecuritiesMember" xlink:to="lbl_label1486109695" xlink:type="arc"/>
      <link:label id="id_466ea37d" xlink:label="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of assets of disposal group classified as held for sale [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:label="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:to="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_328aa9b8" xlink:label="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets of disposal group classified as held for sale</link:label>
      <link:label id="id_663782d5" xlink:label="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of liabilities of disposal group classified as held for sale [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:label="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:to="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5f98604f" xlink:label="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities of disposal group classified as held for sale</link:label>
      <link:label id="id_1786ac50" xlink:label="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:label="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:to="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_33784e41" xlink:label="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities measured at fair value through other comprehensive income</link:label>
      <link:label id="id_2785f328" xlink:label="lbl_EndocyteMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Endocyte [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EndocyteMember" xlink:label="lbl_EndocyteMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EndocyteMember" xlink:to="lbl_EndocyteMember_labels" xlink:type="arc"/>
      <link:label id="id_1ab891f2" xlink:label="lbl_EndocyteMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Endocyte</link:label>
      <link:label id="id_559cd899" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial assets, cash and cash equivalents [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_63b9b41c" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:label id="id_172750e3" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial assets, marketable securities, commodities and non-current financial assets [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7ca31c97" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, commodities and non-current financial assets</link:label>
      <link:label id="id_447d705c" xlink:label="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net sales and selected non-current assets, by countries and regions [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:to="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_36daedff" xlink:label="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales and selected non-current assets, by countries and regions</link:label>
      <link:label id="id_24f609b0" xlink:label="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net sales, by segements and regions [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:to="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_27432d26" xlink:label="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales by region</link:label>
      <link:label id="id_4192e6ea" xlink:label="lbl_label235032989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of nature of change in accounting policy</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:label="lbl_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:to="lbl_label235032989" xlink:type="arc"/>
      <link:label id="id_457ba061" xlink:label="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divestments aquisitions of interests in associated companies</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:label="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:to="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies_labels" xlink:type="arc"/>
      <link:label id="id_49d2e101" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through classified as held for sale, property, plant and equipment</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:to="lbl_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_625c07b4" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of assets related to disposal group held for sale</link:label>
      <link:label id="id_6066a3c9" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through classified as held for sale, intangible assets and goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:to="lbl_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_580b40b6" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of assets related to disposal group held for sale</link:label>
      <link:label id="id_3af4fc23" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of assets related to disposal group held for sale</link:label>
      <link:label id="id_6cd0a23e" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net deferred tax balance related to disposal group held for sale</link:label>
      <link:label id="id_7f1eeac9" xlink:label="lbl_OtherShareSales_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other share sales</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherShareSales" xlink:label="lbl_OtherShareSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherShareSales" xlink:to="lbl_OtherShareSales_labels" xlink:type="arc"/>
      <link:label id="id_7be3c1db" xlink:label="lbl_OtherShareSales_labels" xlink:role="http://www.xbrl.org/2003/role/negativeLabel" xlink:type="resource" xml:lang="en-US">Other share sales</link:label>
      <link:label id="id_6d6afa95" xlink:label="lbl_label1359067097" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other share sales, equity impact</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherShareSalesEquityImpact" xlink:label="lbl_OtherShareSalesEquityImpact" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherShareSalesEquityImpact" xlink:to="lbl_label1359067097" xlink:type="arc"/>
      <link:label id="id_3b6caa8a" xlink:label="lbl_NumberOfOtherShareSales_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other share sales</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfOtherShareSales" xlink:label="lbl_NumberOfOtherShareSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOtherShareSales" xlink:to="lbl_NumberOfOtherShareSales_labels" xlink:type="arc"/>
      <link:label id="id_6db1b7c2" xlink:label="lbl_NumberOfOtherShareSales_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other share sales</link:label>
      <link:label id="id_2d79675e" xlink:label="lbl_NumberOfOtherShareSalesEquityImpact_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other share sales, equity impact</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfOtherShareSalesEquityImpact" xlink:label="lbl_NumberOfOtherShareSalesEquityImpact" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOtherShareSalesEquityImpact" xlink:to="lbl_NumberOfOtherShareSalesEquityImpact_labels" xlink:type="arc"/>
      <link:label id="id_4f13fea7" xlink:label="lbl_NumberOfOtherShareSalesEquityImpact_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other share sales, equity impact</link:label>
      <link:label id="id_35d72bee" xlink:label="lbl_label903293934" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, debt securities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeDebtSecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeDebtSecurities" xlink:to="lbl_label903293934" xlink:type="arc"/>
      <link:label id="id_269c946a" xlink:label="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, equity securities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:to="lbl_label1931018935" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:to="lbl_label1923652241" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozPtyLtdMacquarieParkNSWMember" xlink:label="lbl_SandozPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozPtyLtdMacquarieParkNSWMember" xlink:to="lbl_label1031360833" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:to="lbl_label409451279" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaNVVilvoordeMember" xlink:label="lbl_NovartisPharmaNVVilvoordeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaNVVilvoordeMember" xlink:to="lbl_label861091593" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozNVVilvoordeMember" xlink:label="lbl_SandozNVVilvoordeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozNVVilvoordeMember" xlink:to="lbl_label102668381" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconCouvreurNVPuursMember" xlink:label="lbl_AlconCouvreurNVPuursMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconCouvreurNVPuursMember" xlink:to="lbl_label1808949392" xlink:type="arc"/>
      <link:label id="id_20428b8c" xlink:label="lbl_label541232012" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories Belgium BVBA, Puurs [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:label="lbl_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:to="lbl_label541232012" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconNVVilvoordeMember" xlink:label="lbl_AlconNVVilvoordeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconNVVilvoordeMember" xlink:to="lbl_label1193123279" xlink:type="arc"/>
      <link:label id="id_7f713e00" xlink:label="lbl_label2138127872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon AG, Fribourg [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconAGFribourgMember" xlink:label="lbl_AlconAGFribourgMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconAGFribourgMember" xlink:to="lbl_label2138127872" xlink:type="arc"/>
      <link:label id="id_3e12064" xlink:label="lbl_label65085540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications USA, Inc., New York, NY [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:to="lbl_label65085540" xlink:type="arc"/>
      <link:label id="id_749e4361" xlink:label="lbl_label1956528993" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIBA Vision Corporation LLC, Duluth, GA [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CIBAVisionCorporationLLCDuluthGAMember" xlink:label="lbl_CIBAVisionCorporationLLCDuluthGAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CIBAVisionCorporationLLCDuluthGAMember" xlink:to="lbl_label1956528993" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:label="lbl_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:to="lbl_label426571388" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPolandSp.ZO.o.WarsawMember" xlink:label="lbl_NovartisPolandSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPolandSp.ZO.o.WarsawMember" xlink:to="lbl_label1610589901" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozPolskaSp.ZO.o.WarsawMember" xlink:label="lbl_SandozPolskaSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozPolskaSp.ZO.o.WarsawMember" xlink:to="lbl_label1898723838" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconPolskaSp.ZO.o.WarsawMember" xlink:label="lbl_AlconPolskaSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPolskaSp.ZO.o.WarsawMember" xlink:to="lbl_label1959302877" xlink:type="arc"/>
      <link:label id="id_6d8d3375" xlink:label="lbl_label1837970293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Healthcare, S.A., Barcelona [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconHealthcareS.A.BarcelonaMember" xlink:label="lbl_AlconHealthcareS.A.BarcelonaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconHealthcareS.A.BarcelonaMember" xlink:to="lbl_label1837970293" xlink:type="arc"/>
      <link:label id="id_3892d07e" xlink:label="lbl_label949145726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Ophthalmics AG, Fribourg [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisOphthalmicsAGFribourgMember" xlink:label="lbl_NovartisOphthalmicsAGFribourgMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisOphthalmicsAGFribourgMember" xlink:to="lbl_label949145726" xlink:type="arc"/>
      <link:label id="id_5097f514" xlink:label="lbl_label1352135956" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Ukraine LLC, Kyiv [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozUkraineLLCKievMember" xlink:label="lbl_SandozUkraineLLCKievMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozUkraineLLCKievMember" xlink:to="lbl_label1352135956" xlink:type="arc"/>
      <link:label id="id_68b9cbd5" xlink:label="lbl_label1757006805" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divestment cost to sell</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DivestmentCostToSell" xlink:label="lbl_DivestmentCostToSell" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DivestmentCostToSell" xlink:to="lbl_label1757006805" xlink:type="arc"/>
      <link:label id="id_3bde338f" xlink:label="lbl_label1004417935" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount of settlement in principle</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountOfSettlementInPrinciple" xlink:label="lbl_AmountOfSettlementInPrinciple" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountOfSettlementInPrinciple" xlink:to="lbl_label1004417935" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:label="lbl_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:to="lbl_label969930944" xlink:type="arc"/>
      <link:label id="id_54d2c7cf" xlink:label="lbl_label1423099855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of products in portfolio to be sold</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfProductsInPortfolioToBeSold" xlink:label="lbl_NumberOfProductsInPortfolioToBeSold" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfProductsInPortfolioToBeSold" xlink:to="lbl_label1423099855" xlink:type="arc"/>
      <link:label id="id_4f5a93ca" xlink:label="lbl_label1331336138" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying value of the divested business</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CarryingValueOfTheDivestedBusiness" xlink:label="lbl_CarryingValueOfTheDivestedBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CarryingValueOfTheDivestedBusiness" xlink:to="lbl_label1331336138" xlink:type="arc"/>
      <link:label id="id_2bfacba6" xlink:label="lbl_label737856422" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short term leases and low value leases</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ShortTermLeasesAndLowValueLeases" xlink:label="lbl_ShortTermLeasesAndLowValueLeases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShortTermLeasesAndLowValueLeases" xlink:to="lbl_label737856422" xlink:type="arc"/>
      <link:label id="id_1638753" xlink:label="lbl_label23299923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remaining lease commitments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RemainingLeaseCommitments" xlink:label="lbl_RemainingLeaseCommitments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RemainingLeaseCommitments" xlink:to="lbl_label23299923" xlink:type="arc"/>
      <link:label id="id_3c454913" xlink:label="lbl_label1011173651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities to be recognized</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LeaseLiabilitiesToBeRecognized" xlink:label="lbl_LeaseLiabilitiesToBeRecognized" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseLiabilitiesToBeRecognized" xlink:to="lbl_label1011173651" xlink:type="arc"/>
      <link:label id="id_46c00732" xlink:label="lbl_label1186989874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right of use assets to be recognized</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RightOfUseAssetsToBeRecognized" xlink:label="lbl_RightOfUseAssetsToBeRecognized" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RightOfUseAssetsToBeRecognized" xlink:to="lbl_label1186989874" xlink:type="arc"/>
      <link:label id="id_5c114913" xlink:label="lbl_label1544636691" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss/gain recorded on equity securities and fund investments at fair value through the consolidated income statement</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:label="lbl_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:to="lbl_label1544636691" xlink:type="arc"/>
      <link:label id="id_c04ac79" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on equity securities, net of taxes</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_labels" xlink:type="arc"/>
      <link:label id="id_5fb3768f" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, gains (losses) from investments in equity instruments</link:label>
      <link:label id="id_4dc28e6d" xlink:label="lbl_DeferredTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax expense (income)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="lbl_DeferredTaxExpenseIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxExpenseIncome" xlink:to="lbl_DeferredTaxExpenseIncome_labels" xlink:type="arc"/>
      <link:label id="id_77e968c5" xlink:label="lbl_DeferredTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax income</link:label>
      <link:label id="id_2d4a780d" xlink:label="lbl_CurrentTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current income tax expense</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="lbl_CurrentTaxExpenseIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTaxExpenseIncome" xlink:to="lbl_CurrentTaxExpenseIncome_labels" xlink:type="arc"/>
      <link:label id="id_bbe9642" xlink:label="lbl_CurrentTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax expense (income)</link:label>
      <link:label id="id_5ac027e9" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income effect</link:label>
      <link:label id="id_2c40f598" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Associated companies' movements in comprehensive income</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:label="lbl_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:to="lbl_label757358878" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFinanceS.A.LuxembourgCityMember" xlink:label="lbl_NovartisFinanceS.A.LuxembourgCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFinanceS.A.LuxembourgCityMember" xlink:to="lbl_label1668533481" xlink:type="arc"/>
      <link:label id="id_3d20cd78" xlink:label="lbl_label1025559928" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Endocyte, Inc., Lafayette, IN [member]</link:label>
      <link:label id="id_151d2726" xlink:label="lbl_label354232102" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tear Film Innovations, Inc., Fort Worth, TX [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TearFilmInnovationsInc.FortWorthTXMember" xlink:label="lbl_TearFilmInnovationsInc.FortWorthTXMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TearFilmInnovationsInc.FortWorthTXMember" xlink:to="lbl_label354232102" xlink:type="arc"/>
      <link:label id="id_1a32a075" xlink:label="lbl_label439525493" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TrueVision Systems, Inc., Fort Worth, TX [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TrueVisionSystemsInc.FortWorthTXMember" xlink:label="lbl_TrueVisionSystemsInc.FortWorthTXMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TrueVisionSystemsInc.FortWorthTXMember" xlink:to="lbl_label439525493" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TranscendMedicalInc.LakeForestILMember" xlink:label="lbl_TranscendMedicalInc.LakeForestILMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TranscendMedicalInc.LakeForestILMember" xlink:to="lbl_label1438652981" xlink:type="arc"/>
      <link:label id="id_279b1df4" xlink:label="lbl_label664477172" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Baltics SIA, Riga [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisBalticsSIARigaMember" xlink:label="lbl_NovartisBalticsSIARigaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisBalticsSIARigaMember" xlink:to="lbl_label664477172" xlink:type="arc"/>
      <link:label id="id_5e85347d" xlink:label="lbl_label1585788029" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Biosciences Peru S.A., Lima [member]</link:label>
      <link:label id="id_62d68d5f" xlink:label="lbl_label1658228063" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Overseas Investments AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisOverseasInvestmentsAGBaselMember" xlink:label="lbl_NovartisOverseasInvestmentsAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisOverseasInvestmentsAGBaselMember" xlink:to="lbl_label1658228063" xlink:type="arc"/>
      <link:label id="id_254382a8" xlink:label="lbl_label625181352" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japat AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_JapatAGBaselMember" xlink:label="lbl_JapatAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_JapatAGBaselMember" xlink:to="lbl_label625181352" xlink:type="arc"/>
      <link:label id="id_4cd3abe4" xlink:label="lbl_label1288940516" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Management SA, Geneva [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconManagementSAGenevaMember" xlink:label="lbl_AlconManagementSAGenevaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconManagementSAGenevaMember" xlink:to="lbl_label1288940516" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EndocyteInc.LafayetteINMember" xlink:label="lbl_EndocyteInc.LafayetteINMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EndocyteInc.LafayetteINMember" xlink:to="lbl_label1025559928" xlink:type="arc"/>
      <link:label id="id_68b5f06f" xlink:label="lbl_label1756754031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oriel Therapeutics, Inc., Durham, NC [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OrielTherapeuticsInc.DurhamNCMember" xlink:label="lbl_OrielTherapeuticsInc.DurhamNCMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OrielTherapeuticsInc.DurhamNCMember" xlink:to="lbl_label1756754031" xlink:type="arc"/>
      <link:label id="id_60eaa13f" xlink:label="lbl_label1625989439" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">WaveLight, Inc., Sterling, VA [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WaveLightInc.SterlingVAMember" xlink:label="lbl_WaveLightInc.SterlingVAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WaveLightInc.SterlingVAMember" xlink:to="lbl_label1625989439" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisBiosciencesPeruS.A.LimaMember" xlink:label="lbl_NovartisBiosciencesPeruS.A.LimaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisBiosciencesPeruS.A.LimaMember" xlink:to="lbl_label1585788029" xlink:type="arc"/>
      <link:label id="id_5bdf673e" xlink:label="lbl_label1541367614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares with restricted use</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TreasurySharesWithRestrictedUse" xlink:label="lbl_TreasurySharesWithRestrictedUse" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesWithRestrictedUse" xlink:to="lbl_label1541367614" xlink:type="arc"/>
      <link:label id="id_7fb088b9" xlink:label="lbl_label2142275769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate effect of revenues exempt from taxation</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:label="lbl_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:to="lbl_label2142275769" xlink:type="arc"/>
      <link:label id="id_6108aeff" xlink:label="lbl_CurrentInterestPayable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current interest payable</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentInterestPayable" xlink:label="lbl_CurrentInterestPayable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentInterestPayable" xlink:to="lbl_CurrentInterestPayable_labels" xlink:type="arc"/>
      <link:label id="id_1fc5ed9f" xlink:label="lbl_CurrentInterestPayable_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interests on financial debt</link:label>
      <link:label id="id_6b7c4e62" xlink:label="lbl_CommitmentForRepurchaseOwnShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitment for repurchase own shares</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CommitmentForRepurchaseOwnShares" xlink:label="lbl_CommitmentForRepurchaseOwnShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommitmentForRepurchaseOwnShares" xlink:to="lbl_CommitmentForRepurchaseOwnShares_labels" xlink:type="arc"/>
      <link:label id="id_5e285341" xlink:label="lbl_label130728687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial asstets debt securities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentFinancialAsstetsDebtSecurities" xlink:label="lbl_NoncurrentFinancialAsstetsDebtSecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialAsstetsDebtSecurities" xlink:to="lbl_label130728687" xlink:type="arc"/>
      <link:label id="id_1f883fd2" xlink:label="lbl_label826017497" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions included in disposal group prior to classification to assets held for sale</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:label="lbl_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:to="lbl_label826017497" xlink:type="arc"/>
      <link:label id="id_256b0374" xlink:label="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation charge prior to classification to assets held for sale</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:label="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:to="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale_labels" xlink:type="arc"/>
      <link:label id="id_4b6e3676" xlink:label="lbl_NoncurrentFinancialAssetsAvailableforsale_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total financial investments</link:label>
      <link:label id="id_2b3e006" xlink:label="lbl_label1209757713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proforma net sales</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProformaNetSales" xlink:label="lbl_ProformaNetSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProformaNetSales" xlink:to="lbl_label1209757713" xlink:type="arc"/>
      <link:label id="id_2888ddc2" xlink:label="lbl_label680058306" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Serelaxin [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SerelaxinMember" xlink:label="lbl_SerelaxinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SerelaxinMember" xlink:to="lbl_label680058306" xlink:type="arc"/>
      <link:label id="id_4e4f9507" xlink:label="lbl_label1313838343" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CyPass [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CyPassMember" xlink:label="lbl_CyPassMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CyPassMember" xlink:to="lbl_label1313838343" xlink:type="arc"/>
      <link:label id="id_52281715" xlink:label="lbl_IncomeStatementAdjustmentsOfPriorYear_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income statement adjustments of prior year</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeStatementAdjustmentsOfPriorYear" xlink:label="lbl_IncomeStatementAdjustmentsOfPriorYear" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeStatementAdjustmentsOfPriorYear" xlink:to="lbl_IncomeStatementAdjustmentsOfPriorYear_labels" xlink:type="arc"/>
      <link:label id="id_68901646" xlink:label="lbl_IncomeStatementAdjustmentsOfPriorYear_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions prior year</link:label>
      <link:label id="id_12f0be52" xlink:label="lbl_IncomeStatementAdjustmentsOfCurrentYear_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income statement adjustments of current year</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeStatementAdjustmentsOfCurrentYear" xlink:label="lbl_IncomeStatementAdjustmentsOfCurrentYear" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeStatementAdjustmentsOfCurrentYear" xlink:to="lbl_IncomeStatementAdjustmentsOfCurrentYear_labels" xlink:type="arc"/>
      <link:label id="id_10001b20" xlink:label="lbl_IncomeStatementAdjustmentsOfCurrentYear_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions current year</link:label>
      <link:label id="id_53e07f22" xlink:label="lbl_label1407221538" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plans and program rebates [axis]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PlansAndProgramRebatesAxis" xlink:label="lbl_PlansAndProgramRebatesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PlansAndProgramRebatesAxis" xlink:to="lbl_label1407221538" xlink:type="arc"/>
      <link:label id="id_64c2e5e1" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations, other provisions and increase (decrease) through net exchange differences, other provisions</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_359d5a9f" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effects of currency translation and business combinations</link:label>
      <link:label id="id_73fc698b" xlink:label="lbl_label1945921931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment charges related to disposal group held for sale</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:label="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:to="lbl_label1945921931" xlink:type="arc"/>
      <link:label id="id_6ee3c039" xlink:label="lbl_label1860419641" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment charges related to disposal group held for sale to the date of reclassification</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:label="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:to="lbl_label1860419641" xlink:type="arc"/>
      <link:label id="id_4ed2e3f9" xlink:label="lbl_label1322443769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions included in disposal group to the date of reclassification</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:label="lbl_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:to="lbl_label1322443769" xlink:type="arc"/>
      <link:label id="id_7be11426" xlink:label="lbl_label1459075477" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net cash flows used in from divestments of businesses classified as investing activities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:to="lbl_label1459075477" xlink:type="arc"/>
      <link:label id="id_63a31bcb" xlink:label="lbl_label625103893" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets divested</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentAssetsDivested" xlink:label="lbl_NoncurrentAssetsDivested" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAssetsDivested" xlink:to="lbl_label625103893" xlink:type="arc"/>
      <link:label id="id_7f3ccd67" xlink:label="lbl_label654491613" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets divested</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentAssetsDivested" xlink:label="lbl_CurrentAssetsDivested" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAssetsDivested" xlink:to="lbl_label654491613" xlink:type="arc"/>
      <link:label id="id_28fd0d0c" xlink:label="lbl_label2062437885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities divested</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentLiabilitiesDivested" xlink:label="lbl_CurrentLiabilitiesDivested" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLiabilitiesDivested" xlink:to="lbl_label2062437885" xlink:type="arc"/>
      <link:label id="id_217212a3" xlink:label="lbl_label1484079992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial and other assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialAndOtherAssets" xlink:label="lbl_FinancialAndOtherAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAndOtherAssets" xlink:to="lbl_label1484079992" xlink:type="arc"/>
      <link:label id="id_3b6cb989" xlink:label="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities recognised as of acquisition date</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_411a4e68" xlink:label="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:label id="id_481dd512" xlink:label="lbl_label1209914642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow outflow from net identifiable assets divested acquired</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:label="lbl_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:to="lbl_label1209914642" xlink:type="arc"/>
      <link:label id="id_2dad0e04" xlink:label="lbl_TradePayablesAndOtherLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade payables and other liabilities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradePayablesAndOtherLiabilities" xlink:label="lbl_TradePayablesAndOtherLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradePayablesAndOtherLiabilities" xlink:to="lbl_TradePayablesAndOtherLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_1551e337" xlink:label="lbl_TradePayablesAndOtherLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Trade payables and other liabilities</link:label>
      <link:label id="id_29a54c7d" xlink:label="lbl_label698698877" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow outflow from net identifiable assets currency translation effects liquidity and fair value of equity interests</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests" xlink:label="lbl_CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests" xlink:to="lbl_label698698877" xlink:type="arc"/>
      <link:label id="id_72d7c22d" xlink:label="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from losing control of subsidiaries or other businesses, classified as investing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_469e951e" xlink:label="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divested business</link:label>
      <link:label id="id_79d4ff23" xlink:label="lbl_label2044002083" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of other financial assets sold</link:label>
      <link:label id="id_f9b4624" xlink:label="lbl_label261834276" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities, fair value through other comprehensive income [member]</link:label>
      <link:label id="id_3f7b625a" xlink:label="lbl_label1065050714" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term financial investments, fair value through other comprehensive income [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lbl_label1065050714" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lbl_label261834276" xlink:type="arc"/>
      <link:label id="id_3373fda5" xlink:label="lbl_label863239589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plans and program rebates [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PlansAndProgramRebatesMember" xlink:label="lbl_PlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PlansAndProgramRebatesMember" xlink:to="lbl_label863239589" xlink:type="arc"/>
      <link:label id="id_52f984e4" xlink:label="lbl_label1392084196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US-specific healthcare plans and program rebates [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_USspecificHealthcarePlansAndProgramRebatesMember" xlink:label="lbl_USspecificHealthcarePlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_USspecificHealthcarePlansAndProgramRebatesMember" xlink:to="lbl_label1392084196" xlink:type="arc"/>
      <link:label id="id_3a1be35a" xlink:label="lbl_label974906202" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US-specific healthcare plans and program rebates [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:label="lbl_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:to="lbl_label974906202" xlink:type="arc"/>
      <link:label id="id_52817cee" xlink:label="lbl_label1384217838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-healthcare plans and program-related rebates, returns and other deductions [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:label="lbl_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:to="lbl_label1384217838" xlink:type="arc"/>
      <link:label id="id_518b30b7" xlink:label="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation charge prior to classification to assets held for sale</link:label>
      <link:label id="id_611b2741" xlink:label="lbl_DeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
      <link:label id="id_35974485" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise prices for outstanding share options [member]</link:label>
      <link:label id="id_3da6037c" xlink:label="lbl_label1034290044" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">46.7</link:label>
      <link:label id="id_5698bfcb" xlink:label="lbl_label1452851147" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 46.7 [member]</link:label>
      <link:label id="id_df65a83" xlink:label="lbl_label1098297979" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">54.5</link:label>
      <link:label id="id_26baf973" xlink:label="lbl_label1238972312" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">57.0</link:label>
      <link:label id="id_5d51017e" xlink:label="lbl_label1565589886" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">57.6</link:label>
      <link:label id="id_7925df2" xlink:label="lbl_label127032818" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 57.6 [member]</link:label>
      <link:label id="id_50442a73" xlink:label="lbl_label61576322" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">66.0</link:label>
      <link:label id="id_77b11616" xlink:label="lbl_label2008094230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized income was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:label="lbl_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:to="lbl_label2008094230" xlink:type="arc"/>
      <link:label id="id_13923e74" xlink:label="lbl_label328351348" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">46.4</link:label>
      <link:label id="id_26b025e5" xlink:label="lbl_label649078245" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">53.7</link:label>
      <link:label id="id_15297d64" xlink:label="lbl_label355040612" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">57.1</link:label>
      <link:label id="id_37ef180d" xlink:label="lbl_label938416141" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">58.3</link:label>
      <link:label id="id_7963b4c" xlink:label="lbl_label127286092" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">66.1</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice46.7Member" xlink:label="lbl_ExercisePrice46.7Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice46.7Member" xlink:to="lbl_label1452851147" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice46.7Member" xlink:to="lbl_label1034290044" xlink:type="arc"/>
      <link:label id="id_7638cc32" xlink:label="lbl_label1983433778" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 54.5 [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice54.5Member" xlink:label="lbl_ExercisePrice54.5Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice54.5Member" xlink:to="lbl_label1983433778" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice54.5Member" xlink:to="lbl_label1098297979" xlink:type="arc"/>
      <link:label id="id_625d280f" xlink:label="lbl_label1650272271" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 57.0 [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice57.0Member" xlink:label="lbl_ExercisePrice57.0Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice57.0Member" xlink:to="lbl_label1650272271" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice57.0Member" xlink:to="lbl_label1238972312" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice57.6Member" xlink:label="lbl_ExercisePrice57.6Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice57.6Member" xlink:to="lbl_label127032818" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice57.6Member" xlink:to="lbl_label1565589886" xlink:type="arc"/>
      <link:label id="id_7f8b8ef4" xlink:label="lbl_label2139852532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 66.0 [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice66.0Member" xlink:label="lbl_ExercisePrice66.0Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice66.0Member" xlink:to="lbl_label2139852532" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice66.0Member" xlink:to="lbl_label61576322" xlink:type="arc"/>
      <link:label id="id_1c214787" xlink:label="lbl_label471943047" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 46.4 [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice46.4Member" xlink:label="lbl_ExercisePrice46.4Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice46.4Member" xlink:to="lbl_label471943047" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice46.4Member" xlink:to="lbl_label328351348" xlink:type="arc"/>
      <link:label id="id_60064b00" xlink:label="lbl_label1611025152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 53.7 [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice53.7Member" xlink:label="lbl_ExercisePrice53.7Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice53.7Member" xlink:to="lbl_label1611025152" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice53.7Member" xlink:to="lbl_label649078245" xlink:type="arc"/>
      <link:label id="id_3d7bc5f9" xlink:label="lbl_label1031521785" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 57.1 [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice57.1Member" xlink:label="lbl_ExercisePrice57.1Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice57.1Member" xlink:to="lbl_label1031521785" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice57.1Member" xlink:to="lbl_label355040612" xlink:type="arc"/>
      <link:label id="id_5312799d" xlink:label="lbl_label1393719709" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 58.3 [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice58.3Member" xlink:label="lbl_ExercisePrice58.3Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice58.3Member" xlink:to="lbl_label1393719709" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice58.3Member" xlink:to="lbl_label938416141" xlink:type="arc"/>
      <link:label id="id_11afcf8b" xlink:label="lbl_label296734603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 66.1 [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice66.1Member" xlink:label="lbl_ExercisePrice66.1Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice66.1Member" xlink:to="lbl_label296734603" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice66.1Member" xlink:to="lbl_label127286092" xlink:type="arc"/>
      <link:label id="id_602d9a64" xlink:label="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and divestments of interests in associated companies, net</link:label>
      <link:label id="id_1640eef1" xlink:label="lbl_TransactionCostsRecordedInEquityPaid_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs payments</link:label>
      <link:label id="id_4305d26a" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in investing activities from discontinued operations</link:label>
      <link:label id="id_1cb46ce6" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to revaluation of deferred tax assets on equity based compensation that were previously recognized through retained earnings</link:label>
      <link:label id="id_45074031" xlink:label="lbl_label1158103089" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepayments and accrued lease payments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PrepaymentsAndAccruedLeasePayments" xlink:label="lbl_PrepaymentsAndAccruedLeasePayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PrepaymentsAndAccruedLeasePayments" xlink:to="lbl_label1158103089" xlink:type="arc"/>
      <link:label id="id_1787fdbc" xlink:label="lbl_label1284506961" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recycling of the Novartis share of other comprehensive income from associated companies</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:label="lbl_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:to="lbl_label1284506961" xlink:type="arc"/>
      <link:label id="id_7702ef73" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase/decrease of treasury share repurchase obligation under a share buyback trading plan</link:label>
      <link:label id="id_135f3eb7" xlink:label="lbl_TransactionCostsRecordedInEquityPaid_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs payments</link:label>
      <link:label id="id_1765273e" xlink:label="lbl_CashFlowFromNetIdentifiableAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net assets recognized as a result of acquistions of businesses</link:label>
      <link:label id="id_4a08e514" xlink:label="lbl_CurrentTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current tax expense (income)</link:label>
      <link:label id="id_71e76093" xlink:label="lbl_DeferredTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax expense (income)</link:label>
      <link:label id="id_608223c4" xlink:label="lbl_IncomeTaxExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Total Income Tax Expense</link:label>
      <link:label id="id_352bb146" xlink:label="lbl_TaxExpenseIncomeDiscontinuingOperations_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense from discontinued operations</link:label>
      <link:label id="id_6348f872" xlink:label="lbl_TransactionCostsRecordedInEquity_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs recorded in equity</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:label="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_label85049938" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:label="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_label982152731" xlink:type="arc"/>
      <link:label id="id_31ca37cf" xlink:label="lbl_label835336143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization prior to classification to assets held for sale</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:label="lbl_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:to="lbl_label835336143" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:to="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale_labels" xlink:type="arc"/>
      <link:label id="id_43b1908f" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax assets or deferred tax liabilities related to disposal group held for sale</link:label>
      <link:label id="id_3b7e23ba" xlink:label="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accrued benefit liability</link:label>
      <link:label id="id_774651e9" xlink:label="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_5fb55436" xlink:label="lbl_TreasurySharesAcquiredForCancellationValue_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Shares acquired for cancellation, equity impact</link:label>
      <link:label id="id_71230227" xlink:label="lbl_DisposalsFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposals fair value measurement assets</link:label>
      <link:label id="id_757b03e4" xlink:label="lbl_EquityImpactOfTreasuryShareMovements_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total equity impact of treasury share movements</link:label>
      <link:label id="id_9217c59" xlink:label="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement</link:label>
      <link:label id="id_eb62348" xlink:label="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment charges and fair value gains on financial assets, net</link:label>
      <link:label id="id_2ec0dcb9" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect of acquisitions, divestments or transfers</link:label>
      <link:label id="id_48bf4d53" xlink:label="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other movements</link:label>
      <link:label id="id_1a35a04f" xlink:label="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
      <link:label id="id_39d0eccc" xlink:label="lbl_OtherSharePurchasesValue_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other share purchases, equity impact</link:label>
      <link:label id="id_5209e6b5" xlink:label="lbl_SurplusDeficitInPlan_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Funded status</link:label>
      <link:label id="id_2a14e1da" xlink:label="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges and fair value gains on financial assets, net</link:label>
      <link:label id="id_74f13ac0" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on financial assets sold</link:label>
      <link:label id="id_180b00c2" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in investing activities from continuing operations</link:label>
      <link:label id="id_aca6a21" xlink:label="lbl_ProceedsFromNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase in non-current financial debts</link:label>
      <link:label id="id_5e5a2737" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total net cash flows used in investing activities</link:label>
      <link:label id="id_12daaf08" xlink:label="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divested interest in associate</link:label>
      <link:label id="id_595a0496" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in discontinued operations</link:label>
      <link:label id="id_6f1acb28" xlink:label="lbl_label1864026920" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long term financial investments [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LongTermFinancialInvestmentsMember" xlink:label="lbl_LongTermFinancialInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LongTermFinancialInvestmentsMember" xlink:to="lbl_label1864026920" xlink:type="arc"/>
      <link:label id="id_24014c8f" xlink:label="lbl_label1836731146" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MarketableSecurities" xlink:label="lbl_MarketableSecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MarketableSecurities" xlink:to="lbl_label1836731146" xlink:type="arc"/>
      <link:label id="id_7323afac" xlink:label="lbl_label1544871888" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major plans percentage in group DBO pensions</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MajorPlansPercentageInGroupDBOPensions" xlink:label="lbl_MajorPlansPercentageInGroupDBOPensions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MajorPlansPercentageInGroupDBOPensions" xlink:to="lbl_label1544871888" xlink:type="arc"/>
      <link:label id="id_192e72f5" xlink:label="lbl_label456555172" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Most signigicant countries percentage on group DBO post employment benefit plans</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:label="lbl_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:to="lbl_label456555172" xlink:type="arc"/>
      <link:label id="id_45e2937b" xlink:label="lbl_InterestIncomeOnLimitationOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest income on limitation of fund surplus</link:label>
      <link:label id="id_7686c3c0" xlink:label="lbl_DefinedBenefitPlanSettlementsPlanAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
      <link:label id="id_4d6d4f53" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Past service cost and settlements</link:label>
      <link:label id="id_764909d2" xlink:label="lbl_label949739114" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncurrent financial assets, total financial investments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:label="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:to="lbl_label949739114" xlink:type="arc"/>
      <link:label id="id_2ba0d9fa" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on equity securities sold, reclassified to retained earnings</link:label>
      <link:label id="id_751d39ac" xlink:label="lbl_label1964849580" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net income/loss from discontinued operations before gain on distribution</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:label="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:to="lbl_label1964849580" xlink:type="arc"/>
      <link:label id="id_3a463b8c" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed_labels" xlink:type="arc"/>
      <link:label id="id_2c57b1ca" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on distribution</link:label>
      <link:label id="id_291f69d6" xlink:label="lbl_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax on Pension plans previously recognized in OCI</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI" xlink:label="lbl_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI" xlink:to="lbl_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI_labels" xlink:type="arc"/>
      <link:label id="id_2f7fc540" xlink:label="lbl_RightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RightofuseAssets" xlink:to="lbl_RightofuseAssets_labels" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPayable" xlink:label="lbl_DividendsPayable" xlink:type="locator"/>
      <link:label id="id_6acaf180" xlink:label="lbl_DividendsPayable_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend in kind distribution liability</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsPayable" xlink:to="lbl_DividendsPayable_labels" xlink:type="arc"/>
      <link:label id="id_34ce2448" xlink:label="lbl_DividendsPayable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends payable, non-cash assets distributions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:label="lbl_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:type="locator"/>
      <link:label id="id_484edcc4" xlink:label="lbl_DividendsRecognisedAsDistributionsToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividend in kind</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:to="lbl_DividendsRecognisedAsDistributionsToOwnersOfParent_labels" xlink:type="arc"/>
      <link:label id="id_7adfa754" xlink:label="lbl_DividendsRecognisedAsDistributionsToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends recognised as distributions to owners of paren</link:label>
      <link:label id="id_590635ac" xlink:label="lbl_SaleOrIssueOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sale of treasury shares</link:label>
      <link:label id="id_2476e743" xlink:label="lbl_ProfitLossFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income from continuing operations</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:label id="id_1ffd83cc" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in/from financing activities from discontinued operations</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:label id="id_6a49a8cd" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in financing activities from continuing operations</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_59187aa8" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities, discontinued operations</link:label>
      <link:label id="id_1d15aff4" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities, continuing operations</link:label>
      <link:label id="id_100aa035" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents before effect of exchange rate changes</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_labels" xlink:type="arc"/>
      <link:label id="id_50620c89" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</link:label>
      <link:label id="id_96ecbb0" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents of discontinued operations</link:label>
      <link:label id="id_2334b78" xlink:label="lbl_label36916088" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of discontinued operations [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDiscontinuedOperationsAbstract" xlink:label="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:to="lbl_label36916088" xlink:type="arc"/>
      <link:label id="id_76c64958" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sales to continuing and discontinued segments</link:label>
      <link:label id="id_36af0a7f" xlink:label="lbl_RevenueFromSaleOfGoods_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net sales from continuing operations</link:label>
      <link:label id="id_58501f6b" xlink:label="lbl_label1481645931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change over period, YoY [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_YoYChangeMember" xlink:label="lbl_YoYChangeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_YoYChangeMember" xlink:to="lbl_label1481645931" xlink:type="arc"/>
      <link:label id="id_3ed48330" xlink:label="lbl_label1054114608" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="lbl_label1054114608" xlink:type="arc"/>
      <link:label id="id_43a1a553" xlink:label="lbl_label1134667091" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_label1134667091" xlink:type="arc"/>
      <link:label id="id_3045b2a1" xlink:label="lbl_label809874081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vehicles [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_VehiclesMember" xlink:label="lbl_VehiclesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VehiclesMember" xlink:to="lbl_label809874081" xlink:type="arc"/>
      <link:label id="id_64acc522" xlink:label="lbl_label1689044258" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_label1689044258" xlink:type="arc"/>
      <link:label id="id_5367393f" xlink:label="lbl_DepreciationRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, right-of-use assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="lbl_DepreciationRightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DepreciationRightofuseAssets" xlink:to="lbl_DepreciationRightofuseAssets_labels" xlink:type="arc"/>
      <link:label id="id_4a6ffe17" xlink:label="lbl_DepreciationRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation charge</link:label>
      <link:label id="id_1b8dfafc" xlink:label="lbl_OtherAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Machinery &amp; equipment and other assets</link:label>
      <link:label id="id_2da47e8f" xlink:label="lbl_NoncurrentLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="lbl_NoncurrentLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLeaseLiabilities" xlink:to="lbl_NoncurrentLeaseLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_5905e579" xlink:label="lbl_NoncurrentLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
      <link:label id="id_328c2a61" xlink:label="lbl_CurrentLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current lease liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="lbl_CurrentLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLeaseLiabilities" xlink:to="lbl_CurrentLeaseLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_543a77a3" xlink:label="lbl_CurrentLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
      <link:label id="id_234e965a" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments of lease liabilities, net</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_e7d4ee5" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</link:label>
      <link:label id="id_7097e6f" xlink:label="lbl_label118062703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Presentation of leases for lessee [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="lbl_PresentationOfLeasesForLesseeAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PresentationOfLeasesForLesseeAbstract" xlink:to="lbl_label118062703" xlink:type="arc"/>
      <link:label id="id_171d0edf" xlink:label="lbl_LeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseLiabilities" xlink:to="lbl_LeaseLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_1c665876" xlink:label="lbl_GrossLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross lease liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="lbl_GrossLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossLeaseLiabilities" xlink:to="lbl_GrossLeaseLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_2c03c1ee" xlink:label="lbl_GrossLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease commitments</link:label>
      <link:label id="id_1b0667c7" xlink:label="lbl_label453404615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Presentation of leases for lesses [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PresentationOfLeasesForLessesTable" xlink:label="lbl_PresentationOfLeasesForLessesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PresentationOfLeasesForLessesTable" xlink:to="lbl_label453404615" xlink:type="arc"/>
      <link:label id="id_72b5e1b" xlink:label="lbl_label120282651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Presentation of leases for lessee [line items]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PresentationOfLeasesForLesseeLineItems" xlink:label="lbl_PresentationOfLeasesForLesseeLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PresentationOfLeasesForLesseeLineItems" xlink:to="lbl_label120282651" xlink:type="arc"/>
      <link:label id="id_3a8f2f5a" xlink:label="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense relating to short-term leases for which recognition exemption has been used</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:to="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_labels" xlink:type="arc"/>
      <link:label id="id_3f6e27d0" xlink:label="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognition exemption for short term leases</link:label>
      <link:label id="id_7a5f05cd" xlink:label="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense relating to leases of low-value assets for which recognition exemption has been used</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:label="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:to="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_labels" xlink:type="arc"/>
      <link:label id="id_3ae50249" xlink:label="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognition exception for low value leases</link:label>
      <link:label id="id_375e4cce" xlink:label="lbl_label928926926" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New lease arrangements</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NewLeaseArrangements" xlink:label="lbl_NewLeaseArrangements" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NewLeaseArrangements" xlink:to="lbl_label928926926" xlink:type="arc"/>
      <link:label id="id_c8ad2dc" xlink:label="lbl_label210424540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undiscounted future lease payments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UndiscountedFutureLeasePayments" xlink:label="lbl_UndiscountedFutureLeasePayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UndiscountedFutureLeasePayments" xlink:to="lbl_label210424540" xlink:type="arc"/>
      <link:label id="id_75283e38" xlink:label="lbl_EffectOfDiscounting_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of discounting</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EffectOfDiscounting" xlink:label="lbl_EffectOfDiscounting" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectOfDiscounting" xlink:to="lbl_EffectOfDiscounting_labels" xlink:type="arc"/>
      <link:label id="id_6ac0bebc" xlink:label="lbl_LeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
      <link:label id="id_6447e039" xlink:label="lbl_label1682432057" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about leases for lessee [abstract]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:to="lbl_label1682432057" xlink:type="arc"/>
      <link:label id="id_3e0ced0d" xlink:label="lbl_InterestExpenseOnLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseOnLeaseLiabilities" xlink:to="lbl_InterestExpenseOnLeaseLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_7693425d" xlink:label="lbl_label1989362269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash outflow</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashOutflowForLeases" xlink:label="lbl_CashOutflowForLeases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashOutflowForLeases" xlink:to="lbl_label1989362269" xlink:type="arc"/>
      <link:label id="id_26c71205" xlink:label="lbl_label650580485" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense relating to variable lease payments not included in measurement of lease liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:label="lbl_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:to="lbl_label650580485" xlink:type="arc"/>
      <link:label id="id_63dc6855" xlink:label="lbl_label1675389013" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of total lease liabilities [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" xlink:to="lbl_label1675389013" xlink:type="arc"/>
      <link:label id="id_10622a16" xlink:label="lbl_label274868758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of total lease liabilities [table]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:to="lbl_label274868758" xlink:type="arc"/>
      <link:label id="id_24f1a439" xlink:label="lbl_label619815993" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of total lease liabilities [line items]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_label619815993" xlink:type="arc"/>
      <link:label id="id_67bf33b0" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net sales to third parties of discontinued operations</link:label>
      <link:label id="id_327f346c" xlink:label="lbl_ProfitLossFromOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating income of discontinued operations</link:label>
      <link:label id="id_64213541" xlink:label="lbl_label1679897921" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restated [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentStatedMember" xlink:label="lbl_CurrentStatedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentStatedMember" xlink:to="lbl_label1679897921" xlink:type="arc"/>
      <link:label id="id_5ebed7b4" xlink:label="lbl_SaleOrIssueOfTreasurySharesNumberOfShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of treasury shares, number of shares</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SaleOrIssueOfTreasurySharesNumberOfShares" xlink:label="lbl_SaleOrIssueOfTreasurySharesNumberOfShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOrIssueOfTreasurySharesNumberOfShares" xlink:to="lbl_SaleOrIssueOfTreasurySharesNumberOfShares_labels" xlink:type="arc"/>
      <link:label id="id_22f85f35" xlink:label="lbl_SaleOrIssueOfTreasurySharesNumberOfShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of treasury shares</link:label>
      <link:label id="id_25cdb408" xlink:label="lbl_label634237960" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Detailed information about significant transaction</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DetailedInformationAboutSignificantTransaction" xlink:label="lbl_DetailedInformationAboutSignificantTransaction" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DetailedInformationAboutSignificantTransaction" xlink:to="lbl_label634237960" xlink:type="arc"/>
      <link:label id="id_7eb3758e" xlink:label="lbl_TakedaPharmaceuticalCompanyLimitedMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Takeda Pharmaceutical Company Limited [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="lbl_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="lbl_TakedaPharmaceuticalCompanyLimitedMember_labels" xlink:type="arc"/>
      <link:label id="id_6db37ab5" xlink:label="lbl_TakedaPharmaceuticalCompanyLimitedMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Takeda Pharmaceutical Company Limited</link:label>
      <link:label id="id_ff14c14" xlink:label="lbl_IFMTreInc.Member_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IFM Tre, Inc. [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IFMTreInc.Member" xlink:label="lbl_IFMTreInc.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IFMTreInc.Member" xlink:to="lbl_IFMTreInc.Member_labels" xlink:type="arc"/>
      <link:label id="id_5b8c5fe7" xlink:label="lbl_IFMTreInc.Member_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IFM Tre, Inc.</link:label>
      <link:label id="id_33428670" xlink:label="lbl_PowerVisionInc.Member_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PowerVision, Inc. [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PowerVisionInc.Member" xlink:label="lbl_PowerVisionInc.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PowerVisionInc.Member" xlink:to="lbl_PowerVisionInc.Member_labels" xlink:type="arc"/>
      <link:label id="id_7001a921" xlink:label="lbl_PowerVisionInc.Member_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PowerVision, Inc.</link:label>
      <link:label id="id_6bb5fe48" xlink:label="lbl_label1807089224" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for prepayments and accrued lease payments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:label="lbl_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:to="lbl_label1807089224" xlink:type="arc"/>
      <link:label id="id_10d3bb4e" xlink:label="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:label="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:to="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_labels" xlink:type="arc"/>
      <link:label id="id_e7bd10a" xlink:label="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average incremental borrowing rate</link:label>
      <link:label id="id_390e560d" xlink:label="lbl_label957240845" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions to right-of-use assets</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="lbl_AdditionsToRightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsToRightofuseAssets" xlink:to="lbl_label957240845" xlink:type="arc"/>
      <link:label id="id_f3aa39f" xlink:label="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) arising from sale and leaseback transactions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:label="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:to="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions_labels" xlink:type="arc"/>
      <link:label id="id_1dfe7c52" xlink:label="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains or losses from sales leaseback</link:label>
      <link:label id="id_50d6583f" xlink:label="lbl_label1356224575" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other borrowings</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherBorrowings" xlink:label="lbl_OtherBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherBorrowings" xlink:to="lbl_label1356224575" xlink:type="arc"/>
      <link:label id="id_589c1537" xlink:label="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in dividends payable through change in fair value of non-cash assets held for distribution to owners</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:label="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:to="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners_labels" xlink:type="arc"/>
      <link:label id="id_1a2e3f6" xlink:label="lbl_NetAssetsLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net assets liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="lbl_NetAssetsLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetAssetsLiabilities" xlink:to="lbl_NetAssetsLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_4d789f55" xlink:label="lbl_NetAssetsLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net assets</link:label>
      <link:label id="id_7d2cba5f" xlink:label="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease of distribution liability</link:label>
      <link:label id="id_24596c04" xlink:label="lbl_label609840132" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential milestone maximum payments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PotentialMilestoneMaximumPayments" xlink:label="lbl_PotentialMilestoneMaximumPayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialMilestoneMaximumPayments" xlink:to="lbl_label609840132" xlink:type="arc"/>
      <link:label id="id_3dc6ce5a" xlink:label="lbl_label1036439130" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of employees associated with the product transfer</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:label="lbl_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:to="lbl_label1036439130" xlink:type="arc"/>
      <link:label id="id_3954535f" xlink:label="lbl_label961827679" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional borrowings</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdditionalBorrowings" xlink:label="lbl_AdditionalBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionalBorrowings" xlink:to="lbl_label961827679" xlink:type="arc"/>
      <link:label id="id_43740ee2" xlink:label="lbl_label1131679458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of equity interest shares received</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PercentageOfEquityInterestSharesReceived" xlink:label="lbl_PercentageOfEquityInterestSharesReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfEquityInterestSharesReceived" xlink:to="lbl_label1131679458" xlink:type="arc"/>
      <link:label id="id_79732968" xlink:label="lbl_label2037590376" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Difference between fair value of distribution liability and net assets at the date of distribution</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:label="lbl_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:to="lbl_label2037590376" xlink:type="arc"/>
      <link:label id="id_431c3dd4" xlink:label="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distribution of dividend to dividend bearing shares to consolidated foundations</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:label="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:to="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations_labels" xlink:type="arc"/>
      <link:label id="id_ff7c4c3" xlink:label="lbl_label267896003" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aimovig [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AimovigMember" xlink:label="lbl_AimovigMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AimovigMember" xlink:to="lbl_label267896003" xlink:type="arc"/>
      <link:label id="id_4945ceaa" xlink:label="lbl_label1229311658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities and Right of use assets Disclosure Abstract</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" xlink:label="lbl_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" xlink:to="lbl_label1229311658" xlink:type="arc"/>
      <link:label id="id_79212b70" xlink:label="lbl_label2032216944" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of leases [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="lbl_DisclosureOfLeasesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfLeasesExplanatory" xlink:to="lbl_label2032216944" xlink:type="arc"/>
      <link:label id="id_4b496242" xlink:label="lbl_ReductionOfIssuedCapital_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction of issued capital</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReductionOfIssuedCapital" xlink:label="lbl_ReductionOfIssuedCapital" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReductionOfIssuedCapital" xlink:to="lbl_ReductionOfIssuedCapital_labels" xlink:type="arc"/>
      <link:label id="id_211a2da" xlink:label="lbl_ReductionOfIssuedCapital_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reduction of share capital</link:label>
      <link:label id="id_610df533" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through exercise of options, equity</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="lbl_IncreaseDecreaseThroughExerciseOfOptions_labels" xlink:type="arc"/>
      <link:label id="id_169b45c8" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options and employee transactions, equity impact</link:label>
      <link:label id="id_76378de3" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptionsShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase decrease through exercise of options shares</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:to="lbl_IncreaseDecreaseThroughExerciseOfOptionsShares_labels" xlink:type="arc"/>
      <link:label id="id_4cd892b4" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptionsShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options and employee transactions shares</link:label>
      <link:label id="id_1efc7c8b" xlink:label="lbl_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase decrease through share based payment transactions shares</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares" xlink:label="lbl_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares" xlink:to="lbl_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares_labels" xlink:type="arc"/>
      <link:label id="id_1d05cf3d" xlink:label="lbl_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity based compensation shares</link:label>
      <link:label id="id_1a5eff2" xlink:label="lbl_label27652082" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayment of lease liability</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RepaymentOfLeaseLiability" xlink:label="lbl_RepaymentOfLeaseLiability" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RepaymentOfLeaseLiability" xlink:to="lbl_label27652082" xlink:type="arc"/>
      <link:label id="id_7a957c7" xlink:label="lbl_label128538567" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average interest rate lease liabilities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WeightedAverageInterestRateLeaseLiabilities" xlink:label="lbl_WeightedAverageInterestRateLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageInterestRateLeaseLiabilities" xlink:to="lbl_label128538567" xlink:type="arc"/>
      <link:label id="id_50834b9f" xlink:label="lbl_label1350781855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movements of the right-of-use assets [roll forward]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MovementsOfTheRightofuseAssetsRollForward" xlink:label="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_label1350781855" xlink:type="arc"/>
      <link:label id="id_4004db36" xlink:label="lbl_RightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets at beginning of period</link:label>
      <link:label id="id_63713767" xlink:label="lbl_RightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets at end of period</link:label>
      <link:label id="id_491fa8b0" xlink:label="lbl_LeaseContractTerminationsRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease contract terminations, right-of-use assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LeaseContractTerminationsRightofuseAssets" xlink:label="lbl_LeaseContractTerminationsRightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseContractTerminationsRightofuseAssets" xlink:to="lbl_LeaseContractTerminationsRightofuseAssets_labels" xlink:type="arc"/>
      <link:label id="id_43e3ea12" xlink:label="lbl_label79581278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase decrease through net exchange differences, right-of-use assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:to="lbl_label79581278" xlink:type="arc"/>
      <link:label id="id_750ea0e7" xlink:label="lbl_label1963892967" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares delivered to divested business employees, equity impact</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:to="lbl_label1963892967" xlink:type="arc"/>
      <link:label id="id_23a4b8a2" xlink:label="lbl_TaxesOnTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes on treasury shares</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxesOnTreasuryShares" xlink:label="lbl_TaxesOnTreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxesOnTreasuryShares" xlink:to="lbl_TaxesOnTreasuryShares_labels" xlink:type="arc"/>
      <link:label id="id_2a977fac" xlink:label="lbl_label714571692" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease incentives</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LeaseIncentives" xlink:label="lbl_LeaseIncentives" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseIncentives" xlink:to="lbl_label714571692" xlink:type="arc"/>
      <link:label id="id_752a730a" xlink:label="lbl_label1965716234" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow for leases</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashInflowForLeases" xlink:label="lbl_CashInflowForLeases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowForLeases" xlink:to="lbl_label1965716234" xlink:type="arc"/>
      <link:label id="id_56ca2a36" xlink:label="lbl_NetAssetsDerecognized_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net assets derecognized</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetAssetsDerecognized" xlink:label="lbl_NetAssetsDerecognized" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetAssetsDerecognized" xlink:to="lbl_NetAssetsDerecognized_labels" xlink:type="arc"/>
      <link:label id="id_1b28c052" xlink:label="lbl_DividendsPayable_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derecognition of distribution liability</link:label>
      <link:label id="id_32e2fa92" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Difference between net assets and distribution liability</link:label>
      <link:label id="id_5a5595b5" xlink:label="lbl_label1515558325" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distribution of dividend to dividend bearing shares</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DistributionOfDividendToDividendBearingShares" xlink:label="lbl_DistributionOfDividendToDividendBearingShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DistributionOfDividendToDividendBearingShares" xlink:to="lbl_label1515558325" xlink:type="arc"/>
      <link:label id="id_76193299" xlink:label="lbl_TransactionCosts_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs recognized in the consolidated income statement</link:label>
      <link:label id="id_1fe7672a" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed, Net</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet_labels" xlink:type="arc"/>
      <link:label id="id_4fbc2a8c" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on distribution of Alcon Inc. to Novartis AG shareholders</link:label>
      <link:label id="id_1b6a6442" xlink:label="lbl_label459957314" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net provisions for transaction costs recognized in the income statement</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetProvisionsForTransactionCostsRecognizedInTheIncomeStatement" xlink:label="lbl_NetProvisionsForTransactionCostsRecognizedInTheIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetProvisionsForTransactionCostsRecognizedInTheIncomeStatement" xlink:to="lbl_label459957314" xlink:type="arc"/>
      <link:label id="id_68457d8c" xlink:label="lbl_CashFlowsAttributableToDivestedBusiness_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows attributable to divested business</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashFlowsAttributableToDivestedBusiness" xlink:label="lbl_CashFlowsAttributableToDivestedBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsAttributableToDivestedBusiness" xlink:to="lbl_CashFlowsAttributableToDivestedBusiness_labels" xlink:type="arc"/>
      <link:label id="id_4f1d6584" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other cash flows used in investing activities, net</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_1bf16062" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other inflows (outflows) of cash, classified as investing activities</link:label>
      <link:label id="id_1d66e74c" xlink:label="lbl_label493283148" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and other non-current assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialAndOtherNoncurrentAssets" xlink:label="lbl_FinancialAndOtherNoncurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAndOtherNoncurrentAssets" xlink:to="lbl_label493283148" xlink:type="arc"/>
      <link:label id="id_2b5de5f3" xlink:label="lbl_label727574003" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables and other current assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradeReceivablesAndOtherCurrentAssets" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesAndOtherCurrentAssets" xlink:to="lbl_label727574003" xlink:type="arc"/>
      <link:label id="id_54b5d55e" xlink:label="lbl_LeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current and non-current lease liabilities</link:label>
      <link:label id="id_5b8463eb" xlink:label="lbl_TradePayablesProvisionsAndOtherLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade payables, provisions and other liabilities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradePayablesProvisionsAndOtherLiabilities" xlink:label="lbl_TradePayablesProvisionsAndOtherLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradePayablesProvisionsAndOtherLiabilities" xlink:to="lbl_TradePayablesProvisionsAndOtherLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_cbbfa93" xlink:label="lbl_CurrentAndNoncurrentFinancialDebt_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current and non-current financial debt</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentAndNoncurrentFinancialDebt" xlink:label="lbl_CurrentAndNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAndNoncurrentFinancialDebt" xlink:to="lbl_CurrentAndNoncurrentFinancialDebt_labels" xlink:type="arc"/>
      <link:label id="id_2ce3e4d1" xlink:label="lbl_label753132753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right of use assets Disclosure and Lease liabilities [abstract]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:label="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_label753132753" xlink:type="arc"/>
      <link:label id="id_7eea5c8b" xlink:label="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of lease commitment and lease liability [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" xlink:label="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" xlink:to="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_179a66c8" xlink:label="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of lease commitment and lease liability</link:label>
      <link:label id="id_61aad0c8" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [text block]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_41e189f8" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets</link:label>
      <link:label id="id_74f2bff0" xlink:label="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Right-of-use assets roll forward [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" xlink:label="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" xlink:to="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4b1c78b0" xlink:label="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Right-of-use assets roll forward</link:label>
      <link:label id="id_21983c62" xlink:label="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of right-of-use assets carrying value and depreciation charge [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" xlink:label="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" xlink:to="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3cad94ea" xlink:label="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of right-of-use assets carrying value and depreciation charge</link:label>
      <link:label id="id_59a39235" xlink:label="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of lease liability [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" xlink:label="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" xlink:to="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_16173223" xlink:label="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of lease liability</link:label>
      <link:label id="id_349af9f2" xlink:label="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional disclosures related to right-of-use assets and lease liabilities [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:label="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:to="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2b0fa89e" xlink:label="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional disclosures related to right-of-use assets and lease liabilities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="lbl_GoodwillRecognisedAsOfAcquisitionDate1" xlink:type="locator"/>
      <link:label id="id_41a9be15" xlink:label="lbl_GoodwillRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill recognised as of acquisition date</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GoodwillRecognisedAsOfAcquisitionDate1" xlink:to="lbl_GoodwillRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_5f4cbeb8" xlink:label="lbl_GoodwillRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
      <link:label id="id_20d2348f" xlink:label="lbl_IncomeTaxExpenseContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes</link:label>
      <link:label id="id_24522acb" xlink:label="lbl_AdjustmentsForFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net financial expense</link:label>
      <link:label id="id_2dbe7019" xlink:label="lbl_AdjustmentsForReconcileProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
      <link:label id="id_665e2bc2" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value of previously held equity interests</link:label>
      <link:label id="id_2124eb92" xlink:label="lbl_label556067730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentLeaseLiabilitiesMember" xlink:label="lbl_NoncurrentLeaseLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLeaseLiabilitiesMember" xlink:to="lbl_label556067730" xlink:type="arc"/>
      <link:label id="id_25d32b75" xlink:label="lbl_label634596213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current lease liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentLeaseLiabilitiesMember" xlink:label="lbl_CurrentLeaseLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLeaseLiabilitiesMember" xlink:to="lbl_label634596213" xlink:type="arc"/>
      <link:label id="id_7905e1d7" xlink:label="lbl_label203360922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Applicable tax rate, excluding exceptional items</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ApplicableTaxRateExcludingExceptionalItems" xlink:label="lbl_ApplicableTaxRateExcludingExceptionalItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ApplicableTaxRateExcludingExceptionalItems" xlink:to="lbl_label203360922" xlink:type="arc"/>
      <link:label id="id_65b2ed83" xlink:label="lbl_CurrentAndNoncurrentFinancialDebt_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current and non-current financial debt</link:label>
      <link:label id="id_2db983d5" xlink:label="lbl_TradePayablesProvisionsAndOtherLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Trade payables, provisions and other liabilities</link:label>
      <link:label id="id_71df6444" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flows Attributable to divested business before divested cash and cash equivalents</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:to="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_43e3fc7" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments out of provisions for transaction costs attributable to the divested business</link:label>
      <link:label id="id_4fb71438" xlink:label="lbl_DivestedCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divested cash and cash equivalents</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DivestedCashAndCashEquivalents" xlink:label="lbl_DivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DivestedCashAndCashEquivalents" xlink:to="lbl_DivestedCashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_74caa513" xlink:label="lbl_DivestedCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Divested cash and cash equivalents</link:label>
      <link:label id="id_3a16e3f2" xlink:label="lbl_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax on Pension plans previously recognized in OCI</link:label>
      <link:label id="id_5bc61768" xlink:label="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares obtained through consolidated foundation</link:label>
      <link:label id="id_32f424a5" xlink:label="lbl_label854860965" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customary purchase price adjustment</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CustomaryPurchasePriceAdjustment" xlink:label="lbl_CustomaryPurchasePriceAdjustment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CustomaryPurchasePriceAdjustment" xlink:to="lbl_label854860965" xlink:type="arc"/>
      <link:label id="id_4b0dbe44" xlink:label="lbl_RepaymentOfIntercompanyBalances_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayment of intercompany balances</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RepaymentOfIntercompanyBalances" xlink:label="lbl_RepaymentOfIntercompanyBalances" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RepaymentOfIntercompanyBalances" xlink:to="lbl_RepaymentOfIntercompanyBalances_labels" xlink:type="arc"/>
      <link:label id="id_3ce6e6d2" xlink:label="lbl_label1021765330" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax reform impact on deferred tax on treasury shares</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:label="lbl_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:to="lbl_label1021765330" xlink:type="arc"/>
      <link:label id="id_1d9b087f" xlink:label="lbl_DividendPaidNoncashAssetsDistribution_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend paid, non-cash assets distribution</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DividendPaidNoncashAssetsDistribution" xlink:label="lbl_DividendPaidNoncashAssetsDistribution" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendPaidNoncashAssetsDistribution" xlink:to="lbl_DividendPaidNoncashAssetsDistribution_labels" xlink:type="arc"/>
      <link:label id="id_49b7a9d9" xlink:label="lbl_DividendPaidNoncashAssetsDistribution_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividend in kind</link:label>
      <link:label id="id_4f1253e8" xlink:label="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net gain at completion of spin-off [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" xlink:label="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" xlink:to="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_cd2ba12" xlink:label="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net gain at completion of spin-off</link:label>
      <link:label id="id_4a895e0" xlink:label="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of assets and liabilities of disposal group classified as held for sale [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:label="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:to="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_399cb44f" xlink:label="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities of disposal group classified as held for sale</link:label>
      <link:label id="id_333e63f1" xlink:label="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated income statement, discontinued operations [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" xlink:label="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" xlink:to="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2b60d5f0" xlink:label="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated income statement, discontinued operations</link:label>
      <link:label id="id_6f1a698a" xlink:label="lbl_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of items included in net income from discontinued operations [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" xlink:label="lbl_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" xlink:to="lbl_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6b21ae09" xlink:label="lbl_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of items included in net income from discontinued operations</link:label>
      <link:label id="id_4a52c922" xlink:label="lbl_DisclosureOfNetAssetsDerecognizedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net assets derecognized [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNetAssetsDerecognizedTableTextBlock" xlink:label="lbl_DisclosureOfNetAssetsDerecognizedTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetAssetsDerecognizedTableTextBlock" xlink:to="lbl_DisclosureOfNetAssetsDerecognizedTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_54e8c608" xlink:label="lbl_DisclosureOfNetAssetsDerecognizedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of net assets derecognized</link:label>
      <link:label id="id_68686f96" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of assets and liabilities arising from divestments [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" xlink:to="lbl_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_74c77dde" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of assets and liabilities arising from divestments</link:label>
      <link:label id="id_3a5e6480" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:type="arc"/>
      <link:label id="id_2aebe53" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement at beginning of period</link:label>
      <link:label id="id_14e1d56d" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement at end of period</link:label>
      <link:label id="id_16d7d1ab" xlink:label="lbl_label383242667" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options exercised in share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="lbl_label383242667" xlink:type="arc"/>
      <link:label id="id_364362e8" xlink:label="lbl_label910385896" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="lbl_label910385896" xlink:type="arc"/>
      <link:label id="id_3ff27324" xlink:label="lbl_label1072853796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="lbl_label1072853796" xlink:type="arc"/>
      <link:label id="id_218c01ed" xlink:label="lbl_label562823661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="lbl_label562823661" xlink:type="arc"/>
      <link:label id="id_7e9fd619" xlink:label="lbl_label2124404249" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price of outstanding share options</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:to="lbl_label2124404249" xlink:type="arc"/>
      <link:label id="id_726c27cc" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:type="arc"/>
      <link:label id="id_5f37a474" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement at beginning of period</link:label>
      <link:label id="id_88d7a8d" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement at end of period</link:label>
      <link:label id="id_4f1e5db1" xlink:label="lbl_label1327390129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:to="lbl_label1327390129" xlink:type="arc"/>
      <link:label id="id_738f9077" xlink:label="lbl_label1938788471" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:to="lbl_label1938788471" xlink:type="arc"/>
      <link:label id="id_236bf45e" xlink:label="lbl_label594277470" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:to="lbl_label594277470" xlink:type="arc"/>
      <link:label id="id_1e452462" xlink:label="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for leases</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_19961677" xlink:label="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases and right-of-use assets</link:label>
      <link:label id="id_7213f224" xlink:label="lbl_DistributionByWayOfDivindendInKindToShareholders_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for distribution by way of divindend in kind to shareholders</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DistributionByWayOfDivindendInKindToShareholders" xlink:label="lbl_DistributionByWayOfDivindendInKindToShareholders" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DistributionByWayOfDivindendInKindToShareholders" xlink:to="lbl_DistributionByWayOfDivindendInKindToShareholders_labels" xlink:type="arc"/>
      <link:label id="id_73c6a1d7" xlink:label="lbl_DistributionByWayOfDivindendInKindToShareholders_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distribution by way of dividend in kind to shareholders</link:label>
      <link:label id="id_3b0bcb35" xlink:label="lbl_label373468922" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aspen Global Incorporated</link:label>
      <link:label id="id_505899ea" xlink:label="lbl_TheMedicinesCompanyMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Medicines Company, East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TheMedicinesCompanyMember" xlink:label="lbl_TheMedicinesCompanyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TheMedicinesCompanyMember" xlink:to="lbl_TheMedicinesCompanyMember_labels" xlink:type="arc"/>
      <link:label id="id_3d4865bf" xlink:label="lbl_TheMedicinesCompanyMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Medicines Company</link:label>
      <link:label id="id_26a553b7" xlink:label="lbl_label648369079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Piqray [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PiqrayMember" xlink:label="lbl_PiqrayMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PiqrayMember" xlink:to="lbl_label648369079" xlink:type="arc"/>
      <link:label id="id_3dbe8202" xlink:label="lbl_label1035895298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xiidra [member]</link:label>
      <link:label id="id_725b9be" xlink:label="lbl_label119912894" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zolgensma [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ZolgensmaMember" xlink:label="lbl_ZolgensmaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZolgensmaMember" xlink:to="lbl_label119912894" xlink:type="arc"/>
      <link:label id="id_7679d6e" xlink:label="lbl_label124231022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mayzent [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MayzentMember" xlink:label="lbl_MayzentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MayzentMember" xlink:to="lbl_label124231022" xlink:type="arc"/>
      <link:label id="id_18490fef" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through assets related to discontinued operations</link:label>
      <link:label id="id_c87ee03" xlink:label="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through reclassification to right-of-use assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:to="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:label="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:to="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_479a229e" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Costs of assets related to discontinued operations</link:label>
      <link:label id="id_18f65009" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through assets related to discontinued operations, intangible assets and goodwill</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:to="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_4ee2113e" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of assets related to discontinued operations</link:label>
      <link:label id="id_6422c211" xlink:label="lbl_label1679999505" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated amortization/impairments on assets related to discontinued operations</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:to="lbl_label1679999505" xlink:type="arc"/>
      <link:label id="id_36a944c" xlink:label="lbl_DeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax balance at beginning of period continuing operations</link:label>
      <link:label id="id_f49321b" xlink:label="lbl_label256455195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net deferred tax balance related to discontinued operations</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:to="lbl_label256455195" xlink:type="arc"/>
      <link:label id="id_59b158e6" xlink:label="lbl_label1504794854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aspen Global Incorporated [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AspenGlobalIncorporatedMember" xlink:label="lbl_AspenGlobalIncorporatedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AspenGlobalIncorporatedMember" xlink:to="lbl_label1504794854" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AspenGlobalIncorporatedMember" xlink:to="lbl_label373468922" xlink:type="arc"/>
      <link:label id="id_3dc8af6f" xlink:label="lbl_UndiscountedFinanceLeasePaymentsToBeReceived_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undiscounted finance lease payments to be received</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UndiscountedFinanceLeasePaymentsToBeReceived" xlink:label="lbl_UndiscountedFinanceLeasePaymentsToBeReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UndiscountedFinanceLeasePaymentsToBeReceived" xlink:to="lbl_UndiscountedFinanceLeasePaymentsToBeReceived_labels" xlink:type="arc"/>
      <link:label id="id_334ff648" xlink:label="lbl_UndiscountedFinanceLeasePaymentsToBeReceived_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total future payments</link:label>
      <link:label id="id_4ca139f0" xlink:label="lbl_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unearned finance income relating to finance lease payments receivable</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:label="lbl_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:to="lbl_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable_labels" xlink:type="arc"/>
      <link:label id="id_32f71aba" xlink:label="lbl_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unearned interest income</link:label>
      <link:label id="id_32d528ec" xlink:label="lbl_MinimumFinaceLeasePaymentsReceivableAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum finace lease payments receivable at present value</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MinimumFinaceLeasePaymentsReceivableAtPresentValue" xlink:label="lbl_MinimumFinaceLeasePaymentsReceivableAtPresentValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MinimumFinaceLeasePaymentsReceivableAtPresentValue" xlink:to="lbl_MinimumFinaceLeasePaymentsReceivableAtPresentValue_labels" xlink:type="arc"/>
      <link:label id="id_200aacc" xlink:label="lbl_MinimumFinaceLeasePaymentsReceivableAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments from finance lease agreements, at present value</link:label>
      <link:label id="id_5e2f001b" xlink:label="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest payments for amounts included in lease liabilities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:label="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:to="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_270f5b37" xlink:label="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest payments for amounts included in lease liabilities classified as cash flows from operating activities</link:label>
      <link:label id="id_60c53887" xlink:label="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase through new leases, liabilities arising from financing activities</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:to="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_3255d072" xlink:label="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New leases</link:label>
      <link:label id="id_78469395" xlink:label="lbl_label2017891221" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from non-current to current, net</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReclassificationFromNoncurrentToCurrentNet" xlink:label="lbl_ReclassificationFromNoncurrentToCurrentNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclassificationFromNoncurrentToCurrentNet" xlink:to="lbl_label2017891221" xlink:type="arc"/>
      <link:label id="id_37080272" xlink:label="lbl_InterestExpenseOnLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
      <link:label id="id_22d1162d" xlink:label="lbl_label584128045" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="lbl_LeaseLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseLiabilitiesMember" xlink:to="lbl_label584128045" xlink:type="arc"/>
      <link:label id="id_5bd2b859" xlink:label="lbl_label1540536409" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration payable</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationPayable" xlink:label="lbl_ContingentConsiderationPayable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationPayable" xlink:to="lbl_label1540536409" xlink:type="arc"/>
      <link:label id="id_11db2be0" xlink:label="lbl_label299576288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Useful life measured as period of time, intangible assets other than goodwill</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:to="lbl_label299576288" xlink:type="arc"/>
      <link:label id="id_358bdb60" xlink:label="lbl_label2144120781" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy, IFRS 16 [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:to="lbl_label2144120781" xlink:type="arc"/>
      <link:label id="id_5776de2" xlink:label="lbl_label91712994" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, USD [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsUSDMember" xlink:label="lbl_BorrowingsUSDMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsUSDMember" xlink:to="lbl_label91712994" xlink:type="arc"/>
      <link:label id="id_37cf6b5c" xlink:label="lbl_label936340316" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, EUR [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsEURMember" xlink:label="lbl_BorrowingsEURMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsEURMember" xlink:to="lbl_label936340316" xlink:type="arc"/>
      <link:label id="id_4e1f7ea0" xlink:label="lbl_FinanceLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance lease liabilities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinanceLeaseLiabilities" xlink:label="lbl_FinanceLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinanceLeaseLiabilities" xlink:to="lbl_FinanceLeaseLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_495a6466" xlink:label="lbl_FinanceLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease obligations</link:label>
      <link:label id="id_633ca478" xlink:label="lbl_label1664918648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity based compensation shares</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedCompensationShares" xlink:label="lbl_EquityBasedCompensationShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedCompensationShares" xlink:to="lbl_label1664918648" xlink:type="arc"/>
      <link:label id="id_79aa7a52" xlink:label="lbl_label2041215570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of options and employee transactions shares</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:label="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:to="lbl_label2041215570" xlink:type="arc"/>
      <link:label id="id_6d34d6c2" xlink:label="lbl_label1832179394" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options and employee transactions, equity impact</link:label>
      <link:label id="id_6fef109e" xlink:label="lbl_label1877938334" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of options and employee transactions</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExerciseOfOptionsAndEmployeeTransactionsValue" xlink:label="lbl_ExerciseOfOptionsAndEmployeeTransactionsValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExerciseOfOptionsAndEmployeeTransactionsValue" xlink:to="lbl_label1877938334" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExerciseOfOptionsAndEmployeeTransactionsValue" xlink:to="lbl_label1832179394" xlink:type="arc"/>
      <link:label id="id_347a007d" xlink:label="lbl_OtherNoncurrentReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current receivables</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentReceivables" xlink:label="lbl_OtherNoncurrentReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentReceivables" xlink:to="lbl_OtherNoncurrentReceivables_labels" xlink:type="arc"/>
      <link:label id="id_4871e871" xlink:label="lbl_OtherNoncurrentReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term receivables</link:label>
      <link:label id="id_4529bc84" xlink:label="lbl_label1160363140" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares delivered to divested business employees</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharesDeliveredToDivestedBusinessEmployees" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:to="lbl_label1160363140" xlink:type="arc"/>
      <link:label id="id_5b371f8c" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, impact of business combinations</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations_labels" xlink:type="arc"/>
      <link:label id="id_3787190c" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_4001cae9" xlink:label="lbl_LeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Impact of adoption of IFRS 16 Leases</link:label>
      <link:label id="id_2f708bd6" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Financial debts cash flows from continuing operations</link:label>
      <link:label id="id_7a3ed482" xlink:label="lbl_label2050937986" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previously reported finance lease obligation of divested business</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:label="lbl_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:to="lbl_label2050937986" xlink:type="arc"/>
      <link:label id="id_34924f0b" xlink:label="lbl_label882003723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net cash flows used in acquisitions and divestments of businesses classified as investing activities from continuing operations</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:to="lbl_label882003723" xlink:type="arc"/>
      <link:label id="id_15f358a7" xlink:label="lbl_label368269479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments, options on equity securities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:label="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:to="lbl_label368269479" xlink:type="arc"/>
      <link:label id="id_61acf165" xlink:label="lbl_label1591563240" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated financial effect of contingent liabilities, damages claimed</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:to="lbl_label1591563240" xlink:type="arc"/>
      <link:label id="id_49032bd4" xlink:label="lbl_label1224944596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional amount of settlement in principle</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdditionalAmountOfSettlementInPrinciple" xlink:label="lbl_AdditionalAmountOfSettlementInPrinciple" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionalAmountOfSettlementInPrinciple" xlink:to="lbl_label1224944596" xlink:type="arc"/>
      <link:label id="id_4b8a0c94" xlink:label="lbl_label1267338388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount of resolved action</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountOfResolvedAction" xlink:label="lbl_AmountOfResolvedAction" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountOfResolvedAction" xlink:to="lbl_label1267338388" xlink:type="arc"/>
      <link:label id="id_54d844bf" xlink:label="lbl_label1423459519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Enoxaparin [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnoxaparinMember" xlink:label="lbl_EnoxaparinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnoxaparinMember" xlink:to="lbl_label1423459519" xlink:type="arc"/>
      <link:label id="id_29f14990" xlink:label="lbl_label703678864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Manufacturing Inc. [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozManufacturingInc.Member" xlink:label="lbl_SandozManufacturingInc.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozManufacturingInc.Member" xlink:to="lbl_label703678864" xlink:type="arc"/>
      <link:label id="id_1755f369" xlink:label="lbl_label391508841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">China Novartis Institute for BioMedical Research Co.,Ltd. [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:label="lbl_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:to="lbl_label391508841" xlink:type="arc"/>
      <link:label id="id_6dee5dc4" xlink:label="lbl_label1844338116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Suzhou Novartis Technical Development Co., Ltd. [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:label="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:to="lbl_label1844338116" xlink:type="arc"/>
      <link:label id="id_5443c473" xlink:label="lbl_label1413727347" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CELLforCURE [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CELLforCUREMember" xlink:label="lbl_CELLforCUREMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CELLforCUREMember" xlink:to="lbl_label1413727347" xlink:type="arc"/>
      <link:label id="id_4cf512" xlink:label="lbl_label5043474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Manufacturing GmbH [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisManufacturingGmbHMember" xlink:label="lbl_NovartisManufacturingGmbHMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisManufacturingGmbHMember" xlink:to="lbl_label5043474" xlink:type="arc"/>
      <link:label id="id_4471df2c" xlink:label="lbl_label1148313388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Hungary Healthcare Limited Liability Company [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:label="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:to="lbl_label1148313388" xlink:type="arc"/>
      <link:label id="id_424beb28" xlink:label="lbl_label1112271656" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advaced Accelerator Applications (Italy) S.r.l. [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:label="lbl_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:to="lbl_label1112271656" xlink:type="arc"/>
      <link:label id="id_5fad9749" xlink:label="lbl_label1605211977" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IDB Holland BV [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IDBHollandBVMember" xlink:label="lbl_IDBHollandBVMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IDBHollandBVMember" xlink:to="lbl_label1605211977" xlink:type="arc"/>
      <link:label id="id_50283594" xlink:label="lbl_label1344812436" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advaced Accelerator Applications Iberica, S.L.U. [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:label="lbl_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:to="lbl_label1344812436" xlink:type="arc"/>
      <link:label id="id_6345aa6d" xlink:label="lbl_label1665509997" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Imaging Equipment Ltd [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImagingEquipmentLtdMember" xlink:label="lbl_ImagingEquipmentLtdMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImagingEquipmentLtdMember" xlink:to="lbl_label1665509997" xlink:type="arc"/>
      <link:label id="id_2031baeb" xlink:label="lbl_label540130027" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Inflammasome Research, Inc. [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInflammasomeResearchInc.Member" xlink:label="lbl_NovartisInflammasomeResearchInc.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInflammasomeResearchInc.Member" xlink:to="lbl_label540130027" xlink:type="arc"/>
      <link:label id="id_1af84be1" xlink:label="lbl_label452479969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Technology LLC [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisTechnologyLLCMember" xlink:label="lbl_NovartisTechnologyLLCMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisTechnologyLLCMember" xlink:to="lbl_label452479969" xlink:type="arc"/>
      <link:label id="id_388a06e4" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion of consideration paid (received) consisting of cash and cash equivalents upfront payment</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment_labels" xlink:type="arc"/>
      <link:label id="id_3b18f468" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Portion of consideration paid consisting of cash and cash equivalents upfront payment</link:label>
      <link:label id="id_47a0c115" xlink:label="lbl_label1201717525" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Partial release of deferred tax liability recognized</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:label="lbl_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:to="lbl_label1201717525" xlink:type="arc"/>
      <link:label id="id_300e3078" xlink:label="lbl_label464719186" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities undiscounted</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LeaseLiabilitiesUndiscounted" xlink:label="lbl_LeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseLiabilitiesUndiscounted" xlink:to="lbl_label464719186" xlink:type="arc"/>
      <link:label id="id_34d806ab" xlink:label="lbl_label1619923269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Most material lease with lease term extension</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MostMaterialLeaseWithLeaseTermExtension" xlink:label="lbl_MostMaterialLeaseWithLeaseTermExtension" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MostMaterialLeaseWithLeaseTermExtension" xlink:to="lbl_label1619923269" xlink:type="arc"/>
      <link:label id="id_53edcb" xlink:label="lbl_label5500363" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash outflows for short term and low value leases</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashOutflowsForShortTermAndLowValueLeases" xlink:label="lbl_CashOutflowsForShortTermAndLowValueLeases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashOutflowsForShortTermAndLowValueLeases" xlink:to="lbl_label5500363" xlink:type="arc"/>
      <link:label id="id_30ae4b2" xlink:label="lbl_label51045554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash outflows for payments of leases interest</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashOutflowsForPaymentsOfLeasesInterest" xlink:label="lbl_CashOutflowsForPaymentsOfLeasesInterest" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashOutflowsForPaymentsOfLeasesInterest" xlink:to="lbl_label51045554" xlink:type="arc"/>
      <link:label id="id_5a4733e9" xlink:label="lbl_label1514615785" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax reform effective tax rate after implemetation of new reform changes</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:label="lbl_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:to="lbl_label1514615785" xlink:type="arc"/>
      <link:label id="id_63ed288d" xlink:label="lbl_label1676486797" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax reform effective blended tax rate after implemetation of new reform changes</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:label="lbl_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:to="lbl_label1676486797" xlink:type="arc"/>
      <link:label id="id_3af42b4" xlink:label="lbl_label2021190939" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long term receivables from finance subleases</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LongTermReceivablesFromFinanceSubleases" xlink:label="lbl_LongTermReceivablesFromFinanceSubleases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LongTermReceivablesFromFinanceSubleases" xlink:to="lbl_label2021190939" xlink:type="arc"/>
      <link:label id="id_115b6ebf" xlink:label="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through liabilities related to discontinued operations</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:label="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:to="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_64b9f08d" xlink:label="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial debts and lease liabilities related to discontinued operations</link:label>
      <link:label id="id_a7c0098" xlink:label="lbl_label175898776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings credit facility short term</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsCreditFacilityShortTerm" xlink:label="lbl_BorrowingsCreditFacilityShortTerm" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsCreditFacilityShortTerm" xlink:to="lbl_label175898776" xlink:type="arc"/>
      <link:label id="id_3f8e8cf1" xlink:label="lbl_label1066306801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lbl_label1066306801" xlink:type="arc"/>
      <link:label id="id_44dffa85" xlink:label="lbl_label1155529349" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lbl_label1155529349" xlink:type="arc"/>
      <link:label id="id_7feaeddc" xlink:label="lbl_label167109794" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [axis]</link:label>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrencyAxis" xlink:to="lbl_label167109794" xlink:type="arc"/>
      <link:label id="id_2246514e" xlink:label="lbl_label2121837386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [member]</link:label>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:label="lbl_EuropeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EuropeMember" xlink:to="lbl_label2121837386" xlink:type="arc"/>
      <link:label id="id_4c9a1836" xlink:label="lbl_label849028726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Americas [member]</link:label>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AmericasMember" xlink:label="lbl_AmericasMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmericasMember" xlink:to="lbl_label849028726" xlink:type="arc"/>
      <link:label id="id_295e5e69" xlink:label="lbl_RightofuseAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="lbl_RightofuseAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RightofuseAssetsMember" xlink:to="lbl_RightofuseAssetsMember_labels" xlink:type="arc"/>
      <link:label id="id_164ca513" xlink:label="lbl_RightofuseAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
      <link:label id="id_4947c6a9" xlink:label="lbl_label1229440681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Beovu [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BeovuMember" xlink:label="lbl_BeovuMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BeovuMember" xlink:to="lbl_label1229440681" xlink:type="arc"/>
      <link:label id="id_22f028b0" xlink:label="lbl_ConsiderationPaidReceived_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration paid (received)</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="lbl_ConsiderationPaidReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsiderationPaidReceived" xlink:to="lbl_ConsiderationPaidReceived_labels" xlink:type="arc"/>
      <link:label id="id_3dc9426c" xlink:label="lbl_ConsiderationPaidReceived_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash inflows from divestment</link:label>
      <link:label id="id_56521fba" xlink:label="lbl_label1448222650" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net cash outflows from divestments</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetCashOutflowsFromDivestments" xlink:label="lbl_NetCashOutflowsFromDivestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetCashOutflowsFromDivestments" xlink:to="lbl_label1448222650" xlink:type="arc"/>
      <link:label id="id_1d2114e2" xlink:label="lbl_label488707298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents in subsidiary or businesses acquired or disposed</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:to="lbl_label488707298" xlink:type="arc"/>
      <link:label id="id_45aec51d" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers and other changes, other provisions</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:to="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_6eb0eb0c" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfers</link:label>
      <link:label id="id_6bada554" xlink:label="lbl_label1806542164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentLiabilitiesMember" xlink:label="lbl_CurrentLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLiabilitiesMember" xlink:to="lbl_label1806542164" xlink:type="arc"/>
      <link:label id="id_61717448" xlink:label="lbl_label1634825288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentLiabilitiesMember" xlink:label="lbl_NoncurrentLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLiabilitiesMember" xlink:to="lbl_label1634825288" xlink:type="arc"/>
      <link:label id="id_2e9b8dad" xlink:label="lbl_label781946285" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities in subsidiary or businesses acquired or disposed</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:to="lbl_label781946285" xlink:type="arc"/>
      <link:label id="id_508846a9" xlink:label="lbl_CurrentLeaseLiabilitiesUndiscounted_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current lease liabilities undiscounted</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentLeaseLiabilitiesUndiscounted" xlink:label="lbl_CurrentLeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLeaseLiabilitiesUndiscounted" xlink:to="lbl_CurrentLeaseLiabilitiesUndiscounted_labels" xlink:type="arc"/>
      <link:label id="id_420e4c77" xlink:label="lbl_label1108233335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities undiscounted</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentLeaseLiabilitiesUndiscounted" xlink:label="lbl_NoncurrentLeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLeaseLiabilitiesUndiscounted" xlink:to="lbl_label1108233335" xlink:type="arc"/>
      <link:label id="id_5c23b63c" xlink:label="lbl_CurrentLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less current lease liabilities</link:label>
      <link:label id="id_77f7d595" xlink:label="lbl_CurrentLeaseLiabilitiesUndiscounted_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Less current lease liabilities undiscounted</link:label>
      <link:label id="id_16b54793" xlink:label="lbl_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax expense arising from write-down or reversal of write-down of deferred tax asset</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset" xlink:label="lbl_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset" xlink:to="lbl_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset_labels" xlink:type="arc"/>
      <link:label id="id_45e19527" xlink:label="lbl_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of write-off of deferred tax assets</link:label>
      <link:label id="id_63e83d46" xlink:label="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment charge prior to classification to assets held for sale</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:label="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:to="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale_labels" xlink:type="arc"/>
      <link:label id="id_226b60a4" xlink:label="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge prior to classification to assets held for sale</link:label>
      <link:label id="id_557effd1" xlink:label="lbl_label1434386385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax on transaction costs recorded in equity</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxOnTransactionCostsRecordedInEquity" xlink:label="lbl_TaxOnTransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxOnTransactionCostsRecordedInEquity" xlink:to="lbl_label1434386385" xlink:type="arc"/>
      <link:label id="id_5c1a2168" xlink:label="lbl_EffectOfWriteoffOfDeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of write-off of deferred tax assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EffectOfWriteoffOfDeferredTaxAssets" xlink:label="lbl_EffectOfWriteoffOfDeferredTaxAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectOfWriteoffOfDeferredTaxAssets" xlink:to="lbl_EffectOfWriteoffOfDeferredTaxAssets_labels" xlink:type="arc"/>
      <link:label id="id_59102729" xlink:label="lbl_EffectOfWriteoffOfDeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of write-off of deferred tax assets</link:label>
      <link:label id="id_3df76505" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from current and non-current borrowings</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:to="lbl_ProceedsFromCurrentAndNoncurrentBorrowings_labels" xlink:type="arc"/>
      <link:label id="id_64441db" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs payment</link:label>
      <link:label id="id_11959a05" xlink:label="lbl_label295016965" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Uncalled capital commitments for investments in funds</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:label="lbl_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:to="lbl_label295016965" xlink:type="arc"/>
      <link:label id="id_12c8e5a0" xlink:label="lbl_label315155872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LitigationCaseMember" xlink:label="lbl_LitigationCaseMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LitigationCaseMember" xlink:to="lbl_label315155872" xlink:type="arc"/>
      <link:label id="id_73c71c69" xlink:label="lbl_label1942428777" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tennessee class action [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TennesseeClassActionMember" xlink:label="lbl_TennesseeClassActionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TennesseeClassActionMember" xlink:to="lbl_label1942428777" xlink:type="arc"/>
      <link:label id="id_17248af4" xlink:label="lbl_label388270836" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Massachusetts case [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MassachusettsCaseMember" xlink:label="lbl_MassachusettsCaseMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MassachusettsCaseMember" xlink:to="lbl_label388270836" xlink:type="arc"/>
      <link:label id="id_23bc1d31" xlink:label="lbl_label599530801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="lbl_DocumentAnnualReport" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentAnnualReport" xlink:to="lbl_label599530801" xlink:type="arc"/>
      <link:label id="id_34b5e034" xlink:label="lbl_label884334644" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="lbl_EntityShellCompany" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityShellCompany" xlink:to="lbl_label884334644" xlink:type="arc"/>
      <link:label id="id_481345ce" xlink:label="lbl_label1209222606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="lbl_EntityEmergingGrowthCompany" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityEmergingGrowthCompany" xlink:to="lbl_label1209222606" xlink:type="arc"/>
      <link:label id="id_448d1a1f" xlink:label="lbl_label1150097951" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="lbl_EntityInteractiveDataCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityInteractiveDataCurrent" xlink:to="lbl_label1150097951" xlink:type="arc"/>
      <link:label id="id_8e53da4" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash inflow from borrowings</link:label>
      <link:label id="id_39e22a7b" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Transaction cost payments</link:label>
      <link:label id="id_4f32f729" xlink:label="lbl_label1328740137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GrossDeferredTaxAssets" xlink:label="lbl_GrossDeferredTaxAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossDeferredTaxAssets" xlink:to="lbl_label1328740137" xlink:type="arc"/>
      <link:label id="id_182b8b94" xlink:label="lbl_GrossDeferredTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross deferred tax liabilities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GrossDeferredTaxLiabilities" xlink:label="lbl_GrossDeferredTaxLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossDeferredTaxLiabilities" xlink:to="lbl_GrossDeferredTaxLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_3fcaf800" xlink:label="lbl_GrossDeferredTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax liabilities</link:label>
      <link:label id="id_12baf088" xlink:label="lbl_label314241160" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount borrowed under the credit facility</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountBorrowedUnderTheCreditFacility" xlink:label="lbl_AmountBorrowedUnderTheCreditFacility" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountBorrowedUnderTheCreditFacility" xlink:to="lbl_label314241160" xlink:type="arc"/>
      <link:label id="id_24f2fc6a" xlink:label="lbl_ContingentConsiderationLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration liabilities</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationLiabilities" xlink:label="lbl_ContingentConsiderationLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationLiabilities" xlink:to="lbl_ContingentConsiderationLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_596ae769" xlink:label="lbl_label1500178281" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation case [axis]</link:label>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="lbl_LitigationCaseAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LitigationCaseAxis" xlink:to="lbl_label1500178281" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_XiidraMember" xlink:label="lbl_XiidraMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_XiidraMember" xlink:to="lbl_label1035895298" xlink:type="arc"/>
      <link:label id="id_6dadd046" xlink:label="lbl_label1840107590" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="lbl_DocumentTransitionReport" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentTransitionReport" xlink:to="lbl_label1840107590" xlink:type="arc"/>
      <link:label id="id_287ed480" xlink:label="lbl_label679400576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="lbl_DocumentShellCompanyReport" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentShellCompanyReport" xlink:to="lbl_label679400576" xlink:type="arc"/>
      <link:label id="id_6eada512" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated depreciation, amortisation and impairment [member]</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember_labels" xlink:type="arc"/>
      <link:label id="id_b2dfb88" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation, amortisation and impairment</link:label>
      <link:label id="id_4be49960" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to deferred tax assets on Swiss post retirement previously recognized through OCI</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI_labels" xlink:type="arc"/>
      <link:label id="id_7d4d613b" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to deferred tax assets on Swiss post retirement previously recognized through OCI</link:label>
      <link:label id="id_4eb0928b" xlink:label="lbl_TaxesOnTreasuryShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes on treasury shares</link:label>
      <link:label id="id_22a0ea85" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs of assets related to discontinued operations</link:label>
      <link:label id="id_15b36c9d" xlink:label="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease through reclassification to right-of-use assets</link:label>
      <link:label id="id_55dcd44c" xlink:label="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Recognition exemption for short term leases</link:label>
      <link:label id="id_7a35ce5" xlink:label="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Recognition exception for low value leases</link:label>
      <link:label id="id_40e677f7" xlink:label="lbl_EffectOfDiscounting_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect of discounting</link:label>
      <link:label id="id_2d2e026c" xlink:label="lbl_DepreciationRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation charge</link:label>
      <link:label id="id_1ac53b1b" xlink:label="lbl_LeaseContractTerminationsRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Lease contract terminations, right-of-use assets</link:label>
      <link:label id="id_e5f5961" xlink:label="lbl_CurrentLeaseLiabilitiesUndiscounted_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less current lease liabilities undiscounted</link:label>
      <link:label id="id_7d7ce79e" xlink:label="lbl_InventoryWritedown2011_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory provisions</link:label>
      <link:label id="id_42fb2d2e" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current trade receivables from closely monitored countries past due more than one year, provisions recorded</link:label>
      <link:label id="id_4eb32c65" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of previously held equity interests</link:label>
      <link:label id="id_27322091" xlink:label="lbl_ProceedsFromNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from non-current financial debts</link:label>
      <link:label id="id_7e6f87d8" xlink:label="lbl_AmortizationOfBondsDiscount_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of bonds discount</link:label>
      <link:label id="id_25b1f7fc" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contributions of associates</link:label>
      <link:label id="id_4de13945" xlink:label="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
      <link:label id="id_148d311b" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_67019b8d" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of acquisitions, divestments or transfers</link:label>
      <link:label id="id_f7a5847" xlink:label="lbl_ChangeInLimitationOnRecognitionOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in limitation on recognition of fund surplus (incl. exchange rate differences)</link:label>
      <link:label id="id_6e294aeb" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_4bbdbc8c" xlink:label="lbl_ContingentConsiderationLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration liabilities</link:label>
      <link:label id="id_45ca4585" xlink:label="lbl_NetAssetsDerecognized_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net assets derecognized</link:label>
      <link:label id="id_42ccca61" xlink:label="lbl_label1120717409" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of entitys trade receivable</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PercentageOfEntitysTradeReceivable" xlink:label="lbl_PercentageOfEntitysTradeReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfEntitysTradeReceivable" xlink:to="lbl_label1120717409" xlink:type="arc"/>
      <link:label id="id_43ec36aa" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment of lease liability</link:label>
      <link:label id="id_677ffa06" xlink:label="lbl_CashInflowForSaleAndLeaseback_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow for sale and leaseback</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashInflowForSaleAndLeaseback" xlink:label="lbl_CashInflowForSaleAndLeaseback" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowForSaleAndLeaseback" xlink:to="lbl_CashInflowForSaleAndLeaseback_labels" xlink:type="arc"/>
      <link:label id="id_5bdc50eb" xlink:label="lbl_SaleAndLeaseBackMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale and lease back [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SaleAndLeaseBackMember" xlink:label="lbl_SaleAndLeaseBackMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleAndLeaseBackMember" xlink:to="lbl_SaleAndLeaseBackMember_labels" xlink:type="arc"/>
      <link:label id="id_73fe88ea" xlink:label="lbl_SaleAndLeaseBackMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale and leaseback</link:label>
      <link:label id="id_1b2ddb15" xlink:label="lbl_CurrentRefundsProvision_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current refunds provision</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentRefundsProvision" xlink:label="lbl_CurrentRefundsProvision" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentRefundsProvision" xlink:to="lbl_CurrentRefundsProvision_labels" xlink:type="arc"/>
      <link:label id="id_6f9ec2d7" xlink:label="lbl_CurrentRefundsProvision_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue</link:label>
      <link:label id="id_782da91f" xlink:label="lbl_CurrentRefundsProvision_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue, at beginning of period</link:label>
      <link:label id="id_67f2691b" xlink:label="lbl_CurrentRefundsProvision_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue, at end of period</link:label>
      <link:label id="id_376d9857" xlink:label="lbl_label929929303" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments, commodity purchase contract</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:label="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:to="lbl_label929929303" xlink:type="arc"/>
      <link:label id="id_4c17362a" xlink:label="lbl_DisposalsAndRetirementsRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals and retirements, right-of-use assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisposalsAndRetirementsRightofuseAssets" xlink:label="lbl_DisposalsAndRetirementsRightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalsAndRetirementsRightofuseAssets" xlink:to="lbl_DisposalsAndRetirementsRightofuseAssets_labels" xlink:type="arc"/>
      <link:label id="id_328352cc" xlink:label="lbl_DisposalsAndRetirementsRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of divestments</link:label>
      <link:label id="id_5a93baa1" xlink:label="lbl_LeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
      <link:label id="id_1917780" xlink:label="lbl_label26310528" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of income not subject to tax on divestment gain</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:label="lbl_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:to="lbl_label26310528" xlink:type="arc"/>
      <link:label id="id_6025ab0" xlink:label="lbl_CashInflowForSaleAndLeaseback_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash inflow for sale and leaseback</link:label>
      <link:label id="id_642f7fec" xlink:label="lbl_label1680834540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Suzhou Novartis Technical Development Co., Ltd., Changshu [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:label="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:to="lbl_label1680834540" xlink:type="arc"/>
      <link:label id="id_14fc3a32" xlink:label="lbl_label352074290" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CELLforCURE, Les Ulis [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CELLforCURELesUlisMember" xlink:label="lbl_CELLforCURELesUlisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CELLforCURELesUlisMember" xlink:to="lbl_label352074290" xlink:type="arc"/>
      <link:label id="id_372a8238" xlink:label="lbl_label925532728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications (Italy) S.r.l., Pozzilli [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:label="lbl_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:to="lbl_label925532728" xlink:type="arc"/>
      <link:label id="id_12a3185f" xlink:label="lbl_label312678495" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Netherlands B.V., Amsterdam [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisNetherlandsB.V.AmsterdamMember" xlink:label="lbl_NovartisNetherlandsB.V.AmsterdamMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisNetherlandsB.V.AmsterdamMember" xlink:to="lbl_label312678495" xlink:type="arc"/>
      <link:label id="id_495d47ae" xlink:label="lbl_label1230849966" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma B.V., Amsterdam [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaB.V.AmsterdamMember" xlink:label="lbl_NovartisPharmaB.V.AmsterdamMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaB.V.AmsterdamMember" xlink:to="lbl_label1230849966" xlink:type="arc"/>
      <link:label id="id_3b55a7b7" xlink:label="lbl_label995469239" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IDB Holland BV, Baarle-Nassau [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IDBHollandBVBaarleNassauMember" xlink:label="lbl_IDBHollandBVBaarleNassauMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IDBHollandBVBaarleNassauMember" xlink:to="lbl_label995469239" xlink:type="arc"/>
      <link:label id="id_33884b38" xlink:label="lbl_label864570168" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Saudi Ltd., Riyadh [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisSaudiLtd.RiyadhMember" xlink:label="lbl_NovartisSaudiLtd.RiyadhMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSaudiLtd.RiyadhMember" xlink:to="lbl_label864570168" xlink:type="arc"/>
      <link:label id="id_222bb2dd" xlink:label="lbl_label573289181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications Iberica, S.L.U., Barcelona [member]</link:label>
      <link:label id="id_10409dbe" xlink:label="lbl_label272670142" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis UK Limited, London [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisUKLimitedLondonMember" xlink:label="lbl_NovartisUKLimitedLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisUKLimitedLondonMember" xlink:to="lbl_label272670142" xlink:type="arc"/>
      <link:label id="id_63d11071" xlink:label="lbl_label1674645617" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharmaceuticals UK Limited, London [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:label="lbl_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:to="lbl_label1674645617" xlink:type="arc"/>
      <link:label id="id_19392a8e" xlink:label="lbl_label423176846" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Grimsby Limited, London [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisGrimsbyLimitedLondonMember" xlink:label="lbl_NovartisGrimsbyLimitedLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisGrimsbyLimitedLondonMember" xlink:to="lbl_label423176846" xlink:type="arc"/>
      <link:label id="id_7c7620c7" xlink:label="lbl_label2088116423" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Imaging Equipment Ltd, London [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImagingEquipmentLtdLondonMember" xlink:label="lbl_ImagingEquipmentLtdLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImagingEquipmentLtdLondonMember" xlink:to="lbl_label2088116423" xlink:type="arc"/>
      <link:label id="id_51082ea6" xlink:label="lbl_label1359490726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ziarco Group Limited, London [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ZiarcoGroupLimitedLondonMember" xlink:label="lbl_ZiarcoGroupLimitedLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZiarcoGroupLimitedLondonMember" xlink:to="lbl_label1359490726" xlink:type="arc"/>
      <link:label id="id_70da7012" xlink:label="lbl_label1893363730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Finance Corporation, East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFinanceCorporationEastHanoverNJMember" xlink:label="lbl_NovartisFinanceCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFinanceCorporationEastHanoverNJMember" xlink:to="lbl_label1893363730" xlink:type="arc"/>
      <link:label id="id_1a5c8917" xlink:label="lbl_label442272023" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Capital Corporation, East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisCapitalCorporationEastHanoverNJMember" xlink:label="lbl_NovartisCapitalCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCapitalCorporationEastHanoverNJMember" xlink:to="lbl_label442272023" xlink:type="arc"/>
      <link:label id="id_2db5a3fb" xlink:label="lbl_label766878715" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis US Foundation, East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisUSFoundationEastHanoverNJMember" xlink:label="lbl_NovartisUSFoundationEastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisUSFoundationEastHanoverNJMember" xlink:to="lbl_label766878715" xlink:type="arc"/>
      <link:label id="id_5bd187f1" xlink:label="lbl_label1540458481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications USA, Inc., Millburn, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:to="lbl_label1540458481" xlink:type="arc"/>
      <link:label id="id_25dd15b1" xlink:label="lbl_label635246001" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Inflammasome Research, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:label="lbl_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:to="lbl_label635246001" xlink:type="arc"/>
      <link:label id="id_561808b5" xlink:label="lbl_label1444415669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Technology LLC, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:label="lbl_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:to="lbl_label1444415669" xlink:type="arc"/>
      <link:label id="id_7ffed34c" xlink:label="lbl_label2147406668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Encore Vision, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EncoreVisionInc.EastHanoverNJMember" xlink:label="lbl_EncoreVisionInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EncoreVisionInc.EastHanoverNJMember" xlink:to="lbl_label2147406668" xlink:type="arc"/>
      <link:label id="id_4458c6ff" xlink:label="lbl_label1146668799" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Endocyte, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EndocyteInc.EastHanoverNJMember" xlink:label="lbl_EndocyteInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EndocyteInc.EastHanoverNJMember" xlink:to="lbl_label1146668799" xlink:type="arc"/>
      <link:label id="id_68546348" xlink:label="lbl_label1750360904" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Vaccines and Diagnostics, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:label="lbl_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:to="lbl_label1750360904" xlink:type="arc"/>
      <link:label id="id_2d054e5d" xlink:label="lbl_label755322461" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Spinifex Pharmaceuticals, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:label="lbl_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:to="lbl_label755322461" xlink:type="arc"/>
      <link:label id="id_75833aa3" xlink:label="lbl_label1971534499" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Manufacturing GmbH, Marburg [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisManufacturingGmbHMarburgMember" xlink:label="lbl_NovartisManufacturingGmbHMarburgMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisManufacturingGmbHMarburgMember" xlink:to="lbl_label1971534499" xlink:type="arc"/>
      <link:label id="id_3ce1ce66" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payments of lease liabilities, net</link:label>
      <link:label id="id_7d5a543d" xlink:label="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest payments for amounts included in lease liabilities classified as cash flows from operating activities</link:label>
      <link:label id="id_264ae6cd" xlink:label="lbl_AmortizationOfBondsDiscount_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of bonds discount</link:label>
      <link:label id="id_541ef56a" xlink:label="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transfers out of Level 3 of fair value hierarchy, assets</link:label>
      <link:label id="id_4edf1e96" xlink:label="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amount of change in OCI when POS for level 3 change more than 10%</link:label>
      <link:label id="id_2efc8f07" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayments of non-current financial debts</link:label>
      <link:label id="id_2d28f541" xlink:label="lbl_label757658945" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of US tax reform legislation</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EffectOfUSTaxReformLegislation" xlink:label="lbl_EffectOfUSTaxReformLegislation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectOfUSTaxReformLegislation" xlink:to="lbl_label757658945" xlink:type="arc"/>
      <link:label id="id_3c578d43" xlink:label="lbl_AcquiredCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired cash and cash equivalents</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquiredCashAndCashEquivalents" xlink:label="lbl_AcquiredCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquiredCashAndCashEquivalents" xlink:to="lbl_AcquiredCashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_25ec28ce" xlink:label="lbl_AcquiredCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquired cash and cash equivalents</link:label>
      <link:label id="id_4dc21030" xlink:label="lbl_label1304563760" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of impact on adoption of IFRS 16</link:label>
      <link:label id="id_284baaac" xlink:label="lbl_label676047532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of impact on adoption of IFRS 16 [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:label="lbl_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:to="lbl_label676047532" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:to="lbl_label1304563760" xlink:type="arc"/>
      <link:label id="id_7cee5446" xlink:label="lbl_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated income statement, additional information [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" xlink:label="lbl_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" xlink:to="lbl_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_43467410" xlink:label="lbl_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated income statement, additional information</link:label>
      <link:label id="id_47cec299" xlink:label="lbl_BalanceSheetAdditionalInformationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance sheet, additional information [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BalanceSheetAdditionalInformationTableTextBlock" xlink:label="lbl_BalanceSheetAdditionalInformationTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BalanceSheetAdditionalInformationTableTextBlock" xlink:to="lbl_BalanceSheetAdditionalInformationTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_557771c9" xlink:label="lbl_BalanceSheetAdditionalInformationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance sheet, additional information</link:label>
      <link:label id="id_6c2f9126" xlink:label="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows used in investing activities [table text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashFlowsUsedInInvestingActivitiesTableTextBlock" xlink:label="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock" xlink:to="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6c013712" xlink:label="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows used in investing activities</link:label>
      <link:label id="id_cd95e1f" xlink:label="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CH Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" xlink:label="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" xlink:to="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5424fa1a" xlink:label="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CH Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities</link:label>
      <link:label id="id_71dfb6f6" xlink:label="lbl_label1910486774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ultibro Group [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UltibroGroupMember" xlink:label="lbl_UltibroGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UltibroGroupMember" xlink:to="lbl_label1910486774" xlink:type="arc"/>
      <link:label id="id_86983fb" xlink:label="lbl_label141132795" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adakveo [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdakveoMember" xlink:label="lbl_AdakveoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdakveoMember" xlink:to="lbl_label141132795" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_label1289490857" xlink:type="arc"/>
      <link:label id="id_4b6d4dbb" xlink:label="lbl_label1265454523" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Capital Corporation, New York, United States, 1.75%, 2025 [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:to="lbl_label1265454523" xlink:type="arc"/>
      <link:label id="id_506f7c31" xlink:label="lbl_label1349483569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Capital Corporation, New York, United States, 2.00%, 2027 [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:to="lbl_label1349483569" xlink:type="arc"/>
      <link:label id="id_2f497fb1" xlink:label="lbl_label793345969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Capital Corporation, New York, United States, 2.20%, 2030 [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:to="lbl_label793345969" xlink:type="arc"/>
      <link:label id="id_27dd04e2" xlink:label="lbl_label668796130" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Capital Corporation, New York, United States, 2.75%, 2050 [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:to="lbl_label668796130" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PoPChangeMember" xlink:to="lbl_label1343837424" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PoPYEChangeMember" xlink:to="lbl_label571817371" xlink:type="arc"/>
      <link:label id="id_baa97ec" xlink:label="lbl_CurrentTaxAssetsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax assets, current</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="lbl_CurrentTaxAssetsCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTaxAssetsCurrent" xlink:to="lbl_CurrentTaxAssetsCurrent_labels" xlink:type="arc"/>
      <link:label id="id_6f03bc65" xlink:label="lbl_CurrentTaxAssetsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax receivable</link:label>
      <link:label id="id_1b60e90f" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions and other non-current liabilities</link:label>
      <link:label id="id_4606d526" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total provisions and other non-current liabilities</link:label>
      <link:label id="id_f38218c" xlink:label="lbl_label255336844" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZPL389 [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ZPL389Member" xlink:label="lbl_ZPL389Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZPL389Member" xlink:to="lbl_label255336844" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueOfOtherFinancialAssetsSold" xlink:label="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueOfOtherFinancialAssetsSold" xlink:to="lbl_label2044002083" xlink:type="arc"/>
      <link:label id="id_4fe64fe" xlink:label="lbl_RepaymentOfIntercompanyBalances_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of intercompany balances</link:label>
      <link:label id="id_17ced1e3" xlink:label="lbl_RightOfUseAssetsAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right of use assets as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RightOfUseAssetsAsOfAcquisitionDate" xlink:label="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:to="lbl_RightOfUseAssetsAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_78162c1a" xlink:label="lbl_RightOfUseAssetsAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
      <link:label id="id_23e031e7" xlink:label="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current and non current lease liabilities as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:label="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:to="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_5e1a35c1" xlink:label="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current and non-current lease liabilities</link:label>
      <link:label id="id_2d827166" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payments attributable to the spin-off of the Alcon business</link:label>
      <link:label id="id_5854f481" xlink:label="lbl_CashFlowsAttributableToDivestedBusiness_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows attributable to the spin-off of the Alcon business</link:label>
      <link:label id="id_280cd5b1" xlink:label="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of property, plant and equipment</link:label>
      <link:label id="id_4ae04f6d" xlink:label="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercised options and other treasury share transactions, net</link:label>
      <link:label id="id_1829dad9" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets and goodwill</link:label>
      <link:label id="id_452d236c" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge</link:label>
      <link:label id="id_1af64409" xlink:label="lbl_TransactionCosts_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs recognized in the consolidated income statement</link:label>
      <link:label id="id_7a659997" xlink:label="lbl_label2053478807" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid sales price for a business divestment</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PrepaidSalesPriceForABusinessDivestment" xlink:label="lbl_PrepaidSalesPriceForABusinessDivestment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PrepaidSalesPriceForABusinessDivestment" xlink:to="lbl_label2053478807" xlink:type="arc"/>
      <link:label id="id_137fddb" xlink:label="lbl_CurrentRefundsProvisionDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current refunds provision, Discontinued operations</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentRefundsProvisionDiscontinuedOperations" xlink:label="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:to="lbl_CurrentRefundsProvisionDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_5ae43d2a" xlink:label="lbl_CurrentRefundsProvisionDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue, discontinued operations</link:label>
      <link:label id="id_2214c4b6" xlink:label="lbl_CurrentRefundsProvisionDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue, discontinued operations, at beginning of period</link:label>
      <link:label id="id_64fab371" xlink:label="lbl_CurrentRefundsProvisionDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue, discontinued operations, at end of period</link:label>
      <link:label id="id_305e08c1" xlink:label="lbl_ProvisionForDoubtfulReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for doubtful receivable</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionForDoubtfulReceivable" xlink:label="lbl_ProvisionForDoubtfulReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionForDoubtfulReceivable" xlink:to="lbl_ProvisionForDoubtfulReceivable_labels" xlink:type="arc"/>
      <link:label id="id_17c9358" xlink:label="lbl_ProvisionForDoubtfulReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Provision for doubtful receivable at beginning of period</link:label>
      <link:label id="id_7c5a57a4" xlink:label="lbl_ProvisionForDoubtfulReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Provision for doubtful receivable at end of period</link:label>
      <link:label id="id_569afc65" xlink:label="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit obligation, Discontinued operations, at present value</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:label="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:to="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue_labels" xlink:type="arc"/>
      <link:label id="id_6cf5f158" xlink:label="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Benefit obligation, Discontinued operations at beginning of period</link:label>
      <link:label id="id_4998d875" xlink:label="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Benefit obligation, Discontinued operations at end of period</link:label>
      <link:label id="id_11da36c7" xlink:label="lbl_label299513543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities, impact of adoption of IFRS 16</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LeaseLiabilitiesImpactOfAdoptionOfIFRS16" xlink:label="lbl_LeaseLiabilitiesImpactOfAdoptionOfIFRS16" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseLiabilitiesImpactOfAdoptionOfIFRS16" xlink:to="lbl_label299513543" xlink:type="arc"/>
      <link:label id="id_664f7869" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contributions to plan by plan participants, net defined benefit liability (asset), benefit obligation</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:to="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation_labels" xlink:type="arc"/>
      <link:label id="id_5209ef33" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributions of associates</link:label>
      <link:label id="id_34fc26b" xlink:label="lbl_label55558763" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease commitments, discontinued operations</link:label>
      <link:label id="id_61a2309d" xlink:label="lbl_label1638019229" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross lease liabilities, Discontinued operations</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:label="lbl_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:to="lbl_label1638019229" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:to="lbl_label55558763" xlink:type="arc"/>
      <link:label id="id_4087a31" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase/Decrease through classified as held for sale, intangible assets and goodwill</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:to="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_28188a68" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of assets related to disposal group held for sale</link:label>
      <link:label id="id_1caaba88" xlink:label="lbl_TreasurySharesMovementOfPeriod_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares movement of period</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TreasurySharesMovementOfPeriod" xlink:label="lbl_TreasurySharesMovementOfPeriod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesMovementOfPeriod" xlink:to="lbl_TreasurySharesMovementOfPeriod_labels" xlink:type="arc"/>
      <link:label id="id_21690868" xlink:label="lbl_TreasurySharesMovementOfPeriod_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares movement of period</link:label>
      <link:label id="id_5def5bff" xlink:label="lbl_label1575967743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease in finance leases receivable due to unearned finance income relating to finance lease payments receivable</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DecreaseInFinanceLeasesReceivableDueToUnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:label="lbl_DecreaseInFinanceLeasesReceivableDueToUnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseInFinanceLeasesReceivableDueToUnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:to="lbl_label1575967743" xlink:type="arc"/>
      <link:label id="id_34d7edcd" xlink:label="lbl_label886566349" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other financial liabilities, category [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherFinancialLiabilitiesCategoryMember" xlink:label="lbl_OtherFinancialLiabilitiesCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherFinancialLiabilitiesCategoryMember" xlink:to="lbl_label886566349" xlink:type="arc"/>
      <link:label id="id_eec52d1" xlink:label="lbl_label250368721" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current assets [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherCurrentAssetsMember" xlink:label="lbl_OtherCurrentAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentAssetsMember" xlink:to="lbl_label250368721" xlink:type="arc"/>
      <link:label id="id_354fdd57" xlink:label="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on financial instruments [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:label="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember_labels" xlink:type="arc"/>
      <link:label id="id_273f4f15" xlink:label="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_1_Fair value adjustments on marketable securities</link:label>
      <link:label id="id_38a75dc3" xlink:label="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value Adjustment Increase Decrease Through Changes In Ownership Interests In Subsidiaries That Do Not Result In Loss Of Control</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:label="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:to="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:type="arc"/>
      <link:label id="id_e0e9730" xlink:label="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of change in ownership of consolidated entities</link:label>
      <link:label id="id_92da590" xlink:label="lbl_RepurchaseOfOptions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repurchase of options</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RepurchaseOfOptions" xlink:label="lbl_RepurchaseOfOptions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RepurchaseOfOptions" xlink:to="lbl_RepurchaseOfOptions_labels" xlink:type="arc"/>
      <link:label id="id_4e1c053" xlink:label="lbl_RepurchaseOfOptions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of options</link:label>
      <link:label id="id_3b79b108" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations right-of-use assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets_labels" xlink:type="arc"/>
      <link:label id="id_4848a24f" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_780c70ab" xlink:label="lbl_label2014081195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabrecta [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TabrectaMember" xlink:label="lbl_TabrectaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TabrectaMember" xlink:to="lbl_label2014081195" xlink:type="arc"/>
      <link:label id="id_127152f2" xlink:label="lbl_label309416690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kesimpta [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KesimptaMember" xlink:label="lbl_KesimptaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KesimptaMember" xlink:to="lbl_label309416690" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:label="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:to="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes_labels" xlink:type="arc"/>
      <link:label id="id_5de4f6ff" xlink:label="lbl_label1575286527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.750% USD 1 000 million 2020/2025 Novartis Capital Corporation, New York, United States, issued at 99.852% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:label="lbl_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:to="lbl_label1575286527" xlink:type="arc"/>
      <link:label id="id_5914d9cb" xlink:label="lbl_label1494538699" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.000% USD 1 250 million 2020/2027 Novartis Capital Corporation, New York, United States, issued at 99.909% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:label="lbl_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:to="lbl_label1494538699" xlink:type="arc"/>
      <link:label id="id_5f78509e" xlink:label="lbl_label1601720478" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.200% USD 1 500 million 2020/2030 Novartis Capital Corporation, New York, United States, issued at 99.869% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:label="lbl_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:to="lbl_label1601720478" xlink:type="arc"/>
      <link:label id="id_1a77a5e5" xlink:label="lbl_label444048869" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.750% USD 1 250 million 2020/2050 Novartis Capital Corporation, New York, United States, issued at 97.712% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:label="lbl_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:to="lbl_label444048869" xlink:type="arc"/>
      <link:label id="id_57a4b51a" xlink:label="lbl_label1470412058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.000% 1 EUR 1 850 million 2020/2028 Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.354% [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:label="lbl_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:to="lbl_label1470412058" xlink:type="arc"/>
      <link:label id="id_467a5e1d" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated amortization/impairments on assets held for sale intangible assets and goodwill</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:to="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_28811564" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization/impairments on assets reclassified out of assets of disposal group held for sale</link:label>
      <link:label id="id_7e37dc46" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase decrease through classified as held for sale property plant and equipment</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:to="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_75e51f1c" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of assets reclassified out of assets of disposal group held for sale</link:label>
      <link:label id="id_7eed015a" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated amortization/impairments on assets held for sale property plant and equipment</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:to="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_3eecdcaa" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation on assets reclassified out of assets of disposal group held for sale</link:label>
      <link:label id="id_653fa5ee" xlink:label="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on equity securities, net of taxes</link:label>
      <link:label id="id_6448b9fc" xlink:label="lbl_label1682487804" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of options repurchased</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfOptionsRepurchased" xlink:label="lbl_NumberOfOptionsRepurchased" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOptionsRepurchased" xlink:to="lbl_label1682487804" xlink:type="arc"/>
      <link:label id="id_55dc85a" xlink:label="lbl_DepreciationPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation charge</link:label>
      <link:label id="id_40c54b4d" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge</link:label>
      <link:label id="id_7d17c10a" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization charge</link:label>
      <link:label id="id_3c338d36" xlink:label="lbl_NumberOfSharesIssued_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="lbl_NumberOfSharesIssued" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfSharesIssued" xlink:to="lbl_NumberOfSharesIssued_labels" xlink:type="arc"/>
      <link:label id="id_74f409ec" xlink:label="lbl_NumberOfSharesIssued_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued at beginning of period</link:label>
      <link:label id="id_5895e9b5" xlink:label="lbl_NumberOfSharesIssued_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued at end of period</link:label>
      <link:label id="id_4ad28146" xlink:label="lbl_NumberOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of treasury shares</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfTreasuryShares" xlink:label="lbl_NumberOfTreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfTreasuryShares" xlink:to="lbl_NumberOfTreasuryShares_labels" xlink:type="arc"/>
      <link:label id="id_3deddf6f" xlink:label="lbl_NumberOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of treasury shares at beginning of period</link:label>
      <link:label id="id_74b615a9" xlink:label="lbl_NumberOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of treasury shares at end of period</link:label>
      <link:label id="id_7f6e02de" xlink:label="lbl_label2137916126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not subject to expiry [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NotSubjectToExpiryMember" xlink:label="lbl_NotSubjectToExpiryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NotSubjectToExpiryMember" xlink:to="lbl_label2137916126" xlink:type="arc"/>
      <link:label id="id_3faff48a" xlink:label="lbl_label1068496010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitment for repurchase of own shares [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CommitmentForRepurchaseOfOwnSharesMember" xlink:label="lbl_CommitmentForRepurchaseOfOwnSharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommitmentForRepurchaseOfOwnSharesMember" xlink:to="lbl_label1068496010" xlink:type="arc"/>
      <link:label id="id_3f65b5b6" xlink:label="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for healthcare contributions [text block]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_340a972f" xlink:label="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Healthcare contributions</link:label>
      <link:label id="id_53107fec" xlink:label="lbl_label1393590252" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development commitments for transactions entered into current year, closed after current year end</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:label="lbl_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:to="lbl_label1393590252" xlink:type="arc"/>
      <link:label id="id_3851ffb1" xlink:label="lbl_ReceivablesAndPayablesContingentConsiderationNet_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration payables, net</link:label>
      <link:label id="id_27060644" xlink:label="lbl_CN_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CHINA</link:label>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CN" xlink:label="lbl_CN" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CN" xlink:to="lbl_CN_labels" xlink:type="arc"/>
      <link:label id="id_cac1bd6" xlink:label="lbl_CN_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">China</link:label>
      <link:label id="id_38628cbd" xlink:label="lbl_TaxLossCarryForwards_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax loss carry forwards</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxLossCarryForwards" xlink:label="lbl_TaxLossCarryForwards" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxLossCarryForwards" xlink:to="lbl_TaxLossCarryForwards_labels" xlink:type="arc"/>
      <link:label id="id_3d3df970" xlink:label="lbl_TaxLossCarryForwards_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_1_Tax loss carryforwards expired</link:label>
      <link:label id="id_7429e4f6" xlink:label="lbl_label1948902646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:to="lbl_label1948902646" xlink:type="arc"/>
      <link:label id="id_5c2d9c4d" xlink:label="lbl_AdditionsToInvestmentInAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Additions to investment in associated companies</link:label>
      <link:label id="id_35a27c09" xlink:label="lbl_DeferredTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:label id="id_5725466" xlink:label="lbl_label91378790" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, right of use assets</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:to="lbl_label91378790" xlink:type="arc"/>
      <link:label id="id_536cdf9" xlink:label="lbl_BorrowingsInterestRateStepUp_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings interest rate step up</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsInterestRateStepUp" xlink:label="lbl_BorrowingsInterestRateStepUp" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsInterestRateStepUp" xlink:to="lbl_BorrowingsInterestRateStepUp_labels" xlink:type="arc"/>
      <link:label id="id_3f1e4d31" xlink:label="lbl_BorrowingsInterestRateStepUp_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_1_Straight bonds</link:label>
      <link:label id="id_653e892c" xlink:label="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets other than cash or cash equivalents in subsidiary or businesses acquired or disposed</link:label>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:to="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013_labels" xlink:type="arc"/>
      <link:label id="id_2997004f" xlink:label="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets divested</link:label>
      <link:label id="id_3110a540" xlink:label="lbl_label823174464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentAssetsMember" xlink:label="lbl_NoncurrentAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAssetsMember" xlink:to="lbl_label823174464" xlink:type="arc"/>
      <link:label id="id_6718df7c" xlink:label="lbl_EstimatedAcquisitionFairValueOfTotalConsideration_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated acquisition fair value of total consideration</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:label="lbl_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:to="lbl_EstimatedAcquisitionFairValueOfTotalConsideration_labels" xlink:type="arc"/>
      <link:label id="id_28d66ca1" xlink:label="lbl_EstimatedAcquisitionFairValueOfTotalConsideration_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value purchase price</link:label>
      <link:label id="id_7dd0ab04" xlink:label="lbl_label2110827268" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="lbl_IcfrAuditorAttestationFlag" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IcfrAuditorAttestationFlag" xlink:to="lbl_label2110827268" xlink:type="arc"/>
      <link:label id="id_7612c2ce" xlink:label="lbl_ReimbursmentsFromPlanToEmployerNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursments from plan to employer net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReimbursmentsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReimbursmentsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReimbursmentsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:to="lbl_ReimbursmentsFromPlanToEmployerNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_76f3c7f1" xlink:label="lbl_ReimbursmentsFromPlanToEmployerNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis Group contributions</link:label>
      <link:label id="id_7ce6c764" xlink:label="lbl_label2095499108" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Spark Therapeutics, Inc. [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SparkTherapeuticsInc.Member" xlink:label="lbl_SparkTherapeuticsInc.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SparkTherapeuticsInc.Member" xlink:to="lbl_label2095499108" xlink:type="arc"/>
      <link:label id="id_7b114bb8" xlink:label="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxLiabilityIsRecognised_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deductible temporary differences for which no deferred tax liability is recognised</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DeductibleTemporaryDifferencesForWhichNoDeferredTaxLiabilityIsRecognised" xlink:label="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxLiabilityIsRecognised" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxLiabilityIsRecognised" xlink:to="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxLiabilityIsRecognised_labels" xlink:type="arc"/>
      <link:label id="id_2be94668" xlink:label="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxLiabilityIsRecognised_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deductible temporary differences for which no deferred tax liability is recognised</link:label>
      <link:label id="id_704e7977" xlink:label="lbl_label1884191095" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Integrated Services Limited, Ringaskiddy, County Cork [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:label="lbl_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:to="lbl_label1884191095" xlink:type="arc"/>
      <link:label id="id_8bbdcdf" xlink:label="lbl_label146529503" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Gene Therapies EU Limited, Dublin [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisGeneTherapiesEULimitedDublinMember" xlink:label="lbl_NovartisGeneTherapiesEULimitedDublinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisGeneTherapiesEULimitedDublinMember" xlink:to="lbl_label146529503" xlink:type="arc"/>
      <link:label id="id_6c2d9048" xlink:label="lbl_label1814925384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aspen Japan K.K., Tokyo [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AspenJapanK.K.TokyoMember" xlink:label="lbl_AspenJapanK.K.TokyoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AspenJapanK.K.TokyoMember" xlink:to="lbl_label1814925384" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozPhilippinesCorporationMakatiCityMember" xlink:label="lbl_SandozPhilippinesCorporationMakatiCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozPhilippinesCorporationMakatiCityMember" xlink:to="lbl_label542160655" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisIsraelLtd.TelAvivMember" xlink:label="lbl_NovartisIsraelLtd.TelAvivMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisIsraelLtd.TelAvivMember" xlink:to="lbl_label437644648" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:label="lbl_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:to="lbl_label604974513" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:label="lbl_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:to="lbl_label573289181" xlink:type="arc"/>
      <link:label id="id_2e2703c1" xlink:label="lbl_label774308801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Catalana de Dispensacion sau (Cadisa), Esplugues de Llobregat [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:label="lbl_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:to="lbl_label774308801" xlink:type="arc"/>
      <link:label id="id_49af070a" xlink:label="lbl_label1236207370" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications (UK &amp; Ireland), London [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:to="lbl_label1236207370" xlink:type="arc"/>
      <link:label id="id_2d344762" xlink:label="lbl_label758400866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neutec Pharma Limited, London [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NeutecPharmaLimitedLondonMember" xlink:label="lbl_NeutecPharmaLimitedLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NeutecPharmaLimitedLondonMember" xlink:to="lbl_label758400866" xlink:type="arc"/>
      <link:label id="id_5f46d997" xlink:label="lbl_label1598478743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Coalesce Product Development Limited, Cambridge, Cambs [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:label="lbl_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:to="lbl_label1598478743" xlink:type="arc"/>
      <link:label id="id_2252cc66" xlink:label="lbl_label575851622" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Optogenetics Research, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:label="lbl_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:to="lbl_label575851622" xlink:type="arc"/>
      <link:label id="id_454fa68d" xlink:label="lbl_label1162847885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amblyotech Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmblyotechInc.EastHanoverNJMember" xlink:label="lbl_AmblyotechInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmblyotechInc.EastHanoverNJMember" xlink:to="lbl_label1162847885" xlink:type="arc"/>
      <link:label id="id_2caf6f16" xlink:label="lbl_label749694742" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Vietnam Company Limited, Ho Chi Minh City [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:label="lbl_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:to="lbl_label749694742" xlink:type="arc"/>
      <link:label id="id_c2bfc15" xlink:label="lbl_label204209173" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Deutschland GmbH, Nuremberg [member]</link:label>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisDeutschlandGmbHNurembergMember" xlink:label="lbl_NovartisDeutschlandGmbHNurembergMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisDeutschlandGmbHNurembergMember" xlink:to="lbl_label204209173" xlink:type="arc"/>
      <link:label id="id_3fb4623e" xlink:label="lbl_CommitmentForRepurchaseOwnShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Commitment for repurchase own shares</link:label>
   </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>nvs-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSubsequentEventsDetails2" xlink:href="nvs-20201231.xsd#disclosureSubsequentEventsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSignificantAccountingPoliciesDetails2" xlink:href="nvs-20201231.xsd#disclosureSignificantAccountingPoliciesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSignificantTransactionsDetails" xlink:href="nvs-20201231.xsd#disclosureSignificantTransactionsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails9" xlink:href="nvs-20201231.xsd#disclosureDiscontinuedOperationsDetails9" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSignificantAccountingPoliciesDetails" xlink:href="nvs-20201231.xsd#disclosureSignificantAccountingPoliciesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails8" xlink:href="nvs-20201231.xsd#disclosureDiscontinuedOperationsDetails8" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2" xlink:href="nvs-20201231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6" xlink:href="nvs-20201231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails3" xlink:href="nvs-20201231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails4" xlink:href="nvs-20201231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails6" xlink:href="nvs-20201231.xsd#disclosureDiscontinuedOperationsDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails5" xlink:href="nvs-20201231.xsd#disclosureDiscontinuedOperationsDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables" xlink:href="nvs-20201231.xsd#disclosureRightOfUseAssetsAndLeaseLiabilityTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6" xlink:href="nvs-20201231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5" xlink:href="nvs-20201231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4" xlink:href="nvs-20201231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3" xlink:href="nvs-20201231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2" xlink:href="nvs-20201231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails4" xlink:href="nvs-20201231.xsd#disclosureDiscontinuedOperationsDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails3" xlink:href="nvs-20201231.xsd#disclosureDiscontinuedOperationsDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails2" xlink:href="nvs-20201231.xsd#disclosureDiscontinuedOperationsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails" xlink:href="nvs-20201231.xsd#disclosureDiscontinuedOperationsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails1" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresDetails1" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSignificantTransactionsDetails2" xlink:href="nvs-20201231.xsd#disclosureSignificantTransactionsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDisposalGroupHeldForSaleDetails" xlink:href="nvs-20201231.xsd#disclosureDisposalGroupHeldForSaleDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsTables" xlink:href="nvs-20201231.xsd#disclosureDiscontinuedOperationsTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperations" xlink:href="nvs-20201231.xsd#disclosureDiscontinuedOperations" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureRightOfUseAssetsAndLeaseLiability" xlink:href="nvs-20201231.xsd#disclosureRightOfUseAssetsAndLeaseLiability" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails12" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresDetails12" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails11" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresDetails11" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSignificantTransactionsTables" xlink:href="nvs-20201231.xsd#disclosureSignificantTransactionsTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails14" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails8" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresDetails8" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails10" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresDetails10" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedPartiesDetails1" xlink:href="nvs-20201231.xsd#disclosureTransactionsWithRelatedPartiesDetails1_1df9063b" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails13" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails12" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5" xlink:href="nvs-20201231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosures" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosures" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6" xlink:href="nvs-20201231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5" xlink:href="nvs-20201231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails11" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails10" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails9" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails8" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails7" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5" xlink:href="nvs-20201231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5" xlink:href="nvs-20201231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityDetails5" xlink:href="nvs-20201231.xsd#disclosureEquityDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails7" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresDetails7" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityTables" xlink:href="nvs-20201231.xsd#disclosureEquityTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquity" xlink:href="nvs-20201231.xsd#disclosureEquity" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityDetails4" xlink:href="nvs-20201231.xsd#disclosureEquityDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityDetails3" xlink:href="nvs-20201231.xsd#disclosureEquityDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityDetails2" xlink:href="nvs-20201231.xsd#disclosureEquityDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityDetails" xlink:href="nvs-20201231.xsd#disclosureEquityDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4" xlink:href="nvs-20201231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:href="nvs-20201231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3" xlink:href="nvs-20201231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2" xlink:href="nvs-20201231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:href="nvs-20201231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables" xlink:href="nvs-20201231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilities" xlink:href="nvs-20201231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilities" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails6" xlink:href="nvs-20201231.xsd#disclosureAssociatedCompaniesDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails5" xlink:href="nvs-20201231.xsd#disclosureAssociatedCompaniesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails4" xlink:href="nvs-20201231.xsd#disclosureAssociatedCompaniesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails3" xlink:href="nvs-20201231.xsd#disclosureAssociatedCompaniesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails2" xlink:href="nvs-20201231.xsd#disclosureAssociatedCompaniesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails" xlink:href="nvs-20201231.xsd#disclosureAssociatedCompaniesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesTables" xlink:href="nvs-20201231.xsd#disclosureAssociatedCompaniesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureAssociatedCompanies" xlink:href="nvs-20201231.xsd#disclosureAssociatedCompanies" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresTables" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFigures" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFigures" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails6" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails5" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails4" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails3" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails2" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails" xlink:href="nvs-20201231.xsd#disclosureSegmentationOfKeyFiguresDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4" xlink:href="nvs-20201231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3" xlink:href="nvs-20201231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2" xlink:href="nvs-20201231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails" xlink:href="nvs-20201231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssetsDetails4" xlink:href="nvs-20201231.xsd#disclosureGoodwillAndIntangibleAssetsDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssetsDetails3" xlink:href="nvs-20201231.xsd#disclosureGoodwillAndIntangibleAssetsDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssetsDetails2" xlink:href="nvs-20201231.xsd#disclosureGoodwillAndIntangibleAssetsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssetsDetails" xlink:href="nvs-20201231.xsd#disclosureGoodwillAndIntangibleAssetsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails3" xlink:href="nvs-20201231.xsd#disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:href="nvs-20201231.xsd#disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedPartiesDetails3" xlink:href="nvs-20201231.xsd#disclosureTransactionsWithRelatedPartiesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedPartiesDetails2" xlink:href="nvs-20201231.xsd#disclosureTransactionsWithRelatedPartiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables" xlink:href="nvs-20201231.xsd#disclosureEquityBasedParticipationPlansForAssociatesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedPartiesTables" xlink:href="nvs-20201231.xsd#disclosureTransactionsWithRelatedPartiesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedParties" xlink:href="nvs-20201231.xsd#disclosureTransactionsWithRelatedParties" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociates" xlink:href="nvs-20201231.xsd#disclosureEquityBasedParticipationPlansForAssociates" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables" xlink:href="nvs-20201231.xsd#disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncome" xlink:href="nvs-20201231.xsd#disclosureChangesInConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails" xlink:href="nvs-20201231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsTables" xlink:href="nvs-20201231.xsd#disclosureDetailsConsolidatedCashFlowStatementsTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatements" xlink:href="nvs-20201231.xsd#disclosureDetailsConsolidatedCashFlowStatements" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9" xlink:href="nvs-20201231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails9" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10" xlink:href="nvs-20201231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails10" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8" xlink:href="nvs-20201231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails8" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7" xlink:href="nvs-20201231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails7" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6" xlink:href="nvs-20201231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5" xlink:href="nvs-20201231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4" xlink:href="nvs-20201231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3" xlink:href="nvs-20201231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2" xlink:href="nvs-20201231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails" xlink:href="nvs-20201231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails" xlink:href="nvs-20201231.xsd#disclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables" xlink:href="nvs-20201231.xsd#disclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompanies" xlink:href="nvs-20201231.xsd#disclosurePrincipalGroupSubsidiariesAndAssociatedCompanies" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails5" xlink:href="nvs-20201231.xsd#disclosureTradeReceivablesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails4" xlink:href="nvs-20201231.xsd#disclosureTradeReceivablesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails3" xlink:href="nvs-20201231.xsd#disclosureTradeReceivablesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails2" xlink:href="nvs-20201231.xsd#disclosureTradeReceivablesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails" xlink:href="nvs-20201231.xsd#disclosureTradeReceivablesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTradeReceivablesTables" xlink:href="nvs-20201231.xsd#disclosureTradeReceivablesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTradeReceivables" xlink:href="nvs-20201231.xsd#disclosureTradeReceivables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3" xlink:href="nvs-20201231.xsd#disclosureProvisionsAndOtherCurrentLiabilitiesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails" xlink:href="nvs-20201231.xsd#disclosureProvisionsAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2" xlink:href="nvs-20201231.xsd#disclosureProvisionsAndOtherCurrentLiabilitiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureAcquisitionsOfBusinessesDetails" xlink:href="nvs-20201231.xsd#disclosureAcquisitionsOfBusinessesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesTables" xlink:href="nvs-20201231.xsd#disclosurePostEmploymentBenefitsForAssociatesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureAcquisitionsOfBusinessesTables" xlink:href="nvs-20201231.xsd#disclosureAcquisitionsOfBusinessesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables" xlink:href="nvs-20201231.xsd#disclosureProvisionsAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociates" xlink:href="nvs-20201231.xsd#disclosurePostEmploymentBenefitsForAssociates" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureAcquisitionsOfBusinesses" xlink:href="nvs-20201231.xsd#disclosureAcquisitionsOfBusinesses" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherCurrentLiabilities" xlink:href="nvs-20201231.xsd#disclosureProvisionsAndOtherCurrentLiabilities" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/StatementOfChangesInEquity" xlink:href="nvs-20201231.xsd#statementOfChangesInEquity" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/StatementsOfCashFlow" xlink:href="nvs-20201231.xsd#statementsOfCashFlow" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/StatementOfComprehensiveIncome" xlink:href="nvs-20201231.xsd#statementOfComprehensiveIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails5" xlink:href="nvs-20201231.xsd#disclosureNonCurrentFinancialDebtDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails2" xlink:href="nvs-20201231.xsd#disclosureNonCurrentFinancialDebtDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails6" xlink:href="nvs-20201231.xsd#disclosureNonCurrentFinancialDebtDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails4" xlink:href="nvs-20201231.xsd#disclosureNonCurrentFinancialDebtDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails3" xlink:href="nvs-20201231.xsd#disclosureNonCurrentFinancialDebtDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails" xlink:href="nvs-20201231.xsd#disclosureNonCurrentFinancialDebtDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:href="nvs-20201231.xsd#disclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:href="nvs-20201231.xsd#disclosureCommitmentsAndContingenciesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureCommitmentsAndContingenciesDetails" xlink:href="nvs-20201231.xsd#disclosureCommitmentsAndContingenciesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="nvs-20201231.xsd#disclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables" xlink:href="nvs-20201231.xsd#disclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtTables" xlink:href="nvs-20201231.xsd#disclosureNonCurrentFinancialDebtTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstruments" xlink:href="nvs-20201231.xsd#disclosureCurrentFinancialDebtAndDerivativeFinancialInstruments" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebt" xlink:href="nvs-20201231.xsd#disclosureNonCurrentFinancialDebt" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSignificantTransactions" xlink:href="nvs-20201231.xsd#disclosureSignificantTransactions" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureCommitmentsAndContingencies" xlink:href="nvs-20201231.xsd#disclosureCommitmentsAndContingencies" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSubsequentEventsDetails" xlink:href="nvs-20201231.xsd#disclosureSubsequentEventsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSubsequentEvents" xlink:href="nvs-20201231.xsd#disclosureSubsequentEvents" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/StatementOfIncome" xlink:href="nvs-20201231.xsd#statementOfIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2" xlink:href="nvs-20201231.xsd#disclosureFinancialAndOtherNoncurrentAssetsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails" xlink:href="nvs-20201231.xsd#disclosureFinancialAndOtherNoncurrentAssetsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureMarketableSecuritiesDetails2" xlink:href="nvs-20201231.xsd#disclosureMarketableSecuritiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureMarketableSecuritiesDetails" xlink:href="nvs-20201231.xsd#disclosureMarketableSecuritiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureMarketableSecuritiesTables" xlink:href="nvs-20201231.xsd#disclosureMarketableSecuritiesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureMarketableSecurities" xlink:href="nvs-20201231.xsd#disclosureMarketableSecurities" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureOtherCurrentAssetsDetails" xlink:href="nvs-20201231.xsd#disclosureOtherCurrentAssetsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureOtherCurrentAssetsTables" xlink:href="nvs-20201231.xsd#disclosureOtherCurrentAssetsTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureOtherCurrentAssets" xlink:href="nvs-20201231.xsd#disclosureOtherCurrentAssets" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialAndOtherNoncurrentAssetsTables" xlink:href="nvs-20201231.xsd#disclosureFinancialAndOtherNoncurrentAssetsTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureFinancialAndOtherNoncurrentAssets" xlink:href="nvs-20201231.xsd#disclosureFinancialAndOtherNoncurrentAssets" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3" xlink:href="nvs-20201231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails2" xlink:href="nvs-20201231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4" xlink:href="nvs-20201231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="nvs-20201231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTaxesDetails3" xlink:href="nvs-20201231.xsd#disclosureTaxesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTaxesDetails2" xlink:href="nvs-20201231.xsd#disclosureTaxesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTaxesDetails" xlink:href="nvs-20201231.xsd#disclosureTaxesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2" xlink:href="nvs-20201231.xsd#disclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails" xlink:href="nvs-20201231.xsd#disclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="nvs-20201231.xsd#disclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="nvs-20201231.xsd#disclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="nvs-20201231.xsd#disclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables" xlink:href="nvs-20201231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilities" xlink:href="nvs-20201231.xsd#disclosureDeferredTaxAssetsAndLiabilities" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseTables" xlink:href="nvs-20201231.xsd#disclosureInterestExpenseAndOtherFinancialIncomeExpenseTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpense" xlink:href="nvs-20201231.xsd#disclosureInterestExpenseAndOtherFinancialIncomeExpense" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTaxesTables" xlink:href="nvs-20201231.xsd#disclosureTaxesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureTaxes" xlink:href="nvs-20201231.xsd#disclosureTaxes" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssetsTables" xlink:href="nvs-20201231.xsd#disclosureGoodwillAndIntangibleAssetsTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssets" xlink:href="nvs-20201231.xsd#disclosureGoodwillAndIntangibleAssets" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEarningsPerShareDetails" xlink:href="nvs-20201231.xsd#disclosureEarningsPerShareDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEarningsPerShareTables" xlink:href="nvs-20201231.xsd#disclosureEarningsPerShareTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureEarningsPerShare" xlink:href="nvs-20201231.xsd#disclosureEarningsPerShare" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureInventoriesDetails" xlink:href="nvs-20201231.xsd#disclosureInventoriesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureInventories" xlink:href="nvs-20201231.xsd#disclosureInventories" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosureInventoriesTables" xlink:href="nvs-20201231.xsd#disclosureInventoriesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePropertyPlantAndEquipmentTables" xlink:href="nvs-20201231.xsd#disclosurePropertyPlantAndEquipmentTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePropertyPlantAndEquipment" xlink:href="nvs-20201231.xsd#disclosurePropertyPlantAndEquipment" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DisclosurePropertyPlantAndEquipmentDetails" xlink:href="nvs-20201231.xsd#disclosurePropertyPlantAndEquipmentDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/BalanceSheet" xlink:href="nvs-20201231.xsd#balanceSheet" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20201231/role/DocumentAndEntityInformation" xlink:href="nvs-20201231.xsd#documentAndEntityInformation" xlink:type="simple"/>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DocumentAndEntityInformation" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="lbl_DocumentInformationTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DocumentAndEntityInformationAbstract" xlink:label="lbl_DocumentAndEntityInformationAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentAndEntityInformationAbstract" xlink:to="lbl_DocumentInformationTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="lbl_DocumentInformationLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationTable" xlink:to="lbl_DocumentInformationLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="lbl_DocumentType" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentType" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="lbl_AmendmentFlag" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_AmendmentFlag" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="lbl_DocumentFiscalPeriodFocus" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentFiscalPeriodFocus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="lbl_EntityCentralIndexKey" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityCentralIndexKey" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="lbl_EntityCurrentReportingStatus" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityCurrentReportingStatus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="lbl_EntityPublicFloat" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityPublicFloat" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="lbl_DocumentPeriodEndDate" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentPeriodEndDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="lbl_DocumentFiscalYearFocus" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentFiscalYearFocus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="lbl_TradingSymbol" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_TradingSymbol" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="lbl_EntityRegistrantName" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityRegistrantName" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="lbl_CurrentFiscalYearEndDate" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_CurrentFiscalYearEndDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="lbl_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="lbl_EntityVoluntaryFilers" xlink:type="locator"/>
      <link:presentationArc order="9.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityVoluntaryFilers" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="lbl_EntityFilerCategory" xlink:type="locator"/>
      <link:presentationArc order="9.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityFilerCategory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="lbl_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
      <link:presentationArc order="9.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="lbl_DocumentAnnualReport" xlink:type="locator"/>
      <link:presentationArc order="2.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentAnnualReport" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="lbl_EntityShellCompany" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityShellCompany" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="lbl_EntityEmergingGrowthCompany" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityEmergingGrowthCompany" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="lbl_EntityInteractiveDataCurrent" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityInteractiveDataCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="lbl_DocumentTransitionReport" xlink:type="locator"/>
      <link:presentationArc order="2.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentTransitionReport" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="lbl_DocumentShellCompanyReport" xlink:type="locator"/>
      <link:presentationArc order="2.4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentShellCompanyReport" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="lbl_IcfrAuditorAttestationFlag" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_IcfrAuditorAttestationFlag" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/BalanceSheet" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="lbl_AssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="lbl_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="lbl_NoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_NoncurrentAssetsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="lbl_NoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_NoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="lbl_CurrentAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_CurrentAssetsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_Inventories" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="lbl_CurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Assets" xlink:label="lbl_Assets" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_Assets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="lbl_EquityAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="lbl_EquityAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_EquityAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_IssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherReserves" xlink:label="lbl_OtherReserves" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_OtherReserves" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="lbl_LiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_LiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="lbl_NoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_NoncurrentLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="lbl_NoncurrentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_NoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="lbl_CurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_CurrentLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_OtherCurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="lbl_CurrentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Liabilities" xlink:label="lbl_Liabilities" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_Liabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="lbl_EquityAndLiabilities" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_EquityAndLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Goodwill" xlink:label="lbl_Goodwill" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_Goodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="lbl_EquityAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_EquityAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncontrollingInterests" xlink:label="lbl_NoncontrollingInterests" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_NoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="lbl_NoncurrentFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="7.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_NoncurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfFinancialPositionAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AssetsAbstract" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EquityAndLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="5.3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_OtherCurrentNonfinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="8.8" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_OtherNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="lbl_OtherCurrentFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="3.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_OtherCurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_TreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:presentationArc order="2.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:presentationArc order="5.9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="4.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="5.92" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="lbl_NoncurrentLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_NoncurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="lbl_CurrentLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="4.6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="lbl_CurrentTaxAssetsCurrent" xlink:type="locator"/>
      <link:presentationArc order="2.9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentTaxAssetsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosurePropertyPlantAndEquipmentDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LandMember" xlink:label="lbl_LandMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_LandMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BuildingsMember" xlink:label="lbl_BuildingsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_BuildingsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MachineryMember" xlink:label="lbl_MachineryMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_MachineryMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="lbl_ConstructionInProgressMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_ConstructionInProgressMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:label="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:label="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:label="lbl_MovementsOfPropertyPlantAndEquipmentRollForward1" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward1" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:label="lbl_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:label="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingCostsCapitalised" xlink:label="lbl_BorrowingCostsCapitalised" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_BorrowingCostsCapitalised" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="9.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:label="lbl_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="13.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:label="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:label="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:label="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:label="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.15" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="7.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosurePropertyPlantAndEquipment" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosurePropertyPlantAndEquipmentTables" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PropertyPlantAndEquipmentTableTextBlock" xlink:label="lbl_PropertyPlantAndEquipmentTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lbl_PropertyPlantAndEquipmentTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureInventoriesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoriesDisclosureAbstract" xlink:label="lbl_InventoriesDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="lbl_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoriesDisclosureAbstract" xlink:to="lbl_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" xlink:label="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoriesDisclosureAbstract" xlink:to="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" xlink:label="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoriesDisclosureAbstract" xlink:to="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureInventories" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoriesDisclosureAbstract" xlink:label="lbl_InventoriesDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="lbl_DisclosureOfInventoriesExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoriesDisclosureAbstract" xlink:to="lbl_DisclosureOfInventoriesExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureInventoriesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoryCurrentTable" xlink:label="lbl_InventoryCurrentTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoriesDisclosureAbstract" xlink:label="lbl_InventoriesDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoriesDisclosureAbstract" xlink:to="lbl_InventoryCurrentTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoryAxis" xlink:label="lbl_InventoryAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryCurrentTable" xlink:to="lbl_InventoryAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoryMember" xlink:label="lbl_InventoryMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoryRawMaterialsGrossMember" xlink:label="lbl_InventoryRawMaterialsGrossMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryMember" xlink:to="lbl_InventoryRawMaterialsGrossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoryWorkInProgressGrossMember" xlink:label="lbl_InventoryWorkInProgressGrossMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryMember" xlink:to="lbl_InventoryWorkInProgressGrossMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryMember" xlink:to="lbl_InventoryFinishedGoodsGrossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoryFinishedGoodsGrossMember" xlink:label="lbl_InventoryFinishedGoodsGrossMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoryLineItems" xlink:label="lbl_InventoryLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryCurrentTable" xlink:to="lbl_InventoryLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReversalOfInventoryWritedown" xlink:label="lbl_ReversalOfInventoryWritedown" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_ReversalOfInventoryWritedown" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryAxis" xlink:to="lbl_InventoryMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:label="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:presentationArc order="0.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_Inventories" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InventoryWritedown2011" xlink:label="lbl_InventoryWritedown2011" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_InventoryWritedown2011" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureEarningsPerShare" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="lbl_EarningsPerShareAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="lbl_EarningsPerShareExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareAbstract" xlink:to="lbl_EarningsPerShareExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureEarningsPerShareTables" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="lbl_EarningsPerShareAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareAbstract" xlink:to="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureEarningsPerShareDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EarningsPerShareTable" xlink:label="lbl_EarningsPerShareTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="lbl_EarningsPerShareAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareAbstract" xlink:to="lbl_EarningsPerShareTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EarningsPerShareLineItems" xlink:label="lbl_EarningsPerShareLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareTable" xlink:to="lbl_EarningsPerShareLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="lbl_WeightedAverageShares" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_WeightedAverageShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:label="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="lbl_AdjustedWeightedAverageShares" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_AdjustedWeightedAverageShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="lbl_BasicEarningsLossPerShare" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_BasicEarningsLossPerShare" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="lbl_DilutedEarningsLossPerShare" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_DilutedEarningsLossPerShare" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OptionsExcludedFromTheCalculation" xlink:label="lbl_OptionsExcludedFromTheCalculation" xlink:type="locator"/>
      <link:presentationArc order="10.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_OptionsExcludedFromTheCalculation" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssets" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:label="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssetsTables" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" xlink:label="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:label="lbl_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AssumptionsUsedInTheCalculationOfValuationTextBlock" xlink:label="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IntangibleAssetImpairmentChargesTextBlock" xlink:label="lbl_IntangibleAssetImpairmentChargesTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_IntangibleAssetImpairmentChargesTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureTaxes" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfIncomeTaxAbstract" xlink:label="lbl_DisclosureOfIncomeTaxAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="lbl_DisclosureOfIncomeTaxExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIncomeTaxAbstract" xlink:to="lbl_DisclosureOfIncomeTaxExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureTaxesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfIncomeTaxAbstract" xlink:label="lbl_DisclosureOfIncomeTaxAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeBeforeTaxesTableTextBlock" xlink:label="lbl_IncomeBeforeTaxesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIncomeTaxAbstract" xlink:to="lbl_IncomeBeforeTaxesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" xlink:label="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIncomeTaxAbstract" xlink:to="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AnalysisOfTaxRateTableTextBlock" xlink:label="lbl_AnalysisOfTaxRateTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIncomeTaxAbstract" xlink:to="lbl_AnalysisOfTaxRateTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpense" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:label="lbl_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInterestExpenseExplanatory" xlink:label="lbl_DisclosureOfInterestExpenseExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_DisclosureOfInterestExpenseExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:label="lbl_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestExpenseTableTextBlock" xlink:label="lbl_InterestExpenseTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_InterestExpenseTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherFinancialIncomeAndExpenseTableTextBlock" xlink:label="lbl_OtherFinancialIncomeAndExpenseTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_OtherFinancialIncomeAndExpenseTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilities" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:label="lbl_DisclosureOfDeferredTaxesExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_DisclosureOfDeferredTaxesExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:label="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" xlink:label="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" xlink:label="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" xlink:label="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" xlink:label="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" xlink:type="locator"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SignificantAccountingPoliciesAbstract" xlink:label="lbl_SignificantAccountingPoliciesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantAccountingPoliciesAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SignificantAccountingPoliciesAbstract" xlink:label="lbl_SignificantAccountingPoliciesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:presentationArc order="34.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantAccountingPoliciesAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DistributionByWayOfDivindendInKindToShareholders" xlink:label="lbl_DistributionByWayOfDivindendInKindToShareholders" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DistributionByWayOfDivindendInKindToShareholders" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:label="lbl_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:type="locator"/>
      <link:presentationArc order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="locator"/>
      <link:presentationArc order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="locator"/>
      <link:presentationArc order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:label="lbl_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="locator"/>
      <link:presentationArc order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:type="locator"/>
      <link:presentationArc order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="locator"/>
      <link:presentationArc order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TransactionCostsRecordedInEquityTextBlock" xlink:label="lbl_TransactionCostsRecordedInEquityTextBlock" xlink:type="locator"/>
      <link:presentationArc order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TransactionCostsRecordedInEquityTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:label="lbl_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:type="locator"/>
      <link:presentationArc order="30.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:label="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="locator"/>
      <link:presentationArc order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="32.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="33.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:type="locator"/>
      <link:presentationArc order="34.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:type="locator"/>
      <link:presentationArc order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SignificantAccountingPoliciesAbstract" xlink:label="lbl_SignificantAccountingPoliciesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantAccountingPoliciesAbstract" xlink:to="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:label="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantAccountingPoliciesAbstract" xlink:to="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestExpenseAbstract" xlink:label="lbl_InterestExpenseAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:label="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InterestExpenseAbstract" xlink:to="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InterestExpenseAbstract" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:label="lbl_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InterestExpenseAbstract" xlink:to="lbl_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InterestExpenseAbstract" xlink:to="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherFinancialIncomeAndExpenseAbstract" xlink:label="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeOnForwardContractsAndOptions" xlink:label="lbl_IncomeOnForwardContractsAndOptions" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_IncomeOnForwardContractsAndOptions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnNetMonetaryPosition" xlink:label="lbl_GainsLossesOnNetMonetaryPosition" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_GainsLossesOnNetMonetaryPosition" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:label="lbl_GainsLossesOnAvailableforsaleFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_GainsLossesOnAvailableforsaleFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromInterest" xlink:label="lbl_RevenueFromInterest" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_RevenueFromInterest" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromDividends" xlink:label="lbl_RevenueFromDividends" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_RevenueFromDividends" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:label="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:type="locator"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherFinanceCost" xlink:label="lbl_OtherFinanceCost" xlink:type="locator"/>
      <link:presentationArc order="7.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_OtherFinanceCost" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureTaxesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="lbl_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_ForeignCountriesMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccountingProfit" xlink:label="lbl_AccountingProfit" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AccountingProfit" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureTaxesDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="lbl_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_ForeignCountriesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="lbl_CurrentTaxExpenseIncome" xlink:type="locator"/>
      <link:presentationArc order="1.55" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentTaxExpenseIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeTaxExpense" xlink:label="lbl_IncomeTaxExpense" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="lbl_DeferredTaxExpenseIncome" xlink:type="locator"/>
      <link:presentationArc order="1.65" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxExpenseIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxExpenseIncomeDiscontinuingOperations" xlink:label="lbl_TaxExpenseIncomeDiscontinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="1.8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxExpenseIncomeDiscontinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureTaxesDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract" xlink:label="lbl_ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ApplicableTaxRate" xlink:label="lbl_ApplicableTaxRate" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ApplicableTaxRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxRateEffectOfCreditsAndAllowances" xlink:label="lbl_TaxRateEffectOfCreditsAndAllowances" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfCreditsAndAllowances" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:label="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxRateEffectFromBenefitsExpiring" xlink:label="lbl_TaxRateEffectFromBenefitsExpiring" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectFromBenefitsExpiring" xlink:type="arc"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectFromNondeductibleLossesInRegion" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AverageEffectiveTaxRateContinuingOperations" xlink:label="lbl_AverageEffectiveTaxRateContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AverageEffectiveTaxRateContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AverageEffectiveTaxRate" xlink:label="lbl_AverageEffectiveTaxRate" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AverageEffectiveTaxRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AverageEffectiveTaxRateDiscontinuedOperations" xlink:label="lbl_AverageEffectiveTaxRateDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AverageEffectiveTaxRateDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss1" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss1" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxRateEffectOfTaxLosses" xlink:label="lbl_TaxRateEffectOfTaxLosses1" xlink:type="locator"/>
      <link:presentationArc order="3.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfTaxLosses1" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxRateEffectFromChangeInTaxRate" xlink:label="lbl_TaxRateEffectFromChangeInTaxRate" xlink:type="locator"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectFromChangeInTaxRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:label="lbl_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:type="locator"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="lbl_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
      <link:presentationArc order="17.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="lbl_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
      <link:presentationArc order="18.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:label="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:type="locator"/>
      <link:presentationArc order="4.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:label="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:type="locator"/>
      <link:presentationArc order="5.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxRateEffectFromNondeductibleLossesInRegion" xlink:label="lbl_TaxRateEffectFromNondeductibleLossesInRegion" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:label="lbl_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="locator"/>
      <link:presentationArc order="19.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:label="lbl_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:type="locator"/>
      <link:presentationArc order="20.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:label="lbl_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:type="locator"/>
      <link:presentationArc order="4.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:label="lbl_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:type="locator"/>
      <link:presentationArc order="19.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EffectOfUSTaxReformLegislation" xlink:label="lbl_EffectOfUSTaxReformLegislation" xlink:type="locator"/>
      <link:presentationArc order="19.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfUSTaxReformLegislation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EffectOfWriteoffOfDeferredTaxAssets" xlink:label="lbl_EffectOfWriteoffOfDeferredTaxAssets" xlink:type="locator"/>
      <link:presentationArc order="7.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfWriteoffOfDeferredTaxAssets" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_AssetsAndLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_AssetsAndLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:label="lbl_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InventoriesMember" xlink:label="lbl_InventoriesMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_InventoriesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxLossCarryforwardsMember" xlink:label="lbl_TaxLossCarryforwardsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_TaxLossCarryforwardsMember" xlink:type="arc"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_OtherAssetsProvisionsAccrualsMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="lbl_DeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MovementInDeferredTaxBalanceRollForward" xlink:label="lbl_MovementInDeferredTaxBalanceRollForward" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_MovementInDeferredTaxBalanceRollForward" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:label="lbl_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherAssetsProvisionsAccrualsMember" xlink:label="lbl_OtherAssetsProvisionsAccrualsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MovementInDeferredTaxBalanceRollForward" xlink:label="lbl_MovementInDeferredTaxBalanceRollForward1" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward1" xlink:to="lbl_DeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:presentationArc order="0.5" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_DeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="1.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="1.1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems1" xlink:type="locator"/>
      <link:presentationArc order="2.6" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems1" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GrossDeferredTaxAssets" xlink:label="lbl_GrossDeferredTaxAssets" xlink:type="locator"/>
      <link:presentationArc order="2.55" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossDeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GrossDeferredTaxLiabilities" xlink:label="lbl_GrossDeferredTaxLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.75" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossDeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:presentationArc order="2.8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems1" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:label="lbl_DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:label="lbl_DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:label="lbl_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionForIncomeTaxesOnUnremittedEarnings" xlink:label="lbl_ProvisionForIncomeTaxesOnUnremittedEarnings" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProvisionForIncomeTaxesOnUnremittedEarnings" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedAbstract" xlink:label="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_AssetsAndLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_AssetsAndLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InvestmentsInSubsidiariesMember" xlink:label="lbl_InvestmentsInSubsidiariesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_InvestmentsInSubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GoodwillFromAcquisitionsMember" xlink:label="lbl_GoodwillFromAcquisitionsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_GoodwillFromAcquisitionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DeductibleTemporaryDifferencesForWhichNoDeferredTaxLiabilityIsRecognised" xlink:label="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxLiabilityIsRecognised" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxLiabilityIsRecognised" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:to="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BalanceSheetTreatmentAxis" xlink:label="lbl_BalanceSheetTreatmentAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lbl_BalanceSheetTreatmentAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BalanceSheetTreatmentMember" xlink:label="lbl_BalanceSheetTreatmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetTreatmentAxis" xlink:to="lbl_BalanceSheetTreatmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CapitalizedMember" xlink:label="lbl_CapitalizedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetTreatmentMember" xlink:to="lbl_CapitalizedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NotCapitalizedMember" xlink:label="lbl_NotCapitalizedMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetTreatmentMember" xlink:to="lbl_NotCapitalizedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_YearOfExpiryAxis" xlink:label="lbl_YearOfExpiryAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lbl_YearOfExpiryAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_YearOfExpiryMember" xlink:label="lbl_YearOfExpiryMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_YearOfExpiryAxis" xlink:to="lbl_YearOfExpiryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OneYearMember" xlink:label="lbl_OneYearMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_OneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TwoYearsMember" xlink:label="lbl_TwoYearsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_TwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ThreeYearsMember" xlink:label="lbl_ThreeYearsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_ThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FourYearsMember" xlink:label="lbl_FourYearsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_FourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FiveYearsMember" xlink:label="lbl_FiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_FiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MoreThanFiveYearsMember" xlink:label="lbl_MoreThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_MoreThanFiveYearsMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ValueOfTaxLossCarryforwardsExpired" xlink:label="lbl_ValueOfTaxLossCarryforwardsExpired" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ValueOfTaxLossCarryforwardsExpired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:label="lbl_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NotSubjectToExpiryMember" xlink:label="lbl_NotSubjectToExpiryMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_NotSubjectToExpiryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxLossCarryForwards" xlink:label="lbl_TaxLossCarryForwards" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxLossCarryForwards" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lbl_LegalEntityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TheMedicinesCompanyMember" xlink:label="lbl_TheMedicinesCompanyMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TheMedicinesCompanyMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialAndOtherNoncurrentAssets" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:to="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialAndOtherNoncurrentAssetsTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfFinancialAssetsTableTextBlock" xlink:label="lbl_DisclosureOfFinancialAssetsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:to="lbl_DisclosureOfFinancialAssetsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:label="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:to="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:label="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:to="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureOtherCurrentAssets" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherCurrentAssetsAbstract" xlink:label="lbl_OtherCurrentAssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:label="lbl_DisclosureOfOtherCurrentAssetsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_DisclosureOfOtherCurrentAssetsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureOtherCurrentAssetsTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherCurrentAssetsAbstract" xlink:label="lbl_OtherCurrentAssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherCurrentAssetsTableTextBlock" xlink:label="lbl_OtherCurrentAssetsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_OtherCurrentAssetsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureOtherCurrentAssetsDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherCurrentAssetsAbstract" xlink:label="lbl_OtherCurrentAssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="lbl_CurrentValueAddedTaxReceivables" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_CurrentValueAddedTaxReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WithholdingTaxRecoverable" xlink:label="lbl_WithholdingTaxRecoverable" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_WithholdingTaxRecoverable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentPrepaidExpensesThirdParty" xlink:label="lbl_CurrentPrepaidExpensesThirdParty" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_CurrentPrepaidExpensesThirdParty" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentPrepaidExpensesAssociatedCompanies" xlink:label="lbl_CurrentPrepaidExpensesAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_CurrentPrepaidExpensesAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReceivablesAssociatedCompanies" xlink:label="lbl_ReceivablesAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_ReceivablesAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationReceivableCurrent" xlink:label="lbl_ContingentConsiderationReceivableCurrent" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_ContingentConsiderationReceivableCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherReceivablesAndCurrentAssets" xlink:label="lbl_OtherReceivablesAndCurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_OtherReceivablesAndCurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_OtherCurrentNonfinancialAssets" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureMarketableSecurities" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureMarketableSecuritiesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" xlink:label="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DebtSecuritiesBreakdownByCurrencyTableTextBlock" xlink:label="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashAndCashEquivalentsTableTextBlock" xlink:label="lbl_CashAndCashEquivalentsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_CashAndCashEquivalentsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureMarketableSecuritiesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DebtInstrumentsHeld" xlink:label="lbl_DebtInstrumentsHeld" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_DebtInstrumentsHeld" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityInstrumentsHeld" xlink:label="lbl_EquityInstrumentsHeld" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_EquityInstrumentsHeld" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FundInstrumentsHeld" xlink:label="lbl_FundInstrumentsHeld" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_FundInstrumentsHeld" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MarketableSecurities" xlink:label="lbl_MarketableSecurities" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_MarketableSecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_Commodities" xlink:label="lbl_Commodities" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_Commodities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:label="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DerivativeFinancialAssets" xlink:label="lbl_DerivativeFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_DerivativeFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestReceivable" xlink:label="lbl_InterestReceivable" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_InterestReceivable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="lbl_OtherCurrentFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_OtherCurrentFinancialAssets" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureMarketableSecuritiesDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:label="lbl_CashAndCashEquivalentsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Cash" xlink:label="lbl_Cash" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CashAndCashEquivalentsAbstract" xlink:to="lbl_Cash" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashEquivalents" xlink:label="lbl_CashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CashAndCashEquivalentsAbstract" xlink:to="lbl_CashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CashAndCashEquivalentsAbstract" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="lbl_DisclosureOfFinancialAssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentFinancialAssetsEquityInvestments" xlink:label="lbl_NoncurrentFinancialAssetsEquityInvestments" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_NoncurrentFinancialAssetsEquityInvestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentFinancialAsstetsDebtSecurities" xlink:label="lbl_NoncurrentFinancialAsstetsDebtSecurities" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_NoncurrentFinancialAsstetsDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentFinancialAssetsFundInvestments" xlink:label="lbl_NoncurrentFinancialAssetsFundInvestments" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_NoncurrentFinancialAssetsFundInvestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:label="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentTradeReceivables" xlink:label="lbl_NoncurrentTradeReceivables" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_NoncurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentFinanceLeaseReceivables" xlink:label="lbl_NoncurrentFinanceLeaseReceivables" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_NoncurrentFinanceLeaseReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationReceivable" xlink:label="lbl_ContingentConsiderationReceivable" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_ContingentConsiderationReceivable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLoansAndReceivables" xlink:label="lbl_NoncurrentLoansAndReceivables" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_NoncurrentLoansAndReceivables" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="lbl_NoncurrentFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_NoncurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentReceivables" xlink:label="lbl_OtherNoncurrentReceivables" xlink:type="locator"/>
      <link:presentationArc order="7.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_OtherNoncurrentReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LongTermReceivablesFromFinanceSubleases" xlink:label="lbl_LongTermReceivablesFromFinanceSubleases" xlink:type="locator"/>
      <link:presentationArc order="7.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_LongTermReceivablesFromFinanceSubleases" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:label="lbl_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DeferredCompensationPlansAssets" xlink:label="lbl_DeferredCompensationPlansAssets" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:to="lbl_DeferredCompensationPlansAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PrepaidPostemploymentBenefitPlansAssets" xlink:label="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:to="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:label="lbl_OtherNoncurrentNonfinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:to="lbl_OtherNoncurrentNonfinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:to="lbl_OtherNoncurrentAssets" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/StatementOfIncome" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="lbl_IncomeStatementAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncomeStatementAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="lbl_ProfitLossAttributableToAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsPerShareAbstract" xlink:label="lbl_BasicEarningsPerShareAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsPerShareAbstract" xlink:label="lbl_DilutedEarningsPerShareAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CostOfSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ResearchAndDevelopmentExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BasicEarningsPerShareAbstract" xlink:to="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BasicEarningsPerShareAbstract" xlink:to="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DilutedEarningsPerShareAbstract" xlink:to="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DilutedEarningsPerShareAbstract" xlink:to="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
      <link:presentationArc order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossAttributableToAbstract" xlink:type="arc"/>
      <link:presentationArc order="20.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_BasicEarningsPerShareAbstract" xlink:type="arc"/>
      <link:presentationArc order="21.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DilutedEarningsPerShareAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:presentationArc order="9.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherExpenseByFunction" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:presentationArc order="13.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:presentationArc order="3.2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossProfit" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="locator"/>
      <link:presentationArc order="1.65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="lbl_BasicEarningsLossPerShare" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BasicEarningsPerShareAbstract" xlink:to="lbl_BasicEarningsLossPerShare" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="lbl_DilutedEarningsLossPerShare" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DilutedEarningsPerShareAbstract" xlink:to="lbl_DilutedEarningsLossPerShare" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:label="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="locator"/>
      <link:presentationArc order="16.5" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="lbl_ProfitLossFromContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:presentationArc order="16.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSubsequentEvents" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSubsequentEventsDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SubsequentEventTypAxis" xlink:label="lbl_SubsequentEventTypAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_SubsequentEventTypAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SubsequentEventTypeMember" xlink:label="lbl_SubsequentEventTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SubsequentEventTypAxis" xlink:to="lbl_SubsequentEventTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SubsequentEventMember" xlink:label="lbl_SubsequentEventMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SubsequentEventTypeMember" xlink:to="lbl_SubsequentEventMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureCommitmentsAndContingencies" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CommitmentsAndContingenciesAbstract" xlink:label="lbl_CommitmentsAndContingenciesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfCommitmentsAndContingenciesTextBlock" xlink:label="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CommitmentsAndContingenciesAbstract" xlink:to="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSignificantTransactions" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfSignificantTransactionsAbstract" xlink:label="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfSignificantTransactionsTextBlock" xlink:label="lbl_DisclosureOfSignificantTransactionsTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfSignificantTransactionsTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebt" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:label="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:label="lbl_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstruments" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtTables" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:label="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" xlink:label="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" xlink:label="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" xlink:label="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CommitmentsAndContingenciesAbstract" xlink:label="lbl_CommitmentsAndContingenciesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfLeasingCommitmentsTableTextBlock" xlink:label="lbl_DisclosureOfLeasingCommitmentsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CommitmentsAndContingenciesAbstract" xlink:to="lbl_DisclosureOfLeasingCommitmentsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" xlink:label="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CommitmentsAndContingenciesAbstract" xlink:to="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:label="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LeasingCommitmentsAbstract" xlink:label="lbl_LeasingCommitmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LeasingCommitmentsAbstract" xlink:to="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:label="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:to="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:presentationArc order="1.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="1.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:label="lbl_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:to="lbl_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:label="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ResearchAndDevelopmentCommitmentsAbstract" xlink:label="lbl_ResearchAndDevelopmentCommitmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ResearchAndDevelopmentCommitmentsAbstract" xlink:to="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:label="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:to="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CommitmentsUnderLongtermResearchAgreements" xlink:label="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherIntangiblePurchaseCommitments" xlink:label="lbl_OtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_OtherIntangiblePurchaseCommitments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:label="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:label="lbl_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:label="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShorttermBorrowings" xlink:label="lbl_ShorttermBorrowings" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_ShorttermBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CommercialPapersIssued" xlink:label="lbl_CommercialPapersIssued" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_CommercialPapersIssued" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="lbl_DerivativeFinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_DerivativeFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_OtherCurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WeightedAverageInterestRateAssociates" xlink:label="lbl_WeightedAverageInterestRateAssociates" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_WeightedAverageInterestRateAssociates" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:label="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:label="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_BondsIssued" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LiabilitiesToBanksAndOtherInstitutions" xlink:label="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AverageInterestRateOnLoansReceived" xlink:label="lbl_AverageInterestRateOnLoansReceived" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_AverageInterestRateOnLoansReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:label="lbl_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AverageInterestRateOnBorrowings" xlink:label="lbl_AverageInterestRateOnBorrowings" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_AverageInterestRateOnBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinanceLeaseLiabilities" xlink:label="lbl_FinanceLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_FinanceLeaseLiabilities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails3" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:label="lbl_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:type="locator"/>
      <link:presentationArc order="5.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LaterThanSixYearsMember" xlink:label="lbl_LaterThanSixYearsMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanSixYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract1" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract1" xlink:to="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:to="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails4" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrencyOthersMember" xlink:label="lbl_CurrencyOthersMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CurrencyOthersMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract1" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract1" xlink:to="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:to="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_USD" xlink:label="lbl_USD" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_USD" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="lbl_EUR" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_EUR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY" xlink:label="lbl_JPY" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_JPY" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CHF" xlink:label="lbl_CHF" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CHF" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis1" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:to="lbl_CurrencyAxis1" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrencyAxis1" xlink:to="lbl_AllCurrenciesDomain" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails6" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" xlink:label="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentFinancialDebtsCoveredByCollateral" xlink:label="lbl_NoncurrentFinancialDebtsCoveredByCollateral" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" xlink:to="lbl_NoncurrentFinancialDebtsCoveredByCollateral" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:label="lbl_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" xlink:to="lbl_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:to="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lbl_BorrowingsByNameAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:label="lbl_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:label="lbl_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:label="lbl_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:label="lbl_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:label="lbl_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:label="lbl_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:label="lbl_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:label="lbl_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:label="lbl_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:label="lbl_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:label="lbl_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:label="lbl_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:label="lbl_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:label="lbl_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:label="lbl_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:label="lbl_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:type="locator"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotionalAmount" xlink:label="lbl_NotionalAmount" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_NotionalAmount" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsOriginalCurrency" xlink:label="lbl_BorrowingsOriginalCurrency" xlink:type="locator"/>
      <link:presentationArc order="3.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsOriginalCurrency" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BondsIssued" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:label="lbl_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:type="locator"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:label="lbl_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:type="locator"/>
      <link:presentationArc order="17.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:label="lbl_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:type="locator"/>
      <link:presentationArc order="18.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:label="lbl_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:type="locator"/>
      <link:presentationArc order="19.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:label="lbl_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:type="locator"/>
      <link:presentationArc order="20.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="lbl_BorrowingsInterestRate" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsInterestRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsIssuanceDate" xlink:label="lbl_BorrowingsIssuanceDate" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsIssuanceDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsMaturity" xlink:label="lbl_BorrowingsMaturity" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsMaturity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsLender" xlink:label="lbl_BorrowingsLender" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsLender" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsPremiumDiscount" xlink:label="lbl_BorrowingsPremiumDiscount" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsPremiumDiscount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:label="lbl_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:type="locator"/>
      <link:presentationArc order="21.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:label="lbl_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:type="locator"/>
      <link:presentationArc order="22.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:label="lbl_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:type="locator"/>
      <link:presentationArc order="23.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:label="lbl_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:type="locator"/>
      <link:presentationArc order="24.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:label="lbl_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:type="locator"/>
      <link:presentationArc order="25.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:label="lbl_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:type="locator"/>
      <link:presentationArc order="26.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:label="lbl_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:type="locator"/>
      <link:presentationArc order="27.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:label="lbl_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:type="locator"/>
      <link:presentationArc order="28.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsInterestRateStepUp" xlink:label="lbl_BorrowingsInterestRateStepUp" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsInterestRateStepUp" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails5" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:to="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_BondsIssued" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherNoncurrentFinancialDebt" xlink:label="lbl_OtherNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_OtherNoncurrentFinancialDebt" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueByMeasurementBasisAxis" xlink:label="lbl_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_FairValueByMeasurementBasisAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueByMeasurementBasisMember" xlink:label="lbl_FairValueByMeasurementBasisMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueByMeasurementBasisAxis" xlink:to="lbl_FairValueByMeasurementBasisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueDisclosureItemAmountsMember" xlink:label="lbl_FairValueDisclosureItemAmountsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueByMeasurementBasisMember" xlink:to="lbl_FairValueDisclosureItemAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CarryingReportedAmountFairValueDisclosureMember" xlink:label="lbl_CarryingReportedAmountFairValueDisclosureMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueByMeasurementBasisMember" xlink:to="lbl_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/StatementOfComprehensiveIncome" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="lbl_StatementOfComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfComprehensiveIncomeAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="arc"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="locator"/>
      <link:presentationArc order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="arc"/>
      <link:presentationArc order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="25.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:type="locator"/>
      <link:presentationArc order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:to="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:to="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="1.6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:presentationArc order="2.3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:presentationArc order="4.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:presentationArc order="1.9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/StatementsOfCashFlow" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="lbl_StatementOfCashFlowsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfCashFlowsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="19.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="21.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:presentationArc order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="26.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="locator"/>
      <link:presentationArc order="32.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="38.5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="39.5" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="40.5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems1" xlink:type="locator"/>
      <link:presentationArc order="41.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems1" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:presentationArc order="41.5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:label="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsReceivedClassifiedAsOperatingActivities" xlink:label="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="7.2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:label="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="31.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="35.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="2.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="36.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="38.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:label="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="locator"/>
      <link:presentationArc order="37.6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:label="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="24.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="29.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="34.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="lbl_ProfitLossFromContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="38.45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="38.35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="locator"/>
      <link:presentationArc order="39.1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="37.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_YoYChangeMember" xlink:label="lbl_YoYChangeMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_YoYChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:label="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="locator"/>
      <link:presentationArc order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/StatementOfChangesInEquity" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="lbl_StatementOfChangesInEquityTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="lbl_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_StatementOfChangesInEquityTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="lbl_NoncontrollingInterestsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_NoncontrollingInterestsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="lbl_StatementOfChangesInEquityLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityTable" xlink:to="lbl_StatementOfChangesInEquityLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="lbl_OtherComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPaid" xlink:label="lbl_DividendsPaid" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_DividendsPaid" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ChangesInEquity" xlink:label="lbl_ChangesInEquity" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ChangesInEquity" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="lbl_StatementOfChangesInEquityLineItems1" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems1" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsRelatedToDivestments" xlink:label="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="locator"/>
      <link:presentationArc order="10.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="lbl_IssuedCapitalMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_IssuedCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TreasurySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="lbl_RetainedEarningsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_RetainedEarningsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseInNoncontrolingInterests" xlink:label="lbl_IncreaseDecreaseInNoncontrolingInterests" xlink:type="locator"/>
      <link:presentationArc order="10.1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseInNoncontrolingInterests" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="lbl_PurchaseOfTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="6.2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_PurchaseOfTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="lbl_StatementOfChangesInEquityLineItems2" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems2" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:label="lbl_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="9.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="locator"/>
      <link:presentationArc order="8.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="locator"/>
      <link:presentationArc order="10.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherShareSales" xlink:label="lbl_OtherShareSales" xlink:type="locator"/>
      <link:presentationArc order="7.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherShareSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeMaketableSecurities" xlink:label="lbl_OtherComprehensiveIncomeMaketableSecurities" xlink:type="locator"/>
      <link:presentationArc order="9.75" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherComprehensiveIncomeMaketableSecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RestatedValueAdjustmentsMember" xlink:label="lbl_RestatedValueAdjustmentsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_RestatedValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TransactionCostsRecordedInEquity" xlink:label="lbl_TransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:presentationArc order="9.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_TransactionCostsRecordedInEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReductionOfIssuedCapital" xlink:label="lbl_ReductionOfIssuedCapital" xlink:type="locator"/>
      <link:presentationArc order="6.3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ReductionOfIssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="locator"/>
      <link:presentationArc order="6.9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="locator"/>
      <link:presentationArc order="8.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:label="lbl_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DividendPaidNoncashAssetsDistribution" xlink:label="lbl_DividendPaidNoncashAssetsDistribution" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_DividendPaidNoncashAssetsDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxesOnTreasuryShares" xlink:label="lbl_TaxesOnTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="8.8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_TaxesOnTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsOnFinancialAssetsSold" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="locator"/>
      <link:presentationArc order="9.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="locator"/>
      <link:presentationArc order="10.6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RepurchaseOfOptions" xlink:label="lbl_RepurchaseOfOptions" xlink:type="locator"/>
      <link:presentationArc order="7.3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_RepurchaseOfOptions" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherCurrentLiabilities" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureAcquisitionsOfBusinesses" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:label="lbl_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:label="lbl_DisclosureOfBusinessCombinationsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:to="lbl_DisclosureOfBusinessCombinationsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociates" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:label="lbl_DisclosureOfEmployeeBenefitsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_DisclosureOfEmployeeBenefitsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionsForReductionOfRevenueTableTextBlock" xlink:label="lbl_ProvisionsForReductionOfRevenueTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_ProvisionsForReductionOfRevenueTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RestructuringProvisionsMovementsTableTextBlock" xlink:label="lbl_RestructuringProvisionsMovementsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_RestructuringProvisionsMovementsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureAcquisitionsOfBusinessesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:label="lbl_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:to="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="lbl_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:label="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:label="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="7.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:label="lbl_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureAcquisitionsOfBusinessesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:to="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IdentifiableAssetsAcquired" xlink:label="lbl_IdentifiableAssetsAcquired" xlink:type="locator"/>
      <link:presentationArc order="10.2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_IdentifiableAssetsAcquired" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator"/>
      <link:presentationArc order="13.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems1" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="8.7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems1" xlink:to="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialAndOtherAssets" xlink:label="lbl_FinancialAndOtherAssets" xlink:type="locator"/>
      <link:presentationArc order="4.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_FinancialAndOtherAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="8.3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradePayablesAndOtherLiabilities" xlink:label="lbl_TradePayablesAndOtherLiabilities" xlink:type="locator"/>
      <link:presentationArc order="9.8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_TradePayablesAndOtherLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:label="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="lbl_GoodwillRecognisedAsOfAcquisitionDate1" xlink:type="locator"/>
      <link:presentationArc order="12.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_GoodwillRecognisedAsOfAcquisitionDate1" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodwillExpectedDeductibleForTaxPurposes" xlink:label="lbl_GoodwillExpectedDeductibleForTaxPurposes" xlink:type="locator"/>
      <link:presentationArc order="13.6" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_GoodwillExpectedDeductibleForTaxPurposes" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquiredCashAndCashEquivalents" xlink:label="lbl_AcquiredCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="10.8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_AcquiredCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RightOfUseAssetsAsOfAcquisitionDate" xlink:label="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="0.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:label="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="9.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionsForDeductionsFromRevenueRollForward" xlink:label="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionForDeductionFromRevenueTable" xlink:label="lbl_ProvisionForDeductionFromRevenueTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeStatementAdjustmentsOfPriorYear" xlink:label="lbl_IncomeStatementAdjustmentsOfPriorYear" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_IncomeStatementAdjustmentsOfPriorYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeStatementAdjustmentsOfCurrentYear" xlink:label="lbl_IncomeStatementAdjustmentsOfCurrentYear" xlink:type="locator"/>
      <link:presentationArc order="4.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_IncomeStatementAdjustmentsOfCurrentYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PlansAndProgramRebatesAxis" xlink:label="lbl_PlansAndProgramRebatesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionForDeductionFromRevenueTable" xlink:to="lbl_PlansAndProgramRebatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="lbl_ProvisionUsedOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_ProvisionUsedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="1.55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PlansAndProgramRebatesMember" xlink:label="lbl_PlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PlansAndProgramRebatesAxis" xlink:to="lbl_PlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_USspecificHealthcarePlansAndProgramRebatesMember" xlink:label="lbl_USspecificHealthcarePlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PlansAndProgramRebatesMember" xlink:to="lbl_USspecificHealthcarePlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:label="lbl_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PlansAndProgramRebatesMember" xlink:to="lbl_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:label="lbl_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PlansAndProgramRebatesMember" xlink:to="lbl_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_ProvisionForDeductionFromRevenueTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:label="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionForDeductionFromRevenueTable" xlink:to="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:to="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionForDeductionFromRevenueTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangesInOffsetAgainstGrossTradeReceivables" xlink:label="lbl_ChangesInOffsetAgainstGrossTradeReceivables" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_ChangesInOffsetAgainstGrossTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentRefundsProvision" xlink:label="lbl_CurrentRefundsProvision" xlink:type="locator"/>
      <link:presentationArc order="1.3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_CurrentRefundsProvision" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionsForDeductionsFromRevenueRollForward" xlink:label="lbl_ProvisionsForDeductionsFromRevenueRollForward1" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward1" xlink:to="lbl_CurrentRefundsProvision" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentRefundsProvisionDiscontinuedOperations" xlink:label="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="1.4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:type="arc"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward1" xlink:to="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShorttermRestructuringProvision" xlink:label="lbl_ShorttermRestructuringProvision" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_ShorttermRestructuringProvision" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="lbl_AccrualsClassifiedAsCurrent" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_AccrualsClassifiedAsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:label="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentInterestPayable" xlink:label="lbl_CurrentInterestPayable" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_CurrentInterestPayable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="lbl_ShorttermEmployeeBenefitsAccruals" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_ShorttermEmployeeBenefitsAccruals" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionCurrent" xlink:label="lbl_EnvironmentalProvisionCurrent" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_EnvironmentalProvisionCurrent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredIncomeClassifiedAsCurrent" xlink:label="lbl_DeferredIncomeClassifiedAsCurrent" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_DeferredIncomeClassifiedAsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:label="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationCurrentPortion" xlink:label="lbl_ContingentConsiderationCurrentPortion" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_ContingentConsiderationCurrentPortion" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CommitmentForRepurchaseOwnShares" xlink:label="lbl_CommitmentForRepurchaseOwnShares" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_CommitmentForRepurchaseOwnShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentPayables" xlink:label="lbl_OtherCurrentPayables" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_OtherCurrentPayables" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentRefundsProvision" xlink:label="lbl_CurrentRefundsProvision" xlink:type="locator"/>
      <link:presentationArc order="7.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_CurrentRefundsProvision" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RefundsProvision" xlink:label="lbl_RefundsProvision" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_RefundsProvision" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentRefundsProvisionDiscontinuedOperations" xlink:label="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="7.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_OtherProvisionsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestructuringProvisionMember" xlink:label="lbl_RestructuringProvisionMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_RestructuringProvisionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RestructuringProvisionsMovementsRollForward" xlink:label="lbl_RestructuringProvisionsMovementsRollForward" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherProvisions" xlink:label="lbl_OtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_OtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="lbl_AdditionalProvisionsOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_AdditionalProvisionsOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="lbl_ProvisionUsedOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_ProvisionUsedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:label="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RestructuringProvisionsMovementsRollForward" xlink:label="lbl_RestructuringProvisionsMovementsRollForward1" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsRollForward1" xlink:to="lbl_OtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RestructuringProvisionsMovementsTable" xlink:label="lbl_RestructuringProvisionsMovementsTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_RestructuringProvisionsMovementsTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsTable" xlink:to="lbl_ClassesOfProvisionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PlansAndProgramRebatesMember" xlink:label="lbl_PlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_PlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:label="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsTable" xlink:to="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:to="lbl_RestructuringProvisionsMovementsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="6.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureTradeReceivables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfTradeReceivablesAbstract" xlink:label="lbl_DisclosureOfTradeReceivablesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfTradeReceivablesExplanatoryTextBlock" xlink:label="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTradeReceivablesAbstract" xlink:to="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureTradeReceivablesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfTradeReceivablesAbstract" xlink:label="lbl_DisclosureOfTradeReceivablesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionsForTradeReceivablesTableTextBlock" xlink:label="lbl_ProvisionsForTradeReceivablesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTradeReceivablesAbstract" xlink:to="lbl_ProvisionsForTradeReceivablesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradeReceivablesProvisionMovementsTableTextBlock" xlink:label="lbl_TradeReceivablesProvisionMovementsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTradeReceivablesAbstract" xlink:to="lbl_TradeReceivablesProvisionMovementsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OverdueAmountsAndRelatedProvisionsTableTextBlock" xlink:label="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTradeReceivablesAbstract" xlink:to="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" xlink:label="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTradeReceivablesAbstract" xlink:to="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" xlink:label="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTradeReceivablesAbstract" xlink:to="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixTable" xlink:label="lbl_DisclosureOfProvisionMatrixTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixAbstract" xlink:label="lbl_DisclosureOfProvisionMatrixAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixAbstract" xlink:to="lbl_DisclosureOfProvisionMatrixTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionForDoubtfulReceivableMember" xlink:label="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionForDoubtfulReceivable" xlink:label="lbl_ProvisionForDoubtfulReceivable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_ProvisionForDoubtfulReceivable" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixTable" xlink:label="lbl_DisclosureOfProvisionMatrixTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixAbstract" xlink:label="lbl_DisclosureOfProvisionMatrixAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixAbstract" xlink:to="lbl_DisclosureOfProvisionMatrixTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="lbl_ProvisionUsedOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_ProvisionUsedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems1" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionForDoubtfulReceivableMember" xlink:label="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:label="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="5.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="lbl_AdditionalProvisionsOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_AdditionalProvisionsOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfDivestmentsOtherProvisions" xlink:label="lbl_ImpactOfDivestmentsOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="2.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_ImpactOfDivestmentsOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="2.8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionForDoubtfulReceivable" xlink:label="lbl_ProvisionForDoubtfulReceivable" xlink:type="locator"/>
      <link:presentationArc order="2.3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_ProvisionForDoubtfulReceivable" xlink:type="arc"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems1" xlink:to="lbl_ProvisionForDoubtfulReceivable" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AnalysisOfOverdueAmountsTable" xlink:label="lbl_AnalysisOfOverdueAmountsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixAbstract" xlink:label="lbl_DisclosureOfProvisionMatrixAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixAbstract" xlink:to="lbl_AnalysisOfOverdueAmountsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PastDueStatusAxis" xlink:label="lbl_PastDueStatusAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PastDueStatusMember" xlink:label="lbl_PastDueStatusMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PastDueStatusAxis" xlink:to="lbl_PastDueStatusMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentMember" xlink:label="lbl_CurrentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PastDueStatusMember" xlink:to="lbl_CurrentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AnalysisOfOverdueAmountsLineItems" xlink:label="lbl_AnalysisOfOverdueAmountsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_AnalysisOfOverdueAmountsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AnalysisOfOverdueAmountsLineItems" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:presentationArc order="1.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_PastDueStatusAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember1" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentMember" xlink:to="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember1" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="lbl_LaterThanOneYearMember1" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentMember" xlink:to="lbl_LaterThanOneYearMember1" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:label="lbl_LaterThanSixMonthsAndNotLaterThanOneYearMember1" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentMember" xlink:to="lbl_LaterThanSixMonthsAndNotLaterThanOneYearMember1" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:label="lbl_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember1" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentMember" xlink:to="lbl_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember1" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="lbl_NotLaterThanOneMonthMember" xlink:type="locator"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentMember" xlink:to="lbl_NotLaterThanOneMonthMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="1.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProvisionForDoubtfulReceivableMember" xlink:label="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails4" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixAbstract" xlink:label="lbl_DisclosureOfProvisionMatrixAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrencyOthersMember" xlink:label="lbl_CurrencyOthersMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CurrencyOthersMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:label="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixAbstract" xlink:to="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:to="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:to="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_USD" xlink:label="lbl_USD" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_USD" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="lbl_EUR" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_EUR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY" xlink:label="lbl_JPY" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_JPY" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CNY" xlink:label="lbl_CNY" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CNY" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP" xlink:label="lbl_GBP" xlink:type="locator"/>
      <link:presentationArc order="3.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_GBP" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CHF" xlink:label="lbl_CHF" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CHF" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_RUB" xlink:label="lbl_RUB" xlink:type="locator"/>
      <link:presentationArc order="3.6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_RUB" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_BRL" xlink:label="lbl_BRL" xlink:type="locator"/>
      <link:presentationArc order="3.65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_BRL" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AUD" xlink:label="lbl_AUD" xlink:type="locator"/>
      <link:presentationArc order="3.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_AUD" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CAD" xlink:label="lbl_CAD" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CAD" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis1" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:to="lbl_CurrencyAxis1" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrencyAxis1" xlink:to="lbl_AllCurrenciesDomain" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:label="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixAbstract" xlink:label="lbl_DisclosureOfProvisionMatrixAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixAbstract" xlink:to="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:to="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentTradeReceivablesFromCloselyMonitoredCountries" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountries" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountries" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompanies" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" xlink:label="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="lbl_EntitysTotalForSubsidiariesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lbl_EntitysTotalForSubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SubsidiariesMember" xlink:label="lbl_SubsidiariesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSubsidiariesMember" xlink:to="lbl_SubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NameOfSubsidiary" xlink:label="lbl_NameOfSubsidiary" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_NameOfSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" xlink:label="lbl_PrincipalPlaceOfBusinessOfSubsidiary" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_PrincipalPlaceOfBusinessOfSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:label="lbl_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xlink:label="lbl_ProportionOfVotingPowerHeldInSubsidiary" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_ProportionOfVotingPowerHeldInSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharePaidinCapital" xlink:label="lbl_SharePaidinCapital" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_SharePaidinCapital" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lbl_LegalEntityAxis" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:label="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SocieteParActionsSANDOZAlgiersMember" xlink:label="lbl_SocieteParActionsSANDOZAlgiersMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SocieteParActionsSANDOZAlgiersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisArgentinaS.A.BuenosAiresMember" xlink:label="lbl_NovartisArgentinaS.A.BuenosAiresMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisArgentinaS.A.BuenosAiresMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriosS.A.BuenosAiresMember" xlink:label="lbl_AlconLaboratoriosS.A.BuenosAiresMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriosS.A.BuenosAiresMember" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="arc"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="arc"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPtyLtdMacquarieParkNSWMember" xlink:type="arc"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisAustriaGmbHViennaMember" xlink:label="lbl_NovartisAustriaGmbHViennaMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisAustriaGmbHViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaGmbHViennaMember" xlink:label="lbl_NovartisPharmaGmbHViennaMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaGmbHViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozGmbHViennaMember" xlink:label="lbl_SandozGmbHViennaMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozGmbHViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconOphthalmikaGmbHViennaMember" xlink:label="lbl_AlconOphthalmikaGmbHViennaMember" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconOphthalmikaGmbHViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:label="lbl_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisBangladeshLimitedGazipurMember" xlink:label="lbl_NovartisBangladeshLimitedGazipurMember" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBangladeshLimitedGazipurMember" xlink:type="arc"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaNVVilvoordeMember" xlink:type="arc"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozNVVilvoordeMember" xlink:type="arc"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconCouvreurNVPuursMember" xlink:type="arc"/>
      <link:presentationArc order="17.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconNVVilvoordeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInvestmentLtd.HamiltonMember" xlink:label="lbl_NovartisInvestmentLtd.HamiltonMember" xlink:type="locator"/>
      <link:presentationArc order="18.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInvestmentLtd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:label="lbl_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:type="locator"/>
      <link:presentationArc order="19.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFinanceServicesLtd.HamiltonMember" xlink:label="lbl_NovartisFinanceServicesLtd.HamiltonMember" xlink:type="locator"/>
      <link:presentationArc order="20.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinanceServicesLtd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisB2Ltd.HamiltonMember" xlink:label="lbl_NovartisB2Ltd.HamiltonMember" xlink:type="locator"/>
      <link:presentationArc order="21.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisB2Ltd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisB3Ltd.HamiltonMember" xlink:label="lbl_NovartisB3Ltd.HamiltonMember" xlink:type="locator"/>
      <link:presentationArc order="22.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisB3Ltd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:label="lbl_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:type="locator"/>
      <link:presentationArc order="23.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:label="lbl_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:type="locator"/>
      <link:presentationArc order="24.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisBiocienciasS.A.SaoPauloMember" xlink:label="lbl_NovartisBiocienciasS.A.SaoPauloMember" xlink:type="locator"/>
      <link:presentationArc order="25.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBiocienciasS.A.SaoPauloMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:label="lbl_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:type="locator"/>
      <link:presentationArc order="26.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:label="lbl_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:type="locator"/>
      <link:presentationArc order="27.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozCanadaInc.BouchervilleQuebecMember" xlink:label="lbl_SandozCanadaInc.BouchervilleQuebecMember" xlink:type="locator"/>
      <link:presentationArc order="28.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozCanadaInc.BouchervilleQuebecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconCanadaInc.MississaugaOntarioMember" xlink:label="lbl_AlconCanadaInc.MississaugaOntarioMember" xlink:type="locator"/>
      <link:presentationArc order="29.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconCanadaInc.MississaugaOntarioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:label="lbl_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:type="locator"/>
      <link:presentationArc order="30.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisChileS.A.SantiagoDeChileMember" xlink:label="lbl_NovartisChileS.A.SantiagoDeChileMember" xlink:type="locator"/>
      <link:presentationArc order="31.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisChileS.A.SantiagoDeChileMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:label="lbl_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:type="locator"/>
      <link:presentationArc order="32.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:label="lbl_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:type="locator"/>
      <link:presentationArc order="33.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:label="lbl_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:type="locator"/>
      <link:presentationArc order="34.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:label="lbl_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:type="locator"/>
      <link:presentationArc order="35.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:label="lbl_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:type="locator"/>
      <link:presentationArc order="36.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:label="lbl_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:type="locator"/>
      <link:presentationArc order="37.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:label="lbl_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:type="locator"/>
      <link:presentationArc order="38.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconHongKongLimitedHongKongMember" xlink:label="lbl_AlconHongKongLimitedHongKongMember" xlink:type="locator"/>
      <link:presentationArc order="39.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconHongKongLimitedHongKongMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:label="lbl_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:type="locator"/>
      <link:presentationArc order="40.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:label="lbl_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:type="locator"/>
      <link:presentationArc order="41.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:label="lbl_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:type="locator"/>
      <link:presentationArc order="42.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:label="lbl_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:type="locator"/>
      <link:presentationArc order="43.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisS.r.o.PragueMember" xlink:label="lbl_NovartisS.r.o.PragueMember" xlink:type="locator"/>
      <link:presentationArc order="44.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisS.r.o.PragueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozS.r.o.PragueMember" xlink:label="lbl_SandozS.r.o.PragueMember" xlink:type="locator"/>
      <link:presentationArc order="45.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.r.o.PragueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:label="lbl_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:type="locator"/>
      <link:presentationArc order="46.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisHealthcareASCopenhagenMember" xlink:label="lbl_NovartisHealthcareASCopenhagenMember" xlink:type="locator"/>
      <link:presentationArc order="47.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHealthcareASCopenhagenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozASCopenhagenMember" xlink:label="lbl_SandozASCopenhagenMember" xlink:type="locator"/>
      <link:presentationArc order="48.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozASCopenhagenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconNordicASCopenhagenMember" xlink:label="lbl_AlconNordicASCopenhagenMember" xlink:type="locator"/>
      <link:presentationArc order="49.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconNordicASCopenhagenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisEcuadorS.A.QuitoMember" xlink:label="lbl_NovartisEcuadorS.A.QuitoMember" xlink:type="locator"/>
      <link:presentationArc order="50.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisEcuadorS.A.QuitoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaS.A.E.CairoMember" xlink:label="lbl_NovartisPharmaS.A.E.CairoMember" xlink:type="locator"/>
      <link:presentationArc order="51.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaS.A.E.CairoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:label="lbl_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:type="locator"/>
      <link:presentationArc order="52.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFinlandOyEspooMember" xlink:label="lbl_NovartisFinlandOyEspooMember" xlink:type="locator"/>
      <link:presentationArc order="53.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinlandOyEspooMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:label="lbl_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:type="locator"/>
      <link:presentationArc order="54.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:label="lbl_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:presentationArc order="55.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozS.A.S.LevalloisPerretMember" xlink:label="lbl_SandozS.A.S.LevalloisPerretMember" xlink:type="locator"/>
      <link:presentationArc order="56.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.A.S.LevalloisPerretMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:label="lbl_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:presentationArc order="57.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisDeutschlandGmbHWehrMember" xlink:label="lbl_NovartisDeutschlandGmbHWehrMember" xlink:type="locator"/>
      <link:presentationArc order="58.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisDeutschlandGmbHWehrMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaGmbHNurembergMember" xlink:label="lbl_NovartisPharmaGmbHNurembergMember" xlink:type="locator"/>
      <link:presentationArc order="59.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaGmbHNurembergMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaProduktionsGmbHWehrMember" xlink:label="lbl_NovartisPharmaProduktionsGmbHWehrMember" xlink:type="locator"/>
      <link:presentationArc order="60.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaProduktionsGmbHWehrMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:label="lbl_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:type="locator"/>
      <link:presentationArc order="61.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WaveLightGmbHErlangenMember" xlink:label="lbl_WaveLightGmbHErlangenMember" xlink:type="locator"/>
      <link:presentationArc order="62.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_WaveLightGmbHErlangenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CIBAVisionGmbHGrosswallstadtMember" xlink:label="lbl_CIBAVisionGmbHGrosswallstadtMember" xlink:type="locator"/>
      <link:presentationArc order="63.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionGmbHGrosswallstadtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozInternationalGmbHHolzkirchenMember" xlink:label="lbl_SandozInternationalGmbHHolzkirchenMember" xlink:type="locator"/>
      <link:presentationArc order="64.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozInternationalGmbHHolzkirchenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_A1APharmaGmbHOberhachingMember" xlink:label="lbl_A1APharmaGmbHOberhachingMember" xlink:type="locator"/>
      <link:presentationArc order="65.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_A1APharmaGmbHOberhachingMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SalutasPharmaGmbHBarlebenMember" xlink:label="lbl_SalutasPharmaGmbHBarlebenMember" xlink:type="locator"/>
      <link:presentationArc order="66.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SalutasPharmaGmbHBarlebenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_HEXALAGHolzkirchenMember" xlink:label="lbl_HEXALAGHolzkirchenMember" xlink:type="locator"/>
      <link:presentationArc order="67.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_HEXALAGHolzkirchenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AeropharmGmbHRudolstadtMember" xlink:label="lbl_AeropharmGmbHRudolstadtMember" xlink:type="locator"/>
      <link:presentationArc order="68.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AeropharmGmbHRudolstadtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovistaInsuranceLimitedGibraltarCityMember" xlink:label="lbl_NovistaInsuranceLimitedGibraltarCityMember" xlink:type="locator"/>
      <link:presentationArc order="70.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovistaInsuranceLimitedGibraltarCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:label="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:type="locator"/>
      <link:presentationArc order="71.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:label="lbl_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:type="locator"/>
      <link:presentationArc order="72.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:label="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:type="locator"/>
      <link:presentationArc order="73.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:label="lbl_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:type="locator"/>
      <link:presentationArc order="74.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisIndiaLimitedMumbaiMember" xlink:label="lbl_NovartisIndiaLimitedMumbaiMember" xlink:type="locator"/>
      <link:presentationArc order="75.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisIndiaLimitedMumbaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:label="lbl_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:type="locator"/>
      <link:presentationArc order="76.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozPrivateLimitedMumbaiMember" xlink:label="lbl_SandozPrivateLimitedMumbaiMember" xlink:type="locator"/>
      <link:presentationArc order="77.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPrivateLimitedMumbaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:label="lbl_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:type="locator"/>
      <link:presentationArc order="78.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PT.NovartisIndonesiaJakartaMember" xlink:label="lbl_PT.NovartisIndonesiaJakartaMember" xlink:type="locator"/>
      <link:presentationArc order="79.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_PT.NovartisIndonesiaJakartaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PT.CIBAVisionBatamBatamMember" xlink:label="lbl_PT.CIBAVisionBatamBatamMember" xlink:type="locator"/>
      <link:presentationArc order="80.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_PT.CIBAVisionBatamBatamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisIrelandLimitedDublinMember" xlink:label="lbl_NovartisIrelandLimitedDublinMember" xlink:type="locator"/>
      <link:presentationArc order="81.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisIrelandLimitedDublinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:label="lbl_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:type="locator"/>
      <link:presentationArc order="82.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:label="lbl_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:type="locator"/>
      <link:presentationArc order="83.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:type="arc"/>
      <link:presentationArc order="84.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisIsraelLtd.TelAvivMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OptonolLtd.NeveIlanMember" xlink:label="lbl_OptonolLtd.NeveIlanMember" xlink:type="locator"/>
      <link:presentationArc order="85.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_OptonolLtd.NeveIlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFarmaS.p.A.OriggioMember" xlink:label="lbl_NovartisFarmaS.p.A.OriggioMember" xlink:type="locator"/>
      <link:presentationArc order="86.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFarmaS.p.A.OriggioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozS.p.A.OriggioMember" xlink:label="lbl_SandozS.p.A.OriggioMember" xlink:type="locator"/>
      <link:presentationArc order="87.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.p.A.OriggioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:label="lbl_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:type="locator"/>
      <link:presentationArc order="88.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconItaliaS.p.A.MilanMember" xlink:label="lbl_AlconItaliaS.p.A.MilanMember" xlink:type="locator"/>
      <link:presentationArc order="89.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconItaliaS.p.A.MilanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisHoldingJapanK.K.TokyoMember" xlink:label="lbl_NovartisHoldingJapanK.K.TokyoMember" xlink:type="locator"/>
      <link:presentationArc order="90.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHoldingJapanK.K.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaK.K.TokyoMember" xlink:label="lbl_NovartisPharmaK.K.TokyoMember" xlink:type="locator"/>
      <link:presentationArc order="91.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaK.K.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CibaGeigyJapanLimitedTokyoMember" xlink:label="lbl_CibaGeigyJapanLimitedTokyoMember" xlink:type="locator"/>
      <link:presentationArc order="92.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CibaGeigyJapanLimitedTokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozK.K.TokyoMember" xlink:label="lbl_SandozK.K.TokyoMember" xlink:type="locator"/>
      <link:presentationArc order="93.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozK.K.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconJapanLtd.TokyoMember" xlink:label="lbl_AlconJapanLtd.TokyoMember" xlink:type="locator"/>
      <link:presentationArc order="94.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconJapanLtd.TokyoMember" xlink:type="arc"/>
      <link:presentationArc order="95.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:type="arc"/>
      <link:presentationArc order="96.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinanceS.A.LuxembourgCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember" xlink:label="lbl_NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember" xlink:type="locator"/>
      <link:presentationArc order="97.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:label="lbl_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="locator"/>
      <link:presentationArc order="98.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:label="lbl_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:type="locator"/>
      <link:presentationArc order="99.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:label="lbl_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:presentationArc order="100.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozS.A.DeC.V.MexicoCityMember" xlink:label="lbl_SandozS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:presentationArc order="101.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.A.DeC.V.MexicoCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:label="lbl_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:presentationArc order="102.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaMarocSACasablancaMember" xlink:label="lbl_NovartisPharmaMarocSACasablancaMember" xlink:type="locator"/>
      <link:presentationArc order="103.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaMarocSACasablancaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisNetherlandsB.V.ArnhemMember" xlink:label="lbl_NovartisNetherlandsB.V.ArnhemMember" xlink:type="locator"/>
      <link:presentationArc order="104.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNetherlandsB.V.ArnhemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaB.V.ArnhemMember" xlink:label="lbl_NovartisPharmaB.V.ArnhemMember" xlink:type="locator"/>
      <link:presentationArc order="105.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaB.V.ArnhemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozB.V.AlmereMember" xlink:label="lbl_SandozB.V.AlmereMember" xlink:type="locator"/>
      <link:presentationArc order="106.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozB.V.AlmereMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconNederlandB.V.ArnhemMember" xlink:label="lbl_AlconNederlandB.V.ArnhemMember" xlink:type="locator"/>
      <link:presentationArc order="107.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconNederlandB.V.ArnhemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisNewZealandLtdAucklandMember" xlink:label="lbl_NovartisNewZealandLtdAucklandMember" xlink:type="locator"/>
      <link:presentationArc order="108.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNewZealandLtdAucklandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisNorgeASOsloMember" xlink:label="lbl_NovartisNorgeASOsloMember" xlink:type="locator"/>
      <link:presentationArc order="109.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNorgeASOsloMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaPakistanLimitedKarachiMember" xlink:label="lbl_NovartisPharmaPakistanLimitedKarachiMember" xlink:type="locator"/>
      <link:presentationArc order="110.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaPakistanLimitedKarachiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:label="lbl_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:type="locator"/>
      <link:presentationArc order="111.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconCentroamericaS.A.PanamaCityMember" xlink:label="lbl_AlconCentroamericaS.A.PanamaCityMember" xlink:type="locator"/>
      <link:presentationArc order="112.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconCentroamericaS.A.PanamaCityMember" xlink:type="arc"/>
      <link:presentationArc order="113.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:type="arc"/>
      <link:presentationArc order="114.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPhilippinesCorporationMakatiCityMember" xlink:type="arc"/>
      <link:presentationArc order="115.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPolandSp.ZO.o.WarsawMember" xlink:type="arc"/>
      <link:presentationArc order="116.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPolskaSp.ZO.o.WarsawMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LekS.A.StrykowMember" xlink:label="lbl_LekS.A.StrykowMember" xlink:type="locator"/>
      <link:presentationArc order="117.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_LekS.A.StrykowMember" xlink:type="arc"/>
      <link:presentationArc order="118.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPolskaSp.ZO.o.WarsawMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:label="lbl_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:type="locator"/>
      <link:presentationArc order="119.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:label="lbl_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:type="locator"/>
      <link:presentationArc order="120.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozFarmaceuticaLda.PortoSalvoMember" xlink:label="lbl_SandozFarmaceuticaLda.PortoSalvoMember" xlink:type="locator"/>
      <link:presentationArc order="121.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozFarmaceuticaLda.PortoSalvoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:label="lbl_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:type="locator"/>
      <link:presentationArc order="122.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:label="lbl_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:type="locator"/>
      <link:presentationArc order="123.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozS.R.L.TarguMuresMember" xlink:label="lbl_SandozS.R.L.TarguMuresMember" xlink:type="locator"/>
      <link:presentationArc order="124.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.R.L.TarguMuresMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconRomaniaS.R.L.BucharestMember" xlink:label="lbl_AlconRomaniaS.R.L.BucharestMember" xlink:type="locator"/>
      <link:presentationArc order="125.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconRomaniaS.R.L.BucharestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaLLCMoscowMember" xlink:label="lbl_NovartisPharmaLLCMoscowMember" xlink:type="locator"/>
      <link:presentationArc order="126.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaLLCMoscowMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisNevaLLCSt.PetersburgMember" xlink:label="lbl_NovartisNevaLLCSt.PetersburgMember" xlink:type="locator"/>
      <link:presentationArc order="127.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNevaLLCSt.PetersburgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ZAOSandozMoscowMember" xlink:label="lbl_ZAOSandozMoscowMember" xlink:type="locator"/>
      <link:presentationArc order="128.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ZAOSandozMoscowMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconFarmacevtikaLLCMoscowMember" xlink:label="lbl_AlconFarmacevtikaLLCMoscowMember" xlink:type="locator"/>
      <link:presentationArc order="129.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconFarmacevtikaLLCMoscowMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:label="lbl_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:type="locator"/>
      <link:presentationArc order="130.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisSingaporePteLtd.SingaporeMember" xlink:label="lbl_NovartisSingaporePteLtd.SingaporeMember" xlink:type="locator"/>
      <link:presentationArc order="131.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSingaporePteLtd.SingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:label="lbl_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:type="locator"/>
      <link:presentationArc order="132.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:label="lbl_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:type="locator"/>
      <link:presentationArc order="133.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:label="lbl_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:type="locator"/>
      <link:presentationArc order="134.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconPteLtdSingaporeMember" xlink:label="lbl_AlconPteLtdSingaporeMember" xlink:type="locator"/>
      <link:presentationArc order="135.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:label="lbl_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:type="locator"/>
      <link:presentationArc order="136.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:label="lbl_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:type="locator"/>
      <link:presentationArc order="137.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisSlovakiaS.r.o.BratislavaMember" xlink:label="lbl_NovartisSlovakiaS.r.o.BratislavaMember" xlink:type="locator"/>
      <link:presentationArc order="138.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSlovakiaS.r.o.BratislavaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LekPharmaceuticalsD.d.LjubjanaMember" xlink:label="lbl_LekPharmaceuticalsD.d.LjubjanaMember" xlink:type="locator"/>
      <link:presentationArc order="139.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_LekPharmaceuticalsD.d.LjubjanaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:label="lbl_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:type="locator"/>
      <link:presentationArc order="140.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisSouthAfricaPtyLtdMidrandMember" xlink:label="lbl_NovartisSouthAfricaPtyLtdMidrandMember" xlink:type="locator"/>
      <link:presentationArc order="141.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSouthAfricaPtyLtdMidrandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozSouthAfricaPtyLtdKemptonParkMember" xlink:label="lbl_SandozSouthAfricaPtyLtdKemptonParkMember" xlink:type="locator"/>
      <link:presentationArc order="142.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozSouthAfricaPtyLtdKemptonParkMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:label="lbl_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:type="locator"/>
      <link:presentationArc order="143.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisKoreaLtd.SeoulMember" xlink:label="lbl_NovartisKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:presentationArc order="144.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisKoreaLtd.SeoulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozKoreaLtd.SeoulMember" xlink:label="lbl_SandozKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:presentationArc order="145.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozKoreaLtd.SeoulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconKoreaLtd.SeoulMember" xlink:label="lbl_AlconKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:presentationArc order="146.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconKoreaLtd.SeoulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:label="lbl_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:type="locator"/>
      <link:presentationArc order="147.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozFarmaceuticaS.A.MadridMember" xlink:label="lbl_SandozFarmaceuticaS.A.MadridMember" xlink:type="locator"/>
      <link:presentationArc order="148.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozFarmaceuticaS.A.MadridMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozIndustrialProductsS.A.BarcelonaMember" xlink:label="lbl_SandozIndustrialProductsS.A.BarcelonaMember" xlink:type="locator"/>
      <link:presentationArc order="149.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozIndustrialProductsS.A.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconCusiS.A.BarcelonaMember" xlink:label="lbl_AlconCusiS.A.BarcelonaMember" xlink:type="locator"/>
      <link:presentationArc order="150.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconCusiS.A.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:label="lbl_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:type="locator"/>
      <link:presentationArc order="151.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisSverigeABStockholmMember" xlink:label="lbl_NovartisSverigeABStockholmMember" xlink:type="locator"/>
      <link:presentationArc order="152.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSverigeABStockholmMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInternationalAGBaselMember" xlink:label="lbl_NovartisInternationalAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="153.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInternationalAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisHoldingAGBaselMember" xlink:label="lbl_NovartisHoldingAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="154.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHoldingAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:label="lbl_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="155.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisBioventuresAGBaselMember" xlink:label="lbl_NovartisBioventuresAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="156.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBioventuresAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisForschungsstiftungBaselMember" xlink:label="lbl_NovartisForschungsstiftungBaselMember" xlink:type="locator"/>
      <link:presentationArc order="157.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisForschungsstiftungBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisStiftungFuerKaderausbildungBaselMember" xlink:label="lbl_NovartisStiftungFuerKaderausbildungBaselMember" xlink:type="locator"/>
      <link:presentationArc order="158.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisStiftungFuerKaderausbildungBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:label="lbl_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:type="locator"/>
      <link:presentationArc order="159.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:label="lbl_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:type="locator"/>
      <link:presentationArc order="160.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:label="lbl_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:type="locator"/>
      <link:presentationArc order="161.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaAGBaselMember" xlink:label="lbl_NovartisPharmaAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="162.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInternationalPharmaceuticalAGBaselMember" xlink:label="lbl_NovartisInternationalPharmaceuticalAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="163.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInternationalPharmaceuticalAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaServicesAGBaselMember" xlink:label="lbl_NovartisPharmaServicesAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="164.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaServicesAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:label="lbl_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:type="locator"/>
      <link:presentationArc order="165.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaSteinAGSteinMember" xlink:label="lbl_NovartisPharmaSteinAGSteinMember" xlink:type="locator"/>
      <link:presentationArc order="166.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaSteinAGSteinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaSchweizAGRischMember" xlink:label="lbl_NovartisPharmaSchweizAGRischMember" xlink:type="locator"/>
      <link:presentationArc order="167.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaSchweizAGRischMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozAGBaselMember" xlink:label="lbl_SandozAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="168.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozPharmaceuticalsAGRischMember" xlink:label="lbl_SandozPharmaceuticalsAGRischMember" xlink:type="locator"/>
      <link:presentationArc order="169.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPharmaceuticalsAGRischMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconSwitzerlandSARischMember" xlink:label="lbl_AlconSwitzerlandSARischMember" xlink:type="locator"/>
      <link:presentationArc order="170.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconSwitzerlandSARischMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconPharmaceuticalsLtd.FribourgMember" xlink:label="lbl_AlconPharmaceuticalsLtd.FribourgMember" xlink:type="locator"/>
      <link:presentationArc order="171.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPharmaceuticalsLtd.FribourgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RocheHoldingAGBaselMember" xlink:label="lbl_RocheHoldingAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="172.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_RocheHoldingAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:label="lbl_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:type="locator"/>
      <link:presentationArc order="173.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisThailandLimitedBangkokMember" xlink:label="lbl_NovartisThailandLimitedBangkokMember" xlink:type="locator"/>
      <link:presentationArc order="174.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisThailandLimitedBangkokMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesThailandLimitedBangkokMember" xlink:label="lbl_AlconLaboratoriesThailandLimitedBangkokMember" xlink:type="locator"/>
      <link:presentationArc order="175.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesThailandLimitedBangkokMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:label="lbl_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:presentationArc order="176.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:label="lbl_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:type="locator"/>
      <link:presentationArc order="177.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:label="lbl_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:type="locator"/>
      <link:presentationArc order="178.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:label="lbl_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:presentationArc order="179.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:label="lbl_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:type="locator"/>
      <link:presentationArc order="180.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:label="lbl_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:presentationArc order="181.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisMiddleEastFZEDubaiMember" xlink:label="lbl_NovartisMiddleEastFZEDubaiMember" xlink:type="locator"/>
      <link:presentationArc order="182.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisMiddleEastFZEDubaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisUKLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:presentationArc order="183.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisUKLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:presentationArc order="184.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:presentationArc order="185.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VivactaLimitedFrimleyCamberleySurreyMember" xlink:label="lbl_VivactaLimitedFrimleyCamberleySurreyMember" xlink:type="locator"/>
      <link:presentationArc order="186.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_VivactaLimitedFrimleyCamberleySurreyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:label="lbl_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:type="locator"/>
      <link:presentationArc order="187.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozLimitedFrimleyCamberleyMember" xlink:label="lbl_SandozLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:presentationArc order="188.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:label="lbl_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:presentationArc order="189.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:label="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="locator"/>
      <link:presentationArc order="190.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisCorporationEastHanoverNYMember" xlink:label="lbl_NovartisCorporationEastHanoverNYMember" xlink:type="locator"/>
      <link:presentationArc order="191.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisCorporationEastHanoverNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFinanceCorporationNewYorkNYMember" xlink:label="lbl_NovartisFinanceCorporationNewYorkNYMember" xlink:type="locator"/>
      <link:presentationArc order="192.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinanceCorporationNewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisCapitalCorporationNewYorkNYMember" xlink:label="lbl_NovartisCapitalCorporationNewYorkNYMember" xlink:type="locator"/>
      <link:presentationArc order="193.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisCapitalCorporationNewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisServicesInc.EastHanoverNYMember" xlink:label="lbl_NovartisServicesInc.EastHanoverNYMember" xlink:type="locator"/>
      <link:presentationArc order="194.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisServicesInc.EastHanoverNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisUSFoundationNewYorkNYMember" xlink:label="lbl_NovartisUSFoundationNewYorkNYMember" xlink:type="locator"/>
      <link:presentationArc order="195.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisUSFoundationNewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:label="lbl_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:type="locator"/>
      <link:presentationArc order="196.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:label="lbl_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:type="locator"/>
      <link:presentationArc order="197.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CortheraInc.SanMateoCAMember" xlink:label="lbl_CortheraInc.SanMateoCAMember" xlink:type="locator"/>
      <link:presentationArc order="198.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CortheraInc.SanMateoCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:label="lbl_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:type="locator"/>
      <link:presentationArc order="199.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EncoreVisionInc.NewYorkNYMember" xlink:label="lbl_EncoreVisionInc.NewYorkNYMember" xlink:type="locator"/>
      <link:presentationArc order="200.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EncoreVisionInc.NewYorkNYMember" xlink:type="arc"/>
      <link:presentationArc order="201.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:type="arc"/>
      <link:presentationArc order="202.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:label="lbl_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:type="locator"/>
      <link:presentationArc order="203.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:label="lbl_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:type="locator"/>
      <link:presentationArc order="204.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozInc.PrincetonNJMember" xlink:label="lbl_SandozInc.PrincetonNJMember" xlink:type="locator"/>
      <link:presentationArc order="205.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozInc.PrincetonNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:label="lbl_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:type="locator"/>
      <link:presentationArc order="206.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EonLabsInc.PrincetonNJMember" xlink:label="lbl_EonLabsInc.PrincetonNJMember" xlink:type="locator"/>
      <link:presentationArc order="207.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EonLabsInc.PrincetonNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesInc.FortWorthTXMember" xlink:label="lbl_AlconLaboratoriesInc.FortWorthTXMember" xlink:type="locator"/>
      <link:presentationArc order="208.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesInc.FortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:label="lbl_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:type="locator"/>
      <link:presentationArc order="209.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconResearchLtd.FortWorthTXMember" xlink:label="lbl_AlconResearchLtd.FortWorthTXMember" xlink:type="locator"/>
      <link:presentationArc order="210.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconResearchLtd.FortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLensxInc.AlisoViejoCAMember" xlink:label="lbl_AlconLensxInc.AlisoViejoCAMember" xlink:type="locator"/>
      <link:presentationArc order="211.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLensxInc.AlisoViejoCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:label="lbl_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:type="locator"/>
      <link:presentationArc order="212.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:label="lbl_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:type="locator"/>
      <link:presentationArc order="213.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:label="lbl_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:type="locator"/>
      <link:presentationArc order="214.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:type="arc"/>
      <link:presentationArc order="215.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TranscendMedicalInc.LakeForestILMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisDeVenezuelaS.A.CaracasMember" xlink:label="lbl_NovartisDeVenezuelaS.A.CaracasMember" xlink:type="locator"/>
      <link:presentationArc order="216.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisDeVenezuelaS.A.CaracasMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconPharmaceuticalC.A.CaracasMember" xlink:label="lbl_AlconPharmaceuticalC.A.CaracasMember" xlink:type="locator"/>
      <link:presentationArc order="217.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPharmaceuticalC.A.CaracasMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:label="lbl_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:type="locator"/>
      <link:presentationArc order="167.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:label="lbl_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:type="locator"/>
      <link:presentationArc order="167.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AveXisInc.BannockburnILMember" xlink:label="lbl_AveXisInc.BannockburnILMember" xlink:type="locator"/>
      <link:presentationArc order="204.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AveXisInc.BannockburnILMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember" xlink:label="lbl_AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember" xlink:type="locator"/>
      <link:presentationArc order="55.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozPtyLtdMacquarieParkNSWMember" xlink:label="lbl_SandozPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaNVVilvoordeMember" xlink:label="lbl_NovartisPharmaNVVilvoordeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozNVVilvoordeMember" xlink:label="lbl_SandozNVVilvoordeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconCouvreurNVPuursMember" xlink:label="lbl_AlconCouvreurNVPuursMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:label="lbl_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:type="locator"/>
      <link:presentationArc order="16.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconNVVilvoordeMember" xlink:label="lbl_AlconNVVilvoordeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconAGFribourgMember" xlink:label="lbl_AlconAGFribourgMember" xlink:type="locator"/>
      <link:presentationArc order="169.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconAGFribourgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:type="locator"/>
      <link:presentationArc order="204.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:type="arc"/>
      <link:presentationArc order="212.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionCorporationLLCDuluthGAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CIBAVisionCorporationLLCDuluthGAMember" xlink:label="lbl_CIBAVisionCorporationLLCDuluthGAMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:label="lbl_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPolandSp.ZO.o.WarsawMember" xlink:label="lbl_NovartisPolandSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozPolskaSp.ZO.o.WarsawMember" xlink:label="lbl_SandozPolskaSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconPolskaSp.ZO.o.WarsawMember" xlink:label="lbl_AlconPolskaSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconHealthcareS.A.BarcelonaMember" xlink:label="lbl_AlconHealthcareS.A.BarcelonaMember" xlink:type="locator"/>
      <link:presentationArc order="149.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconHealthcareS.A.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisOphthalmicsAGFribourgMember" xlink:label="lbl_NovartisOphthalmicsAGFribourgMember" xlink:type="locator"/>
      <link:presentationArc order="155.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisOphthalmicsAGFribourgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozUkraineLLCKievMember" xlink:label="lbl_SandozUkraineLLCKievMember" xlink:type="locator"/>
      <link:presentationArc order="181.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozUkraineLLCKievMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:label="lbl_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsAAAMember" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="locator"/>
      <link:presentationArc order="218.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:label="lbl_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFinanceS.A.LuxembourgCityMember" xlink:label="lbl_NovartisFinanceS.A.LuxembourgCityMember" xlink:type="locator"/>
      <link:presentationArc order="200.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EndocyteInc.LafayetteINMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TearFilmInnovationsInc.FortWorthTXMember" xlink:label="lbl_TearFilmInnovationsInc.FortWorthTXMember" xlink:type="locator"/>
      <link:presentationArc order="212.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TearFilmInnovationsInc.FortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TrueVisionSystemsInc.FortWorthTXMember" xlink:label="lbl_TrueVisionSystemsInc.FortWorthTXMember" xlink:type="locator"/>
      <link:presentationArc order="212.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TrueVisionSystemsInc.FortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TranscendMedicalInc.LakeForestILMember" xlink:label="lbl_TranscendMedicalInc.LakeForestILMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisBalticsSIARigaMember" xlink:label="lbl_NovartisBalticsSIARigaMember" xlink:type="locator"/>
      <link:presentationArc order="94.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBalticsSIARigaMember" xlink:type="arc"/>
      <link:presentationArc order="112.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBiosciencesPeruS.A.LimaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisOverseasInvestmentsAGBaselMember" xlink:label="lbl_NovartisOverseasInvestmentsAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="152.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisOverseasInvestmentsAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_JapatAGBaselMember" xlink:label="lbl_JapatAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="152.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_JapatAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconManagementSAGenevaMember" xlink:label="lbl_AlconManagementSAGenevaMember" xlink:type="locator"/>
      <link:presentationArc order="169.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconManagementSAGenevaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EndocyteInc.LafayetteINMember" xlink:label="lbl_EndocyteInc.LafayetteINMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OrielTherapeuticsInc.DurhamNCMember" xlink:label="lbl_OrielTherapeuticsInc.DurhamNCMember" xlink:type="locator"/>
      <link:presentationArc order="205.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_OrielTherapeuticsInc.DurhamNCMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WaveLightInc.SterlingVAMember" xlink:label="lbl_WaveLightInc.SterlingVAMember" xlink:type="locator"/>
      <link:presentationArc order="212.1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_WaveLightInc.SterlingVAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisBiosciencesPeruS.A.LimaMember" xlink:label="lbl_NovartisBiosciencesPeruS.A.LimaMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozManufacturingInc.Member" xlink:label="lbl_SandozManufacturingInc.Member" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozManufacturingInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:label="lbl_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:type="locator"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:label="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:type="locator"/>
      <link:presentationArc order="1.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CELLforCUREMember" xlink:label="lbl_CELLforCUREMember" xlink:type="locator"/>
      <link:presentationArc order="1.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CELLforCUREMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisManufacturingGmbHMember" xlink:label="lbl_NovartisManufacturingGmbHMember" xlink:type="locator"/>
      <link:presentationArc order="1.85" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisManufacturingGmbHMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:label="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:type="locator"/>
      <link:presentationArc order="1.87" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:label="lbl_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:type="locator"/>
      <link:presentationArc order="1.88" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IDBHollandBVMember" xlink:label="lbl_IDBHollandBVMember" xlink:type="locator"/>
      <link:presentationArc order="1.89" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_IDBHollandBVMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:label="lbl_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:type="locator"/>
      <link:presentationArc order="1.885" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImagingEquipmentLtdMember" xlink:label="lbl_ImagingEquipmentLtdMember" xlink:type="locator"/>
      <link:presentationArc order="1.887" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ImagingEquipmentLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInflammasomeResearchInc.Member" xlink:label="lbl_NovartisInflammasomeResearchInc.Member" xlink:type="locator"/>
      <link:presentationArc order="1.86" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInflammasomeResearchInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisTechnologyLLCMember" xlink:label="lbl_NovartisTechnologyLLCMember" xlink:type="locator"/>
      <link:presentationArc order="1.855" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisTechnologyLLCMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:label="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:type="locator"/>
      <link:presentationArc order="36.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CELLforCURELesUlisMember" xlink:label="lbl_CELLforCURELesUlisMember" xlink:type="locator"/>
      <link:presentationArc order="55.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CELLforCURELesUlisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:label="lbl_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:type="locator"/>
      <link:presentationArc order="86.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisNetherlandsB.V.AmsterdamMember" xlink:label="lbl_NovartisNetherlandsB.V.AmsterdamMember" xlink:type="locator"/>
      <link:presentationArc order="104.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNetherlandsB.V.AmsterdamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaB.V.AmsterdamMember" xlink:label="lbl_NovartisPharmaB.V.AmsterdamMember" xlink:type="locator"/>
      <link:presentationArc order="105.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaB.V.AmsterdamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IDBHollandBVBaarleNassauMember" xlink:label="lbl_IDBHollandBVBaarleNassauMember" xlink:type="locator"/>
      <link:presentationArc order="105.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_IDBHollandBVBaarleNassauMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisSaudiLtd.RiyadhMember" xlink:label="lbl_NovartisSaudiLtd.RiyadhMember" xlink:type="locator"/>
      <link:presentationArc order="130.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSaudiLtd.RiyadhMember" xlink:type="arc"/>
      <link:presentationArc order="147.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisUKLimitedLondonMember" xlink:label="lbl_NovartisUKLimitedLondonMember" xlink:type="locator"/>
      <link:presentationArc order="183.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisUKLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:label="lbl_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:type="locator"/>
      <link:presentationArc order="184.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisGrimsbyLimitedLondonMember" xlink:label="lbl_NovartisGrimsbyLimitedLondonMember" xlink:type="locator"/>
      <link:presentationArc order="185.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGrimsbyLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImagingEquipmentLtdLondonMember" xlink:label="lbl_ImagingEquipmentLtdLondonMember" xlink:type="locator"/>
      <link:presentationArc order="185.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ImagingEquipmentLtdLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ZiarcoGroupLimitedLondonMember" xlink:label="lbl_ZiarcoGroupLimitedLondonMember" xlink:type="locator"/>
      <link:presentationArc order="187.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ZiarcoGroupLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisFinanceCorporationEastHanoverNJMember" xlink:label="lbl_NovartisFinanceCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="192.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinanceCorporationEastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisCapitalCorporationEastHanoverNJMember" xlink:label="lbl_NovartisCapitalCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="193.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisCapitalCorporationEastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisUSFoundationEastHanoverNJMember" xlink:label="lbl_NovartisUSFoundationEastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="195.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisUSFoundationEastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:type="locator"/>
      <link:presentationArc order="196.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:label="lbl_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="204.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:label="lbl_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="204.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EncoreVisionInc.EastHanoverNJMember" xlink:label="lbl_EncoreVisionInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="200.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EncoreVisionInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EndocyteInc.EastHanoverNJMember" xlink:label="lbl_EndocyteInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="200.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EndocyteInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:label="lbl_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="213.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:label="lbl_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="203.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisManufacturingGmbHMarburgMember" xlink:label="lbl_NovartisManufacturingGmbHMarburgMember" xlink:type="locator"/>
      <link:presentationArc order="1.852" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisManufacturingGmbHMarburgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:label="lbl_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:type="locator"/>
      <link:presentationArc order="81.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisGeneTherapiesEULimitedDublinMember" xlink:label="lbl_NovartisGeneTherapiesEULimitedDublinMember" xlink:type="locator"/>
      <link:presentationArc order="82.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGeneTherapiesEULimitedDublinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AspenJapanK.K.TokyoMember" xlink:label="lbl_AspenJapanK.K.TokyoMember" xlink:type="locator"/>
      <link:presentationArc order="93.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AspenJapanK.K.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozPhilippinesCorporationMakatiCityMember" xlink:label="lbl_SandozPhilippinesCorporationMakatiCityMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisIsraelLtd.TelAvivMember" xlink:label="lbl_NovartisIsraelLtd.TelAvivMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:label="lbl_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:label="lbl_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:label="lbl_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:type="locator"/>
      <link:presentationArc order="149.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:type="locator"/>
      <link:presentationArc order="185.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NeutecPharmaLimitedLondonMember" xlink:label="lbl_NeutecPharmaLimitedLondonMember" xlink:type="locator"/>
      <link:presentationArc order="185.65" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NeutecPharmaLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:label="lbl_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:type="locator"/>
      <link:presentationArc order="188.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:label="lbl_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="204.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TheMedicinesCompanyMember" xlink:label="lbl_TheMedicinesCompanyMember" xlink:type="locator"/>
      <link:presentationArc order="204.95" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TheMedicinesCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmblyotechInc.EastHanoverNJMember" xlink:label="lbl_AmblyotechInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="205.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AmblyotechInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:label="lbl_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:type="locator"/>
      <link:presentationArc order="219.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisDeutschlandGmbHNurembergMember" xlink:label="lbl_NovartisDeutschlandGmbHNurembergMember" xlink:type="locator"/>
      <link:presentationArc order="69.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisDeutschlandGmbHNurembergMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisBusinessServicesGmbHWehrMember" xlink:label="lbl_NovartisBusinessServicesGmbHWehrMember" xlink:type="locator"/>
      <link:presentationArc order="69.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBusinessServicesGmbHWehrMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="lbl_DefinedBenefitPlansAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_DefinedBenefitPlansAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_ForeignCountriesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="lbl_DefinedBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlansAxis" xlink:to="lbl_DefinedBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ConcentrationOfMajorPlansGeographic" xlink:label="lbl_ConcentrationOfMajorPlansGeographic" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ConcentrationOfMajorPlansGeographic" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements" xlink:label="lbl_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements1" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements1" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:label="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MajorPlansPercentageInGroupDBOPensions" xlink:label="lbl_MajorPlansPercentageInGroupDBOPensions" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_MajorPlansPercentageInGroupDBOPensions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:label="lbl_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:type="locator"/>
      <link:presentationArc order="3.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:label="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="locator"/>
      <link:presentationArc order="24.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanInterestCost" xlink:label="lbl_DefinedBenefitPlanInterestCost" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_DefinedBenefitPlanInterestCost" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward1" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward1" xlink:to="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="locator"/>
      <link:presentationArc order="25.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="lbl_PlanAssetsAtFairValue" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_PlanAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward1" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward1" xlink:to="lbl_PlanAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:type="locator"/>
      <link:presentationArc order="26.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LimitationOnRecognitionOfFundSurplus" xlink:label="lbl_LimitationOnRecognitionOfFundSurplus" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward1" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward1" xlink:to="lbl_LimitationOnRecognitionOfFundSurplus" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_LimitationOnRecognitionOfFundSurplus" xlink:type="arc"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:label="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="5.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:presentationArc order="27.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="lbl_SurplusDeficitInPlan" xlink:type="locator"/>
      <link:presentationArc order="25.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_SurplusDeficitInPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestIncomeOnLimitationOfFundSurplus" xlink:label="lbl_InterestIncomeOnLimitationOfFundSurplus" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_InterestIncomeOnLimitationOfFundSurplus" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanSettlementsPlanAssets" xlink:label="lbl_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="-0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:label="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeInLimitationOnRecognitionOfFundSurplus" xlink:label="lbl_ChangeInLimitationOnRecognitionOfFundSurplus" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_ChangeInLimitationOnRecognitionOfFundSurplus" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:label="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:type="arc"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward1" xlink:to="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:type="locator"/>
      <link:presentationArc order="11.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReimbursmentsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReimbursmentsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="5.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_ReimbursmentsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:label="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward1" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:label="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:label="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:label="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="4.9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward1" xlink:to="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PrepaidPostemploymentBenefitPlansAssets" xlink:label="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:to="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:label="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:to="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="5.9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeInLimitationOnRecognitionOfFundSurplus" xlink:label="lbl_ChangeInLimitationOnRecognitionOfFundSurplus" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_ChangeInLimitationOnRecognitionOfFundSurplus" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReimbursmentsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReimbursmentsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="8.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_ReimbursmentsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_ForeignCountriesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ObligationByTypeAxis" xlink:label="lbl_ObligationByTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_ObligationByTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ObligationByTypeMember" xlink:label="lbl_ObligationByTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ObligationByTypeAxis" xlink:to="lbl_ObligationByTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UnfundedMember" xlink:label="lbl_UnfundedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_UnfundedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ActiveMember" xlink:label="lbl_ActiveMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_ActiveMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DeferredPensionersMember" xlink:label="lbl_DeferredPensionersMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_DeferredPensionersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PensionersMember" xlink:label="lbl_PensionersMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_PensionersMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="lbl_SurplusDeficitInPlan" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_SurplusDeficitInPlan" xlink:type="arc"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="lbl_PlanAssetsAtFairValue" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_PlanAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="2.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:presentationArc order="2.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:label="lbl_ActuarialAssumptionOfDiscountRates" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ActuarialAssumptionOfDiscountRates" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitAssumptionLifeExpectancyMale" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyMale" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitAssumptionLifeExpectancyMale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:label="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:label="lbl_ActuarialAssumptionsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="lbl_ActuarialAssumptionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:label="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="lbl_ActuarialAssumptionsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ActuarialAssumptionsAxis" xlink:to="lbl_ActuarialAssumptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:label="lbl_ActuarialAssumptionOfDiscountRatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_ActuarialAssumptionOfDiscountRatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LifeExpectancyMember" xlink:label="lbl_LifeExpectancyMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_LifeExpectancyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeInActuarialAssumptionAxis" xlink:label="lbl_ChangeInActuarialAssumptionAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="lbl_ChangeInActuarialAssumptionAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeInActuarialAssumptionMember" xlink:label="lbl_ChangeInActuarialAssumptionMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeInActuarialAssumptionAxis" xlink:to="lbl_ChangeInActuarialAssumptionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_Decrease25BasisPointMember" xlink:label="lbl_Decrease25BasisPointMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_Decrease25BasisPointMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_Increase1YearMember" xlink:label="lbl_Increase1YearMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_Increase1YearMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:label="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:label="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_Increase25BasisPointMember" xlink:label="lbl_Increase25BasisPointMember" xlink:type="locator"/>
      <link:presentationArc order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_Increase25BasisPointMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_Change25BasisPointMember" xlink:label="lbl_Change25BasisPointMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_Change25BasisPointMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfHealthCareCostTrendRatesTable" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:to="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:label="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfAllocationOfPlanAssetsTable" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:to="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DebtSecuritiesMember" xlink:label="lbl_DebtSecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_DebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityInvestmentsMember" xlink:label="lbl_EquityInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_EquityInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RealEstateMember" xlink:label="lbl_RealEstateMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_RealEstateMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlternativeInvestmentsMember" xlink:label="lbl_AlternativeInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_AlternativeInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashAndOtherInvestmentsMember" xlink:label="lbl_CashAndOtherInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_CashAndOtherInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:label="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:label="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanPlanAssetAllocations" xlink:label="lbl_DefinedBenefitPlanPlanAssetAllocations" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanPlanAssetAllocations" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_EmployerSharesHeldByDefinedBenefitPlan" xlink:type="arc"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:label="lbl_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EmployerSharesHeldByDefinedBenefitPlan" xlink:label="lbl_EmployerSharesHeldByDefinedBenefitPlan" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:label="lbl_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:to="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="lbl_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:to="lbl_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfExpectedBenefitPaymentsTable" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:to="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:to="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:to="lbl_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:label="lbl_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatements" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:label="lbl_DisclosureOfCashFlowStatementExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_DisclosureOfCashFlowStatementExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" xlink:label="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" xlink:label="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" xlink:label="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashFlowsFromDiscontinuedOperationsTableTextBlock" xlink:label="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" xlink:label="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsImpairedMember" xlink:label="lbl_FinancialAssetsImpairedMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_FinancialAssetsImpairedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:label="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:label="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:label="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="lbl_AdjustmentsForSharebasedPayments" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForSharebasedPayments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:label="lbl_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="lbl_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:to="lbl_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="lbl_AdjustmentsForFinanceIncomeCost" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="lbl_RightofuseAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_RightofuseAssetsMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAbstract" xlink:label="lbl_ComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAbstract" xlink:label="lbl_ComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfComprehensiveIncomeTableTextBlock" xlink:label="lbl_ScheduleOfComprehensiveIncomeTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_ScheduleOfComprehensiveIncomeTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" xlink:label="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" xlink:label="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" xlink:label="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociates" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedParties" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="lbl_DisclosureOfRelatedPartyExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lbl_DisclosureOfRelatedPartyExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedPartiesTables" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OfficerAndDirectorCompensationTableTextBlock" xlink:label="lbl_OfficerAndDirectorCompensationTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lbl_OfficerAndDirectorCompensationTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" xlink:label="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:label="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:label="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:label="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedPartiesDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonExecutiveDirectorMember" xlink:label="lbl_NonExecutiveDirectorMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_NonExecutiveDirectorMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="lbl_KeyManagementPersonnelCompensation" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensation" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedPartiesDetails3" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProfDrBrodyMember" xlink:label="lbl_ProfDrBrodyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_ProfDrBrodyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProfDrZinkernagelMember" xlink:label="lbl_ProfDrZinkernagelMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_ProfDrZinkernagelMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DrAlexKrauerMember" xlink:label="lbl_DrAlexKrauerMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_DrAlexKrauerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DrDanielVasellaMember" xlink:label="lbl_DrDanielVasellaMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_DrDanielVasellaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DrJamesBradnerMember" xlink:label="lbl_DrJamesBradnerMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_DrJamesBradnerMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="lbl_KeyManagementPersonnelCompensation" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KeyManagementPersonnelCompensationDailyRate" xlink:label="lbl_KeyManagementPersonnelCompensationDailyRate" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationDailyRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:label="lbl_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KeyManagementPersonnelCompensationSharesAcquired" xlink:label="lbl_KeyManagementPersonnelCompensationSharesAcquired" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationSharesAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:label="lbl_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:label="lbl_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:type="locator"/>
      <link:presentationArc order="8.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsCreditFacilityUncommitted" xlink:label="lbl_BorrowingsCreditFacilityUncommitted" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_BorrowingsCreditFacilityUncommitted" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPensionFundMember" xlink:label="lbl_NovartisPensionFundMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NovartisPensionFundMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAbstract" xlink:label="lbl_ComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:to="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ActuarialLossesFromDefinedBenefitPlansMember" xlink:label="lbl_ActuarialLossesFromDefinedBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_ActuarialLossesFromDefinedBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CumulativeCurrencyTranslationEffectsMember" xlink:label="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:label="lbl_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RestatedValueAdjustmentsMember" xlink:label="lbl_RestatedValueAdjustmentsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_RestatedValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsOnFinancialAssetsSold" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="locator"/>
      <link:presentationArc order="2.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:label="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:label="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="lbl_NoncontrollingInterestsMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_NoncontrollingInterestsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:presentationArc order="2.65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="2.67" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:presentationArc order="2.68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="2.69" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GainLossOnSaleOfOtherFinancialAssets" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="2.695" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems1" xlink:type="locator"/>
      <link:presentationArc order="2.8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems1" xlink:to="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeDebtSecurities" xlink:type="locator"/>
      <link:presentationArc order="2.62" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsRelatedToDivestments" xlink:label="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="locator"/>
      <link:presentationArc order="2.75" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:label="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="locator"/>
      <link:presentationArc order="2.77" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:label="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:presentationArc order="2.66" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:presentationArc order="2.57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:presentationArc order="2.58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:label="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:type="locator"/>
      <link:presentationArc order="2.6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TotalFairValueAdjustmentsMember" xlink:label="lbl_TotalFairValueAdjustmentsMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_TotalFairValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails3" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncomeAbstract" xlink:label="lbl_ComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssetsDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodwillMember" xlink:label="lbl_GoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_GoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TechnologybasedIntangibleAssetsMember" xlink:label="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_CurrentlyMarketedProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MarketingRelatedIntangibleAssetsMember" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="lbl_OtherIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_OtherIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:label="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="lbl_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems1" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems1" xlink:to="lbl_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquiredResearchAndDevelopmentMember" xlink:label="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconBrandNameMember" xlink:label="lbl_AlconBrandNameMember" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AlconBrandNameMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="10.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:presentationArc order="12.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:label="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:label="lbl_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:label="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:label="lbl_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:type="locator"/>
      <link:presentationArc order="12.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:label="lbl_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="8.5" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="1.6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssetsDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodwillMember" xlink:label="lbl_GoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_GoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TechnologybasedIntangibleAssetsMember" xlink:label="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_CurrentlyMarketedProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MarketingRelatedIntangibleAssetsMember" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="lbl_OtherIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_OtherIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="lbl_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="lbl_UnallocatedAmountsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_UnallocatedAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquiredResearchAndDevelopmentMember" xlink:label="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconBrandNameMember" xlink:label="lbl_AlconBrandNameMember" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AlconBrandNameMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:presentationArc order="6.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssetsDetails3" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="lbl_UnallocatedAmountsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_UnallocatedAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:label="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:label="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssetsDetails4" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="lbl_UnallocatedAmountsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_UnallocatedAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:label="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VotrientMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SerelaxinMember" xlink:label="lbl_SerelaxinMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SerelaxinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CyPassMember" xlink:label="lbl_CyPassMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_CyPassMember" xlink:type="arc"/>
      <link:presentationArc order="2.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:presentationArc order="3.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:presentationArc order="4.1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodwillMember" xlink:label="lbl_GoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_GoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquiredResearchAndDevelopmentMember" xlink:label="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconBrandNameMember" xlink:label="lbl_AlconBrandNameMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AlconBrandNameMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TechnologybasedIntangibleAssetsMember" xlink:label="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_CurrentlyMarketedProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MarketingRelatedIntangibleAssetsMember" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="lbl_OtherIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_OtherIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:presentationArc order="0.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:to="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherProductsMember" xlink:label="lbl_OtherProductsMember" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:label="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="4.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_RangeAxis" xlink:type="arc"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangeAxis" xlink:to="lbl_RangesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="lbl_BottomOfRangeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesMember" xlink:to="lbl_BottomOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="lbl_TopOfRangeMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesMember" xlink:to="lbl_TopOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:label="lbl_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationOtherShareAwardsMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationAnnualIncentivePlanMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentivePlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentivePlanMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:type="arc"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationLongTermPerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePlanMember" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermPerformancePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="arc"/>
      <link:presentationArc order="14.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationRestrictedSharesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:to="lbl_EquityBasedParticipationRestrictedSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationSpecialShareAwardsMember" xlink:label="lbl_EquityBasedParticipationSpecialShareAwardsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:to="lbl_EquityBasedParticipationSpecialShareAwardsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:label="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:type="locator"/>
      <link:presentationArc order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationUKShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationUKShareSavingsPlanMember" xlink:type="locator"/>
      <link:presentationArc order="0.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationUKShareSavingsPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfAnnualIncentive" xlink:label="lbl_DescriptionOfAnnualIncentive" xlink:type="locator"/>
      <link:presentationArc order="4.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_DescriptionOfAnnualIncentive" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="lbl_NumberOfOutstandingShareOptions" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward1" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward1" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="arc"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice46.7Member" xlink:type="arc"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice54.5Member" xlink:type="arc"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.0Member" xlink:type="arc"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.6Member" xlink:type="arc"/>
      <link:presentationArc order="5.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice66.0Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice46.7Member" xlink:label="lbl_ExercisePrice46.7Member" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice54.5Member" xlink:label="lbl_ExercisePrice54.5Member" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice57.0Member" xlink:label="lbl_ExercisePrice57.0Member" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice57.6Member" xlink:label="lbl_ExercisePrice57.6Member" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice66.0Member" xlink:label="lbl_ExercisePrice66.0Member" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward1" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:presentationArc order="2.2" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:presentationArc order="1.2" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:presentationArc order="0.7" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc"/>
      <link:presentationArc order="0.2" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice66.1Member" xlink:label="lbl_ExercisePrice66.1Member" xlink:type="locator"/>
      <link:presentationArc order="10.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice66.1Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice46.4Member" xlink:label="lbl_ExercisePrice46.4Member" xlink:type="locator"/>
      <link:presentationArc order="0.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice46.4Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice53.7Member" xlink:label="lbl_ExercisePrice53.7Member" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice53.7Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice57.1Member" xlink:label="lbl_ExercisePrice57.1Member" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.1Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice58.3Member" xlink:label="lbl_ExercisePrice58.3Member" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice58.3Member" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="lbl_NumberOfOutstandingShareOptions" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward1" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward1" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward1" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="arc"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice46.4Member" xlink:label="lbl_ExercisePrice46.4Member" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice46.4Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice46.7Member" xlink:label="lbl_ExercisePrice46.7Member" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice46.7Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice53.7Member" xlink:label="lbl_ExercisePrice53.7Member" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice53.7Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice54.5Member" xlink:label="lbl_ExercisePrice54.5Member" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice54.5Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice57.0Member" xlink:label="lbl_ExercisePrice57.0Member" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.0Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice57.1Member" xlink:label="lbl_ExercisePrice57.1Member" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.1Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice57.6Member" xlink:label="lbl_ExercisePrice57.6Member" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.6Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice58.3Member" xlink:label="lbl_ExercisePrice58.3Member" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice58.3Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice66.0Member" xlink:label="lbl_ExercisePrice66.0Member" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice66.0Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExercisePrice66.1Member" xlink:label="lbl_ExercisePrice66.1Member" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice66.1Member" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfReportableSegments" xlink:label="lbl_NumberOfReportableSegments" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfReportableSegments" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfBusinessUnits" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfFranchises" xlink:label="lbl_NumberOfFranchises" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfFranchises" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ConsumerHealthMember" xlink:label="lbl_ConsumerHealthMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_ConsumerHealthMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfBusinessUnits" xlink:label="lbl_NumberOfBusinessUnits" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromInterest" xlink:label="lbl_RevenueFromInterest" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromInterest" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="lbl_DepreciationAndAmortisationExpense" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DepreciationAndAmortisationExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdditionsToRestructuringProvisions" xlink:label="lbl_AdditionsToRestructuringProvisions" xlink:type="locator"/>
      <link:presentationArc order="5.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsToRestructuringProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:label="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="lbl_RightofuseAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_RightofuseAssetsMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails3" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Assets" xlink:label="lbl_Assets" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Assets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetOperatingAssets" xlink:label="lbl_NetOperatingAssets" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NetOperatingAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="lbl_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:label="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialDebtsAndDerivativeInstruments" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:label="lbl_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="6.7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="8.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Liabilities" xlink:label="lbl_Liabilities" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Liabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NetDebt" xlink:label="lbl_NetDebt" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NetDebt" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="lbl_AdditionsToRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="6.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsToRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="6.75" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdditionsToInvestmentInAssociatedCompanies" xlink:label="lbl_AdditionsToInvestmentInAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="10.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsToInvestmentInAssociatedCompanies" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails4" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SelectedNoncurrentAssets" xlink:type="arc"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherCountriesMember" xlink:label="lbl_OtherCountriesMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_OtherCountriesMember" xlink:type="arc"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_GB" xlink:label="lbl_GB" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_GB" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DE" xlink:label="lbl_DE" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_DE" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="lbl_JP" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_JP" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_FR" xlink:label="lbl_FR" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_FR" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CN" xlink:label="lbl_CN" xlink:type="locator"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CN" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails5" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SelectedNoncurrentAssets" xlink:type="arc"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AsiaAfricaAustralasiaMember" xlink:label="lbl_AsiaAfricaAustralasiaMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:label="lbl_EuropeMember1" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AmericasMember" xlink:label="lbl_AmericasMember1" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EuropeMember1" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_AsiaAfricaAustralasiaMember" xlink:type="arc"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_AmericasMember1" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails6" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMajorCustomersTable" xlink:label="lbl_DisclosureOfMajorCustomersTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMajorCustomersAbstract" xlink:label="lbl_DisclosureOfMajorCustomersAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersAbstract" xlink:to="lbl_DisclosureOfMajorCustomersTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:label="lbl_DisclosureOfMajorCustomersLineItems" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="lbl_PercentageOfEntitysRevenue" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfEntitysRevenue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="lbl_MajorCustomersAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersTable" xlink:to="lbl_MajorCustomersAxis" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersTable" xlink:to="lbl_DisclosureOfMajorCustomersLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorCustomersMember" xlink:label="lbl_MajorCustomersMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorCustomersAxis" xlink:to="lbl_MajorCustomersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LargestCustomerMember" xlink:label="lbl_LargestCustomerMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_LargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SecondLargestCustomerMember" xlink:label="lbl_SecondLargestCustomerMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_SecondLargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ThirdLargestCustomerMember" xlink:label="lbl_ThirdLargestCustomerMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_ThirdLargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CustomersWithNetSalesOverFivePercent" xlink:label="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PercentageOfEntitysTradeReceivable" xlink:label="lbl_PercentageOfEntitysTradeReceivable" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfEntitysTradeReceivable" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFigures" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:label="lbl_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="lbl_DisclosureOfOperatingSegmentsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureAssociatedCompanies" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:label="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:label="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:label="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:label="lbl_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PurchasePriceAllocationAssociatesTableTextBlock" xlink:label="lbl_PurchasePriceAllocationAssociatesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchasePriceAllocationAssociatesTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:presentationArc order="2.7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:label="lbl_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails3" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_RangeAxis" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangeAxis" xlink:to="lbl_RangesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="lbl_TopOfRangeMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesMember" xlink:to="lbl_TopOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="lbl_ProportionOfOwnershipInterestInAssociate" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ProportionOfOwnershipInterestInAssociate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsReceived" xlink:label="lbl_DividendsReceived" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_DividendsReceived" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished" xlink:label="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContributionOfBusinessToJointVenture" xlink:label="lbl_ContributionOfBusinessToJointVenture" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ContributionOfBusinessToJointVenture" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails4" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AssociatesSummarizedFinancialInformationTable" xlink:label="lbl_AssociatesSummarizedFinancialInformationTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="lbl_AssociatesSummarizedFinancialInformationTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssociatesSummarizedFinancialInformationTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssociatesSummarizedFinancialInformationTable" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="lbl_CurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_CurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="lbl_NoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_NoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="lbl_CurrentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_CurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="lbl_NoncurrentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_NoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Revenue" xlink:label="lbl_Revenue" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_Revenue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="lbl_OtherComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_OtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="6.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails5" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PurchasePriceAllocationAssociatesTable" xlink:label="lbl_PurchasePriceAllocationAssociatesTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="lbl_PurchasePriceAllocationAssociatesTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PurchasePriceAllocationAssociatesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PurchasePriceAllocationAssociatesTable" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:label="lbl_AdditionalRecognitionGoodwill" xlink:type="locator"/>
      <link:presentationArc order="0.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_AdditionalRecognitionGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ShareOfEstimatedNetAssets" xlink:label="lbl_ShareOfEstimatedNetAssets" xlink:type="locator"/>
      <link:presentationArc order="-1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfEstimatedNetAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" xlink:label="lbl_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="0.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" xlink:label="lbl_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" xlink:type="locator"/>
      <link:presentationArc order="0.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails6" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ConsolidatedIncomeStatementEffectsTable" xlink:label="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ShareOfCurrentYearNetIncome" xlink:label="lbl_ShareOfCurrentYearNetIncome" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfCurrentYearNetIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PriorYearAdjustment" xlink:label="lbl_PriorYearAdjustment" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_PriorYearAdjustment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:label="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:label="lbl_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:to="lbl_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:label="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:label="lbl_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilities" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:label="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsExplanatory" xlink:label="lbl_DisclosureOfOtherProvisionsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_DisclosureOfOtherProvisionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccrualForEnvironmentalLossContingenciesTableTextBlock" xlink:label="lbl_AccrualForEnvironmentalLossContingenciesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_AccrualForEnvironmentalLossContingenciesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" xlink:label="lbl_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" xlink:label="lbl_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:label="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:label="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherPostemploymentBenefits" xlink:label="lbl_OtherPostemploymentBenefits" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_OtherPostemploymentBenefits" xlink:type="arc"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="arc"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ContingentConsiderationNonCurrent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="lbl_OtherNoncurrentLiabilities1" xlink:type="locator"/>
      <link:presentationArc order="8.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_OtherNoncurrentLiabilities1" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationNonCurrent" xlink:label="lbl_ContingentConsiderationNonCurrent" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalRemediationProvisionNoncurrent" xlink:label="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionRollForward" xlink:label="lbl_EnvironmentalProvisionRollForward" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionAdditions" xlink:type="arc"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionRollForward" xlink:label="lbl_EnvironmentalProvisionRollForward1" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvision" xlink:label="lbl_EnvironmentalProvision" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvision" xlink:type="arc"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionRollForward1" xlink:to="lbl_EnvironmentalProvision" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionAdditions" xlink:label="lbl_EnvironmentalProvisionAdditions" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:label="lbl_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalRemediationProvisionNoncurrent" xlink:label="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionCurrent" xlink:label="lbl_EnvironmentalProvisionCurrent" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionReleases" xlink:label="lbl_EnvironmentalProvisionReleases" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionReleases" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_EnvironmentalProvisionRollForward" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionPayments" xlink:label="lbl_EnvironmentalProvisionPayments" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionPayments" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvision" xlink:label="lbl_EnvironmentalProvision" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:label="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:to="lbl_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:to="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:type="arc"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:to="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:type="arc"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:to="lbl_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:type="arc"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:to="lbl_EnvironmentalProvision" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:type="arc"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:type="arc"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward1" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="arc"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward1" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ClassesOfProvisionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_OtherProvisionsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LegalProceedingsProvisionMember" xlink:label="lbl_LegalProceedingsProvisionMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_LegalProceedingsProvisionMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SolodynMember" xlink:label="lbl_SolodynMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SolodynMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContactLensesMember" xlink:label="lbl_ContactLensesMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ContactLensesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GleevecMember" xlink:label="lbl_GleevecMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GleevecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReclastAclastaMember" xlink:label="lbl_ReclastAclastaMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ReclastAclastaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TekturnaRasilezValturnaMember" xlink:label="lbl_TekturnaRasilezValturnaMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TekturnaRasilezValturnaMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="3.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NAGAndNovartisPharmaSpAMember" xlink:label="lbl_NAGAndNovartisPharmaSpAMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NAGAndNovartisPharmaSpAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FHoffmanLaRocheAGAndRocheSpAMember" xlink:label="lbl_FHoffmanLaRocheAGAndRocheSpAMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_FHoffmanLaRocheAGAndRocheSpAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisPharmaKKMember" xlink:label="lbl_NovartisPharmaKKMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NovartisPharmaKKMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NAGMember" xlink:label="lbl_NAGMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NPCAndOthersMember" xlink:label="lbl_NPCAndOthersMember" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NPCAndOthersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NovartisNCMember" xlink:label="lbl_NovartisNCMember" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NovartisNCMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:label="lbl_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:label="lbl_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilities" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxotereMember" xlink:label="lbl_TaxotereMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TaxotereMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmiodaroneMember" xlink:label="lbl_AmiodaroneMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AmiodaroneMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:presentationArc order="0.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="lbl_JP" xlink:type="locator"/>
      <link:presentationArc order="0.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_JP" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_IT" xlink:label="lbl_IT" xlink:type="locator"/>
      <link:presentationArc order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_IT" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CA" xlink:label="lbl_CA" xlink:type="locator"/>
      <link:presentationArc order="0.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CA" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_KR" xlink:label="lbl_KR" xlink:type="locator"/>
      <link:presentationArc order="1.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_KR" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountOfSettlementInPrinciple" xlink:label="lbl_AmountOfSettlementInPrinciple" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_AmountOfSettlementInPrinciple" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:type="locator"/>
      <link:presentationArc order="5.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdditionalAmountOfSettlementInPrinciple" xlink:label="lbl_AdditionalAmountOfSettlementInPrinciple" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_AdditionalAmountOfSettlementInPrinciple" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountOfResolvedAction" xlink:label="lbl_AmountOfResolvedAction" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_AmountOfResolvedAction" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EnoxaparinMember" xlink:label="lbl_EnoxaparinMember" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_EnoxaparinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LitigationCaseMember" xlink:label="lbl_LitigationCaseMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TennesseeClassActionMember" xlink:label="lbl_TennesseeClassActionMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LitigationCaseMember" xlink:to="lbl_TennesseeClassActionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MassachusettsCaseMember" xlink:label="lbl_MassachusettsCaseMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LitigationCaseMember" xlink:to="lbl_MassachusettsCaseMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="lbl_LitigationCaseAxis1" xlink:type="locator"/>
      <link:presentationArc order="4.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_LitigationCaseAxis1" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LitigationCaseAxis1" xlink:to="lbl_LitigationCaseMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_FR" xlink:label="lbl_FR" xlink:type="locator"/>
      <link:presentationArc order="2.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_FR" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TasignaMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="lbl_DisclosureOfClassesOfShareCapitalAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_IssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:to="lbl_IssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OutstandingShareCapital" xlink:label="lbl_OutstandingShareCapital" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_OutstandingShareCapital" xlink:type="arc"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:to="lbl_OutstandingShareCapital" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="lbl_SaleOrIssueOfTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_SaleOrIssueOfTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IssuedCapitalMovement" xlink:label="lbl_IssuedCapitalMovement" xlink:type="locator"/>
      <link:presentationArc order="4.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_IssuedCapitalMovement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OutstandingShareCapitalMovement" xlink:label="lbl_OutstandingShareCapitalMovement" xlink:type="locator"/>
      <link:presentationArc order="4.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_OutstandingShareCapitalMovement" xlink:type="arc"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasuryShares" xlink:type="arc"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:to="lbl_TreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TreasurySharesMovementOfPeriod" xlink:label="lbl_TreasurySharesMovementOfPeriod" xlink:type="locator"/>
      <link:presentationArc order="4.6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesMovementOfPeriod" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="lbl_DisclosureOfClassesOfShareCapitalAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="lbl_ClassesOfShareCapitalAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_ClassesOfShareCapitalAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="lbl_ClassesOfShareCapitalMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="lbl_NumberOfSharesOutstanding" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfSharesOutstanding" xlink:type="arc"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:to="lbl_NumberOfSharesOutstanding" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TreasurySharesAcquiredToBeHeld" xlink:label="lbl_TreasurySharesAcquiredToBeHeld" xlink:type="locator"/>
      <link:presentationArc order="8.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesAcquiredToBeHeld" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherSharePurchases" xlink:label="lbl_OtherSharePurchases" xlink:type="locator"/>
      <link:presentationArc order="8.4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_OtherSharePurchases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TreasurySharesAcquiredToBeCancelled" xlink:label="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="locator"/>
      <link:presentationArc order="8.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharesCancelledForCapitalReduction" xlink:label="lbl_SharesCancelledForCapitalReduction" xlink:type="locator"/>
      <link:presentationArc order="7.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_SharesCancelledForCapitalReduction" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ShareMovements" xlink:label="lbl_ShareMovements" xlink:type="locator"/>
      <link:presentationArc order="8.67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_ShareMovements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StockRepurchaseProgramAuthorizedAmount1" xlink:label="lbl_StockRepurchaseProgramAuthorizedAmount1" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfShareCapitalAxis" xlink:to="lbl_ClassesOfShareCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OrdinarySharesMember" xlink:label="lbl_OrdinarySharesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_OrdinarySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_TreasurySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TreasurySharesWithRestrictedUse" xlink:label="lbl_TreasurySharesWithRestrictedUse" xlink:type="locator"/>
      <link:presentationArc order="9.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesWithRestrictedUse" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedCompensationShares" xlink:label="lbl_EquityBasedCompensationShares" xlink:type="locator"/>
      <link:presentationArc order="8.51" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_EquityBasedCompensationShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:label="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="locator"/>
      <link:presentationArc order="8.46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfOtherShareSales" xlink:label="lbl_NumberOfOtherShareSales" xlink:type="locator"/>
      <link:presentationArc order="8.63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfOtherShareSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharesDeliveredToDivestedBusinessEmployees" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="locator"/>
      <link:presentationArc order="8.55" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="lbl_NumberOfSharesIssued" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfSharesIssued" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfTreasuryShares" xlink:label="lbl_NumberOfTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfTreasuryShares" xlink:type="arc"/>
      <link:presentationArc order="8.77" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:to="lbl_NumberOfSharesIssued" xlink:type="arc"/>
      <link:presentationArc order="8.87" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:to="lbl_NumberOfTreasuryShares" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DividendsPayableAmountPerShare" xlink:label="lbl_DividendsPayableAmountPerShare" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="lbl_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_DividendsPayableAmountPerShare" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPaid" xlink:label="lbl_DividendsPaid" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_DividendsPaid" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityDetails4" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="lbl_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TreasurySharesAcquiredToBeHeld" xlink:label="lbl_TreasurySharesAcquiredToBeHeld" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TreasurySharesAcquiredToBeHeld" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TreasurySharesAcquiredToBeHeldValue" xlink:label="lbl_TreasurySharesAcquiredToBeHeldValue" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TreasurySharesAcquiredToBeHeldValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TreasurySharesAcquiredToBeCancelled" xlink:label="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TreasurySharesAcquiredForCancellationValue" xlink:label="lbl_TreasurySharesAcquiredForCancellationValue" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TreasurySharesAcquiredForCancellationValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherSharePurchases" xlink:label="lbl_OtherSharePurchases" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_OtherSharePurchases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherSharePurchasesValue" xlink:label="lbl_OtherSharePurchasesValue" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_OtherSharePurchasesValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharepurchaseOfTreasuryShares" xlink:label="lbl_SharepurchaseOfTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_SharepurchaseOfTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="lbl_PurchaseOfTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_PurchaseOfTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfOtherShareSales" xlink:label="lbl_NumberOfOtherShareSales" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_NumberOfOtherShareSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherShareSalesEquityImpact" xlink:label="lbl_OtherShareSalesEquityImpact" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_OtherShareSalesEquityImpact" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TreasurySharesMovement" xlink:label="lbl_TreasurySharesMovement" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TreasurySharesMovement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityImpactOfTreasuryShareMovements" xlink:label="lbl_EquityImpactOfTreasuryShareMovements" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_EquityImpactOfTreasuryShareMovements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedCompensationShares" xlink:label="lbl_EquityBasedCompensationShares" xlink:type="locator"/>
      <link:presentationArc order="11.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_EquityBasedCompensationShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:label="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="locator"/>
      <link:presentationArc order="11.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="locator"/>
      <link:presentationArc order="12.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharesDeliveredToDivestedBusinessEmployees" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="locator"/>
      <link:presentationArc order="12.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="locator"/>
      <link:presentationArc order="11.25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureEquity" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfEquityAbstract" xlink:label="lbl_DisclosureOfEquityAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfEquityTextBlock" xlink:label="lbl_DisclosureOfEquityTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfEquityAbstract" xlink:to="lbl_DisclosureOfEquityTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfEquityAbstract" xlink:label="lbl_DisclosureOfEquityAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MovementInTheShareCapitalTableTextBlock" xlink:label="lbl_MovementInTheShareCapitalTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfEquityAbstract" xlink:to="lbl_MovementInTheShareCapitalTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MovementInTheShareslTableTextBlock" xlink:label="lbl_MovementInTheShareslTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfEquityAbstract" xlink:to="lbl_MovementInTheShareslTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DividendTableTextBlock" xlink:label="lbl_DividendTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfEquityAbstract" xlink:to="lbl_DividendTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SummaryOfTreasurySharesMovementsTableTextBlock" xlink:label="lbl_SummaryOfTreasurySharesMovementsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfEquityAbstract" xlink:to="lbl_SummaryOfTreasurySharesMovementsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails7" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BusinessUnitAxis" xlink:label="lbl_BusinessUnitAxis" xlink:type="locator"/>
      <link:presentationArc order="2.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_BusinessUnitAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BusinessUnitMember" xlink:label="lbl_BusinessUnitMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BusinessUnitAxis" xlink:to="lbl_BusinessUnitMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OncologyMember" xlink:label="lbl_OncologyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BusinessUnitMember" xlink:to="lbl_OncologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PharmaceuticalMember" xlink:label="lbl_PharmaceuticalMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BusinessUnitMember" xlink:to="lbl_PharmaceuticalMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FranchiseAxis" xlink:label="lbl_FranchiseAxis" xlink:type="locator"/>
      <link:presentationArc order="2.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_FranchiseAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FranchiseMember" xlink:label="lbl_FranchiseMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseAxis" xlink:to="lbl_FranchiseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NeuroscienceMember" xlink:label="lbl_NeuroscienceMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_NeuroscienceMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:presentationArc order="2.4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductPortfolioAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_COPDMember" xlink:label="lbl_COPDMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_COPDMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExjadeJadenuMember" xlink:label="lbl_ExjadeJadenuMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExjadeJadenuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VotrientMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TravoprostGroupMember" xlink:label="lbl_TravoprostGroupMember" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TravoprostGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SystaneGroupMember" xlink:label="lbl_SystaneGroupMember" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SystaneGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TopicalOlopatadineGroupMember" xlink:label="lbl_TopicalOlopatadineGroupMember" xlink:type="locator"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TopicalOlopatadineGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MyforticMember" xlink:label="lbl_MyforticMember" xlink:type="locator"/>
      <link:presentationArc order="21.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_MyforticMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExelonExelonPatchMember" xlink:label="lbl_ExelonExelonPatchMember" xlink:type="locator"/>
      <link:presentationArc order="32.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExelonExelonPatchMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RitalinFocalinMember" xlink:label="lbl_RitalinFocalinMember" xlink:type="locator"/>
      <link:presentationArc order="33.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_RitalinFocalinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherProductsMember" xlink:label="lbl_OtherProductsMember" xlink:type="locator"/>
      <link:presentationArc order="34.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherProductsMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KymriahMember" xlink:label="lbl_KymriahMember" xlink:type="locator"/>
      <link:presentationArc order="12.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KymriahMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PiqrayMember" xlink:label="lbl_PiqrayMember" xlink:type="locator"/>
      <link:presentationArc order="12.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PiqrayMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TasignaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandostatinMember" xlink:label="lbl_SandostatinMember" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SandostatinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AfinitorVotubiaMember" xlink:label="lbl_AfinitorVotubiaMember" xlink:type="locator"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AfinitorVotubiaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SeebriBreezhalerMember" xlink:label="lbl_SeebriBreezhalerMember" xlink:type="locator"/>
      <link:presentationArc order="14.995" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SeebriBreezhalerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OnbrezBreezhalerMember" xlink:label="lbl_OnbrezBreezhalerMember" xlink:type="locator"/>
      <link:presentationArc order="14.997" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OnbrezBreezhalerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImmunologyHepatologyAndDermatologyMember" xlink:label="lbl_ImmunologyHepatologyAndDermatologyMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_ImmunologyHepatologyAndDermatologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OphthalmologyMember" xlink:label="lbl_OphthalmologyMember" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_OphthalmologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CardioMetabolicMember" xlink:label="lbl_CardioMetabolicMember" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_CardioMetabolicMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EstablishedMedicinesMember" xlink:label="lbl_EstablishedMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="3.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_EstablishedMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RespiratoryMember" xlink:label="lbl_RespiratoryMember" xlink:type="locator"/>
      <link:presentationArc order="3.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_RespiratoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PromactaRevoladeMember" xlink:label="lbl_PromactaRevoladeMember" xlink:type="locator"/>
      <link:presentationArc order="1.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PromactaRevoladeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TafinlarMekinistMember" xlink:label="lbl_TafinlarMekinistMember" xlink:type="locator"/>
      <link:presentationArc order="1.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TafinlarMekinistMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_JakaviMember" xlink:label="lbl_JakaviMember" xlink:type="locator"/>
      <link:presentationArc order="1.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_JakaviMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GleevecGlivecMember" xlink:label="lbl_GleevecGlivecMember" xlink:type="locator"/>
      <link:presentationArc order="1.65" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GleevecGlivecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KisqaliMember" xlink:label="lbl_KisqaliMember" xlink:type="locator"/>
      <link:presentationArc order="3.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KisqaliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LutatheraMember" xlink:label="lbl_LutatheraMember" xlink:type="locator"/>
      <link:presentationArc order="12.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LutatheraMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdakveoMember" xlink:label="lbl_AdakveoMember" xlink:type="locator"/>
      <link:presentationArc order="12.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AdakveoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TabrectaMember" xlink:label="lbl_TabrectaMember" xlink:type="locator"/>
      <link:presentationArc order="12.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TabrectaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CosentyxMember" xlink:label="lbl_CosentyxMember" xlink:type="locator"/>
      <link:presentationArc order="12.95" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_CosentyxMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IlarisMember" xlink:label="lbl_IlarisMember" xlink:type="locator"/>
      <link:presentationArc order="12.97" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_IlarisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_XiidraMember" xlink:label="lbl_XiidraMember" xlink:type="locator"/>
      <link:presentationArc order="13.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XiidraMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BeovuMember" xlink:label="lbl_BeovuMember" xlink:type="locator"/>
      <link:presentationArc order="13.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_BeovuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GilenyaMember" xlink:label="lbl_GilenyaMember" xlink:type="locator"/>
      <link:presentationArc order="13.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GilenyaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ZolgensmaMember" xlink:label="lbl_ZolgensmaMember" xlink:type="locator"/>
      <link:presentationArc order="13.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZolgensmaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MayzentMember" xlink:label="lbl_MayzentMember" xlink:type="locator"/>
      <link:presentationArc order="13.95" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_MayzentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AimovigMember" xlink:label="lbl_AimovigMember" xlink:type="locator"/>
      <link:presentationArc order="13.97" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AimovigMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KesimptaMember" xlink:label="lbl_KesimptaMember" xlink:type="locator"/>
      <link:presentationArc order="13.98" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KesimptaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EntrestoMember" xlink:label="lbl_EntrestoMember" xlink:type="locator"/>
      <link:presentationArc order="13.99" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_EntrestoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:presentationArc order="13.995" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XolairMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UltibroGroupMember" xlink:label="lbl_UltibroGroupMember" xlink:type="locator"/>
      <link:presentationArc order="13.997" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_UltibroGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UltibroBreezhalerMember" xlink:label="lbl_UltibroBreezhalerMember" xlink:type="locator"/>
      <link:presentationArc order="13.998" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_UltibroBreezhalerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GalvusGroupMember" xlink:label="lbl_GalvusGroupMember" xlink:type="locator"/>
      <link:presentationArc order="13.999" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GalvusGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DiovanGroupMember" xlink:label="lbl_DiovanGroupMember" xlink:type="locator"/>
      <link:presentationArc order="13.9995" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_DiovanGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExforgeGroupMember" xlink:label="lbl_ExforgeGroupMember" xlink:type="locator"/>
      <link:presentationArc order="13.9997" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExforgeGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ZortressCerticanMember" xlink:label="lbl_ZortressCerticanMember" xlink:type="locator"/>
      <link:presentationArc order="13.9998" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZortressCerticanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VoltarenCataflamMember" xlink:label="lbl_VoltarenCataflamMember" xlink:type="locator"/>
      <link:presentationArc order="13.9999" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VoltarenCataflamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NeoralSandimmunEMember" xlink:label="lbl_NeoralSandimmunEMember" xlink:type="locator"/>
      <link:presentationArc order="13.99985" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_NeoralSandimmunEMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityDetails5" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="lbl_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WrittenCallOptionsHeldByMarketMaker" xlink:label="lbl_WrittenCallOptionsHeldByMarketMaker" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_WrittenCallOptionsHeldByMarketMaker" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WrittenCallOptionsContractualLive" xlink:label="lbl_WrittenCallOptionsContractualLive" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_WrittenCallOptionsContractualLive" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WrittenCallOptionsContractualLiveRemaining" xlink:label="lbl_WrittenCallOptionsContractualLiveRemaining" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_WrittenCallOptionsContractualLiveRemaining" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WrittenCallOptionsWeightedAverageExercisePrice" xlink:label="lbl_WrittenCallOptionsWeightedAverageExercisePrice" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_WrittenCallOptionsWeightedAverageExercisePrice" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MaximalAmountOfShareBuybackProgramm" xlink:label="lbl_MaximalAmountOfShareBuybackProgramm" xlink:type="locator"/>
      <link:presentationArc order="7.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_MaximalAmountOfShareBuybackProgramm" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountRecordedInEquityRelatedToHyperinflation" xlink:label="lbl_AmountRecordedInEquityRelatedToHyperinflation" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_AmountRecordedInEquityRelatedToHyperinflation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TaxOnTransactionCostsRecordedInEquity" xlink:label="lbl_TaxOnTransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:presentationArc order="7.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TaxOnTransactionCostsRecordedInEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfOptionsRepurchased" xlink:label="lbl_NumberOfOptionsRepurchased" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_NumberOfOptionsRepurchased" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TransactionCostsRecordedInEquity" xlink:label="lbl_TransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:presentationArc order="7.1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TransactionCostsRecordedInEquity" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialDebtsAndDerivativeInstruments" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems1" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_AssetsAndLiabilitiesAxis" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_AssetsAndLiabilitiesMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_NonCurrentFinancialDebtsMember" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:label="lbl_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:type="locator"/>
      <link:presentationArc order="1.9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonCurrentFinancialDebtsMember" xlink:label="lbl_NonCurrentFinancialDebtsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:label="lbl_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="1.98" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentLeaseLiabilitiesMember" xlink:label="lbl_NoncurrentLeaseLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_NoncurrentLeaseLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentLeaseLiabilitiesMember" xlink:label="lbl_CurrentLeaseLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_CurrentLeaseLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="1.86" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="arc"/>
      <link:presentationArc order="1.865" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems1" xlink:to="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReclassificationFromNoncurrentToCurrentNet" xlink:label="lbl_ReclassificationFromNoncurrentToCurrentNet" xlink:type="locator"/>
      <link:presentationArc order="1.995" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ReclassificationFromNoncurrentToCurrentNet" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentPortionOfNoncurrentFinancialDebt" xlink:label="lbl_CurrentPortionOfNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:presentationArc order="1.997" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentPortionOfNoncurrentFinancialDebt" xlink:type="arc"/>
      <link:presentationArc order="1.9975" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems1" xlink:to="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:label="lbl_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:type="locator"/>
      <link:presentationArc order="2.998" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:label="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="1.3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:label="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="1.85" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmortizationOfBondsDiscount" xlink:label="lbl_AmortizationOfBondsDiscount" xlink:type="locator"/>
      <link:presentationArc order="1.95" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AmortizationOfBondsDiscount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LeaseLiabilitiesImpactOfAdoptionOfIFRS16" xlink:label="lbl_LeaseLiabilitiesImpactOfAdoptionOfIFRS16" xlink:type="locator"/>
      <link:presentationArc order="1.25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_LeaseLiabilitiesImpactOfAdoptionOfIFRS16" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="1.83" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="arc"/>
      <link:presentationArc order="1.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LevelsOfFairValueHierarchyAxis" xlink:to="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="lbl_Level1OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level1OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="lbl_Level2OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level2OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="lbl_Level3OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level3OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MeasurementAxis" xlink:label="lbl_MeasurementAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_MeasurementAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="lbl_AggregatedMeasurementMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MeasurementAxis" xlink:to="lbl_AggregatedMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RecurringFairValueMeasurementMember" xlink:label="lbl_RecurringFairValueMeasurementMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedMeasurementMember" xlink:to="lbl_RecurringFairValueMeasurementMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DebtSecuritiesMember" xlink:label="lbl_DebtSecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_DebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:label="lbl_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:label="lbl_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:label="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FundInvestmentsMember" xlink:label="lbl_FundInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_FundInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TotalAvailableforsaleMarketableSecuritiesMember" xlink:label="lbl_TotalAvailableforsaleMarketableSecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_TotalAvailableforsaleMarketableSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:label="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:label="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AvailableforsaleFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationReceivablesMember" xlink:label="lbl_ContingentConsiderationReceivablesMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_ContingentConsiderationReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:label="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ValuedAtAmortizedCostMember" xlink:label="lbl_ValuedAtAmortizedCostMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_ValuedAtAmortizedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="lbl_FinancialAssetsAtFairValue" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="lbl_FinancialAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="lbl_DisclosureOfFinancialAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquitySecuritiesMember" xlink:label="lbl_EquitySecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_EquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationReceivablesShorttermMember" xlink:label="lbl_ContingentConsiderationReceivablesShorttermMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_ContingentConsiderationReceivablesShorttermMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="lbl_DisclosureOfFinancialAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="lbl_DisclosureOfFinancialAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_DisclosureOfFinancialAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="lbl_DisclosureOfFinancialAssetsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="lbl_ClassesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_ClassesOfFinancialAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssets" xlink:label="lbl_FinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsLineItems" xlink:to="lbl_FinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsMember" xlink:label="lbl_FinancialAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialAssetsAxis" xlink:to="lbl_FinancialAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="lbl_FinancialAssetsAtAmortisedCostMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialAssetsMember" xlink:to="lbl_FinancialAssetsAtAmortisedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashAndCashEquivalentsMember" xlink:label="lbl_CashAndCashEquivalentsMember" xlink:type="locator"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialAssetsMember" xlink:to="lbl_CashAndCashEquivalentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="lbl_CategoriesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_CategoriesOfFinancialAssetsAxis" xlink:type="arc"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_DisclosureOfFinancialAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="lbl_FinancialAssetsCategoryMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CategoriesOfFinancialAssetsAxis" xlink:to="lbl_FinancialAssetsCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BalanceSheetItemAxis" xlink:label="lbl_BalanceSheetItemAxis" xlink:type="locator"/>
      <link:presentationArc order="5.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_BalanceSheetItemAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BalanceSheetItemMember" xlink:label="lbl_BalanceSheetItemMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemAxis" xlink:to="lbl_BalanceSheetItemMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DebtSecuritiesMember" xlink:label="lbl_DebtSecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_DebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquitySecuritiesMember" xlink:label="lbl_EquitySecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_EquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FundInvestmentsMember" xlink:label="lbl_FundInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_FundInvestmentsMember" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_ContingentConsiderationReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationReceivablesMember" xlink:label="lbl_ContingentConsiderationReceivablesMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:label="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:label="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:label="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:label="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueMember" xlink:label="lbl_FinancialAssetsAtFairValueMember" xlink:type="locator"/>
      <link:presentationArc order="0.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialAssetsMember" xlink:to="lbl_FinancialAssetsAtFairValueMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="lbl_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialAssetsCategoryMember" xlink:to="lbl_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:label="lbl_FinancialAssetsAtAmortisedCostCategoryMember" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialAssetsCategoryMember" xlink:to="lbl_FinancialAssetsAtAmortisedCostCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="5.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AvailableForSaleMarketableSecuritiesMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CurrentFinancialDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AvailableForSaleMarketableSecuritiesMember" xlink:label="lbl_AvailableForSaleMarketableSecuritiesMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentFinancialDebtMember" xlink:label="lbl_CurrentFinancialDebtMember" xlink:type="locator"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:presentationArc order="1.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:presentationArc order="5.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherCurrentAssetsMember" xlink:label="lbl_OtherCurrentAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="5.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_OtherCurrentAssetsMember" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CashAndCashEquivalentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:label="lbl_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialAssetsCategoryMember" xlink:to="lbl_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:label="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="lbl_FinancialLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:to="lbl_FinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="lbl_FinancialLiabilitiesAtAmortisedCostMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialLiabilitiesMember" xlink:to="lbl_FinancialLiabilitiesAtAmortisedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:label="lbl_FinancialLiabilitiesAtFairValueMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialLiabilitiesMember" xlink:to="lbl_FinancialLiabilitiesAtFairValueMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="lbl_FinancialLiabilitiesCategoryMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lbl_FinancialLiabilitiesCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="lbl_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialLiabilitiesCategoryMember" xlink:to="lbl_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CurrentFinancialDebtMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_NoncurrentFinancialDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradePayablesMember" xlink:label="lbl_TradePayablesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_TradePayablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BalanceSheetItemAxis" xlink:label="lbl_BalanceSheetItemAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_BalanceSheetItemAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BalanceSheetItemMember" xlink:label="lbl_BalanceSheetItemMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemAxis" xlink:to="lbl_BalanceSheetItemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:label="lbl_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BankAndOtherFinancialDebtMember" xlink:label="lbl_BankAndOtherFinancialDebtMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_BankAndOtherFinancialDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CommercialPaperMember" xlink:label="lbl_CommercialPaperMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_CommercialPaperMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentPortionOfNoncurrentDebtMember" xlink:label="lbl_CurrentPortionOfNoncurrentDebtMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_CurrentPortionOfNoncurrentDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StraightBondsMember" xlink:label="lbl_StraightBondsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_StraightBondsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:label="lbl_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinanceLeaseObligationsMember" xlink:label="lbl_FinanceLeaseObligationsMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_FinanceLeaseObligationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:label="lbl_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:label="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilities" xlink:label="lbl_FinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="lbl_FinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentFinancialDebtMember" xlink:label="lbl_CurrentFinancialDebtMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentFinancialDebtMember" xlink:label="lbl_NoncurrentFinancialDebtMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="lbl_LeaseLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_LeaseLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherFinancialLiabilitiesCategoryMember" xlink:label="lbl_OtherFinancialLiabilitiesCategoryMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialLiabilitiesCategoryMember" xlink:to="lbl_OtherFinancialLiabilitiesCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherFinancialLiabilitiesMember" xlink:label="lbl_OtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_OtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:label="lbl_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:type="locator"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialLiabilitiesCategoryMember" xlink:to="lbl_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CommitmentForRepurchaseOfOwnSharesMember" xlink:label="lbl_CommitmentForRepurchaseOfOwnSharesMember" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CommitmentForRepurchaseOfOwnSharesMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:label="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:to="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsPrincipalAmountsAxis" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsPrincipalAmountsMember" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContractOrUnderlyingPrincipalAmoutMember" xlink:label="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PositiveFairValuesMember" xlink:label="lbl_PositiveFairValuesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_PositiveFairValuesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NegativeFairValuesMember" xlink:label="lbl_NegativeFairValuesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_NegativeFairValuesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:label="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstruments" xlink:label="lbl_DerivativeFinancialInstruments" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:label="lbl_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:label="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="locator"/>
      <link:presentationArc order="2.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:label="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="locator"/>
      <link:presentationArc order="2.75" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:label="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:to="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsPrincipalAmountsAxis" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsPrincipalAmountsMember" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContractOrUnderlyingPrincipalAmoutMember" xlink:label="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:label="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstruments" xlink:label="lbl_DerivativeFinancialInstruments" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstruments" xlink:type="arc"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="lbl_EUR" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_EUR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY" xlink:label="lbl_JPY" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_JPY" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrencyOthersMember" xlink:label="lbl_CurrencyOthersMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CurrencyOthersMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_USD" xlink:label="lbl_USD" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_USD" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis1" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_CurrencyAxis1" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrencyAxis1" xlink:to="lbl_AllCurrenciesDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:label="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:label="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="locator"/>
      <link:presentationArc order="2.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:to="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MeasurementAxis" xlink:label="lbl_MeasurementAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_MeasurementAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="lbl_AggregatedMeasurementMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MeasurementAxis" xlink:to="lbl_AggregatedMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RecurringFairValueMeasurementMember" xlink:label="lbl_RecurringFairValueMeasurementMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedMeasurementMember" xlink:to="lbl_RecurringFairValueMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LevelsOfFairValueHierarchyAxis" xlink:to="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="lbl_Level1OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level1OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="lbl_Level2OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level2OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="lbl_Level3OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level3OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ValuedAtAmortizedCostMember" xlink:label="lbl_ValuedAtAmortizedCostMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_ValuedAtAmortizedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="lbl_ClassesOfLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_ClassesOfLiabilitiesAxis" xlink:type="arc"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="lbl_LiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfLiabilitiesAxis" xlink:to="lbl_LiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationPayablesMember" xlink:label="lbl_ContingentConsiderationPayablesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_ContingentConsiderationPayablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherFinancialLiabilitiesMember" xlink:label="lbl_OtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_OtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="lbl_FinancialLiabilitiesAtFairValue" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_FinancialLiabilitiesAtFairValue" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsCarryingValueLevel3" xlink:label="lbl_FinancialInstrumentsCarryingValueLevel3" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FinancialInstrumentsCarryingValueLevel3" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:label="lbl_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:label="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:type="arc"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_PurchaseFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReclassificationFairValueMeasurementAssets" xlink:label="lbl_ReclassificationFairValueMeasurementAssets" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_ReclassificationFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems1" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems1" xlink:to="lbl_FinancialInstrumentsCarryingValueLevel3" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:label="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:label="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:label="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FundInvestmentsMember" xlink:label="lbl_FundInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FundInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AvailableforsaleFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationReceivablesMember" xlink:label="lbl_ContingentConsiderationReceivablesMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_ContingentConsiderationReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationPayablesMember" xlink:label="lbl_ContingentConsiderationPayablesMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_ContingentConsiderationPayablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherFinancialLiabilitiesMember" xlink:label="lbl_OtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_OtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:label="lbl_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:type="locator"/>
      <link:presentationArc order="5.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PurchaseFairValueMeasurementAssets" xlink:label="lbl_PurchaseFairValueMeasurementAssets" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:to="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisposalsFairValueMeasurementAssets" xlink:label="lbl_DisposalsFairValueMeasurementAssets" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DisposalsFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:label="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LongTermFinancialInvestmentsMember" xlink:label="lbl_LongTermFinancialInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_LongTermFinancialInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:label="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MaturityOfNetDebtLineItems" xlink:label="lbl_MaturityOfNetDebtLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:label="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:to="lbl_MaturityOfNetDebtLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MarketableSecuritiesAndTimeDepositsMember" xlink:label="lbl_MarketableSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_MarketableSecuritiesAndTimeDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CommoditiesMember" xlink:label="lbl_CommoditiesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CommoditiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:label="lbl_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashAndCashEquivalentsMember" xlink:label="lbl_CashAndCashEquivalentsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CashAndCashEquivalentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialDebtMember" xlink:label="lbl_FinancialDebtMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FinancialDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialDebtUndiscountedMember" xlink:label="lbl_FinancialDebtUndiscountedMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FinancialDebtUndiscountedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_OtherCurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="lbl_NotLaterThanOneMonthMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneMonthMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:label="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="locator"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NetDebt" xlink:label="lbl_NetDebt1" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_NetDebt1" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="lbl_NotLaterThanOneMonthMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneMonthMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:label="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:label="lbl_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:to="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:label="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:label="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:to="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationLiabilities" xlink:label="lbl_ContingentConsiderationLiabilities" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_ContingentConsiderationLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContractualInterestOnNoncurrentLiabilities" xlink:label="lbl_ContractualInterestOnNoncurrentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_ContractualInterestOnNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CommitmentForRepurchaseOwnShares" xlink:label="lbl_CommitmentForRepurchaseOwnShares" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CommitmentForRepurchaseOwnShares" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TenDayLossFairValueVARModelTable" xlink:label="lbl_TenDayLossFairValueVARModelTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_TenDayLossFairValueVARModelTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TenDayLossFairValueVARModelLineItems" xlink:label="lbl_TenDayLossFairValueVARModelLineItems" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TenDayLossFairValueVARModelTable" xlink:to="lbl_RangeAxis" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TenDayLossFairValueVARModelTable" xlink:to="lbl_TenDayLossFairValueVARModelLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangeAxis" xlink:to="lbl_RangesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageMember" xlink:label="lbl_WeightedAverageMember" xlink:type="locator"/>
      <link:presentationArc order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesMember" xlink:to="lbl_WeightedAverageMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="lbl_TopOfRangeMember" xlink:type="locator"/>
      <link:presentationArc order="0.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesMember" xlink:to="lbl_TopOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="lbl_BottomOfRangeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesMember" xlink:to="lbl_BottomOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WorstCaseLossScenarioMember" xlink:label="lbl_WorstCaseLossScenarioMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesMember" xlink:to="lbl_WorstCaseLossScenarioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsValueAtRiskComputation" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputation" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonvestingAxis" xlink:label="lbl_NonvestingAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:to="lbl_NonvestingAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonvestingMember" xlink:label="lbl_NonvestingMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NonvestingAxis" xlink:to="lbl_NonvestingMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonvestedSharesGrantedMember" xlink:label="lbl_NonvestedSharesGrantedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NonvestingMember" xlink:to="lbl_NonvestedSharesGrantedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationAnnualIncentivePlanMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentivePlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentivePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationLongTermPerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePlanMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermPerformancePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:to="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:type="locator"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward1" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward1" xlink:to="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationOtherShareAwardsMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" xlink:type="arc"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward1" xlink:to="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward1" xlink:to="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:label="lbl_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:to="lbl_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:label="lbl_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:to="lbl_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="lbl_NumberOfOutstandingShareOptions" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward1" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward1" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosures" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:label="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:label="lbl_DisclosureOfFairValueMeasurementExplanatory" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfFairValueMeasurementExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" xlink:label="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:label="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" xlink:label="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" xlink:label="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:label="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactLocationAxis" xlink:label="lbl_ImpactLocationAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ImpactLocationAxis" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactLocationMember" xlink:label="lbl_ImpactLocationMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ImpactLocationAxis" xlink:to="lbl_ImpactLocationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeStatementMember" xlink:label="lbl_IncomeStatementMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ImpactLocationMember" xlink:to="lbl_IncomeStatementMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember1" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ImpactLocationMember" xlink:to="lbl_EquityMember1" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:label="lbl_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:label="lbl_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:label="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:label="lbl_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:type="locator"/>
      <link:presentationArc order="7.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:label="lbl_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:type="locator"/>
      <link:presentationArc order="7.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OpenHedgesForAnticipatedTransactions" xlink:label="lbl_OpenHedgesForAnticipatedTransactions" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_OpenHedgesForAnticipatedTransactions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_MostSignificantForeignExchangeLosses" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MostSignificantForeignExchangeLosses" xlink:label="lbl_MostSignificantForeignExchangeLosses" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LongtermFinancialDebtWithACarryingAmount" xlink:label="lbl_LongtermFinancialDebtWithACarryingAmount" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_LongtermFinancialDebtWithACarryingAmount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:label="lbl_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:label="lbl_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:label="lbl_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:label="lbl_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DebtEquityRatio" xlink:label="lbl_DebtEquityRatio" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DebtEquityRatio" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VAREstimateConfidenceInterval" xlink:label="lbl_VAREstimateConfidenceInterval" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_VAREstimateConfidenceInterval" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:label="lbl_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:type="locator"/>
      <link:presentationArc order="9.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsCreditFacilityCommitted" xlink:label="lbl_BorrowingsCreditFacilityCommitted" xlink:type="locator"/>
      <link:presentationArc order="9.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCreditFacilityCommitted" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CounterpartyRiskAbstract" xlink:label="lbl_CounterpartyRiskAbstract" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CounterpartyRiskAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:label="lbl_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CounterpartyRiskAbstract" xlink:to="lbl_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VendorAxis" xlink:label="lbl_VendorAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VendorMember" xlink:label="lbl_VendorMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_VendorAxis" xlink:to="lbl_VendorMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LargestFinancialInstitutionMember" xlink:label="lbl_LargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_VendorMember" xlink:to="lbl_LargestFinancialInstitutionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SecondLargestFinancialInstitutionMember" xlink:label="lbl_SecondLargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_VendorMember" xlink:to="lbl_SecondLargestFinancialInstitutionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ThirdLargestFinancialInstitutionMember" xlink:label="lbl_ThirdLargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_VendorMember" xlink:to="lbl_ThirdLargestFinancialInstitutionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:label="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="arc"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:to="lbl_VendorAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:to="lbl_BorrowingsByNameAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_USCommercialPaperProgramsMember" xlink:label="lbl_USCommercialPaperProgramsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_USCommercialPaperProgramsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_JPCommercialPaperProgramsMember" xlink:label="lbl_JPCommercialPaperProgramsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_JPCommercialPaperProgramsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsCommercialPaperNumberOfPrograms" xlink:label="lbl_BorrowingsCommercialPaperNumberOfPrograms" xlink:type="locator"/>
      <link:presentationArc order="9.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCommercialPaperNumberOfPrograms" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:label="lbl_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:type="locator"/>
      <link:presentationArc order="5.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MaximumHoldingInUnrelatedCompany" xlink:label="lbl_MaximumHoldingInUnrelatedCompany" xlink:type="locator"/>
      <link:presentationArc order="5.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_MaximumHoldingInUnrelatedCompany" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:label="lbl_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="11.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:type="arc"/>
      <link:presentationArc order="3.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:label="lbl_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="locator"/>
      <link:presentationArc order="6.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsCreditFacilityShortTerm" xlink:label="lbl_BorrowingsCreditFacilityShortTerm" xlink:type="locator"/>
      <link:presentationArc order="9.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCreditFacilityShortTerm" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountBorrowedUnderTheCreditFacility" xlink:label="lbl_AmountBorrowedUnderTheCreditFacility" xlink:type="locator"/>
      <link:presentationArc order="9.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_AmountBorrowedUnderTheCreditFacility" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:presentationArc order="3.7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueOfOtherFinancialAssetsSold" xlink:label="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMajorCustomersTable" xlink:label="lbl_DisclosureOfMajorCustomersTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfMajorCustomersTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="lbl_MajorCustomersAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersTable" xlink:to="lbl_MajorCustomersAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorCustomersMember" xlink:label="lbl_MajorCustomersMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorCustomersAxis" xlink:to="lbl_MajorCustomersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LargestCustomerMember" xlink:label="lbl_LargestCustomerMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_LargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SecondLargestCustomerMember" xlink:label="lbl_SecondLargestCustomerMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_SecondLargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ThirdLargestCustomerMember" xlink:label="lbl_ThirdLargestCustomerMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_ThirdLargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:label="lbl_DisclosureOfMajorCustomersLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersTable" xlink:to="lbl_DisclosureOfMajorCustomersLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="lbl_PercentageOfEntitysRevenue" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfEntitysRevenue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CustomersWithNetSalesOverFivePercent" xlink:label="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PercentageOfEntitysTradeReceivable" xlink:label="lbl_PercentageOfEntitysTradeReceivable" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfEntitysTradeReceivable" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedPartiesDetails1" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonExecutiveDirectorMember" xlink:label="lbl_NonExecutiveDirectorMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_NonExecutiveDirectorMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GenentechRocheMember" xlink:label="lbl_GenentechRocheMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GenentechRocheMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GenentechInc.USAMember" xlink:label="lbl_GenentechInc.USAMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GenentechInc.USAMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XolairMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:label="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfContractsWithRelatedParties" xlink:label="lbl_NumberOfContractsWithRelatedParties" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_NumberOfContractsWithRelatedParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RelatedPartiesNumberOfExecutiveCommiteeMembers" xlink:label="lbl_RelatedPartiesNumberOfExecutiveCommiteeMembers" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_RelatedPartiesNumberOfExecutiveCommiteeMembers" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:label="lbl_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SparkTherapeuticsInc.Member" xlink:label="lbl_SparkTherapeuticsInc.Member" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_SparkTherapeuticsInc.Member" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails10" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProfitSharingIncome" xlink:label="lbl_ProfitSharingIncome" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitSharingIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromRoyalties" xlink:label="lbl_RevenueFromRoyalties" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromRoyalties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MilestoneIncome" xlink:label="lbl_MilestoneIncome" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_MilestoneIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherRevenueOther" xlink:label="lbl_OtherRevenueOther" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherRevenueOther" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails8" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FranchiseAxis" xlink:label="lbl_FranchiseAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_FranchiseAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FranchiseMember" xlink:label="lbl_FranchiseMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseAxis" xlink:to="lbl_FranchiseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RetailGenericsMember" xlink:label="lbl_RetailGenericsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_RetailGenericsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BiopharmaceuticalsMember" xlink:label="lbl_BiopharmaceuticalsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_BiopharmaceuticalsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AntiInfectivesMember" xlink:label="lbl_AntiInfectivesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_AntiInfectivesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductPortfolioAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AntiInfectivesSoldUnderSandozNameMember" xlink:label="lbl_AntiInfectivesSoldUnderSandozNameMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_AntiInfectivesSoldUnderSandozNameMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:presentationArc order="4.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:to="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:label="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:to="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ListedEquitySecuritiesMember" xlink:label="lbl_ListedEquitySecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lbl_ListedEquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NonlistedEquitySecuritiesMember" xlink:label="lbl_NonlistedEquitySecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lbl_NonlistedEquitySecuritiesMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GainLossOnSaleOfOtherFinancialAssets" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:presentationArc order="2.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TotalFairValueAdjustmentsMember" xlink:label="lbl_TotalFairValueAdjustmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalFairValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueOfOtherFinancialAssetsSold" xlink:label="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSignificantTransactionsTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfSignificantTransactionsAbstract" xlink:label="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:label="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:to="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:label="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:to="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" xlink:label="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:to="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:label="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:to="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails11" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BusinessUnitAxis" xlink:label="lbl_BusinessUnitAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_BusinessUnitAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BusinessUnitMember" xlink:label="lbl_BusinessUnitMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BusinessUnitAxis" xlink:to="lbl_BusinessUnitMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OncologyMember" xlink:label="lbl_OncologyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BusinessUnitMember" xlink:to="lbl_OncologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PharmaceuticalMember" xlink:label="lbl_PharmaceuticalMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BusinessUnitMember" xlink:to="lbl_PharmaceuticalMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FranchiseAxis" xlink:label="lbl_FranchiseAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_FranchiseAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FranchiseMember" xlink:label="lbl_FranchiseMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseAxis" xlink:to="lbl_FranchiseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OphthalmologyMember" xlink:label="lbl_OphthalmologyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_OphthalmologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NeuroscienceMember" xlink:label="lbl_NeuroscienceMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_NeuroscienceMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RespiratoryMember" xlink:label="lbl_RespiratoryMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_RespiratoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CardioMetabolicMember" xlink:label="lbl_CardioMetabolicMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_CardioMetabolicMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EstablishedMedicinesMember" xlink:label="lbl_EstablishedMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_EstablishedMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImmunologyHepatologyAndDermatologyMember" xlink:label="lbl_ImmunologyHepatologyAndDermatologyMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_ImmunologyHepatologyAndDermatologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductPortfolioAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GleevecGlivecMember" xlink:label="lbl_GleevecGlivecMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GleevecGlivecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExjadeJadenuMember" xlink:label="lbl_ExjadeJadenuMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExjadeJadenuMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_Top20ProductsMember" xlink:label="lbl_Top20ProductsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_Top20ProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RestOfPortfolioMember" xlink:label="lbl_RestOfPortfolioMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_RestOfPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CosentyxMember" xlink:label="lbl_CosentyxMember" xlink:type="locator"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_CosentyxMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:presentationArc order="0.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:presentationArc order="0.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TasignaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandostatinMember" xlink:label="lbl_SandostatinMember" xlink:type="locator"/>
      <link:presentationArc order="0.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SandostatinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IlarisMember" xlink:label="lbl_IlarisMember" xlink:type="locator"/>
      <link:presentationArc order="7.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_IlarisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:presentationArc order="7.85" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VotrientMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TravoprostGroupMember" xlink:label="lbl_TravoprostGroupMember" xlink:type="locator"/>
      <link:presentationArc order="8.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TravoprostGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NeoralSandimmunEMember" xlink:label="lbl_NeoralSandimmunEMember" xlink:type="locator"/>
      <link:presentationArc order="9.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_NeoralSandimmunEMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_VoltarenCataflamMember" xlink:label="lbl_VoltarenCataflamMember" xlink:type="locator"/>
      <link:presentationArc order="9.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VoltarenCataflamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExelonExelonPatchMember" xlink:label="lbl_ExelonExelonPatchMember" xlink:type="locator"/>
      <link:presentationArc order="9.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExelonExelonPatchMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:presentationArc order="6.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RestOfTheWorldMember" xlink:label="lbl_RestOfTheWorldMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GilenyaMember" xlink:label="lbl_GilenyaMember" xlink:type="locator"/>
      <link:presentationArc order="0.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GilenyaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EntrestoMember" xlink:label="lbl_EntrestoMember" xlink:type="locator"/>
      <link:presentationArc order="0.85" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_EntrestoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AfinitorVotubiaMember" xlink:label="lbl_AfinitorVotubiaMember" xlink:type="locator"/>
      <link:presentationArc order="0.95" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AfinitorVotubiaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PromactaRevoladeMember" xlink:label="lbl_PromactaRevoladeMember" xlink:type="locator"/>
      <link:presentationArc order="0.97" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PromactaRevoladeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TafinlarMekinistMember" xlink:label="lbl_TafinlarMekinistMember" xlink:type="locator"/>
      <link:presentationArc order="0.98" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TafinlarMekinistMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GalvusGroupMember" xlink:label="lbl_GalvusGroupMember" xlink:type="locator"/>
      <link:presentationArc order="0.99" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GalvusGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XolairMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_JakaviMember" xlink:label="lbl_JakaviMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_JakaviMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DiovanGroupMember" xlink:label="lbl_DiovanGroupMember" xlink:type="locator"/>
      <link:presentationArc order="4.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_DiovanGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ExforgeGroupMember" xlink:label="lbl_ExforgeGroupMember" xlink:type="locator"/>
      <link:presentationArc order="4.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExforgeGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ZortressCerticanMember" xlink:label="lbl_ZortressCerticanMember" xlink:type="locator"/>
      <link:presentationArc order="8.4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZortressCerticanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KisqaliMember" xlink:label="lbl_KisqaliMember" xlink:type="locator"/>
      <link:presentationArc order="8.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KisqaliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_RestOfTheWorldMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ZolgensmaMember" xlink:label="lbl_ZolgensmaMember" xlink:type="locator"/>
      <link:presentationArc order="10.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZolgensmaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdakveoMember" xlink:label="lbl_AdakveoMember" xlink:type="locator"/>
      <link:presentationArc order="11.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AdakveoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_KesimptaMember" xlink:label="lbl_KesimptaMember" xlink:type="locator"/>
      <link:presentationArc order="12.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KesimptaMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails12" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="1.35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AsiaAfricaAustralasiaMember" xlink:label="lbl_AsiaAfricaAustralasiaMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_AsiaAfricaAustralasiaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CanadaAndLatinAmericaMember" xlink:label="lbl_CanadaAndLatinAmericaMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CanadaAndLatinAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EstablishedMarketsMember" xlink:label="lbl_EstablishedMarketsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EstablishedMarketsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EmergingGrowthMarketsMember" xlink:label="lbl_EmergingGrowthMarketsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EmergingGrowthMarketsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:label="lbl_EuropeMember" xlink:type="locator"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EuropeMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureRightOfUseAssetsAndLeaseLiability" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="lbl_DisclosureOfLeasesExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" xlink:label="lbl_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" xlink:to="lbl_DisclosureOfLeasesExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDiscontinuedOperations" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDiscontinuedOperationsExplanatory" xlink:label="lbl_DisclosureOfDiscontinuedOperationsExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDiscontinuedOperationsAbstract" xlink:label="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:to="lbl_DisclosureOfDiscontinuedOperationsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDiscontinuedOperationsAbstract" xlink:label="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" xlink:label="lbl_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BalanceSheetAdditionalInformationTableTextBlock" xlink:label="lbl_BalanceSheetAdditionalInformationTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_BalanceSheetAdditionalInformationTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" xlink:label="lbl_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" xlink:label="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashFlowsUsedInInvestingActivitiesTableTextBlock" xlink:label="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:label="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:label="lbl_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.92" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfNetAssetsDerecognizedTableTextBlock" xlink:label="lbl_DisclosureOfNetAssetsDerecognizedTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.91" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNetAssetsDerecognizedTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:label="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDisposalGroupHeldForSaleDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisposalGroupHeldForSaleAbstract" xlink:label="lbl_DisposalGroupHeldForSaleAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisposalGroupHeldForSaleAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:to="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisposalGroupHeldForSaleLineItems" xlink:label="lbl_DisposalGroupHeldForSaleLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_DisposalGroupHeldForSaleLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:label="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisposalGroupHeldForSaleLineItems" xlink:to="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_OtherNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_Inventories" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_OtherCurrentNonfinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:label="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisposalGroupHeldForSaleLineItems" xlink:to="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSignificantTransactionsDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:to="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetAssetsDerecognized" xlink:label="lbl_NetAssetsDerecognized" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NetAssetsDerecognized" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPayable" xlink:label="lbl_DividendsPayable" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DividendsPayable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DistributionOfDividendToDividendBearingShares" xlink:label="lbl_DistributionOfDividendToDividendBearingShares" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DistributionOfDividendToDividendBearingShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TransactionCosts" xlink:label="lbl_TransactionCosts" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TransactionCosts" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails1" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_CostOfSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_GrossProfit" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ResearchAndDevelopmentExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdministrativeExpense" xlink:label="lbl_AdministrativeExpense" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherExpenseByFunction" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:label="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="lbl_ProfitLossFromContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:label="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="locator"/>
      <link:presentationArc order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:presentationArc order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="22.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDiscontinuedOperationsAbstract" xlink:label="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CostOfSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossProfit" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ResearchAndDevelopmentExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherIncome" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherExpenseByFunction" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:label="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:label="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ApplicableTaxRateExcludingExceptionalItems" xlink:label="lbl_ApplicableTaxRateExcludingExceptionalItems" xlink:type="locator"/>
      <link:presentationArc order="20.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ApplicableTaxRateExcludingExceptionalItems" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDiscontinuedOperationsAbstract" xlink:label="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromInterest" xlink:label="lbl_RevenueFromInterest" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromInterest" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="lbl_DepreciationAndAmortisationExpense" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DepreciationAndAmortisationExpense" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:label="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdditionsToRestructuringProvisions" xlink:label="lbl_AdditionsToRestructuringProvisions" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdditionsToRestructuringProvisions" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="lbl_RightofuseAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_RightofuseAssetsMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDiscontinuedOperationsAbstract" xlink:label="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Goodwill" xlink:label="lbl_Goodwill" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_Goodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinancialAndOtherNoncurrentAssets" xlink:label="lbl_FinancialAndOtherNoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinancialAndOtherNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_Inventories" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradeReceivablesAndOtherCurrentAssets" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentAndNoncurrentFinancialDebt" xlink:label="lbl_CurrentAndNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentAndNoncurrentFinancialDebt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TradePayablesProvisionsAndOtherLiabilities" xlink:label="lbl_TradePayablesProvisionsAndOtherLiabilities" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TradePayablesProvisionsAndOtherLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetAssetsDerecognized" xlink:label="lbl_NetAssetsDerecognized" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetAssetsDerecognized" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDiscontinuedOperationsAbstract" xlink:label="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashFlowsAttributableToDivestedBusiness" xlink:label="lbl_CashFlowsAttributableToDivestedBusiness" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsAttributableToDivestedBusiness" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DivestedCashAndCashEquivalents" xlink:label="lbl_DivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="7.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DivestedCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="12.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LandMember" xlink:label="lbl_LandMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_LandMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BuildingsMember" xlink:label="lbl_BuildingsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_BuildingsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_VehiclesMember" xlink:label="lbl_VehiclesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_VehiclesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherAssetsMember" xlink:label="lbl_OtherAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_OtherAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:label="lbl_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="lbl_DepreciationRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_DepreciationRightofuseAssets" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MovementsOfTheRightofuseAssetsRollForward" xlink:label="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="lbl_AdditionsToRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_AdditionsToRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MovementsOfTheRightofuseAssetsRollForward" xlink:label="lbl_MovementsOfTheRightofuseAssetsRollForward1" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward1" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LeaseContractTerminationsRightofuseAssets" xlink:label="lbl_LeaseContractTerminationsRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_LeaseContractTerminationsRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisposalsAndRetirementsRightofuseAssets" xlink:label="lbl_DisposalsAndRetirementsRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_DisposalsAndRetirementsRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="lbl_DepreciationRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_DepreciationRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" xlink:to="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:to="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LeaseLiabilitiesUndiscounted" xlink:label="lbl_LeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_LeaseLiabilitiesUndiscounted" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MostMaterialLeaseWithLeaseTermExtension" xlink:label="lbl_MostMaterialLeaseWithLeaseTermExtension" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_MostMaterialLeaseWithLeaseTermExtension" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="lbl_NoncurrentLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.7" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_NoncurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentLeaseLiabilitiesUndiscounted" xlink:label="lbl_NoncurrentLeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:presentationArc order="2.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_NoncurrentLeaseLiabilitiesUndiscounted" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentLeaseLiabilitiesUndiscounted" xlink:label="lbl_CurrentLeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:presentationArc order="2.6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_CurrentLeaseLiabilitiesUndiscounted" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="lbl_CurrentLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_CurrentLeaseLiabilities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashOutflowForLeases" xlink:label="lbl_CashOutflowForLeases" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashOutflowForLeases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RepaymentOfLeaseLiability" xlink:label="lbl_RepaymentOfLeaseLiability" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_RepaymentOfLeaseLiability" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:label="lbl_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_WeightedAverageInterestRateLeaseLiabilities" xlink:label="lbl_WeightedAverageInterestRateLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_WeightedAverageInterestRateLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LeaseIncentives" xlink:label="lbl_LeaseIncentives" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_LeaseIncentives" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:label="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:label="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashOutflowsForShortTermAndLowValueLeases" xlink:label="lbl_CashOutflowsForShortTermAndLowValueLeases" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashOutflowsForShortTermAndLowValueLeases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashOutflowsForPaymentsOfLeasesInterest" xlink:label="lbl_CashOutflowsForPaymentsOfLeasesInterest" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashOutflowsForPaymentsOfLeasesInterest" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="3.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashInflowForLeases" xlink:label="lbl_CashInflowForLeases" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashInflowForLeases" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:label="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RealEstateMember" xlink:label="lbl_RealEstateMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lbl_RealEstateMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SaleAndLeaseBackMember" xlink:label="lbl_SaleAndLeaseBackMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lbl_SaleAndLeaseBackMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashInflowForSaleAndLeaseback" xlink:label="lbl_CashInflowForSaleAndLeaseback" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashInflowForSaleAndLeaseback" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:label="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" xlink:label="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" xlink:label="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" xlink:label="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" xlink:label="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:label="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:label="lbl_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDiscontinuedOperationsAbstract" xlink:label="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="5.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UndiscountedFinanceLeasePaymentsToBeReceived" xlink:label="lbl_UndiscountedFinanceLeasePaymentsToBeReceived" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_UndiscountedFinanceLeasePaymentsToBeReceived" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:label="lbl_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MinimumFinaceLeasePaymentsReceivableAtPresentValue" xlink:label="lbl_MinimumFinaceLeasePaymentsReceivableAtPresentValue" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_MinimumFinaceLeasePaymentsReceivableAtPresentValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FinanceLeaseProvision" xlink:label="lbl_FinanceLeaseProvision" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinanceLeaseProvision" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinanceLeaseReceivables" xlink:label="lbl_FinanceLeaseReceivables" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinanceLeaseReceivables" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DecreaseInFinanceLeasesReceivableDueToUnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:label="lbl_DecreaseInFinanceLeasesReceivableDueToUnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DecreaseInFinanceLeasesReceivableDueToUnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails6" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="lbl_AdditionsToRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsToRightofuseAssets" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquisitionsAndDivestmentsAxis" xlink:label="lbl_AcquisitionsAndDivestmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_AcquisitionsAndDivestmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquisitionsAndDivestmentsMember" xlink:label="lbl_AcquisitionsAndDivestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AcquisitionsAndDivestmentsAxis" xlink:to="lbl_AcquisitionsAndDivestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquisitionsMember" xlink:label="lbl_AcquisitionsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AcquisitionsAndDivestmentsMember" xlink:to="lbl_AcquisitionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DivestmentsMember" xlink:label="lbl_DivestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AcquisitionsAndDivestmentsMember" xlink:to="lbl_DivestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="lbl_BusinessCombinationsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_BusinessCombinationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="lbl_EntitysTotalForBusinessCombinationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BusinessCombinationsAxis" xlink:to="lbl_EntitysTotalForBusinessCombinationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TranscendMedicalIncMember" xlink:label="lbl_TranscendMedicalIncMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForBusinessCombinationsMember" xlink:to="lbl_TranscendMedicalIncMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_AssetsAndLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_AssetsAndLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentLiabilitiesMember" xlink:label="lbl_CurrentLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_CurrentLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentLiabilitiesMember" xlink:label="lbl_NoncurrentLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_NoncurrentLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashFlowFromNetIdentifiableAssets" xlink:label="lbl_CashFlowFromNetIdentifiableAssets" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowFromNetIdentifiableAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:label="lbl_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContingentConsiderationPaid" xlink:label="lbl_ContingentConsiderationPaid" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ContingentConsiderationPaid" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentAssetsDivested" xlink:label="lbl_NoncurrentAssetsDivested" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NoncurrentAssetsDivested" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="lbl_ConsiderationPaidReceived" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ConsiderationPaidReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NetCashOutflowsFromDivestments" xlink:label="lbl_NetCashOutflowsFromDivestments" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashOutflowsFromDivestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentAssetsDivested" xlink:label="lbl_CurrentAssetsDivested" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentAssetsDivested" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CurrentLiabilitiesDivested" xlink:label="lbl_CurrentLiabilitiesDivested" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentLiabilitiesDivested" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:presentationArc order="15.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherPaymentsAndDeferredConsiderationNet" xlink:label="lbl_OtherPaymentsAndDeferredConsiderationNet" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherPaymentsAndDeferredConsiderationNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReceivablesAndPayablesContingentConsiderationNet" xlink:label="lbl_ReceivablesAndPayablesContingentConsiderationNet" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ReceivablesAndPayablesContingentConsiderationNet" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:presentationArc order="10.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NoncurrentAssetsMember" xlink:label="lbl_NoncurrentAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_NoncurrentAssetsMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_LegalEntityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GSKConsumerHealthcareMember" xlink:label="lbl_GSKConsumerHealthcareMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKConsumerHealthcareMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromSalesOfInterestsInAssociates" xlink:label="lbl_ProceedsFromSalesOfInterestsInAssociates" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfInterestsInAssociates" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:label="lbl_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:label="lbl_OtherAdjustmentsToReconcileProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherAdjustmentsToReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefund" xlink:label="lbl_IncomeTaxesPaidRefund" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefund" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails8" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:to="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="lbl_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:to="lbl_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SignificantAccountingPoliciesAbstract" xlink:label="lbl_SignificantAccountingPoliciesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantAccountingPoliciesAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="lbl_ParValuePerShare" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ParValuePerShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:label="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UndiscountedOperatingLeaseCommitments" xlink:label="lbl_UndiscountedOperatingLeaseCommitments" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_UndiscountedOperatingLeaseCommitments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ShortTermLeasesAndLowValueLeases" xlink:label="lbl_ShortTermLeasesAndLowValueLeases" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ShortTermLeasesAndLowValueLeases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RemainingLeaseCommitments" xlink:label="lbl_RemainingLeaseCommitments" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RemainingLeaseCommitments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_LeaseLiabilitiesToBeRecognized" xlink:label="lbl_LeaseLiabilitiesToBeRecognized" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_LeaseLiabilitiesToBeRecognized" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RightOfUseAssetsToBeRecognized" xlink:label="lbl_RightOfUseAssetsToBeRecognized" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RightOfUseAssetsToBeRecognized" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PrepaymentsAndAccruedLeasePayments" xlink:label="lbl_PrepaymentsAndAccruedLeasePayments" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PrepaymentsAndAccruedLeasePayments" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="lbl_IssuedCapitalMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_IssuedCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TreasurySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="lbl_RetainedEarningsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_RetainedEarningsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="lbl_NoncontrollingInterestsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_NoncontrollingInterestsMember" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:presentationArc order="4.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="lbl_GrossLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:label="lbl_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NewLeaseArrangements" xlink:label="lbl_NewLeaseArrangements" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NewLeaseArrangements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_UndiscountedFutureLeasePayments" xlink:label="lbl_UndiscountedFutureLeasePayments" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_UndiscountedFutureLeasePayments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EffectOfDiscounting" xlink:label="lbl_EffectOfDiscounting" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfDiscounting" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:label="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails9" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:to="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_LegalEntityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PowerVisionInc.Member" xlink:label="lbl_PowerVisionInc.Member" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_PowerVisionInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:label="lbl_AdditionalRecognitionGoodwill" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AdditionalRecognitionGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherNetAssets" xlink:label="lbl_OtherNetAssets" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_OtherNetAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="lbl_DeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSignificantTransactionsDetails" xlink:type="extended">
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:to="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="lbl_EntitysTotalForSubsidiariesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lbl_EntitysTotalForSubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SubsidiariesMember" xlink:label="lbl_SubsidiariesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSubsidiariesMember" xlink:to="lbl_SubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeStatementLocationAxis" xlink:label="lbl_IncomeStatementLocationAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_IncomeStatementLocationAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncomeStatementLocationMember" xlink:label="lbl_IncomeStatementLocationMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncomeStatementLocationAxis" xlink:to="lbl_IncomeStatementLocationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OperatingIncomeMember" xlink:label="lbl_OperatingIncomeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncomeStatementLocationMember" xlink:to="lbl_OperatingIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_LegalEntityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdvancedAcceleratorApplicationsAAAMember" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AspenGlobalIncorporatedMember" xlink:label="lbl_AspenGlobalIncorporatedMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AspenGlobalIncorporatedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TheMedicinesCompanyMember" xlink:label="lbl_TheMedicinesCompanyMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TheMedicinesCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AveXisIncMember" xlink:label="lbl_AveXisIncMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AveXisIncMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EndocyteMember" xlink:label="lbl_EndocyteMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EndocyteMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TranscendMedicalIncMember" xlink:label="lbl_TranscendMedicalIncMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TranscendMedicalIncMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SelexysPharmaceuticalsCorporationMember" xlink:label="lbl_SelexysPharmaceuticalsCorporationMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SelexysPharmaceuticalsCorporationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ReprixysPharmaceuticalsCorporationMember" xlink:label="lbl_ReprixysPharmaceuticalsCorporationMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ReprixysPharmaceuticalsCorporationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ZiarcoGroupLimitedMember" xlink:label="lbl_ZiarcoGroupLimitedMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ZiarcoGroupLimitedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EncoreVisionIncMember" xlink:label="lbl_EncoreVisionIncMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EncoreVisionIncMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EliLillyAndCompanyMember" xlink:label="lbl_EliLillyAndCompanyMember" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EliLillyAndCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GSKOncologyProductsMember" xlink:label="lbl_GSKOncologyProductsMember" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKOncologyProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GSKVaccinesMember" xlink:label="lbl_GSKVaccinesMember" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKVaccinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GSKConsumerHealthcareMember" xlink:label="lbl_GSKConsumerHealthcareMember" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKConsumerHealthcareMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GSKTotalTransactionMember" xlink:label="lbl_GSKTotalTransactionMember" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKTotalTransactionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CSLMember" xlink:label="lbl_CSLMember" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CSLMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SpinifexMember" xlink:label="lbl_SpinifexMember" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SpinifexMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdmuneTheraputicsMember" xlink:label="lbl_AdmuneTheraputicsMember" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdmuneTheraputicsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="lbl_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="locator"/>
      <link:presentationArc order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IFMTreInc.Member" xlink:label="lbl_IFMTreInc.Member" xlink:type="locator"/>
      <link:presentationArc order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_IFMTreInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PowerVisionInc.Member" xlink:label="lbl_PowerVisionInc.Member" xlink:type="locator"/>
      <link:presentationArc order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_PowerVisionInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:label="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="locator"/>
      <link:presentationArc order="22.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_BorrowingsByNameAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsUSDMember" xlink:label="lbl_BorrowingsUSDMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_BorrowingsUSDMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BorrowingsEURMember" xlink:label="lbl_BorrowingsEURMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_BorrowingsEURMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DetailedInformationAboutSignificantTransaction" xlink:label="lbl_DetailedInformationAboutSignificantTransaction" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DetailedInformationAboutSignificantTransaction" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RepaymentOfIntercompanyBalances" xlink:label="lbl_RepaymentOfIntercompanyBalances" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RepaymentOfIntercompanyBalances" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:label="lbl_AdditionalRecognitionGoodwill" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AdditionalRecognitionGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:label="lbl_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="lbl_PercentageOfVotingEquityInterestsAcquired" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfVotingEquityInterestsAcquired" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:label="lbl_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PotentiallyRefundableConsiderationFromAcquisition" xlink:label="lbl_PotentiallyRefundableConsiderationFromAcquisition" xlink:type="locator"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PotentiallyRefundableConsiderationFromAcquisition" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:label="lbl_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:type="locator"/>
      <link:presentationArc order="17.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ContractRightOfFirstNegotiationTerm" xlink:label="lbl_ContractRightOfFirstNegotiationTerm" xlink:type="locator"/>
      <link:presentationArc order="18.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ContractRightOfFirstNegotiationTerm" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueOfAcquiree" xlink:label="lbl_RevenueOfAcquiree" xlink:type="locator"/>
      <link:presentationArc order="19.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RevenueOfAcquiree" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_RevenueOfAcquireeFullYear" xlink:label="lbl_RevenueOfAcquireeFullYear" xlink:type="locator"/>
      <link:presentationArc order="20.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RevenueOfAcquireeFullYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:label="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:type="locator"/>
      <link:presentationArc order="21.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:label="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:type="locator"/>
      <link:presentationArc order="22.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="lbl_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
      <link:presentationArc order="23.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:label="lbl_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
      <link:presentationArc order="24.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:label="lbl_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:type="locator"/>
      <link:presentationArc order="25.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="lbl_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="locator"/>
      <link:presentationArc order="26.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PercentageOfVotingEquityInterestsContributed" xlink:label="lbl_PercentageOfVotingEquityInterestsContributed" xlink:type="locator"/>
      <link:presentationArc order="27.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfVotingEquityInterestsContributed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TransactionRelatedCosts" xlink:label="lbl_TransactionRelatedCosts" xlink:type="locator"/>
      <link:presentationArc order="28.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TransactionRelatedCosts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TransactionRelatedCostsPaid" xlink:label="lbl_TransactionRelatedCostsPaid" xlink:type="locator"/>
      <link:presentationArc order="29.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TransactionRelatedCostsPaid" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLoss" xlink:label="lbl_ImpairmentLoss" xlink:type="locator"/>
      <link:presentationArc order="30.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ImpairmentLoss" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReversalOfImpairmentLoss" xlink:label="lbl_ReversalOfImpairmentLoss" xlink:type="locator"/>
      <link:presentationArc order="31.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ReversalOfImpairmentLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PreTaxProfitLossFromDivestmentOfBusiness" xlink:label="lbl_PreTaxProfitLossFromDivestmentOfBusiness" xlink:type="locator"/>
      <link:presentationArc order="32.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PreTaxProfitLossFromDivestmentOfBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:presentationArc order="33.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PotentialReceivableFromDivestment" xlink:label="lbl_PotentialReceivableFromDivestment" xlink:type="locator"/>
      <link:presentationArc order="34.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PotentialReceivableFromDivestment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DivestmentFairValueOfContingentConsiderationReceived" xlink:label="lbl_DivestmentFairValueOfContingentConsiderationReceived" xlink:type="locator"/>
      <link:presentationArc order="35.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DivestmentFairValueOfContingentConsiderationReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_MilestonePaymentAlreadyReceived" xlink:label="lbl_MilestonePaymentAlreadyReceived" xlink:type="locator"/>
      <link:presentationArc order="36.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_MilestonePaymentAlreadyReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_FuturePutOptionToSellBusiness" xlink:label="lbl_FuturePutOptionToSellBusiness" xlink:type="locator"/>
      <link:presentationArc order="37.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_FuturePutOptionToSellBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PaymentPutOption" xlink:label="lbl_PaymentPutOption" xlink:type="locator"/>
      <link:presentationArc order="38.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PaymentPutOption" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_InterestExchanged" xlink:label="lbl_InterestExchanged" xlink:type="locator"/>
      <link:presentationArc order="39.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_InterestExchanged" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="lbl_ParValuePerShare" xlink:type="locator"/>
      <link:presentationArc order="40.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ParValuePerShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PercentageOfShareCapitalInTenderOffer" xlink:label="lbl_PercentageOfShareCapitalInTenderOffer" xlink:type="locator"/>
      <link:presentationArc order="41.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfShareCapitalInTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashOfferPerOrdinaryShare" xlink:label="lbl_CashOfferPerOrdinaryShare" xlink:type="locator"/>
      <link:presentationArc order="42.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CashOfferPerOrdinaryShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CashOfferPerADS" xlink:label="lbl_CashOfferPerADS" xlink:type="locator"/>
      <link:presentationArc order="43.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CashOfferPerADS" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfOrdinarySharePerADS" xlink:label="lbl_NumberOfOrdinarySharePerADS" xlink:type="locator"/>
      <link:presentationArc order="44.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfOrdinarySharePerADS" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ValueOfEquity" xlink:label="lbl_ValueOfEquity" xlink:type="locator"/>
      <link:presentationArc order="45.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ValueOfEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:label="lbl_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:type="locator"/>
      <link:presentationArc order="46.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_OtherNetAssets" xlink:label="lbl_OtherNetAssets" xlink:type="locator"/>
      <link:presentationArc order="47.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_OtherNetAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="lbl_DeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="48.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="49.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DivestmentCostToSell" xlink:label="lbl_DivestmentCostToSell" xlink:type="locator"/>
      <link:presentationArc order="50.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DivestmentCostToSell" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:presentationArc order="51.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:presentationArc order="52.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:presentationArc order="53.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CarryingValueOfTheDivestedBusiness" xlink:label="lbl_CarryingValueOfTheDivestedBusiness" xlink:type="locator"/>
      <link:presentationArc order="54.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CarryingValueOfTheDivestedBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfProductsInPortfolioToBeSold" xlink:label="lbl_NumberOfProductsInPortfolioToBeSold" xlink:type="locator"/>
      <link:presentationArc order="55.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfProductsInPortfolioToBeSold" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:presentationArc order="56.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_ProformaNetSales" xlink:label="lbl_ProformaNetSales" xlink:type="locator"/>
      <link:presentationArc order="57.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProformaNetSales" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherBorrowings" xlink:label="lbl_OtherBorrowings" xlink:type="locator"/>
      <link:presentationArc order="58.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_OtherBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DividendsPayable" xlink:label="lbl_DividendsPayable" xlink:type="locator"/>
      <link:presentationArc order="59.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DividendsPayable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:presentationArc order="60.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:label="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:presentationArc order="61.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="lbl_NetAssetsLiabilities" xlink:type="locator"/>
      <link:presentationArc order="62.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NetAssetsLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="lbl_FinancialAssetsAtFairValue" xlink:type="locator"/>
      <link:presentationArc order="63.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_FinancialAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="locator"/>
      <link:presentationArc order="64.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:presentationArc order="65.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:label="lbl_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:type="locator"/>
      <link:presentationArc order="66.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PotentialMilestoneMaximumPayments" xlink:label="lbl_PotentialMilestoneMaximumPayments" xlink:type="locator"/>
      <link:presentationArc order="67.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PotentialMilestoneMaximumPayments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:label="lbl_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:type="locator"/>
      <link:presentationArc order="68.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_AdditionalBorrowings" xlink:label="lbl_AdditionalBorrowings" xlink:type="locator"/>
      <link:presentationArc order="69.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AdditionalBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_PercentageOfEquityInterestSharesReceived" xlink:label="lbl_PercentageOfEquityInterestSharesReceived" xlink:type="locator"/>
      <link:presentationArc order="70.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfEquityInterestSharesReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:label="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:type="locator"/>
      <link:presentationArc order="71.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator"/>
      <link:presentationArc order="72.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_CustomaryPurchasePriceAdjustment" xlink:label="lbl_CustomaryPurchasePriceAdjustment" xlink:type="locator"/>
      <link:presentationArc order="73.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CustomaryPurchasePriceAdjustment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="74.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="75.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="76.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSignificantAccountingPoliciesDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SignificantAccountingPoliciesAbstract" xlink:label="lbl_SignificantAccountingPoliciesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantAccountingPoliciesAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="lbl_AssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AssetsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="lbl_NoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_NoncurrentAssetsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="lbl_EquityAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EquityAndLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="lbl_EquityAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_EquityAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherReserves" xlink:label="lbl_OtherReserves" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_OtherReserves" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="lbl_LiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_LiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="lbl_CurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_CurrentLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="lbl_CurrentLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLeaseLiabilities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20201231/role/DisclosureSubsequentEventsDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SubsequentEventTypAxis" xlink:label="lbl_SubsequentEventTypAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_SubsequentEventTypAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SubsequentEventTypeMember" xlink:label="lbl_SubsequentEventTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SubsequentEventTypAxis" xlink:to="lbl_SubsequentEventTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_SubsequentEventMember" xlink:label="lbl_SubsequentEventMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SubsequentEventTypeMember" xlink:to="lbl_SubsequentEventMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20201231.xsd#nvs_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:label="lbl_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:type="arc"/>
   </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>nvs-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nvs="http://novartis.com/20201231" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" blockDefault="" elementFormDefault="qualified" finalDefault="" targetNamespace="http://novartis.com/20201231">
   <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
   <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
   <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
   <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
   <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
   <xsd:import namespace="http://xbrl.ifrs.org/taxonomy/2019-03-27/ifrs-full" schemaLocation="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd"/>
   <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
   <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
   <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd"/>
   <xsd:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
   <xsd:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
   <xsd:annotation>
      <xsd:appinfo>

      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvs-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
	  <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvs-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
	  <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvs-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
	  <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvs-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
	  <link:roleType id="documentAndEntityInformation" roleURI="http://novartis.com/20201231/role/DocumentAndEntityInformation">
            <link:definition>0001000 - Document - Document and Entity Information</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementOfIncome" roleURI="http://novartis.com/20201231/role/StatementOfIncome">
            <link:definition>1001000 - Statement - Consolidated income statements</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementOfComprehensiveIncome" roleURI="http://novartis.com/20201231/role/StatementOfComprehensiveIncome">
            <link:definition>1002000 - Statement - Consolidated statements of comprehensive income</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementOfChangesInEquity" roleURI="http://novartis.com/20201231/role/StatementOfChangesInEquity">
            <link:definition>1004000 - Statement - Consolidated statements of changes in equity</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="balanceSheet" roleURI="http://novartis.com/20201231/role/BalanceSheet">
            <link:definition>1003000 - Statement - Consolidated balance sheets</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementsOfCashFlow" roleURI="http://novartis.com/20201231/role/StatementsOfCashFlow">
            <link:definition>1005000 - Statement - Consolidated cash flow statements</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePropertyPlantAndEquipmentDetails" roleURI="http://novartis.com/20201231/role/DisclosurePropertyPlantAndEquipmentDetails">
            <link:definition>2400900 - Disclosure - Property, plant and equipment (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePropertyPlantAndEquipmentDetails2" roleURI="http://novartis.com/20201231/role/DisclosurePropertyPlantAndEquipmentDetails2">
            <link:definition>2400901 - Disclosure - Property, plant and equipment (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePropertyPlantAndEquipment" roleURI="http://novartis.com/20201231/role/DisclosurePropertyPlantAndEquipment">
            <link:definition>2100900 - Disclosure - Property, plant and equipment</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePropertyPlantAndEquipmentTables" roleURI="http://novartis.com/20201231/role/DisclosurePropertyPlantAndEquipmentTables">
            <link:definition>2300900 - Disclosure - Property, plant and equipment (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInventories" roleURI="http://novartis.com/20201231/role/DisclosureInventories">
            <link:definition>2101400 - Disclosure - Inventories</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInventoriesTables" roleURI="http://novartis.com/20201231/role/DisclosureInventoriesTables">
            <link:definition>2301400 - Disclosure - Inventories (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInventoriesDetails" roleURI="http://novartis.com/20201231/role/DisclosureInventoriesDetails">
            <link:definition>2401400 - Disclosure - Inventories (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEarningsPerShare" roleURI="http://novartis.com/20201231/role/DisclosureEarningsPerShare">
            <link:definition>2100700 - Disclosure - Earnings per share</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEarningsPerShareTables" roleURI="http://novartis.com/20201231/role/DisclosureEarningsPerShareTables">
            <link:definition>2300700 - Disclosure - Earnings per share (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEarningsPerShareDetails" roleURI="http://novartis.com/20201231/role/DisclosureEarningsPerShareDetails">
            <link:definition>2400700 - Disclosure - Earnings per share (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSummaryOfSignificantAccountingPolicies" roleURI="http://novartis.com/20201231/role/DisclosureSummaryOfSignificantAccountingPolicies">
            <link:definition>2100100 - Disclosure - Significant accounting policies</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInterestExpenseAndOtherFinancialIncomeExpense" roleURI="http://novartis.com/20201231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpense">
            <link:definition>2100500 - Disclosure - Interest expense and other financial income and expense</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTaxes" roleURI="http://novartis.com/20201231/role/DisclosureTaxes">
            <link:definition>2100600 - Disclosure - Taxes</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssets" roleURI="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssets">
            <link:definition>2101100 - Disclosure - Goodwill and intangible assets</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilities" roleURI="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilities">
            <link:definition>2101200 - Disclosure - Deferred tax assets and liabilities</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://novartis.com/20201231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
            <link:definition>2200100 - Disclosure - Significant accounting policies (Policies)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://novartis.com/20201231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
            <link:definition>2300100 - Disclosure - Significant accounting policies (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInterestExpenseAndOtherFinancialIncomeExpenseTables" roleURI="http://novartis.com/20201231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseTables">
            <link:definition>2300500 - Disclosure - Interest expense and other financial income and expense (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssetsTables" roleURI="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssetsTables">
            <link:definition>2301100 - Disclosure - Goodwill and intangible assets (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilitiesTables" roleURI="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables">
            <link:definition>2301200 - Disclosure - Deferred tax assets and liabilities (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantAccountingPoliciesDetails" roleURI="http://novartis.com/20201231/role/DisclosureSignificantAccountingPoliciesDetails">
            <link:definition>2400100 - Disclosure - Significant accounting policies (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails" roleURI="http://novartis.com/20201231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails">
            <link:definition>2400500 - Disclosure - Interest expense and other financial income and expense (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2" roleURI="http://novartis.com/20201231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2">
            <link:definition>2400501 - Disclosure - Interest expense and other financial income and expense (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTaxesTables" roleURI="http://novartis.com/20201231/role/DisclosureTaxesTables">
            <link:definition>2300600 - Disclosure - Taxes (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTaxesDetails" roleURI="http://novartis.com/20201231/role/DisclosureTaxesDetails">
            <link:definition>2400600 - Disclosure - Taxes (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTaxesDetails2" roleURI="http://novartis.com/20201231/role/DisclosureTaxesDetails2">
            <link:definition>2400601 - Disclosure - Taxes (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTaxesDetails3" roleURI="http://novartis.com/20201231/role/DisclosureTaxesDetails3">
            <link:definition>2400602 - Disclosure - Taxes (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssetsDetails" roleURI="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssetsDetails">
            <link:definition>2401100 - Disclosure - Goodwill and intangible assets (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssetsDetails2" roleURI="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssetsDetails2">
            <link:definition>2401101 - Disclosure - Goodwill and intangible assets (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails">
            <link:definition>2401200 - Disclosure - Deferred tax assets and liabilities (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilitiesDetails2" roleURI="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails2">
            <link:definition>2401201 - Disclosure - Deferred tax assets and liabilities (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilitiesDetails3" roleURI="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3">
            <link:definition>2401202 - Disclosure - Deferred tax assets and liabilities (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilitiesDetails4" roleURI="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4">
            <link:definition>2401203 - Disclosure - Deferred tax assets and liabilities (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantAccountingPoliciesDetails2" roleURI="http://novartis.com/20201231/role/DisclosureSignificantAccountingPoliciesDetails2">
            <link:definition>2400101 - Disclosure - Significant accounting policies (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialAndOtherNoncurrentAssets" roleURI="http://novartis.com/20201231/role/DisclosureFinancialAndOtherNoncurrentAssets">
            <link:definition>2101300 - Disclosure - Financial and other non-current assets</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialAndOtherNoncurrentAssetsTables" roleURI="http://novartis.com/20201231/role/DisclosureFinancialAndOtherNoncurrentAssetsTables">
            <link:definition>2301300 - Disclosure - Financial and other non-current assets (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialAndOtherNoncurrentAssetsDetails" roleURI="http://novartis.com/20201231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails">
            <link:definition>2401300 - Disclosure - Financial and other non-current assets (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialAndOtherNoncurrentAssetsDetails2" roleURI="http://novartis.com/20201231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2">
            <link:definition>2401301 - Disclosure - Financial and other non-current assets (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialAndOtherNoncurrentAssetsDetails3" roleURI="http://novartis.com/20201231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails3">
            <link:definition>2401302 - Disclosure - Financial and other non-current assets (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureOtherCurrentAssets" roleURI="http://novartis.com/20201231/role/DisclosureOtherCurrentAssets">
            <link:definition>2101700 - Disclosure - Other current assets</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureOtherCurrentAssetsTables" roleURI="http://novartis.com/20201231/role/DisclosureOtherCurrentAssetsTables">
            <link:definition>2301700 - Disclosure - Other current assets (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureOtherCurrentAssetsDetails" roleURI="http://novartis.com/20201231/role/DisclosureOtherCurrentAssetsDetails">
            <link:definition>2401700 - Disclosure - Other current assets (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureMarketableSecurities" roleURI="http://novartis.com/20201231/role/DisclosureMarketableSecurities">
            <link:definition>2101600 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureMarketableSecuritiesTables" roleURI="http://novartis.com/20201231/role/DisclosureMarketableSecuritiesTables">
            <link:definition>2301600 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureMarketableSecuritiesDetails" roleURI="http://novartis.com/20201231/role/DisclosureMarketableSecuritiesDetails">
            <link:definition>2401600 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureMarketableSecuritiesDetails2" roleURI="http://novartis.com/20201231/role/DisclosureMarketableSecuritiesDetails2">
            <link:definition>2401601 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureMarketableSecuritiesDetails3" roleURI="http://novartis.com/20201231/role/DisclosureMarketableSecuritiesDetails3">
            <link:definition>2401602 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebt" roleURI="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebt">
            <link:definition>2101900 - Disclosure - Non-current financial debt</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactions" roleURI="http://novartis.com/20201231/role/DisclosureSignificantTransactions">
            <link:definition>2100200 - Disclosure - Significant transactions</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCurrentFinancialDebtAndDerivativeFinancialInstruments" roleURI="http://novartis.com/20201231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstruments">
            <link:definition>2102100 - Disclosure - Current financial debt and derivative financial instruments</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCommitmentsAndContingencies" roleURI="http://novartis.com/20201231/role/DisclosureCommitmentsAndContingencies">
            <link:definition>2102800 - Disclosure - Commitments and contingencies</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSubsequentEventsDetails" roleURI="http://novartis.com/20201231/role/DisclosureSubsequentEventsDetails">
            <link:definition>2403100 - Disclosure - Events subsequent to the December 31 consolidated balance sheet date (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtTables" roleURI="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtTables">
            <link:definition>2301900 - Disclosure - Non-current financial debt (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables" roleURI="http://novartis.com/20201231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables">
            <link:definition>2302100 - Disclosure - Current financial debt and derivative financial instruments (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCommitmentsAndContingenciesTables" roleURI="http://novartis.com/20201231/role/DisclosureCommitmentsAndContingenciesTables">
            <link:definition>2302800 - Disclosure - Commitments and contingencies (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsDetails" roleURI="http://novartis.com/20201231/role/DisclosureSignificantTransactionsDetails">
            <link:definition>2400200 - Disclosure - Significant transactions (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtDetails" roleURI="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails">
            <link:definition>2401900 - Disclosure - Non-current financial debt (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtDetails2" roleURI="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails2">
            <link:definition>2401901 - Disclosure - Non-current financial debt (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtDetails3" roleURI="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails3">
            <link:definition>2401902 - Disclosure - Non-current financial debt (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtDetails4" roleURI="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails4">
            <link:definition>2401903 - Disclosure - Non-current financial debt (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtDetails5" roleURI="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails5">
            <link:definition>2401904 - Disclosure - Non-current financial debt (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtDetails6" roleURI="http://novartis.com/20201231/role/DisclosureNonCurrentFinancialDebtDetails6">
            <link:definition>2401905 - Disclosure - Non-current financial debt (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" roleURI="http://novartis.com/20201231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails">
            <link:definition>2402100 - Disclosure - Current financial debt and derivative financial instruments (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCommitmentsAndContingenciesDetails" roleURI="http://novartis.com/20201231/role/DisclosureCommitmentsAndContingenciesDetails">
            <link:definition>2402800 - Disclosure - Commitments and contingencies (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCommitmentsAndContingenciesDetails2" roleURI="http://novartis.com/20201231/role/DisclosureCommitmentsAndContingenciesDetails2">
            <link:definition>2402801 - Disclosure - Commitments and contingencies (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSubsequentEvents" roleURI="http://novartis.com/20201231/role/DisclosureSubsequentEvents">
            <link:definition>2103100 - Disclosure - Events subsequent to the December 31 consolidated balance sheet date</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType>
		 <link:roleType id="disclosureProvisionsAndOtherCurrentLiabilities" roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherCurrentLiabilities">
            <link:definition>2102200 - Disclosure - Provisions and other current liabilities</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionsOfBusinesses" roleURI="http://novartis.com/20201231/role/DisclosureAcquisitionsOfBusinesses">
            <link:definition>2102400 - Disclosure - Acquisitions of businesses</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociates" roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociates">
            <link:definition>2102500 - Disclosure - Post-employment benefits for associates</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherCurrentLiabilitiesTables" roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables">
            <link:definition>2302200 - Disclosure - Provisions and other current liabilities (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionsOfBusinessesTables" roleURI="http://novartis.com/20201231/role/DisclosureAcquisitionsOfBusinessesTables">
            <link:definition>2302400 - Disclosure - Acquisitions of businesses (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesTables" roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesTables">
            <link:definition>2302500 - Disclosure - Post-employment benefits for associates (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherCurrentLiabilitiesDetails" roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails">
            <link:definition>2402200 - Disclosure - Provisions and other current liabilities (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherCurrentLiabilitiesDetails2" roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2">
            <link:definition>2402201 - Disclosure - Provisions and other current liabilities (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherCurrentLiabilitiesDetails3" roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3">
            <link:definition>2402202 - Disclosure - Provisions and other current liabilities (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionsOfBusinessesDetails" roleURI="http://novartis.com/20201231/role/DisclosureAcquisitionsOfBusinessesDetails">
            <link:definition>2402400 - Disclosure - Acquisitions of businesses (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails" roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails">
            <link:definition>2402500 - Disclosure - Post-employment benefits for associates (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails2" roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2">
            <link:definition>2402501 - Disclosure - Post-employment benefits for associates (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails3" roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3">
            <link:definition>2402502 - Disclosure - Post-employment benefits for associates (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails4" roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4">
            <link:definition>2402503 - Disclosure - Post-employment benefits for associates (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails5" roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5">
            <link:definition>2402504 - Disclosure - Post-employment benefits for associates (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails6" roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6">
            <link:definition>2402505 - Disclosure - Post-employment benefits for associates (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails7" roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7">
            <link:definition>2402506 - Disclosure - Post-employment benefits for associates (Details 7)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails8" roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8">
            <link:definition>2402507 - Disclosure - Post-employment benefits for associates (Details 8)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails9" roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9">
            <link:definition>2402508 - Disclosure - Post-employment benefits for associates (Details 9)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails10" roleURI="http://novartis.com/20201231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10">
            <link:definition>2402509 - Disclosure - Post-employment benefits for associates (Details 10)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivablesDetails3" roleURI="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails3">
            <link:definition>2401502 - Disclosure - Trade receivables (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivablesDetails2" roleURI="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails2">
            <link:definition>2401501 - Disclosure - Trade receivables (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivablesDetails" roleURI="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails">
            <link:definition>2401500 - Disclosure - Trade receivables (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivablesTables" roleURI="http://novartis.com/20201231/role/DisclosureTradeReceivablesTables">
            <link:definition>2301500 - Disclosure - Trade receivables (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivables" roleURI="http://novartis.com/20201231/role/DisclosureTradeReceivables">
            <link:definition>2101500 - Disclosure - Trade receivables</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivablesDetails4" roleURI="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails4">
            <link:definition>2401503 - Disclosure - Trade receivables (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivablesDetails5" roleURI="http://novartis.com/20201231/role/DisclosureTradeReceivablesDetails5">
            <link:definition>2401504 - Disclosure - Trade receivables (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePrincipalGroupSubsidiariesAndAssociatedCompanies" roleURI="http://novartis.com/20201231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompanies">
            <link:definition>2103200 - Disclosure - Principal Group subsidiaries and associated companies</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables" roleURI="http://novartis.com/20201231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables">
            <link:definition>2303200 - Disclosure - Principal Group subsidiaries and associated companies (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails" roleURI="http://novartis.com/20201231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails">
            <link:definition>2403200 - Disclosure - Principal Group subsidiaries and associated companies (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails2" roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails2">
            <link:definition>2403001 - Disclosure - Discontinued operations (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails" roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails">
            <link:definition>2403000 - Disclosure - Discontinued operations (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsTables" roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsTables">
            <link:definition>2303000 - Disclosure - Discontinued operations (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperations" roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperations">
            <link:definition>2103000 - Disclosure - Discontinued operations</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails4" roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails4">
            <link:definition>2402304 - Disclosure - Details to the consolidated cash flow statements (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails3" roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails3">
            <link:definition>2402303 - Disclosure - Details to the consolidated cash flow statements (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails2" roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2">
            <link:definition>2402301 - Disclosure - Details to the consolidated cash flow statements (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails" roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails">
            <link:definition>2402300 - Disclosure - Details to the consolidated cash flow statements (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsTables" roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsTables">
            <link:definition>2302300 - Disclosure - Details to the consolidated statements of cash flows (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatements" roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatements">
            <link:definition>2102300 - Disclosure - Details to the consolidated statements of cash flows</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFigures" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFigures">
            <link:definition>2100300 - Disclosure - Segmentation of key figures</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompanies" roleURI="http://novartis.com/20201231/role/DisclosureAssociatedCompanies">
            <link:definition>2100400 - Disclosure - Associated companies</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureChangesInConsolidatedStatementsOfComprehensiveIncome" roleURI="http://novartis.com/20201231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncome">
            <link:definition>2100800 - Disclosure - Changes in consolidated statements of comprehensive income</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilities" roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilities">
            <link:definition>2102000 - Disclosure - Provisions and other non-current liabilities</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociates" roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociates">
            <link:definition>2102600 - Disclosure - Equity-based participation plans for associates</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedParties" roleURI="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedParties">
            <link:definition>2102700 - Disclosure - Transactions with related parties</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosures" roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosures">
            <link:definition>2102900 - Disclosure - Financial instruments - additional disclosures</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresTables" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresTables">
            <link:definition>2300300 - Disclosure - Segmentation of key figures (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesTables" roleURI="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesTables">
            <link:definition>2300400 - Disclosure - Associated companies (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables" roleURI="http://novartis.com/20201231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables">
            <link:definition>2300800 - Disclosure - Changes in consolidated statements of comprehensive income (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesTables" roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables">
            <link:definition>2302000 - Disclosure - Provisions and other non-current liabilities (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesTables" roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables">
            <link:definition>2302600 - Disclosure - Equity-based participation plans for associates (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedPartiesTables" roleURI="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedPartiesTables">
            <link:definition>2302700 - Disclosure - Transactions with related parties (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresTables" roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables">
            <link:definition>2302900 - Disclosure - Financial instruments - additional disclosures (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails">
            <link:definition>2400300 - Disclosure - Segmentation of key figures (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesDetails" roleURI="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails">
            <link:definition>2400400 - Disclosure - Associated companies (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" roleURI="http://novartis.com/20201231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails">
            <link:definition>2400800 - Disclosure - Changes in consolidated statements of comprehensive income (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails2" roleURI="http://novartis.com/20201231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails2">
            <link:definition>2400801 - Disclosure - Changes in consolidated statements of comprehensive income (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails3" roleURI="http://novartis.com/20201231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails3">
            <link:definition>2400802 - Disclosure - Changes in consolidated statements of comprehensive income (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4" roleURI="http://novartis.com/20201231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4">
            <link:definition>2400803 - Disclosure - Changes in consolidated statements of comprehensive income (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails">
            <link:definition>2402000 - Disclosure - Provisions and other non-current liabilities (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails" roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails">
            <link:definition>2402600 - Disclosure - Equity-based participation plans for associates (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails2" roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2">
            <link:definition>2402601 - Disclosure - Equity-based participation plans for associates (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails3" roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3">
            <link:definition>2402602 - Disclosure - Equity-based participation plans for associates (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails4" roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4">
            <link:definition>2402603 - Disclosure - Equity-based participation plans for associates (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails5" roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5">
            <link:definition>2402604 - Disclosure - Equity-based participation plans for associates (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails6" roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6">
            <link:definition>2402605 - Disclosure - Equity-based participation plans for associates (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails7" roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails7">
            <link:definition>2402606 - Disclosure - Equity-based participation plans for associates (Details 7)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails8" roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails8">
            <link:definition>2402607 - Disclosure - Equity-based participation plans for associates (Details 8)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails9" roleURI="http://novartis.com/20201231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails9">
            <link:definition>2402608 - Disclosure - Equity-based participation plans for associates (Details 9)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedPartiesDetails" roleURI="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedPartiesDetails">
            <link:definition>2041200 - Disclosure - Transactions with related parties (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedPartiesDetails2" roleURI="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedPartiesDetails2">
            <link:definition>2402701 - Disclosure - Transactions with related parties (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedPartiesDetails3" roleURI="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedPartiesDetails3">
            <link:definition>2402702 - Disclosure - Transactions with related parties (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails" roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails">
            <link:definition>2402900 - Disclosure - Financial instruments - additional disclosures (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssetsDetails3" roleURI="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssetsDetails3">
            <link:definition>2401102 - Disclosure - Goodwill and intangible assets (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssetsDetails4" roleURI="http://novartis.com/20201231/role/DisclosureGoodwillAndIntangibleAssetsDetails4">
            <link:definition>2401103 - Disclosure - Goodwill and intangible assets (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType>
		 <link:roleType id="disclosureSegmentationOfKeyFiguresDetails2" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails2">
            <link:definition>2400302 - Disclosure - Segmentation of key figures (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails3" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails3">
            <link:definition>2400303 - Disclosure - Segmentation of key figures (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails4" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails4">
            <link:definition>2400304 - Disclosure - Segmentation of key figures (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails5" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails5">
            <link:definition>2400305 - Disclosure - Segmentation of key figures (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails6" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails6">
            <link:definition>2400306 - Disclosure - Segmentation of key figures (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails7" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails7">
            <link:definition>2400308 - Disclosure - Segmentation of key figures (Details 8)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesDetails2" roleURI="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails2">
            <link:definition>2400401 - Disclosure - Associated companies (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesDetails3" roleURI="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails3">
            <link:definition>2400402 - Disclosure - Associated companies (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesDetails4" roleURI="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails4">
            <link:definition>2400403 - Disclosure - Associated companies (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesDetails5" roleURI="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails5">
            <link:definition>2400404 - Disclosure - Associated companies (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesDetails6" roleURI="http://novartis.com/20201231/role/DisclosureAssociatedCompaniesDetails6">
            <link:definition>2400405 - Disclosure - Associated companies (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2" roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2">
            <link:definition>2402001 - Disclosure - Provisions and other non-current liabilities (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3" roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3">
            <link:definition>2402002 - Disclosure - Provisions and other non-current liabilities (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4" roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4">
            <link:definition>2402003 - Disclosure - Provisions and other non-current liabilities (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5">
            <link:definition>2402004 - Disclosure - Provisions and other non-current liabilities (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails6" roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails6">
            <link:definition>2402005 - Disclosure - Provisions and other non-current liabilities (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquity" roleURI="http://novartis.com/20201231/role/DisclosureEquity">
            <link:definition>2101800 - Disclosure - Equity</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityTables" roleURI="http://novartis.com/20201231/role/DisclosureEquityTables">
            <link:definition>2301800 - Disclosure - Equity (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityDetails" roleURI="http://novartis.com/20201231/role/DisclosureEquityDetails">
            <link:definition>2401800 - Disclosure - Equity (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityDetails2" roleURI="http://novartis.com/20201231/role/DisclosureEquityDetails2">
            <link:definition>2401801 - Disclosure - Equity (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityDetails3" roleURI="http://novartis.com/20201231/role/DisclosureEquityDetails3">
            <link:definition>2401802 - Disclosure - Equity (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityDetails4" roleURI="http://novartis.com/20201231/role/DisclosureEquityDetails4">
            <link:definition>2401803 - Disclosure - Equity (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementsOfCashFlowParenthetical" roleURI="http://novartis.com/20201231/role/StatementsOfCashFlowParenthetical">
            <link:definition>1005010 - Statement - Consolidated cash flow statements (Parenthetical)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails1" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails1">
            <link:definition>2400301 - Disclosure - Segmentation of key figures (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityDetails5" roleURI="http://novartis.com/20201231/role/DisclosureEquityDetails5">
            <link:definition>2401804 - Disclosure - Equity (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails5" roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5">
            <link:definition>2402305 - Disclosure - Details to the consolidated cash flow statements (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails2" roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2">
            <link:definition>2402901 - Disclosure - Financial instruments - additional disclosures (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails3" roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3">
            <link:definition>2402902 - Disclosure - Financial instruments - additional disclosures (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails4" roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4">
            <link:definition>2402903 - Disclosure - Financial instruments - additional disclosures (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:labelLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails5" roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5">
            <link:definition>2402904 - Disclosure - Financial instruments - additional disclosures (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails6" roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6">
            <link:definition>2402905 - Disclosure - Financial instruments - additional disclosures (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails7" roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7">
            <link:definition>2402906 - Disclosure - Financial instruments - additional disclosures (Details 7)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails8" roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8">
            <link:definition>2402907 - Disclosure - Financial instruments - additional disclosures (Details 8)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails9" roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9">
            <link:definition>2402908 - Disclosure - Financial instruments - additional disclosures (Details 9)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails10" roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10">
            <link:definition>2402909 - Disclosure - Financial instruments - additional disclosures (Details 10)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails11" roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11">
            <link:definition>2402910 - Disclosure - Financial instruments - additional disclosures (Details 11)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails12" roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12">
            <link:definition>2402911 - Disclosure - Financial instruments - additional disclosures (Details 12)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails13" roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13">
            <link:definition>2402912 - Disclosure - Financial instruments - additional disclosures (Details 13)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilitiesDetails5" roleURI="http://novartis.com/20201231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5">
            <link:definition>2401204 - Disclosure - Deferred tax assets and liabilities (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantAccountingPoliciesDetails3" roleURI="http://novartis.com/20201231/role/DisclosureSignificantAccountingPoliciesDetails3">
            <link:definition>2400102 - Disclosure - Significant accounting policies (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureBasisOfPreparationQ" roleURI="http://novartis.com/20201231/role/DisclosureBasisOfPreparationQ">
            <link:definition>2010100 - Disclosure - Basis of preparation</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSelectedCriticalAccountingPoliciesQ" roleURI="http://novartis.com/20201231/role/DisclosureSelectedCriticalAccountingPoliciesQ">
            <link:definition>2010200 - Disclosure - Selected critical accounting policies</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsQ" roleURI="http://novartis.com/20201231/role/DisclosureSignificantTransactionsQ">
            <link:definition>2010300 - Disclosure - Significant transactions</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSummaryOfEquityToShareholdersQ" roleURI="http://novartis.com/20201231/role/DisclosureSummaryOfEquityToShareholdersQ">
            <link:definition>2010400 - Disclosure - Summary of equity attributable to Novartis AG shareholders</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsQ" roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsQ">
            <link:definition>2010500 - Disclosure - Financial instruments</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLegalProceedingsUpdateQ" roleURI="http://novartis.com/20201231/role/DisclosureLegalProceedingsUpdateQ">
            <link:definition>2010800 - Disclosure - Legal proceedings update</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsQ" roleURI="http://novartis.com/20201231/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsQ">
            <link:definition>2102900 - Disclosure - Impacts of adoption of new IFRS standards</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSubsequentEventsQ" roleURI="http://novartis.com/20201231/role/DisclosureSubsequentEventsQ">
            <link:definition>2011100 - Disclosure - Subsequent events</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresQ" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresQ">
            <link:definition>2010900 - Disclosure - Segmentation of key figures</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSelectedCriticalAccountingPoliciesPoliciesQ" roleURI="http://novartis.com/20201231/role/DisclosureSelectedCriticalAccountingPoliciesPoliciesQ">
            <link:definition>2020200 - Disclosure - Selected critical accounting policies (Policies)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSummaryOfEquityToShareholdersTablesQ" roleURI="http://novartis.com/20201231/role/DisclosureSummaryOfEquityToShareholdersTablesQ">
            <link:definition>2030400 - Disclosure - Summary of equity attributable to Novartis AG shareholders (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsTablesQ" roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsTablesQ">
            <link:definition>2030500 - Disclosure - Financial instruments (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsTablesQ" roleURI="http://novartis.com/20201231/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsTablesQ">
            <link:definition>2302900 - Disclosure - Impacts of adoption of new IFRS standards (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresTablesQ" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresTablesQ">
            <link:definition>2031000 - Disclosure - Segmentation of key figures (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSelectedCriticalAccountingPoliciesDetailsQ" roleURI="http://novartis.com/20201231/role/DisclosureSelectedCriticalAccountingPoliciesDetailsQ">
            <link:definition>2040200 - Disclosure - Selected critical accounting policies (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsDetailsQ" roleURI="http://novartis.com/20201231/role/DisclosureSignificantTransactionsDetailsQ">
            <link:definition>2040300 - Disclosure - Significant transactions (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSummaryOfEquityToShareholdersDetailsQ" roleURI="http://novartis.com/20201231/role/DisclosureSummaryOfEquityToShareholdersDetailsQ">
            <link:definition>2040400 - Disclosure - Summary of equity attributable to Novartis AG shareholders (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsDetailsQ" roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsDetailsQ">
            <link:definition>2040500 - Disclosure - Financial instruments (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsDetails2Q" roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsDetails2Q">
            <link:definition>2040501 - Disclosure - Financial instruments (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsDetailsQ" roleURI="http://novartis.com/20201231/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsDetailsQ">
            <link:definition>2402900 - Disclosure - Impacts of adoption of new IFRS standards (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsDetails2Q" roleURI="http://novartis.com/20201231/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsDetails2Q">
            <link:definition>2402901 - Disclosure - Impacts of adoption of new IFRS standards (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetailsQ" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetailsQ">
            <link:definition>2040900 - Disclosure - Segmentation of key figures (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails2Q" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails2Q">
            <link:definition>2040901 - Disclosure - Segmentation of key figures (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails3Q" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails3Q">
            <link:definition>2040902 - Disclosure - Segmentation of key figures (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails4Q" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails4Q">
            <link:definition>2040903 - Disclosure - Segmentation of key figures (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails5Q" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails5Q">
            <link:definition>2040904 - Disclosure - Segmentation of key figures (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails6Q" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails6Q">
            <link:definition>2040905 - Disclosure - Segmentation of key figures (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails7Q" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails7Q">
            <link:definition>2040906 - Disclosure - Segmentation of key figures (Details 7)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails8Q" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails8Q">
            <link:definition>2040907 - Disclosure - Segmentation of key figures (Details 8)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails9Q" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails9Q">
            <link:definition>2040908 - Disclosure - Segmentation of key figures (Details 9)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsDetails3Q" roleURI="http://novartis.com/20201231/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsDetails3Q">
            <link:definition>2402902 - Disclosure - Impacts of adoption of new IFRS standards (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsDetails4Q" roleURI="http://novartis.com/20201231/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsDetails4Q">
            <link:definition>2402903 - Disclosure - Impacts of adoption of new IFRS standards (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsDetails3Q" roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsDetails3Q">
            <link:definition>2040502 - Disclosure - Financial instruments (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsDetails4Q" roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsDetails4Q">
            <link:definition>2040503 - Disclosure - Financial instruments (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedPartiesDetails1_1df9063b" roleURI="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedPartiesDetails1">
            <link:definition>2402700 - Disclosure - Transaction with related parties (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsDetails5Q" roleURI="http://novartis.com/20201231/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsDetails5Q">
            <link:definition>2402904 - Disclosure - Impacts of adoption of new IFRS standards (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedPartiesDetailsQ" roleURI="http://novartis.com/20201231/role/DisclosureTransactionsWithRelatedPartiesDetailsQ">
            <link:definition>2011100 - Disclosure - Transactions with related parties</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails8" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails8">
            <link:definition>2400310 - Disclosure - Segmentation of key figures (Details 10)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails9" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails9">
            <link:definition>2400312 - Disclosure - Segmentation of key figures (Details 12)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails10" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails10">
            <link:definition>2400311 - Disclosure - Segmentation of key figures (Details 11)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDisposalGroupHeldForSaleDetails" roleURI="http://novartis.com/20201231/role/DisclosureDisposalGroupHeldForSaleDetails">
            <link:definition>2400202 - Disclosure - Significant transactions (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails14" roleURI="http://novartis.com/20201231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14">
            <link:definition>2402913 - Disclosure - Financial instruments - additional disclosures (Details 14)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsTables" roleURI="http://novartis.com/20201231/role/DisclosureSignificantTransactionsTables">
            <link:definition>2300200 - Disclosure - Significant transactions (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails11" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails11">
            <link:definition>2400309 - Disclosure - Segmentation of key figures - Top 20 (Details 9)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails12" roleURI="http://novartis.com/20201231/role/DisclosureSegmentationOfKeyFiguresDetails12">
            <link:definition>2400307 - Disclosure - Segmentation of key figures - Net sales by region (Details 7)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails6" roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6">
            <link:definition>2402302 - Disclosure - Details to the consolidated cash flow statements (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsQ" roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsQ">
            <link:definition>2011000 - Disclosure - Discontinued operations</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsQ" roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsQ">
            <link:definition>2010600 - Disclosure - Lease liabilities and right-of-use assets</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedStatementsCashFlowsQ" roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedStatementsCashFlowsQ">
            <link:definition>2010600 - Disclosure - Details to the consolidated statements of cash flows</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsTablesQ" roleURI="http://novartis.com/20201231/role/DisclosureSignificantTransactionsTablesQ">
            <link:definition>2030300 - Disclosure - Significant transactions (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsTablesQ" roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsTablesQ">
            <link:definition>2030600 - Disclosure - Lease liability and Right-of-use assets (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedStatementsCashFlowsTablesQ" roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedStatementsCashFlowsTablesQ">
            <link:definition>2030600 - Disclosure - Details to the consolidated statements of cash flows (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsTablesQ" roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsTablesQ">
            <link:definition>2031100 - Disclosure - Discontinued operations (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetailsQ" roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetailsQ">
            <link:definition>2040600 - Disclosure - Lease liability and Right-of-use assets (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails1Q" roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails1Q">
            <link:definition>2040601 - Disclosure - Lease liability and Right-of-use assets (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails2Q" roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2Q">
            <link:definition>2040602 - Disclosure - Lease liability and Right-of-use assets (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails3Q" roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3Q">
            <link:definition>2040603 - Disclosure - Lease liability and Right-of-use assets (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsDetails1Q" roleURI="http://novartis.com/20201231/role/DisclosureSignificantTransactionsDetails1Q">
            <link:definition>2040301 - Disclosure - Significant transactions (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetailsQ" roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetailsQ">
            <link:definition>2041000 - Disclosure - Discontinued operations (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedStatementsCashFlowsDetailsQ" roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetailsQ">
            <link:definition>2040600 - Disclosure - Details to the consolidated statements of cash flows (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedStatementsCashFlowsDetails1Q" roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetails1Q">
            <link:definition>2040601 - Disclosure - Details to the consolidated statements of cash flows (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionOfBusinessesQ" roleURI="http://novartis.com/20201231/role/DisclosureAcquisitionOfBusinessesQ">
            <link:definition>2010700 - Disclosure - Acquisition of businesses</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionOfBusinessesTablesQ" roleURI="http://novartis.com/20201231/role/DisclosureAcquisitionOfBusinessesTablesQ">
            <link:definition>2030800 - Disclosure - Acquisition of businesses (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionOfBusinessesDetailsQ" roleURI="http://novartis.com/20201231/role/DisclosureAcquisitionOfBusinessesDetailsQ">
            <link:definition>2040701 - Disclosure - Acquisition of businesses (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails1Q" roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails1Q">
            <link:definition>2041001 - Disclosure - Discontinued operations (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails2Q" roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails2Q">
            <link:definition>2041002 - Disclosure - Discontinued operations (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails4Q" roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4Q">
            <link:definition>2040604 - Disclosure - Lease liability and Right-of-use assets (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails5Q" roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5Q">
            <link:definition>2040605 - Disclosure - Lease liability and Right-of-use assets (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType>
		 <link:roleType id="disclosureSignificantTransactionsDetails2Q" roleURI="http://novartis.com/20201231/role/DisclosureSignificantTransactionsDetails2Q">
            <link:definition>2040302 - Disclosure - Significant transactions (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails3Q" roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails3Q">
            <link:definition>2041003 - Disclosure - Discontinued operations (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureRightOfUseAssetsAndLeaseLiability" roleURI="http://novartis.com/20201231/role/DisclosureRightOfUseAssetsAndLeaseLiability">
            <link:definition>2101000 - Disclosure - Right-of-use assets and lease liabilities</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureRightOfUseAssetsAndLeaseLiabilityTables" roleURI="http://novartis.com/20201231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables">
            <link:definition>2301000 - Disclosure - Right-of-use assets and lease liabilities (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsDetails2" roleURI="http://novartis.com/20201231/role/DisclosureSignificantTransactionsDetails2">
            <link:definition>2400201 - Disclosure - Significant transactions (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails3" roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails3">
            <link:definition>2403005 - Disclosure - Discontinued operations (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails4" roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails4">
            <link:definition>2403003 - Disclosure - Discontinued operations (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails" roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails">
            <link:definition>2401000 - Disclosure - Lease liability and Right-of-use assets (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails2" roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2">
            <link:definition>2401001 - Disclosure - Lease liability and Right-of-use assets (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails3" roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3">
            <link:definition>2401002 - Disclosure - Lease liability and Right-of-use assets (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails4" roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4">
            <link:definition>2401003 - Disclosure - Lease liability and Right-of-use assets (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails5" roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5">
            <link:definition>2401004 - Disclosure - Lease liability and Right-of-use assets (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails6" roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6">
            <link:definition>2401005 - Disclosure - Lease liability and Right-of-use assets (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails5" roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails5">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2403004 - Disclosure - Discontinued operations (Details 5)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails6" roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails6">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2403002 - Disclosure - Discontinued operations (Details 3)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails7" roleURI="http://novartis.com/20201231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails7">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2401006 - Disclosure - Lease liability and Right-of-use assets (Details 7)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails7" roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails7">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2403006 - Disclosure - Discontinued operations (Details 7)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails8" roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails8">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2403007 - Disclosure - Discontinued operations (Details 8)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedStatementsCashFlowsDetails2Q" roleURI="http://novartis.com/20201231/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetails2Q">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2040602 - Disclosure - Details to the consolidated statements of cash flows (Details 3)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionOfBusinessesDetails2Q" roleURI="http://novartis.com/20201231/role/DisclosureAcquisitionOfBusinessesDetails2Q">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2040702 - Disclosure - Acquisition of businesses (Details 2)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails1Q" roleURI="http://novartis.com/20201231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails1Q">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2040800 - Disclosure - Provisions and other non-current liabilities (Details)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails9" roleURI="http://novartis.com/20201231/role/DisclosureDiscontinuedOperationsDetails9">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2403008 - Disclosure - Discontinued operations (Details 9)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSubsequentEventsDetails2" roleURI="http://novartis.com/20201231/role/DisclosureSubsequentEventsDetails2">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2403101 - Disclosure - Events subsequent to the December 31 consolidated balance sheet date (Details 2)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementOfIncomeCalc2" roleURI="http://novartis.com/20201231/role/StatementOfIncomeCalc2">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">1001000 - Statement - Consolidated income statements (Calc 2)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementOfComprehensiveIncomeCalc2" roleURI="http://novartis.com/20201231/role/StatementOfComprehensiveIncomeCalc2">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">1002000 - Statement - Consolidated statements of comprehensive income (Calc 2)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType></xsd:appinfo>
   </xsd:annotation>
   <xsd:element abstract="true" id="nvs_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" name="NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_StatementTable" name="StatementTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_StatementLineItems" name="StatementLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PropertyPlantAndEquipmentTableTextBlock" name="PropertyPlantAndEquipmentTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoriesDisclosureAbstract" name="InventoriesDisclosureAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfInventoryCurrentTableTextBlock" name="ScheduleOfInventoryCurrentTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryCurrentTable" name="InventoryCurrentTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryAxis" name="InventoryAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryMember" name="InventoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryRawMaterialsGrossMember" name="InventoryRawMaterialsGrossMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryWorkInProgressGrossMember" name="InventoryWorkInProgressGrossMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryFinishedGoodsGrossMember" name="InventoryFinishedGoodsGrossMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryLineItems" name="InventoryLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" name="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" name="DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AssumptionsUsedInTheCalculationOfValuationTextBlock" name="AssumptionsUsedInTheCalculationOfValuationTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" name="AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfIncomeTaxAbstract" name="DisclosureOfIncomeTaxAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncomeBeforeTaxesTableTextBlock" name="IncomeBeforeTaxesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" name="CurrentAndDeferredIncomeTaxExpenseTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AnalysisOfTaxRateTableTextBlock" name="AnalysisOfTaxRateTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" name="DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_InterestExpenseTableTextBlock" name="InterestExpenseTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherFinancialIncomeAndExpenseTableTextBlock" name="OtherFinancialIncomeAndExpenseTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" name="DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" name="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" name="TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SignificantAccountingPoliciesAbstract" name="SignificantAccountingPoliciesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" name="RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" name="RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" name="DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" name="DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" name="DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" name="DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FurnitureAndVehiclesMember" name="FurnitureAndVehiclesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MarketingRelatedIntangibleAssetsMember" name="MarketingRelatedIntangibleAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentlyMarketedProductsMember" name="CurrentlyMarketedProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IncomeStatementLocationAxis" name="IncomeStatementLocationAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IncomeStatementLocationMember" name="IncomeStatementLocationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CostOfSalesMember" name="CostOfSalesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CostOfSalesOrResearchAndDevelopmentMember" name="CostOfSalesOrResearchAndDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InterestExpenseAbstract" name="InterestExpenseAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherFinancialIncomeAndExpenseAbstract" name="OtherFinancialIncomeAndExpenseAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncomeOnForwardContractsAndOptions" name="IncomeOnForwardContractsAndOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncomeTaxExpense" name="IncomeTaxExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectOfCreditsAndAllowances" name="TaxRateEffectOfCreditsAndAllowances" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectOfWriteOffOfDeferredTaxAssets" name="TaxRateEffectOfWriteOffOfDeferredTaxAssets" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" name="TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectFromBenefitsExpiring" name="TaxRateEffectFromBenefitsExpiring" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AverageEffectiveTaxRateContinuingOperations" name="AverageEffectiveTaxRateContinuingOperations" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AverageEffectiveTaxRateDiscontinuedOperations" name="AverageEffectiveTaxRateDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PensionsAndOtherBenefitObligationsOfAssociatesMember" name="PensionsAndOtherBenefitObligationsOfAssociatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoriesMember" name="InventoriesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TaxLossCarryforwardsMember" name="TaxLossCarryforwardsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" name="IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" name="OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedAbstract" name="TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InvestmentsInSubsidiariesMember" name="InvestmentsInSubsidiariesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GoodwillFromAcquisitionsMember" name="GoodwillFromAcquisitionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BalanceSheetTreatmentAxis" name="BalanceSheetTreatmentAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BalanceSheetTreatmentMember" name="BalanceSheetTreatmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CapitalizedMember" name="CapitalizedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NotCapitalizedMember" name="NotCapitalizedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_YearOfExpiryAxis" name="YearOfExpiryAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_YearOfExpiryMember" name="YearOfExpiryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OneYearMember" name="OneYearMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TwoYearsMember" name="TwoYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ThreeYearsMember" name="ThreeYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FourYearsMember" name="FourYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FiveYearsMember" name="FiveYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MoreThanFiveYearsMember" name="MoreThanFiveYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ValueOfTaxLossCarryforwardsExpired" name="ValueOfTaxLossCarryforwardsExpired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" name="DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" name="DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" name="UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProvisionForIncomeTaxesOnUnremittedEarnings" name="ProvisionForIncomeTaxesOnUnremittedEarnings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" name="DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" name="DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfFinancialAssetsTableTextBlock" name="DisclosureOfFinancialAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOtherNoncurrentAssetsTableTextBlock" name="DisclosureOfOtherNoncurrentAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" name="DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherCurrentAssetsAbstract" name="OtherCurrentAssetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherCurrentAssetsTableTextBlock" name="OtherCurrentAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_WithholdingTaxRecoverable" name="WithholdingTaxRecoverable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CurrentPrepaidExpensesAssociatedCompanies" name="CurrentPrepaidExpensesAssociatedCompanies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ReceivablesAssociatedCompanies" name="ReceivablesAssociatedCompanies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OtherReceivablesAndCurrentAssets" name="OtherReceivablesAndCurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" name="DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" name="DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" name="MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashAndCashEquivalentsTableTextBlock" name="CashAndCashEquivalentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FundInstrumentsHeld" name="FundInstrumentsHeld" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DebtSecuritiesDenominationsAbstract" name="DebtSecuritiesDenominationsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MovementInDeferredTaxBalanceRollForward" name="MovementInDeferredTaxBalanceRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationReceivable" name="ContingentConsiderationReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfOtherNoncurrentAssetsAbstract" name="DisclosureOfOtherNoncurrentAssetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DeferredCompensationPlansAssets" name="DeferredCompensationPlansAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PrepaidPostemploymentBenefitPlansAssets" name="PrepaidPostemploymentBenefitPlansAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FinanceLeaseProvision" name="FinanceLeaseProvision" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_MovementInTheShareCapitalTableTextBlock" name="MovementInTheShareCapitalTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MovementInTheShareslTableTextBlock" name="MovementInTheShareslTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SubsequentEventTypAxis" name="SubsequentEventTypAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SubsequentEventTypeMember" name="SubsequentEventTypeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SubsequentEventMember" name="SubsequentEventMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CommitmentsAndContingenciesAbstract" name="CommitmentsAndContingenciesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfCommitmentsAndContingenciesTextBlock" name="DisclosureOfCommitmentsAndContingenciesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfSignificantTransactionsAbstract" name="DisclosureOfSignificantTransactionsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfSignificantTransactionsTextBlock" name="DisclosureOfSignificantTransactionsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" name="DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" name="DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" name="DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" name="DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" name="DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" name="DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" name="DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" name="DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" name="DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfLeasingCommitmentsTableTextBlock" name="DisclosureOfLeasingCommitmentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" name="DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LeasingCommitmentsAbstract" name="LeasingCommitmentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" name="ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" name="ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ResearchAndDevelopmentCommitmentsAbstract" name="ResearchAndDevelopmentCommitmentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" name="ScheduleForCommitmentsUnderResearchAndDevelopmentTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" name="ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CommitmentsUnderLongtermResearchAgreements" name="CommitmentsUnderLongtermResearchAgreements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" name="CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" name="CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_InterestBearningAccountsOfAssociatesPayableOnDemand" name="InterestBearningAccountsOfAssociatesPayableOnDemand" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" name="DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" name="DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" name="DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LaterThanFiveYearsAndNotLaterThanSixYearsMember" name="LaterThanFiveYearsAndNotLaterThanSixYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LaterThanSixYearsMember" name="LaterThanSixYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" name="DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" name="DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" name="DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NoncurrentFinancialDebtsCoveredByCollateral" name="NoncurrentFinancialDebtsCoveredByCollateral" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" name="A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" name="A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" name="A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" name="A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" name="A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" name="A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" name="A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" name="A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" name="A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" name="A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" name="A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" name="A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" name="A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" name="A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" name="A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsLender" name="BorrowingsLender" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsPremiumDiscount" name="BorrowingsPremiumDiscount" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherNoncurrentFinancialDebt" name="OtherNoncurrentFinancialDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_FairValueByMeasurementBasisAxis" name="FairValueByMeasurementBasisAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueByMeasurementBasisMember" name="FairValueByMeasurementBasisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CarryingReportedAmountFairValueDisclosureMember" name="CarryingReportedAmountFairValueDisclosureMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueDisclosureItemAmountsMember" name="FairValueDisclosureItemAmountsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" name="OtherComprehensiveIncomeNetOfTaxFinancialInstruments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" name="IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueAdjustmentsRelatedToDivestments" name="FairValueAdjustmentsRelatedToDivestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" name="PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" name="ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" name="PurchaseOfFinancialAssetsClassifiedAsInvestingActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" name="ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" name="ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges" name="CashFlowsBeforeWorkingCapitalAndProvisionChanges" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" name="A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsIssuanceDate" name="BorrowingsIssuanceDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrencyOthersMember" name="CurrencyOthersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OperatingIncomeMember" name="OperatingIncomeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TranscendMedicalIncMember" name="TranscendMedicalIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SelexysPharmaceuticalsCorporationMember" name="SelexysPharmaceuticalsCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZiarcoGroupLimitedMember" name="ZiarcoGroupLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EncoreVisionIncMember" name="EncoreVisionIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EliLillyAndCompanyMember" name="EliLillyAndCompanyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GSKOncologyProductsMember" name="GSKOncologyProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GSKVaccinesMember" name="GSKVaccinesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GSKConsumerHealthcareMember" name="GSKConsumerHealthcareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GSKTotalTransactionMember" name="GSKTotalTransactionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CSLMember" name="CSLMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SpinifexMember" name="SpinifexMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdmuneTheraputicsMember" name="AdmuneTheraputicsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" name="BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" name="DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" name="DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfAcquisitionOfBusinessesAbstract" name="DisclosureOfAcquisitionOfBusinessesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" name="ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProvisionsForReductionOfRevenueTableTextBlock" name="ProvisionsForReductionOfRevenueTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RestructuringProvisionsMovementsTableTextBlock" name="RestructuringProvisionsMovementsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" name="FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfDefinedBenefitPlansTableTextBlock" name="DisclosureOfDefinedBenefitPlansTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" name="DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" name="BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfAssumptionsUsedTableTextBlock" name="ScheduleOfAssumptionsUsedTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" name="ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock" name="ScheduleOfHealthCareCostTrendRatesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock" name="ScheduleOfAllocationOfPlanAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock" name="ScheduleOfExpectedBenefitPaymentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" name="AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" name="AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" name="CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" name="AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" name="OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" name="TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PotentiallyRefundableConsiderationFromAcquisition" name="PotentiallyRefundableConsiderationFromAcquisition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueOfAcquireeFullYear" name="RevenueOfAcquireeFullYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" name="SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" name="SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" name="SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" name="SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SaleOfBusinessContingentOptionArrangementsFeePaid" name="SaleOfBusinessContingentOptionArrangementsFeePaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PercentageOfVotingEquityInterestsContributed" name="PercentageOfVotingEquityInterestsContributed" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionRelatedCosts" name="TransactionRelatedCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionRelatedCostsPaid" name="TransactionRelatedCostsPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProvisionsAndOtherCurrentLiabilitiesLineItems" name="ProvisionsAndOtherCurrentLiabilitiesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccrualForTaxesOtherThanIncomeTaxesCurrent" name="AccrualForTaxesOtherThanIncomeTaxesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AccruedRoyaltiesPayableClassifiedAsCurrent" name="AccruedRoyaltiesPayableClassifiedAsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ProvisionsForDeductionsFromRevenueRollForward" name="ProvisionsForDeductionsFromRevenueRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ChangesInOffsetAgainstGrossTradeReceivables" name="ChangesInOffsetAgainstGrossTradeReceivables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RestructuringProvisionsMovementsRollForward" name="RestructuringProvisionsMovementsRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfTradeReceivablesAbstract" name="DisclosureOfTradeReceivablesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfTradeReceivablesExplanatoryTextBlock" name="DisclosureOfTradeReceivablesExplanatoryTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProvisionsForTradeReceivablesTableTextBlock" name="ProvisionsForTradeReceivablesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TradeReceivablesProvisionMovementsTableTextBlock" name="TradeReceivablesProvisionMovementsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OverdueAmountsAndRelatedProvisionsTableTextBlock" name="OverdueAmountsAndRelatedProvisionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" name="TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AnalysisOfOverdueAmountsTable" name="AnalysisOfOverdueAmountsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AnalysisOfOverdueAmountsLineItems" name="AnalysisOfOverdueAmountsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" name="DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentTradeReceivablesFromCloselyMonitoredCountries" name="CurrentTradeReceivablesFromCloselyMonitoredCountries" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" name="CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" name="PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharePaidinCapital" name="SharePaidinCapital" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_NovartisArgentinaS.A.BuenosAiresMember" name="NovartisArgentinaS.A.BuenosAiresMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriosS.A.BuenosAiresMember" name="AlconLaboratoriosS.A.BuenosAiresMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RocheHoldingAGBaselMember" name="RocheHoldingAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ConcentrationOfMajorPlansGeographic" name="ConcentrationOfMajorPlansGeographic" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" name="DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RetirementPlanTypeAxis" name="RetirementPlanTypeAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RetirementPlanTypeMember" name="RetirementPlanTypeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PensionPlanMember" name="PensionPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherPostemploymentBenefitPlansMember" name="OtherPostemploymentBenefitPlansMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanInterestCost" name="DefinedBenefitPlanInterestCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" name="IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_InterestExpenseIncomeDefinedBenefitLiabilityAsset" name="InterestExpenseIncomeDefinedBenefitLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset" name="ReturnOnPlanAssetsExcludingInterestIncomeNetDefinedBenefitLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanSettlementsPlanAssets" name="DefinedBenefitPlanSettlementsPlanAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" name="IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward" name="DefinedBenefitPlanChangeInBenefitObligationRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" name="DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" name="DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LimitationOnRecognitionOfFundSurplus" name="LimitationOnRecognitionOfFundSurplus" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ChangeInLimitationOnRecognitionOfFundSurplus" name="ChangeInLimitationOnRecognitionOfFundSurplus" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_InterestIncomeOnLimitationOfFundSurplus" name="InterestIncomeOnLimitationOfFundSurplus" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward" name="DefinedBenefitPlanChangeInNetLiabilityRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" name="IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" name="AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPensionPlanAccruedBenefitLiabilities" name="DefinedBenefitPensionPlanAccruedBenefitLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTable" name="BreakdownOfDefinedBenefitObligationForPensionPlansTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ObligationByTypeAxis" name="ObligationByTypeAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ObligationByTypeMember" name="ObligationByTypeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_UnfundedMember" name="UnfundedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ActiveMember" name="ActiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DeferredPensionersMember" name="DeferredPensionersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PensionersMember" name="PensionersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleOfDefinedBenefitPlansDisclosuresTable" name="ScheduleOfDefinedBenefitPlansDisclosuresTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" name="ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitAssumptionLifeExpectancyMale" name="DefinedBenefitAssumptionLifeExpectancyMale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitAssumptionLifeExpectancyFemale" name="DefinedBenefitAssumptionLifeExpectancyFemale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LifeExpectancyMember" name="LifeExpectancyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" name="ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ChangeInActuarialAssumptionAxis" name="ChangeInActuarialAssumptionAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ChangeInActuarialAssumptionMember" name="ChangeInActuarialAssumptionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Decrease25BasisPointMember" name="Decrease25BasisPointMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Increase25BasisPointMember" name="Increase25BasisPointMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Increase1YearMember" name="Increase1YearMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleOfHealthCareCostTrendRatesTable" name="ScheduleOfHealthCareCostTrendRatesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" name="DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" name="DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" name="DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:gYearItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleOfAllocationOfPlanAssetsTable" name="ScheduleOfAllocationOfPlanAssetsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RealEstateMember" name="RealEstateMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlternativeInvestmentsMember" name="AlternativeInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CashAndOtherInvestmentsMember" name="CashAndOtherInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" name="DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" name="DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanPlanAssetAllocations" name="DefinedBenefitPlanPlanAssetAllocations" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_WeightedAverageDurationOfDefinedBenefitObligationYears" name="WeightedAverageDurationOfDefinedBenefitObligationYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" name="DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" name="DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" name="DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleOfExpectedBenefitPaymentsTable" name="ScheduleOfExpectedBenefitPaymentsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" name="DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" name="DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" name="PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" name="DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_SocieteParActionsSANDOZAlgiersMember" name="SocieteParActionsSANDOZAlgiersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" name="DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" name="AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" name="CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" name="CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsFromDiscontinuedOperationsTableTextBlock" name="CashFlowsFromDiscontinuedOperationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ConsolidatedIncomeStatementSegmentationTableTextBlock" name="ConsolidatedIncomeStatementSegmentationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ExpensesIncludedInNetIncomeTableTextBlock" name="ExpensesIncludedInNetIncomeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueFromSaleOfGoodsSalesToContinuingSegments" name="RevenueFromSaleOfGoodsSalesToContinuingSegments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VaccinesMember" name="VaccinesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ConsumerHealthMember" name="ConsumerHealthMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CorporateMember" name="CorporateMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OperatingIncomeLossOfDiscontinuedOperations" name="OperatingIncomeLossOfDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncomeTaxExpenseOfDiscontinuedOperations" name="IncomeTaxExpenseOfDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" name="AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AcquisitionsAndDivestmentsAxis" name="AcquisitionsAndDivestmentsAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AcquisitionsAndDivestmentsMember" name="AcquisitionsAndDivestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AcquisitionsMember" name="AcquisitionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DivestmentsMember" name="DivestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowCurrencyTranslationEffects" name="CashInflowOutflowCurrencyTranslationEffects" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowAcquiredDivestedLiquity" name="CashInflowOutflowAcquiredDivestedLiquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet" name="CashProvidedByRefinancingOfIntercompanyFinancialDebtNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowGoodwill" name="CashInflowOutflowGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowDivestmentGainLoss" name="CashInflowOutflowDivestmentGainLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows" name="TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReceivablesAndPayablesContingentConsiderationNet" name="ReceivablesAndPayablesContingentConsiderationNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherPaymentsAndDeferredConsiderationNet" name="OtherPaymentsAndDeferredConsiderationNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DeferredPrepaidPortionOfSalesPrice" name="DeferredPrepaidPortionOfSalesPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationPaid" name="ContingentConsiderationPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Change25BasisPointMember" name="Change25BasisPointMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DividendsPayableAmountPerShare" name="DividendsPayableAmountPerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesAcquiredToBeHeld" name="TreasurySharesAcquiredToBeHeld" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesAcquiredToBeCancelled" name="TreasurySharesAcquiredToBeCancelled" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherSharePurchases" name="OtherSharePurchases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharepurchaseOfTreasuryShares" name="SharepurchaseOfTreasuryShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesAcquiredToBeHeldValue" name="TreasurySharesAcquiredToBeHeldValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesAcquiredForCancellationValue" name="TreasurySharesAcquiredForCancellationValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" name="ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfComprehensiveIncomeTableTextBlock" name="ScheduleOfComprehensiveIncomeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" name="ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" name="FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" name="ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OfficerAndDirectorCompensationTableTextBlock" name="OfficerAndDirectorCompensationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" name="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfSharebasedCompensationActivityTableTextBlock" name="ScheduleOfSharebasedCompensationActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonExecutiveDirectorMember" name="NonExecutiveDirectorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RocheHoldingAGMember" name="RocheHoldingAGMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LucentisMember" name="LucentisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_XolairMember" name="XolairMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetExpenseRoyaltiesCostSharingAndProfitSharing" name="NetExpenseRoyaltiesCostSharingAndProfitSharing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GenentechInc.USAMember" name="GenentechInc.USAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProfDrBrodyMember" name="ProfDrBrodyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProfDrZinkernagelMember" name="ProfDrZinkernagelMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DrAlexKrauerMember" name="DrAlexKrauerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DrDanielVasellaMember" name="DrDanielVasellaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DrJamesBradnerMember" name="DrJamesBradnerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_KeyManagementPersonnelCompensationDailyRate" name="KeyManagementPersonnelCompensationDailyRate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" name="KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_KeyManagementPersonnelCompensationSharesAcquired" name="KeyManagementPersonnelCompensationSharesAcquired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_KeyManagementPersonnelCompensationOwnershipInterestAcquired" name="KeyManagementPersonnelCompensationOwnershipInterestAcquired" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" name="ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueAdjustmentsOnMarketableSecuritiesMember" name="FairValueAdjustmentsOnMarketableSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" name="FairValueAdjustmentsOnDeferredCashFlowHedgesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ActuarialLossesFromDefinedBenefitPlansMember" name="ActuarialLossesFromDefinedBenefitPlansMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CumulativeCurrencyTranslationEffectsMember" name="CumulativeCurrencyTranslationEffectsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" name="ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GainLossOnSaleOfMarketableInvestments" name="GainLossOnSaleOfMarketableInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GainLossOnSaleOfOtherFinancialAssets" name="GainLossOnSaleOfOtherFinancialAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RemeasurementsFromDefinedBenefitPlansLineItems" name="RemeasurementsFromDefinedBenefitPlansLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InnovativeMedicinesMember" name="InnovativeMedicinesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozMember" name="SandozMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconMember" name="AlconMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationAnnualIncentivePlanMember" name="EquityBasedParticipationAnnualIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationShareSavingsPlanMember" name="EquityBasedParticipationShareSavingsPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationLeveragedShareSavingsPlanMember" name="EquityBasedParticipationLeveragedShareSavingsPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationEmployeeShareOwnershipPlanMember" name="EquityBasedParticipationEmployeeShareOwnershipPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationUKShareSavingsPlanMember" name="EquityBasedParticipationUKShareSavingsPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" name="EquityBasedParticipationNovartisEquityPlanSelectMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationLongTermPerformancePlanMember" name="EquityBasedParticipationLongTermPerformancePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationLongTermRelativePerformancePlanMember" name="EquityBasedParticipationLongTermRelativePerformancePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationSpecialShareAwardsMember" name="EquityBasedParticipationSpecialShareAwardsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" name="DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationRestrictedSharesMember" name="EquityBasedParticipationRestrictedSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" name="OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" name="OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" name="OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_KeyManagementPersonnelCompensationSharesAcquiredPrice" name="KeyManagementPersonnelCompensationSharesAcquiredPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ValueAdjustmentOnComprehensiveIncome" name="ValueAdjustmentOnComprehensiveIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome" name="GainsLossesOnValueAdjustmentOnComprehensiveIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="TotalValueAdjustmentsAttributableToNovartisShareholdersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" name="AlconInc.EquityPlanConvertedNovartisShareOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" name="AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" name="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonvestingAxis" name="NonvestingAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonvestingMember" name="NonvestingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonvestedSharesGrantedMember" name="NonvestedSharesGrantedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" name="RevenueFromSaleOfGoodsSalesToOtherSegments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" name="ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetOperatingAssets" name="NetOperatingAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" name="CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FinancialDebtsAndDerivativeInstruments" name="FinancialDebtsAndDerivativeInstruments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CurrentIncomeTaxAndDeferredTaxLiabilities" name="CurrentIncomeTaxAndDeferredTaxLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_SelectedNoncurrentAssets" name="SelectedNoncurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_OtherCountriesMember" name="OtherCountriesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AsiaAfricaAustralasiaMember" name="AsiaAfricaAustralasiaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LargestCustomerMember" name="LargestCustomerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SecondLargestCustomerMember" name="SecondLargestCustomerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ThirdLargestCustomerMember" name="ThirdLargestCustomerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" name="DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" name="DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock" name="DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfAssociatesBalanceSheetTableTextBlock" name="DisclosureOfAssociatesBalanceSheetTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AssociatesSummarizedFinancialInformationTableTextBlock" name="AssociatesSummarizedFinancialInformationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PurchasePriceAllocationAssociatesTableTextBlock" name="PurchasePriceAllocationAssociatesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" name="GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OthersAssociatesMember" name="OthersAssociatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AssociatesSummarizedFinancialInformationTable" name="AssociatesSummarizedFinancialInformationTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PurchasePriceAllocationAssociatesTable" name="PurchasePriceAllocationAssociatesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ShareOfEstimatedNetAssets" name="ShareOfEstimatedNetAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" name="CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" name="AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ConsolidatedIncomeStatementEffectsTable" name="ConsolidatedIncomeStatementEffectsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ShareOfCurrentYearNetIncome" name="ShareOfCurrentYearNetIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PriorYearAdjustment" name="PriorYearAdjustment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" name="AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" name="TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" name="DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccrualForEnvironmentalLossContingenciesTableTextBlock" name="AccrualForEnvironmentalLossContingenciesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" name="AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" name="AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation" name="OtherLongtermEmployeeBenefitsAndDeferredCompensation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OtherPostemploymentBenefits" name="OtherPostemploymentBenefits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_SolodynMember" name="SolodynMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContactLensesMember" name="ContactLensesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GleevecMember" name="GleevecMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ReclastAclastaMember" name="ReclastAclastaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TekturnaRasilezValturnaMember" name="TekturnaRasilezValturnaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NAGAndNovartisPharmaSpAMember" name="NAGAndNovartisPharmaSpAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FHoffmanLaRocheAGAndRocheSpAMember" name="FHoffmanLaRocheAGAndRocheSpAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaKKMember" name="NovartisPharmaKKMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NAGMember" name="NAGMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NPCAndOthersMember" name="NPCAndOthersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisNCMember" name="NovartisNCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" name="ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" name="ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" name="EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" name="DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" name="DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" name="DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" name="DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" name="DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" name="A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" name="A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" name="A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" name="A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" name="A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" name="TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TotalFairValueAdjustmentsMember" name="TotalFairValueAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentPrepaidExpensesThirdParty" name="CurrentPrepaidExpensesThirdParty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_TaxotereMember" name="TaxotereMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AmiodaroneMember" name="AmiodaroneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfEquityAbstract" name="DisclosureOfEquityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfEquityTextBlock" name="DisclosureOfEquityTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DividendTableTextBlock" name="DividendTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseInNoncontrolingInterests" name="IncreaseDecreaseInNoncontrolingInterests" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfReportableSegments" name="NumberOfReportableSegments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfFranchises" name="NumberOfFranchises" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdditionsToRestructuringProvisions" name="AdditionsToRestructuringProvisions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueFromSaleOfGoodsThirdParties" name="RevenueFromSaleOfGoodsThirdParties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" name="RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" name="SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" name="InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" name="ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxExpenseIncomeDiscontinuingOperations" name="TaxExpenseIncomeDiscontinuingOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" name="EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectiveIncomeTaxRateReconciliationOtherAdjustments" name="EffectiveIncomeTaxRateReconciliationOtherAdjustments" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" name="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" name="OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" name="OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BusinessUnitAxis" name="BusinessUnitAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BusinessUnitMember" name="BusinessUnitMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OncologyMember" name="OncologyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PharmaceuticalMember" name="PharmaceuticalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FranchiseAxis" name="FranchiseAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FranchiseMember" name="FranchiseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NeuroscienceMember" name="NeuroscienceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RespiratoryMember" name="RespiratoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CardioMetabolicMember" name="CardioMetabolicMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EstablishedMedicinesMember" name="EstablishedMedicinesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProductPortfolioMember" name="ProductPortfolioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_COPDMember" name="COPDMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GleevecGlivecMember" name="GleevecGlivecMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TasignaMember" name="TasignaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandostatinMember" name="SandostatinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AfinitorVotubiaMember" name="AfinitorVotubiaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExjadeJadenuMember" name="ExjadeJadenuMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TafinlarMekinistMember" name="TafinlarMekinistMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PromactaRevoladeMember" name="PromactaRevoladeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OphthalmologyMember" name="OphthalmologyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VotrientMember" name="VotrientMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_JakaviMember" name="JakaviMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_KisqaliMember" name="KisqaliMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherProductsMember" name="OtherProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TravoprostGroupMember" name="TravoprostGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SystaneGroupMember" name="SystaneGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TopicalOlopatadineGroupMember" name="TopicalOlopatadineGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CosentyxMember" name="CosentyxMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NeoralSandimmunEMember" name="NeoralSandimmunEMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZortressCerticanMember" name="ZortressCerticanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IlarisMember" name="IlarisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MyforticMember" name="MyforticMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GilenyaMember" name="GilenyaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_UltibroBreezhalerMember" name="UltibroBreezhalerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SeebriBreezhalerMember" name="SeebriBreezhalerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OnbrezBreezhalerMember" name="OnbrezBreezhalerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EntrestoMember" name="EntrestoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VoltarenCataflamMember" name="VoltarenCataflamMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExelonExelonPatchMember" name="ExelonExelonPatchMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RitalinFocalinMember" name="RitalinFocalinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" name="AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccumulatedImpairmentsOnDisposalsAndDerecognitions" name="AccumulatedImpairmentsOnDisposalsAndDerecognitions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AcquiredResearchAndDevelopmentMember" name="AcquiredResearchAndDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconBrandNameMember" name="AlconBrandNameMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" name="GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" name="CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeAvailableforsaleFinancialInvestments" name="OtherComprehensiveIncomeAvailableforsaleFinancialInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeMaketableSecurities" name="OtherComprehensiveIncomeMaketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProvisionForDoubtfulReceivableMember" name="ProvisionForDoubtfulReceivableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" name="CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_Commodities" name="Commodities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OutstandingShareCapital" name="OutstandingShareCapital" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_IssuedCapitalMovement" name="IssuedCapitalMovement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OutstandingShareCapitalMovement" name="OutstandingShareCapitalMovement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharesCancelledForCapitalReduction" name="SharesCancelledForCapitalReduction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesMovement" name="TreasurySharesMovement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EquityImpactOfTreasuryShareMovements" name="EquityImpactOfTreasuryShareMovements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AverageInterestRateOnLoansReceived" name="AverageInterestRateOnLoansReceived" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RatioFixedRateFinancialDebtToTotalFinancialDebt" name="RatioFixedRateFinancialDebtToTotalFinancialDebt" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AverageInterestRateOnBorrowings" name="AverageInterestRateOnBorrowings" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationNonCurrent" name="ContingentConsiderationNonCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_EnvironmentalProvisionRollForward" name="EnvironmentalProvisionRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvision" name="EnvironmentalProvision" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionPayments" name="EnvironmentalProvisionPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionReleases" name="EnvironmentalProvisionReleases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionAdditions" name="EnvironmentalProvisionAdditions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" name="EnvironmentalProvisionForeignCurrencyTranslationGainLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionCurrent" name="EnvironmentalProvisionCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalRemediationProvisionNoncurrent" name="EnvironmentalRemediationProvisionNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_EnvironmentalProvisionFiscalYearMaturityAbstract" name="EnvironmentalProvisionFiscalYearMaturityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" name="EnvironmentalProvisionExpectedCashOutflowNextTwoYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" name="EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" name="EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" name="EnvironmentalProvisionExpectedCashOutflowAfterTenYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_WeightedAverageInterestRateAssociates" name="WeightedAverageInterestRateAssociates" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" name="WeightedAverageInterestRateOnBankAndOtherFinancialDebt" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationCurrentPortion" name="ContingentConsiderationCurrentPortion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ProvisionForDeductionFromRevenueTable" name="ProvisionForDeductionFromRevenueTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProvisionsAndOtherCurrentLiabilitiesTable" name="ProvisionsAndOtherCurrentLiabilitiesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RestructuringProvisionsMovementsTable" name="RestructuringProvisionsMovementsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RestructuringProvisionTransfers" name="RestructuringProvisionTransfers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" name="TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_IdentifiableAssetsAcquired" name="IdentifiableAssetsAcquired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashFlowFromNetIdentifiableAssets" name="CashFlowFromNetIdentifiableAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate" name="PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" name="CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" name="AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TechnologiesRecognisedAsOfAcquisitionDivestmentDate" name="TechnologiesRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" name="OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate" name="FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_InventoryRecognisedAsOfAcquisitionDivestmentDate" name="InventoryRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate" name="TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate" name="CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate" name="CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate" name="TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AnimalHealthMember" name="AnimalHealthMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProceedsFromSaleOfBusiness" name="ProceedsFromSaleOfBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AmortizationOfBondsDiscount" name="AmortizationOfBondsDiscount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentPortionOfNoncurrentFinancialDebt" name="CurrentPortionOfNoncurrentFinancialDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GenentechRocheMember" name="GenentechRocheMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfContractsWithRelatedParties" name="NumberOfContractsWithRelatedParties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RelatedPartiesNumberOfExecutiveCommiteeMembers" name="RelatedPartiesNumberOfExecutiveCommiteeMembers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RelatedPartiesNumberOfNonexecutiveDirectors" name="RelatedPartiesNumberOfNonexecutiveDirectors" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanExpectedFutureBenefitPayment" name="DefinedBenefitPlanExpectedFutureBenefitPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EmployerSharesHeldByDefinedBenefitPlan" name="EmployerSharesHeldByDefinedBenefitPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ValueOfEmployerSharesHeldByDefinedBenefitPlan" name="ValueOfEmployerSharesHeldByDefinedBenefitPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" name="AdministrativeExpenseNetDefinedBenefitLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset" name="ActuarialGainsLossesArisingFromChangesInExperienceRelatedAssumptionsNetDefinedBenefitLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" name="IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" name="IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CashAndCashEquivalentsMember" name="CashAndCashEquivalentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BalanceSheetItemAxis" name="BalanceSheetItemAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BalanceSheetItemMember" name="BalanceSheetItemMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquitySecuritiesMember" name="EquitySecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FundInvestmentsMember" name="FundInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" name="TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContingentConsiderationReceivablesMember" name="ContingentConsiderationReceivablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" name="AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" name="TimeDepositsWithOriginalMaturityMoreThan90DaysMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" name="LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="AssociatedCompaniesAtFairValueThroughProfitAndLossMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DerivativeFinancialInstrumentsMember" name="DerivativeFinancialInstrumentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GroupsOfFinancialAssetsLiabilitiesAxis" name="GroupsOfFinancialAssetsLiabilitiesAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GroupsOfFinancialAssetsLiabilitiesMember" name="GroupsOfFinancialAssetsLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TradePayablesMember" name="TradePayablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InterestBearningAccountsOfAssociatesPayableOnDemandMember" name="InterestBearningAccountsOfAssociatesPayableOnDemandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BankAndOtherFinancialDebtMember" name="BankAndOtherFinancialDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CommercialPaperMember" name="CommercialPaperMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentPortionOfNoncurrentDebtMember" name="CurrentPortionOfNoncurrentDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_StraightBondsMember" name="StraightBondsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" name="LiabilitiesToBanksAndOtherFinancialInstitutionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinanceLeaseObligationsMember" name="FinanceLeaseObligationsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContingentConsiderationAndOtherFinancialLiabilitiesMember" name="ContingentConsiderationAndOtherFinancialLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" name="DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis" name="DerivativeFinancialInstrumentNatureOfInstrumentAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember" name="DerivativeFinancialInstrumentNatureOfInstrumentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" name="DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinancialInstrumentsPrincipalAmountsAxis" name="FinancialInstrumentsPrincipalAmountsAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinancialInstrumentsPrincipalAmountsMember" name="FinancialInstrumentsPrincipalAmountsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContractOrUnderlyingPrincipalAmoutMember" name="ContractOrUnderlyingPrincipalAmoutMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PositiveFairValuesMember" name="PositiveFairValuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NegativeFairValuesMember" name="NegativeFairValuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" name="DisclosureOfDerivativeFinancialInstrumentsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DerivativeFinancialInstruments" name="DerivativeFinancialInstruments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" name="DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" name="DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" name="DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinancialInvestmentsAndLongtermLoansGroupMember" name="FinancialInvestmentsAndLongtermLoansGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TotalAvailableforsaleMarketableSecuritiesMember" name="TotalAvailableforsaleMarketableSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AvailableForSaleMarketableSecuritiesMember" name="AvailableForSaleMarketableSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AvailableforsaleLongtermFinancialInvestmentsMember" name="AvailableforsaleLongtermFinancialInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentFinancialDebtMember" name="CurrentFinancialDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NoncurrentFinancialDebtMember" name="NoncurrentFinancialDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AvailableforsaleFinancialInvestmentsMember" name="AvailableforsaleFinancialInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ValuedAtAmortizedCostMember" name="ValuedAtAmortizedCostMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContingentConsiderationPayablesMember" name="ContingentConsiderationPayablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherFinancialLiabilitiesMember" name="OtherFinancialLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" name="ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" name="IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisAustriaGmbHViennaMember" name="NovartisAustriaGmbHViennaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaGmbHViennaMember" name="NovartisPharmaGmbHViennaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconOphthalmikaGmbHViennaMember" name="AlconOphthalmikaGmbHViennaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozGmbHViennaMember" name="SandozGmbHViennaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" name="EBEWEPharmaGes.m.b.HNfg.KGViennaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisBangladeshLimitedGazipurMember" name="NovartisBangladeshLimitedGazipurMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSecuritiesInvestmentLtd.HamiltonMember" name="NovartisSecuritiesInvestmentLtd.HamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" name="NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconCanadaInc.MississaugaOntarioMember" name="AlconCanadaInc.MississaugaOntarioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CIBAVisionCanadaInc.MississaugaOntarioMember" name="CIBAVisionCanadaInc.MississaugaOntarioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozCanadaInc.BouchervilleQuebecMember" name="SandozCanadaInc.BouchervilleQuebecMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisChileS.A.SantiagoDeChileMember" name="NovartisChileS.A.SantiagoDeChileMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriosChileLtd.SantiagoDeChileMember" name="AlconLaboratoriosChileLtd.SantiagoDeChileMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BeijingNovartisPharmaCo.Ltd.BeijingMember" name="BeijingNovartisPharmaCo.Ltd.BeijingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaceuticalsHKLimitedHongKongMember" name="NovartisPharmaceuticalsHKLimitedHongKongMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" name="SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ShanghaiNovartisTradingLtd.ShanghaiMember" name="ShanghaiNovartisTradingLtd.ShanghaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconHongKongLimitedHongKongMember" name="AlconHongKongLimitedHongKongMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" name="AlconChinaOphthalmicProductCo.Ltd.BeijingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" name="SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" name="SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisS.r.o.PragueMember" name="NovartisS.r.o.PragueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" name="AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozS.r.o.PragueMember" name="SandozS.r.o.PragueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHealthcareASCopenhagenMember" name="NovartisHealthcareASCopenhagenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconNordicASCopenhagenMember" name="AlconNordicASCopenhagenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozASCopenhagenMember" name="SandozASCopenhagenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisEcuadorS.A.QuitoMember" name="NovartisEcuadorS.A.QuitoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaS.A.E.CairoMember" name="NovartisPharmaS.A.E.CairoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozEgyptPharmaS.A.E.NewCairoCityMember" name="SandozEgyptPharmaS.A.E.NewCairoCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFinlandOyEspooMember" name="NovartisFinlandOyEspooMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisGroupeFranceS.A.RueilMalmaisonMember" name="NovartisGroupeFranceS.A.RueilMalmaisonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaS.A.S.RueilMalmaisonMember" name="NovartisPharmaS.A.S.RueilMalmaisonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LaboratoiresAlconS.A.S.RueilMalmaisonMember" name="LaboratoiresAlconS.A.S.RueilMalmaisonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozS.A.S.LevalloisPerretMember" name="SandozS.A.S.LevalloisPerretMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisDeutschlandGmbHWehrMember" name="NovartisDeutschlandGmbHWehrMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaGmbHNurembergMember" name="NovartisPharmaGmbHNurembergMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaProduktionsGmbHWehrMember" name="NovartisPharmaProduktionsGmbHWehrMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisBusinessServicesGmbHWehrMember" name="NovartisBusinessServicesGmbHWehrMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPharmaGmbHFreiburgImBreisgauMember" name="AlconPharmaGmbHFreiburgImBreisgauMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_WaveLightGmbHErlangenMember" name="WaveLightGmbHErlangenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CIBAVisionGmbHGrosswallstadtMember" name="CIBAVisionGmbHGrosswallstadtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozInternationalGmbHHolzkirchenMember" name="SandozInternationalGmbHHolzkirchenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_HEXALAGHolzkirchenMember" name="HEXALAGHolzkirchenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SalutasPharmaGmbHBarlebenMember" name="SalutasPharmaGmbHBarlebenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1APharmaGmbHOberhachingMember" name="A1APharmaGmbHOberhachingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AeropharmGmbHRudolstadtMember" name="AeropharmGmbHRudolstadtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovistaInsuranceLimitedGibraltarCityMember" name="NovistaInsuranceLimitedGibraltarCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember" name="NovartisHellasS.A.C.I.MetamorphosisAthensMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" name="AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" name="NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozHungaryLimitedLiabilityCompanyBudapestMember" name="SandozHungaryLimitedLiabilityCompanyBudapestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisIndiaLimitedMumbaiMember" name="NovartisIndiaLimitedMumbaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHealthcarePrivateLimitedMumbaiMember" name="NovartisHealthcarePrivateLimitedMumbaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozPrivateLimitedMumbaiMember" name="SandozPrivateLimitedMumbaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PT.NovartisIndonesiaJakartaMember" name="PT.NovartisIndonesiaJakartaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PT.CIBAVisionBatamBatamMember" name="PT.CIBAVisionBatamBatamMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisIrelandLimitedDublinMember" name="NovartisIrelandLimitedDublinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" name="NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesIrelandLimitedCorkCityMember" name="AlconLaboratoriesIrelandLimitedCorkCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OptonolLtd.NeveIlanMember" name="OptonolLtd.NeveIlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFarmaS.p.A.OriggioMember" name="NovartisFarmaS.p.A.OriggioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconItaliaS.p.A.MilanMember" name="AlconItaliaS.p.A.MilanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozS.p.A.OriggioMember" name="SandozS.p.A.OriggioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozIndustrialProductsS.p.A.RoveretoMember" name="SandozIndustrialProductsS.p.A.RoveretoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHoldingJapanK.K.TokyoMember" name="NovartisHoldingJapanK.K.TokyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaK.K.TokyoMember" name="NovartisPharmaK.K.TokyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconJapanLtd.TokyoMember" name="AlconJapanLtd.TokyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozK.K.TokyoMember" name="SandozK.K.TokyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember" name="NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" name="AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" name="CIBAVisionJohorSdn.Bhd.KualaLumpurMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" name="AlconLaboratoriosS.A.DeC.V.MexicoCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozS.A.DeC.V.MexicoCityMember" name="SandozS.A.DeC.V.MexicoCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaMarocSACasablancaMember" name="NovartisPharmaMarocSACasablancaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisNetherlandsB.V.ArnhemMember" name="NovartisNetherlandsB.V.ArnhemMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaB.V.ArnhemMember" name="NovartisPharmaB.V.ArnhemMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconNederlandB.V.ArnhemMember" name="AlconNederlandB.V.ArnhemMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozB.V.AlmereMember" name="SandozB.V.AlmereMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisNewZealandLtdAucklandMember" name="NovartisNewZealandLtdAucklandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisNorgeASOsloMember" name="NovartisNorgeASOsloMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaPakistanLimitedKarachiMember" name="NovartisPharmaPakistanLimitedKarachiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaLogisticsInc.PanamaCityMember" name="NovartisPharmaLogisticsInc.PanamaCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconCentroamericaS.A.PanamaCityMember" name="AlconCentroamericaS.A.PanamaCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LekS.A.StrykowMember" name="LekS.A.StrykowMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPortugalSGPSLda.PortoSalvoMember" name="NovartisPortugalSGPSLda.PortoSalvoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" name="NovartisPharmaServicesRomaniaS.R.L.BucharestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconRomaniaS.R.L.BucharestMember" name="AlconRomaniaS.R.L.BucharestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozS.R.L.TarguMuresMember" name="SandozS.R.L.TarguMuresMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaLLCMoscowMember" name="NovartisPharmaLLCMoscowMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconFarmacevtikaLLCMoscowMember" name="AlconFarmacevtikaLLCMoscowMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZAOSandozMoscowMember" name="ZAOSandozMoscowMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisNevaLLCSt.PetersburgMember" name="NovartisNevaLLCSt.PetersburgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" name="SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSlovakiaS.r.o.BratislavaMember" name="NovartisSlovakiaS.r.o.BratislavaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LekPharmaceuticalsD.d.LjubjanaMember" name="LekPharmaceuticalsD.d.LjubjanaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozPharmaceuticalsD.d.LjubjanaMember" name="SandozPharmaceuticalsD.d.LjubjanaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSouthAfricaPtyLtdMidrandMember" name="NovartisSouthAfricaPtyLtdMidrandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" name="AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozSouthAfricaPtyLtdKemptonParkMember" name="SandozSouthAfricaPtyLtdKemptonParkMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisKoreaLtd.SeoulMember" name="NovartisKoreaLtd.SeoulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconKoreaLtd.SeoulMember" name="AlconKoreaLtd.SeoulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozKoreaLtd.SeoulMember" name="SandozKoreaLtd.SeoulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconCusiS.A.BarcelonaMember" name="AlconCusiS.A.BarcelonaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozIndustrialProductsS.A.BarcelonaMember" name="SandozIndustrialProductsS.A.BarcelonaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" name="AbadiaRetuertaS.A.SardonDeDueroValladolidMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSverigeABStockholmMember" name="NovartisSverigeABStockholmMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInternationalAGBaselMember" name="NovartisInternationalAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHoldingAGBaselMember" name="NovartisHoldingAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInternationalPharmaceuticalAGBaselMember" name="NovartisInternationalPharmaceuticalAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaAGBaselMember" name="NovartisPharmaAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaServicesAGBaselMember" name="NovartisPharmaServicesAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaSchweizerhalleAGMuttenzMember" name="NovartisPharmaSchweizerhalleAGMuttenzMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaSteinAGSteinMember" name="NovartisPharmaSteinAGSteinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaSchweizAGRischMember" name="NovartisPharmaSchweizAGRischMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconSwitzerlandSARischMember" name="AlconSwitzerlandSARischMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPharmaceuticalsLtd.FribourgMember" name="AlconPharmaceuticalsLtd.FribourgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozAGBaselMember" name="SandozAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozPharmaceuticalsAGRischMember" name="SandozPharmaceuticalsAGRischMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisTaiwanCo.Ltd.TaipeiMember" name="NovartisTaiwanCo.Ltd.TaipeiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisThailandLimitedBangkokMember" name="NovartisThailandLimitedBangkokMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesThailandLimitedBangkokMember" name="AlconLaboratoriesThailandLimitedBangkokMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratuvarlariTicaretA.S.IstanbulMember" name="AlconLaboratuvarlariTicaretA.S.IstanbulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisMiddleEastFZEDubaiMember" name="NovartisMiddleEastFZEDubaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisUKLimitedFrimleyCamberleyMember" name="NovartisUKLimitedFrimleyCamberleyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" name="NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisGrimsbyLimitedFrimleyCamberleyMember" name="NovartisGrimsbyLimitedFrimleyCamberleyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconEyeCareUKLimitedFrimleyCamberleyMember" name="AlconEyeCareUKLimitedFrimleyCamberleyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozLimitedFrimleyCamberleyMember" name="SandozLimitedFrimleyCamberleyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" name="GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCorporationEastHanoverNYMember" name="NovartisCorporationEastHanoverNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFinanceCorporationNewYorkNYMember" name="NovartisFinanceCorporationNewYorkNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCapitalCorporationNewYorkNYMember" name="NovartisCapitalCorporationNewYorkNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaceuticalsCorporationEastHanoverNYMember" name="NovartisPharmaceuticalsCorporationEastHanoverNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" name="NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" name="NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" name="NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisServicesInc.EastHanoverNYMember" name="NovartisServicesInc.EastHanoverNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesHoldingCorporationFortWorthTXMember" name="AlconLaboratoriesHoldingCorporationFortWorthTXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesInc.FortWorthTXMember" name="AlconLaboratoriesInc.FortWorthTXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconRefractivehorizonsLLCFortWorthTXMember" name="AlconRefractivehorizonsLLCFortWorthTXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconResearchLtd.FortWorthTXMember" name="AlconResearchLtd.FortWorthTXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLensxInc.AlisoViejoCAMember" name="AlconLensxInc.AlisoViejoCAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozInc.PrincetonNJMember" name="SandozInc.PrincetonNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EonLabsInc.PrincetonNJMember" name="EonLabsInc.PrincetonNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FougeraPharmaceuticalsInc.MelvilleNYMember" name="FougeraPharmaceuticalsInc.MelvilleNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisDeVenezuelaS.A.CaracasMember" name="NovartisDeVenezuelaS.A.CaracasMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPharmaceuticalC.A.CaracasMember" name="AlconPharmaceuticalC.A.CaracasMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisBiocienciasS.A.SaoPauloMember" name="NovartisBiocienciasS.A.SaoPauloMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" name="SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisDeColombiaS.A.SantafeDeBobotaMember" name="NovartisDeColombiaS.A.SantafeDeBobotaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" name="LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" name="NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" name="NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" name="AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozFarmaceuticaLda.PortoSalvoMember" name="SandozFarmaceuticaLda.PortoSalvoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFarmaceuticaS.A.BarcelonaMember" name="NovartisFarmaceuticaS.A.BarcelonaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozFarmaceuticaS.A.MadridMember" name="SandozFarmaceuticaS.A.MadridMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" name="NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozIlacSanayiVeTicaretA.S.IstanbulMember" name="SandozIlacSanayiVeTicaretA.S.IstanbulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" name="SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinancialInstrumentsAdditionalDisclosureAbstract" name="FinancialInstrumentsAdditionalDisclosureAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialInstrumentsCarryingValueLevel3" name="FinancialInstrumentsCarryingValueLevel3" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" name="GainsRecognisedInProfitOrLossFairValueMeasurementAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" name="LossesRecognisedInProfitOrLossFairValueMeasurementAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" name="FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisposalsFairValueMeasurementAssets" name="DisposalsFairValueMeasurementAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReclassificationFairValueMeasurementAssets" name="ReclassificationFairValueMeasurementAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" name="FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" name="MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ReconciliationOfChangesInFairValueMeasurementAssetsTable" name="ReconciliationOfChangesInFairValueMeasurementAssetsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MaturityOfNetDebtLineItems" name="MaturityOfNetDebtLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MarketableSecuritiesAndTimeDepositsMember" name="MarketableSecuritiesAndTimeDepositsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CommoditiesMember" name="CommoditiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DeriviativeFinancialInstrumentsAndAccruedInterestMember" name="DeriviativeFinancialInstrumentsAndAccruedInterestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinancialDebtMember" name="FinancialDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinancialDebtUndiscountedMember" name="FinancialDebtUndiscountedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" name="DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" name="PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" name="PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" name="DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContractualInterestOnNoncurrentLiabilities" name="ContractualInterestOnNoncurrentLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_TenDayLossFairValueVARModelTable" name="TenDayLossFairValueVARModelTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TenDayLossFairValueVARModelLineItems" name="TenDayLossFairValueVARModelLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialInstrumentsValueAtRiskComputation" name="FinancialInstrumentsValueAtRiskComputation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" name="FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" name="FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" name="FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_WorstCaseLossScenarioMember" name="WorstCaseLossScenarioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets" name="CashReceiptsAndPaymentsFairValueMeasurementAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" name="AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForward" name="ScheduleOfUnvestedRestrictedStockUnitsRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationOtherShareAwardsMember" name="EquityBasedParticipationOtherShareAwardsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ShareMovements" name="ShareMovements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NetInvestmentHedgeMember" name="NetInvestmentHedgeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_WrittenCallOptionsHeldByMarketMaker" name="WrittenCallOptionsHeldByMarketMaker" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_WrittenCallOptionsContractualLive" name="WrittenCallOptionsContractualLive" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_WrittenCallOptionsContractualLiveRemaining" name="WrittenCallOptionsContractualLiveRemaining" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_WrittenCallOptionsWeightedAverageExercisePrice" name="WrittenCallOptionsWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PurchaseFairValueMeasurementAssets" name="PurchaseFairValueMeasurementAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_StockRepurchaseProgramAuthorizedAmount1" name="StockRepurchaseProgramAuthorizedAmount1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectOfIncomeTaxedAtReducedRates" name="TaxRateEffectOfIncomeTaxedAtReducedRates" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MovementsOfPropertyPlantAndEquipmentRollForward" name="MovementsOfPropertyPlantAndEquipmentRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherAssetsProvisionsAccrualsMember" name="OtherAssetsProvisionsAccrualsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" name="SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" name="SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" name="SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" name="SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSingaporePteLtd.SingaporeMember" name="NovartisSingaporePteLtd.SingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" name="NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" name="NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" name="NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconSingaporeManufacturingPteLtdSingaporeMember" name="AlconSingaporeManufacturingPteLtdSingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" name="CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPteLtdSingaporeMember" name="AlconPteLtdSingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" name="AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SpinifexPharmaceuticalsInc.WilmingtonNCMember" name="SpinifexPharmaceuticalsInc.WilmingtonNCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EncoreVisionInc.NewYorkNYMember" name="EncoreVisionInc.NewYorkNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInvestmentLtd.HamiltonMember" name="NovartisInvestmentLtd.HamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFinanceServicesLtd.HamiltonMember" name="NovartisFinanceServicesLtd.HamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisB2Ltd.HamiltonMember" name="NovartisB2Ltd.HamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisB3Ltd.HamiltonMember" name="NovartisB3Ltd.HamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CibaGeigyJapanLimitedTokyoMember" name="CibaGeigyJapanLimitedTokyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" name="NovartisInternationalPharmaceuticalInvestmentAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisBioventuresAGBaselMember" name="NovartisBioventuresAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisForschungsstiftungBaselMember" name="NovartisForschungsstiftungBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisMitarbeiterbeteiligungsstiftungBaselMember" name="NovartisMitarbeiterbeteiligungsstiftungBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" name="FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" name="ZiarcoGroupLimitedFrimleyCamberleySurreyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VivactaLimitedFrimleyCamberleySurreyMember" name="VivactaLimitedFrimleyCamberleySurreyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisUSFoundationNewYorkNYMember" name="NovartisUSFoundationNewYorkNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CortheraInc.SanMateoCAMember" name="CortheraInc.SanMateoCAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CoStimPharmaceuticalsInc.CambridgeMAMember" name="CoStimPharmaceuticalsInc.CambridgeMAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ClarVistaMedicalInc.AlisoViejoCAMember" name="ClarVistaMedicalInc.AlisoViejoCAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TriangleInternationalReinsuranceLimitedHamiltonMember" name="TriangleInternationalReinsuranceLimitedHamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TrinityRiverInsuranceCoLtd.HamiltonMember" name="TrinityRiverInsuranceCoLtd.HamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisStiftungFuerKaderausbildungBaselMember" name="NovartisStiftungFuerKaderausbildungBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisStiftungFuerMenschUndUmweltBaselMember" name="NovartisStiftungFuerMenschUndUmweltBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" name="StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" name="SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" name="DisclosureOfAssociatesNetIncomeEffectTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" name="DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" name="DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" name="DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" name="DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" name="GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DebtSecuritiesBreakdownByCurrencyTableTextBlock" name="DebtSecuritiesBreakdownByCurrencyTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SummaryOfTreasurySharesMovementsTableTextBlock" name="SummaryOfTreasurySharesMovementsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" name="USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" name="ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" name="ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfDefinedContributionPlansTableTextBlock" name="ScheduleOfDefinedContributionPlansTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" name="ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" name="DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" name="DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" name="DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" name="DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" name="DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" name="DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" name="DisclosureOfTenDayLossFairValueVARModelTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" name="DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" name="DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ReprixysPharmaceuticalsCorporationMember" name="ReprixysPharmaceuticalsCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability" name="TaxRateEffectOfReleaseOfContingentConsiderationLiability" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectFromNondeductibleLossesInRegion" name="TaxRateEffectFromNondeductibleLossesInRegion" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DeferredTaxAssetAndLiabilityValuationAbstract" name="DeferredTaxAssetAndLiabilityValuationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" name="ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" name="ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" name="ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" name="ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" name="ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImpactLocationAxis" name="ImpactLocationAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImpactLocationMember" name="ImpactLocationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IncomeStatementMember" name="IncomeStatementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" name="IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_UndiscountedOperatingLeaseCommitments" name="UndiscountedOperatingLeaseCommitments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ContributionOfBusinessToJointVenture" name="ContributionOfBusinessToJointVenture" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" name="PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncomeTaxRelatingToAvailableforsaleFinanciaInvestmentsPreviouslyRecognizedThroughOCI" name="ImpactOfNewTaxLawIncomeTaxRelatingToAvailableforsaleFinanciaInvestmentsPreviouslyRecognizedThroughOCI" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI" name="ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" name="ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" name="ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" name="ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" name="ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" name="AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" name="PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherIntangiblePurchaseCommitments" name="OtherIntangiblePurchaseCommitments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" name="ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OpenHedgesForAnticipatedTransactions" name="OpenHedgesForAnticipatedTransactions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" name="AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MostSignificantForeignExchangeLosses" name="MostSignificantForeignExchangeLosses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LongtermFinancialDebtWithACarryingAmount" name="LongtermFinancialDebtWithACarryingAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" name="UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NetInvestmentHedgeRecognizedInTheIncomeStatement" name="NetInvestmentHedgeRecognizedInTheIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_UpperLimitOnHoldingsOnUnrelatedCompany" name="UpperLimitOnHoldingsOnUnrelatedCompany" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsCommercialPaperMaximumBorrowingAmount" name="BorrowingsCommercialPaperMaximumBorrowingAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DebtEquityRatio" name="DebtEquityRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_VAREstimateConfidenceInterval" name="VAREstimateConfidenceInterval" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_BorrowingsCommercialPaperMaximumAmountOutstanding" name="BorrowingsCommercialPaperMaximumAmountOutstanding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_BorrowingsCreditFacilityCommitted" name="BorrowingsCreditFacilityCommitted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_CounterpartyRiskAbstract" name="CounterpartyRiskAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashAndCashEquivalentsHeldWithFinancialInstitution" name="CashAndCashEquivalentsHeldWithFinancialInstitution" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VendorAxis" name="VendorAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VendorMember" name="VendorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LargestFinancialInstitutionMember" name="LargestFinancialInstitutionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SecondLargestFinancialInstitutionMember" name="SecondLargestFinancialInstitutionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ThirdLargestFinancialInstitutionMember" name="ThirdLargestFinancialInstitutionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PreTaxProfitLossFromDivestmentOfBusiness" name="PreTaxProfitLossFromDivestmentOfBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DivestmentDateFairValueOfTotalConsiderationTransferred" name="DivestmentDateFairValueOfTotalConsiderationTransferred" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FuturePutOptionToSellBusiness" name="FuturePutOptionToSellBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PaymentPutOption" name="PaymentPutOption" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_InterestExchanged" name="InterestExchanged" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LiabilitiesToBanksAndOtherInstitutions" name="LiabilitiesToBanksAndOtherInstitutions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationReceivableCurrent" name="ContingentConsiderationReceivableCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfDivestmentsOtherProvisions" name="ImpactOfDivestmentsOtherProvisions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfFinancialInstrumentsNarrativeTable" name="DisclosureOfFinancialInstrumentsNarrativeTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CustomersWithNetSalesOverFivePercent" name="CustomersWithNetSalesOverFivePercent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" name="NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContingentConsiderationReceivablesShorttermMember" name="ContingentConsiderationReceivablesShorttermMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OptionsExcludedFromTheCalculation" name="OptionsExcludedFromTheCalculation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MilestonePaymentAlreadyReceived" name="MilestonePaymentAlreadyReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_USCommercialPaperProgramsMember" name="USCommercialPaperProgramsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_JPCommercialPaperProgramsMember" name="JPCommercialPaperProgramsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsCommercialPaperNumberOfPrograms" name="BorrowingsCommercialPaperNumberOfPrograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" name="AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" name="AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsAAAMember" name="AdvancedAcceleratorApplicationsAAAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PercentageOfShareCapitalInTenderOffer" name="PercentageOfShareCapitalInTenderOffer" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashOfferPerOrdinaryShare" name="CashOfferPerOrdinaryShare" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashOfferPerADS" name="CashOfferPerADS" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NumberOfOrdinarySharePerADS" name="NumberOfOrdinarySharePerADS" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ValueOfEquity" name="ValueOfEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_MaximalAmountOfShareBuybackProgramm" name="MaximalAmountOfShareBuybackProgramm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAnnualIncentive" name="DescriptionOfAnnualIncentive" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfBusinessUnits" name="NumberOfBusinessUnits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" name="RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonCurrentFinancialDebtsMember" name="NonCurrentFinancialDebtsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContractRightOfFirstNegotiationTerm" name="ContractRightOfFirstNegotiationTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_IntangibleAssetImpairmentChargesTextBlock" name="IntangibleAssetImpairmentChargesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" name="PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AcquisitionFairValuePotentiallyRefundableContingentConsideration" name="AcquisitionFairValuePotentiallyRefundableContingentConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DivestmentFairValueOfContingentConsiderationReceived" name="DivestmentFairValueOfContingentConsiderationReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" name="AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MaximumMarginPercentageImpactOfCommodityPriceChange" name="MaximumMarginPercentageImpactOfCommodityPriceChange" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MaximumHoldingInUnrelatedCompany" name="MaximumHoldingInUnrelatedCompany" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialReceivableFromDivestment" name="PotentialReceivableFromDivestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ChangeOverPeriodAxis" name="ChangeOverPeriodAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BasisOfPreparationAbstract" name="BasisOfPreparationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SelectedCriticalAccountingPoliciesAbstract" name="SelectedCriticalAccountingPoliciesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LegalProceedingsUpdateAbstract" name="LegalProceedingsUpdateAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LegalProceedingsUpdateTextBlock" name="LegalProceedingsUpdateTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImpactsOfAdoptionOfNewIFRSStandardsAbstract" name="ImpactsOfAdoptionOfNewIFRSStandardsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactsOfAdoptionOfNewIFRSStandardsTextBlock" name="ImpactsOfAdoptionOfNewIFRSStandardsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" name="DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" name="DescriptionOfAccountingPolicyForOtherRevenueTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ConsolidatedBalanceSheetByTheAdoptionOfIFRS15TableTextBlock" name="ConsolidatedBalanceSheetByTheAdoptionOfIFRS15TableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ConsolidatedStatementOfChangesInEquityByTheAdoptionOfIFRS9AndIFRS15TableTextBlock" name="ConsolidatedStatementOfChangesInEquityByTheAdoptionOfIFRS9AndIFRS15TableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialInstrumentsAdditionalDisclosuresTableByTheAdoptionOfIFRS9TableTextBlock" name="FinancialInstrumentsAdditionalDisclosuresTableByTheAdoptionOfIFRS9TableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" name="DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" name="DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AveXisIncMember" name="AveXisIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" name="IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member" name="IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OCIReservesMember" name="OCIReservesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RetailGenericsMember" name="RetailGenericsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BiopharmaceuticalsMember" name="BiopharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AntiInfectivesMember" name="AntiInfectivesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SurgicalMember" name="SurgicalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VisionCareMember" name="VisionCareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ConsumablesMember" name="ConsumablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImplantablesMember" name="ImplantablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquipmentOtherMember" name="EquipmentOtherMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OphthalmicOTCMember" name="OphthalmicOTCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContactLensCareMember" name="ContactLensCareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Top20ProductsMember" name="Top20ProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RestOfPortfolioMember" name="RestOfPortfolioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProfitSharingIncome" name="ProfitSharingIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MilestoneIncome" name="MilestoneIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherRevenueOther" name="OtherRevenueOther" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" name="ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CanadaAndLatinAmericaMember" name="CanadaAndLatinAmericaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" name="RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EstablishedMarketsMember" name="EstablishedMarketsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EmergingGrowthMarketsMember" name="EmergingGrowthMarketsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RestOfTheWorldMember" name="RestOfTheWorldMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.5EUR750Million20182023OfNovartisMember" name="A0.5EUR750Million20182023OfNovartisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.375EUR750Million20182030OfNovartisMember" name="A1.375EUR750Million20182030OfNovartisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.7EUR750Million20182038OfNovartisMember" name="A1.7EUR750Million20182038OfNovartisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GalvusGroupMember" name="GalvusGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DiovanGroupMember" name="DiovanGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExforgeGroupMember" name="ExforgeGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImmunologyHepatologyAndDermatologyMember" name="ImmunologyHepatologyAndDermatologyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AntiInfectivesSoldUnderSandozNameMember" name="AntiInfectivesSoldUnderSandozNameMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueAdjustmentsOnFinancialAssetsSold" name="FairValueAdjustmentsOnFinancialAssetsSold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProductPortfolioAxis" name="ProductPortfolioAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherSharePurchasesValue" name="OtherSharePurchasesValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LutatheraMember" name="LutatheraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_KymriahMember" name="KymriahMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" name="PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" name="ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" name="TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TransactionCostsRecordedInEquityTextBlock" name="TransactionCostsRecordedInEquityTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TransactionsWithRelatedPartiesAbstract" name="TransactionsWithRelatedPartiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionsWithRelatedPartiesTextBlock" name="TransactionsWithRelatedPartiesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionCostsRecordedInEquityPaid" name="TransactionCostsRecordedInEquityPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionCostsRecordedInEquity" name="TransactionCostsRecordedInEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" name="OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9FundInvestments" name="IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9FundInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9EquitySecurities" name="IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9EquitySecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPensionFundMember" name="NovartisPensionFundMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsCreditFacilityUncommitted" name="BorrowingsCreditFacilityUncommitted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OtherNetAssets" name="OtherNetAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_OcularHealthMember" name="OcularHealthMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" name="A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" name="A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" name="A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" name="AdvancedAcceleratorApplicationsInternationalSAGeneveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" name="AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AveXisInc.BannockburnILMember" name="AveXisInc.BannockburnILMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember" name="AdvancedAcceleratorApplicationsS.A.SaintGenisPouillyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisposalGroupHeldForSaleAbstract" name="DisposalGroupHeldForSaleAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisposalGroupHeldForSaleLineItems" name="DisposalGroupHeldForSaleLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ChangeInCashSettledShareBasedPaymentsLiabilities" name="ChangeInCashSettledShareBasedPaymentsLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowNoncontrollingInterests" name="CashInflowOutflowNoncontrollingInterests" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AmountRecordedInEquityRelatedToHyperinflation" name="AmountRecordedInEquityRelatedToHyperinflation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdditionsToInvestmentInAssociatedCompanies" name="AdditionsToInvestmentInAssociatedCompanies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate" name="FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" name="OtherComprehensiveIncomeNetOfTaxDebtSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionCosts" name="TransactionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" name="GainOnDivestmentOfInterestsInAssociatedCompanies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueAdjustmentsOnDebtSecuritiesMember" name="FairValueAdjustmentsOnDebtSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueAdjustmentsOnEquitySecuritiesMember" name="FairValueAdjustmentsOnEquitySecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ReclassificationToPresentationRequiredUnderIFRS9Member" name="ReclassificationToPresentationRequiredUnderIFRS9Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RestatedValueAdjustmentsMember" name="RestatedValueAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NoncurrentFinancialAssetsEquityInvestments" name="NoncurrentFinancialAssetsEquityInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NoncurrentFinancialAssetsFundInvestments" name="NoncurrentFinancialAssetsFundInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ListedEquitySecuritiesMember" name="ListedEquitySecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonlistedEquitySecuritiesMember" name="NonlistedEquitySecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" name="DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" name="DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EndocyteMember" name="EndocyteMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" name="DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" name="DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" name="DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" name="DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" name="DivestmentsAquisitionsOfInterestsInAssociatedCompanies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherShareSales" name="OtherShareSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherShareSalesEquityImpact" name="OtherShareSalesEquityImpact" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfOtherShareSales" name="NumberOfOtherShareSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfOtherShareSalesEquityImpact" name="NumberOfOtherShareSalesEquityImpact" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeDebtSecurities" name="OtherComprehensiveIncomeDebtSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" name="NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisAustraliaPtyLtdMacquarieParkNSWMember" name="NovartisAustraliaPtyLtdMacquarieParkNSWMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozPtyLtdMacquarieParkNSWMember" name="SandozPtyLtdMacquarieParkNSWMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" name="AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaNVVilvoordeMember" name="NovartisPharmaNVVilvoordeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozNVVilvoordeMember" name="SandozNVVilvoordeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconCouvreurNVPuursMember" name="AlconCouvreurNVPuursMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesBelgiumBVBAPuursMember" name="AlconLaboratoriesBelgiumBVBAPuursMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconNVVilvoordeMember" name="AlconNVVilvoordeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconAGFribourgMember" name="AlconAGFribourgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" name="AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CIBAVisionCorporationLLCDuluthGAMember" name="CIBAVisionCorporationLLCDuluthGAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" name="ReprixysPharmaceuticalsCorporationEastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPolandSp.ZO.o.WarsawMember" name="NovartisPolandSp.ZO.o.WarsawMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozPolskaSp.ZO.o.WarsawMember" name="SandozPolskaSp.ZO.o.WarsawMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPolskaSp.ZO.o.WarsawMember" name="AlconPolskaSp.ZO.o.WarsawMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconHealthcareS.A.BarcelonaMember" name="AlconHealthcareS.A.BarcelonaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisOphthalmicsAGFribourgMember" name="NovartisOphthalmicsAGFribourgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozUkraineLLCKievMember" name="SandozUkraineLLCKievMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DivestmentCostToSell" name="DivestmentCostToSell" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AmountOfSettlementInPrinciple" name="AmountOfSettlementInPrinciple" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_NavigateBioPharmaServicesInc.CarlsbadCAMember" name="NavigateBioPharmaServicesInc.CarlsbadCAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfProductsInPortfolioToBeSold" name="NumberOfProductsInPortfolioToBeSold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CarryingValueOfTheDivestedBusiness" name="CarryingValueOfTheDivestedBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ShortTermLeasesAndLowValueLeases" name="ShortTermLeasesAndLowValueLeases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_RemainingLeaseCommitments" name="RemainingLeaseCommitments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_LeaseLiabilitiesToBeRecognized" name="LeaseLiabilitiesToBeRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_RightOfUseAssetsToBeRecognized" name="RightOfUseAssetsToBeRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" name="NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_NovartisInvestmentsS.aR.l.LuxembourgCityMember" name="NovartisInvestmentsS.aR.l.LuxembourgCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFinanceS.A.LuxembourgCityMember" name="NovartisFinanceS.A.LuxembourgCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TearFilmInnovationsInc.FortWorthTXMember" name="TearFilmInnovationsInc.FortWorthTXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TrueVisionSystemsInc.FortWorthTXMember" name="TrueVisionSystemsInc.FortWorthTXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TranscendMedicalInc.LakeForestILMember" name="TranscendMedicalInc.LakeForestILMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisBalticsSIARigaMember" name="NovartisBalticsSIARigaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisOverseasInvestmentsAGBaselMember" name="NovartisOverseasInvestmentsAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_JapatAGBaselMember" name="JapatAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconManagementSAGenevaMember" name="AlconManagementSAGenevaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EndocyteInc.LafayetteINMember" name="EndocyteInc.LafayetteINMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OrielTherapeuticsInc.DurhamNCMember" name="OrielTherapeuticsInc.DurhamNCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_WaveLightInc.SterlingVAMember" name="WaveLightInc.SterlingVAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisBiosciencesPeruS.A.LimaMember" name="NovartisBiosciencesPeruS.A.LimaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesWithRestrictedUse" name="TreasurySharesWithRestrictedUse" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CommitmentForRepurchaseOwnShares" name="CommitmentForRepurchaseOwnShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NoncurrentFinancialAsstetsDebtSecurities" name="NoncurrentFinancialAsstetsDebtSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" name="AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DepreciationChargePriorToClassificationToAssetsHeldForSale" name="DepreciationChargePriorToClassificationToAssetsHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProformaNetSales" name="ProformaNetSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SerelaxinMember" name="SerelaxinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CyPassMember" name="CyPassMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncomeStatementAdjustmentsOfPriorYear" name="IncomeStatementAdjustmentsOfPriorYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncomeStatementAdjustmentsOfCurrentYear" name="IncomeStatementAdjustmentsOfCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PlansAndProgramRebatesAxis" name="PlansAndProgramRebatesAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" name="AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSale" name="ImpairmentChargesRelatedToDisposalGroupHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" name="ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" name="AdditionsIncludedInDisposalGroupToTheDateOfReclassification" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" name="NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NoncurrentAssetsDivested" name="NoncurrentAssetsDivested" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentAssetsDivested" name="CurrentAssetsDivested" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentLiabilitiesDivested" name="CurrentLiabilitiesDivested" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialAndOtherAssets" name="FinancialAndOtherAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" name="CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TradePayablesAndOtherLiabilities" name="TradePayablesAndOtherLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests" name="CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" name="LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" name="MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PlansAndProgramRebatesMember" name="PlansAndProgramRebatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_USspecificHealthcarePlansAndProgramRebatesMember" name="USspecificHealthcarePlansAndProgramRebatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonUSspecificHealthcarePlansAndProgramRebatesMember" name="NonUSspecificHealthcarePlansAndProgramRebatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" name="NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" name="UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice46.7Member" name="ExercisePrice46.7Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice54.5Member" name="ExercisePrice54.5Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice57.0Member" name="ExercisePrice57.0Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice57.6Member" name="ExercisePrice57.6Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice66.0Member" name="ExercisePrice66.0Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice46.4Member" name="ExercisePrice46.4Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice53.7Member" name="ExercisePrice53.7Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice57.1Member" name="ExercisePrice57.1Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice58.3Member" name="ExercisePrice58.3Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice66.1Member" name="ExercisePrice66.1Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PrepaymentsAndAccruedLeasePayments" name="PrepaymentsAndAccruedLeasePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" name="RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" name="AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" name="LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AmortizationPriorToClassificationToAssetsHeldForSale" name="AmortizationPriorToClassificationToAssetsHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" name="NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LongTermFinancialInvestmentsMember" name="LongTermFinancialInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MarketableSecurities" name="MarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_MajorPlansPercentageInGroupDBOPensions" name="MajorPlansPercentageInGroupDBOPensions" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" name="MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NoncurrentFinancialAssetsTotalFinancialInvestments" name="NoncurrentFinancialAssetsTotalFinancialInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" name="NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI" name="DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDiscontinuedOperationsAbstract" name="DisclosureOfDiscontinuedOperationsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_YoYChangeMember" name="YoYChangeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PresentationOfLeasesForLessesTable" name="PresentationOfLeasesForLessesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PresentationOfLeasesForLesseeLineItems" name="PresentationOfLeasesForLesseeLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NewLeaseArrangements" name="NewLeaseArrangements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_UndiscountedFutureLeasePayments" name="UndiscountedFutureLeasePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectOfDiscounting" name="EffectOfDiscounting" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" name="DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" name="DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" name="DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentStatedMember" name="CurrentStatedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SaleOrIssueOfTreasurySharesNumberOfShares" name="SaleOrIssueOfTreasurySharesNumberOfShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DetailedInformationAboutSignificantTransaction" name="DetailedInformationAboutSignificantTransaction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TakedaPharmaceuticalCompanyLimitedMember" name="TakedaPharmaceuticalCompanyLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IFMTreInc.Member" name="IFMTreInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PowerVisionInc.Member" name="PowerVisionInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdjustmentsForPrepaymentsAndAccruedLeasePayments" name="AdjustmentsForPrepaymentsAndAccruedLeasePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialMilestoneMaximumPayments" name="PotentialMilestoneMaximumPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfEmployeesAssociatedWithTheProductTransfer" name="NumberOfEmployeesAssociatedWithTheProductTransfer" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AdditionalBorrowings" name="AdditionalBorrowings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PercentageOfEquityInterestSharesReceived" name="PercentageOfEquityInterestSharesReceived" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" name="DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DistributionOfDividendBearingSharesToConsolidatedFoundations" name="DistributionOfDividendBearingSharesToConsolidatedFoundations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AimovigMember" name="AimovigMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" name="LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughExerciseOfOptionsShares" name="IncreaseDecreaseThroughExerciseOfOptionsShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares" name="IncreaseDecreaseThroughShareBasedPaymentTransactionsShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RepaymentOfLeaseLiability" name="RepaymentOfLeaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_WeightedAverageInterestRateLeaseLiabilities" name="WeightedAverageInterestRateLeaseLiabilities" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MovementsOfTheRightofuseAssetsRollForward" name="MovementsOfTheRightofuseAssetsRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LeaseContractTerminationsRightofuseAssets" name="LeaseContractTerminationsRightofuseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" name="IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" name="SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxesOnTreasuryShares" name="TaxesOnTreasuryShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LeaseIncentives" name="LeaseIncentives" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowForLeases" name="CashInflowForLeases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetAssetsDerecognized" name="NetAssetsDerecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DistributionOfDividendToDividendBearingShares" name="DistributionOfDividendToDividendBearingShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" name="DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetProvisionsForTransactionCostsRecognizedInTheIncomeStatement" name="NetProvisionsForTransactionCostsRecognizedInTheIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsAttributableToDivestedBusiness" name="CashFlowsAttributableToDivestedBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialAndOtherNoncurrentAssets" name="FinancialAndOtherNoncurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TradeReceivablesAndOtherCurrentAssets" name="TradeReceivablesAndOtherCurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TradePayablesProvisionsAndOtherLiabilities" name="TradePayablesProvisionsAndOtherLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CurrentAndNoncurrentFinancialDebt" name="CurrentAndNoncurrentFinancialDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" name="RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" name="ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" name="DisclosureOfRightofuseAssetsRollForwardTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" name="DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" name="DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" name="AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NoncurrentLeaseLiabilitiesMember" name="NoncurrentLeaseLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentLeaseLiabilitiesMember" name="CurrentLeaseLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ApplicableTaxRateExcludingExceptionalItems" name="ApplicableTaxRateExcludingExceptionalItems" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" name="CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DivestedCashAndCashEquivalents" name="DivestedCashAndCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CustomaryPurchasePriceAdjustment" name="CustomaryPurchasePriceAdjustment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RepaymentOfIntercompanyBalances" name="RepaymentOfIntercompanyBalances" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxReformImpactOnDeferredTaxOnTreasuryShares" name="TaxReformImpactOnDeferredTaxOnTreasuryShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DividendPaidNoncashAssetsDistribution" name="DividendPaidNoncashAssetsDistribution" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" name="DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" name="DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" name="ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" name="DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNetAssetsDerecognizedTableTextBlock" name="DisclosureOfNetAssetsDerecognizedTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" name="FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DistributionByWayOfDivindendInKindToShareholders" name="DistributionByWayOfDivindendInKindToShareholders" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TheMedicinesCompanyMember" name="TheMedicinesCompanyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PiqrayMember" name="PiqrayMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZolgensmaMember" name="ZolgensmaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MayzentMember" name="MayzentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" name="DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" name="DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" name="DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" name="AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" name="NetDeferredTaxBalanceRelatedToDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AspenGlobalIncorporatedMember" name="AspenGlobalIncorporatedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MinimumFinaceLeasePaymentsReceivableAtPresentValue" name="MinimumFinaceLeasePaymentsReceivableAtPresentValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" name="InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReclassificationFromNoncurrentToCurrentNet" name="ReclassificationFromNoncurrentToCurrentNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationPayable" name="ContingentConsiderationPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" name="IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BorrowingsUSDMember" name="BorrowingsUSDMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BorrowingsEURMember" name="BorrowingsEURMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinanceLeaseLiabilities" name="FinanceLeaseLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EquityBasedCompensationShares" name="EquityBasedCompensationShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ExerciseOfOptionsAndEmployeeTransactionsShares" name="ExerciseOfOptionsAndEmployeeTransactionsShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ExerciseOfOptionsAndEmployeeTransactionsValue" name="ExerciseOfOptionsAndEmployeeTransactionsValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharesDeliveredToDivestedBusinessEmployees" name="SharesDeliveredToDivestedBusinessEmployees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" name="PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" name="NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" name="DerivativeFinancialInstrumentsOptionsOnEquitySecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" name="EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AdditionalAmountOfSettlementInPrinciple" name="AdditionalAmountOfSettlementInPrinciple" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AmountOfResolvedAction" name="AmountOfResolvedAction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_EnoxaparinMember" name="EnoxaparinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozManufacturingInc.Member" name="SandozManufacturingInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" name="ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" name="SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CELLforCUREMember" name="CELLforCUREMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisManufacturingGmbHMember" name="NovartisManufacturingGmbHMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" name="NovartisHungaryHealthcareLimitedLiabilityCompanyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvacedAcceleratorApplicationsItalyS.r.l.Member" name="AdvacedAcceleratorApplicationsItalyS.r.l.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IDBHollandBVMember" name="IDBHollandBVMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" name="AdvacedAcceleratorApplicationsIbericaS.L.U.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImagingEquipmentLtdMember" name="ImagingEquipmentLtdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInflammasomeResearchInc.Member" name="NovartisInflammasomeResearchInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisTechnologyLLCMember" name="NovartisTechnologyLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" name="PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PartialReleaseOfDeferredTaxLiabilityRecognized" name="PartialReleaseOfDeferredTaxLiabilityRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LeaseLiabilitiesUndiscounted" name="LeaseLiabilitiesUndiscounted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_MostMaterialLeaseWithLeaseTermExtension" name="MostMaterialLeaseWithLeaseTermExtension" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashOutflowsForShortTermAndLowValueLeases" name="CashOutflowsForShortTermAndLowValueLeases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashOutflowsForPaymentsOfLeasesInterest" name="CashOutflowsForPaymentsOfLeasesInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" name="ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" name="ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_LongTermReceivablesFromFinanceSubleases" name="LongTermReceivablesFromFinanceSubleases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" name="DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_BorrowingsCreditFacilityShortTerm" name="BorrowingsCreditFacilityShortTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_BeovuMember" name="BeovuMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetCashOutflowsFromDivestments" name="NetCashOutflowsFromDivestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentLiabilitiesMember" name="CurrentLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NoncurrentLiabilitiesMember" name="NoncurrentLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentLeaseLiabilitiesUndiscounted" name="CurrentLeaseLiabilitiesUndiscounted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NoncurrentLeaseLiabilitiesUndiscounted" name="NoncurrentLeaseLiabilitiesUndiscounted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpairmentChargePriorToClassificationToAssetsHeldForSale" name="ImpairmentChargePriorToClassificationToAssetsHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxOnTransactionCostsRecordedInEquity" name="TaxOnTransactionCostsRecordedInEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectOfWriteoffOfDeferredTaxAssets" name="EffectOfWriteoffOfDeferredTaxAssets" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProceedsFromCurrentAndNoncurrentBorrowings" name="ProceedsFromCurrentAndNoncurrentBorrowings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_UncalledCapitalCommitmentsForInvestmentsInFunds" name="UncalledCapitalCommitmentsForInvestmentsInFunds" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_LitigationCaseMember" name="LitigationCaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TennesseeClassActionMember" name="TennesseeClassActionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MassachusettsCaseMember" name="MassachusettsCaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GrossDeferredTaxAssets" name="GrossDeferredTaxAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_GrossDeferredTaxLiabilities" name="GrossDeferredTaxLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AmountBorrowedUnderTheCreditFacility" name="AmountBorrowedUnderTheCreditFacility" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationLiabilities" name="ContingentConsiderationLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_XiidraMember" name="XiidraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" name="ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PercentageOfEntitysTradeReceivable" name="PercentageOfEntitysTradeReceivable" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowForSaleAndLeaseback" name="CashInflowForSaleAndLeaseback" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SaleAndLeaseBackMember" name="SaleAndLeaseBackMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract" name="DerivativeFinancialInstrumentsCommodityPurchaseContract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DisposalsAndRetirementsRightofuseAssets" name="DisposalsAndRetirementsRightofuseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" name="EffectOfIncomeNotSubjectToTaxOnDivestmentGain" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" name="SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CELLforCURELesUlisMember" name="CELLforCURELesUlisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" name="AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisNetherlandsB.V.AmsterdamMember" name="NovartisNetherlandsB.V.AmsterdamMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaB.V.AmsterdamMember" name="NovartisPharmaB.V.AmsterdamMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IDBHollandBVBaarleNassauMember" name="IDBHollandBVBaarleNassauMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSaudiLtd.RiyadhMember" name="NovartisSaudiLtd.RiyadhMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisUKLimitedLondonMember" name="NovartisUKLimitedLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaceuticalsUKLimitedLondonMember" name="NovartisPharmaceuticalsUKLimitedLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisGrimsbyLimitedLondonMember" name="NovartisGrimsbyLimitedLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImagingEquipmentLtdLondonMember" name="ImagingEquipmentLtdLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZiarcoGroupLimitedLondonMember" name="ZiarcoGroupLimitedLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFinanceCorporationEastHanoverNJMember" name="NovartisFinanceCorporationEastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCapitalCorporationEastHanoverNJMember" name="NovartisCapitalCorporationEastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisUSFoundationEastHanoverNJMember" name="NovartisUSFoundationEastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" name="AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInflammasomeResearchInc.EastHanoverNJMember" name="NovartisInflammasomeResearchInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisTechnologyLLCInc.EastHanoverNJMember" name="NovartisTechnologyLLCInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EncoreVisionInc.EastHanoverNJMember" name="EncoreVisionInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EndocyteInc.EastHanoverNJMember" name="EndocyteInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" name="NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SpinifexPharmaceuticalsInc.EastHanoverNJMember" name="SpinifexPharmaceuticalsInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisManufacturingGmbHMarburgMember" name="NovartisManufacturingGmbHMarburgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectOfUSTaxReformLegislation" name="EffectOfUSTaxReformLegislation" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AcquiredCashAndCashEquivalents" name="AcquiredCashAndCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" name="DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" name="ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BalanceSheetAdditionalInformationTableTextBlock" name="BalanceSheetAdditionalInformationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsUsedInInvestingActivitiesTableTextBlock" name="CashFlowsUsedInInvestingActivitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" name="CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_UltibroGroupMember" name="UltibroGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdakveoMember" name="AdakveoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ReportedValueMember" name="ReportedValueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" name="NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" name="NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" name="NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" name="NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PoPChangeMember" name="PoPChangeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PoPYEChangeMember" name="PoPYEChangeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZPL389Member" name="ZPL389Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueOfOtherFinancialAssetsSold" name="FairValueOfOtherFinancialAssetsSold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RightOfUseAssetsAsOfAcquisitionDate" name="RightOfUseAssetsAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" name="CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PrepaidSalesPriceForABusinessDivestment" name="PrepaidSalesPriceForABusinessDivestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentRefundsProvisionDiscontinuedOperations" name="CurrentRefundsProvisionDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ProvisionForDoubtfulReceivable" name="ProvisionForDoubtfulReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" name="DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_LeaseLiabilitiesImpactOfAdoptionOfIFRS16" name="LeaseLiabilitiesImpactOfAdoptionOfIFRS16" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" name="ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GrossLeaseLiabilitiesDiscontinuedOperations" name="GrossLeaseLiabilitiesDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" name="IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesMovementOfPeriod" name="TreasurySharesMovementOfPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DecreaseInFinanceLeasesReceivableDueToUnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" name="DecreaseInFinanceLeasesReceivableDueToUnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_OtherFinancialLiabilitiesCategoryMember" name="OtherFinancialLiabilitiesCategoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherCurrentAssetsMember" name="OtherCurrentAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueAdjustmentsOnFinancialInstrumentsMember" name="FairValueAdjustmentsOnFinancialInstrumentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" name="ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RepurchaseOfOptions" name="RepurchaseOfOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AcquisitionsThroughBusinessCombinationsRightofuseAssets" name="AcquisitionsThroughBusinessCombinationsRightofuseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TabrectaMember" name="TabrectaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_KesimptaMember" name="KesimptaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" name="OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" name="A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" name="A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" name="A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" name="A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" name="AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" name="IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" name="AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfOptionsRepurchased" name="NumberOfOptionsRepurchased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfTreasuryShares" name="NumberOfTreasuryShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_NotSubjectToExpiryMember" name="NotSubjectToExpiryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CommitmentForRepurchaseOfOwnSharesMember" name="CommitmentForRepurchaseOfOwnSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" name="DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" name="ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TaxLossCarryForwards" name="TaxLossCarryForwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" name="ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsInterestRateStepUp" name="BorrowingsInterestRateStepUp" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_NoncurrentAssetsMember" name="NoncurrentAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EstimatedAcquisitionFairValueOfTotalConsideration" name="EstimatedAcquisitionFairValueOfTotalConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ReimbursmentsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" name="ReimbursmentsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SparkTherapeuticsInc.Member" name="SparkTherapeuticsInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DeductibleTemporaryDifferencesForWhichNoDeferredTaxLiabilityIsRecognised" name="DeductibleTemporaryDifferencesForWhichNoDeferredTaxLiabilityIsRecognised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" name="NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisGeneTherapiesEULimitedDublinMember" name="NovartisGeneTherapiesEULimitedDublinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AspenJapanK.K.TokyoMember" name="AspenJapanK.K.TokyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozPhilippinesCorporationMakatiCityMember" name="SandozPhilippinesCorporationMakatiCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisIsraelLtd.TelAvivMember" name="NovartisIsraelLtd.TelAvivMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHealthcarePhilippinesInc.MakatiCityMember" name="NovartisHealthcarePhilippinesInc.MakatiCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" name="AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" name="CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsUKIrelandLondonMember" name="AdvancedAcceleratorApplicationsUKIrelandLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NeutecPharmaLimitedLondonMember" name="NeutecPharmaLimitedLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CoalesceProductDevelopmentLimitedCambridgeCambsMember" name="CoalesceProductDevelopmentLimitedCambridgeCambsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisOptogeneticsResearchInc.EastHanoverNJMember" name="NovartisOptogeneticsResearchInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AmblyotechInc.EastHanoverNJMember" name="AmblyotechInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisVietnamCompanyLimitedHoChiMinhCityMember" name="NovartisVietnamCompanyLimitedHoChiMinhCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisDeutschlandGmbHNurembergMember" name="NovartisDeutschlandGmbHNurembergMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>deckblatt2.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 deckblatt2.jpg
M_]C_X09N17AI9@  34T *@    @ # $   ,    ! ,(   $!  ,    !!"D
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ #J8
M   G$  .I@   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q
M.3HQ,3HR." P.#HP,#HT.0     $D   !P    0P,C(QH $  P    '__P
MH ( !     $   #"H , !     $   0I          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
M 7X" @ $     0  !.@         2     $   !(     ?_8_^T #$%D;V)E
M7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,
M#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,
M# P,# P,# P,# P,# P,# P,# S_P  1" "@ !T# 2(  A$! Q$!_]T !  "
M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    $@!0 '( ;P!O
M &8 +0!% &D ;@!S '0 90!L &P =0!N &<       IP<F]O9E-E='5P
M 0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"
M24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M%P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#
M<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O
M;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M      !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B
M0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M              !";&0@56YT1B-2;'0               !2<VQT56YT1B-0
M>&Q 6             IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5
M;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R
M;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M    #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ !@
M 0 " &     !  (X0DE-!"8       X             /X   #A"24T$#0
M    !    !XX0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      T<    &              0I    P@    D 9 !E
M &, :P!B &P 80!T '0    !                          $
M     ,(   0I                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   0I     %)G:'1L;VYG    P@    9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $*0    !2
M9VAT;&]N9P   ,(    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     $X0DE-! P     !00    !    '0   *    !8   W
M!.@ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( *
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M ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "
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M(#P_>'!A8VME="!E;F0](G<B/S[_[@ A061O8F4 9$     ! P 0 P(#!@
M             /_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$!
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\( $0@$*0#" P$1  (1 0,1 ?_$ 2$   (" P$! 0$
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M1X)(93SH.V982]C,@I()>M=<Z4RG/YCI:><D+54T?>%:>IRSP_1GSWT\V
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MC1<JM].O4&JGH0$^9/U=-8NY\S7GB94//1ZI.6%B:Q)VNM+(UR+X^>^GF@
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M1*@W<2 M5&7Q;L7%N5SIYRK:I,7FU967=1Y^05VO[Y,T%C'A:LUP^B<#?V@
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M/K#1HS4?B#E\,]>> \>>^S/!^,YE\6XCJ%N5>GSUZH['G"+H8W,[?WSWT\T
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M]?'^B,;=ZZ\J?;4]M?._0WSGT/1WJW[Y->?*G+R(]TI;ANAO(LG+DS=*;
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MI5VG@W[E[G13ZF7U4:>1]#XNCAXD776./TC:SAJT)?SUPJWD#7Y=.#I38
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M+(M[)W)"IU U>J%W/N?Y[0\G+GOC%6L(&Y@=E2U)>##5NUQKT+W^=^AF
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M-EGSIYZUU^;C8Z   ')OU<?XS_V5_6'^7?UK^%']Z_S_ /A*_2S\W],(
M        -D\_[P?S1_2'^YO\&_O'\*_[U_G_ /"/^EGYOZZTGDL)Y]GCNSQ9
M\\>O+53'SS*&;V>#"6(BE\     V3S_O!_-'](?[F_P;^\?PI_O?^?\ \)/Z
M5_F_A#V_/@OMZIU\I9^H^<ZK#IH7;4R;5-:V?=?QGU&%W/[\_4H7[_X?&.4
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MRWG;N\;J,_.*5F'3[[]+_-?2S
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M_-_(NI2)X7DP_52GR#%-4E"+V8B=DA<*CTQ[H9F.):1>3E3Q6MW._/4MB_\
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MK<F*KN[$2&K8.]]JT>-]I<$RU%9;,93?%?/9?/9?/9?/9?/9?(YV2^.<C?\
MLKE$B=90!PI%5,2OHZ\*<L=0_E:B!QN;5(RNJ:\'[(U 5QD0@[RQ (X1( I6
MB!,)E+!8/,8(!%&- "YGHU-;(CK*I*B:VH.0:L%G_*JZZ55LJ@B-KZHV.&O$
M)26FJY9W7=26.LJ2NCKZ4HN*GKR9VW($\#9$GD8#3$DQ>C7"O^)C$(2&:?\
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MO^H2MA(6N$!:MG7"-=/5#M@!JP98ZT$+YV0 B*2)#'", (]GHU8!4BG!FN9
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MO0:C?=.HM%5LM( /0U6FJLE3X;9<[L"/R_VW?I^]FS<>:U^RK,968;7\[L!
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MIY3J=KMZ7']+K=+T;9:SJ.4TFI(Z3FLSS8[:75=S_IM9LMGJ=/UC/:NK@-$
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MRH[Q)?EXKE:J2>(KW-1?=/N3S[D\^Y//N3S[D\AFB^W_ &^+D=_3Q\Z7@/\
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M5NOOZBMU%QK*<;=#8;,?RE/E: .HT=E35FAOPRPK$7T+W/T6HK>/<S#QU?\
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MF"+*"RZ+9Y8M)(> YJH2"AJ=P$EG.E1^):\^=19=R)30=ZQY=LM')M(+&,#
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M+-IY(V;IY[CQ88Q?MAR[P :YJNIG\0HASA9'G-H2-VU4)03;N G,BHZH#GM
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M$[&N34(#CD*ZSLO+0A$IB:2]F,/M6.4<X70*(=02<.TA*F7H@*=OMPAI#G$
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M/<X-#"X[0JAH4@;EGDH'9!\QC@P@B2J*S14QE,HE! M6VEQ!F3)9 @ #"8P
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M 3QF,5PB]MN%H\MP:M-Z2()'^2>$S*QYS#.AZM1)>R8@D.!8#PI1)43$3KV
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MHIZX?>NVM@>0 "4,D7A)446>%%K!X>#LR7U1;_#L0AP5 )G)Q$TS4)F8<YC
MJ E.VM9R*@:(3#+K[8"E$,O BFE>R+S;SMUL@(" &M1J< ^5J I*N)=6#L82
MQV2'U:8T.<"T$+B1)1UG(^$;  ' FM%!H#%ZWS?$QTT<&HTH@V(*)@*&:J23
MM9:4.ZDD%J*:+7T:J4 3PG)$68[H/+&V[[>Y3\Z(FW:B))%1)+C#GV[CO+VN
M! 59M<E6HH*)*M90U@=QK7'U0;P<3;  "T4(H&5<JP+(M.#05!)4[D28#4(
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M+0 *-&V90J1@LT;4!"25D[ECS+3>#MR?Y*=:89]\&W=MVWV4)VO"B37$3+2
MB3)!DIK#KCMI>005 (V_9VHB=%A]JVQC;#7*&M :"2 I*!'*5P"2-9P^TR^Q
MUS?O3!2 $!HXI6230M$HY@7+=M]MMIQ >T.&X"50E<)83$7;P>"7-+7-(!:Y
MN1:0 DSK,U4K:8QK6<NQP+6M : 552C4)73.4S'+;+3/.=N-US6M#BMQNW>=
MJ@.0.U+10 B+['6[;MMLEA<P%S";FT[7 *A!)(.TJ9*TPVZ^[M8P@]:%4 KZ
MYT$.>RZ'->Y=0I5#C+UU BPRVRVW<Q;A#1N>1<VMW.(!D@,MQ4&8:%/-!]JT
MZ\T-\MSF-WA;AW!KD4@+NP+2XU!'HFW'?*#-.I,X\FWN-PHXDA)$JT5J N"X
MX(#S;6N ^7;+YD6JT[-R]T"TRVXV]KE-$(:4J:[B$[T0&&B_;)!JA*JE5/>E
M,$./E-!?=57.*BI" !*3)Q.9- >9:UQW(W:M'(LR2%:B9@> YL,LER67ENKM
MIVI.M<T[H+;]LFT9 @E03)0*GJ0ID8%FVKB$W.G5*)VT66)CD[S;3AYN[<9D
M!'MV+- H4"FLX>EUPYJSN<0DG N"I.1!<T'1)%9>5<:0YWRD3((S"^RF58\J
MT"H*$G.LA@)X #):QR5X6G 76G<125Q6JAJ6YI@*@Q=O>8X7>7'$-LCO>=A!
MW83!EZO1;=P!P7$RE7U3@NN$ I*>6*#!)XI#B_\ J]])50@%:REI#K5HD.$Z
M@:]X*$&9:9B8$;770^X,D'8M%U 36">8<WS2&H%!* S,D0$JFLI8@-' JX53
M73NK%MC'$;2:$"69]AJ,(XKK77"T *=NY, I!)]\6R2&/851=R$Y@$YR*KH)
MP;MY[?*(4$.!W24)193PT $+;<WRT5RN VBJFLB$"S"*42<"V' DD47M)FGC
MW1Y9<&D$@K3U^V"^\\!F!4'=2B*9YHI^SEYELM-DCB*@))>)24$PLU%0/1&4
MXW[9(!X@_1!Y8\FT\M6IW;@5W+2OU=J)*D&Y:!) <@G-6. J!\J]:4@6LW)T
ME%SF0T@%!0$2#09XS'18=:/)!EE9 $\)5222"'30@;0!0J (O&9WVW-DM2G%
M2 UYQB\]LMSMW:46<M94&$6+3R49NGFI!RB\P%=[46B353*:5SPI!N^4KP9$
MDHW!2,4K(+ N"T XY&1.+A)0=2%SBQ;N.*,!3O&F4HOVF%=X&B(5R]$P6F[7
M=DI9(D-:QS?):DFAH"DJ3($J9J#253,ECK@/-?+N0;_+JFY%3'=5<%G#N9YD
MGRVM<$ 55:05"(B$U"9F&7[%TAXHX(1VM0C&8,P<B(MMMAK.7;\C&AK6A4+B
M@:T$DK4:B9)+&&Z/./"7)QE@!(!<FX@.F2"#VJ3S)OO+;;[;F2%-P140"2BL
M,-IR.5 9$$4X@CMP3 F6$!K &\NT#8QH:UK0H)D&M!GF,T$6F6;I/EBI";MQ
M4I0R.@]L70VZ 6M5A+0X@H5+53ZI("YY*"2T_NW2>T@%KFGY@00:B2@46JI&
MYQ2TT(QJ -:T$(  &@(B*:H*2 L!ETCF.7"%I"!P>\%6XE#66?6>8MO=;+F@
M>4"&;FDO<+FV6X*$7W>B:VXW=H-V7KQPG1(#++'.4*7.+L2) !H:DU49D90>
M:-AV_=D%VHBININT5.*D'E[[G $$@C0$S4%J2QEE#GVK!%C(%TNT@+U )I#^
M6:QSG6]JO)-730 2"!RR!K,8P.:N6"'%YPF&I5RGA&X3. GB8O-Y@N\MC#<*
M2)#0I&)0RF)ZB!^YVVA)%*CM*+HLJ*@BY:L6C^[<CG$E22B ": *@**<ZK;N
M6&';<F%PVR3/UKF91?O/#B+32Y%0' 3)"%2$0@Z81:LVK1(+@I'U1B3,# I,
M$D()D1<LW+9".*$B1"R+9N!"(3D2AG'+O;;<;]_$GA;L> 4 0$N%5)(T4B.:
MO(YM[E]I)"([S'G:"%P[,#3T6QSPP&A(<5.7S)XP\W7 /$T!<XD9DA  <"1H
M<H/,>>T<N&INT7Y4K655^\O#!9:N;7.!1V2-)..(":*M8+#< .N)RJ/"<--R
MYQY8I@J)BE2DJF/,-YKK)^5V)S"$[E$Y$DR1%5+Q (V,+OU:B9P4>Z"U]UK'
MFFZ07+<H 5/&0)AK'EOGBK0519@$A<"M NHG%BX51^Z66TSQP$%]I[=@522
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M;'+@2W$JZ:D2 P'5*H Q@\P.70[MB+*B[MM*314QW+.'/NFVWEPTJYY#0"A
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M'X#\*W\(B[<5KNW5KCE*-S+1>0URA:@M(.&1*=PAX:%0*9 H,ZSZH-T6SL)
M[40\62A,NJ'\K^&9^&*<*!0A4E0%!)0S0$-1)K',@,EY;A440KA#BQIVMF=.
M\QYFT[#]&OT:Q9LEO"Q4I]:9PAW"@<,$\):]D.OML!]P4)FUNI2AUEUX$739
M#7DS+9-)!,\B3-2">O 6V(H;2F8@-()<ZE"JT[Y^B#V$AP-1EW3@$N!8@IF@
M5:H5P-(=:;=.[?59[4S1?FG*:2I!NW51H* +,D.$UX3(F90=04$.MOXNG"0)
M3SD8J4%!AAI/&L>1YOS/0S0[4%9*0M0!N(D2BK>%[>;;V%A2HW A5(%.@,-=
M;?,==,B"4.@$_"'<?#X!$0A*%5F<(%JW<)+,2" ]9D(*(46B1>8'@.(X5"H5
M))""92@,E3!1##;=4@&50J'NP(ASGNH3U(H 02 &HKC%JW;<0;:S(DY:R0IH
MHI4$Q?LLN'>@#*J)SGM^S1:89>B (5O33QKC M6;1WU<YU:CA"!)+]67;.'W
M6V_WNY4QVIUKC2OJ@\M?#@""06U! )0J2T$AIK+-, XV +:)MT3JK]ZNBSA_
M+V;?$T@EQ(4[BJ  ( ,!*=!B6OMV5NM<I"\6P@[20L@N 4]JI?\ .#MC6%TL
M=LTF2BT]HC<ZPTL1"*$:J@"]I.1$X\L6@2URJ0)R!%  @7Y40H*0RY:LGS'R
M1RD,V\-3-%SPKMI%Y]VV=UMJR)1Q 0-D79U'6HI#&M8H6:)(:R$M%ZA#E 0D
MD4F%DB RT7L&-NY8L'>\&1HQ"!@G8XE:$G"+UR[95]L!$)1^[AJ->XY3'HFE
M0T9F@EK+O@,O7F&^4X6SD$F3(@(@ I([:D1^._$ 6!)<5HB5T3*=(V,N$.+3
M.0^J3[/:(8MP-!QR\1 9S/,A_-.0D!3M$D+BHJ-M0,*S,#G#S(\I=H0!2X@R
M)4$(J34(%48<P_>4V.,DHA7&',NWFL54)D"<B[ >O""RY=!O*I"J@-%=(DIF
M!U)%MY=)RI(82.,.>SF&AK&DO)D .\;@2$JDL:1Y(O;'DR!^5QJ =5$E70&/
MPYO[WM,P*-)P4U/=BH$,N.N<)T'OA]YG,L%MGSDH$'4JJJ;40DR!!]$66PKD
M*TIVF/-?;+13N7M55$.MN9P%ZX5FF&,7'<H +NU%1I(!P!.> FI0 *D3Y<,N
M(I UTP.AG#^8=9VL>0*XM0'%:C'JG'ED*TN7"J#UCUQ;=9MM:72)0$NQ#22"
M4,M92(%'.;: D)"><PF,DAKS;5JR54.,NY5(0P;%^TSRV @ -8W8J4VA4P"?
M,#,F$9;)#A))K+PQ.$-EQ+3K-%A"T$J5!I+O/LCRN8LM-M@X0&ANR00-0 @
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MW5%O;B"LA\Z."D >BVAP7UZ8^J"]X0"0U2J8I4KE-$@^8FP.TJFFD7!R^\/
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MHN(# [MW$+A',6FN)W ?Y)7+T3-C4<$Q622").J>Z&VK=NVVT' HQH:%($U
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M2J4CAM$- )K)= 9)#G[4+DE+"4BD>65V[E\ #AC!<RT-Y%2IE4R&'=J8!#$
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M&'.N'A)5:X@:2$,:RT&ALFT4"2SF3Q+Q#OF5NVP"&N %1@20I3OI+T3"P_O
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MHJ:B/,O7$:TJ@F24UD,E0=8K!N6;BM<:$(09'J/6APF:Q:MW+G$%W("%IM)
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MO^>LNS((YVZ0@4D%7R*! 9JX@H!([7?QK^?>3_ZV]NZ_G [/'"-K/XU_/B\
M*3SEY)I0;]<Y:PSFKG\=?G0XD3\;S"@)\Q&^04$3(DF8,7F<Q_'GY\PL:7$M
MYVZ[<P*7-"O:CT3:Z<UD*00[^,_SWR29?[[>W=HW).4@0DYF4-9;_C7\]*)N
M7G;P[!QE%S4I,(:Q;O6/X[_B(W;E&GGG@,( !W.!)<-TVHUBMJAASN:_CG^)
M1<94-YUY#@F&YS2TK-#O1LE)*AHL?Q-^9(30\S?D)S)WR$J*IP6D/%_^)OS)
M 9 <S?F)3!WA1.BKFD-N\O\ QY_$CGW"4!YYXV@"KD)+N*8 V*V2@A2'WOXZ
M_B07FCB YYY#B1)'%P+0LRK;B-H28/\ _4_YA_B;W[<?]4?F'^(O?MQ_U1^8
M?XB]^W'_ %1^8?XB]^W'_5'YA_B+W[<?]4?F'^(O?MQ^*M_Q)S0MY_B.8%SY
M4KO2NM(_'_F?.NO23<][WO*!)EY*SUUK_)N=>.[!:$T2'-YBZ0#2:DICCUF1
MSE#^;\TINV=B==%P355ASK%QYN 4W $B8*+0ZF0R-("<P/,PHBI2J]J)VR@?
MB+@+R!*L@!EU8!)5,.N.O)/8225E-*T5U $" UAUSE>8<]Q:0X%XDJCNUQ%(
M++-T!Y$EDI4A J3[S!_%O NX@(XBA"H2BX>$HWW+Q%L41X(<?NY ZTF2HG!N
M6[P-NI+G(@$RLC+(T12B3@V.7O<+B!+74>P]<EAG+WKG"T[10TD!B=)RUCS+
MM\BW]5'!VZ00-IW^"1YC+P\KZQ+APT["!55X@9("OHJ>V YP*  :5!/?!Y0\
MNMJN*K6O7-<H>ZVTDM!0#&3AT\)Q+-.DH=<+"CB)=28]8@VA8V\N$VA9@JIG
M\RDT,I!(O(IWL<T]O9I#6N*$%5QB[=;(N<OJ6<M94&$6+3G)LW3SW&>'KB^P
M%=[4ZI^,.O>3NN"E4&LA,]?># N"UM)/8?O)-#VKJ8L6[CRC 4[^K*47K36@
MAP RH5&$T/?U>B8;8VW!BH]R&&#</+::-V@;B07&DR3-2J++B4DM-PF]N3=+
M?Y?S!NY-R;I_,N$.YGF'N  ( :A)):YM""">(UDM:H67K%XMN"C@GBU".L$2
M.L,:TAMAJ;&-#6M:J+(-:"I!J)+* PW%O$H7"3RP*0TN(W$;IR<"DLXYA]Y0
MQ]LLD ?GDLP&RUDF=(MW>7>CUD9$=HFM:&8T(C:"/*  8P;0UH:D@!M%5JT:
M%)19M-XA;ZPNXJ:J:HJDSHD/;;<%'RDHXM*$%S5!0[20 $ RF06OM/.TD!PD
M06KQ @ATR*$3$\X<Y[N 'A% UH0-:T#:T   2:"<8Y?8".8Y8$))"'W%511"
M:&>6<<U;N.:3+RP=NYFYQ:_82W<%;/A(1>OT3=[-PR4KW@5]N4!EFT=Q"DDE
M05$D VBJ\,IG!%/,.Y<BYN5$&[8B+M7<FZ5%3BI!Y;F 2"I!&!#7&:RP,G2,
MI$*AN6["6%H"9=X"]0( RJ8?RPMJYFTEY,SNFB!0VN07(R,#F#8(<LPG%M*
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M0:^B&ZG2AZ+!)59UG[8MAKSY=4P7];/2&-:"9X:$=<5/RCU"'7'E7$5).H1
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MX0[SZ+THG? _#C/I,F!N(F>[HL-+J?#7T0%MI(ZQ[8)N,0]8BV-AVJF'?3.
M6_,#ZR%AULE'IU^,.N7+1(I5F'?TPCY"&8$[8!<U%E7Z8_W099>U>RG9&[G&
MSGE[".^$#3+4>^&MMVSM-9LT6O2<?[B"YQPD/Z2P?QP+7#"1_HI$FS&H]\-;
M;MG::E62IZ([:_#2)(!\8MMV!55=/C)8:YI"J#XC2 6]*1N(P,(6C<JX3RZ&
M< G.?AI' BY9]%@[L<.@AS<.@@@!>@C<G24*1V0YN"E/5!:&J?AZ+]]=(71W
ML$ 6[ZFM'>Z+?[SC08.I],,WWP)Y.T[.E,(\YEY;>>UVF86'V;/,*]H5$?UU
M1/&/+%[]YU/]R8QOYF\!;2I#M-"?;DL W^8VM/W7GU"".7YC<!DU_M$-+;\B
MN#NY$E[8.Z^A;]UVFDXXW8>Z.%RE-8:6WU!6@=XREVP2>8FW1V*8)/T6VY7"
MOLAP:,3]J&.^\G97+Q6-KDJ,\QK! '"DZ]T.:TT2A*D8HO7 6NZ?3VRBV74#
M@9]8E7IE!#AXNI[>T0T-&>?M6'I0]9HFHAI"2.NFI@!8(647/LDX=FN,-=EU
MZ#/T7"9+V^N-UQY5>F,-N6V+: S%:4)@6N7L[KBYM&(Q,H-I[T>11#73"'7[
M@F0BDZ4K*!<#";8*B;:G1?9%MG*6-UP.!JT43[4H1MQ4T(3'&$?=XE*R=GVP
M\GES/5DL)^V&)9QG-NGJA6-5P2.)LTGC#]W+U/VFRIX]W=#6BTBKBW3N[I:^
MB05[--(E2"S=AX]VL$U\,H50L<5)IT2"Q?5[M?")!0>S*,C\.Z*3RRARB8KV
MIT,!*X>$$KTE!./PAP("A5\(1)FGA7T3GFYP#%':06<O>W.'W7#/$@1Y%RXC
MUIM=ID/;VP+EXHS/BTRC>RZK.ITJ+A40;5F[N=^B1XE(V!_@[33VF&@NFOWH
M#^8NEHZG'+(&">6N[JA4</6!#UO<74[%-( N<RCOT+AR^[#3S#]O83ZEASK#
MEK@1EF!%Q.8F#D_33U0 [F.+]%^FGHG%Q1B3K\8N>6@<GWIUPUIX4ACJ'MS7
M.&-67TMZ$Q(BD_F6@E2'L;\R2KUJG01NTU]\('FGN@^95,S/N1('E(FI,N]8
M5RUKQ3GU>^!O:I&K_9ZX+;PE3HB0EF77]),*3Q*57= . /WM/1/MXD:Y]8]<
M/N72T*@J#66#_=#;CN61E)EH*9H4[H8"$?+3$+.0@V;EU"1D>W'IG#KCWS29
MFO4B]7O2";G+%HI5ND_7 -QJ3SPEE&WE2>P..6)7I6">:<=Z8M>%]7=IC!\I
MSBGW72S3"ND-++;R,4:=#UP&\FQ7',@#KXH(YQB.&H(.O##YDY2=X>^&[6/F
MJHUVG2D4=^J[W11WZKO=%'?JN]T4=^J[W11WZKO=%'?JN]T3(["#ZC_+P2/9
MI&XM092AML#Q"K^K6 6,%<Q-2,47Q@()]FFE-8<7-3M&D$)AF/=6),!!.8TT
M'M@8IU>Z%H.R71(<K:&=,4T]D-:UH5W5*FD!733O,?-#U !!(PTT@,:T!>K!
M/N^B6ND_#AI'"V7\[W0&FV=Q=2??\M.E(#G-5LL\QIG$FJW^=I]VG?UQP#A_
MG>Z-FPBXN3I4TI# X*%U]T*6\,EJO]'Q\8X6G;//]GII!'O]T %I4?I5E258
M#T*9]/H@O0IGGTS@CW^Z "TJ.O2DOH]$G3#2&M)4D],(MDGBRGUYYPQKE3=F
M<QBIA54@)X)!8NM4/JE!(.&OO@JXRZY4U@ 4/T:0X$]):07"Y4KC@FO=X0%=
M30Z5@+2)02'&:Y^^ [=,+GHOHM/AK"]/7#'X HDJ5&/3*&HZ80X25)5R@LIP
MCU#6'N$I8KK!<[Y3))2IK G-=*=_C"&GPU@RZ2@D.]7[4M%AI!X>S2O%GVQP
MU,$.KT]T/<)!="@DJ3\8!!EC2=/O>KT01TY:CUSU@O<[I+7UPUB25<%RRZ9I
M#4$RF6"3IE#B#4+WSASS0BG8<^FL$>,M-.FD-"5.8,I:>V.$])0"<O;#F8=G
M[/<L-(%982IH%@;>[H1!+OHA[449RG_D]T-VBOZ,D33T0#6]DE\!! ;PK[M(
MM@CB2L]!EG#"Y2W=J9RT]NH@E*@'U0[:U&@2ZRL)CV^Z%+2G;64J=,H/#+X0
M$$D,%&3[?=W0&EA7"NGW8"Q*D.+6S77W:0&;"7&E9T^[Z*?2FD!JJ3[>R&DW
M#NW5GW?-2 USD;+/,:YP!A\-((-/AI#G[R79J[3[U-(8KL=<#UP :'Z-((!I
M]&D%P=/M@DFG7I !)3+Z>Z"U93AYW3GGI .Y".O3T4^E-8Z:IC#7@T3#']:J
M>,!K'XY# C51&GPU@^/AK!+2.J7[4#:X;0<AAV^P1.GPU@A.DM8>7$3ZL,?F
M]L,-<Z4E]Z HI$A!)=PNT%9(/F\(:[<$'5I7BS]%5$Q'Q@N<[IWQ;;MX:8(O
M=I]$!UMLE&5"6Z>N)$K\-8:YWS3[!WYPI;+.2+W0TLJ2F"8:=,H^<H/HP6/F
M*)TDL$.)V@KZC.<X".DO3'IG!"S^$"<T@M+J$^/;&T.,S[CG+T2 #U0Y!PS]
MBX0QFSBW:HF:I +@"%&>8TCA"GX>, I*:=$CRRQ'SST&71(:'-DNONCA"]!$
MQTE!1GC";57Z)4,$I(?1%$!$7$ [.S2 $F?HT]%2OT:0&@J5'2D6W$\2:TPQ
M@&X1M)UT&?<O7 .[A7W=,X#,1VY:1NQ[??#B\S3736 %Z2Z""U88A2>N8KB>
ME(!W4ZX)-4A14P',>A7[VE9P-SY]NF'HJ])1T]\,=O"*B(*5JL- ,QH)3;K!
M0+TZXR/36%-P3-$%%&J],("&A&7OA.F&L.&/PUAY! !T'[4YPPAP(QII]Z &
MF1@AW3U0]P< N@_:ZB@AC@FT=6*?>[O1 DTI/Z8+B<_9K#&%QV5K]--(M@-4
M+ZB((!P]0A]VX27)B>L2GTHD;5)8-:4UI 15'J@))*)+]GIC!W$J:^['NA "
MAIK\>N 02%D4[-8&8IX:PN)!7W5EA'RD TZ2@$.(7WC4>B")ZO9!EPK[1I%L
M P'$*%ZIJU,(+BV:#U"+@>.%/?II$A,Q3A/9EI (FO8OKZ4C< DCE_HP%%-<
MX:T-5QUZM(U^&D&<_AI E0],_;#6 *XT\-,O14Z2@- 7Z>R&*9[M5GVKTI #
MRK%&>8@2E\-((Z>J$:9KJN!SAH<Y)ZQI\-((%.FD&4^FD$$S'T:0%$I=/=XP
M4$I]/?X0ZJ^S#"/FF/HTFOHE7I*)G'Z,X;=#^!$H/7NAOEW"BY#[IJ70N'PU
M@@]/'6-X?PF5-<]W5. EU!(B0TG\T(LD]::P0G3OA3\T^E8!28\:0)=#!E"X
MS^-8!V_337T4Z=*%8<XJJG6G;%LH=M(!8JK@=0N(@ JF'7+MA5*YUIV]46Y%
M*=.G;#0TE5"H<"1K :)$$3G(Z$.*PXN<KRLRL_\ *AQ*[!13_I80#-"9SZM8
M< )GZ(:"*"'&:!4GU:P*[2JSZM<?1 -RZ802:?#2&#"N/3V0'!TU'K&A@;>E
M-(.%?9I# ) %?=##N^L.Y1I V.XAU=U8)<Y%7[/O^,7&;E2FM-( 21^C2"1T
MI ).$7&JJ?0N$!H XC[M/14Z2T@ ""UHFGTY05$_ATUB<F])]# :) ?1I!:!
M,=,H=ND>I5I$@=OPATI$>[3IG!0'NZNGKA2)CZ.GMA4E\-()P3IA$AG[.GMA
M9J/H]$H/26L5Z3UC<7<6?<(XG=):P2/FQK[X 6?36%W*<^["!/'IC"BOPUCB
MZ>,/.?T:P#E]&L)0?#6"%4?"58><S[M8:X]*:^B5P'^5X<0@DS*G[5.^<,>T
M<)*I@O5NAC6B:YZC6-J*")UR$/N JXU)#M1FM,H+A2O;U+I 1M)]*QQ$89C*
MDVQ57%5/$?:Z)B1E+2&N(K(]4JS@*>(4.N$U$'%QJ<_%T ;9$YK3 PTH9U\$
M7B2N7HAL>A73QT@ESL=/>L,MM* >O]7*&O:BGWCJ/M@@W>/^;ZMV&?C#GO?P
MD(@ RK4DT2"P%4'3#6 CJRZ?3"LN+V#NJ[M3X![[B"> -.HCW1,TAC BGZ-#
M"DS/M['0H-!A\&I XJ'U].J&L!"E?!#]E/1% O0:0@I!:6\2T[M.F43'CU:1
M3I*"C>F,;4F,.[1/" $QZ80W:*=.F,$;>'HJ=#!&(QS\(0B?PT@';+/HD&4N
MDX<">+II!"<7PT]$M#\-8KTGKE!<#ATQT@@E?#*)NG .GL$;@>G?!W%2/HZX
M4E8"22 1\W36 <1XTU@@U(@#$0"*S@'$?1K+T3V_5(7&4\0L7-K>))UI/%<!
M[S*&NDBIKG &V8(QS(U@M*(F4J=<%0DJ]XS@$I,IK%OAD'CN4:A<(5Q"=,08
M[^E8N/V@ ^'5Q''W1; %#/HOAW5A!4CI\((-1%QP;CT^L<33LBV1GU^"S4^B
M>UMRHP E/KA[[MR2)1O>9^OM,-"T*^*(M>E(&Q=Q.'6-##B,0.E(<YQ4$2&&
M.FD-R5>G=69BW.6X*@P":=7OA >G4B^N%.*]GA#F$G:LC-#FG".J&(9'HM,H
MW TA29F+EM3,R,PO5PYC.+;6FO@B' =7HN!D^L::0T[.%?N]N$6V8)TPAA"E
MOJ^5))].L29(:C3%/"L%;? 5Q'NC:>GA!<1TE"ADNL::03LX4*&7N@@,( K,
M!#W>V<)Y?5,3H4^58*C#W1*?L@M%LHA!H.SY5RC:+5:)MG3[OP]%Q5QK66D(
MT>L^R+9W<1=GU:Y:>^ TE$(]8UCB./WM-(1%:)_6TTZH'%-:YTZ4!AHU[_&!
MNH?TO=!:VG;F-(>@FNND3$QJ=( -/ATUA[10=HPAZ"?;I"FHZ]/1-W(8<,X8
M\-4>V69AK 4G7M:G>8<H$P((1#CX^R-X !(\>I=( $DARB8]PAHE0PXA\S61
M[JPTN(4:'37UP6&@]G:V P (>F;H)#U6LCI*O5#7.10==-?1-)D,X<25AA:P
M^6"BX+^KGK#7 I/UD3T3,06S^4>H07.*N(TUA T[>FFL*'3,NGC!SS[H:DR6
MF"#<) ZO&?C"-N$ _HZ:B-H*T0)/#0Z0A*54)] A'7"0/T=,%, -ND KEIJO
MHE8WBZQII"[$;UCJR@@VQUJ$]4X7;-<QI]V.!GB/="[$"9CW0 ZUQ K4)4:>
M^ C15*CJ^SE"L8I&"CPEZH5UNJI3JJ!#]P&T4I[H"6E!ZAEI&X,D-1II"E@0
MTF--(N$B0,J>Z$;;'6H PT]%Q5[=-(1HKU]F$':)D?>@AXXDUZ>V%^IV^ZFL
M(TKCCII" 3_G0526ITT@%)']+32#(E!K[H! JJ?-ZDZ802ZHZ]*2BG"FONA0
M.%%QTT7U0"W%0/F]TH).%?FTT]$"O24(<U[H80[BIW=F4\X: BK[1K$^E( Z
M_9#';@JD?0)3QU$,4S!'K$3Z4@@=*1YJB?7A+[4_;&Y4(GCIK":"$.$*#,G(
M]6<$JA;/ZV.7HJ2^$"?$?IZH8BI5.OMIX0UC6J21X$:0G3"!NJO=A%L[N&O:
M4U]T-:P*053J(T,ZZRCII"F9]4.)4,)02&$M,_C <+A#=-O7GF*RZH42<!"X
MIUP-[2 24I*@3#H*0XAW 2%"!,-5$]/1<#9]FFD-<0 %TP[(;:#12DJI3Y>G
M7#7,MK/,9M^[U:0$:%[$P^[&XLX9XCW>Z-NU99CK3Y4->B0$MJTR%!.4OE@%
M!NZQ[NF<*&^K/&0\(=P@$'3'L^&,!H97JE33KI$W3]L?-#CY8"&=-*2RS@,:
MP*=1@A^SEEZ(K3*<J:81P#U^Z&M+9[DQ7U>U8:7A6J,\Q!)!3MTT^,'8/Z6F
MD%@MJY3+B7"LNF<,+F276%>J+6?C+J@BV9!<_=!3V^Z$<)C]+093Z3@.(E+J
MGGTE!<VGAV0?I]T3!4?I9@2E/O\ 13,_A#6N2O5[(MN)XLI]><,:20%UF98[
MISA5"@#U 906%%^)@D'#7WP07&7766LX19'Z-(()3H-():\J:R/J7NAI+IBE
M=-8GTI"#I2'G?,UKIK#2'!>W%-?1$GI36%Q^.L6W)((/J]8-=886.XL$3, X
M]8]\%B8>R'.^L4$SUB"YP1IPX<QTSU@;7'<LT2G? !$OA!DI/T04/#V=R$]-
M8".*8TTU@@"9^B-I;,02#(4H>O&%)X36FDJ]-/1('3\,.^ \E.G7# &B6*MZ
MLH:6B93+ C3*"0Z6V'O-"W7J\8(+1UR]T-"(I&5/U:0)S^$+6'J.'"8TI+.&
MAC0AZM-/& 6T$'=T]</*<*RIX2A&-"'&6GW5\/1%NTD_#2&@"2CU]46V$<2:
M^[&L-\SY0:\55!RQAQF 0HE#P!)*H@]_?.$Q[==(FTTUK*5/"%V'HDZ>Z'!K
M.#X=,HDWBG]J77*$+9]LZ4E!!'$80"<2854_:[J=<3;/^=.E)>BF>DH#3CTR
MPAETO.Y56?<BY0 XI2<\P<^J!K]&D$$RG[-(W.N$O773[T &BZX4QBLS]&D%
MIK\-(<]M3UZ)CI$S,=?TP&K+U^J"U5'OZ:0YPJ9X_M9RB;N(=>GHBO2FL+C%
MM^'4*KUY0UMMXVKDW-NJ^WKC[OPU@KT\8<\2$\![\NR&@$!"N&F"F*2^$$D3
MZ>^%<9Y2EA#9^K372!*#*"7&?9+U0#NZZ:?>]$$<A'2<^^"XGI+6+;$X>RO=
M#7L9CF,VZ*8D>+X:^$-<ZLTTI.LX(-,Y5[O&&EN)3"5-/"L%#Q?#6%)G.67C
M#@ZFFV:S]GQAK0DS]V5)T\( 6:09TAZT'5.FGA#0!(_HRIZ)H#5,NN'(TI#+
M7E\2Z]:T[8#G!9B4] M,?""@4_#2<!!*?;X0;>Q'3STT2&[FR7[WN@I7X:3A
M4EGG! =3K[,(V%AG2O[,BG00' */$07H@,/8P3!G,_LYI :YA4TKI]WX>B37
MW:0&JM.E,HMO7B371<<*0T7#PK][ @9K*/FDL!A,Q]"80HP&OO@J[LG*BGYA
M &[I*' F<;FW#,K]8K37X0-S_7I!)K"@SAI#RI,ZE9XS/?X0#NIU^BZ::PN/
M36+;@^62"E<X#0Z8(RS&L'IEK &/QQA5"Y2TU]\--2",J95@2E\-8<HG\-8>
MX. [!VIQ=,(8=P03PI*O% #:&"'8+#D< >S'(;L^Z&$.!;V:(O%GZ('<A!J/
MC!<YV<-;O**O;3.&!H.'@6G."AP'J&L.<YV'9B*06DDA/NZ0&M;-<$I+.)./
M1(!<9H8( 1II2?AF8!:)&ORZ=/;";CT3!8)#BIJ?H7JU@J$!/T0T[RGPU\?1
M(T FN4$ 27W1; $X#B.%?&2>/5!);/:,=!I#CMX$TUT,;5GV]U/; 5G#("9K
M+[JB"0.DH!22&"-L^W/JTC:&*"4J:R^X@K'32*SCU].K* PLF:>&GHDZ8:0E
M>G5#"73W@XKZU3M[(:'NX5&=%$#+X:01EVY:0U'J5K-54:PT[I=L#(_1I*"
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M9!J0.P$#(I VCI*"HZ2TBX!/+PT@ B733K@G#X0":)%P">7A :@Z(?14Z2@
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M$0RF2G5Q0D]IJF--4KGZ(;'3E3:G;.G?#B79I)OO7OBV!U^SI* 09K[1I2"
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MTH1M*@K,(BRFL?\ #N3J=D.F9H%,.M6OROFB_F/E'EA?W<W2112B*<HN7O\
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M[2?R._*[EII<""-S6%OS*55CEE*D?@.9_*;!ODGY;=DL^8NQM*AQ$A Y;_\
MY_\ E6Y:GD.7JE%V^RL></X!_)"W_P!#97#[D3_@G^']W_H[2?\ AP7'^"?X
M?3_T=K^[]D%EO^ /RGK/(\OH$DU.X5ANW^ /R1:?\#9\>" 3_#_Y:2J_\/:T
M_P"S@I_#WY:!_P"GM>ORU@M'\ _D8 J3R-K]CO@?_P!"_D*?^BM2Z_W?NC]Y
M_#7Y>>KE[/[ C]W_  U^7@Z\O8_8,.'_ /H/Y& /_P"#:G_D2UA!_ OY"G_H
MK4NO]W'_ $S^7_X>S^Q'_3/Y?_A[/[$?],_E_P#A[/[$?],_E_\ A[/[$?\
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MO\Q__)X\'?YC_P#D\>#O\Q__ ">/!W^8_P#Y/'@[_,?_ ,GCDCT__%'(S_\
M6UO'U_F15_Q(O]R:'5S%<,967SZ=HB,0C01'-SZ E0\V*1T3XY.:HK7HJ(J<
M_&YL.R2@! <:3V;6DUD$I"^ZX2 'YP)(F9-%60N@\MPQ[64&Q9:BJKGJJ<1_
M'K-F!I"[4U7M"W1?K?=?=T8HGS559N]*&R_T'2CNG[L8Y\-V/6+( N#L7-9U
MR[K!I+X]U4F>V$$ &% YD9%9?(CGED\R@L:=>45K\JN(XH-UUYVY-O>LFN/T
MJS[7LQYQV9 ;C_?&"^MV&W.ZNE1$SS1>E&[AL,NNA1EM#-*OJ0)E@A*R\(.R
MBNZDMA+-JOF<QX=6L8P;&K$7/5E,*>T"/90LS*FIZU;KB$N1^MCVAQG8N_"W
MR91_=V@TH/[?CS&M^Y41.K%&\"FU@X#V;8M8UFF,.L)C;NK$SLS1;3O<PJ3,
M/!HGO;U#9(89'/R[N#4Y-&]MV@%<VT=86R14F#6AK9]KWN:HMT%=[SH&/#(W
M1R,?*YC7_>ESGF'<31@7K%7;M3&7-5!A*O<GZNAJ!LT10J8,8:=-MZVHK>AD
M285.E5<JJ:U,E;TL)3TBQKDFPG0=,L4(;8XU70PK!80U(R'1VX3"I)(:S]')
MA,!1HFWIIL=OQZ0$"E.U350AIA% !T\OG-"(]NRA58 QCK$N3.%<N>"A/9-H
M'.)C0!)Z;&2JCAD5P^D;^S.04W]AU.GZ42-J\T3G]<"RP#:J'=2>O#8UV&G2
MH$$H[ D$;C+G!O-=%YS)6Y6FY45N.GDO/@X(+W-)#4OC\R.#'9P=8N0);J4D
MU\+L4B5X2_0W1PJ,.5'=*.,/<G5^T1.? ;4QM_2S53?R.QOUTZ:IDQ=W24#A
M7FHQQ0*&F>S?&OZ'JW$P94:N'*JXXIP7[O<K]>JUMLDZJE)+CD1?NZ$ZFQK]
M<(OYKS_0RDX@IC86P.5MJD"K>O*-J/:K5NP"T>CBSFJB?LV_>O/'@O%@9H8(
MM,#9:-W21Z().% 5-D:=D8<%N:82":78%/.LNEC9'ACD_65,.X_A7_"DYW-4
MZ/X4>U(OQ\ON_>/^J?9_.Y=S[GT_GU?;Q7M[ -[@)DV'1J#1Z)$YC"YC=@ @
M$]&,1$5X,]/4DSX(C?Q3A"30!S9*S+#6DZX.HEXA3HI&BK?8(:JV3"Q/5.J.
MDUTBYY-7I7B45H6ME+NF5:9)K#O9WA=?(7$F1BBPB&VUW&DE>ZUYCNE8HU3"
MJJ85*'QG7^*C:%1,PV=GQBW1TI+K'4[]D:[I'&S50@E)$^TBTFN5=AJJJXXU
MMQP8TE'=W?6A8M&X<E(J3+) )*9YJU(9E1?QRN.*Y*<%L)T;ZB5"DP"K)?N!
MJ3HU:I-XJ)%/3M9S3I'122-PKL<05-&!E(=$&B!M8!L[!7H]9O,;-&R,8!;8
M?&=+015URX@R-1;D3[9'N1RNWD;0'+7,#GZTNP$G?^_^<)\T-X*JJM>!'(GY
M9X@&[CK6R5"@LQ)+I+V:^5/)M9)H*P]S=.E"P662'7 ?6HX?TM>B97'CQJ6[
M[S\?EX9*E.[:F+6Q(K8"'QU+T1OGE)]EEO.@B=]R)=&>:F$1%7"]2[!LFKZC
M?#T3C*:NVZ8.@#WJJQ.5A*-4CK[!-&R*1$9?E8F47.?M3CY%JC!K1UX'LHX?
ML5OI:G=RTFGZV:9?^SDJQ@#=)BKXY;A>?$(W9=:VJ';:5XM[*&KK;SA796M1
M\BD])*AX[()S9@DCD>QTT+X8U1"'0J<Z5VW2F$SV:?JK0RVJ+>I*J<V/Z,IE
MJIA>7^']# EVY5I.M6/2U?4V4I>MNJG*-F53K5^%PB9S^'APW6%*Q6+IS8=U
MV>I7L=%6[?F/; 6V,NK&-7,J02FE57(U,)S_ )(=E<2@[@[45"J)ZDPM%#7=
M>Z)TNY+UIT^&/SXL!2^\&HPPY@JX[4-9+1A"5$JZTI<0<.%*<D>QI(RR(1XU
M&^5&UU179<J.Q$/-[U2VFVA1FN0E;+A-(A8+)$B-$$D$=%=3K4:O4C6->OBK
M45>*>EL,06K;G[&5@BLO9$0M=U/6SEAR#$<U[TBD+]+D3"IR_%<&MJ>6A6Z2
MTK5 LX-[FM]%1!&]X*L*(KESFS(>5BKC']37@@TWO1R.IKMP=;%ZOK!)NMQZ
MV1A=$5KFR\]9\IPP8>DB.C;)(@SRT5/*<[J5!8LKNE+:B-FU?$P&%D&4[IN0
M3U,D;TB%C@<6B8U%D2/I5/'"+P(T.OM0FC>TK01M.H1)+"GI:  3&%C-EA+I
M85:%C?"W*JY&(O+JRF>*&YQ?*FPQG-@)":NQS[.0'$ .\N>L3!(> *K*H+7C
M,3I48(>*;&].K]HR\BX75R%0U&YV@;;?NVZE-S;35(/U$]KTPPHB*]8WPQ["
MKU3DJX1/%<\%&5B=6069$WZO<ZUIMZ@V.1CX72([/0Y&HJYQCP5/PX@IC-BH
M!W"M<I4Z>T$:[;M"IY QL<9=S'R1,E8YOW?<[IPN/KQ'L(WY&V)+NQEQ\>TT
MMQ)#2 S>2\85H.%6^:VLT$?GC#QJB".F).ER>A<GAK.TURU=6:,5V5+38$7'
M<'BI@16)Z\\+71Z]2?3\^*Q"C:@O4;59+-6W5L,?2ML<G)S7,<]BM7/CS_/F
MGZ&X%V$90,""3?2W!92HR]0N,<GZLD4C71JBX^J<L<%2ET39]SW-@VR@XH5O
ME=@V!VKQ[L=]F"&'#O5;4-!K"4NEJ.Z$^O-$5/XD_P -:R 8M?765U?W$%_B
M3V_NZ&4+KC_=I/M3';.\>/+JSQ0)4!-E=MIF-5'P$Q-\GKI^/5W[J#]Y"'G0
M:LM-$3:XMO+<JQ<\DRN>&Z1/K 9VI^6C4 K48@R)&HKN47)B*CE7"IC'\G#K
ME\59]VV+1;N1$F0?L.QWQK39= (R4Z8>DS_* ^D;A7-9]%3/W<$OD>Y\=UT"
MG0&MZ=[6K["&GWD12"%MB-O-EWI&W6\*W8,>@C+N7GR<JYXUTM7$26"J;3K=
M'8"(J^5 $;VDM+-D,B##P[HIC8-8T^Z*1>CP5%3"JM;4KFL!?;E.-&C15:A'
M0H4,-5S.U1P(WLRM<JX2/IQE<>*\ H2H58-O.ZZ&7Y!M%+*F-A/;,X-&AQQP
MX719SJK*CDR[[<(OTSQMIB76J\ <;;US^'OJK#" L)'V9%-IIX;[V:U@V[[^
ME$5Z\VX3EQI92,$ZW!:V-]3Y#=0F90:>UF/3MC:*K[?&BM=L 2+88J2(QZKT
MNQXHUR<-TW2-1KDVG!%P$RU9M"@.M:K2>)6JV8S$C9;+HGY8B41HR3+5<JHQ
MJ95-+WG4:]1P,/1")9KW$.:UMHV,4H>9[62L:](YLN:Z@2:JJCD=]W)R;V4<
M!6"O5.CJGQTZY9[F@/7?9>N(3BU&,H^3L4;]DDO>8D:HU^/HU<<:>9;K,,X@
MC=+_ ,0_2681XXY$T.]P#W>$^R+8T[XB='7E6N_6ZDY<00PQ)!!71/3UX,(B
M-1%PG2F$Z<+X?G^ADI MBOZN4\]MFN4JUAA)8L>8CE(##,4D4XM?!6-5CU5$
MPJ8YW=BVO9:4<8PEMFJU-8U@/VT00E!'C@!#!J78Y-FV)L[Y!"N8QCHXVJG-
M;B*U>/X9?Q'K=@]O>YO<_MX+_$GM_=^R=GSCVWGI3/<NS^//ISSXHC1Y:PFW
M73.K7H1HRB_8-B?JL>Y@_=Y=00='67B(M<]7U/Z6M\4_6;A*93X[WRO25;#;
MP\^':-/B[Z,;,[M9)J-D9*(E<Y.I&O:[DBYRB(OO7;=DJ1/)]Y#5-9U>C+4U
MV@\0:F$J4DE.Q/V0J:5PA517N:QJ*K6MQA>+GQM=W^NH0%K^L[9[EJ:_7=O9
MH?L!@Z#<$-J][M9:Z-H#+R,(ARN3*HVDO2JZV)I&G-+KM.KW-A%"J#MC*4-(
M>87O9LT'%-=,!U]L:IU$WLZ6KR^Y45.!)CXYW2O0>_\ >PPK5C$;!KIR-L+F
MQC2CV)++*$GDPUSA\T;T5%5'+A,B?DO<SZ*FX:B+/5-4#5%HZUJPTS% ;Z&N
M>Y39@VD4G2MY_0BIGI9CFNV!Y=EKSAR5K7?X>36:\= 4=C<'1#2:>95&Q[)^
M_&_?TJO2N4;U)SXU@?J^X"YA?R-L! 2U=NUU;UO2GLUS8-A;+K[@JZTTU&YP
ME?Z@3<]R8_7<B*G%0CK.]W;A;4A).[8?M8T40I[DY(/.C[^T%#K",D8N51PY
M(.:HG2JXS[RW;;:]M3P>@9=!5IL"ZOJ@MXE2\K!C[#D>Z*)[NI2!-_4B,1OV
MIAJ[V&<>]36M; -M_'J7*[*% YK3=-UU2DNH6,([88XMB;?616]2M5>6415X
MU_506YCFAODHALD=:T9UY]_9-%00$>71H"2%K=<.-\V-RM4JC71IA5]>N42E
M2GO7"4U6OZ9Q,BK5(W7)]RR/5$;U/<J9YI]/Y_T,Q()K]G:+4#G>>)KV6#R%
MJNC5ZD'N)N97=*BJB]*O;U^"+GPD;J>GFZ&I062[RQXI1]O)'L["]EQD0-#K
M&ILL9:>@N=V5\<;&RL7+I'/7,6N*,B6^W4U-=[1C.E*:FNV=J3#>OKZ_O_6Z
M?RXMDCFF%6!":"ZGO+5@ZG2-\JD\8D2#-" $,VPO\R0TC!BHV7"JJ?:JKEQZ
ME\3WHK=HD^\6U<89!,V1!CU>G=$="[VZ9/X9S']SYY3$BKA.'3ZKJ9$=H\,9
M!:NPDZ3@7KBU<J^,L-&:G-$P_&_J;;?YCXHV];<(CE7@UJSA<:E1>DZB<N''
MQL<VW1-&]Y$0"T141R+6D!6W^.$]9X>.;B%M(/QTMBM#J0?9=7&1["S9SLW7
MY 4K%48AT&9:U.F.0GTB^A%3SD5'-6B7@^-;=)T]B[;V#7 -T01,!Z;LN>55
M&Q00;":<R!%>V-ZN<KUZ?5JU%==FUK07RZ(FO9U;O,5;7:&VM]/TQC1X)S%E
M" OV/2BWV,SU(GE]+55*>HU_B_8''=>*BV[:.V>F.'C=(Z,3B#4)ASY@.POG
M="KP[1+I7N5/O6ECBL'V/X_V&W:G,2?P^N ZB[![E(Q!+"O1',1J C; GJTP
M3?$U8V*J/5,9O&M@#15;5;72%XOKZ7D(<XQCII1/=<,8Y953I5W2N<\5[PS7
M:)CNFM4KE/6+5EE&C<\\8R5@?S'QRQQQL3[4ZF].$_+BL &?'6Q27-;)CW[;
M+LXH50HZ21>+\^-S)9)I&GC422X;VOK:UKOUFIG,.OG_ ([V*ULTULK%\>J,
MI"R]/9V(V3S7B3SE<H%RA$12RDD@;&Q<L<Y,9IRE*40\E-61;=2O:]8VF['Z
MK7HQJ2-S]43Q^J_H8K^P$J :HMNE1;<(VV#Z+[Y&3RXX?-F5(^MSG<NI43FN
M53"KQ[*KGJ[BAJ_M6XUA5RZUY%R%S<QXXZ./F[LT-HPB)E$3"^*KX)\H?Q<V
M'N?7Y/\ %3WK%T_Z;SEU?L_3[4[1ZO[^U]KQGGCKY\5ZA\MVX3%L&B7VD$6)
MK'EP^[ # )B/8O2V0X=AJ1X\%1WXKQ2E.EQPF$D0C%49B-N*BVX2F65(1['2
M]+7/=Y;L<^>/[_\ #VCL]3O%6KLNR+4FNBUV&G3+&K)F8E()1K7K##8,_K.C
M1B\N2YP@SY+3Y5V'NY2T.@B^2V;RV[[G:LCW0ZFHJ+JU@R(DF1RM',&<E;U-
M1'(Y4UMIHB@Z*GN.M%ACFJC?7%195M@2,QG*^=,C45$^OY9X%P&"X\=.:OH*
M$-MVFU%(DW(YS!\'5GKE7"X3*K^6?$/\7ACD%PCIFJ!ZJ"WVF3%4$,;$&$DR
MB,^]&R>GPJKXKE41>7&\DJ)1UDV3=K:;$,=814#>2(5@E%3&&K8AZG-QXHN?
MIQ1*.V8?ZGXKV2\:,5J=T>Y*!.733P*3OB*CGQ*P!L+U3*IA,?1%QJ=*?Y!D
M:"VJJ1>+  =HK#J?R+1= CY8V%6(S8#@;R)45%&2M16R(JN5OCL.OZOMEXM5
M#MIK)J,YM#[=(1&=$8L7&WSCH>):L*=-"1SL)CI:B.QQ\A6A9/U]XULPN_L%
M3U4:*'*-TK6 O;FHJYAR #U+RM_6<LF?#BGMS]M%N=\4E-DIEY.Z"VT 9%14
MX0Q >>]W4&?"S*JBJW&?#[N*147:K7Z!*JVW3MUTZFW*#FM5KF*J)E%\Q/P_
MF_0STKT,-VG8KK6LU+,#9*=ICTPK7,>CF*UV,8YI_.G!FI$ &A+A';]MN2>B
M5.FX*;N1]-+<]R9PZ/65I)CZ+Q'\@MUP,L*:NN"WI8%7W,ACJ4LL*X?WI0G[
M/N"KYG3RSQ%K&M5P +7Z]S6-D7:=@1QR:P3!'@QX8+H:^+DI.Z&N$HKB"DT=
M&OZK%Y8GI_(FM!ZD]UMVD6 MM1[ $NCU=TMZEEC1CVR,\6/9E%1>7X1AU##A
M9:P9V:X22CU/6\QYLOV1\I-$ZGR(";4:BKS:B+RSG@[\BQ:T%@@MZGK56J5;
M5;YS]F87V%QPFL;6(B3*"=09Z_*.5$5,KA>*- #!K0$1K.QZQMM(T?E); [:
M2P25I3L3!(9U90 21\;44I)-(]'\FCW<E5PWY U4;7E*U;54OKUBS%L Q6/R
MW"R]*1RL>GACFGT7PXUX+" JLV0;K8RV?K5;=")3FUJ'C88\PWB..21UK[5O
M.QU-POXIP7VLG2TPM3WRUKD.PZ\+NE1EW2E"UNSN(C#):&5F]L<SI546$*O@
MK47.%^.C5W6@QIP+8"*[!=O5FJY-9=KQY$&^4YKD*M=LOH?L5%:G2JXYJG!_
M7;PN@3;;$DFU*EM$6-"+8G]F7\&HDN,K]%X%B0&J4)BPS7ADJ:_3O41R$-B\
MAC#'496)L23OF=A;CD579ZN?AP=+FJ6D&*7R$9'F3D(.X6%DM*L"M>$:^YT$
MYEK_ 'R)5H.JBN:T.YO4Y>AR+Q\?[;-K82\T#:+KL5ZU68V6>-X=[@7VO:U#
M/DG%:J([/3^'+'Z*<9":,:_++A\!,#;6B1JJF<*U^%16KE<HJ87B?<MQW(@9
MNC#.^ZA3$BZLH#6^W@=S/:^TJ6"?>TJ>Z0B(CD5&L3DUO/*1&FE#G\+$ J'F
MW/TMYWQLFY)L#8T1#2P1Q='I\IW//:.CEYG5S2/>=-W"R,NV2VC:O:!F(93^
MGVJ1W<]?"/(Q!^B*0.<5IE?VK'X<C4147FO$02/?=[B(0W$->\N[Q*8<9145
M7OKNA]M.!)'S[5VSM.$1/+SPN^[OM\Y C*_:!?:A]--=T8/4 '30KN,85SI[
M222-$95Q(C*C6JN%:Y$X($9B)FK\<$-7U@$ V:Q1)R_'A+=._;+W1P<T^&&O
MYMF,N/C0BO3$4\&/5(FJH@SI^]D!;MMVO6=1*"S-)NR!*K34R"5,@8WM;+KV
MP1R.8C55T@?*(KZ#G_<H\10^0-U'EP]GUU/:YRO<"%LFB2-Z#0E%C"G SE5%
M[>K&L1&HB=+N:BMSVS;2Q$S\@Z:)N7( 5NP%UW5V& L$C?9XU>MS)F.G=T$'
MN?))R<G+*<;1JY_Y(.W]=^/+&L2C$HTA0#8-F4R%4J]-T,"8EB,L8[/^JH0S
M78RYKO#C5:FL_(9D4,^1]I)A354B-%;(X$V+2MB.(3TAY>)W994DU]RJPC&7
M$-ZD_9(JHBIKG=MA*;$4$$Q>I5ELDMBW$\78*D?&K.3YWV6/1'*Y<-3Q3"\N
M%UR<ML8S:AVNC@^VTTN%=?W($5F&UWR2/D>UD\5A[WJK;[.IKUYYSR3:A^R?
M(1HL.^,#PH.)KC!PK77;5W;2M?/=VWEPB-G>K,<Q].E!L8<3EJYB7I<C=7UO
M7ODH]1U[Y$O[(TI!>I"=@/ZVH@$XNU-*,E8FQ!LNC^Y"D)EK5=EK4Y)Q2'1V
M"%I*E5:R6BEE]XC;;TY:Z4HKU<^3/BJ\UY<DQ^AGM:N%I'R\72C!MTIV1MNM
MERO:PLL-EL#D\45S5;X_7QL6Z&BW==U>E=,"K)+9KPEAM-D!G)P144." 9MC
MCDAB-0JK[[ID8Y$=]JKA4_A]_"V+WGZ/NOK/<X[^&_MSU/9.[]S\OW)^M_L_
ML_F8^N/NXC,^1%8Z]BT<*D$T_EIC8MR Z]E'JCLOC[OR_/"\^/6ZJ#HG[T%I
MCK0NR3>.?:&M25\[1<WEOA:75,=/F(C57*97EB8S3TYX#35ID:XJULLZ,.WB
MM6=!4;G Q"SQQ@U5+2*KI.IRM16]/T70V_%KH=S'T0A;8+<FS"WZ12UP\7L"
M>ZBR[FIL!55:(NN;1<)C5SJB-<J?;U:W+Z:*QW[=M9UE73SK&E93I5D:S(O2
MO4K%3DGTY>..*I#5=<AV>6O.U"PEQ1*!!XY$<KE#I)TAG&6R?T7O8B^&>:<1
M[%%J[M<T<J('V-4OD;[5V$OZCHE:1F AFSP!@WDN;T=1)SW-PJM:CN-[UA*<
M4":<_6V):;/E;JG1'>4RG2G2D/A^:<^?$ ._\?6]@]RE.RZ$7!& \8\B2;K\
MQIPT^IE*LFN*]0EQ4>SN?)O+Z)P,V0AIM XE*J0N[G2 ;"Q;H*-D+7JFON-U
MJ[=@5V')TN>+Y(B^"]*6CI#67:P%(5AUS7$OE/5'R V>+*7RHA(60A%5'?Z/
MK>['-RKCCY!!K597]D;"+$-L13(OK%+Z?KVQ]3VHUJL>SOO3^?+'-,K7U6Q\
M<6#1;8;)==#)"-A$H!-CQ#'SK)L)0NR&;7K,@1R/5K6%'.555/HG%*0K#7K%
MEJXNUJ$[[(^.]THKVM<YC'JU'<T5<>/C^A<7V C&/$UY5@MD[#D;1H]2=*/)
MO5R)''U<LXPBJGAGCV3KINF1*D[!C<7#JUMQ&9C#I>0W.3>UJRQC8Y)32*SD
MQ%:J*B*OC%:?*J;>FIK L&57.M=X1.M4:F,H7PG5GBR+^0+X\N4I!X[]'2MQ
MMS/URM21S)''@X VL>M&S,,C'=1!OF/&HY&]3$SU#S%+;KUG2[)9@@;L!XB8
MO#ZS>A>C)P]E7 F*Q42^]ZPKU<Y%QRD^.=9,0D+PF J:N4X+3R4E&,N5>9<X
MB319%:Z:8UEG4JN5KOY$X,7*L[EW'V?J]8Q75R)_NPTWNZ 51O3]3CB///\
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M=+3(^L;(58AA8NM<H]L66Y7")GBG>T<D)]?4D6\X<7K.<//4(XG.[6\LQ[I
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M_JD;$OZV%^WP1.-[NC+GFGR#M:]Q5G+GT*0B'1A,MZ?^>@RY.*UHAM \??\
MBTNIPA%:+,%NH.>'-@I%..+='2$? <>J/Y-ZT;S\$XTN'8]G?[:V=Q#MFOV;
MLP37MZ<Z6'IJEXU;#WR-\4CE:.<[H)*Y%5CF(J<;* T?8)K8X7)4CN:S5,.-
M:_IUY.IL8<0UKY&@45J9<.:YB)E%1B>"?(<X6WYI0CL@RSME9SL^A+,U'78Z
M_)$S^UUUM%?[W$&S6]P&TI?BDH<I%9;I1@Z()?,C'!Y6FE+^7T*D+OV:N5&]
M2IC*9XI$Z,R3T2-9MNDOD/K*YBHBHY4?A[5Y^"_A]?T,L$L2303Y2:";#FJU
M>2HK5SR5."PVL&"!IB.X[Z8QK]1E"-:!S=CQ4*B^6J_>P!+3:Y,\G-5/IQ%\
MA)KH#":4H1"_I**%NY]WZ^GS43SUC[+RSX=/V_EPP"(MZQJFM5[VLG8S1.D3
MV(G=+ #@HZ*%L"-L:WV<8TN'JK*Y)7ND1BX1%5R<6*&^A=?=>EDDIW*HN:0E
MKI@?)B-O2PQ6;(R-_P!^:4G5TX\51V>*^O\ :A Z>(UL5B9HJND<,D,ILNH6
M7*<^M@#TC.?ATJGUX.;_   @-=I;2=="U"M>H/C,)L%8OL+CCW2+B61KP?;D
M_-*>.>,<4:(F[JNJ@M<,ZWLPDH5HE]C)F=B"S-*,@G%,L:U"($Q*Q&.7S7R/
M<BJB(B]*)2W\&!DNW*]JL7$5+#CVOV6J[I1$:5KQ/EC>B8Z)&\ESE?PUG6Z(
M0,AP)J8Q+PT5(T91*[-&&C0O@L]CDS/99A+[D57>*I_12]M-V[HIENZWP\>T
M@!\)VD_51X2MVEJA-@E?(NT.:UV5ZQ(G*IE>/C,W:" "3M1V4C<+62H\??O-
M%2:B>AC2-TC?L5-A=05R(O+&<(G!_7[5(:1:3%$:L%0K4]?0==?!*V+SF.PJ
MHDJI^"\OY4X$!-=!"9"H77Z%*F(JS( %VBE87'$]C7-8](HUD9SZD\$5<HJ<
MC1LG=TK8J.]&!QC:*8N,YKTFL$(@(+77/$^:[:UV3 4%5:OF*)1RLZE7GR^-
M]LD!@2'MBSL"E[UNG1D)(V82]H?R9'HC^N(VB.^W]55_1/%/)& JJ])ZY0"3
MD'$Z=MG5T.BEC1S?MZL_=E%SCEX\6-LW7;]C/$A9_>-9$U)&MU_7ZHL%N6PZ
MSW7V^$C1AHOL+A,3U>261K555'I&U%5\.R^GVO\ ADH!=<]Y]F,)HZ;-WC/<
MU=A7=@6'[>\^7V7HY^O^G";MINW&P)2X8TK5KM&-6G]<OBSFY@0+BG8"JO@$
M% <1E7^N'N1W2U>MKO!D8*/:-VANPWVFX-G]PO=L*;)U*WNR1JUNOOB5KE=V
MQ:_95RJ>@QAJ2;[O&W&CAV9VT!W13-9KVO!: 8\8$K@2(<VK'(B"'.4B_+G-
M5%:K>62.RRUMSA^-C6L:KKX/:+ PH_3G;"PYL+BQ=_77>X*"=7+#V=U=TB'(
MW_293JX%[!IVZ[#KT^W;;JVIGZ6!IL6P<8>T0A0*)/,6$*;C=Y>7LRCL85JX
M7(X()VK<Q%\//ZX1LJ[$7); MU8U=&IU3LT[=AC>LZ(^@226-4Y83'(7MN][
M%L&Q'OD'1QSRD3KDNM#@X\\&CFD$@@P*2!@1&K.J(13);JQF1N,-V4(<^0-U
M*ZU\>7=9M:X*G\D9(2>8&,+Q5]OV 4QAW9(@$S6LCZGQ=;'Y)*05<IJ<6H[Q
MM0$7\C;43%;/3@B&[ RH_P!F;&<B+@WGH[DFO2=>OHBHU'BT5><>51',U4>[
M8B)XF&*!M5&4W%]A/D2# S^E7&IF3R1R1O1%[B3>U$7*JY>2*_5#*;'0V$7K
MHL1M8XNI77=B'D'!&,>289B].Z225ZJK20QSF]:Y1W+I3::>U[KM1T9\=;"+
M%:M1FB&:[ZUTFFZ_L,QDRX$VD_8)&.V)U!R*C!;T:[$:NRB:V) _(.X!]8W\
MKLR[8+B?"04;)&)F-/@U'8"D<IS6&G9VN8[H=+Y:-51O;U3*TAU1;3H1E5M6
MJMBU*2(*B(C4_>AB1[YE5J87J5?[R(GZ&S8U*D*OEJS7OB&&+<M&E>^UJ='<
MXTF<-<W*JCNAZ?EQ,574Z^L:H.O&@-OOA)E_9+FQ #5H(440X(^<"H2(N'Z'
M/\S,CFJY&MRK4_A][#$+MWHD,>[%.O3X^]L=W0-W98T9[H]R?TNT='3CEW'Z
M\(;;Z%DJ[!I ;-M[FTL[%N8'7N?]-N$,+CGXHGX<1VM1'"3%Z"TQ;0HE<L#_
M %HY?,;(T838US:YA&XZ5DS'XYPN%64Y!JT&JZE)7)CQE4]<2[LMXF(+SAO-
M>+#R2!! 3IKKE&R229PJHC>:+\?.T8+5VH74!G#>P3'G6],9K!PL;#,+B_+5
MFR/V)R@KKD%/9&QK5:BD?JNMRHVHWOF[ZQK.;+W(G[]*MB^Q?I(B9QX\^(+>
MHAJ!Z:M9ZB86U=D'W;HU8WH]1!-46*(PQ$16^8O2N<91<*M7:[>OP ],."AU
MK58+=I+^RWVR1>>I(R@990 :.5JIAC'2.SXJF$3CY UA4I_[G.UQBMKK_7LG
M@Z&/VZ)XHN<MPG/BF(DT&/8JNUE'!-%("-DAH,84B S'>V;M&89YH5DD8>[T
MD!J%UZ6MS&QW+@>=D#Z\?D'4+]W=1HFQ-1NKT0]4?LQ37E5U^_J5S2,C4<B(
MF4^BG3(.CKX$Q3HV]8&-LNM;!Z&:%KU>>FC50L$CV2_;3B\Q6?=U.54X^202
MJ.7V/L@L/"E5[EER5TW7]CP38G+S%<;Y(F,HGY<#]2=HPXZ1V^V6;I9\/LD5
M#74IAVN*O3=N\LC.@Y>SJJY%PFT<_.&IG'%'NGI^[>D_KO;^OMWKNE.OIZ_V
MG3U?CR\?R_0RF3LURL*JR-=8N51Y*^E!/VW[S*,$*^1@B-$3KZDZ?#./I)J6
MD&:YBQ:4KMUUP&TX^-J=Z*O/OE)%(6S!1+]CD+O=&S,?6URJU5PURQJBK[O]
MHIXHN?;2&DQGZ?ZXQ_Y.%A^16TK)EX&1!5??&O=IZT%D<TVNM-V)CM3[]R;W
M5P]>YI#T]7V<52@*UL5;15+MH0E2M?=KHRA"]'N4PR<]#(T)HC$9U-)(K S4
M7*.1%RLFAZ068:2AW0K;06LQL>.>:)REYF$#D*-!Q.E>:<]E%'K(C%^U,(BJ
M8]+U^]DTG5>\>.?:RFMX[%C/+/>NX_X,?7@XOR2@2P<A#PHU?E"=_MQHQPQR
MVG:8W8?]W&]5?'=E%IE'_P"EY\:]<@(;".TPA;NUQ9#;*FW*P<Q7O5)#1K88
MWSZ^#:K'(QQ98T5?KR7@AI&HDS-P3I.K-$V9],F-$?0#PU>.! PHUK_6WW/'
M&SIZ(WJ5<O/];#DTF73DH-VF8J[L-O1K!9-VNKW-CC?NZ00B;',#\Y44PXMF
M)$RDGW(G$<>WGJH$Q\<F%-58=AM^W5:K@[@TA<9W5T+3 -T1MS4D8YS?-^OZ
MJ.NDKL1.'72>OWK=U"5 P.)-%.'9F5XM8XSC7K7<JJWI;(J>&55.') I]-23
M4ZB5O;B&UV'VZ@J/TR"% I[B\_TW1^K]^<_3C3IM"01'L%EK>SOT"R4]?;&=
M*N5-Q[ O5*!3*94OF/*83FBIPA/8#48K8OC2V0C8,*/(#22*?\P(R4>&=*U3
MC-D8SI%]"2J_J18TSEO%$E#7LUH2%/U;*UZO+2(HU414\P8]JO:]R<^:YPJ>
M/+]#C'^'\TXNATA'L=;VO>=DP,K+#3;[EW([L2-Z%SB1.\<T_%%X3Y"3;]:]
MW]O4)[.[++[&37$+]X03WGI]S]^ZN7=NGR?KVWB($M8:^5NP:2:>A*/UU+I
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M#H!]FMC$[?M&J[.\2U2L)<)L%1[PA^)Z.<C"8QKF93[5RF-J&;5NHU@OXVV
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M]6M;!-,F^\*U'KA?*RF?QSPP#7V(1J.KUKFMFF$JE-Y_:"&Q S41X([R;7D
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MB2O&'[#T[&ZQY#FHG2O6JY^GCI3-!H@)]A%Y:,9\>C)!UW51RJB$X=O[&V-
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MO6TUXDA-AKN8/8#)6O([8&^2>"-<(2'R(<TU5WK.IV(J.P;Q2VHAW9 T)6S
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M1R4XBERO?()6:VY:KUDH-O7FHF7LC:Y4C:N%1$\>6?R_0S%YQ1HS%7E8MBJ
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M9NN,@!>R%K)9$U[7M9H]GB>M$.'=+^Y(VJJK(KE61[LY7JY+N@XY.=&C]DV
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MN/R; =.0 1(DD%.V-;:UMDL8J)&YDKNASUZN>>.\0Z&&C/.+MEGT^#9VI?<
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?E(?5;4JNL3NM/5C<-;UN<JO>K43&55.7+E__ 'O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>logo.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_X0O 17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  "OR    G
M$  *_(   "<0061O8F4@4&AO=&]S:&]P($-3-"!7:6YD;W=S #(P,3 Z,#<Z
M,34@,#DZ-#@Z,#       Z !  ,    !  $  * "  0    !    R* #  0
M   !    (P         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   J*
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ ' "@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MFB_,Z=@-R<*BUU0>Z[T[7^F[T[[:L<4VM]-GOV>K?59;_HT!"1)';3=<<D0
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M,_X.JS]$NEZ#Z?[*Q_1];[/Z;?L_VC9O]+:WTOYC^1^_^E7.XO[,^PX'VO\
M:?[#]1GV;[7Z/V?G]3^T^C^O?9=_I_9_M?ZO_-^M^C1A\TSO'](']W_OOW49
M-88QJ)$>B0W$O^\_??_9_^T04%!H;W1O<VAO<" S+C  .$))300E       0
M                     #A"24T#[0      $ !(     0 " $@    !  (X
M0DE-!"8       X             /X   #A"24T$#0      !    !XX0DE-
M!!D       0    >.$))30/S       )           ! #A"24TG$
M"@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F
M  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M      $X0DE- _@      '   /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z   .$))300(
M       0     0   D    )      #A"24T$'@      !      X0DE-!!H
M     TD    &               C    R     H 3@!6 %, ( !# $T 60!+
M "T 0P    $                          0              R    ",
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   ",
M    4F=H=&QO;F<   #(    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<    C     %)G:'1L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$%       !     (X0DE-! P     "J8
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M_JW-Z#?;TWZU9?3KL=V%1U1OVK&H<YCMKVB+=OH.?4WU-MO_ &U6K7^,&?\
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M[Q_2!_=_[[]U&36&,:B1'HD-Q+_O/WW_V3A"24T$(0      50    $!
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M  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@               0  ]M8
M 0    #3+4A0("
M                 !%C<')T   !4    #-D97-C   !A    &QW='!T   !
M\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:
M   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V
M:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,
M  QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT
M $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0
M9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="
M($E%0S8Q.38V+3(N,0
M                        6%E:(        /-1  $    !%LQ865H@
M                 %A96B        !OH@  ./4   .06%E:(        &*9
M  "WA0  &-I865H@        )*    ^$  "VSV1E<V,         %DE%0R!H
M='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE
M8RYC:
M      !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O
M;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E
M9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M        9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N
M(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG
M($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M         '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A9
M6B       $P)5@!0    5Q_G;65A<P         !
M     H\    "<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9
M !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "! (8
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M949#!5M?20Y"&DKX)7A9Q(L<T;$:74FMY87^W2K!N%E-!,5U!9$9&*DD @,
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M/R>9R=?38O&XG']L;"K<GD,G6U"4E'CJ&@IL_+55=?5U4JQ10QHTDDC!5!)
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MV0RO:?8%=3[1V+3XZBD(.0GH<WEHZZ6%;LU+22FUE/L(\C[$G,7,^U[=<8L
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M:DDY/J>L4?NY\J\L;USG[]6>\<N6%W:0;I$L236\4J1J;C<05171E12$4$*
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MG6VY7W/LO$;\KTT87*; W74)_=3=R9!XFIE@H<O18Y,N ZG'$3B1M,?KYO\
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M?]FT_O?_ '=\/V=1_P >)_<'_?X_WUU6T_P_]_[7R_V=7N&/?'Z?^J4?U?\
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M7R!^XOZY\L?NG^I.O0M?&_>_UM,_\DW]X]G^E\/.GY=;)OO'7K-7HD_\P_\
MA'^RE=C_ ,=_V7O^%_Q7KC[C_9I/[[_Z%=?^DO:/VO\ >C_1S_O\/N_N_'_#
MOM?1_$/#]Q_DWF]C/D#Q?ZU;?X'U_BZ9:?1>']1_8R5T>+^G2E=>K\%=/=3J
M,/>+Z?\ UOMY^K_<_@>);U_>GC_1?[DQ4\7Z?]:M:>'IQXFG7V:NCD9;P_PK
M)_<>7[?^'UOG\'WWG\/VTGE\/\,_W)>71?3]O^_?_-^NWL(15\6/335J%*T]
M?GC]N/7'4DW&GP)]==&@UIJK2AK33W5]-/=Z9ZIB^%?^CK_9R^X_X%_LJ/\
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MWS^&E.[HBG\MS_1O_LP>_/X+_LB7\4_B$GVG^R>_[-=_?K7HWCK_ -,O]_\
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K7;JTUSUCA[:_N#^N_)?[J_J7XW@9K^^?JJ4;_DE?O']*E>&GNT:Z8Z__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>x_pwc.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 x_pwc.gif
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MV=K<W=[?X-_@XN/DY>;GZ.?HZ>KK[._P\?3T]?CW]_?W^/?X^/___P
M
M
M                                                 "'Y!
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M@11&, #Q:> <2GB!!BIP@L\5 W_#TQ__-O4$#E0P<AM0@B"V9X"+^< )&PA
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M '_T9 AV5@ &S.H037!!!5Q'@*)JK0(FX$$998&_W,WM C*PD@Q\0'RS0?S
M2BY0Z2-W$)46\ <31IA!"DI0&!;4X A$- 4Q0WA,"QDDK4S-'P%$$(5EF69T
M"(@>7.VJHQ,P4:]\O<03=, "W!E3 BFH 6D"2P@E@* !#7B 9"7;@ KT@+&(
@@,(3H,#9SFIVKY@-K6A'2]K2FO:TJ$VM:E>+G$   #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>x_coverfront.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 x_coverfront.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" 5/ \$# 1$  A$! Q$!_\0
M'@   00# 0$!             @$#! 8 !0<("0K_Q !Q$  ! P(% @0#! 8%
M!@,."QD! @,1  0%!A(A,0=!$R)180@R<10C@9$)%4)2H;$6,V)RP1<D0X*2
MT313X1@E)C5C<X.BLK.TT_#Q&41%1E169&5U=H23E:3"TC<X1U57=)26H[7#
MU"<H-F:%I<3%_\0 ' $  P$! 0$! 0            $" P0%!@<(_\0 2Q$
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M1M[T +J!$4@"2.]2P%(F/:I0T*23 [578^PDI_+O0 12)\O% 6&E84-) VH
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MGZ4Q"%6DR4\T!0FE),ZMO2*+%00 2H%29"M@/2G848LA&QWI6*@4:"(G?FD
M4S(.T4Q#3FD^:#(VBJCP"%+7"IVCBJ&"XG4D:=A3L#%:FPD)(,C\J $0E3BM
M1$ =J $F#I29E4T"8V0O<Q&]"9#0X2E *5#D<U1#0T@I21)GF*5BH%2"  H=
MZ:? J#7\T1M WH+2,2"EN$\CO0)H !0[3- J,\JDA,T"$E.I(% [!*%I_/F@
M!8+A\,[1WIW0F@5-Z%0=Z-P@QLF8]J38 * 4O?:.]%CL)4;">: L2?+$;^M
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M(([FA::/L-YI,T]WBU^^#XKY,B*V4(Q,W.3(+KSA$'?:JH6ZR.DZ$P=ZM"
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M-5045G,HW7]#51[,\A25)&LF*ZH]'%+L%>YIT.Q-1]J*"P2HSP*D80"M)*J
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MS/YU[V/Z#R9=GTB_1B #I)FH#_VS*_\ !&*UQ]')J/J1T;X]O_L5<Z?7#_\
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MY!! (,@\$5#-"0@**82"3':DQ"AMU0"5-JCOM2&.MD)\AY[4 &4+F=)_*@!
ME1X!H /0L"2DTF CL^&I*5!*U)(1)C>-JD#[Y?#?G/IUG+HEE+$NG-]8JP:T
MP:TMOL["D@V*FV4I6PZGE"T%)!!CB=P9H,))I\GRZ^/O-60<]_%FY>Y$>M,0
M8MF<+P[%KNV*7&;J];=(<A0V7I;4TVH[B4$?LTC:":CR?5$_#KT TG_]Q^0>
M_P#ZW+/_ ,73,=S]SXK?%%A&'8#\1'4S!<!PZVPZQL\QWK%I;6K*6F6$ C2E
M"$@!*1Z 14LZ8\I'V,^$_.73O-WP_9*=Z>7EB</PW!+2RN+1E20NQN&VDI=:
M=0-T+"PHDD>:=6X,FCGDFGR?-;])-G#(&<OB05<9%N;2\<P[!;;#\9O+525M
MO7R''3IUIV6I#:FT$R8(T_LP)9MC34>3RP.)]*1J(V^Q.@/M%7H%@FD 5,#(
M- "*=::,.NH1_>4!0,SQ$K$MJ"AW*3(H$ 3%  *DF8H ][_HKNAN5\WX_F/K
M'FG#6<0>RO<L8=@K+Z MMBZ6WXCMSI.Q6E!;2@_LZED;P0T8Y9>B/;?Q)_%%
MT^^&#!,'Q;.V'8QB+V.W*[:QL\,9;6ZOPTA3BR7%H2E*0I/)DE0 ')%&48N7
M1<<-O.GO7SI5:8DO#6,;REG+"F[C[+?6_E>MWD!6E:#\JA^:5#8R :!<Q9\-
M>OO39KI!UHSETTLGG7[/ <5<M[1QTRM5LH)<9U'NH-N(!/<@GO4G5%VK.?J2
MK2=NU(;!TE1V' %,0:4D R*J)+$B#[U0,!43O02T9I%,*!H&9(% "*W$T@,&
M\0J(-,3$6"%:B9$U+!%KRV)=2?8"L,G9TX3J5BA+F'C0OMQ7*^SL]"%>.!M>
MQ[T+D?H3L+4ZE ""29G55B).-O!;"Y:@Z32?8WT<MS"N75) D^E=,#BR&F2X
MI*4D([0:LR#7OICO30"ELI(@]J8Q2@+$+/&XH :)7/,4 &VE.@R=Z !!C3K7
M$"* ,(0H :J  *=+F@G3(D4"9B6]+H),T[)$#9WVWDT6(!6X([U28Z!*)CUJ
MK$PCYQH")C:BP$\%:?E.U &!(;4%'M0!BPVGS-HU:N:=B9,P+";?&<;P_"'L
M3L\*1?W+=LJ^O-?V>VUF XZ4!2@@$B2 8$F-J&R2Q=4ND&?>B^<5Y(ZC8"O#
M,22@/-%*PXQ=,*)"7F71LX@D$2-P000"(I+D$[/I+D_I=T&N?@.8ZJ7O2+)K
MF,L=/'[QS$%X,P7U7C5HM/BE93)67$3JF9WJ+=T1;L^4B6DM!""J2$@$^IC>
MNBRPCX92?-0 "DI4D2=J ,4-,MI/E'!]Z8#>E85)50)@ *28(-.Q!DK *@.>
M*EL3%3H \R94>?:E8AM>H+\AU'O[4TQ,0GSC3O3%1A@J)G>J04"IK5Q0%&:$
MB2E<Q4@Q2E.G2D\TR&"KR&!SZ4 -("BCSB()H8!:1S2 0#>1Q0 I!&XH #?5
M!YJAV$H( ,#?M2$8ETA!2>?2BPL J(DEO;B@#(U)&IN/2@!"0$E)10 BQ.F!
MSL*8,;&GYBK5[4(EAPGGB@0A']DTBC&PM3B0M,;[>])]#799,+0K4B$[17'D
M.W&BWV0"4)"]JR.A&Q\-/M04=>\IE(X(].]?-V>J&A"E&"0 $TT,% 3"E3(F
M*8A;A.FV=4>"@U4%;"7TG(7)-RX0D[*5V]Z][&_D/*DN3Z0_HQ?_ *TF:_\
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M!SUFFS?Q#*^1\Q8U;,K\%Q_#<*N+IM#D Z%*;0H!4$&"9@BE:)<6:O%,'Q?
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MQ$U9SWX2?T:;'PZ]4K3JUF?JBK,6)X2Q<LX=:66&FS80IYLMK6XI3BU+\BE
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M<5+=B<FV>?<+QSHUE3])KEG)O37+F 9>P["< O,O7@PJU;MV7<7=:<>4@AL
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MCG/F1\;_ ,#^.X!>=1_B3L<]X>]@[]S^N'<+=LG$W*5O.-MJ;2X%:" I<@D
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M;;Q/PB:=CO[CMG1CJ1\)GP?A_.F%YBO^KW4EVW4Q;/8;A[EEAF'I4(6AIVX
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M )0KTIT' AW^6B@X%@4AL0I,4(FC$($^:G84&&T]A18&.!,2!1V-(12#.U'
M4)I7ZT<# TJG>C@5"*VV'%.P0@ GTI6*S(,D:IHL8J$JDR:8@M(!DG:F,$I
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MC";G%39#+RF3<>$@JT:_M"M,Q$P8]*A9+=4,\%AM8.F3/8UJ+@)*(D+W4.]
M((J"1M0#$2930(>MY"5%6XFD6@D[($;2:&:(EV9/BQ/%93Z*1N[8F>>U8LT)
MC?R?C2 =1OSVHL X]!18&;T6 XE$H.U "C3ML*+ .!J.U(8G-*Q&0!VI6/DP
MB:+"F"" #N !N3VHL#U/T-_1Z=:.K6'6V9<?<MLD8%=I2XPYB;"W+RX;.X6B
MV!24I(W!<4@D00"-ZK:V9O(H\'H%O]$_DT6VE[K)F!5Q']8C"[9+<_W"2?\
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M9*B?:K34N@Y/67Z(2/\ FELP1_[2[O\ \,M*SR]#1]'/C/V^%'JR?3*.)?\
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ME)#D=]&J.]"5A*2CV0>K'0#K1T3\ ]3<A7^#V]ROPF+S4A^U=7$Z \TI2-4
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M)^4'>J1+&5("-U)WJD2(%I6/-L/>F +B /D,SZ4,!=)\1)C:(HM  I*0?EH
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M1!,;^]2P&B?$\JMAZ"BV(;4E*!"1%5%AT(! U*WGTIV 1UCDI(YI#$=TA2=
MV)BG8#124@(/,T62.*3( [Q)IJ5!V"II7RR-]Q1N&E0BC!U1,^E-#= K<1/F
M2>-J=DMHP^9M)&WK4LGLPB4:118MH*@M!UD@J.T#BBR:'6E %(WDG:ID^"HK
ME%LP<PH*2#R!%<4ST,9<;<$%/B#VFDF:LV&E'M3L#J*0@'RFOFD>F.H,&?:K
M0T$A,I"?2G8Z,=5H8=!3)2@G^%7$B1QQ2M5Z^J(U+5_.O<P_2>;D[+!@.?\
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M=ZIB?!1<4;#9.G<S4HAB,I&D;2?2@!W0E0(&QI!0.G24@"9VWH 19&HH/-,
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M3ND%0$E*@"4G90"-X34RE=%.AO4#X@<ZLY(Z?X:AZY"0]=WCZBBUL&)@O/+
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M3B6R5CJ6U,R9F/6K8F<_Q-*0X2)_.I,P&7DIW',10 Z5@#4GOS0 :%%4$$4
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M<TQ :W$(7ICF.*!B!)1N-Y]:HD40/,:  @(5K]=J #*21)I@ "G7YN(_C4M
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M"5F_$\S8Q^KG4W.$?8;;#;9+#CKEV\ZEUR$)T!,1*BM(3)(%"RI]BH[1E_\
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MWA.(H\&]L7W+6Y;_ ''6U%"T_@I)%0=G#(T;Q0!TOX:@!\1?3#;_ -=^$_\
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M 53 ):DH,BD)@'1I!)W)H$($?,HDQVF@!M:%:) %, "7(* !(JA ITZ@7.:
M!6/%42R!([4"!"$>&8)U#FJ&(2"W\HD4P!)!^[ CO0D2P5;D#M'%/H!"E/AC
M<C:D('3MX;[J4D;B!S0 A4TG24DS5$F1J5[4@,6J!II@ 4"-1@CT-  @=S^'
MM28" ZG0V?2A"9B=*0$J)D]Z &@));GOS5 %_5GFBABJ2&X5^_0 *O,F*$(:
M,("2?6G0!+(@+3L10P,\34F:D#&0?/)^?CVI"$6/!&YF@ _ZS<;4 $V 74_6
MI?0X]EGPE!)237+D.Z!;V'"$I2%Z#',<UDBV2_-^^?SIB.I-KT*U':1%>&SU
M @B25^M" 7>(]*8S'E*#9"1/D/%7C^HB9RFV*AB%P2=/G5S]:][#T>9/L^@_
MZ,TJ.1L[:@=L<8'_ -#)K5''G[1VOXP,3Q/!OAPSMB6#8G=X?>,6C!:N;5]3
M+K9-RR"4K00H;$C8\$U2[,H]GS,M^J?4YI!)ZE9M4>TXW='_ /65Z&.$?5$9
M..AF_P"HN;;G$\)Q',&:,;Q>WPJ^8Q%+%[B#UPA*FEA1(2M1 5 (GG>KG%=)
M$09]D,*Q*QQK"K7&,+N$OV=^PBYMW4F4N-N)"DJ'L00:\OHT/BQ^D+R=B>2O
MB*S@<:MULVV/7GZXPYY8(1<,O(224$_-I<"T$#@I]Q71CZ*?,3Z4?H^^GF.=
M-?A0R5@F9;!^QQ*]1=8N]:OH*7&!=7#CS:%).Z5>&I!(.X)(.XK+([DZ(1QG
MXVLZX9>_&C\+/3VV>0N^PO,@QBZ2#);1</M-,@^FKP'3_JU>-?))@^SW>?E'
MX5B,_-MU0O'[_J;G*]NWBZ^_F/%''%J.ZE&\=))KT8_2C)GTS_0R?_6^ZF?_
M !@LO_ Q7-J.T5#HOWZ703\+-B!_[<,,_P"]7%3@^HJ1PG]#((SCU4W_ /4S
M"/\ OUU5Y_043UC^DL$_!?U ^N%__I&VK+%]:&^CPQ^B! 'Q+YB@_P#K+N__
M  VTK;/](D?1[XS_ /[%#JS_ /%'$O\ O)KGA]2*/S_$D+&QY-=9D^SWA^CY
M^ [#.N=NCK/U?MG',EV]TMK"L(DI_7+K2M+CCJAN+9*P4:1NXI*@2$I(7CDG
M7"+2/KAAV&X?@]A;X7A%A;V=G:-)9M[:W:2TTTVD0E"$) "4@;  0*P*/$_Q
M06/Z0?K$_>Y0Z8Y!L\F9+4I;*W&LS6B<3Q)KB77$K^X;4/\ 1MF8/F69TA\4
M7':NSQ-G_P"!KXD.EV2<6SUG3)N&V>!X-;^->O,XU;/*;;)"20A"I5NH;"I-
ME.+=(^J'P=]5['J_\/64<Q-7*',0L+%O!\6;"I4U>VR0VYJ]-0"'!_9<2:9A
M-4SS3^D\^'+/&>KK+O6+(&7;W'%X79+PC&+.P84]<(8#A=9?2VD%2TI*W4JT
M@D:DF(DA,TQ22X9RS]')\-'46]ZRV?5S..4,4P3+^567W+1S$[1=LJ]O7&U-
M(2TAP!2DH2MQ2EQ (0)))@*R254CZ8]0\\8%TSR/C>?<RW*6,,P&Q=OKA14
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MC%2-TB9]*F@".DC0H<4@$5X6S>@F:++0B@(2/<4,!ZV#1=(XDU+Z''LM^'H
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M;<DQ)D?2KB)#*B0/$2-4=O6M$#(3I6N2E?F/;TJD(92M:"$)$0#*ZI$V(IT
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M"1I*I'M2EP)LHF(G[T!6\F*BR&@[=DJ23P(XHL!Q+:= @;T[ <0@I!21).]
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MU<' )(B@!U*"7%*U$2-A3 =3O"M9F.*: 0%:E:=(D<[]JM=",5K,AM(((FF
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M2#,SVH)ET)!6H*#A$=HH,&85 KTJV)$"@$(K4D):B5#^5,M$D)5I@P)I,L;
M*3'- #[>TI5N([U,A#UJK2L$?*D[)K"0X_47'#$JD**1I_\ +^%<N0[8=%G
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M"8J%Z83VJA#JCZ<:3_*JB-_2<LOTC]9/+C?6=Z][3_0>5/ZAEYM3D:9<6M0
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M)E(@N(*TD 0K_"J1(SYH"1RGBJ 1<G=Q,GO0 WX8T#S=ZH#"E+CI5'FB :
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M3%WB%T\LVULL'YF6TMK)3PH-MI/E)%=$WLC2)7)]BF66K=I###:6VVTA*4I
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MET!D'TH S7[B@!)I<@)\R@[$:-Z8&*/$?Z0ZC[4T#"<6$I/&],0'^B.^Y-
MJ^6D(32MS2 8%,8XHN)V&\;4 AU+<$4ACBCI$TF# ?65* [4(DCJJQL$"5#Z
MT,DN^4X#J-]JY\G9T8NCJE@0+4!1 V[U"-6:Z_"E+\01Y-@*3$B3A>Y^\WGT
MI#9/Q5*?LR>/0TV,I5^=&ZMR"0J/WO\ S4B0F0VEI &Y4*3 ,M^0A&RAP32
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MI5*2,GCE1&=0H)B*T7)Q2@X/D82X64D$<F:HFMPPM:EJF-J&:))&(;UGV]:
M;H-X(0F$G>E0HVWR-K\T 5125&:-(TI63[4#N^6$I12I.GD30R4K0DZM^]2%
M4#&](9@@;46%,<0M28$5+[):3'$..).M"]"PH$$4$\)E_P %QA5]:H5I"E-
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MFP2J$@P3VK)]FL1S5 X-(82=AQ2Z#HQ:2H>4@&G8^QA0,:9\PY-!(G$3O]*
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M&VM26DC@#;BE0K'3)B%1,S0D C:22%J49]C3H*L>>4="?-,[1WH$T-E(0"4
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M)!B12 4@^*0# % !A([.$DT@""2.:&P$()(BEZ #!"Y)XIH!2 700(3''O3
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MHGOQ2 HF=VB&5;'O64RCE;K8-PN?6H Q28,"I92"!4!&FD,.-@:; 4F12
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M*"S =^#106$3.U(8I*2@)43^% "ZI\A''% &0)!@T 85(U<=J %1I4OR_C0
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M (I.DD)WU<S0(Q!$@'8)]* .F] L3^RY\:82M*#=I+22?IM71IW4C*/UGO#
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M(!]MS2R%QSM0(12E#2M/>@ '1"P20=0G:DP(W"MZM 8N$-E:3)/84R6-.&4
MGN*<0([RR=OPJF "0O3H2-Z!"PO3I6128&?*-/8;@^M2 VH!1U>M "A *)D>
MDU: ;*4D_,#5(E]C$++A$[)VFFP#*PD^'(CUK)B8"EE )09(W^E"Z&AUE:T@
M%:X2>2*0I%HR1G6]R?BS.(6K[Y;96%+\%>E03.Y%=NFU/P\MR./48/-C1[FZ
M>]5<)SI98?B>&XPQ?-/0AVUC2^TN.2GD_7VKU-T=1\]G)&\;V%U>Q]JU4;9=
MPX%B5$QL-ZRE+=P=./%3*UC.=;%(#N(/-Z&"2E96 5>OY5C7N>BL+HHV.=>\
MAV*UV]QCS&ELQHTZB/Q'-#Q1ES9&]XN#4J^*'ISI6VNY*P4A*81S4>3$AZAO
MHK&+?$%AB@JYM+PMH0DI2ETP%[<>]$M.F:0U6PI6)?$4RZ[]P+52@"(;1!_.
MN=Z;DZ8ZVRLHZEXS=H<4]8-(;=7(=F%?2*YYZ*W9V8M6Z%;SLBW?;#]QX25D
MZC2^#HMZFP;+$7<QXH$MPA*EPG?=P>IK#)AVF^+/9;E9-=:5]H*=0/E.C>N2
M4&SKW[G9K[_"!8OA"# 0-A6+B;Q97,388+OWGE<.ZY[CT'O4K@J33X*Y>NE1
M9#:2H'R)0/FU'8#ZUJF83J/)V=G!U]$,AO8$'[=&?,Z6(>Q,. ES <+4?(TA
M8^5UW<J!W I^943SXWJ,VXY)B35E:L.L6[NIEM/W2W%*^4[1![S4XW;.W+2=
M(II\+QEZBV83I&O<<\BNCLPZ$>Q=VVMPPPZY.\)4?*KZ4XPY%*7!9.E>#97O
M,37BN8 ^[<-KA#8:"AQ/)]ZY];)J%([O#XP;N1U/'[[&\RVC6 X/AR[&S0K2
MXMN$>(GD!0XKQL<E#EGLN4I+:EP5[,MJG"<#4JY0EM#2%?<@^9L#U'(KKTO]
MK/@XM1-8%N9YEOKQ=_?/N@^4*,3Z37UF.-)'Y]GENFW][&D$JE2=QS/:M;,8
MKDQ3ZX*1^='937):^D.4W,[=0\'P9[>V+Z7K@@2 V@S_ +JY\\]L&C6*O@]T
M9I>;M666[9.EMH>& 1$-E.PKRD]L'9TUN1X8^)3'&K_-[.$-'_@#"=6_<F=Z
M]?P^&V#/&U\MTXM>U'%U[N*<_>,UZ)A'A)$K#\0NL.NF[EI0A)F)J)1WJA)J
M+M=G4\!Q:TQVU"D*"7P/,"=R>^U>=EQO"ST\.19E1M &E)(1,QR.U8MFVQ(.
MP2 \L*&LZ=E&LV5%\F]L J/(J#WW[5C(Z8F]M4H4X@A!"9[CO5Q-'T;?PT>]
M6(NR%J@)C>OG3TPR%J&XXH ;45E0T@F* ""G"0 GD&M(&<ER:?#PHX@[MOJK
MZ;POE\'A>(<+DW.D2802>]?1;79X&Y,:=0D]Z=!8V&A\PY&]-(3D1?!TE:E;
M;U:1#;(CR)DQ(YHH6XHO4AH_92"F#ID5EG7RFN*7/)PNZ/\ G"B> 8KRST(]
M#< ^8;TD4A1)&],8A!&] ! >)SS2 )*()4!.GF@ ^=TIWI@8"J#J2:  )3.P
MBD!GDF"1/I3 +7I.C03%( D EQ)BF L[FI92"Y3%0P:L=9!!\HDU#-8<(EM-
M@F5<BL)%I\CX5(()_#UJ&4F$5)($)TTJ&(KS0$[Q5" /--(GU$4"E&DC<U0
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M!,&:*$9PK?TIH!LH 7)'Y51+$<2028D>U C$^;F@#"DG:A S"@Z83S5$AI7
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M8<"_5_F9K-E?<PDW&)+'A_9;;?C49 W^E.H+Z(\FBE[S&'WL2 TK3; #<#Q
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M#TH 03$Z>] #LR5'N.*  !6!J1R>: !45*(E.XH (!:MXH P$)^=- !I.\J
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M3NJ#Q30/H/PT^_YT4*SWAJ4L3/&Y^E?G1]Z"?,-:-D<0*:!F C\JI$-BEPF
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M-!*^74:1023+:1WI@)IDS2 4J]?I3$90,P!*22"-Z #@JW50(S2/:J)%3S0
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M]'HT^9,3UWVBNHXX-?O_ *$9WX"KP$EG%71])_W5#TFD])O^ UKOM%ZXH?\
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MTD'S$F@800$@I5SZ4Q&20-)3"3R: ,2%SY1M0,*$D:J!" D'S4#$4H[A/<T
M*UXFDA8VH SS-D)4(GBD J4E,A6U,5C0))T@?W:0"%$F5&"*86 M'GU)5JI,
M+&G" )_PH0#83MXG:@ I"QJ)YVH"Q!I*BA7;VIB% A,>] 48M 4=A0!@0D""
M: $(GR]J"@O#U"$GCFD(5M!DF9B@#"W,3ZT!8X4).],+$\(<Z: ""%'M10"I
M0D#S4[%090@(D46 &D$';BF !C8I3- K]Q>8VB=J LQ10$I$^::31I%JC(DR
M$R>]!5HPI/)$52=&6YLB7O<>U;05]'/EG46C3J&EPGTWKK5)<G'%-JSOOPM8
MQ96>/OM7;3:0K0940.]>CX?5M,^4\6<\.59%RJ/H_D"^PHV*%BX;3,'8B*Z<
MZE=*-G5H]9AV7*:1;[K%L(2DAR]:)C:36"QYEU Z%K--+O*F:1_&,$U$_;6/
MH5 5K%95W$Y\FKTU_P!XOX -XY@HC[Y"O<*YJMF:7*1"UFEKEW^\>&.8$?\
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M#:0GYII.RE0GASO,46_8./<P-PJ.0>]')-ALL^65+Y]J?(6AY*$A(!WBCD?
MPI)$@^::%8G0F@=N:HG@31JW.T4(3H$:4G<33%Q[AH2DCC:BRTTD*$(U&1-
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M )'F2^RGVD],J_)__P!Q$>^ ;$#LBZ>_%(_WU2\:\-?H_P#7[C&7V8^TT/\
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ME?[JI8FBO/Q+ZI+\T2&\E8P%DZ-R. V5?QBEY3#XC#^VOS!7T_QT_*V=*_\
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M'1]OG.V'@=M.!D_S52>##'Z9)_N9K'Q+4/J$_P"']1&\M](%2M.<TE([LX&
M/XFA8\?NOR(R:S4R?TR_A_4!W+71YVW<4,UWY5^R486T@'\)VJ_A\$H[F^?P
M)CK<ZG4DSE..V.",XO<L80^Z];2 AQQ 2HQW(%>;.$(R:1]!@R9)039H5)2"
M4US4=B;&BWI$IG5P(]ZB3I6:QD[/<F3_ ( NM6.94P;%48O@-HU=V;3Z$./K
M4=*A(D@<Q79@U6",.6U^YGDZS1:]Y:5<]?,OZ%G_ /0[NK5R V]FC+4)[ZW>
M?RK:6KT]\R?Y,YHZ+Q5*H5?_ #+^@T?T;'5EQ9T9XRXA/U=/^%0]1IGU)_\
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M[S5?%XU_NE_U,7Z'U3=_%R_Z(DI/Z._H@-U.8BO^RI\P?K!J/BX?\-?FS?\
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M11_9_(ANVRU)@>' Y@ $U+QUR6LVYUP07+7E24+$>M9NO<Z%'_VL>LD:#Y@
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M !H4I>[_ #*^#T[_ -VOR <Q;$U'S7]RKW+JO]]5;?J_S!:3 NH+\D"<1O\
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MTT@'FY\!U*M]J(_6A3YQR/)OQP/J1DFX3JV2PN/]DU]?]EXJ\K_]K_P/RO\
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M\(+&(M^$\MY:V_50G:JRRQ35#Q1RX);B8IJU<L77+VV#OB*)4% &=Z:<ZX?
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MY_U+^)U/_$?_ ,?Z$1_X]OBINA"^HS('H,*M1'_:4UHL*X*\S5/]9?FC7O\
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M79B@01 VIB700UQL8%-"X&D_UU+U-']))#F@$1SM3,7'<Q9.E- O<EV[^O\
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M;?9I0E0TQQ3:H2=DW0%><J TSS6<59IUR<3ZRXPM!;LV702X=]NTU[>AA2/
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M'J)::"@DB8K)]E)(Q8 D@4FZ*I&HOTH:6EU*0"3N?6MH.T<63A\#%QH*-8
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MS(_>VH !((&F.*:&"XKRP-Z0(B.$AU'UK*1K'F++-GM TX&3WP='\U4:CT_
MPT3^9_B<M=VKS#Z2/(VB=0VH*?19+#:S;)K6#X/.E];)LF! VIE!@IB5_A0
MB52#I&U "DR!0 \WX95J(W''O3*B.;*F:DV0!X JC%C+@&],Q8@^6H&-ND0!
M31,B.I4"/6J,P  ?+/&](80.I!(W)JD B00)-(E]AGQ.YVH#@P<U3$%(]:E#
M$3S5""21ZT"84E/F'TH!!  "9WJD'8J5 ^9T2!Q5(770: #30@T=JH%V/)U#
ME8H+'VMTP5"F*71)P\)-TD2-R*J)S9&3L=,*2$D0$\U<SG@:AA7WFYJ$:,W%
MH?OF3/<5K#U,<WT+\4?67]&XV&^B3R^"J\N8GON*^>\77SP_#^IZ'V7=K/\
M\[_P/7),)W,;5YA]4,:AZBH*!4L<)()]* #*$J0"3OZ4P$TA/!I 85$< T
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M9A?J;$=1+)3<!('O-1\/,KXG#[F)Z@6T^5U"?62*3T^1%1U&'W)']/K50"6
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MN+V"[Y^#]5"O!\9XEC?W?U.W[*<_$?\ ._\ ^D]8/)U$P-J\EGUJ&="#M4C
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M)H&F6"T5-LF.U;(\V7$F3 M)0/6FBNQ1($IB:=@&"!]>]+LI"CUHZ&&C<T6
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M%)ICY3$4- !'<Q1T%V%J'O0!TC3H0-2AMM7J'SXVJ21M ]:'P.*W,%7L..:
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MW%""H;'RCFG1#= %6KSMB0/+O0.JX8BD@"0:0T^1#"VRDN*'X4QKB5T"LZ1
M%-\%+D1322= 4=TS2KD(R:Y(R4F3[4TC=L19DQ'%)C2,E7H*+#@Z2(3(G:O5
M/GAG7$)"X*CL30J]1-OT-WE#+#V:+[=1;M6C*W> 3^Z/K0DY.C/(U%6CKB$(
MM;=-FRT&FD)"0@#T[UT4J/.>24W;&G#L(XHH3(SNY !HL-J%5M$;46+:C!N"
M3$=J=$[V(2J02-A0.,FW1CAT$!/\:&RS#) )I61(64E.QHLFA$[)@'\Z?8NC
M-;FR0H;4ZLKS&N@H3^T3-*D&]@@Q\QWIB4FV/MJ&F"2/I04XV)?X;;XQ9N63
MB0I3B2E!5^R:M<JA1O&]T3C.*X7<8'B#EC=IA39A)[$5SM-.F>A"6Y6R&KS;
MT4/<Q"(3MS28KMD5R-0CLJL9=FT>F6+/$)M<$]?U2/\ NS3U#X7X&&D5-U[G
M-5F5E1YKRSZ)=4-K48GTHHM(L5FO[MLG]VMXO@\R7U,D[S/:@IND&VH@A,"#
MS0./(8)!,;4%I!N*5.F=J %2 0$DFF6DFA4DQIDQ-(M<"J\I@"F3)4-J^6/0
MTS*AM>V\]J.A2Z&7"2!08C2T;3%  +"AO&T4P7(.HTF50/XU(C""*= $#MI'
M>A$T.;P%=QM5""Y5I5QS0+\ Q%!)D4T 0X/J*8Z,&XWIV)BT6 XD@ 'L*I":
M#D'CBK(!4HC:D [A[BOM*1M,U4'R1DZ-SF3^JMC'*2#59?0G$K*D7((BN2^3
MLVCK;I"P?6J1+BBVY>>)9)"U)CT-=^E^7DX=9)R5=?@;;Q4*'F;1MZ"NVOO.
M)M/BE^0J'6TC4E(D<4K?N9N,5S2"%ZI(D)1_LT5][)W)_JK\AUJ^/[J1^%.O
MO$VO1+\AP7WE.X_*G0;ON!%W!@!)!$[C>BOO)X]E^1B;T$$0G;C:ES[E+;^R
MOR,3=)4-PG\J7/N6HQ:^E?D";G5_5A(^HHY]PV1_97Y >,E8@Q^57=B6.*]$
M"X^J!IT@C@@0:15>W PI\@SXB]7UH= DUZL K+AE1U?WJE)&F]^O(*@ #Y4<
M>E)JS6$ON1I\05P"$@'F!7-E5&T>7=&F=5YC'K7%)G2N0)]*FRA6UPH$#@TT
M"^5V;)ER0/*D$^@KJQ\&65^8[:)R#*((3^5;$))>@I;3SH1^-#15KV0BF]7
M"8_=VI4)T_1 QI\N\^IHH5+V%C:=6XJJ$XQ?H+K=B?%4/H:?9F\$'Z!AYP"
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M@ZQ(O,5R']ELWP5H7"@WSI]Z[=!D2R4^AO$X1W>I Z&9L?P6Q1@6/*<>LA$
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MT]Z;XSJ=3@^&.J)D)3"5I/MIBL5B4I4X\'?'6RPK>IVT:-71[+-FXIW P[8
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M28A\I3!FD/LZMTIZ<OYOLW+AR\-LE)A!"9WKT]$G+U/%U\ZEPK+^S\/6*NN
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MY97JU8GU)L6[=Q!:*[:TEP))\Q2%*B8]:F?BCE]+_@+!X%DPMM\_O.L=/OA
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MFTI2%)<,3O4%!#PCY4J)G;B@F@7&R$^6"9% )"K;2I*=(&KW-'!7 S<$MHU
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MN+MG86A2%$[E7 HWT0XC8NW2J5.(2)[]ZNQ42K>Z#R_%2"T'24%">*'-Q^9
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M5I[4>3?B8PY>'=257;GS8A9(=*HCOI/Y;5[WA4KA1_._^V72>5K,>=+ZU_\
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MI.X%8R:L]' I2QJ3X)R\SXB-)^S$@#<1S6;BGZG3&4HCB<RW*A(PW_\ .?\
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M7\*^"\>T4L.>5G[5]DO$(:W1*2]OZDYK$&GD**ED:>(KY9Q/KE*U9(M[ML%
M#J/-4.)5HE+67/,C30!%OE+=$M$:@G^--(2?(SA^&7^*OL6F'V[MX^ZH(\)I
M,JU'TK51<N$9KR\'SR9TB[>R_P! +08ABR[?%<ZN-ZK1AM06BRD?,H?O"1SZ
M5UK$L:X]3R?/R:W(]W"CT<"S!BU_F+%[K'\8OW;S$+^5O/+,A4GA([#Z52]C
MJ4/+5KLK"F5K<+:&P(X IMT--SY9OL-P@FS+RTG5%<L\E,WC#@U.-VKC;<J
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M&.*&@9$U/J6"=24$:JI.BE39[-^"G/>:,TL7.0,7";[#L*9#M@ZZK4[;3N4
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MM?0:+6QS13?-'YUXGX=ET&=XX\)G"U8?>M8<SF''[._0UB;K[2[YU!"'VTI
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MQ^:)]7@U:R1IEUNTML+4[</!"4[MZM])K%1;'+)17\9S;H26L+3I@:5.'?\
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M-GP'B^LV>-PU+Y;^7]UV5[J-A^$=1NGUMUIRQ8)P[&67QAV9,/;&LMO)2(N
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M3G:=JQ\;A^U9\7RD<5D:71I<W@--) $$[4I%0*-=PE6H@5F;&DQ*[0TRM2^
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MG?*=Q^=0*[,"EA&H@Q0,<24Z=4_G3Y'0GB(F H$^U+H:'$*CRE,@T)CH>3I
M@"*&RTN!P0N/1/-*QT.>&#P.:8J%#80C0!L-Z H38[! HL*%5!W[ 4FQI&-Z
M""9VJ;'1AA0,T(3I $ &!562*D;[\4FQI!Z^PI&B$@D30 2E@J!!GRQ2;X!-
M6:7,BR6T'LHP"=JZ<#OHYM1%ME>#R 2%+'I,[3]>*WEP<C@_0)H+>=#3"2XM
M7"4;J/X"IM!7')<LN=&^JF;0AS <CXM<-.& X62A$_50IV"BCH^%_!5UXOTH
M-_@MGAK1WEZZ3(^L354WVT2TUS&+;.Y]'_T=2W[ZWQ?JGF!NZMFR%MV-DHPY
M[+7^[[548QNY.S)K+7'%GKC!>B.0<I8>W9Y8R7@UDE,)(19(+FW?6033GFDO
M[M45#'#_ 'BLL0P]G"$:#X;KP[^&$MI]T@=ZF6:;*Q881(;[RWW!J'-0FWV;
M;>> \/LQB5VFVGR(5*SV%4FFZ%+Y5R6-^[M+1Y"E*3X3$I0U^\8YKJQXY2=I
M'+ERQC'LIV)WS#5V]=,);3<7!^]6I,F.V]>IC^1?>>)G>YE5Q#$5+*DI(0!M
ML9GWI3R"QX[-(\^=R3/O7'.9WX\3(K[P(V.]<\I<G;&*2& TDPZ/G)W%9OD8
MZIMOY28FJHNQE8"04]J.@9%<\,*^:A1;Z)!TNN*2TAE3A7Y4A!\Q/:*=;5R"
MY/0O3?I^QE3"F\1Q9/B8K=@/+4 /\W$;('U[UAER17"?)O"+E^!:GG@7%'6#
MJ.J!P)[#VKD3?ZW9MMKH1ELN*(BDU9HG1L@$,6IDQ5>A';.9YLO0]<A"% ^L
M5E)FT44R]0A;NEPPDF)K-M&QH,=QNSRW;.WEXZ$(:V )^978#UJH1W,3=G#,
M1NLQ=5\>TZU,V#;G XT\5K7N+HZ?E?*EIENS%LRF%MG_ &O>I<D^"5?J/8JA
M 0J>>:QI6459]),J2-CWI_@45K,MTIBS=4E?FX I,#@F-%[$\25"" #'%-$6
M;+#,->MVBLH!T;D=ZIB791>HV'!Q)?;25+00"1WFJ@Z?(LK^4XGB;);?4LI,
M$Q^-=MIF.&2:VD.1Z46;'WWPE;GZO6EM:T.E25:TF-,S!FN:1C F,KO66@+F
MY4A"DJ#:$\I]0H^_-2U:"U9/PW%&57)2&TAQ$NHTI,+,<*-9-&J?!.8OD6=[
MHN$$M7;'A$JV)*C)/U J::2]D/>H-OU:H\:]<<D=3'\^XWE_+6#W-]ES$;QI
MQ#3>[=@\4I7YS^R"25 U]/HO$<.&$HS5IGPGB_A>LU&2,L,JVN_XV.#+V"='
M<*N<ZYGM6<=SK@UDRNPM5D%JVDK'B.]E*25;#L(KEPXI9\D^./3\#V_&/$_.
MTF&6/ZH149/[UW_,X/B^+XUC=P<Q8OBAN\1OG1<*?N%:W2J8 5[)V*0-A%>N
MHXX*\/9\AAQY\JVZKIM5^9-Q.^LKK%7++",8TV=BZJXL[IYD-W(N"D2ZI0&\
M+W'9-*4MV'<F=F-*.M\BN/\ ,W74+$\KX#G8IR*I%\D8.Q:W+]V/$\:[6T#<
M/%/=2E3YJ>CRN.Z;[2?^)'BV!*<,4?5K^#1[ ^"S!3@_1,8HJY2'\:Q*YNE$
M-D>1!T)_,)VKY7-*\OXGWN"&W E]QVI=P7BV?&+FDZR-)!T]ZCI2_<=$$I.-
M^EGG'XG\\W64L;P7#XU6SK=Y=!J=G5)2E*0/6"N8]J]GPN"Q0CE7ZO/Y'S7B
MT_.S3TLO]YQ^?!Y$S)BC^,9CO,6OG_ <=;0VZA.P.E  'YUW8LDI6Z^IG-XA
MH\&&<(N5>6E_%41L)Q7397^"V[:9Q!@I! W&X,C\177*<\2>2:X:H\+3X=-K
MG\%IW4D]U_AQ_B=6Z9Y(O,]8E;XI<IG \)2XK$5*,-@A $!7<SVKRXY7+<_1
M_P"!];K=.MN#3R?]W;?W[E2_BCOOP\95MUXWFCJ<+,I:<=8PW"2$Z4"W$EPI
M]RJ!]!7#XEJEFG""ZBJ_B5X'H'I,&:<OJR34OW*-'='KU5LPM;K9&L;0)KS3
MVEP1&\98\R;>U\$$21,ZO>I2OHK=P1'UJND*7JY^4'UK2*VF<^1NWLRG0I8U
M%7W92G?<]ZNGDX7XF<6L4G)]-5^]^O[CA/Q79LQ6VR5?9)R?:W%T]<!/ZVNF
M$R+2V,A4GL3$1[U[GAVEE3R17S/K\/\ L?#_ &@\1CCR+2;ODCS)_P *_/[S
MYA9F=2_B;C;!)0VK2)VX-:YVG/@Z_#5*.GBI=CV84Z[#!@!'^;+W_P!:EE^E
M&N#ZV<^NC_G+A]Z\Z79[F/Z41XU*VJ;-47CIKE#'NH68\%R7E>R<NL1Q=]++
M2$ID $P2?0 ;DU;^5;AJW<#Z]?#O\'>0OAVP1&)OV[6*9H>2';N_NT@K:5&Z
M&@>$@]QS7GSU*E)Q7YG5I]&\C2.E7N;U-A3:5F-1 (3 W[ 5S1EN9[\M/Y<4
MD4/,>=G,.0^W<O@>(#I,R9J)-I\'=IL::^9'E[-V=<TOYYLV\J9B?L+QYR4W
M*5$!L)Y21W!K*,'*1] L&/RT6\?%GF++=Q^J\V82QB"V4Z5+85H*R.\U>1SQ
M2LX,N@AE7"-SEWJQT]ZRX[;6>%7;>'8RYL;"\!*G_9O]XUN]9":2DCRY>%9<
M?T,MF.98:L[YEJU:):T%"2!WK9QV\'GJ;*;FG*[MH?%=:V4)V-<^3':-<>;F
MCE6.6>DK2$Q![[5PY84CT<,[*1>J0EY0!W'->=D[/1Q/LUGBN>*8.QK,U)H<
M!:C;\:56.Z&T.J"@?#VHVAN))>4N GB-ZEH-QC;9U Z0F/4Q4-%IDQFY"UZ"
M@#UJJ'N)C5YXK*D-&-) ]*<5R*3M4.:[I:2WK.J.QK0E6AZVL'"B75D$>]3(
MI,9OK8JA 6%)]S6;*L@%EO6H*[#:D$I<)&[R6RU<YDM82-0!<1.T%"3,^E>E
MX/CW9TCQ_',BQZ=LLK#BW<62HGE0_G7UK1\-OLZY=!*KP1,(0D'\HJ)]DKH4
M-H6=)I!8#OD0I(H! V3?C@(/:DALUV,X8NU45Z1"M]C2:*3&+=KQ$"$_G0#)
MC-HH&('YU+7(S8LV1 !5''K3"R2&EIY /XTDBQQ+'B;*:2)]*!/H/]7_ /%'
M0KUB:9%FJO;531\["%R8F(_E1;B%*1J[G!L&Q&&[S"K5W^^PA8_B*/,]Q>4:
MRYZ2]/KW_A>3L&=G]I-HE-&Y/T!8VO4T.+?#9TEQ=)2<H63$_MLC0K^%)QB_
M0I193<3^"[IK>NARVQ#$;$#@(<"@/\:/+B2YM.J MO@]Z1X<#]KQ+&;P^^@"
M:/*B+>WZ#BOACZ2VZ2VS@UPN1$EV*3QQ%&3-7?\ P<9#QE)=P[$[[#W/V0E0
M5%3Y:-')I%/Q;X'L::>4[@&;&71'ROH4#%2\;]&)3*9BOPF]6\/U?9</M;\"
M=[9SS#ZA5+9)E*:*AB'0[J[A*5.7F2<44VGE:6M0'Y4;&NT5NLK-YA>-822W
MB.%73"AR'&5"/X5#X-8/@CH<\NN0$_M>U'95CH6I7RD$=C06.I)7,=N:"1"4
MIWD"DQC17 B"03S&U) C-0! 3Q28A/& .DG>D@,\3>9 ^IBF/@SQVY(\1,CG
M>@+0'VA)5I"P)XG:@=HE8=;8AB;@M,/LWKEXF AILK)_*J\M^AG\3 Z!@'P\
M]9\T)!PW(6)-I5MXCZ/" ]]]ZI89OT(R:F&QJ+Y.@X5\ G4K,'A+S1CUCA"/
MV4%'BKCOMQ75#%M7+HX5/)+[SJN4?T>W3#+P%QF7'L2QHF-;4)903^':J3Q]
M78I0S3=R.K8)TCZ39,2EK*^0,%MU-B$N.6P<<'OJ5S3>:,?I0U@E+ZF65!+:
M0RQ+: -DA>E/X)3M24W/EE^6L?"-[EC"#B%WX]UNPWO]2*FK+O@NF'NH<?(0
M@)W@) V%-&<C97A#2)XVILE<E5O;A;JY/'>I9HB+I<4L%I,D\4G?H-NC09OZ
MA662-%M8ENX>"DKN!/E([IU5[.GT:E"_4\?4:Q*5-B_TQL,PX0UC6%W2%I=,
M.&8\!7_%J':.:UAAVMT<<]1YB2-"]B;JRXAU1UI.X]NQ^E*4MI<(;S5O714H
M@DUS3G;.F&':0UO$K([5DW9U05#2C-9M&@ZSYC(HH G 2=J; :=$(DP34M6%
MT12TLRH 1&^]5>U#2W'4^D'3A:;MK-V+,J2A,&V9>$*,_P"D*3V]/6IWKMB:
MYI'6<0NFF04I40D\)CBO.F[G9WXXU$AVJE/.1'-.7+&;VTM0B"H"FD2V1\>=
M^SV96G@R!%*7 X]G(+NY4<04U<)5KXXFL6;HJF=,TX3EFU7=7=PG7HU); DJ
M[01VJL>/U95MG#GW,R=3<82NY"F+)L_<LA7E;1Z3WK1K;R#='6LNY6P[ +5M
MEJW3XB0"I4<UG*7L).R?>E)25D!)'I6**95,9O'1*6P#/J: 1H'MT0HP>X%-
M BF9N5HM5(/<[$4V4<QLL.6[=J6N2%*V\OO2)HV]];)M6B$B-0II\B9SC,[2
M;A3C2OVMOQII\F<N4<3QW#UHN7F2D#2LQ]:ZX/@XT_+E97O <]*JSKW(^^>!
M+!:<:42$H>)*0J"1&WX2:Q9DG0CUJ74 %+BRT- 4H@>8;*43_"L[HI*V3K$7
M[-OKMT^*E,#Q4J 21!! ]:5V55$F[>>=0E]&SK<&$)$P-HCC\:%+AIDY([MM
M>C*YG=W$,NYNPG.UJ^MG KI/ZKQMK=39;6F&[DIXU-K_ ($UNE",5:!W.4J]
M>OR/*_7;!W;6]%GB5\I 6_<.+=0"M-\E2=(6B=RK5H.D[;[5]#AE!*&6/$5P
MSY9:1Y\6HT4/[YW)??;2X.)/6UQ:V6%XFN_:NWG$N%;#1_JX.F%^F^];P<8M
MJ*Y[_P!?B>%F\S(H2OA6O7OJ_P!S-_FC+]YE^UMKC#\=L\Q86R[]G1B%E;*2
MRU<K;\1=NHJW40)Y]*4<\<L%M7!I\/DTTW'));O?T?\ B:/[Y^S=O5ZC=)?0
M@PD:3J3#8'<DJ(VHU$H8<3<2='YV?4*.;M=??^!],>F.%6^2>FN7<L.(\&ZL
M\-82^@&(7I\WXZB0?<5\CJ%MRVC]%P9%/#5&\>Q"XPYYM+3P3XC*D$K7LH'L
M)[U5.<77!+^1Q;?N><?BZR2]F;!\$S5AB0%8"ZI3C6Y7X*XUR>!) CZ5Z?AF
M2L4L7;=_QH\SQ#1K4ZS#J;45!IN_6FWQ1Y7=O[!",4PMVV9OUYA9;0FYD 63
MX<U2)W@I$?6O:PIZ:/\ :=?XGA>,XH>+ZV6'3/YGMM^E+FO<W65,MV.-XVS:
M*M;I"5-K#ZDH;2A6F1L3ON8V&]>=')FS3^:5Q1])J,'A/A.+9CQOSFJOCM_Q
M.W9"PB_N<KV_2' \4N6;EB\*L7N0@0RQ(4&U1RLC8#FL<\UB=7P<:QSU6V:X
M?K?K71ZIP?"L/P6PM<#PBW+-G;A+;30^1M4[E7J:\;:\N1RO@]N4E"J7"X'L
M=>; 3;%U$IV(%6XT1>[HT*O+\B?K517)+M<DZT84]IAM2M9 2D=O4T..Y\#;
M45<B@]5>LF5^FV#NWWV](N6TG22J 3!\J0=U*GTKT/#=%DRY+EQ%=M_R/G/'
M?&\.AP[8\Y)?2E_/]QY/Q+K'G3$,N7.8L$L7;BPOL06<4M%-A;SS&D*()_8'
MH*^ATV3)'(W@^J/I]Q\7K=-CAAB]>O[/+]3OU=/A_C5'BS&[UJ_QB]OV&2TV
M_<N.)03.D*43%>;D:<FT?8::$HXTI.W1+QUQ0LL'$_\ I98_C-5E^E&>#F;.
M?7BIN' /6O-?9[V)5%#&_8P:BZ-#TM\!F?LO=.?B(RKF/,[B6;)WQ;!+RHTL
MK=04)49X$FL];N\OY3MT4(IN4C[$YJQ9NZMPZI];K##:H[F)D&>\C>O*P<8O
MF7)[&**\S?'H\\YIZAX3;W"V4WH9TKC[TZ1^9VJ/,VGT./2><D[1RCJ#G]@)
M4^JY2I"3\TS(]1ZBI4K/4QZ6,8VT<7L\:G&'L;<).DDM0>*I3V.SHFE*%)%*
MS5BUQ?73MZHD$R))YK++E<V5BAY>-7VCEUYG3,.7L79OL&Q6XMKNT5K9N6EP
MXT9_9-=NGPQR+D\'Q#52@^#Z)_!YUC7U_P J7KF:=%OCF5TM(N+IOY;UH\*6
M.RMH)K?-NQKYN:/G8SQY/I9U_J';X(LV^%M.-JNW+9-P4 ;MI/K50DI1)<7!
MGF_/F$!#SB4PD SQS7)J(VN#OTV2NSDF+6);)>1^T2"*\3+%V>QBFJ-.TRI3
MAD$[UE3-MQ-5; I"%&0-Q'K31.ZS = T* )%!5@EY*#)%*@L9%VEM0^\"Q/?
MFIVCW48+LK<4MLZ1[F#5;1;B;;.+) 0>=S1129MK=]:!)Y]30-LEN7RHT*5N
M.])JQ71KW[A2P5!<1M4-%)D)+SA<$*!]14DRXI^Y8<G.*-[B&*I24HM[?PD
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MGJ<E0=?B1L!QW,.6\1#R;PKL7O+<VI;&AP'M[1V5S2R+=\T>"\-Q^27:+_\
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M2&)8TI:;<3&J8(IQKU-7*CJ&$X'A^#6K=O9L)2$C<D;DUG.5F:MLFNO%0)5
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M+O#[=U"QK3I3Y5?0]Z\S*N:/HM%EI_-T>3LT]/,2P7$'KRR6\JV4?-;O.*7
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MB>T06U$\CBL32R+<@N)TGUFFE8FZ1$$(.U55$;F267R3&U)C1)V5L>*0 E(
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M5%&GO7+59.DP.^] F:"\N6AK*5C0?E%!)RS/JOM#+W?8C\*F7-#]#DGV9?\
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ME]#IQ]F]:4)FAK@N79(1YE S^%0@L12@E9- R(^[JI,8QXE(8XT=1WH V-E
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MV-!I]S"W+==R9:%RI6M9]=ZZ(Z+,X.:7!P3^T&CAFC@@G;ZX=?F)GCX=LZ9
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MRZN5_(Q9I'G>,QQQ')) K#49H:;"\<E;?2*PPEK-;'-@=1BOFD^JKCC^9?\
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M/DE2[7IYT5>Q,@Z3=O,M--^7Y2"Z"KU["JCAU^7F4_R^7_$R>?PO"]GE)_\
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MGM.2-JE@*>*0"(,*!IH!Q3D).^\5K$SDC37#YUF/6JKV(? V' =U$"@0V\Z
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M54E$;$V7;(>(I?D]?:DU0&I?N@E.L'GB@#4O76I2E%4"#O2* 0I*K8E2Y]*
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MFH?G0%&:@*I!0GB2H 4GV/;P&>:=BHPGT('UJ;"C 5&/<30(34>(- TA8),
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M\S^F-$W#U=BG#NJ]\H)N\TJM$'?0TV&X_'FC9G?;H-T/1!G(-_<P<:SE?/\
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M8#:K1G,;S==IL[):1RH'@\4I$Q[.4!2KF\45>;2K\ZQ9O$M6%K4AGPQM-4@
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M4N:$XY?8F6^0"%??*5I]#4/(6H3:Y)R,C6"#"F^-JGS >*3]29;Y/P]K[U:
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M52Y]@4I /GV'O3[*L'4HJT@;>M(+,6D)@CDTQ6(5*\.9WG^%2Q[D@T*) "8
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MJSC6?/G=05?B3K''/A=Z=O%[#\*L\37;?*IY3F(7#BO6$PW_ -M%..:'HO\
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M>1GR^;EX.<VC:%H\0H@<::[5T<N633HV;2K1L I;W]:?!RRW/LD_K124Z4J
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M*C<*(FL[*.49K4RIQ]97JT28-!2*&^Z?%!!E)X%31H;*Q?<4 IM/ C:@3-X
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M(T%2?,=Z H<1YC0(R)/A?C0,+1!!)_C4EA@))@3-'(Q2V"/,3%  E"4$%!H
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M)1(/:FQ%4S4]"8'\*@9Q[-EX$.$1SSMS05ZE)NKZ%["D6;+#;A;[8()3![4
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M0I#H;"@"#-2V-!E 2VM(23,&I&S(TG4V-*NYJD ^$RWN=SO04$V@&%$P/4T
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MKPFV&5NE9&Q"1,5YT]N62<CTH*45MB> <5RCU(ZM9FO<X6& ./-7URH,+4X
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M%+/$4[9HL<5T@02H:B9-(IJN$., EP$#BDR)NHT;]AHJ5JU;16+9S05C_@D
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MGF'9M>/HH&;<1)$))K-E(Y9F.X<*R 4@=]Z"BM,$N/>P- &_LB0@KW"9'UI
MC;V+LN>*X%*:2-T^M%E&O3KN\0>6V%);!A"1VI,"P6%BXA"5.+,D[T ;=I"$
M))3.G@3S0!)U#PBG3QM0,U.(J)2I02=(!J)*A79S//UV;#+][?*,%ME1'M.W
M^-:8E<DB)?*FSR@M2B0%*!TD[SN9->M'Y8I')ZMKU!! ,F:M?,%"^-_>IAL)
MC0PY2=@9]ZBD<\O.1)::LX,* D4=&,I9/4D(1;:0&W$[>U)V9NWV8Z+<@:E
MGB(H7 *_0U]\PR"5-*GZ5:Y.G%*7J9;7CJ4AL'<" :;09,2;L-P^+_6$GZ5*
M)2V] -M 22K9.Y)VHL<I$NTL+F^6$6]LZZ2=@ELF:+H23NBW8;T[O;G0[?J2
MRCG2#)J99*-(8&_4M]AE+#,*&IEC6I4:BK?CTK">1R.B&!8^^3<)0AI(2E.D
M$<5A)M^IM&ET,N)T)U"(/]J3^51Z<EV1'4//*"6-2U'T&XJ=RCZ$N#?J;"PR
MQBM\4'06T#YB4S-+?]Q<<37;+EA63\+M!+S7CK[$BLI.3Z.B*BBT6F'LHA*%
M+2(@!!TQ^-..\4E'V-DUAB7DZ+AP*'/G 56\5/W,JC[$JWPO#FY\&T8U1YE>
M$D$T[DGV)QA[$JV:9:U:=:3V[C_DJU;?/(J5?*Z.?]3>LN'9,8-IAA%]BZAI
M0VTF0@G83ZGVK=121S3R2BZ*+D/I?C&;,6_IWU)=<<4I7B,6[O/L"*M0?J8\
M3>Y],[6T\FR;^SV#;;*$C2E+;82$@=O?\:M+]HJ3<?[K@+Q'3K<+JT(;07'
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MO7$2W<(>TZ/JGBG<4J:$W96\O%%U=*;?="6]!4 4\D'B:B+LI17J;3Q+ .M
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M+YJ/3"AYD@=^?:M&<HZVF#S3H8Z!%% &A&J=Z $6G28H 4(D3-9R[ ("!%(
M%J.PH $B1%  *3I$T 1G5:A'H::&B3@?DQ +'I%:Q,Y]%L;<%NPX\H_*(HR=
MF<2EXO=*NGE3L)[&L3IB:Y3J6V2HDDIJD$NR$EI))<)(U;UHC*1IL5=0W;ET
MF#!VJUT27[+]O_T-X6RE/+:7#'O)_P :3Z1'ZS+#8X2E:DJ6"(WXK-LM&\"$
MM)$"!Z5%E4-J=["BPHAXC<JM[59"CYQI3'K10[*IB6,O8$TQ;%YQU]PAQ<\-
M(*P 3^9_*K2VDMV0LVXW@V+9?OK+$ULFPGP7&KDPEPD<R=OFVJI95B>Y%XL;
MRJCPOF3IF.G?4JQSMD"X6K#%O.L7MD'25:5)@!$<I!WFN?/E69IF^&+Q6F>6
M>K6-WV8>H6,7.*+6MUIWPD)Y"4CL)KJTZ37!PYW)2MG4N@'5:URI9JRYCJ2W
M:>)XK"R?E]16&IP-/<CHTFIC*/ER9ZIP?J-D2\:2XSF>P0"C5I<="2#7(\60
M[5+&;?#.IF4;^_\ U/AN+VMW=*$A++@5Q]*48R5[BOE?TF[5B]NZ@EM6XV,]
MC63ES0Z(+V)K;6I84(/8FFP1JL6QD+M7!J D1M4L:.1YKO-<G7,34E'+[YU+
MDD'S*-,"1A\J(41OQ/I2 V06D.!0YB)J6(V5BX?%0G05)/)':@"3:,!S%5I.
MI( VD<T 6.V "M*A"4C8^M $QH2H'B#-!:Z(V(.0E0'(3 ]S0,TETXURI(T'
M:>]0^(DKF1YU^(/'67;RPP1AV2SK><2#L K9-=VCC2W&>>5NCCPC5]:]!.SF
M,V'?\:=#!G^U_"I DQIV%'9CV.%*M,BA\=$WR$@ I\W)XI6*7? J1I,_M=J+
M]R6[)5L"\\VE0$GF*#.2KHM.(96?M\N#'"I)=0^VI"4F#X=$9,KRY)6^FB[9
M$O Y;/I=="0V_L-4;16>5V=&F3@N3;W>-X=;ZR;IL0>RH$>]9[9)6=7FQDBK
M8GG6S94I#=RUI/<*DU<8MHYGD496C2KS^TV2&G LI_XR0*7E^XWGE^JAD]2;
MQX0'VF8X\-HF?SH\J'J3Y^5=HD*ZGX^EL,(QQRW;C_1L $^\TG@QOLGXG-Z(
MU=WF2YQ%2W'\T8F7%""M6H)_,&JCA@E2,Y9<K>YD1A-U=%*?Z3+C]\J69_(U
M+@6LK]2S81D)[,+B;%G.V'H>4 0AQ:FU'\5;5*VV:?._4LBOAUS^V/$_6J5-
M]Y=(/YS%:+GBA;']15<9P'-.2RINYS@;0I.P;NU$C\)WIN*78M\KX-A@G5OJ
M0S9?8\%QF]Q$%)3J+<A/N"::C!F<LF9.GP5UN\_6V9$/=3+K%GF-04[H':>"
M3P/I5*,4&]OD]5]-L;Z9O6#>$Y!N;-D)"89<(0ZK;NKO6L$I=&3EM?!>[BV>
M0$ZE)$_LC84W:[.A-- .63CB%$$) X%'!DFVZ(UI@KMP["R"#45?1<FHGFSX
MA,U*QK.2<#8?2NUP8"U\@@*< \RO>NS:E*D>2\DLEN1S=A00@ ]JNN3*Z9+:
M(T$B:'QT:)6/V80Z\VAY4()A2@D$Q^-92D:PBK';IM2"56_G;3,+<@Z@.PJ'
MR:I5T54/.NXHEUIHH*ERD'>/4U"[*E]/)8;E: M+;CJD-NF2H<B*Z#!)1Y0\
M?LMP0EAU9*C*Y.\?2HDS:/(YF2ZPJWPAEO"G[I:.'DOE//L!2;)E[(KN')MD
M,N7-PPM3BB$MD& 1WGUH^\B3]"2X]9+@H?+$=HFI;*2M$"\=G4EHJ=2!(]SV
MH)CV;)BV#++*B'(* 2%&=)C>F:M)=&);9$I;Q!8(W 519)'PX>)B27RTEYBU
M5KN KTB ??>A#XJY#UPW"@%(<4F9&@?XU+D$8Q$8LKB_NTX;A%K=/7;Y :;9
M07''C^Z$CO0ON#RY-_<=JRK\'75*ZL6[C'Q8Y:-Z/$4S?.ZG D;[MHWU1V--
MI8_JX.B&FGE:]2UW7PEY@O,'M,)P[-^7WVC=I5<W:&'$N! _9 @[_C1&:<:3
M1M/23QOE'H7IITWP'HIA+EED#+5QB&)7*4_:L:Q%P(N+KU0D ?=MI[#O4SS;
M/EQ=^YIAT<)/=E+[AF+W%FR7L7PBW-THSX:2#'OM6%Y'S(]!8L251"5G?'6=
M2;#+R@#W28'Y$[TO,G 2TF+(S7W&)YZQ@^(6@RE)@(4ZE$_AWJ)9,N3NCJ6G
MT^)=$G!6L=:N%+Q%QI"4[J*5*43]# %7C62/#Z.?)+#TC98MC+3S!9;?2A/$
MK(DU>3/CAV+%@R3^E')LP?8A>D"[;423WFOG-1/$V]I]/I<65I;S2C#EJ<2\
MTXA4G>=ZYHP4D=4I2QR23$3ARQXA0E"#(,I$'FJA!1? 9,CDJDD_W%CPK,F,
M86$)#OCHC3X9X'O7IX-;EQ<(\+5^&8M1S7)=</S=A[J4"_;-NI7&\A1_PKV<
M.J\Q?,?-:O0>0_E-]K;4$*2I*@Z-2"E4[>]=F.Y(\C).,))-$ZW9;,:)U>].
MG'L&XS7]GV;6U01 5S2;3? XQ<8U+LV#"$S304;5F$$%O^-'?8FMO*.6?$WE
MT8]T@Q]EILK7]@<('.Z!(K97./EKU.#4M8[U#[B?)E&EME/[I 0">8_\\UX+
M7S'UL)Q6&+CZA-I2E.E/'.]9MFJ5 C<[CBJX#DPZIE([14MHJ-UR(@+!B1^5
M0QAR/E(&VU/T#@Q(V([T6+@4*7X<QNG<53!6$H& H(W-2V50X&B#\A,BHL:3
M%-JXKS!$)'S4E(4DUT*NT7HU)')VI6@46/HLW2D&C>D6H-CJ+(Z2I:H">8%'
MF(KRQQNT?</AV[1<<UZ$I W65#R ?C2QR4F-QVJSZV])\GN]/NEV5LG+D+P[
M#+=IU),PZ1XKG\5Q^%>HJ<5%^AY.5[Y-EG9)+RYH1F/E13N*8PTJ)% !H6H3
M% &*45&30 :/E%9R[ 612 9)).] "GB@ 5&1!H BO"./6FADO"@$W <_\IK2
M+)DK-UC-TEC#PR3"UB54YJUR1"-,IKKBBKFLZ-;H8N'=#>D@0?:G0FV0G'U@
M0(B*M,S96<?4LL03  -77!-TSM>5K!"L*P\SLFS:C?\ LBEDM50H\\LL:"BW
M3M![5D[+0RM_Q#!X]JBBV[&B 2(FBA /K;:TE20K3N K<5I'A$ODT-_86>*+
M>>?;("5(4I0,:@G<)/JF>U/<Q;4>8OB>Q?$KK$\&P%QQQC+UP^D72D;!(2K9
M4CM.U<6H<I/GH[]/%8HW$X]GKJ?A^!XM9X1@ENW>+4VI1(^5D 5C%5T:M6[.
M"YVR?:YNNEYCRFLW5P5%V\:0-TGO .Y_"N[39-G1Y^IP.:LYY]EOF'%-7"%H
M4P=)2=B/P.]>G'+')QZGCSQRQ6ZH8??=)TMN+]_,:4HKV%')+MLMO1',XRCU
M,P7%[M:DVSER+>X)5/D5L#![S&]<6>$:N1ZFCRRMI,]_+LF1]XP^' =]:5@A
M7O XKR5&Y,]>?RHU&,*4R DKV/-#?(XJUR5K%;M*&5)*E:>V]9ME4<US-=J&
MO0L0/6J$4582JZ !,$>M,#96A4C8$128$DI,@)/)FI8+DL&%-%:DI4O3([=Z
M!T366G&[Y*R"-B-S,B@*1OBA'A)2DF>>: VH-E!(4M:HCTH&C7XA=-DIB2$'
M^- %4QG&+6WMW;I:M"&DDK!/8#>LI*3BJ*A25L\CYRQDXYF;$<16K5XKOW9[
M! X KV--%1A]YQY&Y.S23O-="X(,._>GV-"R:*'1,TG5629RWP.IF-ZKLAOV
M%  (41L*!7Q0Y]T#*TR>WTH:ODGE]$S#[:[O'P,/;07!QZU+EM&EZ,V.+HS3
M:6<8@^4,I$03M1&2NRY-\1?1$PC#\:QC4;6X=\RM1\-42?PJ<DUZE*$G]" 5
M@UXYB/ZG<?6;I2@"@N1O^-'F+:$(ROHZME;H"B\#3V+/N2L:@VU!D>YKBEJ?
M1'=CT;DKD=*PWHAD6Q0E2\$%PX!!\?<?SYJ/.R,WCIL<.RTX=D7*5HC0SEFQ
M;TQPP#/YU4,D_4)PQ,V8P# 4%17@V&(0@P-5HW'XDBNB,Y'.\6(U>*7G3'#6
M%-8T,M,A.YEIN8^@%:7)BVXHHYSF?-?PW)8<9=PBUOG2/*JP9+1/N"*&FS"3
M@CB^,L8/F3$0WT_P#&0U/]2MTO$_3TJU&'H<V[)99&>F?7IG!UW%E88ZBUT$
ME@OJU1'=,[5:Q7TBO-:^HK.67LNY>S'XO5'+^*W]N%_U9=*%I4.9"N14N*@_
MF'"?F+Y3U+E'J1T)Q&P8LL$O<-L6W0 W;/,!A:3[J5\WYU2E!\(TC%I\FWQO
MI3DK.-DNX9M6G4*D>/:J"A-:1468Y;.09F^&+'\''ZRR9CFIT$E+2I2H#TD5
M<L?[)@IJ/UD'">K/4WIC>LX5G' G+UAN(:>5!*3M(7W&W%9_-'M&F.:D^&>A
M,FYWP'J)9^/EMY>I !N4+^=I7< >E3)I]'2H4K9MLVXO99(R?BN8KI02JQ8U
M,G]]:A"1^!K?%!;7)G'GD[I'A*ZNW;Z\=OKA96\^XIU:CR2HR:W2H\]V.->:
M!IYJB"4MQ+20E:@E)B9%3)T:1)F'7+EH5W5FWXJ!LH.I''L#6,F;P-9C%U;J
M86H!;+JU:BE(@?A2;+KG@CX#;!]]R[<)\GE3J_>CFB"LMKBBP-,:[A""\PRR
MXGYW'!NI/M&U;"I#N&+N3??;Q<)%RV(2H*&_X1'\*R;=A'LT&;,5=O\ $=5P
M^M3Q&DJ"0!^0$4=\BE%MDBWM%,LM6A=;66T@@E/,\U+="JW8C=EB26U:66#$
MI43ZU-EM4C66B"_B;:'' TI"BK4. 0"1_&M%RS#Z5:-D[<ON( 2Z%DC6J8V)
MY%,U?2(-S=*#?AO&5=@@#<?SH%V6+(73+.N>5%O*N4<8Q1QYX-$,,$-!,3YE
M&!_&JBF^$BFDU;9Z.Z>? !G'&U-XIU&QUO+EI&M.'63H?NG/4%?RH^G.]6L*
M?,W1+DE]*/261^E'3'HC;:,O8&$X@A'B?:+TI7=7"AV*S\GX11+)#3JTC7!I
ML^>5>A4LQYP8O\7>=Q&X:)G6 TN0"/2OF]7XA!SY/MM#X9)0MAX#FW!TJ4LI
M?7!U2DQOZ[T\.NQKL-7HI3Z-O?=1UI;U-X<EQ(4(<=?U*_*:J?B,$[1AA\+G
MZ]&KNL])7>)OGT,J*!.C5$^U<\_%$=D?"@4Y^Q&]O$WCUR&[9O\ JV$1"?7W
MJ(^(^8_P-/T=Y*_$V[?5"\0H);9V[>4?[JW7B&TYI:!Y70_==0L3Q*U+3MVM
MMM/RH  C^%*?B,I+@TQ>$P@[EV43'K^_N0I?VUQP*,@37AZO43DSZ+1X,&-<
ME4NVUOKUK=45#N37'YDEV=4L<5T;O#+M#;#;/V@>,3&HFNO'J.*.#-BMV2FG
MKXK4 E#B)W(.]=,)6<DD2TA U+4]I4D_+-=<&ERSFRJ3^D"XS$TTT;5NWE2]
MM7-2]7M=(E:)9%<R?ES-^+86L^#YFPH%2%F9_.NO3Z^<.;.+5>$:?(JHZ/@G
M47";]24WK2+)\F#,ELCM^->WA\1CD52/E]3X)DP/=C+QAU[87:IMKU+I'[*3
M(_.NK<I<Q/-G&474NS:M&.-JI$&S:W'DV'>A<$KD@YJP16/9=O<$#B4)O;=Q
MG4H2$ZA$D?C5XLBQS4GT1J-/Y^&4/<\?XG^C5PM&&>%:=4;D8BLK<86Y8)^R
M*$R$P#XD">:Y?*Q3BY*1Z'F2QRC!H\[=0OA+ZZ=-+JX.)9)N<4L+9)6<1PH_
M:;=:.RB /$3](FN5X)-6D=TM5#S-EG'U-EE0:?V>!.M!24*3[%*MQ6$H-&\<
MB8X$%0\B!/M7.W1JN0T6RN5-2KUJ&QT/MX:M1U:8FD\M L6[D?:P9<(<4O8R
M#6;S&L< \U@JO%*2/+Z5+SFJP$H8-Y@.1Z5#SEK /MX(\D2?PVK-YS18"6G!
MRI !;E/[8]:AZBA_#V*G 5%)/A@(!V%+XDI:8<;PA(3*D"I>:W8_(H?;PY*4
ME,#0K]F*7FLI82__  _]/QGCK'E; FV4K::O4W]U/"6&?.9]CIT_C7=HKR32
M.760V0;/I>^_XBW'#RM2E'ZDS7M;>;/G$[=#+:5[N _6D4&%*/)II@.!T#:G
M8#R%)(H#D60>* %U$;36<NP,5Q-(!N=7R[4 '0 *]DR* (CBMB5=J: V> M>
M.YK4);1NL>OI6D43(CX]>_:;M24J\J=@*4G;'%4C2J!!@TAC%RCQ-*>QI@QI
MUI"-E)[4S)E5S.ZU]G#:!"H,FM?0GU.Q99O4MX#8?OFU:$S_ &143[01Z9LE
M797W,T4%F)N%^M%!81NB@;FBAV17[I3YTZJB1433YJQIG <OJ0M>EU\$@]XJ
M6Z125L\P]1,SVF--W-D[:EU2@4R1,BN:<T^#LCPCSUCG3%3MK>WV!2FX6K;6
MHZH]!)K-*UP6I&GRUA3EAF3!<$M#<(NDW*'+A3;2DK:]22>14.X]&MQD=2S[
M>],\=QY.5L6R;;WUTVV%*N&!X;C:8[J3'?UI?$RA*R9::$U3*I;_  O].,<?
M2[:X_?,:TASP4/IE,]MQ6T=9*1Q2T.-/@NV5_APZ995O&[NTP]5]=-$*_P \
M7XFX,@I'%$L^Z+LWQZ=8Y+:=62\T%J26T(G<I0D) /T%88N4V:Y7\R16,Q7J
M=:D$[)B*B[-JHJ.*ON.6Y\_ET2*S8'.,TN!$)3L5"3[UH25=@I=N-0&W I@;
M2W4T@C4G>D!-;\YU)[5# LN&*A*=!TJ@;TK'9L+AE#-PV2)U":8T;1MI("9,
M2)IC!NGDMMEM"=^Y]:!%:Q6^0RDI3MZT <7ZQYJ7AV"KL&GB7[]12A0[([G\
M>*Z=-!9)4S+++;PC@NG:>\5Z*I.CFL'3/ H':!WF(IKLI&50RS7&4LVVP^\R
MY>( _:T37%'+C]SG6)^IK'['%6%:7V'6XY"T1%:K)#T8G&,>T-?>+\B>>]:<
M]HGA<L55M<)1K4HTDY/D2RP;I%JZ:6[USCS;:&%*44&3V-<^HG2-81N?W%LZ
MEX4]9V-FS> I^VJ4L3Z)[4M(]WU$ZQO%3B67HKEI#664X@MEL_;;A2TJ*1*4
M^@]JYM4FGP>AI$\D>2#U Z/8G>8BO',(<U>-.H($$CVK3#-5R89L4HOY2L6V
M&]7\O-I8P_'<0;;F V'U$_D3%/=C;I)"O*E:N_Q-BWB'7Q9&G%+QLC?=U(D?
MC6BV$.69^C)S5O\ $)B!2@9AO&TGD_:VT@5:VLBLDOJ1L6.D_4_&%#^D/4%M
MI"MB%7*W%1] 8JE%$O')^YN\-^'++Z7$KQ7.UW>[RI#%L4 _ZTDU2BO<I0=<
MEYP?H[TJPP)4WE96).I,%RZ<6K\Q5JD9O&R\879X1@Z?!P;+EO:1L PT$@?D
M*U22Z1%&T;5>O;B1[@\52;7(G3X-7C&5LMYD0IK'\,L[D 0M3S8)C^]S34U+
MZC)X]J^4YQF;X:NG>,K\7!+C$,'4-PE(\1,_V4\Q3>/$^N"(O*NBFCX?NJV6
M5K?R#G6Y41N&T*6PM0[2DG34>57TFOFU]:'&L<^*[*9UW>%7^*)1\R7K9+Z2
M![HXH<<M< L^)NG1K<R=3^H&9[)>&9DZ16]U<. A#BK=Y"F3^\-MOY5#627U
M(%FQ)\<?N-G\+[F(X-G6\MW[=5LJZ:*2SJ,),US3M2I'=ADIPW%I^+7-YT87
MD.S?T%:57-\D; "9;$>E>K%5C4#QLKO*Y6><FV5 ?*./2G1@V2&?$"-13Q31
M+7L8XZXW=:RD* 'RGBHDRX(FMX@\P-1L@[/( [5SSY.W'\O:(]]B*<P>'866
M'!-Z%?="!YS^[4J+?!3E'V)&&L##['PGF%..MR72=_//'X<5T06U&;DF[0X&
M%MVR[AVV4A#A!0Y"OYTF!:L,:1A&7;J^Q#!6WA<-PU=JN-!;'[)2G^=0^$VR
MTCF84]<XI]X0X6MU$[S[U,63+HW#^)W)0EE26PA/[03N1Z4K*2&W<4";=;32
MH6J(GB:5;N"Y<1L9RQ9WN*7CK%OA;EV_=.A#*&VRLR/W0*TA&B'7!VG(7PC]
M3,\W;=UC]C<Y;PPK <>N&P'"/[*/7W)BM_*:5RX1*DI248GJ&QR#T*Z4V5KE
M_+>5L.QB^MT3<WUYI><><[@J.T^D #ZUP9?$\.'Y8H]S'X!GS5)M%D_RK+PF
MS+6&6.'X8TE/E98; T_B.]<TO'.*1VQ^SDKYJBGXEUJS ]K2WB/E)X"B)K@R
M>*SET>AB\!TZ^LK-_P!1L1Q!AQA]2%J63*E;D_G7'F\2R35'I8O"HX.?0TV&
M6]_CS[HP7"[FX4G<FUMRK^->>\.;.[2.V&;385S(>Q1O'L&9+^*8-B%LR!!4
MM)"?J:4\.6"(AGP9IVNC0,YIM%+*@=T[1-<VZ:?)VO$KW0-@UF'#W_ZU(GL8
MI/<R5&;=43[3$+2=33JMXVG8THSE%ESPR2^8W3.+K4@%8TD;"/2NR.54<3Q2
M3%>QITMJ0CTYJ)YJ5(UA"W\Q!.+.! :5ROCVKD\[GD[HX4UP1%7(\37&WI6;
MR)FJB$RMMUS4D"A9:9E/$FZ)[5^Y:_U<I/M73#.S">EB2A?*N$>9.YWGN:ZE
MJ-RHYGIU#D5"V))=2) \IC<&B,DV$E2)MFFW*$%2I*NYKO@U1Q9$; M):\P
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M+P"\4[@M@H*(BV;[_P!FB<?F1"?#-MA]PLK.I:C^-#0T;5"]0-06,O$SR:!
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M.-NDD.TQ!(YI,:'MH'%(=@JCVI%(21ZT#,)&GFHEV $CUJ0,^<[[10 2OE-
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M4S'VH)\-.Z:E@;"U"HT(I%%@PUN/F,J':I&C?6HWTH3O04;2[2I>&F!)&\4
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ML\)N+A"CITF#S5)MD-41;BS=ME0XG;U%5=!0R GL:ERLJ*Y"2H"I- M8]*
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ME,08"E&"(^E4@%2V4K)&_P!:8!PKT%!(ZE&KF@0ZE(&PH /2([S3:!,R(F@
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MX@EN4I(W$4-@D:>ZNM2#"MZFRB#XA)DP:(ODJA D+.XCZ58GP1,19AL+252
M:3!,U'VE;!'F5/-"9+-C97J[F$R%*].]59-4A]]3:"0M82>X)XH :3=VZCNK
MCTJ#4=3?,A0*0?QHX V&'8W^KK=3#*$E*S)*MS33H35B&X;OW0"YI4H_A184
M2',IW+HUMW;8!W$T<B-1C&5L8:MUEEM+\IY1_*G%NQ22HTN%7APK%F47*"UY
M0DZO6MV8)^QLL>9*GE.'>#(CBN.;J5'9!6K*_=6;;B9@R>:SLNBOWF%J2E12
M#,539*1I'6GFE^?4 .8YJ;+2-WEU:KAP)+G /)K:)SS[-3?DOXB\MW2=*M(
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M3I 2;:R6XO4L310&\L;9IDA0(!IDLF/WH0(2JA@D:BX>4YNHR:ET51&.^YJ
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M!#]L6;;%@TV5'2@-S ]*^:R^()29])AT+<4R KH+>A1C'#S_ ,56/Z21I+0
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M/=].\QLNI^QJ23V'<5#U&)]G5'>C776 9RL%D+MG' .R:X9K!+U.K'ED:O\
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M=DC4F.:I(R:Y'V_,DD<16@@DQ,GB@F70X@)GRU2,QP"*8!);"Q- !>'&T4T
M:4B!M56*QP-JCB@5AZ*;? 684]C691B4@&: #@'F@ 2$SY: ,4$3YJSD:Q&5
M?.1VK,M&!N329J@/K3),TPH:>*3!!1O-0RS%<4D!@,BJ 6@ 2#S0!BP5) %
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MO$W#B117,1SAD9Y-MFW!2+=I4)O[4^(PL>I/;Z&O&U&AG#M'LXO$L>3A,N&
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M"NA49SQ.=)7J', T><Q_#)$E6=KX-:@0V4D;SS2>9@L-.D:^_P SW5SJUKU
M]IVI>;8UI]W9JT8Y?,/AZWN"VYQ$FHDE,Z\>+RUP7G*G63%\!4EC$Q]H:B$E
M)W2/?UKFG@LZ(96EP=JREU2P[&6DEK$M)4 2UX@F:Y)1K@Z5SR=&PG,S3L$'
MSCD36+1I7!9;/,39@J)('8U5D&S;QAEP!0IV#'DXHWK.G?:G9(XG$$J22 -J
M$P)5M?C6*8&Q\4NC5)@T"8#9<96I0X)D4#+%97DHTDSM5IDDA0D%0[4WT"-5
M<@%TR)K,H@E92^ 3M/':F@&;X%Q1"1L*3 TZ@I*X54#)3)/J:!#JG_"42=Z
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M0@>M2,%1"O*@R12L=#7&YX%%A096F#O4E <["@:[#^4@GBE98'>E:L8:#3M
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M4'E:AR3[>E=F''5MHQR-%0F25$[JWBN@Q] CL8H?"$.$%#4$03Q3]"5S*T-
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M&!3L7!D_+[ BE8!(2=!XXHL!Q*MH[TFQ&%1!WI 8%230 :2(H ()('B"*+H
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MH!0Y!'%2.@$).\TF48L;\4@&E2#Q4LTCT,*,$F*10T055+!  $'3%9W1HE?
MTX"#Q4[BE&@9)V J6RT(4&I84"M! FIZ*2$+92)F9HL=#905'4.]0V6H\!)!
M5( XI[@VC.DFIL-IA2H&!1=C2KDS0>5':DRJLP(@2!S6;'M"@^E(="02K3%
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(S0-(*I)/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>comp_0001.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0001.gif
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M\/3T]/CW]____P
M
M                                                 "'Y!
M(?\+26UA9V5-86=I8VL-9V%M;6$],"XT-30U-0 L     *4 9   !_Z 6(*#
MA(6&AXB)BHN,C8Z/D)&2DY25EI97EYJ;G)V>GZ"AHJ.45D%1I*FJJY,^#0))
MK+*SM%A7+0 >L;6\J5>9F;;!GD84 SF]R9[#JYD\! I$RM.5S(-33$$S,"(A
M(2HV1JB7F3L $TRVU.N25TDS)!X2!P,&!P<,$Q (!0$)*]8DQ0 08@J[@XJ&
M10ERPL$   <DB)A11,H4*55L37EB P* &>H@!6,!H(6@@ A38ME1P4 !"2!X
M))'2Z,F#!.,B3?D 0(;*GX2FS)"00 2/)X=0GL1B \ 0244D#. 1$JC*# 1R
M6#&D]%"0 $*J,K)1X( /JVB)I%L:*5.. /Z[&ETY(>!!K*YHU^%M%.*!E;V9
MIG  H %*WL.7H@SPN2B3DPD 6&Q%3+DM%A0&B 2Q83"1$040C%0>_2B3D0,.
M&!P $$2LNA\#&" E39O1DPD'##!( ('FH1F$9]<>3BA8$F,2<E1(<,3U%!(
M8.PE7ME*BP0$-% 9@D!T<2Q,'AAH39UZ,",M$62XR*"UM20*#MPM3]V*"P+X
M9&/9$,(UCP$8K$4?<49 YL$$ _2 !1))3$8(# "<,-V :-DP@ ,_^#" "EC0
MT%\A5I00&86U9?*$!P",4,44!TR !0X,9!24!@ @0V)M/BR0%1963,# %/_-
M)P@3#1! U80W'OYD!0L!-"#:%20$\(01 -A02 X$2"!DDGEEPH0%!!F&A0H
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MPAU+)F.$$&F :$\<0 (61.B&MB!#.( !*IG,Z]=W3V"@P7=7.%R"OXPP00$
M%P@84JX,*R<   ID0((.OBD3A08!*!B,::J)UB,&*P%($S J#  2CUC<,$ "
M/QAB1 0 [%!5$A@$(%VQEP1A@ 0[;(W(,/Y6\.#"! *,?( +5Y-B6@+,?2<$
M 0L\B4$#5PQKT%915'" =YD$@8 !-S#$$.@A*T+<@!YLZT0F8B" &9!.$%/H
M00LV\ #T]<(' J@ YI:" TW-9@0&8,()"&,0WBV 477*C:<&<8,",.!=)Z$+
M YY4"!M,8$N0@)#T*/' 3V3B!@#X@-&:@@$QP6  0S ! +2F#B(4( *$$H0,
M\+-#=5AAA!!82V!$ ( *X- *T!D4)8[H'DWT<!,#8<$A5A#$R=A  "$ @=B6
MD@,!<*!:*C@  4!R+2E03 /CR$02)A  $I1P*4S( $%45AHL\*!,Z:,,+BS(
M%B7Z"0O:8X".CO[G%@"8@"TEP _ZAG$; 8B@6D%X!0P.880$+*823V  KLKC
M,+B!LDJ#2 ("&,   YQ%'3F(4%! 8 \=#,)+"/) #5VY2FOH( 'MX>$5-""]
M,RHC&!\@P"\)0:D:J4,*-^GE67)%@P!\4AU3R( ]JCD((C"  !;8TQ548  "
MB*!8;Q3C XWP.&M2(P0&P&$4,"  8P(C [LT"R',P8&EI'.=A:A!?"" PBDT
MZP!"/":?#*  )42R,?2Y A=GJ0XF,*  =LL$"72CT%P9(3M[8H+^$,#.3+"
M  EXP+*V8KH#** "*C,1!P:@ *M];U:"$8#NEC*$+$T."S(H0 ,4.OZ()X F
MIC<Y@(V$-8 &(&"636B 5!.@.BP,03PS_*@@K, $)LAM.($!$PP'83,-I,L'
M!B@2,G+UA-2@,#P).$!_6*<# CR  #% WA.@J0$"V%**^#" 0;D2E!UX@ $#
MR%(!![2KW!DB4#];2A*@68#$7N,!^@G, _)3NY8%( 05B,!?<J:> CW@6E<$
M  ,0\#E%6&$()5!  ""@ AB4X'_+\F<R H.;I^"6BRDHQ!0FH  #)'88'%
M"JUP@>T50%8F"H$ =L!&\B3L<Q!R+G@J(( 66*  .#P)$4BP   DP 5$& 9P
M5EF>*5! /AKM'  H*0P/'*  :B1$H*2QE?[;&$ (%'!1)HZ0  &TA@'*[-
MI!,% I1@$'%:0!&LD(!/[FZM-("  !@0@AP$U40'J(!RDS'=@%:%" H8P&;5
MX0)[:.U:K>)0)HB @ 8\H57O8L(")! 6<1DFE;OX@ )0804R7>XR!VBMKF"
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MVML^@8RL7?.8&), TF$$!PC@!8MP C3CC?KEOBAZ+X*&O0_QA+"3M/;32$(
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>comp_0003.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0003.gif
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M\>/S_^OZ__/T]/+U^?;Y^O____CW]_#O[^#?X
M
M
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M8ZR"A?[6XY(1"K"&5PPB @DX&P>M-@UC5*.)U7@! E9QO%> 4(9G4P8TD@%
M5UCC:%<4B#%B.(UJG,T8KB ("AT80 @>Q(G3^.(T,.C 5Q" "0*I!BM&U@P8
M'."*'1N90)01-1) 8%#*<" TC/&U:F2PA=* AC*4D8<>DM$- RC$& 5BQR0,
M9(\L.=LLTC@08[1";7"<(QN#R,KJG8D)(S#:Y BQ"@!D02"E6P4A+,"U5@2
M#+7$VS1*E[MIO((!#D" $ BA !MJH ')(,,"5D$-(!A  0_@FC).,( (P*
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M&C)(71XHEXP7*("*%=! -58Q ,\YX &L: ,"*G \5P0 CP2=!A" T-Q!O.(
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MX08-<, ,TGA !02RAH,& 0;9R_6A*8D$#GA;U > AAU' &\"<, 5NIX&!R!
MP R0 /&1HR01_)Z'.)-Z&AA.(,J"8 $"X!  2(7% H)@C%_"P@"$!\(!--<G
M?QOC #.8QN8[_XI8   .9RC *G7.^X9)(P@%2$*:"I%A@4QA[=-P0P%0L+%I
M$!^/TV "\OM4B "481KG%L@,#O[@@ 5QP %H8 ,<^#"+$]0[^?@>" <F<*:P
M9WF9H6Y%Q ^0LS/!P@$3:(,9 M!JV,O^ $I02\\% 1<73^NC<1PW #004GF@
M20IP<+-05I1& V[@!GRP5F>026<5 "#$ +$W1WQ !!/ ?[VG$D100Q)T)JM
M.&S !GPP",DP4<JR=!/D $^'?JW0!N<E$(ZF15<W#8)P>X,7@@-@#<J5.]CS
M>: %#:M@##*  &8@?G P"VS  6\W#0T 7-.P9DC0-'RP"G=%!M P 1+0- .
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M %$ Q@%C) .54P;(-V;>PP 60 C68 &'=D!\,#VDZ!%G0@0(1!!C> %H))
MIH730#<S$P24\PK%0PV$9G8HH #)  T,T (&R >+-@C50/X" V ,1P@X -!
M"L4*2 !ZC^,&R< &0+!GU=  $V9, P $RE (,. *L   9-"42" -,(9N,B
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M !,@=N\I$##@ $WW +%7" ?0!EB) !HP7K#0!@< 6HL9-7[@ /\IB$I FP?
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MR5N\L\N\FZL,O[N[OHNZMENZU?Y+O<>KO+Z+O*T;NA)DL@,1#;<POKBP"[>
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M1KY<)(V(( ,9L)C  XPQ#5:D,!IF$, %$G !8+SB !.   $(T(=C5& ", @
M#Z2A1V# (@,(L,  @B -/@P@ PT0@ -8X9%FL $ %K#  0@!BP5$( *"Y,,T
MVB" !( R 4\RX1H.$ $')* 5?E" !!+@!S(<0($!.($)L_Z8 0/,P$O #  2
MHJ$F,]I+C:D!BEY$,80X#,,6#<A )A@  E[X0A,&B$$MAO"&8=1" A<8!0-*
MT$U++" &O& 973+ @3@,0 IM 0$"'BF (?@"! H(Y0!X,(PC & /PXC! $21
M"01LDP!'((8*&& T6[C-%E&PI (&X(%:].(&!8A  3Q "UIX0 $7>"A!"Y !
MLH @$Q5H  -N8 L$E& / "B",[0  #EH4P(54  >>)&V%ZUM-FZ+#6UP8  *
M*( "BX@$ QP0 0,8X FGL,(!%* <!22"$]0A#BA28( [<&(3.%@ 83[ B2^(
M%'1/*$ '&%" %#2E $\ T>=TL/X)J5) D%>]@P,8 (&[Z@<!%&B !!(1B<1"
M  $%L,(3<MF .CPA %U@ 0$4P8D(2& 3.C  !A#P =\8!PP%@  &#- %.XSG
M%!8PP"/$,  GA($ $5#M%BC1  I(0 *>"$$F*<" #W7 ? H0@?M2I%SF2H)^
M^X-N=*4[71E)HW\122,)'" -) R@$*H4P R,@023]&$ ,!@O /P BP,(81J#
M&( 9EI$$/TPC"2(I! "<."8B!* ,TE " (Z$A%9(@P0)  8'&."**L$B#P!H
MPS3($(!!W"D6"S"!-5;AATLMX7\,^.(('E J#P,#Q-,P@@!00(AE!($ NC##
M *;43/Z;$"09GG+C&RW @!?@$ !G@(4 @# -0@0@"R:.@"S,:P12 & )R!A$
MID;@@&48@<+36 ( " '?%@ CP&V(QD;80 8B!T )P'#  Y0L4&A40 *QB,4$
M7OFH5R# !-"(10(T(.%S83D 2P#&"P8@BPRN81J>'$0A9MD'6-"84P1YID^
M(IBZ$$,4)0C &S)!@!FT)1,-X*8OB#$*3*MAT^^\13H]P N-^:(2!8A"+T"]
M"UZHP !Q$ 5,=Q$# N"ZLU8K0"6(<0,$F*(213 %+R!0 6'$( $4]5DMI!"
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M20 (D9!!!  .+YC HQR]$AY%VB?&*".H*L  #6B !&>(AA\.< $"(N %L$
M#*81"P7L(!DO$  !R( \B+X'  ;I,Z%""  SR*\K^I(P 09A00(1N( #, )C
M4( 7V#\%  )=4  8J 8R60!MR9(%E(D74 !C.(,^6X(!((1I4()!8X(%X(#@
M&SY"   EF ::&#^<,+^?$ K*F ,&.  U\ 5+.  5X(5=8*@2H+4A/  M$ :&
M,HM;T/ZF=6JU(QB *;B$?#($?VH 6V &$&B 6P !!J %8CB!!N %*0BV84.
M4=@%+2@!GZF 7GB!B;J+6O 96S W/7 &<-,$<]N#;F(&OV" #K  E-(#-0B
M/0C$ ;@$32B (A"&=_, 8CB" P $!AB"6WB ",@ "W@ !K $9O W^7$;N.F<
M)B@ +W 048P$!]" VW" $/ $"/B 3C@%'3B 2, !I*B!W$B! Q@#4&@"!,
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MLL."5& !"O@ "M"/ G "- V#.E"1(56 +X"$!BB!4^@"WK(!*^@L'3B%#4B
M+V@$\X&Y#8@$\?G(5!@#N_.$,1@#, B! N ;$Y&?E)R?EP368)4NQ-L18XB
M! @%5GB%&0" 0/ # +BB!^H#R[LBJX23!&" (+  :,5!(2@$#0" 0A@$:!43
M: B"3TJ"2)*%+   -\ ]!("%$4@ 0G@P+? C$O #&JB *_X1%B]B!?(JA!9
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M/A"!KAP!/Y"&/AB!0) &.  E-# !.&@&)(@ $C"#$[A,$?"#$FJ&,V@!,X@
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MA2)0 5'PA2((IUJX 0B(@2@X 5/(A!)P@"$H@A?8!2@X:K>PA1M0 5N( P\
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MCF_WA%[']O_XC2GF#=6QD"ZMXN;ZN_A!\(5G^&G8$64@"/3C08=V:(W KH5
MOT^Q>.S2"&!P:(P=B(P AF)%HXHO(_3CD8QOHYN0^/]Q>;0T^9<H>8S-B(U
M @W( B'O02[6Y9C<8I4G/XGW")8OHXR(^))WHXQ@$XHO5I#W'YN(^1[9E(5
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MX:?5V::#;#KHF)EF+L[8X_"VN]DN QKT&;\5.I*;III*XGDDG[)$:4B</%%
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ME(1$&Y"(,72! 1_H!",R@($GI  "=@!9)SC!B3M8 1*GZ$$ NE#&U'6B!P4
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M$YSH@$8YL8@&?  4.B#J*1+AW4U$H "*/(4=*K  '7CB%(?>PJ<.W07A6<
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M:D2RU@2R4BI-,*M.C">:CNAJRFDVR29$>&N0U>5>TF24S:B-^B@TQILW 6F
M-*,,:0:/GNM!\&0TF((Y#40NZ.LN[&LNW((I5$XN!.R_%FR_'FPN]*N^\NM_
M%&S! NPN!"QEY,*_JH)GZ)!D!"R^VL*_+@3%+L0O+ 3$9@;$/NS']NN^RNB^
M!JS'.FQFI&S*"@3%,@[%]NO+?JQC/.S+$JS'ME#-&D3-)FS+WL*V%JU#U$6<
MBJO4"(:;'JW29M4NUF7D[*E@+AD-M:LUINM\$FI]DIZ[HD9Q$FE*X @\9N=.
M*(>1/@>KJ(B :I*'9.=*1*:5"OZH(^0")6QIV2[*9@8,4=9&;71I1BP*/2T*
MB(0*-Y[(3H0(CJB(2TR$@":7T18M_3SM*&7%D'4KY?K-BW*3NMID#I(3.!F.
MO.)0H/*IZ=(GO$)&8?Z+F.Z?45BID\9N:5[(WR:D+0BK[+;*5;K&K%IHE.8N
ME1*'MD9N:K)HYM:/ 9K'\683N8X6,LHH:?1F;E;&;GY&,U+9CZ9&YLVD3C+9
M+1"G<6YEC(@O^;J$+?0N5DYI\%Y=5&$H\6[K52VOWR2O1<HO"I%KZ>HI?U(&
MN[@K]=)).?4I *=K3&I67AX$,H2O:#II8]Y$Q5CE[LXN[S)')-QN3/3&5<8$
MIDZF@/YB!">@;]65[R2\[YDBF/W6S^6>\)S:H#+:B3%F5C(")M6.UKIHK:#:
MYUV"K7'FQG$J)44T$6Q00M P3"<<IAJJK]&(JM%X@B/<;L$01Z \2FP4\0^S
MB!"+B$M\!$8E0B/$:OG:QO"2<$-BK@KORG8T;7:4:-*6\7TTK[XEF?7"20!#
M61SC:0L[&7T"80WO:)V$[3S17PA0 --UP@\P@)R=GP)L@1<\  7\DP=T02GH
M "//7 B, 2=T@05H$1*SV@3?'W3<PMT^3 /T0"=  B>X@ -$  500 0TP!B$
M0 0\@ - 0"6?0A<P\C]UP!:\% 1$ "6/ 2C8  5@ "#:!OX(^U>K-:H8BR@9
ML_&2W,7EPJDS[TK4UBF^Z6!N\I!?[N^?!FK_QJCE>,;J2L1P6$ "*,*F+F$(
M.( $A( (A,$6$  %K$ ()$ "+,*A=8 +=(#U,4(@H_,76\0QLX^,1 (HA\X6
M%  .U,P/A$ (($ $T',BA, !U( .A(#U*:$!S',](X B#)4^>P"<08(+;((5
MED+^);-10.XRD^?D3K,9'\.030-,BXL;F]9^<@:2Y:AN/H;U_G1P]BGV&C .
M<T8,8^-_;DY%8$ #*$*HOB,$4("GE$)"'UPJ_(  ;$$/"$ 7H (H4/08/)<E
M7^E)X*Y!ZE?*V"U"$X!SJ00GG/["& 1?*JB4""1 )*A"*0!?(PB7#9S"52O2
M#Q3 %GAU",!<*FS!!@ T^[+$H,A*2Y>G\=;TDJ!Q,TNV?5 >?)+6.B6C-M]P
M'H.S-]?GY+A0#\904M,?=$%2130"!- <)'1"0MO %M5 5MO4%E#"(FP  HQ!
M)%" (GAQ= ;TEUHP;"NT\D0")8S! 80 )SB")W1  G@!1SW/)8NC)%Q:8&]!
M[XC  8R!#4  &#!"W-I?H1A-&#]VUP6@97L)_8+B>G_)3>MO][[K??)E :M3
M')^N3@.J#%/&.',C!IQS<&P")$@ !:@$;!N  SQ  YC?)JA7 TA  A2 "U "
M)(2 :OXG)+&:Q$!C9<J<KR,4=P^\H:B,@0&$ $I/@@@H0 *(GV]3-0(LN .8
MWW4?  .P7P&$@"0X= AH]U8JJ2=?Z0BC-VK&[WO?!V4?N9=$%C6PVUYNK[D.
MIFC[M!YW\PU?+=?^X.A>HXS:0E(7108T "-L"L@TPLQQ44)C@ _8@!,P0BFH
M5PCT  YL@:**BG ;9 5K7$+W0"E,@J-P@AB<>"=LS@8D\AC@0$4?M@%L@ ZP
M^2)$\HDW.IVGV0<'N:NXKOH@S7D3>:Q5MI+W!;@Z[:??!YWJ1[Z6JQ!N,Y^6
M-A!"^;D:6?[>&^(DF;DVSG];!%.+@2*,P1A8>%3/!FRS-?XJ< )*VQ,!=/4W
MK@\(_^Y%='AT,K%:!WL-,,(8*$(:FK@+/*$(/%(J.((#6$ G=($!V  J:(J?
M7=I<E]H3W[FK*3.G.^37C?IXP,=KRCM[8';J_B5^W_%,8NR4)PB[9N]H<^^5
MH]X.:P0;*0 "($ "-$(D1,_R; $ 9#L0@X(+ (!V)Z56;F6'HUK=WBTH)#0"
M&  "--<IA$$ A$ 84H !]'HD2( ">(+$HWB@0$(P]Y21GO56#OF[:V( MJ6]
MY\5=4+8:>R)]\ 70Z\5:+#TR= O3QV5\%SP<U\N ]#>ZY#"0]F =QTE.5[GG
M_7=1/ $?DN$/S,8/;,' C$$/=/Z!L&Y"%_3 6 M-!+?NAX[$QROJ&) ]&7I!
M)RA"#]PV16AU(\S&%OQ S?W]K&X"&.A W(?PZ[+OIO=\545VT/<%94LS#1X]
MTH_'6C@]TS<]5T0]9TOC-E>]0L1;Y<!Z:0LPX=BFJB?&K5>$.Y9"*8#9YR1^
MI(AG*70P>+)[)0:%00?-)M ^[9]"T)2"%C=JJ84.2A.[%_M9[NL\?ZE/=$A^
M)JIWY8/'3(OET^^%Y@^&YS_]TOM%J:];8N3GD^&E@&R]?<:ZN>KQK-LQ-KNP
MYPZ$+QR\%"<EF%J2"%^=)'T\0$3R)"E208.2"$9"F'!AP8$+(1*,.)%B18L7
M,4:,1/YI6D>/'T&&%#F29$F3)U&F5+D2I+1CRH[%E#F39DV;-W'FU+F39T^?
M.)4E&^GR9U&C/X$A4VITZ=&92J$F178,ZLQE(Z.9VF6+:]=;MKZ&Y?JU:UFS
M9]&.3>LU[5:V8.&N14M6;5RR=+NZ+8N7ZZY:P48&<Y21<.&*DPPG3KQIX2U*
M"A5'COA0$F+)ER^RU+R9<V?/GZ=)4P93YM2:IHM"14W5:6O2.E?C;)JS*LRK
M(UO#GIW[IFIDQHS%MJGZZ>[AJXGG-'8[9+2Y<9]OY0N][MF[::?KK3M=+E[O
M?;'+K0[V;TAITP1;QKQ^HGKVDB/9X@3Y_7O*&>\+G.@I$O[CC!Q!"U#  0DT
MR9C7J!+.N)ZJ*BTVX7BC29E@=EKP- AI(LX8H40B*K69E%'0P@AC4DJJ!EDK
ML3AD@%F1MMVBVHDYD)XQ92WMJ-OKNK&^N^4[M7S,JRVSZ*)KE[MVW&L\\90,
MTJPC;0%,),'NJ\]*PZJ$*,N+')&/OHSTNU*Q+=_;J, ST4QS,VF >RH8%EF,
M*:D6::-3SJGHG#-.F5J<RD_6C+$I4)D&'?2808&1BE!#:;*ST6-:3+2F0-],
M"M*F9OS()0P910VY2O>\U-&<E#$4SCQ+TS/0X'X[T4Y03XPSTE ;A7,F2R^5
M,QC25N6P.2&[(W+))-_B"\D<A_YD\JWPQM...R5MT>N66GZA9LK!Q,RVL"\;
M4BR^QRAZB#^$*".37$G,O5)<<B'C;Z#\WEW($P#5K-?>>SM*1E]]E4IF&7^3
M06;??Y5:IN!^]PUX8(4%_A?@A!D66.)]!5;8XHHIIGB9C2=.N.*/^87XWY$=
M[AAB?J%JAB35+O:888M#'CEDB#NN^)AD;@ZYX8<)5MCAC#TNV6=D#"9:WY]=
MGEAHC#$^^N1CH,%JEZFIKMKJJ[&>^A9>;M&:EZ]]Y'KKKJWFI9>LT4Y;[5W.
M7MMMM6UA9J1A(IG$DTDV\6233?#F^^Z\_=X;<+SUSMN3P@?_.^^^)1&<L< ?
MW[MQQ_X99XP322Z_7&]*,.\<<<4G/_R63Q!_?'*^&:-D$KL;EX22R$_G_/3)
M&T<L<W0Y1SWRQ?WN^^[5@9_D=;[Q7OWWX5O'^W77JSD9XN:3@5[ZDZ%WGGI]
MIX_^>NNK[]YY[[%_/GSMR4^X>O/'S_[\9&)I/Q98VH?__??ECQ\6^.^GO_[Z
MW<]__OGW)S_\Z2]^ !S@ 0GHOOXI<( %_!\#&\@_!,9"%_.;1?GVI0S_%5""
M#XS%*_*WP?]-4(0AC*  0ZA #O)/A?83X IAZ$$5 H.# (3A!9UG#%.(PA0]
MY*$H?AA$( Z1%J*@12:.B,0C+I&)F4"B*9RX1"C2 HH]S/Y$$'>(Q2%F8H=9
M!&(6P?A%*U*1BUP\8A5YV,4O#C&,:@PC#[F8Q5P@;5^Y6,0B&,&(1N2Q$9#P
M(R0:$8D^YE&0C"AD(_:X1STBDI&!;&0?&TE(2##"CXQXQ"4QF4E-/D*1>LSC
M)T$9RE J<A&BF"0C/0G)1T9RE8!T)"1%&4M9>A*4D^1C(O7H2D3JTI:,=*4K
M/0D)- S3#,,T)AK,4$QC*O.8S'3F,J&)3&9*LYG/)&8UCTG,:6HSF]1<YC23
MB<UKCC.<WQ2G-,UP!C*H4YWK;"<9X'D&><H3GO6TYSSC.<]WLG.=9"@#/?U9
M!BV4 9X"U4) RY#0@]:3H/RLI_X6]#E/B+JSGP ] T0;BL]Z[I.=[7QG0<]@
M363Z,Y[]Q&A%U_E/@O8SGQZMZ$$)2M"!\E.@*U6H0P\:49H.U)WL3&A".<I2
ME'K4ISJ]*%'WN=%XCA.9:SB#%*00!:A*%:I5M:H4IH#5K%Z5JUWUZE>_6H4L
M2&&L8#7K6=&:5K*RP9EF8 ,9FA!7N<;U!W6UZUWQ^@,GU-4)>]VK7O,*6+X&
MUJYS->QAY_H#Q"Z6L4Y(K%[_.EC)XC6R@67L93$;U[_V]:Z1K:QG.^M7?(V6
MM 1*1C-&UHS3JA9@_VK&:S>VL=:R5K6RA:UL8YM;?^E6MJT]&LDVAMK=_G89
MJ)69O_Z,J]K7OO:TQ35N; &F7.@&UV&I'6XRHC:2W187N+A=[6RYV]O4HE:X
MTVU>;KLK,^@Z;;FW1>YV>\NSYLZ6N<QU&'EA^S#6MG:ZLK662**QBZ\-6,"\
M$/"!>S'@!$_-;+Y(\-<>7. !?\W!$X:PA0V<X0-+&,,<KMK7&&Q@ ??B;!F&
M\((U/&$)'QC$'+8P+G@AMREY@A..$UR--\$)'-=X>)L Q=XH\3I.T)@2.BYR
MD?>FXWD9F1.="#*-/>%D&T_9QCK&7)%UG&,L<V++-=:QE[V\B2#SV!.DXW&6
M<[RY3I!N$Y^01"=P+.8UZRW+0\9RCG/\932CF<J"6_*\:/YLY$!3(LJO.UR1
MYY5DO7W"/"0YCT?^6UI)WXM-J[K4GBR=*%D=*B;&D HP5N5I%J'*&)4"SJD/
M52I+<YK5IT;UJUT-:TA]>DY4B92KX;3I-GG:UIQ&%#)*Y2N04.- ;8+4H5 -
M:E\'*E*?]G6D7J+JE^PZU&UJ47#L9&P3'1O4R8YUH8[Q)A;M&MI[HI.G:PWN
M"?DZ5)$2]D><TY5:K&7>7*FW+6IQ[VG5^][W+@N__ZTL>0N<2?Y&B\'I/7"N
MT.(7@<$61"##+?]01"$5ASA%'OXE;D6F(!"O>,<[+A&11QQ=DU'(NN@3KX>$
MJ>06[Q9]#$)R^"#$(>T2>4/$Q?Z12$^:YSWO4(B2DHQ$2851#CHVIY4RFN(\
MA40_44IP>H,GG.&J1&\J>FET I-W?R3J*(KZFW:"H*9GB#?"N3IM)K7UCL0;
M.]<QUK.6U*2X/X?@=2\+CH0%E^S<O2O'<#C%M561^ZS\,AL/_+G88_C#1\0]
M%?'YXR'_$5;U"QJ55VUOCO%:9#0C06 W.I^H<O:QSR0X4!_.S9H!#'_1I&C5
MP#RI;C84FN L*CC334Q")*'1@_[TN3&[TVV2W>88G&KXKD58W*YW'A5I6<L7
M#Y3LCBQ@]07OT2]XPUN"GH=C3L^)B1>8YG61Y2V^/D5FS^4R@OZ%2([\E$@&
M*UCA"OY7&"/R]1^M-'PC"T+L?Q"ZX#R(J&(9"@$3@&$5?&,F*,0JE@'J?@-#
M8(/I2"]!5$0V=*$5WN\5;.]F6"$6D&$55,\I,L4C/$1.A@Z[1D4W@*W3I"TU
MD$,FH('V!*9$'- G8G F7O!FCB+8L((M:H$6?+ 6?$%L?&0ZG&0(Q0(LN./X
M@L0(PX(71.'XK,/ZSL(O1*'ZF&7NHH7O?,'AU*,.PN +QR!O. XC/*$1QB!+
MWD41%*$^%$+]Q,0,P\4PQD#Q%@(2QB B[#!=JF1<#(,2!N$ %*  !@ !E$ E
M=BXT0N(0IT$1[6_2\,]$I$$($N $1D #)& 0.$_U6B4:S/[  =R $"P@8(*.
M40(&.*"!"=P &H!#8%8Q F5"%!VD4%A%%@VF3X##7RP%&&H1&@+A J2A!<Y
M&H0.&* !!=8 &B: $)8A!]4N-'#/&)IA!R9  S3  MH &D@-UU:11:*!#&1
M%4V1#8  &UU-3E M OL$VFZ&#4@!&@A! U1/4O $V9#MVQ;%V"1%V9"!'86N
M*$:C5(1/4YR#+'P!!RI  S*@ G* %K[B^/)M6A2.W^9-"?/MWVXA$T" (2L2
M"L>"!R@ $'AA(@ON+?R-WWBA$BA@![:B(IGD",%#+FK![ZZE(2"  CR@ R!
M!.ACXBY"(- P(3IA"S:@$Q2"<_XBKA1JP 9 02%X$B&:LN0T(BA_@"@)XG(,
MKS]NKB(B 12V  /<D" 80_&LDA,@@0+&X"LK@R ZH0N\<B&"LBWK9A)@+BT%
MK_$F8B,&80%.H W6( ,"H! \0Q$#<A$;\?%$8S2,01J"8 >FP1B@ 0DNH!J4
M 1HH2!6E 0;.8!H&X0*283*!X16@X3>PZWZ(C1I>@ FF@1@K2+4,!;M6D3*)
MD2J:H3(I#QAT 1JTKAE> 6JH KMTX391[Q6($29@01I>@ VFX158BTXN(!3^
M+T%FL$0V9"@*91DT0 E@P17R0 %6@1J2(1K8!!FDH1G&TS$[,_.@018LT!BH
MH1JF ?X-4$ :@&$\*R\F*J\^26.UA/$8HH$\%W :*F 0IB$60D$9FJ$:RC,9
MQM,[H;'RVA,:I($:E X:FJ$^CT$:[E,5I\$"!/0#C4(7=[ K>N$#BL 4-$$3
M*F (A,$6?,$7A*$7@/ 7HD48OF(7?,$6?L'!?,%''.Q%J<47B&$4(, 4>.%%
MA4$O0A("1 %&6[1%N4)'>:$K>*%)A2%*;6%*>V%'<;07B&$7F*$(;H 9:J$7
MA*$8B*$OLO1(VRY9RD)*0D(P( ("O* 3!B("?J 4WHR2,L=P#J=Q#J<3(&$1
MADP@Z)10%Z$3P* #Z-03%"'*: X4;  '0"%/':$3$&(2.O[A$1P!_0"5$88,
MXDJA!UB@%")AR!:!Q@1B$Z@RQQ0"%#P!$MPPR@RIR;J@ TIA5@DUCX9L(%RU
M/T!A$2#!4A<A B A$C95+25!4*.L"S8@;SK!4[^@6;<R4"TU3.C0*3&"$@IA
M (2@(_@  ,Q@#49 *(3@!323 _Q  P0!#4S #![  OR@(PH!!!Z  P!3&LQ@
M AY@!%AA&JI!"!S@ <B@,'ON0$I%&H  "*9!*/K@ 9+!&(" $LF &MC@ 2K
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M! 8@%EH!7%T!!8A@&F0  0:A#0( .1F18-/$0^:39T-A$ +!!#*3!KXY&4C
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M AX-G?'%J:/!"!P !5K  BS &'3A <P@#_K !$Q@L@=V$"P@&DP "/S #Y(
M H AKE4+%OJ5!@96%T;@!=9 %CAO.0:[0G4A LZ W$U@!EXA H*@#?P/&"R@
M%=PS"X!@%2I 0Y6 !J1A ECA!2= %O@  I:@#Y1!&D#1.-=@&J"A$"K .,V
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M#C  "4E,+JY;8(#L=$"!'X0@!)W0""4V ?,Q!"4$I9!$4HWG-@GHH =9 \-
MBMX4'5C@!SW 0 @:\8#!NBT"%5\L)!H 5494=:4A:$+0 4>!TDD=Z!CHQ"(H
M4 ,?.& B(:W9931JVLE\(AF8"%5S6N$&6,2BA\8@!#)LRXHV^$$YHB$$&N@X
M#6CPP0R8-T8;VA";Z(I^]- -LI*2T8I5),.*L2C$AUQ1!C/ 0D"K8,4R8$$(
M9=R>#?YD6$4TMB0+,I@A%M4PAC'\0(@$N8$)?7#5,9"A"T(H"?AGD'TUJO$*
M,V3A$#-.I!O. (OB5X,06F@#,I8!#$+H(DF$,!'YR^"*:N ^&:N(A1^R\$GZ
M ZK]JE0EII]O#*[4'-B!/P["!J)D?,<08'!0? -B!C 0!*S0@&O0?,M0"&T@
M(&SP DH0"'F0#& B S+0!Y32!S0  V:0'0[R"FCP?,>P#&8P T#0"@)""D&@
M?F90#7PP".@W)D@  TF@"]  /R5B!KI0#8/ !\L @C+ *,J !H"B#&P@"] 0
M"D, :3;V?[<B@,P1#9SV*[R0!GM0+KN :KO "UKP CE@"?Z_$"]2< G%D E3
M8 LK,P4YH ;U) IWR NUT O4D@-[P 6VD M%$ ,YL$\M4PM98 JXX MZ@$QS
M($]9H DN4PONI )QH )%0 NW("\W$ -2L N[H :3&"]X, >\P N:P ,JH 6X
MP N7D ;_0E$115&UR&\SXPB )PEBP B9,09C( F@, 8_L 62(' \H1"+4#2;
M,P9-$ :>L 6-, :+L#N<H @_P0A%TPE>,#2-@#B880>(L#F*\ -/,'"1$ 8C
M@8Z28 =CT D[LQ<V QA@X 6;XP4_00F>P AB4%K(N EC8 <")P:04%IQ-8QV
MQ0G96%K*&!)=0#1F%0D#.1*E0_Z,;8..QW.1(;$%/Q &A)6- T>.6Z","N$(
M3F!73><S.M>/@7=:]=-:,A  N$$_K45Z-6F3,\DD >A\ST<K 2@-T;!Z:Y8D
M:[8?R1 -TN!!.38-8$0ER  -/'B4TN DT+ D/@E&NL(ETN JQB !I+"4J[<=
MU=!$*=@?5;)Z6<F#_4$KT("49JF EY:%3:)CSM$D6DDE2[(,H[0DCT0-Z&<K
M;1F 'G0,3D0I -9$4JF /RD-<(D,BWEI;!D-RT E7+(,^J. S@<EA_DDT, B
M1ADH@LDET2"85WD,D;DK;1F73;(KO9(R[?10\5)OOB ,PK"'MW +OH +<UA0
MNBF;O?Y #+L ,L#2"[/9"]IV"[,I#*\)4<$9+++I"[8),K9Y"Q*C!AJ03\)@
MF[; "\(@F_ B#/OF4%^(G"U3;[9X;_8VAQ/5;\WQ;Y-QC".Q-? )"N\Y</#Y
M"2/A"9]0"F4A<)P@$O#I%/4Y<*4 "KJ(&?^Y":  "I/QC0>J-DL3=/0YD8@3
M"91 H#JW"93 H/"IH0(Z&9MP"A0Q$@WZC:!0"AJZH U:H4[QGR3JGON)GQJZ
MHJ"0H?AIHAV:CRRIHY(@'33Y'*^0?$OI'#XJ&D1:I#>)I$DZI$UB?"E(74M"
M8\_W)'=I#)=F?'=)732&I0F8I5A*75Y:8U&J)%JJ)($ "_ZZ4H!CNJ556958
M2%U/TJ6V0J6I>2MSR1S8Q21B"D5:6J6VHJ=0JBM/.GW X*8V9F-.ZJ9?^J39
M@858>)=/PJ=PZJ=CJB3;025W6:@.$JAPF9JULH7+T87[1E$G S G@S)>*(@3
M50NK"BP2A:HLDPNCVIJ<QFG3"5&VR8>5H 7_4JL ,ZNV""R<]B[X1HO$VJKI
M":R[8 KKR1P9M:/(XPG'HW/3*@D%61G22AF3\ZR6P0F-L 4^$ 8-:EJ  :W4
MNJW2JJWFBI\K&7C8:AD8*8_NNJTMJ:3U:J_WNJ0XI@RUDBO3]7]/PJE-XJ2K
MQ*^X(B!T>F,!BRL#BVG98:?7@?ZP3IJFJ\2P"&NQ5:FPMU*Q%QM%+KAIP(IO
MQ'J>YIDRYRFJ)#NR*4N>(8LR(PNR(.NR$N4R)GN<N#BO[TI:-ZNSE>$)"BJN
M.RNO.RNT0LNN1#L9E("O2:NT2:H=55FE7.JE4IJ%!9LK&]NQ@9J35LNQF%9C
M<;D=GUJD6TM=5ANUTP=%6)JQ%ZNU8IN%R;":0^HKQ7J>$B6=K6FW+..R+SN+
M(FNKQHJW>JMOMO"J?UNL>)NW)JNLS+H<SCJTC>NX.A>T-VNMCSNOD4NY.HNT
M2ZNYF^M<!#A]U+!Z ^(@5,FV+;BP*0BP"IN9I;NURE ->OE_#BLE' LEL)N3
MA7DKS?ZPDTR2E_SJ?ZS+L6F;FF_[2C!;BRH;LH![LB3+,KX0G75KB\L[40Q5
M4<R;,M*+GOJVK$,Z#8RKHV5QN3OZG\88OI?A"?1)H^6+/(2UK;N3KM5:&9V@
MH9Y@H/ +OY'+N?FKO]61ILE !ZH'"ZD4>1D[I66;DW.**UQ:P*9[>K+@!E9*
M);^;J ELP(IZP'DZ?B.8A?@#MJ)!P:K)I,M "G[PN[JR#(0P*V9K#-6 ?-60
MDR<\*X::J%S*I#DY?<;'191ZP4Z[))=&M1;KJ=P+2\N+JW?;JR\[MX!;B[V:
M!9FP,GUKBZ90LA35"Y8@!S"CQ+9 "Z;JM\F;;XHK&NVYH_Y;D CCJ[Z7,3F;
MT A/8+GJ^*SR6J&@M3LCL05:$WC1ZL;M*H^)4U;C:K^2  E>D<>4L0EU' E]
MK([L2JZ5D;G[Z\B/O)0%&(! P$)Z$@@S<&F4 K!; I10E R<2266%L'((+I?
M0J7+\)0VE@RU(@V%  /3QR5NJZF4HDJI9,JP+)5>NBN<J22D[)FIY"#-, U3
MT )])+Q+LAT/6Z11&QXN?'J#N9/*(,Q3UD?/O S1@ 9$D"#+ $9#A@):T$>T
MHBO0P 9$<+#-0+I0PIG90<H.FR3)@#\NO,*@:\T'>WJB2279@<YNFR2HS"+!
MJVG/T87YYKQSR)SQDIPGLS+%^?[$!EV>L+F\NT";+",,Q7 +PPK1OZ("E?"<
MM\E.VME0<T@+&6 *K[E0R4D+PJ &&9"<LI@+$OV:*G.<*B 'Q#"X,XMOH@K&
MW>MWF$'((WJ,G! !A_'3$_K'#/J-DZ!1B*,2G6#&G.#49O,#.( *=A "C*!1
M"6J@/?NSF+%5D[$[H" YI;4Y9!5WQ[,)(1"N(U$*"(H9 K>2G5 6%4K(@-$)
M F<V3E #J3 &(; (2QW5U:H9@2T)E+ (?IT98HVNH-!7DB "<C,2BHW'\WFM
MC0S)E[VY4IF"RJ +QF<"2&"H/%D(?0 E"K@*?B +MKLDS1 +?#"#QQ GYR<+
MA!H+Q_[0!SAD?- PPJ\ #<@0P, 0"M#W?!;H!\ <"\C0"GT S"7B!Z0P2FLV
MVKM2E=(@"WRP"K02P*U]2(4"#'P "VQP71-<M5 2'4W2#-7MW+IRIGU "*ZR
M#+K@W1J(F,?P"LO0"K'@MN>W"GR0VO\!9*BG9@-"J,CP"LE0"(,P(&[;!X&0
M#.CW"HSZ"L< "YU-"LD@*/Q-*Q'."GZ@"^A7(NQ-*VM&"!SNX:W !ZQ ND#L
MMAT,2\"R;'I0"<(P"G.0+L%2"7*0";V +;=@Q25=B:8P!X"@X_%2"7-0TLT[
M"G)PB*&X!WI@"_5BAAVC,5HLN*9P"WA0"?\B+W)@"<]93?YZL(F_T@N:( >:
M,)QIH *[4.9:#N1"#B^C,.:C,-)20*J%6XNAN+T8U=.+H!" +#>;$ 9>$1)'
M$U7JN @^[05KT:$Z9SQ=( 84V@B2 (R=H A;H B(LS6!WHN24 -?QS8C:@=;
MP B0;E:,11EVISHBT0B3TP6,5:%FI0A>X#4V \B0$ E@8,>,( F)T 6,\ E9
M85;A.C?H>NEFU062H-0VX.GN"5J+('",$ F*T.N2HXX[9^NMCCC1R@FB%>F0
M<.VN_NNJ<Y_X6=B8;>Z:2X#;00TFT 9Y\  6@ :A< &K# ,O0 ,CP I$-@)"
M8 %K  W^NB5^< %!P 'NX8/5P_X!S4 (&1 $,& !2'!]2B "?L9"9V ")@ $
M?[3*,X "0, !^0X$)A $)& !L2 -?F !0* !0;#Q&/_Q\+PE:) !2%#PTX &
M&B $+_  @T"%%O ",C "/("G_T?>T)& ,7\!-)\%TK!(02 ##X! BP0#0$\#
M_[X=)/!=H> & 60&^VX!"/0"93 -F9(D0X8&7\0!F7(!+R!_&#\#&6 ,A2 F
MS= 'DF0F+8 ";$8"2' !V!/R06 "%M!D[47U T(#&*\!JT -;.#U-23><4F\
MS='B<U@",3 #%' $.7 "]%(,0S "19 !<C ,/% "-Z "%?!L>V !,B ",:"=
M-U#Z&?[039SF3A90!"-P!#K^ B(P RK@ ;E "R80 SR@ 9K@"QD "**  3<
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M[)4O6^@KF]ODE[\ 5I%-6& ,8N@ )S8QAA[HH"ZGH( 7$!*)B;TM!#HH"@:
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M@PF<$0-."B,&AHR NW8Q"EO$@ >7F$,E+%$+17D@!WK0A 9V400>,(,8EIB
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MA0QX 1AX 8ZTGV/@ %)8!FE8@_]!@VC4 "&8!LNCAN88A.3;R?\9OFJX25(
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M$48$(4"" 78X11@@L(DNH2F!"EQ@EACH0"VIR4X2G" %*VC!"TY#('E:1@F
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M 00Y* (&3 %EQX13%!.PQ"YHX0MB[**?MHA!"8HP@B@0HSG%P,\11C"$'*B
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MW,?I!/X@3@6(@.R4 N! *E@! 4P/)T3 %J3"!WB (E@!!7!")U2!6PI()_0
M!GS!$T@ MH7 !WP!#AC (K3E6'7(%RA %8Q!"-@ *OR ]"B" RS"@(3 "MA!
M$SB #IQ""'3 &#1"!/3 889 5W5 9(+( E(! G3!$4*A@-S;EZQF:F)):VX)
M;(X)EGA6%=KF;0J<!M$$+" !# !!*T"#&\A$3;0"(>1!,[0!(=3$RR%#3<R
M#/3!,B1#+!@!#"2!N"1#&[P=,/2F!T%*(!)B>-(<4]#*?^4)B'% 3KP"$118
M&]  &6 C*9!"&S2#&<A",^A"$KQ $@!#-;R"&>A)-9C!"/ZU0C,D@RP$ 0SX
M01O( I Q1;<4@C2T0H*R 58<0Y#E@8(E@QG,0! <TIZ@@6^R0B%I 1"T 2L@
MP2NP08/2Q%=,A!\$ E>802P@ QGPP(H:02RX@4HL0T4D UJX@80&02+YA#&<
MP752UYH064W9@A0<@2WT@A;$P U,1F740G>H02;\@B6HP2[T0AP  B\8QB_,
MP1S\PGOL0B6D@9=6@AKX0D8.@2:D01HTJ?Z) A=4%'+$P!SXPBUD*2](00YD
M:1&(@AIH@IB21ASD !2(0A14 A[@ 2_TPAS83"Y !A?, 1[L@G[,9 Z\@!3\
MGRD4@1K4@A3<!R]4P@T,@27$0?YH&,9H_!_J"&!7>J43C$$G+,(/!,@F/ $B
M<((=U)HB/,$F<,\59!8G7$$(U, 82%4CX  +>,$3- (B/,$(#N8*I, /Z%0C
M]$#Z-$%7<JL+=,$8]( D*((-G.:Y)LD!,8(DB$$C@$$'=,+L2$"],= 3@DEK
M9I:6["N:X"L3XF; "FP%E=;-(8,T1(,T+,,4 =DD_>A,0 .028/,Z4DT).Q,
M,(4TQ%82;>S!QE;#@J=XBNQS&>*:H,H4]8$0-(/'*@,T?*S"*EY!) ,P)$/"
M2@.0)</$YHDR4$-L?5W.;E?$ZHDR5(,T<,4RV.S)-@-S20,U*.Q_\2PE<87'
M1NS-WOZLGARL$2UMGDSLP?9L,]RL@6Y0,]Q<,Q02V$)#-" <)2%#DOK'DM84
M^!D&,8!?+^B?,, J<?R?_XG&Z?#"+^1'>?""WJ8>8M#MX!*',.C'+90'E-*M
M_^DM^ E#ZHT.K!J&[>'MY ZN8?C&_]&M,)"./ I#,30NEAE4XY(&W9*9_YW.
M-KF:?\3:7")0*4Q;EVP"*'!"L*FF8,ZE6-%;L(%")^2N[FH))Y2"6'%(\ X(
MEHB5\!Z()Y0")SC") 3O$7;"$VS &!C;L&X!!O0 [:KFF?PK93E0OSZ0;/IK
MF@SL^K)OG!R<%/51'Q&$!OGA?QE1_ 9B_/;1,<SO_IZG_/[J[\@*,'09D=N^
M&JK<G(7ER;M<:!\!@Q3-[_\^\ )3K/X>D3&\"_["[_]B<*K8;_Q.L 33+#)D
M\(4>0P@O\/_^A 7_UP.CL!2=9PDW<!\9L&!$@][DQS9I)704&7YD9>L",1#S
M\.GDPA"O4W?H\$%E):L5659"AQ$?5 X?!GX,,73\\ X3L1 G<1"[[JR"26-M
M"1B[II>(\9<@SQ=C5A6@VQ8L20WH0)B@[[XM4!QC%A,ZD!2V;Q[G\14BL'DJ
M \4B7*H ,@)3;',AT<T-;7.)RP S\A+)7,GZ1ZH0A(4",D' RB"[2B!BLJJ$
M+-;>KZH,Q#$XUP>ORB8/;2B7\OZJ_#'__G$!#]D5<W$.(W$LTW(MQ[+EZL?I
M=,<06V[K0C%^]+(M!_%H!#,0 ^#K_L?TCO$RNV;SCA4HH"8SSZ8TXYN7T+&_
MZG$VZ[%N-G(W>_/,W5P-"X;_BBP#UYPI\V^L5#"K'-&%(K(3H;,4B3/"ZG(N
MW[(]ZS*32G',"'/KXG,0P_(M]_/B]G,0$S0PRRI7XJOY\BL4,C289-9#DZ_K
M_!LUEXE%+]#X5G-M:G-'!VQI?7-(B[02D6=U,45X*@-6%,3"LDHGK\K,IC.J
MH'/( B(TH/+.BK(1U6QTT6RKN'(P$;3H"+-^C X0X_-![VWK;BZL_O/IB ZK
MD9D_%_YT/@_S,)L./S>UY6[EF@#(94GT WTU1HOU1%\S;3Y0986U8X6OF."Q
M1[MUP;WO2,OU7'LP) L&'MWTA;ZPJICG#)^G+M $'Y0<S ERS'%P((*CB?6U
M7L>T"9_P(-.LCJZR"0O$A26#BFZP!YLGQ0(#-/B!8I<RW\4C$@.@*60Q0/="
M)<C!50OS+ER"'%CNX\0!H@YQ+ANQ::?V:D^U0>]SZUYQ+3R.'""J+6_J5L,N
MK8YU<C-S6=M;->N495DS%(XO1[]U=0\<']-U=L^U.,.20" R5E3#J9A6,T!*
MC,W$>>8LI/@GMD1#$+2!NYBW>089-"BRV7*%GB!8($0#S?XNPX6";1+=5G]C
M13)8Z(_^BQ\>PW8!V30@ 2\2P@L@N-DFD4_4;,,> ]ABA2GMW:J(]LM<*:L-
MDPJ4KC"PMBWT7W<(PQO<@/69>)_R,VD0QT*J@0: KMWZ0AKP@"\X!HD[=>CN
M@BET@"@0@XJS+I1RKMZ^:N@B-# K^?^-#FM[Z3"H00:P+CYOJE3WAT*7K[YE
MED9;-&QNB)>/<5J?=?E:]YD/'#=K]YHW\A-%$=:^PC(4PB 0^#&\ L*\0B'Y
M 9W_A%[PP7TB0R!$ "%@\"O"@A]T$C(T0R'X 8A=>"OXP8A>*#3T@08T@]F]
M@DHLNA],1) !@Q^LPC'LURO4K_XK)$-QM4PR#((?')@QS  0Z((QZ,(?4X0?
M1%C" <.ANT(UT 2CZ\(R2,,2!,IB(UR'*^D/[X(49$ FT,(OM%0EF(Z7RM0N
MC()^W(?HV.0ML#;C5L(<.(XPI($+_$8FN+B4\8(IS$$E_()^_ (MI'LOL$93
M*B0MB((HC$8N -3PR4$FE$<OM-0>P+M3F_@HR &T;Y-IXT$EB"DOY,(<C +W
M]4)MT[)-S:J8GPF9BW6_R683,O<T0_18MR9LBKSK4#>:F[P%@32;J[P 3U?.
MH<H(T, ,C  )O L)!(&A%)<0O, ,M"P99  06, :( ,,/( )O,)[LJ,%\, (
M  &!R_Z "0"!!MB%&8R $%C &2R8O.B8!B@!-3Q]U*^"7F2 ;XH $31#!0!G
M+%P ++ "*.D""<@ :L4"'T" !9 !*TA=,@"!.I),&&J %TE '_R="=Q\'TR#
M'U3 .\NTL;\M,%N"!T! #M@"(&3 #93 $)C."Y":"B29&IR ,(A"">R&!V0"
MK.["#8S #5C /:5!Y;] !' !,[S&,.R!!0 !" R!: ""!<P "'B.X)1 )L3!
MGHZ9+XC9,&A!!@P!:A!#)6"-Z/=R+H29!8!'$:23!=S #$2 ]6>"!J@ GZE
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MB' L%AP-5D @%IM"ABZF=(QD0./!QFB&I I1DAL001K)> 4ID@$,8Q@#P<V
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M%KR_'?R^^SO"#9S"]7O"*]S __N_)WS!-_S $1S$\UO$^]L3]+O$*US#0;S
M1WS%^?L37@'&83P67F'&8YS&:]S&;SS':=S&<3S&?=S'=YS'>QS(A;S'<SS(
MDSS(=1S)ESP6E'S(;7P5IGP52('*2:$5IMS*K5S+J;S*K3S+5R$4N+S*ISS+
MM[S+TYS+T?S*O3S-R[S-O_S-N_Z<S.%\RT,AS,N\SK<<S<E\S:N\%6K<QUUA
MS-E<S^$<T=_<T*\<S!M=S>W<R_V\SB%]SR$]SOT\SA$=TQW]T#'=S(O\%63!
M$D:=U$O]$BZAU%-=U5==U2N!U54=U5]=UF=]U5U]U&V]UFE]UC'!R$E!#.S
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MH 0E^$ F>E&+''@@ T78!9%X8((;U((7EB@"+_ 5)%X(:48'K-$M'E@P7EA
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M@$40UE"!0BAA#1/I P^JT8P1^&$:>3""-)2 A!U<0 :FY$,&2)"$"Y#B%3
M!@Q( 389K((,;)#&*D:@ 2&<X S0>(%E80$#[2WA!"C >'.;B9U',K8HU.61
M=^>0"4L0HQ>C>, H>B&,/3R &% H@C2&H 9+Q( 9ZPR8+P !@A)X0 ^],$4.
M5 ""(Q10#1\P@0DTP8L2%$$%%3A"UD4HL07;'9X,OKN,(,P1"9L) HA(12>^
M'+HF5. #/EC!)JR @[E0H0>G6,$8GN  "ECA"RG 7"12,/YC,W5B"S5PL1A8
MT(DJ8" $(2#S&#Z0 @QL@1,K<$ '[/"$'YRB!CX( 05P0+DG6" $.%A!I\RT
M@@9LP N=Z,$&1"!\(R-9$9_?@ =$H(A(A$ 1I7C""EQ<@R^,806=L$&7=Q^Z
M+V!@ SA@@1C*W(0/H)X1F.,$&"@0 1MP O@LH( -.N$%&_@  Y)@!^[7 5^
M%U;0 2&0 C2%*2!C4VOB10=P 3,  RU@#*Y0 "?0!R<P *\0"P3  !$ !W
M !> ! YP "A ! %  Z<Q#:P@ "3@!QO("H6P:6S0:ZZP  B !$0  $$P#3#
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M#6 )<R=@AK,X :5W%[F1&9E@-/(+D3,YD1 !(; "*Q "3W *7>  B2 )-9
MG? $'Q 7/Q "J$ !K]<!3; )C2 !8W *5H !3 5$,W5[.F '%! )J= $*9 *
MB*<*F+<)B! !7U *-5 #J4 !+" )BM  ,M0 --4##  GBD !7@ */[ !G;("
M+( *,(5DC2 &/LD)3T !G+ !3Y **Q !C="3CM %%' *I\>5#2 &,E4%\F<
M!7AA=J"6J. "/0 *:<().I "CL )'A "*L8 ,F0 /Z (C?Y@ 6" "F, @&)
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M 830#, @#4B@!'[06K%@ :Z@,V80HS"@I=   VQP!C0@#;#@B*0@"Q:@'1<
M;7T A&A "I4("](0!&30#!7 A\L+"R(:!'D@ ZVFH\:P!,?+IHPD76UA+_M2
M"[X0=L00!3F0=+1 ,)H0 1[4"X^J J:  ::0"1FP3M<5 \)0P+Q0#%H 3G,P
M GH@# (Y Q)0!,20 ?BT"R0\JAHY,*AZ,0K6PGB7=P750B%I)HX  78@>';!
M C^P9!"[FG/!E,"Z!:?P 8BY"?ZEN0@6T @.6'HI4)J1AY(^T 16T BG  8U
MT%"2T @4, :I4 ,V$,0NA@'F6@.EX E:+%&28,848 ><0 %B@#F,  &.4*^2
M<*\K\ .E@&,=<$0AL 4]T 4]8 --@ H'FPI[G%3'%P80*V0NZSE&C $N4 4V
ML'^>]P.D!V96@!<-&P88L FE1P%-\ --0 6/4 ,?X 11; 61$ 8P505*U3(]
MRQ%M0)]N@(3&, ##-@UP$ !*R[34X #'J1&S+)[#/ U7ZT:O@  78 RPX+3@
M^8/S>0;QE@ /,*2XA8D>"+=FL)YZ:V>O@ ;5H+=YH,M^.PT74(V!6U;DTPR!
M@ "DD/X:R=P'K9  1!$(%V"\L[:V@; &F"L-$$JAGQO0RQ-N"!(MT$ &$E"\
MT_!%LJ +$L!&T^"XK1 !MD,&&L"B,)"Y9M"[;#"DRJ"CVU,-K6 "+?!PN1M,
MTK#10$@&!4&]@V !1.$*"< *W%N\%3<#A2L#9V ,$N"CZFL&T/  JS -I.
MR@ #1J 1VCB>A9"YTF UCB2ZTU".1,(+FD !ID ,PU!VPU !:L ,S% $)=!
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M SIP"FG"95B)F<0*9@[;R9XP!A' ":J0"D^ VQZ "JJP"0O.":X)FRHS"8(
M $+ &]-+ !50 +'T"CXHS'L+A -06@>PHJ4Q P(P 060T6O; +8Q#:Z@ !4
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M"J] #:\P @?0:ZLPU-1 "$);^)@6;W]/^(9?^ <B#810"%Q5Y>+FGW#%"F9
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MQ3E.G@'2G.>4'_@R1*4J+6U+0]M;TY:6OB-:"1IM2 (T="&$%R1C"7SHT3&
M@41$>6U+27/:T) A"R(@<6G 2(8LA-",/"S!1O6$&CR?.%"DE4^BP&@B^>HG
M.+J8(@YI>$,:3.$22Q3A")GH12V* 8@A["&6>QC6X:B8N/X<5((7E1B%X=*2
M"UZH 0I1$,6N:,$+/1PAECJ=R2A4, 2C8)%8CK,B2VCQ"RVD858$'-4"V=C
MT45(><Q##EHC=)X..*%<:EU>7(\3B;/"U7BML^MR^E(#^?#.0IOH05^Y>9P1
MAK"$("1G8A6KQ^NAT[&/+:0Z,U0E'$T#&O9,!C2FT2-%9:E(S4 1H0+AAFGX
MH0*O2 8;"F$C&D5C?$4S1C6 5*9F+"-'<*OL*AX@I&/$J!HH4L@J')",0;"A
M&D*R[#+.5-O9@BE'.41495OQ (@^L9"#/,D462*,-SC@!C&(P2B$,0<)2*$(
M#Z@$,2ZA@3ADP!+#4$,16C463OZE"BVKW(6G=F$J7NQ$"II@1@;P0(Q=WB(7
MPC"%%(@1!3G,JBR]$ 8SU. !7]1"E;[@12V8 843("Y47[U%+W9!#%D1DR80
M%L9<..6,&@QAOL.BB5B?V1?6T0==&QS-)DH1P?DT*\?[BB"SL$F?3;0F%2'
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M@ $W,($ED 97F  B((,1<$"MB?Z:;$.):'"<7E !'YB!%M@#8JB$"("<?Y,
M6U #%W@&%Y@#*5 #9A"QH[B!%]@X^1J%"KB!*?" "!"&*2B!5RF"&!B&!] #
M.G@ $P $0)  "ZN$";B$.7"&.)B"GO,%/(" *3B""E !%*R +) ""\@$0\@
M#5"#7[@!%7B#$Q@"9GB#)BP"38  %5 !4WB##$B#(2B!FIB""M""'7  *7BQ
M_PFZDVBC3O !#WB6)]B 4ZB!$+""$+"!3E@$"/"!+:" +C@%#/" #R"7-<.!
M!\"!)I" )SB%.Z" )F@""K"#3L" #O@ +^@"" @!,)"$#E@!*L" 'D@%*W
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M. (7,+<XB !BD((8\ 5A.((;&(8,T -G  $]((9?\( X<(8A*()BX $U& )
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M'J &73B&:4"29( %)( !((B 5F %!UR&58 ^$G #-I&%^M,(1654((" H9P
M:%B#%I &"Z"(9F@#L33594"&"V@%,X@ 'H !&7#5%K 38Y"%:KLD*,&NE*"+
M_?(%9_ZX@2*PA AXL$R @$SXA5K8 U^X 4!P@3=0 Q6H,&&0 @IHPQRP $N(
M 2V8E4S0 &M]@<[\S&&P #T0AM0D)BU0 6'(@$KP%*"*)5JH@$L(,3DX@5X
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M=0^8NDWHXPY01L&J4CF"9?'V=SXZ[X"?&EP.GR>"!D7=$VDP@<Z%A6@H$F2
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M0R$N<(QI+ $(E 2"-*1A@C8DHP&LH"L9Z+C*OLAF0,A*42_4H(&#C',7HYC
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M)\HH"(6$QF4P!B&TPF)D1H0@2(1\S"N8 2N8)X*<#)("0X1HQI0>!G]*1[*
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ME$A"\.+'*9/D!(P$7'C"!0;"Z,013V!7"?9(.J%@BR>KPRZ2*Q%^0@$/.NC
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MI AS3@(2$=BF(["W)$E0:9IPFH2Z), (3G#B$0Y0Q"E.L04);,(.#A"8PA0
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M/JW3V$2F*" %GF"D:BJ=PJ '/F!(J*4YC&,3!L&J$  !', ,IL$"'B (1@L
MC$'D? B!%@ (NHT 7 @6"( (9H$ 8& FX   _,#7#@!E&( $IJ$:_  )1H
MRF :)O[@ F9B DP %A8 J&9"&OA@V[P- *(P)H*   YH GKM%0# #'P*!=XP
M"O4D",BM%7PJ"\V &IB0LP@A .! &1:@!69"" R !H+ ! "($ 8@"]&@97:B
MB9)B#:: #,A "61A,GRN%"L$48)N#2L%/H!A$%PQ$ ;!&&C.%&F19RSD:$;$
M%TI@"#*A$B[! QS)%M2@"&)@ G8A#4I &'YA#HJ !R0@ZS*@$GIA%S+ $F)
M"XB!%GAA-"P@!XJ@"$K !"R! FZA%HCA!IH+C_;+ F)@#H9A"E2 &'3%5RK
M$GCA%C(! GKA!AS)%V*@!(Y@"&Y  D3! NS1E%9)%*1@P_[,#AF%01BD(!Y-
M20/6RU@V8\5Z"5J"R3@XP0L,H !Z !08PLU.80-^8 MVC_A.(=4$< M$(!5"
M8 M.@1&<0 =$( 2Z1W7R3 ?0QQ.PK/;.[%JFYP=$0'<>XF Z4@=LP ' H!-"
M@ )"0*<VH0-TBA,Z8 ON[S@BX18*JA1ZH  *8 M  9N>( &X; ,<P XX4 3
M8 N>  $DP:)*@0*WP <BX/\H0"UQH 90024I(!%ZP .ZH J41Q'VY?44 4NF
M3Q*\X <BP (V 1$2X .X3 %:C4CRIP!HP(!(2!HL8 +8@ WX  Z2(0@. !9B
M!A8.0 :2< D)P AF80"(8";HC?X/? T!+J@!6$8#&, ,^&  SD ,+Z""S- 8
M"" (9@*$_."GV, -^( 0:&(.%6L".& :6B$ ]'  @J Y^: 0MNH"X( , @ Z
M#X$,4   @L :"H"S5@$ %K$ U! )%H ,Z(0/?"@4R@ % B *\:)2.E$)0%$4
M9:L6"?1 ;,Z#!B0N8D$&&%0&>  62+% )114=L(9/,./E$8*G&$7G$$.*F 7
M-" ']L 2,J 7D'$8SHL.#$P/A $#4NP6##(&I( 8;D43;&$"U("/*D$4*N%#
M:V$8>,"1>J,7 $$*'D -TL $W&87,H$6*F#"F%0?^=%K8N &*@$/]LY)I=$6
M3&$4-/YA H[ ED!@&)"Q%R R'I/F W1)-V!$6'*%]6;BQ2CF"7J .2(!TDIA
M#"B@!T( )GW@%!SARL @$@00 R)!$2"@![3E)6O !J['*UW@23!@>#P!#'2@
M ;I =S@A#!C $3C!$4I!#"3 $W1 >!@A)MUD#)P@4>%O6ZP2*^_E(0Y*210A
M!%: (?1L$YRL U*!!4+ "7J@";;%HIS,)+?  C3*S3B0+ZL@!.P  [KG Y[
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M [1 #LQ."RY !HI@!E0 E_: 1CY@#X1A"#S ORJA&$RA!,(1!#)!&%X7P4B
M[GCAF$O@!3(@Z]+  F"@ M1@:U2@!$Z@!/R.!Z! &'*!%SKL!2S@EO;KP$"
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M5UY)L?[VBAHTKMQ;0VT-O7O7KE"]=/G*12IW[]R\@>,B#38QF".$!B-U\I*
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MK&'-52'K\7*Q&YJ>1-;%V,AF"!G;^PE"Q3+!6UP%#Z/(P1&&D9;PW=,7O?B
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M2X1"5(D0PAIYXA1_;)0O?A/'2N08R,"XQUG2<2I/P\JVX 4M;E "#[S!*G$
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M5A!W-7L*3N #?04*/A!W*8!5PSB3JTJV!=FJLDI+&M<1%H*VB\6;$,%^X=0
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M!BE0MV*A 1X-TKT@#!5M"?WS#,-@B#'  [6M EQ@"D,P#-)@"0S ?U'P#+Q
M 7&@VB92"Q&0"<_P#')P(_,C#5(P M,ID0MKGJ$""BF  YO!"!" " JQ ;B3
M"DWP&8X05-JV8Y)  98C 0$.CV+=&D4HEJ"W":AX'#; "*IP"@T0!H:B"JJ
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M:-&7*Y/&/'"@YX7L4YNLQ5ILS> "%'"GX6+S)+=/)-GJI_Z>K%H0IP>)*G#
M";NB9#D,,]1P0[::T^Y#$$%41IGJQO(P1!13?(XQLKSC[!:6-.&E%EZ((8:7
MB#2RL1?W;*F11X-XW"434^C[+K+U2JNOO23;V^RTT)Z,DJ%=^B,+P** &S"H
MV3JI\#90?-+RJ$AV^23"G#99I!&<@)N$DU)*Z00W.$NIK9-2TIP-$3VW[*K
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MC $"GCA%%[=@4$Z@8@L8 $XG-N $58C! 9) !0MZ@ K(RE.+34 %*IP0 E!
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M-:]N!?YV_W.)81L-4BI "C.)#9.)9@L*%A"#3I 6U3$6,; !?O$"CVJ;#NB
M&Y.$3KB"%.")1TB!$,"!+@@!19"$%0@!2; A4$"$$! !#PB#4_ ""N0$,*#
M-JF!+TB;&F FYMJF;*' 3?B!#=@ &X Y3S"%WMBG2"B%&NB!K1D#%]"G'K
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MU+B?8=N%$M@4E.#.M1,6^F20='F")OA,('4ASOP)#+"E,>@ #Z" &>H$*Z"
M#^@ %62$;]J63@ #)\B;>K.-I0"7FS20Y0//5FP^_#Q3L4#* (44O!P1 %U3
M%4$&J"2+2CF)&1D(7M"$!F@>9I ""^ %7[@ .;A07@ 283"%4> 18@BZ81B5
M71B%QIP(7Q %3"&KY!PU7L"J[1R53$5,7T@#%2"&=@02R/[PA5' %(/@%*SJ
M!5^8@PO $5JHA<L4CS\\50CM!5,PA:#YA32( CF(GJ^L$LT\RYUX14:8DU/
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M8C5=?0+(@SYMXHB-TU5MZ&/MV):.,9Z&*P\1-)Y=_Z/>"-B!(J" '2C4&(@
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M0*43P0O0 ,1/0Q#,@ P$ 32L 0H ?>/;8PK'PM;_1BS(@ S P ML]5: _P[
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M8+"IE409H!*71Y(Q(2*\X%<D807.S'"0FLHD,<LI54?\ ):#])0E:,"H3?Y
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MP"$9+6@:JG\$A%< (0G1_A(:#I&$/V F0T@HQ!_4'(I%3\#I)SW:?%P!E4)
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M"<""!I9E!\[ +4RD!6QP%5RA#9B "1HL9ZA*?A#B!>0M(9"@-JAA%MK #5"
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M(UYA[SSB%4Q&(I+A"?/G9TR"%0!9Q9XP@CO"#80&(0C!!&1CR-R@ M@&#<Q
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M#&V ,Y\!#;X="SXBJ*^ !FL @W%U2-OQ)G;1!X!C)F^9#"1C.4(Z)_?1"K$
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@1!%')+%$$T]$,4455V2Q11=?A#%&&6>DL48;-0P( #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>comp_0024.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0024.gif
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M\/#O\.;P]^[Q\NSS^>?Q^//S\_/W^O;Y^_____CW^.;AW0
M
M
M
M
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M%@@8<(HC Y@0204/K.)%X$TQ](8 7TQPP@H3D-U('#_#H875N$C"B!D*2@J
M!US8@0LE Z#IU1FG&(!!+;BH,( 6<9@ @*/G[:O\\LPW[[Q&++K8]2)VB*>&
M) *4B@L)") 7!@"-I $ "W"$O=:1!E5RF8F?G(U+V+M!,,%3DM $@@&5X,*!
M KF(@$ K*"" %]XP @ L8F&,: $! %@ +\"A:G80GZ,\< !4P"(!(- $ 3KP
M!C(8H *UD!\N6D$H7)A <O Q" D2< H+$"=D9W!#!6!FK::<(@$-: 'OB*0
M*V' 9OZ.H]US<+&N-15G$6_8@  H(3XTY:("$^B)"@BPBA4,+PXE , ;5C&
M%. '%V\(@!I(9X$5+"Q\!." !SIT!D=   (J(-;(OH S '#A$P)8BQV.=XH
MH$"%"/B !TAP@MT\[Y"(3*0BEQ>]/Q4)!-92@\]F1"0$Q(1LCO#" #S@@1&<
MP&_HLQ<8!!"!#4B  "7(10.6]!3I?")M_//?*OP' @^4X 2-8 4!6& !Y'P
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M@ $38).-'Q C7"0U A@@P&.>4@L+H*P2"&A !BA0L*3Z[2E?@  )TAH3[@H
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MF8,I!:5@GT6 G6<) XI@"K7YDS)@"DZP YU)E3BPGC?YH4^G"#!@!*1 ETJ
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M!BA /%EQ3@9H0 $K' (RG;G=>+D! 21U@ (NH3H-1H  7""# &):@@_@0@T
MJ)P$SDL&V>'" @A@A!L"X()3 , $N"B!!W#A!@"<814$T*=J [ !.% @ "I(
M0WTMX  P$D": ?8F -2P"  0-PO)A8 %OIB ]I8@L%Z@!(EQ008 Q('#C-5"
M7:O2 ?X%0* !!%! )AP! .;A0A($&$$N(/"!!GQ!!&1HA KRB@L.%& 1E%
M<[\@@!64<B#"]4 KY-##)6JX%1.  /C,,(%*K"*AN+C  ])7BP=@@,T[Q44*
M B"".$3@ +5@@>GD( 'TL2\-N.#"]CXA@;MI  '-Q>O2]"J  EKV#%< 0 MR
MH0 )9*(+&BX=6%40@%/ (0 4B(,( / &2GC2@15@0"TPP("; H 27VCQ+2P
M :>M@@$0:%N!*P& $-0"TF>HA675<(( 6$ .%4 ?-"-@!RU$&A;T#"[[PE Z
M]WDA"VA6@%T# ((X5$!^6   BHU("?:YEIG<1;=OWD" "OZ<H 0B0$4F!, \
M"# W%VT^H!I:H($!: $7]<Y%+AS @4P0X+\!)QT!--@*?6N  %JH!8(5?08
M*&X$!_#C @B.  N@  4'<$ N:M%P 6CA% C@.'^O*6);M_<$ I #+LX@  ^H
M0-0D.$4X+>""3Z0D$QO8  <X8($_3^0# F!L$DL B0#$$Q>0($"Z/G&%.,1A
M VE00 D4H-V7L@X7F\X$AY.;DI.G*P6)QB (<)'5D9D-"R! @ ;63FN2Q2$
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MP8@# *@K/62%*T"\1DH $& %!&@O KL;$A  5. AQF(S#-B]@0C$2O "$4
M!5B%#6"U*Q" J0&\4R! L''"O1&_76R.-P@ #4(X2A  #7( YKH%!]B 3 @
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MJQN(.-#CE("$*^B"@O2 (:R$-;8A.7 !,UB;4W" 7)T(+F _-4B_@7B F-.
M(1B(-(" ZS-E$&"#5BAC15L!T<'?#AZ."4BGD5F!]O* ^VVNM[D" 9L(.4@
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M@P0(X/Y5"*B$14@_$'#0.&@B"[ #5- 3U3J]E "#4,X$-5 #!*"$1:#-3'B
MX8D##& %"7 @X,8%.:C"M>$ XAJ9O!Z(%F@!.V" $P#I"=@="5@RF(T #:A>
M-P"!$Z@ YCEI/-?S$CAJ  NQ%[:H2UB%G X9]PK@P=" :V,9#+CP6ZB%3(
M.S@^$:J%9?LB.[@%?]P .;B"_[(# T=P>^GJD6'P+UH92G@ #1J"F/(B0B.,
MF] $!H"%#_#PKWM=18L]DB$!T=G/?OVB"6#B3+C ZV.>7)@ 2*)QQ+YQ.?6W
MM:$ 1W"#'#P#]I/;=)L(S491 DH 27B#" ?I") #)X\>0_YF!35S@2MP RQ
M 4<@ <49C,+6Q4M  ,NDS7K/U3-P)PCX&T@ [V/+S]V9\_+!!3MW!%K;)1FR
M]G(6I-I1@QQ3 PC@GJE6HS>H> \:I0Z"!49(:&8>95QP@ AJA##7:F]B)0F
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M7%QT02,?0HP<KHWJA'@!R[E819!:L8!QPX(+%7"$&QRP"%AT&1>26  N[$
M%C0"!1-XDAT>X 9'B!D7&(B &N+@@*Q@80.9B)(F:L$ #5R!*P_HM 0<H8D*
MC" 4<G  +JZ  #4PX@&_W  )(,$% 9B8(^=//P+2L(@'V#8+WG6# BQ"+DA
M%E"""<38(A" %M@!!&2 '%@6Y67=)6" =F4&!T#8*DS %5R""+"693#"&RB
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M0**L@&X-("6@PLX!IC-BQ(/R!6Q,0".<5DZPUHTB%27DU1>DA'TI(RIPQ I
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M!T3 &RS"]*7?!"S"&S@ 8JS:,8Y(&"B LHH !FA"\N$""X1 0K  @9!!9I'
M ^PJ<>Y<[NXN@6C!980@C43 %=1%C,D!<![L:RI *SA" Z0!\]59Q^$$+&@@
M)8@ -2:8ZBH 8DC 7,D<09S 82S"!72A$GI (ZP T"E$"@C7&6S )83%J.&@
MQ/9O0J2  WS!V%4 ;*@ !*"!';@ %3J?!7!!<4& I7$$&2C &]B!!$#B3US
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MH, ?9]B)N<@E<,$#./*>Y$NMX/[68SB&J 0,Z66:EX2*4=!UJG"$)JB "*"
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M=B0A.20XY6HE42 7)$+/U8 2N#N# (Y3)IBJ(0]8P(61!]!P9(+"T5[DC07
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M4SRWL_XQ4>D;Y7,^Z;,^[?.1(F(&4P(G8% %]3-W<,("G5 C+' -12(H1J)
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M4VKAV'[5(7(P\/IG4B?UX_QTAA1B6(VUD4Y!.1+B$C+U+$Y@ E!@ RI +%;
MO>+",E:A DSN3!F#$1H !7P0! L- <@$.8X*+M -)EI B,9B!1S D.*#,59A
M OHC5P0" NSC#![@LH!&(-A, RS@ ::-! A$(8Z%=D   RJ Z+3  BR@!&#B
M%DY@ V:$50CD$B: 69MU4-G  C;@ LJOOS2  RQ@,%9@ U" (BZ!Z$*6=4Z
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M]/46<"I3)H 2Y$0#)D 36L$"9H0$?*(6+&#%,D)Q;J$1"/[ !;#FC\Z%6UN
M U;A%B@@<!T @!+@ Q8A21""!+B@$1"H%?(-:5JB$1C@$WZDAQ[@$ZZ@:'5!
M?QQ! /QL3B2 0\:C%N ,%TJ@_2XAEGMH$7H-<Q@XC-*@E3#6*51@5G!!G7!!
M 41@%2YA 09J7.JL8/@5%R(@(]B@ 29 !,Q )BK ;Y=FF%OFIVQB:2E":\X@
MK/+O<Q;! C)A7T @$\S+@1P ;K78/N7L"BA@877'Z6"H$6@# ^Q@D"XA[P:Z
M5_9+7 !E"$* )P0H!%I"!7Q7(DXA#4X  9:B!68'%VBKAT[!#KK  6!A$2:
M(N#@ 1QG$1C@=#&@N4XAH"7AP?X2 C4$8F0'[0SBH!$VX 0@@8K<@!$8@ UJ
M229$(*>AM7FO5@Y@@R+D$1<<H+02H@1:8T<&;148H;42;JKF1&EN8:6]H %0
M 1* "Q=Z&B:N8'8H@*$R=6 J" ,PH !:8P/X:P,&@Q5&Y0IJZP1: P+BQP5@
M""&T!C!^*R?N=ESB8 @@@(]C>"$J00&.A@-FI"'>.2'8  )\8J?SS]Z\P /D
M8&Q23HE8A0%6=:+K<[A<0 U:X -6M1:\@ 0XX&C.H .<9;8YH ,& [81A")
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M03=T>CD85@(8=M?T"AN @I_P  A 8PRX:>%5"[BV8:_P@+; 8>&U@!LH"0#
M ?TG@','"Y4@ !Z0"U14"R-P 4?X"K+@?CY(8C@W@I0F4?[SIT*VP 4/X BV
M@(2P<$TI!0L14 !+2(&V\%!Y!PMTF&5,F'=JJ H3Z&SM]W]_T !AD LI-(:
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MJ]"/ E@)"S "&$A%%[  ET"4@.D(:EB7E["/GA )KP"0NL8*!GE"M2".;R"
MJ= ()T=0L. &9O" (GD)W,=9)R8)EH")&,@(GJ"$7PF8 2F GO '(ID+9A
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M#E  '5 +*-"DC4"'&+$ !K  6( ++8  CW +XLH*0[  +5  <<"P3&J1$6
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M:,4XC1=GH *V;ZIU9[AHMVWEL0$0!A: +1=P?WYP!FZ\ C$= K=P @4@";-
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M9+8B8FC)WWO6Z7BV80/M $= A>V]A4Q !0Q8VTM YS05:3IV:A1=A5O0@$;
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M%#B!4]@ #,B$*^!;%Y"#6@"!"M>$3+AI5M" #7 $5<:"$5@!HVD%("<!-N:
M*]AN7&"##T !$L"%*W $2 "!+# !Q+@)(R6!-]  .#!0+'CC$&"#,!CH#/<
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M;Q3 @@_@6Q3(@I,_4.!4 3/(A0X [\$=<A5 ;Q3E LW& $WH\]#^!%CH@"$
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MAA=J;,#%OKEP <:YFLA,PJ=L?/ !)!R5X&\70ZCA1MP:?])!79<AID4)>X,
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M 02<02Z4P!ED07V@@%U P&5( @5HSPAP@0N0"$>$EAQ,B#62AFEX !LH5AI
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M (GLL?Y"HWA$+;0 KGR3,U,$%\2BX F(1^ 0+?^P^I"!N=Q',S&W"'P+:[1
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M-OW% 6)IDL,93L?%_=5K=A99A)<2>(9I_9$2 U-3''Y31X<>U8^MV   $F
M :SJ%!,@S4JC2AH@NND6"E  0H,2!@ $*SZ4  !F^ED4+4C@+R   *P2F(4
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M$H#] (5/?0LN , .J)![V@# '@=$(#($T P O,(0+"SX$A,XP*P%4 %&K
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M<@$"R((V+I$$-,L/-R 3,B'3#(81;@$"YG," ),LMI 2%B$ <J0H3DL-GDX
M6$$- L "+B$+ " +3D$ ,F("'OZ@%6"A!8+E-L^T!W$A!02@/@0256A- 89K
M,3GE#4Y@%:Z  _;% ?0+3AKA==0 !1UA%1Y  18A#A)  BJ"(4[ ,!(@)?"3
M97:S%29PN)HR?!C"_4Z@%F91!6ZA3K4P >R 2^'*]#C- AX 8T+/ [S "VH1
MKLJS(BA  G3D''$!!5@+2;W@#;:M%BR  4)**5/D62T"(B5R&Q?S#1P! $P@
M<V#P[^ C# R#!0#4'#%'*2E!0C%#*'2-9Y:0*<C ,+P  W**%13 .DR/=#@/
M%_Z.*GTL,[YJ18?R\4J ;8RO%MR.1IWR"RZ@1NQ0*!8 *WU4 ,@( "3 ZPS
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MSYR>IG(1'J,"*.$*X,H".N!C//[@+HJ<JFOAQ2TB#F3<R6_5 ?;J0+X#!;"
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M.\4*3J8&,(#'#1S@ ,]PP8H3?$<]"JH KQ<+AO79)PPT]K?&-\YQM$TI/%>
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M<.!A!A]P!BNP/Z=#.'+  9GY+(L@ BQ@!V;C"(YP"@(4!@H"G8]SG?L%'G8
M <]2 :H8!E:$0^"Q"@QP"7& /5Z@31O0E=?Y4;]9H1:Z+2FP ?@3:OKC4B>@
MG;DD0&:P+Y30 "UU("X07RYP 1YD <_Y "MP"G;0 (N@-'VS 3F& I#4 @D
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M)R ')$!O5E0+## MQ7JQ&+LJMOI8$W!$IT!9%C!4(*"M"U9AA_D XD:Q8_5
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MV7X=V90]V8Y-VJ+MV.@BD8R-U%09U*[]VK =V[(]V[3-*[5]V^Z1"Z>PJ)K
MQ>JAV_K1"E&\'A:$'[6@G[#@VRAS4"774K7 W.NA"0?5+"W'"M =(, ='JN@
M"8NZG.4A1>\1E>\A!X8I'FE0;S&<+BUWW->-V[YK7.-Q"L.='KI$ 18P 1*P
M,08#Q/%RG< U'[V"HG5#Q#-G86.E!9NS+U9L/?B% 6,E?'VW72U'O<.SK^F=
M<O&D('(@H';C 01$X/LA(5LD'D.@ $LI 1H@WO0B64.Y'K( 7>D]X;G4L>/A
M"!5@5QF  1Y0;S5S 1EP3:'3 ?X>, E%S#TE4+CNK<$H@ #+>0D&D&;\\@:F
M%AZZU-NW< 44FL0\'!YQT*J;1QXM-V@*\DO]?1X: &87U1[7O5(8XRQ7S%5@
M5N!XVE=1K-P<M"#&<RX+@L YQ]_X8L4*4D<+D@("LPJUH $#7C2Y$ $8,VCM
MO5X@GB[A 0*BY" @<"^-D !O4 LJ,$RY0 $J4 MJ$#YDTPAOT$F,&1Y8].A)
M?K$*H@((P#//H@4(L)N)<B#M0Z(.(&Z5P !1R0(;T$_K%;\<<$V#XP47L $;
M0UO@$0;!7FY4#@(>X $8XP@MP 6>BS&M< (6H,#JN9HDT$S7Q B6=IWWH@%L
M\ 8.4/X!9% +)W RZE::7S TH<-/)1#%;O!160 Q*A &'."HI*4!&1#J7&6;
M[[Z:*? L7F !(7#G;& Z6? %)3 !MB8'&A!*(!P>F;  "I95+X-M'D "Y+(!
M!&1#@)GPI!7L0W @+V6DZ-TOR;4!8T4)+1!!&G"I!D3I8!,>SSLAGH,@5Q#L
M8FH!7. !$\!K<H!K(I +:8!+=H"KUG*NB,Y7;F O G.N''#P8/#?X $+#C M
MJ0,>J*  J  '%%H"=7/CN@!<(J#?X$&KK>Z[]>.K"N(O@-OL&Z !*X.G$E#N
M5!ZLFD#!5H0"QG0*%% U%5!7;V"BC1  7#!-#1!)PW0&%_[ 5^,E*Q@ 9F'0
M279  &?@[O$E B  "W*@ ((&'A905VR@ +7P!J*Y]30T5AJP K6 "@S04I3
M  MF %QP"9E0M;B0!15V($,07[CP9;A0Z[60!@J "VX  90 "SA*0VF0"PO0
M4I>@^VD 2YF  9*:-QI@ 9^ F(R@H&_04P4@;N"! :(D!TO#"A!0-5#%56/%
M -:2"0R OQ9 +B*P,A1 0 "!100N@KA<C,"EZ4$M2@+"Y%IA =>9!Y<R:9A
M\!:N%A!<M""1X13'$+A669"#"P**5FX4M((5@1$N%"XH.:B%"\057 PR+7K@
MJ!8)#[B\$,A":94#2KA$<,%E9_YA04<-6.&J52L7+C(.# [<2@8#+@QNPI"
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MN3@##,&%"5B!6F"#!&":## !6( #!?@/%F"!K*D0#F :VRBA +W$.'B MO
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M@0BI@!@+@POP@"X 3#M1 3^*,4?H@ T @>9H%PV8TIWQHQ(8B54P 0YX#(+
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MJX J@P!&6(7S<8ON&&!W5=3*2/X# B@A#O@.!0@=".@.+6  !JZ OV&>YO"
M8FJ!7(@#IL"%"Y#9-TB 7+B"\U"!@3B%M#PG%8#&!_B/1IB*!^&)6F" 4Y $
MA\C3L5@!T;P$![B79[&#Z3 #B3 !#U@%.U  M: F7,"D55"#5GH#ICB%#I@.
M@H <2_V>X=J7*\B(%M  5!"=LI( +N&"HIAA98FD:&(%"TA47&B%#CB!6H"#
MH*B%$3@5@@"!"[B$2V  R)":@9F 5MC/F5 !M>B S<@F-R%;EZB%M!&*H&V7
M\SB%!UB%3"  $T@)#X@=1GB80V.D,%"@;;HI! *!"CT%#-"0*T;+^HBI56!+
M+K&A=OZY@*;P@#%Y  @+@_ 492^HA2' H*UX6UQ !?TX!0*@L"'(B*"1!"<*
MSX+( @LXA5.P@#'! @NHA%L@552( P7810J C##(IS,0@"O(XU9X@!+XB!1(
M&@*!@!%@G,3L5TMUA$SH12VH@*80E%K@X45@!0)0 51@ P70!5U@@ ):A%H0
M@?-P@/\P@?7AEQ(J" FH#QK9B >"!##0CJU@@XRX@A+(! J0!"FF!!D!@R R
MW=A0@*IJ+S70(!" !49  )Z8@,YH! 3XA#C("+<)$!0@%Q+X@%60!!RUI?L
M@=BI@ TXA490 *'  )FUI5MP@?.8#T.:%@SHF@GX#PVP /Y*^ 0(V P*N((3
M$ZD$(8AM@0,+(!W\#$N7:@$7\  &>8-\P@4P* JCP06<L(/::%$Y<(3C< %R
MX0@->8#V8@$")0A1-8F@2$PJLF$(R+!5V @N*(E <X0T/H$KF))QE( *F0#/
M<0$U B!\:9P6<Y,F+@@3L E(&ICJ50LE_F<0X)1^!HEB$9^XN(#OB GAJ(U%
MJ(!:>&S0&&?]6(1E20/M4&%%'8B.@0 3 Q<2V,I%8%$[J9$T<(!5^ ()N07
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M@DB!]0D8@J@8[L8/% H6\XD@2K@/6= $1M@ \4%.LKB7=7)F"+ 2!VB%3Y"
M?JP%6/ZX!#F  #?()=$R Y4U;!(HK>MNG'/B#2R(=!QR .UZ #60 ^P( ^U8
M =;$B33(E?F @]#FB!MB =;,]':9UJV@[,8)A<3T]5SZ#TU( 0QH ,CXE+E0
M3!)@!'[2CE6( $]HT>J,'NN4BQO# (I2L/[)*XFX-?OMXP=X%5A)&A H([%L
M!4/5I]BAEU/@]JBP %1X@(JT$W!![F[J 'F.(,L1$95HBOQ !1#PD4:0Z9>)
MF6UR >C8"%OZDD"K4Y)9 2VH$,F @ [("1BO !2*#9YHWG [[\KMH0Y8$@<
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M(0MRBOYSQDSP&CSS)Q<TLDB:_WR+0#-*#2T8PD'[S!M%UU))]_USD18EHN1
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M4'HFO$(KV((* ( <V$(E:($D=/BD?H*'MT(E#/K*#GNZ$S30PK0_3[F3ES+
M<F]@?ZJ-;WE.E^U)#SEA^^Q7S_IFBV[,AKD]DSP&SS62S_YXYRYVC]=UR[?P
MET\MR/.MC,/XC )V7@=Y^2YYD2]\[&IV-4=Y85.J8JM\S,]Q!]_HR#Y8 CC
M!33S!2S  F@3=3Y\B-;"" A (VSW*G2! *3 3X0% '1!&"@ @73! OS!*ES
M 2R ":CH!8! "41 +9B!UB_ $.""&02 &7P" 9S K;\""V@]!)C!+< !!30
M HS *F#"!FC]!41"+OR!!"C  FA!B)Z UCN >J-W RS "/3] JQ !#Q."A0
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MFW)1HP 4#BA#Q!0&<".5!#;P9(@ XOB$ P6^0&B5$P0P(S8W!!CAE@DLD*2
M%C(1:(@A#G@@E0D6R*2Z2]+(XH("_G #.NE&R.63GOXP8XB66A/@@A7B.$T
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M%=K$WG.IJUUNL@J=IK*N6K"WW&P2EWKQ"U8RN;>][)$ON>>42LK4P"8_&,
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MIW>J:_:^3[XL4A]I3Q4=$A"%)=P4\;RFY2K\$ ]%TMI\415<L2ZRL2VF42K
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M/)#U691UK@GHFU9"D=,)T($2E/["P"DX@  OT,&W<O $JWOG9D+YK0 A@.P
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M::.CH9[S*7_NF&^Y"9RT62RO^1\2)C_347[<4:41=J6R:7ZT":;I>)P,5EI
M(1HE>B446BH0D0D$,0ES01P(\:9NBA52T1MFD1UU81+)015S6A;)D16I :?
M$1MG$1M381WV1A>^ :=QRJ=T\:9I$:AR.AN"VJ>5NJBR41Q7$150(:B,:JAU
MRJ=P>A8^ 1=Z42!]JA%O.A=^2A>8.G_F<QVMB3].^G[4<J.VBF^ZJIQB>JL$
M\B-.2JL-)BQ1>A&!<:=6,:EL86\1Q5#=B*7$R1\"MZL*@?ZEKSFMWF$5USJF
M^N,LNZD71"&N 34>L;HM^0,_O/HM%1:LW>BK+I%PZGIO[;J.W2*OQ;IO30H1
M^;&;[%$MUL$2Y]&O KE0^M.O!1NM>6$MVF&MY%=!UA$LVNJM]Y.M /*P%&LK
MKVFMPT(49N&O'QNF[:>M#=L2!PNQ_"&PW!*QV3JQZT&R*;L>_K>.)MNP:2&N
M 7L<&HNQ]D&R!8LMX$HK,$NSV]JSK3D>Y<.S;L&S9.&S+E&SW=&QUIJS&;&Q
MR+*R0JNS+[NP%76U6VNQ'UNU&=&G6O$4D\"J==&G9GL58QNH95L7:%NV4Z&V
MEWJV9'L6;YJV9<NJ9^NG>VNW=?X;MV:K%6L[%63+K*H1N'A+MFQK%X";MVQ;
MMX6K&G,ZMWK[MW4KN&_KMFE+MX4+N)H+MVGKN9>*N)K+N<R*MY+KMJN;MX,[
MMG[+MXF[MJPKNZ*+N7;[MW(;N)Z[N:5KNYZKNJ#KNGL[N[ KO&BKNZ[+NUI!
MN9:+N(HKN9G;NYV;NG,KM\&KN*R;O'3[M[A+O-8KN-%[N]"[M^,;N,>;N+N;
MO=F+OL.KOMT+O[];N<_KN]M;O+VKO>!+N\.[MHR[N/5KME3!O+/+O*7;%HI+
M%3D:HVCCHPV\G_#)P*>0"OO9P"3JG^:)P1GJG_FRP#$ZP0SLHO7YGQ"\GS2:
M"O7)P?XQRL$F7)\1W, +O&D?O,(MK*$>BL$O[*,?S, S7,.F<,,.K H3G*#F
M6<$[+,$T#,1&?,)H8PI 3,0@[*(4+,$4[*+YXL,.;)X:G*,<+,4ZW,([[*-7
MS,4-[,55C"\9/,(X/,4@G,(87")I#,0R_,)23,94W,9H3,1=;,<1C,</7,<^
MRL4K;)X^G,<17,8I?)]N7"(NJL T:LA[S,8=K,21C,/U><0M[,<P',20[*-]
MK,:'S,=9#,<0K,-CS,:7_,54?,9+#,@J;,FG0,@0[,&<G,ANK,68_,B4C,MJ
M_,=@'*.>K,>Z;,NC_,>.S,LQS,G#7,BSK,MG;,/F><+[F?X*J5 ")$ ")F#-
M)5#-V&S-W5P"V+S-)*#-XTS.$3G.V!R1$=G-X S.URS.Y%S.)G#.VOS.XVS-
M;6+.\OS-]5S-[RS.[NS/WUS-\*S/WZS.UIS/_PS. RW0VIS.W&S. RW/XIS.
M\&S1"&W0#7W1W4S1 (W0'+W/X6S1Y.S. WW-YKS.(5W2#%W.]@S/%,W2%HW/
M)RW0[;S0(YW.-.W2$_W2_4S/ LW/!*W.^:S2-VW1.1W1/\W3!.W0*$W3-AW4
M\3S/UPS4]0S5(]W2/YW-]OS.!?W/_(S16 W347W.0RW/9ZW09-W4Z%S0$LW2
M7NW37.W0+KW5]!S4^ES1"(W6(OZ-U4D]T6<=UT6MUCV]U6.-U0;-UC6=UH>-
MU&UMV"0=UX^-TV:MV'P=U3FMU_5\SRZD  K V9U]&9X=VBYT&9Q-VJ9-VIWM
MV:N=VJ?=VJ7MVJ<MVK']V:]-VZ-]VZBMV[ MV[<MVK.=V[$-W*P=W*!MVL;M
MVLBMVJ#-W*D]V[^=V\VMVKO=V[PMW,F]V\!-V\N-W=:]W:$-W:VMW;;MW<(]
MW=4]WMA]WL/]VNE]W>7=VZL]W<V-WL%MW\A]W^&MV^Q=W.?=WO<-WMEMW[4]
MX+B-VN[=W0A>VO+-W,3]W[X-X>2]W?Y]X "^WO$=X=1MWO@-VPH^VK]-W ZP
M"B-.XOXDK@HD+@MH\PHE/N*L,.(KO@HP/N(GSN(PON(WSN*KX.(Q_N(E+N,P
M+@LLON,^WN,ES@I!#N.JD.(\;N1,WN,X3N*O(.,D/N0V'N57[N0M[N10[N1#
MCN6K$.14/N.K0.-C/N)!K@I3KN5,?N-E3N1/GN5K;N4USN9"#N<QKN9%WN1U
M'N=?WN)0_N-VSN<YKN=BSN=Y7N@Z_N5S/N=[WNB$3NA2GN,[WNB,'N<N;NEJ
M7N5T[NB)SNF=/NB?KN69;N>DON=;7N2/+N>>#NE1GN>4GNJ#KNFQWNJO3NN(
M?NF [N>*'NHY;NN'[NN$C@O#3NS%;NS'CNS)KNS+SNS-[O[LSP[MT2[MTT[M
MRYX+U8[MV:[MV\[MW>[MWP[NX2[NXT[NY6[NYX[NZ?[MUR[N[*[NR>[NQQ[O
MT'X+WC[O[Z[N]U[M^O[N_([L_I[N (_O S_M G_N!D_P"=_L"%_N#(\+#C_N
M$*_P$T_Q%6_Q%X_Q&:_Q&\_Q'>_Q'P_R(2_R(T_R)6_R)X_R*:_R*\_R+>_R
M+P_S,2_S,T_S-6_S-X_S.:_S.\_S/>_S/P_T02_T0T_T16_T1X_T2:_T2\_T
M3>_T3P_U42_U4T_U56_U5X_U6:_U6\_U7>_U7P_V82_V8T_V96_V9X_VPX[H
M*N[FN$[FHF[B)5[F;C_BKA#I2/X.Z6GNYI%>XF%.]U&.]ZW>ZZ\0YG#?YS$>
M^,$N^(1_^)S^][W.]XW_YHH_^3Z>^,'.Y9!?ZWG.^7=_^('N^9%/Y(^OZI%/
M^JQN^(C_^;L.^*+/^JK_^%GN]Y1OXGI?XY=?ZRCNXX]O]X??^ZF_]V_O]J[@
M]I).XJX0_+ O^*L0"Y#.^'0>^WV.Z(R/Z+]?ZX5/ZW+_N8L*MWH:J=UOJ(TZ
M& +<MGH:J(_[MMPOO.I?N*JK_@>LN]N/O*S:O^$_N.?/_?6__>3/_NAO_G<+
M$)8L3:)4T* E@P4G"228D!+"A L'.GSH4.)!A1 ?+DPX<"#!AATC?E1(:2''
M@A U;OXLF3+C090I3X*DZ%%A3(^30E9D*=/@3I<C)SI<:9)A38M'B295.=-D
M390Z->;<"1%GS(TD@?)$J/1ISX*8" [EV='I5I450S;,B70I6I$M10JL*- F
MQJ!$&X;$!%6K6YETL^HT"[9H4)Q^"</%"Y,D3,-A,4VF7-GR9<R4+66>O-DS
M)H&=06LFK?DSY\N;2X>NK!HTZ]:G,WNF;7JT9=6N.[L.K1NW[=BW,>NV.SNV
M[]*[D8LV[3LW;MZRC5.NA#JY]=O.HPL?SKEW:N[8B</^W7RZ\O.OMR^_#CU\
M=O>[W[=^7SO]<.G=17\FWYT]=NOL$G __/2CS[;_JK-+0?X$F5N.O><B;##
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M!:4(BP8&@( #Q%  :\ $!@*P@ 8$8 *1F$,!#F  'PX@ QZ#   P@+%3H
M8X!:<2911 Q4S!,/0QKUJ(>VLOT,@F>[' "TX#%5J,"+!_Z[8I6FN#F(A8)U
MFZ%B%C$P <9!P $6HXP:!7)&CJ!O4#@+TZG\:#POP2Q3IDJ5(,G5.^0=#W@Y
MVV/P5/$(! P1$R@P@ $(L $(>H*2!A@ !S38 @=00 -BT\ 7,T0X.UIL P.P
M0""<-P(&$&Z+:GR(PJB71CJF36&34 4)%J#!A8B% 1Q06#$W5\N?61%B&RMC
M:+)8S E$D3($NR(;:9G+5%I3F<VDR^@D0( "(, +H8B$!"[  #&L0@T2P-((
M"E" 3A*N# IXYP-(B(E ?#.<3)P$!<[IA56T80($"84)#! (C&&"?W5 P 8>
M<< 2   %F,A$"P(  GQ& @0%*/[#0T,1!@1H( %SR$0I5#  ,:"QFV5(@ 80
M(#]+!&(.F%@##3WQ"#I88@YUT. CWA )?/ZT8'00PQRF*(8!>.$4/F/! )C8
M!OZ5 82%*X/IG/>&,OA-H3G=*>$",0$'5*X.=9C$&UQI"3_,P1*>F(,!J>@T
MK"E/KHCZ$<\$TB5#DFE><^4KI_ J,T.*900+.  '5B$& (0@$A8U@2R\D-A(
M# $ )P@% [9 "0+LM *;>PWUYE &^3FP 1,(A)4B(5*>>JP.'7W8' )1ULFT
M80T\="4*SV#31VP@ 61UGA@$4 95R-02:VC#Q@JV!M"BD Y U6EHU5"'$VX5
MJ('@ZOYHU;H9G#KP@),X W1;^]HZP!2%4O4IX6A*5C1BX@('J$,@*%" 1XCA
M *HHP01<@8$OHN]HB W!(T8  "], @$/\,,:$A !PEW  %*M0 $"(=^"3F 6
M&=B"QT)!AP&TP&-:&UT!/%"P232@ 9/PA,DBH( #AF($ FB#*BP& @9X(<,%
M4T$ 4EJO4, 8J2LH6 A:2H !F& 56RB ;@5P@5 \5@RT4($ 9GJ! CS@ "PX
MK%/)>8H5 ."#!L"  P80UE",(0$)*( &"%>" RC@ "UXA18NF8 !7  3(4
M Q@0B L,U $30.$"AFA0PK9 %6(8 7,S53P:@2Z1>EWD7O[I.J[?4:M3B+XK
MFU(TJC\NVM&?$EZD4^4F-DUB!!Y   =4H8$#^,'%$6@ )C9@ #\X#0(/B(1E
M+4& -V! #;,H6VA&< #"IN 4(K6S'ZBW@@,X  %TF$,"%F#G-EA" 7E^0"A(
M,( $3.  )XC%&AB@9@M@H@4'8$ "-$>X$!Q@#JK8  ,PP$D2H%#;#CC ""<;
M"S4$P 64J$":$S &60PA &>@!0D($(@.)( !$*CM%0H0 AL' @$*5\ :+,&
M"5!   @0@RK>P( O0R !KUVOPDU'N#<0( 0&0^P6Y$M?#*RA K(XV"E/^;X+
MS.$680" RWN^BE*8( !M"(3*6?X.@"N4H0"J.$',*Z"*52BLUI)TWAP,0$P'
M)D#.!0G%JXVJX@%HSA*12( '/-$ "?BLR4STUR,60$P&4(!P(QC ">8@ 018
M8@Q"] ,( - &,=A8%B>=PQQBKHH*+.!] =#"*29A"A9$' $.4(,+ +""210@
M PID;QV\^(H3#( 02,W '$ 0@#)@@@(,MX0$JAWZ0*P! &60O19B$?I'A
M)%1TD.S*M< "<M.Z\WU?486KN&J:^&2RZZV:'Z15")B8$VA )(CF4C]4H &.
M6.L&#O (%XQ6<!P(1 A:L!G";0'IH8CH&281RM+:Q0,)8. 5.H#/ 9  $U(&
MP1O6(/Z $9B$)E.!RMJL.2" $U %#J"_E#FG$^J  4"!0.   7B#-L  ^8$
M" B%"G" 4$"! ?"OL+.$=YN$+1@X62 !!YN$!Z" ]@D%AWN +8@$+>  2WB$
M 1B!4'@ CA.#,F,W UB#?$H _SH 5Y( "N@M > Q3VB#_,,$",  =,* ,Q@#
M#Q"[._*$,WH:CY.R0(B\.I@B]1.#-0@  LR$E!L!3)  *10##"@#,;C"AY$
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M$23\9/XT:)E/P,J3_;1/$X$DPP(! J"#Z60 "0@%07R#!&6GM9J%%2B!,SB
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MP[L- /X!"*C&!4@I+4V CF* !)P#!UB!50#;TE0!ZM$"NET %3@%,5#?PU*
M,EB%,7" !@B$#<  PJ&#![  [O.$,:!;!> Q%;@S^A10C$UA%5YA%F[AGE$H
M"!"!@A$#*6. %DB@]W$  [#A7<(R%7 Q$F@ ",#"4)C;R>-?S24?U)& !*"#
M,5@ !1 !"U##"?" UZ#!+5@# T"!5? ##$" D#J@-9@ <[.P-Q" *Y"%=O,
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MP,,1<D :Z$27,PI7[BM]=^,;3!(7H10%*6) A,U,^XB<F8*$H].#':RG!SK
M5[9-_D,B(/O5YQYP!66P3"7LS[9!?CH)(<X#"K84CIQI OUV+8C=;J;3=01X
M[6Q:]AHJU)'1],S_;* N'/X ?3H(IB^+D(0;*$V2-MCUU&\!;HFYPA"&[4Q
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M9@P<]?$1*=P HN'!#*3/#_# )B)"$[P3M%D.ON'<$=P #'2C V4E#QR0<?4
M$1CE)GI&D T/[= E#/ !=J1<V/D;=GPA+N#;39759L$6))$"#<P #2S3G6U9
M[?7<=J4D#WA1?(F3S7E+%/[0'C1! 4)B!3&8!'$"$/R !6$A]WD&A?' #_P
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M15(,E,(IN6K8T68-11M@_@"B%5B!UL<)Y1<>#!X/Z,#@Q!=3WL -J$LHF<+
MN6J<JHLM5)%ML=T]&I%F,%Z:+IAR/9L7>12]#1MG3<$4B-$MM)01V R*@2L,
M2 ' 4=<3@1.>BAYV,!XD51 5] S/)=FSN1(R04' /*53ZAYH#%R,!:ALE )W
MX0'\K2>#696VWBHGS,(,+% &@?XE9[@"=]V!Q/[9,CW;KGULA\)?.?%<-"G;
M>&K&J1D",1H6SS'!+-R"*GK1*5$2* K1MZ'0^FD2)WE&*&TB6]E3_\T"6_T
M=-Q4P6T6%>R/*8P:O.#!\&F/NIR:E#)>$QC,$[Q -!GD)H#")FP"E.E %L6"
M7]7 X)D"[ZDCGFG&L6V/QY6IS [878G/+0S;OT70#.@+#KP1\!CD8=5M_QU6
MBY("V<IB:J!<X7;"+6C4#PP8*.[ O/!@ZFW0VMZ"E)70+"R9='$&%53=K.D
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M!$QT"0)0QGUQ^(X'#*"GLJPB :A;A*S$6!86Y D7['2/A0*)-%R <T%X]%L
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M"D(7!"S1!.(4/N$@'$$#O  "N (%O",76B!0/*#8)L1OQ/XD"S0 !#; !D]
M"RH@#,Y@ 23@"W*! U8A$S( !"S \'AC"#)@.I[B$AKE$C@ !#) RV!!!#I
M Z1C%2J !3@  K1L(#Y! 18DDAZ)!/H.;:#L%&IA V1#$X20C^I.!/3B*;0
M!" ! HA"#BI  U3  I F#AP1!2(Q?#+  S"@5;R C%3 ^P1"$QC CG"0 RR
MLG A#2R@%$M#$AS@XRK GP1"#5#'33CN*5J ?4# #=@@ &^C 7;/_QCC*0"0
M-]Y@9.!  7CJ%F0#"VCJ*6J! 1I%*"1A!UT% J2(A@8+%RR@]C*A EQ@ R9@
M=DXA1^ /%R:@@#B *[P  YI($OX0ID8P0 (R+AA=H 08@0&M3P5$H (*$2^2
M$ .41 M8\$\H0P4R8 -*@.8@P40XP#OT2W<N0"A40$P<0$]40 5:00/$+P64
M) ,H@!)VI0.T;!4:H!:(D1)&@,P^ /I2B06ZX#D<8&P*,$8,:S="YMAPP>Y0
ML0)P8<,$P@4?0!=LKJ)\[@L.9@5$#B@'A0+N(I(&10X(@ UPP0&F,BJ-20)*
M0^56P1$8P#VT  $*#1?L0":_!VDNX0$KH0$6) U,Q.;,12B +EN$X@(3C ,D
M0 0NH )J00XLP XJP!$^ !7<H#3VP@'F,AB%L3,"\ T>H$(8H )T42"N($?*
MPA3?1?X+(  %'& W"J(6L, "[N8Y#D#+X@42H ,5:6H"&&$5&,"$'L!/PB!(
MU  !%F0%#B88+:!OLE(@ZHXK-( R., Y;L$"PL 1(. I+$ .P( (48 @!T(2
M)D#^$*"\I(,"IC(F<\$$V$?L7"4Q+$!),*!+GN(#*"NC5D$-'$ %V$#A6++,
M&O ,7, !4"$3'H $PD V6@$"W*,5DL\VPJ G18#Q3D$-O. !IO(!3@$6($ V
M*D$";B$A^VL%1J8!%8 -**$#MN<-A@\HWX 13*0WW: KT> +U( !U$ +@L4:
M[4@HX&!DY !$GP,77&!$:' Z'.!Y7*4!W EZ:G20]"26@OXE#10$"\@ "TB@
M \831Q/S,9ZO&!%+(%I!#H8  1KF"OI/("J@,V]#2QC!"YS(,Z=$ [ Q$ZKQ
M/<[$Y]*@6E:3%7R.!-1.("* $MY @S[P7=J.$10 #BA! V K=5H%ZG+EOM3@
M LX1IH(D U+@#-(@!:!T(!B2*[1@ U; .R9 G:R1/CB $O*($B3@!-Z@!;Q#
M$[_C W8CHVS0$5Q +X\M"PKU.]1 3""1"^S  MQ#%[3@ QC X/;352+ RT[A
M 1RA A;D#"2 !1;! Y F01=4%^#EJ30 !<+ "[K++8;  4"@ SC =MR@ *WO
M#1KQ]3R #1;A <C "TIT%4C/-/[&B6.$(F00)H_L#!?4E2N>HB3?42" +D<E
MX'E$ZRG4H"=S#P1003H;H5IRY9&8M#%(P =-:&2^( ,I)0%P05(' A84H+<Z
M0SJ$PDG13AK!(P2^(Q.DTP"Q .A2\QQ9$[% 8':X8@(:@4[Y"TLQKX] @ ,V
M0 +^ @/Z!F$P %@S) Z&3P6R@ Q@JP)4P+G.H)8(0A+V4B!8@S)&H&O0P$1J
M@0.V!CP2L#-$=5">P@/,,P).004R#@*,22A600%.,1<@@ 4/0$\RH0%:X0L&
MBP0:AE=][_@(0@0\8'MPH0)<KP*F$@(^ 1K=PPT: #QPSQ&T\8ZJ3@+2 &UE
MHS7?H/XU;; UW0#H[LL+6D$-.'01%"!O=;026H$!I.@"*$$.H)02>O(X%2X'
M!<(1'D MNJ\P2P!MAO&BT,@1<J819%=A%^,0'R"X"M43!X(-$!<+*A,71B"/
M!H(BOX,#U$XVPL#G!$($M.H4$@"6)(!RTY2F*,#8?,X+O-!O7!/J!,(<_2\7
M'B!'(> ^, #Z5F![)*!53$!%%H$,^T8$*"-\8E$@%%$M,J%9GN,"1$ %(J P
M6X  W,,.V); <E8##FE&%4 -<J$!Q.L!AF $," G%\$!,$ $'N #GD($.  +
M%A +&J$!4& %(L 1+-@](HFX$,.'!,(+)& +(*0#(LF.2/Z  BAR!UO! D"
M!1Z@:Q'& >H5>O*H!2; !4A  9"&!9P8BI%&!\%Q [2( UC@ QH YSQ R[Y
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M8K"G;[FK8Y "6_ (B:JO*K "<Q"L.-L"*7 &)NH)=3 "P(H)CA &EN );3
M7H"IF/X0 @WP  >0 !+  &\0" TP !FP 02@ '/@!PX0 0I@  _0 !^ LPPP
M !3@F:&0 @"@!:? H)X0" <  6'J!0P@ 0AP ':K!6T@  L  0\P  H0"2H0
M  T@ 0T0 !DPK <P!ZPIKK9)G8$:G-9INN,*EZD+E^;ZN@^JF:DKNVX9N^SJ
MNK2;DEY+ !B0J#D: @ @ 980"E<P  S@  -P JL0 A+@ 1#PHA(@!I@:FIAP
M"JA0J813 09P H_@HJ[@ 07 JSEZ"J7P"6<9HS-JI)$ZHT!Z"J'@4*X  @9
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M$DL\"22!"CRAA07!0 HED@<BH4"%61H80A6YMG#ABBM:8"DD3#@H8(B_S@#
MA%5,T:" 0-"K !-: AL#I%CJL( 2!-J8I( Y AF@A(OB2BJ #$#R9 X&!M"
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MYX?^^+FO_NFS'_W(=W_TX^_\^:___<P'_O7K#_WRQV &,J !3A#  23  C3
M T3 !!3 30 %!2S !G3 ")3 !-R$";3 "^2$"L1 "=3 #73 #O3 $#1 $!1!
M$23!$B3 $T3!!5S!%53!%H3! GS!&*3!&:1!&+3!&SS ' Q!'AQ ".1 '>0$
M4,@%7##"(T3")%3")63")G3")X3"*)3"*:3"*K3"*\3"+-3"+>3"+O3"+P3#
M,!3#,23#,C3#,T3#-)S"(E3#)KR%)7S#*(S#(YQ#(ZQ#7+A#/(3#/53"/+3#
M)+S#0 3$/N1#0D1"03S$031$.OY41$9,1";TPSJ4Q$=<1#TLQ#^D1$QTQ$S<
MQ$Q$1$VTQ$X,15 <Q5*,Q$8DQ4\415)T0U0TQ4I<Q5)DQ51T156<Q5.$15&T
M15N4Q5[$12C<15?T14BLQ6*\Q&#D1%B<1%U,QEZ\1&=LPVB4QFFDQFJTQFO$
MQFS4QFWDQF[TQF\$QW 4QW$DQW(TQW-$QW14QW5DQW9TQW>$QWB4QWFDQWJT
MQWO$QWS4QWWDQW[TQW\$R( 4R($DR((TR(-$R&GT0RU<1FM<2&(<QX?\PCQD
M0V-,R(O$R(S4R(WDR#2L!4=HA32\!$KHR)(TR9,4R$;8@"^XQ%PHPCHL0I=,
M0BW8 /X0$ $0X"-(P(5<F$,V?$.?-,**/$(7\  /X( /P()5",J=/$(PX(!/
M.,**K(5%J 1<0 4+X *F!$6AQ 5'\  0^( /2 &2M$.N?$E<D(.PK(6R1,**
M_$F9U,J@S,- O$.NQ 4UZ  0\( /&()3P 4RV(!,T,.*]$F[- $&.! .$$Q<
M.(6PM$D^:H%+^ "][  2> ,CQ(*OG$POX$D3P$D/( $UP(4S$(!&@$:41,W4
M5$US?(,TZ46[C$(48  (*  %B  &L ,N%!P+V  (   /($04  "RC$K&)( 1
MP(5/<( 6D,(BC(, 4  )>  !6(#%=,)::  %N(*UY$8L /X !Y  !@  "\ %
M#7&$*G2$ - "7.   #A/7,@$WE   G@ !P@!1@@ 5;F  Q  T>R  'B \@"
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MF64 7#B!!(A/\F0%!1C7(I0# X@ #]@ !*!8S&4#-1W.-U"<1:B%[OT <@T
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M -RU /X'T!M'R$T4,("JS 54)E<"8 %<*&2F'-(N1055Q@4'>>G<S-53X (
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MX5X4D 8LE$CP)!L9''23!TY[H!@)(?.F4 4UG2(!*I<(X()L"TU@$"4&*,2
M!UJ=  )*'+".0>*X+'U*  8MHD#J-S7B &'9#J4) ^)^T< $(*!QD[6"XG(&
MT6[Q@!W-JX &/" "$ZA ZV0" OZUR,E^XF" FJC! ;=@A ,61 :B80 ,HF+)
M!WJ6"POLZ"829 0N)( N-S0 %W0Y2 DRHP'644(!K*. 0C3 N#2@IP55*=H0
MND2)!FR@ QU @ =5L($WG"$,!JC%%61B&#5<X8<2@ 0NX,"2, 2'!%YP1 /8
M0(8W,*!,#+D$ X0"EPMZ80(2<(H%P/0!!AR*(;=PA!I&D(%<0* Y5\A/NM2
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M)HU2\DI70F 5T7IJ5&L1!PFH  X>*),Q1: V;-YD,V93XT(4]H5_N3!)1,D
M;-5 F)1X@%HU.^<5O)"%,% B#@\P*Q?.<(I'-402$'!)<WN)"U9 0%RVFF<]
M==0TLNB6+)!@P$ZZ0)V4:$(!J(@#M<:E $C4@@'E2LFYKN( %%*TP 8^,((3
MO! ,6* #'H@ ^-@0'#C:006L<\H%WM"*WXD5<ES@@A;,P!3S_,T#'FS@*C"
M@B],=Q$Y:<5-7&"4#/,%K]/Q$OY15V"4O5'B 599!8IX>$R&M6 L!RA7)G)Z
M"\MD\6\E*(%B<L*6,-@G)9E(JB,($,_,U01&9-& 09PB!P:D1 TG$4&2/@&!
MS%"3-0Z 16&O8()$RN0$^_E$ G(!!L@J=0$I80-+R&*&"* B%R XR0;2T%_S
M=A 7#) K![Q00Z>\H7"KO EC6(O+0,/"(!B($P8.IQ40 ',1S'1.X2Q0/A2
MX1*=RR+1M&#<E0#E"VCQ@$QPX07T6$"N<%C$*QZ@5>F<PG<.J0 PG]/EYI O
MD>@R&BY*L@@\B^L6$" 19!S0"!LAP"IA6,#_$, 6;ATF*P=9Q %^$J#5*+C=
M[GXWO/ZOPRM"'@02G;.# @C#B@:@XK2*$]>/2BF!\H@*A3<Y#]\2EXD(R(AU
MME+(  ^B@;%<0 Z+8,!!3LL"0+8@/Z:11+=HHX#H>$ #N0J9"DCK 2VH8,VX
MR(!@[$ T* % KEJ  !;0M+>#7"(!P]:U TK0@OPQU"\WX8!,;K**": @,0X
MUP@H8 (0A P$'>!"R[6 0:(8MP5)\L %Z (^."3 X=&F0---X "Y'H0+% A3
M<)K-A0EDP<&0>8#X1""X6E#@!%@X00/LH 7P 84YV4Y=4',EDRY,@ LKT  '
MBEFN*RA #8YXP$$8@7E&0 "4$HA*!4SP]\![H2XIL506*OZ0ZX.(@+8^+,\B
MSH:"!V!KS3W"12,PWY!3=$P%&O"+ ["(^\ZC@,ED<, *3*  .V2">UC04D-
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M"@" "H0" VQ!) S B4L B3,N<:M!(+"T'S!*(! N)6P  O[0@8I; AVTP23
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MH13 K( 8QJ"%&24M R,8P0?:H+Y ,* !A@2!"DJE@$B@*@!J"X47TD2)!$#
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M!:-8T@ (0,%?0J'=CI]@DPY9P0DD"P+=U,&IGE!! F0$[4E0X (\#D49'%
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MIS7A!.R@LQF!$2Z:=!GAFR? #C*AJ$L7!>)@HX&[ E;@#3C G;$@!-3@"N#
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+OXX]N_;MN (" #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>comp_0027.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0027.gif
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M^
M
M
M
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MO; 27[PD? !;P0.QDMFSR0T$"\N9Q7*R+@IPVXL()/2RL$!X6M<+RT +9 <
M7:PRQ"61 $")0+#\G#%"H84!0,!%%)#L*N&%-X88 JU2<-.3O+(L% 7$FPO1
MM/VLRRH"/?OK09SI0G(ON2Q<J_XN10Q 1VBOD-SL;B0+.] JM7(6"VJPG/RL
M;9SE+= (&T#-,@8DC&:RS+V0(,+4H(=E0;\#B? &&!.\$H,.L) @@05W]#*$
M B=@4() 8(CP@@(EY"()!1=<<,<.W]XQ02:]E$("!1.$40D&/3AP 2:YG-!
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M"*N8P [    QC"$ ;:# #U9!@1:\ 9FK(, 89&D'3   #)/(@M0 *1#/96(
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M 5SX\OX=/"D)722@#94(,"O8@ E*@LUA\\K$M3() 1;D@@4LZ (#"C8"%^S
M :QP<AP*D$^T9D$"8(@R+-X0"8&48 )5+L 0$O"%7$0 ";W8P 54)A!+L,$-
M;F!#O&+A !WT @P*@$("\O"*-TSB!"@N ER#T "\-2 ($^!6'N1<@#'T0@)%
MN( *B@P_ D3"%Q;HP0?Z-8<>S+04F8#S&\IP:Q+PH@T"B,2D;ZT"'3" %6%0
M0"Y(8%4*L,#&.!9 )7C<+SRK^-X^(=]F>)&+*Q-! :6X@ CFP( 22, &L+B
M CB0 !1SX0 ;F$ #*&'!'D@  [VXQ  RR1DM*$ ''X  &_X P%T(]. 2")
M!P(0ULXQX ,+N$ LWLH"!:B!"P'@12D $(<N+,![EKQ:+@(P!E8H  +&$X$.
M'E#8>Y\  !638P\>FX4"%$P#)_C"QSGP #5 G +(Q#DK6# !_'&W%RQ@@ @:
ML(%+D(\'".A!+\0 @"V8JR"OF, $.%  '>CB!&5W "5(D%[9%4 7I9@ !BB@
M@4P<0+YW<!HK.-D+!0QAIE,G0=,J_8 >+"(!&C@ #S*Q]PU@X&<;2._?R\Z
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MN\D) 1GPNC?0  ]P -@B!3,0 -=B #)P"!.@X YP $^ "'^ "$JP  Z@ #>
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M@- !%1 (5D  2X #!W  3< ' ?[@!)"  A @"'^0X3@0 'J !@:@!%=@ $V
M"-+/![^O""G  ('@ 150T 6@!(JPL(G@HX*RY+^9"!6 ^ORJ^@> !M$+^X?P
M"$H0  "QI\:#/XUF.*CBX(:C/0ID'#I$)4 301)  &JPHM$- VAP*#C0A$\
M*9!0/# 4Z,^A#!$2/2& !<<!/8$@A!"$( 6B% [T9$24I,"50X&,'@T$B%8O
M7KV</H4:%:JO7JP@.,#4*PP %YC&#!#A*TX"$IAXL5$01E<1 &QT.;B0BVDO
M) @8O*!3*< )5I$4<.C5 T(D720"E(H$0$<O$@,PL>(RA@@#!ZO* $ "2PP
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M<(2/<(D]*I&CE@JN-%8DP(JQ B9QJK%+5AF@A:=@B60,$0;@0A<&+M!EKBP
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M0 'D0(@",&$4G^A !V@U"CD48!"%($">4'"!6I A 860@ ]P 8,-K$&-GW"
M&].PAB,88 TKP "MX#0G69AF5P_[U5&D=8@_ ,)8!K "1&:@  @$, F&R  #
M'D#**ARL:ADX0!7X<  E%*4#&:C: 9Y@B Y40 80J($?</Y0 RDHPA%"0<$A
M5D 01*B,7GR 917V0$M;7NM7@NC#PDHC"EYE;9. ^$/%#F %0QQ"!@>8  1"
M\@@9*. !#J#E'APPSP-D8 ]:$\0C$@(!;1V *'Q@0 T>,<TE& ($$_AE,'&
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M1*3YT54P@!-\G:Y?)8*D)?W: [+BTC>4[@(*@ 4FZN,4#OX4H'%C   8?/$
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MP2<><  :T  &GCA"&VE  #F\D?HE.,,93(  4'Q  S0F0"$4 (1:G& "A1
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M)$@$!CB $UR!/_  "&@"9/,#+#R*;\.=55@ =^L%2E  !@@"$>",P4D !<"
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M[H5+H -&T 5?\(57,(M2H /=5NGNGJO#I;L& 62ACN%=R&"K]&E>N 5>*((
MN 2M"U0&F=1)O=56R-;>$5VG>&GRMKE5V(4-V "FL,IE98KAN 7U\H79LF]>
MT 7QT8$"" ,HH !>X );]+L,9N?F,.(#T^(I%MXEUF*P)F4/?]A!"( CV-=0
MV-<U4?&%91,M0H4U*5B'3841@ %<B(()\(14$&6"'=A]'6LV:3)+0NCT[38$
M%F.^9OY )?\5K$59E=7 HD"$1D#9/SB &2#$I.50#\B CHZRIY4*QQ;;)3=C
MR$9C0#B$1FB$E55:6CL$-&\$+*L"DMA 1]A -)  &1 I7/9EWHB$"0B  %
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M+YDL,((E"7& @0@L9'%' #OTH@L'*YLG@@(!;&<'! RH8,, 7/0B!LZ\E/(
M!KDTS7(O+P P289C]')) Q^F^#;<<<L]-TI9MOABF'GK_24</5 P@20?E*"&
M!%& L< D(PP^ 1*2")#'*[O\P $'0NSB)8MWK](H=*SL_7G>J]Q2P@B]:()
M&#9(P 47B*I0NAALWLDZ&*U\4/H/$?B"Q 2WM-(W!1)<HNA()46WTJ9 96II
MI2Y1FOY\3SC%)-0!11%0R"@6 "$#!JB$,@@A$J  !1-1# (!$[708,$H'\"
M"Q,,C *%!2K , @"/C#!A!>=1-_3LIIUFG_9!3#]XHL!69.:!7+,+H@ 008<
M<0@L!((*XNM (AA0@T<  @WJND$*))"$)"C!"H@X1 'MTAQ[D49?*B1@:ZQU
M0.;D!1"'@* $*4B%"(3  X:HS"/^@*X$2*$"(% "$O> B(WQY6,EFL0 1("O
M(D" $CT P!MZ$8L+*& 5+4@ =X00@/*<APNY@( #+M$+-P2@!;J0@ 1BT8M<
MW $3>1" TGCQ 09DX@UCR 4ON@" (IQ@ &HLH\T L 4(@?ZM%SK HA8OD(!7
M="$ 8N"%)ACP@9#1K9.>_*3<0-*B48*NE&"ZVRW"<(%(9.$ ;7@2'@* A"T,
M8 Y/JD, BL ( -#A%J]@Q ,<D(=;8,YNFP.1YTRI3!GEB 0$B$(,SK8C-8RA
M!)D0 09ZD2%*;* $D7A!%'QA@0WP8@<-T 44   &55(B"P:@Q"PP-Q*30(<7
M0,&4\G;B"5#D9%//PXGT:M(I0@2 "8, @!Q&\0 :I,$ 3 !"  CA@P<4X@@Y
MZ,0!@%"K!Z#"! M8 Q,&X E"/&  9LB>"0I! R:,(E,Q8=:]>F$*0'0L-@2<
M(6Q> RUH(<()!DC"# R AD1DX/X 2W#$"A0@A</\X0 XH$(!I- $#^R!B7P1
M371<",.M<E4O@.CI3V=  "P8HJA*>$12ESJ!*@# "C. P!5PL +4!.8Y)MH!
M $;@L@GHXA(*8$ /.##(7@B6$KW :QEZ 0;TZ *-$D!( +)XLPOT8 ( N$,D
M /""DUT@ *Q8K C < ( S &O/!B"! 8+( 6X8!4*()0E_AK8P1)!0VL;@)Q
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MO, G3R(16$"E88(.4  %Q,!3G_[$'5 S"YQ "Y0 -(\!!TS !K!:2JR""%Q
M0Z=$)DS 3$L""TC !/1 6?,"%UR !'P 6#/R*L2! [1 2DP"&[Q!&]"!!!3!
M\5Z1VO3""8P )JP"$D! 62_-&[R!&\1!$3C *F#" V1V9K<'&## '60"$3@
M*PPE$4B )&1"#SS EHC "_C=#F  OA@W)ZQ"<B?O&$! )+#"&"@ -',U %1'
M+W"! TSW&R1 'D3B;P?WFC0*OMR! K1!)HR! %B":),V*U!1;].! KC!>@L
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M3Q$ *( "Y#,/\!)<MULF9/U)E/["&+3T$[%')!6(N*)$+A0AA+7?%A1SR*@
M S Y)G" QSXE><F1%EWWTIQ$>^B"".AP2MQ]40Z!KG,2RL0!!.@"OD0":HO
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M&,!DHT@P $ $OCVFI  .8O2E" (0<.\5YR?)0X3TP9\KV,01@):7%P"(9(P
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MN*+%@ LM<,"%%8T)5\M:UKH["P98T(42](\BEL:TIGG!B@NPX LD^+5"V*
M'8S:,K$0P072R@"WCD$!/0@" RC-:LRI>PBD+MLJQ@V&@KQJ!Q 80@P:P)Y7
MB  #:5V 6[7YA@:8V@$L((*J@5+/@S>@98K>2&+,_0&A1IAM!; VRDS.60@@
M00B)!0D4&" $+IS@ ;0N,@F<>/Z!-_CB!!: 0A$@8*7%,O85SFI%%@"@  (
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M-WW3U_YC%>(5*&$2X#=^*T%^X[=^)V%^XW<3[!=_[[=^\9=_^W=_Z==^X1>
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M![ELPQN0Y@L1F*U13BJ#WI#P3/[44) BF'S@WE#S@5STH#PZN$08RB Q7[
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M@<A* IOJD#L((33*#L1 -K^ @2QI'H.9[D"'';RB#&Z01(<N 4PD]"#0(]-
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MDQV9( 0\P!<4P0I$,!6]T 83X5J0T0-9$!6ZP 6\  M%I NN4C,5-(U<< <
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>comp_0006.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0006.gif
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MK[&OL+2SL[BWM[FWN+R[N\"_OX&QUX2UV8V[W(FWV9.]W9B_W8&LU,&_P);
MWIG!WYW$X*+&XJ7)XZO,Y;#.YK/1Y[;3Z+W6ZK_8ZZ_0YL3#P\C'Q\C'R,S+
MR]#/S]#/T-34U-C7U]C7V-S;V^#?W\3;[,C>[N#?X,S@[\_B\-3E\=SJ]-GG
M\]#A[^3DY.CGY^CGZ.SL[/#O[^3N]O#O\.?P]^WS^>CQ^/3T]/CW]_+W^_CW
M^/7Y_/___P
M
M
M
M
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MK(0P;1T24'2J#)G$XL<7AL32R0Q9\NFK#*N**L,.L6BB@[OT8KTJJP"G#;#
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M,.]700LT!AG@2!!3 1. "7<  0+!7DC& "I  K]3<7VR!$R0 T]3!%P !3G
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M0#<3H )K\ ".4 =TF%&!XP$>T 88\&%J8 !C< (/4$,2 /XTYI0&92 !T](
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M !"%=+$@0P*1 G'5 +BC>QK4,U (-PI@"D7V%Q9 !.Z8.0 4"R(@>)>P:1_
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M)J:K37,'(/4*#N!'&D &:*<MCO[#,SO'=,JXIP_!NLVC".%Z"C"@9H-@!9Z
MU;!D!*:")UB- [[T!?GR!3! ?+V2!)_5 EV QR\0-3HPKTP0KJ'PWK#0)]#J
M E7C!W[0O#"@KE;0!Z< 66[Y+^["O@E!"9%M"GR[4 P@!Z:0!@KP"AJ@GAFP
M!IBP4W?P.W,55ZQ@ =E%-Q?."G(P :^0!M)V6Y0'MF-@ :.8 6H0"PO@1RL9
M"Q% !K)C==AX @$F"@H(,0YP!J.F )M@"@A !VK-N1[L2&TE22<P2*100JS
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MD ,:8H&"$YBA @L3A0<:<()2L (%&S!!UARA/CE$H&Y@H1(,$ &23.CA!R[
MP2E@\8E3Q((0+^!"+!+AAUCL 09Q 44-2O4'4+AB!T6(A2M L18LN*!4AX!1
M%%SP"5? 8 JQ.$4F5!$+)M@@%:?P RP\X0(MQ&(5L=!"JFJ'+-R5! T9>%I(
M1I& 2XA$% @@Q2-\UZ^O=4 !*G!$NLI@@5AP@ $;/  '0_[0 4BPX0!.>P >
M+K$!=/D2F'>X! 8XX A*(" 6%MB=*!) BC=,@!+@RJ4#YB"*"]@+)JQX !M(
M00(2Q"($!T@!'EA1 31<8@P<$(D'4" *%5R@EVX+P08<$8< L($5 4"!(TX
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M6QK>]88,("P6*9A:"#P0"4=@P+T=C1<17N$[,H  )**(VPF^FX)V@BL6>&"
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M%SD0@1ASVU99JUA !!?0@UCH@KHUA+L%F4<"OU_V/BUH 2 +85!J 5_>@1F
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ML2&<P4,=]/4&&I4B Q?(0 5$=)$(+, !#T@ B"8@RSSL2U]RT->;E"86/7)
M++$PQ6* *2(+9.R9XM(-)2)@O#1$"68,X9D%*;"!K$A%!1+80)Q\UK,4* \/
M"4!!*2" DE(H@$>LX( %-J! .,:QC@N:HT%9E34\LD]B%[E(N"!1IG.)B!4
MBH0CPD6)BI*$9I5PQ*V8<A>8L"(2PY'*1Q[*D$A0)ER7R"A$92(*B:V&%>&*
M!"1B4HJ=[G0U+Q7.:@@2BS( :/X"^=&C33<BB9Q>Y#5)[:A*&2+4ISXU%H\8
M*;M@"M6MEF(DX7)H0R31%((6-*%VI"-""71'LK*UK7ET*USC2E"O7$8$>I0K
M7O.:U_2EU:PZZ2NKUJ?7F-QUL(8];%M9 0EAEJ^PB'VL6_WJ$\!*]D T6"MD
M,ZO9S7*VLYZ=B5$HVQ/1GK6R-1'L9U,+5\>JMK6NA:-I8UM'S,:59J_-8[UL
MF]?AW%:NNNUM^6Q"6MD2=[(,A>.M7G&!NQ16CZPEK!"5XEBIO(%7'OC1!7*:
M7)F\A@U8O>MPY-"_<P51JM U;W31F][UJI<-$RWL)=0@E0U "[S<W<ASTQM?
MJ5PI./[GG1I.AGM0R0J800N5ZRL:@%7@PD0--Z($2AHP4:E%X"7/?8/KI'*'
MJ+VV G)2BB,<P!!-=C82)XJ$X=A:W!53C;:-30,>1+ ?S4" ,I0H2PH0DH<W
MK,$"*$"((S[0@3+D5@6^N4L@Y/"&4XE"-#F&B1PXP '=D&2,(;C+&OHE!XU,
M( XDR  ='!*)$+QD#1[H0&G6P( -E 82DJP37C"@@C(X*7#P_''2-O"!L2Y%
M#7>0<DXA\0;Q.F0#'M (*=) !VR) BJEB0@*-C "$;&A 1C0S1PZ,.6-B*(#
M#3@!*S"@!A-LSH):,8,>Z\"!#0"F%&F ! ?N<@8],U44)O[H  FZZH%/ER(.
M=V&%"C00 A&YN@X=T,!"0,OB9:L50<=-U2L4@($[R.$ &E%PZ=Y BA!P*@T#
M>(,C(' 5!MSA$A78FW8X0 )2Y(5) R"!'$I1@31<XFGF9<,#T$:W6*B;W=U9
M@Z@RX#((6. .=4  M!@@@3&(8@T1N(3C7OJ %% "7>6NYO$:X @Y,, #VB&%
M"CSSBA)D !+=8NI$!O"L-!S ( $@07Y(;G(%H#@ *,A#!1Y0AS<<8"05.$$D
MS. K2$2@!)20PV0H,8'22*448] Y*R[0PQ^*PCYRN$33-E('<CNB 6E@!0$T
M4 96C&$#E]BPB"10!I!_@!5D@/XZ!.(0BU%&(@T-& 4KWNV(,4!1)LS^NX)0
M*[4&)%L%((B%@E^!B5=<H@0T2H.^UL"!5S"@##.DV254\@82M0%-;Y! *61X
M $DTY %-H<1+,B\X$K%!5!^84 ,R1@8VQM,T!8&$QNUU(1&00A1UT%D$,E8&
MDC$$#Q 1A0)60P:/!TX!%LG &O# 1>1;I QM9X!$QG!X'%$"#QS6 !KF7IH)
M+%(49- @0R#1G5A(X-$2@ 09.!!Z1QA (E*A@-PG<A %W*44"W $]&@ !*E$
M&2Q*)&A0!>1!)(@80\P. XQ$@E4)3)160E%6@0D7J[B8U.3.XKW"&XB* U#"
M*Z" !?Z<@ >PT1EXW';0R"5P0 0TP.\P1%Z(  JHA1IT@&:406&$P B0P$B5
M3N;="AIYC%JT7BS,3@2(H ?>" 0P%558!01HA(>] D")0 B(@ K8AP@"3[\T
M1!U,P"M$1W $3T-< @2<% J,01V0#"0\ *+( 080QDBH -#,R24T24J<0)]8
M0'Y 0 >( "!:DX:!82Q0P.](P".<P 2,  ^>P$@PQ -  F^9A@.,!"4LP @
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M3$A 3<(E]-,=8 "OJ-G.2=M&X/[! :S+=^!!&BP <YG& 7S '<P-*WR>=JC
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M9)0<3 !"J,"IA$ %0$\#R $K*/[ ';P"'LSC)9"('+1B*7R D=3!*8T!KX0
M::"$5'P !!U*""".)+#()2 -&C!,/<X=<+"-KS+MISXM^E JLLI$&S8$&> @
MD6Y$WFXB!*[.B%%&*=Q!&SS NCAK X9 '<C!&1C $=;)![#!!S;$!K3!T?!;
MG:!D),WN&>3/Z&Z$(RQ+&=C*T:6 B.4MBC#C&#AB L1!'-0!!(0)YHKJF6KN
MYDIMG-Z!6L1LOR#2")'"&&1  C#3 [B&NH;;" S.C[0O0VB EY!!&NC&ZS$$
M![Q!&K"1'YW![V) &Q2CM'# D.&O;GS(G.;.)6S A81%'(#AXZ((#KX"&9P
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M)(2W1MS!"7P'!DM="*086P#40IA!&7 H1U#':V-JJ89V95DJ*Q#NHVW$!5"
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M\N)K!N8 2"R7DFL#S"H#'"6?1 $!7 ,- B Z$B 6W*  (H$58JJ?RJ 5)($
MY@3+VBV2Z"\&+X0K[F\[:E#W-.3KK(,53"(- H,#>,D#T.!I'&&1$I"1#JD.
MXD .!N 2VF!OV(!MX.HB).$!J.H2UL"K\(D2,$&*"":,/ "=BD($%&6!TJ#O
M9# -W0X_EJ1'R$8'KR,-/" !3N6-8H$#UJ 4*L #TF ,@N<,/$ FR$ "SH ,
MS. -D,.KY! C/ /$KG":EFD"N-"+OC#1/ "'BB($G,CT$OZ U]3P$S'.S_!O
M0^8N.R)A!2Z"C>[0B39 #MP@)=KM#SO@(O;,*,IM#?8F#=BF ISH#%CG 2XA
M$&2(N:+# 09F;[(0F\; O0P =:3'5T(0%*6QST:Q&N&P*8K+ \B O4:G=$9'
M#<1KUSR@(-*@P41@ L9@#P\"I- @NB#! 5  !::04V(!_E;  PB@,T(P#:(K
MT:*+%#+@W2Y@-B"  \C  H9M&A7R*ZJQ(:_QY=X@-53",%B#$M( 5##LPXZB
M#N9",![C;02#,!0#$D*",<I %$K0DD!R(%;**#!@3QA#(A=R)IFB(<T.Z/1/
M!D>@>CZ@ B:/)H'2)D?Q(6M)4_ZBI$(,Y>@61#T&I"CP( V6QDV <BJU0R@Q
MKQ2I,BNUTBAF0 :0RBO'0VRB0EE2Y#N^<BS#XRP#KROSSPBFDNFV$A1S8"YS
M  =RP ;FT@;P$B_ODB[]4B_[D@;H<B__TBX)DR_S$@<0LR_YT@8,DS'_TB\'
MLS$?DS '4S$CTS'O<@GBLC.I4A54815 ,S15P15 4S1!TS1-LS1/LS57\S5'
MTS11DS5)DS1?<S5GTQ5RLS53TS5YLS1WLS9%$S9IDS5=P3.1,SF5DRG>AA*<
M\SFA,SJE<SJILSJM\SJQ,SNU<SNYLSN]\SO!,SS%$SKE;SFSPQ'8X W:P W:
MH#W;4_X]W;,-X#,^Y3,^V7,][S,^YW,]WY,^V],-\O,^]],]]S,_Z[,_[9,^
MU=- #[1!$91 _;-!!W1"^5,_(=1",51!+W1#^Y-!*=0_"_1!,[1"!U1$!;0-
MV.!6X (6+H)%8\%%88%%8?0H9+1%:W1&7[1%C6)&<;1'=51':_1'?31'A31'
M;_1'S3-)E30N*40FG)1/*.1-%B5*I11/^.1*GY1*M31+H;1*F]1*J;1+N_1)
MK11+%X-+PS1*M11,%\5+SY1-RW1-X51.N=1,X?0+O. +NF!/];0+]#1/^=1/
M^U1/!_4+^G1/^910$550#151\311_310([51&95/O2!1!_Y54!>54 ^U4SFU
M4?.T#Y9T5"D/!DS55%W@5&$@554555MU55N554]55E_555%55FEU5E\55V%5
M5WO55E.55VMU57^ 5(T5\&C@*7! 67$@66? 69,U6I<56J'U6:O56JN5!J[U
M69]U6KF56Z,U6I_"6<&56L%U7,7U6\M576$D"10O5-(0+H]52/)O55G5*DPU
M4E9U%'-R7OUU2*1B"O;4"[C "6"@*K  "Z*"7.5N!J; "QCV[+ 2.SC2#,K@
M7%R.%.[H/9K2:XPC.VK(.N2@O=8N9$W$%.058/7#$Y#""V @66$@/&# %6!!
M/U;D*6*67/-U7*GN8*/"5%DV!_YNL&Q^KRDD8 ).H,-R*"D@P;Y$) /DC>DP
MX**0#A(2X#?F(V6M0R;&("%'I !M#^S&,A-B80EJ8 E@816H;@:.0 ERX&!!
MX11@9 :28 EPX#MX0&B7@ =\5@:*8 GF]CN6P CTHP>68 84(1:$=NN:I6B9
M8@)2J)^&\&E @PI;*A7KX"\FPA'PI2[J ._NX)I$@0Y,002\<3'N@&KWK0Z,
M0Q0D( ^1(A+J0&?J!22.8G,C8Q3J0.>.@W4S9G8]-S XZ3A"8B)*,!55%P].
MBVCB211D8G314!+.B3AFPC"4]W;I@% H(<C^(@^6]^JD0A/*E@;0]A!@  A
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M6M1&2+5@?<@% D"=BI@! ,!B@R,Z4I%*1C1ITL))!";7W#0L32<,.*!H(;&
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M$G!"=S  ](0I#N$ >? QHG("1Q@"8P )/D0*'_!N(W J:@$!N'4'%00D/-,
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M!PV0!G*PBQ=3"MP' MJA0)?""B/@ 740!VE  $/R &3 :?[250ERH +4$@>
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M <,#'3IB .9D 1TP!@S 1R,  600 A8P81^*@EA'!J,;!W)@CFUPA'FP "J
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M4 8+E"$EK!A#!SY B5*,X7EE*,4;*EF*%&Q@!)4D11H>P0$:GH #"VU?/ST
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MBXB%5' !/8B@1?"I&] 50'BI'? "F&(J0[B=@M,(1IJ(E!B!QHBX*C.NK%"
M-+@#\?H>"&"IOTJ K&" -. .[QL# /@,45" -\"#$2  2EB#Q$J).C@ -G@%
M!9A  H@#1[B ZC.(0XN^.Q"P.KB F%B#'R*#!Y@#,PB 7ZH $<"#$X X%6B
M.[@#!SB*E!B#%3PS#F %YM&TSGJ %+B#$@  3G,$ 3@!%$@!"J" 5Q %!B@#
M/)BDI8"VI5@U0Z3% OB,- " (/X!+T + 3Q(@0@HLP,8!:/+ #R0K5^+P4,\
M 0)PA#H8K%Z$@#MX@QMTC#20.3F @ LHA4 LB ?0CLY3"(W  D#0@SW0@RG
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M#)LX7#X+Z3S/03+U4<_LN1[UC*_.28CT7,_L(:#TA,\#DD_]_)_\Y$__A!
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MRCJ I8XQ"%* )VA=BS>  #Q+I7!="_? @TJZA,Z2"]@Y IV*H!KX@F-Y!27
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MD_B$0[ P6' !0C ]%^!2+&"!GAJ^6(B"*(@%+'"!YX"!XV6QB_Q8D,U)AGB
MV%"*GG4RJ!!&55.!O[T$?!0-B"&-G5 !$E!ADH41IG3*!B"(.B#D312%# P@
ML2R(#("8E! Y/SP(B7.,-\B,!_ >4ECD.% _@S@#HB 17B.(-CL!LKA<F5B#
MQ@@!QX1D48A=Q-R Q)( ^='ERYT $A K4C"#%+  U[H#)HX$.<@,@B ! %GD
MGB0TQQA@#%@!]P@?%]0.,F  /_Y+"0!T,@5( 118 0A8.QF,!3*@M5B@ %Y\
M"ZTY"4WX B_  BN @2[F@2_NTA?@4B4X7B@X8RUX 1J(5!EX@CYX*46X5) %
MLKJYWH5X!3JNA%"*A,'R8ZI@@#C0UDC0C040$0QXD$\>7PR ,PN(HE#"TZ9\
MLE@8@>Q 74GX7A(QBN_AM93(WAYTUC]F ]<2N51R@%*(@\R(+X]R##SK)L=X
M@$HX <NEXUA0 ]>2Y;*000E0 XRN) D NZI>BSM0@0.X+08@ GO,C#N@@ A$
MYCNM0X%B /?XWF@M"+,5 0D>A5LKN3MC@PO(C&X.L#O0UI8.99D@ ^.(!?]C
MCHP !?Y5  (@, 0**P2?LH&>TH(64%@EZ*DKP+U/. *FPH(^\ 0=H %8  6$
MAN.-$#(ZS%ZMB#B6N 0&D(D.B(\R>! .X !': ,"T(ZAC85^="?XC2\0@+EA
M:HRM=C)$0VT2B8"[M&""B .60*?V@0"U#"8+Q+8Y( !6Z&2$N(1-W$-6$"R"
MD(,M&P](KB3&D(^[BX4R$.L1&*W%: JL*P@(@ 050&$,D.K0&*;$J@.($UL\
ML$'O:41(,(4%2&L&&+Q7P("L(PP&C !3F@ 5N80#0 JH"*"F1 $=EN &>22Q
M_=;>3)PB<!6C8@(7>()4B 4FD )52&,M4(4E(/$TEH(0E_Z])(@:6#@%*/AL
MT/Y3.8Z1", $NTL)25 S5L" "%@-"\  #%"-@M LKM.D[JE-"/B 5A*!JXVO
MJ26E-E-;#U"!#PB!*&\)!8A:!JP #M#E]UBBB), #D#<@F #!NBK"#!;HD"(
M?.6 !Q F: QS"!3!GI2 D\,)E2*E!P"+4MB "]" "JBD= H@2+@$"." #+"
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M$G)NBT?CP I*L (21IUK6_Z,%N<"\,>Z+N"&*]L #(RA! R82!G6.((=1>(
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M9( HD/Z E(C 440".F& 42*E"G!6&MC15UH !HQ)4W[6T'F ^$W"+QE$)&!
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M->@E&/XG<%U"$5(6'H@5'AQ%CD'$U6)7VNP!0GB!S'YLQG:LQ*ZM2FF!(OR
M"RA"+!1!#BC"V<Y D]8 5J0M:=%L5!@.!C  ;$" <7P685(2:=!6RGH6!#$*
MTBTK;9T 2*0$RB I2:G  F!)YLK!RO$'0DB X1:+)&S>04Q"Z<86P\* %L2"
M)T1!%)Q"+$A!>,( #; LC]4NR]:NS+*L#(A%><( #H G#;A (="M"SC!'M!
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M5$!@JOY(U@; /R[@@.R(*&1 7Q&.OK%"+6<$ T1"F0!/&1#&&XC)5V.+0#2
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MI,0=%/Y]P;$"!H#,&?2%![S))4! 1J0;C[A*-;Z" C2%'%R"Y=10+)"!G$S
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M( -A32P5#5"$,$ IU@0W'"NPB84I0:E7&3A<-!/KP9Q8*2",P8#AE1P)'.5
M((H@!"J0E1)\B#6F+08//$$6-GSX\ S%BV$<T<)E"0S%,)9XL9)#!HTE2V;@
M8/(#!@\F-[3$PD+ERP\9,V D\8*%AN092Z#T ,($QXP>3Y3,4**$QHP<GV?0
MR#S%2^3%RYDW=_Y\>>PCB*D;IOZ$%62=,B,YEI(C*E:>-%CGL(+$RO"=,G=
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M_RZ)[XX\NOM !%%X$F4.#C$.,99+I@?ID@=,B:64^.POL4G\LQ!(2.&]CTU
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M 8-4Q((+88B%*JK B%@880H[; (?8M$'%WPB%3DP0D%YT$:.[J$&9XS!%/C
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M@F*C'76!)U0!A!\8(C6Q0(0+IL.''9QB#X:&@B=<40,EQ$(3+R!H(H" TQK
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M). #!(,G!*.:,N!*Y "0-H !-O[0D4C@ \IL!7@O%NH@JZY* 2! #7J"!"$
M2B#, M1F*HD2+S%48("+.DA! @! "AD(LPKCLF9D+A"K%#P (D@K)1;@!-##
M$=2- R"" 4@ /3B KDC@1 L *QPA\,K, VJP MI %!!@/0W $HPE#?A*#L9F
MKSHD -@#!:@M! PL%LJ  M!B U]! 23A%<#LW"8 (DHA)=J@S Y Q/;#6"!+
M-#'@D!Y W23"6.J  .:#$@[ .[PB%B# LJ O%CJ@6CD" ^#Q#2* )R!! 5Y!
M!1@ &BN44K-R4JL%)"]A  ! 4-LC :[GLB[A%1J@@$"L!%*@)<BG : G$E0
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M#PZ6043,0+CY[S3@%?) 03DD/E BBGD9$YIO0+_2EJ'#B:\2EZ7R%4:@ CZ
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M\H853%@)'4&L0L!#>^1#;;8$\/Y !.8B#AA #J+V<)5<,9F\,$?<0"J@-SW
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5'_9C7_9GG_9KW_9O'_=S'_$# @ [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>comp_0005.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0005.gif
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M^
M
M
M
M
M                     "'Y!       (?\+26UA9V5-86=I8VL-9V%M;6$]
M,"XT-30U-0 L     '8!N   "/X 7;EJ98E0HE8"776RQ"IAPE*%"'E*B,J2
M)4V6/CET]2E1J8>(4FT4N+ AQT2H%%[4A'&BP%2).CF\F#"5I4L6,99J%5,@
M09D)"R8RZ?/2)8<X+W)"Z*J414XL.2%="=053J,816)DF=7J14N<B#K\1,B0
M2U>G$MVT]-&A)D*'4I)D2'*HJZV6.C$=R;>OW[^  PL>3+BPX<,DC<18'$2J
M*R8SJ@K$8V-QC2T(#<VP,:/SE+U+8E09Z,K+BT"D'3J)X=@*#$.NEG2.,>,%
M%M)=8OPPB>I&#Z: 8&SF_*)+IQ=42,Y (O"3[,5"9")4U#F10%0[:G2>$023
M*SPS:OXLCC$D(:L>LV<PV9E]^PL^KM#/H/UBCZL=VV?\L.2PE9;Y,=R0AT![
M;-:9#5D@5$H3X_EPB$!0Q*")0%;$@(@K/^2'1%N(=>CAAR"&**) K @1PQ:6
M= %##@U!)MD>, AA2")+P-"%*X;$T,0AAC0!@R "76)##S>TY04,@/#5Q RM
MQ0#;DES\D0<>%PX4!'Z$7*>##TQU@D<>.]CP!1Y&B=;<#$H,1 0,6EC"!0Q#
M,&5%#35D0>(..@Q2B!8Q&.&*'C%0(24>?YC7@PU>_ $%#+?M<,.7>7PADZ.0
MXB$3D8(8LD4,0CCTYA*'$,*#"UG": 4B@1SQ8VPQ9,%)(/XTU" 3@XY5$8-U
M/]C0Q1Y2P"#%B, &*^RPAP$2@Q4))2)(2BXZ%,0,1[GBR0TXN))(JY/!D*4K
M7-3@10Q)E@8#?",MV>2#2THFD"(Q<''#KZZ@LN5> AUA0UN8!*J<GX3$ &]I
M57S4FQ1.W) 2*SOTT% J-_#@RAXO##C2>3>(](D-0B"\@U@:B]5*#SHTA-T.
M<O6F0UN?!'(4Q'@(E(<+?&BB(VEYL.D*%#-,Z$J%%_I@PT2EW/ #O<06;?31
M(&8!KBLP;;*)2,T*Y(D-02"$D&R?6#*##D(\:Z= /@3QR0Q-"'1DN!LM48,.
M;.LP0R&N+)GP#D?(I70G:@L\;_Y"K;1R1 UM)3+##6W7X*>*]A$]R(]Z:!LO
MGGD(DH6WWVW= Y$/DGCH(9]\$4,4\0U))!0#^7RY#J1_?,,>@4SN15 SMX)3
M)S+M(9H@>03A RHLD\8)FC?G3*&%&-I@R"=XQ+ $TLPW[WQ@6"R-B7!(NJ($
MDZ1]4L,1JL6P4 Q'9)'%$3? QNZ-3D3FBHJ%$KWD$E%$X8.3<<\ 11515"&R
M#LS57"C#N]O(WTXA$,'U('Y+.AP,$K<1*=0@%9W0%RH.Q9D^?21Y2JB"%*+
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MC4ZUIT^-ZE2K6M1?!G6H3;WJ5QOZUKC.M:[Y8I1>^_K7P ZVL(=-[&(;^]C
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M!@Y@ J P"7%@!RG@"J+0 B$0!NOG$"- ?P+A!B&  I,@A6VP"",P I%@@BH
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M"KOGNJ(@O:; B,9G"NW[%ZK@GW[A"':0O89&EQ5  0X GQ<0?$OKM %K91W
M !50 0[ BZ0G!M&G>XSPF+I' =WG$(P0  -Y>1_0 -*+L5#K"B0@ 2 P 1\@
MO0+X"IP9!QM@LFZ0G<\S @NPOQ3P (L@"KGH!CN9$!]@?I?W>Z\P!P6: B%I
MNN<J 8PP$H0I 1BP  O:P7L6 6DH"I%0BZ6WP8"AO,H$B5(X"0L G0[1I]-W
MD'YAAQMA!PF0PC7H !+*P831?@E1 5$(LZC7FR;+!I_Y1!M0!%*HC;(9O0M)
M>1U IO[Y.J#D:0*4.,!Q (X76GVBP !3"@H(H(Q6G&42P,6N 'R7J:J?IP$C
ML)"+H $:< 8M\'Z9; +O!P=G$ 840 )4/%46L*$",0&OR )S@ '\IXQS@*PI
M\ J2< $/D +1FP(:P $U*@$N**F4=\L78)E%T $7<(E<[ @A><L:4 0-@09O
M8 *TIX@;()B4QP8/<'F@4,3L:0$^B,=F4*-BH*JAO,)3"0)?N 8=D 87\ 'X
MAS0=H,,) 0HU^0B/Z0KWC'RJ$))Q4('8+ F4^ HI@'^30 &@D %IZ!!B0)X)
M00>NW 8:@ %3&F@5\ %B( 8< (VN0 %MH H,X :J( 9FZOZG;S *+%  $"H!
MMA@&H$<&!K (N)G1VX4!'#"V'R "N^< __L*#<D +N@!YL<"%E"&'6 "HF '
M1.T*$4"$"2$'YKB8JG !:I"+:B#1[SD)G F2KB ""7 &F< (-2D*N7E\JM !
M"P "9,#)"; (E* !'[G- F$!:4C4=E  :B **O"'<%  :<""?]@\(( !9! &
M+& &LMF+?WAY?XQ\H*  /6P!KL"7KY  98B+&Q$" N"4I-<!06RR;0 !D0 *
M&E#(?U8!&U" P/F%&& ': !ZE$?$:J"%,?D*98 !H'"'!G"=U"D&G1?)Q((!
M"IH"(Y !9?@ EGD&G1<!*< (N_[)GHOH"#4I$(G\ )$@"F[P!K:(H). BB$Z
MBJ)0AV4( 8%* LWJ!@B@BY28FF40"1O,"&*P 08PD._)H>#G@0*Q 328GW!@
MV8SH )40!P)>AU)]-"!@ 2R0 B= >_KL"C[L$)&=S]\L!Y9] E&8WR( R-@-
M A\0DB?0N1J TPGAB0(A"=<-:)-\?"1 ?QA !RQP HSH"ADP!V= G:H0 0%-
M 2Q@ BE@A62 H6& H=Q5 6E(>< ,U9YZ!J 7J!?  #G8!@5J!^"X?FA ?P\P
M"9&@K=%,GC&N F<0"@PPD>F\DY.I D!N?B-0!L?G""%  5&=$';PA>FJ *[P
M <HZ"?YFFHS]'7R<"0?TMW[$+.@U/@%J:WFNL-/5%^%P<,-^#,B4%^$8[@H:
M[H 5H HM>7R,,(T[?@+!:94-O H.B,<P;8(/4,]]1@'O:@(P7@=O@)"OX "*
MN@ -* <'X JA&7JV* ;VZNM5=@$;2GDLL(ASGH@C, H/#0=&V08I?($+*0('
M2,PF.P<5.((<$ J4X #&QP@;, )I".0"T=2P*)C3*A J 'KK]P'TEX=XG@(@
M30>H:-0"00$YF)]S ([A6.;Y/NX.$)=(0^\.0:&N( <%FA >0*86+N$5> (K
ML'L= (\.<<@6* !]Z7D^>>*+J0'F7J&!!@$50)$;L !%3/X!:1CR=+ !G><*
M9B !'3 "?^D*%C "YKJ(+ !Z%DK;W#4!$D"1'1#7KK  1$@&'J *"< "=I"8
M$GX RL@"%3 '+!#S3_VP<Y"+JF  G1?%[^<*(/  ZT<)#R#+$Q"%YNA]"( &
M=% !;C[I$4"":-  >#R*9!#KX(<&Z<BF8NH(<Q  FZ@!T><&?(^@U,D\'.
M),!Y&V 'HY#K;V"FQY>F:VB.H)  KP 'X$<"-,Z> 6"+^7H!'> &(U !$F#G
ME&<&") "92#ZW>X D&K)L?UG<$ &94 &:;"0<U"&HC#D:D!Y?6J]HQ";I$ &
M)) &ZV>_+YCHVC4'LT\&:% )6_ZX]7KO"I7  B10!C:Y!LH*!R10!+/J!EN?
M$)20@Q+>?<-XA20 C9-._>)O!\4<KO#X@PEQG25@ K\:"00X!Q9 >6M0 G;
MO>PI"@ QR<Z<$&=4N8HT<(1!5PT=/H084>+$AG;(F"E31HPC5VU<48+ST$X9
M,B7=J/+XZ8TK.XPJ/HBHBLP(-*_>V('H* 4)A@TCI3"!T]6:212-'D6:5*E2
M4 _0,.H@PM6KI56M7L6:E>*D, PB:4T:R0%5L&7-9D49@<Q9MFW+4B4K,:ZK
M22U.I#GH<*Y;OGJG^HT(]R%9P5:I3@H*<>[>OX$;^QVEIF'AQY,'5^ZK^.\K
MPA,%%_Z.^XI%&<^ ->]=G%GU:M:M7;^&'5OV;-IO&=?&??9V;MZK=_<&'ESX
M<.+%C1]'GESY<N;#38F"#IT4*>BFII-Z+NKY=.G9HW/7?CW[=NJBL$>77MXZ
M=>K>TU<77]U\^?/HP:^O3[[[=U%Y \,/CS[VRILOP/<*+'"]]\!+$#SN[D.P
MON_4B\\^]MQ#$+_QI!.%(E7,2V]#!S&\KT+]S".1PNFR&Y##!@6<#T8%"V20
MNQD?)'"Z#\W@\8PSRN"QC#-X)#(C'R_"",@>?PQR2"*3/#)()<WP44DAG\2(
MR"J;Q-+(,Y#,2$LF,7*R2"&_E++(,\00*B)*R"A32RN5'/[SR3'#I')*.=/,
M$\L^DVP234"7M#+.+ ?%D\H[#3722#) F:B.,;:4,LI!%2VTRS/!G)+2*Y_T
MDM,Z]Z02R5%[G!-5/^^D4TDRT&@N5EEGI;4YU S3K*I;2[M,UUQ9^\TQI8+]
M%==>E]I5*V*%-6W88GUU-MI:IZ6V6FNOQ39;;;?EEK.V.M.MUV5[ ]<LQKSE
MMKAQTV6W77??E>T5-T+X@(R\VOBJ6;D>4@6-$$;PB-=)TIAJE(;<>.0Q-?)U
MA0R<W/CJC XM.W:V?D$ 80VRVG!$%8(IKM@R-2!U2)(40#B!8<70(!FS?9]=
MMRQ1>H*HWX-2>Y97B-((00Z*(O[YN#([<#H7J625_2 "--BX@(*#*/ HYH=&
MN&".-R(PX2A&1D#(:5<N@/4A!SXV@8(.+R#X TJ*$V4"#-1(XX$/&D)A#DH6
MH"RI!EQJB!('6+ C# 1<0@V$KZ0.+I("*GF,JKL-AE:I-"JHXP'"(VJ# <=,
M((&X,F!RB((S7,%@)800;D@4DE5O")0W.')%E 7RI>0"4EX!910X(%W$#K@.
M@N,!CCIX8Q(X)H;:%1,L(*N#-5PQ&#I0W%B[(57D\'TV$C1P2!0&<.HPD@G(
M6N3X[N&PPS]&YE"% HZH(B.#O\10P?HYV$_=H47>F!@452)Y ^1<$0HX+.(A
MY1-@)/X@YII),(!DE%B@*T!!@5',P8#0^]\;6L8(#3I$=W<@B__6YQ^JI  %
M7W.#8]XP@<D,9&(I:,$HW$ R$>)/@NB+"P1AIXI1Z$YE6*$ K$)#NA2&H0)B
MJ,#H_,81"JRD#1)(P06R]K4.=.POC'B "3I0 1:$0 *=LT,%1-$!!G1@%"/0
M@ DT,($.26 .1K3,!MC@"@>,(@T2,$$(%N"'KIG@ Q] '%A4P8 [-,X5'A@9
MZ$#0@1.XSQ6,B$ 7 >F*%'P1! YXGRL6<8 S@$(PH+@ QB@ J0BX9)$H<*0)
MI-B!!ZS-#EC+P"1#L %4<D0-%0A#!(K0FDDL %)GH$ **/[ @H\\@ 0F<, )
M7*$""YS@ P[XB@HXP ('I' 1$S !!SIP$ UT0)47\ ]=+*"";4[$#1*(72Q)
M, &.L* "SF0 )%S13556X",5("<XAS*!%%@@!2R!@ E&L #)9.45#IC#5,A@
M@A2LI'2N6,':ZD"!AJ"A V&0"BB\TI )I) 2(7C  SK@$D8D8&T;  %=%J *
M1J S$A(X""T;0H$47L "#-! 7#;PO#JB00(EY-H%GN>*$*PED%BY6U%$H0*&
MXJ0#(W- PU+:$>ZI826OB  E'-& @]BA (=K"!PJX(!(DL(5'6A!0U2PE@<,
M;&ZN> ,&7"&"J6K #'1,J"LVX/Z(-70@K'*]@!+#MII>BN)ND%*% Q:ABL&Y
MPA$+H.0&&O*!,+AB 21-801"XHH/$%,"8FC( PKI$$<XX ">K!Y$KN8*$I2@
MHA15@5R)6C\*[-(5PG/#!2H*"E LH"BO@( =')$ 2+6!HEIY0$A><88P7$!^
M&$CA*,Z@@@W(UA4@0 #P+."*@[2 :U3YGPD,, I&'!<$HPO% U31"'0Z(@+<
M#-@&)$,![E4@:U39*1U%40:NN6(,7&O "5+ @@N\]36]_8HJPC"&+)XUD8?4
M  M2, (' (^IOB1#"/[B2(B,P@X/2"DT'R.!2(P@ RRXL"M&L!:BHF$2,(D+
M""(,E/Z5TJ$!&&!!RU03B06L(@V2/0@)PJ"*!W2H$E$]05J51TPQ-* #:XF$
M>JD"A^U60"@62"A5'C&["<_! YHYIRLD,-I0C 7%#4G!/RN0UZJIH@(3(($!
MVR#7@ZB !8ZPIROFL%VM?*"_5"'GU^*06!9$8A&ZE> 6/1('B@):!8\PL"N@
M]M*&@& MH*@P>Q$"4[T6= ,>D8!'0(& S7Z:CM+5L"O$T+D&P,$1?HB$CETC
M 18WI /U>VI3SKJ"A#RB*&BTPR@N0 DS&-B15#%!U![)@%%$ ':&=44$)C&"
M%"0D$K\&;8N/3!9*O ($*$@()"9Q$%',@01%[HLJ./"52?XH "7R.X@(QI#8
M#E$")B<@YI+[%M<.^.U>NJT '1H2\+^8(&NJN*2R([&!@[P!G1.H0^L:X H)
MHUG-<6C(!7SVBD60 0&+F(,]#V*",#CBN'LV*$(,$+8Y&""E6'XL_"+0D UT
MTJ0'%;@H')"^ GPL$@APA'LKO991,("E,X=$'>=94 U()@)#A0,"&-=T5S!@
MOU,50THW4%E7M""%L9E# ;*<A@"D5;Z@F#@:$#V'^BT@H9$X "5X#*DY! "L
M9?!E0UB SA&X]JS$?( "\SP'98(@VX:/]O,2ZP@X'-<._[Q (56Q@(3UY0%K
M<0-D-<J1NT5B%$JGA.9,D&\AB_Y" I!Z[-=(\[6UN'&F678%,!L. .5"SP"%
MC.(R_4IQ^0D8S<JD ,8E?0<Q_).S:5V  4/! $<LXN3'U<H=(C !"FS@#5GK
M0$@^L $2D($"<( #]QKF5SM,X ,4R+;S+["!!X!V$;*E"?0FH I'Z%85&'!:
M"+[^@11:8"4C_S+^$S-12 ._.P/7 @4,T  ,X(")B0TW<( *^*(T2"L0:(,)
MHHI&.C\#.@,)& 'OFILPD( /(($*J+R&"(,'V("FX8@QTH!N.@@+X AA^H )
MP(D26#T36 L\^X *,#X5H( /D "<8(,(  $?5(T/NX!J:H@5 H$@DB"SD2 6
M4@&N2_Z!RF*!"0 !"8"52+@ #Y BJM  H1A#O2 !";@ #4@#"D@M-&B "W V
M[A(!#.@ #%@;%L@W/)RGO!K#4:@ #J@NNI. )UP+.Q _0S272' $\.*N5?")
M3. NZ(@+40 O1I"U2&"$B7F%O% %3K2>R4 LLE %\)H+@QE%[IH*3O2/1_BA
MV*"_?#F(4_0/K?(/4#B<4.B;13S%AQ %1_BA2( $4>2V1N!$PB ,1TBMCV $
M_Q %1BB*U1"%1G# V&$$ ?*/6'1$[@JA16B95W"$9]1&Z]F+25A$5S"%< (%
M*W((111%50S'</1&=70%4K#$R<B+3827M^ -Q-F-=3DJ8?[I1W(!BW^D"((\
M"H-,.:/)1UH)R&HY*H.,&81<R(FDR(JTR(O$R(R\%G0YEB&BF+P!&8^<"IP!
MF9$,&9'T2) TI)#4%Z- R:)AR9@T27U!2;] C7/!26;A2-,0R8/L2)X\FIV<
MC)Q4#)A<296L29D,C:/1R*9T2J<,.D8(.D>02D=HA*FTRJ"[2JW$RJJD2JZ<
MRJW<RJ^,2JS,RJWT2K(,RZQ<2[9T2[6LRK%DR[&42[1,1EY,2[GTRKC$2K%L
M2[?<2[.\RKH$R[<L2[,TS,+L2[,,S+?TRZ@,IX>@A+2<R[^$RZGT2KE,S,W4
M3,6DRZ[$3,\LS,]4S,:4RS9 S?XV<(/45$W6;$W67$W7C$W4G$W:=,W;Q,W<
MQ,W:?,W4Y,W>!,[@Y,W55 /8B0A04(/9_,W:'$[9U,WG;$[H],WIM,WJ[$WE
MA,WLU$[6E#6'8(3D=,[MI$[KM$[L+,_Q-$_AO$WF#,_Q%$_R]$W3><KYI,^)
M!)?/V(S\Q,_&P,_^_$C^_$_]_$__]$\ )5 !W4]>*=#..- #-= !15#+,$8)
MG<G/8- *!= (M5"%;-#\Y$_08- +19<-U4\1%= '[= .S=!RJ<\6==$7A=$8
ME=%8D4C5J%'ZO%%K <D<G=$>]=$?G8A1"(%,:H.@6<F0:0A&" $!"H/1<IDA
MBH05H/XXHN'/%.A.Y%"%$2BHBO@ 26C)8P$%X\.,,;B %(C,J6BN"O@ E>'1
MY'B%%<"8#T !DA&KH#.^O&G3W)B$ *  ;Q$HETF**0. ^Y(TR5B718BJIXB)
MC<K3OA@%!(" F^$L # @?T0(H],,.)  4=B 6G,(#;@ X5*!!/BMBIP\%8 #
M-^@ =$JLE7"$T<G'2,  '%.K*8H$,3 #2 $%OE&%1> ,-V"!O'((-UBCS<*
M@%F$%F"#F\E$HO@(,7 #.Z"H23"84%@3CE"%"/B*A%@.4-" [_,)"PC5ADC6
M9:5&.S(81F !O$"(]WHDXW0%-Y"K#\@VATB#J/H+$L@V1_YH@328QG9Y!=&R
M'D*J P=0 ^TH"CMX SBH ]B9 Q;8K'2L!#5HU-:(! IXA 1PB9UPA3B  #)@
M@0>PQ07HD,8[I ]0@PNHG[]8 Q"8@Y7Z&H\( PK@F0Q8!2+;  V(M0:H0@JP
M)PP@F MH@35P.SJRQ>_IU@M8@;=B 1/ @(0"IC88@2_CL0[P (]1FA%P*9AH
M VF#B!<< 1*:I\HBC(.X(S0P@0H0((!] *$ A01P!#)8 !  A3E@H3 8 18X
M@*Q) 0U0U:R9@S(B 5:HE4B @-B;.:"XK;QJ@;FI@!3*F#DX+E5H "*5GP[@
M&O_S'I+1@-%9@*&BMH8@@YG;@/Z30(!MC817H*EC4XX)<J^UH0#G6RP&J!X*
MF(-1. "7T*A\20%D%"JUA0@[P(#;T[.'@$*(\)Y\&8'ZJ5C@> 4)P  1" $'
MR!I1\%HXD"NJ> /=*JU8= !*6 0$N-+FB(0(, 4Q0X,P. '*Q4660*>9N"U5
M2#-4U(#GH8HVX)Y18X0-F -I146\O:WJJ8#-*J].<P4T>  *. %*C  )B(#Q
M)8ZF4 412 -'V"Y,>BP3 ($SO,!(U21T:HQ>@MZYZ*6$0"A$HXH, "UNBX1&
MB !O40/N:=[>4 4(:($Y< .^L=ZOP-Z&<(33[0CJW6 (Z!W=FN',H I)D(#S
M=2\0J/X?V@TK>Y)55:4XJ:"* ?Z+-I L5TB#-)P#H?N]VWI&#!@J.T G4Z/$
M2%@D5VB 2$"#/$,.J@"%]YH#$&"!M7  1J"$!N@A40B%5RC?@W $]:H(4 B]
M+)TBJD #\5.# O#4T7T($L2TO""#+WN7@.4CRS"]HNCA;-VL-^C34% %ND.T
M:8D$KFJ(,P" ^AF!E!J%"8#52UJ)2&   U(#=VT(-<A>%:,],=O!!>"(C8H]
MF%(WF#C62# I+K[@KYB >D6.4&@ 2+F :*XZG+@ T)J@29B$L6@(6OVY2 B]
MV"E:JABN](&# )BBAE@%">B 6/.XK\B ^MEFJ(5@'1WG[OYQ "\%9;WJ-T:(
MA!KVB/)2!<FM%DH  4[L -)0!:>]YK^  ]MIB#E(0YUM#,)S"$J@ )R8A [(
M@ OXOP]H&2"\J,Y! 8PK@S3$ (Y0&\?2@'\MCE'X (,Y V7R-HZHA _ @ H@
MF$D @1 "@9Q^'IYNN*D**PJ@+ZAH$^@A@0:V@-$"A9^^ ,E0A0N UVUYA9&J
M&9!F"1-0A0RHPU!"" 6\@)"P [_KEM@YT\%PZ:.@1(KH#[D8A2/&C;>>"+H^
M2 =DC$Z,"+N6T;8&4F3!2+G^:Y<<[,(V[,-&[,16[,5F[,:^BOO$T "%"\@&
MC<A>T<C>S\F.R1#=; DMEY[<E_X4Y>S+'M$!-5$"'6W*ANS-.&T$O5"77&W-
MUM 2]6S)QNS:GFT2E6W5MNW25DG'!N[@/A@W(&XW>(/B1N[D+N[C5N[F-F[G
M;F[FAF[DEN[I)N[JMF[LANXW6(.J=@A0: /M?N[Q%F_E+N_LCN[K5F_K'F_V
M3F[Q9N[X3NXV:-^(8 35=._U?N_U/F_JSN_]-F_^=N_^WN[B=C7$1/ $5_ %
M9_ &=_ 'A_ &']]HC/ *M_ +Q_ ,%\RT_HC.U/ /!_$0KW#A)O$2+\D3;\F&
M1%(45_$O?5*=<7% 15*29)87)^R70?%F,4H8KQB"))86_PT:S_$5KXP@GW&?
M-/$D5_[R)6?R)G?R)X=RQQYE#K<**H]R:S%CFZJ #3C!'3>!VB/RB_0^#?@L
MF!%R:IJ$%!BL*]?1CO *7T2F94EA0X71.?A>5;@;TCBJWN(=<&3S:S&N[YX=
MZ&$!2\N+46"!>CF(#D"#2LZK5T #$(@AISQI[_PZ.!@!$G")4;@)E"&9- <!
MR6"%(OB;7?7N/Y^6)W*((MS$87*$$/"K]ED!1^@ OSH_.%@#H&.M$+A5\=/(
MIK  A\F+6XZ$.8A42@B %%B$#^">%SN#]_NG,V@ ,GB%#]@EP4;UU7B# \@
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>_/KW\^_O_S^  0HX(($%&G@@@@DJN""##<X5$  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>comp_0007.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0007.gif
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M]/CW]_'V^_CW^/7Y_/____?X]P
M
M
M
M
M
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M\(((U8 &I9##"WA#!!G,  :[C> /9-"22=A11:3800V62L'3R" &0UB()VB
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MHH@!@E ($R"V?<L06-  %9"+)_Y NQ/PE0UQ"1H0 B#0 <>H 2)  A6PDJ'
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MB@ !C6C!RGD)$?"A9L  C;@%=3D!2#G6.-G"!A"/%:"];=W4I9 (%A **_
MOW@($8#!-'L"@,T"F9P ,*V=?'T(E0 !A7G;G2K17."V;+"V#3$!^-L!F]L"
M?,R)9:"=I5 &6HT&;CO* >VV*_[ LO1+ 0 KD)7P /-IQ0UQ GW; H>,N66
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ME!5BTT*$4BZ)0)$=)0"K%#4(L$"%%$B($ "#QA"AL1,2.* ,%Y5T+ 105AB
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M4&%:0H9$$DA@##9Q60=_Y04*D& "K?O4 T7 $1'\J@P0  $)C&<I0SP$!!,
MCQ<D((()=.$X(_A5(BI FRTT1 09,$$(O5")"ERD%!;P2QL:-X@)8-!MM5'
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MB <<T/L'6+Z#)\"$&# P5]&=85:AV\ <S*" J)  _&(PCB$,<!-,A $"K=O
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MFA !\$@$/)& VTL#XY" 0WE!G#&0"'B[OE$;0 0%"OB5"M@=$4 !Y4*#[IB
M-Y2 1#B#B:")UB$!," =OJH ,=@:-< $%(/"7P3&8!1&5WN\ "F%#S@#+I"
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M#"3 5*@8N10;!V,N@JK$P(.'2V8HA#G!8>U:,PE6<&' I12A"5NV2,"$Q8-
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MK;M^4,)(8$!; <(GA/A 5* @VL8#:PE2"2AEH+0%<8?\6IB #"0R$@A<5-(
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MF.X 6-F  T(!BBYPH ('P \%KC820Q" !554 "<JP8(,3/Z  !7!@  (@(%
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M%)T-?=:V(S$#6@]S@M24 @4+(PEP3S !$0YW)"APP1L=1*51F,&Q7B!.)50
MSOK D+$J$&$I+%&E2ZB F!' 2A8>4($0E4&VQ90 MW24B Q(0 .0*45R)Y :
M"R G$/XD$&E_5A BE)#!55R+S%JR@$$,I&$D&4#.&4*@W(7%]#H/>H "#F
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MAB%NH4V>/Q 7 ( %12#B# 'H#P-^-@H&0"OVW&- V%8  -H.H( 46, @M@"
M)$% F2,I1 $.H((3   %F!  !Q!! F6Q 0!9J(0%$@ *$A" #&6PS'52,  U
MG"H$U6^!(2P@Y7"= 1  0+_Z6PD @#GB 03 7)GSK_];KBTX6!@<_)P =*R/
MA7D! J"!(P2" X3(Z-V,>:C&!]P69-20W&#(*'" 2$@)-'& 0S  HS% )81!
ML8E $/XT$&EH0)(@ @- !@>\AP6($*$,PLCQ4ZH%5@2 P"%4PHW<# 8<!J%
MQ@- SY(XV/8X@*4Q20:4@7>44!NLA7PD$T($@:BL  >$0BCDU'40PK^5P,*
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M".R;"8B !9! $(&""EP !J0&*8B T9!""!B-"F! !H@ )HR"2"W$!E@;"E@
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M1>F2^.:N)92IO<2OO@#"Z]0+)YAOY0;" 4^O S\OC.A;XL(,W-Z;3M4N29R
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M& (%9 $C00:]7+$'9,![I$0(Z/ZO"1B"%_B%57* !N")"$"/&X  36Y/0#<
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MH( &2&2IMTM0!0QQ> %#D9OC#OX'I-5T*00""076!AQ&2PAQP9QRYE0$ H3
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M#Y$>6_@TD".3=.H"ORN%%[[6D0D4 E4+.41!7! C-]Q$=1W! 'I*(0A ..(
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MB >49)BQ9, EP#"!,+C  ISI@/XCZR@7,X!B B3PP@.L$I'W<.<!=P)!!L"
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M0C$1G%S9)&#F0B(<H9Z.T-DV0^Y(((( !J* @@WO-*U)+D&&^CAB"UHHEDD
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M!2! CS! #-3 <EK !&AKBU  "RY@,+ @1C"I%-0Q*_2("V)$E1P "X)*C[S
M L@ &C5B_S0@#!Y(2RR@3J)J \!  _3($!8@!+)@ S@#+*3NB$3$"VI&!"(@
M"_(+"Q5D BK #!RE!+B  O0($_XP0 42ZF@HH@(V( ,$856"( @@X,I$8%F^
MH +$@ 0J,AFYLBN]\BN)0P(R1@2^H UFRP&0XKTX #T:P(!.8&[6C5348'Y
M 0(0@1,4($$.X=/( #8"H2 0J",:4C<.I!+$X&L&<P(H# 3F1F\>H'\L0! 2
MH8D><B\8R:4Z0FK(PH/THA%-H@)6 SY&X',ZPD5&R"+X9 ,FISTTQ2[G0"\Z
M(K$J(0% !0+:0! 8H"0" 5FZXPN8 @1<R0/\A5I0 #@PQX-ZH@7TR""\JQ0B
MP)$PP(#" "A 0'#HPX)"$RRU<SNY\P,K8@5:4Q,VZRU5RJ[ H!T?8#44PU@X
M( (R@/X#2T$37$ $I"I!O@ "*  %'@X13H $/N R6*<C G32(, 2P$!X1F1N
M' !B&G&U5,(+5B:("@(#5K-]O&,Y6RE4^M,#+J,1*X(VF.T+4(0!3B $2H "
MY$,"#H$,A <"0& $2$ EF:42YV8AC.0B1(0$T$<%'L "5*@B?%,E3*I?W.0$
M$*,0)* D"*$@NK$$H-%!7F63?@2)5J441B!-&, $3)0"!&<(N_-+P31,I<\0
MA.,F!K,2,"$C5" #D&4$CD-%*4+E*N$,%J *+4 %+H$4+, 02$$31N$01(!*
M+((!Q( 4# % $31 #4\"+B$,8N1U/ 542,0\Y,,,1H +0/[C@SH C@"A('*)
M-2R04$/A$#HT$7$" EAQ"TH@$6H#$S#A$F!C!;+ !%+"DD#A$EZ569Q,>4I!
M \@ 5?Z$2,-*$"H .$HB2(FT%$+ I#S#./GD<I@4?2I!$UB, @ JL;I'+^*#
M8G#U56M-3,$U7,6U^+H#KA;E$/YI-VJ& Q##$!1 ?T"% UQ) N2L(^ '; S
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M000L0 1: #AV2 ,NR"1.!B=4P *.LCM"H'_< "8WH%"$Q 4RP (ZA!1P)0-
M( 5W S188#5;8#4OC;HDMR0206D9HJ$\@,5$ %1(@04P  -8H"3,T2(^"IV"
M" .\M/YLV;=]W=<$,:$#T*<I'HX4UM<D+-8^P@HS0N'A&NU^ 003<+ I]I>
MWP^ B^CN\C<_"M@^,(%:" $"1D'5"/A;$P<4+/@^&A@S%OA]/?B#0?@_*L$"
M/.#-FJ($L0^%N:X[$ ' 0OB%83B&EV^ 05B%9?B&<3B'=7B'>;B'??B'@3B(
MA7B(B;B(C?B(D3B)E7B)F;B)G?B)H3B*I7B*J;B*K?B*L3B+M7B+N;B+O?B+
MP3B,Q7B,R;B,S?B,T3B-U7B-V;B-W?B-X3B.Y7B.Z;B.[?B.\3B/]7B+20&8
M#A#VX)B&]WB0";F0#?F08PP1O, +PH ,OF +W/!%VF0- /Z-F<X@@QG8["[A
MV+X.FMK L 0$#?RWF6CX>B8D[\Y Y4C0AN*0/S#!YG"B(A"AE9O"E$W"AE^L
M(@"!#!FO/Q(!/O<C% 09].X7EQ'9ZP8!!%   A[@!#P $;C SU0$7Q0G%!B
M)]6O#!"4[,C$F(FO"#EBF#LB,LZ.%#A@DSQ@4:C*D@1D\J;S/Q#!G<Q#9,+
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MUA?E$N;% S @38_2+DGAOT9\(;;@TN4,$30]1L"7!+S6("X@!28  MM, CQ
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M?(-@@5B<":#H/+(4:Y@ #[> N_X#)L0"UBH209YT&AFU[G*'(@$/MZ@"4#P
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MM!801^1%2!!"*JI07E+J=8B00D;Y-I1!-B36C73G#41 1!2>EQ- =$7($$!
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MT@E 0((+7$! *]@ ":16"C-40 46"-0'&*"!2I A!*4 A 5$< %?D8*-(H@
MCQ B!@Z0P(VH,H0%3. !2P:B OX@:&(IOM I,EC@$J2H(@D068HV2, #)+!
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M44 @&,$(*M I+^ U#*"H@"9 8,M2?. , !5!!GQ5&378KQ00(  6O"" 3K4
M %X0A (J4 H,7! 0 U!G!&I[6\."X "V# , UG & *@!% 0H 2@.\(%2> $
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M!Y "#;&&=9\M$#<#$-D%G4)!"M!Y/U^%XE#N/-(6U 1>I!G"DB?P*@4BZ0!
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M"5@!4'" 44"!,L*"%C@ 4JBIH)D G"$#-:$ $P#"$.@O"] J##BG#2"R0Y
M#7 !UXF;!I0 =9I$@=B;-(BP@L  \#D(-3@X5!2("W"#%QP)"R <+8@G6O,]
M?BN%GOLJ3#@_4R(!E\,"VYK%5$&,^O$J"+" 40@%"# I"%C 4G"$1!B$ ]B
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M@V,C$BMY ,@;P (3+[84B%8<A/YJL"TX!!2PFPA,KPM+@4 9"1'(P(*<@$,
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M@I@#&NV;"RH$KBN%A\2""DB$^?(5-!2($H 3"&#(@Q@$!W.#!MA'#_@MA.
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M/+9*<.#O;1$2<)\#O,O^BJ430 $#!J@]B0 0\<&1* @,?/Y/OOE-+WQ=J"E
M+GB $"@!"<"9%I@ $A"!-Z,E/]HH@0A/*TE7-54G+Y" C/JO@C !=1*U-H >
M_45,@5B# CA1-?+!">"G2]  _16L4I#B4L#8WK22#-B $5#=Z@ $>=H 2#V;
M,4PO.)T]"\ $O#QA%"@^<H)4#("1,/#!"A@V/&0P!?49>]J #0@%2X@  4&!
M"C H(DN!1R%:>E(33&#D2-P0443 4L""!#B#Y,/C9"D(!30!%.AC(\)%\ F2
M()8 &%'%"+//7)S>$J" *>: #0B!YZM$NT25+$B ,F#&ZK $!1BVUYF $-@
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M8K\,-9 >HU47!]#JDI@ &+$X#_Z?# MH@6J9*+:.#/M"G =H0=<XB#/05X3
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MG'/26:>==^*9IYY[\MFGGW\"&JB@@Q):9R4,)-*0!F!4<@!2H#P02"()//K
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M-$9(ZEI#Z4;@!3N2D0);"*2U6K OK1QB#4Z9304 T9P3D$ $$@B%"D &"A!
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MMC9H8(A 5$ #/0"!1#5%@-<;Q4=)83_'-"E>G?."4U3  5*$(@.+A0!7*K$
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M-40HK, X]E#@^>,^@N.;G &\?.-!ODF$&"$HP- )J$">/8T*O@4ZPDDHL(!
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M"83!5R9%)7A T\I'WX) FX#"!*A &$P CNUN[_YND(1;DU"+"/AM"*A3"KA
M\'8%!I !!ICO32!O!<@F&N23"52 )M0%!J@!(5" ;I0"%OY@P!=L0$B@P4@P
M!  +<$B  @9\#'>0YBCH!,FU!@I@@?HZ!H)@ 0E( "F<P7UI6"G\G 6TP1PX
M@$7\;P!SP$2L@0)0, -P@;UA$ER:J^Q0@%XP@+I@@@-$CT^@P"N1P;QD@@4$
M@5,<2G>2@"*(4U>=A ?4!$P\R+&9CQD  OLDJ2&P5V/,@=4, E?PDXKPI IX
M$!M,1 0D@B(<0-L<RN_E3HPTA!J<! @L'2(<@#FM@&G +87@F%=E2:)!0'FP
MBN?L2@M4#!O(W -($&4!@G;EF&Q^U6;6C00@PB",C",P ";8;5D&10:PQQNM
M#)RT@/D2ZUHVQ,>H")ETRR$, O[&1 F2!A[N:D(Y-83^8L(!^*H$N%&+S(;!
M-@3A$H+<((5Z ='2H "D_)Y8<(("( 4A!!@F2$!CB &41 !X:8 :&,+(O/)@
M;4!^A ':G$#GF('5=//'L0\'6)48/,@$U)1/L,"^\,=L  (%I,TH+Q9E.0M7
ME$&8+<[_>@0#M$TB:)R_E([A-(0$ ((EY,L)A 0*@/((Y$B01$64F!-["<5B
M$18\<\!B<0*Y@  3:8'Y!HP%GX!I;(!>_&]R2/)P/H C/!=2G'225L(7A%F6
M) #X@8($1 \IE\(90$Q/0( )K< <K$'.0-#.-40;4,H$38B%)4*K?8<9/$BX
MS3 SH?XK]$@/5_8>W/3K;)@! +2-&FSF ETU":2L4)!T(5B-&'0.!YR!Q['3
M?\",04!,&8S "0@M+'>-7K@)*9 QK(PIVNP?5.?T&V]&J$Q($'7% UC "DQ(
MN- &[I2  R3"-/D$0&U BJ ?]WA/AH5/UZ4D!%T50T" (HP!0\Q&_HPV7(!V
M"&Q0!W&F CF&(/>$3_"03X!!4  &A$A (K20CJA')$] !1#:W+IS W3/"33)
M)>A00U! VYR!N/C3;D5.);0)J%B-!VQ&C!)W9G?!)4SW(?0-=R/% "$;%FR-
M:(Q1&1V6A0W2KIA ?E +*9Q=0\B1(V!4*2B"#H%M#]T6A?Y,=[1P!LN<P&(Y
M:ECH!6-/  B00&<$11D\0 6@P .;#KO0,\&H2QJ0 )N$!H@83(XL4 LD1_),
M2/)<PG+W&"C\S@1X0&"L10F4  =T#G5+8"F@P8-4=D-TA,7,C_=@&<TU!!GD
M.%TS31!HX/4D!3.;DP14'W*'4M5\Q]W=,VH3#.1E2>F4@0-$9-\! KO43HY1
M0&M&]:!,-01 ITV#QRHE0CR=%@CH&7=Y#B:X!"B$EOG R^>,@7%X@#8QA$_@
M3?( UE*T@ 4$1@FPA\5&R'_MUAR<1V0352!$P%L PB6\L\D*]JL0>0;K2)@>
M7U=US@:40"*, @8@0O+T"T"!0/Y^0'I*R),\<1')M %1-.55\11#1  BM+H&
M5K+F-L0V]9U*6<L$N%<&KN@3%@+N,@5#^/I 'P(/[5;E4$A\-D06S\;M\I4\
MF<(TN0F\XLPH^R,Q2_=W>+<2L8PF ((A0':JP_G&4+H]-7-7.<4:@$ 8>$08
M7 "<Y]002<!A)=9X'V6 ->Q10@ G1%)#F#4IY#=H[@NRS)RT!/AC+%; :P!7
M,+8$L"=.G1\H .F^O4G6<)1Z#(*0M4T+Y(@)-/0)@(R-'X9164MK@0)I=9=K
M@<(H(((7* !]D0$G;-7])0+@-(08S,M(?Y!'% :<RU,II$'IF(%LQ#E"3TL$
M3.CU(OY%!4@Y(?T5M832(%3"&<1T^8A%&Y?.&5  )YQY8YA6ECPUNWPY,DE
MBC  =#*[3XC!.@'18:B ^<*'5FQ&SB:"3G]'%C1-!<B*1X!!!5B+=!Q-AJ !
M X1"OAO$K@B+?3/ 9CB E"Y)F7%&01R%=R^0YKU* AQ"(BC 3:,-?N3MA) *
M)=C9&2R%W4X(E)5"&Q@ (2#" XSZKJ !Y:.&>F"%S":".1N,1V1I4C155P3%
M X!7!Z$!"<PTC]6EAE1,CXA$$B4%;!A"&[1!DAT2JCU_0T1 VX@<&I3 YQMD
M&RS W6& %F7 DB+-0 ^,4S>$!V!%A!PS^@.H=K%!IX'.2?Z KEE8??H#&@DR
M (X!1!@,I4!MF-"F5*4';$H-PH"I%*E2+C)(]&"B% H(CDJ5X)#Q0:6.'UMH
M"%4*!$8)"$^N\)!00:!2)AZ4(L&BE$V<$M:4LH"E%!D+$S?D/.$%$P-"I=PX
MD'B2S<92$WJ6DC"(!8A2ER2HL+DB9PFPI"2V^)B( <1*#$AMP0 *98FI7TIQ
M8I"H2X:<*H#F+.7!*R8)84IA$)/3Q8BM#]"4,F2!E)H*.35!:/P85!L&(EL@
M@)C3KII26R[ %2'"[]\3I9*R&926DP6M$\[D/#.Y+H3:ARR 6C,AIQH)I0#=
M37T<>7+ERYDW=_X<>G3ITZE7M_Y^':5H#XD(>D"4>DN%#!XN)=IPJ10B#)4J
M;=!@84S.+18T;"\5@H0(V1 58="JHHQ2UL!@ PP <>RE4@IYR9#Q6OA"@TM
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M!C(@ I&TH058@, 6VK"!"KCADOY<J@#@2J$%GSUW99B< +[2M]T62 00'O!
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M;&0F+&8^#*$-W.  $H$$2H 0 /[!"]A""25 )N(K)YIP+=J@#0P! KR@$B
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MP@ HAC3P70HX$W1) B"P%,8$CG#B@7D6[&893A8(*]W56&>M]=9<=^TU=!E
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M0 G@ IB 6F5P @J@!F=0+W7G'IG' A* )P^P8H'@ %CP!0T %BXP 63  @@
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ML:R+)0#0'KR[PVP  #JQG?55 ?Y#[  .4*LF?!$ 8%#Q^9]R@04#8 "(< (
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M3GL_'&I  %412 #0!ET0 &M 9WHS @$ 4@OP,Q8@0FP  M<# (.R 02P!FQ
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MBP,<P9,+>*B-&;@$ ^((A@I<$0(J@UPH5H !"6KA )@8!'A8UZ<L. 44'+
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M[$X+KKC502S&!&QH4_46HH8742<U(5B#&*YK+)Y80'-JT$ B'% &][;!$9:
MP/(<@>%27&(,)& 5&Z9"Q'\5905B1,%UOG*)"I2 #68HC@K$> (7@-!\+$@,
M<,20H?G%)@*7G!$:-A JP2)7$7Y;WD[R-.,W.J#.1O8;+!\0BB:M@0RV+84@
M&(6G/FFA,:10 PL:H 7=]$1F$M*-"0CPGR]HB@0$4) ($A"6ZPP" %CHYEPF
MH(!$*/Z" ;.1 %)&T:\@EB&>)@  (=00SS HS-;?](  >,<D * A%,%.1'T.
MNK$):!4"/YV D4#A@EC%&CA($@ &$K&%4V-B $Y!A H&D3.G'&(@WC9+(E0
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ML!8O2, '@"4C.0,X2835 (3LP_Z39UF*-)"0,% CGU # 3 LG;@$#2" !!B
MD/BT4#, 3OB" 7  !L ;1!" *P($"#@ !'@ ZH$ 6:.U?Y&  Y@ #A" 0#"8
M%NFU^,@  3" #2" 3RD%3.   E"  R >$ @ S C"KX" _!@$""" 'HP/"(
M\U (,2  #C@  :  E2&# SB  G@E1?BV4C"WV" #!$   L";4K  !G"W ;@0
M$   "[B$@8$ !# D?8/$G:B ^, 4I/@E#3B!OEH(%4"*Z; >D2N06]J)0YB
M$T@!%'@ 11 #"!"!3"P-$;  ZH* W#B$"A@!$,  E7$A2_*_W" !!N ,#\B
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M+S" +_Z@L;SXBKSS.\<S "]0 P=H.3$0"C.8@*T CA.(EC8( ,$@ 19 A 8
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MR""00 5$P"&$ @APP!:XX"%(P&UTP#11B$!T 0EDG;HM&T%X0,R$ FV$ 1@
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M!J@!257"/9*&_@U,[-T@KB0""F   R#*7P3*""F"Q*! (@@ HV"! ) /K5"
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M,,!I8 #Y*%<I<$*  <G=A:K3E4(&K,$H0, EW&.&X"AZ#$3I?1S\P=E H$$
M$  !#$  2%[<"< "0   K% )! "&CL$ 4-  ;$D8!( !/$ "+$!810  @, @
M", #H$ "0-UE=@5=%)1!8L&CRFLIF $#?$'J+"F7/, &9($() "B9)T+_-.'
MT&LI/ #("%0IC, #;$&'=<<9., 7>,&2E4(#,$D#($(;(( 7F($$G,$@-  9
M?,$&O",F!)7;,4@+\&@:@0(A,$!SEF1!N( "J$!_E>H;@?Y7"DS ;3  :80!
MY&' EC0 C0"M6)+!H4&. Y  "%J (3B6"OQ31*X!=5*LX- %F&W!&0!JHG4
M&G@ D*%;U$Y S'B MKC! 6#"%C! &7Q!'\H%)CS "/34 WB!%SR 1PY$!%A
M&*QMRD4 %IB!"20 ((A!OWF FKD  V !K50H XS"GJJ QVK+9)'!+NW)7W0
M!2 "&4 >&/1;&RP(&!@6TC1 RBC99TP "IA!!?A)Z&[!Z$9+"H 7"\37@ZQM
M=X@ !Z1!%Q:$=7G!%SP Z[C+)2S GL"4U[#MP>;M0 #" W1!&#2 ?@8.!MD)
M ]P&H)&" QC"QI[ &6@ XUP"!?YXKP44DB D0$220#=QP0*,Y_7^UP @X-V2
M 1:HWU^0P :H 0AP']UYS0-TA_I6B/I]+JY2E6G2B!><'!9D+"?L69$L "B4
M 'A-5BB4 02<@1=8P$V%00*4 28L0*^6;^$5TAET2KWZFAA% /T^0,%L %5]
M <F%@@F1P0KP*M=E !J,0+^=;'W<7P=L!@-L(@0D(PQ- !J0@@*PQ@1L@)PP
M"AA 0!AD04PI@@*T0%7&TD H AF401F0@1K<52)@@1<@0ABX:0L P&IE: NT
M0&BBP0H @AN<@<1Y :PD@A:8 !BX6KMR!2"DSWO&3R'48X8RHQ$5!"9\ 0ID
MP8=6 OX6I$#\<"^C"1^L@, 7D($)$.,@KX 1G8%KH %H#((-"IX;L  9@$(8
M9 @@.(T;&)$:H, 6@,8EN"<FN&=!! (BGL%WK $*4-% I,%MF!A>+8TO#XY3
M)@(H %XJ@T8B;('"5$(6H$ 7_=<*L, 4%@0AM  *N*<IGT 8-,DE8 $*"%X;
M&%$:D,8:Q%YH#D0@;,%M9 X+%/) K($A8($*&%$8;T$EL,%JX HG=($+%,(A
MB $G !Y':<<7"I[ZH  6#*+_;,$A5$(7 ?-[ZE\Z<\(1Q^I%-PT*"!.7L, 5
M$409F, VIC,H@ &L(!<*'*=+&()';U E"!XHH,%I'$(+?/ZT+%GFX 1CXBP&
M&9Q 'L>)3&=H^ASQ&8  ()S <0V$VJ) #JI!2P@":9CR$:,!<)2!)1W(#7XH
M2)] XL5H36]0QL6)E!$SKF)P"H2F&Z2 "^S),=/&,0L$&:" "UB2&K  &N08
M:X0!+I\!;6@"%V3S0"1"%[VT2P""6M?'"WD!"I"&1 '"&M.)&7"U0+PU012"
M%MP,*),!)!M5))>)0!1"%F0"]34O,TIG(KC "2R:3E3" @3 !>CQ'L?V4&C
MA]R+;-\V;N<$&1BK64@ +8<%74Q M-S%)21Q6=#%*%#+?8#"%M\50?#*FGC'
M7]"%;>>V5.1'?B1W@0S&IX2+POY82G7DB&%0]YK\"YO4"[5@1XD8R'=8!W^0
MPGCORGBGB'9+R5W =W<_-W:0MXHHM[J BK,P3$&(RIM(]Y,TR'[K-W8?>':X
M=X% MTS0!B(H3RCX]W__MV+4]X,'R[64">;JAX-H.'OHR%_TQWS7R4"<P8?'
M22D/"7R_29-42WN =ZQ8MXW?.([GN([ON%>0 HWS.)#?1'6C>%4,>8[?1< <
MA9'C!\"L2US$Q))G193O1)([>9!?.99GN99O.9=WN65@ KU\2[4$C!?0"'(+
M>)'0)+"<N'$<#)Q4@A801(772YIO")W#B!> #'\W"EV, 29WZ9['1"@8L\ST
M$YLH!OX@D(^,$\07R&6CK'> ,SG?0$Y];,&>_'@E@$8@;(FN0'E,8,%51_>:
M@/J+8$(6G$:5K]\*8/&46/@;81B))X*E:#@6N"F(C &L++BGWWFF%T1[,SF:
MHY51,\PH)+F81#J?UT23(6"->WEL@T&).@46($JJHY^$[-A-Y%R$" *VVWD)
M1!!19 %"TX1<>$"<TT4A,,"/PX3 9<)# 9:&R%!.R,46_/92;$&TG,'=/8 ?
MNT18$C"9:&"&5 L*P#/2L"I.T 70A'I.U#-,.):;OX0*I#.!>(%J&X79& 6S
M.<U:R(7;&KRSVS@IK  &4!=:>0&*& <9@,'!T(4A>,$:E/YX&HC!):1<);AY
M(K &<6%&F0E$)82!&;C:)7! "5S"(&# WB#T,2_J)6$ (0C$(.2Y7 R""1\S
M&+#&*!P")I@!&5#&)936=5;(S7?1RS.O&H3!)2 "*5R"=$9&A7C&(8#":%5(
M&+3XU'O!)8A %\C3>T*E&#Q.*#S]0%3"5:-!!"@/"7C!RX<](L"\2Z@')I3Y
M0%A"VV/N&8"!FQ)7*""")80!60Y$**#!%X3]'$A^JWQ!&E@*)Q@19\0H)MC-
M* #-2 W0&HC!<7@;%I!"Z%E"%_CQ)8Q!BR^/UI/!6(="W*O!>\$A(ES"WT^W
M&GR!F\Z&\6N"&(QUULWI\VOU0/XX AB,-2> P"/)^?*# 8JX01BX!BB8 ?0/
M?BB,PO*+P46+QQFDS,^3P5VQ!H,E@NF_/I=@PMG?%4" ,D/FTJ%2!P]6"D,0
MX4%,9,14*I7(0HM+I Z!4G.I5"4P9T =1(1)31B.I4*=(5/IT"B$;2"H"0FJ
M3!B)I#I^#!G*$$Y0!DL!\M*FX4&:-D62--D04R*/1 ^F]&*H%"*)* V%,EH"
M1"6<;+P,<IB(),ZB9]&F5;N6;5NW;^'&E3N7;EVWABQ 8#$*188L%; TK"2!
M!98*B4J%F1!D@X>#(#"H ,$ %!82!T^H*)5!3*('(#* ,C2AA8D,G!">@5"!
MC"$')?Y:0&A12M,&$E@FB,5IZ *$%:7^ANGP>Y"$4J!LXQ8K 40+#!A*J5GM
MI11.+Q,X7"8S84N'RZ5$6)#, !,7$ =5G"BU 4RESQ@P(2)](@-'+WI'/ A3
MO90A"")6N. \UA[+8BL&0+@DA0I6(($!@\K@SH/O<!H#@A)6@,# +<XKA043
M2@&!A"T8**.4#[C 1 '8(- ,E Y$P,V-4K;(  P*4BBEC0JZ@ RA2AQ C 0+
M4((@D1*R  6#!U+@! ,/6-C@ JT.\H(!# !1PX$45&" C%(.85 %#*ZJR@$1
MQNQ@(@@@JX0"0#!A@(06)% /% \\P.*!,4J! ,XSQ^2@(_X(0O( !-S8.,BE
M-"1H 3)2 )%@ @,3DA.%.D_@X(+C+#B!B]Q*D<"-..>4 $04&/  $4,>R&(%
M#$*2() V&$"ARR]*(>$W"S9@P8,)0FJ,!0X(16@0"+!@ 3Z$.-%@A18>)(.!
M"]*X!((0+*C$#=E$P( C##9HX=>0..! W&*KZ[*#0C"IP 05) "D%#8B<-2"
M4!1Y0)-2!GF@%#(L^ *#$1IRQ (,X]TL U\GP*04E]9@ .$<E23A"PD,^6*#
M@]"H "% )I @"/ XP(V+4M9@LX.0[&K9Y9=ACEGFF>/"*0S'U)  ISAU"^K+
M4C@@@Q0&J!H%A$3:T+F4.1 ()?Z+$@Y"X;>@*S%@CH,P,+&4$ES@+]? !E%
M$1TA*&4%J$LI(P-%_U6S%"\0&R0"?N=NX3NU2WG@C.,>H*J$P%Q*; &)K$7D
MH H "00"K0(Y !0N1#AH!11*\2 ,3 R :H/]2CEA-J*/8P ,E*HZ0*Q0(!B$
MC(T'*U.1"3@* 42@J>O[( O4>+B4,2CKCX&W0SBH!<T4H&J0-4H)P0L5#1KD
M]RPZ3(/("ZBKQ$1?'S;#X8,X$"/$## 99(*O2SEC[5"]1ST0KS/8FPP)M/)B
MXPVH\U ]G!Q1X.I2(D@#E /V5@H*"$)%A2A%(7[G!0T<Q V7H4 @.($ J$@
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MG)S !7)D66XN$8&0)*)L( AD&0>H4E#@!*B@\!<)(E,"$D#@),?2:MJ@$\+
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MV7,>A!#HRM6U@<9%5%9B#150CRX[PN6)/. D8EB;!;CH6?XT'X159=3$<"G
M15X6@J[\OG"QQ#=#4@PB"PPPW.'>J-@-!!"[I%,#=&[7AHBM@119T(P:/" &
M8B($P9U[LP ! 0@DVI?E+7?YR\\"!B(A4"Q:X@A.PM41!NQ' OM)A"(/L0#$
M@,$ H?B"QRSA@-EX%Q'^(K5Z2F$"/O%'!.I1'$[Z50HQD+847Q@V3L0POD$D
MP&$DXE?9QL!UK^=--ZD#S^P.LH4,"M![F-C CA^T.P. 0C&^;!'0VO, L\@5
M,_MQ)[\*,#J7((( ^[FH 4'F 2H=)!$C#-&7S;I"7+U(+"0N@%C(X"\Q& <3
MC0*21-9PP8E>0HDQ+-]*$P,U"?XT\1(,J$1F;J?X@\@4$:"HP 9"<JC+2F!?
M$MA?PA!2 >J$X7S,'W*'5$ =K53B */[^2 JT;M0#8+U#D/$[];P (E@85/Q
M H4!<'7]VJ-LN64@&$(R$!AQ[D<%((+H QRV J@;*061$^=LXB5.'$:Q;$U>
M>JX_#@!Y9&4--B5M/$970H6+CLNM@F -/,#<#M 0$("0+NM>@&-C,""0LN\D
M<HZ&J&,"WH@"V( 4'L %U@ $?(@_W,H@L #CN&(](,FMT( 4%&!]5L!?,& _
M"I!T:O @3&! LLP"<$@KVJ  B((-%,!L'",4+(!R0@$$)  J^ ,+SF,.&  Q
M0@]EDOX)YLBP#,WPDQ#AN<K' C@  [207S  !%: "R[@)S"  RH 5]X&.TY@
M APA%+#I! 8J5]"@$C;F(#0!,C" !$HK8KX@$0ZQ$ [1,#;@[AI"$2S@/)Q#
M!&[F"PP1O7Y/ PQG PQB%#: *L+/0"KDY PA S;  BA%,3:@#]-H DZ@U**N
M##[1*+HE T8@). K TX !+X$)P[! U9@ R9@= Y" @+#+$BM85B &54 5P[!
M%0'C('#"#$+@!#2 TD !!"; !&ZC% RC RH@=TZ ##!! \8*^&CD]S* *M2@
M K#)0!"A$@<&&DL!#"P+!+1 <JKG24C! \0": [2.AB@#?[8X#O.X#) H00P
M( - 8'NJ8@)08 ,H0 3AL7(&H1U#PA!#P@O8, ,,AP,(P1(D(",K0 0U8%^\
MH +:\" ICP->\=6VX-428@/*+K0XP! LX4E0X NR!01:B"<[PAU+@; 084=
MP 6P0$T\P!#<('A01A,#R0.*RR@[8@54H-V2"V4JX%!<@ /,@B_8\ (Z*0Q*
M1$FVIQ*VZ0*Z)D2@8J<Z@@52@ THP"*1 S%(004N@"(Y BY?<3;>!@*0\3Q4
MS@,JHB'^$@,T($%")+= (-%0IE,T<F\<H3%.X)*H8@O*IBB^8(W&H"0%04<Z
MY Q5<S59$RYHR2@28?(0 A1XK?Z,$B&X#N(2*B'&#&<4>(TM0.TL2($?BP(3
M%($XJ\,L+L%A2$$V?6ELUN*NU"(1]@4A,,$K)  H+*&TTB(X81,Y<:(2MH<4
M7 ,QSH([BX(LT((4EJPAMK,A-*'WW*(I&B(41J(AG((NG',]U\([1<*'Q',N
M.,$\0PU 3Z(X$P$Y2T$1#E1!U4*TM (]S],HKJ*T F<M<"(0?F-WXHM"HZ(H
M+B%!$<)!&50M!F%#RZ!#ST(WBZ+,F,)A H<4$.% &X)%'[04I&<BRDBT=F*M
M-N#+U (4$,%!6[-(C?1(Z^)"C4(#, Q)[>)"B3,4-L O:Z9*P8 !3L:3E#1)
MG10M$OX!5N@"&J'1$<"T2V$&%.C# S" )ND+33/  R[@--^"2&>&#>9..,%D
M CK23/FT3_V4+B3T3UTF4#UIL02U2^D44 ^U9:XS44.I48UT/U=T2Q>U4BW5
M#!WU4C5U4SFU4SWU4T$U5$5U5$FU5$WU5%$U555U50&U$ B556$U5F5U5FFU
M5FT5&F/4,8^# RC <!24."DU5S^T(2A5&VWU6)$U695U69FU2M&"MEXF4S.U
M6:FU6JWU6K'53$'!!<R ,;UGGTJ  PP23+" #$1Q!!S@:-R4 X@"%%K@X@8!
M$+3 !22 #-9@(@T"%'REBJK"!01& SJI%-!  S1 !4("$_ZLR@/D-%L9MF$=
M]F$A5F9" 4$2 1 0;3T"R0TH(!0*80!,H U" 0T@@"@V8 5 @58ZJ0$RP*F\
MP   8>Q( !/ZHA2"X#RFC1,,80"^ !16@$A21A XP3N )B#G8)XB]FB1-FF5
MUF%C["#=K/(&(1 \@PP\([@.P3B.9;74XP&*BT-RJ!3<P&,X01,.X0P8P!%&
M XKFY@.^[!(&@1!&2!!X:9*6MF[M]F[Q%E6K[2"Z8 0 @0%:P%9<P! (87QV
MPSC:#96\%@* HN1&H0)FA T\YHA*X.@2P1"4)A", P.^Y*YH)7!5( B**V])
MMW1-]W3--!0> "KF!!/P[R#:@/X3!F$,P<0X$L$!KD+X,.8@(*<Z $Q'B&0A
MC\.\1J/ QF>P&"@%\FE[ *%)4?=YH3=ZI1>4Q,F[L,#AALP"SD %""7K^(T!
M4.._MG<O2P%TS#&#'B!14F8]2$ -5D !OL 0&  G .&">(E;(4"A5H "ME>&
MYF#EIC> !7B "1@M0,$"VL %5N#ARN<$LH C+B& ]ND,S (-3F +;NX,MH<0
MH,+3.F)O@JP%#J$0Q@ 3 N@2=K CL. $U.T,'%@B$N%G"GB&:;B&2W=BH\N&
M=7B'>;B'08D4& (\W6):BR)*;U17?3B)E7B)F;B)G?B)H3B*I7B*J;B*K?B*
ML3B+M?YXB[FXB[WXB\$XC,5XC,FXC,WXC-$XC=5XC=FXC=WXC>$XCN5XCNFX
MCNWXCO$XC_5XC_FXC_WXCP$YD 5YD FYD WYD!$YD15YD1FYD1WYD2$YDMT"
M%&AT9C#A58/4(D5IK=KB(LS(@)WSDM_"DQO"*MP"9Y%SACY)DYF".$FY4D,!
MDXWTE=W"E,E0EEV.%"SA0C6A.F4&EQN"$W#SD7&B!1* 0$>T*(J5;8HX1/:#
MB'&B"[Z#4LW"4:L93SF ;IL9)2@@$0A!:9+9 ^AVC[09+0+'LQKB>IU*B"EO
M CQ@1W'":R^A!4+BFC&4/XMC)XK" I3*+';+:VH&6/ESH/[E@I+DY0NJ"3F7
MF:#G%(G58DO=\+)D>)M+H0MV#J#QM*"'N"H*3DS)E9E!.BV(TUV;E#BW8'3!
MY ">>2DAZ<:.."W4P/K$SVL4]!"P "=<8(T6^I Q(0,T '"2N65<P@-T[RU<
MPFN)N"XJ 9.UR("0^4>&.42RE*''R6LFP#)%^E\P[BRN<R(&;2X4-!00*:B)
MJRA82'>26KZ(DQ\IP*FZ.DR->J,=&BTJ 'E2X#+HE',SFK[8,RW8H)=<1A.P
M]RQ< B>"\,80Z ',LP3^JJ&;V5&J SK98EMP@L@PNI'+H /:8'PXIEQ,MB'0
MH%Q4@!1 004@> 50 PTV( /H.?Y$ C<;B^(01OMMZF<%+H'-MJ "8G:?$E8L
M$,$%F$\#V-1=/2!H^I7Y,H!-AZ(47& ,0* "M 80-D #PH "# $3LL 0UDA!
M$@-Y'"$\Y,XDUBC04$)<C+N6:#(+&D #<D<-.*!@'68-O& +1@ 1,  "4" 4
M#@$$; .1VF!T2"!=G0($.@ $@ ),5$ K9!84!@$$)D0BO, ,D,1=<8(,BMLP
M,0">+( 9DZHJ^)L$FE2!,B!+$4$$-@ $J*(2@B ,*@ %#D$$"*0-MH +,O'A
MUL F6SL,1G,"6*"0.J #3L!A+,$$BEM>MJ"DUH 0ODQC,N#+RC4$*H!S$*(,
MBGL%</XB$42  T" 32]A&#6[(0"!"[S ,10!!#A !!"#9\O%1-C@R]" .MY$
M;B;E$DU\R]_F2K3F(+*@ SA #[- Y/*P*+JU PS6',L O \""PZ])8VB!31@
M ]QZ-@8!"VC< \IL QZ@!(),#$##$ QCMD,A2C@ >>9Y##8@HE'  <:5Y(J;
M.L"@I+Z$PPKV$$]@0U<G [H&$ P3$3[. SH@!4(""T!NP"0%"SBAJYB[7"8Z
M(3S@ 40@%(+@-EH\)$?@Q _<D,6Y3V;$$O(NVW&"]:B"J,L7,2J/%-S  ;B/
M T $!"S@$ QA 7)K-AM +#* 2 [A=PZM#2X! R"I9)8&6/YR=GEZEFVP@,Q_
M#1$&P LX8>!U9P-.9@%( (45@!-JSPPN004,@"7PSP'69^LP]H\,5@P(  T*
MX8)>#S@<(Y\DHJI[;0*X(!0 @6LU@00<(PP(P 4"@12PH-TO(1W?9F,4*#H@
M 'DX()"\-BH80%[(H/R0AP4N8P04P L4X=[I1B+Z2P(XX!#@-G>J>@+V!@P.
MD7</8]I&!P*\@.\(I1(( (,Q &/6( %(X0P&X')68'P$(=DZ1S-(H&\0P0&<
MBFMSI6N:0T?&)Q&R\9+VT"DP(# ^HQ*@D$K+;6SZ'&A&1M/81@0@:;/9Y@P(
MH 5:R ),A R@(^B+@Q2<C[G/X_ZXP*,K$"(4N ,4ENW" (,Y$P,ZSF@Y+-V0
M#&(WC"255L@"#,$U1F<"+L 0#N$! +PB^Z4-, 'NV8  S" 1@^<Z3E,F+P$+
M#& E#J^J\K3W#* %,,$+_(6FRJ">V6AX!X$3+, %#G1V)0S -2,,LM,2PD5%
M),(%8M9V,L\")& ,QL8$ ()#I4H+0)6Q4 K1!$2E&CH,(P%0*2P. %62T*74
M!3"ET%@@Y3"DR)$D2YH\B3*ERI4L6[I\"3.FR$H, I424:(4)@DK G$*R6F"
M"D":2G&2D*A4(@FC0'!I>*E-*0]>&GKX4FI40ZTCNE@:$:(2&!"EMI M2\(1
M@T&#$OY%&.-(0JA2@R0 Y83HC -%B"2 HCM!:T,06"4,*D4*0J4P'!IJ<H"H
M;ZD3*Z:&*?5!3*4'?TME$*.PH9H,I31I.H3& :%2AK,VM,"F% @L#3DYN$0&
M@T,SI,%42,3V0"(R'I1*N%2*Q 8VE42J4"&;(Z9+A4J0%5&YU"&YI# Y"F0A
MHP2II;*0A7#HS 3@@Q)(;#B^(:)$94B#W! &TP-,I52<* 6*!(J<H1MB#R22
M@@B)&&)& J68$$1#)-!600F <*(5)I@<X@4$?V5P1BG$L;9&0X#8!5M#%9!7
M2BB:5")(!K2=@,$:E8#D$":G?0%!45J944%#9DB 2""&(/XPR!H,E('(7V$4
MAU8I$\3& @JNE7(&0EIYL$4I&I@1$BB<),(&!%)5H,9K)3;D(HP9N%!*!2&6
M @9I<C84Q@:@,-!<*5Y\  H$I:A1((&EM(&01B&Z,0%($Y;" !N%)*(!"Z4\
MT%PE$& 2($,.B9E(&Q"DJ0$9B#545RES) #*"=!54$9#ASPP%4<62(5))8-L
M4)D%E\V5!0FE7.)A&PR$<<A<(P'R42DK_-=?"X0X8(@@B3 PITS:;LMMM]Y^
M"VY*((&1P 893.!A*96@@ $#:(2T+@8-J!$*!$E5$@$H&<0*BF!76<610R"9
M,4(97' 1!@FQ;A%"0UN<, @#+?Z@H(*TAD@ TB 3- 12EB1\04%D& ,&DE8@
M5 7!80%6@H6PH8Q2062"MI$!)A,@!\(8J?XE@AB'-#KH!1U94((7%1S6FD,6
ME)C!KZ002099?_%6W@0M4(8%)D\:UUPH6VS 0'9:M8&!)A18DIP&6*! EE.R
M1J"4!B!TP<%323/&&B)@2#"Q"E@<TE"@AB V%Q92)[>%?G^I4%F@E9AQ> 5N
MF*#!U2MT^6ARM%FR0KMBE&6!"EM8P!\&8.+]P&$)>7BKBA*!Y,@&'G3A01:(
M><$! U8ZU$7HHR/7$!D;--3AU7X#K@8($.@F1@<.CU *!53^1PI(73C_%V6E
M8!"K0_YDC_#%TG'&-OZIE7#@ 1<@P%G!>VH$:<$<HF%@B(<=;Z!?*6D4JANB
M(%F0IC4DB@1;N$385) "%K0!$XI1UZ8"!#B' .("(OC"!=)0"@Y<QB&#H,!<
M2%""%50F/NKB3-02$:1+>*!N(.A5F@HG+'PUIPT@D( %^A020%#@+RM(04-4
M$(0V., %%,."ZL*%Q"0J<8E,E D&JH()3HS*$1LL@Z :4HC/B6@"H3@071PP
MF=T!P@28"1@(+H.CAE2B R!@"P@\T)PN-*PL)= /\(A2" IH91 5$ RD2@2*
M"3C"$'JD"P5"0AC6#,X4$JA$EAJBEDI()A0<N-I@\L, X/Y5@ R'N&(8=#,O
M $U@<!,XXO9*= (R:H<!I1 #6>9BAN$!R2&Q"<,'C(.)4'CA+Y=(P. XUH$6
M0.\+=O'3+470)>W8!030$D%5)- ]%>2$2&T(4D/8T)E26$"+8?C"B1PR@35<
M0@(_81R &JF>AF"" 9AP04YT$IL2)),$7,!$54I1ID0H0!'*_ L&TB2&QF!@
M@V<X9/M<UZ+D" MQI>@"?T"A -4Y(@%)4<A?0%*&QN#SD-<,11E4-] S#*\_
MPDI1#T/B!@C@R *F^M*I6+-!#$@E1=N3REQ.<)83T&8" <-"<2BP0<.5P@&J
M6T$)ZC6*T30$#:1A0Z+^>:@!=OZ)6JBBQ$Z0<Q%-!"@IKID 5C12H@V8BA1[
MK !(,($!"=!F \D4E;IX92D40$F$VWOA1&(H 4V@X3T=L!2.0,(LK;  .LYR
M02(@()@V *^)C&VL8Q_+K?8T!R0GJ)D"6K &#U"O%(I80 O8X $R;J #46.5
M(R" A3- X"E/;$@&L((!KC9$! P@12@6L%"?.FQX*Y#3"AP BFF!1!!@=,@&
M2K &%BS@"X9@P%P$P<I3L;44#3B,*:HK)12<(00$2,0A&/ 7+ A ?AG$W#]7
M0 "..$ %8JA D#A @C6T8 &T6<M+1V6<%J!A K39@@82.@9K<N #R=.-%W1C
M0!-@@OX#&EB#"RK0&9!H(0"Q$6(9 LJ9V33$$ HH2P76P(4)>" 4$? 5%Q@P
MN(IDT ,%#@D;'@"&,$0*,R!8 PB&=X@&_*4$9-Q3(M9P !6,1@3JXLD9*O ?
M$+1@,'#2W1I$((*G82$-)U! B#KP&S($251?$,,#TO0 \ICI5%Z0P!J\0('_
M>N"?69@ ?\XYY2J#:2Y:=@@(.*"&$03IQ&4@0\H4H0 M?($!1(9 B;:PI)"(
MH -/UL!<-JEH#[ !"V$KA:'A T@Z24 -7ZA !DBQ@0ETDP'RRP!0!RV5,I\!
M"_;"A(/260HS;*P]<)I B-9P11!8J@L/*(,6&' (3"@@$_[JRJ2E09"4#W)@
MT@[XCP@F\#JZ/ !';0# D@/Q "[XV52E*($!!A>&"'#: A@@107 !)(P** ,
MP@;%&!@PAC*,YQ(U.U4A%% 9%2P4!<(B 0;28(()9!.R!"^XP0MNB&PEQ%2)
M<,$)OJ L2+K !%_X"R:RT )#H.$OCG#XFM;P2Y"78CDA*<2<TO!+0Y"/$.0[
M@TZ;<XDY70),.=I""PHQ"#%@XETZH?DU!V<&X 5]6$$X@2#2P"F:*R(,G6'#
M84(!!A*HH0VK.<0*N&"(-&'"YH8P!%;.L-B.](EE)UB3RAV"B#0!R LFV&4I
M#+$F0&2M%%\X@6%GPO2&M&$%8/X !;( H3I,F $D9!#R);IPB344 @LJ4)T9
MNE9WMY?\.8)@$QA*4'&=G.$O@'A/K*+FAH\IB^QS:H/J3#^L+)2 "S]!A NP
M4 DV@"D16#"$(]1>" 2J[@Q]XGU(RJ "-&"""\@)PPE:(%NEO-X1;? Y(M:$
MF#"8@ M-1P$*W& B%)!A$%+Q/2B\X/,6B:'M/QD40P3S?18( A%544/O<8@E
M%9S!GI?8@!FX8 +59< ,#ZN\WE%P=P91"K?7$(F@=FC !:2@!HZ@+CR'>OB$
M BW $*!@!G]!@7\Q"+#W*5^@ H&@"!E1"5GP'L.B<&>@.HA0)1*A%8; ;1VA
M F9@3_ZQYRDM @9E0 H5>"@J@ (E$@H88$IJT"6"\!Z (#^D0 8GD#@'IX1+
MR(1-V"V@L 4#YX132(55.!): 08%8H5;"%F;)A)>:!)^Q(4'=PE/,89GB(9I
MR#$G(89KF$:ND49:\88A,8<B48=V^%+BLH8M\8:C<(=_F(=9\89D=8<D(8<E
M,8> "(<DD48E$X@C@2.'^(A;48C5@X<ID7"(D8@HX8A[V(A;08<"$X9_Y8:0
MB(@AX8=VZ$>I*(IL0A(19Q*1.(FA>"IED!2L2 9),8AB2(JFB(I7.(NT&(IQ
M*!*\"(RMN(=MZ(D.H16"48>%F%#0J(;32(W5:(W7B(W9J/Z-V\B-W>B-WZB$
MTKB-G0B.*_&)Y8B.,"&.X0B)K)B.( &+Z2B/\TB/]6B/]XB/2[2.VKB/^>B/
M_]@&6) %O^0MRB@3P $3EP &+D &4K@MI. &#HD2!KE$:,!S@Y!W2 0*+.)8
M%)E$H. &T*@KX0(*@%"(8I%\X.*1B.$&\8@2@Y %6.!_6SB2+P$*9. "^1$N
M%O&//8F&I* \TJ0  =-8T @2B> !/Z$%.;&2(]$&#> !+6 !%( <TMB/H% !
M@P,"-E$*+G!/+M&48$EWQT(7#. " ]>/*7$(P!6,;;DM(L"12(0(X,6(K706
MVO*&U_)F=F@!'L 0_9B6IM@%</YR+6&'$BJ@.U4&)U1H B&246XY$O63 2V@
M >@!F2RQ 6G2F'AB*3[IF4O( AMC(@7@*9Q@"-E$5DVB+OQT*J!P" -7"1%T
M*I@P@^IR"&D$"H7P9H300):(&(> 0[##FCFB &-P*AYPEXD@6R!Q"<TQ"JIY
M*HJ '*" ".B'&&"(';-YFO!"D*)8"=-YFPYQ"8-P48WXAJ%P"&CC*(L9!J3A
M&(6 EGMY*I<@&/,ABI? 5=NA+(I@"(V8GB&!"=OY*9Z2"/"GG-XI6^<6B L"
MCW78&=11?B !"F^6"/CI%XAA"/"7%7,Q%QLRAZ&0H<B81H[ 54L!"HJ@H:>%
M0XJPG/X \F:N"1(#01*'4)N)4)L_)"Q+P0DR*I[]*1(R]F:58 #D 0J&L)='
M6128D'RD@ CR>0D^VIH".BRO^2DAVA 8@!6AD$:2A* C$0&T 1(I8$WJ@@@X
M,A>:P%5-NH9*6H O"A(:<$\N0!82"I\A\:2!^9EYJA*A,&/*X@;-009]B29T
MP0$L4 $>0 8<  $1DC T$A$-T0(8@#[(H0(F\&P>$%X9  (8P!!K< $D8 %G
M0 JYHP&X826#D $>< &V PH@H +*TYD@832(H165(!6:<&,:0 *+8ZD0X 4K
M< $4D!0>H (<, %C, (B=A^(0&D4L 9JP !J50H'L:GOX?X"&. !<"0P+11J
M9$ "(O877) !H)JA&/!F'H!]('$(J6H!M&$&#_  6_ S#P "I. 1(& !V%<&
M)* <#G$(LZ$80,E@NZ-DQDIDG713'/!&R&$(&< ![=H068*OW><!*1 !)^ %
M&]!K "("&[ !T.*JRO,?E 9I#H$""LL!H_!ZPS(!-G$&1'9@H"H1+< "&@ =
M*G"H)[!#E; !FYH=$4MD00!"%6"N#G$^FPH=A[ !<S$(Q1$*_I:JH% )0L$!
M#_!5',L %E!Y)) !LH,<6+ "DPD(Q"H!)  &&P !QIDC'W!GJG2R*\0?(*$&
M$  !+1 7*U"U]S0Z'J !NJ@B6?YJ(@SA5![@*^K" 9V# 5$C 61D8V$+ 7/"
M!1<  AK $%DP B9 M,WQ22!P4(.  ?[6)8@F 68 "*]46;+3'"3 -A) 9 X!
MK? (3PW!+JA;%B)@ HN:!1@  1*Q!;8+ :^GNQ(! H @!M%*!H% MU:"*/@Z
M)UX@N1D@FWHJO>J8$'S"C*C"  P!".!E" 0@$1J@&X3086!@ ( #!K3R!<YS
M5QFDOA"P<0J0%%[ $2" ?7.P,8702&5Q'J:R$R'" +:#"/MT*B7P3B)QN8/Q
M'QXP/((P .\" C[4 +3!!0? @/B5.M&S)B1@*?C;'( 0)'GR/"'Q ' RP4GA
MOAG4'/[JHTV7<2(1QU/G9"HDD!UD0!H7TQR"<$AD0 !JD$V(0 !S5P)+5@HA
M4!4/L% 4\ 6;40J"<!8G(R58@0D1, B6T$ :(R((T!P,\!]6-!F$A4R7LF25
MH "#<P%@(AB#T,1B8+_XQ !/ 0)=X@%)\06-80+V-087BI@3<4N:0 *3U4JZ
M :H@<0$943C%H0EUA @/,!=M8!>O.AA9  H'$")LX !;*@&#X\B3018G8%]G
M(!R6)BRJ!8IAT)FE]%T@@5DA853JLFZ'PDIJD"ADH+Y&41.!: D.(!6)T #P
M:0"F<@*<(6R*X 8#(!5LH "AP 9F)2+#HP("YR7U)1%F0/X;VJ<4$< ?&X 5
ML]0"([4"Q5$!/49J":4%[BD2V]P0W>PL&".D&6'.+! !I""D3]$"C7$G&W!/
M0C5.@Z,(?@$(SGP&_S6] 0T3US*< -*5PO*F9Q :R6$[FN A7M"Z@8(((- S
M8+ "K.0! ?,OA.L"_@>141<D?<$?6V "A7!%$T%DEWQ.A> :)X#08?( OP0(
M@N+$?8$<6B LK9&H5G$9K;$B#6$"2[8%%$ &7  &!V ()) S7] "= D?AU$&
M(_4!TI$&7Y !1"8&I%$QKB$(@J(57% <QR<D!C8!14V^AV & .VO#_ 3H2 !
M+M!EFRHE7/D%<)0NE6 P$! &BOZ@R+6A:44=!M]V!AJ% 2&B,8'4 F! !B&@
M&]#6$(Y] 6IGM&70!1& ,IB !5A@ J0P2@#":;*3'$+\QK(B*(+P !44=F3P
M7YE3 K0Q%]@F F# L!?J!D'RJ"T""J=5%(>UE^/4'!! 7HE<"BB0'64 T!L0
M*]LQ<(<0!EC0 !)A 1N0!;*I%9:D*?RAQ"?  63@!5J0 'VR)R-HT#1\*A.2
M&%_[3EE)-@[1/MO,W5M@ *% 5_T!'2<@ 0KD$($ !BK00!OP.6= &E.B1IRA
M 6J' >\"$EM SH*(P6K$2BW@0X$T.&6@&\]Q3H=!-85="AVP05G0,&?P &2P
M!62@ /Z3EKA>4,("K>(M\0#HUA :('<Y\1?;O12.0AN7P!E>D!-D%0&&P$QF
M\ 5G(!$?<$\>\"MHH (1O&)D0"@)(0$C#3$;$Z[GL1IN/3@@(0;%-!=JL $.
MS56#0-,9L1W\T3*6=AC"TQ#;70H1L!JM,QE+%@0'_@5D@$T>4 )G\ 6DFTT2
M8!-HGD$-.0'(Y05D83.&@ $L#5@;,Q=G^R!"3#5:$*J*O0:DL#5I=#$6" $C
M#@9HL!H4P-(B8M?X% $M  @?TTFN$:X6@ :23@H!=:5I<M@2D 5D  8F&"?O
MX=@'_E)E0NHZ)1MA4 *(0 )CT!B54 %2!P;%,0*T,17WM/[//U$)?X)BIS(&
MI)$YF:-&M-, RGFAS$(*4MPB(*$(FV(<Y3<L#90R!4@K$=@0QOWBL6((^>(0
M(;8%NY(F-UEE&]00$Z<4$( <B4 KUH'G9  (V60!MD-6-T$&L630Q]=%S>%.
M\*%RP_,7L*$"'H#G92 5YC3<E4$*;= "$-!O&0 &S-(<&H0EI'';EK ?&8!!
M=950;K  ;?UV%H"5Y''+I# Q.J'2%-X?/K03$TX:&L[A#D-D9! !>"X&/)P"
M'9#Q;2"1*R[U(L$%"] G9&  &PD!<T$3"Q(8#*T3G $&6U\*@?#@"S4(56'D
M#4%:A[!0:4 !A, J'2$HG504O?X+*2"%,H/CUBRM%7PJQ)QM)1B03"U0'%3A
MY&0N+.#NYQSP.:TQ >1! DO&!B/#";0A5&^7$0ZATR/% 6= !L74 F>QS0L5
M."KF)5KPYD+R7VXP,J! &Y5^*I>>YF:8!B$" 9NO9"R/&80%IT-%'AC@!O5C
M@;0ARZ].%W;!):(!)HXM)1(QJ*[!3&FN^@<QLA70)<34$%DP/)F#!1HE8Z70
M C0W772VVLS>VJ?" MVC ?7$3GZR3)WI BL@1;M-3K,I(+*1'5V@&R:PF%$-
M$*5*;2A3RA $4 )+/2@(ZL$@-BL$<L%0BA2I4BQ,E$H4 5.I2A!*A<D@,-$6
M@1C1'/X8)! 0@4.*&%0J%0I"&TX0+)5R<4+@!$* %%PJI4@!)C(E2SG*4BJ%
MQ%(H7( "D;!0 T0)$)4:]("HAC"ESEPH1<)G*3 52F%0(Y"MPE(71"CTL*'L
MV3 42JE040J4!$.ERE3DZQ>PX)(8S@P,6PK+W$,Z+68!988LR"P8X6[FW-GS
M9]"A18\F7=KT:=2I57=FP<!#!@9M]UIH,:$I()&E1& IA8D!J# /1JB  *:4
MI@T;5# <Z$4@AR]K-[2@X!P#B!;$QY22<"%4%P^"):S8 ,(B!$(UT<,U)*$"
MB <>$AJ:4()$A42E/' I%?DC%A(6:BD,#03:(*R'2AG! ?XV2O$B ?Y6F("%
M"?H"I0/EF%,H D!*(:.B@<C ) (45C@!@D!*080 -"Q2Z(SQ.*BJ%!-8$&@P
M@6JC#@4'.=@LLH14G$"$$B HI!0+-$ !A DX0<2!4M2 H(450J@@E#4@(,\#
MC%R8L(*-P+ +R<4&$2F1(8MLB4.!).C0A ;:"J64-"*@$H0*, 'E .?4,& K
M-$\P\8%#3G!!($XP\  %#D1B@P$42L#/Q0]U.[2L%EQ4PX%(*<@/! M2Z$"M
M2BP8P80('*GD@8\2>4 3A2Z!0!&03#5A@I9(R%0P$#$@PZ 'YL0(BPJ"4"$#
M$2J9 (05)%A,(3,2V&+55EDM!?X$#%: P#FXO&"  PX4,*X4+B9H(520'J"I
MA0"Y&\0-!D)H=E<1LH4 )1/Z*N6$OD"XP(4+^N7 !0D/74$!-MI0RY+K3I"@
MI0I:1+)%S2K!( (0)+" )H9!0,'-J'C$Y(' R+ @*I\P@:#DBBHPHY06%/@5
MC00DZ@("%JX3: 0+6)  I=6"%GIHHHLV^NC3$BD#C8\4&B2,P/S:"B2:2 EL
M"Q,N^2+JFM88@R:0B"J**%+:"*,EO])H0\5#0 *$%$P<,8F,M05"),B[-PO%
MC3'0%@@3,\X(4A&R$<&H$IKRQB0_CC[*&Q1 P!ZD;:["2$\A-L:@%2[%&:?D
MHTK,:/YI$)K,#!(N1\2HF^J_&:\<;4PV5PB4J1$]XXRF*PBDC3(2 H7R0\K8
M"A!.0"*##<U*(>3LUDWZB':!*BNCZ;Q5]#URN((?/J'':[_DC X)J>02L/TZ
M PWHER*C#+&;1UR@]Q6J9/V=_%JC#5 8!^4,]BV:FI3:V4TS^S-#T^*W..=)
M;3.#,,,E()<V,7#-:6T[!$8 J!! A"& \C.#&<IG$.;5Q'"EL 38VH8&#V B
M#(* RQS$,+7XQ2^#';((&]0 BDJTA!212Q\HU# ]DQ2/(T)4""D",8:WS>Z'
M!C1A0A 8OT,X,3]Y,R+8#'&Y0X2!ABX) ^60]D4PAE&,8_XDHVBR8)XR;B9Y
M:62C:%S @"ZX"#6C&-H#MCC'-N91CWOD(T;,H!8U\E&0"J'C( UY2$0*<HUR
M!,WAMK)(1GYFC9 D&B4IB;1%7D0U& &$&QHYFDM*DCT)L61G,DG&4Z8&DJ'\
MI"GAPDI1;M*5J EE*45S"<JE4I2PG"5I;$FT0G)FE8DD9C&->4QD)E.9RV1F
M,YWY3&A&4YK3I&8R@XG(:_:QFMOD9C>]^4UPAE.<XR1G.<UY3G2F4YW$Q,B<
MBCA)B\ 3(R1X62CH" H1Y <CV0SF/CO3SU*,0IZ;Z6<V2<%/OW# B\E+Q.J$
MY1E-W% @A<0((N8BQQ-LQY]P"?X%)#,J1W>68@UR2TDVBWA-"[X2GB9%:?(&
MX;>4U.2=)A'!Z2@)T$ *Y*6;040&?"+02!X4<ZY+Z2LGNDZD)E6I2SVF&KQ8
M$P=(L)FDZ)]1PP BT2"B ;#B3"&"!9<U',DT:[@<9R(@IT/.DT>D.<0#3G?4
MTV#$!&=QT0K0.)H*+,:D3.5K7_WZ5]"4@018$%LB6G "V0P"$&<8@1CLQ@+$
MNB0_EV@!"@!1@<!H8@LE$ -&!K$[+7!D!2B031'#4((L$$6Q:A@!&# 2E#6,
MX MS4FP;F@(*+Y# "PFIA!H&<8(6$*42:S@$"RXQAX]< @LE,$XE1& !,22D
M#"7  OY77XD%"&"!)FO@5V &,8$YE6$.I0"$(SBAAD"8P 742P$+!%%:KB0"
M%&D0A'J)<@8(G* E@D !"ECX2C&8@+#P:T$)GB66$K0 ;+@E 1<20HBZ*;84
M;7B:"-I2" QPH+284 ,B%(S@ 1]" KQM@0G:,HBZ56(QAS"1;-H0"#"0H$6&
MR, &TJ 0#'>@02R.K$#2D&":J$$")&A))0!4$(.T 1"\&00*4G!'P$99RE/F
MI@HPL ;B /!>:K!-*;9P@"Z8@0%AH8 6'Q 6##AG BDX P@4D!\-K" 0'K"9
M D"PVPJ  1!GEB,(0,!B\WCA "TX@P5*X* #L*#0A_:"G?[YLP$2M $$X3&$
M >A) KT8 @$>,&Z")!"$0W" "Z1@4EA<P % N& #F<3" Z9"!@@ @@S@/4@I
MLF"!G6S "Y<@ &DW$)XG:>$,&,@-1G3-:U]_0"P0( $BV  !,HP! K*A8PDX
M8(@6A,<1$L "EP]U+C6XX $[X4"D25 @+(1G+R$H10C.' 8$""(122HM(A30
M@12 8@L:6'))$@$!4E2" EUP@P7 YX NB0 3,A/$!-90EC&#(0& 2 0&,E!:
M#%\Y$0P@@R JT!9BI0$+,V'# XB,"0FX@ T8Z L9$@ "+HA8#6A0 )2I?'.<
MYYR83VJ:%BQA J@<@@$]$@B 2/Z!L%)<(C\>0,.P[9: 2YCA9"!1 ' F()!+
M,.#A2H<+(!*R!@DX:.I& <[8%P *,5S=0U/G3N1F\A,U5$(!CYR (4@Q7L<H
M6PP^4H0#2$J!7ZT131\9Q&0A@ A$8, %6 5!&"KA ,*+1 6'GK#:,1(",%P"
M\LH#.)+61H&7"8;MY/W('!Z ,H$8P@N5: !)N>!LM9=B G,@ QI[HIM=@: I
MP(VIO0-3"08P#KJ7./T*VN4&D5# DQ9P RA2="W>D,!&NN&-"J#B(NN#!&T@
M0$GP!>*%#BEF+^T"O@_=RA4&_/Z#.F=_^]TO1HRH02VD<.<%7D8*4$"@$EZX
MJ!;F(OY_">B K>" ,U@NBP"%":B$+9" $@ !$=B 2^ _OQ"I"I  #@B@-O
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MP!T5B%MK 2\("R^0&"]8,0_H4I!0 7<"!51M"TLUU+I @2 A WW!!!2X54
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M@$GV,93F" L(!!7X,/)* 15H"?Y.2(-$X&9"X N8PDJ,N(0;(V0R((%G@6E
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MJ-4$A(21D'<*6;+2(0Z\)()V0IF% 1L3J<!A$*4X(L%[B4  BB8HN 8!()A
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M@T\=I0:X,C"P@ATL81&X@H8M)@R?NL0)--"!AB%B:V?8P 96<"(OT(D4+N"
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M R)0 Q>R< @Z%<0%XBW#RS!, K.AV@2^*E-AJVWM:V,[VPA<S$9812MN#U9
M=G25M[7M$7!/I P!W(@E5E#N;F>D!8'QR+L96&]M<Z+$&$'WM^EM[G\#/. "
M[[> "IZ1N]S;/Q7!J402WC61E/Z[-@V?B,/O?6\Q><0$(%2X?UCE<(P@'"3O
M+C>WO?WQB>"8X@I!-R;*-Q%P"TCB*[=(**"]\)E;A-\XG_C#>Z[SD^=\Y!>!
MN48,;JB%6.XC1K](R'DND9([O2-+?SE%[J+SG@\\ZUK?.M>[[O6O@SWL8A\[
MV<MN]K-G^^IH;Q70$ZAVI:\][F1_N]SK;O>[XSWOU6Z[WOON][\#/O""E[LB
MQ.#RD?#=(V04+"D \6>+<"%D'>&$Y#DRI%91'MN$P#$H*F_ 2@P,[Z /;!N>
M8_<OEN(0\U:(( [O]4N :_"RQS;=)0*:$$ [\0@TR" >H/N.H)NJ<@(!N*!^
MJ8^L4?[F52]%$%1(E]A_1 05B^7C"0N"O$E&?G#?.44NX8&(K OKB#^(%A98
M;TRPD$N]&?]&S'#4Y>\^@08Y P7&5"5!Q$5&',^Y A-;I7*C0(-TS^P18&$-
M!,4A0HIA#U[43D$D($5PPHF @B(DC\LE$T4D@@):PNJ%PB$HH$*$P@/B1>,D
M@LL9@LU%H$+$44=@ N<IQ 3P6"DH@B.HF(2!X,T5@L0H@LLE @TJ! D<!RF4
M!B>DG"4D JN @LMDS',8 F3L(,KY($5@@B%XQRB\VV*$@B&4SV)H@D$$#D]\
M"K>=2 @FW40X0A0NA.!,W!/.S/W0AD18 AIR B(@(15.!/X1W@4*7 \2'H(2
M:D4EN-YG8$PB^&&F*.!0]4HKV8=67$+*X6'$$>)$8,(C340HO(<*(,]"($(A
M?H9$ .*,(8+$3>&)+,:=/5XBE&'@5!_"I-S3I)AWE6%6-,J,>8<P1<:?N6(E
M(@(NBB!%Z,_$@4+U@4(BG")!&$00Q$5%C-<L]J) I%P!0B-)@ ((N, &3$ J
M#4(&@$"2X<4+48 A>$ #9, 494 '6 "#@4((;(' P(T*0  +> $&0,!O8%,(
M9$"5%(('L( &/$#L1!%E944A9( 'V,I$(,*368!3_,H^0L"X*,*!W&-!B, 6
M0,",@  '9,#6R$MOL,%.K, )C/[ !'B =W0 (F ! \ .3^!6"'B'"2C51'!
M?32*=ZA 24G R3P LX$"8F3 <9B! T" 4U@ "K3)UF !!GA ^K% $$2D0;@
M \!@(MSD!CP =/%03U+$%V0 "5B *WE1O_R+!Q3"(*R'!93:(5S?2AA"!63
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M"%0) \R(%5'A 92:-97"=RY$!CC*"?"'&F@?!?P& ] C(64L:[@/!SB%(93
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M[40H. "8:4%<1 #GO-644)D*5/[ EME)*0B"7H"";*[  _R&MJS 3?R9MK0
M5ZK1 [217J3 1:G 4-+%P- $"91 ?!=$!DB0!CA*L"3%4BQJ"%#YKI  "_",
M 'G&@@W: )B&"7@/(: \7GBJU)2 "6RN8"2 /]\1T;\X![# :9K+T6T%*.T*
M+%W1DY" U'/ZDTQ/"8@2"S2 04R 48#"@01!"D" &#B" UP6!)0\ S#88N30
MQS+ "I@ '#E)!42]O$YK!;A !1S'(3S 4O,**50 <>^L:D2U!'".(:1H%EC
M';7 P5M LS M-!U: O06.[N !:3.KA@)(CS^T8U E1A,E:;&N!J2!40$%DA
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M8!"3*84@!F$&$F21%%\H 1M00T?KJFH%')B#"CC0P ?LI+N".  )R! 3B&P
M!8#@@$T.$0$LG $"7^"$!R8 !O!NM[N@L( ):J2 O4G@D)5HP"5,P %#H""'
M6\BA!3 Z 9RT8 -NR*Y)$B&!]U* "YH @02"JR$03"![)/X('1<4$"@/G& .
M'N#LA5S @!9@PH=B6&Q20@ !$"BT AGPX(D!X0&W;8$#E)N ^+"P@39 6"<8
M(($90)" L^CG$ P@@TL.X8(<#D( 'ER!"$HQ@144@@.R$8&-TU )!F0A#!>8
M #Y%P&']<J ,1^%$*4!0 D" X(N0PX(#5@"*$+B@%!#0 !DX4($6>*'$I6
M%@V !3,\0 NE2 ,#P@ &!^0P,5D@"18@4(E#7  #746#C9,[@<=>@ 553  (
MME )$D" "Z7@ @;:$(0'(H(!F.!" U3 "1#(IA08L.\$BD*(04@@2Q,@A$DJ
M8%]<S]F M,8"!H"(%@D8H@+B _Z#!DSD935@H 6C8$"@!/& 463 !(8  6?-
MD  /8*$2)8!U*"3 !E!$P QH6 #[.(( $HR! AG80@L:4 HS $4% D'#&A
M IMXP<%:@$ B,*$ #I" $T'P "%$@%7 <,$!*:#D [P0A@1XT L68(,6,##G
M&;%! 2@PPP9>DP*W0?P,6XA1J)"=!08X0A,G- ,$0",!#QY !&< P:X P8"2
M2X#;B0'#!,R@\_%@H (@B"@I'+"D*)L.!( PP2A!-X==8V(.$O# (-;P79Z4
M7 $XP0@:5#" V5X7[Y5"Q -&X^!2G  $-J(/ T8# 4"@85<<68 I3N"[04C0
M-:%Q0/ZI)- &-#S0, H C4X4W,#7M&'.+I%U#C?P2UICHH@C.:1&2@ KPS#
MX-TU":&/!VP.3'F%:"2,3A(Q@3G[O8J["H$&E0KH,B0>C:"(/!FJ6@D'[*D"
M:F##"A.Q@&5#)!'W*84'P* (")3B"QV0C<I/ROD.E$($7/[[%\_P@*=%A-NE
M,#I$B/X3WG"Q,)60P$Q&($$)I"$BJ(@#Q$<"$.$,, \,J@H#, H+N$P_+L$!
MN ,%6$(%5FPC,@ G5D"#.*(!."$-3B@H'N@2#@0B%I 3(( 4+J&TT"_6MF^(
M)* %,X !7R,Q(,"#*FS.5.,!=&,#Q$=:0 $"'&$0#@ 4R/[@@2Y"7QA $U"
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M#<HQUL;HX:I*/^3B"SZ@BKK+A, B-;Q ]H"P)%&  S3BDP0E@TK!!$K1X!A
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MT7<<"_52 Q0<P'CTIT +5 -4H#D@X!+ 8%?"( *(HP"R !3&(-<PX0&^(N6
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MS3P@#-AMA2!"$TJ !$A!!72CG/X#I)4O: M0YPNV"@7. A!LHA2T@)%.X*Z
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MB=S7NS%! D  IAOBB\KRN]=P D!@]Y[""QA@=XHF)!N"N9TB%#Y1Q"$$]MC
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MZ)M3BADH)K 53*0!#+^,SWSJ X%1J& #9P"#%Q  GT24@0MQ4X2SPM"4"JB
M#*'S%4^XX)F*C(("1H& &-: *705BP*!, .G1/ OSHD!!,]<P=6, X@A8N!3
M%]@ 1?ZY1].:VO2F.*5I*"9PJ%)P@02!<  9O&"^2PQ"8^P+0M,<X@$S:.%J
MI-@I6HB6-%*00G*5B$"DBB6&/P:PAV8@2QF\ (8UZ.@A>N.$EP0RB @>!C,E
M2(T+,'#0,'S*"Q@9 Z?:\( Q$/4,F,!"<HQ3 :/@:0T26 $@2,HJ,I  $20@
M@[D448$#;:$I(&AB!O)WB&B5(@L %(@%M0"(LR2B?W5D%6<]JY8HAF"*( B#
M-,/@!2^< 4V8 0/$L!"&+I2!5R+8 !A>-0I#6" 1F#(3;<U7B=,ZI"* D$"Q
M\.0!EQCG>R+=$$8>B$E"&A*12SR,0[[W2 -MC11H0 $#,OZ7EDMF4B!ZY>)E
M!U*LZ*J@#2<X+QI2P( 6S+:V9ZBH0#*0-/7)4@*7J( +:%L&L@EDEF(AQ01:
M0%LR&().#B$%GK(KD F0S825.!$TPS/-+WC!#)4 @[GV5B#,=/-<E IG)1X
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MTH)1@6!! 1@)PQ"E.9-$*2H-%GL6K [)14 @%0-M$$3F1)]X1MO^]KC/_8Y
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M"/ A(:"0!H"50F20"&.P<2-[NJB;NA\+-"*@+?X'-"10/VB+21/@(*L#NQ)
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M9 A2@R I)#D_F)NK8@;/]#&#0?X1_ ,?KP5(% $*#7 (TB06B*  :&(<9<
M?6$F!$&M*D I$'",SV(N'&!Y6L I&[!(:NC$V)S-VERHWM-3< M(:,$!9G#(
M\K4Z][8CAZ W<60G[I)X)+ UWN,9<^8>*Y "]OM<;=  *_!-D<&);"5=/D-'
M%% M<51IGOPY.X+0'?@3R.((7B !+H N"R T!9<_Z@0"8E (TB4L)= %R6%K
M8L  # !)ZL1.8T$"_!-D)  RQH$%MZLN]N&$: L*- ,@*[# #D *47&(\*$(
MK@4>'DAVB% &?^00@5$LND5?%8 &%U")#D)(#A8&VX46#-08*!2PVYS56KW5
M$4E#E?XV7^=L=6?@+O^K*&%=$?/:)17E!D@%5_?Z/0,A 8[@ 2Z@"( P.=!U
M;X(P"(@0"D>%&4>U-OD3V"[8&1XA75@M$ $;U!!0"5ZP 79="%N;>" @0)Z,
MT8A ,Z)U E)-**KG:<3A+E^P0<,6C':R 11A'%K0%)C1 6%@"2U8++A$!JOC
M 2M@UX?@"#G+!B:P.?S32[E<=AWFM5,;.0SM%ZM2"A7 !A9PN7<-'\JD78 T
M='7D/7$A!J;+U=J]W=P=J0VP160G&88MV( TR'Y2"N/=D;Q3"B$@.HR2I2$P
M'S0M& Y4"6) CV3 7MZ#( 21"$H$V(FS!<32@VDA DTS(/X"(@::Q$7W71R!
M=%63\VFE< @@D&'LO83GTA1,5 H1(!F<  %H4 D*\!-N8#%XQ<?.8@@.L$X
M%"^(L@&"X 5(T\4-\!-FTESKDQ:8H $84&46X&+'6$B@L@") #>>$75CLW5"
MXU"#L +-AAEEH#)*<RX'C@4ND>1^P2DG,#\DL#H@,)#9RYFPV=UD7N9F/B2P
MRQ)+A0%Y*0)2 @@6\ $5 #6@P.9@ZK.#B D?L $^#'%GP #@@0&>00IG40HJ
MT"$?,C2#4 $L02F$H'6#\$RD8$HN<I"U"B 9( *1(D8[@@@3$ )W9C\8L!4U
M# (3@*X"<8K0AP&WLM)SDKVG)/X09? P$W 78I#&F64;?+QSMRY('5 &E5U[
MLV[J]'((&*"8(NA*+5 !'6 !O$(&R.MWI  "2:<"AX$!<9$!1H$)='PB17??
M), !@ <J9J$!.?*#E50&J^,?"I)W)(%G(G U" NN9U[O]L[=-+V3L&EK44H?
MA<"3]$H?Y33AE;9[.5N3%5$)FWF2_X[P+D@3-L0C>/VM+A@IME:8FC (>LM%
ME\">$U(MI-#PM0JD'S\A!]_O454*+C 39%=U(T^L/3(*-JKP0LH)]*GC]($G
M_&(2+*"?#."<^S8G$(<( F8R,.>6(=]+%G[O3-_TVQT*%N"6#ZFI2N)*'ENB
MHB<"%?X 3C%O>RN  2%PZFE!!DVA\TY_]FB?]CZR\6J/).F$G"1:DDY("@'?
M]G9_]WB?]]6J]WS?]W[_]X ?^((_^(1?^(9_^(B?^(J_^(S?^([_^) ?^9(_
M^91?^99_^9B?^9J_^9S?^9[_^: ?^J(_^J1?^J9_^JB?^JJ_^JS?^J[_^K ?
M^[(_^[1?^[9_^[B?^[J_^R*+9CFO))AQ]3SJ^]PC_&W*^]Q-]<B__,S?_*!O
M""O@ EFP!2V@ H<P"'<!JSVB" E! G2W]\^*K%T?_A3_I_MB,$.WID!R!DP!
M1V:JF$K*+U'JV'=4+2Q+\9BJ_@G_+X- +\U*_@!12B I@?X%2XTJ> :008.7
M0#&$6)"@P8D1(58<:%%C1HT8!8ZZ1%#-G(,,/98ZZ2710(\(36Y\>::-1)HO
MU<PLR D3Q8X<:PIT:#$,(I00@QHB4_1E1(\GE9Z<"'6ITE*%POP$Y>7A1I>E
M$%WM&;$K3+)ES9Y%FU;M6K9MW6XTI"++! A83E3:TH'J1D *3IP)@B"IT[=I
M"2*:\%#%&:J$#99XX*5,!@I;"Y<R%**4H@D[2V&8Z?CL(1"EO& HY0'+WK,$
M5;,NE8'-7M&7R=8V>TE"I5(A6, N2V)0V[$6L5S%37#$"J4N4 !?R\',P8H$
M):2QR"%IF0FVO6\DV.9$Q$H,>/[?+J5&@MOBW]V_AQ]??EN"*DJ4>JCEA"8R
M1 5B.H.-XB#@HI102CD#@HG:,..2_S!)Q Q.2%%CH5(J <60,AP42), )\*0
MC36VP@2-$0L"I#^!U(  D%! V:J2,BP$I1(  Z&)# 8LLZ# "V<LR!%0UL 1
MD3,XQ'"-A1!I$*6=V&BQ1@F^>(B4-L[P#+\SUC@P2$X$4H2@&DEQ$ P/>O-1
M($[04,.R2LC L2"D#A%(A"WP,\3-";02") RSBO(H4/^+"@1,A8B)9&). '4
MH4((%<@2,]PPJ1(/B0HD#<O\/(^32S"Q<$Z&YH!@C5)*X.)-0 T%!"%0+I'1
M$(8P.?X0%#72^#*G2SBQ4$8+!1H$RTI>/ \3WF LQ9%0 'G(UC8+)4,3%%PH
M*)020.#03T48LD230M @!90S9!7(D3)PNN2"+3P+I(R5/FLC6,M*L<2"U<[P
M )0R""G(5DTA0H2,X00*A0TT- &*$T/."!<-?B\$I8V99.0-H4LF%:A&7@G"
MQ(PV""+%LS<_+D4W2S)^]\(O"1%8H#50LU&@F+TBHY"+V,!29F,'GJ]GGW\&
MVJT#3R !OU*ZF "%$1B8Z1 +4 #!@RY+F6-'I58"Q0,/4)!@-B\D4"$##E0@
MX8$"1=B !! >&,[I$T*0FI0*0$"A@C,KP8#L"1P4@0,M*/XP%00&/+@DA"X0
MG$"%#4HS! (33GA@M8(V",+  XTM)8W$%T?) A!* )L$#R38R7,30A\]0])%
M&!R1+1C 0(U2HE:A@N$2L>"$OJLLY005O#I@H2U(J.2!4L+0"X0[+]< !=!7
M6F."%39XKA0L+&BA@JN4GWV\@K)@P (T9A]; MDG.B$#$D)P@"0P)MAB@]\L
M*$.@$JA%Z 0,H'Z J.A3X  (+),(")1 !!-@ 0DPP &!C& #*9  8\AP :V5
M8@L5R!X8^D4"!FS $2QXVMKH% 8);&%LI2@#!(C&@.D4A (DT< )3@"!E1"D
M#)YC8!LDL (.W*<4+9"  1^0B/XR,-""(B@%";  "@F08 *)P 0&2D""#/ F
M05.40!8,5(HV0$ "JRE!!E0@@?IM<0464('G5BC!+'I@/%Y@0 62HD 50*!^
M&?! "C"  <MXH0$4N,D#3E "!HSA0AH@00DP *A2?"%Q%?C=)3+PN0D,)WLI
MN  (3C""!DQG VZ4  K4]@ Z 0*2'BB-&CR7@5(,8@(GZ  K55D*,[31!"6#
M0+$D0*=*1  3U]N"!;R0G@KTK@5UNA,8,&@!+18$$P$\P01PY((-:" %0<-F
M-K6YS=X5C2!<*&8I5E T#!@RB7=ZB!BZ Y$6?&!%$##-.ADPS%K.[DS68V4&
MP$("+?XRH'Z88( EUK">4I#A$*!HP4.V4)I#="8U&FR A3 @ADHD@$Y=-,@$
MDL(03CC 0AD8Y@.N$@8%/*0"]7/ 2*U6 314 IZ5()U +#";()0&A1LH!0>&
M:<PMKH$"*)Q @31PAN*5PDRSNQ-!H"20,AB"%! 8F 4 80@)$$01\"2!%UI0
M/8/$SH*L+(4;'O 0A%!1(%XH9A;XU;A&XA03$2!*66W*@0(] "<<T")!$J&
MX9@ -9H(:!A04PI , !!!Y#5("3P$)B>#"B[.95-7X.%X2#">&=PP$.X@-."
M5)(0#B"(&7"$$#0<P&:DF(!$UU >W@S" &\R8A9*P\]0&/Y #'62' M^YX#9
M@.(!6G1)"\;S!0L RP$[(0@*&'@)!,@N"WK9PD((N),-)(6X FF#.RMPIU)
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M<#CK& (-G/4"!(2[ @;,AB P70D_!:)$_'Q!!2!0<A$%0@:<3J0"E!(!!$#
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M@PL DP?P#$7@A)?Y#!((! R\L%S*"0MP@PNHD=]*A#:0I>(R@1/[.S>0 $0
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MSD$$4*@FI5,$3?!05*& A>B "> $%-"@0+" #Z@ :BD$##@00Q@L.;$ ":"
M!VBA0: @"ZB<4<" X3 #FQ*!Z3A26K(I$&BIXB(%#WBB],*\4J@=#ZB ]_2
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M5]M(M&Q>BT33B KPM8TP@Z\S7%EQ! 9PD!@6 21$Q) K"];JC=7 C4L(8HA
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M)H7 ,L[)A(@@"!/"0 ;BPL*#)%%W@"@!>;2%PK^(8>1_),-:0D*&"Z32(:
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M:$ '6/[ YAB$(9" %DC )3C"!G0 !A2D&$@ !K0 "/#::+C!3JS YHR %TB
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MQ[X5Q 9(!QLDP%ZTP-MEP6B8@$!,0!M$2@9%$<ZY+#HZ@,6\X2%4Q^.>P7D
MQZ (D6=P)T'L)9,^ %)DP$@6YQF6 @1( !@ZP%J<00!L#@H00!:@ 0D @!I8
MF[GX2W>   ( QR"T@0L<P'NH  '$!:2N01L  ,:! @10 "E,  3LZ@.L!28
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M011"&<"F2C(=%GAB%%V"!.!,"<Q+"#@(!A^"&GAE!O3,^F6763+M2);'&D"
M&H1!U@J"&BB&\!Y$-=_=IDC 593"(8P)"F@+2,],&(  E8B!-E< W2WGVTG
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M[+ <]^!*8ELPW=&VPBL&W@D$I"J'(&0!*.#=X92 <"M% J0=Q"D" KS'"1"
M<NRI&E2" &Q&F+8$[4$ !R0"O94"Z'F!)AB HY+&>)= >8\" T0U UP"#YNI
M"@B MJ   +2!M<7W?'M&&@  %DP+!"3B\0G0&C\Z!35))00X(-]*!1S.!ZA$
MQ#>B"/1,(+>&1WO!M(X&@20" DS%$&J'K-K$)2B Y)"" O[@!954PB'P^B5
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M[RRU!D.I+13$YJSTI2"IFBHDBBF5P$U!#*Q=)PQ3"DWI4FI*@PA2<%"94A8
M ;( $R:&L"Q$7&)PLM2$-('PAK$0"L))#KO5+">!HJ 9":5:I"C(@CPF4FD
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M2H0"M!DP!!-I<?6XE HJN&3:WR#PU@)0I'.L$@;6;>V""A))JTZU8<I/!%!
M\&"+-,%8(Z-2G/M* UMOHJN-!E!088$P1H&  T\Q@ HF%1AH@XW3S_!, A):
M<""-4B1H Y#SL'+3@FD?F"L+K/XU> DRFB<(XR&:5E"@C3;.J\3/%A +F-R
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M6E,OV%,GFN"$$IF3 34,"I.#X,(S"\(),G AJ/1T*B*26!!0D.$+$5UI85:
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M@P&\X'=<:0+@(BL2 0%*P LF@ , 14Q X7G*H +.X@P8@  Q('VTHSH"(:]
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M!<ZG#""@9T2 (EB.5R* 5EP##! B29&GY0I+"1&1#9BG("8K03K@A<0#65
M,_+C)&RSC2Q@-[1"+]KD+CDA <@N-SB!W I"(9#'$ 1A&BM #30A >+' MB(
MFD3@)B:@-EQC<M9"!3B",1Q!"Q*E$AH %"#T(BF(("@@$# A M9% X2B$B#
M5'2D4M?S.,A@6W*C M: -$JA1.?C5;1@$-:@*C2@3;* (QA 1T8P*T1 /A1!
M B1TC_X@X%58)=8LH'4V@"), R&8<EN*P@+.X!#@9!16@(M>)5$3@D!8=6A<
MLA:M!A'1ABX,80$* _D@8UU\L118<R5 @0'ZYSCSU8MR0CTO(6LLC^*BQ -V
M Q0>J"=\@PW<93>^K3TA%L20[J0@0 2T40.^IC%<@%R@@@/,0 LX%B8J(05
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M8FC\)K94 KB %-!@.JJ#(HB3%#!@CM?@ &1CL#]X 4)A##@$$S: /$I@UTY
M/BQ"#?35K=MB 8B$!'BB#0B #*2")]R  ,2 %+Y 4I21#4C!!<@BS5D$$!@
M+L@@EIS9!$B!-3$!%$8  D"!$QX@XQ@ "JDZTU7KR@:*%%*%42JB!.Q)$#C
M74II$#I  SS D-B  T" #+R 7,A >-?@)D@!"S(@ ZS5!0 P"%H.L7 ] TQ@
M7<+ 3_Z\X"Q"0 5*X )0 "I$  5*P )20'=P_7YKY7BR0F(HPL 9O12X( U!
MH020"@0Z  O4P -.P@PHF#D0006X(-?!:A!*W0/L<#RBG=,HDBX,,0. K2
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M!.Y"X.J'-Z_-=MMNG^<%!%AX@(%#'70PMP.8',+ "2LX *D(&W"A@@18#,*
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M,(MYS&0NLYG/C.8TJWG-;&ZSF]\,YSC+><YTKK.=[XSG/.MYSWSNLY__#.A
M"WK0A&0NM*$/C>A$*WK1C&ZTHQ\-Z4A+>M*4KK2E+XWI3&MZTYSNM*<_#>I0
MBWK4I"ZUJ4^-ZE2K>M6L;K6K7PWK6,MZUK2NM:UOC>M<ZWK7O.ZUKW\-[& +
1>]C$+K:QCXWL9"N;R@$! #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>comp_0008.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0008.gif
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M^/7Y_/____?X]P
M
M
M
M
M
M                     "'Y!       (?\+26UA9V5-86=I8VL-9V%M;6$]
M,"XT-30U-0 L     /\"[@$ "/X -RE:1-"1(U&?^D02Q5"40((0'2I2M(FA
M0#\5'PU<Y&C10DA^0C'$U&?3PT4#%6%JR/ 3GSR+6*(T2/ 32U&0[N31=/-1
MGCR<&D8:*%+4T$6A/FWTR#"4HX$T*PYL*(F135&/="YD^<@JPT<<%76,B<D/
MSY$_)344"*DAP9MPW8I=I)8EI)\K1_8Y:[%/780O8QIEM%64HY!Q$RM>S+BQ
MX\>0(TN>3+FRY<N8,VO>S+FSY\^@0U^^,X/&#!DR9FSJ ^,)RSRE3Z=>/6-&
M%89M:M\11:0V:AA0>,N0@AO&G3HP2IN&,454T3L\4,LXPA.3#=^G^S3\Q$0V
M#STMN_ZCQE&'8974>1@FF5%CDY_2J6E$<9C#]&\\HG+(F,,0B8RV3\AF W\C
MZ2"#&\X9R)YOH[P! QRXV8#:#%&(U,<,-ASTB0XZ%+78)O75-H,1*WW2A(!Q
M%(=@0XK(L 1#>O0@71*A+")##S;96(2'HO7HXX] !BGDD$06:>212%)VAPQ%
MN.$D@GS$T(1S(NG!Y)-PA,('AD$P5,1UNQ5AVY/:B3F#'Z*T 8,=DKSA1@XU
MM-&&(@T]@N$<C$ 1@Q&B:)*##FTXV49>HC0! Q)\Q'&:6DS L$0?=AB8WA0T
MU.":)CK4)Y ,0KC11@\QW!&*#3HX"8<;DFPX@PX5)2%#)/Y^'!I)']?E-<<,
M.1#!4!UN-#&=DVD^* IR/=S1AQ',B7+AB GRP&-BF^A@0Q5N( '#E% <V@=T
M,NRF)H)%M?BB).RYP<<2+S A2K80&B$#FDG&*^^\]-9K[[WXYIO9DL2Q9&5P
M#?$QW$UZS% $#9%L4H.88<[ EY<VX."#* Z6Q] .-K D4A,Q$"B*NTC5T$-<
MY(Z\JQ.+8#+#Q P)S">E0>@@RATT$$'#INJ*8D<,S=6PPTT@ZC##E*YB8H>+
M"VWRR%5$] "%# <Q= <,MQ4'H0\S1+T)#C8H-<,.,^"G@[.-?9)##A;-0 0F
M-9"MK RZOA'#B@RUF(0H4<"P8OXH4,R'R0U!M)BSOH07;OCAB">N^+VD_:D#
M#@A:.65#!9/Z.()+!H@':4]T*XJ8'.K@@TU$Y%#%FG' 4%Y2.[3'8V]JB71Z
MEC74<,011N GM914-G0'[R)M0JHH50P]0R11Y)#$S2T:L8@?2<# GPTT<&B#
MNIO08(2OD##QWR8\P" ##U#4%<EPK#5G4QT\(Q1L':'0L(-((OGW""0R1!$$
M#IQP^&Q<T;(!'Q0Q!2DI(@;JHI^T1.$&O;%$7)^; 5*>-865W> OB\N@!C?(
MP0YZT'"DZ0$3F."$W>0A!L$)195F($(2[L9*;MA!$Z+  S?((#V]20()H6"3
M@V&B!_X[:$,,+!8*C%6$)4&80>R"!2$;M&T'.("02'[GFIMD;BUG(]X,ZC #
M.!!A"5"8P2?>0P/I&.$3(,K!")UP&X41(1(S<(*O!!.')$C(!C$1(IW&UA#V
M-4<D:H*?SSSD*H,PAS55B-G_X!(M^XQ/$GV00<Y4J(,:,-"!*A0%!(D@@T<
M< ?Y^Z H1TG*4IKRE(]9TGQ8(K!^M0P&JPP8#/ 0A1[X  IV@ $.Q7@3,84B
MDE@C4!%M<,2&>$]WHO /(^(GA/^1BV4Z.P(?,,$I%C&)>% C@A%R4 <IR& 3
M-B+"2^CD$!O\C"4*$X(HJ,!"&D"B#V^P22BD (,VB )K/OX8PG7XL*MD 5)8
M8*M+*'AP@T_8*#A?&MLB;[(A&]@A#WJH2,G<HK9@>4P4C'#1NF*0(H8T@0E7
MX1B=%HK*DIKTI"A-J9!@8X0ZS*$.\(MD2^L0AT?(%*8N_:4,ZJ (TT!*!N Y
M6!M@.@<T%:$&*UE";83) V+>Q \RT,$='G&>+@GOG'!9PK46<0<<R" F28C!
M$VSJ QG@IPHQD$1NVA-&G 'M3R]U::ILT*50]( &"&O##Y  B4@T2@_D"L((
MD3"#*B+G-O^$4 .)X(='-"HX!PP.)/"*H\9$"VTW:503;!J$(:9)!DW @TLQ
M8:,7+0)#>'"$%%Z !&/*0#LJC?ZM;&=+V]HVYF@SB,%O,!&EW,K@!5-@1 QD
M(P,8S.H%;@A%#680BCB\8#=EE0YK11&$5QG%!AQM2@Y4 Q<XW$ Z06B+)E8%
MK2-(9XL,T82[)E2U*<#@?C#HDE97 P,^>4AAJ-$M<D7!0JFEYA&A\(]TG+"N
M%Z3'.;42Q1Q>,!^;5&&_>)..BRK"FLD54 =7^5 -:,"3^YIW0LTAGOA0\P([
M0&*Z.O.J#&)0A Z+(GK\M*V,9TSC&G]P$WM@!",4H>-0;$+'0([$)W(,9$8X
M9 \K>0LF]L"31>P8R&I91!^*TA5"^<'(<<$$'LSEH3Z0,S&*@ ,=,*@L-]3A
M+Y'80_Y%]J"6=Q[9DQI31!]TS..5[$$PFBQ)W>;@!BQ+V4.+X$-%,$$8H12:
M(9"( QSP_..V.(</>&:,(N %%T; 80Y_X>V3&;&)(3NZ3W9P@QYX! E!V_C4
MJ$ZUJE?-ZE:[^M6PCG6J__>LA9*4I,Z)#*[C0K_$V)HR1=GU382]&&)GIM=P
MX5&M9<WL9CO[V=".MK2G3>UJ6_O:V,ZVMK>-;64W16,-\9"XPSWL<A<;W.3^
MMKK7;>YTMSO7Z&XWK=W]ZW![F]?E1C9D[@WO>/?[WP /MF(666^ K]O8!/>U
MN^.-<'P[W.#];GBR%<YN>C\FX0_'.,0?[F^&9_SB'/?XQ/XK/O"06WSD&T=Y
MQT\N;Y"K7.0M=XS&8TYS;MO\YCC/N<X=8Y">&^01/@^ZT(=.]*(3'>A"!PM'
MC,[TIO<<Z4%7>D&<3O6A0]WG2J^ZT!<JB:4S/>M:#_O3B3YUL8?]ZCZ'B-F3
M;G2T][SL:Z>ZVQTA];A7?>Y@M[O3\:YVO3>=[U[W>]O)#G?!6]WJA3<\VY/>
M=\4?GO&!]_LC)$SYREO^\IC/O.8WS_G.>_[SH ]]Z EU$R*,6/2H3[WJ5\_Z
MUKO^];"/O>QG3_O:V_[VN,^][KL(A][WWE2^#[[P3^6&X0<?^,8G_O"1[WOF
M'Y_/Q4^^\)T__>@?W_K-Q_[RM?Y?_>UOG_O9E_ZE,VQ%\'?__,FG_O6];WSS
M*U_\X9<^]>?O_O<O_]+<I[_[U3]]Z(N?_NR7?O4G@-\G?P-X*OYG@ $(?^NG
M@.B7??MW@+]7?P#X@ MX@?8'@0[(@/PW@1AX*O]'@?DW@A'(@!YX:3N7@BJX
M@BS8;./V;0('@POW@O,&<S2(;B_X;S?(<CF8:SVX@^3&;SD8@P=7A OG<,@V
MA$98A/KF@S8(;T0(A$((;Z"PA$0(A3.8;C48A5J8A3*HA#K(@UGX@UW8A5QH
MA%,H</<VA58(;KW&ALO&AA'';N.FAAX7@V 8AUZ(A6[XA.J6AC)X<G*8AU<(
MA('8AOY_*'*#F'(MV(B.^(B0B$JA4(6@,8DL 0K&5AF4^&R6N(F.X8D?!(J1
M(8J-88F4,0J208F92"2DV$&MF(I'\HJQ)8N<08L]8HN1F(LJA8M'$@J>H(O;
M]HND! IBP 63<(F6X8EB$ 8-X0E>( 8W08O2V E5Z E6L :*P8NS-0I?P 7>
M^ 6%H!BC0(VB\ =6T F)X8G:F([H&!>@0(Z0(8JCD 5I@(SB2(Z4T +AN!B@
M^ =9<(RVZ GD2 9>@(K1F!B3P 4L< 6"8(_9"!>B*(ND6(6%\ !H( J'P 70
MV!"@*(V:R!BXMHFAT GH. E9\ ?NR!CO*!(F"0BB$)&A8?X)8J %EL"1Z0B1
MGYB,CR&*_].1Y?B/_,@2)"D*5F ![:B27P"-N*B.-YF2#=$)9) %E+ 8A4
M ' %+^D9#^  #3$)!?  MKB4HJ &"% &HE ( ! "SW8)"D  "'   V  2HF,
M6<  X5@" -"0HPB+7*  X>@A51@("3"7-@D9DQ  &Y"37)  A" *9P  69"5
MC5&%*@  *.D8(C !53@!!U"3CO$'"Q  "3  !;"1\M(!#. )EN  !*"60+*.
M.6D("1"9:@  +/"0.&D("D"; * "HD&*(1  $H (M1B/\G(" ."2*BD*C;
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M&0J)T(X&^J(#\)QF,  H4 E5: F D*F30(WQ20E3B0BH^*/_:0F!T)A-(0B
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M8B  %YD%<IH($H"W&F"G#DE;JRD!XXH ;(L(%("W%R"37VD :I %"( (:6
M*K"XHA "!I"X<B **:  (D  "; %%B  #]"0:L  "%  ))">"> !$A  #H (
M9$  #V  8R"99ZD #7  *2 *6?[@MP>@MV7 N@3 !5F0 "3@EEI@ <A;")7
M "4@"A@P 1P@  < !NE) 0:@  KP!V50 (J+!G^0O:+ !0B0 -0KH0K  12
MO V)BBQP " PFB<P"A7PIZ*@ 1) B:WK '[) 0^P 0-P %^0GAAPMQ5 G%58
M!@%P @T!"&"@JB@POPF@MVAP "+  -IJ @%@ !VL 1'  1L<F9/PP0NP &;9
M @D@ @8P "HP"0H  FBJ &KYBUX  ')0"0K   F0F%^0  IP "< "FX; A5
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M!)"8(W  QY@!#" *7Y#'DT  (B *%,"Y[RF>HD##)Z &#Y  GI &O7D((8
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MD #@!1&=QA?)$!TP !CP!9;P !G0"6L0 %L@"B!PV$\,"/6-!IUP!>(]QX<
M"(\L"D7> F@ R&R) 9G !BT0GR00 &J@M H0VZA:"6M0 !* !LA)!I.0VYX@
MVH,@"/X%$-,-"0J@@ 8$< *3L 8&,.<H\..B( (FK*!K0 @$?0:5J>!5" +:
M"@@8( "(4 8 4 :=  ((X E<P+M7, F(8*_<+0$,< A\GIC;? %?, G"/ 9
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M"@P#O"0*H.(UV#0 TC0VP**1 0LD2!AXP).'_D-$E$,(,$$4"E;SKB<)#D@
M 04,X(D\WR#00)0(./)D-%%(.& F#!X0Y80!6EC#. 4E@*@2!CBBCK'_.E%A
M@$/$6J.2"A[PP@LQQ*CD! -D-* 3-  HXS4"2A"%"P1:&'(2 S;H<0PRW!(%
M#0PVX!(#QAH$,TPQQR2S3#/)O,0!%N<" (5.#,B@1S+$(/YH $-$44$ 1-0
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M 1"5 ?Z.(.))G5A ;3(0@9G0>"X*T!B$T34! IPA$ ;H@FX8 "'<3$+#'6$
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M+V  !W"V$\B) 0,#+[(J^7"!B/&.G.*2#NH$%#"<^D!1 J",<&*!^DF#2E
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M!!(8E,$')5BPP4 D<. P50.EH=(D$5CR1\9K'Z1"!BQ0((8H*7B  0LL9>&
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MZT8"=R*!($QOF+^7J5.5):!A0G"P.?8R7*Q#XQ@ZJ 8&@((,<<3713@7RE$
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M_ %>3(('&-E/7*M)0<2U%HI.Y$5Z;NNO)JNXCBNYOBF^!8 $/"E0%!\ C&0
M"$NYQJN\SFNJ#H09', (&(!B@,DD> $7=$(EB(%U*"%#(,+1&88EM( !H-\D
M&, )" +I+(859,: DL&"IBF0K<$DB$'Q32SDI $0!%15S!P:"<(5B.S%K$$B
M9 '$T*O+OBS,KI0(+, :$ !$E4  4$ " ( '3,( W(X@   U78P!.( $",#.
M.0 #*  63$("1, #$,  _(P5", %*$ @^2P%%$ -]1(#0, !"$P 7"UN?0
M;  #Y!L@&,!>MJO "  %,$!I]?X2 DB  0! U<2LWNXMWRY%)2  +V& 'L&.
M +S4!A2 ):@  5@"%PR ==#3 X &!AR )_R!VQY" FA/&@3 "DQ" )P$( #
MARSMSBV$!A1 "R!"(0P Z 9 P&3!SUP! $ L %R)&AP"(@R GU " MQ.!AR
MD#: 1?4M\1:O\7Y$S02 "JA!" 1 N*" X\+. $PG /S7\"*" 92 W@% (82N
M8&#O$1* "Z0! 5" !%   H1 PRH*0U@ 1M5. 9CO!"3 PJQ!"%2 !$SM)%!
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M#@:D !K <1C\766100)P2PU=08S@BQB P>9I'0F8@0B8CJ;K79$P(Z%H@&Z
M@@8P0"@_P!7H.9N$ #S&N:W[MFPL!""DXR%4H!1!AQ?,5OXGO)0@G %7O 88
ML%>R^UEN (+B])4@! (7!"Q#'$(.:0E7I"D;F( )\$<G6(%S@ :V^QG5#?7D
MM(6>+$2ODP ACMRMOSN\Q[N\S[N@=BM%AVFVMI)%[WM%<[2*5M8W'_1NEPA
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M0.1%1"00&=LO@  ,Y$+I5*$$Q/(5A04&*I  -$0J >4/547AV6>@)R':Y-
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M@!X9\"8YTE$ 5BC$ 1Q@@"S4R@5B $#VLA  01CB 0@PP 6@E";E32 # )#
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MT04G* $%.."),CP  L7Z@D4Q("@76$$#5UC##R_XS[N00 L2J M5-:""C67
M QBHU <6508*9  %')B$&I9:@>5]+ 0?V(!HK<  "92!#3/SQ DRH $1<.H*
MAJ7 !OX:N :A6F ,HBB#"52 @=F0H 4>D(!&P>J)NWJB$AXH;1(I:H$,9*!2
MB?# 7EU@%Q*P  020$%GRC !#*A@ G^H1&+S]('0J""XNDP#8\N*E^?:Y0O0
M),$*0  !^(& C:(@@1K\&%& V6P#'?! )]3PUF3] 0,1I=@5$$O?0F6A!1\(
MEA>$R@&3 8*T%!@@"1A@ 4%X@04?.$$I.17=#%!K#1"   I$ 8@.;] N6)C
M;2=0*$&T^$K5/<%JH52(#8   UD0A1K6ZS1!(-,"9:I$"$J; CZQ 0!@0 0
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M J[@"\3  S3@WRJ%#-YL!K>$$.V""QH& AJ!"_2K,SQ@#-+@EU0 FK@ LS
M^"H0 JP (#]@(!62:1:%J/"B _S/K_H.LUC T18@#+Q@#"*@941#!8J%XN).
M4,+D"H)E ]1@[^XB(RN![S+2+OY<8&9$P,I$H01@105@B8#4P M*2A1&H&,R
MK5@TH%<HT6! 00)<X O 0/!$H9^LH&HFH!#0X)<Z P,0H0P.D@PL+Z.RP $,
M!@-Z!0S># *J!A'XS@2PP"Y0(+TVILXZ@_.42R\H8%'4X)<<3 LZX58 P0%(
M  Q$1@10ZF,.P0OM0@P&,C'MH@+TA#'AC E7+<B<1@(,1GA$ 0A>#2_P<OY^
MJ )2<R-';F%*H!,6P L D@)$BP*8#6AX$K @8 QB$@'^ (D"#0)D\"(!<P/$
MX NXH W!X %4  TZXX54106 3!0H(0(NP0(HA@/-RJ,>@ QB,@'6@ 6>TA+<
MKC.^@/XZ]^37GM(%ME,96< +*= NSN !B',,%, ,^'($O,""]&+G#N! ]VCN
M'L!I0.$!ZJP*"0@"?FD$#F!.#FHI"> * ($!WHP"RK :SW 4*X4$#@ 4*V42
MTF 2*N !!*(,RN 24(  1K0-&:U7 '%FO.  5,  #*%6.$ @T, Z[4(-IJR<
M/(!WE,>-G F:M@  UJ , & $V, #2O0-$7 4,V'2!.4/ " +6JWL(ND/.L$
M9@9*_8\"O/#/P*43<LX!GI(Q*&!+&)(U^ \ER4"Z[H+;/D,EK8 "+,L"!FX"
M0.,08*BX!*'I2N,:9W" 0,$0(  40,P*V !0U2=,%)50(_Y&(L5@$!P .KV@
M# SA$.Q/#++@A[) !=2@8:P  [R "[P@17V%LB  :+#H"KB "\9 4"1@4<3
M\C@ #/YM@7KU"B<A"X)E3D) "[H2$42*HCBGR[*E(ZW@5L5 5^%%!:$5-#1
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MM"H6Y(=T#$C>Y,6$=UZ+7MC&+OX,P0N8^6,J-LB@A%+PX@^\(!"L!B MR!+
M  P0Q7.J$6ARG@+T) R:'EP @0O@I700Y>(+X1)$(1-XQ]/$('V:?H>**H.^
M@ Q$37@VM1*.!A&\8+WS A 04!30P OZYU+P A&^@)E!87Y\7A#<_G4('Q $
M91+$ /B&!V8*NG,DI1/$( RF)PVJ7782K^<?(')XIQ+^1!36()5!@8U"/PAI
M52 >"$\ *"\$ >O))X?NPNG77G1\A4V^0.3N8AUS:!(^]?7+?DB]P&LX1;'2
M(/;9[@NFQ_ S;:+(IUHEQU?(7G:F9Q+2OE'(@ OJ/D^J9L8:+#1,GX6H!R_4
M@ MRJ/X08G+KU4"[DJ<0PL03R,#V[0+Y\\0+MK]LQA[P7]\>YR01K%O?1P$-
MRD"[ $)0IT*B"HH:Y$6-P4E?ODPR"#&BQ(D4*UJ\B%$4J(P<.WK\"-(@B ,D
M.H4\.5$#%Y0%-T[<L(6ES)D503T0Q-&*@RPT>_K\.=%2"09K:'KBX &(A11
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M#"P$ (# !!2P@:JD@0 @\   VC,!!D3@  !P@2BL   -4,  @D!$ "@P@ ^
M8@,'X.+K)AD"2Q:."P,PQ$E$X($UG" $HL@" K+@!09\011>>( 7KN  <*WH
M 1D(P2'0( $Q<($"#ZD %\K@ /XQ',(#$W :!# 0 D1P@"<KN( 84""!F3V
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MLPH0ZR1_48,$>LF!@F2!EQ"00T%$D+B6/""JHIC 7TZ@ D\HH"@#$98'-/*
MPGD@#):05T&P0) *X(0$&2+8?27P%Q*\;B.58(!"+G$(FZP. H4(;4&L\& 0
M!-@$3/F7!!(D@8]-0@(H=L!4"C'8$&A!%&;(;XD5TF"#</X " I\  8XL $%
M^(O((<BDE$01 6UM]G48:,%&NB>*!]P(G_?;E2A$P$N.*?. :NG$?2_A@.R8
M($,0V&-!,B 9%>A6%&QXP(9^M (IE6$"*UI )5B@3#3XV*Z,;K1V/G  \0@"
M %\@PP H8,($Z)8"?A[$ 20 :@90X!*@+D@A!G!/\V6  E<$A64Q"XI2EZ
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M ALA4G;F)Q*@ EH0 G+3?2UQ N#"!1^@-%P0 I< "E>0 7LD"!\  1Y@B:+
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M:R '?R '8&9J\L,8GI \+?$'\/JQ+PNS,2NSJ8@& V   S  !, !#W$%!$
M!3  )P *AZ!N!4$)G\8C,ZNT2\NT3;L=DR0"@; &TPB!:.1]E@0(1QM)9L(
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M6I[T+_]C=OES ES@$FB0 I&#JE9P G8G"H!0 ES >.Z:H3J3!H60!290+EX
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M:LDD0"" ,G!#3;&"[$"=2O $"D@52S"3/6Q$1WQ$2(S$8%(#*N( QRL#+L"
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M'Q_D.JJ%"#" YM.!@-4@ 2NH%I#8W'Y<&'L^'PU T5G*L!8XC.$-#ISP!.'
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M@S40/PSZU*<-=X*8@ K,W5I6B"SP"XJP@@K @ ,"A55GZ).@9V2':850%LM
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M%/7@CRA "BHA@M!)U*$(#"%4$C7BBJ@)'#-:0"/J"P>!8?XVB/*016 :,J)
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MTGFV1(,8D@>[8R(SF<I<)C.;Z4R!7,$!4WHF-1,$ K]4,YO:1%#WMFFA0FS
M(1GI)NO(J;HL3& %'\B ,5DW"9D\$Q0BR, *)N?->^(SG_ILICD5=!=SDK.?
MW>NF0"%TESW.K$)^ZJ<_%<K-"!V"2 ]E$$/'F3J XK.B%FVHZC3ZPP4%5$':
M4\Y&2_[J((^:=$*'*$,,/SI1EW;TI \2!!G0&"&43@BG^]PI3WOJTY\"-:A"
M'2I1BWHAG1HUJ4I=*E-?A]2F0C6J4E7F4W=:U:!>=:I:W2I7N^K5KX(UK&(=
M*UG+>M3OG"$J?L(3]D+&T9_ JI-JA:E;2_H'69HUKWK=*U_[ZM>_3D@#[$F0
MURI4"0:0='5 60DC >O8QT(VLI*=;$:Y( (U?( ]DVB!"?SCB19 X&&B $,)
MKM#.)F:!!#?Z+ 3*PQ4TJ/8/; C=(;SP2D$$KE.@,,,@6' ")OW! ASH#&6+
M:]SC(C>YQQ7!!L2@@@.4P1,/R (@-K"%SSX "Y9@@0?4X/X"#OC)$QTK0P@^
M  H@3%>B8'B &+R@@,5X  (C2(,@&%"&-4P (0SP@',?8(D_5* #Q%4N@0ML
MX ,C6*F%R4@$Q. )A(R"!1)I"$,<D)*6!&PFK)E._D:4D0E A@7P%1PBQBA8
MC?P. A@Y@18:F^ 7PSC&,IZQ8EL#( Y1$%,;*$$&3! 4"8PB#0R $G,S?*0-
M@0($7JA$6\8YMT9] 3\<X XH.K$"#J!@ F&83B$V) %6D: H-!XSF<ML9AD#
MPB0"P0 :S) V,>"G$#Y:,(Y& I1,9>0Q3+XB!@8; A^O1R!0&DD)N",EJ4@
M(ZH],Z,;[>A'_Q44%F#!(;X  /XTD $"(;) !CIQ" 6(H48E0 0:'C"_2D2
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M)("^'!,%>%@E+  WO@X: , K68(*5,<SF23&/0@+ $ SZE,G9, &L,0C%N1
M+J0]1H@8;%B$B @W86)$8DEC%64]4DN$4 "X$)9;E  +B$(O/DA!@8&B.(@E
M3H@E./Z 6X3 QT@D84& _?@)&KA'1#9(][B$0?G34$9%&<Q%1@K5!F3, 1#)
M"5P!%U  "3R$"=QE7CX$%XR 6P#!"=R9!:236U  21[6<'"!";C&!J"1((!
M7L:':T@ KV%*"3QF*E$  TB &'0""90!&G"267@ JWA(!6R92SD*4!""!Q3$
M)%S<0&P !:# 0YCD&&3"!W!'OJU!)X# %[0 !;" ^#P  V  1W"!!=A-2J2
M%<"9('P 2@8D55WD'XR(%73*))3 0Z@!2WB!!VR %5@,>>W$<H9 %GB')9@
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M4<4D&/X $* / Q@< ^#%!_PL!G0*EDV"&BB A$I O[K1V8YMTI; E$9&&D2
M&A"*L?V! US' V# (QW"!/0K?EV/IZ[/PW@ ";PH S#))"A )XC! %S!'\C)
M?'@!>&5$"V0 (@"" TA$!FR!0%3 O0X "<R'!V"% XS (:A! EA"(#  ("!"
MM(P3TO+.FPA"(;SC1!2%($Q &0&%&MAMOOD&($@)C)J;A[!*"+3 *(C(M!2
M"-#0!%# (WG!!H "DS')!,P64)#! (!!AEZ&B+PH"J3 @"0 %Q0"(BB :5!
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MJ0:%$AOQ8AP" 82'!S-)&E  !%Q-:8"D&Q& AX#J,0'%%UAQ!E! !/S+&I2
MM:D!3@@"!G0EXX@"!QR(5S1*(8 .&8  !'B 6PATQGA!^AI$EU7"@8)'H*+2
M @>E90/%M09H]Z0D!M1N<P&%C1Z"@&@(!>4*JIT >-3G&@R'HW N?(I"S&3%
M&#A*?D4%(J Q&_B(AGR!HGQ91E1 IW2 !_CVC5"S"> I,'=9-WM"59:,!!#<
M"F"!,!FT0#>S%P#%!J#!)$2 ADS03AS$3URK70I$PL3.M?X"ZT),D,HR0 N
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ME-KB8GA!  R &JA  'P !V"]*#B  B1H&0P !("QZP0" A@3U1!& + '%PR
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M\LT_'_WTU:]LD@/4<JR0 ?"*&0,*"F_, @(R-UH$ %KN%B(A8( HK   !CA
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M(($KK&$T@]R+< )0@C(FP (#\,!%#C& 4(JB! PHPP *V0508F00!,A 7@B
M1PL8H!-B.$ &$N  ,L(2ISG5Z4XUQP4#0. +ECB! ;Y3@2Q)  *5.(07)E$(
M Y2@$YZ@@ %(  A!#,""$'! #AG  D],0 *6  4$* "*23S5F%O]@P(<<",S
M . +DG*>"0)@A4+<LDTIM(0!/B"*J9+@#X:07[  ,$< ,*D,!\U 6?<X  IH
M@ ((Z!<H6(    !  2N1**D"@ )/"& G?PBJ*+) @ Q90OX!'T'J1;AP4E%4
MP@&= H$!,( !"8C4KUO]U7<(QU/?_A:XP747%P) (U!(P $<T, # H (+@S
M !-8S%GQXD$(8"1^+)C$ *S2&*-2[0 4V  '#B !01@ +Q%)P(T:,8$!*  $
MY"D! ;Y3@@-, A1B& $&#M !44S@ 1 !0P$PH $-H+ 2$Q"  CY GHYN 2-7
M&, &2*"! W17%)0P@PH< ( _L $ +N"L@T(P@%ZZ1@+TNA  K"#- +"FM2"B
M2P+L]P$#@( $]J11:0L@W=@)%\A!%O*0N^6% #COJP](@QK6D 9+5&(-7_@
M*"M! *MX(@*,S6Z58^@6PB"3+OX&\( :R"PB V0P ^'DE82LL "4G(  (YHF
MZ@:@J.2*0@(3N$@9 M "-2P9$)Y@<RX%-( ZC= U&A# )+80 3IJ 0!@$ 0
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M :F5L 0($)" #<0'$-[V@ @6B)%1J$ !"HA 05H 3%&L0 *=2,,#%& "#H1
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M"C;0@C; "@)! _ ",+[ #*0+)":@#+Q  ;(# 5Z- 591 @;A$/R0.##@"OX
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MX .^PP2220L: RH_QA,@P!*RH-): "\>X#LV (I4; T>X,=@4B_WTO;&BC4
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M8>I8C=D9*1)A0>!*%"XA)>1X/>8DWRK@?QT4#0(@!1[D"QP@ 1@ 6 KA 4[
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M!""#A9D$!*%_!.$0#& !N "0N/Z@$AYH#0 IO1RF$%(ZP@) #1#A 5:*! 8
MQR>! @C@"E9@ !S@"SYI6WQZ$MY< ;A X4 E 21@#1)J.5EL$D+  "YA# !@
M KY  P  $*;H ?Z@$R#@ 4!J "P!$&K)"P  #0!]DBQ@J]9 !! 8;QC.!2Y!
MS$CM"OC. & E  ZASID)E"R!LG&#Q;!D%/.K)2:!S[T-(#T! ^XI@.-0%"Z
M ";@"N 9 R9A@\+SG"RA!7P"]O;HG.8ND-.@H900 -9@L:V$ICYD %+@$+;K
M R3. 1ZI@D3! @0 !7PJA-08 A@ X%7 $A)@ILQO#10@ P#!$RO@/0H+M7J)
M#.!]U/XI +2\P  "1K9% 0@ 8 .^( +T!PT8 $J\#A2XP+\/@>'6#P(4 .#Q
M(@,$(%&B2V4^&PT.CDQDC0(>8(3%D[H]P9I/7@(&H!(H" PFP0+P$D<& .^@
M6*7"HY8\(9L,\=BH0G]X31]C#0URP@HLP0,(P!-&* .^P+TZ?0 ZX0\0^GH<
M8 +,S#Q+/MD8@+:0A=TYX*('8 4.KJ(-H#Z/J1+*@ 0JX:U0@!43H!-6(-(
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M:.$!* X.1HGB$N#0&@!:1)4!($;4(3$M("2P) B %U&(#I@ !!1B!@:>-#"
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MKOKJ+:9!@ 977+'"'Y6Y4(EX:4QB)&,"6.$)! 2$, %#+#9)G"@G#" (*%[
M9@(!BT$)F"$#^*@%Y,5Q4, DKIDP9N^6#(#!)$V+T?))*5C2YQ>BA&&>H RP
MX<D$$H &4@+LHZ \\U9T H(*8_X*  !7QKH"KN@K:3   H[G J)0 @0!0$2I
M"G$0"OR!!*KJ#U2(EQ$U@(("TGK)16HBDJ^80 $) ,Y(:I()A1S  Z!(A H
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M8(T%\(\".- )#%SA));ITTPV$ !*E(!PD[" $JV#)BP X!#6V9,& L ^!CR
M#2SH$2@<\(!#A$4@#HC #0U(T((:]* X0@-,"&    !0!09(@ %0\":!8*=$
ME6!!",*@ (&LJ! &L%N_-D  !,!)%"0H0%]^!QCL6 ][Z]I>]][$@C\AX  $
M^(!(5E!2 7S $V((0%'<=P;"$* D@P+-&@SP@(U8@@-'?<U.".  !D" $ @U
M:"<D, #V%>T#!4C  4QSFP.98  $X( !#%* ?2'"  *1U?[V,!:?!YRE @\P
MI7 D()*1X!4T0BEF 2!0B&XZZP J (4%'""2-8"@!7OQ24%$808 E*$0"4B
M!3)0$DM4(  GX ]QS+  B5K )!:XHB@J8,>1H&$!"#  !29QD(2LZ*P0.(E8
M"T 6,9(Q88A1C%]RFP$%"/,P+!! (\A@@.= K!(8 "U5%(8&!MR4 GVY"HH<
MLK($<B8 $: C2JM"P"\<8 "(T +A1.$"Q7@B!"4=0&+1<H4$!"  #"!#K")J
M@!!X8E<!4L-DK9;> F3 I!OP1"$<D( *:, [62N;  (A"D,<X 'J069J(@23
M676B+M(<2:FJN15*],>0%['" /X>P( *;(0$!#C 6$61B"0F8 'ZM5"@)B<(
M2U @ %$K %D),  ^"F0-#C   2RP$140P&19C;*4I\RZ3B"B$9.81"-09)0T
M].4T=8H((BPQ"0\8I$^F(:"8DQ8<-628$HA8&??$C")+( *P"HDS5-1#)RY/
M0@T'&LDATB!>*U]B/W>&R"$.L48V.Q$M@G#S2":1!C7@F<JKXYZ:!Y$[B%1"
MS]'9&HH>W6>((,)A8UJ#)SZ=YY$, CDE(N"<1V()-0PT.&@@VIR_X($>;^
MEO#$F!$MDC^+[A"@Z40A*D&GI'7"UI-.!$2RO")+K $07VDVBT!A"),LY]K&
M>3284?[TZ:^$KM5V!DVZC:*&#WM;P:(;]GYL+6=OSQK,=%K#H2V1!@T0P-MH
M.34HUKWN,76:19.0PQ^X/.U<C^31GCB$2"S!: O]01"'\;0:(A5G@M^Y$%P8
M0"57)&Z%I&$0#V<S1-8]"6G323WBG@0:Y$# 0FP<+8!0 Y<]GNPU% (4$@_.
M#<.\GS7\@8"' #BFE\[TIJ\.%$Z.+0@8[G1,J[GJ6,>1!P P/M05HCL(P)^F
MKI[UK#?)  HK>X76>R,2 & "7W8ZV=5.][K;749DG_N**B&(N./]H%?7>XL$
M[R+"WQU'@C?\ME]4B4CI2.^%Z''JU*QXQ+.N\OR*T=4]<?[NQ[]H[IA?-^5C
M9(E&7/KSJ@O\ 3&5]\.[_O6PC[WL9T_[VMO^]KC/O>YW/Z-LVP=8*_-]YE'O
M^^ 7AX#%'XGP>?]ZQ6-^RJ"H_/-[3Z/$,__ZV,^^]LL.B@RO;M4''075MT_^
M\IO__.A/O_JS2@) !"+M$&D!"4ZP@A.(X)M9*($)2& [QIC@!/L7*"-1 H7$
M G@F?_2W?Y]3!B5P B5  F,0'"?@@"4@@%E@ OO7 J+C 7ZW?JNC!B<0?$!
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M"5B2!1/P<Q/@ 18 ")/@*_UH 2N#".B((!=A-)/P 4'15%] 1FII 2J  @X
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MT:?S%6I  >R" !I0 7R;(Y4 .]17&'WA!170".LH"BR!<C(2"F\!$4%-?2T
M !*  A@  *W2=%\Q(A> !A8-?3NA->#TV3:"&=^4%\Z-4!*0 %YPR^LW 0MP
M>B\R"0!04P]=&:G-(L[QE0:D!A,PRZGCW10E(X< 6L,'VJ:# 0K 99F0!2'
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M^/ + /[&\*P,S\:(S1,%0K@K@P.L>F "3S:RI)(>8U/JB[MTNHL$SNA;XX\
M3$@+@#-$ 0VPUTH3Y! Q.DF$ 0L N^E'LC1X !0/RL3+LRM$43+#D-1 L8)#
M%KN+ P*RN*20 4SH1) 4.Q$#(@\(Z"2D+0P!9!)$!A@AIP=2Z\  04"1  )+
M*/NCD$*0/(0 $>YZ@"PO ,!)#9I$<7$,B[SHQ$4S!"&  JMB*R2 KDS%T44O
M/!&CD$X^(*"20 8( 10Q $A,IP\*0&L%4EL0 )!.OIJ$"P%$F$2G!RH0Y0P
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M#$I*B( %&,"M##@ *>Y#U0#*P(#NZ,1),;&  SH!"KUD(41:^$X&%K O-!@
M=)4"P7W*5QU$="($! !  ](P%"[H) 0(J 0']"4*,DWH 0% U_G4@"P7&L 3
MHT++#KLRE#)DP0 5V(@#MN"9KG@'$ &XC!IL)0HY$ <464!==1+!Q'@1)S8;
M,* HWB8&$2  =!SY0TC0(@JDI>Y"?P"%)QZ @4MEX"[SNTP6,"0* 8)B$""(
MP 4.\/XI#LS-. ] ! .<AI?&3.!1$/C(73R@@$J 0D\MJ(WZ'!B ->%%CVP
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M*?6$"UB ^?#2KI'20X#24*S2\W'3H\  .;/*,! Z](&-3MB72:C2KD$$).D
M"5K3HY! -[VJ49 F49#3N;0$Y^'3JXS,ZZN$*]TA*_ $4!B#>K$$G3@?DA+*
MHJFGN_!3[ZB$,5W32@ QGP,"I#@! Y!2))756:756C6S,5@ @)DCH+*C3I
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MLJ,)8#*.H(]"6*E)H  )  4-D#-!X#Z]=8""9)$0  ,&(  L !H@X+$,T$\
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M,SCAXS, %5&K6]I<_HV@"3H,H&(R1MV4TP4>YYEAN6" 2_C!'*ZW#>6:1CB
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M ((!0-!XMHKAP!$2.  )=.OXEN_Y)K-"J)>EN8M#@(V:.9) ^(,W)=5 O0M
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M28R:#UDLM?  J*"@$R*^4/RCP@-'49ZL?&!AJ:!'$CD=.D1T L26@H7*D/'
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M0@2H\Y$5B0**!^% !J@C A1,RI2@$ .7-B!!-30,%)8P 5 MT)"V)K$X )U
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M@9^P@*17@!8E7N\FX1<DOX:!=$%:$",&U*[UG7X^]*/OTD(<@-$C""(@VN;
M 0CGJH400[I6E10E:VH-%H"ET?X$ :XS%D0%!%A-"#X@"#!\4@P+@-(&D&>"
M)@O" :?* +18@=(YD-*)51DP@!EX@HF8A8F0CPL( @M8P&4<Q :T2IF<R@8H
M293<!@5 BVNMP:.P 2(H0"SUS &:@ ).'%&TP "$!,MY@"" WR2400)LR@:,
M3-8@0B&0H >\#P=8R]N00 D\0&=X6,H  @H  "+<T5+ F2>@@0+D"V+%X(6(
M0:N 10)X02%<#]U1 !L\2N@$@ D  A<X0"*-R>3<C00TQ!2*00+8Q06$P-ME
M@!S2'!@(0@<8TD&D  .8#P5$3QK^@01H4'?U7&>( 02H 1L,8EV=V2$HP$^4
M!@,>0OX68$]&A( G/,!J/ !'6( *R 8$@$(9:*(@$@1VX-,#>($@?(#]?($[
MN:)#6(+_"8(*' #[L< "D)$%%% (G-VR?,$J]M*2X%A!6($%3 8$?$ G (("
M=-PLUF* (40 6 $2WM,&&,L7'( 7_,$!S,QMC-,:",(!F$$AB$#;=4E#($(J
M"D((:$Z&G).#0, :I,W!+)/S[)8"'(P#H $@I,K%K,$!E$$A1,2JV,T?)$C1
M70 @M(Y))0#S+$ 3/0 +,%I!5L@!G)TD:H$F5L*_N(D",%HFJH E0-ZIT=V#
MH8$#K(;TK21+MJ1Z_$&K'(1LF$5_[-;[C"0)G(IE? '[E?X!!Y3 &6B!3EB!
M!WR N)42 AF$%71 AU!$D'581]@)40!".Y)%1Q#'&A"'$K7 R%Q!0V4!\YQ
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MYH0Q(HQ";0Q<_P$,O3@3 22'H6C.(0S 7YA Q(3'(8S)%Y@A.-D/")"4*(R
M%Q066$C *A'0^6IA*+:TA1A&ZZ+O(4U<!;!?M[H +6/APJR!.7E002SP.(V
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MA 0O/!5FS&D)0J<O$DB$@ "Q#&05)3!4H@#4TP2@HAQLW"G*4H8-(CQ45./
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M@*7F3F!V6QC@\HY+H$6("$L!&B"(!PR0B14'PA*URX(!,%"( 6B@$&( 0*@
M8"!+*& #&D7O0=8KB@W4V#8<>$ _P1QM:>^OR0>@  5,:B!!B%4-*9  (C2
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MS>(0@O[% W+B 0+A!<&C!??""\!#$! F+2!@D8QP#NGJ)' H#>3,2++  TH
M801!!$ @BW0B"T @!00$$": ( (A,JAF# 3!!;)(#1BQ("A  Z;#4#[@"G9B
M#3X !<0 ]BPBA3J!YMJC$XND#$1 !&K""QX@! #!,=Y$#:Q@ ZC&$V;1"RQI
M+ X!!4+ "D !$3Q  JY = XA&(?1%D/@!)YB$L+@#]G#"CH %[=%"SY@DD3!
M"^)D4?9*0 PAA=" #1"!1D) "T1! NZ-"T:@##B@!5:%*T) $%WF"I)Q \U
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MX -02@+.8.6 <#M(("TKX@L&( O2 .*"@@"N8#%1#TC6411.( 0*(0PJX!(
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M3! 4"OZA L9"'0&I$_Z  4R@246 1B@B G+(L]1 :K83! C& \1@$@!T)4@
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MP,H$(2/MIB.M\@^\X) $X2":-@S^( .$R#D)P@2&4 P8X 1 X00JH+4FH 4
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M+QB# *AF!.Z(F$='_@@!!,(N=;!O"=4P_DZP$#Y <)ZYG"$H$PSN =AC! ;
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MAJ.D!.,/ J $T, + * N X $T(#$2("[#40%!  H( ! />"\ [BZ[JXJ3D
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M"0Y( /X#=SI0"T0@7\](H&N4@$ (()R!B!ED!0^@P/\L-UINELT_HI  (D0
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M$220!6JP7Y4 >)Y0 BF@+(8G"B=05Q>1!7"T%.5V)(H5 EH@;R&R&"A0%Y3
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M C1& BF)GB*0$/8Q6F(Q$I,@ @D**V&  >PYH=859AY1",13 CG7.Y;@$"V
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%%AT0 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>comp_0009.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0009.gif
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MZ.SK[/#O[^/N]O#O\.;P]^SS^>CQ^/3T]/CW]_'V^_CW^/;Y_/___P
M
M
M
M
M
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MYTBML 4P('B?=&=_0P@2PPJS-&[,I <W$!J70 @V<G]_!QUDD04O<%U:,@J
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MY21&!#*1H!CF#2W2B ]H8 5TBD,'. "_-/BR Y,PPP7(0$%_3N(,E'02*$Q
M3%(U(@UKP, (^L8&#*2@#.1+I335Q08'W'$2:K"(S#B0QCB\80P7Z.%%.)J!
MXCEB?N-L12.2^($H+4)J9O#$!-[0 0TDK!6. ,$&B@"T#:3 6[-#W$[2, %%
M)6!VKP*J!U+@J!F! @0EH"JL)K$ 4CEI QE@Q!T,"8H(U,$3@\3( ^I0)A-<
M( UF* /)W,!4;K%!=Q9!!0(\P/X(.20 30C(0!I(<=)'+.(!Q</  ^[ " =D
ML 47<(1ABU<!-83"!"-H11$ZX(E&3" 2J&" (SQQ@8$YJ1$'2(,C1I S%?S1
MK9;%;# ON(A6M* #H&C$ U#AB &,X VK&$/7[I  0G: !9Z(0P50P0@(?,L.
M$0!%)"# .&M&P R8P$,#[!")#1 2KVYX@!Q0 8()+"(/"9BB!XXK!PMD-4*H
M0*3Z@LF 8JT" B-P!!L2\"6=>J(('UC7!$JK,19,X*UFJ*8='& Q.3S@(AL@
M0RA8,#-8@6 !=>@L"^"6 D_480*AF$0!0L &5#0B F/@Y 0:T5F269@,CJ!$
M ,;0B/YAX<$-"UB%(Q 7B@N\B@$>: 0<$A"F"9 A$BQP,!LR0(E(4&!VEHP
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M4'" $N"[9VJ%22"O!_"V\V,ZIAH#S$*%%+B !4@C"NH )\D_$2B#[.LLO(H
M2G"2,UB!1F  %*C#15B%"? #B[@##HB "]#!3*2M"E@K:5FUB_BU3.D ^('
M1EB %."[%)BB"?FU!W"CR$N<"! Z5/ R,R XOE.!S7$2#8 ^):P#DH'%G7 $
MR1,4,4D#W8F225J @8*5#_BM5:"$"I@#!SB!2[RV*JD /%@%!X#$59@$!PL!
M-/"UDVD%$] P5(B DC.E,:"^*Q,4"* $,Q@!2N'%$2BX$_[(.$%)@0R 1591
M,2>)@S_" PSX@#*0N@Q,I4-,)?+QA!&@ $&[LPLPG _Q! MH@+>YB#%   W(
M@ :H/8MX XP2M6Z,.#Q, TJQKT>0%D_0+2!<A?RSB!#8)?6K@_MS03:0 VZL
MPTFH ^:+ VBQQU6X VAIA QHR/W+@($Y2M-[FU60PU900(LP@17@%@T8F!22
M% O @Q:BF%;XPU7P! C(E Q<A;8J.'=4GPA8'B<!RE9X -2["!-@E2J9@"0<
M$Q/0%_B9$9O['P>X.@W(MSPHI8N@+5A) V84% 0@F1& /D5Q@&JR"%! @&2R
MI+5KA1'0L < %UX$R4UKA0Q  _Z+B(/[<X#2W !4X)=(X)M3U#E*F 0\4@.F
M<A*;NCP_[#M^D80 TA]6084%.)^3P9>+T( B^,'C>AR7<Y0)B)/MLHBK"K!$
M 8'*I(0&R*I?LXA5_,XX (7GC!_Y>B^4D</ZF@!($)3LDP,,N A&:,&^4A\'
MT# )Q A@NXCBA!_8#*8$ !<G 8$GO(-4(T^RF80)F+P2,L"08BH0R*#X4=!6
M*,(Q@2Z#*Y^!L<=6P)L"O0BLJ@!;"H5Z$3,'N[,_ @'O\@!688 KRL&T%#,*
MZSU/^)TZ6(!;.DD5Z9*=B  Y,)W*(=$XJ#T/B\]5: $1""9"<B&+P / L8 2
ML@.%&_Z!G812A1NQERM2.:B]J:P >CL#I,RX"Z"M!2) LX&?+,/*)T0!#8L2
MKNO G%L%KEI*GN@^K%M+!W.>^.06,W" *$&%ZK%+O'2YUKF(.$" HP$%>FN$
M!*C!=XN? A @G4HW*8N %*@#4\*2$'" ,K R"A,!!KBL$OB XKDT$$@#%GA%
MR]P .4 #!G@Z +4(-HB .. HVNJ !WB#.%B C9I5-F" A+DO.Q@#W6&#PV(#
MRZF$ T @ZV12*<2#QV&!/PK6X *9.U. M:D %:@#%J@>1B#/HM$ $;@ S1N!
M#*"#@B&5"8 A0WV#W!',5J  #Q V!T ##Z-&)]F^>T+-'_[,H!*X@#D8@P;0
M00WQA *HKP5@'(2=HQ*H W%=E!-8@#%8J@P0DQ1(@!(8 5$=F$A@@ Y(@S%@
M@-@2% KX #LP@P^#E1)@ #;81F341C+@JLJI$K6Z)0=X@S=P@&32 "]:1C$9
M@0)"!;XI@SDKU@\0!09HS 5XFPP8@3H( >&9@WUY@Q:%E6>M R'5'%#( %!C
MVHMC6)%,@TE(@%;H/PK* %%( !:X Q.8&3Q(@)=\$;91 (S(@&JARX;; !"8
M@[M!RQ.K@PH@) 5K@SBPV59P +3!ON^$OL-M!3J  ,5='P^H@Q,X&3B@*X:[
M,P:(@S9P .'Q ! P66EK%<A*7/X\<( D>H"!"8$"^DS6M0@*&)B<8H$ZT "9
MB[5M>4PY\ 3A[!POB8 5H-V<BY9;13 '2*158("ZS5A-,B<$4($T*('-_")N
MM(,5R("-?)%02(- &3353!0)"X%"Q(@X(($1:(,HP8,R&(,Q( ,6.!]/&(,4
M#3B+"(4Y*SBO0042NP@[\$?46T7G.<!6X%\30#U1^$,5(!<[(($9W#P4$(%S
M23M4\H3(802T"84_3(&!71V2\8052 %'8 0U\ 38(97D(X/\J2,5Z!M'6(%$
MN0.,A1V7:^'X28$1^!V,V%94H /4DP/48P,14&$/004U4!_(BU52084Q4,0R
MJ8,2>/X_.F$$]5W?%CC 4#"#N$DF12F#$4B!.+F($#"#,P"!&W8#+@:7"5XX
M<LD#.FQ,.@!)4%B;5K@#VEH%-G"4-# !W1T#4'B#B4+B*UZSRZ/#\]E?$T@#
M3TB#48F?_/TC3VB!%$ T-(#C^/F=2"@>2E !R@Q#-MBE&+F# S0MV+%D=M''
M(J 33\ADP60$$R !6WH#<)D$?JF#A'$#<*$$64Z85=#',7"42+@B7S:A,F*$
MXKG@%,"#2/ ?2IC$$9ZG@K.E.YC%.R#D.RN6#AX!^ 'FG4"%,O@M_<U?,>E@
M$0A(C("#$?"M:#&I]5U?<FF$$QA0Y+D(4&"!$5@!.]L2Q/X(6GMV& Z-81!Q
MDC5:!#AH@,:\9PP91LQTD3*X #P(R@ NZ(>&Z,9 EIY00JTX%J QEC)9G3#<
MYXOPM*]I06[!F)!AEEBIF(HNDS8P@1,@Z)!.F6:Q&'NI%'^&&9HYZ6W!Z'6B
MZ*^) SJF&;W(:8M^:9VQZ9BFZ)".@Y4FY*!F&:*FG1F9:*.N:9W9R(R)%DMI
M0::F'>S]Z9E^:J<6:9PF::&.Z+(VZ[-&Z[16Z\C@ZJF6C+;>9[A>F<!PZ;6F
MZ[D^#+FFD+JVZWO6Z[X&[, 6[,$F;,#& Q)0K[YY Q+5"CM &YG>:;[ $CMX
M)$NBJL5VF9[ @R(H A88@]N![/Z@V4V'_J+P>=>[)NLZ.9HR^VJWSI PL:;B
M>9F+X"2W-JU7>8,23+M"O.V.-BUZ.V*0OHA& .Z*P>NZTN?9;FVP=NUM 04U
MJ)*>#AH7B8.E1L6)J1([F&:8[FJM "7[V8O9CA(V@.<RL8,2,IP=_6;AMNLR
M4( Q: ,0B",.S9::=I*W>FN=6P#]I<N<$S"^*($&:(%Y1H!I#HP5 # M&0&2
MN0/RI Q*F  GN8#4;&X0H3RSS%$_$8%V*8.<T3.>>(0-QX@.!^I^J<)6^-5]
M_M+E%HP%R&4,D03([,#EF9$Q..V[M1@0T+Q&_0LG,3D>!PR:M9<%+G$S(*3M
M,\^^SOZA X#GN#E-#-LS5/SH,0'G^'DZ5)"$W^EA=JD#\1*4[K$#/-J).Y"#
M,(R#'%PA5*#"1-F '8[R>8H# 7*2$G W$Q!>,L^J1+4EM(RI3.%C2D #F0L<
M#>"P1;@ 5(@#D.3$*&^4BZ@$+/'E-^X2D PR.[O)!\!$#RBS.,@J3X #D!0]
M5) #1<^0-%2#U9&;-X!G5)@#,?\BXT$%3X?G4"@V-@"P-JD;^B45J@J%06N#
M1CYE*(8#Y%&#!$\W25B$&[Y#./"I-0 P*XP#,QR3+)0#@EZ_.$^[.-!MOD(%
M"R!UY++V1<#V:''L4_ZIOF'HK+K)M1IN50\FG1,Z1<(#"/X/%,)D:'W.D%P?
M$R26@T7Z\O43N7G"["7T $0O%A/PHD2U]E;X%$07U#O ]DJPGX&E*N2:7^-)
MA4CX%3E('%%WO8MPA#TK0XN0A&*SF!,H@Q$F%=-).SJQ+ ^@A)SJL&EFA'5;
MZQ0X7KP"%YXZ-I1M@0HH @QJA16HE@X@KSA8JA3 @ YPYY7-HPDX@0L*DU4A
M@0E@E2_2 $=2L31C@ _ A-Y\ */R  TX 0W 0JQTI@FXE0_5FLFA.BO< *VG
MK3HX/A @3@H8 0EPA$9P@! 8@0E  9[@7 '3L1((@0:H)E3(I+L98>;KK$ 9
MVA;( /\Q@_%AE17 @!.8@!L&A?X/^+&*=*8-2+4[ _P,X,K<<F(&Z.0,*0(&
M",<WB !W7H 2F@0*T,O7A)4;3*4(0 $+<YK<.KD*P"RN2X'*! $V@$A'@("K
M$OZ+@Y\>@YL-:('-IZ(_BA8+.+D-X#(JF@ 6R  -JZ+U^]T:6H5 PUC['!,0
MT( 2>(!D\K"R9]T4F !$:DU8800*4 $-.,154'_V1YO> 8@0(RA0:G5A1 0[
MJSYX,#&A42M*%4*$F#"I50D-+2;$:66B0X4BJ#1L&-%A JI6JUJ-&(.Q@PH'
M=52VJFGS)LZ<.G?R[+GR!(J:)<A,>I B(RI/$Q""2L'"8X8Q%-JTBA.A!(@'
M93 ^Q?XSX02'$BMKRED*PL%65!E"K)A B4R(FG4NV/3D %6D"BHZ9$BY<D4%
M%!5 F #!H*.C"2I,: C5:N.(LW9:I9D@^,S-%1>P,ECD*,)*4 \\U;P3(0(+
M3Q%&(#0A5(-#/#UGTZYM^S;NW+4[/!UK,\/35A%FKDB99T(K%B5:9>B0<DR%
MF@C<M&)CH94=-C4QR&FE8":H!:17J@!1,P[R2,AOLC'?2H.*FA/N+%HO*8+?
M5BH07*C ( -Y[J&W2AJ+U.1 ):TLX%(K%+Q14P6N:: =32.DT0HC"9!FQP/Z
M+5>=>0Y$TLH)*]#42A&.?4:9 @79L1XE^-D48TT<N-8@'/ZH.$":<)%,@D!!
M=W2H&Y%$5L (91*LQ()Y&5!8@DLKK<@&:(]Y8-"%S)G7@1N-(!<*!*%$TF$&
M:-24@7D3UG1!':B8V(H:'5 FYU@/D%'3!BZEUDI1<,K9QF0]>H+ B(TTT(H9
M&I U BH/C-A@(Y PD!(C!8P88$UIH))&!C7-L64+-8TAYP,GK&3&E:W,U0IO
M-;& V9MM*%K"!(Z5H2BBD](D@AFM('#1(]T5.6QNC("&2@2>V-%1*P^A4@!5
MK9#@4GQ5=2H' J1-H@ J)SP5 43,=;=2'=GRF0 HDS XE(Z@M.+!A2O9A6BG
MU8W72@J*HG+ 3&5L4!6S$S!"R?X"[D920"-VC15!0>1-L-(;R$TP4QJIKD3&
M<IXD8"#!K<!1+R,4$#LRR267O!((*=R$2D$9S%&3!G"T @H9^=*EG$'"LN :
M*A.,N&HK=Z1P @,SC=:** S;1,%DJ[2K7DHT50PSLQK44<8$*YB0P@*/8@0"
M)3Z&8!X%,ZVRR@,%L9$""0P4M&,KGCP RJDCM"+'HRC?Z0=RJS""G 8=I)!"
M5AZ%&L%%-H5B1@H<B%R&W8]EO74"CM 4202.;? @JW$XHH#6*S#PQB3K)68R
MZC?-UTH9<5$68@DGI-"<32NF$1>!(5*R$AM7PMO*:'5PT$IB8.Y>W94;4)A!
M=Y2PD/["1*V@D:I\D_ ^_*8I>(#<&G)6=10#D]#8"N:M*'\B(PLL%A,;:IBW
M$@5(UE0Z!2-8KF;4J$ @B4J4/-"SY5H! OB<@ 0[BL"EZO*\"WQ @+TR'QOD
M):.:M*058W# !LS@F]1QT&>,J)<<4F "!C1"-&,IP5,J,8847$!.;Z!3LQRA
M@C&$9V@JB(")( ;#"W2G$2I(P0-<LH$V(,LQ-;%+4BXP@1#(KR8F*,+,W-**
M-_Q+52+L&AP4M9(+,*(.#=B9"A;0G92<X$YQ<\ JU'"E"P1J)6.PFVH<([=5
MG$ O)S"!>#BHQSWJD0U#JLD9HI,!9KD,% X8@R,8<;/E8/Y 9LE93L\@,H>;
M34 .H!!!1]+6BE H#4(S:04J&B"FA]5D)6EPCP8XEP$[E*$#D&!$)"B1G]C9
M)!(($%=-=.0)#X  #Z&X0$$0-S,'N M1D<-)"'I5GYHL0@+,020L"]((#=BA
MBO*"  L:X8CK0*XF+># (Q81RZB1#R6LHM &XA )!SQ"FY- A9=J\C<^EJP"
M>4"4>\X0EP;(H1&-F 2/B!<!RC20,G%Q0$&0]RXSD4 -*=!.\2"0T-Z]QY$7
MN$,D%I"&2,2A@5.S203X1]!51$ %L(P.&^0$@@[8(109B*6,(@$!5F4I%9%P
MA ,<X4])+,X]S0J7318QA@1$(OX$65I%)-#VJ#&M0F U\4 *$CE."#PJ%&%C
MP$;E(*<1;(6F1Y312KAZQ#AH8'CT--D*S-""7I%@E:'8P")"\0 CEJ ,GEB
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M9JH#'G!/=" "$W#  SWPLG?-9( C".0<TJ"R#@BK#$_.@.7J(*<7?6 %*]"
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MYQL5'&"]Z1G!@EZ=;?FLAR]GS=26DSAR[[G9P(?@H&46G&"_O->/&4!;!Y#
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M QB;C<Z;=8YD;8$"(U3 A7B !_@2;IYW**0$"*! V+S!I$1P(\@A"*CWV40
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M\3"= <_%#B+=[W>CB*(10#C'?I8+*JSRAHM66LZ=]C26/2J"-#4"SRLH0Y!
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M-, $0,83,D!C4&$1(J $/" #ZP8$)*#1*H #R4,@3( !,OZ@$3ZA FCP-C0
M!/X'*-*@ 29@_)A"!580!!C@-N1F#"I ,N( .^!#8T@@ MX##R8 !3Q@:-*
M 3H%%"P _BY 1$91 NI@$1I@#"\ 4BJG/?@B SC@!#2  D(C!2Y %MD %#1
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M #5085B!H@C@@@&4]6!<TD@B(8$@H4%0X0,, A+R44"3=&.WXR>K1A8[XE?
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M6P&<.*D#(=( T] XB:6TP55R=&-WOWM<[Z:QJ2B04R,<@9 1B&1^J+!#J.J
M$X<\]3&O"Y%AQU"YXR($#KDKTE3Q.%\ZP@\5KW&N!7(WWL@X D^>"$$0Y860
M^:G MP$6KWP9@PK\H$<#LS&N@!,\OTEX@(K?37"% =PB][9B##O\<&-0D0+1
ME:$H,0OOB?V[XA9WEQ$(SB8<(?-?.*Q7O$"&,(B)7!G])OYYR4=V,56!&YD(
M.&4CEV$# N1 "4;0J15T6  >OGP'044" 2V8!"7,<( Q.B82"G.$\OA7!SR9
M(+[8>LSH:)*&I%+&! _P R7J@("O=" CDHE$@K8I+U0L( U@1FT;5Y"[23#
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M)!M0%(QQ!KU5!@\0-05  FP @];R "S0!AV@ +'%7!6X"G6R:R( ? C@ 6-
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MKZ-W<HH*5^8(&7 N_>8)B\  H5 "&N )E  !Q+0 =U )=<(E8W"VJL,8(:
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M#@\.Y6N(@B$I:&4#C=)PL96R6O[!@P$VT&AC@3C2\"F-- Z8K3LPPQ2SH Y
M8".-%11(I17(6%C DS.4*D@B#S1J!82@''+D1N90B<"3$,Q,HP4$[E2C%4HF
M(,@,I3JP,Y((4(%@C ([L"V"YPS#PX$1V"!H*1 .;462DB)@H5+;('BNONLV
M$#5!. 0+\CDY9,4SH3G0T$"I6[=*PQ/-W$,EA#K3& ,!AL94=MDQ]5J3A1 G
MF"0%)HU%EDTVQF!@$50JT&",V2"5B\,X,"CHC0?:*/  /")Q $^)EF).* <D
MDB1;!AA!Q8%0&N$P!.G6@R0%Z3P(B@43F +E@@S 171%8>>PK14[;)L@!374
M&*$"8/X_/:$(5!X8+H)6Z#AJ A0R+H%D$R90 0^H0HG#C FN<XA9G'.F"I20
M/H5RXJ4FN*.A]U 9(V&F2KB(H RTDD ]%N8[320&U&"#C3HB"9DOID:XSJDQ
M%EBC%6 +9$..2>8XRB&"5%#!(1.N<S(A"&32P X3WEBE ;/IF,VA2!)@R"%/
M_@(QH58TJ(,-I59YC>*QQD#0<48HYI#)5M2HC@T.ZG( CJOK\*2(#-Y@XPT\
MXM5Y=64U,*&-->"HL 7>&*F@$C* )(@@@POJ'7!%)^),%!0_*.'J."H$X8R^
M_FQE#(0Z:*,@2$.!P(RKY7B.LJ8\,8.#!F1RR,R&*/DS O[LS]Y>/;@ORD C
MAR*8Y(W.'9J@\C@F=A04"4K(TD40E*$@H9H$R1P2(0^, '9QT!?K'/A 2CQ
M(BKPSRKD9P(0M($-<,##*LXP@3$PXFX->4,)$@ '3T2J%?YJ1?X*LH8)F.X-
M=RB,)YS$@%5-I#>K4!$JM$2&12CN3F\8 VL\T)N>-"(%9'#(!PZ6L)N=RX1O
M -;-(B0'<[708BW(GB,B 8$(G:8(H>@*FTAFE/5P\6SJH9@*'C""*#J$$1!(
M01U6T)@'YE&/!FI(&$^@')*<!FF&D0/)$+6 2K2"*((L",+6DYJ4Y&$5#TCD
M@EI!@A2LXB.CB<,%/,$ ]5! /_ZMX" H&"")(%$">@6A !E:8083^4DF;^A
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M!108^( )(E A%>R(*2:XP DDD"</.& 28U ."W##B >0  03\(@#N":O TQ
MMU3ZY&SD(#)'Q':V,F%#!$YP =PXXETH>( K[X  %.Q+)J& +FF$*RVFA$(#
M#_" ;KF6@@N@0 *]:0%"+%BA.I!LE>=59D2EE("$Y0&^*7& "3+0 8*D@ *>
M_9IE_9L0#6S ! ^ 0RM0<($4@'<^+*C "2+ &L^0*4^M"/XN0;S6"E+8%A4:
M<)T#WM"*#O1F$A)\GHE"0($2E$"K9@S!"#"ER$PY) X-,,'&"L.@"93 ! Y@
M*:1$X.+G0*"B)EB:!P3\ /WD9"F?;6%=F91"$X2V 8XH@71 P)HY1, $&^B
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MH(*-CFC#(^P=+T^H#A7:]H2"^DTQ-R@HY0WI=[<]4G!KHT*DGUHX4SP!AS@
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M!$9X@Q"8A$DP@3+XE$A( 5<L"#MP! !!A3L0@0)SC49(JW9C@Q+(2$0YQQ5
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MO^H+'6U1ADB!B\ #!4D#&S5$(KM&2E@!$P#1K&$M-D(%,A@!/]" N'((.YB
M#V $.]" /!"!&=W(RR1 AV"! \B6!E"@BUFA"6B#.1"\"X@AKE !-E  "'&
M#G #;2F,$@"!.U"!BL"# _B BR#412@M3"02#TB-#AB!1C !A!@#!< 347 9
M. "! @ %5+@ %K"##1B#HGR ,@@%,]" 1="O(&0!!R #4("#"("#-5@Q#8B
M$1#(-ZBO24B#!4"#-Z"2E)B Q9D ]T, 4$@#!.!.I@B!#7B#%#@ .WB$!5@%
MN"*;L<J SVC3.W  C:" H+@ K?X$ 1-AA %0@3?  ,@J"#@@,#: -1"#@!!(
MC?ID'<!Y$Q*)@+)3E$>(@#N @P28#9\PMJ!0@0VX ]*A,'N- P6(!,=1 SR
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M%4H DYN$NS(2Z+B1P#EB>:.P&V&CM=AI-OF+55 M51N+#3C1K;YAY2"#^6"
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MBL&5YZ-8Z(90R/X+<]QXC^>P*NC0JC^\B DXT8V:")PJ !#X1II5C12@A,P
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M%$@3:<R#5B5,M'I0!_GP-@Y0L9@@B5(%-A!;C;G &@*(H'(^1E#'*J5-8H8
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M4RMXF$;7NP1_A#"7&9C QAFSTO%1'"I\U.Y(<&3@P1LMC(1&!BRL89\<'8R
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M70=D++$);& "_YE-IF0E%A8\P!.AN'<(Z,PN!H3((Y'(J0:$8J<)=* "9_4
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M1:S1B(ZT G34!6-PSZDA0*.X07G@P6SM22M 0&/Y8&BI4P>T&H@A200@"2A
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MVPZ=@'G$''2T!@C=&/AC!*3,"IQHIYW )$! @C3"09' )!+QC]3S+XZ 8I?
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M 0,$FLA QG""51P 6AXXZ,3,0+]6E$&G<4"%&C@P$$:(#?ZPC+#D5$[;"@Y
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MP9Z"6( R:D#K&H;L@0Q[(+GFL2%J@+<96I?@)VK 8@=L% )$8@97F](3:B#
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M <R $JYD%<;@ AYA$1Z@/KPH$M)@ '3" <B@$48  1*. ? @$C9@;2YF("I
M)#[ 7$ZB,A; NR(B(MJ,$NRPXAC@ QSA#A+@.Q@ !'P1&%LA =QE#"K $18!
M>*9C OS-DMJ%@UB* 1JA$2P );1,>PXGF%0@ <3$%EMA!#(@$ABA 2ZDF?"@
M >P@$CP 9.)0)2*"#&0"I*!O$L;@+!B! >H@$C*@+LQ@ A;D ;B(>X0I;OQ%
M)!3@.]C@/1 2F<Q@$LK@+,S@5<R@EU:@ B+A#M)(GR0Q#0X G2; !*:EESC*
M&B. (OXV0* T@,,2@!$H06V (@4NH!%"(>4B@0RFC2:ZRQ/40*<H9F("\N5$
M(JT00 72@ U.@&>(9@PBH0SZI@X:@! U8 )"0;/Z:@'PP!$VX)\(@@V<2X>B
M#W[@\25<Z";Z<3@JY@-P1P5H*072(!0:0%Q:0 /VQ[I00;UP9"!"HA&X+@[R
M:B:J3Q2N!Q5.0*)0( )#(0,P #P8@ W>( +"B 369N1.@_PRP$%0H0,6P0;9
M@IDT[A2[(B[QH*XR8'_P"B@T(#,;IJ98ZCU<<2"BQJY.!0%$XF8HBWQ:@04<
MQ%1:P:Y:2.W$"!48@;&8*HQ.X!TS\>GDP(3(DB\\H02Z"?X/B,<,$J4,-$3A
M.N -QN!80B$%."!E!N(-1$DS6L$,XL $,B!"(B$$-D"-!H(B.\!"/"$$,@ -
M-. R&H$#0  .*DXP.D E(\(,@&1 <<(#*FBS6L$!M)!4HI,-,,03+D -8)$R
M0J$"EF^FIH,%CB4FY-,K>?.$0@"+GF*80@ .!"KVX" ]GTVY"(H@VG$/#6D2
M#,D..D UN\(Y-8)="((21#1K^@IERFP@UJ #3(>V&F,1GJU 5P!)E50\*&$$
M-& $, $\(N0.**(2,R %W( B'.'$Y$ .<"=M'($1GFV6-@"6TF"IU%28 '0%
MJH02;(X22D!*X:*O.L 1&N'9LO[.ES3 [L9$!3(,!$P 5:"S?QIC%<X V!S!
M.]Z@/O9FW;:S2MX /-6C$6PL1U4"#RB *N, %"Z@G"Z@44K@ C+@ T(!%.KR
M(TZ@5$$ I$S3$Z[H EQM8BI S;K'7X;"#"! ;3X@5S[@ M:2].S$#.*K!1#)
MWIXN#NK"$S@@ R[@HF)UJ#: 0*@(50;"6EL!!3"@<,3%]C8@ RI@;>X@K^[
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M8CS !"Y  J1C#CZXP- I(AA!9H!B$81YD2@#J4X@ JHP QQ H@?5@6YB%4Y
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MWL 3GC+AGJFN0'42'JOF%H -/.'R@J0"7!BL3?D06\$#'.1TY,:><@6?0F$
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M%3Q@ E1@5^:G#<B@ G"G!4B/#%* Q0N*CZ?"#1Y\*E8 =T""7>KBYL3DF\C
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M\\#CQPMD1E*:-.$CG@8M4J@8$ZE%"9,J)T$(A>H!I56K(M4$D<9CJSH@(&@
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ME""+G.\1&4P# PSR@%&U(@*C D$$_#63 9A #<DS"5WL<B1'($ P.1H ?2J
M@8-@4(,-D)D#TE"$$;J0/O-3U?C&R*G?1<)7*W&$',08"3M4:4:>R BGY+"(
M58B14W.@UD%"<<?ZG'$2LPN%;KR'!SD T"1U\!>G' ' 0LHQ%)]8R2+@H"B,
MV4$2%A&%(/>HJDC  12=:0D)Q[222,0!17P\""4R\JD<G< 3<$ 1CPQY$$\
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M)R4  J&@!A70;"BP(]!F%1Y<X5QH!J'  -12!PK@,!09 B+ '04 4?O&9P%
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M )F2^B> @B* L[1"FQ^!0W@ "J*W"H^ .5$N],R/7-EU]LJM3H8&68M2!QC
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M0$N5/=DJ/!%3RK8BA^XI4AI24$'59H0-?UE%:$= 6M.VH@43<$ *2.+'"'2
M9:UHPYI",:L'R$QK!UD9(W!D.VBBS!,E\H0*["*WW=W.NV%JUAKR5SO%30)B
M=#/5) X"A_C8Y7#?U9LC#NHY\_YB:+JKRPH;0%""%*RO!"0IX 90 +%5D*$$
M)8@<W*BZ8 :?I:XOL@A&CME4*)G(N8=[C <8XA$V71<!(\V(H+#BB=.FH5LE
M(.4D$* E4'!U3;R<4*E&8J:K9-0J# G!%8D3BOZ96$4E<DXEPXE<)S9D$K+"
MD:&*=- W>*F*=7 #D>"@&*6VX@U$*LPJ3C>E-TRB$B/9+5.4JAY')& ^6W/
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M@&9Y#U\Y"#R@@(,X 4WQCHLR ?N11[#4E#<PPJ?T SP0COY0:('=BH"JP!5
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M0V&YT90G###$56  D3@(#>B \'2$!?"4!? 5DMA  !W0/>73/EV<GKH %?"
M2<@#PUF$"]  "C@H%;@ #)#))^JZ%+B QT*,1I" %@B%#D",-IC4#6"(.O D
M.X!$5&C,$8 ##4C*"9#4T(R#"T !# A-[W&M9F&$2;T R_ $$,B "^#'JY@R
M$.%4#?[0@+)C.<<"K69IA3*@U4FM@*I45J9(B@RH $_9GV.Z@ ]@ R;=*3EH
M!%F3IPB0H3>2UM#;G--AN;FZ@ DXJ W SX-0&3^%5R#" ]F@':R(!'--'WS5
M"N$KBTG S["8A/V+5_M0K:VH3L(\+ZT(A81-$4/DBE ($-PD*HQT(H<=,:R
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M +Z2H158!%" H@QH%0;(@$AP!-$@U0S( .=Z:!"0@(.21!8H PH@2 X2UA)
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M5U6MV,48*F9$"62-99HIXTUV?%#" A.4X($G)*0P&!X+A%"&!PN\508")8Q
MP@<D>3*!!6.PX, ( WG0 FID^C7""2J6E $EK:A0AJ2'F4#!'9F>^2FH97I@
M!D$EH*%3EU(MPA)>H2S0!D$J5-!*&1_HU8&M-#% :AHI3?[$44FMH%)I*Y,L
M$ILC:!%$%$>K5-7(09XHZRQ/T2H[T"1X.%45JB7A@0H+*@STZT"4., (;*TM
M$A5-/+$J[*IYA9+!3 ,]<FU5JQ ;*K_]3NC)NZYM,(:PK:2@@0D83%#I(Q6
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MI#&0!I@*'TD"K:0Q>RLM[-M*!VP8G"L9&;3" N^.&OX_ .MS!P$ @ PJNLG
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M\C$L&!PJQCN8-B# #A+QP 2*C)='L&0,&&4$!$BC/4 BNM5*!I<'-KH_!Y3
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M@39$ @014P$"3$ '<RW"$3&=.?+;60>5ZI,D$/ >'"PP$#EH8/:/D*[D5I&
M?=T$!!$ P0<Z\$.#86!EVG,$]O[3T B*#20B)< 4_<XW!L=3@GAXF-4U+:<W
M5#B5-W@8HUZHP. ,A -0 AY0 /JH@54X@*7\D /$COZT5"L,B4K,"BHP@!"A
M0OI$@@.$@@<N -VE@%L]8"O$@0:L @9*5P>\30,<Q"0!T;%LWT!\ ))L@'XY
M @*L0A%P0+DP0!Q EYDEGQ 6SDV40=(<$QBMP@-0S1NL4BN\00=0P@+0VPB
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MG<2!XA&,N:0!(WB !SRA2@G<0R" "\W2[K#$&G#&",Q2&3R 0S!" MA/"U#
M(L@! V"%X# "&4Q6J<R2J[#$8>T/8 KF(J "QV3=6K;" VA+ 7C (K#!'OJ.
M&3"""&"0">B2'QQ '#A"" R.J)TD:UY(*&A="G"$'(P *$2"-#:"3Z5!!WSB
MZIA67L!!"J  ^9# (EB>4XP!2Z2!!_"FL&B=":@%&7C &[ !6H!""M"%;^Y/
M#4$/^)%$7GB""FR !] 5MKP)&?Y4122D'!N\!"A@BB()2QED1".(HQPXA'6&
M91J@P+)Y  A@EK"P0 <\IVO4@4.$R4$X@D]I$@B4$RJ0@??<0<RA 26L0J^
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MG,!FH8)Q$=9$P,\=Z,_-D);]K,+"?D (-);29  )B)4CS/[6380"!1#+'4#
M Z@ 8Y7 !P3M2%Z ")S2M"ZM@*!"&Y:@(SH $SI:_M'$!)#$*AQE'1!/1]A1
M'22 !NG/!:@.*+R-/%DF7>T.IE#.0%S MQR LJ5CY;CMGD[)(A  *#Z$X[$0
M$+50 SB")RA I3#" .0M+PV$:@$11GG RDS XD8*!71 1J! 1Y(!!CG 6QA2
M%7D/*A"1'' MYR#8_JR1^\S*!*0$0+I&&20**"B 0T2" A3$\_C!!3 IT]YN
M>:!"&I!DQI2 5J6,H:0 V Y$)*0:7H  J=Q$+=F!$Y:1WSE !YB!]RR0[SC%
M"3BH AC*&$1 & %@)"R ]D; &/Z8(&]80*S"31FL%L',W4!40".0[TU<P/E2
M0OJ*;RL YD"D5#HRB?Y60)3,$4(PH E<3RC0@0.D+QD@ ![0F3E1I&>U3A51
MJ*UH %T=9Z(\(WKUT!*1 0NP  * *>Z&\'U,P@.L ![( 0;14RLTVQW4P:IT
M2?$Z!70A+V\D4?0TB1-Z@L7UD /Y#F_062@P (': ;1XPC8]A /801V8ER>H
M$F]@@*G6@0.8@2-T,!!%21#!;ZGRAA13<1%$S$4.Q!T@8!A##V=<P.+$70!'
M6 ?@@?Z\P=S5P1V@'PEH51<)ZQ29TQKYDR-<P J1P05#0+20SE*U,*1&JP@G
M,GO<Q/X;&"])?DWK4)1*#)-4[!XMV5DLML(=,, JQ(&CP8'^:,!=*$ E<*H#
MG)M'K>TZKH 0D>XJ8&O60<L>UET!Y.V?D!VCG.Y  &;@'F@!T-TEDMW;3(!;
M#240%7/C+LY2#<08K)+)&B+<.$ CE8 HW$S[(8#HKD /S:1G50 \\<88,)4G
ML*(GC)'^%LL[*K(ZPP<H9$!JL< #+((*?/,)X QKA2O.(.V<60"ZEB &E> J
ML0$$A, %W$YGA58=5H !-<($D.LR,JM*-/0^>0\9T*'#EE.6.&Y+66/:M6U*
M5'0=LF]&C\"3+ S:;, %',0&;  (T$Q&R*]4/#-A$<L8+/Y ETQ,SD3,*A"T
MS$Z L(Z!W+@6DS3" +1C1RB "G113E#D"MBS=ZXS5+M'@E5*[B'KLZ:J<@ 3
M7ARJ"'V5?B'$')O3=-T!=(F05DL%>T680V'+MUCULC!"1DQH*#C%7)?+'3C+
M"H4"7,/-::U*.%TDHRY+Z;"J5)@9**@=7C0"6IC9,1UV$=U$H^W%LO;JZA $
M)51>5&<V?-BN[4*&CSD%3.,%&BL&CZ$"""P 84^I9J_V?'0VC#V&:^^%)P#2
M;$L&B[3&(W0I:^^VB<6V<_@V;P<W=@!W8Q W;%>I<">WAZS")""9>(""@Z5H
M$"Z&.AFW<E^W8J3! TQ P7X8FO[MJ) B-Y'MV9!.PLMBP$)]]XX2A"=TP)H]
M@+$-J:&!-Y7=1!O-]9.9T%H#AWJ3=R0X+L@86WBOMVN  .;<A#/E*'H)VFMC
MMX-_QDVH00)$IB<0EG4/QB*PGQ 5!BR6 '3=00%X:&-DVD L@%)<0 53M]WD
M2B0U!@6<+RBL-5[4$2(_N(UCQNQUF--F1"1H:!G<A".\P1MD@!Q$0A52S2B=
M@08 8OZ"0 A$"1O@ 0IH0)2D 0B,@+)X @J @+]Y @A P*[% =6 B_@=1"K9
M@86RRDV8 ?,]X3=J4@@H2QO<@>TTL0:<SYEO:-E2N;!$Q!@X  E$@AP\P 9X
M38^G$/Y!A!L(V&E>R$$(9")/7, $#)P(0( RK0(+>( *9,0CQ,$=C  918D9
M4(TGJ,Z=JX &>,TDD&<>@(!TKLX$S 'XR?B-U[IE+$(#L!KB4.<',!4<!  ;
MU $#;( =F(#TF0 ":-P$B,O-: FGU%,&X &GA4(<%);@'83.:+D)X")K=6Y*
MJ$PCC,$$B (H#$ *+'";7YVGD.0BQ($#8(4$7(X)+( 9W$$"4,4 G,#*1D <
MO '8@@("%)@#I($G,+0).$(;P4'OO<WR,8*XFBIO##JE>1$E? #ER2._QPP+
M3 (9K)(=#, (J($-<08E!,#Y=+P^41X<<(P=,&#+S\'HI/Z!HID 'JS6A=OZ
M@Z>)%>6%"-*C)]0!_-!+-&>46T5" Z3"!:B!!X[![+ M$#G"H']+79,Z4'L)
M_+AOAA-$4EV@]YR1Z$J.7F@/1YQ!QE" 0S2"\2Y0*S1 1I!!KI 4Z386_=#5
M"G@ N3<" M3<&7B@&<ADD$A7)$B UY2!6\V6ETQ6[BV 8C.@:W2NF$(>.'H-
M!:RCVS+"K&  K!3+'%Q@1F03SG_^9'QO)ZTY*&PDM021'>A/2M(5)"B/": !
M;. 6)51 '5ZB 87<+E/$^SA "%1%&:C,"&2,'5" \B*H&:Y""H018M:?Z(K
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M)1!D((<'.&.QI#D& 5;DI)8D0!\G,.!68$(!LUKN9YBY@9YIX -D>,"5'I&
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M-__YT9]^]:^?_>UW__OA'W_YSY\EIH-<]ZV_->B'G_[]]___K8.# '  ";
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M15KA#<JG N+C.Z:E CPA%#X #4(A ?!@%:!.9WH'&-FQ'><L$C;@ C0@CEB
M E#@RB(M!#I@%42A!!2)4Z I Z8I,>JJN%J#$@3#-6PG!48F(B SX"M,H%3<
M<2(I$JX8QW081\G*C7%(J"(]\B/CROG>YR0V$21-\B11,B55<B59LB5=\B5A
1,B9E<B9ILB9M\B:C(R   #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>comp_0010.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0010.gif
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M\>[S^?3T]/CW]_;W^/CW^/?X^?___P                   "'Y!
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MM*@@X21$B+5ZA'Q0L7.H[=NX<^O>O<E5#P(0K$ @@*+@A  /# 1 ($"$'A,
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M\"J(!@1D( @83O0 I%)?+!<!"#JL510"(@0!A @6 :9'#R-60 (0I07FQ ]
M$B"%HQDZ@^U>"A1P+X9P1;&H%D ,(,$TJR:L\,(,-XP("YF2X ()2?ZY..MW
M>LB :UB[ZN/$KVDL2F4=Q#KG X$$6"#! #JPL0!)VLB5D2L@I%P'"@$B@$$#
M!32A!Q 0& !   +HH(5%"1!   (/&"A('2HTD)T !5!Z0LX8.&"OHY#J<74
M!^QL+Z8'/*&-I .X$$( *CKL]MMPQWU;'1,$&<#0""C  !IZ8#  QCJ\Q_$#
M^D3Q*QE2]J"'&L.=D$9[+:1"@0 \N,' F#$7P$"=AQ+P01(%=MJ%E$[4\<45
M7RCA 0(,6/%  <W4P0898G D!AA9:#&$!3B"K@ 1UR7]KU)1% C\%TY.P?6#
MVO PWG#9*"3W]-17;_TO B- @A%"&$&" OX'"-&W 1\(H@-*=;3 HSY2(("
M%&X8-0$0'[B/PM$(4&J$E)4GY8(V+'#?!JS  @4,H ?G<$"=5("  UA!" "
MP!; 8P %I($$ :A %M)P @APH!T> ( &-%(" 7C !P5H0)T"Z,#V&< *1!B
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M/<NYSVP(M)X%/6A!RQG.AB8SG.WL9CS'^<YK9G2:'2UI.C^ZS&M8\YH3C>A
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MT<WE;6]5EYWA: ^VR2$AA0EHX $.T( $L@ $$)BT%(*4P#L\0!:B9_X"#Q)
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MX & H0.2UP-1((=L( (_M1EU$ (<H %%0 A*( ,LD"-6L(\!F25UH@<E\ 5
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M=E ",JEX@S %<HD!>@ &G?F5=Q@BM]E\EG<"H4$!XG,=W+D!T"F7&P &&_
M'^ &8N !,FDV;' "1  !9' $+-!!0S $%8 !=4(&(? !&M I5G ".F !%I 7
MVJ(!)Z 17]"9&W %+,$"!-J/+, #6M*/5OX E1N*$Z<G"%D7!Z)2 :3&?QM0
M %JP 0:P!E(  #O@!0,  DXP 0XP!S\@  P  53  XWD!@FP 5K0(EEB $6P
M P P!$': V$P  O@!BD  %A0=<5XIJS6!HF0!AAP 8YY$,GH"D#  (ZQ 7ET
M BJ"!QD0/8M3 :71H'JP 1@0;PV0#0I01E*@ 'K@ GQB L7A L7!!CW2!1)
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M@,DG!PBQ0O $5P "&/,T7^ $'8 E'D E.B(^$3!!W)$&/5 "5K@.=6!T0=
M9? %E:H-8R$(54"!:5 %0N  9- E*N $T_[0 Q9@!0)W 'FA!T?P #U@!8SG
M!E>@!)6K!Q#0!3IQP![@'!_P'ZX@BXX(B8#WK@W  U; #T+@1+KHPH83!E)P
M'T[[ 4* '@+G.D.BGHXZ!&) 4>3X!%9  A+Y !QQ0MH@!$3H2 FP%FY@!4HP
M 4.0!@[ $6" !T0P>4,P>?#X'QN 2 S@!$U )/\#<5VK.")0#X:0!A*@!D^3
M!5VK>!BP 0R ,"30#)HG"!. +1<P"!VJ#27P'W"YA7UC1:R)!Q%@4\[ !E-
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M15C@!?+!B7/@ 4-MF # !'J !3^0!D,0 $1P!V9P!SRP ).A!U1@ "<P!PN
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M?/3X\(#-!Q[R] 0I(*87 S%"&CR4 .:9CPVY1&08H@$$+BL ?.#RH$-/CPA
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MX $4J* !PMJ ")2  >P(00$LF,H))^*#A2.F!/S(@&!]X80'=$TP8D  "7I
M@=FE80(F ,QA"H:"!I" #5J2@0H84*0A4& (P-!%'39P B!,8#M^T<,$C% @
MK9<AU#QP00604H$-8$ +*H" #E2P %B]7 DD(- 01DQ*(VRI[&10  EX4($2
M@",E6KA,"'0P!P9\8 -LJ%(+("(<"FR !_XAB%+C2> ""82 !2&XN@IHHX'P
M'$$!*IA*ISL  :+NP@CR.<$#7, "!0C'"!+H00FBI 2 'YL%M-D .M3# B-0
M8' A*,$1I/'5">A !Q1(2?6-@/U<A$#?&B#)%ZP$G/\T8/-I( /Z.3,8ZS_
M)^U)@@86HH<\M* !(4B##B+0 BVP ,*A!.5V AM@!\] !/*!/<GP 03B!!+
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M;(@Q 5E  AA FJTW&-F &": #BTPG09!!$DP%KXP ;!B!".6#M0Q!21@ AA
M($"P$$5Q?L_@"T-AG,>W,G5 >B1P;>Z'&/6Y 8LE!A.0@+C@?DAA@KCP'63
M "4@ B50 1SE"^=F B/0>L;8 @&P*FG0F: 9 B-  KSA=N$R OE( D%1!BI
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M@@;<ZY0L,( '<641&!C0# W4]:X(+N MXI ! ?3 !WZ= Q7\"@44 . H&0!
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MBT80 A%HP )F ?X#!DBP 12<!00@X  '^C*$"AA>"FQ* @9*((&-H/8#(M@
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M%7!Q3. !6C 2+8 &((  82!G7U  '^ &/B ":P $#" %7D  SX " \ %5L
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M @6P+D@0 #N0!U@P!"+7 &A0 @)0 2? !'EP @5P C+@ 6;896@P 060 2N
M!9HE!4 P @A@8"A  %AP!X^9 @[  &N0 @+ !'J@B12@!0E0 2W  @EP<11
M !A0FC%F#+.("?X48(N5P &DQP%)T 7<J -"T #7%1M64 $@8!8G8(QZ@(R6
M8 0/8)'-R"+:(%=&T /2I0<=(),<(9,1P QV  %IX /AF'G16 =.T .,=P\2
M$!L?X)Y94(]9X ,JT !@4 <5H $NP P\0 %"H ,]@ "J5PE \  D8 2&1@9
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M*B #/  %$N4&8; #&Y  !J %.F   =H Q%B)3'  %J"JQF4"KFE9$S !6)
M%] "*< #/B!C/+"K938')A4,@,>< XD('* $6?  AI$$97$)/?  E58)/= (
M?2$#W( '(F !>E$)'G .?:$!USEO$, "5@ $F.<!)?&M$+ N\M@#]ZD"T8@!
M(> $4G !>K %]?@2DW /$9!YH_<%&J!Z=?Z0!"J  *B) 5)@!$Z@;'#A Q@
ML4D0 3SP!25P71  !FD  2I@!4%P""N*"%KP;AYP D] LEK0%U^ LN_'(CS
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MA7IPE3#>)E=U 3U="48@ ?5*\ >/"$=P%#*2!>R%"4;0>C3NLB&PB]6@""K
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M%BI^-L)CQ:4'%F5].9,P!<\59W4:3/D" ?Z/,S .R&K@P8Y+>D0132$91>&
M$TXH\80$/^CAPD!*)"&<(VY(4,9.$A!$A@0H7+"!+S^!0$A&SH3PT"Y7_ 2?
M& 4"]< U=,U(8XTVWHACCI7PQ6.//OX(I"DR?H1-  $ Y(@3 9P R3(+*+#
M #[4D4 %TCA#0@ S.>-"!WJ T8",$QSQDDXD$#+$!86D@4 =); 7%A!ZG*G'
M'1*0 48$7S8S 3B;E>1,&A.($1P>$GPQ014+2>-$44)44(@1-A4$H!"@12>4
M,^.5)U@C;I P@1MN-&!5(16LLU\%(>C1:"-I.$#&<N4UL&5H$! IQ0(BA  "
M"=WIH<,"'G1P0?XRCK"!X2,NK+K0J67PT !90TG0Z;3.N.' /GI8L(06#[CZ
M0*DZCDMNN>:>6VZ0ZJ[+;KNG#-FD @IHI:D>6A!@7"%D&)&&%@*45(<TNS
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MN1"*<(0DI)'E3HC"%)Y"6INP@@($8($' $ H5@C  1" PP-LH0X4 , $,#
M!:S(55_3@P=(D 8E-"!69BD$",06-Q^H0?X':K%" YZ0!@P4@P0:L$H#+B,6
M#CBC!Q3XPA8DD(Q $6Q]!9()&Q1@A32<  %N (+W)- #-K"@*#VX%.Z:=H)B
M9$%LA8"# 4Z0!!_T8$5.4( 3OF"!% PE $ 8 A!\H) 6#"\*#5A'&AZ0(1)H
M:T (<(P1$@ @)S3 $1, T DR%0DV,&!SA6 !:)R1!00( 0PJ<-Y05 ()*3#
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M"@D X-0%$&#;T-::%B: [  T@" M0 9- # $%C3; -MV@@D   8J (!98@C
M!K10[G,'  "C= $!E!T $SAC"_B^. (4^H$ &. RNPC MX!P;J?N+@ $$,,8
M9I@&:!/@  0 0/X%E*#M A@ VBJH=@'.#0 %Z$$( +CXQ,]6B'LM?!H3=ZH#
MDFTD@)<AV<P:@I&<_NV+*X 1(6!YMJ'S@ %\.XB>O$  $%!N7LN@&)#M&4&$
M ,WO$HDQ-\' BH!=!P10@'S]9@2P6X<_(@V!29!(@P8T4 $.2(L%$]A !?;!
M0 Y @&G&QH %/D 6(!0&L6Q2TYH8H(<D!#ZU/1!;&ABP:1I-8&)_QX0SE,"
M(#@"".4Y/6@A-^S<G]"MF7CW0;>@ 0 DH0Y-@ (%%) $)Z2!Z$A:0@#$!@(#
M#-D>8-@%!*X AB 4(/!9* !JI& /:>"\!%D( % A\  G3*$A"I$  ?Z D 8C
M"$#H/1!^(8@^A $;00$4D,(2ZD " W 9$! F:($,9( O5A %X=<Z * !6B &
M'P  2.%^0, &4O  !7 9(L  "! >QO0 #20$"-  0N$&$  !"D &"%@23D!3
MRR8%728%%H  1J!\1A  *G %$$8012  *8 %"W@W6Y  *$@6(="! "$!#:!^
M#:$&8*  1K@<#8  6B,!#G %\3< H&$"[V<%]N +$T K8C $!W K* <@6:
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M7_  #3!* Y)QAO$ 8XD'- @5/D  ['8 WL8>'V  "H  !S 6Q<D +L #';
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M$X="'H5  B :#A7@! ED1$-0FGIP N!P.*SB.4#1 %JA!6S82+'2 E[B"#Q
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MJ\@>&PL4$G -M=C>N"@&A( "<&+%D[(! /[QKB0 )U&@->8Z%/AC.R_!-"8
MTWX"!%\@!9,2%(SV!0H@(!.@4*T!+$T++*K8V K1V'E@ DPC!02;R)AMZ[.0
M>JH%."E0 $82K(Y0 57^;RJ7!&QJ1 2P<S4G% Q0(+*$R)V+=F)'<4X  &(D
MIE/Q #0W #\'(&G@ 5#W>%=S  )P=AQU!@= N5WG0203STEF  A  -).9$;
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MI>9L<'DE0..4/M?B^A \90(BH+YZ0 408 (?4 %X\)J-, (6P (8 "?^0_D
M11:*S2H($%&+HP:2 0<8X $S/&LG>NO5+PN?0 9D1FEX8@YN  ;2(OZ-G$^(
M*R@&UZ YYD &8F .R*@YZ>_D>PC^I5$'>-+^8B M>  &3G %F94&51!'A04(
M8F5ZA&E@=81Z9(>$=F!B9)%DB(EZ;E)/9)5Z74Y6E'J&>GA@;HJ:;E^(8FEZ
M:E]Z=E^MA*^@A(MXA&Z/D9!Z;U^09(*)=6!LH6)Z=5]PBF"28J9?:LK,I="2
ME&EBPZS0B;F$8$Y1M(2Z1AZ%25*ZBI1JZ%]&6I551O1@\87H=4Z4F$J$AXPN
M-[0FC9(2)=2A08G V-L%$>$FBW8\T,(CYLN6+UK023E"B]>6CUK>$*JS9 DE
M%2UP@2(ST)^>974T56+CKA(8?CHY)K)B1/YGFF25<A(J8ZI@NH #%2H-E6R2
ME22@>#[1-950%B)6-EE*TI 0&W01@:8SR.Q)DIIBX\J=2U?NFKMX\^K=R[>O
MW[^  PL>3+BPX<-WX=9=S+BQX\>0(S>&)Y:RY,N8,VO.# 3IYL^@&Z=Q$GH3
M'B"*2ZO&;'FUZ]=V$<N>3;NV[=N'V[!N';DU[[F_*\O]'=QQ\4K!C\,V#5IY
M7,N\E3MWGDXX9.K#EX]BSAWY:^P$,X//#IP\:^V1<:M?S[Z]^\3HX\N?3[^^
M_?OXS>??S[^_]O< !BC@@'CIYE]SX946W8$,-NC@<P]&*.&$\Q%HX848RD:A
M9'BDMN&'((8HXOZ())886X8HIJCB79*A@($&,%X 2W+=>:>'%?=<X0&-E;D@
M0043&%$C'I3YEF ='"SC!"TXVA@>C]LE*"64TG4'CPC\Z&*D$BQL5\<&,XYB
MI)-15D>FE&CJH8(0L929B!,IZ(%"$%%"1YTN*M!I15AIA(!(:P"9HL,0;II9
M67''$6D=0<1MX@,$83U9RP=Z2'%")2V0D$@:'ZBT':(+!JI'"SW4":&5R%'6
M Q",TJ7ED))]T% 4_%A1@IB;C*;+"5*X.1XA*P8K[("23>""%E)44<4MFH'@
M0BA*0!9"!5^PX<0!1!1Z&1X"Z1%!62'$].N&#UQ1%Q ;5**$9P=*L?X%74)H
M4.D]GTEQCPDFW-2 I[DVH(D(78YX4 /TRI4& WHH84$E(P @Y$T,> B9&PPL
M(T46KN6AQPEQCEN:$YIDP*H2$\AEQ0.$5)#$9\.V[#)N!D)FP<J5I#&$+@P1
M0@0)/"!5!P\D (&($\LDG(86%G@@Q25U&$&)$LL848(. ^D2A0(U'7&I(BR4
M$*T>4631PPEJ6"$"H6!?,78:5HS IAY.U*$$!"9\\84%')!61P\DW(Q+UV5Y
M5982_#2-R!$DZ)",&DV P4(RB"N^R1<JF$":%J0E7+C3;NA00A"Z./'%$-FN
MX8()5E1@+AE=9PYW"$3X $*44=3AAB<EM/Z %!F9TJP$&3J$9<4)*+Q+R!"Y
MTY)$[CKM38(0\"S?@DY>\:.$%BV40*\Z'=QH/?;:%Y*]ZWI@3H@2L#1MAQ;>
MP!B%&!5888(*:Q#4PP,LU(&"#D> \'7")' !6O3@.*^5+W-I$%(:LO<U>QF!
M3HXSP?^,$ (C1(%>2DA>KG1 @H<!X0$RH)X>I#8]/90! GI8@KS@,0(22$ 3
M8H! 4X+ ,U.0A!!.Z,((3< "&(:M!7@( OX,<8\TG"Y;R $""7RPBB<\(012
M8(,*4M **USA"!7$4\">4 (5\",*D7*#D$ZS1&YPD&9DY$%JI! 6/.@C%$>H
M%-LF\($O1&$#9O[C 2C<H (),)$#1NB!""*%!R&0H ?,HLO+%LG(PTC& BVP
M@A,\00@)"*$.# B+"CR0A19P8!0:,,$4/,"."CQ, D\0 P4XD(4L-$ /$HAC
M&AK AA9T( LN2%<B5#"[5Q%"#!'H010LH ,]?  "23C! U2@A 80Z@,/2.8R
MFRDD!F#N 28 PQ<JP(&&;$ %6@B!"FXR 2%,86;;<0+*ZI" +BE! GI@ 2MU
M(*\O), #*L"#"^:I <J @0%*R(($M& %!S C >-<0LDFT (Q>*"8(7@ "4A3
M@1,X(00($ ,;)A $*U@@6T:(I@\<H"EX$"P-!$"!$SCP23)(0 =/D/Y 3"2
M 1*(00H3<$(2)O N$B1)!Y\D@@6^H ,((,(#*-"""&XE5*(:=3L?B,D#-J"$
M%C2@)D-(5U3U\  -5+4!==@H$*R  4+I8@JOU ,#\B4%E(% =R\Z!P,L^@%=
M$@((#<@?"R! .@4T1 =X[ $&9M( >U# 7F#5 P\^@ <*_, *&F#5"1H@@G4Q
MP!X5B%8+*N"$'AB@5#S0@!5Z8(&L&$L*&H@37DN()PV (;2A0-D2,A E#R0A
MES=Y@"E   (IH&!A&^ !,QH !AU@  P^P #<#O !/0;! 2NX@PDNE0$=;/-9
MB1 !";1P@A# K0"#>H 'L*A<%BB !W-[5OX*QMD#"C@!" Y( Q$J<%?EDF"[
M*/"N&RS @RL$=U0? $,)Y+4)(- W#0-@%1#D)0'T0:".4T! "YQ0@7%R104/
M8*(',)"$'BA $R00@1900*G&-/+$*.Z+Q.JB 0EP8 ,7&*<>OJ !#[ *# Y
MB@2DH+!=%!.0A,  :7BF!RQ00 \]H!001,"&!EA##Q.(HRY(<"OOD$#&8F@
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M0EGP 2%@ A. <1I'6QW'*G]W!2@D!)^$""C0);JE L)U!2#PA<WG!"MD"1(
M"R?0)5F0 1!@ <M&!!)E>5H0!1P'9&" 0C!A%@_P!BN@.[H5.O2% BW@=2/D
M +4G AJ0!2Q  <D'@&E0!R(@ ;$6%QOP!"R@!%A2 :UP<F9GAASG!!Q'"%9
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M !W! %'@!B$V*A; -@U *?#@ "'! /6',%K0 $_ !A[@70X0*4# DF10 4/
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MR:2L'XIB*+I !OXE\ $>\#]5XLF6+,J^<B:MH3&[?,D0(@1H(\ED@ '8E2;
M'!QN4)Z&4LJ'PLN/P<C4+"!_?,W8G,W:O,W<;,?5_,WNT<WB/,[DO"&I7,[H
MK!G@O,[JD<[N_,Z;<<[SD<OP7,^*S,[X/!N/?!]XX,R0<0RW0 K^O!@#G0[)
M4 >_P2P=XACL AI.>(6,\=":L=#&D"@-O1H(4:C[K @#M!(;#1ML(,]QP2X8
M5ZC*&1\F/0]'80DBK1IV\-$DDL\R?1@P_1E%TAHZP \Z(&:;_,RG4@<>P)*)
MD!%"/2ZA]RX+H@=;0%^I9RJ-YTM+727;Y#')40%B  81\'NG8@$S[/XQ8%"
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M@!3$P "7 '*(<$OL%K1C! OPD0.5V0 #,A<W6$!6LN=1 !" H  4.L '8$V
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M6!!!8, 1E!#FVDP! !MJ@0$R5^@>(%K1"\[TIH_JJZ**>M2D'LK<0'T$$NB
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M_55,1'!O*;$$ 4<&42(&)L4,B.)DY0($)/Y@"5F'!Q70!>2F*E9@C<UP!43
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MW>@U.- 7S.LM5-R8+.P%*EI0"$@B"';P-(=I',P,(\8A#?@- ;#DDBXRCAL
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MPAO@(Q40+R-9"DMP%L\18>-T"7H0#T(4RVS@CZSL(1<@#UMP$#F*^5G !@Y
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M$A@8,\FPH'A(]["($()FR'2$?^@!R+LE0U594 (4!) ('P*!5]AT =4,L,5
M&4%60R $,^08AH<0PG82) $FGX %TWB?=]?,9K>%]\UY&QD8'E";+/@& TJX
M &1$$!PKN( ,=,;=2QO1@Y5( $#_.K* F:F'7(("&,)A0!U.<#HW:.(#L/M$
M7_4P@N**(:] @(=J"6($HO;1"(V@!CRDC @0#*$.# B4"KZ@@N!8&A1B> "X
M+! 1!TP##)<%@W01L5H>JVL+# Q!"OSCDD\<X4,AW0IOG2 51&AB",/-:BBJ
MK <3%/?6),BJ"(0 5F<? MN;,9\C#-?F=OZ[NVQPCC?:2-:+*+C@LB> AQ0^
M"N@>/ $"E*BW# 2;A;SJX$-&>, 1\&HD!FS!$PPHAP4\D&8]" $!.I""+Q3Y
M !X\@0+LV,!M],H.,$"@!Z_,"P]NZPD'I$\(YK- $K+0 "<D00,Y_BLB.$")
M%&! "BZ@,Z ]7H'@?,)&0!^ 5XSH!!$<X U?8$#B"$H&!GQ""WEU XM$\,][
M($ (^VV&R_60 1%(802; T)A/UDK%HDA#0_0@8A8F<@/ ,4!+<@S ]4.BG1(
M@01IO^J[!T_XK\G[\%7KI,A:TH(TX $(X$J")L2@ A) AB4D:,&&TH#&+*C&
M+_U-'QZ(L";2Z_ZA"RPHQR=\4 (E2)E,E#<((IRPTB@T@PPLL#PBM/#YJ?CF
M"Y=7PC26T!4W^$ ,4DA?(;:B$BDB@@R5AZ.??!"")-!>#VQP@0JRD(0ZN &-
MB# "&[[_"3:@,0VW;."B..C[\%>IT#P@C18@XP3E7XL%Z<,]"<!?_]G3Y0LG
MH -:T!? YRT], +QYPC25W@,V(!.@W@0R#.*-S<'1E1M=F :8 5*X "SY8 >
M^($.&($B6#$3F#)&LR<HJ O HSBAH(''<SN%\C#Y0CHK2"Z? R8J<SFCD 0H
M@ +-0 JW4X/6LSB>@SI%6(,@F(1*&#,CV(10TE1+&(52.(54B#-8T_X&3F@_
M4%B%7X.$7/B%8%@WJ] &6,@*9#B&9?@*:K &9X@*:K"&JJ &:<B&<YB%%I,_
M89B'>KB'4I@&:T E?^B':."'@ B(@TB(@2B(B B(:C"(?WB(?W@*D(B(CNB'
M:P"):!"(D7B)FBB)A%B(E!B)A<B)HVB(FOB)I(B*F8B*A+B*B_B(HKB(JWB*
MIX"*2)*"J6,[N4@Z17@HW8.+Y *,1\B+JJ."Q"B,Q;B+Q*-FQ',\,6@SR!B-
MQSB-RAB,U&B-U=B+S @VTIB-R8B--@B.P^B-W6B#<C('=R G=S 'ZB@G[IB.
M=/".[MB.\=B.\PB/\GB/=5"/=9".^FB/^?XHC_SHCP(9D/1HD/VXCPAY!_Y(
MD !YD ^9D ,YCQ*9D'QXD1B9D80751S9D6#0D5_PD1X)DB+)D24952<9DB2Y
MDB.)DBQIDB_IDBT)DS,IDS1YDRF9DS&IDC7)DQPI.J/P+Q]9DD,9DB<)!D>9
ME!ZIE";)E"CIE$:YE%+9E%/YE%49E529E5:IE5BYE5[9E6")E%<IEEQ)EEA)
MEF@IDFFYE6MYEFKYEFP)ERYIEF$)E71YEW:9EV.IEV7)EU]IEFT9F'(IF'%9
MF&[YE'Y9EWNYF'W)F'^9F'CIF$8I!$$@!)9YF9@9!)IYF9O)F9U)F97IF:$)
MFIGYF9\)FI4)!/ZE.9JHZ9FKZ9JB"9N6J9FC>9JT*02J&9NZ29J[:9NFB9L
M5@I&D)NM>9NM*9N\.9NLZ9NEV9S(R9S/N9S2Z9S*29W)>9W069W1:9W9B9W3
MZ9K&N9GA69GC>9SBV9GG&9KI69W&:9G$J9WPZ9W<^9WQV9WV29_RN9WZR9[H
M29[]:9[^J9X!RI\""J#'69_X>9_SN:#[F9\(RJ /"IX1H9$46J$6>J$:N8+
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MH "BH5=FVP '4 4Z,  2T ,-8+836@<NT  4C &:D 83\ !"< ('H/Y\3F
M"M "$E##*D F1E#%@#NA/*  E;7!##"A:2 ""C  "  "CA("9LL !H $.L!?
M5J  #+  "O /2E#% :  )&"R\MO'$+,%"F  +M%&:5L&22  F^L!!D  ?7$"
M \#&:$NS=7 $6@L$+D   ) $;(   0 4*!  "+!@!J!T7/'(!H"V,VLNX
M"5!Y"#  1E(!4GP #1#(FR,%!(  $+ !!\  !6 <(\$ !# !)A"W"P+$NMP!
M7Z #R7O*:8L CG(">4P"&3  "B &:D"S<4L S; $IVP %5 !""  0.%3!N !
M'W   W#!*F#*D0S-UQ  $& "$A  %H '/?[PN7QD!24  -*P 6AK2&"   ;
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M ><,.MS^!D @  I 0'-\ ,#L! 1P "< 0OB;/G;^ !RPYH KW3)-=CX\G T
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MSOWY]>TV:-"P@7X&^O7ES[-/_[Y]?!OJWYN?7Y_]_?CYU^]'_Q]]_IGG'GP
M$LA>?@06*."! 2J(X'H0/C@@A0XR."&&%6IX88(;>MBAA!^*&**![5EX(H<I
M@K@BB2V:N""+,;HX(XP1VHABC0V^N*..&<IX8X]!_DCCD"/BJ**/1PJ9HY$E
M,IEDD#:\0>4;<%R))1Q68FEEE5YJN>6577I)9I9CB@DFE6:F^269:KHY9IEP
MLEDEG6^Z:6><;>(YIYI<:@EH8X(.2J@_::R11J)KH('HHHJBD>BADDZ***.,
M*DKIH8VB<:FDCOXJNFFGC6+J*:FC9HHHJJ9F6BJJI[Z*::JRLMHHK)="&ND:
M:Q3*:Z^^NJ-KL,(.2VRQQAZ+;++*+LMLL\X^"ZVPOTY+;;681(MMMMINRVVW
MV%H+;KB#>DMNN>:>BZZN;8C+;KN&I0MOO/+.&ZP;[MZ+;U_%1JJIM_W2"W#
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M@B!8H0$2Z,$7+& *#MI!Q!OX0ATT$((/?/Z@:RS(  L&_(D(3WB%)=@>#R:
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MR?,$%W +44!]8K""W;-"&C!)=7 "GF $N95L)T$&4[AJ=6!ARY. +)!;:7
M1[.$F@9X0$!WU]9Y(T0!RN8 ,Y<\>, #GOY@ DJ%:'H@!=3'>%'P!OK7/:6
M '*S!0S@"*:@!"2F!Q:P0H>X3 PP/FJG!T&  #_5B+Z72P?@:A@ 0H 6-0E1
M+UR0 !10*7&P 0;@!4Y0<RI@ &E@ @8@ BBP 2>'! "P/7,0!@>@ DD  %#@
M!0.  KW(8R:   VP!LBC Q6@813  73P+U!'C1XG=35A!  0 +:'"1BP 2T
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M( 1-<(>/" :LYPAB\'8VN02Y99)@, 0<,#16H ,JT !T=(&)MT*@^ E%0)3
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M:@4X=P<3X !.9 *5QP2/105# '-:$ =$"KK!X@[=QQ*)P &.V ,@] #J"$M
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M(&2_V["QB3 ![\JN'X@ GJ"[>) $<2>%EY &*!@%39Q5,)@$Q>H$"<A\I?D
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MMFD9AKR*'1,>()_D:&IZ1@&J!I(W_5-N4,^R9@M1T'P6)0&&R6SDYOZ(.H
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MX#E.3)!%%A601@$%R+YB1 1B>*Y4!4.XH8$+>M#.!FL00>"$%1/,J(3O5#!
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M0FFO8 //0# MQ: -5WJ0'![JD 8$L,$$=L%-$NH@ 7I-0"@6((WG\G@+()"
M#0P@ QQRUZ]=8.,1M1I$$R88@ON0X0%*X4$7%Z:')(RP [DRG1XNH" 4'$.$
M>^QC&E)@ E$XH0&$^.195% "/4P@.;SR!096(81E">$#;V" &)YQ@1^-A %/
MJ(,;ZH 'M=S!!;<@P3'2X !'^( =$S#"*%H 1CQ8PQ5)F$ =X,"&!.3FDF*
M@%"N(8H(D($(A<2#&V[H!J4X[SX?$$$:9E*(,#C%?OVACWU>P<VWR/X@!'K0
M "T^*13SX0$#Y]$!?2APGBV1@PRDE  /W&"'9XATG^2X@&+N-2[%9,$);I!
M'=10T0FLH@6UU V2K*" ZWE@H&=YXR73B <Q4%,*#Z@#&1BP!&ER2(UOF(.Y
M='!)+=#O%7A$XP-,""P5N"* 6]5!%Y$$2AY U!*Y H-3K)#4*%R $&[0V5#
MD 5!#,(#A%D6$-C!@EYR50]4M40#X@0&-;)! CE"AP\7R]C&.C8><\%%'9SX
M'?=%@%X0>,O7XM8#+1 #>..J$F3TP($-D& $)&#!)]\"A"YN: BW4$$MG?(!
M+0V"6&B<P"BN4($T2" $)$C1CX[B -DD3/X%!!"*#B1P N"*X P<R-5E"$DO
MQ))1#VST;1T\X 1]F4 $);G(*'A GPV1(0@%5 MFMAH"C(GA2;H:02H><H3&
MX76^>K" 7D[@"AY H+DE$<,(,% "\*( )\ S9Q[!J$I?QFD0&*#%,0<1!!&
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MGN9;PS9\PPN;OCK<0Y7"/(/P'AO,!2#" RE /SK02PD#!CI&6DFP2-S#NSW
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MUMW2DYW=^5 IEW6X.D !*@#+USW>Y%W>W?ZJW>@M#^L;"V2@K.ZPLHC\WH5
M!MUEL6\:W^:=W_HMLNG=W_# TOL=X (^X-OLW_V]WN,JL?CMIPM.X [^X(9K
MX.F-X'OZMUF<"<08M!X*X %N!]Y'M&Z@V1"N#1=^OA*.WL @!9+6(A=P/DGP
M58SJJD @ 4 6OU4P 2V" 1(02%5P 1,P 1:@(+T*K6;B 14;J>28!F)0L\?Z
M!?/W =I6#;Y:"$Y0 1I0 2)0,* *!$B\K)&@ IMAJI[ZK)2ZY#[;#L[ZJ61
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M(&/"!,4#)(@<^\"@A1(VA2QHXV% U@0I0S+H":&"#8D/>GQH2.,# J&I>DI
M&!+E@;80(=STT% -@I8I#.!I.!NQ&@,B3C!(  =.1 ,G+ABHF )!HXH/8H!8
MT".& (LH$RXDX=% #QD%)*2T4*QG0PLR*$(8,B#B2!<(6:PTL%)33X836E1@
MP"-%PHF7X2*<2*,$@0\K$UCH47))RH0K->MD7*(2GIL&4;(PJ)/&!$: L8$/
M[T&@A!,,'*%' _HQ($86$IB0AA'/=%:>'AZP0(8*SK'"@0YZ.'2,2?Y*A#>$
M'A)H(,4(#_#@1 )2J,CB" [ F( 5;BC AA$-\)#&%1*4  8;$Q !1HAZ?"1.
M!55D9X$+;J3UG@$D (''!RJ0P0)A-:G @!(\,%""%12XI\,&8!A1 1QN&'""
M%!A0,$1%;KC!0 A1]-" +!YLR8('>JB@0 E.I/' %%H\X,0Q'I"@10L3U*'%
M!)"RPAX)9$R!  ]68*!6FE\<48$L4TWPQ9_#W(91$O(-,1Q=/GA0QX)I:""$
M'BPH8((3:WR @11I*% ';V0DT2<]RL9S4+/./@MMM-(VJY >0P 00(KQ0"21
M0SP(J@</(NB152&A$4+$!"4E\($''F@ QOZP-+&2!@/&%"(&76 \8$P$V.$!
M086856(O*_EN\\ F$) !AE2L2'"+'DE48 @',$GPKP1DP(=,&@@P0L%#2Y10
M@0+: $'8"1\XX09)0A"F3% T\6!!&GC(DL867\@"6"$?Z?$%(;GH<04#5N!!
MU\3(L(& &B>XM^0#J.DQ@@N5-* (#R342@8X%@S!Q@-TH5 ",A"(4:^I&"PA
M'QYX[(B>P_X=[<9B$E-<US47-'H,!HT.\8P>1&R@1P77Z.&"Q86\$4$&[FJ@
MC1Y3:+#!C"A()#D#>EA S2FK3*"%'F]0H(@&JPRNAPDJZ'%"#U:<%I31K&!@
M(#C'6'!X>(6ODOX+."&80L$J3YSVUP]U* :'!&84L@&#+'QHA>89!%$(#P/#
M]$52F(U$2!1-Q?[OH"<L\D#H0W2@!P-:@*/D V3H(4DA$UA1QP+W>B#$%P\$
M5>L7.H KDR>\+13@T%TA.*"1#5S#=GKH0(J6H*XE90 /#\@".#94$SR@*@T'
MR G%-A"Y+)!$@7HP'=!@0@(4Z,IBX-":'MB@F"7P"VEV6Y:RIH7#'.IPASQ$
MB+*TP #U9><8H6DAYGA0 @J*8(D@T$@A,$((<-3!!WAP0LB.42OZX,$A6>!1
M3;;P 1"P0 *;(*/9TJ #B>"A#A780DU2]0$61$!A#",>^121&4,03OZ#H:M#
M!+(1 1.$8#!J&()S&)B&>;WG &FPQ!9*D(06)($P**N$""0 @06Z8 (06!T0
M*C !;7R >D [C1,V0()EL,,"$?  'H  @1,,\@-D\  IP3 I5H1 (V*8@"QX
M8 (PD"D$(EA9&IK"NA8@0V-DF(#;]" "(!CA 268)1F.(*AF6  "'I!%"YU#
M"!*(R )+B <&J#$$<*5311]88@BLQ@D'N%$>&"#)7RY031&4($#P>*8>)J"?
M"2@" PPR N&B\(P)E($(#Y E"4#03SUH:43@N (UJ%,(,B@& [<H32%$H!$*
MS,BCT 2"?>K@!@G@40-N(8$%2$!,$J3! OX>& %EE,F*("@C!!9+ N$V\@!!
M#B9\)U!F@!0Q!!#4BP1+_,!*($"7%HP/#Q3(@A_= !$=.*$!#O4 &%C@'J&9
M9@/O X<0"$<(%:0@.=H"4:Z4X)?W;" -#6#J8'+%BOG 3P/.^.>,*K&_()#
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MM[@7Z^$)#*#+*24V,"?@#3=-5H%["*L((GR@#LFJ!$LD0!<=J*5P5G5?(3X
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M?RQC0S?SFS9SE75P!7!PFN=VE6E (E,QA+&XGV')!C54"2E965F0!#-VGO*
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M>) F&Y".A2 F.E !'O!B!J4<C55C[;&0&\ !)6"?CYH%\.H!F_!X0) !%F"
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M>* $!I B" 0TOO0EW,48.H !%YH!:QH"P>4$!%")AT4UG9$,$O$!&O&B1F
M4H ''H "=:  [T-YQ\ !V]Q%8* %#H('+( 91T  V/P!$O&]BB !BQIW)]
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M$AL<DH4#)FT(BDEC,'"7#P\ H8(!58C10(=6J:@#$!7$I8,#1/A0WP\H(/?
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MT,_2GO2N(;5"8UJ;TC3PX)Y[1683/+"('(9, R?HQ0^P)X86F$,')S#!"4@
MFV!8H0=<#,86QN?)4 3!!TY9!QD -L0Z',&4ZQCA$#2+'" TQB1IT,%9@)M6
MF>J!!YNCKUWO*MZSRI:9J\VI28:05--"]#A)*'!/(<I; ]^3#2R(!?Y1?[K?
MHM9!!^?9[VV+:E^]8?;#(-;.,H7 CSHT8!.^K(AI1=J \&JU" 3Y$9-ZV0-E
M2M5**];H%T1"6(UF#'#K"($$E" %$?!"#Q2P2"R>D !V(( %0/"!1]?A@@GH
M( 05> L9&L !#UR %5F @ IT ('*F20*#E"!"!Z@%C98X ,L<(!$DO* %)
M FI<AP<"P"0M+$#"585 GGJ\MPQ8#:Q!./0R36*M''^5#2A@R3DS!EJPAOC2
MF(Z.,>N@ @QLH0X5^$(2LLL['TB*$Q]8AA9\8.,E "$-8(B%&X80!&#\QL6^
M\ %S@6"$N]0!#&H(PA+LF00@;"X-9/A"#_YFC @68$ +H-:"$H;P/BGX@-FA
MB,47W) $:F<1"$NP@SF<XH9%@,$-L3-'L8=8AAYL00A= D47@<"3*_C@A%_
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M AI@!!JP$2V0B.H0 A[@ Q3P4=XQ?#@98G486'I0#KO!"NW !A5(#R+)"1P
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MCP*ZH" )X1M0J?O,8L5>PR0$SFAQYI"46_ZV"%+0 42U =):#&R@ >\P)4Y
M G[L >H@"M;G ,5+) RARR:V.U)@ (Y0 -J4!2O\)!%P%[Y8):90)<+$#!6@
MA^7KN ,GLI30O]!+*L7#9B3PHA.P!&J0%K+P"?$)HQ,0"T 0GB%P"!&<F%KP
MN$I0 6( ?CM;)%]@%1^0(VS@ )B)/6^P 3L8#$D@EQ4<"K6Q.@]  FGP!D-P
M )C0@)P0!?90!XM96EJ@ +W! >9))76  3F2 9/@*SD4 2K@!EIP*SWYN"K@
M*2/PIA;@7%HP&)A*0>B1 '%AKK?@ PHTB?SA!@N0!BI %UIP -KD+HA0 1]Q
MMGD=#7!H8@AT?/ZI@L5)V8T$P0)G,T7B2:!Y8@$,:8\X.-@#Q0(/\%XQ@0 _
MT!(,H*X3"@8)6)B[JQ<50$&U(-<#H@'J\ 82 #@:T[L^0]FWT&D%H0X'\ Y&
M< "L<QI2;)CFD*Z<H ,TERI :,G( :4FUEQO.KKP4P$8  QI8!4J$+HG0"4\
M( &NI@"T@-!9X+N@\ 8)8,H,P' +@ >(;0[X"!!)-<8.J]'((&Y$S:%-N3(@
MX0!TX@3_'#?0G-_R),V_1 850 )XT %J40<<H!9*X(@6T'B4@Q[.5P'<V5$G
M8 45 &L8 &= H %IX %P\Y<<8 $(A*(2NS+YE@(;0 &5&0P\8 %F _X,I0,*
M:B)097!_>*#AB- ![P"F'4[68D(4&["$'.!TSH<!C8LF$WD(*> C59*(&] Y
M'( !(7 ""PP*[.<!%9 GOB@" ?-J! $&%:X"CI(&(. 4-(0"]QH,/Z#B2QX*
M'*!8&2X!$T#<SW!H5H ,=: !>;8.1I"(%D "=Y'A%C !)6!X(6 !&J!T:\3<
ML F1:*+B!(=EHVL2/G"]%"H1@'@!&JWD>28%%D#ET5 &&& !BB$1R.4!%E "
MF'H"I&X"K5J"CE@!VC0>/\$!MW $3KTT]7@7'R 5N=Z3#: $X3R#@GAAU:4'
M4X  [#4-\4<!L&$%*A[#Y7P*R#(%%\ !%?YPMR[P$1E>Z"1;M6HN:8EA"!B0
MYCH0#3W@Y$$@@E;0)5%P#5:  =1N3:#@;!H0 G<1 G,'$N[N=:&P 8\HB.\
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MYF0%+LCF6ROMO(BG[EP'GO;>J%^O2]X@@88('C+(",\7=6[P/4,HJ%HP-V\
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M!&\#1:%!!()H4$(=42A@GR N5+!-!(]EPD, 1NC10F$3=,-!=WS!\T W@YS
MFCS\_*52$AHD-V!?XLFH!PHJJ-3/:SHF4EN//O[H"DB0U-'"$1Q4L%0=+#AA
M@5PZ;+"!3D;\((@4/*3!FAY 6!!"#QADD@24.IBC@@4JH/ 2(A8LE4D(+*A
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M$& @\(XTF*Y=#W #"'2B Q&D@8X?8 ,8V .8!DQ!22^R @3>J!(60. +:8
M<AY@!2.L3"O3V*$!A(# /#&,*1+H#@0.I8(;D>!&8IB H#(1A)6!@0+=J !X
M\E@C6=XH"WF*POX 4J4'"R"'#0UH5.&<H;AH2G,VS;A**P7!@I> DBD0$-'J
M]$ !*RS'#5;4 ]<$\00%?2 %8-A"$!Q0!PAT01 M$$$BD*22#^C$.$1( P.R
M8 4Q2$ GF2B!G\Z#/.4QCW0])(03HD>"#3@!DGJ  !&T((82=$ /$I#+$5YD
MSB,(\AVL$J0>0E MIC2 #7G1@PS\I!2,F@ U$CC42D(@,"M$  \3&,(6Q" Q
MCMI) F!0P@.,  9P@&$L$JB"("S)OY2*H%J9$ )JGEH'"9"&90HB@<"\6J-F
M@>$!N2%!M6HJ"!Z08',DN< Z)# -?C$3&CR(V02F((@)A,\!.F@?(?Z.D!(R
M,$ *62!#!7@ !P>L01#'B4)@&R"%*XBA CJ8F0ZN  >&@L$*6D# %YP TE7"
M:F@4T$,"51*%AK*LC()PPP,$M0&Y>"!)+(BM#HS@MY^IY 3L6HX6EE.&E9Q
M:'6#RQ6FT( AU)$02K# (#KZ## XX0&'TD (HJ ?_#PA"ZB[$3B<D-SE,B4-
M6E#!BVST#'(*P652\*,H]3 $O3RS'M.LKWV7(:1'9-5$+:W@.AX07);UD 4Z
MD )JK-!#J@A""R;9P =:@())E:%$%+,G0G"7"0_LDP-'T$(#.J0"*:JD!VY5
MB19JIX(T#4(+#!@>.'2PLDS@(8\,$-HS(/XPW-6 YYI$N.H&DI &WH!C!#WH
MI!XJ4P[?UB$";M" .".0XQ: 9P+=D4<(B(,H"6R.MZNIBE[+,8$KZ$$)()"
M!O  AIML4A!DU .1!=$EZ_W&.GJXPP.HAJ@'1!7.U>*M'KXP%D&,H%I?AN\'
M! H.*3@W#1(P@QZ$$(*EXB$314!-??(JER^8("EBS@01]*B'+#C@32IPP16"
M3.<3Z$!4@A UB O\Y\,P0 Q#D( +ZJ8#-H0)9R]R0HE7<D?XK@P<24C)GQT
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M%X003&*%'O3- L]6B0BL  :3*$$OF;@>T1O #PD$.!,1!C=<=&^G#0@F$TN
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M!"N#+&F%&FL; ;X"C"H!,Q33AN=4-<VQMA+0!6F@=%>@9Z2N LT"SDENC&2
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M  L"J@X&.,$*>*G#"3@) G^.\Y_\L*$)!%D<(%"@C[T ;$CI\@,*>& ";?%
MRS#  8PR-1]JT(!Z@'?(8D9,LGH8 56'(/X0*TPK"JTQ;#C;DI8VG< "',!
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M@@=$\('',$('CRQT&AS(',0<O))Q=8 (O'QRN>"DT"\^=<#?)8+506!GK*K
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M"7CE 230?SW0 Q< 4C6W ?+W##K0*AZP :R5'Y]0<QS0 0/1 PZ@ ;EG!!X
M'I.@ 1%P G9 !@C8@S/4 SPP2!SH@(SP!-;B I(P!#=8 >D0!1)  :L0!$0X
M3B;0+"=G?'JXA_[XEGQ^N&\2EV(>=P]$( 8,$ )T!".D\3X&-'EN$ )]XPN:
MH0>(" 9?L"Q+42'9LEDGT#<>PE^+00 ZT L<@ )N$ 7Z D2^T!= , !&P 9[
MI1(:L!$Z,!N?P ,80 ;*$R</, 1U(",L,@! X ;?H <8\#P\T!J89@5NH#\9
MLA$,L 5UT "OJ ('@&81@ LI\#8M8 '&  *B\#/$18ULP +RHQ)@, $5 @3
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M!;N[:C1SE98&0P $/> #/! ?:: #)3 $J_Z)CBY@# 5Q F&C%E*@ ZB"'$Z
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MVG40!4C>IT- -^:P9!#2=8:: <6AXT'V"2W0KG+#543N!,9=!T\0-JZ=$G@
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MJFPX0"08=91P L81CD@3V88'>#(*/9B !VYH0!:^L 4RL&$;JX, #]Q5ABR
M@0RNV 8*!H&A:&7A?(7(AU<FD(LZ"*A^FLD""TC .#"4H8-\V4@A,. #?H3#
M&8NXP++6LHU4X>$!9.&&"MS  !^D00H[JAXAG.@$#QBA.85PT)V>H_X"#%2A
M#A]P0L0J!L:*=6R,9"RC&<^(FS!&BS/G,0!.@E"!;?! (B&H@".LH !7^( !
M:L*2'H0 $3LL1VZ/T%?FL!:3HC6@#AX8A!L<X(@T:, "3"+$%PS0A+(H@ Q@
M: 8A)! RH\GE)B=Q'2(X4)>294)\A&#!8+8!A@9T 159D< 1],"0#<5"!#9T
MY8'T5H@04, 5)X!>+P?S@!&I3@EQ=,9&V$<($)"'!/K*0HHNDR-"!.%)[V,)
M%3>0C@F8"8DC#%00BB,$7WR! <10P@!D" QY_-$3)_ 6$!"0LD=0B P-N(+?
M3!&9(>SH! ":!X4J8*9*9$$)V2S!CD+ D_YUO4%@V7A &6Y$B0FD RB$(,*.
MG,#')03*"11R0J *,0%]&2<H$O@4!&XI!@3$CP&YR(("W,"/YY!@$!8@#S^D
M8(5[D105/)O(!@811&^PQ!L6Z%L(M$!"-7F@#@YX3AH\L)=JU64";)R %'ZJ
MARWDT8D2,),3#"#!!>1#"@/00E##$04*1>8+!P#"F'J@@+UHH!X6" 4%?LC-
M6=15*S2U C $%1X4I( 0Z:'$!Y2V-V/LA0C%$:<>TH" )]B!7&KL+&C0"-K0
MBG:TI]FA:$@T$0^XPX,[$A0&_B65(SA@5B?0@-<T<(0C;.1/*ZJ#!CC8 0UL
MX+>%V,(&MJ&"<?YB@ WS"8$*>& !LG1S(D(S 0<F\(.P'E<^&.! 3PMA :4.
M 2-DT( &0B""NKCA QB T$0+D80*>""$[Z"I$N0Z!'VY 009@% X-%#4;;PP
M!.;=RWK-^P%7:& +1<E'"^1K@7PH(1.B,&L#9O'@Q\IE&W+P0 >:!BT"G]<5
M7]! !^Y""!U8@ ,8F*41Y/J*"7#@!!D 0QH@D@2Y'F$$'?5 CH&FE@8,@IGS
M]8TFV$2C#80@'&#0@'<'P44.D ".6= !0/1@A@R$0P?IP(,&EF&!#ZB@!Q6H
M0PL ,F%"].H=$,Y%&KI+0 V(@+TA< 4'WL+,$+A !35QEP<FX)L2+/Y'!^01
MP[\L\",*>, "N8 HE,0C/#VT@#R2+K1P+9 F/+BJ Q%VB*(1.I%)M^U3'JA&
M%"S@ 0J$K 6S,.D&'B2G(4Q@ R?80#7(/%]W3,0*%9B K]]"A@VP.%(>.)<5
MK)1<.TS !'\>A!U$L &OP<T'N-+!+%R7S8D H<T.J8 (6M "#DA28IXMMQY(
MB^YTJ_LVI@TC:A5V63"@%K5IV$L=:%@(/.!;>O+.27Q(%)\ZB&$;8RJ4D3/7
M'QOGNX!@*.+>%IZ-+Y"%1(Z#2QVV0$!*; /@19+*HQ?NAGX7PA\0?W0:OL#Q
M1]^;$&KX0KL)(89PK%QZ'L^&P@NA!I%_//X-E802QUO ) G I! SK\,7WEO
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M.(0P!45+9KE0I13Q!2&04 0W 2*  B:0 OET?%9GM$8  2Q@ BW"!B=P;2(
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M%# !54D9*FXV"7@@!#;-CV[PTX4 !"3@!*3J"EJP+&F@ RJ@!5H !$--"&S
M'E\ &$]=U$8P*Q1=!V^0+GP:!:UE22K@ @/B!&0 &&S-$:"0"A,AUT1@RR%3
M!SY  BJ0('%%!%80C;/"!F-M!5T0"D%-")A=!BU  IFA!U=P I\\$5@=TBK
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M!)N$,$2$ADSQ]"@^;)+& W@8,;@1".A1Q.*-/Z%3)]6H8,X$C\A22 +_B=%
M'5,SEX*8*Q9I^BA"IJ[ZZJRW[KJ01+:8RA$!!% 5BQ8 P0888&BL1_X)!S04
M10,M5-U $CP0N)8A8!HRIBQFHGEF/T)LP0 +53_P0YPHK+UD':MH0!DJRHG
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M_22I 8M$@ A@L (8TBE)7'&U@!8X@1;(8 %.TLP4RS2$&/*$ K>9@/X';&!
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M50L I@* @0IAQ?XVA \*AH&(J=D*Q-+#% *% G,(W0*/6,)9K0!M/:A!6TY
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M$S)Y6;)IK!Z:K"K+F[E9!Q60!3Y 5:.P!"H0!%VB!4]P BN21SI@$%]P 23
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M,<I0=3 !&P $+/  !M$"&^ $-M=]"* #0L  ][ $F(..;' %$Z !$HQF1]
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M')/W 4-0 H6; .'PRBR0@U2!>$K2<7%B 1;0 SJ@ST%PT)>()?-3!YOR!0_
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M5Z:@7=8)'7$A6<  ->@.M]M?R8,'#Q "O*P!YE FG- F0O,?R0<!%;!OH^"
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ME&M3-G$(*[1, S%:>F4[CSZ]^O7LV[M_#__]FOGTZ]N_CS^__OW\^_O_#V"
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-VM"*=K2D+6T! P$ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>comp_0012.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0012.gif
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M]/'W^_____;X^@
M
M
M
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M%6C@@0@FJ.""##;HH&N0$%A:#W\,5YQ#$?(57W/M00*,$ (V9(1W",TBA%Z
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M8:H@"1K  &O@"BR68CNV8R.X8AEV"A[@ ? F"17 @Y,G9!Q&@RXV>:I "$I
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M/8&%6N@57.B%\_<58O@<XD@^^ @^&A:3*B  <+ *I/  !; $'J@*40  %C
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MJ@ !I1@!"7"3"^ !KH !41J(BL  %> *,4  A,"/!5 *21  :] +:U !TZH
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MQG@Q?:A&1A3HK14ET 7   8A@! BL ,(P0'5[ ![  R[X "UH GZ#0QUL '
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MQIH]4_[F'!F55"E$"F.E (8@L#$.@,V52P88 X[!ZHY*P"G7!PW %N0!5H?
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M)AZ@B?YSP> !'!&!I490+4PT^ $&$0$BX/*>WARDJL&Q$"8T@!$1R"8"<:%
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M&;  !U !25 %$Y@!)?  55"$$VB %)#TQ)B!!H" )'!L!6" 0(=IWJT!"+"
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M6K=R[?[J]2O8L&+'DBWKU11:5H0,8$!;:A6( 85B#"#4"\0!17V2*%DC:\:
M1;$4#2*DY  (514,$))5B( *6:PJ8"ATP ,<-08:_!V@R-5;RR=DR3+AF>Z=
M7VD"A%D3 $JOQRK@ %#2RY2#"J<6$XH5ZTV ,[W."$@CJ\8 0ZZ3_%(2H(TB
M!"IZ 38DZTR -4@$1!D4 \":* !,A(%S"BWZ].K7LU=__E34BF0  /A8\>#1
M6E!K-<#QQ4L3F  #01U/34#')R'<AQ\$M_B2 R<V+9"'+PN,TM0$>$04 A]D
M@&&&"!T46)$7$U6T 1K 4.#'4[=L8L<$#44083 0@/))!/X5;?( ,%[4!(P-
M-P#C2RU\Y!!!1!-1!,P(7QR$"9+!C,+'#DC.X< 7F?PT!@6:Z+%' 2I5),,%
M:'CBTBV8F.% A!%L8M,F>4P@!C E<+$D"5X )8=9??KY)Z"!"CHHH84:*BAZ
MJI1B@0&?M5)* PN8D@(!A<2B @&FS"#  "#(P@(!AL1R1@,5K*  "*M8H)LJ
MA120@BRK5% !(0=4X($'*L2@2@P(&+***:T0@@ +K;2RZ5P%*!++( %$X=H:
ML4BR@ BKG<&**1@T($D%$)A2BBMJL"9+& *PT<MVAK Q+G;0#1 978V= 8 :
M,Q#@@08GJ*!&+$E$0,  2[C2'O[!!:\'GU2V=/#!+4\%LX >0Q[D@A^[,*"?
M4R((&4Q%MR20252U/-"P2PAQQ,";P?CR@$H'V2)"+1/L@DE+%>'@@L0CC ',
M!"S>EPD%+<PAPD</I(P3CCHB2=-!-^  C P:<$'&!1&1L"23#0'#"03!V"!U
M&1K\Q(<+$U  S!<3?($#%V5@?)!,#M2$Q@0VR'&!2@]XXDG0<C3))!A+YM%!
MS#\=>CCBB2N^...-.SX5>N N$< )A1220@ QR*)" ;V9T&@IBH@>"PL#W+%*
M P[(8HH!J4)0 5JJ8#  $J!B0(H"&<02KE^]PJ&*6PU$8,IN"9P2 W>R+ &>
M:RK\)OY #(4(X+PA][(2P?"EQ+):$N0&L(0I'A! R!H"A$&N -!))PM=;VP?
M !MI@!=;&)*$P02P#E@ O,&Q]Y_>>ZBRH*?@($=/&@ H;N& I)1L#P3XQ))<
M4#6L-:46$?#%)C)@. TXZ0-" D8>'%"1BM" #KZ80# \,4%@U $B0WJ @%94
ML@X\;2$RZ@1%(G C"2@-&%PP").X4(L"- Q*5G-*"5YP$#1P !0&*&)(OO F
M%=$!$RX,1AT,]Z"&><P3#\C#D")PI@B\ @4V.(@(=E:"P(TP!"W( 04?)\<Y
MTK&.=KPCH=:C@@$@@  ",('V0A" QH0@,*M0A2I.$8LP#/Y@ &^@"P8R@  ,
MK$(!#4#+*B21 @6D8 (0"!<!&M" Y)5K &H #2@9X  "G$\%!W   P1  5:$
M@0 .:  !$M ;P%1  0L@Q"H8P("TK"4 ,U!$ @:@@ <(@!#R@P*YP*,( (R&
MD0)X@_S"$ L/#* " [! *593@;@L 5O_8\]YT)-. '8E&"1P@ U:<  R &,4
M![@ !_+) 5L  PP)6,$-*#"!G.S!@$T9Q0(:-H(+@.$#%V@8*!P  RXPP Y+
MPH0(#E*"';C@3O<IP0?0L &<Z80/3DF;''9P@0_XP@$I8\ G/M$ '3$ &)M8
M -MP.B <F,$%"< $&3I0,A0X8/X'8EB AB+ 4Q<H8 ]D8  9N"#&.G' #!M0
MTD%&H $TP* E* B!'&[@@*<QP!-HB( <N'"!EHS@3DTQPP#.A,>YTK6N=KUK
M'=VS"C@H 0EO.*0J!J$&201V#:58IRE4\88P*$(5]RO$'=Z@BC:\P2U(" /P
M%D!)5Q B"4@@Q,!4 8<P%()_JS $$I8 3%:DP !P@$(4)#$J\Z5A"89@A218
M 0<F1$$1V'I#96-'B.YP=@EM6$0:2H'<0K"B$&E81"G8,(A$CE81RP66&FIP
MAL2ZPA!+F,%?SRE>=1+O*U3J@EQ]H0<ZL)<.63R()[Z0@_<"PQ81<XHO^'"?
M//#4</[ J,7:<-@43^1D2%](D5."00<<@/$@?"!94_+ !2W)(4T-"X8??+$+
MD]J$PYO@ A\\\:97@*$,NT $)FHAH*9H A0+;EDM2CPSD_HA!UR ($7J@(,"
M/67!8VB8+]#P!5"XV"$-TP,7,.$+.6"PP =9"EZC+.4I4[G*7&&/*WPSL+1L
M>16QP'(L@.>;5:P"6Z[8,BMF$  '*.  ;0"-EV,!++1DF7^8] TKM&>"0<KB
MRZX( P#"T LYHX<58TZ+.=,2"VP9NA6J^/*C[WP*19K3T(DDM"E\$V:TM$++
MZ;$S>T M7H19N=1VQ$43*FKJ5;.ZU:Y>7,%*@9;SR-I@M?Z^-9:'2]I5U)H]
MO0XU(=B@B&\E=KFGD,1Z?IWLR"G;UY%S"[/5T^Q$C7?6[2&U5P9(D?MH6]OQ
M2?"WI^+MDE6%VPZ#RH*Z?94!CIO=<6R*NL.M;5^ H<&OOC>^\ZWO*U>[W^R)
M\YS]'3M7@/K1HA8XPMV3\&H'<-\.?SC$(R[QB?-[X0*?=K]_C5B+_R^=&^<X
MP3[NGJ^8NT\C'#?C4"X6E1>*Y6;Q-L?./19WHSO!+J<XSG/NI_&*'.0^_SG0
M@]YS5.B\Z$8_.M*3#FOR C#H_CZXTZ,N]8(1O2NU^-H&;,!/^#8L#_3L=KP/
M8@<4M*#L(XA8NVO^[5N<R1<VN/X0N,G]E%I$30--\.^[*1CV^W0A8K; L2\\
MD6ZUR]MA>S](+78P0IG'7>Y/"?(.ZK @7Y2!"W+=&A<B1)$I.@44;\O[03@!
M]_B. >Y#JOSE/<&%*0:#\XRW20MJV'AX&[[<3;D%#OQK!HO2?/:.]_T +4][
MWRM]XM:>.O*OW?1^]USJ4*=VP1HN[JB @@$M0 0B4+"  D< $3[,Z,V? H,)
MR($,9AA#RL9B!@X,*0>?M\HK&M "3/#A D(MRQA,*E+\C ST@O($ ^!=6 3#
M!^C,!@!1S+0 1<T!,*B0&5P !*'!!Y4,#)P1R_D"6K%0 W!46=77!-@) _ )
M*%#  _Y&X!D)$$%LP-8)RE'DPI*@P-.$WUA$ -H5GPTR'0X>7PX23_+QX/+U
M(! FG/1A145\ $E9Q < @Q]$0!<$ QC P"<T@??AQQ>4@0L"@R;X AWD1$78
M@!(E6(;9Q(J!0HE!F"9TP1S\Q(W@!RAXS05@0C"TH2;@ GZTG1D,V5.(0$U4
MQ"Y, ,@  Y)Q6."!0A> S!S\6#V!@B9X02WXPAC,046\PBVX(1S*P0/,0<.<
MH>1%&!=,807Q1!<T(AG(P7V0&!F0S";< ADP8"8(7T_8@AB0(B>N6"T0&0/Z
MPAUJWE/P 8\,R0+@4-D=Q!XL0#\I! SL3 >LH,N(P C(%?X?<,%]O=4$$  8
M+0"?( 0* $,P.@0QDH$2R0"=<  #/84G> $:_(0MA  *.)E-Y")\%8GP89 M
M? &3_9=<C8)<M6(]@L(%+<D+@$$GK%Y38$(7U.-_C4'I-<4S<IA3Z$$7V-LN
MF($73-$%F%0PX $T'L0GV((F\($M"!@60I@-YEL0AEKR-5_'*=P/ZB#T$<SS
M*=]*SAI5V &/.<4M+$#*Z$@"W,(8+, '>((9],<.)$"!^(':W( &Y$(P1( (
M; #(=&$)L!V1580(<$0)G!$B1,#::  =CL$$@(%6 <,.9",PO  .W,(&0  7
M6$PMO, '514P7( ,@,$$"$A%Y/[" CSE0?C"3[A !XR!!BC$)AB 648 #(8
M4Y1! N! "P1-E0C)7^;"!CQ $^""### "N "&E! &90 6;Y "%B5D]Q'&>!4
M8[9 E9R1)DQ %^# !?!3!'P %U# "%1@0D64G2S,0<  0T@-,)2! WR 0HR
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M@$'<0@,TY]GH!#WI0:&N$3#(01(" S_Z0BXX0(%1 !]D J3:@@/P4T4\X$%
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M@=&"V,("G,E]>$("Z,<$F!33]$@+/"O9N4!@#HC3-H4,U,0MW()2'D0= ("
MX,(#9*T&W( 5+4E%<,&/[*E2"/[54IZ)C<C!U71 ![B O?K$?BX C1S$)OA"
M$]3$3XR VQC0"]Q)+C1(&5P-,&2 2;4M"00.$_'??2[ "Z  #*!5&3P #*"
M"SR 7HX!Y%8D,& "!>1"!)3 "KC !JP ,+A)J(ZJ",B!+41)G9@!&CB #)"=
MWL@!^"F% \AEPR#"%0+#9EZH!9E4O"[)E]I$'@3#"_ !"I@!&&3C?<@ 1_R0
MQ"C@4[ K?&G !K2=2RT)SM["],( 'ZR &9#!U51$L<:<'+0$#=# 4]3!"L
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MBK!DT2,./H*"'0"# 4/TQ0)&X <</(!SJ6- ,+HP H%L8@ XR,0'1  ,$3S
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M ( UR((-)E $" Q0B%/T51*G,* !-!"+).19%ADX@"1@;8A9%R"%9U %(0X
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MP Q>CX$*5&  H0[ M,-PZA@0P!"FF$4O3A&!!43  K+_JP$)D *MME06)SB
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M%]K  PC! Q1 $53!$ :AUHZM -3O#*1-%F!-$022( T!#DH! PY@$59A 3Q
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MVN(3"H!@<C&T%H!E?($!R+ /$P(4!@ 4/($!! (3L)0#; 88N)3M;L 37J
M@L$6;Z$.%.#*&BMT"& 4.N&R@$$3L%1.8V:_"(X$0*$X;>%-C1!+7R$!;.8+
M)B\8-J !'BX"N* 6<L#+$J($%D /ANX+;B$!]@ 48,  :O[!$Q8 &&! !&[!
M#A: !H"A 5(I&!I@B"2@"6K!!GR.#") $P"NW=)P%,A  *KS[A( $VHA!!9K
M G:@%G!@X\S@537A 8!)!.YRDA: #D!A!+:R#(AU67TA ?( %&2@ &IA-@4B
M%QQ@#$#!!@+ -J]T#D"! U;@RT( %.B  4"G 1!!(!P@%E=@%_2  3Y!$S:
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MDU$&84"C8%)&(UX&7RY'8\H"DSDYE47Y<CHYE4W9DM$"E2N&E6=9(E:5!$J
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M9@=LEY4+8@PX8")VX"XA)QA*X %V  <6X+OX0E/O;F<P0L0JJR!@X#(+FRU
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MPH,APHD<I0<Q,@5IB)*(Y02B%@C=%\Q<QRA]PSM!9D;A :XI=1H =40 JE'
M<OR0*T.+!II NU:G X":$0?Q('#&$T ]V/N<<X'AI8$AU8&A VSGS %/T!/]
MT(,! E8'GQ&%K0E:K=/$O/7YV].D%,B9+6Y!WS"" H@I(5# #D;A FQ !!B@
MW3KA G@0R#9! ]X]WI-H!3<@M#RAA_[=!3H R#1! @+\ ]Y] DK DBX !2Y
MNG1F!$J@$R;  78&#2B@!"B 8C:A VP@ D9A!%X@!"* #%"  CJ 879@ V!
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M0&L$ "*8K0>V@'&Y@.)"+3X=@ 'C\P'8BP\M--2ZI4'&" ==@+58D $3L&#
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M:\'D<1(P=<SYDD==X(("23"T2$ =P&BR@"^^// )3S=:I<D%+XS0P0:^>.(
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M40I0$'N+$8#&%PEXA0SD\@!DB@D,#"00*%C=DPB(FP-@R(4#/#NI ASJ7WS
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M :.P"P7@ GS@ FX26?C= 9;;$WG  '6 !@_0$%S7 2C@!SD@ (QI +B@"1.
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M[7@!&?ZS\77@/15@"YFP "Y0 BM0R7'V "-PN62P,B0P024P07P%##I"'9U
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MP)3HY,2 .=2B!$PA"@V]D@ [\(\ H* #N9!VQ"22@7($8@"W+H #6W3!?'-
MXP4L\@ ^["(!2F* '&QA&+,@*Y ?PT$MO& ^4/2Q%BZXD@WF)#P]>(($!""8
M!F[AJBMU(0*=\,4"Z& +'!0@1?[ N,LMY"#%DK&E%@O@4@+RX(D2% !BP"C#
M SR!"0CXY@4KZ2 .6I R!)5&!+[XP@5P@8@(,&4"W*+!)]K"!0/4H18=0 %/
M,/@))P+C!AH !1\8$)P.3" 3NZ+0!/"C 1C4PHB4.9MSNO9.K8T-GEH36]7
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M,N +',"1;HO"+&Q"#DRV3CB9AV@!, @&35@J&,@9(O3 3? 8&*2+A]@+P M
M3=S$/-LT!4Q !,PT!OS$3J..0*N#"\ *E]F$#7BR!CB:(=H %/B 22L+3;B
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M/IC0%=@%$<"/"$BAX"BJA_ $HX*(%HC4AI*(\X$ 7X" $&D+4342X 0#'#"
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M#:"+'3AC%.A-/<61,:C?%G@ W1P%^!59#39@&\B9!UZ %@B&_(V+9 J,C_B
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MX-V-TX/.68&4A3,NH "[$!!,L)727N[_:VU17+J(QF*%6]TN-H]Z.CN<@T
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M-PBW69/"42"!2+2OG!FX#+>Y<O-RC *%FLD/>7.45*P0D:B%$2!"/G^.3N
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M&F'#A(%0X$RLA=:$,VHL" 90ZT#+P@6([4U$\1T_[6)/.G>MRV:7,L]I6A?
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M)PODL<D$?@#SP 5=@;( &71<((%L(7GA !>^H/$ )W9(X$M#(> 03!T.Y+=
M"<#@(,(F7FP03!X.N #*)P\@DL<"F1P4C 1-U#("#L"@T( <^@D$PX4X%$ &
M<\!,L,,H)9QIQP-ST*$ '[<D( ,?(VQP6P; Y/#!)E]4%Z5!&LB1201[X#%!
M3@]LD,<(#W Q1P)@?D!#)RZT8-\ 7^C!*3 N1."7#"V,TD(("S5Q 1]C. #*
M*!MD>M GO/+QB@(P\%&"!AM50(8F&VAD4# -"(2@0;Z0QX=A.8EPTHXZ@3'G
M!3B\LOY"@# LT$(=68VQ20<:[8B#K5P8X 4P7'"@"1D7^(((!"L4]&TM+<"
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M,P&/V2$"!@D!&B0UK02,P@[' @8:.-"2%8K@!<$(QG!NP8"TX&!O-_@=<W!
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M%I=!Y/Y 7&C"U8Q!4X"""W0 "L0%)EB56?;$,ZI%"P1CWTP+%U"E?<S-=I4
M&/C"#53$+=#D$8F S)G;0>@EKV!>6H*D7:7%5ZG7CFVD"-  4F)"'6P=Y_RC
M#9Q9&<D (8[!\O@"7(J 4F7"!WC,&(B #'""#/B!'4P%%WS43W9 ";#1NR$9
M%SS58$620:R);<[E9^9!,." M>FEM<U!%%E5&>VE7D:,)I! !]" +T D]-@
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M?, #?/Y  Y1 NTYIE1I$!,3$T^*FE]9LTQ(I'7B;S=+LBKJ!MU%II9TM9&A
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M!&Q.&;B0' @ %W2.3!#R#N2 #7@,&,)*N_D"!6Q.864" _Z(3@FD#@/DQ,B
M@BU, $4 $;4(!!V(!YZ<$TO(1@<%CFR( 04 JP;08:[4P0#\" <$B /\<@X4
M0*HQP/(X !_D0@5X@;*"%KM2P/)$5G,L#2+98==VY X4 !T(%QE^Q(MGN!X
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ML&P A)<5P(!U:1',@8P;,G+4(4C0UH8-G@CR@0 L&+!-#GP!*[, #$9@&\@
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M@N20#!@.OLN(#O5@2/'-+X:;F81;[@:F!!HOJ&,3XDQB8)--(GB(#_\(VH2
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M B!M0!PP0.P+$1"!8@[8& 9\X64,",8'/H"''5S@5Z!00)?TX  RD($!T6%
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M%/'$#KZ BSSP 13,3=8F;G #QOB"## P@UQD\",\%"8898 !%R9E"R[(@)S
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M\G A @:E!/2%[%X!!HP06!X $V[!!<#P"Q*JYFC ?FZQXVY*Y&R $W(O(\:
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M(0_*8%):0*WX8 PJZ7GLH"-N00[F0*IRH01*H&(RTO,:YP'B P:^X!/&P&Q
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M.4HC3<TC@33+6!A@ \BG>5Q@ 4:@%J;G"V1@0IAF HR2>B#&)# C#R2@"T*
M'X."4@^,!$* ##Y*1CC@ CQ# ^RI [0J!&(G,C+K 3)F##)1 C(E(T!A QR
M/FR  O#TAV '5BE@>8Y5!N+S/49@ H1&!'@U.F8$=FY"5EV  40 %&J! @).
M Y*1#Q[@*X-A!$1@!R* O$P"!L+U%7!@60W5?O @ED9@*$"!K.A  HJI>F2
M JX4=Q*%0\@K CJA+62D!+[@4-VJK"B "S8@8U[! 58 !R+ 8$1BL:Z4 \*-
M+O;J-?XNX 5D@ &(DD9"H Q& GP8P'XB8$L8(%\FH"9J@4]LX *T% 9&  P8
M@"_*0 /P:E7-HP@AP!.@A6$F8"A>X($ZP %<(#W3L"=L8 $Z0'B&HPEP0 ,(
M] %*X$+4@TI00 8X@ . @4KN10(B$@)NH 0NP#\N1&@](P<HP 5HP $2B@8R
M!BRXH 1& "!'[H,<\>)2U$4?\>$,-U<.TK88\.,4U1>,@SX6;%T(XA.(XPN
MPB)%PA;8#1B\ "A<H";HZ@4M=P)>L%P:@)YR(6MVP7._H)E$(&/>(RH68"-'
M@#?)0@Z.%A0<HWHRD2"X8$)*0&=$ @?(PGJX(Q;]8P28:/X#6M8!/*^@;($
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MR&H%:(0+:H(!#,H3'.(#OD,UJ_Z' D@-,I(V 0[(9H!A&<O83K+N?4JU#/?
MTUHQ& P@8B@@*@[@V1P9(7Q!,X ! IY-I0K"/U;J4+"$CP"9,"* +AVE]HR.
M$1571170_8YNY')N#,8 !7!! SPADFS !6!@ 6J!##07?'\GX);()2E@ DH
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MUQ](F7JW%J;6YBA1E57TZ$*E58#NN2].]E % 4?N,,C"#A;@.S;"*#)A0KJ
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M(4TZQSU^[O..!!Q@ 0<XNJVTH 4$,4,&@ &*%HA@!'I"*/XPZ' Q8* A*[>
M00=&(,LO?&"3'3&#5V!F!AB@1F4HT  80K!(AS8,%P: $2<2Y()#@6$$%FK!
MB5[A A&(H"DRV%<.0"$'/G#%!K<S;3"XL$Y,V&($(B@!7#2V@U]E!11<J,-O
M6)29K' $$[!M =@($@$*?4$,P-B%D3[[D-S)(30;T4-F;& OU'Y G*N5PU\_
MD8/#XE8.'.! 3;UC.]FRM0EF@ R%U$FF'6R%"W(H@6SZ$X' <(0/OY+!&5W
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M@@AZY ":#: %%ZFR+VS1H!%'P+00H5L$0%&&#)QH!.-!A 0< ZD)3&4KF&"
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MX"XTDP<,  J ]S,>Z FC("N5$4:WT DMP$O!H $HT  L W&:L FC4 %D0"W
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M6R%&!F,P 3D FSO@"V1P45\P*J7)!6NU?/,G3B$@!YI0 <$Y!KWB=_+2!1W
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M #DJ1]KJ57040^ B0^"S+9G9K=,Z >I*<F-0!RV0 &$X$'R0 &0 !@:P(C1
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M!I Q9.  <@ &!54+4U89%,!2WB$ H" #$Y '8Q !9CQL><2MVEI#^=2MX!K
M]W0Z?!#3GH #7N <?. +KJ8',% 'F*!B=. "7) QF  1,:T59F #>F +7\"P
MN4.8+4,&*Y '?&!0U0P&8/ %=) T$!NRFR!HG4"^:=T%A_XZ%;Y@!ONR!\*!
M$2_ !6 S!P/C"V/P CFPU3/S!3C0"9L R*W4MFVV7I$"&KE0!O,+#'.@,YNM
M,W7@ N:\$:>,,#L  ]T!#'CP CN0,71P**#05'D BKX$ SL -L[I B%["W/@
MGG2P%;70!"\PTG0P,,W=,F*PUS3R MWAUAZ#"5R0"Y@@2WP@2QV= W,S!SEH
M!YG@UEN1"UF!".O%!Q3B"U]P YN0!R<B!S90![< !KB !PH3#-#(W\DE!^ZI
M)C&=!S P6ES1W2WSV+G(!9TX4&6@-<%0!BX !@_C"V  JI\P!KL XM5LM[&Y
M"1EA4RV>"9] !K?@X02!%S"04_X:8P8N '9L!=UPH=UDEPERT )H#1&C)P<H
M, >(H&)2+@=^H&)[4%0-DPM>X )\H =6 PI3 77FJ=I<X04O\&F9,!J3C1&?
MZ1VO.5ZF30.:@."U,-)Y\ 4:40<PH =\H"=R<#!\4%1);@;Q$@QHH#AR "-H
M\ (V8+^C0]86%-9(:.F? T6:GD"8@ )>R3L0-ZV;/NJD'D6E?NK9,D>>D\!>
M3>E%*-;6:BXR=4J&9$@<Q4W39.NJ4TBZ;DZ39$H@Y4FY_DZI]#M:P1AZ0 -Q
MSE' TR_N:0:X?D[\$CL TU+,%$W$+NVH4TV^/NS%_CNF%.VW1.W0E.WU!#O'
M'NRV7O[MX_[MYDXWY.[LWUX\X7X4HDZMR98Y,-1/S/:ME.GJ(H'J C_P!%_P
M!G_PHZY/K.Y! %]L=404"$\^][[MW;X[733Q$9_Q&E_QI8/QI=[JF-[P!#S
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M#N# %^P21FE9901HH\"U'+(^O/ZQ$F_%=-[[-F!.8."" 9BPQ2A&\9R-V&
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MAG)+&RC$I[LA)F\,ML+)!2JD /F1@=': 6)T%E P@(K:"!HHIEKX+YT(Q,1
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M#UF5#1 !7^"##; *NY*!$$"!#=" L]@.#=BO C$@;KF\"ET5#A !%\,$"N@
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M%4\3>B&#'$[*T(2*P/CD@B8=G 0<2<!(Y(H* MSABBD8"/X @@(0K!)% !@
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MX (ZB"!\>6" &;[P@)D!!P<:X$03\)<[#H9N G3H @%L-@$-R $'#-@3,#I
M/SD(@/XG'4"#W(+1@@?8# <.&$,9$F :H>@! B/0Q"T6T (Z@&\M$9##'"8P
M.,Y,8 YV2  F0+&!"]2A%@OX0 MNP8<%Z*$.$; %'V9XN MP@0\;$ ,P$,&
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M$ %(-,&36S@ %*VSRBL<D"9@2&T7#&A5&SLYEQ>J"!07 @DH<OJ!,0"#!"T
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M (3!H!D"HBU !!A (10" 6! &'B  RB")!B  <R 0;A"# 1 %*P! 9P $RI
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MGVW4@F6Q+UW0#QUTP JP[Q?X @Q$ABU\L)%U $XBR2?\I AP 2:,0"W@@'%
M64L"%P'K5_?8Q0N$\.\R3P>@@!YP00>+\-A%Q@Y,'AGH(X/Q,!=X@2_<6";
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M1;3S0PR,3V]$%&# !,R (M2M*?AT4#M$.R]U4O\T1$B"1$AU4I>"*DC"#&!
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MD+F:7, &D!U@< ('A, %I HGC$ .3$ _?\ #G)E$?@ ))/[%#<A WD&5'#!
M!+A=2C5 !*3K!8C ,HD$#BP >FF[#5P -MZ'(6> &#?&>Z)5BC$/901],,C
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ME?X)!02D2@D@97.IDMF\Q<6MHDJ>A  1XPI UM9-"$!,\ 0L&+!;#C:,(+'
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M1CPQ 1C P#MR^$ID.K  #5S  38HR!B")((9 >9P.'# S/X\$8%=1N!X9#
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M/,$&N/[@%C3()!#!J@)O#&3 3/A !KK@*7Q!#T:!"\C( ;Y@!7' !D8KT?)
M#FR*#U[@\G9@!]ZD]W" 1RHP^$0L%XB0+0H"%'R/*WP08%:($6% #Q"-?B+"
M%_*@%KH ZU(LX.PKN@)NOM0.QF[H,JJEV&!@!>*%#!; "\R (?)B L2# EZA
M)C9!,,@@ 5YA$R:  _A@$PQ !%X TSY@$V  .7"@9W9!#R1 /": .VC@ N@
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M_FI;_OX37RY"#D;@*@*, O)@+*XDJ?"JKH#!"]9'>W:) ;&HK;A#1U3K+<B
M>+8C8C;G 3 1H4"!#Z3B)G?!!EX (^@ YKB"!,@@&$I !&XA08$!!9("!GR&
M15ME0%O$05L"BLA@!$;G7S2@(0I"#LZI.3<B$]X"![1G%#CH"WZI$X*!.3Z0
M)V8D MC"#LXC!,S %W 2(Y3.+1@2J R@=VR!4WOPW.JC C)2 J9C U;().K@
M/ 2R%O1@HIK3$[[@7H#N%JXUJ,IE Y9.#G9B P2$"RZ" 98.M!AR$P05(^3
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M2:>87]8IIIQ@FMFEEVC^>>:<:.X):*&& MIGHF0F&D:39H !::223DIII%]
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M<YJL8$4WP]=,::HB%N9TQ39-P8IK7G,5TW1F5.09B_.-1S_$T2=M^E>+8*R
M!,$8!3"\4 ),]L43#(!B&T4 2I%L @(/T00$/@:,%JQR)!'( S# ((*2P" #
M"9W+04CPA3DN8!-R.4@+;  ,7Y"1))YPJ&#J, &^Y"&GYZFI2/00@07A8 7
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M]!B@#0HY N,++-8#<(;)U3NH8A +<( D'&" *%3  *3   '&*H 0N**8,<"
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M.1B@#J!("C!*@-L\4&#,!S$#,$L 1O?W )F ?'Y@"P+ !;4@ _;%!2-0$#:
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MB]0$U0<#&P4*#O 3'[!(%; !GI '!J!<"U 'GC ""S!FLCAC* !37W",H)
M']"#-I!0?# !P< '#L"&UI@+F3 !1T4!V#<&MGB0P' #'  *?)  )+=!%;%5
M!;  "T   J $J_ &A" ))B  A/ & / &53<(@Q  2] +I)  'F (!# #5#<
M4= +,S  BO!.IE !!] &K" )<&"2*I"2;!"3O8 $   '2"  =] +82  :@"3
M,U *:@  -0 ' * ";S (*Z0ZJ666K*%/YI$A90   %!@(0%;1#5;#EB, [<
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M)4U&GE  M8 #0"@#:4H!F\ '.8VG(I +2(8(">!==*H0=NJ8@=J[,O %F;
M!W&\-A" -N %2H@0&88#79 )"OYP$'@ 3'*M$#8 A#C I1F0P1>0";15$)SP
MR<6%9,C7::(*PE2: #QA"^_YPL#@S@6Q@<3)4@#J"7P 3$+XHFS$%[\Z 0'0
M!ZM +ZP !P*  3'@  $0![( !P90 '# "JJ DB!@ 00 !Z?@  /@ +.-!+VP
M! &0 &OP3@S  *;@"G P +%M 0 P"&',DU$  &H@"TA@  D  @0P=R8P "<0
M 5-)" !0 4NP !40R/Z10\RC/*[A3ZMC$BO@@ >A:2H=4BZP 8C0!0W BL"
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M86#VUQ$%41 5J[ &)L $@\ $AOY "#5 "+%@]X5@"&DP"+*0!@' !MT4!B?
M J"U"F0/ C500K,#(/!ML 7B//9=$GO@;P61"9F_^09A!OKXT@5AMF!  I;Z
MZCD@?&R4M5'ES-CG:RR<"::=!SAPCR>* EQ@0)]_ T=5!VI6!\?V^3:PJ_IH
M1(=: A>*";O0@_]F RB 9 B1!XCPM33@_#]KJ0GA"33@">UI_06!!OK87;<@
M!N:92U]0I<?6^[ZP_+>P_'F  F9 PX[I F" "W7-!P+J"V3@PF4@GOQO8"X
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MT+,1&1(**)!#5=F@! 4!!AD>6X(%N 0/$\"!!A08$C)<H 4H: #>,!$!')1
MLQ3@8?X)QG"+"Z"@!!"\9EXF\ D4?.AT9VI!"ST!713,KQ,0>&K_1#.!$K2
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M7M Z"ETK=F 06^OOU$!H-(#$CI^["P*$+D&@K?7C^K<6"^BG ])#@ S?0K7
MB,#J<O$ 6^3![\  @P G\)L-,$[ ,Q'!CRZ"!P,4KQ,*\ 6&"3*!37B" 1>1
MPR9&8?Y@8&@Y7\B,CA.@RF  NT(Y1/ % V@(D#L>T>HX&L %!YB)6S P/B
M,S(7T6" GKBA3,B$ :BX!'")&]BW8&@ 5#HN&5"@"6@[J-L$QR((/@ U"M"#
M56L+8<&!(:J#, D!I; %,&@3!Q@(3>"X"V@[K<L$7*N,!0B&%> ]^0*%6G@
M8# N@H@ '-28@T.?F%&X+H0;,%29,&(:4LF#,+F(+GB!3T!!8/B .C"#H&L
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M^1F+[%(5"3TG3$B]D&@!3/B"&@(G<H& 8. $#P6&,0 USVB" 37*M^P"4(L
M)+JA\;@(T M&KZ, SQ"!"@I)3OB^<_+%%!T#$A# =S114.@DJK ]D7@ .;@%
M&ZB>B[Q"M"C/%9B^U\ $?K(*Y..^5_*$U+N 5YH#DD,/KA@!GE05%""]!R P
M7%B]"5B="ZPDGT(@\W.)UT0@%+A/4I&#;;H("="$;\N#6_@ $>,$,P@A.Z
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M3*" $5@SW-. %Q"!"."]S(*=#>@ =YN),H"O"6"<3G" %O"%#" Z^Q(H'^:
M#T",'A8!"K"%FHL/'-##WNHV;U*)"1B!"SBW9:0 %,#AT!"#"?@7%,C<![BZ
M!?/A$0!B!Q !&3"S-YR ^RFZ=5+1,VY.%\")Y\R 0_L +F@"S=(V+VY9@=0L
M&:" $I  S*D%#=  1CZ>%QB/6U@V"Q,6'*X%3Y!A7PL)'/Y@  J   BX@)E
MA CH  BX.F PH0VX *([#:D5B0_X )OPC$SSXM6I!0H84IJX@!'(@!H:)N@@
M9E\E""Y(@+B: *]H@BGN@*/3@P]H @GRQ9357E!) )"L'R?^@)G8 !(8@4^#
M#G F@4_;B#F +PK@BS8['J@<!3N(XT6^A=)DC_G9@('P @6XTL&$CSR(K!&
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MX-P6< $8@ K*W3?H^ (=HP!, -&6\# >%WO#/WS$S_1<GW>T=]<LJIJUC_?
M4GIO>8"R;&4NT$J"6!WSQ 69)X@5$+O)(Y(7B(G"3WS43WW5OZ+$&F&/[W:.
M/RS9)WN*R9D%@"LS4 #D<#1-: $/XP)0@[1,Z(*4\\4 ^!$O& "J  -56WWG
M?W[HYYFV1WK"4BQ[[WCL?_USS1DTP(0]>R5Y; J%R*6_*8'O^!0QZ(E/&(.+
MT ,=C/Y^^(]_^7>3,[_^[WETVF]\9)=\<Z7\^?]_@  F<"#!@@8/(DRH<"'#
MA@X?0HPH<2+%BA8O8L1H:N/&4QPY>OPH<B3)DB9/HDRI4F7(E2Y?LJ08#-C,
M@C5MWJ0Y\&;.C#Y_ @TJ="C1HD:/(DVJ="G3B#!-M>PHLF54J1^K8GWJLFI)
MKB"WKO1J,BNJIF;/HDVK=BW;MF[?PCTZ52O=NEF_X@7[4BS+N7Y!WI5:-B[A
MPH8/(TZL>#'CB'R[7JTK>?+DQY$O4TXYN#'GSIX_@PXM.G'FO"1#6C9=&NKI
ML:OU/O78:C3MVK9OX\Y]^V1JUB-3W_7:6^MPWR@?%Z=;ZOY43]W.GT./+GTZ
M1=XPD_\F;KURRJC85Z.F+GX\^?+F0<-^'3O[\?3JWW<]+W\^_?KVB5(-:[4[
M?,C]U0,W56 @W5>@@0<B6.!__/7UVG=_\36@?W9!E:"%%V*886T+;B?9@\:Q
MEI58WP68V2D:HIBBBBNRA1E7^3&HVE_[T<CAA.#%V%ID)[+8HX\_ FD1@":N
MIR.(#MJX5Y!+,MDDDW1YEZ241$Y)DI-78IFEA59]6&6-,^(HXW5@GI;:9A %
MT],O--44S"]I$@1G3KSD]&:=:PKD9IQQWH2G0+_X*6=S&J;9W)L"\4*0GX J
M.A"></HY$"6SA&8)I5IBVI![4/Y2-B)['7ZJ'69'7E8<:J:<Z9 N1@PAQ!!;
M $/)$*T*(<0O@,PZ!!&) &/)K$$$040PLTSQ0Q!54"HK$;-J 8PN3@Q1"3"S
M+"LM,([\T"PPO1 AQ9I:&+$F+5(8>T6B50P1Q! _8,'B%:T.(04M D$21+N\
M$%&%0%<0P<LLY 9!!:60_$")LT/\80D/NJZK;:\\S)**%%C,]$<J"V41!*\2
M_1$)1H!  LP61F1:LD(W-N@EIZ.2&JK*7VZ$RJ *Z?*#$X!<T4,BE?"P12.)
M_ &,%CP TH@4$%/"PQ6 9/&'+D44$4DB-@-S20]8/+)%#X[\(@2[P/SQPP^6
M"$3%#_[]'DPT,%?\ ,PO1!31"" ]6 &,$T(DD@@@UJHH11!99/'#$P)9<;8N
MP&310RJS]) %,' _D@@0)#_20\BZ\*"%+EFP7446(0LT1=U$-')$(+P<$2FB
M>,[2<Z*.JJYG045<,1 OOB"D^B^O U.$OK3PX(C)PQ=49(Y'PLAREU(F_W*J
M#=7<+"]"7,&S(\'(DJ@6/QR>2 ^S\#R)3G_P8# P@O2 2B66 P,\(,$,<03)
M5MQ-]BP_9"R\+@SS@D40Y_? ?(]PG!3ZI8M>]*B ^PK"[O 7A$"XC0A7P((0
MKL4^"U;"$NRK6;N D0H>;$P@F!-$,'[ BRMD 0N-*,@OWOY%!$  PV]$\)A
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M;$B$ ]0!@-7! @!#&7B!0'B!&X!"!#S "]2E!GR "/@")TS  [A ,-P""HS
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M!(""+21 .Z+! 8"BQQ[$!Y0C!<3E3)SG)PC$!O3D3(S"1WH!CKI M"X$*#C
M/PJ$E7;L!M#L'#S 3.0" _!F=*ZG"!RJ!FP"U=Y'R/:J=[(EX*F&RG4*1;@
M [1 "S# 81KE M@ ,"ZC'A1 $W E"I"!!D2N 2PC"H0 &=#  W!!)S1 MS(
M,*"M#7!!!BBH%S H)P!G ^RM'I0FN_*M05P &CRJ 7#M0("! S3!!VS 3<C
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M#P0H< 'NU$%<^D(7A$ +["XFK, (E",PR,$([*9 [ (.9*@(W"<FH$ )F.U
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M)@R #&C"#IRL+W#\+=C >FZ" \A!)U" 06I ">RM",! ,(#!GY*! ^3C%W0
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M!QML@,$37!CH\8*;5A"A$S 6V*43!N381(/!QH" #ST<B(Z#%3SI(@ Z<"'
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MNA)6.69%#0E*Q1),*& .%92L0="0-+>.CRTIC.EE@X&&F5R6$Y'U!07,QM?
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MR<Y((%P,8PD')# ()A8 C$PP0#LM" T%?@22&Q0%O#@1@0-R56:#^($!9^/
M62*0!U (* ]R#D&' OUF2W=)Q&0%:X>YZMR";IJZ827QB$%<0-5L  P7, L9
M6H "TXQ! Y_P Z^ L8(7U((,?:%7#G;QA0_X8@P2>-LF(K '4&C 8QKHPBT6
MT)41,& .\'5QKCW!APF !66=&/Z# G"!B ?@;!-[JL4$_* K"O#!%_)JT@X\
M88.^>,(FG"B!=43 6IM=^D2V^$L=/N"Q+^"H('-PB ;\D(D.>$+. -9>2UQ
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M%.2  1J.#BXCW3J$ G! 4_HBW,BO 8)! EX %- @ B#'$.>B"QX@#S9!!B+
M/\Y%$[H %/?"-/B  D"! @BQ+?XF3\XT  +,8 =PX$AV00)D8!-0H"_.PE\
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MT[,3XG,3XI,^Z],^[Q,_ZW,^];,]W[,^U],]T=,3]G,]]Y,^YW- T9,^UW-
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M:FF=ET6A]$4+**#PPB8::0?*#A":E"-'-\;YG2^=R/B=)[< XXD-%.9H)Y6
MSHC'#GE@=(L7>&"TB2^!-NJHAERN)N1S(H+Y(5*72K=EER$N:5($)<B!!@T)
M@/)@)@[ ^,D#NW0D 1]Z<O'HK#VBH,$7$M!PT0=??""'GB*\2>NPQ(Z&Z:8D
M:MF*E<@F*VFEJZ%TP:^?34#&19EP8<=GF4QPD2]F>.$),+AH<A$HGURD29X8
M9;NMGOZ<7+3)*,"L:\88N+3+11W?X<$%K,&8\0 =>7KB!1GY8A(!%[8$DRXP
MM8 QAD5ZUI('%^,"<XL97\1;[,>ES1'!1;LHL,DG%P!CQPC M%"HL"#'+/-'
M/P)I,Z6;@FGBI,U&)^T7MH"RQP7C@G&!&2.T $PF$I![P0M?/%"'+0K8 LP'
M')#K@*F?C7'T""LLO< MGC30\ ,?X+ "!!9Y;08)8;?<P1@4W ","PRT<$L>
M#LB!PP; C,' !YMXPL#2$>R 0P1HDC !%S(L8.H'-I2Q0!T8SJPY2)^AD ,P
MC*+0Q"U-H_&")BALKOKJ&_4<6\_(HDCBD9%2YVE)&SAPP?X%"<  S"L.4#Q!
M)IX\ (P,+F";:@?\BO!!,'8 ?E$M#KQR$06%<E%""7-LU_=%(^P0# /T C,!
M)GZ,#/$*P8 B0:MYF.L+!)T 0X$?]7JK@1D7@9'U"#BX2 ?X9X!Q>2(3K$N@
M1SH@!O#<(&PN0 $',-$"3H"!!.92H 8_]B78>3!G'TP**E!"@3)HS!<7Z((F
M%@ #%, @ G3X! 2 H0$Z;,<7#ZC%&&R "!S@ !,W^ )X]L" %KY  B8$Q@,T
MX!T)F"IP*%BA$2%@!R\H[3LRS-,NNH""%CA@7!. E28H@(L'/)$3QB-!$D<P
M!F"0P0$4L &[-KC!#X !/#2X(OX?-O8%,K2@6XRBHR =19OI0,=25[I9"!?Y
M+)B,\"04H!8PO/ !--ZB%KBPB"8J (P.7$MC#K"%)T2 @SSDP08B&-=G,/&
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M7$*?E;JN)1>E&:"IL5 (#,  DC ! [ "#=  I! !!E *DD  'A +*B  (.
M!4 (A0  +" +:P  8; &"[  %0 ']T@($:  #E #IE !!' "!O  IQ & 5 !
M 5"M([L 5.H "2  :^ *">  JR ) Q"P%6 !KJ & ( ! YL$K'"@^;EIKT&,
M 4(??9*+<3)@#M(F1YLY27N)2RLG1DL<4(N)4^NTQ5BU]L&)6/L?6ILF1ZN*
M$?:T7OX;M<&(($6KM%<[MFA+M6F[BL$1BK^XM?M!M$3[(D,K(63;M1#RM1QX
MJ1E0 !&  0D0 #6@"F$P"+'0 @) "&P  '#P!HY+" $P [*@" 4  H5  )3;
M!@(0!;T0 P.P"!9:"K&P!@$0!KVP! &P!KW0L%&@!C-;"*S  @.P!J;0  I0
M"F\@ #7@"A:  =NJ ";@"A4  :HP"-I*" ;@ 3SZL[3!KM![=+;QMR!@ BH0
M!M 9!M_*L7=0"IH; P>P"B*;!JUP"A40 8.  )3[!@$0!;+  IKJI:; "FD0
M % @"R9P (S "HQ0 "R LV<0"ZZ0 @10"*U@ 1D0"WT@ /XSX+L8$+,&,+PU
M>PJ&H (60 '+V[SLV9])FGMIUQ&5X B0,,(D' DD/,(F7,(H?,(K# DIK,(P
M_,(QS,(RG,(RW,(W7,,M?,(VS,*/4 F^H0LBS,(\7,0N3,0];,0XC,0[W,1)
M;,0Y#,5,?,1&_ BZX!N5\ A4#,-+3,--O,4OK,-;/,-*3,4W;,9>3,8J',:.
M ,2^,0N-,,91K,9T+,=?;,)G;,=CW,5<C,9I?,-:_ NHX:X%7*9;BK,U( M)
M( !P@+\0X  JP+ !@ 2]4 H*X &$@  LT LB&P;O6\"Q((BQD :=*PLS$ !P
MT MSN@2F>P:K,, 'NPH0@ &N</X' ]"[#A !KF (!* "L8 !$2"E!U (J\
MS NTJH=<6&6!M8%]5, #T!S-TCS-U%S-UGS-V)S-VKS-W#S-3^ ;EM#-XCS.
MY%S.YDS-EN ;SPS-/7#.[OS.\"S.5/ ;?] #/Q#/^)S/^@S-0G#%/G*I&!
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M0I6H3]4^[[VQZQ<Q!Q5@6A?@!6?;YDW;)KXP]QK1!0^ 0%*?M(?/+GR;$9G
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M18:D,*)%4!@(AHL1"MH$ 1SXZ, [$1ZHPPP#/ EF@?M 2< 73A;88Y,(_ON
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MOWSG6B*X#070(UB2 D]PJ!X?&F"1?5G'> G13EW 8( .;& "&]!<0;X0G@Z
MQ@7J$E1!<  #6T2 ()B@ #!P@3*%W(*$Y7O/ S:!B0C@!PRWV,4#;.&+]VDP
M5!,8PT+, "Y@C*$#(]A$"3P!@_X-H.$Z&@ -,/C00CY<*"%&0,@!$P(U6!RP
M!0OH0 <:L(%@^*(!T .&"&*4"8*4(0._,]L%FK.+N@%C SGLX0: P0!4B:!J
M?^N;%!VWQS#])'&)XV/C!+DE0$*E(6QJD08>( (1$,"(("2(YT2 +Q$8D73
MN-\M?"&##]Q@ J )@:/X$D*VB(!U,.CD)X<U@@A   ^^>$ )4(""$>0-.TXH
MGA0EXPA886A6/>P #$(0*A+ L01@*(@G0C@"#;2@!+($GQP5$@%/@()SEX-
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M(8,.@$(/#/C/ _:P$%CBC" MX,T.7@"*"H"%(')X@"8\,8%VYJ&%08TB/__
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M Q,!!3/0#]X85?@ @V8*HQ5&@;RA@/^(7JJ8USRKURC\ %O*#3W8 QO(@P_
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M K2%A5@$&F2 N^C!!0S$ R1AJ>P!7_B$#*P'>?!! GQ !V@ 6/A"!WR #3#
M'-S%!GA!!H!%'KS  ;X AP"%+2R ;?1$!.B!+[@ 2)H(#,! LN""4:*( R0
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MA,$!*/Y  6! *1"" ,R +*P! *3!&1!  QC &K#"*MR! ,2 ++0! $"!*F
M 2B  92?!3A !0@  82!+*B :;H""Q!  @S #,1"#)BFRR+  A! $JRF]$!C
M!GD3X\D(-1)$4K0+#G0G S2D U  &1 $'3S !,B!)S" "]R  ^P ,.1"![0
M#DS >EB$'$Q %WR # "#)C  #-A U (#'SB #+C !% E073E#H1 ;=J! TP
M&%I$'2@MTSHM#C@ 7_C"!Z# #F"MEE" "," "%" 0&QMUU(E)SS "*3C"S#
M")C$VL( !8!%"W0 !00K ]R "&C 5#[ -]K"!-@ %U  4_Y,@ C@P 9LP$#<
MP 4\R+%Z @78  QL0&)X@@.L@ Q<@(H" ^MZP06 81E,P >\0"<XP); ;0Y$
MP$;B@@:,@ QTP 0\X0A\P0[@0(%& $ELR0-X AH\ZPK0@1G<!$Y\@@. Y01\
MP>.Z"X"X  TXP#=BP@-T@0RX+OJR1/1.;_4F2PE\(P5\ .MJ0,*,0 C@P -
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M#$ 'K$(;3.PBL.S!"D 4Q(+)WH%RG,($.$#,QNL %((K8( %F$(%', 9M$'
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M675D._Y%XP)#"3 BM1\R283E0.@!#,B O -#!$AB,$3 *'S!=(;0BK? P&]
M;5I$)V [=X,!&CP #A#Q GR"'-BV)T  J>*'142 )XS T3:%!$0$?V3&0(S
ML6+V0%# 1K["/,I 'K@ &'!!!]LCO4.O!)  (G"$&8 Q32>A&;R )WM"+92T
M"# B%YO%3T^ CTX < /#T_/++72!?"?I0%; ") $*$" :)QW3^2"%\  "8C\
M''BW'*#I ZP'':BT1>3!*8ORS&_"'#1 T,H  R1B34CM.FI )[> \@IS24P
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M6<*#0HRBBBF=>7[J*)][I@J5=(GV*I<%[@-K V%'$%:K$F0 )I/=I-ZM# W
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MX M\<&(-O?8!#9#@!5C-BBU$&(Q4915%>LCK!-"@%1RL!2Q@X.D%4+1>KVV
M+W)8'1>DBX+J!D>^B7S+!S+AB_X <HH#.-+$"KY !CV2!A,4T, F]Q@!#6B@
MH\#81 (YV8$.\ <KQ?6%+32\@1'DZI.R?2$P7B!9$?!%!)@(A@9P=(O!+0D&
M%^# ![ S B@%H[ =6#$P.F'C%92 O5YSDA<NR\<E=> T;0E.>7B: 21M8@'-
M"88+-M ",VP@#YHXC]>.&PP40*O&:E4>08%!%56PHA#)%"@<6#  %<#+%*M8
M12$D 2]5N +/\&K**FJ9E%,,^BBQD,0B]LS/H\RRS:Q("KS:' NI]'.?3D&*
M/BDM:$57VBEH)AIIM$(:VWAEU$7#Q2= S99:L85HGY"K5X+Q"1*G.BNE9O43
M7Q/J!_YXXA:498NL/<TIO@0[U(-I#ZQK[8GZ<>J"6A%;,%9=ZT_4#]2@MI57
M7L&7N6QM2='.RK5#K95:8"?<C"./5LH0'677VM?+%G9!;UVT6U38:S#<D8_B
M;=&_?1L[P7"W5E9-ZV,+O#WK)NB\!2YP7/3[WVB.4'H/Z%V D_B)]/X*J'$Q
M['B/AVBUT/9WSUUNHMDBY.DB>:BGG2Z"$SL7N2Y:+7#DBX:+]HF>6'FZE')/
M5\*D%+&H@0% @#.>UUGGJM!Y5(!6"E0<?=+9A J@.1UUJ4^]9\2V^M5O?G6M
M;SW4/N5ZW;X>]G1Y FMB)VCMS/YU.4#NTVEW>W8T+O*VO_[=[5E'\R<Z$((.
MC,!_=/?[WP$?>*Y+716GL#/5$9_XJ6<:H(J7NE4$'WG)>[KADP=\Y2TO>7]G
MGMAVY_SGN>YQT(^>]*5/L^-1GWK5_W.?C$=ZX@=J>MG/'MZT-[OG;9][W=L>
M][OW_>]/OWI_"G\JF+[T\8/6>DT7__7'']KO>P]\Z4-_^M6W_O5E'WWL$S2@
MR.^^I8GO>N*K7OR37O[QC2]HT]N:Z[Z@>+INH?V_?]CCM5@V*/A08?>S)?Y7
MW__+2\[L;L'=3F[K^L_Z\N"GP@Y'9*1H@L'C;,$6:@%2KJ\ MX[]^,\K=N'5
MMH]H,##8?,'FKH_3& ]H"&W\4/XP_,X/_%+O^<2.UJH-&/Q IB"C ZI*X+B@
MHP@.+,1@=6#P*RC@IWZ0E890Z_@@ 2Z  BC@ ;HB&%K CB8 !>AC=[*B%EBC
M]E1.AYR(-$@CHL('[+(0[&(P+7R#-%#G"\,P*^2 PRX 27;0 3VM".<N74"A
M0+ 0V>B0##Z!!KV"$R+@ B#  2[@ 6XPWL 0*^J@*PI*#HF&$R"+E3"! ?;-
MZL#"!0R)U>J =Q)*5R[+$.'P$\LMX3PQ#$D##ZHJ6F"%"]/PB2;LXU91]L:O
M%,K/*@B/ZOHI_38M!1$/%>1OZ\; >L2M\AY@JU:.4)SHTW9-]O( 5V0$#0K
M%^8 NOXH($[  *& 8102( #1; RB(]5BZ ZQCC?8 RQ>P%D<+BT$AX*DKQS#
M#BS0H 3,X!A5#D< R&NB#RQDH*]>D),D@PCE1Q^YSA;>#ROH8)6PA%<Z$#)R
MP(GL3^L0H1]'< 5)\/L"JOP:C_DNDB)93Z F4A<5S06MSA>XX*!*I LR*U.
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M?N4!FB.1CM$7)$!Y,RD8(B!TQ/<T;N$6.F$%'F,$BA081D & .-2[.8#^.
MOP("\D</Z@("H"0K^.  )HP""L!=,8$+.*  TJLOL^(5$L 6/L%:#,XK'@!)
MW!08'@ -/N$58,!-7B!.R( "1OYA$]@'%.8 :\\$6L[$#%P#!D:@%AI@1SH
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M5[SK%K9**UY !J(#;GPMP.2 :B3$+=:\S''@RU;H/M36:PR@%II 'W>!.#1
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M$WSJ@*<2\*$(E"@7(@ %*(@"C#PP8,,XD"4!?%("&J2$L%V8@%A\X;#XC,"
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ML0MCV"^".$&$Z$;@UX?X8H@HDHCXLH16*($.*(EJU8,3R(-RM3Q6:"[T$@*
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M)G+PE5-$<2G)+7GPDP435Q@)B968;6?%EU1G1AFY,?2RD^4! ZI"!B]Q"S3
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M%,"'#U &Z%D6Z(00$9 'P< !+G +F;  4!EI#N +)$"HKX5FX3<!"_(9G2
M8P *$S !G2 ' SM82$$!F,"L"+$",G>>#W D.[!,+4 !F\ )"1 A*WH+^?0A
M++L'5.EG#C4!]A%1:8%A"-$)$? %P? %!_@)$Z!4@_( &OY@!MD16<KH$R/0
M KB !PD@?H5I5<#@:L"P /8!E\' E#]1G[FX4*_P +C D%?1M50+M!1P9@YP
M 6C0(C>D 'R@E1H!!@%9"P[@A0.  G7@8.LT79O  'MP"RW02#*E"5A#N)Q6
M C&2 *NFKZ79,F0P 6PFLL   7>" P/S!0N%"1 0#'9P '5P"QU06H,2 1K
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M&H)JDBC)TT[E![BL!U3\!:K&!67!1@B16(KV$H?L"[PU!QS4$^C< ?KV&7B
M$@;R3NYD,Q'0"7.!"79)9^=1DQO6&K0<$[J$ RB! Q7W&5W@5\857W/ R@23
M!PY0-ZFA!T*I!S?!A[4 8#+BRC'! 'KP"<]+ \'0 %WP?8/RK7VYQ6 <B:!-
MB5WL&'HQL0=X%UN+,S!0 "U2V*("'I^0 Z5%?EJ]Q_XE2\N$"^O8 9J0"0R0
M'T*R1'Y  A& VI]!O3>40\55"[7 G',+7"LP!GO0C08S,'>35,$E!]2;7V#0
M II0 ?DU!AB!""0P 1%0"[^='_XR@ /P06?$5%(Z&P'9DL0Q$0$N  ,P8 -U
MX ?A?3=><&(OP-ZW8 98Q0<;D OS#082P!LRD ,$*,\K( 85.[;:S" K9R+S
M30%-!@PE@**@8+!^< $H,.&:,M\BH0$E0C S2C 2P D_;1=U4,\B$KG%RQOT
M,1L!%44V P,;L ,RL(MC\0$/L%!BAQ %OI1,0@<?T,CD)P>XM;$$,\ R2KE,
M N+   -!YP)-0#!@@!&I<50:8*PJG2L-O2;.N@ TD-\VP ?EY!I)V3)<8  =
ML $/X*84("P;#A8N$M1!-P*M80.T9P-8)>,P$Y:<EG=.U=!W0P$HD!]& I5Y
MYYH=$/X2AWP0'8R^P)W?.% B97T3[/U.(*L:$X @9O!- 5D!Q&$+!HL&*# *
M._=2M =WP$ ?!(-<2=&0\28"=GZ'>B "I>L+?& 5\783FK !)# &=29C+?()
M#;!C0G(GGF"R#T JP."7'1G:CK,\*M39TI9">Z&&=G'5)4H")0=*[H@0F) >
MPWX+*Q ,^Q4?$1 ABR5+0HD".X 1( X;&L0')';=.@3K+D!/M[".KX=4(2&D
M+3!G)_>3[=[A^DD"1PNO')4#+RU!][X)Q $#+> +#  ;FC"3K%68!3WLH[Y(
M%" FH(#.#!!)-A F=^D3:1H?'T!;MG67B) M#"!F%/ )K_Z0:!9.67/6PPW[
M,H[^'\OD /NAM9Y0"R>.U7GW&:*%$(2\"WL6XW>>(9&+B@B!"/X'#!G0KFA@
M!H6-$&Z $7(P&^@4D6%G6")1 7.V \FU +E"ZP-362*!T49NM B1!\OT:2!M
MCVFQ3 AQ 2^!T2*ATNLQ!P>9S)A])9O0A;)ED'?A,'SX;@ABUW26\6Y:Z$"W
MQW: " /K&K@5JV@Q H1Z 9*."9Q 6 Q,9HPV:I%^V[;=]$A!/R)@U/$])G83
M;V==>[5N,Q4[$A/02.:&)[+EW/03;PM0UGJMUAFF5[:PCGG )(=>D$SR <?X
MDWI@%12 9!NP!\$  0_U (O$]/Z<("W)CA 6>>W9[O[>;HG=7H.)T0KT(@$4
MX,$DT0FC &\$! PR ! :\N1P8 O8AA9\/H@ MB-"'1P#] "3\2#3)@;!@.4!
M\ 48,!H7].Q@X$N/ 31Z*)0!IE%31F D< "[I> 6%PU^P#PH\5%$!(T?/W)(
M*.(#L X>D7JTH6'/C@<&<8B$:M* F3T7Q@"S02$/%P>CA![<4$N/ SEH'.P9
MVT#31SL,T,AA4 ?8U($.;@'C4()/"0W QG#XV"4 VV ?2/!!$5CHAQ:(=B00
M RH!,#(;/FK,@U:.@SS && :2Y'!&#L.MD+VPR7!%U +? GML(%32V"U(C3)
M.G/.!/ZA&OD8\.B ST<'?H!]&,&GQ87-P/@XF*L D:<%=>9\T.N%01XZ#CS-
M@0[,3."@&BC(,9. -!>O71R  F8<MX@,H.10D.[ S!RT@"EA)F!0F"FH$9IK
M88/9)I #-V!\<:"%8.;@#Q@Y@.LB CN^6  46PP A@[^@@*FC@5,[  %8!Z8
MJ,5,]  .0^#,8$".+@:08Q0%YJA#! 9NJ>-"C3:PH<70@(D@-!)$\.,Y8#!9
M@(SPR%#2+F JL&L$"C:Y)0&#-AE AH_ >&B,!3;!K8X(@'GAA8]@@ &W8!AX
M"QA;". O$P?(J.,!-#YJ@0!/@,%.#CM&6, 6&US K0P%Z/[XTA<S%J C#PYQ
M(\-2.R+@ Y$V-VJS!1$P\<Z&7!:HY2,R'JB#C 0V >6 +Q0Z,AA3<M5U5UY-
M.8777WL5=EABBS7V6&2#/5;98IEE-M=GB8VV6%1,+.W:L>KX8MLON*@%DR1K
M(4,C.5K8855@=OFBA3$T"H:,%Q#)@[Z;]MCEP0C)>$6H<L_]"!,87)ACK%OP
MY2.3EN28C0P9\JC%B[U0N'4L7\!P88S9\E 3&#TVIL-<@S[ZV%]@,J'!!7R!
MF:,%'- 5RA,<U,P$!AGNY!<7H0"& >&/ZG"AY8\J;@&,V3A)\A4R9HL0C!:^
M4/HC7+JP89--R"C8T"2%TD0&&/[NE"-DW%KPP@P4L+SI!DT\&:-@$T')P>;<
M<FB!CH] P7(L.3RB(^0Y5A7:Z=(VX9HTZ6A8NPR$ZW@!AN,\L>,CQ\?2H XN
M7$"8LY_I4WG?NG/8I!8L!8>!\(,_*CTX,II6N@[-<\;A%KOKQM+G&^A],/:Q
M_,@:&$T>I(-S.7#!'7<Y7,ACC]OXL &,6\S0I!:ZA<H#83HTK[ZE,L3>"YA.
M9'CAN!&MIV^4'1!6&/M"/\K#!1O2KYMN1 C'!!&\<38]>D]L^/YE,W*VX8OF
M701\$1J#'()Q/CT$;'<<4R P0!&]!R[-!GP !0#/]Q$]L"]],&O!N#Z"+!"&
M$%J[4OZ6LW0U+1$*"X4J7%8*70@L:6%+AC.D80UM>$,<VO 3)&E=#GWX0R &
M48A#'(L(=D!$)";QAP\8H!*=^$0H1E&*4Z1B%:_U0BR>4(M9'&$*2YBL%I)0
MC%P,X:].(41W0<A:P;G6&M,8'0C%D4YC>2,-@_)&3[B ?C)<8QOE^$<W_A&.
M@YQA'0$IR$-BZXZ(C,XB2V,'TO11C:7I8R#YJ$@[TG&0DI2C&>ACR4O&D9.A
MS"0E@U-)/VH2AX8,QB@924A8IE*5LRPE(:W%2E5*TI%SI*0KZ^C&6UJK6<,D
M(Q97F,5G'?.89>Q5,F'H3!):49K3I&8UK7E-;&93F]OD9OXWO>G$8OHJC,:*
MUC*;*:UPIE.=*IRF*[&YRU@&T9T^;.4KM1G(>FIRGC>$IS3WN<I_?C.; >5D
M0 5Z4"!*LHOB9"$YQ[A.+T)4HNC,(BH0>E&,=M,7!LTHMGSQM(Z&5*0C)2D1
MMTA,E"XTI<,R)TLG^E"'GG2=9ASB/FN!@Q[&\Y)FX!DL02D44' !!SC@PL;8
MV$M3)G448/B(+4!JT(H-%0==<)D@1UD+IAZU);8PD21!48*@W&('[GL%%W*
M@R;8; Y2S4%/&7D+,3RM#'=RCDS 1LNCUH%^UK)%"791FEOLY1;M2B1-ME=#
M6WC$$_VK@W*2JM6M6@L/QT'E#_[M0%FAT*&)H P&5REF/\@&C0M<*&4F5K"Q
M?-X"<+< :0W_:<E;<FPB8RC4+?ZJVM8^5J>XQ2N>9K.'B<SS$UO9#!CHXXLO
ME* $*1/*2]6I3)4^EXPME:A%J:B1+PB M*,TY+5P$!J.CL4.!-A!$V#P&IW^
M,(\:N4 3?XB+ [B "UT TJH,JA%/4 A;HYC 8678@NUB)@ 'DLX <L %&22
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M*VU>]_@+P1!+W:($E%.C  6Y\ 0%;%&' 0:#V7[3.-BD7;?9^ (4P<"9'#H
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M&]BY$^&_#B"33G  8$ #"<B^!K 2%%@ $:B%33C #CB*-<$W37" 8-  @W$
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M#25(\.F .I 0*@L4-#A',.@)"OA&8%B!)OB()G"4H'B(CT !/T!/R"D)/EB
MO3@/)&F)"#C#"\"#Y7B06E!"J30/_E ^09D)!C@.3AB8TL".7/"%!#B.V#@L
M%BT4+?Z%N2.9/I_(2&#8 WP+A@8PTQ:(@ ?H +<"AM\#2F,JOI4"5#]])B#*
M _Z8#2]X@6,[L\5,G07 &1'HGTZ8 &7C@CEA #F9"A?X!)C,RCG0!."P%N51
MQ0=Y@$)A44_, [0$,1SP! 7 @1?  ?\ A5"-"3,0@V^<C1$0 V 0@0<8@<<1
MORX$'T2@ 1J@CNLT*H%X!0EX&FO['S$@"F#P@N1[ 1M( $\8 3B-$@: 51S
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M!)<!!0]S(%_(6MR8@$PXLL2UA6#63F# Y>7X,@BX!6<&AE> L\<52?*\A3S
MCVL)W0=8%5D&&U^8@$))W8^X =9E #_@!%DQ".%0PJ!)$T2H0J$ 9 CQO=T=
M5#_#9^ UH88Z7NH"(E]0O<OE T\P7]H(L";@CP$VE =0MOX=V,41(! ;J%\<
M_(CK;9$'P84$ (6)3I<>%H^6,%6AL(,&&(57X(0/0(\/C1 2  50(  IM8Q/
MB(U"R039& -ZE@$9J-(5IIL.F(F!'DRCPH4-N !U@QH%8.+ZX(-7: #Z^(0J
ME(-F'67"D("!"882J&D<E /</1$XJV9N0X$ O0 XW4*#$($S!@.83%)0J 5/
M$ $*T(@,\(C9B#\7I8D/D96QD  8V*@Y( !N(P$-^*LE=$U)9  UX015 >;9
ML-\=73 9B "6F#4' .4XV47[;3<X0P$@C0#2@@'K% I"/)(OD(NS@S,Y" P4
M4#A@5C90@#/[VPLY@,E;: !UT_Z(BE V'- ,&=!1+LC9-_X(+A !,E53'+0!
M#]N!P(C09B9@+L,]TN $F_ %Q1X+/7!%!@MBK7!AM,T-!J"?V "%/,@ "WX
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MN$4#QH"):Q9S 6,@0P)D1\2(E0A"'</8@918VB;>BD4H&FV"WO(8/A"%#Q$
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M'&R (5H+%\! "TQ ")3SOSR I/SRA948)G" )>_))TRA0G"!;N$!"MQ !DQ
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M%B@8P$\)- Z$"0K8"2?$$Z<)Q4;/3@& ! P C$P! RXX ";L @2 Q/_2 0&
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M3LJ!0.&!J5WA RCD]4S #LQ!';0 <4*.'\B!""0+%[AH"\  )LA!802#L^,
M]1"6013=3ZQ B15;X=PXCI<N5@=YV38LK_5X7=P""K2 =""$>LE$"/@!#>=!
M;/+!M2VZNX/""L@!VUU64)B)&>S"!+2 '33!&3D 16!$)QA 'E3 (ZH$"7Q
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M^$"#6S30 (<6("#O@@URC8 \!_P"I@6%[%O! ;0Z$(&+!SJJSP8-O+B! AM
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MP  ,@ !8P!4(H0 ZP $$P (((?X6UD !!H "*J Y]4\[58 !4F -!B -9'8
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M!3I%1GRB 0KU+^< 2L+'GH&!#AQ ;L @-2*F(#8 *8&A"WH"RHEE7'#@+A;
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M0A<8@27#%SA09(9+  .#1@ED[<GG+J \L LP&0-3 D541;!Q,(APD8!&.HT
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M0!O@H( $*" #BBA$ SP0"U.4HA6#6$ %N+>**"C@ *!53Q@48 !)&$<1-4B
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MX:>UT$ '2#""G6V" D113))/ @I(2H3/)@Z&)RX0 @Z$8"H+:0&X-R#N"&Q
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M #K+1!@]4JT$#'@@ &B0SXJ!P9N0"1 @2L!P"S%+J>3&"71@ +90"PZ5"RA
M$N+TU5$;$1WP!;X !J3AS\' !U(!"A-@ [M !ULH ]^\"0QP1Q.  Z#P!0(P
MH<"0!P)@U3)P@: @ 7K@"RWP$S9P #F@"505#'BPSN-6*'[-V67CPV%)87<
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MQG.>[PR*,2R $WCN @<XP0<'-$DO)*#!)\HP+#TWVM'%' ,+&P;71U/,%Q<
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M!:" /=@#!H@ #8F !OE/&V#-(*I0#?@ '"@!!P"06M" %BB!$,@*#2@!%Z"
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M7M;S @?@@AR0@0? GXDP P( $!3HR)VM"%"0@)8HQEIQ%U+&/KK@,#M8D!(
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MWH4&,$4'^+-FP04*8,L%V!]0$/OV.-(+<#$^X0-@V0$E@0&C9A.#R 0CY(!
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8?OTK8.DZ+E02MK"&/2QB$ZO8Q6(H(  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>comp_0014.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0014.gif
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MZ^?HZ?#O[^/N]N_O\/#O\.WS^>OP]/3T]/CW]_7W^?CW^/;X^____P
M
M
M
M
M
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MD4ZUH4]]ZE&[NM..-K2E7XUJ4GM:UI^FM:X_C>M>[[K6IF;UK%7]ZU+S>MC
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M  O8$][7>D;F?2<P!JV "@E@!JPV?J&W99SG90V1"AZ @K&W"!SP":U !@V
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MB#5: @\P@6<@P840 CP)"@MPP#8K$*  NEO@"(9@ "+0!F9  /UK!@R@!H6
MB@W1"0> @F]XB6[0!DE<@@0Z$[K:BG>K?B)0 @XI!@D0!XK@ 7TJ!A:L" 1
M!HV@!16P"JG  !-P!F[P "6@A@S@F%Q@ "Z8 2%0"&C  .ZG" >P!6Z@ @=
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MD+L;D *'L+5@8 @K( '_%\)B( $2@)6?8 ")T)47@'X+,/Z3UZ? (H '96
MYFD"$O &R+O&H/"*:- &#&"$04 !AA '_^P(*/  9= )HL  L(H&#= )5&@!
M:. &#'"=--R:%'$&#/V8_(@"%JR&\[P*9EP":( *#3 !)& &JX !(U (9\
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M$<D*BP !6%F&_+CY)?A_);#&( XA\>OM#U"3P:X%J*  =>KU6+J\MVH<@["
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M@PC_XI=M2401!1 %"ZB2" -0PG$.- #O6O =\T0M \MRTNH>9\"W0*H5;W@
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MK13Q  ZHX $E(%@KP&" "G3@ 0\PT@4, ($O/Z !F/E$!A*P 0XH  /[H80
M?$8;#!Q@ A* @'()=8('L* $_F$#&0AC!@6H0& /N%4"VB 1,;#*LZ_!  80
MLH4$BX !0.HH!N+2@* P9:XD: %JWS(!TZH3(B*80$\MH!1>?@4CBI4 "$C2
M!0:$A0&Z8D$#6O#G!*"A#.LYR 4J$)<K@\8,#-C "7*#F@QG8 6DAFP=9X('
M [3K$Q5PM@2PXJZAN:L,1*,;!MP#KO^&0#=I$'(K)@ _E_Z%H,3IW2:BO6RD
M9)X-! ] F5TS-T/J?*X579B1*"ZP+6RC A2Z54$). "!3XCA "<H<KW,< #/
M6" P:D"L*#"P+8&T2PN%QJD#7M4*_J;" (\+P@6>QU,6>V"Z66' 1A7PP2(.
ME0L&$4,"3+""!D2K$ >H@",4H8 2&!HQH$@ [P!^$"9GJTH(;P +JL2  'V@
M4PCXW4&P/A,7U'HNOVND1 Z! *L1UGF.X%W=(G6007!R$ @!Q1BT8 8J\5 ,
M<Z<2&[9@!N.@H@Q: !(/V3"=0=0G$5P P_Y0@0?:*(+>-VV!(K0PAL@XWCR<
M  ,7!DF)+VA!IA)IPQ;*$!E"[/ZO$T,%!1HPXW<MB*'NU4,#*#Z1Y$+@[!.9
M3S(/WVX&+219$5_P"B?8@(I!O.@38Q"#4M* BD4DHC#%?T\7P+#V5C1\"VEO
M11RTH 908'\IO$_^5_"PA3%TD>1BV,)06?&&N@]B\N9WVO6_X@@P\/T3RX?^
M5]R?AN[S)^VH& /Y@XA!,+_+0P-*0(6LJXVU$X4 5,#SX(0QX(+E^PI#> ,W
MN$ W: ,J&80NZ(('C(,"- 0W($$W>+PV\(+I> -%F+VZ^8(/4@0@(4 'NBK!
MF#OA*(0M2+RO $ M6 2A.P]'\ (M6#0>^KO DP@VN$$'RKT_(4+S, 3$&RPW
M^(+?&?X$YLD]5N ]17"$* H-#/@$#\29^.$]F5H\*'L3-#$@WBO"5B@]_=L?
M0L"9 CD(-  #S& #FJ$]VQ,#+JC!0R*_D7,C(VD#+>@"ZAO$ZGF<1[@J5D"#
M"I(,Y&L0_FN%1.@"+4B[0N@" G2?3_ ^--""#]*_4 0%0A".5<"#%V$_142/
M02 _\W,$#UP[5L"#R'"$QU&$+MB"7+(+-'@1^J,[4,"_+J*$J^H$-$#$@W!
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M 3;S&4+(@ ;P $50@Q)R!!+8@!"@MSCH@ R I#]]@# ZCT'P@&IZA++!@Q;
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MFJT2 ICC4($?-3  -E $$BB+X#6/)ZJ ,7 #;9,('2:$A_XICQ-  !#0@DY
M-Q68CA"P #QP T1KA30@9Q1P!#< @!)H@[D@@3;XK.I3 !^\FW;!BS%X PS8
MC"4C@3B 9O09 0P8A#9X +]@"CQ UP\"8#%X ]LE.0585S)P@$]8A!.  #-H
M'E2@@!"( S(P )EP5TQQ )]Q@0%P 3=8 ;(S#Q"0L3<X ?K@GPH8!#>  'C[
MY0,H"0$8 38P P)@ P72&Z<)C!,0*V R*Q68@$%X PFHERT0@!9P Q>HU>.
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MA/BY=H$/5/@$F6(<S+" [B $F@(#3A4#,<"3KXB#!R 8@9&(1C^1:2IVR6@
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MC ,.!X)8U?$E8/B@%BB@D#0<H/X3M\16(I["A<:Q(CFL6("/UE*A+A 3F6]
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M=52)[1S:;FU3R 72[B<J.("DI/X!J@GK21P T_H% 6A2^Y#E(13 "JBF8V%
M3604"AA5)Z@  0B/!72%!O;249P'>BV8(NA$Z(FE&W@ 4K#"(1#E)]Q75*4"
M&ER@(8P('*W %N@L&D1 "&#1&RB1&G3"&:B )CI"$*A (H'"&H!"%Z@ "O*N
M"D25.'J:%Z@ & A*!6BB*(B! Z2 Z<YN$&A,'!#,%H0+(:B %CS"&A21&ZA
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M"X" ?KC!!4" "8B""8  3,-3")0 *ER'(G2 ")0  41)'## "G"! SRJ]U4
M"7P!!8"&(PC  W' # U>3;OUNNI&%UC8%"G !T0 'L0!A8$"!71 %VQ !2@1
M"SS !D3;6[0  X" "J!%P50?"+!&E( " WB !&S!)^2%![0!*E  !W1!PRE1
M!F  !D3)!CS "9Q  Y  S?$/DRFBI+9"'!# !]"= 70?T9" %D! U$P)&&@
M!X2@COZH0 @8P@ 8!2$DT5HH0 N<6,!FBUYP00.,"!X@P*ME  -@D048SP#(
M-*^P@8QIP0&8 2B80 -P0"8W]0ITGG@_Q+TX$PJHV&8< -IMP(.<JP2@ "IP
M001XP:1]*N9XAR@<P)9-@*AL@ 9XP0<L'N9@]U.T  1PP9%;9$V0@6>_WDX!
MVN;)&AF P :\!!D@@ J<  8@N198&)JMHQ=  /7T5_XZP$.]A"(010@D@JU=
M!NKEB,MEMDDQ2!M@  2<0"<HPF%7D/$X@O#)'BM@MQ;8691TPN!Y@04D!!A
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M 6 3&RB)"M1]?9S'%AQ &;T$%QA82"6$%'DU=3  UVR> F"$"D"6_1E/!TA
M$7' 1X8$R,N%%QS3&"S((&B6N,6*!3Q4QWZ""E&$!6@B%)D>7$!$X:""=&A5
M?C /PQ/E")P'!<3*T$2U!^36PGM&0IA XZR,0J"0QTM*]E"'1V]EW:Y*QBO
M036 CURW5XO*%#5AMK21&V2 YCW"[HA!U]:WD7! 31 -17C!"BG$&2Q61 S
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M88"5%L#PP)$S4//  A?BG$"@!](8B%DMXOSOJ8+(6(Z5-/)B99 'GD)%C!9
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M(88&@(&!K[1+I%3 "D(43#O^4PO! G,&";;" F1P"!=RB$*AC&%E96& "M+
MAKQP8@$Z:L4*DO@8+201 B9@H/X7SE"8$?CD,9T PP@,4*AHLB0-;IC A^#"
M0L9$!!08P$ 7"!$"03T&H<Q1  Y/.#,WM* "?&&#MS "'[>T @T2N-1C2M#$
M'_&E$PF8640Z@;=3-4".6D"% ES 0 <>=14-$&%!_A*4!@SG,1]BUE,^D0!#
MA,",E[1< M@ *8QPL U>  ,90C<7%\RDC&L9CMG 8!O&?6Z)=ME"!>9R4N)
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MT$ ,$J H5BDB&H AP,  7  5-D "TB -)*"L(N(0_$XE$$ @6 $4)" $9,\
M?"0!,.0Q0H#H%."N'@.TZ*MLWJ#TPJ"0SD $/*_%%  -Q@ #?F\$(L ,R."E
M6(P$QJF(KB[K9L)N',$ 0L 1TJ"UPJ0HQB !' @#,D#Q>*KRZ&X"VH@##L -
M0.'WW(4!,* #-B!&0N3T3$ !5F\!3$($&, ,V, "INLQ3( MQL ,V2#C4,#Q
MZ(9"%D'?U$!... C"N($HH,B$.#S-F!E%L$ "M$+Z.:I2O[ #$I@ #CB $RC
M#1@OA1)B S) #;K@/>;C]^QF+SR@$ C! $#JWH;B +8@#3A@ L!PM X !7#I
M!5O!! S@!+K@! Y@! JB(-0  -9LQ'QB 7].!"K@ *X-3>2-.+2@)<P -PR!
M!-[$+E !8,K@#;IB%;;  SP@K^9"#'QD%;J@,;K H PAKT#A=;H %+@ O+;
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M$"B&(0"54TFU5$WU5$'BCQZC:5;UC[!1-7Y*44'";N+J4V+U5E,#5U^5.4#
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M.<$ TH!/3P!.$_4QS #6C/4-%L#2SD#9')4BI-AN89AR$)=PWVT+#&$00.
M&H,-!J"&Q4 ,O@ B"H$*!\$0R" !MD[>X!*%CU4!&LU4%43,(L(+N(A2(,(1
M5E*.HS;Y0#!.;]A.1S-\Z?0!7M,S3@"14S:.O^6WS-=H(_X@!3J!-H]J<FL,
MD.\4%5# $?SF+>B8D^<4O3+9414JZ+:6#2[  ": R13-*Q3@+=2"$_R,#5!2
M)=B #>P"%*2B#=)7+];@$#JA 9;T$]+@MT"A$UBA#0H#%=@ /%<!8IAC#7)Y
M+CB@,SZA+]K #0#U#=(@DPVAB/W#2TPC9/3"S]#@4S^"FG\D#5"R$U!!%-3
MW;PB#=R"*<;YE%E!$5B)$W"$$PR!#>2GU])@,3,&;AF $)23. +C#=I \:#Y
M@08"%1XZHH4B#M3@>-(62]%@9O9%\3)S A3!+A0!#=RM,3@!.""H,(Z*$]*
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M6 XBI(B*:)6 4RNEXJ%637N]"E0K:_BT6P);@.$!!"8@1!&+/Z%P$G=OC/%
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M*6R 5"HP"!?P!H:P,R@P:UI  17  ;'A!<:R"!R  2#P!B3@ H[@ 2%D12%
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ME, \8-DC^]@ /<K0?PW8@2W8%NPMW)$!%H 1$S \#4 "0;$"JR%OK=!2)V4
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ML3!.AG2)$S;:<..--MI@ Y478?X290$&((" @0D..8G!00J("*G[U&(0)$-
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M\-U'5@"C-71@ RQ(FPL&00(+#&(1(," &CK2!39HH0)B$$4*,""05GB!$)\
M@1#C, @+/( $&%K#_[2@%E"H8 ,@:.&B5N  #/RK%6#8P/N6LH(D!D\+&SB:
M$9'RA@P\( 2<Z ('TI"!#33D:/X<X( 408(*%FR@ U!C@QC<H($-0 T,K=Q>
M(CSR!ABF8$:K:($B6- "4(B@ 1M@ R=4()4MM-"+*L  "G[R!C:28)AK<(0*
MU+((%=RH%9THP3#EYH@2#%)%'P%#!MZ0OO5EI 0<V-] M/"&%6#@!&Q[1 DT
M (($K4("8[C5"23T!B^L(0,A  4:!FHV183  Q/DFR&TD +(9<P0)>A1*[:@
M"$=PP &$7"0IX?B1A"[46LG4 @9(0(EMNN 0#&L!@S[!/!)@I!,H2&(+D=(&
M#WC GQQ#@08\@(>.5  ,)25!1;T @0FLX$9I<%\+J'+&0K"B!81@F NTF= .
M LX+._Y,'1K(8(8,< "H;,  !$30B3:8(9!#&8066A%(<7XD%2I )/R@UP$.
M9"X-9!B$!C(&5@ZHX:)'VZ'<'A&"!G!@?AWIQ DXH$2/@(&44N2$,#GPAD)@
M0).<B,._6OG)#2QQ(%L8:/>>"I(W&. 18]N &C*0@8-T1 RD'$-)1 $\@[5"
M!)24@ HZDH8+&N( &2C!(!0Q@(D$0 5L<($!,*2"![#ADP58;4<<P0('@.$3
M9C  "M)H (X<L UOF$#T).(";8DB 8, Q0-80(@M-"!C)Y  (0JQ3]TJ  0N
M8 H;)O !G5E@GVV00 @< H$K=D&^'^$ "49"" 5X81 I:/Y 1"3P #*080$8
M&,,9"!"K$W3WNRH"0P/8\ 8+<,X1!M@ &M)P (RXL1!L.(#<6M  ^PKU$UI@
M !<X =QH28 $@Q## 8Z7!@&4@ U@($ A.]( ^/6G# HPPR XD+1.'  #:-""
M GC8!0-DS (,$(,9&&#"-!A ;A#H BJZ,#Q'@/,!8RCH M+05Q%$RP(D((08
M&##.;:4! B5H2 HD8" )G$#/(,!#I*38@KNYH %&4@0*'B &4(#! "M@PPH0
M@%*1,0D"BBP4!CPPB#,D0$Y;( "LF!PK#B2@!6Q 00)6NX8$C&$0(I! 5!HP
M 1$\S\^]C,, 2N<T.2U@ F9@0_X#2F#1":!BV(D0A0%$N0+?(0448VA "PK!
MB0:H8!!=0 ",&$2& XB@E08X'B<>,-7X1L0!$B!#&_1XJ@>@X U@5A$%!@P!
M X]! "= GP-,P(8,X,H1!_""(K@0;:=%( 1D<(0"4*&(!,!/4 HXPTL9X(4?
M-V 0>'B ;SW""1@KH@N];L4$AL<&$$ @%8\P@ 7$P :S9B0!>V8#*"107#$@
M(%9L*$ :%$$"$+Q5R&_0]!(U*X8V5* #N7W#!3PY$8X/(GWTN30K#)"!,Z0A
M <0SA *V\(84*" B8(Q#L^6T @*XH TG2, G%%$""(P!%31M10)ZJ-.6EZ#/
M##@1*_X$78(E<B #AGC# P[2@@-X8 6?* ,"S-"&$ 1@B2>H ),N#0HO,$ +
MUNH(.PTQ!@(D* 44$#481!%Z+6#4TIAVP<BV,  6M&$%!UCM"0QR!@NLC21Q
M"+/!P'  3D,^8RR0P!O<((&/AN2VV M9TC#0-#:D21$&")XA]C:&MSEM#:A
MP#@5H?:/)&)VK1!#^".0!E38NB.<8$!10*$ %9%A9"OP@$=$L *$D H2>+82
M&)F1\ "W<IH38@-H<8&[Z0@2X!RUJ   [(\,,*]6R   A+Z.N  6*+WH00$#
M; 408!4%L!944(!/^(0$&"=(:P4)2I:,40.V48&DH[^@$/ZT[!E!,(B 5F@#
MB^L(#, (!KDM^R$65# QX3F>!! M.R,5,\* #X3!9],MSC&AMU* H2"PCG@
MT6H%M3.#$0R"I)./"@@716B=4S& 3T"#\#N#O=$"$/@""7B*-X" CM@";6D%
M!XB0!#@V]0L*E'$ CT"#O0$#!E"+%KB 5O" J>L("S 5")"3CI  ^.FVCV"
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MC6H%QT.*4<P XD$%^8" ^4&#- '2CC@# [S#H!B$$@#0!I 0"# C5J@X"%
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MUZF 4&0%#4@T$<BU5CB V&H_:/Z+%F:7F]T1HI!(!68G U;P@/+2@ H06#!
M  Y( 3'7DE00=QTR<<N]3T(,\?+:  KXB7@_QD4J2C-8/S<P&C;0<A4H@0=X
M80;(G.W+&)K3]B?[)@:0@$)P@P,@ ?3J:WI5 !5( ;Q[-@H. 19X@#QSA ;
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MNDD=$3R7-B\IAA>S5SC#3W&,LF)COI7/DLL'46K5F^&BJ:W,N' =0XHLM<B
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M(#<,&0,'9B471P0A#B#0P(.*:<1DJJ ":^C$"#"@J%:(P0V*V, #0*"(-$Q
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M<23 D5@DQ#C" <@&@JQ!WS'$!)B+ G !1@SE2Z2C&0"E%IR)Z;T$)V($)Q@
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M%R  5 V*!+>"!N@5N\&G1[XOGK! #K%"A38%*E0' :1A(1A"(70"(21 3)C
M![#" KA717Y"&K&$(RPJ8SC #<]'72XEEP2D?O!D$&!I US'?K5"(AS <+"!
M .>TRNJ'UYG![@[>&U2H2V! E? A1G3!42H )[%:BL!RB/XQ! I$5"?X#L3
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M@#.*<MBJ8C^ @6"K"I1 !CA2ER1]&A3 !H@"7Y. "U!)])"!P\6T1-3C?R!
M"IP W2,("*. "9P;O@O5"F2 !+C$)TQ !AA\!ARZ>SH6<2P "*3 ]/WCF8I
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M;. 8L[C&-E:PBR3"(@2QR HV&@DT<R0C5![A 16D*H]5Y"($O>A /59H"Q\
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M)S8<39V*$!2&.,09"I"&1 PB%?YCF( 205)#J&Q 2:BA[\N0*\,8B_#-K5#
M6@L*S4$T@,-Y9 !38KD%"K72!!S$ !<NV8H3Y/@K;3# 5F.T9]^&\,EDNED(
MW^ !"R 8#XYP!!A082"5N* %A[A?"UJ08= ,X@,6*,-?%A$$%N"A@81801<X
M46/%L& +(4N$80;QK!5\P<;-:@@;/@$&%FR.#;@.V2#N5(A9UQH5>5F$&%9
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M#( 2.($!6.P$"$#Y-J !0J#N&/Z@*R"@ ECD ()@%4Z  32 #&*0 K8 !!Z
M@;I $-,B P:1!1 @1$#  KK TBAB@WQC RB@-^C% #XE!$2 %2J  \0 !#0
MLC2@ DB $@A 3'#"V""Q%;H0!%:  X:K%3( .%@C!8[BOFBN +0" 5 "!0R@
M*SYA/H) 0^J#!": "T)@ IR$!<IB!2I@ F)N,RY" G2O . E'+G$ [@  T*
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M.SA(%!; 5@V!*)@D3T8B%4Z43 R4#<*#HH!C1;NG*[K@_S+@\K)2'\WL*@U
M3+ZB#!(@3QI +"1@ [XB6X5E#/S2$!0@3S3 5:O4P Z $SBA #!0!/ZJDT
M-EJOQ?X(,X?,X"E<H )48E._0@T&P&-/B"$>@%HHUBBXHP3F8DI'C %600RH
MA! R@ -0 12R(I!08!0A0,5F=JU48!-S$3." +FV #,D<<0V=2%JDE-(( A
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MX (#<#,.&B 5-DNK6J$%(*#O7* #<J@3C-8+/*!/TR,!+  %F.)242#PML
M+@\%0. K+M5V_+(0\&PA1. B&/[@#;JJ C"0(3C 0^HC!="# 3:N,L&K5KW
M(,9*0647U 9 $4"A AZ !$:K/RS@! R' S@B_UP$)A0 !+H@SU(D*Q?B9SNI
M A+C 7QO"WC+H43A@1>A21C",^K6CG*8$LBW$_QV1$"C UA@(2*@?=G 0%'V
M3QB@1^J2, U4(7@#U+9  =+BA9.K*TC@!#X! 5@@\+1@ &!' 5"A"[A ! S!
M#91C3)!VF<4"NJBYOLQ B$<+=%3@ >9B$1Y  DK 5J&"!.9"\1 H CII%1Q
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M+,"@NPSA "PJB..EB7%'6W>F D)$"PH %<B@6&=V7H(T2-U3JHHYVKZ2(5
M*5N 4S2C]<0"=QFB"PI@8\]:0@IXCK\T3)F%#=ZW EMA"W#<*"C^VD>V D:K
M#0RT"_XL[$^J([0G  @Q0@1:8 /:I 0FT&8KP*<X87C=P%Y;(<-S<8%;X11_
M\33P&&=(I8LSU6@EGCM 8)?KJPTH]&7FA04X*(>90ITKXCMV# /J8WFA0GQ
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M*$%C5<(T;]1/-MQ)SPSX(H0-_%)&$V<!,- 1#@!0QQT@6@E,TPH,!(&M2&Q
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MQ@!<O.$" Z!H 98;8[7R20,DM#%?(: <0,(;9"30!BIM*D4(  <V! 9'K31
M1BL)H*%G*R%4P 89'M(D@0=GK## 1(Y,<$$&(CQ R2.0"51"5PTU)((#*[DF
M$!JTC<' 3@:,\08)%0 XTA@-(%1(G&V<H$!DK&Q P&^MB- 5& F(P08&& "H
MR !RH<* !0V5P,)')& G 09KS"K0"0(<* 8 :NA:0AM>2 "!(V(,(,8;)T@
MH$"H5.!!&TW== ($:9S10$:=&(B@@@HT> *D@QRP2B<*H/YP1@D"$,1% F>8
ML8$ ;[2"@@-FG/& 1Y\\,(*F"?2T8BLM*.!%*Q2L-:8!K:P 01MF>'# &5 K
MT$4JLZ91P)NM;   2FDD $8;'EB02K\!R,H*!B"T 88%#"BRQ01Z[ID >!BL
M8)\%;*CQ0(Y+-?X1*"Z@T,H8>:ZXQ2("G>&!!U,+U#4'*'S2RAL:?R2*%B@
MB(8''(R7U$AX*"+* I3(!@()@R@2V!D$]250I* $J$4JGVBQ<1J<H;(%!T(U
MQ 5K .:N+R>@!'%\;&:0<,A'71S(Q?8*3C0F"6"#L@('(M27%"<HK-6]0(J
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M.D 9H\U7 Q=:L/W>:BN#F/!?<Q45M3/$J'Z70$5L\0UL2&Y-V\ N49CA 89
MQ2I@J=(V:!P4;' V)SC>.(S_<A6*>80*'<$&_'(,0)V(*ALZ+9 *R'.+D5FY
M.FEN<U0\ B&<\& G@F>O!XBA$XY@0"<4T09ZDX<#Z;2/&CK!AJ'O?"F?: /
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M$#+%"A# +AKH<!1&"!*@ I/5 "CQ!1F  @9 ")\P(<]2.6G@ !M0 18 "F\
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MBJ0 &K !@B(06F"'4C$(05D!'+(*3=(&#R H%D"/%: !'" !%K<!,PD&7-@
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M/PN21V21JF[5$%K@;37%&AM@-3;922*H M;9 .QB!KS*MZ=K E+! %Z0N83
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MIA6A V@^M6+5"B0$$9U B>#0J@0%19U42%BXP,6B5H8,G %EID$K,@]$MIH
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MR<$QQM.@!R5E2$[0 !<(H$&@4,$# +9 #;3  2#HQ"I*4*LO0. !*F#%("Z
MH$6ML*,?K4P+1" &"'A $21 J7,\X( +;$@1&P##"!ZP OY6H$ !#>! X,2
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M@QD&L $-@$ $8U"$ +Q4" 'D!0*[=8P*&  & 1AB$05HT@9*T )17'DI:<C
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M,Z  !]B 'R*#"G@ $WB4"+  +?@OI1"#$+"*0<  !^  :.( 91N!(2$#"7
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MK$(! QBA3H   R #1S # 3#-+1B %F"#276#59@K%WB$18FL22F! $"8#%"
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MO]"".\]Q>&H# 3@1' $!:@D!%MB"#[**VX, "-B"H1.!%=B"EJ()5&B!!Y"
MO. $$, 53BB!1M<"5N"$ \AOO=B ,N  "7B#,<A"D'"!1H\8"OIT".CS5AB#
M"8  -/Y1B2%!!1 XD2_P #6X *6X=#L4B3&H@%QOH$DQP4GI@@ P!)ASA$^X
M1 B 1#$@A %H!= 2!0FHO57H ERG\&!3  B8#I$ @5F4%$4XU:.!EI^R *OP
M D$$ :N@V< )"3(P@"TH@-<8 P\@@QK1"#'H #,0^)K(@(1H@PPPE3; @ ?
M !?Q@@ @<7X+@$%8!0[0@DLO"1"$  I(E8GP@ ;  %/Y;S$0@5%DA1*810\0
M0A-(! [P#U#P@!-A PMX@+.0#8A"35QQCEJU (WH=1>@PQ98% G E9L"@Q!
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M0@%DN-&1@!9=M,@ F0EI"!H F-%*?!RL\L $K<CDEPL **+( "9<!($$H$C
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MI $5*A!0[&(IRUG2LI:V5)T:>J>?5B1"EPIP0&@:5*X#;  #WFF% AIPD8&
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MANQ(%V2&!V@*!_B9</C%'%:D6XZ*&4Q&P$#'&CB HK@! P@8@I0"*&S)35A
M<5B5>&P!!-P01J0"=$#0=^V32H) <4A NR"0(A""M$$'5+3E6VY*"/2-433)
M11A"@V7 &B#(^<0D@NP'(+%!8$@E0W" "5  )65 08) *B2$HCC"CA ">FP
M!)CD?VS "6@ !(Q,&U! "%A 09P  US ALPD!I! !:B5NFB "53 A6R T;A!
M!81 !12$.8I !W" ->Z&ICB"!OX4I >DS!M0  A4  >!Y%:8 &@H0M[P"G8\
M@'6A0N1TP;>0@!JD 6>V AK$2686J.M81 ML 1R, 4Q^P&)8! 88S:N- <*
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M/"H&J, [@D(#)$(J=*FLO0'_G*8'L.-%B.@EQH$86 !2<?XJ1DS :!*".[E
M&K# "HC QAR"87(KTH**3E[$"4P&!80.C9  !V'$N.Z'![C (AB""+ C)P@K
M1A0"_Y2 XI D*(R!?SAKKCC"(OS0!AAEKMQI8(I ?F!FTIJ%18B " S"(+S!
M!GR+!93 %FB!"/S0!;Q!&Q!L*ZS "H@"\J  ?W["25U$(2C > +*(/ /)4
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M!6! 5$DG*TQ W\QC/>8RWQ].47"!E&1 06# .^;A0CY %WR!-X;&!G"S#W+
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M$-IZ0X)6NH# H!).8*6!-UKI1(&6C!JD7R\@N*@$&SG(V ,S%&$@MYP[6<2
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MCUZ70@6T)!I9X8]"(,.(:I'<3PRXP",.8@RV@'$600MV#^YPCP.^-5W7L!/
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M4& "./X!%!B@?Y)G$!: !%3  F)/"X;%$+I  CA !5A!!$"@"\S%-BQ !;2
MU#:Q"R9 "X+&?A]@"^ X+?H(#"3@*T#@ ES !!J@65@A#2"@ LP@UU+& DI
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MEDP@)OY@PW)["C\!1&;E$]8)%,0@ [8##X'" S(&#V(,!=Y  YXM";/<!2L
M U2@!+IG> [&(##@#5+ !5;!(#*@#0R!4#@ #]R  5! /20@H1PA 1@'%1!
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M0[\\;J4YH=DHA@U$H05JIQ#B198PN3/,IQ4J5S J>BAX8PPJ8#OBA&!0@0+
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MT]/?OP#FCW[K>]_PV%<_[)7/@-UKX (+"$'U'9"!"5P? @&8/Q240$*@*<$
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M)!10%*C0!04G :YA?#@76 ^P$!" :2X" ALG$V.0 (I0"*C6"I]0?01' BO
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M;$X NUC_X!>A]/ /(?[## #[XL!D%1 V"3S7_3 U%D^0@A$;F  +2B$*0EB
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M4(6'&Y "192"#"(H 1M,@9Q2G($+H'B#%@;1 A000G2EJ' *!I$M4(1A!"Q
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M2( A*)& !+@L %L A0,F$ 0%9. 1&4C  [ : @",P-^)N$, &! !! S #2Q
M@ ,Z$/Z[3LD^#4   YB$+@" -&@%$@" U0, "0@ -0B! GB  G"$+QB ?BN
M.QB%!3@ "="Y%6B%+1" VP. ,R"%!'  5NB" ?  ?[L#4JBY^JJ !_D2%@FV
M#-&?])F1PMB1MT$8)8&-ZS"0@;@7?"&2-LD3]2D/P "-56N5>HF(4_ 6JBD5
MW[C!+C&3X0B.)FP57/D('MP2+YR7E9JI*23"*B03+/3"B""%L_, !F !3T@
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M@ ,XGN<#!4(8@V9<  L@QX4D!0B( $Z0@ = K!2HN@6PN#4P U48JQ,(N T
M%4^8)@7@HS4H@Y$D@!+XQB!P2))KA41(@ ]H!)(C!4(H !!HA3J4IG)$ T3
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M: 6,:_X$9PJ%%BB[5IB$5B"#HVN%$'  -!B ,D"YFJNY#"B:"& C2EB!";
M!]A$CRN=AW,F0F&!":B N>&$.WC  <B 1)B$#1B  '@ &"J "7B %QT!5$B!
M PB !0B"57 #"A  S6.$,P" ?,0XSQ+-0EB BXP ";" 2;  "'B;"HB &@N
M+_BZ4D $4'RQZL,#; P"9Q(B$@B]5LBK"Q" 0LC%MP.%)^6$4W"#LG,# !B#
M5O"" ,"#.R*#=XL "F"(2= V5$@$!/" 5;@ !^"$0(4 4& $$ZB\9RR%#%@
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M % 8A +0-IUK@_AD !"H@':CTO:U@%0XR\";@ -P!%.0  4H!1$0@" X@0&
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M]D(:/M[H@5]:X9 .>:+%4)N5.Z(5G! #R!/-\DC?7-..0+FJ'?WO[&0ZY&-
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MN8$)F( AR!\&A!XJ;($)K #IB?[!"9Q X;%!R8$!QG5!)Q!""92 Y'' )[A
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MYN'@%HP?OSH"&H[ E%*M"W@H&;!"" S"(#2AJ:W !BC !)H!!NSB$Y[!V#[
M)[R!;W:"LFY %P3H(9#!"8""%P1G":R"LJ)"!JR"AH+"!GS!(G0 *A2"#%Y
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MC]_=BD+6M4 +^*8'=$(:;  )./Z"OW:!%I! &X NPZH:>K)!$*B !7[ YG'
M(SQI%^PI%VP!"+@>_YE:*HS!V8[?9+( !+9"1VNE&73!(%B 2XN (L#TT(+M
M*I!!$/AH*VS!!N2THKF!"[! "'""&'+>^+7 ZVW!04XK"00!#38%8XX?!W "
M%S3>&(CH&' T-P+SLAZ"5;="$)@!;39U&Q!"$PY<+RJ"!&Q>X(X!$LOE^7H!
M!V1FHBWL3I=A"IBE%N(B*X  1(@ )31E*YC!%Y1!![!M[.HK'BI:",Q@6X.
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M*$(B<$!3G&('"*W3X2<KB($6</Z"0XKA+*,"4;-"!FQ>WAE@,;_>":R!&8
M4KL 6"<:&8@H67.!QWE!FS^V&;3 *G0 V'* 9%,=&B3"%G0Z_\$P(0QA7MLB
M.\IE"V8<)2IA&7RML[:""!A="<1!FHHF&NCMY3*I!HB"!E!="WR!&S0A*+Q!
M\R8:!]BBJ44Q?M<&!V"H$A:"WE'YA2;O*KR!**RN\6JYT1'B_JU"#99=*JP
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MJPE$<>*BIJ(#/CT!AX=RR=U*I@$C!JKL'-A MFC CVOQ  K2T!]4<""46ZV
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M(QSC Y9,/$+ 9PHA-Q*A U8A+D[ #%@A_8Z#"Z##<#J!<T9CR1Q#!;X %%+
MV#+@$\@ !6X,!5(! UY/ EQM12BI(12A(="$!%" W;1 75!A$;1),L#@$T+
M).@# R!'"]K@3<Y !11A D0A#0JA$QKB2#:) SI!)3AA F!.DD#@#3@A SAA
M19S"TL8@/5@HSDZB%2B@!3B!!;9 %+1 "T0! EY/UQB,#2K@$[ZO$RI@]AK@
M$T@-]1H&343@!.:$ UA! \S@$VC$#= @%39 $:9%$1S! 1RA#":@$TP O[:
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MLPR+UN$<L%++L.[\U8-=V(>=V(O=V%?+$58@2E>'-AXAT>YLADC<'^_L=ES
M!9 &L<RJ$$I@QPY"%'96U]-BD_[TPNF<I\AP':E0 0W8J"G-X+@=H0LNR1#.
M?8:VLBCB@LD$;'SL=]HAAP6H[?M0+<9<[*?,"J[\[ Q,X"T&OM]]RKPXP7Y7
MP44<ON#9?-H'3,+B@FXO[KO$9(5FZ]A#_LNTD0 P0 ( X$HXP0!60[(^P0!
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MH Q"PD .3!"9 #ER"T AA@Q@ 2):;*@( "B LMXA8P"P+PD$H *& "4HXH$
MBJ#BP*6@,* GW:C$O0@9 .180@$#Q420* Q((!4#7BP"0 FIM & =1 H,(BD
M%BP20KAE! ""(V  X)H$!J!@2.IW)&L&*FBPT4H(D(X10/X(BI  K!@ C/$)
M"0*XP6QGCJNJ_/+,-^_\\]!'C](G;*C0@ "#@$* @*DDFE B*FP@00&$B*)N
M*V,0@$$&& A@@N9J*)7 NA!\7,"]**TRP00Q:6Z&YK8#!6!L@P).(& "&=#
M;@Y!*Y1$220H&$!O&!""9!G"!0;00 86!09%*&  ##!!0V*BA@0\P $/\)Q,
M?B:!-HQA 11X0^K,$!,-->H3: !%"UR@ @NX( %)018 :C0A!-@( ''0$4$(
M$0#7L*!J?&& >#S @)V P@L@J( ![L6!*B9$"P(HPR(P<("&!(DB&7# P0"
MD+0Y@D\2,H$!DI(&$F!@3I'!T?X*4<"B?YEG$!L"GL..IH -:( "B0->$KD
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M4(%.:,$ ;\A2!<@"BDY\0A$'P  H5L&! &@AK!G844P\X!H(J.!'O5'*!!#
MAF\>*VUNX*0 *L &VU2@#8CAC@<&T )'8"EM]U*@A61&@D(0@@T&X!\&$+ 3
M"RA@K.D94,(0%X)6'> 3(2B (:#<M-2%K14F&-N_K%,P,7!) FGPP-@*M@)"
MF" #J?BF[=(F(?J"H1,)&.D)"'  A*R!G80XP:7:=!H=:8  9D"8%E!Q  BT
M(<$ 3<"&"P& $?U*$600P 3(H/Y?J"B@ CLRLUW,P DKKP($ BA%W#B4ND%H
MC  /@$ !>CR 8R'WU\ .MK"'?18T5"!-%LCQ6!O T THE2\D^! +)K O+31
MJ8; P)52@ I6V(0,AT  %Y4$BA&DJ58)8047&A#H?:5A BZ 0 +"U G50CM-
M'# )*$AP[KU C0$RE$!OF"0!"2%+ @EHP U#\!<,3),@,8FX5VZ%OWTG  $B
M"&)_/$"104B@ 2,*ZB*LQ  54$0,$$!(4%%Q@@8(J T4,"$1/=8 ESQH!1A8
M 9HO19 N..#A))C <BQ $1)X">42 @,$',&D!&P !11 A2&<2@(2B <\$MJ1
M%GB3K?X:%>(!''I#!1#P ("BC]W2A>\#\ !?WK3= IS(P @(XG$1!)4,#T!
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M\G( 6/$FK5 "(L)^T,$<>( *(2  %A8 G) L;\ )(8 (K>!J:!  8K *BC
M*= ) _[ <9W4&11@ !L18@G!6".5$G*&!CVC<ZR ,B# "IG$ &G  6DP!A[P
M*1C0 #GZLH([N(1+7"53 A8  BBC!0<0!#4+6H]@ "9P& :@"$$5M,<R* 3Q
M 'I2 @0P$"1P )RP/P2A!A;#"!NB E36"FY@ HU*6_[CI41FNL%G 1 @"A0@
M 0013PDA"@K@)031!@P@ *[120(BN\B3!HJ0!B! !@K0LVR7 0J ?H5;O=9[
MO<NS(_6F ENW;FXP %T0N160 92B1OG2$"XCM/4S2A#0N97;"OS&KP]00[KU
M !XP ?&"'BN@"('7"FL07%Y:'6VVN]65'3$Q 2G+OA40$_YH$!NS"F@I>P:,
M,H@3H#?TXP*M0 $0$+C8V\$>_,%P43(J8 BG=F "X 7I @*L>D[\8@#3ERP"
M$CDRT0 ;-@)\<SMU SPMT 8.P !)02 &8#LG@"._@0"LH#D:, C,8@*FU !M
MD#8'J%XQ$4LG$0)4EJD'4@(;H',K8@)@,%L#L2-;H%0D4 &1>P:L0$]."L)L
MW,9N#!;\10*L  $;PBP83"ENX 86X!I\= *S.@@0<(#.)A,;$"_3UA K, $[
MH06Z@0$&QWX(XJ7:!@(F8 %Q(@(+P 6(8AV&D $)L%P[P@$=L",;P%!T*C>%
M( $8, $2T'LRX0( D@'&RB2]X?X(&'!10E5,;[S+O-S+!/$)$_"I+1 !G5 O
M-=()(7 E'M 0V09P;8%]8D&]7Q$G9,$*A"&!T!P68;P_'.S+WOS-;"P*Y)=^
MS>,(+B#-SZ<%LPK.[-S.[&RCY*R'H6*D@TO/S&//9X@J^.RG?RB#2 I[?LK/
MO<F>^.S.-EC0!IW0"GV]GZ "(V1/2@061@J@N\<5HL "Q2>!JW"@Z6:DE) 4
MB8#!!('08A@3"M,53*>(9*BD,6'/AYB&G) 4G+ %&SV&%,HJ#;$(5;7&*CV$
M_[/&R0,*ZVS3#]@)'[$*8" ".U'3! $*(S((KI$0)+V$8W!/G# 03MUM8-$&
M8%""AO[0!6QZA@=J!L''TXPHB'&XA6!@K!*XAB9]@%VA",57"&#@771(GU[:
M E/M%0@=$V\ 4%/H.&"@;!S=U=EYG5T1'26  BUP B-@)EN OGA*L^S\M5ZR
M(R7P7FT! F;2T.C,%C$1 C5B")_Z%H.@1B@Q :<AT)P &G%A HYK$6VQ"@Z=
MM6PGT&<! B+]A6YP 7#1 KYF" PP"/AL9*B !^FJ%F# (5JP+OXQS@1! A:P
M A* /V"@+9C4S6(Q!F6]HEGK=W+Q!DTS/99V,!*P!24P 3N:%HH@MW*Q!8A5
M%EM0@E#8!?3-%G8#!B>  %[ !;;3 (.$+' -SH>025&M OZ^Q@EB,#M>&D2@
M$&-H  :-I@@1<0B<@ $H8!*\&AI@ *==P=7&V@EB0 96H=-</1".D $GL BL
M,! QK0A=\,@6\J4$X09?X*M*(0:HNF$GD<I@,%EC, 8YRM7[4C,0L 9*2A4J
M9P9B\!%$\09?\ @)\=6*P DPP@$DH B&< $B_BDR<09A0 D$\>1@,-0.,;<3
ML 52+N)V?1)*"@ICD 8Q<3*KH!/] 09H8*3>Y @G<("&0!%S:Q5IT$%*L045
M, C11Q1T'6-*009B4'Q,=PBV%@(@D BHL 48$1.$X 7*Q@G5=7\$@0IE\.C"
MUVBU,>:?(,Z@( (>D B48,9C</X&$XTL"=#4"M W/DP0*- ;1;H(S[(O,F0A
MK!#A,08*Q6<(7J!3<\L*;(!_?#$&8I 4J= W9D#B,D'M#+[L:C 0]E7F/!%C
MK."K:'#C1\,AO"0&8MX5BP &9T 10MT)AAWJ'3X("4P07L Z?ZX L]IEBT@4
M;.!WG/ %C>8;7P"GJ_ 1GQ#D5M$W3H82;.[NQ=X;7G "C] %TQ33KP,*K# &
M</H)2WT&WJX4(#^K'C\27I!$2O%<8! _!0$&7OX5AN#:!%$!A) & :,42<%T
MAA#@;YQMA7#K/'(O;R !*Y#>5_1L*A F%E "7D !HL0!&U !:* &#6 !9) *
M"_ ):?ZPQX-L?5K< A* P1Z7]$(W(1;0 B+@ )V0>1E""&K$!0^P IQG.Q9P
M,2\%OQV@!14 4)0P 22@ AB  ?2\!0VP 6Y@"!) ]HQ.$"W  5T0]J@P @V0
M<4:' 6 @"AE0 BX@ ?L2 A70 B30 ":A=$F? &G@!H/25PU0 BH0 <<B"AN@
M^1/ =B)  2U0 @VP^*WP *_# !G0[!6@!2L@^B>A")-_ AF@5(H  2$@8FD@
M 6B? 7N!<BH0^C7"^WRQ=*C  2  I0RA 0_0-K=W A6 4@P0/XHP 2B@ A*
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M%0S*:$4$W=[0L(O(5B3!R.].-.0-XUKIY(%54 "J%2X@P"^L$\E : O"6)K
MC%90^:X3'D'@ "$6NE3C@E9 2 &A#<9@A0&F)B SO%8248 3V!QHQ84H6V&C
MPQ!.0(@#W49J98)"6KF@H#9>:R4.AD9R! %#$(+ #5 .:&/-!T:]4XL^/WU
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MD"CLVPD/**A4+#E$ T9%!K&1@ 2K$$4HC<0Q:GK@C'$ DQ:,LB&BY645;R!
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M2N" @UB$(LPF"\B #6 (%6"8%&"8C_" J0*#!V #5#@0#=B YE(?"DB!#*@
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M_"@#1UO19.N"("BMVT'1I%0I!WJ$#(C+'<U21F&*-%T0ZV/0@_ "\TA23L@
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M-[@YH .%("B!+EB+-W $3@ -,(A)EE"#TI@J&8L#$E !*3($_U'!%XJ##&"
MQ= "R"R4ED@#0TA:G2JE,+N/./XH#2ZF"\ 0 4-XA$'X!"3)C'QK) 9:V9JE
M9#>H@'@\@[VCNX0<BI,P"E + FN)DC#XF5\+RWF=@#,0@[KIF!'  Q>($PD@
M#Q9 @'>)@%3QCT4( 0M $@\@@418 :)1-A+H'\#=@@'X#A,( 3P(@@U8!>Q*
M 44 /4,(@J]BB5]A@RWHIE5P  P@2_\01@^XP@QH 3P0@?A8K"]8 PEXJZI
M@Q:P/#$P #!  ^:(R A  S-X@! AQU;X0C;H H/[#Q1(@Q,8 +)2 ,8 E#?
M@!F!"4,( 1ZC*<(P! 'XCF'Z! D8@SC @)40@08H@5Z=@#'@%9Z,51([ PP
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MTW(@_VF%!BC=I#R!YJ [S5"C$X! 1UB)!PC'V"$#8.'>5H@ H$F#[6F;4F"
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MI7&P<P0'0BE:L%J%J@+)DEY M!(%0=0@"ZU@.N(P84*;5H4FH-H(4R#"5B#
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M,($XN $"5BQ)&PK@O1;DY@S NM8*-@.!3W3B :M0PP/B< @,9 H-SL--IC8
M@D6XX0 _,H'!JM* ,RA""P?P5 92L!D%H"(%!CM!9Q+P"4X\8 R+2(%J)'6
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M("@%0^ M1XB  R4HUAM L $MP.2P6VD!*/!PFJ-M-C4<H)E@6D0PO*JI+(9
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MV'S"7W0""XR A[R!(9A!UF!&'(3 %IC!0+B!T03B1D#D%LC3E44 %P 1&Y#
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M$)%3*BSA1HS!0(Q!@Y3$%[Q/*G"!*$2 ?.CMAVS3!J!!)PC+3';"I,RFP'1
MKXSIH/%.*[1 9QB8T9C ^3A Y^S)!W'2)XS11IR!5C 8@/XM$,V]4BN4P0-.
M@))<YDMHB14M+A!M0:B%*TQ0@!J82DD<&J9L1#-JS4943G:<4TMHR6DP@!FL
M[KK02AL(3-LJ!PE\P2KL12>X@4L8J$:XP$%( .A8 &!IP4$XQHR  @B\(@-,
MT!@HPAI(2%JV0@EL02HP@"+ 1 :,01QH17JR@OUR2!?X[P1IP+AIA CDQ41P
M0)P,0A""S2!@4PMX@$=8"Q)NA"$X%-CH!B&DS/\AT'O51P: UA<PQPE\D B,
MP7&@ @S.CFLH G.LP@-(R1<DAI"Q;1,Y DE\@@4@50:P# :XU4'0R,6(@:ZR
MPIVPPF=L1!-!B[2X $$:H6!8BOXAE$6%?D+S6'!N@.!L=DPBL&T$ )/ZX$2#
M< *P&,*0 (DCH((B.,*X"&K>I@TK=$("H QH',)E?,>,5(#ZR.-'\)($& T*
M@$8#^LTL<8(:2 LK?(("@,+>$"^TC,@;:$5MP(\%D(2XSL<B,%LJ*K$C<,*(
MB$"I[@A,B.^=),<G %&>I#'9KG(KJ$%YE 4'G$$A:,4JD(%+5$<0J$ ;#$1U
M(.7T"L8$0$ )[,IWL,8J;$TK?(&9:(0)L  K*$AH0( Q%T)N<( 9P 2(1/+L
MZL8&C-![E(;R]=*(I,;)30#KD!0G-$4C1T"69),:],8J5  ;IC,K),*(D$$H
M984$8/[ ]:S "3@%*[CB\Z+>6JS"(D#G@IR (LPJ3VQ &]S(*D"S\L+$\+8!
M!XQ "3"'&'Q [R0&2VH-!DB [%X$@KG$B9R&1N#L(+2 %ZA?%'''"(% R^4K
M=4@ I?9$RVV$8'$ "DBBGC0?/F^%2TH*%Q2A>\"''EY%"8Q!$9; "-&5UV8$
M*[0 I>0;!Z2DFQX&WBA$14B F[4!"@R9I%2 7G@ *G0!A>6&"53 "/"$6;=
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MLU$;T(XHTN"&$F@A.&" P.H2ZX6)#,*P]QI$"4P *$-\H )FZH0+2-!8DX@
MG6: @ EX\H@5D(!(B7C#&V:G"/X+O*$$*MC1($QP@DN*H00L. I$!G&E+D"
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M0>V@0$$$Q* MD)I! 7+!#"<0 ((RN* !O)ZW2+R0@3>(H0*@P$L;(C*1$)0
M#RH8+AOFO050/&!#OUD%"7BO MIP @):. ,'&F 0A!#BZFUH;RLB4!(1D& 0
M*Q@N*"K @HV3P!$>,&HK)K 6"H@?XT<B0!#.<(%Z8484+GB %T3!@0CP?A 1
MQ8,$0H0$.( -6  "0.$,'" %',$%ADL,)" -R. ! $4#), ,Q$ !0B0HT$<"
MH,4%#B!&)" .U*"]S& "'.&I,O[@!!X!#2K #4HPG%:! 3[@##9@ KI@#!+
M$0Q! ?9# PI!"R*@%<(@ ]Y# E)!HUH #T( !1*B ;3- BB@V:!M"OLJ!&)N
MIDQ"$:A""T3 )%P M1S 2PA*%!3 #58!%78$(42@8,YE+B @$11! 8 (_2;B
M=CY! HX"ZE#A$Q;!$2)$!1A@ S)  E+#),9 !"2  4K"$4RP;%#!!"6 )T0!
M F!#!)8#%1RA#]&* 1QM#!I 5M" XUJ!!2*C=E A1-B&-KP ,/9#!'CK=B9
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M"\K@!%;A 4* -!4F DZP$R!@5K,4/EHA%20 -L;  RH/,+5*!28  @1D%5*
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M(Z0"0#(!#*$3#,#%;'$[3L YW/X  KS$#(CJ@[?##&R5$,Y(%+C 8K< ,#!
MU<9  '2)[L0 #,0 0U"A 8Y""X,# N!$!182%"1@*5Q  QYQ!18A#;B1#,!S
M^Q;!OJ1D%(F2I)2E =) 9O;C<(^, 3*4!\= 7BE #%"A#!5!!0[ $<R ,1\2
M#/2H$QB@$Q[',5K@ !2!$P9O.#0O5EI@ #BA$Q3@6$Z@ Y#L >PU#03 PQ)@
MK$KP2!9 +O18.!H'(?*M!(8N 3A![8@G5PJY$ CA -[ $4J@HKIB$<;@ 1!-
MJS#C"PB@F,#.E#MS$13 ,4:@ $2L*M W X+% N0B U!@$<K@ 6P/I!2A!&K"
MNP"E O[0 !0:8 PZHR;:8"NBF7H*H3.+:L9 H 0<(0T2(%B&HB@,XKOZ;+BT
MX (8]@%*@F=Q4DO6+ITNA !4U@!3I@(6Z@%;X:3FN9Z/JE>73L."J@).; &8
M8P,:0:\*X00T8!%(]@U"HPL600NN5>D&H1 R@+7,H.S&-Z.1R! JI"H Q$C0
M@$C08,8>[T TS0-X!IK\9'@4000V  4&)B.V@UQ&@ 1  $X*P0-"  WF+#N>
M)G5RI5@&YA-:($;,@)14X!,*P9TP@Q"2)3M<8 ,\X-'XQ$_.35RX0#D,P9('
M(5*PIA-*( .ZX L !2': $M)X$ ^P9T481G-@%#% % P(_X1[ 0%QK8$/  $
M7 :L%4<4YH,$=.I%@B-*3&(0B$5I?DJ.6HL%6,=*@B-8S;(51F1KQ. 0,!K(
M&(5#)*T-0( $\  ,O(!QT^8P',$6^>6'6""CM$"JI>PN3L @V@ ^.D5N*DIM
M7HPA3@^- *0_"F$9M1-=*!9 8-I;3F #PB5AR(<2+H5#BCM<))M"^,7?TJ0F
M(Y(A<,6X(>9?7CI"P'HYN( G6OJE8QH^9)IP 15?3*(33" $QF 02  5TG4#
M0 !BTL01W$!1P(!"+ 1#=)$0%.%:L1$%@L,,(F4_]N4@6J"N\EMWQ45'$EL7
M#8&H<V(%.F #"H9M$ 5J'(1G=O[$#(S;#!0&Q#5ZQ$F\Q$>\!631Q/=&,^80
MA]H@ 3)H"D_ 0E2\QFU<B5[(GHY)?<J'?WC'<" H?';GGKR'FX+<BKZCKB:G
MDXK\G7:IF\1#GKAI+N2C.'_\RKM)AHYHE0M\R[&H/$RIA;X'/)1<F11(R\FC
MAXY("F^\S=W\S>$\SN5\SNF\SNW\SO%<6\,WS_F\S_W\SP$]T 5]T F]T W]
MT!$]T17=QK%UT6UHS[^#S?N&R&$(TAU=SO7)TDE'TB^]TSW]TT$]U$4=<!#M
M6=) S<YC%1C:/#ZAIT*'Z\PC.,5#H@SG#?P-<-( H7B-(KBLQ;=#$8CH<MJ@
M!;0 8OY&R!&JB@T,"89N3%F"?7)8P0V 2!&,G6]D?3M:'7,.;CM P=5]_#M
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M 5(KW#T]VQ4<MXH$6R)@DC)X(146P%,K)/"(0BC@(%N8U" LH!?!'.(!2]G
M&4JPA0:UH@0EV$H+2K *-4"@)FQXP"K:,( T*(\W" #+%C+0,@_$IGXJF$!"
M-A"=AKB! &>(2@ATP@:!I !_\6D%"JB#@52Q(E2MP$ &10&!5!U !3%I@1EL
M\@!0K/X" 1D$Q0/FI0#A?.^#K=" 8%B!@2MJQ07M804$G/*&";R!<A'C2PO:
MLSM1$(("!'&$ E+1"C!<\3H)"0%?6C,0#PA& ;#Q8TL:$!,Q&  4;7 6!M3
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MX F*0O!Q*_&S0%L'L@'R>.03#^ N25.!P%9 ^!/%:E $&G% I1PE-!'KH(.
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M&[ !JR *#P 1*4((PL(!)0 !>-(379  9P!3 Q$'U;8G/OZY)1)!" \0 B5
M <CB8B>07"0& IEV'%T0 20@ @.3+A"@)QZP"MXX$"+010Z "E]P-XHP 2(0
M D0S1QO!"C@9551948;0!@P@ B?0 (,0/'EW%*@  CT) 6(" 3]!-C_1 A-0
M A,P(&GP "80 I!!$+UA CB3$&G5$!L <@E1 G>S'"<P 1D4!+"2 =11 84
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M!C@0P1JS\2H3WEIS9D,1-I&O'"NS-K%P!&$&R@,"+%.N!/XQ"'@""HK@/)0
MJFPS-@4!%<V:!IG:$(.@(ZB@%-Z*&,PZ;5=[""MK:.@J.FE@"&8P$J@PM4X[
M/8X 2,QB@*8T$!F05RO[J]Z*K3%1"*M "?ECL._&K4O7"0Q9$0$&%405!^B*
M"ED8!ZZF%0E+*HJ0")_ JNNEAVR@!LI3M*BP"(I@"(90$6\@)HZ@JPE1M$-A
M"(I#2Q-!KC/!!E)F@9$*N[$KDE[DJF<F$8HGNTDA3+F;NQO@.G"!MHXE?2P
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M6Y!$Q.D!+/  @18!:>0(CJD%E$D0:_  QRP!",(*]>("$_XP+R6P JR@ERA
M 7R1&*TA*P_+"BO  !V@"%P0[2>@ /[A!A/0 B+@ 7[<"BS  !Q@"'-TI!K
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M S$ 1%9H"36PB$_-LT,Y!##PU>>X3##@2U8X S'(N;"L(7]3!%9(GD\8 S,
M' L8%*,))TX@@RTAB>Q:I!-PKTI=!!;(CO7A!#%( Z-9!/Y48 ,Q@,8O/*&
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M-P!&#PA?2V&#"B"X#3"T3J@ $4"!#/B9P$,Q"<@57FJ%()BY,@,%!EA%5("
M0U"C%4A(YZB?$P@Q+R0]^R&!!C"#VE)='.I $6B!">!+DC"!!@"!16 #"<"P
M#4"V5OB"">@"#W@1R3"#!X@;""B-3Z@ %-@""I -K1.0T&KA^QR6!]""%1@B
M@DB:D/ =$DB!"<B3<#*!%/A?E<H.,G@ N($ -BT^[AT!4R64#4B/"8C#$."
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MZ[[#S5 :"1"%>=:S!AB2+0 %!S":[I$,[S^(,["*BEGOY/C1%&/?$0D.@*A
MZ V&5JW2%%31 E4#5 87.4+S@,VG+BI:86!C<..6$@8SI#&XXF(%%8=064"%
MYT(KAX:Z*%"TL94;E@8MO ER(0XJ$6@<?EJ#H42J!H,6+>+TJ4V%C1O.M%IE
MD&DK5JU6K% TP>"@IC-732#42@N)5AO(&-R@QM!6@QS,M'K0Z5#;011:37AC
M4,6)EOZK!J6 (&JFAS&M(LA$)4'F1C<-S' Z(Z*J05:K6 U:\6!5"#"M%DD
M-;;L!A&%6&6 "*$5&!!1*8,0\_!!*Q%>#'IPX4@1)4ZH(##FI&C1ZC$<6H7H
M8E"$\@B.2"BO.J@5"!"$6&TPU$F"PYG>OX,/+WX\^?+FSZ-/K[Y\FM4&4268
MCOT!5*DGCB,_KJ6!HE6?/(3@G54BN-!*&PHDPAIW!HVQ 64&O;&:"R,8Y$*
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MP*H,<&*(>X,41]\8#)CYP'2=*-#)3!O(QE]+#R1(61<UKM*!CQN)$H%>GRB
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M.B^4H 6&0!(A++ !"ZQ 3EP)808FL*HW6, #7=15"RP9/_[4>2 #&#B!0]C
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MZVO?^ZKU.W(2A0MX^B"@R@D57)@K9QD['JFX 2I]Q2^#&^S@!T,XPA*><'I
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ML[,;];\#/O""5^_I"KP>5K3U._Y(;JU4C\M.LJ("#)T>/.4K;_G+1YH5(H#
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MF*+K*4(#&,T&< &2.,(#O,NM;4!TS(0+:(  &L0DW9WB&/Z""X !_3A"*7C
M X3 O:G,&'2 !<B:&;@,&.R;%FP !^R;(X# !73!!I3!:QB"!4C 120""&A
M"%A;99 =!WC&&4  !8R!(P2!&6  *H!""?P1B"Q""X@!_70>&6  "( !%XA"
M"#P "'2"KZ  !02!58C""?R16/R?&-@=_I53FJ& 0VS!O[@ B+1 &V3 (C&(
M!W   "J*"%C %A3&&P2BGPD*4KK $Y(!"%0 6K!3".09-[6"%W# !KC,)S"E
M%C"05"Q"!D" "8A"!G1!"%"D03A"")1&A[P!&(#!<11"^XA AXC!&*B !9P
M*\2!WJ5""BA.68W!"NC08)A @?YT BQQ0!RH20-XW1@T  ; Q1MT0 :4P+N,
M@1FHP J@0@N, 0:0@"&40 481FFZT &.8PAX  @8SQ@,D)" @@L(A4RTP&MR
M10=P  E0@AV2  =X #E5A0HXP 8H@C3%V?!416]RP,QLA!AH91LH1Q<@972
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M!*B!J5B %CA"(3A &W " D74 7B!(GQ" 03!(K0C(0Q" H "&=0(ML44*U@
M5'@!DHS!8CA"!2SH 8# 3YP "%""(>S<8<R,"F"+R+;"&61 (15"FX#"?LC/
M!*C3\"P"!1R*5:3!R)3HMDC)!%!F1J!"T;3"KK:".?E&BSZ("I3IF;Z!(AP
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M'QO"*I2Q!7#QV1C$>[;"&@ .K'0>HKZ&#6T$AZR").^>&8! =(V%"G@ 95J
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MA@L#1X,>-'33744&,UP@E  %D5#W5FX<M&KA8B:J!8I:=='0<(*9O1?*H*@
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M$(((Q,81&OA-(29- @;PV1 6$ $&J%,?"W#  H:@A 4>,.FE-:0$9T@%!X+
M&1'@ 14:H#5D&N("@I2 J;OQPL4MH!M.?"#+(UC%)SC0@@U(@"Y[T4 (!!T@
M#FS@ G<!A08X@8*'#\($BA*#3_Z/F8&)EZG,3';R:H+2Y@SLAA <4$$%E+,!
M9H,"!&D'P6\?P E4;* M7JB0V#D  ?BTPB(;,($&6ED(#& <JV^ G!KZ<@(7
M5."I*YXUE<<@ K+_1@T7@'896B&&$H1 !(; J2,LH!,R6. #-4<%!QJP@46(
M8B0:\.D;)H !$UB@1AY"?0,T\(@3@*#:&YC6(8)]@1HIP@,M@  Z+4 "W[?"
M#"$X@04DX",RD @5(3CZ"2"V!5Y78'7REHFW.=$=3EB 5FD@>^<5^F/SVTE^
ML#S#78W<"@:(@A &N,K,6V&!2C7 1XYX+AM\BH&59$!F7,0%VF(5'D 4#,$
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M0*#B6B$"%L$$#A$S)< XS60"/.1O&F(\6Z$3QD,"L.JC&B+:.L$W*"8"KY'
M!@$,4/Z@.Z330P#D#>SK$AL"!,9@%1H@4^H/G" @4W!D%?S%PBH@4SRD!*+2
M+?Q$#+2@ =Y@%0*T%5B 1#[!-,@$%2BT0T3A("-B%&&3$QRA H2($,!@!3P1
M+BGFKBH@9>) '1OB#=Y,*JFE)<WD-AJ 42:@-V8B,3,3EE(4%+Q@!M=BOSS$
M#2(08K2%PI#OZS@ BU;COS#C#SG R]P #$8@ KN 0#0/ OYP(B(3# R KGSC
M++0 #,! 0Z 30D$L/ %$.89P#,Y$.6OC"V PB\"@!'!*# A$/1WAT#)S:<
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M;_O$"^@#=]'@KASA .3) 0IA3%KN8W<8*T7D*IC79 'TQBZP A:+ J9*9,!
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MQD]  TA" YX'PFJW5 &0%>;ZJ*E04XTB B#&!*9*!2C@!"; ?T"A]3H!QT1
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M*2LD,! "*@>C,($) [6P@0<:J.C";&6(XG ')TSD2 :YM4#"0!LXTD)T@TR
MP6QF*H*!!Q=\T8HB$JS2 5]!4.<1)1R$@'$K*G@QD M=@!+VV*TDG<8&K7"R
M=GY]LOZP@034K7G>%A?@G)='@V 00M5J3O? GQIP@$&JK7"@\(B=Q,&!"AA
M !<H'@@>;4MJ8O# PQR4$(($)K?BA@4>6&"<1Z#0U@H8'@P4@AN?;* X"@*1
MH(4$:6R1G\\6A" "W+,6;_SQR,,JD!80D+=!NJU8\*L$CK0A06Y:,-"*"_FU
M<@)U(8"P$ 2$L '!0"0\XD@"7"6."B$/M++%%@--D.% 6DQ@@0.H:7%T)PS@
M1!H:H"(%4*<+>BH!!13!BA%T 14;R(T80H G"( %/V]RPVG:1H;&>0 5JX
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M@:E!2%4GLO-40+GT02#(P!6C=!$N>'05$^!$(BP ./=,8#FLF$ GTGV13TR
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M *(P"&PB$*OP ..5KD([M'3("0TP 0H '"3P  8T$*#0!F9!*"%@ )/Z+P'
M=ZW !0  !EA%.0:0-(3B 0F0 ">0"JN  2.  L.!!@V@  Q /R2   T@ 8\@
M B#@$4'  -^7%6CP "X  0>@ AZA!0J0 !" +RLP !:"*V-K J@ "A9 ;F#
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M6]S-WCPKC:0"?\L%#5#!#'R]'< !!V!7*B"\!#$& 0"'6@  8\ ) @ ]'.
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ME $%H  &8"9E$-D8_ :#8  ,@ $4< #3+ !-.GL,8 #5J@:.H->MH*QF( H
MC@ &T$&%X #X30"\80$/#+ID,P *, #J-Z[1P<B\T<X)<,<OL@$ROL)*B<&#
ML H,D  (, #MG18H,  $, "E,ZSYX6[CO1P-P%79?>58WA0RE2HJX "LV !6
M(S<<G@$700@6D "QBHII0 @3H0@#P *.@ :R) IM4+4(0OX0M1TCDG(AB7#&
M<M(*@Y &I/(B>\XCZ85\HJ (J] @;H(*=9X;GZ!'#V*'?Y4&*>0&\Z@A#L+H
ML<A$B9XDBE * \$(TEBKEJZ1#""%=A@GBR")K9 (:6"LD=@6HF &H4NN;9GE
MNK[K0B$3WJB1E*D( D S8#FONF6N'?&/&("\-<$**%"JO![MTJX9'C$D05$A
MCK$1H9*65WF8/AL3X'ZGSOKM2RD72CF8SKJ8<!F7)P$9R*X3[PZ5/O&5Y_Z8
M\3[M^+X9;I+%F9KO_IZ7CG "HO&1+9$1;8 O7<!$J"$&"M_M&FG6#D^5Z@X1
ME+ 0;Y!2+*$"Y?0&8O"1CL"U4/YX$([ !1DA$F<9F;(*F0[_F(AA\C.1$ET@
M%Z( BUG)\8OQ5V+PB2="$$85CG'@;P<!"O]*F8:)!R&@,/6^[C(AC"^B!6W1
M[H2YCB%@&=Q.$UU04-81'5S 3Z]Z OFT",<" C")$F3OM$._[FG)CS?A\IP0
M40^R!8TB\7HZ$Q%B!EQ!$V#2"E_@BVB_O#+% G$P!@KP*^9.-AZE EF1$067
MZ\_:KU'Q32V 3@R1>QY! AB@!8)S-9>/ 8Y1!B]E$(F@QCVY"$X,:ZCF$&YW
M J<[$"IP@!( />SDT%LP@AL  O%F'-H.+/YR[VD$\=I1>J?!"260&_>.-P_+
M$P*<*/YI<#YB\*H&L ):T#%ND  :+P80T' E(1!!E!,N(!]8#!&$8%=T8@(S
MN10<0#^\WPH-0/77C08)S4X;M IIT&DUDQ_3AHIC\ D>4'<G,@:[B@H 8<;,
MIU:B)#AJU>J-F$4)6RD:\\;AQ$YB"(GBU,H1*T.'6K%20R;C)X2M.'5*Z B4
MH@AB0'5!X0B,HHFK6I%0T:I- X</%(%9T2H$FE4;/K%B-;$5P4\DQ7A,.89-
MPD^@/KF)*C$A*S1C,B;$,\:00U%FT"15VHK-F$<.49TY(RHEJC02(7YUM*J-
M&50.XX@9N[1JFX2% $\TPV;1A+X)476I8*@O)ZD3DZ91D/XRP:<W#?I^4B!9
M1 (+#R& 2I@!3"LO'-*VZD0"A*)4"-L05"1F:JM5CM[N;F5HS*"$<2"\D;LJ
M31G4K2BA<C0(52=.8E"J24-6(.I/)3PH8D4PX9LQ-%N!ZM1I^&ORY@E!8"-W
MXB<R:5+-G8N*$ZHV:#]VP""$A-@H+2%0/'.L@3+<8F!!MSKY)"*'6$G##-1
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M9!6/F)U$/(F*$\1!!&)8 195E$04)<0+)C $4?WC!:@23P4ET-5JV' "%#Q
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M*4@]C3BIA* $!&B]A,  % *+CGH#'<F +E@$SD,(,0 Q5-@ ,- "1U N16F
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M 00B!#:8KZ+<@%+Y"!2P@ Y @0[H&4X H-[0@ VX@/@9*;>R  F8@$Z9% G
M  H@C*20K?K#  G ' _0H Y2BO=H@9:1CY<+ 09K :Q"#4[(@%5H0 ZH@*
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MD29M;@$3Q]B/&YD(L#:/JA %K2 /J$@?-D"% M<(_F"3(TH#I<;G!G<3<*D
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M]490+VG AB%18N!!C2!4@,H(&5Q "1L)J>0!20^ PL$9J;!B2$):D-#*%Q_
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M T% A?[%'E :@KRD!3^S (LP0)*U.> K7I@5!08!AI!MX&<86&<KXE 6123
M$8IHP%<&L9:O?D4#ZX03*ASP"$4L0 QIP(!,7A(IN#" 2AJ0Y_M8T8"Y&((
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M@$HXD?X!':5@YRC@P"H)H@*W;X C.F?YJKM @36Y@0(;F "5V  95)P  QL
M 2JK"H*HSRS)@YB5S5M!B0UHX (G6 4H,H#*3\B2DQ 0<V[HCHK'LV40%:^
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M<0R"XU"'&TQ "/Q1DM6I&> KV#'K()PI#GV6(G0!"53I&.SII#CJ"0"JSI(
MH?(I<9[ "N1A,>WLTQK-";" C[CL$1$("8@!E69$)X!"&PR",T&E&ZS"K9KM
MKKK?HOXLQBJXK NL&0I,+4%LR0E@%:U,:T\H;<D2B B401=\92%D@"&@@ N
M HLN82&4+"HH $JYR;Y\@@)4R 6@#1-E* F 0850 @LL+7$N AF0A+":@+/-
MA#/92QL4POAPQ!9 @!9XAR(\*EO<*QH4IVE\@0C&*>\"B'BI%QB,P0*01 EL
M !J<@)DH0J.8@00H10LD@!AH00.(P!A4 %JX1I11 *"&QP.<@"$H[U].0-!I
M1TXP10AP1AD<@ F@0222A$H8 @,LX4M$$1--P I<0 @ Y9%<@".0%!F2VQAL
M 0,\@G U3YA0B0(DPBID0 FD00@@RB$0@ J00094$Y:MP/Y?P*#D;,$96("_
M@  $M D$G, 8- "5@(!0B8$)\TL'$$(+((HB' #*H,(6C(P+9(#.7$ )E($(
M()I.C"OG;H$%J"D$Z*]XD4!U*0 7%(Z_!!P:F,$$0%HA,4 7C(%0\8L#A  :
M/(*ODI8+T!M:E( #B !5_$9(_(8B$(*7G<$$3)H%I, @A !:F$$"A( +S%H<
M/( 8D $#=!L(@$ :%-XJ<(("<$ )@()C.2'.[<L@$ IZK1,**, 6C 'L9@3Q
M[59(6  %B  AO $#L(&Z.H)E@$"U'< JN$ "!*\"=%L7$)\7'$ XJ<0)_$P%
M5  9<($"? 4)Q ^*K )O@ 'S*OX%"T"OE3 K!:#%&%C &H!!!;3$2V@!,3<
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MQ%4<Q6@P1+V 09C0!@1P@AHD$T@X0F\P4=W01PG('&;'=2>DA B$TW2U!!=
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M(7B/;K[P#1YL[YP!)4E2"7"NE:/2%D &")0!T_@**A""!XB E]?O2]R-DXM
M!JC!X+*"2H#KOIP!!K#"@<%F;[/%$#?6XG14[V'Z1G\3Y[)")SP OW4!UOT*
MU<&[11@"M" X0?@**U#O2I2["*",C!JR!R!*K7#FY;!"-GK!6N"D"K# :0#5
M5]7>"&P H'F+YQA'9VP!9D@2!G  IH, AN@24X"""G@ "D# 7&R & SR9;1
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ML=1XCH5.TD" RPU(< 04!5A10:%63L"3#0=44.&!+5KY%_X%/">XKI4*KK.
M3S(40*72035  34\&13H##LS<$0ZTJ12X= '$OVH 3,>\<* 05AA@+PW'D@<
M@I8K0.,0!P;"_2)4%NB$D+=:B0-X+3!0I! &G -U(!>:/T2"-D8_T((,4/$
M!$JL*H00B!\)@3L4-'#D#05NZD@ %ZYNX#PGVQ\(E -40&,,,119!05.'*&
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MR/)80/X%5,'3"1YB 0J0@0L*<(0;)+";3T2.#0UPCE18,C;N=L$,#^#2"32
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M+0X-**!$113LBE!A"QS@(QSA %;J$QZ $-K (D) (D+ #ML"*5"! 23"$19
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M.G$HSJ@"<B((O'4##L(,0B %)$ %O" #(*!N6H%Z(#,DI?ZB#5YD($Q <D2
M,"0 4B$ TZ3BXP;"#;YS#2S  RQ@TU(A2T"@ V@B!+H@ BHL'@]A\SC <T*P
M%83K.=@ %9I32J7"#210"Q[@/+Z6@84#%2Q #4R#)-Z 5PJA %9J:E.A$!2
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MBJ05#(L,P$ +#H 5ND %/J$$3H 0R*!^T..LAR<-MB #H/[B#4Z@$,;@"\9
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MO U000R6T!$JH 3,X N^<R/.0[X6(?TN"01^@TJ*(K?CR0%LRP00<R/48H)
M0 3&( S.8&S8=@S 0 VVH 2<X[OP0"C>8&SR)/Q2H0-$H0) 010HH(L*QV4D
MP 30E/XU;(@3&@".#,$$-*\5UN [L6)L^0+ -PWI6H$,"&3"U(#"YWPN+DD"
MM. -/, Y)'Q !H(-?% X9(+?/P.Z%F/WZN8!+NO9V: #%.%'W JZS< -&"Y3
M6&"9+60"1*%%M.#FPKH#T8/=IR><1<';443(+T-J/735Q" I44$"!)77/Z%:
M.(+W" (#>?T+\"H-#D&)\Y,%+* +!@$#H*)(H-S<=9P0-Q BP,JX\KRR,<,,
M=N)B5N'XI,*IR6 )*V"9!F'S.J $]L<,:K+'NNTQ@LR@%T(1UI@5\( +N&"9
MMF %U. [C=C>QZ -.@'O5( -3$"/X>X>$Z$"DB($$H MKOX'BWZBZ4'"#= Z
M4UJ .RB LD/ #/!@ SDAG]LXUT^U$Y!B!3)%$?+J(L*@D"6 /"X@K@!"18A6
M&\:T4C1!5*L6)UHY;,4F JM6CB0L!.&PS8-6'L0X] "F50@NK5!)Z 1F8*LN
M S&$!,6 T"((K5(Z!(-1109.BB0TG-@JS@-4K4 U4,3I@*)6JQX0,D33H196
M8C"V^E+!H8N!CB 0#0&&50-"#C6 ^>3UH,45;1RZ; 7T#8-"G$IL)+'%81</
M#CMU@1LB@Z%.&S: >OAP$(569!H !=&0J HTK22 $E4!Z,0Q%DI.\(@X@Q:'
M+#@X9+7JPR-'B]GP!:J(P2?/G_Y,J'"XI40K%21:=4+<2@T&AQS(4-PH@7(K
M"'%:51@TJ#/$SBINMS+!@07<AXH:'/Z4X TK")Q(HRCI(<3?,M)1Y67H$/Y#
M5 S2N UI2,.&I:=;N3"A54,/=.+( FUPHD4"JQ"252N#9&6!?:V@$<=XCB"V
M2BL8@"90*QSHUHH6&[1B@7)IO+$*!(N4E,!2HC!0'@@D#6(12WJ)X%P+G;B!
M@!J(&6(1""%Q)(98ACAD02)?F-;*&QOAA*0;#EH4A$J.A%0>8FY8Q$J7'OZ%
M2@-L5*;((Q"D APGA4F)1U0AL@*"=1N$),$@P-V)9YYZ[LEGGW[^"6B@@@[:
M"I!$M?[""0&W#0)!"2%,<*$+"Q@'U):ML  B"[T1(H$)(5@PVPD8J"#!7VY,
MX! (?W7RP">H8.#!"0_XZ%"&7W10U ,K%NJ3"!64IX%'4!&U@FY [68!J7^)
ML@$(*$#0U@:@<1 2%PF$U !*5NW5RAD,E' " W@XXL!*?)FK507@ZI9A?,E6
MX$(KB30 &08CD#8!"A6<!\:Y/:E0K%.H3& !*".,E@8$*'#0 2N+#'701F@T
M@$()%5R(&!L6<+!%5B*,Q@HJ'FR P@.@:<% ANH"E^$;%K5RPKX>4/"(0X:H
MI(4('P/'*BJ##) !!19(\,9!$(  @@073D1&"X"IL,&8B/YU,8$*%IS'B04B
MF #!D144+<$:_:4AG08&.?( *UY,L +4?'T=!ZJMK($J"@T%1< A=[(PP0DC
M,-"&6)0XI,+=+1CP6RLD8(""!*.I &*QVQ4%0:P>8' H!R,^E&$+O2VD6P,7
M$H)!!EQ0( J-#KT10:&-BJ!T4[O^V*L%Y850P0FR%M)*(:]+L @K#O!W0@9M
M6P!@%PF0H<A&75C%!4:HX-["!F; E6$A&X'TD1?=0N!V21QXD ($]G';R@12
MQF$1*AMP4/(9]!VYG4; J=$ ">':]T"9#Z"Y"B_![&4+R5?N6I$&"0 ,!!7H
M1)T(!<$(2G""%*Q@GE Q.XHD#OX49DC#L0:!,8=@T#>#\TV60'&&-+3+06/@
M#RKXXXC9L$(1$UF%&LR0.,1\ F.*0)-#1-%!H,2P)(Z82">RA!A"C(%^#F$#
M&1(W1(K,IA6$N! -05&S5GPB2XE PQ9!,4,M9FF'K6A#XE9PMQ^-06^%LD G
MS-"6ARB1=UH,X2?0P#NZ:!$/K'C$%#E!!BF5Q(6[ J09#H,81=BI=Q9Y1 Y;
MX88QA% 4&(LB<$9HLS%X\"&=F")$I 8<%+@ %88H1"%*B4A4F$%^B'%$NUAA
M!CH"1Q%C6"13TG"&V;1A.+NY7KM$L2M''.:%#BF$%QU$$52@ F/$/&*&V-"@
M.PUB#/Y?/$B[CBA"_C@$#RWL2Y:P^1!6. (5:-BD6Z['LRQBDX:<D-HG&J#,
M76&2@RJ$RR)\"!QZ H4#:)BF)SF(AD/=\R%O2(,RR4+%(BYEBWVYD'*<([;Y
M7"B*PG0()\8@R(P\T2%D;,4BB(+),I(ABXHX5#;OI(A<<N(P)748GD"0%Z 4
M8@RR5 0:1K=,DUIPISSMJ4]_"M2@"E6H9)" IB"EIXD<8B-#%51/2J ""#RT
MJ7[ZA/>HBA@R' F6^.PI*O;'%*SNZ0T8P!R@/J$UOOUEIQ,)5E-%U0(.@.!8
M?**K6 %EB U,P)-W[:M?_^HGNW)N@H(%R@KOU*Y5'/9/@OX-+'#H>BP!KC!#
MD0WGY/;TB'+JU+) $<61%HM8Q#063XV%+)Y0P08SA/!.HPU4:UM[V=C"-K:/
M?2QH!Y58/[4!H7NZ[6OQ=%O@4"(-"G%L1LR@S<8&E[6)_(U@EVO8_F#H3H8P
M0]'Z!-G%EI:TTS5N;768!K[F23. +:]YSXO>]*IWO>QMKWO?"]_XRG>^]$WO
M*M+0'+$Z0IMW(@0:6#&(S6)5%/EUR" 25X@N=(&)AF"#&M; W^YFJ*N*#1E=
M#5&S8QVB$SYK!26.9(@2TM:"'49,(K((G-2]EQ"(!!2+Z[O3Y7HTPN,%U(D,
M;(;9Y@D4O.63(9#H4]3\:1#%;?[%(Y@X*$.L]J<ZAK&3 1N$!YQ!NJ*E\G?_
MU#F5W.D-"M""4986Y#T10@$F;<#UNO" %JR@ 5>UP-$X\( 1+'85&TB<%T#F
MH IH %81L$^&.+#6AX! M0RXRHA X)$F)W5/W3E4AD3@O15.)#:.#I2,%0V<
M+\3T LU1]"HP4#09>[=6$;2KJ$?LV@\LA3<L@^!$M/" Z[5A 5JX-.&N%Q<W
M\8D#N&;N4 W; +U-A%O'.O5V// 73+-5BQYH,:F?#.V?KJ(XB&EQ21$C"AH[
MQ!% _@1_'5;<(-Q&$8N-7BM$H;1L4C9/DN;N08"\""1.9%@/D8!]&+"K[LRF
M E/6HOX$G%8K,5" S(LX 0'PG I'/((39=A)6$% AE5HDRB'L$A52G*L13B;
MA'MRA(@I\O&#H"J* O0H4!8Q<F=W='*;!44&MZW33\RNLQ;59@I*,!&B"%&G
M%3VL3OV(&$XLV1&/3"8113O0*H?VW4%?\D,PUHE'$O/9UMZL*)QRJ14<!#$O
MW.PX\<3MTW0 -%S0LLN!0_2P>F +Q\)#9RH:5LL^VZ) QN K?VC1)2.EE4 ^
MB$Y!<:$))&([-MDVD &?3QHZ) 1?F.XG/I[MB71U<J+(DB.ZNH@B;QN1:"NB
M0Q8AWFB+GH)HA@!-0[""";#"$!N+D$,XXX$,\+<3L6?<1/Z"D(' 7,@0&6#@
M7T2DKXMM9Q 1<( )0 &\5K"' Q88Q"IDWPHS;.X$Z$S%?J(_?31P(O<9B)<H
M1!![$IC4=R:U=V56,$5E.L<@&7)# U9X!B] (-MBZ # @TZ!CX^@!"2PP ;*
M<P+:]R1\@0(&H0CZ<0$Q%0(JX $0H'5WP@ERM0%:APHEP %R560(P0(9\ #&
MH0+"8@$84 (>L 8.M (<:!RML 48<('ET0+5<QM T048L $9H#=I( )6$P%Q
MQ 4LR &#HP75@P*L #4@8!ALT  .R!&*Y $J< $10!:HP$ @ %6( 0*%( K9
ML0$/$!)?A0$:  *'00F:@P%:Q_X)]E=69I T=Q,'%N !%M 6&0(*&E S4-(*
M(O &BX !(G !WL,**_ ^=;8=<="$$R "8[ !$# DG,%\=M(%*@ ".#((+&@!
MM.(0X5(!";8!,2-\:+"'%C F@\ !*H !T!)WGV"$&7 "JR &#  !8@ 5#] ;
M9X !#"0EG^ !') !3B,&#5 J8?4@&R@!9O!\_/&!854"]N$!*\ !$# :W5(!
M&P"'K8 "6F !>7&"<C4;CM LNU@2), !&B "1)$(E%@&#B$&$Y !*3 !>I,A
M7H 1HA "NF@=9*".)\ !%](%N8<!1P("C9<AJR "+M !$U "MI(!(F !2($!
MQ04"AOZ0&R3P %[0 A8P 4NA"!G  1<0$HO0 1L8:QS1 #9(&"!@ ?<W>BD9
M02+3!:OP!@,@!BLE 4?""1(@"H4P 42A!ILS$<M8$A$""IN#1B)Q&YR (UT
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MP"1: "!:L%;PV08O<P*%P K<Z?X9E! ;%R(&!H"D5X$1) !P'G &G;  4%H
MG. ^"F$C'M!X#]$ )9 *)E$DAM$*7C 0=>DZJT "%T!* S!E(M 0%B VK% !
MBM )!2 VL$D1$; B+( 1K$ "1:>2GPHHB%9&BP$1L08&9I  ;3"#9@ &8&
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M>&V)!AN "A&@$%MP-Q5@"&Y@JJAJ'Q,!!B-0@2K0!FR *X4R!BL0E:^B 5O
M7VS 2QYP/9Q $RF@=1-1 83 !2#2!@[ JF:@ +T6IH/7-E(!(*CP!F(0 L/Q
M!M+Q( \1JXCT!J@"%K3I$"L@ 6Q1$@[0!6(P!AG %_\X.7@031J0!I1 $V=P
M+L1Q/5L)%Q'P"5OP.;Y!),1! F,@!BRP ),V!M?*;1+ K?X7,@@-0 :GR@"L
MBB-NN13O.! /H 62RP$B8 :?NY EL09@((Y2VGA <9'H:!JHL+P:,!!FX*SO
M*B07>AA?0 *<P !C  9D  %=\ FM0Q$6H:&SX22KJWF@"K]^(JIM(!T)PZIC
MP := #4I6P84:E&R6D,]$8 N<#>*H 49X!5: "(N ")4&X_SMP)&2A2\]BII
MP *%H (M0!) \0D98,&&D,%?60%=, @7H#>B  8B8"#;\:W'(@%LH CQ\A 5
MX#T5P'[!X0"'59-3]*Z(P:;P*J6XUK!2BJ\#R!',TSZML*^50; 3@&2X00%;
M, @98"=52@(+0!D9TA-$,<0DX/X%J-"6AQB@"J$(K1,"AWBJ15,">;%NW#,1
M%YD&&($FS><IXFM='?N,<1 !*L &HM0*0UFR;>"LV$<B4H,&6^L0%8 '4#D;
M9@(*;=L* -2P7J(&&A"@O]$"( +'PRBY!_)T&W &6_ &+9 "!E$"&? %;I=%
M9% "#! 2&4*_'^$1#WL"\4(4&! '7' W9R !92"Y;(!BJ>#$EV(X*( *O3<&
M:."L)+HZT92OB*0ZVUL35@%)C"L"K (&8B &:7 DD!9W># <&=(1)#(()$ 9
M^W2.$+ 4J!"5\($F:#+.K: !!1@&9] <%4G"_7AN*:P <5 (9J;-:L )\*$R
M[ABH./X"N=J,!HI !DR2/MQFD&=PIT/B$) R$6;0 9Q@D*PZ$*(P 8M@@R+Q
M%Q7Q&UQ@ H[  "F+OX[0%5PL$369)9S !1PP//%KTWVRO;%\'(?"!:! -B(4
M:,Z!3B" !C/M$%5( OSA%&#P.0J,&% "E:# .A;% $MQ A=@'R  ?8@A*BH$
M ABP(@AP(3"!"N+K$"EP+W*8 !)2"*_:"0,@2*D0DA60@HG  (&6(3M,.%HG
M"K@9 06V'2%@%5XP'/>*MDI<N6'1 '2D 7\AG15M"*O 5PI %JP@&VCPC%K
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M"2D<6F-&ZR<T*PV53/1 ZR.Q2"<C3TB)S'."1S-^^@O1C)G*??7OY]_?_W\
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M]MD7__<?CWQDA?_WX[?^_-VO>/.#/[_JWSWYVY]_O@M  1Q  BQ  SQ !$Q
M*$D\5"&^OG"M_>*/*H$5!:Q "^2[SC.Q8]()">' "_Q $#1 1]@"+MB"+I@*
M_A %4( 0-V(41V"!T\"505@!3O[@A!)8D[X @\ !C,]P$C=H 7,9! 58"58@
M!#9(A)#@!#48! <Y!.88+9X0@P? C1"L0BLT+5#P A> #U#H A>(02=100AI
M P$P  (@  #0 +$X+!=  "J,D#<  +B1$A< @/@!@**:P A8 - H@$%"+A4
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M5U2>R=@  W $%Y"1-L!#5" ! W :,PA+4"" $'B2N1H("^##$Q  %2 $"3@
M5#@#  @"1Q ! 6#(FB@! 4@#1:B H60# $"#3Q  BO(" 3"!5I" !UB%>>R"
MQ.( OLB ! BJ 9B-A B! FB8A&B#!!B?B.2)TS0$-5" #," -,  3D !%WB*
M-@B P*E+O&Q/]\R6X2&!"@B[ G"! V!(")B G5C$S#0 0D"0.!" $G@-"T"
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MJ$,)6 $4"(%$H(0# *- 3$6"@ !#  6O!(/G[ ([Y%6435E7Z00"( %6>
M* -'   >P0 %B#$.()+3; '!& 0("-@'^ "^\%$$<  48)W,J( #P ,V4( $
M$ $,& JE. 0)0 "EB0!4:($&0(@OZ@16Z$<%.($'6,_!L$H(. $&. 0W2(""
M004RX (AO,CP7 50 ($#< %V28 -$ $(0 4O8( <?00"@/X;$(  "6  !SB
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M-VD9C/!+"KX3\<H-O@F)3ZB;7/Y=X,F@!!+^KOZX,!D&%$*@I@*CP.," ]R
MEF5A04!)$*4 @TXXA*(ZKC/@#%!@80@Y!.]MBR]X*[BD+#%PA/$=C(@I*@7.
MDDU1B#%@B^7%#4,@@8FQ$P?,553@ LCBXAG.X2!^$C8@ =R 8:]PA"AV8?@J
M+L#PBD9J83<^+U&XWM%J@2SE A=" U#PRRU&KDZ H@1;X@C,B^P8!#*@%044
M@0Y(B#*(5%K"(!:A@(<8!/4Q$ AI@6=2"!*(80,9!(%-%2X8IPD.B08@P@$!
MA8$Z$@<HA#>@5/W8 AEM 49DE#+8I%I1 %9P U[N"PBHD(3@ (K@' F!%J60
M +Z1$OY#0)B$D  7F-X5 042$.10 1XR^(PXP)_)*H2+C&;)G:60( /[5><T
MF%#$T@(7$(&[78$U4 0&,)!#8 "K $2WZ@]%J">T( $+,($&&%$%;(,(4(H2
M ($4((@'2)&T0(/W98,SJ)N[0L%E684UV*:WDH"8>8I'\,6,;EZ_L^*1\0Z%
MZ 0R4(0O.*OVX  54.E"*(.?J4::F90S>(-K7@7,X 2Q4(2=)HA.$(4ST.#1
M0@,U@!!'D"'](.J::1DSX)Y/>.DQ"$VOH&2V, S)4 A#* /I) @T((O\^9&,
MR8@E1@6TI&0DS T(<(-_\>HK\6JMN)F/^)<!*AF%Z!E1P/X #9X35*AJ5, *
M4$ %;PX!E7[JTSB#<7H2<!4%NGV+,"*6#/K%)W0$"^!@-/" J!A$-D"#D@&9
M6JD)5% #B\Z+2NZ+DAB$,R@9+9(K,C@+MPU25#"$G<E%,ZB0Y#BE5?B$3S #
MB6B#"H$9D7H,HX:,XU:(1N*)3K"9KAB$,K!.PSAIM%@#W]0/C%Y#,\">R!V$
M#"@([IF3C>1%P0CN0K 9QC@#9MYN@E 9UT"LFGB$5!B$K8&,C"@)-_AJG9[?
M1I*(&]TJ+U%-A3B$"[BK&%S3,P#G-'"#1:  2SF9P0@!$E#I12 #M&R+#8@
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M5I@,1;#S$G@ N"D=B*8 2V9Q#S !KTJ%3^CT%IB 1UB#!]@KAIJ 1Z+4R>"
M,A"!HVR#@D$+P+7 ##@#0PB1">"$+PA-%.!E, C-UTB>A!@#1N26A#@!&>'2
MGF@ B?CUN'D:7JX -5B%):\5]*E%]FD%W:^F44Z(5&X%$EF/>\(2+:@)@6J%
M%/"K%@ 7%9"1-/ G7VD%JC5_!2B). "7# !S%1@#5'  P:@ IWF-\E>$C%(
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M'(5LU0)$PN\8@((0C>%S52^H$'QJ12BMF84%Q78AD >L.5( >2B(UL 7!6F
MD!:I*?Y2EA94>46"5RZ!ER$;916DB (I$=(5%P*UXE1OP?G7Q6N& !4"%ZVH
M0%DK6QCG" 04!6%A!O2-Q($'B648I)!#$EFDD4<BF:222S*YI LI=)&5"&.0
MX)P%(*"  @B:J>6&7P5Q\H H ^%A 2H0= 8*8*U(0$@K;_"V 7T;G+$*FJTL
M M,&'F090@6<0)!?*UY8"*0(#J&0%449@0?*%E,AAT$:!1WR'2'?D;#@)X]Z
M<%DAFF4&"IJL)!8' RN<L,(#"QH%"A<H=-I*I>%5(.HC!8W!'GB+L(!"!:P]
MD%)B+A1:T%\E9)G!0A X,@8$J*J@@")FN$20([UBH-TC$?Y\LHH$)"2Z04__
M?3308;!Y4= &:8@*)$$!7F=!(FKT- $AI+*Q4 D=J>"87V"@$$)9:)QE%"5=
MI<&!J*B(U8)#%<11D 5MJ&9&*V:,F\99$! BUB<0@')!7*A,<$@K)CS P1@7
M/P!M Y\E9D%?;[JG1D5!H"!N*WA40) H@'52DFF789!6*VW8U8H'9*P":"HA
M66#"8@6)"DH<R+V)M5&)J)#"!%FU(!IV%:AP @H-+-(*&UDV,*D**6L$GF0#
MV<E)GK45A,<%UW%P1IZM<&#&*JPD\A2SK*PBAF,-F'!""J2IY\ &8(@U!H4W
MP=O!RHI4P+ 6K$E ":XNN0KK9?X96(PWQB<&V08$8BDU 4&*B 3"!BF@0,*-
M1FW@'"O>I;)SOP_,E.I(76CY'1L8,*Q!&=>= 8$*>#=9O?778Y^]]D?&H8$'
M%)-A>TH6?'%((8Z(;M3<?BG"E:!O6) *L^5QUI8AK<1QV086,X0&*X&.10*L
MV  7S*<(3KAO)Q8ZD0C8L@+6$,1YU^D$!+1@B$38!0-%D=5W6B&S#'!"5!94
MQ-X,,0&Q$*)SP2I()QQ1B(]<T!&I*<@G). "0R@".;032ZCF-QM=B640#1"#
M(]"@G0>0IQ4M! -[Q)((-:7!$(9P1&< 4Q=%$$(1CD@%&?Q3B"$N(@WLH80$
MQ@0!-/X8XGR=Z0T$$I&<KH @;AQ@U^[ HY";5$ 1]!H-_\#@$A)09@6*JD *
M"L$)Y*2A)XDABU<VP H'W,HG#Z.8!RF&NE:@ 2P:8],@P"0F"[BI+8>@B"/,
M(($MM&$"BRB$%L?$&.M8IA47<$,G&- %10SB*8/ VE]DV !7LB%2DSH:UACU
M" "R @\M6$ 2RW.C06@FED91PP/,X @PL"9L- &!(ECIB%6XH )L  4)S& M
M,UA@@02YP#!1\8!/>(=ZT#2*!M) NU:,0$:QE$ GL9.@-DB1BL'C!!H@-P;_
M7*<+[/' 3&B7FL\I)B$@.%,+<(@<E?6F$*TX X:")!;7&?Z%=L%+CP=8T,U%
M/$(L8N% W)33"C!(  V=4,&+3M 14$Q@!>>[S HJX($.0" "#LSC]HIJU*,B
M%:EGFL"8'*$ _VP!0V"@3&*ZD &*0$9I-EE%!E[4@)2(2G0/< ,KWB"2##RO
M8JU80%^\H("7@D4,'<F 3CXF&B"!8 6H^&+:WE"<ZQ#BK:WH@@-:P06[L*($
M'.H"!1Q3B 04Q N%?2$*RT("UJP" VR!P*10P<V;) *R+VT 9B! $$/ ,04&
MH8! $@,&S82 *B70CFJZ\ D&W,]4J#B!"1ZR,@@<@A-H:\V/QC"N,720!#T1
M+GE.L, 6:&1P4@F!6$A@H1"P1OX1!QBG ZB')P:0IPT"<$0:D(.&MJ4A MJQ
MRG11\8@#I,8,D"TH>!Y!VO*.C0UB2,!,)N"E5E" 8A8  RK,D#0T7*8%'"#(
M"=@S 8VPP0"=0%I!OK !433 39_PP!H+0AJ"<" K$WC#(%Z#G>_@ 61^*=<&
M.H(*##QLF&W@32MDTHI'B(D#SFG% ^)"$%#\,@X== .-Q<("#*T&.ZS1SP.,
M4PCV6"!=G5  &PIQPHMI1BQ?,%,K@O 40T0 =F(I! '2D@@%?.*%K2@$ \BP
M/.2  0)K,$,#; *"O*" #;2CR!K*(@;FP<ZP[)E<*R*4FA:PI@$NEH 9.(&
MA)"V#/Y,#<Y9QF"!,<5A:C=I@P,2<XC78:8K9N@9)AT#NS!40"PJ>,V=_2*!
M%Y6@!*A0Q'1:008&H((5G^@$*#) X#0DH'V!22JQBVWL8QM%! M4S8L0=P(+
M;" #:3,**U"  7%U8A6=X, &,& "5KSX5J# 0&?>AL.SA&"8(?A,G#N0@@M+
M!=H9($\.-2 "$$3E)N=E"QDJP($*_+<W)LB ""P\DQ!@8$ @(,@B&."E5)P
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M1,#*@/X+3CB$ FS " A+05# (6P 9?B<7V0 "]"+0V0 !3SR&.Q-*Y2 2&+
M"B02<!C%!'RI6+C! ZS" ]0J:J3!!)S!:ZT107!!]V)?5FB!=J1>'#@72SA
M">#2!-33(E10Q+(%%\PO%]AO1N3O_@XO0:!""SQ "W#"AHP!&/18<"+P%ZR=
M%YS =R@" Y0!&]A+*S2 RJ# C0 P"[P!!S@$^ 4O :R,%F1 &K# !E"/&T!
M&("! @S",;T4<H0 \;A5)S% )WD "/3'69B! [!!Q(J"C=0D[LIT*WQ"/R'(
M:&BJI!Q-0: !;R":3[P(%RP9!:2$-CU *(U!'&Q(9^ B>/YL 5@(!MGN3&H
M2DI0P+21@$;\F5$@$7(9"P1HU*AYV :)A5"C@@+$Q4L')ZA%""_GA2.0%@B4
M 2J$@ >@0L*<2!NLD SA5T&TP%X9AZB0![, <GDL "@D2D&D 6(<:1R( 6N
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M@YW 47N0(9R!=D  "(B "'2 OXA%%SU'6A@"!?R%(I#*P9P,<(B !8Q["'"
MH!#$"NA>*T",6L1%%W3 "7 QO[\!05B CP5)BAG%(22W030 *(S!61BSG_4$
M19C5/JJ8E1F$!TC !'Q&!73 N+/Y:% ,0;2 #KH D,@XXD2K:JR!6$ '>$P
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M!1="@# 3HF$@8MA "=Z@@@&=(0/6Z4+1TL"!#4RQB*PR8RL>21 M.(556^#
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M#4P [5)@T\Q"^9@O!*QM-D[ ZQ3B#1;A"]K.!$3MSK:@*UB!_ES@[/8C?;0
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MH PFH!@+I@2V!@4P8 Q:@ #*!0(\H/AL)"%<X +,@ 4FX!.0!R_ 9Q7&0 %
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M<,3  0;" KI@#2"@=JIEF AE EK #/A%%)-T1T2 /=R  33$)E !GU)@:S!
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M#+S !3Z! 427!"S),?]E,=K  W[*+97OD.*)8[> %4;BE]ZC,@S!6$17!"P
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M!9I#!72C3L@#1CHA!3L!!+C(#1*@32P@5NMU"T0A"!+% @;$$!Q@)  6 U:
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MUX)!@$ 1GP"!-COQE; H)WV+8 /B6F$4@02A+T<9CC;1T,A5S(TDV@0!"TK
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MT'/KH?X"7"$L."P&.CP(:". #; *GRL0:E#$9Y  ;) &#: ":A#$#SL&8E
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M6!_ T-6\IHA1 JR0JA.!1301 1@V!KSJ>^1SSFP "@^['LV*1#)%"8NB$16
M/ES ILBL+270 +.RO-JB4B#@%VL 2 G=@$#G &,0!F"0!C/'*"W@ H/  F:@
M :*0"+0,!F) U">1 </X+:S "1<@ F502B.@2\E*9R?@ -I$ 6(AQ!7<"M[[
MSA20"$N#2EW0"0P@!F  !F?@"*74>Y.R1A.  FF  G9$ 7@@K"=!",>) 3DG
M 7RM B9A5VD@ ?0#!FS0$9RP!?X>$+!JE#7:XMA0G0:?L +TBPH/,%X >@81
M<,YKT!%39@$5D HHH$( S09,;)HK,%6!8ZD?( 9EH$BH$)YH[!LY 4@I<!4
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MJHL>9##?%W@8'@T1F12F :H?)& U2G2@R246**!-BV"]BM0:#,#:Q&("O?$
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M=EZP,F"!,OAAGX(8/BL0H5)S'MLT1A/@!A3EMX2A+AE! C8Y =JDMDAQ AC
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M&",1S &G>&LF$!,3 XL)6B02+*&AA0H**? 2@B!QT(-6)C*P4#'!Q2':$C>
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M( 2V-,,$2F*:-E3 8S)& 09 (88&3( ,@W"EID!0 @DXJ)4I@(^#7+"!%CP
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MZ;C$6 49F,IL?-Z +F2* R$X0?X%V 0"$%1 #)T(MPHLT E#3$#;H)  B5:
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M.%!LB?Y(:@8?"[PCNC5 A0LX%%2 S#*@P$;Q#.#T@I!CN(NKIT'8)4*PYA,
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M %,4P@)P4/F5@$J(P!N>!@J, *$$W%"0SX)4@%!(P%Y(!.4-!$>"0@/HQR=
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MM%8G<( &1"7 ^$;NF8%E<((&@$ )<(PAH  O68!^L (&N/Z4!'# !-P$*H3
M!7A "<1$$(050:3!!&! !D@ :(@!36S Y?#7Z2SJ@E3>;)4 !%0 !'R I7 I
MSX'7.0D)VU@ 5PT2!Z0 !O!'^5E2&E1 !TQ 0XA""&3 !GB >*# /WG6/[4!
M VC!)UB ?2Q"X.024P7)@HA !FB !U")ICJJ0J1!6*E!;E; !A#*!6P !I0
M*G2"!1P7*^X?O'& 7@K*!7!FM*9(%X!6*VA (3R"!8# "73!]&R!/KG :924
M!YP ZJR"J:X!!7#D"DC1(') 5PX%.QJ"NV+ "6P +U5 H&P!_WB (8( :'P"
M^K!!!; <%UA F#Z0(7S3(,1$(OYA@ <(T13%Z02 1_YD@*X>0GF1P 9, %+@
MP014:B$MA$T-Q /T5D&\BL5NIV@9@A2! 9C^W@DH@EV$ 91]GD$H:RM0K4"L
MP 5$9<QL@6AEP#^!@@,$DF.>ARYYP 2 !E6,P4^1 ?V  @BH:8L.Q > U@7E
M8ZAYCADD42NL@(.=P00X:F(-A*Z*0!=P@%MI00-HD8Y>+N9.$=T11)>L5W+<
M:"K<Z% 83B<@E70Q5+M(A+,EB8*L89>$KNK8AR+$3&W8!R6\U^>DCB*8;D&L
ME^$8X'ZL@IBU0E@DXD"(PN((R6PIUD& %U78'87E6WX9Q'%]PF85!.QN"BB(
M +RV0OXB# N($$;Q%B^Y&(*+GF"1""]0446YY)OW]MZF_ =#:0N>=(E$L *>
M;!_G%@7'&4+]EAI0J2Y0W2"(C&X XT1@V$>7B$*)[(O_]BZN/26I=<GP=DE%
M..- X$$74I:"B(<%;U,"'X1Y6C"[$ 5@>:^EQ,%)' *ZR.X#."%!' +"V,<J
ML.Y$;,KP&O 4"?! W&YC4*= G(#I1@1./+!D)@?YTJ1D;BZY&"\V:<OY$@MA
MX"^8B&[F7C$69[$6AX059P11C$&OML;T;C$9@T07=[$QH0()9$#7D".I+<P@
MS%+KR;%!=($ZOG$6 TD9[S$?ZVAR'!,:'T0@]['"E,M##/XR\Q*R(J\&KH&.
M^EJ21!@.8^07(F.$)'LQO.+&0WQ+6RSR15QR:*@O*'LR*9>R*9\R*J>R*B?R
M*F]>);<R+"_R)Z@ &CC" '8$6QS)?AS7)8^R0XR!3PS(4(C!&I9:FY@!4["%
M).>P)9'+<=TH6Z@*-DVSEA""Y;[R94S$ *YGF[!"&:@ !9_4$A>%%_^PYO:/
M?+!1N%%S,W^R()NS0X!"121$.(_S:H#!KY4$+W4!"SRC%JS 9&T," B@%:,Q
M--OS0(Q!HI(S4'W"%U?5.SLS/#?&,C-T.U^TEE"Q16,T45CS1E.G1<@S0A\$
M1;BS-MM):QUT+*]T09R !LB?9?Z(<SF#01VI&CM_! KX!QCOAP+0[N:20?EA
MP!KU!<IHA$"H+2[?4DSX<D@D @.X+U&L0&<-@OHPM8^U+5\$ 2^=HR:>8 A$
ML<*P0@,8IUBHHCP:@.,I!(X]Z!A8P 6X;VL0Q0GPV$/P';?,]4U#!"UMG3%9
M]7U0 #8?Q!;8DE]GLPITED:DS48H FFD 9*R-&0[!">H;>R@0BJD,ZV<H!G@
M[M-22^VBP@IP@ 0+#%*!0AK0]8($RB?,"H-0W"\M@BA4@".T@1N+0@MH +MX
M !I(R+B<RD(T"#)KB!F ;PV[0 8H E%PPAGTXB&<0<R  )&<P:RL@HT("8D,
M!/1^SOX:W,CQJLJMP.]J<ZZ2J($VW4OQL@$:B,<G3 <EI +:*DFS:%.[+@3^
MKH(A)-AZX$\:P'!!M,$9A$LKQ &\$$0AU <&1%ZC<,E!=(*5'.^\B(A[+,2C
MK F2>.-I$TLK',(CN.L6I$BTI,(BF '"Y$AL<.9\/$IX7TJ$:\I I *]0MEA
M$DM(+=__N9:6!LQRAP<K#()7D(AO>PF=G$HW!3G%'0)X.8+ Q<%P?TX;&0+%
M%6^QY,JM2'-2L4!M)?<9+&EML$=!',*$Z(JR=(<\%TNUK <Y<@(:' @;0  A
MN&^(YPI%*'>U@()S[[1!,$E5L0%W=\(J),)_(X2@/@)1^/[Y%!?)4T(/,8O"
M@UM*<!S(O<3.N"R"(AR"(\S+D.QI9*>R%Q 2&:BP4G77C"4E"EP 8D^3TCR
M0JS F$I !%S3&=P,!HR5(_ -E:Y7V';AS8((!G$ &BB"_J@ *!1-"=@-=2K9
M$L'9!J0 !RSFR(R @*I!_&2 /K% !J# W+[QMAR[IJ: M),J(_V3MJ* 2BD)
MF)9 W@15"E% '5'43=*$"%C <!R2"&3-"N1ABJP"!;@$2HU1"%  _;S2)UQ
M":P R*H!(7G!*#T ";""&[0.!ZB8J$D/*.09"E3 "#@- X '6&F2(5)O!I
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MC<"\&&J%N# 0L;95&#!D.T5 D4 TWP94)# Q)-"N!84NP"^#N##"(ZI6',D
M%0^T>,B%I$ XR$+5$&ME$"V5 O[EDPG&J,"A5C!XHY4M%"IH.1<X83,P1P(;
M [BZ)A#%D,!.ZFG+33GMU--/00U5U%%)+=54T4!0K8T*ZKK+@S7B8*"%$U9H
MH(R'M!O#@0VT$*6@J[I(*HT&6D!A!0;,0$6#"4)P R/M5MB"D!5.4$0%MS30
M"HRD1)' )50D6 375LS:3D0/T%AD*#<:8('6!LX 0P(64%!! 2M;R=6C-V1%
M@04&SNCBJMX>\J!"^EJ)0-Q5(N!DBZN,^N ,,Q1RX!'M%"EJ@D188<6,N-A@
MM;9\ V15.Q*Z *RW051(X0$\67CHC)#V)!G'3C!]CC!*)A@0#).T<( #+[33
M3K1"5/Y0X67F9F-.D9+4:^6"QU;1KH0X0X  A#-$>\2""D@@A%SB#CVH BM9
M8>,N"\1>A8T,(-5N%35"JB".J#FXE9+ 5)"O[U4@ *4W%^(D6(*]6 '%@57R
MG$\,5AH2;94)K-R@A3?NPIB! 5M19/-Q#V' (>W,H,JH%E8PA-65>NJMB^0^
MV4*%#:AR(Z16XF!5 ZX/7;WS%E1HKA6AC,J #<Q/\JU:DP?Q7;MM6_DO>2[B
MZNV3!P8T6H6:C.+@#'4?*H0B+JYJI8N#&C@A:0Q*$(KDAQ:18%",4/%"!0\H
M:,4+-+^(RX$&QY H[;C@($9#Q0,<T1LO5:4^5:%+"4C$!?X)%.M8=VL# "9T
M'C:8+U&S.LD75  "BBR0#$EIQ2(4,)LO0&!6QS+4J6 80QG.D(8UW%*J6G42
MMEW ;4 9A"$<,3_KI4&$K4"1_A3"!@DD@A! _(1V"O$%9+TD#B'00AO,H 4/
MO&@D"#%)M\0EB@@TJ#=B2!0'""*2-*A+.V^ 0% ,L0A0_.80@U"$(XQR(^*\
MX0&':*(B1*&% K8B$:WP 'X\4!\('$(]/=D?WM)@!I/\[R&&T!(%G.6;ZED
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M1 (> H8&=T$FP1()B411@>H%J+[K?4T)^&L"0^;5 VF1<"(:X!)')(4,(;E
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M*"$56O[@ TZ@/%I!U]K( T; *Y-OB:YG= !M$"= <%B!ER"B4>!)WT9  [J
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M5L$%,D #OB! ]E(+6.!N2J!1"J$#,@ $OB7,KD_]AI1+':$]%&' NB  P:#
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%! 4$ #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>comp_0026.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0026.gif
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M^>KP]?3T]/CW]_/W^OCW^/7Y^_____CX]P
M
M
M
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M2(>"R(F6&(J?6(EXB(FHZ(:=]HJP&(NR.(NT6(NV>(NXF(NZN(N\V(N^^(O
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M " 0";Q@!S&JHY\P#';P"9N0!P)A!V$ IPR1!P#P!L4P 0- ";1@ 0@ #'R
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M)7  KRD# $ )E/  %* ";P "FP ")K )^PD #ZJQHCNZ-44+". "'D "DF
M78  5<H 'B"W)U ,+V  DFH'"! !&F !) "G%/  NQL!"$ )%F !A6$' # '
MR NGO="QM5  ,V"Z%%"\#" !3_Y:#'!  A=PK,$0 Y%*NP> "R)*F9H0 )]Z
MJ!1@$12PMKW0 &]+KK@PM[<)O7@+ 'M; "8@$"]0J,4[ .$JER:  .5)"10
M #4@ERHP #%*NWM*G<;9 780 3G  NG+!P' !.])NAJ\P9M$"P=  UX@P1#
M!P40!J!P !5 O>0Z ]\;IP4@K'-I 1% "9NPI+K  1 @EUR;!\AK!G([M <P
M [AP "2P"9H@"87K!>"JF0A@#"P<HS6;H@&PF\A;I7+9 0[0G7; !;A0O,4
M# F0OQU KJ8KK)MP $":!P%0!KA@ #!L P( !S7,!Y0IE]Z;K)2@ !(P"0C!
MJCY<#/X5X  D*A!CH *?, "M:0##"@#3R<&._,CS$[\SH FOR@*?$ !?<+0G
M8,1(7 PQ$+[JB;RS*Q#=60;M*0<:0*U<ZP)IP  10 QO,  2T 4DD+RX@)[%
MP (#4 9I\ !67 PT8+%RP  ($ P^FZPJ$ "XP)X78 ,2T)[S60QO   G, 8!
M( '#  (!X (@   D<*CRV;0,\ 4<RP O4,!A@ L!0*VS>@ ?( <L( %U+,T
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MN("U/BR^#P !/#VK)4 !A6L9@WF77%N:UPN;L1G8I_D6@>G9E7D9FZV>80
M"_P6I2V8<HF\$TO8L!W;<R+:EFF:J&D''/#:E?&7R\<:M.T6:6";GAD:>2 '
MLGW<R,T:R/?;G,3<G9G<T96=T/X]W:SGW)=AW=2=W=J]&390FK=9 N7Y!O\;
MT9^-FJ&-$)^PP#/@LN1MF9?)FM'+$)L@J7EI$7(0L,90WL#  K@ "HF*FI]
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M$)JU2)ZBH6 7OL#E 8R HT0.8(NQ1('$/DLY2(>0JNR+IHKQ<Q@N\BHFAAR
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M!AXY<$43;V,-+FR@ A9$P"2L::(M!0("=H&'.A/XSG2&,3F!V$%*)1B1ASK
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M#@8&P/Z3#DH_.I $#X"T(9\#]*&%6S"<=Z&!O##C*C'*S($EQ* -"4@]^(J
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MF*Z!5]%9F!IP,#:W 1:R*/!H,X$H 7:Q@[<AJ,H0WV)X@Z6/L>II<\-NBDB
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M0L+>#/Y"#@F]$3&JK5U]5C$& [H]]]U[_SWX=-92 1=\G-"Q9, \\!(<YHY
M@1QW.,"P!2R54$(D70P85P<6&%-,)!Z0ACQ8P&)?H, =Y/" WSCD23*(A!@L
M,(P8L(H+ J $)1ZPL4<% &AGLH,"LP,4PWG& <(BPP1 Z( \V"$"DK"#!BQ
MBPR:(0_D*P8#7A(,!FQB$PXHP\MBP*,*Y.$-#+B:0V8  DFDX0$N"(8#P!7%
MN] A I&@@P<H@(LO.,4!33J< Y@0#!*HAP%J>8.Q/. U"\2 #S,P4E8<P!5+
M,"!'%LN#!&Y$ 98X0#1_,<1=@O&!%T1B!A?8"P7&-I.QQ/X@#W"( %HHX8 P
M3 P]LR-+4<+ !Q'@2!(,@,,<'I"3/## #'MQ2 OE8(<)+&>5<PK&^KKB "],
MS&9J<P <X/" L9$)5PYI'W4.U9I#E802#"A#N.;P$ HH4P0JR ,7)'"ANW0
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M)) &":@ @_ !'(R!!]R!)9C "@ /E9W ;?E:))1 ,%0'JG !S,&&"2!DE(B
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M^\5>S$$#P $4Z9 )R0P-&,(+Q,I !EQ)O5#_T(()X!(>)849I% 5*=,P?$#
M4H0&%.T,E/-=8(P8D4#F@'!KW/XK&4#PGZK- 7@!'YB 4XP!S+@FSBA4#"
M):1!\D+ ;1&P,[>B P25OU)K!-"!'<Q/,<Q [YJ!"5TN%YQ,I?#!I!X%;K2'
M(6@4'&L 1TI ">3Q;_P/&AV%+:F $,&\F!O UM"K'<S   !E#._&V+A\K%J.
M)B# [Q6P!2B^4P6*%\*!%P&#AIJ$W(Q%%T2""/"$.+6$' 2# DQ6#JR(%;4/
M2UK !W"HQ'R%^C@M+F"3(0@\1$S1!I$ ,2$*K G_XFH.LMY30=G U=" X=8
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M0Y)BX+CL$RX,M$.%$^AX\ 079)M(A1FB&V@,&HJI(X]B=.&BA!D6"^8+%LP
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M!-HNQ-)"!!JE9::"!H"$!IK-!DC@-5Q  QSLE?3X!"C ; Q!!%R@9MQ)!3Q
MR= B&%;@FB\ +5#RPTJ@9V OSDA@EM@S4'^. MX%%U3@4BW@%O:3F$3IQ_*E
M T" :S>!%F*3:R\(&(()%R2! DQ  _I0%QR@4>@ !.OY1G)@ BCA!4;6U#[
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M3JRZ8,&!",[@<4KOOK!?E4L.V $(*H@  FMMGO !4B6\L)0AEA);S!T37/K
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M\ D$Z,0.$Q#)ZBJ6AF)$ %02*$8.GH6+_NG% FT9PU5VDQ<19*H8+  >BB"
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M $:^X,8OJ/<-=[ #)6*C"0?8I7,3H A*A0OP8I0@#<B]<@F !PPYS%HM"W7
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M-<02-9SD\0_Z AWP!K'R"6-P:Y]0!AUP?G\'#"S@!?*S4$R4;!-(@148/G:
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ML!^,IDQCLAO*- ? HP&7)0(840SLY'N/LBO=1&B=\U$'<%"?H$5UA@L0T!;
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M&T8W R)P+9HCWP[A B]WAGDP!EPP#&1@TR50=C<==10@99!</RHP:'LA!V,
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M0#">4D7O>60&3"C&'.[3 <JPP 488T%=_K/"#FB"@[VH"HS"P+*SS$!PPW!
M+<PP'1O<C"B\^H@*$?/"@VSB ?Y@&@W[%" \GR#-:1. D45PP0!4ED2(*FCE
M1TZ@%@[0X2 >J .%C)-)_* E=B;IH$DD  P03.HX21%!<FXQ ?/,L'>C#-Q!
M;! [!<#( L&01)$00P*(V#  GR@#RR2@B4,=I 1D2XX$&%*!@7#!,T@\R!LF
MA+J#D(!U9_%74%X '*'<<(F1E(PF$/"_8J!MFM:!TB.-Y0!@&$J*!U$B"MT"
MATU ]"<*T 4<#/(9]WV$:. +DG%XA4>3^"0.WIQ+,%P0/Q60X19=<H$RBX$G
M2E"+3'"8$ L-^%.@!E6H I1 %(&!@([PY %PZ!29^%F,2#Q@#GF@ $Z\4*DY
M/( /P_Y@P 8!4XP)N( 6?(! <"QT ?180 9W. %T).& -_!! \"I <[>H #/
M="VA(I'$ ]X0"0W8]*&6*,88/FJ!.N !B:NADP<2E0:(E@$C=H@ 53B)MDCD
M00*3P(4"N@ ,,TP6 BMQ@!PBP0(%6$(2#)!#'CKP@+/0 @)<0PP%LC8'!N3,
M <)[PV0E(!YU04L#GJ%=/9%"V:LD( R4T JP6"")WC+4(R/+0S Z$(-(T,!3
M:PD 45C0@))X8 :2" ,"R& GD^TP87* P&$XF9LQ1&($DHF$ N8@AP>LH'.$
M$<I91&"!:W8F$NIY0QY(4%9*,  .^ W1 \J0W0-00@[WB?Z1 I+"*[^1(;L)
M( PP+/!1LZ#*,Q0PSG^24X(/4.*&7HC$"0[C(XHR8!7%8!PN"DF),C  ."9(
M<2\44!^I]H1,,7#/#/3K,$G8X !YT&QE5A&!\(S! < 1&A=.>Q@6E( 29G
MBRZ0.BO^1ZS+*888*L7>I&A FAU8X4=N.&,71* &,ZC!"S)B@($\E073"8,"
MN  '%S  0G#XTD?,<( Q\($$D'%=,<@PV0@D!P0JB(07 M SNZE !9YS#0TB
M$0,-8$HH=% P,.;ZZ? %U %QX(,+3AD,#<P@$@PKQ@C(1*$OU((!,'F AD$
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MC!EX@+<0BCS8UE@-AA@M$TVPF&U%V1=(@PI(4"7U@)[YU/S\4B[@/9X 5@_
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M ;L/I.1 ?L644,)UV5&R(A>'C85<C"K@J\% ?#2P+ 4:G>!!%QV<,%94731
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MHSSVQ6@37KA@, P1DL_A#F Y^!5W"'(+NY4O/VM36]H(,@D80; 8FB#*)\8
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M/>1#5_XSTGJ>E*0.K>C=QA"&JW'TI!@MZ4K1.5.4\BBE[NPG35,J4I[*-*,
M_2E/N6G4HR(UJ4K-ID^7ZM2GGJ:IJY0J5*-:SZIB-:M:7>H<?E*+.V3NE"<%
M!E6-B@O&T2*LI;'#'D.JFF"<SC41$4TO0#H,D)(&&'C JVD^$;U@=$*5H" F
M^BAA6.5=DC5_,REI>A%7K%'",W(5#5]5$\=B@$*M,0'&8T7C5]/00B$G_>S6
M2+L:7!!V(9IET6@JBS5<U# U<%U-'NB05YB:UFNSW2ION4D+5F5(!&SD6E2^
MX +1\*$#D9&#F6Z7@\ZRIJROB8H7[.,!<0WU$Q#1&B4FL/Y+,4BV-* 809-J
M )4+?< $,/H$D,Y#E? NQ /T<^MH1! !_%'BOEV3Q$&&88' G#,8R;%  SI@
M@?X:-$9>"$U&3S,')TIW+QP()VORH $#%PH7+)C4219D51H,1 /3A"B_+$#-
M3;P@*AW8RD(+<ER#<H2^I_G$"T(" G%9]F@6N,C(+* !%F1.$ATPL/PV 34+
MM!5KU+7/4(L1AC9HK@(I2JEV8WL2  3K9XVQ:-;&0)[NKK:W8BXF#8XKB;20
MAJ_K&T9J 98 ^P20 A( 1C :)8<1%,,.+.!R $\K&F"X5C)X!31IJLNB7?(U
M*BHP"S512]<_#\-;Y?S-C2 W&OX*Y" 8M+B 9EC@@8B\H 0Y^8*#4 L"6E"3
M%A) -&I6H(!?4D("Q PT09@X3SN )7K "+,DDB+H<09CG%_ <VO'.>ABW,&)
MJGVH7:E")].L3WH*H ,PWL  8'0A!O[%"0DHL=$TQZ0&?L&%R,*:;/W$)-8$
M^<"O2&.#<8LF&-$&0;MI+9H]104$&L$K7U4&C$TXH"-AH  H<$$"GN#" 6:0
M* ,^H9(Q]"(/#(#I7O@]FF@/(\R$-M:-@@%2OD:/!3R6S-0DD#82B&&S88Z)
MQP.9D_Z&E=QCGCDOD8P+#T! !-7V@@MX8@</>$ $,GP!%RH0 SN(@ +M1A[2
M8!6C2?ZUB184^01[7C0:28R !![@DAE^20O[Y,$#9A)M#D8 @AFP^05O\$F,
MPC[VO1A)!#)(^QLHH(DRP,H&MJ4%"814*$W,8 P4" 8<+B!H%FA=,9J CX&_
MY(4+D" ''!@+'") @8M$0D@?N$M4<!%+@KS +UTX':Y_%A@/]-##! '&"1X
M DW@HF,=P&X,WG"!$2O(2QZ9<Z4ZX($2Q/$$P#N!+CY! JUKQ XVL($(-M&!
M"*A %S+ 25Y 4&/12.(!F=.P!Y#9'A>,P< %+6YH$+UA#_P*#R H 0AP$@P9
M6. $,]#+9X#^2QK,:0ZT ,&1DJR"*MG!OLC!C;A2"5A #/X0DQR(FEI8 OXA
M3"30P2^1AAU\@ @(G4CXQ0S\A.UY0 ZX0/IH !=P@ 50 BY\@(O@ @C80=D@
MCPK@#Q>H0 U4R.E\@=C-0$A\0$<87_=MQ0S8EO'!R!S\TJ,L"2VH@ RP  7(
M0(H8GY!\"8MHP/'$3)=\2<+A@B30GV"PU:Z\P'%1GIF0@$)DWI&8!!S8@ QZ
M0'[, :6H'9)]A@B,0(K%@>6MT0<Z1/>= (S(P0S4P 6 @$+,A'/800G4 (.1
M@&(,@PT W4'$@7EISD"4B0BXP+FL71[DP0-00!?0PI[A L5X@.K17"AVS2T\
MP%'(@040!1<<P!M8S@-$0C"8 ?X% -$ V$&&>  MT,$#$%.=Y0%SQ8@+U$"R
MY(Z(Y< *>8%$;8:^Y9FR60+T%(,7J("J$44:Z(4=T)\&% H#D( A] +R#$6E
MZ,4=!$@':$0#D$ >!,,76)=F:$!';$(%W,(F#  -X$3V<=%G^ 4P2, M?,(
M&,\7,,4;A ??H5GLR4!H10!=( I>O0$+?$#T\,$,6,!=< $+Y $':(*HE8YD
M2(($4$(P>( -_%M"@HD'G%%,F*0<-(0E1 "_8 4P< &(4("@O &(J(!F4 )3
MS,$ C($FP.(%,(Z[% A!F("@<*3V$80(S !G20"U#8 -7"$#X 3YB48)F$6&
M'(4&F/Y$&82&#73 WUB 7GS!E9B 9E@ D@%#"<12'I# +ED >9B!$WU!:%A
M!X"">U#*6. /'5S;&X" )*!B"2P'=%%A4_@%B!5#!=C!)S1 "7K! 6@. M2B
M(E(%!73",'C 8C[ V' !DS4% T2"+LP >Z2!!X2$R/W%#UG &  #)3C )XSE
M8QQ H8" 9B"2'0S%,)" <-&" _R$!NR()BP30[&( \B!30P7!?P$_D0" M""
M#1Q7L)E!@+2'!2@$= I(1[P!3XQ! 9Q1TCSC83B " A.<A&$![Q![,4 XCA
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M:$:D OZL>6E"<SQ3#J"CAGIMUN#"S'Q%2(@;0;B #;#97]#!AR*,9JC: 2$
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MG&Y$8_2FE57*!XC&I6+)"02&A87?\?Q6#41(\W I MS"7LB%%_P8>EA &-B
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MF&"[9 %&)!B<*+K  :04!44%(;Z:8FS":!C_LP1H0B(S).6Y^CGF[LBZ C$
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MF.I@6W!".,-#%T3@(&3N"TA@)>0J7DO@ 3;! *%H66R@ I!& 3R&+LR@-KE
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MCS<N/)3*H9P&#HH0%^1 =+DB$GXB@@=BD6_112+A"TC"@S=!Q-!X*8H1$W*
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MI PLP/Z%"VQ@!SC 2 +F&8;8@-&!)DUD+Q3@#9^.9H83Z-(&=) #5&)@@UY
M()$TL$$P') #(++L/V]PYB[E8 >H6,"8PP1![<P4@0=DI6)?@!$<]E(Q&V0E
M3G&YG$9HH($QYL!2O8E4;T!@!TGX$(@-@(,F)/(A#T5R&#5XYY+HH((T',02
M<.D"@PY2BS!T+BL[_!L:2? Q$OA'9EPXC8;&H$7[_8J2E&)HKA14)C*T]*5
M^8D$0& #)?7&#(8<0\5*8 9S]<8%;S#J,*Z8'ZC0,2,G(,.\-'*038PQ AZB
MP&-68AX-P(\K=JC7# CFTOZ9]:QH32O^V&:"VGU1!(^Y0_Z]1I7 K'3@#GRH
MFULHP;R#W$$%7+"#&;Y @DWHX@%SL(,=*+&XC'R! F30A KH@,*,T"(87^@
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M8+;,DCLC=X#+'3('F;C-[3IXEMXD#[6W#G@&C<5810PT1+B8? (!B7M JEY
M"[\5PP08X9DN+%<K362.#PX@+PC@PH7D<>%=)V#063(R ZB 8((B..DJ* $[
MTM!B\@Y1 "W6[R05&*9^.FW],#JP<CK%GP4?TX!_5.V!Q6V<!1A! B= "7"
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M%\4IFR_Z71D1#'F HRX1";7R"?["U)?JN:&+*0D7HY92.J546B5EE597*J7
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M$T"2*E Q;X"#VC$,P2".(- 0(;FT^8-5NE@ /;)-Z^2J8_X$K"[PISZK$1P
MNO@3# W0L5OBB(DJ:OA2)>H6$[M*"2*0J'Y47,EJ5LY'JTV[N_EC"<.9$1]
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M"QPD</X""P"G9BR8@0LZ$(Q(4* $*N! #9[W$A/8R (F/!GC>J* -UCB(9&
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MK1B&+_[()P"SM&$P V*R@P?(JTA@@&.;OVD\N6$@%!?0@*NH$Q(H*6,@HQ?
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MB  6P#G>*(82\!D! 1!JM%#$0_Z1@:@!$^$ E=D;.]"$! B4-& (6>D<X9"
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MQA6!PWU<=:$KG@#->_$ 2P@+HX12I[B4,BB-0+$ ?F$;,L"/\M"GF5$!*Z&
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MK9'Z+=']^ U*:("+8 C[T:F4B/Z !XP 73!NCIB# S"&', /[Q"QR"R&7E"
M8-B)L?B Z!"]RZI'\;X*6@C8QJ,%X !9Q_B)GHF/,FA38,D-+S"6X]%9A^4/
M!:B%J]$E$)"DG" !S2-9C"3IC8@ /\L4!Y H8[4$(F[J*D>W/-HC"="$D#*!
M#R"![3FK/)%6][ LS^6(MAJ:NBH!$/  VRA,Q:* 5+&) HF!&OB.S2 QB.@
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MIPLP$G?2@& 8XYPH W1M%$^9)NZ])ZO\BE<Z%HO8%1(H]&"@:8:(]%C^#*@
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M48Q/;&(B8W"!00RH'PWZ#W8':M_[N)(^A\2@!JFCH0U[\X473(1QM-"$1\S
M@@+:[OXKP)C!"Z+X A5@9!,S\  (O,"\/+  !">80TKJYY+C(*4&+W#@SH!!
M 1>8I"HV<(!!:/&&,4S")'D8@QVN8H8Q%)&% W&!!)A'O.EY0 1C& H>/H"Q
M]-1F&"[(@4/F8((TX ($8.1@W$CB/H?4@ NV4\X,(%FY#GY%#@%@  4F4  &
M+#(EGS@ #8H1@0BDQ 8 D 0M#B"#G6A@ CW!Q0'8*)A:)( %Q<@# -)0C#8
MX"E%R8, S/>58"3@!#6A@ :*T84!9,\F7 " 0FC" %J.  *4,<T#0$ 39/I0
M)V, 0 E9< "#@&  [T,-+080RYA8P (.L4 V>X<3#A3@G/ZXL<$ 5E&,$P!
M$SO!!0-6R0 &#( E#CB ""X @ Y,A P".( &' " ?0XE$@#H7F,\(($BTH0,
M ,@>4CXQ $A*@J(%&( 7"&(" 20@ " PB LHX($/_%. FPC %S8H.DL@0 $C
ML   K$F&  BP)L"0@ >*(0D 2  .FQB )WL'"@'X,!@/H$!.@,$ "1@E#P,
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MP0 \  P-3)3F V$! (X( &.>X !Y".8G&.  !'PAX!Q00  .?A 6*( $!=#
M1%Q0  D40 0><<$ .FZ"8LBAF<5@00%4.8-B=$ !-_]$ =3YB0"P<2)<&&PQ
M9@  OVP4ZA!H13%>$'8![-H+>T?FL-^I%1MXG./^;+OW!M"! P" YI]X0 $>
M$ $!Z&\H99\E I+[A@)<M-%Y'X # B""80#C PC@^E-H,',$4  8GW" !3H
M@/D-900*P'TQZ'" !R@=(T,Q!$A3[P",U6  %"B -8<!@@!8X "[+L,MQS#\
M!FB"ZA<H0 !V"0P1D#X :[=# /[.:O1B)(#CM.3" "9@ !.P]" B4(#N\7H
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M2;Z3)FR5^7B8.<8=>QE -GD  VA3 -# )XA  -""+6U6"12 NYD!^&A" -@
M,!R +4I"! #62 5#&22:7&6//-V>!M0/' PE/.&;N^'" WP 0S" !A@#+? E
M4D3"U7V"7+5!*"85(MH!,,2 _K@ K@F:5IQ  I1%"0R A4E  Q3#.[U!,-"
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M",#:<9$'1, !? )D%L,*) !*D( "& 0)-$ %QFRJAH$(5/X?>CZ &WY! 7"
M!FC  +!12IQ MDK" 0!4![3?Q!)5,7R3)KB S78 +<&=I4J""W2  "I$F(+H
M&DI -I$=/.5J,=!D57U"#N3K (Q!H(;CW'E!/H5C,92 S9;MM Z$!CQ Y#F4
MUI6%"QR +L0  G1 /YT4XZE0QIP5)6B")=P7F'$!!5#G=B;5)^2KV4T$K0Z;
MX&&,JIX I<IMQM("U09#A7(%#9 J!3@3""A +0R$O(5M,6R"!C0<, R#!K*A
M.#Z 1[0;+5A 'KB9!(2C(T(/7M5 QW$9 %0"(BH$I3)!,3! 5@T# Y3 ,#S
MD6XG'" $ 1Z5*"U$')1 !ZB<N?YJ!:,6ZMJ!J3_-71C8  * A"Z$0;Z^9#'D
MY4#DP #D@05<P$#DZB:<E M$)<IY0+,&@#3=P5O%V'E^ EDIG)<-P"[UE05
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MQ@VR,87BVH%L D@ [EU%!QC # 3#= 88.L[ $)O +5A?)]A2)+CD S@3, /
M U#01JU0 (P=,ODNLCZ%H&5OL%;=)GP3'^33!<Q!"8!3/EG &T#52@! &3CD
M".3!#)#%_SG %TQ$%QR  OS;:OZ"D7$B4TZ5780=0 6\@>X1)@!80BA:P Q
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M*'  ) &##$3 %TQ"!8#1'?CN;=B!'T= %U1%'G3 / )W'O#<JQ^3!8!1'ES
M6MTS&5" "/ /W'4 5ZBJ,7T!T5-"!61O'E2 5K0],Y:0&<1\3S^ !G0!@\&]
M LR "HR="Q#5XF?/&! ],-1X8-7D;;Q!PN> "/@0+9P  ';!4$A"VU% ">D5
M?KZ](5R  V1Q,'0F\7& N^F5!?QR+;   -+ ?EG _% "<Q?#)*@]!'P!,>""
M"C@ "'"!!H""'52 0E#"!R1:#OYT0.O.  AX!!Q0 /YECQR(H0TD_3"(  Q;
M E1"@.KW+EO;0 < !B[\+P.P@$1$0 =88 =D3U4R $"X<%%BV# O$U@ <^'
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M'C%,P PO$(%32'P"8'#A 2;8! V8(P<)<.$%$<"%'"Z D?XQ +4#8 G;&T0
M+AM0  0P+,9^^YNC8#" %J"0P RX8 %$=D$"-J@! Y[C ;!4DQ82B $7-*"!
MC'#9!@JX@R:\P@7DV. +;KR*%QR0-EI8( 84;\M^/R [K*2!A<4X@:9@++ (
M;&(5_8M 'C;A4Y-00@((D\0#BC$&!W29 6T)0P6Z8 (-!,,2/LU! 5] GQQ4
MP 8+2;-,3H#;37R@XKW0  E:;8'!N( $8^@ Y-K4: <@Y@5UO[MM'\""3YCA
M 2#@PQN .@*Y$)P+)K# 3E;0$!4D -+UM3S#)O"^8G@ :\6P +,? )D)Z(H2
M.5+-&_*-%0> HO3ZI0\N''"2IOY2P@' H$2D/M"6!R!V&+7O8G8HL"#PAG10
M)JF! CJ F0ZTAQ8SL$ $U.+S&&#$V"1PP8@.C!A0(/92&(D BHR,$0D 2 /D
MD4&![9!O#;#X!<Q1@07G -1-U6"*D:!!IP=5 KE(P#%R@/KFIX*S, (GBD$"
M7L+GQ* 8&( \:"$2&@E=-, .+,$!!H,28@P8* "?'@TC5  [1BA.*  7[( !
MJ*<81LW,, ($R  CZ"T8BH@R,,<D8N#<G *:7,"JH$X.>$U8+" 2@B$!WBC@
MFH<U-L$%+. !/  QX XCZB #9\ $,((!S,(,@&K,,*+N8J4#+*@8;,"+X$ S
M&BD8(OX! <B% C1C!I1# B+%!O(@#V"-,+RH QQC*HKA#A"("RA@2C@/(S3@
M<"( &%[@>LA Y$P,(_*L&.2P&/XP!@KLT);".[@P6LS@(CX!P6!BD3P/,>XC
MI*")!)#M*KK@ 6B!%D01C$1)%[2N&.:@J6"B% ,D ^T.([I !8"A =#E!30A
MZ:@B/6; !FIQNQ[@#8#!](KA I2*NT; ^]YHSPZH3TK1).X  BKP$_B@J5*(
M%H8A#S'" Q!K#,[M!+"&_[QO$RA!U^+D 2KO\M016RA \SR@#K:Q#1_ !53
M!1!D4SZ!X6+EEUX .P9CDS0!@8;A!%:PXX:A"Y2#&+*1//[*H!XCP#'.B$@F
M !1T(0*"H0OH0V!>0 (X $5XX@5<(!AP 1AVPD*\B0&&80;@Y-3>( Q(\"K*
M( (NH'5D2 2&(1A0Z3'6;6@B0!/NI))$X -8@ 5,H -TP0)\<AC2 $[R (%*
M8'0@PP.L:$&:,FO,P(L^$."NT%DJ (V^RSLH@)\  W+,( (LP 5Z@?;HT0@]
M;-HTX&FNPN%L+P-9*(0^$,=P 0[.K4DD+0) (Q@L &A8  2\J 18(OBNP@7"
MH%LBP!AJ#AAT30<?XPOJ\0$F <<:9!,P0P16QRW:Q/$P4!(*HI&BR 9NS"K0
MJQ8<@ 56@ 4TP. Z8)B*P1 0"/X7:F %5, B[P"1? 0#R:,7>^$/8V4.WO#W
M$E$37( %EJP8:D YFD2N3&*3%!$7-JD@* &1;&#ZAB$'4*/?IE,$5DB<$"D'
M"HP+F",,2, DQL L:0!& !,B+L ."B(8)* BI"0U),$"1D I: $"RC!2-&H&
M=J(.6'$3[&U3R"LCIN@+7" ZS@<Z,G#-,.+C'-0D6, ,-*$!UE(Z-@7Q"J("
MDI("/F$]UY(":BJ*H ]R]&4M)^"7ZA,C., QR. ;L6:$3,(".@$.O&@PF&P=
M?90=X7$;,0><)&$"',JA8,0".N\Q#F"KTL/S^,!!$7 ZH*D+4.,Q[,W"R(,%
MVN*,0/X0,0BR!&JJ/7 A#R@ [TSB!4J))\SS*L),$A1@1"*A 50E3EB($D[
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M,#@@=R0 L=Y 1*G8BSQ Y_Z$ ;C $B(A#S1##,X(%T@ 3B2A (1CM,JD!$P
M%X VB$)*U[S U3+9\[J ZQ0 =:'.#$+P>L$EK>JU *9" [#F$_3C*MP7C2)
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M(L0@M024PJ;C1 6VPGEY0M"T[@4&(X9+P P@;E2W6D0_*TXLRVD> \Y<H ;
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M8,,,"D 8HP0YC&'!8V990 :RP_Y\,8)"-:A03 XBE-$=+2)(0,.&$8S!A0;
M?++O' S\ZT"V7%A@!@LKA!7!"3:0T$$Q;UB@;9L1\/'& Q_<$>I;$:0'1\XK
MS%",!1]PH8($P<B1<PX=T *,""R$80%)H?YK :T;T2)!"3:8T,%_-G3@!0DF
M+.2 S1W0:DD$,]1@@0A:!D-""5U0D$,Q=!P:@P45-<I%!R"X0 ,#D@03-PT6
MF#"#"Q*$Y  H7CA@ B5R1-"!'(86PP0$-M3 0%IXY_ " GB IE 7#Y00"6LQ
M<"$!'3P!TYT9%LR6AZ0S1$ +)0Z\8(/=Q=A0)$%>T*"!,2<<5DP'<."B 0U?
M6""G0O[54L+$S,6XP+0(:4185FF2$$Q#!)H,TX$+9FB0:0D==/#&)P^H8 ,(
M8KL @B[$#UP..!V\-J()!KC !A1X 8 HT 4;7* 6PWC 3FCQ , \  21>$,$
M2.""Y6G #"I@ ;@J)H(O1$("%BB. S02# G0I#2;J)D-1% 9#2BG&"5HDYE^
M",0@"G&(1.P)&7*FE@=THA@5H(Y">O& F ## <"(A 8B-(>YI.43/"L&!?*2
M@R*!P(09"^$78T>2$8& ))5JFD;RP+/?*40%3)O#D]IH@9UTP806R&(QNJ W
M$=A (1YX S 44!%0'*4T8T!B!#(%1\$M,4([T<!17L N.?YT$8K!")I ;N&
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MJD#J5KTX&)1I$V@*!1*B@?&8X0$/^0IBLFD&O0FS&#/PH0N:10>.?D(!6Z$
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M%0->@( 0!X51*(5B0@D1\#AD0 %&%P%98A$/4!% I6OL%Q53-0Q3%1,LH +
MP!K90C_IITPL< )J& 'G,R*%U%(5\4@;,GD/, 9A\ "!PP!1(0<'$!,2(!A<
M4"0N4 )JV $9Y0$A6$B;X"O%T 9=5!JSHD]1<0<5T%+1<0#C00%EP O:0F+Z
MXW3--U@!-XEPP#,-I70B0 :TP  : 0<:,%4:,0=6M0(J4"@&D <.!2YA-P:]
MP19DP 4*D"G$= (A] D1<!B?QVP60 =Y<#3AY$"&F'$.0/X+U%@1$I ID7
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M6V8OFA  N)$'#$ +M<"!P3 '#_X #&-@3%^P>@$7 6!1A3UY>8&B'!%0'&&
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M#&$0 3"A,\NX%;I0VZJ7+AGG8C:P&244SSUA!Q61!GS /[B F%L$!WE0 B_
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M5Q9@"<-P"U,;#(EZ,Z3N15D_$+TQ#!9@5JJ%"W#0>Y37-'GA.9(\2)N@)S,
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M<P(3#,&%-Z+#.XM!'72N[K@_.=1#0920) S"-HD$"'(_$CS!3^@ $G@1/*"
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M(VD9!L2*A(B0"!>X"EUP"EQ04['(BL0(C$U(PZ>H'BFZBGM5#H6AA3XJ@33
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M=1IEF_[B=859!I&#"EC@I]&F[;3 F!D=1*!2R7!!!:QKIAU*@+7"GH &;]!
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M! "#7:YCE'@ '8@D+NA",$A /1V/7S8C5QQCN+ %"7S-'.!$5A9#&M0&,$@
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MN"D=/( D  /2M9=)N6VS.47$??[( QRF!<20!UC _8D@8)B%0<=GH!2#"8"
ME;U&#/RE#,@KSK) Q\E%$_;%(E),!V@ 4^1!(ZOI3J3C::P )9!!!.P+*A>#
MN1QP 7S"'5#'[@&67^C>!;S&S)R51EME$%( (K] !P#K.9[>WF&&%R" :<BG
M'NVG)80(7X4(Q'&%"@@((8OA*'?!:MZSJKV&!73!R"  9%A P:#U65& [DE
ME(! %XM 0=X&7@FV!-HR=MR&/'M!,)" +NE$=H@ =YRG1E ")4R 8]0 )>2
M-6OQ:/O>X#SV#-Q))%A9TYJ-0>@,G="""S@-&?A)=]Y&I-TARR7*.G;QE;B
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M5T2"!_YTP 70"2ZP  =H0'BG@09PP)"E!(=U *:+_?-#/^^<%,,6%@=(JT$
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MR( 6-D$$2F5Z"&(2*FP5%$ .*JI88F0,'" 2AI%-8H0%W/1&"8(!%F1Q$K
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M @HE#T3  ^J\(3S#"X9[-$JC*)Z#!"Y5!,9/:TY@51;$7>9O$^J ,V@A/3P
MT6C-,B9[*VA /=8V$@"=!,**$H3; <7M H03+V@ T69@-#!]4!:$!AZ@:,!H
M,SI  YR;!9)D#$IJE2)@2#3!YUK6-=K@ \K'(]_ C]RU;B@$2,0MBD2VM$B
M'C6213+E$TS S*O##M0*17#A#OZ8Q;<Y8F@5O,GD:D@&@@PN '@L(*@_V@&
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MP3J-!8# ,"<ER&T[@A8R2 -M$'>;8'G)T8%6<0<LH@GW4BI?D /)00M?, ;
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M36U1!J(JW G7$-Y3#'!04Z1.ZI<A!_RA3R5B"<;B$+)V[ B2!L?F$$5U&7!
M*^GT)2( /B00'M1<#.Y*_O 244\GJPQ4#)ZV'0!13*"<8/YV/ SL4"Q/PF)<
M@@ET$$G@Q&'%7I@0&"-',0UWADFX-5%@ASR?(DRT@TN2 UK%R# H9L&,0 V2
M:#EX6*P$I88J2@ 364S3@YPD/KFP(3#2228OB@&SP--.0@]=!(Y)"$).L0C
MNGP0F"-&,1!O!&K%Y0!H,1.?7FPLALM.4*B?B@VC(%$HI8^XPC#LXJ*8)0K%
M:#U 60L.PT\.[(ID($F@!%R;"H\Y$3./0$V2@DF8^4E!GC<6KK(H9EE@"3/
M6 H\L9$"SV$6-(UY;(&,P(J;$%3\5'@.Y6(V).B< 7LW!4VT* #=9 $7EXD*
M/N&24#'H=N[=O7\''U[\>/+ES?Z;EU-X$P,7PV90(,/$0LN[J1W,(.-A(P@1
M7T0X**8+!&@80P+J9I!@#"XFP"6'$HH9(X(Q;& OIC=PB:"+,52(C(L'%8*@
MF$\DF"'",8KI  0R7  A)X&@8F$,$@Z@)9('R@@#! H^N0.!+H)QS!+$BHDD
MQ.(L(,&%@T2BY( 3QBCAH#PB(",,$2389$HONG!@$TUP(LNIH$"XP"8+8AB#
M@A-Y*T:. %@@@001>*+# 29F>$"3^BP@:  02B#A@SF*F8"GH#8!H R!\ !
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M-9?S1-*Q! NH#:MX :=@@1*XA>"0@T@X#K(P \.QBW'S  F8 UJ@!1"P 5K
M!08 AAAPBCQ@,I'X +/0LBXP@#'0!,O@"2BQH =(B;PQ,133 "[8GSP!AJ(I
M!A78#8(YGG)I#!&J 010KHK@%HF1@^/H@%:S@+EP@*?KFXH8 P2PB7^9&!48
M!ERHB3( BSLH &6)#73JDD"C 5R@! B0A+2P UK@ @/H!,/)E#< @;'"$#C
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M>\0%D@"<6/2IB@@&@R0+T_B$!QB&$?""8.B"#N@$O#"_/)@7_0FR'' CFAP
M+^ )$9@!@GR 2,"% \@![2H:3)!/9RD,+K@[3;BUG"+)3]10THDGH4" 6J@!
M<!%-A#@V3 "&YW@*3; #$1@+#WB98C@!13$<72 #"2"#%F,OY3&-+O@0+O
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M^X0TR0'+Q8V)X (6& :@8 'JT("Y<+;3>R *: D5B+))7?Z63;#2Z4H#$W@
M%I@N$I"#%[ $%@#&8="$#GB2$Z".8.""_[BPB2 ZU7V0AGD!+\@#<JW4FPC<
MRZ4$&1E>LO"5BK"$"="98XV)2!C>(#-.[3#6J2!1WI@CY34-5K$!&N "9>D
M!C:&2#"-CQV&-# 0R_V"3\@!I\"%"D A+0O*N] %@O4 %<C@)2H&#YA"B;F#
M@WB($?@H;4FI8FB8+BA2#:A$G[J##K 9^Q$#U/  9:G-IZ ,$OBAXU%6#0,7
MH, D_!$(3#6Q-EBJ[[,!,2 59U$!"J"<U,"7/K4!.0,*$H #+Y S%_')A.D
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M+A@!@>B"L/F9LG$ 7_D$ 3@1,Q  .AT&$VC=%U" .H2[O9$.%%$!S#@ GC#
M&QR!B(K"&URIA8:57=0 I^,QZ7I+IH.+$DB*!\B4M2.#/]$<#2@#&KBUPBD
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M+43@ !!\@A;H \$)@($L&T2 4OX6TH 'SN<K Y( !"\@2"3J9X%(C:%R:>"
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MI==?:["E:D4@BC/XWP,2@@L)\$$3 X"#2T!@ARY8]7<6< D)(E4,$T21 3'
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M#E3.QXT$+6C9)XB*^DT$^U5$(>E"B>$"%X  '<"!'>R+"PB;)E17;KE-9,1
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M")" "1 P"-  !(1$R_IO)G\K"9R ,=""0=7Y,L9 _;A !5P++H" )Y: 1MI
MHT1Z"5Q C$B !,Q L]8 !-#"%Z20,?$O[((EA@1#=96! U# &)B/-GD CK&
M"*S ,+S " RZFU>]U==''C!JFE5+ W ;8O6DET58C))G;!=$&6Q%@Q68&3P
M_&B %TI<)+S3%R" T@AJ&&D MS I6,+!G*Y(?YJ9H'AD,3#!/IN@4T68"]@
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M'(:" "=X*0=M)?'"2T.+^>"PD/ZYC>0!@FAQX)->;Z.P&#H@4LGY8DP0B:(
M>9XC9$E*<%JD$B0U:8SP[3AKCI__+9X\3=!-: 9@AF$"#E3+ R*844)*<+;G
MS,%Q;5C1%\AS.X88*!@' -,P(L 'R!3##/[ZQ*82L@F:%&,3%5%!2DXDAV @
MX((1L,,*R30,"=AA@W* R IJD!!7]>)H#BG/ UYBD@C0H2$/H 3/$.*X-$2'
M1A,RR0G&YH+HO( +D9C>&S:3 U%AB6LS:)L&2N,"^E1 4IK(R5K2% /-C6$S
M-2C-':8'A\U\XH")L^,=\9A'/>ZQ*N4B5$RPI M@>  $*J  F#R@OLH5PPL*
M,(,N"/[) @O$+R&@. "9RN" &='  BR0P(9R0!^3U*"300O*)BQP A)X "$Y
M**6A^("[S>!" R1P$$0^00$2O, "NI$#!5C0@56QX %Y",8(Q#+#7TE !2S0
M@"@5="0NE#(FHB$*^!*B"5T24DMP>$!<ND0A%@3H$QZ(P0B:-@P5B.60S\'?
MDLZDDI=X 9@6L(%)NG 6+W6I>[2X  E.0(%-..X-(RP#!UQ@@_9]3 (G8 $'
M#O.)(*F@ RR(0%L28@P5/-,"9XL$!$KP @G,@6<E"*:HC&;2#FRQ9UNA10<
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MH1.3J:QR&Y*'.Y@$M;W@3F80<Z7F"M8. 6J(9"DAA\LF)+WE^4H><"'(3U@
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M).T!C0N:D 1C!@R49$6@;PM&P!LV[4F"=,$!&M2,KAE@!TK,_$RDJ@4PY'"
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M+<:@KR!/-3:A+N2B&-QKUYI. \FP#,W0KO@GG7"CZ=2(@Z(#%Q@ -(IA#A
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M@)(HP0:*X>. 0A+6J0340A)T@Q9RP!C>CG*,H0M X /& !>^XRN>*F1P(0:
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M@DD"7J(+Z@44UNH#4F(89D $OOZ*,V/  2[ #HCA!1*P SBS%T3@@SLI(6A
M+#1 [SX :6F!!=K"9S7 4"2A V:@ADGJ:"M0#C3 D#!T&"H7#M#6 R0@GDRB
M,VP&IC3 8C6 (!BN(3P 4FAL$RH*;<'0AX_6*RROEE9  R1U!%Y@:<9 DCP
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MP'G::7*>PP$T*P<(9+!0A)%8HC**P9*X "3 )$8(P@/:XI4C8E.V%S(VY&Y
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M C+3!O OO?QE+(6JM/#'C^)Y) AK*S0R!C[B+,A@>H3\!2X[I[UB4-Y@14I
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M.O57-J-79L02M ,$5$:M<6$,M,4+?K08)J$O*"5D)  4*($$Q. -WL +3&#
MYJ ,RJ"4[98,-$%%@>,RK(DM&N)A@Z(" H3M :*8"#BT)!0#8:;8L$\4!"8L
MQK"8"C*?'LB! R</K6%MS)@9EOX&A,0NQ21Z*2:G3)E/)5NZ? DSILR9-&O:
MO(DSI\Z=,TF Z%4LF @1Q6:<*%G&0C$;+XH!LT )I89B'ER4-%H, 2V(#()%
M4EJ,5H2M2VG9:5C,3@*R)2E1&%:L@YB2+JS"3?M@:S"XGQAH*H8+@IV2#'$-
MNQ"II >2GX*Y#$:B ZU/'4@8*_:A3,DT=%Q^.2KA;S )GRA% %9LDX1A)\:4
MC&1080U@#J+B8D!+$XF2DDY+B%J,RR=)$.!*0O"W)0D;)6F4*/8@<1X%N#Y)
M<.Q2-6I@$R25%/X&K0VB)6B4?,$%UVF($E K3&NA:1<+KHM9X%/LPIQB(4N^
M$?D>'/XQE#1&!\7(T%1A82'@F"0/.-8!'!(QEU9")Y3PR72N6:"1 Z  1MI[
M8A5#AX$H&:C!8,5HD <N#K $C 2#C2%""</@@@ NQ6CB &H>)%3B>20,^$D$
M.A93 UO%1(*6!W*4U($=N.154@VX\'%!278X4)(92G'Q5EH1%).#519(6,P8
MDDAR%$IHE33,;T@^QY\%=P7%0!HEG1G&!R6Q8!4E$S@& AS /,!2692 Q>2.
M8P(C@H[#*+!*2\$8.4:;7ZCP7C&"%M,%@'*\-0P)'GQ"&0G8Q<2 ;;AM$N:G
M.>Q6S!=CMC0,!=[!X:= !(W)Q0@EA<%E%\(60ZQ$7Q03 ?YP75CRDAE$J7#2
M2#Q=BVVVVF[+[;6XB" !"!1TH..W)*@ %9)6 4-!5'),9:H+)U"P23$O=/ "
M#1KD( E8Q;PA 0L=J #7"1VP4$*(+>%B ;F?6*""J4>6I((#%E1  0B.F1'!
M"1:85Q(M%.@(AP0&JQJ7:W#!-4,%)4W 1$F;6&"""18D"E<8H&$25+O!6< "
M!7.1H')P%02=PU+QT0 ""\9$YH(%89 8L <DH.;"!2R<T&RGM&APP@D:L-1%
M!"JP8*1UJ\I\74EY5"U",+18X$(,,TB01RU@>SS9>I],X%Y)P#! 1C%Y') H
MAT4YD(<<'O@GTEUSD^ "!8/-H?X %V))JL('^5[ 13$T.# '+AJ0,*]W2&I@
M@PJA6S CW190&'($P]AAHAP&PEZ2!IV1<;0&(.-(TC N>!"#ON9QH8 <D61I
M> !Y=!FP!BY<UE)!'P3SP9-Q26A&P!RP,,P=T./B@0EVRS@&!2RH$,&3-@1*
MP0DD7$ +,!Y\$/4;+W$M"4B)@ 464)W@+$ "%H  !,. U0MF\ ()6()A'8",
M9DHFL!,8XRNO40H%<9$#"K@ 7X^1 "XR59+/P,E3#0E&"9IVG^:@I0(4&L:=
M6F(##3P0>;!RC%MN5!D6W&]MNBH&KTHR$+$, Q@=& $+1&"!8.C/B5!45EH"
M]@$1Z/Y"(</8F$A.4"T6G&1EW2JC&<^(1C1J@@[ :4D>[. >7-PB9)<!QE8\
M8 =*S&%5DI@>,#8A-Y?00@YM7)(=Y+8VP%#B,L&PP_1>,IE-=&(3B2H&*.0
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M@@+'EMB!!C8PZIVXD)B[X&*F-M$%)<@2#%U(>*%PT40M>ZJM3?AV)KBX UR
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M(61@ -\TG[#M,!Z\=DN011.1E2W>NPG][$D"*"TQ>M'M5/*)^XO=Y-]6&"Y
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M<V ]&I 0E. !*B \)1$# @@"RU4&5A$#9Z,!'G DI3(#(P QCB$'6H.1I?(
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M+/ 182$!4ND 80!*%) #,=(2+]" <'$'4T%U+7%$C]H%7?[P?A90+[1 !EU
M 23QJ2= $B!R)+KC'Q&PM&/  $]""V7 M%^@'H 7#'3P.&EAEUG&(B7! 9+
M!=;X%$<"!X\#%S+ !7DPMF.P&S2PK,8709U!?3FJ.I^PD'_Q"?K%%63!%#UE
M)S2 J%0A(9LP!DSP )WQI"M2.-AT-_M1$4G5JI2 I=T7 5MD!CF "RI "23
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M$EU#L-5:"]<L.,S! H]$ ?O!S%/3=5($#*@Q!X]S!PCT?+;C(O52!GZ!% F
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M04(B6=*RO!,73T()"S0&_=@29A#F688^GB.%HA.BO($ &D#J[1L6\II^&XH
MHU[JGP IR0X!ZA;1$F\!6P'E%* 9%@_L5AY3;&T0' ?R%OX0 7'@H!U@-?3"
M&Q(0&2*@XV3B/\" YAZ0'*E;F$O20B0P0#I*LC)C 1=R,V!9 LGCB78  2Y0
M II6*DTC 9V1,R1>'R6N$!HP0"/P:*4R)'8^!J=W <  RW0 -\!@T8YAT4O4
M 0&=Y-A1F2R01<'P,'5S-WSP-6%C ;5@':@1M+ \I$OFY/!+"7+ %E4V4_C4
M5&X5,G- 9+0@^B[!!RZU,':0/SK2? H!4,\G19J[$44W!Y4T2!YF?%"!^)2T
M"9NP1&2Q4$&1**T?,HY42G:@^<4@O8^Q4!#54U77*=71^[V_=.7T37+@'E']
M'E56+YTP,9P48,R.$HE" TT12_XE40LZLDRH(4<"9@=W466"2U)'TE:HHG=S
M@!]MQ_YJ]3"X8 >W#A#%!!:CI6E8,6!R(@TD&*S8,%H#:=F):"D8+6 ,[]R!
M.!!8Q(&@YF"2:.=3,4T9@=7)(_"CRXBX<!',2'.3'(&;(C@<N&J.IH'&\FBZ
M6$PF0V"?.FU:.E/@'3L'C7[:5'433TER0 K\!(=KA)J4YFS=9&>F)8A2!98P
M$XRJ5:?%\M#AZ9).2X9;C6EEN*J8,9!%!?*1XY26VF!V[ P<EF<AK9.UY$0=
M&*DP0UP1:>D26,OI, N;\BP6V/CQR5Z4AKTT*D>2P&"@8(/$9<E8Z:VM%[JT
M _13Q/[&E#L^_!1,PT*W#)4O9][<^7/HT:5/IU[=^G7LV;5#5]N<#][MSX>9
MR:W\8)D(,<(O!T9'.QT*+TY8.+G>/O.#GQ[4O!]>;??[:.G A!<D>*.__G#Q
MH(07*"A#.U#20'!""IL;1@)**M20H4\DW/!#$$/L#\#2S"-QF(/^>X@A%$NT
MC\3J4F2,.AE9M+#&8CX!;SD8PR-&.ESNR*-'YWJ4"D8CI3.FDQF+G.Y$&WG$
MS\4677RR,HJF9.A'Z:",\DL7);%#-C"EM%!+\T2TTLDTJ]N$/^N()+)()-6T
M\TX\\]1S3S[[]/-/0,L,=%!""S7T4$3MI,4&_GJD)(PW^/X#IHPQ])KCBPP'
MDN2+.[*#<8S7UCRSS6+(6.@V4DL;AHOR<#%CC/J,>C5605>TM<DO$;.!S%M%
M95'%,@^*9 PS7:+5*"X< A#85&^CA%A?34RUQ"\V62Y3H\@@(ZYB-OG"JX'F
M,&,@7'A-%1<::(ARV>K"P';.&P>RPRMCJNSU7H'&R)!=[D:MU5<O1>777UI
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M$\CL#0Z80=$D)@D)O& &%GCF%_X\\(4+@$\YV)O!65]S 0]\S (9<8$&_O8
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MEH@QK,2?8I"$I[H%AY"$&G@M<B&(F$HWQ$E&J9BK#/F =3R.8A !5CFCP]"
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M$7 (5W((=+&!)N6*!48=(W(TR.@ E2D##0 &&QA'.0"?&0B=L_H $  *6O
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M7C)OKJAHD':+AY%P'B'Q?AD(,UC-)AF83\B!%4^2V#ZA^R[NX/,W,R@#)E
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MK!R;=!"'!L?1PL!QFHA%5(^5IRDJD2\A+(?2<.!K&2T'1.\K*!)TVD&[G9Y
ML[:VEOZ0[!B;95R,&8U_,=K!#@U/B[=I-!Y&"<,\ %\62!-1ZA TP^3++<6
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M*#,M)",*"]7(QA=$P"UY<($;:Z,ZDGP /K)\$X%8P(5A=,H#=N##<^2W& _
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M8%K $B8M!A]LU1:'Z&)>401&:,=2!IKI J8\K 47Y!4,%X1J>/B3@Y=P(0+
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M@.-F= + & PP1$E;@0X@"6+!C^MVP'D:1)+/LD?"8S.*PP""5@P/U$9_YKF
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MHREB],Q-<9R3"FAB#(S37LPC"'#$&Z BF[R 6(Z-43K$"YP@&)Z 29+ <<1
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M@EA )'Q.#<1 6JB50CC J5C /)_ .G6(=7C 5K1T#8  !XS21=? P[5)%VB
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M)P*"R0/IGB0!8M2@.;]B6J.65B S* L^!J"#MAB BP]DZ!,,F$\'TB"7$LP
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MM(\2YOX@ 8Z";L*L#."E-=)G9X9!Q!("#B+@_13"#@(@75K# 2)@&&C! >S
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M-D0@!R@!!&00<L $%R@ /(:#$AS@#G"/$CZA!(3++"/@"WJA5>R "RB WQ[
M U[ 7Q"@#,;@ 50@SMZH0QQBIV:C"T($#DS@!41F&$#@"\XH&$ @ IC #C*#
M!">&#A0 %[PS# '1 JIH!CS #KQ@/>3"3%E#!4J $K@ 7FCD"^J  @1# 30A
M2?+$ P##@88A#6SQ:R)3 EQ $CZ! LR@(9HO,"'@JF8 C]Y  8["!D2 #\*@
M W1A(39! O)@="AA$QP@,O+@D0J@!N  !)KD#5!55>'E#?X\Z7[X P+"\ [J
M< ZF!Q=>@ +*8)?T!5Q40+3 DBT0P 7>X&XZ@ 8HX4%?P '2  X8H$QHX +D
MH L4('J\0%;(@'4^@0MN(@'PK!80(%HT8"3#H $<3@.^(!)$('KLX '>P PD
M(%2F,D\L0 ZP\!/L0$EJ0 ',  X<@"54@"7U*4TJ0!+>X 'B B(V@00T8"!8
M@ 3LP ;\*\]8Q<*.(A@TP 4R-LR.TCOCPC5)0"T/X 0$@P/\A@5$P YJ( *
MP6+L0$:'00%*(+V8,#8D8 PH003  P0H  [, !,5; YH  %DC0,=@B-Y3L!R
M8D-,#R+B@"1 P)Z>E@.WXWA (?X2E&31E$3D;$A36+;/#F)0<N)K[$"M[HA/
M%<#-'D ,Y, #2$<$G F?WH ,&B H$!9<:" 2MB)!__9FAL$,3H "R*088D!2
M_K(8'.!A0F9Q&U=D#$@22(($HF=A2$(-"X2?9J !OHH"IK-$5F$5RK(#YB,-
MVH06*J#/A 9EHN<!' 6 L.PH7%/=;"!UTJ;/#*@8X( $XB,2/L 27E8AWD %
M*( !JF@@L:\."^D Z6#9@F9@N%#=[$ "&Y-#7$"]_(5'-L%*S*!)[&!0-*%
M9B(H-"!YZB(\1% N2*HC)"5E[&?..@#I0,L!O,+A-L%RBL$02$+\5,<!(E,[
M_U<.'/ZB/@*E;(NA ]XC$C@D$I*PR2A@+:!'$^;H $$K!CJ  50@&(*!1,;
M(=#)>FS ;% %!+A@&!96(893=0044,PE3R3P1<8@7S2! ;)T/U[N2;2I*^5$
M$B*A5&P +VJ@!J!706J57R%SE\H )Y:&_3Z"OS2 ##0A#58(%RZ@#*0X?O*K
M,4#&<EF -2*!EEI"#@:R2\: -TAW("0&RR:&4X("&&8 )ZBV/=Y@(,.DBD1N
M#GC%->5@$VQ  FSO<CM#(B@B">]  3P@JA0@>6CA( N&,PI',_(  IZ$^9JD
M"V9@#AP"&+C7+"P@(Y )1R1 $VAA=F@ 3.*#!5ITJ8!8*/YPKB,GQ0$V$W!G
M632X;"G8E@9F@*I60&'^XB&^8&L,QSAQ0G)+19E60 5,H#FXBP(F:"%>P 0T
M849?2@) 01=>0 1XCB7$P&GB8X"=PQCLI3'>2BF"X0*B0S4@0CT7H@,D8 1(
MX !8(LYR9!-H( P&$AC8;&$2P.%>5YIS[$WD(@TXYPM5I Q6CB+8TPY&@#!"
MP@/>P!B(!(*M) (I@G/Z[ 2N2)(LT Z(@00Z0 7\204XE;_:5 4^ F3(T@%8
M(*1)X(Z'MZP"2A..A"%(8G"=@SHB00[<(B$T@ _4I,\D8!A.X*61PQ(49":&
M(5DV@Z0.CCZ([<JDQ $F@F'.I/Z2).4%%"]J%.3S;F&KA^$.2J4HJ!2.^H4V
MTH,^*Y8%3H"M^RL2%(2X0E@X@&$8?*,.2B67'X(-=VBM5Q8/[G4"7B#4OL $
M!!4JZ#HI.L,$+'<A3L!R(4(.#H $2$ "CJ,83  \EAHB/L .#LOG8D,&2" &
M/%DHRH:DV+@8Q.!$3[080.".14 .2 6G5<!OJB>/4P4VD$5HJL<,= $7&* #
M2, #$F M^-42-,$2"!8$%W$V/KL,<,%B0LT,$H,&:. _@ &L:- U685?3*"E
M!>-%0$%)K 6I22)EME=!WL!%-L$,(J"O>Y>6XQLT)%8R%."-1>:RQ: 82O%P
M=1A58OY@4R27)#Z@^0CN8>@@716C&JE9%P@C,CBL0YI"$TB"B17B!:)D B8&
M7=+"*Y;ZF7QF:2)!$BB!!GCEMKL@!AI*![L B6*9 (ML($GM8R!D(6@@B.0$
M*J+(?LW;<FE!8::B>YL$#I8M1RKOK'*Z&%2 L8?,2!+BO*]D#(XG,QRN4XGC
MFH2T1FA7,1<"+NA@.A0"+L!7(4[@"TC@@)R9B1N"J9T*&A?"!MQBIQ  SUA@
M61G +"0!*EX J[G .T-G!4R8 CL$*EA9,V[!*I "K34AL4L-E&!Q#D*BNA<7
M5>0@$N(ZKY$I!Z8/U+JS-31 ]_)$*?A .P,#T2CAIR+B"_XVH9&,L$M$P 9:
M\(*"X@3TF]%:@@[ZE"T D04@0@5\)RY(BF&+H0Q\.0V:(UP@= ZL)%B$<B'D
M(%3D0-8H(+?YXP&:3Q6# 0DI(1),5##H0#LG06AD@R@>@#44(A(,H$ BP \5
M(O>>1 9 )@?@Q7$6@JK\(J&"H9-'F4.^8% *Z$I4)J$(.T<^@0X<^!,*3K[C
M.TEH0!(2*53&X'?DP  FH@%4@!+FZ*@= /\PGF;_2TGL  +R0!- P :"H0&\
MX!-L")!/H!&-KXD4YQ/D@ $$H[V/XD43PB0V06'+I@$F)@?\Z$VLMD@B),F;
MHAA680!H0:U:HP!P0A(4(!B$P_X%1%PDAP$7$("01.ZNG61.8(/E-V$.+$/=
MCJC/', 0-.$%!H@2_!D$FH,!^)0!EC102I!'4)X,$( E6$57'H"/61Y02' ,
M@J$$\)L$1$8%!(Q?PW .&& V38 &@D&*\)Q#(CN*>6[$#*#R;5HU\@!;-4,E
MM]T"P,/;F9J&C($"#N,-&$ \+5S:]P<!I-D!-B&Z#.@D'=0V2J $-@$."D P
M9  $)KA^[6   -:YX.A_B\$&0@1 !O(--N%HA%V2E(XDM.))/, 2\B !4D])
MJ/]PE:(#8H"]M\,+).D3Y%?=(#[G3C3\@UT%N8 2O,#.?]O]OX!N&E;.%X($
M/@0$,O[D#C@$(CX3((J!<+')# -<+%A\DL,@1S &FHH!<["IV+!B92A\BJ3!
M RX/9(H5ZS"FV(49F\8$:".R)1P+Q?(H,$/)A85@+8O909 CSQ@%)2.8:3E'
MP3 Z#"X6TV0 EZX#E(K=06 C#QF@(O,DH'%G#@</P(J]8%$,#X"27V#F+#:F
M@B1*%LH4<V#I4])@'DC,  &3!)=B#SI(BN3 SMQ(P2APV916U]K'D"-+GDRY
MLN7+F#-KWOSI!0@0-7 5"\8%1)@Q>8;%+2'","X-95@;#D8CV*>_.DF(Z')Q
MDPH1):*V-#,T)VU<MUR<,!.)!3!<+VH4HV4#IRX:($Y$#?YF@Y9(.W*+Y?BT
M%'?+$B5I1%5J(]*F+B*[1"KVJ?;TO2!FU"J&:X;WG">$I%0QNLPPPV@V@%""
M)&M)\H5(<I3@@B1>E,1'"2#D<%%WN$CGDT0TO%",;R?(08>(?)"01TRL5;>6
M&27@TH9A&,V6 P@JKO4&"2#0(%H> \$!WXYA?,""=T1Z<&0QD3PH$@.66)03
M'"2,$!XE\*TU3'?\S>"!""NN188(()C ATAEZ$7)#)'( 8=(;\Q13"]><D&&
M'!9Y 9QA<[C@ @LFK'@1,#:(1D=Q7$1$B0D@Q" :6T;"\2 <;XCTA0@D&$;)
M7Y2*-$>EN,0@P@F86*H;;SGAXOY"#EUF%U%.G[#@P0FOQOK!"5&VE$>6%T5"
M0S%D&+:)>5_,=UV94='R@@G,N8!+#MYQ]U^>)N10TR9EA!G&F;2P\$$8VTHI
M$B5>B!1)"1ZX,&U+E)SPY9O]B781=+AL(IU(P,CPR3#^C>NN"&^VM D+'8"
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MVBGA #/,P0(P030<_#[2$EP@#<4H00TD(0)9*T7Q,=#$B^60A@C@H1@B@+$
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M)UM# BD[!Q]0N3I!U2I@ I3C!1X  ETVB4J1* )Z+[$"I/^A*GDD!R0P(5P
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M$Q% X3$13)+1^&T>]=C#PY1  Q7C!2X@@Y$@"7"@N..R8;U%.2GE O-$"S3
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M>0&^,32XPPP+: && CGRB"".^'")8 Q*/,@L!P7(@,.!,HKI@H(XOF" AOB
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M!((MP0R018/(KE(2_560)3I @0L(I8F9<\@%N++>.$3 KOXK$$$D:,$"$LP
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M/_&%%>S28TRI[UO%/6YRE[LB=OZ@)248$!A-#(Q"#L&% X;G:7+"VZ",P>[
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M K& #PB&X'&(&F! %P"!LDJ S*HG,M@$&L"936  .:B5@?[1 &YB.=]ICCR
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MT #;H(0#R(%-&(,'2+4QV 0;6!<NX" GE(1-< ')\Y<T"(8O6*] 40FDL(0
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M#(G:5%S8K)OPR]0\4A" $[78QC/%!3.@C&RMD<"(1V:ZCD]POM TUW,UU[]
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MZK;NZ\;N[-;N[>;N[O;N[P;O\!;O\3[7*";O\R8WY=9H\Q[O@D+O]W8@M_P
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M!L&0U_Y:ZLA*.RPMA\29S4(=,Q=1BA0B(GC#,#8A@6#0P@4DJ.5V-- 8.(#
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MUF[968">)*!/BW9F)A<8T# XD=X8(J&7RH0R)CE!E8X\23'Q" N0P";D0<D
M0P*\P";,@9#40H1,D0AH@IE$@BXH@!FL@GH\Q!@@@%;0P?[%/,3]!4V2A(1
MT, GS $"7(P$W($F"(DFE "%O "+#-";C< ,I* "A,$PT !"J(H+0, ;Y,$,
M* !"6$#F6  >J <M1 (%X!P".I_;R0P<?$(7'  EA(&"?$('R,E#7(3Q(8!:
MQ-$F(, =T$*A>< +?$)HX$(94  M( 4)-(T7_%"&F0FZ7)6%@%:9*0!]=,!)
MD*!C\ 09! !,*-,#=$&91< P= %KS-,FP$%+4 +%!,.99-ZQW5 7: #0%$,)
ML$ GS,$DFM(GF !B78SO/80-:, !E@9ML&&QZ)/J2< 7?,)?#0.5K<(=.("N
M24 -T +UR1LEW%>2J,K C$%FX/Z)G(P!^CU &P # [P!G&R,"W3 RPV,?VF=
M-FXC-^X+#03?2)A,%\0%+KP ")@ GD$,.LG2.>8/I)P ', 43=!+) B3!;%
M_HP!"(A YIS,H565"9!!)+" 1*@48)! '-#"_H33P-'+)Z0!+I0 FM! )WF3
M"WR$'8R!%Q3%+0S0"S#70!:DA8P!H)&D!<T ""A%,=S"1XZ!))Q O&W')C19
M#3!.39:=VDA?#)' -[K ; "#-)H!WHB<"& $Z-',&&P'17J'%W@ "PQ=%ZK
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M''P L@;,>CI:'QF7WJB*!N2!8J"-_7B>H-K+)_07NM* 6C%ML?YJKJICMX)
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M+E^(^]3 =GAJE4(>^#*DWFRO1N_+)D1 NG5!E8C>)UQ$C@3&'8QT M!(AKF
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M?X)M$\")U/(B O@DTVCAYJHDY3:%[X8CV"*!F/)@#D#A1^3  23A$T @/V9
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MHQ@4 %(BP3W%U2HEP5P=  3@ !>X $55-2),8 8V@4Q$:$!=H!->@ &R!I^
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M>$N$*2KW<H=!\#9"!=CE#N#@#4#P9>DX3+E@.P0/&)XP*&C "W"!78MA!CJ
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MRL ![, 8 !X.F+$I!":A)8'"TYI9P/<+R" ""H8U8H,6"L A60"3'62/-J$
M_H<,C+4+/K07:,@BUK8B= $!5N,.[J@B7*!0LV=I$OH+!L!4=JDBPJ<,7!\\
M&4!KTR#>YQW1: R7=*F@N  !P(<"OH:;7@!^7@!B(B?8._Z!IVSGDM3* 62
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M!O =FU B BKPF4UL()$5QL4FN!")U6Q2@E%=31(7H)?/+ "*37BP+6%003%
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M"77P )I0A/+GC^9V@XU)+_LU WO2!2<Q2J($5B=@$RS5 0]07QR EI3  G:
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M.YM "Q])(B9*(G"P2#%R1K_=)YE9,",!:Y)T=S;O]F\/]W'/:%\0 817RAT
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M&,SM!5KDV R:R ,%]EP&GUEO$PQP01[R<(('@*(8?BW7'  P*#HPH R;:/>
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M6G@)35BG^0B&2""A!IR/87@_JKB%U3"+2+BJJM"_4ZDPL*B_MA!!K_# M2#
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MI@$!?<N!XK* ::R!*L&(,;BW8LB!WAH4+U"C+J&N5N, U2H&)BBN". ")NB
M"="=#R"!#JB25;!.]O((%7" #OX@P!$P 1%P@8O0  4KEBI1@1@@ 0HH@Q>X
M@ Y80!:H 1)@3V1)@PY0 0W @V(PA@L! 1'H)0F0&:O A1(H 1)@ 4]DQD@0
M@1G(FC(0@0@P/2^X(T$Y 0JHR*!B4*++P!=X@!*#2SH2@5?D&@Y8@;MXTAE0
MH_T,!@N8 3(%ET@0#+C\ !$@@6 8@Z\R@T&) 3K:HYDH*PAP 5J0S:6:%8[!
MD5PDLZ'I#_H\ 0\ I1*P 0D(AN)B4DP%,Y%A 62YK)X3@?\C%;A:HH(@ 8_
M30YPHDT @1+8F6*@@0>X"SF("%PX@3E2@1@*!@'5TD3Y.Q*0@*\B PHHM2^Q
M/P](%/X%_8@1T 0-40$.N W@L  X"(83$ $0>(&+.($NF(#LZ39>"2L^(0T0
MD"3D&H-/B "=Z  [:#+>&A0L0D8X_ )/? !@8($]PP47B"$;4(\'T 5).*TP
M.(!@*(.BTXM>T@@/R!X&,+UYB\4'$ K:&085$",1@(-A> "\D(0"\"2=Z )#
MHH1LV0[;S /4*P85P!>9+88QX(Q;^3HR6(@R4(#/^1>&L B+I48)V(3-^!Q*
M<(A/,(#^T"7_20-F!-3;8,GJ,8D#Z-=-@";B*(:D0)8X90ANX2^O](A:V"4[
M*!&>I8WUD( (U "4S8.ZHH$OXAJH*@/!8 $.0!:KDH3AX/X..6",%W  21 (
ML(4#\I"#!!"*]5*8L?J$ KB-&*"-#MBXX0*& SB./'B XZ& :TD#P+, R[F
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MRQ?X*A7P" F(0[4,LBOQ1 30!!M .T1YHH48));4"5R(@S"X@ ')W)DX 8_
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M8DA0F,8#R3>16=0H5BO"IV)D0!2STY*$!ERT(N!Z&$'7, \6/HFQX!'$2 N
MA[Z841(P'@LD54SVT.&%"@FT<%EP0>.E':XG7$S(*4?!9 MS H>I2(,WK0?
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MQ1B,'2>MDNRIGP!3C+'%W(++*F94*R])G^1T+$G4DC1JOZ262B<M;Y [%RX
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M2!(&)U]G*Q9003$@8(FM4'<5/^6#!((1 ^$4XP0QD4 ;!H\ PS"$/3G1A -
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M@$>&(DF@1PUHA5_0 +GL!_"TQN^AA''0P)M$)%"400U  "Y( N:1!"BD@1>
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M0-6\@0C40G3 P5,60QDX1AAHP!L$[1W@ @G R##0PB3R:.-BBH^FZW"01!H
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MTWU"J*&6!B!(#$! '@PL?2@$%S  AU+" ,AKABW'HVB"5"2 1&G" 7" !5S
M!#Q:HZE(3@3#"2S':KX;H)V !-QE#'"?45@ C(" ,HTNKE"C;5B L@*@973
MDK"  DR3!7Q NY!!!%3)^_"@O*9& 0P$8UH+"(@ 7.!FG4R)T+U%7!1#)$0
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MQ5 ^\8 2:""$(AC#"\(P!C-\H@R\<$@P2N"%8'RB4N4C#@@LX$1*." D<#C
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MM(9!$_HI&!Q@$B""S,CGEN)"9YK+A4"((%Z .'(@K6(-(F#,/KX %\R@BV(
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M\*P-^L(@[, U:*$MILEF]Z?!EOY5>9<W6;,C39CW+C]!8:%W*B(A<DV"0%:
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MH;Y,8@Y:*.A8P 2B#I7CV23R8 (.P@6(R++:PAB6+'#!* ^NA1;2(#THH0Q
M+QC:( \B 9\,0@X 5T2"X9\%XZ.0 UL=X@XZM2 B(73%-OY( #8D^" S EH.
M#H(UI->4PZ0@ZB!:EX,U)4H^N! -[4!U$0(.."8DMJ-I!+<,TF,39E<^?)I,
M  <L5 D-*[9@H187TD ._N*DBN%N)9H2WJ!2AH(6B%8^HN.FMT."338:)P2,
M#*))O$,7YJ!>WB!@<,%  GIZ]=6ESR,-]HYP%P-VSX+Y-( +OB(8TV,83%8.
MN$J-%B,/7-J(G-8.R)&4VQ9XAV$.3)FMW<V%^+IB]AH[,D*M'P.,Y( .AH*@
M)8R0:($GE@8]RH ^:($?=>%GWV ")*%GS$""0=<Y%N,36!LG(@&Z@.%<_;8Q
MS0!9F:\]]MJ(3/9-X& ".&-*%OY)3DS6#N; 2"Q!MJ'60QY##B0@#X(!I]UL
MH\\B&!9)7H)78)EOD8T$9QNKN@47HP6C?OCQ2N# E$F)8AU"7K:#M*WU/%1
M <CQ B+E!=I2GO?;(7#A 33!&#3@S2)! M3-D\X32#;3853 !53  9J+!CK
M"P3J+"P@63S@.AZ'!1PF/DK  V+  AB<!1R )RRI!C;,($C !+H KT:%"R2@
M(6A@5300TTZ@I0['TDI@&-C%!#04-QAOGU3 82YD0#V@P2& 2TY@CO 8!$J
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MQ:11 @@P:3"&)I1\DJ%*'\PD"7W%Q& #3U]L0HE4&AQEYD4=A &WW :I!()
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M@XXR6)KA!=:(?5GI&S>SE0>X$CWXD+]B!MZ7DHSX";P3?69(DG=A!W'7A+A
M"7)).9(QEQK1"V:PB\FWAV!H3.[(D,68E,81"2?)&U"YDT[9D7<1)87"DFP)
MCPL9F9(Y)X8(2/UG'!=  ]MX'/XI-@-<P 4V\!"=V 5#%F5?( $O8 $FD$*2
M( $N4 (6T'\I]0(/(!K!H $/89921TG D43?<YB]T05O"9%Y4'HNX'W&P4B1
M@BUVB"(.$'!WX0(A6!,L8(EQ,1/ R1NU4)W$80=YT8X'019A@T>_(2.0J2NP
M&(>1$&L@4 ('D <N\0$\)@FJ90,=<$&:0&OZZ"@ZH9O8Y 661GL0L(,&P06B
M.9D(VF2Z8%=IL(BXD :"LX[*5R,39@8$ZBAOT!0#Y'O)9PQTX&5810%I@ O\
M-UK!@$F1 $I/8P8),1L0(P? P'_#L%[)EP8M&5'!( ?X.:*S81J_* EF$$Q?
ML#!D:?X0M^!$D:".0)=?<I"A!@$3D9![410,VK<)!S S$' 4%6!#+) C9M!
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MM#,Q!FZE*!+1BB+P H;@%:I6$P*R>$AC 2J062()&&6R"6EI 7)@$\:@$II
M37D@FL#  *M "[:F&M4T<5X %OYI$P$QP (.\!#^Q (NX+>%\@D"X@(#=Q!
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M*/R4-J6)%(1! [8Q,2 P$R<@$9\@/FQA0A,17^0F%L/)*4RMP370 $E*;AY
M"2J0U3%PF87!.S8@-6XZ&Y1E$#1P9L45!E*3<5,S#.I"%VM" 3/1"Q.C$D8M
MU:QR&IU1H+YX6P<1I9>!56HT-?YY(0%_<1O%  <M20%)4A[<UU7B(P&^<Q-F
M8&ES@!N0G-H\;!>7I"PN$ ,7T"\:T#QCL )@E80J,0>\"1'D!4O T$4&$4BF
MTQ>Z0 $00@%/41M =RPTK!\Q\!*DJS))N'MT2DB.TBZP,2U4533P41+5]P!
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M4//)IP"T4 8 H0%8L1H>BN4 ,8S6@S#%'GPJABL"1 EVAN6I4*P8L >T-#T
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MP?-4J&P8$6CP:;3S6,A2@S?,0)$$DDCP0J,*[)## L72F"$8"@S92"L+N7!
MI1(H@"@,S/QDS29@2  L L4LD2"II,9XK!@+[!!)I@=TH@0!LR0PRP(:2V!1
M N5> \V!,.@002:V3D4U55579;555U^%-5999WTUCZLB>8P6$#SP<*!B/*#Q
MDPB07$D2#42P@*P".P!!A*-HX74](3N "!@/(*H! DHV&2V8:QL$P0*5C!7!
M0\56 L$L2KRDI ,19DS2@[7>,/[O!$BMN\"PE>"P(%S3S"C!A0\LX,.G S6:
MH8(3-!-) Q)HZ*(#6D3H*3,>SYM# @TJL" "Y7!YUP(7C"&( @M,[@"W8DR
M].'SBJ&A Q48':,\C>#8#%H/3F#AX)E.Z,"#$G#S0)-;.BA&#@QUTL2@&4Y*
M]SM*/G$XAB\LH(668X<A@1)<.A@(6EU$4H&+,9Y*BB47)*"%"Q:+L2'-3SP
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MJ+02BZ&)30!#FF4@%BW>((>D2 )%&B$!'"3AZHA$9*T%PXU+=?$&UT0D#9(
MAB8U809:L$ ZGV@L6RB1!ACBXEQV>(-A<)&V4,/0I<!@=K':$%=4>>$$F5XT
MJG#QACG@S1!O $8'%)L'./1"WXO,P]AHD89F R,.</ 5,(:CY6&$) ^],4.S
M"1/OB*1MV#!\@5[.8FQ:F(&[2)%#''39%E2O=9%)*IX=*-X!2 4S$A*8 S""
MX:M;O&&UQI1#K%5U:DX'DXP +^,,.G"!L$60Y(JM-5&.LHHT-+<81,Q#+301
M@3=X6V5Y2$,H@8&IE9Q /A8 W_[*"I9DQYXRW1LA)D1 $8QA']$2HCY!D::]
M63E(P!#'5-DGSMZ68;!IBF%P 2W*P,JYGP4.<LAK6\X^AL"3H6+CQ@4)9H +
MVG+ $DE9A1G&KA'PXH6[2>F$!=*0[#D@W'ARB#G:9Q*83Q#<SZ^WIPV+P04*
MS( %#*"$KR= @V&\  0T8./L._"!&&Q]8198WB<H0%T-'.4#Y4V2"$[ !1#I
MQP-\H\!1OC !%Z@  MU+VPQ^;P$X#,,#+&*!?&S@@ _8 1B]FT&"5T8""XQ)
M K9OP&KM(($<L( $PZ"$7YN.ZRN!".J(,C@6NY" 3]B$!W !%XB L*"$@7H!
M"O".E?X8 PEP 1:( ++@EQH @0NT ;NQ@+ @ 1HY =9Y $B1 .X:P1G0@+#X
M"#") "X) P]@ @I@CI^R@?\S!F H <FC -.PN FP =\;B!BX !<X 0A0CA@0
MF1-X $N@A>+ FCQ8OKJ(B.N+@8FPEAF( 0A8BZ10/A7 FC2@@"ZH'1@1@2ZT
M"0O0"1<X/PW0G!<("\Q[@&*X@PC0# <0$EKPD!?@@*.0@PA@ 1:@@#&0B(&@
M! JX"P]0#0M0#@W( XZ@!1IP !#0A,R"B=HS@>4!!A&(CP=@-[7Y@/@[">?0
MB!,X"0I@ >PYC[@#DT&*@) @ PN8@0_8#)/0" ^P@SN0 /XN4(%W6R,SI 0\
M\0!*Z ( JP$1R $)$(/SX @7.P'O6#\XP*93J;^U\K8%B@$0>+<3N1F#*($.
M2*$(^@(-5 &J.X@+Z (/X(**>@#  90WL( 8D+YA" ;D>P$-& $0*@,+9 $'
M@)0NL  V"XM/Z( :6)LC(PP+R $1 (JIB(';,XT1((,]I( PV 0.X,-AH(,*
MH %1U(A^=($2N*B\>8 .D(-/$!D74#(J2A]$! 5-H(J'3!P+X (2\(#$@[V?
MI!4[\ H;, CU.) P, XXX(##H(HNX(TZT0E<<(!>X(.A\ ";\ #HHP4'XH+-
M\(#G<!0[P 4&.(I:4  B! X44?Z^:+. 7CH7^3,0C7@#H" !$%",+[@ SC .
M,_B4"/ (4TD*$KC #DB#U] ULBP&8Y@ 5&( B'BY7X$PRC@/Y%B+7K"18(
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M@<J  $BA!4S;")XX#Q.0CV"XF@BP -GLQ0C0  O ':E$DM((P)N1#!&0#])
MN 8H-!N9/4:4B57(B&+P A8 !@=P3K)X ")T (A8%!3)@7?K MRP2>"X23GH
M"9)Y >,HAC(8!C,P%34LAA*@D1=X&SL BJT+#$D4CZ0 3@4+"IT0@;?Q J
M@<;Q+$?$R1[4"&(#RDB=%3O(RQI8TARHC"Y8'BB< 1=X@0; !2XX&%P@4)J
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M" J@QA$"!A#8!#/ C!9-@RC&'EI8WUF# $M8X196#+W;6#)\ QT\#^7##6#
M1=!P#Q: )Y$@#4GX! <8@TW( Z"PP_.8V:0IRCD BAY=X,(-6HV0 2^0",5@
MH;V N:WD$DH,AO$P!CXI4!O(4DFP!!8VKD_@%QE E1?@DJ3 'AO0.!9H"+\\
ME17H3Q#H1URX@[Q,"AHXD&!3 3R #A>8!%QH/N8,C'WLB?XC9(E>* \W,:9>
MU0CG,08-\+F#>(RT>91,<P^"G0%*\ H\-M@$E8,CG5:@Y8))1II-L("!4-Q"
M+F+C:$[2%=30U0BD!-H<L(1-Z !]I"(SB  6[34OZ LHUHC5S9#FT#@X (I)
M&)8M[H473K*XX@"=L-%9DP!@F(#'VP1+0)%(J%6E^ (&D#CMI>A4H0/WP ^-
MH('-8#-=X(,(BH3E>5$$F0BQ^)J&H 4'D*0.D*1<Y1 / ##"[$4X" 8'H)0"
M0$OQ.(J1F#V2:$N6&$+57><WY9(/V*,NZ. N, [<2YP#H(4)9 L1((NOX-):
M.!ND6, S%0GPC("<@X 8JU'3P/Z$ RA,"I D(-0$4'  L\B#!AB&$O"L_"0,
MJFC.E#8+2= *8?G-@R[/8&C,37A0N&D4XL"-VRDGAX 43; 44&" M:"# 0"G
MQ@8.R%X(/]( 92D!2YB#HNR_$<V;8VZ+"!B;55  W( #!AB&/3P*,7 /)=[#
MDO0*%@#+FY#.L[T?KZ"!J^""-/GIE!X#O[Z\&LA#8TT2"^ 2$*EI;WN @HD!
M[S@_C5"!2*B0S4$:]SN/2 B00AP&&WB,-Q;-CCB5$W"@3W@ !Z"\"( 4\BZ8
MBRX!?4R M;@#!-@*","F1884_&!:VCXBGJ0%7,@#!- )VAFW*DPSUB#"I$!H
M25J(2/[0! ;PMA(P"*/^#C,8!H)4B@*P@T]0 (WX@CQL0(A ZM>PB9EE7@5:
M9$&U"HVX4EI @'K.0T9!F!(V@;>!PS<8@7I^C!/\W07RMOI+$A)@X2\5$,A^
MF61F0ABI#.+^E3*%D-Z3"19@CC$+LXHFJSQXBBY@#BQ7"@U\TWY)9B\ RWP[
MBGS#A4BP@!*H 2[H(!5 2UVIG=O9!!=H(Q7HGC;Y !<  0X#ET=QR:/0YJ.P
M@0C0"1C<E9Y8 4P;@R4=@P.YG1GW5$T8C:2 7^^1I,AY@X,QOU'JH%D;C3R
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MF^ B!\83@8@XD <YE.A6)#PD0/X#*M"!8B8''< %)8H6#+!ES4@2^,(GR!"
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M<(  ($ ;6 (#-  "T+@P4 (&)#E$8\)#)T )9#$P\#@&,/Y !*Q"#!P !#0
M)]!  JQ  !A"& P !## !_3"O"0Z)7#"!"3 CP=2'2AY!F3  ]@""$1 *>!"
M"1C F9<!%9<Q$R!  QS "O "9U^ !1B  AQYJ7\"+D@X S! &P #+9P KAM
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M0@8!P$,QX@  )MBB! &  ]0,P(5<G,  =IA$"6HPC# (H $4:  (,8B+,@!
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M) P\3, \'[B$,-H05DTD2[&K,($")O"""+1A&&T@+25648*V8D 0 ZE##NY
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M  B1YR&(X>=..X<=E[00P!Q[2"R,&!^-\1$Q>M10R0D'O)$_ 'GHGP=AS"
M0$*0 QX@ACGPH14F,  ??M&&'"!" A0HQ2\"9@@N", %#,D !?2@AQ=90@(2
M: 4MOO"%7>TA$PP[@[\TL)@&ZH$8C6&9S6Z(PQSJ<(<\[*$/?PC$!Q4M$@AH
M 0DTD 8$? $!ST$ "!!1!P54P!<N,  E+%*# -1@=[P 0^,DX@ Q6"T/"*!
M!2C0@1)<8@(4V)XA1E"V"31 ;WP#TW@$ 4</4(!PB  ! @@  3MXH@4,&,"?
MSF  "U#  AUX <$D,( %L* 5;_Y$P  @H(<T!. +O6 ! KCR  WDH0$9N  %
M;I6)"V2 =XH4$@'  )%6\.$ 8VM%%NM@FQKXJA61LE%#N& #3UA&#YN!C!X0
M< $>%8<!%$#0:;S$$ A<('\0Z( %$G ^W,P@ A7X0 ':@+L<\&)(9[#! /:P
MO<UT@ $7F( '-# '$3C@$JW8VQEH@9X]<,   \! )3[@ )_DHA>5J!)QGB"
M.6B0/9& 5CL]8"4'@( AO,B%)VP@ 0Q\($IZ"  -+/J!!E1D#IO,A4^"B-*4
MJG2E+&VI2X,XJP>=" $N$(,#3E"!/12@!H@H8P4J$ (2E&(%!U <@D;I@#EX
M0@\2./Y '7+Q!@5X  *7N$25-N(^3I@Q$[E000#T  P0-, 39A" &7JZ M.4
M:H8@R%X8VM"*-PR !7,(@R<0\0 +X(X&O^!$&_A@!RZL900+T(,8TD"2 ;S@
M#0$PGB?YX(D(:" 3#N" 0_:@U M(8#RM; ,! (0@8%4P%R X . &@!OHS*$
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MF"  $1C9M"38& H(D 8V'<P +LA%U4! @6\13P(S2%0I2"  %I1  &\@U!.
M48( Y*$4"G@ +<+03P]XE&P,& \$'M *.UB2@^C!,P8X(( 9_**L,C I)S31
MBAP4P  .(( #:.,! 1B@  L(0 =RP0<*!, !"B#R4R"MY >\**%[^\ )O$4)
MVTCP !1@ 04 8 8C*=H, 'A"*_XZ4( 0("H3AFB  T9@@&3.P0 *H, #&NOH
M"BC6 P;0'*D[(( /Y.*W:"1 "W[Q@@# ]33_^D":MUT "5S@2)1(0 188('W
MVH'!K2B%' [0; A@U]$?%M$F^@WP@ M\X$'4Q"<0$8!VQ7L.>6"P+W(P  WT
M6)Q93 !<G9D'&IQ !HK[2RG>\ 0]*',.*U#!&Q@2AC @2$8F&,,<GI")/.1
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M",7@"#R TEG@ SQPU:*@U<5P!3TPS<60!3MP"(V["%(]!=3<S3L "+H,!$?
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MU)-M!5A !#[ "H0N"B7N!"=-ZXY0XK"-TF-=SF]]U?I^!?W>X%JP TSMR$1
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MU%4.%-!)!&@ 8"XH8!,7[HD&VD!BF$Q@#GHMQAL:8(<[F"$"+B@&,,I X)R
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M,(,PX-C7+YC#%RQ<#$K0@ FD+D:KLUZ,3XR<#R^(PQA.P)"TYX#M;WA!)%;
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M"9 $,W" &*"$Y?H !." %(B $0R%)7"#73"O05"# ' #-_ZH3Q%<@5D8A 5
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M_&I02J,G!=THP66GPY6O3O,@'GR)%X6M"T7&.2 !%O@ "PL&%J" :BR&$N@
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M8 ABANB"++ZJ8= %7+ $,H4P4" #"_/H2;6P!Y $H 8&7 #-HA;C,7 ]AN@
M.4AC86WCS<P!W>H .1XM36AC%+X#,_, F;)7KU0R"CBUVO[4A/'VM5K5@!K0
M+0](U^B=2QXS@UQ+ R.;@,W2A#O@X3U<+6-X QY;V+:SLO0MAB_@:\)C@=M:
MK9=H\-JT Z"N7JY>K2Z8 *V%+;@^4ERH )RJV676UV6>!*(NADEP@-'R6: =
ML@Y(YV+P@E+] GH%CPLEL!=8.2BEA.V[QS3@L0OMM6+849O&6:Y5+@5BK@ @
M!%OZ,Q.$ 3; @/HL005  #:@+@I @"5 @0!0 U5@  9 @0P @"6(3P'@ $)
M!8DJ7(NFKTRKIT62IH=VH5!C@"Z8 \<Z@$^0@U7]!!#0 )(B@52D44QX@$A
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MCWZEXUI%HK>_<Y&N:?/#8"AL]ST6<.%B?TSD&S0 $PN $8AI; LE$,"'9CK
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MX*>VN  QW=/$7SU@TF]&@'PBZ(UPWN !$W1@$M%4 0TH$(/F3& .P)(!9E@
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MV,U?< 2#"M2 : &A$X;8&!3 '-!"DPU9 =S")TC 9N2!75%"0P6,&9R7'2C
M=I# A4  );#4' 2#)^4("X08Y6D>\S7 &,W2)@P#'#  +4Y@,7" E+ 4TVE)
M ;S!9K" OWE>8FW%"RC4!03*)R@ <'0 7P1#2_F('41?:3"3)>973(B @Q5#
M#0R-P(A4,#S.3@S:0)' 400#=H28!LP!"\ 0'*1=EAE0FIF$"$T2)OV//8+9
MNY"+/NJ>!D6$/_XC0'856HV-P,0 67Q!"4S>&] !GLE$';16R/D)7L$!!<B!
M&226"OY9GR*-P K P1N8 5;4 $/R"Q= 9'#D@1G81\J-WP=8AZ@,0P6D"BC
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M#&D:X)D'B)HE4$ P/&!PT$*D1?Y%6Y# &QA64UABM"EE:(9<5%%D)%Q 3&A
M>3&(4J[I,#SGKP3#!"@;F#B:LTUD,4@ ;.4! "S&V<@! E  H,*$"2B <#B
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M[WV/"_3&GUR #6A >^$4D8() [@ %\J0!/S5#%@ #6@ "_P+D>&$ UCF"#2
M!EB !D@ D^63"G3  PP5 -* !!?A',2N!D@))?R?!1"M!#R*'3A =S4 '.A"
MD7&&A@V#!EQ D2 '!>BI!<2D!VB (/]56P0#!UR ';GR#,#RO=A ,06  2QC
M :0A,#P  T03 "!'P,1  "C   R M5W,"P0  PR !FS&# S  10  IA4# @
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M; =DUGI-_6"M0=*+5\6Q_$"Z2#CZ[IRH3 2#")RC!WSCJ/..G+*Z\> "!Z@
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M0A.>$(4I5.$*6=A"%[X0AC&4X0QI6$,;WA"'.=3A#GG80Q_^$(A!%"*? @(
!.P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>comp_0016.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0016.gif
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M\
M
M
M
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M[^Z"2Q KUO*#%%#)5X1 KP3![WGIB9I)J-=E9S-_F+9RB7Y@\$+$?NK1.J-
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MB6BI4(X/%?$L5]1B#5W#K92G3.4JVU830]A!#W9 A-X@1'4RYH5\=+"#'>B
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M:(EYV(F36(EMN(F*>(>'F(I,&(JC:(J7Z(FPJ(JG2(N26(NWV(JH^(@:\HO
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M0XNRI1<;Y%D(#C  $& ! J  A. (CP )C."YC-"YD-";D3"ZC@ )ZKH)*D
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MP.,S, '_F@!RZP$F  @<(+,O(.USL L<( -VX-8P#+^'_/X O  ##] &-Y
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MA0-YP0$%!$>K:90):&**%Q@68_ -7Q[8118)6., "EY\F<PF$P ;L0,44&@
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MXP$84'!A@E#DJN,!"F(XCX56P?Y# 88+%@.!CCE_KBF# 7<!]A0^L)3+!:1
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M4EP3.>&:H.016#!  4)P@@0DP &0"($ [L P FB $"$( +@&<()-8&$ HAQ
M""S9+OZ&7&$33PA "IIPS$B\T@F/> 1![N (!41@EP%0 4<6H ((#& )AQA
M"A*!  P0X@0!@%A)I+EE+CLS$HY I!_<4I->** OTLGB8!9P,BK5I -UZ)6<
MP%H33RS ,'6P#0K"0M85<6 Y'E >+VBV*%[LX0'QD\%RZ/"=F^BY-7I\-"]H
M\+I>L$PNHR! E>XJBS\\(#<XJ P(HC??&QK:,#0X$$=SBZ4)W# 0XFE ?/I
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M QBT%)LX!0_(@ O8  E %#> P1BP(SD0%#D8M3V@ 9%$%([9O6-)"42HI9*
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M"(0W4/X 7KC@L*H;,+(X3>& 0*B#"_ $/_B# I"27I  *6&#%_"A=?*$/9B
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M0!*?P.\/OP&R^SM!$ Q2T$ 1EX,*!Y#JUO$=#VN;W>X?)U.UGEGHV(53<5)
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M+!.<W(N-<3X02QUE\Q)'V1X<R0L'*OMB2B EH! SC0-) (I ;&Q^>>:;V^&
M')_(^,(GELRA@-S<-AWI5VR@*I OH0!2 1R\2 "(0!, STL=04L01R>@Q'"!
MNTK+G?X2I "OU -==J^7D[;6GZ8W]YQ&Q9]-SQN$XV, NGT0"PYXT,$#A"(.
M9\VQT.'X&Y';(= &?X@L@APU;"ZS2G8Q 5((!'*\,%?_6""00+A  AGH!0E*
MT(8:L,$.B*H)@Z3WI[U ;5RAN  *[% "94W $\'#%2_L$+0'Q  '-7 #F6A
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M18DL%F#"7'!  @R 9 P<)PL"]J($D*Q ABL / Z<,9*IY(4?^%D* L5" IW
M]&ZEQHLWP&P!H3@("/C%PU%7FRVF?C@1C3B0 >U"%H$8 0!.E@$'\*(4"7B
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M "!U  W,PL?0@2P$%2@D +<U0-G,  >,@B P0"'QQ-Q=7U;@G:881FQ!7(I
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M673I036G/'51F/-IO"[7%BQLMOZJMPXJ6"CNZ$8P,T<F6E=%7B<%843OW^@
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M#>B+&RCU2.SZ5T-XC&T  ^0@0/ 2*'#70(.]#-;A8Y APX*A*#24.)&B1"]
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MTLDG/Y)MM=A0HU+**[',4LO2(ED-D4FPXR6/ .SCA90_>GEC 0=&\.V-"2H
MD1<:<)AC A6F$XB4 %RP<($*@"J(.>>>D\ .!0$QA2L]^)M#!!!N0"B..6*8
M@*4]'J@ CH&@:(^7.>ZB880.#OU$ E[V.(P7.^H0J T//#C4P(O2HXD7%Q1
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MX\4G&("8&O*B#C*4P%)X48I3Y$$"I/!$#D'HF9[\A$FR,/[%T4IQI/D0Y4'
M\R+">O=%,8Y1(LHSXQG1>$;:3.03@!B0+&( @,-<0"^F,( $-G"!$K" ;!1
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MMWRQ5_Y\@7=[K==WV1=\XS=]X==]9;=^8Y</KF!_JV!_KZ!_ =A_^]=_"5B
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M 11  :K $1K  BP@ 1ZA"0S@ "!  2# $>Z  1*@ "P $9Z@ )"]"6[\$>Z
MU!.@ :Z $DX= PJ  $* $IR  +Q' "P@NID@ <P= ]I\US&@ >X@ 1:@ %K
M"@: "3:A!0: $)H W V  #" $0@A 52@W!F QE-  .X VPN $-A:-K1M(CR!
M3]JF% K@P-QM )AL%^9'%EP@ $!H%R[  &*!#JZ/TTF^Y)>P_J0=U4OU$3Z
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M0($(N"06$9A !2HP 0]8IQ,4F  ''$ #$C9D#AS8P TP\HD1;, %%N1#!S;
MAH&Q@0-Q:(@IYA"3MOUA 3B(2=G4Y! =H@V+HKC 0U  Q:_!CX1:C-]#+N 2
M,FIPC6PL7PC?",<X(L1_.<F# 5S"BS<8(!>Q6$ H<E% !);" &'BQ2P>( ,L
M0F<.#OB$*21 +U,LH ZR@($7>9&'!72B%!=(9!X\L(L+=((7+N!#32*"@AOT
M:SN?D(#8>$$".(1' GALHRUO.3[B>%".O.PEZ>B(DPC4(8LX*(4L&!"+E[P
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M3SZ@%V^E-"_D@(!:6GW\Y/<)_K*N=>NE'R%*\TDOZN""&"BV.G5P@_WM?[9
MQ( %;SAI*>:Y"WGP!FW@!CCP7K+ !B90!\DQ"OLW?_144PM% VQ 00VA!_S5
M5X+ +P_Q!S$P![( !Z80"!'X!RZ1!P@4@ CT!RZ@!Y:0'9\P@;&P!WY 5@\!
M")X0!R@0<X;$!C3P"9\@2YT0 R[P3=7Q!B[P!A68"W#@ C4 3;TP!S+0!['0
M!K*0!\G4@1\H!Z,P@@^1!Q10?F$HACG1=>O'/UR'/VBX$/YE-(9X(@MV\  '
MU89S2(<-8X9WJ%V+\PAL6!.BE47]TC:O](</ 6-39XA85$9M,X@T,3!:-#:/
M.'4#(XGQHS85AD5C(X@/@5&:Z'V<N$H.X0LSH'%U2(ICB(=XJ(8AY%VER(JM
MZ(KA<8JQZ$M>XQ.9:$8\(5ILHQ2*>!.\J#I\N#IJ]!*^N!3"*!3 ^(IN@RZI
M>(9E&$?,6#3%\W7)2(W5:(U$\8RRR$'IMXHVD0MR0 (>1D&S,$,$18PR,0@X
M< ,W@ ,SD";GZ(DRD606 0?R=HL/L80E4 )E%8^+J$7)80>CY L1U OVB(QK
MXWZ&- <Z5$9E] GZ=8OS:!/&V/Z/#F$* V-9>S!4@'"%#A$+=O! $/%;5G2/
M_2(*19A%<L4+HU 'A$9I@M"1#?&1(<D+(UD3N= & '=*)4F2O" +<T!!?T =
M8S21,F&,=:"2!SE=VMA+TV.&XW83UL8!=H '''!M#5$!H[1;/1$##L!5-T #
M:4(4=J!6N<!2.B$+%, !>4 '#I!-0A$G-F!*U-80I3 !M/ =:B,*"U"!/Q$1
M<I!N-+$'^[84L?  T%1--8 "%/! 3]<!I$4=L< !-\ !R>0'B52+O% '#,>!
M8,@+<% !-6!\0"4"'0 ##:!8L] !-[ !O]6!]Q@1O!:!V]%'"+1?F/D=$B!@
M%)EM3/[)/M!X/L#Y2TKI$"KU$"  <J,@ </T!OAD!X<E"WOP!QBY"YU@7B=&
M=&M#"C!VD;Q "WL ",EA681&0 UQ0..T :6P"WA9"N9F2'T5"">H3"+@D:*W
MDG8P"I06"U;84IW@!W%R8:7 !RI(:+X0)VV0GKP " ]@"=8QG@_Q"7B@D@T1
MH'F EW[ 8#X)G@-S5G\P2J:0!PPT"A?@"WT@E@TFH11Z0*.T"_'Y;OU"!RC0
M"WF0GPX1GR?U!A=@"KF@GA;15[*03+D@G6,3"WE :+NPGWMPH@W!!@Z0 ,FT
M /.W630  @U1>!Y5$2\0)B! $FU3"G8@EK[ 5S3J$+*@!_ZFH =5&A&59 !>
M1 KNUA!L-6!52DT+H)D@%P.R! +Y"3^SP >!(#8L\ )M\PGX*9.^, IY$))G
M%0ACY9T_VE=(-P@140H2@)=Q(@-M, MX\&9(EZ&Y\ =]@((K2:8OD:BUM LP
MV5<;( @-4:AX) NTL JA0 N=VI>XA#["^9N^F3[=*!$N"8H+P"^ZV D)X ML
ML  ;  IU( $RP (*0!U=) ,JQ387X (2\(Z\L%X^Z0ON&5/:"@,K20'3"@+F
MM@<2, ,<@"]0D$TR@ .Q0 $/, .T\ "K\ (R10);6@+\E)]QX@L+\(X1L9_S
M=@$V0 '^] D/$ /V50,L< 'X0OX'$3 #'M !,T!:/S4"=# +%>  ,Q +*+
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M/K08$X%0  >0H4[TI ^Q"J3'"Q0P2F_@F9F[ ?S(?[Q 10C9>QD 0QP@2!-
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M3U<=5[UY'?UUV&./77+&:2J<=M%QEWWWUW6'?96R>1?>[M6+1RIUXY,/JM;
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MY52K6_Z%($_I&,=;H3 2$Y5)18V4$E,0U7(E0, (7+ !!>C&$PBHP!S<0 $
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MY<*MAA0<>(JO!WWLR_E-R85.8?XK4[(' ]2&%W[=12P6X(E9G.(4#UE% MJ
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M*870@PA2V(#QDX41V(-<\ 0#\ 19*($." 0<R ,YX  3 /X4YO( B*B TZ@
M. $169B%7"B%#="-!^B.7HB F(F #OF$".B^+'$38SJ%7I@%&? -.) Z7G@
M:;L!V2B%;[$#"> %.)@ 3T@N7G !&4BN/5@ LXF -EB%&&.(.?,$!VA"7H"]
M(N0 #7L K*"%!UB0"0 X!#S$EU# +H.L47B !WBS$+DVBEB--V 7!J X7NB
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M!'3+2/(>40*?/.,OH5L 0]12]>32$6- 5ODU8W,;S"$6,$,E=Y&<Q/FU6&M
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MZ)=<$ 3"TI=1B-C%[#62J39J"81.B(I9^(.D EA98!LWX(!AZ9!8 !& ]01
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M:7.!?:0#.+B(L./9=2U$63" ^_"$D("#\W*#JW4)%'  $1!,[0616;C$0-B
M-L@[%Y %IFZ..I!<2W" ;XD A=4#M;3,7#  [DN0ICQ,@^#!";@/7XB M(BY
MXR"(MJ:F NA J)S9A\B#ZH@_AE",%[AA&ZB2J&& P6P/-H"3H6[*\..#L@/"
M7BB J;(#@MB%-=>C'[)LI,#T[UD*3;<@.^(U/ "  ,B2J+#N62N%S^8%"JB-
M-H .-Y"-!I"!&M!%WW@ #PO-$EB%3VAOB-"#>B*,!YB!6=\ %P %FXP*-H".
M&1!NXG;S+HR%/A@_$."3&W@!!_Z8%FNS-WW!@9+LOF=."1@8C#;_T!^Y@-JX
M9LR2%#OHS*_<!5!8 !R@@39H #KP[C:@ 1Q(@$#VR1_9 +[SA/F-@!BX 2BH
MD8[H#C[HS!'( XM<JSK(@P>X=R@PSBN)#YI;USD(47ZW' D8!1?P #:H@1B
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M((N5X)AYCS4P"R\1K*B<*:/DZ9P+DLD!$2\54-3)8B9T^88=DX4T4DEYR")
M9;,L$(HI#FP6BPLS)<?+)QLL%$@#%=&B4AX&B"?( C/!QTL@-/"2!VD-L?'
MHRA,(),)-40DAY 25*;<*+$X4!::?T4D 56\^+% +KTP@"(M#^317"<D\"*'
MBR4\&OX1 WOP<DH"H2!;UJ8.D<:+&]+V!((,$9FB "A#ZL78"RKEX@$MIDS@
MTZ=_Z2'!7WTXP,MMF]GD@!Z\Q)* )[(XD%O"?#"5!TG8REJ +'TLQHL-\+W
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M&S1'+!+39JYD' 00,*XF:N[FH=F*3%#:;JHF7XJC9^;90")E<AY(6%H  2A
M Q3  +0 )"!"K2V(N"V(L5G8LW47N/$7)3#")J@  10")=@8N$4">%8GK5F8
M(U!")!C;<M&:>S((=XXE4!(8:P:(!,! ']@!'O1!2X(('_XL@!O$P ,,31R8
M0!R$"@OT"4^\T6P"B"@T0 VT@0*@2"]X@ C,@00 "WD\@ RTP0)DRR=<0!Y4
M@'C P;/P5D10P!N<S010A)8(Z-6X0 F%TBHT@$Y-%@S0BDU("5Z5@!S5:&/]
MARPL0&$JYY*:5UAB0 )<@2/<@0(P ") @A4\@1,\6!/< 81@@14@PB-@P1,P
M02) 0B)PZ2,40A,40B%D@ $\P2$PB!5<02%8 2,X I8ZP2$\ B$TP2%8@1,0
M@B-$PB$X01,0@A40 GQ>P1,T 2(X@D_>IW/E)XA<0&6V!2C$ ATL1"?<0!TT
MDR>LPAMDBR"(!D\P39_, $1X /Z)7$ L!,*GG$T@2  .>-4< *9N=0"MS 08
MR4&[S(("R(0(?.@?,  OL &PL( =:.@W1<0>W$"QS,E<JL0@2, -Y,(<O(#-
M*"EYM,$;^%1$]$&T9JHI0$$="&,I@( )W$LOV,$-*&DID (I/,HNV(%U@$)9
M] *T4L1,/$ =Z)0HL &U^@(HF (.D$@>L($^C>L>-$0I--$HY.4GE((?W(!,
ME(((E$!@U@$+E((-](%*S$(<L$$3R<(<L $*/<:W6I$@V, HM-%X6&QEGL(H
M@,(-A"Q/#%4=L$%+>0(.H&LQ3<P<R((>. "E0,P;M($BB0*L"H(LB((GW  I
M],(;S/X!L\B"'+ !9(HJSUK1S*K$*;S!&U@1DYHMUM0G!A0 (6P"(D"  B3"
M!PP !A@ !B1" S  (R1" E@ );3  4"  31 (1#" *3 )EA! #!!$QP  R2
M%5 G(C  !#2  D1"" R !? M)3A!YB;  $! (AQ"! @  S3  #C!)OQM!-0M
MI$ZJ@%4J@.A!MOS'!<QE*.0E*"S ")A U59 ';C !O1"+SC "+Q!!8  #=
M S!,142 :()"PJ#/1YR""=B32L@! VRL+U" #'2HD*B$'RB2'02,!^A,61@O
M+S2 3,R9 Y@"\/*"" !"&SR*;:$ "-A!!^S+'#3 ".Q/1/[, 0. P"CHP0+<
MP!LL@) ,@B.QP:ORQ/WF[Z>,@@' @!RLSW@$P@1D0+9P@ O\ 0?T10 G[TJ
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M"$) Q_X" \Q"!M\35<^"!.A4( "G!!S+ GA$# "%DBQ40$\&*/A.1." 7J!
MZ92 :BR'ZJ3-7^BS+)Q"L30&+R0 "I5"2'  ^-Y ]"S W\1/<X202DB )?R!
M2]-!;T2$(T5$#.Q+ X@5!^A!+GR)PDC 9H!P1.A!0?NQ2+AT!3B&)RQ&*2BI
M"T#!1]!N!'R"*#C 7_@"#.2""%@/&[@(4:+R(#JI 4! !%C "B3"(U3!"6
M!!3 %1R" +3 "AP (W3N4T:"!$# '1"S,2-S"AS H#IS!$" (XC;%1@W!!#
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MX ,*80 @8 4,  ,HX0,0@ $*H!":0 !PD $2P(0B@1 0(/X#-L$) J )F&
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M G:!,48!%!B@$V2! ]+T(B0 #G+!!?X#9/R 0'R!!B:@#WKA J)1#A) ;#Q
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M 9PO%K 4!RIE%O*@/4!A*TAV/6Z@4F2!/TQ@)&( 0OKS-TCA;'F! ]2#%^(
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M&L%FK@=1>C"@V&. "%"#3C%X,(I:L0!B@""EB'!@#1-\QPL@MG72002[!)(
M'UOE),B'O#@0B$X.#,)+6*;@,,%6.N5AHB<1S%'BB25:PLL#;)!"0P#%Y62*
M W60,@(*O,2R0"P\R;( #KRX8(-.*!PH P>A[+' ;9YY,((L>ER7!VLFW- 3
M W.04OY"";SP82(H$Y0EE$ZR3% 9+WLT( @H$I2%ERDT%"#*'A0\IE,L"; @
M"AT+.+8!#*:0UN9UO#@)E T;A,(' \5%H%2;A?)R01V?+;!?#*O,80 <LBC
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M@B087[QW@NHU=,OE$DA'5S?P+3DA"\#29YU@?-(V&Z1" GH@ Z2"48' !X%
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M'. !>--LZB8!Y">!5:,?N7 !%2"#&0 ]'<!E.L$!2I$3)F!Y;Z <$Q \HT
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M"+<1.YX[4'0P.%):!R70!\>81WN NSHR"WGP"2[ )'1@ C/09X* NR$8"S9
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MJF=BRU(&?)JJP*O.B(%V-K0T978@"AP#.SW@*6=@AE&K +O8R>MOR8$L!$[
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MAZ8E<]C '"-PV-69@ //D04N/<"H5*$@ AH:B!X\((,)N, -(& ;+V0! A&
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M%! 62Q"6&BB;S_M !^"QDI"#J'"("# %%B !.7 #&F  69" &G@#.1 !EI
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MBCM,/SX4R(',PT"\+X.4+;&;JT\H@)>0A04@A;^HC%A EDBLC+A3.@=(FPK
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ML($'"( 4*=J!F(4 B(KV 0$$6)>@"@0 (-S#%=V,#=;%K=JJ*M92#( CU ,
MP,,YJ #B5$(/P(J.21% \ #BK!"H ) V< %:8($$<(!7:X,%8( 1>(DYN( )
M: -=X 4:P($\*(%3, $ZN $)H ,/V8"\](#L^ ,/.(5.  #!( 47D( -P"<\
M&]WUI=?$M5"U9=L &($RI0$ J(,_ ( ;:%T:, 4 P D;  !2& 0 \( Y, #
MB $ <! /. !9: ,#H("/&(@\</Z !;"A-P  "?'?I$" !" !42" ! @X!)"
M$B@ 2MD#^ZT4 /@$4 #=I&B8$@" 6,!?$63?&T97]]7A],FK3BB !3@ !
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MA@D.?F2* ^O9U@41P[W2 QH6TC<B2,LU9QA:T7G5!@>\L-4!"+N5$I1>=;V
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M/- @"'Z4PL GH)02P1R\3- M0F^<-B$+O$0 <@2\R/%Z!7O.S L<(QPD2P-
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MGCFD+C, 8(@78J)X\M:V \F@5T8A!SFL=( N O%6[- ODQW$#BS8@R7*Q M
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MS,T[FG,G74FD4W.(7^[86Q?-@09MN)1M*!IBV)BKKW4=[ 4/LPNU/J04!:A
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MR4(@S!XD\LG=[((HB,8+:!A$!*!5?"(G?I=_>")-=%HJ ?Y9/6(/+U!=U3V
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M0E2MN<:I21P.R8*B3J3LDT2"!7F:Y!R'YY6%3<E"RU3%I0AF6>SLI:" 1IH
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M?!,HC/XG'L +.4A !BY00"=*08$'8(H/$J"!!TP N NXX &?B,$&9E !%[P
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MUH87Y&(#^LQ%!3[!!DSQ(@90Z 41)3HQ7CR 5+V 5FW$]DYNKN(!P91 #5S
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M,21@96) O_A+\**$OT# #^R  T[!OG:%#G@&W?0@K@@*@XCB#1*EXK#H$VE
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M%DK B=CTM1CR#>@@$*1,T+KOU'[G0I\D%DJ@%\[T%/".8EH-(TRO-MY@<V2
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M0. + ?Z'FDP@4 :A$3?@!?02@DP@%O@ %#K!M4:A1RRAQ+,,D6N !$H@4'#
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M1U>?\#);*" ! E9"'"0H6 2F[+$481NL)Q@O@4S ("_*Q2(!5)]<9\)' U'
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8:(JGB(JIJ(JKR(JMZ(JO"(NQ>!@! 0 [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>comp_0015.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0015.gif
M1TE&.#EA_P)]!/<   H%!1(*!1,-#! ' 1@1#A,/$!82$QH5%1X:&AP7&"$=
M'B,?("8B(RDE)BLG*"TJ*S$M+BXM,C,O,#4R,SDU-CLW.#TZ.S0T/$$]/CD[
M14(_0#Y!3$5"0TE%1DI'2$U*2T!$3U%-3D5*5U)/4%524UE65EI76%U:6TE0
M7V%>7DQ49%%:;51><6)?8%ED>65B8VAF9FIG:&UJ:W!N;W)O<'5R<WAV=WIW
M>'UZ>X!^?P!5I@!;J0%7J !-H@!CK@ADKP9MLPENM )GL YRM1EWN!)MLR1\
MNS!_O0!'GUYK@F1SC&)PAVM[EF%NAH%_@"V"OG"!GG.)K'6(IWV2M'J/L#N(
MPDR6R$>2QE"8REF<RT..Q'Z8P&.>S&*BSVVITG.FTWVRUUZ@SH6"@XB&AX2'
MCHF'B(V+BX6(CY".CY&/D)23DYB6EYF7F)V;FY&4FH^/DJ">GX*8O("6NJ&?
MH*2CHZBFIZFGJ*RKJ["OK[&OL+2SL[BWM[FWN+R[N\"_OX6=PHNDRXBAQH.J
MUX^IT92OV9&LU8FXVI:RW9"^W9NUWY"FQYJVXIRYY9Z\Z9>TX*&YX*"_[:"Y
MW\&_P)C!WYW%X:+%X:G*YKS7ZK;2Z*7%];'0[<3#Q,C'Q\C'R,S+R]#/S]#/
MT-33T]C7U]C7V-S;V^#?W\#7ZL+9Z\G>[N#?X,K@[]CG\L_B\.3CY.CGY^CG
MZ.SKZ_#O[^+N]O#O\.WS^>?P]_3T]/CW]_7Y_/____7W^0
M
M
M
M
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MF(F,^(F0J(BEZ(F:>(J=F(JNB(BL&(B4J(J,&(NC"(JT"(NB.(2"Z(2^^(O
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M=_#+3-P'!DT* /T)_FRV';T'*= "K: &'H#5L% #)& #BFL'>2 &7YT+;/
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M  !FT <ID,(OL  WL GMW0=^, %T\ D,P"<V0-T3H >B0/X"E.L (= ',,
M:E#GL<L!9D *3G"[+]  >E#G>N )$W #UIJ& DP*GX#M<, !K7 '$("NMM
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M1TP )(DR0(4<*H,&*<@ R9$+)G\0//@#B4F F@<R-"H4X0$D%@?^9#+)9(L
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MDTX;3J#,#P1RZ43$]FI(@49!"7V0+Q'9RN4&#W.QQ8Y4)K"E S7 %*,#6QZ
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MQ$7D@[M8@QN(EU"XOK@X@1:P$$H9 VLIC):D@4^X@R&ZOD5,@1=X##U82CW
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MN$ W$S.X!4] @.44C/-8 Q,0,QUB@##+A9OBA$+/A08(A?$!GL!<D4CYKUC
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MA<(6-[2!!.>0 R#5BW@3P:+ ZF4&/=B $P3I _P>D@HHGO[1#S;H Q0'@D4
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MW*Y'_2GG[H)\"-Y8;)VY0/! )M"T3C3@(2<@JRT88 L\5( @#AC%'""0GE;
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MT>48C $7L8! +-;@SU55H&EJ:/OU9D>*46 :%Q20U1Q$@XL0V&%L,4C!"RI
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MO[4"9G5"'[C"&E29*W1 "-P"'$Q [7C !S& 'LS"'#Q LH 8ON2;[ @$+C3
M]#C JAA.*DD.'1Q ']@"27&4WWP" Y3!<)*"*/AF/;Y1&XQ:!\2/!CB!%%8
MMS3 ,7I-*92F+7@0^EQ<'PQ.+HR" J2"+3B! MB"&D0-V-0+"<!"P!$@*2!
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M N2#H,:$'(0><  %4, -Z$+JE/X "9S2![3"!]C NQP.#*!.'51 ^]1 ",0
M'O2D&H 9OH1 !W1 TXS!V>1"&5@8&W2 "= ,&FQ"J@Z$_VS"#!#/V-8:0KQ
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M"6Q4KZ9.QEC V;@"\:A!Y]C!B> !/L$"1_?!66^$L+]$=Q/)!/A+>O[5!*0
MQ;Q JCJ!PG' 7]%07_U^ J\*#"3]B<S *;*8!=R"!>Q8(MJ" :CI8YV1E7N
MO] !C!5_&N/3<FUBQL3 JMP!C-G!@>>"&VV1UYA!U.@/*)"-^_D!3E*,+4A
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M5NJ@)TA! 9"C#([C!7I"#SJ #<3 F1*F#R*F(\3 QZ1(.0I1"+VL!M*K(V0
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M5*$C98'&B[KC!D*A%<(I=FVE!D;/QY3C<?7V(LQ @4?A#O( %^B #6J@#O1
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M!E"V!G* #G!A#,8@!H:W!F!@J5J! U+ %43B#F(@!O: #D)#F9>LU]5@%F[
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M8 =P8 %]D =Z4 "NP 86LE8SL?X)PA>6A/$ ]40";U$*$^ 19J 56M,':]
M;8**HD";)- RN! *H-  >H '?@ !H^(@&& JZB<)=# ![O0 )#$GZ^D1#^ B
MGB!\)S"/P;$&.50#&QB2N3 !GU 1:' =P*9RM F?8B":N< &%> '>+ '!J :
M"1H*FA=3S5D1H# !N% !3*N!,6<+DE '%9"F-<$'!4$'M'>(., !+;,3+S"/
MH^"I%M$';=  G@ +#X +GE 0ZD(2#] 0"1H"M5$#$9,[>A<*MY "+2.N2GMV
MF^!\:D 8$^ P>R #I%<>.6 #LP #,> )=Y!#=&!O=S "L&"=+8L!3& +#3 2
M][HP??Y@ 3G0FK:5 F9@"XGG%>8Q"YM0!QC@AS9A$V6@%:U0@*V0 I3S E;4
M&4J3"ZG  +F@>@@[!P8 %Z!! :(0"Q(P$K9@O!@0(6*0+*D@?#,0,4H;54>W
M!T=7$30ZF!X1"Q!@:A@ *C40FEME #OB%V7P +I6G_-+$@)9&-H8 QYP*A/
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MGO  .) #?)X+#B!6(!\<;# !G=7N7;,3>B!\)=D:#7 #8P ![UN)#W #9=
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ML%H91: 8Z$#T:_SS#WEA.R$&DZ$4H %SA6K% S32@>T-BG;]RD4=/H"H,4Q
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MQ6M)')$63, &.&  8>3;E$XQ6"#:LP4&8A#!N"%0(!8 W@0P$+>&4,!^:FA
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M%L !6'A0:80637,)'*BVW,H(7)@ /<!04WT -7 %6-@A!WHS)QB=!\@,26"
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M#/"$/@B46$@!%<*! TL%"Y@4"A"@NCLZB6C@$I"!W^PO\0F467@!"E@2#OB
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M"C@ :!+@B%.3CE\F@1NH P^(FA= 8I/F@!F8"C7@@!.8@QA  S^XKQRP T_
M@!+P  P0(!GX@!AXO&\E@7@[,6>2E X0C9PV*!/ %"7E@!K()=[S*_8S*!+
M -1KB/XQL  +2.H3H:ZY/8$/R#Z!2*:#7B( O84:\( 7>#P\P 48P  3X%A/
M^( /..O]. $KFH46.&DL"Y<:^(#+YD.&^  :* $;FT8.,($YJ(&958"&$H.3
MOFIG N@Q: &/N(,\;8@:6(E6*('INH,.J%T#TX 8Q(,)L!_>[@ F7E@!LI5[
M[0 2T!)JC9R&2 $@L8.910,+P( 0F&$G@*CI"P$F-M)<"#U" 67AHN]5(83C
MZA-"8@D3@ L[(*GPL)T]L1U"LAU<$/ O0?"DT!-8V&_- !,3W1,'=X@3>! (
MT*L#+Q02,*_K69+-<(#K(? ^:0'*T8@(YQ-M?)8)_P@#FOX%FYD/-L!F@= K
M/CGQU% C$_<3!8?P%0<3 =?. 1]P6RGP!.]Q6/"5_1[66S">&R^,.:" (6=R
M<!04&F^(6  6&V?P1-GQ%Q&(%(A"FK5OKR.N-0$N5EPD51'E1#&##@B!#W@*
MJ]D888%$2=$00AE<,,<6:\QS1)F%D]H88^MQWHES0O>8%" 0<0D/'-@XYZ$8
MFN&Z05FI5!3S53ES2K^3/*D4+B]TCY'RB(%T3@]U41]U4N<8_;3T2P>[_BQU
M5I>>5G]U6(]U68]S-.$?5D3UKDGU_<SO6>]U7_]U8 ]V84\4KL%U76]%DDD$
M0DB$86]V9W]V:(]V44\38[?O:OY'<_OF=6G?=F[O=F__]DPY=D.J]D\V&C4'
M=W1/=W5?]VX7=W?W&I)Y17:?=WJO=WMG]7<G\U.Y]DH_FE7?$Z(8E2NVMGT9
M>#XIA?"@6$5IA0[Q]5L ;T$Y75BWR(G94&N!^%OH P&WLPZ$>$<SHR^1>$39
M]$T/D]P5]&%/!90G%%*H<D[.=YC/]5/9V5NI #&%&4&QSOW;%F?9\ &:\?K+
M!3A@ .8UE$]P@!=8^3A7@V4$LY7O@U86UU)7 _/R!**D%5#O%PKPYC AA0L'
MFA&XQ.5\7QGDU6:)@5;>$PL0#:[3 PVHY9]P H@. >4&MWD&C!P >8U(A:V<
M#SA( _YY 1A;B(' B9E0$%[U,+RL#Q8.( R5445^C_FB.?<OZ0,/^(#=>G!+
M$1<NMPI2 I<9L@5/*<4^<:%<: $ 1<=DV7B[WP\^T86E0*DO<?DL5_ L3W"9
MB0$-^@0PZB5/KX/?HP#6F7 !+WG7MQ3CEWU+69(9$*A; 'WEAW#<]_'C!YI;
M.-P)>1&BG'&P\'H93#\!?[(N7W[U(*'DMS8& (\!R]I-V 1/F*Y8("G+93:^
MQ1D:7S9DP0$8/9$]<?GQ[T" :% J%\&"!7'9,I@+ED*#"0W">MBP(,.)!#=!
M4 CK%L%8N"P^_&APEL2.N3S<H6BQX:&6+E_"C/G2D<R9-?YOUJ2)<R?/GCY_
M @5*Z)%(BRG0J#&1ZV.?#AP^A,IUJX;3,03[?.@0PE,N4#345)@EJH,%'![F
MY'H!BY2,,A@L^"%HQ@())S5RA:BCYP9!5RE*XHKAZHZ#"58_WLEQPT*'J+G8
M=/@P(Z&8-B/,D*(  4:N31XB<PU58PT%6V;$O)!PQTR%$*YRA2)!HL.>7'=L
M+/;0:ND-#AQR7/3P@00IA3@Z=.!+!P=!/S,Z?Q@^RK:8&R$*VGDPP4PH"V4X
M4*B="TX'#S$D@L( 06T',24DH,E%:@8;"JY@G?BLAR"GZ"-$'90+'G<M])<G
MPOTG5P@AG)=+#718D-)2+3@FP_XFMISP 0=X+"5&=#/@@@<$$(SA2@RY]%%#
M#HP!F$H)%LA0PWX?E2*#&N#109 G_D6U1PY.>)#+#%S5@5P)N^6BA@4AB&%!
M1;:TT( 'GMPR0P@>6$7* [G8$>0G"WH@WD<SQ%B!"17E@)P8!%G !VPA(-='
M+C!LDHLG)22D1GP<W6!#+KNYPA%!=Y0 6P>Y<$("+B',,I$8'G  8BD</'#"
M:[GL(<$$?I9RPFQUH'C#&!S@ LN+,LR08RA7?L!5# UT4*="-IAQP@3 P38;
M;09M4L,8&&!0IRTVD/ !<VJ805 H+^2B!W(C%)?BH&+ TD&EESK(R2TQP)EL
M09O(X/[$IGJ$0$%*MUAG[$><<*"!&!JD)$H(T7&R4D%!Q:03OOORVZ^__P+\
MB+VV0- *+ \PI&4?MJ@Q 2XSE !+*Q+8 0L#"]/Q@"VA ' #)[90H$8L=PA@
M1RX+D,)QQ6-4D$L=$)#B5T8DT.$* Z^I\8%"MS0 BJDUM"*2&@+L 4L.%-B&
M04(S^%E" W>T8AH'I&BIARW9S<*Q#76^V(H> K !BP=\A0 'BDBOD8 GL)!P
M8@TAP.(*!7#$ @%7=WA0U T?Q-U!&:TT$$LN*90!"P2=V,9!+FT(H(9C!<K@
MRB@'S %+P\TZF8L-=WUD2QI3YS)!Y)XHT HI LRPR:)JR/Y'@<$3U'E'!R6E
MPD!QY-D">RYY8&"GTKF,P$8N#W#0!T,?I< <*0[84D)\J;CN20,$D=!'+"G$
MT$HH#+ALP":PI)!"+LG!XLD!K!-4B@ YP+() J'D7J<>%M@& !J@Y&*W])[8
M\FNS#8@"%E&2B"<@( E;K$$IN9! * [&I4-]H R[*U1!:M" M9W@!+D8 P5)
M(#P*'/ !=+!%'Q@ "S(EZ0!UBM!2!E>#%'0  UQ92BD>L!M84* /-EI#V-QD
M$#-@H!6Q*,$,;@$'"Y!")+"@00I2D8L86"44&=%# ,SPB5R00 :P" 4"S("+
M"=1F$TJ38A\:I9 *E, 5HE# )_YRUP9;^,$!4?F('@! !UBT@0&VJ ,)"#*!
M3WA"8YJ3 2D8<*'+T:%WN3##=>A0 5)(A )^N$/OQ#8=I@B@#ZZ P =:08?I
MU>$ZN:C )FXA0EC (9.XL$ >.I,Y>^TD$3S1%[YHV2]9 BR7N@R8O>PP :I!
MH VYR('XE&6XXN3"%:TH@P8)P@$]:*DY$RC(!\Q6L% @#3;3+ 'Z0$$_$K!N
M!&O(!0=J4Y1;4( K+Y"@2-*@P.&E GM]T ,:%) +$WC+93HKPSL]8(=6.* @
M)1AG*R:0D#*(SQ:DT ,.IJF&9K*A4 ]PC"M2P08+2$(/>S# #&\! <=X0@+D
M;*4$;/X!APID=*.DH$.0 C0#X'Q"I/+)2 I>,$\U*" A'\%#2R> OUQ0 !2N
M:$!"0M$ />2A#Q)0PQTDJ8<^', 3K3 #&G*4 JMXH ]XF( D\ #5.L&"$W6H
M0'PF$!>#](%^9I@!+!2 U#Y08 P'F\$=*F(#/TDQ%W0091TB)L@GLNXCI("
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M!PE$1 9(*X'P;#$"PF6:(+B@P!5A8)6"@"5].;4!#0ARM5RH^2-TT-E6"^(
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M&]B7*WR !<3 ![ .1Y0" Y  ,W% 0L0 !C!2". "&SS6>=D"![R &6S'GT
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MD(+VL/YK*_#9PEB )["!&6"8H=;!&/A00:R-'BA70:2"&7SK]MG"'D@"*7C
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M(( GV/Y,"7S 8%  &L3 ""2$(X'I"-PM+-0C+D! X4X F(8 1\0G'8CHGE%
M!!4$!P@/+D@ +P*Z&%  *<R">)J! GB"@E5 LGQ]'PRER">+:XK!!&2I,W$
MU=5C'4S]#'S +0!4L:0""]E 5,:GP_U&"FPM1_C2(G5 &WP !7$$&DP ',Q
M'^U! Z@6!L!9)Y9!!8R!+=1C(%)>V-< YE$$+$Q?*6RJ]VH0+,#"!L87T 7)
M:,CV1/"<&4"C+? 7!PPM,+(Y 3^_T2[SYCZ<RY >SY "'/Q50=2!4L ^*S:
MY6C0!+"@K2)?_ZU![UC YM$D\C73GB7+)DQ3#? TJ*M?+OXPDQLV'T$\0)W(
M4.X!! 9/N=1@R)7+#(E<%NX<G%$C%ZY<KAJ0.G@Q%X8UN6[E$L/@18H/#TC-
M<A BQ8D&.##FBA&CY4$;)PZ&:G#K!<1<(]J0FI +%@1<.5X<[$,AUXL01A_8
MRN6)E"2DN6PQL$7G@\L;N>YTP"@QQ9A<-7)$/$@*0:B#$O9XDG#P5@-8>!C
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M>S;1@#+H5E41"@$>*R"6$=3@%OZNZ( D9E&7RNKA%A" @RWZP("J5M,6=0"
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M_, _H*.#+(,-0$$U/R$R-20W4OXE!A8$(_8@)28-%\H@!62 LCHA#^R !&[
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MJ_<7>>H0N-5+!#,AL]5;OW?6(B$/80 S9L$B6N%)$")&VN!4K<H6SHX$2>$
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MA")"4TL@#9[B RH.(CW!(/#1R,P@!N(6%]@E%=Y"(GQ",M#@5I$"']N R28
MAE_X(CJ #GKRA>_F 7U"BTS@G)>+#41!;$+BV[K#/["%HHO& W*@%$A!+0&,
M%$H!B/[J3P(ZH@R*4@8L1&M$H2</HBM:H :0PG_&)VGL@":< @/Z( 8XX 5:
MH 5HP)I# 1_Q ([I*05JP )LP14DH#,/HA,F@.4.@@1$E[?DS@$& FDXSRY,
M0!0^H!.&0SA^8@O!9_-:H@/J0"+0H -D( 44HE.*HVY<@0A;0 -"0C#8[*%
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M#&[!#+SB!:J<#1R LA@@1W"! 2A)BA_ 2#V .T:A:8.% ;)&0!@$,%K D.=
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M"YS0 3)P<@71"10  3$ "Q9 %!" 7;GP@2E0 517%H>6"VU@ 3+ <R2H 2^
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M6,@!5[%=$] &ME "!LD!P#8&'R #%" #./ !#:!,YRB9)_ZP:62I7WA@ 2F
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MGNB#*)E;8X 1K0 !4.&V;<IX)=%AK<D(ORD #B"; D %F?[P!P2@ I#P>0(
M"/E78\)IN0KP!YD0!0.0!+1791>P")G  ILKG"O  A(P '^P ILK>2@F O(7
M /6W"!$0 <O) (40O$R@";;W90P@5L27!*B7 >?Y (33 )V7 "B0"8E0"([
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M\!4+%/!J=E")X<P3>M"68P!N=O  )&P&"N"*_'42$\JY%K8 $R";F <)<6
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M#M  C3 %O$F\QNL(#\#PFC<%5"  (# (!P "BR '*! %C$!'+'"_@V!4@%#
M*$ %$9";KJT 4L":%P (2P  2D"B ?A?4# (!"#8 1!_(F  W5FCC0 %*! (
M.'4(<+40I<  D<L3+WP4HV"D&IX0:^")W Q,W-P*G0#'L/Y0 Y'!$QA,"@E0
M$'2 L"_PD2)(K05=S.W]WK45 G@U!H>Z";X8 M8F$':@%9TPI&!<SV+@AA3[
M +H:T85J!MW*^K?0 9&K /!8:%DNDE/*$Y^ L!%>$)P@M8QH!K;P:1V $20
M7Z4: ZUP +O4 '!*Y!@K:J[  -/ZL4:J40R J]U&%2%@"[80"AB K1- "G3@
MB7TU 05M X1Z_J30 +: !P"!(=<M"7ARY<*@)M>$30=EM#G(0:&M7"G&'$R1
M!I:!@WL8Y*K!YF '-+EPY7H8<<X=#@<]X<AUQ\)!FA0ZN8(P*Q>I![GH5#A(
M1R %/QAM'(1#9^/)/A]KK!G9AOY/RQ<Y#E:M2 )4G@1S9CV(E6L3AQ"N#MZJ
M*"/B10I]<NG1@/'BA!D'2>2P]0!6+@YT?';(%>/%P1PA%MX1>P"6GA0'U[0\
MR8D"S10&S.1RQ4#,P5 (_(JMP.'300PB,<8PB1;'X%8'=&Y2\+9E+EL6<(12
M8R"4JP:M#LYPE3=4+AN7<Y6 B59X+AJ-<XT!3%.#VEPO!F,P"/+$03,M:]2-
M-6$X'< 6H.8B<=3)]E(/2AVDX9OF?/KU[1_"CW_1$@8$ HA0(8)&4$C@CT48
MD4."!!*0((Y&J%A @ LR<& 1%!3(P  "5%CDD$0.B2!$ Q!0HI%!0#@@@0.2
MR(3 ./X6<200!$1@A!$H%D#@@ P*622""PJ!A(D"E,A$!00 .<2!#!IIXH %
M-H@@@QXCP,_'1OZ(X( #(OBC$2@42(" "P+)KQ 1$E!  29,M$" !<ZD(I,D
M5 1$B@6T%($01EQ0X  %5(#DCP10R(0) IC(1 0$NG3A  0(0(&0_ YYY"3[
M6G% /IK&L""%"43B9";Z/&$ !EO$HPU5,2@X88*23#I.I!%"D &'"MKH X(4
M0@AA+QD<<(LF&1KPI(WM<DEC.Q),L^4$#EK=8R<,2!@! U+F,Z,"3TTC18"B
M<N&#@A0P4.N3R6Y)X=D)],A%C E:T*"N#S:#=0X$U"!E OZT0*$ K10T.$$"
M=FDB@0$*)H" !+-:X8 $$C@PZX0/8L#!@CGJ* '6.B PH84*3#LH#7$I2",B
M/@XZR0P$**   ADHRH4"4NP@ 58_)'"V!(K4$'<"A4)Q(.--)CBA@Q=.LH"3
M@_J0((42.C#KI!>,>Z&,7"2&H6(T/'G@A*>CSJ4/HDF .A<8,&C5CEQ"21CF
M7"SP!">=\J5(!G7=LJ AS,@JP8+A7NB 8@S,\ 0"KSF Y0X/ J-7!GK%X$",
MC&S)B334YAL:AAEJF*"5#MS28[84+O.@A!9"P&"65B#8*P<&]- #,%@^(*$$
M:W-A(^@8)B %%@X^.(&"DT_J1/Y4S XPSEP*.&# *IHL^("S!LRB2 \'W-9#
M@1I0XH!B#LSH8S;:8NB C0ZB;4/7"FHXJ80'0@$%YQ(XN)8F$R#PQ!9>3;!@
M%%AS"<$'4D ""_B& WDXR"SVAX'AV&![LZ# <.JP.%!80&(DH$@?%* 6.N#,
M C.PE'U$.,))X<=$5)##(@B!I$$ @A".T-,AJ$"%0S!"3X"80B$*\0=&H.
M?XA#"B?E@ @0@@J!8(1^XD"%04#B$"V<%" &8<)!4.%%'8+B(0CQAT(X(HN
M0-(B_D %+[IP$%-\8A@/,84I'*)#C"@$"AG1H?PP(@Y1&(0-'2%#)+F0$(L
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M]RBO::&#-4B!!1"\$>H#WPNO\]J>4&" '1PA/6@ '!B6T? #![ !&7@?B)H
MB,@7&1@#"D"^^?!",&2 T7 %"F@!'&B SW ""7"":MF+32##&0A"^8* X3&]
M7# !  B64%" L)"O30"*7&@#P:HL@2&]G\@%.%BP^JJ#R5BO%P" @2$%!? -
M3U  &_"#._ OOJ !VLB%'(B.4&B "?"JHAL%!N"$AZ( J/"\R<"#![@#W$B
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M6/"$@;E/P6N%,<"#V!F5,6@#F?H$"RV\^8@!$J" O2 %"# +"U ]G(@%/8"
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M !NX 0803QMPV1- #4_0%YKHA'_% 0QP!3V8  M@ U+X  BX@;QH"/(9 PR
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M2T\N"J3F=(#IRI:K7*WJ,,#;$:&'H&GDFGF!,$>,7"G*(&P30C+E7"W0X&I
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M@"V>#'@8!T&-T4$N&!B62Q\-Y,)&C+ <<)-%A\F)T"%U$@()$P LD0D5!&1
M108"R/'' "A 0H@CA#0B10 91$&HH5,$L,(B##P011(.2,&(HB@ \  (&5PP
M!2 (,)#$!@,TT<@AA2 0 9X!7,"$"@)LL$@CD.3*Q  +;/ZPP05*0!(H"RL$
M $(FO/JZ001*-$*LL2 P4B<C(@B01!( &'I(!@=<H*@( 23A @ J#!* ")F
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M&H(BI2 [G6 J!PQ(![ETI*+%RT56X>*)OG* .W8)SE$X8 (XR* ,FX!!;4I
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M,ETK7MX,MF(DS%TI/, >S((>.$"&P<(#T($,K9!%E(%C!*!=M,\(M-;^.(0
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M7\% ^XQ!&<0 !=2 "K[,#4# (,9-^^!&"-S$^Y1!:QV&1=Q!")! ">#&"<R
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M9H%B4/0! C&  Y80#G@AEQA.RV4,$R*\18'K<J% CU0:^,P6!D@AY8#/7&$
MEA;P>[.$@NX8HQ,4HW-EL%30T* 4+.T.FI.68W2#I%:\@ YY*(-C8/$Z/!@)
M12$@1?X9](0S_[AB#6S82"?&L*5<A (63\H<<I!4AC809Q-FF!**QI#!%W6"
M!O7)" /Y, 8(;8(XHH@1&U:5D3VHBUL#\9@?PB40/C# 7PT0H0:B11@G"@2*
M ^& )^"@AL]$,!<8&,4-R@ >@;@"#6HX42I((1R^I0P"L+C%L2;3!C2\SB"W
M@$#N/A#%7)0B!+9@0PURT0(]N")F(/D$;4:QF-+E 4DEU(X>RD @3ZAO?[:
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MC T8R!@.UO6 1#T@6AF1 05N0(,'N,(#<Q"(!<C'AC@5AUIT0 !KGD4!D$A
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M$E!I!&)@%CJ! 7;#Q/ Q!F#!34E->1A TB1!$GKS 5:(#A[ %D)! /; $_R
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MK 1"$D(8N3("%W) A"W@9@POA)L+RHZW@R?@$]K @.^W@RE@EF0 !T8 9.T
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M+EPB;* 41<06S)DD\O$U-A4\RV(=]8P#0X3X!ELAZ& !$# EAFE[P,PABNC
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M1@P64$,(QI.#NK6B.;DP01O4,)YUHN<$:QCFBA!@23T@0 VI&,D8&K"'[Y0
M#13(@58ZT %7F*$":AA!:%I!@1N4 0*<R,4#AO2"T,SG#O9LCP9QX( ^;.(!
M9JB!!33I(IS-@ %WV 0$2DH!6[BTI(Z9:0TJ (O=Q* ,#P"B%B$4)05 D5 .
MD$%CAI2*!^2"E&@HP3/+A)3G]?[AI37@#2D8D(L3/,\$)$B#!8;J@+K= 0 ^
M"@$=2J&37-QA9'J@P <<F55+UG&N=*VK7=%"*3X&1J]Z[*M?*?='L+!A;UF9
MH6@LJ(99Y&(3;;O%8%''AAK98@2?R(HMVD *4B#)$V@;+)FVL@DQB $467%%
M&9S $5OT052>&))JV[D:''CG(8\MTVJO@Q58F $' 5WL&/Q@"V&UH@VP\$2T
MK((#2=A65*\-Y&#G4*$^X* TU(*A:EG;BE18][:<G07J5M3;/ 14H6) XD/@
M< /:9*45;$ /'Z:;%=TZP4>XN.TL]!";3;BBN:T@4W!A& HGH,$Z#[$%&])0
MW("&(OX'9K!.@ =<&0%;IQ5CN ,I/L'?S^J!=UGQ!!ULX0?%JM8ETD645CC[
M$%&(H<&YF 56/&%>.OPK*YO@""SX@)M69#@60[I%*S2T"23==<A$+O)<,<=7
MO%S*+DO^:U^3O*DF!W8LGCC!>LR2@R'! @Z E",''FCD,#^NRV*VJW1LP 8,
MF++,;&ZSF]5B%R@[.2]RIO-<FJSD.0MFRF!Q"2G$<-RLD)F(:R&S8;H\:,7D
MH@_> 63B"M.YL"0:TIV;=%DX5R% 6IK0@E[4H#4-1TUO9=-FL;2IU0*+-8BA
MMV]NM:M?K14]RUK/=9[U(1X!ZUSK>M>\[K6O?^UJ6\>EUO["+G;E^"P64@-[
MV:Y6-K,+_>QH2UM1QJX+L:N-;25/>]O<[K:WOPWNQ5D[V^0N=UXVIQ8]Q,")
MR6[WJ,$2"L5V6BLNX<.'RE2#MG6DU%QY-%>Z?(L:R BJE'YWI,'".<9$::B*
M-OB\%WV4?SM\WG?X &DWS3E1'WSC#0^WQS]>YDSAV=PDMURM_8APL)#@ !R>
M*P5@.&DQ^,PPML!!H.MX"QSH6XX64&X>(GX6PZ1!@VNQ!4O9#?*D*SWI)6^Z
MT^F"[+)XH@-JD--#/ &+=\9B*Y<U T=NX0>DD8DQ?"B#D%N!!C9L_>IEJ(-A
M-E'*U+8!#0,/Q6^'F!52A"H4K?XP P[[EP8U4 87GK"%A=.3!C;(.Q=^:'M6
M..'WV-@"#E[?"BEN@1VTNWTKKE"#&M!#+5CX00QG5\,:UNZ)6W 4.&@0_&(G
M &A;Z+OSGZ^,*UKEHX?<H0S?98/5KQ[<-( ^%Y[P^T-F$8K@NJ(.$  *?CQ_
M7,9L8A.PN/ 8C+8&%!*I]=;Y!"SH(/RLY*CEG5\#@9>._O0S[G+79O^PY]+^
M6<<_4YWZ2A[ W.D:R" 6#(B63TJ  Q_  9SC"AQ  V-  9N $C6050Q8 AA0
M S7  %@!=U/# 92A!A0@!B70 ;9@!@UP+;"@ 3. @&2B!P]@ S4  8GA$K=0
M$**0 /XQ8 ,0<!\NA0,U<%$60@(<X F?( %B8 ,:@![AE#7W<0?E9&7X$3\(
MJ%Q9T0"B0 HQ> ,34"LNT0D3<!H5Y"(5$($,P#N>H('AY JX0 $AH &=T <-
MH 8XP &VH 8-H!EKH$%9= -3"$,I4% RP #O<@)LH '<L0:_ASP?8 ,OP$MP
M0 %FD (U$@H-X%2D@$HI( JA( $V@ -:^ (8P %MX#LW$ ,5\ (V0 'W<8)J
MD ,<H%ANE0,D8 &B0@,<( 8<,!Z@4% X8 $WIWZYJ(N)\G1W-'+CQF1T,7]W
M1 B, &EX   "D ?]1@&D50)0Y!.T\0!H R"ULE;X@0$:\?X0)& @:B <%O!
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MZ1,*I.  [)%40R@0MO !#@B2F?$0R90+'G1)Q;$)!H 5$/!93@L+#8!?>*
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M&'3@ 1WP I2A!SC@!!80 C<W SAR ^\= A@2 X9A$=5:EW)K$1_0 :4A!@U
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MHM$*)2 #K> ) E #RB4&X]$F"1$ 3(& N5 #->();>@'3IMS'P"C&O ;)<
M?;(&!\!9"O "K9 #PN$'K7CP=. *%*]=6+4'#@ *-3XE,:]?(Y 8L<$ HU '
M!G#TB=$ RO4]LS !RI5!IG$\H7"!*B-X;6  ,Y\"%&8BE][P,-, -2\FI. G
M@M<'2G4+(8 5;Z?S(< =F"X*Z_Y4&AB  ZZ@!P;0+GXF #&0[R5@2J-P(9[@
M &4"]Q E>*00^'[ ,DT*"PQ0"BQ3$7#P06R X\.Q9AQI"P+P GV "R<@!K8
M )]72(OU0JX@ PK +XU;"H6"!K=@2+& !P[@"J" 5=^A![&04:3 "; Q'$L]
M. # \V:@5+Y7)EI( >#H"JV  0V6XDME :0 +B+* *(R4M+RL+_A@ZUI *%_
M/9W@4BY1 P1D&*G@^F;)!ZX0 UJCW_+*$1QP JT "@B@6<14K)2M@ZV@!@(
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M=!<)@?X:.G""QVQ" 'E IV,<P $SV. !&RM!!\I0 @788@P/4,,8(- *3S
MK&[SP$^<, $TQ*!4?4" &-0P@3O$H@$Q6,,' &81)S#@#I]H@%U*X% ;-* ,
MH6@P>N0[A@:T%P*D2 5*&?N ,8CA 2'Z (S*$!.@^+!&:*# 4"WP 5N(@0%V
M (5\85&!&?RW2S"Q"!KZ:I&LMF%::$"Q&0 0S!-\0 TA&$%4,SR&#EVD J%@
MPY8F8+!-R'<3#7""C)<4VER$E@0@XH0",&<!J"'EOT/%0 =L40+VD> I%DA#
M#0[@(J289'MJZ,P,=NH)!.! #>3)10D$U(KT6B0&%BA#"OX0<)D7*/D#\=D$
M AI#!P98S@#B2_2=Q  +!:#(1RBB7 AF@('MH0<"8BB# &,45!+$QQ,*P,$:
MZ)P+-"" #;,6-*$Q4+M<X$$!,DB#!EX0HQ"L 0<0R!4$)/28%$B $W:H&P1R
M@&&M8"!W'5C("_Z4-37(@ %U '6J( "I&HB)*Z5 0%7G68<*<(4-".#+N=.I
M!UQ@P*$X[BZ <[&'JY8 5!:0@1IFH  [Z $GN; #3NZ0:1S0.[.4@L :S-"!
M"KBB#IVQP89CU,E6-* &98  ?6(P0ZMZ:H8RJ RR.""#"F@%*79X@,4[0 %8
MU,!=GCIV"<@:@P) :K@)2PMSC?Y^=*0CW9'/A60?+@.KP.5B#C?@JD5TE.JC
M^.&68CBE+2Q.BC[PJ \X$ -U8'&LIV_BZ6.?*'*&ABE8H.$&D]37'#9A"[E9
MQ!9L, ,I2B&^O)_=(GW(@1.H,XL]V$448A!#VI\.T,$S!1;YTL,8[@X'+-+A
M[H%7 PZ""?FD!-,B>[ %Z$$/"SQHD0XVH/LF<&!XB[B"#:UH13#[(/E\D8+Q
MK^I#JO: )-F;=&@#?-<8)'$+S'OB5<I7H@WZ\ F6V2+Q6]G$#69D]3'<@+!7
M(<4MA(X+.)1A%)(8TQU8OY4^3%(/:O1$]Z>/GE#@ M^U23SMCT**,ZU;#+!7
MXMRW0OZ*,K@!2,&%.I 04A@#'("4%PB,QZ #$^B$\SN*.9@P5PB,/GB%K8"%
M-A@%5\B75D# 5X$%,Z@)[Y"2-)@13U@2/5B0V]LM=]$B6UB2#H05XL.%A&,L
MW6A!KTO KFC!&82_3$F#-'"%3SB2?/G!/G""3?"$4<@%M1N\,>"#+A*E:],-
M#;2>41"#.X \3_"0__$.Z\F%3_B$6_ 0%+$ 2>"*/E =2BF), R%"H(#&_"$
M33BEH3N8I,M#/=S#0SH$B[E#0,2%-)  ; %$0SQ$1$Q$15Q$1FQ$1WQ$2(S$
MKO $""@#.*" WI%$B[@%-1@3_6 C34Q$4IB!!F"94#Q%5/Y$F%OH !B8@Q,(
M :9+1>+BPSQ<+EJ\1;$@A+J(1"V" U8Z&.$*QD%!&&$4QKL QN&*Q5A$QJAI
MQF'LKJU8QD#T"JI:1BV21FI\KFOT(VQTQF>$QF^,QF/TQCLD!300 ^(+1VU4
MQZ\@A>!BQG&,1W(4QV=$"E<0 Z-!Q&[<1WK\(VDTQGZTBVZ,QCEP LRCQGF4
M1T:4"UO$18=\2+CX0UF<2(JL2(N\2(S,2(W<2([L2(_\2#^"BX:$R+4HNELT
M25Q\)%1\$Y!L29=\29BLR(&,24F<29KD2)M,1>0:R9%\BYXD29)TKIL<2J(L
M2J,\2J1,2J5\2:"\15M$2>;ZR?Y#6"ZI/ 2A!,1;R &>8KIMM(@ZX N!5$B
M5$AP5,4:>+JR+$MEY$:$C$<S>$>O>!-8:,*H@LNO&,NES$N]W$N^S,NF7(NJ
MI,7 Y,.T2(1#C"U3'"X\^$60M 4<L$.7-(.\(T:_LH@T2,>^S$S-W$S.),J_
M_$S07)A=!$1;J !1H(-.S)0P+(GJ0(.J@P6F" 58T(,R0$M/, .#J0XSJ+JD
M4 .AZ(I22(/?++[/<P5WA(4PS 4%:87MT0,S&*!6\,WML84V0(/$%$,SJ(/'
MF(50L 4ZH U2>,M6>#I),(,^:H52" 7+@Q5;B$$@J4,E*@.CB 61T0I7X*@R
MR!?N=/Z%-( J]$ #.LC)SAQ0 BU0 ]T*DAS,T(P8!8T+B;S#TAP!&T@!X^F#
MA:,#EZ@##'B0#1$#^B !"\"!&"@.[6B1$C@V.]C0\DJ*%KF!!T#+4?")&W"
MRX@!$C"##36F"0@!&] 1)*&;<;&>&/  ,<B:7J( )Z@!#4"2$*@!,U P>9L
M)S@!-P,%!_ Y6."$!K !%W47&\  <JH,-6" UE* P/B -("%$\BDHL"%#TB!
M#Z(#.(* QB !D8B!#A"##L@54$  &+B!":B,/*B Q-  ECQ01$U41=U,MFA0
ML7!4D5Q0AT1)1T+$!H"JZ@(%-K*#*XF!%% B7%,,$L"L#O[X3O?H*ASP+(/!
M UUZ0J1(N5SP@U;8 S:B$>H\U6TIB!DXC_?J@ZN"A12PA>@)'AS !060#,BS
MQZRRB!%0 U>@+8O@ %:: 7=9@\< A85@ S8R _HH ? Q"(2XBG61"#R0B$*#
M TK<B@?PA%98 *8 A1JY@<,1E$6M5WN]UZ*4U+" U$72UZF4F*N$T DX)3.(
M@4^(-X:[DI3840D9 \4(@3DX"A( &@:0@12(@0F8 UC@  KX  G!!1F   YP
MFZW0KY'-A?O*I!AX@%)@@T_ED>V8,J"XQ\I8D/%)@1; TT]5@P? @!KPQ&I)
M'#5(@>,XB@F(/UR8@T\EA1IX@?X2B+>A=9S1<)LBI;Z3,S9*\0"D. TU.#8>
M<2CHL!V<@(4/F( /$#I\35NU75N-]%?!) NH=-NQ6#I#-)VG$X,96",ENA(D
M(04X0  J4XP18*41J -1V*E4< 57B(6^I0-@XA%74+CAR91,T8.@:(,0@(52
M@(54P 4T\"PV&1V)N 4)0(QS&KSQD=7$=04LLH5-2#)T\B:+& -;F@"[\*?=
MB@&*4H-4:(5D,:=UB8\;^;#MX0/@@H4[B \Z,%<3H(/EW0IN01D>\9I;:%S^
M$5"VS5[MW=Z0W%>Y71A^!4Q_?="APX6*M860VP-2>#18"($-"0',@H!-P)N_
M\9D/\/X8"N"+4L  4CB!-8$ /V ##>"1%\B5QS #G3&(&G %!C :+3$F^K"+
ME2T-6YB.D.N#+H*E&4B!6[B%$ZB#D[J,.I@GQ\" ,L %4:"=WEJ0.W  -E"#
MV'"%!$"2,5  3FPR7).(Z@(U-A"%3K@*T;"%$(@).B"<J84%!I!"/7 /$N&1
MHIH(_[$ NN->*JYB*^[>[_7)APQ?0])% ;6%%A"##[  )\H!"DB!&_"/4!AB
MG]6/QI"!/J(!KA*%#^B '%UC._X36\#3.-*-VM"0. *)/<  #F@0-^8*/;
M),&%$J ./N  #^" I8D!#7@Y'D&#-AN,=1L!.X::4$"LA/Z0 3A @T]U @Y(
M 3B 4ST &#KXDQG0@SZ@ !+H #3#A13X@!BP$C_8V/@P(L:"9 Y(0U$H@<<8
M!?I(!1*(Y!DXU"MN9F?>7HDQ22[.XBPF7T",!131%Z^XSZ'C*:[@Y@ST8ZZ
MS:Z S#LT9UC(YDTTYZUP!6;.!1U*$AAISX3\HV+Q(W;>YGM^9G[NY[2E9H N
MBX:<9K.PYK[$WE0,!1((@3UE283V9XB.:(D&)%PDZ(#6P]&<Z$.$!:S3:(_^
M:)">Q8O60XNFQ4CXHW=6VX<.:99NZ9!NU)&.Z2YFA)6&)(2NZ7YT:9W>:9X.
M19D6I)]>BXSN"E< !5$PCE"(O_[%K5NOZ.BF3FF]:^JO<&JGQ@52T")RICX[
M6$W(A 4[' 6H)LV[6UM;V.>H04M_1*84R6= !&= 9,X[Q(5-,&LVN2E#Y.B>
MMN(LCMO0Y.OC&B2_#@N#?@D)X  &F  ,P(!96*4[K!,.^(!7(042J&3B@P'@
M.X%"ABVO^(0/X(#7T;M3R]$8T@ ,B($QZ0,['@&TA@4$J(C'$ //&@4,J( 1
M>( 2D&L&2+40*$0^ (!N641;&&/JP&FE5+,(%L?B<>JO2([ML1T)4.X[%**A
MZP3,^BJQ-+0*ZHH*X(3QH>N[W!V$(.Z\ULP^!&J&#.JS".RXJ%1NK  *OHC
MZ&BGWOX$!9 $5["!>#,=(A$VZM #$D  )"D!&7"%4@"OKA P9[4#!6C"%@@!
M5Z"P@B@#"2"%E*@,4%" (Q&#Z8$5"@"FV:T?"<BF6:  _W" /D+BIVN!$CB<
MX8+N5E"I>M;FNZSJKI#OG%21&K?IKO#$LN:*[1&%YQZN@<"Z1$$8^^D*9N8E
MZ&Y&/4!8@1(NIYX%\HGJK=CN\4FU)<] (L_Q\:[7HU-OI -S]%Z+@#T8"RB-
M;+&!&*" ,6*3%.B $$A#=,+;34RO\2C9/Z%=9OKLQ:C9^8&<K<" .J"H5 F0
MT:BZULB%&/"?7*B 24&*5 "OZ1&#^.",9AP%J*F!TVV#+?X9"*5(SJ.P@388
M,QAQA5O^@!$1=0P(A1=H !*@CASH@#RUB#(H(.6A%PL!EU]SG";ED1I0 Q*@
M )_Q!(8.@5<1XZ#BBC$(##75G,98LA"@ 2=>Z! @J*VP@24;C!J@@!K(D1-(
M9@GA VQ! S.8 0JHC.2.@5=I@V_-!5LC@3*(MS6D=.;9XU>Q@1 1XQ)CDQSS
M;,)"BD6O 0MX@5O@@S798]T@!0Z @!:(!2(] ?RR"(7V !) 2UMX 0;X $^P
M!1F0=32W@+D>H6#S@.N"!5AH 229 \RJ@5!P7IDP)PI@#T_H  W V^OL\@'M
MUY\6\^+B>>8J3&RT@(C=V@XPCOXD9A"H\82,TY<]^PTU!QXVF!;3>5=N?X$.
MV&<<1X\$( 4_(.'#Y>@%.8%ST@ &;(J*L,=2:5)XCH],^HI..-41 !]@5_0U
MV0H&*(&N@5*R2@@*,$X!D(&P\P/Y99H.H#V5F @&F(-6:(,#X(3U?8%6R(%D
MV80*X)%2S04&B %108#[? !R6P-H@>U;F(4.,)C'4(,-,8R(30$Q$ 4*H(TH
M8A"^@(/3M8@'@'P<.( ^2(TE68^Y$0W4GXBC?7$\<(7?.#GJ69+'T ,'"(54
M*($:J0,!* /EDZ\3 )6K0P,2N 5;\("8$H A3(.%LX@9<(!.<(41F(%7NHP[
M=PQ;4/X##! %7+" %J@]!2 %6Z  ";D#-XL:3H  @.ACJX0,6* @Y,E%@1.L
M![@X-=@$*T>'7!/TY#H!X18L!K9>U,@%P40K3PA(V7I !Q:= *$\J<DE<R;-
MFC9OXLRI<R?/GCY_ @TJ=.C/0T:/(DVJ="G3I(Z:0HTJ=2I5HT^K8LT*E1&N
MG1;FY+J5*P0<F23JD&(@B0^G!S%IPHH!H5.N&#+"YIK#02:I":YRE2G!!DV'
M.[GZK%'C::89!VURW:&0JRNI!W]S@?+@X:\%.GACA.S:"@(L5P9(J2&1ZT6,
MR38OXGJ02J:&,JW82! [<P(HF65:M&+0I\\F"&I<-9C9:OZ"V >A9'*"D%&,
M3#4E9'+HD\N3Y%RP/.&Q$!/"<XNDZ'R8Z<G6!#5^),6HV-75QC(U0E)X/@N\
M!32Y9&  QR@U4;"8'A5E%),MK?0QAG1SA)!+"OZMAD9#N9 B72<8T'1"&3*%
M\D N=.R5RRC225)!+FJ\8)$:?4@B@P>P2)?+:+:XUH(3,HGBP&K4D0#63'V4
MN)!,%7R2QP2<$'> =C+-(L&"#>BVQ@@*221B##G,]  I]GWT@B=Z1!@#=15L
M(A,&GO1AP4P6A*)'"D316:>==^*9IYY!:=6GGW\"&JB@@Q[R"$\6E"56"&S(
M],$=G# @!@XXH+'8D W8@&,N.?Z<D N.:$282RH3V$** K/(5!PN=+SP@F&I
M6# "*:E.@!<H#WSJP!HS?; KCB6,@==RK>1"F!G7F>$F7IZTF(L-,^CA 8@*
M=,#!!PCX@=<M%)#2%1PF>-* I#B8X8DHM?(UP2RV0##K+2$FV)5U,EFP1RZ;
M2.8)!B>L04),$RQVRP1?MJ@INS5,.D9",X601PRAM+!'19YHP&\)9LC4A@D.
MM#83!6G6(6TN).QJ P<WK.%F&^EY*-,):M"(8P=^Y$!=5V.Q(5JM<XS0U8FW
M;%M*"1A!,,.D8N@QB@2PY'(NCF*]H(98J:#(@2L4,.U:'B5:D*U"H< !@1,W
MY*#&K/XRT1<+*+4"?<=>'U]8@H*Y6+!)*"'<,08=:-00TPM<5O!D@42ZQD&:
M>R*>N.*+,VXGH8__>17DDU/>U",WY]29:R0\-O)*#,RT![%=A6BI3)YXI.:N
MHI(:B@*:>H(K3;9@L+I,MCCPY VJS5&!IM5QF,LL#)A^]64E%)V+*PAX)E,(
MJFW7P0F,YH*#"9[B$D,+-"$D$VBVI'Z8*Z%,<#,I6.>"0?-L[/6R3&M<GPL'
M]N([L@TRE? 8P#)QNPFZMX0@%AS @TQ&<;CWA6 &N;A!"((U@I#DP@2/P8%,
M<(& \N0"39!)3RY*L!(#X(@4$L@%'*Z4 HRM!F82B,6(2OY @K.)I08PD(D>
MDD,'Z(V" JBJP0Q*@",.V($OFUA."$GEFAC,*1=Z0!<)8' _W>0"#UR3Q)$^
MX0ET0>9WQL-=>6*@P HP1#IE@!YRB%6"$O3!%24(P:S,1+<GU0T6"DB3) [P
MB<;A,8]ZW*.>)%>Y/P+RCWX,I%$8P9,',*HK'%A=!_R3 PJH(09^<<T+#O""
M$(3@!3BJP03,$ (/Z"8M?XD!!= PA@?XIRMBJ0, 7D "$GR@-W5@@!-JX( !
M/4 ")H E=6S1@1"880(0E$EPB(4A &Q/B0HH@<DFJ:8$,,T6"\!(5R1A@,LH
M1 -FP($#1)$+!ZE!!J0!!>@*R/X IOD! F40 P32]($/Y<(,')0 1OJ0'#10
M@ UCL$ (8.& -.$B(AD)@1H\T"D_B$L,#,"(<@#@GSD X#GXU"<&/F +$RRR
M!AQ E4P:D"TZ**L#4IN #=80 P7L 0X<(@&71F8&5[S.4Q)(YDPR1"D.@(Y]
M($J=)P! G7LUP EE8(#H%,#"4#  56*) 2W5T #/K$H O:'))A!@ UQ X$D/
MT$X*1$H"#VB1 ;-:0WLX2:P'; *FMI@%!F*P!@H$JWH'0!4%H'>"^SG 7B*I
M)P4X, ,*B((.".(C80MKV,)J99!'42PA&WL(QCIV*9!-"B$,M9,^G.U>9]O$
MV?9@ _XU_.Y>=!@M'.HPDSS8(&<SL<4>-*4''.3@@#,9Q1WH  ?;7L83-Q##
MZ/90ASG0H0U/N@4;;,#0U>KA=YLX8"O48 ,XA)9-M\,#%*-XF5M@0!)FR$$I
MAF0#-. (%GKUU!YT(PHQ.&&SY2'%X=+H';WF80R;L,4<8-&'K-U7)G6P@6D+
MZ(3TVH0/?X'%<?4P!C_8H@TXHL,-RH!-\8GJ29L84"O,H(99;*(/K<B6W5(E
MBEL<EP+4I$DJ<E &4O !0U3TE!YNE@=LDD(,.7@.:[MBB^/FHA.TM<&*HZ@B
MF_0!+.[-A8!E8H?GUN06K4W5#2PDD_N"6"RS4,,-GF0C"?Z7QQ//&?)];:&?
M7$@@%*48[V'+;.8SWRFR:E[S'Q,1J,NA.<YY9,!4Y6SG.NF!!!S 7)EG(88&
M]/?./K&%!F1 !Q=65]"*7G29V1R5R3H:D&X&)"$202<^\WDF-\/T3KJ2Z9GH
MYM.<=@U-/MT34YNZ@C2Y ],XG6J;O%HGL=9T368-:U73NM2R]DE7-B&&!R>9
M)YD>-4XP9PLS&*;8N^ZTKF_=[)M\.L%.F$.B&6WM:^,1D)!>[*,CK91)>SLK
MD< VN<MM[G.C.]WJ7G>VP_UMK$@.W%11[+:1,MEZ-Y8KE]:CK<O<;U*SF]>%
M_7<>"6[M6QB\<0FW\[#5W?!9N_X[XA)G"KZ9XF8X!SSC&M\XQSON\8\/9>*1
MK;C(_X1QH=2A!CDP';3MU(H3+[JV/]$#1T]];K'8]R>DH\O"T:R'K.&D#_!D
MMDU(8>6>A*+'0;$QCFL2"J_EA+VAM6)-@"Z*38BF!GS.[TX(_.P[=246"^N)
M'X[NBI7HQ!8)Z7!-9M'B.MT6USFF"XB\1@<;B&% &+)M&YI>DY(#/I DIXJ\
M"[5P6W#  DZ@ 0-0:),UW,!.'#A!*GJNN*[H@0%E.;5S?B*#0 ^E*W10H.5W
M38KT<*([.A'+#,HBAB2J&P(LK[7AZ,0&:?U[#0H4BBLJ4@HJX80-'<.)$RKP
M 0FDZ?X6+\  !_KY9.C5  ,C6%,'.R>3_>UD$P[94U?V,*=0=*#:.!F! %I=
M/0  %">N %W? (XA#H0V*%<S)DU8@Q<Q5*0%'' N [)EA@2\0 I4  8 VTP4
M7N A8 (B164MG R$2M,@ "<(CTS<@BW< @ZD@"T8FZ=@W4S$PGS=CG?  HV<
MC2U(1 C>@BN(A2O<T7;\CB=8"BYT!4.LU@G>C@W21"MTX"WD0(M@3BET8 %M
M@FY4@#=IUDQ@V(/9 C#!CJ7@""X8DR?,BL&<X"V(00EP%"?H'4VXP@[^CJ9P
M5@A"X4Q( FEL NH!G0D"G:>0@!C<@AEDRA!ZRF08TTMP8?X0KM87D@[+2=UD
M3(W360H+55!X@6#Z6(JYU$0?< C";8<QX4@L9(TG;.%VI (>7(=W%&((T5@,
MB@6.A((18N)E>&*6/0 LD((%P,(7QI]8=,*#\8$",(T:J C^R40*R( MV  "
M1(C;> N'[$&)8 <ID,(=56 >GHZ;X(@K."$'_@XL@* M_ X+S8(D&%,;:$"K
M <UJG0X&>0\BW<X'M%-7B (?@@(LZ!"ID8($4N <B@(W:IFF;<)LT(09))$M
ML($&YL(,A(18T"/XS 0:=$H9=(K+7*)-5,7@*6!"0HYEX00IK*%,P$(#/$<V
MRL!==,!?W$$+1 <$Y #"B45JO/X !V# K.@!!IB !6@'#-  !=P!#B@ !H0"
MOI" YJ#!"W1 &:"')-V 1E& *RSA"9! :W""7W4 !$@@'U0 "5" 9Y3D21X=
M&D@?3$:' ]R/3+"/ $H@#7Q "FR&><""!Y0 !WS(4 I@(N4"&S3 !,S!3P;E
M6;[ !V@=1KUE2"BB"52 'W@"!#C #< ""9R !\0 YJ@!!LRD%'8 CNA!"\#"
M!X0E=;!!"H0 !,%""## "^B!!<C !VQ5+OB!25K V,%! T# ':B4#"3>+, !
M9"I0##Q/!JX(!H3EK,@@AF  "\$"!\!"#7R 7^((#G2 38Y/4,+?3,S +WW
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MIJY)NXR(:G!+#5 (!V0+G%)'*!@ 1FP" ]Q"#%3 K,! S8("'.P%+F22*SQ
M=_6!B+2 :O3!:>2"<]#!G*#2=C@ +M" @43( V#,)_C(J(C*")',L$:(O,
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M*'!\+;X *:SZO4  +KS ?Y>(@-=!BQ2XX933^M+-<US-@HC(J.#(/K74^\B
M@=/0V=X+ \P&-"Y0J-3 0-K!7D2+3.3GID+ [TQ 7+'D-UE Y-T,)RCN6QCT
M'0PD#OS:I^?")SQ +,1""'R )\0" ECE7M3!7G#J3&-2MJ3 3[F':XQ 0IS
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M0XH&M,$.=/!L'P[ !CTTH&D/H(,M/& !\GY #9[@@!ULYPDZ0.!7$*B#*SR
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MIG8%%#0 1>H/)T0A!5+ (HY"4CC@$_;E#DY@#TA %/C/W7(AVSK /BXQ%UJ
M/U:.#B:$ =)C4GJ0)-:@-6)/%KMG]FK/]FY131*A=WSO4."+,1X@8RQFF>C
MP4*![_8 #<; )\XB->I #2@1!BPC3W+@!OC+ EQBIW)!##Y !C#@#@0N%T(
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M X"1#1B  I:*WW A?KL1AF'  SZ !&R!$T@ -VPA!D+@,QJB!JY",7*!!D+
M*K#1V5\@3Y!/!&7  QX GF3 '_XQP 1PP1.4O374  -(0#J1&@,ZX 6"DPXH
MD02()PTL@ 0*<0X88 +L0 ;T:Z-" +7PP D4@ ,V@02"I00PJ@WV=0)LP 8X
M "EM@01.0-G5(R,^ ($?  E+H Z<H'_% .(\8:MJX 100MOEQM0Q8PQ"P %0
M@P[<(@?WM00:8$9@ "Q< <9,@ %&8!:<0$4\8"_8 -\IX!/J@ $4C@Y69^'S
M( 50=NG#<>/_K (]($7$J@:<(AW58ZMNP0-" ;920 %*(!4^X 5*P &XMP8X
M0#-&H@W6W408KP8(5CE+P ($>RRXL0,@X'IJ8 9NML%'H .F(G=,@ 1$XP/,
MXM9U OXC,: &E+,!'K\Z9@$C.<"P2,'4/\ !RJJ8^PX&UDD#1L #1B+MX*,\
M&" $(#WB0\!#\* !$*I@*,#L$_"7.( $A!YO-(#=9^060.-V T0,/" O/"KX
M30 #6"7F2< "5"('6X#<;=A;6J#BRQWS\\)B051%.,!_;HC2N_],+'U-X)J*
M%& "(!V6-. !,""-=(03U* U.^ F%.!ZS,X6L"L7.FI".8$-ZM<$Z& 3D@<@
M*+CR=&!4KAHM<H6@DPM7+E@2;J&98"L7!CUM/N3*=8(.*0%U;I6)L;%%&U@I
M-G:TI6#CF%!K7FQ\H2;7K5P?]HPZ$"H7CI0.1X38B*'-Q_XZMCI!<)6+#H5<
M'LKD(H6@#QL9&S7L(=6 Z9H2N4JLP=E'CX=<H9Z2J)-KPJ>#6-/>W)@KS0-;
MK@3@P=G&4XV-%%JIP<I@;)\''.EXJK#1@J>-G"R$/9'+E@-0&S\AP#QA1BXT
M0V/TM .V0<U-B$W R>4*0JM2$AZFS!5C3:L&J7+-&9&KA9E<9F3FZJ 'SX%-
MGV6:SK6I0:X7-BI#J.DPA)-<,F[0IF#+$X9<%$BUFG!3 II<GAXXS 4'@\,9
M96Z7RK6'HH08L'!I> S+ JR-I!AP1RZ<,&"+#!.00AM6P]%1AP8;D0 6!3U)
M,@%M).7"P29Y#/4)8S(PV,$:L/X<EXL:&CDD0X8;ZE'!33FTD-Y&-Y3BR@2S
MT%6'!16),90,UVUT2P5LC6* *"[VR!L&<SSD0"AV2!86";DLT$HN;.2QD2T,
MS,>&'K \T!-JMG#@"1Z,Y6*"1C=YDF$'GJA!I2TV5%19"A7E$!U=?/;IYY^
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M$ ,9>5 _/?@6K+@)K\@<BM@GG7 '!@$@G<@:=K('[8:)K; '_X$9I<@'946
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M@)T9FJ)9EHA"F:DFDP'DEZ99F5Q%5O575CW9:K"Y/YV05F")F+B9E7Q""AK
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MB1PP 1R0"C&  2//YUB2\Q]0!OU!@6C 10#23VHE+)6! Q]  Q40C*LE!F.
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M@"S$OR2Z"(FH@W.ZOP]X@%#Y! P( 0IP#5 @2 S0"#R@QPF8@1SH@ GP"#K
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M %O  %'@&/LY ;21"S:0! 5(BQ0 5=YX%@_H S%XEA#8IP. $S8(@5!H (+
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M@TG1<?:LL%B D=FV6  ++K!@X HN=SSP0HLEI&)"'K)A,,H'?=Q2$0YC;-(
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MM (;F/X9^"T4')P-L#U ##!?0O!='>1 "]A"[(@" ZC!&(2?V)S=)E3D13Z
M2^W>J&$ 26S"]SD$&M@  [0"PB3$!)#"&DS &OSC 934!+K-+1P71SS'4=4!
M'>;"!,!(H+'!!*A!&:A! M#D^J2$)ZC!#:0-L2'$4UJ(1D& #9@!&I! 5,W
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M <#")X!-!P15*R" ,Y78*!ZJ/?YD](UH!^A!*#R 2LQ;&HR:&2S4&M A+)!
M2B" DQ"$@"Y4'5@ G,'""B)$RX2"!!3&T%[>,WEH\^U$[^0"LL*" K@")Y!B
M+FS" 4#4V>7"%S'6 R11"*00D%U9BT(E84B *%Q70G1M4KA,$BD V\!"%/HD
M891!!=C3!&A4",!7G-8A^R5$#, 9&EAJ'UBG6&8<&O1D*!A5*HCI6-Y8G(4"
M1<8%!,""*X!AA=R!I;; O-8@*3C 7-R =$@H!4R:J"*$"?[D#01X9BZ0P!CH
MP=%>'AVF@"/6P,W(  T 2R@L4$20U&?2CP9@4;!:")ZQ7QXPY)B:#$+8@.%R
M@ E4A!E,K=Y8P.:1!0/8PB?R@4@8P"\-"'$J5EL18(74@ 8@!!P\SP.$C].\
M:TBT@LL:&T+000)L6OD"1:]@@%/U0;\:U5+!C9,([2B8Q_V\7L(6<) @B38V
M;$0HP/S8PK.]P 30Y)AB@ S8  ?,SPOXG DX0(V"#1XT@ G$P ;90@AT0.59
ME!H@0!H$7[$AI#O>'@7  +\!VZA]X]4N@$;AP 2$GCHB! 84#2D8P&.8W0ND
MV2U\S5SD01NFF00Z*D* FQ\\#_X.8, .>H!&Q0 &O, )0*Z<N<C?%@15M4(J
M=-H)H%Q?,$ +**O!/&474\ 7VX(&8$\96$ %?X"F127X7; -:)KTE$ *4&CT
M(<"\QB\"B &->$ ,,,U8*.&,X,()^!P$T$TIM->A&I4>M"'1A42Z5IX]YHR2
M[>Y"2>BE$E7>5L"\'96_@JI%6&H)!!4'?, +K)KE6H#-U  $]).JI8 %.$D=
M( #KO@8%Q( %I)"N#@A*"D01;B!0J)JG/8T,., '5!N,N$((0, '4  >X\($
ML">-8:\$0  V2P#RAM+WD@('A, )*.=8W$ %O, +/(#VIFLCDH )M (EVS,L
MW *TQ?YRK-5A%D. ^:P<OUZ@9UI ZZQ!,%O TN'< $=.N!RL?T TMT0+F(76
M*R3$)MQ!:HU%6="6L4H"4\B%'\0N*1A.16R"'3P3;^5"*D3%1PBP8-B!EUAN
M8? &C("%!!=&2@@'3W"H2LR78>0T30.%$=6&)_!!NOS+)N"!0>@"1UP%@?P7
M0=S"'NS!EM0H2\_*5CRU/(4'3+BK8!#UJ0;&F');9"!%/?'TDAW8U7['@!S.
MU>)!\)1"7:1$4(\%*4"U2JS6:/"%=5@'*:3T@ CP5MM";0BP!73")N3!7.03
M('[$'EQ&0KR/B@BV5HQ)5Z0%=P1/9(,4*>P+@8""3P^V=/XT2?N(0G0A2$_H
MC5N/A0R,@: %3RA(=G) !D^'R2WTQHS906T4MG*T;T64@F=4A98-CP'W2#5&
M3G*WAR99"??9::6XI[;< 88LFI(A3NEJ"<0PYRF_4HA4C$/SCT3'Q\+J".,-
MDY1(-X*X9R>I]Y3  F@0;(2X-U()%9>, DBER1[Y#WU_2"O,EW<?TE\M=[.,
M]P'79X GN((O>.,<=Z<0>& 5"B:5-X-7N(S8BEV.17\SSH:SD(/3TH?/!R(4
MEH4?B'R7.(HS>(@+ENLE0G-']0=P@(R[<84DUT+50'\V\CY!QBQT )5=V8YS
MA%/=0@D$AI+@4)0\BH"$PD*IP?[\N):&C\5L<R9SS 6&OQ2N $4);&$]H74)
M8(62G#A#*?F.@Y)%_)J&'_E$,8AB$,BO\#>6Q[DMV$%(Y(#Y'#F6[P%AX +5
M'<P)U M'U&,2%_>8)\0) %@?HE2<!WE?"969ZPLY E.4KW>!= *V OFM0/FD
MWT(=:!DN1(E\J_FD9WDKM%.9DWF6!%2A&/BJL#IY:V,)Q<0F7#=&N^P'6!2$
M1,9&/P@=+,@M- "MIXAQ"49.'PAD#BE9=TA28)V2W$']/H"Q[@D;].23,.&B
MIX@M7&\E,\DF(( 5D8(M+V8(Y,$KIL522>@FE("8'T@$AQ;+84E28-BUIPA!
M.,':=?YX /I3>L_8UI81G+BZY#P+P..'JQ "11.(^T;)+#@!OC2$\[0N\+5!
M"M@ 95A&_(83+,#!+>3!+93%AZG!7-S!"9@!'V '*91 ZL4"_M9 "L#(PJ?
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MA9=:=@(ZC$%BH>! 2?RBAA1(I PM,-LH<($+-EA/(G (@?0F$!%;0* 598#
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M!CK  W N#R!@ CHMU!K@SEJ! NAXULS@ S[@D=;R <HH@WY6129"C]I*)$D
M5CSV>UFYE9V"?'=I?,F7;WW52CT! ,R %&*&4O[#2VP'#00 #9HN!SI@*#K
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M9$Y TNJ@$RC&>T1A F8AUSX*%_S;!&Z2OZ5:6-+)%?PB*5R!-.I  =0 ]3@
M*;H%7R^G#>C 0S[ +HFM%$ J,!0M4NO  ^"DNV* 64*!%/+,OR6B8SQES&U
M#" 1-HGBSK9E#@XJG62@6/Y4C&F2(?P[VC["!CZ  8PR%U0VG [$%DX@>VU
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M) :@5!R% 'P "TEEI">0A@SA 3 ;-5I(%&K0"@V00*!760U0&DZ'"X0ZL6/
M1TG*$"6 NTPF(;?T %>J %!"!P 0"JX F9[@ ;? !DI("I5FO2@% ;%P"S+
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M"S?0"F70 !S@!Z$ 92@-'ZW"JR0 K;7D 1V <+,A ]N,WCB0GB' &17@%9Z
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M]"EFR@0MKBB% Q+3@8;B  (/@"$=#L !#E!@:1*QE(QL,0LF0F /-].-+1Z
M"QODZBT.(&HN-%!2C9)))B\XDN6VU0 \;((PM-N01!3X5\ &5K G>M%@'[$A
MC6RB/1@901W04 $;U  ':&A%"/Y*$%D<K*0$. G!2OAD 8WHP0$XJ($-Q/ )
M3T *(R<H%PP]P0'6?L .F_ .+L+Y@<M*%@ZI*%M&V."\C=0 #3GH@PSZP('R
M2(!D%DB,)RC@).>&TS<8L($9J">39YZ.J]ZY!2[8 "0)(&4., U!#KV#D12H
MH8[2"9T:M/6HZFH (Q@H31IP]X!8XD(4$K!%(O>4.IEX8 ZV+5D/(=#6B5@
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M@S:  0;($ _0@%#@BMEX #1  P<@)SW,"-N3B%:@@,N@@(TA!0:4B1(X 3C
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M3; ^T_ZD%]VP@Y;1@VR;!32@@>5,A9#R@TMR!34 !?>QB[A[M&;Q+B> L::
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M4"(@6F(8!B A\H<F&N)K<.(AJE\ KH %9, %;( 2/*+\S5\HKJ(J$L+\Q5\
M0@$"2 $CQ"+].<(42,$@-((4T&(CO.(KKE\K7F(QZM\=DH4KA$ K7""%:,B0
M?6 NZ $SHH$-J*"%D(D:U(!:-0:/A04=X, '?B(N+(8HG/X -$:CA9@C6" &
M&\Q +G3C-9+%)UC -DZ9-R:(@)#""2"&@W2(,^9"#LP!/%H(@N0 '8A8"H1"
M-#[C/^+CA^PCJ"Q("'@"07I(A=2 &N3")FQ"+M!!#*3CC[5""4AD+G!"1\HC
M0!Y(6.C!!&BDCWD"2C8D"I(%"83C5Z2"'C#('HA"+I3!2V:/6+Q 1_IC4.9"
M*7Q +(2D6N& &7"C41HE*71 "X"%+> !+.2"&6AD22YE5S9C#/B!5[9"'N0"
M+)B *T#C)ZX%^S5"!@C !63  @2 "C""^C4")33"'RX")$"")!)"(_!E73I"
M(S "(V1"%#B %#1"(T3B8A)")OZHP   0B9(00/4XE]F B1,WR$0YF!*HC&"
MYON5(5F4 @*,0E\\0$5Z0EBR14RVA8"400GLA2<\0%R$@@,PR"?TP5L(2 W$
M0#RN!2@XP%R40!F@10F(@5@\ $K^!2DT0$GB 5J^11]49 V\HR?L9EHX)Z@@
MA@V\HUJ:A0=H)%G<@ S8A1\\@ 5(YR9,@%AH@!WD0@O<P%I,P!ZXQ2S< 5>:
MQ294)(CE AJ$0#<R #/&P#ORA07<05I\ @24)0-@96$,8R-L0 +\02,$P@44
M@&(> A.H0!(,0N_]P0JH !.H'R-0P0JP0!PT B T@2XR 2"X " ,0A), 1.L
M !0TPOX49( "K  @!$(2_('N08$*N, ?V*(22,$4K( 2A&:3PI\ ED4J,$ J
MN (>;,(+Y !6ZH$GH$$*\,%7D((-O$""D@)\YH(MP$$N@,(,Q(!]T@$$R$ H
MD )*TL$+X$ JY,)JWL$)K$%8C$)'CH)O)FA8? *;ZD%8H,$YWH(:,&,?R, ,
M]"0<2.0F9">E?D4IU($T/BHHY&E[ZL%"Y@(>G&:8MJE8? (,X( >6( TDH(:
MW$$K>((G?&DNM$*F2D*!+J0K?&H-/"@G8, (D&4JW  ,9&HNO"H.= )$VH ,
M9"HH8, FQ( -2*<>/.HGY.DF2$(.G*D9O, :"$@*F $;F/[ H=*JF!8KN.:"
M*^! #&P"!W0DJ9+K':1"#G3D&,2 &7 E+(A!#*B!@-P!*.  #/1G*$1K'UA
M2?(!+.""&=PK5]X"&K1 &8 *'X0"'-!!*& L!W3 -&;G';R #93"5SBJ#'!"
M+I#"!( *+G@"!WA IJKK"PRD6*C!"XP!J( "N6*G+=Q!F#)CJ$Z P(8"SDI"
M*'1 !^!!T'X%=AIK*HC!;M9!#." =%I("Z#!"VBD*\3 !*2!1.+!!)R )]0
M#L#!"10K+LPL&G0C!^A!&0SEB%0M&B#(E8K!)GSIH6X")[!!"F3J+.!!)\@
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M"O=!2[I"*D" 1'I"T=Y!*4R &.!!!]CC@I! "N1!#'! +J1!!WS%Y]K" 82
M#$PK!'PM&W!T+N" 0G( !^2!&F0T2LLF!5C "X2"2_,!&FC @X:%+32 *]"!
M!J2K#+BD1.J!!'PM#CP &]"! ARJ"8!E##0Q6'@ !K !&S" ).2"4_N!#)SC
M'C1 &\P!!)  +!A +M0  [#!'#"U+10 #!SSJJ; .QH Z*; JHY!!=2!&AA
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M5+H>[/%7C+8=K#.&VX("@"I8?,"AKH%LYL(84*43;.,:K/XSV^8"!6AD+#0
MJ$;VD$'PF3[ 0G("4(=%"!QJ@7Z%#)1!*$  8O!TR8IZZU8[#(#"O,,C X2"
M"8RGN-H"@R[K5\Q .-8Z+ RG#>0 +M1Z+$! *T@ J*8 7^>"!T1Z)]0F&IAG
M8U  6LX #'Q%#8Q!&XS 5]CQ+$#RDH\!+'!X+MA &;#!.L^"<6K )K !*M^X
M@XH%**SJ+#1 R/*T+92 9*]!/._%,#X""!! '!BF$@Q $S !=SN !"R "BP"
M"AB  #1 ^A; "C!B)F1"'!C ]C8"U+\H 13W(FP  AS">,>!>4M!=C,!8V;
M Q1"!$0 [^G](KSB'^:W^N&W ?[3(3):2"OPN2>D^B;L,0G@>PC0P0C< 89
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M< V_E#LH#PYRJ:"4&,:(BR8,)-$/I13\V^T@22AH#X+_7/Z1H!4.<DK!!*Q
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MZ6<3G3P?>CRUW_TP+%_M9[@:"UN80K''/TWNGQ4.Z*;T^D^Y?B-\]F\ D\L
M220!%?X0- P0_Q:P ?D/ 1F0 D\/ B4P_T;$ =UN_RXP TW/ R>0)FQ!#$J
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MZ030@ 2(CB9"(%E$ A1T50R^M0-@ 0<N"5DF@M4J@Q0&PQ9:@-5(X#M.P ;
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MZ  "(* #=B87T@ #1.(&9B 4M /?%@4/2$$ .@8.NN($1*0#ZD#MZL*1CO0
MGN,6K/ZN,1D 7P:J8V[A=]P2U6*@%0Z@8\@W%[0U(R;@#DJ! ;+FAV"!>95E
M*02C#^R *#C'6S1@*:*S*.H@>0JC!:0'7G.! =[L /X# OC %02 ;L#U%D@!
MGU(@<U\ !S(B!A*M!12JR2C@)%F")MA5+3 @#W"A6%G%@F%! ,: AM$CM7Y%
M O#@++X#%+H"!GCE%DY@#4(! B3"!,1N0O]# M##%12@%>X@9RHE(R2AL^R
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M_,"36_X2KT<05U;&=)+RG?H@9UY@#?H@MI9)V2";!J8F)@]",RD OS_" _
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M P1PA-1' \:ZH@!4)'@P+AVXA,#!#!8PIL>9(70PH 4UU-!!#*1LE= 8%<Q
MP7#(6H1106LTD*D,'-194 D*6% !!#>49@(',4" H"T3D*"3!2>\\)0K#MC2
M"@8IO$#!0!S\FP(%KK3"7BXU,'B+!)[ 4H$))GOBR@-?D?+ +4&58"QG&DPP
M@@3ZYK)RRR_G4D%_>N"7&AM]Q)9+![B%XL!TJ]7 0'!FW^'*SR9C9(8$,6#P
M0D8;)?X7R@0OQ*!!3GT\$ ,)&)#WP02B^/2W!;#H(=[-.,Q]+'HUX-) >PXP
MAT$)+SRPR2P5D' M;@GA,K@H'6")P6\O:-"Q205EG= '"!IM"RP<E!##!*#
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MP">"@H8Y-"T7>0"ZT$E!B@.,H :P:$ H[%" NCMY-R,W@P"BVR,S-$ ,I<!
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MO.AFGO[BE IU< =Z@$AT@'8/!E<M=B&EL ;.ZE>2P"L8(D+*>[[H.U?.([O
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M%:6H')R-!FM@ *30$0F1F+XU ;P2 N4BASH& XQAE[S7&L2:$&90 7 @VP?
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MN@,!: -2N %7P\=YDZN! K:[" 4.T(T'>!0(*#(.D &ARH5/<( [*,?W:(/
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M/A@# ILAF\"!#Q@!].@#7:H-WA,(/!B!#!T#-O $$AW1GQ #GV2#H_NJ%^B
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M'7HDYDD"I.1R"P.?>/* 3ZXT@- $G.3"P1S&"0@!0K=( .$F/_&7 "BYS,(
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M>FP+!A7 $L./"?THQ@00)P.8I80!?;B#7]X70 NL1@\0:-L)*,"7!(RA%0U
M20V@1:@.C6&!SP'77XH3B@:<P&-HD0$)/F"+5CC ,5IIQ65B8)&/R, &,G#
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MJ]$Y&1S;&%8YDK6-=4P9?+R:G=RI5:VW@ !%VBK7N=)U/J'H4UWSJM>]?HR
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M$9'1_+3! [B-SK$&!I! #)# ,IX&!>  "<  :<PA!H2"#'Q1*)!"!>R.V,7
M!V# &MS!-]9;,DY 6UB&##A!!2"$!90 #71 !VQ$]-0 !? $*4B/#'  3XU"
MGW!"!>0)!VR$3\A/,@Y<$^; #'C +<""&];  R"$'E# #9S=37BD"32 5MG"
M"9! #4S ?\A !=1 "S" M[VA#)R  N34'$+.D]! "7C 1DA A\#" [B"O,0
M\^2$^(%$+NPD:=1)#:4$ YV  \S$&&  #G! C_A$#*P$!X3 'ZJ-!3W+!!C1
M":@E3OX6CX'0R2S, (]@ !RXP@<\P O@P@SP1!E80 VLSL8\0 K(P 2P8V+X
MRDV0P!K<@@>$RI%4Q"9L @/,0+FM05PH#PU@0):(Q!Q,0,V@755I0&(^3]K5
M0 >LABM P/($4 R$@-K PAS2#EC@ 4C@P 34P LP0(>L76GZ(0-\0"BH!FY
M8PI0Y(M\0 V,@ 0]!@PX)P6P 2R00 .TP/G=1!AZ!Y-U9WN58718$ 5@P 2
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M'[@QAC2&-=_$5U0$14"&3:7N"3N2)R#)'42H)Z#!&(1 5L1 &O#H35C ^UI
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M 6^+B'-&QQPH@"BDPCSFBP.@7*6\9PM09&[_A/:F!%BT IWE B^"S8'P<1O
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M5N2 !GR !^B1!R#$5& [OMX$ME, !3P E_<X!U1 ^.'&\6"@!UQ&,;V*#4Q
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MH@8VR(I0G- "]?CN*+[Q%Y*$%T?A$2Q!=&S)G8Y""@[D  -"R0&'<H&'$'S
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M,,,#8ML^4GQ@!NJ!@&-= 0%8A" B:!")'QP J]2*(0<=L!PL'*"'5J2B#Q-
MD2=\F)%93  /H%M>"O#:NCKDHLFDJ(,!*-86#;7%%J(8!;E(H6!;3  -K6C#
M VRA!P.P810WJ"DH$'*+O^;"AG(>Z\K(2(+^(L ,H5!#^')PHW ^N0#R(_8#
M;M@6/:1TE,7B@*IUFPL;R* 51(O%#"H=@T.^P 2DV,0#,#(V3GC" ;F;P ="
M844ZM.X.N,  '&Q!!P7B00!V"$4)4F"+-%"@$_LS",@XP8"D%(44P.IJ5F!A
M7U+D6_XH.!#)S-D$4>W> @,T,@,V:W  ,VS"%A08 RG:  !/E$("1*\!^OH
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MU" $'  &\&=3R"OKO(Y)NE-42B6/W(:%/( "(B(%E',4'/Y@%FXA!'( ?<;
M_=  !G)A!,Q#*-C@HI:M%?8 6V* /MLB#\#&$RR@!#6&#0ZC)F]2(AI/)HG"
M =)"%!Y ,A@L%UY@B7)!$F[A9Q2&*X3"_@:C =1'SSX1J?C'FOK \TX 0?/-
M0LWHWG+F!!;"!"R' KZI%3RA%51.(C0 L'"R$C_3%1Y <BC ,BC Y'( 9+A&
M@48S(R3!%GXF%@Z, S""(4(A%3QQ\MY/W'J+\"8BX[BT#;A4*#Q ?JR",$B
M,"-H>I*0H7+A Q8BRB1" C#B#KPT%^; B;;*0HOJ!=!@[82C ]I*(CK FB)L
MT::GU3+"1A65A71K!L1)!N3' O[X"RZ=""0. $7<3B+4@$MK@#XK@&+ \F;N
M:JIXI0'D!P/BCE<NCQ1DRG)N@#XEXHADP'*,4M_4B +4J0S$#0,P@@]8\ 76
M(!0NM0]P(0^<QZVT!U@G0PU8< 0N*J $@$9",",P:Y]0+Q<^X0 F:OKD[,C<
MZO;Z0'O*2"L8X/)"X0!(H6LR8ILF0#)^)A<8(*Q*\2:^TV"8!!7GY%ZUCA#
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M[D -*& 7$<ZV!*#N2&!B)>($S&B?&, ,U( !!M8""A4#TOY@.!C  Y3V 6!
M*/R@ =*@#1K /"9"77EE F:@_>@S!2K-#!!O#![ .3C  MB@:X]H2'O+B5ZN
M!-(I!B@@XS0F%PP6)!2@"S/"=^."=C3 #&C@ SB 8D;@.E^ :4;#$P3@!%Z@
M!!9&(H2S*=1@ 2:N >!@#DK OF;@87IK CP !KBGZ&1 X]1(OTR@%4:X#M"
M_WRI7D^"7YN$B>U5%4/E7Y&B#B+R1G% !JIT,')'(O2@)&=ADOH@/.8 L(;W
M=9_.L2Z81F!AUWAE5>] !FC@NR)H#+ZB7W"!#H0&%L8 !SSA#GACNG*A"F4
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MN3/\Q#.%Q%$\3S8<)LX;3K@NPA\D$E1\Q6W\QG$\Q]-$O&3<O%I\)O8[-^
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MS CF,-:"R, MDZQDOKP7BA?<8+G$2<%8<G$"-(S'%7CX  EF,0$<>*(41=*
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MA0>'H1$",T *+ (?9@$'#NB.:V  9A *S6%^8X +=' >@JP&G6<O8E"%GM
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MT7%N%K!A"2,&Y^8X1BJ6%1*Q#1!'>O$_/ T=!3'G'!8RKXBRQ7'&;>)'4>(
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MCA0>J"N$%.HHH4$&. D1;+%SD5>C!N26((<Z*+@SA!+J2($#^F"A( 4V4L#
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M"_@$7!@3MW(53VB#?].(91H%-O[80#O /?R P693)55RA4T3I5:PA4\ JHC
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M3>N #]  '-((&:@ N4^V5%@23WCB2]7)[0L%#O"X:=P(-:" Y3P!6<Z%&:
M#/" 1R'CHH.#Y"SW]JC\LL^%$5 [T-G/#J" P](K)":!%/" #K@.6#B!02X!
MS.@ 46B%^Z #]AA*I@@%#5C.PQ]I!\"@$""!96+P&P ,B6B%&)@!#F51"_@
M#C -G6R0/*B $*![CNC%$*" V+$%$.;*NA@?/LR%6'B;&,C5/G %"VB5C2 ,
M$KB%$4"/A3 ,@,A#(42%-KD.YLKQ(D4'#J1RV4K!H0,)5P?IF)@3(XTM#+GR
MG#AX)V0-- =MJ.GX,62ND0<[I?X0HX8$PERD/(3 <..@&!RY<!T,Q:%$#3,8
M'M[*U8K#AULD_!P,L<D6AU@'23'%,,-6KCT5/EA84_-G+DX&+.;B\[6"FEQ"
M2\Q 8X%4B3YC<Z7!\ &#IX-E)"#DHY<"G%PXQ-C\\(&#C*0']]!4&\)"C9JX
M9'#P4#%7'PR3#;KB8!$6!UM^*N2<D9:F)PL=6I@HDRN58@XQ;I%&V^J#!]M<
MZ5#P$..#782P9L388\'B&KT8-AU<8R$G=,,#9WQHA?"0HT/>OX,/+[Z[^/+F
MSZ-/KWX]^_;NWZ-_='<L*:ZV')-*A= Q6?H/YU_U7W_] 850*+ @5." "/IG
MV7RA:/Y74RNCC,5?+K (6!-703$XEBT0CC6AAS6E@M98H9AXEQHAA;(A1+F4
MP,:'#1[D6($**HCB?/==994M0!4HR1C1<6!<*"/F<@LH*1X$"R@NVI3A+5#:
M- M$&U+Y(H[[M3@64#/61(J .!R9RP1YO#C@C0D2R"8;=1ST@FICB<+D7:0
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M11V*] $]<)!]'RP=^:8ENA=R!X:BBX3NF#6'$'!M<;:0@>I@@0M/3"!IK6!
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MB3,00 AR, D4C\1 DS7I PD^4(.Y=0 ",[ *&ST@@:W@8@PE" $H6S$&/7"
M;]7$@1D8:H,0E  Z9G" !P@)E$VTA10I($%/:\(!-L!  VQHT@Q(0 +HV ('
MAD73;%+P@1<@KP,E6$,%N'H0!'X@#0?A9PHP $J$J.$!:$R>&C!P@@BQ800A
M0"="0)&"$D#V(HKQ5@?0\ (+#-83WFJ#:@>K!GWJH2V2&"L.N&(&.O@2%&7
M  Z2@@L<+/1"8J!#"#H G1D\@/X$[,P%=3\@FU2$X ' /$@J1@ !EH; ##'
MP&!SL0GBN@@7-6@ "7:)!A*$0"RP& ,?.G D-8B1#07- ;GXD LV0."39$F?
M&BR@!D^4H'ZY^(3Z.$!(5PPG!0_!A1A"0 )0LD&TA>%$"92'H/2M@0,DV'"'
M26#@EGA8I,YZCRMCZ9X:V]A8A$C$LCP1@!R$0@T-F 4L**"'_2K*# (0@R1@
M80,.<"(7ORQ%'AP "EPPH -M@$4)**!; YC!7[+QP!AP@<M<>$( :@C%#(HD
M!@V$PA,- "4)Q! +/5C ;T"I04B2$HH#K+D&'AE#14B! ;L !10"P $HV,
M6-@" OY]N(4,<% *!2"(#G44*"GVT(!/8/E(0VR%'B"@!\N>@ %H.! $]H +
M&L@@%R200"<\P0 ^W,(!21Q# $IABPK<(19FF!]0/C!8KL2@N! @A0S6P 89
M531!>8! 'F A%U"$PL$#&D,,<M&&!W09 T<20TBX4H<Z=D /(^$$#$HU%DX\
M0 ^D@('JQ&"!3=A*#,_)!8 ;N>Q6"" %=<#%"2BJ!S7GX@0U@,4F*) *4%1
M#*4@"QL\$H+?H6$$-7&-)SC1 $(J_!9[8"(:/&"+34P TIZ=!1L2N D&]"$4
M)'! JMA @5"$0@.(R6XH](   64[!ZG00P+N$(H0O.# '?Y(12LZ8%>(4&#@
M3@@)&_@8B@FHSP(D" 4?$  +.S"1#1PH$0?Z4 <Y<L .I)# )F A@\I,X .A
MP,$!X! *!L I!BSU1 5.MNA0E&&I?GA '2P"E#GP410=R($MT$"!J1QD%FIX
MO"W&^8D^_'SM;9^!:@KD!PC0P17GA@4L)M"B WS8%G2 @"=:4R09[+T".-=)
MM+L"@#IXX@'1-,-2[P 8#I22 VJ8Q=FYBX$/38 4HGC7*$3A +7?0 .< < <
M0K'77,S@!;#X! 5(X8H&G$S!S9H:CG-L?HC1\BZ<6.I!,* '.!RE]0> Q1K6
M>!%%Y1XA-5#- Z(LZ\&2 @1PA?X8))TKQ (HF $3 5%04$"DU1,I>$(H-$#K
MK5U;A% NN-,(?<(E^0L7T4$HB$(,X!!0? +[5=!@Y8TGO$!(?(!!G% K. !"
MX$"W20"%N,($$%FM8) )Y$"-D%XGP( )P(BWG  <H!5"3, K:!H$AD("L!,'
M%$92-)4=6)7UB4((I!<524!20, NE<4ED<4-Q!H=U #?Y  3X4!(  4>,!$H
ME( )D$(+>$(WO8"+I( 3($0#P((D=,!8[(']P<(LD (?/,"2,(!5P*"AO$ ;
MQ (#;,(G&!H>EAT&W5 NQ( '')F%4 !4\!M-N(*N(!@)/0 =U$<NV$'R?4(H
M($ H0/Y14- <0E! <8#"4MU;^TD5)G)7'^8"'O2A@^$<#LC10:3@,N4"!5R0
M4D!'+!Z$!7B"&F'2FLV=]#T W@21#9P *?1< E"%@37<0<" &=P" _@!)'(
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M )R4@<8=! .0@B0 :>KBPK(=Q"BD0B@P5H-=JJ:V1U$:+\[0$(!X@@+$ !W
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MI3Z-@C[5!!V81"R,@5T'F5(7R,155 IX"Q[$P UX+BF( 3L%]5;&0 UD"!Z
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M%0M>@*$"N&((00,GCBV# 0SP:$6"%"P@I8*P8($ %CL^R 6# 7.) 8<12\%
MAA@X< 66">S(Y8,T<AG#@F!KR"45>.5]B0,28B@! E?T@& ":R= Z(009IA@
MP#H>X)&! 3V1X 89.FR%W!%KP""&%!(=C(,89)@WEPYPS0,.!O:\)06))X C
MESLJF(\4 U.H,(8/.K!(A@[$P&"-7&J@H 8_P]I5!A(Z&//$I9NZ#NNLM=Z:
M:^O:^QKLL,4>FVRR$SGD$?B6<_Y%C('*$%7B@9:=A8&68%%@0+P^.> V6QCP
M!):VD<7R@=MFR.$6!F[+A0/;*ACHC@YR:86"Y>"8*I<'6B'E@+!L:2"43A[
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MP7FPD  .4C.E-:C5-T(<2 ?N0 <.A,(3.BJ)9RF*!L>XX@X>(&0Y5340-9Q
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M6N+(,3@!03Y@ LJG%3[@_M1@M.@ BQP" SY@+!2D!B; B;#$%DJ@ D2#2BR
M/E0F%#Y@!@RP?"C, D+ /H*" 90$%DJ@ SJ 599##*P%%D[  C"  _1B#2:
M R8@)P:B%6+ 4SY@!))G(&;!SUS&(NY WBYB%"H @&J  U( #<#M#ECNZDJ@
M#E*@?.B@ C[  @;$0R@ AX"-@6[@!"D #SXB%#A  @$I%.PI%T9A=>B Y28H
MS ;"%?X\P&52P$5"00-"  .(A Z%B>7T(.C>P@TQX%](@0,$ Q ET 8<(TT^
MP&-Z8R!*P-R,R /L#RMJ8(<^ @U6$!8X0"/N  (^H 8Z !;TH D'<?",B -.
M2U>&!BTPX!;T( TK* 5F<01>H@-:@ 0PX 0L@NF(Y .F@E]"@ /"@@D7A;[J
MH )*( =LP 1:P18![ -2P ,>C"1>@ ,\( 0\(@2."HW6$%DB$ ,X852\R14X
M "O&@$ARP0,\ 1=,( 1>P$WXP P$!P?:AA0^0!#GT0R^T (@IEW03R$7LCK@
M3_W8[Q @TB$G4CO> SJ$@B0<PS30RQ;X0J,T)!1<(R@LPOXG;.$%HN@B0O(C
M6@$KT&M,8&(N,"(E17(OENTCDDW;5E)$/B(6RF\@4H@@@&(Y</(B;+(KR.E'
M+L(&1*/[?C(4@!(HX0,60 $H9[(H_V(T%(14;%(EX2,4C,<T;%(GP'(Y0H&<
M+L,GKY(JA%(L;4$C/V(6-.6?S.*!FH,H@?(6\ *D@)(HI<@37$$O?G(M+@(6
M?!(^3,,6)$/K' ,&Q@ XAI(MZ0(F#%,M%Y,J6E(O*_,K)Y,A.],SI:.WTD,B
MNV,TUX\0I@T\WH\BQ4;^Q+)K/*';<K(5-  #_NLS;U.2X, "AC$A&;*P% 4W
M;Q,.&@"0<*L#S+'9:H!&@I,YF_[3.9TC;%1S-<'&$0@A.Z:M.J<3VK(-MWI"
M.E+!-9]3/*'C*VAR(1MB/!FR))C-+<_/%M0L/>-3/IM-.\]#.H7+$?)3/TNS
M/L.&$(IK/@-40 >40 O40 \403NS/U=SVDZS.E%S0=OC/K>#.Q/40B\40S-4
M0S>40YW-.R"R.O4S(D<4/$03D_BS1$,T1*V3VD93/%Z41,M&-&&41&G41$=4
M_CI41W>41WO41W\T/:U32*WS$(2T2(GT-)/408WT-+=C2)M428OT.J7T2(U4
M2I^T2:OT.I.42H?T2(OT0:$43*FT2Z$T2\^42+VC$+3#2ZO43+E42>%43A>!
M/ <O+/XK\S#Q5$_ME$_S%+W>\I_^E$\%U4^O4FWR])\2E4\5%5'G\BH)]5'5
M\E 'U5 C-5$;%5/WU#(=E5./!5(#M5)!M5,=XU,955,S]5)#]5@*=537:E4M
M]55%-5;[5%5)M59=%5 ]]59+-4][%59SU59;E5=Q=5%G%5B)E56-%5E_5>L:
MP5F?%1*>55JGE5JKE1*J-1.J55NWU5D9@5NY-5J_]5F]M5O%=5O)U5S3]5NC
MU1+"$TC?%5[C55[G%4B5P%[O%5_S55_WE5_[U5__%6 #5F 'EF +UF#ME0ET
MP3GH@ W:P&$?UF'9  XB]F$EEF(C=F+;H&$Q]F(AUF,_%OYD.39D1Q9B+99D
M2S9C-U9C4[9B659D5;9C5_9D9S9F399F0]9D539G6[9C=_9F3]9F?Q9E?]9G
M959C>?9H7U9H239HE]9HG=9IFW9II19J:99JB39CJU9HK_9FN39BZ6 *IF +
MXF *_B!LPW9LRQ9MU99MY:!LXT .X#9NQ99NS59LR=9LR;9NU?8/S-9N[Y9O
MY4 ._D .ML!M_;9LMT!M%==L!_=P!==M&3=L_]9NX\!R)U=RSS9OX?9RIP!O
MQ39O-7<*XM9R(7=P)Y=O#9=OR]9TR_8YWBL48E=V9Y=V:]=V;Q=W<U=W=Y=W
M>]=W?Q=X@U=XAY=XB]=XCQ=YD_Y7>9>7>9O7>9\7>HFW6QF!$1:A$<C56ZOW
M6:WW>M%U$:RW>JGW>AO!>KDW?*G76Q>!>M47?1T!?<$W>^.W>MD7?>O7?M?W
M?<&W>]=W?+&7?:]7?<F76K^7?.7W?+W5$<:W@+7W??=W?>'W?<6W>B&!7BO8
M@B\8@S-8/KL#2<&C3=,T_K@#A,L#A%D42<6#29U4A+N43-F4@U^834=X/=(T
M3;/S2_/SA!N432U2@WO8AW\8B(,8:\0&1:/-AHLX.VXT0L<C1".22%<T.].#
M$.A4B*O8BJ\8B^DUA)>8@[$3.U$4A\,8B<O#19MX2J/M/SVSMEPS6)L#/I<-
MCK-8CO[GF(Y]5(03.#_)UR'YDUQM&$+'PXN]^$,OR4'3@WJ-.(WK6)$7F9$;
M64&W@Q'^0 4B( )$8 H884IIN(1=6#O6](6S5$NW]$@=00HR  0*(4PU&4N=
MN)"C]$I;V)-5N(M!V82%= JH@(:[V(7/5(1!^3HKE#E<X06.:? N R%@0094
MKC(_H@Y<QS5<H=:NYN<$2K&JDB2B*6D< J9V$C?>ZA,N @]B@+5R4C(E$P:,
MXTX_XA9@P#;-  8NXA-0,E>78]GP@A0(3M[$TEW7F)XG%0\$9YXM0@SB:"!D
M(([X0"1KRZ!G-2OI^3G><A80PA9( "CFN9B7N5AQ@5$0XOZ-'?JB^1FC%:2V
M4JPH]9F<[UDPC/($1&,&DJ<36,ZD)=,QRB".;L$Q;."4VI@Y:@LOTJ"Y0OJ;
MPO,P\<(,[@4^.WJG@\+TZK2<LY(&]LXU6^%JW!4[M(,1XH !!,"4#>  +MEZ
M\?@0%@$2(&$1K--;L^.L$3A;N0-=&T$[' $2*@&3#P&!]7@!%J )IJT1QKJL
M$UA\Q=IZ(<$1Q+H1'I01QMJM#P& G54[%B%;KXVN]_J(IWBLY_JKY4^P&^$"
M&J"P([NPFW2L(:%($X&L]UJ3^)I(0WM,LV,1Q)(41,PY/.&,QN4EHT,,*D"Y
M4*A>;( -'$ ,_0 !X&($4J .3OX 4I;C?^   \:O =1@#/PH%_;@ 9R; 8S%
M#": #6+  JR9.NY *)W# <H/G "@#AY#?[;&H$ZCO#M3#6H"/C^"28X%#^ "
M KY[.?0@+2$)WP;B*IBM @3P,QWC!0CEO:TCQJ2#8GPC%4MNQK#F!$IP(/B+
M:]CEHB-IP+D&+W*@!;C;.E)0.OK@O+,&DD5  )1@K)D@ EP@$Z2 "0!!"0"A
M$:; !5Q@"KXW"IB@$!8!"IB E)D@$%R@"08!LIE "J: !7A<_@ A"5@@"JJ7
MQ5U\$)H@ 3) "J98"E@@"0 !DYD@"OZ "?Y ";S<!0KA#UQ "?(SDEU@!:1
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ML59#0GNN,@ARJ'$P)U<-$WE*X,CUH$,,6QSPM(* A@V$/KE2A%B3@D$IR+G
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MB, #' &)_17$L[!KP 48 8@57& A&6B$0!S!"*+\P0 J"%TFQG( @40  2)
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M1"94$  Y9( !?RC$'Z9@N03097"T\U\F"*%<1T3@ HYE F\S,5I $&(EFD.
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M] $+$X &U7*$'V '!V@:;P(!@P1-)3 #J> V^R(#"N ',1(#KJ '!W 'KJ
MKP$!K< )LD$*&J &:6H'MF8:!Z 'J?!KP3(#K5 '%-".4)@A)O9KJ4 '4L2*
M:(!GW^@W,6 &W0@+>GH'HS !*7)3$\ &J2 #./)KK7 '%;!-BC0"I? UI+JH
M;5 @38,!,. $%% :)<"'6&@+>-  GD '#Q *L% C?2!2R*$' # O 7( ^V(&
MLO8)%&!(>A)4+R!)@K:D#& ++T"*&*!W:' ;;- *8@!1TOY" J?T JT 8__&
M :3@!P;02J3T&6J   SIAJRQ!VS8 '=P+GBV@I11,0=9 VDS5'5 "@W0!ZU@
M F7PC5Y6B@_0!Z6@-#/H87*3@%M3(J$@&ZEP-[#PI@T* !8:L:1  A!"I*$@
M PQ@( SP8L@*"R- BHKW&$A)"(SP!RHP 1$ !4R@ HQ0G+!3$2YP 6!Y",RC
M A'  BZ  J*U "XP ?E#&(YP"+_' @X@ E*Y"$RP.2B0$$NP 8"P"+&3/6H+
M8(G36X2P BK@LU2P 5( "4D@ H- ""B0F?@3 4E@E8X@MQ6A BRPM2X@$$G@
M"$^;.$JPM0,HMO&# H' " (4 ?X;P 0;D!!4( (9, AN>P%0P B+( <@H%JL
M>3I)T#\9P)I)  *9@Q*J)06^Q7B)L&"P0'5T0*UI8$C:80,Q  LVL"^E(*(X
MX '0\ABC< (F0 (D$ *:L0<=@ $M>3!^HP<AP ')"QEZT+S/VP),Q0$< #?B
M=B,DX &U80LU@ $A8&(J5 8M0".(ATLOT $E\$HU($1C@"%T\ $>(#)#0@(=
M8 9+LP;=<6ZIA!QTH)-'Y $BY1LM9 LX, )BD&NI@ -"! LG8 :DL!Z@<+XC
M,$R/P2(?,$*DHATP0%&I<K]-4[\E4(<D_%%IP &CB"FP4+\D,% SL*!BT$+(
M80;X8?X''D *+=L!(0"?98 T(KH)8%(#U.$*-H +L9 J)'"&FY ""=D"3V@'
M'#.J#$I+'_!3I+#$/R6C)K"&,\!BWF2_MP3$*F0#@\09'D "MZ0'Z6C'$9*_
M'W8'MM "V'('6L)2GA IH5 "'Q"\34/%\#DD'U 'Y+K%))*.*#('>J",32,#
M'4 "G9#(QI(&'N !:$<'++49)U!&F?083?0!U.H8=W#(?2 #>2!NF2QU4'4L
MI- &(U3('2"OCE$#J10A,S#'^T8C-2 &'Y4+'TQI:>!&;,8:H-!%0"8#:X I
M-^ W>)!6T@8']<8!9;P'_HL#N #%R]D'(> !.2!DJZPD9?ZDOIF<0JT< WTP
M W>@P=Q\ [=$SA\ SD<6 B30!N>L4E0W&AZP-#N[>$@YE8O "(V@T(:3"9!+
M7).#6HOP"%,97^,3 (  "0E=$5N[ .VET(R 8/&%T#X+"0\=7Y%KTBCM"/&5
M8(V@&"V=E*&#T)" TB@MTQ6QT J]M2S-TJBU&"W=")"[T!;MTC.MTZ%3TL05
MTDD9THN@T88#"8E@."]]TXO!",M9T%J]U5S=U5ZMCA"2U5\-&7O@I6,]UF)]
MUFKMU1>[UFX-.#_,,6G]UFA-UWVPB; 0 F!"UWS=UW[]UX =V#N+E(M!$0-(
MEH?=LXQ7V(?MLTT MH1AV(6[ OYD299;:]F831&7C=B+/8!:8=F'H!6,?=BB
MG=@#6-B&G=J,I]J$W=FG7=FA#=NGK=B=+=FV'=NNO1C*&=ABC1QS_=4I,]>_
M#1ETX')\C1P5]=:_/=R"K7B]W=S._56(]=MXH+/0#1D/Q-Q<O9RW8 8A$ (Y
MT-:/H=W7#=?E?=YFI-SHS;.MK5A(";GM_=Z,QP@FS=&*U=*?#;D(UMH(Y@CP
MW=K_O=\ 'M\$/N %#N#^S7C_?> ,'MKM38#K'>$2/N$47N$6?N$8GN$:ON$<
MGEC\+=D-WK/[S=D?#MO[[=\)3M@@#N(J7MHA_N(PCMKV'>,TSA@=?N,X3M?,
M3=YKS?[C.?[C6BW>7>WC0*Y"1 X@1PX@K)'D&P[@+PWCALW2R%G@_HU@:HM@
ME7WE[\W3%&&YLZU85N[B6W'9BUV[A.WB->[93Y[F:>Y 1?[F<![G<C[G=%[G
M=@[=[LT(A2 %W,?B [[1A[#G<;#@[JW@> D(AL,8BP (CG796C$(C$$(CR/4
M_8WEX</HE)[0H$OI+'T(F,X8S.5YA [C6A$%@S[:;,[@/LO7:K/5X[G5GI#<
M<,T)0@[K_>3<GI!X"V8+Q]'<N" T6ST*H]0:P;2SGV!#9P@@K7[6GJ 'SG[K
MG:#KN1 +B^P8LU#M6AT+FUS0GKBS0B,*$HKCH9"$@*,',/ZXL['0!S\T4J_4
MW*V0['/=[07-"155C"-5!N)YUKP..*Z0[(H'"WW@['MP!Q2U[2WFOD!>V%P1
M ?43/J%=VHX^@(T@!1=PMU,0 %2[V!2A& (>VBRP -T%!0D=!69IM?X=7TPY
M.4S@  J@ ")0"%I1Y8RP\ERY/(N^ 0F 7]3%! _ E2Y 78"0$@BP 8,PY0]_
MX)#+%0807F2IY34^U?']WP7(Y(\A(>2N>'M@306=+#OK"H48W%U-:QX&(*)0
M&K&0A05=)^QRW,E1,;%0 6Q5T#4  )J!''4PK6/_-R%0!VR0)$8Y"X^8]URM
M 1,@P R0)K!0 8-D1IN@]2K4^/Y$S@F.#SBL<0)[O6!5! .5RN'(D0)%"3AK
MP  )7-!X  #XP1K2R@94#SC:ID)YI7@O<$L;K-40 %6LP0$G(@-LDP++.M8=
MR&(_C"E#IM6;< #?30*H42*/(0D.X&4O@/!-'MON]1-:(=19X?!;@?W37Q"7
MM0*9D+:$\=)[RT"!B1-M&1. \ <*X !,$)?@T_X'D $=<1=3D 0 P +DSP@7
M?P%CZYN,< $ 86!)$@$9*$T1((%)A@%,&DTPT,1%04:'+!YJ5*@0HT2%'#DB
M9-$C(XV,& 52@*(1QD*$&CFZ&%/F3)HU"3W"E4OG3IZP1/',12JG3ENI<E5H
ME6MHJ_Y20)7FZC,BZ"V>J:C"<J7SUE!1L';>(F5+ZTY727F2HJJSE5&>0W.!
M!;H) JY8&&*E\KHS%%!7$[+J)*5SJ%">H\2Z?1JT:2Y.$ZAN=9IK[==<3AB,
M>?J"01V]B$?E>K$FEUB=H](B#DR6+>"\.S'HT1D*09_1D=.Z2OUV)ZF_NR/K
M5ML[5ZF_+]0D;AL8@R?D87?BRMWSI^!<KOY2M;5XYZR<ME*GI9YKU-\89G02
MIYPBS4Y8T6L_+</@^.@/#S:-#H68^BW2.ML#+26M-4H #SSGGJL MA?@\(XG
MW("R8(^G/&"0@9UL> &H5MP[,!=86IF%@EETBZ&&7.#(\/ZSKZ;;:1,*@+*#
M@Z<VF6"H6RR 32VS?N.Q1Q]_L\BE*1A@8 $5,F$B@@4B8 (2.2)P(0.5%AF2
M 062".0 $3A0 (1!&IGB @0:4*(10EP2@8%!-&%A "I<&$"*3!R)@(%",EA
M@0L@B6( %S09A  5S#RS$242D$(3*OQ<E(5,(%&A@"F8.$!.*0)P88H!',U$
M!0&HJ&B104100 $5&%&B 4L9D,(14DT]!! M(1FU5!5JPC77FA[IT0D/2##!
M%D]*J &#"O;*@P(.9K @MQP^^" %7-0P+Q<3/O$$@QHTJ,"36TPH-H0Y2("
MC5QBV,26$T+@P(E<0/&@! SRP/ZE!*]LX*"#%VX9ME@*]LJA@Q!2B&6G&#RY
M(P49*B!AQ.I"8" %4CBH(00(Z,C%$PY"6.XI5R" )11B,9B E%!(\/>3C#GX
M (,^2"$AISY@ (T$#W*8Y0,&3F@EA5),^,D5$FS)P0,/:G#+AA9"$"N4$$(P
MUQ.!-;BOE \LB($#/.[((9=/./  QUR&ON,$&2P(P2L<.NA@AM%>8/<&MS"P
MHS8<3@"-CQ/$\D.&4? >0^"A0TEAM!0ZT*!K.A2VX(/68DOAEA0J?@".7&8Y
M'(.N4V##E1)T4N.&7"2Q0(,9*A@E!SU:09F#"3AA# ,.8@AA+] Y*&&$K%ZP
MX0,),/[+@083*&@!%U%2N &#7/3 X ,.2-$C!M#'@"6$$C@X[@7S8 BA@QK2
MJL,!"-83 ^P29B$%>0SZ>^$$Z7-1PV98]N# A ]:Z>/]/620I(,3-L[%&* 5
M.=;A@ ,8:(4?($"!.^BD#CF !0GP)8'[Z"0'#+  )W!0@AA ( 8Y*4,'/A"#
M_E1 0CJAD"T80 ?2] 87-?A "#Z8BA+@"P*T@0,%/" ##.0%#P]X !OTH($:
M6 "!N:!?"#P0F)S0"$8RTHE<TB(&!E  -EFCV(^TN$4@'8(0CBC$"@B @CC(
M00 @F,(&!#"%.!Q 3TQ8Q"'":  5 "(.I7*!" ;0A$4L(/X#?V#!IPBE$4@
M(@()&,0&#A"(0S!"! >80D88D %',&(%!\#3!0:QB$9  A(9V:2KW+2$AC0"
M50-0 B, P0A11D$) (#"(DY9IHV(0 !*2 ( 6  ( 8@@$R@0P*ANF81-%4(!
MON0  J@ !0&XP$RZ@B9-8,((_>PF!#HA@1X^80#FO( &MV@ ;=B @+^0PD*Y
MD $IQF"B7%# #Z$0 &S8L#X%J*%>Z]/#!'+!@4TP3RDGN 4,1->)&M@" K:
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M!0Y$EPL,<$)C.Z& LKU2@S)@57DD>!D$.">6.CQ@!GFXG 5L$8(&9JP#F_B
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M>Y,$C!R-Y_,0#5"#8ZR#5H !<SFI5"!*JL@)-L ^"Z"*/> ^G=  VH"!^?B
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M !NP 0S@+G$CK,#P P#@@\ T&PB ':J  <S(@P+("@O+A0JF 0Z@&3TPMQA
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M@84%X%"'!BB* S*  P380(KGU(%?.%A:&1I0 CI(!@UL@$ G0C$!/4PL%S@
MW K%,('+Y&($QPO:"2X5 ART!PX)L($>:&B!.^!"/"T00_X)<D69'>H! WC
M!0?84 <&B$(2S^G ![X7 C7 P#8=J, <9+ @.CA@#9Z80!N:Z"S*-  6)Y@
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M.8LE<P!I0NZ(+3Z3"@KE@@\?F%5O)A C6$#  AWH  4XX8J'$HMN'>&#;7
M X)8$2(<F @%&H9H@D@ %)Y8"BE,XP?;% 15!,'!&-;0'LR=0(4/>4 I/) G
M"[0B%,Y*]2U.8(.QA,)M0QE#*\[ED>>HME@7^7(?'$1C!>6B%,]90PCF@ M>
M!PF_HO $:?%'UX+TM=SF/C>ZX2(EMN B!..\08<]4-X4[- 6."A!#/*+B_R:
MD]4=,,H:0$*!I>!9 J[ [2U@48%<B.%XMPB%^3!0I9ZFH -;.H@=)C"!&-P"
M=+CPRB8XP&B*]UD-(N; 'G"!B_Y1/$<,$IA 6"N7BQQHW,!>;E,;7C K6(3
M6[GJ#942@!8,P*&(!=E0T1P $Q)X( 4G^,#Q[D !"J E!;_!\ ?V,&;XV.8@
M)KX#<U+!PQA08%*4 5\+#MBZ80U$#::21(3IL#8(M*"G)+@,O"A#D05EK#D(
MR%&"&F+2B[1"L@79J:Y:$NT7I" %'/#$XD[P @S<0A10)@C8]PV+$FR"#B7
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MP$1P3U)Z@AIP '"\@&C0($'X 925@0S4@"W,P O<":6U@BWH :N) 7T$5F+
M!5XL(6(FIF+.!2-080S @@WTHQU(0"B0@@8,C0VXPDRA!=E8#*10W9C11P:%
M@@>X" .XPAUM BP\P"VH@0+X02IT0(8L "SD0 @83'P1A"<L ">\U0W$POBT
M0@G,P"CDA@W<)B<45R<2A!Y P">,0@78 1V@EBOL5!G<0!U0IV6QV=(TWZ8
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MY  P$LL#\,T=- "!E($#[,',*$",O-8GM$(*4(!C<<6D,?Z<!Y0"^PR9:S%
M'YS10#21KL1 *^0!HO;A N2 ]TA1+IR !O0!A/%8R2QH)SB ))2"*R&$!40,
MC!#$"6#J6,$"!ZB!*ZC! 9 "'RQH07AG+M@ #IR(4I2 &.R;_^2 /;5;>.2"
M!J"!*ZS! 81"5\+"'I@&XZ7"':!('XE"##! 9''"?,)"'R! '5 70JB8280"
M32F6 M1*"[1 *^S!!,3")C1 GI1 PXQ;+A@A8-R%$RXF7@EL7T5"8&V"KN&!
M(N8"',A;6*6""8R0=#$L;.@F<.$ X1 (A*V21<P <-2 6]7 +9A!"M0 !]C
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ME5N$M\R!>6,.;ML 2,#"#( O8[C" :8!LJD4"83  ;$G&U"OZE2ZS*Z!'J0
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MC08NJ\&6"W.!@(1/XLN%CI7N\P0/#UH!I8)2]"@ !S\*P@6A7#C@#(\0[/B
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MJ9.D<O[1PP17'!#W7T[L>B"%&61XX=H' !.LY3I(R"6%,@H")5*C,! E%PF
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M# 3@!F*@H43)*$X !O# !M3/#AY@L00 ;&J-0 Y-#0SK 3+%TQS %OS@ >9
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MFAX7( !JIE9B35Y&9"<74+(5Z&6'YX03YMT"*J "9KB,?QR..$ 2O,9L7^#
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MF,$:M),+&Z0(!Q4@P0L*IC8'5& "%7! *&Q R0\XY06>!>T, (.+$&" !!;
M 2DX\((Q?( --ZB#*\*#JJ[ H%& 2M5$[,  /=#!;#BX&/X;*E!7G!C0 128
MP 0<X%@Z0, "$WB!Z#+W %#88@0AX(#?$#+#&X0B*@2! P74NPG1DJ &9;"
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MB.+F$O$!!R1&BP28"W,0'LBR*LL7)(0(B!4Y)"=HD4!2)=5G"U]B!B6E'&;
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M'D:KS8D')' +USD"-J +L& &=?[P 20@('B# Q:0(IZ@6JT  QX@ R>'$&A
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M)]+WB+#3 7G0XK@@UY/B"G?0;PP0"KO.]:*>$VH$6ELD'D?O$AE-$*F@0IR
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MY4N8B6#.5#G3IDF9, DQ"@EREH4;>"B@N46AQAT+.7(IL#7F1,=<?!K0:9.
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M@)5;N5PH Q;Q"'#!-1?DC?BXE,K0 P_ A1!H@1?X %OHA"ML#1SX@!FH@,
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M@:TIT.$:!0CP"#QP@._(L0E@#^"(@32P3X,[@:WQ%:<IR8A@@-WX,L7L U!
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M0E6/P$B1-L,;#7"%8 JB$^!&/L&!.Y R5S@1Z+C1CWH!'D,#2ZD!-1"-K86
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M!0CP URH .)H!1Z)@;>V #MP!8*\A2-1#R?@ Q,@WA667]5* 5P%FX*8 3.
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M6"F!+T<2C.B)49 .#O  #  ?# @@,!'O[P.<!R@Y#]" Q.V1"EC*$R"(0^F
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MT8<QKF$E8N! #M @B5R,H@4?N %!6B&#$<2@)).<8 BZUY!4K.$6:*!#"3[
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M[XU"*0"4'G12^!F1&>0&!NC6 ^R$"="!'LA,^.6>&?Q%1-2<*UE *H3")C"
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M-(K8B %9PD#M>(#!S (%$,1EL?X$Q8R>)\P/&\S &6:=+<A6R\12UDR 3X3
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M;ST.4EA*(#H<F*".&C10R0-<;BGA!!@\L$T@4BQH(0032IF@E5Q:T6H,#&*
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M""&N9)"2Y "3$KA#*!S0HAR\@!-H5 .@(# H69[K715HE"2TLA]X-< P>##
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MH0NE4 J-9YU.( 388!.LX_TV)8-D< )Q*.@>K46L, R[:R FC!1>H!7F(+P
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M$C:E!L9@ /6 !M3 :NB@!@13-UHA#:8B#VA 5$H"8T)!,1]%XV!AJO+,%<3
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M%+H&)=: !!"@)2"@!/K "3A #UY 46S@!/ @63W! C1@#^" !&;A # - D@
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M0)$V(8S(R47B"7@%8F6])CK3I SJ(&QB8 TTID3,0 _PI4YLX07FH-6@#0)
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MA256 ^\@!F"A LYL4V::,B(:AT U%R3! VXA?A(K*$0!Y6P@<!=K$.D !MI
M7>8)#1+-5T8'X3! %&2 #M+ .LQ"6]C&MS\!%VJC!M+ >QR7 AKE!&S->BS5
M#C00#TY@%!0[! AZY_:#TUY';$( %W8J<-C $V+9!%) ;@)7$@H%ASR!O%$B
M%^823QK@!4Y QW!8I[V& SQA!K9V#E".-G"!#R;@*6R!GFXC%'!A#&C 18S"
M$_>@8]2;5]P% [0NU'K$+$AM$QX@OBGSK/H  %#X!MKBS*H: B5A!,X"6IS#
M E[&!&S-F(J%*!S@3F  #DJB#_Y\!@): "I,  W<Y190PQ9>Q#:4QP;00&]P
M 37D*7!# <=+0%]:P0,FP /RRW=P@6]@X55QX03"2W+:S )X(S(UT \^H!6N
M/ 6TG 1(H0%P7,>"!0^JN"12 $U(>DA2FLXW J4S O80X@94)A>.]FM53 ^L
MPP)&LP-NA41"P ^\VU$@(!8^H:AHY73SH 8J:B#HH!0T $+U X,OUSE^O"7,
MH 1FP0P4R19NH17,;""X"Q<>($P;P&W*A2@:8"!BX 3N) 2PMGKEV198!([Q
M8"/A^!61["C,P 1@@4*GP@DDDP+*XU%.("_N4" Z@0/6IB"J(Q4N,EOR0+>O
M(WBJ5_Z;)=H62H$!0J</8F!%!F(.\%&1.&&T[R:Q<&%N#$54LJ+$CI(.JG<&
MX. .9&D6/!36+R@&Z&#?4UW.Y,<6',#*9F ,3 "A<.119B+0NP<JDTM4"*95
M!J("FA)YI#@5TEEZ L:[]0 &G&!;P-1#8(%$1N%&!*(;::3D()PI0D$K'N4M
M'P=I X440,D&ZN4O7.%.2.$$:, .  4#K&P,FJ,5C"(&EADH&@ /<.$3CB/"
M"R(&JE<@^J $/ &XY\=%D@)P>C>0O(CKRT"*V%4O>HT$/E$/XF1\AA&.>NT.
M3F /'!L76F&O7AP7H"?I' ,'RJ 5XHDH%'<&C-N0GCL4)/ZF/&"!#61]05;L
M!6 A,40C+_1F%F;!G>M%G2#?+#A=<@S)%1XE+#(G)C] ,I6DSH5H(1%0)"8R
M]D1A =" %.X#*/ND%'0MNQQ=-!0Q#P! #^I$*,?B%A@ !_H@M ZZ3S:9N#A
M#+!6)QY9YM<E9^W( VQM$Q2@1VY&*,<J4-:@%<8  .2G) 2D#SCA!;PD<?L9
M%#@ O7*!,8S] #JA#1! $HP'31H@!A29 >"R>G?GYC#@93@!(!:TR*4&@ZU/
M#W#@<A J%ZY<(=+DR@,!%"D,;$)1R,7Q(1H2N3C@< 4'@JT0=#A2\ 1K0@TQ
M$V1PY!B*0:I6)338^G"C%9P&N?[83!"U"<,M"*1RD8*02Q*$'#<8I+R5RXF'
M5)X<@%*3@F.,,;8>U&D%PP0L"&-KA,A%(DW8.J[4YC)#(<<+!J!R@6HPHV/0
M":1L8<B3HP0I- )BR9 0:ND=5P;0M$HS(=<8#J0\/=A$JC)'.A!"F3F1RQ8'
M"JURB>'0*I2%30[9TG %.E2#4*Y.6(!%H2';&K#T[*8I8,SDC27FV.[4RH,8
M6 K\S+(Q@TZ)7!(\J7Z1R]6#7"?HZ/%@2T&H5B\H\-8>VP:"._#ID#(3 ]>$
M/+#LQK*@)U>#I!.TD4L).,!RAT$E"&@+!*W,P($G?)#"!FN>2-#?0[EH4$<N
M,SSP2?XI%+"!BP1MP&+&6C%\X,0($-S22@.VY )8#37D$H-S)# %0QG=,>")
M*S% , L&8MC2QW<V?-!*&R6<%2,):N3"!P8S<32# IZ 6*));$79AP7@P0!+
M'^IY8((D>80R(BFM\%CEFW#&F<LA=-9IYYUXYJGGGGSVZ>>?@ 8JZ*"$TOF(
MG!QY4@('(E&5A@<S])%"'S? HE2-L+0@T@U]Y.+'!QW(@ LI)*1 @@<I<:2&
M!S+T<0)+)W1 0E(R6)H*#57!QD8''8PQTPG]Y;()J#&XHA>H9M206D>K:9!"
M*C0MRH$-,7)4R@DDL,'&#6F<4 ,',M@R2Z\A<- ?'6S$1O['!QZXF4L*_=FB
MEAAZE-"*#=!R-,8>GX'J:R@VO)F'&=V]T$$(#8D!6RXV-&2+&GJP01J&07W0
MZJ2VI'!P0ZZ4, 8I-N"B;"ZMT!!C*F9X$H-$&%KE@1VYX!%E+FNDY$D('<1@
MJ2<C="#F7'?DPK//E@IM1BH/<O1 L#.-P6O N76@!G RT "#!KYZPL%E".OK
MP0<IB5(C1["8,(8>:'"4Q@TSB=&!!W!4"4L,'7R@71L?Q- '#(0EE0LL!H>P
ML%(WE,%!UV7T=P>[.7"$!Z]-]D$P#4G1$24L,IFQB2<XY$)'SGS$@(<8?G-$
M@PDA?##"@VW S G.,=C2!L&YH/Z1DAHDV )+"AZ4H%T-'-?@B@DOG/#!'+GD
M<# >;TJ<BPPRQ(!!X[F$0D(')_BMAQJB4&"++;'G0@,L<""?R_8:X:)&T+G8
MX<$+H>/1RJD=\)&+**AN4H8M,\28N-"=JQ(;RB #D72G!O[KSR<"9@L9U*T/
MN#B!J:2V"0Z0[ &E0Y0&YU2H#GKP@R#<DR-"Z,$1[HD0CZ"8G%2XP9E0Y4TL
M;"%'7BA##=+0+S6,S09Q4*-JS0("L<@AG&(H1#G=\$UZ>('NI";#(VK0"66X
MQ2@@T D8MO"(1,P%#>%U/@G @B3>BU,623 5CG1B(T5,XPQSZ$0<#O%-;51C
M$>/XQOX<$G$G0(I2M692+5B,0$UHZ "B8-$U,WA AGN4HQLWF$4NPN(&B50C
MG1*A)Q.2,%"6O.0',[DG2FHRA(>2(0NS*$12*A)1ICSE0RQ7)? 9ZY2P%*(M
M<O"!$% OEE5*10Q2ERI<HE)8):@E;. P 4G8435,NY],?)G&5%;)F<PT)32A
M"4M7V (-,-/@'480@A240H-X2%WVF$G.F:C0;[J+Y2?7R2=."LJ=["04/#W(
MB'+:\Y[XS*<^]_E,?M;1GP -J$ '6D-J$O2@&NS@//NTT'@Z]*$DI&0D#(K0
MBEKTHD6D9A9O2%&,>O2C( VI2,OY041 ]*0HS5-#&1JH2/Z,]*4PC:E,9TK3
MFMKTIG)*J4X/L=*=^O1.A&!$%F'AFWN&HFA%/&H-27$'6X"BHSELA2B$Z(E(
MXE1.?*BB+>RP+ W:@CU:K&II[)"&3LD1-['\ZD'/(R>U^O,@172%'68!BEO
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M2:(A#&A:I4 "'Z !_6$&T2,!,7 +*<  (>!E^O0G"Y5@W5:%/(52$R4GFV
M>G +:@ F+2 1L+ ;<* !LV :=U '!G$+(6!:"* &MD "%A +>!!J'+ ):N
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M G!! <:B!K;& &)P"WC0(FH0 K&0!VAT OGB>;G@?']# 7G0"@*@!R*3 K"
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M)B^ :*1@!S@  ;B !A*0 PL#?4@*C@V!!C(Q)*\$!^[E"KR(&3- .\EZ$2;
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M."80"P[0!XUGK7#BDQR1O#Q',A9P"ZC"$6\J8C- %:E 19-5+[? O&CF"77
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MR'2H% >R6BV&!O<-*ZD.EJ7IAA1F>:H.#G*Y5K 8<+!%C>1DJ$'%/!YU")8
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MFP7TT <(J/,3KA3#!.K3$#A   TV4( >0!%$#JAA#@Q@2@A>P 9E(JL%<+"
M&OA@@864@ WBH@,./+#/!I# #F.002H,, ,U0*! -:AJ# 3@$8B((01U,,&,
M&M"*5$! ##V-02J@F88'J($4(:" O$Y0RAH\P#T60(,Q6]$!9<V ;*YX@!;U
MV( 8? ("KH!#6]L@L3N<P 2I&/X!!0[($$Y,(!<E54-\(F*"$Q@S>1+(11T@
M< <GF&L&+[A#!1K$@3+0H0$]N\4$.("&&53 %K"@0 [6  $]2(("*147',2
M*C@D0 QH4( DQ,6!/M S%Q;P(0;Z (L)3,H/%>C '4C1 #;0@0*PJ ,#2&!*
M"6BWJ+DP0P?JD((9N*($$W!LNM 06HA(P@(<N(,K*G"#[5*3 2&8P:3LD-$)
M5-0C=.B +3@P!IE^HA4?#O%"].  -.2  6MP!0-R@8,31)1-+WA!'3J@,1ND
M] 4WR,4'G%"'!@0+R$(^H)*9#$*(X( #>7@!#7(A@P:HP<:P\$,#:LP ?:8@
M;@=X ?X:)I #6 Q,# QPPB;(Q@<'V,$,(8!%"DHIBI+9@ %>9@ L/$%C-"2
M30SY9:(5[4N$['(SP E)&S(**0C<(@1<NU@N)C#!#WB"!BFBF+D@T+10C(L"
ME;/%[A@B"K*)86$?X /89J%8#&C  @YXU S:2@((U(HA\\W0N"P LC&4L00+
M.4$=UH #6%1:(Q(@A05<80L+J!AD[)T!J&50J]640<LF8$D,4@#)A:PF!2SA
M TX\85LUD'7+,[(;SQ;F,]NF0%EWF(!,0+'4AU! $@NI0!U&\0%8,(!,I&B%
M'B:&1#/D0:*N@$ K,$ *:L>B SWKP![J,"X$WR 5#UA('?Y*, L'@$L"NW.%
M!.J#"PAP<18Y\!6"$^N U=QAK70(T2U6<P*N54 4.>A8+L;PMQCD(@8A<(4>
MCLT0"U#( K"@@VUW3(*L$*ZU*X.%*T2IL@D\"A8$=0\L;K&'"BRD%<6> "XV
MH452 /<#!PN%+1KP[U;X2-,6S 4'\&"&HN>"#^.B:][Q[M8\++P&,Y(!&L )
M*&[)8 RVD,!J5D.#-" 19!CP!/\6XH1O4JP$MXCX0B(NB8Q*P@%:% 5.5E.#
M N7 UREKA0)V!Y$1YP(#K:@!FDZ@AS7XF@TGB(7L&\*!*WT #;$H^PC8A LE
MNIL4[=0#1&R.BP<$RQ6DZ$39(?ZE<NXBT.Y[@(@>-+#EH%^\!,K*Q0@TN1JZ
MWJ(!.)&$!R2^$-NZ @.W@%*S&;BP:.>B!C'W@#YX 8TQND-;"(%@-$53P 7<
M#<_ "!D0@U#*A0I8%#\()3:HE5%+LCX(@3Z B,BQ/YD(!97QA J8@!+8D(H(
MA?KZ%#W8/7:R!7IYG3Y0 %8Z@3[H V.RNU:0@1,X@0\@A0F !0G,A=R!B!>P
M S40@W-Z@1-H 0T@A1BX SY(@5MX@!-(@10@OA&@,CJHE;[2LA$($%AX,/9J
MB!(XH%3HP110F3((.A*@ UNX!3H 'PC(0O@ )P+, 0@XII"A@%: B!F@@U%0
MF3N0@/X)D %<N(&.F91%5!$,& 5!W(1C@P LU$*.D(&%J!I2F!A<J(,7*(5Q
M68U.6P@_<( F? $.\ ,.@(468 .=PX,>&;]<N -S68,2P(6). 'TZP!/2,4L
M!*I1Z(#$,8,[N &-F8@*8(K_8H.BPP47F0 , "$V( %<& ,*F  \( 65F3A%
M(2LSH  )R ,U*+I)"<*5H8$3> 'K(@4-F( 0\(@\F( )B 'LX8 -N84;, ,8
MF(-;P(64,[HQP(43Q$(.F(,Z:)P=^[$428$#NH,2B(&P^CHZB@%04P,2B $(
M  4["!%<@ $T\,<^2(']:L(6P#P]^ "(0 ,^% ,3D0%-(OZ! ,$%6," 572(
M._B ]R(%#KR%((H!#,A"$I"!;6R2"N K,1B#6!B7S9J 882#!VC"$^@ 6""%
M%DB!$DBC/IC'AWG*)M1"YYG'%A"*7 B%%T@!_=@R4,J%$K"Y!LJ%,F"3U9 !
M0:JV7""]5JB F82 6$@%Z[*%&S"!%ZBO/4 5(/(_-("($E"I/O!'-$"RB6#
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M W.AN/Y<F"IDS(494)L7 +5H^P0.H)8[R"@-  5<" $X")%,4]&ZN[^&J "
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M*)"5@0%D'L/ :@C1\3\(@848:PA0((%MWL^BXX0/8,L<,/Z#40@!K4D4.^B
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M (<M#SBD1NT-YT+'";<T0+(->F KT D5EGD__OGK7V:>_?O_/P#5%"< #E"
M="I@GOX>\26<D, F.%#88H27%374Q5)\NP$.VL84,0PJ%R^@PR=L<(,\V IF
M'' %!D)5!\2$P"1WL-O/F!0*.M#  NJY@4!B(*2%=2 $:I@7!4@V@F%)H%M#
MR44:: "*#]P" FJ@PQTFP(8].* &#NF)&&@C$(B]P#60&44=:H"!SIW+2Q98
M5V"D)! 3O.HK6:2 >,R  QS8H@TI$,CJV$ !-N3B:U?Q62Y*\9\)H &*%&@;
M!'*!!@[<@0YF@$"(3K*7Q#@ 2EPB!0/XX D+O(I8'R#!!Q"PNPXT  $V0=3,
M @,'$^2"$QH0"!Y2$#,[S.$.CF%;3.IP@PE,R(MT2($K>/ZY!FL%1@\DZ(IP
MUJ ="[0BF *I ,E@88%8G"2/%EA#*VR8"SX\[R2PR ,:LO6"-:#$;A_8@S1Q
M<0M/P.$$=DL!3'+Q 4_H$(^P>$$*ZD '&9  #G/+A2LH *!0H*L$F.K#\VSA
M!T_]R (5DB8L.O"ZI=D!AGG$@!KP<#B!D&P&"L,EJ.S0S3;$P!5,R84?;C8!
M (5@=P+! )-R<;L'"J0Z KG#"?#0S8?0@0)W@ ,;6/4"#IB!9 $]@>7VI]2E
M,I5__4-@ *,JU:E2U4Z)6!,A'M&G+H4 )#=XRM[ZH@;B. 0LL)CC&F"Q-#'@
M<$)T",4-;H 'AM4%%(E+82[PP/[".ZS/;KC  "G,H $SW(%R8K"*!\FYI;$R
M(&@2X,L(UM4*"LS" WK "1QJL,190, ,:"@D7SIA PJ,H',VL I/G/8"/G9.
M#!@HPQWZ)1"=! 8G?;BC4-@U XW49H>;L,$FS* =-.2 CFSP&2G\1H=ZJF\-
MK Q0XB0PAL_2012BX*48.J &,ZRA#WKMB43[ LF>Q();:W#+"##@@9(Q!@Z\
MY!LL>#**!LP,)VR8V^10\H)//( -:%"#'6"1 N:@ 0-CP /E4L!77.CT9YMH
M 5#0UM4QZ&$,+W!(!5JAM*A@8!0^F:9 7-&!#\X@#:U %QY@F M)4* &>0B!
M)P:,$_YC*A('=: -6M2PAKFE@(_TBC$=U$F_%&R7#9X8 S%A\2F!$#0P) ")
M,2.:@LPJ#*8 C58'0)&+3E#T>2(>\ S4 (<[ F@B3LA%"]:@3K#\4B D12%/
M]A 1" #( R[]F8=?,P8<I&%A%"A8+O10@N,N;#S7Y"X)<]&&%S" C[8P PD:
M\*BF4KK2^ZOJ 3&=)JA>5=-JZK2G_Z= ,#VY- JK0%TVH;#2:"2"WMQ@6\<)
M&6G6)10=B)1$S$"Y%HH*AAS@1 -"91GU(#8&Y&RED<3@,PB$J@,VZ00#9-K6
M%-C UKG P!65(H;',"#/>5B:A23UKY/<8G&P.JE ZM47"_Y8A0)!0RD"J&<"
M(85@7A4P"63,<$<Q=+,$KH%F@![0JQKPD@/XI@,IKIN+/: +%G!P101;H0"2
M!68,$*!F+@@4%'S'@@&EB,4#+!D*.E_2U2=9@\\X0;E<X-06$!.(&G#1 IB4
MFTFEX.4)M*BR7,#A ^WKBY4XP =84(DGS"R%!%Y:H1/7YRHK[[$KM)D'NSEY
MU1,HA84%4H.YC4(KG5B50.CPO!1(J%2?6 ,,T3"&-;1@MGJ8BD#T<+;/%!0D
M>'B!';09@V=90,LHE*9GZL!+D2I:FS!00RH<@!-0("8&/SI!]%*Q %C8X8Z*
ME@$*;?L!>3H!%GTX0"=.LD>!</X #QD42 F>E8L8Y* 4G/L,"3@!;D63XCUU
M^$ ?7I4+&.!P9I;^/?#-%.KA$S^J4"U^FQ@1I@ZXI@:#@D!=)IL"'$S )$0B
M!2YP$JG7O&?>-]$^]&'%RQ=@P ;WH1>FZ+!Y7/Q9!B/(P0P<H(<RB(=I?08H
M!:9/@:%X@)EP<  -I(#,D ($R, --, -< U*/4 -I( %V((:/  .I$ (E!E:
M4)]-? !K*4H(Y  -0 !,X$3444 +3, '&-T#<("&@ 1/D,"S6%P-=(#E95]@
M?)X9>,($Y$ .C, )!9% 2 (&?( -O!(G,& *5 #?/$#[Q  '[%+TX "[G0 "
M/(:B./Y "I 2*>@$3^#$!]R +2B )9'"Q/4$D[$*E_0! MS@2=7!>K$!!-Q
M!\Q-/PG$#'@ _)F,#4R #<C R"P, [Q*G]2! =1%@2S,U[B<OE0 7Z3"!&!<
M*$P #C@!"71 'Y0+RZU78-!!#MX !I14@=P !#P7A/#0U<2 I.%2+FA 'Y0.
MM4& )^ "!YB #?Q%+I1 "." !Y <K%  %\+$'7P (SY0"3"3!7B&*T# +>3
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MK91^:<R2H=T>;9\"W6_YK,QZ$&ETSM\"+LPZ#$"90$EZK/Y4U;ZNZZM2+II
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M'AS #80XQVX1'N#" < +:P2: 6CQ&_+<!*R!&$! *JC!>GD0'3W @9V1757
M&JQ**]1Y#+0!!VB''CPZ&D! _#I5NO9TCE+5OV*:!/=$*S0 ?UO B:-++CQ
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M;<C -6I"T5$%7R1?WL%5RA!BB.)J 1B"R%RM'M@B15QFG1 )8PK,90,'6#2
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MWK(J9=! --60*&8 +N4G%  C%S;!+TV@ 3J %/3 "?1 6))D*/I -"4C+5Y
M5W+R$W0C%:X+ Q0&!G(@!"C@#F0@-Q_R!"Z+!/# E\"#%-10#CL@%,R  2H
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MNTR%#S]@W0+#%5H =C\$/%SCN8"D!%[@#NA@#%Z*<Q@@ I_#%1Y@#."@#=8
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M\ )Y4<&# 1>8N2(! P\,@0M95&$'I\B%$8C@7"N@U0A&*()4)LP*'TJ6$K2
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M:  !*5 0(<"D-5 #,C 3>H  ,< &.*  8S ?MK 9N9 #$KH6=FJ58@$+(0
M!V   / " @$ %+ 1")  N6 ' %">    #J!$L/  !T   /[  (2) P5P  !
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M 7DL$3F0RP5A R, H7J:"Q@0T;DP R'0 B.@S+F@T#?@ 53* 2R4"S(@!K#
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MB@%M[?X F0L+$. *I: !;=T!@)L+,YP +, $*"  &U (&> "F; " P (+A
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M"8AJ"]B< H?ITKGPHBZA '%+O..="VSPH&WP !(Q!M%]W6XK$AY0H;8S!A
ME36@ %X: A^ EW_=F)R, 5*!!AB I]C9"H1AZDNKWC% Z@Z:"R5PF#N^H<_!
MHJ$L[+D@";F=!P9PE+:# X%MXF3; *10!^6KNV^^$0RPRF&1 @S  19  ;F,
M ZPN%69@[DM+ZG?  2U=OK#@VF*LT4 )L.4[ :PAZ7N- +T:"@TPUA/0F#&P
MI10 KP^ %*=[!PQ@.[:3Z0T? P7AYCLA .1N&Z20Q) *  B O@+  "F_ )N=
M"S$   _0  "PV"+! 0SP  \  /[A[@H'0 )2$0L,0 &X0 $   $*(+^Y808
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MZ'"TC"N7*=0(3 5AUJTV-DY,N#7K 2P]'1^$$ECJ0:X4: 1^H).KQ@R@N6S
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MLH:SE.%9'_@))QB7BQ,,!R,-X81%3, YC;5%11@P@RM:$0H*M @">)@-!/K
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M@ ,MP,QWG?N8$G@@!!^ BJL^4.!KZH$!P]%(#@B- PSP^(,8BDLN]L" Y7!
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MN*.#$,F%!NCKYFFCCG@!,_@KKPF!SV8,C'+?&,X-NPF.30(% .6K-<#I'.@
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M?P,\X (?.,$+;O"#(SSA"E\XPQON\(=#/.(2GSC%*V[QBV,\XQK?.,<[GNR
#   [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>comp_0021.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0021.gif
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ML!-SMAIWN YPM"1\NR=OM !'GUYK@F%NAF1SBV9YF&M[EH%_@"N"OC*#OW"
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M__CW]P
M
M
M
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MJJS:VJW:RJS3RJT-PJK+&JW8ZJWE*HK4>J[C2JWMNG_7NJ[=>J[9NJW/"JX
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M![X !Q@@"Z5P"CL0X-&A Y.M'!! V*9 V-(Q"A+P'2%@!\JQ"Q(@"\ZA!BT
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M 2C@[9_0 K\NSIZ !WB0\'"@!R/  ZR0 R'@]'^P BG0!A&A!WE [<GO"[:
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MX('62B '-7DB#B.H!2L^H0#R^((4ZS.4*0KRF9/XJ11N6!_1*) O)((M!'M
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M.*(0FM!$'1+@ DD\@BF9,P ,(M$($C2@$**S'%.J\+<H. (2'7B (2I0@41
MP@*NVYUD%'$[2$2FKG&5Z^].<OZ9/]3"@]>\0 MJ,-AUU;-"'' >2WIQ(@R,
MP@8$"<D%$'J#%5V %(DJ 0]$P ;DF*\%<IC#QWSRB\#68 8V@(A!,D":.82
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ML((:T* &$('5OD!PLQ+$X1<FT0 H^N#?=X(*HSA0<CUIT8+,DF\&BYH-'.Z
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MN%($<N,7!8 6N\D#"< #/9" XW@ [)N/&&D1-Y!"K4$!6!L%!T"H&M":76B
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M@/Q1@!GH RF0 %L(A1(X+UP @?X,> ,Y& %D"YX>T ,/ *9CT@%<R($'F -
M8!5?*,Q?3)>VK)"%?"<*: - &($7BX,#- 4/D4A'>0!2@(.(N0,*,,T64*<5
M )L) 80;R(!>.#8U\(,2^#F)4 ,*C /=*Y)(RA$4"(%/F(4%P E94 !TNH%=
M>( ="(0>"($=S @]@$D82YDYZ$1?0($4 (2KV04^>$$JK$*;B@(9<(*S$(1(
M2(2Y>@(28(&D:(0Z8(&!&X1&: 0L, $3P ))8(3( =$Z4*J"<P$G^( G&(I"
M<((7J -!@($Z<(1&N-#$\<(G>(*.\]%'%-(AC8Q(O)M=>(-Z.0D_L"/]DP,E
M!9:",/X%_4@7WL0^6O TCP )7X@##W*#$F&%DN@#[.L# ]F%-0 \A'+,&8@!
MYS.(*+V#%F@!L"L(42#,%.@!A*J%)/J#3U@46<"!%="!>HE3<$NH'%"!/L"4
MDV"%'%@!.#B14?"_46B)D\B#%K !,B*%&L#/=#&%2@6*F#R)46BQ&G ^4*C2
MF7@2@[B#IKLD1W4N7P $-+E+-2@%.$"30, !3W$^48"L2]*!%6@#O;J#'4 H
M/1 LF3 (792"4I@#.F4H3Q 3K;&#20(A'5BP7;"#](@!F;B#&H #66A64(@1
MHH$#ANJ%<^67@5(#DR@%';@!3^@$@H@#A@(%'$B-<NV$<O[M SO"0#P 5UFP
MU4^X&8F@A8&2@O/R!6$%O2,TH1B( :?ATA:X 2V"&Z"@A5^ %A5@HG U"$"P
M(Z<YL150&5+0NCZ0%K8I!3;0JSEH 15P@_-:$&L\PC[  5JX 2EP@Q1(U3^P
M(^=[4H.@ _GPA5,(U& <A2/$4I/X Z#%">"C@_BA!4!PFCY8B#,%/%K*E$<%
M"CS U--S3.<Y"5/( =*  Y/P$EE=+EG0 >N\P1,1@3D8*#?U6CTAFN_; 9P@
M!5!ET+M)#$>0A*IZ!$8DBD<P7"],!*6H*D9$-\/MG$20! I-W,"M SC4!,,E
MBL %44EP*LC5W,,PW+IZA( CTO[2M9VY:JO<401>Z-O6==W7A=W8E=W9I5V#
M:,S:Q=W<9:X<2 %0X#9/U-W@%=X*$8'4JMT3R(%/@ ,)N,'6%86 &5X4D(+A
MI=[J95#CL5Z:2HQ"X-YSVU[OW=Z[.HSN!=]S.XQ!D $L: 3R-=_QY1WN/0SS
MC='=05W3M5_(6%W7E8@<D<0T"8K^Y5___8E>&"])K(P"_HG;)6 "_)T#!HK^
M_5^]DK_;)9J[ >"9^IU]6:S]19$'UL>[,3';!>&@\!)5Q$ &[F )YN"^-> !
MIBF]6F$$/@D[:$D7'F"[&2]:6(,9P &B_5\"K)!::(-M>6$!KN <.1$\V X4
M+K<5;O[B"H9BO('A'Z9@(+;B*U86-U+@#X9@V'7$NWJ,JKH=PK5?,+[?1JQ?
MQ##2[&7C-G;C-X;C.);C.:;C.K;C.\9CW3WC[]WC/O9CR#"Y/!9D(Q[D0C;D
M#C[D1&;0!5;D1G;D.#;C/RYC2:9D-:[0+G[D3-;D3>;D3O;D3P;EW*UD(HWD
M43;E-9;C4M UUR4DV*V%&IJI4E@P4E!8ZOT%4<!DH/@$6N(75\W=4:CBN>.C
M<FNINV$D7/#AOC4%7F;0J?ED"QQ>4UAEU^6HV24[FMJ%2;+=4 CF4/9FOR6Y
M4C;E<1[E0D#E1<9=%2"(7*[@%E@4'*;".2#+F8J!H<& <OZD*:ILW3D8NMJ;
M9A>> \ZJC%KQ+]DZN]FU@T4Y!62[F]ADT!QXL0!^IJD]P-8-@9#*Y1,9P #6
M7Q@[#G:&78DHE=>UVYE*@759@W0!Z>N+78G /0O.GGA*DY4RB6[^YIOV!7+6
MZ9TFN7-^8"45X8(HI'+[9WVI# 3ZW[K[B1DPGY.HA:(>8(4%:E]8,!Q8%%XV
MMI\XJ6C[:'V9ZFO*(R22C2_[!5I04Z%>91X8ECP2@08(QN^HP;_"&U@V")-0
M@T<Z:UDXZ[HVB P+"ISP/*'V"5JX@/^HY31I7KZ6ZM^IA;TNB!)PV/_X";/>
M*UNXF_+;E\3NDAK<%ZA&Y#F"0O[%NYLD XH+*$>D_HF.F@W\Z)*OYA=>Q@!:
MGF9:^&J?0.V%79>I5E)I&FQ<F 7L:FV@\(FGQFE0YNG$/>[D/MW^U0,-"(%@
MA9\9<(/"M@\1\(# [(45T"):2(%=Z /*T@ - %XI2)?6*H$1&&:""8$4" &P
MW<OI=5E<Z(4<$ $1P \U2"U06&L_(!(VR $;P( 4^!!3"('ZZKS9@)8Y\( 0
M*('M9I 1P(\U>(!O0D(0$($1<*,VN&NM.1'QH  >V+,>$ $* !=<J $4& &P
M.:$+4*=K\H Y@ "VX2(D"@$1:(%?" 09ZQB/6.\0L"0W<#P<0!8*R %:"*%=
MF($2"/Z!Z2D(3Z"042B!$S#"D^ \#:B!% ";51N!$( (6NBN3ZB!74 !G/B%
M% "E"\\SAK"!-<" 7L"!23 %'T,9I]D!#;@/+I&($D@7* \!#V@))%>#$J"
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M:%B"'6GQH2 /.VPE"AXW8.#+)_V%-E .:I3R@!YW]"&!4OXK^<)!(+Z,<.!
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M&W?DUB)H-:P4XR@0P$'L'4\-Q(% (.#12[47S$:DD7X2%$<+#\ Z$"UKH.!
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MH#X2P$5:BM06OGQ"B)Y0HEJ U .=7"!@9CE%"X18@DGJTA<]H!LMZ-,"V;4
M#J2 @(XDX DI.K.60PS@&KRYBSCL<B!YF"0E06@<[+&SG>Y\2/CB*<]YTM,C
MC6C70:H& AYDH%,0J)8OZ$"!'JP@!,;)P05TT(+ZZ>$!?A*6)<NEAE]P 'X@
M,-%*TL,#-;1 F[G\DRD6  I34, &.9  :V[ L(+0(35!'$@,3.0&"?RG 7RA
MP!]Z48(4](!@UN* &G:@@5K6(/X">MC%"5#0@PL8:096),@=%M"&\LFK?+N0
M4% YH!,\*"!,6Y$ #VF6FE)@P 8[D$!9?)&# PC(>#I0PPP>X(D=B*9:>5B
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M*1X$33JC+S0E0=0"3@X$6<SD_N2.+.VDYOU%HQTC PXB;[:A1F!AVZQ*#<Q
M#6! "N#2*93 "#R779J5!FC I,$!"(R "F3&+]R "(B $-4 '-3C3,X !ZR
M#?R)&K !"DB'=(; "!@2'DC'W=Q%#9AG6>%3'N!*" 0,&^! 6.ACPX4 !]A
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MMPB,") 5O]" O_B""BR>0C-TY!#$'Y25'L2 4JB [*! "[Q!&\C!^<S:#(3
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MD,L:",L(=*M[-4"!A:<+4<#@"O[WDD6 [EXK+3EU6E2+"IB].*9 9?2 !.0
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MB4@, +"&'0!@![X8XQKB(  4^((&8>0!&7WQ1C7(00 IB C^YD2+\9TB>;W
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MWORFL_Y:%Y<QXH$4 >A!8N80 )+80@$N+ 4$&@ !!<AH2&^\@RD"P .<V $
MAHDC"$L1@#+ZX@[E'8@D-0"(&0" %-'UA"D4H(-?\+,6/!  +=P0  VT(7EJ
M , =^J  U&HW!IYH+QU& 8&?:( "OD@O'$8A8$"T<4H^Y9@H!- &#(B@$XWU
M9PA,,<9/^->5 ) %&UJ0/P#40@T!X  <9C$#!?BA%V^4!0H>((L][$!'/0"
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M 3S( P!Z$@!6U( !WL:NCE3-+.->K'6C>, %?D.+!BQ4G@1(B2R _@L"J-/
MI9A#"E+PB5+\_3>[<( 7L\B*4W2U\@WPH@T$T)Q.3-(R!YY! _2P!SWTH1,"
MN$$?]H"'4L!AH(E)3 T(0 I:6, #DXXGV.GY<@'(HN<.&8"_YR#KI1)\8XD9
MA0"66H(&)$ /175L*0301 JT8 )QD"$%_I#&%QM^(#Q0P%1X0 !3U.(/<A!!
M  C4 _X"G&4- 3A%"@CMQ .4PA1YD/\Y<2Z.$& J1""L'$"=-$ #!"^>]$
M.DQ<K@X.HL<7^F  <F 4.$!%YN !4H#=N&TJ:NP43D!)6$$ UL 7N.Y4Y&
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M#_",*'PA#AJ+#P@@M"Z  "B*L6S@#A!@H>;K!D2@V"Q-!Y*'R;BBUNR@#PB
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MEZYI%V:C1#;O$B&# ,"U-BPI4)+G%/K5>71PJ4@A8$L)/DZ! ):O5Q5$%MI
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M H%P)>!'WF !'D #=D$/LLL!W("-4& &+,!6><NW-H('3A<2YX"W,. 7]@
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MHBLM92$!RDC'%  .6$C@_"GG/. $+J")N*P/&A 4+NPU!/[ L:(<%&@A$.A
M!1J.J0)-N@_DZB@C /*@%P((ES"W-M[:%Y3M$_ O]?; O(1R('JNCD? RQ4<
M O2 #UH="\>;OAOU#<#8^GJA/6M#'3\(+LK\;E.B#1QJ7@ !U".B!/X@!<H(
M ?3C \\P &1!&7$U[)Z$/SL!I':!!L26 G=P%T#O%((<#UH]U%M [#XH+54\
M9+YZQ<F57!L%NAQZ()9H%'YA%@K3 %2 %Q)C%S*@ 50K &8AEN; R&Z"S>0)
M /0(BIC1T4"W%%! APTLS[;QE=W"Q?BP#S1@#LKR)1Y@!&J! 'HJ,7*  /
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MXF,%P62^$ )@00<K\ L0P!<UD(N=$!US!P("P1=_$"%>(W$V G$9X0M^D(2
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M Q&8A/OSA0RX@3[  %^J+#4* 5J@!3DHD1*  T!@%SU  6UIR12@A1+( 5K
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ML@,=4IR" 1YWE/#&'3SX!$*5O=0RB@8-#.36)'S6\(><LFB0&RZ]M&"W"I/
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M1G FK(9B<2@ 02<^42,,=1!M(:0C&UPR1\YYX 0IV,4<_E***XE %J.XVBB
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MP),L6X(Q&48]R6_5@"Q(D@6SH:[50A\<<!IBC2?4R (/1Q^H%!TQ60PC1,0
M1V(*XFWL */4\"ZT0"V(@E\A\))1VQ=B&9ZEL$%X0NI-FXT=1&"8PN$L1 T;
M1/W@Q;=16V#<@>=( 1Z,PN"<V8!8!'4@\(V1@@>@1"/!2 A?62)^0FK^5I(-
M9&#\P3D1XA?VV$"F1([]V,L\A/X2Z>LR$"!XP@78P';\0@IL5\8  @88Q2Y
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M%%5@=/["_^9!),V 'A (MQ7X JS &OP""MS T;C$*!#]''C M+0Y0>3 U?0
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M: TA"5Z[ *:8#*4HD40579311AU]%-)()9T4TD8HO3112S'=E--&%0'QT)A
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MB I4,(HW","O(,A!*>[0 )A00 VXX$&VWC@*3TA .PWPSBX<@*?]7&0'#>&
M3GWA 3K@0@)S*,4.V@("G5)@#?ZCL($"=L&*!^C!%#D0@"P^ 1H<5I$C<*"
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M\@D4**!$!T<$9@,%\( 6G&P7!OXQ5.#+/=<T)FJA-#) D7 -3Y!B(:&*)U9
MU[)T%."2(GS44-,T0FJ /T.B12NT<UBA:C"3%D3A+S.5%,ZQ0L0J5$ZA%<,1
M7BR4(HAJ%T9!-6.BTIB))JAN14$U)F@A+T$$%UKQ1*^T29^T% [*6::4(H#T
M$P=T4@1TL)A562'%$=M1#SB@!-1*Q/@B$%9@%U(  D# %-3 !EJ  T" )W9A
M!0KO"E=@#2B@#]R@ 3# 2=3 @D!@$'G@C>)O!':  T; #E+@ J;+(2#@ O:
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M9L V(.Q,L6@&[N," D%/)N$K'OY@2 U@!V""/WY!1G=A%P@*/Y#3GDR& ]R
M1^;@8%;13F#M->35-#+J!M1E++0-JFB!#48@1F&DC1%@.A#7-!J )QKM=DI0
M FQA%Q; 1T!!N78@-YZ/2B#L1^()1 #A(-1 3KO)"7^A#>P7%R"@342A 7;A
M$VX-$*BH*)93<7TA<3]A%^"  VX#.'3 +H1".!K@8FR! EK)4'; )G+ )D3L
M B@38V"0)%+ ?M^I#TH!@3J! PYF!M#-FWS! >ZC%")L%%BDB!# .V:##C0@
M?.%"=P!KH$EG!$CB IPD [@- U+(GQ% *_  -/!@.5"'NB0 %'"A%VQ@[$P!
M K1"%/Y^2P\$0 ]60GI]00X,H#0N  _T)D+0(EX6H#1.=R#:Q-(\(:]@@A0R
M8"5F(P=2 $12  [DX"1$(A0P"R86RA<R8#+?IG(@]0;F0D>6)2@26$TEH$B:
M0A8E ";TP"ET8(L)H$VP5J,>8$&E0#QPH#@69Q=P(0&*HQ,\*0=0@_@0 @0"
M09;I[68V,5&6DH;_FH7\.H:6\5"P+Z7\2<L.0V:T)4*..'G !0-&$**"XG$I
M8C.ZB0ICXP;4J&] 9 <X!P.\4RZ*"%#R  5N! Z6[@*T9#8NAR1X8+HTP*]D
MX0[:X +N([1YU"NZY1<F #NVJE:N,'2&HSAF@ZVP@UF8N?ZX*:($ J>9W"(H
M##8.X* &#@,_D%FC*906(J 7[-5D,J TDMN-%(>K 2,.=(!J CE" GD7U  '
M?N$!W&#I/  B[E8*O/,/X(('PED-[*)I+'J"."20;>&1Z""U$X ) [D5W0 U
MOMBN;V9J_.(*Z\@X()0-LB4<::0' $$-P.8K) XAZ !03N"!4R /YB #[@ .
MXD !^ D7@&RH"4R0W(E0W, 77==LU,DX3"&OVA*L(B0%J*P%XN 4'& .WL#%
M_@)6L@4V1J$&\ 8.>F !A.(\<4!+>MDK/+ /M@@#@*</D,=43*;UTJ^(CH4A
MQ*E"=D&*[> -YH !SDJ0\+ 6P/YFEGHH#B-$ _1( N[ #>A@ 5;.4#P!#F[
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M?**EY/G$(+-,GDF@U<:=Y0UE&SP85[)! RL:00A$MPL:@.#.:(2#!^3L@1R
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M4'Y @0=L$ -@%HLUL#%U]7?$F%1^AV&)LBAAT0.>@ (XL0(2T )XT LE@ .
MT *(51/1F >D\ !W$ @@Z L2, )WP ,0(%"[X08:4 KI W\ST!$BP@9V  (7
M<""8D?X"3B$!1M$#)3$8%# '=T !0E$#$- "=O +(1 #=S #"@ *M* !;= '
M(: >!&F0^H0!7Q<"M6%\/# 6F+$#%" '<]  ,"$!?6 +$M #=X ""^ =#: &
M=H !M2%W>! 8$"(":A ((3,*(N !&]2*'E O,8 ">I #9=-)_>()$@ '>' !
M=U *#7 K&( ;H@ !OV #*@ (-S!2?H !@2 '#\ *. . 778!&Y,<=)  P0A)
M,X!8-J :1($!>C * L #=\ !.T,4$4@3<8 6^%$"#Q$1>" 85(8WD>)<=^D+
M'M <*I #@3 ":$463AD'#=!2(6 #>[ "N/$)!L #<G !(OX0!TKC"VZ0 '#0
M!A  B EI$:I!0&UX G:0 Q+P"Y_0 +ZP!Q1@!R,9"+^P-)Y0 FW0"VIP?#"(
M 7L0DV-A ^*W PM@,]=AFRWP.G+0 (/4"2 @ GP E3>0$+_!"A@ !^Q7+^C3
M"26R C,A 1"!&0.H!CUS X?I(+07$;00 ;4P![N#!PBP!@$9*3/P ',P!PO@
M(0_04K3P *4@"P\@2*OB()0X,JGR&!L#,']0 P:7!P>0 _:)&[6  3R@!R(P
M$WJ@ "J BK "!P]X'9-B![6 .WH F;>I "O  P/S"240E! H?FO0 'G$ 6O@
M!R,@:6ME0AI6C$0*>(D0>(\#(?Z]L :XT0(XMP=,@@L/H!V8(3@'P0IC 3G^
M<289$0K4(P4>@!F4\3@Z"D&11&\'40.T,H!>21,^&2/&<0/\,:9@T0"DT :J
M 0I D@/\\5P]@'._  %$4X];I14W\!,:\ ERP!\B@GJ5\3Y%<3=N("$A>1^D
MB1%9Y@8SL3(1L9=$P0?]DC?7L1LA\ >RH (CY08W< JS>1#HV0<40#3/M )"
M85D7@'2^X D'XP M<" W\  C, (44';D(0)E:!V>4!D?HCJ8$0?]PB,], (2
MH %C<0?*RC'0 B</AR%6XA+( 434=@'BI@> D ?/&A*@8 H1P&^8:A_VF1$#
M(7<6LOXS.9"/:!2KIF <Y)(6/ %E4C!2P8,]0'=6!?I#W_E<@,,QA[D"(,%F
M.X 36Y,<S-(5._,'%&!9NP K>00!:@0"I)@RGO  @" +<8  Q$84=F 0M" !
M2Y289"$A_9.F.%%I8($!I5 +$+$+*Q I&)!18'$!&B!G>1A)%WL2#U"+UM&&
MI\ 8OW0D@6"5;'2NR-4&,_&O$>&T:$H3FGH0'! 5&M )<M =3F)V656D9GNV
MA*):=% "-3 "!I<>!]$&%# #*Q #(] 0F,$>)[$+4B V&: >#M,+&/ )M=
M(_!6I#FW*] "(C **7""OR +&$!:Z.<+&) J&B!N<C$*#?XF"R-B ZRA'R.5
M'"$ "C>@ 3&PN"C0"S0U%+Z0 F_ 9A[@!RBQ1&S6@T0Q));["3MPB[U "URQ
M!\(2++Z@ 2C@I%>3&QYP 6?H"ST0 \=5<+T !PJQ"[U@&#3!?B%10[^ DKO
M!E_W!CK0"2H0"'T  3'0 G8+$U*  1?@9W'(B7&R$Z$4$5-!*S.0 I\ A+?*
M72'0!Y^ %KWP!U(K NJ1''. %I!$"RJ0%(.993BI;#S2 "&  B+ <>4Q D#[
M3CPB ;+ 9KB" [V0',%1"A4R _YA%[@ !PKWM9'$%>QY$#GP$]>3)*4P"A5$
M :P PK^0(350 CV3>;0@%RK@I/XGL 8Z"1;CIH68,0J[T0):^!\H=S0ZT NB
MH'E-LALK  ).N@(JH'X'P0<L8Q(C Q%$H0% ES(1! (>@*?J,3 H  $IH ((
MH(5S\!N]8 =64KDU02L.0PL8L$3< 3VLT;/.]H_["P?U6#KIR[BCT >X0;I^
M4 /!B1D<$ A_("')01BC!B<]T#,IT :_D!P@\ >!D!31.P-$ 0*!Y@&!L .C
MHKH YUU\,J1H>\L7-EF+H@<1T")\,%(K$,5S("S3T\DS !(/4P(5D0.J@P%@
ME@&BX+G.:R5V $?E@3]5Y<2]I:8.(FXNC#WOQ'0V4%5W@"4+(7F(M42ZZS,A
M'!$2(/X*O=DBO3*'-^ 4B:H'<!0(0,('PRLA:/PX>92E<W C:X 1G9P7CAH1
M*T K8IH4'B K$K&NGW UHJ 'R],+[J)/NS *F%$*&D K*+!!Y&&<#&6G$<$#
MN#$#M2'#!C<P9!@*3!((SXH9)> W:C C0*JGOB!P]IL J$44;P "G2!Q'J"%
M>*L'#9!$T1(C?W#'$:$!L8<!_,8:8((+5LBU'D)ZJ*$5M!,2A].;I6 *&-";
MO!((@, ').,<!I=Y!T$!8+8+)S4B!Y$W1)&PU[<>47P0XYP;&' ?QC$#<U@>
MY*$'UQ,1$WD0MO  \DQXOA *$F7(!W$*$0!#G6 ["-$==_Y@$-P\;K1" =HQ
M,K1PTQ71 ZP!U<\E%Q)EB5H=V;V SQ%! :/@?>Y<"H! S#(2)Y@1PUGASK5H
MSL^%T+[ R@?A 9[ !MHCV'2%R\J-MKHL)Y_#"J(@ AJ "\9611?@!J4 !Z5'
M$]6-*QGW!Q!P [\@ >*&G@BZ"R@A!TG2!J40!V.MS[Z' G7X7"J0CV4$*D0Q
M!X,K"A^-'B=2"Q(0!Z:@!@'P"5VB!Z4P-ARST@\E 6&D&8YAH)<5 U]1$U\Q
M.1"( CM0 L81& <QF C!$*00 MC7G*P0D+[ !L[,SBH>0R#  Z50.E6!&83M
M'!+0":,0 C_1"R%@'#UBT!ZP _ZE@ <&$CZCP HD[@MA1PJ6]0"R\I&3LR +
MP!,IT#.8(052FP%[P'07:!U$T0<*X 9_$ <*(!1[L !R, KN4AMVP #_*04-
MX!2>X#?NL4$#/3)L (,L<1P<( IZN@<C$P>EH 92[0D1<(].4;BXT ;=00%H
M\AT(03R L !.T0!F?+1.0IH:( J?@"^PR@J?$ (>\$\-0 >[H(ZBP-_" 0(Y
M('L"\,:YX0!QR!I*'KH" @*BX"3)$0JR#@H0T >E8*6/LP U@ =Q  <- 0@-
ML >A<)G/-1HJDP!Y8 HW  *DM@/$; L&L"!PE,"O.X<K\!,>< .J)P"V( 4C
M( N!8/XZ<B%6N]  :((9%* >&(!\<W 7?D   MX#QF$D>; 1!G$'7"%8)$DP
MV@;MHR !>$#M$N+A<*+B+=6_EML'#80'I; #(]!SB[+<W^5!XJ54MFQ"2*H<
M3+H#H# #GT ' ]'1C-L")4<PG$0+6]D&G= "LB %\+$#=;0#R0$*,W$*';,"
MY70'(9 "=M #0A0'OK0#\,$#Q%00>^DBOL1J%AP'4G XG< Z-U 1<P#1+I4"
M(X #%8$+.M!5! '1 (D:O(5Z>3 1O? )3'.*!Y'9(\ &H*8^*,!,+< T3-0"
MD2(+;:L"]<1&AYD'S(/,&")I.0!FM5 #(I ">+L&)3 "4OX :B?@]1&A X05
MMB%0 IP$!Q"G,B)\')]0"G-("H&=%A:, EH4""D0 C]*%)Z0NBE0 ^^4@OID
M [="%+4P [50"@=4 AUX$'4W J1("HP[ U5A"G,(![ZT"SGP"X 0Q1W9)'.X
M!B&@!DP9$S.D TUT(F_ /!"W!BE@\C, (?M!%WDEJK(P R"P!FR@1;)0&^!Y
M$&^@;:;PN+00_3S"\][!.@"18Y>O7[YDU6B18D6).[Y\]1D!HD?!7K[RS'$X
M"46(&;4<.NS1QU=%7R$_J7'8":6</ Y9^B*5H@0='K)VX4BA!E0+66I"??QU
M8]3'-G9\L9H18H4H7WA*N FAHOZ40T\I1."@Y4OEQUT\5OA2H\)A13UQ'()"
M,>*&1U H/SJ4U:('6% .I7C2FK;&K+=]_?Y]FTCP8,*%#1]&G%AQHD:+!3=V
M'%GR9,J5)2OB!5CS9LZ=/7\&'5HT9T\@3-&Z46+T:M:M7;^&'5OV;-JU;=]N
M?8=#;CVX<5L&'ESX<.*((3D^7GRP(I)_"X[]VYQS\^<C_4J7_C$[]-?;/7OO
M;"<%"AL>^X+7OAF]YNIOUZ</W?Q]_.N *TIOWSI_:_SJN0.USKW_SEMMN_E(
MVFZ_ ?T;S< "?0F$AP;A@FT^VI3#,$,--^00,>9\ S%$$4<DL4033T0Q1157
M9!%%POX4Z3!&&6>D<;!&+&PQ1]QPU+%''W\$,D@AAV2MLN1J1-)&X"";D4G*
M/GR00=IX)+)**Z_$,DLM.5-PRAR1A#%),<>L#$K-J-2R%C1#Y&NV7;S[92 L
M:9'3Q%[,$_%.W]YL;98N.Z-SQ$!!;%/'6D@!K% 7,0R33,2<=+3,#3'3K)05
M0@C!CX_4  $$C#YR Q!?;L*TAP1U",$#-S;MU"R' HD(!41]H:4&$$(0E362
M0 @DP!99P<"C-07TA0.1Y//EAAQ\)1%!SPHZ 8_HX!OMCS?\*LB3W:8#S-H%
MB05E6V0#6?5,<W>YX!-F^\J/CI9\T0"O^"J:H8T0"ZIAC?YU/WN.C;JT8P.O
M4S#(2C2RZ.!V%#6RRRX0"6IPJ* ],)(% T6)]2U2C3>6L=$7P=L% QY*N:.!
MH73@P!10(,!HE#8(Z,V&%$PA!01]^TJJE)4QVD$#4D"1  Z8&L"CE!TN&$B$
M&DK9HP%U7<N@5WY=FP\7"O"$S::_:BE8Q_5"Z*U" >48 >-.,)C6/SI$ &V4
M"P"[ P2,06.%QXIJD+"7"V8=306AL_MS7\"JF\$M^SSC8 ]?.>C-% I:XV&&
M +OLY&USU9#\+35:,$B".D_D^+'01Y\4O$_0=B@$.7IQ@!6'^GC[CAHD4)R#
MAGQ9 P6"QOH% Z9\82.%7AXPQ?XA0!Z'0W>''BCE$PD^VH%SDG;)08011+KA
M=SU6!:0$$6S !=X_?+%4A!:F\NL3%5!8X92^YAAA!+?H@&.'#' 8Z)061E@!
M?>[V  $*X! L7[0A+=>* \)\<8H<D,03;8 #!TJ@KDZT 7Z]:(.Z9)&4"39%
M6FN@PPPR(#1? ,)Z<.#!Y]R @A+8BQ8\R$,)0" M6O3 *3.DE1KZ  )UJ2%^
M"J1%#M+"A[.@0 0SD(4O2J"&&F3 7IL:WT&RT@=[):\$;'#()V1ROMU]@@,7
MT$&<=,#"E@0";;NH0:^T.((:>(0/;5 #!V;0M5!\<5FB,&+_WL>!%;B! V0I
M00GF,OZ*+][@%[BPP0A04!=2J$$/(6 %"$MP@E#8SRT\F(4L>" '3/VK#2-@
MR%OV8 $-V(L#;E"!!FZWAQ*,8")OZ4,)4'"#K,P@!SG0  \*THGQ\,07?X##
M"GUABA6, (G6*04.*D*]76@1!2UP7^$**!+<C8^8(VB!Z[23NQ+(P1=OD  (
MWN4+.(13#[7( -E ,#Y?Q &4KOH(_);X2PQ@0 J^J(4-6"@J<L5A9B5X&)Y^
MT0/K->0/]9Q+1<QX 37(0@-Q* $'V-F)5N(/1*23#*0PNM'E@$=/Y&- *#[Q
M.(>40@))],4(I%5''NC  _[[""V>DP$WF.)Y<#GI+@K6A_X&_$*8 ]F#!MZR
M@AB<X@\-,,4-( :O/9 " GZ(B^XP$(A?9  /O[A#"+*S"PWT9@U?L8X<,#"*
M4H1@![ZP 01 X3B,J'(7> #!YWP!B@<$@I@-: H'=F&+O?V! A7I@5@*TH<!
MP,$4:_BK'P2P TUAH"4:4 ,K2K:+&T@. R$8A2<60(I2/* /ILB! K)2D3QH
M8!<A\\0O$#"#40!B 9_H10)8"X@&@.(7"R@!'G:A@Q*4(A07:$@.)"<*"NQ"
M%A'(@RQRL)L38!84#>C$J'RA@Z_H@0"BZN;9Z*2!QB*L!YG#YPY"H"X>M. 7
MCML%*(1Z AWT@A47^,,N@@<\!?[\P10<F$M!7LA#5E#@#K(8H"T^H@<)A$(4
M(7C;04N!BQ6L8;_J0L$:=A&(#-!B% 2H 1]V\8 9D.(&"^C#**#KBP9P5@"&
MY8%0V8 "6LB" YJJ""M0T&%?7*##?5A >B\PBEW,(*&^P(4$/+&+%J"$!ACX
MQ"@@H >]:8H',?#%' 30@S_0HJN[@!]7)-"KTO8" R+I >>*G%(L^L)3O<A
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MXFT]L %*+B"+7[ <$!AHR E0T >L15DLOK %+42AAPC,XOX3&E"*0]H @E&
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M*.P!6^&L9@^^E@Y96.1RZ8P7=/[P!S]OOSB%@6 %>^'OS@:-_,!%=L(87'!
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MJ $.^#KQZ@$.$)HYT #;'(406-A?T(.*--:!4'P,N.'(#: :H($'Z(U;-:
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MJ8>.LN(G&N#.KKJ'DX7<ES*V8@@%2#$WA@2E@PNI0?64"8<^<."JI9!%]BZ
MWUK0B \KF(.!4KK2/*F!%A (A69E\1-RDKC$%V*1.M^IXA6S&'2-*.9R3($
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M0 C@0 D<R4*XP>B%@/,  @GR4 BH% _$G>E!#>=Q@!\!16F$P I4BQJH5L+
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M#RC&>\@=!O2 "F0V0^C!8^#$#(S &Q!R0\!T#3P C>1!>;324O0!.@>/5^P
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M/TWB 44+5+ #J(8-7,!?ETLVZ8@H8 U!)IDR+<4IA%PO$/Z4[AA-O*G$,]?
M"(!V$FE5$M5""%QV\IK"I8- \#"8*8F"/W6C#?0 UCB>!0351"@$C)3"+)1*
M+P3%'F004OH!6M  &Y31><@)H80"CW=%(BULSSQ&^1PT87B3!B1@H*\*\+P+
M!CBS\VA "B %"@2(<G, #L1B"!19"2@'+J# !1C.<D"+0EZ +7@1E]3]"E1$
M+C<D\_P$G2 %=LB$C1,)JD2,CDA9&VQ*+RP1ICS(.W/,2^1&&]C-@^" Q/]"
MR*U!:LR #52-WB0,!+"2!. !*637";"?=O>"%&P*!;#"/"V$()7 "&3%"F@W
M0VC816T)";'"&_0&#=B ^U!&"OY(K2F8"BWL!39SOBW0P65(0"F8S96D@%Z+
M &FIF?JHF=P9AL5I8IQ^E2^,0&OD!@:,0LL^#2MB $"4VC%G1BT,MEA1^%7K
M0BE?=$KX\G5GA"\,GFA1V.6KU 5:$GTQ-.6KAAI?O6RPD?7 1@T;&'KX^N4+
M3\5>ODSEL!$BH@V3O6ZHV:5Q(X\VM!S8H'$CPPY?.22$@ /2%ZT2%TKP\27+
MX]8+M3)T.DE+PJ\<</JHL4%JQAQ?.)S^XH&#:EV[=WTETKM7+R2^?P$'%CR8
M\%^_A1$G5KR8<>'#B17=Q"M1JDQ?+=I(7!%'%H12I$K)^BBQTP)<(/64O?!)
MXB@)OOYFF&1U098O."DNNY%XB@(M#'I,C9(EJ^/&XAM)S6GPQY0#.ZP 1>P3
M0F(&47JHW\2\2\+'CK9 GK!!%0,<6Q%F3J3.H8\O0!HDSFCSBT+M'C4D8A@%
M"$15VA)+P,,B.DH9A9596)'@$U),D:46D.Z(R!<Y<-OHDS8:."4$.4PA9;A?
M>ODED!HRF&FF$/+P!04ZJL+I#@A8W,B&'"0:RI9)./#%0@Q+$4&/&CT9RJ%:
M)/"$% ]KVZPJ"FH9(44=(=B%C1DD4@,_D.!0P3T,0.(!OYEVN-*7WMA X10#
M6?F%E M\Z82"STIA91=0N)0(A3A\&:6K'L:C@)51,+@)%/XV2U"C%%%D846B
MF>Q 028,6/N%-CA&8(644V392*(4W,H3 UDH6,.44CC8:(8X9FA/@E$D"H4"
M%>V02 0!;8CIIIEN<&H-#/S890<X9'FM-8= \$-%W22BX)0\(I),HARDF&$7
M&]98 2>%:/G*%SLDY-8BC'KCZ )-0_J4)"DDJN$H"$9AT$&0\!!!HD]@+.6/
MBFK@0:):?8%@)%]2:&.7!T)QMY:-9.%#@QM.TM$74NAX0(^A:N,*%PX D6B6
M"'KY8X4=/)%#C1)JTX%&7W2@R]G))FO,Y9=ACEGFF6D>+#*6?>% MYE28&/3
M-7S18"I<2@"E85]6L(Z60!IXX_XM%';Y)87Q5# IV-K<B*B&_VR(* ?<GI*C
M%@@^,@4"DACV!00\ !%VAAS[J,^7"P+!!8*,07F@E%DF>+"4[D :)0$V:JF%
M![)]&4%?@]RZH#T_,I"HA35^>>!!'J@<4Q0_X*,%@C\V"D$H-4:XB0>31HA)
M:F-G\H-L6D#0D@,Y)'I@E#A"N$F*-7"1()0\'P!/(@X$%($'7ZT%6-^9_H"@
M-C8(V"40-BOS10)0[M#@HQ7P\VS3DUM(\80=<+&;%CJT?ZHBS"7JH06);H(#
MA(,O8-'L0"SS1&_;")B%% A(X8M)G* 7H_#7+C!PAY"(H$"ONLD(IC**<+$/
M J<0!?X%!/4J.F3@-'"@2\,V6(M?^.XD$K@4!'[GB1*0JP49>% +9B +!6S$
M#0_8R*!0@*L5_&(7*&"8"FK0"U @X$<UF,%H]D4C%(R'2$#C -!6\@=?9  .
MN]B#W-K I3E0IRZ=>( .?.&&!@C(-;^@Q0/$LD6)V($Z%.C$V+P# ?#<9&QB
MF8&^8.,4$/BLA_B[R1WZXXO4[ L^-7 *26C4 PS@ 0X-F(KH=(0"4  B QMI
M0T5PE;D2N*$7$)C%5B#0"S> X#0UL-8N0,"!7[CF2C=(&P[2AC.6U8R6M;3E
M7Q1Q2UTFHA"-6-E=5L"BF>2@4SF@G2E$( (.H(LJ9KD !OXN #0=[20$TGK*
M5&0Q@MK0 3\U2$$+0E I'=4 !"%8@2VRB; 1["*;(P!!#':QBQ:4H"T>Z(,M
M>-(+%8CE#QX8 0=^Q(H5;F4$2/0%*#R  0QX@#5;08$(/! 3@$FQ$V#3 >U"
M\" WX!$%IO!$\G2PFFU%@$4V*&<**H:"$'@@!\Y"209H,*,V<>"?A\R!!T*
M D7-(0,CR$"L0-*"]N A G.PA4I#D(('@60-/<U!"6SQ"4<A])\GXP$(1( "
M6NQ"FQ*A10I"  (;;"0U4Q&!HJZ:T]K X9!L/1HI,A #7X@BG+.KBQLR(((<
MG& D>-" ,C.&BQ5HSQ0@^&=F/OYQ I#40$"F6&<88W)64TAH%!)2 P=$, )6
M@814+>A%"0+XBQ*P:@\:" %[%N6+&*@ G"6XG =:0"&?S4V:NYA!6&N ' Z
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MHN?=E@6(A"?FH<<<VC5/!+O=_FNX0R8P$?<V;)P[\!GX[,QW4&"I)](L7<\
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M.  '-/[%#9():/9@MCX!C$8A!4:@!=BLBU)@"Q7E#]2 #3C 3+:B!3B@!U(
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M^B,/*/[@$V1!KWSA 7*@%.Z@.!NF#S@ %W[!"'?! 9;L3HY&!/ $#_H##A1
M#TZA!BKB!JCD#^!&0;;16MC 6C3@[QP'P6S %%@! _[@%_A1_O@@)4%B!Q9@
M!%X-E/R@%$R!#S" UFZB;3IA$*T% K:.#D)@]/R@%^2@(N:  -:@$VRS(ZD$
M#B(B*2W#(-IC#BJB$R0@$ 9516Q %GQ5BB"@!>QE 3*% N9 %NY  G8A#P@
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M6[@CS@Q4H1^DEVVC(K9B!6YB:L2$C5E;"E>;Y-+/+CH!1G10 DJA!AZ #>0
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MM_NV3EO''5,A<PMU]T_QTOIUM7VWW>W?@ ].>.&&'X[XV8(G2W?CCE=M=]7
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M*<$<?N& &. @ S'P10X@@ )0L (#-LC!!4Z2 P^$@ >_6$$*I("!P,0!!&T
M00M,R0$<[$ #KP'$!7HP Q10Q@8A>$,(UO!"NMX  G?PA0X6 @@,]" &)2!5
M+UKPUPP<AQ4<F$$.), 6-^SQ!"H0C 16D%<4,&0&)>!!!C#[!P?<8 88J,$-
M/,#0'1PV$!<X*@9ZDY(\<* -(QB!+W@0@UVD  (QD$4(;.D+#$@E!"UP0P;Z
M@ L52" &M2@!@^"  1Z@X 2]^$0#;' #"?# %WJ8;@E*L#A]"GC W(I;#]-U
MX/NY"_Z@>4MP3Q3!BUGQJ3()=<-AK[N0$+B!(6W8L =.XHD,0.@/'!@G^R[0
M' 3Z0@XE\,4(E.H+.*!T!A=.@5(;(!=6"#,T&UY-6/! @93,802_@ !N*.#
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M/-'14M@]!>R#MN4O/[4']Z1_U,Z:@W&HB$1@6R4VV.\H$MJ&9?= T1*PHFQ
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M\ LS4%LU,!*00@&+H0=]Q@%>X0L/0 IP$ (0P@-ZUEN^@?X"@8"*#&%7U]4
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M3VKRY8\%4)#CDXQ&6*.F74[00?Y97WK@H \X()"%C1(&$F&.3B[@HP\,DL5
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M<8 .25&7B'5% ]J% PI^ 0'KM&&&$I %2G>! ISX @Z3M:(5+=4(0[3)$(Z
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M ABF9G("-RN$/&.$1B. .K"S0?BS+8@$*:P#0B.$!GBD7XJ11(" #8"$#:@
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M [6!/L!<J:.T@U%85%_(@V 1!0^0J;V@A0P(@8\PA0B8@]0(EQ*X 5/  P6
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M@Q H@74T6\J[@1)((/TP!1NH@1:8 15(CEY@@V-.23B09I;# 8&@!=U9 >M
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M18HH"F'T(@>>G!+B0326F% HI93ERPV$"67*01YT(HN3 ]7BR8N^\!$"4+Z
M$(B7"-$XIE!'^E++!;+L(D(;O_0A0HNU(&1*3 ?1X@F?:MFX"RANGFFH7 .1
M\J505*9(9X-\FE7IH'X^&=0N$/Z958J6"_% 00@6V4(!B[_H.! N; X$"HN]
M6(0C+A?T\0NL8(*RJD(]Q) C! ?= 8(O?90TD"D,H B6B@/)THE<'WZ908>#
M]O+)CBK&I %7$/V! 05.IM!&CI J1$LMYY8P1T*&CGFK3V;=P0&BCU9D PX(
MD5(# 0[AH@&5N\S;(KEE'5K10S+Z8@JD/[F(T"?)FG5*LC_Y,@J<S(+"8&,;
M^_+8974XX$ #+DCR1,@.//$(R#!L8((DC63AP ,--#&( 21HD$ '@DB2104-
MT.Q((:ZY( $CFLA0P!5)8Z%)(QLXP,@'$S3@71V4:4)(:H\8<M]P#S1]10$P
MB V#)OZ5 )<%%@XT'9T,T9FM"0P%8/%((8TP0@+0'A02!0-1:()% U$4HG<#
M'3#"R'^2Y*V  B8P0F""DU/^6",:/RE!(+Z$@$<(N]0"04@<U* "!34,M$,(
M*81 Y0XKU, !!X,.E$<&*&!@AR^TK##"""CP^3H-$DBQ P@4Z+3###$(IJ$?
M&LS@@;AZJ#"#L*-XD ((:?D2QP4CU'#!5Q"M 0$&=/S2>PDEA 21*1Q(D (M
M)<RP @8K0+2'!BEHP!&@3%6%!KZP@0Y\08H0E" $-; (^%;@ 12\" X<H($&
M^."+/0CK("5H00LPD *S]($#*JB0BDJP@A2LX!>TD( MX/[P@ O<81(8P$$(
M)#"17=0 @:WSA1PX, ,.Y,$7;* !"EK@"T#LCP-W.),;5F"]"^CD%S7X'?!4
M]#L1Y, 7N"A!#R@POH1Q( 1(68,O8K"##+AA@"$X 0BTA *#^*($.BE!#DJ0
M@1E0[" V6$,*"%,+4X6% RC@0 ]\T0)U^:(&="B%#T>0Q:'DX *UX,$#-/"'
M.Z#N#A[HX!(/8A$<&-$BI7  ' :UJCY8X$D+T!!$Z,#!$40(!#_\R@U:\$,0
M\.D"H?A%"=+X"0ZD0'H#></WPM>A8:' >P-) 5D^ 0*F9+$C/(BF3?*@ 11H
M0%USF,% VL #661  BIPTRB>"?X"A^A! A2@9BGN, /4#644=OB4B4!P @_<
MP"+ZPR8<AC4"'&A@!6XH 07ZV8<2W  $$EBB+$:P@B*:!7;VNTL?%K.+%I0
M!2HPBQM 8#\@<8QC]GF,# [P@D%@H0 L$(0)"K %00"M U%X32%DD  8#*(.
M#7C $UA0FD0<SA!-H)O=.B.:.D2@ 5)C &L>80(#9$$3B9C !A(1"1D@P (-
ML$#D'/$(30C--8H@SQ6>8)W^3,8)CXA-X93VA #,U!&3:8+='D$" T0A"@1P
M02$0\ %-N,  @V !7B?#@D(LS@0-J -J2%:YQR)H01U!01MH<8%=@  4?^#
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MO%,>W$$?Z$0+D(4AB0M$F*!-X/["+E@ *_T=0Z2%+%P CL#!:=6=+%! +:0
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M:[:!Z.G 7:  >*Y /PW8+SP (/2"!#B)%#1*!)@%*"C D5C$=@%%"2B NDB
M'PQ$"*319B($'9SE0(B"K.X.!)!"O Q$":".'L1G15R !9U%6N0 -=D$>R92
M=O'!N%;$1EAK'SA72""M*'SE0(S 2("H["U 2(R2G/A/P6I B[XH9\W K?;!
M'=2"Y?[)0@/L@BS0CHZ2HGWT*,"]P)MN36-)0BQ&AB!8P-C8#,DHW MHPA,
MC0%8@"#,1B-(J@,80 +0C28X00,8@ %\@$$60LC-A@DD  ,D0 1@@>08@LH9
M  0H@/IZ[Q5,P/M&0%3)P/\R  (4@ MHPA5$  $8P &_1F34P04D0 ),0!TT
M ONJU,O4 04T0/[6P=.Y3!U8P)L.#L!YZJ>*XD&$3^:Y8+OJ1"]< %>H@"Q1
MP$BL0+RU !D=1!M@P Q@ !G)@@>HP KXBR&=I/_YZ@!!SPQX47B6  %A@!SL
M@9YP"P7,@.^\R X,\0IHCL'LP /H 2V 0 JT@*7UB02@0/XO'-_H&82*S8 &
MY!-"!,L,],"LV4 6=<*UE< )F,4(E$ ,J(!Y"4D,X( G_@'W324!@L!$R $7
M^U"*74 ?QZ1+AH0:+ !4?JM>TL+OM( %D )FK0 .Z( $ ,(:]$0K<;$'S(!9
MD,^U%05'A'+\40"0P-9#<0 K*-C #(0:@( .V$  ZDY9G #]1"0>0 #L>$6,
MSN<(X!:QF(5%N*9%M $!4$D>7$ -@$#([L)5#(0.<, -J$X.A,((,D1XR<%=
M@+$WVX#&Y$!Q=I,;B[%!^:&*-  KI5AVF8)8W@ .X"T-Q)MXTO"P1  M^ $7
MKY%9V  'Q( 8?XG@.IX \(4?=/ZS0_T"TDXA1.  -^71D UQ!IPD!E0Q!]S+
M*$S 1AW$'US;"'Q082K$&G"3+(# ZDB _T"$!79Q3,/!$', 832>+WBH :T8
MZMF2!9"1&V! 'Z/ K'$ XH[>BPI++3Q3"T1D'=M !M27Z#)O2K3'?&C&8SB"
M(&!!'43"; C"(!3(?-3!(!3"6JLU(RA")*#4%=R<Y0C"7J\U7*\I2FE!IR8"
M(;!U(R '%ER!:Q3(?NS&?GS&HEX!G1(((PC";NS&8R="9*]I6!?"G1K"HF8!
M"UA']4(V%AB"6A=V(:C-9[?P@0BVU[VP3$@EF+B)+P\$*\A%)^C!H-3"F/1V
M0IB"'OZPR$, @A\$Q6_W BM !"Z$!'V2 A[03B!L#BUDV;48&$@)A1[LPBPD
M9\4,"B#T >;(0DQ(BHK(12GHP<7LI9.PP5W(PICL A_PGHKT@B?P@:8  E>4
MPBS\PK64=WFS@AY\"2DDER^(0G\'Q2C40B\4RH[\P1[(Q2_\ 5?(@BP )D($
MN*.0WPZ(UM8.Q!_PP:)L8.Q!F\;<@8VLP*Y&B<B&^$&40G+50H5>0"G\@53+
M @HLRF\?Q"D<MQX<DWD?Q"?\02_LPBC\ M "A2A4J(V0PF(N1"U<BXKT >MZ
MR+6P@J[LSHYLH(:4LH[_=GEGV>Y )4)X H3'^)/X]Y@86/[I05L>G0M%H/=P
M[X(?9-F@R$*RJ,H>L/F;)X2Y'$0@[,'RYOE\NYH>H$CR,DNE;#,*V$(>),LH
M%#AYRP6=(#H5%KA0Y(&3Z/A7JT1[!*-AVT<CO(SE@#HD%(A\1 :!W!R!W,TC
M<$98WYQ\5/#=1%U;*P)D-$(DO+J"&+8B@'IG*,(C5' B!..G-X*ID_6PGSH+
M,P($)  +%(BKXWI[H+KUMG;E* (O</JV'T0+Q!FW<[I+UP 1XSFXFSM%A'1C
MABS'S,$E,T7 H(26T9,!?=&YV_N]XWMLXSO8F40>/.Z^VWM[# TD6'MG"#QD
M#4TLSL;$%4@L.CR]%?RU&TC$M_XPPQ<"?/RZ?5"\Q'LJJ,J;OA^&82@OE'$[
MR'>$*.X"( !"=Q\$YI@\2KR\O5<XR3/&+/1!)\2\QI1R8\1\2O1\R^_[SP/\
MR8^BT ,*I!@]T"-$TF_[Q',\@B#[TTO]U+L'PU,]QR?DT&O]UG-]UWO]UX-]
MV(O]V).]2%W]V:,]VF]\VG>=QY?]VV\,T\/]W--]W=O]W>-]2+7V;%#.:[?U
MVK.]VL]&U ?^0;I]WB-^XBO^XC-^XSL^W5MOY#O\Y!O5Q"6\P5=^Y5^^46G^
MPW/^YTL^Y1=\Y&^=P5_^PUL]YEO]Y$<^YWO^P5O\2%F^ZHN^[)N^Z]-;P&4[
M7BP]4/Y !&(\A$4 ?R_\_IG<"F+LG5KL7?';!/$KOT\PO_,CAO #!?4KB_$K
MO_5+_YD ??1K/_5[O_(S?QX5/_)G__.#1?G[_OD7O_9#__,?O_&[__;;A*W
M__R[/_DW_Q^RO\%TO_@#A*]>O@3^$DC0(,&# P<*9$BPE\&&#0\NA"CQ8L6&
M&!\ZU(BQ(L2#(!F2'$BRH$:/$U.R[-7Q)$R9&CLF% G3I$J1%EM"?#AS8DV%
M%H/2K&B3J,^/0WU)<NKH4=1(4:,ZM13):55)5YU*>F1U:E:J4[]^W8KUZ5BJ
M5"6173L5ZEJY;N5*?12WKEVVCL1&LM2U:]BS@"W-K=NVDO[:O';C>KU$D6ED
MR9,I5[9\&7-FS9LY=_;\&71HT:-)ES9]&G5JU:M9MY8<!4N4*%5HUZ8->[;L
MV[&KY);->W9OV[9Q]XX=?'ARY<N9-W=>.S?OWKJ#__9=O7GTY\MA[YK<!X\>
M\7KRC#<OOOQY\NK7JT_/'GY\^?/1CW]/W_S[^_CYY[??WS\ !9QOO_H&#/"\
M\O0[<,$!&Q3P00 +A/ _^":\D#T,W3N0OPC[\Y!#^4#$;\3X\J"%H%!"^83%
M%EUD$91/5(S1Q1E;C%'%3VA\\<45>?P12!Y]#)+((EG,,4@D@53R1R:+W%%'
M%4.A[)-.//'$RBNUU+*3++?L<O[+*\$,<TPL01'S3#/17%---<O$\LM.TL32
M2SK)C'/.+KWL,L\Z^=02E"S?_%-,/^7DTM ^\43TRS"_3//0-B-EE,P](;W4
MSD;K++1211'UM%!0Z125T$Q#9?30/P5=E%-'*3VUT$U=?;/5.!VEU4I9RXR4
MUS-W3?15.._\%-$]4Q6ST2T#K7748$L==%)H2774N]"0\NS:RK)U33.#MD7(
MEV\5$I?;<LT]%]UTU5V7W7;=?1?>>*T==RAOM:U7,J2N3<A></'UEU^ !0YW
MX( )/MA@?9G:=^&&_P77IG[K)5<AR" +::B+=V)*XY H^KCBD#?FF.2,2Q89
MY9$Q7O[98I-=3IGEDU6^N.65/489Y,@ZSMGFGFN&F6:98WYY9J&#5KEHHG\Y
M&FBB?99L9ZBEUAGGR9A6^=JK;Z;Z88RU_MKHL$7N6-ZRS3X;[;357IOMMMU^
M&^ZXY9Z;[KKMOAOOO/7>F^^^_?X;\, %'YSPP@T_'/'$%5^<\<8=?QSRR"6?
MG/+*+;\<\\PUWYSSSCW_'/3011^=]-)-/QWUU%5?G?7677\=]MAEGYWVVFV_
M'??<==^=]]Y]_QWXX(4?GOCBC3\>^>257Y[YYIU_'OKHWR8[:LW([NQZKJW_
M+'NAO>]9>ZNG=AKF\"WK'GSIU5\_=_39?Q]^Z'EQ)1>%YOYW!7_\<^D%EOSK
M)^@6^;N%0F[1/U<,,&/YHU\"74$07L "@;[0!2S^=PM5M.(AN8!%0S28B_LI
M\'^^T"#^ AA!5Z@"%D,)8/XLMD(!^@)_#8DA#$F(/UXP!1:9B 4.,Y'"H?!B
M%0G9!2HVT<#)N"(3JN"A#Q42BTP842$Y9")3<J&*6-RP%_BKF!8%$@M5F- 5
MD!GA"^-71C->YA(_(,-!$/$#(1B!"$+P 2)4\48A"*$(8KAA%^PHA"ZDL M&
M,,(=_ZB07!PACF\, R\&@@D\ML(7MSA"$AJ8"R04X1:]*(,0?O #)%R"(&7X
M 2A]@0@?7.(2/A "$>((A#7>$/X1J[SC#[H@P2]P\@=4@*0O;GE'(2@!E .!
MQ1WA:(0?3*$71SC"#7WA!2/HHA=(&.0=@;"(A:0!EV.H'R_$P$DAD($B8?A!
M S&!A%F606=D^ $0?C &7?B"F][48R]TT85."J$,#.EF)\5P,308\P=' *48
M?F!-7ZB3$KZX!!+NB0:!**$([U1(-Z<)A#&<$:,9'4H:TW"05)S!#$D@@AG.
M@ I4T+(2AYC"''W!1S&8X0NT;*D07AK36@XD%T4H0AG.L%(S$$0,@_RI+P[A
M@S6:TJ%E\$$7+K&((OP $[Y0*BE-20E8E"&D1.#I)MAH49"681&]Z((/Q' )
M- 1T@/YC$((9*G$&(V 2IV8PPQ2$\ 4S'*(725@F0>@ZP"/L5*YG4.(-*>&#
M,63B"SY(JE$Q$0:6+H(*;VR@$H2 B5N, :H6J81A,^'8GYZ!K)@0@V)],=HR
M7&(*/^"J&4+K6(<VQ)13H 0BC E!(2 AB[_L12I^4 1$4$()/D@H$H@@4:#^
MX*5R3:A&F6O&3/R@HY"YI$*>BTY?8(*L,S6B-',1T^T^DR Y/0( A4 %>!8A
M#%-  D0@"@LD'*$7MS "$IB9QHN6 0A4%:Y"IF $9K+QE$-Y[A<4PEJ'QA2!
MF-WA4)0:57@JLR%]S>MX)7.&)>SPI/TL GPEN.%>A $)2?XPPF2+,!!UIH(I
M:%@"BE,!A#!,>""[\/ 7E !+'QS"%TE(P@UY,4EF'A*3!+D$%T )VDNP-A.\
M'"5!5C$&AQ)7H@-)PP^4V%PKFY&C-^EQ$?;GB^>.81.6&$,2HFK/2[CB$AY6
MZYG3S.%>Y#0)K8!%&PF<2DN8X0<H5B@MA9#0-(K!(;S0L2]82THT[/<E_0WC
M4-K8A32( 9R'MB8C>4O@F")B$X=(PA@H<D-UDK+'1$ "$J90!")D\J]3F((2
M %TQG";6$K?PHT/H:D0O"*&!J= Q0W]ZBTUD(A/[&P@O$KL(67OA(+4^B"N4
M\(-6W"*7R1:"#U4A4XOE(@E*2/Y"+2W)Y<@HH;A#Z:82E*!J*%X9W=![;G1?
M(I!+_B\3??R!=?DX2#=:DX^S%((U<2IB:AX!%;Y0JR]:H<:#V),* ^%HNP6=
M!*DNN90^,&@O^AO!@<12IT: [Z$IT8L;UK&6MQPD$)*PX*&0P0=<?3 1O-!R
M4_N5"%WH A76R!14* $('4W%K ER:UOCVA=I&,)+D;"$5F#W!T%(LB]2$5Q
MMX+GS9PV02IA3!S'0@C()@@??5AIFQWBC2@^9!+J)]T@MQN;4Y!Y%\Z=;K<O
M;Q,&S]@EF?G<,-PB%O8LLQ#04 E*K&+K?/<[X VIXT50(M:1+((1OJ#6O?IB
M$3<FR/XPIZ 0J%=^J@2I*D3Z:]R+ P&O'O3%9FON"TJXDI="V,0M*%'>R*!\
MZ3W&[4#ZFF,*DZSUGR3O>@4RR?_=6A>J\ &!O6Q472#B$(AH8"6&(%  %H'W
MOOAK_41)A07? OH*F3Y!=*'QAJ0"#*24=>6WGN?PD@$1T2P"4@AJ\K>_GWF7
MJ"LF@)W":)*=(,^M>>3Q/?6AJ'6*"B_Z"&(1_$CF4HN4#N$'<&P@QL 'S*"
MQLJ:"NL+7"$64@O%$BW<&*V@AD(7CJ#/;J&<A #%8FK!M"V$!B+S'@P)_J?B
MI$^@?NW,%,*1DH 24N$2E"BF*"$73&F-!H*/-.B8PNC02OZ/(!RI"!8A%39!
M!T$O%PX!" "MC:;@$G"P@<+ "8NJU:0L"EVA%:8@"$C)%:)NLZ9 %5PA#8(
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M?<6XB*/7@\EF%WA@!FI@!GA %KP3:0RB$^ @AB7#%%"D$]P@.(7S,7WA#O9
M)/Y@#<KG>GZ!%+P#%-H@.&4!!]AX!MB@6EJ3,@:"%GK %K2G%^  !=Z8(.Y@
MC6F !TR!($"A!X(3,F2A%,BG?%(3,%O9E<$%#CK!,2^&%G@ 10@"#U2@!G+
M!F9@!FC!#]:8C>=@($;!!M@X!NZ (." !MAX!U)YEL^G,FA!E,/G$U @#YC"
M%%A!(?J #?Y@*'9A#MI@%!2"%/[6H)P)0A0F62%JH09V8"A(X99A6)()@A9(
M@6/<( 5NF3![X9#]6 _VV!?^  5"X 3\@" \H0;8N 94@ X(@A5L( 1"P);+
M96<A80,(H $<P  ,P D<H1#XXA%H]A%^.!&@@J3OHF8;%A*&6!)@( $$01+
MN(QKVJ:'5XF'HA868 ?B0),O())! PX\0)4I P3ZP!?@@ -2PR!:0 >&(A 4
MV3-Z00+>^ XRX#(&XA,0H U\F@-.0#1HX0$XF6I,P0$" 2-60 /F  YF8 '
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MJMD72N&;[P %F&(4/KQ:1H$6\  ../L3,,"-[V %3.&;V_ZYNSE[%T9A%_
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M:/)" 80\44 =6100Q2 $F/#(%02P,(@!,&B"10%.:.*" 74T$N6>?/;IYY^
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MC90%CKJ3[+=/692%3-G !!-4X,(@CM1QI00)7,&( 3*0@0$*$04S2:(1%;!
M'1+P CD1H$XO0$ ='%&(0PT*$A;,X)\PJ,$.&BI135I<(&Q!"U*@QA>>J$$-
M/! #7]1B!!>P3EQ 4(,9K$!$%R#%2/!P M7XHA,X^D4O[I X#("B(A@8#V5
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MHKA9 X2_*.,'<Y9" NBS@ZTX@!#%86 R/*G(#:20+0#+8A8$)H4"3D$90#"
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M/%,1(/YE1H#0"2@@%K-$,K-0 F>$9<EC!UV/ C/P79/V&!1 ;5GD"W067R.
M4[C0Z'WAO+X@ 2$=D:5" 8F+ 2.C >,A-VWP"1%X H#6"R&G7Q$HUA5*&2/0
M NMA=:8N 3E0PB6_)' 0 >S1!W.,-025&JL!"(@7&;N@!F<!NS@"!Z9!%,\K
M[++_)'_2K<8.6\I^^PB\HT96(X$0 6K  SS@C!B" Z/[":,0&BHO!Y:2![?Q
MYN"N8ZE'+&MD[AD@CM7C!K8 7CPI_=DC ,MC"WQI&7SESB$L"PA (S:F)*:@
M 0<PF8.Q!@$  O ^B'BKN1+P  U@?CR@ 6M@ P"A0)8O7_ZF!* @^ ; '%^
M&CS 0] 3(((&$1+$^ O$GQJB9N!1X4N/!X)\./BZT8.6A%V]?A'L P(F28P>
M_G0ZZ:O/20R!7!*D10%7GQ"]?-%!B.'/KUZ=9'*8P8/'FHB^W*1XL /CG1"^
M=OE*$9%"*5\>0.5PXXO'C5T2:OGJY<;&+PA2>;0!](N"*5^X*)P*P0=N* T8
M9TG8(75-H#\DOZ[(XVML+UD4K*[PY6>$K PM;X#@ >=DFQ:^(NA0W,?7!5%>
M*8SRI>$/04 S+H!X2S!$GE\O+XRJ3 LCV!R^F![MX8M#9(*=)/BB!2'W<(*R
M.(P@1? 3A=X%)0CW)2*RT>TM??Z5>N KS@BOON[()/@2E&7J]>W?QY]?_W[^
M_?W_!U"_1 8DL$ ##T0P00479+!!!Q^$,$())QQ0$5[N&P6#KV21 !?::@%$
M#X)X:$$6" BB(P-?YBC!%SS8\P4#X"[XRI0+?-G#+5]Z> ZC&=R@A<:"A#1*
M#P X^*04'  H3H,'<DN!@%)J4:#%^G;AX  V2/&$+Z- Z4$*-3QHX(90Z.!!
MC1L6\$".6FJXPZL(3GII% )"$(X' /*010&(3.F$%AL 4 T0 DZ@SJ@>3E##
MEQI&B$B/KG0B*0>M).B$H!SV\"2GF(8+X8]."?+C)!62$RD'O7;9B: >$"J!
M#8+@*/Y,A3: ^L,65&5I #Q1(##*%PGVD(RL-FI(@2PU:A V4[!N\,4"4+3[
MY)<+^-KE EIF0'4.###J!0-G/_F$E0>^DDRU!P;ZY$0W2MNEA!R* V4![;XE
M+<;9?!EEVM_@PB [&7U18Z 8Z6@O!V9](>7<4RZP9;@_$(#-JP;>\ 4$AEKR
MP[*52#$JV/A N!5<"D0D&$9?1AC/N),)6J,K4AHP>(1&07#V#9H"Y+EGGW\&
M.NCZ*"2Z:*./1CII"A41F;IVT76#@C=LH* 64!KH 0X,Z BWA39 ^!8.F0)9
M@(=>)/B$UZ]&.=>7-C HP08/7GHIA35H:2#BAM$U:@T"!/X@ ( 26I(  8-#
M , 460#8F2"CY@!  0("  #1^EH 8+KS + !KAD N& !!?8E: <!&I @ !%Z
M&51RRMNH18(!'A!@]+)(]Z430M520#@]OA7IQAJ8O8,"-W1PJX\;<02>H L
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MYT=_^M6_?O:WW_WOAW_\Y3_^@-??_O?'?_[UOW_^<WG0Y74N]#H.X\BPGP#
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MK^P/HW"#!IB< 2" !GA+I[PU:2*(4E   ."!+UL! "" [83//50# $@ \KH
M & ):SH!_20 !#   @B<#" %! " %*".$K#/U0" "?B*ET !!#4 !&!0  @8
M#_50 4" ! @!LF@=!DW0!D@+G^1#-VL+ ,",E]@#RFF4EX < P < S@ P$&A
M$0@ !!"  2#1!I""T@%0%46 !E@#G8@<)56 &&@)#@" %GU1.Y2%%1@!E,'#
M.NQ)^'S!^H #(4V<+KT/.A"!&'@+48#0)LW*XJH%&I" A]" B# *6K@!"5"
M!@"!\O0%%%" )?(%4"B!!S" !?[(@"NZC_!I@ :@ #4(EEW( 0I0@ 7@@+N$
MCAJ84P? @+>45#W531&I+O^P22JM(# US^&0 P%8  A( 11H5 10IDWCCU*
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M'U-8  /H'/Y5 $N2# 08 ?0E9E^0YP8H!5N   )8HF!A!;D%@ !H@%PM 0&
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MR $VD)VNR .)58 0B  '\-<06%8!^(1:8-93[J/4]04=L/[I7^"!TEV $(
MHVT-% @ #'@#N#Z 3,F  WB '$ !B>7H^." !)AF].I7 [B5"WE:!*A6.>.
M MC7:/YF-^L#!D" 3SZ/!ZB2Z!T%#E#>4HA8!M@#6YB%],3FE[B!FJ6#.("
M * #NM#:VYC=%NF#]@2!'8@ QF86?G7=@OZJ]X41HQB!!)" #WX1?Y4HB?[?
M6IA>_"9@!#!@6I@$"5@ /0X7 H 6HT!C =@L&UB  %BB$[@3F"GC4%@#K4T!
M.-@%$!  ZTD! 0B 3 F! :" -EB3 +B5%MA3" @!!YC=!Q ! [^14E#/%8@A
M <" 7Y "QO$$@04 A($.&V* $?YP ULX@0"XHQSXV$:9@6 U  70@6 2 06
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M *?) P*XF):UM(I6\6N  ]A8@@8<X%F/*0IZ)L K5@$Q  VP 0T.   C<>
M#1B!/0V#KEY \#"((0 "L,,'!!C@-6>I%@?S*0 -G*6IB*$J L""07 !#BX"
M0PM!=&  !?S!+ >1Q6%2( ?<'( S$!# #[G3K3]LC@(EF/Y*P0;3!Z!Q!#$
MD$LM&F8;*L)M2 P@@&#8@X ]H/4L[$. G"#JBTEL428A&<$ )+"#%21  *.Z
MSP,D  $$.* !LMC% Q3@ !$8E"@U4"<"'%6" 31G!=_SR0I2Z0L<"$!I1Q*
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MCB,YEJ,YGB,ZIJ,ZKB,[MJ,[OB,\QJ,\SB,]UJ,]WB,^YJ,^[B,_]J,__B-
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M%FP %E3!@%3 %2PL(><UK9+NJR8$+D! FJ" +O<"+DP AG" %*# !=#-'(2
M"*2P+["!&M0 !LP 1(&"_I)+2O2 _JI.&_0 9<< 7^!!"/Y,,5C8P%8  @>
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M#$(!N/Z (U1  T2!"Q3 $Q!" ;R )F!! /S[!C3 "PC"YNHUPQ?RI_9U0HP
M'& ++7@ *70"?*.O#=1"F-#"'VC (LW:%Y]"8E5&R$F 'NP"'D3 +TA!"-1"
M=BM0"UQ *3!,[-C<S1B)!#3? _0!+71%*-"%HZ@VG@A &XR"*3@ @R- X=6
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MB+*^$J*<@8>>1_E#V-O6 % 6"I9"U1<=2GCQC@1T2K2T/GW!P(8WW%CCZ1)
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M@ <IP05'UJ#"M  I<!<HDVQB4"A?@.!K<]  ;F8@0\'!(06]H,4%2I026_
M!&OHP1KN$!C9B&(F>D (4-J EA5T:!<S"($:0CBLE<AF#UNI#PZD0A(4Y&$.
M\D)-:0 A+#8T2C848,4*Y. M 0E%%FW0P/G6,(=:A  /LR&%!F3#D1S$P%C&
MVH$;]?X" 0$EY!-;D0T-'H.!&=!!!43I0TX^HH:5D*0%;U!80@"Q%8?-0F12
M0-\?=K"'$)0H!WNB@P?:!(H;:" #K+C-"'S2BQE@H'Z]0%I"CDB2A,1A#GE
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M'&[,L[D":*$1B3"$([2P@.M8H !8T(0@',  /C="!@:0P (@((A&:(  #*@
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MZD *'+B ;&2S@P2(( 0<. '3;& 7&<NH5@](P1I2L!\X7, -4@"!"-HT!P.
MBP; #L$H-4 \#_P052C(9EKN5PH!C(H65VN##1R@!SHX@()JN0T'F$L $ S<
M ]W*7PYD3F5?W, GHO@+!VB%S!"T0.9$0>?IN;+OX0-[!Q>X@2P>(- <:(#<
M0[J#!-1@ PK02MX2)Q('1K6+$3 ? R#J)F[LL  WT.LAV*_%+T20 C9@0"JF
MX8$#9J &&N!KA +E0" $-.!"]N !5 ,$6DM^(FIPS",+L, 0%&$W($$0FB *
M!@$+!*$0MJ !-J 1"@$2'"$+9/X@"@RA$12!$9X@"A@!"PBA$1HA"SCP DTM
M!W5P!WN*;FZ#%)+*%T1ADHYEG,+I)^1 #=[L$\"%"6^C#Z1@SF3!#=K@%!)"
M%)(O%&AE%^:@!_* (SI!BNA #4P!%((&"GM'%I)J%[C$(/B*6CZ!*N; )F1C
M%T"!%=@ #I3)%P A"G?"%O# %&CAS=S0-#JAD,*P=H+&#]2@D$Q#%OI@#R1Q
M#TB"%D"F*E@)SF!-<#KA#;BDLDIAP'R!%$0Q$'H $$+1$"4Q5B[D6'2"*T11
M+X!$%C9Q)SXA%GFD678"$!SH#\ B$)0)#]3@L4PC%.Z )#I!"MP)KA2*%>"
MN3KA$_YDH16Q1 WH(&3T0 H>RQ1:L1/:A!;JQ!1,P1.D %(^P9<"@2J ,4BD
MP/P:9@WB0!8FP31^)5;VH ]D@ZTFSA>)Q/A(00WF(#+^P U H1?T@&GHH,OZ
M0 W<D1;>  \*D13N0*!\(11*D2IJ 0[H8!=$@4L^80W8(/E,PQ-DH1< P1[U
M8)(<4@UP\<V$D"5OHQ?L0 G=9!T-T1'S  Y*@1;T8!<ZX4@^P18X@@YV+!34
M  ZH A!Q\0[=Y [48+8*\0FYY!)W(1 2Z0ZDH'YNXQ/:@ V"D-[VH&KT8)QJ
M80[4X!B5Q>MHYSP:X1'.HQ :H1(RRA$D 08*@ &BX-,*X?X1)$$2^DPW'N$1
M%"&C=,,1-(<'$3,QS:/46"?5(O Q(3,R)7,R*1,W[H "X$ -2*,R.;,S/?,S
M01,TR8@:0[,T3?,T3?,3.",":2$''N"S4#.B?# V:=,T..(RWV --O/.:K,W
M(Q 48%-PT*,\%G,W"@$N!<$#/TTWCO,XA],X<Q '34TZ%7,Z9Q,TZ^,Z?2LF
M(9,W188[*U,4W  .1-(VP=,\0_,Z.4([.Y,])TYP1(-(?!,]::<7W+.@ZM,]
M[TP]ZY,R1^LQO5-P: $0]N<\=P$./F@[W_,S>9,](\,''91V E1!Y=,'1^$-
MWJ \Y5,R)Y0^!:=#^R0[N?,^)?Y*=8Y3HTCP+ZMS15F4!V5G/F$T1F5T1FFT
M1FWT1G$T1W5T1WD41^6C!$G0.5MT2(D4U!RS1]/S/'%C/>L3*/H3/6<30C?T
M.VVS0Y&4-B%41*\T,IGT09=T2R541ZTT)N,3/G&C09_T3,_T%TAT2L'T,^5#
MU%2T2'F*.HT4/1@S,8_T3?FT3_WT3P$U4 5U4 GU-.GT4!%U11O!/;740WWK
M#SI$%O[J%VP@%MG4/G"##5K.31-B%]R@!$+@!D21!VR :7PABV2A%FK !F:@
M56?@%:LE#W&1K^; #?XJ(4[A#P(A$/X ^F8!#N;1-&K!#MA@MFK'*5[1%.*@
M#5S23/[)%%.I-+@\E&Y\4#:DH%E'X17MDW9(\B=>I \J2Q;T@ _V@ \ X2'L
M8 VH0A9FE104;#9"5#[9-3+WDUIOHQ9:8 5:H 9:H 3H0!9@BTCN(*JVU5GI
MTUX!M#X^@2+UH&^D=4'YL$.B-"%V@!0HE%,I2P0X8 0^2P\:Y"=NP&+=0 7R
M505B@")KH0UZX%83P@YX(#@[@0?B8 ]MT7A@50]Z8,Z"A =TEE1,8\/R*"9;
M\[(:[!%KP%0YHC4%2DI-@R3N@( ,-5&E5CWL=&KAXT5[$PX08IMZ@0VLD#+I
M($%Q@Q9&   P10 >P&(E  %4)00 P!1D00 4P $>H $< /Y<>@$'!H "'(
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M%@))F6C!#=Z %8+01FJA%\Z1#>2 9M<  '* (^0  %!& QY F5:  $I!%A3
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MB.A  D9@4I)6@-5@!*B'!S*$).A (AJ@%F@-K4>  FCA%TJ@!N!  [HE!R)
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M#@"HH50 0&;P )(JS"0+6),>! < O?E"0P#QF4) ;&L X(<GNHXT%"TB2/!
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M8 &2H0%K$ (7D&Y<&%R(T97JN (C  +()A)]@&4C4 J!,&(VT%31%6>&:#F
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MLD$G#) 'I:0R(0!2?;  MG0# ]$&R[D" ;>3.L"?M=  '/ZA!P_0*P+ !J*
M"QG0,''S"Y]P 6,#!^ C$D)1)ER% 1/R"=FE![$AJB4BJ)%Q$)HF"[B097/0
M2;Z0H8SD2&X '.C#$F@Q"AI ML$2&QSP2J4:A _@"::02;3  TO$$\FY(SRQ
M!PU@ S10 S70 ,7A;5LU R9X$&Y0/3O0-Q105!RP!W\  HP7FX'@ 6P8:H&
M (<'!SKR(:# 3RK  >LE ;<3>-]!%2?1"PVR,JIT!_E41K1@+_>3 AK "K6@
MN2A1"QBP P% 52-Z)J7S%R*P)+*  :<@"P*@!F75 # H0*30"2- 0SZ"(*:P
M '. "W,0& HK"KM GQ&!+<73+_ZZ$20@,#EOT (.)2NIZ0MY$*X@X%&:TTH6
M*PL3P >[( <$, JF@+3EHY,'$0</8 ,NTE0K4!JEDR$(, .>L$$48$N H  Z
M.Q I@"VTH &:I  7W! '40(X@ LK61HK$,*L40LAP :U\ L=6A"'-18>\)>3
M4BK:RJT0]\.&28J^$ ?"J =]@ "F4 ,FA;"^X 9:PP-M(CG200NB4*,0)0=)
MN4)Y< %_H =^H "DH ?+F8^^$&@CD:!R8((940I\( 40<:@B00J3@5NT\&H\
MD0$>91BUD ,H  A\, <*0 N=Z0M<R!.G (J^0*44P JL4![*"0A[0 <&T L[
M@#.34OX"Q:$9(N$'?,$!/= '?: #SB(2:S 62,H9'O$'5\('2*4'?[  @2"5
M7GP'"% +HJ &;( 6BXH0IM )$0 (>@ (#M ;L_ '=$ !6V$CD\*Y%/)_4;(0
M='G)*<&V?7!9P?P'#P!L,W?,%% <(G N(] ';B"OCP$>Y8,#5:@'Q&$'=W '
M_Q0A,S"M;2"$5 %FZM0]GE9O=(DM?;"6_&S&P_('$+ &:[!8ORF*DR*UOJ "
MT%D^#MH'$F4*&) A>,(*<Y"J$W4!]QP*$)$X7/DE\S:K8.Q14.@&>^ ',5 "
M=-4'PGP!(&5F+KPC)4 ':Y H(ZP"&FIAQE(^-Y9$K' #//YD.\*L1VFQ"X/4
M @,A H#0"3<0 YM$)DBM(S3*.VN+$)WP'S2 !T)8(10 !V_ !CTR S=6,XL3
M4E"(&)OL"WXP CV$!\+<7@-5= \3,?;S"W4ES"' 52406+TP"GI0 WRQ VW2
MS&P3Q*[EPZ>2V.*7"'W'-ES"!KE,![50,P=1"NCQQ#B",U2( GK0!O=3Q#G
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M;-$##.B!.:98PV1]<0H-E*(-;Z"-+"[0/60W>P]2N(,,=S&"/Y1 %K1 @,9
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M @$-R+3L6(/S"(4',$.)NP.K&/Z!A^N*./ %.NB/7Z"446" 9]F%)8D[+=2
M/H 8B5"#Q&,#)_$%*9@!6B OB;@!7^N/6H@ Y(DVR].#6D!-#"B%IJP(HJ
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MBGO$FZS=%0UXEQFL!0A@!5K A5K@U2.U$ R('J>5B%(8H!R0.#TPC0]N2>>
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MDC#E  W8;(E0, _7@!4P2U%\$A0H+U]0@T2?H35(@1LH:[IY P\(@1E R='
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I4ITJ5:MJU:MB-:M:W2I7N^K5KQ."-:QB'2M9RVK6LZ(UK6K54$   #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>comp_0023.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0023.gif
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M]_3T]/CW]_'V^_CW^/;Y_/___P
M
M
M
M
M
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M;#@#9C!\(@2CB?FO3!$-6#M")E &4WQA[87@ 1Y@!O]G"FWP 1[@!0C!!FD
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MHE (%8 "B9 &$)!\$/ &A6"*7(D!@J &"8 (J(>9IF ")J )7Q!ZA*$% 0
MF;=ZBK  5FD!!9!YFC"&8/"%IA *$4 *'# &"'$)#4 *7, !"+$%(" 1$E (
M@F !"&$&8ZD!)5 (:!<2'%"";?Y0 :+0D(MP"2)@CPTP"!)1 :39 26HDZ0
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M ?4Y!BVK"#[+!8!8EAX0"H WBCEJ"@V@@AH@ FV@ L3;=FUPL6F F(U*Q2K
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M(46(2[-@@+N0EP9A6(K2$*;%(A,JKG8!R8P.2$J)0*(X0S#!B7X"L*;FQH#
MC$58N*LGB<[H: )#)#*# T@<$"1$1,R"ZB<+WJBIC <D;,$%K+0:JS,',),H
MDP;"4Z0!4]I82Z(Q1II(A3?(*,&4%K:H200M:J*@D$+^HN@-#"12 8,T-/'
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MN4YVMI.3+DA;2WXROY5XX"K23- E=(3'1$0 G^X$:$!#*8@0>* %G6*#&;J
M 10@9@UG6&A#3;&1$A0L$238  HT$8H61&\+B]"$"3Q @F)IH4@Q"H,'/( &
MZ6%  EH82QH@@(&"7>($'Q#!0MJ0!C 4J1 ?X  9NI =18R  RH012=(X( 2
M7$(4C0O!(1,'( \H2A1=2$,(7E,4#534 O]D)U@%NDZQ(N@2#H"#)D" I!88
MP R%X$!Q@N#60G0 )!AX !<0<?Y6U*P@0ZTQ!,4T\)A-Q:EJT<' <B"0!IMF
M0!!C240&;&@9+80"#!WA@@%6T(:SCJ$0+"" )C0Q <:R %,02D,H7  "39B!
M NXQ!7HT88C%D((!)"C$&!1 BC<T@$P8X,M8A3O<25YQ$X8(065:\"]-,( 4
M,[$7 T1A3^_11"(2*(09H.("K3!"%(KHPE^"<%*!.:!80/G+&(JS39KMA!1.
M5008^-(%((%A0"2!@"C&@(%+* (1!KB$)GJT!0JT8:-VU)=I%M(=B43@$B*X
MBBG>$ 'B2M@+9.@>+D5Q0P5MF).:(!5,6*B90BCJAYH@@09:\(%4K: % MS2
M>5XL0/X)+,(#:?B)"5Z,& ZT!0*A<&QL$[*"*9FT)HIA#"FF9XJ4KL0N,DG(
MR&);I-C&DP*:"-0)2G""%?17 M$+@P8<L#_BZ8\+%HK AJZSB W@F!2*@-)8
M0Z$!"91@ PQ '%@5%S UG<";,/G)(LJBH!.L[""3*JN:S%"^EZ3A8B[Y21L4
MX*)(QJDCL=4*"XKS)N?,Z1+2[0">"BL1""#N UN BB"N1:G/:"%@VX0 (20B
MAHZ(P;HU"4'!5(V81/R%"U6+S:3<D !1B&0BB,LFA\8"@=:0A $K,\7O;$4Y
M[)1@23NBL'!#@!:)@&'5$@$E%&,:9V3:*]P2"?!$+,#2E_ZT1R*,D$ RW[N2
M=!L'31]DB#$3DV%Q4R04Y^Y@ 5>H;^]*R8R(-H61\4B&"+3!#!6P@":ZD( N
M[%$K7*#X'FM#@3*0)!054 $;/&#=- !@)XEH@!FRJ@!$K#8S9%CL&!R (OJN
MY 03<(.@S:"&$"0 $:BNR9E'BAU15, $; B!!DBQ" 4<].8)?=9$,!#R%B1@
M)PM0B2@6H A#+& ,9["  ]8I"GZ;8A$)R,Y8U# I*6G  HI*PPA48 %BP=D!
MLMJ"%HYJBA5PP -/>R\',F !)&F! :1M0V5,(09#%6)T<S1[Q'["A1.8H (;
MF-0E/* !#+AH"X<O0R@\X,(JZ?[/A9K? ,HHX@82C&P")A;#!3C0@>R40+YI
M*$3:B/PW'I* CR:8F;V2C@'KN2$"#SA!HC=C!A2, <OG00$9<OT3[I:!5C])
M0PFQ+ (P9- +T1/$";9PB3&LQ\03<<.6Y0,T*+9 48)(@18N808W(,+$HMU$
M<R# "(9<J@MC80,60(PQ(($2D*K$$(A"((0O, 7G(PDR>!5!( $5$ 0\6::;
MN8TU@9B6T*<Z  L&T(0T0 "?,('B*(,+F)038  W8*&9 0$)PH E48PW" 4+
M& -1 (.9T0*:( $T602Q4 S8NCE,@!<8E!=-H( Q" 6:"@5&8(!2V((," 52
M^ !#R?X/DK" /-L1 6@#]9$N09B 3AD#J*B "R@$47"TV))"4[@I4V !3M&$
M#+BTG_  K1@:+Q"%%N >2N*5-5&!L3FF2Y" ,2"HZJBP2BLY  "5B6"#!UB)
MG["OFOB ,6 #;DN#D6"#2R,!>;$7-0 #"0B#LUJA2<D H &#.7D.,C(#%<@O
M))L(\=N5+="$!A@+,^B(#& I>.N$"3BD]_JT,1B#-*B =P&*2XLV06@!#4@#
M,@ # XA#]E.#*1$4=#N,$Y$(-IB2GS@K#MHC4_@U0B(%&I(P16&O-UB#:7K$
M:8(F0$-'5MHE<,(F%C@!/%2C=-RE;V)'=@H%$_@ ?6.Z+_[9)OX" YKH%!(
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MDH"Q &%YRT'0!$IS@2)!A.!2QE!8 ,NI #1A &&9Q3!2O7FA"?5J509(&0S
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M:9K2L!.TL)0G(2'!$[NP!5,@KYL]R< &1" 8300+ RH@Q0D88 &9L  #&O
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M5IUCC2G!,VNTB$40KP2&%,4$TD "0_)>%&\PP/,E  )1$$5) _4 8B! 7IQ
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M8'& 875(OM!$T95 2W%'4V3":)C2B("!!,!;D4#14.W+OVU'C7#FD!69-"H
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M5E$)A]"GP%6-BU@J?IK9[<P$""S%!5@Q099-*+R';U9 Q+'!)'U 3*M+2(A
MVP:B-$* _&R5^PV$"1R1S+ !R#2(;D=D26+.\AV2*'/$&* $Y%9O61]A4)5
MA2@")/Z<!20\HR%\FP$F(A7FH"@GVV27.'CT%.YMQ-BH][#F#4C*2H**A$FF
M0<,"X.W92@1_SAYA9 LV "&0E,B1 &M[6.[-!PO<8S\##@=81PGP5=]TC8.3
M9$BTP <T'XDMG_WI=QOPV8>)8PB\@2@4&9:W 8D)6&2;.)IC!]%I ,8,Q =T
M;;E(AP=0 )T_ )?S[XFX0>^VR9JW^2)H "MF@&"4P)MI0?*LP%)L 05PP 0D
MV).(G =@3F'9%6\!CMC,CWF<P9T3,PN06J1@@%=X005LP"[FQR7D"0;XG:=7
M,O.N0 5P  IP@/:F.:W'A5&3[8VYD8+<YXN "$J3[7SXYOY9:$*![ICGT'2O
M<T;XD6U+H]R*A@4V86J&6*J&H  O%D*@S43:JLA^3!2N\QB/-1BONU$AX$ZX
MBX"4GN&==[>%?;>T(]J[U[I;6$ XV_%V: EXAL<EL+59X#M%L(N\!SS5J,X)
M)%@A#(+\.?H7D$!TA?,;-&ROG(!K<&7"4P0;>$SZ\)@9T-U4*$*28<Y$@4$;
M),)RD$ B+ (*X#9%*$(\BL(9R(P6F$""N<$BA &Y3D\;G( *;,9-"8(2;L;K
MG4X7F !4BH0@N Y/@T$)U HFM($@D,"P&0JR"SS53X<#_"T&  8+),!?P#-9
M>4 9G$ ";#;A$J,7((P7+$X"?/[!&#! WH !!) !O3CO0)2! YQ (3 @OT[
M:FR _L$!&!B OCF "(R!!2RK-"X 3Z2!8=>S(&@ 8HA:"!C' G36NHU!!;C2
MDXK!%BC^!"^<!JA &Y!7@Z1!W+/K@&A =)B+K12 DSWIF#Q0U<]^. $?"@Q5
M"S0."O8413A O@K:+*'UQXW.%GQPY,ICZX!=QX4$3YJ"-R<EDK3:0&P![D!
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MB0L++BED @]$46$$Q*Z"8 M%P@C@NI'<X(L-!P111(.=5(@*I!!,<<,!%52
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M#05R IVQX 0_^9<F?@(&OI" DWOL G$NU #-F($#(P$#FTADB@UPYQ*3HJ)
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M\_"1MH!-NN<_X$ !< (%)@ %-( $.B__!L(%\H4"T,,#SOY# E:B!#01 SS
M!$B  :X#"TFQ 7Q#$?+E!"Z +"R  P:M*P:A K3@ RZ (DA@ [K  A), QR@
M!(;*-[3  J!L)Q:!TO+PQB*C!4B!DU:@>3)D4M+@)51@ E8@ SJ KT(#*=Y
M$"1 #TEA!& *S$I( DA R]CL)R[! X*QN_A-!#  $W0##B8@ H( $R! !$Z
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MHTP!R0EB!9"PO4CX-S#$ NYJJ]W@+10RIPU71<C"ABSID>;8% RAP^HG$0)
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MA@0&*>* *%I@,'H76E:  A<3Z&2!!Q7D:!<$B'@!HBEI-*#""0R\C,($*Y3
M "*,.-!KWII8<(+J'E70[42%- !K R*H4$%;I(3 P0H0--3&!"V(X $IFDA/
M?5LJ,.!!(L@B H%!:5A@2@@?!$'!LAY*T(4((1RD@50-_.J5-G3 #)HS!0$G
MH@@*;4!(8JC=1":P+!6PH7,3T00#+E$(!O3( R30$@-( ?Z&]IE"$ PPA0HZ
M2!$*=0$#$V%!!U\W$1)XC $N$44#>D*!<YFP+2-T@.T<Z+[:>4 %$\% &@8Q
M@0I"($H&*8$63 &&VH&!8"E#V0=0$"(S)")OIF #"\^0)=F98G"Y600"LO0
M-VC" #DRA0BX8(H&#&(B'^!"*-A8%>:9H@4K6(0/8>* )@G)%$XTQ02(2),B
M:0D"&$F#",? PA. 8"(A4 H$>D6!)YWM!"PP105<8I ,UHL!.KE$"<=@)*>$
M(!1D- 4'JJ2 4C) (A+ " J(.($W*.H,:LC D21@HS'T)!3$4X0")/(4L A"
M 1#@(?5.4((2.&PMIM  C'SR+?Z]F& %U*IF&@I!Q1 TY!(4V@(1^R(!16B
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MD?:583D1%O &#=DC;[ !&<"/EV "X)@C:8".&+ !.J&+$Q$&"CDBND&(=W4
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M711^8J %AG )9V,&,@VY8* )6?,2;( 1;O!\;/"QHB &$I@&7Z ";E(3:8"
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M@$P6X0!5C2]LH2%(&!*0I:N80@P(>(,H"H%',30@-"<PWP=0,*XQ+*(!*$%
M2+IBBC!XP"("L<B %*"D,VP+-OZ+, !++J& ?1' "Z$I 9],@0(2B.)JIOB
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M6N?+E$TH$J<!"&1@?0_-^ E6<!F!&0#/89CULB(@ O>5:FLF4$$U$:&("83
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ML8 / #0"#2O!,QF3Z(*D8@,'4(%[80,&4H0.#0,7Q0@SN/XB-IB )X,14="
M$W #$GHL,' #'J6N!D@#+6  %$B#"!"($5B ,%!2C'"@-W #"MB-!]  -N@"
M!=@M-1N#G*0 +4B$4"D."3 #6:J)WWF#^G.C C@!-IB;%&D#!T #-I" ,;B.
M,JT]"'"C"1 #0>@ @4B#;A*$"+@$,#"@PRF$"&B#-Z@ /*N "<C.-J  OV@
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MXZ-.B++FUOW5,!9(A!; ,RU( 5+H@I"X#J'6:B?N&9M@@[$.8C(C#BWH!%-
M!!'P@/Z'+HBV+% 48+E",=T/\(!".8^/0)QFE1$5D*V/J.P.@8/.>4G.7HT/
MH)7.)I)]3 .PS C23I$/00$?7),H5IJ)#,C71FW69FV)?$>%#,AQ51 >4<<4
M&8.$BFW9IDC4'DC@#FX4&9%4F<@;R>W0;F[G?NX@X6WHGF[JKF[KOF[L5L8:
MS(GMWA!#&$P+845\+ 4V@-CL/F_.UH)22945:**,8 %Q50H7(8@TX!--R "D
M1F_][A'S'@CS+H0')AFRC!CB> ,W<8&?G9?]PA5K"QC;A9G\'<QO&0@(1XB.
MN8E+A@F$0(1[P9:A600X>*Z)D[2/R(0ZB$BXA83]7G$7\?Z >0R!.DP;L9M!
M#? @10"#1PH#"S"!"F")>S4!KSD)<1*8# "!(;6)?OH H7LV#?@ "S 0$@B!
M$9@5O)'C! V!#*@ 1KC!)M< 5A&%##B!#Z@Q8<$ $JB H,$.$BH$0Y  !S !
M3<   P&#"@ !P!$6"T"!J%AL%N]SZ-TJ2BDL46B#*&+B!!C+(1\!)2D[+G#7
M,6";("@M4>J :6.JT&C49 *G,,BF#5A5 MB-#Q"5#=" AR@![3F<<9DC!?@/
M=785N'D6K7):0:(465H$)<JT)5*$ ]B;A/5S7U^0PB(%,F@B1""5!N .!SCP
M+S>#7#*=%KC'E N%+>"/!G !+?[H @R([Z[K1@N@+Q^:'I:P(H*(:"G2X:UQ
MV!;8 @;UEPB0"5&0 $88A#K9@B(,@VE*K8UTW4S8 CYY".V*W+6<X6$4!0NX
M,C.HJ2BN;>.&;7_LE>!>[HQ<$8A';ML&2%Z*R$MD>-G@ ,9\B2[X&D, @9=X
M@'%L 100A?430V=/UX.8=A^JC@*MQ=%R#Y85$YZ=GFW9&H1@ ?6EKZW!A <P
M@Q?#DG<W$)*=ZS$@@24JK_,:*Y30)-?%!(:&%TI?A)(5EEX'DAO1JS^*JC5B
M;N=&*; G5]3Y (BUTX10XU%VDT0SA 1("/6[IFJ+4%-P,PP0)2](R=FJMD$(
M,H9#"?Y8.ZJP0H@5V-HF6@%-0A2%XHZ_(YFD,@&"D@ W" ,<*H'P'5VS@ !(
M* 24ZF5&J"O!\3EBU 0O-Z!-5 04"('6(YD6$('</!K(.XDMSI672 1&$B@&
M!(,O*X2V%"735 $/6":H?0MH@8/8;RC>) %PT03]T5F_B.Q0F%)N58L/*.S3
MT5I-+8/1)($LV0('. $#,0,1,($ SQ7\T.%RAJD$T80%B"(SD( 2V),-"#0K
M,?D=_8 3:($(8 ,ZC_('4 V <%'"%*()(#I@N&2*E"E302J(D&#&5"@0&D),
M*&1*0QE3AB:$,L7BA"D0&4: D)#(E*(*(#Q<N$1*)<4(E_[:."#!08.HEB5.
MK(!0"!$#$J0F(#*U!>($,*8*36!8J$+#JE:O8LVJ=2O7K@NUI-AT59.$2Q6Z
MF.K2@24$,&\VH&C(D,2)1"<VF$I3X8T;"8BZX#6%8<PEB84VH"W!X 0;10S:
M)+*0QM2##&S +%"HH<2;%!)(M9G@YLW>A:8N&1"19DL#A16T*#*AXE("A848
MD%*A($V7!2?45%CA<(,@,Q0T:3)@@LT)JF8<;%FD!BD:!PH9OH&0ILU94RL2
MG)CL=3Q73:*J+H(3,A$IA0U#:5HH*.FE2Z':L\'T/OY"-X*R*L*&>PT)TL9Y
MIF@24GL-(;=1&HFP<6!_<%2E"?Y#IYVG21MO7!C*&XJ8LDA\ERQRVH6+"-B0
M*.XM2)Z++\)HFAH! (#6A0A*H$DB!F@RA@:FG)""B@Z4R- '))2HD 5EB"**
M"QZ(\L"*$GA'@BBAP*$ D"$PF*0'6IA"@1L-45"((%0V%$8H&831)!<95'5)
M:PUU@)9&FG0!IP=> -D"D"HTY,!*9G! 2@.%A"(*!V V$%\H#L0W@4)D"$5*
M@E5E,$9#B#A@2@L>Q!BJJ*-J=:.+'&A*JJJKLCIJ(@\H\,98$H"H0@ADX+7!
M&*0P5)J*)%3PP*X2?" ""2$$L=$;9HA0$@8C&$N"*29LL5 H*&B@ @9<A$FA
M*4B)\?Z!*:)<.,$'(QSK GH5\$I*"R:8 D8&)XC @2EL9$!*!4F=P,)I$X X
MQ@=RDF L"&9H H%"ET"0H%\-@5$!!"2$U- $@O"JB0/N BIAJ^.96FI6(7^<
ME7VF645RJRJ7W+)7]6&ER00EBH*!!B.84@*@"SD 8G^;*K (!F.."R(8*92@
MQK0[$Y0SF*:D8*](W/I:@9D35*4%)ABP(1>(#%WB@%@E@5&( O$)8J\H&G3!
MI2DJ^"DSB&1 V6A#EV!"UH@YBI*C*6]D6$&U#&$PD2F)=,H"TRXSWKCCCT/^
MN"8,^%P( *!R:D8A'D@K5P4E&,*& Z&DX8!_$C@E)P;K.?X@1B$@@&#*!\)Y
MB@$BHH<0)=$.M"&8"H6T  $II?LW 9]@*U#"(&,LH(D@#)C9 00EBF% [Z:0
M$-?D*XE!E;:"J-$ (9HHL/#9I#C0@B9;/"#(5&28)GH;@KR6,[R1XY^__OOS
M+\H6_)E"#*DJA @\P 53:4(%'@"!M]( @@\8+EX1+,0(OG0>,UQ/%%H0 1CL
M<HD.-J0+*TF@!T[@'C8\,%4-680%S/! C9C"#"%802):T+5!,.! :9A,*+00
M'T(X)5X?"(&L-*&%D&SB?Z98@PB,]@$/B.$J;7A)JG;(ORMB,8M:W"(70X2;
MKK@! W[J(AG+:,8S0HY75R%9R/[4F+(W;H4A<HPCRNIH%4VT0$%884@H2I "
M"=U(92P+I%SHB,9#(C*1BEPD(U<UQQ>QK)&2G"0ENQ+)2F(RDYK<)"?/& HT
MB$$,92//);8 0TZJ<7@ )(\@_K/'3L9L0%<LA,_R=XE58B44)=+DCD!0@A H
MX'A=P0 (DG))13(D#=+21 9J21X3<.F8J#3%&*0&(VEZ10L-B*"HI$([.O9+
M9&G 0"%7AC]%-*!B;V! )PB4E/>$*!2%.24B7#FNA12)%((X3R).>;@WC"TD
MB[ G102QRX:8*2L )$7%ZFD50V!L7%W00'S.0XKS&-0J0Z%((54 +U.)0A"U
M;"<B_/Y9"$-P%)$5HR:H<(G+E%;%8RJ2Z5@*>8'>D6RE5=$I/!OB!JQI9:4H
M\)>IQI87.+V'IC6URI6NPE-6+4*6#'%,Q1:1 $U<@I@:( DS5= ^%C"@ FT@
MA0@T\ $+)*5M'#A!(2R  IMMP0,0(.H)-& ""VA$!"$@@04R$)\V4. #%? 3
M*4BP 8M<QS0AB"+VHBB"#81  PI! 0=$$(%^2L !)M"$!2Z1B J@H ,-B*(H
M0("!$#RQHP.Q"OU,"RA2;.8#$A@(64\+ JEA,W^%T(#--#*&#;B@ AH D2)"
MX '+F*(-*GA(,Q>R HBT@%L.T0#;"GDA1!Q7 __A0@,J /Z_&VFB!!@83$/2
MD($,@$ A;U"!%BJ @:AFP $CP*,9"G=4]#*B3U91A =L)JMQCHL%'M  F"Y!
M,98,9!$>Z( &KO<F#23+%&[00 <\X$Q5N4$!#$#I?AFPA3" 80(XRX#A-C"9
M!+! 01DQA0O6$B^J<$$!A= G D"4 5 E(H>76*U 3)&!SDE #:)H (5D]D&W
M=:%S51D#G#3Q@%!\(7:F\$()0H& D)QA(F, %?H6H0@$:"0-$$@+.4VA!30U
M1 6T?<\#NB:*"4R$ 4XA7X\NT! N1 "-#$M#)YXS/ 4(0A,AP!D(OF"*,\70
M '40=+-<@ %-+*("H-+"!WC5 ?YN(@@"9@@%&QH050N  9<?0($FB#(4Z*V/
M*FD@P!LT00(0D&(,%5"$OBH@($$X0!"AX )5AFH:LHPA%&I@ *?MO.6&2* 0
MEV! ? K1J1#XR0UX"<,&SO,!ISA 5EM8G*JX$(  *.U&CJ'+"<#0G@:X( A<
ML("T("67%=MZ2*+@PFK?8(&&A" ,IL!$64X#!A=0("X9$ \'U$"_E%UD"UHH
M00,"^!(V/$H4:0!5PK5P@HV18+9=H^9:1 $!2""" @C%F@<T18I$V-DT*I"6
M&N& -89X(78T,84$&$$"IY!"$?<>PP,QS3^&A.%'""4%&:1&J''=1 MC-H.+
MT_"C"?[(*H8R[\)H3F !48#8W&9 JBE"P"VNY04,78CJQAJBB/".T1004$0;
MD,H&<KZAS/&>5MHCH(@6"(<A:"BS1T3Q]H4X[SF!AH!8"D$E+J .AA;0@AO<
MT((\?V #9#@HJT(1W9"ATV-A2\,:V&#04$1@EZ0HDRG$:JW1T;LA<*!*2?C$
ML%#@6@N"H/)&#*<!SU.%(1;2@ W3\(:D%,(,9DB*!]*  OAE@ 5L\#TB&"*(
M+4" ),?V.,@_8XI!4$D$U3HTZ]-\OX:\X>7QDKE&/'Z)$ZCK*5@+ON:ZJ 5I
M2>C8U+27"BS0 EF3XN@<_Y8K'4AS%;B "W1!&X2""IS "?Z(0I0Q%)#X"P9,
M!A>80 D40B)\AAMY@+F=1P4,0AN4V=8EEP4PA 5$'0AT@1I9 "'@G6F  :A(
M"("M 064P-:Y0<+<1\@E$PD\ )18@ D$072)QQ=\0 .DG>,H0F;4$0; CREP
M@1N@#XNLF(!!C,BU0+VQ'@BX7J=H@=2$ +QD0$?4WI#]1R@\P")T@;C\C719
MA7EY0'Q0&OB!@2&XF!MT2M"-B\(8 IH@VCJ]P>:P'D/8"GP@A^XL! 5,A% L
M1.B9C1OP(1IEAUSPA!F "C6%@"8@P'DLPM*YF!G@A0IT $-=A& 8CB)$754(
MP@-4Q01,A@:(1X4X  R1P!N(@?[4+)LFJ('0F5=RE9D%7 ]@,$CSL !A/479
M;<0EA)':&4Z9:$(#, 0;?,81-03TD "?G$:KI=\B*,!3D0K)H-. ,$0BF,L&
M^%7?B)[5C(M%A  YN@!)'-J]=5WJY(@B3$#V!$4B0!"=P,]TB$ %=,P'9$ (
M2$ =F,:%B((#O)8H?,!I28"L])<(P-GU%47?,$)!()3('9H&<!#?F5D"2( $
M/ !5A)\(8 !)'(4QD9X@;,!%5D5N14X):("\< D8E%G0C1X*?,$),  ;F$'*
MA4'*E8!+A$"S#$+Z:%/7M$M#F$ &@ $'2%D%3,0CF8$$>,$)\ T&1.,$5(L9
ML!Y6/OY% J3 3&S<FE1ELI" D%R(MG@!!X *&F!-"B!E"TB M&@ !VR!!G2*
M9WC!"E! *"B" ZP =TV$I($!"+C-X[3(&KV!/<F2A51%(3#A?L@%?UR*B5#$
M&RB$(HB">3#(@6C(.S7$!BH5@GA,(1C(8K+!04'::0">7"B$(*Q!0]275<@3
MB=0''[4!AR'(A<B$((A'&K C&J5!"XC'(A#"W?S'!ZE)(5"F*UW"?R#*>82!
M&982;&@%&P G*<K28@9!J,G%&+B <GHG@4R$(' C=WH+(G!F0[1!"Y@!V+B2
M&8B0)DQ$*("!&#""M[2! +K')71!$+P3T=W?9\)2);7$3_Y>C!W%B,[ME000
M5(!:Q1A(0!AP0:X9*(-2J!FII,BH2BL!:(P,@JXMTB5)4R%T@0BE#(C"T<BL
MT82F*(J6TXJ^4AV9"ANQ:(72J#G5Z(WB:([:J(XRSH7RJ(7.D8_^Z) 2:9%F
MDP1<@ 4H*0;HAX'&:(M6Q2_"J(NJ*,IXGJ580)&TJ(S.Z)2.P6M=4]=IRI62
M @>PAY ::9IJT24@ N* @2(TWZ@PQ BLEB/)#I^( N! #A>88:C0DBF(@+H,
MY$JH::%2D@1LW*&-0 ALW/"M !L4@AJ P0840B&,VBK]1 R]00MT@'B0 I^:
M$($<RVYN*@=,!C-J !J80AETPOX8O!,;](X,D0 ,%4+!J!"#J, 'Y%&(F $;
M>( )* 2]?="2G><B!%$;B$<87,(;)((@3( &_&4:G( '+.B'&BJ12H!XG(D;
M$()D^-@#I  B; $"I,$8*  )M,%F%%()# 0&4  ;G$$":$0(A( @< &Q&5X;
M%()]9< $P*N\MI4([--5H0!M*6A.BB; >)R^3D 4Z5X%!($@G "<%(( ,-X'
MV,L66(F,F0(C,$!B,L!*9,"]7<("A +;) (Q<8@$@$ ;=('=7&O,HE&V-H1<
MPH<84(D&;%\0= X$#,('%A()P(L&)*$J+D*GN"8FA( +P$<9C)FNT$D4C8"^
M=4)9*/X"E;25*41 &R0("92 *#  &5S"9:J@T/&?(HS9X8Q9%\2. 2HARQ72
M8H6""(  ?(+*!4Z+C1@BS=FF(B4"!E5,3V"2)D#"5=P2Y(QM(]&L8'0 "3BN
M<*AB0[3 "3#4B@%85;"KC]E>&Q2C&V$ !S@N"0 *!ZRG*4A>21P0Z($(!23"
M%KB H82N"/#);DT .9Z'"JC  I;<(D3%H5%)VQ#$9V2 K)C*&)0 &W!!%TBK
MIN M";SNFY6?!/0M(@4!!)2 ![2BVF*C5Z I]W(%0YP!U\V%NG3O>%  3H4I
M>=B%JJ!B0T!M0ZP$M#9$.HX+Z?V=:9@ 2<CO1C0&TBK%(OZ$0! U#>G:8TEH
M2BC01 NT0 AHA* P2'W D!>('$. @=DJ*#Q*!=9X0;/(3ER9C >40"N1@ <H
MQ+5ACXT@Q4),P/2BT2(P6PA1"07"5&9N1:)HQ4O5\%4TR58 T!G@!0#9L(I(
M$RZYT0T_*46$C(3(U$NM%*)52(PPP!F GP.D ?WX24.^#9>$0@/\1QJ@6==Q
M"04DH05$T1 )0A<0FR TP!D( @8(1P4P%JAA#P;LDP(D12(D@!F"04*V00.T
MP2(@P!@4 @K$#A]-@!8,P@F0DQH3" ,HQ5J A@%$$1SDKE6  +&!K=MH +<T
M!\9 ST(<BH5BA36.XAU7 !=@P/X$]$XH3&MUO0U63D8+G-?V504B<,!Y_4<(
M/\4'G <8"#+ZN1>A!L%Y/8T*P/(B<$ '9$#OA*\66(#M3)D9B(()R(MW6<6F
M;@$Y)<).<  ,R1K;D(0;T$X:@,GOB,()/&4BB ()4-=$:,()>($%>  <1,33
M\)<&$,>AH<!25$ B: )=UNT;Q*69O@@7<.8;H!9CA0$,(>M"=(%"((( Q]!D
M+'1#N,ZX;,$'E(#/"(((?("^!9 W#Z<BE,!D*)$2C@E#F,$0;9P@C+ *K-(E
MH( 'J$_'HD6(H,6R]&)E-LPU!]$7N!(9_,<BF,!$<(%[/#097<(&3 "A6@48
M* "[!?YG HB!)H!!IX !!T/ 2D  !A#@%D@9 >N> VQ:&S!;D*0%F-&<(+B!
M 03:JRF%&7: IDR +H:"!U1+&X *&R1 JUTOH+8 *0@ "US"('#L,@H %Q2"
M)E3 F*S>H3$ (ER""2! #*4<%ZR%!(R5 9  QHQ W%B-*!@ %VC""#0 (BB"
M K!'O-%/GA( UZK !@P/K<S$F'1!7 B?S';3&W".V1U0@.H=  # X(R%&J@
M ^!8VEY"!)"+)KS!&$AH0B+; +I!<Y@&&9CM!X@!(MS;":A J.69&=CBTVT!
MK** R*GR_$[ %\"0>#?$WYV %@SD@90 49D"<)17!+P!&_Z\ 0(,0@OL#,.8
M@@]##)=8 !/.B9R@ 7^'I"FX6Y(UA-7@VGZ_05\+0LJ1QE.P7F2-@<]L 2W'
MR#&9*(9:U_>^Z(E6:229"@N4 '^0RXEW*1II@DE0WM\D*B4J&P2$!"(LW02@
MP!E@ $ 6* *SEP!>3UIH,=V9@@B:0"&<P!A(BWO'D+U(0)%W0=?X2EZ0  2
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MZ$N'/A2B?4F$02=*BN @(A0MR !V0.#"$"@I RP@Q2(JP"S?A$(, 6 6!%
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M=P(/:,"%*AC#6DS! @UD@)P+042 !1Q'@13" U0!@Q@,88*1F?&OJZ8IA\:
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)LU,[ER,@   [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>cogo_0002.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0002.gif
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M]^SS^>?Q^/3T]/CW]_+V^O7Y_/____CW^/#O\
M
M
M
M
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M%H2%P"2R0)> 5*L\D( "J[!WF 8.("! :G4ZX$ ![[$Q  ,.M%K< "4\I<$
M"5C0 0.(W35K PRTJD # K01Y 8$%">! N=2PF9="F#0[KL&I1@= 0HX<.X
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MB\\A8%G[X]XI/F"=-PQD402@ QH,0P+(D.XZ+BO,'20QL_6U#P6">0,F[N4
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MMSLF( 1S\$#0=F0+X*KSN0I K6K!&(DXC#%TCMM5\1C+W_[Z%S>4H"-A"F
M 8   P!HH"Q"T"H=6<H"J(","HH6@!861!-T)'!["("=50C& *"Q11D"((!^
M=5,P"&"%'@00E@; K,*VT  ! M!' 0!*($;8L(8E8!9,T+$]&L8.(Q50@+X!
M &3#L]A1VS.\ BQS62LHF@$"0  *@-$U_PJ "7V<2DM9"CNRD+$!%@ TD$WO
MOVA.L_Z:LW(*(UC  0V80 MN488*"/D6:\# 6BI0!E889!(:0-ZU,,0""C@
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M'  ELY)HK(X>*S2K10"80*Z'5KUI^LI^! !J\)T)$ $0  $3< O$#!^GD"P
M"P%6V08(\+7VR6HIXQ26   JL$,&< K^F@GB# $3\P;?J0#M[  44!2R\%CZ
M(0+_FF"U%0 -U 8L1@(:@  L(Q" \[@?, !/VBZ/5A![0/YE(T Z"=!% "!D
M+!#+9_#2%F6<"@T ?N4"[R&;$K!=)X ) >!7=P"A<2  P8%@II.<"B !<.NQ
M".T>;:2?#! !@-I"#G  9J&TQ'MD)$ Z1K/-_#@+:/!.'U '%W *:& !&Q!I
M$T '>_ J L$"$F"3&!!J&' !#70&&QHD'H##$]!2,SH!F)#6S&8!'^ 4FD !
MD^8!EE,&%(#6%J !D28!<8 *=1UI=>T4MW!K2E$&$G )H4LEV3$!_$D'&,
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M(#@785_^]*>K;1%68D"G@%\*L0H5< %HT (*(&0_X6L/K0'ZX6L2P)&4<!P
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M&%\4!7$)E+ */&;M%&#F-[\*@_[0;JLO$*R ^Z4I]YIM'WD@4!J@:,5H 77
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MGA$85I"-$80.+VP!&A1P!PQJ\!2:N0,<Y7@'%?QN!7]#@=C*N*F1Z4$!J[#
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M0-(CD6!!!#I./34X#QH0&JR!1Q$,@"];T-/2(,K0@;&))%4%T5*_$Z"SZ:
M:AY@6!FF8^B"8"(K&)CQH1LZN*ZS(+HW,1@E.J4E5#B' :BHY?<2$,EH#UNS
M+<A#! H2A^WYAW!XD[9FD79UIU,T8"WXU"+/P())L%P]/6=SY"4_><H?BJ%Y
MOH5-,+ &-DQ !#4*+P<VL)\E"_ZQ("VP0 DD<+\S*& Q+9B ZH>9']5GMWVI
M7[TM1+^?"EAJ#A$X$,/DJ@(+H* %3PJ!7((XB5]"1A4GP( ;N/D6F*! !2(
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M8V4468B N_2M#7D68_4M0M-4^'0(<HP# ,@@F\B])T64?#,"+0U.#> 6=9N
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M3H( C_4M*^8:[IF 2.T3AJRS!Y"? +D4#( ##W"+3/B($Z0$%Y"T$[" %EL
M/?#=%C@#2+H%#"B#-6  P!(/%>AC/;@%)G8!$""<,G  %.!B ]( #7 F]6 #
M#R@D!7 ,"N"9_+" 3I6T$6 L#HA>"WCB50@T/8B ,]@(58B$!$"!,WB YB@C
MA!CF#Y >)L[3[(D ,R5GNM$6!\B$"T"!6;Z%!9 %*S...O[@@.: @ \H@Q"
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MHL51Y7(36"3+!&UTR\!9#E2R;_X"DC")P%EE-)#:"H=2<,(MY&)XB0+LSIK
M;IDH0$F5(4C)01VJV;(&K .=X:W%\;YD05$5W$&1>Z')&X<#<9RA !N2-% L
M&LB6I*PMB$+,@,RJ>+ ;)@K859(>#5S5@@'E GB' R"45!K)M\BB@;X>J[9!
M)/CJY)ZN 5"9$M,,E'3"K NP!&TDX8XK]6ECKC(!EE1;;8O7P>5!I&H/'%>2
M"'8W<,<<L]I"[RU.VU+&!P)-$,D:F!KE5-]>EC$FNI2B\E0(/=O25E1E.'5'
MUVU*,(?8^OKX.NRQRSX[[;7?.*\&&(C RN,07$*'!>JMX%L9$E!RBP@88*!F
M)"-\I_[9*1Y\)((&%Z2VQAD"K5$D'1#X&T+N(@ K$.X8%#F0<B71L5M)F$QN
M"QT8;+ !?G%\EA\('*@PAP=L-&@+)BR@ EET0!9>X8 %-*,^UY0D#B&PA28\
M,($)G& /9W#/DDJ2"0Y@H 0H0 -_YG>!<YWA AIP'AN*)!T,K" $IBF#!30@
M@OG < ,:.$M)5/$!#IR #AO0@P8,10$0ML #)KC !IY$ M/8XA(<V  &-..5
M%6C  G>P10F8N+W+D8 .'J #*B@P0 ^L0A8DR%V1(A$F-?X(@#:,HFI"\"2Q
MV$]X-+F$\?"G/Q]&(@2W8$/V5*"!+H( #3'90 6RU[R@4?X/ T9P41E,.$.C
M#)(.(%@#"5Z218&08!*7(($L/+ 05XC2%I$X@1XP9 L7()%^8EE%_E# 1Q$L
MQ&BJ. 4'/0A"BZR! AMP00A<<8(\J$8#_L*B:4I@@0^T@":J2!X&4K-(4SIO
MA2L0P2308">+4'$$= @=JCB02%M(AXI61";YSF@^@<P" \=D12-3<XGY6>!\
MY"L!&@5BND%^I)1Q2 W?-($&#Y1 ?D^:E_)8LD5C%:F&&L"$+'8H2PQH@C0L
MD,1(<%=/4ZXQ3+;[*$A#*M*1OBXQ,/J(B^84M/'5J(RW*]:+/((6'-UB%2J-
M:4EN&J-;H(*E,IH3+GCWHQ.\Q/XBI[AI36\JB_FD%*;[<JIJCAI3B^CG%"@U
M"DV*^B*;=@4H+I71575J$9G:"!6! JM/<3K3%EUU7VDEWUM5 ]6V\F@%"IS
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MTTZOM=,$'>XP/H5$-\:V [*0W^MC'5'B7A..D531RV,,4[G*.RW)*GQ9U I
M0'D.V UT1XN;YT97(*(IZ@D8@ $+8$ "5YS3?V6$"164!(Y(':]%XL" #7
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MRN($WU\.5S3Q 3XO:608T(!OVM" ";P!%3O4P)M/LYM ?6 WF@#!Z1$3DW"
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M+)R! ;B!*KC  H E2XPE0VA&'" +$JF")B@ K5F$7[X("80 0K2*+1B FI
MP& " IR"8D;"+90 FO!D).A+&2Q .KH!9$TB*AAF3V"&FJ!.6F )5)Y") R
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M76HXP PBR*ORRY+0 ;+(0B;HP8-BAG)DAHM02G5AV8F0I/YE@(Y 6  E0(5
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M83C &?ZX@0CP26F#ZAU('UL!N( C (#, 02L 7)3XK<\C@=@<B2P@=*T 02
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MBMW*PB0QY=6W@KGJI0LY[YE+EUK8DJ5"Q2H5CS<G%JBJA)ZHDANV,!P1HM_
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M#F^V.($1[H#02YP =0*RP!W68$U;[$$!,VW )!XK$(^"5#1N> Q#I6+6.UP
MHQU% 25(J<Y/KI:UK:U)0Z1F*]+2JP-S^!MBA'2\LGB  UW%BPM40$ 1D& "
MDZC?*OXB< J'ZM4#=XBB"$X @3V<@7"V8$&CQ$.7.#A@#G&(@W)64-VO_A,"
M=I(F5$I0AEL\B"!N@&Y YZI-#7COMX1SS^9&0(*,VN(#"X"(!\9S@0[LM@.K
M@$!VNHK@Y-K"#20X 7P1"MMD;J"#%^@11"F!@7:=BK2.VZ@FO(>:/%A %@]
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MEJ_YZH 2%) P#"!?X(,5)B .+H$ >N0.1 F=-H&7M@6=FH0%.NB!3N 6T@]
M9$'U_,^IE$HYRJ!%,"H2XB#'2& $5- .Z"7S,.0,0 #U5&$$"&<6-L!+CLD#
MFJ,A3L"LYB\!3HK,(L$!-*H"]. &$<,#5F 2P.,#"$<6-*X,]NBNEC"?#) "
M?&,#?&,@'L865*#W2.,4&( JT( "UNNG**&R9*_-".#R%$ 61@ ^J&@^&D Y
MZ \Q4H";5.\.)@\$VNX XP!#Z 4&'Z\2+9&39D8#;F$2:/XP$EIDQ#! !4+
M-5K  C0 !%3AQ5:  RC@+VQA#BR B2CA%CQ@ICP %6RA!"P@TN"#$C1@ S
M#FPA#3)##;B"#AY Z>*"!@?"&*'";C2@1=J@]^)@YM* FPA"$C#  \H@#4:1
MR3S1%C0!&!V,^2""#F(1 S3A#1P-#EJ$#B!@/DHQ&E4!#&UQICK@5S  ?]8
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M6;EU6:&U6K>56K?56ZO56HEU5[455Z_U7-FU6]?U4N$U7N55/QM!"JS "JH
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M >M  SB PE# 3F2YG\]4%'R D6V@!G!Y(BB! !+@ 1Z  4YF$@:  5A!!0
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M$Q3^G@  !"HAXHF$ 0C@$B @ !(> ))PRJ4"OD,[  8@ !!@C3P   0   (
M MH%JRF*$@!@34Z% 0# J!O -?[4FZ(V   V!"9.H0S.X S*H V$10]4@ 3V
M>B/6P 4./.B'_@R,_DZ$?NCUP#=/QP5(P 7Z(RY<  V&WNF=Q 6&O@WX9!)4
M(!)4H>J+/CLD@>R'O@P>YQ*TW@@T2@_@/NZS@Q)<8 3$WA;>/NIU1R &005&
MH SX6=YC^2F^0 P<N2!480[H8/+IX Y48?)'Y [>X,!M4$ T@;S=FPY0[-C!
MI TNH5N23QS; +G;@"KTZKON0/+K8 ZV!5L&WQ90(0YZ9!7BH& X/P[J@ [
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M7$.:588'!MAXG"9QK,GGL!IOS''''ONJ998?CZS3509TT%9(9>0!  >XH#1
M!JI D( !!2A00!T/(F3+7'IDDM5B&9H 4R8(-'")+96X>HH*(])4P@!TR&('
M P:<,OY'B@^>])A7DKK0IRH>'CW)8 8\@/#),&ER]*V7-'" *EF?80LN$BB
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M88>FU(.3W,*_I.P!=3.1A2NO,\I<ZG*72"QD'W5B+0^$P ,)@%5/3G&Z\J!
M3O%18D\V\"Z9G,("M+PD+Z^)S?YL!K&2.,%$ VAYAP;(@BJK:(LL)H&Z6SAI
MG&GJSZU:0+%SKB(FIS@8361!B7D>1YWVU Y56-%/Q]SB$GR#25LP 8J:7")
M^[Q%)?2IS8A*=*)5XN9-O$G+2S  $Q]P@0,P,8D*@( ";)#%!?B&"PU08@.K
MT(0%-$ "#9@K#Q4(@04^XH852J"%@[$ ""Q@*C2((*82D(2:(M$&#YP  Q0X
MA2PPL I4;, #&I"3*C:@ @\XH$C(.<548=HWF6[  =&DJ%G/BE8C0L4GF&
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M @-M@(D(S+5@^E:3 G" 20A<( D*H!# 1"ZTH7=92+8RH)H*IN4;)*"""Z0
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M7<IU:/ZKMG99F,%Z!( K+(D@!3D  WZ "$?*M$\8GE^;!54@ME50"&4[ ZU
MM#,AN5; !=:X!$@P!$_ !S(JNP^X5CTA"Q6P I&@ 6,R AX0"2R067M  &40
M!P_  7-  L>E 1+@!G&@ %\A:!-P!Y3  )&@!\\5"0-0!GI0 7*B!A)P!VR
M-[I6;XVE';A :I'@ 21P"RL  6MP85JV4IU&!\FV!@#<!@V@"2+0:;8  9'P
M 26P"2<@)_E; GHP!PZP;A5P!VO0 9F0 K:%%$)0 S\ AX; N0YHM'=HFC<;
M Z3 !7*)LS)!HC?@ S<P Z/P"C(0"+"PA8,9Q;::D\!;%?Y7, .CUPH]  :D
M$ -RQXTP@ A3NPA0$ 13@ @R(*2DV0JDH"59<)0RT0,\F00WL .DX ==,):<
MP(P]0(L_8'E2^J5U/ J&$(\PH053RHQ"2@.1.G/)P:!?]Z@RT F%,,GBN8:V
MT 1"L .-Z9XQD9J)Z @Q  BP( .$P,4W@ 1S!X1 ,,1R2PJ+4 ,V$)$Y\+N;
MAP./P B&Z7-B/!U6@ .61Y.CV@F T 54<0@PP F0 )"+  .76CBD( 4$2 L\
MP 1J[,E]D -#*9Y]'!-/NK,^^ JVFI59VI/@*WM820MPZ( :HR5CL) \@08\
M,QF1X%DPP0%N4 D2 !,>4"29X/X M[ ! K0&[)ML&G 'J[!#LB!KDR !5!%D
M$*!!<3 ))0D3;G!<5'$&/!-8F' )RQ83$T )E-(:^_( XG8&(R )F14)^Q()
M%3+1I>4?.X0!>L "'] 6FD"".\$(,# &C= (/3 $MB $<&N/!HF%3> #]ZB#
MH)?5/?<%#=H(4LH%L0 #P=(',/#46\FD,I $U"DEHF #.> %06"X3TB%6YD$
M#.FE?E $@"")I-"-7PH3.G@$/"N6.7":CZ"&K0 (+] $7U#%L* $/= (CC &
M;ORHDP@3Y4B)0S #61"K$2G*!!@%+V"9SB&(L >'\LC9GAT#GGR".!!_M<#9
M?_H#@?[0"MO,=C*P!6+M@'SXU$F@ TPM!B^@M]:\J"]PAX2@UF+JA*(\!-FX
M!+4 !K/I*SI(?F   [30C:80"(P]W3C0F2]@HU0  XQ@.+2@ S+0!5N9B%E
MA8(8@U>0CS$PV$%0V#$8HJ6<B?8' PZ(A4N0!#^P5F49!'P0!&O<,1-9'B30
M%UN!$B?6(BPP";;E 766"1#@T-VE!Q1]7!AP![=@;"K0POSE7AIP"G+6'1C
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M3I[B$$2:;9D+GP4FF!-%O+:EE1FZL(5IIR,FA98><.##"[IM*02&K\G26PA
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MJMD6/UC2+*'X'V'*8XL?2"$'C7A"'@$1BQE, 1%:@,$Y[U>N<]FB$3+HQ!2
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MH@HUP-LO&:&(?YXEH83YP@Q&$4E2\*$0H1S%#6Z0A#NFY5>5H28$-N "#RS
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MTK[PZH$@_&"#(_![*S'W08FN,(,;8'<&A^3!# R6,RZVCA/;BKC''V'EH<W
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M:%XV<?A >7'_ACO(P@5N6L'I#6.+2T#&!/ 9[$U=*V /2_[ 0BD(F1^U F[
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M#6AD&AF8**J$%=1 7=51#7#"*!38%7D!*83" =[E:?I$"][3?Z&F/P:%'\1
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MQ&B '6 "^+$$!8A&"VQ 59P"5Z@$X"W<*;A J*0("7S IF!?7C#<$[: !$@
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MH$$0>OY 5F#+*23&IVC !I@P&W@ !TR(6<0!!DRUK]F")(3O"L292M !!WB
M$:R- UA 1ZQ!5T\()9P!RWTPV5A &9A "E"%4OMS&53%)8CQ^&E '=Q""73
M!\2ADZV !WA K]$!&[A !:2 6BAM7SQ<47.V0=LS3-2<;-"J+1Q "&C"'21
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M,S 0V@%5,($@#3H@L*.-\\<_PXT))D'C_!88 *&-2"3P !,K,($M) "'.S"
M-!?IP @N08++8& ":5B# B(Q"0-$B0,;L 4EV#<'T]TB >Q)P!K:H  ZQ %\
MJT #XT@@/\51X'Z#*4,"U/ &$_[:(@(KB ,'CC.0-K0N>J<(@0L((H%(L, #
M.P.!+?3W 1M)0 ^'4Y\$WM WZIS@ UX*@2T\L )*4& %$U'% U11!P=HHGBA
MTP#?)D"0-E#@(+( G1XTD 9;-* .JF" )C0A ;Y1H"@GT "-X#B!!$(@$B@\
MP2DL< <2M( @$8A$"SRP!RPNA'$ED)]$!M& .]C!6I&XX XUJ $)2% !96$
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MQH8M;D%0+B$3SD !O@4"+F%W"&MV5J$%*""G-$"77,,$I+$!,N&',F$5&.!
M(F$U5D$$&L 6UD ",N'#Z$ 6RL#E[L !)JX!>#!M4H #4($2@LPL0X 5]  !
M""L!7($;/=$#5@$3H,@X!#0%X&AV["5M5( #_G*6</(.;C&@%(0.CF,W9N(#
M6$L6),  1.0!+(%SB$HA)V 5;L&3;@$-"N!2--(#GDE@+B$!( 30+@$[$ )Q
MRL:[.( ",*$K+X$ &&4-^),.YNL4-$"=$N 66  *WZ8!UN 6-. $I)'3O 6!
MA-0 BI0@4D %3B$!]F 53*  I/[.1%%T#F)# :3+ EQ 1(HN)!="/64! ]I
M#^9K%3P DBJ 4*GP$I+1%NJ@"#>/-2C@##YT0.FJ!!J@3@PB$QI 0,N@ V1)
M1QJ /QP54DNL!6PCA 9/%=9@ .JD >S( J1$#P*5( :UHUQL TY@%JYL$M:
M*ZR#L.X  =J $K*TH+BC ZK4'-'4/@GB ERT ;@"#1"@(?SK5#= %A3@*)T-
M-U:4(%YCMDYA-&8!=33AZ&S! F*5#E*+3&7" [9H!:!P \+H#@S@B30Q\]IL
M7]G JRYA K8( V(U#L*S$AB@* 2G42L!%8:UQ*9%<$A2%CYLJA@S:QSS;%H
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M+M82+O[U2J)'(#1@9B]! A)1 @)%(20Y#C!@(+KJ()!'%A* -_(@ 5@%!1Q
M1SH',I,5(3KQYM(4-%I$,\[ Y6R!!%"@4EG#0 -*2FJ%-\L $PA 1]Y1%EJ
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M$N+ @2B +DF 8]*D#F[! SH  QHB,D-@[6JM 3[ P\>,0N:-;$'7@F5ACCW
M =A %3"@ 5:30!=7QK.<U5O=U5]=/ (\M%NK,1YC%2" 5=Y"*0,[$T9(LNE9
M%N:+0>X;G#F B?-<7K=(%AB 4YYYAAP.D-0@?9X2+1^#754A!.PHH"@EC"ZA
M%0D'HQ*@6%*  3)& 32!#99H.'$' 8H%/V]A#R#0OT"B!60$UN\=W_-=WY]"
MUMW"PX=5%53A QY@D3R+ B9@SBV@#:P.+<Z@ X12(M: 16_FGJ"W3NB@#5P
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M8<&!)OX1)L7*8C@XR1I,,F&K=9]$%M865?],8T3.Y>2^H+E9M4%2ACH<^]\
M#WC?;)'FR("DSO$<=F7REASOPB2X/5KA+40J\(I;7. *ALR8@07OO\5;X1B\
MN,A'3G)D<Z;D*$^YR@M)U7F"?.4PCWE4"XXH\FT"%XC)-K VH;.%-#LS'9>Y
MT(>.O98?!GFLS4D<&(!B$2D-=/-K@Y[H8$;E27Q^@;FZ+58P(D[9A75NT!,
M,P?U9I>A/"\GNMK7_CHAC4%X,P()!ZYYI/QEO2C75 6!=30+!]!8=5-#G0:$
MS1B0K""G;$^\XG&7\<!< M4I@!0=VE"&"[" @J_DP/WBX/X #<2A7Q_0TQDZ
M\($]\!'5*J"4 S!0ATRT(0Y'R7!!.N !&%T"#6W 0 B>XMP/+$H5*?" "/Z(
M N'["B.0#8%*6N" #Q $-&>HQ1TH;X$#S0$"&'"E!S@ (TJL@0X?. 4:7DE>
MT+C@ [[OC9[3OOCVNY]D1B_,<.&P"A68L04)T(,F(+#:%#_*\Q2# J>P!P_
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M FL0&AM >2 P0*?0 B' !J$A0# 1"0*8-*/"DC2Q"K,0'BI 4Q,40"=0!J<
MNG3@,_SC7SL?,S@AAT9E"^;J^CHA"V?0!ID !RS)_+*0!EI]WYA1$11@EYVW
M"AZ 807! 'K& 1,@ 1 @ 0XP')+  0J0 !\0'FZ0 "T>'U3G !3@XPN -@V
M GFP )]A"Y+0 "JP9A00_@ ! 8,L6[9DE8&   *:@K;B4$# H,0I6Y<H0'!1
MD 6$"9E<0+"@J>($""ML;<!@T<$$"Q,4M%BC8 (%"A$:>.3(44&=.PXN2F"
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ML_0(@ 1-!CA!6P\R*&& 85]2  T%C$@ .@D6L!3:H2[IL2$2"J!  POR:H.
M;_,=5UVGGX8Z:JFGUB^L>JG&NBFS*GYSJ \,T&  DU!D@,F&,"!@CX+T("$2
M-S2U<4>?>2153 4P2  36RH^DJ@Z MC6H!;*N$0!"%1TN(Q3 F@!Q@304"&
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MS.L<2# _-&RK)W>(PQT80!:S:& YR')#'/2  170H0$M^*<M-##B.FS@#A7
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M4FP(/Y@!&U!%&Y@!0X *CO, /^J $]BM&LF6,B@#!H 0#2"!.<  H6@!!_
M-&"#!OX0@5-8@12H! -8 3>0 )-H P=@@S)( -MHE T@@3BX !:0A1+8N64R
M+@R0##KXNCF0 #>8.4J0 (?2!!X* 0^(!!!X,@VH  ^( Q78N5NH !C3 #V
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M35  #>@ #D" Y<" %;@#.U@!"9B%*'N#<=&#.[,%$!.Q@MB$$JMB5SJ<$["
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M@P?8$0K8, ](]55/32&KXA5 @2\>' F D"*G0?]@A!D(!%.\)@.9A.5N@S2
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;)_[B-_[C1_[D5_[E9_[F=_[GA_[H5[B    [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>cogo_0026.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0026.gif
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MN!QYN2-\NRI^O"%VN#%^O$-LF$QSG49PFU%VGU=\HT]WH&I_I8)_@"R!OB>
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M\>?P]^[P\^SS^>?Q^//T]//V^O7Y^_____#O[^#?W\"_P
M
M
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M,VA<"PR%0<(0=FN%+>9"@F= @VXZY=K_W,@[L+7.8=BDOO9A:0AF$& D0@'
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M"S^@<I" "_A1!1O5/4Z7'MN'$\/P4/?$2+@ =1NU=*' *LTE#*( !CE@!6V
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MB*CL,8![YB?.10Z*  8P?.$+2W?ZTJ/.=*E3_>E-+X+&-VY)W(%T6^\.Y'1
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M!,"M$FNQWFH G !@E,  (, ":(#&:H $2( &/(#&@NP#/  $*( !"  !,*L
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M$, XWW(!W/-@W (O"P#%[I!$X_Y.*ARQ#<VG1V)86(C-V-S51&@!4NNFD5Y
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M+#XY"KPQ FP_]S=KLW[[MS-Z  2 2"_ !\AR^-P"!.BJ &A Q%=#'@0  P@
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M+&=+PY1Z9F[.' '!S*$S<A "L!0-RN$,LY)9NB+&F;U %V@G]YNRBVM7"H4
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M'$(/)@C!!SX0@A+H(17AC@G!J0%.R" <XQSO.,)K$^F'I.)OY^Y;88&IR"H
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M@ FA\1.4.0?L0.0: G,/>P,"&IR#P1>D(!D6H0(H0!>$:&FNN0+ 3 :/.J4
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MH27OFR(A7,$+25:"3(;H"],B1C:&H"TY5KH$ X]2BD88#Q2>Z($8=J"9-^:
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M-V&(!S&'X4<7K*(0J,(JJ40Z "@UN9 $X\&)QC *Y0$&;V #;$ -0X!,HL&
M2K%S.=!S^?ASB^ X_OAX0X(S^,8Y%%*#7L<*KK!8JI"#.U81J@!*SP!*YP61
MG$->U.!Z.B4+@J Y,+EB4[4@R.@_IZ,**E8(:,)PZT5 @=!.$840]'<0,O9G
M]O217W5M'D$-$A240+$#8U -<6 #/?<%.D -.9D#.  &U4 $AV>%1XF4GS80
M_G%38>B*K^@:%0 #]3)#;F) )>(_(XEL!&%VZ'2(8=4YJ>)G?2 (?4$8?<8F
MA' E%?ZQ(;9 :]*P"@E3"1I2:,]!"P%T>1C29U?%<6;CDM202FY'#8*&53RV
M;_CR;(7P8P1A"E;0=R%##59@5M4 !%U0#<+0!G- #7+P2SD "3ZWF<"U"6/!
MBJ<6FJ@V%FTA5Y-QEAJY&#.X<!'%>=50"7_ @P@)=8R%'<:8"B1(=8^49@>!
MC8$0:^>%.8+00ZS2$?5T)7V '/BG$R)((8PX-9N79\= ->$5-K/ (=,0!T3)
M'G/ 0<;@ SLP#,.  [$U#+A@!K^T XDRGS\W$+'@ 5TV;V*H0F+&$<()5:1S
MBYG$<:N B(#0%X7V;'VP=G89>P2!#36!FX+0$;"0"8 @&?YDB3FW '!3HT@$
M%0AX8F,*T1?*4!&D5V@M.975MG ?,0I(T'>B,0S"0 >-4 V?X(#48*@_(:.(
M^0.E()]#JF#!D!O]2'3YN1878&](YQ'*8'7 5DYCPI4$80VN&:*MXF&U< LT
M@8W$LEANHF.9(P@#H5TC<J:$T"+4, B!< @#L0JDAY5]< OGE8=KTVJ'J K@
M=6=Y1Q#$X!F'N7/JY@R3Z5''9P-A4 UV,&0=<P0\ JFI^ SC0JD$8JE?9A5:
M$%:#E'9K":6C]S[',$[*B)!\$1RC-Q!"=:NI%);'6J^N<JN"T HE6!,[Y@<X
M]F$<\7 ZT4[6D!!#!"<G\FR&4/X++]H(3?%6G&B%I" *.! $Y_$(U9 $-F '
M$O1R5M"?W1I]'-%XE<J4]S$D%? "8B8^AL!U!70A(ZHPTE"FI(<,0!1 BG!K
MU9 *@U"O# D>N*I([]47MJ!8FSJT%D-_"/5UK@:Q(/$)HHAN8N0#16"%CQ -
M3,$#*&,,R?1R8T!2^&BR/\<'CA.NXBHTIR86F#H#G/ 1/$01>8H7-:$*LK *
M<\)+S] '(J@_'6$(8:EFR;).Y2,B@7"E9 ))DG2;7&4JIW.(,(A4JW<AA!"
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M7$"Q(0YJZD+U"-X@"66.ZB;;_(Q00$-[ R3@?_CCBXLHKG^W8^"S-#.$9-D
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<%-(T(S'5B$YO^E.@!E6H0R5J48UZ5*1J+R  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>cogo_0005.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0005.gif
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M__CW^/#O\
M
M
M
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MXMNX<^O>S=MEI@8#$!@H@*" @=H7K<XDB$? @@*40RQ(L$>@A ,!3MAN^<'
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M#\*)Y4\+,(<,2^!!;3C(!8I3N45;S1,T0L!UC6,U"R- J74( )>LMI*#.$
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MJ(1W+# <;_ 45)5<NH4X#T(@)F!&). 3;" !V,-T2D-J!7$E":  $8 !%_
M2R0R>X@' Z  %- 8>S !$W!]6KD #M"1WA0 $^!JIC4"CI*42_E3;R=I$R40
M'XF BO( >_ )'Z H$. +,'-&7OE]5E0'%J@0<R4S)= )GY "(D, J^8+]G6'
MFG   J![ .(BJR)H(V "(! JFG"5*M )== ] > M++( @V4")["9G3ECJH(
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MI<-Q5AW@'MXT</*1'@!0C6T I5EU5AN $$FS-+MYIWBJ;**')TKC "PP,')
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M%T!?!D&N3]$!]#DTZ7(MN#*W_#D*G]"W428M!N4>:OM8!.('Q;3%3*@!$K!
MNP !\)40<1 "*= 6AY-2< ! LOX !WB@"6D9"^NB;WZP!H?A>@(A^US&('O
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M;U]'-M *!0I4^H0$DP\DZ$ PB@MM,!2V@X$46%A #E\VD: %%BH8Q9<*.+C
MCSH8T, /#=Y "(06UN/PIE 2("$366P"084*8CDP Q),\.43"0:$X ]?4J
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M;98(7CMWO4U"D*"!#B"6B0,\0F!CH318L&Z#-! R;\8*"$*.Y.A,  &A$-8
MQ0&"PHOE,/ B^,3)B'?F.4HR8O[0JA<LDVI""BAL *(77G88PI<P9(!SD"K%
MLL$&&F1@ JH>GL#B!RQV,$.&/ 6!P9%<;" BT!U,L:&))&[@91$KV:O +UL=
MQ, $$RCXP)<]&'@CC3<4P*.3Z#2P R'$?7G@M5T@>,V3-M)H0# '8HJ%6832
M^+36GC\'G6>">/5[ 6)/HB]=!%8@$#T)A#4NE X,],43XN#HVY<U(#B!L 8^
MD8.$3518P8^/?1E.@A!R#IVG(SKP:!99\*W/E_M \P6"/>3P8# X]-@ (3F@
MCP"$$4C0H&\),GGH L$LA<4.Z.]N7J?T?@%E PIT#AB//1J3 "Q4P*('",D7
ML'" +_Y.,!'C&!"!,]J0+TK AK_UK@0/X /C/K$'@-7/@Q_4R2-DX 2$Y((*
M5D!*5WRA"Z?XXA$TV $2@""#*?@"*UH1@@U6T0LLP$ 0ON#!$QQ! QM081$P
M,(L2:# $,M& %&KR1=ANL(-<S(0-M+L AF82F.(LP ^9<  ?[( '1.PB$X?[
M5< 2]X!0:.8!LZ!#!-[P"1#\BHT'= "*=->Y"- /A'\$I$Y4D!D)?N "PIJ)
M!5(@!SFTX $$>=U '@8"+6ZB7[A#2!LR\(M0S (CG]C "O#@AQ1\0%BT^,4G
MTL" :@52(01I0<MPD@;H(:03!=B%D1ZR@3EP4'S0"Y4L0/XQ"Q11@'T$P8"Y
M4) &$@C&E38A" E&AI!/+" DQ?'%['Q1)(#IS1<[0HB]%(BP8X536@M$2 G:
M<)A=@"(6L!C1"HY@ CH\TYX>=((,K."(*;R@ACDT4RUN  1?7$$&5+C"%7IP
MJ"-:": NE($7?+$#(K2B!S(HA)\2T0H:! $+5V@"7;:"@UQD:0>\P,(0;G&E
M%#3F%PP0S"=L)8%?(?,-+V7>"F:A"30B) -K;&-X9($!)1E','?T!05H5P%:
M/?*>3WWFZ%@T&0H4(!2R*%5",J$ 6 V$ 8EK .P<$ H[0 !6(UB +]X0/E^
M@@%"8@RL/O  >$8@?+^ @&!BT?X=J/JB!140Q1?]D+,](!*6%/C$)O"P@"9E
M2U1^6, NZM 8Z>Q&!;54)[#8AY!Q$404$MA 5_NJD#T8P ^[^ 5#%G;-@/F%
M!05(W/G\B@&"?.!33-K<!0AB/E^00%4DF @#1.6)"Z#H$S5RR6B5BZM:A%0&
M,FA"27]0)E_4PDNNT $0H.(++\"@$8V @95^8 ,SD8*&OO !0:$@@U6 =Q%D
M,XLO5F&#(N1B"#C A2\:00,?Y,(MK$A(+":0 0I #Q1\34@$$B<T$+"H#@\P
M@05$X(L_3, 7&4CC3X$5U#SB(0*\2HW#VN@+/SQ@!(EQR"PF<(%6+M?%/5M#
M44G\1OY-G"PA;$ /05C0) [$Y!<?R!F-.L""EMG!(03A0P4T< %SP:&6(' #
M0L*U@0EH$:ISB  %)D !!QSD QA*3QVR7",#$>0/%UBRJ/# HH),]007N, (
MY H[Z>B'LPQ\L2_N0($+5, U#MHL04P@F$VPV'HC^X4*X$R"$:6A#0E1] 48
M[=<H6Z]CF4!S!00#'/3DV=/K6<4DX(*06M1":-6M!2]<8:82KB(7O&!%%4LM
MM%ZT8BFM,%,NEJ)J7MC"%:?N12U84>NEQ,76*V1U0G:QATS@B[4'%*TL0@(+
M/!@6(['H*K8/F!Y8$"04?)C%+SSQBUC0)Q9X^,0N]"B+<?Y_VMT>]*--I ?-
M;N?D%Z@0[;OM5^^;R*+%,\&7)\;Z[EB,*#;^MHDL]$CO^WW" ;[1=\0E?I-X
MWZKB$\>XBR^>\=KXL>(;1\@<%M"Q3]L*Y "G>$\($B E<=SE-#GURVER\MC0
M7.8WQWG.<?(+8.A\9Y/Q>="%/G2BY\KF14=ZTF>N]$_'_$I/Q]),:&T3IRND
MZC<!MDQB?G6G._WH1F=ZV,4^=K*7W>P:/WO.\1<?6(3B$PLO3ML_\0F#'QSN
M+L??QT$1"KYW$B?S+CHL_LVA7?2]00/A=]H]K0@P/-$7I.@")5+AA4D@)!5C
ML$(81KV(,)AA#&9H_--7@7G-Q_Z%$&2H(B_($(A3DP(,\7V\%R3A"T*,@0QC
M"$0I3!^&0B"D%&,(0R40THM!@&%1"!E$&%R!D$",X>JPP, %+' !OIE\2'@.
M#>Q2]Y#M/V0-3;)#RQ7_S%E@@ (26$ %(("PA,S" 1&H0 4: .:4LP>3.O/X
M*T>;B0 ,C":92(#XLX 'L!N4<PP9PZ:<"X]:V@GZ<4#I0( ^>P -4+<(&)'[
M,< TD!'^&;_/ 807V *$R((7L(1%<($R\(5%N!H;D $;J+PH>"X9F($7"(0K
MV:\6;$%*0"\96(I:H $=V"XK@($:&+5"> $4] $9N!HE=(0=S(&E^ (9@($:
M?#P:@/Z!$(R+(H !*H@+'YB!*I*)#^&#3=@$34 DF5BL]("LKR,(3Q"6'^'
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M@)(<,8Q#''2R/C9((SMXM#? @ QH 8*0 QRK#%O1I(=@ PZ0A3=:& [@ !.
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MPS\"!06 LPQ  'R4"3\@#FQJ6X0PUD]XI&B"@_])" H !;JUVQ4(6XS#@ C
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M!T9C#DE#$J, <SN D@2!=ID>"(.#=C$,!F #-U@ 44D#"3 R@X2#+%:KQMB
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MS7B0</Y$9I[XL4<(;L#]F!\/:-3!"250U0"\OLC"P%.S<^E+!!)*&$H??83
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M=0HE$J2DL_&"$HRG0M) &,P:*_1 :@KE(K";*_A ?"XD#20"/I'"#=SG#=
M=L8:%LA ?SJD#?A *V2GK-5"$!@G#]" %=0:)=A ?-+ &2@HN9$"A0(E#]0A
MABZ.(_X8YWH6 D5*9E=6PH?&6BH@I$DR 6^Z6HAJI QL ;R%:$L.98HNCD56
MY@UXZ(LJUW3:)0T\0K7Y9$*>I$S6FMT1@D@^J'"^6T4**13\* '9'1@(*5':
M6BO8)PTDI[4EPBCN &92Z9!] 1PB02[,VY7: !&D*7)9P2@^:;.1@@RTI[79
MW1C0P"1(VQ3@0(+2&Q7X:9 I 1"8I[-5@IM>&R]\I+350BG8FZ,*62OLY?A5
M:K21J:5FJJ9N*J=VJJ=^*JB&JJB.*JF6JJF>*JJFJJJN*JLN'::*'O-]A>B%
M1*R*Q%Q.GUCP)J;:ZD?L9*V>);!V16XV'J_6YIM$)60VY?[UC>;T_>BM%NM6
M^&JP6MZO2NML/"M8Z&IMSFJR5BNPSFIYO&IF)F:P.BNS&BNZ]BI)O"B[MJJ^
M[>K P6M;K (6A '>$<(5)&@N;,$8^$(A8($7=,$94&HA6$$K#,(58" *3N1&
M\ (88 $K:$0K8,$8\()!4L$CY + =H$7-,+E4<(5-($78*9&3$+(=@&C5L(5
M8,%>.NP5$((OC$$7= $6D,%>5L(4$.E&A($76*Q!8@$8N&DE4(&70L(4/&HO
M+,(4-,$8R&0MS"S'UFQ85 (6. $6D*Q!BD$34$%8^@+58@'2CL$57.@88,',
MVJPOU + KFV_DL$5M"P8]"LO#/Y"$S !&22I+TQLT/J"(%R!&& @%IR!+4BM
M+[ "&&QMU^I"%^PM*UC!?+Y)*QSN%"S"WC7"TH:!*_A"(U#!GOJ")$C!'28L
MP%Y!*:R"W\[L(*3IYG9M(5Q!DM:"_[EI*5@!S/K")%!!=/J"(U!!$X"!OHI!
MU%)L1^2"%XA!FM;"%9"H+Y "%C0!%N1N*F !%IB"1H@M&?A"(& !+SP"%32"
M1AB"ZVK$+6!@FK:NPE*L+?"KQ(9!$T@!Y?I"+OSM\5Z!EZ(%(:PM&.PI+WA!
MO_9"(4"!$_BN029OX04"%02H1G!O &>N1CC"TH(! R/L&-@=\UX!]8(! 6NN
M].;")/Y(02DX0L(";ABTPLPJ+.Y2@A4HK!5(PL0JX!9@0>U"1BZ<@1,T 2&X
MJ?]"01.<P2T4+@$_;,!BP1?X+Q50KR^<0<_Z B\4@A3L<)I*0L)R[!5TK48D
MPA28P=[I @;.K!A<P22H;,!Z =<67B+H\!G@@@][Z21, 27HPA60@=V50LYJ
MQ"IXP=9"0LD><$>8K!-T =;V0B(T\1C@@L;N[=/::TB,00S(0.Y"P0M\9"W0
M@ _X A7((PW @ V$)16\@"E  3<2(T=(@@S$P/4N+PT@IR] P@N002N H@S(
MP)1NQ""\X0[(@$?Z B&\H1"\85C.,@Q<;R6\\A+XP@_(P/X\VG(N*,(J.QX0
MR(";DL$K!V@A ".*DL$+$.D5P  .[$ ,#$$OK,(G$P%8% (M&_-'5@(.R, /
MY  ,B(&_OG(9F+(,&($O#($K^VDKQ^$\]\(0P  5P&\-%($O7$$,!$$_$P'>
M?:(,$*DGZ[,1@+,XET(ZPV<,N/,JG/)$DL(+9&F92+0,[  .M+-&;",.]( M
MMX(J_S,EOT IC $PPB$,-,(DO/0I*X$O> $,^(!,:@$,$.PK/VXCO#(>#\(+
MD*@88'(M^T N1+(^^T#EU4(-R$"_EH(_^\(BG+(0G')R.L(KT^A%RX! *P$,
MX()+(^A P\"C^BL,R ")9H$QQ_YA$;B")!ND&_9 2!-E+>! #/3K*L" %JB%
M$KBR#% N#>B +X1!# @!$<" 84_""V2!+XC!"\0RGLI #23U7HZ!,>\R=/K"
M$KSAHVXE#!B"+Z1S$=A=8,M *PB""V""(NLS$)""'-H #!3"(-!T;9?")\OI
M8S2!# P!$+Q $VC$%,3 -L. 36NT%O1".L.A+?<"%""WW1D!#:1I<>- 2-LT
M(>#V]=H=.2.!#'!T*\PA# C"-,?A+_O"%&AS.B<W#$2!1@2""Q0".+.U+SS"
M"\2S))!B@\J &?#M"QR"XP&"+K]A@*[W-L< $.3")B?G&>0WK0Y!#]" %VB$
M%-# H_[F=1(,M Q 0B]8Y"0/J"GP B] ,R#P0@]O!!;D)4+[0BKTIU.;@@R<
M020W 2^L0A/ @)>V@F4^ZFUG02[00 \\JB30P _X B.,(A,<<9S6LPVD B^$
M07D_ @Q<Z-T% 0ZX*1+L@ UD*9C:P' ' @Q4 B7  !.D*184M2[0P'"[9J)R
M12M@]T=.LW &MG[6@CVO0HC:P)(+PB@.=Q+8 "GT@DN309 ON6M:+&H":&DC
M 2_H0 _(Y!@0 <DJ 0[<P!6D[=Q*=2_D H_;M!/8=RL0@0R00BWT)P[H0BK(
M0(6;213( ,S6 G7:@HPC@4R2<Q3T0@_T (GC0! <M@QX;_XO6.PES"C\/H$,
MK((9S*,[PRFE-D%_2D$"CR(2^&L,- )$)ZB4P[$-)(%K=GI'M (/)&0M@#-1
M[@ -1"=_X@ O3,(H#H$O^.8-B'.HYX(9P"&-7H$,D"P4]*=PY@(O&((,B $O
M+#4.P#L5P #,Y@(3Q, D] )#VD KC/<_R^M(U.6C<G44\ (/>',1V,!>"L(0
MI *=;L%V3\'>E0(-!$'FD@$,E($KR  09.XB@#(4S&-R+CJ)[D!_KL*I]^?!
MCC;\!G47H'@OU +#"WJ:BCF)DOCRRD"F\P*X0\9XM[@7.'HCP( 42/TF/P(X
M1^@.^(#4PZ]ZX[PO( $.:*X]6OYLUR]">2OQL"]>2,HZ/6\$TCL!#9@"&M^V
M("BQQ6+"VJ]T([""#$R!1DQS(;@"A1XY)/AW/=. ]ZY",=>"(KR]W5UT#V!F
MB IT(\1 $Z0I- M"),>D#_3 FW=$)>RU$NQ FGHR9M8"3 YT#!BQ;Y="%\B
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M&,O/?'$+1PB$8K_@!2^B,J)&.(5/D"#%JPIR$/P4XA(R4(01%_$#BEB$B4V
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M%LI@$&H!#,!($KP 1FJ1#,S@$M+($+U "I@B)DC!"YI@&@WQ"UP!%[X 4\:
M0 AA#("*%&IQ&8U$%05AW@ZB%+@@I+8@A!3A"S"B%R#A"J;@#!2F%I:1#,9
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MA%PEF<Q9*C@$GU;A&GEA?PEL-?X>@3%VH#QXY0:$Q4D&!"GV2E_"F4^ 8 >
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M%J^ )S0-",3 "\*\ILOE7&9"O:'H+EYX"W" #.C%%X)E"X" "H8 GO:;3WS
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MV,X747@ELEA5"RLD2$Q(@,%88="(,,A@!ZL8@B-U5 HG5"05-/@"2!N"A!N
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M J?' @[@CKZ@"28P D1($A  B7Z0 #&Y!_PH FLPDP *"RLP FL @8#(G2F
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M!\**$ V;LM[CFKX@I26!*W#0E7) D_=*FL(: 6#HE".Q 0Z0 1C@ "?@"W!
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M"Q"0?*7]"Q=L?Y6WP?.<IK2=!J,Y$I48>YE@  ]]K,*8 0": 7X@!S#M"VS
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M;T"LH(@!-_D!_\< M(?.>+P^=9  <K )BUX'L2 "<9<!R\L&'@"P*LL"\V@
M],<".SGNH*@!X3@"06Z##S"&(T"Z?A "3[J2D%BXF[#*L3"O&+RYSDB*>RG1
M7_(+$?Z@ IL@ :-) BR-FPY9A@CPG@[P!YY0 03I )E@G:3ID"30V"2P IW8
M"9[P 2-J HWM":<[J_*XKA]@J;CRE<#@"[L ?'FP!VO(L<D7"PG0"VU  :@?
M =)9G7LIL$A].K&0 M\Y B+PD7+ E+.0 EM: GG@=G  $!LZ[/&UBX4L7[]8
MS/+U*82&% S9;$KHR],'.[Y\M:F@T>,O7VM$5,33 0,)3QK9:%)),<V'-)]*
MA)+#L@5#7T=*>.39T^=/H$&% F4SPBB)#YY^D8#E4TX:CW@^F/"4!D\F.1KW
M9'V32>.;3;&@\OPU@:*O6"DR:'@#,M184% WB0C!!T\:6/XM?/G)6E!"RJ&!
M!0\F/$L%0Y"R(N)ATU,658]U-FS(Z"L-*(UI1O%<XZ>G'S@61X38LV=%K!8@
M8:4!*>=#K%\J/H M$8OGG T>]WC  .*L'#X:Y7A^\V'%)Q2;[!"\++P#8>C1
MI0OU T)@'5^A3(#T*,?H"#:VLY, @8?/";3@?<'YH.)3BDQX\/P\H:*BG T9
M3&"V_"ES*%]8^( -3YABXQ.%=M'(!+VXF^[!GSX!X0(60$KA+(W\:$RCM!@J
M:8/00@HEE TW6<,7.^;SY8[Y7$O!DQ7\V",CD/SHP(.[$-KD@SQZTJ"R7=;0
M((,6$ *&A5P*8@$87UKX8(U/2/X Y8U/0CD1)!52J A"+KOTTA=9_(@ .Y]V
MZ8"_+Q/B ,TTVW33RSJT=!!..=^T\TX\'_P PS0]X#-/0 .-+I8.$&J34$,%
M5711GS(!8<LO9=E /$;)TFC.GD#2U"<',87TTDQ]@66#L7Z214%0/PTUU51_
MP:G2!W_A;M:?YNP4*$\]]>556CE=%=-9=(4U36$_[56Z7HO=\EB>:#&465]9
M7?;58?$\5M=-/XH6VI^";57;;Q/2=9=$JQTJ5TO!37?96M5=5U4.DQ7J5G!=
M-?=>?//5=U]^^_7W7X #%GA@@O&=-=M0E1U,684+!A1A7Q5NV&%_)98VJ(DI
MUIBPC/XOWCC?CCO^>&222S;Y9)135GEEEEO&EZ\Z]+!CCCHP5:Z..O"@MEU<
M]Q#990C_P'D./SR-Y0Z<Z?"OUCU0!;K:7>R@U*=8\*B#CCKD$&4H/LJ-]NF"
M/R'((SZF[FF3L0/[Q6>PH].$)8UV81LH/^">5U3/VK:SC0Y 0.""$$)(%*01
M%!@!! P<6%HP6F5A@$U<]9Y. @E&<^ #2_$8  00/DB@KTP92.EGR:<#J0X
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M@,D\8 ,@J:=&(N )34@ )'R@8AK^F4GT)& .%DG +S11@)3  8 :Z(L&YH,
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MH2] \0!?@$!U1_2%"5:@D1%L0 YL:($!-E*"69 @!7Z80PB*'($3=(]D(.D
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M/B*(4#@!$_@#/*@??TO 7:B [RL:H) # "(?H/0%!H"#4+B E5(!!R"M-:"
M3U#3O3  F#!1>%2!!%B!/$@XC1@%!@"0W.F(OH$%%7@4.W  %#"N!V #4-"
MQN@ @2NT!*P TH*8GM@ !TB#/C 43UB /-@$#,H$QNHK+:$V5;4Q 6*!#3 1
M*OH$ ^B ]22!$@"%#YC-E431!C">GF!1-O #/U !*]L$!J@1 >(#[HD@ED@#
M"A YY]D#!$B#5-*C"," /9 PV_[P *H@#Q0Q !!XT)$1)LPY-'AY@PE A#W
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M8U*R@80#M>6I.0.5@XO+Q$L!<R(!TL(#$!B!66"#%/  ?&(#*QNE._R%3X@
M33D+/T@ IEQ)RS11%G5-$#B!U>))7YB L9$%LV, \9@#3]B#D[*#?W(SC9B
M-B99'R.JD]HRR4J*/T#5V.4)DDL5"? *6E@Z/E!86OJ?#+DM[_2(3^RV4&B
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M^2#RM/2),'$036#(#Q\9QWG2!1>*.AB 7KV !1"%%U7$NSD!1P(F"HB 7HV
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M@(XOO/Y!R\S'6^Q-?NQ'"7#%[1A3!7G B QA"VC-3&*5'=P*MCU838  '&A
M+,1" W32&D2+@1A$!;A70G" LTT&0U2 \F! $4( 1<B'+$0 /Z:=@JP)D.T/
M**",78R U"R(!,3'!K" !JI')L1,PK0!0XI(+#C C.@A0T:1PW $G20$9_P"
MM.$4PB% &\@!',!!6LB!B]D%5!270C2@)TB 1T $#F+;1<A.?:2-9!98"@
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M''A 0ASV.NV"!X""Q!$312#70>S"+VSSL, 6"#")+/S!-'7"1UYV0I  G5T
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C76M;WQK7N=;UKGG=:U__&MC!%O:PB5UL8Q\;V<G&=$   #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>cogo_0027.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0027.gif
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M_/____CW]_#O\-_@WP
M
M
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M*D "(#_&P$LP#!20@T"?H+#8#79]*.B@A!;*D7H'6+"?"0<H8,P, #!PS 0
MG""0"0",X,P+ !   0$!Q.!,(P H0$&IRZ0 0 0J) ! "OZ; O# )0K$EP +
MNR  0&[+0 # "\U),("%!!PP@*:5E'JJ LXL0@ !#2@P0 *TR') ? >DT,EV
MG1RC  %[$B+   \<$$!EAJ:K[KKL#A3BB+_)8, !MN1 P /.3-: ,<4T0, E
MG0C @"S.</)M+YL8P$ "-6"B"P,(7")@#"X\8X,!$#S3B8.0;4H BIV8&*!
M'2B0 "&[O" M)YPHK$ -ENQBW0O/%#-" 18XL_$!C>B<P &@>$M (,@H<  B
M?%$@@"#0M>OTTU"WAF@'6FD%@X.ZW'#O,[U\NQD!##Q*0 2$$"+( P,,TO(!
M@ ADS (&/' "#ISL-<.]SLSB(/XG?!Z @"Z!!$"!9<^,0("E?%D(R";%MCVJ
M 0F,C CDO- R;R7.@'*  : 4\RTAF!"PP V()-(! 25$K?KJK*_UKKL4),#
M,C9X:A<) M0 J0K.I'"M <\Z<$##\^*W%R<6F!N  "8X4\/6LES'MS/J$0!(
M"@'8 -T( P#KC#$/X)8PT () K:;*<Y+"RV;8[YST L08,@B C1P&]@,#-[Z
M_OSW+]4S%!"15I91@Y_!ZFX0L,MD)" ! M#G;A0XAEY\P0MH7*)X;JN<+C@1
M _G((@<#<$#>]O8;>U$  @88660,USP*^2L0C".?,RZ(@.D% G*^L-P!,*<Y
MSGEN /Y2(H "9 &78NQB%_Y+HA*7.!3U*. !)+@1 DQ$"V?, &-VT46M&-
M7^BL  E DB4ZT !0<&(V!--9 !(@,5E(JQ. \-0S9F& !;1@9+1(@,GT-Q +
M_.P&MEC!MV1QQM*X[0$&.,$N9M' Y@T( 3S\62J.T0 #!.(9_EI!,6@!FO!H
MB(F@#*4H3[*,!@P 5 $8P $H,#(8 & !@1J!  # .ZT$ E0&F"6LDA4 %;X@
M - Z@ !(X Q7*D OGP* ! 9R@@080'M<>48'#@"! G1J "L8%0 "@!^M&$P
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M"91CX)XY U,K:$"G(IBW!P S  P($"T0,#M9"!P:*P@ :?X @#P (,T9*P!
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M)A  3/,F,F@O$! !$3 !UF0+M@ V2&2.(]9HH-(I"T"2 *@:SL "N>,,)S
M.< +YL8+NF"6K*,5%?(O K&("LB.NN!ZSVB0A7B#C7@#OA@X*# 0*#  -\ +
MLV +NM!SZ7(,$'  T[,"!]  #? ,.:D;!)"#E)0 B; ,QA !M18^JL$+%!
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MX-1U#+W "IZ@"9; "@J."Y5YYF?."ZP0 B   A_PYF\. AI0XQBN 4%@!:(
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M"IG?^K"/ 3L "?/]_&(Q#'P !450!(=.^? _[CU \"/?\Y@/Z5$. H8_!*M
M]^?1#  1J\\9,F?2I$&34.%"A@W?\,C@0>)$BA4G:O#PX8,&#!B$A%+F3.1(
MDB5-GD294N5*EBU=OH39\MDQ7)TJ,2J4\] A13U]*EHD0H-&$!LU9.AXX4(&
M'42VF +6;*34F%6M7L6:E>2S79TL?>+D2=.FL9O,GCVK218O7&QUO?VEJRTJ
MBW7K;KBHXT.&"SN\)-,:6/!@PB:'U4E29,EBQHT=/X8\)<.'BACM2K0LL2AE
MI$).4?XM'%KTZ).@8<DI4\9@0]8(6:,Y\S #B,NU)VKL&*++,9&@2?\&'ISD
M,EXV%>E4Q"CY3^:+@&B@[0$C98W5.7;4(&3+JI!3A7\'7Y)KITQET9Y'GXD5
M6[=RY<ZU'5^Z] T;^'[HTCW\?OXE#R-!8@DF(".PP,:.@$Z^VC#:K",B5NFM
M/PG#:^8T,LPXZ#4-%5*#H3@@4O R#8;Z8(,+\ /,&=\F9%'"9739!*=">&*N
MQN:>BXXBC$:$KCH0.L) !RM.6<:[%H^TJAA4RO/D///02PN56]YR#Y>WVF)%
MHQ#K&I$B'33H2Y05D233*JF8T8,)Q0QDTT#)*%LP3HIPP_Z "F B+#-/JV*9
M@XPR7-LP4(8,@BA'^3*S2"..=NB"&3T?'>R9D8KQ1,:>E+,Q4T4.<6ZR^"RK
M;J..=MCB%R,A?5296IA\$DKTS+/22BJOY,63+>W2 *^+<NT,PC%1194J5YX(
M<, VCWW,B-ENE0^W#+9P%%AI32)FC]0 ?2V-#@5=2(T/(V(6UUSWPB (4_"<
M-MV4GL'EDIR6TS3>2X'( %&[HK-L.G(Q&,*4(M5%DA=-,G$52E/,:G63*7&1
ME>&W>#'%T'!QU0BI+8K\%6 6I1K&CF*1!;DQ)WJP=V*+:/L A+Y.$4E2C?-L
MQH\RR,B06YL5(A1<DT_>#"D[7_X&FIE:(IE17J-]ZA3.+8<:L;J.@H"DNXR!
M%FV9)3=I<JR$"W:REEEGQ667B!4LF4N)-FCZ PQV8(7J,DMA(L"0YV9,LIUM
M(Q$I+?1SF\58V" ##6QOMOF,;R6^VP,00.@1@PTF<;EO2)>IA1%!DL/TZ'@Y
MI7<CO"O:@/',4L:@KTG^E9RT70:&<NNMT=*$E5P<!EO@LC'3T61RMY@Z]=&D
M2H:.->F&3 DVC4!<09WE4WD'"'T'3ZJ8KQV<<)PUC W$6V_GDC)^A8&^3%IP
MTKS\GA(!PO'$;R-WAU&D#S^P9VXA&,HF7SV8:TTZX467_J>D%2H25)?D30PW
M0KA3[_[B%YA7$(MN<IN;\>RVOO@L#@-=0-<""],,8LB!9M8C7!K.H!#94%!$
MN/G *%2D0?[L@A*70X3YRN><('&/67GS2"XRR,*6+(,\"'.2)EZ'/[1PXCU?
M:XLINA2N)7YJ VK; ,MX2!BID *"Q,/B$0IHPCEYX )5 (P"I_@26)P!0R!<
M2/42,L(1XDPV6UP?J/@"K3$&!QJ<*)H,S<<(>NF*BT]4&P:TD*(ZKN089#E+
M_LXBEOMQ#8BP:XNLJJ0+4RPK7)Z[B&V8LH$+%E(KS:B#W(R%1;I-D(N769S:
M@G G3UXE9H%3(^':F! 1TG)0V5O>*2WR1 P0 7QB;.5+=/YQG,SI\6B'X*,-
MY20N$JULA<$D"3#JEQ9'PJZ:FO!:K*B$"V%DPI*ZM(M&+F %^$%S)<#+0A)(
MN<XE' &<J)3(1C[P/'.RI!G*Z,,'T8B]6([06X5Z9Z**@H$0Z!"8]3S),C11
M"'@9<X;/&9$?=:D#O3GJH.'CA24X44U3;$V1!5-+>QJV"U$HTX2(^L %J( Z
MA*)D&%'X&#N)-P4X!E14*KRH)Y/1IUKN$X0(R=G$:LJEO$7QF2UUB3#(YU ]
M)E,#7PIH,X-@JL@54A?3K*8U'^E(5+!%DG+9128P<#>3WD65O$&J27[A0)F2
M\@BY#&AE-G*!4*35,&O T&I\NOXA-8JPA$PTVZ=$55>[LJ06,RHF4X^9M'J5
M-7=DFTP&,B"*8.(B$UG+:F9?A37W7 FL)8TK*H=2KC 6]A=,,%Y;B3>@(T@T
MM#IJ)B2.BE1BO.%/L]PK;%B#VX5D;ZROM<A0."G;JA9V),_0Q.44:TSGY"JB
M@25KRDIT@2UXTK*:Q>XF/IH_;59I=8X]I5%424B$2N474##>%54;LA[ -43N
M959*96M78J3A3WSE;:!B^1K?DHV"HTLI!HWK'62X:[D.I:$.@"L=$M4I)#D%
MV%6S.^%6T6*;5]K%)&P(WNTI:KQI'084CJ7.]1*H!T,-[6CK"N'PU5>OO074
M&?*[3_[>RC@-/%C<@H.;$0S,=\#..,8B"I'8 R^VCX]]IW@]@E8-AM5)CGS=
MDX88N_XU#!?%H 0&4J9CS/!HM$2(5CV'\834TJW,;74"\KA,U!]1EL6I(\8:
M7LQ76>)LOX+[Y]+ J>+9(E48B#A$(HK,7(@N>$1%X?$.?AD_80P1+1U%9"*U
MYJHHIT*D<O'%)'Y[J,]E<E>8))%SU4:%-TLN&5$X<XF)U]XU"Y1Q&? 5-)7!
MAKSFMB%J "JW9/RA3;<:,Z(Z5ZG#MXL8#MJA?/24?ST=(J:!:FVLA)XQ7*?=
M1VM5+)JXWT?UUXEMQBK#6IZ8O3"Y)<;AIKKFM(,21JGJF?["5\<\VL@&$MC*
M9NR!9C->XYTW-&=!/0317.1P/(]"SY;Z@J'&1O"1Y[-GBF4@!-"6G#$HX>C,
MBF6KY]$VUKZJ"UNX4,L<YE[ ,[*C'TT"FGI0+[M+Z=I6"W<H&0@">>N83X3T
M=+?<4N,(]4U"'F  Q<Q6&ME>_O ^MU(8-$*X'CG71!&!L]P94+3OW,4(K&YV
MRI%^\L7-X@E: (-A_=-%II/M:]S%$P.QKF,IBK!N5:<:66\%I[MMD](J%%(J
MK="GS6W=$'P/ZB$9 3BS/^V1,$,S&,5..J$SP/)P<WAQHXVYY#HA"$;LY+)8
MGS"E"^8)5ES)2KWP!23 37:Y:OY@!TR>XB_<KG*Z(8CT/ MP(6/QIYWS>^^[
M?4BOPPU=HBHM94,99SV-0>3$:XYS0:+@N)D]VB$47F.\.+A/*I'Y:E[;$]9'
MV'HDF8MH< 'P<07O:*E01V:@FO7L;&W07W\;6(]1&7+V*6YK:6,Z#VK^-];]
M^C-"5V<4=XK+B(1 ,QK$*SZDH9?%$[GM61"UN0*J,08;.01*H+ZL0QAL$Z)K
M0QA0 )LK>X2?XS*U,;DIXH/A<0RV.[\"8;6 DKN&VP&9BQ]KV;E!R3<8$YR^
M6Z/= JH/\<!E4L"*6)P-,)56L@3**T!CXJ,:$KD$I)C8$S;^N 2D8PY&F#*+
M>R3S@/XTK"F+CK+ 1O*$SI*+:("$'00NILF ((P?J7"%E#O!N;$;,00_'K."
M_M,@O,NYFFD(U] [W>*OF\$E-P0L!5$;(7 ^'F*%(2M"Q0NU6U&_]5$;*5*7
MPR(^G]@:[-,$1<HXLBB+"[Q M(B56.F^T2N[=RJK+_._U%&&*%A#],LQ_9,K
M#'#$%GL#P;$_-KH]6[J9-V+%BD@I+["JZ#M$\^$<R>*1'1,1);R,C0@!\$F7
M8SBFJLLN[$L+##R+50"[M_"%1] R/P2XH!LMV6K"/-$#$B00-4S%Q9B"7 RN
MO=@!OO&=/K@O?J(E&\P6VQ,40C'&U\H '9JB!_Q%12! S?Y),(:[)'Y1%TN
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MKJO]#;Q#H_7$03O#P1JC03<"D:;!S!33 -OLFTS0VI+5E#[=F6W%FY6UR^^
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MTMXIR,)>$>C!O'DOCR5<[68%WJK*5B!6GT291X"2Y'IH%7CF1%U,R+6N46&
M$,2L]9YF]BI0AX@!YW[6[O(NP?DNR_H2\+86VUY1&*SOW:4@RGR-$(0I]SH#
M,,!N_?Y=%GPZ&C<I!?-:+U\&\$[L*1*,\.P.DYE<[E8J[62-S)"-85D&QAN
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MH8&X-P<2#;NB#T,="#O/MY@""?[[$[B"4]0ZU/<12OS"1>PW7%?'<!C5'FZ
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MQH#  /Y2T  !?,(9+P! "^R*"% 0H!()2(0S).!1O;&""K>U A56@5%:',
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M7D  %D$%&& 3"" %9F'JVFGSP.,8%( "<LD90*X8BB$%3J 32* 2:JZARF;
MUD(P=B FEF$3U&L&!, 24L'98FH +$$%*, "1N !+@$1 .#)X&L%! $ %L$9
MCN$&MQ \:*$!$@#1!F(7%F$19.$! FP@>H$$S.X8 D'&OO[FU#A@3S2  ZH/
MF6[@ 0C  FSA!M+)&1ROWIK) %3  /+)"N>#%HA/N C"!-@-HUJ $5( MF2Q
MU)2$&7X@ ^+"P R($PS@ 5K  E(,U!#@&:[JS63  &Y  2K@!%1 Q5+@YX@J
M &8  DB@("RA 2@@!A!@!F8! .HM$)!,&)NB$V[ %YR!%@*@!3@! +!@($Y
M =0)F4; $@K@Q_A/^N)N[NK.1G0A '(@!Q   02A!@2 %P)! 4;@!:A+!1H
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MC\$$","]1),7&(  /'07"$&O1B#%K X'*NP/X?$ES&D ""  'F"I, $!"&
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MCW2!$V0AHY6=($: $TX@VQ+ H!Y]+)AAO#GB"?#FLT$AP0R !(K!(D\9 BP
M I[!!(W!$DA 3%O@&;R.MZ1)0X1I &: E/RP$(_!^ C"& +RAG?M0G&=(Y#
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M@,O)S0:<J,0-.B$!!:B $S+HQ#-R0($2.(\$#5B$"6 @/2>M   )(,$R'C"
M P1"$ _X2@TND0+SR7&.T&D&&\Y003.T;R"[0 3T7C +!2@ A/!S!@30\@
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M6("K%.#$ *;U*/2EX;MH""\T"6"#2@!" 1"HQ  VYPRT/J,&'?PO( ;Q44X
M( <ML*\)]7LFO<+3OY),D#-DD -=!, 8*UNPH0_=)R(E(B@Q$ @O9# P0'12
M3H!(00M2D (3'(46)&#$0&;Q46<T(@(G6-8_-S$"FM2)4>=L0 =4/1!*)L"J
M9PJ$I3'M$V?\U0$Q\)$-4H$4%42@EI1"US#419$5"(   0B  BQ1N>4B<!D$
M5HO0) $ "$!  ;J8ZWT/T(&\&F "MD4Q8;AC 0LT@-B(;K?@@A4G=\O;(PO9
M1 ,"L()YJ\E6MO /3(PA"XX>$?Y%1P2%AGSQHD94 B;N64B'_/1P8\QB(@>*
M-2..J>^,+WB[8N)3I?:D8$5%"10L (1GPZ0GHL6[R!ION<M?#O.80X?C;:+Y
MN+:U<BTI;%0VMP[/<R[SH M]Z,\!G=&)CO2D*WWI3%?3B3S;<Q?!1A=$6L8N
M'(YE9U1K82?2A2X$WA0)G;SC&H'&J)J.]K3+G!G&(M8QF*&DC]U%$+^R[0.6
M/0*$'ZP Q_CE S[*"PJ,G4TI09(+" "8 ZC U .Q 0V,!,DYLSQ,+U#!0HYA
M@:&]X $J. PA<J#VT(M>X[@8A"(.H0A!X*)"*:.(9V[ BQ9\QAG0R!7G_.FQ
M!AC@$OXY $ -5'< !O3"=;"3W>:BGI]G6"(2E8A$)"R1$M3,P! G", .,0(!
M!N@H7!W5''W:1(L7#( "(3(! &YPB:HV8',/8.'HWP__!=/B$(Q0A"(*<3%:
M9)L01$$K1V<A #2 %)5%$,HU>6+B"Q3@$';1 IPP A&@ +:@ )> 0YC %Z02
M"86 >H<0"4121*#Q#"<@ )L0 SMT#!)P X&  *X&#8CP  J0 N(Q ,*3 (LT
M)M!D )7%60I  &O41B-0 X,@ P<8?T5HA.6""X5@?XQ0"*LG*)P  P\P7YXA
M",80 P*0;UP5 +Z0.?-A*<4 %I4P$"=@ ,<@50^  RN "/Z58$R6\@R5L(2*
M$ D5442V$5WZ= #Q%  I0 L/T ";P CUT@@ < *=4  -8 ,2( #3@GS1 5Q[
M)F<WH L', ,*@ @=L N2X#]'R(F=6'?.8 N%4'],Z(24\3Y,<0+N\A;%0SFT
M9 (1T"F=P  $4#5D"""=( M0%0@,< ,'0&MV$@FH9W\=6!Q&Y Q4> (*$$^*
MUT 0X PI< ".5@R5XQ" 8(QYU5__]5&= $@T<#SJ1G>>*([CR"FT, B%H(&#
M<#&[X   0 &,T"V=T F[(C2"0@$24(-$*":7D$X)01$G@  W4EW7Y0P)((:-
M>!W-L A*B B%$ E$9$3&T $#P/X).Q-/!( \0>$,)Y  ,/%;_P5ZT06"V B)
M *82ND "FR  9MA&Y.B2+\DFP* )\M@)FW CM' "T]5]); (#1"0*A$(!7
M7D@HQT ;,?0 K&@! B V4D9E5I9U=J)\E% )E/!\O2-^T@0!EO,5/>@">]A
M!E )@Z!(W%-EYZ<RL[<F>D5^_@4 +K,0*+ (NQ  O$ #$P"3>:F7(.8,.M0
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M L8 #1:0AC!0 RE0 PAP IL019O#I<5%'"]P I5( 1?#F_XMD(,=(# *4 "
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MR:T%:[!"EXN=@ JX2%H"D  W0/X(5E$#@9@(Q] ",G ,9300T",A #"$,4
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MZ S85"*1.1!=(RM6@HOL@A,T<$8@+ $B%6YB&25\ 0XHQ )N=>(&:W3&,DP
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..3=Q$3NQ$3_S$!@H( #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>cogo_0059.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0059.gif
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M^>GP]_3T]/+W^O;X_/____CW^./@W0
M
M
M
M
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M&4232W(C!\0L4!<!<$ ;!F2^YX4   C0@ C9B6!  F'#P1S?7)&?9^ *@1
M;B$U,&@""*@$*B00   8@ )AH$]G1N(Y"'R$8Z#[%&T^$  OF(([1UF=]Z:E
M@I'0+@2TL # 3M&  CR"$0* @'"XAYWCN?"%Q@J2 H9'"P\(0 7XHHQ P! ^
M51 P _YF>,,!MA<U(M'""]83"-_8EA(7>* !$B3! "@0 @.H<"#TZU>>_*60
MJZE (*500 (P48J/':46:C"!!1(  #/0P@0!&() 0$0!"]$"1* 3  62XH$
M@,$4 '1=RQ:0G6GAAA8YLYU5W$@+V!B@$BB$0$(8$;7YP/"2F%2,=:+VA@>9
MP0$"Z$(LVO49#@ @#(T CD#:X#5:"*P!1C19 S*R!@"ZJQ0GN-PB$L" 6J"
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M(B*@* %  K6@*KXE4R'@&?W%!#4P W? $$X0 U= "TL0 UA "U@P S<P XA
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M!P  &8 Y!2 I#U *F(  "$ ! H &F"  5G$"JL)+"@ 7%I"5<A  @A$+(P
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M7XIYD\"'#NFX'%F=I= DJ, 9L;@MMC$&IZ!0&2"37J"!+Q(!!@ "!=  F'
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M W> !?EWP:>,P7XWI7&7D(9+I6=^D#^@D>I\RVXK@3AQ"@20E35A5!@N$&K
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M4R#J6/ "@S +2C +:=B:KX[*;/X(],S__'W'\X9+!(\+F[Y9 .(S$K%0*)$
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M7O #0S@APC-X B?\<,8RCG$/EEBC+&M,,D*WL="S='')9&F:DQW@ 2,8P0?
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M8,!76F;8HZ    \PP '2+0$%V*@4"-! ' PP!@6  0.46(2E^87A&XCB%3F
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M9HNV]]NZSXBQ%K,Z6N(> ]  5(B%!YH)1H@60?F  S@%%D  #E@6-0"*_/D
M!* $!T"<WH@%#T@ $/@ %3B!LT. ![(\#5 ! AB#$RB !JN%6 @#FD"*/WP
M&:2%$QB -\"-@?B.79&5$Q" 4H@6[B ! ?"$%& 66IB "Z@.)E*7(32L6,"$
M!Z*%R(.##_@_'%J-6K(3 L $+W" V!&D59@%'IB!'J %.X"!&X@26I "15B*
M51@CYF&>]%.Q:LM#^[LZ:8M':J,>[B$ R4F*0(R6_+%$.OY!G.I0@^IH UJ
MQE,  0%8!$<H#PHI'R]@ 55P@*B)A0.0034("NQ(%O^@&0_0A)UYA!,(@#@H
MA09H@%)X  :  _3H@F,\CP#010 8 E18%4T 1O"1@ G E 0P 0@@ "8Z0KZ*
MA08@ #:0 Y\L!>PP 4<( 6ZYD1/H L@YA3!@ "Y4I"2@A2R!@3/\@3N3$BL(
M@BJ@ K]8A2EPPSZK ?93-*L3#1@[M&>#1[B$GOPC@%-#BY001)68D>0X 0*
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M#8BYC;, !O*"PY,5VEB#%3"#,2 !&^D"C:"%!Q !51 !-5B!,VB#+S8%$Y
M#"C(54&%1O" Z!R#*L8 $: $%*" , "S"K" ,F.$$$B#$;"  JR%,4!B,JY
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MV]07"^AT%T@)!G(! M< !?B #C@!%5B$! B)0*$%W# 06Q:!G4,[ U0 *AN
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M'"0+B*#%%FB4D21,81.T0(3C>/"*@_1@B"$Y0G^,(D4H(I&* 'KB^\(4Q:+
MLBD2B00!.'"0-Q   [7P @,4, %&R"$!#6! (^3P  4\ "('P0 &:#&&!31
M! , PR<LP#\P** !(Y# '+Z@@4980 $* $,I-*  !HA@%F4  !^/YD<1K8
MC* %"@( APPLP  N"$,#:+$!%(3A! ^27@V(8(@H".$)M-AA#4@1BAJ PER*
MV-$H0.')'PRQA45\A.Y<V4J1NJ^6)5UE^Z"BRB0>A!(&T$!U&@"!13R@"XU(
MP 1*X0$#H!,#'*@$!\Q(BTL$8/X-F!! !<Q@ 0& (1( <(%3,V"&"0# #2(
M "; 0  05*(%#F@$&."I!GC.\UBHX LC@EF*6L0! "O Q %,H( Q8. 29'##
M"D%"HTN.8@<S( ))=J2$3\; $*ZH 0Q;F),:C"^E/YF$2$V*4J% -HJ2G:P2
MZT< F-*B%0UX "H<X042,  "M.A" "Y!BTJ, 042.(!X7&" 6NS1CF"H!!O/
M   0CA4.)B  *A3(/U.HH04:&  9QAK/LAK+# 0X !P.LH@ &'01)V"$"E@
M@@LT8 C1X^&0;' '4LRB)':@A1!G,-A!.($66C!"*&@!A>W)J(A4FJPJ37I9
M+*D/2OXC+4IE^?N^EAI E_X+  CDT,LT8""@+ @ )E#1@ :$(04#< 0M'A "
M6H25CVV]+1O'"B(O   .)P#N&OGW@0*PH P"*(-RF6NL%03@ \^CA1P"8)#F
M6$ . H@%&1@0O9!0@1-+$,(.:"&*&;P"$3!HX7JM,)XD6&](J-SO?EVITBGV
MI+)9+I!*O[QE2DCD$01P@ <P0!!&A!4.E5"  VC1 @"T8*PK2&=J&5%B' <
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M (/&I@Y,A6_=??WK)2LA<?&)5_SB"Z]XR3=^\JES_.(17_E@+4SJ=0<9%'S
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MH?'I'D]HX=EXX?3]2A4VGQ=6H22$X1D&128D8,S<G=_1R(TT#N#QB%[Y79
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M")C;!I3"!!1 ,$57P:7)&20 !!3 PYV"!MP/ [P%01H  6Q + @2)C2" B0
M,Q42 )3!RV"" :B .J51&;Q%(QA "I"! M "!JR "H#!@WC=##C4(%S!($2!
MK<W (/[,@@UDP2;, BSD  QLPBC@@7R)9&>2I)#PR#4^X?HTHFG2TF4%&,M]
M&7+X9P*8(P"802TP0 *DP9R!P5C%0:.MP3LMPA@(P . P24\0 -@0AL   O@
MD@2P 0@ @!R80 !T06\R !MX0 !0PCZJ@2E(@$) @ &8 8G=&0)@P"G$ 0<X
M0B40@ =DV 00"BT\&R:PP0FH@@H 0!M@@@,T@'DF0".8@0"DP0I@%1IXP"FP
M 0"$ 1P,:!^A#"I,P(9AP ),1PD   /TY -8  2,008T @FX@.=)#T8<A"N,
MDAW,0 [,0B' P(XLH W@P2O,0!;0 A,\F7Z8DDT8ZTR<)/XKU6@3H>9_B=E*
M^429&8 %+,(BR $JJ(("1-,C!( 7H (!J$ +$$ L7! CO%,:T$*CU9$C]9@
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M :Q ++ALH88!)C3 GD) GSZ":M6")*A!&G  /"UG5I"  ;"! NQI+("!'*B
M&7F  +#!(A  &&0J@?ICQDP3D083!*R! G3!053  30&(V2 (P0 +:A!A*Z:
M#22!1L0 #"06R=5$#LC"T<*"^56!TT:M-9ZDS$7K2OZ7]3K6]<(2^30< 2
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M",#_ED(%, "WTT*HC_K4 63]5H*(EP(#1).>C<$^@LA8'7(C"( 'M,(^(BD
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M+(   WD"!HQ!+)C  Y  "WB )HC O99"!EAH(W0\!H#0*:" 3+41F3Q -*W
M!G@ !W1 \TL3!O"QJ[9\!C@ !]AI(U@J<TR^_JD"!#" "UBZSO-WP<B3N4*(
M.J;)OTH^^N>,7C\T\9S !7P 0,"A-9#@+((':=5"N'"@0H(.&4:$>+#6&TP)
M%T+4B#0P5IN+$4&&%#F29$F3)U&F5+F294N7+V'&E#F39DV;-W'FU+E3I<.)
../($&%3J4:%&C*0," #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>cogo_0030.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0030.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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M46=/C7EOT&D'MXLOW14Q-+RS2U*EG\Z>UXN!=IH!4/\ >U>@@F1C2I5U'I:
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M_(;$>N-%"'$Z;WBUR!M:Y8MTQ!4\Y:+H.05#"P+:1%%M"Z/O)7Y1-K*HM+$
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MMB_BSB=@#A[353V,\62-*2FZ0VMX*=6>R&DW4?D!#%BR/GH7"2?1KYC[V^:
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A+@'4:Z&-V-MJCGY8Q3;82^F3G^8<_P!45^[1!_>&?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>skill-x.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 skill-x.jpg
M_]C_X01G17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  "OR    G$  *_(   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C R,#HP,3HR-B Q-SHQ.#HU,@   Z !
M  ,    !__\  * "  0    !    $J #  0    !    &0         & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
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M 0,1 ?_=  0  O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
M 04! 0$! 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!
M  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]'ZU;=5TVVRBQU5@+(>V
M"1+V-=]-KV_1*!T_.?1<_"S;'O<ZY[,?(<6.8\?2KH]2G;Z>0UG^"N8RS]SU
M%8ZP,)V ]F=<<?'>6AUK3M((<'L]\.V^YJP<FCIE=+K,+(=<,D9+LIY,ESJV
M_:FW/VM9^DQ,EM/I?Z/U?34^.(E"B-R=:_[IK9I2CDX@1I&/IXOZW[G_ '3U
M:2H^OG_Z/_M+ZG'^&_T:2BX3W#-QCL?L?__0[WKE'4LFRJFBIS\1H-EFRQC"
MZUI;Z%=OJ;7>@W^<L]-WZ14,;I/4#=0[+P]]EEP?U"TVM+'-]UNVFO<Y]=#<
MGT[_ +.S^?\ \,NG25F''[8X>&J/[_%_S?TFGDX/=/%Q[C_-\'_._0_]>*22
M259N/__9_^T,<%!H;W1O<VAO<" S+C  .$))300E       0
M         #A"24T$.@      \0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    2 %  <@!O &\ 9@ M $4
M:0!N ', = !E &P ; !U &X 9P      "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!2
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 $@    !  ( 2
M  $  CA"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-!         (  3A"24T$ @      !      X0DE-!#        (! 3A"
M24T$+0      !@ !     CA"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      -+    !@              &0
M !(    + %4 ;@!B &4 ;@!A &X ;@!T "T ,0    $
M         0              $@   !D                      0
M                   0     0       &YU;&P    "    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   !D     4F=H=&QO;F<    2    !G-L
M:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)
M1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M#$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M"D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<    9     %)G:'1L;VYG    $@    -U<FQ415A4     0
M &YU;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%
M6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%
M6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX
M   '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG
M;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O
M;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/
M=71S971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H
M=$]U='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$
M%       !     0X0DE-! P      TT    !    $@   !D    X   %>
M S$ &  !_]C_[0 ,061O8F5?0TT  ?_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( !D
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M "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0
M;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$!@      !P (     0$ _^$-
MSFAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN
M/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP
M;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@
M6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U-C8Q+" R,#$R+S R+S V+3$T.C4V
M.C(W(" @(" @(" B/B \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"\B('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(B!X;6QN<SID8STB
M:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM;&YS.G!H;W1O
M<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(@>&UP
M.D-R96%T;W)4;V]L/2)!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*2(@
M>&UP.D-R96%T941A=&4](C(P,C M,#$M,C94,3<Z,3@Z-3(K,#$Z,# B('AM
M<#I-971A9&%T841A=&4](C(P,C M,#$M,C94,3<Z,3@Z-3(K,#$Z,# B('AM
M<#I-;V1I9GE$871E/2(R,#(P+3 Q+3(V5#$W.C$X.C4R*S Q.C P(B!X;7!-
M33I);G-T86YC94E$/2)X;7 N:6ED.C@P1C R,SA"-3<T,$5!,3$Y-C1!14$S
M-31$-T9#-$1!(B!X;7!-33I$;V-U;65N=$E$/2)X;7 N9&ED.C=&1C R,SA"
M-3<T,$5!,3$Y-C1!14$S-31$-T9#-$1!(B!X;7!-33I/<FEG:6YA;$1O8W5M
M96YT240](GAM<"YD:60Z-T9&,#(S.$(U-S0P14$Q,3DV-$%%03,U-$0W1D,T
M1$$B(&1C.F9O<FUA=#TB:6UA9V4O:G!E9R(@<&AO=&]S:&]P.D-O;&]R36]D
M93TB,R(@<&AO=&]S:&]P.DE#0U!R;V9I;&4](F5C:5)'0B!V,B(^(#QX;7!-
M33I(:7-T;W)Y/B \<F1F.E-E<3X@/')D9CIL:2!S=$5V=#IA8W1I;VX](F-R
M96%T960B('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z-T9&,#(S.$(U-S0P
M14$Q,3DV-$%%03,U-$0W1D,T1$$B('-T179T.G=H96X](C(P,C M,#$M,C94
M,3<Z,3@Z-3(K,#$Z,# B('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I(B\^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N
M/2)S879E9"(@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#HX,$8P,C,X0C4W
M-#!%03$Q.38T045!,S4T1#=&0S1$02(@<W1%=G0Z=VAE;CTB,C R,"TP,2TR
M-E0Q-SHQ.#HU,BLP,3HP,"(@<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@
M4&AO=&]S:&]P($-3-B H5VEN9&]W<RDB('-T179T.F-H86YG960](B\B+SX@
M/"]R9&8Z4V5Q/B \+WAM<$U-.DAI<W1O<GD^(#PO<F1F.D1E<V-R:7!T:6]N
M/B \+W)D9CI21$8^(#PO>#IX;7!M971A/B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(#P_>'!A8VME="!E;F0](G<B/S[_X@?824-#7U!23T9)3$4  0$   ?(
M041"10)   !M;G1R4D="(%A96B 'UP #  ( "@ ' "EA8W-P
M                         0  ]M8  0    #3+6))0T.<;32EK:1%]A1M
MF+!1#!)M                                          EC<')T
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M96XO96-I4D="+G!H<    &1E<V,         "F5C:5)'0B!V,@
M"@!E &, :0!2 $< 0@ @ '8 ,@     *96-I4D="('8R
M
M %A96B        #VU@ !     -,M8W5R=@        *\    "@ 5 !\ *@ T
M #X 20!3 %T : !R 'T AP"1 )P I@"P +L Q0#0 -H Y #O /D! P$. 1@!
M(P$M 3<!0@%, 5<!80%K 78!@ &* 94!GP&J ;0!O@') =,!W0'H ?(!_0('
M A$"' (F C ".P)% E "6@)E G ">P*& I$"G *H K,"OP++ M<"XP+O OP#
M" ,5 R(#+P,\ TD#5@-D W(#?P.- YL#J@.X \8#U0/D _,$ @01!"$$, 1
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M[U/P._$D\@WR]_/A],SUN/:D]Y'X?OEL^EO[2OPZ_2K^&_\-__]865H@
M    IG@  %'^     %A96B         ME   FB   !%=6%E:(        "+)
M   3X@  P=#_[@ .061O8F4 9$     !_]L A  ! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,#
M P,# 0$! 0$! 0$! 0$" @$" @,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P/_P  1"  9 !(# 1$  A$! Q$!_]T
M!  #_\0!H@    8" P$             !P@&!00) PH" 0 + 0  !@,! 0$
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&O?NO=?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>skill-g.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 skill-g.jpg
M_]C_X03817AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  "OR    G$  *_(   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C R,#HP,3HR-B Q-SHQ.3HU-0   Z !
M  ,    !__\  * "  0    !    %: #  0    !    &          & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
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M 0,1 ?_=  0  O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M,  X0DE-!"4      !                      .$))300Z      #Q
M$     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN
M=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M      MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P
M3V)J8P   !( 4 !R &\ ;P!F "T 10!I &X <P!T &4 ; !L '4 ;@!G
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0%(            *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      !  2     $  @!(     0 ".$))300F       .
M     #^    X0DE-! T       0   !X.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         ".$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$         @ !.$))300"
M   $     #A"24T$,        @$!.$))300M       &  $    ".$))300(
M       0     0   D    )      #A"24T$'@      !      X0DE-!!H
M     TL    &               8    %0    L 50!N &( 90!N &$ ;@!N
M '0 +0 Q     0                         !               5
M&                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M&     !29VAT;&]N9P   !4    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   !@     4F=H=&QO;F<
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M# P,# P,# P,# P,# P,_\  $0@ &  5 P$B  (1 0,1 ?_=  0  O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0
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M041"10)   !M;G1R4D="(%A96B 'UP #  ( "@ ' "EA8W-P
M                         0  ]M8  0    #3+6))0T.<;32EK:1%]A1M
MF+!1#!)M                                          EC<')T
M\    (ID97-C   !?    'AW='!T   !]    !1R5%)#   ""   !81G5%)#
M   ""   !81B5%)#   ""   !81R6%E:   'C    !1G6%E:   'H    !1B
M6%E:   'M    !1T97AT     $-O<'ER:6=H=" H0RD@,C P-R!B>2!#;VQO
M<B!3;VQU=&EO;G,L($%L;"!2:6=H=',@4F5S97)V960N($QI8V5N<V4@9&5T
M86EL<R!C86X@8F4@9F]U;F0@;VXZ(&AT=' Z+R]W=W<N96-I+F]R9R]E8VDO
M96XO96-I4D="+G!H<    &1E<V,         "F5C:5)'0B!V,@
M"@!E &, :0!2 $< 0@ @ '8 ,@     *96-I4D="('8R
M
M %A96B        #VU@ !     -,M8W5R=@        *\    "@ 5 !\ *@ T
M #X 20!3 %T : !R 'T AP"1 )P I@"P +L Q0#0 -H Y #O /D! P$. 1@!
M(P$M 3<!0@%, 5<!80%K 78!@ &* 94!GP&J ;0!O@') =,!W0'H ?(!_0('
M A$"' (F C ".P)% E "6@)E G ">P*& I$"G *H K,"OP++ M<"XP+O OP#
M" ,5 R(#+P,\ TD#5@-D W(#?P.- YL#J@.X \8#U0/D _,$ @01!"$$, 1
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M[U/P._$D\@WR]_/A],SUN/:D]Y'X?OEL^EO[2OPZ_2K^&_\-__]865H@
M    IG@  %'^     %A96B         ME   FB   !%=6%E:(        "+)
M   3X@  P=#_[@ .061O8F4 9$     !_]L A  ! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,#
M P,# 0$! 0$! 0$! 0$" @$" @,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P/_P  1"  8 !4# 1$  A$! Q$!_]T
M!  #_\0!H@    8" P$             !P@&!00) PH" 0 + 0  !@,! 0$
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L^K75U)G]1]M_</[G\0_5>/\ 4?4>'%J^JI3QO#T>%33^GX6CP_ _1IHZ_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>skill-l.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 skill-l.jpg
M_]C_X04417AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  "OR    G$  *_(   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C R,#HP,3HR." R,SHQ-CHU.0   Z !
M  ,    !__\  * "  0    !    &Z #  0    !    &          & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
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M 0,1 ?_=  0  O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M[0T<4&AO=&]S:&]P(#,N,  X0DE-!"4      !
M.$))300Z      #Q    $     $       MP<FEN=$]U='!U=     4
M4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN
M=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /
M<')I;G10<F]O9E-E='5P3V)J8P   !( 4 !R &\ ;P!F "T 10!I &X <P!T
M &4 ; !L '4 ;@!G       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0%(            *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M       $    'CA"24T#\P      "0           0 X0DE-)Q        H
M 0         ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ !
M *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M   !.$))30/X      !P  #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@  #A"24T$
M     @ !.$))300"       $     #A"24T$,        @$!.$))300M
M   &  $    ".$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      TL    &               8    &P    L
M50!N &( 90!N &$ ;@!N '0 +0 Q     0                         !
M               ;    &                      !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG    &     !29VAT;&]N9P   !L    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M !@     4F=H=&QO;F<    ;     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
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M 0,1 ?_=  0  O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
M 04! 0$! 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!
M  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]'R^K4T6'&H8[+S(TQZ=
M2/ WV']%CL_E6N5&]V8VZMV=U1F!E62<?&K#74@3_P!J#< _)W?0W;L;])_,
M(G5L,4VUYF"\X>9D75566L +7AQV?K-!_1W[6_1?_.L_TB#DMOLNK_:'21F9
MC 11;20<=X^E^G]8_H-COS,AEWO_ */ZEBG@(T".HUOAX[_P_1P-7)*=R!O0
MCAKC]OA/^R_6>Y_S$^/U^NM[:.IFJBQQVLR*WA^/88'T;)WT/_X+(_[<M6MN
M'B.)^2Y#J72]XSJ<RNDN&'ZM&/C5AE3;7FRBK<Z/5R7M<UCOTFRO_@5;^V9>
MS?N]O[*YC_M1N]*/^W/;M3CCA<9"JUXOW?EXEL<V3AE$W8KA_?\ G]L\3__0
M],ZAAG,QS6UYJM:YME-H$[;&'?6[:?IM_?9^XJS<WK#&[+NG>I:--]-M?IN/
M[P]9U=S&_P#6U\SI*2/R^KAJ].+B^OR,,_F]/'Q5ZN#@V_1XO=]+],8_3K+S
MD7]4:Q]F6P5&AFK*Z6ESFU>I#'V6;K'/MM_[;^@B?L3I6W;]G;M]#[+$F/2G
MU/3Y_P!)[_4_G%\QI(^OB\/_ !NN'_U7_AK?U7!UXO\ Q[BX_P#U;_U-_]DX
M0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ',
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M(%A96B 'UP #  ( "@ ' "EA8W-P
M     0  ]M8  0    #3+6))0T.<;32EK:1%]A1MF+!1#!)M
M                              EC<')T    \    (ID97-C   !?
M 'AW='!T   !]    !1R5%)#   ""   !81G5%)#   ""   !81B5%)#   "
M"   !81R6%E:   'C    !1G6%E:   'H    !1B6%E:   'M    !1T97AT
M     $-O<'ER:6=H=" H0RD@,C P-R!B>2!#;VQO<B!3;VQU=&EO;G,L($%L
M;"!2:6=H=',@4F5S97)V960N($QI8V5N<V4@9&5T86EL<R!C86X@8F4@9F]U
M;F0@;VXZ(&AT=' Z+R]W=W<N96-I+F]R9R]E8VDO96XO96-I4D="+G!H<
M &1E<V,         "F5C:5)'0B!V,@          "@!E &, :0!2 $< 0@ @
M '8 ,@     *96-I4D="('8R
M                                         %A96B        #VU@ !
M     -,M8W5R=@        *\    "@ 5 !\ *@ T #X 20!3 %T : !R 'T
MAP"1 )P I@"P +L Q0#0 -H Y #O /D! P$. 1@!(P$M 3<!0@%, 5<!80%K
M 78!@ &* 94!GP&J ;0!O@') =,!W0'H ?(!_0(' A$"' (F C ".P)% E "
M6@)E G ">P*& I$"G *H K,"OP++ M<"XP+O OP#" ,5 R(#+P,\ TD#5@-D
M W(#?P.- YL#J@.X \8#U0/D _,$ @01!"$$, 1 !% $8 1P!( $D02A!+($
MPP34!.4$]P4(!1H%+ 4^!5 %8P5U!8@%FP6N!<$%U07H!?P&$ 8D!C@&309A
M!G8&BP:@!K4&RP;@!O8'# <C!SD'3P=F!WT'E >L!\,'VP?S" L((P@["%0(
M;0B&")\(N C2".P)!@D@"3H)50EO"8H)I0G!"=P)^ H4"C *30II"H8*HPK
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M P,# P,# P/_P  1"  8 !L# 1$  A$! Q$!_]T !  $_\0!H@    8" P$
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'7W:ZYZ__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>cogo_0029.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0029.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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MLHI)D&[]KBO)Y:23\Z/!!3-F+7&; !;3BEXH=/0X3%C)^%L5.*)ECAM80C8
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M=S*+Z1([V@>U'/<U9+LQTUB([LB0D BKET*NR:PTA30)]*J_B9J\"JT)R*8
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M_3;P]/\ WLZOTUJG3>L;8W>=+7VVWB"^D+;DV^2EY"@1WVGW?H:PSH2@]O\
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MYA;>TMK[[3T4GYCIGFN7>6$O3JCIOKP_N=:PO_W^E&H]-^/L*ZXGIL^F+C<
M$I\F(ZL=L$))_P!JJH_+:-53XO:/C!/E/SKE*NLETK=DONR'%]<J6HJ/^M;&
M]G._BRQ,N(D)4%9&/PHYU@K4=OET#PR%K4TH_P ,\9 Z'US5;6>QD\:B,DME
ME2V'D'*>,CN#T/TI...F/E>42+2&MM7Z#N+5\T9J6YV2:WP'8$I31(]"![JA
M\B,4LX1FL-!IR=-Y39TKHS]I'XY6%MF#JFWV/4T5L!*G'6#%D.)^;C9P#\]M
M9G84L:[-*OZJ>UE'2&BOV@W@1JYF.QJ8732DY:PEQ,MCSF!D=?-;!R/F0*R3
ML)Y[R:U?1DNL'0^E]4Z9U=;&[MI+4%OO,)8]U^#(2\G\=O(/R(!JETY4^T'D
MI]!O>/44G-$X,EF!MYZ>O7%'$9;Z+L8TAA<HZ_(W!!)/1..?QIE*'2VQ9PDM
MRZ*&\3_M.>#WA8B9&N^J6Y]TCIV&V6O$B05=DJ'PIYX)4>.N#6BC1G)_(RU*
MD5])QQXG_;1\6_$",];=.HCZ,M3F4D07"Y.6CL"^?@SWV#\:W4[./U,S5*V=
M% 39DZXRES9TV1,DN_S7Y#BG7%CYJ4236M1BM1,RYYR]BT:4Q'2&' MD'J[U
M!^6:=/!"4LR75(1&C@I2$^\[Z'T'K5R?V%P.@VEIE:@,':<@_P"M,Q#NO]GE
M<5/>#3T9:L(:N;[J<].2,_Z5P[]9POOD[5LOADL?Q#G'Q*GKTS 'F6N$YE2D
MD[7G.ZC]#TJZPC&Q2G+ZA+J+N8\'T>T_8I&G;<-/;%K88!+*B"2$GG:?IS6^
M5=5JG)O9RIVSHQQ%:*J\0[@&F9_E;7]J-@2VH$Y/ ''2NW0^$.;.+4BZM3@$
M_!?1MSLK$>ZJD*1+(W!@'^"A)Y*<=\]S7)]2N(UF^3R>B].H*A'BD/OM.ZSC
MV7P4U9<T/M-2FH3D4(W\I>>P@)/X*4:YEM3<9->#96?1\H7$H0-HSP*U'/&Z
MA@9QR>_<5"=C*Z+N:PE$1QEE!2-SH25.9^0Z#ZTLFQXQB,HD<LI(+[CJE<J6
MX<J)I42:'GEX2>?I1$-=N% CI4(;DE*\))!(SD'%0@3T]KC56B;BFY:1OMPM
M,]:D[7(4A3)X.<JVGWA\CFEFE)=@IYB^BX_^VC]IG_Q/D?\ I&/_ (U7[2-'
M-GUF\5O$*V>%WAU=M<7)CV@6QGS&HV\)]H<)PVC/;*OQXKBTH.M647T=><HT
MX979\T]=?:W\;?&B"O\ >&I1I^V^>\RY;;/NCA0S@I=<!WKXQW KN4;2E%9P
M<>I<U)=/13BH;33:O+;2,'.?4^I]:TI1BL)%,GRV^Q@[OW8W#;\A4UX%6?(F
M](;B-ES85'IC_>@T/G[#BRM_O!SSI"06&AD([+/SIH[[%9*&#N0E*3M2,=!C
M\JM0H\D. 6][E6[RU8!Z]*9OXY$7R>#L']GVMV7X.7",MU24_O9UI82>J#C*
M?QKD7&)--G:H9C!(ZJ-LB6V0/96$-LXVI2A. D?[UE=1RU(N<5'H4O,2&+.\
M76$OAU21@GICO5E.4N:*:ZC&&6<X:VMML:O#S[%MCMK;=204("2$E0R..H^M
M>MIN3M]GDXO_ .HMO3X$*PBX% 2?+PCC')%>;DFZG%GJDTHZ.8/MUW/]V^"]
MMAK0#)OU]07%C@[6T%9!]1TJV#VX^-%=QHX =7A6 *M,(D5\*W$ 5.B8Y:$D
MD*&]#J5 G P:F4P\&O(RGOH8"%AH%Q;@0G'&3W_(4CT3;TQ?&2?>!&/2H'B)
MG;\)/(J P8<4$)"AVX-0 WBD27ER$Y[( /KWI5C(^=:"V%_W?^$T^$5YE]SZ
M<_;ZUL\QIC2.EH;G\*Y7!Z9(2.A#20$?D5&L-DHN7(Z%TY)-'SSM<H6G65WL
MJU LREIDMYZ;CP<5T8O$FC"_I0:D.92I*<8%,Q0<^ D@=L%1H$&3C(FMI2%!
M/OYR?N^M3L)(;6VTT@(83_#Z!2N-WSJR(H4:4I;BDD<$8-,06F HM[H P DF
MCCXL5+Y'7/[.R4%>&M\9W<HO#A(],@5RJ_1UZ+TCL4J#J1D=.36+R:'M FX2
M"ZPZ L[$CBNA0BLY.9=5&XX*-U1M_>,@K&2XE77MZ5Z2BLTU%'FYR5.JFRT+
M9(8GZ19E,D%I,5*L>AZ']:\]63IUFF>IMY>Y24D<2_M"=2()T-HU#A):8DW1
MY/H5D-I_, TT%Y%N)'&3JL\C@]!5AD$5*(_"@%=B(9;0Z7$(V*/7:<;OK0Q@
M?L9K)D7!:B,M1QM2"<^\>OZ4LGD&!VCD#Y<440T6D)(4>] #[&EP>2W'4H*Z
M@BDE+ ZADS"5LB-D@ K)6/Q_Z4T6*]!+>?G3"'T$^W1:9EG=T6Y(?*PMJ;C<
M<XY3G_6N=Z?%K+9T[R2\'"FKW_8+U!N[7*0]Y;I_NJZ?K71G\6CGKY;9)XKY
MDQ4+2.5X-69T*U@Q.;/EGD<BBP&L1L(9"-HR!G!'6HF!A>*D^[E62H^\!_2*
ML0!;S"E_A9(QSCY5 9QM#V<K? 6E:L[D$D].,4_\ (MN>&=.?LXKCYMDU9:.
M[5P0\?\ "4_\Q7+KK7ZG6H?2=M"2&8;C_8)(K(HJ53!=.3A3R1^5)"8*P#R1
MFNG3AB2.-4DVFRGM6#,A;BR:]%:?2CSMV\RV2OPAN"KAHJ]1%G=[-)*$<=$J
M3N _.N%ZK35.ME>3T_I-3W+=)^#Y_P#VU]0.WCQYNL8I'E6>'$@-@>@;WJ_'
M*JII9X[+*^Y8\'/K@\Q6Y/!JPSFBP5>Z.W6H'L0EOAJ.MW *D#(![GM2MC=#
M>+'#$8(6K+GQ+/JH\FD#G(NVOW>W6F 8=/ -!DQY E[=7AME"05+5M'XU1-[
M---9CD)J9W!+0.T-@ ?E5R6$9WV>\I[[Z_\ BIB<3Z+?M#KTTY+T/;4X#C<6
M6^M/H%+2G_VUCL_L:;EZR<(:MC)D65]SJ4G</PYK;4649H]!C14L7&TL/!><
M<<]!4IO*%D%;@TE*P-_09(]:L:$1B( 4K5C!X-1$'Z5*9:0X.2H]!Q^M6+2
M9; #P(Z!6"?K4 $YJPJ"YS@[?SHY^#"EB2+_ /V;,A7[_P!=L;CPW'6/KN(K
MFUEW^ATJ#T=S7E[V>T*P<;E &J:"S4++Q\:9&94O+&P*[<5V%##.#*>D5IK
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7P%GD(2V5-J/.#5Q0>\U?]J?SHDPC_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>skill-m.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 skill-m.jpg
M_]C_X1#117AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  "OR    G$  *_(   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C R,#HP,3HR-B Q-SHR,#HU-P   Z !
M  ,    !__\  * "  0    !    &J #  0    !    %P         & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
M @$ !     $   $N @( !     $   ^;         $@    !    2     '_
MV/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.
M  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="                  #V
MU@ !     -,M2% @(
M                    $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0
M  'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L    %&)8
M65H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,
MAG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P
M    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0
M    0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY
M  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0              $G-2
M1T(@245#-C$Y-C8M,BXQ
M                          !865H@        \U$  0    $6S%A96B
M                    6%E:(        &^B   X]0   Y!865H@
M8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P         6245#
M(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N
M:65C+F-H
M         &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@
M8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M          !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I
M;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !
M6%E:(       3 E6 %    !7'^=M96%S          $
M       "CP    )S:6<@     $-25"!C=7)V        !      %  H #P 4
M !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($
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M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ %P : P$B  (1 0,1 ?_=  0  O_$ 3\   $% 0$! 0$!          ,
M 0($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !! $#
M @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"
MT4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6T
ME<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$
M!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,5
M8W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3T
MI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]%;D
M7'K[\;>?1&(RP,[;S98PO_S6K06-?DX^)U[(R<EXJIJP&.>]W 'JVH^/U_!L
MINLR-V$[&:'W59(V/%;OYJW;[MS+?Y/^$_0_SJDE FB!I4=N[##)$<0E(7Q2
MW/Z(=&1PG7.Y/2;^OO9FY#!ALI+78+7-_3>US;/6R=6O9N:W]%B[O9O]2_\
M2?HV=$EP#;B]7;^M^[Q)]R6IX/18]5_H_O<#_]#L^L U=<JR3CU9;?1K;74^
M]E3FVBRST7^G<1ZF[?\ H?\ A5'.SK'9>([/Z15]J8^</U<J@/W'V_HFN/Z3
MW;?[:^>4E9%U&^&^'3^>XN'_ *GZ6E*N*?#[G#Q>JONW!Q_]6];]*CJ/7)'^
M2"!.I^T5+57RJDF>B_\ )[?ZZF3];PG^>NQ_XFXO^\?_V?_M&-I0:&]T;W-H
M;W @,RXP #A"24T$)0      $                      X0DE-!#H
M /$    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q 4@            IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ !(     0 " $@    !  (X0DE-!"8       X
M            /X   #A"24T$#0      !    '@X0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          (X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300        "  $X0DE-
M! (       0     .$))300P       " 0$X0DE-!"T       8  0    (X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #2P    8              !<    :    "P!5 &X 8@!E &X
M80!N &X =  M #$    !                          $
M !H    7                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<    7     %)G:'1L;VYG    &@    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    %P    !29VAT
M;&]N9P   !H    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!0       0    ,.$))300,
M      ^W     0   !H    7    4   !S    ^; !@  ?_8_^(,6$E#0U]0
M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(                  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  7 !H# 2(
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MEJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#T5N1<>OOQMY]$8C+
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M29Z+_P GM_KJ9/UO"?YZ['_B;B_[Q__9 #A"24T$(0      50    $!
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M0YQM-*6MI$7V%&V8L%$,$FT
M    "6-P<G0   #P    BF1E<V,   %\    >'=T<'0   'T    %')44D,
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M('8R           * &4 8P!I %( 1P!" "  =@ R      IE8VE21T(@=C(
M
M                6%E:(        /;6  $     TRUC=7)V         KP
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#]?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>cogo_0028.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0028.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
M'0   @(# 0$!            !08$!P,("0(! /_$ $$0  $# P(#!08$ P8%
M!0    $" P0 !1$&(0<2,1,B05%A"!0R<8&1%2,S0E*AL0DD8G+!\!8T@J+1
M%S5#4Y/_Q  : 0 " P$!               " P !! 4&_\0 *Q$  @(!! (#
M  $#!0$       $"$0,$$B$Q$T$%(E$R%$)A(W&!H;'A_]H # ,!  (1 Q$
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M]5*,MJZ.;^L8UR0_;X<N6MTRW5#E!PD-@9/WHWB25$\LF[.D?LB:YM?$#@Q
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M<5>)$KBUQ/GWI//[LTA8CI)Z1TGE;S\\$_6NWAAM@D<F;N;11$F0XJ7(E)4
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LTZS)Y$WFQ/ )!^);2DNCZX"ON:+)5.S,U*-;77)U'Y;I_LUDI?@^I?I__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>cogo_0032.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0032.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
M'0   00# 0$             !P($!08#" D! /_$ $(0  $"! 0$ P4$" 8!
M!0    $" P $!1$&$B$Q!Q-!42)A<0@4,D*!%5*1H0DC)#,U8G+!%C1#@K'1
M)1>BX?#Q_\0 &P$  @,! 0$              @,  00%!@?_Q  Q$0 " @$$
M  4# @8" P       0(1 P02(3$%$R)!43)A<8&1%"-"H;'!!C-#4O#_V@ ,
M P$  A$#$0 _ .CG,2EDI)Z1:0N3L9H4ES,!TB- IC";93G"EC2\-713)^EY
M42XU%K18*%32DE!(.\)D%'@CV4'F!70&+]BT.)O?Z14@H]#$@\P*Z0LHP30L
MD@Q93*-BT95DGJ(M$1$X9-E.'SB29980H*VZ:0)1[<#6\"RWT/* L*K" /EW
M@HA1Z"6IQ.4C7:-8(UB$/'39*B>T ^A;*TP+N.D=X6@I'EP4NVB,&15)G]\]
MZ& 915YS6I2X'14-_I+18PH6$ "+N8A ANH<L1FZ02&OD^E&;)43%,D8C>::
M0MU(,,3X*9*RK2&V@+WO$M%&*8!^!)T$+:]@D864E)UUB_8@J;5IFMO LM.D
M,RJVI@0=Q@FSFT24FXV!UB),IR5%%Q@O7;N!YP2BR*1#X<<2DK!O<GMY1&BW
M(G+J)-CU@&Z+7(E2E#3-%=\EOHDL+JSUDC[J03!1B%'H))6"+6C2+L1%D3$3
M"PEI:K7TBG'@"3IE;EG 7'$VZWA+6WDMRL^ME2Z.\59'R52:-G73WN(%_)71
M6)L6JC _FAMW$A8DI\(UZ0!0J(0)SB20#EZ1;&HQMFR5)MM%IT7=$9-S\NVN
MQ5XKPS<A5NR3DIE+S0*3I -V&*60H[P)8MGE]3%D=F*?S!O1(4 -P8J12*+B
M_B5A7!LLM56GVN<!<-@V!/8J-@(7:0<<3GT"0>T95,2.SR,))II;DW CG/7Y
M=C:Q"K6/XP6Y/@8M+MY9"UOB=67G_<:QB>AIFG-0KE'2^W6Q$6N/<MXDC'+<
M2JUAMD/.-2T^PI=BXUX0KT&MX%RH6\6[H).',:8?Q0VG[*GVUS&4%V74;.(/
M46Z_2!;3%.#B3I1<:J!TZ;1:"]A]A5U":TYF4 ,H%SY0<.PX]!&]XESL^C\8
M?NB)VL476QKS$D'J#$W(KHPS3\N)=>=T 6BI2HE65IEQ"%J6#>YA#=A.)D*L
MP5I\0B$*O.IRN+%XI]%,K,VF]49-_FAB^DA81H ($$R9!WB$"FL"P](:E<;#
M&JMU#RA$@F4F?SKJ*DW\(,4K;H!ECI;J42N^HAC5!(D<M]0=#%-L-*S H.-W
M-[#6!W\T@7?L 'VI/:<I'!O#[3$JIN8J3^5,K+"^99)L5J'W0K0=]>T3)-0X
M'8</F,U=PGA3B-QN*J]C1Z:5+3:U*;#J+)2+WL@=!8QAGJL<75G<P>%Y6MU<
M!'DL"5"@#[%HDJ"PTE+22#EL1U]8!:R*9O?AKE'[%:QYP_Q4^R\_2),,N(.9
M:R MQ:@.A,,6M@^S)/PG(^4#W"^+,6X8K[&&,<,I]TFR&FYE!OD<5LDCJ"=/
M(PU9H35G/R:/)A=-%CJ]6J^ L2LU&3GG6FTV=9="MT'\]-B/*+=]HSN*Z9M3
MPSX@R7$'#S=09>;,VP W-H2=0;?&/(P]&&:<>R=4\\F=NVO+G%KITN()\=!X
MV2<],S*'4I3,. $?>C)O=FA8U189!YY4DWF=4;^<-BWV*E%70J8SJ;L7%[]X
M-R;(H)"&T #<Q2[!G%4.4J/*4>PA@A<E>GD@A;G6!EP@;LK$T/\ R3)\X:OI
M++&$)M %&;(/.(0)CI(2;=!#8_2&,TJ*@HDZVA-6$^BF3SF2>5;2ZHN*Y%LL
M%']V6U9]=LT-DN0D3(89+2>6_P!-X%Q&1;LA,25)RFRA"5ZKND+M\%A<_E"7
M)038S&EDEL1HZKAR[QSXL3N/\3\R8HLE,%B0EE7(<#/A2K^G-F/U,>?UFJR2
M=0/9>&:##!;LO1L52Z:S(2R9630G*W9.1"0 D6M'.2DSLO;U[#N8IJ&T$-RB
M"HBY5EUM#E&25L%N-TGP0%0E\K"RBU[]1K"VV,J@5XIPK39]U8G9!LE)YB%Y
M-B-1KZQ4<TX.[)ET^/+!E QVO[4892MME:6W/=W$@#,@#98/U.D>KTT_,Q(\
M)K,7DY62O BKOX/XB,TA]I;+-1!EUA7[IU*M4+3W(V^D:$J.7E]7*-I,O[84
MJM=)M$0&,?U1(#K9 Z1A-T2?D=)1L"'QZ,\OJ,CI.6""/ 2!$78$^APWJRY?
MI#'V98E>FU$E:2=+Q)] HK<V *FT!W$,7TA$_F5W@"A7-7WB%T$=U\G2YV@;
M8RC&ET!M1MT,2R20-:O4UMU-U()MFBTP91X/FJ\\+-9E"VN\1Y*X$2DXH^F,
M5S\F0D3*@D=,QB+,*61_)6\=8VJ1PS-):=*G%M.(:-]2M7A_O"=0TX4CH>'<
MY;9.87P9(X2PE3:.Q+Y9EF50'#]Q1\1OYDDQQYP6QL]I')<TET*DS+N.J)?2
MA1!%AH"8RPDDSH33<3.[,-', -$I.HVAV]%1C42JU=QMIP@@$D%6L<_-.GP;
M\4-RY*J\E+QY3J<P-U'-8@WZ&%Q];H*<?+7!2\;\+Z<F4F*]3'%LI4T53#(4
M2%'N.T>JT<''&F>0UZ62;20#QBYYNITF6YB5*I]0:6RX5>)OQ %-^Q[;:QO4
MKB><RP<;1O&],\I\.$@YBDW'G$[7 C"W[DM6S9UBVETQGVHU*;1.T\_L#1,6
MD5NY,CA\-SWBZ!<C$%$N6OI:"2%R=CIHGW59O! E<F"<R]>IBGT6DBO39/O[
M!OK>&+Z2Z18!M%"SZ(0(TQ\7TA0X0T+MKTOI%,NK8,*R":B]I\QB)E21%O)F
MLQ+2%$ #87A62:BS'ECR-5,/S#B0Z"#UN-HJ,S.HGU;PZ/=)$3BARYB;;RI[
M]?[13>YT;_#I5E80ZVA3ZE-IND/(!OMI&;/!6XGK=)-\2957*>\C.EI(64'J
M-8Y?EN+X/0QFLD+9XTV^[=(8 ^4@FUO,P33^ 8PC'FROSX;$TZU,3#(58* "
MQ;T$8LF-MFO'D48\,KTQ[HU,%&=.8B]KZQ<(;6F5/)NB>X@F&O\ #KJ$ZI+:
MKQZ;39;QT>9SX_6V:;XF891.34_)N!#T@\'1I?,@*\28UPZHX6IBK9O7+N-U
M&F4F9:65-S3$NZA1W4E2 08/'RSDKT/D)4_2&7PVN^R 8FU!J;',HAJ72EJV
MAW,2D6I.QZMADM9S%J**<R.=92%$I!BFBD[%MD^[NW%H$(KLQ\:_4Q3Z+796
MIG^(M_U"&1Z+)@ND$B(+/.88A05)A*LVW2$CCQ@%+:[Z:1"P7U=8^U'0#\Q@
M67(E:#+RJQF>%XQ:F[X,TZOD=FD2#\_FY8";ZBV\#CDTA$J1!<7PB1PHS.2P
MLF0F4N/6W"-KIAN&W)V:M/-0FDB,QY4W_=F7',1(I$K[J@OO+6E/*.6]RI1L
MD:]8#,DYGL]%C;Q[GT!)'$"@2=1<?HO$Z4Q"[+W4M#,U=7X;&.?J(RAS%G5T
MSCJ/1'V"$SCI$U@MS&+*[2R&%E:2=4J&X(C'YLWZ6^33+!MJHV@++J\IBQ\5
M.N3M383-N7EY21!4\ZD;D= (T8HS?'8J>*,8.;X2&\IQ9X-)F!*4>H5:17)N
MAER9GF7&P7#\I<-P;]]HWY-,H4VC!@UT,T7%,*TK-,U*22%)"D*&503<W2H:
M&_6-.)P4/3V9<T9K)3Z-3^(V'ZE3,<U6C4U)<"738I&@2M/S?]PS%EVQW2.=
MJM)+)EV1]S</AG-/O<.\,N3,U+3;K4LRTMV75F;(0<HL3UL!&C!E6=7$XVMT
MF309?+RJZ5_H^@S3<RIE+?CTR"",MT8TU^291D?*=8N@7,<FNTQYH!J82GU,
M43?$09I*DDH<"@K30Q:16]/H4F84EE;:TF\#5,;=HA'D**R0BPUBWT"5F8!]
M^0+?-#5T62V1?:!H"T*Y<2B6@K/ZJN!TA0\2@$MN:;B)1:X!?4&B:NZ%?>@4
MK))HLE#E&.5=:K;PK-C9GDD^23Y<LH6;)S#8VA,8.J$22(RO8<14://)=&8*
M8*B@Z@V__(;%;1V**61,'>/\ T;&3(G<3TYZ:2VREN1:3HTW>Q4M23<+5T%[
MVC'/(L<MTCWFDQO+%077N#VC< >'>&U>]4O"LE(*!#[KA_6..K&H))T%NT9]
M3J7DJCIZ?38]+;C$F<<41F5PH:6X4-FK-*6L) 2$)(T-A](PY<.V2=FG2M9<
M4IU]B"P#3I1N3E9=VG-..20Y8<MXK'>QZ7@H:KRW2[&/3[L=/HFG\"4=MQQ_
M_"-%;YX_76DP$+%K6(UOI&J>IR-4Q6#1XHQ>U=&+[)E:3)N-4]EIE 3F2$ A
M"0!L!\H\H+'!M;C/GA!/D".,9&KX>Q8OBTAIJ;I##\FS.-$Y7&T$E*GNQ"%%
M)U[QHO\ DTC#BPQEJ=S?L%3@<Y,O"OT5EQMRF-5)J8D5H3X0AX9L@'8>4'X5
M-O+*+^/]F7_EN+''!BR)^ING^$N#9*JT<3+22VHBR+1V?+9X3?90*A39]N?Y
M S9";;Q;QNA;E\CJI4-Z6:;=:4L@@7$!MD5:0FEE_G)3G6+$7N8I)KLM?8(0
M809=*L@^$7@6:(/@AYYM(O8:VB_8(I;XM/I_J@H]!$J7T@VUT\HL2^SWF^L2
MP;"\X@*U\K0&TU6)2@);4D]C%52)8,*FT?M=T@_- 1[)(GJ7)..M#+>'.*EV
M9FW9.R<DVTD$@YNL+>+:-4-W8^#;"F%(78A22DCN(%029;I-5[ NQE7I&2?9
MERZA+#:"3XK!)ZWCBZN<8SIGT+PK'*>)37N#)7$>DU9V<7+A]RER%S-ORR<S
MCJ@+Y&OO'N=HYDLJEE1WI8-F%Q]R#XH\7<,^[(KBY6>]W#:0W+AG,^4Y0 "G
MH8U2COR\=48\&18L&UE PKQ8;74).8PY2ZE*L.H6)UF>0/"1\-R-+^G2,F7'
MME;-F'*I0X"2.*LG/-I8G5IE'0BP05#(OS2=C!;FT'%Q3JS"<74^IT1^29<!
MF3F"5 [B.MI\D7CVG"U\)>9:Z(.N46E5O"3.%JRPX[*3TVT)D-JR*<0"%%).
M^4VU^D%J;QZ=-?(&A6_-+BZ06N$.$J51:9+R5(9+4J5AQ"57)2D'*D$];) C
M?H,<88=U<GD?^0Y\F?65N]*2K[/D.3K+>0 #4:QT6SC**("IR3*WDK*$WOO:
M"]A,DK'DS3V52@*DI/@[0OW+G!;;*1R\L_D%K!72!: BR],I_8TWZIA;'Q?!
M7ZHXE#N6QU%HC7 =\E(F' 9Y)M\T,2])>X>J4,Q]8H4Q?-'8Q5 T&@B\'2-0
ME0LE7H8":2(#6> 557K_ 'X7&/)).RW4-(# U%H8U3$M[>"06IM)U6(MNQT9
MHCWWR'_U:B1"KW.A4_3RN377VC,)5R=G'Y;#\V6T.!*UMDD9@3F6 1Y7CSVO
MCLS_ &/H?@NH4] ETP-U3B;A+A8FET;&,I5I!,^L,R*Y.1+[+BR;9<X(RF_2
M"T^FCEYHTYI9I+=%\?V+]-T"6J["D3?#_$S[RK929(?$J^77-I>VYC3Y=+;M
MY"<<<O4\BK\H%V.YL</\+S>()W!U3E9!!;07%OM)45+*DI2 #<FZ3H(!::<G
M<D5++AA"HR;*]PCH6*^*BUU3$M#<HM'<2$R3<PZ>>\3LM2/]--@2.IC/G\N#
MVQ?)6/'D4=\^$$B6I,M2ZJK[/)6PPOE@J5?-YD__ '>%:>XSY9-1+?CZ+919
M05_&U!ISJOV65EIRH/)! *RD)0E)'5.MSZ1Z".*&HCZCR^MUF;00K"ZW=AZP
M8VE$^A"$I0E";)2D: 1KQ\4D>:3WMN7(1'AI;RAS9$B%GQ=Y(O!(SR5,>S)R
MREOY('W'25P*-R+U KS'XNT5-&;'&F75@'W5(/1,(:-<45FMILZDWZ&+K@DN
M.2DO"\\CU)B[I%I<6/CN8@!]$('$-I\X,=8A:1E5Z0&1! PJ6E5=M]^ CV4R
M?E)EYJ6LV=H*2;8N569C+SKP"PK0ZF"42MK'S+"4M!3FXT@(QY&3CPJ!YQHD
M7&Z>Q7&57*<K3B!N+:I/U!M'*\3Q4]QZ+P3/'_J8*:%A*D8PEWV,04R7FY%!
M*TMOMYLJO+MKKIVC!H[A/<^CTLM7MQO''GY15)_ -*IZYEEUJN%IQXJ)35'@
M5FY()\5_[1T5G4Y-)\FC%ATB@I^6OP1+>!Z2F9;=EZ TVPC($N/DO*NG;XKB
M_6]MS&7/J-O%FJL2C>/&E^@\J<]]A.G[-'*"VU!92-"3&-X=_J1S]1J9=,B'
M:@4)9D2L%Y8YBE#[T7@B]ULSY,JVT6?ALU/3/%NFS@41)R6'9L*&4GG+<>2,
MM_("^L>@T;N-'EO'/Z38G!^85#6UQ&R*HX4.PAO;?2#8:(6>_?I^D&9I]L=S
M0O*_[(!=CI?04QL_MZAYQ<C/'LN3'BETW^["6:H]%<KJ '$^D3V*GT45W_/I
M'G_>*8:^D?E(O%BA?*3W,58-ARR@=(8:]J,"P/$/*%S85*@85<!-7< VS0$>
MQ4B=D4I+6H[1HZ0*5LL$LA(8T'2)8V)B5I=(VA<.7R7/CHKN+Y>6G:>Y)OME
M33P(6!OKV\XF;&LT7%BHYI:7*LL.T#NCR<M0)"<H<^M++JCS&'M0EY&X4D]P
M="(Y$8[(.,T>IT^H6?)&<7VNOT*W/5*2?<*5O,K6D[DZDCK&&,:;V]'IUE>U
M*15:UB"5I1)FWF +^%*2-8SSBY2IFGTJ%L&F)\9R;[RI1LI5FU-N\;X8]L3S
MN?,I9:[(N1G'9V80A-^:^<O]*>\4JND1>M\ET9K^/*-Q/X;X6P0QSFL0/S$M
M5@$^%,HT I3JST2";>I$=331<$E']3#XG@QSQ[IK\&R^%<2X<'$"JX"9JB37
M:2TW,/R2TEMWDK/@=2%"RFSMF'6XCIY,4H^I=?X/(1DH\>["8ZNYM;3:%M?#
M&J2^"(G]9A-MKQ:W+LSY.9<=#J<5EE+_ ,D%%<ESDU I,NO//*UZQ)B8%VEO
MW"!Y1G9LCT05<;"EI/D8O[$?10G$C[02#W@J1;XB2_);.N7\X+:A8OE-_=_.
M)M1 T':*-9@7\WI"YE^P,JL :T]H/C@(]B63<DDE"+'2-#*79861E:2/**&1
M[$+:-[P./LO(5?%1(" DD7(V@C+GYX*W4J;*5^F+IDVV5^%0;*=%-*M\23T,
M(R8E.+#TFIEAR1<>S6''V&L7X1JA4J?5,2SY*F'0+'+V5V,<2-)'O5J)-_<H
M53%6GE<V8?6H#=2CH(B<45EEEEVR&7)*EUE[EE]P:)3W/GY14LM\"HX>>"UX
M-I\\F83,J;<F)IY80TPTC.XXH_(@;D^GJ=(K'<YI(V;(Z>#GD-M>%O#A&"9=
MS&N,'V35?="$HS#ETZ5N%+0%=5DZK5M86$>HTNF<*?NSQWBGB7\1NA#Z30'B
M-[2F(ICVCZMQCP555RS5-<3(4Y1 *')1K125)/Q(6<QL=K@B/2XM/#)B<7T>
M2SY98,L5'DZ%< O:%PA[06$EUVB99"I21#50IKC@4XPOHM-OB0KHK8==8\]J
M=*]*[9V,6:.5%YG@I,TWJ;$PM^M;D*;]5#JIW$B?Z(D>PI_24&34K[15XCO_
M 'B9.A./L(DJ/V5L^4(9L71"UQ.@(TTBUV1] _=TJ*;]X)%OZ2: %AI!BSV(
M0,R]H6C7(:JME7$F"@;5;^,N_P!4!#L!DK*/96P!KZ1J]@4N2P,O%2$^D+FQ
MT$)+AN;"%D*QBES,S8;[0R*,V17P1%'YBLZE@A+*"\O\+#\[1<E#MDP1E/(H
M%&JBJ-Q PDU5Y=WG)6X[DL/A(64J1Z@C\XX690FY-?)[7!AECJ*!I6<%R/N8
M92T2H@Z6L1Z1AF_*]9TH8'/THKV'^&-6QC5GJ!A>F+FE-!/.F5W2PQWSN#K_
M "C4P>GT\]5)./N#JL^#P^.[*[?P;.8"X5X9X:RZ7Y=L3=8+=G9YU(44@#Q!
MH?Z:._4]8]3H]%#3+[GB?$/$LNLE<OH]D:^>W5QZ7@W!BN'.'IM(J>($+1,E
M)U9E=CZ%7PCRO':PX-OK^3BY)[FU\'-]Y\B23+-G52KJ\XV^9MCM1SY8M\K+
M1P[XJXNX/X@8Q9@6I^X5*724I4$YVW$J%BAQ!T6D[V/76%SA&46IAK))/^7T
M;G\+/TE.'ZB)60XS88?DIAH!*JE2&^8TO^9;*C<?[2?I'-GH:7\HTK,DTYLV
M^PQQ,P)Q*PU]N8"Q/)5B1=1FS,N#FM]PX@G.@^HC ].\<N;O^QJEEC*/"(FE
MDKGU*OI?Z;PN=JT5!.3"*Q_EFPKM"GZ84C3W+DC*R !8?=@,<7%\AY4ET#AT
M?^53]8>P']),I!RC3I%BSVQ[19 RKVA:-<N1H]\*O*)(I(&U:_BSI_F@(]BV
M2,HZEI#>8:7WC2G? /7+)QNHL,M)4H6Z;=85.27'N.AU9[+5*6FR>6I._P",
M2,6^05)<\@DXV<:N'/#%DR^)*RVJI6);I\L.;,D6T!0#9 .P*B(Z&#23S\)<
M&'/J(P3:?)%\&,=XEXI8'Q=B.?I,M1Y8+3)R4NVKFNH04$E:UG0K-QL-('7Z
M5:5[/>C=X7E\R4<@%O9SQI-4+$6,.&5>6KEL51;\KF^4N#6U^AM?UO'C]5)8
MLB;/?8L3S0>WL-.',+.XHFII<RV^W36+I<F&_C?U_=MDZ7[GH(T:72O6.I+T
MF?6>(QT$*@[D&6F,8>PY26:;AV19DY1E-@VA-LI[J.ZE=U1Z'#IXX8[8KH\1
MJ=1ESS\R;M_X*AQ"QK3L&X9J>*:L^425-EE33[B>B1T'F20FWG'0Q04Y*S)D
MN*]/-G(+B9C6J\1,85/%M6<6MVH3"G$I4HGE-_Z;8\DIL(Z7/1AZZ=E*S<IS
MQ"]N\!5%71CJ 6$-Y;W*TZ?6).Y5R7%4N#PIL+J3Z13[*44U<ER36'<6XBPA
M4V:QAJMSU.G&%!Q#TJ\IM0(]#K%QE[25@9<>[F+9M_P4]O.>:G).F<6I%$RP
M;(55)1JTP#]]QL>%?G:QZZQER^'X\UN#I_8*&HGA23.@6#L58?QQAR5Q+A>L
MR]4ITV/U<S+KS))&X/4*'4':.)DQRP/R\J.MCDLZN+%5?Y?($0I<2"GQ$'BP
M?M-/UAKX9&FH62Z5)RC7I%BURA42RZ88SM FH:O_  +@67[ UK/\4<]8&/8E
MDE)J:"&[^)6:Q UMVC1;?I]B123W+L:8\XI\.>&$@J>QMB21E5\DN-2:59YI
MX#9*&QKJ?2&XM//.]N-<_P!OW*GFC#U3-.>+WMF8RQ=SJ/P\E%87IRW#FFKA
M4Z^D;:VLU_MU\X[FE\%CC>_+V<G-XC'+<8@%HS,_4<3MU.HN.SCBLSCSCZBX
MIQ9V4I1WUZ1W,<-LDDN#"VY/U,W-]GFJ3<YP>2O"3S351579R20ZM&="EH4D
MK64[*TTM'G/$EOU$OP>D\.E&&%5\L)+O CAQ7\82^+)2AS-/K<RXTJ>6R5)E
MYO+J4K1<V!-]4VCSF70XI^J1UL7B^?$FH_ 4):AJ8(9;8;EVF@0AM LD)OMI
MI&_'LQPVQ1RYN4YO(W9C--<<YKB>6TVD&ZCK>"W[70*J79H9[??%N>ISS'!V
MF3"6TN)3/5<MJ\2TW_5,D=!\Y'72.KIXW#<8,^3:Z1I&Z 2;FXC494J5$14Y
MAB50E]XV3FL;))/II"Y\!)6-4S$W4"E2Y4RS"5!2<Y_6*MY?*(&]P;5&5*BZ
MM2Q\.P]8M+D$7DL+1&BCT/%M2;'8Z:1.BG)+AA6X)>T+Q%X+UQJH86K#KDGF
MS3-/?6I4M-)ZA:>_\PU$2>".JAMFA'F2T\TTSI%P<]IWA[QRI;+=/FFZ97TI
M_:*/,+"7<UM5-7_>I\QKY1P=3X?EP2]/*_T=;%JUEBDR>5_%@G0@7O\ C")0
M3KGHT6TJ?1*>D%=E?@5G,#1 S':*- V>%TK$!+@OV!O76RW4G%$Z;_GM$@K=
MBY+BP(^TWQOF>'-&I&$L+SRY7$F)II,NU,H"2J2ET^)UU((U44I*4]CK':\-
MTG\4]TNKJO\ )S]3G>)[8FG%;FY^KU><KE6GYF>FWEE;C\PZIQ:SW*E:F/7P
MPX\<4H*C@SS9)3;;NOV*_+SGVK66Z;+J\#0*W%#<^4!=RVH-+C=(O$PY+X?H
MTS45@9)5A;R_,@:#\;0^;VQ<G[%P2<TD; _H\)1RL\,.:[,.S!DJQ./J3?1#
MCY!MZV$>/U4MTG)'H]/#RH)&\[,FF0;9<RI#Q205];'I'&W[W4ND:J<>8B'+
MBY)-K6U[0Q270#Q;>8L@\78HI.!\)U'%-9>0Q)4N6<F7G%$#PI!.77<DV '<
MB#A'S,BBA>3B#?N<4^)6-*CQ"QU6\8U1];LS5YQR845F^5)/A3Z)38#TCT,8
MJ"44<K(U+DJKI L#M;;J8.2VN@(O<K&BK+!;(N#T@&BR.?"^8))"BHG4]TCS
M_M ;63>AVAI#:$I2G;>#C&BG-'I;*MA%N)-PLM)T0$A2S^7G%)45>Y<'K3C3
M!RBU_P#F#3:Z VQKU<LL>&ZS4J+4I*J4F<<E)V6=YLL^T<JVEC90,:5&.1;9
M"'*<.4=)N!/$Y'%?!-.Q,Y;[1;O)U% L+3"+!2K#8*N%?6/,:[2_P^9I]'8T
M>H6?!84N8!H1>VD8[--5P+S"++#4!>X@#0-I@%*%$:Q32[93Z!KB1]2:DI!%
MAK].D%;YB+D^:.=W&#%8XB>TC6JBEPKD\)TT2<NC<)=4HH!]0D*_&/:>&X5C
MVI?TJ_W//ZG)NW/WZ_8IN*IM=/I2[>%;HO'1S.H7\F3#&ZLC>$<DHNU"I3(S
M*.5M)(\[F$Z5=MC<G'");C!.+DN'SK;2\JZA,ML)Z'+>Y@M9+;A?W)@5Y$=(
MO8YP52,)\&\+R4E242+S\BU.3( \;CZTW4I?<D&/%:N52:1Z2*X#G4'$\PJ^
M+*G0><8H]4:'T,%*<?<2VD !))5<Z 6@Z4(VQ>.W;-)_TC?&*7I&&Y'A#2Y@
M+FZFI$_4"CY&$G]6C_<=?H(ZGA^)JYR,FIRWT<[4FZBH]=HZM5P8(N^S#-L\
MU*<ILH&Z%=C RC:OW)TQE,/>ZMJ<? +JK)2E/S*/: <FHVROP)D9)3&9<T0N
M8<\2U=!V AD8UV*'19&>YV@R"RT -!IWB40:33ONJ=4W61L(!\(*(T8:<4?>
MGC<]!M80*LIDS)38]\E^R2(TQG4DQ$E:9N+[!U24NM8MH7O #01+S26[_,%E
M)4!Z'_B.;XS'<E/_ .[-7AL__%\&Y7))W)_".!1UV9.5!$#0#:$;F:#$^4I:
M5?<[0,G:LI\\ BXBU!NBTZJ5^8.5N1EW'3K;4)-A^-HVZ:#S98X_EJ_P9L\M
MD99/=)G+KAK.+K-5QA7GS=ZH5U697=*1MZ7)CW.B22E7V7['G)MM)O[O]Q[C
MYD++:%*T!V\H/4])$QJFW\DC@9E+%+2A*;<]:E#TVB\2J"^Y'S*F1?%1HUO$
M^#<'2Z<_ODZT2@?-F=2@?WC'XEDJ*BC1H\:E.V=D<+4V5H]"E69%O*VAE#8T
M&R4@"/$YKEE;9Z*$4H#XL_&\[<V\1$"_9HMR;=$57ZS)8<HD[5JHXAEMB7<F
M9A1T2EI*2H_D()0\^:BNF5+(\46F<6N-_$FH<6N)59QG/JRB<?M+M@Z-,I\+
M:1Z 1ZB$5&*BO8X\Y-LH10,V@L.T&+H2Z4MD&VEKF(^2QC+M^\NFJN$<HZ2J
M;6%NJ]>_3R@%R]SZ(*!43<VACY%#A8U2?*"JB"BI*$%2E#PIN?[1395D8M*W
MW"ZH$#>\*?(2,#KB7%\M*B .T5?L2K'LH&VW6R%W-QU@X.Y(&<4H.0?/9'Q,
MO#O'FDM%S++U=U5-?!ZAU'A/T6!$\0Q^;@=^W/[<BM%-X\]KW.EZ98%(*LU^
MOK'DU*U9Z3:C+[J.Y_&*Y)M04[F%C3&_XFS>!ET1<LUB]KJON4+AS4 VM.:<
MF&V @FQ4-5*_"PCN^ P6;5N?PK_NCF>)9/+P_EU^YSSX+9QAI^:4G_.56:<]
M0"!'JM%]#?RV<;)[+[$[CMLE;:KWZ 0W4E0)6@M>YTZ7*Q8E"4(':^YBH<11
M<N)$[PCPZSC3VQL)4F90DR]'8$ZH6N+M-E2?_=ECD^*SJ2.AH8^ALZPJ"6)>
M38;\("22/./*+U2DSL74#,\I18N=22$_3K^5X#O@/JF:>?I#^+R\-8 EL$4N
M:#=0Q(X4OI0NRDRJ-[^2B!'7\,P[;F_T_P!F#79/,Z]CF5?,,Q'_ ,QUC NC
MZPN+;]HA!HZV*C,F60O]0P;S![_R?]P+]3I$/IM\*<RI%D[ #8"+E\(LP-CZ
MP2%#MY26VPHJT@V0:H<6MKFA%RZHV_I&W]X!D&<_-IEVU!2K*.D+FZ"BK(I+
MBLF<;F\)L/:/93G(2'%7T.;UAD/_ &%Y.$T$WAI7F<.\2,/5]S]VQ.R<ROR"
M7$W_ "C;FJ6*?W7^C'C>W/%'7S)S/UC7B0OQ)(Z@ZC_F/%N.Q[?@]3!W%,7D
M7%!!'A09XXD*:6";::'^WK%=-,I].CGU^D#QAS*ZSA5MY:9>ERGO#Z6S;,Z[
MM]0D;QZOP+"L6"6;Y_Q71P/%).>10]DO[_)K1PI:3+8*HHR9><VZ_;^IP_\
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5N:27RSTFG>[#'YI%E]TC+3&6?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>skill-z.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 skill-z.jpg
M_]C_X03Q17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  "OR    G$  *_(   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C R,#HP,3HR-B Q-SHQ.3HR.0   Z !
M  ,    !__\  * "  0    !    &Z #  0    !    %0         & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
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M 0,1 ?_=  0  O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M']#;_J3_ /_9_^T,^E!H;W1O<VAO<" S+C  .$))300E       0
M             #A"24T$.@      \0   !     !       +<')I;G1/=71P
M=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L
M<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M     0      #W!R:6YT4')O;V93971U<$]B:F,    2 %  <@!O &\ 9@ M
M $4 :0!N ', = !E &P ; !U &X 9P      "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B
M;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M  !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M          !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
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M8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M    "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 $@    !  (
M2     $  CA"24T$)@      #@             _@   .$))300-       $
M    >#A"24T$&0      !    !XX0DE- _,       D           $ .$))
M32<0       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M     0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M 0 M    !@       3A"24T#^       <   ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M   X0DE-!         (  3A"24T$ @      !      X0DE-!#        (!
M 3A"24T$+0      !@ !     CA"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      -+    !@
M%0   !L    + %4 ;@!B &4 ;@!A &X ;@!T "T ,0    $
M             0              &P   !4                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   !4     4F=H=&QO;F<    ;
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<    5     %)G:'1L;VYG    &P    -U<FQ415A4     0
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M &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %
M: !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$!@      !P (
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M(" @(" @(" @(#P_>'!A8VME="!E;F0](G<B/S[_X@?824-#7U!23T9)3$4
M 0$   ?(041"10)   !M;G1R4D="(%A96B 'UP #  ( "@ ' "EA8W-P
M                                 0  ]M8  0    #3+6))0T.<;32E
MK:1%]A1MF+!1#!)M                                          EC
M<')T    \    (ID97-C   !?    'AW='!T   !]    !1R5%)#   ""
M!81G5%)#   ""   !81B5%)#   ""   !81R6%E:   'C    !1G6%E:   '
MH    !1B6%E:   'M    !1T97AT     $-O<'ER:6=H=" H0RD@,C P-R!B
M>2!#;VQO<B!3;VQU=&EO;G,L($%L;"!2:6=H=',@4F5S97)V960N($QI8V5N
M<V4@9&5T86EL<R!C86X@8F4@9F]U;F0@;VXZ(&AT=' Z+R]W=W<N96-I+F]R
M9R]E8VDO96XO96-I4D="+G!H<    &1E<V,         "F5C:5)'0B!V,@
M        "@!E &, :0!2 $< 0@ @ '8 ,@     *96-I4D="('8R
M
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M65H@        IG@  %'^     %A96B         ME   FB   !%=6%E:(
M     "+)   3X@  P=#_[@ .061O8F4 9$     !_]L A  ! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! @(" @(" @(" @(#
M P,# P,# P,# 0$! 0$! 0$! 0$" @$" @,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P  1"  5 !L# 1$  A$!
M Q$!_]T !  $_\0!H@    8" P$             !P@&!00) PH" 0 + 0
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H<G^Z#ZGZ;QFU^/XGB^)1:ZO$_#HT>'X?Z/A:/!_3T]'$]@KH8]?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>cogo_0025.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0025.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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MPH;$_B,_?1;-R*]QQ?(VT="A-)=N<HHR\3R!1_1I'51IL,:1FRY'(TK[.ND
MM\\09C"FFE!4>U(=04$H!^.00>RNB?3>N]H-,O\ L?\ !YOU75W+V(?R9KM/
M&W47LD^USQ(T]/@/7+2FI;J[<E6]#@05K=0%H=;*M@M)*ACH16Z4=\W$Y+^$
M5-^#;O"OVJ^"'%%@1[-K6';KF4CQ+;=U)B2$*.V!SX2H?NDU@S8)1?9IQ9MZ
MZ+C'*>122V4J2"GD((5^T#W'KFE7Q03^X/ZE ]V<.*%@L%K#M+.**'0N7880
MB>;KVHF,B3;#VP!.=JJPZ'&1YT0)6UG4 @X/>LJ 8_>6<D%).WE0S"B#%W3S
M)) WS4A;=4,V)<@K>>,6@N&[?B:COB/'/U(<4>+(7_RC8#]XBMD=/.:I"Y9(
MIE/<2/;FNS#1A<.[ W:PYD)E3/IY"_D@?"@?/)K5CT<<:O)R+>64OH9G[6W%
M?B+Q%*7-::NF24K/.8Y<Y66DCL$)P,_=6N&*$.A,YI_N5Q?M0)N+S=IM^$11
MA;I'VD#J,U<I6Z06.-*V/M/K0Z]SI._-@?+K5Q)((+-K(Z-X@Z9UDVES-IN3
M4A02=RT%8<'_ $DU<WY*AP>Q>C=10;K8(UPB+#K+T=M]DI.1R+',G?OL:X^?
M"U.C9AS_ !IGR3,2Z\5 #&Y/G3(XE_($Y\\K@$]?:"TUQ(LSMBU1'+L0?2-O
M)4$.Q7 /TC;G5!]>GF,4K-CAD6V2Y&:?//!+?%\&%^(FBM2Z&?FVMAZ/JN A
M2VD7.SD27VFR?A][;;SX2P,#/U3VKFST.6#N,3T6'U'#J(I.>UDOPK]G&[:@
MNB+SKQV+&@ MJB6!J4A4A83N%R0@Y2#L?#_&NCHM!N^65<'-]0]34?[>G?/W
M-0M,.M.M0TMI0RWV3VQVKOOA5 \SWRS!/])-IG^JN(NE]>06CF9$3'=5CHM"
ML Y^6U9<JVS4F:L-RQN)G6\6UF]0&I\-SPWRGX%XR$N>2O2G23DKCV)3473#
MS@S[7O&_@^ZFQVW4CCD2(L)=M%T3[Q&('9O/Q(21T*2!Z5EE",W4^Q_*^43<
M.@_;HX4\2H+%IU('=)7A](RF6KGA+<[I#XW&>P4/OK/ETTES'DN.:^)%NZ<?
M8??3)A2&WH[@"D.MK"T*!Z8(R/SK&U3^:Y"JOH8:17L'"B,^5,CM?"_P$VTO
MD2S#BO(U/-!JFK0[YC5D*UM3R4-EP*  ^(D[8'GZ5ECS)1\BY-1Y8 :_]I'A
MYHU3T6'=6KY<^0\L6WNI<"3^VOZH'IN:UPT<\G?1%E4>C,&O?:$U]K$+B^_(
MM,%2B3'@Y1D?M+ZG^%='%I,>-<B9Y'+HJ2?=0W(7)>>6XLC8J43_ !I_"Z0"
M3KGD'G+LU[P77"%+&2"1G%"V'&-_H0EVOLAY6$+Y3W-"Y!+&B':>EM9<9BE\
M/?1JWY5 =21V._:@ER^$'5$_IZ[LH9662I;Z24AHI(4%#S!Z#UHXN@&/I2%R
MHSA6OF6H?&<;?(>0H^T"NSTF]@SB"K6'!*)9'9)=GZ>>7;G$]5>&#E!]?A-9
M,]1BI2#BOGP7'Q XI\..&C+2-1WE!G2/@C0VSS+<7UY5?92#YJ(%95#+DG2X
M1IBX;6^V8)]HKB'[77&-,NT#3:;+HOQ5>#"L-W0AR4WG*2^Y]9:MOJC"?G76
MT^EQXW35O]S'EG.?TE%VQ%YM5A>8BW2X0GI",2VT2%("BG8I6E. HCR.V:[.
M/!'9N5._T.;/(XRV2M-?J0=A0^F8Y<X3KXN(5B,_&?4T^'.N0M!!V^=+ECP[
M7.:0&_+*>S&[-F\$.-W$=AJWVC7,-^_0&D!I=P<Q[\,=U8 2X/3&:Y%NCJSQ
M1?TC7VZ;1"UWPDCW.QCWM,/Q9#;G+A2>7"BE0Z@C!VZU>3Y0HK"G%M,PG9WG
M$6M#[:DGX 2DC(6#V-3'=65D:3(;6K'O,:'=8,$!Z.HI==YOB"3T01WQUS2M
M0MWR2"P\/DZ6.\)=0E#BAA77:IBR^"\F-OE(M/AOQHXB\)IHG:.U"\W&<.7H
M3Q+L9S]YL[?>,&F2Q0GVA%22^YK7A3_2 V&>40.+&GE6I2R BZ6Q)=CC?[;1
M^-/S!(]*QY-&E_UC899/ZS8>DM5::UG9F+]I.^0[I;I 'AOQW@M)./JGN%#N
M#@BLDU[<MLNS5%J2X)_(\Q5669"]H#7[L2V-Z.@2?#7,3X\X(Z^'G#:#Z'<G
M[JT:'3IW)F:<N3*NJ+5$+9=C$,N-9\/DVY2-\C'K75I52%;K 9>IG);""ZA+
M,CF+;J$_KCJ?D>M+NPJ&%WGKYN5*B?@%4V6D0JG5..'.YSYT#&(9RCET)%4P
MT2UL0'"5%02VWU./X>=$@6?69R3<7&V6TH04\N?M*QW4>_RJ)\E>"9*T^[#E
M.2=J*K!+U]B#6#]AXN3-%2+Y*A6S4<4J4PR[X?O#[8^$<W4;$]",XI>2"E\6
M,@Z5F[;%PXT<TQ,@3[(Q,6\L^*N9].L^1YEY)]!0.>U+:B-MNQ;^RNG;;BWN
M6.W^ZD (<,9.-CT5MU\C1;W);D3:9!]K?AO:=&:X5=X;3$2WWN,J5X2<);0Z
M@ *P!M\0(..Y%=C0Y7+#4O!R]1&\I1W!>T6F]7I06WXZF%@(;*3N2Y@'<#;%
M5JI)8TON331_O-F^]*Z'LD*$VB/;FFEI'-G&=ZS-12-;;LC^*&E6;AI68^W%
M!<8!<<:2-GD$<JPH="<$XH&_(R/V/,")"3:[Q==.*/,B'*<80>Y2%''Y8I</
ML#F7DCW&FTOK4D$@90ZTL=?+(^54^R1!R\VMBPRXK\)XF+-2M:$J^PL'!3GO
MUK+./MNT:$[5$Y:7P\D G.1@CSI\)VA,HT.D$Q9'AN#Z,^6VW;[Z:F+:+>]F
M[CA=N"/$FW7-J07;+>%IA76$5$-N-Y&'0.@< SOWZ&E98*40E.472/5G^UFG
M?^),?_(FN;4C1[LOL><NO=0R-1ZDE752P4RY2G$GOX0^% _ 5U=/!0QI&7)\
MG0":BD#E#*5;X^/Y4ULI<=E274^!J+Z-2DM2<$C]H=_PI#[&KE')[Q=7S ['
MI49:0W922E;@.YR:$*QMNMWFJ@K)6$KP%)=(/*1RJ^1[T2!;&_A&/<%!>V^,
M_/H:JJ9.R9CJPA)YL\VWR-$"QW9;_-T;JRQ:PAN<CUIGM2>;. 4!0YQ]Z2:I
M_<*+K@]=K?=H]TC0K[;W J+<H[;Z%).00I(((J*/:9+X1(.%+B"A9!!SD8ZT
M%5T6DV9;]MQN$A.CN=*7Y#(DNMA6_*-DYQW.>A/3M74]-5[F_P#>#GZSB:90
MOLP2&WM83K,XVT\MV45H2XOL/BV]?2M.>-PONF(TS^;MT;[M*%> A2T8QMBN
M8Y;CI.&WD5N,1+L1YKE"O$21@^M!^@:CP>7_ +1&DF]!\>[FPRWX46Z<EQ8
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<?Q0L87]XW-)E)/&V-BJG1'>,O_53^-+LNC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>skill-y.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 skill-y.jpg
M_]C_X0/#17AI9@  34T *@    @ " $.  (    ^    ;@$2  ,    !  $
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M     0   !R@ P $     0   !4         !@$#  ,    !  8   $:  4
M   !   !:@$;  4    !   !<@$H  ,    !  (   (!  0    !   !>@("
M  0    !   "00        !(     0   $@    !_]C_[0 ,061O8F5?0TT
M ?_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$(  4 !P,!(@ "$0$#$0'_W0 $  '_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M0DE-!"4      !#B 1<C!Y>:WYN=)$D4?"D2.$))300Z      #Q    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P   !( 4 !R &\ ;P!F "T 10!I &X <P!T &4 ; !L '4 ;@!G       *
M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! !+     $  @$L     0 ".$))300F       .
M #^    X0DE-! T       0   !:.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         ".$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      -#    !@
M%0   !P    ' ', :P!I &P ;  M 'D    !
M  $              !P    5                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<    5     %)G:'1L;VYG    '     9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M    %0    !29VAT;&]N9P   !P    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
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M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!0
M  0    ".$))300,      )=     0    <    %    &    '@   )! !@
M ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  %  <# 2(
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M    % !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #
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M  H !P I86-S<                                     $  /;6  $
M    TRUB24-#G&TTI:VD1?84;9BP40P2;0
M               )8W!R=    /    "*9&5S8P   7P   !X=W1P=    ?0
M   4<E120P   @@   6$9U120P   @@   6$8E120P   @@   6$<EA96@
M!XP    49UA96@  !Z     48EA96@  ![0    4=&5X=     !#;W!Y<FEG
M:'0@*$,I(#(P,#<@8GD@0V]L;W(@4V]L=71I;VYS+"!!;&P@4FEG:'1S(%)E
M<V5R=F5D+B!,:6-E;G-E(&1E=&%I;',@8V%N(&)E(&9O=6YD(&]N.B!H='1P
M.B\O=W=W+F5C:2YO<F<O96-I+V5N+V5C:5)'0BYP:'    !D97-C
M  IE8VE21T(@=C(           H 90!C &D 4@!' $( ( !V #(     "F5C
M:5)'0B!V,@
M                          !865H@        ]M8  0    #3+6-U<G8
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M.,DY(CE\.=8Z,#J*.N4[0#N<._@\5#RQ/0X]:SW)/B<^AC[E/T0_I$ $0&1
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ML":PX[&ALE^S'K/=M)VU7K8>MN"WHKAEN2BYZ[JPNW2\.;S_O<:^C+]4P!S
MY,&MPG?#0<0,Q-?%H\9OQSS("<C7R:;*=<M%S!7,YLVWSHG/6] NT0+1UM*J
MTX#45=4LU@/6VM>RV(O99-H^VQC;\]S.W:K>A]]DX$+A(.'_XM[CON2?Y8#F
M8N=$Z"?I"NGNZM/KN.R>[83N:^]3\#OQ)/(-\O?SX?3,];CVI/>1^'[Y;/I;
M^TK\.OTJ_AO_#?__6%E:(        *9X  !1_@    !865H@        +90
M )H@   175A96B         BR0  $^(  ,'0_^X #D%D;V)E &1      ?_;
M (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$! @(! @(# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\
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F;*N^"ZD.Y37C0>&:"5+-5U5' V\C/6E<$::5J:TZ-][!'0GZ_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>cogo_0031.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0031.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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M=HH2P^ [/A1Y"T-%4)(,5A>4MH^J8678$06J '$TNOZJ(-%BZ"?;%?53$H'
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M&ZCP6#@?:9AS:10R_36U,H4@;Y-] N-DH_MU\3)BF]5]Q&ZZT,/S*P_-K;F
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M4 <AD -NI,=%))49)-V5_P!\\/\ \'6( 14I;KQEV;72+K6. '0>)@,@HBR
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MDB?_ &5S\,&T2F>KH]76VM*J3/W(N/Z*YQ^$0E'K=,JV4+-(G\UKG^BN<O\
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0]\CU/_A$_P#LCGX8A*/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>cogo_0035.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0035.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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M&2;U-U+-TY97U-;R^^0W'0.ZW"<  >?-)J;LGM-*;VK+,^GW3"X'18A_MB=
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ME:;,7I8 '7'RI'^\?WI-W0=?80Z'["D4AS^XE:/_  $?\:N>@UT)+M_I7/\
MC7+HZ?H&Z(4+"^ .^:3;+,1B$SKF>]14@+/0UW Y1D4U]'/HU,@K:Q@8[8[;
M@>^:2X[LH7%M2*P=9^DT.VS7;NQ!\82I"W" Z?#9'.%+*CRHY[#X1]:\KK]/
M*F>X]GXW70LAL94[5EG<BW*="$<H99<+Z2<%3B5C/..,=Z7"64F:FWDB755@
M;,A-T\/PT.1%%Q">/WG9/_56H,B2QR6E]D+JSJ"SZHTMH'7MK3"AZTT_XFGY
M24!")BV5JW$ISE*^%#GOC..:5K-/NK<X>AVFUDOD5<_QP6CZGZ:1=[6Q+94?
M>[;*;DQ7T@$H4%8!P>#C)K+A-USX1OPEF&9$?Q]$ZWLU]F1NI.J]2:QTM."G
M8@C2DQ7X7&2E:$ !U.>Q!R*W:H0L@G4L,6Z[TW+3SY_? CU98/9W:A-?_4=9
M39+^,)*5 ;4O'*E*4L#)3@?K3YJ224'_ ) K7F=1+XY\K^2 W>C^F-1]3V]6
M.Z69B0X2PW;;8AXN(:XX6X>RG">3Y"EVZITU;4R;-!&FU._ZI_CM+_\ 2P/4
M6^6C1VC4+D88@Z>MBI#^./D1G'XG^]>>J@[[<9SED:VU5U;NMJ.:FM-=:)ZL
M7.SWBV66XPKTS'E.7IZ3(WLR9"W"I"FTY^'"0 <8S@5Z6Z#TU7QKH\77='56
MNWW_ .0@TDU;I["$A_:X4#Q!Y%0[+'U]:IJ0W"R35H:,S)\.U36&U/;PE*G'
M0C*<=P?2E2[RBU!\89TCZ=PQ;]'V5A3K;[AB-J=>;QM4O')&.^?^J]'HXXK1
MY3R$LW,,L$(WGL!5TRGV 6N>-N?ZA_>DW?:'5V$&AR#^8%)IZ#G]Q*\?^"C[
M5<]!KH1W97^5<X/(Q7+HZ7H'*D4([;,,IL+ )!%5'--$1GN]"I:L^5-@^"6L
MB">,-#ZFCD^,G-YX,(RDH;))R1Y4N+Q+)T-J>&1GUXN#$'2;R9ZXS;#GPI2I
MLN2'5XXV)'9(]36/YI[XXB;GA(8MRT<^M>ZBB,3)S)\7]ZOQ5O.C"EX'PI \
MA_>LFJ'TIL]7.2RT0EJGJ-%?;47T)Q&84&FTC@K/F?7&:L5K<\(3.?Y EKJ!
MK"RZBLMVBWR4[.TA*:D6ATKR&=NU10!_21GOSP?6M2"3AL?LS;F]WR1?VG9O
M2NI6-<:5MVH/$1_FXS9EM@8\-TI!/'D,FO)VQ<+7'\'M*L2@FQ_FV9%VMX@O
M[%I"< K1G!J]5NQP\'*4HRRF1QJ+HV%E4MV].G=Y+RK ^F2:=*<UW(M+6W..
MV+P@<8TU:].?_(/R2\F*K=E2AR:J6SD^$RJ^\R?_ )_W*L^W/UG8A:,1HFTR
MT+N.IU[I6P\M1$'MCRWG _ U=\/I,2=CZ71Y[^H-8W%51[EV4JT?$=3)4\5;
M&4I!<5G&<]@/4_2M+6R4E@QM+5\<<$PZ)LCL>;""G=J0L@\_RG&*S\/&665R
MRQ732PQ;G?HD'W%4W,D,D.@A 22,D+'8C/:NA%S8V4E!<G2"R6MBT0(-KB,E
MMB)'0TA).=N/+/G7I-,]M:1Y+5OY+FQ^/+91CRJQ^RC/Z6 6NDG:A7^X?WI-
MWVX&5KD?-#JX[=U#]*52N";)8DB6V1AM(^E6AJ7 P7NY[99@X[#YJA2Y.;X&
M_;]:/(K!MA0&H<9+>W!":1/3J"(C%B9\H2HX-'%<'+O AGD%KBCDN".F)_B2
MR5#T%)BOJ.3><I$;]6[JW;D0W'$^*[**F&VDME2EC *O(X K,\OA1X1J>)KG
M99S+!SSZ\^^M7V?/F;8[*W=WAI;_ (:2,))S6)3C:>QDFERRM-UAMF?/:FHV
M*:3X84?X;Q(RG'F,\?\ =/A].,,2UGA@*_[[;YBTO$I6\W@@G.,C&?R-:\&I
M1RO11GE3:?31UC]ES72-9]'+1?X,A+5UMT9%ONK:NP>:2$I*A_2M.#GUKRNL
MC*%[_#/6:=_)4G[79)Z.I[EACF'=H3S1!^4@D GT(Y(_6@A;)=#DU'L&M1=9
M+@\VZU$MRU-8PE2@>U.W?)RV'\B2>$1-J36MQN;0BNI6&P2L@9 S]:="M/DJ
M6R<CG[[14R3/ZHW(O+*E-H;:'T ';]:]#HL1I2/'>34IWL&+0U)=0E(2=K2D
MK0/+([U5U$XQ?^2S%;8D[Z17'D6=#TL%(2?B5Y)SWY[BJN<K@F/*Y+3^S!IM
MR^:^M@<+CK,98=5AT*WHQD*('!';ZT[2U[IH3K+-D"_SF$RB ,A. D^@K?JC
MM6#S-CS+<+4$X)('(II3LY>0%U[RTD^BA_>DW=#:QRT2Z00G ^:ET]$6_<B8
M63EM!^@JR6%Z!:^H2+H7<<]L4*[ 9IW&CR0.BFBM)!]*YK/#)SP,DILI<(/;
M-2DEP*SAY$4OY,>53+\ ML3J42PI&>:5]IR7LC+JWJ%%OLZGH; =D,99<*O(
M+QA(/D<BL?R\TX\&UX6N4K/J92SKMI^Y7&UR+C=FFT^]/>",+ 5O;&5H&?G4
M 02!V!%>?T\DW@]M97'9P5HO6BKM=94F8A*VQM2A+3G[OQ.,?#NP<\?E5[;&
M/**L:W)L%$=,)R9$="_WOCKVH4O.[MP/IVQ^-6'J&@8:?ZB]?L-VE^*+A^\6
MRE_:AUH_(X$\84/,^AJAK99Q@VM''&9%GM6:;1+BAQN. XC)_P!P'WK/</9<
MFMR(YG69YU*TA9/D0>:4FUV):P1GJBQRX"WI0;W-MIW*P/K5RNQ-I"I)KDH?
MU4L+MTZG3RZ2%O.;SGS'T^U;D;'"O",#45IV-LSLNG$M.OLK00&EY21R",9J
MLTV\LKR6>$%MIGR(30MS#+;96X%)6Z>WT]*G"0N.8\'1'V'='P[?!N=X>N-M
MDR0M"4,Q?B4T"@$E1QV^U:&C67E%#R,WC9^2T3Z4I</T.:UHLP;'C@S\<@)
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MBJ%>NO\ K>-G3_/LV]3J%H-'7196WOBWC'OK@OATVULGJ9T]L&M41%0_VG&
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9&F9%;4.\1UMR.!CL!1*3)<4)_=S1 G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>cogo_0034.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0034.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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M(M$?K\C]&!(.2$F@^0D4YX*_3^-&,LU0Z@JQC&U+<6AHWE-J\-73<8J*.?0
MRU!$]:3ZU"12EIGH#SE78BCCHF.V#=\<(N;*1WH)+Y.^1JO*IR?WA1)CJT$
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M;@'FR#D?6AQMJD7?34UR8,:REVN0S&9@!*DJ1RG!ZGYUMQ4'#1@>7&46V>>
MVA4ZWXO04R$HDQ[&SX\D.H5R,LYSX9'3*R!CZ4W!XL)9E-]?[&#YGFO'XTH+
MM]?R:^U&/[T5%9/F&^,?ACTZ5L;25]GE8=-(=1=V$5QQ[<&4&N9P4:/!\)Q7
M8JJ$$$4E)4@<N,_.I^0I+5@*^B1^E5]",]JEZ%)VQCK)I\VU:G.@32[V,2*J
M\%S[R?SH["XLU 7-_A_C42&H0EO8:^&A[.97MPRJX+.,;U+*LHVQ5LY/+\JA
M$QC3!R^M\MS85FIFM$->X:JVGI_> H4.^"=*201S=:(4RG^/4E'N?_9"^P\Z
MCP7R\D@*6G&%)]0:Q/J]8VF>T_Z8R_V<H_-__#(ZW=1W"^(A:BG?]K:<.$(5
MR^\K21A*CV&3O6-M0O'VST&3*W.IOVH/;_I^SWU,)K4JVG?=DD,MH>QA)[=-
M\?*NQ8,V-U0V7'/&_A ;K;0,Q44--WY:K60$H#KPYU(&Y2%YR>W45:6*2=\2
MIDQ2G&KT0,/2,%C#L9Y/CM@E"E2"I(VZ= .FU-6">5<:$2?HJ_P1MOOM]3>F
M]/1'EN%U2N9G)4E!QS92>PQ2)XO2^X9@\J4VHQ+!@QWVHOZUU2G/B SLGU&:
ML8\EHGR$N+LT]P(TMQ/M6LE7_4%JEBUW.WQXT.2TRVW":MC:$K9PH'F<=4M2
M^8*&<@;XK>\./LMGS_ZCDY9>*+:U,,23^]3<3;NRLU3T+Q/V*!\LT8MBRAE)
M%<S@GTB2&EI SA=<@@E*5.>4#<;U'R&^@:?MLEJ8IQ3>Q5GI4NQ22NR'UV2+
M.M.=L4#[&1*AHK&&BW;L@>7P]R:YNSK9^=>#C9/+T&:A:(;M -.<S.='*-C4
ML5%V>HGF<.?2HZ0<7;(2]H"[BT<]*B4K1%*QBL9N"1_JS4+H-DYVWHA+ ;BY
M:7KCI-<AIGQ';<0YR]26B/-65]8P/-@4H]HW/H'DKQ_)X3_O:,R2;'9[XZW"
M=:8=CO+=2X,??3N/R!K \:6U9[;*HULD[-PABZ3B0A,U#(N%D;'NL.$W-+4U
MCFW 25@AQO&,$X(Z9KTOIQR04I/^!.&7DY9^EX?^?^Q-:NTYPVBPG(,5[6SC
MT.,E3L41$D(>/4%Y2@".U!+"EI-T'"7UF:]+TTG^EE2:PTM9;SIZ3"TRVY:7
M'FREV3-N)D/M@X_9LH\I)&1E1P!TR:=X^)TY7_)5^H>/YF"/'R6E^SO_ % _
M0>GXND'R&GW'D1&4L!]Q7,I:U#?)/RR?QK'\Q>YH#Q'3Y%JZ&TY*UKJFTZ3A
MN!LW.2EM:CT;;SE:C]$@_G0>(O5FH _4\ZP8Y21T67!B6NV1K?#:"68C*&&@
M1N$) 2,_@,?*O0*XND>&E+GM]L =2_XE*?O*%6%M6*3:T.HS8#:0#VJ;(:%5
M(P.M19%!5H]"4I=!)^*N3#H)RI""<'MG-2B6M$;)ND;F+9()Z5-B]L#-?*!M
M3A3T(H&OD).F5!S&N#LTLY%9Y<E &_6HL90VF<K;"B",XJ5L">D5[*>YIKI/
MK1LJQ8K%>Y5DCTJ&@X/9#7AX"Y,ISUZTMH.]C56/T@DCUKET,?1*^*OIMBF4
M*_4\N$'F\5(6EQ)24JZ%)&,&N<5*/%]$QDXODNWU^AG#7?#]SAUK!-Q88==L
M%S5^J=4G>,[UY%_/&<'N*\SG\;^ER6^CV7@>?_6049=HB-:1Y%Y@MLQEH\1M
M/*T\HD<H[8(I,L[BU3-W%*46W#3*]O<7B/[BJ*[=PKG.''6W"7%I'8Y^M/\
MZZ?1;>?R>-.6P:M<.9 2Z%I4VIP84M2B58]233,6:3O9D>3RF_[1VSPXJ.%,
M1&]T)475Y^T3MOZTC++E=B\?MJ(=Z!X@2N%EZM&MHD!F<L7%J"ZPL#]8RXDA
M6">AS@9JW]*A3Y&5]:O)C2_!OS3>MK-KW3<:_P!FE!3;R07$*P5-J[I('0CY
MUM.*>SRSN.@=U*/[TCZBB6E1*7R.65$-I(]*Y L]\ZB#D]-ZYH@*M(J*FUJ/
M4JJ PB>^$GY5*.FZ17TN8I,UQ)6<I6?RKF GL::LG-R;$4YRL).:ZSODJK*_
MO#\J&PRY=2ZU=B*#<1\$\^,?*C21SD['4*^)EV_Q)#^5*'3THFD@')M G(<Y
MYR^7H37?N)JNAY"2"Z<CM7/H.*V0MW2DW2/D=J!AKL:K4H7$ 'H174AOP2Y/
M2C2%,^I2I]:66QE:E!('U.*'IA:GI%/\3N+.E;UK%G@/9(INLTM/3+H]G"8A
M9!!SG?96$_C6']6EZF%N/Q1Z+Z'C]/,E/MV47K6X:LTWS+B,N2(C!P%!).$C
MIGTK#CDAD]M[/51YX6W6@#>XHRI+A5)8Z;XY3L:<E%*B'G=\A@K5,J:ISD9)
M\3L!VHE-1Z$SO)V>(DAUUU?.DI"1DD]Z7*;D]$1QI)@OQ<U=>H^EX]@TZZMB
M:N8S(;>;^-"DK!2$Y[YK4^GY::BF9GU3&O3>CH/[-<RXQ-(0IERCJBRKJ@OR
M 4@'QP E0(&P)QDCYUZ&"Y'D,J:+&U"2[)2I)PGF%=*/$&+M"S15X: #U%#%
M-RUT#*Z%MP@[[XJ9TF=%.K89:)0E3#O,,X5M4(((W0WR*RD$X-==,Z6T5;<D
M_P#<'R/OD4>J%\79!7=QPL/M%1Y0@D"HI!;L!.=?K44&/Q$OPCIERPXIMT^1
M:J**T*G+9+P/TCX 2E:M_0FIDB%(DX#4GQ<.@D^IH05LFX[4CG)0G;'I7+[1
MG4B'O,2:;@RZ&?(!N>E"R?DCU?\ N VZ$9^5<AOP/;I<+?9(ZYU[G1X,0'"G
MI;J4)SZ GXC\A3*I6*[=!K9;6FTVEG4,AQSWJ8V%1D<NZ4*'QCT41C;L*3RN
MQ_#A4C$%ZX?/6_BWJ7C"YHZ8ZZ_JB! 3J%$P);;9+2C)84UG)R?"R<5YSS<M
M891/1^!ORH-!/?HCDB))CI^%"202-R.N_P"=>;7M?(]A7-44K=]+)][,IR"E
M63U&P-6%-OIBW!+M'I<=B&R5*:;0,; )%2K8,DO@@I2"KF5R<J <C;^--3X[
M$/2!%%JTI=-1VZ)K27(8MDB4E,I3(R[X(.5%(^0'7TK3^GQO+$QOJ4ZQR?Z'
M1OA]9X=FX:Z?DV0.N1'$F1%6L$*,=62V3G<$HY20=Z]/"?#H\MD5A2T?TO;G
M6FG6VI8!4TMU)4E*\;<P&Y&>H%6(UE>RK)4F =KXWZ8AZE/#CB MG2^K6^4"
M/)=Q$FI.R78SY'*I*]L!6% ^4C;-=DP-ZCIBH9>'>T68IO)P4E) .!G\\CO]
M1M2:XJI=C+Y/DN@QT.GE8>)[D8J$2P@?_P"#42TPEME7W08GO[_;-1R++QJK
M!^[9\-[]VCCT5)+W ER#[G\*DXM6T:HT=)M*(4QR*'D(Y>5>/Y5#]S"BDD19
M7$5*/N+:2@G (&U,70F57HF(\4MH#BVTX(S]*ZCDR1@OQ6G0Y(Y0@=?-M2Y5
M\Z_4;%(8<1^)?#;1MG<?U5J&VVILMDI$ET)*D@9RE'4GTKHXG/K^3I34?G_
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MX-ZC>T7QFTEJ=UP--MW5J.\3\(:=):5G\%C\JG.N4'8G$VIHZH>ZP_\ ./\
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652"7W[6OI<?_ -+O]*[TT=ZTOP?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>cogo_0060.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0060.gif
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M;&FMZZ -V* -UGH..GNS3L66M_4.VE /ORFN3EB+J- )E; )J= )R#@!$V
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MHXH'#S/9M)(0F/T* ON*M1H0N_L:NS/  3, !!A\P4!PP;JKNT>@!$;PNXT
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M (XA@G2%B'PL9!K!"&UL))*1T*H4JLB-*$9!O\8%)PI8B,((1K"<$?Q"'=A
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MFBO@31"K096+8,0(16C$#X6H$14_\I&4\89^NAJ%)X)E@OV%0!/T" LZE$7
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M>( '?8J'?0"&*" !$J@ #1@-TZB"*<"Q(""!"X@ "K" #_X0.27H*R7P 0P
M BO@@R90GU @!5+P R4(OQD  AG8-!'P 2%()29K*%!(K%R) LV( BWP@0B
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M*J@"(X@Q QB  PB"3H@" 5C1$9@< PB  @!+D!O%P%$$1>@#*P "'BV
M"(B""2#2"1 1$!"  H" #2 Y2.@>20"C)O4#(4"%^/@&F$S)E.2%7> %J3BV
M+UF*0 J'*8&&;W &IRB@8*B%<!&&9^#/9.@2-W$&81W0T;S&V(L+=YB'J8LD
M0 %$%W*,?G@,"HW0WFH8?.@'Q6B8Q;"02$ [#1 !E3""(_[X 1$ @0OX30]P
M  6851S[  38U KX@2$813;X@T58!$6P A_P30,0  .(  T(. ?03<$3@B-
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MR^G"YD'%F$F/SB4%V/ #@.V#@OD#V/0#/(!)-4@"$[P>P+21$8@ OI2; "!
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M9P8H&N)"+C0#.:S#.IPF-O90@L;)/=1#N-B<-P"#-Z2#/@ #% P!!LC !LB
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MX,[RK#J$UIGU0^K2P\\2!3T +=!N#SUXPRO 0C9H@SB(QSQ  H1UZ$X%P1%
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MASCL@ 8+\-<B >"#*7 N")#AY/Y#%<1)S#E(!GPY A*4T 0^$# 1B3#A)[*
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M5Q92-08SPL$,\$DY%Z3N!2CZH/X&-G ZVFD8,4 !6@<XN*$+.[@!MQ$*  F
MNS  YASGDD!?)UBA"4UX[!HVVFY%_('=5K  IU9C:$B;QE,S]/>_%8WO/,R!
M#J9:F:1I .(08]H+.MB!#M+@AC:400YTV,,A3-$+;)B#&[FX13)\<9;OYB?'
M;W(&R/-WC6<@(QA$M<4QC/$-<( CJ\;<]9N8D8UY2&,9N%C&-%Y1BD]D6<M=
M>$U [T#T$<?A#G:(PYAM< ,5,$"1>P5 !#!*(8P^G7-+,+Y?K:YN/.^9W8^T
MP -V\ 8T0&2&J"K[16"$]E!5Y%2F@G2D$5[IHM]=!SH(@QO0'P?2J,'=IQ#F
M-I)Q"_YC,_Z[QF4J'*&1['!H(QO72 ;ECX''\B=_E.$6E*$ #Y 9W($:I $:
M<F$7(J$*F&#GO("0TN -X. -W"#VT@#,P,P.WB#;;( &7H !N@T"&JN^FNZ#
MV*SXEH QF@#K[HP/UL 0L*X)E* !%* &X  ,R, BR$ ,QFX,Y, ,^HZF#NWZ
MO@_"5&:UXD[\[([\OD ,WD"@! H.\J -V* )3.$5*N\^&.^(XD<IWBD<HD$;
MT' ;L*$!H8'&\@<=P"$<C.$ OV$:J&$=RL$<IL$4UL +_) -?$[H[B .""GV
MT"_O!A';N$#;;J $$R#I'."3D&!"D( (AL\2BZ_JJ,X*9OYP#=9 IY8 "'2P
M!EI$9F;JA<9@=58F%2T"1BS"%(W0T+ O%=]@97"*!EI+![(M#<IO(;@@##@B
M#MZ@#:R0%[T $%(!&.YC>GZ-R:2*J>(D7M"0_[(!&WJG7080'0@P\\2A :4A
M%02!"?S0RP!* ^$ #FC/ XD.]M"O"[B@"W  !U@ !@YJKPS ")@ L(C ")J.
M")0 HY; ZC1J!@V!#PIL#4)1 @C@ ;J@#6[I#"(L(EO1#"J"(F$)^R!L9;[O
M12@R#W2@!6X@"LLO#,R/!W[Q';/-[G2Q(66C$&BC:;YK/WYA&L '3N)D&>IA
M&G72'=*A)].!'<9!'+CH'\3A&_Y2H0_^T/7R+@[.,0/AP [L@#3VX [R#BK;
MBPN^( QX( =:( 5,< #L$0B< -PJT9,J\8,2PPJP;J<,(<\*P1">;08DH  4
M()58QQ6Q;R+U3>Q@QR(I\I:^C^THH@T.S@5 K!==3P?<@ =XH$: 42LATS3Z
MS@[4P&9X(:V2*WK$IQB:YDWJH1[>H1[.X1U(\QW,X1S,01W201O#H1S^ 1A&
MH3%<S_4FXBF;LNU&*RK!;") , RX "LU(@=BH 4,B@#VR@'$DNGXL1(M\05C
M4"T+K \*@=T,(10UH  (@ ?)P-_R4B(#$]+D8-]LBB+83L/H8&6$D L2KA<W
M0@>^0/X7%S,,VF ^10,.6J0VX> ._B 1TJ(MX&>J2 ]\BJT7/K,>N@$T#=0=
MM"%KS"$:ZJ8=OH$80&'GQJP+P*!D6@@W1RLB',TI\^ -/NL+6B4X<^ &8& !
M'. XQ=()&*L(&.O9CF\@^6#/IK,/$!((.* !!N !TJ -8(F5OG,) U.&:HHB
M^NX--K144BL,YD ];V 1%5,'?K$+@'$Q6R,TYA,=.S -L# VNG!8ONM^ E0I
MX*= #?1,Y^$=NL$<UN$;O"?U#,$/Q[$+2N8#X:"T',T.,BRF[I0.4N4+1+15
M&+-$6X %,F"1'& &D@ AQ>WX!&RG\*P0"N'.G !')4 !&OY@!^*@#6@)=EPQ
MWUH15$^%91@-#URD[>B@%E/K"S3P!FX !WI12J?4]=H #.93/D,C53 0'>U@
M$13A%%YA+&QAQY9!&J2!3(O!3)4U-+>!'=J!'E[!$-B@_&;S#5YH YGR'*$2
M*O< *B_L0V6)55BE5=I VW!@!U9@D1I@!I!@#5CT14$)!M<MS_@@'Y% !BS
M 0J@!E*+"B.,#,: 13*+18)T(E,13Y44 Y>T1C0P[NIN$7_S'1TS7*EP[\K
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MH 8LC?XD>< -XL!]XP $VPYGZ4!/]<"T2BNU[* +5J!TYD#04(1V-"(,6&
M!J !-(!=_S%>&4.G[DQV:= )B$ &., "5J &%B(#.;)K40IX-:R%6B@P \ZE
MYC<U/HMUZN %4H &<  K*RQF*$)4D# P7R1O;W93&>$DCD%:XH6:D*(?[($>
MPA<T^Z$:!"$):(!"W5$KVP =G?@V435/4\-3O  %5( ,4#%& IA5QJ &", S
M+(!=TZS D" )0LD3L8X3UZ!V;S<#5B 02N<,O+:D:"EE@+?M:NI%\"!E(.UK
M455X-; -SB]V5& !6L &T. +0DM43(.F:)CM+E=/,S ."OXA%7BA%YPA6IQ!
M&(J-%OJA'_@!B _7'F A3GV._'3 "IDR6V^V[_HT#S+P#>S 5$'W 5*@"^Q@
M9/( =N0 1<(S5&H@ 1S <F2@C)/ $)# ":35$]O2(->X"2;Q0=B@"!@@!LP@
M=4@%(D[*5 F68%7&;O%M#D@KBD<%-=H _2C"9U%@ 5[ !J8P>3_%D8/4>&_6
MM+A6#4BA30 WG(SH%OK!<,/7<('8&TXA"2QM,2DW6YN8,.6 E4NX#M:N$5\@
ME3304YB4PWKY8H%9 1S  CC@0<S8"919F76*7M> ZEBT!BHP#1Q  ::/5$X'
MA"/"A2R"15P$G"'M1?[X0U$C-?YJ: STP L68 %8P)UE9F7X+IP?N51LENU&
MJP[H0 T4P;:$01@RV1>8PA8,MQZ$>)3#UQ1D (,#2J#H<SX9&G/_.%7G0 QH
M0 5: (MCV%295&4Z"Y@-A@-2X$'*N,#XVL#>\@\*#)J30 WR8 ^*8  ,H OP
M (M!V&0@8KV\6:V5FJG3VD5<))9-6 ]N@ $,^0:^8*9N2:DA+.#,<^WF0'-M
M=C12P1>"X1B(P1FFH3,+5'P--'P%885;@ 9TX!S-&DN),4OGES#G0 =<@ 5N
M  PH,A7[CA5IZI=7I0UHX*XC1(R5V08]45([\1/5( /WH <"  )^$(6%#C5&
M5:?;[OYD1F6/Q[FT]*#M]I@\)T(^3R<,\H &&  &BGH*PY.NBW?M+NPI=3HB
MKHTI#P$8:B$8XLD9?,%GM*$;Q#=EP]<:@* &7!47;4 '%KJWB=&)0^-%N. &
M8B '6F6F6+$,B) .B%0.:J<-;N"N'T2,C]D&&8$1_B"[R1H+V2 " ( "L+C#
MX*"6RI/1* *$0?BT<%.G;3:UN-:GN=8-]( N5, %N&#[O%.;NZ_[3"L.D)R%
MX&!G<^2V@B%[T@095C:@Z>$=A)@14J %=@ '<L_"=:#MSCF5[W0^-XP'7)4+
M6D6YC7!EA!N<>[DUHGM=(:0&C+D&#8$1]J# ^&#KMGOH\OY #U8 +#& ##2R
M[2[7:V69]H8\(BX[ED?5FR$M-6Z)#L" "[RR>;E N4&5"<LV9X71I69:_>:
M#4XA>19\G*2JS+?Z,ZUA$%(@!LY5TVB@!6H@!5B@"^C@5INX3\5 !V[ !G(@
M"%FQ"&G*SIN[N5=\T#D 0A3UV9B9F24U<#8U5?>@"QK@<%: %M6:A%&FA="1
M*5-K5-W@1>ZWO?WT^VJ*WX;6!E"  >Z[;5>]5.5Y(W,:EHW\O6VO[3X"&'AA
MP8LH>\P4H.D!%F; N*-P!W*O!!5@ 6Z@-32P[]K@"W*@1'E@Q$,KJ3F,,.%
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M#&:4XRGUZ$8]M%&/6"#!:S;@7)92.#\4T !*+4AA_A[0!3<038*SR4L9N47
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M>E(Z.A.$L.'-%] P!CWH*+$\D8E-S^+8<?) #ZL2(JO:XKT\9,RR8'#!#>8
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M0L:0DSJ8P0LP8,$;\)"0<0_9.-,BU8U_DUX>ROPNA8"%-];!C6MP(QGI<$;
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8)A-F0$(9PS>T2'(CAV%XX 9[4 T! 0 [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>cogo_0033.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0033.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
M'@   @(# 0$! 0          ! 4&!P(#" $)  K_Q !%$  ! P,"! 0$ P4%
M!0@#   ! @,$  41!B$2,4%1!Q,B810R<8$(%4(C,U*1H6*"DK'!"313<M$6
M%Q@D5%9SE*+A\/_$ !L!  (# 0$!              $"  ,$!08'_\0 -!$
M @(!! $"!0(#" ,       $"$0,$$B$Q!1-!%"(R46%Q@0:1H14C)#-"L>'P
MP='Q_]H # ,!  (1 Q$ /P#Z"B;'<20E>Y'6D*J [@I*XYX5IV&.=%"RX*TU
M"E0D*S5L4!2"M.*PG!/>A-<DL;J\M1)(.])1-Q^4VVD9(YU*)N%UR2.,8-&@
MJ059T%;3@&-A568O@804%,PYQ\U41[+Y?22\>E*0>U7%9K=.=A1 >!0" *9%
M9MCC#@!IUT4L N[B4NX.<T&%"&<?V>?>FCV(*[(H"<X3UI\A"0%>VU5@,5+/
MEJ'M170T>Q&K@=N X^59=0VHFK&9R&VPY^S&PK)B;?9>_I']C("$^YKHX^CG
MS[)%?MK0KZ5>RGW*TX?I0 64A^U2A@.I3GWQ5=%ZR(&N5M97&4IB7C[U*HDI
M*175Y!2XH%15OS-6Q5"T&:>'HS2RY9!N-Z4!@^X0,=JA!9*=XE!1'*H%=AVG
MI*'"^TGH,9S29([C0I4>QE\,P^G(XN]5QQTQWFXJB1/W6$P$^8X<A/(#)INB
M*5JS0]>[>&@^'<C&<<C1H3U/9H5KUK:TJ#?EN\0R=P!L*91_(CE0RA:E@/*)
M/$TH' 2YL5?2FJA4K/;J?/(>1VSB@Z"DQ'-7EC..M&+Y%VBRS[3%GM5D^R;:
M'H6*2@48NNA#:B!G[T:"N",RI!$]*4[=:HR1M471FD&,K*E>I6=ZHCA+7E3B
M2:S84E&.]:HK:C&WN9(K\,VI0^U7797MHK?A]Z%"T,@GRU9"CGZU4FRM(_39
M4B.P2V\K?;&:6;? \7M(_<'"I(*CDG>M$>BV+L8V X;_ )TLNPOL:)<..5*
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M.V:#"@&W6<7><E1SL.E2K*YW7 _3I8L@J1Q<Z;:BM;J#H,4Q"$JSGB&U1H:
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MU;[ZPJ;;I"'$GYP#DH]B*CY8LOI5=DB0,JP:B*W)F,I"?)-1JB1;89I4);F
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M/>I0L@_@[U-HMG[@%3:2S% !6D!.^1BIM(F[->NWG@NU,<2OAUH:4\<9P@N
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M&+Z7'\CHX8I8')>Y#OPR:M<TAJC57AW-4XBW/R67F4\60VXM)&<^X'^5>/\
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M/W>WP4DK2A44*SS. D_U5_2NK**J-]',@_F=&^!:V;9'*$ %;>=B.22HG_)
MH3G\UL:,4X\'/7XV?$1-CTK;O#RVS"B9=EB3<$H5@B,A "4J]E+R?[M9,DG!
MM?<U0@II/['#107)636*3LV1Z'\)H)3Q ?+311 $NJF3%W!Q($6$5MQP1DN.
M$>IP'H!ND?>D;W,:DD1N[3 I:OK5<^^!H+[FZQ("BISH-ZD19#13R$MN+SD#
M<4S(NBLK[(-RU"TV03QN!(QR(K/-W(OBJAP3N[7<0&$VZ#GS"!Q\.Y4<5>VJ
KHI7Y%TFV.1;:J=<7<.+W2@\_O2R7'(\2+NK*U#!.]9GV7I<&'!]:@:/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>cogo_0061.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0061.gif
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M8XIQ;)ET:8=X=IEZ=*5L8ZQ[:Z=U9K-\;+9Y:*9]=;5\<K5M:I-<8LEZ='^
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M<,L"=7!=3V=\0T8<Q9$+<[JGOOX!3?"3K?KULG>T:L40AWN"EW1(#.V!#OB
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MT+F0U8,F BP  S30U4V !5DPUVRP"(I@"9;0RY80W,;]"9W@"1G>"<(=W)N
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M+*628J?+IZ :;ZJJ\$GJG*S6Z\H77MZ+K\NSZ%&KK6BH@?ZK&6-<8Z&& (\
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M <$*5^A"(/;F",)@8H<T' 4^\^D@!V&2$ZI0Q;XBM)C':.:@"&6B0A8*!S[
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M@ T(@1BP F=U \^<238P)2E%L4M<A$QXA#]8 RGX!SXH!E=8MUDAM3UMKW5
M.#/!M)=XAF1 !EK0@SP8T5'4B5(S.A+%S=W A8IL2\JZBG/02*AXM?JPU%[8
M!7O%SNV4#TZMG?M1A_&D!S0  1"(@1Y@TE,U6.*)@;5-LQ'8  58@ [H@",H
M@A'@V!$8@3"(-FZ -C"HU2#X@1'H 2R@@058  U8@ V( 2Q !"[( DF$@_%9
M4U)Q@TQ0A$#@ BR( @HM!BTBW?Z=W5!F AHS\1&H>89G0(9AL(4]R -7V$)<
MP%;;73?;R%&)W+I<1*\7Q0JKS;UV);NJ, =S6(]ZS=&OZ*-P"4]<X[+QO <X
M& & 9=L8@($1B-M%BMLF[8$0"($-V #&#0$U\ ._G=@1N ),2 5NX(91^(,F
MX((F"((>^($_0((08-P%>-B Y9IY7%F%X+DW@(.(\0/'E (_X -AV#P\A2Y<
M^(9TR*6#E!S_ZC5D0 9;:(79M9);4+>2H(5UPU#;Y5V!LZGV E[A_09<2H=W
M:!J#"X_7N06OY06YL)F]I#1O30EZX(,1^ "_[8$8F $7V-Y%<@$AZ($/X($C
MF $/\/X %U""18""&'B!)3 "( "#36A?;BB%1# Q/V""*8B"01 $!PV!$>"+
M(!X"--W!XIH$1%B#-% #-Q@$/P $0.B"T-T#8+!=7!#A6D"&C?PIW D'H/W6
MH<W@#4Y:HH,N$28Z#SY"QD% !6P6C#23;\@],)S+;($&7NC:6'@=G?H6<'F3
M^? &<%$)=K"$& !8@ 6"&8"![14"[HT!#W@!+/@')5""-; $4  $/Y!9(V""
M2NB$R> &3I@$=U*$02#C0;"$16@#+'"#R6V")R"")TC-D;,$1U@$+$B#-W #
M/QCC2 @$*A@$8+ %5\!=/Y[(:%C&=("[T1F=W(F)UXU=//Z@71(^.G:[JVO]
MX*U#!]OCCNYH-3-Y(-M;!]Z+8;1C:%] FGR=#[[TAO 43VJ8!V   H#U6VJ,
MY46*6"8%@B"(@240!$%@9C)NA$M0A#^  B^(!$_8!O<%L3%EYDL@!#\0A$MP
MHDOX@RNX53#X$X6(&$A4@S=@@S7P@S4(A$@8!',6!J*S-UOX1%X0Y/L1!W'P
M+R'I-68@6EO0@SV@F=VEI0\F.MR4Y"+C+ ;JC@@TF=P3NVBAR^2=8;2K86^Y
MLJ80(6^BAY3TAFFP K5]@1&@QNZ] BM XCXY8"A ZF:.T$'8032-!%*8C&WX
MGC'U V8FA,S.;#_X D)(-D2((?Z%H*KQH3PU:(+0'81(((0HL 1[L[<^MMU
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M%C.:<0WC,$E#[$#:5YMV#6Q\B$C$4(,/@E*\@7(M7&+@CT@#L3Q">,&B(/A
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MSP-&7RV@6\;D@Z^LVT6,@XX8XFV\@X:50R_T@M;%PBXT!(4(!](@S;+4"CU
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MIW_:X1\Z0TVYPZ#A%%*"0^_P"%.:X(/B0:P0"87@HR)=9:UHZ"92@W\RF"T
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MD/A"+<@W*X1""M9"@SP$IV!*SV&*V3>&.$R)IE&#77>RB6A\@]2S,AQ#%7Q
M!Y0Y#!A%%?[I%RQ"X2V"G/"]^#_"@_]!%Q3*O>*]XC^!'ZR!)> #/$0^.<B!
M 0P ![1 ';C#.'!^-12]ID4*0%@3I\Z>/77JV*$[=PY=.&O6F"$;)LS5'EO)
MGB5CIOXQ(S*-'I$)L^4*%[-OXM#5.[CP7+AOWZ Y0\9+ES%>OF[EBK639ZU;
MNI)94Y>NH+U[1>G1LU>/GCAQUZY1LS8MI,B1KI IRYI,JS0N'C9T< $C!A A
M6*Y<X?+ER]I%BQ M @3H3]T_@-IBX<*E21 F6?Y&B=+$C;]\\-J1BV=N1X
M!R"<<:>.F;5KR:H%Q5QMGL&"]-"%1M?-8;2-R&:U:B4,(T=D&Y/%7H:,MBM;
M)06*JY=.W+F7WY[%7*9KEZY<M'S*XAF+E:M<MY ]"S>P(+ZE]>X=55>O'KJG
MU1YF'C8,ERU;PI3%5H],6B@8'SJ(@$%V1A A0K+L3;OER_Z?+5NX^(^__[C(
M(@LA['-BL"W^@4*-;/B))QYWXB&''%8P"" ""!C(09G,O&.FFLPP$T>I@M01
MC:%PPADQF6%2:^6BV)YAQL:,E('M15MD&>:99U"JYYQQ6/PF&G"D<4:7)7.J
M)1?E0N%)EEIPT26Z@=PIZJB"ZBEJGM"@DBHS]*Q"+[;,,NK&F!@Z^,"#L>@S
M2P@DF+C""BZN # +*+0@L, KFD!PB"NR:**)+1S,II]WXFD''GGB 2>>.3"(
MP(0$ &A!F7&"JN:;:C*JAB!UUDDJ(9;$L:::C2;:HQ5:8HLH(QMIC8@V663!
M)9GIQJFGR)>.3'(X77"9Y<E8HOY4#E<J:0,R'>ZPX^X>:.VAI[OO'J)*)(J$
M84V]C)*11AH@.B@W!!="&"&&'N1LPLZT##1P"RT JQ/0(()XX@HFEI "BC0L
MX2>?<>1I)YYT)*Q0AP@B:,   EK Q9UGJL$FLVFJ$:<H>]CY,K26K/GQQ5E<
M<468UUI[)D>./AIFI.@RYJ[(<**)!IJ8:-+E%F-QW6E*7&_SZ)EOQKD.NZ.F
MK78II\)4-9ENA7E%F&%BPX:996R4QA<<0O"@@W-=&.&%&'Q $$$BB+A"B+2(
M,#1M)I@@8H@@FGABL"6>4(./>A"C<$)XTG%TEQTDX)!# $YPI1[P0L8(':5*
MI2=%A?Y::I%55UK90]>4-[H1W-IZ9&8ZW8ATZ;>8E"0V%YZ5>[(66VC!1>CI
MZG&J2Z-1[.Z<:QZ:ZNEN3?;6:F>:8:8]'$2 +]VP1^@AAN:;[T'Z(*;'=VU#
M[Q.""2J>8"(**03Q)^&"&X7''4?I,(%A#AEH(( )YDC5FC/1*=6>==:97"&'
M&M<%F))M$1V4M48CM*(-CW0A(J>X8R&FLYDS4L>D\MSF.;&3W3)^%(YQ."5%
M]D"'T@RRG= \!1OAX8K+NC4,CZRJ&M*(1CGJ0 ,1>$T^Z(J>]'KP AQ.;PA#
M(,(3Y-;#M@G!;E*0PAJ2H0\)P8.)\,#'.MP!#W+8@&&%@_X !![0@ $TP SM
MX%0RIB&.+X4P'>LX1SI %@UI2.1_>Z#%:VJ4LA]1+"/#*!G53J*.? R%12YY
MQC*&4R5BW<(6M[@%+H:Q)&0XXQG2 ))34#(J21*$.]ZY!N-(1"97J/!,+82&
M-/K @A"$X&OG&H&Z=EB](%P!;4QXPA/F-C>ZV6TP4<A&/N2!&'CD(XKY>,<Z
MY,&*%*@/ H5[P ,HT( ".$ 'TDD&-3I##^NHPQWO0&/E@",16^R!)$)K3>=^
MY*)A3$D8HL.2.$H7CA\Y8S9+DF#L%+D,9SAR:+F)I$'JX0Z54'*$XJ!&-2[Y
MHF[9 A;H$1FHP"$,.:A +!UX4_[87%"6'?[@!ZQ,VQ5>280@$$$(0\ ;]X@
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M80$+D/=>Q9;I$0@!>VE!T!7P-84>^. '/K!$/_CQ#GF0U+$+WR43@6V#"9R
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MQ.$9< &J'.F<TJ$YKW,O^R$[F?$HPA# OA,E-P8TF*(-XV\ZZ.H9T  %(C,
M!"  !@  $J ,7FP<[& %,),'QC$&-)/XR'%LUM$#CL ?4K! D])+EW(?\H$,
M+J $-.#5LB]-LP_\1/'[?- '%Y0"#, !)&!#69'B*&#*5O'B(& "4H ,;@$D
M]<F#T&$[K&$D>!%(4H(WS@$A\"<[L_._C,(,*?4,BY%+EOYB'C356GC'*;X!
M#UJ@2)%T)@<@ "S@#%P!',9!&9) >:9T!EQ 2D&S!V; ,Y4 &Y322Y\23)&2
M%EJ@0=$4!6)332?T$^^1[5[-!!B   K@ >Z+ C9T O!.+"W@ B8 F0[R 2:
MXUA!'++$'DP$':KA?Z)#456"K#ZH.B 5.^VA&/LR.4.R7<70.Q&3'JXA' K"
M&<Q !=PG -Y3 0#@/0/6  ) !>* %7C*'?8@!-R$!VK5,UU@!D232@/4'Y*R
M'[HT-7<53.]A#$H@-I'5$]5T9$W@ F:S!)+) 0A USC+RO".%3,4O\32((50
M CC  EJ@"NX '?2!'KK!&L8I&/Z8*DC00?.V8S+:%3OUX=>R UZKHR^-<3#)
MD%K801S", Y4X$B-]*;>DP "]J:\%O#HD[3&80S:A ?6$08T<SY>( 1(<Q_
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MDJ=XAX\'K  ;ID486,$6OL$>"!1,=W5 XT #NM($+&M[L?ZO$P&2*D>V0D\
M*Z'5^[(LRC 4?>N.^M3W<0_R O!K II8 E1@#$)!"85")<;A($8%'[IXB]^U
M+^7U+W^-@>6U=CZN%6Z 8 L =P,@ 6BW=@,6  0  6YJ# Y6&<Q@#,P@#N@
M%LS H7[ > ?9'<BA#LS #G;!%78!^F382^>VD>WA!JBR$[N2;_NV*CW10=\4
M6=%T[K),[G8P_$;Y*N>.%0&:?2D@XO"K<(J3#, !']YA'!BB4#\7.W79:9-S
M,'MV'I)S8$XW&LI@ ORU -9X@]W8:Y=9  9@62. #.A@A,> #,S@#.I@#OC
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M>B13CLH.Y)'.M,PS%5G-!2SBH?Z498\AV8H X[H'J'"(0QV\O,U-?J*/.21
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HUH!64P(*.. "(XLF9*195VGR*1(V+G%PME[BU"B^1%O**2(# @( .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>cogo_0038.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0038.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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M]*UTO@YT75LH[&D\EZ:F'7%B[BK!2AI80MU;&1;Z*VJ+ZV7,[2R0K=0&D*?
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$#9__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>cogo_0037.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0037.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
M'0   @(# 0$!            !08$!P(#" D! /_$ $<0  $"! 0$ P0&!P4'
M!0    $" P $!1$&$B$Q!Q-!42)A<0@4,H$5,T)2D:$C)#0U8G+!"25#4[$6
M%QA4D]'A56-S@_#_Q  ; 0 " P$! 0             ! @ #! 4&!__$ "T1
M  (" 00!! $#!0 #       ! A$#!!(A,4$%$R)1,F%QD084(T*A4M'Q_]H
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M2(=PNRHN-K.XZQ3)&B ^"W+%NT52+/ *J2003;I$%$#$8'/=\A#]!1NDQ>6
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MHY]]MK$IH_!PT!D7>KTYR-#8\MM!6KU%\ND6Z>.Z=F?/+;!HX%PRI*<'TE9
MN98*))W))CI+\3G-<F=U9BNXL8@"1*-*F7<K>EA:(, ,4WQ#C.AX69\30=25
M@&^VNOR!BK._"+M+'=*V>BW"I/N&":7*2OA0S+@90-+WWC%)G1KDN##\U,38
M;:!N -;"$DAT_ <?6[)(<2PE15E!#A&@)[1D2DI<%G:%&>89IUYJ96E"UI4H
MN*5:W=1/0#>-FQSJ*[*'/8]SZ/+SVN>+RN)7$Z<33YU;M'I!]SDTW\-DWS+
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M[$FW^EXQ:B;O@Z&BA3=GIY@.GF0PU39%2%%SEI2KOK%322LT]LM_#DA[E+I
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)H^]^0A1K/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>60
<FILENAME>cogo_0036.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0036.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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M:KQU-7.2Y]WHQ26T N^A8Z$N)@NI'>@E2"PD))^F*G[W-<G+04Y\%6WCL?\
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M-;:DO<20R9E[<<B-RD%+K3"U;DY'W=P"2!YC%6-,W4JRJ+@RNMM4Z5.A_O\
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M_O!I[X)WU5^=96Z7L7;0]SR5U"RY9Y"9T'*$')?;3T6/,X]:]_);7@\NLG*
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M<R^58_Z-;,O,W_Z/44VML8J[^CM;_P"C*B-J!-]FW%JPW\B4XAX+%S2M0*F
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MQA0R%9S1(C)W.:$AE22,D X!KGP0:5^QQVG[H$GLUNJU!^UA4F X3RN.H^)
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J;2T]OV?H_4$9[Z),A)_LJLN2_P"2/]Y+,LN$W['M/^G('_VK.VHM9/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>61
<FILENAME>x_cg001.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 x_cg001.gif
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M]^?Q^.SS^>GP]_3S\_'V^_7Y_/____CW]_#O\
M
M
M
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MKHK"<.DB:$PQ+L6*=?T=B&J/*<*@0XL>+7.N'P,,%BA8P'J! PU]6.9RL,#
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M]D'"!AJ,T,=FIKS1@08<E!#(0*; (0<<PJ"B @DQ"B)"!OX<Y'&, R2B8.9
MHZC @08?U!'C+7%4$)X#<<3QF(QS&F !0;I(8*$ MYDRAQYS?*8'''#$QH<(
M_@E$2 D::"""'P;E<@<(L*HPBD"BP-$ >!3 L<= HJRPJP=SX'*D,'7$ <<H
MQM3Q 2'_;1NN!W+$F.C"##=<$82-EC<0"P6DMVXQKV0@0'P"$"" !7T6<X<!
M'@/0,0 CS+5' !W?T>@!OJW0\0$# " "!"2NF2(*!7C<L0 +C!I*  <HT%T
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MB. -H;   @8 !X&<8@(6@(#2*,C(1F)G<JUK0 -HLR?M^<99!UC60#)@  1
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M"8D "?Z+<(B20 L( 0QE< ;#4!; 8 9D, S$  F)P D&00M<< C%P F)L C
M0 QG8 ; 8!";D 660(BL:!-/\ (QX *Q& ,VD @%\8>'T (M( DT\8<&X8LF
ML0BZN C$$ ,M\ 7%$(G%\(=:T (O0 MHT (NP N5H(N>J 5%D 8"T0,M4 /*
MJ!# V(KB&!);, ,T\ ,^X ,T0 ,QT D&L0I!, 2Q4!:Q( 1!$ O L ,Q0 8&
M40DX\ 3$L 8Q0 .T0 OVN K%P(U;(!!H@ /\.(X0V1)8,)"<, S < CLR 7
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MG^RH!%APGS^ DS\0 T*@"%R HQP:!>:8 T^PCMZX!><I"Y!  RVP"E4: YA
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M6R %+@S:K-W:KOW:L!W;LCW;M%W;MGW;N)W;NKW;O-W;OOW;P!W<PGTK&=B
M$U3<P[T4R)T4R\W<_R>(QO#<(_Y6",T]VZ, =2N!"AT  1!@ 4I6#*$P@,;M
M)Q>S(18X$7.A"QR W2<R$'W0 44B!\.U@?0])>,-6(00-2#P)!((6+<W"AG2
M >12@7\A#/EMWQHB##0F#!> 3JBE@9PS"$%$"!D@?-97W(0  80E(]1=#'A@
M9 A.+QS &Q+0/?T-$<;0 8, -0:! OY1W'=! MZ5$%)2XPC! ON= 01SX2O%
M ?I"X\4P=KF@//J2@ NH3PD(X$?B!Q!02)HG$'/P*"IP=_4=$?JD"QOPXPE(
M1>=MY1*!"PU.W,4P".O35+Y!X44"X?>-X#:^!_3UX"H00B 00CS>Y6;.WVM^
M*R?VX/Y_D$<L(0P0  *D\"< H&3Q4N4;\@;O]1&H #.(OB&$0.4",0(*4MT1
MX4J/H0=P8A&Z< #K$BK_L0($8^<(@0H$P'\,H4VB( PE(-X,,1>X0 #4,0HH
M8.GG'0$EP%M\M0 "H0+8]A"10@*A( IO  !%%>*O7@PB(.D%80',[A!R8.(?
M 62^@0*AE^R-[NH%@0H%H!@E@.HC\2(#L0!PH!D66 )S5@<O[N408>K:OB%X
M4%D:L=RYT.H'(0JU#E7D\DVVGA%O,#WZ).Y(\-T3 0'K?A%S@0(:8-X$00%T
MKA*D4  $L0*V@@H4@ *^X1OT)Q"CT >!PC<E@ &F$"*"$/X(_R<*?Z +D9$J
M!($*^I0+@(!/O0%??3#JN/('B2=\'2\,*Z!<Q=#Q7@4*..]]@3!]\*4O@V#T
M [$+?;  A' ,7C?F2E\,N? '*UX0NQ R+I\+"T *JI !(I *5#\7&1\(=A0(
M[2<,@= 'CZ'V"C (QT)\KFX,?P *[K0ND\'RIL!;<E\0A! (^B(,@K  @C 9
M[7<+?0 *\U=-\B-^@9!F_W$*#E '/]YJ<@ !HF ,+. !QA (CT 9CP\B,$00
MG$?V09XAN/ 'A3!_NCX?OA$*)O\?++ NN1#ZD9,!<R ,?7#M?E(7AP%?M@]8
MIH]]7F4*?;!(Q(?\@;!(<Q$'$OX 7P*1\7W@5:BP^]&O +A@#"%S"\=2]:*
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M!PH>&-R)R*'] CDP!3'@@"%"3SX-1F!PH *BB@DE @4B".4^$0"D8*3[.L#
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M*F:#MSH09&/+@24 %UP2^$T$]5"08"!3"$#%C_'V\'ZI UI%@08( CY<C*(
M!"&%FOX2@@L$6"MOQ>B# !IC# 3XX6ZFJ!X$!? 2"O9!& K(B@E 9(R!V,%"
M$<G0ABCB@6>%* _%D$ &!@(!"\P0/"-X T%6\"@,5@H.%R!(+AA@$I:UJAAP
M ,!*CA2* *Q@)'*P $&$L0"(9"!N@2B ,&Z1 )#TJQBB*$!7-."!8KSA #E!
M11@3,D7MR6$! W' 'NX&P?$<T0 ]2:,H,&0M.&"*('AX(T$*\8= $$(8QGB.
M1DQ1@+#@2( HP$!&JF>* %S.!)DAB @Z0! XS.%N'OA(I@KP$@/ BF(CX !!
MXA"'8N"J& I EJ6DMX<Z%J,!A# &_F3" 5WL0I>'VQT*Z?Z PL8PX%'7RHP?
M^O?!/>0" =XR %$JT",&7.X$!)"+NE Q .U9X%G$H@VB[A8!"B#D4*C(Q0%^
M9:D(0 T <A!(,3CPM TU1A 'L(LQ)+"R$E ,!,BBP,J*@<5@)B2"+]E# -+'
MAP0L)0(#V5"E*D D8[PB ;I8 0580J[(-:X8>)!>LUJ( CG&A 0YO-:CWK"<
M3!$@%,8H0).,X9UB[&$!%[HEUU"!"@),)I7W(0@$F@0(K(WBC@3) !E9< "0
MG )_MQ@ 2V[!@<@50Q41L F'FC4!ENRAH:!0XRWPHQ X-& @H!! ?2I0GP7\
MZGVZV$,[41@*70Q@)+K@)0SQ /X75LFD "-$P*\<T*1B0+$8=% C+@A %11L
MTI8E15XQ7D&P.?8.-*80  (*T!#0B,(.&@  *XMQ 59BR(()^0H*%-"0ZWU1
MG8((1!\ @(L2(&L@* #1'BQ$/9!HX ^&$<4S!_A,GA4",1X2!@-^93]AT%*>
MSQI("4#$ !8,HI +F,,'-6"'N0P$#^,9RI'^4$L+V.%"2UFMU<C+!T$H@!"(
MD8,!(!J>$V)(0PJ@2 <$*H$71J"D&-">!^A)B#W@"[V5B@ *K$L(V1@F9D'9
M$"F,A"0%)$1@"V:4,9!C&,EL$22"N&EC#3,*!!AC!8[%4"$,X\6$+* Q<=P8
M!$^X@OY4$J0!HAC% 08A"$'<00 -\6X@<12!"02 (@A(W@K28K\#F#B2/E&
MMQ+ G'0%90\%0($?JDH0#;QE(!]H50%"&(*:8ID/D=- #D%(D *W$@36'<0%
M*$:![&'$&'2NPZDNI #X8.@E#$B>']JI@3IEZA:OB/*WB$*!/: " 9';8F[4
M=0KA%L,$)4CG[HZQ(H4XX$8#D< =]&<877BO.@HAM!05\!(.M&H@(+84&4&
M@E(#&88]8A8?ZBB($XZ";"$)Q I""0'MH:(ULRU-!@C1AT%\0'IXP&0<#K""
M0 AO8P26 +(<\,+)Z.(/6"O*37F6D)PB(!7": " NR*(!OX0Y %R')NER3@8
M!%P+Q2ETP 7J4!:%H"(0<#@ 12B@/5%4& 6I' B*[I8]PVQ@-A9@)0G(6(<H
M6H $RR8$RHI!PSH040+FS06H(N* Y$6 *P: K2#V( !AS"&2,_R5B(&C@#>\
M9( &L+EE>V>,$13@:9LQ12,)(H<#(.0")6- ^HJ1BK6AH X0J-0;,&",01P
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M,DJE=%$*@L@)/ "WC1.H$R# %XH)5- ==U27>!.+C=LK@OXH 5,8-?!+" \
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M7\&%[C&)@7B2G0*!)!(& ;B%0:BW@J@67%"FL' 84: M!C"&6S!57:@ZNE
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MB%!(D5 CB#F8C3<HF16P80ZH%$?CH.P\IE!0(#LV!E:VDD"(@U02 :7#!0W
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MB:'E'5-@@)&034NOWZ:HK,E@SO-"<(1?L8=R]%6_EC7<<.:( )0Z<8?OC%R
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M'0B(H@L< ,170@:Y&*,"!L:T2H@P?2S@9B#EYG* !'N@,@@ <.@2!P!OW)P
MJPC4)T ?S<I;# 4J&)-+!F%^T,%?%)Q%G 4,B'*+ P^(@HL""99@@5LC:(0"
M6"I @(HP<R"@BS *Q.SF31: H(LN&8"U 0.AY*(" UX=0%\?#X@&P I%'1"?
M!"#D@@H'!0BCRP)[&(.* WL4 T%MJ"Q0")W"&&A* "K@@LH!OV8WB@)]"%.'
M 'OH(H@ ;F9 G3$>:$1G"1C<!/<Q;HDRP*6XU+&R,'GL;0P!Y1530I4>#,!'
M+H$(X/YP,80<X!<<R=()R@%,PG&!,:8LP/P= ) PJP70MOI7D+E0;<(N*%A
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M ).8@@&,T22EA"#DS:3A! I @%L(@L>8VQ"Q2@JB@@&@"AWP841$0']T2DH
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M.  &K$D !4(#+!L&5-0$), H4/[-B93 <]V! _(@!&0  _P$]67 !,P<"CB
M+DC _3W&_%$(!V3 J@S2"#P 8/Z$Y1A:CF! ':C $/$! W  !\S! ]!!(/R<
M!HEB+K#  80E U" ,>@$!X" '"B (*2*,@W"**G)7^)0@@D2(> 2"$3:7VB)
MVTS K^#":F  SB'- 3Q5"31 !C2 0- A4P4"@OWF7)C"!:D5+?;27SA 0HP"
M!%3 ; 10(3B ERS &!$'!OS*"6$("(0)''RF!\P!;<8!2N0"!T2 <G:%+C#
ME$D4:U@ ! "19J:$(1F#764 !\A!T8R"VU42$J0$'F# %R+FP5"(!&3 G!QA
M!EB  _[ UJ?X1IWMUSX-D@<4@'+(53%$P&88!058P /8!$X0Q &\AP1H2/=<
M%XI&0 ;$6DKT00*X30=HE0=@P 9@P (XD7Y"@ 8PP!0R'0<X -T8!H@4P![P
M@0.F@@-,@ 9L32)JJ)QPFT"J @1(P ;HY:O85%ZUA')V$X)29E5()2HP0,^9
M@%;I@HM90 C$S$K=@@5,P)NNR +TG'QX@ 8$0@:<!=[$IAP@0"BH@+O])RX
M0L5$301 B6M]QLRMP +@@O<P )QIQ"U\B7)NQIX)G'=R):NVJJM.D2D40H#>
M I, U4V0@IN(S" 50@#A2(,-1"C,"3T5ET01@J'A!*(5Q_[15(>MGL*&Y5U^
MV!U0&8._B8*L90 >Z8(6_A7T,9U;,(DUX8*X A4JA()C[0JD@%)QV9VAZ>I
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MJQ:NX1XNXMI6;L5KG7( "TSI*F7LH$ANXG)E01+ T_@)Y=[)YHJ  ZQ "2"
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M2I! <^"C0I")4$_)AFZ) B%5E=C!1]):!<QU.K[!"%P%'$/'!TC B1#& C%
MR-P$'*BV,6S6;!^26\\&AA3M;#P 'BD02TP YIR@'UC \MF!ED0 ].0"". V
M!ZP2*7C' M3&(!B$!.B&'+CC?=&44$A9G6@%;MO$*%3 1X& BCA (%QT1J."
M!'R4"$@.!^Q!!J"$,%",!)QT0A?X^[Z! \APG?S!]-A)(1# 1V73?KF6J2@,
M*$!X@O[]! @0P!OD&@CD#X@PC2[4P39_P&# &1Q]J31JQ+[H#S8:& "( ,/-
M 2[%CF&00@+<]'+9Q)C0QQY<T/\0ADC=A#  @L"D# #00;LLRRYI@,B< #JF
MDXK0T0>Q@ 2DPL@(P I\"!]DG$J@2YWBP35)  L<C04(Q/\P#_8,46ZT'XO^
M8WG0$F%0 'CF C#*1P$P3Q\<@&=%7P&DPN=M-R$,0 >@ B@(0 !=P $(@BY<
M7XXM@$W0,0S[4/0   OHPAP #J:_5%L:PRYH $2\@4L^]%*5C0-@^18BTC@M
MT;[01T_H#<J$RQAE@,#D@@7EAU3J0BZ$@&OJ0JO7DRZ,@/YDDQ"DV[K!Y )\
M0$KDK%0N+  <'(X"J,=\F@*M/-.G^-$-O9BM=QL'W)<PD  NB8( 7,J\((#D
M,,XHZ((.TD<=/("0"^0B_\X'H4Y/8;AEI8@Q%(S"U"-020 =3 X#X$$ ?;C^
M\(^!'[SZ8I$6U;-;($P\*\C2%8,%G$4"?IR"-+C$GX4';$!Q= IQ_4]1# #U
M0J*A*@#+&LR(ZH(!4'LN_,]#OY1J(4 @S(E;D,!PP+ (#)&-P7" J%@=J/#;
MO1X?B)@](5,D$M=CB2@$B  IJ!Q?IH0).*!^J8)5I$0#;$;+$)<P_ '/O &+
MKD"5[(%H0<!ZRI>PMHJ;&!3ET?[B4!U/-$<? ]T8J4%Z2D# 4SERV^C&*"+
M(!#7RYA"*&24?"# 7*A"+:V3+NP"N&"'UX]C:#CA7Q!&+H""P!2#"<P.$H %
M^;GY0SV']Z K.!U QR) >91 G],)9P[;/HV32@@AVG1&O!N=*9#; K3M7+%
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M!8&W1BQ&A,OX(@@4! ",D@,4,B(%@5N,60K %DU!X,*,(-#+@SA44*$840X
M<ZGF\K@HH^:*046%!(KY8(3%RCJF& 8H*[(L/''A@X#Y,C*%.9P:RDB"/7(I
M )4P86,14V% 68 %IBQX*BJ",M! E3QU*@8RG!@(<TZF(BT&A Z>6F$%+HF*
M:RV"(+@KK[T6X,TW@MX@;"9=%/Y # %2%FNLH <BDX E@CAP4P%1A#E E$V-
M&:15T18H[3]"3A/FU15>,T:VXB*]XX!1")I@J!*BT@A!"I0C: ZGDENN.8(*
M28#%!2(;03L6BT'!.NXR*H7/.$(U%].9X BU*,H4* 2COS#[J* %!L'H 3]0
M.8!%!@9!!0$\_UC4OLC0A4T!$XL41E.09]I#E5$.R%)#/D3[]DJ?!XVLF#)O
M,3?3()ENVNFGH8Y:ZJFIKKI%@OP H(Y<C"FD@$]1(6 W4 30"P0J$5#%&%0*
M&"H4 ?  B<O]2LB(C[!RX6-,$?\LY@XSBQ%$ @ON$K'NEK"Z0R>"/%#O0X<*
MN,N8#/[T6@&"I5"!0!4^'BWF  ,Q$L4 4XS9(]8)XL:@7D H6(J@DN<C,"X(
MBH0*(PCD*&B$ON*[PYA<%(A;(]]R@4"$0.! H&]3((B@<(Q0"+68/ #P5?A"
M@B6$@+M064"]C' YP)3$[LIE@?H:B*RS6]X<8#<%AO+@M4(B$$8@@D+Y[^@$
M<%$7H;C0L@)CJ>LCG+O0&U+5!P ,100:6,H*,#"]+[$' 7&S@'+>I  \%00"
M*\A('$A#G8/ER@086 K#]B<,MH%N!!Y\2\F,)H$0\(8"5B+ A!3@,74YL"4%
M8)\$<%6'TX@B 7BJ ^\& 0 #J: "2T%!#8\6 504A" JD/[ 4@H! %3@8E&B
M$4 >BO$ H*%HBJHH@,;>IA<&&,UP=@N+U> 81SG.D8YUM*./]K  !CC@ ',#
M3P(L0)6XC:!NMY@ _/YH 1)88#H><-/K*# !##3 0&^37$9080$*6, S1($
M6EY7 4FNT6]8P:0$)J"!F&1D#@S(  0\8#-CC, !1T&(,#S@@ TX@"QPR<4%
M$#"*0*1*1'JYA04D<)0_M @."]  !2AP*E$P@#0H^!-!^L  #G! #A'PH F^
M)AH'@,5Y1"G!!>;  E B)X(M2D4$,, !.'P@@O?)2"%J YX%8$ #'+!.1G2Q
M ,0LX"["<(!CB@$! \53 QA(0/YWA-& W>@B _!DP(,$D<]0- !S#+B)*"
M%@CL9@6T>LQ0F)<L7 R. RL0P44$<8!0P>$U*Z@E ]Q4C SD[DT.V.#1!F<!
M"$RH&":888L$@0"LR+-1#;A)-C$@@0N$:"9_<&4$,M <7&)U 7HQR7R, <N(
M(.!!>9K )A^PFVGB21<8*,\*2G"Y*TF :QYX0 96"1=C?  ">-4+>!002 O$
M+0) P\4$$#"4%0!2D&$T$"1'&;([3I:RE;7L93%K)%& XDPS085CE+:+(A4$
M3)@$[9P05HQ0@()%/YW):A&6B[T58Q2$>,OO6A2*0;!O)K@@Q/,R<HI!4/5H
M@P#N=?[ 9(S.RG8FM4TM^ ;!VIFH$#9[TT4H;I*+$-T"3\;XS$Q,(;QB=.!P
M\0%::ILDN2ERC2B=1<4@EM)9@-[I+;JH[WXH)8@I I1%HB!$=[M[)N5>Y[L9
M$<8&[6M@M65D%(7;KR[8AUM,#N)4]&WOBT#!*-BX%J#L8VY!V L;0A#51?8C
M<:,(T=D$%Z0QMQ $<54KW?G"913,RA-!<L';HQ$"QN!-,5P^6Q#4$F7!>0(M
M05;<W$(\-[--=O*3H1SE&C&YLE3.D96EK-<7/?<6#M  $CK @"DB$(J4Q5V6
MT7P='1GC<VI.\YOA'&<YSYG.=:XCEG]4.CC<X4R!J(-\[_Z8,@K9F<[&>/&@
M"9UH12^:T8UV]*,A'6E)3YK2E;;TI3%=9^*X.=.=]O2G01UJ48^:U*4V]:E1
MG6I5KYK5K7;UJV$=ZT2?)U<N>BZ>&8UK6==:UW=D<J^#!&RG";M'Q):CKHU]
MY5W_VD?)WO6SH1UM:4^;VL\VAAQLU284R"3!N(C#;/D .JOE(@X<EIHIYK 8
M.9@;U D6!AP 7:-0D" #'NA#U KQUQRQUQAQB/!,"%%6.,[A%'*<PUWDL-^I
MF6($0'.R+N P6Q?U89DW"H3#9R2,..A"X^RFT8?K@% YWT%C- J%"![[6I3S
M"!3ZGEJ2700*\28Z%P:@@ <ZX/X!#7C0H+L9!0%@[,@8.1M&82MXU;#V'52(
M&=%1([J6IVRD%BW])EP\L:U=] 8"B& .*!A >8=^(VR>AM@6 &,NNI@KU\31
M& @ 1-/A#B-=)^#>#DAYK7F$W@=LP&-RMZ,I!/!O&(D [%C/%0E>,Z-;$  5
MMV# T7%$$!%X<% SQ_N.@$WLMU  "7"OKP) <&)DA3[R,WG#19X>=ET\?LNS
M8[0P$M#WF0!/K0,9\)9A+(P>][;'N1!487XG4%OW&!<<#G&(K]/90,2J,!SN
ML2Y<JUVHMTCWG*ZU]-U\6^*C=_LN.D7:BH$L,,'8&+LGQ *;&X#(:*JWO>XL
MP\^S>_Z _C0"<3/?7>2?H*OE7Q<]/G"+F$NA7J3WXDUIJLM%Y L"V*BWXNW#
M9B_>=@]9CHM%D@8!C\5%^N=&<B'>"@(5;,+Z8@3FPF^#4&"&K*Q_C(&@; W0
MA($#Q^L$)&4KNF_+2JM%.%"^;JO]:*0&BT$#>*I%>+!,9LL4BHA&() I$&0F
M*K#65(SZ=H^J<"$!+BE!.JL.V@G-\"PQ9(\],$ !'N .EDXN&* #F@,%>$H.
M($ ")& ^WB"D*& W6 07." E/* Y_  $X" "%F %"$(.(8 "Y, !%(Z5TE "
M/ 85,F "(H $EJ(//  .(, S+*=$\D0#\L "'@ #IJ@/CO[C%BZ ?49!)22
M\CQ #CP  D8J(U1! R(  DC@/$P E3C !8T!!2)  C#@+DK@?X0A%WE# LKC
M)FYA P+A ;@$#2]  B0+%"K  B) W_!@<"A@/@AA<") )FCB)2+@#V(C#C)
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M*P] H#@D8 /J;SORI;G@\5-,X27$"".V<P&@)12ND ,^HBE%  )0)B,R"@)
M  6,)?X0DND:G^(-1& !0& 4OE$#SF0%(H "]'(Q1O*5)N 67H$"%$ W$=&M
M1H @;B/-1A,;7^08[/,-6. -5N!21&$!^" 73($ 2N 6ND<Y9$<.UD(8[&
M=(%G+J1BU,R?2 4A\   [$ 7"F$ AH*?<($O#V 0[0 !1.$8[B#P3&(%M*LJ
MI@< YD 75   Y$ 74. X4&$ ,L 4Y! K_@!*?6A0TBTV/J)Y1"$7KH*#4"#'
M(L W2$ #N,8$$$08_@PN2B":A&$%!F(/O@40OJ.$[ L%(D@S)F /4,$G"NX.
M&@(5Z,X8'"4R_("@C.$//K KBX$4KN4Z!B&'6A !.F"+%OZQ)12 = )A 01O
M ::C(' !!8MA$ 3 WFZA/>I &$R! 3P(!)+0%"PD,2A@%'*A!-Q"*PU@0OC
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MH!0(2ZFBF ;2 P$<]KQ3*2X"(B$D+S9'@;%1"FB:2H!K=@*E##(<[T.@9P-
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M 7?<LL!E)##:07+"? "!!@MTE@L'#FC 0 DVE56" V/)@8 H?$A:S 0@@L*
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M\,QK?O.<;[)-UCTS"B!+&!V00 <88&@)K$!@\B,!YA" ,5-TD5^J$H4#WE"
M:F5E!/X6T( Q0 &!!4C@\AR@P.G%Y)D1;* #%EA !&OB@0B</I02 %$#/E)#
M]2T 4WFXX!O"!@'^$,5S%Q!:J/S+@06$A0,\(A4#CB.(\KRM@A0 @04.P$#1
MA<T##["4*M"_ -S&(@S0,+JP A-@?P?0?H30 $5B 2OE (*@ 63!=:*Q *67
M ;MP"VN!(1NP=1!  A' 0!A@ A0P ;G@ 0IP>\>@ )8B A+@ 0NP-F5! ?SA
M-\&$%R^4?D,2")-D 2 0 301"@(S,]OE&3R4 1F /RGH ,W&,XG7/ K  !XH
M!Q&0,@E@:L*@ #OD0O>C&J-0-DJH<IU'AF5HAF?H9*A0 /[,@Q,59 $V41B%
M4 P.$ &F %408 $T,0BFHA]KPP>6@0H$$ (2)0QU6!JJ4APT@0+,\3([50(%
MP!95@A(H( %:90"J@B8@\1&4"(<#@ I^D!""L "A(VNK$DHDL#,V\0:2@@?)
MP0$K$@H+@!H'0""7LW5%- KI\5$B$$HS5 QP@"NVABUW("DK,!Z&8BK"H'X&
M48%^LP!\< L $!8ED!.@ (D>XA(6\"O&  $M]@"7H0!L@0$+$ JA P$B042H
M< L$<!RHX#AC<B\SEA(4! H$8(<'T!G&T ':43GYX1K,,28-@#%R((NZD28?
M)0@$D(09@ $=<!P5B!77J(94H?XLJ&<0+& RT1815X%Y:.B1'PF2FA<'\;,+
M=J@ AV$3(G A"Y"*4.,9:'(+EN$9#M 'SL)05B,(=? ;6Z(=FP$'A.!Q"N!$
MQ9 CGJ$"I*$YGD&-^J$'<Y@?"[ Y9@%R"?$!'% (0%<D47( +'!W92$(!E "
MH246L @K>V!M<4,5%F(0N[  8Q@<H, '\E8,@U  8<E,U(8K)4 6RIA26ZAS
M=5  _<0 */$&&Y$EW983-A$*@K('!2$*PX-!@M ^;"$!?%0:Z!B.E8,!=3!2
M-:$ 0X(MA.(9GO0J]>0?A(  A*!S=T  X=%CL%(6R_@ ^5@6@6  =[ 'N>D'
M<7(XK_[S%C;A (>Q%J*  !*C&GM0 "K0!QT9DLWIG,_9:XNX8D&D&E"5(9O!
M/-RH;)LY"@5I$Q90!TBQ(,(P A(0 G4 6CP9$VWC 1_P 2(@@!_P!B4F!V^1
M  \%57"P$M6W&<"! (]08@;1?402 1_@ 1X@ ABC!_J" ,Q3%J 0?040&J]8
M5+ B!_]6(62!"W9S%W?P !P !RKI*B @ ;DG97>0EV1A$K5T "#0GB*@ LS$
M&9\1!X[' 4,'APF@"[N  +KP!D>$"\4W G@  50A 2CQ+Q  (D3$6"@0.+ES
M%S7H&7&R!S$9,1.CG D!AQ7QA]'V 2"  J[)(CYC$)EX;/Y2AGB 5PPG,!1O
M\!8UT0#":0HDD2V!T $08  '"9U[RJ=]>G VD0>)DS')P0 $4@P90!\N:1#A
M5A9(DPL% #<GZ2,+L@<'\"\4@(@.T@#^:#7]% +2-@(Y 0$H(1:,PI\TJ1ND
M6@PF8 H(T6U'-"9.(5DK4"/_ @JADY U)'[%,9>P:2B,0@(KDA<"AQ=KF#\7
M0@B700BMV:&2HI>]9$BE^3?8X@!BTIT;X!(K,"<'49 ;4 <: !PK0*8.H!1
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M94M. ]&@QD "0_$55#$!'J *J) !TO842/J+ 7 A/B('N? J&-,'"( !Q_%
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M @ EJ/X-"@B42WE@F=@B 26DU,#6)ZT]8<50" A[U-IJ$!E S446PPA37G-
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MX3$( B/'<),O*A@'N8 R(*\LMS <^E+9YQ46/V83)$@!!1$*LZ.$QSD8-?$
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M4Z!<^/X@_5*\@7 AX"1<,C &!>R*82$I!Y8M!@13\X)J! \&$@5,4P2@,Y0
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M"*, F+P?/R\SO(N8Y@'O@0H2DH(>5/B43@OP:W8 &PBV#B0#<W#.'H1%" *
M@A0%X.4@)8""0NP1 FS47CAS,;S*C6 /(WP#!1Y@&JC885;'3-$TJVE'0B!
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ML.02Y&*=Q:##I_C0)0M0@,@B* PX!U*'"EB4N.M=@040<($"5@"M#"!+'33
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MHFB4A_XD98P5,$#)'M@/19L=KRR65_*@(B][ <$K V"K):?X%2H(8-T#WF(
MX1S(D J(BDE9=%)]T.U *&"B;!?C%0HX1F(6HB94 (TT#!_!^<9FH*T.9 );
M++I>?7FH/6@J7FFT:8H@O9 \S"47$>B#!* 2 3*#*FDR#\51LU07EVD_34&_
MVT)88$8IF8JBIQ@("W)T /9'ZD@'\0LH M"O%0^D$ ?TD@A9V7!:,H#!J:5P
M&H5!"H4G68A!B*R9*S]\@99F2I4@\0L,\)IG8HC1.( MN@.U(PL.D -4$(!?
M^8#ML(!H$P!10 4?08E,BI,Z^)3,0;0ZRX5"0X]L"90O^?Z5@7B%ZA$&!M@.
M#ER!>Q&&#1(!2+FS@2B5A;@%QX"N[" J4,$HOX *E9H=6J$H8> #]-/!H-"V
MUK$C$9C 8C P!X2/%H.#.%D(4""+/K <$3B!8E@ ,@L$ = %I<$D$S@?I;HF
MI\*.$K"C5^.#+#DJ"_ 3"&"80%"<!AB<A:B[L<H)\1 3*6*K02   ]F@%4"_
M"  >43B3=Y(;// C\?"B%2HB4C(-"N [@[*CL".!0! &#B@!-AHK;-&5A9BL
M8G@.%C3 @4! 7<@ 5:3!^F"LY/H)41BA4*A#-*2IM=N@.9@TND" #>Q R8*F
MOS@JN@@V8V"S@8B 0 C!7P$!L?[  +Z[F3&$QL&KI5RZ \NQ ^6[C(;*I7B<
M/'JL/ (X'IEXG5P,A3P!A5P !5_)/0.1@P0H(*@H!0/P+T.Q*$,1!$/!A3H
M #J)Q2,J@%Q0@9! A1(0@/18@050@1&(@!:K'#S A5! @'Y1 (&! #*C@$$9
M,%.X!>_:% :$ #J1 P4H!&.P@_2!"A6T UT !00@LQ*0'<,P $+0!3XP %00
MF5\I@9\0!B0S!D#X,EWP UV4 !!X!53  %0ICUO(!=OS"P9 @:;\H]. %!1P
M %/ A<3;+9]$  P@!%&H PI0 #L('#J!"@OP@)Q8B?OJ U1X@P!XA%JR %+
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M T&(@,K(!3B  UR( "K)A0&3 /'9E&[Q VX;A D,A(]%+F/8 /'P XZ!@P8
M38*X6/[V")T1:+'2PX"/[8!J_8S*D(,(Z%J+:-*)$E>+TH!;$(9_.1%3P(!
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M8?BML3$%PK@-NJ#RD%$(44"@>@L$ ]E13 J=,+D;G204N%J(4!!R%,D%%I
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MQ:P@@!]6Q?& ,,<=L-,">3@TA_X%Q00"0!T.<:!!47-L5\P>7!6%"@16%:,
M:QIXX)!JQHA"P$?&1*"? AL6\P8#QQ704#$?H% ,"P<T9 H!#8T@@D,6R)&C
M 0V=<J0Q-^Z6P(,.H5* +L6\HH$Q?C!PD2 +%!,""*9M*%J1*CJ$ 1S%9!"!
M518\,&>0_EG$G0,7D:"D'#+R&!P&>W!8WAP$C'(< : 4XT!Y.>XH1WPL*%D,
M'A>:HD" ?%IP$2@"Z!+( 0<*XV@Q=@@0'"X&&,>"A]EIN"4*%%QD2@&7A5 1
M!$TJ%TA=H8#65 +&H"+ ' Y1$&0>"!PH2@%!UD5>,;IXE!,'%ZT FBC]%9.+
M EM"</YMCMOA@D!,'F#GP$X>,-4<<WV$6)0$$1P(R@"FN-90!(R"M),)"; 6
M"@&ZZ$+ HQHHR<>.&=8G# *$6C""0W<(@$HN'+"&IV$;<]RQQQ^#'')>M0J
M0 $'YN4:"GOH@0>_#5S&@''<H>:0*8*H,!IFEZ6V'0<JY(D**J8<(,@@@P0B
MP"U]>)DG*0CL$AK4>RP0BB"$P(& ,<8L8)P=#%A-2!P(%#-"BPZ!4%$Q*)Q9
M3!P9%)/'=GL$6PP%?.A20!^$$"*( *;HH@ '=[!F5QT5F!>O!7?DHC??@PS
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M!(Y5@J#@8@4.,"EW,T (4<#G-<KA76H.,(A<\,$ B>) !FX!"@9<0"8 0$'
M':!0&?[BBP_,RM,;'*"+6ZP  *)6@0, =X*1OE$.N1A% 91L 0\$/ /8J8P*
MED8 H)F ?PXSC@@DD"@),"7N0$Z <>J  !1,\T1Y @4 ^B",3"TV!'IK$P9>
M<8QL-84 =;A%X-Z@;U-)X&#0,I-G@%87/BB@A2U: :&G-(A;#( 0H2K 8MY@
M5JZ)A^BOP(4&$.=ZS+PA%Z&0P(F(9L%K#B\7<2B ,$A1 #[D8I0F@4-#%V!"
MC):NBI8"CB[*QYJ'IV@$!.N \A@#:7"7  "F.(66'"*"%A&" (+0!1\ H-"+
M4* @NCC 1Q2P6#Z0"042V.L)!, HY^_'5$4 "?B.TZ6('_X8 P$LR" (CC'T
M 9G4104P0"'D@AP<@"XTSBN 0H_HPAX P)OLTC\=P"GD36QYR!YD&/[)2Y,,
M @*4P ED@ *8PBZ8@%]1VPWB8 [^EC%@ )'A!@<$AP8DAR!\0%-P0 5H0""P
M33%P +\(0ML0@DWDVO*@E@1@3-QD )[< DQ90!UX@"IT!0?,BPF$4ATPP(:@
M@AA*0 E@"V4(R4[)P9;= 5<$0HL$0G6)P+7IGP1H0.&D$ 5  +.5" =$@#$0
MPMDHQ[6I  1(0 9H5]!X  ,\!BG4@4F\P99QD@1,P 3P3"4)A!Q4!'\PGP/<
MQO)X' 5$P/\X1"Z(P 1D@!^\#?ZV2( $8$#AB((%3$ $\(HNU%T$E.)G2, *
MK$"3S &T& ,'?,0H4 !VC "AU($Q(J/-K$ >C$))U<4>0$ %0  2%,4=' !C
MZ((':*(%B-,;-(!)F()"1,#\E #IJ ".P$%YM [X%,,@M(=3<>,=J U",0I#
MY<<@1  J^$&7\6-KD, L>L"6Y('$% (%6( (% (&,$X&V&"%C"-=# (%Y*(>
MF(>F&4<Z(DX?5(I::6(%),<;O$DZSB('#!= 50 '!((*C  J5(5#Q./$0$ $
ME, *[%11D("2"<,&- 0'S,P@M$@X6D &_,$*M(@'S PA6-06SLL)7$0'U,=R
M68 *$/Y"!(3"*%B4O#!E!$2 <>A"'R)((U9B!.R"'#Q*+A2=6P;(,\J$\AAE
M48S 3C3%&\C!+3"$+B3 M>E@8 KF8$J;2?%%12X/BNQ%+@ 58RXF4'V,,2AF
M4> "9/J%9.Z%,1AF7B!F:]1%'Q"%,&RF170FD.$%9MJ%8];%+FSF:!*&,7B
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M0UWQ!2BTA782!BJ,)V#@PAW @>%M:)-6V^,, HX6DI]]Z9+R:9_.:7R.#$\
M !@"*(P"ZJ%NIZ$>5(>>WZ)VZ*,Z:HQ":J).ZHAZF:&R (XT*G<^*E!=1!X$
MP/S$)YX4JJ..:E%,P$YE$P!,P/XL+@ #) JE>AFIFNHXL62B=E(?$, QY(FD
MGE,H@<)W'12M.LQE.$ 0F>KR !4H@ "V((ZGZH4=&( 5SA4I "JM(FJ,:LR)
M7FIZ(L9'$%Z66FJR>@8 1("K;ANB=BJE0BMLQFH&N*&?RNN\TNMIYJBTE4!A
M:>C/. 0)Z"M@8 !*U.C&9$"3A)(*.L0N:(!9A4SC(*:_@8Z5VD4U#FRC&$=U
M L;D9)A3\<]E*EU,*(>1G:<>&8/$&FHH&)1%9$3%"@8"Q.H@C%2]RNS,9B@J
M&!P(4(@Q[ ]1SI8= !HH' ,+/(C.:@#/_@&SB<(*](X*B*9'<4 DU84I@  '
M@("/P/X!**P !M2@S7C XJ" DOA'+DC/T]ID*%C6"* ,'(0"'%P VMJD*,C!
M3\E!!F@ Z*B CZ!"+;E-T:IB'FR !H!27<C! TQ 00S1'EA -#K$W,(D7I@"
M'$W61<0!(9PM3L M(4P0H>1(<A "LZ&"2'@ 7<#/-89>GKS(M$A/Z+K('@0"
M!FQ #0D"T:W E<A!*.#!3((  Y M[A@ 3IA"2EXM!UP Z=2C[#Z(2!F#*2CM
MVW(2!A!E!%Q&'1C'' C"'&1%X>!"6IS/K36;6H3 +3!5Z]I<4>!!9&AN74@
MB5A1"13.'4R$YP:O(X9"9+C5&R3M!9B 8KJO!I#.(-1!(/Y(:"2)[09T ,\X
M58?X+"Z,P )D "#DPAL,[<XNUBV\02A\0(_917H0:C&4P@ 0ZAL4[<P\0AV
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M'2C/'#S *!!"(8C"+6#/'M@$GG0 M#@8HM^"PHS"C8H"*E@32L#!"NS/"$F
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M"'(L!4;)"P&,>CH4T40579311AU]%*=1;!QI!054$ $!(XMY(P"V1/&O&!:
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M=@0EM&0$T@]0*@ #*( #K@=92/Z@#B8@2&Y! 3+@ U#@ ,@#%W '!!!114K
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M1F'L%J, F^(I!"(..*1*!,+O$/XM1XC#)/I$2(@#4+PL5)2K-K9C#]ZB#P!
MA/ D*U"C1O? S1B@?2+ 6]9B,; C#MS,%%1,3I^$#Q) (D0"):B&(D0H,3+U
MDDS&C^KBR48"6Y[)*"7 15 A >)D#Y2K#S93($#@#7:A,03B$ 4B K "%Y@,
M%PY +"&B\P2"1'!! +Y##@YS^VRC -RC)79A 3)@!$!@!+!"&!: ";.' /@@
M23("%X305N7K2DPA6;%O 4;N#33PQO* !3A  7BD 8S$&/K@+>) 28(.."0"
M8#-B%Q+ 7>'$5#Y",N8U1%>@65). 70!##^@&/) +"0"7!Y)%.) !18@2$*B
M>]I#&/[N(&,C(KL$X2TDP@+L,T[;8F6'Y@[@DT<D(@/((P+&J3X%H@/8DRE*
MH'B$@0'XQX9,X "VPP[<[%KJ+@XVDCL*@ TAK3T&#3^"1 *$,B56B04PX"UR
MH7,RP@%\[DK5@A!4@"DB#P&$02KI8R1(0V(= Q4@  )&X-500AA4QB@.(//>
M  4 0!CD@"/8A,#<PBW%RQC:0Q<ZL#:PXPT<( YBK@.P@Q .P ).0/56H@_@
M8 0. #TR &3")%0"MRVHCCM$UP_$(OWDE5B,X6X%(P,P@-@.@B/:4B)Z-B)&
M@"Z(:DR1)& +)Q 8H^[J;E6P:P),8(;F#0'B9 X6X'$E,?XM]H  ,& %,J,1
M&ZT8D( #VB,H6!8I&@ K,NY#G$("2J",$K57"D(BUI8$6"=25]9[G;4/<.'%
MD""2 ("*%" *I\PNT)=/N$T!OC<C5( !X@5Y46DQ <!(%@ K)$!6) (:FQ<#
MW&P0 D!%-#,.Z-<$!L 8UG?#[/))_F1$WN58'>-JAV8]P.8-..U@BD$#%  $
MSFO[6J(.)&"<6$)&CO<S@ 0.X" .KH@%1%<7F*S\"*;1!"5=_[8!Y&"'Z\"7
MFI2W[  4($ T&H!&7A4)_L@8",'-).(-_JB(12%=MV<$DDP%+%8.$N" _ !M
MVF-[9M+-%L3:L@("+JYT G!DT_ZV#CZ,3T1!$#YD-QTN)?P@SXJ! O*@QVH6
M/_@C F2E98?'9Q'-8HM!6T7!&"B 0T&! ];#9$=$!':8A_BGEC#@:C+B%!#@
M%D+&(] 3D$>".DM@#VC-C'PD(R) ,53C/B! $'1T3;1W2HOA$4H,2F^1$+4K
M#TAE'57B;OE';Y08#N2 @^" P.A@ 5^U!,ZV&%0A"1D@%(211B. F>L ?'!A
M#CR  $(6IQQ  ^0@%"K 2&YVWIY"!0SW#PP5#,6K&/Z@(%:@.)887!6 VS"
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M*8B9[J!]5,&V,V(HOF,HBB*H._[D-'IE0HF$D !!,KRF!"*LCZCN%%8&,S*
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M4Y%02  "'5B!!6K2!PE@0 *.$<4%%C."@=4A A*0P&\(I($(0  %,YG#13!
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MC)Y6I+X$$(5Y &R*6QS &'DX*7X@ZP?B3H!;-_OL3 B1U<!@0 /E,@4!4:&
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M!6@ .U7P C$0"\5 #%7@ B^P!;J',;(@!5*P"<6P"B[0 EO0@#=Q!2W@ K1
M"Q;8"<7 "ANH!30Q@3H!"2W0 HO@@3HA"U.P S10 TN@"3-!"U:0 S%0 T^P
M"C-!@S:(@SI8$3RX S_X!)R@?OZM9P@Q ($OX (TD @5D0A4(('N0@9ND 8^
M,8%GT (O<(3T(GMH((:9,!,LN(+%T 0M$ /#P H6*(2:\ (M8 9LJ!.REP@Q
MP 56< :PLP4Q0 .U4 Q6$ ,Q0 8L@X(O8 G%X M-< .1D!.+< --0 RR (&5
M4 R\$(F3""^LP ,\((0[P0L^@(@T, .(" N<Z ,N$ ,^H(HT((2_X(J#J(HS
MP J<& 2(^ ,T$ ,V0(I.:'JRMPJ#Z -F0 8^Z )-R 4ML /O,@0M4 7Q8@DW
M( 3I1R^9<(WQ]Q.&  346(?,6 RS, 0WX(CN<@4]L :','RO<P4QH .T, :(
MR 4UL?X*DF )XB<+W3>$LA" %<$+EB )G>".%0$, ]D*!UD)J9@(U<<*E@ ,
MYU=^M-!]P( )K$ ,##D##GF"F&"0JT )^D@3OS"0G@"0#;@)FR![M2 +Q*"1
ME!" >TB%AL +B_"+8U ,7#"(PJ<)/M@$Q9 (5'@(-OF+]C@&5"A\F_"3PYAZ
M:X"(FU@,E< #.-".6A #01 +P(")\?<+K2![P* )DH )XD<+0Q #55 +[B@+
ME% )V;@)DA!_LA ++ZD)PC@,<+F2*SB7G%@)$7F0_$B.JS ,=JF&K2 )FF"0
M+3E\K< +""D+P[ (,T #DM!\JZ )VE<1^&@)*"D+E2 )G/Y >ULP!%M@ T*P
MABPCB#GP!#$P QWH@;P@!3'P B^P Y,(!2YPFL6P"5#I@9!P [3I CN @<4@
M"3P @3&P!+ZP"2]  S3@ D- "SYX"(?0G/%'"SO@ H>0!E@I"53XG-'I@X#X
M"X=(FS<0@\5@C;3Y C>PB;)G"8C8"<20BF0@! JX [I8$5S@ D$P$SZH!<3@
M@T\P$_08 [1@!OQ)?#YX!<2@A -:$?28BTUY>H<PB$T0E\1'#%?@ CI  S H
M"X.X!J[X"YJP \%I YNHA,[Y D(HB&)( VMPD+*I@%7PB[*P"(.HBYG BR$H
M!,*X"L[)!<^)E?$GE#[ !C&0!/Y\.(O%P E# ('"*0G%, RG* 8@6 EED*2+
M\)TN\ 2R\(N(0(ZL*88[$)5D,)M3V 26.7R)\ +=:#KPZ)R_2)P5\00N<*0[
MZ0*Q4 F(J(,(^@/NR JTR062T 1WNIN(" 5GL ,MD 2\(*0T< 620 LUH)V\
MH(I6& F#2 MH()RL, ;.J0636JD'^ 0OT -L( 9]6@S9:0:KP 7-&8#P&0.9
M  S."8M#\(O4&)"S('Z', ,ND BSH(H'*'LX&@.4  S]6 R(\)R'0 NJ"(BR
MIZDQ(*6H.:&<-PLU,(@_. 1H4'V6D 0SL -J  O&F(JP"*332 E5$(^_D @V
MJ 1I /X,8U";:U &SRFE94"%5["3-@H)+C #W6<#,2 $9^ #+U #XG>N+A %
M3_"+21"4'(J(5<"',2 +O+"M2K &K!D#&!B+OP@$EB &+Q $L+ %SKD%E1 +
MSVF%2O "0L &@A@#L\"<-% )FZ $,""!-G"A2E #!EDZ<9J*-. #F<F;-( )
M==J'#>H"!Z@$+F"/%7&CE*"?/P@,\&BTZ?D$3_ +M("(2CL+.N"TQ: $:%D,
M6^ "0&D&/TB.B.B(M9 #+F (7SL#42F;6F"K-# &K" +FS"8%3&KB;FMET@,
M9JL$LX<&OQ@$Q* )B%BL4HF(BD 3:("(01"6Q.J!?!H#^?Z'K:2W"@^+B(AH
M TV(H$)0$9LPF3_ "<! "XL@"=K'G33 BDG@ ATX"[]HA6@; TU I6=;#$]Y
ML9" B)SJ CE0B*L@!4RHF;]H!14AB#/ "\,[ TT@"\!@L;.P!L8["U-ZBM3H
M \Z9",TGB#V0@:TIA*SPG)%@C*1;$;6+!I-@O)(P"ZO0"JS("4N @W0*IX@H
M!JH: SE9#(= A35PJR^@ \50KTT "[^(CA7!"FJ@!+]( SH@"T+@ E<@@Q71
M"JJXB;(@MP>HO3\@"ZX8H_M: W&HBE)*"V-[")3 H06\HC1 #%80G$"8AH&K
MBO(YM@=8#!L:L30Q"[CI E!0??Z<D+G3BHA26@RT  51R 35!Z0Q(*W%B8B3
M>*V>RWFR( E<8(.\6PQ?<*?#=\0Q$*-3BP9+,,$Q((2U2XU\2@,Y0 ,V0 /-
MR0G9:87$P F(* L 2P.R\(!1@!-2O,2SF@F2L*I!V9I_[ *(6Q%:(,9"\,7/
MZP(_4 R8L*I Z@*2()0W>(,S\ (^( N5JH ]P 7B-Z6R$Z>\0 R^& ..6*$Z
ML 5<P 5G@'U-&@,YL). .A,OG)MK4+D5#+49C(2S0 Q2[,$Z$ ,'^*5[ZYSQ
MAZ H# L=S,0M7 E4*,M<8 :V7 R1H 5!\(MK'+B(F G#L*UX:(B,3!.K< ,_
M: @S ?X,R>R\%5&Y,Z"0K:"$->#.%>$+/C@%,T'/PIC%H/=_/5P,OV"#E6RZ
MLJ?',?")O'FJ:%"A,\#&&)R>@U@%LUS+:  +/^ "BEC% MO'--BP,\$+M)"9
M@RS.,= )WDD#^<F' FL%Z5P160L,PNR!:<L#Q= )B-B$Z>L"D<#)LTS+:!"C
MOL"Q/Q"%B(O%+B.(LVO1-, #QCR(4;D*ED"<$KRM8D 3#P@%%5&A0)NV/=!\
MDF #-A +(!H#D$".(%P13?"#,^#5Q<"V.D ,K$"P,?C!+K &O*#$FFD)G! +
M6X &S<<)VZJ[L]H)PS"V@(C.C<S$*IH&L\ *?6N(/ZB#LO[0 P7+B39H V@P
MV94-CS60AB2\V0(M>E PA8:PE4L9 T, QC'P X6MBM&7P*;]QKI8NP/*"[^8
M?[!@"9Y@V3J0")+@Q3?:FK2@O36@BX:-K,P; \,<H;3@G1*:R 8ZP,M=#,#@
MBM_K O*\N^5[R7:;@;\8"; PB$?8"I6P"I'P!;J+!C)  ]D(.W':C3O9AX;8
MG&. !3$  UY8#(8PL62HDR_P XF@N,X)#,88 TK !3GP H@+HG*\!91*MLP:
MC\%:$6R+PM!Z@UH@G2X B%C0G&(@B#" !K\0 RUPH8H[CA8= YA #-O:V#(-
MQ,5P!M])M"\@!<4@"P1+ U#@@_XQ$-R=*J>MV:4]OJU KH0P?MJBI\>I^ /@
M&X63> 8'W)ZQ *R?F 8)RP:'X)P3W8:#& 3)_0(SP 5B, ,[V^,\L)[&/;P7
MRPLV<*=<X(HY$("K,)D,/@7/"906^]*M"0O < -W>@91@(A"Z(H9+'N/7,D:
M>(-E( O &J:F6@-CL*$P( F4  ,N4 :28*H^P-1-#8S=" S?[,K#@++F:<9,
M[)Q:ZX&U<)8OD -B8-;Q9PE! (%Q78C%@*^\BYTN\-^4:@,[X'TXO@/-9P9S
MO@2\D)T'. Q":I[_K0D7+(8UT+F60+"8, S J085(=-+,!-/8 ,Q?(,V(,^K
ML 2S.?X#08".4B #!:P#-5 #-C#,Z1Z%6!F53AYZGI"K+O"*/K#63)RK+Q )
ML6 #,E#;O^#$^KVM)H@)//"<0F@&-4";-'#.4[I\E<"G(1W?NK@*13";KOVC
MDWD%#YZ<A<B'-N *%8&CP9B!3?#)_+F)PQ#)*OB\,L"X.OF<5O"E,F"%6/O)
MM3FYQ9 &P*F 0]"$M2.1ISREO/#T2*@)FR"3J_#E,5 &L]<*H<F)O)"9Q- *
MF!#0G,@*S??TF5D,P0#U!ZGV8U_V7;^#FM )36_,F+ )<Z_V9K_VO3 3O?#T
M3_\+3[_W,[$*F+#U%9'VO. +?N^8Z@S8HK[OF1<+FF )J_XP@?RH?7D_^)R0
M?)FOK,4<D)V@">4W!E/0PSM9 [\P#&R?@6&O>X.,D"9(?$]/>\1@TC3!"ICP
ME7S/^&M_RK3 "IS_]E.;"9L0M+R@"6&O/9GXBC;PII#__#KWDL6P""^ZK1;N
M$WK\ F%Z;[I'"U7P!%L@]M __B?T^ 63"58P!$(@!4N,$RP8"T_@! Y,_O1?
M__9___B?__J___S?__[__P!13.! 8@,%%BQXD.!"A@:+)50(4:)#A0XA4KSX
MT"#"AAHU7LQ8,6+#D E-;K2(D6)'CR)#BOQ(4N9*D"TGNES9,B9.GBH7WM2)
M4BC-E$5UG@1J=*=-HS6#!GT)\_XHRXX<>R8=NA1K4J1485IE.M0I4*<YS6;=
MRC#CS9,;L8Z$&W8F3[86N4H%F_:KU+-]_?X%'%CP8,*%#1]&G%CQ8L:-'3^&
M'%GR9,J5+5_&G%FSYD5NI#R1$AJT%">A38=V0D7T:="J/Z_^['KT:=*R69L>
M75J*:MU/?-/6C3HTE=FT4;NFW?KU<M+&:\-.OCLY\MFY35,)7ERX:=W(FT/G
M[CPU^-/9C0<O;UL\[O/BU;<G_QWX>^;AAYL'7GZX\_3KXZ/GCC[^ F0OO_L*
MU,\^[_!+<+[XMJL/POXB'/ Y^"@$\+@'^1NO0N&*D&0P6)#K[K;;O!,-Q==0
M5&ZZ#?Y5A(ZZ_4YTCD7I9JPN.>TTI'# #I=S(XW$6&&$$DF.9.1())54,DDF
MGUSR22>C9')***F4Q,HC(VF2RRV]5!+,+9GDDA(GP=0RRRJA3//),HL$,Q(S
MC<3RRBKC%%,2---D!$TV[6R23S^E!!1)09O\LU!&#JU3347S!+3/,/.,1$Q+
M)3%32D8=7?/*2\/$5$M)"^UR4C<#97/03B/=E$\[/QTSTRI;311*6/4,=4Q0
MI71E,%[XG!)2.;V,DQ)+C=553V3#I%7*.$^5=5<]/RTVSV97/55:7*-%<I/-
MO@4W7''');=<<\]%-UUUUV6WW<S64FHJJ.*%EZIZ]\I*K/ZO[L5+J7K+*DNK
M?/F==V"A"$;X8'H75HMAE@+>ZZY\YY(H88,?IA@MN0K&^.*J^O48WXP/LKAC
MD.4BRZO 2D9Y9)M8YIC?MJXB"6:9FYK+79UWYKEGGW\&.FBAAR:Z:*./1CII
MI9=FNFFGGX8Z:JFGIKIJJZ_&.FNMM^:Z:Z^_KCHJPO)2>6RPST8[;;779MNR
M8=J&.VZYYZ:;[D3,@(@+2PPZY(R^B*$DC3/2V/LO8"))HPTSU$BC$K$'V@0,
M,\PHPXPS)L<\\\S). .8OFBY6XT0!X*E$3/2P*1NU5=GO7775P*&AAAF$0@8
M%]#0Z!?9:<])%BT6D8465@SY@OZ7OB3APA'C!9IED2\*)XH--#;!Q!+K,:D>
M>TL\V;YZ2S31I E9SI)DBD56V22-*8P_Q(I*6,'$#"W>?KU^^^_''VM@=*"!
M%H&&Z0'N!@*%))B%%EG@W4!6L867T.(+3S"$0997C%ZH(1%G80,K8M$%-)S!
M@Q[,W ?/0 8S%&,,L3#+)JQ /X%@@@N4T()#)+&%_-70AC?$X<^ \00:T& (
MM(A%$&@P RL0@QA:Z*$5/$<1,ZPB*)2XX$J:\ (6JB$,AS!(X\S"AE9( A'#
M  88Q3@,,I81C$7D @ISLH4$:@0-.6"A1K;0BAS6T8YWQ.-E5A&#'L9@$VMX
M ?]>L/X*7_"1!B\8G03)D!-B+)(BK$"#)(C!B"\X8I%?H$07*B&0XJDD#:LP
M4F!HF,:<T((+*_&$%%92B37DT96OA&4L_6()/NI@!X<P@P]HH(,@'((8_),=
M#1W"BE;F! T3'(@:QF<),_#B$+THABP. 8PM.%$3B,C))T,)F"X0@Y0KD84C
M'<(+3:PD?5E[G"S5N4YV,D863NBA$"RQA2?$0 =FH*$8^%@#2J D%D)2B1I^
MX9!>"+ 89 A&,8#1B8+(PJ!X6PD;5E&)1/HEAM^DB"D%4XD(IO-HM%C$(1S'
MKE4@<UR_<"(PG)C111@B$ZOK1#F_M8HE+D9XA.%%)8+!B_XVZDP6-14,,5!(
M#$X\I!4>;:=*RA"#&%2A&%.P00]K@,4KQ& &3X#=%W("#'$J\(*\2 075/H%
M1&R!%K3H B,\EX:>"N23E6!$8+I0#(Q21 LF/0L:4B<U-,1@"$W8P0V\9:XS
M0$(@-=BDN2I1@V)4X@8428-?GV #(>"5*"N#3!JPZ%%>K*\QQ/B"#  J&7@-
MHP:=>,I?"M(*+13D#$NP%T5F<8,AS,(*6%T,&1+YN&%8P1:" 48,*AH83KB
M%[28@2]X,0/_)94P2>BA#XH!"7O28 ?&J^<,H) 30R36(8>XA$XL$8EB( *;
MQ5"#_UJ!36(0KAB'6*E#U@!*\OX"YJ)J7$DB%@$88!11:FR(05$%<H88C*]<
M2\ =,7X /7$5Q!(]:"R$#9((%\@4&$,00L^N<,J_]"(&0%7,#ABLF1W(]#":
M8&PQT+!=P6 BQ<  \6&$H(C Q "_@+$LCHM!"QWX@A8U:*YS!9,$J]8 C#60
M7123,(,9]"". P'&71VR"JU2!!/[I008G"C28O2I&)CX AT-P8J4S-=8J:4(
M ^OJ$&!4(<8I2<-^HP:,&1C6(T.X0C'2(--AG,%_D)B"%.1,BS7,8@MQS42@
MU;!$WTV!"^,[1.&@*)!5%%,@:^!!$EK9@TB@@0ED6"(OR$"%+1A8@F"0@A6<
M6 D:"_XD$7OCQ1>DP$:WQN(0'$[$%*9PWDK\H!B6\#5!:L &@QAZB8>0PA1&
M!XQ/;L$)K)!%H&5JB%4<@@E;6!XQT*#KPF%*$DZ8 IG/0&:WQK<8J\B"%,A@
M/$0$00BX@V\BA D)*TRAE;/(@@ZR4$Y@G$$*62#WN:U A4@D8A.5'@@D"7*&
M&D !F\! @Q.L,%B%J@'< E[#8*LMD$H$>K2RV,(4P#!0@4CB"5;@A ],+! 5
M2D$-]$O$-9F@A2 78Q-/R &VU_ $2SQA"A1O^6@%T@HGY* +M/!$)8;13('
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M&=@;6?YX5A$/3=4F;Q*"1KCNV=X+:9Z*[C3H@B%8 F-X KZ$]>^^@4B6)3*
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M1!40@5O1 ,M(0F_MP!9TPB'TET%\Q!(D B(,P0X,""O8P! <0B)4@:G(Q!K
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M%Y7@@OX+5K&=!Q5&$HIREPU\4P9Y 4,')+&74YHP%=;10D4_PH*>#I*)--@
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M%W5Q%ZT097CQ%S]1$X$1#LU@!F) "H!A"H0 $&]'G810"*#I('!OFB:"%=0
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M3_74&].@":(@(R+B"LH)*6C@"IXJ.&[1.]0S$J+0#+BKZ?84!25A*X"A"83
M)@1")%ZB$YX*$FK,+7:&(0R!!X1N%<1#+"KAJ:(D0H* _*8@0K;@8-Z")90
MAKS,)G[@">C"#,9#FM( C"!A*R2A)Q$B"9:C"BR""SA"?7"IJ*CC"NHQ"*Y)
M$FI@(C8A?)*,,JP'C,0@!B+!0<= P!#A("2A*2K!!2*$-UA"IL;"!=:#(81
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MXZ-:(7$_-3%:0B!+]G$A%P7SP@P.8>TN0A*4X# V00F"E0O)P"8X00O60 N
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MU(08$=&P%9::S)(E,)G4,!L:@,["A0N5..?<*C4D<ED00JQ"RQ--W$D),)H
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M\,$+FG#5C@SC4[-8SQ(>B8D80$$H3>!!++!$"TU0,P><6(4-3+.$)O@@%L"
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M>Y&U(<.*&^3>1"S1PKT&QX,3OGP+9QB1)&25(J.(_2]3)(. */'^)?B0<&>
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MY"6LN4'C  2,(4CA#$)HC2QB8/Z2,P3A-#1X A]C8*A%"',+.W ,%X;PA"
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MUE.M0S21U6EZ;DRE7L1:%,&[-\,[WO'B@B2X *PDP (*XMF$$)ZPYIJ@@6S
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M8'!!#?A :^SI&3H>3NQIG_YI>PZ'+$ !$3R!(2B<<9U!#?3 U^P4% @M9]0
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M0US!U\AE,:@!#ZS"?]*$N\W$(0C:%1260Z#!452!L8U-894!1NS =<%O,>A
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M)= @WX"4HZ>:"(BJVPY?J)?Z//[$>:#XVP5I4Y@!#7#U#BS0.L\$#:P")]S
M3)A;J^8X2 "7>29"4'#!(DG[6@RY<B<%+%P9&N@=,2CY&AVZ1,!.$X@FT"6%
M%)2!-\-%<RU'#:"/7EF"5>A>F,E$F#L$%\0)&>)@ZR1%IPU,)?#.$"8%) C:
M+P0!)&#$%.C778"N.P/#<J"G?>H6NJL[U _,V,B)@ZO$NQDB%R :MM=0$-1-
M+=E"<&PVIA.P(!9#&E@M.YM6SXUZ)L3"V#$2[-2"C9+8I3=!6L3"7?URFA_/
M*E "(W0"[0!#)B1"&BP1^O"$95"")+"^)*P^Z[]^Z[L^)5 "ZE/DS>VZ:\_
MA$POFOYRG.4L'%UP 2MQ00^8'.M\#24L\7S7S?4Z!/^QBA;H'1?H@(*X@$RL
M00X 2#B^T!B &NJL][*&&=EXQ);#CB=,NQ4$#@IE8VWL@ S$XVA"&\'$@"<D
M14@,P:CDG4,055A G;\#1#%:,2P5*U9E!S&#!G<L*J902HPO!G^DZ<6+5B07
MFHHI&>++("87G!86DS5#5C%?-& 9'+/$X"47*84@,KBI1C$S4@SRBI%RAZ1B
MP&HD,L@FIZ:<!CWM,,BIQC"3-H!MBM$SQB&!,U854UHL5HRNQ:0\T6GVX8Y,
M)=FX&"M$3+$D:1X6N\*SV"JQQ;0(T50I20Y@Q6J0+(;&Q_[-D<6:H#%8I8Q!
M+E>*03EC4!,-A083+>ZXI1@D&KR&^G!<;(L/K8=\@$:-EI826H37FIRQR2":
M,<4.U1@\BT;DS9)>>#*XA'(Q2SZ&S"Y9!:TE%Y6*T1!:S(J0XY'#D@:V@TPQ
M7@47$MMQ&DV,V3NH)WG"21(/[;5HS'["Q6 .AWQ[B*\1JZ0 !1R0P (-/!!!
M!&<!(PU**CED"TP07 2,1%J1)99.#@&#N@.O(.,01!1)1)$1$SDDD1-''!&1
M0\A *\$899R1QAIMO)$8&SHLB9(;I$A"B%F*622((8LL)CXIE@C2(.E8 >N%
M'<VXH8HAGA@LDQN>> *AE#:+Y?Z&):;0HDA9<JC""2=L6&NS8BKQ<8D@4I+%
M!M**X4*+ -F((8MB>J#$H$KZ.VR'*8: 8K"%8(G!3B1;(,^@&]8($ T;?O#!
M!BE^"1"60J=0 PHGBO&!$::<*B81&Z9X0@KM2KIA/X%DP*\8(6S888<:BNJ)
MBAV:2,(&K4H")@D@,"&&AI2*884'*:;8":8AC"IF$Z=D"6((*WC8K9B@,.,!
M"BAXZ,J24XMIZJD;!J.3%V*>&"*++<# P99BE@"BDE662N0&0Y<@[0RTS.-H
M(32"D*+5(0:;:R%?H!ABBAVF+2:-(JR0Y(=>B*D!-X&"@,(+,J;0[HG3K CO
M3LHTV?X!BBEN4,0@A0[A@=4AAK"3#!ZL""(Y)%]HB94H#0+&"2%<=LP\"0V2
M!,X@ "1F"AY6'0)EA1(AH@HI;';.SRH$I"6()*30-A+>;LC""C0D+<80%ZS@
M*X@LM%#CAE58<:LD3;1T(F*@.B1CB"T22:P6&V9C0X:W%SD[[1T.(4K9&R6?
MO,99K'ARH6'( +3-A32)9(Q%.A\ZC=,*G*@51!)1/4356T3$]19;L8ORVFV_
M'7<#9Y%*P%\JZ21STH9I]!=*:HN9:UHZET42PX:F!+=&%P(&$P!GB\4W3B+9
M5$!@*CF>F,AYZ45 65)2WJ!AN&;>^9*$=)]W@V9)=-A,*OZ)/$!@+.F*F"=Y
MX7T8[Q.()%K"M9[$3SQVXL4L&+B[ ,FB$I:07N9<(14##@,3)"%&2WB1*&)P
M+1.2P)Q Z#>,2AP+>9ES#C$$*$!.9$(AMAA,_P;#-5Y(HF-#:13ZZG*&*A#C
M>POY7X X08D5QFH3-E#(!3MA&/\EJH-#XYX)*2' HYCEA &*A0@#)$ #4NM^
M"^%A3X)8DDU( AC#(-_T2!/!DFS,. /"!'6&*!!+G,\YLGC?*C Q&%:03PIC
M68CO2/*^61 #&)!82"**Q,*%F$]^8:3%;,:8.TM*3B%;P-]FMO#%I1TA+O(C
M QKH)PFZ%(@+P. "(SBQB4VT4OX3KFRE*YNXB"\,XVV7U.4N>3FCT?621MT!
M)C!_.4QC'A.9 C+#$&Q4!2$< @TU, 0P#99,RJ5A"$HHYNUD(:P$$6,(2T"$
M&71D37/6:!6F"Y F;"(@2FB!.FI@A2$RL0A)=&*:%-N1@&Z)!D\2:!9G($;/
MSEE0@Q[41L"(Q#81VE"'/E27J]CGC"I!!C7D$'>C@P5UBLG0@BXB#?1[:"3,
M@ 9!0K2AC #4@'BA3H/0(CS$, ,E2C>4"H'T(61 8$FX,(PSX*\\ G*%&8B1
M2Y0>%:E)5>I2F=I4ISX5JE'E)2,*\LN6"H@12DN$8=HDB0XE G@#ZNE/8R0+
MHAI5JOYII9Q'8T2,G=*(K6J5ZUSI6E>[WO5VF)A8@%AQRI*D83:\0 1=)$&&
M+P"/0X-IQ5Y+\@5@D#5!0QTH7BD[($E H8NB>^.!("&JNFPV0*.K1!- 6UG3
MGA:UJ55M0X?A&@&E878!$B@QNE )%H8'&&  QB\6<9E9^#5 8_42@F!QUM7B
M=7 !THN,9'8DN")I4,>5[G2I6UWK(J@2P+V)&09TF6%H04A]-8@9%#L16FAW
M(<)%D$)<(5"T7K>@V5U$HE9!BU@TJ"292,,F*N%<@:1A!Y&PTR4:L=*>(&(-
M "J&(I8 C!#9:1/#R$0CPFJ051@"$7:B1&*:E(:R\:@1]?Z-!3 (]A 8PA?%
M*5;QBL]Y!J7U1 LB78@:2,,), @E#8U0@T/6D 8 L<*;P1V&&E)BC- *B!5$
M)2B+C;F%(*PA"PH["!&TT 4;>*T88KC!%IZ0!-(NA!-,T,$49F>H,RSA"0K1
MFQ:X8 .C\,L*6QC"#@;S@R5H80LQ8(-!#G&#,FCA!AR1!(>O$(0S%,U.3_ !
M%ZIP S$ PS.1R$%<F5QI2U\:T\7X+OW0@-&2;+5)'V:%L@R!.:\2J*=J^.>
M:&'<3/,2&%/83 \*4B4+SX 8>G$.%%RU$%8L11&]5H)#=J6<'R")40:I 75R
M$$I%]$<6,5"P(9PBB?Y 8BG%>/["VQ*1;2& I@JT@@)Z7UUN<Y][NHFP!#"
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M.LX@[@8-9H$7;. +. $1".(P<* 2-@%BBH$-S.4&%$D$#?X"VPSB"9B OVR
M+HZ0%W9@#'!PXERB4)Y "&CE"86 TCZ0"[N0"UEA"+@ FY!.B-0 #3@!BCJ!
M# R!%F1L(2Y'%FJ!%FIA%F1A#FMA%=(@#5;!?&HA#F>!#F<!%JY@"PMP$?BF
MB;P 53J$%\B@AK0@"<P@NP3D$*:@7F8!$J7 >18!"AI#S?S*I'0"<_(P?="@
M"9Y@/]+II;:@"::@Q$Q"$HBA#'I&"+BK$+T0%W.Q[FBA$1H!J QD%0[!#-5
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M()K *"R!"-[E2HHA$WS ":QDAN3L"7@@_FH@G" Q0(1 D6CA8>*D8Y* )H?
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M.9Q7+^Q2<Z,J%ER !CKX<VE@G\9 .PZ!F2!!!M(@K#8&4C0!&"ASC9) *[A
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M87UDX &Z?*!>A!BR>^\;@A3,X/Z#?9F!"&G8PD:+,8O,:.$)/,B9FMA8"QK
M[K!J)L;I0.RTY0SA"68( C&%T 0I=.$&9&;%#;8PAAOX2A) L$* :@!23\C
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M8/%(3H4&5J#?&F(@FR40DQ<SH%NDBI$$-ABX!BK2PF5A3OWJ8WX+5U!K%="
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M")P07 /A [RP!7L'#$\0*+P)56E@ P+1!'F3$#, 4F9P Y70"4O0!.#3!$_
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M]!(I,OZ '&O@ [!F<K1PBDN0!#<B"5F=J[VH"410 T/0*ET0!%! >44""4M
M!D/  U P&0QZ!3;@UT10USJ;!*8S!#>0,[P !842!);$.K"6,T#-V/)2))1
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M-PPH#*$'[<3!FCBQ3AZ4M!BP@"4[?<"#\_A*"$VUS<'(0X2C$.,,-\C!#=
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M 4/#:CD10\.%" T3@TL; I5(#P]5H05[0"VR T.-I+@@D@X90A%"M'2AT&/
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M T[DE+/-QP(QN!!?6XF1"V5(ZH0(1 ]40BW00,T,G&OX &%8 J^81AH,@10
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M77?TA6J"UJ?9CG3P &6D@1_U@(=M0E*]Q*4=)"_\@EC*F^5P@1F0 7#)YJ:
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MA!14PO["#U!*']D)7YU%&OS :OP <#6!J!)$),!.&BP!!55!$_#"H2"?%_V
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M%%27+.3]$O38&E"1%D#1LA?$P1\&+T@!I%@"D*Q"$[12C_[5]!;T6"=(V"I
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M8LY#YMQN!E@P(J:&-("1I896BC%5$EDDU0HC+I:8A18IKBBFEE,17(6B+X3
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ME,0^C/Q31^VK<C%F@%E7/Q% \FU"F$Z\"MQ\MA@D^O4LM#S>$U/$MU+1;4,
M6PQ.^& 5/=B9)F(@8\HLI0ICL&*]&\**&<@BRS8N!B6:( 6#:V67'UFX_YQ,
MZNF2&KJ4+M>O6$$,5G!-/U%9I"^PMI(D:R43K-N">;L(MI@\>CQ&#%J8&#Q?
M28\'RAG:@DZ,K*[_)@T-E3 #V)*P,+S%(@E)6 HM)1QUJ4_]:6=2W"]6L00>
M,&1KQ9A"F*PT:7 IV07'B0'HHB8=+):$:T(N"6"VH#]@-/ZA%E'+'A0V&5V;
M#X,'!@<RXDA2HX:@(0:-; A3$0?V53R!(99(PA( U .8!&%35F)\,2+A YW
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MMF1-]F11-F55=F59MF5=]F5A-F9E=F9IMF9M]F9'UEUUEF?0PEVI2"U\-EJ
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MX>C7X@].OND!001@W>4QXA9 (>I)OAC@( #P .F+810((/X7TF+@,8+?18$
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M,0^(D$H?#4A0U93>?@LN1A*8)D@"AOZ'5;@0 =@0!E(EUVAU"X!R2[/&F$*
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M!TPSEQ+A;%'2EES!3@HQF1*13FZ9$I6I%<=@"I]I"@,6&J+Y'L:0!WB0"[F
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M OB:,XKRJ]FS$#ADH*B  A] 0L4B B 0/*8@ AX0"AKPL@B!"@2@%^"*!Q[
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M) 5 "L6@&P+!*L50"D9<&:AS!VQ4 H'TK C1 6;# $ 2-[<@# C066^@-AS
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M-1$C0FBV'9(Q"#C&/9(# K" )Q$ ^3"&!H":/0"*-K&C%5B1[91"!H!-T,R
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M0B"!E9Q]=A4$$'#AF1B.8E@5Q"E1%OC:.\@ "T2*;$2%4%B "V'// @@@%"
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M'P](D,$=KVYDBC&"A'#L+7@<9NY84B(65D=PE+J1,9<6\T;!N@@42@'?8I
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M G8A(!3&T$ !2(**!GBM&"70XP205 P.M*LN6GR# D#  ?X,E*H0I?P "B;
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ML&?A]F$#WX4^^;TH#%\6 Q<HX  *OEK^]\,_F!TIQ #V$(A R$$ !!W0 >
MBD<$@@-<45GL 7[$WP$BCS&@0 (\TP)X0!ZXTU0AX 12H,N @@$ $$VDB,5
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M*&  *.Y" 7@ '+S!"K2A4F3 !83"'AR $GE/5CP *8""" Q [:"C*G8$'R!
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MY$(1D58<0);GR&I9C@4%8)!:L$#4*%^,Q$&I["A;'&-TJ(PIB( %6  *U*G
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M2Y  (00"!FA.64RC!KBE!PA F2H8!J@1M98?4*@6!WR* (+M@,D,B02B<%@
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M!(R*1"F !!#"T0BJ=$0 25!BTP1 =3@ $N6!VQR&B2@%*#3 $2Y :^R9,"A
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MRT9P0&R(PI%$:=QC0)GV09.@0-%DS[SW'BGBCW4TJG,@(=^&<>J#0(2P0 /
M")-3LW3T'XT-@@A833'M@C&L0'3LP4(:@Q]LTX&0NP2,0"03I#-J3\>H@L7G
M0@*HDP9P@"62[DX@ ![4*:30%&.OP$19P*.&A2@PD9$"OWF,D?YP/?D+0N)
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M,_(C0EY<[0T'Z'M@ 0\^*L\!!SB8")<((FB@ 2@/+(8%!B!@8*UB0)!R- M
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MW&T,4 K1AI:>\4% 'D)K"@PTX+*BZ6USXO"WXM[Z?+D81094.XH"U,$4=2#
MB?UE 3IQ( $JJ$,$EL0!">"!!0N@"<+V< <#*&HU<FB < 0P@BL? *ZKB6@Q
M!/'KT*F *@30@!S>((#?2$"B@D  QS* @4#$@0$5<L $+O"&RGYI#@]8&H.*
MP0%+F8( &%C!' Y $E,<( ,6X,,M ("+7'#X- K0# 8^\*P"< 0 ()A#"0J
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MT*083/X 32:@3,#F/8!N 7 $%2"F1@K@($B/-Q0 %S8,H$PCL I.HE(++A"
M2") ,Q:@P3;LIT0C M9B%!0@11[.362E&#P !$#"P^2O3.K@133O(W8ATR"
M_18# :9*U?A %PC 30(!)WHB17X$). @R9!  4*C W+0RT!" GX# 4A"-.Y
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MBX$"]O[@%@[@#O9@#Z+KK"P&!3Q%!$A  M;%% Q >&R0 MPE)M1.)/3@(^R
M^P:A243')7)2-#C@*JPF(X1A#WP3O@#304! ,#CFX2Q#,'#D#OHE DR #_:
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M(^3 -_6 $4%! "Y ] H S70! C@ #T2 PR8 W:IVU&"/R<!#8H0A =@/#@3
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MKB0P51"$+.5)@%1[8DS.&96'JA5J)XW5KF(L(%H,B!E@+F""8(4 -H,$&00
MI(L%$"P.:%WCV1B@E@-<$8-"%$@+R[=/Q VD#U8-SD!*,-MC=NX!5XR 30H
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MG<57$8%37?,!,(1 I1B+LO@1)0 (VB(,'A *QL !J6(1?M 9!'$+'6 !;Z"
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M&? &=HR!&V WA$8 '@ *A:  P8(2?H *<N  NB *&* !#>(!%D *T'8;*T
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MD;:WH-BO4 CQ*@'*R  P+AO)82SI @?2> !,#JBA4 ()\OZG$* G> #4 N$
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M/F^0 $P^ :S"!ZQB3S2!Z7.3XUS9[KA_LARS %22!VN_K1%@2Z=B%/PTSK>
MJW<0K_ZG( #HP0 ?1 !SG 'M@B=HY6VH\ ?2+1 5X%N=40(/[]K=__#D4=9O
M8*Y)5246EB230KK9$QLC 'RH$&N+NE=#)0$&W2I1+4RL<RX I@L"8 H 48)#
ML6*!".P2IN#6(P?&BNFR0,%.,8<.2X@@N*(#03D8BDE801 5!V.#$.0BJ&)B
M'0@$719CX*=8'P<N,<@I1@&%2 XH'9*P0- 4@3O&")@BB $$P3H2,*!T20@
M'X(H)!1[<Y4@"$+%0(PHE@L!U6)W$!AC,=!AAA($<7'0]7+$A[ +1!&<XQ%.
M2X(BNCHDQ$!8,5$+4*)2H,M4 50$X< II@'C0[BY#B MI/Z@6$>7#@05\U!!
M%"@,"H1UB$,0U &'+UV_AAU;MLO5<1W>.NK:(083%!V^:1E' BY3J'3A*L:G
M)9\(D4O<*JX+I8>=K6=?QYY=^W;NW;U_!Q]>_'CRY;5;>..[F(*_YBD6@P/
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M?Y" "( #J#"&.G" #"B*")" -YB# PB)7)  #^ #$3"0]S %#UB $[B%-V
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M$@10 3R0@#ITC3Z@  $T!A!(%Y;H-!"@@#WHDZ9SGT(H #(2ACK(G5OX$6-
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MR6@U0O09! "%@K'%3OL#%.B7(O$ L?R2P2@8!N@QHKR#JW"("K Q,_O'.E
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M(EZ+M /('4XUA9/<U<WTD%W%!;J9SVV=(#]0 .0P!@^ MOC,R@18&(= @8%
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M-ZB)%'V/A46% L@="U"2+XD+#I  !BT6T*B.6P!"_./6Z!49$U  #J@ $W
M\!L/BW0)!IB(='T-"R!;!X@:! W):NV#MR$(W4S:-S4% T"*") )^7T)FD26
M!M@)?"0(![@#71" Y>$ $W4\,^$=01C7C)410JN I'0)^LT1UA")^X,#2&(2
M8U@9F^L-!4B[\=M/0UF!I2 !0^$#S>@ @54;6;*#E+P2EYB ^V1!7_,W#/B1
M!5B\.E@>AXB#%'H3CHD,6'0).1  O5F+$9@ ^X( G!CAG?YQBMC(@^80!@IH
M&EZ+M:0XU13A U$@@ 8&TA6(U '"#4/!@U+[ S6)6)^9VV+H  HIAA(@ =?D
MU3@3AI6\)13 %>T3"HX9!#(FC'^45>#,SY>0@$"0 [J8UA#@ U3  )_A ,=#
MC.-+"H'=C&X#A01(6^ 5WIG$"5#X,RFI5T'0&1#HD!W37NDE9?<@A3THCKD4
M&?V[ PO( (L("H;Q  7PN0,XGSOHP&.(  0D 008FXGK-8DI@3C@  &X"PU>
MC_OCHPPX  [0@ Q8@ C #U)HP3S @.DT!@@ @3M0@0EHS@XX(?A @#I R10R
MA@3 4(>X@(&H SUV@'8D"&1&5_Z/C(,#P D[(( W>$&/0($#  $\T,+&\ ,$
M>(-[*4,!R$D1$8$$J -'+!+$$($[Z( & !^7N#8\4X4%&($\Z,.AN84#P !1
M" 32) A5+(;Z6P$\L!83$P$""($]/8"WR04*0( 2V-,"H+P]"( ?(X@$H!"=
MWH -P( $L !PI28;)0@6$$,YN-&,;<$[R "6D4L3N ,44,!<\,%2BEU070 \
M>(,(X)8^Q ,V\9D(4&,G]#;&@490D,8[H)69<("AR>&=J !3(04"0 YJL0,6
M* "7G""V=D@3VXP0Z !Z"5F74 "R-!4HX<O(Z(W6T,=708#S<=;@A8K&_!+'
M.#V4[?X*$'B88G#>42[ET0:/%W0)$ZA6D8$XN@,%R@N<-Z"*.S@^4R +D@,!
MEG,-52@*IBR!%4 %/H@+5#X@U!$$.I"#X\Z>]]@Y+FP-5%B!$A $8X #-!&U
MF0 !%3"%/4 )XWF)0/B,[':)UGN)/%"AK"L!@[V]3SDY4(7N$S6[BR +M5L>
M4#B?"8SHN/S@OM,-/D "E,"%_";.V_/M];'HL1&%B_#8UQB$UWV#T2,(/A@!
M$( #!W\5.D"=/7 55*B#.9"#.; ].7NY7!D!0XXG&5:^01(*%#B!4,B%-] %
M45@\JR.(._" -\CNUB ^$Q@;H4+9MQF$7PD%2#(%%(@XA_ZXE%(PDCK "9/U
MP&&;<:WSKPHBA/MYB<),*@(PVE P@(+FR0XPAIM[$AU^CPG %8=@ 4;) \NK
M@W2A" D@WA(@ )Q8# XXF@RY@Q(X@&>1C,#)#=+V\_*XA0.T SSOSS^W(!#
M%4/G#MB<)%$X 7*5('8L+SZHM]X3-5 P 170&B83A$?(2CPHKSZHMU$(\5#H
MQ\7#!18H@5$8A*89!-^FB"Y4@>,3!-X1!CPX-T77]43:!3CX@+([F1/#/R 3
M;'4KLC4"(WL;]G@B,F,/LG5RB./6M!,#)V$W.#T[(R #.$-*]F2/)&.*L-A
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M))))*DE8"0R4P($"H!"VT!L3'*0 >BA 8($#?0C4!P0<1' A"2N,H,!J$D1
MP0H.N&:,"1%< ,%/Q<R' 00F%O-'F!&88%$&*FB@  E]4," !K]%L(=W'$Q
M 0:@X9+!!!940%$H<F+%5@1_]%'!0'%X(!L%+%!PP!QU1)# A:94*H$&N9CR
M0'YOB% ,'Q#@"==],T[0)D4+W;$  Q2@0F $%400RD$C7'@,!+>\ 5,&<F"
M@2@1+.  *()(L!T%CQ1#2 2.BK#0!;P*Q $*'2S002!<6B"2,"!(8 $%M 4"
MP9PL%/ZS!P,,2'"+'!V^X<$)$""P@D!\"+R!"+>:4@&^&>0G$"X:8)!!OL6<
M0O$$&EQ<D8@S_K2" HAJ)U &;Z!R@&9R>* "! R,L) '!T.@BP1T-4#A0KE8
M<.Q""@RB2P&7X=RA!WF<Q %,##B]$,!+-C3'B ,Y$-M8N2C;U$*C1!"!EQCO
M!^%#LP%76G*FJ;:11;? (0A<0%I]-]YYZ[UW6\6 <D!]*X!J-U]P(% "XA+
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M!G@)+HC)53#++6" G#! ;#P"!%# 5= %!L1&51# RC5(M$2$!JF&! R%*$S
M!$2 !FB&&-9-,010!4! "31(*%$ "EQ*'D% X^S?FD# PBW& FB&"A"/!7"-
M:BS%Y)S  K )!H"("+"7"M0! ^#"!Z!4.]5;!^C)".@?"&S)A A$(#C 58S
M;Z""F5'4K9A)ETD ],@!!^2!')"9*4B !%3 31W$'<06"  ,']ADI1SE0\P6
M!!AE&YD \43E0"$'RV'8!(S !#! %'8 "PI#!-#%!(C+0HA" T1 + 9,L(3
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MP5#X!$V=[0$71@ FV3 $#<(@T/[&(T=$#'G  TB>!UQ(ZMP&'.QQ'W3 62W
M(*ERX(9R51S 'UE4K%$S-Y\OHJT 'M0!,WY/=C" *&! C\"!AN&" >A"'GCH
M?3U$WR7$*_187Y6 %KV$$A%/<# 4W[W2'"# ']R"A-!O-ZNL-4>/05!-1!VT
M0P?O2BA=765-<Z:&"7! _@B;91:#(Q6#':@>+W?'/!^(*H3$*PB >AQS,7@
M/U.8_##5SLF5'TS40P-N*"]$'"S ;C* O]2T3\ON!$!86@; * C#]2%$* 3
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M2$!E#T0?2  $; G=07?J+K>?PSF/"D,8[00+>, *4*"@+SK?S($ U,%LJ(
M#,58B$(!W,%BKT"Z%2FC$^X*5!\N.  'V $'+, K=#JJXPTJ",")>X#7:>$<
M^!VN85(Q# (>()(IY =C[\1D./YV7HO$+NQN?-!%*#QQ'^3!>Z2Z:O9!!!
M!2P$">QQ!IRULE?[H18#'01R5%IH* B RZB$!AB/GZQT^[)H764 =$S0R\P&
M WC !ZA.-2V "2 I\F0 )T&&M:LF+HB"'=04='C)0OR![^4[P0M&M,\$P!S
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M(50.6"$4/"98X%I3+0_=<EHQP"/CNP.!@&*03%E $ CN]4 .$/PL!H^&ZJ
MW0CX*(:04H5AP()<,;"@=P9^;=8#"!#X &71U;Z%@PI&((2!LZ'/7GM3(N#
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MX6),?/X-]:U$I'W@X#*8W!*N3L24%1(+7\]<"3$P.,)S$.*:U\"_B*#W*H1
M P77%\V)V$1]=PR,'KA@#,5PNKM7H> 7N" '6ICPR]&>]I>8&L; \(&K:<&%
M&.1\('(7@B:T/9!?K"(688_!SXL1[*/'( <33H,+=.#?0R0\"3&(PB'0H.1$
ML,(2]26S+W[@@C)X'?%GIP4BM!#U%QA<[:4WO4DPK(,U0&(-43=Z,>9- RS_
MP@<Q> +!;<_=+9@\X,+FQ21<;?"2[\#P3YZ%US-,BS&\0 G<]<4B% $,3%B>
MPYGO.B*>O EBF&$*@,<PW4\??O$/I H9EB]]73"$"0]#"?YDWX(0Z,OBD,=
M"4^8P0LV_H,,NSKXQ?C""VI@PBR-!OS+$-1,%F:A!ER@!Y8-!FI@Q.H+RWAA
M!UY #(J!$N@M!M8@$6 @!L2 #?)LV,9O!$V/"W# !WZ@!WS@"0S!P8J!%[1
MP68@"7YL("0A".1K!]" NS2!!V8@!LY@"X!@"XH!#6Y "'K!ZW @"/QK$6Z
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M@ 4"2H !+B(#%F"$4*$ 7N4.%* #Q$@P1( $J @#,$ $%OX@@XK!!")@!""
M \I"%!R  T# +6WG(#4 >_(%*D)@ D!  PZ@)OA  3P@ QS@6G8A R1 !!@@
M(8I! D@  @ F<C)@ S('AB!  SY  =@C0N$S8^+@03E@ H1!%#IG D*A#Q!H
M!19 !"K  N[%#UZ4 R  =AQ"&#A  D9@53ZE 1@@ WQR(!I@$#S@7(JA!!XR
M$!;  SB  48!%PK@@5 @5$(@ E1@ HRR D0@)XZA0R$@#G)A2N-1(AC !$#B
M%@K@FH2F-0N@,F=R.2UQ00&@+4HB C+H:: % BH >Q1@4T3A9+J3?7)F4D1
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M'*!W<"$!_C("9D@L/V("4  54"$"$F(4" !0WB G .!J^743C4%N39(D5N
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M6<=W%,+2(71A#P3!:):B6QI%, 18(0@A#RA&%4Q@?4:XC/!RL5 A+DM:$/;
M'UE\S(VB.4$G:_:[&%:@?46A 3B@0XN7!1P !3 @ U#&23.  83A%B"  C+
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M;KE[GS;E$<";3< E]RB%',(XB^$4#B .4.$/3I7 $P $0/X  QA ,"#>%/H
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MUXYXAOYIP@=+%?99,1J8L*9$A'1FZ'6FO%'I0:(H8"9(F0I#0"J1^DDJ>+E
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M@ *RA KO'4 %QO#<" CX$UPH /XZ@5@ !S+@ &09HP,1$($#H(83#TQ  G#
M@ 4V:$#QV0X#- D% T0P @8HKH,HB4 #<D&( \CI#9\CEE-N(0$,@$ !<XF
M' 0R"$[AXBX@6(#N!-& $Q @$*! 0*<L4 =1', I<F# ""R@ 6. (@$M(40
MR(6 K>1" 3*:E 8VH(!?&4,$$."C!YS2P KT;@/7RX ".&<,753  E544S'X
M9X'>]6$!)?  !&*% 05$($MUN*$%AG>F.""  Y[#P.YHAX%+CN( ].* D^S
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MQR5F9H$!*- P(1 \ D$"]T,*0K0JZ=0!/&9 HH,!3P1(IEAKV7."3\1\C44
MTW5:&K05FL4CCY,L!: K'O!@>2!J$N-%6'4' U6!O<.(\>9^ I$*%-9, Q$!
M1A%OML(I?]!JQ2 (D")S8Q,Q!5@J+   FL$' )!Q0(, %@ H"B!E-@4 3H(*
M6>>#<Y$!,H8*!: *QE!"J&!#?Z4 $/ J?7  HY *<D".CP1T@(0!-8( @: +
M   'M_X@"E@R0D;Q/*. "AOP8'U0 (& "G) .;5T/R/@3\6P L>U!\AH3&W1
M 4*'"P< '<9@ 0LI$"O  *%@"B, 3H$  'YP"T'T*QU  4:Q @U@D7QD#+=
M5 *ADQH31*.0"P@ +AF@ :8@"LMC4P?@!ZI0!R[)7#4U :<U8DZR @(0!ZC0
M!P+P,0@@!Z@0" Q  3!(::KF2*!P #"6)W&@+JA0 @Y@)K?  !(G$'&@ (2
M"@=D#((P1DKQ!@7 8XAI%@N  JB <R9E @!@-'80 ',1<C+B%!U0<*8@ >D4
M"@60!ZJ0!P;P*Q)0CAYP 'N@E<2568.)"BJP "U! 1-U"OZOA0I[4  B( RY
M8  L0#,.0 *F8$/EZ!DKL  DX %W@2X00 *H\'EI2 <$<#]Q-0+&R0 %E(G
M]SW#)0R!8 "B@ IP( "P*&.Y>0MQ!5&A@ !BL0<&P)&BI(O>>"-. 16ME0$*
M(Q GH(-R(&," 4"],0+65%:^ UJXX &M)0(4, &.)! CD(;%$ <4D &&<P'&
ML!<# 0H5 "DB\"N@< &#D6X:8#3&\ 8Q(0)RT@<58*%3$@<U50>.M ?<J8IZ
M\41P4%.ZX &R<@?3\Q-P$!,?@#-[$!-T)Q"C\"^!Z: @T%H+.A!\<*3;!'$"
M<1:#$5R!8!=^*! E$#<J$%5OX/Y6)J!;$G!.-C5+*P 5@V *]U,,*D 5 H$
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M]:2]*P:CB@&!.YPI4'N@P%@@\% 1X/&?@\I(BTFP$SD$8A2:J@,<7L$:7*
M%'@9I:KN8 P^& \$&!A!! 9< CL4([I2OHU5(E"'8]@AI'V0P-0R *8]<$6&
M1YF*,:AK*UPL@!!W18]*!S&L4 SXFKBPP-XL@(H5<"!J#\!%*)0)'%,X( 0@
M\$!&OO,K85 @D';"0QX@A&04Y.("<\, *E@ (!4<$15S>J<Q'# B17, %%DY
M:PD,PP%L>F 0<LA 1AYPBT&4Y@T%I3,NN&**/F!E*(-858-1P(=<B 8/=K7
M+8Q1@OY1:,#6&-CH?)W];&@;QV2_*YS>^" !7&#@#4#E0UM9P *"' ]-22JK
MOF+3 5U<9]8DX&U25J6+#DP- DVAKD*&#!I2X>)7NT %!E3! 9?=0BAW4$&<
MB@%PGA1";_'>BJ:8](83*8000<V +C0P)5#LIPYWZ ,\#Y.!-R"A!!G)T5>;
M2NY&'840N:!7DV+B&)&B0 6 R>=FROR84QAU$"79P)0\X$8_C(!7K\B-MI"
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ME.I!48S0AUM=JPN3* <Z*K <]@@K(<=8@SVX3!DS"%NF4*#+5B45,P@&6(F
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M ,.P4?Z")@#@JLE"(S#B3#0AM6A"#-" #C =#1R;#[A +M+ "^B@&+Q ]LU
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MPA>T@;-QPA>0 2P4@P\\ 208FRI6@0NL 2W0P!FPP1H,FRR0 1EDFR9 0B6
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M_$ Q\/Z"&GS!U&D!ABYG;-*H)3B<+Y2?)AP"?+("&2S"#V1AM30!_N$$,-3
M03*A#\SE1)Q!#.A;$]1 K_T;!0*#;&Y!#=S@(@3!4?+"$LR ?BI"@WHH+:CH
M,#0"%T@",8R!"W#!O#UF^;W?(:P"&WA")<0 %*R"#UP!'?Z<+)S!%R"B)(#!
M_$T$(WP!Y,%"FA;#(GP!P5%"#/SJ(8"F>AH%&]B ,49!#VC"+>KB7NK L3U!
M#&0L#>3 \9U:8G9D*[R )%A""PA!#[S *B0K,#1!$21K*] "$)S!$OS *L2
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M7Q>#$%C! @.V#RR"-2>"#23"&.Q 8@]>);!"$_S O:%!Y[5S]YWL=?NO)>C
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M1_;OY71C#9*B"CBJ&'XA!A)!%L8#H- @!JJD21ZB#&R (7)@"P8BP5[ $IK
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C>]=W?Q=X@U=XAY=XB]=XCQ=YDPU7>9>7>9O7>9^WDP(" #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>62
<FILENAME>x_cg002.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 x_cg002.gif
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M]_3S\_+W^_7Y_/____CW]_#O\
M
M
M
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MJ8&@ZN39\XNT[]_ @PL?3IQC'@(+%B!H8*LD!P,(+GP6X*" =$\![-*9^>$
M@@H&A_Y] (! >8$#"Q0(>' YK:T&"@YT$$8'P ,!)\2^94BG;OH"!2BP0 $#
M[ $70R:L!\ <PNP1@ $!&-A;"K$5<%MQ&&:HX88<=F@2!P0H(&*!$H5D(@?G
M2?=+!@ 48. G!C100!WZ/4324!.))$P'YU%@D D *$= !2!H< !Z!'! $8X>
MX>C0+0TD4,!\M4  @ *A+)2CC5Q&!(@ (A+@P <?#*@< A<*Q&1):Q84B@(
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MH=BLP2EW[+P !U4-UL!F\X7"@?[(=PI32PH3-,"  QH8*- *7KMABP@-+."
M&R'UP<'+#FQ@^$"??.   PU<@&FI>PBPP-$ZDM(B ! X5$H)$< \@0J3,M2&
MURO84D+C:PMSR@>X;]>0"!Q@P,<I&B1WP:N!7)"<!6<)\X<&(VA "@LFQW>!
M!GR, ,$!"2C  0=\"@,*""\W8 &-P\Y! <P0B. SP/#'+__\:5E+@ BG+B
MC?Q!+4"6@^E5 % @$!4 P#MV@< $#F =OP H &W@0 "4<R@(%@0%!XS,  [
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M=%.YW+0%*&0XH!'<XA0<1H"XMA>?/-AB#Z5,*!QN*"+2C79 @Y@.9%HCD#:
M20&,ZACI!&*' !V@L,@AP&@V?*@[9O;*6,ZRAS;,P J';J[Y%,:/L[DK!B1@
M "P0QOY+*RP0"2  97X9T=0:L4^:@N0@OS"%)]J07>GT86D,$L@""Y"!84"@
M5]45!@5\BS2&A&+ 'T,(0_(P  8,X$X,18\ !%-%!#C (6$54;=0<%A;Y$\
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M%753QW_ZLQT,!4T#L +UU2L$:"E]\ < ,$U@8ROD1 "VA2(%XQ 5J#^^)CK
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M 7 @ @=P3[LE#!O@'2]TDPK > 6$' BPE-G5 !Y0 ?N$D"Z54+L5""HE 'X
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MY[YS4$*QQ4/R(;-E_5;;CPP7Z-W?;)CT%[-?U5]^41M^G?U_#/SH9YAAG&*
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MI$N!.7@ -/0$ -@R89B  P0%I3,!+)0C _B#4LB !?" 3Y"[/>P !SBJ#YB
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M!VC+/P  >X(J>%( *P0 8*L#Y]2H]5JF.UT! H  "'" "#BJ/SB 4\(]AH"
MN(.HK/H0F!J  BC1POB%4'"# 0"F08C54PQ*F7+'.BB% O@TT0* 4T"%6(4>
MG[LC]YN#J0P%!9B\G>* "Z O-_#1*2R #%B!!8NA.&,(XOJ@/< A#[  T7(#
M\Q.B81#*-F"!$.S$% @ MVK6]J% T7J# P R!PBJQI.C8?X0A =P".EJ@P^P
MT5/45"V:@S^:RE.P4H;8 !A:@"#BGPRXJ B (M!#A3M"QV%(.F%( 3<D'T%P
M Q,X "@R@3D=!K8Z!7 5(E#X/C\R  [0LLU$@#=@@38P 0&85;4R ?'CL S
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M"-2%I!+(V&7=/]N4P!I:/?:54=.\(A&PXJ#>3UB^  (PJ+)BB$!P3@CT@#D
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MB\F! L**/%4IS![RM:&6HQR\9-"UI]1E90KB?0S*&R+-L6-(E^6! 0<??X1
MDLE-28HI(YOT*BDB'/HECW1JP&<<'Y<*DAT=C$!*33JJ18>>?,8H$AV#TMJ!
M!BR -(P;T=:100>!P!&M(!YDL*HPI3@HTI+'8JN6!4/N(7%^*:!0 @IWX ?2
MCVMY=SCBB2N>^# *>+TXY)%+/CGEE1\>2@G,6KXYYYU[_CGHH8L^.NF6#T,*
M$@YH7CKKGX/TR02L=@<2*1$0TSKNV'GVX-@)9K"15\GUGJ!UJQMON%JK&\X[
M3,@+[_Y\\]&OI?SSR%,__.[$1W^\]M5Y9@I\R6=?_?+7C5]^\=JK+_WYR7?O
M/OSDRS__^L^?[[WS[6]O?OW-X\\^_?@G/>A9;X#O4Y_FF,<=ZJ6/@/J#WOWR
MIYWA6>D"#AA$=A+8P.IQ;WW,BJ !.\B\ZVF'%+]07N^J4PNDY:Z%+GPA#&,H
MPQG2L(8VO"$.2\? '/*PAS[\(1"#*,0A$K&(1CPB$I-H0"4RL8E.?"(4HRC%
M*5*QBE:\(A:SJ,4M<K&+7OPB&,,HQC&2L8QF/&,-=XA&%W9PC6Y\(QSC*,?%
MJ7&.FPM%'4D5+0G:L8]^_",@G6B*$3B@ 1/@6P8%V#\';OY0+2OHBN9L\8D\
M+O%!)0#$=>IP 18FTA8>N(4M,L"F6G#(?6<3!APN@ %55@ $M,) !E2)@FB%
M @+A>P-_V'*80/*RE[[\I0M)@8 ,_"$4=CB !RA).I!<P)78 84!-!@Y"(0K
M>18H0,SJ>(L#4"0$;)H#<I+7  QVP %S@$,<X%"8.@P@#NG,0 %VQ $5".,4
M=-A &\@S+P[0@9/ _"=  RK0[EB  VJIA0#29 H5LBH0@=@=3E88DE ((GQL
M(9/& )'+>@KB;FO1  D^@A-1!"(XO]C# D!Q0F&@ A!WP\DOHM.*<@&"A:1P
MJ4@HP"?B"4("=0CG+Y!6B]T)0OX4?XD.?O0U@5-D+P_4$<8'G*F6.C1 +2-X
MZA\6, Q;S&$ %P#%,$)Q 0+08:4#/2M:TQK'/6*'% .(3N],( %A:" T]53
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M\,0!"5K 1B( 8F&D0 "HN 4"B#6'"5AG O0TC@+D(Y[@U($!DD()5!3 K^B
MTDK%86M[PRSF,1^1=@! 0 $VVCRGR.X["!C&+Q* ( GTP10&$(1#_R" 6K3E
M2Z=(  CR\*4.4$D0G]! =1< !T\((A0*&!(%)F 'CX8$LTI! 'Q0X,I0E/@#
M.0/$)^03F9TR."2  &Y(3"$(%B  )S>N#A]N8@LZ*  _O_X-[@)"L4W^V (!
MID RL>@0X.0X8&4BD$ >ZE"'/("DRM7)<4.&L8!.D;G:UKZV$8<! @*@@'IN
M)47P0(("Y'# #;=00($/0%U"BZ 6I4A <$!2I@D40#,9B$ '\OT!.D@;;?D&
M@8F&L0(+(* "&[4T*6H<DA*X\A,*"(X&(N"!#GC@ P4Y\5H@\+ ] +<6&K#
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MK7E"4ST5XEE''13 9=R!!PB UV25,J$>!5:@!2H.*7!  RR  YB*2"S([HQ
M!!06F_Z00@:$CQM   504T@(P@1,0 14DQR,( 6\RA](P I:UEJ8 !+4$P;
MAQNP %14!@8)0J1)P&$$ADAT@-<$@D'=0@=00 ;LP0H8E(2HA0CLA&?\@@7T
MP;,X  54'8= H0K"00>@@BUL$EOT%0O]!8>DP,X1#R"\H 1,0+" Q ?DR 1>
M(!_VH1_B77?\@D45CX0E1R$FSR#61Z1,#MDECEG1422U&7>\"R713@.HV1]F
MHB9FH@(MD"?.#AHE3!U5QR>\RB:>(BJFHBJN(BNVHBL&U!Z^HBS.(BW6HBW>
M(B[FHB[N(B_VHB_^(C &HQ#%(A<1(QT)(S+FHO$8XQ,Q8_XR/B,TQA'W.2+I
M-9(3U<((0( A(5(B31 3/9L!"L,?]%SE, L*D ? Q4^8,*,I<$ '_$(' (_N
MS*/\C,#)) <I@( T@2*A4%K\?(0(9$S1!1#_M,%.N0X6<@@'T(PS'@[M:$!P
M@ *;#$,(1 GBM-$2T6.JN4@?[-8_\N-V>,8)!%Q(M,'(K XI*<X'J04N? "8
M#21WI*1&AD0*F)T!Z=I'AI!2Z&-.NH^V5<@$70 ?.%8&K%(&3$#YM4PL[4EP
M30!)VL+*A 0=^&.VU=,P_8$GT(&Z-:0.A:0U>N/NX0<@Z.!70DX$%,0E25 @
M6-8>@L0(3( )B4 U;LXY2M @(/Z )$*.6SH= XU- EP%5VI.!J26-TJ.9RB
M'P@#BL D2"+.*8! <$R C"B %^JEYX $' P;()@ [D  (J43_] !<G"EE1R
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M@B!L8:+23$A\PD980&'L#DA\:'Q:21LLE6>4(D351T0I14FI12C45$C8 @,
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M.,#'38#664<*)  #?, O/,"@7/X =5F  ?#)"D  ;:66>'1 !10 G]3! F
M!'0 2(2A4D@ !WB  R"()S  JX"$C 5%!& +"CR !NZ<!M2M; C#"B@ V0X#
MO! NG&G !&P  T1;D0K#"5QM U2L=9C"!&RN VS$(#R "5P !$2 ?B(7!72
M!0AA=:P R3; SM7.!63  U2))SQ "1!<&Z  !2! CD0%"EQ !1S?1SP )C'
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M!8!$!CQ9'G3< 6@ N-U" =A5!KB2)K6@C]D"%8O$YGY'-'$T@@P#!6C8'P
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M=7@2!81 RRDZM6V]!Y@ !2%NT(:-"#C=(,3H6GBW=9"?OP:WA]'')Y"Z,UG
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M+K#(E@E43:B#"TRQQ83 2"F 8SL("&684 PXY10"R-03/CH0",46/@ZHQ10
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M@4+M(88S7$!P(G(+ _3!@!8=QAVP$Q%(12@!NG%# .!CD4D) P0UTI#@YJ
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M^DX!X!*B%&](2A)0\-:P##_!]ZK.>;Q) FKG /5O19#@RV)Q"2GF\9HN 4L
M0ABQ#*4O_(J1\CZ ]^Q'0PCI XW1%A>P$V7Q&,$O!:0$#NREM7YA!28 %=J
MP)PQ',71(^B (O2O\3CH^=H (V[A#H?1"","! @@6U@1$_$O(CC@ G0C-YX1
M]'KL R,"<<1/U<Q1^MYD'*$Q_!3C'9VODD!A#4W! )!$:U[C>2! !$#H \S/
M^43 I][.IRQL!!/P%PS@OYP.12("G?Y@(Z=1>9Z. 92OM6 2(6]P@ !1(Q0
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MWH ]A&'I,H "*H!<BD0BFN0Z-& "7*Y0&X #)N "RHX$%/Z@ 4C %EPB4$2
M RC@ -C)W2JH/8:!QSC  D1UO!8  R @6S@G*S2- R(@0_K@ =#%SF8K1TH@
M4VL$%S1@D,)#(C+U.SS! 32  C* )'2,!!*+#D9@ @X DJ B69<5/S) !*3U
M2^Z@MB0H%!X@6"F@%3PB!3*5O6PA WQK6&LA MX@ 3IK%"9@0DZ) 4I 716@
M0S*. PC%(WZ! Q2  =K %$ST2CI),_:U =ICFB8UD!B6 Q*- SQ 57,DN]R
M  K%_VBUFX2!&))5 QQ &.FNQB9 !"  =^J'8E!%6T.@ 9S"%BR, 43@%N85
M C!"!73" 2 I,S1@3O9@4B6  _[FK@W^SP$TPU,6( )&Q2).80(P "DX,5I%
MH &XA12ZRP(>X"4^( ,^H (.X,).1#TN8 &^K)(J")(N11B:]@(NH%:%010<
MX$XAH &"8[->R<ZVR!8P  ,^H %H@A0LS !,]6DB(@6(8^F256A9XVG[5F$
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MX(')7C &LP!JAP2:A!3PM 3<  +^CBXRXA80X#4J@ (*OP.<(@/<P.4/1 %
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M@0"M_8(#!DJ()T3XBT$<8#1[,!AD.)"!6MBB! L"@09^48L1\$P8.+R%+3Q
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M2+]<Z8_^N/_^!];U$7!W,/=7?ESW)"5P&-%U=\RF;@Z8?'L0 <, "@O@  O
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M@K$'@/ZI*1E0$V1I 1MPF4(I#(-P"TX9AOAEFIKB"<DIFU_H!G2@(J2@*J8
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ML@QP''?  "M  AI$1$ZQLVJ+)'*PL>^1!PM@P1@<%C5TOH@S 1JP7<4CM*#
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M#< !;U#XOI&./4*S _$ LT4!PF8DK',*#J !E&]AO,0NGR S(Y"^3U+#8\$
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M<0D%0*OSY F[60$)2)L5@( 5X  &4(D475&3X X%*$^?@/X1%%*!!&@@[/@
M"8 ##[" OM  %"(!!(A0.CB $O" "W" )TP8#>" $4" G4B8#W  2 JD% "!
M=#0(-V  $]C,%S$%"/  P>R@R2F!7<* 5@$.Q9 #6Z&D<A.$!"B!$U  "PD$
M[$&! WC$CJ  [UFHP! ]^3@V85@ HB$% WB1O9H#Y!"P3YC#KXQ4P7/- ,B
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M!=$+@13PF=Z8@%M1#3FPD4%(@0H@ &9L!-(8 $\PI#90C3:X \EZ#02PU(Y
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M3YA@[MZ#"0$K"PB$/T" #5KJ.?B$$U@ E<B=#&&?*A6*9J*).<B<07"P[R"
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M <-& #5AP$%U)HC "C  @::UQ002T( #:D$*!@1U ;BBPP&21(&6YN$ :UE
M'X2! 8$! @$I8,$"_C",$BA@ G'XQ0"BQP=XEB !"6E>.D4P@(+M@9\C., 7
MA]&!";R! Q>(" 8D8-.0*D0$"QB!!BB@%9;8H@"Q44#91"" /=QB PNX0,%6
MX  5<& ""6H#!#C0@%-\  (V10 )%/*!"+RA Q9H4 ?ZR?Z23QS  QX 00$*
M.XSDDM4""1J5R"*PDN2:@ (7^,4P#G H0&!V 0:A% T54$.6U,$!#A"!"N'9
MA@8LI8JV0$4"6$> !#6@(B(@@)>&D8$(E, #"RB!9.;@+CH@  0*=8"Y++
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MA@-ZQF=U#6,!<#+!!.P@C!1HA03J-$7"Q50 BB94F2Q)]RD\L) $W,)D].T
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M^-A*Q/X!JUAB'>K+')"*,'C T9#" :1B',@! (!"(-S=0J B6LZ!  S=,%S
M 8!,'SC>,'#DKYD-'-#! GB+4M"%+PI+ F20!31 "5A+H0V.'*P  =C-+1C
M,)4 !8A"*(0",#T37BS 4I0" 7!/VRR&&SC U[R$*516HH@ D"24"IB"N\S:
M"JB "K! 'Y6"%64&'?R8!5C8!:Q "JC &PB"38J ;*Z ''#/'I0 ! !96P3"
MSH'$!>Q)6KQ3OYF>]K&E,.#!.FZ,Y_W!P:D.GW$ '#R;OCS 8J+3?[%$/:F
M;-;F$8$1!GA"!]C"!8 "B>&=DH#"(XX)$*F R1V2NY"" _YPP!L$0@2@2 FL
M !T4$ C\0;8) R!0G*(-QPG(E!^BP&RN0 (-PMU9(Q^\8B_:HL"L0&+F01L
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MN$%]_<XHM<F@89V(*0FJJ=/]0<H" -$*F-S([4P)6-]*7$J$9@ (#,)Y?8#
MU()I>OX P)6?3-%=F1@/,/8,G=W1["F 06! ]Z6FR,A4!)(K!3[8YQ7 J;Q=
MTD%%'YE>[XD>A#) F%A ]VU,2\'80IB EF9$W)*)1%S0F%Q$'6C?ZG"$&[3=
M(>84*=A;6I5:]'A #;5%*!  $'U"4Y7  @8N0_@00([  I: Q2U +A4 C< )
MPZZ%S$D&QGV;M=P!H2JL1AYJ@CC 1VI,H3D)8.Y8I]B!#RD$2WI"&H(K_6C;
M1P 8J<3M*5SL!7C;2I!BTJF. @P3"D#%R2H$'<"AZJ@ 5QX(,#:.+5C 27#
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M'$BR((Q )8,1$":("#B 2L0! O#!(,ST,/ !-+7$%JMR7U-S@H" 5PB" '1
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M^/>&^-\$^7O_^8>%^:._>JC_^KN_\.?"*[0_642"&)3!+OXHQ"R0@1F$02Z
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M51B?= %07:#:7N2B"2X8@^9R4 :1Q *FBI!$(A*Q6B+I:4&$ .9 E/LB#\Y
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MF.#6<D'5_,(7K.!&F@ 1@H M OY#"DYD![P@3 Y!"&[ "NJ"" QA(.I"")*
M%XB/"(J@(Q)!"': "G(A"8P <Q!A-&9@"%*(W-:'J6XM$XB "%8!&)* "##'
M"XA@"A(B"XA "&I1"89 "+ C%[: =FJ@"I1&"_S0%H=@"/"#+G@11J1 :2Z0
M&9O1&7TG%K!@"&<@!Z2 0MS$!VY@$F(!%>5E+&Y$" R1".8#%IQ@,"@E$52#
MJ4YL&#(!$F+!$G1,$FC1+'(!"VX 1K"@(]ZG4\*@3VI@"TCB$8@@"-IB((6
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M"8C !_"OG85@9:$L&+)@"*: ".A$#&I@!R07&*8 DH=@B85!$G @!X; +,R
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MEDH4SC*#<E'E4.@D3"RT1$8]]*J0%4N(^)PF-F24GS T6/ZF&5L!#LCI@3L
M%==1M2J$R! *14*A,)1(:N(.%5$AVYX9'2)I),\Y'96K"E4AJ%MF48&H,+3,
M$*MF7.7 %7Z']!+#V =%DLNWJ<20BG-1&;M91CXD(EJ8?/,='B:&F#$&&HM0
M@G7?B">N^.*,@WD&#1F=L8,L2->0B\3?!GJ6W .Z\)'DE-?H5YW+$1),+U)
MIF]_F,3PYXU8]!D;2#3,,DP-9YRN]=4[G#%,+U641HAQL<2P"46W^=*+R,$
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MGU&A"CRP$Q+#-IW G%$!CZFX$/%H8T7!0>*B$PHS!<&#!A71FC\#,?1'3U9
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M!):!!OM3W/[=;,#0IFTQ#'^UT/>&'P:!-6B7"ZK@*JO)PF26ETV6EP'JO#5
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MLXEP&B4&0[.4V1I2AADYP@9[644,VK0%&Y4A)H80"!A40M&&O,D5WVD+)V(
M%5K$P!+ T,Y>?. %#6E!()T85!/2J1%)/-$H,U"8$<]F*?Z) @,3X O0&% B
MA+9,8@>?84@8B'K%H^8"6,(8PA8:XH4D $:I;:'$;#9! XUH@JL-D8)05[6E
M.JW2?=$!CT'1\H@D]:(,:>6!%^!7A1C<!5K2$@)@SL #P%!"+V<,I"4%.]A7
MQ2(,9UA%+H#1"U<HP@N!)6QD(VO(P0!C"#O [ YN((2:Q ('Y(G%$(H@A418
M035,:!,F># $+'A!JK!( A-(:UIAJ"((0OB)&'I0A!XT;!(\$,+);B;!)^!
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MYRG=0OYX8J@XVAB25:T IT(XR!O( I"( 2Q8/&$@J"[(A5\/!C2I,/\TA!M
M&5)[ 0>?%R<H:)$]@R"09&'  J28%R8(HBVX8:V 9]=P&)7HA26@@2W@8"P8
M H41@W%U =J04PX/.8;@/#.P!%G(!?*TM/_6]Y7#2R\1#).,QABB!3+  H/0
MBD=H+2\"RIH !HY,3438 EM/A$I(BV0<"KZ-(5?H'U@@N4=8D0H'2+0Q R]8
MA4R (HG7@@>I7RM RZ 3 V79.:-88F:DA"S(R(8H<]BU A\,22P0@Q7!A)/&
MG"S  KY\A M/!,3+A32P@BT81D/JF-JR=<+P211)!&F3^?ZNEQ;GU@I7,/I>
M.(/,G2!-D%%98)5=N%6[,XQ#P((PZ)V&+DLKH/N&L 2,#*2.M TY:XA,J,N[
M)'RC,$IZ\@(TF(6J8XA)6(.ADWSJY4-%.#),J$L^Y/=.)01=)X3/,"Q/UPA*
M. 0Z+81%X$.W#SJ^7(4'D83\4PA-B(A-]IZ]4060+/BK5H1-.P-#(/C=%WZ]
M*ZECQ9U-"+/,X(4AN+WA=_[G=Y75@WZP<T"B4[]!3[L'A$#LO_[NY_Y<J(*%
MTW[#D'[T&PP%IHR&,SWR5XSJC\#".#GW-__VWW[&*+J?XW[J>PSYK__I]___
M!PAA @<2+&CP(,*$"A<R;.CP(?[$B!(G4JQH\2+&C!HW<NSH\2/(D")'DBQI
M\B3*E"I7LFSI\B7,F#)GTJQI\R;.G#IW\NSI\R?0H$*'$BUJ]"C2I$J7,FWJ
M]"G4J%*G4JUJ]2K6K%JW<NWJ]2O8L&+'DBUK]BS:LL$$KDVKM*U;M3OAQJUK
M]R[>O'KW\NU[,!B9+5BP:$'DZR'@5!_/;"HH"YA ,JI\/HZLJ>3:6&0*!D,D
M)1>B2!\C(4(8;$PLD[ER"3Q#">.A*; &TK58:-+$6&(@?QPV:^TL,;T>:CI#
M,MAO8;EV^VTN%M@,*6;*A+G1I';"8$TP"<-N,=B.1-W9[K@LC(8DGSM>"WN2
MWB0E&OYT*<5(!&Q+FHYKS6PQN+;7#.:9MI$75@A4Q2$7:1*#(8=Y5Q$6A4R4
MRA*[@+3*#6NIL@1K#AWR@T0/)I1*#9"Y$L,LSJGH%3 T<#(0+2X(*$MJ;!'$
M&T&SU"@,CG3Q!@PKP^68HA"B#>3+>FO]@$DPJM U#"N''>3+*U(.)$N*!/D2
MRS %Q9*E0#V&V9TL70K3RPZ1T+56,)4-!$PL;!K42Y1O"A2GE\&D\D-;P023
MAA*<W6EE=['00IM LG1XY:$'Y<(*;^ UAJ@P5NI(T%JYR&)0+(OZ6:F?6E2!
M(X]W"LG6*VN9R=DA/=P8"ZG*[5BJC6QUZE^BIQ;:9:QL9?ZZJ4&0^0+L0+FH
M@J.0AU&2 R\'?4FI0,-%(L21JIS*6[.<54EI++H*A$D-*<)20S##%K0E7;UT
M6]"E?ZGBJ4!6/KJF*F#>:>^*^3+DK4'#T, >CS&\ELL40R3QQ"Z]"#'I)-<E
MD8ER4A0QA!.[!",$>T,0(A 6QB4B!!,^)-@=%CP($4:1Q39! Q$;]Q"&%$+@
M8-XC( =16D&$"#&%#SB[,L00.PMIA@]#\/ >+$#OS%HB3+"EA&)/F!'S#9@
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MI4X*=D'6 !*3CT!,3][8"#2WQY*9ET#M "%$3HH& Z@20AC0 /!$@@M401J
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M4!@E%UOBFTK  0DLT, #$4SPP%G(,.,267+)915#O&!(P0LQS)"F7"SCY1#
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M&F<CP9 BRKK*G/Q-$;!@!X(A&$ O)5;"#*RP)&:!'"VD"!'A!GP'$;PQ3G)
M&*5 "&P *;@O!F=P%GA1*P0N%Q!AHBX"\-QDVR["#*A/2/ZJ;_1<"!@>825<
M;OR0CP<L(0<D81:20%QR( UBP2'4 "-H #=H(1C.2E]F 3$PKPN7+T":("1/
MLC^V[0E&KP"/SBNX"E#T)47J9P>&["ZN\1KCH^.> - ,"#  ;Q)H01-B0$0N
M@@H8: 0M)AC.J]9BPGOJ2#C8B0:V0 ONT R28P=6P1'2<0??HRN_TC0*JPIB
M80LF80O( .V&H"NWP O8D :R"^W<I0ILY\,FBB$_0_8NPE)V@?V"X0O-B 9V
MH2! ; OH,@W@@A)8+ 922#*%0 883AB@X#[<XP:[LB#*2[AXH'AH@0989 P@
M8@>DP"NU8 V(I25V 'M<R$:"@?[%MB 1G" D?$!/,$$</\-2;* )T(0*(..O
M6.('V*@5<7 V(@XI@N$FMX (;M,)"$861-$5A<$*IA!^>B$3)J,)ALSH,FL\
M)@)^LJK&QK,@>J"^@NX!U2<2)D(()"\2BBP3-O&0%O$BR*Z?T@3T;,!"Y/&@
MB$ *S" 1M&_HP@_WGBT6M2@'.$$DI/,05"0M<F]$G(PEB*T_N/(.M\ ,<L$5
M?#-.;" 60HVH3/,0<B\ATU$*KH\FXXD&@.&))C*AP$]#U<\E,"$&*' (=F"B
MC&5K@ $O7P<=]44;9>$$A^>[$C$BMDT*:A)[<,I3N$H+N@(N>+(EA&#TU *L
M)J,7;/Y@R AA!I) ")+@#5D""AP008#AJJ220)8I)H:!?F1Q3;.")6))),8
M"T+")(-E!K!FJ!PSX1YA"YH *:J#)7PA+-&E(&X@IR[""IH(^TC""C#M(GS
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M8&"P("0A&LGL07/@6FK@C:"I(*J@=KW#1\C/-PUA/;0H&6]07V;6WVCP1%S
M,C@"+<R@;:6"$KP@G^1,$\; \_ V08)A"@JJ%Z; 0M! >K8 -[8@/+/ .5=C
M"+( F*: BF[SG$@K"1CN#"CK$,*@CK)S"RY/"%+H#,C74SCO"5RG%Q !?5O+
M%ZP :WPAN89 L:Q.>K!@FK! >JP@?PA)"H:@"/2-$'J.R?ZL0,72HP@890H"
M)!&&;!(XSPGRDOR*X$.J('\,80FD(!$X@0ER(0QD)!4D2Q**0 F&@'S/(.^
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M#A-N("$0; OJ$1%XX9X_0@L6L_[E5=]-T6!$R(!,X+;D?0$+QG#75S]V=L"
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M6))(#[&HH@HMJQ5LW1B%@BBB%$P2%HLB/"S'W Z3Q;S?%<E:EP9X.2#",2S
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MAV)IH0<R#ALBX"@)Q?,(DB<)+O[063_@=^LH/P@)9=GQ!/ J:KDE!?.1"SO
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M96$:E+,<4((]T'(#I$&E6EH6F?X0FP+-!8FP!+]"",\!##N REH0!BMHE[&
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MC$$-A/>I' B!"4T0P@TP,@L:0 7]W=FC8,_@"QH@.>R$1O] JG!)'[ R!YO
M1/O+8/[Y'W@P&FD_O1*&2+ !3T$$IE."$!*&)+@D+<BI@I""PD@AS)@%X=D$
M6/ P(9J%&1"2,"@A(0BA8+ !1X 6ZP*6X!*&'A! 8:B!X[DO@B"$/<*B;6,,
M19# )M@0'PBL&L"E69@\FI"%&="47)@!S% #"0PDIJ,$"1(-&FJ)&G \%F2X
M)Q2&'12L4GJ"-B*(51(&/",(^-N@-'@85<@13+B!I<B!WXD$IA,&+2BA#0L7
M89"%8XJ%&7B72)"A3=@!:>FIQM@EFD"$'""C0,JC_K.5@"N()RB,J],$$'/
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M@1T Z1JH(+D4 OY:0B>>.Z6@A!O0 BT.K$B0 2P8@V)N.HRAB5LTB!JXI"8
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MF,$,*$'P1&BP(L09/&\Y$QLP^, 4>/ *TD1(L0XEI((4H <MC8$F !1)!!*
M,<HA.!3P;(Y#KP+PK TFV, CI/X"%A"7F>@2%3F'HIZ7%\N. UE.6Z3!PVH"
M%@N9$V2"(_R Y^3*$SB7+^P Q;[83ZB-*ZC!^JB-*A "M;7$5B#")HC!#9"&
M%L3 *&M!#8QL#;1%+NI2%&P8(LS6)J0=?+C %E!""7YL&M0 (>1$NTS.$[@&
MG0$P46F!O;G &6#"%DR:%"A!)HR:#1#("[J")M3 ?X3!6K>UW)U!#4R")-2*
MRR@!#UA!MSB"_FS"$\1%"%J!)6#!=E&"%?Q 8@S!)EC"#W1++NR %DB4#2S&
M#]R4" &8))5!,&'"&&R?%0@!)4@"Y:A%+QQ"#9S!R\I  @^ATCP"8*?"%.!@
M2ZR0%?[4QACT "9D@A"4#G%;PN0TMJ^4Y>K4@!EDPAG$0& 8FBJLPIGH3F>R
M2V5@H 02UQ)8P4 I%C=-08C$P&$UQ0W8-"7.@ACD0"+43/SM0#2_<TK\P!G<
ML<HL=!@PRBSL@!FD B'L &D4G"M<1;/B,XXX@A54@>,\P5==S9.5 9"RS_U"
M+GR,[X(+6R3DP$"$ 7ZX@@QI C82!8"!TQF@"0W4$1E\CW8JAT>801$!181<
MZ@Y@@C8J6"9XHPV=S&SLQP_DF"]8H%NXARNPA$ < B@IH7-4U4!XES#,@./0
M0E:\Y16UK)"U[NVE=6<H*(E(PI\<Q\R$APV,"#"H22?(4/[W;O;;:I5 4$'<
M( )]"8'M;(&>@ %Q"5TL3%O+3@*4$43?)4&WA,&/:T^7O9]YN4P3=%(PY "C
MM>8FO%OF#(52] +KO$5068R6G1M6U9I A-63S_A U, J[ *U,=7(!D-K"D/*
MC,43E,QLD;K+/$$LC=&'&%,L,-*'$'E@#,&E*A0.FH'2]!VRK8S!40(HK8=S
M!,90#<0AH,?("<1H$,2]F0>CX'6!_(#_I-45]0)::4HL/$5Y-\SWE-5 5,':
MQ("F5#F'SYZ#+2R],J82:(HJU#F@(P3;SBQ:5 'PNCMPM<08+)^G_$M09<46
MU$ /6,%,#$%P,@9HF,=BY((3U/[ R&6%EMJ $'S!4^0 HX^Q#22"*X3HD^Q
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M6A8J:+7"2 $-2VB"1,S002S4 /XC8*B!&,)@ T2))!AX&@,3+"<A1[6(!I8
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M@ 500!!Z=0Z0@ 568 YJ 4KVX%]555>'X1>DI /^51ALX0TX@ .T%2'454I
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M Q1@!3S! AI@!$1U#B:@ BY@?_Z'H00F@ (^P(0S0 %J6!@X &VSV0,@( (
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MH\%6PP6! )Y6 T:@@1V@9<]7 .#@%CP!OX6A!#"@QDF P26:%.(W!6YA$!S
M=JN0&#K@ ^( !(*YOP3)$PI@!=R S=^ 57\! 8Y9D$H@R%%ZPP] 7$4  0#A
M%MS@ & 5 MS<%"! 7NT  $1@#PCY!"P@RT&@>_>@ 41U#PX@C%692?B@R6\A
M$ A@?BD65C4 "83!#AJ@>@$ !/:@CSEBU(5!$,P;(? <(=K H[>6#VXA#PH
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M&DXI^ 7S+0H/PN+8%5:':E 'PD@U^#71E@)0'AQ<F RAA+ .*H"&I/!FF,1
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MN$ ,\H8+YQ@11D:.P;)LZGB/^ A]27, F)<8R-(_9L%VI/"/ +(?WW-[;5
M?")I4$=SA=>0)# N!1F0#IF/%OE#GD ")6 "(G!=%W<!"<  #M  #8  :$(6
M=)  $.  (WES%;DC#>D06C*1_@:0W'B1.%E]*'$!&7!*(",1<!  '"(1H!!1
M\$$*1HD]$W$ >/.34])<.1F5&/=0WJ0")O"&C"8*GQ *$18*G^"$#-4 3$0*
M=@  ,_ZW'@#2 $0FE6R9D[;P "-P)0D /2'# AR@$!,!"O@T#']0+:30&W]I
M"BO0+J4PF$0):W7  L%&$88Y$9]@"K5 !^>X!RQ@!Q+Q"W6P &VPF()@"WNP
M B:1!Y?'%7.P A[9F7T FM6Q K0# BD@F'-@&J;@!BRP2[\ ",.P!TYA"W/0
M!FO9EL )'Q"T?!DP7@S9!F=T("-$"E,S#(  CJ?0!FW@A)_  FXP'78C"'^@
M F]D"X) #%\7;+]0FGC3F9]@9\&9GL\G$8*0 "%1!\;Q,1*A A\0"@!0*WK)
M%P+P%B6P,'%P !]P7"E1 @?P+: 07R+P7.V"8Q;0!@HC$?X=0 &XT3(X-@%M
ML $0@&D@H  7L* 1X0!KP0$00";452NUX  ?T ;U%!$08!\=X !D @*SDS@0
MD"T4X%D+H@ HH (+T"Y(^0$-, >V$ $@D%C&J9Y("A>.E <E4 *+>7$2<0$A
M )!/L2F_$ H-X!0K$)\1TQM_H*,IH !OU 8+D (BH "](0$6, (H0  D00H%
MP 'B10!C<:(IZ@ V P$<$ %'FJ1^FG*FX !_P! <D%(?PP)4(0+ED9\P,350
M)0QITQ!Y  # (E6&(@ ^22+"0!XA80$K<J9J1AUTL#$<,*4@XH&;LS.,I1H0
MH3,MH1$0,$*;,UX3 #TEL!<3 ?X!$-$ U_5JDU8 F2$,_C$7G?&GQFHE M !
M;4 "-D2EBR:E8V-" Q !#P ! & \ ],8#4 *1/(3G\ 3<*IJ*^ W#R)0)5$
M,-,!S56H+5$K$< AQQJO)[<' C !"C !-ZD>X?-,!G 'K8  ?($ C@H8<& 7
MPY 'X@,(B$$*N&HQIH H<- &4$$0V=(_2;(]06$N!60:#G!=$F DPX !K\$
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MVQ!N%,$27,/!L@'&:0L%@*ILNQ(.8PL(0  -P0$3\ <HVQQNP"L[L4$'D!@
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M0%$'!?XP ?$(%R( &-<]$0APZF2Q @3P!I[@M3@*,H) 8_PS$0HPDRI#& (
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MP987'6B#QO0JT" E.AK@((+Z_A)KL#X>$&8/"$RPH %8_5,1 E&$Z6-="QB
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MX0((\BU0>,(3<%" GVHAB#8@0"@+R(D%Z"",7GTB$*!8@!UL40#\!,43=T#
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MR2EV:A "3,!$"G"S N#' E%9P W>;0.4[" !B#!@4;1RLT;FH+\$L&0H<*@
MHR#5)2B9BJ%U+<@?X$8CA@'LCD8NY$B ^6$/> P$WO&P!XP;EK&0);(!$X8%
M*HNL%X, 2I(EB07J8+L%DH2?MO@ !4(0AP< R;D%P5##2/(!Q14$$)0N""J,
M:8(&T+IQ\;W5($EB2$BB&9$@8*A*"C#5ECVD#@NHQ2UNH<_^S,&NPL####LP
M:M^\A .ALYHLP>;)>N[!F#)N;ZDD %L+V $7 E!;"OSL3:W<8;(E^0L)+$"1
M!@!E#_X9L /-'*!PH9A" >W;PZ<*<H&1,.!KP@C$ ,13 !]R1:F "2.VUWF
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M"W RRUN0 DD)HR1'"'!/_GF#L*L(#9  O[R V?,$!OD 08B\NGF)ND0!0(
M4/@#BOH+0!B+0+" MW@(.'@@4K"8$D""<5D_?TR!QMD#N5J REH,L6R !>@
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MV D$0! $4%@.3P![RSL-.ACXPL$%JE.(!(B9;BJ./:B%-N@(;ZJ$H?C-A,@
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MI";E9TE/:M*4JK2E+B4H2U\ZT86^@04O(B).<ZK3G?*TIS[]:>\@*%00YC"
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M)!@!IOY;$X=HH\0" ? -;0JP!\T18#L9X$MH!A!B >3Z QX0AI+5K?#D!:(
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M(6 C2(:D8U0B#;#@1#R")CJ"&?A@+TP$%<2 $,!C#)A!$DY")KA"/,YC,/A
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M1H4IF/ZK,,C2Y(0"OLH.*2CKR%AKN'7% F3* C0 Q:"081F= [2%29S"!"B
M!3R  >#;Q&;5<\F/6\R! A"$&XS*,)2 1Y70 5D0_-0"!2" !4!  <0<1+3%
M^+S/,)C )V"7SY+/'@0 S8G5^O"-RV+5]?Q" O3L KA!#$T$*@B L4T$"EC;
MQYJ$)\0*;90L"]5.!1P !#Q  R" Y[@L]GP046!$9@@" #Q IBB  ZQLR#ZM
M1H " N0:5H%""93$G?SL!MFKPK*6TOT" NQ!;ME"I0#N2K#'2?P" W3 K]!!
M ,R,XK;$MDU$!BS'1!Q S_X'!&3 K^1! %@;6]A$ EA;Y?YR  =00.76Q# L
M0,^:0K^:1"V<VTG4AVP111_8!FULB4Q$0!OD%BZX 0$ K%1T0,==S-T2A"UH
M0 04K4R0@G>D!%%\ HIMA/$&+JG]P@%P#7SMG#   @A\@)R,31N @ CD3!ZL
M%\AAF0=\0"A4 +X111Q<KTGXGL24@ >T 53L@2#L@0:TQAQP0!P0A?_N00:T
M!AUP !S<5UC0 018P!S8P@H\;GO40;T8&RGHKQL@Q2VD0(C\#5'4P0%8D K$
M'%L,\/-P!PJ @ G4#1V40AZHP"\@P0)P +[=P0>  ,7\ 2" @@CD&DI4&BF@
MF4;8 2G4 0>D@'C8 AR8P@IT0/X<G$0>[##%D((=B(((=(#8N,>;A<(#]&P>
M/ <<]'"Y:$3M4NY M$$#;$#Y\D&HY9<G:( #H, M!,(# #$'](%)A(((>( =
MI 0$--A& (!'@8*1-;!)_($(?, <$$4@[ $IB,!@3#('" ((0-I$L$JQR%P!
M%$L<?, (B)@IE  'Y($/"X,=G XIM 8IV-I&L  (C,#,A$('-, )U (IC(HM
MJ, 'O#!TK._[YDPMG, 'I( 0:V]P?4(*R&U*$"X=D,(HA,(2WP8"V $?. !?
M# ,%< !K-,!#=, ":$ )# ,@$( ;V$$&',"U",,%;'-*V*U-G8IX?,#"T,$"
M7, )V/Y! ;Q!=A3 "N"S!9A-/Z.(;>3!Y^;!+\"! H@ =HC !.P!R<X&*"A
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MFP(DC0D 0$8T0,?]Q,-86@1\0"# 00.$F @PP K<PAN4QRWXV!Z@@ )("1P
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M" Q P3M8\.K6'Q# (+",? 'UD/P!ICD [+0!D+1T';B%"&AROL4!'=!!"31
MSZ;  H@ ^E: 3F1 \!*$"6R'92=Z>;SRWLCZ%A\ 8#- 24RZ@;2&[NI$'#S)
M>L#U 4R "!1LJ,_6'WQ Q*H$X7:Q,"A 'HQ" AS/!-1!+;1*']P"7MBZ?2RM
M6U0 RD+7DB'%!0C;9FA$\V2'@Y# D*S LG\ P&':1+  M/X;>)!T'%5@AYL
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M%!Y@22TVT)]A@( 42"C0&U96+_X4#.,#VQ/!"EE@!YBT(0XKB, $SF4+$%"
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M/(&U($4#&;! @=I K@A((,(@$)>#'&;G#BQHO@VWBW8.PX< J.03>3NVS2#
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M". R\&,/AB$"5* 6-% _.N  3/Y /S[  /: %$Y@ 39B8&R!R##$ PR ZDP
M!H<! D; KDA&&/)  3RA%E9@VASN".<B-I"D!*Y#!6XC*7Z!%#Z@ Q9# 3#$
M#H"C#D2@:CQA1A[B UCC%KS/#]AD.?)F#XYB&!K@,HSG%AR @$0@O,9&2MQ,
M*A! 1U8B1&[A %KH%U9@&,8%3YY#!/[C; ;B#5#B%Q1@>T; (PAQ(!0Q 1%
M%&#C#_EP(+3C%AZC#UC"2F!#,V!K=Q9 0$#C/ J@=+*#(C*@,V2"(DA!2BR
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MP.^:LW3D'1=! 04:(]?JH#1)X4GD@ [VX%T&8@0.0PH[#(WG '[:8 ]*(P.
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M17ZR1;O,I2]_"<Q@"G.8Q"QF6)"D)"Z%J4F!0&0HS+8G@XBBEZ \92TRM4H
M:4DZI:A2*Y5B("*2PD)G@M E!>.D0= +EJ4DYSC+R<YVOA*>[S2F/>]IJCO=
MX@.F0$%RX(*!#I3@ X%JP A(8 &%G:( _URE04#1MD_"X?X-3OG$!X8"!RP=
M!5-G(05%6PF(#) B-4D!A0;.\H8(P,>$4;G *,.2@6CB<Z8T)=*J;FH+^7!
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M%(SU$@I[D7/@ %&H ;1K HFK."0'!R(0!VK6=[B0 7&PB0HB"-1* 5Q6 G;
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M"RG@!N #!]GE-12Q4P;1 >]5 G%0"P<P1X#C!DAP$9:, '<0M+]G :80G+4
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MU_'L.,+E6_ $LU 4L< $8< 5*5\JOH (0[#P1C$+6^ $@OZN1%R."%M@$+U
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M[.!BI-7"#AYI!4ENMIHST$0J<E.&,K@ &)R04[\X(05-NH 0XJGB*F"PA>_
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MM=9X AT<#U\0 L@[".%*MBN8)!W0@EQ8+WKIA"WH@4F N5W@D(*(&&!8CXB
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M/;$5*O[[@<UJ AZX'2&0&@GD,/_<#E,2TD<0L%E(!!NHE%I1@BP% Q-[$2A
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39T(SFM*<)C6K:<UK8G.# 0$ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>63
<FILENAME>x_cg003.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 x_cg003.gif
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M]^;P]^?Q^.SS^>GP]_3T]/'V^O7Y_/____CW]_#O\
M
M
M
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MIBPX3!XBS&J"K0+MD6L?QMSAJP@(#Q3( *9",)PQ?:P:  4##;-'P1R8L*=
MH+PA1QW&#/)!!A_8VH<'+.\Y3!W>BC+,&QED\(9FN*20\PKD&8/+'/^.P@<(
M!BAP0 G,\O%!T@:8$(=_NMCQP:PJ!%P0*"C "\(>TXDJ]MAD?0"H 'Q,>HPN
MW<(AJ#&@."   0+,3< (K4&0Y?X'(P" I  1C&+!;08<.!DJ=0<P@@1^%\Y
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M%P!7=S *37D  R9N#E!(!I8< L$!,Z24S@93!^"!!:$*O?$;R3,"QW(7=>
M07DJ(B5NF*0 6N,'6X0  #@(!R"9(P8!X#&+QG !X"%/@3E#'#,*AODVA! !
M?K4GA" !SE@F E$'<-(]H$00I] !@S4^#) "O&"3Q%F<";&%?( 9OO07NO""
M@: U \$+NK!('3.=P]$HTVD,:/ZD<K3A!U-W$+P "H% ".P2'];I',B@"^M%
M$*D0"'P0"''7,: P" =IG1>#"]'Q&-/)"WDQ#"_X!UI3%]@Y'&LSG2G2G'W@
M!YMU$/YY&?$I$ .*(M8IH0:J'-/I'-))G0*1H9I1H+J0%[$Q7P01HG<Q#*(P
MGIYQ$*HP"(%0"']HG# :HRR!1@@"'V=!BS*:HSJ*%6%%)1:!"D@2 .47)&G"
M/!0A'VIB$3ZJ$4F:5D>!>3BZHU(ZI0Z!"\1" 0A$I5JZI5S:I5[ZI6 :IF(Z
MIF1:IF9ZIFB:IFJZIFS:IF[ZIG :IW(ZIW1:IW9ZIWB:IWJZIWS:IW[ZIX :
MJ((ZJ/Z$6JB&>JB(FJB*NJB,VJB.^JB0&JF2.JF46JF6>JF8FJF:NJF<VJF>
M^JF@&JJB.JJD6JJF>JJHFJJJNJJLVJJN^JJP&JNR.JNT6JNV>JLX(2:(H:L'
MP:N\BJO &JS".JP;D0F)L B+\ B)0 FU@!#!< 9J\*MA$0QF< ;%4 R0D B;
M8!"UP 6)8 RK@*S!4 QJ< ;!8!";D 670*SL"A15T (Q$ ,N$*\U\*T$(2:'
MT (M( G&(*T#X:_]&A+^"K +0; ((:V/H*^+4 PQT )?$+ !NP7Z6@MIT (N
MT N3H*^(8 Q:P 1I(! ]T (U0 S_FA &VZXH2Q)8$ ,T\/X#/N #-$ #+K"M
M!;$*03 $LE 6LR $02 +P; #,4 &!D$).  %Q+ &+%L+ML"SK& ,/- "6R 0
M:( #8Y"R5HL3*TL#FT ,P7 (,Q #8A ,JP +QC +6ZL)VQH,K$"VLK (F2 0
MX;JN Q$,E? (DS + E$,LL *7-L)M0 +J_ + A$,L, *YVH,O< *>+L*JR 0
MO4 )BT"S ]$*C_ (K9"WLK *Q> +D1 )S?JOF_ (S#H0L\ *O6 ,E9 (39NW
MF; (D4"VQD ,FJ )Q? +.^ ":! ,D  )IVL,P> )C8L&+#L+Q8"VQ# +/A #
M6$"\M5 )>"L0LR )C]"X ^$+J?X[NE>;O2.1M3EK#+]  S&P!97@ CF !C3@
M XD@KZQ0"2^@ V,0KRYP!FSP O*J!6*R"3S@ B] OVM@#+8 OF>0!"] "3[P
M E@@$&S@ C3PN6?P DJ@!B_0!,:0"#7P A8+!:<;#%+0L!8K!<30"^!K!3D
MKS6@"0(!"T/0L"]0 VP@$$WP D_P!/0; XM@#+ @!"Z@KS%P!J@;KY50##40
M T_P Q:[ ]MZ!BP;#&R0M)L0KXO  RQ+ R\P"U40 T,@$&8P SJ\!21;"3>P
MORM<P]H[QAZ1M9D0#+5P!C*+!I[@ CH0KT_P"/'*"I[ LC'0!#M  U\+!3\
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M@ @N@(#Q/<T!%+! "!S )!%$P ,,*%2#_!<!SM2AB1/ 0-R,L8(%"- 8;XB
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MJUY4@8 *8" #$H! ?))663EH%1?H% @#ML.!!("B.!E(S9T H+A=1-<8NE"
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M82C@73WC%M9>>!=L%_"N*S$% ! 0PH0,XP!+O$NP$_H!?/X-PGZ6G4 =@-8
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M%#@[!8 :! B!I *!%!A#GH&9?@$ 4O"# GP]/A"H?KH#"& 3"Z"#R.FN@8B
M5>(96'RQ!9"8UC,&5,K"$4"N";H#[ A"S"D.7%#%T_*.TW(,KVN ';&L/8"#
M!0"!&60.:62-!_B>85@!9+* :8$#]I$##F .&&.34="U%/Z(L&PAQ3P0-F.
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M)6&3#P 15 B! $ %4+@U73"%<_,O34VG!) #N%0 S2*K"?Y@$Q1H3?9L%P[
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M"#?!NO;4"3LHR 0YD+G6'J_J3+>6R0FH@ UH@#QB$(R8G %1"%!0'*\6BV&
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M%67LM/YU 2MGVBG'O'G-(J@P "\R$#G4#H-)&1#<1,LJ@9,JI 01H)?&OJ.
MT( @+18X%)-$D):.:"!#M?'<;=\:-O0AU'II22M9]XJZ HQ0 7TY*E1\JH*9
M.&#$@[NB+A10!ZH68@(GL,B @?H4AQF#!/!U*I2C+.4I4]FSQGB5*EH* %4D
M]SF[D,!C<$$!"PS%&&)%JY!6$!(4+ E1$=B%Q)ADV'$IA%2'*:,32:J""# )
M%1=6"0<\@(I!]V$ $V(!!"KB(O,(@">X8$#*\M(13?+DP"X;B2-< Y0(:$\/
MFQT6KX2"IN^B+6>%T/0Q. !J?37@**< P"C.-Q!CH$ O??YH)",?YK6^B4 A
M=5!64&8-ASZ:H(^G90 I^C8N#J! =PIYU;!2X9IC2!<H#-#2"B8FW9'HLR-W
M4$!CW$+24^QD)O@<]"GN   \?B #"AG$2XU1@.<,HP+NA4\7&9#7S/QD)-ZT
MR!SPJQ=RCTL$M&$!@.M N_Q*2G C>"$?P T4"PSFC!8),HR,88)O6J2OI2O
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M:6W !$A>QLD! P2:'"Q (-!!-0U#!V3?!UA :G33!EB$'0#8XED$'[C>!%Q
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MGL(%3!*!3H )W*D"@-JS]$%%Q/[)PWK 48 "!\ L P1"'3C04.@"!]1!!BB
M'+@0 QB(6G@)!3#  _1!(>00!9@$'Y"KS.8C"# ."8R0!,Z!!KP%(2SN"?C;
M!/ (3X"1ZRC '^2%F0"% \C!^4V 24A.R @2D^1!"=R! ;#&!XSN!QP+4@S2
M&RSK2GU*C53MT('3]2@$+H  ;G"K\R;F,<#! RQG5/"" 1QG1Y# %Y6IJ:!/
M!V# 1V8A..D%O/7&'1  8!S'0IX*+R+ 'Y#$#*G$':P&+^Q!HQB#%!+"+MQ/
M7H6-9%!&'PA '>!"9CR'"&A QJR%E<4$*NC""$ *N?$!+QS'0)  ;^ "!B!
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M7<SWQ4&AKEV+C/8%S'YC ?!AQ 2 &(X Z@&1R'C7M71$Q(W$ [QO,#5?(T'
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MU*A(P+W$!OC5(/R.2JQ]QD,%60R:*=C'DDE&A8Z\^F^EQ@S@&K)'1^A'#(I
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M@0A&( $$X)%D:JQ-"BPPMD$0@ 5,61P9K6@,"U1Q7:#0#Q ;T $G8D N)2
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M2!Q80@'T[((#=LB  RZ@)3DX  (KR( 0'X*03!HC R80 02>XYO@1*"O"!1
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M %3!\3Z"]AK"W!P"%<S/>E*A /Z&X0X28!!4Z8K.[2+,#![3Q0!.P7I0P0#
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MZ#S@ [1(%UH/VM)($>DNFBS5(1(*/HCN+TT -%3U@3Q"51XC \AQ&%3  CH
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ME*4 "(DRC $NK:<W>F-M(50V#51"#((%R&("LI<^ _ A2#3 K()C2S-U(8"
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MN28D 70U<!P78+"#^GDD""UX@I$.X8(9P$V*>1N(_-[7HRVT('^9:,$+[@9
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M5$"F ]#I SR0=L\(369PG2.7D^4Y*;64556P!9ZI2D%9 U/0"G87 T;9<C_
M":N@87"3DCO !;V !?@C"=SU E* ?-WS0.ZGE4IG [4 "X<(";;H IT#0#VV
M!L*50#BGEGG$.:DF5Y7P3+Q#5\JX$&^70!2W4(F 1.437TE "8E F8: "#!
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M>'\GU6R%!35:D\6T 9%(:+N A!@P@TMXT?ZK".YQ"=[-C:NS*TO<@?GR\T?
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M6+\GHYSR:L3,< 8E(MN@H48Q4$),3-&IP8-%B,@93"0D<FIJ#<7^(*40/M+
M4ZE_0DO,#F7XTLL2GY5QPRS!I-'"?0A#,46)-9 K";2RQ!!),*S<4-1N,YCM
M8G0U@%L=(_O58.8BT,X293 N5K))#+,0 XD+/KXKT5=0V!*,%I;EO<C9._B)
M!8-J00%<,4)P$4PO3Q17R]\. 3VB17%RXB+@D[C@UA85$OYCJ1!:_-)+$L51
M$H,FP5Q"0U(2B7&D&0,AV9BRF1"3R0R<L+2(S3PD08P:)Q93B:21V"!++5K$
M$ S+85)D2#"S!.'6[,JAD=U+9PP4S P6S6!FD7?^TNGW-31) W)8#-$++$)D
M-TL,RE=E+F90DAD&%2>>)*(&:CC#$,CR$L]91!)IX@0-7".%#M&/&*P00@]L
M-@/75 $X:[A!E0Z1/5;$P!B0J($O@I&(%SS"&#FX3QH\82%C2&$(M3A&(M8%
MI4/T0A:2.H@D$D.,1;P@,WZK!#$2N(I@3 )HU#M#&9; 0O\=ZP=D"$8M>"!"
M@AD#%C&0Q-YJD!E)O  -OYC%#?Y6LHBZ!8,2-(!0#;Y#B1G0(G O\!,*:W8W
M8^3M$65$Q&*XXX-$.*IFF[C!$Q0&HEZ4P34JJXV;8F +L;Q@6L:HU(M,,PLN
M) (6M5C%&KX0$8W]9!)?^$0M?%(,6BSB"P\KC>+4<(E53&(*F:F%%-:PB54L
MP@I@G"0QBUD;8DA!",J$@MK0(X0A"(&0QI#%$I+ E#4$80A#T(TQGK"[;NYN
M"@_;@GZ@8"9O F4*!YF%$Y3)!;5\H0=#4,,5AED)(FA("J\R1B8J5 EH"J%)
M/\F$-H]V$'&^10J0F@44AE",?AZ$H$,(@J?*, 0F&((10W#A1R1BBQVD80E!
M6,)MC/ZAB8*FX2 C>\D7!%J+*2A3"PWY!1-@M,DEP"@84+A%3YZ /#6() V3
M($(P#D&&ID#!);V8 C1E>I!%!"$)0Q#/00QQ5"0!YR(U6DPVAP"N20AA"5RX
M1!'NPX5G!B&&,PD"%! AA6,M 61*60(TS^"37N10F[-:9Y>*$5=C+(&G*LSJ
M*N@:A#+TU"*;"\(4#L$>#P5!"%9  W 2H:%$9!6'NV/%& XABUV1Z:^8$- J
MF.":,S3IGTS0 B:6L(A:+,$U91!H&IXY!.11\TDT<4(BDA0,A%9!46*Y@FTU
M<9 U&($1O2C"I)[BA$,D@KG%P((1+)*&KG(3D&1( QM[ ?Y;IM#B"<K\@D^T
M #R)2#0(?EK,FH;0@W<6S+;%D@(WBV%1)AQB$4/P13&V8 16=*)"FI!J0-%#
M)&-HX3Z+$ (3OH")(?S2"8"4P3"-R9I@Z( &-BV&#U(J$2CTIS2UR()<#](*
M^*ZE%EHR!,*$\:,R% 65!]%"K%)2"2U\LTU/V*N%>^SCVO1"QNTQ63%;^)-@
MO&<V03;-DI6L,6($2<0T$,:%UM)DU1AY-E!>S2^B;#C:V/0E458+,8@L%B&3
M29)B,?,-M[ 2U?1"S6(F#9M-TU]87&M;LTDR:JI,&B^19A$>%G.8<8-F"YG,
M)UQP7R100J8H,X)-J+SR@MODY?Z>U/DEQ) SDP_=GDM;Z IX_O%J@O$$&M @
M?^!#=14BLP546P'4QBC#Z'X2B<S(. HO0)@:PD!(M6",-)E82<",(8P:^*G8
MJ\@LJ9OM[&?+QM/05HVT;VB+&I1TVMK>-I=CR.V"\4 *3G!.CZM-FIKUR]Q/
MW8%>=E#C<\OZAK2RS%K43>I:5/C;+D*U"S9AB!;P>Q6]B &J7Q WB?SB"PGK
MZ$]D@09(%(,17YC$4;E B2[\Q91K2<,^?]($'L\XWM\>.<E+WF?2>-K>J@&<
MR5ON<FW[XA*=X/3+H8V[3(@\-L&X9,U[CB>"T^ 'AS@##VB0@R @XDLTT$$,
M/J,Q5OXTPC1JJ#,:2G0),O2B$8J9Q2%\H067="(S[9DUR#W$9XE\H= ^7SO;
M?:[RML,]VF.O]VO>'O?:V/WN>N<V+:" :B%48G4QT,$9/L,%@H-M+; 8]%K4
M<'9AE&?63 G&)GQ"B_+8%Y5HZ+AJN'#VO7.[&+/(.]Y+_&-:E)@8K>#$)EK?
MB6QG(K\'"@XE$$&)YIK^-;\H^[.OIOA,RP869O9NW9\H&T#_A,IKV?):9O\3
MEO?X%VJGC<U(#_KKZ]TG9XA!#.0C!1N@NE,(CL$,A"MFA?\9L3]9169Z@5EA
ML((+B.!"+VC1!4@T) UJEX2/S%T+9F/?MEV)8L@8FJF<6O[ @A8PQ2JX ,^Y
M$FL8(,JYB[7X!"RX0 [LP [\@ VXQ2^(E!9 @0W$327<0 \T 0\,#:&8WT'0
M A8D60$:0R3<@+RM!@S2G00>Q VD5+$E@8?98&KXQ!*XA5ILP5P46[V-E3'X
MP@RH"&O\DQ"$3[0L00_PP* 1 Q<$P4B-6@SV0 \$ ;E(Q,!!R@/^Q _BX"HX
MU1G0&VVHA2PD!L24!C&06 26(0W2(#%HP1:.1@#R86PDP0S00&,\ M#]@&)
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M0MB,O0HS=2B!)."+4?2 %%1"+:"!P@E+>YX%&QAA,8Q(+<C+002!?J@%%_#
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M2;.F39?$:'0RN,I%*X/%,(XD)G1D0X3%" J)%+&H,2MDC!T]&,SCQ* &9]7
MZ#1A08)CL  EF"11QX)=*1:;>M"J08Q+#DET.S%M2[9HC:UY(I(876-V(_ZH
M=!;P7[R%=W R5F.6U(B('Q?<M/[#ZE^$P8HJ:D+UJ[$S?(&FQ5@KQZ^#FVH@
MM!M,"(\M9ZNH*1P9,D5.-2X'-FR[Z=N(ER-WQ8KYX),RA0_:W7VSN?/GT*-+
MG]XR)Z6SQ680)C9FR! N:Z' *JC)2C$KFSJ2\<[%KY3%3R45/&/(F*8E19(0
M+HB&QY!#24!R$"U2%#'$2<94H449001QG3&R..%$$?49@\8A:_!P6AG>:8'1
M+#DD @415QP%B7=+I&?,&%84E.$0AI15$"1%% &%+,;48D4G0\QFU1I%.,'$
M>)5PD<@0/"!7T"%!"+%&$V:=Q08::S08Y1II)((#1VAX)P4MQK0"A3 00A%,
M)5481/Z)2@<=LH20K!24B1!!<"&&%,9(D4E!LSQ1C!C7^7+%$$64X=$:7CIF
M#!>1=/?6%30$@5PP77BGI#&4%+'$$JM\=48/0R3B0WH[+")%$$Z :<PF2U Q
MQ"(&&2*$$%2 F<D.&"4R!5MC+'+&0,5PX=T9!1D214&<+,'$JWKAL$,5#1FR
MQ!!3<&2,+U8$ 44B/?1B4"5!Y,#$3Y=,.X1\5/T@B78%/3&;,9F8*]\A$!6D
MQ760M#K$GL5@4<D36JQ"1 U%L%*+%-$.\>9X!_4BQ1!"H&'0(MXQT:F%:9!!
MA!2S8+&QMV88HD:#3!5$\1)/**K%(E@$L02.Q'Q!J!9'4?XRA!-#$#;&#3VH
ME$:%BQB88D%;+*(%$4/@2-W23#?M]-/0'<(L1=9U1,P:-?AB#!9/].*+%+ E
M0>Q3L-% F!90>"V%6$U -,L,+19#0R:TT$!),)G4$"?6J\S"A0O7>?3$%L1H
M)1\7-E!2"QHT8'1#&L7T4D-Z6\0PQG5B+%%+,%>D.8L-5LP"RPVS26)#)KTL
M8L-X8K2HR.2TC.&"@)'4L$HPB>!:2PRA,EQ0)#3,4DP:26#: AJS9!(#88O$
ML(DM9[@ ZUFR&V)+)<NO&,,7E!2C!@^S]$+&#@U!D68/)_42 WQ1$.L1)3'(
M4@PB0AAC2PR)U/((Z$^E:8P:Q?[S07VT\ 1BU(('<OD>*WQ1AAV<)@DU4(,G
M#L**'R#/&  +1BV60*Q.U" 3P8!$#3C"!1[(0A95B,$JBE$#(6RB%BV3"@T6
M40Q8-$8O-UA%+<Y @V+@QAB)T!M"H% #,Q!&"E;H12^@P 5CQ$B&--3*+&JA
MA2;$Z1 F#(8:ZF>,)#S!%IL80@U.DY!$Y& 3Q%A%#"11"^SM)R$SF$40,0(%
M,V2$!I#PQ25BD DU-N1MOX#%^HHQB1\D90<\6,/M%K$#- JR&*N@@2V"L1[E
M^. +M6#%#8BUB,GU(A%Q?$H,*&$+(=Q $K/H01.Q@+]:3,(%FC#&(W(8#$/T
M ",["/[""Z&P!&,<H@?!" 83C3$+/A;C$N2;11*VX)@JB*5VF?A%\W#4 QZ\
M4 J]A)HVM\G-;D*MF#.8 1DE0HP;\&!6.U@=,6E@K;<18Q(^Z,@..M5(A;1S
M!L&@1 ^ R 4I0#('B[K"6:S0Q!T(J" UF,1!I) RKUB!3<$8H3'B5 Q:\$"A
M6BB>,7H1O()P]!>UD.1\6M0#11BD"K#A DFC9(Q2&2,(<B%(#R)1##Y&A!8-
M"<8OC1&)'3C$+#Z02T%^8!:/B$&CQA #%)(:!+30X&+&X &L6C,%L: $-K6H
M@;<,THO3X,ZG9> ,T9::&HP(03Y"0,2BAL *@F2&!K$LB/X/S+),B:CKCD+9
M! V, 07D$&0):S &#52DD$[-X$%R6Z%C:IA#P4[01<'@!/IH,$Z#0*%%$[7!
M42)9C$04KW =F<4-=G*&-!5C!V^L 2=J@<_)4!8U/GU*$_DSA,(0PP;I\4$3
MGT L9QH$#<7[ 5/0P)=:<(08E6"(,7(0V(H =**Y4:,E&B(4@D@BMADQRP^F
MQU>(H+0@8\"3A99JA= \A:2P(@@/Y+.#DE7B!T"\ 2<PTA!AV (P>>.(%.RX
MM2;V0*T%J4(3MRLG^'KSP A.L()9\@L?O& )ET%+#1)!BUNL8@EIRH0->+DI
M$\JM%IJ(YW(WL0H;-&$)36A"%OYI$ PM9 (+K4 #VXBPJ27426Z+(4@3!.01
MA]U@!S1[RA<*DE7'5$(*3M@"#ZY3A7IMP@9,V%03YLG1K7*A;+$DR!J*)P:Q
MS.TL3X#5#A2F+!XH(ACL;(H:H'"%)]0V$B+NHEEJ0!B"2$&H!;$38(RQB'AR
M@4VLH(&W"%(%,9@,!ITB2&J<:%ZTH,%\56AJH<\BHH+L(!.E:8@2U"J,+.Q@
M!U+PA2W2G!0MP$8(146(2U7'X27XH!9)$,*)1Z0&7W2T(+HTA@X498RY&@,2
M3P#8#6"!9EY/)@9)V,$E(@+8@E"B!E"(\A)Z\ O/.ML)@[M!>L*;HQHD0<H\
MJ$0FGOZ;HQUH[2S(5(I)"5()[ +FRSV!!1:0(X3Z$"1OGTG369<$!2E<@0<-
MR0&_5J5<5B@W$3RHP1 >-)^E4D6U9T$#9YI,M-FJ@2]5L*.6.3-F)IR8!V;9
MP8/@V9$Q[. &G"I((IP@!2WL@"/'*8@5A@S7LVS9&#WH'J;VN>">^_SG"*[%
M)RK;%!HLNR#8*T:@:^&+7A"%($](Q!G<=\91UT*)Q*@*7P\AA:L]^CI,-&!F
M_/)!@^P;*%()8YJJ,.2-4E:-E- :% 1$4#[%\1>_R'HQM++5+C,F<"M:ZI__
M?A8EP"H'CPA&+X)9C)#>%R%/>-G>ZR<)GLNYI0HE2Y0(HOY2FQ>O\SF:P>.[
MF#XA,,@J0?@7N@;*UASQP!A;$ M!B)OG,R0"LTHP"U=:X00S=53'=E0"G@_R
M@T=@BB%-S[HQG*1!QMN:UXT4+%2UC3T0+G^%3U539&- 2!:[I0D(R@0-?)'\
MAEA[$C&X1$.2L"=NHUG]BZ^*!SUBBZP=)!.&-$83)(:11XB8(#FA(F>0!!EG
M#$N@<;+T>JO0 ZOP PUQ!CC0"DD!3"VU; 31"K@"75I'3(<0/['"11M5"2PT
M<%RP=O6R!;!A#&: <4U$$&>P5#4@"<WG%\;P P]""?&$$4K'!:J!-?.%<V B
M!4J"!4U4 ]>!$=SV PJ%*:\'=/XQL0IOA"G&M@I[\A%X PF9H(,>50F0H").
M^(7:1 SL0A!JQ!'H@W100!"3\&WC<5K+Y@/OD@EIR&>OD1$NTQ"4,'X%(04"
M4@6A40DO 'C$P ,EPP:2-ELA%0R2H!H3!3BR=19"4"_W80QUTW<M<@9!0! A
M=1TEN#79M DO(""8F!!)( NV9BT'L0-1P@4^57D.41];H%&;(#V%<08QL%@[
M(#&Q9Q!-P"::<(OZ!Q&]2&G:0A<]T%QCH!K8PQ&_\"R3\6V/A6K& ",%L8AY
M@EF<X(%IE1Q#97S$4 /3\PAI<@@96 Q0L"="D(*+\ )M10,"]6O<AP9<E DN
M$"=5(/Y>]!A9C-@$5G46X/<5.U AD\ 7BE!;:"!BLY@>7^!P7%,0M) $O2 W
MJ]A:9Y%<#?$(>CB($O,6,[ 3'9$$,G 2BY"1/;"13P %]3),OA0#&"%P9Z%7
M#1%HQH (M540,Y!E.6(V[2)X-5E,1U0O5U80*PA[$A519O$%&O4+I=A2#Q()
MKX<%*<@*,; UXM4\WM(V**$2OZ*)=E.#2T@)!@:&+!$,/1 #6]4++^ ^QO +
M-! #HQ<1DW %:+ (:. %#[((5Y &BZ &Z"&6?KDTMU5G.6)3K. R3R!R:'$#
M#G=:A"$+AKD#2Z@^:G5:LV4,#20%0H P.>(E5D $)6,R-?X@!5)P X3!=D0V
M0L&@,%GP!5Q !,2P!2U(3"XSF@+"=P7Q!0)%#%<@!%- .N#5(K[@)5= !.F5
M+5+  Q!!"S6@*@?125D@ES> ")70A)<7G$/P!-FR>2LR!*+) P6T*%EP%K6@
M,*-I?(?@ P0A.4L8##/P+@<!"3=P!5. !CV '%]P U/P!$R 65W4 QXQ!&I%
M"3?P!+TI(!O$G3<P/0 J$3QP4)O  U#P!#S +R5D!3S@(1#" V]BH9M0##]@
M!?U6 XP@FT_@!6,P!4- #+^P!$DPFF:A"3= &HES$/](AA J!3A &%*3(ZB2
M!60P*)AB T6P%DR0F3N (,DE!?Z7Q0-;Y9 \@ -Q,@8\, 4\T(]H80,[088O
M4"%EP .1=@4>D0@O\!/V@9_S.00JL0.88! '!*7U%TPV]F]8X!:3< /8- 3'
MA9E2<*0!UG9!^3]\L07<>9SF 1B8::%CLV3.MD^LH*%7< ,2@X%2X 5JL 1X
M<@@R, 7&< 5-I)M!, 4[\"X7A734^9=]H0-Z6! ]P%)=A%1P>07G)A52T F1
M !YL*@5>:*JZ>A.UX!2+]Q674 ELX0M3$9' *JP-(Q3$>A"S0 E0U1&9((++
M>A"^0 F40$;3&CD>T0D>&2?"@!>90 E-:@L>$0RQN@J4P)SF:A"7T#W3FA&3
MP&NU</X9M7 )CF%<Q-"DOUH0[;H6;,$%[3$)'BD5L5H0G7"M#ED4HD9D(D47
MO5 )CN$+BL(*DN +D6,0PA"K3I<0E3 )J+@JXLI5=M&K;U$)E> 4L# )OM,1
MXK91I#%1DS!ZQ-!'!>$[FZ X7X&*($6M;%$,)GL4^?H5F9 >Q> *1,9KF^"Q
MU#H)G?*Q">$*'C$+DA G$3&O#3,5LS )5)NS5'$)<1(,]^H4Q. *?H&*FR )
M9(H9E' );H&NHS>MOD F4N$MLJ&(\&$0K1"O;"H40=L1F" )MV 0>!,GQ, P
MLP F[[H*>NM1?-NDNZH6:4 #-# &P2 ,7$ #/R!4B_ #(?Y"3E- $* K%4T@
M7IXQ"_[SN*B;NJJK8 TY$\'0I;*WNK([N]JDDMT48;1[$()$ SKP IR0""V
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M@ ;R U6KT B'$*O%L B-X(7%0 F-L'H49 B&H#2U<#N'@ A-^@N'< C!D 2
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MC">;FD DT8)B&"*80JNQM#N-9N9E0@@?S0&H\(EA$\U@%K_HQ7M#6&.!/.&
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M$9.%&H@/@#(?JI&8*OBS3+BD_HD;+!@<S/J0)J@63*0(**B61\@6*%@C8PA
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M)LX"3/XZ"$-P8C[; 2@H+RA8@XWD@A,IC"D8R#O+@BQ8GDT8D!Q^"RZ@@DK
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M!T''4?Z/ 2R<-#UJ%TI8*8$P/OTHU..T@J(TT&+'XJ06B%F'L8% :F.PO('
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MT)T9W#$-+>B.1&YPA=4FP4P,J<4.LG"((3S!(6JX;CAKHPB'8@F+G5 ?+6(
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M_2 )6^3%#CSL2[@:;*Q!YD@!:OR L\Q !J[&2>!7)?#0?.19,$Q!1F#!^]2
M+3 0^#&K5P29,%R!5#24[ZJ<3_XXQ,.<0;M<2F?L !D RLV<P<,LB:% ;PSX
M@AD JA54"/+=#D.(05092Z=XW(+H'P3IX /9@$G\P@S0 C&\A2+-1K)H1!$-
M@5#DV2\, 8B< :!N2C 0RE?H44[,  =2HYK@11LA#RQP"%#@2@E/!2LTK7_!
M3!(5!:;$IO-J@@K+DA#X!0U(S ]4G1#@"A0T8Q.,QPT(4PUP @K#R:PD@178
MS^_BI1K$D#' KD7L0"LPD*;1@';D@.)( I7 1I#5@MJ,#OA)1[%DF1C7QJ,8
M0Q7,R"]H+'N][T(XP6FAA3Q:02)M<#!X H,9A?,:@RT<SG\U:B!YQ&VX;@))
M F6E'/Y#2(NBF5GA&$F664@E^$+L@"87F L7O ;9P0(4$/!7R.WHCK)]F._P
M;3#HN0;$2 R:-#)'@*9#I$%)(<1-0@'[N(KJ3 ]LD.0.4$'6J $37,%7V2L+
M[4 GP +;,L2+0(SB3,(7>\7C.H$^<@Y&_-=T(+.9&*FW_!<7!/,0%)-U[0 3
MY$LXCS.<\  4-&9LW=40W  /I %+M#,/X 4KT, 2_"D4W, J:,&L+(0A?.%<
M,,?NDE,-!*T]-\$2' ;M^=3#>@0C!(/_>$4/Z T':TV^H,2BA(2^= 8G7($3
M:,%P?L6Z:(UVK R/;&$0W$ 0T)TQ$,F"W&03V'*:\,",U?Y ,/2"/4/!3=Y
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M$P#IL/\V)-S =0[!C@2#$PR!%?Y<%T/<@,0H$$-4J!4DP1-,06&]V1,(P16
MD3$@\W7C"2?<@!-@P5UXQPUDP14<&(BD00SP]P[4!D#("@)%R@U)QHSMH(1P
M$@]CJURL0HAP"Y$L6LC<8,5E"\)>-609RW2#8,%9$XUMX7%138U.LG@LL<+C
MC#%6,;7<J&D,S0TK0Y;X,C;&IQ,>)XE:>7+4V*P@2PHFHLACBI0B5XP5F[BJ
M!@]B8Z8@#%9#8BTA1:S<.(02H:0:.X34>!(,828>3Y9R,O:K!BMCP6[H-<:C
MDK$F2YZD'6.,&)0B6;A\P>'+C!2$Q&YL0FC(12^4Q:3PT *4[D0H:HSU&C(D
M[9J)2_YV$$/H:_65'6D>UBB-4-B2)%/4(N12A:VQ1#>D+!GR:R\3UC<,,:ZA
M.6%A8T(6&4L.9<H.+5J#*4]K)K=L8U:X&#-4PTI!3<;2W-!B14T.J69D?#%6
M Y/-($X**JR8'?HSYA$A4.I%""BR^$*+(.@Z9(@G(OFAEE^$8*)!*X(XQ@K]
MGM#/F%IJJ,48+G;(8HD@;.%)!BW80B.&+(RI0D023Y($.2AXD"BKIG*0X@DI
M:K!.#9^ 8HX8*8*X@H?T;*'!L^(Z66*)19J0:H=)?IP%J((B0:B,&J@8#8T3
M)YRBAR?,*\[--^&,T\U%I/A"&#GQS%///?GLT\\_ 0U4S_Y?)JE$JXDVB>0D
MA&HQKU%&Z9("C6 @H0Y12!8MAI:)?!&*L4H@"0FA62C9E)9-FSKIT:PNF80Y
MA&@QCQ@30;,4H54JH8N58#J=:)9#@YDDDQ$/W:H2YE@1JIA+(O$+H6) =7;4
M2&R=19)<?8V$DC:-J602$R=J!9)>B)DR0;]Z9;382R0!MSAB.ID$%K:(H:22
M-FLYU!9]91L"DEH6\1&A3BZ1C95BA#&7ED/%>,+-51ZYI%B/=LM$DA8G2I@M
MBU'5U,U.+N;4W 0ED1BE3219=$1'':4+BD-^840P1%-^%M742JME$E=]I<3$
M6<"]Q=1#H:5D-UO,"\;=9R_I!/ZA@R'QE0:ZEAW6)F-\8:Z7.[-:^.E(#)V(
M%95]/:F75XO)=[9")P8RF$W&1<E:6XV!6]2TCRGN$I5K6"A6MBJ1Q-.G"P[&
ML\@HM5K0Q=EZE?''(8]<\LDIA[R)]"J'?);H,N_<\\_C_(%S/S/1(H:90<^S
M[<J%V"EURK7@X9 U;BCC]3]GB6'IQR.QP8Q$F$B"VS[;N]WXXY%/7OG5^ZQ$
M,^;WA#YUZ?ELF_KJ7[_^\4G\TKZX5<AX3WE!O8>S$H$C+_]'02LA@PSKQI<S
MF$5D4S_/5= 8(Y'A^\Q$\?@!&$ !#I" !33@ 1&80 4ND($-=. #(1A!"4Z0
M@@&T7_X%,2BG"V;031ODX =!&$(1CI"$)33A"5&80A6ND(4M=.$+81A#&<Z0
MAC6TX0UQF$,=[I"'/?3A#X$81"$.D8A%-.(1D9A$)2Z1B4UTXA.AB,.)3=%Z
MGUG?LSY3Q8EH98I99$L7N[A%+6(QC,\:XX_*F)4S<M&*8ORB%=-8C#5>D8YR
M?.,6Z^C%-I)QCVHLCAV_N#I ZI&0;@SD'P692$0N\I"-+&0>XSC'2-Z1CW@T
MI"4KB<5+:C*3=91D'P?)232"\I.8]",HZ>BG-:Z2DJ<TXQY#&<M-RO*5LYQE
M&6.)2RK"<I>6]& 4@1E,80Z3F /,1",,P09#+'.9:W#F&O[8H,QD,C.9SE2F
M-)GY3&A*$YO5A.8TJ:G-:"ZSFVRP)CBS^<QQHM.;UZ2F(<3)36J:\YO=A*<Z
MY<E,>KHSG/@DYSS/:<]X_E.? 7WG0-FY3W;>TYKY)*=!^^G,=]*3H/><J$31
MB=&"KJ&B&GTH1S,*THUV5*0?)>E%08I-CWJSHB-=*$++"=%T-K2E"A6H/Q,J
MTV;B-*;U/"A/ >K3B&ZSICIE*%%S*M29(K6G]DP#W? T"S*4H0QG,$,9S' &
MK6+5JEG-*E>O2E6LCC6K5A7K5;4:5K":E:IH9>M:U>K6N%KUK7(]*UWC6M6Z
MXO6L>IVK5_N:UKL"MJU^'2Q6S?Y AJ@!2BN3Z((8N!!9R4Z6LER ;&4QFUG+
M:I:SD[UL9SG[6=!F5K2CK6QI3>O9U))VM9A%;6M?:]K8NC:ULSUM;7$KV]S2
MMK64M>UH?PO:X'9VN*'MK6^/J]KD1M:V8N@"_/1DB[M2E:UG$*MUW5I5,Y3U
MJWK5[E>WJUWQ6K>KV$7K>:OZ7?..%ZWJ12Q[TUO>]YJ5ONX-+WW;*]_[HI>\
MVUTO?L5:AC$LMI@%-O"!$9S@S!'MCYAD\/H$Z6!-/AB6OIQP@SGY8 I+^,(0
MQO 5-2S*#%O8PY0L5HA3"6(2;WC$'68Q@RE\XDK*^,(QMK"-:]QB#^-XQSJ&
ML8Y+S/YB%;M8Q$,.<I%I?.04)QG%$6XQBBM,Y"5S&,H<5O(OA<QD*=_8QS.F
M<HF'S$8C_WC,7GXRF&DLYB076<%M=O.;X1QG.<^9SG6V\YWQG&<][YG/??;S
MGP$=:$$/FM"%-O2A$9UH12^:T8UV]*,A'6E)3YK2$_QEI3&=:4U7SG"]6%JG
M1R:H3.QNTZ4V]:D9MX48Y& ZSU("#72P U+GJ1*)6(@QSO""'PP.U;WV]:_A
MA(48T, %J+')#&B0["G9[PDP&()P6D"#60.;VM7>M+!U,(,D(.00PU;V1,K%
M/YRA! LN@,)E&"&MB?1B-PCY1;NW^&YKSYO>?=:*L'>@ _X:M.@),>@!K$T4
MC#/\@ 8\*$.;$B$$&N3@"B?90@T6'@2(2:$*Q=C$A#)!I!UPSA=:V $-QH"&
M(:2G&&;8P;"?@+IZKYSE<-Z"N:/P@H4D>PHSJ(%GH/ "&B2!!B^H.$]>$(,D
MY. %/.@%%R"> XF7H04S* 8E=$[L8;M@6#F?@0]BD/4@&,,,+?C!&)K0 A>0
MK>5E-WLQM_ "*YRA!65HA0N2(*,:U,L%.Y@7*VH0@TSX8@8QR$XQDN""FE3!
MW @Y0PQJT"V4SR(1-(A!&G(W@S(4 Q8G;X(Q I\>8ARB#.@[^^=![\2T6Z$2
M+X!"U\>P"!?H(!A<B,$.)*N#%_Z8@1(NH,$6(H-U'YSG!9<?"N*AE?5A$6,'
M+EC#)&P/+B[ W1A8:/H.GI"&:8>>^M478MJE\ M8^\ %E5!]#H)AA1CH0 <U
MJ($0@O"[U9>?!CX0PK:OX((F:.4,+JA!\/6.M>*O01+VQ]C+HR KQ@#K7L %
M8@"JK"\!%5"'RNW<H&#89N 7$L'^B@$-7* '<F86?B$3AHTZ?($63L(*Y,_P
M$.\8*D'X],\%T"!W:( +?F$3+*\8_&<6K.4'8@!S%C '=;"&5.W<9(0&E, 8
MN@W\<B<&MF 3#.'D%H+[EB 3* 'K%J,*7N\+:D%&=L 8*&$&;&!8?*$'8H \
MG,_VAOXM!I:@&'*@!:I :83@!6KBTG;P#>$P@J3 V>K&!5I /]"@!73'&!;!
M!E[@#UV "[1B%7[@#\6N"3RC_V+@""ZAZV+ &":A!5K@$E*#!EH <Q!A"7A@
M#41PVRBA!@K0!2Z0[.*P%$T1A#:!$2BQ&":!$3:%%3YA$LQ#%@PAY&QE?L;@
M#,(&(38!$1+!%UB!$;BD%B"!$3R#%=/-%Q:!$FX!(9H@!BS#&&3A$")K$>#M
M%+$Q&Y5(^UI@!\;@ 5_@(+1Q',D1A-*(S=B,Q_#H%J"@YV) =CZL'.5Q'G^(
M%L;F&NDQ'_5Q'_FQ'_WQ'P$R( 5R( FR( WR(!$R(15R(?X9LB$=\B$A,B(E
M<B(ILB(M\B(Q,B,U<B,YLB,]\B-!,B1%<B1/+6](TD],TH".(6]2LH!:\B3S
MY"5ATA1Q 1>,02891Q=08289YP] 8!ANTAA0H02 TD]>@2@I9Q NH Z"<D]P
M$B6.X120X29- !2:$E#R!A10 "%D,B61H01>82+R1A1.H.P&X0WNH"@'"!5
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M046T 09S!40@.R_ !")  ?Q !"(@3(U!%!J !2C@,/VS#AP@ R! #A!B!$P
M!!8 0_?3 3#  4S &'#! A2@ 635)#^5 Q0 !/:  AK@ G@A;TH@ C   JXS
M%S*  BR  E1!%RY  1Q 5B4 $(SA E"  R8@ :Y3#AA@ CB  TK &$ ! BY@
M C0 5XV!#R  !29  3H *'=! ZR5 O02%Q@@,P.A 2;  OY,8 (2M=3RI@/L
M=$T7%G3RIA"^,T\\0#^-(1<,P"KWP $Z8 )&(&]&  1(U0!DU10D8 4LX $F
M0!4\=2)$H0!VD@\JUB1WP4;O  ).H%P_ "A-05XSH )<=@_V= \R  X(0$$9
MX X0 @7^M"'SQ@XH0"B5E')8P *,@5=/U5*/H0 :=5RS$P!R\PT X ^,X0WF
M\Q0( "E% $D'@0%<=A<8P#9%H #V !52<A ,P$8%5DM100$(H27A51=T00$N
M0!? - _.M@*RD@%L,@/*TAC@ &MU@0$"(6]RU!C@E3M1( (6LP!L%!408 2,
MP0(:TQ@X8$Y7TACZ  #F<E'-=OX#VM48Y@!)=T$!4 $9#(!I<6$"((#E*@ )
M.@ "&H!TM[0 /B $0  $1L!+$<)*N?,.'"!$&Z!1J]<80$ !*I,/"F!0!> -
MCF$8(* QZT "@I(/$, T4P!)W80/!* /A+( <I,#RA0$_M(.II</ B %3@$H
M+6!V1V 4(#)O4. #4  "'. "0#1R\H8%D%04 ( 41%=$$>!K/X!VI[9>?W<Q
MI]<4#" 7$$(5#$ 7!!051 $5.* #C $NL;,#>C5O.C9$$V P)\(!P-48)F!.
MC2$#9+4!ZN 43I@!]D 7"@ 43,$40($ *E,!&O4!X-<!X-<8"&%Z3>"")?6"
M3: ![OX@.-G"7B>B O* %QCUB%/3%(8A 7"A#Z87(0!A/E=N6P?A&'#A 9
M4I,G*PN !>0 #N! #IPW1!5@+C.@,5?R&$RA#PC4&#H@,G%! 79!='W4!#K5
M#I T;^J  8#2!+#63>[ <Q&" N84*%-A$":@5SO9&/:@-R<B SK5&/+ ,Q]R
M!02@#B)4!#99<AIXDU-  C!U&!@5(5+  VAW3UV9?0N60AV@*&]7%#P  C)
M Z#9+CO@+UNR N1@=0=A <(7 6@8(1S@.B- ARV *1G@ C3@F3,@$$3! #@
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M#QZ  A[ +HVA!"B=+?H  B;@ 7(\,!%U(BR@43D@BC^ :8V!!2(= @8[1#]
MTRF@2=]  635 G+S JZ3$- 3(>3@ P)A!2Y8%"9@ BA@ C+3)/L@UQ4YE$%
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M*3MF;RADP-$%*6@DP)7R8C0(SGM(@)$J)XB0@I!&CTVVA[T-D@#!/K\&,BH
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M:]0;'X NJK  9UD':P0*=>!+=OY6(\,P"O?A.E?A&WU@!XX 3TM$C&4C"@'
M)'T@279& 0A@2L;@ 0P@ .##9,8@6AHQ LN8$3:E8;@@ -&FE75PC88R 2,
M"KV1"CO))+C@(GW@APO)F_2((Z#05K#QCZ@F-Q@Q!PWP 1U@ 19F#!U  2CE
M ._3G!K B\.P"Q.  2;0 &TU"@1P$2A@/8R%,=$9 A8P 2G  1B@ )[!!PJ
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MOA1P7*)I0F?C0!X@2\?0J\;  <HUL'4Y)2L00R5  '56M54+8J[U4]]ZN7O
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M(W"8%J !H$!+H)5 #B *A2 "J^D;%E  <,-!,$T*AX0+J#  7U4(!5!J<$
M*.!W#* !'; !#. BH!,(HX!*Y/XS# ]K"G[  "&5N;(I!P"@.!Z6,T%%"GO
M !6 %\A95 2PEAMP :@& 3"U8S7R-%^2 E"#"S9-07VL"]OYUP;@,WO UH.0
M 06@CP* +* 0 '\9" ?@.A PN6'5!P&P.D@@$KL;H*J 33ZT)N:[&IP;,H,@
M!W)$6P#KCP7P 7#  A\@ #+5R2%@"G\P 7;]6A00"!-;!Z4 9A<P#(,:TC++
M 1>@%!$ 4RDB DS2&Z+P ;IV 9QDGQC1 2?@0A<P07+@,[\1"!E  1_@&6]P
MVR-P)2[]K4V4 @>$!!A#"!JP6ZG  7#C!]^S.":@OLMZFBF  1\P"KN&$0@L
M'/]M ?X=L"*X8#DH<P$<<"\<D%5\$ C=52.190'4LA&X\ &IE%SO39UW, <X
M@P*Y" H;D %P@ HA8PR!,-_#, )X\3$9GC,D$,P:;F=:PN3!W$Q.! (+5A0T
M_ &! -=7GA&WK+X^T\5\U0>RVP'):)%[$)R[, (SDP(=NB&X4 (4, $:(#)N
MSB(HD)P=8 *YB H5B@*I4 )C- JR13,V.P>GH &F  JS5=X+^3$54 %4;AMR
M -+&L &9#$@=X*XXIH<Z4@*2_AH=$"W$/>FKSNK TAMW8)#$(0(I?3V.:&X,
M]X;K48B22"'6 9L50 $2@%.YWG(#:(A=B'$J:.O^F(NX<OZ*B/@FLXE>^U=Q
M)6(A_W?LX@&(K8ZHU3X;5]R\JNXI@WL4XL[MYX[NZ:[NZ\[N[>YSCY,"*!#O
M#DSO]6[O,6SO\W[O^X[O]:[O]/ZB]/[O @_P!,_O_@[#!F_O"7_P_M[P^YX"
M =_O!S_P$^_P]S[P\2[Q%?_P&?_P&)_O'0_Q(P_R%Z_P'V_Q\H[R)I_R'H_Q
MW:8;IU "(;_R^+[Q(E_R-*_S+5_S/-_S+D_Q)+_S)Z_R+(_R0+_R2"_T1I_R
M/D_T'Z_T4#_T.<_T1=_P?RIGI5&[R.#%7>_U7P_V82_V8T_V96_V9V_VNX#V
M:\_V;>_V;P_W<2_W<T_W=2_WYOZ>*W9?]]:B]WWO]W\/^($O^(-/^'X_ZNZ.
M^(FO^&1(B5J$]XM_&FO8^%&R[2R7AL3X^)!O4)FO^:Q>Z[["^9]1)YW/ZJ(P
ME\ !XZ+Q&Z= YY$?B:"!"J9)^DJS.!J!"T7%$;<O-L< "N)T5K^6!WB ;'L
MCDD.:72&*['O3[+O$7Q0 K(Y^^%6N]./0' 0 ,NZ- %@Q.5N*!8P)?U5[)?8
MO!9P0*)  >1SBLO!V-YN^:\?_:(!"H3L9MF=TN^\ !.@ ,$E)1JP 1/01'8
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M49^F2(8CQH #9[+8KCJ@LW&>:2<U]>*!&494J$-MEB@"L)\Y># M*LB:"!A
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M>T%.8?Z"QC"_S .\]"M G]"%$1"*\C! !FQ E**1RQ&%")@ L(& .9"U0#"
MX7&M*@(:R)@QA2"(OW! $CR-_E&4!N"G$EQ!%E0=8P@$#WH#$>B P" DO3F(
M7#  ^!B$("F*$CD14:@04? #41 !$=@*4W"J%+"+4S@!$+B.D+ 3A=H%%A@!
M%5"B%LQ"A"@$K]"NP-!", S#F#@;^+  /G@#H=F#QTJ("8B1%1 !4&@: [@G
M_K,# !B!.A"! J E$&  %#@%4TB %< ;H3F&!J" "UB!8[" $/ #$5  (Q-#
M!^P($$ %$AB!K9!$3=Q$@Y@ .  F7"B$/S'"#R*(%)@1"_Z@&@78A3\P*6.P
M \P0":P8*Y(:"6.X@ LLB 9(#@B(')EQA*HY*$YTP!1H$!9  @. PF%<QBQ$
M@0X !;+HJ%28 "5)"$)@ %1H +N@ #](@66!Q96AOQ49CD%8@-!@@ X8@1$H
M@0)HD0; #:9X P.@@!*@,69,OXZXOX(HK$B\1W]$/[%P$]]RC!58I878!0AX
M PL@DQ'(@,9Z1<P 1RH:#BBZGC< -SX A=EXQ]) A3OX  $PL7^T/LOPD<JX
MGE(8295,OUVH#OI!"@;P@ $T&0>(D0&! (-\Q1FQ Q\I" G0B^ IB M@OX*H
M _G!#6;RP3-JKI4</U/0HIN!Q/ZFG$KKPP  Z"10"( L60$5F2DY" #^H@P"
MZ V*,@DY4!P&H!J\R !3. 4$(($[R( (&!X#V"-=: #N,"&1I$KI\X@Y@(O.
MX4O!=#Y0>$C*N(,1 P6R.@A4L(/&\ .8,H7&DDR#X .P&00D>!!4*!,YP JD
M(XAAD(.V:KO!C+Y & $2V,O27$W6;$W7?$W8])P;T;N3FLVO.+W9]+*91+[8
M9#X![$W@#$[A'$[B+$Z%& 9)24[E7$[F;$[G?$[HC$[IG$[JK$[KO$[LS$[M
MW$[N[$[O_$[PC$XL-$[R'*!3* $52 'U7$_V;$_W9$\42('X?$_YK$_ZO$_\
M;,_Y5/[/_5S/_LQ/^ Q0_010_/S/]^Q/ S50 O5/ $50]U30!;7/ A50"HW0
M"J5/!QU0"]70"X50]C2!:BQ/$1U1$BU1$QV_U+$\W$S1V_R,TRO%F531_HO1
MSV@\PVO1%[4\V\S1 40T'(71Y</-&LV\8=I1(352)"72D^#1(.6\(;U1%TW2
M).U1%NW1%SU1+,U2+=U2+NU2+_U2, U3,1U3,BU3,SU3-$U3-5U3-FU3-WU3
M.(W3$PT&.@4&8 B&8I!3/=W3,.2"&LB!']B!'1 "-0B&L9D%1I@$0^531FW4
ML;&"&*"!&(@!%Z!4(>@%@\A3H]#4GLC30VB!&)@%1QU54OYEECS=@DA5!$I8
MA"205"M "#Q5"#JUB44M"&%("&+X!8:(U3QEA!C0 5\XB%DM56(MUM3 @DBM
MA8((AB"@ 1H0U6(PA%;M 2Y0UCSE!"G8@1QP@DHPAEEX BB@!&,H!BZ  C0P
M!D58@C.XA"'8 2BP!4H0@AU8 E@HB%K@ AZ@@218A(+8!"B0@DVP@AW@ 4,P
M!DC(5QH8@D,PADA8 F==@D@P5HF=6+30@DB5A7$U!C28U$<P!BMX@1D0 AIX
M@1V@!6/(A$FM@1V@U$RPA1AX 38P!F+P@1=X F/@@A:@@1EP@1F( 1^@5!IP
M@20PAE[H 1?0@9]]@34P!DEX ?YGK=21705(L $:T($;,(16 %DLD((7@(%)
MH%BP#=N;L-AG-0A)H-1$V 07L(%$, 98^ $7V )C4((82 )?"(8G< $HD 5)
M181QI=LJ,(8QB($90 -6:-48. -6@ )G_04T>($D,-1$B-1@J(1(A0)6. 1)
M'0-C0(08J %;$%P7$((\700R@ 2Q35W5;0AD+=O2G=1%.(,8^ %B* A4%8)5
MD-2"-89@F(5:@ 5)7=AB$ (7"-S!K0%#38//5=9$< $:6(4DB $A*(,SX(*@
MK81-F-1N)0:XY5Q$<%Y1302G=5<T6(75/5_TM=U(#=V"0-88X(0M&%U-/0,7
M\ %*"/Y:?N54OHV!MAW>&##>&-@!3%7>&E#60XA43A!99YV!&O !'(@$39C4
M2S &7^A>8VA>'5!68UB#I'4!%U"$] UAL,U39-6!6"B&7C $9\T!8Y#=&M!5
M8X""&!B"6JB!Q"V(29 ",=@$24T#WEU9XW6!' C6-'"!&C#9 W[6*G !*2B(
M8J"%6:A<[:7@'X@![XU475V%5EB%6J"$*)!>3A5A,2965$7:(%C9H(W859C4
M+5B%1!C9I<4"(7Z$2OB!%FB"7G#6'SB#)I@!&GA5V?T!(HZ!'##9R:6!6I@$
MIU6$53"#&RC@3+"!&, $WNT!*[Y@(]Z"3M""%A "98W?H?X=8U$NU2H 50^>
M5!Z0!(.8W!=P@5;&@F) X29PY1=X 1ZH5RZHU!90V3LVABT U6!5 U UV31H
M 1=@A9MU91< U9AMVA;HUE^P@1;@ K>55!BHUAMH94J-@8@=96]NU$M(A$48
MYT7(A-H]"%A @RT8@V[-5$CX@BTXA& MB$70 C6H!4Q@A&[=A$1@A-IUXT6H
M759@A$68YTPP@RTHWX*8A45(!&MEA+0M"%DXA#38!*)%!"[  C5 YF_N:(_^
M:) .:9H(8X4@Z4Q%B##FU)0^"),F:9=FZ80P:9&>:9JN:9N^:9S.:9W>:9[N
M:9_^:: .:J$>:J(N:J,^:J1.:OZE7FJF;FJG9L9%2XPH0XNI'I,IJ^J]\=&V
ML-&G[FJO_NKT&X8R"8$0$('%W$UK0P@6(,U!6"L+Z,RU& 2BQ(7Q5"FT* 0/
MD  +@ .S6($ F@F[1NN70(4/($V&P.J7& 84>! 6"$N&T(42L#!40(:8& :P
M,04AF0G1))D0J(.'L@F"J /#)*D1(!FB::^&J&I<T)"%L&RQ8"BP9D$=\H W
M0((3( #20.R7.(9\L3LY   4\(,Y4 #6$=*:L#P_6(DSLDF>$::P6%*#L ,!
M*#-.64B>"4R:X,B;**8 B!QBD@E=,(#DZ  ]> E5"(!,/)ZS9@@_*)(,U&TJ
MFH W8/Z!%$" XD[KPS:(#)@AK B$ %B!8QP! 5 H^%:(O_B.HPC*5_1NP8[M
M\;L>\NJ# FB,V$"(82@%FS&+NGZ0"= + 0, Q]X% : :@M@%4V@,L\"^@3@%
M\/"_%$^=8<B %&"*76@ 0&B,9$$($[\17C"%\32(4P" ]AH& C@17D&Q#=$%
M41A/#:>,!N #/".IYS$+73BI88" .WB *?<_^&(* TN=6D()IH -A#@%Q&B
M]+ZH@S R0DJ@@D &+(_R5+!'CI"=X1F$/U$%.E>%&SR(",A%8T@%0S$(7 @P
MA$@%0Q\(&L>*0A^8&.EOJXCN'8&P&).QKO'RTJ(L!L#"8?X0A?_Z@P;X<= T
M!?C2'S+?/E)W\&WK1PL/)H/  W?:!0FA ,#A(PCP#Q.HOQ08 4C\K :( !3H
M\)GB#4++<<B"@ N@16,X 2-L@ H(!(IP +M@=A$X1$*(]GOB@\$@ 05P%5S
M  5P ($0A0F9@!$PBV*\  C8CSUP  QX -@FB& O=KN8@!)8*P9 2B+A@ ?(
M10V0@PRP %W(@&Y7*%.@  O0"*90@1)( 0/H/F,@!%:I ($@" XXDZ&@&L.0
M@Q2"@'8Y!82?@ ]@"D*P !9H#X<J'PQP@ E0 0A(CK,R!A'PP0YH$48O )C*
MF7 G#52P %J_ + A"%QA@ A !?Y0:(""9  -V$ 1T.M:-P@621L">)!C( $(
ML !>T2X.. X)L O1?(,=@JP&@("&)$JQN!:#^(,=&83M@(#,?@.B!P$.$(@,
MR,5 Z(TY08R/\0_2@):@,(4]0!-)2G:&N@,-0($(4( 2"&T'2/;84O4G(Q\4
M0 #85HB.0B/(<8!VP0 08 H6F";>!H2"H*L0(  [$!C$WX5A@ , P VL:,.%
M.$O$& 2<EWF+0)C;OX"2&0$$PGU1. 8,$)JO&G@4&!Y<Z)1AN,LOS !T2I$[
MWW1C. #X0 4(*"4+V*N$P) '.0&R<,L'J2#$H  %\(,'V04'V(/0<  H9"ZG
M$  Y4/[QA-@GI.A*"^B98_@# ="4 G"08U"!!B ?@( PQYBQ#R2,!0I@9Q@N
M WN,;= P3%<) :*,1:AC#%4!4'L<#"-($%>!BR)U0;"#[!B$%,>.E9@@\N4=
M"+N.@1(PYQ@N!'>,E=! \$Z$D"(M3"A10D2#/@113-!ES$^!5,92"#6V@H,Q
M.0#>F#JVQP"J8WP R#%VC" A Z90H1)% 84Q50H(&1LF0:,?MS@%K# &X0U!
M/PV,F5*@:YB"06H9C#+; %=7F6TOID* QU@= '^.B2(@ZEA)8Z(@4!:I>C7K
MUJY?PXXM>S;MVK9OX\ZM>S?OWKY_ P\.VY0 ! 5VO6;\X?X-"Q045" V()4@
M Z>\-@92$,A8AP\$CS'83K"!']416*A=?:QI>A B"I9X"H(@'*$?XE_U;@Q.
M!F-W9!K# 7K4.;;'9*F@<@<#+,VA2BJX.*!1!!P,@MQJ<Z6W&@0/&3.( WD-
M<XPI>2" "D9PJ-; =GXPX" J?!A@# H7O*9+8QL98-($:1%D 1S'Y/@= J:
MD@ N</41(R$,B)1!'4">0M P!UPT@1T$_0$!!::LIDH!HV0HV$.$*"#2, F
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M"Q\"L)W+A653"#'F*1+PDS@ :SR#0$6WU"*0,'DRLI*=+&4K*]EA3* !#FA
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MU($I2  K1L %0$!@1&1(B (X ?ZA!'#),)Q+762 !&1D:MA!=CD CX# &WS
MAXA "H# .EH23&"5CQ&$",!DK9@":EG !@P#*MRC VS&($A CZG+J!%$(#2
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M^0W" @"@E#" 4[T$'. *"."'"=2/GLG!5BGF>X# R2H;E\C,,2P;*1A Z%Q
MFH!"!C@  JS 6E0F*"A&>I2+H)C(6HQ"!C2 ZJY%8E!&(E6?:#*H3$P =UW
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M0.D=2&MZI$)GA<@%-(!5\!0"'/X$*31 !H0$'S@&R.((+B #G.:%!@":EU&
M5;B2Y<@2=\S/NXQ +JP'(>"" .")!!#&'$2)!F"-5F#H'(!D(1C3!\CJX1 $
M$F! AS3 XNHF41-$+B3 I@)FVP2(1/@'! B2B;#+=LP+97R =+H-'#6$ U&%
MB8QTO_IJ7C@ $FB.!M"(0X=32PD&=UD CX#L"@@ 7D3K3Q" 7CN 4%PRMEQ
M-*L* RQH:XP !4A%@5*&*43 !!#*"%0 42VUF^R4*,,E6Y2)G92'+F#L3BI
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M;IH,)?'@PT6[P)T-!$[[MR=\M(\$*<0>LMN\HS$+UN(&*'119.G""J@?<)"
M#N(&+ZC34E)623EAACA>!0@I;^B\E&A !'340Y5[X]U\UFN])J5"&-;&,00"
M+.><* @\\13"'?B!Y45]LHS<VF_]V\-]W,O]W-,]U,>=V]=]WNO]WO-]W_O]
MWP-^X O^X!-^X1O^X2-^XBO^XC-^XSO^XT-^Y$O^Y%-^Y5O^Y6-^YFO^YG-^
MYWO^YX-^Z(O^Z)-^Z9O^Z:-^ZJO^ZK-^Z[O^Z\-^[,O^[--^W@%-;N!][>O^
M[O-^[_Y;/BX04&M<T[.EQ1W(@1R(/=;/1!_P&BX0X&67GWK QA91?_*%"=#X
M6P#)G,R)W^VG1R',KN^+?]:)0M.XQGE*SL#<@=/(01TP,/7!!@54D[T=.Z(=
M0Y3-!E=QUVN(  &.__\#A#&! PD6-'@084*%"QDV=+CPF#$3=$ ,'*9A&*X,
M E%9L#@,Y,!C=4K4&68LT(@Z'$3=$;CG%"%C@TJD0&4,% H4IXS]V3,'5!^!
M=TX:PZ6B1""<?%C<1+D'Q9MCN/;(D2FG1!YCH_+ *7'3% H3H%#R>3/L3@DY
MQ_@TF&-,E%A23^6,\C-4EU$-&$0->U-BC[%A6.U(!#4,3O[1AXL9-W;\&')D
MR9,I5[9\&7-FS9LY=_;\&71H@[HV&!M!UEB?$\943?#3I\,*@;A2J$BQHBBH
MLR, J:)@JD\#C;M0?0#EX1@$5(3VJ+)@"I2%82 VB$)5P1@I#0*'=>B#ZH*I
M/0X"#8OXX0,JM;@0W,'%8HXN$H3\.#BU9\,Q%J9083 F(@-01,'-A#UPH> 4
M7"X@113I2 @0%PN.046#B(9) 85A]K@#F0QPN0,$79#8984^4KA+M!157)'%
M%EU\$<8899R1QAH+BL@/".ZX( 6!0AC%J A6>&./B 0+A)! !C%20SHT\&,/
M. 3B8# _[M@#%1&,>8,#%G2Y0_Y*8T@ )0742@"%#CX$(J6#E^;H(TR!SC2F
M.%,^$.@".$B:PP\Y!-( %U3DD,,C$P81C(\Y.GAKNSMD,^:$05@XU!@4!KG#
MI9/J* P7.^:P !1<.!!!S14:N-/&5%5=E=5677T5UEAE/>B#.0CAPR-4VC3J
M H-VF:...>PH2@44='FCCSY,P%,75$8H81=12!CF%+0^Z*,$@3HP)05*07DV
M+SHWVC(//Z0T4@2E1 $A%2V/T6 07:S+HT=C,CC% E%TV2A28Y @01<YZK 7
M)2V-\6! I> 2 =J!Y'")@V%%  659C,(9(4_X'C+R%D]_ACDD$4>F>22+SL%
MNS\'L?X##XXF.*ECA+ "I(,2ALE #CB$LU=+4$30Q8([YIC6 SE6&,$8$ H9
M2 /9C%S!A#DR0,:.-P2*J(0,[K@XE5W[^& /E@*!((\1<,/ CSP@,"4I8^I(
M]X.*+ECK SE8T'($I2+J (6K4YL %1/@"*2"._C( #8REYS %),=?QSRR"6?
MG'+-B#/FF*E,T2#<8QHW***89R)D&+*^M.XD5' 1[*9=]O#CI&'X^(,CF&\6
MI:!!]L@+E]4'(L$//LCBY::(3+FC\3K>"$0H8W;Q0W75PQVD/+)P6?J8US@*
M=Y@-4!MHD%V,\0,49' 'Y0[<41%?%=\K?Q_^^.6?GWY72_Z?<3JK&XKHC5(8
M2ALSQS!;_0A80 ,>$($)9)7H$F(DT3&0@?M#2,PHZ#>"1!!S!E&,!#.H0 ]^
M$(0A%.$(25A"$YX0A2E4(6,<Z#<,@JZ!*Y3A#&E80QO>$(<YU.$.>=A#%N&B
M#[(+UT "(8<Y+.\8>3"B(QK"!YD0!!?AT]L$!Y&*#CIOBC 4B4!TT<(MFF)I
MW"E*Z"XXD]6]T(=I5.,:V?BBB(A"!;OX2D$LD((ZQ($0N'!+'3+PJ(0TB"<$
M*<0'1#&NA(@@, 0!A2$=0@*G'(0/6M)4(A," H6U$9.9U.0F5\2!CN'"/P*)
MP.>. 9*08(X$^0+%H4!1"%.(X/Z5P,$<43@R CE<RQA\4,LQ1.$!HZ1@3B*R
MXZ$"48(XBN(!)L@(4L@R#-O49C89T( ICE4"-2&F!"XI@2B0(8<-<A*<X13G
M.!FB 1"@ %H1,H]I$@D*$ZP !86)R!TZL LX2"EG65H7+K C"@YPYV*D8, J
M1Z"+.Z+BGQX 12XTD(L5K "A+#A&"70!E7WUX1C&V04'CL*"4W"@;Z5$ 6[R
ML+L+X*(.(QC&"G21@CZ@ */DE.E,:<K)#?AA%(=1IT! H":C*"D09(G(()8U
M!S_=H0ZG$ $I_CF"4<BA>;T42 H(D0*5L& $ZT+%!.I APX$X@/B&X35""$'
M%%0$!/[MFX"G.N"'L*)D62=YF%$\E2^$CN N*6B P6K:5[_^%8<<'8B"9J,<
M@8A"8') $4JRI2=CR($.63)%FWQF@G"98EPB&"L<FB6*?5H %[IPA"X^0+L5
MU*%!4=12!W"QBPJ$-E0:N$D>EL6_P&B *"&PCBY.@8&J8LPE: 3L<(E;7 +>
M*X.X8  )2F !2B(D)<8@1- L4 <[D6)<&6!!!T> @CLP8! 4NL,(\F *_ZP@
M!?3,R#DC5@H,8(P"ND#!G5B07@Y\J0-WL$#?3L('P)5@<!/80]CZP!(3%&(8
M$PBD<1G<8 >_KUHB$<4@!N$^%Q*D60(9Q1]0D8MAH():QOY !@8^=S4^A%=\
MN,A#,P/)'/$%0A2[>(.?1.&'79@")(08ZA[$-Q/H63A>X]/7^=)'I[R@0A4/
M5O*2F2PYX3)D.G%Z3"%$0 ++-AG+6=9R")]\D A^^49>)L@WK[A%,RO$BUW>
M\IK9W.8"JMG-<9;SG&74L<S-#\Y:;$R>Z=QG/_\9T($6]*!#8PHX[$(%N)@#
MI8P!AP^,P -V. 8)1" "%/1X&"*PXD)N',- 7)(AJ!A8!E%;YIB)@A<#Z729
M9W,:.?08(:KPDT# .@(0:*6,#(&#A3FS:T+_&M@B.\4==&&'70AO(!?@@R@H
MAHL)C$(47**U OR$P8@$@J^P=OZ>0')F08%H>R"@"(&(!1(J+HZY*"S)X" J
M<FZ_R4&9@RC*$+<-EXU$!&K,IH#"Z#T,>EO$&'PAB+;O/)!_&QPAO"C*!1X9
M;(<_'&2"Y<@_<8*J$ 2B XK)A6=%$<A,0Z /N^BN"79QH1.$U0Y$$4&2C:&+
M8H6U#X'I Q]0D8$W=* P<CC%,590@A(D^0XB**TH]BJ^23N #SP?@0AP-Q4+
M:"#:P[!#"DCP 5T,@P3HQ,5',_@&EXCI+BN@-.[\P#"7U('JQK!#;"S@%%)8
M>@7'(.H*-J"4%+SA R60.PHTO:X1),9FE=I%'4A @D/)%N*)5SRL-*"!$'P@
MM!! #_X#9$(A8Y2 =H>=,1Q\REA>"F4$RY; ,,)+KQ)@;R830$9X\6"U.NP:
M K@8!@5PP72HC(\$I\A 1O0.@N]A^QAV6!8H*B20-]3A&"\;@=5(A0HUF< ]
MV^$V!$:0@5ZEQ=[#R,,N=D$!T_P,%!@8QBL<X)1 %.(8]_H#!3XLG0FHB01\
M"$0$0)P!W(T 6Z&B4F$(T:8,-'SQ E  8X0E_(TU,.+#V"\/'$ %+ !I(F+8
M-F2*B,HH6. -(LT8I 9:]@ "/(0@^&@$=N$._.0G4($$IHI,XF($6& %!F76
M?*1Q(N);C,$XM,5WYDK\4F!IW@ /AH$%6. #[$!4,FAC0/YBQKIE;W#!G>
M XZA6]1.?YA.($X!!># _OI@UCS@E?(B$%(@$*QFLFCM#08A#O:@9>Z@-NX$
M\0:0#=MP1=907 I+%SB@PDZ!]C@"J'Y/2T! 2M*+%,CB#51@#^R@D(P$%,@"
M#E)@#V1#!>0 %R0@(C @<$Q!#JSF%08!%-KD&%#@&#Q@+H:J(M[ :L"C*."@
M,*3C!.RN#]Z@1XX/%[8C(EA@U%C14<0%%2!@&(K!^TQ *0+AGX:!_@3" I2B
M T0A$'QI&"Q@%P)D2^J@"UONI(S!CH8!/71A$"9@*_[I_UC-#;O1&RTC/51M
M C:@ RP >G9%(G -(9SM#P:A;OY,  7Z8P6,8P\&!@422?=4X ,JC$?R*T)6
M0 1ZY$RH$06\PQB0@@\?"R-F@P+V@!I+H -D(B+J &)6ZE#@@'P\( [02:D&
MP@XDH ,T@+6.001,X*LN[[0T0#<HY03,AN$$@O#J  3L(! F@$L*0P.>A4KZ
M( X$XFM*0 1.PJJ,X@/NB0/:!0"_42F7\C&^:1BXST+L;(,*SB)XIW4P1Q3.
MR$B&B)=\Y\,Z"!<:QS=PQQBH:2!0X9%VH6,,L"SI[<YBYVHBXG*Z2#&.@1>X
MCR!, =9V3L2H4B^O2'5:[@Z:8M-DRQ1"IV-6S8**@2= @L^8$C(C4U9:HH(<
M!Q1 ;?Y8)%,S-Y,S.],S/W-6'A,T1Y,T98B"*O/,T&PQ1',U(2* _HHU720V
MVS V9].&;+,T<U,W TT$$V(81L I4L%]A@%W3J$P%L(4WB S44(%+BD0D*!Y
M<&*,QF>[KD8..J #?(H%.J\.7E @7JDH=D$$BF>+ @'7?/";P(P0$T)0&FT7
M7NT@Y$4U!V(/#N6-1H#7N-&"T,C7% )W<$%_)H,U'3'7&D(7VD8P<*<E0HT$
M1B4I/:,O?%#-0.$#0(K,"A2&Y*!B/I$L'<(X$T(Q#\(O= $.CJ'(0*=#&2(B
M<.%<;*1CF&,K(H(4#JXAY" O*NA26"T31X $0$ %7H$.(/Y"!4* 81YT(41A
MU##T(42S+QIB#LY(@OJ T0Q"0S.H/>$L0KW3,P('@E""VJ8JN'AE)B1))#8(
M%";@#U) 2^Z  WSQ[-IT ^S H!P UC(J EAN!(!3%"+ )2P &P7C5+8(% !
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M8 ZT#VE M^5*;@]&0.ZV0[8Z $B\)Q J A1P(P.:I4)P%J\&04+^X$ZH]A6
M9A>>#1=H)R(N(!!T@0%V81#\CRPZH!#>P 2.@0+X8/;>I9[CB4*/@?AVH0'D
M[=KNI/XCCF$/>L1X/(D0"'80$OH"2J[M! *OR,@85D!*_  $AL$!K@<7C\\4
M&N IV0\.K&;J1&'T"N&^A ,ZOL1MED6VAF&D3U(%K.MJ%RG9 BDB]GEU-& 4
MZN #T@_Y%E4.>#H#FIL:32%J)Z1"0,&3P*/F^OF?.VA/=T$77DNSDMH1M/K:
M2"#YW,-H"[I"\D8@KG'U3F%?AJ$.^H8/@%,XDE%I^V8/I.,">.(#L.T4_.!J
MQ\(/\F.\,N@.Y-@C/'<8_,!(1L EYB 05, EC.:E>2$/),2:=@&E^WO2 L$/
MX@X#Q.<#F"@#_$<E5\ E?G *=^] AP$#EH3A*"S]3,%<!OY!.>P,)_+C6.48
M&[&WT52 .RA@5!S )3( 2$A #SYD2^+@&, KBY%O'F?# 08V.>L)/*Z.X5B
MIQU:0;J(X5"9+<ZWKP?A#P@V$)SB773A&.GD:TU#*O:@&#@@Z532&(^A S*V
M =!RLX>A MX3O5F@+OZI(X;! U!!%(_A.O>9LQ$*-_Q .M;\:EXVP:HEOBSI
M/[[N-</,#B!@!2Q 2[8S@S8*)[(%%4! %"C :,8B@Q;I4P?Z9O)B:Q2F.WHL
M^41 !10 %W26] CE8)0J)RATB["P#^XH:DF!#[2T+/?Q!&4,".\@2UJ.2CY
M5Q-=!2C%%$Q@V>] !:RC(KJ:Y?Z<J8^($VGL:05 H YPH2)(:Q1090["=#Q'
M7"!6(! &AR#JJ5) @ 600)#G<:Q+N+XR:A#R!)[&.O,PQY-409PI;A!6X.&W
MHMU.G0FCA0/:="#""M'APF8F  [@:1"@*FEN(N/$&2<:487]_110)2)2P*=
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MKC(,IC0",4$" +F(0^$27]$1%X6.P^B,(W ,>T!2*% ':V,IN  '#+ '@<
M<!$(U<@KID ")1 '@D4!@6 5DC,9PY "%T12(3 ,IO C*CD"$K%$!L1)$6 =
M@=  ^48T(@!S\O8!](0*/W,,<R ^$J<0U2@1;Z@"<M@2@P "(& 9$S!_>W@,
M*D "LOX30F_P ;/"$W/  '4@,:;(*VO8ADOQ![,T![#2E2*@CR6  B:@"X$1
M.8.02Q?P!^]D![CPCQEP3!9P 7(D0N01"">3 50R!X[3*'(R @R'$B7@ 'S
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MDQ&AHGX@D#)6H0J=0R2AJQXKD!/'DP*$8&] @@*F" K'@ (9\ :,$4N$D *
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M^'JT8<" Q:N#0CB%=$L(G>B#$;B##N@G>^,A/\B .O"^3JL+%D YG*")4Z
M/) #.Q"%#F@EK^@1"K #.:@#40@$$; ##Q@$#_ 5HLN(^%*( 1N1-SB%'PJ$
MJ1 +%?@1J6.!X; U/MC $\0%$3@6$%",/OB #E %'+.##]@F5-J#.7@#%OJ
M4QB! 1&!8_J#'S(&/C Q%@(!,<0%Y3.&42@!."0$%+"G/ "%DB@!B/@D8]"
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M &3TQ/Y,(PW9:XP1J":(RSB+L  (8XX2@["*<XP(4(P*<"3O@BMV$A<1,PE
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MB50]IA*-/;% A?$9B!"8*U10TDR$,#L@A3M(2X58-:KD@\Z""1-(@3Q @5V
M R'I $)X0M$P$;/;D YPA#]PGT!(",+S5NA0H0\XCMS\ #JP" \8 8,%$3[P
M -<;"SZXC/@8D+KB@$^\ \4H 548AA2 C@ELMSW8,I1H%4]E 3LX4;^ -!,:
M-AK*$/YAE(,Z^2E=V)F"N ,5 (4[L$:<8 %)*P54Z(Y=4*Q3T #XZ!!0L .(
M-08_N+ QA=,Y3(57S46:\ -4*(D>U=JM19MY(9Z\:1JO12E>+$NR89[[^=H&
M$5O"&=N7V</"65NVK9FSS9IY*9P8B5L'>8,A;;F6&J':\9V_R=L1R8"*&5R>
M*0:;<0H\L[('F9?#Y=K(E5RND9KI^UK7<1SS@IZTE=O0P9_ Q1E86IK2L5R;
M69W.39IAX(,F]=S115VTW1J_O9F[+0290UO3M1I0D /W>=W)]=W?!=[@%5[0
M'=[B-=[C15ZY*=W,65ZN;5Y1>][63=[II5ZM#1X&H5OEJ?Y>[=4< 9+=[;U=
M\!5?U(F]UZ6=M/W>N4$<]8V1Z'5<;OI<SD6@\"7>GZ%?[I7=F+$XT1$<@C'>
M]@4=UAG? =:<04C%VU$(#F"\NY@9.  UA$265^.#/IBK],T:G1".XB&B\)4?
MESDBQ^B#G#Q<40@-MT@Z$M 0!TN!3\&VK7.08QBFL1@D#_@)8R %"- 07'B
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M, 5#I:Q=Z P0P$>=:&<'ZS0(>& (* %<*"W$8%0'"Q46R@ K!;5J-*@XY("
MC(C_@(X/N+3QT PFH4S:L(MZ)9!0Y$L.N*[L(K?^V1=<F !2\HHYB+"2N .S
M]D>%& 3P$H'Q<H#S.["56('8A*X*B)/4( &>^["T,Y4,4/X!#KBDE08Q3$D!
M XHA$B60 4D[ UD(C]  L/ UT<@ @@G%W'N\C:*\U;JKP,P*F@#0.NB#1^NK
M_K" -R"!_%"(%&"\V#,,%NB VFV-#PBPLC0%_]J Z[H 79A'4&@ -[: T+:#
M%'B#NUH*JYJEUCC4&E:M&&T\)#,)H[P#/D"%":@K].H*BGJG%5 !.UZ(4=3#
M4XBTE'C##KANO4B!U=)'".NSJ?+K$>B/#G#KL5"!-T"!2R5,$K:J75"^%."
M/N #!M"GBL #$8BT8^ #"X #0Z+J,?<;/W@#/F S!^$U7[L#$D!/=H)? 3.!
M$LB XN:[78@WD3P]<ML%B<:%>/X;"Q+6A?WRU$?5A3DUA@@@!%30DC^7R[(\
M 5"H@US4P%U(9UBS _!A*UU @3A8O*;XR1GQ-E-XP 81@?&X@ ')@%00@3QP
M4^EC%+J4T HR 8L*!*LCA1_JB%2Q@&$ ZZ4\AMAH-%!(@148A%%0 13@W=-
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M4 $3$]JQQ,%&!' 8QC".L550!$47%G@;H.[*L!%!-BAR<2NKCB&*5SY3%[I
M16EV 8K8/',7I]5JHH;AUE& 5A2:)2QN<ZO;W?(6J*# A1UN.Q /H "SJ+#
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M?SG,M5,,DL]\XC6_^4!PGO.=&T/GZJ[Y=( >\Z$3O>A$%7K0_UV,1"0B.I5
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M[KHA&M" Y:&!"ZRU^74=T%'F1 ;U(U#F*OQ"%L\U)>AR&F!U)!X"%-! )]1
M$HQ!EQJS,6R!#N3A([A ,:"F:>: &"3""ZA!&?@R&=I 9OZ[@"&<\#]F<1GX
MP!F@[Q-4P2*X@!F$]B,<@@M<M#$\P0ZD-M]5IMC,@H5B!Q2HZ6_8@FP/1!0(
M@6>3@1JTP"'$-BOH ,O*X X80D:G@1;L<-M*9C"XP K60'!7@B&0\")LP6[/
M]2ST0! L;":T@-K:0#"^[)Q:GA3L]A90IP>+ZWB_@"2V0"_4P@MHPB3,@,NV
M@MB:: MTJ==H02..01ET)B9ZX@L.-Q_3@!"8 1BLX ]0HP_,I@](P64V717X
MP&5/9#?.XPY$@LD:0ROT0A/L0!H\P0MTG1(,)RN\P"1$@85*@@M4@@XLP1KL
MP _,@BX'XR(H-GQ:0<@:]2;00/YW'D(,9 (-$* .;$%B0\$,]((2''/8\*8Q
M*()#=X<F#.<61G/.Z0 85D(-E*EYI[:W>D* &X.,KH$.5((+[" W]QQ9&X.*
M^[AZ^H"%WGA,ZC83&@),4P)E^D(Q+((A3$$,W%XO) +W^8 OT  #^D 5S&G7
M/7780+1U4#!U# &*@B,)@ZF,_@(-/+@06(%Q>\(6_,"<>N"&%^8,& .1=Z>>
M$@-ELH(';P&A!C5K&D(.H,$-2($8C&$.,& ,>&L.4.,3A#$Q]  /E-TA$R N
M4R\!LH(L1$(,:$(--$$:"'DQQ$ :D.$/%/;I3J84/"A(/X$83*<.L)\2H%\O
M\*%3BOX?='RG(M"F-U/F+&PK)9QR;8[!(FS=)-@ (GSU+$1"&D"!#<Q"$E"C
M><\<E#_BRXIQ9[O &A2\Y9T!=8[[&EA!#Z2V)*P"(A^"$-@ -E;E(J#!)JP!
M#=3<L\NM%]<F<9-'+5AL=30![T;'MIJ!X34TCZ-!UNWJH^? @_M $D"E!R?"
M(JB!+%2!$OQ&+;C 1-( 7M8"#UQ!84/")QO#7/<")1B"(J\")KP +8Q!?8[[
MS<8 ,$I!&'-!#LSJ#_1"#UB!0$?"=]9"U2N>8^] ,7"!6T\N18]'\@H=%,!B
M+^2G%>B? 1J#Z/&Q#0!GS_U G0I!2J^Z+UQ\%<!Z#'1=(OZX]1CLP".\@'-6
M BLTP0\L0B*H 0!*MBQX<<339H^#-Z,? I$WW2*X=1G4 #$\P=0;M93CI:)*
M>=/EP!@4-B*8 0WX0A)$,#(O(9A[[78X\S]R8760Z>D6<!JT^2^8MKC>N9Q#
M 9TSY2'\PJP7@Z73?B4,NYQ3HZ ;PXAKO188=2540F5F@@VLP3D38N\_ D!@
MZ1&,AAEC0JQ$>E'+V XLQB!&E#B18L6(32H9*V:1H\1B/F995!,CF#$S+3;5
M.&.,!Q9:+CQQ"<+H!2MC/J1 '&/#V"P7E(RAB6$LTXM5K=*,<6&HU0M8$&71
MN+&F28PQQG*(*1;#$%8NQIX(T?Y(:8V5&(EHI#&V)L:J&&N,;<H4:48F&D\6
M&3+D:X9:5C2$B.TX..*B&#IHQ.!D;(R0'#02/^F1T=9CR$$J!E/B8DF,&L$H
MP9!5"\:D,RU\)2F2YL:E0RT>07$AR4::,RYF]1#[A,9&1BVJS'J!QMB,*K5L
M:"%#Y.EM*4U>R"K*94F-7L5FD/2Q$+F6,T9JG7E1TE@E%]1M!%L$@Q9A]Q6+
M+;%%>%:3CL(]N[@Q*]@-*VIPF&6-%MSZ"@T8Q,K$A3*T&"*8*'*(Z)<8;L@D
MABUZ:N$+0UI(1 H:&(NAE1K&&)"52V"89947L)@BAEHXG&\)'8PQRY@J;!".
MBT-@0/Z$E18P@@VL([[:Q"HNAO#EO?<VT4*B6IJX!"(UF)ABB9"*@6*2C2!J
M4B.)?(DA!LA$W.$)K)+ "HI:6LC!BA?*B(1 8\1[I*I:A.B!"Q@JH<0%-*20
M8J-'7FB,AU^2N+"&'HKAH@9#B$"CEQ;@$H\1*%H@9HL6# EMEC)<.*.&*B:%
M*X8=7WCDB85Z\&')5[]4Y*%#G(05HHTR&<*86GSXI2-6;(AAB1U>.&.3%[A@
MHH;Y*FG!ARI@0^.%8M"P08A1IPP5AR:"<>$J'=(D)@@:KHBAAU5:.&,-&"+9
M!(8J!EP$BSFEB"&2'F@(\ZL<HJ@EAB"D:"$G+FWEB OB"OZ.:!57*=KHBS9S
M<"$)S6: X@4I9H&!$BMFH(6&'JP $J(!O_@Q$6,H>2%/E*08 I(_9VE!"(8.
M:J$6*V#8Q)@8K##&AAHJT>',)&CTI08N$FD!$RYB*".&*HS!(H:'S9 $AEJX
MN,&0(-2J(8:,JGB!C2\3AJA>,KNJY 7(()MAAY(H&1,R'\B;*)A#MD C)%D:
M$2:81F;9I*M@U+@B$HW2V&*20X+I1 LM-#%F$4A0/@0B8A!)XY<T=$9D$F-D
MX4*+3'2BX9 N,B)*BS%",@:215!&9*-91"<]$T,(SF1U68Q9I9&ZRX:/L:X&
M0V,ECH+1*PU(?.UI#"LRVJ017_X.D;*61CKIT@HNGGI=HDK:6"61U"O)8A%$
M-J'DY$W46H6++(":I9%>XMJ""YND+TF2DRFQO!+_LY"(1)!N$6: 12.>XKO6
MM4(+6UA%\":R$4BH 2*S@ (4*&B,1%1A(Y5( C%Z)X4EJ&57.9D(YM*0!D.D
MH1:+^-PB#I<(2OR-$@<CAOR4% PT<($2OR.<%LAGA3'0K#Q:* -#>O $-'QA
M/L5 Q!0,00QB-.*!P4@#%Q87C%JH@1*TF%XQ%I$%W$WQ@8>H1#&N.(F]+ )V
M$+3(1A(Q*PR5+1-BJ44/FL<16:@!B)3(B.Y85\%.:<%RTO,%&V6Q@YY!!!)7
M0$-)&OY!ND10SABT^ (:(H$(E)D/?<5(A!J"@0@M3(*%QN@%&<8P"43<C8"4
MVT07$K$(H+C1(T315?#4\!6"2203C4CA(DK"B@W)\F^S^%_O8 E#B/SM$+U
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M,X:,%".':V'#5@1EZI)DH@5R;K="$_&#9 ^&"W$]^,-A-8L82"()[(6(#K!
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KC=WXC>$XCN5XCNFXCNWXCO$XC_5XC_FXC_WXCP$YD 5YD FYD-$X(   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>64
<FILENAME>x_cg004.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 x_cg004.gif
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M^.SS^>CP]_3T]/'W^_7Y_/____CW]_#O\
M
M
M
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M!=(*[[;O_IKNL[!RNT&;% 1VL$ JW,A F/P:L"H"#M@RJW;M.NMQKA[S&NO
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M<FLW 272!X=G?9*'<FV!,Y2D?T"2!WRP!UIX!QIS G.2 %,T"AHP-P9P"H0
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M,<6S I3996K$6A1 &L/C(11U!W\0/<4 E8QRG:RE=,*35 H0#'$@4C02#![
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M2Q"?4#L=Y!K.YBQM61VC"$F.$"NE\(BF8[D+A<T&\$P[*8$5 #D<0"O"EV@
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M$*=PQ?X9BW+.YE!-@TE0@+=ITQ (%%# !3%#S[[$4%^N:(<OJI<L&=0)5,+
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MSP(<$P2W:$H<S'D<@QI@ )A933!$T$H 4* .A1I 68K3OXK4P9RE"<8(K$D
M"^ A=P,XSK<^$:UN"E("$<SH=HCBR 2HP))X@&8 Q-,44M"&!!HX)@$X -&'
MG")%1.DF ZI8#'P-( /(L44&NNE*#\!!G+7!A::(X@"/H&(#HVPDT'3R+1,$
M54.6_,0 2.@8B#PUK0VX0TE'&OZ  2@%=36"%P9,4%,/#=4A+'AG6L]C*E2.
M4H"M&.73C(>"=[K(D0_0D#I)J),*#&  (&!!4AD0/A:(LP">>6< E+>"3Q;
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M!84U5V)0!"W=!3-@VAGX@2XX2&B]!/><V*98A7^,!'^U 6$X1ST=V!G82"&
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MA%O<!$[0S::H6#1X6=8=84Y@A4R<!48XA$FHU-7(A$,P!+7F18=,@UDPA$0
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M7$"74"BH4E !&5_S$[B%4UAS%$ !%T#R4 B2<+R#I[.O4,*%*T\G+(,_7*
M!W@#/#"!TJLZ(2>&4'  Z2D% BAQ<SD! U !.T ! C"2_U+T<#F-]3'PVFF
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M05P$8P40B,H$) "*8,1!7L5HP&C,-R(3-.DB?"  'LQF@!&%( 0D48$%B^&
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M\%5BN&"WZ6& 9HD!7&(HP*AS*&Q]'BJ"YX$M,''HW4X:X <4X0*XRSQG^1J
MW<Z446'NFF8_^4#7B^BB 1Y(P0EJZM%0R,$#"8# 8B"0D"(I0 (*<.I-J!8S
MZ@%% OY_J&B_' ">DEX$ A:1ZB<:8!0B0N\.T"5&!;(V(!25@I'%0+ #_&#6
MW(7B=+9,P)I60)_RK?4@LI& 1?@Y6A.(DQ@D&/'!N)>5K"5@,1!Y$TY."Y'L
M7(0":DGF18**S+:N%1 +D.MX*_ &O%( *Q=906%QH8!"X.(6ER6:"SP:+[EP
M#",K@DCJ:'01:1'# AZHWTZJJTP1R4P!I:Q> Q[" ([T00(0P1Q'3D"6FU@
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M7'79A!RX6QM*5>_0G-ML!@5H!TGX02A\0E]Y&[ -5@*TC4,<E9,EG0N<Q[J
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M"@P$+JA *9" L:0 !VS KG5  W" MX ""#R@30^"!M#='&A6'Y0:"OP/LZW
M57* !K3 GW@^=ZC.()" ULL%(71 .&'("@Q"UJ. MP:^![L[LVC MMS$OSN"
M!T3HB:#  1-),;3;!M#!6X6 P[JU^WX"BY; 4@*^UZ4'"XQ^QP9"J9G 0*R
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M$BA.H<AB@RF=\@_.[R?@4B:8,"E](C!;(A0XT"=.L'ID32MQA32$@K.$PA&
M4"9P@1#0"15@,2?($B;XPR<*@9RR(A  (1#ZH%9*833_ ,T,0@78,JTJA3&U
M9R$>P (L8 (,P&H*TAY7A,7HL2>Z<1L_@QC\8B?;,0)&HD0(,B=[;>RH$9U6
M@ X@P@&P)B=(  "80R'[L0]>[3=@4(DHH'E\TR#J  %, "=-Y0#L\1[3TQP+
MDAO+D?X8!N'I0*(^$/(F!'+UO@9C6&  .,8"P D&S;,W^5&+ZL"C#.)@(( V
M;5,9L7$<5<_9'.^0/J$ %&<G]S$H=X< *B</)LH#?F8=#[(.&&"80-0AGE-
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M4)5H!)!D$'BC02Q@8:F##Q9@02J@ >Y@$)AN+/KD$_+  %19 ?P 3Z9C(2C
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M!,%80?[." ,I(=8@'C# APS" )R[0P%0UA&%!(D8 <.FH;A#K!", $I2\LQ
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M%RU?L81+Q'I?,0IQT'XUU0?1(GK0-WZ&MQJ!"!B)03 MH0)2J(1\\ :QYWK
MASH0\0=UL#"!\%'U%T5RD("*07[F!P=YL"1+V =O( H%2%AR< =+0HC7 WS-
MAWJ-A#*6@GA^4PB!<$1S  <%)QT3\!>@8'PUY8&$0(5I,0%/Q7?'B(S)J(Q@
M4@KZMHS/*$(D\6G&"(W5^(QZ9XU>,A!7IGG9Z(W?"(X@M(T-< *$4 <)0!_A
MB%MP@(GJZ([OZ(UZT@*"  <(H(OPB(\AU <8(P@H\#C1"$*# %< .55!D8_N
MZ(9?02RB!)"P8PLZH7?8J) 8!/Y VC@E7+);BP-^GR&1*[.,NX6-#+DR(8E;
M),F1>A<,;[ :;BB1&#DE0%.1(R1*';DE7P*2%\F1.$F0'AE.+! ")&"0/"F4
M,0F2-$F1-RF.)7F,'0F3.CF48))[%)F31CDEJ- K)< Q76*4,!F15!F5,:F0
M5#DEGU!;*K"%-IF3%@F53GF0;>F6;PF7<2F7<TF7=6F7=XF7>:F7>\F7?>F7
M?]F4?RF8@TF8UBB6A8F8>GF8B=F0C.F8CPF9D2F9DTF9E6F9EXF9F:F9F\F9
MG>F9GPF:H2F:""F2HVF:IPF6AMF7BSF:,PE $<F6J"F;LTF;M6F;MXF;N:F;
MNPF/Q?XP"('0!W_P!YHT0L.HE[9PCU_B"-(W0H,PAX6I?U\!"L_YCKA ""W9
MA=58"GA G8W2CB"$A7_0!WWPB\_HG,]X>#75C79IG.I8"I04"G]P$,!Y)J=P
M$./9CJ!0?\(G%*$02+A "E_AG[Q)H):)7 [0:Q-@ +<DE1P9# CP)"Z9EA/9
MH$^9EC>I+VSI&1$P,C;I >K4 &2%.3*)EDZYD+'ID?%"(I7D90U00;"IEJDY
MD4M&C2MC"P7P32)IDC Y#.JA 5LX$(,  J^%-Q3:)12@ +U& 090=:YEI&#I
M6NC5H%^9D_<B%"[@,260CB:)E$1IHCZQ$R$1"ARP)'=P OX2^J06VA*410P=
M8  3  $2X![$0 <!T&L6H  : $UKDP K26,L$0RV$ *?L!JVT <H(">!.JA_
M5Z"-JI@@U"2MUP<#L)%@4J-WV0?*%$(64&%@@ACHHWV(N20%!!$C<9"A<$V6
M"HT#T0<6Y8#G$UJY96>==&+0" '@P9I?(0*PI!!+,EBYZHVF&@I-1!!P\&#+
MZ#1)!R*8,Q!UX#%Y,V/QH@$<0 =?@0%2\I[9%1)U@ $0< *X< HE4&N&XJCE
MBIAAT3M+D@ Q50<:L '5*AHN50HJ4 PN($=VL $94#3!D )DT@(&:0?W\0<P
M]*U?80LJ4 H@,"/!P +NNHE]0/Y2>0 ''",'AC*O4>0QN& "'+ !,84'?@"Q
MN  HMI!#H.%"AU("WZ4J$E '+& !(Q!X)+ !(+">ME "&= <"M$:&L!NN, "
M@Q "%? )H\ !%Q!3;T (;V !( !%Q;"S_D(3'$L"C"(F>P0!$U =[)@U^:H"
M?C,6+F !(5">P8 "'%MA?& '>W !&7 F3:$"UL8'$; D(B:S'7 FP: "<E)S
M6W8"@PAB(M"=?\ !&8 "4@5' ]83 T$(%_  (& +<- !?*!PN$I.,*1$7Y$^
M1D$ <A0(^=JW2L@"'.LODU@(&- 3=X !&[!U04E8;!$"M<&P@W "%U"P5K$!
M%7 ':/XG%(20$BS@ ':FL1O  2;T&80PN"3@-\&P AFP 89R"BU "!YP <[2
M,FT+O2<P 7P@J/U"$"V "J60 >Y1"GW0:"20"\00O1J0 LF[ NYJD,4P!S $
M!RZYL;\2."TQ!^9$#!9P)P.!$GOP.0[W.0!,2<2@"R!P 0;)!Q50P.;JP'39
M!R"@'65R-3YF (S" A/P":*#%A#@92=0%>OZ,1*PP1101Q2 %K8@81 !4Z=0
M1*,  A@PHL.$ 2=P)C,;"B.73_N8!X.  @!0;7"E2A9F$L4P 210"H0@=1Z2
M "$ !\%@ 7N ,X;R!C05#'[03QAA<GM0"!10%;@  2U@&OX,<): X0 H\ EV
M8 #:X0$8\ FC$BK%E@$JN!9_( =PH130)9"/LBH7\,8/4!VIX"3OF1!^P!B?
MD+I!\7&"!%.B(+T#80$-< >E"SQKV@'.\C#$H#UOD#UY5KV4(@%/E0$G4 IW
M0$R]-0K%< =UL%.AG!IV("82\'=YH !^$ HQ$0RHT&)\(%4$@0I-1GES8 !)
M, @M@,=%]0F#0$&?80$B( AD44 #X0<)P <3$<KV8KJB\ #Y] 8'X'4YN*Z!
M\!:Z& H%L >H4,4BP0 4X ?ZT2IJ)@<^C "&@3GIO'4C<"8>$ +C:P!8,Q!_
MD !W\ D7-R<?ND@I$0H$X &!H/X""0 "@; "C-0 ?G$'2<H'?$  B8$ @8 +
M+2#)! ,"%3![2U;-)%!5.'QA^=1>Z (!EU16M^0!JDL6@]"LWR$(](@!R+=)
M<5)N Z$6+&$'P; 'C#*^MU!A>"#4Y?G 2YV/J)  !L#'7F(,#C !)#4!;9(W
MT7(*8\8M,Y08#C (#QIX"Z#*%:!3U%0,CF,5Y98>7X$*G$40@>!3.F47,=<2
M#Q 2&P!+-O(')A$,VB<!3U("FLI&C0$\$Y!W+1$=!?$_H_(QR$$0)P B/@&V
M+<'*HQ!9G(8+R(419D(0F1QG<\4'J-!I3H0+;ZU./1$($C 0NKN_]Z$ $^PJ
M?S&K5_Y!+-KG/U3R4J5 *V6*87>=4Q^U-HTW,XSB <?R)S."';IVUZKB!\_J
M$X3@,>E,$!.S5JI(,RV1 0V0H J@1 Y KBR;$2W! 6A17DOB "QT"_TL%,ZB
M$EA!5P3!+2'08Q/@TL0P!U65 >Q6 2DP$+?PG!/ ;G_C5GJT9&F]*#NMSAM7
M81/P/Y#D $'A$/@+V6CUV1L\UP#,&K+LRY_A /\3 DF* 5Z,/P9PI]NV)'%0
M54GE$\M&G$P-XWC)4@-PS5X2# LP%F6Q382P%AO@%A-52YV#6;[A)@CP'F\A
M*R1R A%<"@X"$1$= 33;WI0Q$'*@ .]Q 1 0# ;1%"QS'_X;@"\V0KZ^#,(A
MGD^4XQ.X:W_=,0JIJA 13A!^01 (L2H0P %M$0&031 ;@!9<LD-, M:ZL ",
MPE(]P4]G@M@ADA,:_N9!\08*8.>)D4@$P2I0HKU]BCFD:N&_9+ JH,\,H"HI
M,$2E@@HE,2&EH.4DZ  (>A^147BH4 !&5"$7TK]K?CD>DA1WH+_=LA&-P6#\
M% J$@  @<.<;("E",:N*80"SQQ-='C\=_>DI\3L080L*T!- 8P&LFQ;,8F\C
ML=AXX!44L+#$D +5X1DJWDA !P&_6P=<XE 8Y.F0P0"H@ J,Y"BV4 RWT#"9
M;,1Y!^%!41->*Q^XX  XRP$>,/Y>>+ 6=XX![\(<#" !M:O8%=1*$TD'YA0,
M.-M(\*4"%,#:A(4 MZZ3P!KC)7^,8E*I=)@ LOUMQ3"LR=,G<U(GH90G>Q(*
MHJ N?W('B5,H1A$()9#@PO2/Y#0!I9 \F%(,W$L0(,$RL*18=,YIMF(O(8'F
MSK/GP;*L7^$ /!/8<0T5,,$_O3P0(- J-V$+IW 'M*/.&WCL<M/98*T40?4I
M<! (%E4[<P,8A* "!8 *A##DJ@8E>X!<?LKGNY)6@>34*W K)) 26J&$9$SG
MP>/FYD<'&%,,%[% ?:X423 *SP)2U6[HQ7(G>:"_K.I7=Z% T!$*CM U?4(L
M%'!4O_YB C@3^B*0 C=^ CRH F@Q[8"Q *6 .0;Q;\-V"K? X0V0E7A@UA;
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MQE!HH#@-S-_25""YT=1!!7-PYR!*\8D3R.%\@5 !1+WCAUCR 8V!I VZ2T$
MKI2B!2H(ID#XH (6E*D0H?CQD> MAR1U\A.A@/>4 G$"Q @D#RJ(PV3^< H_
M.)LJ)\#,"4ZPDS>@%A=R4$%?1N,'5*[1.7%0@1T^% QUPZ%-@3@%($Y@<^?4
MX01?1#2 <&Z"0<1A/S)1]QN.%(BH[.$@IQAXJ'$!!Q5P4"-]4,$*K@@*"*'
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MDXD[4 'W2S:30 5$:I35J1T.:(&/V9M2<(#%DX !"08'L/Z >D, . B&4?$
M2+F+0&@>%0@&"BB5&5R\"8@V#O" .O  "(BDWFD_"=" @V !"*"YT.B1H @%
M #@*6T" $I*)!G ES#H!9*N(%?"\O<D-"LB#%GB T"&!*LP 5$( %DB!#'
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M\ML*@2 $%JF(R5"! 4G.5(F)!; 8!D 5)SF*)A0($&@:$F"8%4 V8O@58O
M9$.:8A"$!)@,#DB1J-$?F?I%*EDN!L@)1FF T,%!-:T#%GD#3D//@QJUK9$
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M/ K(^12A@RA+L&B!/Y16,7,22+D(#E! ^F*88G"!TJV#0"F!"1@X%L  %J$
MWRB&#5# F97@+[F(M3P-#V#>4^.;3Y-*!-B %6C.A0V).\" RF,C!4A("M"4
MBQ!38E  %J@#/>Z#KT"@$6$1XPJ*8O!C%N@2#* >9ZR#.:@#/I:D-\@ 2801
M5TM67*"#!\ #/<Z#@'F <!L&#B@$"A %H\&)C"A#3SR2<X0#8X  #JB#4/
MWYB:)<):TL"HS/23VY5*&0$!#:@#.J@#/NC5;CE78N@ X"B!W6#<%(& Q=-C
M/[!)S]@(!^#;ZJE'$K@#G P,*_Y&GV(Y42]&W+<0%=R=U>(1 6RF@.QXM&+8
MWS?0XP7*GT%X PI8@.8LFV$+!1) %>X=#3X,A(+XF@=(IP_) #7Q P:P U^^
M@T HAEN!*<X W*VU+Y$=C0< $".5WTU=41.P+PH0 7?V@\#8 (IA6@D>CXOP
M \DSEN:3SN1A 0\XK=_%7=+-"$#+CD$NC#M(G QP0CWF R6:"<_!"+VTA0TH
ME8L(A+>H"(P+A6]$!2Y5D0NY"$'PO8/( P_X@Q+ A0QP!(/)C?A(A06HY >X
M SV^@R)ZX*=.WI9QYSX0C0BH/!P\O5]N:X$@ 0>@F%.@9XI8$26Y4QXSC*.P
M6N_8BOY!P%%B0 [ZT]XLG!>;>,@6" 8)V+)0  $::6B!0"#>[5P820&V< %D
MVT2A340]WH.@J !Y*NI2;1RGN(@,-0Q-[&EHMN6%B ,/R-PV6V.78("(E1N,
MH( !R4F,T#=B@(!@NK'1$$_R5)'SI)&)?3]<H#J,V(#A$5H-L05* X7FX!$<
M6HL!<8$0>.E13DB!N 6J+08%"*9@.(!20!B!2&ZNW1374+TR\4,:90%^B8,+
MD0,^8<#3&&:+$6 )OE</< H.:$-CL05 XZ.# (&!K8!.#=K14%K*X"!'*)8X
MT%0\10@IC8-[!8$".X%K,:[0$0%4\^,1(091V,[AWAYB(/X$A> -XW!IY\C&
M5C  KLB#_,T(@D8*4B5?,V&,-W *". R4FX 048Q@:" G-@ -0T!HCD!^RH!
MY"$$T1!IG= 2@\:($UB//?"G!X&1%6 +[,*(!Z">#P&T10T]@= #MSDVC!B$
M\Z*)[HC0Y^(3$T@-@+UR)#$>A,AN8E@!W^.1# B!HQ !$$@!@2!Q'C$24?#S
M6X"43Z +D>2*"<8 ];2VAM'@C-" 2P?*-]" >2$*I\8%[3O8G.@ BIF HR@!
M&L4%/GP)WP@&8*2_C+.+OD!8@Z 7%Y>6*4E>IS54>4I,?B&P@5@/1^TCB;6:
M#5"3+6Z!; V!+P$!N P$5* .)?ZR!6%%0]S.,9 (A@&8$H8XMQ,@ +U0O1;H
M V"T"=)QS]1U  V D@2 E!/($0DH%9HX=Q  &5Q0 ! (!#O BJS@ #\1#M&X
MR#VP@P10$SP  $@'  ,)*07XT.]6@ U@;04 9MQ!<028 S_8#A HAD'$71=0
M #ZP PP@@$X*^:N<#7D>#5\]$[IA *N1 #7!@ $9=Q/@N@%=B,?I Q)H4%M
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MF!+H_.3U*TPF85K(18NU%*4 10@88&(#((H BAG$U[%N_.,CO^K! ($$.."
M%*@0 ODY04B+00()9, ![0P$ RP@@A<2@P\BO$,#,+ !$93632& @/-1D!$\
M(("'?"BG!_!:G;IK)2N0G8 %2& !"S<$!X#()^@2!E@'*OX\P.-1P.$1( 94
M@ 58DFEDP$A!@'/9 @1P1@-:@ 7PQAT\@ 9 0 FP%P0X0#"L0,EH!01H0 ,X
MC_I83P3<'C%4@$&(10R>0@-P5 ,P0 9$1!W@%,]T0#RI ),E7Q$:X1&B5RDL
MQXSH3C#TB(;H$7F17%+H#BX,@GW4!2H,@J#$D?6\6(=@H6OT2"A\5^\XX<Z
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ME((%B/X,4Q1$OJ0L!!2""FCK:@Q"-U% H7X>HE*K.3;D!C3  U1' \ !!D#
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M5FO$'10#:MA)(0Q"G,51'RA ,?2!8 M$1F3V(-O$$&K%8Z++CD'V1A!I0U@
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MA57!H% ,*$0L"I([P:"7&*@(* T@2(683PS0"H,YB#& ,%LDZ  E!B/*( X
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M@ [30[#@1005$Y@.*,@2$1#,"Q<@F$ &]O,74$CR 0H8@2Y>$@$@U4%Q(]Q
M!^HP,;=4! ):66-;)A"S"\RE#G<,01T:X(<[*"XN?K' "((2!P2T1@).S,/)
M O&  6Z .C0I1@4LX*XZ?) 8<7A _#)##$&0<)/1M(@?'-" 4+8 6 ]0S0F2
MDX<H@O[ .W58CFV2]\2N$,,/AR%&(29 '@[L< 43#,8)+H@E#('$72@X0!TF
M0AT56*T8)X"? VZGF3TDH $,:$ "]N)%"F0@9<0HQ00TX $YP%&D$%BD"2;
M,J]<QP^[<>.A@L$!&)(  X=2XB9#RD+[7: !S#J5!!:)16*H$1>F%.D$"'B"
M">B/J#J43R!&1 P.>(MO#B@D,33   @XX $DH(X@B#*(0!%C@AIXP&B*@0L/
M;+(!< G3 6:2R"L*"!?Y(P8J^O0D\_T5L($U'_#^LIV@F.(3JBE% TY#'(O
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MQ% UN.L-[T(%B.<OWE %\$ A@OZ! T/0\'2B#DQ $%#I+_A  *DC, 3!!.K
MP^Q !7@P(CXA/;HP%%JB&/)@$D>ES7 !#NT@3HKP#E* ]$#Q!$*!! !,(P9!
M S!@4CA #@;!!.B ._I@$FD+0TPD(@)!<8(A 82*)NI@(&AB>C++AK2">P#0
M(C* 2R+" ,0L&!Q@$)YN/B; 6P0(9BK1 <#B)4X@ >8@].R/',O1',D'0_@
M%]B#!"($GQ3 !>2  1[/ RQ@#K&$&#0I QH%%!*@!%A@ QC  A5O 0B* 4)
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M2$(7%.!M;@$7^&LZ3P 7O',.*$ U!$$!BN$-]"DB2(!</J$.X#,B\H 0[@"
M<,$%2F$TSI$_^],_!0L7' #M(F !%J Y=&&/(B)83F&@+$("#(\$ZLF(%%0
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MFTR 8ES@)#@  ZJ02A3'8SR.4-#E.#K"*5I@*AQ !!2P!1 @#F0DLHX* 3;
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M: *G= )8"(!:>*-0F>1U >,9\_[Q)/(@ 42 <@8(*#RU=0-9D%L70P 0%0J
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M&.;  T2 &1L##]JD8-6B#I+@QED@#H"B%%2 <NR@Y8SYSM,C*/S !6R<!>Z
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M. <0Y0\&*D4#B $* JP :G_K"00XD+D&2,IO7R,)6R#P,&+,P4*A(, >) ,
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M3(!O=1C2U3+#6RT+=R&=&LD#;&L\N_4VN7UE@"Z* EABG&*<Q7# *.9" 3[
M@5(J+L$;^I6!&@XW."W@WX(,6I!!$,"H&6B !2AP 02HQQ8(L,]L6\OI3GOZ
MTZFM[^<4P)8-(2 8J3AU:32" A:0 )\.&(3]3H,*C93@=L3(@Z+>)@H'W<+2
M/$$QG]D2@A20,GUW5D[\^@4DWIVBA'/!P/8^L^SN9. -\N-)'0I-C'X>VQ:#
MV&)I>/[U0/<%9@6EDD!PB!&!JBQ+3+BPGX+LAPH4'J0N* !Q Z""@"4R610K
M,TA= A$!@V1@)PF0<@AT\09N9R1%;U T>T8S3J,I $JX><.0"J(F8J"E("'
M!1R@# '#!FA 3#RU!\![VP!BX&NH<4 .,R,'1;>@T'=)<S$4F[U ].K>,Y]4
M8 =+# :TT>/T\:EF"*V0#+ \"6]"V4P8+1D#X$*94,%%,#8P0EXJ!]1@#[O8
MQXZY8!#@H47!(#%&0(%2(.D"Y&+ !"K# -_T=!2G$($%-"(( DB*O!K@T0 (
M<0M"A)&/+SQ%'0@ !QO"7)FV@#Q^<3?)0)1"!0% Q2!T:?Z+.@A@T"4H&@EP
MEQ%(=8FMI"Z&"(8HX[I0  2H*(4%OC87R#<O,"@(8!T2?HHD * J?UBF+>[P
MMY-B(!2I\$"-\A5[076;]">]3@@F$/L0! ![S"]%!G#G!Y03@P*#;H%U4E$"
MF?,N":U X4[F<@L&O,%W#-A)!)MLD#=T*A4M:$ QZJ 25+1@ '/T9Y]@"R>@
M?RS ;23Q'\00$7: !WCP!I$B&0C ![; !PCP&"#  <($ @90;R8T/PD0![;0
M!PD00 :A"PDW$@M&# _P/QZ  6[G 856" DP9UY'#*V  (0E 8-@"R4  37S
M "AP"J$  7SR!F]R$!H1!TG( OX%=Q\#4 <P 0=!!AJ.M0<$L!MSX%ADUX5>
M^(5@Z!6:8QZXL &/$0PK0 $!<QHA,&@@9UAI6 $AUQ8;4!LDL$B?-0$5@&4(
M@80;H%D7$ QP$!RV  *X8 O45!!ST'AN=$MY0 )U@80:@ =_8 '!4 >#-@>#
MIA$NL''<! )[%P=$T1,@L!*X( (54 $JX#FX0$VMJ!R8:$$30 %QH )*00Q^
MD(H88!+34@<;, $>H!RX0 )JJ )JXX;-4A?!4 (3@ %X (D]08P58#B2,43G
MPR]PH(;!6!"EP %JN&X"UP$5$%;SLXT(X1$5T &1$0PI@ $<T =VD#;]4@$6
MT $K8?X'TE4,(= EGZ !D(0!&F '<R$(&$ !%E ;A8@!(% (T<5< _,)>T@"
M=5!!"]%<&;&/^%4QP7 "%* Q?L%<!($*AH@:('!AV^4!R%(<I^ !:NB&?,!R
MW#1 Q( '!H00HQ J&' N<4 0(? PI;4!]A%1AA:&1%F41GF4#U%B5P$>(L&4
ME1,,P0 !ZZ<5A[053MD6E[0;<X802AD25[EC)W&57[D05N&4FX:58'&59[DE
M7-&52_DY)]$"(P06A$ !8XF4>)F7>OEI:YF4KA46FX9(]B4T=WD2?1D29ZD1
M@E4<?LD1B5DEA]F87(D5@FD0CSF9E'.8D9D1?="7GN.9DOZQ37LYFJ19FJ:I
M2@JSF91S8:?9FJ[YFK 9F[(YF[19FWFIFK:9F[JYFUZ(F[SYF\ 9G,(YG,19
MG,9YG,B9G,JYG,S9G,[YG- 9G=()G;XYG=9YG9%3G=BYG=S9G=YI)=I)E+8
M.5\!"BFBA)@I.9IC >QI 2/ F "R$:6  5]7G7U)$(10*GQ051HQ#.B9$ .#
M"X)@GTQDC0#2 6@7G_^I$(DY6VPE-PZZ$6OIFY6YH)9Y$*V@@$-IF:R8,X#3
M$X'2GF_PF5FAE"J0*HZ9G@RZ$!Z /8&YHA>:$'?P 'B(FY>9$/Y)2AY@ ;I@
M H#P.@J(2('P'J!IF2X0:SPQG_[U*1N)<1 Y*ID<>A"?()IMV1,<<)XM1'HQ
MNJ"?<#(**A(:$0@;H!&$L!MEN!MNJ:)?:J&FD $=$ PA@(%S)'5M00C@4:0'
M,0<.,*<]@0%+]*7@9J%0NJ:ET"4&80$#P0$78 $5< $0P > TC'L*6 '$0A/
MPA-_0 $#LTD:,0AZ<! X%#FZ@  L4%E[< %4M*$)<0HJX!?A&1)[('.#X(9:
M40JJIJ8 2@RQFA N8!Y4H@(=\)=1PB,R1YDD]#?@D0J,5UEV@  PZ14:P">O
MZI4)H*%BF%FX,*U7H1%P  &1,0$[H0) =):Z9*P1] G@D1JB%CC:JA#1JJJ"
M^A"M]_X0?2!NB$E"WI<5H>!A1<<66/>7)8 !IU ,"Y8$MH6>S?-UAMD3!L '
MX!$,*@"?\5FO"O&DVTH,)J"EP?81:K$",)$'VA0,!9 $E74'NV4H'A"!<R&4
M1H$4;&$')B ".SD*1R$Z\!HE"9@6:]$6>$40?Y06IBAP"5(0IH$=RA$,#H(@
MADJT?O!LFV)*A\A%E3$<*9(=/KL'#> >PD$<!C&P?=5H?5 <M4-"VH$=&A$9
M(RB:PR&Q!\('YA$9I^ 'HDD?N/ &&AL><GL0"+(81F4+4),9;_$><?NVQ7 *
MEU4*EV40@B ?!:$+*R$('7(+</ D!#&"99L0".(@N- "U/Z7KF%4$'SP@2JB
MH8/0()!1%,I1")T9 DEP$'X;#'Z /;,QMZ9+M$6A(9(!" 1A#/N&(JZ[(O,#
ME=+A5!H:#(3 )I4Q(:+0M8?DJUL+GQ,"):D0#+<PM,20"B)PI<1@ 3*1K0 2
MN"-Q-7N IH.!I:-AO;@P1:%PIZX:&9/A%[B@!\@TM7P0&$@[&L41O7K;!PJ"
M"AE@ J0!H/%1'%$[.N#1&"[B !\Z/\11""YVOETR&XE+"!*@F'TPH)F#&\%+
M2O [&A 0!ZF0$L(T'IB;MZ41&QS<'QID9UR7"G'%%EH''_GA%G%22F^AL%WK
M'VW!'K(F&R#2'1UB"W(@ >M[(/XF7 QPZR#HX:O#X2!YYP%0<1#@AQK$@A#V
ML[P%$7R940H.$ C)PQ-SL"FVD 0#0 (K\0D3D "^4;<#$ )&-19< A(D<;!C
M4B9GDB:E4 H),$LAP *8YA<70P(80PPA ',@8#X-1PPK,#,2( ),R7^/! (R
M<@=#@@<4< (', B 8@'00C;U*H,2($P3T  4, B:,P$AX #210$I( &,LJ,C
MX'ZZ&BP;  $4X!>/^GVS BF#MIXBT ";"" E<,D3X$_YDH$_\U,-(#8B9"C&
MP@$GX !DLP(,P $=8 'Q%$.^PD,;D,KJ(0?!0@&._#H>  (=&0<YN6^H00'=
M[ !AXO[%\B(!$C ;KB*PGW K'*# ""'(Z?(U?5#/'XII4,(U!5$P(9"39AHH
MT4P4%*P"!I!E\Z(!'E !FP@CC9P!"Q ''J !!O _K#,R1M@32)//\I4!LPB5
M$C "8I, 'FTV^4(0II,!#S#+(H !%W :IX !#" !,I$STW=='C K$' :94@!
M^A(<*G K$P "/(DND"(W<=  KQ(,SMBO12$!&< !G8(+&K#3>! ,&H !(L
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M+9YK$C+FO"=E'CIEUA;B /^C$:" 1\3  GQ@C$71 G4062W !RE0F%D1#!U
M ,*C$,;@?J-3.N,2#*E3$-Q%##RM*FYG0C%E$#PX"#*G"QM  49% 3)A (!C
M) 9A"@9PAA:P*7>P*<!44^=#>OXB;#^U(0)%,TP$\2V*^4X4H&0GE #<6"H1
M85C030RYK(9^$4>Q%U*CT3D"EX0$NQL4T %L)7,DN!NIT%_Q>0=5Y<""H8,C
ML=0LX4$$@13A(5,HE!D8L!,6,*;?Q]D4T+KO*A@ZY&BEY@!!L0?3XP'^] 9D
MLX00X+,-L!.4S$T*0 &0),]@Y"!HLH FJ$62,0 MX!=O (2200!$,1=Q$$9)
M0 "1N"EU0#?(1 P+ %YHE!&D5G1>&GRZ,$/*X0%\ @*Z31 M6! EH&G8H0#8
M<P=U%I6#%@()5Y7X98+K,QL+X!?!( $N P+SW!T)X!<K4%7<"R<5 P&M^UDR
METB/4?Y"P3.QY901$R WA*!_\0EDAU@ P8$!%31F(B7DX]0\))"M?Z!#V?,P
M!G =^A@9'> R)&H'KA,(0^('!'"&"Z 4(<T2!<"8RF026R=3\YX9%2 3)#"*
M*B :7OP;.*3@AG)MNOH ^[XR@.!B$, 6,N:&(. Z!?$&$5"YNF17Q='-+*$
M1A5!=0$"DE(,,_]]0:$!(U1"U$M#H%40@4"1!7'@G(X[@*2PXAT* G"+'XR+
M&U<'8.X H$"P&S"PPU09&S '9@>_(; KY_20'4A/F)X!M(@:I(Q+#X"F["83
M-R<F%VAGJ!'>E4M*H$3A6/%*"8#@M&1+F5[%O.1+?)"%<?Y0:'TP)*5 3"
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M#.(8R(,WH N!WWP'66F@#> @1H\>MPM! @2B4NB!/L;=@Z*)B"/F(E(4LF6
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MC^1[M86!RXAI(22<&BAKV8)5,+_Q8EC ;]6E+&1*$+'WN"4!6\S_B\:!3K;
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MBP#_,!<THS@N*@S@N4RRQ "Q\<-Y[5NH:>\O 7.PQ2"<AXL!Q,$6J,#Q!C1
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M"$2YI*BG3Q!N.Q28P GD<%9BF((#&1#!)TB@H^TD(12DLRSW7V<!#]"F%!N
M_1U_M">,N4"[Q( #[-O/$BBI $&W& $*L 5$H0 +V #!>)- L  +N  ],3VS
MP 4/R( )Q( 6D Y4:!0*B*53D/Y $/B$$VB!4@"!-X&9"7@#+:NX.PBU_/@?
M0M@G0;B  GR>8 "!IPD!)]&]6]N:EB$JY"B^/4$0FC"%#>@]$@BBZ?" )7($
M&K* /4+!X< #RLN [Y$\RMNC%@@86P !DZB#%9P_$%B*]5D2(^0)"3B,.BC
M"6BC@9"\!<284  !T.! )/( Z8@#JPD&%9@ JDBC"F"]'-I"A0"%#%@25RH$
M#.B]%=B="D"-P.F;]\N $?B$T1,_A9@_BIH #, #@JJ(4L@ "0 !.R@!W=*
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MA2KH@4F02%@@ B* !1_:!1Z@5AZH@9&%V%G@ 1BH@2&8UAFXUJ!56J(U6F)
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MF0PDIG0&+5"8&/DJB62D XPAQ.9_2DBU8 PQA;\,@SX7DLXEC/4C+5#!.6K
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M 1,HSM)- 20$0254@OP1P2X<PA>@2!,8 1%HP; 5A!G<  ],@>]\05,Y87A
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M.,DN[@ FI$A8;,(-^ X0.,<,U,<8O$3AM.0.T,X9,$%''/["#W0$)/# G=F
M(?S")O# __V.PZD"#_#"H3C,[1$#$XSAP$W",%#"#:S"].1 R:P=Z54!OXU%
M)OS"1]0.#[S+VME%:$@",&S"3!+##J3&$)1,V Q#)=R *@R#+]0 *Q0$[,V-
M6"P<,9Q@>)PEI2W">@Q!T;1(6'0!& X#&[PD5DK'76;(2\S%IE0"#%S!)?3"
M,!C"3UIFE!S+,"A![/$%,#S!%1S%&#PF(MS 43A@_,R16%RFB !#3X3%) #!
M[-1 +6@?P  #$Y"'),Q [U "#*@<9=; )@R#6_+&H% "9]P;1$2!X^S"#_#
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M(9![%=AHR:1!$(QA+"05.\;&)MQH12R<)O3 $TS!(3 !S@S!'I5&#B ZHM/
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M=*P2>25")7K1@RFDP0HS0(-%AE"%0S0!"O$2P@_40(Q(Y. 0:9A!U C%A"A
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MR%Q%X&P@0B@U0791 Y(,8P9VN@%ZA  7/.<-!D>6"*(&LH64\1D3S.Z-+VK
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M"29E%6#@%23!:=! "E "&$@PV7ZA^<!$$M1@"_P%XO*D(0IG5$AB#'#@"=
M3%""QUS0!7E!(EZ("'! &%AA!BHDA\8 !DX-(8 @.<@ #7! ,71N(' 1,&Q@
M2Q(B"D[+)%#"%>*/:+(#$4K/-1YQ,2;!"L;D]-01-LX@G5CB%VP +1+B#%YF
M!VPOP&PO$VS@$/@Q$2KAE!Z!"VC@912AT(Y&NK+N)=I*^?[.K_E^@0T,LJVF
MSP8\+?Z(0?OX#%J*#I9 (A*X0-Z(X0K&9A=L8!=@P0;6CQB<8 W@<25&(_XH
M 1$209N@L L@ 1:$8"-^@'/^CQBF8%(2(@W\;"#P:B-V0:W4"3U^H'AJP.:
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M;_ )(QI'Y9Q@)<; '?\G(ECTEA)G(* @ML2 " Z"$F!@7HJ0("1!1.H/)91
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M^2'L9!AP+ LJ5AC2 $I\H0Q,69[QBW5N>A)^H0U<H2-H(2(N%3"@E3\E@A&
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M1/:)%;2A"L<)!2P[!?ZUUI/!!FTB"1,"!4#A/S_ S@*V5UH0<RQ;=8#!"EM
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M32=#Y& '30 S%KH@!!Y$PHU6(((2JG#16)2/&&6('A%D=H8A,,'=Q2'"5*R
MHEE H0E,H ),)$&%K7DN-VP0 A&$\$U*1$\(* +R$"Z&&U4(X09$""M1IL $
M)DQ!A9280AJ(D ,:GX])9?C"&(20 [,MM@I%Z(',,!$Z(3@G%D00\R&,L@B$
M#2%6B^C!#H@ C#2HP1=$F) BC/[R<B848<%%TD+THL"32:AY&$[X"!N*P(0A
M&.0,.>!!%01R!B( B"2^4,*?<QV%'AAA0FH(^Q (M L>'"(*12#"[C*Q'%8S
MBNALX+K7I\!P7']7(&LHC";P'@5#?!P+,%$";F;.D5T B C8)48E>B"$*H@!
M+8$6"A&6Q\]R#^$+ MG$$P[Q\7Z710L]& (:?O#=:\?>V5]8*9E\ 85-R][:
MO_B"%'"BA1MLXA>&V,P4L-L%&0GD%41F10U4>(B':,+YCWD(*V8@12*L" ID
MA8)[$@&#3ZJ%)(>X 2Q^P8CT"?4CWY'99690B6%\1Q'#D(0-7O%H*\SD/XR[
MD"(:>?[4W,B.IMB"H_J%1Y@!91N"6/B%+4@(QYF$ZE$48M@!LL"*]/B=6KB!
M79@O4:$/NM@![?D!8/H6A=@!V$L$$.$KV\D,'<F$]. )21""7_"%*< "MIB$
M&[ 72/B1%_R3*IB%H3.*2< !MI $QO"%&U""6! &,?"*3HB03=B!86@41ZJ"
M']0(!=D$&X"I-5B.)XPC&$ #\ZB!K2""1>B%'*@9JK"*A\F/A; H24$+FYF!
M+M@%8& "NMB%[)$TT0-#,P &F_",+AB"6=B%,8"!C^ RW5M$V?J%*;B5V_J/
M]F/$140#M( "JQBD&P!$V/ %8%@^%GJ%I'"%&4"$$%J%&?Y0A!!2!1O()"7P
M#+8 !E=H JM0!,9 #A0)MXR(!%_@ BHH-6'  AG1D--P%Y%@Q2IB"_.(@BUY
MA),PD:73@OS  K+"'IX @JSX"Z\0 XJ1!*]  ^IX!1X0ABC)B;#AB440'2YH
M"C4HC.]0*"B0-&'X OMHJTFH@4C@"8& !! 9!B#0A$89HVP9F[( !H&0A300
M"224!6^QDC6PC_#@'3;PBD:1F6&H 5C(NRAD%%LAAB[H%6"P@5O9@OQXA4W(
M(6+H0F+H!*\0M(R8 G.1@G[!#1&R$0 ;,MUXE#)XE.K8PLNH@<<0G>JH@6%0
M!1Q0BBHPEQKX*Z:A1*>DL%F( O[16@TMJ+VGM#:! ,>!Z+Z!H(67D+XH8((F
ML)83$@A7V$0*(0(>T &S23@>R '+:#XIRC7#F )FE!YB4 0%N0J.L 'SRHC"
M"4LF,(),' @I:#"!8(4(8468V@2[[ (F"+%'L#0S+ N!T *CN ($>I9K=!!*
M$(DG.(.V0D:A&H8TH(MA0(.,&P,>J 5B0 0%V0).@86&60/5J((>< (GP#BR
MR@A% +<>,(@/60T>2(R[>TN:),@OX0(FL (M2 A?L &&M('Y0 /[V 7FK(+G
M[#$>""$@J(0.J0XIQ)Z&,(U.T; =N)4ON#S58 ,OS(RN4 HH<(XG*!4G$(A(
MP $HT/Y-)U "8. "3A$(25 :KGC&6?";,=@<@:B161!%I9@"-+C($"("V+M*
M"V4N68""@\H-8*B"0+G0V+/$F- PA8B/Z1.(BQ)%[AH(7I@$AI@*8'#16' <
M[" "1?B31& )--@211!*(1"W'5BI1)@%+,B/+'JT*C!2"O&*#KDH'T,$EF"#
M_*BTC%@"-J&/:=S,7KB!:U252O *\Q2(3O"+MJ"$)^ (-.C.@?@!GD@$=20K
M(J $*. 1+6B74$,),=N%0R"R2 "1 LD$<F242G@_8E!.*,"]03I"+O660K+.
M^W@"G-B%'XG.]A$/5="$S-A(8>A(NLF-3E""2A#*;&&#POX84\.0PJUT#JP)
M"B:1%(<1"!6JEMPX!*41"$Q5"L<9AC5X".4C2LQ 2O>H@24RP0 $46,M+F"@
M K-)"RA@MF/U,H$P _^\#Q*%#YP@ AJ+L1QY!:!$017ZDUAXEV^= 4<"0 :1
MA%V  9ZP"1[=2Q%$#2 0#$V @5FPOH;X!2:XTB&[%5\  O?(!)S)B%F8@=V9
MA1TP"F?,")W+%FK,CEZID2YM(:]0B]\!!B$@T<2+ IC@ F!3!'7-2R!@"_-\
MC"'0V+2(CG/1M7AA H% 16&P/IZ(!!A8A4NX"1WA$2N$B2%PCV'8@J2(SB6L
M =?4".I@FX%PF1ZK@7,C!N);R?Y,38I?$,E"A8)M*IQ8J:)===J_8$'V,)<A
MJ!E5@(%;\=>!8 /[4 N@F 4>H ZE8! OP8*'6(@MBP).$33YU# H4#.C0;!G
M[=O<.@,NV(5%F )]]%MGTX0<") K\))8Z &VF 4CB)Z60PE8Z(%?& 8J^ &T
M.PYAR-S"H3$TP('(;()8&8/EZ0)$R(%5F 0"50*.& 8N$ (G.):!0(2U+8(M
MJ*)$Z($H^('-W 3+I8DR6!XM0 0=8(50S0@FR,:CW9(MJ+9>Z &>& ('N00%
MX3DG$ +*VP4<Z(Y8B#> JP+J6(4>Z(%A0!.BZ-[<X+DFP#R1V@6L>P()],@<
MD!XBR/X$V.V!4+$"@9B$'&B"OUB>*8#-M,D!AE138F #U;@$ 3Z],Q &(6!.
M)<B!V@FRM/B!*02"AO!? !8(1"B/,3D$B< $U,D$(5 *@,.UA5$#):B>T,$Z
M'<HV)H""+&B78!L"YAP"!6RA\$$8F !>I5A<7"$"(^@"(G!6PTUBLWJJ!E/B
M9]NS0)T(E%B%R1 0\XF%3!BU6- $2:J)AG N6FB?72B&8:BC*.8=X</338BP
MC-"H+I[",9F%!<H)EC!C9VFK,YZ**(;CB5ACFD"M5; F_U"U6#MC1M$$-AX(
M5W!!.]+'8J@)3"@M )N(-A(&%9H*\RGC(FFC<H2)60#(-OZ6XEV;"&P11KO"
M#DQV&H$X8X.\#'3:!4 =Y=5@B5JHXM7PXU NDB/J%B?N95_^92561&#.*4MH
M HS$+6$>9F5>9F9.KF1N9J6*!5.$9FJN9FN^9FS.9FW>9F[N9F_^Y6?^9G$>
M9W(N9W,^9W1.9W5>9W9N9W=^9WB.9WF>9WJN9WN^9WS.9WL.9WT&K#SAYW^V
M4(#N9X(N:(.>L($^:(6>YV'(A$J@!$JPI5DH,Z7ZY#*Q:&=;A41 M(%XA:FL
M$UDX!#6PJ 5)9(%IM#&)!5LRC%%[!8HN$V#@VS@:M3&I!#0PZ2^!!#5 A"[&
MK5AX:(C6A(2^$U?@"55@XV1*B_Z&*.H\^05(L.4'$@:H7NA[]I8;^ $@R $C
MTYJ3B#36XC%OI(E5H-J\]%-%].I+LZV;F8(:H@2RT@+5:"TUF $GJ(*LUB$B
MH,DQ49ABA;2!, ,"U1&]+E2>I!--\,F@6],56:LT^($OP(&I)H9+P ',4P+U
MF"#*:EOJ<2V:4 ,8D#<EN $AZ.F^!J"[RA$F,(K([.LF, KM[ BC$ 8H>&F:
M> (=R(K:4@I7@ *86(6/'6JJKN9-)8Y?X(*U*(M, RI*L+3WF &0$%4.$X@>
M%2Q(.(G#R9-$  []N#)<&XJTJDPZ$5&4$(+%YA?[N!-6@XDN.(W*D)/B)(8J
M*,R*F?X!O5Z?C]8IE\0K,UB"-L:\TO:IMH("<X$TL]B2*)9:.J%."(H%H"R2
MX-;GBX0]'G .3*!)0W@"Q,N-2[BX+6"+6. "[ BB+Z'',W6C+XB"*5@I 6J"
M+^BB+B#,1-C+M'B"'9@"6(B$.,4X<8.Q)VB"14$),\B$,C "*Y@0,U %-  U
M-!C+!8,%*C "-%B$6)$C56@"DM $*GB"+LBD6+"")YB",^KR)Z""J8:$'G_@
MKU#+(L\-M[2"7Q@#+%@$(W@"BUSR*! WFK@![UYE_Z(*QU %*F@"*RBD)3B$
M-# "*@BA0YB"[LM*6AL(H4")+P V7^B")IB"]D.$+T=S5OX;!EL$@BUQ@C0X
M=,(5$RC(JH+H:RZ [C3XIJ=B<7L1AC. A2Y@DC-@A57?\HPXA"-A X& !36H
MA2E8CUC(@BF8 N-D@AWP@H:H!+LL ]1BMVPQ RHK]B>P@OD =)G8G6&X]3$P
M@OW("$2(@B9H8EHH@TR@@NQ;4'J$@A)1!(Z @C)(!".8;9"@4P1"!$H LVVC
M!)O."$K0ZUW  AMH@DG SA!/##PZ!"-XQ-5(FBC8"E6@<2I8A3>'B6%0@[%\
MBS2H!/)QKP?'9DKP B0NDAK8LH%H'8T0"4708%;@ ?>@!!M8A$W0@G%D!1C(
M)/*&;QNGA!FH'2NT"$+5"TE0A?XNF V$T03(X$G^&@]@B(09$ -,V-.&<+U,
M8(6JH(FL/H1,P$V! ((?T(*M@ (FV(0O=0^;. .EGP&Z.$ H:(-8Z)!%4(4Q
M:.&E, -8V%.<$((RR/LPV?4<J 15F((6A@4M  ))V*98Z (@@$ SF $VR(0O
M:$7XC@)5N(1\L:/:(!,528L:. 0DYU)<4Q1-Z!P5XAY5@ 4F< ]'10G?Q81*
MN 1,.%1&^155>(0;^!W4AX4F8!)A>]DG<(+$@ (>2(1,> *>%(@#'0*5S0@@
M (VHDH3B484L^ %AP!XAZ()]KX$?,'[R&0@Q.#A-&(*FL#(F  -5V-0RB 6P
MF(59(/X#'F $8 @;P:\"BNF11_D%(+ *^#"$5]@-@-@UC,<A5VIL_")F \BA
M3%"&#"-VID>F342F$%,%H\HE23,6$9M2!1:E&9B(2>%"[(H--9K4U(A%S(E*
M+%MFJGQT0TTL53-V$2-&! VQB,(>M>P) UA0(42MS&BHA4=$)U$R4<)Q:%>:
M&XMVQ?I)[(F3395RJ"'V",873(=FK HJ=R[=NG;OXLVK=R_?OG[_ @XL>##A
MPH;WQJHQXP;3N\-L5 H:<0P18HHJEQF2D)A,(8?D;IGE"F%0)8J(*>$2$=@L
M8DRZ1/35>@C(H#PT8;HAUPP0NK%T$UN40^X/2<-B!MUE _YH1&) S,B](<FY
M2F*9;,CU.6Q-Y:!8L!";-*,U:D-R@5!2>)J8+*8WUL]B:M2&INCI%0VI*ZF[
M&">2;<@""W9!==);4=:-%U0913!AQ"6HL4%,%&/(5846Q"QQ4U! )$),);X$
M=09&9D!!EQ(\,$$$$4SD@-$AW1%C1A7$7 )4C$\0L\D."8EQ(6IG!/7*#<+,
M]8L63-P U"*;%75#AW4-!,EY(-FP1E#".'EE#:KLDB Q7<X"RPR;!/5+9$7Q
M\" G/&R87E WD'E@&C1$P403-U2WA8;$0)'&,#-,$A0M1.X085 U:/(+<L0(
M$Q,M-I!WA4I$J/9E:U, 6444<OXY 2040&+1!3%54$C,#; $1<1G H(XUPVJ
M$,.*#8TY\=D5,WZ)D"8#6@?D;T'!,J0F-617PS"2#-=4;8<QVZRSST(;K;33
M4CL+#C#\P&1=C4;6'!;^O?@E%#<(\04PPMB@2G-!L5)#8TI\MHD0.1!A7D;S
MULOH#DY, <44-#QRB!('9I+?7*S< &(B, I!26)3]#M%#7%N>%)$4)1!# ]N
MLC%P1,.<RH5JP@S#!D:/_%"4,$ 8$3$.:4'2 XJ!$D-)#BA.E]VL!T)!X1H&
M2T9,(@9SX2,P.] 2"0Y4^.M$DG*)Z4I0FTQ2R4>H?98#)<-$E$C*2T3"Z$HJ
M#6,(%?Y6"'$A&B6NR]!<7/C710\1#U'9,(></805Q&BR(S%=@(<:(E/SH&T5
M3$@$Q&^-;4C47*O$HIQ,$6UQX:M7[H!J1$-(@@F;Q$GRV\?$O-(%%57@0"8E
M;.YR0Q0NUQ81&CU<4DDE7Q1!BVM#1-S#WL+QT$2W/, :D1*)(+PN$8G0,J1W
M*FU2! ^J!@4%&7Q:&=$9FTYQO4TA4?C+#O4)G;*,= %S0R89N5M:A*0&-0M"
M;$A1ERH[AT5,QP=B"8LD0!/A$0>B%@$+:, #(C"!U%(%&F2"%W2=Z4U$V5]0
M8B$)(R@!9&2*R"J H8H:;(8)Z\F(<$I%PAQ0R$FK8,4J9O[QB_U%I!(IFXLJ
M&",T(1!G$K- E"I8X0J!S 4(W9H)47A LT, 35&S6(-_@L*%&3T"A[8YQ"I4
ML8I=,&X3;+@:NPS!1<[4@#DS20L;8"2711!M;\1(WRPFP0-8J$(5D5L7,7:0
MEKG,0$KPTEC8B+0_VO ,2$2 0B9^\0B,H %'03141.!&C"T\ 1:;4 4M@**$
M)V0"&)+ B"8*][? +>$S&=D!D<I4 U2-2@<^D@L7#-:<&_CIE >"7[K*M(-7
M'.@'E+C? 'E0B6 U!Q,S4$1<F/"@2[ )&#:01!ROJ*TR#"PZ1"'"%U8QR5GP
M0C*;0,,,.F$J\A%C"(\0T.B ,/Z)1S4&"R9410GYY"GH$&D,&.D9,4+%I^MA
MB7SBBX42(E@F^N2H?3-Y7ZEF<8-?(,)NQ/@%K%2Q Z;$P@;#N(Q<E"B)&89S
M60K<*$<[ZM&/=O0QW=J%%9XF,&)H091B&A45DC.#6,PB0;S @0"5 "O]X5 )
MK C*(7I3A<"A=!:O\%(5I'B@Y D-1D.0$@]J,PLMT!$(N.H2F<P9%%G,X*:'
M8!-6OT*)&MP$9:#!2%"V$#DB;&8*7  &$1KSTR Z+BRP,H09NT8TH^T@<EL*
M2B: -)=%P.!,PM@"#*;C!"N)(9K$Z$&$E!#-7\P@$\. @0.? )ZUT>4'YFD.
M%S95"?[G$>,0B_@3*B'&-T]6KC2BW 0/2HDF4;KB!2:LX S\&MH9Z(X)U>E2
M?6ZP4T;9H%0^H<5C<E:)&@BCALU1@\'"$I?5!>4)7Y"+%L@3$35T)R),H! ;
M,$H&3<#""')10EIV("K.S$!J7@F*)F8 C-]L1@L4(L)-V8##3Q'#"CTHY7M"
M B0MB*H*0$)7\8@QAB9$P;5!25]]PM(:7O17P/%+4DSC8N"!(16^%0X*&]B$
M1KD0 23Q 2F)2VSB$Z/8+HK*P0]^@ ,BX%)_*9L$#;10!AY0:!=#Z%D/JC.%
M'FLA!Y\Y PZ^\ 4<A(W(1D;REX0P(2%4(2)?0&$5B "T"?X7(1:/^)QS0*()
M'%AARHX;+Q%(Q8/SWB!L7<L!%ZYP _*IPLI?T )X$L%E7ZR(,E#@VH_+$&18
M_?@,?Z9A#ZHP94.QP4!SR<0,B# ,+I!5F;!:! ZZH 4<Y&PN:6@T%'0P!BN8
M1PAI6&@3F' &WD5$15,80Z&#8H4AE,'2J4N#8H.2@U%3MSMCR,$7IL #7!8U
MUEI0WP>9\I:]#<%>FP#A7"I! W_QX SKG<N7>? $(<S 3;&8VQBBO= :_/87
M0%!"F''@N+-TH0N81E!S8)&#+9"!"T9 7"UJ0 28]H#'4)W+&# :$H]-80AD
M8,(0?#$,@I>!"CV0R;C#? ._GOX%P.O=Q PV8R&)%)D+ZW;"='\\A2\,@0E$
MBH)*WLKQHBA!![6)!0P,5:3(!L777,A"#LSSA.KL4":&X+45<@"KYA6AA0DZ
M!)O=7!]%</D''5+"%5+L]*=#/>K08D4F,)$)!\;/PK) 1!I.(AE(L,'K19D$
M(L!"'E6P@0TQSDC:+5P42'1]+ICH^B]^.Y=86.(7O;AI1FRTBT2PP>W$J40F
MT!!!5613+K%@0R)L- NLIW87?"^*)-C@STNDX1#D(08FT' (K,L%&(#G^RPF
MGYU*#",6#AS&)DH9BT,@8O-TH<4BTO"@70!%%9N?1!H.[\$TN"DHE$!$7"XA
MBUT(/OY6LH^%VS>1AD6XMA+$IU$LAF'WJA.CA66RNUQFH8B"$$.2VZ($&QAA
MHRLM@@T4:WV9B%<)-*RO^]]W8-WG0GM(#.,76R.&*_*^T-J#DUS(PN31@MU5
M0AID6LV@0>.AB5F@@=A]"2)\WI5L0G.H7E"@'1N@DBO(0O;M@BND@90$!>1P
MADR\0@>ND24X4&+(GEPDBF20W2[(@NZ08%%48) PWOG)@B4  ^LUAROD8'+P
MG>[5#%E)W1$B81(JX1)&RPV(8%]PT S87AI,#!-:(1,*PPQP7Q+^R8.@&# <
M@A  U=,90OQ=X1FB81I."QW9!=?P!1O*!1O"8=#0Q1S6(?Y>S&$:Q(4;Y@4=
MP<(75 $7F!Z4W.%<V"$=_H4='F(<]F%@+*)>/.)@K,LA4F(;HD%KP*$<OJ$A
M2B(A!D4##5 A0B(>!@8PP!OC;.)>:*)@1*(:NN(KPF(L=B*TM*(HRN(MXF(N
MZN(N\F(O^B*U: M=_$(M(N(O&N,Q>B(R*N,R,N,2N@(3,,XCS@(4G)]C$$,:
M$ 47C%HEV@4P8$)$4,(J^84P?(',]( :3*(:F*,6Z Y*,1+G(0XED!4:&(&*
MD!<JTL4NT SG=0$7F*$C&L8J)F(J\@U9$6,H&N(E,(4J3($B%L8<3B(F,,4O
M,,%.'20GSD4B%,$(U<444 Q"^OZ%^/V-RX%D'YY!$:P/-W)B&N#:0^9%+,2)
M&FQ6L\A" )9D,^)D3LH%+9!!,+YD#;3@75C!A1Q"V C&*AB+92A:7P@#$11!
M);R"S<P(UQ!!#TP"+#@$#LB$M 5-%8 +< 3<(R0"?O1 -<[%%LP0&O" (71%
M2QKC9SD+,"1()?#*1D&63 A#&4P.LQS'DN#%#0P1891!$QW"/OI%%+*?8%S!
M&$J+(1A,%>P)LR""O^ED95IFZ!6%3&B");3*U$S""MY :\1"*?7"YK'") B#
M&-S$N1"#"_G")'"?+$R"*PP#"BX8(ZB/,"Q"9=C.)%8"):"B[-S NLC5-0[G
M7$3!P/Y@U4UA27H@PN=<G%ST0&0&A4;.0(G0PJ(D!NCM H@D9B5, BI2#?VU
M1B94@H+%PB10S"^T!B:@GER\@GH62=7<A29<I6147W+T@EQ@@@X%127TAGOZ
MI'5,@N!1#2I5U&=- B]@0H!6@K:LPB34PEUD@G\RBDQH7T;<IUP( WAB8B;<
MP"0 133^YF8(@^Z8)SXFQR1XW3#D1B7@XS!4PH/\P)G(*"4P"89.@FWFR"3<
MU"QT@1/@TC#*Q7AVWS#L@B68'C @P@[0)C"T(V=$A$S@'8^>9FIJB/[AZ.PU
M!FM<B0/Y@B5XX1JU!BO\PBZ,@4W5TQD( VS6Q2S8B#!,COY,J(*(YN,9$,$J
M-,=I@MYE^JDQWL\PN-L63 $1Y "J_ (4#%(.1,AO $4->-T93*46]$ 40,%V
M\0F%:$H6/,$-E$HBW  4/,$31%-$6,0-&,$J2$(/:,$3]( 2)$0L" '$ ('I
M[<!GK,LN$ D/9,^!M%=K" '$D8:=Q5S3N>$B'.?HP.08+$'-X) ; H$ <99(
MY, NS,*.*5Q*5EF00<>J!FE5.A ;Z( 5$$$3, 4E]$ 70($0" %0L &K#E)"
M5$*A*6H+5ED6] "0Q)0#P<\LK,@4Y(  50(/:,&Z_D U H-5E*,H:0$1X.ML
MQ0*2$,$EJ$(.9,$4",$/8.(6#/Y!%@#!F 5%+Z0(P()$@Y9!$("$%@A!%OS
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MP&E( G (Q2%DH1K(8!$0Q>"KWM,V6POSPOV<!(Y9$ P B5KJ7A>@+R7PBA*
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M &I9YTK7NF9&&#-P(#%6 8,M88$(_LQ"TG[ A5ELL)U_7<4VIP.+T5R%"#>
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M0,"0,OYE".DY!3@@0KL  SP@!$#P SI +.VQD2([MW2[BVA !5I@C'7+AIN
M%J[0=L/ "LBR"XA@"'B8I;NP"&R@>X%;AH)K;VRP" O"0O_S7Y<P(*PPN8FP
MEJ('"6@ "2)("\PH"6F <+70BK' "9BPNI>P@;!@"(FP(,B8"9>0"9QP"6JW
M"1&TM[S;N[0XB;Y+BP.S"C.@=L%[O,B;O,J[E+N !F8)1538B8F8DH28A\M[
MO=B;O=J[O=S;O=[[O> ;ON([ON1;ON9[ONB;ONJ[ONS;ON[[OO ;O_([O_1;
MO_9[O_B;O_J[O_S;O_[[OP <P *\C9M@O.F["\ WP([X5/Y*(&Y08&V+0%U1
M!(12)5X6B0G542'2FVT!TS1ZNQEI4 0[@A2&8 1*T,!S6C"ITAG]QV]EI0E-
MX!&94"W#< DH^40! S73^X<?(03#L A*21F5L#:2,0M0 #9.H*=M> ;ME*$+
M@B@;/!F58,'6"S^!%!DEY4P*K(=X-3R+H 8S,)^8$'/8!@F.:6\S@!22&8HU
MY(REV&@,A!17( 25, F3, 4WX)Z>H01;UXLO,U>P@( ](%98A7+7)F8(,P1
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MO R&3H@Y)$!,$J2DAF%>S$@+6%S1?B AA*N/F"\"+'^, 'F8)"-:AHDDM(%
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M/Q'!.?F%*B "*+"M$VP,<0K!V<.PA+@A-U,K&P@S33@L'(2!3?"%&>!!O?C
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M6@*JFK?Q""4X)&+0A!VH/DS0@KS\255 D,9P C/+"+QID1IA@Y* BRA0F2O
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MF&PRG+) *<_J@AEX1\JPC(H0 A[RA:73B64K;R$@.2;1CZZTB/O.[[;8@5]
MLT'2A!/)[JZ0Z'_FBBUM[!HPBS'(#5>8@:$@"R(1-&-7 B6JB*UH%I4& DT0
M!AL(%54HO9((%36P=W)LGD0H"RH@N6XBAC6P<(E$#5/*NMNS@2MA [$@@DI_
M:E4GAOY$=@GFDJ2LFF7ESH@S$(A.S8P8TH*3@054EZV,,(-M;I:@^(4<.!%J
M#NTH\ A]CR1*P Y=HHA=NPV,./,3_J'H1,I YQ-(4 5%:)&.J*>$4,&9M'I2
MA(09L(U)N $R^ (NX($RR'F;B 6G6K#Y8#"NT(1:^P+BGA6R-1:XT(+-X-HB
MF,0K*((Q: (B^.9*N($O2'L@((Q-8%=!(3DM^ $R*'PCT80<R (NR(&3J8*B
MZ@(=@(U4B8H9*(X9\#0N$0(EZ (K*)6Q( (]-MC+R $K^(+-SXX?H-XA&!E[
M2:*!2(.)(!/=F+(A6)@R2+>1IQ23THA7P.G:ER,H"()&T/Z)(@*"(JJ(1\"!
M),4!O:!<6&D=FK )2,"!+NB"[<^,E]F@(>DF(^BN+CB#'. A(ND",)BY'QF"
MZJ@JOJB"P:<"(8#L6P0(([S4*"%&;-B-2\0FX>C2Y48B@Q(/W?B"A<F-7<3,
MY/A")<<F8HMP;#F3H\Q&(AL+&IS5 \J8'EN&23PX1,>D85"(G&'2Y%?-33.(
MJ9H!E-@4+L1H"9DR)L<88D*/#ILRA$R3(1ICEMFBQ<:D2C.TE.D1M>J0,5&$
MS*HIC B3+U5R*'7RQ>"F%V<.$C-T@PN6&YB(/5%*TPR.+U]N+"(&I<M!)D$:
M$XL%8PW?FIHW<^[L^3/HT*)'D_[F/&:1%IJ*M!![Q)IF%1AL@)6N;?LV[MRZ
M=_,.6HGF*D24*F<2QHHFL56KB+$"RHHVL5VJ*LN26.6LP6$AAQTW&"N6=TN^
M#&9*(PEY35>()A&;5<G@KD2&7M7$E"82>E_R7=6<E&A7++004PMX!VV"'"::
M:/;+(I#\LLIX/U"B"1KO201,(FQ,)U$F:$""W'<&R<)?=-/MPDIT*!JTBD8A
M251#@0:IHM&%&6Y(C#"5+#<C<S1Z=P@B;1$#C(J_J&@<B(<<(N2($C6W(B7"
M5&;(&@IJ1LLB^/DRW"I"_G*@092@,>.-$KEBR3"S+&?0<RTI&6--K*0QR2^J
M(,<*&_Z+0%?9(6ED8A MRP5:$X-L_+G9+I941TPE:+"W8$A?2@1+@<(\DH:5
MDM94R7WU(:+@)M/-H@@:"DETB7F<#0-)&K', IXKBTJU9W*&($(CI36IP@8;
M:X:(HR4%SE*#@+T9>RRRM;E:H(_TK:A*)N,E.RVUU5I[K6Z:S&#()6K<L":V
MX=K&F+B;;2'$))08,05IZ)7[+KSQRCNO;KXH,D05].J[+[_]^ONO9NZ6M@H7
M57Q19L#4"BS1P@(OK%NOF=7TL,2[H6:%(13SIK%G''>FL<?E/CRR:"%/?%O(
M(#.LZF<FG]PQS,!L,8:4 -M\,\XYZ[PSSSW[_#/000L]-/[111M]]&8N(\VS
MTDL[_?3.34,]-=556WTUUEEKO37777O]-=AABSTVV66;?3;:::N]-MMMN_TV
MW''+/3?===M]-]YYZ[TWWWW[_3?@@0L^..&=\;(+XC5G)W6UPTB[VRZ,Z_P+
MK9\!HWANP_@X&C"[S()XLI=[Y@OF]$H.VBZRAD9Y;YIK)KIHO9Q>V^:Y^>)+
MXIJ5_F_DG@E9^-O" '$##\1W 5T:/ZR<\&@.)\WR)$.P_/+SL_!0+,S/:T]]
MQ=MG]_'S:EC1?<)1("*QANA1S,HA-'4B!/D4-W$#$#WD(,2AWS,/&DU0I*&9
M(5SDA$/$KV7<T]_^B$$)RO!D>?X.-*!$$D&#+4QO96E@B?<0>+)8\&!S3\ .
M^?@RA$>%,(0-4Y7U5$<R\A!P8D/ P0YND ,MT$@1/.#>"@V2!F=IL#;H 08/
M8.% 8*2!-< +7@T2$0M89&((1* )+5S$+TDH#W(V@!/2SL"ND"FAA1*Y@85@
M)HD;*I",I/F!&CQ'BRW<H'*YB0(:-,,#21AD"8:0%TW&  4987$W0B"@R]2@
M$M[(X@:_(X82E"(:(+!G=J+9A0T.:<!#2&]B-V##$C6A!"%(:196PHT-\G<L
M7WR+,[MHA"*/V#9AV,!4Q/C%#!H3"RMI@@QGD&(OTO %2, '/P:I1($F008T
M_$X2P_[\72Z_0$)B0$*9E*AB33(Q!C)8"1:8D 49R"!$@VCB"X;@()PPL8I8
MI $HL2@#->LSAC+P\)QD"",E9A$),$PG$5]PD296T4TZ5@(,D:C)(KQYE'A2
MX@N+0(XP#O&%#K'+(,TTQ%':@X8QT.()@#S((GC0A4YP<YH(6T46@("(7U3B
M![-0 QEN) LT@&$PF@&"(B3B"Q@("PW*K DER%"&-:EB$[M(@T9V8=-85"&.
M$ED$$+0P'"4@XA)?0(3B)O&%-+AQ(6,@YD'H- E>2D6GX/HI&!)!DTM$00D'
M506STC &.OXR%DYMWV94488QN"@20+C"<&KBBS2 01'J(_Z&&BJI&56L\T;
M: 09$($>3'SA$*_H8$V<$)5=4&(7;/C")\]9AED0@:T__4)>@4&)7QRBI9NZ
MJI RX8I->'-/F? F+'A0H$H<TSO7+$,9A+B)*OQ $1$EQ@W8>I :L&$I?XI%
M)7[1"/X,8Q%@.(3BSCF&]P@C$3O@PJ%>FUN#_.(\B\AKF':1B19FPI9K\L4.
MMBE--3 KE:KT6BR"]!EAU. ]PX#-'M?0 T;EP!!LF$%$.*B%- R!79N P5&$
M4-PR# $18YC!=- @! =#N#(\X,(AB*!(+/0 #5D0@A0T<P@<) (1.7A/(F:0
M!31,P9#$4,0-RO %)>2@0#2Y0OX1G!"%85P"!VA@ P\B0@PT\&"B.'A/)7!0
M!C;H8"_$ ((0QL"%'5B!"P^>CA9NT 5O6>$*:IA!"Z? !$1\.$)I00,.Q( C
M)3"!Q3^@(%+&K 4AC"<6.,B"&IZ0 R'CR PW>$)CV) #-J@!!X^H3Q-V\ 5?
M9 ('5%"#%F; GTS$V! ]*&Y-?H"&SNU"#4Z0TB:@<H@BP#DFBT@##Y83$R@8
M81:SR$$5U "%_O)E&&K8010:\X0B? $-.<""0;1 A$-PH0>2/%<:'K**8=C
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MX?<0A&;@Y.\<6A0HTBMTW_%MDU5J!')(%C&\@K7>HE(  5L"PPT,Q_U)A"0
M RUH80_&:N1&QW#LY%)D!"QM2"88Q7Q*Q"ZP1R+$+!$<VH%N!L=)!"3 P'0\
M OQP*U^L 09MPH$,+:   6WD *@((S%LKS"<X&8, 5=IJ+1L0N69XJO<(7<M
M$[6P01<@QS!<P3*I@1@<+,*VRWS- +E>71D:A'YM1"Q5@HQ*Q0V@ 27LQ$$
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MX@JSF2$'DYC%+"YWR8%LX0J&4\3NP'(#B@B#!YNTH(4HH8I-J%,8FMA!XW8
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M!H:/J2B"2](@#6Y $J"G9]#@@?IR2W  #=@ WS(D;+(2P( @;)@ "A!A"I1
M(/"J"\K "7) &X%A#'(B4+IL#.1%!4WB3>/T)3+A!MA@#68@;/AH-G" ;;C'
M9R#U)8! ",B "WB@T;Y@!GCS!A !$7AD&,A@3ZUG"O!G%V" -XC *"0ABE[B
M%X2 "B!!"VA$NS#B#&:@?H1!"8Q #08IY ;"5@AE!JI #2!13F(!![1 #9Z
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M"WI T@SG$5C&C*[K-N?D8_HDGLR'%=!@# #-17@@4(;*9@J7;%Z 7W1,,LN
M2'=AIVQ&#>YB"C1'(]9@/&D*4AG""<*&!^J'(9Y $9CE"S!3#<H2>IKM:>-C
M0<F@"V9@&,K "ER$K%8AG];8%2IA3#$3CH4A$V9G(+9V&(IK?\9 ".*S#**
MS"KH-B2*92)''IT2!ZQE4!@":VI ,<I 7N!'L8A +#.!!YQ""$Y%(R+A9UPA
M#0[Y+DIK(.HU5H@!2.L7 ;E@$38.<"CAF,#$BT=KEIEC$9H B(YC>H;O$&:
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M!KC&$&X@$2#!0P9BJ.QR(&H@4 [AN.A6653A!0KG5Y@)&'Z L:=W*!,5$J8
M!CA3)'B@"0PBQ^=VPGZ "B9A>C=IB.RC$N!T<.B8&)P@0!Y5$HQF58DC>F0&
M.(A 2X! 6**["*K+"%IZ!F*.%F!@%GJA!AQ&N[0QCK8T5F> #4RU\!X,4A:%
M$LA@7B+44,A<)(2@190M#28!"V! N21!FB:!"91 IS1DG'N 9,:@!Q9A$898
M"YB)69#H$&YE$:( !KAF#'1@U(>X4,IC"0JG4-A@$H@ PYB "28!);]Q%G+@
M/KD@!_Y"(A8*N!69!2ARI3RZ]KIF0-*A0 @")E.Q@&&(  >X9A;:O!*F;3Y^
MI!(F**^B"7M@80;*8!*Z( 51_/S40!*Z@"$D80B&P1#^<,EIIMW=KQ$H;QC2
MX&THP0JH "(3@=0.(>8J0> I:R ,H?H4@?F H0RFH LD&1.HH HV@1%@CQA8
M@3N) 1$*SQ4HZQ>HF.*+(^ )IR8F03!V(0V$ 19< N81Z-HP$([B*"BB!(&^
M0 LF01C:('94(47K?2Z P1"& <A$HA)HGA@@(0O(8!8RH5X.8:$P@9AFX0NF
M8!&J_B5@(6R@5"06@;LV0> O(1+\3!.26]=F0;;&  K88/Y_E-P*@*@2@&@8
M#N%&)L&_62$1;"82+GZ]=Q 2.FP3DOOM\2(-_)N>D:[MQ^!&BAXG10(3P,#G
M=&U+B$<5DCL-=.Q8U*#S#Z'9>H$,IN +; 88U,!.?B$-+J'H]P?SIX 25D7?
MRR^M/N;H?H$#(6&9<5'V>;^9(B7F>C_XA=\!F_@IC-\\YF\ N=$CO_(=F=\?
M/Q(YBI\AE:/]$M(7H$ 6$I(@%?*O$R8YX,]<V&\YO'_X$2O\R]_\U7_]V;_]
MW?_]X1_^G],X)B?^[?_^\9_)8.&-4^T"-^$+ ((+ER^3B!D\B#"APH4,&SI\
M"#&BQ(D4*UJ\B#&CQHT<.WK\"/XRI,B1)$N:/(DRI4J3F*9D&D9L%AHMQ")9
M435L6*PQ:%;Z_ DTJ-"A1(L:/8HTJ=*E3$/RFO(K81HR6V BW%*PJ=:M7+MZ
M_0HVK-BQ9(<N6D3,JL%A-BZE13B+9MFY=.O:O8LWK]Z]6LNL6J@EUL(NPO@:
M%JGV,,+$BB<RWOBXL>3)E$?"' -KX:[(7(!5_@PZM.C1I$N'15-IHK"JID$/
MF_IE3!K!!C4A.KKJ4,)ANPQNTEVQ4I9-)(%%C0BK2Z*$NPK_0N.YHJI)G!+&
M6H0IX:]*DV8EA!5Y41J%FK0TF2+IX"\UZ1%6:M.[M?SY=#'UE*AI#'W*OV8H
MP7*%$_XS+$=,(D\<]<@.":W"0U2'\.#08[/,0(8L;WEDU15E2"2$2PG]D%HL
M,] VD18Y3-$#$\>ID0,40JCH6PY,/('#(P?%8H-W"0'#PPS$'53&#%PH$F07
M!LT"PP['I?5##*SL!V647 US1700<:&*E(H)<T,F!T$"PRL*[1+?0<*4Z= N
M5AZYI$&_Z(B0A94(D= F-_26B!+$J)D0+V@>E,D-S!6V&T)E_CF,+##!-,48
MD<VR))>:[,8#)3'A\ MON\&)4"(S]#9,#V<00\F(!BE!TS [F&'0(S/\0LL7
M.]2 )DR+1,%%JL14 D.6!JWR@J6Q# %$)&]A\L,/DVK);/ZS1%$R:F0(8?*%
MLV-)>Q!;EEHU!!?$+%(%,;Y,00014^B(AA!%#.&E*D0<5X6-JQ!A!!%C%+:*
M$4P,X2A,:=#+A*^9#%$$%&?H>9 F0NQ Q"J2#($&$3E\ 9,P6I0[A2\(*;Q#
M$:E14JX0XQ%SAAIGY" ,&E]P<802JDQQQ!"T)6*N$&A]<0,/6B2&2<@] 1.%
M#3W<1\PO3PAM2"\\I,%$BCJR,42]7B)TAGZ%'4R,$U83H\D,O D!ZC UJ#)+
M&F;DJ) 2;*AR@U51Z/JKA;$(P843!U6AA;+6[LTW2E]8ZA P4/32MU=F]&!(
MA#:DEA,Q6^C)!IUF(-PH,6SP /Z+,(O X(LJ,_!B$!&Z*3$J,#\41#HQP AA
MZ2$_]!8)#\( 8\,AOVP"!,(&"4/)#3A) D,BOWB>71557'9@MI/8L,HPJ]10
MR3"PW)#X%C.D01P7,V3R2Q0U8/)+$U<0$\O8Q+QR@R^]/"$&I[#4,(DPT^LV
M_2,:'S0+$,)/J,4NO0Q1+4GP0$YW8H@P<M"3'=@()KLP7^,*- /"Q01M<*E!
M9FZPK1N@A1AGFH4P8$(+'@1*,$K+Q Y^5+@4JE COYA"EB(SC"DL:X5,>04,
M:C"#-25$&-"CVA"(<0@B$ ,1.* $G'C0GIKL8A4V.(X2=$,%(G#O+58P0B:B
M,PP>+/[B%\VY024H 82#)"*,"%E%VXCQ"#(2@PB1^$4-7/&+7I1/,(U311,=
M%RZ#"-!Q43B(%K!@D#) P2"'L-LO/+.+2=S 0E48%4*X,(6#[)$8.\A.8H"0
MFEG8@!8&04,DA6 (+@I#",!)R"5Z, 68[&!;>ZK!U#@X!AJP\A4V*!-,UH P
M,0SR%S9HSR2"\ ,:&$D63:Q<(=GB*QHJ<YD/F<43_J*086 !<,Q,RB^4 (-4
M-H2'C#,(% 9Y"(2E00@Y*,(FA&&#9/JF!DY41-&XT(,;0,$[O^@"$'!PKBP2
MP0E-: (1*,$&N\&D9]DB!MLT1K.#_( 2L)B!$YC@!"<00?Z==M*8$]#0.%;8
MP''>@@D6O$4,,0"2&&GHXS#0P(0I?&& Q*@<0IZP(9BP+2I>5$BEB$$+&UB(
M9.$" A'Z*=%2NBD+.=@@,8" %@;60$R[TL$42$2,]W&*&$JX041_0*NC]F08
MPIB%+XQ'#%FPLQ)AE(*-S%?-M*HU)E#(#D+&1<VU&N47F,!66FK@%H, 8P8V
M"N*>CE0&'@RCIK:BA2IJ8!4EN!-4L3@/,238V$ABD(,<'(8BZ&202/P@(6R#
M22(P2PPA3*(7-? .3-I$C$W80&-6V,);**&@+1@))EHP4DA'BH8^LH@V/["0
M2]_RQ[=40D&J2DU",!F311KD#/X]74YA'N@F(E A,7@[2"?N" D<&!<A4BUC
M#3JA"4VP8@>Z.8.@$ ($FLCB!K,8!A >]@LWOE"N]%WA5]UI$%5 (:_U]0H/
M$1&+5U B13 YQ ^A8 6#5*(&Q#"#$**2"1C,8A<SR(XF8&"C&]R&&&70DX:7
MJZ<S/)@8JP "+2B<FO^!-K^F^JQ";<0$N4!B"8G91 T\T[4LF8Y5K7T+%FPK
MACRBE!A:2-XA8""8)VBA39N8P9-6QRHN;?<@&AQ&3G=ZAD%>KC>R (*O8&*&
M&\0B%K" 16^:G$E1[6D&:]C%*\9L%5>4=BW$X(+NZAQ&'C4A%K^011=HX%IB
M"L8,-/X850/5V=]$[VT,7=A%(IZJ:/^2DP<YZ,$8CJ,(N\6""$IX @\@D98N
M",$).0 U,= @HR]$83D#9@(3?D"< 3?AU2_<P@^BT(,-+T)&4>A"']_*A" (
M6(@&80*H9]&$(32A!Y8\".Z.DX@>.$$(78#)0-YR[0;;E@V1A,5/IV"(*O11
M$D'(XT$6T8,H_( U[IVR0<80A%#F0$=JR,*[T]V#D1UD"I7. 0]P<)]=#T$'
M.R,&)G+P@YSY.SZQF'>V?F"CMVP"!X*AQ1,4?@9*#),'WH%%$+*D-$1'>N12
MJL04TF!7DA]%&/$E5+9<K@I-H"D6FUC3+,3TP&%L@A5J$?[&)C:1&%EH8DW
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M&(1#:(0\6(1'J(1+:(-)R(1/"(51*(5EX(13:(57B(55B(5/J(59N(5(^(5
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MP'4@ 0;Q!@I@OZA@ *5@"PR "Y_0!^5\$"U\TOA[OR=L"H!\ H?LF.]+ A2
M 0W]$>_+ B(0" 9P"\00"@P0#,60 +),#"JPPDHM AF@ $>L 0A !W#M "60
M 1G  ."L A(@ A*@ @81 B'@ 0Z0QBW@ "$P 1X0#+:P 0P@ 6#\OL5  2#@
M 1*0 6^0 100 0&L"QQ@ 2'@ '?@S!/  2   :& "YLM 7- # [@!\0P 2
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MAEX*:-[#E"P"'B (!KT!'4 ,(.#1">$!:U[ ?;#'G@S.!P$!!TT!O3WNNNT
M+A#/A*  =F#)?  (@> '! #(#1#JQ  !81[R!A$(I&X"(OY>P"T@PF^0 "O0
M!P^\U.^+ 7N "PBP!PLMZ:$0# I@"WQ@X.^;\' I"-BN F6L%'4  <8.!PY
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M8&*L=<,9*X0/;P8%!RI@!Q,$+10>*/(=MFQF%$29T*/NX"DD\(8)D#@B+>
M+@CP$E#$F ">/<&*ZA" %1 "NBD8! 8T\)D$:, /A'! 3U#TAMXYP"8A4$"?
M\X<B%H3"#@@81##NP(" ,B19?MB# C"P!S_,FAB$4  ?0E$"#' D67SH]@7
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MJ6$ / @%4 @%6X@1"(@."M@R/%,-$L$9R^,71]"M4CB%8' ]^$,/0CB!>^M
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M6@CQ*);D@*&\FEPD:@%IV:P4 /XC/V2!$""!$#"!^]F##,  .E.?8EB!^7L
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MXD:)8""P_^V ##@/YU -?=E%==EJNLXYD<FS04" FF%ES+ZER^F./] ])L$
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M:S N:Z4W ( %@2$$ "JPE*&=:0/0(TPQ'O!,4!"M,'M@P&R;:Q@_5,0@)'"
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MYA&#!*@%H.S!'6! :ZP%*AC 0YR" EAB4(1%D9E",1 " IR'+AR@KEB.+2B
M+=B" 9@,+E2 XI% !PA$'!  P#S $58$LYU'DAE*!G 7,?!!G<"C %5A?<D<
M,9 " AQ''AQE*2AE8*P CQ$"A&R:^@D>OQD (83"5H;"0SP&4[A:NN#!5:C+
M .B?.3**_PD$"3P%F0SE6_H-()!E8U#.1JQ HM0!F<$9!E" !FA*'#B !D#
M"> $!D3)'M2(D2 $@]P,!Y0 G/Y]E@I @*_4 0/ A0F,!T-@@,@Y8F!&0 F$
M!0DDCBU P$,L%QR2 %*4P@1HP ;$ 0A(! 4 @D $PN;A06 .YNAE0)E  )O
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MH+DJB+H6W  ,S  3: )"2((0\/D/' (QP (0], BI#H4Y/X %Q #&JSY(=Q
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M+F#"V6/!+U2"UW/[(B1Z+Y0]#/X0@2P0PR4P B8@_>(7N<$C?"+P^2/(/1!
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MB/DS)%P08%@#.QHZ)0"&#:+ CX?ZH("@0!)H^2$))."X! 24GC:C#%3PEYA
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M03"*@0LZ3N -$F"8!X)&@A40A 1R0%PJ!.BO8'A@D>>TA0>:Z(&* <L/#G
M!4[Q"49:H $A")@*)G"!#/B2&!.L( 'N6 Q/8H "<@N&"#"0 0S<<0XFB$,"
MS/4&!T @!1UP >$$D0!=%"00"/Z05R@L< %P^JL.#I@ "4CP+@]P4A <>"$#
M(!8("GC@I8& P#Y+P8?!*="9G+Q#"%P@ 0:PH'02R, JA5A5P12C!0Z(G$)P
MT0 0L( %)YA (0CB 0_02P4+# 8#@A:,!C!,! :  RB(X0((L*X% U >02AP
MSF?5H0&E"$8?VDD"!!0"%QE0 &(O8#;#?B*Q"A@$+AI+##M(@!BWT( *Y'<*
MH-%+ A3$!08P5@<(0*P/#I 7 Y09"@<TE" 9. 'B#&(!"@BV!'@S13M+P0!Y
M58 !>"A%]!YP!WJ]-!@9.*<*".""3^R0&"106AH+@@$&3'8/E%-;!@1K@@46
M@P(8"_Y&SA(7@#C@HA0(L%T(,) Z$A3 7!.8V>1"T8<&G/1V!A"%06P16EP4
MPP(E"(8N*.J].D3@%,7X!,]P@0H$L&L%&)!7'"AP/F)8  -@)6C0B-$"">@0
M#PGHW0HN "P5*$T. UC!<_T@P&#@00#J'%9)41&O4F2@!#QL@.WZBX?$K2T8
MA!C 2"4PTD Z8*?T4H R<<& 4 1C#PX8+C:)40@$#"(8H4A T.HP@#WH8L&A
M*,9AJ_R "%H5S7>A70)4NA!=-, #'!O!!-19B@0T+WG1N]XGDD>,$ R2('T.
M=-T*,H$DT'9:$ @C,4"08Q#,EA@G1J-.19#C2(, C1L@1OXJRWIH@CB K'RX
M(>SVT #VU0&"P8" CR% @B<CV@*'2T@!"3(() =#7K;H0R\3ZFF"0&!<@(@A
M[/J@@$B342%KI=HI%$ *OJJ3(!:(PYCINL($E.(3"H @+O26."039 -S*,:U
MX<71"[N-&'N@@ 4&N#H#](\@$K#=($KH/W/[JP^8)<8@&% 0#V!, 8&(URTD
M:Y +Q!H%N<7E6N5&#-+R<(6E((&FX:!O8F0@:A>O(K (88 )^*T L"0&A2F&
MBSA\\M$%"<$Y*=!(8N0[R7JVQ2<8D#);$R0.&"!&G/U%884AFQAA*T8#4% P
M(*89Z2 9;0 \ %U['[$4 0@%G_['Y_!WV0$#&T !L'?. F U6<SURH#MI,6!
M$10$GWXHQ@(8QLTW9,#/LCZ!I5NPN1"@@" G,%M==<II8G"@BL%PP+C@H  -
M9,"B]I1 !0Z? 0KXN!0=<  #!$RX/PLM<7H(.H<#$8%@N> "'D"! WHW 3Z<
M+YG$J$,"-H!XQ%O1;,)"^\L'@/@--#?:RN0F"50P],I!@! M;CWB82F(!L:V
M#K9(P#TGP+ *S Q8#,!;Q!"P7X-,( ^J_V1!:.TO/D"@U@X8%@?.JP#$:T #
M%-AK0K>JBP38 1<)N&.]3J"T4KR2!!P8I MT"BP)L(N;3@"J9DS$XB44&D"=
M5( !#OYO S  TS8 #HHA  \GO C"#S"KMVY!]?(E!1R :FRH7G(NH: O<1J
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M \S& 1MP 2C(%NAP/!N K(@A%"3  FP+@P)A^XBA R@(%28 PTQ@ O8+ _)
MU;*R#B8@&.;$%BIQ]MX  0XG%-;-MD!Q9+ASYA:(($"@D;R)/Y/P[PS) 1J
M*/TG!#(I]53/ 3@@! "K#^H T()%!!X  UXTX_8MAOPERNJE#QY@JC:@=7"A
M!#: #_ZS%"#  CS@!."N%!X@7L:3 UR H"@&N$[A#C0 Y_XLU0%DK0Z0DA@J
M8%Q<8$,G@ -4*#M_M21T(5[HY5QD\86@"6+BT2!$:86HY19"81)7![*<)V"4
M-1ZMM5K5$+^NIWFDIQB8U2#ZZ7YPX1/@[2!P012B51>&91A:)A2Z!V+^2W\*
M A3Z1UEQH5<+PAAP"-<:T0^"81 JQA9XZA0* 8? -5A:1EG#$H.NL5G&%5GD
M=5X)0A3,M2"& 6*ZB5H+ MMV"-=PS5<[EK]>C5X6EB"P;85P2(4D-A@^81('
MH0\WR7]"05Y6LV7V,7Z$)6-;AEPK9V$E=N8L%EB'%B6NTTR>!8B,]B,(06P:
M @(X216C=4R2%C!"B0&^:CQ[%/Y:($)IB=9K\0)M.J)K\8)J0V)L$Z(0,M9Y
MX)$0VW9]1N)L,X):XK8BH"P.^D!IZ?9K]Y9O^]9O_Q9P U=L!9=P"]=P#Q=Q
M$U=Q%Y=Q&]=Q'Q=R(U=R)Y=R*]=R+Q=S,U=S-Y=S.]=S/Q=T0U=T1Y=T2]=T
M3Q=U4U=U5Y=U6]<A".'," -A+05E7==V\Z)L7>@A?,9E@V4#]LISD#8A/@98
M)@<76F  6T@BE 44AFOV=/=Y$:(_E3=ZH7=NH>=M.\<AC#9F'K-Z'Z+EJ%=\
MB6=XRU=Y@VQ;QQ=ZUW<AKC-:KA=[V?=VB18#W+,%A'9K$T+2\"#[!I<#9 TC
M;,W"PO[D.DMA!6BP(4;!MP#C9C!(;^>W'AML9(:%=6C(@?SGCIR7AUHG=6X'
MU_P WG1-9+['64#1%/P@9>PG++]'MNY(8NM+:(N!$/K@?C[!#]P48'#!#WK'
M%G;8>T#M>NJEAX+!#^2FQD9F-0.!A@VB$/H FE!A TA @X/OGNX(%:#)AB?Q
M:60-%_Z ;2N(#R81%69HB4O!#SCXOP+AB*[G#_Q ,G6A=YA6B!,&@Q5B$/P@
M8\&G($PA8(*O=;Z'27N(@SJX>4ZAB.&E>V9H9 +F(_TG$/Z ;T(!A!>Y9;D'
MU_K 7.^8@TYA#8&0A_H $-2P$'!08/U@C1$"%6Y8D>,'A?X)XA8X"!?@U91S
MB)L8)H<GF6-;F2!T2(>-[I-3N" * 8\AV%)(00$@)A0&@&%P80%,@00@S0/@
MKL,VIP'J1G2B)@-0DQ@H"@0T( %DS;ZZ>0+ IP&&<-,^*0X>X 0T8 /J101
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MY@WBX UJ3/X>\0V*2'[XIXCLX)$#@0#*50&*Q02DL [@3A!,\(L&H0\"H03
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M0DF!!!!(+L*Z"0(&A1"S M.V/%V,+08P2TS4?>!2-9%)*80!"*>4(@%(@2
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M+,6'+69@/6\HT!RBE <!>2HV</A4&F7#-H7@@0/B"F,%/,"K/$S  A, "S%
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M01S\0$+P%J,%=: 2D$4]:E*[[10^/%5G*4"50!!+-X3<"BCP.[.Z2E:!5K:
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MP0@,JEB!4L&%0=@/"8 9IZ* 5) A+Z. %=@#J7J(/R"6VO["A0PL@0E0$@]
M"#_X"=X@".5!B%>I&A&Y (F@"(O "%LHA0KHB(\(B9$HB9/ E8K8 ,&8 )B0
M"83HP; + 0+TB5X9BH((A& X"F*P *]X@XH)!0N("O.9GJQP$S#:BH@2"[(P
M"Q&P UQX@Q7@@YMZB[B8B[KP@+MH"PKB"UOXB\ 8C%*( "@)"_<)!>' P%-
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M^[A@./Z%^)A<OA"1=0/<TT7=U+TP4*BBN_6 %2@X8KBX#D"%6A+7<C(!I'D
MU?G6)$@,0N  %\" /4 %75$!%&@I-U&F%7@:5-@ @7(!;UL_$&@%Y_4(%UA-
M!YA671$V7UI4[FN+5%7=\27?\B4P-KD#\06N-XC!45(/]-$-WJB#!>T_7,"
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M"&;X@OZ$'D>,'TB!/5#8!0P408PJ_. 1D"11)Y,7"1AP@AB<V(43<F"(*<"
M)TO GBI>, DEN <2,+C$#IQ@B!K&!#6_<.83<EF%_\A1$S;0WR%,:@/""4T8
MG935+DK9TI?(AS[V61MH,O&?60!!>Q.[05$K<0,8H&$+.:"F4M&'"6*,B0W<
M*1 QU!<:&]RD)IC8 1>&&H6BZ&JI*:J$(<@0@TK BR.+0 059M I-R%B"$
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M;.>&C(X4]B<Q8(%S:8(W[L+>X/XJJ #!%1BKL7;B83F/8@$(-D7=%.3 #^@
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MK.^:Q"(,@2KD +211!2XQ"$T[DAL@N]Q;U^ZPI"MC1*\+OWNKP9I5R5 P7\
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M< &R -WRH @.> 4;Y$ .6,$N#/X!HIF0^_1 )<O1#<01$0C#)@C!%\;"*_3
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M%@S!JRYL?25]T>\O:"1"\X"T2,1$)@P##.@OK2%8-Z<&%^  #E#!,/#"$,R
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5\LLQSUSSS3GOW///00]==)L" @ [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>65
<FILENAME>x_cg005.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 x_cg005.gif
M1TE&.#EA%P/' O<   H'"!$-#A,/$!81$QD5%AL7&!X:&R$='B,?("4B(RDE
M)BLG*"TJ*S$M+C,O,#4R,SDU-CLW.#TZ.T$]/D(_0$5"0TE%1DI'2$U*2U%.
M3E)/4%524UE65EI76%U:6V!>7F)?8&5B8VEF9VIG:&UJ:W!N;W)O<'1R<GAV
M=WIW>'MX>8!^?P!-HP!4I@!7J !<J@I;J@%CK@IDKP)GL 1JL@MMLPIGL!)M
MLQELLPYQM0=PM11RMAISMAMWN!UYN19VN!)DKB%WN"1\NRM]NR-UMS)]NR%O
MM !%GD)^O()_@"R!OB: O36$OSJ#OT*"OC6&P#J&P#R*PC:(P2^%P$.-Q$J.
MQ$*'P$:1QDN2QDZ5R$^8R5*6R%29REN<S%24QU*/Q6*>S&J=S'&>S5Z@SF2B
MSFFBSV:ET&NFT&ZITG&GT72KTWJNU7VQUGZSV'6CSX6"@XB&AXF'B(V*BY".
MCY&/D)23DYB6EYN9FIF7F*">GZ&?H*6CHZBFIZRKJZFGJ+"OK[&OL+.RLKBW
MM[R[N[FWN,"_OX"MU(&RUX2UV8FVV8RZVX>XVI.]W9B^W<&_P); WIK!WYW$
MX*+&X:7)XZO,Y:G'XK#.YK/1Y[;3Z+O5Z;[8Z[S1YZ_0YJ#!W\7$Q,C'Q\S+
MR\C'R-#/S]#/T-33U-C7U]S;W-C7V.#?W\3;[,K>[L#7ZM#?[N#?X,S@[\?@
M[\[B\-/D\=GG\MWJ]-?H\]#A[^3CX^SL[.CGY_#O[^/N]NCO]^;P]^?Q^.SS
M^>CP]_/R\O'W^_7Y_/____CW]_#O\
M
M
M
M                     "'Y!       (?\+26UA9V5-86=I8VL-9V%M;6$]
M,"XT-30U-0 L     !<#QP( "/X APD<2+"@P8,($RI<R+"APX<0(TJ<2+&B
MQ8L8,VK<R+&CQX\@0XH<2;*DR9,H4ZI<R;*ERY<P8\J<2;.FS9LX<^K<R;.G
MSY] @PH=2K2HT:-(DRI=RK2ITZ=0HTJ=2K6JU:M8LVK=RK6KUZ]@PXH=2[:L
MV;-HTZI=R[:MV[=PX\J=2[>NW;MX\^K=R[>OW[^  PL>[)282<,\$1->S+BQ
MXX6*2T86*BSAY,>8,VL62\R6Y\^>@1DLM<=4PV*?(Q(+U8=/(5L"+\<TM:?4
MYMNX<Y?U4V"!@M^^%3C@T&=@* ,!#H!BF**  @:W'!9;T:# @.L*0IBF:9A4
M@@ %//X-(U;*5*GH F^5+R5;M_OW\'L:YB,@P8$#!N[?)Q# A&$5 3P0 !SC
M(638"0(<D !Z"YDBX $*W*<  @,<0 AWP\@18  G# ,* =_54> = 21 P"?Q
MI:CBBC;Q,<"$"01G0 $)* # '<,$$@   8AG6&4#*8;" #6B1XQAE]GR  $+
M&$"  TL:H( !"&P7I&63*7:D@4@:A)ABG@0@9B >.C= '<2(1J("!7Q"#) %
MQL90>RS6:>>=!<TG@ (#G("+9Y]L0( "!&0@$"EUV*;0@0,@H "#"9$0P)0-
M!'(+,)Y(8  # Z 0YTN(F5+'<L.TXEP . K$QZ0%*.H0G?YXQBKKG?0I($ 2
M!)FBH $2#$/*''G(H:@M<'"0008C]($8"O4I@(M >[PAAPJD"F2* ?8=0 I!
MI(B9G&@"!4)"!AB(P$>7A+SQAATY<H#!!^(-DX>['EQHF![JDEF'!AB48-HM
M<I [@J*FR!$L*8&,@*T!'KPAR!X=T&@ "6]L1PP?'V"@ 0F%C*8"OQS4 >FL
M))>,VWP#+!# "G':D@ "!E0PS!T "   '\,(\MV.  P00 ;%#'-"HPK AD?/
M &Q@Y#!V3#K ")_.#(<<<D1G2P8!^)QU !,H:@*/#;PQ  $$7!?(">!9%P#.
MPTP 0-(D .!D  U\8D$ ,R:W7/X?2/<1 @ 1F@C "0P \/)W )!IRMU:7W="
MEW98Y[//=4=M\N68#Z:GK2JD"8PI(X (@(A\$,   800<WH"&,!QPGV#"UU?
M L00\B(!'!@TPHL![&$Y0<10,*D!%F @Y0 -1*?"BPN,30"$"I+]/*6B&?^;
M &4GD "V8Q,]0 <Y]C8 ('5 \#*O%]Q1P@,+7W!!*,),0*0!&%B ;0"X#K/J
M]A!LP !^"4!%Y@9(P,"X*$(,@  $'F"B[8T 90H(0"%*<;M3",0.#Y! [H9V
M@$HAX  $P "XY"0H/ETH3^,QC(8X):)A[(%)'!H&"B9%@ H0X@__V]X# A&(
M"&"K /[+N0"("! "3]0!6X3:P"#RD"T&#&,0+QJ [T@AI0#@H4![V!,0!5*'
M21U@$ *! X@,8 K5@= #HG'0 090@M\5\(UP= O*7@9" B"Q "0HD!]X5PA3
MO.@ %7A#']A3(&;5*$(&F(!H)E/" 9S02T>B@ $229 ,/,^)*Z!AO-[@M.+,
M;$\#(),%+HD>2]IG.R$@4@*  44^^0X44A* B RSIC:-QWX$\  Q;G$+6S#@
M.WGXA":!80MBP(%(#!AA')?)S+6XR#[/8<#I%%0 3PUCCWPBTP1*M$8[0D .
M!ZJ/@G0X,H'L+H)Y<.,P;J& ! P@CP5Z0WT,8 M.:J^,3/X;'JGVN  !B'*2
M,C-,*@_P ,0,S3ZW:&7O/#0H68[H=BBZQ?\@)$UI:D\ )6C:RRKZG%V%HID@
M#6E9#M@I7MZB#_;Y#HI(&@AAF&(#!K@. 6 &@! (3963C*!-#=(T/GT@:G=0
MP1M6,(A?"L!36](0H4QASRI=4)^J N4_*2G0"D$ 7 <]0#$&T5#?B>)XLYP9
MJ\1CB\#547H% $ '-*0]M!*@ ,@A$YQ$2M>Z5D5/*LN?0.39SSGH+XID$H@M
M^@"'#FC/1+;()*$P@(%!.3).AKF6]@R HH'8 CD!(  I'G#&%-[4/L"0Y\NV
MHU$#D,I%*B/3!> Z@8$,] %8G?[?5J/X2AH%(*QYH"&*@,'9 82 %*$ A2A0
M80I3X&)-!P@$*$ 1BN(65YEVC:YTFP)! :C L[:+H*?VP,<^5$ #4!,(5VWU
M"7O2TQ1CO"KPAB&I*3$@$, @!B@L4(#3>6 8'0!1T00"C ;@1V8JJ(]3\SFE
MTSI-E'9LK4!>&UO[S-96KZRB' 9RAST1(%X#A8!B^+"'.S37L>P2""CNP(=S
M3??$*%8*:@7P!H*$PDPB^*O*/.$) !P@ "I A2WB,"@"V&)Y,8K.#!G XJCA
M8DE3&L #(. D1"XG3-NS0" (8<D(%B<%JB2M%T_[(G\.XP( W5*&&XR K79U
M&*=0T/X!&+ !/_PU0A#@0"E(0:0"5( /?^  TLCD@>&M(!!U0,".* "K%!OZ
MT#693XEP+"?)"B!W^PL GP.  "9-$P!00YN"GB71F1*@6@,Q!022DZUVCNT/
M!9H#WIQD1^18,P64/H"6363@[Y"I F]5\# ^(  #P%8@:-M>0A?M.V)LTSX
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MG"A(C*$9FAFI SE@FRBHD)NH!  9"2BH"I: @EC(""BH!L,P"2@("<(P"91
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MIR\0IY.P@E+PGBS !)O; D*@"&;@K8>;OF;8!390 ^U($)-@ S>P"@(Q"3<
M!#AZ S>PN)D@QB*X"F(,"4V8FC20!D( !)/@AT# A5@\F-Y+$&D !#Z@HL.0
M";OK OXS0 6RD(,+>I,Q0 6\P M[B05*<()UJ+E9 )\Q$ 0^/ Q4  110*A
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M*WWP459R4H$U#,5@&H'@(W\PXV?M!S-N"Y?2!S?W4AZPXP,!# 3^+,#@*L-
M2*3@!_%R"V\  :  +J'@!ZY21J;0!]%1"AY^$(/ !SM.#*9!=H3G*WY@"W8
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MPP 'U0X!XRXT$_ !!U_>*9  U:X8UY8!AO4'MT!9 J%RP# '#/ !$B!"?L
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MY;TR'@"1P-:P"!J(#9O#8!@I"<.&$1-XJ\ ?AR$4WDKPR>&)#L, !2 TS ^
M0,/^'!CF2 $PAQ7J#$.!8""I :6&?2CA4*><!P[[G!CF(43%$<,,A!P&(M2P
M/1 <RJG@D)@"C14L')0@X> $%0]]8G (:L&P6P=25,PPC! !4\-L,> @==@G
M "^'C6CH*4"*6\/L,& );(&<8756DC50DD&?IQ:"?G (ATY0#T_G^&WHD(&G
M8@$&WO[RT%=GPH.#!EB]("'D+042+%B P&"@PP=VAJV(JA/""K(L9W\^>.O@
M;)W%C1]'GESY<N;-G3^''EWZ=.K5K5_'GEW[=N[.#Y(*<(  \>-^#!0SON<
M,6 9AT$@9(I GS]_^ 0P9<K ;%,)--BQ:1@.-@BDCT PV& 8!=XHD! $7K+
M 3D\.2X4!?HJ!0'13AAJ@14*'"0!P@X:IH$]='K CV$P:$ .1W2:( .2O-)I
MCYZ&">3&4 !SB)0^4#B@K10=(J0!G4CQ(P4#;B%$H8,^48B/! 8Q4 X"<#1R
MF$$<"$N!84BP@! #/6B(!! < H:!I3S(Z:"#/#'@@SMF\_XD 6*FHM #!MY
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M!&2*,8(%!T(.S24%@PK!@." ( (2,$%I&A@*#QRD%!U@B2A2,[EAT*&]P.#
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ME>H 6Y( 9 F$WL, "[J%#U"IZ2*&"J O"\ #AR !PD@!"" ?%"R.07@ !8
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M Q8)(^%$0T8:OIVX6Z@  !!,3*1C43*%#=B4[*'/UY LB# %0A"<!?"$SL(
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M(#\[LBCN4I"/;<4/MR!NXY9#"T$=(XZ /G@JZF:F>WEP6:09MXL=PF" $S&
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M$U,XR"DH",P,$8B]'?*PAS[\H>KV  $<R00.[!D&**PTO3@-8HD'D8!)G*A
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MP&0XD  2K. [!_'.&SX @=7,9#%VF$,"[!.6#\ !*"*5P -.H"^X,"<$=)@
M!F+7  E$D@ =L<5+ZM  K,BD% &XA2D(@ $56& "'4#!!1H@DP=(X -=Y< 3
M3?('!*Q@,28IA6)5@ $)<" A#1!*(#@KAP78H4L#\( *O&*+4VCU T3*0 7J
MX $("&4/!$"!"2J@ "TBA $=4,$&$@",-SS *0S0B'(D\!(2+, #(SC! %*3
M!P/,P0X^'48?! #;#Q#@<7O@KG=S28S1OJ%J#>&9!^I0 9L-PRQ44X!U41
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MT:0)W4R$PB>L74>% @&D"O=<U4ST1DQ8P GH6&%(P'%8P(1P !P00P"X"0G
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M-.F23JG#2M #]:F4"NP&R-!,#$("6$"?[,]NE-+#CBF][FN4VJE,X,%LC 6
M0JN8"DZ1K(4$B)&;%FS)HL]!V '=B(T<Z"#^?,#EW2CYN*ERG((". >O)(#2
M,9# WN@(G$\(&, "B*L!S$8>$  *,4 "I #A5( 'S035%<X(>,PG&(1RA*VW
M*M+DH)D=E$(IA((#-(7EA((!=/ZKC&3AK2: Q!$"JA;"!K'/@=+K03Q 4)(,
M*11I890 5#@1W=8(!CQ&XF%6[U (9BTNCMC!$3W =)X,ZRT>SDP QK:(EDQI
M!YC C8K+$;7(*1Q WPY"W];(SDV&0*11&@5''=PK' 5" /1H(4! T@E'!)@$
M9TZ ![26'&Q !90 OHZ \.+!V;I8,1Q 0Z56A+F2;IB''Q"#';#N"#" '$@)
M)%7FQZB150P"*0P"">A''Y343'S""9Q *-W'+/E!'P@9,4#2'!P)'. 2D/@!
M,-0!0[5((92 '%R'Q.E'*- -(7S&+>0OR"+4"8!LQDY&+/G!,<G$B&0 '\R0
M"OSO??Y  -?D07L.P@FHP/)E\)OPS4QXPK6\ 3"T[4$$P@FD@-F< %8,@HQZ
M;0R[RA_8PB?0E"EL, OY[_\,!23!@1CYSPEX6=[8 DE5+WR\@0F40@=8!:\0
MP@18 (FR[PE@*&6>0/D0@@64A$R('@K$%'ST 3#,P6>0PLTYL3Y]D@D.!4G-
MP<7LP6;@$VO,QA[4#"!XSQU_@IB  K>\P?*-4L!>R2B5TB!8  7<0;*8PBWA
MXRW$4A*H@*"(Z!U39R0%Y,>P+0M3'0?<<$2UTO \DR<T4RA)X:@UU$EH0 38
MP7*>P!QT"IA-QBV Y\=(L"WP 0D,U5#(P?F"POL>1!(<$?YMLH@=Z*#5P85,
MS(Q;E,<*S(;W&,!$J$D&0.]!\,$!<,"N-N_OF$(=M&YAK%U K18QE(("D  =
MQ%4HPN4#^,$IH&L(A,+260 =>$#0!)D%Y-4'<"4*)( 'A( *#(!)!$("R($<
M1&/8?$!5@$" Q 0&8$ =<, $"$4[C4 =1("#@!:2J4 !T"EU%D *E(!PF4(K
M'!93\@H"'-0"B !!P,4M/  )U,$#X-I,) "50< )O,$!P$0=., $6 4A',!_
M,0!,%,:;#4,(0$!PP($"R$$*Y-0M# !!L5KAD,!W<-@($$8=/-= VT?74:<!
M--A,',8=H%2J2("<-JPG9.W.WOZ%DF7 'H0 'BDUS(6 ZI;'5KZ2C0Z8!:1
M"A!T02G <67 4Q?&'3P A@T#'B# &W2C1OSH!\C7.MX!!/0==1[T"B2 ?@PU
M!]R8GZG '$P-^ZB  LB- IC@D*)=!O!6F842A([%BKP!1,!R '14"#3$&R@
M*K%M I3 '#P &AX$*1#F'$C !G@/!+@1E[03"G0U7(3" &2 "E1 !71 "E1
M!,A$!E" .6%5HHU54,P!1,R?3-1! H!>X(U@42&T0G- C<&!'1;.B#C "9P)
M WS 'G  890"PPT0"=BC7S! !.RT ;3$CU; &XR  82,4UC -7( !U38IYQW
M<YR))_[4QYL<@+P0@)V,&L_! 2BP$V3(00\?A(@3LC?S$& !@ 3D:C$H  <
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M*1Z$@"5=8C OC<!]5)E6EII"L9DDZ'M">E:T[,"3=4V0@A6TX 4Q>!;OV24
M.D/@Q0R@@CYP(%^@",##OC, 03W@ XU*P'(P8!F86>8QGWD;209@AT!LX +>
M(T8%Z/*&BLSH 1SH@PH&D)=/&  %??" ;>0G 3OL(0%3F?Z)"A*PASM0( "H
M^)A72 ( "TV$B7T 06]"$0 4!&(%F?I* E0'QX3T87TC2,!1]G" .O A C:<
MB0+L0(QVE6D$#=!BGWX#@9^!)@3N0P@(W.>!+/9! H,3 7\>TR46E<( ;^A#
M"A20 6 XX"@($9L<_ "F8?C! 'O8PP@(H )B/.!35%1=EDJP/SMLH !] (8
M:K0"B7QB $GP0P@"P! O@>0R"MA#'A2PGH:-(!!R.$")5-#)820!CGE8@&4(
M08 L\2&9@2!! \@V(+X<L0$5$)<M&$!-$JQL ]I9@0&F)0<%8J !JN/  _9P
MSS>MP#0(&40!C+D!7X&F$)WL _X&)H"8$>QN)H$(0!("<8(%W,*$OBG% (IC
MBZZ$@@!V\$,)#A "8F! @ GI  /&B! Y" DA<[#6&TH:B R8)(8)J< &O(00
M/ P !<2H0\[NX($<FB( 7O%$ $ID )T9H$A\^%K"%/!3"]"P,%C:'L(^6 <
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MSQ?28 A^( K<4!68@ 9H0 G2@!?*H LH(1*JH MP+QC&H H@81*Z  TRX0G
M4@G0@"R[P"0M@2B-TOB&P1?08 AT0 C. !M3H0NZ0!6$@0NJP!(600A\  T\
M#Q-G(/IX(0=B0 N&00ABP <X3PIBH :$H0Q:@ :BSQ<P,PN&80@ZD_.B( 9T
MP"\5<C8K30V.\!!F0A(>(146X0=H( >L !-F 0NP(!74  IX(1C20 ER8 C
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M5DDQ5P&1#_DP'[%&8G_3V>5O&.S\!=IZ65V@!!'6WHN]]6J@!:P@"ZN@!6R
M!L6="<"U!=Y4$EZ4$EM "'2!%X* #]_1!0A<TR9A#0X!.A,B$@RA065Y#:Y
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M%!*Y6?[\<A:2L$1"*&O9A*Q"$K6C;"PRP8-02J(&G/!%)'R@3$KLTA*28.Q
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MM4@JAE"#(FB"$SO80A1Z((32S4((4:@"#]8H$!]PU"*^:!^FF6!K><VBVU'
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M=X0)-/[ $&1 B<*P ])$!4<Y#+M@ T/P)SU@ Z2&:$AY V:)77'F N>4$I9
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M40IZCBI=Z8+L0!4Y1DU:"-L%C<["G987R) =6P/(&HFP8[B?$.I+1],)Y-:
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MLXDB#EVX@2Z0A#.P@1:A!'C,+TF8!2*THCEZ0(/,B4EH D,XA"%@DHN(!#"
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MM[;PK!C!L$PH@S. *UTP!#!X&UV A(2@A(^)A+A$#G]. ^3@A34( X<<AD8
M TD8CO@L@QQ8 W92 EDX S0(-ECPS_4EB(LN W5S!9X3AL5C9;6C A]8A/S]
M:$G02EVX! &ZA#(X)DNN A] A&  -%EX84TH@S+PDUB@A%DHSWL1!D4  P:Z
M%I)6!+;P!41XD80(2!S^DUF(A#"H#D8 @X"%BS"X$T!Y N'-A."0!?^,P4F0
M!4H  T58)DDH S2XEU30!%<( S4@C;)FA,BC6"50!$H8+Y=@+S5XU!^,QN"X
M!"QUA?XN^(%% ,0U4.@57@2F+HB4'FJ'](7$UC@CD6P030Q&" -(Z.F64(3+
M/@A*$((MN*14Q#!=2.RWP82 Y>=K00.#K@W#4(15<+X<0 12@6=YSN@8Z;8_
M 8.^'HA82(/7'@A( (-)L%+E;:_@P(135>.T5H,@!=@8L8180 ,TJ"E?6(0<
MB$A:R(%8. 0PR-N5 @.:/@AB504P6 / R 15N.FPN&@P6+/@+@,L$X9&"(/R
M)C%%*(.B+HC][N_[N@(;T $?" LXFX&WZ0)$C@Z&V(*:98A($+MTOHA84 1E
M#0SJ@8\KB!(UJ"A*N(%#6(,8B U7V($M:!;JU(07\(TFH?ZQ-%B3,B#"-! "
M1(CQZ@B>+D"2!MD"'E"#+ @"#%:%*J@!+B T&]""-+ ")H,4&U"#-A ST+8!
M,U"#&SBD)T<-Z=MD@"W-7%F$I3HCR^B!3>D,N6P#-,"=?>;R8/BR)V@"7XB@
M15 $HMG$+ BX&7@4+&B"1<B"X+($+I^-'L "1&B"5!D&.E&"IQ!B,@ #'4BE
M&+<,5>!'1K"J](&S MF!?6DE_N:!!A&"(" #-; !A^%)(E"$-4!.,Q#U/"KP
M0D%<CF/UA*@2W[Z!+!"(+2 "1" #"?(\R)@%%[@Q&AB;8<@$*,BW61@RHB:"
M6F<:(:B"18 "W:0!)CB#-(B!??[1!:11 RV(@4.2!7R$!/ 1""Q@EB[8@851
M02K(32F8"DO8 5W@9!++ 4C'1R3A"418*E^0OIE8 T8( AICK#=!*BNH@2Z8
M!1!,H!MH S9P9XB@!1$B(EQ_/MP("7[W%H&X@A[0=B 7B#((@D,@@QV@E8)Y
M C!< Q@?2(- A(I2A!C8@C2@@H='C3*H 2I +1N  C08@Q@@(&$@^45P2Q75
M EI/ XYA"RR(,R@(ADNP 30X!!XH1TJP 5#?@7*, B;8<R$("RJ @I\WO*5X
M D7 @AN(5VUBA T?3"7@@ARP&AT8 W?"V:AY#UA8S0F_"%WX 1<0@@ >"&+X
M)?@@ _Z@0))DTAQ8@(PG:!"4DP6R4H^Z:Y)O7MXF^19*$!$"&8ABMC#U&/>#
MX+:O,3N7^I&!BH4<D-&U%XA4((ZNM _J&"5:882[.A;5%T1-!*R$4(2L,@C7
M%XA4#XXUP DT>(A" PP?@)$8.,U'>!1% ! MJ%P*5@+9$8BT%X@ER$(HN)Q)
M$*!4X+2F,W08^8&_83S+B'Z0T &\*@/LD (:DYR6:#QE_!@T""SH9PG&^I/
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M$:(!T:;$(9 !&P !U)1!$!BL'1U@%N  %F2"%/  %"1',*P+#X#1$W1!F>T
M.'52$2P3;2B"4[ B+-R$&C !&A!!#@F$$@"%+E"!$@Q!%MC)Z<8)0U@"?4C!
M(41!#PA!+204T1*)*B1C$(#!V?@/#K0&$[!!UDI":=P 1EW"$.CH+ED"$>C
M$,!")&"*) A!@+'-(V1!&@C!#2#4J_2 JP)3Q@Z!J@2N$/[TP'!N 3-)#J[$
M@A1( @X@ B\, 2\,[0YT03 H@0TJP<#PPL"2(I>2Q@WD@!(\00Z<BL5^QM$2
M@1 PP6Q@+>PF4N.^&T>*9224I6X0R1;P:[^J$AK@  '?1GA$PB_4:1KX $EX
MX:M(7 ZL0:$.B4/A;&5\A;:IB(,HPNU<CFM 0IWX0D3X@B;L0$.Q""74@"H(
M@R+ $Q/T0%P\ 650 13P@C"@@:&T! UD31K@2B2X0.[- NIRA&KH80RDB861
MQ")@1-YR 4U$G)W02F(X2$!YEP^403#\0A1<T22XP (+EAC&W0Q$0C D!208
M&$GP @VXPA4_02SX0A>0A2"-A_XL3,DPF$$,I,%=9$'(*4&B= 'I+DF*"$%]
M]EI"H0_(V"8-"$'?>+$P_ (68(%KJ(%I9,(? >\5T(0:O  :W,0TT2J_T802
M[( JZ,(/_("*X4NC^@ ;Q$44[("*H4$.Q%,-6,4L]$!82 86%.E5'$(,2((O
M/*)TT,!= (A!8 %BL+,:0(E+S,!"TD 4R((O^!IG^$ :\((NU( "ZL(0I(FV
M/1DON,(+E($O/((+F($O^)@OZ*I5E$@J" ,DY$ M"$,;D 6C22&VL(0BN, C
M9'&*/:IY.0EK'8*#%LD/",/F=* N^ "1# $8/%5(#$;0Z,)@Q*D2E $AHT\D
M\/2$</Y:=EF5;9*!$LS"+- :+W3&75P!%!0G9+R3:PA*7/C #3 "&&(D?UI>
M&5@")7#")5R")<BU)="U7;]U%&QIFMIPSK1+#,S #%#JY]W #@3![@Y0.'7*
M+OR"8 4#5.?9) @2*?]"4O "+63+%4/-\@:30>E"9I#>49&&:#]2M3KT+,1"
M%FR!8L7"!>.,7WP(3TS$%3V"A$Y"2)0J</C(9PN#+*"!:30/9_R$+W#UN4V"
M#$0"U#H6.B.$+@CV) 10?6#409#!AVG":O3 ;R@"TLB3W65/KP9#<8(!KHP!
MR)*!F6'&%6<"<3MW+&C"/>G";VP!IL""$+$)I9W4ZC8W#?[P!_71!JC0S. ,
M!&L) 3/%+O.$R8A>Q7 ,PQ2\56D]Q1"$9VZF$5J,U3BJU@\XTA=;R"SL0A8+
M]I5T&?*:C$U@TV((P5+8K!*RB[E))K;8258L;0U$%4WH0B;<0/#IE 0QS] M
M EFL.$+04VU@PD7$ !5XF6=OCB5 =YX]1!2 $5D-RF" 86G11+1(& W0Q"==
MQ6,E![UH>5=<#- HR2R@TXK-!CD)0TD-:C DU3#\@&-TY"'$@BXD B,DB"+D
MN2+P.9_CN2(4!'#U]23Y@A*X )(G#0U$PJ!"!ZXD+Q20VA,,P2S@W:8U2:0/
M02R8.>0ICWOP0HN$#ZD- 26LP?Z\D%6%^U!]1 (CJ $C2//MS(^V.-0N58YL
M=T5*\--!@(Q#D>O&^,DL; $3;$$6I B<#,,R/P&FWT5.[T /M,=!@,V?9 (G
MB/8L7\6SG"(;])"URT(.!/0.7,(8X$"R/T$1I FC>",8], -%($L6$BD2WHJ
M&$EMS#=QV/?'U45T&]"$@$E-V!%#8(%3G0'Z/(KVE*H08!26PQ9M!('<)(FB
MA$09W "DESNF'(09'(EN280:0$%+[( C=8HEQ RI,8$2\"L7T<8E#'1-(.>J
M"+F2-,N$< HM. PP69.=N,(;@81T+$*OD0$/K,9AZ1%&I+A47],BU.B07^"#
MO !+T/X <S[CJ*^!%(32$T0Y)TSY=\1=F$O!=\[RYFA/W*W:,!Y"#O#GF#\!
M,YEY+/BR=^V ,B;[$"3*#]C<1FJ"(41!%RP"GC="(_!])$0")."YCC&"WR/"
M5JW=H%.-+TAA;A!#P,I/# B#A?AI^JA(&L$")#P*;UM^SM,$#5**002/0*2/
M,'C00;#/,&Z%9!P"]5U"+& !&<0)+,Q Y/0 1=4$.+$!;1/4L*#JT$4,3F0!
M3;@"<.N$A<@"*WIR<Z^!U@=%=*>/<1.4M;,B%_@)$*VSAOM 7' *4 Y$+)S!
M0D#K,(P!HD()[ ON#$#-050M5^A"HN0VN=BF#60A)9S4OOX_E1((C2VFZL![
M]\  !!,TPY0@&C8LBIJ#6L8,$W9P6!!(!Y4<.IBJQC U3QP>] 5Q6*H7J4 J
M43(,#92#PG9D&D;#E2H:P80]_!A1$<2'F&9\K*'IH**3$1=I'#H,%@U?KVH$
MNUCC(ZP:NH;-FDHI!LEA4RP-P[3CX:&34LQT5-1CF%B(/B1U%&9C4L=A3[H,
MJT&IX\=%/B#&8C3WS,&OPV+9X'6P,-6$9J\PB@+RX \PD'G4-7KP"9NJ-&#-
MFD'5H2)?/R(-<UIS&(^VD%FW=OT:=FS9LUF766.)TB1)NG57DF1H#2-)PXE+
MHH3;RBS:RYDW=_X<>G3IL8/-B/[[,%4,6L.$6!8Z3!>-B<*48.%NF=')I%1U
M*1E2&F60CZYXS)H5 R\O(7Q!IIH1BQC">E#B(RE^T.H)+1YBA(;#( HB,%UZ
M>"P2%_X2A@GS(OD/J1GJVL&B8*[XX: HN/@HBBP.DH0O+AX+:08'A_&E!H.&
MX6*(82)!BR(;+XH!*!K7.*@+'LHX2)<8L'!JC8RR<RD8*-JXT;R#?!AH&$1(
MO"**ARB1CZ4AA]E""(UXJ,F,GGRA096#*+GAH"VH\.4A8:+8X2_(L-#B(#,>
M>VB+)YR:)(98AEG"(H04&D8+R]9:XZ&*+J)!&%KP<^@*+"'BP@9+A/%EC9%0
MXNB@&OXP>8DD'K!$I,MA?"@*)$MB^(@&EX99I$Q7+:*%AK;LI&(8368Z2!,;
MHIH*O 85V<%-%_"RA 99TBH3*U? VV'*-G(\J(?5'C+#AE0>NN2%N,R0+R0>
M:%ES/"6 Y8()T[!@-JE=#G*%!JJ8Z.(F7Y3@ :^'(")7#5U\B06*&VY28R@F
M-)N%!I*>J+(-&LS\*!8>K-UAM>D\_IBV-)1[#9$T#'W-9)!57IGEEEU>:8>N
M'IKEADNJ8F(()H*P]1(BF! "BH]FP5GG4U79X:8N;G#*H2YZ@&('&Q^Y@8DH
MME ))%Z4P&$5S*H$(U?PH,B9!Z! ^JH(++8P[Q$?MM"9"?X'R^"!"2JLJ"L2
M'*B@0A$?TACF$2" U85H@(>1Y>>$BQ(X))^'4$(Y2;8=!HJ<0'J$!RA\X (B
M35S0:I8@NF#B7UL?P>$)(;#XJ(PM.LK$9R9XX&1&*X20/:Z0<G9/.5YTCJ*,
M(7SQ98>3.0GB(4ENP#K+65GKPC(T5+2IBMMYR#T*RZ\0LXLC05(#B,F@@#45
M'SZ2A.XAHI 1HC-JV"&'&_ :A@U@'0H"*!ZZCF6((8H00BM*N%#GEB8,'W1M
M&(S FA(L1XD>_,P*'TD%#Y@V0:=DC#WJ\D43AD"%-)2!",+0Q1!P( L%'@01
M/'A"#\@0%.8-(7<K0<,.A""$&_XD2AA;\ $4>& Y3#@N:(0)@A" ER-8[,!>
MA-D!510!!-<]A PY<,TE?/ ^&T1!.0]IPXNB8!&:D4078Y.=V9S&PRD- X9R
M>=D:F_,0-52A#&0HPQS!0 8YE@$-:)@C'>=XQS) 861L%.0@"=DRFH#$%TP+
MB;A (HQ46*L_9O.(3A2)F$RP[Q>7G%%K="$PU#BDDL-0A20AXPM5..4CC\A1
M*K0"$5EHXB%,\T4J/C(\C]Q$E(R$B"HP 1K6I*)-*\'E(4N9B9.AD#^3?"4N
M9Z2)8WYR):G0!#-AH8E0LA(RKE!.OT"B2%L>9$^MH=-*0AD+6$)DG*816#!"
M.8Q=?/Z$F)L\2#",^9I90I*<$#DD,[&I3\8)<Y+Y5*=.-%$+1!XTH/(<1BU.
MULEA$(,JPO!F)@(I472*DY7ES 0SA:&)8.Z2*C>I)"Z_21!-M<:<OA0H,9FI
M"ET>1!::G.<_"UG3U@0C%CG5Z4YS"@N>_C20-A7J4(E:5*/"9EE'C0YVJ!"#
MCBF5.9)H F>@6E6K$I*F'F-$$9;HFJQ>%:QA%>M8R5I60<["5D7]ZG)VH8A3
ML7&MTZF%(HYI5KN.-:XM2T4B@GI7OS+GGYYLY%\)6UC#'A:QB57L8AG;6*%^
MBIF.E>QD*5M9I>;5LIG5[&95MLY(N,$-:$A#&AA15\Z>%OZUJ57M:EG;6M="
M!!-@@$0@?6&),_CHM;G5[6YYVUO?_M8YP3A#$<J 2UDH$A)EP"QPF=M<YSX7
MNM&]JAI:0)*/*$(,85C),"BQ*.E^%[SA%>]XR0L;7J1A$KK Q!8841=$* (,
M:V#26\NK6,&"=;GUU:]OZZ3&_2Z6$7B911:" 0F#"H,1NSC$1'1QTO\^&,(1
MEO"$PYJ&FQS")<*HA+2$,9F#K('#%#8K)G)#"4I4@I2QZ>7+=)%6Z'0TO\[)
MJ6LRH5*7::*O(*'H;&*!S\1>PGLW-FUS?'&)&!/5%RD6IXDG8>)*& J8(!GE
M:]!*R%5$=CJ3"(QO?:&08#"""_ZQF$47&@$&3Y7!$(:"Q/Q$3%9?S* &/OB!
M#VXP/=9D=0?C\2IDVBN;!3&+-C1]B"I>,.39Q/4A>]LN2'+0"/\>&3*,8UP0
M+-)?-&AF&#_(B: ALX47'3F_R\UJ7D?=@X#!!M(@>8+W("TP_[#OT*V)L<!6
M005$!RL&$=4)9#SW@Q[T@,X6><*+#G*%HT2:$22Z<P(=M>O7<%H8-!C@LHF\
M@U.EVK*Q&!(FM)O :WMO$H;@;FFPW69"!@,N#DDU6P(]C#8<&S:32&9TL PR
M:$+&!_!9(P/U9!D?3,3/Y;[J(WCTLBO\3>"NR$&]!RFLV3!\NYKXC%P><H4J
M'<1%K_Z)1-A8LP9X1R>>($L#J7@[BR&Y @REL02D5AZL,+1E..8F:[3I>Y$6
M'B02%M%$%:B !5A8J2U=@*0D;)2**E@!"]:"A!!^P 6J7,(*32@NDKI 7$5P
M/!)G',8:XA()*]SM,+,X0RRJP(A@F.$CPD #$Z"0)TO\S2%E,%0LL@"%*K0R
M*)&0JC B\1=?_-$*\/GWC+9@,[I#@0I*GL37NT 57I@A$UDH AH$1@DF,"$2
M3S"(P-K  Q\<20@E*\(61C9FQ&LE$CEAQ",HT82@ZF)T4.@*SJ/ A*FW(4_#
M. -)O Z%--A$[EOX&]WW9BMA#%<+D_C]0=H !2@\8K!2</[4&IR?>X@P@NV1
M0,//88.)L3TB4P=1!1:@0'K=VXH773C,XJ& !J>H BHH; (3Q 0+-*2""D40
M4RS0<(G:Q\+[FD"2$ $*G@!6* $1).'RVB(3FD 'JL!:J \*$@4BQ*XJS@ 3
M\J\-_DD38J"=+$XNN$ *(&,6N* (S@!7D&0+OBXN(&$(FHXJ\(\*LN"C\FZK
MHL!L[@\-ZL)D9@$,!$82IB05L, *JB"8A"$-+N\O8J$+F&;,0B)?>LL7X.[O
M3H41Q$ -?&$7MD!:AD$1E$SF!DD2OL!F7B,8:D -CL,2+,$7DL1L-.T^2FL-
MD,=5XN(%YH<,1C 68J"T#L$'A/Y!%:I'$H3A$FP@$E*A"TY"&(+@"C !$7;@
MV+#B(WBA4+#B$F)!"\P#%F) "< @$V0AUQ#B"5+A309B#0#MS8#";V#A$&8@
MJ#@E"R %"Z[@1J# %;"B+7Y@$A:Q"2,"#6(!$6(@J+""$ICP,4 1"IJ,!J8$
M*QCA$K1 !JPO$Y0@"O!B"GB $::1(WRA!\H@%1BA!D@BX[I !K @"]')![H@
M$Q@A!N)"$>!BY\KD$  M.WR!$>0G%:* 3\*C.R;!%V1 #6(!$G+@,*Y@"#)!
M$H1 *<:$"33A*RC0(6K <KA "5(!$WH (A6!!B8!$[3 !5R,-3H0$3"!'#5#
M*A A%?[4X >$ 0OL)ZDBX2[P[S%2@2"'80R" !,R076&(1->( J,XP;*PG.P
MP!+ H,Z*,O[(0 @T(1/\QMU<  TP00V$<1;2H 8:P1<6H0=<01-N8$A<+09$
MR06(4A)B ."(Q:G6T!(PX2&B@!8W901UP@>P !/FD2.$H3)BP1)J(!94(0N$
M0!*" 13[\ ^W"PMB("K7H%!8H@>X /HV4AABX*THC1+I"A$*,PJ@(!,F808.
M01AF #[2H$QT80;*D+= S#0HCS7:0"O. .+"T&5B809B(/Y<@WA\@&B(H&NH
MH(54(0>$H<J0H@8.@]UJH S/@!9CP5:D@BH.(2Z%(/=R0/X3+B$C#@(-"BXR
M)H(1RL29#N(1@F 8+"5W"H.>9@ B_$,8% $\36,'2((&+&<6;N(AQB"9N* N
MGB +;$(Y?( 1F@!+A$$B#X(6V"<5N"\2>  \9D KS !8A,"[;"#W *4LN$-,
M,"$CVB!>#H(,S*,+S,,,  TD#F$]$V@1 )1V#F('=C%BAH$,^.0G(((&8B':
M+$<7YH=&Q"P4N2LC8H%2#B(3I @B>&$C1:E'@P4L8 ;Z3,,&P! BHL!1>$ A
M>!,B&(A7"L0B<H#-:@ 6:*$I[F-D*%$6-I'[>,*1HA 4#45(9X$T;X)'LZ3@
M=-%(^T1X'**N,$(8DF)D&B7B8O[@<?J'"3X"!#LBXSI"$JIS&,[%-')'&'H@
M+M8@+@'P()@3)+0@0Q'B0VYN&!AU&+" <V*A*7BA##V5GHKT$@(##4B%W=9$
MWW8K$RQ"%\"@S')B%;J $<J@:^H2-FW**EZ@!]I))V: S2!"$D@D#=[R$M;F
M3C["!^*"!F8/.0_B6+'@3JA"#:9@1G: ":P@"J@ "'+N+H?A$CAN&,J %I_@
MC!BA"K(@9Y""!I)(-H7AW=#)!F"A;3QB!X B$FX 6_7M(?044%Q'%8;@!H0
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MNYJ\"VS (M0@;.Z:2(N@%B9!!K9@AK8,.\*R'@^""@":)UT ?G)@!ZC<(;B
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MV!:+1B(UP D#P0,3PG*ST!&JX ./1! ^$$$#<0.,)0P^D 4%H0CJLQ!18 8
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M:G %., %H,4#F$8T3, W!A(%-- #/!(%$70^0U $[J$+4OYP"$_0 THP<I'
M-D*P55B@!EI !#Q 33%&!$^@!C[0A4H2F$6P(U)P!D%P \^1$&#@9YF#$KX
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M!F(T4$[E YG7%BCUI?145L.@!&'2,*$$$LL)'=RCBK&K300)/PIT!40E:[%
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MP0,E5(T2-DC#(6[ (T78@ I%4(4D8D"%,G0A;\-@A$.'  LN$"P3P&S##-C
M*!YL 1%#*.1"&+&#A6Q!",.(80UML(8VV !?DF"I*F@ ._Z#^& 1/[")%L@@
MA9<%0PA4@,06AD 0(01AG37@PD..FE0E$"0-P"R##R0VC"LH81%;\,%7S "$
M+5RU"EA(0PP$B84A(((+81V&$G@ !C74H)","$(0TC"2'!1Q&$)(@R]T\8M?
M5$07,_C@,"SQ EK\M0T^H"$9NG"%I@VC#9!;R!.>0[!4U* ,A^B!GV*Q@S0@
MX@;4G$0,(K(#'EWR632HPHAJ4%H>4'.6:0IL012E0X.H81>08M5MC:,+'KQ
M"&T32 VJ@(8S="$(//)%#3Z8.$<!\:_CR@$F:F<35WQ.#4BCQ!,(%@L:"$,1
M?2P(48<QA#+H\ 6@+$@-;+*#@/YBE <"1>\PHD [AL2 !SWHP7^_\H/V+A.S
M5\"7,'8P05K4('TOL$1!4OM!-+QT$B] (1>VX"B+,>I^6""#07YPI(@P0@;C
M0X,VS12)^Q["!RRY7R2$X(IN<63$7*!F=&/!A)?)SR U,-,2HIH^!\NBP,.H
M 2VD:1-%.%@2]RT(CH=Q!BBW08;#4,2+GPP8:BHAI9BH047,,.2,T,!;2K"!
M#W@0!!PT8B(TV,(9FAN$= EA$F:(HX)3$87*1H(&*Z%"$$"B!!X5A :\F(0-
M.N(D2VSUNL.@0ACBV]A?=J30PJV2)-P\BRW48@V-TT4:-*$&.WD2T\R)Q0MB
M\.?3!/ZC!E@8'Q?$F8EVEF%\+XC%+&@0C-%ZI :$B4$'L8=K\DY9$528!2/Z
M& 4F,!<-1! ,#6X7U_N1Y 81'L8/IC>)%U^A"!U$PW,6@C=-E(U$!>%!OX1!
MB1P*(PJ!ZZ:MRW &%\!B$BPMR"->2I!N#F,2F!V&AI?" Q]LP5L_6&X9U&"#
M@);XQ+9F A.VPN*!\T +WII$#72&DAU<0A,.AL1+A>!783 "#5>P 56$,"9,
M[" I)J_"#'31\IO @J5=$((:;-T$R)$ACHX2#$9?BG-P-^&^2^!1*34VC"X4
MDB<S\)80SF#N61@6SLS=P@UN2.=B4P)RS4X9JPTRA:J]^?Z;94@K]X2  RRX
M.7TVB(@/[A>%@.I"OL/@Q1!X@(6/G7I*P@ #6U2Q/RX0(PV66 ,D9*&LQ/H=
M.8QH@K=,$XP93' 8B(C!,#)! T4@ A&*V. P?$ )1"Q.&#?0A"IFL(A%?#[T
M/K@$LLW ""V\[ E6:#TB)+$3VY'+?FW) ;6$P0.[12*'48A"YW5_QV'@[98]
MP'@.(1TX3>S4\Z#?WHL)\@AD$D2GR]1^P(<L#$ATP:%T2R,B%C$),QEDI0O9
M 1B6">5E@L$&4$A?'J.0TH7\8$\Y2 4M^ L?^ M-N($M8(18$ *'$()"H[E4
M., $# (24K2"Z*R &P+EBX0C,?X#@@&Z@E $B^$"0E,_2&@<(BH(35BZ+O@Y
MDM"!0O.!D9((78B!6C"(--"!@EBY;,.$;XJK8G$AB5"".=(U-<@]]9$P,]B!
ME[H$N-/!^[F"P.&%NY.P,MB!(5 5QQL25>B"BY"$,' #@T #'E@9+02/VIF$
M^>@F8(F!M%@F@E"#S;&;!:,\-WP$@CB#*X@C2KB")Z *-+ NS:L0'Y@C7[ !
M=[F)&_B@'BB^%U.#_,J$N?$^UN$('[ ;;OL9?/$%&J".&'NI@HB$& ")0V I
M&3,(+H@J1* A77@!7Z""^D(8QB"(E2((@M@<\,.R&^(%4:2$%YN%B[J(MQF&
M#GR"K?Y8@K_@ J0YB!KXBAW4/)8: V4T1)BX@2(2ABUP,$9X,8;P&3/@'#8(
M.F7#,NEK/FHAM!1<.BD;B2<(L6$(@B7)$6DC%TNP 8]HP&%8@RCP0Y@IEJ&2
M""DHNV'H@6I;)H0!&USKMX+(@7&Y@KJK@:UXA#),)N8SPR AB$SH@L()"2@
M A:JR.P(AA?8$X)P!1>HD)I2!$@(@I^;A1D(@EJD 3LY!!M0A$@( LY)A1:H
MNQ@(.E_H 2R0A+1J'(E"A$BX A?PR!UH@GXQ,U!T,%_P@2L(RCQ:B%1P@3U"
MOB<(*!HHPTH;ABW @5DQ,=T3 B!J*(.8!!EX($6(@94Y2_Z"N(+%.8076 1*
MR(*7@H49@*0MR &H683,(Q<N^!P_P[(7. 1*V *+B809 ,$8: \:&)=8:($A
MRX&1RBA(Z 0NF $_V8%9&89+R+S%C(3RLX&F284>8((GT (?J(@A@ ))6(,8
MV!,NP+]A"+>"0 3($8:(DX0VF)QL*[M,$$7;M(%#,)E%^$0?V 'D8TY4<0$2
MTSP7H(H=**)9> '.\8$"\X%+(X@@2+#/C($UD 0H>$E)>($U0*,?\(5@N($L
M8(0N<('[>8(<<QA-H(3S1*,=.*"/')*S68-R$RQ58 0PT"[<X<_B$ 81(@E#
M^*!)R (LN#0LD[Q>D3 LH(((7?Z##U($Z/2%%.N"]E.L*LB"3&B$QAL&30B#
M?D&$M("%0NM0*_C0&3R$-*!1&G421+#!I2BT64@H,\H"*O"K5, <F!*"3+#0
MZ5&%2YL$NZ$$+(B",B@-U;DDLD@%O[+ OW %S[3+)_T*5[BT_UP(1<C11?@@
M1K")I (#6<B$IC'3@I %-8J$+2 >3< D?M,%5]BJ8%@#*MB"N;F$=,F$,A32
MF]C3/MT7FY@%1(B)-1 DK*@!EV"$-4@#-*A1D3"$1O&%-: *1;")-L6H(TF%
M'" +1EB%JNPH-8@(3=@"*N@"%NT"+T@%2'"(2, V3, 3S=N"*&C5 Y625% $
M-0!61/ZP! /EU6)=B$? -Q@1AB @H%E@@A;4#D38L.+(@@@UUFO%5OLP&92!
M#8,1''(Y&)!I#5)1&G 1&4IPNM\HUY'IC-[P5FX%F'))!2M@@B'H KQ C8G)
M5W@MC[2H198I&=1PPWV-5]/05_H@UFR-D815V(9UD2QTV(B5V(FEV(JUV(O%
MV(S5V(WEV([UV(\%V9 5V9$EV9(UV9-%V915V95EV99UV9>%V9B5V9FEV9JU
MV9O%V9S5V9W-$+=(#)_]6: ="*'%C,086J,]6J,MVJ!%VJ5-6J956J*5VJ:=
MVJBEVJNUVJR%VJU]VJYUVJ^M6JX%6ZP5V[#U6K,=6ZT56OZE15JV;=N!>%NX
M?=NU_=FXI5NY;=N[U5N[Y=NY[=N\)=NS#=RT+=O!1=O#-=S$U5K!75S"9=S"
M;5S$C5J14(K6@ Q?T"=@T:?+U5S,!99\ZES(X%S"TEQ],MW2]=S,)=W3Q=S3
M55W715W675W/;=W4C5W:G=W7M=W:E5W8Y5W<]=W<U5R(=0U$(((A$((E:"HA
M2%[F50+FA5[H5=[FI=X@8-[IG=[HO=[MK5[NS5[MQ5[NM5[J_=[H#=_N)5_M
ME5[O9=[Q/5_U/=_I=5_NA5_V7=[T55_\E5_[K5_\G5_J[=_S_5\ SE_P+>#\
M+=\#)F %7F %3N #?N "CF '%OY?_C5@_[5@\[7?_XW@^&W?#%Y?#,;? *[@
M$;Y@ 09A^]U?$];@!B:"OEN-5"""O/(!&@X"(JCAO J"'+9A':YA'.YA'?9A
M(1YB(MYA(SYB(^9A(5[B(B;B)@YB)D9B*$[B)Y[B*U;B(S:"(^,-7YB%+P;C
M,!;C,2;C,::Z,D9C,#[C-$;C-69C,G;C-Q;C.)9C-:[C-K[C,J;C.][C.HYC
MJ@-D.+;C+_[C0281029D0P[C0$YD,S;D0F[D0W;D2%9D/<YC1+[D1<[D.=YD
M3>YD2M[D/I9C4>;D+T8N@Q5=S^5<R)#=SE7=T 66SJ5=6<Y<6HYEW+WE5XYE
M7;;E7?Z6Y5X&9ESVY5D6YF#FY6+V!<C@V65FYF9VYF>&YNU@6'BE9G&UYF_%
MYG4-F6T6F6ZNYFQFUV@6YW$FYW(VYW-&YW16YW5FYW9VYW>&YWB6YWFFYWJV
MYWO&YWS6YWWFYW[VNVGVYX 6Z.I A"S0@BQP0S0@)"XXY=,0+/2A!"+HPH&F
MZ(K^CJ.D 1?8T1C@Z!EHE&U%F8O( A@(NBAH >E\"$()6(MFZ996#2Z( 1V(
M <X)11V@ 69\#8%Y >M*A2]05)<&ZJ >#BV(@1J@ ?UDNJ*^Z=+0A#/0 DY:
MB%E8 Z':-B&(@2!8A%D0T)6AA45@A.W1 C P$X*@A"[H@OY(U#T+/#DNX"&A
M=FN*ML474 (?>($C^0$:8(*;WHI#B $7>($6B(%"^RB_=@$7B"K)H0$::(%+
M. / %@9):($9>((6>($7J &%:(/*!NP<< $MXV@:^.LG:.BW)FUZUH+KY (7
M:(-?S,ZB]@57B($90 1:.(09:$-A^($7X()8H(0=B,]9L!PE< 5?0!N6HH15
MTX$VN +0WB(:B($GN 0VF $:0!HI> %J@@4EN $4*NWNOF=;= $(#6]%< $M
M0 3+5I87^ %-@ 5-R.U%R(07@$Q7< 77$0PLV.F"((.8%H;4:LN)J('PO$].
M+ @JD&N8>0$?.(-&: KO=G!\3O[M*X"%&/B!)]!H1G@!4<6"52ML%XB!R50$
M^7Z!PJYL&<J"JR0(,XB!'%@WCLX$G,AM,7D!'>@4,G"!/L*$&^AK#X^"_7SP
M'W]G+G@!P?"!Q,8U#->!8!B#!,<$3(C$3(B%4(3,)M>$3&B<+,AO,K'L_(N!
M(]&%'3A/38CME1$&R6$"'9($-8@"'7"!R@+R-V]G(0>B+I !&H <S NS^[2!
M?ID%,]@"3- %YTXP-NB"OY ='WCQXF[Q+I^(W-ZK'K#L$8QMT18"'QB3)9@F
M.-?T=<:"%N@C\[Q.?&P!&M@*+/!P'YB!%KCLRZOL'\B!D[83>E/L2T"#4>]O
MOXXPN_YS@1!3!<EI 2%@@ACH(S  [!^*@1=0MTU7]G)F R=H+UV@ BNP$TEP
M BSP"&$X!"6H@>RD#4F( HW+ IOPA3)X HAJ!">H F'0!"NP LOPA2QP@B?R
MXE5PB-,&(FP?@L1^ OA:]GZ/9\G )>)E#5F@ 1L@ UB(F!<HEJ 0>']W>'8&
M:'/U31<XZ1<0[8?'^$UW!410@S5(PXP'^9 7^9$/ZH@G^9-'^917^95G^99W
M^9>'^9B7^9FG^9JW^9O'^9S7^9WG^9[W^9\'^J 7^J$G^J(W^J/?$&* #Z5'
M^J;_#Z9'#Z@?!JEW^@$!!EM8"&+ ^MC0>N0PA:U/#JKW#?Y@P 76L 6J[_HW
MOX5!^ 2Q7PA;@/NS1XY0R .#((9/( 2P3_O4( :TEX-; 'HY" !0F/IA (4%
M 'RH1WN[+WQ28(#$7WR.</N^MWL4(  Y*/S"5WS)%WO*+PAB>(-2Z/L$N(/,
M]_S/SWR[%WL^D #4EPBHOP4&*(7/5WI"> !G?H,W<(\W4  *D( $V /3  8'
M0  %,/X0 'S&7P@[((2L[_RL?P! * @^2  &:  #& &E+P4%P/K(5_HZ8 "E
M%W]B&($16/;:]P"W_PVE%_P*8'I02(#D?PU2. #Y'XX"\(3B8/H"^(2I]P2P
M!XAA @<2+&B0V+ ]#0P61&@K ?ZI@H$6,JQH\2+&C!HW<NSH\2/(D >']0$0
M8AA"D2H-$B( 2B ? )\8 CM@IU2I01 @($PY$"&%-R@U(KPC06#).\2(@3)P
MLM2!6QEM>3)HZX"IE5JW<NWJ]2O8L!U1&6#@LRM"%1XJI! (*H'4/;8$AAHT
MC-0@4R3L# -5H@Y"40MLS2%A5R"Q.R8 "QQ$ZM2;LXE/R)%:;$Z"$U4']K&5
MAT3$.B5F"KSUY@0?@J10:!X&S,Z"$G8)S>W,AT2>E,3DD @$:G.?$RJR(DXH
MP50*%!$%EE)QHI! 6PJ6W]Y#R,%9L=JW<^\>$B$I"!L^>"<Z;,X#@G((T3P0
M:" P OYW!)YRGGH8'P@<_ @D= +%9J008AIQPTBP DH*)$%0(14,<XH"I<AA
M GL"F6*?A7;=XD=B[TD QU#EB3@BB26:F!$Q%7P@079=J= !*0"\]!8PQ 3P
MWC D8'#> !^HP, &'*B0P A])8"!"2H0P!<P%F10!P<5%#,,!Q X*15B%EA0
MQP<,F'(+"0ELP%]/#42 0@@,>$ ""0-$= H#(] 1 0D"!7) $G$DL <P)2B@
M 7\'I,9 !">\80 *KDU0P1LC&$!>' [4@0(!5:7DQP$>K-"! 5G=J8(<"O#U
M4$0C*/ &"!),T.*)K;KZ*D/$,$#("AN$"&LI!&P0R%P6 ?YC0!_%>9#!,(,8
M\,8=$( (!P,4R#&,' C808<"[&&V@02AE&; >Y\,4*!/I2" @7,W#N/)L<FJ
M,$P="@Q3B@$;/,#7"!? >B^^^>H[4@< *L#J2@@E<10)Z8&"0(T('(:"!\/8
M 1=^ T@5B+NE!'!?'P= :\% &#P;@@)8#B5'>@)YP(% "$3DTP,(#M- G08^
MFX'+PRP0"C$*; 8A0C<+]$"P#[2%'P/#X%&T0!:<),&ZPQ "W4!^&("+0 WD
M87.%IB0 S"T)M'(* ;V2@/2^99LMU@9UCH"ROJ%LD, !$,S7WA_%H7#4'7L@
M==0P&="!D@K+L3E,'@%L)LR[ _[,U(<!(A-DR@ 5?G!2'G,'DEX>1YE"@% "
MP5'RV:&+/OI6<D! DEEBK4 !2@?4<56-!QQV0@?G.4C,'D<10\A"I&R-TBU8
MK97""2D\L",')]PZS 5" 3,,Q</<HG!!# 2"N 0<,E_', I\@ (**Q!0Q^;@
M@R]3]Q4V$*SU*/WAP# A%/G\&PWS84 %)&A;W!ZG(S2!7 A@OA08CA@(L(51
MAN()BI"N@0Z\B!QJ-XP3-*QLQ @%"@# EX,<H&XI(8&#W@6'$T# 7L.P0.>*
MM8(2)&!==HC K4CA$J<50"H^N04Q2@$Q8I3@),,P!1SNYJ!D/>@ <T$('!CX
MP"4RL?Z!GI# \P)!-J\@9 4A# 2P&(!#V2$D!;6;PP0$DCD[%4TPSR-&UTJQ
M@0W880YTX,-,.J"\@E0 #DLIEKN*@8#-#&1] H& WH91 >XE  5UF$,=^F"*
MIM3AD'@(!-46H+Y@-8 _)%D("<C3Q0K:H@X>","S!K('T$F #Z8H@!P::0=
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M4( Y\$$"._*F*)@G@3[(@0&IBRR 3S0"BN*+M].\0P@(8)=_$B0^% "!!R1
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M'S@.5A7(*=Q%'SQ/*'B50'P/,?C!9H0:L"'&6N%$8RC23$[=!$!-OB#$($A
M!10)2LR*1=C" DB1.V4%5OZ24P+#"13). W#)V!)65H(EN!"KP"#F%5F7G8F
M5R!$"$@ !> D1J3 !P1"V!A)C1C [*!,'3P 61V ''" !1! 7,6)EB0 U*#
M WS  YQ 6'5 !H0,0:0  WR >!"#+6!  CP JZ&$!.C2 UP '%B !#0 IFG
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M6X280#@FFSD,!EA I:&$Y%J W@C# ]P!/(7 7-A""@Q"C359L6P !I0 EJA
M**C -K\['*[G&_ $R/Y0V.1*KPQI" 3"'@Q :G   :C ((C/67;  40;,6!1
M'H3"V+12 CS+ RS(CKZ' C1I'OX<P+[SP7#%#P2(@B@\0&[L@0*H "B8* >$
M0B D@,G_T #804(N!#SUAP$00ZKN@9:Q#MCD#WOT)D"4(J0@U+ 4"@(%TA"
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M&<7S+*H4H#\AB( I2A$"P!'# 1YBB@@PZ)$!E% $9;+% /X:4HP$!"AE3!E
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M%BH'%Z1M,A0.CK!E'OWQ5MR1P\0)%VRA(/V'+@S2'O'B%OZ*X1\=\B%OI0X
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MQ2" #^J  &(#%QC  _H !0B@2T+A28&M07C8(A1 A$Q! B2@,MY61J3SE!Q
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M@P4+$A1$Z',[N/#AQ(L;MRUG@4$Y"6[FB5M0A02;I_VNY)!A<>-A#X 6A-,
MH2D$10=413J3P\QA2$N)AG!KV(<-!.4$@'X\O_[]'?_ Y ]@@ (.2"!>%+P!
M%GL&> (, <"Q-$PI ]@!UB -6  !!E_A@15!$CQ(T!S;%63*:S0U@,$(=20
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M%;Q$!**$$(,K#(,,#X1?&AZ8Q#4\$!;Y?((J7 $)7J8"$V)D1 ES$(,Q#(.
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M#%# !-S3$EC+FFTBD8 ?#G*+#2#@ 0IX2]X>-VW(]:H.#! )'@(1DC? NU(
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M"W%0 HUG@"<@!UTR#'XP '/B 77 '7[0!R1P!RP!#'-@@5_2![8P"'9 #'?
M "-@=/Z#4 (J<#6!80MO(&XPD@"AT #4-PQ_8 N!4 (L&"5^4 QX4 (D0Q"#
M< (T.!6!8 LJ< (T1Q"A4 )O4"*;-PBPL0?P%@H(5Q"H 'HMH0<-$ )@^ DG
M@ +)!Q:@$ (-4 >W8"&HL (F<'/#0(<G (8& 0$E1Q# $  W=X/]9Q"@D (F
M0'_#$ J>< MO\("-6 *D\ &X)Q*$8'X%00@$@((G@(,0& <D4 @K(W)4: K
M40H)@ LK87UO\!6D0 (-( >VT I[MQ)V4 (72!#Q9PHHX(1/8H)U4'O*%SJG
M8 ?<9A!GMP?:9@LA\ $$X0<'H +,@2##L $5D <H\ !?P?X!$& !&$ ,H5
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MBE^A&WI0 @]P"Z&0 0L0 JTP%%%2 1@P!QW@ %\A!P,  BJ  0H0'Q;  7:
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M;6(!XEH0T<H=)!,(_ED,=H "''  L+&FA,( ?R ,=I  *_!]K$D3'A!Y$3(
M<N '>S  )",!X\<!*3"M:S(,"U (@6  $HL"(C  Q$ (X2$2&!"'!O 5(L$
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M%G= !W60!X-P"PQP G5@O7T ;Z  !QA IT&A OX)%B!@L0LK<@/A"0<P GM
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M4SJ-/-G(J"<'X,LBY5L?P'<"K$$0MBP4'<(=6RC)%2#)<JPZSN89%? !\V$
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M6)AQPY$'J/XG:A\1&XOV=%8WE_Y';7C?]@XO\A OH4 ZK;OL<QK7</]6-X-
M ,!0T((3<BQ?$'G0!YMS\P=Q=@CG<XAS]XF3\Y.S^0K?\ !7-W\P>R6/]RNQ
M .Y7*$C7\(._]SK_*\ 0ZC5_>8[?$&U/\;2O/FFS-F=?]UA3 8#I"<8X%I7\
MH$"^$2*A ?1N$7L =DA2>W(8Q^X\&\30Q[U?.[80P%'"!U+2!\5&A9^@@*<0
M^?2\F?!6"'6L??J'BYLYM^X!#,FH?A@W#'G0A-E'"LT"#'T  1MP;X3P%<
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ME#?G>, #@S P.,,5%+"#.% BE/4/.B4E@8&8,CW(@P?>(&&!"0PJH0$Y4##
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M00$RL(+%9>H3"*@ALA10%HGL37FE/,&SB/&&"0W#$X2\4.H^P$5;^)%V.WD
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M4B  $#@(BH*27/&#"2BU6V" WP$A H #/B@88K! KC@V.P" G,D( B"1"J@
M/I # M -%8"7T0" G; %!"BG84@"!=B#/* 2N6  $O@#58D)",@AY5F4/OB
M!5@<0C  ..B#"[  B9  ZOF(%.B#J:H 6P &!,@ AL" ">"#.2@ ,T$6EE"
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M, W1*$7"+$S#/$S$1)NY&<Q- P;\F;D"(0&$ 1!@((6I@LQ-VQS!&!!$B2/
M^0-BJ#&E2DS2+$W3/,VSP2G,5,VGF#DY'$G6[ O(?,V1K$V3H<U,F<W6E,U*
M6D6QC$4/_,W@A$V1*L[A-$Z1,J6+VTWBK _7' 8YV"O9+$[6+ 8,> "<M \
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M@Y @@:*HIEI=6(8E$&+0 &#P@)+Y!(HQ!3.T!3FP/EM8@3=X@ZFDV$'P $\
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M6S"=F_FC&30%&;X/B4@)7-BC5I@ 4/"#$SP88?* [;W5#$ %"_B$0+@ 8O@
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M!0%20/X8#EBDTR(%I0&!0<B)3T@D40A8"1@$3[  J767\#B+-YBB5O@7 ;\
M"KX5R1FP"K(%3R"$"2 %0EBUSTD!": N[_[P2DW?;<0B:)G'3T"!-T@!Y_ED
MZ*21_[7<^8:YG"B9J_4A0D@!%7!53\!4BT5<NMB D,@#.4@U/N #W.D 5)L
M'\_ME0".3'F#"DJ"$_ $?QPC.<" 8E[A=0-Q+H_3"L"RL6( /1C(T]U-MQ4+
M#@ %*)MO4+ 38$!$#UPT4$  0G"$@+V#.U TAPL$5""!8B"$=*J 9[: X9B
MTY$#89A&@[P%:2*%"V"P8?C:6_CI&%[L.%#9SD(+";B%A_[N<D_G4CX0G,=@
MWZ765&J<@S?@ U!H6UNP#N$V&5,H <N&#Z15"5O@"%QHJJ+P:#D(#SO 7SRX
MA82H)!5 6!))<3ZHREM( 4Q"@6?V@]::Y8R #SY@RT^_=FPFAA+P< '1 TOA
M &O'=G'/YMG<3W>>S7F>3O6L9U, 5WC.3?YDSY?N]'&O=WN_=WP7=WJ/U'SO
M=W__=X GTTWB*[X2'%O8:.KP4ZB>*/]P38G0Y]JDJ-9D"ZZ(:=WD]Z=HUJZ&
M5&+PS5L !5 0!?64^-WLZN6X^.ET3H,P^8!O^<3<79NN2/K  )W> )X6W#;T
M"[)+SXX0!1JYCSK8'_W U(YX@_[UKH\A1PC)V\U!P'(5$)SE..I,D0,(P! 1
M]P\L3YL,$#F7[_I2)&E!O86 QA&<,H7)) 5W@DYRRX_G"N4Z."Y1>/O^DHI/
M.&10D'M4.&M; (410->5( 5X15:CN ..*.37.!/1EHL[^,5B*#9;$'E38&";
MD(FYEGJ#6 '=,*UA:(6H?2%WA=?G.-:U#6$U"XG>"834*X4J-OUV?[MN%8E^
M+2MV71JN]WK;1\P,D ,_P.P)P-<1,)/J=N2#" 45>(//?B$5H("S\(!!^ ".
MQ@!'T.([R -"(.+KR !/\( Q]G7N8("-P10/X.@.( 048%?<,J-2R$#E>@,*
M,%<,V/X#$J"-2NH 1Z;CI-L#"0 %L\_::\T0B8 #@/C0QPX'6Z<P["GQ9AB*
M.H$\#"-!0<ZM#77D,# U;!@?$H,TW/+#H".)81)(W)E0*A"#%+;>E-B3P10&
M6\0LX H1B(Z*81@T;@PJ="C1HD:/(DVJ="G3IDZ?0HTJ=2K5JE:O8LVJ=2O7
MKEZ_@H6: 84<.+=P28 CQ\/"0A-$>9 SC-@P6X$(!0H5U-.)8;<^>>)PQU:%
M.YZ([9E082/=4Q8,$[LC]TX=4QHV>@"%@E22$Y\(^BDY[-.P$1KIABI)@L]<
M#+<VUMDSS (Q$H&&O;%#S),G#W9L;9@[3$Z&.2LRE'IS9_ZCA5NF/O61,*S$
M<C\C-EX@M=&6IT$50/TIL;'F!HUWX 0*4??"1CMS[/#Y)/Y3J#G!9X;-KW\_
M__[^_P,8H( #$EB@5QR\MI$I$&W4 # J=!!'"1D$]0D*;ZBP'%V!]+7'!X%D
M.(PI=FS0QQXC)+$<8R-N\,<== QSQQRFJ!>1)RAHID(@@7RV4%W$?'#:,(.4
M% (A&VU@RT9PV.$3,2<<J0(?@W@02(K "?=&'QOQ,8(*?R!I2@ER>!(<"D?>
MD<)&'V@W7 F>L-F'CQN4\L%K(!*RD"D4#N.'"J:<\(8GMG"@1Q_JX6>@HHLR
MVJBCCT(:J:230E5!*<30A<H#>_[PD4*2$- US 1'ADJ46Z:0L$)%;PPRPBUO
M*$<',1* LE$@KL)*2 :@8!"'+040XLD$P(P BB,>V'+';Q9\$@A[<6$Z3"@J
MZ2J*'"((M\(<PT1 S BWD;"''"?<XL&?BVVD @=^Y%&!'Z%D0(H<KCY@2R@,
MW/*MB!,T:T IS/5ABP0[/@#*'AL04\$;I&#@B1\HS!6"';PZ,LP&%@Q9P2UW
M2 ",I92"'++((Y-<LLDGZ[='@L, (X<**L !C"VRT47(($@1(\<@P*Q YAV1
MD? &,:#<[,EM<]T1]&MSO/'N+7O8,8)>(=S<APEOO ;*"2AH!(H*H>9\&X<Q
M"^<):?X_!Z+1(* 0\T8<GMS1"FL;?:+""E_:6@+9@Z002'R# .4)2GS@HB *
M=Q#R1Q\CR$&"DAW8$>XP1&_T*I0;X;71'BH,LH<I?JR,LNBCDUZZZ:>CGKI3
MWJ&B^D;G"<4!,*[37KOMM^.>.\K1@NU4J;\+)Q3P0='U.UW S,[84,,3K_Q1
MI3+&O'#&-P]]]$C=<DNT/VZ_?//*6Z^[^..37[[YYZ.?OOKKL]^^^^\O'S[\
M\]-?O_WWXY^__OOSW[___XLL='_(4/&2![U0 :-WQ -;(!0H/.")0B_%:QXH
M])) 8C0P>-<#( <[Z,$/@C HI"!!J.00@CZ@  /#\$1/COXBAZ,]KP[)8TKF
MC)*Y$2AI#C,,(0][Z,,?NB]GR2O11OIPBQ-(X!.@  0<<'$*%*"@%+>H  =,
M00PZD !,P]@#2@ QC-O<0@4D\$100.$'.:! >W_8@Q],4:L^G$ .F#(1'TI!
M"E(X((U@7,$)+#B'$_@!B((<)"$+B3*R38X"&U#!:^I0$#D\H _ V$PH$"8"
M%3RH#K<(0;,X0(H44*@"P.  'T!A :#,H6!U@ @#3D *.-3!$_%JW# :X$HY
M8,T"?+C))@D!G%LT[A8HF%FM#&G,8R(SF?TAHU ^\89Z>4(\<H#1,$AA!SE0
M8!AP8$T%Y'"'$-0!!;>Q!0FIQOZ@X-6A#AN9B>R&,8<\G"E,&YC=18;A 8U\
MX!,34)8&"+$GVVSQ7\H<*$$+:E"H$ -!&^E ( ;1%SFHTQ05"(4M**2"+56@
M$+;XA"G@L)"'#.,#E=S(()0TC#KXZ *V\,#2]K "UA"C)BP]J5P*8D]3FH([
MMK#%+7BUI8,"-:A"+2A=ZF"!.B3A L  A0-"(0>YM,("@;A# TRQAPK,+ 1^
MX(!>1D""$8R &!<@!@I2< <+V"1&#^A(3R[PFFF:X@)Y",&V7#.<A81@!,#
M #'LQ@<$K9(0&_ $JX9JV,,B]H>BL$,>$C2(4^Q409XKA4;^H"1/V$$4DRMI
M>B97Q/X[O(8N3//#W-A6%XV8X@XW&X8HZ&(+C=RB@:T=QA]^@[E8CL:DB=TM
M;WMK3!J5X /%-,H>9./;XR(WN8:4G_ T^+W*%>6 WB,*<YWKW.HJ-[O:W2YW
MN^O=[X(WO.(=+WG+:][SHC>]ZETO>]OKWO?"-[[RG2]]ZVO?^YI/&$'1KV_Y
MNUO^^G<8^O4O@#<RX/T*N) $3DJ \8N_!F=7&+K0A2\<;.';Z6(+6ZBP4-8
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MQ()6*@6A'H4LO, 9;(04^$":I?Y!PL*"(KQ FJ'!(KA ,$3!$M2KH,F R;K
M$%A" L9 %\0"#E+!X95!)+3 )&"!"Y"!#^3 NI[!(UC!+JS!"RA"O1["&;1
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M$\R J_F PHUA)"B!(U*"M.; $&B!#_AF5Q)I2"L!#0@#*,.L)=  ,CX"F,V
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M+]/ %<!F$"A!#V@<. J!#=P +WSO$-0 $\S;#?CTW/OG$"PH#N@"!7.8*MR
M$-P C-MOH'?%$]#V_R4D:?/>5ZK9"S2F,#1!#S !#LQ"&PPX#6";(K  G/+
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M$'9 ACHH"A1O"6.-(-A 0)1@N@BBFW;E!3YJ3V+@YK@-+93K$+[#KEJ #*Y
MG81 I@C"#%R #=(@(A;AW@QA"V*A!JB $[S"%VA "![A!KX-YAH0$PZA"A!J
M"A6""A8!$<I "["@"1 B@M()$[YO&,8@\W*C(J3@I<Q S-A 0UK +9Y@!F)!
M"FA &(( S-Z)+(;@$O)0UX+J!0HI$3D("Y#B=1B!"*R "5Y'"9@@"@@++;JI
M##*A"3 !++3 !30AG0Y!#>[C"80@/9Z.!6"!OF)!!L# &/>%H*HC$BAC$FQ
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MJXL@+&'FMJ!SE&LD?, ]T6;ZI#!VN" &0H3TO/ ]U^()VD 1N* *HD &(&%
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45F,WEF,[UF,_%F1#5F3%-2   #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>66
<FILENAME>x_cg006.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 x_cg006.gif
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M__CW]P
M
M
M
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MRGKD( -#XB'++IM@<$ #\7X+7QU)"I2! 09D0"!U HSK[,8<'S4" 0L0,-Y
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M"QA1B. 5@0[-@9GG"9>*$" *7VQ"7X'B *Q U#H3PDH!(?XB@ ;XAY \@&P
MR/+%+BB S0Q8H$P 8(.U % D!4R .@DX0//R9:7BL&=AM/ %!X843N) LT>^
MZ(, 6M0 >2)48YP*5&O6X,H#2( #*DJ  ,:SBPF\BTD2"%&K)N +$[QK 4X;
M@;[F1IXU]$D "F6,&UH* 0ZT"@$"2%(FP E5$E&G1028T'9FZ@L1O&M:Q$F
MBO!IT?!80"\32  !1K )"Z@N4!= P1P>&J$(7, -OM   !9P  PH3 $ ((%
M8L$PZFA@ A0R43 7RUB*N %V5%W@ 4KPGBI%= *@^(4?BA, 8%'@  <XJU&Y
MPPF!J !""K"7!0P +P[\(0^J4_Y  2ZS3@E\XA=_X*P(\JJO"8!&%F3JZUYB
M(0(8P8N+K$F('O G@("^H4\(:%T8(P2+7SB@11#HQ"\RD48/^,)&LLW :V$5
MLMU0M  9 ,0>R$N W<P3 NV4!:<68 !EIO1)HKAI!][SB0=L#P*^N-:T1A"+
M7;B!0B[UQ1_^Z2U97)< 8A-("<!6AX.L:2ZB&)(!]ND+44"@10Z0#85:1(=
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MS7$ 3C,7&B M!0 !(@!3,!):)?Y(?B SC]@(,D"6!WW  2)T1[[@ 7UB "6
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M\EW4@6DA=0#7U3JP, ))""$E,)F_L 8-T*_9%#\# 0K%5?ZQ#9 "F6 !"N
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M"Y3 UZO@ RYP!>/="I"@V0*Q"HVP"+ ]$+6 W,.-U_A]$WJ]U;Z@"S00 U<
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MO& +D![4OH *5'T(8> "/R#0OO[ ZCI@"W[O! (1]S-@"X< T0X=!$'M\2Y
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M)[]\\\]'/WWUUV>_??>+!/]]^>>GOW[[[\<_?_WWY[]___\'8  %.$ "%M"
M!T1@ OX5N$ &-M"!#X1@!"4X00I6T((7Q& &-;A!#G;0@Q\$80@E^ OWD3!9
M)MP1"H^G0A&6AH4MA&$,93A#&H+P%QPH067N,(%,^.*%E$'A)S 0"U^ @A.5
M^2$*?XB0)'KM,BI\H0E)F </*#$T4:1,'SH Q<ULXA,^_$ >?.B&!OP!#R
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M)!1[6*DO=@J+/HC"K1H8@5UE<?Y(/"A@$X=LJR_HVD/-!.*6&8 #$_N 582
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M$&02AF("%LA 07UQ!Q#[@@T.^( $2("0"GB  Q@HP"+WW  1^ (">1 %!!8
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M^ , 6(%8^(4W&#Q?V(7<\P4,F+L22+LU\ "$@( VDH4&,*@5T !?8 $'&"D
M0+PT*OZ!5O,%#S !@&N Z%J Q/(%$RRX"8BJ.U@R_?,_O-NR)I,I65@ S^*
M9V)#7Y %!H!#[DO!'E* 'FH <?(\"_2#'A2%!2 A)BRD/^C!4%  H!* U),
MY(*#!9"I31B %B2A.5!!F<(#"T2(,OH% M K#FBI#/0%.1B\0)B !7M 7WB
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M3J,,SKS.!]R%T/2%#O2%M%33J'1(Y'* 13JD/(  U]PH"1BYLZHH%?H$"L
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M60"%^/.\,O(%.R"Y6"#0G2HGA! % )"#''U<4%+ /XB%.3B 4P@%-GY?O2)
MO)L^6"B!"$ I-O:ACE6!:<NA.:@H2H9-4NH#!""!$L" !0A!N1H -Y"%48"
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MF03N\N7P(<2($B=2K&CQ(L:,&C=R[.CQ(\B0(D>2+&GR),J4*E<^Q#,AH@-
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M0Y^(\, <VQ7 PJD(K#D"!9G *^I7OD!0PA\M>X#"3G<@@$<F&U"P4P:L_K&
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M(PCTXCO+<US#_H $7]3480L(Q0(;5JSI!?)'_,MJ0ZCG"WPM)P0Y+$$<9<$
M4,3" OY;%8%2-+11^CI$!#F4J%>5X@LN>F(6!]A2)E80$3$]9!,"J)L$),R3
MI97V(0H052/M9L$_""!#%*T;+ Q V(=D,V,$>-,"&+KAJGP&3)/-+(YSK.,=
MJ["4(E !"2A@@7E65Q34](4(&J""#T" AY^9P =4H #-;<*T#ND$ 3A%@/&!
M0,'9DP +*& '7Z0  2A P8>1Z@LY'(60$,B "B2@@8;\(0$B0 $"Q@0+.:\
M A_82=X<,H+H=@TR>IPO\&JUIC<@P 0DX-\'%#R43OC"!- 2P026!PL&>& %
M([B !&81BP7 M _Y(J\#5L !!R0)!,S4EP'FPX$&K( $"?YP$I86  &9C"#5
MJSXK1/Y@J?H<6!9(FX-<2X" (:4, @B0@ 0<4(!!^F(3#(CR J(U"PC0< 1R
MF44*]%FB Y1@09ZUBN1@$0 :8_, $HB M$7PBSX(H#19DP S09%+'O.[W_[^
MMYU"$0<ZR$(6==N$U'Y1.B*M !"S6/&99-&'%;R*%@M?<.EV<?%/S&<3*6O
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M-6D<2H[-3RW8'$!+BV2""B!!P_SC+_A<+/P!(]&(**B ''S%++C!"HQ2M7V
M!!"C2\#"&JQ P_A"**R!"ES30Q@71!S F/U('*B *5;8"JQ 2W)")X1F:<S+
M"H2"!C3%R:G &ZS)J('"':1 0F[""K" 981"S"'$++3! K"!96 )&ZRE0VR"
MO+A!XWQ2 U3-F2R'=*Z RZ6E;NX$%T'>"K1!+$# B.R6"HQ('E3'+^3!FD@G
M:H3G FB="M!G>'("+*S &E3')W "**# D&P"?J1,'ZB &[ =1BFH6?R!!EC
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M6."+"K!  C3%+A (!$04(8G NAHF NR>" Q 58!"KSZ A*7,&C3NH\V'!)Q
MCB1 5U K=D& 5.R!7*U GOW(;;P(!C0$&SA &Y1 K/D"!V3 BT" #L*" W@
M&Z3)+VQ"!BS !YA8^S@ UN"+PFJ *3U+Z2J 'JH,!7Q "G":0_ *O") R!&4
ML,[!'T0;"4A<M(W PRG ";BKAE4 C20 F#BL";AK:#V)S+@!R0((J'P "G#
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MB)& WA@S>UB 23GL3APSZCA52K%11)G !3S$!+"'K+;>3@!6 2" "D8$+2Q
M!N#702S8 I  BK)!J  3V^5+[2#5+.22&XA;'Q@*'01.1\/)5V0"&Z!9M*04
M83I$;6,PG(P1+8S"0;V2WLQ" OD"#S])7,V2<&G7O*%/2W4%!HF C#W)2\>,
M%F'.'0S%='ZI+ZD91*+7+&T> (7<KD1VM;5!"IRG+Y1 @%7.Y_I"!B"GHK+
M![B%+)A25\0+)3F%&6V"W_00>R215+JF.[>?"N353H38+T# F+6V=18S+N[=
M"F" ?OXL%TP.T94Z0";4(PI,)QL(0![@M2>8D:"*+!*L  K4F[Z1&3.UT.ZX
MP3G.U_+,$6[J4[>N0 .PP71R@.^H!U)!0,@M4R(A ,)LY01<";S47@2\R=UF
MWWYW'./LQ)WE<@F4-@&,2=;000' 6<.0=(DL3VV3HU*UWTYPP 6LYAI( !W-
MP9>K@-24P %TP(4ZRMUND333D<,2I7(/F9(0U]3D02A\S)>N@#F'"65+8QQ
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MD\Q"'(   0!ORDA 4_ ! [0?.G\46M&"W\KD5AFN&:5 M[O!'7AD@+ !!PB
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MRN^- %9S"!0 9 E%@#E]$8$J60@XU" )]J@C 3=\D<.VAN:@+X^7QBJ@%TX
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MLC/HX8!0F6,"#82@,,O$*V!A40(--#4BG0"!!E#@'B<]:Q=K($&)$#O.]W2
M X!]2$G6@($2;*4A<7@FA]:PP5VP@01&R>E)S-F&D8C6#8TM)P=T"Q%0C.">
M^>2$*/Y^^9\?-4\#)(6<0]:0R95RX(N?2*Z(4##92PDDHOWD9T%$,8(,D(!A
MHF5-*#<Q@F,A84Y_K8\$PZN!$EAF%Q:8J"7QFU_][I>_&9G%)R8@K$CVE\ %
M-O"!$8R1AK @0 EV\(,AO)$&%"S"%;;P1F0Q NE<F,,.'G!ON@/BO70F(G8=
M\8C-9&*==>8/#># !D4\X!236"*(L7&(:2QBBIBXQ"()"8AGC&*(K'C(G9GQ
MLW@<XB 7F<@Y;G*.3_QA$D=RR5'&L9$=0H?/\KC*.'ZRCI/<G11W.<9EAK*5
MKUQD-:]YRE[>L8Y[0V0D2X0#RYFSE'V<YC/3^,MHOK&>X?XLYXI0&<Q\=E:/
ME0P5FG:8T8VV))X'G1%(:V32":XTI=_LZ$CO^<*7WHBGE55INWX8U)HV]:E1
MG6I5KYK5K7;UJV'MX!==9!<P?HBM8YUK7>^:UQ ^)D?P0*ADY4'8&8E#)C%"
MA\8RJP\4OG"S.2UI]T [DG,8SR^0!J0XE+K OW##G-RPX63]H@USXO9$_B!2
M2\+"M UA][D+@H)@[F(% H7(^F:!A!6L0 5#\84>/D#B/^RTUP4W^,$1?I&&
M$*?&#1\OH,\\$HOF.=._@,"T" V1!FSWQ&R.B,.BO>F)_'G'#0&!$C$=XCL$
M" 7$BDBM6-. .5EOSB%_]) -H/X(7QC@N9F.R"T(P%%)-WP%7[(YQ"?HJ8?,
MY9V(GL@FKM(9/03 3B$.1 )^D8D <* #'I" <S+%AZ]D@@1EA7?"T9YVM5MX
MP0K:2],Y1,P.H"D62,9UW3M3 NR-!.\/J35%=C'KMR.& O>%"MQ%@FN6J( S
M#1?EL[+]D%L(7B1]U_$LB(D957YX%I3?/ ?=@A%1'(!A$+$\ATA=^K=_^O#=
M<0!WMA,16< ]\&:4$.)G@6M9/$L6&V2#?R)_Z[W8>O83X426.MX;6_]=(J9Z
M2 98((%K/\0#D(D),2? F34 A1;[@X#AUQY^\8__PF]80 ,RL)4V2( "&-BI
M*#(@ ?X(Q.H#(B#<A('$ 3E0H $=F+;?)("J2."S5H7])"!K?()?5. #EF,#
M(*<$($ "-$!5[F "XF\U)D"D,$4%VL\""D,4.( .,,#%7@0/', !2D $O"(D
M-.J-EN,/)N" O@B)#F@T3L!O.N!%], ")>"+<ND#@"(67 @"2( T.D %($ T
M1 0$+, "..!%,H$")@ ",.8.&( !*" 6WB IU,5(<@8$^B 4)& !(. /-D%!
M,J$)2Z(@ B$&)0 .(H(-+' "?N17U(=0I":%2F0"YF06W,\7<(<"-&!.=B'V
M%D#G1F(71J "\,;<4H#]_M A9*$!7 L"*(!,9@$$I+ $&OY"R]8@"9-+%D!
M B3@ XPBM5@@"9-G%SK@#3)  =H $%8(K$2B!"H  S# ,C8!E2Q%-XS"#30@
M)7(&%#8@#OCO W:!(5* 7U8 IWI# 0*E(4+! &+A R#C(6(A 3Y$=5C+%U(
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M 09(B1#C",%K):S"/4;@LR8 8Z0&8#1O G1+:A8@4QRG(3"@I P4ZHAI+]C
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M! (.#PI@3D:O0=GB4>K"0T1"HF*A ,;#,2#C90OBA\!(0>; A@1X1/[$("K
M%T: 6$:$+U&E,&8! AY$=>9F :J$#AR -W09.V*043<82 J@,/K -F*UL3X
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M[LQ*R]\; KA$XK[MO40"X .0%P-<V-\U @\T-R.05R0D(#<(H-.1I0[VIF%
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M_B8"-_[7%(;8/QTP 7TP!T%R7@#E$MU5$+109N]4$(%  921"0"P!CWQ"0M
M$(@E,J*2:@'"G&ZW=3?A .'Q"7:D)#;!/=&R:V2&'[^@ 0ZP/)!&/04A DK(
M$RA&G]&C!\G6D(*I9GGH$FGE$B*@;5\R 58!5G[P!@LPBP[C *GI'20P:"/0
MAN<6;5W&= :1 01W@Q-6 3;Q!P 0"_CS"Z-0 #%C NDS4P8!AA"P78\R>GF
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MX[,+6*(!"T J>6$!2+"BZ"H 1W$5RLD8'" !85LII<@1F^  #[=4M."V&J
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MX X=3_6DBS&NY$C.XRH=Y5&^XX]2  NI$RFP*F3&U3'>U_ZRH $(@"P%8*\
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M"6B* 2$@"WF0 2QT,Q]?\VRP$^/8 1]@1FR0"2R  24 $+M"J=CERU>L%+\
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M1J"@H#D0J*,/"PKS@P 0/A6 L@E$[&."+7U3*M"0_F" LPGN-B"D38#L(X4
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M!58V$P@IB2)T5OD%Y7IXU@VHU1</:.L>].6Y68"B+1*)1082,($4N/07*3@
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M6($'Z #. $65$H#KR@ TP8 )R(COD+'4$R2#T(,$\(4Z./Z %4@!$5" /3F
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M!Z@-!3 !%J" !>  E4J;#7@ RH"%!R@!%4V 3_@$"!!5Z?B)\?  S3.(.6
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M RC$$LH$)?CR 02A_!*' K[,@4 FLMQQ0)<$]"'+'P=\\$L'(\Q41P*#TC%
MG06X)E52#)DP@2RGH*";+PO@H5(>464R0*)Y" "I3[(HL((LFSC@0)ESS+I
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M,-8O9/X$BQ$@EI@5 A3 !LD$+3  !%! !32 _;56L)Q6'PA ++")1BS 6#!
M)H1" ?Q!( 2"6\)")C" +[1!@\R"%R+$!^#!);D$ @R0+!C*'7"$@;7!P=R!
M*:H$!@S3)R2$3$# '4Q(YKR%<L3" CCDYBF3'D0;4YB&2EC ':!)3^W&"&0
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M'I@H;B6:"JA =+Q%*?68BC+M5$99>"Z$G&" T0[$0K" !22 !,B"'"# S:+
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M1=#)<4ADBBR4&0@8CXC-9<;PK5,4(T/0@5,P!_>2!QW<L <4JD90B$J<  J
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MIW3$"DA5$G-&4\)"+(# B_A$'-SC++B!2<+'QK !1\R"ZN["''@T7_NU\Q9
MHOR! 5R>,RY6:P% 'NS"*"S '?S" JS +(#" GC&!3Q$&^BG+ 2*:PP6H-SP
M)E#(+OR! 'P.!UQ -F]S'IC%3*R! ^P&'6B++-1!.GZ !9S"+)AL0[3BD,8$
M./\$>'Q" >#!+F3" =P'"&A')S#WFAR ';C$ GP 2R2 "H%" \3<5\3;+GP"
MM*P7IJB$!/>I:+%! &CAXU!FH4@+.HI"+ " ' @0RJ'%"/[4209<".K"@@H
M0"982^:(WBS @@3HA AP7+9X4YJY! !8ERC(51[<00H(@-L8!31!,_[L@@5
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M*4$L@%%00"P3P'J#+ZK%T<SZ@H,"80,%]%CDCH""  <X@*@$0HL&." "#SN
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M1J!O9J$L=B% .X$6\ 1(<.?<$)/OSJ@M[F#02D %V,!\^)%%12+N5$,B,J$
M6 9DSC,#)"(/N"<QMJPR)."1\N!&]Z4!Z&,3)  # D@"*.( \-(7Y( X!.(
M,D$6"& Y.H$ 7B<%DE0- 0 4CFWZR$0@_L  &&,7) #CC(EE[$ 6V3$TM306
M)@ 4TI)E"F),O/#]5DI@6DW1-OZ@!A&DWF8! 03$#1@)0@>"8@2"#ABP,8I.
M 9L0"!^P"=O  6J$ CCA%Q+@$WZ! ,!& B!$% K@IM+RIA0 <9" [+!)!1MH
M($2@-'9A >"@98YK()0M1%@UV! 3!:AJ,8713G[$ @:# A#SIZS,Z8",DSQ@
MISYA F)!HI C 11D! [ %_@H3 %@.;!&+MB XO[ 6E\)7B0"!6Z4N1+%%_!@
MI;0I1"Q DT+&DW9A)M\P>]Q((F)J.3Z DTB@%'VA$YP.!9@D#XCH2-;@ :(N
M3G2. UR)$7MN4SI@QO(@ *#%%SP .\"U$8-( F+A^)142@] -<"(DQ0 &SVH
MDU2R#_X.0"L^9,?TKPHI#M&D;43P L^T!_P&0@. I]'NDZH 55_68$5]01%*
M2CIW!@,8"78*(!8 52MF81JW;##$KD%]81L?1"#RHS7D#LV %I+4)0, K7!<
M!$3=\?YX8U-_9*P$XA/Z93IBKT77%C07XD-@-(@.P#!  0)8ATDLH@$$94DJ
MHRA9AP$F)!:N="(:P!!E(0,@H ,<0 1@S7 1]P$""HSZSW>P$GRH:,>D3R!.
M $P%H@WR%@)*PT@FX  DIB8;+[4\B(I:92?C)(DD*32!$JFHJ:;6P '8C0X(
MX$0)8&?^H ':!P*FXRGU9 $R0 ,6@+<:%7D%X@*P4B"LTOXB1B!O&P [+K%V
M2F:O;"N0+.!90BDQ,L$!,. "?A=V#,X7Y!+6.!.I-N%[,0 "NDU[%""\'& Z
MO+=]<@^,]+8$HK=/P783%B SZH !CB8#,F,6R+%X=RP/"*!+8#(4Z0\"NM)(
MZ?-MLFGX/B$6C+07 ><74J )K>X &E$V[#9$\"" -28S-.#=7E,!="4$X$,6
M." "J AQ( 4S.$ "< 9Q($-=98TG0P$ ]&,CHFMV ^0.6"WS+'8",L"#2D[D
M&N,7.@ ".* !=F86#C=Q0T!X848"$J,V9E=@8B$!A(4-&( #/E<B7O$\91$S
M,( ".L $\G<6)BH#-L!X"^(CG?[&/JWN 21B+441 G9T(":KC,GG5RS@97#.
M").6 >:P&B6 0;7Q08D6G-A-%K07+^!@ 33 2.4"%C"(CK%Q(!@M1-^P5:SW
M [!WVNSO#@B R=C6E0UBQ @"Q@;2#[X$DP8BEL/4#_QB5MGD2S9A#XA31/*
M\4!AJ93EE?I@3@6J3"P%%H(9ZR)"6+QR(#9!F2T"XM[D1$;*,HX$FE@FE]RK
M2R@$1W;!#_[ 25Q$%OP@L9+E0HQD5K^$F0GB$_K F[*YD_X@,T*!&4'!*W+Y
M%_X G2UBG#$4EI=9H%,"%OK #_XCH06"FX/)GF>5E^%Y6/J@1 :"$]KY1S)@
M3H.D#_X2(YL#^DINZD=,FJ3-5E\W("1B@8X">IF0 Z.#1%?@>9XQ8T6L65AN
M643Z8('I@"*:K2XR 0%.)?8N!!:\4EARF6D&PZ#+!$:L^:-?"9K+9*9Q&4"#
M:,28.HCZ %ZH>2+PJ&%*Q*1E8>I$!25YIBZZ<B!VH0\"0:&]NB R0:1Z>=PH
M(IO!&JQO.:+)V2)$@2(6FCCIVE+TNBYX&A3T^5>.)&8Q(P/$^I4C^SXTA#/V
ML28LFT$D&REB%)1=X@XJ[4\, K/M@R&@=PU6( $2)11*  '8;;1YXC]"6[.9
MA2+>0+YNY0\T;[9WNVW[8T"T@[)[NPMOXK7Y([AS0[99E_ZTX\.WA7NXG1NX
M?QNZ^<(_H/LC:((D_@ )UJ!$:*$-*%&T;8*Y3R.LJCNYI=NZQSN\TQLGJL,D
M\B"A>%N^Y]LIZ-N^-0*V[UN\]9N_^]N_UU8AB^Q47&(_"7Q-SH1%BUL[$+RR
M,>0@.&J]'<4E9IHB&/S3(L),D/D.ZNI2_ELH%-S#-_N5NB\O#4)>!.(.,GI9
M5CRVG;BZ!XIEJL[K6#<D%FX@]"!$0$  AWO&_V06(*"NW/LJEJ:ZUP#0>#P[
M\H[(]7 @5H ^;H5S,>VY?>$$!&7)1;O&]P/*;V/ARGL@_,!7*@"8>IS)@P,#
M>*.R+B03'GC+&P,U">U;E\7&A?[[RGW[RKT. U5# IA41) M%AY@Q'#N#^Z@
M&0WQN5LB%!9 *W"4 &)P()# E6BI 1J@BO#B>2ZB!" [Q#>=TZ>DWA:BGB,$
M^X+BV%CF)$]"(D)NK%5B%C!UQ4LB!:S<(?: P^VCREEW#1@S(3BA.9="(@3-
MZC@&Q E"KG]! (XS 5K"F@7BN5[]N(E;G$KR4^H-6& C#[3BS9FF[H#;)P>B
M R1 ,*_"/-V [C*!$]A  *;#/#?A!"Q@!,YEV#M=WN5[%Y9#%I8)*H@S%J:C
M#R8 !'ZC#]8@#FQD%^B !2:D$THD%D(DU7PJ)%=@#DAB$R ^%!K .YD1#]:@
M#F -%OZDJ.XX011F@0[TD0Z08$+\@ (\0&UZR2+F8 U*[LO^@ 68F'4_ >+7
M2S(V80W<0'3Z .+[+8Y7@#'@6YA_X0Y40.?U%G98(.(' KZ;_I4N1)\_04'^
M8 W:0.4 901@0>!/9 WTU@:IPB!"@3$VX1-$ 0D&WB!LB05Z7;O57@UQ:PW@
MX$0"0:%6X-/#E 5&/DCB8 5")!-4"B\^H4LJ:PV:D[XR804(G2 VX4I& ;3=
M6@U'C Y^"10XH0%B 2HXDM@2HP\@8 3PT@[60+<;AJB:'A36@ WHB&?<X/ A
M&IU=GO'R@.F#9Q-B@0UXWB+N8 V^:!/ PLO^ +@L8SF,L/XM-F'%/$!_YNJC
M\P )&'\B>'_CDP5$!L*7.&$!.']\)>(-U/B%?,$$O ,K", #!GS>SU_>8TJ>
M"L"O0(!*5X-:5X !)H#=)!4)1, M5V,4HI@%$/?R%  @?OER P"6KSX'?(%H
M(,($@PV^(@J\<X!$B P-0OE"H,>7!PMK,$C8Y>N/ A$H$KSQ]6$"A@FS9D'H
MP )""E]K&DQ0X:O#!U^Q(&A@(8&#0 @41J HP"*B4Z=Y#HP(@:'!)E]O%JP8
MT>"30! 2UFBP0%+"!!(=&I#X$*+ 5:>_,D@PP4&"B(@BPG*H(,O7B EB&\3R
MU2".+PD9)G#PI:)!&Q0.1#%VT/ZA! 8'@Y%H\"5K@H8U$T;X$BC0LB\4)TM(
MH"#0Z:8%'U(H6!'1A(,5'ZPR3A!"]02!%B*,,(&@1&T(:SK _/5I@0<5"U#X
MBO, @HE?$YI^:O!A10/COC) &(Y ].B!#2*J(-!WS@)?@&5U6)#!3R<$E3NX
ME>AKQ03&#$S QB\:9 ":!:T)-)8%%_RR1P(JH-:'+Z,\,,(:"DB7B0$^C5
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M(%$SOM# (3.Q)O4L*P5(!)ERX<* 3N["C-%RRAP8T!^>_4*+6(+4)NC<5:?
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M%)2 !4K M0]:!EH@"!%1"V"@!1(;$8,;!4$@!800H;P@"%"@!%90JG9+ S,
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M-8A:>86*-!L9\H;54KB0<V1^4#,?@"RYOJB"8X, J!>Q0B"( *X/F# J+-C
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MX$8$G4B$]7+$16RO\7YO1O""$/[P0 _P  \(0;8<;F/P /!0K_IVQ!.(Q&-
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M;!BCRT-:\86'2J1P!8Q&LC##%R><*$.,,02YI)<:,&O("?ZVB-HA1*MR]*5
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MX068B0%07U"&4CPBMT[IP24HT0.T3"(&AXB$KW31"!<@HA2"T$DC7H (U-8
M3$((JR-LX!Z/&L(28WC!U9"R!"+T)0;2,82!DO"$2CBB!NY15P]>B88:0,(1
M0]"!+])@05]8MS0?!%L0'[).2BRA0P'^41;>! DEP/%.3* $)&J@'T6Y0%3K
MJD%&"V'0::&&$C$H!"FZL ,P2:@,I$!##&Q# T8XJX1"T$^)R4L&&H2Q!K^A
M[UZF0/[(<'Y3$&)814-J00@MU Y(D"A#+2Q1B4I$N1*4J+*5K2SE*==B3D/V
M\I>_W LO]&\E*&W?$_(T$;2E1@Q&/(03&D6Z+D1T.AQ=!1:6$%:)+(()3' $
M&HH9'R[,F S](X6-LH*%)$AAAY]Q11>28)E*MB(+B[;2(6:LJ$/$9SOF><03
MDK#I=6G!:ZT80R%Z 09+.4+4ODA"T29RB"<LH0H"FT@NM+"$+$C"1H=&"BL<
MD0LTD @1HJ;$%!"1ZERHH@L/Q (7?((&*6R!%(] 2RNTT 5%E; 455B"%:1E
M!BNM0@SJJL55%*T%E>0"#)4<,)X&(9%<=&$)4)!4(Z"PA/XN6*H1LYY"*@(S
M:VY^!A)2F (C5L$%EL6;(4:^"!B6@ 4GOTTBAEC"$QY1!I^$8:BDJ$)\G4F(
M/KO'(8AX@A4J<08P.2+? U]*RTV6BS#4.].6G'4A#@&]GVPA$;X(@[0J\4IV
M,R$*-9>(&7K4"S,P 0R7L!$E7ND06X !6(6 'B["8*E"/($)96A;U-E6ACSS
MNG:\$/L36LV++EQ"(JW ,Z,=LHC?6$(*NI[5%;1@""(\88=GZ)\93!8IA\ I
MXK,ZP_1*(09!=Q',JCL$R2=2"6V#+CZ'R,43>F8V,3QJ\V(X@^>?P M"-+3Q
MI3?]Z5&?^K@7BTEHI+#H2#&$H?ZVX@:\5+TN9C!4U>^>][WG?4.H@!;?#W]7
MPF>;6Z3C(T@<8A6(+E(86F$(9Q*?^KZG_&>N;[KL)VG[2Y):0QX!A>Q_WT=R
MA3SWCW];(1 A"%?K/E) %_\@O1\O0CBRD:Y/?Z042?]$V?^0^B_]Y&]K?*3[
M K!)WN^O?B0 &1!(*(_RON ,_ _[O*_ZG.01YH+RFJ\ @8/Y)%#_H$_Z+' $
MA^\ D22IY@__&L\$M\>VM*\56!"<8I $:; &;? &PZDA$$%2/B,7)/!'EF\5
M/A  ?0$,HF_Z<# )E7 )F; )G? )H3 *29 1RNDS:L'Y"([YL'!(C% $I? +
MD207_OZC!R4"$69E21 .. +M,QI!6GY!2-)0(E1!YTZG=%@'#/$P#_5P#T=0
M%7[01R*!\<#" _]/2$(0"?D0#-4E"VX 740I"(:B%^@)_?9BTZ  A+#O*GRA
M%(+ 4BAO!UJ-0NHE=.ZB3E202'I!""0H$5FQ%5WQ%4\G#+I)(G@A"UP0*8)P
M"QW0YXX0%J/PJ1Q""*9$:G2#(7Z /&X1&#DP"!"Q$'^"@%)H(H)@QK:/_FY1
M:J0 O41I K?G1]Y0(G) @F;0%\FQ',V1"6W!"I2Q##@*$)E/\?2O"TGO'&VP
M%AY&"%YI+'I VQRB%J*@!H1@TWY $*I@")X Z)B ")+@4/XF(DJ"AD6FHX0$
M80B"P RR@.VH !5000AJ8 DPPQ'V;KT<@AG! BVLK1"$@ ?<XPM**!>DP"<6
M@0B(  JD!27U"95J0+EN2T^*@ I6(0N&  IFI1&28"9M+0L0 0N&P/YZ00IH
M( BV8QSI<2JILBI3C]<8X@V=;!>#$.R&Y QZT2I)D!=ZH-U0@0<L A5\  SN
MCRYJX$N:*+9<H=Y\015HP!%T <-LK2&LRQ1^DIQ<!"T,H7!8P0Q:($=H(!)X
MH:TD(1?^AQ)Z(3@PP@?8HG3<QQ<6X07,8!4@P056X;TF92/HBQ1X!:G^IQ1R
MH0R&H!=6(>)L0T(<8164H 8:@?X5@L D2X97?D E?$!,6D$*JH44=D 0=$\L
MC?,XD3/U:N(,LT 9":X07L$*4($42@$52N$ZIY,ZK_,ZI: 5!&$>DY/W;.@G
M:LL7M,-'"H,A[BDP!B(+@*4AJL"Q]L*9:),@+,('>&ES;B1'2L$UUF6H>D$C
MP&0(*C/NCH*J)((9_4)@J$ _>F 8P^016F&I5((7@$_#LJ JRL@A!J%#@D8B
M?&#3'A1XYLA0PO-$431%C:D1O* 1,'#R@J02V$*M:-0,T(!&T>!&<U2MW(('
M513U4FDXTK,]_N^%R$,UI .0HH 'T,P)AL#X>.)(JX8M*L(7<N!S[H0M=J">
M3"$E'/Z"$)Y "C(+3$ARSR+B$.@C+C;M:'RA)U1#"-","7@@/ Y!98( >K+1
M(:;)(;K@?-+'*H1@"9C@"50R3%H$$EAO/7]T41FU45,0$3#G#*; ^'RD%AH!
M#*2 "A\!$B#A$3:54SGU$2)!5#VU$:1 "QK!W1S5R] @D]9E!L)(",[O8HYT
M!Z3C0EQ$W9)C)XA"AY!B"+"B2HG4(6[@<;;4%[I4)<S@!BQ!)7J@3>!E(DH"
M,],T"#;-$*1@$H8E!Q9!%UHA%W+!#C_SMT+H:O:T"*OB3T'16\&U(?03.!+5
M1U=U7NDU/ ]!1JXC2!X!V8J-$ Z!$ HA8 M!K="@$/R5$/X.]A 0 1&JX'&D
MLEZ/Y#'U5'R4P+YHL7#4\U8CHJ*8K I:!/BR1Q( DPJTC5(:P1(D)$?6LU-P
M(82J J%4@D"WIA &PB@2E"U:00FBH'G 8%AR(0E:H;\D@@9RQ F\XUS!H,-&
MPC1\U@ELHP<RK66JR!DAMFJMEAS[31 $@0F,C@WK*4@B00WD=2(>H1FO-G4:
M0:M>0O=D%?ND  @V#40<@A&.PC1X8 J"  ILJQ6"(,^J@ >"U3LF@0F6H%2T
MM)Y:P0=P@#IO8 JL0 R2X":&@!J7AD*J]3>R( :8K"F'X&\M(A><M""E ",,
M00:F8%J$KX.N9"%X00J"0 IXH/Y[H#8^YN@*9, KSS9W=3</>T$,K, +<'=K
M/LT,QJ ,SN ,C!=YC;=XD;=YRR!YS> )QG9W3:<6'($AL^(:2Z%VOC6%*DD5
M&F$6B0(2(J$7:D$E:J%E(2%DY)85[B(72@$C6 8P<L$VSO?6VH07SK 54"@7
MSG#P&L'6 %C(5L$G;(')=.%W<J&22*$1C"@K4*@7SO 5F(QZ+?B"GY 5R Q(
M>,$4+.&#03C*0'C*0IB$0=@4G!.#GQ 1;* ," %.'U:%97B&:;B&PU-=.@L,
MDHT$8]B&??B'F9#\TH\;@;B(C?B(D3B)E7B)F;B)G?B)H3B*I7B*J;B*K?B*
ML3B+M?YXB[FXB[WXB\$XC,5XC,FXC,WXC-$XC=5XC=EX]Q3DC7NOAT_/#LF1
M5W?1]'(AA0G0F^28;?IX=6ABB&F1'O^XC6DP%7F@!WI@!SR2 AV0!S@JAN\"
MXSBPDN]82! AC(@X_Q;PZ#!QCXDXE*GV 8G0D2T9%;I6D \!![QCSP1&%X;
M792$DX&$$8QHM>:*B L!-<K 8D19D$.Y(0XA>?C/E/U/"X)7D'O!#'V!%&Y
M51U"$(;%$=:PE"_""G"@T3A"")X*$52):B\9$(_T71O0F'\9G(F8":K0D!.1
M%V9 $$J!-:S !BJ82#)Y=68WG&9 R$:G"&L%"AE!D(8$?OY\Y ;P9@8$^)M
M491BH)J1(@VJQ13:$76D676JM)A](08$IA40(86K;21G]4A(888F@@I:8%/F
M(W668%/BL/I^()7960]Y@096D2$2ZC@,81#"B!<HH7\Q0Q4L)<D$(8P"U%*
M"FSZ!Q(2H1UU 6%S 2(G0A<*(1&L9)1ZH1$$(:%_8A L+SXL116&XA%R0+@<
MHKK21HR^=<94P156X3O5I1(2H:M- S'(-A$<05W"@@[S.JH!1(!;@1 ,@<R$
MNG]L@1029L82)FHDHJV_*(96P3L90256H0MLR04_DQ ""!-V8 RZJ1<PX0?
M@#1K0!64>A8M(1$8 70*V!8,0?ZN'2(2$D%22#-H>V$2RI(4>*$0:  1I,44
M!*&CH[E#:B%D+.&W;Q$X?AN%2,$62F&I)T(2S( 4%D%\)*(2 I2J4X@\(L'0
M!,&U5440*.TK5F%Z>L&ZCP.P?8(7&D$'!.'(;*,4!!BH'#,C;M,46H&0>!IT
M)"$16J05/.L1ZEF$2J9]7!6U"$$7& (R4VB'*"&N+:44TKH7+$$)KL S5L%2
M'B%P? 3"<P&X;8$0!B%D.EP0A RU7#L7#@&[&0(S),%D*$$04MLA?. 13COY
M8CH)6>:XB8(&&FT57& H)J$WNN &;H<&6@0-8&(20<F:;D""=H"/9L [*I(@
M(";/&OYB%78 "K!@21T6;&Z@3G@@WE3!!J@ "Z:@H?_/$-#2"GC )ZCE56_'
M"CIR2@SA!I*VS:=%(8: %[Z@"*1)J^J'!\P "WP 3%27%N$,#9@@>;0@",3@
M)51""R"&">2IF7< "\# H#<Q1L# !J:D%&*D"VI :"K*6[X\FKX\[NP<"W8
M,,  !\Z"D8%#"'( W/:OHO#E!OHB"VB@;45)"W1 " @A;K2\8!(%#(;@-)+
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M+?> A5=AA<FE$*15@ &#@L#]6/J$=+:G<V(@38< !54 "9; !;UP"%U3$*K
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M("$$*:<*3.!I9D!0$I<%\C,:)?Y2"V<G!$A!"E3P"P5QER5A!41PF&?C+XP
MF4\P3G99!D,0!+!'6F10!%:P"H$I!6^T"$M !$]3$/J"!4.P!(0C!37P5$'Y
MEK-)F[7)BP4B"059()"0C*9A!H(5"751"FI@!I$2:@5Q"7TSDK:96KQ0 X+
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M!NNH=6%0!EU;NG[$"Y.P'BC6*Y;4"Q>Z"HA@)A>:E8U ,ZV@(KC@")!P,JP
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MJZ9W U40%\II>WY7**V$!3=0%V-0W5#@!&T4 R52"#70!?%="9>Q%U?@(63
M V6 !3[0%UH0!&&P!."*8CS JS=PD_NMLL01F8]P V$@!K(ZHUB  \?X'%F
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M0!*EH!'G;("(4F0A(_'10B7,\(*)]8 )IB#%$K3@"Q]LT!0>Y%P,#D&*,-#
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M-E2H%8/X0QIX! O1A5S0B!H<B434C"2 @CRQJ)JY 3Y! Q(IB%IXP2,4A/[
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M$+!=R*%C7L- !@+(P5#T"Q2G(<@(B-4!UQ1I :-PX7E6  %!>0 %,O$:V#)
MI$S8:"$@"T2'"' 3H\RB!+& !0)"9X*/?"(Y)2B!G$*!@%G$(@&.D@D;D*;$
M2V)R9C=:R"8$\$>YQ*D@OX  ""1P(P0<QA?RZXSZZG _0C'M)078!0A@=1Q?
M? !##/D L60R!YF-*I4@D:!2"((!T3!@;V712O,(@IH&I/*-:$'A WPA!\19
MAUB%>QH1"8*'=OE"*;LH0.A\<?Z662A@<ICC3R;;Z<Z,-6HD;D")NL[D .GX
MH@W@K(UU=/F+ U2'> NAQ2\^D8!?B&*,OBAC =&X%5GTH0"6P@ <T9@P"1IO
M/ O F@(H* '%+*0. =C%5D)GN^E8<2=6V<J6$K"[A7+@G3*=Z8!(T$N"(*!X
M??'%"JQ2%P$LX"P02,%/%/ 1-YCLEP3I P.. @ 1W.@#%1@/ ?Z@E;3X@@.Z
M'$DF\/0+,8ID%@=01$-P11 (E,T7%9!.=T3Q"T8-!(2S^(4;(@ ?!,BA)V:%
M#$$H5Y8)9( .)4B >!8@Q_6ICVL+D8!H.E"J7WCF%[-  "AD<0 X:&4"#J@G
M33M++OX-/N43"&!!S62" @?  A804(RYIC>2"K 0*JAR(0.>PBA8B&*6PCJ+
M+Z2255B!419Y -JRB,2!V*I22Y -0&6ZFHGIR80#L,J$ $H "EC@00#2$99)
MK]8  L(B PT@Z<J>-<GIB(:SGETO>X5'U3SL8A<LB.5<W!#3A;AQ>H$HT0A,
M4*$Y/#$/&B#('^3T"0M@)@(4L!0>'D !""!A- 1TR-$HX( )WV("^@&+!8*D
M@;U]@$@\=<"3*N,+67A  A/0,$&P0IL+5,<""_L#!A;2A@_T805BVL2*5]P)
M]^8A POA@%IH\0$%3^ PLZ# 0/[@ ,"J8 /MG3*Y9 $""/Y,H $G4*^99,$!
M!C @ XYBE,<(\@'2&D4#$U;! RH@S4](0"NF)(@*5D*""7,I%K\H)0;6X(;-
MHB#"4/G  RZ4 4')H@,*X*-,]H#-3%!  0S@U$LFX+$5B.</Y>$ 'BS0!EE$
M )(2\%A"RTSE4Y_Z:)J! */'!!9GN7>*KW;O+!14F\IB#2((!4ZL<]UKOLC"
MK0V!A:7XN1:^U$4G!*$ :<-B:U]/\5'/?O4GH(+J:YMI%KC^7FHG(B"P:'O6
MT3;*JXT2"]ZJB]@2PAH%RF9NC!F[(5J!BK6G& (T8CO?[ W%LV7*90/]>R*Q
MH  %1D !"_#V0?I>N,T"7B:'._X(X@\!A8CG\HLWN);A&M_X1:Q-;E&.Q.,A
M'SF]20YRD:.\Y"%'N<E9[O%RMWSDBYJ#55=^;)F_'.0Q3Y)[55YRD>_\XTD"
MNLN%SO*@]_SH14^ZR9%N<Z*WW.A-7_K3<:[SH?>\%]$V$WSJ[?)CYWSG4S^Y
M*(D^='(#'>PWQWK.I9[KE#,=ZG"ONM>C'G>KS_WG>">YU.7.][O7/>]D#_S?
MZ;[VPNN=\&%//-N;SO''0S[RDI\\Y2O_^$S(80Z:IP/G-3\'SM/A\Z$'O>@]
MOWG2BS[TG]_\Z4T/^LZSGO6DA_WI8?_ZVJO^]KA/O>KE( ?:J[[TI=?]Z$>_
M>M?;'O[UQ?=\\'F?>]L+__BX?W[NH]_\UU-?]L&_/O&A#WSD*]_[VP=_\JO_
M?>9WW_SC1W_XP6_Z.<2!>V6"11R.GWS>UU[ZW.^\\=G/_/?S7_X)H/3M'O&E
MGO6M7O,=H  N7^Q-'P,B(/N5G_;]GP1F7P*NWP,N8 ,2(/9!X/EIH/)%8 B*
M7P62H/J9H/-]X/I17P/*09"0A"CTP1_\ 2#08 W>( W:8 [FX [B( _>H _:
MH! "80\6(0_ZH!$J81 681(BH0Y"810R(1 Z(1%*814^H10>H1;^8!=NH1=V
MH1,>(19RX1AF(1B:X1**81.>X1I281M^(1S>8!^44YG,POX,OF$>&F$2BB$?
M3B$::B$9AN$6NN$@7N$?<J$5QJ$@%N(2'F(<@J$B?B$C0F(D(B(ARN$B9N(D
M;B(FJF$E^H$-6=XHDF(IFN(IHF(J[E3BR9O,Q=K9C5O/88W0\5/7R6)MT&(L
MNF+969VQU9OPY"*RW2(PWJ(P[B+/U9TOCELP^MHO7MW-*2.R,6,TSF(Q-N,R
M6B,UXF(VOB(V]F+;Q=N98!TQ?EPM#M[A$2,Z6J,SYF(Z)F,W2J,WOJ,Z/F,Y
MPF,U]N(];F,^TB,R0J,^NN,_]N,T F0]]MI <B-"\F,[7J- JN)#0J3X2%Q$
M4F1%OI.X#4BM80UG/ A'RL4F>/[D7,""J5ED2<)%QF7.5_$%**"D0^P+Q'6;
M2<KDQ@T%@<A$&P1 JVT"]NBB/29))SR2FSCC05JC"!A @Y0C1@XC-W[ M/#<
M4B;E3$IE)V1 !$! Q<U,702 =$!%I$B$' 0 D?AD-8K 3<G:6?[:4DKE6LX,
M*&A 9HP K\E%&Q" !-2D^\CE17R"8,C% ?R83?I""+ 06Q)F1<0" JP */0!
M %!0S60" B" #27,=CR$;7! C5T$0Q7F9M*4+!B635C GDRD1,C$"GQ !@QF
MG0P%'%C*'PA*)N1!)GS "KS5;-+$)@B$"GB B9W8&H# "O!6'G!")I@ 2N["
M"Z$ 7O[(P@KHAD[-P2>X00<HPB_H6/&( @J  !PLQ'-&IU69YL* 0 K\07@4
M6R"(  CLS2S(@2RL@5IX@NTH$&>B8FEBIB]P@D[-S!],0,X(3P,8![APP@*(
M0GYL)RBX@0?$YVOH21^@ +' )BR0P(]=)PB(QLFDTA_H 4%\ I%\ @F( &;)
M9X@6B$ST@<ETR"P-R IT0"@ P&&HYB\ P':4@)#!@0",@&=8 (4ZP-7L9)_%
MP0%(ARQ( 'J.@ 2<A0<TP+O0PD+(PG?@ 0HHP"?L G.*0'5 10-  !NHP )L
MP!JL@0!PPDXHP K@ 0;\C0,\ !NL )>RP)<>1@DHP C(@?YIK-$=)( <W,$]
M'<4!) <>X,<:Y($%U-AHBNBU50#-?8 )] 2AQH5,!,("R (#$-!D5F9P#-AM
M",\"2, :>(EK;,H'R,$'*(!K_&@7?8)HL4"G70TC&1,#1$4'H!,;Y $%"%FA
MVFJC0D4LE, 3S07/K*F8#@7\^((*7 T=-%"+%(!,^('2@ ( +(P?'( +#1A!
M<  !B<!F\9,,+<0(3&L"?!)!/  ^08!+4 !M8 "+,,QA/,"$D4RQ2(<(6!(%
MT*8"V-"U= 4!5&A7 <<>,.JM3AD&6 ""EL !A"G-U$4!C < U V'N,DN>"5_
M&(4#L$B>(A9(L% =^!%!7 "Z,OX 4.Q%+("0?D 3Y+B6K?CKR;H%"20  A0;
M7)3F5 W/&A 200GK*KT!$=F!HC"%0GP" [C69(&"!TS ")2E PS8&45;GXE2
MOL2' L#@@EBI#A7$,?G" G  T99  ; !PRR,!#3++V2 ='S 2DP/"W1 ;I61
M"(B SXC5HO["!R" !0#GUJ$LQQ'<0JA ?=+,8]*$"%B%?T*$'PQ &\C!ES)L
MPQ3$':"$!;!!DJ2 8A1-0=!" W0 T9)  :!-)C#H&L3!I@Q%!QP !JQ 7M9M
MZ5Y$+(A""DC DO:J^F3" =Q! YQ2S:G GE1+7K0+.WV"OL#'9(E"!WQ 'MR!
M'OS!3?[$4=).ZJ)L%"U\34,X@ 1)  59@&@HP!KH 1[H028XBMZ,C9I8A]B2
MK2^8K;#< 1[@06S* BPH0,MN0AQ@@"29;N2)[C)E@O?,3" < $W0 @(4#7XN
M1"G9CG!\Q"\XP,(H;K%LK6E!KLEX#:">;R;@!0D@ 9D&PHWRZB;<;#K%[P9+
MQ!WH5./0+4E 2#=MZ030A+!NP%3$@?K<@:+X@A_(#"@,P,+T0;2N@?JT"(=X
MP $Q1!M8$@CLR2PL  3Y @0LC-3Z0@8TB$HL!&L6\=X44Q+31@G$JTX(*W<4
M23RUB++Y0@((2K]R\"7)!!U8T@H(&1B_R7CDT7XHP)7H'/Y!6!8?]16*%K W
MH80*N/!TB <=3)4Q<7$<K)$?8  'A(*784!EW,&$^4).A7 8F^ZOOL21H,_Z
MR,P<.8  G$4)<$H**("85!)!S$'E#)<O=(( 6("?8>Y?80 =B$!D)K%3^H0%
MV%$("*@Y"<#3^L(![ T#B-BF=H@"B( <8,"<409!-,#Y3$"$?< !4.@'+("C
M',P*O$$#?$2AK-%.% !@C$ #U*$CYQO85H!@+<!?9N6B  !-R,0(! "'K$"[
MR(0;9(4HW8( B$8!\ $H;]2U@*H(% "Q_-E(&-0(,(8)P\<"N+ &Y"\VC\ <
MC, #D*0WQR]\F(<;K,$"I,N ;/Z",G7('$"%8'60<60T0?1.QE3&+.Q08A3/
MQ8D "WB,'P@3UL3!2GO,+]P!2>*!I>0!9^S!7\)"8L2!4>Q07W%&'NC''V3"
M'XB "IS7)J  ">R-+-1!QL'"7ZA RT*TOK%R56M.+' TD\J!HV1"AJX)91($
M'QC''83.2+^&"H2 47/()VAT3XO 3Z^)',.F'E'U2UUU&/_"'-@4;^YU8 LV
M^*#Q8!NVRT+;,Z*E/[+C4X*+WG6C,J:C*RJEVP&C8U?C4(JPM^T49Z.)>A5V
M(R<VUV4V6H[+M]DC45)VW[WQ9>/C63[E:+=B1G!9:-.V9Z<Q;I,V:78V;[N:
M:!]V</X+]W 3]Y35FBCP&W(KMR@L-W/S6W(_-W,[]W)#-W5/=W0W=RA@-W9?
MMW1WMW57=W)_-W>+MW*'MW1K-W6#@GE/-WNC-WIO-W@W]WIO-WW+MW/'MWB7
M=WXSMWU#MW^W-W=G-W^SMW@#.'(?.'D3>'.[-W8G>()_=WLC-X%'-[^Q))KL
M@GW'RWO?]WY[MWY3N'N_=W4W^(#?-X,O.(B?N(>?]X;7=XF+N(FW>(5+]X.7
MN(JW.(K?MXW'=XSC^'B+.(^O>(I_^(XW.(3[>'^+^$-G1!^HP!JP !*P0)M&
M.95/^91#>95;^95GN917.1)(>9AG>91[^9AC^927^9=S^?Z5GSF;MWF:LWF7
MM_F6O_F<U_F7ASF95_F8F[F5IWF>2_F8AWF>XSF:(T&?R_F6(SJ:S_F@:[FC
M@SF8[_F:QSFC4SF@;SFD,[JD1_JB:SF?NWFB"[J>>SFD1_JDV[F?GWF@<_D:
MI,!+DPDH/'FIMZF75SJC@WJJB[JAHSJEA[JA'_JO?[JOWWFN4SJ<T[FJ9SJI
M;_J@<[JB"_N?J_FH/WNA=WJTS[FG([NF6_NIL[JN6SJ48SJU$[JI!_NM([NV
M-SJS=_NS&[NC3[D* '9QTWN]V_N]E_/>1?8O)F-2HATZOJ/*J=V^_V-48J3!
M:Z._+W94RIK<,?RL^5QD%_S$%_Z>S4%CO[_BPU\\0")\6JHCQ@,\/H[EQJ_+
M/FH\OV=C._H=R:/\QTMVRV_\P7,\RP=DR%_\R1,\9<\\P4-\SONCS2M\S/O\
M8@^CN*D\S8<\0>+[THO+O\^V0S)]U&-;:DN]KM7,'0(W6\!7U8_H$G']U[N%
M95K]TT]\/?T"=5 \M/V"GRKENGF;,1JC;,=V*_Y!K9J]VN<!7H2" W"DNJ@+
M!RB0B6R=9E<J.2[48*8B';3I&K"!&\@Q06P";VZ"" "^;>_4"C0 DX=4?SB
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M! ]@.J B@4RP4M+A,$#BE^Q$4XH-"93:I8"L4.!@H0P@\%&"RG[IP($0.&A
M,_DR6+&S4(4=EMABC3TVU%CJ&NB-2B.]XX&!%N!CH#D ($R#0$-00*;/*!3A
M@&5%@-6761#(PY<U*,@D@4X= )"$@;X;R $Z?!$!75]*N,^7!6P"!8&,4" 1
MH@T\0R J!7Y:(X-[&_TLE%@(*$&@#C>< %T'6B2( /(D" T_!ZH31;^!.'#
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M*A('E*DQ<[]8@/$XU$/\'" V7,2 #2WP  M4  .M.I5E5)62=6;%G;Z@@!L
MJ0(1:1$JOF"0+Q3P@5#.DC (E>E,:6K&3;"O7 2(*7.:=9+/T"D.KAM(')[2
M(Y1H0#,<@)U ($"A21XF#A;81 %"![Q'#B1\DYR#+ 3 /A+ CI@VR8, E^(9
M7WP =?Z[8$!L_H"!-C1* G2JFBQ&@<>!G \E$F )!&;DBSL, $4'P*E5$-,'
MLE5+@*" Z$ JT 9?0$!\OI"8)_04KU\T<4W<V@3V2E2 6,Q" 5WQQ0K>B1((
M.)9-HF4!K%J#DCD(4 0A&$@F%%:H96TB*RRETPA 5=-C;0(!:%%*"32U"P5$
M]K&.A:/9.F$ \@A$ T53#!O.24'"D$!35!O(KWQA!X5!I0&5R6;[>.A;\YX7
MO9 22 F@Z9D#J&FYQ5%H7P4R @%:RP2X+0"=1%" -WSB#02@+'T0DX<#Z.$3
M*5C +#91LA4X@!:^0 !+#I O!DC2%Q&(PR[RYSX%9& 6G_X9@54JH 'MV"@E
M#]Y$)D8P .-5X+T#Z<-^/[$& \0B% 38$'3^L DV$" %O^#$ CC@ 0TP@+(K
MZ.0F.C"!ZOP" A_XQ%A%=ED29.(- &C1G'"I@#5\X@X,H$!%OI.)6 Q@)!JX
MP(HA<!]8$$"T*,AA[*STYF6E8**S:, )IGP 2=;! 'WX0P8*$!\"+"L3 9 #
M*)[F%PC8*[[I38Y FK<4#*!%!*": P'JD(D/-*"\";W7HU"2AP#$XGB$$<@*
M&) 8#6 @$W<X@*8X00 Z?,(- -AB"!P  @ZTF2 %N$,G5H" #4D:V<E6-F38
M5((5RZHHS(G%!]@'D0_\@@X8F/X#!29@K_+,4@(6B%,;M"EC#)RG*TA H D-
MYVQ][00%BI@92_J0@0R(9 -^P8,%Z"2+$E#  L%"R2[P_(%,Q*%1=7BC;L[-
M@9' 8@3EG<,%.( '16A F'?H0Z':$E4*E"#46L&1"/" *)AXB YN0%>\$9.)
M)86E RSA []W5Y%=J*".&YO%"#+"/*4 3!:[$$%&\.!8K8  X QM P5 T <4
M[&(7(Q"F+]I:@0I(TI\A7_:D9S@CB'@ +7,0^!TJ, $0')MS)3#233[ B5OY
MCR"540HL/F"!-=0A6'ZP(QOTUW(YS"(%C>K#N3L@VJT?'O'*%@72)\#SC0K+
M#:Y1ROX&EIIXX70@>6Y07'I+D()0_<(#RK7\Z&7J!PS\)!8(*'=*(DUZU[\>
M]H]'#!WFC!@0]+4QK6^H[%G_Y-5,ZC$^->ONY9:)"5A= C$5OA)UK_OALWXT
M7Y,W8Y:/&-%=G_4RC#UQ_ /]YWL?H?'MOA*5\N2*E0 "%H"A\[???O<G?OG#
MM/Y-?N)[.,IM_JWW/?C'3WP.83^:O@\ R\A2#&^YJF^CQF__Y ;_&LK\G@\!
M'?#_P(_\")#_+O!4+# #_6_X]@\"=V\#/Q $%Q $)0,!/1!SXH_WRJ\$>6\6
M0"'4%) %0U $:= #!W $<[ &18,$OR\$49 '=; '$U ';?ZP!&]P!X.P!H=0
M Y'0")?P"$40"!>P^MCO_:X0"[-0"[>0"[O0]?H@!9!@!<9P!5B #,^P#,WP
M#-5P#%F #<LP#=<0#ML0#=OP#=U0#NL0#\G0#/>0#]?P#M\0$.LP#PLQ#OGP
M#@E1$/4P$ V1#A%Q$!6Q$0VQ#Q-Q$2?1#ATQ$]6P$AW1#P^1$2/Q$2D1$^<0
M#2_Q#)% !7:J6$ !!4JQ$_]P$4\Q$35Q%"'Q#T41%&E1%W7Q$WVQ$3EQ%_M0
M#X'1%O%0&#]1$)5Q%H>Q%DG1%Q6Q&'$Q$W.1$*L1&WF1&N,P&2UQ&K&1!5(
MN8A#%F#!',\1'=-1'=>1'=O1'?[?$1[C41[?\13FT1[O$1_S41_-L1[WT1_Y
M$1W[$2#_D2 +4AVCS5A^810,DB$;TB$94B!A(2(C\B'/<2(#LB(S4B,WTB(Q
MLB/S4;B\4"1'DB1+TB1/$B6YKORL<#7N;S$:\/>6@R7C2+V< S)F,C+TSXQP
MDOI6\B5;4(VZ#Y": R8#4#B \">M@R=MTH:6DOR(DEB<TC@ ,"6KTBK-1ORN
M4BNWDBN1PWU"#@]RRP0%0A2T#RJ+(Q08J2O74HE";1;,+#'>\B5FBX<$0NLT
M9Q;N8'_F0 [03CGZ8*>FC"T'<_2D:2>4,ET"0/3P(P!(#05]+Q-.;XDF*"F!
M#RHL@/XP-L$"(NP)0_ .A,H)G9 ""7/[,H'4G&D![@CW4%,U;R(#=&DGYL#K
M:B@0 F ""$3]X$[V'M,'0R0 U^"P=A/Z-+,H#E J21,YH\\B&@ #7.8PFX.)
M+$!N4* !-(CW1&<3$D YRJB"!*4#<](B.LH'>S(YM1 4W& !G.4.#"!("B"R
M\*  %&*J),D-)LH-8"46QFP%D44@IN,N@T\RN N0W$ \(P.X9K \$Y180$$
MC <%G PJ26L"LD(6&J^]9D$$ZJC<-D'-,L O_F "&  #/N$/*F,/5J .7DBN
M?@$%)  #ZJ $YO(7^,0"8&<6.& !(ND30A368.) >G1NXOY@#2)@ N(D%#I
M D0 #CIJT%XM$ ;"!/* !"1@ T3K$S@ X-;.#2R@0(Y30=6H#SX@ R1 ("3@
M#1 C508" LAH;IZB! X#1'WA!)+'AC(A.AA#%CZ@+3A!1$2! SP$P]I #H9T
M I2OBN1NJ.J&#0B$!&(#%#Z AV+H$RB .=5D$S;@ H#4#804 HKT2S_U. (A
M-UKB3JV#9E: 7.8@ ^A 57YA DX@%#)AH4I$ >8@%.[ <F8!/?- %@RJ0@*
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M TX %D!A6F4B$QC@)^+ -=C8M/#" -H"8*9N%A8 !>J"#32#F B#$[Y+ T@
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M>"C EV(.^J Z=B$/=GF]?:O$42(3YD""8YP59<&F^[LI-?X\)< X,39YX/+
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MXPG@[K-%#N".A[-L*'[1'LN/  (&"D>O?V>BK;  1K @ *>VMK\"&K!$LK!
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M$:!P/H;Q!FLK B- !W];&G10*J3Q"8-31R20)X]A1;3P)^/2!T.#MD B"P7
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M[#T*Q@[+IN'0+* "*% !$?T+($<N0-8B&&8]OJ!:&)%>&%'>IH%I$@ !$C
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MID8VB<4"+F23-A1 )*"P0/ L\!NGA&(""XC%)B3 E \,:1<@@( %M/04#BC
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M4#B2-U"6 14,%F"S/4#-B'10I\B$"! %#* %"P"C!<F .6"#.[@#%:B=P&@
M3^@ 4""!+MH-F_" /"307;"9WPL1UL"#"X"Q#KB<.Z@>OY"NC;%$ZY&##F
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MDA4@#;782I_4314PO@=UT%_  !7PC)" F@KR@ \0!5$H6#"QB7'-ECH8 0S
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M:XH^\ RA3 A_XM=^%8T * JLX9EF4I8W>DM?\ , $ E10/X 'TG5C< 442@
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MQ*_QF@H3@-*M* @\0( PI@JBFFWXFB\(T(^\^:ZGN("WV?[M!).*4+" V[(
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MCCA0 14(A-U(@6G$ ,(&!1#X=OT1^#Y%@88J@3_G]8['J[-F0<*@@XF !0A
M A:P /Y1G 4V<(,V$,(A*XH1P(--@!J8DP4/$ 6OW@3E U)1^ .:YQ(+D 56
M7!5[_H-MV04,J(_^M5;QU4<5^ 5"11IH&@'G0($YR ,+R-(+V-U9@(6SN4J&
M(@X4X E[]@1[E@4+B(7+H!8+."C=X2 *Z8.TP !1R.@ZDP466(-U]_B^YZOC
M?( '_LD..)>9R8,\$!U9X- Z2*8_6P,6Z( B MM=F(,YB(,^$(50Z0.9 P4Y
MX) 3R 05P.D5V(,U,)B=3P@]:(,\B&B0P(_+]H30<,454 $\N /#Y("-1('V
MK$(Q:YP/2"#2F(.24($_6($%80,\< .BF^4$^H3=SX"T(/ZCM:--Y?/[Z]>K
MHAX%4""430@-[<ZD/A!_/V *$9B(%+B#3- =63BC6?" I?#J62B*3"AJU_$%
M]#$!@P&%#B !ICC!CP ($GSPL/'URY<O$71\]2$AZL/!#G]\90*%!X2O61E
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M)E0*1BK%)<X$X5! 14S WT! )GP"2FY"7O4!R#46!FR'$DW$+(R1+Q28B1P
M43E0)O3"C/Q"]='CVMW%D7R"P(124@;"$R+<+6S '-S"R\3(+BB"35R&*/#*
M\,""!VR'0[H+1GI (.!2)L1(G-5<2VR'*- 9/<;(+ R(PK"'0_YC63K5?IF,
M+PA94M#"+H" '.P'1>0**#R1MG "50IEK@"-Z[!*)F 2T%S&K "D T% )^!,
M1&:$K6%E**:2*& (]X5"@DQ +'"0\( "-=;231%(9Z*&0/XU9H"P"@FLP2Z
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M D\-\,_(0@- EH;TP0_3\ZS@@2/GP>--@&8]3TF Q!HL@"S(05// @/L BU
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M" @-MGQ""XO6=>UA"-#J4R4^*.29'(Q"'TC)'SSZ)\A!'_YL0.?2A!?E@0<
MXLDR'KL\&K7O<\1^P-V^P>K[1!ZX1^QA$K6W77'<HW"40(@TJ.MO*2P0!\"R
M:A_82L_# N6P^I=0("_6(-I>55508$0)(1:Z(3>94U5,H5701Q1RX0Y:OQ<F
MX?63?_4/(?FCOSIQ2A[TP;4H9-BD/Q3?X3D5852,4*VLY_/O?Q92!?77($#X
M\O5+8$&# P\F5+B084.'#R%&E#B18D6+%S%FU+AQ(4&'!//\>>A1($F#)DL>
M-(E294*6%%\B/!D194R%-F4R]%CSUTN<'3^FI.FR(<&?,&<23:HP%ITXL'QE
MPJ,TY]*+/JU2C0@JSIQ=$F.N+/Y8LR)6K1S1IE6[EFU;MV_AQI4[EVY=NW?Q
MYM6[EV]?OW\!!Q:<\>A@PX<1)R8\5G':PHTA1Y8\6>-CQGHM4]:\F7-GSY]!
MAQ9-$9:LCE!'IU:]FG5KUZ]AI_X3YTVLF7DV?-BPR=<?4 WSW'*X2456A2MX
M+U3!^XZO3REB1Y<^G7IUZ]<QAOK%1I3*";-\]?GP2\2:7[M^A1*8Z;>L"G\(
M@LI4$-8F]+M^^]KTZ>2O3>![DD464<"3)1.C?A%0E%U$F0 6_ 3B)#_]DL/.
MP@LQS%###?6"98T*Q_( A0-]"04##411@0,5=@&!C1+ZR,2!$GZ9 X4U5NA-
M Q8LF/Y#%!-\,>&$$=9 "(4/5+"@$U$P^."/%3K9I(,5. B%22>1PX,!.C8Y
MP1<5UD!A#E_<6$$%%'RQC<,UV6S3S3<S!(F%.[Y*J(T/)AASC:DX&%.6/W:)
M(P1?/HA%%@L(M" 0$'AS(PY03/@#A('D\.B#,?LH(10)"!)A$Q$X\04/%#;M
M=#X.]"LA$PUF$>6!%MFH[Y</P(/3UEMQS557R5B*121?8''@ES6:\S1-%%A8
MHP1?.H@%% KB<'03#L#+XU$5Z'#CLA'X"^6#39;UI80_.OA*%!$^&4$@$@Y$
M=9,4\- @VCAD&;8#%3+;5=]]^>W7WXM@>0#03SA=H4@/ O[QA8X-?)FC U\R
M !0#J-S8Y0T2_L!@CG0_P0"_#BQEX1<W6 #E84(W$?.7%=HP62 0#J1@ED]!
MT< 76N)8&3P)/MDDWW^!#EKHH=_<Y(,/.A!I$PU">8._65 0TP19\O @J@]
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M+70A"=BO?)Y@I0RB%5P@IH+ !W@ABX2 "'I!$&*@%'+ #+Z ],B@!DZ/"'@
MNZ( O\)("V*@!R#A!WX@@K+@!J" "JE  5^@"G)A"9S "80@%Z+ !I: %(A@
M!P)P"6VL"JY  5T@"A90P;" #&N@$J0@!IP $FS@$5!/")+ !I6 !Q1L+51!
MQHBNA*" "::@CSII"<Q "\C >@P!NQ(B%VA "03!# 3I!W8 O\I0MFIA!GQ@
M 1_A$6)@!YR %6K@"0;0%[AP!V2@@ +P!F**%&Y@"%[0%WI  M',%PHA%V^
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M3FD5/%,ZS4 7J( &6H$*]-(*2/YO$1 !RA AMC0*[ R!!C0.$@3!!1[!#&"
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M%Y1@EW3 -#%AS+JI7$47AA_A"<<LMV*+N]!W()>@!?GL!0C(DT;/?AIA"+0
M/76!!G(J"*[@/0_I!TYL+91 92TB"++5("ROC\K@!2Q!!W+*!ZI *"%!"WS@
M/>\H",2,#.055\T(0Z\(/DOAB6K@$>!/@BR!!H;@"YQ@!\AI^$@VC [5%Z#
M'A^A=7V %L,(RRCA@%$-%Q8A!D36"088#"PVF"AA!J#@!ZR5(2YYLU(5.YW
M!\HL!KY@",PH%WZ@S+RO!W?3D7S@!5RA0B'KO%8-%[.@$IA $K8.%;BP$8(
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M"*IHT!?(T7U!$*9@U<_<#)RX"DB5="E!"@2I$8Y T@BA!SIU+4H;HL4 "J:
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(N\B+BA$0 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>67
<FILENAME>cogo_0021.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0021.gif
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MZ/#O[^+M]NCO]_#O\.;P]^[T^>?Q]_3T]/'V^_?Z_?____CW]P
M
M
M
M
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M*R=$#8<NGD!]01LT/8L !9V88'0:?NHB1P<69$#X0"R4<((K=F20]'0!$."
M3W5,*FT" &"3 A*0,(+<(@('Z)E [%" !#R >PB0T7MN 0$%#&!8#S@  9R'
MAP)<3!>?8)<!)AB!! Q@>[KHH %*D+,6NO"%*#$!J80V%%;XP1)2:D%ZY#.
M 8" //Y^$,  )E ! *B) $=X   .L)TVZ"(- %@2 $DE #4PYA8=Z*%\"%
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MPQO:.(!F?:  "\ #*^0PS@SHX@-JLH,GCJ ="M@A$P<<("=V40$#\"M=$$I
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M@ %(L <"S/)$TL;P&@! *9F&(&D?2."P4HH # AD%AXR\T.33)X.'F #NWA
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M 0H0  !0,[8(+>VC'YFE"\EEH:@S3DQBBYD(;FPG=0?DEN;98 /P ![B1WI
M,,I%G!I@  )0 &817:YD$+>0 1:# !(PI * ?6_% /E1.&DR &HW=0K08 G
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M@$O'.A2?D!P#@"DJH"8L)%'&,:X'< !L8AJ6( '*H1X*</XUF#"RR&%C)JL
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M(0JB(!91$ 2)L 2,(!"U, 5>4'?P7'>B$ .( ,2C$ 5=H,-4D 6L(1908<-
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M S^@"Y-@W$^0W*D  T@0 U<@"2_  P?NU$UP \[]V%7P JF0UT$P S$0!3O
MX:+ "#/P S<0 S=0"Y'P CL0X;J@ S?@ QQ.U;T]XQG%$E.0TE,P [@0"4&=
M"C- !;4@W^,<";E " ?-""\P"#X>!+2@"#% U>5-$$/=!/4< UZP"C$0!KHP
M",K=""^ "&,  Y0@"Y,0VZIPU?L- X 0!C$0"5$."86@"[%PU:EP S? "+8
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M*(%_4Z1@&UQ% S[7=7UZ0$&_! _,?V(7"L#VV/A$%Q5.L*\]H "T9(()*G"
MA9_L6 "]%1:P1(T2$N1P* '! S%$$4<DL<2Y;GD@!>(X.2 .71J(KCKJAG+
MDP0[6:"3Z5B)D:H&;&1E1J4\00".OSB)4* /W! ( D[N$W(P$Z>DLDHKK\32
M*#@B *H/.&ZA8 X/,O!#ESWP2,^$#48H<(4&/+#$ODX<$/YJC?I848$X-C;H
MH$Q=. %!@Q.46T,3@=+P9(T&.N#$CSTX4:,Z"0'=8 7B?@)A!,<V,< 5/!RX
M0 XU%N@ $TOL$.B-#3A T\P..'A#EUO6L&2#3++$-5===^5U-!#@:^Z6!5+
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M1>_PT($.-(<$#6A!&S;0@/AI(%*[:$"<#J<+.3R B@O@A"<:P 8\1& -ND@
MW6"X2$8VTI%1N40*1L &Y=R"#L2YA<<LX2<XC* %RME%'7CS$U? 00UJ6(,:
M[&6DO]3A5GP@P0G$YXHTC"!6UV&#"2R!AP)A(GB8\!,GVOXF$%K:<BBJFV2,
M]G"K4%+G$G[RP]#$QXD4D !-NYA#CQZY36YVTYO?!&<XQ3E.$DWP/^>DWV]
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M8-XNC 4.G,!PF;-\YMRF@9C-\H0;U/I@_<Q%+70^&"48O 9.4$5\D X:+]
M%1FOC)3(/:4RT* 1 @F$##X2\X\S_"=$CSHE<! $6PS"!9(Y^L(5;@H:@$'J
ML"'#"[I "2^X@.2,>/N6H\(32,2@"8(P0Q!B<&2G=.$%1N^>)&: !$&< 0DQ
M6 12<!&#"T_%!DCX22UV8(,S"/YB"C#PB5&F$ .(-R456/ !N%^8BLESA2>
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M 43@B2;0 5&H@;FDRUH0A26XMRUE4K8P@Q<8A8/T-P>]61?*@@N3A1D8L3)
M69ML!%$(31W-O5S(V)[]62=@2C+( 7Q+1YXXVE<=1)-01%I@!*6*@MFL0!M
MU:^+U22@51OX"84=!1MH H&@A?XKV($PG(%(T('1K<(7D 7<\\(QF %'  (=
M2((YG )36%W!Z46%%(BWM$XM0%DE*$SXU%S;_0F?1(09@$B!(-Y4" 0%/< 7
MJ%<8L#\()-[&C 4= %.!(-)!#3](=(U<"((78(2DNSQ;8(3JU(6V-4:<S#4=
M:#I1R 4R%0A(D(13D &/G8&0Y8E(D $L(%7@XX)'< 'J,P/)I (: #=1: 1<
MR%BS>,YS)50JX0E20#Y21=4JV%F[RX7T:X2J%8@+G8)<4(6QY8F3$X@\U84D
M( M=^($FP. FC809N$J>$-,>0(52O8$=D(08F,M618)8Y0%<L(4?T(%1$ 1J
MC-Y!</YAGKC+C0N^"K2ZN_.>RT.%))V"D@W917@!1VA42 P#&DC)I/I4C,P%
M1S %1PB$7+ %WC,+7/@\71@#%T"$5!B]$T9"6MC?A5C,'@ WVA.Z0TSB5! %
M'[@!W26YZ'.!K\L"JTN"&["%P*0!6E!6^QL#&1B%L> )27@$6MC=P=E1Z(O>
M2@"\S L#&(B%<-7<'1@Q@5 %&SBY;?N))KB!;6N"&(@R9:U>R4"%0D"%7 @#
MZH6P6J,")9 $&LB(\!4\U""X&/!-3%S!>3PLA156'MBV*W"!(. )I0P")!!+
M55#0DLT(G@CA>[NW'$"%CPT"TZ7>#KV!7([)"3.+>9U=[_Z)!'S3YQR@QN=L
M A^( 5)@!"-0"\%]@2C867;5!2Q OF.=U1VH 9[@U5RPR:V%SI(K+'V> 8IP
M4"3@@1GXNC[5@1V@@<*<2B&@@52P5*F- 2TC2V/$@A>8VQ;J62Q32%K @1UH
MS;<C!2/ P;X[UQRH 3I^2H=LA$=X 2&@T%?]"8NL!3S6YXRPOBMH NFU29](
MTBCCB5U T'N;QW>\: B, 26X AUX 55 !)W< 1QX@50P@T9^5!= A7P>N1<0
M@\V;U<#A"2Y(0($P R,8!"(5 G=&A4 P@LRKA1GP :"(3*8>/N8SA7LK;"-X
MA$$P OW+N1GH@A_( ;.E@1LH7_XS. 47P$A1< '_?8U4$(0N" ,OO-]",,9:
M"(0L$(1Y0P5",$:!((4O\ )JK 7<U@5;( 0/C 5"2 1$( 1&H(7[Y8*@)(2H
M0P4RV-017 3"6(1"B+KND85!2 3C7H36P\,R^#Y5((0>T]E 2(3?5L$G# 0N
MB(1', A&Z#A=8 3$?HA18 3) (Q%,&[N3DF!>(0L*(.Y500N:(1(((2R&(0K
M"(.;-84PX +7E@1"6.X)Y\L6(@4R&(,<%84O((/;1@59&.Z%((3%^%?"@XC_
M'H4PN(($=XQ(:%A=4 5!*(/S)5HR\ )36 1'R 5<I%>!H((:,$3Z'@3C5H13
M1 3H@_Y +D $4R"$;6,$+F")!'=RDQ"%)Q^(,C!#MD@$)0\<4B"$=W/R[Z,$
M+@CL)[]M&$L$_>YQ,6#0M6@$Z]Q&0I@)0HB%-!>(6BB$*R"#=T,%+?\ZX39&
M6J#S6(.U*A "4$.%&HB!3[PQGD2Q5+B!IZQ@$"F+70"XN!.-@RD,GA,I&SN,
MN,.X9M9KMM@GJ?.XF0L,R_B+HUMUGL.ZA4/U4*?UJ5ND3_\WLD,R3==TH'"V
M6.>,I!N$2IBW;IL,RWAUK0L-7;?B2B\1LVAUQN@Y:0]3Y*;EP6B.RP@Y>;)U
M0\<S9P<G<-<H8!*25VB+6[B4H>B$&,F%( F2J1BEH^"$^/[AGD_P WK'H:!(
M=Z&X!7I/#W<'"M_PD'T?BEO0)O?Q@Y%A!9_Q!%?(!8)OI%UP]Y%1"EP@^'R?
MBKC[!(H7B'A'"NCIC8.7"H$O"I!G"I*?#7)O#X^_#HC_B8W_CQT)DDJZ"I0'
M"HP'"GL7G][@A+]X!1MQ^:SHA J0@ Q8 !5(#PDH!05) 03!CEU @08X&VMI
M@ >1  E@)K-3)P6Y!0FH%@_1A32X@ HXH<+9!1)P /+( -[P (_QB_2(@"?9
M>DYX@ _X#0YP@ J@@ @8I@UP$7?2!4O8'59(@TNAIS?0E-^XA B8@ QX@!*X
M%#Q8 '%9 #]X ZAY^Z/(GI+YB_Y+4  *J( (L  ;R7:B^ M^41!=,"$.\;B_
MP(1#RCH%88,%<'N!L(,Z"!T)F(78UW<' !8^@J %"1#3)Z86X(T00 \!4:$X
M 7SAWX0[HH RP8,Z@"?[@)1Z2GVZX(0)*'HXT@56D(!1:B4,R'Z>J"(F.9(&
M /T*J)<]<)<.$?[LIQ^!J #827T-H)K>$($'R  *F #Q 8A7%RZ\PM3 1*D'
MK'3EVJ7K(42&$!U&K&@1HBL'+!Q^2O!&EX-9$5^]NJCKP:>(GA1PNN6J181;
M)F<^S!B*YJT%MU@YH$CS)]"@0H<2+1J1!(6%MSQ4T*6A3L50/A_FTE5G0T4*
M;USZ0?X@1U<IF19OI?S4P"2;#RH/P'G(:@*)AR32/(QP21=)HWKW\NWKUZ0?
M!Z]NO1JAH:BKA0\=CE #L>I,/A2 5N#S6!>*$[HX/1#JB@("/P_A')Y*T_3#
M6PU<Z6+%VJ3J0S,AZ_(3X6$IUBM* +[]]W?%5PO4..1D8,ZMGA%G*98(\6E$
M@ZY=N=JU\S115F(K6L"C:U=5#QE*YEJ38"$FWVQ"?$\Y^^\;"1'_R+E%(4X'
M"WMTX8'*RC (G.BB0@,;R.:0)PR\-DL"LV#2@08GB*2+'1MHT()#;-Q!0@5T
MS8*251MLP(9%&NRQA@? J;@BBRHAL)!#KM % @LG3.#8+OXM+(0'!QO0I4D%
M#Z3@$P5S2%1'9V^(9HD&&;S!0F)JN!)" R!\L@L+'FQ@ARYL@/"=7%]"Q(H!
MG^SA@%9L-)"!)99\I$L;3<;Q4!X6TK5+&GQH(%J+??JIEQ^=/<3) KNHX8<&
M?.QR@@8=6*+++"F(F(<NAWST"H=J>+"&+K>DT.@?M:W!A@4@N/()!@^8,&&G
M*FBP :5MK.F=0WM$($$;GU @AP88/*H+'")^A=$%:D!P2RZD/12'!AIPR@>G
MFZU H0<=K+ +*VGDD0$G*330@2=X>!?'!AVLX5-RF=S"PAP:7/#H)R-LX $G
MK&CP0 FSK/'));>NP8H*,G&2QOXG&SA00G6N=L"G'.42]Z=%#JG1%$1^V/$*
M!:1=(!HFG&+9J&5P.& !5%5A(BA$'>NR1ATC:/40'M6F(!/++K]YR089D,":
M&ICHDD<'',RLRP7[.81)@V ZM8(K&S1P AX41-#"+"VPEDD'&8S VG\:!&B5
M'2N84!0(*BA=TP(K<!+' KJD, +16^51P2V8.%!'<PEFPLHG)U10B@2'W-("
M>W@XD,DG'8Q]@5V<M0&2*Y+EUD%;/N$!0 C;0;PYYQ$Y9(=\%GUP@29(AWJ>
M'Q)X,LL';+BB @:8$/E5<0GLHL$;LRQ@AR=I!%!W [O@\4 ?MVA*E@.WO/$E
M11) Y?Z3!'2PLD$)G' 2P1NOK'%8"Q=TPDD#>60202>S@,#I A?@W3G[G#L4
MF">L>*+E2446ML(MED@P"QL;['*)!&XAAZ9HP 2>L$,!/D*C6_3+%7@8@!X\
ML0$3&(\"F7!(54 P@D]8P@%^X(0$UA *R+ B! $J!0+6T+LD:> 5K+@ K3H5
M@5=\8&QOR( NWD !3GBB FQ@Q0)*DH(4E,(!5WK*+08  CS,(E!XN 4(TA"*
MU;CB I9Q2+I<$8 T>&(-G?$ "W1!KENTP8*[>( ?2D@O\,GD$,F+SP5)<(*Z
M24!^#7A%%?=#&\[YZ&QX24 +/.$&!_#G-B60T"8FL(E.5/X@D!+91-J.L(*/
MX.$V$M  )_Z @$[PI!.[\ ")), M2R# $V;10RE,@$,([.$5#N#$+C[ J0KH
M 4QMN$!%WG"!7<0A H@SP0;JE8!3-0 /I3A!!FYQ 3C< @\5R$4+#,"&3!2E
M RWP8T9*LHN>I($%X.-$)@CEG0BXYR&>2$ %+E"!#'R"#9C$A!\,T#2HM*8!
MM]B D72QAPJ<\14=8,$F--$&0D*$#Q=0 2[7\*OV,91%#I'#9"R"SX=TX"L*
M"<$).*&)."2 0AUPCBZ*!*:.+$5<AZG+*Z[7&M]0AQ-XN&,<U *1",3P(1;X
M" FB58&[L$$$(-&$.3DQ A-P OX3<BC4 Q;:T*6RB)07L  %/+"0"%CF$PNP
M1#@E\(8SS<$3,I$#"%YQEH=PX VNN&I6X; ''.KB#CCD UL?8A:*L"%%&P/I
M"LS6B0<XA!4/L,\;,,$)%32E*K.( "M><0!.V.$P$0C59CJC >_L4!>N*,4?
M+M"&G)1$AB49 1O$JH9+W )=#<B$*_Z*E\X@% _:T84E<*F+"O1!%RW0S/5D
M8HD)P+8IK&B '\)Y :LU( VD1<WF,N"QB/A5)JG5IP9FP8 ^"#8#FIDL53:S
M@!2H( 6<V@,N+5!;HNTA%Y<]Q :F59F'O"L-O'F(:#*PAUTDADEFHR68MJ>T
M74!4%_Z8H%@;XN+771PA+@^Q!!\> $Y.), 2:=&+"CZZ"X=8@@6W>,!-7(DE
M%OBA 2I 00I:(+L( #475?%$ ZY$D1-8( 4G4,&_*N"'AES8GWV8<"8HX H(
ML"(#('"Q"N! D3/N9P0?T  UF:KDOURB4&"Z!0F6,JP-?,6('>@ D#\BAX]&
MY#ZY:*,"=-$!/,R!>2%-Z6T\,4/^5( $\6$%',3DD U<<\*=6H!H1G G"HBF
MIR!AA9V=@F44J& K$H#EDA/ME\"4%GJ7V(4E&K""(;9 -#%[0#++G)[O[,($
M;[!J=U/ @DQ<Y2&\XL\N):*_3NW"K43SSF+<=H)<[%4DGOZ0P"LF,((4H& %
M]+1L! 2DRSAPX"2PQ!8AWT!4"^Q"@N;J0!M2BZR5>D(7) BC4"O@@+NDYK2I
M9<TG'B"2-SAM;'S@9TAKNYM=Y'87F>"M'_@)OB&*VC*>&(&VE;HYAYC IW;V
M0QI2NQ">[$(/&P@% UPLZOUHP$@4L5M%\H#+"NQGMGUP10<VH 80J+>\L[V$
M"=)@'8A4QA4<Z$ :RC;;6M:*H'8V08K\0 &)L4?#<PFT'1R@@A.$V!,M0($?
M@\*) G";:+SAL64A@*<5?(*@E6+-H9W3=,4XQ U<UH5E/D 7_Q(R R32A1PR
MD(N_AN#KMY!-MZL=TM INNU$V?Z%!,SVD#<@(!<=R.?=3_**$USS.Z+9<D4J
M0*GO5( W';"#55/"AP.X H2ZN/5#% #98\6!/6#B P+*R8((.(0$CM&%!433
MAB]%H.)OH(,*I@5?74@ J,AU.^PK\CZ^5F0"=_FM6/9F!\5,  ]Z\$!.7G.!
MK>CD(9EXA1V*K8LY8 4/)WV(6!5C MX4K2(HN&8G8O)X"+S:+4GNU 34_H$(
ML.<"P]J#?#XA-$Z% &[69J:XH:]]$DS3,KI(0VDZ=3A71 #<N'Z3+I12;#V$
MC V(V7 "0=D*UN%2-CT$)K!")E2<&L05^V2" ?C,0U" "NP"!)2$7^E3!FR3
M8BR2+OYLP*_IPB8X &O8&7B1%WME0AIPF0I<$\418"8TC%M\R07 H/*MP#55
M'Q8YP-=MA@$L";JM =R\@M(I2VN0@"5P'WP-#M"]'DW$ 0*8@!HPCBO<@@*D
MQ"LDP"VL 'N,@/J80/_EP@( %40,W4U Q"U8P C000:D2 JNP1P\P%=T /:P
MC1_LPHN@6!K<X>. AVT]P!ND0 8X .W$'B.:!/AH@!J,P &(1@6\R3+I0@)X
M0A&Q0!U P#7I$DA)@ 2(0 @\P :(A&:)401H0 G,$":T#1"90-.00!VL0 +4
M0?^<#0LLP FH@08T@(#H L<]A -8!O[]C / P1LL ":X$OZ[1, 1Z (S-B(U
MFD0?@"%(-<"OI$$$S $+-  KJ$D=R,$KS4%3F$ %U $+$ ")<*,W+@ KF.-H
M-$57B!Q$K,$$J",$W 1-@8E#K,$"W$%'V%I''4(#M $<- "7Q,@"J!TK#,!A
M!,8;O($##!X(E$D.18 =Q$<'$,J$7%@(N((('(%QK($=7,!RW<(!7,(7@IL"
M0)$%V($:Q$0F((#(/<!^L,$"((<$D$ <)*(NU&08O0$$R$$:+, G8 ("J,%)
MX@A#T1T65@ %[$0"E 0*[4(><-\;/, <'*7/5, B!N4!B(5#5)(N].-)^('A
MX,$;I-,K2 "L14 >V(<)V$$%:/X&&NF! ]@!'%1 !;PEET!$)BP !ZB!"21
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M_)51UD4H.)_2K %<X@&O?(0)T/ZT+HP '!#*0[# '_C50MQ:W8A)"+C!+1!
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MR,458M ^A=9"%(EPX RJH H:;+41,* C#920"TIL#Q$O %XC7C"("@,L##
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M"9#@]G!A"E[ \?[,%KYL$#@I"E#A!>1P%%P AUY@943!!<* %FC@!L)@!VA
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M>9Y%$JR+"Y0F%KX@"*A DQ3A"8)@3%6!1GU5%\B "5U5"1(A#$23<H!'B[Q
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M%F>+(Q:TX!/7-FFY!&E7I5V*]F+2EF>65A<280NHS6JM16N=9$%.=G$95T5
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M(708G .8*3B!F\5W(>Q  Y8B#0R BE_" =0Y<L49 DC"%3)7G&GD!"3@+$[
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M&O;RY=LM$@BH 4IX-,H&";= H(L)$XP 0@@@T!8NE54FD,DN&VPZ%4H;LO+
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M>,X,6U &2&!%5[! 2WK6A29&)!,.=""W;=CL05@AF1%X+ 6L2$$*5R"@-6S
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MMG8GY'_Y%G@F2EK;!U2@EB"PFL(;@GB$K"!\:GC4R1V.[C=\0!=I, !M;O&
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M"#!>F.&CJ^,'#R !*!J6DI, ;(A=!D!;GK 4-F<3<U XGP  EI02!K )-=$
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MPWYVL  HT 8@\!&?X+\-W%$4(",/L >OB$T:@ "ST F#7,AYL L)8 %G>I&
M;,K/)A0(H0DLT%L(T4T(\EL'\0>?< NY]0JC80E]R"DI(#BW  =K$&%W@%L+
ML0G)50?+42.8$(I%56(J< C/0VW2!F&><$,TQ@H$5ELJX 8DEENN$%YUL"BY
MB#\&-BEW0&V8<75@]P8I4+<FU37:^FS29E[8A:*V86N0F!!_H *0N1\_XB7
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MB4@\0A4%>4H5]GB#'R!(E81@1.DD"K-(@,XE-TC+L=R$LF4Z01*2@(0DI@G
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M/W.E)<U4C(A@74>6%Z1"$"\(@_XB;L#4*;R@"8 (S%1A@ 5(8.&_)A9FZ9[
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M-)  5\!*71C57<  TDR!FU0!!# !/+@$"1B!3-@#!]"%*NT$%K" VW09.S"
M#+B @V0%2QC1S'0 5W"%6VB 3&@!#0#/KE1&3@A577  2Y ##=B%6>"$ ^#/
M$ZU17?@ .@#)-6#,\FQ*"4A)!XXB$571$3"!!SB!->:#6;B%$K!/\'R%$[A)
M!_A0E&5&3FAB@4P!71B!"(U1D^U-!Y" !0#.",B%"&!//+@ 76@ ]DP!$]B%
M1U8!XE1<J:B O9S2!'"%$=!D75 #I73B;>5B&P;=<%T \(S#.\A;"< #NXUD
M5WB 7/ $YYP 9KZ%2&8%VY0 L/Z,75V  +!D 1'H9K_D9AO& Q8H ;O-6<U5
M@X+86%VH +^<8O6(0TM @ N@R FHQ@ VX3>U6PJH@SJ(@&IDA5R8 Q!P!6&^
M@#>XA07PA%G8!2[E U46R@SHS8KN"1'E5A:XR0LHX4!^Q#A8@!(8 1(@ 03
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M#(R %0U(%P7(XHD:2D4"!6(B!OYUT88(<((3F;C !@G30#Q5Y T58,4N,'&
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M""3BX5"TR!$!)PX $PKLI4*6< G?R,*)!7!7!9]@ 4=8@  3*(T"T.U#6#/
MADY(DRD1>).I&F )3 A@#7[0 $C9, $_V $!F A=7"N0!EVPP"<>2!!!)O@
M"8^@ +.H@.DB0#3.&L85#IC#)SPP1:CE 0\:OH4#U- '$"0 /Z33W*A 0($<
M'X 3F$B <RZ0"3_ <8X@F(BI0F&!-GR6!&FP@"5N<0$VM,8G;(A '^:P@!/H
M(@&:N 4%6&#=\++A<'XHR!LB^2 6VRH"Q+N !]KT@!1X@@TC)0$'_- &!81L
MP5_D3@,LP *OP-@D?,@ *Q#0EOX.3-$$&N!2 TI1FI!8  _#^L0;+J"+.12
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MC"=%?((G;$)(L  &,$5&441<ZD('9$#VR,'S?<4"G*=7+5\FW!I3S)RIK
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M"NB' <@!KS6'W]V!>H4()JRM'VR L6$;'["@'8@1'%Q"!X 4A?E!"@R #'J
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M!%B!#VZ)RD9D#?;B%H"H#BP@WD2H#6:*#PQ (@AL#P (A^)0)T[*TCAA#AQ
MB5@@%U:$#S"@#BK@#7K(#U8@:S0 %@;B%:+G6%0.#\)"%P[! "I"!3R$OTH&
MES)@#=HP.[S026PO7<;C!.K $Y[-)IPD SR !3J 2BZ!)O*%!0J0X_#"B#3
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MTD "1DZ:+B$-6$*57 $66:0!]N!\FF0#) * 1 =YN"H%D(<@UFD@0L 2;L$
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M=6=G UASQ#585C7HH$]99&U0XG:[U'B/%WF35WF7=R=0E/[(C.435()YC04
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MLT;7AH1JZNP"RLJ/*Q9I6'&RE)!5AH1OWNQIH8M/1EVN.)C4VJ)E)DX"=9%
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9Q2I:\8I8S*(6M\C%+GKQBV ,HQA?$Q  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>68
<FILENAME>cogo_0039.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0039.gif
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M^?7Z_/____CW]_#O\
M
M
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M$KQX  *(Y/),"@2,\,PL"AS0IE@B-.Q")",H0$ LF<Q;;PW&2$  ";!D L$
M*T##2 (( ,)+)PD<4$HQ%O_!S ,$R* +)@X,\-JU//?LLVC(94L0# 9X.ZX#
MT+QR@ &PO$(  L6 *T$IL6QR+B*9/!V#0+P,1\(?DX#X# P$.'!?M^\]$TD!
M"AR#R  0E$B8"!(*A(O%@62-@/ZLST@R<''/ &) V[@<4$";FRQ=BC$*##!(
M)P,HP$@LL9! 0 H_9Z[YYFR5=X %N8F @ +&U$#  \Q 0X$ @. 0  G/H'#
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M8M%?#K F,? "#E  @_ ,-\ I@/X  PA@ ,P'BFBR(83U)P< E=E$ ?K$#(S
M4X, D?M$ .P(" -0 ;K "Q10 #OHB*HB%C;'-[FP"!@6)S 3 )8@$,M9-,P@
M"<"B'J\W9<S@E ,0BLT"18C ;[@$ !90(KYA P*15C10#$NC BJP:F9#*@?
M#*_0)QSH* A@@ +!+0;PF^(A%K28 #*P"V$R'(>T"0& GE4E)L\P" (PDR0X
M/ )T#/ T+RC:H^FI".63>V16/VF%(0,!*<T$#=S9*BXP )18#*A2 2;P*J+D
MC:]2?9H"  V@:HG'EF]U" !P2$XS./ZUIC;W5HE& 6_J=VU'+<;0 B8 :8&
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M U*@!<M-X&8=#*W@!W&P!F50!F00!F1 !F>0W3'N!CR0 1YPXQVN :(]VB
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MH63*O3$"'20\X;)V>[UI<#6*I VAKPHAN_DJAH#M_6-YW]J@Q'R%H#W&BRV
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M.5550RC'XCHNL9NW.E40N)F,7 !2><S0P_G/T: B](10*+M4?MR-WQ#.)<,
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MS[#5W$2 A,$BV^(:A6-*J#T#EO[,&)-8T(6U+59C[8FX;9G;F\BFS:Q%=5L
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M,!DX,Q""^I S&1:QF3HM=,YUHA-%E7D3.5,QSUT>QXY%PR%!N=,389#3(U?
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M(9,(AY362'5"AYL6!9<A:E^&)5[5G$XA01. 'CD%6L6-CW(<G3*6&*HB:D<
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M2!K2#LXM:<)M:4K'M EC'W1M:7&@&EB9X@K%I_IM1R1#XE&MC=[M5\V9K6)
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M$2WP%B0Y@)8,<("G-YE% N:X"U@8(+;&8($#),!!$B2 >WNE0#/1! WG_6$
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M  A@!+Q0 71G$P(@$'ZA @I@ "B@&!3! !A@MV#@%02 ^ )! #!.,&!! @:
M !* @YYA$S2L(6)!K)X!!4YN$C@F9-HQ&=P(%PB@!J !MY[A!0A@%VB@ !R
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M3& !RA)$8F$%)& $+('A[NH$QN@51H "C L:7$#=MJ49E/Z 3DS%HJ!AXPX
MB#*! !#A%38!%4O'&!0@!EZA$^!HI4@@%Q ! /A-32VBRE; &&(U$(I!5E4*
M '#@$!H@[6@@%]X)2H,%%(J *(H %)JHRD@ %@9N%9%O%Q  ?U 1%SHA>7(!
MCFSD)CAAFZ"!$U#@%0[AA6!!! B@%+QJ%P(@&E0@KVCU*YQA#JY@#,3@"N8
M*S)! !3@#P1! 0# V<82%"V@! !@!:!A! #@!5+@A3 A7<'I&2! 8!]Q%9Y
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M%F 67J$  ,',.D 7,($9M65L7R)3S_899@$!'F %5@ %P/Z( 0YM (I!FB@
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M6C=2N"3DV;64Z(-0]P!*(/PZ-%;'R!4-#'T76.<(H.<40+E0M_&2T$%RP0+
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M%TB4!%@ &FSQJ1_$,6F@&B-!!4Q $.HRB&QS$UZ@!&H /)DA$$J@KD D%VA
MTLH4%VB !%9@BF.!'#F!!(Q17S*A!G! IF8 H6TS=B2!!M3-G -@4IV$$4G
M!=QG$6[ !FK !F8@T0*AQ**!!D: L+0])Y0AY$5>(@Z! 01 5D5 !:!!!0C
M #2/&>2[O#<J%D(RO3'AWJ:7GOX$+;X_,5ZA8; /(!.181* \I3L/!8JX"8D
MJP&F6.5$/N2QXK)/('8H80$HT $%(0!0X1D68.$D00 .X08(P 'LD"=Y2Q<&
M<>Q-U3INHB$;8,=\E1E*H !:?J*?005T*!-PBP1\?,"9,RM^92MN KY<].-K
M)AI@@:A B:)?(7G4<BWGTG?\\AC9DBV_QP:%VS26IQ@0R"KK$Q8R;?$;HA/
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M9821RD*Y!&+;,S <H  *(G&RRV&OQ,(@?L]0DL !#.C"3 (QO-+)*\7LMTL
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M+G\($/Y2G':>8$!+!E# 0@(#[!() PX,@@(C-U#@B,,1\WE&''_ZZ@   "C
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M0P<\8!,CL  %(-  !YPG$BN Q0#,=3 6/B0587BA]5PUFP(,  7IJH$3)^
M!;A@(19PP $$D;)JF0 !Q?B#"4*T.$71+A8D.$X"&!%'.UVK#&<H9/^>P8P4
M&.89/Q0!,R3@@ E(0CG4*H&Q7H&(&R3  ;K(!")@$ #9S(D3C"I&($B2&@7X
MAH^E$, S$)%%+<IRECM212INF8KKB2D2"S'&! 15-QS0#  2 (X>@^5+8/J-
M(7U[R3-XB MC&. //Z,E0X*!R_Y4^"$8"\%%#5#3$%X @%J4400!%. ?AU$@
M.), 0 (L,  '@/,/)W@&#3I'@%HT#$]N6(,<TB WRIQ 4##0W@TT%!IH0
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MJUYV=[[TK:]]H\N,:.@W&J!5P5P $( $4"*0%DB@0V@ @ %+2A<*F %RX+.
MB#)#!!*@ &IN4)WUWG?#'.ZPA_4%B40D8A&&<(1K7T" 091B$028&2(S4A 2
M*. 8S] %:CJ+"T X:1?@G!TN@F:=+GTI3&/Z@YG0I"8(W/Z AW#ZL).?#.4H
M,\@9CC"$B$O,E$=1(AJ9B"AR'&" :3Z#!&I"1)A%D(!#,((!&E1  A)P F.@
M  (F$( "O'J=??4K3"P0&"(*=C +W* &QY2RH0^-Z$07!1J1L+*(V[80%QA
M 0>P<RV8H8 .%$,0 "A%"A8 "P10H!,T5%RG[6B,0#!N!1@<! %TI9U.@.P9
M#A! !#"G.0:0P &(,-X,1*?H8 M[V,*&AB-&G @L4\8% S@$+"2A@!%8@@ 6
M.,$( B"#%#@@$@$@62X"<(A# * 3=4Q!OQ2A@@/$1 &BT<X%,PBU8W3P@X?X
MA0L"00$5G)#8_.ZWOSF\"$(80O[@3"U(# 10BL-88 &,., *+"$)1VS"! [
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MFG?.!E3D+!(A4@R+<)LM/!2:_ S($"*GO NQ,,=R-L'KBPA]J[F4X+K(@0C
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MQ\("0_ZM8(\4"*9] IM+ X/W M"P J ] 85  V%" 8@M L9P>T,-(@\@ [@
M XK "/\2$RS@ E6M"['  INP KD@"),Q Y$ "(< UO;A"!( U[+A NZ8"W;-
M"'EM6 XP"3 0)B\0"9%@R2;@ L6@ KF0U9%@ K$P"]M&W\\0 XS@"(V;NX.
M"":<"9UP%[TM";_] M)]' RQUWU=*EFW"2H "Y^12<A+ 8(P"", %(K  I%
M K 0"Q, "!=< R)0"XO0 2K^$RKPU"]. IE0 QY<V LCU51MU;&@ AT."Y0@
M 9FP"7<! W=M LQP"!1@X]"  D<M5#[\Y 2$"_&["[4M _Z;@ L]L]C/P F_
M30)+O;DQ(0.(30+0P @LX @FP+2&D77/$ & , C<K-_%P @UL';%P(V+H +U
M%!.'L*LH  V?Q DA61"=4.1C#@L28-9A$@/W_82B7#[.M E/& $NW>;MD^19
M&@DQ$"82_@)\G'6<H *XX @4\.95\$HI+H*+[<.]6=[;: **D +W;0%37N5(
M#3PL@ G!&0@ZF7SC6Q V, $OD *;FP)U?0.P< BB 0NP<+S/4 *#L F>? *P
MP%9#L=@R<-0#!MC6R G&0 &E  LB,)K/$ VRX>@&H2N[  N1H%+:21DW<A@K
MH M;Z=.Y4$^22"4G8@&!8&18H?X+G6,N*  +F= !FR!*X/<BCH(1QP$(D6 ,
M*P -HTL"%_4"C3():\04B] H*) +,$ 2U/+N,?,,O* KDO 'N[!&0(,<U=%X
ML'!O.!#MTRX2)=#RNN*<QX!UK] !KR #*?\D2@AXUN@(.B_M*Q +/J\A7_Y3
M@/(2-" )S, >NWX,&B_*(J#N%M#NR*#9_.[O+Y +L-:;!5$*=[&ALU'O]UXJ
M+@ +*4!C0QW4SR0:59P]D9$+BI C'K()AS/T%O *-B #G%#UE$$)!6]D3[+U
MA%=_05&@,6$"J!$S-+;DSZ "-+96^J@HDH #F& "#3\!"C0(G1 -@M/P[E(0
MBST#D_Z@]:^PZ\\@^#7@\LENR*'O8*]@[6%B K\ [_HX"380[0NJ"R+@"!_>
MZ&&"1)TP%+40\+%P#":@$)DP [7PA+#PA)]NXL/\##?_ KD]8+' I+SP"IO0
M&X(C">ED#%N_K(91_5E2[S.SZK!0?S'1"<X?$R< 3N\.$,]*L7AV+,4N"Z]>
M=<CT[)DQA2@H*:KRC!D)8R6,/<M40Q*@8B^*47@%BZ'#%Y@>[@H4Z)DD&<]@
MP;(!XYF%: Y9%'L&S>%/H$&%#B5:U.A1I$F5+F7:U*E/&HB JI@%XP\F2J5B
MK8BDB,:S8I%4#%+$(A,F3#Z?O8#U3$8F&:\<DGAF8Q,O"_YG*?$$F^)9)YNY
M4AAS<6B37QN4?A93X?#/C4B,8#@2[/ 0((>1_@3516'S(+.4-G$B^!":BUUK
M9VWZ"DCJ"T4V;DI"&\OA+@H_%RE2Y/)9BUDT;*> IJL%-+^Q7#QC%&C7BV<I
M>$J2;6$2)4JX7ES%U,FAL17/E#]S% BO7F,PAA=W@=QA(D0SJF!5&!,:LXXJ
MF*&$!4T&)DO,JH&1M1CY0Q>&*,'D%X<8<PPRR1BI[)G+'"K%IET&<P&1P^J2
MY!D7.D%AOUA>B 5#%8QIP3"_6,!E-VA0^*N&7$3(1$%>H,EOOY\T RH2%S*A
M 1-&,'O(&!6@04X7BTCP*9;&4O[(Y2=);G@F$*D8$42L&S-AQIA(6 A$$14R
ML003'MERZZPR:X@DQF<VJ6&7\"A4Q)%#H'$$!\$F4:2&9TSXI3%* /UCDAFX
MVZ2X0TZ8Q$(8H &S!1P<>J6Q9Z(IQH3]8)$!%INT0\ZG$YC!027KL-O%!;ET
M"<\G&VRXM!:9_B !E\R"'-#2P%:(I@4.972QDZ]\ZF2&Z)1,@<EG?O&KDYAP
M82$6&]%B\)DPA212JF=.V/1)%](;1!)=;,3N6A7:*@A+;/E$P4] B?-).J?J
MM?=>?//5=U^?7!BD)Y],B"43%XI!1!))3C#F#Q1TD2X3*4W0Y14;E(Q.KA9$
M2P&7/_YLP@&&:%*X2P:^C*E@M<9P,2&7"8SAY(&%83#&)V-(DBF!B7$.E!)J
M<7UF$@LDZ6H78T;XY05'?I&X%!N804&26"PX!@9 8G$ EU<L*.8/S")10*X:
M BGF!KF@2J&32"#(I1@18J'$R13:$H&97$R 1@299%P$!US\*D$J3D3@Q0:Q
M<:@%DX)W^VX$F4QXQJMG4-A$%YE5D$N$XNQN )%9+,@%<8,G@:4Q:-(M1FN'
M4I#+!4QN^..8$V3SNBW)>9'A&(>.L1D6G%_1V02>1?"9D\9V65D"EQU@YH\7
MG,X%![Y3H 06OXQG^9A,((C&A%D&R5."6#9I3')=2&9UI/YB&&$6:*$5R<4J
M8TP J>U)!AO!)Q&F?*8&OKEZ9H0I^8036N/:XTBVM#\(IAB<0$'==%$**Z5.
M+BS 1 W^8 P4_ $:$XA%)U@ #1- 36LM>08B;( )$RRL5"+0!>,VH;4J*&(3
M+3"8)#(A,QP ZAF<$ D*%DB7GCPM:L> 7BU6((E?4  6-9#1W&YBC$"X@!DU
M&$0Q:H +L>""!A;X"4E^ 0%8N&9[*@$1(.)7J1VF;&43. 8GM(>"6'!B.0)L
MP3,P9T?]F:R#X<$%YD16/MR5,7Z'0(0$< &:_=D %RI0Q#-@T#+DC"R0]=.B
M]S!C0A0NC%-WC)PBF+$(M>Q+E/ZC)&4I30D43,B%2E.:!/Q**"M$& ,3,*!!
M:DHA QKX[&=,PL0L7@*#0/C$BL48&PPX 11&**(8'P+3,RJ8B4C$PA@U8!:V
M#M&3/!D#E&"QP0S*]HQ<Q,H&-'A%+%1BL&>\0@97Y"8,Y%(,&APB$CGZ0TGD
M8HQ!^ 0:@8"!(D+YN!=\RB&PH,$-IL.3-QEC$M"(!%@^%#YC?(AB2OK#)J[4
M3X>T\H(.8:A#Q=,0*\*@(9) J*06VA48D%&CS-"%8L0C Y%2B9>[8 ;A7K&(
MAP03+#>0P3%[)!5H9!.GW"3G3W3!S(8^,YK3+ 8FB@&-0<R@H4=]B".<60-H
MSF(OL/Z0BR(8L<R=&E,\-!#K(?07SEC1 !71L,$@7B&55]"@!B7%UD9Z$@@:
M/.IG=NU)/6,A%W.F$P;LI 0M4Z-.=CH$B<[$!5L'T0FI.$*9'RI&-^6R"< V
MY!"PU$4D(DI1>V++E8>P"H]R\2%)&'8Q-HA+3P9!@X:^!+:98*A//,G4?6*4
M0C*(A$O%XZ9,2,(8-6ED@W 0B)LZA*K-?*8CM%H,731$N2IY4UU[--F'-+28
MTGT(#AX;B5=$(H<;@48A9*!76,1V;&\!RB1DX!*%?)1"G)6$6EYQ09V>4K_[
MY6]__?M?  =8P ,F<($-?& $)UC!"V9P@QW\WU!:C*-!^?FG4"JLE@KW9,)
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0:V '6]C#)G:QC;WK@   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>69
<FILENAME>cogo_0043.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0043.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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M&7.C1V4OEI&07$I&_P QZ^;VKS?J\>J=,^@^A9?<2M$IT1)8A0$QV6$)"4\
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MQ<&MDY61S:</ G>$NFQ,H.4#(*DCWQZ_E08,5W(QYY[4+T$-&L.W&<U'*B&
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M(/E1DGJH_P *K2T!6S<-E9RLU*LNQ0(;2@[N!5^"AC)<: 4<X2GJ3U/TIBT
MQ"4C9!#RL@JZ#Y4<'\J!G'0,W#W53Q74I=Q:]O&.M>3JCJH7BA6<J]:A"6:1
MLS%XOD6(^DEE)+SO/5"!G'ZTS##O/J2;48V66^\I]94E9.#C.>@]J[^.*A&C
M!+;$PG \I&*(JS<(5[4MV'2-PX"0-O6IV)U%=HQBK(M&4(3N]>E4W126[$I#
M W?LU;5#D5<7JBZI@F5!=6\I^*C9(<3A: <(>'M\C\Z8I:IBZJ79 ^]::LE[
MMBG7P4*:*=YSM+1!Y*?Y4O+BCG73(K7^31Q^1/B3]W&Z?^ =(N5PN+WV99T
MG 2CG[B1ZFMT<,,,4V8'DR9):#&G]$Q(1\5<CXB0O!62<TG+RW+XXQV/!OME
M):AAII.&T "L;DS6XIGWG/!- E;)X1@L#.Y1)I@%FW ' '%55;+<FU1JN0.@
M%595"*BIS)6=J$C)JULCT@>R3<9V ,M-TV244 E8ZNZ#L;:'.WD_2AQ.V[+E
M%T#=J?\ :_C3[8'5%(@ GFO,F\<1^5<^E4R$][/6NZ<GW-?/=,AE ]U*Y/\
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KA(2Q!E2U/?Y3"E ^B>#_ $JH1^:H.;J&SGO[3D_^8.?_ #->CI'#J1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>70
<FILENAME>cogo_0042.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0042.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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MA;>"&T:^-G=31XSN?.M6-6@92K@D6U:4,0 ?WH@=QK%>R32%7!QY;T5 -DC
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MI\,^Q7V>^V>Q[;NS6PXIM^1=0C1(=01 2AD*[.OLV"?8[4Z#OLYN:"@^"U-
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MND1A%'X4@#)CP[XSOOT%>C63_P G!X[4:>.UR9V_H,?)<*'4L[1J6?R)QO\
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M2)7V\S5-BZHQ@T!=,]@U"41G#EG/96XCEP"/2M,F9X1)*]8LV32)C!$=#2"
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MN*1+&$I^A3 ]:5M#W,AN%_\ E4^5$Q<>B9F^.ERZ+3$7ZCZTE=E@1K$I6[N
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..^R._B;?YK_ZU*95'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>71
<FILENAME>cogo_0041.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0041.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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MWQEN80K:7%J(2VA)[$DU5;^K@1CQ_+EIGY+:MF7V[7F=<)\E+<>8\N0^ZOJ
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M<G;^%>/\U;3LSYXI)W$E)UHFVMHC3VUL+'&%HQ^]"X(..6453)S>L8;C>X.
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MNEF:3G!.<XJ43V@PA[:L/] DX..]%^H(70MF4T%) /M1+E'2X(;Z-JOFSMJ
M4<BEQI*BV,H/0U!/9M%<)!!/>N.9UDI* E63UJ3DS$]H*@./8_H./:I?1"]D
M;PI=\QF[;B=R'4 9[=:3)(['V,ET/D2FWS^%X85[*%3B;]A37V-$)&?,3QGT
MIL^ (=DUS\":6,,.@%DYJ4<B-"&)">*@EGUT)!X)&:AG(T>>\JSMJS_7M_>H
;;X)7="==$>3/>;Q_6557EVRN^V1MYJ :/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>72
<FILENAME>cogo_0040.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0040.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
M'0    <! 0$               (#! 4&!P$("?_$ $ 0  $# P$& P8% 0<"
M!P    $" P0 !1$A!A(3,4%1!Q1A(C)"<8&1"!4C4J%3%B0E,Y+!T1=B5')S
ML>'P\?_$ !L!  (# 0$!               " 0,$!08'_\0 ,A$  @(!! $#
M @0& 04       $"$0,$$B$Q!1-!42)A!A1QD2,R0H&A\-$5%E*QP?_:  P#
M 0 "$0,1 #\ ^AV#6FA#J=.8J4 ;>]#4@#>]#0 -[T-  WO0T &P>U  P>U
M!D [W*@ ^#VH XH'M22&1S![4A(,'M0 ,'M0 < Y&E6B"QY4/H M5 "@ 4 "
M@ PY4R [4@"@ FZWZ?:IW(*8-UOT^U&Y!3!NM^GVHW(*89+2%#.GVJ=R(;H[
MP$=Q]J-P6#@([C[4;@LYP!^X5%A87A>HHLD,VUE72BP%>$/2BP!P >H^U+)K
MW YY=/[A]JBT . .XJ:56%G1'!ZC[5#5 #@CTI[ X62?BH;L#G /[OXI: '
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M:#:UV-K@VMA@RF9;CSC.$*<W,+_\P U/RJ6T3L;+9X4^/VV_@[>V[W9[@Z]
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M\GC]7/ZOI/0OX29HMVQ\ZRR9;/#8DAQD(4-TA2=2D=!GGVJQX]AS)Y%(WO\
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MNRN4D.&0AW&^*B3H+L72EMG0+3]Z2[Z&479=MF]8^0,C%-VZ&?'9/LQUO'F
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0 .UUK_\ $H^]=#TS+R?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>73
<FILENAME>cogo_0047.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0047.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
M'    @,! 0$!            !08#! <" 0 (_\0 /Q   0,# P(#!08$! 4%
M     0(#!  %$082(3%!$U%A!Q0B<9$5(S)"4H$(,Z'!)+'A\!8E-%/18G)S
MDO'_Q  ; 0 " P$! 0             " P !! 4&!__$ "T1  (" 00!! $#
M! ,!       ! A$#!!(A,4$%$R(R411AL2-"<9$&@='P_]H # ,!  (1 Q$
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MKP^0<8KH9(QR0X9<;B^0L[(?<C@H;*2K@\UR\>#W9U9H;X%&_P -[#;BCR'
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M&7_47%%9$NX^+EXKY[9J6BN?(Q1 %-[B.U8)FF )U(!EL^M'B[0,RMXP4$#
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M.*?[B2&(T"P6[:SO)P,4]2M >2]-2&V=RF]W6DSY$S[%N87E.[FR&T@'DG
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M<'@<4R4Z9)"K=D.18[KT@?=# 4/,9 Q6;/-/%)F[TF#R:W%']W_!EE]DR_\
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M:;E%A1YJGH[:4-[B<=JTY);DCS4TG)UU9Q;KLV]<D,I QCM51C?)47M=4.!
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M'!.:T4 2>/;_ -)JJ(=:LFO0+Z#NR.H%*"[1:AW'[1DMKQC;BI+H&*H9H?\
M-!K.AIFNM6ELWDN+&0KICFMF/ZBYWN#&BH3\P!N.RMQ73X4YQ48Z-FPVFU28
MT%N.XC:M/7GBIN\!K$WR74L0XH(<PDCJ!R:"V-44D?19:D N-I" >02,JQ43
M(U9;M <>D>\+4"I:LD^G;%4^4%&E)'XN]O5L7IO^)&<E:/":UC9TRF58_'(B
MK*%?OL(KSGJF+;/<CVOH653P2@_%_P \$;$5F:@+=!#I&%>1Q7*60Z\\"@Z1
M [8'G'-J7$[!V!J_<(L1:8TW%(5ESGR%19 9XZ09TOI.3<KM%L5CCI>G2E'#
MB^0RD=5GR %/P[LTML3)J=FDQ>[D/UMH+1=NT/8T6Z"$E1(6_(4G[R0X?Q*4
M?GT\A7JM/I8X.%V>'SZR6KEOET&Y@P%+[=16B3MH2H[?^P0U/]SGEM384A]M
M6[/8I/;ZT*=,C5H*>&R^$A#^=O) ]:/@!V#;AIYAQ?O+<5*5 ?B2D#/SH=S9
M3TZ[ LB(['RI2214DJ,\L;L"WHDPWL)/\L]:D1+31E23MWA74DT](LA\(?JJ
M$LN^T1M7OX='8XI#1$^#C214XH'=GI0RX1$Q^M[#KKI\-!.WKY4F*;8Q<HK2
M-(V2Y2Q*NDQ;^Q1PPUP,^1-:8M15!^VY<C-;5-6V-[K;8$>&CR:'./4GFK;O
MH;&"79?;DOJ_F.*Q\Z'@)65UN^(Z6>4I R2#U]#54':2(M0:@@::M#]VN+NR
M.P!G'57Z4@>9-1\ KY<"MISVU3KE(;3%T:LQ<Y!,@[\?3%4I7P,6*G=B%_$[
MH.]^U2+I/6'L^M1D:ETY==Q@NK2TZN(\G:Z%*40-HP"#6'7X7GBE%'4]*UL-
M'E;GTQ6;TC?+)*$6^6EZ"\]RD.#X5^>PCA6/0UY7+@R8F]R/<8-5BU/..5G$
MBT20_P#=9 5WZ9'RI-_DTT[^*L8;'I&=,*8MO9=E2GAE"&QGCS)[4W%AR9FE
M%&?/J,.!.65TC6-+PK%['X#S]W=3,O<T!3R&B,M)[("ORI\_,UZG0Z6.FANG
MV>&]1UD_4,NV/T.V_P"(+Q)'N\31DI]O(!*92>!Y]*V7)NSFQQ1BJ&:T^TFP
M7T>[R _;I"SM2W*3@9]%=#3MR:%[9+ODM7%Y+<N"\D)5XCJF\9SP4Y_M5,M%
MTY&,*P>^*IHA,U+DM'^:2GR-6N"[.W)3$DE+[(Y':B;L%I >[:;1<8KC<9X)
M4M) ]*%*A+QV8[>=*W:S2%M26%%(40E8'"N:>I4C/*'/ ,^R;A_V%_0U=@T6
M]=E+CC@2,JYP*4">>S""Y<IB8R1N2GE?RH6KH."NS17HBG%*CC<E@*_ .A/G
M1_&ARC1.U%0V A X'I0T.CT7$M=ZA9VX=K9</"0./4T)".,V?#4M75561E6]
MZ8MNIT1VKN%.,QW?&\('"5JQ@9^522LD705M]HM=M:2F+#:;2G@!*0/KYU2X
M#;=$KL5IQU,I#8#S23E21@E'<?Z45@VEX%O5NG+EJ+2MQAHVF:I*G+:\[^%E
MWJG<>J1@8)]:S:K#'/B<?/@V:'6STF99$J7G_!EEA;E2;:C[<L[L"[M?=2X;
MI&YM><9]0>H/D:\EDP2Q2<9(^A:?5K-CO'+L=$7(Z;TXRN.Z];G\J#R4(2%O
M<_"=WX@#_:O0>GP]O%'CD\;ZK+W]1+FX^ 2WHO4VJ'TOS%F/%7\:MZB5JSSS
MFM_M^3FRR_'8^$:)8M'VK3\-+;,9*G.ZU#DT:5"7)L)IM5M7RY";5DC.1G)J
MZ*LE>M[DGW5;9"$0W_$6E74X&,#ZU*LJR^GXBI>" >1GRJR'V[TJ$/L \XJ$
M/4C:0H$@_.H0\D-QYC19N#*'$$Y3D<BF)_D3*"95^Q8'_H_^HJ]P.PPC6/C*
MN"D,@DGL.2:%?N9'^QIGLOTRFP6LB0WB6^C<Z>Z<C(%2S5C@DK#! 4ZM)  "
ML#%!Y&TCQ3:4N) [T1%P=J^$<5"=D:SXZDH/X$^50EG><)VCI4)9*TK H;+H
ML;P48J%V<$\C:HY^=6G119C+(W;CN2K&Y)Z&I?-A)\ J_P"GXU[N\>;;;8/>
MV$\/$YQGS\\=O*DYL,,\E*2Y'8<^3!!PC)TRF]H.&W-8D75\R7&?C*2K@*\C
MZ4?M)"_?EX#J"A(!2D T5(!MOEGN5J(!.:E$L['PK %6T1.RRM95A) .>2<<
MU01YN4$DYS@=ZA#P'(SYU"'H.*A#W)*2K.,'%0APA27CD9(W%/SJ[!VHN>Z(
M\A5E&1,Z<<EZN0^]\+44^(H$<*.?A'^_*A;,^/&:):S]^L8^(J.ZK2'6ND5%
M8\0)3^):SGZU01ZXG_$)2/R@FB11PZXG&!RHU"(\:0K]ZA1VE*MPSTS4(3;4
MCM0A'OI4(?9 ZU"%RVM*D.*P,@"H7=(,QXHA.>\E60&RHI'?%&E13=\ 60_[
MV\N21CQ#N ].U5V2J(]J?*I1#H$YJ$.5*4%#GO5,M%H$DC/E5!'RR0/G4(<;
ME8QFH0^W*\ZA".6ZIN,M0/Q*&Q!]3QBJ(6[='*"-_P"!E(^OG1(J1U[T]^E-
M2R4+:VT(O"A@ [\JXZ[1FJB+71=M:_O$+(Y*LGUR:LLB<&V<I/Z2?\ZIEGHY
M>4?2H0Z"$==@SYXJ$.L =JA#[ \JA#T=:A"-?6H0^1R>:A Y8&_NG7AV6$_T
MHET0NW)19B.N?J&P?O\ _M1$E^PM)42$'I5,I=$XZ599X>AJ$(\\T)"T2<#F
MBHB9X"3G-2B-G([U"S[\PJ$LHW)7B7*V04J(+CJGU@'\J$G^YJGV4GQ8Q2%^
7ZQ E8&Y:034?!:=B_P#;2/T#Z4)9_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>74
<FILENAME>cogo_0046.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0046.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
M'0   04! 0$!            !@,$!0<( @$ "?_$ $$0  $# P,!!@,$!P8&
M P    $" P0 !1$&$B$Q!Q,B05%A%'&!"#(SH14C0E*1L<$6%R138G(T58*2
MPM$EHO'_Q  ; 0 !!0$!               "  $#! 4&!__$ #01  (! P,"
M! 0%! (#       ! @,$$1(A,05!!A,B43)A<9$4(S.!\&*AL<$50E+1X?_:
M  P# 0 "$0,1 #\ V3W\5^24I(SDYSTJK4D9329((+*QE(_C460!K+E+3X$D
MY%),3(YPNN'@U(!'DD8*"A W')J>!:7 Z6"6_I2[C,$WTK^*(2H 9]::0#^(
MF[2RHN#<1G'D:"/)+$)FMJ$@$@\5*%L)7,M*C[1Z4PZP5U(92N[;./O_ $IT
M@910;0V(Z8"2K:,#'%.EN-IPA!$6*%J*U#%)I".U1H93N2<T+PAFLC)YT-'P
MJPFDD W@33,;5YFGP$GL>*DMYY50- MC9^5N3@&GU C=MT)<W _*FR.N22B2
M%*4D$TAGR&%NR& H]"*FB2"JB#FC"$]II"*TALR$*W;B<^U9\O45=T$#&](&
M5T.D61-]2>]"3R:)0[C\BS$13@W]/I2SN,EN.&T;%8S5F!:2PA57X9_VFEW!
M8&W*0EF5SYJ-*2R@'R(-:G5&<(3G XQF@C'<DBQS_;)?^8JK&$#)OL>HU4[*
M&TJ(Q[T#:044V-77@7>_Z$FAB\\CREDE6KHLQNZ!4#UI9W%E-8R-575T;N%]
M...M)D3DT+,7=7+9R>GG0X"53Y'LE]QTX3P".M+4D)IR&#DI<8E)&<?2B4L@
MYQL)"4X\OPGKY>E,]AF2[+1<0"0:' V1-V/M7E*L?2E@*+RSV.^6GD)(SS1J
M.1/D/[9DQ$DGRJ2)(A8]:,<^I"!F-;VTM D<XYK.R5#E+"AT&1FG0CAR*''0
M>0<T?8=$VQ'2E@ #Q8J!O<9/U#!Q*D.\XYJY2>2YV.RG+1^5/W 8"7Y($H'W
MI2&:(=4-)45$GFHXO<6<"3H2PG@9^=&LMCP:W&#UWM]HANW2ZRDQXS>/&KG/
ML!U)]A35*D:?(]*-2L\1156K_M26ZVSS:]+V@RW61R7!N/S(R$H'^X_2J<JT
MY\&I2Z>E^H\?0K6[_:8[5+^ZIJ/>8ML95]UJ @N+ ].\2 ,^PIT\;MEE6U./
M")30G:'K<S<RM178ND;^[D9*5ISXB<]..:GAN!4H4VL-%N6[[0^C;5.1;+Y<
MVY*R4CO8J#QGJ"/6BE+!GNS6<P+CL]XM.HH3=PLD]N0RX,I/0X^5 FF13I5(
M?$CVYPB&U.$\@447AX(M.=QA:&EN/9(J27!'+8+ P&FN!FA &;C2UJR!3CQY
M&Z6%B2DJ&!FI(\#OD/K8?\*D?Z:*)*A<]:,<^I"&<F*E*=H21\C6;*."GAB:
M8K3;>XG\Z2;$QH.X[[TP?6I'P"FQ8W!IL8WCTJ/2LCQSD:..I<6"D^=6:>Q=
MCP*G\(_*BQW&8 ZC<*)"=O4JI/=9&;VPB*WK*=RCS0*&>!..V61&HKQ$L5L=
MN=P="6T?=23@K/H*:=54EZA[>C*L\0,J]IO:%<M97)Z*Q.+,1@!+CC:B.XYX
M;1_J(ZGK6;*<JLLR.CHT(4(8CR5XW ,E_P"%YCM)Y4V%<J_U.GJ?EU-3*2B@
MG!OD);/#@QD]W'PWL(R"G"U'/57H*!Y:U/@?X46'IF9%PE\0$+4A>U6T#=@\
M9J2G-+8=1U;E7:IM<"7J1YYI;R<NJVH9RD(Y]J=RSP-**78O/L7U!=-(/1DS
M)QEVUPI:+N?UL=1\G48^Z?)8^5"WHW0\Z*KPPS5RF6YEO+C#G>H6D%*AYU+&
MHY^I&!4I?AY.$A*QVM2%;G$5,FY;$$XQBLR)^1&0E& #3R>"!)#)D#O-N.*2
M?<=+<3EMI"TX'G4BDQ=PHM1)CCV&*EB2H<GK1#GU(0C<)"&VMY5S5.>"KJ!Y
MV\%8*$YXJ$%#1R>2A2L8/K1(+!',S5N.'>LGGSHTA+DG(:TN <5-$LQX'K@
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M<40CZD(H<U7'P)K4$ YJ3)&)M.*4L8%#+@=<CZ*5_$M[CYU&B1%AV//=D^7
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2OTI=?^;*_P"XUF?@33_Y4__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>75
<FILENAME>cogo_0045.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0045.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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MR5J<4V&U$'<]_MWIL?L#3?-$<B7;HN5S94>.$_,7'DC Z'<TQK:KLA0<O0+
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MD]>Z"\2M)^)=G<O&D[CYZ&E>6ZPZ.!YE79:>GUY4]-/HSI1<7R,YNYW)Q4G
M*BD;9HB#YQC('UJ'T2B?36$NK(WW/.JV0=$>N;IY#E2XAM7R5VZ//AT^5M5F
M'(IN@9N5/2!ZSBF !7XA/_XA_6I(MFBV#9QTU6HNV/PD%-<^!B=H@*B3O7;F
M+9!(^4USY(B!Y-"&5>Z?YGGOD4?8GV=H=5P[XI;X8:Z8FG7:!9;?,NMTDI88
M9)"EGI@5%OV0DI<1[/-WBOXX6B_HDH;NC;-KC)"6V6U.)<>Q\W%C;^]1*45R
M7L.!P5OL\I7W5D4..SE?!OQ@LEA7  4D[I2K&^WOSI+GR7%!T5%CQ"8%P;0J
M(^PV\E:@V'BXP\>1P3\I':N<O1*C78LO"ER93C"'2GCX7&T_RNY&0M)Z*'>I
M4D@91L'@7)R!=(;SC[RF9/F-.+<SGBQZ@KL=N?O1MH#8[+K;]61+O&@L.G@6
M&UI&1G".+"?O@446!*#+AIGQ;>\.;TSJ33$E:' @**?,(0XSRRZ.1S@8'O3D
M_L4GBBUR>V/"+QFM/C%I5%XB+C,W)CT3X3:R2RKHH9W*#T--B[*62&QEUZYS
M1@'[)P3U .*ZK(H*TP<J)[YJGD8^!82/3]J"(;$5U2L*P@#%687Z$2 VG%K_
M '92/3MG'.FK\@]!7PSGY?Z4-HXT&Q?Q%^YI1;+ =OTJ)#%T0JYT(+!Y'+%$
M^@8@N!VH0RIW4G\4(SR)_O1OH2=(.$Y[=Z6^P^DSSS^TCX@KT]#%AA%Q]R4V
MZHM)QPE1^4JSSQTH9R]%C28>?(SQW\3KG4I>BG3,XIX@V'W<,\6>9&<D]*K2
MEM->,'-\(96C]G'4-^?\];+C1>3PO!>_$/?H:ISSI%_%HI3+5;?V6$6QM1FM
MLOI7E14UG(/+Y30?J8HLKX^2_)'._9V>0]'=::+T=!X?0D\21]/:F1U,6!+0
M3^P2W^S6[-0Y%?>94&U!:%*1@@<P#WI<]:HG1^.E+L@D_LSKBH6II2>(#'IV
M^M1#7IG3^+DC-;[H>Z:+NA1=K:U(C+(/$^VM3:<#"  .>/?E6KAS*?1C:C2/
M#V7SPTU==-!ZACW'3\(-H*DF2EOY'&NJ2-E '[U;3KDR<L$[3/>UJEP+M;(U
MTBA*F93274J2O(]0SC_ZIME%Q:80M,9*3E(W!HD"U1)ID(XU<., FJ64=$L"
M@ .72A097K@F2M\<'&4GMRIT<FT1)#VW::1)80^^ORP4@G'.L[-KYQFXH:H*
MD,OP&%_Z@U'ZS(=M0QL/\1VM%#T/U?(FB0;Z(ET5"6#2/E-#(Z(*$DC.: ,K
M%T _%5;#E1SZ$H'EO&'!>DYP4(4K/; I<0ZO@\PZXT[<I4V[W)=Z$* PP%NY
M(7(<!W3Q*(]'?">XICC]-EW$^4BV>"G@?%=M*]2265N./I#H"R0<$[;'^M8N
MHC*2='IM+*$*3-(N-E@VMM$9MM(7PD$8%8N:,K[/3:7;5T5\V\H >P,+.PQU
M%5G"3]EZXKBB!=O0)3;JD!*LG) Y4<6TJ*\\2NSX;>CRG'1PG.=\5TGP1CQ7
MR)9O#LV$CEOM3,4@,T:16=8Z#A:@LCL5UK"N *2>>QK>TR>ZT><UL5M9YCM=
MW>L5YDVB^6]UU=ND%@^4K"\#MGN-\UN8I*D>0SJFSUWX$ZSDZNTFZ%M(2S:W
MA#84@%.4<.0E0[CO3%RS/FJ9I"BH@YSR-2Q;&.D^2OJ:HY>QT2Q._(0.U NP
MF_18+#:(LZ,.-*2HCJ.54\R>[LF$+8Q18DMY:+AX<[;U646I6PWCY.?\/1>Z
M_P#J--W$;']Q=902MW'>M8.(^ (0,BB0R71ROD*,0!RP2DX'2@D=$&0HA(&*
M ,K=T_S51[BCET)78!>T/.V64F,KA60,'&=L\J"':0Q48_J6W"[*-L@I3^'H
M)D25@Y)5D81GF<=^0JUF7TTBSIW<TV>@O#@0;?I>/:T(PX6P#WP>54806UI]
MFM.3<TXF9WY$AF^3 \KCX'UI3[#->:U/$W$]AI9-XE("GM+!*U*P$I&,U1ED
MKHU,:4E;%R'.)!!_,11+Z@,DFN&0R0M$92TK STH90M\$P>U<E>DI64$J5_J
MI^+Z>RKJ)M]#"$WQ6Z4IY6 H#AK>T#M.S$URM<'EOQ'LK*M7R[XP>!"W AX!
M)(2/S$#<CO6QAC:M'D-7%J1Z@_9XL:;1X>,SWXZ&WKL\9*@E?$GA'I24GG@@
M9IJ,K)V:8X_'2A064C(.-ZEBB;3!"DGAWW-4<O8^)85CT)/M41^Y,D-M-25Q
ME+6583TS5#49H0ERPX2?I#A^\O-D*2V.'KGK566HW?T\A.?/)Q^.^QI?FE]B
M/(!6'=QVO0H-#]1!0D=J)!OHB7R%&)!I'RF@D=$"H RLW-:3<P >611B5V#W
M=A]RR2V66U+<+*N%*#A1..0]Z&/]2#3,VM(:$N1;EQ2E"5>9P#=*0!E63WK0
MRQN%C-//9D5^S4M M2@V]+\PI1D)!.X2.9'M6-!-SW0Y/29&L>+;.DV5C7VK
M-$V.X.KNE\MT=Q:N((5(1Q';<D [?>LG6X)2FY179L?':J./'LFS-KIXW^$Z
M7S$=UO9D+<( 29(._;/(506CRQ7])J+Y##)TI>_V&C5P@7.+YEKD-24.+2I+
MC*PM/">N1MO41P2C%MK\%N>HQY))+UR!ZBU=IK2=K^-U%?8$!A)4.*0X$\OZ
MFBCII9*:0&36XL=J310&?'3PZNAX+-=57#'5AI:D_KBK'Z26)6S/EK,>9TAC
M_P")NBDVMUR[WV-;6TGU*DDMI [DD;5L:"2?#,;7?3S?!D5XO=FN-U%TL]XA
M7*"M:PE;#J7&WVE[$!0V)!K:T^-QNSS&OS1FT\9ZAT'#79]'V>T\"FPS%3A*
MAN 3Q 'Z9J-M(QG-R8Y="CN<FN?00[TB"$9/O5#)V.B6)8/E@^U DV&QE:F2
M6L$;J.U>>^3J4Z0>+ACB3&0EC"MCPY-/TV%P@K.RUV+/W7M^E6=J*ML)T^VK
MS'3M6NBXAXI!2D9J>@WT1+.=J+<A30+)4 DYH9.R(@8.1FA#*O<&E"Z9R.>:
M/L4U066U*3PIW*@<8I4I*/(<(M]&.ZBUY;=!VV6/(7.F.2O(:B1@%OR5!1"4
MIQG]3M6FFO$N>R<3D\C=<HS/Q,T#XXZEC6S6>O)<VWV2/>H;D?3-NG^7'<AO
M.);<3*+1"W'#E.X.$G.U4UJ5BN"5<&M+1>>LN5[I6NN50'K?4.G?#=:K3!\+
MHETOB63-<M%NBHQ&3GT)<=(4<D8PDDJ.Y-8^/+++-[WP;TX0T\$\4+9F]JN>
MJ]7W9F1J'PDL\(R9BXRX+, K<0@\G"I6,C[=*/-]X2':64\R?DQH<Z=\-[#)
M\9G-/Q+Q<K%#M=I4Y=F+/+=B,NREJ!8SCTE0023PBHU&H>FPIRYMB-+I8ZS4
MR25)+_LSR%8(%D\=;S:&H4_5'Q4,&W(N\DR"V^V3YB4J<V2%<23]J+%D\VF4
MWQ0IZ:.GUCQU=]%KU!IO]INP2(4C2C>GH]OD<"WX_P "VYY:?YDYZ]/>N:Q5
M3'SQZM.\;X+;I9$V\R9%HUM#58KTA(62RYF).85U2#D)5W2<U7BXPFG'V,>]
M0<)48TQI"_>%\^Q1=*PTW:U7)XRH\<-!'P[BG"I2'/\ 1DYR*WL6=X8-RZ/-
M9?CY:G,H8^+/>=BOD6YVF--5%2RXXD!UM"^,(< '$ KJ.U%#(LRN)D_(:&?Q
MV5X<O?X&'Q#*D%12>HY4UKT48RW<C32Q"VR4C&":HY5R6(EA6D^6D4N-]#&'
MQ)2(C2'2<\.<U@ZR%YK1T9J/9^G7U,]O"4K2 <$XZ59W-I) 2RJR#SH_YE?T
MH^1>]#G3WSNUL(MH>.#*17,9Z!%')H1;!9GR'Z5+!B!!9 QPU 97[CO<A1BY
M=GZZ+D1[5)?A)2MYIE2T(4-BI()P?8U5U+:QR:^Q?^,A')J<<)NDY)/_ "9%
M8(4AZ&G5,/3$:!)G\+Q5'.SWJ/H3G<[@G%5='JIXVHO^X]K\Y\=II)J#7T\<
M*K- UZP]J;33FG+4\TS)7&!8DN X;<20M)(Z#C2,XZ=:'49U*7X1GZ?2N"=]
M^C*XZ8NGO.,S1+]OF2G/.EIBK3)*WL;K\PJRH'F"0,#:L]1COM2-7%&>SZH!
M"KS:93;DQ%J>2XC&$/H0A2CCD-S^N*ER4)JWP/A;@VHT1:>TO./XUJN_L($N
M:4$-MCTQV G"$(SU W)ZDF@U4_,U3X0_X_%'!;EVV_\ !E5\T\U:]=1]7V=A
MLS$$N-(6HEIS.RDN=<*'4<B :N)PPXHQETT9V>$\F9RB^4^.#2FM3ZBN.%/^
M&T]PE.0(\AEQOZA64DCZC-4GDA-<2+>.&7':E"_]1'?G]57%+\"+I9%H0<<;
MTQU+SC>>:D-HVXNQ*L#L:+#EC.:YN@=1I9[&ZJRG2)-FT_JG3EL?ARG8CD)<
M)"EC(04%&%*5U5SV]ZUWF>WDS=+I*S6O2-=\*+5(M^@;<S(25+*GG HDY4GS
M" 3^E6OCVU@;?MGG_P"+\D<OR+V?VI?\(N#BBE"<-$9%:"5(\NI;G8\T?ZV%
M'E@FJ>4=$L9/$G'M27?H,4>:^FX%OC/!M].55]5@3AN]BV'.3(Z26LC)ZBLS
M!CG)@-H&RW^<_K6EX)"]Q<M/?.[6@C00\7\H^]<Q@&>="+8++.<I[BI8,4#H
M2.'Z5 97KB@?B8WHO0OLG\M+B5LKW2XDH.V=B,4C)'<FBSILG@R1R?9W_@Q^
MP?AUOUMIN!>/-*H#I5'(!*?W86.8V )/]:P\3A#->5U1]4UT'F^,<\-.4DG_
M )IEX@R@Y<92Y(*1YBB@J&ZLG.<]M^5#Y/+)V9CQ04([>"M2)S8O$EU]WB.^
M=LX2!R':JN];W%FYBQ+P)T9U=-61[C?'K/;):(,!E?ER[LG<M?F"?]0]N5!+
M#/4))\"Y9(8D]I?53+4C1[#%AU$Q?(TE*VTR&7O,(QLGB5SSG.<T^6GEBQ59
M6P9XYLUI4J,:U7;[$FWM7'4VJFK.B(ZMM*R]P'S<924@;J(/2FK%/48D+U$X
M8<R;98?"7Q3;OEKCQ+M(COOI):1+0?+\[!P.)/0D#-5,FE>!NNBWCU$<KY?/
M^P]O4UAF;Y#KI*1G(YX]_I4?'QVS;99UOUXDN3.M56RZZK;B6RR.,M.PKHBZ
M2'%\_(;004)]U'^U;4Y;TH(Q]+#QY)2?W/2&G46ZVZ:M<9U*/,1#9!.=R2D$
M[?4UKX8J"4)<4?,ODM3Y]3/*_;#_ (:),02D8&_*K"G71152Y1WIEE#(=;1R
M!JMD=CHH<J)0@J':EQ[#?1VBWH6RI[!*B,U&5M\"G'V+A:%/N*<*U#?I1:;$
MKNBNUR%?AW^JK^W\'4BR6%1#CN*J(TD.N-13N:YAOHBX1FN0M@TI"=SUJ6#$
M%3\IH0RNSO5<QFC?0M$QP001D4F0R/Y*K?Y7PD"6[&;:9$D$N2@QDI(VR-MC
MBLO7X+C<?9[;X#50U24,LN8_FE7H3-3Y$"P,SY,-Q*TH*$K6/XB/Y5?<5ESQ
MRQQ4_N;,,V*>>6&+M1,3\1-:W>TP)RH"5J?F/HB,<*=DE>W$2.VYI<,>_)9>
MU&J\>%QB4>T:ZT%:8J-)W&_Q[;,*E!:):5(<>5G=1)V))/,'-:^.MO1B*;R*
MKH;-:=M5O+LC1>L(]MDNK27(R'"E#ZCN20?YOL*8VGV@L>FR2YA-+_W[F::R
MTS<+M>%S=3ZQ:EMQ\A16OB# Z[C9(]Z)3=;8Q%Y=%/')RRSL@T1J>RW"YN6#
M0]S_ !#X8GXMU(RTTD'HL;9^]5\C<>9H#;Q_+9N,M%S38K5-O$DNSG(YXNAX
M0HA)/N1C:J$,>W*VC5_6SGA49EBTCX?7*5'8U'(E-MQGPH<._F*2D[#^];&F
MPMR63['F=?\ /X=)CGIE%[V^[Z-)MMENMT4$-'@;&R0>PK7C62VSY^V\CO[E
MYM>F)$*(I4AS) -2EP/C%Q!;*WY;SR1RS5>8Y#-20IHY[4,&KH*70^M\5*[?
MGA/*K#BF15H5_P %Q:1L.(C>D[GC?!5DE9S@?GH_*Q=CJPMX<<)J$:B'+@"4
MC Q14&^B)6VXHJ0ID$@ H)Q0RX!B \L@4 PKLW_-!]:-BT=\1[TJ0:Z!8)4I
M<AOFDC'"=Q^E1MI4A:DTV[_ OU!!3<[8^RDA2U)*N'NH54U^+R8N/1K_  .I
M_3:G;?$O^?1@=[A*2^]'D1>-(5LOO[UC84KY/:ZB32=":7HC3FLH:;->K;'?
MX#Q(\Q R@CD0>?WHHSV2X':9U'9-6CEC23%E<6R]<@Z\IIV.TM[RW$I0Y@*R
M5#.< 8/3I6KAR9)1["E'XW=S!)_^_)4;WHJWW*/(L\J:I<.8P(KK:5('FM)_
MD5@;C:ARY,D5R^ IX]!=QC;7L)TGHRQ:/AHM=CMS<:&@^<M#3?"2/?O68OKG
M8C4Y=^.J+.Z)NIY39;) 6L(;0.8 Z_859VMM)=F8\WCPN<GPC5[5-;898MI7
MZ(Z4LI2.6 *V8X_'%?L?-<^7]1EEF?N3+G:+RW;VPI*,\A1J9$770Y8U0J<T
MZA*<<Z9"5CHR<N&P6QK4MUXD]:5,>AJ02T2.U E["?V'ENN<9J(&U8Y;U;32
MB \E,5W:4RH%320,]J1.:HKSE'L4?%.=S2?*)WHN5A/[QW>K"[-5#=WY1]:E
M#'T1*HQ) [0R(70&L>H[4L-%;G_YJJC8".Q2GV'Z%T0D./X)^8TQH0NSE.,E
M1Z&H<%).+]AX9.$E->G?^#+=9693,CSF^1)21V'.O+R_EY)1^Q])Q/SX(9'_
M '+_ *%%QLK<=IF9;I& I*2K',CKO]:+99,,C=T5#4T.;-9,A]D!U"M\$#B'
M3ZU9Q9MG ,L$LKM(K%IMRXUQ*G&U*2$Y&V @U.?+Y%2)AAEAG]2'=Q+02@,N
M+4\\I*0OV]Q0X,6R.YE?598SGM19] 1^*^-L( <6A+FZ>X22<?:M328E=LQ?
MG-T=)]'IJRP/1G&I"GHY/"=Q5_I4SPR_F2==!4:Z2TX"E' VYU"2&*!;M*OA
MUEY15OCO1-)+@9&-,L5DYN8[BD3+"&PY$4""()#2B,@D9[&K:C<2O*(O=0]Q
M <9Q[FJ<X%>:]'SA-)\8O:7.Q?Q':MHV4.OY:E!OH^*I@D@=KB(D!4D;$BN)
MHJUPWNJ_>N9$>PA(('(TD-],4,GA^(SSXJ,2<A1X%<6P *M_;>H;H*K*O?HC
M;U[>BRD_NGV4E22G.>(;?2O,ZN'BU/[GO?B9^704_7_PH$Z2Y94.6N3QI4VH
ME&3LI/3Z4UXTV3BRN**=-NMP?EI7\/E'F#"2/3CO]:[8BW'4');FSW\.,^0U
MDYX1NKZ4N6/FQOZE-;3BXO1;:T66SZR-E*^<4R69J-(JX\*E.Y%N_9[MSMSU
M U,<)+,)+SJ_^8<*1_<UL_#W).;,?^(II8UA7LO^KK%^$N&2E)+#RB$;?(>U
M7<V/:]QXJ4*DG_H4Y$I.%H1N:B"?H5+AEHT3YI0\%-J'JSN*-M4'!EVL?^\I
M$QR&S?R#Z4N/8Q'U104XQDTUY=J%M"FZ<:4$I/V[4C>I,JY9-.A+YCOYOZT5
MH1N9IEA22ZZ!1HVT._+7P\J)(-]'"Z,20.UQ$012%%1(%<&F5J=M=,'I420$
M>PL_PU'VI;[#?0F2DE3Q HA5'V,EM:P\ZDJ99!>=QMZ$#)_M7*FP\<7*:BC)
MM*:R&NEWR_"3QR&KH0IL'=MKA 0/I@9^]><^6MZA-'O_ (Z"PX:]=#35L&WW
M:*J6A*?-0.#;F:5#*WT%+"D9E.A.MI(;=(0@_HJNE*0<<5*Q-<)DV(E2G'^)
M>Q'Z5RG*N0UA5[D4J[Z@DLD/&.M]]:@A#8W*E*.$@#N3TJ()Y'P%*H*Y'KWP
M7T1*T3HYJ/<W4.7.8?.EK;3A 4K?RQUX4\A[UZS38?##;$\/K]3^IS.3Z718
MM4MMKM4A+B HX!;XNBLC>KM6OJ,UQW-%.E:):><9G0AY2E8+PQD*/M2YXN+B
M*GCMEAM=I,2*H*"<YS@#>D;9+M"_&XAEF24J<2K8]J3,8N!JG ;P>E*5V$B6
M/$+B5+4<8&U.>.T [*[J5,I*?+C*!)^U L'(F>-ODJ_PMY[-_P!:;X!7B9L=
M@4 ZZ3V%+1JH>EU'#W^E&@FN"!9'.B% [RDCFH5Q$2'C1^<5P5%4N.1=B<9"
MN1H&Q:L/8:=DJX&6U*/7(.!]Z%Q#5O@=V;0<=L?$75PO%Q6R$*PGZ>]%&-]A
M;:!M9?"(T3?(L* F*A3*HJ5CF2K8X-,C"[H?A262+/!?[/FHG--/3I,SCQ)N
MDF-.!WX4!? DX]L5Y+4N4\D[]'OX*,<,*]JS=YC00N0N.]QMH5E*@>:3RQ4P
MBHN@9.U90Y:'Y+RO)4H(+F5)[T[:ABY@+;E95/D%S"2C?GVI<E?"&PK&DW['
MO@GX='4NK3JV7"0NU6-Q7P;BAL[,ZKQU"!D#W.:U?C-'N>Z71@?.?(*"\>/L
M].*!" V !O6ZCR3Y*YJ=;KS*N$@)0 1GZBF/HB/8;'=*4B*IK*0D<('.I;X.
MV^QE#L7Q;16[.<0/R-G!/U-!NV<@M'UZ+;+4"T&UEP[Y)S_6ERA')V<H@_G-
MN8"!CZ TF6EV\Q!EPZ&,4<+!)(]0Y5T&X]@,INK)KL9T>7C;O3T)G)E6_P 0
MW#\J:(3N-GL207'0:H(U$/O(' "#1!OH@6T5;A>,478MJ@&4R?F+G/;E7 I^
MCF-;E2%)R]Y:59PI0Y_2N7*L,%G0K?:)K$B8RLJ=V2I\X;)[;4R$$^617V+.
MS%-TA>AP1T'Y?)  S0N6U\H*,4^@&(W=($F+;Y2BZI3Q4%9Y)P13&XN.XZ-M
MTR#Q);2WI949IL<*W!G'3'7]:'"VY_@8JA)'\^M1,1])^(^H;06PS#NI3,CX
MY<2L<>/?CSGZU@:W$HYFT>QT^5RA%-FEZ=OLEVU.0)*LK; 25=5) V-49<2L
MLQO;M/MM;C,(<<<"AZN(@JR13U'GL9#)NA0#:;3>_$/5"-.69)1%XP7Y.<?#
MM9]2R?[4Z&!Y))(K9]8L,'?)Z>TY9-/Z5M;&G;%P)C0VPVCB.%N'/J6KNHG)
MS[UZ'%BV0VQ/%Y<TLF1RF%/C.0DGB[8W%/VT([$]W0GR4C /F.M-C/<J%%?H
MY*N0Q]U+"CY:$A1)W/;EBID2C\)$B+@H7EU8]*14)40^0%RXS@^4!MN0X=U!
M0S]J@[:3+?DA =N*UL%6R6T8/_\ *-<+D"4;? ?' #0+3OF!7("NE",N@*$]
MWT\W='"7#PD'?)VI-;70J4;%W^ 8?_$/ZU&X#QE^L1_>NU21?18A_#%$&R#;
M)"N5$@)$4AM#45V;(R&&4E1SU/2ICVV"E?1!,DI;FVJ.<!F9%<2!V41D8HXK
MBCO3.HT9F_0G[%<O6XT,M*Z@]"#4R20RO: =+W&3:IWX/<5$^KA&>]3*.^+H
M)\-4/M5ZD@Z9@?BLB(Z^^D%++;2"I2C]JK0@FZ8;C?1D"=;7B]3W?Q1#C;#Z
MCA*DG#85[5;K;P@:5V9QXE>!;.LGV)+%P$*4T\I<28A/$V.+FAP<PDX^QJIE
MT_E>XT\6MVI)E%59]1Z3U"=.ZGM_PCSS8$>0D\;#Z<<T+&Q..G.L+48)8GT;
M^FU4<RI,9VUQBZWJ+IQJ:PU(N3OD!S=:4C'7'TY5.'&\LDB,N9:?&Y,VJPV#
M3^@+0+?:6O\ :7@/B7U##CRLY]0Z =!7H<&F6.*3[/,Y]7+/)R]!"H,RZCS7
M5K:0G<8."?O5RJ[*$W?08Y<+I ]#C9DMXV!V5^M3NHZDR6 ^BZAMUQEYCRUA
M?ENHQ@I['D:E-,AJB5:4RIZ4$^E!RJH[9W2)IC@85Y$='$^\, ]$IJ7QPB%R
M216&+?'+RPE:N?%US7*HHY\NA:\AZ=(+[JE*3^4=O_RHY9SX#H*_AB>#*BO^
M1/(#W[4:="WR=NSXH.' "I7) W/ZTMQYLEK@$\A?YW_TJ/&#M+/IX!3KF>U9
MPXL&3P\-3%V^0WT?8Z6#(:0]R<7P\^N*-IKH"/U=D.O$!C2TOR3@@ ?;B%3C
M;DZ8;2CT5Z8^J?9+9<T?/;WDA6/RD4]K;PA2YNS] N2T7EA;*@/4.+;F*Z:X
MX#4FD,=96TL2&[K'3D*4.+ZU&%M)D2=M(L,-U+T%E84E22@921UJO.+4MR";
M;X$-ZMEOF3@ZF,C/4@8WJS&7!"ZI@,C3#+G[IMKA#@P>WU^M2GMX)X8IU!H]
MJ\6M=@O]L3<+>L[MKYH/1:5?RD="*1EA'*J:'8LKQO=%E(TGX6^'6C)[VH6$
MR+E<(CBDQBMTK;941\Q[J'>DXM+BC+<BQEU^?)'8VJ_8L4&"NYNF4XWG)*B2
M-S[U?BGVBC*5*AY&B(; 2I.PW HW]78OKHG3&8"^(H&3U.^*XZR!Y\2'5\!(
M;0.!*>_<UUD@*(9BNR)+A])W [^U1RN2;LFA1"YF4^<*5ZE>P[5ROLAL^%DS
M7L)3AE.P%3;9W1WY(1E"=@D^I0&-O^^>:)$-6+Y"GY:E1[8?AX^<.O8]2_\
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M' *5+(6Z0/Y>@HJL@$5<XD/,9&%/'8(5G9/19(Y9J&Z)[/RU!;/E%1+>0I9
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=:*K ;(Y,B-E+95Q+_(.M$ T<9_\ ;/ZT7 )__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>76
<FILENAME>cogo_0044.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0044.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
M'0   @,! 0$! 0          !08#! <"" $ "?_$ $,0  $# P,!!@('!@0#
M"0    $" P0 !1$&$B$Q!Q,B05%A%'$(%2,R0H&1-5)BH;'!%C-#T222\!<E
M)E15<I2BX?_$ !P!  (# 0$! 0            ,$ 0(%!@ '"/_$ #01  ("
M 00 !0($!@$% 0     ! @,1!!(A,043(D%1!G$4,F&1%2.!H;'P4C-"8L'A
MT?_:  P# 0 "$0,1 #\ ]YNVI;C@6RR2DCTJ*KL1$(U;BQ&M;;.YQQ)! I:R
M7F31*CM*RU1T)4E6 1FGE'@K)"D_,CLWUHD@#%77!1H8OKF$A/W_ -!7F3%X
M(7]3M-C"0>/:O8(W\@Y>JWG5=VA.-W%>P>W9+,8EX[U=3UI6TO$EELCX5W/[
MM"BN0B%NW^$*3G&#3U?0"?996,XYKS))H:]CE00PXR<IWGSKQ4G2?":'(NBN
MMQD9'G5\,]E$0<23C(_6KK*/)Q;P2*CI4/OD9]ZAMEMJ(%MA!&Q62.N:&V2U
M@L,NY3@>5#9Y$4Q6X(&/.JET6.B#\JJPD>SFTI/U@#[T;V*>XT=V/05XN4X>
MKH<6.&7N%#U%9E5F5@'"Z$>,%*ZWZ'.8VLO[%*SC%7BGO)G)8RA36W<G$J<"
ME%/J5=:T-[7& "EN ,EA?U@TMX\I/(!HJR5R%5QTXX2<?.K9/++/A9&/&#4M
M8(P1#X8*2$#)SUJ,\$X&&V@*  5UI2QA8HM3T%,1SSR,52'+"-.*R)\9T(4O
M(Z*IV'6!>?+)^_!%3]SRY)HKZ>\YJC>#S#T1??( 2<8J<Y*KDO-H!XW51H(D
M5Y++;1QC)JRY(<5$@( 23X1CT%%2QRRO'L=J67$@)KSY/9:(B@H/(.5<4.4<
M%HO),TVI R>=W-+M\A$1R_"$*/K4-%D6OPGY55A(]GZT_M "BI\%<<C/N]JD
MG)GG=O+/VA!&>N*Q92V+)F1CR&6XT<PO P"O'7TJE5[4LC:B\%1O3D^0TH]Z
MH)'I6B]='HF$> *SI[O[NB(XXO?D4U^)7E[@:7JP/#>CF6FTJ=R3CF@RU+VY
M#[, F[V)]!Q'9W(Z9\ZF&L2[*N O/QDPU;5M8--1MC8N >,!JUE&U"@DD^W-
M M"Q+<W<Y"6I"%' S0XK(9MI<&-ZH[2K%I,R$OI=DO-DE26QA*><9*CQBG(6
M1BBBT=EKRT)\GZ2-I92TY&M)+6$A_O"4K94<XR".4\=14^;"789Z*4>$<V[Z
M4VB'8*;W+C2$0-VPO( Y.['A]?EUKVZ+Z*/2S-4T3VR]F6K0Q]0:PANKDIRV
MRYEMPD?>&%="*AM>P!Z><>T:2A 3W:@ZDI<^Z?7W]*&\GEP13P"-X/-6BR)E
M%*75'!'%$R52)RA38\*1GYU/)['R1]XO>.\ ]JK)\$I8+B5(4D<@4L^RQ5G8
M5L2/6O,O$L_A/RJK"1[/UI_:*:(NBON,M6($5E*5O;4J.*QK,)89GQ[#@EMQ
MV T$C)\\4IYD5PAG+BCY&N[C*MJUIVJ..E4E#+316-K7 ',A2]2MJ84 I6.:
MUHQ:H62%/UX1H\168P^)<W$#C%*_B5C:A]+*]137%F=\7$A)8/.,<T&>UK)5
M1;!LO27UNY\0\"A(].*+5J;*H^D]Y"D*&K;U:>S^WN3;LM90VK8AL?YCJ_)*
M1_4^0K3A/S:U)D5TSE/8CS?J;4G:MVL7=:;%,N$*WMJ\;##Q990CRRM/WSZ\
MTM;J8P_*='I/"9266@W [,)D>*W+O\L2W@CO'$GQ(W@^'KU/SI"7B+3-^'A/
MI%S4_9^)$91:8((!;22.0"<G^=#?BJ3PPW\#SR9 ]V$NR8%QMA=?C(>F?&,H
M:_RPOS3MZ#/7YU?^*B\O ^<"Q([+]8Z?#TME2W6DY[I"%%):]=ON<<TS3XG&
M3Q(2U/@DH+*->[#.VW7FD)@MU_FR9ME2 EYN8ZI2T('!V9X '%:U-JMZ.<U>
MA</;D]HJD1Y]J8N,)T.LR&TO,N Y"T$92K_\HL8F-*3]RA'EJ*B'"./2B[2L
M9\9)URPH<*Y\J]@G>WT=EE8;#J\U#2P63;[)&"I:25=!TI=KDL1R<@H'O42+
M19>V#NR>>E4#='%I.;B!Z&C)< XO+&C:?W:KD+M1GT7(4E>?.LB<7CDQXODN
M377.[W \@4JJXMC+EPBK:$.W&5W2ED@4W*G$5@$HMLBN:?J:[-25+SGBM"JM
MSJVLM);'^HRZ<U W.6$.KQ\ZQ=3IW7+@:IL;7J'$7&(T@;B,8XQ4II0Y&5-9
M.U7)M,19) PDG-,5[)Q45[EO,^#!=<Z8D:[O E3W@&$DAL<G8CS 'K[]:-J9
M^3!1B;OA&EW/S)H(6_3MJTY;&K7:VNZC-94GKXU'J3GSK$U$]KW(Z[3Q5OI7
M0,E(<<<4$C )Y3Y5EV6.3-F-2A%98/?MRW-RG$YYSS2S@VQA2C&(N7*V(;0M
MQ+8)]:(GM>"-BFLB+=DIWK2L83YBM/3R4DE@R]35AMY!\"!;/K%J/*C-+CR3
MM4DC@UL:>6SIF!K:(S1N/9)=)\>#*T7/&6;>,P5D\EHGE'Y'I[5T$7A8.#U]
M&Q\#J;>\0I:<\<U=2R(*'&".-&>[T=X#@'->;+QC@8'ELNQTMIP*I+@(0=VE
MIO">M+-\DE1\DE!)_%5GT3'L*A([D<>540:717M/[3_.C>R!1[&K>*H'P9T9
M+3#7'7%9LDYK!D123.Y4AQR']D,DIYI:%3@\LM*2X1%IZ)= \7&B4G/7-:,)
M+&"R622[6Z1,NS+3Z^\2?0]#3:>*]R(VO?R$X-C^KW@L$%)Z$4E-JSM!8)Y&
M>&RV\L G/%)64),/!G5WBN)94TA1&](3@'UI>I26KBO;_P"C,:\\@QFR(\3B
MVU !&./*M:^K=)LZ'2ZCRZU$7+Y&:#R4-.93CIY[JYW5QYVG5:&3QD$/1&V4
M%Y9\7' \Z5\I&HK&R"60EE3B$)Z<#'GCSH+2B7CR*=Y=;1!WX 4H94/2E9OD
M;K6$9O=RVX5N-@*)\C3>FFTQ3516UE:-:798BK2.$O86OH&P?4UU%%7F0RCF
M-18H/#-5L;3EKFVNY!9[Y"D)40<[VR-IS^M;-,7LY.1\1Q(TQV4MD[&^0L9%
M7EVDC$CUR7(;8>3N<XJ663)GV$(2"FAS)9%D%/2@LEE>2!A' ZUY=$KL(_Z?
MY54-+HKVK]I#YT5=%$,>3ZU)?+,7DO3%8'(YSS2EJ7L9&<%F-<I24%+ASTQ2
MLHX([8>MM[D,,%.T@GG.*O7WR%3:]BO%N3CFI&''U;4[<$G@4_MQ#)>-F7R-
MZ927Y+3:3D)]*2L]7 :N6'DOOOIB+#K:AQUYI>::?)?*01:N,28XRVD@E*LX
M!]J-2HO4)AZK6U@[?4T8ZRE6/ 1D>N:;O>,FOIH.32,]N+)?><2A_!"MN2.*
MYC4Q=D\';:::J@F5DV9]P%3CBECIM/17RH7D2P-+51('XC:V"V 1E6<>F107
M4_<*KL\BO?[/%R4+4"%CC!\Z5LKY&Z[<HRZ]V=27>\CJY23GWHU4=L0-UF]I
M(.:3,=5CD1I*<J6K"3CKCFNQ\*YIRSD/%FU=A#6Y(+MJ0RL87&PD'S/IS\JV
M(1]CF]1ZC1(FUV+'6E0(#*><Y\J"EF3,>7&<!!MPHQM&1BK%(LG4Z7$CBA6=
M!#X$$@\&EVT6*LU.WNQ_%4KHE=A!?W$_*JX#LJVS/UG^=%0-#+4EC+'X@6\!
M^$^=9SFTC)VY>3M4!D.H2C"O7%>K<6_4$BLC(BTH$(%+>58X%,-UIC6Q[1;F
MVZ0NXH2$%.<8'GQ3*G#;P \O+"_=S;<I*VTKZ=3YT-0A-EL.)=;ENO?:OK!'
MFFD-9!I;454FGN"%M4TF>RXTZG"U[58^6*6T3EYOJ#U;=RE%\L)NN%IMK)"D
ME>%Y.,'/G6E9ZGAG4T+$=Z//G:OVVW33>H9=LT%I25J%<96QU489&\=0#@],
M\BLJVF+L;S@W:+)>2LQR9UI?Z3?:S<;FN'?.S>198HZ2)C*D*'..>.!Z564J
MJNI99:%6HM_-6TC:F-9_&:2N%_$3:N*E+I2GD+P.2/8UGSLC9N<?DU(U2KQN
MZQ[GE_M9^D'JQA]R-HN1'?6I843N1M:2>@*E' IJB%4L>8A'4WWQ;5#X,M&H
MNV-Z"N=<]?Z>B/.J"V(HO#9>!/.2E/&#[T[):>,L*'9GQ_$R3D[4G\&N]FG:
ME=;G!:L.H;;(BWR'C<I2?LI*#^-)K0JNK@E6NA-QNG)SERS9F;NXY#>E!HN"
M/'+Q;!P5$ X&?<C%:"L]+FG[/]A*W3RE*,<8SQ_5]%3LG[<).I-8QM(WZ*(Z
MI\<JCN1P#%"D<=VE7WE*!ZD\9K)H\1;N\N73Z&M?].QAH9:J#YCW_99_<W-R
M4B,WU_.MA<\G&/TIH_1;@F3X4G./:AVHFN68X+P<4G@C%*./(7!5G'=W9_BH
ML?RDQ[+[B@$#GR%>09E>UD?60Y\ZDHACJ2QGEN#<U!//'J*S+&H]B$8Y1$T@
MMW'NU'@GBB0JW\E5E,<6G2TRD!&4X\ZM.AY&LMQ ,RXM1[TPMQL;4CG SUH\
M:\5@%+;+D:79$&XQ@0U@XXXH<,IA7.,N$!W[2% H:5R>>*9<59ZF>V1CZ5[@
M6[2KA97[.S#A!UR=.[E;F_:&@E.\J/'.<=*Q=3;*B<5!<-F_].>$Z?5>;*Y^
MJ*;7W]AGO[X^KB]%W!3['>8(QR1U]J:U$TJ]R-+15R<U7+Y9Y[OFBM8RPVBR
MWP:>M+0671%;_P")FN*SN)=ZMI&>"D;B?.L:-F6G-9.I52YA!X1DMJ^CU<+5
MJ"3>&M57RZ/R7 KXN8ZZZ6AC!2 M1"@?>KWW*;PHH]I-!Y&;/,;-ZCV_ZDT?
M(ML%I/<&(&G"H9!61XJS[6TO3\C]<(VR]7L>3-+]F4*'KZ9#O,-Q<?XP3XX4
M1W96.B5@@^'VK0E-U1BWV9T*(V3E"2S$T.\]ANE[@J7/<L-M6[<@#(PVEP+Q
MG:-I_",\ 8J+-98Y+/1:OPO2Q3V1Y_J267LRM6AXS;=M^)"BK>$OO*6D9YP.
M<H'MT%45TK+-S(EI(U5[<#;?+A(L>C]02[>WWDIBUO.H23@[T)W8KI-RA0\?
M\6<XX-W17_DLB#]'5QN_WC2SS3+3+MKG=X$M9([IYLEQ/ZH!K%TG\R^"^'G^
MQL^*6K3Z"_\ \DE_1-<GKY<9U]1<<\((Z9Z5U/L?+'ER;)83+;3H[I6<T.;P
M$A'C@+%"E8QY"EFR^&4YR2DM@_O41/*)CQ(ON-J4D8QR!4(*^B.UMXN6#ZU8
MJACPFO'C/+0XU%=[ASC-(7PSR(5MKLOSK8%R&Y+*DD YXJ:+-G#"8ST$E2 (
M?(Y2,4V[(L,UB(F7=Y2YR5CU%,QE%P$Y/D:[.ZMYA*4JYV\TI&"EG!:$L!-L
M.1UC<1SSS5Z[>'$+*+@U(J72*X];')Z4[C&=#B<C@9!'\\TCKDIU97:.A^F[
M7#5-/I__  "V^8])MJ&))5M:6IMM9\TGQ8/H0/*LNJYRJPSKM10H:ARA\)__
M *5IM@2E+<D;MZTA2$DY"4>7'YT*=:3Q\CE-ZDL? /?#EN9^,N#C*&U<)6O"
M<G/& /.@V0<(YD/PE&UXJ);S;&9FC7%,.'E*W<XQD@<\_.B^0E1O?W%*M2OQ
M6R/V/.>JW';3=F+XY&<6TTDE['!2D=3[\<U.I_GTK:6H;IU#W=#WI?45@U A
M"K1+;=44!6/NJ QG(]1[UD2G.M;9&_"-5N9P]SBX18,B8IAZ28Y=22E15GQ>
M]/:%>=+!E^(OR89$35TR<_IV_"*IIMXPBPA:22<J<"20/_:3BNAD_P"4X_H<
MQ%KS5-]=_P!2_P#1QT$-,WIRYP9"I-IA-+,22O'>2'W$@*W@?=V#*0/SH7AM
M+E9YC70K]1ZN,-,Z4^9?X[1Z*<ER5(RI7!]*WS@<L[M#BD2%%1SD?WH5BX"U
M/+8Q(>W]>*7:#+@K7$$EM6?.K17I/?\ <$/PCY"O((R&V?M/\ZL50?KQ!E\E
MU"EJ6DX/7BEI/=$SW)-Y#6G):G$J2\K( &*3D]K6 M>&PP^EIU)2D8!IM)83
M&7S$4[Q&:3-0DKQG'E3T<. E.ODNPYXAG:VK.*4EZ.F44M@5CRW'UI4XOCK5
MH3B^ FYOL8FQ&EVQ^&MY"/B$;0?W3Y'\J].M2K<5[FIH-2M-=&[V3$=RSR;;
M&4\MU16%%2FL^$%!ZI],IW5SLM/Y$))OD^CK61U4HS@N,?Y77] 3<==6U;BG
MW9 0W"3E0!P$CD\TG*_?)-\8'*M,H^B/N93:-2S=>:FD:DFKD-VNVA34",L'
M8ZL\E]0/D.B?UJ)J5KY9H;H45[:ES_O(P:B[2]762'(:,*)+MS,<?#I0DI*0
M.<*)^]GUIF.;%M?1FSIA5_,3Y9Y![3-;]LNN=3256UJ79+,Z>[4TRG<'4J!"
MLJQQD'&!3]4:JZMG9FWWW6V\)I!+3=]F:#@,QWG5#NA@+!*2GR !]*5G0KFQ
MJK5ST\4/&I+W>+GIZ??H#JL0X?Q#<A&=BCC@_J"*3TR_#W[&-ZJ]:NERC[##
MH_3]UU9#?L+%RCQIUW;84F0\"4(&0I0..<E*3CW-;FF?XBO/R<]K;'H\V8S@
MWS2MBM>G8B(,5#6Y*B7E(3M2X[T) \NE:^EJ5->PXG7ZV6OO=TECVP')2DG!
M"@$^E,;1/)U;=JGB4*! 'E0YK""5OD.L$*)!XQQ0&$9\N&,-8/G4K\I"[+Q^
MZ/RJ$%9!;#_WFKVYJ^"B&/8/6H/&,..N!U2#BDL\&9M8Q::)\0(& !2EDL-!
M:HO+#<N:U%22?2GD\Q0SNQV)FH+BER8ES.  ,4Y%/8 E++.(<EIYX@+.?G2]
MD,@VAE:6KN &U#I2ZC*+)9:B_$**4%1QD T]5%XRRT$V\%B?"^,04EQQ"TC<
ME:#C<0.A]126MTT;HN2[.A\.\4NTD_)?Y7@QS5FG(UYA3K;A*$7!ONU8R"#D
MGFN(<91L^W)]7BUY669G>IVN-./O2(%O8GP&YK+<ES"\P(R@$J?[ML;G$I(&
M4IY YK4T,H:K$)/!FWNVARMA'<:K9=/3KS;&I UWI)Q#P3C:WN"TGC(*SDCS
M\JUO)VRVMHSXZ^F,%-U3S[\H4=:Z5L-FMJ+AJKM.$AAQQQ@0++';*U/X^S'A
M)4 <<DC XJLJ(I9#Q\2MU4ME%+7]$>7M::!DZWUHARVHU'8]-&0VXMNX2PJ0
MZG !:2E/ 25#E1.<=!43MA17QS)E(Z'5.Q2U"VKW1NVK5VIOL]AZ:9:2P74)
MC+0!PIL>7O6/#,IYEV,3DHQDDL)A3LGDHE=HT.%% 2VV%!  Z(0V<_SQBMWP
ME.$$F<]]0S4:&U\HW=A2(SSKCGS5FNB@TTCY^XOE@J[3EKW%K@=.*LT0F3Z+
M?=<>=0LD@#S^=!MZ0>I\L<=Q0 I/4]:787L_2%%:6P?6I7Y2%^8OJ60 /E4(
M*^B.U\W(GU.*(40S[153QBCV?K M^QI>RK9$0<DA@L;A90HGVR:S+/4T&KE@
M(7$,N1%.+()\N>E.K.%@F4E[B%?5A2MH.<=*UJUF"%-W)%8%I$G[1V@6IKH(
MGD;XKA6YM0YX:6<F>;0R0MH0DN#-&A:TL(+6R4G<3L2, ]#7FT^?<+SMQ[&=
MZSA/VF<Z\R@F)*)6VO'19ZHKD_$-'*N3FNCZ5X'XK7JZE5)^I"]9(RG7G+@X
MQCOCM7^0XK.A)PDO@Z#:I)X_,?'K!"807&X<=UL J*7F@I(.>G(K7JU6UX9;
M\3+R\?N)-U@3U%],-IEAAT[C\/'".?F!FBWZA8"4ZFU_E>!4;L,IJX-K6I"F
MPLNKZ@$@>](ROWK:*WJR4M]CR*VH+B7[FTA#A*6%+=(/D.B?YT:%&>S.G;%R
MX&_L U5IRS=HK O4A8D7M#MMM)"<H4_C>O<?+PI.*Z#04^8VE[)G)?4-K5'/
M64>B+C+CA]QM2N%5H5O"R<C9+*](*>D1RDIWBC)BV99+>BWM\A>U><JQT\J#
M:\X'*$.)4H@@GH>*$,'2B5)1GRJ.N"4D$T)"DI*AG-59=+)S;4I%S(QYT5$-
M(9\"O8(P8VNU2%S^^R<9JMD'9$SY1PPI%4MD%O:.O-(/3.'++QB=7'XI44AH
M<'K3T*LQ1Z414N4)]92@C"U>5/);8X%U#+(8VG+FEXN(<2 30L;F&44&8,*[
MQ% K>21GSH$Z#SBC0K;"+[(W\&JJK 6N&>#YW/<.+0H4.::Y#UM1>UE&[VZ/
M=[<];Y(\"_$#YH7Y*'H?+-#U%:MJ:D,Z"^6GU$90^49*_?%Z2>[F[C+&[:5I
M3D8_WKF9:5'TV&JWI204;U%IN2T'D34J86,Y!S@U$*O+?J#>=OCZ +J35^E6
M!WB;B@(*"-I4!5K8.?"+TSC6LR9ANLNU*SP7U,PIK9W).5)7N(%$TVE<7ND+
MZO71<=L3%[OJQUU4E0?6E<[."E6%(1Y8],UHS<,\&(IO+_49-*75F7JC0L"&
M\3.B7@W9P(^\VPADH)/H"I0%=%],U?B-1L_1G+?5]RIT*E^J/7EUDNO/!P**
M24!7!]A3&NI_#WR@NCF-'9YM,9,$R79 ;40M6?G2J8?'(Q=F*W%O/;U$^+SH
M<QJM8-(5Y_.J!#X?P?,5'N2@H"1@ XJH2)\MG[25140QFR?6I(,?D7=UJ8ZD
M8.!Q5\"DI8%:X:IN;,[N@OPE0J,8![MPRR;M+,$.).,XS\\5=(\WP KA-E!U
MIY1Y%%711+/)&-5ST.%*5# JDN2ZE@(0+_.D+'>*&":]![>SW;X-6L#Q,,)R
M.>.M"EMSD9@Y8PS[**5.E!&,4O.MQ>[L)OC/T?!2F/--17E;P0AM1/Z?[\4Q
MH]+*RQ*4<9 7WQJ3VOE&#:6U9:NU_0<F?(2VW.A3I-MGL _Y;[#A03CW3M5^
M=<UXK5^$U4ZOCG]V?2/"+_Q.CA:O]X%"^=CK=P;4MJ^382R/]%9&?RI#\5*G
MA(U'I_-[>#*-8]C:[-%<>7=I$A?EWBE$G^=&AKY2]A>W0I+.3*E6&<RON$(5
MNWX*BG/ZTR[MW)G^0UP2NZ0EMM]^LJ+JN0I0Z4%V9854-(>OHYZ#?&IKEK"=
ME9=6BWQE*'X4G<X?^8@5]&^C]/*-=FH?V7['S+ZYU:;AI(^[R_W/2FH-4C3K
M<63(::6PN3\$L*Z\CP_TKH=1X71K>6\-_P"3BM+XC=I?2UE+_!:C7NT3#M0S
MA9^\E0Y_*L'4^ ZC3O,.4;>G\6INXEPQNT MCXAQ+!V@')%8>HC*M[91>?L;
ME%BEEQD/'"]PQDYH&V7;#\2]B0)*5('N*AX]B5':\!;&64X'E50WL<6OBYJS
MQQ1ET"&/>C]X?K5BAB1EPE3U%]0P?>BM? OQ(XE6JP29'>EQ)!YR".M5Y)<$
MN@XY%MB+8E+@P4C)R>E2F2XK &E-6]^6U'1C8H#K1 :0=9T/:7%!:MHW<T'<
MGT%4/DMN:;L5I87+D.MM--#<M2S@ >YHM54M3-0@LE;IPTL=TW@!VOM);GO?
M^'(I,%M10J0X.5GRV#]VMY>"Q@L6+#^#&GXM)O-;RALLLN;\-*O%Y=1M*"6D
M9Z#UH5M-*:A6N4'IMLDG*?N+DV2\;3=[TM:B@I^'90#P!C*B??-/82LC!"D<
MM.7N>*OHX:^8L_TA^TOLAFK[I5UN*KS;E$^%;@;2EY&/<;37$_5^DVZC?%=X
M/I'T=KO,T[ID_M_0]/W2&Z4E&]>><9X'S!KBYPDI/)W<91GAIB'JN Y/:3'>
M4XH('(QU_.HA%IA)QBUV)+.AVIDP)[C:TGDI2.3[T;+0JZUDXO\ IAID=RVV
MGPIP!CG%%KY[*3Q[#IH2T-VK3EL9:;0E*V3)4K'.]9)K[3X%1^'\/A#W]_[G
MY^^I-0]1XG.Q?E?3_8K=L%U9@:5-Y>!*(LN*Z0!G!W["K_[5IP<8/[/)C>JV
M6V+[6"_IEYEQ'Q"MJ@M.=P.0?]J/:GG*?!ZNR,'M:RQQ8N+L%"'HZUH5T!;4
M,]/.L^>GA;ERP.+4RKQLR'K=K.]1FP9BTO))^ZL>+Y9K*M\&T]_,>'_OZ#]7
MBM]7YN4-NG]31+ZCO&V^X=:5@I*\Y]ZYWQ#03T4]O:^3=T.NCJX[GP_@<4K"
M6D%9 S^E9JY>#4?$<LK0/%<UE/(]J*VH]@ESR@]\/[5X]@\Q7E]U#YPM7ZTP
MV*1!#4Z0F2G*UXW#\53'G(5HT"YOJ79<IW))2GD&J-<\'CJ!9[A*C"Y#[&*R
MD%;ZSQP.B?4TY16[91BD)V3\K,FRS8[BW>]/KN;,B0AUMQ7W05 H3GJ/(\5K
MR\,C3;S[B$->[8/'L9IJG5EUUK?6=&_$N1K<A06]L5E3@2,X4?GBMS2^'U:&
MMVQ7+,JW6SU,O+D/%HN=OM(:BQH8VM("$C&U(..OOS0+83LCNGVR:7&I[6%+
MO=YK\5BVM.9=<2G<GR0.H_.AU0C7F371>ZR5N(Q># OI._2R8['?JOLOT598
MMXN;K8<GO/OJ#;2E'H-O)42<<^E5IH>Y6R7+_P !)W*<7!/H\$W[M6NNG.WJ
MU]KJ8A@R3+:G/1MQ("%CNW4YZX!2>M8?U)3^)BVU@ZCZ;N>G::>3^KVDKU U
MSHN%?X+G>(EQT.@@YSD9KYS9"4_S+D^H56XZZ*$BW2VTK;^ 2O<<"A>5R-.Y
MX(AICZIANW"8I+;BD<(3X@*ML17<YK:C+=:WN)IS3,R]W5:V?BG/A8Y4/'DG
ME0'D C)K9\&T/\1UD:DO3[F%X[X@O#=#.U_F]O\ ?L9)V7?2P3J'6YT=J2'#
MA6UU/<P)$=*MJ5@[4(63U!\E<<U]?JE%25:Z/A.JA.R/FOLTCMLDORM"+M44
M$N/SXB.?3O05?THTZW+"7R@6GLBGGX#VE4E:T!O(6/M&\'&[R*2/3%,W1P!@
M]TLC:BX/JN#D .92TUWBR1RGG@"E)5\?<.GG/Z'R)<U3)#P3D)9^R"!R"K][
M-5E6JT$C/>L%6ZZIC:;B*DW<EJ(T<E:5^('RP/.KQI\WI _,447]-Z_UFI/?
MQ9ZH4=X!33"L*64=0I>[H?84GJ/#=-9Z;8_L,T>(:BO_ *,OW-6T9VA(?G);
MU&I+3IPCODC"5GT5CI7.Z_P3RDYZ9\&UX?XQNELU4>35/C8_[Z/UK#V3^'^Q
MO>?'Y7[GE^[C=)]<U=H7C+' ,,;"TKP,;@3[#-56<X07LUBWVZV1FH#.I6W$
M?%M%V.T?N.E/5!]3C!QZ4]IM)*WU?[]Q6_4JN6U?N NTG5%T#<9B*?@( 84I
M++0&"1P![$5T_ANEA#B79SOB&JE)XCT)^D;P['TO=IK,M7=.1'"I"NB%$CD4
M_J*T[HI_(I";V2V\"UV8,*N#\N_/@%UYQ0!]$XXQ3.K:CB"Z%].VTV^Q_A!#
MUPWR<)V^(D>>/*L_#<&OD;W+*?P7%.+^K[Q>4.8<##I;.,[<)./Y>E"D]JC7
M^X9+.9O^AXSLW8U<.TO7:]=ZL;<:CN/(3%;=3]]MK #BL\^(Y.*UG&'_ %'_
M $1G.4XXKSRWV*'TL^PIN)K&%J:#&4;4@MMSXZ4X*6'%<NH(Z[3R1^=9'B^C
M6II5R^S-WP+7JJR5%CPURCU']$2=(L^C7=(7"3W@@L@1'LY$AD\)6G^A'D:^
M7^)Z*>DO<9]/I_)]=\*U<-52G'M=HWRQVMV3$5*=>SN41SY8-9<<MR6.C9LE
M&"37.3]J2W1_@"B2\EME'VCCCAP  .23Y# HL*_Q$XPJY; 2M\B$[)O$5W^Q
M_/'Z4/;'_BRZ(L%B8$2UQ4.!D$^)Y&['?'TWX./X<5]1\%\)_AFF]26^7]CX
M_P#4'C?\6U.(-J$.OU]C/>RKLUE7-Q,N2RXV75!84$XV@'BNBTNESZI='-6Z
MG"VGK27;IDFV18L]16EIIM06KDJ6.,_WIU<3?P(I)II=L=M'6@J@)D.>!49S
M*5>9&.E*W6*3P$JJ<4WDFTR#.N%\?=4?&0TC/4 52UN"BOU+5>IR^Q;MD1=I
MCN,.%!2I*OM,<@>9)]JHY.U(]"+JSGDR:'<H>O[W<-:WB:Y'TS9'%1X;>?LG
MW$G"G23[]!YTTK-L5&& ;KS+=+/V'R.ZZ8K%P;CKC/R?M&6=OB:0>BG,]"1S
M[4'*SAO@LUC\BP3M7R>Y)#!?0T<G[7IA/0A"/[FO.J,>2[DYI;NQC[Z7_P"O
M7'_Y"O\ >@>77_P7[$[I?\Y?N7+FUMD[E=,5\^9VWN%M$V!F_P!V4J2G_AH
M[UP'HM7X$?F:O1#?/:$LEMAD8+K?7-36:4(2"W<H*Q,80I/+;K0(6C'HI.1[
M\5T\*?(E%KI^G]SGIW>9!OW?(LZDD,7O1\Q(3AV.Q\0R?1.!N'_7I3M*=5OZ
M"=C5BR9/#O:HW9M-9:5M4\ZF-\\Y-:\H9O4G]S-W-0:7N/&@;>+=IEA>SE2
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MZR4=DNAYM\9IJ,5]VE*4DGIUJ)/?R^R%%1X1Q'CA>9"DYW'*0?057?N6"VW
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37Z8 /..2QWB__-Q?^=52#R?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>77
<FILENAME>cogo_0052.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0052.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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M2TGR2?/UKHOY#-GQIEJLQ+8R3N)\>N:?)6A7XL8ROJ(&0 1GDTJ*H<N25MQ
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KP_,3WJF_H92.JG"/J4/O1K[([X(VDNIR_(Y?/AY)]*-(A_HE[SUH@3__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>78
<FILENAME>cogo_0051.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0051.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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M[X5) [D#Y<X-J4-6V)C'<$E?(T_%$_U8;[)U#5]2.:I"3UP]#IH:.(0P]K6
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M*?9(VQ+.7!-H8Y0;0-]  PKR$F+/.I8<3,(\T9YN0+>J%!0_RP,E0R)T(_\
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H?8W(Q#(783IB4MPTH L0!?$LX(,$#;"V&$6O.V1V'3'!'CEX$D__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>79
<FILENAME>cogo_0050.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0050.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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MXSQ18<F&Y X)YHL.2O,'W_Y5-AR5Y@^__*BPY"ESX23@/#\Z7@JWEA<H:?\
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M&Z2WE>%#BHZ$0,_#:+96 <_C3IC$BTX,,I';(%6(>/0V4D'K5B)1AL34DEZ
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I,XV2E*$I*3QDYQ7)\S)>G&/R:O&Q:G*1,?+<_P E7_Q-<7<C;MD?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>80
<FILENAME>cogo_0049.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0049.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
M'0   04! 0$!            !@,$!0<( @$) /_$ $80  $# P," P8"!@@%
M @<   $" P0 !1$&$B$',1-!410B,F%Q@0A"(S-2<I&A"1468H*QP=$D-%.B
MX1<E-4-68Y7P\?_$ !L!  $% 0$               ,  0($!08'_\0 ,1$
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M<NF\;8+"]C38QG]*OMN^7E0G5OER%C;M1(WS56NM*/!U-J@RH8.5H25+2?\
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MXW#N:Z#0^AMY[,+R/U;;5?09: _#3UBC6=>IX5^;A7V)X?@V_:I;4X#/B<J
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M,+'PFH!R MP]U>/6F8Z$KE\;1I"8S/Q*^M)\#)X!37RXJ;</'&<J\Z+4!LY
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M#GV5U$("1@>0JPH@G(YNF?ZK=1G&\I!QYXYK/U^%2:/CDW>BM;](91<4-2'
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MZU?%V+U'%F=Y6J4ZMV.@PUA&2F[%*R!M)0,FNI2WK"./;]-\C2S6E,J4!O
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MR76QN<?>=*U+]$ISP#]J49<YP2E6E'!B/5/MO]O=5&X,):E)N;Q<:1RE))X
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#C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>81
<FILENAME>cogo_0048.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0048.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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MSK21Z:*W2W>#KVN^S*U*2PA+:668X_@=WE1;'3(SU4?-5<[4MP.[H4LG"*S
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MJ2X U8=%V2RUW24\CCBDHEC?YBKU/WJ43>$[O?!)62TGSI8<%*0!D2FEY+I
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MS;>KNX;A!5NC.Y*'!ZKP"GV(S7-]/],BM7++D_%=';]4]8GET$,6/\GW_?\
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C?>AY&\!.FI"C;SQ89PWRMU6 ?;SJWPBM\ODUAK]Y^] !_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>82
<FILENAME>cogo_0062.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0062.gif
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MOX*NUHBOUX2PUX:RV(RSV8VZVXBTV9*VVY2ZW)R\WIBWW*&^WZ*_X,"_P)7
MWIK!WYW$X*3#X:S%XZ7)XZS-Y;#'Y+3*Y;K,Y[W/Z+/1Y[;3Z+S3Z;[8ZZ_0
MYL3#P\S+R\C'Q]33T]W<W-C7U]#/S^#?W\#/Z,?4Z\K5[,3;[,W9[=/:[M#7
M[=?=\-G>\.#?X,S@[\[B\-7E\=KA\=SJ]-#A[^/BX^SK[.CGY^/C\^GF]>7L
M]NSJ]O/L^/+L^.;P]^SS^>CP]_3S\_'V^O7Y_/____#O[P
M
M
M
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M:,HG(()!&I 1"<]U8C:MP(\%LU:01( +/>ORQ2UH0(.0+"$&*<0>ED8V$"_
MP P#F04E?6%!&TSE%D1DBLXZ)HPD^: S&1M/]_J3D&&TI!9$@ &*SH4@@5PR
M$L<@!E8X8:],$(.2LUB/)61 /F2\CWC(F$(:$88+')YD/=1C0XL86(,=Z$ '
M/SC)?Y@PB8NED3$R4(*F/I&&%W#R$S&0@@6'L)X0M@PAB?YX01LB$4&IT>U'
ME)R+""_1/\7=(H\Y7,NV2B2X%*$I1$!KV Y\T= 6S>)F^%G/&/IISU9H* H"
M"5G-UE.+<>ED/5L$$>%TP ,/AG1$2Q!C093(@UGH:RI1F*84$"H,R,F@/ZP0
M6G68N1ZLG,ML,/O!$E@6A?[9*P8ZN$*:+%B#;WXS)(:H'N[4R,(HH,D7#FL)
M*V00A;'Z8#WKR1R"L,(\&@C#D2!M41-@,"L?U !+7G!E%(= 'QM(H40-J9</
M6\++@3QO5L&ST,C::BS,A!4]_T.&5R>!)33LH 8'U!30UL/ '0#ALTLPX\1F
M1"$BF+$3,A@":I7 )TY.J40L8_[*,'@PPA859 HQJ(6,;"#.?Y(FB]J2 ;9\
M43A: "FAR##&)0]7$&'8P :=D1<Z=6#&@S"V11N5H"<3,34%DFVD5,'H0$(T
M-C)D; B?]>+:HF"#^M@@9;XJ&S(RAUA-24*-:-!73XGHJ1OB3""2L)W@IE0S
MF $A"DRP 0XH 9LR#($&]<$"+&L A*4N"QEN6)>H@% 81XZ!GUZ<VJP6U9JT
M?K)%076K&QZ)N!@HD&67@!D::."#E@QC#42 ,/0J:I")R0!H_HP:&&70FF%@
MB0?,G>T]U02#5[DOLI,%J]MX.Q#J;189G&!FC^_V"4LH0618IB'(:"B#D84P
M:6NX9/[-B"%"6A*D%338 1K20%N?3(V%XOKOMDB(VD0Q#[G!96Y7F+F&,8R+
M%L)0G*<("1]:W"QER,BN0.3#A(,U=DI6+"D-,@JB&' 1!KV,42W,Z M+( N4
MB$/8&G(:5^I%0A@9NUE/"Y<R2CP6EJ9LL38+!,A+\,J9+_Q)&L;E"[,:HZ&U
M4T(G+D$]">;QP#P,;A;8 $0KGFMDZQ&E6Y?93!AR9L\WU%<-?1%L6A2"OPJI
MG0X6<0Q?F+&4^%D$X1R$)2!XPAB10@86(AA%KUZJ?_KB5Q]5VK',QN!=Z\GR
M#SXQBUFTPEAM\"TE;(>,ALELMOX:W+AB(+0:&D.$BW X*_X<M)Z);5QQ'UH$
MKUXH/($%%Q&S ,4EX1140"/K< W%V+C6)0,4%4@*MSA&[7)K,RJN1Z1KX0$E
MG?S=%OFO!K0D;Z>S0(M6R$\8M%A7"C7U[]\JKD(W,U:!9H4&'&(6<C281"LL
ML2T)>@=971C&,1:AN/.<:@W#N,4,7SFE*(CU9KX(MR=$;JS:P0D9#&R30*9
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M!3R6?U6PAE)P!4W 21BF!#H !<QU"4YP!54@!570!)<S"UK@ T#@!6/A3%A
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MH<(PH1/:"Q%:HB%*H!VJH SJH@LJHB-JHC)ZHP=J#)JR@CZZ@HHQ.I1 "99
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M"BM@ 1R0!YK)O9O[O*PKM@,,LAZLO N<LDI,LV'KQ%2\M]$+O\/) 0!P *2
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MNE ,I% '#7  Z[RSA?G1")S/OLRL;PK,B3RLIJK5A#S!4"O"ZP$'!=  "<
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M/%4 "S_N"2S#!E2.Y 4+"VF06F!MV7D*P7K:P X<W:U0"3=C!8=P"%=P,VD
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M@P8@','K$2F)B $,,&)H:@@N5L'"M9]ZXF'(-FQ9I94E8ACD4"QBR>0-(VS
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MQ*L1HF'AY9 P&A'0AD9B*?B)@GE@I!$>:-@2)T'!O,(5C,TL)(:169/A"<M
M/@/%.F%C;Q7%K< $+RS([JT,+*K I!<U:!CBN(-[422,0W#K\A557JD$)R)?
M(7R(6'J1SPI86'*IO/.XF,^CR:"PS@9,LJ:!"#::6)4E,2"L'R9<<9=&_"(3
M:0B#*OZB( ,QL*D*OX#%$(+SBM?]SR]0 !TAM+>*CM&*!YC0!(K.D*P6%6(0
M16"#][CB.%5XHA9I.4;E9#C#'/U(%>>BD5UH$(-2K<(R,5##*GH0 QT !0:%
M@$5L@K7#0CRB*7F!D1,G!IL7S 8K4&$#&V"@@XXMQWR%2$A4:C"\5E"B-T,
M#0TJ@8DG-LLUJ9#""W2@!:!@8167VH$$7\"&3.Q0$2"Z(7 6QPN(T$ *U9(-
M+P9#O4<4)#,)Z8$$':((DV M#3#X@8!BP 0K7"1HKP 6?UQ1,.J)A FN(,(+
MM# (DU1A"#L4 R]>V:94#)$'1CP$++Y7R!@\@@T;40*VI/[" Q@<[''HTDKD
M:$B6&"[3F6>QX3'EDHDJ4&$0WDL%%JC !DYI 0@\D,)J;EB&(?! "8,PGAJ&
M\(,RI,$):<@$%:20N#<XP6X8TX(32.>$BKB"#4[P0BHTT3I5-,)D=L)2):S
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M_-YU'^<XO8+E&&WH 0Q@@*@8Z%<&32!L6B[!$O_V=[] 0 1D%6Q?R=Y0*ZD
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M!#MI1M4#Q4)<BV' $W<SBV&P!#.P@BF(@BLH!(Q[.TZ0B*0+1J D"U!S!2:
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M F;-!##P OY0K33XFQ-+!7I7 RZX)BQI!"T5&P=+ RX(2T8(E\-J*>-Y!$Q
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M5?9%)C2E80 9CYUN.DI<F;!(W"[LS*(8C(H;UAXMW,IK>F!N/YUK8KA"%<1
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M "0!8US 3E\ 8SST'^]G"@# 'B!#,D2  :#"!AQ +C@&1?^Q'0# '12# DC
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M+HAR -!S,C! !!1#!B" 'GB^'\QV*3# I8L",A3[C\?V\'_^;..!<=>!E1\
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M7Z?=[61YWI@6&V2HXL&56*%!!D1*5QQUUQVO>>I7I3S^]LPIOYUU=%FY3R#
MMY#!AELDC*+WXM=.&=/*6FG%E?W,?Z5?VU/?&\6JHX:?7XLA7MY]&.6JA7<S
M)DP#!AZ, 3ZF(<A\B*G$(RJ1P 0^0A69R!C,#N) EK4B;\^[6?(.\HH0S<EY
M')2,M-@@@QH 3CVW\,0G"B9 =ID+#(\(48DV 04F1.$'/I#"%*10B2=L8A6
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MY[0 #!A!" [A$,2@":"@U99@"[2 "YC@J)X "PZ!#82 $5[A!ZIN#:J FH8
MV98 #!8A# 3Q$8" EI1-G'P@#?B04MA(5:)Q9E:EC0;%>Y9@!WI WWX'&:Y
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MWH;@"KQ@KFB :*1 ')$58:R'5COT7G;)0Z$S5P%U1W<4*!_D$[;@;&#@7F.
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M^&9JD-=Q!ZH $S;A8Q)R#89@O(# $52A"WJ@##8!&5WH"5Q9$Z@@#&"!!Y2
M#3;A$(9 /QJA!S;!"M0@R,XQ"35-"3!A*;<69SZV9EW6<,LX4A.#NFI@!V2
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M5D*2",2P"5*8FC:AAGE8N3.AAJV O,BR9RH!"TA,IS7._S#AR<N($)[ "IK
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M7JXUQ6QQA;YEH0M9V/46LO"57=>,5GVKF1:RH(6^*3O9O3:V%GB-["XDFU;
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MST,$IO[C"F'0!*K24)2E)&U94:L3E_[VBIY7$5"@"$S 4?WA@YKPEUBP"&?
M!6S3$E& D [176A%6\_S W8Y,5T(E']7DYO5>):9AIA9GCNQ/EO "ZW0"V<
M!2BT48"2!EB 1,'@!>^#E^Q3GW#R"G/H!; @!)JP1QSB"B3I"-,WD-,#.UA0
M",_B"L" G2("!6SP"PHB!-C"EE$C)&"0751%(2@"!1Y$GTX$"W?"$;'P*6(3
M"UB 6)UBC =8"=!9!6 PG[/$>F+0GU:P!F-G:]18D^CYF%B19>SYDUD102S&
M!'0%!HCH'V#07HC4/V7 EJX@!CH@$9N@!/US!JU)+5_@3OY#$ :$H 50  N'
MH 08$2VXB7!*H 6'H*6/P$+A- B#( 9AD0E"\##L^ ,2%J:'H#]F B@Y(Z6N
M!()%M!;4505K0%5*, C_](1#,!(;> A<0 2J ")@8*@P2&5).GZGUG!6)IE,
MZI,:5&9,M@HNF :IB3NOU@JID 9>4 :!&@MKL#97<:MAD'7LJ 9UH0EGX 5L
M0!'!=%:.@&^O!SZJ\*N50#W1Y)F[,TJ,D!Z+X*O':H ^H8F*P AB<$@%H4!E
M *K<91,5@0D.T0A=<1$VL2K0Z@5\11&;8*R'-*KG$7&+YH6D>C^IJJKMN898
M(78-H1+G02/FM0F7^*Q;02-_%_Y>S2,BNW<5W 436R-VDT9;*;*;;]$0F+5W
MZ!HK;/"&8W<F5C<1*V&Q#D$G(L%>$_NRKI6D#^>8@7=DZ[&> ?MX4R=X%C84
M$M8*/B,9"N<>/DLQ1IL32"LI'86.=FFTFPF9/Z&T,E:SLV9^-=MD6)N>HC-B
M@39G>,9G>]9G84NV8&NV7^M_)89T6>MH4Z9CM&63A[*O'_865VNS (BW1>JO
M<5M^^:*SENFVBX:D03EF>_MHLC:WS]B8Y,=I-'D5GC8*(U '1Z$'*H "*1 '
MIX ,N: "<2!G<G "NS 'H8L,IW "'B "?G 4Q6 '(. !=% ,1K$'*L "*8 "
M? !G>_Y  J10#"G@NRAP BR0#,CP!R/  28@"I_FGOP:8UM+N#B&?H<[?DRF
M:8/;JC9K9K ":!X   =0"D;1 =UK  !0 'EP# \P *2 #*00 !-0#! 0 +M@
M"@E@ !.0   0!\B@"Q@   O   !0 ;N #"'0O05   $@ LA  @"P![I   9,
M  -P ,70!P*@ !)   "@NEIV##RK9(&KN,XKO7G+'B#LO-<;PH4B:L_[C!WS
M8[G  !%@ '-@%",@ 'J0"WF@  >@"W$  '> #'7PP\@@ 0E0#'0  '* #*B@
M 2" #'(  "&@"[T+ "6 #"8P 'J@"Z3@ !.<!!JL"PA0 ?[)4 S%(, =, !]
M0+P5H,1&=U++VV:,V;A:^YZ+ZW>*:[?EF;@NUG HS,<B?$F;<%]V  !S\  5
M8!0++ A&H0( P >E,  >@ P<0 #J&P$)D Q\   0, )[(,#(8 $&H+Z;JP 0
M@ PGP,#(8 K^>\I@?  48 =X4 >:V\@2D )^$+N?-K@L/$G3",AU[,>D2K/,
M"[UR3,)5JW1H]6,9H #(, (#H+DBH,$I=0<   ?($ $,0 H,@,A$C "R@ Q)
MP  !T+US< P.L "?K L0@ #)< ($P  *D  +L,@F  "!H L*H  $D,%*K LA
M@      ,H,8<O,>%6\<3,\S-._Z]'M.O-^MW3VK,$\W07M9D)44*!U !?C "
M < " PP B]S*=( ,*5  (T  ;5P!"H *9:P+H< "^LS$E6P4NZ  #W#* A "
M<K !!7#-]MP'NG  $K +NK +<%8,Q[ +?D "!3 !;OS&'KQP>HO0O_S0U6NX
M=OS'%4W,8C:P1&%H<6  "V  "(  $H ,*B  >6 *?$#6ZAL*!]  "*"YQ;#2
MNS "!J 'R% ,$5  N^##(D#&*   (W#% 0 (FXL $8 ,*!  ?A#&%9 +N2 +
M+5T!"S *ZYL $9#+0 ;'Q4S1X1C'+"S12 9X#EW5CMO+U'NJ#:W5%6,4Q?
M!# *LOY0"AH0T@MLP.0+Q"E% 0" UBGE  &@"Y!0  -  ?\; OJ; 0/= ,"=
M"PH, 'N=# MP &G-P Y,  (@  ,P +M0S040 0H0 #2\9=+8O*?MF+Y\S*H]
MU1;=MM2;U59]S&S[VH];TRG0V\1K G_0!RF0!"Q !Z-L%'UP H'@9W/  KJ
M#*)P A\  G@@9\5P!QW@ 77 X,BP!\AK%'6  LG@!R? NRC  B5>XL/K!R7
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<OV]>6&_TM@4(UW#Z_FX+=^]; / /YP5B" @ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>83
<FILENAME>x_coverback.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 x_coverback.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" 5/ \$# 1$  A$! Q$!_\0
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M+( 06Y>NZ %L9=F:_5199'H,/L+62&).IN@ ( #1G;V0 !H<B #8,SBWL+H
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MMQ;<W0,4RX%CMW0)B,UY' Z"^Z!^P?50 -SKZV0"$YK=$#%-=<VL@!8ME==
M#+0 2$ .L)V*"+ YE[ZIB0EHMHH%R&W:J1 38]D .,-@@ G27TL@!+0#K= "
MT &=!= "<WH@!2 $*):&W= "+7<@!5] .R  @ '460  +"R "MW0 8U-D $Y
MV4V0 37$NM;1 "VNR]$ 'G/9 "FFXN@ T -2'*4 !  0 F31J &LWH@ P;H
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M9,B'E!%T )0 8<0+( ,.+M"@ ( &<^B 788%S91+11 :+A #=M;H 6UH=>Z
M"<+&P0 ;6@BZ "(L;(  'XE&P#L!KV18$=[\\@8.JD ZT- L-T &@ ( <9\*
M  38II -RZHH ) ! "9/@0 R@  V0 H&Z #0 FY0 C,4 (E) L$#0R@D!  0
M $ :CKEZ+09!3F@92!U0 Z\ L:"@ @#G#CL!919./0I^5YU&B3)#4@R#RZ(
M(:"SSN@ QS&M#'G9 !%H<+$( 477-W?(( *QO<[=$ #I9    T" %96O:!9
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M'K<G>Z '& '=  > -D !A-[=$ *=N5) -2[( ./S#51 " $O^% #=@@ B+(
M-NR #0 VXFY0 +! "'@%I)2!#"9," ")L@ KE &ML,^RT&046W^B #S7;\D
M"/4&_=199'H4[1NB0PK @7%T -21NS WZH :Q+%,*PF%M1BV*45#&]V1LE74
MQPM<ZU[ O(!-@39#8Q&'8KA6+1NGPG%**OB8[(Y]+4LF:UUKV)82 ;6-D78#
M^[[% A2 !;REW9 !-=F%T .MV!0 CJ@!8^SOT+A8^J.@&C\8" #0 $ !- ).
MZ8!C9)@&D $  ;H (_'9 !H " $RZ-!&]]T!0HC5%BI!9VM.VJ!A@GH4 &W<
M( 4X#+L@ R!EO9 #()S% "_NE "&;7[H /1PR#2R !(]K0 !J@!M[B'@ G=
M,4XV==3*A%-LYW2^R2&PGQ9C?IV0%BFV=\F:([$&X@G1,! U>0=NR7N 9 .E
MM$P#0 W/>U@=TF-"IB QH.Z 0RF2 @ ( " !MLJGV(%SW2 5F=G N;$H#H=
M Z),$W8DDWM?1(M0J/<IH&!^FR&"$V2"@$ G,1KW184@G(!BG 64T4,;RD:W
M2'8#L@$&0+($%8=D!8AP#38:( CR?'\ME)"8J,DG4E,03^B@6((H&!A.8:H
M6XFVZ Z P WN@3#?LF) 9JVYU2&VT)< TDD:( ;?J0@:'AJ0%$M$QZEX.P0#
M#L.P0*D(E%@+:)HC)4("9$.Q=H"@ FMRG*=;( *3R_#I\D,2%!)EB0=SW*1(
M(;CYH 7-\=O1 "02&DA "6DF]S?5 "P-%%@!Y.5( F:[H (M(:=3L@!N#^>/
MJE;L!3"&@FVY4D H!P\US8J0 N3N4 +9M= "D -3( $6R  @!+_A0 V4 $-=
MT *0 $ %8=@@!LDW0 W*2-D#0T@D!  0 +#L@#6CXC_E*T&0# 1%GZM-[(
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MH 1+>VET ) -A<( $)" ''6L=D ,O^% "$ )<@ V[( - ""@!!V2 8^:9()
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MT*:(R$)D 7 0 D@[]$ .Q$#<V42Q="2T[V0,) !M(!N39 !O(L#= ";&U^B
M /,;#4H 4W4*+ -( 6* $YVNV<"@!F1IW(L.Z3 1E+O*!<;IQ =8T,WZJ8"T
M .,^% !H " (S&D'4( <0 E_PH :)!0 2 %-V0 +@;E !N^$% #0!(T0!'D^
M()$D$F,"  @ ( V!^(GHK[,@7Q$ =46 MQ%PWJ$6 ,H^]NBP"-FGT46T6Q ^
M6&&,S5#BV)@+Y".C +N/Y I63/D+X+895>UK[:4>.<4M-10XEC-3Q)B,;M6B
M@I3GBI_\MFT\5NQ*R1^>?)IE\D.#Z;^T9A#N(/ +Q)PHLS.J>%L3< !]YE.^
M0?JP+5/Z69H*I(A> W"6'Q^S9X?\)8QAM/64<G".'1U5+41A\<K9:=LCFN:=
M""7E*"^1()7N;/('$_C%QO[#OM,#P^JN(\4QWPFQEM/B-/AF)U+ZJ7#**H<Y
MCS32R$O:8)&/\I):]C0",WF5.YXI5[%RBLD;]SZ',+9&MDB>V1CP'->TZ.:1
M<$>A&JTF>F'8H"CBOM=X;0XQX.'!\4I65-%7\4<,TE5 ^^6:&3%Z9KV.MK8M
M)'U5>3Z24.)'EW <0QW^SO\ : J.#N(*FLK/!CCRI=-15DEW^XN!RB4V_P!=
M "UDP'\R+)(-6@"M7AE3Z9:_UL;]T>J_&M\-5Q/X'U5+-%/#4>(M))%+$\/9
M(QV%UY:YKAHYI!!!&A!"LGVOS*XIT_R,Y[=7BQC/A![.>+XKPW5R4>+XY408
M%25,3LKZ<3![II&$;/$,<@!Z%P.X1EEMB/''=+DU'LK\!87X<>SWP+P[AM-'
M$Z7!Z?$ZQS18S5=4QLTLCNYN\-OV:T=$\:J*(S=R;(OM9^$^%^,'@+Q5P]64
M<4M?AU#-C&$2N:"Z"LIXW/%CV>UKXW#JU^NP1DCNB$);9)F"_L\/%C&?$WV?
MX:3'ZR6JQ'@_$#@S*F5V:22E$3):8N)U+FL>8[G6T;5'#+=$EEC4N#E/!,;?
M9G_M#L7X-RBEX6\6(3+0MVC;+4.=-"!T\E4R>+Y2A07R9*^Y)_/CO['ICVF:
MZOK/#ZE\-,"J708SXF8I!PC22,-GPP5%W5TX[<NCCJ#?H2U6SZK[E<.[^QU6
M@PN@PBBI,&P2D93TE'!%1TD#181Q1M#(V#Y-#1]%/KHC?W/"7M)>& \??!KQ
M1]H.EA=/6X=C3?\ 1B1HN[_1_"<]+.6>DTDE94:;\N,]%GG'>G(NA+8U$].>
MRUXJ?\LG@/PIQK45#9<2]S_AV*V-R*ZF^RE)_P V5LGRD"MQRW1LKG';*B3[
M3EO_ +V[Q.__ ,4Q'_[$4Y_2Q0^I'*_8"QS!^&_9%P7&,<QJBPJDIL3QB26K
MJZID$<315.\SGN(  4,32AR3RJYG/_8TPJIXJ]J/QA\9N <.GH_#/&)*FEH*
MCDF&GQ"=U3&]CH6D .#<LTEP+-$P&A<0HXE<W)=$LG$%%]GLQG#&"?Z4.XR=
M0M=C'\-&$"I<XDMI.<9C&T;"\EG$C4Y6@_"%=7-E-\4>,O%4#_\ "A>& L+?
MPBD_^UZ]4/\ :(MC^R9[.Q#AC \3QC!N)*NA:_%,!]Y_A]0'%KHA41<J9NGQ
M-<T-N#I=K3N KZ3Y*K]C@_\ : M</93XM<X:FJPO_P"WHE#+]#+,7UHVOLCN
M;_\ >P>%_?\ T9I?W<GC^A$9_4SS_P"V/B/&?@E[1OAS[4T/#M1C_"6!X>[!
MJ^*,V%(Y[IFR NVB,D<^9CW>4OCRDZA5Y+C)3+,=2BX'>>%O%/P']K3@:LP#
MASB./$HIVP3UF%R'W7$Z%\4K)8Y#$Z[FEDD;'"1N9EQ\1NK%*.145N,H,[#S
M+DOD/F<XN-AU)NK&RM*@WN! LD2$_=(0(2T$"Q0 9T%R@!-BI60VL;>"2+=T
MO<-K 0"+%2(BI+B,1^H*0!M\HU0 &.!ND^2470K,.Z*);D-]9/\ %M^2:X(O
MEBHVNR-%NB+H-K8EWE.JB3Z BK$VA+P2+!+:R""<TE@ W!2:H+&GM>TCLD,=
M86#RM*!,2]I+[! UT(L02WJ$# -T 2CL4,F-L^(**&Q;@2+!28D((<%&AV*9
M:QM]4T)BDQ#;OB*BR2!D<2#9%!8HC352*Z;(TDX:X6O;JHV3VH<\MAW.J:%)
M<!7"D5/@&860"Y$%H.O5(ER)()&7J@.A&VAW"  ?-J.BE9"FP[C4J#9=%,0Y
MP(L.Z1,%1J]H[IHC+H3J"&_FF0'G6RBWU0 V' "Q0 L-+A<*++%T$\7%@@8$
M !VH-D $[1@" $Y'631&2L&1R=D=K$N:;HL-K##26BR+#:P%CFBY42Q"L[;(
M 0#<7Z! !M <$ (-R;= @!=QDR]4 %$"QY>[:UD ",BUO4J+[ /.V^7J$@$&
M7H$K 3'$]I%PA(!U[<[2WNF TT.8_79$>P%N!(!&RF HG0( 6SX4 &@ ( :0
M ";:H ;D<"U #=[H " #! 0 1:7.T0 MC7.\I0 W(X,V0!&?JZX2)(),8$ '
M:Z3="!8I;D%FP();=7F4)HLX./1  <;R7 W0 MXLX#T0 EVNBBRR/0ET,51&
M^FJ;\J5KHWVWRN%C;Z$H7)8?+KV0Z)WLV>VW7>&GB#EH):N"NX<I:F?RQR.E
M>R6CE:XZ9)FQ-#7;7>!O=9L?R3IFB?S0M'T\QW"X\<P/$\"G.6/$J*IH9"1\
M(EB=&;CTS;+4U:HSK@+A_"HL"P3"N'Z>[V8;0TU!'E;\0BB;&+#UR[)+C@;Y
M/EG[9F+R^TY[6U'X=>%C&XO)0T\'"M/-3G/'+.)))*J7,-.5$9'!S]K1./99
MLCWSI&B'R1MGU1PR@CPK#*+"HI3*RAIH:5KSN]L;&L#OJ&W^JUK@S$E ''/:
MJT\+:4W_ /WPX5__ .S2J&3Z0C]1IO''P<X3\>/#_%?#WBV,LBJG&:BK6,#I
ML/JVWY51'ZM)(+=G-+FG=.45-4Q1DXNT>&? _C?Q-X'\7/#?V0?%J@D?B' _
M'T&(8/7!Q<SW#W&M:(VN.KX3S620NZ-+V&V4 9XMJ2@_8T22:<D>C_[0+PVQ
M7Q*]FW%&8#22U==PU6T^/BGB:7/E@B:]E0&@:DB*5[[=F%6Y5NB0QNI&C]CC
MQ+P[Q0]G3@[%*2JCEK,'H(L"Q.-KKF*JI6"/7T?&(Y&]P]2QO=%%>1;9,V'C
MEQGAOA[X.<:\8XM.R*##L#K"W,;9Y9(G1Q,'JZ1[&@>J<W46Q15R2.+?V<WA
MEBWAW[.U/B6.TLE-6<7U[\:9%(W*YM+RF14[B#J,[8S(/\+V]U#"JB3S.Y&=
M_M)_#VOK?#KAWQKX:S18WX>XI$]T[/B92S2,ROOVCJ&0N] ]R6:/&Y>P\+YV
MOW-YX-\>4?M)^)F'>+M  <$X,X6IJ2G9]UF/XI&V:O _Q001Q0^G.<G%[W9&
M2V*CH7M!\:8GP;X6XM-PT;\1XX^#AS &7U=B5<\4\)'^3.Z4]A$2IS=+@C%6
M^3GV">S/XN\,\'TGA]A/M7XS#P_A^'C"8J)O!>%/C]U##&67<"YP+2ZY<23<
MDFY4/3DE5DM\6[:.,^PA7XAX*>-OB;[*7$E:9/=JAV)83(\9!,Z -:]S1TYM
M,^"6P_ZL]E#%\LG!D\OS)31Z?]IW3V;_ !.!_P#X4Q'_ .Q%6Y/I95#ZD>0/
M _V6."_'WV'811</X93<<NQ#$YL-QDQ!LTD\-0X1P2R;F)[;QF_PW:X?"J8X
MU.'XETIN,_P.[>P_X^U'B=P#-X><:L=1<=>'X&%XI23,$4DM.QQCCGR"P#@Y
MIBD &CV@_?"LQ2W*GVB&6.UVNF>E=C\U:5'A_P 5B/\ \*%X8:__ )GI/_M>
MO6>7[5%R_9,]PC8?):"D\[?V@A__ "4N+/\ ^ZPO_P"W8E7E^AEN+ZT:_P!D
M<W]F'PP].&J7_P")/']"(Y/J9NJ'B;AGBO&>)N!GQ,J:G Q308K1U4+7QR0U
M4 EB.4W#XW-S-U%LT;A;365IVB--<GAWVUO9GX2\"L%I?:1\"*J?@G%L%Q6G
M9/1T,Q; UTSB&34X)O$0X /B!,;F$^46(-&2"A\T2_'-R^61[A\/L?Q#BSP]
MX7XJQ:D%+78S@U#B%3 &Y1'+- Q[P!T&9QL.@LKXNTF4-4Z-&=@F(3?6R  3
ME-K%  ?JS1 !C9 ",A]$ ^A!.H;W4BH7(02#V0 3W -'J@!+-'9>^J "<7.)
M+>FB!@:26W*'T"'V=%!ED1,K"X[H0V(4T5,"8A+GAM[]-5"0TAMSN8&D"U[[
MJ T CE$$Z_) =@$H<_, 0-M4!7 ;FD.+[BQ0 @;H&2"\6.A2LLH)FX*2!BU(
MB$_9)C$Q['YH0,6F(1E+G&R7N2L6!;3LF1$EP((%]4K'0P^,!I#MTB0-2X/!
MT .B$1ET%;JIHID&UA=L4V$70;HRUN:X425V-,>'..FR!,)L3B\O)&5QN$!8
M3&Z.3!!,%QZ*!<@.:"+-&MP@8)@3*T=A="(RZ$Y"7%UU(@*S BP!0 AK"XN
M(TU0 ]'\#?DHLL70D[H&$@ $V%T !A:\V0 G.<Y:=D *<<MK]4 (^-VB %@9
M19  ?YA8( :/9 !QBWE/5 ! Y7VZ( (#6Z #Z70 +W;;U0 8%F>JBP$-8;YK
MC5(!K9WR*B \)FD@6.J=@.7MJF TX9CHF@%W\H"D 2 %-< +( 4TAQL$ $]X
M9N$ (0 ASQ8Z% #3C<( 2#9  +P"!8ZI * OJF MC22@!;R&:#<( BR#,$ ,
M@7%TB0 +FR8!=;(&*:H2(L-0$;$MRQ[K69QHFW2Z 'HAH26H $@NZ_HDW0TK
M$6UND23H46W&ALG7!:<K\<?9K\)_: PZ"F\0,#D.(432RAQB@E]WKZ0$WRMD
ML0YE]<CPYM]0 =5"4%+LE&;CT9_AWPK]IC@&BCP;AKVB\&XHPRG:(Z=O&G"S
MIZR-@T#755+.Q\EAI=X)249KA,;E%]HC\7^#GM'^)V'2\/\ &'M%X5PU@M6T
MQ5E/P5PR^FJ:B,Z.8:JIG>]K2-#E N-[H<)2X;!2BND:;P-]F3PA]GNBEC\/
MN'W_ ,2JHQ#5XQ7R<^NJ&;Y.98"-EQ?)&UK=K@VNI1@H="E-R[.JJ9$'1 '.
M/&'P<D\8J*CPJK\2.)N',.I*B"L=2X.RD GJ8)FS02O?-"]]XWL:0UI#;C4%
M0E'<-.N39\.83B6"X-3X;BW$]?Q#5PYN9B-?%!'//=Q(SM@8R.X!M<-%[7.J
MDE2(M&3XX\$^#N.O$+@?Q1KV2TO$? E<ZIHJNG:V]1 YCVNI9K[QYGYP1JUU
M[:.<"G!-IDU)I4;UL>46S7MU3HB<0C]EG!N#>,\1\0/ [C;%/#C$<9.;%L.H
MZ2&NP:O=<D.?0S6#' DD&)[+7-K7(,'"G<71+=:J7)88UX!_Z?UN'5?C;QQ6
M<<4.%5+:REP!F'0X9@QJ&_#-/3QE[ZES;G*)92P7/E1MW?4+=M7RG66@!H :
M&@"P %@!V5A64O&_".#^('!N.<#<01&3#<?P^?#ZD-MF#)&%N9M_O--G#U:$
MFK5#3IV9CP'\%N'O 'PVH?#?ANOJ<0AIIYZN>NJHV,FJYY7YG2/:SR@V#6@#
MHP)0CL5#E)R=LKO$?P,K?$;BW!^+)O&'C+!?]':QN(X108;%0>[4=4(G1&8"
M6G>Z1Y:]XO(7 9SE 2E#<^QJ5*J.CT5'64N"Q4-1C%1654-/R7U\L43997AM
MN:6,:(PZ^M@T-OTMHID3S]7^QIAF*>)]-XSU?CAXA#C2D#&P8K"S#(G,:R,Q
MM;RVTHC+<CG-L6FX-C=5^GS=\D_4XVUP=1\3?"NI\4>!3P!B/B+Q#A5#64KJ
M+%I\.AHVS8I$Y@:]LIDA<(PZQ)$09\1&U@I2CN561C+:[*3P,\ *7P#PQO#'
M#7B/Q1BO#L?.?%A&*,HW0PS2NS.E8^.%LH-[Z9RTYCILE"&SICE+=RT4W%/L
MH<*8OXQS>.W"?&_%7!7%=7 (*N7 WTW)J26Y'ODCFB>'%[0P/!T<6-=;-JD\
M:<MR&IM+:SLM%255/A\-)48C+53Q0MC?5R1L:^5X;8R%K0&!Q/FL &WZ6T5A
M X'C/L<T6/\ B?0>,N*>.?B%)QCA;&1T6)M9AC#3L8U[6L;&VEY>4"206+3\
M157I6[LFLE+;7!WS"J2JH,.I:&NQ2?$IZ>%L<M;/'&R2H<!K(YL;6L:3U#6@
M=@%8B!SCQS\!H?';!Y.%^(/$CBC">'9VQ>\X1A4=&V*HDCDSMD?))"^4D.#3
M8/#?*--U&4-WN2C+;RB?X1>$\G@UPY3\'8?X@\1<0X+04T=)AM'B\=)_<(VD
MG+&^&)CW#6UGEUK:63C':J%*6[DK.(?!#%JOQ0JO&#@/Q2Q7A3'<1PNFP?$:
M?^&4V(X?6T].YSHN9#+E<'M+SYFO!^5S=.'-ICW<4T57%/LX3>)^)876>.GB
M37<9X3@U4VLI.'*7"X<)PE]0-!+41QN?)4$ D!KI,MB1:Q(*<+^IV"GM^E':
MS&UC&1M#6@ 6 %@ .@ V"L( N@ K:@]D *OZ( (:$D[=D !IS$]$ ! #;H]0
M^^R=D=HF<'E9@>H1=AMH#+Y?,F0$Q'[>QVL4D/V!&[,'Z?>*?8,4P?=NH.7L
M22]QX:62LDN BZ_1%C?(V[RFR>ZB#C[@3W$!F9MQONDW8T!I\K& ?#U2&.N
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M9% /M\PNF 1()M:R%P DBR=@*#+]4T[ (BQLF &NRF]D $_SF^R  =D ,G5
M!%OJ@!MUV["Z $@%S@2+62 ? L-[I@*:[*;V0 J09M0=]4 1B@!A^CA9(D@
MV-T ^0NMT &#9)JP:L/-Z);14;;*'#*38+09AIL?G(.P0 [T0 TXN<=MM%%D
MD&19H/5(88V"DBU"2,R #(3 (FR !KE+NPND D.):T]RBP%$:@IT $ !  0
M$ $1<60 EPR-+MTDJ$QEIS-SGJ4R(:  =&W0 0/ES%  !^R<W[Q-P$ %D'=
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M_6D=+)# @ DX]@"P[*P CM;H4  :D ]$ *(&UD $0 T6" $H "  @!,GP_5
MF$ +;;I^Q$;<T-.@M=( D %,3:-O0H ;83F+;Z7V0 XP9;M&G-U;Z! !1 <Q
MXMML@ S_ #/H@!,@&AL@!* #;LI(A+L,?$F1% 9#F.Q4"Q=![Y3^'X?1 PG_
M !A ![&_5 !  ;! !.!)%D +((M= !'X24 $W8( - "9/.TN:=M4 &[2)CAN
M=T '8%HN$T*70S*XAAL=DRM"HVYH@X]M4( P1D(&UT %:S!;15R[+8]  !%R
M$A@'DW2Z#L5I][4*1%]"'^4YAHWL@AV$T.)S Z),E$6"#IV0B04@.0.&][)-
MDDK 6_::VV"0ZX%$6-E(B*L.R!#9:+'1)C$L%W !)#8'.L<M]4[%0OH$Q (!
MW"!C;VF^FB3&F"[AI=(. ,<7D@'9 .AP[*1$;NXZ J-DJ0;,U]24TQ.A:8A$
MQ(8;&R3&AKD@N:X :A(=@?\ S2SKHI(@^Q N)"T]$"%-E:W1HM=1+1>6PLW1
M #'+!E#B$ )>#>S39 "0TMO?J@!0<YNQL@ G>8W=J0@ 'S$..I" #S.[H +=
M !97#4E !H )P<1Y39 #0+M0XW0 Y& !<#5 "B 3<A  0 64=D -D [H 78"
M+0( 0@ VJ+ 4D $ !  !(V*  @ ( 2[34( 4-D )( V30! D;*0#K3< E #4
MNAT0 $ ! "9/A0 S= "FE !.W0 0^*R %6'9 #;B3U0 C([J24 *#6@W 2 ;
MD)!M= T-ID@( W(5ID$L;=Y[#5)@.7!TMLHV% 3 2=U%@&+)DT-1ZDE PW?$
MHE@+VU0 +?>[H 2Y3B ;5( U7+L .^%*P$*T VB[@.Z #>S*=T )0 -$ ,S?
M&VR"+"/H@03_ (?D@!,8UV0 H_L-/1 !,^&Z ">TN%AN@!ISB;1:W.B '"VS
M<OX/U0 F-V8?521"78H?$F1'FVDB>TC;11+5T-OT 2 #_B" ">"6V0 ECC?*
M4 .( !=]U  RY1:Z  @ ( 2;1M+>XL@ Y'9&,-KV0 FF!8QS'&^;473B*70A
MWQF^R96'?2U]$P"C_F.'3*D N/S0!I]57+LL0H  62&-D]4$$*B',!=V2+?8
M4X"VR9$3LAC7 $J9*T#?0H0F_L!,0$""U?Z62[&*;\02)M(*/REYMLA"?0@L
MS/#O5,C8MSOM"WL$Q"7W28T(C)S.OV20V,M)M)J=]$#'(00T?) F+C)ZE ,4
M^V4J0D-N)R**"0B[NY4B IER#?5)DHA/N#I?9(F*;M<[J+"AN3J4K"AH,-QJ
M@"4W4)@$;64@&"<KB?1 #;7YB?1 !H -  L>R '!:R &G[BW= !W0 2  @!#
M]T *9\* #0 W?[.37J;( 7'\)N@!IU\I0 II):=4  ;% !,W<HL!:0 0 $ $
MS?5  )RO#>Y0 IVZ ";8E !N0 AR: 4P:*0"M$ #0[V0 T@ ( 2_X4 ,=2@
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MD.:&%M];)@(;NDQQ[%*)8!   )V"* !!&A0 $ %<7W5H N,[CWV0 D$!UNJ
M&Y-2 -R;!)=B84;38NZ V^J9$0_S2- 0 =LVK=>B "(R[H !\HN4 ! !.#7
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M0$=T78#1TN$P'(M&!18!CS.L=D@%EP=H$ #( @"/'$Z.0R.M9)(!]CVW^B8
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M@AQ Z)  7+7,=H2$ & 0&B^PL@!$A!<& 6MJ@!SXW7V2?+)(6!;1,8SD/=!
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M/N";( 23FTL@ @PC8H 6@ V[)H U(!#I<I(R_J@!8-Q= #3CE-MT +#P3:R
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M4H (:ORH <$8UN4 )(:-B@!(O;460 $ !  .@N@!&=SQY0@!1TCMU2 1F*5
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MZW0,%M;H )RBP$EP:$@$<PG5217+L;MF<;DH$.- &RB6BLH0 H ;( )[&D(
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M! $9V]P@ E) !, ( "  @ VZD( <RM[( 1(S8CH@!-P[YA ![H (@&U^FR
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M.FZ!6,&'6YW0,&_E'1 "E   F^Z %M-C= "7.#C:R &WBUK( 0I( )@!  0
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MXBDQH) QGE:W4 '!'J@ I39A:$ )'PH )  N!N5) -O(S;A, D '8]D  ;A
M"W$6.J &T #*#J>B !FOI;9  0 $ -D&YT* ' @ G?"4 (&Z3 4H@-R]$T W
M8G8*0#T>C5%@*2 "  @ K@]4 &@ ( (@G8)H!3-E( T !  0 #LDP&9O@4&
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MHL T@"S#N@ G.;:UT (:0#<H 7S&?B0 &O:[8W18"V[)H U( ( "  E8 0V
MS,TVO908#"B $ "Q*LCT  +.4@'FN%AJ@!EVAU0 U*UQV"5H:$-:6FY"C)VB
M2:%M()5:0VT+&Q3(OD18]D"IFU?Y@+=""M392&;M<Z3[I;9 "" XM>W8I,!P
M6M<;IH!+K[E)@#>1CQL!JE[EBZ#:09.?]S;U1^(?@*D>W,,I\O5 4&"PB[4"
M"> 1J@$(%S=IZ[(&#(YGQ6U0AA%P!L46 AW=JB IS[Y0], Y?+( >Z&)!/\
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M ">T@H  T"  @ KH 2@ $7%D $X"-N;OH@!DFYN@ E) !, )6 $6 $P @ (
M" "(N0>R %$W0 U)H;H (:BZ '1L@ $7%D (R6UNDP#40$$6/S33H \I18!C
M0) &@!.<7M9 "W$92@!@BXL@!LML+W46J <@W*$ Z1=33H!318)V :  F %
M '9 #4OPH BG=12L VJ6T!;1<)K@ G:%&X DUR 68( %PH[0$I.-  Z*)+:
M&Z+L*H"!FU<>EE8V4()JG#L&&393;H0&BQ,GI:R/Q ;B<6OR$:#JD@8IMN:;
M=TO<G[!EQ%]4#H,.# R0-W]4"[ UV6^FZ!M6&'W<!;<H"A9L'.;?9 A(!)N1
M:R $RFYL@:$$>4 =$4,-HR^J* #?(#;71'0" "YUW:!1[ (L-[C4( (@C<(
M2Y-$)!)D1%K.)020J E[R'-TN@3'':J)8)(L-TX]B8V-3;IW5B(A/(V0 B._
MFL+H 7']HXY_*!U29)"LNVNR*&'-\0E&I'10?8!#S.,FQMLD'L,QCRY3U4B
MZ\9[=+)H!#FY1>ZD @BZ3"K 0"HV% #5),*#R^B=A0,OHBPH ;KLAL$A:@3
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M;'00&79*@H;+ 2#KHI45AHH!+]DP$M49$D*4:&*:T$74D@#R#U3H!"0 2 "
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M)@*>2SX=$GP2020PK!2LCM 0+(L35(20#NF0 UC>R*LD@G@ Z*+& .(T!18
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M ( "  @ ( "  @ 6'9  9\=NB!,,I -#<*NV,=V%DTV)B7[:)D1NY.Y0 3D
M ;( -  0 $ !  0 #L@! )N=4T1DZ")-]RG1&V%<]RHLFN@7/<H&%8=D $[X
M@@ [VU0 1<#L@!NY)-R@ ( ,_"@ AL@ ( "  F@!:^ZD AX%AHD G;9% *;L
MDP#2 :)-SJ@!>9MM@BP"4P$OVND 3";G5% *=K9)@-O<X&P<5%@&WS"[M2A
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M1!<=T (>1?=18"+CN@ []B@ ) $=D &PBVX0 1^),:#2&(?>XLDP$_-( D#
M@!!O?JDP%I@! @( ,?"4@$LV/S3&&@ ( "0!&UCLJP&[GNA"8IFI4B(;]@@!
M"  @ 70 +CN@ ! !/W0 E !MW0 3QM8)HA((;)D0B=4F370G*#U_5(D*V0 3
MCH=4 -ZH %CV0 2  @ ( #G@-M9  !N-$ ) -]D *30 4@ @ 6'9 !'=18!)
M -2#T0 V ZXT*CR \K !;T0 - F EQ'=18#;]U!@*8/*F@#T3 ;(=ZJ/(!)
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M8FP N4P#L6NLX6/JA< /,WNI *?J-$  ;! "7/:&GS"]D 1\Q.Z2?(!'4*P
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M#F7":( 38XN@._EN^BBT2M SMRM^2 3&W$$Z('8H.: != 6(* L""($F %$
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M E:82Z";ND5BK)U8 10&]:-++1^!4*#>I49HE ,DFWHJR8";NN@ W&YN@ D
M)<TDW"!V*0("  !=  <,N_Z( 3<.U"!]"@X-%BK(]$7R$YI>]CQL$Z%T&]X.
MU]$#2$MES. [E*PH)["'W3&$[9# :OJH@'H-T  VMH@ OF@ T (.ZD5 0 #H
M@!)-T#2H) P*2 4#8*28"@+BZ1-!;( 1S6^J5!N#)!:;(:#=8@&RB D[J2$P
MDR(%%@!OQ) &7:[J5#L =ZH:X"Q+M 5$3$AP!007##+@>J5%FX*X[HH-P687
MLB@W!Z=PB@W ) ZHH-P$Q!/%VD%#&A#3E^2BAM"LX]4[%0'/!86ZZH;"A-]
M.R0PD# @ ( " !LDP WS&P40%9#W" $%P;H4 ((S#1 #$K7DM ^Z@!]C,P"
M#Y80 ?E&J !G" $OD&EKH 2XE-$)"&BRD1%MV463CT-N^(I$@D !  0 $ 'I
MU0 FQS7*D@%'4I@(>TNV46 L--@D 0V\WZ( *]]$ $19  S6W30"7$'92 )
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M )U&I-T";H2]UK:)T+<&'9^EK(Z%]0.MD6&T41E"1)*A!L3>Z!B'.L;60 :
M#:;&Y" $V\U^B %M;FZH )S<O520!'073  -Q=08"23?= "CL@!(W0 ;MD )
M(NA< %E]4[ &7U18 R^J+ -( T !NXN$ $6V=GOIV0)NE8OF @-#;)T14F_8
MB8SB4>#8;-72/8'L;=K2X E:]'IWGR4S'Y+7QT&FED]SA6(>,?$]16SB@F=3
M11.(L0UU_P PO:+PF''!6[L^'/X^UVJU$XXEM4?WD(^/G%GN<K!71L?J YS
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M296I\\H+R.%@-4;:+E*$OI"+0$#H0YHN@3$%Q:;! A8-Q=  .R &+E2HAN8
M;Z%'0FVP-< [*=CHH[F(*S0]S&;-U2?(Q#K.=?JW1(.@TA"7'HW= T!I(^-
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M $'$"P0 II(&;J@ $]2@!,;G$N!M;H@!-W<P ;=5) .ORWLS=,!.MK.4& $
M [:( ;LXFY0 I  0 $ ))(32 %RG0!A1 5E(U.R Z%,%FNE<X-C O<]$VO\
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MM;X:^,?#U;-2R<"85CL]*V\PP+&(Y)XQM=].[S-O\EHQ><AF>V2?[^#E9O\
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MZAU3$793IOZ*:Y$..! U" &>J '(]B@ I-_H@!*D@$.!N="@!8_DVZW40 @
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MRX0^7NGT1[$Y3E+N@02L(:BZ #;EUS=M$ ):':D[(0 !!0 9U: A@-$6-E$
M6/9 #L0N"/1.)&2M$?%Z^/"\)DQ"4C* 0T;F_13T7_,Y7"/L4:J2PX6Y,\Z\
M0UTV(8F^:HDU>2-]/1>UT\%CP[_L?,-9G6IU#C=+\>#+SSTCZR?"Y9VLJ6CR
MQDB[CZ=U?CC/+%RVM+\4<K/FPXW2DG^1D^(\4G?6187)"]LD%%/*X%NC77
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M0+=$@&\AONI ')HX(8";>:ZB L#+J=4 #+?4_1  S:6* $6\U[H - !EW;1
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MS'QM+6U5?B7CFZ.>MJ&U=2ZEIY09:AM\LIN1=PN;'I=&7R&&'"A?\ Q/(_\
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MHD=@S:>MEC-13M;$^%UL\9M\7J'#4>BW0GN5,XKCM;-+2N+7AI.E[A6("42
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MF-LX+C.(44]'$VOI!*V-_,80\Q-F:?O2D^:P_"+:6ZE=7'IJ9Y_/K+C12/\
M$WA?A.GF$'#?O%0YI<9H:>/EN[<L2!VGK?5:_P!$<CDRUZBRQX8\6G5V+Q85
M6P"D$T;9&Q5%.(>:UW6X%G6V\MO50G@V*R_%J_4='1OX=P_7PATG#]'6LM)G
M9&TLG)M<%I;V[JJ/,J-,TJLQG'OA7(8G,IF4S:"NP\5D$M1.V&(YK@-SR'5P
M((TZI*#WDIM.')Y*\1O";%>  *G&*JAE%2\Y64U0)#'<]"/B*ZV.7%' S8N6
MV<^$\A:8B2ZVUU=])EO=PRTP"M-,UTD(=S:5PF!8+.+>OY&RHS13-.FR4J/=
M'L?^.7#V$XG447&%W8?7S1T_O#RQK*/. 2Z1H\QB<=W;M/HLD.)T:L\%+$V?
M1?A_%Z+$:B%C)(9V2?"V,!T0:&^1S'?>!&H(^NJZ&%G(R1HU\$.2(-;IH%ID
M9D[ 00#<J)(2-E) #9, !H&P 0 TX7E ]4F )#S#F;H&:$!1 7]T(  >' @;
MA  9K>^J #?( W)9 "6[7ZH #R1L4 !^X'J@ 6TL-$ %:_DZH )T9(UULF@
M""P@"UE(!BJ&6 .[D_5/&KFBO*Z@SE4KO><;J9)!F;#E;8[:E>NTJJ%G@-?+
M?GH:Q\/=0MIHXPT/GCB;8?XKG]%M@Z:.;G5J2*7A6:6*HK\0E)G#J@C*TZ$^
MJU98[E9R-'E]+)2/,'M!<,_PWB+$N(*, 02.DQ*/+IDD8[S =ERM7H_2@I^Q
MZ#QOE?TC42A_?9N/ JNIY*7$\1BRN9(^F>PO%[M<QSOW6++C3Z.SH\LH)R9O
M,6XSQCW]S:-E/$UK-'-:!U3AA;Z*]1K]GN6V#<8\2U$+>?7 D. ;9W3JM6/2
MW]1@GY6=-8V0*W&\<J,4J8Y:R3(UU[AQT'9:5@A%\G-GJ]3E?#.%>/\ Q54<
M8U^"^&&"N?+(VH;6UCB=K?#^BYNKVRFL<#T'CEE6#U,CYY'<?\*JC!^&'L=&
MUM2Y@SMR[$[A3G@J-&'#GE+4/DS_ (62RCA'%N$:DEE3AE6*F!E].7?4#TZK
MGXFJ<6=[/CDJE]RWIZ>:"N)IYWQV-QE<0KMD6CFRR3C-&D;C&-&E-._%9W-T
MLV20EOY*'H\%_P"D,SV-XQB$;RPU#'CLU)8+=#>J<59&@XN.&X76554VPIX'
MOOZVM^Y5WI*$;*XZIY)41_###HZ8?Q&:QRM(%Q?+([4D>NJC@TZERR[6:MP2
MB=+@=32Y6Y_,!8GK=:W!11R/4>21K/#W!'<0<546#1G,PRB28G\ U-_DL.NG
MMQI(Z?B(+)GE?L=OXPPSGTCXV@%K7:?3JO,9.>3V4.'L+W@W&#BN ,GD>YSX
M/[N]SC<N<.I]5.$K+)*F7) ML%I2X("<C?PA(8B1H %@D-#+SLDP8BY[I"!<
M]T * 0 B3= !C= "QN@!)W0 2  @#H%O16E0H"VZD@"<DP"Y>;4*+5DXND.-
M'EY9Z)A^(VUI;(1;8I(?L CT3&"V;0( <,0Y1L1=%$;$-:8KFV^B70^Q#8[D
MFZ*"Q>3*PCU17 6-L!S[*7L17U#DT<3Q(*D$L$73HG$AD;71YOXNI&UW$+(:
M4?W42S32GH'#5US\BU=?!)-HXV>+4),FX+PZ]@,K7$YAHW,NRTJ3/+)O=)$J
M2AEH)&B:(972--PZY&H5V'NC)K'\AXP\?*23&^/,;J<6.E"]Q'HP=!^BY&L3
M>9V=GQE?HZH9]E;WG$ZGB#$JT?9W@AAT^ZVY6'&[;9Z/''A'?JHW<YK"&QM%
MST4,BW&_"MIEJ[%ZAD3Y:6C;(QCBW,3U"R>E9JEJ=B.-^(?%5=5<04C!"T<J
M,YFV!LL^?#2'AU>YT9S&>%L(XT=2Y:9L5>Z!WNTS;7#_ /%;<++CR^F^33DP
MK-RCC.+TU3%(YD]N;#=I_9=-M0./+U,KM(V7@IA%'B'$!Q#$8R^&E(CC;W>5
MGRR1KQ8I2:;+'BS%Y8,=J:;#HVE].Q[WYO)EL[;987CMG0W[$9O!^)L7KL2B
MB<YK8Y<Q=>4NL;>N@5J@DC'+*Y2.E\/XF[$*-M/*<CFC*;Z72Z+*W(CXK2MF
MB=3R"S<Q -MBI;N3-/'M.?8KC5=P]C.#UE,0V:EQ:E#';>4OL1?UNM^DDXS3
M_$Y?D,:EAE?V9TS$,+=-QC6.HB :5YE%^ARW_==C41_6.CS&AG\BL]!^R-P_
MA^(X[4XE7M?[UA\<-11FVF:YS77%U,?<]3H)5P>OZ>*.DQ9F)QN EE>(I3TR
MGJL\>SH]JC4?$0_ZJ^)6Q,OP_56"&QIND 3W:AO=# #&VS#\(N@8W%*Z?SN!
M'+[I+D'P.$WU[ZJ#$1Q<Z)$A7P^5 A;]8_J%)="#B^,)(DAR07>2$B35D>KF
MIZ=@?53.;'J2 +VLH28]K//?BCXI8K-B8PK 3549E>YM*:=G]YF<T>9Y#O((
M@-"X]ES-1EN3BCJ:/!24F>9_$?B3%*AE?B^+4TM?(YFDIKG!C8(]@Z0,L&D;
M-:=5BW4SL;>.CR?Q1CXJZJK,%*RG;43\PPP/\C01Y1G.N4#IU)5L(E;E1S+B
MW%ZH3MIZ.7EM@;<NZA;\:.=G=V9^DQ^LHY0*:ID\QN^2UG#O:ZM9F62BVP3C
M.2CQVEJ):5^(4\-4V4T\S["<@Z9B =>W11;HMADYX/I5P9C7$7BIA'#O$O!K
M*WAK!9*>.+$L/YC9"#&7MD  T?FS#7TOT6#4:R,?E9W-+HIS2R1.^>">".FI
M,?H,6Y<E2Y],UD! #HVLS"0?4B]_6ZCI,L7*S1JMU4<W\4L(QOB_%78)/5\G
M#*2I+IJ5DPM4$'8EIMJKIZE*?)".DEEAP>:O&7POQ67B*HJ.'\+H\/PITO.9
M#F#7P/( =&2;YFBUP1W5V360:I',GXF:FY"^".$V?QJ![J<11MC:WFB=V=S@
M+9V@#X[_ $LN7FR[^CK:/3O$^3NG%7&F*X'BG"/#E#[U)CV)1S1F("P$)<UE
M\PZZVMI>X6:67TK^QT5B>3-%F?\ '05_"N)8)%B-?/!%B$CH<0# YS2W(2ZU
M^I&GS4---3EO)>3@\:43C/$'#.(UU77<ZJ,L/O!>Y^3,'C-< CM<7^BWK.D<
MF6)S3*3%^$:+B"JEJZFLJHJB46>(X (G. MY1?3316?I.U&5Z#U'99UF%4M=
M-2.K3+))20-ABNP-Y31T%M[[JF6>S5'2;$;[ V2'#XX*:1Q!(9?4$>BI]2Y&
ME8JA9H_%Z)D%+PYA$T=1(RGP!E,\1O;DO+)(7Y@>MLH[ZK5'*HHPY8O*Z/"7
MBO5X_P 2<<U]-B-6)644@@AC RMB9E\N3Z;E=#'--)G)S8VY-?8YU44#\.>X
M3D.<UP RJU-&;;L[(]'5R4=6RIC <6NO8['T0R"=.SHW"E><*FD="]S8:EG,
M):_+D?;1U^MNW58,T+.SAR)1/7/LT^U1Q)P1CE%P-CKCB>$.M'$71$RTMS?R
MNW(.^4:)X9;&9]3A656SZ5<"X\SB+!&US*DU.:Q$I%KM.H'T76C+<K.&UMDT
M7DFQ3&-M;D;G* $.-SF[H (2&]D ' /M7D[), 1Z!]^ZB ';"W=  <;90.J
M%'R-^>J $-))N4 +O<Z( +E]4  2:A #48)F+C<(78"OOJ0!/V"8!,?E!L4
M&&^]31PG[H<XIQXDF59OH9QV1M=#B.(.C(#??-+_ ""]AI)[L#H\#KX;=1;*
MCB:>H$]&'U3FVEEG(MH,K/V6G"VVD<W5144V,\!44,>"4[[DE[G/W]2K4J23
M,:J6Z2.8<208?C;L5P7$(0YH=.+2#1P)-Q]5WEHE+2I,\#@\X\?E<B]E_N9_
MP+X2Q?AG!.):&FPVMQ3"XIF/IFT[<]52BQO&X7\S1T(V"\KK-)+32:71]1\%
MYC'Y#3-O^^QVN\4.#L-QBI@Q*LJ,/<US08JVDDB(T[FX5>++&/U&G4P63B!/
MPSQE\-HRTCBJD.9VN0%UA^2T0U>'W.?/QN=\IK_0SV*^-TW$.)5G#GA1@-=C
MF*2.,;)O=^530$CXR\[GT4)36=N.%-LMAOTB3RR7^AJO!+P>;P=4U?$G&-7[
MYQ36YG.E<[.UAZMN>@V6S1^.EB5R[.3Y#S..>2K-YQ%%A=93F-\K"]NCO,-U
M;ETDI<48X>4PQYW''N/_  MKF875\6^'TE\:IH/>60W\LVMBT^JXVHT&2*<H
M+D]7H_+8,J4)/@Y72>-7"='4C">+V3X'C#!_>H:J%_+$G<.[+GK+M>V?!TY:
M=98[\?/V-+!XJ^'513YH>.L##K:#F:_J$Y3Q/IE4<&H7?]#,XOXC<!RRY&8I
M)BCP[,V/#J9TLCCZ6 ",>58W>/EDLNB6KALU+J*Y[]_W"^%<"Q?Q"QEDF*4D
MV!<-0'*89'_WFI(U +=F^JVX]+ES_--4C#D\AI='^JQ239U^B$448HJ>)K8H
M/(QK6[-Z?,J4DH\(C&3G\S]R:60Q',\:J#)'??9]X3BIJ&3C.MU95WI8&C4M
M:/COVZ+B>2R_Y3T_A]-MBLJ]S?\ $$3I06N&VA7+<ML+.XWZDJ,EP/B POB*
M;"7N 9B+3)=QL+C^JA'AB[5G1F$$D7"O19[ =NI"&I=@D-#2!B'[I,3&Q\92
M$.H ) ! &^R #.R $H )R:$Q*D(Z*;BSAW5A -SR^7YA%@$[>W4)-H*%,V2)
M(&9M[7U0,,&YL$K04P#S@Y=;(M!0B$':VI0FAL4'-+LH.O9.T*F(F=8 #NDQ
MH%FD M-SU1:0Q3-!JBT)@:?M4[1&G9&Q9SC0NBCDY;I7%GS%[)QYZ(Y..SF.
M*\#U>(44C,*A?4R,BJHY<OEYDLI%OG8-"W8IJ+5LYN2$IQ=(*DH9,/;R:EG*
MFBB:'-?]UPZ%=E9%-+:SS#Q2A*6Y%1Q%)+[I)*)821;X=]PM.";3MG/UD-T*
MBCR![16$24?%O$#W$Y:NCY["?O79K;\ED\AC:R.27!L\-F@XK&WR'[,^%MH>
M$35@ZU4K2[T(:N7"+4;/8XI1?N=GFPDU#B7$AAW;E.JHR2?L=/!!20T_A+#:
MB)T7NU5<C_5QNM?\EGWS]D:WIL<ERSC7B;X8X\<4ISP_PQB-07#)F;";D'U*
MA)9I_P"5F>6/3X'S)$3#?"SC7A##'\18MP_)!#AE.^=SYK-R-UU.OJLV32Y'
MRT6QUF&'^9'+^$.&78UAF)8C'34D]9B526Q"HV;!KJ/4E:,N.<I)Q1DT^IQ0
MQO<^1GPMX/Q*E\2\3X3$3'R-#*T-C><KF@_=5>3#+V[):?61=J7"99\3^$/%
MIXCJL1AX;JI>?*]I#'9B=>UU6L>3[%_K86Z<D3,&\(L2I7M=+P-B$;SN3$57
M*.;I19?".G[W(W%#X95\5+S/X#5-?N 8[61'#G?^5BR9M-!?4C)XO@&)4E4^
M"JH9@'/\MVJ?I9(_4C&\V+)]+LYSCO"?^E'%])AD!(BIJBGK)=-A&<Q)[; +
MH:+'NFK.-Y3.L6&23Y::_B=)HW4D^(5N(1S-YM6^Y;UR]UVLTHMMGE-'&44D
MT>B_9-FI_P".X[2P/:]E/A^9I'7SBZX^JCPV>F\=-.6V^3TV&B2G;FZK"CLF
MEPJ4U-"R=V_P?DKXM$&N1U["3J-%9:%3&W$G3LB[$)RW\W4( -I(\SQ8(NNP
M"!!;(0;YMO5*T,)NK;#>R@ TUC@-04AAH(CF9H;J4T 8(.Q2&N!P#-LDRZ-,
MK\;BS4XBUM(0#]%5*R:1Y+\1,7&"<0<6@LD?BE8*?"X;C_HM"07NE;ZODLRZ
MY62-Y79V=/\ +A3.">,].X8?1#BG'GO-0Z..&EIY UD8:+!K6-W 'Q&USMJJ
M<B2Z-<);D>1<>GCBQ28AOV32XQ#*0"&G4E:,2LJRO[&#Q+[6*HJI-.8XD$]0
MM\:2.=/E\F9.I*39G-;X?X7%6XAGG8<H^ VV<-53E=1HW:3'NY/I+[(&)\SP
MLI*5KQFI*^6%WYW_ *KR^O;64]EXR4?2VG?*R'%<'DKHZ5]0RDQ!N:22 ^9Q
MM;*>H'JGI<^WMFK/I8/HQ3*Z7#GR4SX(2V7RMD>VQ;\_]ZEDRW.T.&+TX51G
M,<P&"O>6S31U<IV$>H/R3ED;=H2Q[NT7_!'A5A6'9,8Q>9L4Q-V,=\48[J4<
MB]V2_1TN:+S ?#5_%'C)%XCXE Z'"<$I(J7":9HU<YC7?:R>MWN-NY!Z!9G+
MUOE9=##Z/ZQKDI/: X.AXKPBLPR8FGJ6M<ZEJ#\4;]VG\[)[O2DE#E$<F%9X
M/U>#B'#?+@PR'!L?R"OAB$4C@?+(!IKW/KZJ[=S9SUA25+DF5W!$X(J<+ABF
MC>-6N=\*GO3]P>*4>D2<.X1JAE,F&0!QUTU54Y&B..URBYCPS#*-CG39&31F
MX8P]>Q^??HG"2]V1GBXI+@SG'5;58Y!-BM66B6-\1C#=F,8+65UM\(P9<*AR
MCQIQ?033\5XCB1!RRU!&;IE LNICE44CB.-R;?W,%Q/2B*:E %A5?:'U W*V
M8Y;C%JX/&TF9@MS2EK!FU-O56\]&!FVX.JZ</E.*MS4(B>\-)L!9I ;\R3HJ
M<JOHW8)6CIWL]\&\0>(OBAAV'<*C,,/E;55$\LQ @B8/,XGZV 6=I(NR9:7)
M]J> L/AP# */!H'L,=/$QC<HL+9&F]^NI.JW::3JF<;*ENW?<ORX%QL>JTE2
MDF-RF]V%(D,R-T &M@BP") T)LF &R$$-;L4F MP.4Z*(!C:R # &Y0 3Y&V
ML39 #8D:6Y2Y%@* #6@LU0 O, -2@!.5HU0 -QH@ K%2L!$HL$6@&6$7+;ZH
MM /40<Z>9[02 S)?\R?V3;6RR#6Y[3GO$V&FDK6>4@5(YWYZKU'C'>*F>)\M
M&LQS7Q)KG4.>1S\K8Z![6WZN>1I^2[6EQ.<Z7V/(>:UL=-AW2=#OAOB;:SAT
M9&YC#Y1Z*[/#TZ3,?B=5^EXW*#M._P"ISZKH7R<2UDDT_ECE>XW_ ,R[L,SE
M@5'SS4:.,/*9.?N_]3I7A;/AW"\U;CC \TTMFR",7)<;V_5<CS&+U72XZ/;_
M  ;JHZ7"YUN[X_B->)+:OB#WFNAX686!E^9+%&#8[="4:.&GPP_6M,M\QJ/(
M:V>W2XW'\?\ PSFO#&!OJIGM9@V&1NN-986O_+RJ&;4:>4EZ6-?Z$?'>/\CB
MA+])U#;=>[X-32<'8[*]T=#74M*XG5U-#RM.V@5N+6PQOZ%_ JU7A=5JE\NH
M?\66L'ASB44-SBU4;DYR7W_53>NC)W'@R1^&LD%66;;^]_\ 8Q_'/ H8QL46
M+U$;S\3VNW*ADUB]B</AR-\R?]_N*"CP#'J/#*B*FXEK7.Y&5K1.-P?DN=/4
M.5JSO:;Q<,-5(QU31\08G5B*N;0XL+6O5T4;GC_:M=5X]N1K?31?J%FPIO#*
MI>W+'Z_A&3#*=M0WAS!0ZUSDI0'#ZK7^C:-])'$R>1\O'ES_ )_[E4<:EPZ.
M.F=A=)3RRN'*=''9U^^G1;<6FP8TG&')R,WE?(9TX9<M+\V3*2.*@QNBPYM4
MR661SI9G-<3JX;*.KGL7IJ-&SQ&C4\JSRR[C94D3(I!9WP"WR*\Y.-2/H>.>
MZ*$1<^JQ9U-D<6,:'W57+=$VTD>C? #&^;A-?@KI!:E+96#_ #&Q7'\GA33D
M>E\)J'*L7L=$Q> NC-QJ2=%QZ4H4>BR)8I6CEF-M.%UK,3C9F=237:.[.I4.
MF51?W.K4%?38G14U=3 !E13AX(V)ZA7IV6+H>L0IB&9 <U[()(1>R0!.(MND
MQ,9'QE(0Z@ ( *X0 "00@.Q**#H22I(3"3(G177V&RL9$$8)>"-FZE08 +@7
MN(V422 U[2%)#H2?YA=T*/<DA;#9Q)ZJ#[ #3EO;JD J+61H30"0T#.X?$"G
M'L'T,.)+M4V N'4D*+ <<,NA2 %QN#JI)"NG16XW4/O$Q@N8F&8CUM8#ZDW5
MT"C+(?X9I1%2DG=TE_G8:IR=.BJ"N+9D>)J8<ZKG9J7/LNSIGP><U2^=F*Q1
MW*H)*@1A[F_"T]2NIB^YQ=3PC@WC1PY%Q-P\_':>/F5N#VEY?6=I<,S/6P*U
MZC3^KBOW1PM%K%I]73]RC\"XOX7@7\,FCY,E-52/#'-U?&]V9I ]-ER/0J-,
M]YI=6ITT>CL,AJZJE9+$(8&V_P!8UH+O754*&SBC;.;R<J5%Q2QRQQY)L9I8
M1?86O^04^O8KJ7_64G%$F&![!-C$\KV_#RX_B^5RH1QN<V5YM0\<4GR>8_:J
M\3J,832^&?#M943XMC<\3*IY>,T$#3ME"AFPIO8NV"U=0W2Z+OP;X!X;P3AU
MDM3A1J"QF7[;OU5F'1I1MHQ9/(6Z3.7>)E..%N/L.XWX7PJ6DGHYBRIBB?I/
M"XZB_INL>HPN#W11OTVJCEJ$F=&PKB/@WB3+BF%\0U8,LA+R,K^4ZWF!%[A5
MPN7L6Y<<5U(W%%#A%8&F+CG,&"]IH" /J"M$4X<I69&EF^5SJO[^Y.K:EM'"
M.7C]'5,RGS,V;\[J;N7L"4<?4K.-\9X\RFDJZJKJXXZ:)@<Z8V#0;FP'<GL%
MFRXK5FG%J4IT9' N&Y8< K.*<5I7LQ#'J@ ,>+.;37L&^E[7^2OTF#9'<_<Y
M7DM4LN38C+R"2IQF2"G):.86W MY;V4<CMM%FGBEMO['I#V51_#^.9Z9VC*K
M#I6.]2 #_19M3%^F;O&3C^E/^_9GJRE&=QBZ#X5S3T):<.U7]XEH7.]6#UZJ
M40+B0V&O=6(3&#NI1*PP" I@(?=WEZ*N78P 918*(@F M))0-L,[% AO*;73
M 2_X4AH7$@;)$6Q02QC5=$V6FE)WC%PJY%R/)7M*T%#@G$5=Q6]SXIJ3#88V
M,#<[)GEQ+2ZVUGAK=>ZY6I6V39U]%+?%19XYXNXJY&$5PJJ5HQ>HJG5,E23G
ME8]S;/C8[9C 3<6[=UC3WLZ,H^DN.SA?'>-C$GV&2#) VEC+6W(C;W[DG<K9
MA5&;([.9X[/9D<$9TZK<CG92CZHKDSG6O#JD8SA6*OIW!DWO$C'N(T .URL6
M>53.WH()X;][/9GLJXE_!ZR; 6R!\508JUNNATL\_F%Q-;'=\QWM MLMI[7B
MY6*L<QS&",M!:2;&UNRY5M.D>A44_F.=<5<'233O]W(#0=P5-Y&D2EC4^"GP
MW 'TDQ,@SF,V&MTEG=$5AIT6E%14QJF_QO%Q3,>26LO=WY*:R-K@M6'[G0<
MK<-= Z/#*O.&C46L414D/+T87Q&IG5<\D8<2X-N4E-J11DCNC1YNXOA;1ULD
MC:*2;(=<@U'JML%N5F%I1)7!>,4N-P?W2N((=D?$XV>TCN.RAD;@78HK)T;:
M+"YI,HCKR&7\S>ZS/*7O#0U4\.TL+7@!Q))=J[NIXYN3*<D5%&$XN@;08=4C
M-H6FPW71AR<74RJSR_B6#XMCN+5E#0X?(^. &::2U@T$GKU/HM>Y1JSFQQO)
M&T<GX^?&S'(Z2)VE/2Y6BWWCNNAI_I.=Y&2ED2_ Q\9 =<A:H<G)9I\*K*-^
M&0 2%M=3O,%LA+9(7:AQ]6&_SNJY(OPR=GL/V,^*_#[A;AVJI<>@&'5V)FYQ
M%T1DN6ON ;6R!VQ)V"PS;W&W)#= ]_\ AGQ71XR(ZO#,7IIX6N#92UP:(W6^
M]J=-M=EKQ3HYV7$Z.P1S<^SP +#HMRE:,"6UB'O:7$B_Y*):$3870 QN3F4@
M%1@W#N@0P'PX.T"B 3#F)L@ SKL@!J6-SB+!)@,N:6FQ2 ?B-V *2 4\$[(
M!U!0 &Z"Q0 "0-T (F^$%# CL!>'/9]TV44!)>?=:=TK=G-R_P"T=OT5E7$B
MG4[*/Q"P]L?N=6&^1L89?L5Z#QV:JB>7\OI[;R'F3QAQ5TN*24,;KAC6M?Z6
MW7L=!#]99\=^*M2I891_%EQX0/+L%FC:?,':CZE&OC<G1?\ "LMNE5_C_4I,
M4$<&/8EG/WW?^-=+21O OS/)>4EZ?DYO\/ZEMX:8F:UF*TLQ)IV/CRZ?/HJ-
M?!/+R=7X6SM:6:]T_P#<MZ[CS"R3PS5R.;637:&Y"6D;#S;*F.C]2)U,WG(X
M,OIM\E)@\+J+$2"W*USC:ZPO#LE1UL&J>2#D;'!*UK:QS-#JAP5EV+*[-2ZH
MB=3/=<#T5#C3.A;DK9S#BSF55:\-L6-<0-56U8N$5F$TC9"^-UKEKK:^BK4:
M)*148?@]*'EP:>8UP#]-!]5/$D4:B3LJ^/.,<"P&GB95 O#@6!K6$DGY!;84
MF<752I4<XDK*.H#,8%+E8]I9$)-+7ZV7;QI1@IL\7G;R9'C1-9AGO,,&(T\P
M?40R!X+3N.MURM=+<>N\+C].*-Q3>9@?:X=8@C5<3)'FSV&')2H>EH6RN;+'
M(8Y!N1U'99Y(T*5G7/ )E9_&\1<&6A=31L+KZ9L]P/T7,US3BT=[PJE')9W&
MO^U-NO5<!*CU\OG?)SSB>@:[,+"Q!NE)%+5$OPMQ&I]SK.'Z@YO<I&R1$[Y'
M=%/&_8FF;IP("M&,R[!(:&7$!)@Q!U2$)#3FOT0 X@ KA "4 &-T#B$03LI>
MXI"2+)D D =$O<:!2<T*@VDB_JHW84*;D -QJ4 Q.3LFB28G9V5,E8IQR#50
M: )K@[9&T!;#9X*B F,.N]U]%*/8WT,GS-S]+V3$&R]]#9*K#=0ZXESPT[VN
MGL8MZ0G[F?I<A.*(2[W%'B%7(^6I<+9<S86D]@VY/RO8*^,7$S3:GPC084/=
M*")LH\[6YG6]0H.+E)4.,E"#LR-:SWB*9SS\;LPNNIIY>FDF>?SKU).CFW&,
MCZ.HR1? \6 [%=G"VWP<'6*H.SG4TL5).V2I+!S7\LQNU)S=0NYB:4:9X#62
MECRJ2?X#>!\ LFKWX::J:FJ6LST=4P N+;WL0=[+FZC!=\GK_&:]PBK5D['>
M%O$_ 6M?'/A6,1L9</YO)E^1!%B?DN;#>FU5GI<DX9$I710,XF\2V'(. Y7.
M'WFXFP-_97*4_P#H*4L;_P#R&2\0:KQTXC@BP_!,(HN'RXY7UL]7SWAOHT"U
MTECRY7\JHSZO58=/#YG9$X"\ L"X<?\ Z0<45\V.X]._F35LXVOJ0T=-5LTW
MCU"6Z3MG"UOF=^.H)I'7*EM-%1B.GC#& :!JU2Q)*D9(:QMV<_XCP*EQ0Y*B
MG:<SM21TNL4\4;Y1T(ZJ4HTG1Y_XZ\*L?P#'JBM\/.)#A;I)>;+3RP\R*2_=
MO18\NBG*5XFD;L'D\&&.W,I/\FAJEQ+QG>&PSPX 7-&7F!DH!]<NP*J<-1#[
M%OZ3H<O,E+_0T.'T'B_5,+JCBS#J5NEFP4)<X#K;,;(6+-D[:+5K=)C^A/\
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MCZ7.XNY,$;KP-).NK2+Z]UMP8T^6<O4Y6W1Z.P]YE8UY?G8(P X?);;,2X5
M (;<[W*!)4(<7'2R!A%]@?0( 8YQ#6N%KE*P%ME=([(0 #V18#P%A9, $70
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M'BV(25 U)MV488TI-FS4:B>3"DV2N!6F3'(I;7RO;;\UIV+]'R/\#%IYM:W
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M>JZ4LEQMGF<>"2R.*]BCQC$Z;GY(*+(9F$22OU<;>O2ZRRR)G0QX7$HZ2I;
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MB!]%6OCDCH\6;010PR RSO>P216!T;&;ZG98,L79U,6=;#VUX<\&<.GBEO\
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M4EC??9S3B+B6JQ!KI72V%CH-%W='I,<>6>/\CY'+FX3.>U.(U-2]P=*<K3H
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M3PUX-I\! 8[$:UC:S$Y"+#G?=83V;L!LO;^-TT<6*WV?.O*:B>?4VNC0 26
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M/^\%VM#^S9\Y\XV]9"CL7#T1=@M3*=.5$&_/9<+42O5K\SZOX['7AIN_\O\
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ME99&7L5V*2<Q^:_=6P@-R]BD=?/>ZTQC2*Y<NQ;90 0X W2<1IT0:VFBE <
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M+C8&-WQ?/8+2]5%M2KAE4<23MLSG%7@Q[1OB35-9_I%C[,)J(XF\A\@9#F+
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M63*Y9*.KB@MMG5^%<DN$FM:!EJ6\PVV-UOTRXLJSNBWHXVWT:.BNR$,2)56
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M;^(:+:G5'"EVSKW@%2"IXAP]KP"75#;WZC1<'XE=:=?W]SZ+_AI%2ULFOO\
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M?.ZPYXM8\;_,[6@RJ6?/'_X_U*G$*6U07#8ZK9ADMIR=3B;RVC-<01$-<0-
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M1O\ "2+CJ,B?Y_NXY-9[3?\ Z"HK_P#SE_[-7+^$.<TJ_OL])_B_QXW'^?\
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M/+^1_:$**-S&/+ANH1XF3GS@%8>YL+HP3]\?NMTU\AY[#/;F1TFNG;-P'B<
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M$[M45=<]SHR0T>5609FS*AB@CY[V6^(N LM*?V.;-(Y=X\<20FKIN&J=X_\
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MZJG-3^Y3XD,_D.Q2U+VHO\?!3R),K8V<M_+:+@GJL6+EV=G5R].&Q%[4P9*
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M-XD[62V_PJWQ^9Z D-R1;1>'5T?7T[=$<:N-^BDUP"=L/*$AF^)).4G1:RH
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M4YN@CVB'Q)"Z/&;C[T3;^JCB99[##(RZ(YM5:^"**6OIV7OE&BJ:&RN!<PD
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MU))'^Y<O#\V4NG])[1PJJ$[6$6L0%U7T9Z--3&P("S2)(EM^#50!C;V @!H
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M/"[.,/"_&\&B:15"G?4TI'_7LLYO_A 63/RC7B,UX)XJ[$>!L+J3\1B82.Q
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M7DV>-$K D9FN^(I@1)J9LNK=4F-,C4\;XI#9IT(_=5VGPAO[CF(S\S%V-O\
MRZ=@=Z&Z$J8)VN!4LS 20X6(5G?0TJ[*JNJ[:,-]%5+@."LC<Y[\Y^2IDT-$
MC.>FRC8P\X0 GWJ7H->B:[ 9QF:26AJ7/!U (U5TG95+@RH-G:JJBF[8L/:#
M<*<6*2LD$":/?4*Y-,J<65M13N82+;JC)P60YX*?%FLCIWMD;G:]F4M[:Z_H
ML>3YEP:X*D<4\&YO<'X]@!'+;A6+5-,UGX67N/T*JQ)HLDT=5P.-^)8Q#1-;
MF:XM.G9;(\LK.X0,9#3>[-/E9LMB(HB50)O;LFB,T0BQ[C8-NK.S,XL>;3O<
M,I;NG'ADY1='FKVR<'9_"^'\3(U@J9(">V=A/_PKTGAVGPOO_0\#\6P<4IU[
M?ZVSSW@#VL@R _"_7ZKVF%IQI>Q\DU\6YW^!I:MK"Z"K.\+VD^@.BUR:DU)>
MQQ<3=2QKW'JN6\=B=4MWS45XHT[.<\0O]VK)&DV%[K'J>)NCV/CUZF),K&5H
M.SE3&1N>&CNO 3VMX0PMS3HZ#]<[ET\$DL$/R_J?+//*_(95^/\ 1&ECDS'1
M6-G%:HO\(%B%AU'".[X[F2-90M)&@ZKCY&G(]IIXO9N]B#CSFO&5IN00M.G3
MLYOE9)XVC(5T,A<XAO4]5UXR1XO+BG]BI>0TD'=6E2((UJ ?\2RYSIZ1?,C8
M\/ N?&&ZFQ7/G]+/18.9I(M^)&G^&2&VF0A5X.9FG7<8'?V.<X";8U"3L)!^
MZZ;3::_!GF(M)Q?XK^9Z3\$H)7^*5#,UMV!CB3?HO'>=FHZ!Q?=_T/K_ ,%8
M9Y/B#U(KC;__ )(L_'J3F<2ST\>KFQ,)';8K-\.Q<<,9/KG^9TOCR2GFGCCW
M2_D>;\<88JXYQ:[B5[')4W<3XWC3PQV3X8B&&5E(X.;:YNA-"].5=%36M+I!
M8:*3?!6L;<BNG81?1*+8Y12X(,VQ"N3"'97N)$A(54NS8N476%REKV$Z G=7
MXY>QS=5CX-[1R":%L9-]$9(-<G-TN5;MDC.X]%RL0F8!H':?DH7NBF;YQ4,C
MC]B) ,R-\8]D?3D_I11<2PMGI@TZD;A5SN43H:"?IY.#G/%'#<51A,TU/!:5
MC>8".I&O]%GSX5/'QV>O\9Y&6/41C-\/C^/!$AK&5N$LT#GAC77]"-?U4-_J
M8[-$\+PZA_:R/A?G):!L57A^:Z+=5QRRUQ-X92"QULK<GT\&'31W9"KI 9#?
MJ-2JX\F[+\IMN'HS%1.?;60_HNABXQ_F>9\A+=EK[%FTA\^AT"?;,+6V)/CB
M$M3EC=<M&H49I-\%,).*399Q0\L$6L%D<N.#=&%ODE4_+#CS#8%K@/G;19LJ
ME)<'2TN3%CG<W[-?Q7!U?V9G/H.(L0I)_(9J9SP+[V+;KSWQ/!9(J<.>/]SZ
M#_AK*>E<L&;AM\?Z'HJ8 V(7@X]'V-\.AI,#33R".-TFWE)6S$M[HQYY>A!S
M9SO'*KWNI==Y#05Z+2PVQH^?>0SK+E<BB>Z!C[7))702='#<HN1"JGM%2 -B
MT*W&OE,^>2]15]A$T[,IS Z;:*45R1R2X*:;B2ICG]V$3RUIMLM2Q1JSBS\A
MF4W"N$)-==V4W!W34:+/7<E<AHU1>-[CJGMID?64H\&>X@M(,X^ZMV)\'E/*
M1]S!U[P7ES3U6JZ1P8\RLIYZE\;A<^76ZNPRJ7)++C4DJ,CQ76MCH:J5CB V
M"1Q/46!6G,THMK[,['BL.[+",ONOYF']GW :RJSXIB,W-$;R&WWN3?=<?P^"
M3BYY'='J?C_6X\+6#"JM'J##:.DDH+ L#@-1FO;1:\B<9GS_ $WIY-*[[-Y@
M."T[6,+(]2T7/T7(U.:3;/>^*T&*,8M>Z1I_X;3,(-M05SGE9Z5:6%!R4L?W
M8VW0LKHKEIU9*IJ<@#*QJIED9NQ:=5P6\-*YL>>1K0!V652MF]8]L2EJX\\K
MBM^/HRY$5M1!Y?57KHPY(\E#B=/8.("TP=(X6LA<V5T5F;7]5*<C/I\9.AFR
M51!:#=5PD]B-<\48YY/\/Z'5O!1\;9*R^_N[FCYW7"\TG<3W'P1*+4TONSAG
M$4KCQ[BPZ<MWZ!>GTS_Y./\ ?N?*/)?_ +@S_P!^R(OAC)RJ6N8XZMJ<Q^1V
M62?9VO%NK.C,J(WLSMS&_HLS[/2Q?RD9\\68EP=?Y)2(*4?<K)GL#R;&WR5=
M,FI0(SIHLQW4BMRC8U6RQ\LV.N4_LD[!2B4'/BDA(=>X"CVA7%,8#HB;9FI)
M,GNB6#1 Z&VYWT5^.+;,6><48[BO&<*PFG<:R7EQ7N]^@:T#74]%NCBXIG*R
MSO)':<2GXOH>-L;K9\*C:**B>8HW@Z2$;N'=7Z>4)IJ'2(>5TT](U+)W+V^R
M_$D15KGG)%I%?0]4VVV8,:V1^;LE&1Y8&AU[=TG$-_/)68A':82.V 2G&XFG
M3Y%CS)FH\#<-;7>*&&@-N(&23GT  '[D+#KHI12/1^ ;R:N_[[1[AX;C!JVN
MZ 67F\S/J.G7)T>,Y8&]K+G2?S'8@OE*>N-W'YJY=%B*FLI65L4E)(P.#FDC
MT*J7/ /@P5=ADM#,Z,C0:JIJA-V5-2]S!L;),2,GB\#JSB3!7@:1U3GNOV#-
M5FGV371W;@1CZFHIH8QTN?0+?NVHH.P1-$<38V#;=8INY(L70;]E($.QC3Z)
M2&O</[[5%A#ZBBX\!Y-/(T?RR2?JIX5V62[,I1RYW /WL%M3X(%I%#F-Q:RC
MT!(,8:/HE8#,-KB^UTF!*HZ-E0\M:-7. 'YJKA<CJ^"IQ7"ZIW$<]/&!=K6M
MT.RBI;F61CM7)73.%-(Z*23S V*MC+:.7*&*B+F-S-MLHR6XJ9$9$Y@LJ6G9
M*+X%!I V**'8L1/.ME+:A#@IV@@Y0GM 8QF/)AE0XC9G]0E[$9F0 +M0@S>X
M+$&R*)$JG((<%).F)C59&XNN.R,O*(X^S.8X"(G#LL+5*C;['&<)IW83Q]Q,
MR%MF5CZ>N;ZN='D=^H*A#L)<H[5X5X6^:>7$IPTB&P;KJ5KQH@W['5\A#2M?
ML"(DXOH$D*78S'$^]]%;$J9,BB-KGH%)$I?2>;_;'%^#,.E<1:/%8P?JQX"[
MWA95D/#?&$=VG7]_<\P8#)=\K 18N:X+V^C=RDCY!KH\)_F:U_V]!)EL792?
M]RVQ7R,\^ODRJR+S^;$PEVKFW/[*%_YB_9LDT8GC:E/+]XB.H-C=9M9"UN1Z
M?PN7YMDC'4M47Z7-P;+G1G[GHLN+:>D>#X?<N&\,I9#YF0"X'KK_ %7>A"L4
M$_L?&?+S];6Y9KW9J*9K38VW5KX1QTMTJ-)A,0N--5R]5+['HO%8.>344GV4
M9)W7*:N1Z^#V8Z,]BU03,[72^ZZ.GB>:\EEYHS];56N.MUT(1]SA9LWRTBGJ
M'!K\Q5[X,D%:(.8<T'NLV56=#$W$V?#1RS17&[3^RPY85C9V-#F_YB*?V9;<
M326PF3Y']E3IE\YN\IEK"SFV%.Y>+Q#KG'[KJ)TSS?<8O\4>H? -QEX_I6C5
MW*>?V']5X;XC5:9GVOX G?EE^7]4->.-01QSB OY61L:?GE"L\#&])#]_P#,
MJ^.<ZCY/*OPC_(X)CC'5&(@M[Z+U"^5'RQOU<H4DC8XLCKWLHHN;*2I^-2]B
MI=E=4[N4HE63LKY!<E6Q[()T5\PL2;*$D:X,GT$AR#74%2@RG41W(VF#5F9K
M3<Z:+4WNB>=E'TLR8QQ%&9)GSCJ5G2J%(Z#G>9R?N55,\@V5$XV;(.F4^+M=
M+*R)MO,+GY*4G32+-,U%.3*RJI&.A<T-!:6EI![$6_JG:;1NPY))[CGON!PF
M66B&L9!RGTZ+#&'IMP]CUJS_ *7%9?<:PAMG./K9&!;;)ZMVD/XW*6M9%FU(
M3RNN"K11MN0W0-L !NX *,&3SLW]!$(:.-O^%=+Z8)'DL\G/(V.AI:21N5!/
M@K;LDP3/;71Y3_,&J3^HC2V_O+<RN"PVSI[!7-RD9G63(./N= \$,>CC\1J2
MCYFL^:+TU7 \[#_EK/H'P;J;\EL?M_NCU;-E#W-#@;&^AZ'9?/$JB?<).YW^
M"&4 66.U?N^'/<>UET-##=E./YK-LTO".;2U!F#W-=K=>JQPV,^999.:W%.\
MRF6Y?=:N*.6U+=V(E>1*''713AS$ADM3Y%EPE8!D322).\BI#]-@]/.WGN#0
M6C6XW4/5VR+(Z2&6/XF7Q%O]Y(C-MPNAC6Y;C@ZKY)^FB-SA3,+7G,;:6[JQ
M1W]&26;]'5/DJ\4>V2F>]H[*[&J='+U[63"YK\#FN(SN@J'M>"1?HKGPSBXT
MG'@JYIHY1?L;6^:LC+:QS3,'Q=(X4U=1@W<^,AOU!"LRR:A(])XF*<\>3[,U
M7A%@[<,X:$/*L9G<S;;17:.2AAVUV<'XKU;U6NN^N#IV'X;5N9>"[2[>ZKRY
M81.5I=)J,L6H\6;?!\3Q6F:R-\1.4 77&S04N4SW?CM3EPI1E%\(TM+BQD+2
MZ-PU[KG3PI)NSTN+62FU\K+>G>V?S!P'H5FNC>DYLMJ,,!\PZ*B3.EIUM?)/
MED8V BZA"#;LVRDJ,[,\.>ZPZK?'@Y\J(DD1?< [:JU2,DU9G\5(#G-[+1CE
M:.'K5MDT4[' N/35.;*,#MC517>Z2F0@OOV-E?IX+)&C%Y34O23<WS9O_!W'
MGT]662'-[T3$+'X2=;_HN7YC3O(MR]CU/P-KOT>:C+G>_P#N8CB?!YH>/ZD/
M<![Q%-;3:S0?ZKIZ;+_R2=='E/*Z-P^(YPOZU?\ !(R?!\[Z!V)M>TV%1DN-
M+D:*C)PE+[FOQSK)/&_\K:O\C=T&+DP -A<;^JKC%OD[+U4(*AR2I8_60Y3V
M5BQO[&+)K(7W1#J:FGC%S("GZ3^Q0_(8X]LI)L6@$KP#U[JQ:635F*?FL49-
M61JG%J=PMK^:/T21'_CF)>Y$DJX(8?-22.#M-'!2_0U]RA^=DE>Q_P 1-/)2
MS.#64D@)_P 02>D4>;)0\W+(]NU_Q#QRO&&41,,9:\^4&_HI0Q*')=+43S\+
M@\X>*;,3QR@K8JBJD="YDA,8)#38:7[HRQ]:#C[4;/%Y'I-5"<^7:_M&2\*J
M44?!\;W_ !R<R5Q&@U.R/'8_U"7YLU_%&7UO(M+I4B\H.(:)K&A\;VWUWNK?
M7@WT<W+HLMNF7$.+T$K0[FAH]5=&4)*[,$\&6+J@Z^2&>+FL<T"P^\JW)7M+
MHPE+YTNCH?LTTG/X_J*GEEP@HGB]MLSF_P"Y<WR,JX/7_"^-O*Y_N/9/#K )
M,W8KS6;D^H:=4S?W_NK=.@7/:^8ZR?RE%B$@S6'=7I< I$ ND:Z[' *M().R
M#BE''4Q%S@ ^UKV2<;(68C%: PO>PV(!WLH.'!).C,3LCCQW#KMN6<V2W?RV
M_JL\H<C<Z1W[PHPPFADQ%P#F!W+8ZVVFZNR237!"43HC1<@+(GSR6)>PX&:[
MJRQ[1RXM8!18*-! 7<#V2;L$MKLA<0TXJX->C59A>W@<G;,%/3OHI-=;GIHM
M;=(%R3Z2K:  =U%.T)\$I\S2-"I"L;C<-TF%EI@51$VK;GV#KJG)%J+)QER'
M75L5%C6*O<WSO:8V./0Z&ZIQQ;5ESEN7!SZI@K,0KP&1N\CKN?T-U.-R=$7\
MJ)TX9"QL3=3;7YJY*BI\B(FM(U'5)QL$Z0\V!KDMHUR/"G:&C9220VA+V-C&
M8N!LA]$?<A8O:?"*D 9;LZ_,*H)*S'TT=RX7VT210XT[%20$:@J06(82RZBU
MS8KL>SM=&;C52;M41BJ=F>Q]EVOLW<763(J9JC*T<#XLXACP'C6EGE! J&/B
M(O\ %EV'ZK/NVLLJT>EO#^-M+A-" 1G>T.D'>XNM^)VBMHW1=Y2++0W0U$C2
M6O<H3$U8(WLN!960=LJE&N22YP$3B!L%8.71YP]KBFYWAW',]I/+Q6G=\AYA
M_P#$NSX=UEY/%?%L6]+:_OL\IX"P-J)!?I^R]SI([)-GR'72N"-E0Y6T[K&_
M4K?&JI'F\]N94LE:RIEB>#]G(;>H*KERFOL=!P<H*2]T4O%AC;A<KG[-(-_F
MHYFO1;9TO%;GG21@L!HS55U, +-DG!U[ KD8X;J_,]9KLRQ8I7[(]&814,$3
M& V$8R@77I._W'QO5XVY-_<TU%.T6)%T2AN79RU+TI-M&TX?:)H^9:WS7#UD
MMKH]=X9+)#<B[E=D!%ONV62"OD[65[?E,MB@/-(ON5T\''!Y/R$93E=F>K19
MY%_O%;H]'"FN>2LJ#F4GR68U1#WD 5$^6:H]&RX>>1/$+'X3^RS9OV;-N@;>
MI7[_ .19\4._YN?'U(NJ=-]1O\JWZ9SFD.7%XCMYA^ZWI6SD+Z%^9ZA]GC7C
MZE>7;P/_ '"\3\3*M,U_?1]B_P .[EY5/_V_U17^.;C_ *<8I8_]7_X0M/P[
MSHH/\7_,P?X@VO*Y:?M'^1Q6M-JKFG[IV7HIK@^=Z653MC%:#8.[BZKHTR14
M5)US=@I?@4M[>2NF\SB>ZG%%,I7R0Y6[V*L7!%<$&>/0J,N33"0=%(&@MZW4
M4Z99D2<&:? IPV7*3?LMF+G@\_K(<66V( 34[A;5HO?NHRQ[6RJ&:TF9V-]I
M"+=5E^K@ZOTK<09F&665_<^7T"C/EMET::21&DB(!C/WNJI=HVP=0HQG&-!,
M:*:II&?:QV=8#<=49K]-RCVCM>(SQ658\G3,]A+3'$W.;N<02?Z*&.-13.OJ
MGNDZ&,5?SL0# =&A5Y7\]%NE6S#98X-#FJHF$:7U4\$?F2,>LG6-LWC;-8T=
M NAD^QY2[E8'31GK94KY2<OFZ0&'+44\U]+VLK$MS3(]1DB]$T<AL#99I0HO
MQ9WD]BLK:DR3<EH-K[@JIQ+_ %.=IT+P,POWOQ)PW)=IB?S''N N+\0SCCT:
MM?W3/7? F&6?S4J=4K_U1Z_?"R.1[F$ZV;^07SAOV/T N?F_O@0HC)G%  PQ
MV8774\9SD.#\0K;I3F396 R-C:+=UZI\'S*#W19"<"9+JU<HQRXD(G800;>B
M<94@G'=(DPQ>0:)[B48DA\A@I']%6OFD7J7IP;,9-)S:EQOLNO%;8(\C+)ZV
MH=%/BLY8\$*_$CE>0R\D.6?-2DGN/W4TJG9BR9'/3M&$Q^')4N)&A5LES9@Q
M.K1EI20^][ &Y4?=&B*N+9F,4A]]XB@IR#:2)SS87VZ*;>[(H_@=G33]'1RG
M]FE_$[AP)@,7\-A#V976Z!//E<.#D:330UF7UI<NV=1P+ Z<L:+=.RXF7/)O
MD]YHO'8XQ5(TD> 0, (;^BP/4<]G;CXV*YH=_A%.P:1[*MY;+UI%$5'2M8=&
MV5;E9-0VC[G&-NA22LFY-+@B5^(S0PBS0?JM.&"LSY\\HQ*)N.AA?S6@&^FJ
MVRQ?8Y6/7)7N81XAI079W6T3CA9&?D8_<RV,<247-D DZK;@TKE%-(\UY+S6
M+'DDFRA_THI,V0N<->REDTDC%I?.XGV0<3QZ,6$1+[:DE6Z3#M[,7FM?ZU1@
M7'AUQHRGQ"&,G*63!P(4-?I=^"<U['2^%?+2T^OPX9^[_H:#Q)XBAI>/H)HP
M'-=3N.O^)@4/'X'DTNS^_<Z7Q-K(:?S*U+?"B_\ 5(S>$QMFPVJJ6-),U<\[
M>BGFPK'/8_9'*T>KGJ-/+-C]YO\ A2-'14M>ZG8&T[66VL=UFE*,>CL:?#FR
M]DF3#92 9OBLJ7JMG".A_P %]?YIE;/@IJ97QVL -[J2UTOL9I_#.)^Y7S<-
M,CUN4GY":"/PMIVN2+)P]"2#FV-U'_B$V/\ _2NF7(*BB>\!MM D\[)_\,B_
M8.GH9&.%B1;JCUVP_P"&QCRD47$C)926/>7!/U&R2TRCT<?\1VLP_AS$:NPN
MV)P /4NLW^JL67;&3_ >'3^IJL:_$Y_P*.5PI#&XWM%)^Y5VBM8DOP8_.?-K
MW+\45U$][BUH(M\E3BY-F=)<DK$9FTD+"UH<]YU%[*>:2QHSZ>#RR:]D0C4U
M4GV;)'D?-8KDY<&V..$8ML]%^Q]A4HQ;':Z>>1[FQ1,U.@S$G^BQZW='MGI?
MAUPR;G%57^Q[#P(%C@0-RN5FX/:X#>-O[HTD=%SW]1TU])F*XGG.UZJY#0PP
MWNJT)C%8\M%[7%DQ&5QRHB#77:+J$I#HYC7XC)4^(&%8?2 O,D+P /Q9@W\E
MEE+YJ!\)GL#AG#X\)P^*AA<1&V(-(MN>ZMR="NV7+/B"SI>Y9'L>3+ ), V_
M$%$3&Z]S,L<9WD=E4X<$#-8YA=V'+<93O;=:(RW<#3HR<TDM)*6D:7ZHZ)=D
MV*M:6BY&RDF1H>AJ YJL2L5#F$.GFK@T @9QJ%5DXBR2[+K%J45&*SOD9J[S
M$>M@%#&THT371 =2<H_9C)?>P4XM7P*71GJUF6=^M]4R+&8Y+&UD")<,FB7N
M22)3OA&5!)E=.^2X%MS9(0*R(.PZ>,FUV$JLC(QM,ZP:[K(,Q]$D4R)3FW"D
M0&7P#<%)@,GR.2Z&0<7@YU.90-;6LJYJ^2V#X/-7BE@$M3Q]PNQS2Z)^*0EU
M_P )OF'R\OZK%-<EZ?!Z:X.K655:SDM :RX# = %MP=D6N#?G9:9#71'F%P4
M"&XV^;=2AV1GRBPC8.2X;W"M3%*/!P[VH<,Y_A?B3S>T#HI]NK7_ /%=CQ4J
MR?W]T>0^*<>[1O\ OV9XVP:-WO%ALZ-WZ+WF"[7Y'Q;626S]YJZ6)T,;O-?3
MJMCCL5G RS4VBIQ-G*K63 _S8[$>H2FOF3^Z.AII;L3C]G_,I.*H9*K JE@T
M<&C;T5&IBW@DD=/Q<UBU46S.X5'[E+2&V4M *S8UM43L:J7K1F=3P2N+FM!=
M<KI*?!X36X*;-_A(=/D8W6_5:'*HH\MFA<Z1TC!H>13-:O/ZE[YGM/%8O3P(
MG3N\I(4$J->1VS,XD[-*#W6_$><UAG:]UI7:?>*WQZ.!D7)63?%9#?).'5D>
M$7J&#U54^S5 VF!L#:F&WX3^RHS+]4S7H76KBOP?\B9Q0+T[]?NK/IOK.AY7
M]F<Z<>7B,+AT?_5=%\''P\QK\CT[[.[O_EK327U;3.-OJ%XGXF_].S['_AS_
M /=%_P#'^J(?CBQPXWQ*_5L1_P"X%?\ #B_Y*/YO^9A_Q"_^ZY?RC_(XW50%
M[W:]5Z/)T?.=-R[(]?Y6-%N@5;-4BCJ;V.G1"[*9KAE>X7*N1E;I41IF;V3&
MG9!G![),O@1FDL?F*C1<UN5%SA=21.P@Z&RNQ2^8Y^JQ?(S6%XDA+/Q"UUJE
MRS@IN+*"6(T]06[B^ZR..V1UH9/4A9#<+2$ ;E527)LQNTAJ=EO-;95-<FS%
M*T5]53MEC<'-^+0BV]U*$Z=%J>U[E['-)(GT%=-1/O\ 9/.7U%]UGY@]C]CU
MJDL^*.1>Z*KFNEQ1_:ZSW>1F_:HX$:S &MEJR_;EMO\ -=#3I.5_8X&O;CCK
M[FJ^)@=?=6SY9P>G0J&%C_B:JIT7XXN0U,3$8 -1S"/TNIQ?1'9]7Y#AJ' A
MK7:N5614@P1VR'((G.E:77-SNJTN R2J9W'V;:4.X[FJG,!]WIWD#YN:/ZKS
M/Q1.M+%?W[GTC_#?%N\GEG^:_P!4>F)#ENP:@N+KKY\C[?'Z:_,;3&6'%43W
M8-.Z-I+FL)72\>U#*<;XAAZFEI''XJD4[C'-<9M=>Z]DH*<4T?(O6>";CD);
M12O;GC+B?FHK<N&7N.*2W1[$.9GWV"FTJ*/FODF0,!: 51.=&O'CLCXNXLIC
M&WJ%9BY=E>J6V%(RSZ01N+V7U'4KJ[]T:9Y58%AFY1]RAQ2G:6..M[*_%)IT
M<C7X(RBY,HGU#F_8.(R[[+9'&GR>=GJ9Q_5^QF^(7/FC+P!Y3VZ*R>-*)ET^
MIE++3,56SAF9@W.ZSR23.YB7RTO<:P*F]^Q7G!@+X8G 'Y[J["MTK7L@UV3T
M-/M]F_Y'=^$Z(TV'P/&;5NMUCU$K;1L\5@4,:FO<Z/P_J&W'1<3/PSZ!X_YE
MR:L1:#3HN6^ST:2H @8X&]]D61<$,OIQMJI6RO8GV,RTP+=+[]TXOGDC+&JX
M(5;0&=@8-++9BDD8,^%R5&>JN')'2"UR#ZK:M0TCAYO&*4N+(%;PV]D#LH=F
M/JKL>IOLQ:CP]1X;_B87%^'*N*1\K8G.-]5U-/JX_2SQ/EO"9HMY8VS/RX57
M%]Q3V^85V7/"*NSF:/QVHS/:HL%70SQ,<9(P?*=@GIM1CDJ+]?H=1@DG+HB\
M'1U QDPQ1>:P>VXZIYIQ]#)&75&CQZF];@GB^I2_H;'Q*IJB;B;#Y!']I-RX
MSIIJT!5>.R*$'M]O^YU_BO'+)J8;^Y+_ &1JN'\ &%T'(F;?F.SD.Z.7/U6?
MU9N?[CN^+\5'1X5AY^_[S145*0V^V3X05SLC;/4:7#"'0W54A>_-(3]%F3:.
MC*$61#!%!=S<USW-U8I%$L2^Y5UI\SE7+([(/$ONRJDS7W2W,@U7N*<X92K"
MK<),@8PN32(9)_+P93&N9*YS@!OV5ZBF<Z>:5T<;\;F!O"4M-'?F3O /R!!*
M<N<<H_D:](HPU&/(_P 3G7"L[8^'FM.F5DC0MFGGMQ)_F9/*0<M9^]$/!HWO
M8V1Q &ZJPIFC622>U$?$*F2NQAM'&WRQ^70?$5GSRWY=J+M/C6'3^H^V:FAP
MDTE+SYH0'V&C@K\<:Y.5FS2DW71Z%]D:FRT_$518W?40L/R#21^ZY&N>^3O[
MGN?AF.V'YGJW!&-):N7F9[G#%)FV/_0VCT7/?U'1BKB9NNB9S23?=6KHE1!<
MYK#Y>JC'FR,U1&Q"9K:=SCT"4G1%'->)<7;%',\N&;[JS3F3H@>$^!/Q_P 6
MWXJ8@ZFP7#H!,ZVAFE&<6^6875>.Y3$TG&F>K8"6V]%8^14BQCULX[J#X)KL
M=42P"3 (D@BRB(C8BTE\4WX-1\U./04*F9'60.:2+[IIN/0**1AN(L-+"Y[0
M;@JVVU8=,S['.9\1*+%9,AJ2T:%6*;0Z-+PJ(W2"1V][J.7YH4"^JB_KHVNQ
MF46TR-/YK-!^Y97!$Q")D0&0;]U;C^Y%JS(XE3ELCGVWU5I'@K6]U&4FGP%"
MQ(YNRAN8^B;#4$M%[*Q#=@,;9-0-M4ZLB(E89&.8X:%I&GR4)*@[7)A6^1X:
M/N7:/DH=*RE]T2[DLNFG9"2H -[W4FB*=C<D0=YM5&AD>9EXBSNH3+(LX;XW
M4TN%4\/$\,3G/P:<U9:.L/PN'SUN%BR-FF%/@W7@%Q'!Q+2G%:20/A, >VWX
MKVU5^GDVQ3X.W7T-UO:(*3HA5=4R.X!U40L13RO>X$633KH?9<0M<6 6W4DV
M)N^#FWM%8<V?PGQ^X-A12.^H&8?J NKXN;>=(\Y\28XO0R;_ +X9X*PB1YF:
M;?ZLWL%]"POI_@?"M9!*+7XFDAJ7.8>@(6R<E*)Q9XDF1L8;S*6.=F\4@_*V
MJ4G<$U[%VC>W(XOW155MG4LK2;YFD%.:N+-^&U-,SF*1AE72,8-3&'%8M1\K
MC7V.SII7CFW]S<\.P3>2['$NLM4$ZY/+>0R1Y.S\&X2+&6HOHP%H!]4]5.>*
M*H\]H,>/5YI*7L;N$!HL-ER)<NSU>'Y5M70X^+-$3JEO;9H]*.VS.XI (SFU
MT70P<]GE_(K9*D9_%(8VL;(+W=J=5L@[;1Q=1C4$I+W*2J.5]PIR*\7*(],[
M-5"W0Z*J7+HT2;A"T="P*DC(9.<V9H[Z+!J,LDMGL=WQNEQSFLS[H3Q22(G-
M&UE+2I-V+R[VQ:1SR=O]ZC>!JUUUNGU9Q]-RFCO_ (#8U-2\785(TLS5#A3.
MNW2SK'\]%YGXATT)Z>;?L?2?\/?)98:_'+BVTOW&B]H2EY'&39( <E9$'/)U
MV: +=EB^%\KEHW&7M=?Q9U/\3,'I>3A+%U/ZOW)=?;LXW60-BQ*KI67+(HW/
M;?>X[KTJGNQQD_<^<9,2TVKS8<?44VOW,J*UN=@S?%HE9.VU;*.M $O+&Q3H
MJ?/!#FB:P7%U9%F;(MO1&>RZ+8HLA5$9&P37)<FBOE%M3T29H@_L2,.J1S
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M.K=%IHP[Q$TD>4MN".R5"<K11UV1V9K1KN%IAT<^?U'%O%*HCQ:*:.G RQ7
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M8VN+/0V"/$N"PM[Q@+Q^?Y,A]WTC>;3%1BT3F>3EW'?LM6&2.;JXR4:HRE=
M/-Y>A73BSS>2%W9D,7P[F-/V-^ZZN&:3Y9XSR>BE*/",7BV#31,?-"XY@=&6
M_JM5[G\IY_T/1C<S(XC-(QKXY1;0C4I9-TN'P:]/!-IQ,5P##AV+^+SI8',=
M58726=(!\)<X 7_59,3QSU;KEQBSV'D9Y])X7''J.2:_T/9G!=''#1,&X)N!
M;;T7#U$WN;/2>#T\<6)*[-]1-BY/E8!9<J3<N6>LPP48\$N&4.:- J)1OW-,
M9[?8K<:'-BD8'? +W5^GE3,6O@ZM,BX'*19I?H2K,T;Y*-'-_2S31/ 9HL9V
M8I)$6HFLXZ*V"]S+EG3*.MJ7/<6COW6N,>+,LIV0 'N=<Z*:,\GN),,1.8YM
M+=E)$&BEQ=P:',[*Z"X11FG7!A\8)?FZ:E6QE1P=5CWE5@\9FCFC.F4'7NC&
MZD/+^LPT=(\*6.CQR $?#4QJORDMVGG^1N^$HO'K,?Y_T-3Q:P,XADE!U\_[
MK)I97CH['E(UJMY5T\P=*7GKI:ZNE'@<'NE9=1/:6*N2+D1ZH6&>WHE%TB;A
MN?928NTM!.:^FZL7)3E6PRM2XYG$"^JLC$Y.?-5E#C=4X0^Z1/\ ,3?,K)Y-
MBHQ1QO,[?!74<):Z[O,7=>RS6;8Q)TD1$)(]%%LOBB+-(6Q6+5';98YTNC-X
MI,-21:UU9!68\G=G/L5&>:0;AS2/DMF+@Y^?V,5&UL6-5A8;9B)+?-3E&TR&
M*6V46:RB<2UOR6%1Y.VYU$G/G ?'2M%R_<]E?LW0>3[&*6=1S1TO_5[_ .I[
M6X"A$'">$4UOAI8Q?YZKA9W4[/J^ACMTR@=!PQH#-ES\KLZ>-4,X_<-!:;:A
M1QOFB^O<S<CW$V(5H)"Z=UW9#][1-*R,^#AWM)8G%AW"6*AC[2"FE8T;7)%A
M^ZQZKA!C?)$]FYX?P]A-W&XHXVGY@6*CI'2'/GD]=\-2LI<-;/4.$<(8+O=L
M/INGG52;)09:1U4E3_T:+(.AF.7Z@=5GO@MJNQ7NC9#GJB)G#746:?F$4*QY
MN=C<L3A&.S1HG0!L;<W)U[H? FZ%AENJ5BLC8D\PT<SVB[LA1'YI4'XG%VUT
MIQ>1\AT+K6NI_LW1+=NX-=3OCGIFV.K0M:Y1'HK<0I<HNJY($K(%(\Q/:2.H
M*JW432+H5 E+"/ND?57-;XBOV'*T?_*6JN[J/U 2B+V+QSA'2D;V"'&V).C.
MUCM+@[FZM[0F^1R"4,C!)2:V@G9'Q#$6M:0#MZJN4B2*-E0^JF,;0=3\U7%[
MF.3VG2.$\!9#2"JG%O0A1R3]/Y4**W*SG?'A8_'\L1L&O_-1W<BJT5L+_MY0
M?1617-D'U0I[A=,0G-Z)IT.PP;I[B+5B3HD^>248D3$_MJ=T4HS-O8*F2+8N
MCFOAG%-18[Q;+G\U3B4;1IL&QMT_55XH[6.3L[#ACG. )'5;%R1HN:=I,@-D
MT#+EDC88,W4Z65J1!JR@Q"9TY<W8%+;R$GQ1A/$JF'^BE1%>^9P&W<'_ '+?
MH?ESQR?N.%YI7HYP^_\ L>%\K'51EC(U>X$?(D+Z1":>.,U[GP+4IXYSQOV;
M+V#(Q@((U"V-[6<.=MF&\4\4J(Z2CH*:<QB2?F.] W8?GJL.OR-1C%?<]7\+
MZ:#R3RS5TJ_B9K#<8K,5JF1EX>.8+D"VJSQSSR05N^3M:G18M+%T7'AF'/K_
M 'AV[\[C\R;I^.;FMS.;\2M+#L7M1WS WW@:/1=S_*?)M:OG-=A-Y2UAT]5D
MS?*K+]!^N:C]C6#R-MZ+F=R/9?1CLS&)UAE>ZC++:EV:_=;L./:MYYC79_6G
MZ%5[V0X9Q'130Y,UP3>ZLQQW3LJS9/2T_IU9E)#F>[U-U:Y&6/"'&QWD8T:W
M< E*=>PX4W3-EAL0AC#0- J7+<C3&*C)47-#,YS[6T'JL&6%H]!I,CC(AXS*
M?-&1MK=6Z>-&?R&7>JHP.(B[G_-=**I'GH\2.B^ ^5_'6%0.%Q+411W[>8:K
ME_$4:T$I?8];\!O_ .OXH?\ 52_U1V_V@'FIK(*1SLK::,'_ #6M^2\?\-OT
MDI=W9]7_ ,0X?ID'C;JJ_P!*_P!C@N*U9C9'.UF9T8N&7WZKVCC2<?N?%I9=
M[CE2^C_4I*L&:4,+LI<,Q].ME-*BF;WN_N,\L,\_;5-]4&/B:9#JGVURWNL^
MPVO46^B%,_R6R]5*$*91J,MPZ&&D/-CIZJ;X,D5O="W$1L+0,U]55+YF;</Z
MJ+579$>VYV34J"2W$*J#HW9VC-Z*4N597&52<!ZE D UL3N.RI<J-^+%N79(
MR9GAM[*U3W&2>!8UV2H(P"';ZV6F/W.=-/H7B9$$60-N2+I9'P3QP:FD5M.X
MO86V];K&N%7W-^2Y-?@<^\>:$2TW"TK=Q7/B>;="W-_18\_U8X_^[^A[KX=:
MPXLJO_+?^M&<GG<RGM$<Q<=ET)O[&?'C3G\QJ,"IQ38<8KV=)JYUE>H[4D</
M79'DS;O9%KA7EBWO<N5J=QLP:KF7\"RC(8-[K#E7);I>AJ263,"UM_JL[Y-V
MVBUPJ=\TL,8CS.=(UH%][D!9M1"L4G9T=#D;U$$E?*/=&%TK:'#*:B!N(J>)
MM[6V8%\KU;W9W(_1NACZ6%8?P%]/S1)470=H"@2+M@!W5QG$U)O2S,.Q8;6W
M5N#ZU9FUC:P2HXKC7#IQ%TL^M[N"]SAU&V"/BVM\9Z^6;9SNJX>FPJJ<^0'*
M7YKCH%V<>J]6&UGS[-X66BU#S+[G5^'N**"+"H635+6.:VQ!W7%SZ1Y)GTOQ
MOEH8]/39+Q#':&>F @F8[.+WNHPTTHNC3G\IAR8T4,CF2W.X6Z,=O9Q)262V
MBOJ::)\9RB^BN3:9DEBA.%G/<?K(J>J?"!?O9=7%"3A:[/GOE-1''F>-*S*5
M4=#.2)FP$.O<'==#;*E:.3CGECS&T9WA?A_!<'X[JZ_!Z&.&2L@B,SF_>LZX
M61X<>+-*6.--KD[VI\CJM5H<./42;4)<'J#A-W]SB</1>:SQMM'TOP\[Q)FS
MHS=I%R-%R7&FT>HQS^5#C"YHT*K:+-R(U:^Y?;5L@L2GC6UE.>7J*BKI)325
M BOI?JM57%F",]DT::EG#X[W6-P.QCS6AJI>'7U4HE>3DHY;&4Z]5KCT9Y"F
MM!LG[E \#E:\ =%/H1E\8<<SSZJV'THRY^V8W%'&Q4T<C.B)PZTETU@-TUQ(
MKA\V$ZKX>4@CQFG+1J^IC6;R4OU,D=OX:Q?\U!_B6O&+@<>D:WH'W_-4:/Z3
M=Y;]N9VGDRR$DZ+1+HCB[+^F>'L:YIT(53+XB\0-H6Z)Q7RC3^8SV,/O"6C>
MRL@C-J9<&/Q&L91TTDKR,X^$'JKUPK.!EGNE1F(Q)5S&>3<]!LLV1\FW305$
M^GA#7#YJ-E\8DN9N6)U@E9;5(IZTD-Z)E<C+8P;P/.QZ*4#/D,/B+'1L,NZV
M8SG9_N8.H>&8W(XNL)&M!*M^Y1=)&JI*VBAC:^>MC&GPC<+/&"LZ,LOR6/#%
MX3B< I8N8--7#T5TOEPR2,*?J>0QR?\ ?![UX2BO@&%BV@I8O_"/]Z\IJ95D
M1]LT,;TZ-E0'* .BR93= &-0YXP1TLEB[+V^#,S1@R%O97D4P,ARO:1>XU46
MZ8I='FWVJ*EF>GP.^:2O'-+>N5M[V^MEAU;]@QKW)G@3(^APVA@C;]HV,!S>
M@OJGI.A-GJ[A&SF-E>XR2M:,I?KD] -OS5^HB"D;(6M>P6,T!I@! "F;I,3%
MJ)$BXDS/22C_  %/'^T'['#\6B]WQ*:U]'75F7B0H<EQ@.)./V;RVQ"<<E.B
MQJR^G:VJ&@Z=%I7S(AT9^OC]V< /U6?)':R46.X?->1@)W< G"7L#+/$Y'#B
M&H>+:N _(!205P6DM0'0%I.X5C(%%43 ^7H$XL)$6IQ!D<=@1=.1 J'S.JI7
M>;0GHJ6K);C3\)82R6</++GU46MG)-?/P=/Q:2+#<(RL:&G*?V6:/ZR5D]NQ
M' \>J#58U(\G9UUH<.2C=P17SR1S: ><:W3(IV/Q'/J4#%D60 ;=D  MTNI>
MQ.)!KWM$;]=055(DC%<'"";B/&**-[63>_0S$.ZL<P-)_-JA'L9UK#Z1L;=+
MK4A66U.P-<'$;*2(L7,_.W+=23L"KFB-_-=3(2,IXA0!_#<P%]7-'ZV_JM.D
M=9(_F<KRL=VED?/EI,&(5T.=UHJJ:-M^P>0OH6G_ &,3X9Y*"]9\%U3U36TI
M?(^S81=Q/4+IJJM^QP<F)O)279S/CNK.*UD;\Q(9>P[!<C62]629[7P>+]%Q
MM%EP!A.:I?4.8,E+23U+_FV,V_52P1<5^2;*/,ZE4H7S*22_B6?A]![NP/MK
M<V^2NT2]/&CF>?GZCH[3P^^\8'8+KQ=H^::^-,V>"&SP>RRZGZ27BG4S6G^5
MF/9<Q?4>SG^S,5B,@_B9L="+?NNEC?ZL\?J.-4A#FB.EE=>X L+J6+[BU*N%
M&9=?,2$VBN/1-HFN?(RP!U"3Z(5\RHUT-F0&^[M%4^$;8.YEC2_9$!NN87U6
M7)T=K3/YRNQF1P!?87)LK,)GUABZSS/(/4K?'NCA)\MG1?9^C,WB/@T0Z5D9
M_(KE_$CKQV3]_P#(]?\  ,;^(<#_ !7\SL?CU-;')0#\,+2?KH5Y'X>CNQQ?
MY_S/J'Q]E]*4U^"_D<$ED;5SOGO]G""!_F]5[3)Q/\CXM@_68'^)6.<3,9CO
MVZ*1&J8'6+/FA]$H_40:IESKT51>XH@2@NNT=-4)T53AN5#.0WML%7.9HT^#
M@=#76L&@JG<;O1OV$F(7\S=4;P]%_8A5+!G=II=:HNX(YF6#CE9!CD-+4Y03
ME=KKT537)IADJ-66;3=X<U. \WV9/HF-=*UKMLRUW2.7%;LB7XD;&)7/?E:P
M::+/DGP=''AN71&H67+QEU OK\UFE/E&R&#=;,MXIQ,JL IIG@DT=8V1O^T"
MT_H5+8I?,_9K_8W^*U4EG>%=23_TY.>X3&:VLB;]R(W=\E=B6_)7V.MJI>CC
M;]V; 2!E.X@6%SE6B<K9YUQW31.P?,8& ]B5.'$:,VK^MEDR/.-SLL.5\FK2
M8[C9)IZ8O9J%0C7[%]P1A3JKC#"*0-)$M5&"/2ZQ>1ELTTF=?P&-9O(8XGMR
M2V=MA]TWMT(-OZ+YA^TDW^)^BMOIY$OP_J,C;ZE&3ZJ(X_I_B!0)EVQI)L=E
MIVHSB,1S1X?.\'5K=%=IXIY$C+KGMTTY?@<TYA,;]=;GHO4QBDU'V/F'JMXW
M/W*S%\,HZJB)DANX];V6K%EE"519S-9HL6;#<UV8*IH9X:AT3=(NW_%=B#M;
MGV>(RXY0EZ47\I)H&T^;))G8&Z7+RE.^T:-,HKY9]+\2SDK60-LRJ;:VHT48
MXW+ZC;DU:PJL;I$=V,0B(Y)!93]*394]=BCC[.:\3R/=435,+<QZ679P[H15
M'SW5RCEU;;?#.-\0\155%5N>X/ :_7Y=4LVHI6T>O\?X^&;'2-MX;3-QG$_?
MV:@M9&/0"Z>3)OCOC]J.5KM+Z62&GE][/3O#5+RZ=K #86_9>6U,MKX/I/B<
M2CC2-G00 L&GF.ZY625,]1@QJ459)DHW1"X&G19][-$\,5T09Z<.866T.JFI
M&9P2,_7M?#5-/^(76V#3B<?.FIIHN\.J/L"+K---,ZFGDFK&*JJDSD-=^BGC
M@GV5Y,LMQ +W9R>I5RX(;FQYCCW3(H=<X@'U&J;Z"C-XZT-+[*R#X,N?W9B<
M0D:X.S=#96-TCF[5.5,E<)439"YQ;OJ4MS<B>/!".+E'6_#VCS\14?E\@J+G
MZ#18_(R_52.Y\/8ZU,*^Y'XG^UQZ=XV\]_G=0TGT63\DMVJIF9J7F+.&FU]%
MKK='DSR;QSJ)HL$(DI&7U5,^%P:8.WR/XL<D30.UU&$FT2R)1=F1QJI>T7:=
M!:ZUXXKW.+K-1/J+.?X[5^_U8A#28VFQ 3R2YX,F''O2<NQZE@:QH#6VV62;
M9T\4%%<$^*  @V2LN4:"JO+$;>B2['/B)25A)!![JU(QR;,GBY<79+Z*2I%#
M;DC+8Q&YU,YK=@-EHQ2^YCS1=',<> BKF-.SF.)^8V5\^$C/B5MV/X9'"^2,
M26.8"]RJH)V:YN&TT^$S0T]?'*6MLTV'Y+7D6W SCZ64LGD8<^Y] >!7NFX<
MPMSQ<FBB/YM"\;JDMUGWO1.2PI&QIV >6VBQN2EV;XQ:':[S0^;HB+29:K]S
M*59<R<ENY*MNU850<3W.-ST"4?F[*W?1YP]INDCDQNAK\UI8<*JFM-KV)(LL
M.H5R+$DHCO@%&(Z:F)<7NY0)<>I5NE5<%4G:/5'",OD))UMJM&=6*)N1L/DL
M!K#0 $ *9NDQ,6HD2/6_R9!_@3A]8/Z3B7%SQ#6O<S0DV*TY8KLAC;LJ*/&#
M32%MOA5,8I\ESDS:X1C$4[!9VMA=:X5T52;(N-$O)<#L+J.2.[L<6R)ASW<V
M,W^\%35%B=LOL2/_ #Y5 [!U_P!E-=A[!U%4!"2T^96JFA=%1+*>47DZG5-)
M%<FREJ)'RN(NDR-DO"Z21[P>BE&"?8SIG!.'Y09)&W[++J9<46X>R=QW5R-P
M\!KK:'HJM/%=DLLVCB=<"*T2#XGG5;))69$VT-R$N<"[<*II#CV2H/A2)CAU
M30FQ;&M(U'5 T&]H L$F^":X*+%Y.6R0WZJJ39)'*\/KF4_B[2PB?)_%X,H%
M_B=&[,!_V;JJ+>X?^4]&T)F>SR1DW6Z+%2HM(::LD;84QN>^BGP+@!PZN+P'
M0A@[WNFFD)KC@B56'U1>6@Z-]%)R1':WV93CJDJ!@4T67-\+MNM_^"OTTX^J
MC!Y'&W@:]CYX8S3NI>*,8I\N5HK9B!_M77T/0W/'R?#O*14<TDON0,8Q%D=(
MV .MF-W>K0M>7(MJB_WF+2:=RR;F<\J*ZJJJ^4\D.839BY/J2E-\'L(8,>+$
MN>?<Z7P=0SP\'8]CLQY1=1FCC;;XLQNX_P!%T,,9/#DROJJ1XSRV>,O(8-+'
MGYMS_I_N'PD!&QC3IH%9CX445^5>YMG4^'YG!S&M/Q#5=''['A-?!4VS=80]
MP.A4,T4UR8]#-PGP;*(![,CMB%QD_G/==X^3"8LQK*^0MZ'1;L<FHT>:UF&'
MK;O<1),?X>X$[@W5T71DS4XJS/EQ[J3?!0D76"TV9P=;J$/H(OFS3%D3I&1A
MNQUU6.<V=;3X8MVT3PQK8@]H\PT"I<G+AG3C%0CNCV4&-22Y2+[$]%IP),Y>
MKE.N3*3F[KE;5WP<B+.J^S% RH\3Z(O;<PM=,ST<-BN#\4Y)1T$J]_\ 8^B?
MX98,>7ST'-?2K7YVC?>T+B'+Q_$,CA=L3&_6P*XWPSC7H1?XO^9ZC_$K4;<^
M2/X1_DCBD4?N^%GFC^8>8\]W+UF6*<J/E>@K]'<GT5T[R,A:?B.JB#]QPM%K
M#HA]#CV1*J^MU67NB"UH=.6G:UU%CQ)2?(B3*UY%M%"2Y-</E7 E]2(FV;N5
M6TD6K))],C-EGF?F<=/DH)63>1I"*H9766F/$4CGR^?))L@U$ >;D;(?)*,(
MDJFE>+:^B4. S-OLLJ20%XMO=72D]M&;%"/J)C=4P9R\FY6=KDZ*(].YS9'Y
M>HL53/ZHFC%)QBZ*#Q+AC'!-?,!9\?+DO?\ QJ3E49FKQF&"U6-I<N_]3GG#
M%,Z*A$\H\\US].BU:=.*M^YM\ED4\NV/2-,8A+2,TVNK&KHXF[;D9/PG*PLC
M(T#2K+K@S9_FE;^Y;PQA@#F]5@:W/DW0GZ<?E+"-N6$/8$H);J#/-QQ;XG4?
M ? *'&^,H*V:1K3AS'2M:76YC[&Q'RW7G?/Y\F+3SV]<'O\ X'T.#5ZG'*7U
M\\W]D>F7C(2YPS7NOGT6T^.#[3.3B[GRR.]UOAT5DJ?(1:JD%G=W4:)&I8P%
MU@%I,Y"X@<(,(J21J6:+3I%>5'.\K*M)/\CEU,_-3ESM;E>H:J1\NPRW861<
M:K64=(7NZMT5^"&YV4Z[-Z>)+\#E>)<1R"LR\UV4GNO18M,W!'RS5^84=0TN
MAO$\3DBIV2AY\X!:$8\2E)Q?L/6ZZ6'%')'_ #%--BE3+IS'-!%K@ZA:E@@N
MCA2\GGGVRM;6XC!-85CGP@^82&[K*Y8]K_ KEF>6'-W^'0_/.9&A^8@?NKNN
M3&K;IG,O$[#:.AHGXI,6QP2>1[NC''NLF5PV/)+H]K\-:G)GRK!'F2Z_$TWL
MV4PK,(=5NRO+JAP:\?"6C066)3?Z,G]VSK>4PJ7DU&NDOXL]9</4H$0N.J\Y
MJI.SW7C,:4$:^@A L+!<K)/D]-IX?*2ZN(O99I5#G9HG!45.4$D'IHK5*C!M
MNRDXCI#[L^HC\I8TN)6W#)N21R]9!0A*7V1!P6MYT0 /P[K3EAR9M#E<HDB=
MXSG11BJ1?)W(8(U![IC0]&AB0\]IR9NB;Z'9G,=-\Q4X=&;/T8.K9S9'M;I9
MQNK)<G/CQ(U'"5)RZ8N(ULECY9IRK9"CJ_AM 78E%-^%CG_7NN9Y&7RM'I?A
MW$FU(I<>#6X[4"VA)'YJ[2?LS!Y'_P!693$QRYN3U)6M?29\G.0TF MM#$RW
MP[^JIF7XP\?DRM)&P:HX>1:Q[8V<ZQS%.:31QDMD<;YAO9;9_+'@\["7JY*9
MFW- F)&]]5G;X.A""3HM*9HMLL\F;H15$P- 8=.B479/(J(-2X!IOLK:,<I<
MT4=3)F>]HZ"ZDF42,S7LYDSAV0W1&"M%!BT66G>/13QRY*\D+.2\9 QS13 V
M+38_):Y/Y$S'CC6241NEDO)$Z/RZ#93QTV9-0W%&OP"G%3B-)2O:'<QXO?JM
M.H=86C'XU[]?!_WT?27@G!(?X524L9#1'3L  Z =%X/79:R.)^A/'PO!%FS@
MP2!C"7$7[KG[Z.DHV)K<,I@X,-K$;(4^2;C2,CBN'TT=60+ +9!VBMH9CHH
M="-E-<$=IYV]IB** SU>A;2X7*-1]Y[K _HLF;LA-TB!X&W;243P=70MN>ZG
M@[*H\Q/3?"4@YENBT9B2Z.A#8?)<\U =L4 ):23J4 .LW28F+42(S5#-%(/\
M"</K%+Z3BG&4(;5N+FW\RV9>B&/LR4S?MGEN@NJ(K@G)\ES@=48B/-V6B'!"
M3-),1.QUQ>XZJR2)#%'#DG9VNJ)JD3CV6N+7.,5A!UYA2]R:Z(KLQT<;@JR(
MF0,6<8Z4!ARF_1394R/% TAI+!<M!*FHVK*F^2\PBGN\6&B71(Z;PM!RZ>Y
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MW_T-MQV^V"U#9"+E[ /SV6S5/]0[_ \QX-?\S%K\3)8,[+E6/$Z1Z#6*S?\
M#\V6H@/2ZWXY<H\EKX7"1TO"H27 ]WZ)9I5;.;H<3E)(V1M'"TD6 !O^2X^/
MG(>[R/9@Y.93/S3RDN_UCMSZKL05(\7.>Z3?XD"MEY0<P6/,3DZ1&,7*3%X&
MWE5;76N52N"]?,[-W%,V*F#R!=^EK*O(F^3?@G&"VL>H8QS =%1(V8*;+*6S
M8K@!5,V](S6/QET.:_WELTZ.+K;:HQ-1*7.L2?*5N3Y1QDN#?>"&(##/$+"Z
M\[-D:PV]7 +E_$:]31-+^^&>W_P]S+#YA7_?*-EXPU,=9QIBD[2'#,UH/R"P
M>"@\6DC%_=_S-'QWECJ/*Y)K[1_D<TEGM(UAU;VZ+M9?P/':.3?#Z(CV-,A-
M@J>3:Z^Q-IK&(7L;*7L)+D9JAOIHDQM%8YMI";Z64)=%F%_-1$D%W%4FJQ%B
M$!9/P_S@1VZHHDG[$?&8^74M81L%7/LG%*B$6 M&B0^!B*,DVTW6A-&24&2Z
M=KF.+.ZFI+HIGCDOF#>VPOZJK(78':(\H==N6^_151][-.H3VQVD'B][(^&Z
MU[ND-_U"GB?R2?X$X1W9L:7W.;0539&7;L;*Z7TG1GB<7R6Y=:(:_="<.#!7
MS%M2S%H!'8+7)G/R0LD0XEK8]%1NL(PV]@Q/%)O<FTU-I)4^4:[745:^5=LL
MAC3GNETN65E%,]MZ:ETC;UZEW53:_P D>BS+'_\ )/O^AI,$DJXJN"!LK\SI
M!D(<='+-KL6S!)M>Q9XK(YZW'%-JVO=H]M\(4U53<+86*Y[G5#J=I?<DZ=%\
MFUDKS-4?J'QN+T]+!W9;K,;38+093$^+,U5#PXPTK'.O(0ZPV%EUO#[7DEN?
ML>4^+99(Z6#QJ^7_ ".">ZOGGD;5NRN(%@=[67N$ML4XGPN+];-*.;AD2/AJ
MBJ:[EMF:^0>;E@ZVOO963U>18^%P9,/A=++5M.:ONBTP[@2'B/%(\ G#X*4#
MFU#@/B"SZG7>GB^5G;\5X&.IU>S-!J*^YW'AWA'A; J2"FBPJGY<$)@NZCC+
MG ;%SW;+R6HRY<S<D^S[%H=#I='"..,>%P5N-XUPOAS)**CP6B;=I!,$+6]/
M0!4X99,;NS3J<6++%QKO@XEQ+PT^KJG8AAKC#U#@+$?3JNUC\MF2J)XK5_!V
MCR3WS2LP&-&3#JIL6)QQM<]P:)(S9OS<%Z+QWDWD:CD5,^9?$GPS^@.6?3.U
M]O\ 8R<O/HL;D@D=:DG_ +TX=&GK?\EV6VIQKZ7R_P #AJ*RZ9-+YU\IVWV:
M\,8_ 65S&G)5'GM/0@O<+A><\OFAMCM?9[_X6TF3]*S3FO\ I7\+1Z+AIVY;
M?LO'2F]W)]2]-4J'N2 4)IHGPF.,C: -57(LC1"J6QB]G#\U.-F:=>Q7O:^Q
M<&$V'9:(T^#)DN/*]B#CN%,Q6BS!P#V@66C!-PG7L9=9IH:C#O\ <RU)-RP^
MCF86RQGKHNC-)\HXNFRN*]*?!) ZJDV?B28B"TZJ33(*4?N*+FV^((IT2W(S
M>/B\I('570M)&?+R^"#A]$TO+K?$;J565P5&IP&%CO*>]BLV9N/9KTZ3X.IX
M?!_"^#*BO>TLYK729G;:6 7!;]74QBN>?]SVF*/Z-XV>67"KC_0XM-.YLC7.
MT#WDKTL([<21\\4]VK<I=#=-%[QBCGVT#=^FZ.%$W_5D;71I9IA24CRYP:"!
M:ZSJ+LGD>V)SOB?$GS'*W5I%KC9:U484SBYI2R9?EY154+0&@G18YNV='#%1
M0]*"YY(!*472)33?1*@!#+$62D3Q)KL*9YB:7G3*G$CDLH.8)*ESS;4Z*=<6
M9-URH%60(2#I=19;'LII6N]W(L=+J#+$K,AC(<&$6*L@TBN4)/V,-Q! 9:<B
M06:>I5T7S<3-/'PGDX1W/V5? KPRX^P*KQO'XJFIK</Q(,G@YEH9&V#HVN:-
M7: ^B\]Y'63Q6Z9] ^'O%X<JC35?<SGB-X9XAP3XPG^(M+X<2$SZ9Y;>-L+7
MES,O0-&UO1:/TR.>$>;;1CGXB>DU,LE-*V>X>!G-=@U"0+A\$>4]_*N?J(U*
M[/6Z+-^KVI&SI8AELY8F[-A6XA#RI<[1H#93B-.REQUX?&+&ZT8T)LIH@79+
M"^JNDTN&12OH\S>T="'<*XW+U=CU,&^NI6/+TR&3V*CP7JRR"EC.F4$'YW*6
M)_,5P^@]1\(5#3/&<X^$+5-V32X.IP:L#AMW7/\ <U6AUQ%CJ@3:H0SXTV*)
M);NH,D^@TB(Q5?"[_*I0[$SE?',=PYUEN_RE?N8&1A+  +K,U\Q8GP-PN#2<
MQLI)B9=8:]I>TAPT(35@F:_!V@3P/#@'<P6_-39(LWU=-308@(Q]N9]>^7JJ
MI.NB571E'S.J<7?)&"X!C02-0-4L5N3'/H<Q"+2]CJM:1F;%TC2UK193]Q(U
M.!1$O:<IV5>5I(L29T##O+26=IHN7D=O@UPX1A.,/M*HDK;I5QR496CEF+D"
ML<P'JI2*UT&\Y7Q_)0$^AZ%UWF_9($3VMS!!8)>W+KT18$*JFMH#HJI/DDDR
MBQEP=2/-]U4V2VM'G7Q3K13@S.< />(P2?\ ,%5D?S"29[-X3?$^DA,CP 6-
MM?J,K5U%]*97%I<&N@+&L-G:=U"33Z&1:D!QW%LRFI*NP!4.;'!HX:^J>Y#I
MF&XO(? PD_>*MPM59BUD;[^QY5\9(*>;'ZB*>$RM="W+87L;+N:'-\_)X?RN
MGW0;@>=_X9*R=U/'&Y\I?E#6BY))T%EZ7UHX<6^3I'AHX\V?+Z4(MR^R.G<*
M<+U7"U-+#BE++#72M$\[)&EK@+7:TCH;+IZ2,5BWQ=M\GA?B#-ER:GTIK;MX
M2?\ JRHX]EO100G0S5'-(],NZAJY5!)^[LO\%'];*7V5?ZF?PWRY2J<;5'7U
M/)M< >2]@(ZK7!GF=>N&=BP!D;HV&X.5@*KU+:(>)C!O\BZQ2MB9ATC.<V^4
MZ7W6+!CDYVT=W7ZG%'"XQDK.:/>'->2=2XFR["7!XQ.U;(?+YDK<IOW]%!\L
MMC:1;X2R!N( A[;_ #6>I;CHIXU%--71<253I,2BIXO.(]'VUR_-6-68]TE)
M5[LT5)"YCKN:1;NL<FCOX<<D^42Y2#'8*IFMJD9_'6EU/8 GS']EMP\'&UB;
MNC!U =&]P<"->JUM^YQU%],T7 F)LPW%65F< L<WS$Z#54:S&\^FE%*V=/PF
ML7C_ "6/)-U&^6_S-3B4]7C'.K'L<]SWNN0.E]%GQ8XX*A9IU6HR^14M15VW
M_!,R[HG1/>US2WYJ_(T^C!I8O']:H:J&NL#8JLUL?HA]B7'X3U03CT,U$CGN
M]W&K7))D9<\$22(,VW4)]$\$:9"E!!U%E4:D")CY+Y&EUM[('M<ND.X9.&5F
MA&Z(\L&U'LD<21CWF.H_ZQMU#+P^2W&MZ^7DJ[V;=VB@FGT3E&4/J0T&LOT4
MQ5 D 6:7,%R-E.+=E691V.A;HGNA,AU4LC11IXR7%$:G?F>]LGEL-+]UDW'7
MV)1N15<9Q/GX4QAC 3EHWR #J6V(5D))8Y+WH6BQN>J@_9,XQPUB+JNFCS'J
M"K\4G/&F=[R6G6*;HT[*ESYVM O<ZIQE\YQ)8TH.R]CEY8'R6Z5T<J4-PP7R
M E8G+:^2^&/=TANIK&R-$0%Y+6%MP.ZDY.ZH<,33W/HU?!? ?$W%+GC!,(K*
MWE,+Y.0V^4=+DZ"YT5.I\A@TG.2:3^UF[0^'UGE\E8,3<>>4N.#HGASX,>(=
M;Q)2R\1<.283A<$H?(:DM!?8WM8+B>4\_AR8G#%-5^9ZWX;^!]3CU2S:N#5=
M6CU;&(F-:R-S[-8!9VP TL%\ZRY7EFY,^V8,7H04/L*N.X5=EIL5L,I&Q'#Z
M7$Z1])5L#F/_ $5F+(\;M%.;!CU$-N0Y_P 1>%K*ADE1A[ YV7IH5W]/Y:4:
MC(\-Y+X/Q95+)B7)R^KPRMX5IZ@/HY7UAD<6WC-\O07M\UW<>JQ:F2;E2/GN
M7QFJ\/BG&./?DMM/CKV7N6G@]6<00<3.JL<PJ7W6L/(9(Z.S1I=9?+/3RAMP
M,ZOP;'RD,SR^1AQ[='8,:]XJF\JC9Y)76:YI&JX$6XQ43Z;-QG)S7"9FJWAF
MGC9RJY^1X\U[^8^EE:DJY*FW[&<QC#,.?3%D=.YKK:.>=6JV"5F7.WM.+\=<
M,QSB4O',&P"ZF&?IO<>-\EI5J4\;/.?$F,8UA>/,P&6H>W#JR.:&-CP;O>YA
M:T7[7*Z,-?E50OY6FOWT>:Q^&P14LBC^LBT[_!,]S>"6#185PY18?!%E93P1
MQVZ"PV_K]5R_(R3:BO8]3X+%L4W]^3K\$ LN'/L]CC7R@F9E<3T44R+CR,\Q
MHTNF)NB#,TO)R]U:C*^Q+6^0M=U%DTZ=B:W*A+HV\LM*MC)MV1]-*-&/XBP]
MU/+[[3MN#_,/9=/!.^#SNMP/&]Z^Y&IGYFMS]1=2G&N43P3W+:R0Y\<;;7W2
M4G(GDQQQO@:$H=\)1R0>TKL3IY)W AH([W5Z3VHC2O@1#$V$#*-;*2X%1H.'
MJ=Y<]Q&EQ?58M6Z2-6BQ[I3?]]'3>+)A1^&C \V!IW ?6RX>AYU_]_B>P\O+
M9X)+\/Z(X%/4FH;#RS< #]UZNN#YC&>Z9;X!&#"^HEW<=/DJ&K.SB=(&.5X?
M$*=CKD@Z(BBO/D4E1@\7DS/;$/JHYI6S+@Q[4QRDB!8VRILU*+)@@%M0H,N7
M0+9=^B (.)2N(+1L1JI+@ADE:X*F.)QD! 5M\&%1J=@KA=HMW"BRZ)63.#8G
MYCT54B_&8[&G @V0N29D<58VHIS&=@2K<<MCLIS8O6Q;#O'L3XW[GQ3CW#1D
M 94T<==&WNYCLI_[KEQ/*0O<>U^%LRBHP^W!U_VD:$OX?PN:.&$N]_9$V[?M
M TM-VAW0$ZK#H_H/0>7C\QTGP[>T<.X2YP<1R&#07^[Z*[5\E7CWMC9N(IV-
M;F<" .I"P.-'466$O8BUSF2,+F:W.BE%6^PG.*C:1EL1<3F;D/Y+3&,E[E+R
M*7L5\=VMT:0YK7%7*K^<@[:N*/(/M#\4U%/6XAP#58>>;6U45>Z;,/LF7S,/
MU!"QZB25I$5\W+(7A#4N:^",NO9MCZJO!(E5*CU-P9,"^-X.@:+E;TK#V.QT
M4C'4@L>RPEK'=M4"#CU==)DXDENZ@R3Z#2(C%5\+O\JE#L3.8\;ZQN:-UO\
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MIW9TS .$,8Q -]XGY;#KI'8667)Y'(EM1IP^"T\EOFF=+P+PWIH*832O<XD
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M-4U]A986T_L4TTX%;3S9LI$@M;T-U#*ZAL+L,7DRK,^T>\\3XB'$W!7"+8Y
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MW7$ULZB>PT>.Y4>0\-<Z1Y!<XDN+G&^I/4E>?G+<SOXX*)T/ 8V2P1LDVO\
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MJT:8<.C-U;\TSI.^B<40FRNJ9H@VSQ<G9:,:,N1D9U4QC'9=--EHHSI\G/\
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M&X4&N1.0ZP7<+*(T3(FD-U[*/N6#<9'.#>I3*GV.UC28G#LU*/9-]'..)6.
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M7$"62M;\18<I['NH23;7V]_Q+L=-2KZO9_9G&_&MM?B_"4Y=,2!6P @W^'.
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M#-TD?.OB7!4MT5_?)Z[\$YQ5\$83(6-\\()TZW(_HM>I=QB9_'I)-URC>5[
M18Z6[+/B5&W4/>K9GZMH#BX7NML%P<R:ME9(XM)<-RKTBMNG0H><7*)(G!"8
MM*GS=U2T:8+W+&-Q=$]UAY5&,$R4I4(+R0=E-02*IS=#,CKBQ.ZGM1GE)D=[
M;QN))4U&D14K*R1MY,KM6CNCHF*>X1N$L;0W(T'3YJ,G;)Q5<DZLGSQ,=?<
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M *Y[1\LY6GS&+;JMOV_V.=\.ZE3\9#)]W_5FW><SC?NN6>A?+&SL@0T@J @
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MK-O0$77/\TWZ^XZOPHDM#'&^E_W.E"]M=UR&>KCUR(2&((%MD%0E  0 $ !
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M6Z2.OW4)]DT1X]E4P)U ]MP4,:8K$-8G$==%57)9:VE5P<0W%\=8=WF"1O\
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M)\%L7^!5MQ2JC!#8!?;94L<<DOL2()ZNH9]I*\=VC8J&VV:?6DH]$H02%EW
MV^2>PK]9_8ET$+IYF,RDANNRLA':RK-)Y4N#30,8PV) RC1.3#'#:.1N+Y,@
M%U6F[+ITEP7,#1' UCM"+Z+1%TC!E[%<N.J86O(!;M=3YA)->Y52U,'#)Q71
MU+P$XP9@>*_P+$:AC*2L-CS'6&:YM^MEPO.Z9Y%>-7^1[+X2\@M,O3RRKVY_
M>>D) <ATZ+R'O1]4[Y(UCV0^.&)\K@BO_F%0(H%B=@@ 6/8H VSG!HN2NF8P
M9A:]T"%-<#<W0 E[FNT!U4)$D#,YL8:>BCT, D<0,^W1.P'R]N0Z]$R#7!"F
MFC<Q@#M3Z*,/J9.7[*)1XT',JHCW&BZ>BX@SS?G%>:'[_P"A)IJ<N8,PUW4\
MADQ*D+E@#[ CX4H2H<HVR!BE(TTQ:T:G6RTXY&7/#@STU,T-(.X6R$CESBT4
M]=2AU[C3HMD&<S*B-%2, 399C9/IZ5@C+G;V59L7/ =921R09NVZDY<$'!%9
M)21AMT796XJ/)65<0M:VRIFAIF:Q9F1XL.A55$MU%-+*!I=1:&I$.>< 6NJW
M'DE=HAS5.4"[@+JU(I:*W$L2#HCT%ELPNF<O61W19A\0JI8Y^>&W##?]5V(3
M^0\/GT[]6SKW#/%;?<(06M#0T+DSG<SVV''LTZ9NL*XNH1&W-*T7T3FDS1AR
M/'&S2TN.4TP!CE9KV*CZ=E\=6RPCJQ(\&]A;<J,L;19#4[I%@\Q.IPYKV_FJ
MJ:-KGN1&L;7#2?\ *+ID;0T]K@#=I0#Z*QH:V4D]=M%:S-$8K8&R1/#=7:65
M;+)_0S,U\!CN<ES>RA(JC%E/5-J"QUHB $H\BFJ,^*8S3DR/RV-E=5HR1=2)
ML5%&'90S/ZJ)H:OD>Y7)>0&Y;=$[([1FMFRLN38*IHT1^QE*ZM#7?9.N>GS5
M4^C1!<H[7[+A+JO'Y&ZYF09OI?\ JN#Y#H]G\.]L[DX@!]^ZP>Z.]CZ9%J+$
M7"&6(AOZIHC(9EU8&AOFO>Z1%"A65]. (*IP V *LC*D.DR0.(<6+0TU+7V%
MK2#3]$][1'8C.>('M(\(^#=/A>,>)57585A6*5+,-?61,YL=*ZV9KG6!-CE-
MR!H%6Y*N2U-OB)ON$O%_PVXZ:R7A#C[ ,7%5&)(VTM?&]Y:=1Y+YA\B%+T8R
M>Y%3RR^F2-;A55&99&.=;*=21H+[:J,U)%L6B4YS9#G826WMF N+JE2:?)HN
M+0B<!L;BY[=N^RG&<;*G%&-Q!C,\CRS-KI9;<<D^40:HS&,@S4Q8&$#L197S
MY165.%8>RG<)3I?5407)8WP/8L0\>0WLHY013QTK9P2\VTW[*IH<11PBS"\3
M9@%&N2SV*^OABI:FCIY) )*J8LC;^(M;F=^04D1-A14L#F ,-VM\OU&ZO1#L
ML8Z%O0:*:H5,FT<$43P2S7U0Y[>":C:+1Y9(RPT:.ZHFVQJ*(KQF%LCR!V:2
MIQE)"<409@R$A[G 6UU*N4F5-)<AE_.8)2#KMHC8&\9J,6H:*)S:ZL@IFY2X
MF:1L8L/5Q":5=BW6</\ $KVA_ WP^AEQ#B7Q,P5H:7---2U+:F>0VOEY3+D_
M6P]5DR/&GRRR,9RZ1Y:XU_M,N$L)S,X!\.\0KJAI<T38A.*6%S>C@QEW >BH
MEF45<461PM]L\Z>)_MV^/?B/":"'B"#AR@%VBGP:+E.<T]Y3=]^FEME"6JR/
MBZ_(FM-!<M6>?)ZJJJ*A]7-.Z6>1Q<^1[BYSB=223N55;NT6TJH]Y?V4!R<8
M^(+P26_PZC;<[WYI*'[D)^Q])FS [.00#,G0E !-<"ZU]5,="@X$V!28 .X4
M1$JF!:[7LDU8X<2*#Q)H_P")< X_1AN9SZ*4@>@L?Z+5I'MSHY^OAZFFFCPU
M+,63MBCUY3 /TO\ U7T!9-_S'Q']']"/IKV)M(ZS#*[8#7YK1%F/)#FB' ]U
M3(ZJ>/.=UK1R)\\EC 6E[+G0;IOHHC^T)-2#+3.B:ZW50]C4D97%A/3MT>7$
MZ!"Z(2M/GHH.7G:;_$[<*-6BS=3(S:=T;G.RZ65;5,V0^:)%>XO(:WX3=1LL
MV6AR*0T[L[/A;T[J49;79"4-T=K$ME:^2+$F-$>:6\@[VZ?)6QR*U(IEA:B\
M?:HNI,1@JSF@L"[XFC[JV/(I\HY$=/+&_F%F3;*>EDFD2C<;LS$M/[O7/=(/
M+(;7Z+"X[9'7CDWP5>Q,@A+HL[19['Y2%9C5$<TMU)=%_*&C"9XW'S&(W^>4
MKI__ (6OP."K_28M??\ J6%!%24]#3U! YAIXQ_W0J,242[7O?)EU$_GX<PD
M:%BV-WC1P(QVYV"6E_N=[: +G952L]#I'N=&?G! -UR\O9ZS2_05]400HHN$
MY(S%:0:*R**,KX(\<[Z&ICJ&7Y3)&YB!M=2NF4]H?@H633U6&YK":;F,OUS"
MZDDNB,F[LG8;A3(F55-.[[2!I+ >KMOV4HQKAAV%0-CIJ%L3F-M$]Y&H^'HD
MN$-59FI&M>QY.EW%9'[G1A[$%T! S ;:JECHF40+67<+ J4>R4W425)4D1\L
M#<Z*RC/O++!P8VDRMRN(V0^$2A*V7;0UP#B56V7$J&G<UX>&[C1)=D9=$\YC
M:^ZO1CR=AQ:NL-U9[&?W'J6LEH:V"JC^*-X=]053DMQ:_!F[3M*<9?BOYGL#
M@C'X^(^&Z/$HY1(71EDA[/&X7@M3I_1R)GVKQ^K6IQNBX<; K/EYDF;DZ31%
MD:XNN!HJP3";Y?BTN@3Y#SM[H"C9N (U73,8T"2XM2&.M:0TWZIB$92'75<N
MR2#D<+)#$L-V%SCH$ *YN8$"^R+$^A!B9RF7&J<(U-BD[Q1*3B9KHJRGOU'1
M=/2+Y&>>\V]N6$G_ 'T2:1[B-C\/9/*J,V&::Z'X@YY<>W=5I-]%J28Q7-:&
M:D+1CA(SYY1JC/5+&.)L0M<3EY(6BGK8R20.A6W'='*S1Y(\<8</+K;>RDV$
M(-$UL;Q&[[)U[=E'ENC1=*R-*Z3E%KHW#ZA3VM(RO*V5\C)"[86^:70M[?9!
MJXV!FUSU4)$TS&\02!GFN T--S?0:JJZ";,'B/$E)3/:SG7SD@$:_FHMCBGV
M4\G%8?\  3;I<*%NS2H_*F5]7Q Y\S7"6P U5J391*2B1L1Q3[$AKS>UUI@J
M.?GBVF4T-7SVN$IN"#^Q71A/Y3SF;3_/8_A/$-0W"8&\XWS/#K'UL%R-]S/6
M^C+]'1?X9CM7.!''.X.&X)LK]R;HS+%)8U9HH,3Q6G;]E7O8X]05)RHE#$28
MN/\ BC!P7-Q5TSFF]WBX'HHO*TNR^&FN6Y=%QAGM"XI21-;BN'T]78F[F,RN
M*I6:2[.@L<*KDU&'>T%PM51M-5A=;3N(\W+LZQ_-1]6WT'I?8N(_';P\J UC
ML0GA+M/MH"/SLGZL?N)Z>8(_%3@2>0M9C],"/Q7:/S(5KS0?N9UI\D>T2F<;
M\*5S"VFQV@D<=F-G;F/ZJ&^,NF2E&2CRF5.(<18'3R9I,3I!?O,W_>H2:7N1
MC&3Z12U_%/#LS,@QBC:=;?: W_)*,X_<)X9OI&>9BN&NE<^.NA> ?NNNK5./
MW,OZ-DB[:)C,6HFQAXEM\U%R1?&#^Q K>*:5A+&2"[=+J#R$UB_ I*S'3.?M
M'G)Z*MSOLN6)HJ*S$*/5[)'$MU&B4IJFBR..2:;.\^R?5/DEQU[OA<R,_P#>
M*X&O=JCV/@8O$[?N=]<-7-/758ESR=V*VVF0Y0;D7&B&31&>TW0G0I*QEX.9
M#([6'R[L!*0]K&#$;E.PIGF[V^\#I\;]FC&:A]L^%XG1RQ.=TN\L<?R<JT[B
MT3C)*1\Q*&JK<#JH<3PFNJ*&LAIXW-GHY'0N#@+7!!N#?LK5P-R5G6.'?;X]
MJO@>"GP_"_%2MGIJ898V5]-%5.:.V9PN1\RI2D.,(R]CK'"?]K;[0V#P&+'N
M'^%<<=TD=324[SZG(ZU_HJMUOE%GI1.B8-_;!XV^,-XC\$:)][9I*/%7-/KH
MYJG%QNVB#Q7TS44']JWX3XF,N*^&O%5&XFQ,4T,C?TLKUD2?RK@7I-<-DV3^
MTE]GBH%IJ3BZG)W8["VOM_M!]E8\\6B'ILD4/]HE[+DS@RIQ_'*-W43X4\ ?
MD2JXY8)\LGZ<J+N#VX_98Q8?9>*M)3WZ5-)/'^[$IY,<O\R%LFO8LZ7VH/9X
MJV?W/QCX8=FTLZKR&_\ M *%Q?4D)*2[3-+A?C+X88K';#/$+AZJ+@<HCQ*$
MW_[R*][1+=[48WQ?\;?#3@"?A'C#'N+J)N&4V-/CK'4TS:A[624L@:<D9+B,
MP%]%%R4:;8HW*TD;?PF\>O#[Q8X.QCC?@.HK\2PK '&*NE%(YCA(V,R.RM=8
MN\JE^DP)K&T^3C]=_:@>S10EKH:3B^JD V;AC&93V.9Z/TK&N27IR*V?^UB\
M!0;,X.XRD('Q-A@8/R+RE^FXU[$7IYWPRDQG^UT\.*6FDBX>\+N(JR4Z,-75
MPP@_/*"4GK8>R$M//W9S#B#^UI\1JHY>$_#/ \-%SYZJJDJ"1Z[:I+5RE]*)
M^@O=G.<:_M*_:AQIW]VQW!\+&UJ3#&'_ ,=U+](R-=B]"!BN(?;1]IWB2%\&
M(>,&.Q1R-RN;2%E.VW^PT%5RRS:Y8+'!/A'*\=X]XVXHD=)Q'QEC^)O?J\5>
M(R2 GOJ;?HJ&Y2[9:J72*!P!NT7 (L20";*%7V.PY(G&$/-B=B>ZNJXD5+D8
MR]5#83L,-N[124>1-\'T&_LGJ,#$_$>M>VX]TH(FD='&1Z4^$V52=M(^AK 8
M_*[<:%10A9<'.%DT-!M(;)<J0VPR[6X28NPVNU%TJ"B7',V^QV4HH5TP8I3,
MJ<%JJ=XO[U&^ ?[32-4\+O,FBK-!QT\D_<\$8S2.I,>K:<@?93&/3NW3^B]S
MI<BGCBSX_P"0PO'GFG[,A55<*>(Q G7>RWQ39P\THQ[$T7,-@TZ76U32.*\,
MI=%S!3ORY[BP]5+>FJ*G@EC>]](D.T8452'O1F,<(<6M&]S^RBA9'NI&=-Q(
M6CHH[TBZ.-R0@R96.8=RJIRMG0P0<8\D1@Y1C$K2=#M\U"B\)TC&P5;"PYXS
M8:>EU97RLQ__ )$RG$TSZ1H:7-)?<_(JI7V:]T5\K)5#*:/, _1VA<3J5HA-
M0,F7'ZA=TD[)6EID!-NA6O'D4N#G9L$H+<)\DKWQ21@W&@/6R&KX9!-QJ2*^
M*.2FJO.\OCGNYKFF]K='>H6>G!_@SH0<9Q_%&BHP)*2H:\W\CA];+IX?FQNS
MA:I.&95]RSI*:.2DA:\N;DB:#<:;*"5/^!7EEOMK[LMZ4-]VBC9JTMT6A<I1
M1R9?+-S9+D<WE"(+)GQRHZ^@U,+,]BS&,D#&@A<G+%IGL-/EBU14541+#EW5
M*-3(ASN+6DZ9@-%;!-NC/FDH1MEW#34T B;*R[7F[[CMJ%HV5V9(Y%(KL1J&
M2UCYX06O8/)8:754I*R]1<OF)='6"NA?+)=M0Z/);\1"G%[D0DMKIE/43NCP
M$R!CC().7KUU4)*HACFG(K9R8HV,RD$$9OF5GDJ-^.:H.%S#HX'55434AWFM
M&9F70*<5R1S27IL<IXPYY>6^5HZ]U=5=G/W7T3J1TCI [0-V5625K@U8(M-V
M:%@'*:T;E4M-FJRQA<'!H'064XHA.21*:QTEW-M8=U:C/-;NALN#-1NK?8RO
MAT)F)++C?HJZYY-"O:Z[.Y>SGQ-9M1P[6R.+W,YD-OATWU[KSOG-,Y2>2'1[
M_P"#O(I8HX<M[NG_ *'<)V%NIMJO,)[XVCWLUME^8SE+M EM8#3SK;LEM8[H
M0B@W(VI??8+I&,2T>8FZ0#W0)@)<+ NNJY$D,N.9MU$8B$N\[#U/Y( 4W0&^
MFZ:[$^F.;L9961^ID7^SB4'&55'2OI:R71EB%T]##U(M'GO.S]+)&7]^Q41<
M>87 S/)%)8"V@NM<M,F<F/D%!=%?4>*N$M+FQ4M2;;V:B.G6/LIEY%Y>%[%3
M5>*5$YCK4E5]0M$(Q7L9,F>;]RED\4L.:7!]).VVV9P%U-;4^BESG)=E-B?B
MU T@187,YKMCS6C^BOCDBND8YXY2]RBJ?&6LIS:FP:,=[R$E5RRUTBZ&)^[(
MK_&S&70R%N$4[2 0/.XJOUG]C2L-\65=3XT<1PLSQX=2%YVN"0F\\E[#_18_
M<H:SQ\XQC>[+244)[MC-U6]3(L6D@5-7XV\?5-F,Q".$.UO'$#?YW4'GFR2T
ML#/8CQSQ+BD@.*8M)*T Z!H;I]%4Y2D^2Q881]BEGKY:JY:]UW&S?2R+)^G$
M6VIEDDY;+M&VJDN64Y$DN"4_*0+DD@:_-:H(YF8B5T]06]==%;$SY61Z&9V8
MAVH:#?UT*V0ZHXN:MQ48%43?P[/F^&5P _VBN6OK/4K_ -,;' ZO+:9P\QZW
M5_\ FLS5^J2-%/B3RUKF$@==4Y,<$551B<M5(8!?,XZ-_P"*SR;;HZ&#:H\C
MS<*-/!S:JP(UR W*6QI<ESG%]#U/0QRM)@8X7U%]$]ME>_YA,E#*R-\DC<X;
MM<;*MQ+XY+(-06S@1L81?1W6X5<D:DH@I<.\KGLB L1]T*&T4E%JB/B>'2Q2
M"2-H#K:^4'11DJ'!19'HZ=TES.W,[[@  UZ[*M%LH1+VG!HHP9&97G4:JZ,F
MC+.$6Q;\6=)I+/EZ6"4INPCBC0Q+B,;18#,!U)W4=[)>E$A2UM9-I&3;HGO9
M#TTF-24]2!S'$@#75%AMX/3OLAYG46.3D7!=%#^[KKDZSW/4>)Z1Z#J'%KB0
ML</I.W+ZB#*>M]TAH9MZW0,;?\2 %,!MZ( :.KR-M4 <S]I;A$<7> 7'6 P4
MYED.#35<(&N62)V8'UV4/=HAU)'QX!;)21OZ\IK7>AOJK.R;7)G<8BRR6M?J
MAEL.R-3Q&5F8:65?N62=$^*!V4&^ZFD1LEPTX! +?*5,3Y)%92QMI\C6 C?K
M=(#,XC$YHRBX:- ";@*N5O@E%E:[,3<DZ=O^*I=HG8D>4. C80>I;<CY*+0[
M&OATLH]>Q*P<P[$;>JC=#H^J/]E)0Q5W@5QJRI?S/><=,):X W::8 _753B^
M+_$@UR?-/Q"P67 .*L8P>H:]DM#7U$#F.Z6D=WV3:^4$^3+JDL @!^)MRM&-
M%<B=2P!SAIU5UE;98FB%KG]DZ(D62E#3>WZ*+0QCD@NMW44#=$BH@#:33[JL
M71!/DJBH,N%-"%QR)L^E7]E/A+H>!./,<=%9M7BU'3,<>T<9+OU>%7)VF5R?
M*/<YO?7?JA %>VJ$ 0)SW4P%@W0-"VBY0-NB1$V^O9-$&N+)T;.:QL3M1</_
M ."AB^7(/,M^*CPKQ]1OHN-<:B>+<NND%K6W-_ZKVN@_809\D\RMNLR1_'^A
MB:S-S'7-QF*[&,\GJ2702@BUUK<6<B&9?<O*.0V#"3JB*IDIY%*-$US/(3=6
M>QFLRV-MRS,%KW<?V5:)2^Y02-R3.)'795OLVXG:&YFV&>WT4&O<UQR5\I')
M=)RW9<H'="C8WDHB8N\PM$C1<5##'I^('?\ )63^5)_<SX_FD[]G9#8^,TP9
MERVZJJS0E[E?4\QY)C.@496RV-+LD4TSX/M+FY4X2<64Y(*:HMZ&OCJ)6N>+
M/:;;K9CR;WR<_-A])<=#]'2O?!(0<S><_P"A4HX]R_>59,RA./WI%EAKBV1\
M8/E(LM>#C@Q:Q[OF]R\;GGH*9T>C7,!*DUN2:,$WLDXLLZ8%D,70-: KHJJ.
M=EFFV.N<2[0*O*K+])+8RKQ>'-,UP7(SQJSV.CR6XHJ*EK@"T:.6-';D-4-(
M))AFW!NKL"^8R:S]G7XEAB9!C(:VQ8-#=7Y.C'B[HJ#3R- =U.ZS25,WXG<6
M%5ODHV05$;/Y+LQ(^]?HI?3R526YT3\2AI):2FDIW!T4FI _$K9I-&>'!GL3
M(=&6-;E+G _*RRS.CB5C C,+FYCU"J+D.-R2%[&:EV@]%*/9#+S!CQ<]D?(N
M!EW/=3G*E1FQ8K=EIAC&@-9\1)W5#9LC':73 6O#3T03)].;$*42K)V6,!#(
MR"+W4T5LBRBSBTZ*Y=&27UL1F$C0T*J1JQKHUWA)7RX9QUAC'26:^I:QW^4E
M<[R&-Y,%G<\!G6#6N!ZXJ"ZV4MT;I=>(2V-Q/KU[XQD,--K_ "3 9<WS'5)B
M867U2(FQ:;/M;HMYG"CT>X[Z(&+8_1Q/0H$$'9C?HH2[)(+*W,YQ=H$AA0N;
MFS#J@ I-=M+H#L<C: P,O>PM=2B^;(R7RJ/V,[QU YV"159T?'+RRVVENZZ?
MCLC4U#[V<'S>/?C]9^U<?F<OQ*0B#+:Y+NFB[#7XGE99$UT9Y\.:6V0D.WUO
M9/LQTDW0U/3L&C2YHZJ7059F\>:6N9''MO?J55-\EV-4BBE<'9I'V BT*6YD
M]J((8R6-TV7KLDV2BB!*YPOEC&NJK;-$2MQ>IRAICRM<.QV49$U^)EL7J7RL
MY6A<2#>RK?)*]JL1'"[DL?EN[8CLI;2.\;EY<>LS=3LGT0;W#3'4L4@>''O:
MR5BIDBDR2U+<FQ4H=D9\(N/X<R,ESGWOKJMT$<K*RNQ!T1<0+;65D%;Y,N>:
M4;134S\LKXWN :6NN>HT*UULBY(Y"?K95!\6S.X+4N@:ZC.K<Q=<[ZE<AR<9
M6>LQ14\6PU=)7,C A:1Y=;W5T9;GR42@XK:6U/BD<P='F'E]5/AD4G$C5.)2
MZ,C:W1UM-_FHM(L5LFPS21RMG8YY?;4$W!4E%$)3:+JBGJZEHY@)S"^@LDXV
M3W[8IEQ-A=?)3.SMRQEOQ#Y*$H,LQ9]QCJJ9]-49&M!R]2LDG1T4VR?1U+Q$
MW760[*-DMOXAXJRIEB<^^4-T4)V68TBKP4N]_9&XY]SKT54'R73CP6+Z2IK)
M72/E<-; 6V"N7)FDJ%##"P92W,>Y0XE>]KA .&AQ:.7IU]$;0]1DZ##H(@-<
MVG4*.VBQ3LB5T.:%QSD6TV4&VBU),]&^QXX'"N(Z<@>26!P/4W!']%S-:ZB>
MC\+^L=?8[\_[0NOT6./'!VD]ULKIQ=UK[(HDA@O+3;=(3=#;Y3FV":06 5#@
M+90G06)C>7O=<62J@L54T;,2HZO#I)"(ZZ!]-*+ W:]I:1_WKJ#^H/J1\1>,
ML'/#W$F,\/.86.H,0J8+$:V9*0+_ **47P6M&1KV"4$6U";0TZ(M(VS,@WNH
M57)-_-P64+,F5I%P>JDF*J)[(K^4#U4K$+DBS@F^@"3 SV-0YAE M<JMDDO<
MII*6PW*B21'?&6FUDJ&F,O&NRK9)#3K*#HDCZE_V26*,E\).-\.#!S:#'X*G
M7[P=!M^;;)Q5\,'VSQK[<?#D?#?M)\>T4$19%)B7O<8M;25@?;Y DJR?317%
MVT>?%G+@#=-=B9*IQ=RT15(KD7V'TX-G>JF5%J^E#6!P._HFV.B#416&RC84
M0'Q6=?LD)H>F:#0N<>JM1!<,HW-U46BY.A48&9H)L"E0GR?7'^SIP#^!^RYA
ME<]@#\8Q>JKBZVI;S P#Y68%4N>"N2^<]/..I/S*8QCGDZ90DGR XW:ZL 4'
M6.J!CS+6N$!=DF 7!".E85::)E.XY2_\%C\Q=1ZFJ"#W8I-^QXM\79HJSC[B
M"JB8&QR5[BW+\@O;Z..W! ^/^5R^MK<C?W_H<SQ'R39 +WUNNM@^8\QK_D7!
M(P^/8@DV*Z31YR$:]R\I\S6YR-NBC&.YT2RR<([BT8UKHLQ-E&3VNBZ&/?'<
M9G&H[R9[?"=/KHGL]RISIT9VMB<VJ?&-@J91Y->&:78RX&^1P&@NB,;+9Y*?
M PT%Y&@MV32$\C16XK_>7543=!$P&.W1P4<GS6B>%[6I/W(K9(I86QQC-87<
M1T*I;^QLBN[X(I%Y0#Y6NWL@78VP@%V9QL#H.Z%R3O;30Y2!GO <97,!<+V4
MX<,AD^951;8'B0=%/ 7VY<[OJ"M.GS7<?Q.?K=*DU-?8TE,V%T>:(^9RZ<$F
MN#AY924OF+?!8Y/X3 Q_W+B_I<HQQ:@DS#K,J]>5%JP#DL%]@M"Z.<_J;#!:
M3T5,I67XHM,8KH\[V. O8ZKF9U=GJM!+F#_$SE9*?>'>4#*=E@43O2U#^Q)P
MQKS)FR"UM/FM&*%,RZG.Y12KW%8KDR^9V5Q^(=D3E?!/'C5*17-K 6V=&+#0
M'T2:3''(XJDAN>3GQ"%K,UK^4[:I5Q0G*WR(PZ*HCIQA<C6W$O,:;ZCT^22;
MK:.,?=%=CL<L6*&C8UI<!GM?J>BIR+YJ-4).*LBQZ&TSG.=V5-5V:5^!*/+I
M(G/B:'22#_LH3H4U:&V./) ?YG7O<H?)"+VNT7&$2@S-:6@6242;S-\47V\M
MCIV]5+:'J$R%A;8E-1HA*5DN.5V:S6@@(LC^9&J!+53&.G;?6SB>A5J=HSN'
MS6-SM-* 6'.X="HN-ED9N/-=%IPI[S+Q?A3X<P=--&18;$N6?5K9I)?@:O%3
MED\MC?\ UI/^+/:K'N<!"\[1BY]=%X#)S+<?<=/]&S[4)<P,%P3V44RQQ2&'
MY0;D[I2(U8G,S\25AM1KR;#/U70_$R!V U[H 26GIL=T##T:PANWJH2)(;NY
MS7M"B 4+;- .]D +E_P)@/0 O:FN [*_BZG,^!51>-6VD%NZUZ&36=?O.?Y3
M%NTK_=_,XMB<N0N+[: $+T<>59X#4_)*B-A[A)YG-!OZ)X^RF2I(*KI(9)BU
MIL,MSKU4FB-F9Q:@B=YG/U:=-53*);%UP9*LH)GRR,:\9"=+=5&K+E)(:;A4
M\,187C52V4BA9>2#B%(]E*Z4/8UV4[A5N-&F,[,9/AE3/>=TI()UL55MODMW
MT,S8+/TU<T9A?K9&QC<[ :>2YEC;E;(;1M<-;!2H0U484Z< DM!:-4G&P3H@
M28:;'-8N!Z=E':2LEX=0".K+FWLUF8:]5;CCR9<TZ%551/\ &]UKZZ:+;!')
MS9.3,UV(/UL[4W6Q8ZY./+.Y<%#-B4C,[0R0O<-3T4G+B@ABMJ5D""L=3U6<
MMU<+67-SPH]!HLU\,NHI*N;[?+8 :6&ZH3HV.+DRSI)'Q-;,ZX'WE-2%Z9:4
M<7->'/.A.8(W<DE#Y348/3<][8BP?56P9GR0HUF$T#8JSE3, 9;IH5;'LSYI
MU!%GB$S8Z)T)-FW/S1-<$=-*V<YQ6&/WR\=]3U7-EV=Z!(CIYV1-E8T>347"
MC1=8BLE-3&(VW!<+DCNJINRR"HC8-2%M>QP'WB&_)50X9=D?!=/>*:9T;FDB
M]PKDZ,LD2(9.99Q;Y5:G9FEPQYYB8UPC%R[>Z9'DCQFY(2VDE(J<4F,;>3&+
MN<?,J9HU8Y6=\]C:KE=)Q/3OV:VF<-.I+@N3K%:/4>"[9Z.SGS?-96NCK8^F
M0Y@,Q*18B(_XDF1D-/M?U30D-W(T*8Q49LXD=4@'(Y) "6$9AJ-.JJGPT21\
MC/:WX==PM[0'&U.(RR.JKWU4 =^"4!]_S"<>Z)W:1P]EYG/S=+[*;'$B4PR5
M#K[*++$7$65[1H=.R$#+*FY=LP:;@64R(36N<ZP'E-U$"CQ./,\"VEU6R?L5
M,\;>R0[*^HTUL@1#>5!EB&'*EDD?3W^R+M_R=>(I+1IBM,2>O\FZG$/<X#_:
M54(B]I#&9WL -3A-!.;:7.0B_P"BNG[E$#Q\LAI -T(&2Z75RU0Z*9&FH0\6
MV5B*T7!:"QK7=4$R)4PMU NHM"*B=I$F4[&ZB)@'VF'.+NA(5J(>Y2.W298"
MQ(O;1K;G\U%L:/M5['^#/P;V9?#G#Y6EI=@[JIX[F23,#^JJ2II%3=R;.R.%
MKA,9&>,NR$@%QO<1;13 =R7%R@!Z, #1 #\3BUUALG7 E*I4387-%-.]VPC=
MK\M5;AAORHKG/T]/,\*\=UIEQ6ND:;N?6.!O\U[O!CK!$^%:S5.6NR?G_L8Z
MO!-2/0+5AX,NL6Y#^'O(B8\6N7!=-GFXND:"$DQ$%+']2(ZCZ&3W:4PMW"JR
M?4;,#^3DS^-/#&YR+MOJKTOE.?DEMR49JL>Z2H=*!\2KE'DMQ9+5L9<PN:7C
MXME&J1IC/<18O*YY+M+74$7LK7/Y4$]2!=SG$Z[;JER[9K6/A$#)R)L\.D-1
MJVWW?0J-4_P9/=N7XH!N;D;C9!-\<C#Q=U@/FCMBL7#'GK(HG#RN(S6^::[H
M.HMC,.>F?5R1'05&4'N$H7&VON694LFU/[&DPO$F1S!I?L1^RZ.#,D^3AZK3
M-QX-I1U ]R8&;:V_-=&^.#S.;'^L=DV&9Q8T$=%*/1GE"F&PZZG<J#B3C*AR
M9X8QSR+V%UERX[3.QHLVV2,M('5=2_)&[,3HL#@SL^LGT7M)3/@IVO<T@@@F
MZGC09)?*OS*/',]0][XC;/H%GG;D=+%6PCPP 4#9'.\['92.ZFUPBA<MCV'4
ME359R&M:UM]QJB*9)K[$*69U/B;)&O)<PWU.EU7+B1;#Z2GJI9ZS%IZ]SKG4
M$C;=5/F5EZX5#\LYA/.;$"?\0NJWQR:OP(I?*#)47W;<@[#Y*M=A/Z253,%0
MT6-G?HI+DILN*6BDB+)&$.-U)JB/9?-!<6/D%B-[)DR69<Q;'%OU3;$OQ+""
M+EPAQ^)VZCTA-@ Y3#8 !^I/537!5+LAN8)976ULTE).V*?$'^1L/#*F;4\>
M<.QY 6\QCG_359?)2K3S1U/AR'JZ[3S_ /:OYGK%UVO>X;FQ7@;W'VO'\LFO
MR&IIG9=+;IH<F1G.S_%T[),C865OK^:06;)N;-E<=.RZ-&6QT:[I-?8+"?IH
M%'D+":!:R*^Y*Q!.5Q#-"=T4AH2!*-C^B*06.QBXU"*0K%AQB<,N@4/<D,<1
MN<>'JM]_]6M6D_:IHQ^0D_0:?X'!,5+ZFH<P.O:Q/R7H8M[3Y]FJ65J0]AL4
M88&ANH4HVBIU)M"9HK&9[MVLT/92MD&JZ,=B9,DER200E5KD-S113R,C%MB%
M$FFR#68AGMD=J AR%&",_B$U35OE#Y7"-C2<JI;;9KC%)=%9"YH^R:?*=;(L
MEM'X)BX\Z636/4'LFF)I(CU.222*9CP0/*ST&Z3#HC3PNYXSN^(72=V)RHB,
MC8V21KM0A18>HO<D,EB9S!$ '!N7Z+3@ASR<_6Y:BW'LH*ZLF-XW2'0V&FRZ
M.V"7"/.PRY92N;M%,[#S4U+@!<*_'%M+<9=3.,,K6/A'<O 3PGPCCSA[C!]?
MA$50:""-D#77OS'/!T(-_ANN5Y+6ST^10QND>O\ ACP^/R&EGESQN2Z_T//&
M/8)+A^.U>&R1Y9::JEB [-&P5LVLN/<<[!">GSRQ/V1>84P247N\HS2#JL<H
MN+HZN+*LF._>Q^>D^Q,=M&_%\^B*#<RUP&B<]K9YG_",HOV4MJJR<9NZ-9@]
MQ*)8M_Q*6-\D<])<&J@<)"'R"[[:E7^YS6M_94XYB+W#EQOL!T4)S9HQ8DNC
M*SQU,T[7,:7&^RQM6=9%N8JD0-B#CYAYA9*2X)0E<J9%,&=S6TXRAIULJ6K-
M*:0NCHIZ>M822&MT"AMIDG*UR657'$*@ES!<J3[*'T'9G+RL;8J:=HHEP^1'
M+(:"=TQ$2:<Q7:V+S7W2<F61@NRL?*)*HEOU5<F7PBDT=Z]D,FGQOB.%Q\LM
M- YH]1(ZQ_)<W6KY;._X*<GD:OW/2+MW+"=Z+JR+.2E[DK9$=NHBNQB6X?FO
MT4D-"#F<<P.Z8P1EV:UT@'F&VQLJY*U;"+L^<7]I#PV,/\6*'B$,#1BF&4[R
M[\19GC/]/R1'[ED*:/',$@$[FC2]U-EG1&?]G.&NW)2!%O1O#20UMP;(1(NJ
M$--RYGE[>J:(RX%AA',]!IZ)L479G,3)#@J9%OL4[VO<3<W^B0$.2-CY"QV@
MMOV2(HAU5,ZG(!&9KMBHO@FG9#>-2+*MHL1]+/[(O%FNX6\2L#+!=E515>;N
M',>RW_=0GP'N<J_M0Z8T_CXR0_%/PY1N)[V<X#]%;)_R*TDCQ*LQ< ;H E4W
MQ!:X=%4C4T+C=MSV4^BI%QESV<.FR&3(]2TAI<HL12U))?KT0D)A1C^Y3-Z"
MUE-$'V4;]'),FAV%KI08VBW,;RA_B=N/UL%5,DC[O^$^ 3\,>%?"'#M6S+/A
MV!45-(.Q;$TV_,I1[Y*G[M&J>;:_F@9$F#I-8C8>B%V ]3QN:V[E,"0[X!\T
M(!41)O=2H&/Q9=01JI12Z(>]B<7K!AO#^(53S81TTQ'SRZ%6Z:_TF*71DUDM
MFBR2/",SQB3:FLF^T+YC(#Z]]%] FGCQQBCX!I)QU>HR9)<\_P!$9N:61]8X
M.=>RTXX1V69LN?(\[@WP3\+9F8 X: W"UNSG8Z:+N(V:>R4'3'EBI0)#JEW(
M<,VP4I1BRB.6<>$RCJGFJIRU_F%S=6P2JC/J).U+W*.K:6/:T[#90GP6X%N[
M&V!KG.!&F59I2=G5QXXJ)6U;^515+FBQ#0&GL256VTF:%&+:LCS4SF8<Z!SO
M,6 _6Z@Z2HOC&;::Z(U/#&VE=3R$$/.E^_1)254-XI;M_P!B'9T4CH:C1PV<
M-G%%5PP;;5Q&PW[2S>J%V1OBQ=0V2E@,^:TALUNF^JE);59*$M\J#;3WPQK6
MBYDG<YWH=%)1^3C[D99/UO/LAJ4.IY"YCCY=_1#3B[01K(J9M.#<5=B%%)%(
M_,Z*4#7L5U='D]7&[[1YKS&E6GR*27:-7$W-&US= 5K7X'!DZ=,58$ZIT*VA
MR34&ZKR13BS1ILLHSCSQ9"H(A3/EDE8"7'RFVRYZC]SN>M7TL>JL1;R7Q7^[
M>R4Z2^4LTTI3G^L=HS+I'R#*3N3E]%D:MG8QY*2YX)&'849I>7,[KFLI0C?8
M9'32B3ZPFG+FTS\MVAI(5E(K<Y>QEL0:(7ND/Q'8K+-4S3B;E%$*$M;"]UOB
M.OJH)%SE8NKE<Z+)?0CLHR2HMC.5]C=+$'YH)1F#VV 4%%6.4VXBJ-A8'1DZ
ML.J$D0<FB[PNJ= X%[M':*3BVN!PRQ@WZG1</J3..7$?-T(4UC?N4Y=5"Z@3
MZ*(1 2/^(:$I[%'LA'-.?"9)EQ-C;M$>8!43DD:H*4NR//722QC)<:;=E%2;
M9=+&E&_<+#^<V,OD<2YVE_1:(156<W).5[;.E>!E$*WQ#I;-N*1LC_EE M^Z
MX_G).&.E[]GK/@[%')JG:^ATOPZ/3L@T<>NB\923X/K4;IM]D.4G928"6-!O
M<)"H7D;V2"C4B2YT.JW69:#S._$?S37("3(01<G\TZ <#B1<%0EPQH6T"U[:
M]T(D))-SJ4A"X]B4+H8H#F-)]% D0N)9,G#5<TG_ %2U:3]JC!Y'C _W'!,1
M>XUKFL);YNG9>B2^4^>99?KF3<*C>7N\QT 4JX1"$KDQ6(-='3S:FYM^2;!]
MF)Q%A,CR#87T0NA%!-2O$CGN<2"=BH433*^HC8#HP?DADXE+5MR%P/\ K!E5
M'N:D0'48C&=KM0G0["J6<NDF=8;(8F1F-D?&PQL R,#CI9(0PZ=\KB7BQ:VP
M4H\E>3@B2,,$?-<;YEJQX[.;J-1MX0U'*8HWU#P+.V6]85#&I'!6LEFU$H/H
M@/A$A,Q%\WF%PHXGN8:O]5&T."F$$K["UFWT^2U0>Z"9R\_ZO52C_?1ZF]BJ
MOIZC"^*L.#&\WWBGEOU-VD +R?G$XY%7]]GUSX$U"R:6=_C_ $/+GC#4X97^
M*&.RX(T"B-=+RG 6)RC*?UNNOIUOP19Y3R.50UV6*_O@K,*@)C;)?5IN3W"A
MG^J@T"?H;G]RVGB#&F0M!$S"T?/NH&LG8312LP^.)IS2-< 25*OE(W4C2<.4
MAIZ</<[,-3K\T\2HAJ9VBZ?5".G=(-]PK).F5XHW%%#4O$Y_NXSW.M];*ENS
M;"(PVG<R760@#J#LJ7V:5T*GQ2G$3HZ9Y<YNCB3JHN2]B4.^1B&H=*VT?E=>
MY(W5;+MU$YHF:&3%Q-G"]RDT1WEABD=IVOL!G9<64,G#)X_F1#C?ED+3KHGC
M=HJS*I#A>'^4"RF540<1D8UE[V(ZJ+-$2D][A%2;65;9;%<H[Q[)M3S.+\39
M]UV'DV]0_3^JYVM?RG<\$OULOS/3;MW+ >@7N0ZHV"3&0)9,IRWW0B0V\GED
MW3]P&F.=E'F/YI@.1[H >BLVX=JE-5$4#P]_:9X-434G!'$L<0--)!64<COP
MO:62-'Z._,J$>DR>-\M'SZ@M[V=--5-EPBLBM4MD)]%$"UHW!K0;;V021;T#
MB^4"^G9-$9DVL&6,M;H3V0R,.S,8A&23?H54RTJ)7AIL-PHC]BO?&>:ZYTLF
M)$:H>YPREQ(&P)V28UV0I!:ZJD6H^B_]D$.95^)<'XH<.=;Y/DNHQ!F*_M3(
M3_RP836DW]ZP& CY![Q96L@CPP5G+0( D0=/HM6,KD:K"/,&YM=1NK&4^Y?/
M :&V%ODHMDR#5.)N+Z62&D4LK2ZY[.0B##80:2< ;$*<2'N43_B*&6&Q\&L#
M/$WBMP=P^ZFYL==CU%&]KA=KV\UI+2-B" JY<\4'5NS[PSV$KFM;E:TY0WL!
MH!^22^HJ_P HV=1JD2&VN8-&M ^00 L$[74P%#71- /P 7.B8F.QV$P%NBDB
M*[,_XM5ON'ASC<[38B -!&EKNLMFAC>I3.5YB>S09#Q?0Q9<-> +:77T#6*I
M4? / OY69>HD JW:*R#_ %:*\G_JFRTP35FNJT,QXNBZ8T.;;NB*MCR.HCCH
M0(B;WT5C1C4G9G*.<FGJ@3=S7G*IXGPRK4+HKJQAE8)22"W0ZJ&17R:=,]O%
M<#>9KFM#-"18D=5FEV=6'$2$:?GNBHCJ9)2XWZ@#902]BZ_="*QH?GF(T;$!
M91GC;Y+X:B,4HE;)")A9HLJ_3+'G5!2Q/GA;!(T-D9_*(^\?56M7P9T]I'I[
MR$N<P C39$.7;%DN*I#U5%FA:7C-9VE^BLE&T50R-.D,19VX?+8D_:DI1O8R
MR5/+'\BJK9GQM<]SCKZJ#XY-V&"DZ1?^'N(1P\QIWD.JV:#(H6CE>?T[G3^Q
MTJGJ&F M:!H-%U8RXH\3DQM2MBA(E8MHHONVUTGR2BJY(]2UY (<1]53DA1L
MP9')D*IAFYPY0O=NM^RR22;Y.I#=&G$8I(HV2.S .-MB-ODJ]O)MQ9:0]SO=
MVWOYC>QZV4>C1)\D5]6US2'7N2HV')0XX:ATD0C;=KQ<+/ENS9A^FR#(U\(:
M)=!8:!5_F6W]B4U@FI6RU #7= $VK5LFGS0S(\QDR#=NJJ]RR704E6&3-K,H
M#)Q:W1#=<E:5JBTIP:@MR:#<JZ#,VHBY*D7.'ST,+,K'E\P.M^Z4LJ7!+#H]
MW?9)]ZGDD'.\O8#8CNJ7DW\FQ:?TG3)3(C(+C9429KA%) DB+6FRE AE7RL>
MCNP ?);(=''R_6=;]FF+G\58C5_]73N:#ZDBZX/Q#Q']W^Y[?X"K)GG+\?\
M8]"RYLSFW/3JO(1Z/J3X;0Q(TM%RI,0(NJ2 <L.RD!I7#,%M,J%6#8G:ZD(
M9)-F@"Z0Q]D-FYTZ%8!\2 #.ZK?9(='1,!VP.B8%1QB<O"]>W_V:U:/]JOWG
M/\K_ .E?YHX"]W]]=?J\[KT"7R'S=R_7,T>'Q@1N([!22X)7;9#QB0MIGZ;)
M>P/LP574D!U]R=41?RBDN2GE<,YN=SW4'V21&EEM"YO771)]$X=F7FF/O%P?
MNZ?-4-\G2C](&XA11U&:2SI&C2QNG:LA3"BQ"FQ&:1YB=9N@TT333(R32(M5
M#72NY<+@(S\7H%;&+?1DRS4.65TU.V"5K0"7 ?0K3!*$6CCYI/+EBT1ZACZR
MLCIW?ZS?T 48NY%^6'R"Z][JV=D8!RMLW0::+1DR6J.=@P_/N)?N $8 [*./
MLMU2^4@XR\L;2BW<'\ULBZW+^^CC9ENE@E_?9UWV:,=CX:QCC9SW -IL!EG.
MMO@<"/U7&\MB^:#_ +Z/=?!^I4,FHA]K_P#[(X%&Z*KQPU0!',8^37U/_%;,
MN.M/%'%TN;?Y')D]N?Y$A\#N<Z5G=17$$@^K+*:ZLM8QGBIR\Z!^OIHJ<AT-
M.RSX?DSQ.8X6MG NJ\;X+LL;E9>>^_PZBAC U=OZ*VZ13LLB3U+Y,SF D$W%
ME%R+5#@B453*'N8=!JHJ1+9[D>6I<YY:?_N*E\FJ'!"JWD1O+#EN-PJI1->+
M(K'N'F1,B:9Y'9R=G:(QJNQ9I6:XF%E.QD>[NBNGUP8HNFR76TY=%"3_ -7_
M %5,XFB$RNC@A9-F>"2E!)(61VQ]\C XV:;?)3LK*/%8+DP_=?YK_-5LLBRK
M924U.\=P;J+2HNQM[T=Q]DZ>,\=8NS.VYH387[.%US]8OE.[X5_KI?F>HGFX
M-NZYFVF>DB[BR+5_ $V!5S_$$(D-AKCLT_D@!5K, (U3 $>Z0$N/>VU^ZB)G
M$_;(X'@XZ]GCB',RU7A#&8K3&VSXKA_YQFR;5DH.I'QZI ^[:B4YI,ICN.P*
M*LO;HE53 Z)A<ZUG7U^26VAQE;'()2,K0"1Z)H;+JB<0YOJ4R#+2L>,EP;FP
MV49$8=E!7N 9S+C755LN,W5F[M^J0#4H].B!(KY]RDR2(<O54S+(GO/^R+KI
M&^)?'>%7/+J,"AG/H8YM/_$HI^Q)KW)7]JYA09QCPACX_P!?ATM+_P!B4A6%
M2/GZJ2X" )$'1:L;*Y&MPUS2!8@[=58RE=E[ 0T@GHDV39 JY<V9I%M4KL3*
M:;XB@2Z%X?8QU TOEV1$C(SK]'FZE[DUT>F_8;PAP\4N%,1I:#WJIFQR'*<X
M:(PW-WWVNL4VU,T."<+/KM(<LCOM,^N_?U6C&V8MVUC:*)=@3BN1/H#2"=U:
MRL78]DD2CV2(0==%(8[&/MFIR^AD$KRHY_[0;LOA+BEC8FIA'_\ L&B[/@U>
MJC_?LSQGQO)P\)E:^Z__ +(\KRNYF8= 5ZY]*SY1B=Y)-&.Q1N6J.774[*W"
M9]8N";@U[?5:T<M%W$<K[JWV,TN9DMTUXLO?3]%6T6+AE$RG;'+1T^^8/O96
M054B,TVJ(&)AM/0F)A!/-Z%0R.EP6X,;XLC4S/>G@'_U>-SAZW4$MW)JB]BV
MLB1MBBDD+@2YL5_K=4.-,W0G:0NM DB<X"UV/-NUU8X_*9]_SO\ ,KHXG<ML
M@-]EGVOLW*:? )7Y22'-#AM<JPJDK&*GE5):XC[5NFGZJ36_\RF+>.U[#$H:
MT9+W"-M<#3;=D:IJJ>"F(E<&LOJZZ;E&$79=CQ3R3^5<F,Q?%)J^8T[!:&,Y
M@>ZQO,\GRKI'I-)IHX([WVRUX9Q5M#5L;(P\LVU'1:-//9.WT8/):5YL;I\G
M6\*KHJB%DL4@<QPT-UVHY55Q/G^JP2QR<9+DMVFS[E6_B<YJT2&U$+[^4_*R
M>Y,J>.40%K'C,!JH3C:LTX9N+2(SPR-[B1>XLN?D1W]-D*E\=3%(\LO9_HJ'
M%F[%DIT1'POY@DE=L=U&B^4MQ+G?9C3=H!%@3U*DV112U<<D]>TO\O)9876:
M7,C?BX@B)*_3.;9AT4+]RVKX&VEWNSM#OV3?15[D-N9[RTG0[JI]EMA/G?+&
MVF9$7C>]M+I6ZH=)<LD04V*O\N9C8[; ZV0TZ"+5FCPB&-D+FFQ-Q<]TEP64
MV6'):=C^:1*ON/Q'(P-OL@DG0]GNT**7)*<ZB2)I&\HBXN0MF-='%U&1<G:O
M95AYE!Q%4.%BQT;/V7F?B5_K5_?W/H?^',&M%DO[O^2.[S?RV?5>8Q>Y]*R/
MY8?O&E80 HL KCND!IA\*VF<! .Z #:UH!-T *SN+;)-A0W=_8I6.A>8 "YL
MHLE0(9"\^9-#:HE,U"?1%<]%+QR\1<*5SG&UVM:/F2M>B3>95^)S/,R4-')R
M^Z. 2DNKLS-;NZ+T55&CYGSZS9J,-Y@;JT[!%E\4TVV5V-/')EN;*+Z)>YS^
MO<"7/:;I+H'V4\S7/>QP%[#5)DD%.V%K[.> 2-E%DX79FYZ4,ES$Z#6RHKDZ
M$7\I ;# V1[S%YC\.FZ*0K)L,+*:E<]D=F[YO522^Q%M>XW1RNFE-_A?HXK5
M@BWV<;7Y8KA,3+2L,KB2+-/E^2TY*1SM)N;;D4V3E5DLMK/9&[ECN2LB=2MG
M7G4H4B5AM*Y[P7,L"!^=M42G;(X\6V/)9ST^1M@+ +3A9S==!RXB9BLE96U=
M/&QV;*?-Z>9;8I[Y6<*>1..*GRN_PY'<-XGFX?=Q*V&81OQ6A?0B_P!X.>T_
ML%GUV)Y7"E==_P #M>&UD-+/43<JW+C\7NLSA_NYAEME+6F._<=%?J4G"*1B
M\=-0GDE)\OK]Y=4D)=3@N%GN.RQ2:W_N.MI\<UI_F7-_T'*R)T5$;Z'LL^3H
MZ&#CL&$25+,I<" 3HJH6C7)*1:UU3)*\Q W(M<7]%-R(K'[D2.LK*1YCGC=&
MQAL"2J[:9<H)H7-C,+6YHXP[Z(W#V(9&)0U#>8R/S/T=Z)HC/\&3*+W=X!<&
MOT.A5E)HH4I1E;(S(9&XG XRM<P2 Y1U'94.+3-"R*2->61R5T5:+-AV#?4;
MJQ*W95.5(MW-;-"][CK]T>B4XBAE2[95,:QSR2[K94I%KFF"=MO*!OLDV27)
M7XK& T7[*+)QX,Q6.?S[93JHNZ+H/E'7_96SP^*#X@T_;4$X/_=*PZVDD=KP
M=RRRK[GKA[BP.#]!=<R5>QZ7'=.R#439_+T"BR9$D:2= A$A48(;8A)HBQN3
MXRFB2&R0W4'5,"2'"VZA1$8Q3"*/B3":SAW$XN92XG!)22MWNU[2W]+W^B?(
MX]GQE\0? OB3@:7%:ZFGI,0PV@Q":&*6#,7>[AY#3M;3KZ++'/&+VMG3>FG*
M.Y(YW59)(6OO<'6ZU7N5HS4H2I]DB@#"S= VRYH6M,@:#<IE<G[$VL:X&S&D
MEP49!%&>Q2S6Y;JMEWL9Z5KB[0=4A"GL<&D$=$$45=4#GV2=T33(<O553Z+(
MGN3^R7Q**G\7>,L,<S[2OX<LQ_X,L[23^H5<23-9_:P2L;'P#&[28LJR&_X<
MX%U:^$5I?,?.MX(>X$6()T53[+4$-TD#'X0;[*^!7+HU>#190#;J%;V5+LO?
M-OEV3:1(@UX 9<Z&Z7 GT5$Q8;YCH$B*$T#FB9XC-\S"I1%(HI0>:X.T-RFU
M;+%T=W]BK%<5A]H_P]PFFJRV"7&@YS/7E/5>Q.:L63))8VD?95A#NO96U!.D
MS+C3?,P[)476@G:M("*$V@HFD$:(($N(MO9QMHI#0\UT;?O#5*R0Y&6\P.OH
ME)W%I#A2FI/HY=[1]28?#IU%>SJFNA>T=PTW)_)=SP/.IC+V_P"S/"_'BKPV
M7'_F=4O_ .29YBB)?"YF[G;#NO89%3/DFDDFS*XPWE5.4;C?YJ>%\AK(-HD8
M,7'5NMBM:9RE%^Q;@OSW+=+[J:DGP5O'*+W-#Y>.6ZQV"3&N7P9ZMJYH":B(
M:QDVM^J)248VB482G.O88J6<VACG<;-,S23TU"JR.U:-F"&WL701&.22XUR7
M^BGBI+DIU%[U7V*VSC++8;LM];J+6YLMAD4(JQ^H%HYGNT#VZ'NINJ,\6W.U
M]RNC BI=[%4;>#?&=R*V=YYOV@W_ %57YE\N>@Z4O87.?^$V/96XN'R49$I*
MD4V)8CR'BT@ _?T5>2>TZ6GT^]<HS];4SU\C6A_D#@<O=8LDWDX.O@QQP*_<
MCU$&661P&A&BL@DK+<<[BD6&$4_,8)K:.&A5^+E69-7DVO::[A[$9,-F;S'W
M@)L6_A_Q+5@GZ;YZ//>0T\=3'A?-_/\  Z!150J+>8.!%[]_5=:$MQY+-B],
MG0C4E-=F>2X) ^$A2:M%473LASBSS?8+%EC1V-+.W0S4ET<#90/*= 50T=&+
MH@PTXG?FGERMWRGJJW&^37"22J1'KZME6X44,0;ROA*K?+HO3XM=$*HLUEY)
M+RCXQU"JDGV:L<XI*+*N1UPY^76^BI?"LTQ^9TAJ7G!@+GY!U!3;M$%&F1P[
M)#-*XV:!H56^B23%8;SG16:TWO?Z)1Y)2BUV6,3'O<<LF6PU4FF1@T6^#@MC
M#7'4'511:RT!OLHM$[%@':R$ H$@_)-+DHRR:5!2R'XK[E;8Q9PLL[9Z,]F*
MDY/#..U8'EDK&-)]0S5>/^(7^L2]_P#R?8/@6"CH\K72;7[Z1V27X6>E[KSV
M/A.SW.3G:E[6,N<WNIV1H(.%CJDP$V2 T]PUNJVF< <#LDPH!(!LD%"V[*+)
M( U-DAT)E80I#064M-VHL&R0)VB,EMTY<BAP9CQ$JK<*3AQ_F2L:!ZARW^.5
M9U^\X7GY7HI+\5_,XK%E-0+_ '3<_)=YGSY=FJI'-+ YIT(48\LT2=)%-BX+
M\[3M9-Q*G,PV(0Y2X#8))<$MUNRB?(0YP'0J!,K'$35!<976%PH,T1(<T,,\
MYB;,?55>YJ716U$GN4X80#%U<=T/@:Y"9B(F8Z(O 81?5-2%*-HETK8VTI=&
MX%WHM^%_*>?UD'O&0YP>7R7O:UDV[*\<:5$7W3,_.-22J)(W8WR6=/"V%H-M
M4*-DY2I%?BU:Z.XC.G5:<<3F9\B138/!G?+42#1K7$+HGF(KLSV-DG,YN[C=
M0DN"[ Q-2\.IX7=G-3R*X$\$ZREY25+7L:Z)PTT-]US6N3U*G^J5$Y[V3@ME
MV *A*-EN.9!CEE!,$(NYNH[655>QJC,CMK7&J%1+2N>[;?=5/NS3"2H?J*P2
M-TN&]!V4@W4R+'64[1D?( [L4N <V'FYKA(R<"QO9NQ3[(%Y0P$TV:;0.['5
M32XY(3#CACHZZ-XC+[FV^RA)4PAR:O!*4/#N8+9G7 O=2Q]D<W2-%'DIF.;(
MP$$:=5*2,Y4\H&1SB VY55%\>@JAK2YMON[JB79IAT0*YC7_ !;*%EAD<8CE
M;,#&!>^FO5-]%D.T=@]E"0S^(TDQ;K'03$GM<@+G:]VD=[X?XRR_,]7U+BX.
M^:YIZ5=,@/-B@8U(XAPL@: 2XH#@0Z]]4#0R=R@!P9KCYH(DR%Q9*U[6EQ!V
M"3Z'%TSYD^-.+\,<"<<>(V!U&/RROI:ZHI(\.D=Y;7+FY6>E[DKERPMSL[>+
M45CH\C1%SJ"+.-7.<YO^4F_Z+HQ51HYF1WD;)5+FC U '75,:+W#[F5KV[64
MD5R[)M:\GEB/XA?-\DF61,WB[P'Y#N#95,L*QT(!S%1#V$3@V)]$R!4U+27$
MG9-C1 FL%3DHNB>T_P"R?;G\>\?8/B/#4UOI-$JX<L)NJ-5_:R2O/%7 %$YW
MP895N(O][G6"N:XHBW\Q\_9+YW9M[FZH?98N@ANA=@R53F[E? KD:K!R\D-/
M17)%:+ZQ,;@-[)$BJQ%Q.G91$RGG>"'-&Y"*(H&%M/O('9CE.(I%14@BH=?N
M4WV33X.U^Q2TN]J;PZMUQ@?_ &)Z@_J0I_2S[.-\AL[HHP^HK?0YF%E91 0'
M Z)V K7INF ;.9?51=$H]CC2;ZI$F2H_@^J!2^G]YR?VF\W^BN'M'WIS;\@N
M[\/_ +7^_P 3PWQ__P"C_O\  \W4?E)S;L;F/R7LLBY/CVB?)DL5G9/5N>TF
MQ)Z)X5R;-6[7!*P*1K"6NZE:ET<B#Y9H)&L,+LNZ<5<B.=[<;9"ED,<1'?17
M2B8\64A.C!HY[L#G92;*J4>#9BG7)!$O/PI@>RS&O;MZ**C:+)9&F38>5#')
M/)H'MLSKHII5P1<D_F*FCB,LSHQOJX]K*,>V5R3DE0FJNZGD+?A:B7,26)5-
M%?,YL<%G*NTD:XIN14R.SO+G?14]FFQC$:MU!0R3@:VL/JI3D\<=Q/38EGRJ
M)CWR2U#^9(=R198')RY9Z.,8XUMB2J6G#G>4(BK91EG2!40V+@X:@._97I!C
MG=46> PM=A\9:+V&JT84G PZZ;69EO!#Y"VVZL43GSGS9?X%B$D;O=)76-M"
MM>GR-?*SD:[3QDO4B:JFF<0'G9;%?9PLD:X)8F-B0I64;:&2'S2VT];GHJ,D
M=QMT\]LK&J\WC,+7-\OPZ]5G<:X.G'):*Z.1Q<!8BPLHU1;&3D558S(\2%Y:
M<Q LLV1<V=+ _EHCM>^7.V86UM<:W52E:IFAXZ=Q([H8Z6<RM+GA@N01HH.'
M-ET<U*AFL;).;GRM&NZJ?)?'@KGS9H,NN5[LB@WP6+LL8'M8UIBO;+8Z)Q#(
MK)4!< ''JK)=%$/J+BA:0,[-NJB6<DX.=G\MM5%DO<E1D@Y7;^BB6)DIL32R
MYZZJR",F=E8QTACECD^.)VH]+K= \_D=2K\3TQ[,-9%-P/C<;2<S,1N=.CF"
MR\7\21K4P_+^K/L/P!E]3QNH?_O?\D=AD^&_H%YX]^^_X$5^A3$-/<1;*4NP
M8G/)W0(V#FW&ZV[BA(0W0E*[&XV)?=SA;2R5@HT.M.46*&@H5H6W&Z70= ?\
M(^26X8'&P2L&@G#)'K]Y/=S0I*HI_<Q_B27-P-L+C\4UQ]%U/'?-D4E['G/B
M&\6G<'[T<B;'_>2"=UW'R>$79J*3)'"QH!O;5*#IE^1-JRFQ5SC*X#:RL<3)
MNMT8W$FY9'.SBW95MT:81=&>JW-9(YXV>[0*ILN4&4U9GANYK2Z_9099&2(\
M+886ESR<S#<GNH;:-*E?"*S$PVJS9'6%KW2ER6+@BTT, I@2QSG.^[V22L'+
M:/TD\D4@BRAK;ZK3CGMX.5J,/J.T3I9HY6N#18C2_=6N:*8Z=_<*F:& 9W F
M]TER32V,.LJVM)C:""WJK8PM&7+G2;5&>K)G33<K<G5:L<-IQ=1FWRI$F&G=
M#3OC81>Q!/S5TLB,L=+->YG,<I'0Q%SG Z#9&],<<$L?+9#>3[NUK1<FRME&
MX&>#K)9=X=A)JZ)DM&\,G;J]C]W?)<UI)GI8/?C20ICGQ2&&I:YCQO?HH=ET
M6XB8YA$97QN!+=;=2/15RC1JQ2W#,T\C7!\9:&.&KBJ6C9 IZNN=2/N7\QIZ
MM&R@Y5P2<&^13#'6N%4X-C.@L>OY(M,-K0^X0QQO<,[;"X(V**)V;#"Z6JDH
MHJC,V0/ S!O96JZLJDET6\5##*YAC'F&I:=TG3$K79<T#VQ1&-S"'@HBB.1W
M1,=*YQ:"+Z*=%#DD&ZE9(S/RW75<HEN.5H8R"Y8&D6[K/*)K@^"#41%KCGU%
MU3M:989O&H0 9=@T9D/[$XO;R=:]D"-DG%F)5(;?+0.9?U+@;K!K>51Z#P7R
MS<ON>I*D92YAZZKF7:L],UM>TKWZN+>R+ +*+:[H 3:R8#;_ (B@DAD[E #P
MMH;I"H=)S>5H%_\ $;!1<DNP4;/DS[?7"K,$]I#&JK,[E8ZR#$6- ^#/&+B_
M?0A22CNLO@VHT<%D:(XAGMY?A Z!$@KW9'IY.=)8@@7T4;)J/%FIPZ,6S,V:
M+E-$'&W8[.2Z0$?>'5#)+@S6+W,X%OB._952)^Q%8;N>' G(H]C]AN09FFW9
M,K*FI;=V6^Z;)(K9Q949$71/87]E55O@]I:MIF?^L\+8BT#NX.B(_9+&K8LB
MX1H?[4VIEJO%SA:C>2!3X,U^4],\A_W*ZN45RX/#-0+3R#_$?W6>7;+X]"!N
MDALDTP\UUH@J15(V6$L%VO\ Q"X5J96D7#/A/R2),J<3:6'4[I"912.S/=Z(
M]A>X_A>M23_A(33(RX*FL&6ID:3>Q3;)1Z.Q>QA,(/:C\.7'KC+&_(F-X4'V
MF$_I9]H<C@-7 D:71%>Y6^A5^BLL@(:1F(OLH@.M[J78"FN%TJ)1['!N$B3)
M,/F\GU3?"L7U?+^\Y-[3L@CX4PV4M)#:@@_D%WOAU;LU?W[G@_\ $/(L>@WM
M?W:/-+*AL;I[@Z1Y5[62M6?'M,_3G3,=5/#I21T*CBX-6HGN5$_"VD&]]R%=
M=HYT8.+;+SS",C.IP7S)E>HENQN(S,1R[$ZW"T]HYD8.+L:SQL#KBX+2"$;;
M+EEV%33DBCF8&DM#] J$ZX1K:W+<V$]\QCBA)N9#8 =$2XX(1=H?;$RDP][G
M6YSW:.'0=DU&D2<TW:*J>K:8JF-H(L,WT5;Z:+X0^:+*$U9J&6!5">Y'0V;&
M(:RSQ?8'JG&'(.7!6XX[G0OC!L+*.=7%I&W0K9)-F;A\\K8QU)7/OV.U/B-E
MP(701B1OW2+A615<G/E+=+:Q-6T/:YX&[2/S6A\JPQ.FD3N&&AU'D.[1;\E=
MIG\IE\FZR67M,T%X&4ZK2E?)R\ET.21.IY.8TV*3X=HC]2IFDP>M,T;6N-K'
MJM^&3E$XFKP[':+Z,#+?NKDCE2?(65N8W'10DB<)./) GBC>+@N!ONLTOE.E
MA7J<$:-UI7!Y#LK"[3LJ4]QTE'T:W.ROK(P]O, N!=RHR1?9KP9%T5-1,_D_
M9M(-[K')NSL0IQ09EYS(86_S-W^H[*:FJ2,\L+MNR1RFRP2/>0'-! "-G%DO
M65TD4U7&&3L?;[-HU:.ZHDC3%U3)%.^.1OE%AZHBJ)3E?1,CRECVM.PT4WRJ
M*4MKMEIAC9!!J;J-46)\D]D;G"Y&MU!\DT6%-'F:"D2)=M /1619ES*RJJX7
M1SQU8<+'RR-_$M<9J+LX^73N7"9WKV5ZR..#B+ '2 2NFCG:>A%K$+R_Q#@E
M.2U-\)=>_N?3?@'/'%BR>/?U.3Y]NDCOD_D!!UM;9>3A+>K/ITX[71#>;ZJ3
M*Q(MU%TD)AV;^%.A6:M[K^79:O<K2#;8@W3&-C4GT20"C8B_5,!<9) N+)":
M#<,AO>Z@^QC;I,W1"$^AR87C:/DDOJ89/V<3'^*F5V'TUC:TAT_)=;Q?9YSX
MF_9+^_L<I9$'3@W_ $7=/!+LT-.V\6;\(45V:9_24N+.RM<;=%>WP8%]9SS&
M)Y.:1L'=5EDSI07!GYYY'O;#EV.]U6V6CAI7MD!<X.:5-(J3*>N@EYL@!RAH
M+B1JJVC5!T07.,C.4)-'=,JC1+>1Y\L,A?&;9=,J=4*4MR&G.,S=)+.)M\E)
M,SR";-((\C]#:XUW5BY*KIL?AD<0/,=1=6Q1ER3#J,P!=O<+3%'/ROELJPS+
M/SG&_HM,3E3^JRZIA>D?,6_$"53)FN/1G.(FB2$:;A-.B,UN5%92PF6F+[6R
MD!:X2W0./E_5Y2;@U5)FDU+)(SY2#N.ZPYHUR>@T61RCM+F6:"OCRU=FR@:/
M ^)5IWV;4BO]WAMG'EY;C?\ Q!0F:<%4RFQ&<PG):\1)T[+/-F_'R5KZJ-X+
M*<%]M,I;_55E@\R)[>5-1.SAW\QCMF)U7067$5*Z5T<4\.1LI #B?LR/0]_0
MIU8K]S48<VLH0(PX\H6M8:%2Y1%TRZI9H(Z^,M=J1<FWZ(]Q/H<E-<ZM=)E
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MH#-3XEXP]Q,<;FCTT3]5D?184'B5B[?CC+OFCU6'H"9O$?&=FL<+^J7JLGZ
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MT7GFFD>_<TY(AR-FDEC$H+!;4'JG'H4^RSIJ%]/3YY)/(3H%:D966L-7_#A
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MMB.*2MO]QA/0W7FO*YJ6T][\+::I2R'0<A#2XGJN"^SV$'N38E PG( (&R
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MSM%JQXYM5[,YN?58HR4JY1?X9PW#2AI#,Y[$+5CTVTY.H\E+(^71K<.IN3&
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M2I+HKWM\R=B^:91E!(10U*QR:E+8F2[^754RESM-.3 XPCE_ =I+U\T5+%$
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MSW6LR6#-;=!).P9QV0,4#<70 : $V=W0 65_X@@!!C>!?.E0#<F=K;WOJ$)
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M5E!21T5/&&P4XRP #4-ZW[E>1S9I9IGTO!IX::%+L6;V^$H'5";'LD,(FW1
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MTM[*W1:F>DS6E9E\II,?D-,X2X915>(97<NLE,8!^S/XNZ^B:7*]5%2A^_\
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M\+.%WS AS\-B=9PM:]UX?5-3R6?9]#'9@BC6N<&N([+,;!HZFZ0 0 $ #1-
M(?;HA@&RUBHH!1(Z%30F"_JDP0+CND,!<+=$ -(  W0)CC +FZ:"*LQ'C3X4
M4_C1X>UO %5CDF$LK9H)O>60B8MY3P_X20#LFI;1[>;/"WM-^R/@7@3X=_Z9
M.\29\5FFKH:.CH9,.;!)42..9Q%G;!K?_-U-YJCP$$G*F9_"_9<B?@U!C.(\
M2XC%4U]-'4RTI@%HB]M\N_2ZQ3U[BSK8_&J<;'6>S7A4)S38YB)'I&RRJ?D9
M471\2K*7&/!_ <*D)$M;/;3S. "A^GR9<O'1B96OX,P&!VE$T_/6RK>LG(%H
M<,!VBPFA@;R8:2G:"#8AFNRK>:<N&71Q8EUV<\X[IXX3'E%CFLMV%W$YVLBD
M4.!-8^O8'B_96/IF; OF/1_AHQHI(W-VT_98)<'<QPX.@U0=(S5IT6=NS2HT
MBDK*9CC9PMY4@,?C>&1D$Y#:_9.#Y*,D3.4T7)Q*E!:;<]F:PZ9@MD9&+(N&
M?1OV7O$JO\1?#84N,978IPG72X%6SW&:;EB\,A'^*(M'^R5NQ*XG"RK;D.N/
MU?KJ%*B,OJ!FOI>_I=(!$EKA- -WR/;*!>Q /JF!0<.9J7$,6I,ITJ0[;;,+
M_P!5#W)/HOM%)$0) &W<(0#A-Q92 38]D +9U28"KCJ0D /+Z( 9>/,=$ ((
M/8H ($WW0 ZR-TC@P7U49=#K=P8?Q(XA&'TWN+'7.<7L=M]UZ?PVF=;CPWQ1
MY)8X>FCG=?7\NEC>8\[YC9H._P P%WVZDTCQN-KTE*14XAP\R@I#BV)N)GF-
MXF$6+1VLNIHX;7ND>:\ODWIQB8[$"]S'.N2";_)==M4>547]_<R6-47O$.?J
M-5S-6^#U'B87PBBFB,4(<#8MUU7(Q9]LFF>JUFC]3'%Q^QJYI+TT%0X_]+CS
MMOU'0CT1JLN]IHGX[#Z,7%DK#:N6G8"Y[2':6OW6=9*.@\-HD\:QMGP:CXAB
M/VM TTM6>A!^$_\ %3SRW8E)&728]NJY^S_D8;W&JXBJ:7#*.-[JBJD$<0:"
M3F.VRPY\M5(Z.#1^K!XCW'X><)0<$\&8;@,8/.9'S*HV^*<_$1W&@7E-3+=D
M9]%T./TM/&)HC;JJ#8A#GV-D#L+G>A0 OWD_A2$&Y^87*'T*7"%![;M%P-%#
M9\I9ZE.)PGQVIW3<5T36@D&E T^:]'XN:CB/%?$2<M7?]]F1I>&XW#/.+16S
M.N.RZF.5R.+D58R++!2-E=B^)-'*@TIF'>_>RZT<FU6SSSPK+)\%-55=5BTK
MI<EY-FAH47J'+DFM*H^PJAX#;,YM7C)YA;J6$)8\#R2W2+,FI6+'L2+:OCBA
MI!!3,LQ@LUH&PZ+7.*BN#%AR[Y<E=PI_=\5?AYMEG&<DG]%IT.=.>UG#^(?'
MR]-Y(&LXAP3#L>HHZ=S;2T@+HW=S^'Z[+O9]%'/B?W/!>.\W/Q^KBGTGR<OQ
M;"'TI+'QGD3FP&7X2/N'T'=>5U6%X#Z=H/)0\@Z)N"89!1Q9(=<RY63(YJCT
MF#31P_,O<TV 5+\'Q6#%&7O2N$H ]%DS_-B9NT%XM0FSU'@]>,2PJDQ&X_O4
M8DT[E>0GC>.33/IF#,LN--$AQ!<;%1+K02B1&S+TLD2$9CW* #:\L.:^R:!C
M-?14V-4LF&5O_1IP1(1N#NT^GFLAB714<)8C4U%-+A6)Z8E0/,<S3H7-'PN
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M (GK_ J"##.'<*PRD>'PTM%%#&X;$!@_K=?.\T91R.,ER??=/*+P1R)\??\
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MB'!M[@]+*I_(K9:[R/Y2+CM)2XRT>\6#P+!Q[]%3.>[DOAB7N.>&U W!_$3
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MC9;M3"AK:^BUH\1JHP>@F=I^J+!P15XH^:J=FFJ))_68YC^:C;*W!%2^GC_
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/"TMH@P+II4 ,OJI ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904325142040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NOVARTIS AG<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001114448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">2,256,822,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904323883032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated income statements - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 48,659<span></span>
</td>
<td class="nump">$ 47,445<span></span>
</td>
<td class="nump">$ 44,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments', window );">Sales to discontinued segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales from continuing operations</a></td>
<td class="nump">48,659<span></span>
</td>
<td class="nump">47,498<span></span>
</td>
<td class="nump">44,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">1,239<span></span>
</td>
<td class="nump">1,179<span></span>
</td>
<td class="nump">1,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="num">(15,121)<span></span>
</td>
<td class="num">(14,425)<span></span>
</td>
<td class="num">(14,510)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit from continuing operations</a></td>
<td class="nump">34,777<span></span>
</td>
<td class="nump">34,252<span></span>
</td>
<td class="nump">31,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="num">(14,197)<span></span>
</td>
<td class="num">(14,369)<span></span>
</td>
<td class="num">(13,717)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(8,980)<span></span>
</td>
<td class="num">(9,402)<span></span>
</td>
<td class="num">(8,489)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">1,742<span></span>
</td>
<td class="nump">2,031<span></span>
</td>
<td class="nump">1,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other expense</a></td>
<td class="num">(3,190)<span></span>
</td>
<td class="num">(3,426)<span></span>
</td>
<td class="num">(2,609)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income from continuing operations</a></td>
<td class="nump">10,152<span></span>
</td>
<td class="nump">9,086<span></span>
</td>
<td class="nump">8,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Income from associated companies</a></td>
<td class="nump">673<span></span>
</td>
<td class="nump">659<span></span>
</td>
<td class="nump">6,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expense</a></td>
<td class="num">(869)<span></span>
</td>
<td class="num">(850)<span></span>
</td>
<td class="num">(932)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Other financial income and expense</a></td>
<td class="num">(78)<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Income before taxes from continuing operations</a></td>
<td class="nump">9,878<span></span>
</td>
<td class="nump">8,940<span></span>
</td>
<td class="nump">14,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Taxes</a></td>
<td class="num">(1,807)<span></span>
</td>
<td class="num">(1,793)<span></span>
</td>
<td class="num">(1,295)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperations', window );">Net income from continuing operations</a></td>
<td class="nump">8,071<span></span>
</td>
<td class="nump">7,147<span></span>
</td>
<td class="nump">12,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution', window );">Net income/loss from discontinued operations before gain on distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101)<span></span>
</td>
<td class="num">(186)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet', window );">Gain on distribution of Alcon Inc. to Novartis AG shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperations', window );">Net income/loss from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,590<span></span>
</td>
<td class="num">(186)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">8,071<span></span>
</td>
<td class="nump">11,737<span></span>
</td>
<td class="nump">12,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToAbstract', window );"><strong>Attributable to</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Shareholders of Novartis AG</a></td>
<td class="nump">8,072<span></span>
</td>
<td class="nump">11,732<span></span>
</td>
<td class="nump">12,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicEarningsPerShareAbstract', window );"><strong>Basic earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations', window );">Basic earnings per share, Continuing operations</a></td>
<td class="nump">$ 3.55<span></span>
</td>
<td class="nump">$ 3.12<span></span>
</td>
<td class="nump">$ 5.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations', window );">Basic earnings per share, Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic earnings per share</a></td>
<td class="nump">3.55<span></span>
</td>
<td class="nump">5.12<span></span>
</td>
<td class="nump">5.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutedEarningsPerShareAbstract', window );"><strong>Diluted earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations', window );">Diluted earnings per share, Continuing operations</a></td>
<td class="nump">3.52<span></span>
</td>
<td class="nump">3.08<span></span>
</td>
<td class="nump">5.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations', window );">Diluted earnings per share, Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.98<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted earnings per share</a></td>
<td class="nump">$ 3.52<span></span>
</td>
<td class="nump">$ 5.06<span></span>
</td>
<td class="nump">$ 5.38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basic earnings (loss) per share from continuing operations. [Refer: Basic earnings (loss) per share; Continuing operations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShareFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basic earnings (loss) per share from discontinued operations. [Refer: Basic earnings (loss) per share; Discontinued operations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs relating to expenses directly or indirectly attributed to the goods or services sold, which may include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, unallocated production overheads and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Diluted earnings (loss) per share from continuing operations. [Refer: Continuing operations [member]; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Diluted earnings (loss) per share from discontinued operations. [Refer: Diluted earnings (loss) per share; Discontinued operations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByFunction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'function of expense' form for its analysis of expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35_b_vii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByFunction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2019-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2019-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations. [Refer: Continuing operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_vi&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from discontinued operations. [Refer: Discontinued operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_vii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph ea<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_ea&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 98<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_98_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2019-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2019-01-01<br> -Paragraph 39M<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2019-en-b&amp;anchor=para_39M_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsSalesToOtherSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904323975784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated statements of comprehensive income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 8,071<span></span>
</td>
<td class="nump">$ 11,737<span></span>
</td>
<td class="nump">$ 12,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Other comprehensive income to be eventually recycled into the consolidated income statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities', window );">Fair value adjustments on debt securities, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges', window );">Fair value adjustments on deferred cash flow hedges, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments', window );">Total fair value adjustments on financial instruments, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Associated companies' movements in comprehensive income</a></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="num">(482)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations', window );">Net investment hedge</a></td>
<td class="num">(201)<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation effects</a></td>
<td class="nump">3,194<span></span>
</td>
<td class="nump">352<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Total of items to eventually recycle</a></td>
<td class="nump">2,937<span></span>
</td>
<td class="nump">304<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Other comprehensive income never to be recycled into the consolidated income statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Actuarial gains/losses from defined benefit plans, net of taxes</a></td>
<td class="nump">143<span></span>
</td>
<td class="num">(467)<span></span>
</td>
<td class="num">(359)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments', window );">Fair value adjustments on equity securities, net of taxes</a></td>
<td class="nump">250<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Total of items never to be recycled</a></td>
<td class="nump">393<span></span>
</td>
<td class="num">(514)<span></span>
</td>
<td class="num">(346)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="nump">11,401<span></span>
</td>
<td class="nump">11,527<span></span>
</td>
<td class="nump">12,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract', window );"><strong>Attributable to</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Shareholders of Novartis AG</a></td>
<td class="nump">11,403<span></span>
</td>
<td class="nump">11,525<span></span>
</td>
<td class="nump">12,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests', window );">Comprehensive income, attributable to non-controlling interests</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember', window );">Continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract', window );"><strong>Attributable to</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Shareholders of Novartis AG</a></td>
<td class="nump">$ 11,403<span></span>
</td>
<td class="nump">6,948<span></span>
</td>
<td class="nump">12,417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract', window );"><strong>Attributable to</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Shareholders of Novartis AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,577<span></span>
</td>
<td class="num">$ (207)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81B_b_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81B_b_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to cash flow hedges. [Refer: Cash flow hedges [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) from changes in the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to hedges of net investments in foreign operations. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 39<br> -IssueDate 2019-01-01<br> -Paragraph 102<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=39&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_102_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 9<br> -IssueDate 2019-01-01<br> -Paragraph 6.5.13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=9&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_6.5.13_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82A<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82A<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2019-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2019-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of the other comprehensive income of associates and joint ventures accounted for using the equity method that will be reclassified to profit or loss, net of tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82A<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904324062664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated balance sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">$ 12,263<span></span>
</td>
<td class="nump">$ 12,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">1,676<span></span>
</td>
<td class="nump">1,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">29,999<span></span>
</td>
<td class="nump">26,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="nump">36,809<span></span>
</td>
<td class="nump">28,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments in associated companies</a></td>
<td class="nump">9,632<span></span>
</td>
<td class="nump">8,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">8,214<span></span>
</td>
<td class="nump">7,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Financial assets</a></td>
<td class="nump">2,901<span></span>
</td>
<td class="nump">2,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">892<span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">102,386<span></span>
</td>
<td class="nump">88,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">7,131<span></span>
</td>
<td class="nump">5,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Current trade receivables</a></td>
<td class="nump">8,217<span></span>
</td>
<td class="nump">8,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssetsCurrent', window );">Income tax receivable</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Marketable securities, commodities, time deposits and derivative financial instruments</a></td>
<td class="nump">1,905<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">9,658<span></span>
</td>
<td class="nump">11,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialAssets', window );">Other current assets</a></td>
<td class="nump">2,523<span></span>
</td>
<td class="nump">2,680<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners', window );">Total current assets without disposal group</a></td>
<td class="nump">29,673<span></span>
</td>
<td class="nump">28,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale', window );">Assets of disposal group held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">841<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">29,673<span></span>
</td>
<td class="nump">29,504<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">132,059<span></span>
</td>
<td class="nump">118,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">913<span></span>
</td>
<td class="nump">936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Treasury shares</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Reserves</a></td>
<td class="nump">55,738<span></span>
</td>
<td class="nump">54,618<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Equity attributable to Novartis AG shareholders</a></td>
<td class="nump">56,598<span></span>
</td>
<td class="nump">55,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">56,666<span></span>
</td>
<td class="nump">55,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Financial debts</a></td>
<td class="nump">26,259<span></span>
</td>
<td class="nump">20,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">1,719<span></span>
</td>
<td class="nump">1,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">7,422<span></span>
</td>
<td class="nump">5,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentNonfinancialLiabilities', window );">Provisions and other non-current liabilities</a></td>
<td class="nump">6,934<span></span>
</td>
<td class="nump">6,632<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">42,334<span></span>
</td>
<td class="nump">34,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">5,403<span></span>
</td>
<td class="nump">5,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Financial debts and derivative financial instruments</a></td>
<td class="nump">9,785<span></span>
</td>
<td class="nump">7,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesCurrent', window );">Current income tax liabilities</a></td>
<td class="nump">2,458<span></span>
</td>
<td class="nump">2,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialLiabilities', window );">Provisions and other current liabilities</a></td>
<td class="nump">15,127<span></span>
</td>
<td class="nump">13,338<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale', window );">Total current liabilities without disposal group</a></td>
<td class="nump">33,059<span></span>
</td>
<td class="nump">28,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale', window );">Liabilities of disposal group held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">33,059<span></span>
</td>
<td class="nump">28,264<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">75,393<span></span>
</td>
<td class="nump">62,819<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total equity and liabilities</a></td>
<td class="nump">$ 132,059<span></span>
</td>
<td class="nump">$ 118,370<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2020-01-01: The amount of resources: (a) controlled by the entity as a result of past events; and (b) from which future economic benefits are expected to flow to the entity.
Effective 2020-01-01: The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets other than non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer: Current assets; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale; Non-current assets or disposal groups classified as held for distribution to owners]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities other than liabilities included in disposal groups classified as held for sale. [Refer: Current liabilities; Disposal groups classified as held for sale [member]; Liabilities included in disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax assets. [Refer: Current tax assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 56<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 56<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2019-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2019-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2020-01-01: The amount of present obligations of the entity arising from past events, the settlement of which is expected to result in an outflow from the entity of resources embodying economic benefits.
Effective 2020-01-01: The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities included in disposal groups classified as held for sale. [Refer: Liabilities; Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 38<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_38&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph p<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_p&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 12<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph q<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2019-01-01<br> -Paragraph 22<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets or disposal groups classified as held for sale. [Refer: Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 38<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_38&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph m<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentNonfinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentNonfinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph m<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentNonfinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentNonfinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2019-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904321303512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated statements of changes in equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Equity attributable to owners of parent [member]</div></th>
<th class="th"><div>Share capital</div></th>
<th class="th"><div>Treasury shares</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Total value adjustments</div></th>
<th class="th"><div>Non-controlling interests [member]</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity | Previously stated [member]</a></td>
<td class="nump">$ 74,227<span></span>
</td>
<td class="nump">$ 74,168<span></span>
</td>
<td class="nump">$ 969<span></span>
</td>
<td class="num">$ (100)<span></span>
</td>
<td class="nump">$ 77,639<span></span>
</td>
<td class="num">$ (4,340)<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity | Increase (decrease) due to changes in accounting policy required by IFRSs [member]</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="num">(177)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity | Restated Value Adjustments [member]</a></td>
<td class="nump">74,287<span></span>
</td>
<td class="nump">74,228<span></span>
</td>
<td class="nump">969<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="nump">77,876<span></span>
</td>
<td class="num">(4,517)<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity | Previously stated [member]</a></td>
<td class="nump">74,227<span></span>
</td>
<td class="nump">74,168<span></span>
</td>
<td class="nump">969<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="nump">77,639<span></span>
</td>
<td class="num">(4,340)<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity | Increase (decrease) due to changes in accounting policy required by IFRSs [member]</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(177)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity | Restated Value Adjustments [member]</a></td>
<td class="nump">74,287<span></span>
</td>
<td class="nump">74,228<span></span>
</td>
<td class="nump">944<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="nump">77,876<span></span>
</td>
<td class="num">(4,452)<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="nump">78,692<span></span>
</td>
<td class="nump">78,614<span></span>
</td>
<td class="nump">944<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="nump">82,191<span></span>
</td>
<td class="num">(4,452)<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period (Previously stated [member]) at Dec. 31, 2017</a></td>
<td class="nump">74,227<span></span>
</td>
<td class="nump">74,168<span></span>
</td>
<td class="nump">969<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="nump">77,639<span></span>
</td>
<td class="num">(4,340)<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period (Increase (decrease) due to changes in accounting policy required by IFRSs [member]) at Dec. 31, 2017</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="num">(177)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period (Restated Value Adjustments [member]) at Dec. 31, 2017</a></td>
<td class="nump">74,287<span></span>
</td>
<td class="nump">74,228<span></span>
</td>
<td class="nump">969<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="nump">77,876<span></span>
</td>
<td class="num">(4,517)<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">12,614<span></span>
</td>
<td class="nump">12,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="num">(406)<span></span>
</td>
<td class="num">(401)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(482)<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="nump">12,208<span></span>
</td>
<td class="nump">12,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,129<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DividendsPaid', window );">Dividends</a></td>
<td class="num">(6,966)<span></span>
</td>
<td class="num">(6,966)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,966)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Purchase of treasury shares</a></td>
<td class="num">(1,973)<span></span>
</td>
<td class="num">(1,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(1,960)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReductionOfIssuedCapital', window );">Reduction of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options and employee transactions, equity impact</a></td>
<td class="nump">434<span></span>
</td>
<td class="nump">434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherShareSales', window );">Other share sales</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-based compensation</a></td>
<td class="nump">756<span></span>
</td>
<td class="nump">756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan', window );">(Increase)/decrease of treasury share repurchase obligation under a share buyback trading plan</a></td>
<td class="num">(284)<span></span>
</td>
<td class="num">(284)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(284)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TransactionCostsRecordedInEquity', window );">Transaction costs recorded in equity</a></td>
<td class="num">(79)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(79)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold', window );">Fair value adjustments on equity securities sold, reclassified to retained earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_IncreaseDecreaseInNoncontrolingInterests', window );">Changes in non-controlling interests</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl', window );">Impact of change in ownership of consolidated entities</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Other movements</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInEquity', window );">Total of other equity movements</a></td>
<td class="num">(7,803)<span></span>
</td>
<td class="num">(7,824)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="num">(7,814)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period (Increase (decrease) due to changes in accounting policy required by IFRSs [member]) at Dec. 31, 2018</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period (Restated Value Adjustments [member]) at Dec. 31, 2018</a></td>
<td class="nump">78,695<span></span>
</td>
<td class="nump">78,617<span></span>
</td>
<td class="nump">944<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="nump">82,194<span></span>
</td>
<td class="num">(4,452)<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Dec. 31, 2018</a></td>
<td class="nump">78,692<span></span>
</td>
<td class="nump">78,614<span></span>
</td>
<td class="nump">944<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="nump">82,191<span></span>
</td>
<td class="num">(4,452)<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity | Increase (decrease) due to changes in accounting policy required by IFRSs [member]</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity | Restated Value Adjustments [member]</a></td>
<td class="nump">78,695<span></span>
</td>
<td class="nump">78,617<span></span>
</td>
<td class="nump">944<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="nump">82,194<span></span>
</td>
<td class="num">(4,452)<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="nump">78,692<span></span>
</td>
<td class="nump">78,614<span></span>
</td>
<td class="nump">944<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="nump">82,191<span></span>
</td>
<td class="num">(4,452)<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity | Increase (decrease) due to changes in accounting policy required by IFRSs [member]</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity | Restated Value Adjustments [member]</a></td>
<td class="nump">78,695<span></span>
</td>
<td class="nump">78,617<span></span>
</td>
<td class="nump">944<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="nump">82,194<span></span>
</td>
<td class="num">(4,452)<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="nump">78,692<span></span>
</td>
<td class="nump">78,614<span></span>
</td>
<td class="nump">944<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="nump">59,275<span></span>
</td>
<td class="num">(4,452)<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">11,737<span></span>
</td>
<td class="nump">11,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="num">(210)<span></span>
</td>
<td class="num">(207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="nump">11,527<span></span>
</td>
<td class="nump">11,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,638<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DividendsPaid', window );">Dividends</a></td>
<td class="num">(6,645)<span></span>
</td>
<td class="num">(6,645)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,645)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DividendPaidNoncashAssetsDistribution', window );">Dividend in kind</a></td>
<td class="num">(23,434)<span></span>
</td>
<td class="num">(23,434)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,434)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Purchase of treasury shares</a></td>
<td class="num">(5,511)<span></span>
</td>
<td class="num">(5,511)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="num">(5,480)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReductionOfIssuedCapital', window );">Reduction of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options and employee transactions, equity impact</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-based compensation</a></td>
<td class="nump">833<span></span>
</td>
<td class="nump">833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff', window );">Shares delivered to divested business employees, equity impact</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TaxesOnTreasuryShares', window );">Taxes on treasury shares</a></td>
<td class="num">(189)<span></span>
</td>
<td class="num">(189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan', window );">(Increase)/decrease of treasury share repurchase obligation under a share buyback trading plan</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TransactionCostsRecordedInEquity', window );">Transaction costs recorded in equity</a></td>
<td class="num">(253)<span></span>
</td>
<td class="num">(253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold', window );">Fair value adjustments on equity securities sold, reclassified to retained earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_IncreaseDecreaseInNoncontrolingInterests', window );">Changes in non-controlling interests</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRelatedToDivestments', window );">Fair value adjustments related to divestments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl', window );">Impact of change in ownership of consolidated entities</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Other movements</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInEquity', window );">Total of other equity movements</a></td>
<td class="num">(34,671)<span></span>
</td>
<td class="num">(34,668)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(34,557)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Dec. 31, 2019</a></td>
<td class="nump">55,551<span></span>
</td>
<td class="nump">55,474<span></span>
</td>
<td class="nump">936<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="nump">59,275<span></span>
</td>
<td class="num">(4,657)<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="nump">55,551<span></span>
</td>
<td class="nump">55,474<span></span>
</td>
<td class="nump">936<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="nump">59,275<span></span>
</td>
<td class="num">(4,657)<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="nump">55,551<span></span>
</td>
<td class="nump">55,474<span></span>
</td>
<td class="nump">913<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="nump">59,275<span></span>
</td>
<td class="num">(4,657)<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">8,071<span></span>
</td>
<td class="nump">8,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="nump">3,330<span></span>
</td>
<td class="nump">3,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="nump">3,387<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="nump">11,401<span></span>
</td>
<td class="nump">11,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,016<span></span>
</td>
<td class="nump">3,387<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DividendsPaid', window );">Dividends</a></td>
<td class="num">(6,987)<span></span>
</td>
<td class="num">(6,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Purchase of treasury shares</a></td>
<td class="num">(3,056)<span></span>
</td>
<td class="num">(3,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(3,038)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReductionOfIssuedCapital', window );">Reduction of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options and employee transactions, equity impact</a></td>
<td class="nump">806<span></span>
</td>
<td class="nump">806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RepurchaseOfOptions', window );">Repurchase of options</a></td>
<td class="num">(89)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-based compensation</a></td>
<td class="nump">730<span></span>
</td>
<td class="nump">730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff', window );">Shares delivered to divested business employees, equity impact</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TaxesOnTreasuryShares', window );">Taxes on treasury shares</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan', window );">(Increase)/decrease of treasury share repurchase obligation under a share buyback trading plan</a></td>
<td class="num">(1,769)<span></span>
</td>
<td class="num">(1,769)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,769)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold', window );">Fair value adjustments on equity securities sold, reclassified to retained earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRelatedToDivestments', window );">Fair value adjustments related to divestments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl', window );">Impact of change in ownership of consolidated entities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Other movements</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInEquity', window );">Total of other equity movements</a></td>
<td class="num">(10,286)<span></span>
</td>
<td class="num">(10,279)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="num">(10,134)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Dec. 31, 2020</a></td>
<td class="nump">56,666<span></span>
</td>
<td class="nump">56,598<span></span>
</td>
<td class="nump">913<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="nump">57,157<span></span>
</td>
<td class="num">(1,419)<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="nump">$ 56,666<span></span>
</td>
<td class="nump">$ 56,598<span></span>
</td>
<td class="nump">$ 913<span></span>
</td>
<td class="num">$ (53)<span></span>
</td>
<td class="nump">$ 57,157<span></span>
</td>
<td class="num">$ (1,419)<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends recognised as distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 107<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_107&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity through changes in ownership interests in subsidiaries that do not result in loss of control. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2019-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2019-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReductionOfIssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in equity resulting from a reduction in issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReductionOfIssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DividendPaidNoncashAssetsDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DividendPaidNoncashAssetsDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueAdjustmentsOnFinancialAssetsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueAdjustmentsRelatedToDivestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueAdjustmentsRelatedToDivestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseInNoncontrolingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseInNoncontrolingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherShareSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherShareSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RepurchaseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RepurchaseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TaxesOnTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TaxesOnTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TransactionCostsRecordedInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TransactionCostsRecordedInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=nvs_RestatedValueAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=nvs_RestatedValueAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904324075640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated cash flow statements - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperations', window );">Net income from continuing operations</a></td>
<td class="nump">$ 8,071<span></span>
</td>
<td class="nump">$ 7,147<span></span>
</td>
<td class="nump">$ 12,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLoss', window );">Reversal of non-cash items and other adjustments</a></td>
<td class="nump">9,881<span></span>
</td>
<td class="nump">9,122<span></span>
</td>
<td class="nump">1,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DividendsReceivedClassifiedAsOperatingActivities', window );">Dividends received from associated companies and others</a></td>
<td class="nump">490<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="nump">719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="num">(703)<span></span>
</td>
<td class="num">(793)<span></span>
</td>
<td class="num">(816)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities', window );">Other financial receipts</a></td>
<td class="nump">464<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities', window );">Other financial payments</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Taxes paid</a></td>
<td class="num">(1,833)<span></span>
</td>
<td class="num">(1,876)<span></span>
</td>
<td class="num">(1,506)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges', window );">Net cash flows from operating activities from continuing operations before working capital and provision changes</a></td>
<td class="nump">16,378<span></span>
</td>
<td class="nump">14,272<span></span>
</td>
<td class="nump">13,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities', window );">Payments out of provisions and other net cash movements in non-current liabilities</a></td>
<td class="num">(2,437)<span></span>
</td>
<td class="num">(924)<span></span>
</td>
<td class="num">(638)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems', window );">Change in net current assets and other operating cash flow items</a></td>
<td class="num">(291)<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">576<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations', window );">Net cash flows from operating activities from continuing operations</a></td>
<td class="nump">13,650<span></span>
</td>
<td class="nump">13,547<span></span>
</td>
<td class="nump">13,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash flows from operating activities from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">1,223<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Total net cash flows from operating activities</a></td>
<td class="nump">13,650<span></span>
</td>
<td class="nump">13,625<span></span>
</td>
<td class="nump">14,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(1,275)<span></span>
</td>
<td class="num">(1,379)<span></span>
</td>
<td class="num">(1,254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Proceeds from sale of property, plant and equipment</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">857<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Purchases of intangible assets</a></td>
<td class="num">(1,310)<span></span>
</td>
<td class="num">(878)<span></span>
</td>
<td class="num">(1,394)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Proceeds from sale of intangible assets</a></td>
<td class="nump">380<span></span>
</td>
<td class="nump">973<span></span>
</td>
<td class="nump">823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities', window );">Purchases of financial assets</a></td>
<td class="num">(230)<span></span>
</td>
<td class="num">(302)<span></span>
</td>
<td class="num">(205)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities', window );">Proceeds from sale of financial assets</a></td>
<td class="nump">723<span></span>
</td>
<td class="nump">1,152<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities', window );">Purchases of other non-current assets</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities', window );">Proceeds from sale of other non-current assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies', window );">Acquisitions and divestments of interests in associated companies, net</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">12,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities', window );">Acquisitions and divestments of businesses, net</a></td>
<td class="num">(9,957)<span></span>
</td>
<td class="num">(3,760)<span></span>
</td>
<td class="num">(13,683)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities', window );">Purchases of marketable securities and commodities</a></td>
<td class="num">(1,900)<span></span>
</td>
<td class="num">(228)<span></span>
</td>
<td class="num">(2,440)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities', window );">Proceeds from sale of marketable securities and commodities</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">2,561<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations', window );">Net cash flows used in investing activities from continuing operations</a></td>
<td class="num">(13,055)<span></span>
</td>
<td class="num">(1,067)<span></span>
</td>
<td class="num">(4,590)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash flows used in investing activities from discontinued operations</a></td>
<td class="num">(127)<span></span>
</td>
<td class="num">(1,159)<span></span>
</td>
<td class="num">(1,001)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Total net cash flows used in investing activities</a></td>
<td class="num">(13,182)<span></span>
</td>
<td class="num">(2,226)<span></span>
</td>
<td class="num">(5,591)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities', window );">Dividends paid to shareholders of Novartis AG</a></td>
<td class="num">(6,987)<span></span>
</td>
<td class="num">(6,645)<span></span>
</td>
<td class="num">(6,966)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares', window );">Acquisitions of treasury shares</a></td>
<td class="num">(2,842)<span></span>
</td>
<td class="num">(5,533)<span></span>
</td>
<td class="num">(2,036)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions', window );">Proceeds from exercised options and other treasury share transactions, net</a></td>
<td class="nump">748<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Increase in non-current financial debts</a></td>
<td class="nump">7,126<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">2,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RepaymentsOfNoncurrentBorrowings', window );">Repayments of non-current financial debts</a></td>
<td class="num">(2,003)<span></span>
</td>
<td class="num">(3,195)<span></span>
</td>
<td class="num">(366)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings', window );">Change in current financial debts</a></td>
<td class="nump">2,261<span></span>
</td>
<td class="num">(1,582)<span></span>
</td>
<td class="nump">1,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payments of lease liabilities, net</a></td>
<td class="num">(312)<span></span>
</td>
<td class="num">(273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries', window );">Impact of change in ownership of consolidated entities</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities', window );">Other financing cash flows, net</a></td>
<td class="num">(147)<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations', window );">Net cash flows used in financing activities from continuing operations</a></td>
<td class="num">(2,158)<span></span>
</td>
<td class="num">(16,884)<span></span>
</td>
<td class="num">(4,077)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations', window );">Net cash flows used in/from financing activities from discontinued operations</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">3,257<span></span>
</td>
<td class="num">(167)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Total net cash flows used in financing activities</a></td>
<td class="num">(2,208)<span></span>
</td>
<td class="num">(13,627)<span></span>
</td>
<td class="num">(4,244)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net change in cash and cash equivalents before effect of exchange rate changes</a></td>
<td class="num">(1,740)<span></span>
</td>
<td class="num">(2,228)<span></span>
</td>
<td class="nump">4,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Total net change in cash and cash equivalents</a></td>
<td class="num">(1,454)<span></span>
</td>
<td class="num">(2,159)<span></span>
</td>
<td class="nump">4,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">11,112<span></span>
</td>
<td class="nump">13,271<span></span>
</td>
<td class="nump">8,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 9,658<span></span>
</td>
<td class="nump">$ 11,112<span></span>
</td>
<td class="nump">$ 13,271<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's financing activities, related to continuing operations. [Refer: Continuing operations [member]; Cash flows from (used in) financing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's financing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) financing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) due to an increase (decrease) in current borrowings. [Refer: Current borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's investing activities, related to continuing operations. [Refer: Continuing operations [member]; Cash flows from (used in) investing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's investing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) investing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's operating activities, related to continuing operations. [Refer: Continuing operations [member]; Cash flows from (used in) operating activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's operating activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) operating activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for dividends paid to equity holders of the parent, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from dividends received, classified as operating activities. [Refer: Dividends received]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for finance costs paid, classified as operating activities. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from finance income received, classified as operating activities. [Refer: Finance income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 14<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire equity or debt instruments of other entities (other than payments for those instruments considered to be cash equivalents or those held for dealing or trading purposes), classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of equity or debt instruments of other entities (other than receipts for those instruments considered to be cash equivalents and those held for dealing or trading purposes), classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inflows (outflows) of cash, classified as financing activities, that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 21<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_21&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for changes in ownership interests in subsidiaries that do not result in a loss of control. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 42A<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_42A&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 42B<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_42B&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire or redeem entity's shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsToAcquireOrRedeemEntitysShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from non-current borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations. [Refer: Continuing operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_vi&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProceedsFromSalesOfFinancialAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PurchaseOfFinancialAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326165864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">Significant accounting policies</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">1. Significant accounting policies</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Novartis Group (Novartis or Group) is a multinational group of companies specializing in the research, development, manufacturing and marketing of a broad range of innovative pharmaceuticals and cost-saving generic medicines. The Group is headquartered in Basel, Switzerland. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consolidated financial statements of the Group are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). They are prepared in accordance with the historical cost convention, except for items that are required to be accounted for at fair value. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s financial year-end is December 31, which is also the annual closing date of the individual entities&#x2019; financial statements incorporated into the Group&#x2019;s consolidated financial statements. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The preparation of financial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the year, which affect the reported amounts of revenues, expenses, assets, liabilities and contingent amounts. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Estimates are based on historical experience and other assumptions that are considered reasonable under the given circumstances and are regularly monitored. Actual outcomes and results could differ from those estimates and assumptions. Revisions to estimates are recognized in the period in which the estimate is revised. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Listed below are accounting policies of significance to Novartis or, in cases where IFRS provides alternatives, the option adopted by Novartis. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Scope of consolidation </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated financial statements include all entities, including structured entities, over which Novartis AG, Basel, Switzerland, directly or indirectly has control (generally as a result of owning more than 50% of the entity&#x2019;s voting interest). Consolidated entities are also referred to as &#x201c;subsidiaries.&#x201d; </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In cases where Novartis does not fully own a subsidiary, it has elected to value any remaining outstanding non-controlling interest at the time of acquiring control of the subsidiary at its proportionate share of the fair value of the net identified assets. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The contribution of a business to an associate or joint venture is accounted for by applying the option under IFRS that permits the accounting for the retained interest of the business contributed at its net book value at the time of the contribution. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Investments in associated companies (generally defined as investments in entities in which Novartis holds between 20% and 50% of voting shares or over which it otherwise has significant influence) and joint ventures are accounted for using the equity method, except for selected venture fund investments for which the Group has elected to apply the method of fair value through the consolidated income statement. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Foreign currencies</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated financial statements of Novartis are presented in US dollars (USD). The functional currency of subsidiaries is generally the local currency of the respective entity. The functional currency used for the reporting of certain Swiss and foreign finance entities is USD instead of their respective local currencies. This reflects the fact that the cash flows and transactions of these entities are primarily denominated in these currencies. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For subsidiaries not operating in hyperinflationary economies, the subsidiary&#x2019;s results, financial position and cash flows that do not have USD as their functional currency are translated into USD using the following exchange rates: </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Income, expense and cash flows using for each month the average exchange rate, with the US dollar values for each month being aggregated during the year </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Balance sheets using year-end exchange rates</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Resulting exchange rate differences are recognized in other comprehensive income</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For subsidiaries operating in hyperinflationary economies, the impact of the restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period is recorded in retained earnings in equity. The subsequent gains or losses resulting from the restatement of non-monetary assets are recorded in &#x201c;Other financial income and expense&#x201d; in the consolidated income statement. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Non-current assets held for sale or held for distribution to owners</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Non-current assets are accounted for as assets held for sale or related to discontinued operations when their carrying amount is to be recovered principally through a sale transaction or distribution to owners and a sale or distribution to owners is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell with any resulting impairment recognized. Assets related to discontinued operations and assets of disposal group held for sale are not depreciated or amortized. The prior year consolidated balance sheet is not restated. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If in a subsequent period, the criteria for classification as held for sale are no longer met, the recoverable amount of assets and liabilities are reclassified out of assets held for sale into the respective balance sheet lines, prior year consolidated balance sheet is not restated. The cumulative amount of depreciation and amortization not recorded since the date of their classification to assets held for sale, and any required adjustments to the recoverable amounts of assets are recognized in the consolidated income statement. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Distribution of Alcon Inc. to Novartis AG shareholders </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During the first quarter of 2019, at the Annual General Meeting (AGM) of Novartis AG shareholders, held on February 28, 2019, the Novartis AG shareholders approved a special distribution by way of a dividend in kind to effect the spin-off of Alcon Inc. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The February 28, 2019, shareholder approval for the spin-off required the Alcon Division and selected portions of corporate activities attributable to Alcon&#x2019;s business (the &#x201c;Alcon business&#x201d;) to be reported as discontinued operations. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The shareholder approval to spin off the Alcon business also required the recognition of a distribution liability at the fair value of the Alcon business. The Group elected to measure the distribution liability at the fair value of the Alcon business net assets taken as a whole. The distribution liability was recognized through a reduction in retained earnings. It was required to be adjusted at each balance sheet date for changes in its estimated fair value, up to the date of the distribution to shareholders through retained earnings. Any resulting impairment of the business assets to be distributed would have been recognized in the consolidated income statements in &#x201c;Other expense&#x201d; of discontinued operations, at the date of initial recognition of the distribution liability or at subsequent dates resulting from changes of the distribution liability valuation. At the April 8, 2019 distribution settlement date, the resulting gain, which was measured as the excess amount of the distribution liability over the then-carrying value of the net assets of the business distributed, was recognized on the line &#x201c;Gain on distribution of Alcon Inc. to Novartis AG shareholders&#x201d; in the income statement of discontinued operations. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The recognition of the distribution liability required the use of valuation techniques for purposes of impairment testing of the Alcon business&#x2019; assets to be distributed and for the measurement of the fair value of the distribution liability. These valuations required the use of management assumptions and estimates related to the Alcon business&#x2019; future cash flows, market multiples to estimate day one market value, and control premiums to apply in estimating the Alcon business fair value. These fair value measurements were classified as &#x201c;Level 3&#x201d; in the fair value hierarchy. The section &#x201c;&mdash;Impairment of goodwill and intangible assets&#x201d; in this Note 1 provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Transaction costs that were directly attributable to the distribution (spin-off) of Alcon to the Novartis shareholders, and that would otherwise have been avoided, were recorded as a deduction from equity. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For additional disclosures, refer to &#x201c;Note 2. Significant transactions&mdash;Significant transactions in 2019&mdash;Completion of the spin-off of the Alcon business through a dividend in kind distribution to Novartis AG shareholders,&#x201d; and &#x201c;Note 30. Discontinued operations.&#x201d; </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Acquisition of assets and businesses</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Assets separately acquired are recorded at cost, which includes the purchase price and any directly attributable costs for bringing the asset into the condition to operate as intended. Expected costs for obligations to dismantle and remove property, plant and equipment when they are no longer used are included in their cost. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Acquired businesses are accounted for using the acquisition method, unless the optional concentration test is applied. The optional concentration test allows for the election on a transaction-by-transaction basis to account for the acquired business as an asset separately acquired when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The acquisition method requires that the assets acquired and liabilities assumed be recorded at their respective fair values on the date the Group obtains control. The excess of the fair value of the total purchase consideration transferred and the fair value of the acquired assets and assumed liabilities is recognized as goodwill. The related valuations are based on information available at the acquisition date. Acquisition related costs are expensed as incurred. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The application of the acquisition method requires certain estimates and assumptions to be made, especially concerning the fair values of the acquired intangible assets, inventories, property, plant and equipment and the liabilities assumed at the acquisition date, and the useful lives of the intangible assets and property, plant and equipment. Estimates of fair value require the use of valuation techniques. These valuations require the use of management assumptions and estimates, including value of comparable assets in the market, amount and timing of future cash flows, outcomes and costs of research and development activities, probability of obtaining regulatory approval, long-term sales forecasts, actions of competitors, discount rates and terminal growth rates. The section &#x201c;&mdash;Impairment of goodwill and intangible assets&#x201d; in this Note 1 provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Property, plant and equipment</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Property, plant and equipment are depreciated on a straight-line basis in the consolidated income statement over their estimated useful lives. Freehold land is not depreciated. The related depreciation expense is included in the costs of the functions using the asset. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Property, plant and equipment are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the respective useful lives for property, plant and equipment:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Useful life</div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buildings</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20 to 40 years</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and other equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7 to 20 years</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Furniture and vehicles</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 10 years</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Computer hardware</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 7 years</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Government grants obtained for construction activities, including any related equipment, are deducted from the gross acquisition cost to arrive at the balance sheet carrying value of the related assets. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Leases and right-of-use assets</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">From January 1, 2019, with the adoption of IFRS 16 Leases, the Group adopted the following accounting policies for leases and right-of-use assets: </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As lessee, the Group assesses whether a contract contains a lease at inception of a contract and upon the modification of a contract. The Group elected to allocate the consideration in the contract to the lease and non-lease components on the basis of the relative standalone price. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a lessee, except for leases with a term of 12 months or less (short-term leases) and low-value leases. For these short-term and low-value leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease to the end of the lease term. The lease term includes the period of any lease extension that in management&#x2019;s assessment is highly probable to be exercised by the Group. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the Novartis incremental borrowing rate for the asset subject to the lease in the respective markets. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever there is a change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The portion of the lease payments attributable to the repayment of lease liabilities is recognized in cash flows used in financing activities, and the portion attributable to the payment of interest is included in cash flows from operating activities. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are initially recognized on the balance sheet at cost, which comprises the amount of the initial measurement of the corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease incentive received and any initial direct costs incurred by Novartis, and expected costs for obligations to dismantle and remove right-of-use assets when they are no longer used. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease over the shorter of the useful life of the right-of-use asset or the end of the lease term. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In arrangements where the Group is the lessor, it determines at lease inception whether the lease is a finance lease or an operating lease. Leases that transfer substantially all of the risk and rewards incidental to ownership of the underlying asset to the counterparty (the lessee) are accounted for as finance leases. Leases that do not transfer substantially all of the risks and rewards of ownership are accounted for as operating leases. Lease payments received under operating leases are recognized on a straight-line basis over the lease term in the consolidated income statement in either &#x201c;net sales&#x201d; or &#x201c;other income,&#x201d; depending on the nature of and underlying asset to the lease arrangement. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Prior to January 1, 2019, the Group applied the following accounting policies for leases: </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Leases that transferred substantially all of the risks and rewards of ownership were recognized as finance leases, with the leased asset measured initially at an amount equal to the lower of their fair value and the present value of the minimum lease payments. Minimum lease payments were the payments over the lease term that the Group, as leasee, was required to make, excluding contingent rent. The underlying asset was accounted for in accordance with the accounting policy applicable to that asset. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Leases that did not transfer substantially all of the risks and rewards of ownership were accounted for as operating leases and were not recognized in the consolidated balance sheet. Payments made under operating leases were recognized in the consolidated income statement on a straight-line basis over the term of the lease. Lease incentives received were deferred and recognized as a component of lease expense over the term of the lease. The future undiscounted lease payments under operating leases were disclosed as commitments in the notes to the consolidated financial statements. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Lessor accounting policies were not substantially different from those applied upon the adoption of IFRS 16 Leases, as described above. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The section &#x201c;&mdash;Impact of adopting significant new IFRS standards in 2019&#x201d; in this Note 1 provides additional disclosures on the impact of adoption of IFRS 16 Leases. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Goodwill and intangible assets</font> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Goodwill</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Goodwill arises in the acquisition of a business when applying the acquisition method and is the excess of the fair value of the consideration transferred to acquire a business over the underlying fair value of the net identified assets acquired. It is allocated to groups of cash-generating units (CGUs), which are usually represented by the reported segments. Goodwill is tested for impairment annually at the level of these groups of CGUs, and any impairment charges are recorded under &#x201c;Other expense&#x201d; in the consolidated income statement. </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Intangible assets available for use</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has the following classes of available for use intangible assets: currently marketed products; technologies; other intangible assets (including computer software). </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Currently marketed products represent the composite value of acquired intellectual property (IP), patents, distribution rights and product trade names. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Technologies represent identified and separable acquired know-how used in the research, development and production processes. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Significant investments in internally developed and acquired computer software are capitalized and included in the &#x201c;Other&#x201d; category, and amortized once available for use. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Intangible assets available for use with a definite useful life are amortized over their estimated useful lives on a straight-line basis and are evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the respective useful lives for intangible assets available for use and the location in the consolidated income statement in which the respective amortization and any potential impairment charge is recognized: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Useful life </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income statement location <br></br> for amortization and <br></br> impairment charges </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 20 years</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Technologies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10 to 20 years <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold" <br></br> or "Research <br></br> and development" </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other (including <br></br>computer software) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 7 years <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> In the respective <br></br> functional expense </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Intangible assets not yet available for use</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Acquired research and development intangible assets that are still under development and have accordingly not yet obtained marketing approval are recognized as in-process research and development (IPR&amp;D). </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">IPR&amp;D is not amortized, but is evaluated for potential impairment on an annual basis or when facts and circumstances warrant. Any impairment charge is recorded in the consolidated income statement under &#x201c;Research and development.&#x201d; Once a project included in IPR&amp;D has been successfully developed, it is transferred to the &#x201c;Currently marketed products&#x201d; category. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impairment of goodwill and intangible assets</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">An asset is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value-in-use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or CGUs, and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group&#x2019;s activities with regard to: </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Amount and timing of projected future cash flows</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Long-term sales forecasts </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Actions of competitors (launch of competing products, marketing initiatives, etc.)</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Sales erosion rates after the end of patent or other intellectual property rights protection, and timing of the entry of generic competition </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Outcome of research and development activities (compound efficacy, results of clinical trials, etc.)</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Amount and timing of projected costs to develop IPR&amp;D into commercially viable products</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Profit margins</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Probability of obtaining regulatory approval</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Future tax rate</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Appropriate terminal growth rate</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Appropriate discount rate</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Generally, for intangible assets with a definite useful life, Novartis uses cash flow projections for the whole useful life of these assets. For goodwill, Novartis generally utilizes cash flow projections for a five-year period based on management forecasts, with a terminal value based on cash flow projections usually in line with inflation rates for later periods. Probability-weighted scenarios are typically used. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Discount rates used consider the Group&#x2019;s estimated weighted average cost of capital, adjusted for specific asset, country and currency risks associated with cash flow projections, to approximate the discount rate that market participants would use to value the asset. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Due to the above factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impairment of associated companies accounted for at equity</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis considers investments in associated companies for impairment evaluation whenever objective evidence indicates the net investment may be impaired, including when a quoted share price indicates a fair value less than the per-share balance sheet carrying value for the investment. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If the recoverable amount of the investment is estimated to be lower than the balance sheet carrying amount, an impairment charge is recognized for the difference in the consolidated income statement under &#x201c;Income from associated companies.&#x201d; </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Cash and cash equivalents</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash and cash equivalents include highly liquid investments with original maturities of three months or less, which are readily convertible to known amounts of cash. Bank overdrafts are usually presented within current financial debts on the consolidated balance sheet, except in cases where a right of offset has been agreed with a bank, which then allows for presentation on a net basis. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Marketable securities, commodities and non-current financial assets </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Commodities, which include gold bullion or coins, are valued at the lower of cost or fair value using current market prices. The changes in fair value below cost are immediately recorded in &#x201c;Other financial income and expense.&#x201d; </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities are financial assets held for short-term purposes which are principally traded in liquid markets and are classified within current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#x201c;Other financial income and expense&#x201d; in the consolidated income statement. Non-current financial assets held for long-term strategic purposes are classified within non-current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#x201c;Other income&#x201d; and &#x201c;Other expense&#x201d; in the consolidated income statement. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities and non-current financial assets are initially recorded at fair value on their trade date, which is different from the settlement date when the transaction is ultimately effected. Quoted securities are remeasured at each reporting date to fair value based on current market prices. If the market for a financial asset is not active or no market is available, fair values are established using valuation techniques. The majority of non-quoted investments are valued initially at fair value through the established purchase price between a willing buyer and seller. Non-quoted investments are subsequently adjusted based on values derived from discounted cash flow analysis or other pricing models. These investment values are classified as &#x201c;Level 3&#x201d; in the fair value hierarchy. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group classifies and accounts for its marketable securities and non-current financial assets in the following categories: </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Debt securities are valued at fair value through other comprehensive income with subsequent recycling into the consolidated income statement, as they meet both the &#x201c;solely payment of principal and interest&#x201d; and the business model criteria. Unrealized gains and losses, except exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are recognized in the consolidated income statement when the debt instrument is sold, at which time the gain is transferred to &#x201c;Other financial income and expense.&#x201d; Exchange gains and losses related to debt instruments are immediately recognized in the consolidated income statement to &#x201c;Other financial income and expense.&#x201d; </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Fund investments and equity securities of the Novartis venture fund are valued at fair value through profit and loss (FVPL). Unrealized gains and losses, including exchange gains and losses, are recognized in the consolidated income statement to &#x201c;Other income&#x201d; for gains and &#x201c;Other expense&#x201d; for losses. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Equity securities held as strategic investments, typically held outside of the Novartis venture fund, are generally designated at the date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. Unrealized gains and losses, including exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are reclassified to retained earnings when the equity security is sold. If these equity securities are not designated at the date of acquisition as financial assets valued at fair value through other comprehensive income, they are valued at FVPL, as described above. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Other non-current financial assets, such as loans and long-term receivables from customers, advances and other deposits, are valued at amortized cost, which reflects the time value of money less any allowances for expected credit losses. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group assesses on a forward-looking basis the expected credit losses associated with its debt securities valued at fair value through other comprehensive income. Impairments on debt securities are recorded in &#x201c;Other financial income and expense.&#x201d; </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For other financial assets valued at amortized cost, impairments, which are based on their expected credit losses, and exchange rate losses are included in &#x201c;Other expense&#x201d; in the consolidated income statement. Exchange rate gains and interest income, using the effective interest rate method, are included in &#x201c;Other income&#x201d; or &#x201c;Other financial income&#x201d; in the consolidated income statement, depending on the nature of the item. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Derivative financial instruments</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Derivative financial instruments are initially recognized in the balance sheet at fair value and are remeasured to their current fair value at the end of each subsequent reporting period. The valuation of a forward exchange rate contract is based on the discounted cash flow model, using interest curves and spot rates at the reporting date as observable inputs. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Options are valued based on a modified Black-Scholes model using volatility and exercise prices as major observable inputs. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group utilizes derivative financial instruments for the purpose of hedging to reduce the volatility in the Group&#x2019;s performance due to the exposure to various business related risks. To mitigate these risks, the Group enters into certain derivative financial instruments. The risk reduction is obtained because the derivative&#x2019;s value or cash flows are expected, wholly or partly, to offset changes in the value or cash flows of the recognized assets or liabilities. The overall strategy is aiming to mitigate the currency and interest rate risk of positions that are contractually agreed, and to partially mitigate the exposure risk of selected anticipated transactions. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Certain derivative financial instruments meet the criteria for hedge accounting treatment. A prerequisite for obtaining this accounting-hedge relationship is extensive documentation on inception and proving on a regular basis that the economic hedge is effective for accounting purposes. Other derivative financial instruments do not meet the criteria to qualify for hedge accounting. Changes in the fair value of these derivative instruments are recognized immediately in &#x201c;Other financial income and expense&#x201d; in the consolidated income statement. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, the Group has designated certain long-term debt components as hedges of the translation risk arising on certain net investments in foreign operations. On consolidation, foreign currency differences arising on long-term debt designated as net investment hedges of a foreign operation are recognized in other comprehensive income and accumulated in currency translation effects, to the extent that the hedge is effective. The foreign currency differences arising from hedge ineffectiveness are recognized in the income statement in &#x201c;Other financial income and expense.&#x201d; </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">When a hedged net investment is disposed of, the proportionate portion of the cumulative amount recognized in equity in relation to the hedged net investment is transferred to the consolidated income statement as an adjustment to the gain or loss on disposal. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Inventories</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inventory is valued at the lower of acquisition or production cost determined on a first-in, first-out basis and net realizable value. This value is used for the &#x201c;Cost of goods sold&#x201d; in the consolidated income statement. Unsaleable inventory is fully written off in the consolidated income statement under &#x201c;Cost of goods sold.&#x201d; </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Trade receivables</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Trade receivables are initially recognized at their invoiced amounts, including any related sales taxes less adjustments for estimated revenue deductions such as rebates, chargebacks and cash discounts. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The provisions for doubtful trade receivables are established using an expected credit loss model (ECL). The provisions are based on a forward-looking ECL, which includes possible default events on the trade receivables over the entire holding period of the trade receivable. These provisions represent the difference between the trade receivable&#x2019;s carrying amount in the consolidated balance sheet and the estimated collectible amount. Charges for doubtful trade receivables are recorded as marketing and selling costs recognized in the consolidated income statement within &#x201c;Selling, general and administration&#x201d; expenses. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Legal and environmental liabilities</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis and its subsidiaries are subject to contingencies arising in the ordinary course of business, such as patent litigation, environmental remediation liabilities and other product-related litigation, commercial litigation, and governmental investigations and proceedings. Provisions are recorded where a reliable estimate can be made of the probable outcome of legal or other disputes against the subsidiary. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Contingent consideration</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In an acquisition or a divestment of a business, it is necessary to recognize contingent future amounts due to previous owners, representing contractually defined potential amounts as a liability or an asset. Usually for Novartis, these are linked to milestone or royalty payments related to certain assets and are recognized as a financial liability or financial asset at fair value, which is then remeasured at each subsequent reporting date. These estimations typically depend on factors such as technical milestones or market performance, and are adjusted for the probability of their likelihood of payment, and are appropriately discounted to reflect the impact of time. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the consolidated income statement in &#x201c;Cost of goods sold&#x201d; for currently marketed products and in &#x201c;Research and development&#x201d; for IPR&amp;D. Changes in contingent consideration assets are recognized in &#x201c;Other income&#x201d; or &#x201c;Other expense,&#x201d; depending on their nature. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The effect of unwinding the discount over time is recognized for contingent liabilities in &#x201c;Interest expense&#x201d; and for contingent assets as interest income recognized in the consolidated income statement within &#x201c;Other financial income and expense.&#x201d; </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Defined ben</font> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">efit pension plans and&nbsp;other&nbsp;post-employment benefits</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The liability in respect of defined benefit pension plans and other post-employment benefits is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions in which associates are employed, while the net interest on the net defined benefit liability or asset is recognized as &#x201c;Other expense&#x201d; or &#x201c;Other income.&#x201d; </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Treasury shares</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Treasury shares are initially recorded at fair value on their trade date, which is different from the settlement date, when the transaction is ultimately effected. Treasury shares are deducted from consolidated equity at their nominal value of CHF&nbsp;0.50 per share. Differences between the nominal amount and the transaction price on purchases or sales of treasury shares with third parties, or the value of services received for the shares allocated to associates as part of share-based compensation arrangements, are recorded in &#x201c;Retained earnings&#x201d; in the consolidated statement of changes in equity. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Revenue recognition</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Revenue on the sale of Novartis Group products and services, which is recorded as &#x201c;Net sales&#x201d; in the consolidated income statement, is recognized when a contractual promise to a customer (performance obligation) has been fulfilled by transferring control over the promised goods and services to the customer, substantially all of which is at the point in time of shipment to or receipt of the products by the customer or when the services are performed. If contracts contain customer acceptance provisions, revenue is recognized upon the satisfaction of the acceptance criteria. If products are stockpiled at the request of the customer, revenue is only recognized once the products have been inspected and accepted by the customer, and there is no right of return or replenishment on product expiry. The amount of revenue recognized is based on the consideration Novartis expects to receive in exchange for its goods and services, when it is highly probable that a significant reversal will not occur. If a contract contains more than one performance obligation, the consideration is allocated based on the standalone selling price of each performance obligation. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consideration Novartis receives in exchange for its goods or services may be fixed or variable. Variable consideration is only recognized when it is highly probable that a significant reversal will not occur. The most common elements of variable consideration are listed below. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Rebates and discounts granted to government agencies, wholesalers, retail pharmacies, managed healthcare organizations and other customers, as well as chargebacks are provisioned and recorded as a revenue deduction at the time the related revenues are recorded or when the incentives are offered. They are calculated on the basis of historical experience, regulations, the specific terms in the individual agreements, product pricing and the mix of products, contracts, channels and payors. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Refunds granted to healthcare providers under innovative pay-for-performance agreements (i.e., outcome based arrangements) are provisioned and recorded as a revenue deduction at the time the related sales are recorded. They are calculated on the basis of historical experience and clinical data available for the product, as well as the specific terms in the individual agreements. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until the uncertainty is resolved or until such history is available. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Cash discounts are offered to customers to encourage prompt payment and are provisioned and recorded as revenue deductions at the time the related sales are recorded. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Shelf stock adjustments are generally granted to customers, primarily of the Sandoz Division, to cover the inventory held by them at the time a price decline becomes effective. Revenue deduction provisions for shelf stock adjustments are recorded when the price decline is anticipated, based on the impact of the price decline on the customer&#x2019;s estimated inventory levels. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Sales returns provisions are recognized and recorded as revenue deductions when there is historical experience of Novartis agreeing to customer returns and Novartis can reasonably estimate expected future returns. In doing so, the estimated rate of return is applied, determined on the basis of historical experience of customer returns and considering any other relevant factors. This is applied to the amounts invoiced, also considering the amount of returned products to be destroyed versus products that can be placed back in inventory for resale. Where shipments are made on a resale or return basis, without sufficient historical experience for estimating sales returns, revenue is only recorded when there is evidence of consumption or when the right of return has expired. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Net sales and provisions for revenue deductions are adjusted to actual amounts as rebates, refunds, discounts and returns are processed. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these sales deductions. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">&#x201c;Other revenue&#x201d; includes income from profit-sharing arrangements with our collaboration partners, and royalty and milestone income from the out-licensing of intellectual property when Novartis retains an interest in the intellectual property through a license. Royalty income earned through a license is recognized when the underlying sales have occurred. Milestone income is recognized at the point in time when it is highly probable that the relevant milestone event criteria are met, and the risk of reversal of revenue recognition is remote. Other revenue also includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales, and is recognized when control transfers to the third party and our performance obligations are satisfied. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Research and development</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Internal research and development (R&amp;D) costs are fully charged to &#x201c;Research and development&#x201d; in the consolidated income statement in the period in which they are incurred. The Group considers that regulatory and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained in a major market such as the United States, the European Union, Switzerland or Japan. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Payments made to third parties, such as contract research and development organizations in compensation for subcontracted R&amp;D, that are deemed not to transfer intellectual property to Novartis are expensed as internal R&amp;D expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been achieved from a regulatory authority in a major market. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Payments made to third parties to in-license or acquire intellectual property rights, compounds and products, including initial upfront and subsequent milestone payments, are capitalized, as are payments for other assets, such as technologies to be used in R&amp;D activities. If additional payments are made to the originator company to continue to perform R&amp;D activities, an evaluation is made as to the nature of the payments. Such additional payments will be expensed if they are deemed to be compensation for subcontracted R&amp;D services not resulting in an additional transfer of intellectual property rights to Novartis. Such additional payments will be capitalized if they are deemed to be compensation for the transfer to Novartis of additional intellectual property developed at the risk of the originator company. Subsequent internal R&amp;D costs in relation to IPR&amp;D and other assets are expensed, since the technical feasibility of the internal R&amp;D activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Costs for post-approval studies performed to support the continued registration of a marketed product are recognized as marketing expenses. Costs for activities that are required by regulatory authorities as a condition for obtaining marketing approval are capitalized and recognized as currently marketed products. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Inventory produced ahead of regulatory approval is fully provisioned, and the charge is included in &#x201c;Other expense&#x201d; in the consolidated income statement, as its ultimate use cannot be assured. If this inventory can be subsequently sold, the provision is released to &#x201c;Other income&#x201d; in the consolidated income statement, either on approval by the appropriate regulatory authority or, exceptionally in Europe, on recommendation by the Committee for Medicinal Products for Human Use (CHMP), if approval is virtually certain. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Share-based compensation</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Vested Novartis shares and American Depositary Receipts (ADRs) that are granted as compensation are valued at their market value on the grant date and are immediately expensed in the consolidated income statement. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair values of unvested restricted shares (RSs), restricted share units (RSUs) and performance share units (PSUs) in Novartis shares and ADRs granted to associates as compensation are recognized as an expense over the related vesting period. The expense recorded in the consolidated income statement is included in the personnel expenses of the various functions in which the associates are employed. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Unvested restricted shares, restricted ADRs and RSUs are only conditional on the provision of services by the plan participant during the vesting period. They are valued at fair value on the grant date. As RSUs do not entitle the holder to dividends, the fair value is based on the Novartis share price at the grant date adjusted for the net present value of the dividends expected to be paid during the holding period. The fair value of these grants, after making adjustments for assumptions related to forfeiture during the vesting period, is expensed on a straight-line basis over the respective vesting period. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">PSUs are subject to the achievement of certain performance criteria during the vesting period and require plan participants to provide services during this period. The following paragraphs provide an overview of the accounting policies for the share-based compensation plans that grant PSUs. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs granted under plans that are subject to performance criteria based on Novartis internal performance metrics and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on assumptions concerning the expected performance against the internal performance metrics throughout the vesting period. The assumptions are based on the Group&#x2019;s targets for those performance metrics, and the expected forfeitures due to plan participants not meeting their service conditions. The assumptions are periodically adjusted over the vesting period. Any change in estimates for past services is recorded immediately as an expense or income in the consolidated income statement, and amounts for the remaining vesting period are expensed on a straight-line basis. As a result, at the end of the vesting period, the charge during the entire vesting period represents the amount that will finally vest. The number of equity instruments that finally vest is determined at the vesting date. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs granted under plans that are subject to performance criteria based on variables that can be observed in the market, which for Novartis plans is the Novartis total shareholder return (TSR) relative to a specific peer group of companies over the vesting period, and that are conditional on the provision of services by the plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on the total fair value of the grant over the vesting period. IFRS requires that these variables that can be observed in the market are taken into account in determining the fair value of the PSUs at the grant date. Novartis determined the fair value of these PSUs at the date of grant using a Monte Carlo simulation model. Adjustments to the number of equity instruments granted are only made if a plan participant does not fulfill the service conditions. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs granted under plans that are subject to both performance criteria based on Novartis internal performance metrics and Novartis TSR relative to a specific peer group of companies over the vesting period and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on a bifurcation into the components based on the performance criteria related to Novartis internal performance metrics and TSR, as described in the paragraphs above. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Measuring the fair values of PSUs granted that include TSR performance criteria requires use of estimates. The Monte Carlo simulation used to determine the fair value of the PSUs TSR performance criteria requires the probability of factors related to uncertain future events; the term of the award; the grant price of underlying shares or ADRs; expected volatilities; the expected correlation matrix of the underlying equity instruments with those of the peer group of companies; and the risk-free interest rate as input parameters. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If a plan participant leaves Novartis for reasons other than retirement, disability or death, then unvested restricted shares, restricted ADRs, RSUs and PSUs are forfeited, unless determined otherwise by the provision of the plan rules or by the Compensation Committee of the Novartis Board of Directors, for example, in connection with a reorganization or divestment. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Government grants</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Grants from governments or similar organizations are recognized at their fair value when there is a reasonable assurance that the grant will be received and the Group will comply with all attached conditions. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Government grants received to compensate for cost are deferred and recognized in the consolidated income statement over the period necessary to match them against the related costs that they are intended to compensate. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The accounting policy for property, plant and equipment describes the treatment of any related grants. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Restructuring charges</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Restructuring provisions are recognized for the direct expenditures arising from the restructuring, where the plans are sufficiently detailed and where appropriate communication to those affected has been made. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Charges to increase restructuring provisions are included in &#x201c;Other expense&#x201d; in the consolidated income statements. Corresponding releases are recorded in &#x201c;Other income&#x201d; in the consolidated income statement. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Healthcare contributions</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Healthcare contribution levies and fees under governmental programs that require the Group to contribute to a country&#x2019;s healthcare costs, other than programs described in Revenue recognition in this Note 1, are recognized in Other expense in the consolidated income statement. Provisions for healthcare contributions are adjusted to the actual amounts levied. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these healthcare contributions. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Taxes</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Taxes on income are provided in the same periods as the revenues and expenses to which they relate and include interest and penalties incurred during the period. Deferred taxes are determined using the comprehensive liability method and are calculated on the temporary differences that arise between the tax base of an asset or liability and its carrying value in the balance sheet prepared for consolidation purposes, except for those temporary differences related to investments in subsidiaries and associated companies, where the timing of their reversal can be controlled and it is probable that the difference will not reverse in the foreseeable future. Since the retained earnings are reinvested, withholding or other taxes on eventual distribution of a subsidiary&#x2019;s retained earnings are only taken into account when a dividend has been planned. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimated amounts for current and deferred tax assets or liabilities, including any amounts related to any uncertain tax positions, are based on currently known facts and circumstances. Tax returns are based on an interpretation of tax laws and regulations, and reflect estimates based on these judgments and interpretations. The tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made requiring payments of additional tax, interest or penalties. Inherent uncertainties exist in the estimates of the tax positions. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impact of adopting significant new IFRS standard in 2020</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following new IFRS standard has been adopted by Novartis from January 1, 2020:</div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">IFRS 3 Business Combination amendments</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The IASB issued amendments to IFRS 3 Business Combinations that revised the definition of a business, which assist entities with the evaluation of when an asset or group of assets acquired should be considered a business. This amended standard has been applied to transactions entered into on or after January 1, 2020. The amended standard allows an entity to apply an optional concentration test, on a transaction-by-transaction basis, to evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this optional concentration test is met, the set of activities and assets is determined not to be a business. The adoption of this amended standard on January 1, 2020 did not have a significant impact on our consolidated financial statements and is not expected to have a significant impact in future periods. However, this will depend on the facts and circumstances of future transactions and if the Group decides to apply the optional concentration test in the assessment of whether an acquired set of activities and assets is or is not a business. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">There are no other IFRS standards or interpretations not yet effective that would be expected to have a material impact on the Group. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impact of adopting significant new IFRS standard in 2019</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following new IFRS standard has been adopted by Novartis from January 1, 2019: </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">IFRS 16 Leases</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">IFRS 16 Leases substantially changed the financial statements, as the majority of leases for which the Group is the lessee became on-balance sheet liabilities with corresponding right-of-use assets also recognized on the balance sheet. The lease liability reflects the net present value of the remaining lease payments, and the right-of-use asset corresponds to the lease liability, adjusted for payments made before the commencement date, lease incentives and other items related to the lease agreement. The standard replaces IAS 17 Leases and related interpretations. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Upon adoption of the new standard, a portion of the annual operating lease costs, which was previously fully recognized as functional expenses, as a component of operating income, is recorded as interest expense. In addition, the portion of the lease payments that represents the reduction of the lease liability is recognized in the cash flow statement as an outflow from financing activities, which was previously fully recognized as an outflow from operating activities. Given the leases involved, these effects are not significant to the consolidated income statement and consolidated statement of cash flow. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group implemented the new standard on January 1, 2019, and applied the modified retrospective method, with right-of-use assets measured at an amount equal to the lease liability, adjusted by the amount of the prepaid or accrued lease payments relating to those leases recognized in the balance sheet immediately before the date of initial application and did not restate prior years. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Results of our impact assessment: </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The undiscounted operating lease commitments as of December 31, 2018, amounted to USD 3.6 billion. This includes approximately USD 0.1 billion of leases with a commencement date in 2019, as well as short-term leases and low-value leases that are recognized from January 1, 2019, upon adoption of IFRS 16, on a straight-line basis as expense in profit and loss. This also includes USD 0.2 billion lease commitments related to the Alcon Division, which is attributable to discontinued operation in 2019. For the remaining undiscounted lease commitments attributable to continuing operations of USD 3.3 billion, the Group recognized on January 1, 2019, lease liabilities of USD 1.74 billion and right-of-use assets of USD 1.55 billion (after the reclassification of USD 0.1 billion from property, plant and equipment, and net adjustments for the USD 0.3 billion recognition of sublease receivables, prepayments, and accrued lease payments recognized as at December 31, 2018). For the lease commitments attributable to discontinued operations, the Group recognized on January 1, 2019, lease liabilities and right-of-use assets of USD 0.2 billion. This does not include the discontinued operations right-of-use assets and lease liability on finance lease agreements of USD 75 million and USD 89 million, respectively. There was an insignificant increase to retained earnings upon adoption of IFRS 16 of USD 3 million that arose from subleases that were accounted for as operating lease agreements under IAS 17 and are accounted for as finance leases under IFRS 16. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As a lessor, the Group had no significant impact upon adoption. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">For additional significant accounting policies applicable to the discontinued operations business see Note 30. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326014456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfSignificantTransactionsTextBlock', window );">Significant transactions</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">2. Significant transactions</div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions in 2020</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group applied the acquisition method of accounting for businesses acquired, and did not elect to apply the optional concentration test to account for acquired business as an asset separately acquired. </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &ndash; acquisition of The&nbsp;Medicines Company</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 23, 2019, Novartis entered into an agreement and plan of merger (the Merger Agreement) with The Medicines Company, a US-based pharmaceutical company headquartered in Parsippany, New Jersey USA. Pursuant to the Merger Agreement, on December 5, 2019, Novartis, through a subsidiary, commenced a tender offer to acquire all outstanding shares of The Medicines Company for USD 85 per share, or a total consideration of approximately USD 9.6 billion in cash on a fully diluted basis, including the equivalent share value related to The Medicines Company&#x2019;s convertible notes, in accordance with their terms. The tender offer expired on January 3, 2020, and on January 6, 2020, the acquiring subsidiary merged with and into The Medicines Company, resulting in The Medicines Company becoming an indirect wholly owned subsidiary of Novartis. Novartis financed the transaction through available cash, and short- and long-term borrowings. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Medicines Company is focused on the development of inclisiran, a potentially first-in-class, twice yearly therapy that allows administration during patients&#x2019; routine visits to their healthcare professionals and will potentially contribute to improved patient adherence and sustained lower LDL-C levels. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was USD 9.6 billion. The purchase price allocation resulted in net identifiable assets of approximately USD 7.1 billion, consisting of USD 8.5 billion intangible assets, USD 1.4 billion net deferred tax liabilities and goodwill of approximately USD 2.5 billion. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Results of operations since the date of acquisition were not material.</div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz &ndash; acquisition of the Japanese business of Aspen Global Incorporated </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 11, 2019, Sandoz entered into an agreement for the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. Under the agreement, Sandoz acquired the shares in Aspen Japan K.K. and associated assets held by AGI. The transaction closed on January 31, 2020. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Aspen&#x2019;s portfolio in Japan consists of off-patent medicines with a focus on anesthetics and specialty brands. The acquisition will enable Sandoz to expand its presence in the third-largest worldwide generics marketplace. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The purchase price consists of EUR 274 million (USD 303 million) upfront payment, less customary purchase price adjustment of EUR 27 million (USD 30 million), plus potential milestone payments of up to EUR 70 million (USD 77 million), which AGI is eligible to receive upon the achievement of specified milestones.</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was EUR 294 million (USD 324 million). The amount consisted of a cash payment of EUR 247 million (USD 273 million) and the fair value of contingent consideration of EUR 47 million (USD 51 million), which AGI is eligible to receive upon the achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD 238 million, consisting of USD 196 million intangible assets, USD 26 million other net assets, USD 16 million net deferred tax assets. Goodwill amounted to USD 86 million. Results of operations since the date of acquisition were not material. </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz &ndash; retention of US dermatology business and generic US oral solids portfolio, previously planned to be divested </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On September 6, 2018, Novartis announced that it entered into a stock and asset purchase agreement (SAPA) with Aurobindo Pharma USA Inc. (Aurobindo) for the sale of selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, for USD 0.8 billion in cash and potential earnouts. The closing was conditional on obtaining regulatory approval. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In March 2020, Novartis took the decision to retain the Sandoz US generic oral solids and dermatology businesses and on April 2, 2020 entered into a mutual agreement with Aurobindo to terminate the transaction. The decision was taken as approval from the US Federal Trade Commission for the transaction was not obtained within the agreed timelines. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The cumulative amount of the depreciation on property, plant and equipment (USD 38 million) and amortization on intangible assets (USD 102 million), not recorded in the consolidated income statement since the date of classification as held for sale was recognized in the consolidated income statement in the first quarter of 2020. In addition, an impairment of currently marketed products of USD 42 million was recognized in the first quarter of 2020 consolidated income statement. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As at March 31, 2020, the assets and liabilities of the Sandoz US generic oral solids and dermatology businesses were reclassified out of assets and liabilities of disposal group held for sale. The prior year balance sheet is not required to be restated. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the Group&#x2019;s consolidated balance sheet at December 31, 2019, the assets and liabilities classified as disposal group assets and liabilities held for sale consisted of the following: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31, <br></br> 2019 </div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Assets of disposal group classified as held for sale</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 169</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets other than goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 475</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 181</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 841</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31, <br></br> 2019 </div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Liabilities of disposal group classified as held for sale</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other non-current <br></br>liabilities </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 4 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There were no cumulative income or expenses included in the other comprehensive income relating to the disposal group. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions in 2019</font> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Completion of the spin-off of the Alcon business through a dividend in kind distribution to Novartis AG shareholders </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On June 29, 2018, Novartis announced its intention to seek shareholder approval for the spin-off of the Alcon business into a separately traded standalone company, following the complete structural separation of the Alcon business into a standalone company (the Alcon business or Alcon Inc.). </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Novartis AG shareholders approved the spin-off of the Alcon business at the 2019 Annual General Meeting held on February 28, 2019, subject to completion of certain conditions precedent to the distribution. Upon shareholder approval, the Alcon business was reported as discontinued operations, and the fair value of the Alcon business exceeded the carrying value of its net assets. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The conditions precedent to the spin-off were met and on April 8, 2019 the spin-off of the Alcon business was effected by way of a distribution of a dividend in kind of Alcon Inc. shares to Novartis AG shareholders and ADR (American Depositary Receipt) holders (the Distribution), which amounted to USD 23.4 billion and is recognized as a reduction to retained earnings. Through the Distribution, each Novartis AG shareholder received one Alcon Inc. share for every five Novartis AG shares/ADRs they held on April 8, 2019, close of business. As of April 9, 2019, the shares of Alcon Inc. are listed on the SIX Swiss Exchange (SIX) and on the New York Stock Exchange (NYSE) under the symbol &#x201c;ALC.&#x201d; </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The dividend in kind distribution liability to effect the spin-off of the Alcon business (the distribution liability) amounted to USD 26.4 billion at March 31, 2019, unchanged from its initial recognition on February 28, 2019, and was in excess of the carrying value of the Alcon business net assets as of February 28, 2019, and as of March 31, 2019. The net assets of the Alcon business amounted to USD 23.1 billion as at March 31, 2019. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">On March 6, 2019, Alcon entered into financing arrangements with a syndicate of banks under which it borrowed on April 2, 2019, a total amount of USD 3.2 billion. These borrowings consisted of approximately USD 2.8 billion and the equivalent of USD 0.4 billion in EUR in bridge and other term loans under such Alcon facilities agreement. In addition, approximately USD 0.3 billion of borrowings under a number of local bilateral facilities in different countries, with the largest share of borrowings in Japan, were raised. This resulted in a total gross debt of USD 3.5 billion. These outstanding borrowings of the Alcon legal entities were recorded in the balance sheet and financing cash flow from discontinued operations. Prior to the spin-off, through a series of intercompany transactions, Alcon legal entities paid approximately USD 3.1 billion in cash to Novartis and its affiliates. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">At the April 8, 2019 Distribution, the fair value of the distribution liability of the Alcon business amounted to USD 23.4 billion, a decrease of USD 3.0 billion from March 31, 2019. As mentioned above, prior to the spin-off, through a series of intercompany transactions, Alcon legal entities incurred additional net financial debt and paid approximately USD 3.1 billion in cash to Novartis and its affiliates. This additional net debt and transactions resulted in a decrease in Alcon&#x2019;s net assets to USD 20.0 billion at the date of the Distribution of the dividend in kind to Novartis AG shareholders on April 8, 2019. The distribution liability at April 8, 2019, remained in excess of the then-carrying value of the Alcon business net assets. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Certain consolidated foundations own Novartis AG dividend-bearing shares restricting their availability for use by the Group. These Novartis AG shares are accounted for as treasury shares. Through the Distribution, these foundations received Alcon Inc. shares representing an approximate 4.7% equity interest in Alcon Inc. Upon the loss of control of Alcon Inc. through the Distribution, the financial investment in Alcon Inc. was recognized at its fair value based on the opening traded share price of Alcon Inc. on April 9, 2019 (a Level 1 hierarchy valuation). At initial recognition, its fair value of USD 1.3 billion was reported on the Group&#x2019;s consolidated balance sheet as a financial asset. Management has designated this investment at fair value through other comprehensive income. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The total non-taxable, non-cash gain recognized at the distribution date of the spin-off of the Alcon business amounted to USD 4.7 billion consisting of: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> April 8, <br></br> 2019 </div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net assets derecognized <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;20&nbsp;025</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derecognition of distribution liability</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23&nbsp;434</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Difference between net assets and distribution liability</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;409</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Recognition of Alcon Inc. shares obtained <br></br>through consolidated foundations </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;273 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation gains recycled into <br></br>the consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 123 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transaction costs recognized in the consolidated income statement</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;114</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;691</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="4"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="4"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> See Note 30 for additional information. </div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For additional disclosures on discontinued operations, refer to Note 30.</div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &ndash; acquisition of IFM Tre, Inc. </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On May 7, 2019, Novartis acquired IFM Tre, Inc., a privately held, US-based biopharmaceutical company focused on developing anti-inflammatory medicines targeting the NLRP3 inflammasome. The acquisition gives Novartis full rights to IFM Tre, Inc.&#x2019;s portfolio of NLRP3 antagonists. The NLRP3 antagonists portfolio consists of one clinical program and two preclinical programs: IFM-2427, a first-in-class, clinical-stage systemic antagonist for an array of chronic inflammatory disorders, including atherosclerosis and nonalcoholic steatohepatitis (NASH); a preclinical-stage gut-directed molecule for the treatment of inflammatory bowel disease; and a preclinical-stage central nervous system (CNS)-penetrant molecule. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The previously held interest of 9% was adjusted to its fair value of USD 33 million through the consolidated income statement at acquisition date. This remeasurement resulted in a gain of USD 14 million. The fair value of the total purchase consideration for acquiring the 91% stake Novartis did not already own amounted to USD 361 million. The amount consisted of an initial cash payment of USD 285 million, and the fair value of the contingent consideration of USD 76 million due to the IFM Tre, Inc. shareholders, which they are eligible to receive upon the achievement of specified development and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 355 million, mainly intangible assets, and goodwill of USD 39 million. The 2019 results of operations since the date of acquisition were not material. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &ndash; acquisition of <i>Xiidra</i> </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On May 8, 2019, Novartis entered into an agreement with Takeda Pharmaceutical Company Limited (Takeda) to acquire the assets associated with <i>Xiidra</i> (lifitegrast ophthalmic solution) 5% worldwide. <i>Xiidra</i> is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease. The transaction bolsters the Novartis front-of-the-eye portfolio and ophthalmic leadership. The transaction closed on July 1, 2019. The purchase price consists of a USD 3.4 billion upfront payment, customary purchase price adjustments of USD 0.1 billion, and the potential milestone payments of up to USD 1.9 billion, which Takeda is eligible to receive upon the achievement of specified commercialization milestones. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration is USD 3.7 billion. The amount consists of an initial cash payment of USD 3.5 billion, and the fair value of the contingent consideration of USD 0.2 billion, which Takeda is eligible to receive upon the achievement of specified commercialization milestones. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The purchase price allocation resulted in net identifiable assets of approximately USD 3.6 billion, consisting mainly of intangible assets of USD 3.6 billion, and goodwill amounted to approximately USD 0.1 billion. In 2019, from the date of acquisition, the business generated net sales of USD 0.2 billion. Management estimates that net sales for the entire year of 2019 would have amounted to USD 0.3 billion, had the business been acquired at the beginning of the 2019 reporting period. The 2019 results of operations since the date of acquisition were not material. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions in 2018</font> </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &ndash; acquisition of Advanced Accelerator Applications S.A.</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On October 30, 2017, Novartis entered into a binding memorandum of understanding with Advanced Accelerator Applications S.A. (AAA), a company headquartered in Saint-Genis-Pouilly, France, under which Novartis agreed to commence a tender offer for 100% of the share capital of AAA subject to certain conditions. Novartis commenced the tender offer on December 7, 2017, to purchase all of the outstanding ordinary shares for a price of USD&nbsp;41 per share and USD&nbsp;82 per American Depositary Share (ADS), each representing two ordinary shares of AAA, which expired on January 19, 2018. The offer valued AAA&#x2019;s equity at USD&nbsp;3.9 billion, on a fully diluted basis. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of January 19, 2018, the expiration date of the tender offer, approximately 97% of the then-outstanding fully diluted ordinary shares, including ordinary shares represented by ADSs (hereinafter collectively referred to as &#x201c;the outstanding shares&#x201d;), were validly tendered. On January 22, 2018, Novartis accepted and paid USD 3.9 billion for the outstanding shares tendered in the offer. On January 22, 2018, Novartis commenced a subsequent offering period that expired on January 31, 2018. As of the expiration of the subsequent offering period, an additional 1.8% of the outstanding shares were validly tendered. Novartis accepted and paid approximately USD 60 million, resulting in an increase in Novartis ownership in AAA to 98.7%. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was USD 3.9 billion. The purchase price allocation resulted in net identifiable assets of approximately USD 1.9 billion, consisting of USD 2.5 billion intangible assets, USD 0.6 billion net deferred tax liabilities, and goodwill of approximately USD 2.0 billion. In 2018, from the date of the acquisition, the business generated net sales of USD 0.4 billion. Management estimated that net sales for the entire year of 2018 would have amounted to USD 0.4 billion had AAA been acquired at the beginning of 2018. The 2018 results from operations since the acquisition were not material. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of December 31, 2020, Novartis held 99.2% of the then-outstanding fully diluted ordinary shares, including ordinary shares represented by ADSs. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">AAA is a radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicines &ndash; including <i>Lutathera</i> (USAN: lutetium Lu 177 dotatate/INN: lutetium ( <sup>177</sup>Lu) oxodotreotide), a first-in-class radioligand therapy product for neuroendocrine tumors &ndash; and a portfolio of diagnostic products. Radiopharmaceuticals, such as <i>Lutathera</i>, are unique medicinal formulations containing radioisotopes, which are used clinically for both diagnosis and therapy. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &ndash; acquisition of AveXis, Inc.</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On April 6, 2018, Novartis entered into an agreement and plan of merger with AveXis, Inc., a US-based clinical stage gene therapy company, under which Novartis commenced on April 17, 2018, a tender offer to purchase all outstanding common stock of AveXis, Inc. for USD 218 per share in cash. On May 15, 2018, Novartis completed the acquisition of the common stock of AveXis, Inc. and paid a total of USD 8.7 billion. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was USD 8.7 billion. The purchase price allocation resulted in net identifiable assets of approximately USD 7.2 billion, consisting of USD 8.5 billion intangible assets, USD 1.6 billion net deferred tax liabilities and other net assets of USD 0.3 billion, and goodwill of approximately USD 1.5 billion. The 2018 results of operations since the date of acquisition were not material. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">AveXis, Inc. is focused on developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. AveXis, Inc.&#x2019;s initial product candidate, AVXS-101, is a proprietary gene therapy currently in development for the treatment of spinal muscular atrophy (SMA) type 1 &ndash; the leading genetic cause of infant mortality &ndash; and SMA types 2 and 3. In addition, AveXis, Inc. has a pipeline of other novel treatments for rare neurological diseases, including Rett syndrome (RTT) and a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &ndash; acquisition of Endocyte, Inc.</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On October 18, 2018, Novartis entered into an agreement and plan of merger with Endocyte, Inc. (Endocyte), a US-based biopharmaceutical company focused on developing targeted therapeutics for cancer treatment. The transaction was completed on December 21, 2018. Under the terms of the agreement, Novartis acquired all outstanding shares of Endocyte common stock for USD 24 per share. The total consideration amounted to USD 2.1 billion. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was USD 2.1 billion. The purchase price allocation resulted in net identifiable assets of approximately USD 1.5 billion, consisting of USD 1.5 billion intangible assets, USD 0.3 billion net deferred tax liabilities and other net assets of USD 0.3 billion, and goodwill of approximately USD 0.6 billion. The purchase price allocation was preliminary at December 31, 2018, as the transaction closed on December 21, 2018, which was close to the Group&#x2019;s year-end and therefore did not provide sufficient time to complete the valuation of the intangible assets, deferred taxes, assumed liabilities and goodwill. During 2019, there were no significant revisions to the purchase price allocation. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Endocyte uses drug conjugation technology to develop targeted therapies with companion imaging agents, including 177Lu-PSMA-617, a potential first-in-class investigational radioligand therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC). </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Corporate &ndash; divestment of 36.5% stake in GlaxoSmithKline Consumer Healthcare Holdings Ltd. </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On March 27, 2018, Novartis entered into an agreement with GlaxoSmithKline plc (GSK) to divest its 36.5% stake in GlaxoSmithKline Consumer Healthcare Holdings Ltd. to GSK for USD 13.0 billion in cash. As a result, Novartis discontinued the use of equity method accounting starting from April 1, 2018. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">On June 1, 2018, the transaction closed and Novartis realized a pre-tax gain of USD 5.8 billion, recorded in income from associated companies. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">For significant transactions in 2019 for discontinued operations, see Note 30. There were no significant transactions in 2020 for discontinued operations. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfSignificantTransactionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfSignificantTransactionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326025832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">Segmentation of key figures</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">3. Segmentation of key figures 2020, 2019 and 2018</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The businesses of Novartis are divided operationally on a worldwide basis into two identified reporting segments: Innovative Medicines and Sandoz. In addition, we separately report Corporate activities. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Reporting segments are presented in a manner consistent with the internal reporting to the chief operating decision-maker, which is the Executive Committee of Novartis. The reporting segments are managed separately because they each research, develop, manufacture, distribute and sell distinct products that require differing marketing strategies. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Executive Committee of Novartis is responsible for allocating resources and assessing the performance of the reporting segments. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The reporting segments are as follows:</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines. The Innovative Medicines Division is organized into two global business units: Novartis Oncology and Novartis Pharmaceuticals. Novartis Oncology consists of the global business franchise Oncology, and Novartis Pharmaceuticals consists of the global business franchises Immunology, Hepatology and Dermatology; Ophthalmology; Neuroscience; Cardiovascular, Renal and Metabolism; Respiratory; and Established Medicines. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Sandoz develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. Sandoz is organized globally into three franchises: Retail Generics, Anti-Infectives and Biopharmaceuticals. In Retail Generics, Sandoz develops, manufactures and markets active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a broad range of therapeutic areas, as well as finished dosage form of anti-infectives sold to third parties. In Anti-Infectives, Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by Retail Generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products, including biosimilars, and provides biotechnology manufacturing services to other companies. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Income and expenses relating to Corporate include the costs of the Group headquarters and those of corporate coordination functions in major countries. In addition, Corporate includes other items of income and expense that are not attributable to specific segments, such as certain revenues from intellectual property rights, certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations and sponsorships. Usually, no allocation of Corporate items is made to the segments. As a result, Corporate assets and liabilities principally consist of net liquidity (cash and cash equivalents, marketable securities less financial debts), investments in associated companies, and current and deferred taxes and non-segment-specific environmental remediation and post-employment benefit liabilities. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Our divisions are supported by the Novartis Institutes for BioMedical Research, Global Drug Development, Novartis Technical Operations and Novartis Business Services organizations. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Novartis Institutes for BioMedical Research (NIBR) conducts research activities for the Innovative Medicines Division and also collaborates with Sandoz. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Global Drug Development organization oversees all drug development activities for our Innovative Medicines Division and collaborates with our Sandoz Division on the development of its biosimilars portfolio. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Novartis Technical Operations organization manages our manufacturing operations across our Innovative Medicines and Sandoz Divisions. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Novartis Business Services (NBS) is our shared services organization that delivers business support services across the Group, such as information technology, real estate and facility services, procurement, product lifecycle services, human resources, and financial reporting and accounting operations. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Following the February 28, 2019, shareholders&#x2019; approval of the spin-off of the Alcon business (refer to Notes 1, 2 and 30 for further details), the Group reported its consolidated financial statements as &#x201c;continuing operations&#x201d; and &#x201c;discontinued operations.&#x201d; </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Continuing operations comprise the activities of the Innovative Medicines and Sandoz Divisions, and the continuing Corporate activities. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Discontinued operations include the operational results from the Alcon eye care devices business and certain corporate activities attributable to the Alcon business prior to the spin-off, the gain on distribution of Alcon Inc. to Novartis AG shareholders, and certain other expenses related to the Distribution (refer to Notes 1, 2 and 30 for further details). </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The accounting policies mentioned in Note 1 are used in the reporting of segment results. Inter-segmental sales are made at amounts that are considered to approximate arm&#x2019;s length transactions. The Executive Committee of Novartis evaluates segmental performance and allocates resources among the segments based on a number of measures, including net sales, operating income and net operating assets. Segment net operating assets consist primarily of property, plant and equipment; right-of-use assets; intangible assets; goodwill; inventories; and trade and other operating receivables less operating liabilities. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Segmentation &ndash; consolidated income statements</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate (including eliminations)</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from continuing operations</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 39&nbsp;013</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37&nbsp;714</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;646</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;731</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48&nbsp;659</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;445</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to continuing and discontinued segments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 792</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 783</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 189</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;981</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;871</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 39&nbsp;805</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 38&nbsp;497</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;835</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;872</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;981</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;871</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48&nbsp;659</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;498</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;092</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 53</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 63</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 168</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;239</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;179</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10&nbsp;927</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10&nbsp;050</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5&nbsp;252</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;334</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;058</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 959</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15&nbsp;121</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14&nbsp;425</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&nbsp;896</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 29&nbsp;539</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;636</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;601</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 245</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 112</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 34&nbsp;777</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;252</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11&nbsp;657</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11&nbsp;617</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;076</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;218</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;464</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;534</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14&nbsp;197</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14&nbsp;369</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8&nbsp;118</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8&nbsp;152</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;862</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8&nbsp;980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9&nbsp;402</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 922</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;586</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 176</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 167</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 644</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 278</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;742</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;031</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;871</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;069</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;831</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;749</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;488</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;608</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;190</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;426</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;172</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;287</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;043</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 551</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;63</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;752</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&nbsp;152</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;086</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 670</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 656</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 673</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 659</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;869</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;850</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;78</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 45</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;878</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;940</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;807</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;793</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;071</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;147</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net loss from discontinued operations before gain on <br></br>distribution of Alcon Inc. to Novartis AG shareholders </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;101 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;691</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;590</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;071</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;737</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Shareholders of Novartis AG</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 8&nbsp;072</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 11&nbsp;732</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Non-controlling interests</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net income from continuing operations are:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 91</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 245</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of property, plant and equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;912</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;952</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;282</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;283</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;110</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;318</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;345</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of right-of-use assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;273</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;247</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;41</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;41</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;330</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;305</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;080</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;509</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;370</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;315</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;462</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;836</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on property, plant and equipment, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;324</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;116</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;101</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;440</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;202</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on intangible assets, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;768</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;632</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;506</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;914</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;138</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges and fair value <br></br>changes on financial assets, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 153 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 18 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 182 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 20 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 335 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 38 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to restructuring provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;217</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;229</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;98</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;165</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;98</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;354</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;492</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation of Novartis equity plans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;714</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;761</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;64</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;67</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;180</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;239</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;958</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;067</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate (including eliminations)</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from continuing operations</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37&nbsp;714</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;892</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;731</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;859</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;445</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 44&nbsp;751</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to continuing and discontinued segments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 783</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 741</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 177</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;871</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;836</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 82</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 38&nbsp;497</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 35&nbsp;633</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;872</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&nbsp;036</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;871</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;836</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;498</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 44&nbsp;833</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;092</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 63</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 62</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;179</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;266</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10&nbsp;050</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9&nbsp;870</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;334</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;530</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 959</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 890</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14&nbsp;425</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14&nbsp;510</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 29&nbsp;539</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&nbsp;951</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;601</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;568</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 112</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 70</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;252</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31&nbsp;589</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11&nbsp;617</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10&nbsp;907</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;218</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;305</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;534</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;505</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14&nbsp;369</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;13&nbsp;717</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8&nbsp;152</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;7&nbsp;675</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;814</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9&nbsp;402</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8&nbsp;489</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;586</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 977</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 167</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 505</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 278</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 147</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;031</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;629</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;069</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;475</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;749</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;622</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;608</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;512</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;426</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;609</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;287</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;871</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 551</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;332</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;752</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;800</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;086</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;403</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 656</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;432</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 659</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;438</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;850</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;932</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 45</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 186</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;940</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;095</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;793</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;295</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;147</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;800</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net loss from discontinued operations before gain on <br></br>distribution of Alcon Inc. to Novartis AG shareholders </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;101 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;186 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;691</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income/(loss) from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;590</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;186</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;737</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;614</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Shareholders of Novartis AG</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 11&nbsp;732</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 12&nbsp;611</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Non-controlling interests</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net income from continuing operations are:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 245</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 292</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of property, plant and equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;952</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;075</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;283</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;285</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;110</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;122</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;345</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;482</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of right-of-use assets <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;247</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;41</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;305</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;509</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;214</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;315</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;366</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;836</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;587</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on property, plant and equipment, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;239</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;101</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;60</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;202</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;301</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on intangible assets, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;632</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;592</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;506</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;249</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;138</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;841</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges and fair value <br></br>changes on financial assets, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 18 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 107 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 20 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;113 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 38 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;6 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to restructuring provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;229</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;395</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;165</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;98</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;94</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;492</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;521</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation of Novartis equity plans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;761</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;645</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;67</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;53</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;239</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;220</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;067</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;918</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Depreciation of right-of-use assets recognized from January 1, 2019, the date of implementation of IFRS 16 Leases. Note 1 provides additional disclosures. </div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Segmentation &ndash; consolidated balance sheets</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate (including eliminations)</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 83&nbsp;112</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71&nbsp;225</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&nbsp;825</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&nbsp;468</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 32&nbsp;122</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 30&nbsp;677</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 132&nbsp;059</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 118&nbsp;370</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liabilities</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;15&nbsp;472</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;15&nbsp;332</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;786</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;804</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;56&nbsp;135</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;43&nbsp;683</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;75&nbsp;393</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;62&nbsp;819</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 56&nbsp;666</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;551</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net debt <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24&nbsp;481</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&nbsp;938</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24&nbsp;481</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&nbsp;938</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net operating assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 67&nbsp;640</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;893</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;039</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;664</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 468</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;932</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 81&nbsp;147</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71&nbsp;489</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in assets and liabilities are:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total property, plant and equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;863</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;632</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;849</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;888</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 551</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 549</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&nbsp;263</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;069</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to property, plant <br></br>and equipment <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 926 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;114 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 229 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 217 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 110 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 143 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;265 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;474 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total right-of-use assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;489</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;487</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 133</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 136</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 54</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 54</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;676</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;677</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to right-of-use assets <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 264</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 454</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 67</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 49</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 346</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 537</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total goodwill and intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 56&nbsp;839</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 46&nbsp;336</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;817</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;892</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 152</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 83</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 66&nbsp;808</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 55&nbsp;311</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to goodwill and <br></br>intangible assets <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;235 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 647 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 105 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 68 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 85 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 52 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;425 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 767 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total investment in associated <br></br>companies </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 194 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 128 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 8 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 7 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 9&nbsp;430 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 8&nbsp;509 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 9&nbsp;632 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 8&nbsp;644 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to investment in associated <br></br>companies </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 24 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 44 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 7 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 11 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 31 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 55 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents, marketable securities, <br></br>commodities, time deposits and derivative <br></br>financial instruments </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 11&nbsp;563 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 11&nbsp;446 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 11&nbsp;563 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 11&nbsp;446 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debts and derivative <br></br>financial instruments </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 36&nbsp;044 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 27&nbsp;384 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 36&nbsp;044 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 27&nbsp;384 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current income tax and deferred tax liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;880</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;061</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;880</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;061</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Note 29 provides additional disclosures related to net debt </div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Excluding the impact of business acquisitions </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows countries that accounted for more than 5% of at least one of the respective Group totals, as well as regional information for net sales to third parties for the years ended December 31, 2020, 2019 and 2018, and for selected non-current assets for the years ended December 31, 2020 and 2019: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="11" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net sales<sup>1</sup></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total of selected non-current assets<sup>2</sup></div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="11" height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="11" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="11" height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div> </td> <td></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Country</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 800</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 848</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 795</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34&nbsp;904</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33&nbsp;032</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 43</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&nbsp;484</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16&nbsp;280</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14&nbsp;618</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39&nbsp;889</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28&nbsp;893</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">France</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;442</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;442</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;505</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;115</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;933</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Germany</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;518</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;120</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;972</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;607</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;554</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japan</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;804</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;656</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;575</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 313</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 309</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">China</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;573</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;214</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;953</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 714</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 684</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19&nbsp;038</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&nbsp;885</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&nbsp;333</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 40</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;837</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;296</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48&nbsp;659</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;445</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 44&nbsp;751</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 90&nbsp;379</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 77&nbsp;701</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Region</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18&nbsp;715</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;933</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;259</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 47&nbsp;798</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 53</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 46&nbsp;103</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 59</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Americas</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19&nbsp;725</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 41</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19&nbsp;713</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 41</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&nbsp;032</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40&nbsp;391</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 45</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 29&nbsp;389</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 38</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&nbsp;219</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;799</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;460</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;190</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;209</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48&nbsp;659</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;445</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 44&nbsp;751</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 90&nbsp;379</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 77&nbsp;701</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Net sales to third party from continuing operations by location of customer </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Total of property, plant and equipment; right-of-use assets; goodwill; intangible assets and investment in associated companies </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s largest, second-largest and third-largest customers account for approximately 17%, 11% and 6% of net sales, respectively (2019: 18%, 13% and 8%, respectively; 2018: 18%, 14% and 8%, respectively). All segments had sales to these customers in 2020, 2019 and 2018. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The highest amounts of trade receivables outstanding were for these same three customers and amounted to approximately 14%, 12% and 6%, respectively, of the trade receivables at December 31, 2020 (2019: 14%, 12% and 7%, respectively). </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Segmentation &ndash; Net sales by region <sup>1</sup> </font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> 2020 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> 2019 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change <br></br> (2019 <br></br> to 2020) <br></br> USD % </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> 2018 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change <br></br> (2018 <br></br> to 2019) <br></br> USD % </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&nbsp;484</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;818</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;296</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&nbsp;342</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13&nbsp;789</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;864</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;718</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;458</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;097</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;469</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;649</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;635</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 39&nbsp;013</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37&nbsp;714</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;892</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29&nbsp;643</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28&nbsp;573</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26&nbsp;258</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;370</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;634</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;231</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;115</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;963</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;142</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;491</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;754</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;501</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;341</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;363</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 772</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 784</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 779</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;646</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;731</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;859</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;089</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;111</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;557</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;620</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;626</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18&nbsp;715</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;933</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;259</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&nbsp;484</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16&nbsp;280</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14&nbsp;618</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&nbsp;219</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;799</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;460</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;241</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;433</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;414</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48&nbsp;659</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;445</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 44&nbsp;751</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36&nbsp;732</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35&nbsp;684</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33&nbsp;491</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&nbsp;927</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;761</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;260</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Net sales to third parties from continuing operations by location of customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand. </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines Division net sales by business franchise</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> 2020 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> 2019 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change <br></br> (2019 to <br></br> 2020) <br></br> USD % </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> 2018 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change <br></br> (2018 to <br></br> 2019) <br></br> USD % </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Oncology</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;958</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;880</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;874</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;738</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;416</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;174</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Tafinlar</i> + <i>Mekinist</i></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;542</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;338</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;155</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;439</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;585</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;587</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;339</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;114</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 977</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;263</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;561</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;19</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;083</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;539</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;556</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 687</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 480</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 235</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 104</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 653</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 975</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;099</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 635</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 755</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 828</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 474</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 278</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 71</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lutathera</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 445</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 441</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 167</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 164</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Piqray</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 320</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 116</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 176</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Adakveo</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 105</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tabrecta</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 35</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;070</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;189</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;139</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Novartis Oncology business unit</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;711</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;370</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;428</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Immunology, Hepatology and Dermatology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;995</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;551</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;837</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 873</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 671</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 554</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Immunology, Hepatology and Dermatology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;868</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;222</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;392</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ophthalmology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;933</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;086</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;046</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xiidra</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 376</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 192</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 96</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Beovu</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 190</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;911</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;463</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;995</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Ophthalmology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;410</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;776</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;558</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Neuroscience</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;003</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;223</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;341</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 920</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 361</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 155</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Mayzent</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 170</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Aimovig</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 164</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 103</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 59</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 51</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 60</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 80</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Neuroscience</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;323</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;773</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;429</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> 2020 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> 2019 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change <br></br> (2019 to <br></br> 2020) <br></br> USD % </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> 2018 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change <br></br> (2018 to <br></br> 2019) <br></br> USD % </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cardiovascular, Renal and Metabolism</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;497</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;726</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 45</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;028</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 68</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;96</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Cardiovascular, Renal and Metabolism</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;498</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;750</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;050</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 67</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Respiratory</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;251</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;173</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;039</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Ultibro</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 623</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 630</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 703</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Respiratory</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;900</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;825</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;767</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Established Medicines</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Galvus</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;199</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;297</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;284</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Diovan</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;003</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;064</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;023</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exforge</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;025</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;002</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zortress/Certican</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 452</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 485</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 464</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Neoral/Sandimmun(e)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 393</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 419</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 463</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Voltaren/Cataflam</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 360</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 417</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 445</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;916</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;291</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;587</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Established Medicines</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;303</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;998</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;268</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Novartis Pharmaceuticals business unit</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 24&nbsp;302</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;344</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 21&nbsp;464</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 39&nbsp;013</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37&nbsp;714</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;892</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Net sales reflect <i>Xolair</i> sales for all indications. </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Top 20 Innovative Medicines Division product net sales &ndash; 2020</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>Brands </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> Business franchise </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> Key indication </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> US <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of <br></br> world <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> Total <br></br> USD m </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td width="21%" height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Cosentyx </div> </td> <td align="right" width="1%"></td> <td width="21%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> Immunology, Hepatology <br></br> and Dermatology </div> </td> <td align="right" width="1%"></td> <td width="21%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis, ankylosing <br></br> spondylitis, psoriatic <br></br> arthritis and <br></br> non-radiographic axial <br></br> spondyloarthritis </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 2&nbsp;516 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 1&nbsp;479 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 3&nbsp;995 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;562</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;441</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;003</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Entresto </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, Renal <br></br> and Metabolism </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Chronic heart failure </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;277 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;220 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 2&nbsp;497 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 859</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;099</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;958</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular degeneration</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;933</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;933</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Promacta/Revolade </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune thrombocytopenia (ITP), <br></br> severe aplastic anemia (SAA) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 833 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 905 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 1&nbsp;738 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br><i>Tafinlar</i> + <i>Mekinist</i> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic and <br></br> adjuvant melanoma; advanced <br></br> non-small cell lung cancer (NSCLC) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 569 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 973 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> <br></br> 1&nbsp;542 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors and acromegaly</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 837</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 602</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;439</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Jakavi </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF), <br></br> polycythemia vera (PV) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;339 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 1&nbsp;339 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Xolair <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Respiratory </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA) <br></br> and chronic spontaneous urticaria <br></br> (CSU) and nasal polyps </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 1&nbsp;251 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> <br></br> 1&nbsp;251 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Galvus</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;199</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;199</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia and GIST</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 315</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 873</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;188</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/TSC</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 644</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 439</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;083</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Diovan</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 879</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;003</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exforge</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 964</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 980</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy (SMA)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 459</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 461</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 920</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Ilaris </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Immunology, Hepatology <br></br> and Dermatology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS, <br></br> TRAPS, HIDS/MKD, FMF, SJIA, <br></br> AOSD and gout) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 400 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 473 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> <br></br> 873 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2- metastatic breast cancer</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 318</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 369</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 687</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic iron overload</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 138</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 515</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 653</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Renal cell carcinoma</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 259</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 376</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 635</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;126</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&nbsp;790</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&nbsp;916</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;216</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;881</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;097</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division sales</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;342</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 24&nbsp;671</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 39&nbsp;013</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Net sales reflect <i>Xolair</i> sales for all indications. </div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Top 20 Innovative Medicines Division product net sales &ndash; 2019</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>Brands </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> Business franchise </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> Key indication </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> US <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rest of <br></br> world <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> <br></br> Total <br></br> USD m </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td width="21%" height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Cosentyx </div> </td> <td align="right" width="1%"></td> <td width="21%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, Hepatology <br></br> and Dermatology </div> </td> <td align="right" width="1%"></td> <td width="21%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis, ankylosing <br></br> spondylitis and psoriatic arthritis </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 2&nbsp;220 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;331 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 3&nbsp;551 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;736</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;487</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;223</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular degeneration</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;086</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;086</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 804</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;076</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;880</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Entresto </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, Renal <br></br> and Metabolism </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Chronic heart failure </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 925 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 801 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 1&nbsp;726 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors and acromegaly</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 881</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 704</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;585</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/TSC</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;003</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 536</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;539</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Promacta/Revolade </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune thrombocytopenia (ITP), <br></br> severe aplastic anemia (SAA) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 691 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 725 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 1&nbsp;416 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br><i>Tafinlar</i> + <i>Mekinist</i> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic and <br></br> adjuvant melanoma; advanced <br></br> non-small cell lung cancer (NSCLC) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 481 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 857 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> <br></br> 1&nbsp;338 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Galvus</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;297</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;297</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia and GIST</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 334</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 929</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;263</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Xolair <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Respiratory </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA) <br></br> and chronic spontaneous urticaria <br></br> (CSU) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 1&nbsp;173 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> <br></br> 1&nbsp;173 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Jakavi </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF), <br></br> polycythemia vera (PV) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;114 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 1&nbsp;114 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Diovan</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 86</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 978</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;064</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exforge</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;012</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;025</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic iron overload</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 450</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 525</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 975</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Renal cell carcinoma</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 332</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 423</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 755</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Ilaris </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Immunology, Hepatology <br></br> and Dermatology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS, <br></br> TRAPS, HIDS/MKD, FMF, SJIA, <br></br> AOSD and gout) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 304 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 367 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> <br></br> 671 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zortress/Certican</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Transplantation</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 169</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 316</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 485</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2- metastatic breast cancer</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 230</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 480</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&nbsp;679</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 17&nbsp;967</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 28&nbsp;646</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;110</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;958</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;068</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division sales</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;789</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;925</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37&nbsp;714</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Net sales reflect <i>Xolair</i> sales for all indications. </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> </table> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Top 20 Innovative Medicines Division product net sales &ndash; 2018</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>Brands </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> Business franchise </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> Key indication </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> US <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rest of <br></br> world <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> <br></br> Total <br></br> USD m </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td width="21%" height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div> </td> <td align="right" width="1%"></td> <td width="21%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div> </td> <td align="right" width="1%"></td> <td width="21%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;765</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;576</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;341</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Cosentyx </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, Hepatology <br></br> and Dermatology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis, ankylosing <br></br> spondylitis and psoriatic arthritis </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;674 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;163 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 2&nbsp;837 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular degeneration</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;046</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;046</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 806</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;068</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;874</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors and acromegaly</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 817</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 770</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;587</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia and GIST</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 440</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;121</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;561</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/TSC</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 929</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 627</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;556</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Galvus</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;284</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;284</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Promacta/Revolade </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune thrombocytopenia (ITP), <br></br> severe aplastic anemia (SAA) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 581 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 593 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 1&nbsp;174 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br><i>Tafinlar</i> + <i>Mekinist</i> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic and <br></br> adjuvant melanoma; advanced <br></br> non-small cell lung cancer (NSCLC) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 457 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 698 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> <br></br> 1&nbsp;155 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic iron overload</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 521</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 578</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;099</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Xolair <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Respiratory </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA) <br></br> and chronic spontaneous urticaria <br></br> (CSU) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 1&nbsp;039 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> <br></br> 1&nbsp;039 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Entresto </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, Renal <br></br> and Metabolism </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Chronic heart failure </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 556 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 472 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 1&nbsp;028 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Diovan</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 84</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 939</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;023</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exforge</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 983</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;002</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Jakavi </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF), <br></br> polycythemia vera (PV) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 977 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 977 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Renal cell carcinoma</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 404</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 424</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 828</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Ilaris </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Immunology, Hepatology <br></br> and Dermatology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS, <br></br> TRAPS, HIDS/MKD, FMF, SJIA, <br></br> AOSD and gout) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 262 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 292 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> <br></br> 554 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br>Travoprost Group </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Ophthalmology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Reduction of elevated intraocular <br></br> pressure </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 194 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 323 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 517 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zortress/Certican</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Transplantation</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 145</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 319</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 464</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;654</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 17&nbsp;292</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&nbsp;946</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;210</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;736</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;946</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division sales</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;864</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;028</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;892</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Net sales reflect <i>Xolair</i> sales for all indications. </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> </table> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz Division net sales by business franchise</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> 2020 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> 2019 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change <br></br> (2019 to <br></br> 2020) <br></br> USD % </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> 2018 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change <br></br> (2018 to <br></br> 2019) <br></br> USD % </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Retail Generics <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;244</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;590</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;880</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Biopharmaceuticals</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;928</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;607</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;436</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Anti-Infectives</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 474</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 534</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 543</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;646</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;731</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;859</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Of which USD 694 million (2019: USD 784 million; 2018: USD 826 million) represents anti-infectives sold under the Sandoz name </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The product portfolio of Sandoz is widely spread in 2020, 2019 and 2018.</div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Segmentation &ndash; other revenue</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate (including eliminations)</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Profit-sharing income</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 835</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 732</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 835</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 734</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Royalty income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 107</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 104</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 168</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 300</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 147</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Milestone income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 201</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 231</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 55</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 54</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 67</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other revenues</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;092</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 53</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 63</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 168</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;239</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;179</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales. </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Innovative Medicines </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Sandoz </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Corporate (including eliminations)</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Group </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Profit-sharing income</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 732</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 874</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 734</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 877</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Royalty income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 104</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 162</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 147</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 188</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Milestone income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 201</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 128</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 45</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 231</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 173</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 55</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 67</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other revenues</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;092</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 63</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 62</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;179</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;266</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326178728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Associated companies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract', window );"><strong>Disclosure of associates [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory', window );">Associated companies</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">4. Associated companies</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net income statement effect</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other comprehensive income effect</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total comprehensive income effect</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018 <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Roche Holding AG, Switzerland</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 677</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 662</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 526</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;56</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;94</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 75</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 621</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 568</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 601</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">GlaxoSmithKline Consumer <br></br>Healthcare Holdings Ltd., UK </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 5&nbsp;910 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;557 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 5&nbsp;353 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies related to continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 673</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 659</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;438</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;56</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;94</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;482</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 617</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 565</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;956</div> </td> <td align="right"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="20"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="20"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> In 2018, Novartis share of other comprehensive income recognized by associated companies, net of taxes of USD 511 million was recycled into the consolidated income statement as a result of the divestment of the investment in GSK Consumer Healthcare Holdings Ltd. No Novartis share of other comprehensive income recognized by associated companies, net of taxes was recycled into the consolidated income statement in 2020 and 2019. <b></b> <b></b> </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has a significant investment in Roche Holding AG, Basel (Roche), as well as certain other smaller investments that are accounted for as associated companies. The investment in GlaxoSmithKline Consumer Healthcare Holdings Ltd., Brentford, Middlesex, UK, was divested on June 1, 2018, to GlaxoSmithKline plc, Great Britain. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Balance sheet value</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> December 31, <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31, <br></br> 2019 </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Roche Holding AG, Switzerland</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;407</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;445</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 225</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 199</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;632</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;644</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Roche Holding AG </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s holding in Roche voting shares was 33.3% at December 31, 2020, 2019 and 2018. This investment represents approximately 6.2% of Roche&#x2019;s total outstanding voting and non-voting equity instruments at December 31, 2020, 2019 and 2018. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Since full-year 2020 financial data for Roche is not available when Novartis produces its consolidated financial results, a survey of analyst estimates is used to estimate the Group&#x2019;s share of Roche&#x2019;s net income. Any differences between these estimates and actual results will be adjusted in the Group&#x2019;s 2021 consolidated financial statements when available. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following tables show summarized financial information for Roche, including current values of fair value adjustments made at the time of the acquisition of the shares, for the year ended December 31, 2019, and for the six months ended June 30, 2020 (since full-year 2020 data is not yet available): </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(CHF billions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Current assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-current <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Current <br></br> liabilities </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-current <br></br> liabilities </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">December 31, 2019</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31.3</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 56.4</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24.1</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23.1</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">June 30, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 55.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(CHF billions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Revenue </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Net income </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other <br></br> comprehen- <br></br> sive income </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br></br> comprehen- <br></br> sive income </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">December 31, 2019</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 63.8</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12.3</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.9</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11.4</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">June 30, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;0.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">A purchase price allocation was performed on the basis of publicly available information at the time of acquisition of the investment. The December 31, 2020, balance sheet value allocation is as follows: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> December 31, <br></br> 2020 </div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of Roche&#x2019;s estimated net assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;585</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of reappraised intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 117</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Implicit Novartis goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;233</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current value of share in net identifiable assets <br></br>and goodwill </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 5&nbsp;935 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated equity accounting adjustments and translation effects less dividends received</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;472</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance sheet value</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;407</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The identified intangible assets principally relate to the value of currently marketed products and are amortized on a straight-line basis over their estimated average useful life of 20 years. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2020, dividends received from Roche in relation to the distribution of its 2019 net income amounted to USD&nbsp;487 million (2019: USD 460 million in relation to the distribution of its 2018 net income). </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consolidated income statement effects from applying Novartis accounting principles for this investment in 2020, 2019 and 2018 are as follows: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of Roche's <br></br>estimated current-year <br></br>consolidated net income </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 913 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 910 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 799 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prior-year adjustment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;64</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;129</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;125</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of fair value <br></br>adjustments relating to <br></br>intangible assets, net of taxes <br></br>of USD 26 million (2019: USD 24 <br></br>million; 2018: USD 40 million) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> &#x2013;&#x2005;172 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> <br></br> <br></br> &#x2013;&#x2005;162 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> <br></br> <br></br> &#x2013;&#x2005;148 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Partial release of deferred tax liability recognized</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income effect</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 677</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 662</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 526</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The publicly quoted market value of the Novartis interest in Roche (SIX symbol: RO) at December&nbsp;31, 2020, was USD&nbsp;18.8 billion (2019: USD&nbsp;16.9 billion). </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">GlaxoSmithKline Consumer Healthcare Holdings&nbsp;Ltd.</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On March 27, 2018, Novartis entered into an agreement with GlaxoSmithKline plc, Great Britain (GSK), to divest its 36.5% stake in GSK Consumer Healthcare Holdings Ltd. (GSK Consumer Healthcare) to GSK for USD 13.0 billion in cash. As a result, Novartis discontinued the use of equity method accounting starting from April 1, 2018. The divestment transaction closed on June 1, 2018, and Novartis realized a pre-tax gain of USD 5.8 billion, recorded in income from associated companies. See Note 2. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">GSK Consumer Healthcare was formed in March 2015 via contribution of businesses from both Novartis and GSK. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Until June 1, 2018, Novartis had a 36.5% interest in GSK Consumer Healthcare and had four of 11 seats on the GSK Consumer Healthcare board of directors. Furthermore, Novartis had customary minority rights as well as exit rights at a predefined, market-based pricing mechanism. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consolidated income statement effects from applying Novartis accounting principles for this investment in 2018 are as follows: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of <br></br>GSK Consumer Healthcare's <br></br>estimated current-year <br></br>consolidated net income </div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> <br></br> 119 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prior-year adjustment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of fair value <br></br>adjustments relating to <br></br>intangible assets and inventory, <br></br>net of taxes of USD 1 million </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> <br></br> &#x2013;&#x2005;3 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Pre-tax gain on divestment of GSK Consumer Healthcare</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;790</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income effect</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;910</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326384504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest expense and other financial income and expense<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract', window );"><strong>Disclosure of Interest Expense and Other Financial Income and Expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInterestExpenseExplanatory', window );">Interest expense and other financial income and expense</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">5. Interest expense and&nbsp;other&nbsp;financial&nbsp;income&nbsp;and&nbsp;expense</div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest expense</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;708</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;714</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;877</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense on lease liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;67</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;66</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense arising from discounting long-term liabilities and capitalized borrowing costs</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;94</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;70</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;55</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total interest expense from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;869</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;850</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;932</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other financial income and expense</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 91</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 245</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 292</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;52</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;52</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;39</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency result, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;135</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;160</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;68</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other financial income and expense from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;78</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 45</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 186</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInterestExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of interest expense. [Refer: Interest expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInterestExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904347048712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfIncomeTaxAbstract', window );"><strong>Disclosure of IncomeTax [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Taxes</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">6. Taxes</div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Income before taxes</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;786</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;097</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;887</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 92</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 843</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;208</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;878</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;940</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;095</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Current and deferred income tax expense</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;932</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;186</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;615</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;168</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;961</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;988</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current income tax expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2&nbsp;100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;2&nbsp;147</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;603</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;137</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;93</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;120</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 430</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 447</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 428</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Deferred tax income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 293</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 354</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 308</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income tax expense from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;807</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;793</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;295</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Analysis of tax rate</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has a substantial business presence in many countries and is therefore subject to different income and expense items that are non-taxable (permanent differences) or are taxed at different rates in those tax jurisdictions. This results in a difference between our applicable tax rate and effective tax rate. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The main elements contributing to the difference between the Group&#x2019;s overall applicable tax rate (which can change each year since it is calculated as the weighted average tax rate based on the pre-tax income of each subsidiary) and the effective tax rate are shown in the following table: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(As a percentage)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Applicable tax rate</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13.6</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11.7</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14.3</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of disallowed expenditures</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of utilization of tax losses <br></br>brought forward from prior periods </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;0.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;0.1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;0.1 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of income taxed at reduced rates</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;0.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of income not subject to tax <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;0.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3.7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of tax credits and allowances</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2.3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of release of <br></br>contingent consideration liability </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;0.2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;0.5 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;0.2 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of tax rate change <br></br>on current and deferred <br></br>tax assets and liabilities <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 0.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &#x2013;&#x2005;1.4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &#x2013;&#x2005;0.1 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of write-off of deferred tax assets <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of write-down and reversal of <br></br>write-down of investments in subsidiaries </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;0.8 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;0.6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 0.0 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of prior-year items</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of other items <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Effective tax rate for continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9.2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <b> </b> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Included in 2018 is the effect of income not subject to tax (-3.7%) arising from the portion of the non-taxable gain on the divestment of the Group's investment in GSK Consumer Healthcare Holdings Ltd. attributable to Switzerland. <b> </b> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> 2019 is mainly related to the revaluation of the deferred tax assets and liabilities resulting from the tax reforms enacted in Switzerland in 2019. Refer to Note 12 for additional disclosures. <b> </b> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> 2019 is primarily related to a non-cash, one-time deferred tax expense for the write-off of a deferred tax asset resulting from legal entity reorganizations. <b> </b> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;4&nbsp;</sup> In 2020, other items (+1.9%) include changes in uncertain tax positions (+2.0%) and other items (-0.1%). <br></br> In 2019, other items (+3.0%) include changes in uncertain tax positions (+2.6%) and other items (+0.4%). </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The utilization of tax-loss carry-forwards lowered the tax charge by USD&nbsp;29 million in 2020, by USD&nbsp;11 million in 2019, and by USD&nbsp;19 million in 2018.</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For the amount of taxes attributable to discontinued operations, see Note 30.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfIncomeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfIncomeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326344984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Earnings per share</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">7. Earnings per share</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income attributable to shareholders of Novartis AG (USD millions)</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;072</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;142</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;797</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;590</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;186</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;072</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;732</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;611</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Number of shares (in millions)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Weighted average number of shares outstanding used in basic earnings per share</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;277</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;291</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;319</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Weighted average number of shares in diluted earnings per share</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;296</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;319</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;344</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic earnings per share (USD)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.55</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.52</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.00</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.08</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.55</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.44</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Diluted earnings per share (USD)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.52</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.08</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.46</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.98</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.08</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.52</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.06</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.38</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Basic earnings per share (EPS) is calculated by dividing net income attributable to shareholders of Novartis AG by the weighted average number of shares outstanding in a reporting period. This calculation excludes the average number of issued shares purchased by the Group and held as treasury shares. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For diluted EPS, the weighted average number of shares outstanding is adjusted to assume the vesting of all restricted shares, restricted share units, and the conversion of all potentially dilutive shares arising from options on Novartis shares that have been issued. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">No options were excluded from the calculation of diluted EPS in 2020, 2019 or 2018, as all options were dilutive in all years. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904325110744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Changes in consolidated statements of comprehensive income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAbstract', window );"><strong>Comprehensive income [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock', window );">Changes in consolidated statements of comprehensive income</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">8. Changes in consolidated statements of&nbsp;comprehensive income</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated statements of comprehensive income include the Group&#x2019;s net income for the year as well as all other valuation adjustments recorded in the Group&#x2019;s consolidated balance sheet which under IFRS are not recorded in the consolidated income statement. These include fair value adjustments to financial instruments, actuarial gains or losses on defined benefit pension plans, and currency translation effects, net of tax. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> Note </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Fair value <br></br> adjustments <br></br> on financial <br></br> instruments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Actuarial <br></br> gains/(losses) <br></br> from defined <br></br> benefit plans </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Cumulative <br></br> currency <br></br> translation <br></br> effects </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total value <br></br> adjustments <br></br> attributable to <br></br> Novartis AG <br></br> shareholders </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Non- <br></br> controlling <br></br> interest </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total value <br></br> adjustments </div> </td> <td></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2017, as previously reported</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 395</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;5&nbsp;064</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 329</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;340</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;21</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;361</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of adoption of IFRS 9 on retained <br></br>earnings and OCI </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;177 </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;177 </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;177 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Restated value adjustments at January 1, 2018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 218</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;5&nbsp;064</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 329</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;517</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;538</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on deferred cash flow <br></br>hedges, net of taxes of USD -1 million </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 12 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 12 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 12 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, <br></br>net of taxes of USD -5 million <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 13 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 13 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 13 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 95</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 95</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 95</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes <br></br>of USD 69 million </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;359 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;359 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;359 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.1</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 320</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 320</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 315</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;359</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 415</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 81</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 76</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities sold, reclassified to retained earnings</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 227</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;5&nbsp;423</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 744</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;452</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;478</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on deferred cash <br></br>flow hedges </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on debt securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, <br></br>net of taxes of USD 47 million <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;47 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;47 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;47 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes <br></br>of USD -313 million <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;466 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;466 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;467 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.1</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 354</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 354</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 352</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;45</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;466</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 398</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;113</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;116</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities <br></br>sold, reclassified to retained earnings </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;95 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;95 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;95 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments related to divestments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;30</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 120</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;5&nbsp;919</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;142</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;4&nbsp;657</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;4&nbsp;686</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, <br></br>net of taxes of USD -36 million <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 250 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 250 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 250 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;201</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;201</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;201</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes <br></br>of USD -3 million </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 145 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 145 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 143 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.1</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;193</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;193</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;194</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 145</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;992</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;387</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;386</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities <br></br>sold, reclassified to retained earnings </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;150 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;150 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;150 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments related to divestments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 220</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;5&nbsp;773</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;134</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;419</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;448</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Includes fair value adjustments on equity securities designated as financial assets valued at fair value through other comprehensive income with no subsequent recycling into the <br></br>consolidated income statement </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Included in 2019 is a USD -358 million impact related to the revaluation of deferred tax assets on Swiss post-employment benefits that were previously recognized through other <br></br>comprehensive income. This revaluation resulted from the Swiss tax reforms enacted by the voters in 2019. Refer to Note 12 for additional disclosures. </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">8.1) In 2020, no currency translation losses or gains were recycled through the income statement. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2019, cumulative currency translation gains of USD&nbsp;129 million were recycled through the income statement mainly as a result of the spin-off of the Alcon business through a dividend in kind distribution to Novartis AG shareholders. See Notes 2 and 30. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2018, cumulative currency translation losses of USD&nbsp;946 million were recycled through the income statement as a result of the divestment of the investment in GSK Consumer Healthcare Holdings Ltd. See Notes 2 and 4. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326189784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">9. Property, plant and equipment</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of property, plant and equipment during 2020: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Land </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Buildings </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Construction <br></br> in progress </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Machinery <br></br> and other <br></br> equipment </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cost</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2020</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 512</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;463</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;350</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;674</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26&nbsp;999</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of assets reclassified out of assets of <br></br>disposal group held for sale <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 11 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 117 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 36 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 168 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 332 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 433</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;038</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 595</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 115</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 847</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 296</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;265</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;465</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;57</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;656</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;201</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 695</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 110</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 956</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;797</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 555</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12&nbsp;377</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;248</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;038</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28&nbsp;218</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Accumulated depreciation</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;5&nbsp;124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;60</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;9&nbsp;726</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;14&nbsp;930</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation on assets reclassified out of assets of <br></br>disposal group held for sale <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;58 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;101 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;163 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation on disposals and derecognitions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 433</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;543</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;004</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;491</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;827</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;318</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;228</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;447</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;373</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;731</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;108</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;5&nbsp;807</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;66</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;10&nbsp;063</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;15&nbsp;955</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 536</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;570</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;182</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;975</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12&nbsp;263</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for purchases of property, plant and equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 256</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Capitalized borrowing costs</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Note 2 provides additional disclosures related to the reclassification out of assets of the disposal group held for sale. </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Depreciation charge includes USD 38 million (USD 20 million for buildings and USD 18 million for machinery and other equipment), representing the cumulative amount of depreciation charge on the disposal group held for sale for property, plant and equipment from the date of classification to held for sale, September 2018, to March 31, 2020, the date of reclassification out of assets of disposal group held for sale. See Note 2 for further details. </div> </td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of property, plant and equipment during 2019: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Land </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Buildings </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Construction <br></br> in progress </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Machinery <br></br> and other <br></br> equipment </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cost</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2019</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 696</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;135</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;042</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 17&nbsp;155</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;028</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of assets related to discontinued operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;61</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;615</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;655</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;678</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;009</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification to right-of-use assets <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;122</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;127</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of assets related to disposal group held for sale <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 57</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 332</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 630</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 112</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;001</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 355</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;474</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;75</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;551</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;774</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;409</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 512</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;463</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;350</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;674</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&nbsp;999</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Accumulated depreciation</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;6&nbsp;328</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;11&nbsp;924</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;18&nbsp;332</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation on assets related to discontinued operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 562</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;541</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;118</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification to right-of-use assets <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation on assets related to disposal group held for sale <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation on disposals and derecognitions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;170</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;674</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;846</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;447</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;898</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;345</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge <sup style="white-space: nowrap">&nbsp;5</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;51</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;110</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;205</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;43</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;5&nbsp;124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;60</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;9&nbsp;726</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;14&nbsp;930</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 492</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;339</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;290</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;948</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;069</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for purchases of property, plant and equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 220</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Capitalized borrowing costs</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Represents the cost of assets and accumulated depreciation at January 1, 2019, related to the Alcon business reported as discontinued operations. Notes 1, 2 and 30 provide information related to discontinued operations. </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Reclassification to right-of-use assets at January 1, 2019, upon adoption of IFRS 16 Leases. Refer to Note 1 for additional disclosure. </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Note 2 provides additional disclosures related to disposal group held for sale. </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;4&nbsp;</sup> No depreciation charge in the disposal group held for sale for the period from January 1, 2019, to December 31, 2019, was recorded. </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;5&nbsp;</sup> Impairments in the disposal group held for sale for the period from January 1, 2019, to December 31, 2019, were USD 2 million. </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326079432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-use assets and lease liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract', window );"><strong>Lease liabilities and Right of use assets Disclosure Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Disclosure of leases [text block]</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">10. Right-of-use assets and lease liabilities</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of the right-of-use assets of continuing operations: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Right-of-use assets at January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;677</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;554</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 346</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 537</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;330</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;305</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease contract terminations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;63</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;98</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of divestments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;17</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 46</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total right-of-use assets at December 31 <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;676</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;677</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Lease contract terminations also includes modifications to existing leases that result in reductions to the right-of-use assets, and reductions due to sub-leasing. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> No impairment charge was recorded in 2020 (2019: nil). </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the right-of-use assets carrying value and depreciation charge of continuing operations at December 31, 2020 and 2019, by underlying class of asset: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> December 31, <br></br> 2020 <br></br> carrying value </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Depreciation <br></br> charge <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31, <br></br> 2019 <br></br> carrying value </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Depreciation <br></br> charge <br></br> 2019 </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Land</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 528</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 537</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buildings</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 963</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 207</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 990</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 194</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vehicles</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 155</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 129</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 87</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and equipment, and other assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total right-of-use assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;676</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 330</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;677</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 305</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the lease liabilities of continuing operations by maturity at December 31, 2020 and 2019: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Lease liabilities <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Lease liabilities <br></br> undiscounted <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Lease liabilities <br></br> 2019 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Lease liabilities <br></br> undiscounted <br></br> 2019 </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less than one year</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 286</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 338</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 246</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 295</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between one and two years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 229</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 274</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 202</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 246</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between two and three years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 186</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 226</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 163</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 202</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between three and four years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 148</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 183</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 138</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 173</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between four and five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 129</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 160</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 119</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 150</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;027</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;326</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;081</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;419</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total lease liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;005</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;507</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;949</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;485</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion of lease liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;286</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;338</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;246</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;295</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current portion of lease liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;719</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;169</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;703</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;190</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At December 31, 2020 and December 31, 2019, there were no material future cash outflows, including extension options, excluded from the measurement of lease liabilities. The Group&#x2019;s most material lease with a lease term extension, representing a lease liability value of USD 0.6 billion (2019: USD 0.6 billion), has a determined lease term end date of 2071 (2019: 2071). </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2019, the Group completed sale and leaseback transactions for certain property, plant and equipment as part of its plans to consolidate sites. Transactions resulted in net cash inflows of USD 0.7 billion and the recognition of USD 96 million of lease liabilities, and USD 37 million of right-of-use assets. The right-of-use assets value reflects the proportion of the property, plant and equipment retained for a period of one to five years, with two five-year extension periods for certain right-of-use assets. The liabilities reflect the net present value of future lease payments. The net gain on the sale and leaseback transactions amounted to USD 478 million. There were no significant sale and leaseback transactions completed in 2020. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table provides additional disclosures related to right-of-use assets and lease liabilities of continuing operations for 2020 and 2019: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense on lease liabilities <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 67</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 66</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense on short-term leases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense on low-value leases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total cash outflows for leases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 379</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 339</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cash outflows for short-term leases <br></br>and low-value leases <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br> 11 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> <br></br> 15 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Payments of interest <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 56</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 51</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Payments of lease liabilities <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 312</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 273</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> The weighted average interest rate is 3.4% (2019: 3.9%). </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Cash flows from short-term and low-value leases are included within total net cash flows from operating activities. The portfolio of short-term leases to which the Group is committed to at December 31, 2020 and 2019, is similar to the portfolio of short-term leases the Group entered into during 2020 and 2019. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Included within total net cash flows from operating activities. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;4&nbsp;</sup> Reported as cash outflows used in financing activities net of lease incentives received of USD nil (2019: USD 33 million). </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The net investment held and income from subleasing right-of-use assets were not significant for 2020 and 2019. Income from leasing Novartis property, plant and equipment to third parties for both 2020 and 2019 was not significant. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 30 provides additional disclosures on discontinued operations.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Section Presentation<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326197576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and intangible assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract', window );"><strong>Disclosure of detailed information about intangible assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory', window );">Goodwill and intangible assets</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">11. Goodwill and intangible assets</div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of goodwill and intangible assets in 2020: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="1" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill</div> </td> <td></td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible assets other than goodwill</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="1" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> In-process <br></br> research and <br></br> development </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Technologies </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently <br></br> marketed <br></br> products </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other <br></br> intangible <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cost</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2020</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26&nbsp;825</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;429</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 884</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 43&nbsp;548</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;558</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 53&nbsp;419</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of assets reclassified out of assets of <br></br>disposal group held for sale <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 10 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 276 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;112 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;400 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;580</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 196</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 218</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;014</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9&nbsp;272</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;274</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 339</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 674</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 412</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;425</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;421</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;101</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;572</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 916</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 208</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 58</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;568</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 205</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;039</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 30&nbsp;321</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;893</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;115</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 57&nbsp;333</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;384</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 67&nbsp;725</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Accumulated amortization</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;301</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2&nbsp;005</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;721</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;20&nbsp;969</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;937</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;24&nbsp;632</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization on assets reclassified <br></br>out of assets of disposal group held for sale <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;107 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;816 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;925 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization charge <sup style="white-space: nowrap">&nbsp;5</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;72</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;215</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;175</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;462</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization on disposals <br></br>and derecognitions <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 421 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 101 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 39 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 567 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge <sup style="white-space: nowrap">&nbsp;6</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;515</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;40</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;338</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;914</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;92</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;46</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;267</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;145</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;550</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;322</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2&nbsp;193</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;885</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;26&nbsp;566</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;272</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;30&nbsp;916</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&nbsp;999</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;700</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 230</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 30&nbsp;767</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;112</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 36&nbsp;809</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Note 2 provides additional disclosures related to the reclassification out of assets of disposal group held for sale as of March 31, 2020. </div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development </div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> No addition for the disposal group held for sale for the period from January 1, 2020, to March 31, 2020 </div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;4&nbsp;</sup> Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use </div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;5&nbsp;</sup> Amortization charge includes USD 102 million (USD 73 million for currently marketed products and USD 29 million for technologies), representing the cumulative amount of amortization charge for the disposal group held for sale for intangible assets from the date of reclassification to held for sale, September 6, 2018, to March 31, 2020, the date of reclassification out of assets of disposal group held for sale. See Note 2 for further details. </div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;6&nbsp;</sup> Impairment charge includes USD 42 million on currently marketed products that were previously classified within assets of disposal group held for sale. See Note 2 for further details. </div> </td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of goodwill and intangible assets in 2019: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="1" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Goodwill</div> </td> <td></td> <td align="center" colspan="13" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Intangible assets other than goodwill</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="1" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="13" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> In-process <br></br> research and <br></br> development </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Alcon <br></br> brand name </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Technologies </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Currently <br></br> marketed <br></br> products </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Marketing <br></br> know-how </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other <br></br> intangible <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cost</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2019</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 35&nbsp;700</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&nbsp;167</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;980</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;253</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 35&nbsp;412</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;960</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;253</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 69&nbsp;025</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of assets related to <br></br>discontinued operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;9&nbsp;000 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;249 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;2&nbsp;980 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;5&nbsp;369 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;4&nbsp;440 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;5&nbsp;960 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;572 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;19&nbsp;570 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of assets related to disposal group <br></br>held for sale, net <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 3 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 186</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 342</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;550</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;914</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9&nbsp;069</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;069</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 265</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 243</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 259</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 767</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions <sup style="white-space: nowrap">&nbsp;5</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;75</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;544</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;436</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;055</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;61</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 49</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 254</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 335</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&nbsp;825</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;429</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 884</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 43&nbsp;548</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;558</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 53&nbsp;419</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Accumulated amortization</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;406</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;120</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;758</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;21&nbsp;218</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;906</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;304</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;30&nbsp;306</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization <br></br>on assets related to discontinued operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 101 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 4&nbsp;184 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 2&nbsp;592 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;906 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 128 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 8&nbsp;813 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization charge <sup style="white-space: nowrap">&nbsp;6</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;42</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;657</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;137</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;836</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization on disposals <br></br>and derecognitions <sup style="white-space: nowrap">&nbsp;5</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 70 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 494 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 419 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 983 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge <sup style="white-space: nowrap">&nbsp;6</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;984</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;105</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;54</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;175</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;126</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;148</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;301</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;2&nbsp;005</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;721</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;20&nbsp;969</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;937</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;24&nbsp;632</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&nbsp;524</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;424</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 163</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;579</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 621</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 28&nbsp;787</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Represents the cost of assets and accumulated amortization at January 1, 2019, related to the Alcon business reported as discontinued operations. Notes 1, 2 and 30 provide information related to discontinued operations. </div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Note 2 provides additional disclosures related to assets of disposal group held for sale. </div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development </div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;4&nbsp;</sup> No addition in the disposal group held for sale for the period from January 1, 2019, to December 31, 2019 </div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;5&nbsp;</sup> Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use </div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;6&nbsp;</sup> No amortization or impairment charges related to the disposal group held for sale for the period from January 1, 2019, to December 31, 2019. </div> </td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2020: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="1" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill</div> </td> <td></td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible assets other than goodwill</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="1" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> In-process <br></br> research and <br></br> development </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Technologies </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently <br></br> marketed <br></br> products </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other <br></br> intangible <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21&nbsp;718</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;548</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29&nbsp;645</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 925</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 35&nbsp;121</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;274</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 152</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 227</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;122</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 42</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;543</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 145</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 145</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&nbsp;999</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;700</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 230</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 30&nbsp;767</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;112</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 36&nbsp;809</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2019: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="1" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Goodwill</div> </td> <td></td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Intangible assets other than goodwill</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="1" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> In-process <br></br> research and <br></br> development </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Technologies </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Currently <br></br> marketed <br></br> products </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other <br></br> intangible <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&nbsp;750</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;339</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21&nbsp;720</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 520</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27&nbsp;586</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;767</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 85</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 156</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 859</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;125</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&nbsp;524</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;424</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 163</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;579</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 621</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 28&nbsp;787</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Innovative Medicines and Sandoz Divisions&#x2019; cash-generating units, to which goodwill is allocated, each comprise a group of smaller cash-generating units. The valuation method of the recoverable amount of the cash-generating units, to which goodwill is allocated, is based on the fair value less costs of disposal. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following assumptions are used in the calculations:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(As a percentage) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative <br></br> Medicines </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Sandoz </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Terminal growth rate</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.5</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.5</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Discount rate (post-tax)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The discount rates for all divisions consider the Group&#x2019;s weighted average cost of capital, adjusted to approximate the weighted average cost of capital of a comparable market participant. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value less costs of disposal, for all cash-generating units containing goodwill, is reviewed for the impact of reasonably possible changes in key assumptions. In particular, we considered an increase in the discount rate, a decrease in the terminal growth rate, and certain negative impacts on the forecasted cash flows. These reasonably possible changes in key assumptions did not indicate an impairment. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">&#x201c;Note 1. Significant accounting policies&mdash;Impairment of goodwill and intangible assets&#x201d; provides additional disclosures on how the Group performs goodwill and intangible asset impairment testing. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the intangible asset and goodwill impairment charges for continuing operations for 2020, 2019 and 2018: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;768</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;669</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;592</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;506</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;249</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;914</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;175</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;841</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> 2020 includes an impairment of USD 485 million related to the write-down of IPR&amp;D related to cessation of clinical development program ZPL389 for atopic dermatitis and USD 181 million related to a partial write-down of the <i>Votrient</i> currently marketed product. <br></br>2019 includes an impairment of USD 416 million related to the write-down of IPR&amp;D related to cessation of clinical development program EMA401 and a USD 108 million write-down related to the cessation of clinical development program for MOR106 for atopic dermatitis. <br></br>2018 includes an impairment of USD 400 million related to a partial write-down of the <i>Votrient</i> currently marketed product. </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> 2019 includes an impairment of USD 442 million related to the write-down of IPR&amp;D related to the discontinuation of the generic Advair&#xae; development program. <br></br>2018 includes impairments of USD 220 million related to the write-down of the allocated goodwill (USD 183 million) and the currently marketed products (USD 37 million) related to the retained Sandoz US dermatology business and generic US oral solids portfolio. See Note 2. </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2020, there were no reversals of prior-year impairment charges (2019: USD 37 million; 2018: nil).</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Note 30 provides additional disclosures on discontinued operations.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326086376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred tax assets and liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Disclosure of Deferred Tax Assets and Liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDeferredTaxesExplanatory', window );">Deferred tax assets and liablities</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">12. Deferred tax assets and liabilities </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Property, <br></br> plant and <br></br> equipment </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Intangible <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pensions and <br></br> other benefit <br></br> obligations <br></br> of associates </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Inventories </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Tax loss <br></br> carry- <br></br> forwards </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Other assets, <br></br> provisions <br></br> and accruals </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax assets at January 1, 2020</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 108</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;469</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;078</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;446</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 255</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;596</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;952</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax liabilities at January 1, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;390</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;610</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;291</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;287</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;325</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;5&nbsp;910</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at January 1, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;282</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2&nbsp;141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 787</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 248</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;271</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;042</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;282</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2&nbsp;141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 787</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 248</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;271</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;042</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 89</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 110</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 212</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;164</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 71</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 293</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to equity</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to other comprehensive income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;39</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;945</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 408</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;501</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;53</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 58</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;35</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;241</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;918</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 797</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;343</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 497</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;314</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 792</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax assets at December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 189</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;351</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;137</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;502</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 507</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;658</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;344</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax liabilities at December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;430</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5&nbsp;269</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;340</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;344</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7&nbsp;552</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;241</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;918</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 797</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;343</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 497</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;314</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 792</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After offsetting the following amount of deferred tax assets and liabilities within the same tax jurisdiction, the balance amounts to: </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 130</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets at December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;214</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities at December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7&nbsp;422</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 792</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax assets at January 1, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 191</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;722</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 273</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;175</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;782</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax liabilities at January 1, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;622</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;5&nbsp;384</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;273</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;474</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;805</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;7&nbsp;558</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at January 1, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;431</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;151</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 915</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;248</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 273</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;370</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;224</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;431</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;151</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 915</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;248</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 273</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;370</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;224</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net deferred tax balance related to discontinued operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 82</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;403</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;123</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;248</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;217</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 858</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 74</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 605</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 308</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;818</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;113</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 298</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 354</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to equity</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 75</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;83</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to other comprehensive income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;313</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;289</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;45</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;47</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;282</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;2&nbsp;141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 787</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 248</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;271</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;042</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax assets at December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 108</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;469</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;078</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;446</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 255</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;596</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;952</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax liabilities at December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;390</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;610</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;291</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;287</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;325</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;910</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;282</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;2&nbsp;141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 787</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 248</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;271</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;042</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After offsetting the following amount of deferred tax assets and liabilities within the same tax jurisdiction, the balance amounts to: </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 43</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets at December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;909</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities at December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;867</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;042</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> <b> </b> <b> </b> <b> </b> <b> </b> <b> </b> <b> </b> <b> </b> </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Notes 1, 2 and 30 provide information related to discontinued operations. <b> </b> </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> <b></b> </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table presents deferred tax assets and deferred tax liabilities, which are expected to have an impact on current taxes payable after more than 12&nbsp;months:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD billions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected to have an impact on current tax payable after more than 12 months</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Deferred tax assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.5</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.3</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Deferred tax liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Deferred tax liabilities have not been recognized for the withholding tax and other taxes that would be payable on the remittance of earnings of foreign subsidiaries, as the Group has the ability to control any future reversal and the unremitted earnings are retained in the foreign subsidiaries for reinvestment. The total unremitted earnings retained for reinvestment in the Group&#x2019;s foreign subsidiaries that would be subject to withholding tax or other taxes if remitted to the Group are estimated at approximately USD 27 billion in 2020 (2019: USD 26 billion). </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Temporary differences on which no deferred tax has been provided as they are permanent in nature related to: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD billions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Investments in subsidiaries</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill from acquisitions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;24</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The gross value of tax-loss carry-forwards that have or have not been capitalized as deferred tax assets, with their expiry dates, is as follows: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Not capitalized</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Capitalized</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020 total</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One year</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Two years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Three years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Four years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 51</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">More than five years <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;400</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;291</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;691</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not subject to expiry</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 323</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 683</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;006</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;780</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;025</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;805</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Not capitalized more than five years includes USD 3.2 billion attributable to US state tax-loss carry-forwards, of which USD 1.6 billion relates to The Medicines Company, which was acquired in 2020 (see Note 2). </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Not capitalized</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Capitalized</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019 total</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One year</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Two years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Three years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Four years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 46</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 62</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 127</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 164</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">More than five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 125</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;214</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;339</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not subject to expiry</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 310</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 345</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 648</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;338</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;986</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tax losses carried forward <br></br>that expired </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 14 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 9 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 8 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Deferred tax assets related to taxable losses of relevant Group entities are recognized to the extent it is considered probable that future taxable profits will be available against which such losses can be utilized in the foreseeable future. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The Basel-Stadt cantonal tax reform was approved by voters in February 2019, with parts of the reform retroactively enacted per January 1, 2019. The newly enacted tax rate resulted in a decrease of the blended cantonal and federal tax rate from 22% to 13%. This change impacted the Group&#x2019;s Basel-Stadt-domiciled operating subsidiaries. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Swiss federal tax reform was approved by voters in May 2019. The enactment of the Swiss federal tax reform required the abolishment of the holding company tax regimes as of January 1, 2020. As a result, the holding company tax rate increased from the current 8% to 13%, effective January 1, 2020. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The enactment of these Swiss tax reforms required a revaluation of the deferred tax assets and liabilities to the newly enacted tax rates at the date of enactment. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the impact on the revaluation of deferred assets and liabilities in 2019, as at the respective dates of the enactment of the Swiss tax reforms: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Income <br></br> statement <br></br> continuing <br></br> operations </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> <br></br> Equity </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax asset <br></br>and liability revaluation </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Items previously recognized <br></br>in consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 234 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 234 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Items previously recognized in other comprehensive income <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;358</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;358</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total revaluation of deferred tax assets and liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 234</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;358</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;124</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Related to post-employment benefits </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDeferredTaxesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDeferredTaxesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326188008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial and other non-current assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract', window );"><strong>Disclosure of financial and other non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock', window );">Financial and other non-current assets</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">13. Financial and other non-current assets</div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Financial assets</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;577</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;524</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 366</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 233</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;979</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;790</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term receivables from finance subleases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 83</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 66</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other long-term receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 125</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 104</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 625</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 399</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances and security deposits</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 89</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 159</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;901</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;518</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Note 29 provides additional disclosures related to contingent considerations. </div> </td> </tr> </table> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other non-current assets</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred compensation plans</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 471</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 414</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid post-employment benefit plans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 202</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 148</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 219</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 176</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other non-current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 892</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 738</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326171528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_InventoriesDisclosureAbstract', window );"><strong>Inventories Disclosure [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">Inventories</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">14. Inventories</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Raw material, consumables</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 967</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 751</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Work in progress</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;324</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;024</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Finished products</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;840</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;207</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total inventories</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;131</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;982</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the amount of inventory recognized as an expense in &#x201c;Cost of goods sold&#x201d; in the consolidated income statements from continuing operations: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD billions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8.5</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8.5</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8.3</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the recognized amount of inventory provision and reversals of inventory provision recorded in the consolidated income statements from continuing operations: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventory provisions</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;702</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;752</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;603</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversals of inventory provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 255</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 218</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 216</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The reversals mainly result from the release of products initially requiring additional quality control inspections and from the reassessment of inventory values manufactured prior to regulatory approval but for which approval was subsequently received. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InventoriesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InventoriesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326197576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfTradeReceivablesAbstract', window );"><strong>Disclosure of trade receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfTradeReceivablesExplanatoryTextBlock', window );">Trade receivables</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">15. Trade receivables</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total gross trade receivables</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;310</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;396</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;93</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;95</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;217</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;301</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movement in the provision for doubtful trade receivables:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;95</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;126</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;190</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions related to discontinued operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 54</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables charged to the consolidated income statement <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;59</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;89</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;47</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Utilization of provisions for doubtful trade receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of provisions for doubtful trade receivables credited to the consolidated income statement <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 53</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;93</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;95</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;126</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Notes 1, 2 and 30 provide information related to discontinued operations. </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Provisions charged to the consolidated income statement from continuing operations were USD 30 million in 2018. </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Reversal of provisions credited to the consolidated income statement from continuing operations were USD 44 million in 2018. </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the trade receivables that are not overdue as specified in the payment terms and conditions established with Novartis customers, as well as an analysis of overdue amounts and related provisions for doubtful trade receivables: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not overdue</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;714</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;763</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for not more than one month</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 150</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 161</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one month <br></br>but less than three months </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 118 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 123 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than three months <br></br>but less than six months </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 102 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 103 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than six months <br></br>but less than one year </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 77 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 96 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one year</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 149</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 150</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;93</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;95</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;217</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;301</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Trade receivable balances represent amounts due from our customers, which are mainly drug wholesalers, retailers, private health systems, government agencies, managed care providers, pharmacy benefit managers and government-supported healthcare systems. Novartis continues to monitor sovereign debt issues and economic conditions in the countries in which it operates, particularly in Argentina, Brazil, Greece, Italy, Portugal, Russia, Saudi Arabia, Spain and Turkey, and evaluates trade receivables in these countries for potential collection risks. The majority of the outstanding trade receivables from Portugal, Saudi Arabia, Spain and Greece are due directly from local governments or from government-funded entities. Deteriorating credit and economic conditions as well as other factors in these closely monitored countries have resulted in, and may continue to result in, an increase in the average length of time that it takes to collect these trade receivables, and may require the Group to re-evaluate the expected credit loss amount of these trade receivables in future periods. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the gross trade receivables balance from these closely monitored countries at December 31, 2020 and 2019; the amounts that are past due for more than one year; and the related provisions that have been recorded: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total balance of gross trade <br></br>receivables from closely <br></br>monitored countries </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 1&nbsp;505 </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 1&nbsp;588 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one year</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 55</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At December 31, 2020, amounts past due for more than one year are not significant in any of these countries on a standalone basis. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Total trade receivables include amounts denominated in the following major currencies:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;311</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;466</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;668</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;384</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 437</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 466</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Russian ruble (RUB)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 288</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 341</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chinese yuan (CNY)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 208</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 279</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">British pound (GBP)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 191</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 202</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Australian dollar (AUD)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 153</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 125</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Brazilian real (BRL)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 148</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 165</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canadian dollar (CAD)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 125</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 129</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 89</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other currencies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;564</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;655</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;217</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;301</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfTradeReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfTradeReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfTradeReceivablesExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfTradeReceivablesExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326156456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract', window );"><strong>Disclosure of marketable securities commodities deposits derivative instruments and cash [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock', window );">Disclosure of marketable securities commodities deposits derivative instruments and cash</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">16. Marketable securities, commodities, time&nbsp;deposits, derivative financial instruments, and&nbsp;cash and cash equivalents</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Marketable securities, commodities, time&nbsp;deposits and derivative financial instruments</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 111</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 110</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;609</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities, commodities, time deposits and derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;905</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 334</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Cash and cash equivalents</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current accounts</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;750</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;247</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity less than 90 days</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;908</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;865</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;658</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;112</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326098440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherCurrentAssetsAbstract', window );"><strong>Other current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory', window );">Other current assets</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">17. Other current assets</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">VAT receivable</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 544</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 508</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Withholding tax recoverable</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 73</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 108</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid expenses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 943</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 898</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Receivables from associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other receivables and current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 963</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;165</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;523</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;680</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other current assets. [Refer: Other current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326200056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfEquityAbstract', window );"><strong>Disclosure of equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfEquityTextBlock', window );">Equity</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">18. Equity</div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movement in the share capital:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Jan 1, 2018 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Movement <br></br> in year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Dec 31, 2018 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Movement <br></br> in year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Dec 31, 2019 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Movement <br></br> in year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> Dec 31, 2020 </div> </td> <td></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Share capital</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 969</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;25</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 944</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 936</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;23</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 913</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Treasury shares</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;69</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;80</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;53</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding share capital</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 869</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 875</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 856</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 860</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movement in the shares:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>Number of outstanding shares <br></br>(in millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Note </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br></br> Novartis <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br></br> treasury <br></br> shares <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br></br> outstanding <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> Novartis <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> treasury <br></br> shares <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> outstanding <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> Novartis <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> treasury <br></br> shares <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> outstanding <br></br> shares </div> </td> <td></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at beginning of year</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;527.3</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;262.3</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;265.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;550.6</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;239.4</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;311.2</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;616.8</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;299.3</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;317.5</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares canceled for capital <br></br>reduction <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;60.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 60.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;23.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 23.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;66.2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 66.2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be <br></br>canceled <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;32.6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;32.6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;60.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;60.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;23.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;23.3 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1.2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options <br></br>and employee transactions <sup style="white-space: nowrap">&nbsp;5</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 18.9 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 14.7 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 14.7 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 5.5 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 5.5 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 7.8 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 7.8 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation <sup style="white-space: nowrap">&nbsp;5</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7.4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon <br></br>employees </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 0.4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 0.4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 0.9 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 0.9 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total movements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;60.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 52.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;8.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;23.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;22.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;46.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;66.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 59.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;6.3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at end of year</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;467.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;210.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;256.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;527.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;262.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;265.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;550.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;239.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;311.2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Approximately 103.0 million treasury shares (2019: 117.6 million; 2018: 121.6 million) are held in Novartis entities that restrict their availability for use. </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Novartis reduced its share capital by canceling shares that were repurchased on the SIX Swiss Exchange second trading line during previous years. </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2016 Annual General Meeting (AGM) for transactions before February 28, 2019, and under a new CHF 10 billion share buyback authority approved at the 2019 AGM for transactions after such date </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;4&nbsp;</sup> Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;5&nbsp;</sup> Shares delivered as a result of options being exercised and physical share deliveries related to equity-based participation plans. </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">18.1) The amount available for distribution as a dividend to shareholders is based on the available distributable retained earnings of Novartis AG determined in accordance with the legal provisions of the Swiss Code of Obligations. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend per share (in CHF)</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.95</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.85</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.80</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total dividend payment <br></br>(in USD billion) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 7.0 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 6.6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 7.0 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">18.2) The following table summarizes the treasury shares movements:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Note </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Number of <br></br> outstanding <br></br> shares <br></br> (in millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Equity impact <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Number of <br></br> outstanding <br></br> shares <br></br> (in millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Equity impact <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Number of <br></br> outstanding <br></br> shares <br></br> (in millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Equity impact <br></br> USD m </div> </td> <td></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be canceled <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;32.6</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;897</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;60.3</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;351</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;23.3</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;859</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;160</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;114</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of treasury shares</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;34.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;056</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;62.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;511</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;24.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;973</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 806</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 210</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 434</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 730</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 833</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 756</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 263</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;8.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;490</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;46.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;450</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;6.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;520</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2016 AGM for transactions before February 28, 2019, and under a new CHF 10 billion share buyback authority approved at the 2019 AGM for transactions after such date </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Shares delivered as a result of options being exercised related to equity-based participation plans and the delivery of treasury shares. The average share price of the shares delivered was significantly below market price, reflecting the strike price of the options exercised. </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;4&nbsp;</sup> Equity-settled share-based compensation is expensed in the consolidated income statement in accordance with the vesting period of the share-based compensation plans. The value for the shares and options granted is credited to consolidated equity over the respective vesting period. In addition, tax benefits arising from tax-deductible amounts exceeding the expense recognized in the income statement are credited to equity. </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.3) In November 2020, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD 2.5 billion share buyback. Novartis is able to cancel this arrangement at any time but could be subject to a 90-day waiting period. The commitment under this arrangement therefore reflects the obligated purchases by the bank under such trading plan over a rolling 90-day period, or if shorter, until the maturity date of such trading plan. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The commitment under this arrangement amounted to USD 1.8 billion as of December 31, 2020.</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In August 2020, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares to mitigate dilution related to participation plans of associates. Novartis was able to cancel this arrangement at any time but would have been subjected to a 90-day waiting period. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">This trading plan commitment was fully executed and expired, and as a consequence, there is no contingent liability related to this plan recognized as of December 31, 2020. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2019, Novartis entered into a similar irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD&nbsp;5 billion share buyback and to repurchase Novartis shares to mitigate dilution related to participation plans of associates. The commitment under this arrangement therefore reflects the obligated purchases by the bank under such trading plan over a rolling 90-day period, or if shorter, until the maturity date of such trading plan. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The trading plan commitment was fully executed and expired, and as a consequence, there is no contingent liability related to this plan recognized as of December 31, 2019. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2018, Novartis entered into a similar irrevocable, non-discretionary arrangements with a bank to repurchase Novartis shares. The commitments under this arrangement reflected the expected purchases by the bank under such trading plan over a rolling 90-day period. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The commitment under this arrangement amounted to USD 284 million as of December 31, 2018. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.4) In October 2020, Novartis entered into an agreement with the market maker for its employee options to repurchase a portion of the outstanding written call options. A total of 3.7 million options were repurchased under this agreement. This agreement was terminated in November 2020. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.5) The impact of change in ownership of consolidated entities represents the excess of the amount paid to non-controlling interest over their carrying value and equity allocation to non-controlling interest due to change in ownership percentage. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.6) Changes in non-controlling interests represent the impact on the non-controlling interest of transactions with minority shareholders, such as change in ownership percentage, dividend payments and other equity transactions. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.7) Other movements includes, for subsidiaries in hyperinflationary economies, the impact of the restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period as well as the restatement of the equity balances of the current year. In 2020, the amount recorded in equity related to hyperinflation accounting was USD 18 million (2019: USD 22 million; 2018: USD 38 million). See Note 29 for additional disclosures. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.8) In 2019, transaction costs of USD 253 million (2018: USD 79 million) net of tax of USD 36 million (2018: USD 20 million), that are directly attributable to the distribution (spin-off) of Alcon Inc. to Novartis shareholders and that would otherwise have been avoided, were recorded as a deduction from equity. See Note 1 for further details. No transaction costs were recorded as a deduction from equity in 2020. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.9) At December 31, 2020, the market maker held 1 million (2019: 13 million; 2018: 11 million) written call options, originally issued as part of the share-based compensation for associates, that have not yet been exercised. The weighted average exercise price of these options is USD 60.09 (2019: USD 63.90; 2018: USD 62.70), and they have contractual lives of 10 years, with remaining lives up to three years (2019: four years; 2018: five years). </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In December 2018, Novartis entered into an agreement with the market maker for its employee options to repurchase a portion of the outstanding written call options that are not exercised in exchange for treasury shares. During 2019, this agreement was fully executed. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfEquityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfEquityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326082856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-current financial debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract', window );"><strong>Disclosure of financial liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Disclosure of financial liabilities [text block]</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">19. Non-current financial debt</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&nbsp;298</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22&nbsp;167</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities to banks and other financial institutions <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 188</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total, including current portion of non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28&nbsp;531</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;355</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion of non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;272</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;002</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26&nbsp;259</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&nbsp;353</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Average interest rate 0.3% (2019: 0.2%) </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">All bonds are initially recorded at the amount of proceeds received, net of transaction costs. They are subsequently carried at amortized cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognized as a charge to the consolidated income statement over the period of the relevant bond. Financial debts, including current financial debts, contain only general default covenants. The Group is in compliance with these covenants. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The percentage of fixed-rate financial debt to total financial debt was 79% at December 31, 2020, and 82% at December 31, 2019.</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The average interest rate on total financial debt in 2020 was 2.0% (2019: 2.4%).</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 29 contains a maturity table of the Group&#x2019;s future contractual interest payments commitments. </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides a breakdown of straight bonds:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>Coupon </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Currency </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Nominal <br></br> amount <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Issuance <br></br> year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Maturity <br></br> year </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Issuer </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Issue price </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020 <br></br> (USD <br></br> millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019 <br></br> (USD <br></br> millions) </div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4.400%</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2010</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div> </td> <td align="right" width="1%"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.237%</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;000</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.400%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;500</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2012</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.225%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;497</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;495</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3.700%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2012</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2042</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98.325%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 490</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 489</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3.400%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;150</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2014</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.287%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;142</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;139</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4.400%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;850</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2014</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2044</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.196%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;826</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;825</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.750%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2014</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.134%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 737</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 670</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.625%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2014</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2026</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.697%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 735</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 670</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.250%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis AG, Basel, Switzerland</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.640%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 568</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 517</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.625%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 550</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2029</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis AG, Basel, Switzerland</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.502%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 625</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 568</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.050%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 325</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2035</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis AG, Basel, Switzerland</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.479%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 369</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 336</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3.000%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;750</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.010%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;737</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;735</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4.000%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2045</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98.029%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;220</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;219</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.125%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.127%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;530</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;392</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.625%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2028</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98.480%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 607</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 553</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.800%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.609%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;000</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.400%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.449%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 998</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 996</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3.100%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2027</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.109%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 992</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 990</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.000%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.133%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;536</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;396</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.125%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2027</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.874%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 735</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 670</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.500%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 750</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.655%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 919</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 837</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.375%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 750</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2030</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.957%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 920</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 838</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.700%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 750</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2038</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.217%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 913</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 832</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.750%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.852%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 996</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.000%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2027</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.909%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;245</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.200%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;500</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2030</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.869%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;493</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.750%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2050</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 97.712%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;213</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.000% <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;850</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2028</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.354%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;255</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total straight bonds</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28&nbsp;298</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;167</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> The EUR 1 850 million bond issued in 2020 features a coupon step-up of 0.25% commencing with the first interest payment date after December 31, 2025, if one or both of the 2025 Patient Access Targets are not met. These 2025 Patient Access Targets are the 2025 Flagship Programs Patient Reach Target and the 2025 Strategic Innovative Therapies Patient Reach Target, as defined in the bond prospectus. As of December 31, 2020, there is no indication that these 2025 Patient Access Targets will not be met. </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables provide a breakdown of total non-current financial debt, including current portion by maturity and currency: </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Breakdown by maturity:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2020</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;002</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2021</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;272</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;067</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;631</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;583</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;546</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;321</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;142</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;139</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;302</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;252</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After 2025</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&nbsp;638</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;991</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28&nbsp;531</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;355</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Breakdown by currency:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&nbsp;848</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;889</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&nbsp;888</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;861</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 184</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;563</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;421</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28&nbsp;531</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;355</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The following table shows the comparison of balance sheet and fair value of total non-current financial debt, including current portion: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020 <br></br> Balance <br></br> sheet </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020 <br></br> Fair <br></br> values </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019 <br></br> Balance <br></br> sheet </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019 <br></br> Fair <br></br> values </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&nbsp;298</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31&nbsp;359</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22&nbsp;167</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23&nbsp;701</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 188</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28&nbsp;531</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 31&nbsp;592</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;355</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;889</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The fair values of straight bonds are determined by quoted market prices. Other financial debts are recorded at notional amounts, which are a reasonable approximation of the fair values. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326088040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions and other non-current liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract', window );"><strong>Disclosure of detailed information about provisions and non-current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory', window );">Provisions and other non-current liabilities</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">20. Provisions and other non-current liabilities</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued liability for employee benefits:</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit pension plans <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;538</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;469</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other long-term employee benefits and deferred compensation</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 637</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 546</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other post-employment benefits <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 543</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 612</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Environmental remediation provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 642</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 592</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for product liabilities, governmental investigations and other legal matters</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 181</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 200</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 984</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 958</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 409</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 255</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total provisions and other non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;934</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;632</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Note 25 provides additional disclosures related to post-employment benefits. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Note 29 provides additional disclosures related to contingent consideration. </div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis believes that its total provisions are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities in this area, Novartis may incur additional costs beyond the amounts provided. Management believes that such additional amounts, if any, would not be material to the Group&#x2019;s financial condition but could be material to the results of operations or cash flows in a given period. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Environmental remediation provisions</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movements in the environmental liability provisions:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 714</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 692</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 761</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;48</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005; 83</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;21</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 82</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 809</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 714</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 692</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current provision</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;167</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;122</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;58</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current environmental remediation provisions at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 642</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 592</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 634</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Releases of provisions credited to the consolidated income statement from continuing operations were USD 21 million in 2018. </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Additions to provisions charged to the consolidated income statement from continuing operations were USD 7 million in 2018. </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The material components of the environmental remediation provisions consist of costs to sufficiently clean and refurbish contaminated sites to the extent necessary and to continue surveillance at sites where the environmental remediation exposure is less significant. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A substantial portion of the environmental remediation provisions relate to the remediation of Basel regional landfills in the adjacent border areas in Switzerland, Germany and France. The provisions are reassessed on a yearly basis and adjusted as necessary. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the United States, Novartis has been named under federal legislation (the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended) as a potentially responsible party (PRP) in respect of certain sites. Novartis actively participates in, or monitors, the cleanup activities at the sites in which it is a PRP. The provision takes into consideration the number of other PRPs at each site as well as the identity and financial position of such parties in light of the joint and several nature of the liability. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The expected timing of the related cash outflows as of December 31, 2020, is currently projected as follows: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Expected <br></br> cash outflows </div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due within two years</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 181</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due later than two years, but within five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 210</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due later than five years, but within 10 years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 338</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due after 10 years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 80</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total environmental remediation liability provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 809</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Provisions for product liabilities, governmental investigations and other legal matters </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has established provisions for certain product liabilities, governmental investigations and other legal matters where a potential cash outflow is probable and Novartis can make a reliable estimate of the amount of the outflow. These provisions represent the Group&#x2019;s current best estimate of the total financial effect for the matters described below and for other less significant matters. Potential cash outflows reflected in a provision might be fully or partially offset by insurance in certain circumstances. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis has not established provisions for potential damage awards for certain additional legal claims against its subsidiaries if Novartis currently believes that a payment is either not probable or cannot be reliably estimated. In total, these not-provisioned-for matters include more than 3&#xa0;000 individual product liability cases and certain other legal matters. Plaintiffs&#x2019; alleged claims in these matters, which Novartis does not believe to be entirely remote but which do not fulfill the conditions for the establishment of provisions, currently aggregate to, according to the current best belief of Novartis, approximately USD&nbsp;0.5 billion. In addition, in some of these matters there are claims for punitive or multiple (treble) damages, civil penalties and disgorgement of profits that in the view of Novartis are either wholly or partially unspecified, or wholly or partially unquantifiable at present; the Group believes that information about these amounts claimed by plaintiffs generally is not meaningful for purposes of determining a reliable estimate of a loss that is probable or more than remote. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A number of other legal matters are in such early stages or the issues presented are such that the Group has not made any provisions since it cannot currently estimate either a potential outcome or the amount of any potential losses. For these reasons, among others, the Group generally is unable to make a reliable estimate of possible loss with respect to such cases. It is therefore not practicable to provide information about the potential financial impact of those cases. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There might also be cases for which the Group was able to make a reliable estimate of the possible loss or the range of possible loss, but the Group believes that publication of such information on a case-by-case basis would seriously prejudice the Group&#x2019;s position in ongoing legal proceedings or in any related settlement discussions. Accordingly, in such cases, information has been disclosed with respect to the nature of the contingency, but no disclosure is provided as to an estimate of the possible loss or range of possible loss. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 28 contains additional information on contingencies.</div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Summary of significant legal proceedings</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following is a summary of significant legal proceedings to which Novartis or its subsidiaries are currently a party, or were a party and that concluded in 2020. </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Investigations and related litigations</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Southern District of New York (S.D.N.Y.) Gilenya marketing practices investigation and litigation </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2013, Novartis Pharmaceuticals Corporation (NPC) received a civil investigative demand from the United States Attorney&#x2019;s Office (USAO) for the S.D.N.Y. requesting the production of documents and information relating to marketing practices for <i>Gilenya</i>, including the remuneration of healthcare providers in connection therewith. In 2017, the S.D.N.Y. and New York State declined to intervene in claims raised by an individual relator in a <i>qui tam</i> complaint, which continue to be vigorously contested. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Government generic pricing antitrust investigations, antitrust class actions</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Since 2016, Sandoz Inc. has received a grand jury subpoena and a civil investigative demand and interrogatories from the Antitrust and Civil Divisions of the US Department of Justice (DOJ), and a subpoena and interrogatories from the Attorney General of the State of Connecticut in connection with those agencies&#x2019; investigation into alleged price fixing and market allocation of generic drugs in the US market as well as alleged federal False Claims Act (FCA) violations. In 2020, Sandoz Inc. reached a resolution with the DOJ Antitrust Division, pursuant to which Sandoz Inc. agreed to pay USD 195 million and entered into a deferred prosecution agreement. The Sandoz resolution related to instances of misconduct at the company between 2013 and 2015 with regard to certain generic drugs sold in the United States. Under the terms of that agreement, Sandoz Inc. will continue to take steps to enhance its compliance program, employee training and monitoring, and will continue to cooperate with the US government&#x2019;s ongoing investigation into the generic pharmaceutical industry. Sandoz Inc. is also in negotiations with the DOJ Civil Division to resolve potential related claims and has recorded a provision of USD 187 million. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Since the third quarter of 2016, Sandoz Inc. and Fougera Pharmaceuticals Inc. have been sued alongside other generic pharmaceutical companies in numerous individual and putative class action complaints by direct and indirect private purchasers and by 54 states and US territories, represented by their respective Attorneys General. Plaintiffs claim that defendants, including Sandoz, engaged in price fixing and market allocation of generic drugs in the US market, and seek damages and injunctive relief. The actions contain product-specific complaints as well as complaints alleging the existence of an overarching industry conspiracy, and assert violations of federal and state antitrust laws as well as consumer protection laws. The cases have been consolidated for pretrial purposes in the United States District Court (USDC) for the Eastern District of Pennsylvania, and the claims are being vigorously contested. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Lucentis/Avastin <sup>&#xae;</sup> matters </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In connection with an investigation into whether Novartis entities, F. Hoffmann-La Roche AG, Genentech Inc. and Roche S.p.A. colluded to artificially preserve the market positions of Avastin <sup>&#xae;</sup> and <i>Lucentis</i>, in 2014 the Italian Competition Authority (ICA) imposed a fine equivalent to USD 125 million on the Novartis entities. Novartis paid the fine, subject to the right to later claim recoupment, and appealed before the Consiglio di Stato (CdS). In 2014 and 2015, the Italian Ministry of Health and the Lombardia region sent letters with payment requests for a total equivalent of approximately USD&nbsp;1.3 billion in damages from Novartis and Roche entities based on these allegations. In 2019, the CdS upheld the ICA decision and fine. Following the CdS decision, several additional Italian regions and hospitals sent letters claiming damages for an aggregate amount of approximately USD 330 million. None of these claims has been asserted in legal proceedings. Novartis continues to appeal the CdS decision. In 2019, the French Competition Authority (FCA) issued a Statement of Objections against Novartis entities, alleging anti-competitive practices on the French market for anti-vascular endothelial growth factor treatments for wet age-related macular degeneration from 2008 to 2013. In 2020, the FCA issued a decision finding that the Novartis entities had infringed competition law by abusing a dominant position and imposing a fine of EUR 385 million (equivalent to approximately USD 452 million). Novartis paid the fine, again subject to recoupment, and is appealing the FCA&#x2019;s decision. Novartis continues to vigorously contest all claims in Italy and France. Novartis is also challenging policies and regulations allowing off-label/unlicensed use and reimbursement for economic reasons in various countries, including Italy and Turkey. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Japan investigation</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2015, a trial started against a former Novartis Pharma K.K. (NPKK) employee, and also against NPKK under the dual liability concept in Japanese law, over allegations brought by the Tokyo District Public Prosecutor Office for alleged manipulation of data in sub-analysis publications of the Kyoto Heart Study regarding valsartan. The charges against NPKK are subject to a maximum total fine of JPY 4 million. In 2018, the Tokyo High Court upheld a not-guilty ruling of the Tokyo District Court for both the former NPKK employee and NPKK. A further appeal by the Tokyo High Public Prosecutor Office remains pending. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">South Korea investigation</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2016, the Seoul Western District Prosecutor initiated a criminal investigation into, among other things, allegations that Novartis Korea utilized medical journals to provide inappropriate economic benefits to healthcare professionals (HCPs). This resulted in a non-material fine in January 2020, and the Prosecutor has appealed the fine. The resolution of inquiries by the DOJ and the US Securities and Exchange Commission (SEC) regarding this matter is described below in &#x201c;Concluded legal matters - US Government Foreign Corrupt Practices Act (FCPA) investigations.&#x201d; </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Greece investigation</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis is providing information to the Greek authorities investigating allegations of potentially inappropriate economic benefits to HCPs, government officials and others in Greece. These authorities include the Greek Coordinating Body for Inspection and Control, and the Greek Body of Prosecution of Financial Crime, from which the Company received a summons in 2018 and 2020. The resolution of inquiries by the DOJ and the SEC regarding this matter is described below in &#x201c;Concluded legal matters - US Government Foreign Corrupt Practices Act (FCPA) investigations.&#x201d; </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Antitrust class actions</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Exforge</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Since 2018, Novartis Group companies as well as other pharmaceutical companies have been sued by various direct and indirect purchasers of <i>Exforge</i> in multiple US individual and putative class action complaints. They claim that Novartis made a reverse payment in the form of an agreement not to launch an authorized generic, alleging violations of federal antitrust law and state antitrust, consumer protection and common laws, and seeking damages as well as injunctive relief. The cases have been consolidated in the S.D.N.Y. and the claims are being vigorously contested. </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Product liability litigation</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Reclast </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">NPC is a defendant in more than 20 US product liability actions involving <i>Reclast</i> and alleging atypical femur fracture injuries, all of which are in New Jersey state or federal court and in California state court, coordinated with claims against other bisphosphonate manufacturers. The claims are being vigorously contested. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Taxotere&#xae; (docetaxel)</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sandoz is a defendant in more than 3&#xa0;000 US product liability actions involving Taxotere <sup>&#xae;</sup> (docetaxel), an oncology product, many of which have been transferred to a multidistrict litigation in the Eastern District of Louisiana. The complaints allege misleading marketing and that Sanofi, as innovator, and several 505(b)(2) NDA holders (including Sandoz) failed to warn of the risk of permanent alopecia/hair loss. The claims are being vigorously contested. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Amiodarone</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sandoz entities are named in less than five individual and multi-plaintiff US product liability cases involving amiodarone, a cardiac drug indicated to treat life-threatening arrhythmias that have not responded to other treatment. The complaints allege failure to warn, off-label promotion and failure to include medication guides to pharmacies. The claims are being vigorously contested. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Sartans and ranitidine</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Since 2018, claims have been brought against Sandoz and other pharmaceutical companies alleging injury from carcinogenic impurities found in valsartan and valsartan/HCT film-coated tablets and/or losartan marketed or manufactured by Sandoz. These claims include several putative class actions in Canada. Claims have also been brought alleging injury from carcinogenic impurities in ranitidine-containing medicines. These claims also include several putative class actions in Canada and a multidistrict litigation in Florida. All of these claims are being vigorously contested. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Tasigna</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">NPC is a defendant in more than 80 US product liability actions involving <i>Tasigna</i>, alleging that the product caused various cardiovascular effects and that NPC failed to provide adequate warnings about those alleged side effects. The actions are pending in New Jersey state court and in federal courts in various jurisdictions. The claims are being vigorously contested. </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other matters</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Average Wholesale Price (AWP) litigation</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Lawsuits have been brought, the latest in February 2016, by various US state governmental entities and private parties against various pharmaceutical companies, including NPC, alleging that they fraudulently overstated the AWP that is or has been used by payors, including state Medicaid agencies, to calculate reimbursements to healthcare providers. NPC remains a defendant in a putative class action brought by private payors in New Jersey, and vigorously contests those claims. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Aimovig&ndash;Amgen dispute</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2015 and 2017, Novartis and Amgen entered into agreements regarding the development and commercialization of <i>Aimovig</i>, which the companies co-commercialize in the US and to which Novartis has exclusive rights in all territories outside the US, excluding Japan. Amgen issued a termination notice in April 2019 based on an alleged material breach of the collaboration agreements, and this notice, as well as other ancillary matters, are the subject of legal proceedings between Novartis and Amgen. Novartis disputes Amgen&#x2019;s allegations vigorously. In 2020, the court ruled that Amgen did not have grounds to terminate the 2017 agreement and dismissed that portion of their lawsuit. The collaboration continues during the litigation between the companies, and will remain in force until and unless a final court decision terminates the agreements. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Shareholder Derivative Lawsuit</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2021, NPC, Sandoz Inc., Novartis Capital Corporation and certain present and former directors and officers of Novartis were named as defendants, and Novartis was named as a nominal defendant, in a purported shareholder derivative lawsuit filed in New York state court. The plaintiff, derivatively as a purported Novartis shareholder on behalf of Novartis, seeks damages and other remedies based on alleged conduct by the corporate and individual defendants. The claims are being vigorously contested. </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Concluded legal matters</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">S.D.N.Y. marketing practices investigation and litigation</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2013, the US government filed a civil complaint in intervention to an individual <i>qui tam</i> action against NPC in the USDC for the S.D.N.Y. The complaint, as subsequently amended, asserted federal FCA and common law claims with respect to speaker programs and other promotional activities for certain NPC cardiovascular medications ( <i>Lotrel</i>, <i>Starlix</i> and <i>Valturna</i>) allegedly serving as mechanisms to provide kickbacks to HCPs. Also in 2013, New York State filed a civil complaint in intervention asserting similar claims. In 2020, Novartis finalized its settlement agreement with the S.D.N.Y, the New York State Attorney General and the individual relator to resolve their claims. As part of this settlement, Novartis agreed to pay USD 0.7 billion, and has agreed to new corporate integrity obligations with the Office of Inspector General of the US Department of Health and Human Services. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">U.S. Government Foreign Corrupt Practices Act (FCPA) investigations</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2020, Novartis reached settlements with the DOJ and the SEC resolving all FCPA investigations into historical conduct by Novartis and its subsidiaries. These investigations were previously disclosed in Note 20 to the Consolidated Financial Statements in our 2019 Annual Report and 2019 Form 20-F under the headings &#x201c;Investigations and related litigations &ndash; Greece investigation,&#x201d; &#x201c;Investigations and related litigations &ndash; South Korea investigation&#x201d; and &#x201c;Investigations and related litigations &ndash; Asia/Russia investigation.&#x201d; As part of the coordinated resolution of these investigations, Novartis and certain of its current and former subsidiaries agreed to pay USD 0.3 billion. To resolve the DOJ investigation, both Novartis Hellas S.A.C.I. and Alcon Pte Ltd., a former Novartis subsidiary, entered into separate deferred prosecution agreements (DPA) with the DOJ. The Novartis Hellas DPA contained no allegations relating to any bribery of Greek politicians, which is consistent with what Novartis found in its own internal investigation. To resolve the SEC investigation, Novartis AG reached an agreement pertaining to internal controls and books and records violations in Greece, Vietnam and South Korea, which also addressed certain internal controls and books and records issues related to Alcon China&#x2019;s placement of surgical devices. Other developments in Greece and South Korea are described above in &#x201c;Investigations and related litigations &ndash; Greece investigation&#x201d; and &#x201c;Investigations and related litigations &ndash; South Korea investigation,&#x201d; respectively. The matters disclosed in Note 20 to the Consolidated Financial Statements in our 2019 Annual Report and 2019 Form 20-F under the heading &#x201c;Investigations and related litigations &ndash; Asia/Russia investigation&#x201d; are now concluded. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Enoxaparin</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2015, Sandoz and Momenta Pharmaceuticals were sued in a putative antitrust class action in federal court in Tennessee alleging that Momenta and Sandoz engaged in anticompetitive and unfair business conduct with regard to sales of enoxaparin. In 2019, Sandoz agreed to pay USD 85 million to resolve the class action. The matter is now concluded. </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Summary of product liability, governmental investigations and other legal matters provision movements </font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;369</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 340</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 351</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions related to <br></br>discontinued operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;42 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;863</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;116</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;118</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases of provisions <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;52</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;107</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to provisions <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;230</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 220</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 487</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;369</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 340</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;306</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;169</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;126</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current product liabilities, governmental investigations and other legal matters provisions at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 181</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 200</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 214</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Notes 1, 2 and 30 provide information related to discontinued operations. </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Releases of provisions credited to the consolidated income statement from continuing operations were USD 107 million in 2018. </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Additions to provisions charged to the consolidated income statement from continuing operations were USD 220 million in 2018. </div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis believes that its total provisions for investigations, product liability, arbitration and other legal matters are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities, there can be no assurance that additional liabilities and costs will not be incurred beyond the amounts provided. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other provisions, contingent liabilities and contingent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2019-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IAS37_g84-92_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326085544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current financial debt and derivative financial instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract', window );"><strong>Disclosure of current financial debt and derivative instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock', window );">Current financial debt and derivative financial instruments</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">21. Current financial debt and&nbsp;derivative&nbsp;financial&nbsp;instruments</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of associates <br></br>payable on demand <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 2&nbsp;085 </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;836 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other financial debt <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 976</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 719</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;258</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;289</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current portion of non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;272</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;002</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 185</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt and derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;785</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;031</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Weighted average interest rate 0.4% (2019: 0.5%) </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Weighted average interest rate 5.0% (2019: 12.9%) </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated balance sheet amounts of current financial debt, other than the current portion of non-current financial debt, approximate the estimated fair value due to the short-term nature of these instruments. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Details on commercial papers and short term borrowings are provided under &#x201c;Liquidity risk&#x201d; in Note&nbsp;29.</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326122872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions and other current liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract', window );"><strong>Disclosure of provisions and other current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock', window );">Provisions and other current liabilities</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">22. Provisions and other current liabilities</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes other than income taxes</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 749</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 471</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Restructuring provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 459</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 438</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued expenses for goods and services received but not invoiced</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;167</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;046</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accruals for royalties</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 732</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 653</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued interests on financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 133</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 98</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for deductions from revenue</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;256</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;595</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accruals for compensation and benefits, including social security</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;286</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;464</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Environmental remediation liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 167</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 122</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 56</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 114</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for product liabilities, governmental investigations and other legal matters <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 306</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;169</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued share-based payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 269</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 326</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent considerations <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 62</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 78</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;769</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 716</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 764</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total provisions and other current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&nbsp;127</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;338</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Note 20 provides additional disclosures related to legal provisions. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Note 29 provides additional disclosures related to contingent considerations. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Note 18 provides additional disclosures related to commitment for repurchase of own shares. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Provisions are based upon management&#x2019;s best estimate and adjusted for actual experience. Such adjustments to historic estimates have not been material. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Provisions for deductions from revenue</font> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movement of the provisions for deductions from revenue:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income statement charge<sup>2</sup></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> <td height="1"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td height="1"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> <td height="1"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Revenue <br></br> deductions <br></br> provisions at <br></br> January 1 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Revenue <br></br> deductions <br></br> provisions <br></br> related to <br></br> discontinued <br></br> operations<sup>1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Effect of <br></br> currency <br></br> translation <br></br> and business <br></br> combinations </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> Payments/ <br></br> utilizations </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> Adjustments <br></br> of prior years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> <br></br> Current year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Change in <br></br> provisions <br></br> offset against <br></br> gross trade <br></br> receivables </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Revenue <br></br> deductions <br></br> provisions at <br></br> December 31 </div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">2020</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US-specific healthcare plans <br></br>and program rebates </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;981 </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;5&nbsp;560 </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;107 </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 5&nbsp;739 </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 2&nbsp;053 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-US-specific healthcare plans <br></br>and program rebates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;769 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 167 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;2&nbsp;597 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 7 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 2&nbsp;940 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;14 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 2&nbsp;272 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-healthcare plans and program-related rebates, returns and other deductions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;845</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 67</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11&nbsp;137</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;51</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&nbsp;094</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 113</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;931</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;595</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 234</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;19&nbsp;294</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;151</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 19&nbsp;773</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 99</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;256</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US-specific healthcare plans <br></br>and program rebates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;883 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 0 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;5&nbsp;183 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;193 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 5&nbsp;474 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;981 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-US-specific healthcare plans <br></br>and program rebates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;625 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;28 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;19 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;2&nbsp;467 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 2&nbsp;659 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;769 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-healthcare plans and program-related rebates, returns and other deductions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;754</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11&nbsp;698</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;868</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 103</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;845</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;262</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;19&nbsp;348</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;220</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&nbsp;001</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 104</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;595</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">2018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US-specific healthcare plans <br></br>and program rebates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;590 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;4&nbsp;158 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;90 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 4&nbsp;541 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;883 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-US-specific healthcare plans <br></br>and program rebates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;356 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;78 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;2&nbsp;182 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 83 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 2&nbsp;555 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;109 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;625 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-healthcare plans and program-related rebates, returns and other deductions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;726</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;51</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;12&nbsp;227</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;91</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;956</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 441</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;754</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total 2018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;672</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;129</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;18&nbsp;567</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;98</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 19&nbsp;052</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 332</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;262</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Notes 1, 2 and 30 provide information related to discontinued operations. </div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Charges to the consolidated income statement from continuing operations were USD 18 248 million in 2018. </div> </td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Restructuring provisions movements</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 438</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 507</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 153</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions related to <br></br>discontinued operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;8 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 354</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 492</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 534</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;268</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;479</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;145</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;87</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;72</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;33</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 459</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 438</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 507</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Notes 1, 2 and 30 provide information related to discontinued operations. </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Additions to provisions charged to the consolidated income statement from continuing operations were USD 521 million in 2018. </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Reversal of provisions credited to the consolidated income statement from continuing operations were USD 31 million in 2018. </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2020, additions to provisions of USD&nbsp;354 million were mainly related to the following reorganizations:</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Innovative Medicines Division restructured its field force and supporting functions in Region Europe. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Sandoz Division initiatives to realign its organizational structures to improve competiveness that commenced in 2019 continued. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Group-wide initiatives to streamline Novartis Technical Operations through the setup of operations centers and implementation of new technologies, in the Innovative Medicines Division and the Sandoz Division, continued. In addition, Novartis Business Services continued the phased implementation of the new operating model to change outsourcing structures and transition activities to service centers. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2019, additions to provisions of USD 492 million were mainly related to the following reorganizations:</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Innovative Medicines Division restructured its field force and supporting functions in Latin America, and following the <i>Xiidra</i> acquisition, its Ophthalmology field force in the US. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Sandoz Division initiatives to realign its organizational structures to improve competiveness. These initiatives include reduction in its headquarters, global functions and countries workforce, and the closure of its development center in Holzkirchen, Germany. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Group-wide initiatives to streamline Novartis Technical Operations and implement new technologies, mainly in the Innovative Medicines Division and in the Sandoz Division, continued. In addition, Novartis Business Services launched the next phase of the new operating model to change outsourcing structures and transition activities to service centers. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">In 2018, additions to provisions of USD&nbsp;534 million were mainly related to the following reorganizations:</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Innovative Medicines Division&#x2019;s Oncology business unit initiative to streamline its organizational structure. The objective was to enhance agility and efficiency, resulting in an acceleration of operational execution. In addition, a program to reorganize the Japanese business model was launched. Region Europe transformed its approach to market in light of the changing product portfolio. The objective was to speed up patient access. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Group-wide initiatives to streamline Novartis Technical Operations and implement new technologies, mainly in the Innovative Medicines Division and in the Sandoz Division, continued. In addition, Novartis Business Services launched an initiative to reorganize its organizational structure to achieve cost efficiencies by shifting activities to global service centers. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326163544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Details to the consolidated statements of cash flows<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract', window );"><strong>Disclosure of details to the consolidated statements of cash flows [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory', window );">Details to the consolidated statements of cash flows</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"> <b>23. Details to the consolidated statements of cash flows</b> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.1) Reversal of non-cash items and other adjustments from continuing operations</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation, amortization and impairments on:</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;758</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;547</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;783</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 330</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 305</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;376</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;974</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;428</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial assets <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;335</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;411</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;871</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 895</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gains on disposal and other adjustments on property, plant and equipment; intangible assets; <br></br>financial assets; and other non-current assets, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;478 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;1&nbsp;234 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;902 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-settled compensation expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 738</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 758</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 673</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;673</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;659</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6&nbsp;438</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;807</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;793</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;295</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net financial expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 947</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 805</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 746</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;881</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;122</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;486</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Depreciation of right-of-use assets recognized from January 1, 2019, the date of implementation of IFRS 16 Leases. See Note 1. </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Includes fair value adjustments </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> 2018 included a reversal of a pre-tax gain (USD 5.8 billion) recognized from the divestment of the investment in GSK Consumer Healthcare Holdings Ltd. (see Note 2). The net cash proceed of USD 13.0 billion from the divestment was included in the consolidated statements of cash flows in the line "Acquisitions and divestments of interests in associated companies, net." </div> </td> </tr> </table> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.2) Total amount of taxes paid </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2020, the total amount of taxes paid was USD&nbsp;1.9 billion, of which USD&nbsp;1.8 billion was included within &#x201c;Net cash flows from operating activities from continuing operations&#x201d;, and USD&nbsp;88 million was included within &#x201c;Net cash flows used in investing activities from discontinued operations.&#x201d; </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2019, the total amount of taxes paid was USD&nbsp;2.0 billion, of which USD&nbsp;1.9 billion was included within &#x201c;Net cash flows from operating activities from continuing operations&#x201d;, USD&nbsp;38 million was included within &#x201c;Net cash flows from operating activities from discontinued operations,&#x201d; and USD&nbsp;79 million was included within &#x201c;Net cash flows used in investing activities from discontinued operations.&#x201d; </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2018, the total amount of taxes paid was USD&nbsp;1.8 billion, of which USD&nbsp;1.5 billion was included within &#x201c;Net cash flows from operating activities from continuing operations&#x201d;, USD&nbsp;164 million was included within &#x201c;Net cash flows from operating activities from discontinued operations,&#x201d; and USD&nbsp;139 million was included within &#x201c;Net cash flows used in investing activities from continuing operations.&#x201d; </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.3) Cash flows from changes in working capital and other operating items included in the net cash flows from operating activities from continuing operations </font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Increase) in inventories</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;543</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;382</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;387</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Decrease/(increase) in trade receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 137</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;544</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Decrease)/increase in trade payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;324</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 553</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 252</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 229</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;160</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 316</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 211</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;167</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 941</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other adjustments, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;291</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 199</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 576</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.4) Cash flows arising from acquisitions and divestments of interests in associated companies, net </font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2018, acquisitions and divestments of interests in associated companies included USD 12&#xa0;855 million net of taxes (USD 12&#xa0;994 million before taxes) from the divestment of the investment in GSK Consumer Healthcare Holdings Ltd. (see Note 2). </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.5) Cash flows arising from acquisitions and divestments of businesses, net</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table is a summary of the cash flow impact of acquisitions and divestments of businesses. The most significant transactions are described in Note 2. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of acquisitions of businesses</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;10&nbsp;173</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;124</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;13&nbsp;660</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value of previously held equity interests</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 242</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments, deferred consideration and other adjustments, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 62</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;36</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used for acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;10&nbsp;006</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;851</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;13&nbsp;701</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows from divestments of businesses, net <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 49</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 91</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used for acquisitions and divestments of businesses, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;9&nbsp;957</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;760</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;13&nbsp;683</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> In 2020, USD 49 million represented the net cash inflows from divestments in previous years. <br></br>In 2019, the USD 91 million included USD 4 million of net cash outflows from divestments in previous years, and USD 95 million net cash inflows from business divestments in 2019. The net identifiable assets of the 2019 divested businesses amounted to USD 196 million, comprised of non-current assets of USD 159 million; current assets of USD 96 million, including USD 11 million cash and cash equivalents; non-current liabilities of USD 18 million; and current liabilities of USD 41 million. <br></br>In 2018, USD 18 million represented the net cash inflows from divestments in previous years. </div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Notes 2 and 24 provide further information regarding acquisitions and divestments of businesses. All acquisitions were for cash. </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.6) Reconciliation of liabilities arising from financing activities</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Non-current <br></br> financial <br></br> debts </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Current <br></br> financial <br></br> debts and <br></br> derivative <br></br> financial <br></br> instruments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> Non-current <br></br> lease liabilities </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> Current lease <br></br> liabilities </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2020</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20&nbsp;353</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;031</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;703</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 246</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;126</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of non-current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;003</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;261</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;312</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest payments for amounts included in lease liabilities <br></br>classified as cash flows from operating activities </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;56 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New leases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 221</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 73</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, and other changes, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 65</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 832</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 392</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification from non-current to current, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;067</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;067</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 250</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26&nbsp;259</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;785</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;719</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 286</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> <br></br> Non-current <br></br> financial <br></br> debts </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Current <br></br> financial <br></br> debts and <br></br> derivative <br></br> financial <br></br> instruments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> <br></br> <br></br> Non-current <br></br> lease liabilities </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> <br></br> <br></br> Current lease <br></br> liabilities </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2019</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;470</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;678</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of adoption of IFRS 16 Leases continuing operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;471</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 268</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of adoption of IFRS 16 Leases discontinued operations <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;89</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 246</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 40</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debts and lease liabilities related to discontinued operations <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;47</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;246</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;40</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 93</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of non-current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;195</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;582</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;273</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest payments for amounts included in lease liabilities <br></br>classified as cash flows from operating activities </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;51 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New leases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 362</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 131</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions and divestments of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, and other changes, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 129</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification from non-current to current, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;003</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;003</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;156</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 156</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&nbsp;353</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;031</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;703</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 246</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Lease liabilities recognized on January 1, 2019, the date of implementation of IFRS 16 Leases. See Note 1. </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> In 2018, financial debts included USD 89 million for previously reported finance lease obligations of the Alcon business that were reclassified on January 1, 2019, to lease liabilities, with the adoption of IFRS 16 Leases. Note 30 provides additional disclosures. </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Represents the financial debts and lease liabilities at January 1, 2019, related to the Alcon business reported as discontinued operations. See Notes 1, 2 and 30. </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> <br></br> Non-current <br></br> financial <br></br> debts </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Current <br></br> financial <br></br> debts and <br></br> derivative <br></br> financial <br></br> instruments </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2018</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;224</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;308</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;856</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of non-current financial debts <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;366</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;681</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, and other changes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;48</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;462</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;93</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current portion of non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;190</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;190</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;470</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;678</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Increase in non-current financial debts was only recorded in the consolidated statements of cash flows from continuing operations. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Repayment of non-current financial debts was only recorded in the consolidated statements of cash flows from continuing operations. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Changes in current financial debts included in the consolidated statements of cash flows from continuing operations were USD 1 687 million. </div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For net cash flows used in investing activities from discontinued operations, see Note 30. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Section Presentation of a statement of cash flows<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IAS07_g10-17_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashFlowStatementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326142136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions of businesses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfAcquisitionOfBusinessesAbstract', window );"><strong>Disclosure of acquisition of businesses [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsExplanatory', window );">Acquisition of businesses</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">24. Acquisitions of businesses</div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Fair value of assets and liabilities arising from acquisitions of businesses</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 137</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 196</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;550</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;531</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired research and development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 342</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;224</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 218</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 476</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 60</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 381</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current financial and other assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 84</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 195</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables and financial and other current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 90</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;112</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;977</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;107</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;874</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current lease liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;44</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables and other liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;144</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;178</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;627</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net identifiable assets acquired</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;669</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;938</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;000</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;112</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-controlling interests</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;26</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;580</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 186</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;084</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of acquisitions of businesses <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&nbsp;173</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;946</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> In 2018, net assets recognized as a result of acquisitions of businesses in the consolidated balance sheet from continuing operations were USD 13 660 million. </div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Note 2 details significant acquisitions of businesses, specifically, The Medicines Company and the Japanese business of AGI in 2020; <i>Xiidra</i> and IFM Tre, Inc. in 2019; and AAA, AveXis and Endocyte in 2018. The goodwill arising out of these acquisitions is attributable to the buyer specific synergies, the assembled workforce, and the accounting for deferred tax liabilities on the acquired assets. Goodwill of USD&nbsp;74 million in 2020 (2019: USD 98 million, 2018: nil) is tax deductible. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IFRS03_g59-63_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfAcquisitionOfBusinessesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfAcquisitionOfBusinessesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326159672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-employment benefits for associates<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract', window );"><strong>Disclosure of defined benefit plans [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory', window );">Post-employment benefits for associates</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">25. Post-employment benefits for associates</div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Defined benefit plans</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In addition to the legally required social security schemes, the Group has numerous independent pension and other post-employment benefit plans. In most cases, these plans are externally funded in entities that are legally separate from the Group. For certain Group companies, however, no independent plan assets exist for the pension and other post-employment benefit obligations of associates. In these cases, the related unfunded liability is included in the balance sheet. The defined benefit obligations (DBOs) of all major pension and other post-employment benefit plans are reappraised annually by independent actuaries. Plan assets are recognized at fair value. The major plans are based in Switzerland, the United States, the United Kingdom, Germany and Japan, which represent 95% of the Group&#x2019;s total DBO for pension plans. Details of the plans in the two most significant countries, Switzerland and the United States, which represent 81% of the Group&#x2019;s total DBO for post-employment benefit plans, are provided below. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Swiss-based pension plans represent the most significant portion of the Group&#x2019;s total DBO and plan assets. For the active insured members born on or after January 1, 1956, or having joined the plans after December 31, 2010, the benefits are partially linked to the contributions paid into the plan. Certain features of Swiss pension plans required by law preclude the plans from being categorized as defined contribution plans. These factors include a minimum interest guarantee on retirement savings accounts, a predetermined factor for converting the accumulated savings account balance into a pension, and embedded death and disability benefits. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">All benefits granted under Swiss-based pension plans are vested, and Swiss legislation prescribes that the employer has to contribute a fixed percentage of an associate&#x2019;s pay to an external pension fund. Additional employer contributions may be required whenever the plan&#x2019;s statutory funding ratio falls below a certain level. The associate also contributes to the plan. The pension plans are run by separate legal entities, each governed by a board of trustees that &ndash; for the principal plans &ndash; consists of representatives nominated by Novartis and the active insured associates. The boards of trustees are responsible for the plan design and asset investment strategy. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In December 2020 the Board of Trustees of the Novartis Swiss Pension Fund agreed to adjust the annuity conversion rate at retirement with effect from January 1, 2022. This amendment does not affect existing pensioners, and its impact on existing plan participants will be mitigated by way of defined compensatory measures. This amendment resulted in a net pre-tax curtailment gain of USD 101 million (CHF 90 million). </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The United States pension plans represent the second-largest component of the Group&#x2019;s total DBO and plan assets. The principal plans (Qualified Plans) are funded, whereas plans providing additional benefits for executives (Restoration Plans) are unfunded. Employer contributions are required for Qualified Plans whenever the statutory funding ratio falls below a certain level. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Furthermore, in certain countries, associates are covered under other post-employment benefit plans and post-retirement medical plans. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the US, other post-employment benefit plans consist primarily of post-employment healthcare benefits, which have been closed to new members since 2015. Part of the costs of these plans is reimbursable under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. There is no statutory funding requirement for these plans. The Group is funding these plans to the extent that it is tax efficient. </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables are a summary of the funded and unfunded defined benefit obligation for pension and other post-employment benefit plans of associates at December 31, 2020 and 2019: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment benefit plans</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;066</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;179</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 746</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;073</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit obligations related to discontinued operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;662</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;385</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current service cost</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 372</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 336</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest cost</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 222</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 330</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 29</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past service costs and settlements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;102</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;168</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Administrative expenses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurement losses/(gains) arising from changes in financial assumptions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;791</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurement (gains)/losses arising from changes in demographic assumptions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;193</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Experience-related remeasurement losses/(gains)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 184</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;132</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;22</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;810</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 283</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;264</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;256</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;30</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions of associates</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 186</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 169</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 49</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 25&nbsp;602</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;066</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 632</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 746</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at January 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 19&nbsp;810</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;838</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 134</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 119</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Plan assets related to discontinued operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;424</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;40</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 257</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Return on plan assets excluding interest income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;318</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;656</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;620</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 304</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Group contributions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 464</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 420</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 74</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions of associates</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 186</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 169</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Settlements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;193</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;264</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;256</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;30</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22&nbsp;317</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 19&nbsp;810</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 89</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 134</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;285</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;256</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;543</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;612</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Limitation on recognition of fund surplus at January 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;65</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;68</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in limitation on recognition of fund surplus (incl. exchange rate differences)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income on limitation of fund surplus</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Limitation on recognition of fund surplus at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;51</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;65</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability in the balance sheet at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;336</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;321</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;543</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;612</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Notes 1, 2 and 30 provide information related to discontinued operations. </div> </td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The reconciliation of the net liability from January 1 to December 31 is as follows:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment benefit plans</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability at January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;321</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;409</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;612</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;954</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less: net liability related to discontinued operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 238</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 345</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current service cost</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;372</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;336</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net interest expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;58</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;77</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;26</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Administrative expenses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past service costs and settlements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 117</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;126</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;35</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;190</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Group contributions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 464</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 420</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 74</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in limitation on recognition of fund surplus</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;336</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;321</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;543</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;612</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Amounts recognized in the consolidated balance sheet</div> </td> <td align="right"></td> <td align="right"></td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"></td> <td align="right"></td> <td align="right"></td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid benefit cost</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 202</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 148</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued benefit liability</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;538</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;469</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;543</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;612</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Notes 1, 2 and 30 provide information related to discontinued operations. </div> </td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows a breakdown of the DBO for pension plans by geography and type of member, and the breakdown of plan assets into the geographical locations in which they are held: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Switzerland </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> United <br></br> States </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of <br></br> the world </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Switzerland </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> United <br></br> States </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rest of <br></br> the world </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&nbsp;807</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;788</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;007</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 25&nbsp;602</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&nbsp;106</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;552</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;408</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;066</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof unfunded</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 701</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 516</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 1&nbsp;217</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 670</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 466</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 1&nbsp;136</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">By type of member</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Active</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;837</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 665</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;573</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;075</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;167</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 630</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;400</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;197</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred pensioners</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;290</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;819</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;205</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;517</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;722</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Pensioners</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;970</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;833</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;615</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&nbsp;418</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;939</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;717</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;491</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;147</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&nbsp;396</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;487</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;434</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22&nbsp;317</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;457</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;311</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;042</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 19&nbsp;810</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;411</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;301</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;573</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;285</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;649</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;241</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;366</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;256</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows a breakdown of the DBO for other post-employment benefit plans by geography and type of member, and the breakdown of plan assets into the geographical locations in which they are held: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> United <br></br> States </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of <br></br> the world </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> United <br></br> States </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rest of <br></br> the world </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 543</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 89</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 632</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 658</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 88</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 746</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof unfunded</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 454</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 89</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 543</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 524</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 88</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 612</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">By type of member</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Active</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 80</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 105</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 121</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 157</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred pensioners</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Pensioners</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 446</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 510</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 522</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 52</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 574</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 89</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 89</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 134</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 134</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;454</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;89</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;543</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;524</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;88</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;612</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the principal weighted average actuarial assumptions used for calculating defined benefit plans and other post-employment benefits of associates: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans </div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment benefit plans</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Weighted average assumptions used to determine benefit obligations at December 31</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Discount rate</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.6%</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.0%</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.6%</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.9%</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.6%</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.4%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected rate of pension increase</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.3%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.3%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.4%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected rate of salary increase</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.7%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.8%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.8%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest on savings account</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.1%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.3%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.8%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current average life expectancy <br></br>for a 65-year-old male in years </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 22 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 22 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 22 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 21 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 21 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 21 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current average life expectancy <br></br>for a 65-year-old female in years </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 24 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 24 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 24 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 23 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 23 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 23 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Changes in the aforementioned actuarial assumptions can result in significant volatility in the accounting for the Group&#x2019;s pension plans in the consolidated financial statements. This can result in substantial changes in the Group&#x2019;s other comprehensive income, long-term liabilities and prepaid pension assets. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The DBO is significantly impacted by assumptions regarding the rate that is used to discount the actuarially determined post-employment benefit liability. This rate is based on yields of high-quality corporate bonds in the country of the plan. Decreasing corporate bond yields decrease the discount rate, so that the DBO increases and the funded status decreases. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In Switzerland, an increase in the DBO due to lower discount rates is slightly offset by lower future benefits expected to be paid on the associate&#x2019;s savings account where the assumption on interest accrued changes in line with the discount rate. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The impact of decreasing interest rates on a plan&#x2019;s assets is more difficult to predict. A significant part of the plan assets is invested in bonds. Bond values usually rise when interest rates decrease and may therefore partially compensate for the decrease in the funded status. Furthermore, pension assets also include significant holdings of equity instruments. Share prices tend to rise when interest rates decrease and therefore often counteract the negative impact of the rising defined benefit obligation on the funded status (although the correlation of interest rates with equities is not as strong as with bonds, especially in the short term). </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The expected rate for pension increases significantly affects the DBO of most plans in Switzerland, Germany and the United Kingdom. Such pension increases also decrease the funded status, although there is no strong correlation between the value of the plan assets and pension/inflation increases. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Assumptions regarding life expectancy significantly impact the DBO. An increase in longevity increases the DBO. There is no offsetting impact from the plan assets, as no longevity bonds or swaps are held by the pension funds. Generational mortality tables are used where this data is available. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the sensitivity of the defined benefit pension obligation to the principal actuarial assumptions for the major plans in Switzerland, the United States, the United Kingdom, Germany and Japan on an aggregated basis: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in 2020 year-end <br></br> defined benefit pension obligation </div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in discount rate</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;885</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in discount rate</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 942</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One-year increase in life expectancy</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 993</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in rate of pension increase</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 589</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in rate of pension increase</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;143</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase of interest on savings account</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 62</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease of interest on savings account</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;30</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in rate of salary increase</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 61</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in rate of salary increase</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;61</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The healthcare cost trend rate assumptions used for other post-employment benefits are as follows:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Healthcare cost trend rate <br></br>assumed for next year </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 6.3% </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 6.5% </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 7.0% </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rate to which the cost trend <br></br>rate is assumed to decline </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 4.5% </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 4.5% </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 4.5% </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Year that the rate reaches <br></br>the ultimate trend rate </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 2028 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 2028 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 2028 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the weighted average plan asset allocation of funded defined benefit pension plans at December 31, 2020 and&nbsp;2019:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(as a percentage) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-term <br></br> target <br></br> minimum </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-term <br></br> target <br></br> maximum </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> 2019 </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 36</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Real estate</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alternative investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and other investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash and most of the equity and debt securities have a quoted market price in an active market. Real estate and alternative investments, which include hedge fund, private equity, infrastructure and commodity investments, usually have a quoted market price or a regularly updated net asset value. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The strategic allocation of assets of the different pension plans is determined with the objective of achieving an investment return that, together with the contributions paid by the Group and its associates, is sufficient to maintain reasonable control over the various funding risks of the plans. Based upon the market and economic environments, actual asset allocations may temporarily be permitted to deviate from policy targets. The asset allocation currently includes investments in shares of Novartis AG as per the below table: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> December 31, <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31, <br></br> 2019 </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Investment in shares of Novartis AG</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Number of shares (in millions)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Market value (in USD billions)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The weighted average duration of the defined benefit obligation is 15.4 years (2019: 15.2 years).</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s ordinary contribution to the various pension plans is based on the rules of each plan. Additional contributions are made whenever this is required by statute or law (i.e., usually when statutory funding levels fall below predetermined thresholds). The only significant plans that are foreseen to require additional funding are those in the United Kingdom and Germany. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The expected future cash flows in respect of pension and other post-employment benefit plans at December 31, 2020, were as follows: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Pension plans </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post- <br></br> employment <br></br> benefit plans </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis Group contributions</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2021 (estimated)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 404</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Expected future benefit payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2021</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;245</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;198</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 41</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;191</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 41</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;182</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;165</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026&#x2013;2030</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;651</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 181</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Defined contribution plans</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In many subsidiaries, associates are covered by defined contribution plans. Contributions charged to the consolidated income statement for the defined contribution plans were: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions for defined contribution plans continuing operations</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 501</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 422</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 443</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For defined contribution plans for discontinued operations, see Note 30.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2019-01-01<br> -Section Scope<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IAS19_g2-7_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326031752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based participation plans for associates<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Equity-based participation plans for associates</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">26. Equity-based participation plans for associates</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The expense related to all equity-based participation plans and the liabilities arising from equity-based payment transactions were as follows: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense related to equity-based <br></br>participation plans </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 958 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;067 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 918 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities arising from equity-based payment transactions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 269</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 326</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 273</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Equity-based participation plans can be separated into the following plans:</div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Annual Incentive</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Annual Incentive for the Novartis Group CEO and other Executive Committee members (ECN) is paid 50% in cash and 50% in Novartis restricted shares (RSs) or restricted share units (RSUs). For the Novartis Top Leaders (NTLs), the Annual Incentive is paid 70% in cash and 30% in RSs or RSUs. Both the ECN and NTLs can opt to invest up to the maximum cash portion of their Annual Incentive to receive further RSs or RSUs. Any cash is paid out during February or March in the year following the end of the performance period, and the shares are granted during January in the year following the end of the performance period. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Share savings plans</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Associates in certain countries and certain key executives worldwide are encouraged to invest their Annual Incentive in a share savings plan. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Under the share savings plan, participants may elect to receive their relevant compensation fully or partially in Novartis shares in lieu of cash. As a reward for their participation in the share savings plan, at no additional cost to the participant, Novartis matches their investments in shares after a holding period of three or five years. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Novartis operates share savings plans for which associates may only participate in one of the share savings plans in any given year. The most significant are listed below: </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; In Switzerland, Employee Share Ownership Plan (ESOP) participants may choose to receive their Annual Incentive (i) 100% in shares, (ii) 50% in shares and 50% in cash, or (iii) 100% in cash. After expiration of a three-year holding period for Novartis shares invested under the ESOP, participants will receive one matching share for every two invested shares. Associates eligible for the equity plan &#x201c;Select&#x201d; are not eligible to receive ESOP matching shares starting with the 2017 performance period. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Leveraged Share Savings Plan (LSSP) was available to key executives for performance periods prior to 2016. At the participant&#x2019;s election, the Annual Incentive was awarded partly or entirely in shares. The elected number of shares is subject to a holding period of five years. At the end of the holding period, Novartis will match the invested shares at a ratio of 1-to-1 (i.e., one share awarded for each invested share). In the United States, both the LSSP award and the corresponding match are cash settled. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Novartis Group CEO, the other Executive Committee members from 2014, and the NTLs from 2016 are not eligible to participate in the share savings plans. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Novartis equity plan &#x201c;Select&#x201d;</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The equity plan &#x201c;Select&#x201d; is a global equity incentive plan under which eligible associates may annually be awarded a grant subject to a three-year, and for selected units a four-year, staggered vesting period. No awards are granted for performance ratings below a certain threshold. Executive Committee members and NTLs are not eligible to participate in the equity plan &#x201c;Select&#x201d;. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The equity plan &#x201c;Select&#x201d; currently allows participants in Switzerland to choose the form of their equity compensation in RSs or RSUs. In all other jurisdictions, RSs or RSUs are granted unilaterally. Until 2013, participants could also choose to receive part or the entire grant in the form of tradable share options. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Tradable share options expire on their 10 <sup>th</sup> anniversary from the grant date. Each tradable share option entitles the holder to purchase after vesting (and before the 10 <sup>th</sup> anniversary from the grant date) one Novartis share at a stated exercise price that equals the closing market price of the underlying share at the grant date. As the exercise price does not reflect the decrease in the Novartis share due to the Alcon spin, one-fifth of an Alcon share will also be awarded to the option holder upon exercise. </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Options under Novartis equity plan &#x201c;Select&#x201d; outside North America</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the activity associated with the share options during the period. The weighted average prices in the table below are translated from Swiss francs into USD at historical rates. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Options <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br></br> average <br></br> exercise <br></br> price <br></br> (USD) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> <br></br> Options <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted <br></br> average <br></br> exercise <br></br> price <br></br> (USD) </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Options outstanding <br></br>at January 1 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 3.4 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 60.9 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 5.6 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 59.9 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sold or exercised</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;0.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 58.4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 62.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 60.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 62.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 60.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">All share options were granted at an exercise price that was equal to the closing market price of the Group&#x2019;s shares at the grant date. The weighted average share price at the dates of sale or exercise was USD&nbsp;91.7. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table summarizes information about share options outstanding at December 31, 2020: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>Options outstanding </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total/ <br></br> weighted <br></br> average </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Number outstanding (millions)</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.4</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.8</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.4</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2.6</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remaining contractual life (years)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1.4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise price (USD)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 66.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 62.0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Options under Novartis equity plan &#x201c;Select&#x201d; for North America</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the activity associated with the ADR options during the period: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> ADR <br></br> options <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br></br> average <br></br> exercise <br></br> price <br></br> (USD) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> ADR <br></br> options <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted <br></br> average <br></br> exercise <br></br> price <br></br> (USD) </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Options outstanding <br></br>at January 1 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 9.6 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 61.9 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 15.2 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 60.7 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sold or exercised</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 59.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 58.6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 62.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 61.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 62.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 61.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">All ADR options were granted at an exercise price that was equal to the closing market price of the ADRs at the grant date. The weighted average ADR price at the dates of sale or exercise was USD&nbsp;92.2. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table summarizes information about ADR options outstanding at December 31, 2020: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>ADR options outstanding </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total/ <br></br> weighted <br></br> average </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Number outstanding (millions)</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.4</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.3</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6.7</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remaining contractual life (years)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1.5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise price (USD)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 58.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 66.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 62.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Long-Term Performance Plan</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Long-Term Performance Plan (LTPP) is an equity plan for the ECN, the NTLs and employees of Group units with specific targets. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Participants are granted a target number of performance share units (PSUs) at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. The actual payout depends on the achievement of the performance measures and ranges between 0% and 200% of the granted amount. PSUs granted under the LTPP do not carry voting rights, but do carry dividend equivalents that are paid in unrestricted Novartis shares at the end of the performance period. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The LTPP awards are subject to a three-year performance and vesting period. Until 2018, the performance criteria were based on Novartis internal performance metrics. Starting in 2019, for new grants the performance criteria are based on both Novartis internal performance metrics and variables that can be observed in the market, which is the ranking of the Novartis total shareholder return (TSR) relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">TSR for Novartis and the peer companies is calculated as the change in the company share price, which is translated to USD at the relevant exchange rate, including the reinvestment return of dividends, over the three-year performance period. The calculation is based on Bloomberg standard published TSR data, which is publicly available. The position of Novartis in the peer group determines the payout range based on a payout matrix. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Long-Term Relative Performance Plan</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The LTRPP is an equity plan for the Novartis ECN and NTLs. The last grant under this plan was made in 2018. The LTRPP performance criteria are based on variables that can be observed in the market, which is the ranking of the Novartis TSR relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. The TSR for Novartis and the peer companies is calculated as described in the LTPP section above. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Other share awards</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Selected associates, excluding the ECN members, may exceptionally receive Special Share Awards of RSs or RSUs. These Special Share Awards provide an opportunity to reward outstanding achievements or exceptional performance, and aim to retain key contributors. They are based on a formal internal selection process, through which the individual performance of each candidate is thoroughly assessed at several management levels. Special Share Awards have a minimum three-year vesting period. In exceptional circumstances, Special Share Awards may be awarded to attract special expertise and new talents to the organization. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Worldwide, associates at different levels in the organization were awarded RSs and RSUs in 2020, 2019 and 2018. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, in 2020, 2019 and 2018, Board members received unrestricted shares as part of their regular compensation.</div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Summary of non-vested share movements</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The table below provides a summary of non-vested share movements (RSs, RSUs and PSUs) for all plans: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Number <br></br> of shares <br></br> in millions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br></br> average fair <br></br> value at grant <br></br> date in USD </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Fair value at <br></br> grant date in <br></br> USD millions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Number <br></br> of shares <br></br> in millions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted <br></br> average fair <br></br> value at grant <br></br> date in USD </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Fair value at <br></br> grant date in <br></br> USD millions </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-vested shares at January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 25.8</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 71.1</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;835</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25.7</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 77.1</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;981</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Granted</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Annual Incentive</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 93.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 103</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 78.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 86</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Share savings plans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 95.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 399</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 83.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 349</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Select North America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 86.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 286</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 64.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 339</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Select outside North America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 89.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 179</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 67.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 175</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Long-Term Performance Plan</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 85.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 213</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 68.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 172</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Long-Term Relative Performance Plan <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Other share awards</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 78.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 117</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 67.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 129</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vested</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 74.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;024</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;13.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 80.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;068</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forfeited</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 75.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;151</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;328</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-vested shares at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 24.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 78.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;957</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;835</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> LTRPP grants in 2020 represent incremental payouts based on performance criteria under the plan. In 2019 the LTRPP grants are keep whole awards granted due to the spin-off of the Alcon business. </div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At April 8, 2019, the Alcon spin-off date, all RSU and PSU holders, who were not entitled to the dividend in kind in the form of Alcon shares received keep whole awards in Novartis shares to compensate for the loss of the Alcon value from their Novartis shares. These keep whole awards were accounted for as a modification. As they did not increase the value of the original grant, they did not lead to additional expense. In the table above, this is reflected by a zero fair value at grant date amount. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 44<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904347055768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with related parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Disclosure of transactions between related parties [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Transactions with related parties</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">27. Transactions with related parties</div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Roche Holding AG</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has two agreements with Genentech, Inc., United States (Genentech), and one agreement with Spark Therapeutics, Inc., United States (Spark). Both companies are subsidiaries of Roche Holding AG (Roche), which is indirectly included in the consolidated financial statements using equity accounting since Novartis holds 33.3% of the outstanding voting shares of Roche (see Note 4). </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <i>Lucentis</i> </font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has licensed from Genentech/Roche the exclusive rights to develop and market <i>Lucentis</i> outside the United States for indications related to diseases of the eye. Novartis pays royalties on the net sales of <i>Lucentis</i> products outside the United States. In 2020, <i>Lucentis</i> sales of USD&nbsp;1.9 billion (2019: USD&nbsp;2.1 billion; 2018: USD&nbsp;2.0 billion) were recognized by Novartis. </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <i>Xolair</i> </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis and Genentech/Roche are co-promoting <i>Xolair</i> in the United States, where Genentech/Roche records all sales. Novartis records sales outside the United States. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis markets <i>Xolair</i> and records all sales and related costs outside the United States as well as co-promotion costs in the US. Genentech/Roche and Novartis share the resulting profits from sales in the United States, Europe and other countries, according to agreed profit-sharing percentages. In 2020, Novartis recognized total sales of <i>Xolair</i> of USD&nbsp;1.3 billion (2019: USD&nbsp;1.2 billion; 2018: USD&nbsp;1.0 billion), including sales to Genentech/Roche for the United States market. </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <i>Luxturna</i> </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2018, Novartis entered into an exclusive licensing and commercialization agreement and a supply agreement with Spark for <i>Luxturna</i> outside the United States. The agreements include regulatory and sales milestones as well as royalties payable to Spark on ex-US sales. On December 17, 2019, Roche acquired Spark. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The net income for royalties, cost sharing and profit sharing arising out of the <i>Lucentis</i>, <i>Xolair</i> and <i>Luxturna</i> agreements with Roche totaled USD&nbsp;217 million in 2020 (net income in 2019: USD&nbsp;101 million; net expense in 2018: USD&nbsp;34 million). </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Furthermore, Novartis has several patent license, supply and distribution agreements with Roche. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Novartis Pension Fund</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2018, a Group subsidiary provided an uncommitted overnight credit facility to the Novartis Pension Fund, Switzerland, for up to USD 500 million with interest at the US Federal Funds Rate. This credit facility was not utilized during the years 2020, 2019 and 2018. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Executive Officers and Non-Executive Directors compensation</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2020, there were 13 Executive Committee members (&#x201c;Executive Officers&#x201d;). There were 15 Executive Officers in 2019 and 17 Executive Officers in 2018, including those who stepped down. </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The total compensation for Executive Committee members and the 14 Non-Executive Directors (13 in 2019 and 2018) using the Group&#x2019;s accounting policies for equity-based compensation and pension benefits was as follows: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Executive Officers</div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-Executive Directors</div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and other compensation</div> </td> <td align="right" width="5%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.6</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20.7</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22.5</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.6</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.1</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30.2</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24.8</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26.5</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Post-employment benefits</div> </td> <td align="right"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div> </td> <td align="right"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 41.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 40.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 42.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 46.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 45.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 47.3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 69.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 63.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 67.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 79.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 72.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 76.3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2020, the IFRS compensation expense increased due to higher cash and other compensation. This increase in cash compensation is mainly attributable to ECN members who joined the ECN during 2019, as a result 2019 represented only a portion of their annual compensation. Other compensation increased on account of higher social security payments on vested equity-based compensation. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">During 2019, the IFRS compensation expense decreased due to lower cash buyout payments to new executive officers and the forfeiture of equity-based compensation as a result of the resignation of an executive officer. These effects were partially offset by higher equity based compensation of executive officers appointed over the last three years. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Annual Incentive award, which is fully included in equity-based compensation even when paid out in cash, is granted in January in the year following the reporting period. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The disclosures on Board and executive compensation required by the Swiss Code of Obligations and in accordance with the Swiss Ordinance against Excessive Compensation in Stock Exchange Listed Companies are shown in the Compensation Report of the Group. </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Transactions with former members of the Board of Directors</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2020, 2019 and 2018, the following payments (or waivers of claims) were made to former Board members or to &#x201c;persons closely&#x201d; linked to them: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currency</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dr. Krauer</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60&nbsp;000</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 60&nbsp;000</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 60&nbsp;000</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dr. Vasella</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&nbsp;228</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Dr. Alex Krauer, Honorary Chairman, is entitled to an amount of CHF&nbsp;60&#xa0;000 for annual periods from one AGM to the next. This amount was fixed in 1998 upon his departure from the Board in 1999, and has not been revised since that date. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2019-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326098440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CommitmentsAndContingenciesAbstract', window );"><strong>Commitments and contingencies [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfCommitmentsAndContingenciesTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">28. Commitments and contingencies</div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Research and development commitments</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has entered into long-term research and development agreements with various institutions, which provide for potential milestone payments by Novartis that may be capitalized. As of December 31, 2020, the Group&#x2019;s commitments to make payments under those agreements, and their estimated timing, were as follows: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2021</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 449</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 691</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 325</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 483</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 281</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Thereafter</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;003</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;232</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In addition in November 2020 and in January 2021, Novartis entered into long-term research and development agreements, both of which did not close as of January 25, 2021. These agreements provide for potential milestones payments by Novartis that may be capitalized. Based on their estimated timing, the payments for these transactions are expected to amount to USD 549 million in 2021, USD 248 million in 2022, USD 160 million in 2023, USD 415 million in 2024, USD 515 million in 2025, USD 1&#xa0;409 million later than 2025, for a total of USD 3&#xa0;296 million. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Commitments for capital calls</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group holds investments in funds in which it has committed to invest further upon future capital calls. As of December 31, 2020, the total uncalled capital commitments for the Group&#x2019;s investments in funds amounts to USD 87 million. Note 29 contains further information on the Group&#x2019;s investments in funds. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Other commitments</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has entered into various purchase commitments for services and materials as well as for equipment in the ordinary course of business. These commitments are generally entered into at current market prices and reflect normal business operations. For disclosure of property, plant and equipment purchase commitments, see Note 9. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Guarantees issued</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has issued guarantees to third parties in the ordinary course of business, mostly for tax, customs or other governmental agencies. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, Novartis AG is guarantor of the Group&#x2019;s issued bonds, credit facilities and commercial paper programs. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Contingencies</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Group companies have to observe the laws, government orders and regulations of the country in which they operate. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A number of Novartis companies are, and will likely continue to be, subject to various legal proceedings and investigations that arise from time to time, including proceedings regarding product liability; sales and marketing practices; commercial disputes; employment and wrongful discharge; and antitrust, securities, health and safety, environmental, tax, international trade, privacy and intellectual property matters. As a result, the Group may become subject to substantial liabilities that may not be covered by insurance and that could affect our business, financial position and reputation. While Novartis does not believe that any of these legal proceedings will have a material adverse effect on its financial position, litigation is inherently unpredictable and large judgments sometimes occur. As a consequence, Novartis may in the future incur judgments or enter into settlements of claims that could have a material adverse effect on its results of operations or cash flow. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Governments and regulatory authorities around the world have been stepping up their compliance and law enforcement activities in recent years in key areas, including marketing practices, pricing, corruption, trade restrictions, embargo legislation, insider trading, antitrust, cyber security and data privacy. Further, when one government or regulatory authority undertakes an investigation, it is not uncommon for other governments or regulators to undertake investigations regarding the same or similar matters. Responding to such investigations is costly and requires an increasing amount of management&#x2019;s time and attention. In addition, such investigations may affect our reputation, create a risk of potential exclusion from government reimbursement programs in the United States and other countries, and lead to (or arise from) litigation. These factors have contributed to decisions by Novartis and other companies in the healthcare industry, when deemed in their interest, to enter into settlement agreements with governmental authorities around the world prior to any formal decision by the authorities or a court. These government settlements have involved and may in the future involve large cash payments, sometimes in the hundreds of millions of dollars or more, including the potential repayment of amounts allegedly obtained improperly and other penalties, including treble damages. In addition, settlements of government healthcare fraud cases often require companies to enter into corporate integrity agreements, which are intended to regulate company behavior for a period of years. Our affiliate Novartis Corporation is a party to such an agreement, which will expire in 2025. Also, matters underlying governmental investigations and settlements may be the subject of separate private litigation. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">While provisions have been made for probable losses, which management deems to be reasonable or appropriate, there are uncertainties connected with these estimates. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 20 contains additional information on these matters.</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A number of Group companies are involved in legal proceedings concerning intellectual property rights. The inherent unpredictability of such proceedings means that there can be no assurances as to their ultimate outcome. A negative result in any such proceeding could potentially adversely affect the ability of certain Novartis companies to sell their products, or require the payment of substantial damages or royalties. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the opinion of management, however, the outcome of these actions will not materially affect the Group&#x2019;s financial position but could be material to the results of operations or cash flow in a given period. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s potential environmental remediation liability is assessed based on a risk assessment and investigation of the various sites identified by the Group as at risk for environmental remediation exposure. The Group&#x2019;s future remediation expenses are affected by a number of uncertainties. These uncertainties include, but are not limited to, the method and extent of remediation, the percentage of material attributable to the Group at the remediation sites relative to that attributable to other parties, and the financial capabilities of the other potentially responsible parties. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 20 contains additional information on environmental liabilities.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfCommitmentsAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfCommitmentsAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904323716136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - additional disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FinancialInstrumentsAdditionalDisclosureAbstract', window );"><strong>Financial Instruments - additional disclosure [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory', window );">Disclosure of detailed information about financial instruments [text block]</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">29. Financial instruments &ndash; additional disclosures</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables show the carrying values of financial instruments by measurement categories as of December 31, 2020 and 2019. Except for straight bonds (see Note 19), the carrying values are equal to, or a reasonable approximation of, the fair values. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> <br></br> <br></br> Note </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> <br></br> Financial <br></br> instruments at <br></br> amortized <br></br> costs </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> Financial <br></br> instruments at <br></br> fair value <br></br> through other <br></br> comprehensive <br></br> income </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Financial <br></br> instruments at <br></br> fair value <br></br> through the <br></br> consolidated <br></br> income <br></br> statement </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> <br></br> <br></br> Other <br></br> financial <br></br> liabilities </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;658</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;609</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;217</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 963</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities - debt securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - equity securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;111</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 466</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - debt securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 366</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances, security deposits and other long-term receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 297</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Associated companies at fair value through profit and loss</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 211</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 625</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20&nbsp;744</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;173</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;827</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of associates payable on demand</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;085</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other short-term financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 976</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;258</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&nbsp;298</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term liabilities to banks and other financial institutions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;403</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18/22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;769</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities (see Note 20/22) and other financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;069</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;005</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 43&nbsp;022</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;263</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;005</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> <br></br> <br></br> Note </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> <br></br> Financial <br></br> instruments at <br></br> amortized <br></br> costs </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Financial <br></br> instruments at <br></br> fair value <br></br> through other <br></br> comprehensive <br></br> income </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Financial <br></br> instruments at <br></br> fair value <br></br> through the <br></br> consolidated <br></br> income <br></br> statement </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> <br></br> <br></br> Other <br></br> financial <br></br> liabilities </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;112</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;301</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;036</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities - debt securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities - fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - equity securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;158</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 366</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - debt securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances, security deposits and other long-term receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 329</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Associated companies at fair value through profit and loss</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 186</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 399</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 21&nbsp;839</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;215</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;323</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of associates payable on demand</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;836</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other short-term financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 719</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;289</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22&nbsp;167</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term liabilities to banks and other financial institutions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;424</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities (see Note 20/22) and other financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;065</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 185</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;949</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 32&nbsp;623</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;949</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Derivative financial instruments</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables show the contract or underlying principal amounts and fair values of derivative financial instruments analyzed by type of contract at December&nbsp;31, 2020 and 2019. Contract or underlying principal amounts indicate the gross volume of business outstanding at the consolidated balance sheet date and do not represent amounts at risk. The fair values are determined by reference to market prices or standard pricing models that use observable market inputs at December 31,&nbsp;2020 and 2019. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Contract or underlying principal amount</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Positive fair values </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Negative fair values </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&nbsp;679</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;779</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 151</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 96</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;165</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;75</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 269</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;110</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments included in marketable securities and in current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;760</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;057</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 102</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;185</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows by currency contract or underlying principal amount the derivative financial instruments at December&nbsp;31,&nbsp;2020 and 2019: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> EUR</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;432</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;376</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;871</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&nbsp;679</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;432</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;457</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;871</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;760</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> EUR</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;373</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;760</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;646</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;779</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 269</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;373</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;665</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;057</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Derivative financial instruments effective for hedge accounting purposes</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At the end of 2020 and 2019, there were no open hedging instruments for anticipated transactions. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Fair value by hierarchy</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As required by IFRS, financial assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. There are three hierarchical levels, based on increasing subjectivity associated with the inputs to derive fair valuation for these assets and liabilities, which are as follows: </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The assets carried at Level 1 fair value are equity and debt securities listed in active markets. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The assets generally included in Level 2 fair value hierarchy are foreign exchange and interest rate derivatives, and certain debt securities. Foreign exchange and interest rate derivatives are valued using corroborated market data. The liabilities generally included in this fair value hierarchy consist of foreign exchange and interest rate derivatives. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Level 3 inputs are unobservable for the asset or liability. The assets generally included in Level 3 fair value hierarchy are various investments in hedge funds and unquoted equity security investments. Contingent consideration carried at fair value is included in this category. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 1</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 2</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 3</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 159</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 159</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities and derivative financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 185</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 185</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt and equity securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;153</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 460</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;613</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 366</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 366</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 625</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 625</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total long-term financial investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;153</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;451</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;604</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit and loss</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 211</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 211</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;046</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;046</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;194</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities at fair value</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;069</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;263</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 1</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 2</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 3</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 61</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities and derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 126</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 163</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt and equity securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 976</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 581</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;557</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 233</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 399</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 399</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total long-term financial investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 976</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;213</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;189</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit and loss</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 186</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 186</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;036</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;036</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;29</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;185</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;185</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities at fair value</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;185</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;065</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;250</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The change in carrying values associated with Level 3 financial instruments, using significant unobservable inputs during the year ended December 31, is set forth below: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="13" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="13" style="border-bottom: solid #000000 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Associated <br></br> companies at <br></br> fair value through <br></br> profit and loss </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Fund <br></br> investments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Long-term <br></br> financial <br></br> investments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Contingent <br></br> consideration <br></br> receivables </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Contingent <br></br> consideration <br></br> payables </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Other <br></br> financial <br></br> liabilities </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 186</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 233</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 581</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 399</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;036</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;29</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value gains and other adjustments, <br></br>including from divestments recognized <br></br>in the consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 57 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 151 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 34 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 173 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 206 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value losses (including impairments and <br></br>amortizations) and other adjustments recognized <br></br>in the consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &#x2013;&#x2005;18 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &#x2013;&#x2005;8 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &#x2013;&#x2005;39 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &#x2013;&#x2005;90 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &#x2013;&#x2005;3 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments recognized in the consolidated statement <br></br>of comprehensive income, including currency translation effects </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 33 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 40 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;62 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;2 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 123</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;123</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash receipts and payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 63</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;61</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;163</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 211</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 366</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 460</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 625</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;046</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of fair value gains and losses recognized <br></br>in the consolidated income statement for assets <br></br>and liabilities held at December 31, 2020 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 39 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 143 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &#x2013;&#x2005;5 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 173 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 116 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &#x2013;&#x2005;3 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <b></b> <b></b> <b></b> <b></b> </div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> <b></b> <b></b> <b></b> </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="13" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="13" style="border-bottom: solid #000000 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Associated <br></br> companies at <br></br> fair value through <br></br> profit and loss </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Fund <br></br> investments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Long-term <br></br> financial <br></br> investments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Contingent <br></br> consideration <br></br> receivables </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Contingent <br></br> consideration <br></br> payables </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Other <br></br> financial <br></br> liabilities </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 145</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 251</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 488</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 396</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;907</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;10</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact from discontinued operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 163</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value gains and other adjustments, <br></br>including from divestments recognized <br></br>in the consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 12 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 35 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 195 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 1 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value losses (including impairments and <br></br>amortizations) and other adjustments recognized <br></br>in the consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &#x2013;&#x2005;15 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &#x2013;&#x2005;89 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &#x2013;&#x2005;48 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments recognized in the consolidated statement <br></br>of comprehensive income </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 49</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 229</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;401</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash receipts and payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;53</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;64</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 186</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 581</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 399</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;036</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;29</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of fair value gains and losses recognized <br></br>in the consolidated income statement for assets <br></br>and liabilities held at December 31, 2019 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &#x2013;&#x2005;15 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 12 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 35 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 106 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &#x2013;&#x2005;47 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Notes 1, 2 and 30 provide information related to discontinued operations. </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2020, there were several individually non-significant transfers of financial investments from Level 3 to Level 1 for USD&nbsp;166 million (2019: USD&nbsp;64 million), mainly due to initial public offerings of the invested companies. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Realized gains and losses associated with Level 3 long-term financial investments measured at fair value through the consolidated income statement are recorded in the consolidated income statement under &#x201c;Other income&#x201d; or &#x201c;Other expense,&#x201d; respectively. Realized gains and losses associated with Level 3 long-term financial investments measured at fair value through other comprehensive income are not recycled through the consolidated income statement but are instead reclassified to retained earnings. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">During the year, the net loss and net gain recorded on associated companies, fund investments and long-term financial investments at fair value through profit and loss were USD 92 million and USD 427 million, respectively. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If the pricing parameters for the Level 3 input were to change for associated companies at fair value through profit and loss, fund investments and long-term financial investments by 10% positively or negatively, this would change the amounts recorded in the 2020 consolidated statement of comprehensive income by USD&nbsp;104 million. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To determine the fair value of a contingent consideration, various unobservable inputs are used. A change in these inputs might result in a significantly higher or lower fair value measurement. The inputs used are, among others, the probability of success, sales forecast and assumptions regarding the discount rate and timing and different scenarios of triggering events. The inputs are interrelated. The significance and usage of these inputs to each contingent consideration may vary due to differences in the timing and triggering events for payments or in the nature of the asset related to the contingent consideration. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If the most significant parameters for the Level&nbsp;3 input were to change by 10% positively or negatively, or where the probability of success (POS) is the most significant input parameter, 10% were added or deducted from the applied probability of success, for contingent consideration payables, other financial liabilities and contingent consideration receivables, this would change the amounts recorded in the 2020 consolidated income statement by USD&nbsp;260 million and USD&nbsp;324 million, respectively. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Equity securities measured at fair value through other comprehensive income</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Equity securities held as strategic investments, typically held outside the Novartis Venture Fund, are generally designated at date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. Except for the investment in Alcon Inc. with a fair value of USD 71 million at December 31, 2020 (2019: USD 382 million), these are made up of individually non-significant investments. At December 31, 2020, the Group holds 56 non-listed equity securities (December 31, 2019: 53) and 34 listed equity securities (December 31, 2019: 29) in this category with the following fair values: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Listed equity securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 862</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 843</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-listed equity securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 249</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 315</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;111</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;158</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There were no dividends recognized during 2020 and 2019 from these equity securities. In 2020, in accordance with the consolidated foundations Alcon Inc. shares divestment plans, Alcon Inc. shares with a fair value of USD&nbsp;331 million were sold (2019: USD 976 million), and the USD&nbsp;13 million gain on disposal (2019: USD 62 million gain) was transferred from other comprehensive income to retained earnings during 2020. In addition, in 2020, equity securities that were no longer considered strategic, with a fair value of USD&nbsp;206 million (2019: USD&nbsp;33 million), were sold, and the USD&nbsp;137 million gain on disposal (2019: USD&nbsp;33 million gain) was transferred from other comprehensive income to retained earnings (see Note 8). </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Nature and extent of risks arising from financial instruments</font> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Market risk</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis is exposed to market risk, primarily related to foreign currency exchange rates, interest rates, and the market value of the investments of liquid funds. The Group actively monitors and seeks to reduce, where it deems it appropriate to do so, fluctuations in these exposures. It is the Group&#x2019;s policy and practice to enter into a variety of derivative financial instruments to manage the volatility of these exposures and to enhance the yield on the investment of liquid funds. It does not enter into any financial transactions containing a risk that cannot be quantified at the time the transaction is concluded. In addition, it does not sell short assets it does not have, or does not know it will have, in the future. The Group only sells existing assets or enters into transactions and future transactions (in the case of anticipatory hedges) that it confidently expects it will have in the future, based on past experience. In the case of liquid funds, the Group writes call options on assets it has, or writes put options on positions it wants to acquire and has the liquidity to acquire. The Group expects that any loss in value for these instruments generally would be offset by increases in the value of the underlying transactions. </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Foreign currency exchange rate risk</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group uses the US dollar as its reporting currency. As a result, the Group is exposed to foreign currency exchange movements, primarily in European, Japanese and emerging market currencies. Fluctuations in the exchange rates between the US dollar and other currencies can have a significant effect on both the Group&#x2019;s results of operations, including reported sales and earnings, as well as on the reported value of our assets, liabilities and cash flows. This, in turn, may significantly affect the comparability of period-to-period results of operations. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Because our expenditures in Swiss francs are significantly higher than our revenues in Swiss francs, volatility in the value of the Swiss franc can have a significant impact on the reported value of our earnings, assets and liabilities, and the timing and extent of such volatility can be difficult to predict. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There is also a risk that certain countries could devalue their currency. If this occurs, it could impact the effective prices we would be able to charge for our products and also have an adverse impact on both our consolidated income statement and balance sheet. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Subsidiaries whose functional currencies have experienced a cumulative inflation rate of more than 100% over the past three years apply the rules of IAS 29 &#x201c;Financial reporting in Hyperinflationary Economies&#x201d;. The hyperinflationary economies in which Novartis operates are Argentina and Venezuela. Venezuela was hyperinflationary for all years presented, and Argentina became hyperinflationary effective July 1, 2018, requiring retroactive implementation of hyperinflation accounting as of January 1, 2018. The impacts of applying IAS 29 were not significant in all years presented. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group manages its global currency exposure by engaging in hedging transactions where management deems appropriate. Novartis may enter into various contracts that reflect the changes in the value of foreign currency exchange rates to preserve the value of assets, commitments and anticipated transactions. Novartis also uses forward contracts and foreign currency option contracts to hedge. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net investments in subsidiaries in foreign countries are long-term investments. Their fair value changes through movements of foreign currency exchange rates. The Group has designated a certain portion of its long-term euro-denominated straight bonds as hedges of the translation risk arising on certain of these net investments in foreign operations with euro functional currency. As of December 31, 2020, long-term financial debt with a carrying amount of EUR&nbsp;1.8 billion (USD&nbsp;2.3 billion) (December 31, 2019: USD 2.1 billion), has been designated as a hedge instrument. During 2020, USD&nbsp;201 million of unrealized loss (unrealized income in 2019: USD 44 million) was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge. The hedge remained effective since inception, and no amount was recognized in the consolidated income statement in 2020, 2019 and 2018. </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Commodity price risk</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has only a very limited exposure to price risk related to anticipated purchases of certain commodities used as raw materials by the Group&#x2019;s businesses. A change in those prices may alter the gross margin of a specific business, but generally by not more than 10% of the margin and thus below the Group&#x2019;s risk management tolerance levels. Accordingly, the Group does not enter into significant commodity futures, forward or option contracts to manage fluctuations in prices of anticipated purchases. </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest rate risk</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group addresses its net exposure to interest rate risk mainly through the ratio of its fixed-rate financial debt to variable-rate financial debt contained in its total financial debt portfolio. To manage this mix, Novartis may enter into interest rate swap agreements, in which it exchanges periodic payments based on a notional amount and agreed-upon fixed and variable interest rates. </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Equity risk</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group may purchase equities as investments of its liquid funds. As a policy, it limits its holdings in an unrelated company to less than 5% of its liquid funds. Potential investments are thoroughly analyzed. Call options are written on equities that the Group owns, and put options are written on equities that the Group wants to buy and for which cash is available. </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Credit risk</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Credit risks arise from the possibility that customers may not be able to settle their obligations as agreed. To manage this risk, the Group periodically assesses country and customer credit risk, assigns individual credit limits, and takes actions to mitigate credit risk where appropriate. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The provisions for expected credit losses for customers are based on a forward-looking expected credit loss, which includes possible default events on the trade receivables over the entire holding period of the trade receivables. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In measuring the expected credit losses, trade receivables are grouped based on shared credit risk characteristics (such as private versus public receivables) and days past due. In determining the expected credit loss rates, the Group considers current and forward-looking macroeconomic factors that may affect the ability of the customers to settle the receivables, and historical loss rates for each category of customers. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s largest customer accounted for approximately 17% of net sales, and the second largest and third largest customers accounted for 11% and 6% of net sales, respectively (2019: 18%, 13% and 8%, respectively; 2018: 18%, 14% and 8%, respectively).</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The highest amounts of trade receivables outstanding were for these same three customers and amounted to 14%, 12% and 6%, respectively, of the Group&#x2019;s trade receivables at December 31, 2020 (2019: 14%, 12% and 7%, respectively). There is no other significant concentration of customer credit risk. </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Counterparty risk</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Counterparty risk encompasses issuer risk on marketable securities and money market instruments; credit risk on cash, time deposits and derivatives; as well as settlement risk for different instruments. Issuer risk is reduced by only buying securities that are at least A- rated. Counterparty credit risk and settlement risk are reduced by a policy of entering into transactions with counterparties (banks or financial institutions) that feature a strong credit rating. Exposure to these risks is closely monitored and kept within predetermined parameters. The limits are regularly assessed and determined based upon credit analysis, including financial statement and capital adequacy ratio reviews. In addition, reverse repurchasing agreements are contracted, and Novartis has entered into credit support agreements with various banks for derivative transactions. To further reduce the settlement risk, the Group has implemented a multi-currency system, CLS (Continuous Linked Settlement), providing multilateral netting (payment-versus-payment settlement) of cash flows from foreign exchange transactions. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s cash and cash equivalents are held with major regulated financial institutions; the three largest ones hold approximately 14.1%, 12.6% and 9.7%, respectively (2019: 12.6%, 10.4% and 8.3%, respectively). </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group does not expect any losses from non-performance by these counterparties and does not have any significant grouping of exposures to financial sector or country risk. </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Liquidity risk</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Liquidity risk is defined as the risk that the Group could not be able to settle or meet its obligations associated with financial liabilities that are settled by delivering cash or another financial asset. Group Treasury is responsible for liquidity, funding and settlement management. In addition, liquidity and funding risks, and related processes and policies, are overseen by management. Novartis manages its liquidity risk on a consolidated basis according to business needs and tax, capital or regulatory considerations, if applicable, through numerous sources of financing in order to maintain flexibility. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Certain countries have legal or economic restrictions on the ability of subsidiaries to transfer funds to the Group in the form of cash dividends, loans or advances, but these restrictions do not have an impact on the ability of the Group to meet its cash obligations. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Management monitors the Group&#x2019;s net debt or liquidity position through rolling forecasts on the basis of expected cash flows. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis has two US commercial paper programs under which it can issue up to USD&nbsp;9.0 billion in the aggregate of unsecured commercial paper notes. Novartis also has a Japanese commercial paper program under which it can issue up to JPY&nbsp;150 billion (approximately USD&nbsp;1.5 billion) of unsecured commercial paper notes. Commercial paper notes totaling USD&nbsp;4.3 billion under these three programs were outstanding as per December 31, 2020 (2019: USD&nbsp;2.3 billion). Novartis further has a committed credit facility of USD&nbsp;6.0 billion, which was renewed in September 2019. This credit facility is provided by a syndicate of banks and is intended to be used as a backstop for the US commercial paper programs. The facility matures in September 2024 and was undrawn as per December 31, 2020, and December 31, 2019. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In December 2019, Novartis entered into a short-term credit facility of USD 7 billion, with a maturity date of June 30, 2020 with a syndicate of banks. On January 7, 2020, Novartis borrowed USD 7 billion under the facility with interest based on the USD LIBOR. On February 14, 2020, Novartis repaid the full USD 7 billion initially borrowed. The facility expired on June 30, 2020. </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table sets forth how management monitors net debt or liquidity based on details of the remaining contractual maturities of current financial assets and liabilities, excluding trade receivables and payables as well as contingent considerations at December 31, 2020, and December 31, 2019: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="11" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="11" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="11" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="11" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due within <br></br> one month </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one month <br></br> but less than <br></br> three months </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> three months <br></br> but less than <br></br> one year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one year <br></br> but less than <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due after <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, time deposits and short-term <br></br>investments with original maturity more than 90 days </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 13 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;571 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 25 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 5 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 21 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;635 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 111</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 111</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments and accrued interest</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 110</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 159</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;558</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;658</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;609</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;781</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 135</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;563</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10&nbsp;621</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15&nbsp;638</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;26&nbsp;259</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;10&nbsp;661</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;15&nbsp;802</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;26&nbsp;463</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;10&nbsp;621</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;15&nbsp;638</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;26&nbsp;259</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4&nbsp;195</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;218</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;178</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9&nbsp;591</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;4&nbsp;195</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;2&nbsp;219</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;3&nbsp;179</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;9&nbsp;593</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;93</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;84</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;194</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;4&nbsp;288</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2&nbsp;302</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;195</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;9&nbsp;785</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;321</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 479</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;10&nbsp;612</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;15&nbsp;503</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;24&nbsp;481</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="11" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="11" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="11" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="11" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Due within <br></br> one month </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br></br> one month <br></br> but less than <br></br> three months </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br></br> three months <br></br> but less than <br></br> one year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br></br> one year <br></br> but less than <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Due after <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, time deposits and short-term <br></br>investments with original maturity more than 90 days </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 20 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 26 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 16 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 3 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 57 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 122 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 110</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 110</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments and accrued interest</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 79</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;712</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;400</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;112</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;746</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;505</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 170</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;446</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9&nbsp;110</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11&nbsp;243</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;20&nbsp;353</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &#x2013;&#x2005;9&nbsp;150</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &#x2013;&#x2005;11&nbsp;355</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &#x2013;&#x2005;20&nbsp;505</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;9&nbsp;110</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;11&nbsp;243</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;20&nbsp;353</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4&nbsp;243</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;373</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;230</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6&nbsp;846</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &#x2013;&#x2005;4&nbsp;243</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &#x2013;&#x2005;1&nbsp;373</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &#x2013;&#x2005;1&nbsp;230</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &#x2013;&#x2005;6&nbsp;846</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;130</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;185</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;373</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;402</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;256</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;7&nbsp;031</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;373</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 103</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;237</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;9&nbsp;104</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;11&nbsp;073</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;15&nbsp;938</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated balance sheet amounts of financial liabilities included in the above analysis are not materially different to the contractual amounts due on maturity. The positive and negative fair values on derivative financial instruments represent the net contractual amounts to be exchanged at maturity. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s contractual undiscounted potential cash flows from derivative financial instruments to be settled on a gross basis are as follows: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due within <br></br> one month </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one month <br></br> but less than <br></br> three months </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> three months <br></br> but less than <br></br> one year </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Derivative financial instruments and accrued interest on derivative financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="1%"></td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential outflows in various currencies - from financial derivative liabilities</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;930</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4&nbsp;096</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;719</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5&nbsp;745</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential inflows in various currencies - from financial derivative assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 904</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;114</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 710</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;728</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Due within <br></br> one month </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br></br> one month <br></br> but less than <br></br> three months </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br></br> three months <br></br> but less than <br></br> one year </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Derivative financial instruments and accrued interest on derivative financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential outflows in various currencies - from financial derivative liabilities</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;814</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4&nbsp;624</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;952</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6&nbsp;390</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential inflows in various currencies - from financial derivative assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 807</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;656</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 922</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;385</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Other contractual liabilities that are not part of management&#x2019;s monitoring of the net debt or liquidity consist of the following items: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due within <br></br> three months </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> three months <br></br> but less than <br></br> one year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one year <br></br> but less than <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due after <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contractual interest on non-current liabilities</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;82</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;468</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;846</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4&nbsp;251</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6&nbsp;647</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;77</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;209</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;692</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;027</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;005</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5&nbsp;239</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;164</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5&nbsp;403</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;769</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;769</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;639</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;345</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;046</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Due within <br></br> three months </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br></br> three months <br></br> but less than <br></br> one year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br></br> one year <br></br> but less than <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Due after <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contractual interest on non-current liabilities</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;36</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;428</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;531</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;439</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;434</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;65</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;181</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;622</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;081</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;949</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;222</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;202</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;424</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;62</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;582</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;383</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;036</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Capital risk management</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis strives to maintain a strong credit rating. In managing its capital, Novartis focuses on maintaining a strong balance sheet. As of December 31, 2020, Moody&#x2019;s Investor Service rated the Company A1 for long-term maturities and P-1 for short-term maturities and S&amp;P Global Ratings rated the company AA- for long-term maturities and A-1+ for short-term maturities. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Value at risk</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group uses a value at risk (VAR) computation to estimate the potential 10-day loss in the fair value of its financial instruments. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A 10-day period is used because of an assumption that not all positions could be undone in one day given the size of the positions. The VAR computation includes all financial assets and financial liabilities as set forth in the table on page F-69, except: </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Trade receivables</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Other current assets</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Long-term loans and receivables, advances and security deposits</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Contingent considerations</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Lease liabilities</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Commitment for repurchase of own shares</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Trade payables</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The VAR estimates are made assuming normal market conditions, using a 95% confidence interval. The Group uses a &#x201c;Delta Normal&#x201d; model to determine the observed interrelationships between movements in interest rates, stock markets and various currencies. These interrelationships are determined by observing interest rate movements, stock market movements and foreign currency rate movements over a 60-day period for the calculation of VAR amounts. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimated potential 10-day loss in the fair value of the Group&#x2019;s foreign currency positions (including foreign exchange translation risk), the estimated potential 10-day loss of its equity holdings, and the estimated potential 10-day loss in fair value of its interest rate-sensitive instruments (primarily financial debt and investments of liquid funds under normal market conditions), as calculated in the VAR model, are the following: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">All financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 587</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 355</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Analyzed by components:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to foreign <br></br>currency exchange rates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 199 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 89 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to equity <br></br>market movements </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 62 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 31 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to interest rates</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 197</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 187</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The average, high and low VAR amounts are as follows:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Average</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> High</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Low</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">All financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 568</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 659</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 322</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Analyzed by components:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to foreign <br></br>currency exchange rates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 225 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 515 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 71 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to equity <br></br>market movements </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 78 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 261 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 21 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to <br></br>interest rates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 329 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 912 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 173 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Average</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> High</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Low</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">All financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 348</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 385</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 303</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Analyzed by components:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to foreign <br></br>currency exchange rates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 143 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 195 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 86 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to equity <br></br>market movements </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 36 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 81 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 16 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to <br></br>interest rates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 233 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 303 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 187 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The VAR computation is a risk analysis tool designed to statistically estimate the potential 10-day loss from adverse movements in foreign currency exchange rates, equity prices and interest rates under normal market conditions. The computation does not purport to represent actual losses in fair value on earnings to be incurred by the Group, nor does it consider the effect of favorable changes in market rates. The Group cannot predict actual future movements in such market rates, and it does not claim that these VAR results are indicative of future movements in such market rates or are representative of any actual impact that future changes in market rates may have on the Group&#x2019;s future results of operations or financial position. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 35K<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35K&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialInstrumentsAdditionalDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialInstrumentsAdditionalDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326030312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfDiscontinuedOperationsAbstract', window );"><strong>Disclosure of discontinued operations [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDiscontinuedOperationsExplanatory', window );">Disclosure of discontinued operations [text block]</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">30. Discontinued operations</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Discontinued operations include the operational results from the Alcon eye care devices business and certain Corporate activities attributable to the Alcon business prior to the spin-off, the gain on distribution of Alcon Inc. to Novartis AG shareholders, and certain other expenses related to the Distribution (refer to Notes 1 and 2 for further details). </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Alcon eye care devices business researched, discovered, developed, manufactured, distributed and sold a broad range of eye care products. Alcon was organized into two global business franchises, Surgical and Vision Care. Alcon also provided services, training, education and technical support for both the Surgical and Vision Care businesses. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Consolidated income statement</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019 <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from <br></br>discontinued operations </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 1&nbsp;777 </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 7&nbsp;149 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to continuing segments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;809</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;153</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;860</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;983</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 949</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;170</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;638</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;754</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;142</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;585</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;113</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;126</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income/(loss) from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;234</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income/(loss) before taxes from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 58</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;260</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 74</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net loss from discontinued operations <br></br>before gain on distribution of Alcon Inc. <br></br>to Novartis AG shareholders </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> <br></br> &#x2013;&#x2005;101 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> <br></br> &#x2013;&#x2005;186 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;691</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income/(loss) from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;590</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;186</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> The consolidated income statement amounts are for the period from January 1, 2019, to the completion of the spin-off. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> See Note 2 for further details on the non-taxable, non-cash gain on distribution of Alcon Inc. to Novartis AG shareholders. </div> </td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Supplemental disclosures related to the Alcon business distributed to Novartis AG shareholders </font> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Additional significant accounting policies</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The accounting policies mentioned in Note 1 were used for the reporting of discontinued operations. The following additional significant accounting policies were applicable to discontinued operations. </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Intangible assets available for use</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In addition to currently marketed products, technologies and other intangible assets (including computer software), discontinued operations intangible assets available for use also included marketing know-how and the Alcon brand name. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketing know-how represents the value attributable to the expertise acquired for marketing and distributing Alcon surgical products. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Alcon brand name was shown separately, as it was the only Novartis intangible asset that was available for use with an indefinite useful life. Novartis considers that it was appropriate that the Alcon brand name had an indefinite life since Alcon-branded products had a history of strong revenue and cash flow performance, and Novartis had the intent and ability to support the brand with spending to maintain its value for the foreseeable future. The Alcon brand name was not amortized as it had an indefinite useful life, but was evaluated for potential impairment annually. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the respective useful lives for available-for-use intangible assets and the location in the consolidated income statement in which the respective amortization and any potential impairment charge were recognized: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Useful life </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income statement location <br></br> for amortization and <br></br> impairment charges </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketing know-how</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25 years</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon brand name</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Not amortized, <br></br> indefinite useful life </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Other expense" <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the activities and more specifically on appropriate royalty rate for the Alcon brand name. </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Revenue recognition</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In the Alcon Division, which is reported as discontinued operations, surgical equipment may have been sold together with other products and services under a single contract. Revenues were recognized upon satisfaction of each of the performance obligations in the contract and the consideration was allocated based on the standalone selling price of each performance obligation. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For surgical equipment, in addition to cash and installment sales, revenue was recognized under finance and operating lease arrangements. Arrangements in which substantially all the risks and rewards incidental to ownership transfers to the customer were treated as finance lease arrangements. Revenue from finance lease arrangements was recognized at amounts equal to the fair value of the equipment, which approximated the present value of the minimum lease payments under the arrangements. As interest rates embedded in lease arrangements were approximately market rates, revenue under finance lease arrangements was comparable to revenue for outright sales. Finance income for arrangements longer than 12 months was deferred and subsequently recognized based on a pattern that approximated to the use of the effective interest method and was recorded in &#x201c;Other income.&#x201d; Operating lease revenue for equipment rentals was recognized on a straight-line basis over the lease term. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Net income </font> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Included in net income from discontinued operations are:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of property, plant and equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;42</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;235</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of right-of-use assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;174</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;052</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on property, plant and equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on intangible assets <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;391</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to restructuring provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation of Novartis equity plans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;93</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> 2018 includes an impairment of USD 337 million related to the write-down of the CyPass currently marketed product, which was acquired with the Alcon Division 2016 acquisition of Transcend Medical, Inc. </div> </td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Balance sheet </font> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following were in the balance sheet from discontinued operations for the period from January 1, 2019, to the date of reclassification: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to property, plant and equipment</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 113</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to right-of-use assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to goodwill and intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 36</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="4"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="4"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Cash flows used in investing activities from discontinued operations</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash flows used in investing activities from discontinued operations include the investing activities of the Alcon business and cash outflows for transaction-related expenditures attributable to the series of portfolio transformation transactions completed in 2015. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments attributable <br></br>to the spin-off of the <br></br>Alcon business </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &#x2013;&#x2005;39 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &#x2013;&#x2005;29 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Divested cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;628</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows attributable to the spin-off of the Alcon business</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;657</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other cash flows used in investing activities, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;88</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;502</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;001</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows used in investing activities from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;127</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;001</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Cash flows from financing activities from discontinued operations</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2020, the net cash outflows used in financing activities from discontinued operations of USD 50 million was for transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2019, the net cash inflows from financing activities from discontinued operations of USD 3.3 billion (2018: USD 167 million net cash outflows) included mainly USD 3.5 billion (2018: nil) cash inflows from Alcon borrowings in connection with the distribution (spin-off) of the Alcon business to Novartis AG shareholders, partly offset by USD 0.2 billion (2018: USD 0.1 billion) transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders (see Notes 1 and 2). </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Leases</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The lease liabilities recorded in discontinued operations on January 1, 2019, the date of implementation of IFRS 16 Leases (see Note 1), were USD 286 million, and the right-of-use assets were USD 276 million, including USD 89 million and USD 75 million, respectively, for the previously reported finance lease obligations. For discontinued operations, there were no impairments or significant contract terminations of right-of-use assets for the period from January 1, 2019, to February 28, 2019, the date of shareholder approval for the Alcon spin-off. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Net assets derecognized </font> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table presents the Alcon business net assets at the date of spin-off at April 8, 2019: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;858</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 269</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;906</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets other than goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;121</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 732</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial and other non-current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 526</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;469</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables and other current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;787</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 628</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;713</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current lease liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;269</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;538</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables, provisions and other liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;751</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets derecognized</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&nbsp;025</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Defined contribution plans</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In many subsidiaries, associates are covered by defined contribution plans. Contributions charged to the consolidated income statement for the defined contribution plans were: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions for defined contribution plans discontinued operations</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 104</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In March 2019, Alcon acquired PowerVision, Inc. (PowerVision), a privately held, US-based medical device development company focused on developing accommodative, implantable intraocular lenses. The fair value of the total purchase consideration was USD 424 million. The amount consisted of an initial cash payment of USD 289 million and the fair value of the contingent consideration of USD 135 million, due to PowerVision shareholders, which they are eligible to receive upon the achievement of specified regulatory and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 418 million, consisting of intangible assets of USD 505 million, net deferred tax liabilities of USD 93 million, other net assets of USD 6 million, and goodwill of USD 6 million. The 2019 results of operations since the date of the acquisition were not material. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For additional information related to the distribution (spin-off) of the Alcon business to Novartis AG shareholders, effected through a dividend in kind distribution that was completed on April 8, 2019, refer to Note 1 and Note 2. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDiscontinuedOperationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of discontinued operations. [Refer: Discontinued operations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDiscontinuedOperationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326389208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events subsequent to the December 31 consolidated balance sheet date<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Disclosure of non-adjusting events after reporting period [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Events subsequent to the December 31 consolidated balance sheet date</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">31. Events subsequent to the December 31, 2020, consolidated balance sheet date</div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Significant transactions not closed as of January&nbsp;25,&nbsp;2021</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In November 2020 and in January 2021, Novartis entered into long-term research and development agreements, both of which did not close as of January 25, 2021. For additional information see Note 28. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Significant transaction closed in January 2021</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In December 2020, Novartis entered into a business acquisition agreement that closed on January 21, 2021, with an estimated fair value purchase price of USD 235 million. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Dividend proposal for 2020 and approval of&nbsp;the Group&#x2019;s 2020 consolidated financial statements </font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On January 25, 2021, the Novartis AG Board of Directors proposed the acceptance of the 2020 consolidated financial statements of the Novartis Group for approval by the Annual General Meeting on March 2, 2021. Furthermore, also on January 25, 2021, the Board proposed a dividend of CHF 3.00 per share to be approved at the Annual General Meeting on March 2, 2021. If approved, total dividend payments would amount to approximately USD 7.7 billion (2019: USD&nbsp;7.0 billion), using the CHF/USD December 31, 2020, exchange rate. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2019-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326102728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Group subsidiaries and associated companies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract', window );"><strong>Disclosure of subsidiaries [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory', window );">Principal Group subsidiaries and associated companies</a></td>
<td class="text"><a name="anchorNote31"></a> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">32. Principal Group subsidiaries and&#xa0;associated&#xa0;companies</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table lists the principal subsidiaries controlled by Novartis, associated companies in which &#xad;Novartis is deemed to have significant influence, and foundations required to be consolidated under IFRS. It includes all subsidiaries, associated companies and consolidated foundations with total assets or net sales to third parties in excess of USD&#xa0;25&#xa0;million. The equity interest percentage shown in the table also represents the share in voting rights in those entities, except where explicitly noted. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>As at December 31, 2020 </div> </td> <td></td> <td></td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share <br></br> capital <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br></br> interest </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Algeria</div> </td> <td align="right" width="1%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Soci&#xe9;t&#xe9; par actions SANDOZ</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Algiers</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DZD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 650.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Argentina</div> </td> <td align="right" width="1%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Argentina S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buenos Aires</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ARS</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 906.1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Australia</div> </td> <td align="right" width="1%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Australia Pty Ltd</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Macquarie Park, NSW</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals Australia Pty Ltd</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Macquarie Park, NSW</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.8</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Pty Ltd</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Macquarie Park, NSW</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.6</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Austria</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Austria GmbH</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vienna</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma GmbH</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vienna</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz GmbH</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Kundl</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32.7</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">EBEWE Pharma Ges.m.b.H Nfg. KG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Unterach am Attersee</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Bangladesh</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Bangladesh) Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gazipur</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BDT</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 162.5</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Belgium</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma NV</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vilvoorde</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz NV</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vilvoorde</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19.2</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon - Couvreur NV</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Puurs</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 110.6</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Bermuda</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Investment Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Securities Investment Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finance Services Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Triangle International Reinsurance Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trinity River Insurance Co Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 370&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Brazil</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Bioci&#xea;ncias S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">S&#xe3;o Paulo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRL</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 265.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz do Brasil Ind&#xfa;stria Farmac&#xea;utica Ltda.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Camb&#xe9;, PR</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRL</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 190.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Canada</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals Canada Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dorval, Quebec</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.2</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Canada Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Boucherville, Quebec</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 80.8</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Manufacturing Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Boucherville, Quebec</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Chile</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Chile S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Santiago de Chile</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CLP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">China</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Beijing Novartis Pharma Co., Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Beijing</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals (HK) Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hong Kong</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HKD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 200</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">China Novartis Institutes for BioMedical Research Co., Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Shanghai</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 320.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Suzhou Novartis Technical Development Co., Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Changshu</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shanghai Novartis Trading Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shanghai</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.2</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz (China) Pharmaceutical Co., Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Zhongshan</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57.6</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Colombia</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis de Colombia S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Santaf&#xe9; de Bogot&#xe1;</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> COP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.9</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Croatia</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz d.o.o. farmaceutska industrija</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Zagreb</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HRK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.6</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Czech Republic</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis s.r.o.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prague</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CZK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 51.5</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz s.r.o.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prague</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CZK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44.7</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Denmark</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Healthcare A/S</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Copenhagen</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DKK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz A/S</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Copenhagen</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DKK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ecuador</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Ecuador S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Quito</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Egypt</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma S.A.E.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cairo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EGP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 193.8</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.77%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Egypt Pharma S.A.E.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New Cairo City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EGP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 250&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Finland</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finland Oy</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Espoo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 459&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>As at December 31, 2020 </div> </td> <td></td> <td></td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share <br></br> capital <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br></br> interest </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">France</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Groupe France S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rueil-Malmaison</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 903.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma S.A.S.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rueil-Malmaison</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43.4</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Advanced Accelerator Applications S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Saint-Genis-Pouilly</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76&nbsp;734</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.2%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CELLforCURE</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Les Ulis</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.2</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz S.A.S.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Levallois-Perret</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.4</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Germany</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Deutschland GmbH</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nuremberg</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 155.5</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Business Services GmbH</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Wehr</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma GmbH</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nuremberg</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.6</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Produktions GmbH</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Wehr</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz International GmbH</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Holzkirchen</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 A Pharma GmbH</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Oberhaching</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">HEXAL AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Holzkirchen</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 93.7</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Salutas Pharma GmbH</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Barleben</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 42.1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aeropharm GmbH</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rudolstadt</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Greece</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Hellas) S.A.C.I.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Metamorphosis / Athens</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 233.9</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Hungary</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Hungary Healthcare Limited Liability Company</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Budapest</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HUF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 545.6</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Hungary Limited Liability Company</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Budapest</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HUF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 883.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">India</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis India Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mumbai</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 123.5</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70.68%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Healthcare Private Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mumbai</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Private Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mumbai</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Indonesia</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">PT. Novartis Indonesia</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Jakarta</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IDR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.7</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ireland</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Ireland Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dublin</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Integrated Services Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ringaskiddy, County Cork</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Ringaskiddy Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ringaskiddy, County Cork</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Gene Therapies EU Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dublin</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Israel</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Israel Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tel Aviv</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ILS</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Italy</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Farma S.p.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Origgio</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Advanced Accelerator Applications (Italy) S.r.l.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Pozzilli</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 119&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.2%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz S.p.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Origgio</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.7</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Japan</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma K.K.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tokyo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ciba-Geigy Japan Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tokyo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.5</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz K.K.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tokyo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aspen Japan K.K.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tokyo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.2</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Latvia</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Baltics SIA</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Riga</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Luxembourg</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Investments S.&#xe0; r.l.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Luxembourg City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finance S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Luxembourg City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Malaysia</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Corporation (Malaysia) Sdn. Bhd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Kuala Lumpur</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MYR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.3</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Mexico</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Farmac&#xe9;utica, S.A. de C.V.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mexico City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MXN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 205.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz, S.A. de C.V.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mexico City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MXN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 468.2</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Morocco</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Maroc SA</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Casablanca</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MAD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 80.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Netherlands</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Netherlands B.V.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amsterdam</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.4</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma B.V.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amsterdam</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.5</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">IDB Holland BV</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Baarle-Nassau</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.2%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz B.V.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Almere</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 907&nbsp;560</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">New Zealand</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis New Zealand Ltd</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Auckland</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NZD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 820&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>As at December 31, 2020 </div> </td> <td></td> <td></td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share <br></br> capital <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br></br> interest </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Norway</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Norge AS</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Oslo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NOK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.5</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Pakistan</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma (Pakistan) Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Karachi</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PKR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.7</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.99%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Panama</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma (Logistics), Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Panama City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Peru</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Biosciences Per&#xfa; S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lima</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PEN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Philippines</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Healthcare Philippines, Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Makati City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PHP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 298.8</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Philippines Corporation</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Makati City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PHP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Poland</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Poland Sp. z o.o.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Warsaw</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44.2</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Polska Sp. z o.o.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Warsaw</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.6</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lek S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Strykow</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.4</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Portugal</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Portugal, S.G.P.S., Lda.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Porto Salvo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Farma - Produtos Farmac&#xea;uticos, S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Porto Salvo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.4</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Farmac&#xea;utica, Lda.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Porto Salvo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 499&nbsp;900</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Romania</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Services Romania S.R.L.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bucharest</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RON</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz S.R.L.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Targu-Mures</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RON</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 105.2</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Russian Federation</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma LLC</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Moscow</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Neva LLC</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">St. Petersburg</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">ZAO Sandoz</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Moscow</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57.4</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Saudi Arabia</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Saudi Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Riyadh</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SAR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Singapore</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Singapore) Pte Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Singapore</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Singapore Pharmaceutical Manufacturing Pte Ltd</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Singapore</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 45.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Asia Pacific Pharmaceuticals Pte Ltd</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Singapore</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Slovakia</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Slovakia s.r.o.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bratislava</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Slovenia</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lek Pharmaceuticals d.d.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ljubljana</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 48.4</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Pharmaceuticals d.d.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ljubljana</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.5</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">South Africa</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis South Africa (Pty) Ltd</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Midrand</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ZAR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 86.3</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz South Africa (Pty) Ltd</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Kempton Park</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ZAR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">South Korea</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Korea Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Seoul</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> KRW</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24.5</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98.55%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Spain</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Farmac&#xe9;utica, S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Barcelona</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 63.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Advanced Accelerator Applications Iberica, S.L.U.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Barcelona</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22.6</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.2%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Catalana de Dispensacion sau (Cadisa)</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Esplugues de Llobregat</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 450&nbsp;750</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.2%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Farmac&#xe9;utica S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Madrid</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 270&nbsp;450</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Industrial Products S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Les Franqueses del Vall&#xe9;s / Barcelona</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9.3</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Cusi, S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">El Masnou / Barcelona</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10.1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Abadia Retuerta S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sard&#xf3;n de Duero / Valladolid</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sweden</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Sverige AB</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Stockholm</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SEK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Switzerland</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis International AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Holding AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.2</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis International Pharmaceutical Investment AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Bioventures AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Forschungsstiftung</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Stiftung f&#xfc;r Kaderausbildung</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Mitarbeiterbeteiligungsstiftung</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Stiftung f&#xfc;r Mensch und Umwelt</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Stiftung der Novartis AG f&#xfc;r Erziehung, Ausbildung und Bildung</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Basel <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Overseas Investments AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japat AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 350.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Services AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Schweizerhalle AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Muttenz</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.9</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Stein AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Stein</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 251&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Schweiz AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Risch</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Ophthalmics AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fribourg</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Advanced Accelerator Applications International SA</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Geneva</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9.3</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.2%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Pharmaceuticals AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Risch</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Roche Holding AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 160.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33%/6% <sup style="white-space: nowrap"> 2</sup> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>As at December 31, 2020 </div> </td> <td></td> <td></td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share <br></br> capital <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br></br> interest </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Taiwan</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Taiwan) Co., Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taipei</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TWD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 170.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Thailand</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Thailand) Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bangkok</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> THB</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 302.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Turkey</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Saglik, Gida ve Tarim &#xdc;r&#xfc;nleri Sanayi ve Ticaret A.S.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Istanbul</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Farmanova Saglik Hizmetleri Ltd. Sti.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Istanbul</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.7</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Ila&#xe7; Sanayi ve Ticaret A.S.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Istanbul</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 265.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.99%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Grup Saglik &#xdc;r&#xfc;nleri Ila&#xe7;lari Sanayi ve Ticaret A.S.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Gebze - Kocaeli</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ukraine</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Ukraine LLC</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Kyiv</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> UAH</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United Arab Emirates</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Middle East FZE</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dubai</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AED</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United Kingdom</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis UK Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">London</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.5</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals UK Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">London</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.4</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Grimsby Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">London</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 250.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Advanced Accelerator Applications (UK &amp; Ireland)</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">London</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.2%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Neutec Pharma Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">London</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.7</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ziarco Group Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">London</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;904</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frimley / Camberley</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Coalesce Product Development Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cambridge, Cambs</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United States of America</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Corporation</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 72.2</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finance Corporation</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Capital Corporation</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Services, Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis US Foundation</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals Corporation</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 650</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Advanced Accelerator Applications USA, Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Millburn, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.2%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Gene Therapies, Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bannockburn, IL</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Technology LLC</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Institutes for BioMedical Research, Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cambridge, MA</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Optogenetics Research, Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CoStim Pharmaceuticals Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cambridge, MA</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Endocyte, Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Navigate BioPharma Services, Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Carlsbad, CA</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">The Medicines Company</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Princeton, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amblyotech Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Oriel Therapeutics, Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Durham, NC</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fougera Pharmaceuticals Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Melville, NY</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Eon Labs, Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Princeton, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Vaccines and Diagnostics, Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Venezuela</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis de Venezuela, S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Caracas</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VES</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Vietnam</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Vietnam Company Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ho Chi Minh City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VND</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">In addition, the Group is represented by subsidiaries and associated companies with total assets or net sales to third parties below USD 25 million in the following countries: Bosnia and Herzegovina, Bulgaria, Dominican Republic, Guatemala, Kenya, Kuwait, North Macedonia, Nigeria, Puerto Rico and Uruguay </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Share capital may not reflect the taxable share capital and does not include any paid-in surplus. </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Approximately 33.3% of voting shares; approximately 6.2% of total net income and equity attributable to Novartis. </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Significant subsidiary under SEC Regulation S-X Rule 1-02(w) </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;4&nbsp;</sup> Fully consolidated Foundation </div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">m = million; bn = billion</div> </td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of subsidiaries. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B4<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B4_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904317771080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory', window );">Scope of consolidation</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Scope of consolidation </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated financial statements include all entities, including structured entities, over which Novartis AG, Basel, Switzerland, directly or indirectly has control (generally as a result of owning more than 50% of the entity&#x2019;s voting interest). Consolidated entities are also referred to as &#x201c;subsidiaries.&#x201d; </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In cases where Novartis does not fully own a subsidiary, it has elected to value any remaining outstanding non-controlling interest at the time of acquiring control of the subsidiary at its proportionate share of the fair value of the net identified assets. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The contribution of a business to an associate or joint venture is accounted for by applying the option under IFRS that permits the accounting for the retained interest of the business contributed at its net book value at the time of the contribution. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Investments in associated companies (generally defined as investments in entities in which Novartis holds between 20% and 50% of voting shares or over which it otherwise has significant influence) and joint ventures are accounted for using the equity method, except for selected venture fund investments for which the Group has elected to apply the method of fair value through the consolidated income statement. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currencies</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Foreign currencies</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated financial statements of Novartis are presented in US dollars (USD). The functional currency of subsidiaries is generally the local currency of the respective entity. The functional currency used for the reporting of certain Swiss and foreign finance entities is USD instead of their respective local currencies. This reflects the fact that the cash flows and transactions of these entities are primarily denominated in these currencies. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For subsidiaries not operating in hyperinflationary economies, the subsidiary&#x2019;s results, financial position and cash flows that do not have USD as their functional currency are translated into USD using the following exchange rates: </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Income, expense and cash flows using for each month the average exchange rate, with the US dollar values for each month being aggregated during the year </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Balance sheets using year-end exchange rates</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Resulting exchange rate differences are recognized in other comprehensive income</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For subsidiaries operating in hyperinflationary economies, the impact of the restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period is recorded in retained earnings in equity. The subsequent gains or losses resulting from the restatement of non-monetary assets are recorded in &#x201c;Other financial income and expense&#x201d; in the consolidated income statement. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory', window );">Non-current assets held for sale or held for distribution to owners</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Non-current assets held for sale or held for distribution to owners</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Non-current assets are accounted for as assets held for sale or related to discontinued operations when their carrying amount is to be recovered principally through a sale transaction or distribution to owners and a sale or distribution to owners is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell with any resulting impairment recognized. Assets related to discontinued operations and assets of disposal group held for sale are not depreciated or amortized. The prior year consolidated balance sheet is not restated. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If in a subsequent period, the criteria for classification as held for sale are no longer met, the recoverable amount of assets and liabilities are reclassified out of assets held for sale into the respective balance sheet lines, prior year consolidated balance sheet is not restated. The cumulative amount of depreciation and amortization not recorded since the date of their classification to assets held for sale, and any required adjustments to the recoverable amounts of assets are recognized in the consolidated income statement. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DistributionByWayOfDivindendInKindToShareholders', window );">Distribution by way of dividend in kind to shareholders</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Distribution of Alcon Inc. to Novartis AG shareholders </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During the first quarter of 2019, at the Annual General Meeting (AGM) of Novartis AG shareholders, held on February 28, 2019, the Novartis AG shareholders approved a special distribution by way of a dividend in kind to effect the spin-off of Alcon Inc. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The February 28, 2019, shareholder approval for the spin-off required the Alcon Division and selected portions of corporate activities attributable to Alcon&#x2019;s business (the &#x201c;Alcon business&#x201d;) to be reported as discontinued operations. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The shareholder approval to spin off the Alcon business also required the recognition of a distribution liability at the fair value of the Alcon business. The Group elected to measure the distribution liability at the fair value of the Alcon business net assets taken as a whole. The distribution liability was recognized through a reduction in retained earnings. It was required to be adjusted at each balance sheet date for changes in its estimated fair value, up to the date of the distribution to shareholders through retained earnings. Any resulting impairment of the business assets to be distributed would have been recognized in the consolidated income statements in &#x201c;Other expense&#x201d; of discontinued operations, at the date of initial recognition of the distribution liability or at subsequent dates resulting from changes of the distribution liability valuation. At the April 8, 2019 distribution settlement date, the resulting gain, which was measured as the excess amount of the distribution liability over the then-carrying value of the net assets of the business distributed, was recognized on the line &#x201c;Gain on distribution of Alcon Inc. to Novartis AG shareholders&#x201d; in the income statement of discontinued operations. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The recognition of the distribution liability required the use of valuation techniques for purposes of impairment testing of the Alcon business&#x2019; assets to be distributed and for the measurement of the fair value of the distribution liability. These valuations required the use of management assumptions and estimates related to the Alcon business&#x2019; future cash flows, market multiples to estimate day one market value, and control premiums to apply in estimating the Alcon business fair value. These fair value measurements were classified as &#x201c;Level 3&#x201d; in the fair value hierarchy. The section &#x201c;&mdash;Impairment of goodwill and intangible assets&#x201d; in this Note 1 provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Transaction costs that were directly attributable to the distribution (spin-off) of Alcon to the Novartis shareholders, and that would otherwise have been avoided, were recorded as a deduction from equity. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For additional disclosures, refer to &#x201c;Note 2. Significant transactions&mdash;Significant transactions in 2019&mdash;Completion of the spin-off of the Alcon business through a dividend in kind distribution to Novartis AG shareholders,&#x201d; and &#x201c;Note 30. Discontinued operations.&#x201d; </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory', window );">Acquisition of assets</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Acquisition of assets and businesses</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Assets separately acquired are recorded at cost, which includes the purchase price and any directly attributable costs for bringing the asset into the condition to operate as intended. Expected costs for obligations to dismantle and remove property, plant and equipment when they are no longer used are included in their cost. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Acquired businesses are accounted for using the acquisition method, unless the optional concentration test is applied. The optional concentration test allows for the election on a transaction-by-transaction basis to account for the acquired business as an asset separately acquired when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The acquisition method requires that the assets acquired and liabilities assumed be recorded at their respective fair values on the date the Group obtains control. The excess of the fair value of the total purchase consideration transferred and the fair value of the acquired assets and assumed liabilities is recognized as goodwill. The related valuations are based on information available at the acquisition date. Acquisition related costs are expensed as incurred. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The application of the acquisition method requires certain estimates and assumptions to be made, especially concerning the fair values of the acquired intangible assets, inventories, property, plant and equipment and the liabilities assumed at the acquisition date, and the useful lives of the intangible assets and property, plant and equipment. Estimates of fair value require the use of valuation techniques. These valuations require the use of management assumptions and estimates, including value of comparable assets in the market, amount and timing of future cash flows, outcomes and costs of research and development activities, probability of obtaining regulatory approval, long-term sales forecasts, actions of competitors, discount rates and terminal growth rates. The section &#x201c;&mdash;Impairment of goodwill and intangible assets&#x201d; in this Note 1 provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property plant and equipment</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Property, plant and equipment</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Property, plant and equipment are depreciated on a straight-line basis in the consolidated income statement over their estimated useful lives. Freehold land is not depreciated. The related depreciation expense is included in the costs of the functions using the asset. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Property, plant and equipment are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the respective useful lives for property, plant and equipment:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Useful life</div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buildings</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20 to 40 years</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and other equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7 to 20 years</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Furniture and vehicles</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 10 years</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Computer hardware</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 7 years</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Government grants obtained for construction activities, including any related equipment, are deducted from the gross acquisition cost to arrive at the balance sheet carrying value of the related assets. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases and right-of-use assets</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Leases and right-of-use assets</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">From January 1, 2019, with the adoption of IFRS 16 Leases, the Group adopted the following accounting policies for leases and right-of-use assets: </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As lessee, the Group assesses whether a contract contains a lease at inception of a contract and upon the modification of a contract. The Group elected to allocate the consideration in the contract to the lease and non-lease components on the basis of the relative standalone price. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a lessee, except for leases with a term of 12 months or less (short-term leases) and low-value leases. For these short-term and low-value leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease to the end of the lease term. The lease term includes the period of any lease extension that in management&#x2019;s assessment is highly probable to be exercised by the Group. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the Novartis incremental borrowing rate for the asset subject to the lease in the respective markets. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever there is a change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The portion of the lease payments attributable to the repayment of lease liabilities is recognized in cash flows used in financing activities, and the portion attributable to the payment of interest is included in cash flows from operating activities. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are initially recognized on the balance sheet at cost, which comprises the amount of the initial measurement of the corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease incentive received and any initial direct costs incurred by Novartis, and expected costs for obligations to dismantle and remove right-of-use assets when they are no longer used. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease over the shorter of the useful life of the right-of-use asset or the end of the lease term. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In arrangements where the Group is the lessor, it determines at lease inception whether the lease is a finance lease or an operating lease. Leases that transfer substantially all of the risk and rewards incidental to ownership of the underlying asset to the counterparty (the lessee) are accounted for as finance leases. Leases that do not transfer substantially all of the risks and rewards of ownership are accounted for as operating leases. Lease payments received under operating leases are recognized on a straight-line basis over the lease term in the consolidated income statement in either &#x201c;net sales&#x201d; or &#x201c;other income,&#x201d; depending on the nature of and underlying asset to the lease arrangement. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Prior to January 1, 2019, the Group applied the following accounting policies for leases: </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Leases that transferred substantially all of the risks and rewards of ownership were recognized as finance leases, with the leased asset measured initially at an amount equal to the lower of their fair value and the present value of the minimum lease payments. Minimum lease payments were the payments over the lease term that the Group, as leasee, was required to make, excluding contingent rent. The underlying asset was accounted for in accordance with the accounting policy applicable to that asset. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Leases that did not transfer substantially all of the risks and rewards of ownership were accounted for as operating leases and were not recognized in the consolidated balance sheet. Payments made under operating leases were recognized in the consolidated income statement on a straight-line basis over the term of the lease. Lease incentives received were deferred and recognized as a component of lease expense over the term of the lease. The future undiscounted lease payments under operating leases were disclosed as commitments in the notes to the consolidated financial statements. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Lessor accounting policies were not substantially different from those applied upon the adoption of IFRS 16 Leases, as described above. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The section &#x201c;&mdash;Impact of adopting significant new IFRS standards in 2019&#x201d; in this Note 1 provides additional disclosures on the impact of adoption of IFRS 16 Leases. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory', window );">Goodwill</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Goodwill and intangible assets</font> </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Goodwill</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Goodwill arises in the acquisition of a business when applying the acquisition method and is the excess of the fair value of the consideration transferred to acquire a business over the underlying fair value of the net identified assets acquired. It is allocated to groups of cash-generating units (CGUs), which are usually represented by the reported segments. Goodwill is tested for impairment annually at the level of these groups of CGUs, and any impairment charges are recorded under &#x201c;Other expense&#x201d; in the consolidated income statement. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock', window );">Intangible assets available-for-use</a></td>
<td class="text"><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Intangible assets available for use</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has the following classes of available for use intangible assets: currently marketed products; technologies; other intangible assets (including computer software). </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Currently marketed products represent the composite value of acquired intellectual property (IP), patents, distribution rights and product trade names. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Technologies represent identified and separable acquired know-how used in the research, development and production processes. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Significant investments in internally developed and acquired computer software are capitalized and included in the &#x201c;Other&#x201d; category, and amortized once available for use. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Intangible assets available for use with a definite useful life are amortized over their estimated useful lives on a straight-line basis and are evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the respective useful lives for intangible assets available for use and the location in the consolidated income statement in which the respective amortization and any potential impairment charge is recognized: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Useful life </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income statement location <br></br> for amortization and <br></br> impairment charges </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 20 years</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Technologies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10 to 20 years <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold" <br></br> or "Research <br></br> and development" </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other (including <br></br>computer software) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 7 years <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> In the respective <br></br> functional expense </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock', window );">Intangible assets not yet available-for-use</a></td>
<td class="text"><div> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Intangible assets not yet available for use</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Acquired research and development intangible assets that are still under development and have accordingly not yet obtained marketing approval are recognized as in-process research and development (IPR&amp;D). </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">IPR&amp;D is not amortized, but is evaluated for potential impairment on an annual basis or when facts and circumstances warrant. Any impairment charge is recorded in the consolidated income statement under &#x201c;Research and development.&#x201d; Once a project included in IPR&amp;D has been successfully developed, it is transferred to the &#x201c;Currently marketed products&#x201d; category. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock', window );">Impairment of goodwill and intangible assets</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impairment of goodwill and intangible assets</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">An asset is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value-in-use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or CGUs, and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group&#x2019;s activities with regard to: </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Amount and timing of projected future cash flows</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Long-term sales forecasts </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Actions of competitors (launch of competing products, marketing initiatives, etc.)</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Sales erosion rates after the end of patent or other intellectual property rights protection, and timing of the entry of generic competition </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Outcome of research and development activities (compound efficacy, results of clinical trials, etc.)</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Amount and timing of projected costs to develop IPR&amp;D into commercially viable products</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Profit margins</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Probability of obtaining regulatory approval</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Future tax rate</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Appropriate terminal growth rate</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Appropriate discount rate</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Generally, for intangible assets with a definite useful life, Novartis uses cash flow projections for the whole useful life of these assets. For goodwill, Novartis generally utilizes cash flow projections for a five-year period based on management forecasts, with a terminal value based on cash flow projections usually in line with inflation rates for later periods. Probability-weighted scenarios are typically used. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Discount rates used consider the Group&#x2019;s estimated weighted average cost of capital, adjusted for specific asset, country and currency risks associated with cash flow projections, to approximate the discount rate that market participants would use to value the asset. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Due to the above factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock', window );">Impairment of associated companies accounted for at equity</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impairment of associated companies accounted for at equity</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis considers investments in associated companies for impairment evaluation whenever objective evidence indicates the net investment may be impaired, including when a quoted share price indicates a fair value less than the per-share balance sheet carrying value for the investment. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If the recoverable amount of the investment is estimated to be lower than the balance sheet carrying amount, an impairment charge is recognized for the difference in the consolidated income statement under &#x201c;Income from associated companies.&#x201d; </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Cash and cash equivalents</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash and cash equivalents include highly liquid investments with original maturities of three months or less, which are readily convertible to known amounts of cash. Bank overdrafts are usually presented within current financial debts on the consolidated balance sheet, except in cases where a right of offset has been agreed with a bank, which then allows for presentation on a net basis. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock', window );">Marketable securities, commodities and non-current financial assets</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Marketable securities, commodities and non-current financial assets </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Commodities, which include gold bullion or coins, are valued at the lower of cost or fair value using current market prices. The changes in fair value below cost are immediately recorded in &#x201c;Other financial income and expense.&#x201d; </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities are financial assets held for short-term purposes which are principally traded in liquid markets and are classified within current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#x201c;Other financial income and expense&#x201d; in the consolidated income statement. Non-current financial assets held for long-term strategic purposes are classified within non-current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#x201c;Other income&#x201d; and &#x201c;Other expense&#x201d; in the consolidated income statement. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities and non-current financial assets are initially recorded at fair value on their trade date, which is different from the settlement date when the transaction is ultimately effected. Quoted securities are remeasured at each reporting date to fair value based on current market prices. If the market for a financial asset is not active or no market is available, fair values are established using valuation techniques. The majority of non-quoted investments are valued initially at fair value through the established purchase price between a willing buyer and seller. Non-quoted investments are subsequently adjusted based on values derived from discounted cash flow analysis or other pricing models. These investment values are classified as &#x201c;Level 3&#x201d; in the fair value hierarchy. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group classifies and accounts for its marketable securities and non-current financial assets in the following categories: </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Debt securities are valued at fair value through other comprehensive income with subsequent recycling into the consolidated income statement, as they meet both the &#x201c;solely payment of principal and interest&#x201d; and the business model criteria. Unrealized gains and losses, except exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are recognized in the consolidated income statement when the debt instrument is sold, at which time the gain is transferred to &#x201c;Other financial income and expense.&#x201d; Exchange gains and losses related to debt instruments are immediately recognized in the consolidated income statement to &#x201c;Other financial income and expense.&#x201d; </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Fund investments and equity securities of the Novartis venture fund are valued at fair value through profit and loss (FVPL). Unrealized gains and losses, including exchange gains and losses, are recognized in the consolidated income statement to &#x201c;Other income&#x201d; for gains and &#x201c;Other expense&#x201d; for losses. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Equity securities held as strategic investments, typically held outside of the Novartis venture fund, are generally designated at the date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. Unrealized gains and losses, including exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are reclassified to retained earnings when the equity security is sold. If these equity securities are not designated at the date of acquisition as financial assets valued at fair value through other comprehensive income, they are valued at FVPL, as described above. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Other non-current financial assets, such as loans and long-term receivables from customers, advances and other deposits, are valued at amortized cost, which reflects the time value of money less any allowances for expected credit losses. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group assesses on a forward-looking basis the expected credit losses associated with its debt securities valued at fair value through other comprehensive income. Impairments on debt securities are recorded in &#x201c;Other financial income and expense.&#x201d; </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For other financial assets valued at amortized cost, impairments, which are based on their expected credit losses, and exchange rate losses are included in &#x201c;Other expense&#x201d; in the consolidated income statement. Exchange rate gains and interest income, using the effective interest rate method, are included in &#x201c;Other income&#x201d; or &#x201c;Other financial income&#x201d; in the consolidated income statement, depending on the nature of the item. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory', window );">Description of accounting policy for financial assets [text block]</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Derivative financial instruments</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Derivative financial instruments are initially recognized in the balance sheet at fair value and are remeasured to their current fair value at the end of each subsequent reporting period. The valuation of a forward exchange rate contract is based on the discounted cash flow model, using interest curves and spot rates at the reporting date as observable inputs. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Options are valued based on a modified Black-Scholes model using volatility and exercise prices as major observable inputs. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group utilizes derivative financial instruments for the purpose of hedging to reduce the volatility in the Group&#x2019;s performance due to the exposure to various business related risks. To mitigate these risks, the Group enters into certain derivative financial instruments. The risk reduction is obtained because the derivative&#x2019;s value or cash flows are expected, wholly or partly, to offset changes in the value or cash flows of the recognized assets or liabilities. The overall strategy is aiming to mitigate the currency and interest rate risk of positions that are contractually agreed, and to partially mitigate the exposure risk of selected anticipated transactions. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Certain derivative financial instruments meet the criteria for hedge accounting treatment. A prerequisite for obtaining this accounting-hedge relationship is extensive documentation on inception and proving on a regular basis that the economic hedge is effective for accounting purposes. Other derivative financial instruments do not meet the criteria to qualify for hedge accounting. Changes in the fair value of these derivative instruments are recognized immediately in &#x201c;Other financial income and expense&#x201d; in the consolidated income statement. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, the Group has designated certain long-term debt components as hedges of the translation risk arising on certain net investments in foreign operations. On consolidation, foreign currency differences arising on long-term debt designated as net investment hedges of a foreign operation are recognized in other comprehensive income and accumulated in currency translation effects, to the extent that the hedge is effective. The foreign currency differences arising from hedge ineffectiveness are recognized in the income statement in &#x201c;Other financial income and expense.&#x201d; </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">When a hedged net investment is disposed of, the proportionate portion of the cumulative amount recognized in equity in relation to the hedged net investment is transferred to the consolidated income statement as an adjustment to the gain or loss on disposal. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories', window );">Inventories</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Inventories</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inventory is valued at the lower of acquisition or production cost determined on a first-in, first-out basis and net realizable value. This value is used for the &#x201c;Cost of goods sold&#x201d; in the consolidated income statement. Unsaleable inventory is fully written off in the consolidated income statement under &#x201c;Cost of goods sold.&#x201d; </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory', window );">Trade receivables</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Trade receivables</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Trade receivables are initially recognized at their invoiced amounts, including any related sales taxes less adjustments for estimated revenue deductions such as rebates, chargebacks and cash discounts. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The provisions for doubtful trade receivables are established using an expected credit loss model (ECL). The provisions are based on a forward-looking ECL, which includes possible default events on the trade receivables over the entire holding period of the trade receivable. These provisions represent the difference between the trade receivable&#x2019;s carrying amount in the consolidated balance sheet and the estimated collectible amount. Charges for doubtful trade receivables are recorded as marketing and selling costs recognized in the consolidated income statement within &#x201c;Selling, general and administration&#x201d; expenses. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Legal and environmental liabilities</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Legal and environmental liabilities</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis and its subsidiaries are subject to contingencies arising in the ordinary course of business, such as patent litigation, environmental remediation liabilities and other product-related litigation, commercial litigation, and governmental investigations and proceedings. Provisions are recorded where a reliable estimate can be made of the probable outcome of legal or other disputes against the subsidiary. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory', window );">Contingent consideration</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Contingent consideration</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In an acquisition or a divestment of a business, it is necessary to recognize contingent future amounts due to previous owners, representing contractually defined potential amounts as a liability or an asset. Usually for Novartis, these are linked to milestone or royalty payments related to certain assets and are recognized as a financial liability or financial asset at fair value, which is then remeasured at each subsequent reporting date. These estimations typically depend on factors such as technical milestones or market performance, and are adjusted for the probability of their likelihood of payment, and are appropriately discounted to reflect the impact of time. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the consolidated income statement in &#x201c;Cost of goods sold&#x201d; for currently marketed products and in &#x201c;Research and development&#x201d; for IPR&amp;D. Changes in contingent consideration assets are recognized in &#x201c;Other income&#x201d; or &#x201c;Other expense,&#x201d; depending on their nature. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The effect of unwinding the discount over time is recognized for contingent liabilities in &#x201c;Interest expense&#x201d; and for contingent assets as interest income recognized in the consolidated income statement within &#x201c;Other financial income and expense.&#x201d; </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Defined benefit pension plans and other post retirement benefits</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Defined ben</font> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">efit pension plans and&nbsp;other&nbsp;post-employment benefits</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The liability in respect of defined benefit pension plans and other post-employment benefits is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions in which associates are employed, while the net interest on the net defined benefit liability or asset is recognized as &#x201c;Other expense&#x201d; or &#x201c;Other income.&#x201d; </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory', window );">Treasury Shares</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Treasury shares</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Treasury shares are initially recorded at fair value on their trade date, which is different from the settlement date, when the transaction is ultimately effected. Treasury shares are deducted from consolidated equity at their nominal value of CHF&nbsp;0.50 per share. Differences between the nominal amount and the transaction price on purchases or sales of treasury shares with third parties, or the value of services received for the shares allocated to associates as part of share-based compensation arrangements, are recorded in &#x201c;Retained earnings&#x201d; in the consolidated statement of changes in equity. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue recognition</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Revenue recognition</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Revenue on the sale of Novartis Group products and services, which is recorded as &#x201c;Net sales&#x201d; in the consolidated income statement, is recognized when a contractual promise to a customer (performance obligation) has been fulfilled by transferring control over the promised goods and services to the customer, substantially all of which is at the point in time of shipment to or receipt of the products by the customer or when the services are performed. If contracts contain customer acceptance provisions, revenue is recognized upon the satisfaction of the acceptance criteria. If products are stockpiled at the request of the customer, revenue is only recognized once the products have been inspected and accepted by the customer, and there is no right of return or replenishment on product expiry. The amount of revenue recognized is based on the consideration Novartis expects to receive in exchange for its goods and services, when it is highly probable that a significant reversal will not occur. If a contract contains more than one performance obligation, the consideration is allocated based on the standalone selling price of each performance obligation. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consideration Novartis receives in exchange for its goods or services may be fixed or variable. Variable consideration is only recognized when it is highly probable that a significant reversal will not occur. The most common elements of variable consideration are listed below. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Rebates and discounts granted to government agencies, wholesalers, retail pharmacies, managed healthcare organizations and other customers, as well as chargebacks are provisioned and recorded as a revenue deduction at the time the related revenues are recorded or when the incentives are offered. They are calculated on the basis of historical experience, regulations, the specific terms in the individual agreements, product pricing and the mix of products, contracts, channels and payors. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Refunds granted to healthcare providers under innovative pay-for-performance agreements (i.e., outcome based arrangements) are provisioned and recorded as a revenue deduction at the time the related sales are recorded. They are calculated on the basis of historical experience and clinical data available for the product, as well as the specific terms in the individual agreements. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until the uncertainty is resolved or until such history is available. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Cash discounts are offered to customers to encourage prompt payment and are provisioned and recorded as revenue deductions at the time the related sales are recorded. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Shelf stock adjustments are generally granted to customers, primarily of the Sandoz Division, to cover the inventory held by them at the time a price decline becomes effective. Revenue deduction provisions for shelf stock adjustments are recorded when the price decline is anticipated, based on the impact of the price decline on the customer&#x2019;s estimated inventory levels. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Sales returns provisions are recognized and recorded as revenue deductions when there is historical experience of Novartis agreeing to customer returns and Novartis can reasonably estimate expected future returns. In doing so, the estimated rate of return is applied, determined on the basis of historical experience of customer returns and considering any other relevant factors. This is applied to the amounts invoiced, also considering the amount of returned products to be destroyed versus products that can be placed back in inventory for resale. Where shipments are made on a resale or return basis, without sufficient historical experience for estimating sales returns, revenue is only recorded when there is evidence of consumption or when the right of return has expired. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Net sales and provisions for revenue deductions are adjusted to actual amounts as rebates, refunds, discounts and returns are processed. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these sales deductions. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">&#x201c;Other revenue&#x201d; includes income from profit-sharing arrangements with our collaboration partners, and royalty and milestone income from the out-licensing of intellectual property when Novartis retains an interest in the intellectual property through a license. Royalty income earned through a license is recognized when the underlying sales have occurred. Milestone income is recognized at the point in time when it is highly probable that the relevant milestone event criteria are met, and the risk of reversal of revenue recognition is remote. Other revenue also includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales, and is recognized when control transfers to the third party and our performance obligations are satisfied. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Research and development</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Internal research and development (R&amp;D) costs are fully charged to &#x201c;Research and development&#x201d; in the consolidated income statement in the period in which they are incurred. The Group considers that regulatory and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained in a major market such as the United States, the European Union, Switzerland or Japan. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Payments made to third parties, such as contract research and development organizations in compensation for subcontracted R&amp;D, that are deemed not to transfer intellectual property to Novartis are expensed as internal R&amp;D expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been achieved from a regulatory authority in a major market. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Payments made to third parties to in-license or acquire intellectual property rights, compounds and products, including initial upfront and subsequent milestone payments, are capitalized, as are payments for other assets, such as technologies to be used in R&amp;D activities. If additional payments are made to the originator company to continue to perform R&amp;D activities, an evaluation is made as to the nature of the payments. Such additional payments will be expensed if they are deemed to be compensation for subcontracted R&amp;D services not resulting in an additional transfer of intellectual property rights to Novartis. Such additional payments will be capitalized if they are deemed to be compensation for the transfer to Novartis of additional intellectual property developed at the risk of the originator company. Subsequent internal R&amp;D costs in relation to IPR&amp;D and other assets are expensed, since the technical feasibility of the internal R&amp;D activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Costs for post-approval studies performed to support the continued registration of a marketed product are recognized as marketing expenses. Costs for activities that are required by regulatory authorities as a condition for obtaining marketing approval are capitalized and recognized as currently marketed products. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Inventory produced ahead of regulatory approval is fully provisioned, and the charge is included in &#x201c;Other expense&#x201d; in the consolidated income statement, as its ultimate use cannot be assured. If this inventory can be subsequently sold, the provision is released to &#x201c;Other income&#x201d; in the consolidated income statement, either on approval by the appropriate regulatory authority or, exceptionally in Europe, on recommendation by the Committee for Medicinal Products for Human Use (CHMP), if approval is virtually certain. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share based compensation</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Share-based compensation</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Vested Novartis shares and American Depositary Receipts (ADRs) that are granted as compensation are valued at their market value on the grant date and are immediately expensed in the consolidated income statement. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair values of unvested restricted shares (RSs), restricted share units (RSUs) and performance share units (PSUs) in Novartis shares and ADRs granted to associates as compensation are recognized as an expense over the related vesting period. The expense recorded in the consolidated income statement is included in the personnel expenses of the various functions in which the associates are employed. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Unvested restricted shares, restricted ADRs and RSUs are only conditional on the provision of services by the plan participant during the vesting period. They are valued at fair value on the grant date. As RSUs do not entitle the holder to dividends, the fair value is based on the Novartis share price at the grant date adjusted for the net present value of the dividends expected to be paid during the holding period. The fair value of these grants, after making adjustments for assumptions related to forfeiture during the vesting period, is expensed on a straight-line basis over the respective vesting period. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">PSUs are subject to the achievement of certain performance criteria during the vesting period and require plan participants to provide services during this period. The following paragraphs provide an overview of the accounting policies for the share-based compensation plans that grant PSUs. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs granted under plans that are subject to performance criteria based on Novartis internal performance metrics and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on assumptions concerning the expected performance against the internal performance metrics throughout the vesting period. The assumptions are based on the Group&#x2019;s targets for those performance metrics, and the expected forfeitures due to plan participants not meeting their service conditions. The assumptions are periodically adjusted over the vesting period. Any change in estimates for past services is recorded immediately as an expense or income in the consolidated income statement, and amounts for the remaining vesting period are expensed on a straight-line basis. As a result, at the end of the vesting period, the charge during the entire vesting period represents the amount that will finally vest. The number of equity instruments that finally vest is determined at the vesting date. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs granted under plans that are subject to performance criteria based on variables that can be observed in the market, which for Novartis plans is the Novartis total shareholder return (TSR) relative to a specific peer group of companies over the vesting period, and that are conditional on the provision of services by the plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on the total fair value of the grant over the vesting period. IFRS requires that these variables that can be observed in the market are taken into account in determining the fair value of the PSUs at the grant date. Novartis determined the fair value of these PSUs at the date of grant using a Monte Carlo simulation model. Adjustments to the number of equity instruments granted are only made if a plan participant does not fulfill the service conditions. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs granted under plans that are subject to both performance criteria based on Novartis internal performance metrics and Novartis TSR relative to a specific peer group of companies over the vesting period and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on a bifurcation into the components based on the performance criteria related to Novartis internal performance metrics and TSR, as described in the paragraphs above. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Measuring the fair values of PSUs granted that include TSR performance criteria requires use of estimates. The Monte Carlo simulation used to determine the fair value of the PSUs TSR performance criteria requires the probability of factors related to uncertain future events; the term of the award; the grant price of underlying shares or ADRs; expected volatilities; the expected correlation matrix of the underlying equity instruments with those of the peer group of companies; and the risk-free interest rate as input parameters. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If a plan participant leaves Novartis for reasons other than retirement, disability or death, then unvested restricted shares, restricted ADRs, RSUs and PSUs are forfeited, unless determined otherwise by the provision of the plan rules or by the Compensation Committee of the Novartis Board of Directors, for example, in connection with a reorganization or divestment. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants', window );">Government grants</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Government grants</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Grants from governments or similar organizations are recognized at their fair value when there is a reasonable assurance that the grant will be received and the Group will comply with all attached conditions. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Government grants received to compensate for cost are deferred and recognized in the consolidated income statement over the period necessary to match them against the related costs that they are intended to compensate. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The accounting policy for property, plant and equipment describes the treatment of any related grants. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory', window );">Restructuring charges</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Restructuring charges</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Restructuring provisions are recognized for the direct expenditures arising from the restructuring, where the plans are sufficiently detailed and where appropriate communication to those affected has been made. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Charges to increase restructuring provisions are included in &#x201c;Other expense&#x201d; in the consolidated income statements. Corresponding releases are recorded in &#x201c;Other income&#x201d; in the consolidated income statement. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock', window );">Healthcare contributions</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Healthcare contributions</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Healthcare contribution levies and fees under governmental programs that require the Group to contribute to a country&#x2019;s healthcare costs, other than programs described in Revenue recognition in this Note 1, are recognized in Other expense in the consolidated income statement. Provisions for healthcare contributions are adjusted to the actual amounts levied. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these healthcare contributions. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Taxes</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Taxes</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Taxes on income are provided in the same periods as the revenues and expenses to which they relate and include interest and penalties incurred during the period. Deferred taxes are determined using the comprehensive liability method and are calculated on the temporary differences that arise between the tax base of an asset or liability and its carrying value in the balance sheet prepared for consolidation purposes, except for those temporary differences related to investments in subsidiaries and associated companies, where the timing of their reversal can be controlled and it is probable that the difference will not reverse in the foreseeable future. Since the retained earnings are reinvested, withholding or other taxes on eventual distribution of a subsidiary&#x2019;s retained earnings are only taken into account when a dividend has been planned. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimated amounts for current and deferred tax assets or liabilities, including any amounts related to any uncertain tax positions, are based on currently known facts and circumstances. Tax returns are based on an interpretation of tax laws and regulations, and reflect estimates based on these judgments and interpretations. The tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made requiring payments of additional tax, interest or penalties. Inherent uncertainties exist in the estimates of the tax positions. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations', window );">Impact of adopting significant new IFRS standards</a></td>
<td class="text"><div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impact of adopting significant new IFRS standard in 2020</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following new IFRS standard has been adopted by Novartis from January 1, 2020:</div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">IFRS 3 Business Combination amendments</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The IASB issued amendments to IFRS 3 Business Combinations that revised the definition of a business, which assist entities with the evaluation of when an asset or group of assets acquired should be considered a business. This amended standard has been applied to transactions entered into on or after January 1, 2020. The amended standard allows an entity to apply an optional concentration test, on a transaction-by-transaction basis, to evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this optional concentration test is met, the set of activities and assets is determined not to be a business. The adoption of this amended standard on January 1, 2020 did not have a significant impact on our consolidated financial statements and is not expected to have a significant impact in future periods. However, this will depend on the facts and circumstances of future transactions and if the Group decides to apply the optional concentration test in the assessment of whether an acquired set of activities and assets is or is not a business. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">There are no other IFRS standards or interpretations not yet effective that would be expected to have a material impact on the Group. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impact of adopting significant new IFRS standard in 2019</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following new IFRS standard has been adopted by Novartis from January 1, 2019: </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">IFRS 16 Leases</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">IFRS 16 Leases substantially changed the financial statements, as the majority of leases for which the Group is the lessee became on-balance sheet liabilities with corresponding right-of-use assets also recognized on the balance sheet. The lease liability reflects the net present value of the remaining lease payments, and the right-of-use asset corresponds to the lease liability, adjusted for payments made before the commencement date, lease incentives and other items related to the lease agreement. The standard replaces IAS 17 Leases and related interpretations. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Upon adoption of the new standard, a portion of the annual operating lease costs, which was previously fully recognized as functional expenses, as a component of operating income, is recorded as interest expense. In addition, the portion of the lease payments that represents the reduction of the lease liability is recognized in the cash flow statement as an outflow from financing activities, which was previously fully recognized as an outflow from operating activities. Given the leases involved, these effects are not significant to the consolidated income statement and consolidated statement of cash flow. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group implemented the new standard on January 1, 2019, and applied the modified retrospective method, with right-of-use assets measured at an amount equal to the lease liability, adjusted by the amount of the prepaid or accrued lease payments relating to those leases recognized in the balance sheet immediately before the date of initial application and did not restate prior years. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Results of our impact assessment: </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The undiscounted operating lease commitments as of December 31, 2018, amounted to USD 3.6 billion. This includes approximately USD 0.1 billion of leases with a commencement date in 2019, as well as short-term leases and low-value leases that are recognized from January 1, 2019, upon adoption of IFRS 16, on a straight-line basis as expense in profit and loss. This also includes USD 0.2 billion lease commitments related to the Alcon Division, which is attributable to discontinued operation in 2019. For the remaining undiscounted lease commitments attributable to continuing operations of USD 3.3 billion, the Group recognized on January 1, 2019, lease liabilities of USD 1.74 billion and right-of-use assets of USD 1.55 billion (after the reclassification of USD 0.1 billion from property, plant and equipment, and net adjustments for the USD 0.3 billion recognition of sublease receivables, prepayments, and accrued lease payments recognized as at December 31, 2018). For the lease commitments attributable to discontinued operations, the Group recognized on January 1, 2019, lease liabilities and right-of-use assets of USD 0.2 billion. This does not include the discontinued operations right-of-use assets and lease liability on finance lease agreements of USD 75 million and USD 89 million, respectively. There was an insignificant increase to retained earnings upon adoption of IFRS 16 of USD 3 million that arose from subleases that were accounted for as operating lease agreements under IAS 17 and are accounted for as finance leases under IFRS 16. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As a lessor, the Group had no significant impact upon adoption. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">For additional significant accounting policies applicable to the discontinued operations business see Note 30. </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock', window );">Intangible assets available-for-use</a></td>
<td class="text"><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Intangible assets available for use</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In addition to currently marketed products, technologies and other intangible assets (including computer software), discontinued operations intangible assets available for use also included marketing know-how and the Alcon brand name. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketing know-how represents the value attributable to the expertise acquired for marketing and distributing Alcon surgical products. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Alcon brand name was shown separately, as it was the only Novartis intangible asset that was available for use with an indefinite useful life. Novartis considers that it was appropriate that the Alcon brand name had an indefinite life since Alcon-branded products had a history of strong revenue and cash flow performance, and Novartis had the intent and ability to support the brand with spending to maintain its value for the foreseeable future. The Alcon brand name was not amortized as it had an indefinite useful life, but was evaluated for potential impairment annually. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the respective useful lives for available-for-use intangible assets and the location in the consolidated income statement in which the respective amortization and any potential impairment charge were recognized: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Useful life </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income statement location <br></br> for amortization and <br></br> impairment charges </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketing know-how</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25 years</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon brand name</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Not amortized, <br></br> indefinite useful life </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Other expense" <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the activities and more specifically on appropriate royalty rate for the Alcon brand name. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue recognition</a></td>
<td class="text"><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Revenue recognition</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In the Alcon Division, which is reported as discontinued operations, surgical equipment may have been sold together with other products and services under a single contract. Revenues were recognized upon satisfaction of each of the performance obligations in the contract and the consideration was allocated based on the standalone selling price of each performance obligation. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For surgical equipment, in addition to cash and installment sales, revenue was recognized under finance and operating lease arrangements. Arrangements in which substantially all the risks and rewards incidental to ownership transfers to the customer were treated as finance lease arrangements. Revenue from finance lease arrangements was recognized at amounts equal to the fair value of the equipment, which approximated the present value of the minimum lease payments under the arrangements. As interest rates embedded in lease arrangements were approximately market rates, revenue under finance lease arrangements was comparable to revenue for outright sales. Finance income for arrangements longer than 12 months was deferred and subsequently recognized based on a pattern that approximated to the use of the effective interest method and was recorded in &#x201c;Other income.&#x201d; Operating lease revenue for equipment rentals was recognized on a straight-line basis over the lease term. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Net income </font> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Included in net income from discontinued operations are:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of property, plant and equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;42</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;235</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of right-of-use assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;174</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;052</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on property, plant and equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on intangible assets <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;391</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to restructuring provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation of Novartis equity plans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;93</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> 2018 includes an impairment of USD 337 million related to the write-down of the CyPass currently marketed product, which was acquired with the Alcon Division 2016 acquisition of Transcend Medical, Inc. </div> </td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Balance sheet </font> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following were in the balance sheet from discontinued operations for the period from January 1, 2019, to the date of reclassification: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to property, plant and equipment</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 113</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to right-of-use assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to goodwill and intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 36</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="4"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="4"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Cash flows used in investing activities from discontinued operations</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash flows used in investing activities from discontinued operations include the investing activities of the Alcon business and cash outflows for transaction-related expenditures attributable to the series of portfolio transformation transactions completed in 2015. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments attributable <br></br>to the spin-off of the <br></br>Alcon business </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &#x2013;&#x2005;39 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &#x2013;&#x2005;29 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Divested cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;628</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows attributable to the spin-off of the Alcon business</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;657</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other cash flows used in investing activities, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;88</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;502</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;001</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows used in investing activities from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;127</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;001</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Cash flows from financing activities from discontinued operations</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2020, the net cash outflows used in financing activities from discontinued operations of USD 50 million was for transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2019, the net cash inflows from financing activities from discontinued operations of USD 3.3 billion (2018: USD 167 million net cash outflows) included mainly USD 3.5 billion (2018: nil) cash inflows from Alcon borrowings in connection with the distribution (spin-off) of the Alcon business to Novartis AG shareholders, partly offset by USD 0.2 billion (2018: USD 0.1 billion) transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders (see Notes 1 and 2). </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Leases</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The lease liabilities recorded in discontinued operations on January 1, 2019, the date of implementation of IFRS 16 Leases (see Note 1), were USD 286 million, and the right-of-use assets were USD 276 million, including USD 89 million and USD 75 million, respectively, for the previously reported finance lease obligations. For discontinued operations, there were no impairments or significant contract terminations of right-of-use assets for the period from January 1, 2019, to February 28, 2019, the date of shareholder approval for the Alcon spin-off. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Net assets derecognized </font> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table presents the Alcon business net assets at the date of spin-off at April 8, 2019: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;858</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 269</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;906</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets other than goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;121</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 732</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial and other non-current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 526</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;469</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables and other current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;787</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 628</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;713</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current lease liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;269</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;538</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables, provisions and other liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;751</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets derecognized</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&nbsp;025</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Defined contribution plans</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In many subsidiaries, associates are covered by defined contribution plans. Contributions charged to the consolidated income statement for the defined contribution plans were: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions for defined contribution plans discontinued operations</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 104</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In March 2019, Alcon acquired PowerVision, Inc. (PowerVision), a privately held, US-based medical device development company focused on developing accommodative, implantable intraocular lenses. The fair value of the total purchase consideration was USD 424 million. The amount consisted of an initial cash payment of USD 289 million and the fair value of the contingent consideration of USD 135 million, due to PowerVision shareholders, which they are eligible to receive upon the achievement of specified regulatory and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 418 million, consisting of intangible assets of USD 505 million, net deferred tax liabilities of USD 93 million, other net assets of USD 6 million, and goodwill of USD 6 million. The 2019 results of operations since the date of the acquisition were not material. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For additional information related to the distribution (spin-off) of the Alcon business to Novartis AG shareholders, effected through a dividend in kind distribution that was completed on April 8, 2019, refer to Note 1 and Note 2. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for contingent liabilities and contingent assets. [Refer: Contingent liabilities [member]; Description of nature of contingent assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for decommissioning, restoration and rehabilitation provisions. [Refer: Provision for decommissioning, restoration and rehabilitation costs]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2019-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 36<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_36_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for non-current assets or disposal groups classified as held for sale. [Refer: Non-current assets or disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for subsidiaries. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 30<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_30_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DistributionByWayOfDivindendInKindToShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DistributionByWayOfDivindendInKindToShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326028872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock', window );">Respective Useful Lives of property, plant and equipment</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Useful life</div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buildings</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20 to 40 years</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and other equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7 to 20 years</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Furniture and vehicles</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 10 years</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Computer hardware</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 7 years</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock', window );">Respective Useful Lives of Available-for-Use Intangible Assets</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Useful life </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income statement location <br></br> for amortization and <br></br> impairment charges </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 20 years</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Technologies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10 to 20 years <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold" <br></br> or "Research <br></br> and development" </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other (including <br></br>computer software) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 7 years <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> In the respective <br></br> functional expense </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904347065400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfSignificantTransactionsAbstract', window );"><strong>Disclosure of significant transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock', window );">Net gain at completion of spin-off</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> April 8, <br></br> 2019 </div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net assets derecognized <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;20&nbsp;025</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derecognition of distribution liability</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23&nbsp;434</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Difference between net assets and distribution liability</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;409</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Recognition of Alcon Inc. shares obtained <br></br>through consolidated foundations </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;273 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation gains recycled into <br></br>the consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 123 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transaction costs recognized in the consolidated income statement</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;114</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;691</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="4"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="4"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> See Note 30 for additional information. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock', window );">Assets and liabilities of disposal group classified as held for sale</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31, <br></br> 2019 </div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Assets of disposal group classified as held for sale</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 169</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets other than goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 475</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 181</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 841</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31, <br></br> 2019 </div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Liabilities of disposal group classified as held for sale</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other non-current <br></br>liabilities </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 4 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There were no cumulative income or expenses included in the other comprehensive income relating to the disposal group. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfSignificantTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfSignificantTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904406076344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory', window );">Segmentation - Consolidated income statements</a></td>
<td class="text"><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Segmentation &ndash; consolidated income statements</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate (including eliminations)</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from continuing operations</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 39&nbsp;013</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37&nbsp;714</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;646</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;731</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48&nbsp;659</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;445</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to continuing and discontinued segments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 792</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 783</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 189</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;981</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;871</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 39&nbsp;805</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 38&nbsp;497</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;835</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;872</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;981</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;871</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48&nbsp;659</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;498</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;092</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 53</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 63</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 168</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;239</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;179</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10&nbsp;927</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10&nbsp;050</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5&nbsp;252</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;334</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;058</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 959</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15&nbsp;121</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14&nbsp;425</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&nbsp;896</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 29&nbsp;539</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;636</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;601</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 245</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 112</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 34&nbsp;777</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;252</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11&nbsp;657</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11&nbsp;617</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;076</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;218</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;464</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;534</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14&nbsp;197</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14&nbsp;369</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8&nbsp;118</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8&nbsp;152</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;862</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8&nbsp;980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9&nbsp;402</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 922</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;586</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 176</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 167</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 644</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 278</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;742</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;031</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;871</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;069</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;831</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;749</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;488</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;608</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;190</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;426</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;172</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;287</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;043</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 551</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;63</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;752</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&nbsp;152</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;086</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 670</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 656</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 673</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 659</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;869</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;850</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;78</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 45</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;878</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;940</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;807</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;793</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;071</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;147</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net loss from discontinued operations before gain on <br></br>distribution of Alcon Inc. to Novartis AG shareholders </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;101 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;691</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;590</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;071</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;737</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Shareholders of Novartis AG</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 8&nbsp;072</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 11&nbsp;732</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Non-controlling interests</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net income from continuing operations are:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 91</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 245</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of property, plant and equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;912</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;952</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;282</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;283</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;110</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;318</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;345</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of right-of-use assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;273</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;247</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;41</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;41</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;330</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;305</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;080</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;509</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;370</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;315</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;462</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;836</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on property, plant and equipment, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;324</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;116</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;101</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;440</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;202</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on intangible assets, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;768</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;632</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;506</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;914</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;138</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges and fair value <br></br>changes on financial assets, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 153 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 18 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 182 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 20 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 335 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 38 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to restructuring provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;217</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;229</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;98</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;165</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;98</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;354</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;492</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation of Novartis equity plans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;714</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;761</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;64</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;67</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;180</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;239</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;958</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;067</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate (including eliminations)</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from continuing operations</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37&nbsp;714</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;892</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;731</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;859</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;445</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 44&nbsp;751</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to continuing and discontinued segments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 783</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 741</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 177</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;871</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;836</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 82</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 38&nbsp;497</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 35&nbsp;633</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;872</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&nbsp;036</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;871</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;836</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;498</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 44&nbsp;833</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;092</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 63</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 62</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;179</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;266</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10&nbsp;050</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9&nbsp;870</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;334</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;530</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 959</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 890</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14&nbsp;425</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14&nbsp;510</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 29&nbsp;539</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&nbsp;951</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;601</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;568</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 112</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 70</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;252</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31&nbsp;589</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11&nbsp;617</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10&nbsp;907</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;218</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;305</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;534</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;505</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14&nbsp;369</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;13&nbsp;717</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8&nbsp;152</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;7&nbsp;675</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;814</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9&nbsp;402</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8&nbsp;489</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;586</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 977</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 167</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 505</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 278</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 147</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;031</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;629</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;069</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;475</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;749</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;622</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;608</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;512</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;426</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;609</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;287</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;871</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 551</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;332</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;752</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;800</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;086</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;403</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 656</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;432</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 659</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;438</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;850</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;932</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 45</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 186</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;940</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;095</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;793</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;295</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;147</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;800</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net loss from discontinued operations before gain on <br></br>distribution of Alcon Inc. to Novartis AG shareholders </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;101 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;186 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;691</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income/(loss) from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;590</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;186</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;737</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;614</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Shareholders of Novartis AG</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 11&nbsp;732</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 12&nbsp;611</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Non-controlling interests</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net income from continuing operations are:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 245</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 292</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of property, plant and equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;952</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;075</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;283</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;285</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;110</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;122</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;345</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;482</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of right-of-use assets <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;247</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;41</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;305</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;509</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;214</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;315</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;366</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;836</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;587</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on property, plant and equipment, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;239</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;101</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;60</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;202</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;301</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on intangible assets, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;632</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;592</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;506</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;249</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;138</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;841</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges and fair value <br></br>changes on financial assets, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 18 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 107 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 20 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;113 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 38 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;6 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to restructuring provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;229</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;395</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;165</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;98</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;94</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;492</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;521</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation of Novartis equity plans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;761</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;645</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;67</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;53</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;239</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;220</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;067</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;918</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Depreciation of right-of-use assets recognized from January 1, 2019, the date of implementation of IFRS 16 Leases. Note 1 provides additional disclosures. </div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock', window );">Segmentation - Consolidated balance sheets</a></td>
<td class="text"><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Segmentation &ndash; consolidated balance sheets</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate (including eliminations)</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 83&nbsp;112</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71&nbsp;225</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&nbsp;825</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&nbsp;468</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 32&nbsp;122</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 30&nbsp;677</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 132&nbsp;059</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 118&nbsp;370</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liabilities</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;15&nbsp;472</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;15&nbsp;332</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;786</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;804</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;56&nbsp;135</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;43&nbsp;683</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;75&nbsp;393</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;62&nbsp;819</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 56&nbsp;666</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;551</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net debt <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24&nbsp;481</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&nbsp;938</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24&nbsp;481</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&nbsp;938</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net operating assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 67&nbsp;640</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;893</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;039</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;664</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 468</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;932</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 81&nbsp;147</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71&nbsp;489</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in assets and liabilities are:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total property, plant and equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;863</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;632</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;849</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;888</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 551</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 549</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&nbsp;263</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;069</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to property, plant <br></br>and equipment <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 926 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;114 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 229 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 217 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 110 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 143 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;265 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;474 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total right-of-use assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;489</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;487</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 133</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 136</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 54</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 54</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;676</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;677</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to right-of-use assets <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 264</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 454</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 67</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 49</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 346</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 537</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total goodwill and intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 56&nbsp;839</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 46&nbsp;336</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;817</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;892</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 152</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 83</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 66&nbsp;808</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 55&nbsp;311</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to goodwill and <br></br>intangible assets <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;235 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 647 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 105 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 68 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 85 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 52 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;425 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 767 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total investment in associated <br></br>companies </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 194 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 128 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 8 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 7 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 9&nbsp;430 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 8&nbsp;509 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 9&nbsp;632 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 8&nbsp;644 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to investment in associated <br></br>companies </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 24 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 44 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 7 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 11 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 31 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 55 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents, marketable securities, <br></br>commodities, time deposits and derivative <br></br>financial instruments </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 11&nbsp;563 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 11&nbsp;446 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 11&nbsp;563 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 11&nbsp;446 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debts and derivative <br></br>financial instruments </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 36&nbsp;044 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 27&nbsp;384 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 36&nbsp;044 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 27&nbsp;384 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current income tax and deferred tax liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;880</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;061</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;880</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;061</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Note 29 provides additional disclosures related to net debt </div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Excluding the impact of business acquisitions </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock', window );">Net sales and total of selected non-current assets, by countries and regions</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="11" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net sales<sup>1</sup></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total of selected non-current assets<sup>2</sup></div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="11" height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="11" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="11" height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div> </td> <td></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Country</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 800</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 848</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 795</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34&nbsp;904</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33&nbsp;032</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 43</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&nbsp;484</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16&nbsp;280</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14&nbsp;618</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39&nbsp;889</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28&nbsp;893</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">France</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;442</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;442</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;505</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;115</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;933</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Germany</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;518</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;120</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;972</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;607</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;554</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japan</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;804</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;656</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;575</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 313</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 309</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">China</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;573</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;214</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;953</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 714</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 684</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19&nbsp;038</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&nbsp;885</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&nbsp;333</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 40</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;837</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;296</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48&nbsp;659</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;445</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 44&nbsp;751</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 90&nbsp;379</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 77&nbsp;701</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Region</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18&nbsp;715</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;933</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;259</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 47&nbsp;798</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 53</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 46&nbsp;103</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 59</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Americas</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19&nbsp;725</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 41</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19&nbsp;713</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 41</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&nbsp;032</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40&nbsp;391</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 45</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 29&nbsp;389</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 38</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&nbsp;219</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;799</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;460</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;190</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;209</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48&nbsp;659</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;445</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 44&nbsp;751</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 90&nbsp;379</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 77&nbsp;701</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Net sales to third party from continuing operations by location of customer </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Total of property, plant and equipment; right-of-use assets; goodwill; intangible assets and investment in associated companies </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock', window );">Net sales by region</a></td>
<td class="text"><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Segmentation &ndash; Net sales by region <sup>1</sup> </font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> 2020 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> 2019 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change <br></br> (2019 <br></br> to 2020) <br></br> USD % </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> 2018 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change <br></br> (2018 <br></br> to 2019) <br></br> USD % </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&nbsp;484</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;818</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;296</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&nbsp;342</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13&nbsp;789</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;864</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;718</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;458</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;097</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;469</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;649</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;635</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 39&nbsp;013</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37&nbsp;714</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;892</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29&nbsp;643</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28&nbsp;573</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26&nbsp;258</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;370</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;634</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;231</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;115</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;963</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;142</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;491</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;754</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;501</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;341</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;363</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 772</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 784</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 779</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;646</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;731</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;859</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;089</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;111</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;557</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;620</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;626</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18&nbsp;715</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;933</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;259</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&nbsp;484</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16&nbsp;280</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14&nbsp;618</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&nbsp;219</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;799</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;460</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;241</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;433</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;414</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48&nbsp;659</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 47&nbsp;445</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 44&nbsp;751</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Established Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36&nbsp;732</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35&nbsp;684</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33&nbsp;491</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Of which in Emerging Growth Markets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&nbsp;927</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;761</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;260</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Net sales to third parties from continuing operations by location of customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand. </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock', window );">Other revenue</a></td>
<td class="text"><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Segmentation &ndash; other revenue</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate (including eliminations)</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Profit-sharing income</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 835</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 732</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 835</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 734</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Royalty income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 107</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 104</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 168</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 300</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 147</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Milestone income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 201</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 231</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 55</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 54</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 67</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other revenues</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;092</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 53</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 63</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 168</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;239</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;179</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales. </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Innovative Medicines </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Sandoz </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Corporate (including eliminations)</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Group </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Profit-sharing income</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 732</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 874</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 734</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 877</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Royalty income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 104</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 162</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 147</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 188</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Milestone income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 201</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 128</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 45</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 231</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 173</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 55</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 67</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other revenues</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;092</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 63</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 62</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;179</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;266</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock', window );">Net sales by business franchise</a></td>
<td class="text"><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines Division net sales by business franchise</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> 2020 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> 2019 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change <br></br> (2019 to <br></br> 2020) <br></br> USD % </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> 2018 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change <br></br> (2018 to <br></br> 2019) <br></br> USD % </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Oncology</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;958</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;880</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;874</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;738</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;416</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;174</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Tafinlar</i> + <i>Mekinist</i></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;542</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;338</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;155</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;439</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;585</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;587</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;339</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;114</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 977</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;263</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;561</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;19</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;083</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;539</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;556</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 687</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 480</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 235</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 104</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 653</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 975</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;099</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 635</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 755</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 828</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 474</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 278</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 71</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lutathera</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 445</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 441</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 167</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 164</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Piqray</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 320</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 116</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 176</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Adakveo</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 105</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tabrecta</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 35</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;070</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;189</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;139</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Novartis Oncology business unit</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;711</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;370</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;428</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Immunology, Hepatology and Dermatology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;995</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;551</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;837</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 873</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 671</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 554</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Immunology, Hepatology and Dermatology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;868</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;222</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;392</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ophthalmology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;933</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;086</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;046</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xiidra</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 376</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 192</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 96</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Beovu</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 190</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;911</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;463</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;995</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Ophthalmology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;410</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;776</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;558</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Neuroscience</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;003</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;223</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;341</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 920</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 361</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 155</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Mayzent</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 170</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Aimovig</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 164</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 103</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 59</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 51</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 60</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 80</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Neuroscience</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;323</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;773</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;429</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> 2020 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> 2019 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change <br></br> (2019 to <br></br> 2020) <br></br> USD % </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> 2018 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change <br></br> (2018 to <br></br> 2019) <br></br> USD % </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cardiovascular, Renal and Metabolism</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;497</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;726</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 45</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;028</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 68</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;96</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Cardiovascular, Renal and Metabolism</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;498</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;750</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;050</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 67</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Respiratory</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;251</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;173</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;039</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Ultibro</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 623</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 630</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 703</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Respiratory</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;900</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;825</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;767</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Established Medicines</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Galvus</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;199</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;297</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;284</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Diovan</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;003</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;064</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;023</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exforge</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;025</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;002</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zortress/Certican</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 452</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 485</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 464</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Neoral/Sandimmun(e)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 393</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 419</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 463</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Voltaren/Cataflam</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 360</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 417</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 445</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;916</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;291</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;587</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Established Medicines</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;303</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;998</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;268</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Novartis Pharmaceuticals business unit</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 24&nbsp;302</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;344</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 21&nbsp;464</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 39&nbsp;013</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37&nbsp;714</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;892</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Net sales reflect <i>Xolair</i> sales for all indications. </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock', window );">Net sales of Top 20 products</a></td>
<td class="text"><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Top 20 Innovative Medicines Division product net sales &ndash; 2020</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>Brands </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> Business franchise </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> Key indication </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> US <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of <br></br> world <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> Total <br></br> USD m </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td width="21%" height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Cosentyx </div> </td> <td align="right" width="1%"></td> <td width="21%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> Immunology, Hepatology <br></br> and Dermatology </div> </td> <td align="right" width="1%"></td> <td width="21%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis, ankylosing <br></br> spondylitis, psoriatic <br></br> arthritis and <br></br> non-radiographic axial <br></br> spondyloarthritis </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 2&nbsp;516 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 1&nbsp;479 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> <br></br> <br></br> <br></br> 3&nbsp;995 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;562</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;441</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;003</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Entresto </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, Renal <br></br> and Metabolism </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Chronic heart failure </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;277 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;220 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 2&nbsp;497 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 859</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;099</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;958</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular degeneration</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;933</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;933</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Promacta/Revolade </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune thrombocytopenia (ITP), <br></br> severe aplastic anemia (SAA) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 833 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 905 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 1&nbsp;738 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br><i>Tafinlar</i> + <i>Mekinist</i> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic and <br></br> adjuvant melanoma; advanced <br></br> non-small cell lung cancer (NSCLC) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 569 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 973 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> <br></br> 1&nbsp;542 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors and acromegaly</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 837</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 602</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;439</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Jakavi </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF), <br></br> polycythemia vera (PV) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;339 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 1&nbsp;339 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Xolair <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Respiratory </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA) <br></br> and chronic spontaneous urticaria <br></br> (CSU) and nasal polyps </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 1&nbsp;251 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> <br></br> 1&nbsp;251 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Galvus</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;199</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;199</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia and GIST</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 315</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 873</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;188</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/TSC</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 644</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 439</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;083</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Diovan</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 879</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;003</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exforge</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 964</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 980</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy (SMA)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 459</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 461</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 920</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Ilaris </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Immunology, Hepatology <br></br> and Dermatology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS, <br></br> TRAPS, HIDS/MKD, FMF, SJIA, <br></br> AOSD and gout) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 400 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 473 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> <br></br> 873 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2- metastatic breast cancer</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 318</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 369</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 687</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic iron overload</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 138</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 515</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 653</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Renal cell carcinoma</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 259</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 376</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 635</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;126</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&nbsp;790</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&nbsp;916</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;216</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;881</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;097</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division sales</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;342</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 24&nbsp;671</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 39&nbsp;013</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Net sales reflect <i>Xolair</i> sales for all indications. </div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Top 20 Innovative Medicines Division product net sales &ndash; 2019</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>Brands </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> Business franchise </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> Key indication </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> US <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rest of <br></br> world <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> <br></br> Total <br></br> USD m </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td width="21%" height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Cosentyx </div> </td> <td align="right" width="1%"></td> <td width="21%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, Hepatology <br></br> and Dermatology </div> </td> <td align="right" width="1%"></td> <td width="21%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis, ankylosing <br></br> spondylitis and psoriatic arthritis </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 2&nbsp;220 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;331 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 3&nbsp;551 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;736</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;487</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;223</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular degeneration</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;086</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;086</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 804</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;076</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;880</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Entresto </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, Renal <br></br> and Metabolism </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Chronic heart failure </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 925 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 801 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 1&nbsp;726 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors and acromegaly</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 881</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 704</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;585</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/TSC</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;003</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 536</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;539</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Promacta/Revolade </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune thrombocytopenia (ITP), <br></br> severe aplastic anemia (SAA) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 691 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 725 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 1&nbsp;416 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br><i>Tafinlar</i> + <i>Mekinist</i> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic and <br></br> adjuvant melanoma; advanced <br></br> non-small cell lung cancer (NSCLC) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 481 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 857 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> <br></br> 1&nbsp;338 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Galvus</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;297</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;297</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia and GIST</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 334</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 929</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;263</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Xolair <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Respiratory </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA) <br></br> and chronic spontaneous urticaria <br></br> (CSU) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 1&nbsp;173 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> <br></br> 1&nbsp;173 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Jakavi </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF), <br></br> polycythemia vera (PV) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;114 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 1&nbsp;114 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Diovan</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 86</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 978</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;064</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exforge</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;012</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;025</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic iron overload</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 450</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 525</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 975</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Renal cell carcinoma</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 332</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 423</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 755</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Ilaris </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Immunology, Hepatology <br></br> and Dermatology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS, <br></br> TRAPS, HIDS/MKD, FMF, SJIA, <br></br> AOSD and gout) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 304 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 367 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> <br></br> 671 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zortress/Certican</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Transplantation</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 169</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 316</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 485</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2- metastatic breast cancer</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 230</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 480</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&nbsp;679</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 17&nbsp;967</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 28&nbsp;646</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;110</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;958</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;068</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division sales</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;789</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;925</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37&nbsp;714</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Net sales reflect <i>Xolair</i> sales for all indications. </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> </table> </div> <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Top 20 Innovative Medicines Division product net sales &ndash; 2018</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>Brands </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> Business franchise </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> Key indication </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> US <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rest of <br></br> world <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> <br></br> Total <br></br> USD m </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td width="21%" height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div> </td> <td align="right" width="1%"></td> <td width="21%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div> </td> <td align="right" width="1%"></td> <td width="21%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;765</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;576</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;341</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Cosentyx </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology, Hepatology <br></br> and Dermatology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis, ankylosing <br></br> spondylitis and psoriatic arthritis </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;674 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;163 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 2&nbsp;837 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular degeneration</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;046</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;046</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 806</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;068</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;874</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors and acromegaly</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 817</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 770</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;587</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia and GIST</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 440</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;121</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;561</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/TSC</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 929</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 627</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;556</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Galvus</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;284</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;284</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Promacta/Revolade </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune thrombocytopenia (ITP), <br></br> severe aplastic anemia (SAA) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 581 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 593 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 1&nbsp;174 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br><i>Tafinlar</i> + <i>Mekinist</i> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic and <br></br> adjuvant melanoma; advanced <br></br> non-small cell lung cancer (NSCLC) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 457 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 698 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> <br></br> 1&nbsp;155 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic iron overload</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 521</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 578</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;099</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Xolair <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> Respiratory </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA) <br></br> and chronic spontaneous urticaria <br></br> (CSU) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 1&nbsp;039 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> <br></br> 1&nbsp;039 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Entresto </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, Renal <br></br> and Metabolism </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Chronic heart failure </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 556 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 472 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 1&nbsp;028 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Diovan</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 84</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 939</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;023</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exforge</i> Group</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 983</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;002</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Jakavi </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Oncology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF), <br></br> polycythemia vera (PV) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 977 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 977 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Renal cell carcinoma</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 404</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 424</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 828</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br>Ilaris </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Immunology, Hepatology <br></br> and Dermatology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS, <br></br> TRAPS, HIDS/MKD, FMF, SJIA, <br></br> AOSD and gout) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 262 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 292 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> <br></br> 554 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br>Travoprost Group </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> Ophthalmology </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Reduction of elevated intraocular <br></br> pressure </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 194 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 323 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 517 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zortress/Certican</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Medicines</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Transplantation</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 145</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 319</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 464</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;654</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 17&nbsp;292</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&nbsp;946</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;210</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;736</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;946</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division sales</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;864</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;028</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;892</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Net sales reflect <i>Xolair</i> sales for all indications. </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock', window );">Net sales by business franchise</a></td>
<td class="text"><div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"> <font style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz Division net sales by business franchise</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> 2020 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> 2019 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change <br></br> (2019 to <br></br> 2020) <br></br> USD % </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> 2018 <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change <br></br> (2018 to <br></br> 2019) <br></br> USD % </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Retail Generics <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;244</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;590</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;880</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Biopharmaceuticals</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;928</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;607</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;436</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Anti-Infectives</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 474</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 534</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 543</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;646</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;731</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;859</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Of which USD 694 million (2019: USD 784 million; 2018: USD 826 million) represents anti-infectives sold under the Sandoz name </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments. [Refer: Operating segments [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904388162136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Associated companies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory', window );">Schedule disclosing information related to associates</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net income statement effect</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other comprehensive income effect</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total comprehensive income effect</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018 <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Roche Holding AG, Switzerland</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 677</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 662</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 526</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;56</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;94</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 75</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 621</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 568</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 601</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">GlaxoSmithKline Consumer <br></br>Healthcare Holdings Ltd., UK </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 5&nbsp;910 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;557 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 5&nbsp;353 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies related to continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 673</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 659</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;438</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;56</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;94</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;482</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 617</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 565</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;956</div> </td> <td align="right"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="20"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="20"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> In 2018, Novartis share of other comprehensive income recognized by associated companies, net of taxes of USD 511 million was recycled into the consolidated income statement as a result of the divestment of the investment in GSK Consumer Healthcare Holdings Ltd. No Novartis share of other comprehensive income recognized by associated companies, net of taxes was recycled into the consolidated income statement in 2020 and 2019. <b></b> <b></b> </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfAssociatesBalanceSheetTableTextBlock', window );">Schedule disclosing information related to associates, balance sheet value</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Balance sheet value</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> December 31, <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31, <br></br> 2019 </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Roche Holding AG, Switzerland</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;407</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;445</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 225</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 199</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;632</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;644</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember', window );">Roche Holding AG, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AssociatesSummarizedFinancialInformationTableTextBlock', window );">Associates summarized financial information</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(CHF billions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Current assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-current <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Current <br></br> liabilities </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-current <br></br> liabilities </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">December 31, 2019</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31.3</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 56.4</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24.1</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23.1</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">June 30, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 55.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(CHF billions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Revenue </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Net income </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other <br></br> comprehen- <br></br> sive income </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br></br> comprehen- <br></br> sive income </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">December 31, 2019</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 63.8</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12.3</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.9</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11.4</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">June 30, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;0.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PurchasePriceAllocationAssociatesTableTextBlock', window );">Purchase price allocation associates</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> December 31, <br></br> 2020 </div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of Roche&#x2019;s estimated net assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;585</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of reappraised intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 117</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Implicit Novartis goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;233</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current value of share in net identifiable assets <br></br>and goodwill </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 5&nbsp;935 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated equity accounting adjustments and translation effects less dividends received</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;472</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance sheet value</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;407</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock', window );">Schedule disclosing information related to associates, net income effect</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of Roche's <br></br>estimated current-year <br></br>consolidated net income </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 913 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 910 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 799 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prior-year adjustment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;64</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;129</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;125</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of fair value <br></br>adjustments relating to <br></br>intangible assets, net of taxes <br></br>of USD 26 million (2019: USD 24 <br></br>million; 2018: USD 40 million) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> &#x2013;&#x2005;172 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> <br></br> <br></br> &#x2013;&#x2005;162 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> <br></br> <br></br> &#x2013;&#x2005;148 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Partial release of deferred tax liability recognized</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income effect</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 677</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 662</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 526</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember', window );">GlaxoSmithKline Consumer Healthcare Holdings Ltd., UK</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock', window );">Schedule disclosing information related to associates, net income effect</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of <br></br>GSK Consumer Healthcare's <br></br>estimated current-year <br></br>consolidated net income </div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> <br></br> 119 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prior-year adjustment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of fair value <br></br>adjustments relating to <br></br>intangible assets and inventory, <br></br>net of taxes of USD 1 million </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> <br></br> &#x2013;&#x2005;3 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Pre-tax gain on divestment of GSK Consumer Healthcare</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;790</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income effect</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;910</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of associates. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B4<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B4_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AssociatesSummarizedFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AssociatesSummarizedFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfAssociatesBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfAssociatesBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PurchasePriceAllocationAssociatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PurchasePriceAllocationAssociatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326075512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest expense and other financial income and expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract', window );"><strong>Disclosure of Interest Expense and Other Financial Income and Expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_InterestExpenseTableTextBlock', window );">Interest expense</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;708</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;714</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;877</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense on lease liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;67</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;66</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense arising from discounting long-term liabilities and capitalized borrowing costs</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;94</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;70</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;55</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total interest expense from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;869</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;850</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;932</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherFinancialIncomeAndExpenseTableTextBlock', window );">Other financial income and expense</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 91</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 245</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 292</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;52</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;52</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;39</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency result, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;135</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;160</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;68</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other financial income and expense from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;78</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 45</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 186</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InterestExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InterestExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherFinancialIncomeAndExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherFinancialIncomeAndExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326090872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfIncomeTaxAbstract', window );"><strong>Disclosure of IncomeTax [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_IncomeBeforeTaxesTableTextBlock', window );">Income before taxes</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;786</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;097</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;887</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 92</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 843</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;208</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;878</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;940</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;095</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CurrentAndDeferredIncomeTaxExpenseTableTextBlock', window );">Current and deferred income tax expense</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;932</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;186</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;615</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;168</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;961</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;988</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current income tax expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2&nbsp;100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;2&nbsp;147</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;603</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;137</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;93</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;120</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 430</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 447</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 428</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Deferred tax income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 293</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 354</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 308</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income tax expense from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;807</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;793</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;295</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AnalysisOfTaxRateTableTextBlock', window );">Analysis of tax rate</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(As a percentage)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Applicable tax rate</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13.6</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11.7</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14.3</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of disallowed expenditures</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of utilization of tax losses <br></br>brought forward from prior periods </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;0.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;0.1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;0.1 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of income taxed at reduced rates</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;0.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of income not subject to tax <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;0.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3.7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of tax credits and allowances</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2.3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of release of <br></br>contingent consideration liability </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;0.2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;0.5 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;0.2 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of tax rate change <br></br>on current and deferred <br></br>tax assets and liabilities <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 0.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &#x2013;&#x2005;1.4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &#x2013;&#x2005;0.1 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of write-off of deferred tax assets <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of write-down and reversal of <br></br>write-down of investments in subsidiaries </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;0.8 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;0.6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 0.0 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of prior-year items</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of other items <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Effective tax rate for continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9.2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <b> </b> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Included in 2018 is the effect of income not subject to tax (-3.7%) arising from the portion of the non-taxable gain on the divestment of the Group's investment in GSK Consumer Healthcare Holdings Ltd. attributable to Switzerland. <b> </b> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> 2019 is mainly related to the revaluation of the deferred tax assets and liabilities resulting from the tax reforms enacted in Switzerland in 2019. Refer to Note 12 for additional disclosures. <b> </b> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> 2019 is primarily related to a non-cash, one-time deferred tax expense for the write-off of a deferred tax asset resulting from legal entity reorganizations. <b> </b> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;4&nbsp;</sup> In 2020, other items (+1.9%) include changes in uncertain tax positions (+2.0%) and other items (-0.1%). <br></br> In 2019, other items (+3.0%) include changes in uncertain tax positions (+2.6%) and other items (+0.4%). </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AnalysisOfTaxRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AnalysisOfTaxRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CurrentAndDeferredIncomeTaxExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CurrentAndDeferredIncomeTaxExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfIncomeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfIncomeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncomeBeforeTaxesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncomeBeforeTaxesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326346456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Earnings per share</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income attributable to shareholders of Novartis AG (USD millions)</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;072</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;142</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;797</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;590</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;186</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;072</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;732</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;611</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Number of shares (in millions)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Weighted average number of shares outstanding used in basic earnings per share</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;277</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;291</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;319</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Weighted average number of shares in diluted earnings per share</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;296</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;319</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;344</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic earnings per share (USD)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.55</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.52</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.00</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.08</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.55</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.44</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Diluted earnings per share (USD)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.52</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.08</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.46</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">- Discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.98</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;0.08</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.52</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.06</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.38</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904406243880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Changes in consolidated statements of comprehensive income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAbstract', window );"><strong>Comprehensive income [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ScheduleOfComprehensiveIncomeTableTextBlock', window );">Comprehensive income</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> Note </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Fair value <br></br> adjustments <br></br> on financial <br></br> instruments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Actuarial <br></br> gains/(losses) <br></br> from defined <br></br> benefit plans </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Cumulative <br></br> currency <br></br> translation <br></br> effects </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total value <br></br> adjustments <br></br> attributable to <br></br> Novartis AG <br></br> shareholders </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Non- <br></br> controlling <br></br> interest </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total value <br></br> adjustments </div> </td> <td></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2017, as previously reported</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 395</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;5&nbsp;064</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 329</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;340</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;21</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;361</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of adoption of IFRS 9 on retained <br></br>earnings and OCI </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;177 </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;177 </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;177 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Restated value adjustments at January 1, 2018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 218</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;5&nbsp;064</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 329</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;517</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;538</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on deferred cash flow <br></br>hedges, net of taxes of USD -1 million </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 12 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 12 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 12 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, <br></br>net of taxes of USD -5 million <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 13 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 13 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 13 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 95</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 95</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 95</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes <br></br>of USD 69 million </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;359 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;359 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;359 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.1</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 320</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 320</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 315</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;359</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 415</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 81</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 76</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities sold, reclassified to retained earnings</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 227</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;5&nbsp;423</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 744</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;452</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;478</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on deferred cash <br></br>flow hedges </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on debt securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, <br></br>net of taxes of USD 47 million <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;47 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;47 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;47 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes <br></br>of USD -313 million <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;466 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;466 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;467 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.1</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 354</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 354</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 352</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;45</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;466</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 398</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;113</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;116</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities <br></br>sold, reclassified to retained earnings </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;95 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;95 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;95 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments related to divestments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;30</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 120</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;5&nbsp;919</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;142</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;4&nbsp;657</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;4&nbsp;686</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, <br></br>net of taxes of USD -36 million <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 250 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 250 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 250 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;201</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;201</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;201</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes <br></br>of USD -3 million </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 145 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 145 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 143 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.1</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;193</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;193</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;194</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 145</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;992</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;387</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;386</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities <br></br>sold, reclassified to retained earnings </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;150 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;150 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;150 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments related to divestments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 220</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;5&nbsp;773</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;134</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;419</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;448</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Includes fair value adjustments on equity securities designated as financial assets valued at fair value through other comprehensive income with no subsequent recycling into the <br></br>consolidated income statement </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Included in 2019 is a USD -358 million impact related to the revaluation of deferred tax assets on Swiss post-employment benefits that were previously recognized through other <br></br>comprehensive income. This revaluation resulted from the Swiss tax reforms enacted by the voters in 2019. Refer to Note 12 for additional disclosures. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904317113912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PropertyPlantAndEquipmentTableTextBlock', window );">Property, plant and equipment [table text block]</a></td>
<td class="text"><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of property, plant and equipment during 2020: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Land </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Buildings </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Construction <br></br> in progress </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Machinery <br></br> and other <br></br> equipment </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cost</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2020</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 512</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;463</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;350</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;674</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26&nbsp;999</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of assets reclassified out of assets of <br></br>disposal group held for sale <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 11 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 117 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 36 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 168 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 332 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 433</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;038</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 595</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 115</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 847</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 296</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;265</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;465</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;57</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;656</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;201</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 695</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 110</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 956</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;797</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 555</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12&nbsp;377</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;248</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;038</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28&nbsp;218</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Accumulated depreciation</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;5&nbsp;124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;60</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;9&nbsp;726</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;14&nbsp;930</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation on assets reclassified out of assets of <br></br>disposal group held for sale <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;58 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;101 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;163 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation on disposals and derecognitions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 433</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;543</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;004</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;491</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;827</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;318</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;228</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;447</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;373</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;731</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;108</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;5&nbsp;807</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;66</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;10&nbsp;063</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;15&nbsp;955</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 536</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;570</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;182</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;975</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12&nbsp;263</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for purchases of property, plant and equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 256</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Capitalized borrowing costs</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Note 2 provides additional disclosures related to the reclassification out of assets of the disposal group held for sale. </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Depreciation charge includes USD 38 million (USD 20 million for buildings and USD 18 million for machinery and other equipment), representing the cumulative amount of depreciation charge on the disposal group held for sale for property, plant and equipment from the date of classification to held for sale, September 2018, to March 31, 2020, the date of reclassification out of assets of disposal group held for sale. See Note 2 for further details. </div> </td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of property, plant and equipment during 2019: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Land </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Buildings </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Construction <br></br> in progress </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Machinery <br></br> and other <br></br> equipment </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cost</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2019</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 696</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;135</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;042</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 17&nbsp;155</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34&nbsp;028</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of assets related to discontinued operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;61</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;615</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;655</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;678</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;009</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification to right-of-use assets <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;122</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;127</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of assets related to disposal group held for sale <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 57</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 332</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 630</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 112</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;001</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 355</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;474</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;75</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;551</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;774</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;409</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 512</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;463</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;350</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;674</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&nbsp;999</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Accumulated depreciation</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;6&nbsp;328</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;11&nbsp;924</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;18&nbsp;332</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation on assets related to discontinued operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 562</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;541</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;118</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification to right-of-use assets <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation on assets related to disposal group held for sale <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation on disposals and derecognitions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;170</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;674</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;846</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;447</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;898</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;345</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge <sup style="white-space: nowrap">&nbsp;5</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;51</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;110</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;205</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;43</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;5&nbsp;124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;60</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;9&nbsp;726</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;14&nbsp;930</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 492</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;339</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;290</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;948</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;069</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for purchases of property, plant and equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 220</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Capitalized borrowing costs</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Represents the cost of assets and accumulated depreciation at January 1, 2019, related to the Alcon business reported as discontinued operations. Notes 1, 2 and 30 provide information related to discontinued operations. </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Reclassification to right-of-use assets at January 1, 2019, upon adoption of IFRS 16 Leases. Refer to Note 1 for additional disclosure. </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Note 2 provides additional disclosures related to disposal group held for sale. </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;4&nbsp;</sup> No depreciation charge in the disposal group held for sale for the period from January 1, 2019, to December 31, 2019, was recorded. </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;5&nbsp;</sup> Impairments in the disposal group held for sale for the period from January 1, 2019, to December 31, 2019, were USD 2 million. </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904325964712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-use assets and lease liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract', window );"><strong>Right of use assets Disclosure and Lease liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfRightofuseAssetsRollForwardTableTextBlock', window );">Disclosure of Right-of-use assets roll forward</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Right-of-use assets at January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;677</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;554</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 346</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 537</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;330</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;305</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease contract terminations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;63</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;98</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of divestments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;17</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 46</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total right-of-use assets at December 31 <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;676</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;677</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Lease contract terminations also includes modifications to existing leases that result in reductions to the right-of-use assets, and reductions due to sub-leasing. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> No impairment charge was recorded in 2020 (2019: nil). </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock', window );">Disclosure of right-of-use assets carrying value and depreciation charge</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> December 31, <br></br> 2020 <br></br> carrying value </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Depreciation <br></br> charge <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31, <br></br> 2019 <br></br> carrying value </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Depreciation <br></br> charge <br></br> 2019 </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Land</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 528</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 537</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buildings</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 963</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 207</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 990</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 194</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vehicles</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 155</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 129</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 87</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and equipment, and other assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total right-of-use assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;676</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 330</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;677</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 305</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock', window );">Disclosure of maturity analysis of lease liability</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Lease liabilities <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Lease liabilities <br></br> undiscounted <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Lease liabilities <br></br> 2019 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Lease liabilities <br></br> undiscounted <br></br> 2019 </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less than one year</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 286</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 338</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 246</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 295</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between one and two years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 229</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 274</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 202</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 246</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between two and three years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 186</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 226</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 163</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 202</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between three and four years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 148</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 183</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 138</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 173</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between four and five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 129</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 160</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 119</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 150</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;027</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;326</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;081</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;419</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total lease liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;005</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;507</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;949</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;485</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion of lease liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;286</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;338</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;246</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;295</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current portion of lease liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;719</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;169</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;703</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;190</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock', window );">Additional disclosures related to right-of-use assets and lease liabilities [table text block]</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense on lease liabilities <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 67</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 66</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense on short-term leases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense on low-value leases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total cash outflows for leases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 379</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 339</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cash outflows for short-term leases <br></br>and low-value leases <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> <br></br> 11 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> <br></br> 15 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Payments of interest <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 56</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 51</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Payments of lease liabilities <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 312</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 273</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> The weighted average interest rate is 3.4% (2019: 3.9%). </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Cash flows from short-term and low-value leases are included within total net cash flows from operating activities. The portfolio of short-term leases to which the Group is committed to at December 31, 2020 and 2019, is similar to the portfolio of short-term leases the Group entered into during 2020 and 2019. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Included within total net cash flows from operating activities. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;4&nbsp;</sup> Reported as cash outflows used in financing activities net of lease incentives received of USD nil (2019: USD 33 million). </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfRightofuseAssetsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfRightofuseAssetsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904347078616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and intangible assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract', window );"><strong>Disclosure of detailed information about intangible assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock', window );">Movements of goodwill and intangible assets</a></td>
<td class="text"><div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of goodwill and intangible assets in 2020: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="1" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill</div> </td> <td></td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible assets other than goodwill</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="1" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> In-process <br></br> research and <br></br> development </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Technologies </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently <br></br> marketed <br></br> products </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other <br></br> intangible <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cost</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2020</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26&nbsp;825</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;429</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 884</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 43&nbsp;548</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;558</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 53&nbsp;419</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of assets reclassified out of assets of <br></br>disposal group held for sale <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 10 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 276 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;112 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;400 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;580</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 196</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 218</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;014</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9&nbsp;272</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;274</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 339</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 674</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 412</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;425</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;421</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;101</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;572</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 916</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 208</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 58</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;568</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 205</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;039</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 30&nbsp;321</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;893</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;115</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 57&nbsp;333</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;384</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 67&nbsp;725</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Accumulated amortization</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;301</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2&nbsp;005</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;721</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;20&nbsp;969</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;937</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;24&nbsp;632</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization on assets reclassified <br></br>out of assets of disposal group held for sale <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;107 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;816 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;925 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization charge <sup style="white-space: nowrap">&nbsp;5</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;72</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;215</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;175</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;462</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization on disposals <br></br>and derecognitions <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 421 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 101 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 39 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 567 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge <sup style="white-space: nowrap">&nbsp;6</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;515</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;40</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;338</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;914</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;92</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;46</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;267</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;145</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;550</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;322</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2&nbsp;193</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;885</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;26&nbsp;566</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;272</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;30&nbsp;916</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&nbsp;999</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;700</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 230</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 30&nbsp;767</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;112</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 36&nbsp;809</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Note 2 provides additional disclosures related to the reclassification out of assets of disposal group held for sale as of March 31, 2020. </div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development </div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> No addition for the disposal group held for sale for the period from January 1, 2020, to March 31, 2020 </div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;4&nbsp;</sup> Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use </div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;5&nbsp;</sup> Amortization charge includes USD 102 million (USD 73 million for currently marketed products and USD 29 million for technologies), representing the cumulative amount of amortization charge for the disposal group held for sale for intangible assets from the date of reclassification to held for sale, September 6, 2018, to March 31, 2020, the date of reclassification out of assets of disposal group held for sale. See Note 2 for further details. </div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;6&nbsp;</sup> Impairment charge includes USD 42 million on currently marketed products that were previously classified within assets of disposal group held for sale. See Note 2 for further details. </div> </td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of goodwill and intangible assets in 2019: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="1" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Goodwill</div> </td> <td></td> <td align="center" colspan="13" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Intangible assets other than goodwill</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="1" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="13" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> In-process <br></br> research and <br></br> development </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Alcon <br></br> brand name </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Technologies </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Currently <br></br> marketed <br></br> products </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Marketing <br></br> know-how </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other <br></br> intangible <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cost</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2019</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 35&nbsp;700</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&nbsp;167</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;980</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;253</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 35&nbsp;412</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;960</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;253</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 69&nbsp;025</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of assets related to <br></br>discontinued operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;9&nbsp;000 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;249 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;2&nbsp;980 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;5&nbsp;369 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;4&nbsp;440 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;5&nbsp;960 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;572 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;19&nbsp;570 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of assets related to disposal group <br></br>held for sale, net <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 3 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 186</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 342</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;550</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;914</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9&nbsp;069</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;069</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 265</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 243</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 259</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 767</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions <sup style="white-space: nowrap">&nbsp;5</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;75</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;544</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;436</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;055</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;61</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 49</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 254</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 335</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&nbsp;825</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;429</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 884</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 43&nbsp;548</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;558</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 53&nbsp;419</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Accumulated amortization</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;406</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;120</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;758</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;21&nbsp;218</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;906</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;304</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;30&nbsp;306</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization <br></br>on assets related to discontinued operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 101 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 4&nbsp;184 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 2&nbsp;592 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;906 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 128 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 8&nbsp;813 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization charge <sup style="white-space: nowrap">&nbsp;6</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;42</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;657</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;137</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;836</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization on disposals <br></br>and derecognitions <sup style="white-space: nowrap">&nbsp;5</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 70 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 494 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 419 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 983 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge <sup style="white-space: nowrap">&nbsp;6</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;984</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;105</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;54</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;175</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;126</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;148</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;301</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;2&nbsp;005</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;721</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;20&nbsp;969</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;937</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;24&nbsp;632</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&nbsp;524</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;424</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 163</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;579</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 621</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 28&nbsp;787</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Represents the cost of assets and accumulated amortization at January 1, 2019, related to the Alcon business reported as discontinued operations. Notes 1, 2 and 30 provide information related to discontinued operations. </div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Note 2 provides additional disclosures related to assets of disposal group held for sale. </div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development </div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;4&nbsp;</sup> No addition in the disposal group held for sale for the period from January 1, 2019, to December 31, 2019 </div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;5&nbsp;</sup> Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use </div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;6&nbsp;</sup> No amortization or impairment charges related to the disposal group held for sale for the period from January 1, 2019, to December 31, 2019. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock', window );">Allocation of net book values of goodwill and intangible assets by reporting segment</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="1" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill</div> </td> <td></td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible assets other than goodwill</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="1" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> In-process <br></br> research and <br></br> development </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Technologies </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently <br></br> marketed <br></br> products </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other <br></br> intangible <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21&nbsp;718</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;548</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29&nbsp;645</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 925</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 35&nbsp;121</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;274</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 152</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 227</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;122</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 42</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;543</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 145</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 145</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&nbsp;999</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;700</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 230</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 30&nbsp;767</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;112</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 36&nbsp;809</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2019: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="1" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Goodwill</div> </td> <td></td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Intangible assets other than goodwill</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="1" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> In-process <br></br> research and <br></br> development </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Technologies </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Currently <br></br> marketed <br></br> products </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other <br></br> intangible <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&nbsp;750</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;339</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21&nbsp;720</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 520</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27&nbsp;586</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;767</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 85</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 156</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 859</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;125</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&nbsp;524</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;424</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 163</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;579</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 621</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 28&nbsp;787</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AssumptionsUsedInTheCalculationOfValuationTextBlock', window );">Assumptions used in the calculation of valuation</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(As a percentage) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative <br></br> Medicines </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Sandoz </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Terminal growth rate</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.5</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.5</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Discount rate (post-tax)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_IntangibleAssetImpairmentChargesTextBlock', window );">Intangible asset impairment charges</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;768</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;669</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;592</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;506</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;249</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;914</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;175</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;841</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> 2020 includes an impairment of USD 485 million related to the write-down of IPR&amp;D related to cessation of clinical development program ZPL389 for atopic dermatitis and USD 181 million related to a partial write-down of the <i>Votrient</i> currently marketed product. <br></br>2019 includes an impairment of USD 416 million related to the write-down of IPR&amp;D related to cessation of clinical development program EMA401 and a USD 108 million write-down related to the cessation of clinical development program for MOR106 for atopic dermatitis. <br></br>2018 includes an impairment of USD 400 million related to a partial write-down of the <i>Votrient</i> currently marketed product. </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> 2019 includes an impairment of USD 442 million related to the write-down of IPR&amp;D related to the discontinuation of the generic Advair&#xae; development program. <br></br>2018 includes impairments of USD 220 million related to the write-down of the allocated goodwill (USD 183 million) and the currently marketed products (USD 37 million) related to the retained Sandoz US dermatology business and generic US oral solids portfolio. See Note 2. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AssumptionsUsedInTheCalculationOfValuationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AssumptionsUsedInTheCalculationOfValuationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IntangibleAssetImpairmentChargesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IntangibleAssetImpairmentChargesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904332418728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred tax assets and liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Disclosure of Deferred Tax Assets and Liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Property, <br></br> plant and <br></br> equipment </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Intangible <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pensions and <br></br> other benefit <br></br> obligations <br></br> of associates </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Inventories </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Tax loss <br></br> carry- <br></br> forwards </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Other assets, <br></br> provisions <br></br> and accruals </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax assets at January 1, 2020</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 108</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;469</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;078</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;446</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 255</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;596</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;952</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax liabilities at January 1, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;390</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;610</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;291</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;287</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;325</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;5&nbsp;910</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at January 1, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;282</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2&nbsp;141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 787</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 248</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;271</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;042</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;282</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2&nbsp;141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 787</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 248</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;271</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;042</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 89</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 110</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 212</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;164</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 71</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 293</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to equity</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to other comprehensive income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;39</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;945</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 408</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;501</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;53</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 58</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;35</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;241</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;918</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 797</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;343</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 497</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;314</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 792</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax assets at December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 189</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;351</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;137</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;502</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 507</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;658</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;344</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax liabilities at December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;430</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5&nbsp;269</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;340</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;344</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7&nbsp;552</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;241</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;918</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 797</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;343</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 497</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;314</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 792</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After offsetting the following amount of deferred tax assets and liabilities within the same tax jurisdiction, the balance amounts to: </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 130</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets at December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;214</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities at December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7&nbsp;422</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 792</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax assets at January 1, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 191</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;722</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 273</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;175</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;782</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax liabilities at January 1, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;622</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;5&nbsp;384</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;273</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;474</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;805</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;7&nbsp;558</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at January 1, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;431</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;151</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 915</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;248</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 273</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;370</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;224</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;431</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;151</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 915</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;248</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 273</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;370</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;224</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net deferred tax balance related to discontinued operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 82</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;403</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;123</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;248</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;217</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 858</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 74</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 605</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 308</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;818</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;113</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 298</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 354</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to equity</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 75</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;83</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to other comprehensive income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;313</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;289</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;45</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;47</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;282</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;2&nbsp;141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 787</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 248</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;271</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;042</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax assets at December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 108</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;469</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;078</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;446</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 255</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;596</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;952</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax liabilities at December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;390</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;610</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;291</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;287</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;325</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;910</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;282</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;2&nbsp;141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 787</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 248</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;271</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;042</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After offsetting the following amount of deferred tax assets and liabilities within the same tax jurisdiction, the balance amounts to: </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 43</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets at December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;909</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities at December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;867</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;042</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> <b> </b> <b> </b> <b> </b> <b> </b> <b> </b> <b> </b> <b> </b> </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Notes 1, 2 and 30 provide information related to discontinued operations. <b> </b> </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> <b></b> </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock', window );">Deferred tax assets/liabilities, expected to have impact on current taxes payable</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD billions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected to have an impact on current tax payable after more than 12 months</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Deferred tax assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.5</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.3</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Deferred tax liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock', window );">Temporary differences on which no deferred tax assets have been provided</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD billions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Investments in subsidiaries</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill from acquisitions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;24</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory', window );">Gross value of tax-loss carry-forwards</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Not capitalized</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Capitalized</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020 total</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One year</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Two years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Three years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Four years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 51</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">More than five years <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;400</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;291</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;691</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not subject to expiry</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 323</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 683</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;006</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;780</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;025</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;805</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Not capitalized more than five years includes USD 3.2 billion attributable to US state tax-loss carry-forwards, of which USD 1.6 billion relates to The Medicines Company, which was acquired in 2020 (see Note 2). </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Not capitalized</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Capitalized</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019 total</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One year</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Two years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Three years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Four years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 46</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 62</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 127</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 164</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">More than five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 125</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;214</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;339</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not subject to expiry</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 310</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 345</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 648</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;338</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;986</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tax losses carried forward <br></br>that expired </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 14 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 9 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 8 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock', window );">CH Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Income <br></br> statement <br></br> continuing <br></br> operations </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> <br></br> Equity </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax asset <br></br>and liability revaluation </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Items previously recognized <br></br>in consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 234 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 234 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Items previously recognized in other comprehensive income <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;358</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;358</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total revaluation of deferred tax assets and liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 234</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;358</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;124</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Related to post-employment benefits </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_g&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904336701784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial and other non-current assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract', window );"><strong>Disclosure of financial and other non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfFinancialAssetsTableTextBlock', window );">Financial assets</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;577</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;524</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 366</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 233</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;979</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;790</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term receivables from finance subleases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 83</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 66</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other long-term receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 125</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 104</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 625</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 399</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances and security deposits</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 89</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 159</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;901</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;518</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Note 29 provides additional disclosures related to contingent considerations. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfOtherNoncurrentAssetsTableTextBlock', window );">Other non-current assets</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred compensation plans</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 471</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 414</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid post-employment benefit plans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 202</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 148</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 219</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 176</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other non-current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 892</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 738</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfFinancialAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfFinancialAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOtherNoncurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOtherNoncurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326185976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_InventoriesDisclosureAbstract', window );"><strong>Inventories Disclosure [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventories by class</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Raw material, consumables</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 967</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 751</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Work in progress</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;324</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;024</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Finished products</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;840</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;207</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total inventories</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;131</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;982</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock', window );">Amount of inventory recognized as an expense in cost of goods sold</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD billions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;8.5</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8.5</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8.3</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock', window );">Recognized amount of inventory provisions and reversals of inventory provision</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventory provisions</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;702</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;752</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;603</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversals of inventory provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 255</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 218</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 216</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InventoriesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InventoriesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904335596600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfTradeReceivablesAbstract', window );"><strong>Disclosure of trade receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ProvisionsForTradeReceivablesTableTextBlock', window );">Provisions for trade receivables</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total gross trade receivables</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;310</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;396</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;93</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;95</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;217</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;301</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TradeReceivablesProvisionMovementsTableTextBlock', window );">Trade receivables provision movements</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;95</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;126</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;190</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions related to discontinued operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 54</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables charged to the consolidated income statement <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;59</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;89</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;47</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Utilization of provisions for doubtful trade receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of provisions for doubtful trade receivables credited to the consolidated income statement <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 53</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;93</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;95</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;126</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Notes 1, 2 and 30 provide information related to discontinued operations. </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Provisions charged to the consolidated income statement from continuing operations were USD 30 million in 2018. </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Reversal of provisions credited to the consolidated income statement from continuing operations were USD 44 million in 2018. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OverdueAmountsAndRelatedProvisionsTableTextBlock', window );">Overdue amounts and related provision</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not overdue</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;714</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;763</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for not more than one month</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 150</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 161</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one month <br></br>but less than three months </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 118 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 123 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than three months <br></br>but less than six months </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 102 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 103 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than six months <br></br>but less than one year </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 77 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 96 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one year</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 149</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 150</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;93</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;95</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;217</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;301</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock', window );">Gross trade receivable from closely monitored countries</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total balance of gross trade <br></br>receivables from closely <br></br>monitored countries </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 1&nbsp;505 </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 1&nbsp;588 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one year</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 55</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock', window );">Trade receivables denominated in other currencies</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;311</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;466</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;668</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;384</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 437</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 466</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Russian ruble (RUB)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 288</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 341</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chinese yuan (CNY)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 208</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 279</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">British pound (GBP)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 191</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 202</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Australian dollar (AUD)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 153</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 125</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Brazilian real (BRL)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 148</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 165</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canadian dollar (CAD)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 125</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 129</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 89</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other currencies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;564</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;655</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;217</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;301</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfTradeReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfTradeReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OverdueAmountsAndRelatedProvisionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OverdueAmountsAndRelatedProvisionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProvisionsForTradeReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProvisionsForTradeReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TradeReceivablesProvisionMovementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TradeReceivablesProvisionMovementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326157016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract', window );"><strong>Disclosure of marketable securities commodities deposits derivative instruments and cash [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock', window );">Marketable securities, commodities, timedeposits, and derivative financial instruments</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 111</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 110</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;609</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities, commodities, time deposits and derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;905</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 334</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsTableTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current accounts</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;750</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;247</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity less than 90 days</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;908</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;865</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;658</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;112</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904377961208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherCurrentAssetsAbstract', window );"><strong>Other current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherCurrentAssetsTableTextBlock', window );">Other current assets</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">VAT receivable</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 544</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 508</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Withholding tax recoverable</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 73</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 108</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid expenses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 943</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 898</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Receivables from associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other receivables and current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 963</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;165</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;523</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;680</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904347086984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfEquityAbstract', window );"><strong>Disclosure of equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MovementInTheShareCapitalTableTextBlock', window );">Schedule disclosing information related to movement in the share capital</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Jan 1, 2018 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Movement <br></br> in year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Dec 31, 2018 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Movement <br></br> in year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Dec 31, 2019 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Movement <br></br> in year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> Dec 31, 2020 </div> </td> <td></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Share capital</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 969</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;25</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 944</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;8</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 936</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;23</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 913</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Treasury shares</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;69</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;80</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;53</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding share capital</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 869</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 875</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 856</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 860</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MovementInTheShareslTableTextBlock', window );">Schedule disclosing information related to movement in the shares</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>Number of outstanding shares <br></br>(in millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Note </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br></br> Novartis <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br></br> treasury <br></br> shares <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br></br> outstanding <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> Novartis <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> treasury <br></br> shares <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> outstanding <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> Novartis <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> treasury <br></br> shares <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> outstanding <br></br> shares </div> </td> <td></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at beginning of year</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;527.3</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;262.3</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;265.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;550.6</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;239.4</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;311.2</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;616.8</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;299.3</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;317.5</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares canceled for capital <br></br>reduction <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;60.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 60.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;23.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 23.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;66.2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 66.2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be <br></br>canceled <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;32.6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;32.6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;60.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;60.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;23.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;23.3 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1.2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options <br></br>and employee transactions <sup style="white-space: nowrap">&nbsp;5</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 18.9 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 14.7 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 14.7 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 5.5 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 5.5 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 7.8 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 7.8 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation <sup style="white-space: nowrap">&nbsp;5</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7.4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon <br></br>employees </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 0.4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 0.4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 0.9 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 0.9 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total movements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;60.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 52.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;8.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;23.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;22.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;46.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;66.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 59.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;6.3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at end of year</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;467.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;210.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;256.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;527.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;262.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;265.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;550.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;239.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;311.2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Approximately 103.0 million treasury shares (2019: 117.6 million; 2018: 121.6 million) are held in Novartis entities that restrict their availability for use. </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Novartis reduced its share capital by canceling shares that were repurchased on the SIX Swiss Exchange second trading line during previous years. </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2016 Annual General Meeting (AGM) for transactions before February 28, 2019, and under a new CHF 10 billion share buyback authority approved at the 2019 AGM for transactions after such date </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;4&nbsp;</sup> Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;5&nbsp;</sup> Shares delivered as a result of options being exercised and physical share deliveries related to equity-based participation plans. </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DividendTableTextBlock', window );">Schedule disclosing information related to Dividend</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend per share (in CHF)</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.95</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.85</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.80</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total dividend payment <br></br>(in USD billion) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 7.0 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 6.6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 7.0 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SummaryOfTreasurySharesMovementsTableTextBlock', window );">Schedule disclosing information related treasury shares movements</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Note </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Number of <br></br> outstanding <br></br> shares <br></br> (in millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Equity impact <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Number of <br></br> outstanding <br></br> shares <br></br> (in millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Equity impact <br></br> USD m </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Number of <br></br> outstanding <br></br> shares <br></br> (in millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Equity impact <br></br> USD m </div> </td> <td></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be canceled <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;32.6</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;897</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;60.3</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;351</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;23.3</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;859</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;160</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;114</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of treasury shares</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;34.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;056</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;62.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;511</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;24.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;973</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 806</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 210</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 434</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 730</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 833</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 756</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 263</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;8.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;490</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;46.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;450</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;6.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;520</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2016 AGM for transactions before February 28, 2019, and under a new CHF 10 billion share buyback authority approved at the 2019 AGM for transactions after such date </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Shares delivered as a result of options being exercised related to equity-based participation plans and the delivery of treasury shares. The average share price of the shares delivered was significantly below market price, reflecting the strike price of the options exercised. </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;4&nbsp;</sup> Equity-settled share-based compensation is expensed in the consolidated income statement in accordance with the vesting period of the share-based compensation plans. The value for the shares and options granted is credited to consolidated equity over the respective vesting period. In addition, tax benefits arising from tax-deductible amounts exceeding the expense recognized in the income statement are credited to equity. </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DividendTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DividendTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MovementInTheShareCapitalTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MovementInTheShareCapitalTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MovementInTheShareslTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MovementInTheShareslTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SummaryOfTreasurySharesMovementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SummaryOfTreasurySharesMovementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904326071736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-current financial debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract', window );"><strong>Disclosure of financial liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock', window );">Disclosure of non-current portion of non-current borrowings by type</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&nbsp;298</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22&nbsp;167</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities to banks and other financial institutions <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 188</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total, including current portion of non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28&nbsp;531</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;355</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion of non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;272</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;002</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26&nbsp;259</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&nbsp;353</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Average interest rate 0.3% (2019: 0.2%) </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock', window );">Disclosure of detailed information about borrowings</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>Coupon </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Currency </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Nominal <br></br> amount <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Issuance <br></br> year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Maturity <br></br> year </div> </td> <td></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Issuer </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Issue price </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020 <br></br> (USD <br></br> millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019 <br></br> (USD <br></br> millions) </div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4.400%</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2010</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div> </td> <td align="right" width="1%"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.237%</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;000</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.400%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;500</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2012</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.225%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;497</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;495</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3.700%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2012</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2042</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98.325%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 490</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 489</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3.400%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;150</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2014</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.287%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;142</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;139</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4.400%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;850</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2014</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2044</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.196%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;826</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;825</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.750%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2014</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.134%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 737</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 670</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.625%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2014</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2026</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.697%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 735</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 670</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.250%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis AG, Basel, Switzerland</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.640%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 568</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 517</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.625%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 550</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2029</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis AG, Basel, Switzerland</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.502%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 625</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 568</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.050%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 325</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2035</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis AG, Basel, Switzerland</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.479%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 369</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 336</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3.000%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;750</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.010%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;737</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;735</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4.000%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2045</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98.029%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;220</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;219</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.125%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.127%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;530</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;392</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.625%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2028</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98.480%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 607</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 553</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.800%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.609%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;000</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.400%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.449%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 998</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 996</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3.100%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2027</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.109%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 992</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 990</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.000%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.133%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;536</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;396</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.125%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2027</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.874%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 735</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 670</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.500%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 750</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.655%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 919</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 837</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.375%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 750</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2030</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.957%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 920</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 838</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.700%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 750</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2038</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.217%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 913</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 832</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.750%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.852%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 996</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.000%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2027</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.909%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;245</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.200%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;500</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2030</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.869%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;493</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.750%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2050</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 97.712%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;213</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.000% <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;850</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2028</div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.354%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;255</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total straight bonds</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28&nbsp;298</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;167</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> The EUR 1 850 million bond issued in 2020 features a coupon step-up of 0.25% commencing with the first interest payment date after December 31, 2025, if one or both of the 2025 Patient Access Targets are not met. These 2025 Patient Access Targets are the 2025 Flagship Programs Patient Reach Target and the 2025 Strategic Innovative Therapies Patient Reach Target, as defined in the bond prospectus. As of December 31, 2020, there is no indication that these 2025 Patient Access Targets will not be met. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock', window );">Non-current financial debt including current portion by maturity</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2020</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;002</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2021</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;272</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;067</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;631</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;583</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;546</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;321</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;142</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;139</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;302</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;252</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After 2025</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&nbsp;638</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;991</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28&nbsp;531</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;355</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock', window );">Non-current financial debt including current portion by currency</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&nbsp;848</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;889</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&nbsp;888</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;861</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 184</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;563</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;421</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28&nbsp;531</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;355</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock', window );">Comparison of balance sheet and fair value of total non-current financial debt including current portion</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020 <br></br> Balance <br></br> sheet </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020 <br></br> Fair <br></br> values </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019 <br></br> Balance <br></br> sheet </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019 <br></br> Fair <br></br> values </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&nbsp;298</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31&nbsp;359</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22&nbsp;167</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23&nbsp;701</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 188</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28&nbsp;531</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 31&nbsp;592</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;355</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;889</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904325245144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions and other non-current liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract', window );"><strong>Disclosure of detailed information about provisions and non-current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsExplanatory', window );">Disclosure of other provisions [text block]</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued liability for employee benefits:</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit pension plans <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;538</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;469</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other long-term employee benefits and deferred compensation</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 637</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 546</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other post-employment benefits <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 543</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 612</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Environmental remediation provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 642</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 592</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for product liabilities, governmental investigations and other legal matters</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 181</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 200</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 984</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 958</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 409</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 255</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total provisions and other non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;934</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;632</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Note 25 provides additional disclosures related to post-employment benefits. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Note 29 provides additional disclosures related to contingent consideration. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AccrualForEnvironmentalLossContingenciesTableTextBlock', window );">Accrual for environmental loss contingencies [table text block]</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 714</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 692</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 761</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;48</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005; 83</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;21</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 82</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 809</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 714</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 692</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current provision</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;167</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;122</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;58</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current environmental remediation provisions at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 642</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 592</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 634</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Releases of provisions credited to the consolidated income statement from continuing operations were USD 21 million in 2018. </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Additions to provisions charged to the consolidated income statement from continuing operations were USD 7 million in 2018. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock', window );">Accrual for environmental loss contingencies, fiscal year maturity [table text block]</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Expected <br></br> cash outflows </div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due within two years</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 181</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due later than two years, but within five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 210</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due later than five years, but within 10 years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 338</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due after 10 years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 80</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total environmental remediation liability provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 809</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock', window );">Accrual for product liabilities government investigations other legal matters loss contingencies [table text block]</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;369</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 340</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 351</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions related to <br></br>discontinued operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;42 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;863</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;116</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;118</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases of provisions <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;52</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;107</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to provisions <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;230</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 220</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 487</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;369</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 340</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;306</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;169</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;126</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current product liabilities, governmental investigations and other legal matters provisions at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 181</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 200</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 214</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Notes 1, 2 and 30 provide information related to discontinued operations. </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Releases of provisions credited to the consolidated income statement from continuing operations were USD 107 million in 2018. </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Additions to provisions charged to the consolidated income statement from continuing operations were USD 220 million in 2018. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2019-01-01<br> -Paragraph 84<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AccrualForEnvironmentalLossContingenciesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AccrualForEnvironmentalLossContingenciesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904372316952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current financial debt and derivative financial instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract', window );"><strong>Disclosure of current financial debt and derivative instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock', window );">Current financial debt and derivative instruments</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of associates <br></br>payable on demand <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 2&nbsp;085 </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;836 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other financial debt <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 976</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 719</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;258</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;289</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current portion of non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;272</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;002</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 185</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt and derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;785</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;031</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Weighted average interest rate 0.4% (2019: 0.5%) </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Weighted average interest rate 5.0% (2019: 12.9%) </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904347061656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions and other current liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract', window );"><strong>Disclosure of provisions and other current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock', window );">Provisions and other current liabilities</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes other than income taxes</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 749</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 471</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Restructuring provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 459</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 438</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued expenses for goods and services received but not invoiced</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;167</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;046</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accruals for royalties</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 732</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 653</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued interests on financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 133</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 98</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for deductions from revenue</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;256</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;595</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accruals for compensation and benefits, including social security</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;286</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;464</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Environmental remediation liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 167</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 122</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 56</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 114</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for product liabilities, governmental investigations and other legal matters <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 306</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;169</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued share-based payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 269</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 326</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent considerations <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 62</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 78</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;769</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 716</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 764</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total provisions and other current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&nbsp;127</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;338</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Note 20 provides additional disclosures related to legal provisions. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Note 29 provides additional disclosures related to contingent considerations. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Note 18 provides additional disclosures related to commitment for repurchase of own shares. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ProvisionsForReductionOfRevenueTableTextBlock', window );">Provisions for reduction of revenue</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income statement charge<sup>2</sup></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> <td height="1"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td height="1"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> <td height="1"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Revenue <br></br> deductions <br></br> provisions at <br></br> January 1 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Revenue <br></br> deductions <br></br> provisions <br></br> related to <br></br> discontinued <br></br> operations<sup>1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Effect of <br></br> currency <br></br> translation <br></br> and business <br></br> combinations </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> Payments/ <br></br> utilizations </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> Adjustments <br></br> of prior years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> <br></br> Current year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Change in <br></br> provisions <br></br> offset against <br></br> gross trade <br></br> receivables </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Revenue <br></br> deductions <br></br> provisions at <br></br> December 31 </div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">2020</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US-specific healthcare plans <br></br>and program rebates </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;981 </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;5&nbsp;560 </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;107 </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 5&nbsp;739 </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 2&nbsp;053 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-US-specific healthcare plans <br></br>and program rebates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;769 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 167 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;2&nbsp;597 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 7 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 2&nbsp;940 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;14 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 2&nbsp;272 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-healthcare plans and program-related rebates, returns and other deductions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;845</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 67</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11&nbsp;137</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;51</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&nbsp;094</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 113</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;931</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;595</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 234</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;19&nbsp;294</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;151</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 19&nbsp;773</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 99</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;256</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US-specific healthcare plans <br></br>and program rebates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;883 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 0 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;5&nbsp;183 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;193 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 5&nbsp;474 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;981 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-US-specific healthcare plans <br></br>and program rebates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;625 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;28 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;19 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;2&nbsp;467 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 2&nbsp;659 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;769 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-healthcare plans and program-related rebates, returns and other deductions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;754</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11&nbsp;698</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;868</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 103</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;845</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;262</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;19&nbsp;348</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;220</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&nbsp;001</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 104</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;595</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">2018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US-specific healthcare plans <br></br>and program rebates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;590 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;4&nbsp;158 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;90 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 4&nbsp;541 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;883 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-US-specific healthcare plans <br></br>and program rebates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;356 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;78 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;2&nbsp;182 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 83 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 2&nbsp;555 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;109 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;625 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-healthcare plans and program-related rebates, returns and other deductions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;726</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;51</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;12&nbsp;227</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;91</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;956</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 441</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;754</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total 2018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;672</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;129</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;18&nbsp;567</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;98</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 19&nbsp;052</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 332</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;262</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Notes 1, 2 and 30 provide information related to discontinued operations. </div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Charges to the consolidated income statement from continuing operations were USD 18 248 million in 2018. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RestructuringProvisionsMovementsTableTextBlock', window );">Restructuring provisions movements</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 438</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 507</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 153</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions related to <br></br>discontinued operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;8 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 354</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 492</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 534</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;268</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;479</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;145</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;87</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;72</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;33</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 459</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 438</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 507</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Notes 1, 2 and 30 provide information related to discontinued operations. </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Additions to provisions charged to the consolidated income statement from continuing operations were USD 521 million in 2018. </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Reversal of provisions credited to the consolidated income statement from continuing operations were USD 31 million in 2018. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProvisionsForReductionOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProvisionsForReductionOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RestructuringProvisionsMovementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RestructuringProvisionsMovementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904336703144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Details to the consolidated statements of cash flows (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract', window );"><strong>Disclosure of details to the consolidated statements of cash flows [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock', window );">Adjustments for non-cash items from continuing operations</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation, amortization and impairments on:</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;758</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;547</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;783</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 330</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 305</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;376</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;974</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;428</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial assets <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;335</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;411</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;871</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 895</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gains on disposal and other adjustments on property, plant and equipment; intangible assets; <br></br>financial assets; and other non-current assets, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;478 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;1&nbsp;234 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;902 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-settled compensation expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 738</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 758</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 673</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;673</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;659</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6&nbsp;438</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;807</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;793</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;295</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net financial expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 947</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 805</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 746</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;881</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;122</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;486</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Depreciation of right-of-use assets recognized from January 1, 2019, the date of implementation of IFRS 16 Leases. See Note 1. </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Includes fair value adjustments </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> 2018 included a reversal of a pre-tax gain (USD 5.8 billion) recognized from the divestment of the investment in GSK Consumer Healthcare Holdings Ltd. (see Note 2). The net cash proceed of USD 13.0 billion from the divestment was included in the consolidated statements of cash flows in the line "Acquisitions and divestments of interests in associated companies, net." </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock', window );">Cash flows from changes in working capital and other operating items included in operating cash flow from continuing operations</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Increase) in inventories</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;543</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;382</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;387</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Decrease/(increase) in trade receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 137</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;544</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Decrease)/increase in trade payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;324</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 553</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 252</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 229</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;160</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 316</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 211</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;167</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 941</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other adjustments, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;291</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 199</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 576</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock', window );">Cash flows arising from acquisitions and divestments of businesses</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of acquisitions of businesses</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;10&nbsp;173</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;124</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;13&nbsp;660</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value of previously held equity interests</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 242</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments, deferred consideration and other adjustments, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 62</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;36</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used for acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;10&nbsp;006</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;851</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;13&nbsp;701</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows from divestments of businesses, net <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 49</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 91</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used for acquisitions and divestments of businesses, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;9&nbsp;957</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;760</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;13&nbsp;683</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> In 2020, USD 49 million represented the net cash inflows from divestments in previous years. <br></br>In 2019, the USD 91 million included USD 4 million of net cash outflows from divestments in previous years, and USD 95 million net cash inflows from business divestments in 2019. The net identifiable assets of the 2019 divested businesses amounted to USD 196 million, comprised of non-current assets of USD 159 million; current assets of USD 96 million, including USD 11 million cash and cash equivalents; non-current liabilities of USD 18 million; and current liabilities of USD 41 million. <br></br>In 2018, USD 18 million represented the net cash inflows from divestments in previous years. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock', window );">Reconciliation of liabilities arising from financing activities</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Non-current <br></br> financial <br></br> debts </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Current <br></br> financial <br></br> debts and <br></br> derivative <br></br> financial <br></br> instruments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> Non-current <br></br> lease liabilities </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> Current lease <br></br> liabilities </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2020</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20&nbsp;353</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;031</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;703</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 246</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;126</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of non-current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;003</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;261</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;312</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest payments for amounts included in lease liabilities <br></br>classified as cash flows from operating activities </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;56 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New leases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 221</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 73</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, and other changes, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 65</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 832</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 392</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification from non-current to current, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;067</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;067</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 250</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26&nbsp;259</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;785</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;719</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 286</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> <br></br> Non-current <br></br> financial <br></br> debts </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Current <br></br> financial <br></br> debts and <br></br> derivative <br></br> financial <br></br> instruments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> <br></br> <br></br> Non-current <br></br> lease liabilities </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> <br></br> <br></br> Current lease <br></br> liabilities </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2019</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;470</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;678</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of adoption of IFRS 16 Leases continuing operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;471</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 268</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of adoption of IFRS 16 Leases discontinued operations <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;89</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 246</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 40</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debts and lease liabilities related to discontinued operations <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;47</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;246</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;40</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 93</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of non-current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;195</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;582</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;273</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest payments for amounts included in lease liabilities <br></br>classified as cash flows from operating activities </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;51 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New leases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 362</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 131</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions and divestments of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, and other changes, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 129</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification from non-current to current, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;003</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;003</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;156</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 156</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&nbsp;353</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;031</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;703</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 246</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Lease liabilities recognized on January 1, 2019, the date of implementation of IFRS 16 Leases. See Note 1. </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> In 2018, financial debts included USD 89 million for previously reported finance lease obligations of the Alcon business that were reclassified on January 1, 2019, to lease liabilities, with the adoption of IFRS 16 Leases. Note 30 provides additional disclosures. </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Represents the financial debts and lease liabilities at January 1, 2019, related to the Alcon business reported as discontinued operations. See Notes 1, 2 and 30. </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> <br></br> Non-current <br></br> financial <br></br> debts </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Current <br></br> financial <br></br> debts and <br></br> derivative <br></br> financial <br></br> instruments </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2018</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;224</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;308</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;856</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of non-current financial debts <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;366</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;681</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, and other changes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;48</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;462</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;93</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current portion of non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;190</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;190</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;470</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;678</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Increase in non-current financial debts was only recorded in the consolidated statements of cash flows from continuing operations. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Repayment of non-current financial debts was only recorded in the consolidated statements of cash flows from continuing operations. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Changes in current financial debts included in the consolidated statements of cash flows from continuing operations were USD 1 687 million. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904377882472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions of businesses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfAcquisitionOfBusinessesAbstract', window );"><strong>Disclosure of acquisition of businesses [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock', window );">Fair value of assets and liabilities arising from acquisitions</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 137</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 196</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;550</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;531</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired research and development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 342</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;224</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 218</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 476</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 60</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 381</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current financial and other assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 84</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 195</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables and financial and other current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 90</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;112</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;977</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;107</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;874</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;14</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current lease liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;44</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables and other liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;144</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;178</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;627</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net identifiable assets acquired</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;669</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;938</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;000</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;112</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-controlling interests</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;26</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;580</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 186</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;084</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of acquisitions of businesses <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&nbsp;173</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;946</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> In 2018, net assets recognized as a result of acquisitions of businesses in the consolidated balance sheet from continuing operations were USD 13 660 million. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfAcquisitionOfBusinessesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfAcquisitionOfBusinessesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904323869864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-employment benefits for associates (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfDefinedBenefitPlansTableTextBlock', window );">Summary of the funded and unfunded defined benefit obligation for pension and other post retirement benefit plans table</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment benefit plans</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;066</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;179</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 746</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;073</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit obligations related to discontinued operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;662</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;385</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current service cost</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 372</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 336</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest cost</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 222</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 330</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 29</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past service costs and settlements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;102</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;168</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Administrative expenses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurement losses/(gains) arising from changes in financial assumptions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;791</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurement (gains)/losses arising from changes in demographic assumptions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;193</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Experience-related remeasurement losses/(gains)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 184</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;132</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;22</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;810</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 283</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;264</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;256</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;30</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions of associates</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 186</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 169</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 49</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 25&nbsp;602</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;066</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 632</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 746</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at January 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 19&nbsp;810</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;838</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 134</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 119</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Plan assets related to discontinued operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;424</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;40</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 257</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Return on plan assets excluding interest income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;318</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;656</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;620</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 304</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Group contributions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 464</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 420</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 74</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions of associates</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 186</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 169</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Settlements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;193</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;264</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;256</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;30</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22&nbsp;317</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 19&nbsp;810</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 89</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 134</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;285</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;256</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;543</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;612</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Limitation on recognition of fund surplus at January 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;65</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;68</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in limitation on recognition of fund surplus (incl. exchange rate differences)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income on limitation of fund surplus</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Limitation on recognition of fund surplus at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;51</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;65</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability in the balance sheet at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;336</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;321</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;543</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;612</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Notes 1, 2 and 30 provide information related to discontinued operations. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock', window );">Reconciliation of the net liability table</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment benefit plans</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability at January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;321</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;409</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;612</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;954</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less: net liability related to discontinued operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 238</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 345</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current service cost</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;372</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;336</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net interest expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;58</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;77</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;26</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Administrative expenses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past service costs and settlements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 117</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;126</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;35</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;190</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Group contributions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 464</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 420</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 74</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in limitation on recognition of fund surplus</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;336</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;321</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;543</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;612</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Amounts recognized in the consolidated balance sheet</div> </td> <td align="right"></td> <td align="right"></td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"></td> <td align="right"></td> <td align="right"></td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid benefit cost</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 202</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 148</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued benefit liability</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;538</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;469</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;543</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;612</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Notes 1, 2 and 30 provide information related to discontinued operations. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ScheduleOfAssumptionsUsedTableTextBlock', window );">Principal weighted average actuarial assumptions</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans </div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment benefit plans</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Weighted average assumptions used to determine benefit obligations at December 31</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Discount rate</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.6%</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.0%</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.6%</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.9%</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.6%</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.4%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected rate of pension increase</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.3%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.3%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.4%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected rate of salary increase</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.7%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.8%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.8%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest on savings account</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.1%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.3%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.8%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current average life expectancy <br></br>for a 65-year-old male in years </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 22 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 22 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 22 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 21 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 21 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 21 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current average life expectancy <br></br>for a 65-year-old female in years </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 24 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 24 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 24 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 23 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 23 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 23 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock', window );">The sensitivity of the defined benefit pension obligation to the principal actuarial assumptions</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in 2020 year-end <br></br> defined benefit pension obligation </div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in discount rate</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;885</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in discount rate</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 942</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One-year increase in life expectancy</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 993</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in rate of pension increase</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 589</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in rate of pension increase</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;143</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase of interest on savings account</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 62</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease of interest on savings account</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;30</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in rate of salary increase</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 61</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in rate of salary increase</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;61</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock', window );">The healthcare cost trend rate assumptions used for other post-employment benefits</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Healthcare cost trend rate <br></br>assumed for next year </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 6.3% </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 6.5% </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 7.0% </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rate to which the cost trend <br></br>rate is assumed to decline </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 4.5% </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 4.5% </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 4.5% </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Year that the rate reaches <br></br>the ultimate trend rate </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 2028 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 2028 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 2028 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock', window );">The weighted average plan asset allocation of funded defined benefit pension plans</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(as a percentage) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-term <br></br> target <br></br> minimum </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-term <br></br> target <br></br> maximum </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> 2019 </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 36</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Real estate</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alternative investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and other investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock', window );">Asset allocation, investments in shares of Novartis AG</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> December 31, <br></br> 2020 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31, <br></br> 2019 </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Investment in shares of Novartis AG</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Number of shares (in millions)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Market value (in USD billions)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">The expected future cash flows in respect of pension and other post- employment benefit plans</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Pension plans </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post- <br></br> employment <br></br> benefit plans </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis Group contributions</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2021 (estimated)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 404</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Expected future benefit payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2021</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;245</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;198</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 41</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;191</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 41</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;182</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;165</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026&#x2013;2030</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;651</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 181</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ScheduleOfDefinedContributionPlansTableTextBlock', window );">Defined contribution plans</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions for defined contribution plans continuing operations</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 501</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 422</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 443</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock', window );">Breakdown of defined benefit obligation for pension plans and other post-employment benefit</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Switzerland </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> United <br></br> States </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of <br></br> the world </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Switzerland </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> United <br></br> States </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rest of <br></br> the world </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&nbsp;807</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;788</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;007</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 25&nbsp;602</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&nbsp;106</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;552</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;408</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;066</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof unfunded</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 701</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 516</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 1&nbsp;217</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 670</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 466</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 1&nbsp;136</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">By type of member</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Active</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;837</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 665</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;573</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;075</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;167</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 630</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;400</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;197</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred pensioners</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;290</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;819</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;205</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;517</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;722</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Pensioners</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;970</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;833</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;615</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&nbsp;418</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;939</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;717</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;491</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;147</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&nbsp;396</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;487</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;434</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22&nbsp;317</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;457</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;311</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;042</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 19&nbsp;810</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;411</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;301</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;573</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;285</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;649</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;241</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;366</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;3&nbsp;256</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock', window );">Breakdown of defined benefit obligation for pension plans and other post-employment benefit</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> United <br></br> States </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of <br></br> the world </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> United <br></br> States </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rest of <br></br> the world </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 543</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 89</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 632</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 658</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 88</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 746</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof unfunded</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 454</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 89</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 543</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 524</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 88</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 612</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">By type of member</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Active</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 80</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 105</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 121</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 157</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred pensioners</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Pensioners</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 446</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 510</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 522</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 52</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 574</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 89</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 89</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 134</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 134</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;454</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;89</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;543</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;524</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;88</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;612</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDefinedBenefitPlansTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDefinedBenefitPlansTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfDefinedContributionPlansTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfDefinedContributionPlansTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904315993256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based participation plans for associates (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock', window );">Expense related to all equity-based participation and liabilities arising from equity-based payment transactions</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense related to equity-based <br></br>participation plans </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 958 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;067 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 918 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities arising from equity-based payment transactions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 269</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 326</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 273</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Schedule of unvested restricted stock units roll forward</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Number <br></br> of shares <br></br> in millions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br></br> average fair <br></br> value at grant <br></br> date in USD </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Fair value at <br></br> grant date in <br></br> USD millions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Number <br></br> of shares <br></br> in millions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted <br></br> average fair <br></br> value at grant <br></br> date in USD </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Fair value at <br></br> grant date in <br></br> USD millions </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-vested shares at January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 25.8</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 71.1</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;835</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25.7</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 77.1</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;981</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Granted</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Annual Incentive</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 93.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 103</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 78.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 86</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Share savings plans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 95.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 399</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 83.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 349</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Select North America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 86.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 286</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 64.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 339</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Select outside North America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 89.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 179</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 67.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 175</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Long-Term Performance Plan</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 85.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 213</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 68.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 172</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Long-Term Relative Performance Plan <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Other share awards</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 78.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 117</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 67.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 129</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vested</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;13.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 74.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;024</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;13.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 80.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;068</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forfeited</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 75.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;151</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;328</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-vested shares at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 24.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 78.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;957</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;835</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> LTRPP grants in 2020 represent incremental payouts based on performance criteria under the plan. In 2019 the LTRPP grants are keep whole awards granted due to the spin-off of the Alcon business. </div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At April 8, 2019, the Alcon spin-off date, all RSU and PSU holders, who were not entitled to the dividend in kind in the form of Alcon shares received keep whole awards in Novartis shares to compensate for the loss of the Alcon value from their Novartis shares. These keep whole awards were accounted for as a modification. As they did not increase the value of the original grant, they did not lead to additional expense. In the table above, this is reflected by a zero fair value at grant date amount. </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember', window );">Select outside North America</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Disclosure of number and weighted average remaining contractual life of outstanding share options</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Options <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br></br> average <br></br> exercise <br></br> price <br></br> (USD) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> <br></br> Options <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted <br></br> average <br></br> exercise <br></br> price <br></br> (USD) </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Options outstanding <br></br>at January 1 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 3.4 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 60.9 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 5.6 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 59.9 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sold or exercised</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;0.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 58.4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 62.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 60.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 62.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 60.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory', window );">Disclosure of range of exercise prices of outstanding share options</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>Options outstanding </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total/ <br></br> weighted <br></br> average </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Number outstanding (millions)</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.4</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.8</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.4</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2.6</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remaining contractual life (years)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1.4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise price (USD)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 66.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 62.0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember', window );">Select North America</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Disclosure of number and weighted average remaining contractual life of outstanding share options</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> ADR <br></br> options <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br></br> average <br></br> exercise <br></br> price <br></br> (USD) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> ADR <br></br> options <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted <br></br> average <br></br> exercise <br></br> price <br></br> (USD) </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Options outstanding <br></br>at January 1 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 9.6 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 61.9 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 15.2 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 60.7 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sold or exercised</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 59.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 58.6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 62.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 61.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 62.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 61.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory', window );">Disclosure of range of exercise prices of outstanding share options</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>ADR options outstanding </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total/ <br></br> weighted <br></br> average </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Number outstanding (millions)</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.4</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.3</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6.7</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remaining contractual life (years)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1.5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise price (USD)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 58.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 66.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 62.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the range of exercise prices for outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904387538008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with related parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Disclosure of transactions between related parties [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OfficerAndDirectorCompensationTableTextBlock', window );">Executive Officers and Non-Executive Directors Compensation</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Executive Officers</div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-Executive Directors</div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and other compensation</div> </td> <td align="right" width="5%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.6</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20.7</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22.5</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.6</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.1</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30.2</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24.8</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26.5</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Post-employment benefits</div> </td> <td align="right"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div> </td> <td align="right"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 41.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 40.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 42.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 46.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 45.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 47.3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 69.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 63.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 67.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 79.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 72.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 76.3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock', window );">Transactions with former members of the Board of Directors</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currency</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dr. Krauer</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60&nbsp;000</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 60&nbsp;000</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 60&nbsp;000</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dr. Vasella</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&nbsp;228</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OfficerAndDirectorCompensationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OfficerAndDirectorCompensationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904377964232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CommitmentsAndContingenciesAbstract', window );"><strong>Commitments and contingencies [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfLeasingCommitmentsTableTextBlock', window );">Leasing commitments</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2021</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 449</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 691</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 325</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 483</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 281</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Thereafter</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;003</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;232</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfLeasingCommitmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfLeasingCommitmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904391347512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FinancialInstrumentsAdditionalDisclosureAbstract', window );"><strong>Financial Instruments - additional disclosure [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock', window );">Disclosure of financial assets and financial liabilities</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> <br></br> <br></br> Note </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> <br></br> Financial <br></br> instruments at <br></br> amortized <br></br> costs </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> Financial <br></br> instruments at <br></br> fair value <br></br> through other <br></br> comprehensive <br></br> income </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Financial <br></br> instruments at <br></br> fair value <br></br> through the <br></br> consolidated <br></br> income <br></br> statement </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> <br></br> <br></br> Other <br></br> financial <br></br> liabilities </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;658</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;609</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;217</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 963</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities - debt securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - equity securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;111</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 466</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - debt securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 366</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances, security deposits and other long-term receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 297</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Associated companies at fair value through profit and loss</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 211</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 625</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20&nbsp;744</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;173</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;827</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of associates payable on demand</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;085</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other short-term financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 976</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;258</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&nbsp;298</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term liabilities to banks and other financial institutions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;403</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18/22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;769</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities (see Note 20/22) and other financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;069</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;005</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 43&nbsp;022</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;263</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;005</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> <br></br> <br></br> Note </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> <br></br> Financial <br></br> instruments at <br></br> amortized <br></br> costs </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Financial <br></br> instruments at <br></br> fair value <br></br> through other <br></br> comprehensive <br></br> income </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Financial <br></br> instruments at <br></br> fair value <br></br> through the <br></br> consolidated <br></br> income <br></br> statement </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> <br></br> <br></br> Other <br></br> financial <br></br> liabilities </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;112</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;301</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;036</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities - debt securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities - fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - equity securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;158</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 366</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - debt securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances, security deposits and other long-term receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 329</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Associated companies at fair value through profit and loss</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 186</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 399</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 21&nbsp;839</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;215</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;323</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of associates payable on demand</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;836</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other short-term financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 719</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;289</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22&nbsp;167</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term liabilities to banks and other financial institutions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;424</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities (see Note 20/22) and other financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;065</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 185</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;949</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 32&nbsp;623</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;949</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory', window );">Derivative financial instruments</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Contract or underlying principal amount</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Positive fair values </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Negative fair values </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&nbsp;679</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;779</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 151</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 96</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;165</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;75</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 269</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;110</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments included in marketable securities and in current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;760</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;057</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 102</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;185</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock', window );">Contract or underlying principal amount the derivative financial instruments, by currency</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> EUR</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;432</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&nbsp;376</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;871</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&nbsp;679</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;432</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;457</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;871</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;760</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> EUR</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;373</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;760</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;646</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;779</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 269</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;373</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;665</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;057</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementExplanatory', window );">Fair value by hierarchy</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 1</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 2</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 3</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 26</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 159</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 159</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities and derivative financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 185</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 185</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt and equity securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;153</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 460</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;613</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 366</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 366</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 625</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 625</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total long-term financial investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;153</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;451</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;604</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit and loss</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 211</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 211</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;046</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;046</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;194</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities at fair value</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;069</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;263</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 1</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 2</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 3</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 61</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities and derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 126</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 163</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt and equity securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 976</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 581</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;557</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 233</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 399</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 399</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total long-term financial investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 976</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;213</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;189</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit and loss</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 186</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 186</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;036</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;036</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;29</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;185</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;185</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities at fair value</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;185</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;065</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;250</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock', window );">Reconciliation of changes in fair value measurement</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="13" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="13" style="border-bottom: solid #000000 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Associated <br></br> companies at <br></br> fair value through <br></br> profit and loss </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Fund <br></br> investments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Long-term <br></br> financial <br></br> investments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Contingent <br></br> consideration <br></br> receivables </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Contingent <br></br> consideration <br></br> payables </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Other <br></br> financial <br></br> liabilities </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 186</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 233</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 581</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 399</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;036</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;29</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value gains and other adjustments, <br></br>including from divestments recognized <br></br>in the consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 57 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 151 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 34 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 173 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 206 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value losses (including impairments and <br></br>amortizations) and other adjustments recognized <br></br>in the consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &#x2013;&#x2005;18 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &#x2013;&#x2005;8 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &#x2013;&#x2005;39 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &#x2013;&#x2005;90 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &#x2013;&#x2005;3 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments recognized in the consolidated statement <br></br>of comprehensive income, including currency translation effects </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 33 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 40 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;62 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &#x2013;&#x2005;2 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 123</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;123</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash receipts and payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 63</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;61</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;163</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 211</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 366</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 460</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 625</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;1&nbsp;046</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of fair value gains and losses recognized <br></br>in the consolidated income statement for assets <br></br>and liabilities held at December 31, 2020 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 39 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 143 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &#x2013;&#x2005;5 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 173 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 116 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &#x2013;&#x2005;3 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <b></b> <b></b> <b></b> <b></b> </div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> <b></b> <b></b> <b></b> </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="13" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="13" style="border-bottom: solid #000000 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Associated <br></br> companies at <br></br> fair value through <br></br> profit and loss </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Fund <br></br> investments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Long-term <br></br> financial <br></br> investments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Contingent <br></br> consideration <br></br> receivables </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Contingent <br></br> consideration <br></br> payables </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Other <br></br> financial <br></br> liabilities </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 145</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 251</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 488</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 396</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;907</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;10</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact from discontinued operations <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 163</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value gains and other adjustments, <br></br>including from divestments recognized <br></br>in the consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 12 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 35 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 195 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 1 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value losses (including impairments and <br></br>amortizations) and other adjustments recognized <br></br>in the consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &#x2013;&#x2005;15 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &#x2013;&#x2005;89 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &#x2013;&#x2005;48 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments recognized in the consolidated statement <br></br>of comprehensive income </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &#x2013;&#x2005;6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 49</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 229</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;401</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash receipts and payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;53</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;64</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 186</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 581</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 399</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;036</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;29</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of fair value gains and losses recognized <br></br>in the consolidated income statement for assets <br></br>and liabilities held at December 31, 2019 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &#x2013;&#x2005;15 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 12 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 35 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 106 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &#x2013;&#x2005;47 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Notes 1, 2 and 30 provide information related to discontinued operations. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory', window );">Equity securities measured at fair value through other comprehensive income</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Listed equity securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 862</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 843</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-listed equity securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 249</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 315</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;111</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;158</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock', window );">Monitoring of net debt or liquidity based on contractual maturities</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="11" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="11" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="11" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="11" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due within <br></br> one month </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one month <br></br> but less than <br></br> three months </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> three months <br></br> but less than <br></br> one year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one year <br></br> but less than <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due after <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, time deposits and short-term <br></br>investments with original maturity more than 90 days </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 13 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;571 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 25 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 5 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 21 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;635 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 111</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 111</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments and accrued interest</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 110</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 159</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;558</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;658</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;609</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;781</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 135</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;563</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;10&nbsp;621</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;15&nbsp;638</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;26&nbsp;259</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;10&nbsp;661</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;15&nbsp;802</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;26&nbsp;463</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;10&nbsp;621</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;15&nbsp;638</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;26&nbsp;259</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4&nbsp;195</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;218</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;3&nbsp;178</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;9&nbsp;591</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;4&nbsp;195</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;2&nbsp;219</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;3&nbsp;179</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &#x2013;&#x2005;9&nbsp;593</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;93</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;84</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;194</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;4&nbsp;288</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;2&nbsp;302</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;195</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;9&nbsp;785</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;321</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 479</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;3&nbsp;166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;10&nbsp;612</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;15&nbsp;503</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;24&nbsp;481</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="11" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="11" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="11" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="11" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Due within <br></br> one month </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br></br> one month <br></br> but less than <br></br> three months </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br></br> three months <br></br> but less than <br></br> one year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br></br> one year <br></br> but less than <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Due after <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, time deposits and short-term <br></br>investments with original maturity more than 90 days </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 20 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 26 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 16 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 3 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 57 </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 122 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 110</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 110</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments and accrued interest</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 79</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;712</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;400</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;112</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;746</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;505</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 170</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&nbsp;446</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9&nbsp;110</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;11&nbsp;243</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;20&nbsp;353</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &#x2013;&#x2005;9&nbsp;150</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &#x2013;&#x2005;11&nbsp;355</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &#x2013;&#x2005;20&nbsp;505</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;9&nbsp;110</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;11&nbsp;243</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;20&nbsp;353</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4&nbsp;243</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;373</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;230</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6&nbsp;846</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &#x2013;&#x2005;4&nbsp;243</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &#x2013;&#x2005;1&nbsp;373</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &#x2013;&#x2005;1&nbsp;230</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &#x2013;&#x2005;6&nbsp;846</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;130</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;185</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;4&nbsp;373</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;402</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;256</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;7&nbsp;031</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;373</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 103</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;237</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;9&nbsp;104</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;11&nbsp;073</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;15&nbsp;938</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock', window );">Derivative financial instruments and accrued interest on derivative financial instruments</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due within <br></br> one month </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one month <br></br> but less than <br></br> three months </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> three months <br></br> but less than <br></br> one year </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Derivative financial instruments and accrued interest on derivative financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="1%"></td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential outflows in various currencies - from financial derivative liabilities</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;930</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4&nbsp;096</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;719</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5&nbsp;745</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential inflows in various currencies - from financial derivative assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 904</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;114</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 710</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;728</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Due within <br></br> one month </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br></br> one month <br></br> but less than <br></br> three months </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br></br> three months <br></br> but less than <br></br> one year </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Derivative financial instruments and accrued interest on derivative financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential outflows in various currencies - from financial derivative liabilities</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;814</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;4&nbsp;624</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;952</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;6&nbsp;390</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential inflows in various currencies - from financial derivative assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 807</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;656</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 922</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;385</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock', window );">Other contractual liabilities of the net debt or liquidity</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due within <br></br> three months </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> three months <br></br> but less than <br></br> one year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one year <br></br> but less than <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due after <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contractual interest on non-current liabilities</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;82</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;468</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;846</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;4&nbsp;251</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;6&nbsp;647</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;77</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;209</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;692</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;027</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;2&nbsp;005</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5&nbsp;239</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;164</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;5&nbsp;403</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;769</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;769</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;639</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;345</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;1&nbsp;046</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Due within <br></br> three months </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br></br> three months <br></br> but less than <br></br> one year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br></br> one year <br></br> but less than <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Due after <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contractual interest on non-current liabilities</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;36</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;428</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;531</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;439</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;434</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;65</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;181</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;622</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;081</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;949</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;222</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;202</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;5&nbsp;424</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;62</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;582</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;383</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;036</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfTenDayLossFairValueVARModelTableTextBlock', window );">Ten day loss fair value VAR model</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">All financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 587</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 355</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Analyzed by components:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to foreign <br></br>currency exchange rates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 199 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 89 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to equity <br></br>market movements </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 62 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 31 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to interest rates</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 197</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 187</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock', window );">Ten day loss fair value VAR model, average, high, and low VAR amounts</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Average</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> High</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Low</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">All financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 568</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 659</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 322</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Analyzed by components:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to foreign <br></br>currency exchange rates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 225 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 515 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 71 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to equity <br></br>market movements </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 78 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 261 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 21 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to <br></br>interest rates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 329 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 912 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 173 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Average</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> High</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Low</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">All financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 348</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 385</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 303</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Analyzed by components:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to foreign <br></br>currency exchange rates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 143 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 195 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 86 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to equity <br></br>market movements </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 36 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 81 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 16 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to <br></br>interest rates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 233 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 303 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 187 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of derivative financial instruments. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for fair value measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IFRS13_g91-99_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: Investments in equity instruments designated at fair value through other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 11A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_11A_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfTenDayLossFairValueVARModelTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfTenDayLossFairValueVARModelTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialInstrumentsAdditionalDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialInstrumentsAdditionalDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904321624872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock', window );">Respective Useful Lives of Available-for-Use Intangible Assets</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Useful life </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income statement location <br></br> for amortization and <br></br> impairment charges </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 20 years</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Technologies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10 to 20 years <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold" <br></br> or "Research <br></br> and development" </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other (including <br></br>computer software) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 7 years <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> In the respective <br></br> functional expense </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ScheduleOfDefinedContributionPlansTableTextBlock', window );">Defined contribution plans</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions for defined contribution plans continuing operations</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 501</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 422</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 443</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock', window );">Consolidated income statement, discontinued operations</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019 <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from <br></br>discontinued operations </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 1&nbsp;777 </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 7&nbsp;149 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to continuing segments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;809</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;153</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;860</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;983</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 949</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;170</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;638</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;754</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;142</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;585</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;113</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;126</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income/(loss) from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;234</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income/(loss) before taxes from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 58</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;260</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 74</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net loss from discontinued operations <br></br>before gain on distribution of Alcon Inc. <br></br>to Novartis AG shareholders </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> <br></br> &#x2013;&#x2005;101 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> <br></br> &#x2013;&#x2005;186 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on distribution of Alcon Inc. to Novartis AG shareholders <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;691</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income/(loss) from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;590</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;186</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> The consolidated income statement amounts are for the period from January 1, 2019, to the completion of the spin-off. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> See Note 2 for further details on the non-taxable, non-cash gain on distribution of Alcon Inc. to Novartis AG shareholders. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock', window );">Consolidated income statement, additional information</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of property, plant and equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;42</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;235</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of right-of-use assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;174</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;052</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on property, plant and equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on intangible assets <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;391</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to restructuring provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;13</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation of Novartis equity plans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;93</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> 2018 includes an impairment of USD 337 million related to the write-down of the CyPass currently marketed product, which was acquired with the Alcon Division 2016 acquisition of Transcend Medical, Inc. </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock', window );">Respective Useful Lives of Available-for-Use Intangible Assets</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Useful life </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income statement location <br></br> for amortization and <br></br> impairment charges </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketing know-how</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25 years</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon brand name</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Not amortized, <br></br> indefinite useful life </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Other expense" <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_BalanceSheetAdditionalInformationTableTextBlock', window );">Balance sheet, additional information</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to property, plant and equipment</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 113</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to right-of-use assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to goodwill and intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 36</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="4"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="4"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CashFlowsUsedInInvestingActivitiesTableTextBlock', window );">Cash flows used in investing activities</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2020</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments attributable <br></br>to the spin-off of the <br></br>Alcon business </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &#x2013;&#x2005;39 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &#x2013;&#x2005;29 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Divested cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;628</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows attributable to the spin-off of the Alcon business</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;657</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other cash flows used in investing activities, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2013;&#x2005;88</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;502</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;001</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows used in investing activities from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &#x2013;&#x2005;127</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;159</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &#x2013;&#x2005;1&nbsp;001</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfNetAssetsDerecognizedTableTextBlock', window );">Disclosure of net assets derecognized</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;858</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 269</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;906</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets other than goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&nbsp;121</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 732</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial and other non-current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 526</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;469</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables and other current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;787</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 628</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;1&nbsp;713</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current lease liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;269</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;3&nbsp;538</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables, provisions and other liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2013;&#x2005;2&nbsp;751</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets derecognized</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&nbsp;025</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> </table> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ScheduleOfDefinedContributionPlansTableTextBlock', window );">Defined contribution plans</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2019</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2018</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions for defined contribution plans discontinued operations</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 104</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetAdditionalInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetAdditionalInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashFlowsUsedInInvestingActivitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashFlowsUsedInInvestingActivitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfNetAssetsDerecognizedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfNetAssetsDerecognizedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfDefinedContributionPlansTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfDefinedContributionPlansTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904373939096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Group subsidiaries and associated companies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract', window );"><strong>Disclosure of subsidiaries [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock', window );">Principal Group subsidiaries and associated companies</a></td>
<td class="text"><div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>As at December 31, 2020 </div> </td> <td></td> <td></td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share <br></br> capital <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br></br> interest </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Algeria</div> </td> <td align="right" width="1%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Soci&#xe9;t&#xe9; par actions SANDOZ</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Algiers</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DZD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 650.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Argentina</div> </td> <td align="right" width="1%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Argentina S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buenos Aires</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ARS</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 906.1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Australia</div> </td> <td align="right" width="1%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Australia Pty Ltd</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Macquarie Park, NSW</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals Australia Pty Ltd</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Macquarie Park, NSW</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.8</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Pty Ltd</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Macquarie Park, NSW</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.6</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Austria</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Austria GmbH</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vienna</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma GmbH</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vienna</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz GmbH</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Kundl</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32.7</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">EBEWE Pharma Ges.m.b.H Nfg. KG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Unterach am Attersee</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Bangladesh</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Bangladesh) Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gazipur</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BDT</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 162.5</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Belgium</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma NV</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vilvoorde</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz NV</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vilvoorde</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19.2</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon - Couvreur NV</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Puurs</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 110.6</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Bermuda</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Investment Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Securities Investment Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finance Services Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Triangle International Reinsurance Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trinity River Insurance Co Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 370&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Brazil</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Bioci&#xea;ncias S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">S&#xe3;o Paulo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRL</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 265.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz do Brasil Ind&#xfa;stria Farmac&#xea;utica Ltda.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Camb&#xe9;, PR</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRL</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 190.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Canada</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals Canada Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dorval, Quebec</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.2</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Canada Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Boucherville, Quebec</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 80.8</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Manufacturing Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Boucherville, Quebec</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Chile</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Chile S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Santiago de Chile</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CLP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">China</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Beijing Novartis Pharma Co., Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Beijing</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals (HK) Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hong Kong</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HKD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 200</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">China Novartis Institutes for BioMedical Research Co., Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Shanghai</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 320.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Suzhou Novartis Technical Development Co., Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Changshu</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shanghai Novartis Trading Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shanghai</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.2</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz (China) Pharmaceutical Co., Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Zhongshan</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57.6</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Colombia</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis de Colombia S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Santaf&#xe9; de Bogot&#xe1;</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> COP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.9</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Croatia</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz d.o.o. farmaceutska industrija</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Zagreb</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HRK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.6</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Czech Republic</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis s.r.o.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prague</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CZK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 51.5</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz s.r.o.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prague</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CZK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44.7</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Denmark</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Healthcare A/S</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Copenhagen</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DKK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz A/S</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Copenhagen</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DKK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ecuador</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Ecuador S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Quito</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Egypt</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma S.A.E.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cairo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EGP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 193.8</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.77%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Egypt Pharma S.A.E.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New Cairo City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EGP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 250&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Finland</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finland Oy</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Espoo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 459&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>As at December 31, 2020 </div> </td> <td></td> <td></td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share <br></br> capital <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br></br> interest </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">France</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Groupe France S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rueil-Malmaison</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 903.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma S.A.S.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rueil-Malmaison</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43.4</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Advanced Accelerator Applications S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Saint-Genis-Pouilly</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76&nbsp;734</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.2%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CELLforCURE</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Les Ulis</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.2</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz S.A.S.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Levallois-Perret</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.4</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Germany</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Deutschland GmbH</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nuremberg</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 155.5</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Business Services GmbH</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Wehr</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma GmbH</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nuremberg</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.6</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Produktions GmbH</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Wehr</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz International GmbH</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Holzkirchen</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 A Pharma GmbH</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Oberhaching</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">HEXAL AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Holzkirchen</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 93.7</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Salutas Pharma GmbH</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Barleben</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 42.1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aeropharm GmbH</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rudolstadt</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Greece</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Hellas) S.A.C.I.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Metamorphosis / Athens</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 233.9</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Hungary</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Hungary Healthcare Limited Liability Company</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Budapest</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HUF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 545.6</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Hungary Limited Liability Company</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Budapest</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HUF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 883.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">India</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis India Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mumbai</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 123.5</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70.68%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Healthcare Private Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mumbai</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Private Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mumbai</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Indonesia</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">PT. Novartis Indonesia</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Jakarta</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IDR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.7</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ireland</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Ireland Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dublin</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Integrated Services Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ringaskiddy, County Cork</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Ringaskiddy Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ringaskiddy, County Cork</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Gene Therapies EU Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dublin</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Israel</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Israel Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tel Aviv</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ILS</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Italy</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Farma S.p.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Origgio</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Advanced Accelerator Applications (Italy) S.r.l.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Pozzilli</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 119&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.2%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz S.p.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Origgio</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.7</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Japan</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma K.K.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tokyo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ciba-Geigy Japan Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tokyo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.5</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz K.K.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tokyo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aspen Japan K.K.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tokyo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.2</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Latvia</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Baltics SIA</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Riga</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Luxembourg</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Investments S.&#xe0; r.l.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Luxembourg City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finance S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Luxembourg City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Malaysia</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Corporation (Malaysia) Sdn. Bhd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Kuala Lumpur</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MYR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.3</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Mexico</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Farmac&#xe9;utica, S.A. de C.V.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mexico City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MXN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 205.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz, S.A. de C.V.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mexico City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MXN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 468.2</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Morocco</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Maroc SA</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Casablanca</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MAD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 80.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Netherlands</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Netherlands B.V.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amsterdam</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.4</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma B.V.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amsterdam</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.5</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">IDB Holland BV</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Baarle-Nassau</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.2%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz B.V.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Almere</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 907&nbsp;560</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">New Zealand</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis New Zealand Ltd</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Auckland</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NZD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 820&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>As at December 31, 2020 </div> </td> <td></td> <td></td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share <br></br> capital <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br></br> interest </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Norway</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Norge AS</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Oslo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NOK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.5</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Pakistan</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma (Pakistan) Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Karachi</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PKR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.7</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.99%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Panama</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma (Logistics), Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Panama City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Peru</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Biosciences Per&#xfa; S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lima</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PEN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Philippines</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Healthcare Philippines, Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Makati City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PHP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 298.8</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Philippines Corporation</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Makati City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PHP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Poland</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Poland Sp. z o.o.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Warsaw</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44.2</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Polska Sp. z o.o.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Warsaw</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.6</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lek S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Strykow</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.4</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Portugal</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Portugal, S.G.P.S., Lda.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Porto Salvo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Farma - Produtos Farmac&#xea;uticos, S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Porto Salvo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.4</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Farmac&#xea;utica, Lda.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Porto Salvo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 499&nbsp;900</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Romania</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Services Romania S.R.L.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bucharest</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RON</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz S.R.L.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Targu-Mures</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RON</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 105.2</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Russian Federation</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma LLC</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Moscow</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Neva LLC</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">St. Petersburg</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">ZAO Sandoz</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Moscow</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57.4</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Saudi Arabia</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Saudi Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Riyadh</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SAR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Singapore</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Singapore) Pte Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Singapore</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Singapore Pharmaceutical Manufacturing Pte Ltd</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Singapore</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 45.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Asia Pacific Pharmaceuticals Pte Ltd</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Singapore</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Slovakia</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Slovakia s.r.o.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bratislava</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Slovenia</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lek Pharmaceuticals d.d.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ljubljana</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 48.4</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Pharmaceuticals d.d.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ljubljana</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.5</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">South Africa</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis South Africa (Pty) Ltd</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Midrand</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ZAR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 86.3</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz South Africa (Pty) Ltd</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Kempton Park</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ZAR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">South Korea</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Korea Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Seoul</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> KRW</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24.5</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98.55%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Spain</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Farmac&#xe9;utica, S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Barcelona</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 63.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Advanced Accelerator Applications Iberica, S.L.U.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Barcelona</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22.6</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.2%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Catalana de Dispensacion sau (Cadisa)</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Esplugues de Llobregat</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 450&nbsp;750</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.2%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Farmac&#xe9;utica S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Madrid</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 270&nbsp;450</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Industrial Products S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Les Franqueses del Vall&#xe9;s / Barcelona</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9.3</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Cusi, S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">El Masnou / Barcelona</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10.1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Abadia Retuerta S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sard&#xf3;n de Duero / Valladolid</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sweden</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Sverige AB</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Stockholm</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SEK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Switzerland</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis International AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Holding AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.2</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis International Pharmaceutical Investment AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Bioventures AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Forschungsstiftung</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Stiftung f&#xfc;r Kaderausbildung</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Mitarbeiterbeteiligungsstiftung</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Stiftung f&#xfc;r Mensch und Umwelt</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Stiftung der Novartis AG f&#xfc;r Erziehung, Ausbildung und Bildung</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Basel <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Overseas Investments AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japat AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 350.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Services AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Schweizerhalle AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Muttenz</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.9</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Stein AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Stein</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 251&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Schweiz AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Risch</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Ophthalmics AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fribourg</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Advanced Accelerator Applications International SA</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Geneva</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9.3</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.2%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Pharmaceuticals AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Risch</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Roche Holding AG</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 160.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33%/6% <sup style="white-space: nowrap"> 2</sup> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>As at December 31, 2020 </div> </td> <td></td> <td></td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share <br></br> capital <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br></br> interest </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Taiwan</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Taiwan) Co., Ltd.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taipei</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TWD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 170.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Thailand</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Thailand) Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bangkok</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> THB</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 302.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Turkey</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Saglik, Gida ve Tarim &#xdc;r&#xfc;nleri Sanayi ve Ticaret A.S.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Istanbul</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Farmanova Saglik Hizmetleri Ltd. Sti.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Istanbul</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.7</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Ila&#xe7; Sanayi ve Ticaret A.S.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Istanbul</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 265.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.99%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Grup Saglik &#xdc;r&#xfc;nleri Ila&#xe7;lari Sanayi ve Ticaret A.S.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Gebze - Kocaeli</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ukraine</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Ukraine LLC</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Kyiv</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> UAH</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United Arab Emirates</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Middle East FZE</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dubai</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AED</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United Kingdom</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis UK Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">London</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.5</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals UK Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">London</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.4</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Grimsby Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">London</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 250.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Advanced Accelerator Applications (UK &amp; Ireland)</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">London</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.2%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Neutec Pharma Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">London</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.7</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ziarco Group Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">London</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;904</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frimley / Camberley</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Coalesce Product Development Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cambridge, Cambs</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United States of America</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Corporation</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 72.2</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finance Corporation</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Capital Corporation</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Services, Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis US Foundation</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals Corporation</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 650</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Advanced Accelerator Applications USA, Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Millburn, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.2%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Gene Therapies, Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bannockburn, IL</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Technology LLC</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Institutes for BioMedical Research, Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cambridge, MA</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Optogenetics Research, Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CoStim Pharmaceuticals Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cambridge, MA</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Endocyte, Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Navigate BioPharma Services, Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Carlsbad, CA</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">The Medicines Company</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Princeton, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25&nbsp;000</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amblyotech Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Oriel Therapeutics, Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Durham, NC</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50.0</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fougera Pharmaceuticals Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Melville, NY</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Eon Labs, Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Princeton, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Vaccines and Diagnostics, Inc.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Venezuela</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis de Venezuela, S.A.</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Caracas</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VES</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Vietnam</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Vietnam Company Limited</div> </td> <td align="right" width="9%"></td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ho Chi Minh City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VND</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70</div> </td> <td width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">In addition, the Group is represented by subsidiaries and associated companies with total assets or net sales to third parties below USD 25 million in the following countries: Bosnia and Herzegovina, Bulgaria, Dominican Republic, Guatemala, Kenya, Kuwait, North Macedonia, Nigeria, Puerto Rico and Uruguay </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;1&nbsp;</sup> Share capital may not reflect the taxable share capital and does not include any paid-in surplus. </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;2&nbsp;</sup> Approximately 33.3% of voting shares; approximately 6.2% of total net income and equity attributable to Novartis. </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;3&nbsp;</sup> Significant subsidiary under SEC Regulation S-X Rule 1-02(w) </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"> <sup>&nbsp;4&nbsp;</sup> Fully consolidated Foundation </div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">m = million; bn = billion</div> </td> </tr> </table> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904321420152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 08, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share | SFr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Operating lease commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NewLeaseArrangements', window );">New lease arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_UndiscountedFutureLeasePayments', window );">Undiscounted future lease payments</a></td>
<td class="nump">$ 3,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">1,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_GrossLeaseLiabilitiesDiscontinuedOperations', window );">Operating lease commitments, discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations [member] | Previously stated [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 58<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_58&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph B11D<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B11D_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GrossLeaseLiabilitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GrossLeaseLiabilitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NewLeaseArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NewLeaseArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_UndiscountedFutureLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_UndiscountedFutureLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904324120296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant accounting policies (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Apr. 08, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">$ 12,263<span></span>
</td>
<td class="nump">$ 12,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">1,676<span></span>
</td>
<td class="nump">1,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Reserves</a></td>
<td class="nump">55,738<span></span>
</td>
<td class="nump">54,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current lease liabilities</a></td>
<td class="nump">$ 286<span></span>
</td>
<td class="nump">$ 246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member', window );">Increase (decrease) due to changes in accounting policy, IFRS 16 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Reserves</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 269<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations [member] | Previously stated [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904287011848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant transactions (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 06, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 23, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 11, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 11, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 07, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 08, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 21, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 15, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 27, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 22, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Nov. 11, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Apr. 09, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 06, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 06, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 06, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,173,000,000<span></span>
</td>
<td class="nump">$ 4,124,000,000<span></span>
</td>
<td class="nump">$ 13,946,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperations', window );">Profit (loss) from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,590,000,000<span></span>
</td>
<td class="num">(186,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share | SFr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(792,000,000)<span></span>
</td>
<td class="num">(2,042,000,000)<span></span>
</td>
<td class="num">(1,224,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,809,000,000<span></span>
</td>
<td class="nump">28,787,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Revenue from sale of goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,659,000,000<span></span>
</td>
<td class="nump">47,498,000,000<span></span>
</td>
<td class="nump">44,833,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,531,000,000<span></span>
</td>
<td class="nump">22,355,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet', window );">Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,691,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_AlconMember', window );">Alcon [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners', window );">Decrease of distribution liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PercentageOfEquityInterestSharesReceived', window );">Percentage of equity interest shares received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember', window );">Roche Holding AG, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additional recognition, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,233,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SandozMember', window );">Sandoz | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DivestmentDateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, divestment-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation, property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation, intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment loss recognised in profit or loss, intangible assets and goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (42,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsAAAMember', window );">Advanced Accelerator Applications (AAA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Portion of consideration paid (received) consisting of cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,900,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additional recognition, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueOfAcquiree', window );">Revenue of acquiree since acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueOfAcquireeFullYear', window );">Revenue of acquiree full year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PercentageOfShareCapitalInTenderOffer', window );">Percentage of Share capital in tender offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CashOfferPerOrdinaryShare', window );">Cash offer per ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CashOfferPerADS', window );">Cash offer per ADS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NumberOfOrdinarySharePerADS', window );">Number of ordinary share per ADS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueOfEquity', window );">Value of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer', window );">Percentage of share capital tendered at the expiration of the tender offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer', window );">Total percentage of share capital tendered after the subsequent offering period of the tender offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer', window );">Percentage of share capital tendered at the subsequent offering period of the tender offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer', window );">Consideration paid for share capital tendered at the subsequent offering period of the tender offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nvs_AspenGlobalIncorporatedMember', window );">Aspen Global Incorporated | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value</a></td>
<td class="nump">$ 324,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 294.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Portion of consideration paid (received) consisting of cash and cash equivalents</a></td>
<td class="num">(273,000,000)<span></span>
</td>
<td class="num">&#8364; (247.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (336,000,000)<span></span>
</td>
<td class="num">&#8364; (300.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment', window );">Portion of consideration paid consisting of cash and cash equivalents upfront payment</a></td>
<td class="num">(303,000,000)<span></span>
</td>
<td class="num">(274.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Contingent liabilities recognised as of acquisition date</a></td>
<td class="nump">51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 47.0<span></span>
</td>
<td class="nump">&#8364; 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="nump">238,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additional recognition, goodwill</a></td>
<td class="nump">86,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherNetAssets', window );">Other net assets</a></td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="nump">196,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PotentialMilestoneMaximumPayments', window );">Potential milestone maximum payments</a></td>
<td class="nump">77,000,000<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CustomaryPurchasePriceAdjustment', window );">Customary purchase price adjustment</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="nump">&#8364; 27.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nvs_TheMedicinesCompanyMember', window );">The Medicines Company | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Portion of consideration paid (received) consisting of cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,600,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additional recognition, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CashOfferPerOrdinaryShare', window );">Cash offer per ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nvs_AveXisIncMember', window );">AveXis, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Portion of consideration paid (received) consisting of cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,700,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additional recognition, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CashOfferPerOrdinaryShare', window );">Cash offer per ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherNetAssets', window );">Other net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nvs_EndocyteMember', window );">Endocyte</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Portion of consideration paid (received) consisting of cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,100,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additional recognition, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CashOfferPerOrdinaryShare', window );">Cash offer per ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherNetAssets', window );">Other net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nvs_GSKConsumerHealthcareMember', window );">GSK Consumer Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Divested interest in associate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations', window );">Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,994,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PreTaxProfitLossFromDivestmentOfBusiness', window );">Pre tax profit (loss) from divestment of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nvs_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda Pharmaceutical Company Limited | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Portion of consideration paid (received) consisting of cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,500,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment', window );">Portion of consideration paid consisting of cash and cash equivalents upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,400,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Contingent liabilities recognised as of acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additional recognition, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueOfAcquiree', window );">Revenue of acquiree since acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueOfAcquireeFullYear', window );">Revenue of acquiree full year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PotentialMilestoneMaximumPayments', window );">Potential milestone maximum payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CustomaryPurchasePriceAdjustment', window );">Customary purchase price adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nvs_IFMTreInc.Member', window );">IFM Tre, Inc. | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 361,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Portion of consideration paid (received) consisting of cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(285,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Contingent liabilities recognised as of acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additional recognition, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Divested interest in associate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate', window );">Acquisition-date fair value of equity interest in acquiree held by acquirer immediately before acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination', window );">Gain (loss) recognised as result of remeasuring to fair value equity interest in acquiree held by acquirer before business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired', window );">Percentage of voting equity interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember', window );">Continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,660,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperations', window );">Profit (loss) from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,590,000,000<span></span>
</td>
<td class="num">(186,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(858,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,121,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Revenue from sale of goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,809,000,000<span></span>
</td>
<td class="nump">$ 7,153,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DividendsPayable', window );">Dividend in kind distribution liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,434,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed', window );">Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,409,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet', window );">Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,691,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations | Alcon [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RepaymentOfIntercompanyBalances', window );">Repayment of intercompany balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,100,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DividendsPayable', window );">Dividend in kind distribution liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetAssetsLiabilities', window );">Net assets liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AdditionalBorrowings', window );">Additional borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations | Alcon [member] | Borrowings, USD [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations | Alcon [member] | Borrowings, EUR [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations | PowerVision, Inc. | Alcon [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Portion of consideration paid (received) consisting of cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(289,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Contingent liabilities recognised as of acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additional recognition, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherNetAssets', window );">Other net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 505,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | The Medicines Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The acquisition-date fair value of equity interest in the acquiree held by the acquirer immediately before the acquisition date in a business combination achieved in stages. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph p<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_p_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalRecognitionGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional goodwill recognised, except goodwill included in a disposal group that, on acquisition, meets the criteria to be classified as held for sale in accordance with IFRS 5. [Refer: Goodwill; Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B67_d_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalRecognitionGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised as of the acquisition date in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph IE72<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of difference between the carrying amount of dividends payable and the carrying amount of non-cash assets distributed when settling the dividends payable. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRIC<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 15<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRIC&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_15&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends payable by means of the distribution of non-cash assets to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRIC<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRIC&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial assets. [Refer: At fair value [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gain (loss) recognised as result of remeasuring to fair value the equity interest in the acquiree held by the acquirer before the business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph p<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_p_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph IE72<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for intangible assets and goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in dividends payable through a change in the fair value of non-cash assets held for distribution to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRIC<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRIC&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets less the amount of liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph IG63<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IG63&amp;doctype=Implementation%20Guidance<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfVotingEquityInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of consideration paid or received, consisting of cash and cash equivalents, in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]; Cash and cash equivalents; Consideration paid (received)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 40<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_40_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the disposal of non-current assets or disposal groups classified as held for sale and discontinued operations. [Refer: Discontinued operations [member]; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from discontinued operations. [Refer: Discontinued operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_vii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph ea<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_ea&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 98<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_98_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueOfAcquiree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue of the acquiree since the acquisition date included in the consolidated statement of comprehensive income. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B64<br> -Subparagraph q<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B64_q_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueOfAcquiree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AdditionalBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AdditionalBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashOfferPerADS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This expresses the amount of cash Novartis paid to the owners of AAA per ADS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashOfferPerADS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashOfferPerOrdinaryShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This expresses the amount of cash Novartis paid to the owners of AAA per ordinary share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashOfferPerOrdinaryShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CustomaryPurchasePriceAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CustomaryPurchasePriceAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DivestmentDateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DivestmentDateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfOrdinarySharePerADS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfOrdinarySharePerADS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PercentageOfEquityInterestSharesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PercentageOfEquityInterestSharesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PercentageOfShareCapitalInTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PercentageOfShareCapitalInTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PotentialMilestoneMaximumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PotentialMilestoneMaximumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PreTaxProfitLossFromDivestmentOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PreTaxProfitLossFromDivestmentOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RepaymentOfIntercompanyBalances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RepaymentOfIntercompanyBalances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueOfAcquireeFullYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueOfAcquireeFullYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ValueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ValueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_AlconMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_AlconMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsAAAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsAAAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AspenGlobalIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AspenGlobalIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_TheMedicinesCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_TheMedicinesCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AveXisIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AveXisIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_EndocyteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_EndocyteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_GSKConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_GSKConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_IFMTreInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_IFMTreInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_BorrowingsUSDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_BorrowingsUSDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_BorrowingsEURMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_BorrowingsEURMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_PowerVisionInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_PowerVisionInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904319089848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant transactions (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 08, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet', window );">Gain on distribution of Alcon Inc. to Novartis AG shareholders</a></td>
<td class="nump">$ 4,691<span></span>
</td>
<td class="nump">$ 4,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NetAssetsDerecognized', window );">Net assets derecognized</a></td>
<td class="num">(20,025)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DividendsPayable', window );">Derecognition of distribution liability</a></td>
<td class="nump">23,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed', window );">Difference between net assets and distribution liability</a></td>
<td class="nump">3,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DistributionOfDividendToDividendBearingShares', window );">Distribution of dividend to dividend bearing shares</a></td>
<td class="nump">1,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement', window );">Cumulative currency translation gains/losses recycled through income statement</a></td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TransactionCosts', window );">Transaction costs recognized in the consolidated income statement</a></td>
<td class="num">$ (114)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet', window );">Gain on distribution of Alcon Inc. to Novartis AG shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_AlconMember', window );">Alcon | Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DividendsPayable', window );">Derecognition of distribution liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of difference between the carrying amount of dividends payable and the carrying amount of non-cash assets distributed when settling the dividends payable. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRIC<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 15<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRIC&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_15&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends payable by means of the distribution of non-cash assets to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRIC<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRIC&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DistributionOfDividendToDividendBearingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DistributionOfDividendToDividendBearingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetAssetsDerecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetAssetsDerecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_AlconMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_AlconMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904322621128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant transactions (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract', window );"><strong>Assets of disposal group classified as held for sale [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">$ 12,263<span></span>
</td>
<td class="nump">$ 12,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="nump">36,809<span></span>
</td>
<td class="nump">28,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">8,214<span></span>
</td>
<td class="nump">7,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">892<span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">7,131<span></span>
</td>
<td class="nump">5,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialAssets', window );">Other current assets</a></td>
<td class="nump">2,523<span></span>
</td>
<td class="nump">2,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale', window );">Assets of disposal group held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract', window );"><strong>Liabilities of disposal group classified as held for sale [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">7,422<span></span>
</td>
<td class="nump">5,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentNonfinancialLiabilities', window );">Provisions and other non-current liabilities</a></td>
<td class="nump">6,934<span></span>
</td>
<td class="nump">6,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialLiabilities', window );">Provisions and other current liabilities</a></td>
<td class="nump">$ 15,127<span></span>
</td>
<td class="nump">13,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale', window );">Liabilities of disposal group held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis=ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember', window );">Assets and liabilities classified as held for sale [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract', window );"><strong>Assets of disposal group classified as held for sale [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialAssets', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale', window );">Assets of disposal group held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract', window );"><strong>Liabilities of disposal group classified as held for sale [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentNonfinancialLiabilities', window );">Provisions and other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialLiabilities', window );">Provisions and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale', window );">Liabilities of disposal group held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 56<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 56<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities included in disposal groups classified as held for sale. [Refer: Liabilities; Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 38<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_38&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph p<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_p&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets or disposal groups classified as held for sale. [Refer: Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 38<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_38&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentNonfinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentNonfinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentNonfinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentNonfinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis=ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis=ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904406072200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NumberOfReportableSegments', window );">Number of Reportable Segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NumberOfBusinessUnits', window );">Number of Business Units</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NumberOfFranchises', window );">Number of Franchises</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfBusinessUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfBusinessUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfFranchises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfFranchises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904317459960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 08, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,659<span></span>
</td>
<td class="nump">$ 47,445<span></span>
</td>
<td class="nump">$ 44,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments', window );">Sales to continuing and discontinued segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,659<span></span>
</td>
<td class="nump">47,498<span></span>
</td>
<td class="nump">44,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,239<span></span>
</td>
<td class="nump">1,179<span></span>
</td>
<td class="nump">1,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,121)<span></span>
</td>
<td class="num">(14,425)<span></span>
</td>
<td class="num">(14,510)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,777<span></span>
</td>
<td class="nump">34,252<span></span>
</td>
<td class="nump">31,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,197)<span></span>
</td>
<td class="num">(14,369)<span></span>
</td>
<td class="num">(13,717)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,980)<span></span>
</td>
<td class="num">(9,402)<span></span>
</td>
<td class="num">(8,489)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,742<span></span>
</td>
<td class="nump">2,031<span></span>
</td>
<td class="nump">1,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,190)<span></span>
</td>
<td class="num">(3,426)<span></span>
</td>
<td class="num">(2,609)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,152<span></span>
</td>
<td class="nump">9,086<span></span>
</td>
<td class="nump">8,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Income from associated companies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">673<span></span>
</td>
<td class="nump">659<span></span>
</td>
<td class="nump">6,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(869)<span></span>
</td>
<td class="num">(850)<span></span>
</td>
<td class="num">(932)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Other financial income and expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Income before taxes from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,878<span></span>
</td>
<td class="nump">8,940<span></span>
</td>
<td class="nump">14,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,807)<span></span>
</td>
<td class="num">(1,793)<span></span>
</td>
<td class="num">(1,295)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperations', window );">Net income from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,071<span></span>
</td>
<td class="nump">7,147<span></span>
</td>
<td class="nump">12,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution', window );">Net income/loss from discontinued operations before gain on distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101)<span></span>
</td>
<td class="num">(186)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet', window );">Gain on distribution of Alcon Inc. to Novartis AG shareholders</a></td>
<td class="nump">$ 4,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperations', window );">Net income/loss from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,590<span></span>
</td>
<td class="num">(186)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,071<span></span>
</td>
<td class="nump">11,737<span></span>
</td>
<td class="nump">12,614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,013<span></span>
</td>
<td class="nump">37,714<span></span>
</td>
<td class="nump">34,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments', window );">Sales to continuing and discontinued segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">792<span></span>
</td>
<td class="nump">783<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,805<span></span>
</td>
<td class="nump">38,497<span></span>
</td>
<td class="nump">35,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">1,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,927)<span></span>
</td>
<td class="num">(10,050)<span></span>
</td>
<td class="num">(9,870)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,896<span></span>
</td>
<td class="nump">29,539<span></span>
</td>
<td class="nump">26,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,657)<span></span>
</td>
<td class="num">(11,617)<span></span>
</td>
<td class="num">(10,907)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,118)<span></span>
</td>
<td class="num">(8,152)<span></span>
</td>
<td class="num">(7,675)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">922<span></span>
</td>
<td class="nump">1,586<span></span>
</td>
<td class="nump">977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,871)<span></span>
</td>
<td class="num">(2,069)<span></span>
</td>
<td class="num">(1,475)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,172<span></span>
</td>
<td class="nump">9,287<span></span>
</td>
<td class="nump">7,871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Income from associated companies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,646<span></span>
</td>
<td class="nump">9,731<span></span>
</td>
<td class="nump">9,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments', window );">Sales to continuing and discontinued segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,835<span></span>
</td>
<td class="nump">9,872<span></span>
</td>
<td class="nump">10,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,252)<span></span>
</td>
<td class="num">(5,334)<span></span>
</td>
<td class="num">(5,530)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,636<span></span>
</td>
<td class="nump">4,601<span></span>
</td>
<td class="nump">4,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,076)<span></span>
</td>
<td class="num">(2,218)<span></span>
</td>
<td class="num">(2,305)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(862)<span></span>
</td>
<td class="num">(1,250)<span></span>
</td>
<td class="num">(814)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="nump">505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(831)<span></span>
</td>
<td class="num">(749)<span></span>
</td>
<td class="num">(622)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,043<span></span>
</td>
<td class="nump">551<span></span>
</td>
<td class="nump">1,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Income from associated companies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments', window );">Sales to continuing and discontinued segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(981)<span></span>
</td>
<td class="num">(871)<span></span>
</td>
<td class="num">(836)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(981)<span></span>
</td>
<td class="num">(871)<span></span>
</td>
<td class="num">(836)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,058<span></span>
</td>
<td class="nump">959<span></span>
</td>
<td class="nump">890<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(464)<span></span>
</td>
<td class="num">(534)<span></span>
</td>
<td class="num">(505)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644<span></span>
</td>
<td class="nump">278<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(488)<span></span>
</td>
<td class="num">(608)<span></span>
</td>
<td class="num">(512)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="num">(752)<span></span>
</td>
<td class="num">(800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Income from associated companies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 670<span></span>
</td>
<td class="nump">$ 656<span></span>
</td>
<td class="nump">$ 6,432<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs relating to expenses directly or indirectly attributed to the goods or services sold, which may include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, unallocated production overheads and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByFunction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'function of expense' form for its analysis of expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35_b_vii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByFunction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2019-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2019-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations. [Refer: Continuing operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_vi&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from discontinued operations. [Refer: Discontinued operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_vii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph ea<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_ea&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 98<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_98_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2019-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2019-01-01<br> -Paragraph 39M<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2019-en-b&amp;anchor=para_39M_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsSalesToOtherSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904321717224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Interest income</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 245<span></span>
</td>
<td class="nump">$ 292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet', window );">Impairment charges and fair value gains on financial assets, net</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AdditionsToRestructuringProvisions', window );">Additions to restructuring provisions</a></td>
<td class="num">(354)<span></span>
</td>
<td class="num">(492)<span></span>
</td>
<td class="num">(521)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember', window );">Continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Equity-based compensation of Novartis equity plans</a></td>
<td class="num">(958)<span></span>
</td>
<td class="num">(1,067)<span></span>
</td>
<td class="num">(918)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember', window );">Property, plant and equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(1,318)<span></span>
</td>
<td class="num">(1,345)<span></span>
</td>
<td class="num">(1,482)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="num">(440)<span></span>
</td>
<td class="num">(202)<span></span>
</td>
<td class="num">(301)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember', window );">Right-of-use assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(330)<span></span>
</td>
<td class="num">(305)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsAndGoodwillMember', window );">Intangible assets and goodwill [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(3,462)<span></span>
</td>
<td class="num">(2,836)<span></span>
</td>
<td class="num">(2,587)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="num">(914)<span></span>
</td>
<td class="num">(1,138)<span></span>
</td>
<td class="num">(841)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet', window );">Impairment charges and fair value gains on financial assets, net</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AdditionsToRestructuringProvisions', window );">Additions to restructuring provisions</a></td>
<td class="num">(217)<span></span>
</td>
<td class="num">(229)<span></span>
</td>
<td class="num">(395)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Equity-based compensation of Novartis equity plans</a></td>
<td class="num">(714)<span></span>
</td>
<td class="num">(761)<span></span>
</td>
<td class="num">(645)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Property, plant and equipment [member] | Continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(912)<span></span>
</td>
<td class="num">(952)<span></span>
</td>
<td class="num">(1,075)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="num">(324)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="num">(239)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Right-of-use assets [member] | Continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(273)<span></span>
</td>
<td class="num">(247)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Intangible assets and goodwill [member] | Continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(3,080)<span></span>
</td>
<td class="num">(2,509)<span></span>
</td>
<td class="num">(2,214)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="num">(768)<span></span>
</td>
<td class="num">(632)<span></span>
</td>
<td class="num">(592)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Sandoz | Continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AdditionsToRestructuringProvisions', window );">Additions to restructuring provisions</a></td>
<td class="num">(98)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Equity-based compensation of Novartis equity plans</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Sandoz | Property, plant and equipment [member] | Continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(282)<span></span>
</td>
<td class="num">(283)<span></span>
</td>
<td class="num">(285)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="num">(116)<span></span>
</td>
<td class="num">(101)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Sandoz | Right-of-use assets [member] | Continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Sandoz | Intangible assets and goodwill [member] | Continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(370)<span></span>
</td>
<td class="num">(315)<span></span>
</td>
<td class="num">(366)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="num">(141)<span></span>
</td>
<td class="num">(506)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Corporate | Continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet', window );">Impairment charges and fair value gains on financial assets, net</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="num">(113)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AdditionsToRestructuringProvisions', window );">Additions to restructuring provisions</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Equity-based compensation of Novartis equity plans</a></td>
<td class="num">(180)<span></span>
</td>
<td class="num">(239)<span></span>
</td>
<td class="num">(220)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Corporate | Property, plant and equipment [member] | Continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(124)<span></span>
</td>
<td class="num">(110)<span></span>
</td>
<td class="num">(122)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Corporate | Right-of-use assets [member] | Continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Corporate | Intangible assets and goodwill [member] | Continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="num">$ (5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 104<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss or reversal of impairment loss recognised in profit or loss. [Refer: Impairment loss recognised in profit or loss; Reversal of impairment loss recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AdditionsToRestructuringProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AdditionsToRestructuringProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsAndGoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsAndGoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904318277352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">$ 132,059<span></span>
</td>
<td class="nump">$ 118,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="num">(75,393)<span></span>
</td>
<td class="num">(62,819)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">56,666<span></span>
</td>
<td class="nump">55,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net debt</a></td>
<td class="nump">24,481<span></span>
</td>
<td class="nump">15,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NetOperatingAssets', window );">Net operating assets</a></td>
<td class="nump">81,147<span></span>
</td>
<td class="nump">71,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">12,263<span></span>
</td>
<td class="nump">12,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions to property, plant and equipment</a></td>
<td class="nump">1,265<span></span>
</td>
<td class="nump">1,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">1,676<span></span>
</td>
<td class="nump">1,677<span></span>
</td>
<td class="nump">$ 1,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill</a></td>
<td class="nump">66,808<span></span>
</td>
<td class="nump">55,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions to intangible assets and goodwill</a></td>
<td class="nump">1,425<span></span>
</td>
<td class="nump">767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments in associated companies</a></td>
<td class="nump">9,632<span></span>
</td>
<td class="nump">8,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AdditionsToInvestmentInAssociatedCompanies', window );">Additions to investment in associated companies</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments</a></td>
<td class="nump">11,563<span></span>
</td>
<td class="nump">11,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments</a></td>
<td class="nump">36,044<span></span>
</td>
<td class="nump">27,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CurrentIncomeTaxAndDeferredTaxLiabilities', window );">Current income tax and deferred tax liabilities</a></td>
<td class="nump">9,880<span></span>
</td>
<td class="nump">8,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">83,112<span></span>
</td>
<td class="nump">71,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="num">(15,472)<span></span>
</td>
<td class="num">(15,332)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NetOperatingAssets', window );">Net operating assets</a></td>
<td class="nump">67,640<span></span>
</td>
<td class="nump">55,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">9,863<span></span>
</td>
<td class="nump">9,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions to property, plant and equipment</a></td>
<td class="nump">926<span></span>
</td>
<td class="nump">1,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">1,489<span></span>
</td>
<td class="nump">1,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill</a></td>
<td class="nump">56,839<span></span>
</td>
<td class="nump">46,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions to intangible assets and goodwill</a></td>
<td class="nump">1,235<span></span>
</td>
<td class="nump">647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments in associated companies</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AdditionsToInvestmentInAssociatedCompanies', window );">Additions to investment in associated companies</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">16,825<span></span>
</td>
<td class="nump">16,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="num">(3,786)<span></span>
</td>
<td class="num">(3,804)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NetOperatingAssets', window );">Net operating assets</a></td>
<td class="nump">13,039<span></span>
</td>
<td class="nump">12,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">1,849<span></span>
</td>
<td class="nump">1,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions to property, plant and equipment</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill</a></td>
<td class="nump">9,817<span></span>
</td>
<td class="nump">8,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions to intangible assets and goodwill</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments in associated companies</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">32,122<span></span>
</td>
<td class="nump">30,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="num">(56,135)<span></span>
</td>
<td class="num">(43,683)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net debt</a></td>
<td class="nump">24,481<span></span>
</td>
<td class="nump">15,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NetOperatingAssets', window );">Net operating assets</a></td>
<td class="nump">468<span></span>
</td>
<td class="nump">2,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">551<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions to property, plant and equipment</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions to intangible assets and goodwill</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments in associated companies</a></td>
<td class="nump">9,430<span></span>
</td>
<td class="nump">8,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AdditionsToInvestmentInAssociatedCompanies', window );">Additions to investment in associated companies</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments</a></td>
<td class="nump">11,563<span></span>
</td>
<td class="nump">11,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments</a></td>
<td class="nump">36,044<span></span>
</td>
<td class="nump">27,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CurrentIncomeTaxAndDeferredTaxLiabilities', window );">Current income tax and deferred tax liabilities</a></td>
<td class="nump">$ 9,880<span></span>
</td>
<td class="nump">$ 8,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2020-01-01: The amount of resources: (a) controlled by the entity as a result of past events; and (b) from which future economic benefits are expected to flow to the entity.
Effective 2020-01-01: The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2020-01-01: The amount of present obligations of the entity arising from past events, the settlement of which is expected to result in an outflow from the entity of resources embodying economic benefits.
Effective 2020-01-01: The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net debt of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AdditionsToInvestmentInAssociatedCompanies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AdditionsToInvestmentInAssociatedCompanies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CurrentIncomeTaxAndDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CurrentIncomeTaxAndDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialDebtsAndDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialDebtsAndDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904322780840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 4) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 48,659<span></span>
</td>
<td class="nump">$ 47,445<span></span>
</td>
<td class="nump">$ 44,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 90,379<span></span>
</td>
<td class="nump">$ 77,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember', window );">Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 848<span></span>
</td>
<td class="nump">$ 795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 34,904<span></span>
</td>
<td class="nump">$ 33,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 16,484<span></span>
</td>
<td class="nump">$ 16,280<span></span>
</td>
<td class="nump">$ 14,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 39,889<span></span>
</td>
<td class="nump">$ 28,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">44.00%<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 2,442<span></span>
</td>
<td class="nump">$ 2,442<span></span>
</td>
<td class="nump">$ 2,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 4,115<span></span>
</td>
<td class="nump">$ 3,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 4,518<span></span>
</td>
<td class="nump">$ 4,120<span></span>
</td>
<td class="nump">$ 3,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 2,607<span></span>
</td>
<td class="nump">$ 2,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 2,804<span></span>
</td>
<td class="nump">$ 2,656<span></span>
</td>
<td class="nump">$ 2,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 2,573<span></span>
</td>
<td class="nump">$ 2,214<span></span>
</td>
<td class="nump">$ 1,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 714<span></span>
</td>
<td class="nump">$ 684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 19,038<span></span>
</td>
<td class="nump">$ 18,885<span></span>
</td>
<td class="nump">$ 18,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 7,837<span></span>
</td>
<td class="nump">$ 8,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SelectedNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SelectedNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies. As percent of total selected non-current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904324195480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 5) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 48,659<span></span>
</td>
<td class="nump">$ 47,445<span></span>
</td>
<td class="nump">$ 44,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 90,379<span></span>
</td>
<td class="nump">$ 77,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 18,715<span></span>
</td>
<td class="nump">$ 17,933<span></span>
</td>
<td class="nump">$ 17,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">38.00%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 47,798<span></span>
</td>
<td class="nump">$ 46,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">53.00%<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_AmericasMember', window );">Americas [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 19,725<span></span>
</td>
<td class="nump">$ 19,713<span></span>
</td>
<td class="nump">$ 18,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 40,391<span></span>
</td>
<td class="nump">$ 29,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember', window );">Asia/Africa/Australasia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 10,219<span></span>
</td>
<td class="nump">$ 9,799<span></span>
</td>
<td class="nump">$ 9,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 2,190<span></span>
</td>
<td class="nump">$ 2,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SelectedNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SelectedNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies. As percent of total selected non-current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_AmericasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_AmericasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904322773544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 6)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CustomersWithNetSalesOverFivePercent', window );">Customers with net sales over five percent</a></td>
<td class="text">The Group&#8217;s largest, second-largest and third-largest customers account for approximately 17%, 11% and 6% of net sales, respectively (2019: 18%, 13% and 8%, respectively; 2018: 18%, 14% and 8%, respectively). All segments had sales to these customers in 2020, 2019 and 2018. The highest amounts of trade receivables outstanding were for these same three customers and amounted to approximately 14%, 12% and 6%, respectively, of the trade receivables at December 31, 2020 (2019: 14%, 12% and 7%, respectively).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=nvs_LargestCustomerMember', window );">Largest customer [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PercentageOfEntitysTradeReceivable', window );">Percentage of entitys trade receivable</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=nvs_SecondLargestCustomerMember', window );">Second largest customer [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PercentageOfEntitysTradeReceivable', window );">Percentage of entitys trade receivable</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=nvs_ThirdLargestCustomerMember', window );">Third largest customer [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PercentageOfEntitysTradeReceivable', window );">Percentage of entitys trade receivable</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMajorCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMajorCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfEntitysRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of the entity's revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfEntitysRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CustomersWithNetSalesOverFivePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CustomersWithNetSalesOverFivePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PercentageOfEntitysTradeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PercentageOfEntitysTradeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=nvs_LargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=nvs_LargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=nvs_SecondLargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=nvs_SecondLargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=nvs_ThirdLargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=nvs_ThirdLargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904323405288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures - Net sales by region (Details 7) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 48,659<span></span>
</td>
<td class="nump">$ 47,445<span></span>
</td>
<td class="nump">$ 44,751<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember', window );">Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 18,715<span></span>
</td>
<td class="nump">$ 17,933<span></span>
</td>
<td class="nump">17,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 16,484<span></span>
</td>
<td class="nump">$ 16,280<span></span>
</td>
<td class="nump">14,618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember', window );">Asia/Africa/Australasia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 10,219<span></span>
</td>
<td class="nump">$ 9,799<span></span>
</td>
<td class="nump">9,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember', window );">Asia/Africa/Australasia [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_CanadaAndLatinAmericaMember', window );">Canada and Latin America [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 3,241<span></span>
</td>
<td class="nump">$ 3,433<span></span>
</td>
<td class="nump">3,414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_CanadaAndLatinAmericaMember', window );">Canada and Latin America [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_EstablishedMarketsMember', window );">Established Markets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 36,732<span></span>
</td>
<td class="nump">$ 35,684<span></span>
</td>
<td class="nump">33,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_EstablishedMarketsMember', window );">Established Markets [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_EmergingGrowthMarketsMember', window );">Emerging Growth Markets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 11,927<span></span>
</td>
<td class="nump">$ 11,761<span></span>
</td>
<td class="nump">11,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_EmergingGrowthMarketsMember', window );">Emerging Growth Markets [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Europe [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 13,484<span></span>
</td>
<td class="nump">$ 12,818<span></span>
</td>
<td class="nump">12,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Europe [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 14,342<span></span>
</td>
<td class="nump">$ 13,789<span></span>
</td>
<td class="nump">11,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Asia/Africa/Australasia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 8,718<span></span>
</td>
<td class="nump">$ 8,458<span></span>
</td>
<td class="nump">8,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Asia/Africa/Australasia [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Canada and Latin America [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 2,469<span></span>
</td>
<td class="nump">$ 2,649<span></span>
</td>
<td class="nump">2,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Canada and Latin America [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(7.00%)<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Established Markets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 29,643<span></span>
</td>
<td class="nump">$ 28,573<span></span>
</td>
<td class="nump">26,258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Established Markets [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Emerging Growth Markets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 9,370<span></span>
</td>
<td class="nump">$ 9,141<span></span>
</td>
<td class="nump">8,634<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Emerging Growth Markets [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Europe [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 5,231<span></span>
</td>
<td class="nump">$ 5,115<span></span>
</td>
<td class="nump">4,963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Europe [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 2,142<span></span>
</td>
<td class="nump">$ 2,491<span></span>
</td>
<td class="nump">2,754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | US | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(14.00%)<span></span>
</td>
<td class="num">(10.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Asia/Africa/Australasia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,501<span></span>
</td>
<td class="nump">$ 1,341<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Asia/Africa/Australasia [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Canada and Latin America [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 772<span></span>
</td>
<td class="nump">$ 784<span></span>
</td>
<td class="nump">779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Canada and Latin America [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Established Markets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 7,089<span></span>
</td>
<td class="nump">$ 7,111<span></span>
</td>
<td class="nump">7,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Established Markets [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Emerging Growth Markets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 2,557<span></span>
</td>
<td class="nump">$ 2,620<span></span>
</td>
<td class="nump">2,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Emerging Growth Markets [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 39,013<span></span>
</td>
<td class="nump">$ 37,714<span></span>
</td>
<td class="nump">34,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 9,646<span></span>
</td>
<td class="nump">$ 9,731<span></span>
</td>
<td class="nump">$ 9,859<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_CanadaAndLatinAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_CanadaAndLatinAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_EstablishedMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_EstablishedMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_EmergingGrowthMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_EmergingGrowthMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904288727416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 8) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 48,659<span></span>
</td>
<td class="nump">$ 47,445<span></span>
</td>
<td class="nump">$ 44,751<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember', window );">Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 39,013<span></span>
</td>
<td class="nump">$ 37,714<span></span>
</td>
<td class="nump">34,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 14,711<span></span>
</td>
<td class="nump">$ 14,370<span></span>
</td>
<td class="nump">13,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Tasigna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,958<span></span>
</td>
<td class="nump">$ 1,880<span></span>
</td>
<td class="nump">1,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Promacta/Revolade [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,738<span></span>
</td>
<td class="nump">$ 1,416<span></span>
</td>
<td class="nump">1,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Tafinlar + Mekinist [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,542<span></span>
</td>
<td class="nump">$ 1,338<span></span>
</td>
<td class="nump">1,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Sandostatin [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,439<span></span>
</td>
<td class="nump">$ 1,585<span></span>
</td>
<td class="nump">1,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Jakavi [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,339<span></span>
</td>
<td class="nump">$ 1,114<span></span>
</td>
<td class="nump">977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Gleevec/Glivec [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,188<span></span>
</td>
<td class="nump">$ 1,263<span></span>
</td>
<td class="nump">1,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="num">(19.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Afinitor/Votubia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,083<span></span>
</td>
<td class="nump">$ 1,539<span></span>
</td>
<td class="nump">1,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(30.00%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Kisqali [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 687<span></span>
</td>
<td class="nump">$ 480<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">104.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Exjade/Jadenu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 653<span></span>
</td>
<td class="nump">$ 975<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(33.00%)<span></span>
</td>
<td class="num">(11.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Votrient [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 635<span></span>
</td>
<td class="nump">$ 755<span></span>
</td>
<td class="nump">828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(16.00%)<span></span>
</td>
<td class="num">(9.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Kymriah [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 474<span></span>
</td>
<td class="nump">$ 278<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">71.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Lutathera [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 445<span></span>
</td>
<td class="nump">$ 441<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">164.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Piqray [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 320<span></span>
</td>
<td class="nump">$ 116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">176.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Adakveo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Tabrecta [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Other [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,070<span></span>
</td>
<td class="nump">$ 1,189<span></span>
</td>
<td class="nump">1,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(10.00%)<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 24,302<span></span>
</td>
<td class="nump">$ 23,344<span></span>
</td>
<td class="nump">21,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 4,868<span></span>
</td>
<td class="nump">$ 4,222<span></span>
</td>
<td class="nump">3,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Cosentyx [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 3,995<span></span>
</td>
<td class="nump">$ 3,551<span></span>
</td>
<td class="nump">2,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Ilaris [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 873<span></span>
</td>
<td class="nump">$ 671<span></span>
</td>
<td class="nump">554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Other [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 4,410<span></span>
</td>
<td class="nump">$ 4,776<span></span>
</td>
<td class="nump">4,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(8.00%)<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Lucentis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,933<span></span>
</td>
<td class="nump">$ 2,086<span></span>
</td>
<td class="nump">2,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(7.00%)<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Xiidra [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 376<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Beovu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 190<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Other [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,911<span></span>
</td>
<td class="nump">$ 2,463<span></span>
</td>
<td class="nump">1,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(22.00%)<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 4,323<span></span>
</td>
<td class="nump">$ 3,773<span></span>
</td>
<td class="nump">3,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Gilenya [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 3,003<span></span>
</td>
<td class="nump">$ 3,223<span></span>
</td>
<td class="nump">3,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(7.00%)<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Zolgensma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 920<span></span>
</td>
<td class="nump">$ 361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">155.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Mayzent [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Aimovig [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 164<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">59.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Kesimpta [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Other [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(15.00%)<span></span>
</td>
<td class="num">(25.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 2,498<span></span>
</td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="nump">1,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Entresto [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 2,497<span></span>
</td>
<td class="nump">$ 1,726<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Other [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(96.00%)<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Respiratory [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">$ 1,825<span></span>
</td>
<td class="nump">1,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Xolair [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,251<span></span>
</td>
<td class="nump">$ 1,173<span></span>
</td>
<td class="nump">1,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Ultibro Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 623<span></span>
</td>
<td class="nump">$ 630<span></span>
</td>
<td class="nump">703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(10.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Other [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="num">(12.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 6,303<span></span>
</td>
<td class="nump">$ 6,998<span></span>
</td>
<td class="nump">7,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(10.00%)<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Galvus Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,199<span></span>
</td>
<td class="nump">$ 1,297<span></span>
</td>
<td class="nump">1,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(8.00%)<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Diovan Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,003<span></span>
</td>
<td class="nump">$ 1,064<span></span>
</td>
<td class="nump">1,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Exforge Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 980<span></span>
</td>
<td class="nump">$ 1,025<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Zortress/Certican [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 452<span></span>
</td>
<td class="nump">$ 485<span></span>
</td>
<td class="nump">464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(7.00%)<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Neoral/Sandimmun(e) [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 393<span></span>
</td>
<td class="nump">$ 419<span></span>
</td>
<td class="nump">463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="num">(10.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Voltaren/Cataflam [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 360<span></span>
</td>
<td class="nump">$ 417<span></span>
</td>
<td class="nump">445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(14.00%)<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Other [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,916<span></span>
</td>
<td class="nump">$ 2,291<span></span>
</td>
<td class="nump">$ 2,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(16.00%)<span></span>
</td>
<td class="num">(11.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BusinessUnitAxis=nvs_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BusinessUnitAxis=nvs_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_PromactaRevoladeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_PromactaRevoladeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_TafinlarMekinistMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_TafinlarMekinistMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_SandostatinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_SandostatinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_JakaviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_JakaviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_GleevecGlivecMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_GleevecGlivecMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_AfinitorVotubiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_AfinitorVotubiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_KisqaliMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_KisqaliMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ExjadeJadenuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ExjadeJadenuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_KymriahMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_KymriahMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_LutatheraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_LutatheraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_PiqrayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_PiqrayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_AdakveoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_AdakveoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_TabrectaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_TabrectaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BusinessUnitAxis=nvs_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BusinessUnitAxis=nvs_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_ImmunologyHepatologyAndDermatologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_ImmunologyHepatologyAndDermatologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_CosentyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_CosentyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_IlarisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_IlarisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_OphthalmologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_OphthalmologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_XiidraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_XiidraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_BeovuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_BeovuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_GilenyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_GilenyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_MayzentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_MayzentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_AimovigMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_AimovigMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_KesimptaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_KesimptaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_CardioMetabolicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_CardioMetabolicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_EntrestoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_EntrestoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_RespiratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_RespiratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_XolairMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_XolairMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_UltibroGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_UltibroGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_EstablishedMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_EstablishedMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_GalvusGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_GalvusGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_DiovanGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_DiovanGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ZortressCerticanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ZortressCerticanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_NeoralSandimmunEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_NeoralSandimmunEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_VoltarenCataflamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_VoltarenCataflamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904319455208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures - Top 20 (Details 9) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 48,659<span></span>
</td>
<td class="nump">$ 47,445<span></span>
</td>
<td class="nump">$ 44,751<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">16,484<span></span>
</td>
<td class="nump">16,280<span></span>
</td>
<td class="nump">14,618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Top 20 products [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">29,916<span></span>
</td>
<td class="nump">28,646<span></span>
</td>
<td class="nump">26,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of portfolio [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">9,097<span></span>
</td>
<td class="nump">9,068<span></span>
</td>
<td class="nump">7,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Top 20 products [member] | Tasigna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,958<span></span>
</td>
<td class="nump">1,880<span></span>
</td>
<td class="nump">1,587<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Top 20 products [member] | Sandostatin [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,439<span></span>
</td>
<td class="nump">1,726<span></span>
</td>
<td class="nump">1,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Top 20 products [member] | Afinitor/Votubia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,083<span></span>
</td>
<td class="nump">1,539<span></span>
</td>
<td class="nump">1,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,738<span></span>
</td>
<td class="nump">1,338<span></span>
</td>
<td class="nump">1,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,542<span></span>
</td>
<td class="nump">1,297<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Top 20 products [member] | Gleevec/Glivec [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,188<span></span>
</td>
<td class="nump">1,585<span></span>
</td>
<td class="nump">2,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Top 20 products [member] | Jakavi [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,339<span></span>
</td>
<td class="nump">975<span></span>
</td>
<td class="nump">977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Top 20 products [member] | Exjade/Jadenu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">653<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
<td class="nump">1,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Oncology [member] | Top 20 products [member] | Votrient [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">635<span></span>
</td>
<td class="nump">755<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Top 20 products [member] | Lucentis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Top 20 products [member] | Lucentis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,086<span></span>
</td>
<td class="nump">1,874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Top 20 products [member] | Travoprost Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="nump">828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">3,003<span></span>
</td>
<td class="nump">3,551<span></span>
</td>
<td class="nump">3,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Top 20 products [member] | Xolair [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,251<span></span>
</td>
<td class="nump">1,173<span></span>
</td>
<td class="nump">1,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Top 20 products [member] | Entresto [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">2,497<span></span>
</td>
<td class="nump">1,114<span></span>
</td>
<td class="nump">554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Galvus Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,199<span></span>
</td>
<td class="nump">1,416<span></span>
</td>
<td class="nump">1,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Diovan Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,003<span></span>
</td>
<td class="nump">1,064<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Exforge Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">980<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
<td class="nump">1,155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Zortress/Certican [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Kisqali [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Voltaren/Cataflam [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Cosentyx [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">3,995<span></span>
</td>
<td class="nump">3,223<span></span>
</td>
<td class="nump">2,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Ilaris [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">873<span></span>
</td>
<td class="nump">671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Neoral/Sandimmun(e) [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">14,342<span></span>
</td>
<td class="nump">13,789<span></span>
</td>
<td class="nump">11,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Top 20 products [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">11,126<span></span>
</td>
<td class="nump">10,679<span></span>
</td>
<td class="nump">9,654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Rest of portfolio [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">3,216<span></span>
</td>
<td class="nump">3,110<span></span>
</td>
<td class="nump">2,210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Tasigna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">859<span></span>
</td>
<td class="nump">804<span></span>
</td>
<td class="nump">817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Sandostatin [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">837<span></span>
</td>
<td class="nump">925<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Afinitor/Votubia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">644<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
<td class="nump">929<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">833<span></span>
</td>
<td class="nump">481<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Gleevec/Glivec [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">315<span></span>
</td>
<td class="nump">881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Jakavi [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Exjade/Jadenu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="nump">581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Votrient [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">332<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Ophthalmology [member] | Top 20 products [member] | Lucentis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">806<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Ophthalmology [member] | Top 20 products [member] | Travoprost Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="nump">404<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,562<span></span>
</td>
<td class="nump">2,220<span></span>
</td>
<td class="nump">1,765<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Top 20 products [member] | Entresto [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Galvus Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Diovan Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Exforge Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Zortress/Certican [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Kisqali [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Voltaren/Cataflam [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Cosentyx [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">2,516<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
<td class="nump">1,674<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Ilaris [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Neoral/Sandimmun(e) [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">24,671<span></span>
</td>
<td class="nump">23,925<span></span>
</td>
<td class="nump">23,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Top 20 products [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">18,790<span></span>
</td>
<td class="nump">17,967<span></span>
</td>
<td class="nump">17,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Rest of portfolio [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">5,881<span></span>
</td>
<td class="nump">5,958<span></span>
</td>
<td class="nump">5,736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Tasigna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,099<span></span>
</td>
<td class="nump">1,076<span></span>
</td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Sandostatin [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">602<span></span>
</td>
<td class="nump">801<span></span>
</td>
<td class="nump">1,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Afinitor/Votubia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">439<span></span>
</td>
<td class="nump">536<span></span>
</td>
<td class="nump">627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">905<span></span>
</td>
<td class="nump">857<span></span>
</td>
<td class="nump">939<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">973<span></span>
</td>
<td class="nump">1,297<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Gleevec/Glivec [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">873<span></span>
</td>
<td class="nump">704<span></span>
</td>
<td class="nump">2,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Jakavi [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,339<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="nump">977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Exjade/Jadenu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">515<span></span>
</td>
<td class="nump">929<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Votrient [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">376<span></span>
</td>
<td class="nump">423<span></span>
</td>
<td class="nump">983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Top 20 products [member] | Lucentis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Ophthalmology [member] | Top 20 products [member] | Lucentis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,086<span></span>
</td>
<td class="nump">1,068<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Ophthalmology [member] | Top 20 products [member] | Travoprost Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,441<span></span>
</td>
<td class="nump">1,331<span></span>
</td>
<td class="nump">1,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Respiratory [member] | Top 20 products [member] | Xolair [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,251<span></span>
</td>
<td class="nump">1,173<span></span>
</td>
<td class="nump">1,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Top 20 products [member] | Entresto [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,220<span></span>
</td>
<td class="nump">1,114<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Galvus Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,199<span></span>
</td>
<td class="nump">725<span></span>
</td>
<td class="nump">1,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Diovan Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">879<span></span>
</td>
<td class="nump">978<span></span>
</td>
<td class="nump">578<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Exforge Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">964<span></span>
</td>
<td class="nump">1,012<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Zortress/Certican [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Kisqali [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Voltaren/Cataflam [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Cosentyx [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,479<span></span>
</td>
<td class="nump">1,487<span></span>
</td>
<td class="nump">1,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Ilaris [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Neoral/Sandimmun(e) [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">39,013<span></span>
</td>
<td class="nump">37,714<span></span>
</td>
<td class="nump">34,892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">14,711<span></span>
</td>
<td class="nump">14,370<span></span>
</td>
<td class="nump">13,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Tasigna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,958<span></span>
</td>
<td class="nump">1,880<span></span>
</td>
<td class="nump">1,874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Sandostatin [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,439<span></span>
</td>
<td class="nump">1,585<span></span>
</td>
<td class="nump">1,587<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Afinitor/Votubia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,083<span></span>
</td>
<td class="nump">1,539<span></span>
</td>
<td class="nump">1,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Promacta/Revolade [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,738<span></span>
</td>
<td class="nump">1,416<span></span>
</td>
<td class="nump">1,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Tafinlar + Mekinist [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,542<span></span>
</td>
<td class="nump">1,338<span></span>
</td>
<td class="nump">1,155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Gleevec/Glivec [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,188<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
<td class="nump">1,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Jakavi [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,339<span></span>
</td>
<td class="nump">1,114<span></span>
</td>
<td class="nump">977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Exjade/Jadenu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">653<span></span>
</td>
<td class="nump">975<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Votrient [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">635<span></span>
</td>
<td class="nump">755<span></span>
</td>
<td class="nump">828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Kisqali [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">687<span></span>
</td>
<td class="nump">480<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Oncology [member] | Adakveo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">24,302<span></span>
</td>
<td class="nump">23,344<span></span>
</td>
<td class="nump">21,464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">4,410<span></span>
</td>
<td class="nump">4,776<span></span>
</td>
<td class="nump">4,558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Lucentis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,933<span></span>
</td>
<td class="nump">2,086<span></span>
</td>
<td class="nump">2,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">4,323<span></span>
</td>
<td class="nump">3,773<span></span>
</td>
<td class="nump">3,429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Gilenya [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">3,003<span></span>
</td>
<td class="nump">3,223<span></span>
</td>
<td class="nump">3,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Zolgensma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">920<span></span>
</td>
<td class="nump">361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Kesimpta [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Respiratory [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">1,825<span></span>
</td>
<td class="nump">1,767<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Xolair [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,251<span></span>
</td>
<td class="nump">1,173<span></span>
</td>
<td class="nump">1,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">2,498<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="nump">1,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Entresto [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">2,497<span></span>
</td>
<td class="nump">1,726<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">6,303<span></span>
</td>
<td class="nump">6,998<span></span>
</td>
<td class="nump">7,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Galvus Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,199<span></span>
</td>
<td class="nump">1,297<span></span>
</td>
<td class="nump">1,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Diovan Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">1,003<span></span>
</td>
<td class="nump">1,064<span></span>
</td>
<td class="nump">1,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Exforge Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">980<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Zortress/Certican [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="nump">464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Neoral/Sandimmun(e) [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">393<span></span>
</td>
<td class="nump">419<span></span>
</td>
<td class="nump">463<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Voltaren/Cataflam [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">417<span></span>
</td>
<td class="nump">445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">4,868<span></span>
</td>
<td class="nump">4,222<span></span>
</td>
<td class="nump">3,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Cosentyx [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">3,995<span></span>
</td>
<td class="nump">3,551<span></span>
</td>
<td class="nump">2,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Ilaris [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 873<span></span>
</td>
<td class="nump">$ 671<span></span>
</td>
<td class="nump">$ 554<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductPortfolioAxis=nvs_Top20ProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductPortfolioAxis=nvs_Top20ProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductPortfolioAxis=nvs_RestOfPortfolioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductPortfolioAxis=nvs_RestOfPortfolioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BusinessUnitAxis=nvs_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BusinessUnitAxis=nvs_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_SandostatinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_SandostatinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_AfinitorVotubiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_AfinitorVotubiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_PromactaRevoladeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_PromactaRevoladeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_TafinlarMekinistMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_TafinlarMekinistMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_GleevecGlivecMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_GleevecGlivecMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_JakaviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_JakaviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ExjadeJadenuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ExjadeJadenuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BusinessUnitAxis=nvs_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BusinessUnitAxis=nvs_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_OphthalmologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_OphthalmologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_TravoprostGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_TravoprostGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_GilenyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_GilenyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_RespiratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_RespiratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_XolairMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_XolairMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_CardioMetabolicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_CardioMetabolicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_EntrestoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_EntrestoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_EstablishedMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_EstablishedMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_GalvusGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_GalvusGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_DiovanGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_DiovanGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ZortressCerticanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ZortressCerticanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_KisqaliMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_KisqaliMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_VoltarenCataflamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_VoltarenCataflamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_ImmunologyHepatologyAndDermatologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_ImmunologyHepatologyAndDermatologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_CosentyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_CosentyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_IlarisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_IlarisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_NeoralSandimmunEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_NeoralSandimmunEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_RestOfTheWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_RestOfTheWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_AdakveoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_AdakveoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_KesimptaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_KesimptaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904316380248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 10) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 48,659<span></span>
</td>
<td class="nump">$ 47,445<span></span>
</td>
<td class="nump">$ 44,751<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember', window );">Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz [member] | Retail Generics [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 7,244<span></span>
</td>
<td class="nump">$ 7,590<span></span>
</td>
<td class="nump">7,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(5.00%)<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz [member] | Biopharmaceuticals [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 1,928<span></span>
</td>
<td class="nump">$ 1,607<span></span>
</td>
<td class="nump">1,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz [member] | Anti Infectives [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 474<span></span>
</td>
<td class="nump">$ 534<span></span>
</td>
<td class="nump">543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(11.00%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz [member] | Anti Infectives [member] | Anti Infectives sold under Sandoz name [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 694<span></span>
</td>
<td class="nump">$ 784<span></span>
</td>
<td class="nump">826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Sandoz [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties from continuing operations</a></td>
<td class="nump">$ 9,646<span></span>
</td>
<td class="nump">$ 9,731<span></span>
</td>
<td class="nump">$ 9,859<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_RetailGenericsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_RetailGenericsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_BiopharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_BiopharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_AntiInfectivesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_AntiInfectivesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductPortfolioAxis=nvs_AntiInfectivesSoldUnderSandozNameMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductPortfolioAxis=nvs_AntiInfectivesSoldUnderSandozNameMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904323826648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 11) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ProfitSharingIncome', window );">Profit sharing income</a></td>
<td class="nump">$ 835<span></span>
</td>
<td class="nump">$ 734<span></span>
</td>
<td class="nump">$ 877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromRoyalties', window );">Royalty income</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MilestoneIncome', window );">Milestone income</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherRevenueOther', window );">Other</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">1,239<span></span>
</td>
<td class="nump">1,179<span></span>
</td>
<td class="nump">1,266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ProfitSharingIncome', window );">Profit sharing income</a></td>
<td class="nump">835<span></span>
</td>
<td class="nump">732<span></span>
</td>
<td class="nump">874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromRoyalties', window );">Royalty income</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MilestoneIncome', window );">Milestone income</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherRevenueOther', window );">Other</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ProfitSharingIncome', window );">Profit sharing income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromRoyalties', window );">Royalty income</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MilestoneIncome', window );">Milestone income</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherRevenueOther', window );">Other</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_CorporateMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromRoyalties', window );">Royalty income</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">1,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">$ 168<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MilestoneIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MilestoneIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherRevenueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherRevenueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProfitSharingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProfitSharingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904317738136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Associated companies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Net income statement effect</a></td>
<td class="nump">$ 673<span></span>
</td>
<td class="nump">$ 659<span></span>
</td>
<td class="nump">$ 6,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income effect</a></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="num">(482)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Total comprehensive income effect</a></td>
<td class="nump">617<span></span>
</td>
<td class="nump">565<span></span>
</td>
<td class="nump">5,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies', window );">Recycling of the Novartis share of other comprehensive income from associated companies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(511)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember', window );">Roche Holding AG, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Net income statement effect</a></td>
<td class="nump">677<span></span>
</td>
<td class="nump">662<span></span>
</td>
<td class="nump">526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income effect</a></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Total comprehensive income effect</a></td>
<td class="nump">621<span></span>
</td>
<td class="nump">568<span></span>
</td>
<td class="nump">601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember', window );">GlaxoSmithKline Consumer Healthcare Holdings Ltd., UK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Net income statement effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(557)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Total comprehensive income effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_OthersAssociatesMember', window );">Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Net income statement effect</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Total comprehensive income effect</a></td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of the other comprehensive income of associates and joint ventures accounted for using the equity method that will be reclassified to profit or loss, net of tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82A<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2019-01-01<br> -Paragraph 39M<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2019-en-b&amp;anchor=para_39M_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the total comprehensive income of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Joint ventures [member]; Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B16<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B16_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_OthersAssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_OthersAssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904347100856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Associated companies (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Balance sheet value</a></td>
<td class="nump">$ 9,632<span></span>
</td>
<td class="nump">$ 8,644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember', window );">Roche Holding AG, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Balance sheet value</a></td>
<td class="nump">9,407<span></span>
</td>
<td class="nump">8,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_OthersAssociatesMember', window );">Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Balance sheet value</a></td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_OthersAssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_OthersAssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904405796760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Associated companies (Details 3) - Roche Holding AG, Switzerland - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInAssociate', window );">Proportion of voting rights held in associate</a></td>
<td class="nump">33.30%<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Proportion of ownership interest in associate</a></td>
<td class="nump">6.20%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DividendsReceived', window );">Dividends received</a></td>
<td class="nump">$ 487<span></span>
</td>
<td class="nump">$ 460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished', window );">Publicly quoted market value of the Novartis interest</a></td>
<td class="nump">$ 18,800<span></span>
</td>
<td class="nump">$ 16,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life measured as period of time, intangible assets other than goodwill</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of investments in associates if there are quoted market prices for the investment. [Refer: Associates [member]; Investments in associates]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 21<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_21_b_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfVotingPowerHeldInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proportion of the voting rights in an associate held by the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfVotingPowerHeldInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 118<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_118_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904321596440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Associated companies (Details 4) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,673<span></span>
</td>
<td class="nump">$ 29,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,386<span></span>
</td>
<td class="nump">88,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,059<span></span>
</td>
<td class="nump">28,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,334<span></span>
</td>
<td class="nump">34,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,071<span></span>
</td>
<td class="nump">11,737<span></span>
</td>
<td class="nump">$ 12,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,330<span></span>
</td>
<td class="num">(210)<span></span>
</td>
<td class="num">(406)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,401<span></span>
</td>
<td class="nump">11,527<span></span>
</td>
<td class="nump">$ 12,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember', window );">Roche Holding AG, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Current assets</a></td>
<td class="nump">$ 27,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">55,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="nump">22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Non-current liabilities</a></td>
<td class="nump">23,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">30,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit (loss)</a></td>
<td class="nump">7,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="num">(700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income</a></td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2019-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2019-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2020-01-01: The income arising in the course of an entity's ordinary activities. Income is increases in economic benefits during the accounting period in the form of inflows or enhancements of assets or decreases of liabilities that result in an increase in equity, other than those relating to contributions from equity participants.
Effective 2020-01-01: The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904406027208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Associated companies (Details 5) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Balance sheet value</a></td>
<td class="nump">$ 9,632<span></span>
</td>
<td class="nump">$ 8,644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember', window );">Roche Holding AG, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ShareOfEstimatedNetAssets', window );">Novartis share of estimated net assets</a></td>
<td class="nump">2,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill', window );">Novartis share of re-appraised intangible assets</a></td>
<td class="nump">117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Implicit Novartis goodwill</a></td>
<td class="nump">3,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill', window );">Current value of share in net identifiable assets and goodwill</a></td>
<td class="nump">5,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived', window );">Accumulated equity accounting adjustments and translation effects less dividends received</a></td>
<td class="nump">3,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Balance sheet value</a></td>
<td class="nump">$ 9,407<span></span>
</td>
<td class="nump">$ 8,445<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalRecognitionGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional goodwill recognised, except goodwill included in a disposal group that, on acquisition, meets the criteria to be classified as held for sale in accordance with IFRS 5. [Refer: Goodwill; Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2019-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B67_d_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalRecognitionGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill resulting from revaluations to fair value. [Refer: Intangible assets other than goodwill; Revaluation surplus]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_118_e_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ShareOfEstimatedNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ShareOfEstimatedNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904336152024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Associated companies (Details 6) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Net income statement effect</a></td>
<td class="nump">$ 673<span></span>
</td>
<td class="nump">$ 659<span></span>
</td>
<td class="nump">$ 6,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember', window );">Roche Holding AG, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ShareOfCurrentYearNetIncome', window );">Novartis share of current year consolidated net income</a></td>
<td class="nump">913<span></span>
</td>
<td class="nump">910<span></span>
</td>
<td class="nump">799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PriorYearAdjustment', window );">Prior year adjustment</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(129)<span></span>
</td>
<td class="num">(125)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets', window );">Amortization of fair value adjustments relating to intangible assets</a></td>
<td class="num">(172)<span></span>
</td>
<td class="num">(162)<span></span>
</td>
<td class="num">(148)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PartialReleaseOfDeferredTaxLiabilityRecognized', window );">Partial release of deferred tax liability recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Net income statement effect</a></td>
<td class="nump">677<span></span>
</td>
<td class="nump">662<span></span>
</td>
<td class="nump">526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax', window );">Amortization of fair value adjustments relating to intangible assets tax</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember', window );">GlaxoSmithKline Consumer Healthcare Holdings Ltd., UK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ShareOfCurrentYearNetIncome', window );">Novartis share of current year consolidated net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_PriorYearAdjustment', window );">Prior year adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets', window );">Amortization of fair value adjustments relating to intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_GainOnDivestmentOfInterestsInAssociatedCompanies', window );">Gain on divestment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Net income statement effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax', window );">Amortization of fair value adjustments relating to intangible assets tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2019-01-01<br> -Paragraph 39M<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2019-en-b&amp;anchor=para_39M_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GainOnDivestmentOfInterestsInAssociatedCompanies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GainOnDivestmentOfInterestsInAssociatedCompanies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PartialReleaseOfDeferredTaxLiabilityRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PartialReleaseOfDeferredTaxLiabilityRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PriorYearAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PriorYearAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ShareOfCurrentYearNetIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ShareOfCurrentYearNetIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904318318360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest expense and other financial income and expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_InterestExpenseAbstract', window );"><strong>Interest expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions', window );">Interest expense</a></td>
<td class="num">$ (708)<span></span>
</td>
<td class="num">$ (714)<span></span>
</td>
<td class="num">$ (877)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease liabilities</a></td>
<td class="num">(67)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions', window );">Income/expense arising from discounting long-term liabilities</a></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Total interest expense from continuing operations</a></td>
<td class="num">$ (869)<span></span>
</td>
<td class="num">$ (850)<span></span>
</td>
<td class="num">$ (932)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised due to the unwinding of the discount on provisions, resulting from the effect of the passage of time. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InterestExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InterestExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904318237560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest expense and other financial income and expense (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherFinancialIncomeAndExpenseAbstract', window );"><strong>Other financial income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Interest income</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 245<span></span>
</td>
<td class="nump">$ 292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromDividends', window );">Dividend income</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherFinanceCost', window );">Other financial expense</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Currency result, net</a></td>
<td class="num">(135)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Total other financial income and expense from continuing operations</a></td>
<td class="num">$ (78)<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2019-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends recognised as income. Dividends are distributions of profits to holders of equity investments in proportion to their holdings of a particular class of capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherFinancialIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherFinancialIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904325226632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Income before taxes</a></td>
<td class="nump">$ 9,878<span></span>
</td>
<td class="nump">$ 8,940<span></span>
</td>
<td class="nump">$ 14,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember', window );">Continuing operations [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Income before taxes</a></td>
<td class="nump">9,878<span></span>
</td>
<td class="nump">8,940<span></span>
</td>
<td class="nump">14,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember', window );">Continuing operations [member] | Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Income before taxes</a></td>
<td class="nump">9,786<span></span>
</td>
<td class="nump">8,097<span></span>
</td>
<td class="nump">11,887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember', window );">Continuing operations [member] | Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Income before taxes</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">843<span></span>
</td>
<td class="nump">2,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Income before taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="num">$ (260)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904324301576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="num">$ (1,807)<span></span>
</td>
<td class="num">$ (1,793)<span></span>
</td>
<td class="num">$ (1,295)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember', window );">Continuing operations [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current tax expense (income)</a></td>
<td class="num">(2,100)<span></span>
</td>
<td class="num">(2,147)<span></span>
</td>
<td class="num">(1,603)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred tax expense (income)</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">354<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="num">(1,807)<span></span>
</td>
<td class="num">(1,793)<span></span>
</td>
<td class="num">(1,295)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember', window );">Continuing operations [member] | Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current tax expense (income)</a></td>
<td class="num">(932)<span></span>
</td>
<td class="num">(1,186)<span></span>
</td>
<td class="num">(615)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred tax expense (income)</a></td>
<td class="num">(137)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember', window );">Continuing operations [member] | Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current tax expense (income)</a></td>
<td class="num">(1,168)<span></span>
</td>
<td class="num">(961)<span></span>
</td>
<td class="num">(988)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred tax expense (income)</a></td>
<td class="nump">$ 430<span></span>
</td>
<td class="nump">447<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (159)<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>181
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904322619768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Details 3) - Continuing operations [member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Applicable tax rate</a></td>
<td class="nump">13.60%<span></span>
</td>
<td class="nump">11.70%<span></span>
</td>
<td class="nump">14.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss', window );">Effect of disallowed expenditures</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfTaxLosses', window );">Effect of utilization of tax losses brought forward from prior periods</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TaxRateEffectOfIncomeTaxedAtReducedRates', window );">Effect of income taxed at reduced rates</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfRevenuesExemptFromTaxation', window );">Tax rate effect of revenues exempt from taxation</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(3.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TaxRateEffectOfCreditsAndAllowances', window );">Effect of tax credits and allowances</a></td>
<td class="num">(2.30%)<span></span>
</td>
<td class="num">(2.30%)<span></span>
</td>
<td class="num">(2.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability', window );">Effect of release of contingent consideration liability</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxRateEffectFromChangeInTaxRate', window );">Effect of tax rate change on current and deferred tax assets and liabilities</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_EffectOfWriteoffOfDeferredTaxAssets', window );">Effect of write-off of deferred tax assets</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries', window );">Effect of write down and reversal of write down of investments in subsidiaries</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods', window );">Effect of prior year items</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome', window );">Effect of other items</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AverageEffectiveTaxRate', window );">Effective tax rate</a></td>
<td class="nump">18.30%<span></span>
</td>
<td class="nump">20.10%<span></span>
</td>
<td class="nump">9.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Effective income tax rate reconciliation other adjustments</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Effective income tax rate reconciliation change in enacted tax rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain', window );">Effect of income not subject to tax on divestment gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense', window );">Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax rate effects, in aggregate, on the reconciliation between the average effective tax rate and the applicable tax rate that the entity does not separately disclose in the reconciliation. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce current tax expense. [Refer: Temporary differences [member]; Unused tax losses [member]; Unused tax credits [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 80<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_80_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectFromChangeInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from a change in tax rate. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectFromChangeInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from adjustments for the current tax of prior periods. [Refer: Average effective tax rate; Applicable tax rate; Adjustments for current tax of prior periods]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the expenses not deductible in determining taxable profit. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfRevenuesExemptFromTaxation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from revenue that is exempt from taxation. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfRevenuesExemptFromTaxation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfTaxLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from tax losses. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfTaxLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EffectOfWriteoffOfDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EffectOfWriteoffOfDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TaxRateEffectOfCreditsAndAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TaxRateEffectOfCreditsAndAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TaxRateEffectOfIncomeTaxedAtReducedRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TaxRateEffectOfIncomeTaxedAtReducedRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904323826008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Details)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareLineItems', window );"><strong>Earnings per share [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Profit/loss attributable to shareholders of Novartis AG | $</a></td>
<td class="nump">$ 8,072<span></span>
</td>
<td class="nump">$ 11,732<span></span>
</td>
<td class="nump">$ 12,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of shares outstanding used in the basic earnings per share | shares</a></td>
<td class="nump">2,277<span></span>
</td>
<td class="nump">2,291<span></span>
</td>
<td class="nump">2,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares', window );">Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options | shares</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of shares in diluted earnings per share | shares</a></td>
<td class="nump">2,296<span></span>
</td>
<td class="nump">2,319<span></span>
</td>
<td class="nump">2,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations', window );">Basic earnings per share, Continuing operations</a></td>
<td class="nump">$ 3.55<span></span>
</td>
<td class="nump">$ 3.12<span></span>
</td>
<td class="nump">$ 5.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations', window );">Basic earnings per share, Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Total basic earnings per share</a></td>
<td class="nump">3.55<span></span>
</td>
<td class="nump">5.12<span></span>
</td>
<td class="nump">5.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations', window );">Diluted earnings per share, Continuing operations</a></td>
<td class="nump">3.52<span></span>
</td>
<td class="nump">3.08<span></span>
</td>
<td class="nump">5.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations', window );">Diluted earnings per share, Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.98<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Total diluted earnings per share</a></td>
<td class="nump">$ 3.52<span></span>
</td>
<td class="nump">$ 5.06<span></span>
</td>
<td class="nump">$ 5.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OptionsExcludedFromTheCalculation', window );">Options excluded from the calculation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember', window );">Continuing operations [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareLineItems', window );"><strong>Earnings per share [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Profit/loss attributable to shareholders of Novartis AG | $</a></td>
<td class="nump">$ 8,072<span></span>
</td>
<td class="nump">$ 7,142<span></span>
</td>
<td class="nump">$ 12,797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareLineItems', window );"><strong>Earnings per share [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Profit/loss attributable to shareholders of Novartis AG | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,590<span></span>
</td>
<td class="num">$ (186)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basic earnings (loss) per share from continuing operations. [Refer: Basic earnings (loss) per share; Continuing operations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShareFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basic earnings (loss) per share from discontinued operations. [Refer: Basic earnings (loss) per share; Discontinued operations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Diluted earnings (loss) per share from continuing operations. [Refer: Continuing operations [member]; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Diluted earnings (loss) per share from discontinued operations. [Refer: Diluted earnings (loss) per share; Discontinued operations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of dilutive potential ordinary shares that relate to the assumed exercise of the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OptionsExcludedFromTheCalculation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OptionsExcludedFromTheCalculation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904322660760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Changes in consolidated statements of comprehensive income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments', window );">Fair value adjustments on financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities', window );">Fair value adjustments on debt securities, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges', window );">Fair value adjustments on deferred cash flow hedges, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations', window );">Net investment hedge</a></td>
<td class="num">$ (201)<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Net actuarial gains/losses from defined benefit plans, net of taxes</a></td>
<td class="nump">143<span></span>
</td>
<td class="num">(467)<span></span>
</td>
<td class="num">(359)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation effects</a></td>
<td class="nump">3,194<span></span>
</td>
<td class="nump">352<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Income tax relating to components of other comprehensive income</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(289)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnFinancialInstrumentsMember', window );">Fair value adjustments on financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome', window );">Total value adjustments</a></td>
<td class="nump">250<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRelatedToDivestments', window );">Fair value adjustments related to divestments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at end of period</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnFinancialInstrumentsMember', window );">Fair value adjustments on financial instruments [member] | Previously stated [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnFinancialInstrumentsMember', window );">Fair value adjustments on financial instruments [member] | Increase (decrease) due to changes in accounting policy, IFRS 9 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(177)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnDebtSecuritiesMember', window );">Fair value adjustments on debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities', window );">Fair value adjustments on debt securities, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnDeferredCashFlowHedgesMember', window );">Fair value adjustments on deferred cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges', window );">Fair value adjustments on deferred cash flow hedges, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Income tax relating to components of other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnEquitySecuritiesMember', window );">Fair value adjustments on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes', window );">Fair value adjustments on equity securities, net of taxes</a></td>
<td class="nump">250<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold', window );">Fair value adjustments on equity securities sold, reclassified to retained earnings</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Income tax relating to components of other comprehensive income</a></td>
<td class="num">(36)<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_ActuarialLossesFromDefinedBenefitPlansMember', window );">Actuarial gains/losses from defined benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="num">(5,919)<span></span>
</td>
<td class="num">(5,423)<span></span>
</td>
<td class="num">(5,064)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Net actuarial gains/losses from defined benefit plans, net of taxes</a></td>
<td class="nump">145<span></span>
</td>
<td class="num">(466)<span></span>
</td>
<td class="num">(359)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome', window );">Total value adjustments</a></td>
<td class="nump">145<span></span>
</td>
<td class="num">(466)<span></span>
</td>
<td class="num">(359)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRelatedToDivestments', window );">Fair value adjustments related to divestments</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl', window );">Impact of change in ownership of consolidated entities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at end of period</a></td>
<td class="num">(5,773)<span></span>
</td>
<td class="num">(5,919)<span></span>
</td>
<td class="num">(5,423)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Income tax relating to components of other comprehensive income</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(313)<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI', window );">Impact of new tax law income tax relating to deferred tax assets on Swiss post retirement previously recognized through OCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(358)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_ActuarialLossesFromDefinedBenefitPlansMember', window );">Actuarial gains/losses from defined benefit plans | Previously stated [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,064)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_CumulativeCurrencyTranslationEffectsMember', window );">Cumulative currency translation effects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="nump">1,142<span></span>
</td>
<td class="nump">744<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations', window );">Net investment hedge</a></td>
<td class="num">(201)<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation effects</a></td>
<td class="nump">3,193<span></span>
</td>
<td class="nump">354<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome', window );">Total value adjustments</a></td>
<td class="nump">2,992<span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at end of period</a></td>
<td class="nump">4,134<span></span>
</td>
<td class="nump">1,142<span></span>
</td>
<td class="nump">744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement', window );">Cumulative currency translation gains/losses recycled through income statement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="num">(946)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_CumulativeCurrencyTranslationEffectsMember', window );">Cumulative currency translation effects | Previously stated [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember', window );">Total value adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="num">(4,657)<span></span>
</td>
<td class="num">(4,452)<span></span>
</td>
<td class="num">(4,517)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities', window );">Fair value adjustments on debt securities, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges', window );">Fair value adjustments on deferred cash flow hedges, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes', window );">Fair value adjustments on equity securities, net of taxes</a></td>
<td class="nump">250<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations', window );">Net investment hedge</a></td>
<td class="num">(201)<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Net actuarial gains/losses from defined benefit plans, net of taxes</a></td>
<td class="nump">145<span></span>
</td>
<td class="num">(466)<span></span>
</td>
<td class="num">(359)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation effects</a></td>
<td class="nump">3,193<span></span>
</td>
<td class="nump">354<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome', window );">Total value adjustments</a></td>
<td class="nump">3,387<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold', window );">Fair value adjustments on equity securities sold, reclassified to retained earnings</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRelatedToDivestments', window );">Fair value adjustments related to divestments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl', window );">Impact of change in ownership of consolidated entities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at end of period</a></td>
<td class="num">(1,419)<span></span>
</td>
<td class="num">(4,657)<span></span>
</td>
<td class="num">(4,452)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember', window );">Total value adjustments | Previously stated [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,340)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember', window );">Total value adjustments | Increase (decrease) due to changes in accounting policy, IFRS 9 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(177)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_NoncontrollingInterestsMember', window );">Non-controlling interests [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Net actuarial gains/losses from defined benefit plans, net of taxes</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation effects</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome', window );">Total value adjustments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl', window );">Impact of change in ownership of consolidated entities</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at end of period</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_NoncontrollingInterestsMember', window );">Non-controlling interests [member] | Previously stated [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_TotalFairValueAdjustmentsMember', window );">Total fair value adjustments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="num">(4,686)<span></span>
</td>
<td class="num">(4,478)<span></span>
</td>
<td class="num">(4,538)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities', window );">Fair value adjustments on debt securities, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges', window );">Fair value adjustments on deferred cash flow hedges, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes', window );">Fair value adjustments on equity securities, net of taxes</a></td>
<td class="nump">250<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations', window );">Net investment hedge</a></td>
<td class="num">(201)<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Net actuarial gains/losses from defined benefit plans, net of taxes</a></td>
<td class="nump">143<span></span>
</td>
<td class="num">(467)<span></span>
</td>
<td class="num">(359)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation effects</a></td>
<td class="nump">3,194<span></span>
</td>
<td class="nump">352<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome', window );">Total value adjustments</a></td>
<td class="nump">3,386<span></span>
</td>
<td class="num">(116)<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold', window );">Fair value adjustments on equity securities sold, reclassified to retained earnings</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRelatedToDivestments', window );">Fair value adjustments related to divestments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at end of period</a></td>
<td class="num">$ (1,448)<span></span>
</td>
<td class="num">$ (4,686)<span></span>
</td>
<td class="num">(4,478)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_TotalFairValueAdjustmentsMember', window );">Total fair value adjustments [member] | Previously stated [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,361)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_TotalFairValueAdjustmentsMember', window );">Total fair value adjustments [member] | Increase (decrease) due to changes in accounting policy, IFRS 9 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (177)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph ab<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_ab&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 90<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_90&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to cash flow hedges. [Refer: Cash flow hedges [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to hedges of net investments in foreign operations. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 39<br> -IssueDate 2019-01-01<br> -Paragraph 102<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=39&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_102_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 9<br> -IssueDate 2019-01-01<br> -Paragraph 6.5.13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=9&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_6.5.13_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueAdjustmentsOnFinancialAssetsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueAdjustmentsRelatedToDivestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueAdjustmentsRelatedToDivestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ValueAdjustmentOnComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ValueAdjustmentOnComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnDeferredCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnDeferredCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_ActuarialLossesFromDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_ActuarialLossesFromDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_CumulativeCurrencyTranslationEffectsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_CumulativeCurrencyTranslationEffectsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_NoncontrollingInterestsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_NoncontrollingInterestsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_TotalFairValueAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_TotalFairValueAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>184
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904317222968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">$ 12,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">1,265<span></span>
</td>
<td class="nump">$ 1,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">12,263<span></span>
</td>
<td class="nump">12,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment', window );">Commitments for purchases of property, plant and equipment</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingCostsCapitalised', window );">Capitalized borrowing costs</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">26,999<span></span>
</td>
<td class="nump">34,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment', window );">Costs of assets related to discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,009)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment', window );">Decrease through reclassification to right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(127)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment', window );">Cost of assets reclassified out of assets of disposal group held for sale</a></td>
<td class="nump">332<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Impact of business combinations</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">1,265<span></span>
</td>
<td class="nump">1,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and derecognitions</a></td>
<td class="num">(2,201)<span></span>
</td>
<td class="num">(3,409)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation effects</a></td>
<td class="nump">1,797<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">28,218<span></span>
</td>
<td class="nump">26,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(14,930)<span></span>
</td>
<td class="num">(18,332)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment', window );">Costs of assets related to discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment', window );">Decrease through reclassification to right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment', window );">Accumulated depreciation on assets reclassified out of assets of disposal group held for sale</a></td>
<td class="num">(163)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment', window );">Accumulated depreciation on disposals and derecognitions</a></td>
<td class="nump">2,004<span></span>
</td>
<td class="nump">2,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge</a></td>
<td class="num">(1,318)<span></span>
</td>
<td class="num">(1,345)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment charge</a></td>
<td class="num">(447)<span></span>
</td>
<td class="num">(205)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Reversal of impairment charge</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation effects</a></td>
<td class="num">(1,108)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(15,955)<span></span>
</td>
<td class="num">(14,930)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DepreciationChargePriorToClassificationToAssetsHeldForSale', window );">Depreciation charge prior to classification to assets held for sale</a></td>
<td class="num">(38)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ImpairmentChargePriorToClassificationToAssetsHeldForSale', window );">Impairment charge prior to classification to assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">536<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember', window );">Land | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">512<span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment', window );">Costs of assets related to discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment', window );">Decrease through reclassification to right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment', window );">Cost of assets reclassified out of assets of disposal group held for sale</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Impact of business combinations</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and derecognitions</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation effects</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">555<span></span>
</td>
<td class="nump">512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember', window );">Land | Accumulated depreciation, amortisation and impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment', window );">Costs of assets related to discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment', window );">Decrease through reclassification to right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment', window );">Accumulated depreciation on assets reclassified out of assets of disposal group held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment', window );">Accumulated depreciation on disposals and derecognitions</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment charge</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation effects</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">6,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">6,570<span></span>
</td>
<td class="nump">6,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember', window );">Buildings | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">11,463<span></span>
</td>
<td class="nump">14,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment', window );">Costs of assets related to discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,615)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment', window );">Decrease through reclassification to right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment', window );">Cost of assets reclassified out of assets of disposal group held for sale</a></td>
<td class="nump">117<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Impact of business combinations</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="nump">433<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and derecognitions</a></td>
<td class="num">(465)<span></span>
</td>
<td class="num">(1,551)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation effects</a></td>
<td class="nump">695<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">12,377<span></span>
</td>
<td class="nump">11,463<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember', window );">Buildings | Accumulated depreciation, amortisation and impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(5,124)<span></span>
</td>
<td class="num">(6,328)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment', window );">Costs of assets related to discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment', window );">Accumulated depreciation on assets reclassified out of assets of disposal group held for sale</a></td>
<td class="num">(58)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment', window );">Accumulated depreciation on disposals and derecognitions</a></td>
<td class="nump">433<span></span>
</td>
<td class="nump">1,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge</a></td>
<td class="num">(491)<span></span>
</td>
<td class="num">(447)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment charge</a></td>
<td class="num">(194)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Reversal of impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation effects</a></td>
<td class="num">(373)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(5,807)<span></span>
</td>
<td class="num">(5,124)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DepreciationChargePriorToClassificationToAssetsHeldForSale', window );">Depreciation charge prior to classification to assets held for sale</a></td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">1,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">1,182<span></span>
</td>
<td class="nump">1,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember', window );">Construction in progress | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">1,350<span></span>
</td>
<td class="nump">2,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment', window );">Costs of assets related to discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment', window );">Cost of assets reclassified out of assets of disposal group held for sale</a></td>
<td class="nump">36<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Impact of business combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="num">(1,038)<span></span>
</td>
<td class="num">(1,019)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">847<span></span>
</td>
<td class="nump">1,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and derecognitions</a></td>
<td class="num">(57)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation effects</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">1,248<span></span>
</td>
<td class="nump">1,350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember', window );">Construction in progress | Accumulated depreciation, amortisation and impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment', window );">Costs of assets related to discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment', window );">Accumulated depreciation on assets reclassified out of assets of disposal group held for sale</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment', window );">Accumulated depreciation on disposals and derecognitions</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment charge</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Reversal of impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation effects</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember', window );">Machinery and other equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">3,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">3,975<span></span>
</td>
<td class="nump">3,948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember', window );">Machinery and other equipment | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">13,674<span></span>
</td>
<td class="nump">17,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment', window );">Costs of assets related to discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,678)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment', window );">Decrease through reclassification to right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment', window );">Cost of assets reclassified out of assets of disposal group held for sale</a></td>
<td class="nump">168<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Impact of business combinations</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="nump">595<span></span>
</td>
<td class="nump">630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and derecognitions</a></td>
<td class="num">(1,656)<span></span>
</td>
<td class="num">(1,774)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation effects</a></td>
<td class="nump">956<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">14,038<span></span>
</td>
<td class="nump">13,674<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember', window );">Machinery and other equipment | Accumulated depreciation, amortisation and impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(9,726)<span></span>
</td>
<td class="num">(11,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment', window );">Costs of assets related to discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment', window );">Accumulated depreciation on assets reclassified out of assets of disposal group held for sale</a></td>
<td class="num">(101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment', window );">Accumulated depreciation on disposals and derecognitions</a></td>
<td class="nump">1,543<span></span>
</td>
<td class="nump">1,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge</a></td>
<td class="num">(827)<span></span>
</td>
<td class="num">(898)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment charge</a></td>
<td class="num">(228)<span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Reversal of impairment charge</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation effects</a></td>
<td class="num">(731)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(10,063)<span></span>
</td>
<td class="num">$ (9,726)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DepreciationChargePriorToClassificationToAssetsHeldForSale', window );">Depreciation charge prior to classification to assets held for sale</a></td>
<td class="num">$ (18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in property, plant and equipment resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingCostsCapitalised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest and other costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 23<br> -IssueDate 2019-01-01<br> -Paragraph 26<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=23&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_26_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingCostsCapitalised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual commitments for the acquisition of property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 74<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_74_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals and retirements. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e_v&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 98<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e_viii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from transfers from construction in progress. [Refer: Property, plant and equipment; Construction in progress]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of reversal of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Reversal of impairment loss recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e_vi&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 98<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DepreciationChargePriorToClassificationToAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DepreciationChargePriorToClassificationToAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ImpairmentChargePriorToClassificationToAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ImpairmentChargePriorToClassificationToAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MovementsOfPropertyPlantAndEquipmentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904317209512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease liability and Right-of-use assets (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">$ 1,676<span></span>
</td>
<td class="nump">$ 1,677<span></span>
</td>
<td class="nump">$ 1,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="num">(330)<span></span>
</td>
<td class="num">(305)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandMember', window );">Land [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">528<span></span>
</td>
<td class="nump">537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember', window );">Buildings [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">963<span></span>
</td>
<td class="nump">990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="num">(207)<span></span>
</td>
<td class="num">(194)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember', window );">Vehicles [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember', window );">Machinery &amp; equipment and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="num">$ (12)<span></span>
</td>
<td class="num">$ (10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>186
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904336042328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease liability and Right-of-use assets (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MovementsOfTheRightofuseAssetsRollForward', window );"><strong>Movements of the right-of-use assets [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets at beginning of period</a></td>
<td class="nump">$ 1,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AcquisitionsThroughBusinessCombinationsRightofuseAssets', window );">Impact of business combinations</a></td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">$ 537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="num">(330)<span></span>
</td>
<td class="num">(305)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_LeaseContractTerminationsRightofuseAssets', window );">Lease contract terminations, right-of-use assets</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisposalsAndRetirementsRightofuseAssets', window );">Impact of divestments</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets', window );">Increase decrease through net exchange differences, right-of-use assets</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets at end of period</a></td>
<td class="nump">1,676<span></span>
</td>
<td class="nump">1,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets', window );">Impairment loss recognised in profit or loss, right of use assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MovementsOfTheRightofuseAssetsRollForward', window );"><strong>Movements of the right-of-use assets [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AcquisitionsThroughBusinessCombinationsRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AcquisitionsThroughBusinessCombinationsRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisposalsAndRetirementsRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisposalsAndRetirementsRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LeaseContractTerminationsRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LeaseContractTerminationsRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MovementsOfTheRightofuseAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MovementsOfTheRightofuseAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>187
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904323255560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease liability and Right-of-use assets (Details 4) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis of total lease liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">$ 2,005<span></span>
</td>
<td class="nump">$ 1,949<span></span>
</td>
<td class="nump">$ 1,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_LeaseLiabilitiesUndiscounted', window );">Lease liabilities undiscounted</a></td>
<td class="nump">3,507<span></span>
</td>
<td class="nump">3,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Less current lease liabilities</a></td>
<td class="num">(286)<span></span>
</td>
<td class="num">(246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CurrentLeaseLiabilitiesUndiscounted', window );">Less current lease liabilities undiscounted</a></td>
<td class="num">(338)<span></span>
</td>
<td class="num">(295)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current lease liabilities</a></td>
<td class="nump">1,719<span></span>
</td>
<td class="nump">1,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_NoncurrentLeaseLiabilitiesUndiscounted', window );">Non-current lease liabilities undiscounted</a></td>
<td class="nump">3,169<span></span>
</td>
<td class="nump">3,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_MostMaterialLeaseWithLeaseTermExtension', window );">Most material lease with lease term extension</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Not later than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis of total lease liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_LeaseLiabilitiesUndiscounted', window );">Lease liabilities undiscounted</a></td>
<td class="nump">338<span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">Later than one year and not later than two years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis of total lease liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_LeaseLiabilitiesUndiscounted', window );">Lease liabilities undiscounted</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">Later than two years and not later than three years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis of total lease liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_LeaseLiabilitiesUndiscounted', window );">Lease liabilities undiscounted</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember', window );">Later than three years and not later than four years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis of total lease liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_LeaseLiabilitiesUndiscounted', window );">Lease liabilities undiscounted</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember', window );">Later than four years and not later than five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis of total lease liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_LeaseLiabilitiesUndiscounted', window );">Lease liabilities undiscounted</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis of total lease liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">1,027<span></span>
</td>
<td class="nump">1,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_LeaseLiabilitiesUndiscounted', window );">Lease liabilities undiscounted</a></td>
<td class="nump">$ 2,326<span></span>
</td>
<td class="nump">$ 2,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CurrentLeaseLiabilitiesUndiscounted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CurrentLeaseLiabilitiesUndiscounted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LeaseLiabilitiesUndiscounted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LeaseLiabilitiesUndiscounted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MostMaterialLeaseWithLeaseTermExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MostMaterialLeaseWithLeaseTermExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NoncurrentLeaseLiabilitiesUndiscounted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NoncurrentLeaseLiabilitiesUndiscounted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>188
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904406193992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease liability and Right-of-use assets (Details 5) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease liabilities</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed', window );">Expense relating to short-term leases for which recognition exemption has been used</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed', window );">Expense relating to leases of low-value assets for which recognition exemption has been used</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Cash outflow</a></td>
<td class="nump">379<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CashOutflowsForShortTermAndLowValueLeases', window );">Cash outflows for short term and low value leases</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CashOutflowsForPaymentsOfLeasesInterest', window );">Cash outflows for payments of leases interest</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Repayment of lease liability</a></td>
<td class="nump">$ 312<span></span>
</td>
<td class="nump">$ 273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_WeightedAverageInterestRateLeaseLiabilities', window );">Weighted average interest rate lease liabilities</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_LeaseIncentives', window );">Lease incentives</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to leases of low-value assets accounted for applying paragraph 6 of IFRS 16. This expense shall not include the expense relating to short-term leases of low-value assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashOutflowsForPaymentsOfLeasesInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashOutflowsForPaymentsOfLeasesInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashOutflowsForShortTermAndLowValueLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashOutflowsForShortTermAndLowValueLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LeaseIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LeaseIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_WeightedAverageInterestRateLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_WeightedAverageInterestRateLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>189
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904406064504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease liability and Right-of-use assets (Details 6) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">$ 1,949<span></span>
</td>
<td class="nump">$ 2,005<span></span>
</td>
<td class="nump">$ 1,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">1,677<span></span>
</td>
<td class="nump">$ 1,676<span></span>
</td>
<td class="nump">$ 1,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=nvs_SaleAndLeaseBackMember', window );">Sale and lease back [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_CashInflowForSaleAndLeaseback', window );">Cash inflow for sale and leaseback</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions', window );">Gains or losses from sales leaseback</a></td>
<td class="nump">$ 478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) arising from sale and leaseback transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashInflowForSaleAndLeaseback">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashInflowForSaleAndLeaseback</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=nvs_SaleAndLeaseBackMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=nvs_SaleAndLeaseBackMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>190
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139904288236248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and intangible assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">$ 55,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">1,425<span></span>
</td>
<td class="nump">$ 767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Reversal of impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">66,808<span></span>
</td>
<td class="nump">55,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">26,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">29,999<span></span>
</td>
<td class="nump">26,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember', window );">Intangible Assets other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">28,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">36,809<span></span>
</td>
<td class="nump">28,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember', window );">Acquired research and development [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">5,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">4,700<span></span>
</td>
<td class="nump">5,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_TechnologybasedIntangibleAssetsMember', window );">Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_CurrentlyMarketedProductsMember', window );">Currently marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">22,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">30,767<span></span>
</td>
<td class="nump">22,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">1,112<span></span>
</td>
<td class="nump">621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_AdditionsIncludedInDisposalGroupToTheDateOfReclassification', window );">Additions included in disposal group to the date of reclassification</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount | Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">26,825<span></span>
</td>
<td class="nump">35,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill', window );">Cost of assets related to discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill', window );">Impact of business combinations</a></td>
<td class="nump">2,580<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency translation effects</a></td>
<td class="nump">916<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">30,321<span></span>
</td>
<td class="nump">26,825<span></span>
</td>
<td class="nump">35,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount | Intangible Assets other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">53,419<span></span>
</td>
<td class="nump">69,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill', window );">Cost of assets related to disposal group held for sale</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill', window );">Cost of assets related to discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,570)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill', window );">Impact of business combinations</a></td>
<td class="nump">9,014<span></span>
</td>
<td class="nump">3,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">1,425<span></span>
</td>
<td class="nump">767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill', window );">Disposals and derecognitions</a></td>
<td class="num">(572)<span></span>
</td>
<td class="num">(1,055)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency translation effects</a></td>
<td class="nump">3,039<span></span>
</td>
<td class="nump">335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">67,725<span></span>
</td>
<td class="nump">53,419<span></span>
</td>
<td class="nump">69,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount | Acquired research and development [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">7,429<span></span>
</td>
<td class="nump">16,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill', window );">Cost of assets related to disposal group held for sale</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill', window );">Cost of assets related to discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(249)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill', window );">Impact of business combinations</a></td>
<td class="nump">8,600<span></span>
</td>
<td class="nump">342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill', window );">Reclassifications</a></td>
<td class="num">(9,272)<span></span>
</td>
<td class="num">(9,069)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill', window );">Disposals and derecognitions</a></td>
<td class="num">(421)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency translation effects</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">6,893<span></span>
</td>
<td class="nump">7,429<span></span>
</td>
<td class="nump">16,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount | Alcon brand name [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill', window );">Cost of assets related to discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,980)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount | Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">884<span></span>
</td>
<td class="nump">6,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill', window );">Cost of assets related to disposal group held for sale</a></td>
<td class="nump">276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill', window );">Cost of assets related to discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,369)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill', window );">Reclassifications</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill', window );">Disposals and derecognitions</a></td>
<td class="num">(101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency translation effects</a></td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">1,115<span></span>
</td>
<td class="nump">884<span></span>
</td>
<td class="nump">6,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=